PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bhamidipati, CM; Mehta, GS; Moehle, CW; Meher, AK; Su, G; Vigneshwar, NG; Barbery, C; Sharma, AK; Kron, IL; Laubach, VE; Owens, GK; Upchurch, GR; Ailawadi, G				Bhamidipati, Castigliano M.; Mehta, Gaurav S.; Moehle, Christopher W.; Meher, Akshaya K.; Su, Gang; Vigneshwar, Navin G.; Barbery, Carlos; Sharma, Ashish K.; Kron, Irving L.; Laubach, Victor E.; Owens, Gary K.; Upchurch, Gilbert R., Jr.; Ailawadi, Gorav			Adenosine 2A receptor modulates inflammation and phenotype in experimental abdominal aortic aneurysms	FASEB JOURNAL			English	Article						immune modulation; CD4(+); T lymphocytes; GPCR signaling; physiological regulation; inflammation	TNF-ALPHA; CGS 21680; T-CELLS; AGONIST; ACTIVATION; ISCHEMIA; PATHOGENESIS; MONOCYTE; MICE; RECRUITMENT	Activation of the adenosine 2A receptor (A(2A)R) reduces inflammation in models of acute injury but contribution in development of chronic abdominal aortic aneurysms (AAAs) is unknown. Elastase perfusion to induce AAA formation in A(2A)R-knockout (A(2A)RKO) and C57BL6/J wild-type (WT) mice resulted in nearly 100% larger aneurysms in A2ARKO compared toWT at d 14 (P<0.05), with evidence of greater elastin fragmentation, more immune cell infiltration, and increased matrix metallatoproteinase (MMP) 9 expression (P<0.05). Separately, exogenous A(2A)R antagonism in elastase-perfused WT mice also resulted in larger aneurysms (P<0.05), while A(2A)R agonism limited aortic dilatation (P<0.05). Activated Thy-1.2(+) T lymphocytes from WT mice treated in vitro with A(2A)R antagonist increased cytokine production, and treatment with A(2A)R agonist decreased cytokine production (P<0.05 for all). Primary activated CD4(+) T lymphocytes from A(2A)RKO mice exhibited greater chemotaxis (P<0.05). A(2A)R antagonist increased chemotaxis of activated CD4(+) cells from WT mice in vitro, and A(2A)R agonist reduced this effect (P<0.05). A(2A)R activation attenuates AAA formation partly by inhibiting immune cell recruitment and reducing elastin fragmentation. These findings support augmenting A(2A)R signaling as a putative target for limiting aneurysm formation.	[Bhamidipati, Castigliano M.; Mehta, Gaurav S.; Moehle, Christopher W.; Meher, Akshaya K.; Vigneshwar, Navin G.; Barbery, Carlos; Sharma, Ashish K.; Kron, Irving L.; Laubach, Victor E.] Univ Virginia, Sch Med, Div Thorac & Cardiovasc Surg, Charlottesville, VA 22908 USA; [Su, Gang; Upchurch, Gilbert R., Jr.] Univ Virginia, Sch Med, Div Vasc & Endovasc Surg, Dept Surg, Charlottesville, VA 22908 USA; [Owens, Gary K.; Upchurch, Gilbert R., Jr.] Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Owens, Gary K.; Upchurch, Gilbert R., Jr.; Ailawadi, Gorav] Univ Virginia, Sch Med, Robert M Berne Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; [Ailawadi, Gorav] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Ailawadi, G (corresponding author), Univ Virginia Hlth Syst, Dept Surg, Dept Biomed Engn, POB 800679, Charlottesville, VA 22908 USA.	gorav@virginia.edu	Laubach, Victor E./E-8818-2015; Meher, Akshaya/ABC-9797-2021	Laubach, Victor E./0000-0001-9673-5383; Meher, Akshaya/0000-0002-2802-9599; /0000-0003-2180-9178	U.S. National Institutes of Health (NIH) [K08HL098560, T32HL007849]; Thoracic Surgery Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL098560, T32HL007849, T32HL007284, R01HL087867, R01HL057353] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thoracic Surgery Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health (NIH) grants to G.A. (K08HL098560) and I.L.K. (T32HL007849). The Research and Education Grant from the Thoracic Surgery Foundation also supported G.A. The authors thank M. Bevard for her technical expertise and advice for histology. The authors also appreciate the administrative contributions of A. J. Herring and C. S. Dodson. The authors are grateful to Dr. M. Angulo (University of Virginia) and Dr. C. A. Whatling (AstraZeneca, Molndal, Sweden) for critical review and editorial commentary. In addition, the authors thank Dr. M. Angulo (University of Virginia) for her technical expertise in the timely resubmission of revisions. The authors also acknowledge the initial work of Dr. Hong Pei (Joel Linden Laboratory, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA) in the area of A<INF>2A</INF>R and aortic aneurysms. The authors declare no competing financial interests. This work was presented at the Annual Scientific Sessions of the American Heart Association 2010 (Chicago, IL, USA).	Ailawadi G, 2003, J VASC SURG, V38, P584, DOI 10.1016/S0741-5214(03)00324-0; Ailawadi G, 2009, J THORAC CARDIOV SUR, V138, P1392, DOI 10.1016/j.jtcvs.2009.07.075; Alexander MR, 2012, J CLIN INVEST, V122, P70, DOI 10.1172/JCI43713; Anvari F, 2010, J THORAC CARDIOV SUR, V140, P871, DOI 10.1016/j.jtcvs.2010.06.051; Applied Research Ethics National Association/Office of Laboratory Animal Welfare, 2002, I AN CAR US COMM GUI; BRUNS RF, 1990, ANN NY ACAD SCI, V603, P211; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chehata VJ, 2011, CELL IMMUNOL, V267, P39, DOI 10.1016/j.cellimm.2010.11.002; Curci JA, 2004, J CLIN INVEST, V114, P168, DOI 10.1172/JCI200422309; Duftner C, 2005, ARTERIOSCL THROM VAS, V25, P1347, DOI 10.1161/01.ATV.0000167520.41436.c0; Eliason JL, 2005, CIRCULATION, V112, P232, DOI 10.1161/CIRCULATIONAHA.104.517391; Emaminia A, 2011, ANN THORAC SURG, V92, P1840, DOI 10.1016/j.athoracsur.2011.06.062; Ernens I, 2006, CIRC RES, V99, P590, DOI 10.1161/01.RES.0000241428.82502.d4; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Gazoni LM, 2010, J THORAC CARDIOV SUR, V140, P440, DOI 10.1016/j.jtcvs.2010.03.002; Genovese T, 2009, SHOCK, V32, P578, DOI 10.1097/SHK.0b013e3181a20792; Guo DC, 2006, ANN NY ACAD SCI, V1085, P339, DOI 10.1196/annals.1383.013; Hannawa KK, 2005, CIRCULATION, V112, P241, DOI 10.1161/CIRCULATIONAHA.105.535625; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hasko G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003; Heron MP, 2009, NATL VITAL STAT REPO, V57, P14; Institute for Laboratory Animal Research, 2011, GUIDE CARE USE LAB A; LaPar DJ, 2011, J THORAC CARDIOV SUR, V142, P887, DOI 10.1016/j.jtcvs.2011.06.015; Lappas CM, 2005, EXPERT OPIN INV DRUG, V14, P797, DOI 10.1517/13543784.14.7.797; Laubach VE, 2011, EXPERT OPIN THER TAR, V15, P103, DOI 10.1517/14728222.2011.541441; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Linden J, 2011, ADV PHARMACOL, V61, P95, DOI 10.1016/B978-0-12-385526-8.00004-7; Mazzon E, 2011, J RHEUMATOL, V38, P2119, DOI 10.3899/jrheum.110111; Moehle CW, 2011, J THORAC CARDIOV SUR, V142, P1567, DOI 10.1016/j.jtcvs.2011.07.053; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Riksen NP, 2007, PHARMACOGENET GENOM, V17, P551, DOI 10.1097/FPC.0b013e32803fb78f; Riksen NP, 2007, EUR HEART J, V28, P1085, DOI 10.1093/eurheartj/ehm032; Rizas KD, 2009, CARDIOL REV, V17, P201, DOI 10.1097/CRD.0b013e3181b04698; Sharma AK, 2010, J THORAC CARDIOV SUR, V139, P474, DOI 10.1016/j.jtcvs.2009.08.033; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Thompson RW, 2006, ANN NY ACAD SCI, V1085, P59, DOI 10.1196/annals.1383.029; VALENTE AJ, 1992, CIRCULATION, V86, P20; Wagner DR, 1999, AM J PHYSIOL-HEART C, V276, pH2141, DOI 10.1152/ajpheart.1999.276.6.H2141; Wang SX, 2012, NAT MED, V18, P902, DOI 10.1038/nm.2711; Xiong WF, 2009, J IMMUNOL, V183, P2741, DOI 10.4049/jimmunol.0803164; Xiong WF, 2004, J IMMUNOL, V172, P2607, DOI 10.4049/jimmunol.172.4.2607; Yin MD, 2010, ARTERIOSCL THROM VAS, V30, P1825, DOI 10.1161/ATVBAHA.109.200303; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646	45	8	9	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2122	2131		10.1096/fj.12-214197	http://dx.doi.org/10.1096/fj.12-214197			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23413358	Green Published			2022-12-28	WOS:000319667600004
J	Ehrentraut, H; Clambey, ET; McNamee, EN; Brodsky, KS; Ehrentraut, SF; Poth, JM; Riegel, AK; Westrich, JA; Colgan, SP; Eltzschig, HK				Ehrentraut, Heidi; Clambey, Eric T.; McNamee, Eoin N.; Brodsky, Kelley S.; Ehrentraut, Stefan F.; Poth, Jens M.; Riegel, Ann K.; Westrich, Joseph A.; Colgan, Sean P.; Eltzschig, Holger K.			CD73(+) regulatory T cells contribute to adenosine-mediated resolution of acute lung injury	FASEB JOURNAL			English	Article						ectonucleotidase; lipopolysaccharide; hypoxia; Adora2b; inflammation	ACUTE KIDNEY INJURY; TOLL-LIKE RECEPTORS; ECTO-5'-NUCLEOTIDASE CD73; EXTRACELLULAR ADENOSINE; NUCLEOTIDE PHOSPHOHYDROLYSIS; DEAMINASE DEFICIENCY; DEPENDENT INDUCTION; HYPOXIA; INFLAMMATION; PROTECTION	Acute lung injury (ALI) is characterized by alveolar injury and uncontrolled inflammation. Since most cases of ALI resolve spontaneously, understanding the endogenous mechanisms that promote ALI resolution is important to developing effective therapies. Previous studies have implicated extracellular adenosine signaling in tissue adaptation and wound healing. Therefore, we hypothesized a functional contribution for the endogenous production of adenosine during ALI resolution. As a model, we administered intratracheal LPS and observed peak lung injury at 3 d, with resolution by d 14. Treatment with pegylated adenosine-deaminase to enhance extracellular adenosine breakdown revealed impaired ALI resolution. Similarly, genetic deletion of cd73, the pacemaker for extracellular adenosine generation, was associated with increased mortality (0% wild-type and 40% in cd73(-/-) mice; P<0.05) and failure to resolve ALI adequately. Studies of inflammatory cell trafficking into the lungs during ALI resolution revealed that regulatory T cells (Tregs) express the highest levels of CD73. While Treg numbers in cd73(-/-) mice were similar to controls, cd73-deficient Tregs had attenuated immunosuppressive functions. Moreover, adoptive transfer of cd73-deficient Tregs into Rag(-/-) mice emulated the observed phenotype in cd73(-/-) mice, while transfer of wild-type Tregs was associated with normal ALI resolution. Together, these studies implicate CD73-dependent adenosine generation in Tregs in promoting ALI resolution.-Ehrentraut, H., Clambey, E. T., McNamee, E. N., Brodsky, K. S., Ehrentraut, S. F., Poth, J. M., Riegel, A. K., Westrich, J. A., Colgan, S. P., Eltzschig, H. K. CD73(+) regulatory T cells contribute to adenosine-mediated resolution of acute lung injury.	[Ehrentraut, Heidi; Clambey, Eric T.; McNamee, Eoin N.; Brodsky, Kelley S.; Poth, Jens M.; Riegel, Ann K.; Westrich, Joseph A.; Eltzschig, Holger K.] Univ Colorado, Sch Med, Mucosal Inflammat Program, Dept Anesthesiol, Aurora, CO 80045 USA; [Ehrentraut, Stefan F.; Colgan, Sean P.] Univ Colorado, Sch Med, Mucosal Inflammat Program, Dept Med, Aurora, CO 80045 USA; [Ehrentraut, Heidi; Ehrentraut, Stefan F.; Poth, Jens M.] Univ Hosp Bonn, Dept Anesthesiol & Intens Care Med, Bonn, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Bonn	Eltzschig, HK (corresponding author), Univ Colorado, Sch Med, Mucosal Inflammat Program, Dept Anesthesiol, 12700 E 19th Ave,Mailstop B112,Res Complex 2,Rm 7, Aurora, CO 80045 USA.	holger.eltzschig@ucdenver.edu		McNamee, Eoin/0000-0002-3331-3148; Westrich, Joseph/0000-0003-2406-6891; Poth, Jens/0000-0003-2534-5382; Ehrentraut, Stefan/0000-0001-5747-6737	U.S. National Institutes of Health [R01-HL-092188, R01-DK-083385, R01-HL-098294, HL-560569, DK-095491]; Crohn's and Colitis Foundation of America (CCFA); German Academic Exchange Service [Deutscher Akademischer Austausch Dienst (DAAD)] [D/10/52531]; German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)] [EH401/1-1, ES 371/1-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092188, R01HL098294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083385, R37DK050189, R01DK095491] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America (CCFA); German Academic Exchange Service [Deutscher Akademischer Austausch Dienst (DAAD)](Deutscher Akademischer Austausch Dienst (DAAD)); German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)](German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge Kristann Magee and Sheema Rabbaig for technical assistance. The cd73<SUP>-/-</SUP> mice were kindly provided by Linda Thompson (OK Medical Research Foundation, Okalahoma City, OK, USA). In addition, the authors acknowledge Yang Xia and Michael R. Blackburn (University of Texas Medical School, Houston, TX, USA) and Edwin F de Zoeten and Colm B Collins (University of Colorado School of Medicine, Aurora, CO, USA) for help with addressing questions that came up in the review process of this study. The present research work was supported by U.S. National Institutes of Health grants R01-HL-092188, R01-DK-083385, and R01-HL-098294 (to H.K.E.) and HL-560569 and DK-095491 (to S.P.C.); Crohn's and Colitis Foundation of America (CCFA) grants (to H.K.E.); German Academic Exchange Service [Deutscher Akademischer Austausch Dienst (DAAD)] grant D/10/52531 (to J.M.P.); and German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)] grants EH401/1-1 (to H.E.) and ES 371/1-1 (to S.F.E.).	Aherne CM, 2012, GUT, V61, P695, DOI 10.1136/gutjnl-2011-300012; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Colgan SP, 2012, ANNU REV PHYSIOL, V74, P153, DOI 10.1146/annurev-physiol-020911-153230; Collins CB, 2013, MUCOSAL IMMUNOL, V6, P960, DOI 10.1038/mi.2012.134; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; Day YJ, 2006, J IMMUNOL, V176, P3108, DOI 10.4049/jimmunol.176.5.3108; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Ehrentraut H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032416; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2006, BLOOD, V108, P1602, DOI 10.1182/blood-2006-02-001016; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, ANESTHESIOLOGY, V111, P904, DOI 10.1097/ALN.0b013e3181b060f2; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Frick JS, 2009, J IMMUNOL, V182, P4957, DOI 10.4049/jimmunol.0801324; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2012, J IMMUNOL, V189, P4566, DOI 10.4049/jimmunol.1201651; Grenz A, 2012, J CLIN INVEST, V122, P693, DOI 10.1172/JCI60214; Hart ML, 2008, GASTROENTEROLOGY, V135, P1739, DOI 10.1053/j.gastro.2008.07.064; Hart ML, 2008, FASEB J, V22, P2784, DOI 10.1096/fj.07-103911; Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617; Hart ML, 2010, J IMMUNOL, V184, P4017, DOI 10.4049/jimmunol.0901851; Karmouty-Quintana H, 2012, FASEB J, V26, P2546, DOI 10.1096/fj.11-200907; Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780; Li L, 2012, J CLIN INVEST, V122, P3931, DOI 10.1172/JCI63170; MACATANGAY BJ, 2012, 19 INT AIDS C; Morote-Garcia JC, 2008, BLOOD, V111, P5571, DOI 10.1182/blood-2007-11-126763; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Peng Z, 2009, J CLIN INVEST, V119, P582, DOI 10.1172/JCI37409; Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schingnitz U, 2010, J IMMUNOL, V184, P5271, DOI 10.4049/jimmunol.0903035; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0; Volmer JB, 2006, J IMMUNOL, V176, P4449, DOI 10.4049/jimmunol.176.7.4449; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Zhang YJ, 2011, NAT MED, V17, P79, DOI 10.1038/nm.2280; Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907	59	84	88	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2207	2219		10.1096/fj.12-225201	http://dx.doi.org/10.1096/fj.12-225201			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23413361	Green Accepted, Green Published			2022-12-28	WOS:000319667600012
J	Lu, J; Vlamis-Gardikas, A; Kandasamy, K; Zhao, R; Gustafsson, TN; Engstrand, L; Hoffner, S; Engman, L; Holmgren, A				Lu, Jun; Vlamis-Gardikas, Alexios; Kandasamy, Karuppasamy; Zhao, Rong; Gustafsson, Tomas N.; Engstrand, Lars; Hoffner, Sven; Engman, Lars; Holmgren, Arne			Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione	FASEB JOURNAL			English	Article						oxidative stress; thiol; ebselen; isothiazolone	ESCHERICHIA-COLI CYTOPLASM; HELICOBACTER-PYLORI; MAMMALIAN THIOREDOXIN; STAPHYLOCOCCUS-AUREUS; RIBONUCLEOTIDE REDUCTASE; EBSELEN; ANTIOXIDANT; SELENIUM; STRESS; THIOL	Increasing antibiotic resistance makes the identification of new antibacterial principles an urgent task. The thioredoxin system including thioredoxin reductase (TrxR), thioredoxin (Trx), and NADPH plays critical roles in cellular DNA synthesis and defense against oxidative stress. Notably, TrxR is very different in structure and mechanism in mammals and bacteria. Ebselen [2-phenyl-1,2 benzisoselenazol-3(2H)-one], a well-known antioxidant and a substrate for mammalian TrxR and Trx, is rapidly bacteriocidal for methicillin-resistant Staphylococcus aureus by an unknown mechanism. We have discovered that ebselen is a competitive inhibitor of Escherichia coli TrxR with a K-i of 0.52 +/- 0.13 mu M, through reaction with the active site dithiol of the enzyme. Bacteria lacking glutathione (GSH) and glutaredoxin, in which TrxR and Trx are essential for DNA synthesis, were particularly sensitive to ebselen. In growth-inhibited E. coli strains, Trx1 and Trx2 were oxidized, demonstrating that electron transfer via thioredoxin was blocked. Ebselen and its sulfur analog ebsulfur were bactericidal for GSH-negative pathogens. Ebsulfur inhibited a clinically isolated Helicobacter pylori strain with a minimum inhibitory concentration value as low as 0.39 mu g/ml. These results demonstrate that bacterial Trx and TrxR are viable antibacterial drug targets using benzisoselenazol and benzisothiazol derivates.-Lu, J., Vlamis-Gardikas, A., Kandasamy, K., Zhao, R., Gustafsson, T. N., Engstrand, L., Hoffner, S., Engman, L., Holmgren, A. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394-1403 (2013). www.fasebj.org	[Lu, Jun; Vlamis-Gardikas, Alexios; Kandasamy, Karuppasamy; Zhao, Rong; Gustafsson, Tomas N.; Holmgren, Arne] Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, SE-17177 Stockholm, Sweden; [Engstrand, Lars; Hoffner, Sven] Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; [Hoffner, Sven] WHO, Swedish Inst Communicable Dis Control, Dept Preparedness, Supranatl TB Reference Lab, Solna, Sweden; [Engman, Lars] Uppsala Univ, Dept Biochem & Organ Chem, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish Institute for Infectious Disease Control; World Health Organization; Uppsala University	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se	Vlamis, Alexios/AAF-5152-2020; Lu, Jun/E-9701-2017	Vlamis, Alexios/0000-0001-5068-6459; Lu, Jun/0000-0002-1699-8835; Gustafsson, Tomas/0000-0002-4495-8267	Swedish Cancer Society [961]; Swedish Research Council Medicine [13x-3529]; Vinnova, the K. A. Wallenberg Foundation; Karolinska Institutet	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council Medicine(Swedish Research Council); Vinnova, the K. A. Wallenberg Foundation; Karolinska Institutet(Karolinska Institutet)	The authors thank Dr. Scott B. Mulrooney (University of Michigan, Ann Arbor, MI, USA) for kindly providing E. coli A326 with plasmid pTrR316 and Dr. Hiroyuki Masayasu (Daiichi Pharmaceutical Company, Ltd., Tokyo, Japan) for help in determining the MIC of H. pylori NCTC11637 and H. pylori YS-16 strains to ebselen and ebsulfur. This work was supported by the Swedish Cancer Society (961), the Swedish Research Council Medicine (13x-3529), Vinnova, the K. A. Wallenberg Foundation, and the Karolinska Institutet. T.N.G. was the recipient of an M.D.-Ph.D. grant from the Karolinska Institutet.	Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Chew EH, 2008, FASEB J, V22, P2072, DOI 10.1096/fj.07-101477; Comtois SL, 2003, MICROBIOL-SGM, V149, P121, DOI 10.1099/mic.0.25896-0; COTGREAVE IA, 1989, BIOCHEM PHARMACOL, V38, P649, DOI 10.1016/0006-2952(89)90211-6; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667; Gon S, 2006, ANTIOXID REDOX SIGN, V8, P735, DOI 10.1089/ars.2006.8.735; Gustafsson TN, 2007, ACTA CRYSTALLOGR D, V63, P833, DOI 10.1107/S0907444907026303; Gustafsson TN, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.413427; He J, 2012, BIOORGAN MED CHEM, V20, P3816, DOI 10.1016/j.bmc.2012.04.033; Hoffner SE, 1997, J ANTIMICROB CHEMOTH, V40, P885, DOI 10.1093/jac/40.6.885; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; KAMIGATA N, 1986, B CHEM SOC JPN, V59, P2179, DOI 10.1246/bcsj.59.2179; Kloc K, 2003, SYNTHETIC COMMUN, V33, P3805, DOI 10.1081/SCC-120025191; Kohanski MA, 2010, NAT REV MICROBIOL, V8, P423, DOI 10.1038/nrmicro2333; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Livermore DM, 2004, CLIN MICROBIOL INFEC, V10, P1, DOI 10.1111/j.1465-0691.2004.1004.x; Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104; MLOCHOWSKI J, 1993, LIEBIGS ANN CHEM, P1239; Newton GL, 2009, NAT CHEM BIOL, V5, P625, DOI 10.1038/nchembio.189; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NOZAWA R, 1989, ANTIMICROB AGENTS CH, V33, P1388, DOI 10.1128/AAC.33.8.1388; Ogawa A, 1999, CEREBROVASC DIS, V9, P112, DOI 10.1159/000015908; Osajda M, 2001, POL J CHEM, V75, P823; Perrin D. D., 1980, PURIFICATION LAB CHE; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rabinovitch I, 2010, J BACTERIOL, V192, P4963, DOI 10.1128/JB.00539-10; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; Rocha ER, 2007, J BACTERIOL, V189, P8015, DOI 10.1128/JB.00714-07; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Scharf C, 1998, J BACTERIOL, V180, P1869, DOI 10.1128/JB.180.7.1869-1877.1998; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Uziel O, 2004, J BACTERIOL, V186, P326, DOI 10.1128/JB.186.2.326-334.2004; Veine DM, 1998, PROTEIN SCI, V7, P1441, DOI 10.1002/pro.5560070621; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Windle HJ, 2000, J BIOL CHEM, V275, P5081, DOI 10.1074/jbc.275.7.5081; Zhao F, 2006, CANCER LETT, V236, P46, DOI 10.1016/j.canlet.2005.05.010; Zhao R, 2002, J BIOL CHEM, V277, P39456, DOI 10.1074/jbc.M206452200; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	46	114	121	3	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1394	1403		10.1096/fj.12-223305	http://dx.doi.org/10.1096/fj.12-223305			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23248236				2022-12-28	WOS:000316940800012
J	Nagahashi, M; Kim, EY; Yamada, A; Ramachandran, S; Allegood, JC; Hait, NC; Maceyka, M; Milstien, S; Takabe, K; Spiegel, S				Nagahashi, Masayuki; Kim, Eugene Y.; Yamada, Akimitsu; Ramachandran, Subramaniam; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Milstien, Sheldon; Takabe, Kazuaki; Spiegel, Sarah			Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; lymphocytes	CANCER PROGRESSION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; EGRESS; ORGANS; LYMPHANGIOGENESIS; ZEBRAFISH; EXPORT; MICE	Sphingosine-1-phosphate (S1P), a ligand for 5 specific receptors, is a potent lipid mediator that plays important roles in lymphocyte trafficking and immune responses. S1P is produced inside cells and therefore must be secreted to exert its effects through these receptors. Spinster 2 (Spns2) is one of the cell surface transporters thought to secrete S1P. We have shown that Spns2 can export endogenous S1P from cells and also dihydro-S1P, which is active at all cell surface S1P receptors. Moreover, Spns(2-/-) mice have decreased levels of both of these phosphorylated sphingoid bases in blood, accompanied by increases in very long chain ceramide species, and have defective lymphocyte trafficking. Surprisingly, levels of S1P and dihydro-S1P were increased in lymph from Spns(2-/-) mice as well as in specific tissues, including lymph nodes, and interstitial fluid. Moreover, lymph nodes from Spns(2-/-) mice have aberrant lymphatic sinus that appeared collapsed, with reduced numbers of lymphocytes. Our data suggest that Spns2 is an S1P transporter in vivo that plays a role in regulation not only of blood S1P but also lymph node and lymph S1P levels and consequently influences lymphocyte trafficking and lymphatic vessel network organization.-Nagahashi, M., Kim, E. Y., Yamada, A., Ramachandran, S., Allegood, J. C., Hait, N. C., Maceyka, M., Milstien, S., Takabe, K., Spiegel, S. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels and the lymphatic network. FASEB J. 27, 1001-1011 (2013). www.fasebj.org	[Nagahashi, Masayuki; Kim, Eugene Y.; Yamada, Akimitsu; Ramachandran, Subramaniam; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Milstien, Sheldon; Takabe, Kazuaki; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Nagahashi, Masayuki; Yamada, Akimitsu; Takabe, Kazuaki] Virginia Commonwealth Univ, Sch Med, Dept Surg, Richmond, VA 23298 USA; [Nagahashi, Masayuki; Kim, Eugene Y.; Yamada, Akimitsu; Ramachandran, Subramaniam; Allegood, Jeremy C.; Hait, Nitai C.; Maceyka, Michael; Milstien, Sheldon; Takabe, Kazuaki; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Maceyka, Michael/B-9277-2008; Nagahashi, Masayuki/AAB-4202-2020	Takabe, Kazuaki/0000-0002-6435-4241	U.S. National Institutes of Health (NIH) [R37-GM043880, U19-AI077435, K12-HD055881]; Cure Research Foundation [KG090510]; NIH [T32HL094290, P30CA16059]; Japan Society for the Promotion of Science Postdoctoral Fellow; National Institute of Neurological Disorders and Stroke Center Core [5P30NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD055881] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016059, R01CA160688] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047463] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cure Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science Postdoctoral Fellow; National Institute of Neurological Disorders and Stroke Center Core(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health (NIH) grants R37-GM043880 and U19-AI077435 (to S. S.) and K12-HD055881 and Susan G. Komen for the Cure Research Foundation Career Catalyst research grant KG090510 (to K. T.). E.Y.K. and J.C.A. were supported by NIH training grant T32HL094290. M.N. is a Japan Society for the Promotion of Science Postdoctoral Fellow. The Flow Cytometry and Confocal Microscopy Shared Resource Cores were supported in part by NIH grant P30CA16059 to the Massey Cancer Center and National Institute of Neurological Disorders and Stroke Center Core grant 5P30NS047463, respectively. M.N. designed and performed the research and assisted in writing the manuscript; E.Y.K., A.Y., S.R., and N.C.H. performed the research and analyzed the data; J.C.A. measured sphingolipids; M. M. and S. M. analyzed the data and assisted in writing the manuscript; K. T. designed experiments, analyzed the data, and assisted in writing the manuscript; and S. S. designed experiments, analyzed data, and wrote the manuscript. The authors declare no conflicts of interest.	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Boujaoude LC, 2001, J BIOL CHEM, V276, P35258, DOI 10.1074/jbc.M105442200; Breart B, 2011, J EXP MED, V208, P1267, DOI 10.1084/jem.20102551; Brindley DN, 2009, J LIPID RES, V50, pS225, DOI 10.1194/jlr.R800055-JLR200; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Fukuhara S, 2012, J CLIN INVEST, V122, P1416, DOI 10.1172/JCI60746; Grigorova IL, 2010, P NATL ACAD SCI USA, V107, P20447, DOI 10.1073/pnas.1009968107; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hisano Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038941; Hisano Y, 2011, J BIOL CHEM, V286, P1758, DOI 10.1074/jbc.M110.171116; Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449; Kobayashi N, 2006, J LIPID RES, V47, P614, DOI 10.1194/jlr.M500468-JLR200; Kobayashi N, 2009, J BIOL CHEM, V284, P21192, DOI 10.1074/jbc.M109.006163; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Meissner A, 2012, CIRCULATION, V125, P2739, DOI 10.1161/CIRCULATIONAHA.111.047316; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Nagahashi M, 2010, WORLD J GASTROENTERO, V16, P4003, DOI 10.3748/wjg.v16.i32.4003; Nijnik A, 2012, J IMMUNOL, V189, P102, DOI 10.4049/jimmunol.1200282; Osborne N, 2008, CURR BIOL, V18, P1882, DOI 10.1016/j.cub.2008.10.061; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Pham THM, 2010, J EXP MED, V207, P17, DOI 10.1084/jem.20091619; Sato K, 2007, J NEUROCHEM, V103, P2610, DOI 10.1111/j.1471-4159.2007.04958.x; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Sensken SC, 2010, J IMMUNOL, V184, P4133, DOI 10.4049/jimmunol.0903358; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162; Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845; Wiig H, 2003, AM J PHYSIOL-HEART C, V284, pH416, DOI 10.1152/ajpheart.00327.2002; Zachariah MA, 2010, SCIENCE, V328, P1129, DOI 10.1126/science.1188222	32	116	121	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1001	1011		10.1096/fj.12-219618	http://dx.doi.org/10.1096/fj.12-219618			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23180825	Green Published			2022-12-28	WOS:000315585200015
J	Fargier, G; Favard, C; Parmeggiani, A; Sahuquet, A; Merezegue, F; Morel, A; Denis, M; Molinari, N; Mangeat, PH; Coopman, PJ; Montcourrier, P				Fargier, Guillaume; Favard, Cyril; Parmeggiani, Andrea; Sahuquet, Alain; Merezegue, Fabrice; Morel, Anne; Denis, Marie; Molinari, Nicolas; Mangeat, Paul H.; Coopman, Peter J.; Montcourrier, Philippe			Centrosomal targeting of Syk kinase is controlled by its catalytic activity and depends on microtubules and the dynein motor	FASEB JOURNAL			English	Article						tyrosine kinase; breast cancer	PROTEIN-TYROSINE KINASE; BREAST-CANCER CELLS; ANTIGEN RECEPTOR; GAMMA-TUBULIN; LIVING CELLS; PHOSPHORYLATION; GENE; DYNACTIN; ADHESION; CARCINOMA	The nonreceptor Syk kinase is detected in epithelial cells, where it acts as a tumor suppressor, in addition to its well-established role in immunoreceptor-based signal transduction in hematopoietic cells. Thus, several carcinomas and melanomas have subnormal concentrations of Syk. Although Syk is mainly localized at the plasma membrane, it is also present in centrosomes, where it is involved in the control of cell division. The mechanisms responsible for its centrosomal localization and action are unknown. We used wild-type and mutant fluorescent Syk fusion proteins in live-cell imaging (fluorescence recovery after photo-bleaching, total internal reflection fluorescence, and photoactivation) combined with mathematical modeling to demonstrate that Syk is actively transported to the centrosomes via the microtubules and that this transport depends on the dynein/dynactin molecular motor. Syk can only target the centrosomes if its kinase activity is intact and it is catalytically active at the centrosomes. We showed that the autophosphorylated Y130 Syk residue helps to uncouple Syk from the plasma membrane and to promote its translocation to the centrosome, suggesting that the subcellular location of Syk depends on its autophosphorylation on specific tyrosine residues. We have thus established the details of how Syk is trafficked intracellularly and found evidence that its targeting to the centrosomes is controlled by autophosphorylation.-Fargier, G., Favard, C., Parmeggiani, A., Sahuquet, A., Merezegue, F., Morel, A., Denis, M., Molinari, N., Mangeat, P. H., Coopman, P. J., Montcourrier, P. Centrosomal targeting of Syk kinase is controlled by its catalytic activity and depends on microtubules and the dynein motor. FASEB J. 27, 109-122 (2013). www.fasebj.org	[Fargier, Guillaume; Sahuquet, Alain; Merezegue, Fabrice; Morel, Anne; Mangeat, Paul H.; Coopman, Peter J.; Montcourrier, Philippe] Univ Montpellier I, CNRS, CRBM, UMR 5237, F-34298 Montpellier 5, France; [Fargier, Guillaume; Sahuquet, Alain; Merezegue, Fabrice; Morel, Anne; Mangeat, Paul H.; Coopman, Peter J.; Montcourrier, Philippe] Univ Montpellier 2, CNRS, CRBM, UMR 5237, Montpellier, France; [Fargier, Guillaume; Sahuquet, Alain; Merezegue, Fabrice; Morel, Anne; Mangeat, Paul H.; Coopman, Peter J.; Montcourrier, Philippe] Equipe Labellisee 2007 Ligue Natl Canc, Paris, France; [Favard, Cyril] Univ Montpellier I, CNRS, UMR 5236, Ctr Etud Agents Pathogenes & Biotechnol Sante CPB, F-34298 Montpellier 5, France; [Favard, Cyril] Univ Montpellier 2, CNRS, UMR 5236, Ctr Etud Agents Pathogenes & Biotechnol Sante CPB, Montpellier, France; [Parmeggiani, Andrea] Univ Montpellier 2, CNRS, UMR Biol Phys & Syst Biol 5235, Montpellier, France; [Denis, Marie; Molinari, Nicolas] Univ Montpellier I, Inst Univ Rech Clin, Lab Biostat Epidemiol & Sante Publ, Unite Pedagog Med, F-34298 Montpellier 5, France; [Coopman, Peter J.; Montcourrier, Philippe] Univ Montpellier I, INSERM, U896, IRCM,CRLC Val dAurelle, F-34298 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Montcourrier, P (corresponding author), Univ Montpellier I, INSERM, U896, IRCM,CRLC Val dAurelle, 208 Rue Apothicaires, F-34298 Montpellier 5, France.	philippe.montcourrier@inserm.fr	Andrea, Parmeggiani/ABF-6554-2020; Favard, Cyril/P-6392-2016; Coopman, Peter/G-7416-2019; molinari, nicolas/Y-9681-2019	Favard, Cyril/0000-0002-8304-2980; Coopman, Peter/0000-0003-3720-523X; Parmeggiani, Andrea/0000-0003-3025-4266	Fondation pour la Recherche Medicale [DGE-20101221267]; Institut National de la Recherche Medicale; Centre National de la Recherche Scientifique; Institut National du Cancer [PL06-111]; Ligue Nationale contre le Cancer (Equipe labelisee); Ministere de l'Enseignement Superieur et de la Recherche	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer (Equipe labelisee)(Ligue nationale contre le cancer); Ministere de l'Enseignement Superieur et de la Recherche	The authors thank the Montpellier RIO Imaging platform, especially Nicole Lautredou and Vicky Diakou, and the Fondation pour la Recherche Medicale (DGE-20101221267) for microscope funding and Lise Roca (Centre Regional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France) for help with statistical analysis. PA-GFP was a kind gift from J. Lippincott-Schwartz (U. S. National Institute of Child Health and Human Development/National Institutes of Health, Bethesda, MD, USA), and the authors thank Andreas Merdes and Alexander Dammermann (Centre National de la Recherche Scientifique, Pierre Fabre, Toulouse, France) for the GFP-p50-dynamitin plasmid. The English text was edited by Dr. Owen Parkes. This work was supported by the Institut National de la Recherche Medicale and the Centre National de la Recherche Scientifique. Financial support was provided by grants from the Institut National du Cancer (PL06-111 to P. J. C.) and the Ligue Nationale contre le Cancer (Equipe labelisee 2007 to P. J. C.). G. F. was the recipient of a Ph. D. fellowship from the Ministere de l'Enseignement Superieur et de la Recherche.	Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; BOUCHARD P, 1981, P NATL ACAD SCI-BIOL, V78, P1033, DOI 10.1073/pnas.78.2.1033; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Campbell KS, 1998, J IMMUNOL, V161, P1728; Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Colin E, 2008, EMBO J, V27, P2124, DOI 10.1038/emboj.2008.133; Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; Dhillon VS, 2004, BRIT J CANCER, V90, P874, DOI 10.1038/sj.bjc.6601567; Faruki S, 2000, J CELL SCI, V113, P2557; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Geahlen RL, 2009, BBA-MOL CELL RES, V1793, P1115, DOI 10.1016/j.bbamcr.2009.03.004; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Guo J, 2006, MOL BIOL CELL, V17, P680, DOI 10.1091/mbc.E05-04-0360; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Higginbotham HR, 2007, TRENDS NEUROSCI, V30, P276, DOI 10.1016/j.tins.2007.04.001; Hoeller C, 2005, J INVEST DERMATOL, V124, P1293, DOI 10.1111/j.0022-202X.2005.23685.x; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Ikeda K, 2011, MOL BIOL CELL, V22, P1321, DOI 10.1091/mbc.E10-09-0741; Ishwaran H, 2001, J AM STAT ASSOC, V96, P161, DOI 10.1198/016214501750332758; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; Kholodenko BN, 2003, J EXP BIOL, V206, P2073, DOI 10.1242/jeb.00298; Kulathu Y, 2009, IMMUNOL REV, V232, P286, DOI 10.1111/j.1600-065X.2009.00837.x; Kunze E, 2008, HISTOL HISTOPATHOL, V23, P539, DOI 10.14670/HH-23.539; Larive RM, 2009, ONCOGENE, V28, P2337, DOI 10.1038/onc.2009.99; Layton T, 2009, AM J PATHOL, V175, P2625, DOI 10.2353/ajpath.2009.090543; Levy JR, 2006, INT J DEV NEUROSCI, V24, P103, DOI 10.1016/j.ijdevneu.2005.11.013; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Mochly-Rosen D, 1998, FASEB J, V12, P35; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; NAGAI K, 1994, J BIOCHEM-TOKYO, V116, P1176, DOI 10.1093/oxfordjournals.jbchem.a124646; Ogane S, 2009, INT J CANCER, V124, P2651, DOI 10.1002/ijc.24237; Park AYJ, 2009, J BIOL CHEM, V284, P9418, DOI 10.1074/jbc.M809040200; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Stupack DG, 1999, J CELL BIOL, V144, P777, DOI 10.1083/jcb.144.4.777; Sulimenko V, 2006, J IMMUNOL, V176, P7243, DOI 10.4049/jimmunol.176.12.7243; Sung YM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007445; TERRELL GR, 1992, ANN STAT, V20, P1236, DOI 10.1214/aos/1176348768; Tohyama Y, 2009, J BIOCHEM, V145, P267, DOI 10.1093/jb/mvp001; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; Uckun FM, 2010, BRIT J HAEMATOL, V148, P714, DOI 10.1111/j.1365-2141.2009.07983.x; Underhill DM, 2007, TRENDS IMMUNOL, V28, P66, DOI 10.1016/j.it.2006.12.004; Ushmorov A, 2006, BLOOD, V107, P2493, DOI 10.1182/blood-2005-09-3765; Walter WJ, 2012, P NATL ACAD SCI USA, V109, P5289, DOI 10.1073/pnas.1116315109; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Wang S, 2004, WORLD J GASTROENTERO, V10, P1815; Xue L, 2012, P NATL ACAD SCI USA, V109, P5615, DOI 10.1073/pnas.1119418109; Yan XM, 2006, MOL BIOL CELL, V17, P634, DOI 10.1091/mbc.E05-08-0810; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Yuan YF, 2006, CLIN CANCER RES, V12, P6687, DOI 10.1158/1078-0432.CCR-06-0921; Zhang XY, 2009, MOL CANCER RES, V7, P634, DOI 10.1158/1541-7786.MCR-08-0371; Zhang YJ, 2008, P NATL ACAD SCI USA, V105, P11760, DOI 10.1073/pnas.0708583105; Zhao SP, 2011, ARCH GYNECOL OBSTET, V283, P1113, DOI 10.1007/s00404-010-1546-6; Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270	72	7	7	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					109	122		10.1096/fj.11-202465	http://dx.doi.org/10.1096/fj.11-202465			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047900				2022-12-28	WOS:000313103200012
J	Wu, YL; Song, WH				Wu, Yili; Song, Weihong			Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis	FASEB JOURNAL			English	Article						Down syndrome; Alzheimer's disease	SYNDROME CRITICAL REGION; DOWN-SYNDROME; INHIBITS CALCINEURIN; EXPRESSION PATTERNS; NEURONAL APOPTOSIS; ALZHEIMERS-DISEASE; CASPASE ACTIVATION; GENE-EXPRESSION; MESSENGER-RNA; DSCR1 ADAPT78	Abnormal expression of regulator of calcineurin 1 (RCAN1) has been implicated in Alzheimer's disease (AD) and Down's syndrome (DS). There are two major isoforms of RCAN1, isoforms 1 and 4. RCAN1 isoform 1 is predominantly expressed in the brain, particularly in neurons. In this report, we showed that there are two translation start codons in RCAN1 exon 1 serving as a functional translation initiation site to generate a longer 41-kDa isoform 1 (RCAN1.1L) and a shorter 31-kDa isoform 1 (RCAN1.1S). The first translation initiation site has higher translation efficiency than the downstream second one, and the translation initiation of two AUG sites is by a Cap-dependent mechanism. Short-term expression of RCAN1.1L protected SH-SY5Y cells from oxidative stress-induced apoptosis by inhibiting caspase-3 activation. However, long-term accumulation of RCAN1.1L in SH-SY5Y cells promoted oxidative stress-induced apoptosis via caspase-3 activation, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that the apoptosis ratio was increased to 499.03 +/- 47.56% in SH-1.1L cells compared with 283.93 +/- 28.66% in control cells. Furthermore, we found that RCAN1.1L is significantly elevated in the AD brains and patients with DS. RCAN1.1S is expressed at a low level in both human cells and brain tissues. Our results defined the regulatory mechanism underlying RCAN1 expression and the roles of RCAN1.1 in oxidative stress-induced neurodegeneration in AD and DS pathogenesis.-Wu, Y., Song, W. Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis. FASEB J. 27, 208-221 (2013). www.fasebj.org	[Wu, Yili; Song, Weihong] Chongqing Med Univ, Childrens Hosp, Chongqing City Key Lab Translat Med Res Cognit De, Chongqing 400014, Peoples R China; [Wu, Yili; Song, Weihong] Chongqing Med Univ, Childrens Hosp, Minist Educ, Key Lab Child Dev & Disorders, Chongqing 400014, Peoples R China; [Wu, Yili; Song, Weihong] Univ British Columbia, Dept Psychiat, Brain Res Ctr, Townsend Family Labs, Vancouver, BC V6T 1Z3, Canada	Chongqing Medical University; Chongqing Medical University; University of British Columbia	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Townsend Family Labs, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@mail.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; wu, yili/0000-0002-2369-6974	Canadian Institutes of Health Research (CIHR) [TAD-117948]; National Natural Science Foundation of China (NSFC) [81161120498]; Arthur & June Willms Fellowships	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Arthur & June Willms Fellowships	The authors thank Drs. Philip Ly and Fang Cai for technical assistance. The authors thank the University of Maryland Brain and Tissue Bank for Developmental Disorders for AD and control brain tissues. This work was supported by Canadian Institutes of Health Research (CIHR) aging pilot grant and operating grant TAD-117948, and National Natural Science Foundation of China (NSFC) grant 81161120498. W. S. is the holder of the Tier 1 Canada Research Chair in Alzheimer's Disease. Y. W. was the recipient of the Arthur & June Willms Fellowships.	Abbasi S, 2006, J BIOL CHEM, V281, P7717, DOI 10.1074/jbc.M510775200; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Bertoni-Freddari C, 2009, ANN NY ACAD SCI, V1171, P18, DOI 10.1111/j.1749-6632.2009.04886.x; Casadei R, 2003, GENE, V321, P185, DOI 10.1016/S0378-1119(03)00835-7; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Cho YJ, 2005, ARCH BIOCHEM BIOPHYS, V439, P121, DOI 10.1016/j.abb.2005.05.002; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06-7246com; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Dierssen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017010; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2006, FEBS J, V273, P2100, DOI 10.1111/j.1742-4658.2006.05217.x; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Ermak G, 2012, J BIOL CHEM, V287, P14088, DOI 10.1074/jbc.M111.305342; Ermak G, 2011, FASEB J, V25, P3306, DOI 10.1096/fj.11-185728; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Genesca L, 2003, BIOCHEM J, V374, P567, DOI 10.1042/BJ20030267; Harris CD, 2007, FEBS J, V274, P1715, DOI 10.1111/j.1742-4658.2007.05717.x; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hirakawa Yasuko, 2009, J Mol Signal, V4, P6, DOI 10.1186/1750-2187-4-6; Hoeffer CA, 2007, J NEUROSCI, V27, P13161, DOI 10.1523/JNEUROSCI.3974-07.2007; Iizuka M, 2004, J VASC RES, V41, P334, DOI 10.1159/000079832; Keating DJ, 2008, HUM MOL GENET, V17, P1020, DOI 10.1093/hmg/ddm374; Kim Y, 2009, J NEUROCHEM, V111, P344, DOI 10.1111/j.1471-4159.2009.06318.x; Leahy KP, 2000, ARCH BIOCHEM BIOPHYS, V379, P221, DOI 10.1006/abbi.2000.1897; Lee J, 2008, J BIOL CHEM, V283, P3392, DOI 10.1074/jbc.M706707200; Liu H, 2009, FASEB J, V23, P3383, DOI 10.1096/fj.09-134296; Liu QH, 2009, NAT CELL BIOL, V11, P154, DOI 10.1038/ncb1823; Liu SC, 2008, EUR J NEUROSCI, V28, P1980, DOI 10.1111/j.1460-9568.2008.06497.x; Liu ZA, 2012, NEUROCHEM RES, V37, P1420, DOI 10.1007/s11064-012-0726-0; Lukiw WJ, 2010, MOL NEUROBIOL, V42, P10, DOI 10.1007/s12035-010-8126-4; Martin KR, 2012, HUM MOL GENET, V21, P3025, DOI 10.1093/hmg/dds134; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Minami T, 2009, J CLIN INVEST, V119, P2257, DOI 10.1172/JCI35738; Qin LL, 2006, MOL CANCER RES, V4, P811, DOI 10.1158/1541-7786.MCR-06-0126; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Ryeom S, 2009, J CRANIOFAC SURG, V20, P595, DOI 10.1097/SCS.0b013e3181927f47; Saeki M, 2007, J BIOL CHEM, V282, P11786, DOI 10.1074/jbc.M609347200; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shou Y, 2004, BIOCHEM J, V379, P805, DOI 10.1042/BJ20031107; Sobrado M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-48; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; SONG WH, 1995, NUCLEIC ACIDS RES, V23, P3609, DOI 10.1093/nar/23.17.3609; Springer JE, 2000, J NEUROSCI, V20, P7246; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Sun XL, 2011, J BIOL CHEM, V286, P9049, DOI 10.1074/jbc.M110.177519; Takuma Kazuhiro, 2009, Folia Pharmacologica Japonica, V134, P180; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Ventoso I, 1998, J BIOL CHEM, V273, P27960, DOI 10.1074/jbc.273.43.27960; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	64	56	58	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					208	221		10.1096/fj.12-213124	http://dx.doi.org/10.1096/fj.12-213124			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038757				2022-12-28	WOS:000313103200020
J	Gavins, FNE; Hughes, EL; Buss, NAPS; Holloway, PM; Getting, SJ; Buckingham, JC				Gavins, Felicity N. E.; Hughes, Ellen L.; Buss, Nicholas A. P. S.; Holloway, Paul M.; Getting, Stephen J.; Buckingham, Julia C.			Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system	FASEB JOURNAL			English	Article						endotoxemia; FPR	FORMYL-PEPTIDE RECEPTOR; TUMOR-NECROSIS-FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; SEPTIC SHOCK; LIPOCORTIN 1; EXPRESSION; NEUROINFLAMMATION; INFLAMMATION; ACTIVATION; MD-2	Unregulated inflammation underlies many diseases, including sepsis. Much interest lies in targeting anti-inflammatory mechanisms to develop new treatments. One such target is the anti-inflammatory protein annexin A1 (AnxA1) and its receptor, FPR2/ALX. Using intravital videomicroscopy, we investigated the role of AnxA1 and FPR2/ALX in a murine model of endotoxin-induced cerebral inflammation [intraperitoneal injection of lipopolysaccharide (LPS)]. An inflammatory response was confirmed by elevations in proinflammatory serum cytokines, increased cerebrovascular permeability, elevation in brain myeloperoxidase, and increased leukocyte rolling and adhesion in cerebral venules of wild-type (WT) mice, which were further exacerbated in AnxA1-null mice. mRNA expression of TLR2, TLR4, MyD-88, and Ly96 was also assessed. The AnxA1-mimetic peptide, AnxA1(Ac2-26) (100 mu g/mouse, similar to 33 mu mol) mitigated LPS-induced leukocyte adhesion in WT and AnxA1-null animals without affecting leukocyte rolling, in comparison to saline control. AnxA1(Ac2-26) effects were attenuated by Boc2 (pan-FPR antagonist, 10 mu g/mouse, similar to 12 nmol), and by minocycline (2.25 mg/mouse, similar to 6.3 nmol). The nonselective Fpr agonists, fMLP (6 mu g/mouse, similar to 17 nmol) and AnxA1(Ac2-26), and the Fpr2-selective agonist ATLa (5 mu g/mouse, similar to 11 nmol) were without effect in Fpr2/3(-/-) mice. In summary, our novel results demonstrate that the AnxA1/FPR2 system has an important role in effecting the resolution of cerebral inflammation in sepsis and may, therefore, provide a novel therapeutic target.-Gavins, F. N. E., Hughes, E. L., Buss, N. A. P. S., Holloway, P. M., Getting, S. J., Buckingham, J. C. Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system. FASEB J. 26, 4977-4989 (2012). www.fasebj.org	[Gavins, Felicity N. E.; Hughes, Ellen L.; Holloway, Paul M.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, London W12 0NN, England; [Buss, Nicholas A. P. S.; Buckingham, Julia C.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Diabet, London W12 0NN, England; [Getting, Stephen J.] Univ Westminster, London W1R 8AL, England	Imperial College London; Imperial College London; University of Westminster	Gavins, FNE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, Hammersmith Hosp Campus,Burlington Danes Bldg,Du, London W12 0NN, England.	f.gavins@imperial.ac.uk	Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423; Holloway, Paul/0000-0002-1947-4885; Buss, Nicholas/0000-0002-8226-4311	UK Biotechnology and Biological Sciences Research Council (BBSRC) Integrative Mammalian Biology (IMB) fund; IMB grant; BBSRC; GlaxoSmithKline (Stevenage, UK); BBSRC [BB/E52708X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: researchfish; British Heart Foundation [FS/09/020/27184] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council (BBSRC) Integrative Mammalian Biology (IMB) fund(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); IMB grant; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GlaxoSmithKline (Stevenage, UK)(GlaxoSmithKline); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation)	This work was supported by a grant to J.C.B. from the UK Biotechnology and Biological Sciences Research Council (BBSRC) Integrative Mammalian Biology (IMB) fund. F.N.E.G. is funded by the IMB grant. E. L. H. is funded by a BBSRC doctoral training award, and N.A.P.S.B. is funded by GlaxoSmithKline (Stevenage, UK). The authors also thank Dr. Pascal F. Durrenberger for his invaluable help and expertise, and Prof. Richard Reynolds for the use of his imaging facility. The authors declare no conflicts of interest.	Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006; Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Akrout N, 2009, CURR NEUROPHARMACOL, V7, P296, DOI 10.2174/157015909790031175; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bamberger ME, 2001, MICROSC RES TECHNIQ, V54, P59, DOI 10.1002/jemt.1121; Banks WA, 2010, BRAIN BEHAV IMMUN, V24, P102, DOI 10.1016/j.bbi.2009.09.001; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Bylund J, 2002, INFECT IMMUN, V70, P2908, DOI 10.1128/IAI.70.6.2908-2914.2002; Cai B., 2010, MEDIAT INFLAMM, V10, P642; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; CIRINO G, 1993, BRIT J PHARMACOL, V108, P573, DOI 10.1111/j.1476-5381.1993.tb12843.x; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; Damazo AS, 2005, AM J PATHOL, V166, P1607, DOI 10.1016/S0002-9440(10)62471-6; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Dunn AJ, 2006, CLIN NEUROSCI RES, V6, P52, DOI 10.1016/j.cnr.2006.04.002; El Kebir D, 2008, J LEUKOCYTE BIOL, V84, P600, DOI 10.1189/jlb.1107765; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; Gavins FNE, 2007, FASEB J, V21, P1751, DOI 10.1096/fj.06-7842com; Gavins FNE, 2010, TRENDS PHARMACOL SCI, V31, P266, DOI 10.1016/j.tips.2010.04.001; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Hoshino K, 1999, J IMMUNOL, V162, P3749; Imai Y, 2002, GLIA, V40, P164, DOI 10.1002/glia.10149; Jacob A, 2007, LAB INVEST, V87, P1186, DOI 10.1038/labinvest.3700686; Le YY, 2000, J NEUROIMMUNOL, V111, P102, DOI 10.1016/S0165-5728(00)00373-8; Le YY, 2004, J IMMUNOL, V173, P962, DOI 10.4049/jimmunol.173.2.962; Lefkowitz DL, 2008, FREE RADICAL BIO MED, V45, P726, DOI 10.1016/j.freeradbiomed.2008.05.021; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Liu N, 2004, J NEUROSCI RES, V77, P391, DOI 10.1002/jnr.20167; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Merson TD, 2010, NEUROMOL MED, V12, P99, DOI 10.1007/s12017-010-8112-z; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x; PERRETTI M, 1993, J IMMUNOL, V151, P4306; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Peter C, 2010, SHOCK, V33, P405, DOI 10.1097/SHK.0b013e3181b77e82; Pytel P, 2009, CURR OPIN NEUROL, V22, P283, DOI 10.1097/WCO.0b013e32832b3101; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Sam Albert D. Ii, 1997, Frontiers in Bioscience, V2, pE72; Sandanger O, 2009, J IMMUNOL, V182, P588, DOI 10.4049/jimmunol.182.1.588; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Tsuge M, 2010, MICROBIOL IMMUNOL, V54, P417, DOI 10.1111/j.1348-0421.2010.00226.x; Turrin NP, 2006, MOL NEUROBIOL, V34, P221, DOI 10.1385/MN:34:3:221; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Weighardt H, 2002, J IMMUNOL, V169, P2823, DOI 10.4049/jimmunol.169.6.2823; Yona S, 2004, BRIT J PHARMACOL, V142, P890, DOI 10.1038/sj.bjp.0705858	59	57	66	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4977	4989		10.1096/fj.12-205971	http://dx.doi.org/10.1096/fj.12-205971			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964301				2022-12-28	WOS:000311838300020
J	Hudson, BD; Christiansen, E; Tikhonova, IG; Grundmann, M; Kostenis, E; Adams, DR; Ulven, T; Milligan, G				Hudson, Brian D.; Christiansen, Elisabeth; Tikhonova, Irina G.; Grundmann, Manuel; Kostenis, Evi; Adams, David R.; Ulven, Trond; Milligan, Graeme			Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs	FASEB JOURNAL			English	Article						GPCR; RASSL	PROTEIN-COUPLED RECEPTORS; FUNCTIONAL-CHARACTERIZATION; INTERNATIONAL UNION; SORBIC ACID; BINDING; GPR43; IDENTIFICATION; ACTIVATION; ALLOSTERISM; DISCOVERY	When it is difficult to develop selective ligands within a family of related G-protein-coupled receptors (GPCRs), chemically engineered receptors activated solely by synthetic ligands (RASSLs) are useful alternatives for probing receptor function. In the present work, we explored whether a RASSL of the free fatty acid receptor 2 (FFA2) could be developed on the basis of pharmacological variation between species orthologs. For this, bovine FFA2 was characterized, revealing distinct ligand selectivity compared with human FFA2. Homology modeling and mutational analysis demonstrated a single mutation in human FFA2 of C4.57G resulted in a human FFA2 receptor with ligand selectivity similar to the bovine receptor. This was exploited to generate human FFA2-RASSL by the addition of a second mutation at a known orthosteric ligand interaction site, H6.55Q. The resulting FFA2-RASSL displayed a >100-fold loss of activity to endogenous ligands, while responding to the distinct ligand sorbic acid with pEC(50) values for inhibition of cAMP, 5.83 +/- 0.11; Ca2+ mobilization, 4.63 +/- 0.05; ERK phosphorylation, 5.61 +/- 0.06; and dynamic mass redistribution, 5.35 +/- 0.06. This FFA2-RASSL will be useful in future studies on this receptor and demonstrates that exploitation of pharmacological variation between species orthologs is a powerful method to generate novel chemically engineered GPCRs.-Hudson, B. D., Christiansen, E., Tikhonova, I. G., Grundmann, M., Kostenis, E., Adams, D. R., Ulven, T., Milligan, G. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J. 26, 4951-4965 (2012). www.fasebj.org	[Hudson, Brian D.; Milligan, Graeme] Univ Glasgow, Mol Pharmacol Grp, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [Christiansen, Elisabeth; Ulven, Trond] Univ So Denmark, Dept Phys Chem & Pharm, Odense, Denmark; [Tikhonova, Irina G.] Queens Univ Belfast, Sch Pharm, Ctr Med Biol, Belfast, Antrim, North Ireland; [Grundmann, Manuel; Kostenis, Evi] Univ Bonn, Inst Pharmaceut Biol, Mol Cellular & Pharmacobiol Sect, Bonn, Germany; [Adams, David R.] Heriot Watt Univ, Dept Chem, Sch Engn & Phys Sci, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Southern Denmark; Queens University Belfast; University of Bonn; Heriot Watt University	Milligan, G (corresponding author), Univ Glasgow, Mol Pharmacol Grp, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Wolfson Link Bldg 253, Glasgow G12 8QQ, Lanark, Scotland.	graeme.milligan@glasgow.ac.uk	Milligan, Graeme/F-9426-2011; Rexen Ulven, Elisabeth/S-2026-2017; Adams, David R/E-3916-2010; Hudson, B. D./H-4845-2013; Ulven, Trond/H-5500-2015	Milligan, Graeme/0000-0002-6946-3519; Rexen Ulven, Elisabeth/0000-0003-1243-7587; Adams, David R/0000-0002-7154-7332; Hudson, B. D./0000-0001-7059-0091; Ulven, Trond/0000-0002-8135-1755; Grundmann, Manuel/0000-0002-4473-7851	Wellcome Trust [089600/Z/09/Z]; Danish Council for Strategic Research [11-116196]; Canadian Institutes of Health Research	Wellcome Trust(Wellcome TrustEuropean Commission); Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	These studies were supported by the Wellcome Trust (grant 089600/Z/09/Z to G. M.), the Danish Council for Strategic Research (grant 11-116196 to T. U., G. M., and E. K.), and a Canadian Institutes of Health Research Fellowship (to B.D.H.).	Alvarez-Curto E, 2011, MOL PHARMACOL, V80, P1033, DOI 10.1124/mol.111.074674; Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Claeysen S, 2003, J BIOL CHEM, V278, P699, DOI 10.1074/jbc.C200588200; Congreve M, 2011, ADV PHARMACOL, V62, P1, DOI 10.1016/B978-0-12-385952-5.00011-7; Conklin BR, 2008, NAT METHODS, V5, P673, DOI 10.1038/nmeth.1232; Ge HF, 2008, ENDOCRINOLOGY, V149, P4519, DOI 10.1210/en.2008-0059; Guettier JM, 2009, P NATL ACAD SCI USA, V106, P19197, DOI 10.1073/pnas.0906593106; Hanson MA, 2009, STRUCTURE, V17, P8, DOI 10.1016/j.str.2008.12.003; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Hudson BD, 2011, ADV PHARMACOL, V62, P175, DOI 10.1016/B978-0-12-385952-5.00006-3; Kebede MA, 2009, DIABETES OBES METAB, V11, P10, DOI 10.1111/j.1463-1326.2009.01114.x; Kenakin T, 2007, MOL PHARMACOL, V72, P1393, DOI 10.1124/mol.107.040352; Knicky M, 2009, J SCI FOOD AGR, V89, P2659, DOI 10.1002/jsfa.3771; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lee T, 2008, MOL PHARMACOL, V74, P1599, DOI 10.1124/mol.108.049536; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; LUCK E, 1990, FOOD ADDIT CONTAM, V7, P711, DOI 10.1080/02652039009373936; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Milligan G, 2009, BRIT J PHARMACOL, V158, P146, DOI 10.1111/j.1476-5381.2009.00421.x; Offermanns S, 2011, PHARMACOL REV, V63, P269, DOI 10.1124/pr.110.003301; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Sasaki K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020360; Schmidt J, 2011, J BIOL CHEM, V286, P10628, DOI 10.1074/jbc.M110.210872; Schroder R, 2011, NAT PROTOC, V6, P1748, DOI 10.1038/nprot.2011.386; Schroder R, 2010, NAT BIOTECHNOL, V28, P943, DOI 10.1038/nbt.1671; Sina C, 2009, J IMMUNOL, V183, P7514, DOI 10.4049/jimmunol.0900063; Sleeth ML, 2010, NUTR RES REV, V23, P135, DOI 10.1017/S0954422410000089; Smith NJ, 2011, MOL PHARMACOL, V80, P163, DOI 10.1124/mol.110.070789; Smith NJ, 2009, J BIOL CHEM, V284, P17527, DOI 10.1074/jbc.M109.012849; Stoddart LA, 2008, J BIOL CHEM, V283, P32913, DOI 10.1074/jbc.M805601200; Stoddart LA, 2010, METHOD ENZYMOL, V484, P569, DOI [10.1016/S0076-6879(10)84028-5, 10.1016/B978-0-12-381298-8.00028-9]; Stoddart LA, 2008, PHARMACOL REV, V60, P405, DOI 10.1124/pr.108.00802; Sum CS, 2007, J BIOL CHEM, V282, P29248, DOI 10.1074/jbc.M705077200; Swaminath G, 2008, ARCH PHARM, V341, P755, DOI 10.1002/ardp.200800096; Tikhonova IG, 2008, J MED CHEM, V51, P625, DOI 10.1021/jm7012425; Tiwari A, 2010, CURR OPIN INVEST DR, V11, P385; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Vinolo MAR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021205; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; WALKER R, 1990, FOOD ADDIT CONTAM, V7, P671, DOI 10.1080/02652039009373932; Wang A, 2012, J DAIRY SCI, V95, P1371, DOI 10.3168/jds.2011-4886; Wang A, 2009, J DAIRY SCI, V92, P2696, DOI 10.3168/jds.2009-2037; Zaibi MS, 2010, FEBS LETT, V584, P2381, DOI 10.1016/j.febslet.2010.04.027	47	60	60	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					4951	4965		10.1096/fj.12-213314	http://dx.doi.org/10.1096/fj.12-213314			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22919070	Green Published, Green Accepted			2022-12-28	WOS:000311838300018
J	Hulpke, S; Baldauf, C; Tampe, R				Hulpke, Sabine; Baldauf, Christoph; Tampe, Robert			Molecular architecture of the MHC I peptide-loading complex: one tapasin molecule is essential and sufficient for antigen processing	FASEB JOURNAL			English	Article						ABC transporter; adaptive immunity; ER quality control; membrane protein complex; molecular immunology	CROSS-PRESENTATION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; TRANSPORTER; TAP; EXPRESSION; HLA; ASSOCIATION; COMPARTMENT	The loading of antigen-derived peptides onto MHC class I molecules for presentation to cytotoxic T cells is a key process in adaptive immune defense. Loading of MHC I is achieved by a sophisticated machinery, the peptide-loading complex (PLC), which is organized around the transporter associated with antigen processing (TAP) with the help of several auxiliary proteins. As an essential adapter protein recruiting MHC I molecules to TAP, tapasin catalyzes peptide loading of MHC I. However, the exact stoichiometry and basic molecular architecture of TAP and tapasin within the PLC remains elusive. Here, we demonstrate that two tapasin molecules are assembled in the PLC, with one tapasin bound to each TAP subunit. However, one tapasin molecule bound either to TAP1 or TAP2 is sufficient for efficient MHC I antigen presentation. By specifically blocking the interaction between tapasin-MHC I complexes and the translocation complex TAP, the MHC I surface expression is impaired to the same extent as with soluble tapasin. Thus, the proximity of the peptide supplier TAP to the acceptor MHC I is crucial for antigen processing. In summary, the human PLC consists maximally of 2x tapasin-ERp57/MHC I per TAP complex, but one tapasin-ERp57/MHC I in the PLC is essential and sufficient for antigen processing.-Hulpke, S., Baldauf, C., Tampe, R. Molecular architecture of the MHC I peptide-loading complex: one tapasin molecule is essential and sufficient for antigen processing. FASEB J. 26, 5071-5080 (2012). www.fasebj.org	[Hulpke, Sabine; Baldauf, Christoph; Tampe, Robert] Goethe Univ Frankfurt, Inst Biochem Bioctr & Cluster Excellence Frankfur, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem Bioctr & Cluster Excellence Frankfur, Max von Laue Str 9, D-60438 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160	European Commission; German Research Foundation [SFB 807, TA157/7]; European Drug Initiative on Channels and Transporters (EDICT)	European Commission(European CommissionEuropean Commission Joint Research Centre); German Research Foundation(German Research Foundation (DFG)); European Drug Initiative on Channels and Transporters (EDICT)	The authors thank Drs. Rupert Abele, Peter Mayerhofer, Andreas Hinz, David Parcej, and Roger Draheim for helpful discussions and comments on the manuscript, as well as Hanna Fischbach for helping on experiments. The authors acknowledge the generous support by Daniel Oprian (Brandeis University, Waltham, MA, USA), who provided the anti-C8 mAb in the initial phase of the project. The anti-C8 mAb was obtained via the AIDS Research and Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, Bethesda, MD, USA; Chessie 8 from Dr. George Lewis). The German Research Foundation (SFB 807 Transport and Communication across Biological Membranes and TA157/7 to R. T.) and the European Drug Initiative on Channels and Transporters (EDICT; to R. T.), funded by the European Commission Seventh Framework Program, supported this work.	ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Burgdorf S, 2008, NAT IMMUNOL, V9, P558, DOI 10.1038/ni.1601; Chen MN, 2007, EMBO J, V26, P1681, DOI 10.1038/sj.emboj.7601624; Cormier JN, 1999, INT J CANCER, V80, P781, DOI 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; Dong G, 2009, IMMUNITY, V30, P21, DOI 10.1016/j.immuni.2008.10.018; Estrozi LF, 2011, NAT STRUCT MOL BIOL, V18, P88, DOI 10.1038/nsmb.1952; Everett MW, 2007, J IMMUNOL, V179, P7646, DOI 10.4049/jimmunol.179.11.7646; Garbi N, 2003, EUR J IMMUNOL, V33, P264, DOI 10.1002/immu.200390029; Garstka MA, 2011, FASEB J, V25, P3989, DOI 10.1096/fj.11-190249; Ghanem E, 2010, J CELL SCI, V123, P4271, DOI 10.1242/jcs.060632; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; Hulpke S., 2012, MOL CELL LIFE SCI, DOI [10.1007/s00018-012-1005-6, DOI 10.1007/S00018-012-1005-6]; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; MARINCOLA FM, 1994, J IMMUNOL, V153, P1225; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Oancea G, 2009, P NATL ACAD SCI USA, V106, P5551, DOI 10.1073/pnas.0811260106; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Panter MS, 2012, J BIOL CHEM, V287, P31172, DOI 10.1074/jbc.M112.387704; Papadopoulos M, 2007, J BIOL CHEM, V282, P9401, DOI 10.1074/jbc.M610429200; Parcej D, 2010, NAT CHEM BIOL, V6, P572, DOI [10.1038/NCHEMBIO.410, 10.1038/nchembio.410]; Paulsson KM, 2006, J IMMUNOL, V176, P7482, DOI 10.4049/jimmunol.176.12.7482; Paulsson KM, 2002, J BIOL CHEM, V277, P18266, DOI 10.1074/jbc.M201388200; Paulsson KM, 2001, INT IMMUNOL, V13, P23, DOI 10.1093/intimm/13.1.23; Peaper DR, 2008, ANNU REV CELL DEV BI, V24, P343, DOI 10.1146/annurev.cellbio.24.110707.175347; Peaper DR, 2005, EMBO J, V24, P3613, DOI 10.1038/sj.emboj.7600814; Petersen JL, 2005, J IMMUNOL, V174, P962, DOI 10.4049/jimmunol.174.2.962; Praveen PVK, 2010, EUR J IMMUNOL, V40, P214, DOI 10.1002/eji.200939342; Raghuraman G, 2002, J BIOL CHEM, V277, P41786, DOI 10.1074/jbc.M207128200; Rizvi SM, 2010, TRAFFIC, V11, P332, DOI 10.1111/j.1600-0854.2009.01025.x; Roder G, 2011, J BIOL CHEM, V286, P20547, DOI 10.1074/jbc.M111.230151; Rufer E, 2007, J IMMUNOL, V179, P5717, DOI 10.4049/jimmunol.179.9.5717; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schneeweiss C, 2009, MOL IMMUNOL, V46, P2054, DOI 10.1016/j.molimm.2009.02.032; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Simone LC, 2012, MOL IMMUNOL, V49, P628, DOI 10.1016/j.molimm.2011.11.002; Simone LC, 2009, MOL IMMUNOL, V46, P2147, DOI 10.1016/j.molimm.2009.03.006; Simone LC, 2009, IMMUNOGENETICS, V61, P43, DOI 10.1007/s00251-008-0335-x; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vigneron N, 2009, EUR J IMMUNOL, V39, P2371, DOI 10.1002/eji.200939536; Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287	52	20	25	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5071	5080		10.1096/fj.12-217489	http://dx.doi.org/10.1096/fj.12-217489			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22923333				2022-12-28	WOS:000311838300028
J	Karakikes, I; Morrison, IEG; O'Toole, P; Metodieva, G; Navarrete, CV; Gomez, J; Miranda-Sayago, JM; Cherry, RJ; Metodiev, M; Fernandez, N				Karakikes, Ioannis; Morrison, Ian E. G.; O'Toole, Peter; Metodieva, Gergana; Navarrete, Cristina V.; Gomez, Jesus; Miranda-Sayago, Jose M.; Cherry, Richard J.; Metodiev, Metodi; Fernandez, Nelson			Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single particle image analysis	FASEB JOURNAL			English	Article						dendritic cells; monocytes; phycobiliprotein	MHC CLASS-II; INVARIANT CHAIN CD74; DENDRITIC CELLS; LIVING CELLS; RAPID INTERNALIZATION; CYTOPLASMIC TAIL; EARLY ENDOSOMES; MOLECULES; BINDING; ENDOCYTOSIS	Major histocompatibility complex (MHC) class II-associated antigen presentation involves an array of interacting molecules. CD74, the cell surface isoform of the MHC class II-associated invariant chain, is one such molecule; its role remains poorly defined. To address this, we have employed a high-resolution single-particle imaging method for quantifying the colocalization of CD74 with human leukocyte antigen (HLA)-DR molecules on human fibroblast cells known for their capacity to function as antigen-presenting cells. We have also examined whether the colocalization induces internalization of HLA-DR using HA(307-319), a "universal" peptide that binds specifically to the peptide-binding groove of all HLA-DR molecules, irrespective of their alleles. We have determined that 25 +/- 1.3% of CD74 and 17 +/- 0.3% of HLA-DR are colocalized, and the association of CD74 with HLA-DR and the internalization of HLA-DR are both inhibited by HA(307-319). A similar inhibition of HLA-DR internalization was observed in freshly isolated monocyte-derived dendritic cells. A key role of CD74 is to translocate HLA-DR molecules to early endosomes for reloading with peptides prior to recycling to the cell surface. We conclude that CD74 regulates the balance of peptide-occupied and peptide-free forms of MHC class II at the cell surface.-Karakikes, I., Morrison, I. E. G., O'Toole, P., Metodieva, G., Navarrete, C. V., Gomez, J., Miranda-Sayago, J. M., Cherry, R. J., Metodiev, M., Fernandez, N. Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single-particle image analysis. FASEB J. 26, 4886-4896 (2012). www.fasebj.org	[Karakikes, Ioannis; Morrison, Ian E. G.; Metodieva, Gergana; Miranda-Sayago, Jose M.; Cherry, Richard J.; Metodiev, Metodi; Fernandez, Nelson] Univ Essex, Sch Biol Sci, Colchester C04 3SQ, Essex, England; [O'Toole, Peter] Univ York, Dept Biol, Imaging & Cytometry Lab, Technol Facil, York YO10 5DD, N Yorkshire, England; [Navarrete, Cristina V.; Gomez, Jesus] Natl Blood Ctr, Histocompatibil & Immunogenet Res Dept, London, England	University of Essex; University of York - UK	Fernandez, N (corresponding author), Univ Essex, Sch Biol Sci, Wivenhoe Pk, Colchester C04 3SQ, Essex, England.	nelson@essex.ac.uk	Miranda-Sayago, Jose/F-9620-2014	O'Toole, Peter John/0000-0001-5295-2001; Metodiev, Metodi V/0000-0001-6810-0719; Karakikes, Ioannis/0000-0002-4348-600X	UK Biotechnology and Biological Sciences Research Council; Wellcome Trust	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Prof. R. Lechler (King's College, London, UK) for providing the M1DR1 transfectant cell line series. The authors also thank Prof. I. McLennan (University of Birmingham, Birmingham, UK) for the monoclonal antibody BU45 and Dr. K. Guy (University of Strathclyde, Glasgow, UK) for the antibody DA6.231. The authors thank the UK Biotechnology and Biological Sciences Research Council and Wellcome Trust for support.	Basha G, 2012, NAT IMMUNOL, V13, P237, DOI 10.1038/ni.2225; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; BREMNES B, 1994, J CELL SCI, V107, P2021; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; Castellino F, 2001, EUR J IMMUNOL, V31, P841, DOI 10.1002/1521-4141(200103)31:3<841::AID-IMMU841>3.0.CO;2-D; Cefai D, 1998, J IMMUNOL, V160, P2223; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Cherry RJ, 1998, J CELL BIOL, V140, P71, DOI 10.1083/jcb.140.1.71; DAVIS JE, 1990, J IMMUNOL, V144, P990; DODI AI, 1994, EUR J IMMUNOL, V24, P1632, DOI 10.1002/eji.1830240727; Dugast M, 2005, J BIOL CHEM, V280, P19656, DOI 10.1074/jbc.M501357200; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; FERNANDEZ N, 1991, ELECTROPHORESIS, V12, P523, DOI 10.1002/elps.1150120711; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; Greenwood C, 2012, J PROTEOMICS, V75, P3031, DOI 10.1016/j.jprot.2011.11.033; Griffin JP, 1997, J IMMUNOL, V158, P1523; HARDING CV, 1989, J IMMUNOL, V142, P12; Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x; Huppa JB, 2010, NATURE, V463, P963, DOI 10.1038/nature08746; Illingworth JJ, 2012, IMMUNOLOGY, V135, P198, DOI 10.1111/j.1365-2567.2011.03537.x; Koyama-Honda I, 2005, BIOPHYS J, V88, P2126, DOI 10.1529/biophysj.104.048967; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lightstone L, 1997, P NATL ACAD SCI USA, V94, P5772, DOI 10.1073/pnas.94.11.5772; Mashanov GI, 2007, BIOPHYS J, V92, P2199, DOI 10.1529/biophysj.106.081117; Moldenhauer G, 1999, IMMUNOLOGY, V96, P473; Moller F, 2000, J BIOL REG HOMEOS AG, V14, P299; Monji T, 1997, J IMMUNOL, V158, P3155; MORRISON IEG, 1994, BIOPHYS J, V67, P1280, DOI 10.1016/S0006-3495(94)80600-9; Morrison IEG, 2003, BIOPHYS J, V85, P4110, DOI 10.1016/S0006-3495(03)74823-1; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Newcomb JR, 1996, J BIOL CHEM, V271, P24249, DOI 10.1074/jbc.271.39.24249; NYGARD NR, 1994, J IMMUNOL, V152, P1082; Paul P, 2011, CELL, V145, P268, DOI 10.1016/j.cell.2011.03.023; PIETERS J, 1993, J CELL SCI, V106, P831; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; Pinet VM, 1998, EUR J IMMUNOL, V28, P799, DOI 10.1002/(SICI)1521-4141(199803)28:03<799::AID-IMMU799>3.0.CO;2-5; REID PA, 1992, IMMUNOLOGY, V77, P539; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Roucard C, 1996, J BIOL CHEM, V271, P13993, DOI 10.1074/jbc.271.24.13993; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Siebenkotten IM, 1998, J IMMUNOL, V160, P3355; Smith P. R., 1998, MHC, P133; Smith PR, 1999, BIOPHYS J, V76, P3331, DOI 10.1016/S0006-3495(99)77486-2; Stumptner P, 1997, EMBO J, V16, P5807, DOI 10.1038/sj.emboj.7590555; Thayer WP, 1999, J IMMUNOL, V162, P1502; Toomre D, 2010, ANNU REV CELL DEV BI, V26, P285, DOI 10.1146/annurev-cellbio-100109-104048; Trabesinger W, 2001, ANAL CHEM, V73, P1100, DOI 10.1021/ac000810t; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; Wilson KM, 1996, J CELL SCI, V109, P2101; WILSON KM, 1993, IMMUNOLOGY, V79, P331	54	17	20	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4886	4896		10.1096/fj.12-211466	http://dx.doi.org/10.1096/fj.12-211466			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22889831				2022-12-28	WOS:000311838300012
J	Niu, LN; Jiao, K; Qi, YP; Nikonov, S; Yiu, CKY; Arola, DD; Gong, SQ; El-Marakby, A; Carrilho, MRO; Hamrick, MW; Hargreaves, KM; Diogenes, A; Chen, JH; Pashley, DH; Tay, FR				Niu, Li-Na; Jiao, Kai; Qi, Yi-Pin; Nikonov, Sergey; Yiu, Cynthia K. Y.; Arola, Dwayne D.; Gong, Shi-Qiang; El-Marakby, Ahmed; Carrilho, Marcela R. O.; Hamrick, Mark W.; Hargreaves, Kenneth M.; Diogenes, Anibal; Chen, Ji-Hua; Pashley, David H.; Tay, Franklin R.			Intrafibrillar silicification of collagen scaffolds for sustained release of stem cell homing chemokine in hard tissue regeneration	FASEB JOURNAL			English	Article						chemotaxis; bone regeneration; osteogenesis; angiogenesis	ECTOPIC BONE-FORMATION; AMORPHOUS SILICA; FACTOR-I; ANGIOGENESIS; BIOCERAMICS; DISSOLUTION; KINETICS	Traditional bone regeneration strategies relied on supplementation of biomaterials constructs with stem or progenitor cells or growth factors. By contrast, cell homing strategies employ chemokines to mobilize stem or progenitor cells from host bone marrow and tissue niches to injured sites. Although silica-based biomaterials exhibit osteogenic and angiogenic potentials, they lack cell homing capability. Stromal cell-derived factor-1 (SDF-1) plays a pivotal role in mobilization and homing of stem cells to injured tissues. In this work, we demonstrated that 3-dimensional collagen scaffolds infiltrated with intrafibrillar silica are biodegradable and highly biocompatible. They exhibit improved compressive stress-strain responses and toughness over nonsilicified collagen scaffolds. They are osteoconductive and up-regulate expressions of osteogenesis-and angiogenesis-related genes more significantly than nonsilicified collagen scaffolds. In addition, these scaffolds reversibly bind SDF-1 alpha for sustained release of this chemokine, which exhibits in vitro cell homing characteristics. When implanted subcutaneously in an in vivo mouse model, SDF-1 alpha-loaded silicified collagen scaffolds stimulate the formation of ectopic bone and blood capillaries within the scaffold and abrogate the need for cell seeding or supplementation of osteogenic and angiogenic growth factors. Intrafibrillar-silicified collagen scaffolds with sustained SDF-1 alpha release represent a less costly and complex alternative to contemporary cell seeding approaches and provide new therapeutic options for in situ hard tissue regeneration.-Niu, L.-N., Jiao, K., Qi, Y.-P., Nikonov, S., Yiu, C. K. Y., Arola, D. D., Gong, S.-Q., El-Marakby, A., Carrilho, M. R. O., Hamrick, M. W., Hargreaves, K. M., Diogenes, A., Chen, J.-H., Pashley, D. H., Tay, F. R. Intrafibrillar silicification of collagen scaffolds for sustained release of stem cell homing chemokine in hard tissue regeneration. FASEB J. 26, 4517-4529 (2012). www.fasebj.org	[Nikonov, Sergey; El-Marakby, Ahmed; Hamrick, Mark W.; Pashley, David H.; Tay, Franklin R.] Georgia Hlth Sci Univ, Augusta, GA 30912 USA; [Chen, Ji-Hua] Fourth Mil Med Univ, Dept Prosthodont, Sch Stomatol, Xian 710032, Peoples R China; [Qi, Yi-Pin] Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou 510275, Guangdong, Peoples R China; [Yiu, Cynthia K. Y.] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China; [Arola, Dwayne D.] Univ Maryland, Dept Mech Engn, Baltimore, MD 21201 USA; [Gong, Shi-Qiang] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan 430074, Peoples R China; [Carrilho, Marcela R. O.] Univ Bandeirante Sao Paulo, Biomat Res Grp, Sao Paulo, Brazil; [Hargreaves, Kenneth M.; Diogenes, Anibal] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University System of Georgia; Augusta University; Air Force Military Medical University; Sun Yat Sen University; University of Hong Kong; University System of Maryland; University of Maryland Baltimore; Huazhong University of Science & Technology; Universidade Bandeirante de Sao Paulo; University of Texas System; University of Texas Health San Antonio	Tay, FR (corresponding author), Georgia Hlth Sci Univ, Augusta, GA 30912 USA.	jhchen@fmmu.edu.cn; ftay@georgiahealth.edu	Elmarakby, Ahmed/ABF-5055-2021; Carrilho, Marcela/D-1154-2013; Gong, Shi-qiang/HGB-7742-2022; niu, lina/GWR-3585-2022; Yiu, Cynthia/B-2183-2009; Hamrick, Mark/K-1131-2016	Gong, Shi-qiang/0000-0001-9796-4081; jiao, kai/0000-0002-1901-8329; Chen, Ji-hua/0000-0002-1151-0693; /0000-0003-4090-6205	U.S. National Institute of Dental and Craniofacial Research [R01-DE-015306-06]; Georgia Health Sciences University Extramural Success Award; Innovative Pilot Project in Regenerative Medicine; National Nature Science Foundation of China [81130078]; National Key Basic Research Program of China [2012CB526704]; National Center for Research Resources, U.S. National Institutes of Health [P40-RR-017447]; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR017447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015306] Funding Source: NIH RePORTER	U.S. National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Georgia Health Sciences University Extramural Success Award; Innovative Pilot Project in Regenerative Medicine; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program of China(National Basic Research Program of China); National Center for Research Resources, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by U.S. National Institute of Dental and Craniofacial Research grant R01-DE-015306-06 (principal investigator D. H. P), Georgia Health Sciences University Extramural Success Award and Innovative Pilot Project in Regenerative Medicine (principal investigator F. R. T.), National Nature Science Foundation of China grant 81130078 (principal investigator J.-H.C.), and National Key Basic Research Program of China grant 2012CB526704 (principal investigator J.-H.C.). Some of the materials employed in this work were provided by the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White through the National Center for Research Resources, U.S. National Institutes of Health, grant P40-RR-017447. The authors thank Michelle Barnes for secretarial support and Frankie Chan (University of Hong Kong) for help in STEM-EDX analysis.	Alt V, 2011, ACTA BIOMATER, V7, P3773, DOI 10.1016/j.actbio.2011.06.024; Barralet J, 2009, TISSUE ENG PT A, V15, P1601, DOI 10.1089/ten.tea.2007.0370; Chen FM, 2011, BIOMATERIALS, V32, P3189, DOI 10.1016/j.biomaterials.2010.12.032; Collins MJ, 2002, ARCHAEOMETRY, V44, P383, DOI 10.1111/1475-4754.t01-1-00071; Davis DA, 2005, BLOOD, V105, P4561, DOI 10.1182/blood-2004-12-4618; Deshane J, 2007, J EXP MED, V204, P605, DOI 10.1084/jem.20061609; Desimone MF, 2010, ACTA BIOMATER, V6, P3998, DOI 10.1016/j.actbio.2010.05.014; Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602; Dove PM, 2008, P NATL ACAD SCI USA, V105, P9903, DOI 10.1073/pnas.0803798105; Eglin D, 2006, J MATER SCI-MATER M, V17, P161, DOI 10.1007/s10856-006-6820-6; Heinemann S, 2011, ACS APPL MATER INTER, V3, P4323, DOI 10.1021/am200993q; HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151-2916.1991.tb07132.x; Higashino K, 2011, TISSUE ENG PT A, V17, P523, DOI 10.1089/ten.tea.2010.0168; Icenhower JP, 2000, GEOCHIM COSMOCHIM AC, V64, P4193, DOI 10.1016/S0016-7037(00)00487-7; Kasten P, 2005, BIOMATERIALS, V26, P5879, DOI 10.1016/j.biomaterials.2005.03.001; Kato M, 2006, BIOMATERIALS, V27, P3927, DOI 10.1016/j.biomaterials.2006.03.013; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Kim HD, 2012, INTEGR BIOL-UK, V4, P37, DOI 10.1039/c1ib00069a; Kitaori T, 2009, ARTHRITIS RHEUM, V60, P813; Kuraitis D, 2011, J MOL CELL CARDIOL, V51, P187, DOI 10.1016/j.yjmcc.2011.04.011; Lindhorst D, 2010, J BIOMED MATER RES A, V95A, P783, DOI 10.1002/jbm.a.32902; Mao JJ, 2010, TISSUE ENG PART B-RE, V16, P257, DOI 10.1089/ten.TEB.2009.0496; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Mieszawska AJ, 2010, BIOMATERIALS, V31, P8902, DOI 10.1016/j.biomaterials.2010.07.109; Niu LN, 2011, ANGEW CHEM INT EDIT, V50, P11688, DOI 10.1002/anie.201105114; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Ratanavaraporn J, 2011, BIOMATERIALS, V32, P2797, DOI 10.1016/j.biomaterials.2010.12.052; Santos MI, 2010, MACROMOL BIOSCI, V10, P12, DOI 10.1002/mabi.200900107; Shen WL, 2010, BIOMATERIALS, V31, P7239, DOI 10.1016/j.biomaterials.2010.05.040; Shirtliff VJ, 2003, J MATER SCI, V38, P4697, DOI 10.1023/A:1027414700111; Teo AKK, 2010, BIOCHEM J, V428, P11, DOI 10.1042/BJ20100102; Thieme S., 2009, TISSUE ENG PART C-ME, V15, P687; Tsai KS, 2010, J BIOMED MATER RES A, V94A, P673, DOI 10.1002/jbm.a.32693; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Wang XD, 2001, J ORTHOP RES, V19, P1021, DOI 10.1016/S0736-0266(01)00047-X; Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002; Zhai WY, 2012, ACTA BIOMATER, V8, P341, DOI 10.1016/j.actbio.2011.09.008	37	40	44	1	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4517	4529		10.1096/fj.12-210211	http://dx.doi.org/10.1096/fj.12-210211			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859369	Green Published			2022-12-28	WOS:000310574200014
J	Tang, HB; Lee, M; Sharpe, O; Salamone, L; Noonan, EJ; Hoang, CD; Levine, S; Robinson, WH; Shrager, JB				Tang, Huibin; Lee, Myung; Sharpe, Orr; Salamone, Louis; Noonan, Emily J.; Hoang, Chuong D.; Levine, Sanford; Robinson, William H.; Shrager, Joseph B.			Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems	FASEB JOURNAL			English	Article						phosphofructokinase; muscle; diaphragm; mechanical ventilation; Warburg effect; Ets	CONTRACTING SKELETAL-MUSCLE; MECHANICAL VENTILATION; BREAST-CANCER; MITOCHONDRIA; CELLS; ANTIOXIDANTS; METASTASIS; STRATEGY; SURVIVAL; ENZYMES	Glycolysis is the initial step of glucose catabolism and is up-regulated in cancer cells (the Warburg Effect). Such shifts toward a glycolytic phenotype have not been explored widely in other biological systems, and the molecular mechanisms underlying the shifts remain unknown. With proteomics, we observed increased glycolysis in disused human diaphragm muscle. In disused muscle, lung cancer, and H2O2-treated myotubes, we show up-regulation of the rate-limiting glycolytic enzyme muscle-type phosphofructokinase (PFKm, >2 fold, P<0.05) and accumulation of lactate (>150%, P<0.05). Using microRNA profiling, we identify miR-320a as a regulator of PFKm expression. Reduced miR-320a levels (to similar to 50% of control, P<0.05) are associated with the increased PFKm in each of these diverse systems. Manipulation of miR-320a levels both in vitro and in vivo alters PFKm and lactate levels in the expected directions. Further, miR-320a appears to regulate oxidative stress-induced PFKm expression, and reduced miR-320a allows greater induction of glycolysis in response to H2O2 treatment. We show that this microRNA-mediated regulation occurs through PFKm's 3' untranslated region and that Ets proteins are involved in the regulation of PFKm via miR-320a. These findings suggest that oxidative stress-responsive microRNA-320a may regulate glycolysis broadly within nature.-Tang, H., Lee, M., Sharpe, O., Salamone, L., Noonan, E. J., Hoang, C. D., Levine, S., Robinson, W. H., Shrager, J. B. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems. FASEB J. 26, 4710-4721 (2012). www.fasebj.org	[Tang, Huibin; Lee, Myung; Hoang, Chuong D.; Shrager, Joseph B.] Stanford Univ, Sch Med, Div Thorac Surg, Dept Cardiothorac Surg, Stanford, CA 94305 USA; [Sharpe, Orr; Salamone, Louis; Robinson, William H.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; [Sharpe, Orr; Robinson, William H.] Stanford Univ, Sch Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Noonan, Emily J.] Stanford Univ, Sch Med, Div Hematol, Dept Med, Stanford, CA 94305 USA; [Tang, Huibin; Lee, Myung; Sharpe, Orr; Noonan, Emily J.; Hoang, Chuong D.; Robinson, William H.; Shrager, Joseph B.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA; [Levine, Sanford] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA	Stanford University; Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Pennsylvania	Shrager, JB (corresponding author), Stanford Univ, Sch Med, Div Thorac Surg, Dept Cardiothorac Surg, 2nd Floor,Falk Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	shrager@stanford.edu		Robinson, William/0000-0003-4385-704X	Veterans Affairs Merit Review grant; U.S. National Institutes of Health [RO1-HL-078834]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002022] Funding Source: NIH RePORTER	Veterans Affairs Merit Review grant(US Department of Veterans Affairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	The authors are grateful to Dr. Sabah Hussain (McGill University, Montreal, QC, Canada) for sharing MV limb muscle samples and Dr. Marlene Rabinovitch (Stanford University) for sharing the fluorescent dissection scope, Dr. Alejandro Sweet-Cordero (Stanford University) for helpful discussion and advice, and Dr. Xuhuai Ji (Stanford University) for assistance in microarray data analysis. This research was supported by a Veterans Affairs Merit Review grant awarded to J.B.S. and in part by U.S. National Institutes of Health grant RO1-HL-078834 to S.L. The authors disclosed the research results to Stanford Office of Licensing for potential intellectual property.	Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; Crowther GJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE67, DOI 10.1152/ajpendo.2002.282.1.E67; Crowther GJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE74, DOI 10.1152/ajpendo.2002.282.1.E74; Danshina PV, 2001, IUBMB LIFE, V51, P309; Ferreira LMR, 2010, EXP MOL PATHOL, V89, P372, DOI 10.1016/j.yexmp.2010.08.006; Fogg Vanessa C, 2011, Chin J Cancer, V30, P526, DOI 10.5732/cjc.011.10018; Fredriksson K, 2005, ACTA ANAESTH SCAND, V49, P1101, DOI 10.1111/j.1399-6576.2005.00718.x; Garcia M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000615; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gogvadze V, 2010, MOL ASPECTS MED, V31, P60, DOI 10.1016/j.mam.2009.12.004; Goh J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-191; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552; Hulsmans M, 2011, FASEB J, V25, P2515, DOI 10.1096/fj.11-181149; Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC; Ishii N, 2007, CORNEA, V26, pS3, DOI 10.1097/ICO.0b013e31812f6745; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Jahnke VE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008637; Kauhanen S, 1998, ACTA NEUROPATHOL, V95, P165, DOI 10.1007/s004010050782; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Krause U, 1996, AM J PHYSIOL-REG I, V270, pR821, DOI 10.1152/ajpregu.1996.270.4.R821; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Leite TC, 2011, FEBS LETT, V585, P92, DOI 10.1016/j.febslet.2010.11.009; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Liddell JR, 2009, J NEUROSCI RES, V87, P2696, DOI 10.1002/jnr.22093; Ling HY, 2009, CLIN EXP PHARMACOL P, V36, pe32, DOI 10.1111/j.1440-1681.2009.05207.x; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Maughan DW, 2005, MOL CELL PROTEOMICS, V4, P1541, DOI 10.1074/mcp.M500053-MCP200; Najafov A, 2010, P NATL ACAD SCI USA, V107, P19135, DOI 10.1073/pnas.1014047107; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; RADY P, 1979, J CANCER RES CLIN, V95, P287, DOI 10.1007/BF00410650; Schaar DG, 2009, EXP HEMATOL, V37, P245, DOI 10.1016/j.exphem.2008.10.002; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Sepramaniam S, 2010, J BIOL CHEM, V285, P29223, DOI 10.1074/jbc.M110.144576; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Siu PM, 2009, LIFE SCI, V84, P468, DOI 10.1016/j.lfs.2009.01.014; Sotgia F, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-62; Tang HB, 2006, P NATL ACAD SCI USA, V103, P16977, DOI 10.1073/pnas.0601565103; Tang HB, 2011, FASEB J, V25, P2921, DOI 10.1096/fj.11-183798; Verschoor ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013565; Wilson LA, 2005, FASEB J, V19, P2085, DOI 10.1096/fj.05-4401fje; Wu SB, 2012, BBA-MOL BASIS DIS, V1822, P233, DOI 10.1016/j.bbadis.2011.09.014; Xu RH, 2005, CANCER RES, V65, P613; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808	53	81	87	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4710	4721		10.1096/fj.11-197467	http://dx.doi.org/10.1096/fj.11-197467			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22767230	Green Published			2022-12-28	WOS:000310574200031
J	Kurt, S; Sausbier, M; Ruttiger, L; Brandt, N; Moeller, CK; Kindler, J; Sausbier, U; Zimmermann, U; van Straaten, H; Neuhuber, W; Engel, J; Knipper, M; Ruth, P; Schulze, H				Kurt, Simone; Sausbier, Matthias; Ruettiger, Lukas; Brandt, Niels; Moeller, Christoph K.; Kindler, Jennifer; Sausbier, Ulrike; Zimmermann, Ulrike; van Straaten, Harald; Neuhuber, Winfried; Engel, Jutta; Knipper, Marlies; Ruth, Peter; Schulze, Holger			Critical role for cochlear hair cell BK channels for coding the temporal structure and dynamic range of auditory information for central auditory processing	FASEB JOURNAL			English	Article						hair cell-specific BK channel-knockout mice; in vivo electrophysiology; inferior colliculus; discrimination learning	THYROID-HORMONE DEFICIENCY; K+ CHANNELS; MOUSE; EXPRESSION; MICE; HEARING; MEMBRANE; DEAFNESS; CURRENTS; PRESTIN	Large conductance, voltage-and Ca2+ activated K+ (BK) channels in inner hair cells (IHCs) of the cochlea are essential for hearing. However, germline deletion of BK alpha, the pore-forming subunit KCNMA1 of the BK channel, surprisingly did not affect hearing thresholds in the first postnatal weeks, even though altered IHC membrane time constants, decreased IHC receptor potential alternating current/direct current ratio, and impaired spike timing of auditory fibers were reported in these mice. To investigate the role of IHC BK channels for central auditory processing, we generated a conditional mouse model with hair cell-specific deletion of BK alpha from postnatal day 10 onward. This had an unexpected effect on temporal coding in the central auditory system: neuronal single and multiunit responses in the inferior colliculus showed higher excitability and greater precision of temporal coding that may be linked to the improved discrimination of temporally modulated sounds observed in behavioral training. The higher precision of temporal coding, however, was restricted to slower modulations of sound and reduced stimulus-driven activity. This suggests a diminished dynamic range of stimulus coding that is expected to impair signal detection in noise. Thus, BK channels in IHCs are crucial for central coding of the temporal fine structure of sound and for detection of signals in a noisy environment.-Kurt, S., Sausbier, M., Ruttiger, L., Brandt, N., Moeller, C. K., Kindler, J., Sausbier, U., Zimmermann, U., van Straaten, H., Neuhuber, W., Engel, J., Knipper, M., Ruth, P., Schulze, H. Critical role for cochlear hair cell BK channels for coding the temporal structure and dynamic range of auditory information for central auditory processing. FASEB J. 26, 3834-3843 (2012). www.fasebj.org	[Kurt, Simone] Univ Ulm, Inst Neurobiol, D-80081 Ulm, Germany; [Sausbier, Matthias; Sausbier, Ulrike; Ruth, Peter] Univ Tubingen, Dept Pharmacol & Toxicol, Inst Pharm, Tubingen, Germany; [Ruettiger, Lukas; Zimmermann, Ulrike; van Straaten, Harald; Knipper, Marlies] Univ Tubingen, Dept Otorhinolaryngol, Tubingen, Germany; [Brandt, Niels; Engel, Jutta] Univ Tubingen, Inst Physiol 2, D-7400 Tubingen, Germany; [Brandt, Niels; Zimmermann, Ulrike; van Straaten, Harald; Engel, Jutta; Knipper, Marlies] Univ Tubingen, Tubingen Hearing Res Ctr, Tubingen, Germany; [Brandt, Niels; Engel, Jutta] Univ Saarland, Dept Biophys, D-6650 Homburg, Germany; [Moeller, Christoph K.; Kindler, Jennifer; Schulze, Holger] Univ Erlangen Nurnberg, Dept Expt Otolaryngol, D-91054 Erlangen, Germany; [Neuhuber, Winfried] Univ Erlangen Nurnberg, Inst Anat, D-91054 Erlangen, Germany; [Moeller, Christoph K.; Schulze, Holger] Leibniz Inst Neurobiol, Magdeburg, Germany	Ulm University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Saarland University; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Leibniz Institut fur Neurobiologie (LIN)	Kurt, S (corresponding author), Univ Ulm, Inst Neurobiol, Albert Einstein Allee 11, D-80081 Ulm, Germany.	simone.kurt@uni-ulm.de		Kurt, Simone/0000-0002-1820-2597	Deutsche Forschungsgemeinschaft (DFG) [DFG Kni316/4-1, DFG Ru571/4-1, SFB 894 TP A8]; University of Tubingen; American Lebanese Syrian Associated Charities (ALSAC); U.S. National Institutes of Health (NIH) [CA21765, DC05168, DC008800, DC06471]; Hartwell Foundation; Thyssen Foundation; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006471, R21DC005168, R21DC008800] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); University of Tubingen; American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hartwell Foundation; Thyssen Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	The authors thank Jian Zhou (St. Jude Children's Research Hospital, Memphis, TN, USA) for providing PCre mice. The authors thank Karin Rohbock, Iris Kopschall, and Sylvia Kasperek for excellent technical assistance; Clement Kabagema for maintaining and genotyping hair cell-specific BK channel-knockout mice; Stefan Munkner for stimulating discussions, and Michael J. Shipston for critical reading of the manuscript and giving helpful advice. This work was supported by the Deutsche Forschungsgemeinschaft (DFG), grants DFG Kni316/4-1, DFG Ru571/4-1, SFB 894 TP A8; Graduate Program of the University of Tubingen; American Lebanese Syrian Associated Charities (ALSAC); U.S. National Institutes of Health (NIH) grants CA21765, DC05168, DC008800, and DC06471; the Hartwell Foundation; and the Thyssen Foundation.	Brandt N, 2007, J NEUROSCI, V27, P3174, DOI 10.1523/JNEUROSCI.3965-06.2007; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Engel J, 2006, NEUROSCIENCE, V143, P837, DOI 10.1016/j.neuroscience.2006.08.060; Gellermann LW, 1933, PEDAGOG SEMIN J GEN, V42, P206; Holt JR, 2007, J NEUROSCI, V27, P8940, DOI 10.1523/JNEUROSCI.2085-07.2007; Jia SP, 2007, J NEUROSCI, V27, P1006, DOI 10.1523/JNEUROSCI.5452-06.2007; Johnson SL, 2011, NEURON, V70, P1143, DOI 10.1016/j.neuron.2011.04.024; Kharkovets T, 2006, EMBO J, V25, P642, DOI 10.1038/sj.emboj.7600951; Kirk C. E., 2003, JARO-J ASSOC RES OTO, V4, P445; Knipper M, 1998, DEVELOPMENT, V125, P3709; Knipper M, 2000, J NEUROPHYSIOL, V83, P3101, DOI 10.1152/jn.2000.83.5.3101; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Kurt S, 2010, P NATL ACAD SCI USA, V107, P8481, DOI 10.1073/pnas.0912357107; Langer P, 2003, J COMP NEUROL, V455, P198, DOI 10.1002/cne.10471; LANGNER G, 1992, HEARING RES, V60, P115, DOI 10.1016/0378-5955(92)90015-F; Marcotti W, 2004, J PHYSIOL-LONDON, V557, P613, DOI 10.1113/jphysiol.2003.060137; Marcotti W, 2003, J PHYSIOL-LONDON, V548, P383, DOI 10.1113/jphysiol.2002.034801; Marida K. V., 1972, J PHYSL, V188, P285; May BJ, 2004, ARCH OTOLARYNGOL, V130, P660, DOI 10.1001/archotol.130.5.660; Muller M, 2005, HEARING RES, V202, P63, DOI 10.1016/j.heares.2004.08.011; Oliver D, 2006, J NEUROSCI, V26, P6181, DOI 10.1523/JNEUROSCI.1047-06.2006; Oliver D, 2003, J NEUROSCI, V23, P2141; Pyott SJ, 2007, J BIOL CHEM, V282, P3312, DOI 10.1074/jbc.M608726200; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Sausbier U, 2006, HISTOCHEM CELL BIOL, V125, P725, DOI 10.1007/s00418-005-0124-7; Schulze H, 1997, J COMP PHYSIOL A, V181, P651, DOI 10.1007/s003590050147; Smith D. W., 2004, AUDITORY SIGNAL PROC; STIEBLER I, 1985, J COMP NEUROL, V238, P65, DOI 10.1002/cne.902380106; Tian Y, 2004, DEV DYNAM, V231, P199, DOI 10.1002/dvdy.20106; Walton JP, 2002, J NEUROPHYSIOL, V88, P565, DOI 10.1152/jn.2002.88.2.565; Wersinger E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013836; Winter H, 2009, J NEUROSCI, V29, P2581, DOI 10.1523/JNEUROSCI.3557-08.2009	33	20	20	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3834	3843		10.1096/fj.11-200535	http://dx.doi.org/10.1096/fj.11-200535			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22691916	Green Published, hybrid			2022-12-28	WOS:000308391600023
J	Song, FP; Peng, Q; Brillard, J; Buisson, C; de Been, M; Abee, T; Broussolle, V; Huang, DF; Zhang, J; Lereclus, D; Nielsen-LeRoux, C				Song, Fuping; Peng, Qi; Brillard, Julien; Buisson, Christophe; de Been, Mark; Abee, Tjakko; Broussolle, Veronique; Huang, Dafang; Zhang, Jie; Lereclus, Didier; Nielsen-LeRoux, Christina			A multicomponent sugar phosphate sensor system specifically induced in Bacillus cereus during infection of the insect gut	FASEB JOURNAL			English	Article						bacterial adaptation; in vivo expression; transcriptional promoter fusions; Bacillus thuringiensis	PLCR VIRULENCE REGULON; LOW-GC-CONTENT; ESCHERICHIA-COLI; IN-VIVO; FUNCTIONAL-ANALYSIS; 2-COMPONENT SYSTEM; GENE-EXPRESSION; GENOME SEQUENCE; THURINGIENSIS; PROTEIN	Using a previously developed Bacillus cereus in vivo expression technology (IVET) promoter trap system, we showed that spsA, a gene of unknown function, was specifically expressed in the larval gut during infection. Search for gut-related compounds inducing spsA transcription identified glucose-6-phosphate (G6P) as an activation signal. Analysis of the spsA-related 5-gene cluster indicated that SpsA is part of a new sugar phosphate sensor system composed of a 2-component system (TCS) encoded by spsR and spsK, and 2 additional downstream genes, spsB and spsC. In B. cereus, American Type Culture Collection (ATCC) 14579, spsRK, and spsABC are separate transcriptional units, of which only spsABC was activated by extracellular G6P. IacZ transcriptional fusions tested in mutant and complemented strains showed that SpsRK, SpsA, and SpsB are essential for the transcription of spsABC. Deletion mutant analysis showed that SpsC is essential for the G6P uptake. gfp-transcriptional fusions showed that these genes are required for host-activated expression, as well. This sugar phosphate sensor and transport system is found in pathogenic Bacillus group and Clostridia bacteria and may be important for host adaptation. Our findings provide new insights into the function of 2-component sensor systems in host-pathogen interactions, specifically in the gut.-Song, F., Peng, Q., Brillard, J., Buisson, C., de Been, M., Abee, T., Broussolle, V., Huang, D., Zhang, J., Lereclus, D., Nielsen-LeRoux, C. A multicomponent sugar phosphate sensor system specifically induced in Bacillus cereus during infection of the insect gut. FASEB J. 26, 3336-3350 (2012). www.fasebj.org	[Song, Fuping; Peng, Qi; Buisson, Christophe; Lereclus, Didier; Nielsen-LeRoux, Christina] INRA, UMR Micalis Genet Microbienne & Environm 1319, F-78280 La Miniere, Guyancourt, France; [Song, Fuping; Peng, Qi; Zhang, Jie; Nielsen-LeRoux, Christina] Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China; [Huang, Dafang] Chinese Acad Agr Sci, Biotechnol Res Inst, Beijing 100193, Peoples R China; [Brillard, Julien; Broussolle, Veronique] INRA, Avignon, France; [Brillard, Julien; Broussolle, Veronique] Univ Avignon & Pays Vaucluse, UMR408, Avignon, France; [de Been, Mark; Abee, Tjakko] Top Inst TI Food & Nutr & Lab Food Microbiol, Wageningen, Netherlands	INRAE; Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS; Chinese Academy of Agricultural Sciences; Biotechnology Research Institute, CAAS; INRAE; Avignon Universite; Top Institute Food & Nutrition	Nielsen-LeRoux, C (corresponding author), INRA, UMR Micalis Genet Microbienne & Environm 1319, F-78280 La Miniere, Guyancourt, France.	fpsong@ippcaas.cn; christina.nielsen@jouy.inra.fr	Lereclus, Didier/AAD-8293-2019; Nielsen-Leroux, Christina/GRS-3334-2022	Broussolle, Veronique/0000-0001-9840-4262; Lereclus, Didier/0000-0001-9047-9104	Major State Basic Research Development Program of China (973 Program) [2009CB118902]; Institut National de la Recherche Agronomique (Department MICA and Mission aux Relations Internationales)	Major State Basic Research Development Program of China (973 Program)(National Basic Research Program of China); Institut National de la Recherche Agronomique (Department MICA and Mission aux Relations Internationales)	The authors thank S. Chamot for technical assistance and anonymous referees for valuable suggestions. This work was supported by grants from the Major State Basic Research Development Program of China (973 Program; 2009CB118902) and from the Institut National de la Recherche Agronomique (Department MICA and Mission aux Relations Internationales).	AGAISSE H, 1994, MOL MICROBIOL, V13, P97, DOI 10.1111/j.1365-2958.1994.tb00405.x; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Arnaud M, 2004, APPL ENVIRON MICROB, V70, P6887, DOI 10.1128/AEM.70.11.6887-6891.2004; Arnesen LPS, 2008, FEMS MICROBIOL REV, V32, P579, DOI 10.1111/j.1574-6976.2008.00112.x; Beier D, 2006, CURR OPIN MICROBIOL, V9, P143, DOI 10.1016/j.mib.2006.01.005; Bouillaut L, 2005, APPL ENVIRON MICROB, V71, P8903, DOI 10.1128/AEM.71.12.8903-8910.2005; Brillard J, 2010, APPL ENVIRON MICROB, V76, P2562, DOI 10.1128/AEM.02348-09; Brillard J, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-183; Buelow DR, 2010, MOL MICROBIOL, V75, P547, DOI 10.1111/j.1365-2958.2009.06982.x; Daou N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000675; de Been M, 2006, MICROBIOL-SGM, V152, P3035, DOI 10.1099/mic.0.29137-0; de Been M, 2010, ENVIRON MICROBIOL, V12, P730, DOI 10.1111/j.1462-2920.2009.02116.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Duport C, 2006, J BACTERIOL, V188, P6640, DOI 10.1128/JB.00702-06; Fedhila S, 2004, APPL ENVIRON MICROB, V70, P4784, DOI 10.1128/AEM.70.8.4784-4791.2004; Fedhila S, 2002, J BACTERIOL, V184, P3296, DOI 10.1128/JB.184.12.3296-3304.2002; Fedhila S, 2002, J BACTERIOL, V184, P5554, DOI 10.1128/JB.184.20.5554-5562.2002; Fedhila S, 2010, J INVERTEBR PATHOL, V103, P24, DOI 10.1016/j.jip.2009.09.005; Fedhila S, 2006, MOL MICROBIOL, V62, P339, DOI 10.1111/j.1365-2958.2006.05362.x; Fortineau N, 2000, RES MICROBIOL, V151, P353, DOI 10.1016/S0923-2508(00)00158-3; Galperin MY, 2010, CURR OPIN MICROBIOL, V13, P150, DOI 10.1016/j.mib.2010.01.005; Gohar M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002793; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Helgason E, 2000, APPL ENVIRON MICROB, V66, P2627, DOI 10.1128/AEM.66.6.2627-2630.2000; Heurtault B, 2006, J LIPOSOME RES, V16, P205, DOI 10.1080/08982100600848736; Hsiao A, 2005, NUCLEIC ACIDS RES, V33, pW627, DOI 10.1093/nar/gki443; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jensen GB, 2003, ENVIRON MICROBIOL, V5, P631, DOI 10.1046/j.1462-2920.2003.00461.x; Kato N, 2006, INSECT BIOCHEM MOLEC, V36, P1, DOI 10.1016/j.ibmb.2005.09.003; Kolsto AB, 2002, CURR TOP MICROBIOL, V264, P95; Kolsto AB, 2009, ANNU REV MICROBIOL, V63, P451, DOI 10.1146/annurev.micro.091208.073255; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; MAHILLON J, 1988, EMBO J, V7, P1515, DOI 10.1002/j.1460-2075.1988.tb02971.x; Mascher T, 2006, MICROBIOL MOL BIOL R, V70, P910, DOI 10.1128/MMBR.00020-06; Merzendorfer H, 2003, J EXP BIOL, V206, P4393, DOI 10.1242/jeb.00709; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Mols M, 2010, INT J FOOD MICROBIOL, V137, P13, DOI 10.1016/j.ijfoodmicro.2009.09.027; Moskalyk LA, 1996, INSECT MOL BIOL, V5, P261, DOI 10.1111/j.1365-2583.1996.tb00100.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raymond B, 2010, TRENDS MICROBIOL, V18, P189, DOI 10.1016/j.tim.2010.02.006; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; Salamitou S, 2000, MICROBIOL-UK, V146, P2825, DOI 10.1099/00221287-146-11-2825; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwoppe C, 2002, J BACTERIOL, V184, P2108, DOI 10.1128/JB.184.8.2108-2115.2002; Slamti L, 2002, EMBO J, V21, P4550, DOI 10.1093/emboj/cdf450; Sonnenburg ED, 2006, P NATL ACAD SCI USA, V103, P8834, DOI 10.1073/pnas.0603249103; Sonnenburg ED, 2010, CELL, V141, P1241, DOI 10.1016/j.cell.2010.05.005; Szurmant H, 2007, CURR OPIN STRUC BIOL, V17, P706, DOI 10.1016/j.sbi.2007.08.019; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tetsch L, 2009, MOL MICROBIOL, V73, P982, DOI 10.1111/j.1365-2958.2009.06847.x; van Schaik W, 2005, J BACTERIOL, V187, P5846, DOI 10.1128/JB.187.16.5846-5851.2005; van Schaik W, 2007, J BACTERIOL, V189, P4384, DOI 10.1128/JB.00313-07; Verhamme DT, 2002, J BACTERIOL, V184, P4205, DOI 10.1128/JB.184.15.4205-4210.2002	56	9	9	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3336	3350		10.1096/fj.11-197681	http://dx.doi.org/10.1096/fj.11-197681			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22611084				2022-12-28	WOS:000307162800023
J	Buffin, A; Goldman, S; Deneubourg, JL				Buffin, Aurelie; Goldman, Serge; Deneubourg, Jean Louis			Collective regulatory stock management and spatiotemporal dynamics of the food flow in ants	FASEB JOURNAL			English	Article						nutrition; self-organization; information centralization	SOLENOPSIS-INVICTA HYMENOPTERA; IMPORTED FIRE ANT; DIVISION-OF-LABOR; SPATIAL-PATTERNS; DIMORPHIC ANT; REPLETE CASTE; HONEY-BEE; WORKER; AGGREGATION; COLONIES	The organization of complex societies requires constant information flow between individuals. The shape of the food web organizes itself according to the spatial distribution of the individuals and of the stocks. To understand how the spatial organization of the food stocks changes with the colony needs, we monitored the flow of radiolabeled sugar solution inside an ant nest at different degrees of starvation. The spatial dynamics of the food flow revealed stable patterns and fine-tuning regulation of the feeding process. The complex collective regulatory stock management task can be reproduced by a surprising simple model that integrates a positive and a negative feedback proportional to the number of ants that already received food. Spatial analysis of the food distribution showed that sucrose is heterogeneously stocked among individuals and also heterogeneously consumed. Furthermore, we observed a regular spatial structure, leading to centralization of the stocks: heavily loaded individuals being at the center of the cluster and weakly loaded individuals at its periphery. The centralization of both resources and information in self-organized systems might be a widespread phenomenon that deserves further studies.-Buffin, A., Goldman, S., Deneubourg, J. L. Collective regulatory stock management and spatiotemporal dynamics of the food flow in ants. FASEB J. 26, 2725-2733 (2012). www.fasebj.org	[Buffin, Aurelie; Deneubourg, Jean Louis] Univ Libre Bruxelles, Unit Social Ecol, B-1050 Brussels, Belgium; [Goldman, Serge] Univ Libre Bruxelles, Hop Erasme, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles	Buffin, A (corresponding author), Univ Libre Bruxelles, Unit Social Ecol, CP 231,Campus Plaine,Bd Triomphe, B-1050 Brussels, Belgium.	aubuffin@ulb.ac.be		Goldman, Serge/0000-0002-9917-8735	Fonds pour la Recherche dans l'Industrie et dans l'Agriculture (FRIA)	Fonds pour la Recherche dans l'Industrie et dans l'Agriculture (FRIA)(Fonds de la Recherche Scientifique - FNRS)	A.B. is supported by a Fonds pour la Recherche dans l'Industrie et dans l'Agriculture (FRIA) grant. J.L.D. is a research associate with the Belgian National Funds for Scientific Research. The authors thank Ir. Benoit Collette for his availability and help for the use of the gamma-ray camera. The authors also thank Jose Halloy and two anonymous reviewers for their valuable help in improving this manuscript.	Abbott A., 1978, PRODUCTION ECOLOGY A, P233; ANDERSEN M, 1991, AM MIDL NAT, V125, P29, DOI 10.2307/2426366; ARMSTRONG PB, 1989, CRIT REV BIOCHEM MOL, V24, P119, DOI 10.3109/10409238909086396; Ben-Jacob E, 2000, ADV PHYS, V49, P395, DOI 10.1080/000187300405228; Beshers SN, 2001, ANNU REV ENTOMOL, V46, P413, DOI 10.1146/annurev.ento.46.1.413; BONAVITACOUGOURDAN A, 1978, INSECT SOC, V25, P275, DOI 10.1007/BF02224293; BRIAN MV, 1977, ANIM BEHAV, V25, P1047, DOI 10.1016/0003-3472(77)90055-0; Buffin A, 2011, INSECT SOC, V58, P177, DOI 10.1007/s00040-010-0133-y; Buffin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005919; CAMAZINE S, 1991, BEHAV ECOL SOCIOBIOL, V28, P61, DOI 10.1007/BF00172140; CAMAZINE S, 1993, BEHAV ECOL SOCIOBIOL, V32, P265, DOI 10.1007/BF00166516; Camazine S., 2001, SELF ORG BIOL SYSTEM, DOI DOI 10.1515/9780691212920; Campbell S. L., 2008, POISSON STAT RADIOAC; Cassill DL, 1999, INFORMATION PROCESSING IN SOCIAL INSECTS, P69; Chambers PG, 1995, ANIM BEHAV, V50, P1513, DOI 10.1016/0003-3472(95)80007-7; CHEW RM, 1995, AM MIDL NAT, V134, P75, DOI 10.2307/2426484; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Cook SC, 2010, ANIM BEHAV, V79, P429, DOI 10.1016/j.anbehav.2009.11.022; Davidson DW, 2004, OECOLOGIA, V139, P255, DOI 10.1007/s00442-004-1508-4; Debout G, 2007, BIOL J LINN SOC, V90, P319, DOI 10.1111/j.1095-8312.2007.00728.x; Depickere S, 2004, INSECT SOC, V51, P81, DOI 10.1007/s00040-003-0719-8; Depickere S, 2008, ECOL ENTOMOL, V33, P225, DOI 10.1111/j.1365-2311.2007.00955.x; Dussutour A, 2009, CURR BIOL, V19, P740, DOI 10.1016/j.cub.2009.03.015; Feneron R, 1996, BEHAVIOUR, V133, P791, DOI 10.1163/156853996X00477; FEWELL JH, 1992, BEHAV ECOL SOCIOBIOL, V30, P387, DOI 10.1007/BF00176173; GLANCEY BM, 1973, ANN ENTOMOL SOC AM, V66, P233, DOI 10.1093/aesa/66.1.233; Hannonen M, 2003, BEHAV ECOL, V14, P870, DOI 10.1093/beheco/arg069; Hayward R. K, 2010, THESIS U BATH BATH, P201; He HS, 2000, LANDSCAPE ECOL, V15, P591, DOI 10.1023/A:1008102521322; Holldobler B., 1990, pi; HOWARD DF, 1981, PHYSIOL ENTOMOL, V6, P297, DOI 10.1111/j.1365-3032.1981.tb00274.x; HOWARD DF, 1980, BEHAV ECOL SOCIOBIOL, V7, P293, DOI 10.1007/BF00300670; Josens RB, 2000, J INSECT PHYSIOL, V46, P1103, DOI 10.1016/S0022-1910(99)00220-6; Kumar M., 2008, IEEE T AUTOMAT CONTR, V55, P743; Lachaud J.-P., 1992, P153; Lendvai AZ, 2004, P ROY SOC B-BIOL SCI, V271, P2467, DOI 10.1098/rspb.2004.2887; LENOIR A, 1979, Bulletin Biologique de la France et de la Belgique, V113, P79; Mailleux AC, 2006, J EXP BIOL, V209, P4224, DOI 10.1242/jeb.02461; O'Donnell S, 2007, INSECT SOC, V54, P203, DOI 10.1007/s00040-007-0945-6; Oron AP, 2006, 68 U WASH CTR STAT S; Paul J, 2003, J INSECT PHYSIOL, V49, P347, DOI 10.1016/S0022-1910(03)00019-2; RISSING SW, 1984, J KANSAS ENTOMOL SOC, V57, P347; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; Schelling T., 1978, MICROMOTIVES MACROBE; SCHELLING TC, 1971, J MATH SOCIOL, V1, P143, DOI 10.1080/0022250X.1971.9989794; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Seeley T., 1995, WISDOM HIVE SOCIAL P; Sempo G, 2006, INSECT SOC, V53, P241, DOI 10.1007/s00040-006-0864-y; Sempo G, 2006, BEHAV ECOL, V17, P642, DOI 10.1093/beheco/ark011; Sendova-Franks AB, 2010, ANIM BEHAV, V79, P473, DOI 10.1016/j.anbehav.2009.11.035; SENDOVAFRANKS A, 1993, B MATH BIOL, V55, P75, DOI 10.1007/BF02460295; SENDOVAFRANKS AB, 1994, P ROY SOC B-BIOL SCI, V256, P305, DOI 10.1098/rspb.1994.0085; Simpson SJ, 2004, ANIM BEHAV, V68, P1299, DOI 10.1016/j.anbehav.2004.03.003; SORENSEN AA, 1981, INSECT SOC, V28, P129, DOI 10.1007/BF02223701; SORENSEN AA, 1981, INSECT SOC, V28, P383, DOI 10.1007/BF02224195; Sumpter DJT, 2003, BEHAV ECOL SOCIOBIOL, V53, P131, DOI 10.1007/s00265-002-0549-0; Theraulaz G, 2002, P NATL ACAD SCI USA, V99, P9645, DOI 10.1073/pnas.152302199; VERHAEGHE JC, 1983, INSECT SOC, V30, P347, DOI 10.1007/BF02223992; WALLIS D. I., 1964, BEHAVIOUR, V23, P149, DOI 10.1163/156853964X00120; WALLIS D. I., 1962, PROC ZOOL SOC LONDON, V139, P589; Weidlich W, 1999, DISCRETE DYN NAT SOC, V3, P137, DOI 10.1155/S1026022699000175; WILSON EO, 1976, BEHAV ECOL SOCIOBIOL, V1, P141, DOI 10.1007/BF00299195	64	13	13	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2725	2733		10.1096/fj.11-193698	http://dx.doi.org/10.1096/fj.11-193698			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22456340				2022-12-28	WOS:000305912500002
J	Cummins, NW; Weaver, EA; May, SM; Croatt, AJ; Foreman, O; Kennedy, RB; Poland, GA; Barry, MA; Nath, KA; Badley, AD				Cummins, Nathan W.; Weaver, Eric A.; May, Shannon M.; Croatt, Anthony J.; Foreman, Oded; Kennedy, Richard B.; Poland, Gregory A.; Barry, Michael A.; Nath, Karl A.; Badley, Andrew D.			Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice	FASEB JOURNAL			English	Article						single-nucleotide polymorphism; pathogenesis; cytokine	INFLAMMATORY RESPONSES; KIDNEY-DISEASE; HOST-DEFENSE; MCP-1; POLYMORPHISMS; ACTIVATION; HUMANS	Underlying mechanisms of individual variation in severity of influenza infection and response to vaccination are poorly understood. We investigated the effect of reduced heme oxygenase-1 (HO-1) expression on vaccine response and outcome of influenza infection. HO-1-deficient and wild-type (WT) mice (kingdom, Animalia; phylum, Chordata; genus/species, Mus musculus) were infected with influenza virus A/PR/8/34 with or without prior vaccination with an adenoviral-based influenza vaccine. A genome-wide association study evaluated the expression of single-nucleotide polymorphisms (SNPs) in the HO-1 gene and the response to influenza vaccination in healthy humans. HO-1-deficient mice had decreased survival after influenza infection compared to WT mice (median survival 5.5 vs. 6.5 d, P=0.016). HO-1-deficient mice had impaired production of antibody following influenza vaccination compared to WT mice (mean antibody titer 869 vs. 1698, P=0.02). One SNP in HO-1 and one SNP in the constitutively expressed isoform HO-2 were independently associated with decreased antibody production after influenza vaccination in healthy human volunteers (P=0.017 and 0.014, respectively). HO-1 deficient mice were paired with sex-and age-matched WT controls. HO-1 affects the immune response to both influenza infection and vaccination, suggesting that therapeutic induction of HO-1 expression may represent a novel adjuvant to enhance influenza vaccine effectiveness.-Cummins, N. W., Weaver, E. A., May, S. M., Croatt, A. J., Foreman, O., Kennedy, R. B., Poland, G. A., Barry, M. A., Nath, K. A., Badley, A. D. Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB J. 26, 2911-2918 (2012). www.fasebj.org	[Cummins, Nathan W.; Weaver, Eric A.; May, Shannon M.; Barry, Michael A.; Badley, Andrew D.] Mayo Clin, Dept Med, Div Infect Dis, Rochester, MN USA; [Croatt, Anthony J.; Nath, Karl A.] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN USA; [Kennedy, Richard B.; Poland, Gregory A.] Mayo Clin, Dept Med, Vaccine Res Grp, Rochester, MN USA; [Foreman, Oded] Jackson Lab, Sacramento, CA USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Jackson Laboratory	Badley, AD (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	badley.andrew@mayo.edu	badley, andrew d/O-9022-2014	Kennedy, Rick/0000-0001-6164-4967; Badley, Andrew/0000-0001-7796-7680	U.S. National Institutes of Health [AI-40384, AI-89859Z, AR-056950-02, DK-007013-32]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI040384, R21AI040384, R01AI097241, U01AI089859, R01AI040384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR056950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007013] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge support from the U.S. National Institutes of Health, including grants AI-40384, AI-89859Z, AR-056950-02, and DK-007013-32, for this work. All authors critically reviewed and approved the final version of the paper. Conflicts of interest: G. A. P. has offered consultative advice on novel influenza vaccine development to Merck & Co., Avianax, Theraclone Sciences (formally Spaltudaq Corporation), MedImmune LLC, Liquidia Technologies, Novavax, Novartis Vaccines and Therapeutics, and PAXVAX. All other authors declare no conflicts of interest. The authors thank Allan Ackerman for technical assistance with the study.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Bharucha AE, 2010, CLIN PHARMACOL THER, V87, P187, DOI 10.1038/clpt.2009.221; Choi AMK, 1996, AM J PHYSIOL-LUNG C, V271, pL383, DOI 10.1152/ajplung.1996.271.3.L383; Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730; Chung SW, 2009, CELL MICROBIOL, V11, P199, DOI 10.1111/j.1462-5822.2008.01261.x; Cottey R., 2001, INFLUENZA VIRUS CURR; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Hashiba T, 2001, GENE THER, V8, P1499, DOI 10.1038/sj.gt.3301540; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Kanakiriya SKR, 2003, AM J PHYSIOL-RENAL, V284, pF546, DOI 10.1152/ajprenal.00298.2002; Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2; Katz JM, 2004, IMMUNOL RES, V29, P113, DOI 10.1385/IR:29:1-3:113; Kennedy R, 2009, CLIN VACCINE IMMUNOL, V16, P1105, DOI 10.1128/CVI.00109-09; Li Y, 2009, CLIN EXP HYPERTENS, V31, P534, DOI 10.3109/10641960902825461; Mok H, 2005, MOL THER, V11, P66, DOI 10.1016/j.ymthe.2004.09.015; Murali NS, 2007, AM J PHYSIOL-RENAL, V292, pF837, DOI 10.1152/ajprenal.00254.2006; Nath KA, 2006, KIDNEY INT, V70, P432, DOI 10.1038/sj.ki.5001565; Nath KA, 2000, AM J PATHOL, V156, P1527, DOI 10.1016/S0002-9440(10)65024-9; Nath KA, 2001, KIDNEY INT, V59, P106, DOI 10.1046/j.1523-1755.2001.00471.x; Pittock ST, 2005, KIDNEY INT, V68, P611, DOI 10.1111/j.1523-1755.2005.00439.x; Poland GA, 2008, VACCINE, V26, pD35, DOI 10.1016/j.vaccine.2008.07.065; Sambo MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011141; Saukkonen K, 2010, SHOCK, V34, P558, DOI 10.1097/SHK.0b013e3181e14de9; Sinnis P, 2008, CELL HOST MICROBE, V3, P277, DOI 10.1016/j.chom.2008.04.009; Sladkova T, 2006, ACTA VIROL, V50, P151; Tracz MJ, 2007, AM J PATHOL, V170, P1820, DOI 10.2353/ajpath.2007.061093; Tracz MJ, 2007, J AM SOC NEPHROL, V18, P414, DOI 10.1681/ASN.2006080894; Trammell RA, 2008, EXPERT REV MOL DIAGN, V8, P515, DOI 10.1586/14737159.8.4.515	28	36	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2911	2918		10.1096/fj.11-190017	http://dx.doi.org/10.1096/fj.11-190017			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490782	Green Published, Green Submitted			2022-12-28	WOS:000305912500019
J	Weber, M; Lambeck, S; Ding, N; Henken, S; Kohl, M; Deigner, HP; Enot, DP; Igwe, EI; Frappart, L; Kiehntopf, M; Claus, RA; Kamradt, T; Weih, D; Vodovotz, Y; Briles, DE; Ogunniyi, AD; Paton, JC; Maus, UA; Bauer, M				Weber, Martina; Lambeck, Sandro; Ding, Nadine; Henken, Stefanie; Kohl, Matthias; Deigner, Hans P.; Enot, David P.; Igwe, Emeka I.; Frappart, Lucien; Kiehntopf, Michael; Claus, Ralf A.; Kamradt, Thomas; Weih, Debra; Vodovotz, Yoram; Briles, David E.; Ogunniyi, Abiodun D.; Paton, James C.; Maus, Ulrich A.; Bauer, Michael			Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia	FASEB JOURNAL			English	Article						sepsis; pneumolysin; pathogen-host interaction	COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; PULMONARY INFECTION; HOST-DEFENSE; PNEUMOLYSIN; METABOLISM; SEPSIS; PATHOGENESIS; MACROPHAGES; INJURY	Community-acquired pneumonia presents a spectrum of clinical phenotypes, from lobar pneumonia to septic shock, while mechanisms underlying progression are incompletely understood. In a transcriptomic and metabolomic study across tissues, we examined serotype-specific regulation of signaling and metabolic pathways in C57BL/6 mice intratracheally instilled with either serotype 19F Streptococcus pneumoniae (S19; causing lobar pneumonia), or serotype 2 S. pneumoniae (S2; causing septic pneumococcal disease,) or vehicle (Todd-Hewitt broth). Samples of lung, liver, and blood were collected at 6 and 24 h postinfection and subjected to microarray analysis and mass spectrometry. Results comprise a preferential induction of cholesterol biosynthesis in lobar pneumonia at low-infection doses (105 colony forming units/mouse) leading to increased plasma cholesterol (vehicle: 1.8 +/- 0.12 mM, S2: 2.3 +/- 0.10 mM, S19: 2.9 +/- 0.15 mM; P<0.05, comparing S19 to vehicle and S2). This induction was pneumolysin dependent, as a pneumolysin-deficient strain of serotype 19F failed to induce cholesterol biosynthesis (S19 Delta PLY: 1.9 +/- 0.03 mM). Preincubation of pneumolysin with purified cholesterol or plasma from hypercholesterolemic mice prior to intratracheal instillation protected against lung barrier dysfunction and alveolar macrophage necrosis. Cholesterol may attenuate disease severity by neutralizing pneumolysin in the alveolar compartment and thus prevent septic disease progression.-Weber, M., Lambeck, S., Ding, N., Henken, S., Kohl, M., Deigner, H. P., Enot, D. P., Igwe, E. I., Frappart, L., Kiehntopf, M., Claus, R. A., Kamradt, T., Weih, D., Vodovotz, Y., Briles, D. E., Ogunniyi, A. D., Paton, J. C., Maus, U. A., Bauer, M. Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia. FASEB J. 26, 2424-2436 (2012). www.fasebj.org	[Lambeck, Sandro; Claus, Ralf A.; Bauer, Michael] Jena Univ Hosp, Ctr Sepsis Control & Care, D-07747 Jena, Germany; [Weber, Martina; Kohl, Matthias; Claus, Ralf A.; Bauer, Michael] Jena Univ Hosp, Dept Anaesthesiol & Intens Care Therapy, D-07747 Jena, Germany; [Kiehntopf, Michael] Jena Univ Hosp, Inst Clin Chem & Lab Med, D-07747 Jena, Germany; [Kamradt, Thomas] Jena Univ Hosp, Inst Immunol, D-07747 Jena, Germany; [Ding, Nadine; Henken, Stefanie; Maus, Ulrich A.] Hannover Med Sch, Dept Expt Pneumol, D-3000 Hannover, Germany; [Deigner, Hans P.; Enot, David P.; Igwe, Emeka I.] Biocrates Life Sci AG, Innsbruck, Austria; [Frappart, Lucien] Univ Lyon 1, Dept Pathol, F-69365 Lyon, France; [Frappart, Lucien] INSERM, U590, F-69008 Lyon, France; [Weih, Debra] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany; [Vodovotz, Yoram] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Vodovotz, Yoram] McGowan Inst Regenerat Med, Ctr Inflammat Regenerat Modeling, Pittsburgh, PA USA; [Briles, David E.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Ogunniyi, Abiodun D.; Paton, James C.] Univ Adelaide, Res Ctr Infect Dis, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Hannover Medical School; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; University of Adelaide	Bauer, M (corresponding author), Jena Univ Hosp, Ctr Sepsis Control & Care, Erlanger Allee 101, D-07747 Jena, Germany.	michael.bauer@med.uni-jena.de	Kamradt, Thomas/E-9971-2018; Kohl, Matthias/R-6096-2019; Paton, James C/A-9920-2008; Claus, Ralf A./Q-4035-2016	Kohl, Matthias/0000-0001-9514-8910; Bauer, Michael/0000-0002-1521-3514; Kamradt, Thomas/0000-0001-8443-5893; Ogunniyi, Abiodun/0000-0001-9308-5629; Claus, Ralf A./0000-0001-7232-4088	Federal Ministry of Education and Research (BMBF) [01KI07111, 01EO1002]	Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The authors acknowledge expert technical support by Brigitte Specht, Edith Walther, Maik Balduf, Dr. Elke Grunow, Dr. Karen Felsmann, and Kay Stotzer. This work was funded by the Federal Ministry of Education and Research (BMBF; 01KI07111 to M. B. and U. A. M.; 01EO1002 to M. B., R. A. C., and S. L. for the Center for Sepsis Control and Care) and was performed within the framework of the Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis (PROGRESS). U. A. M. and M. B. share senior authorship.	Balachandran P, 2001, J BACTERIOL, V183, P3108, DOI 10.1128/JB.183.10.3108-3116.2001; BENTON KA, 1995, INFECT IMMUN, V63, P448, DOI 10.1128/IAI.63.2.448-455.1995; Bergeron Y, 1998, INFECT IMMUN, V66, P912, DOI 10.1128/IAI.66.3.912-922.1998; Briles DE, 2003, J INFECT DIS, V188, P339, DOI 10.1086/376571; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bruggeman FJ, 2007, TRENDS MICROBIOL, V15, P45, DOI 10.1016/j.tim.2006.11.003; Chung TP, 2002, CRIT CARE MED, V30, pS51, DOI 10.1097/00003246-200201001-00007; Cobb JP, 2005, P NATL ACAD SCI USA, V102, P4801, DOI 10.1073/pnas.0409768102; Cobb JP, 2004, LANCET, V363, P2076, DOI 10.1016/S0140-6736(04)16460-X; DAVIS CC, 1991, J INFECT DIS, V163, P799, DOI 10.1093/infdis/163.4.799; de Lima-Salgado Thais Martins, 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P258; dos Santos CC, 2010, CRIT CARE MED, V38, P894, DOI 10.1097/CCM.0b013e3181ce4e50; Dremsizov T, 2006, CHEST, V129, P968, DOI 10.1378/chest.129.4.968; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Dunham CM, 2003, CRIT CARE, V7, pR145, DOI 10.1186/cc2382; Ewig Santiago, 2002, Curr Opin Crit Care, V8, P453, DOI 10.1097/00075198-200210000-00014; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonnert FA, 2011, J SURG RES, V170, pE123, DOI 10.1016/j.jss.2011.05.019; Gordon BR, 2001, CRIT CARE MED, V29, P1563, DOI 10.1097/00003246-200108000-00011; Harvey RM, 2011, INFECT IMMUN, V79, P4122, DOI 10.1128/IAI.05418-11; Henken S, 2010, ANTIMICROB AGENTS CH, V54, P707, DOI 10.1128/AAC.00943-09; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; JOHNSTON RB, 1991, REV INFECT DIS, V13, pS509; Kadioglu A, 2000, INFECT IMMUN, V68, P492, DOI 10.1128/IAI.68.2.492-501.2000; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/ajrccm.165.6.2103038; LEROY O, 1995, INTENS CARE MED, V21, P24, DOI 10.1007/BF02425150; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Marquart ME, 2007, INVEST OPHTH VIS SCI, V48, P2661, DOI 10.1167/iovs.07-0017; Martin-Ponce E, 2010, CLIN NUTR, V29, P501, DOI 10.1016/j.clnu.2009.12.009; Maus UA, 2004, J IMMUNOL, V173, P1307, DOI 10.4049/jimmunol.173.2.1307; Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273; Maus UA, 2002, AM J PHYSIOL-LUNG C, V282, pL1245, DOI 10.1152/ajplung.00453.2001; Maus UA, 2007, AM J RESP CRIT CARE, V175, P958, DOI 10.1164/rccm.200610-1533OC; McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191; MELLENCAMP MA, 1991, J INFECT DIS, V163, P102, DOI 10.1093/infdis/163.1.102; MOINE P, 1995, SCAND J INFECT DIS, V27, P201, DOI 10.3109/00365549509019009; Nes WD, 2000, ENDOCRINOLOGY, V141, P953, DOI 10.1210/en.141.3.953; Nollmann M, 2004, BIOPHYS J, V86, P3141, DOI 10.1016/S0006-3495(04)74362-3; Ortqvist A, 2005, SEMIN RESP CRIT CARE, V26, P563, DOI 10.1055/s-2005-925523; Park K, 2010, J LEUKOCYTE BIOL, V88, P1081, DOI 10.1189/jlb.0610318; PATON JC, 1983, INFECT IMMUN, V40, P548, DOI 10.1128/IAI.40.2.548-552.1983; QUISTORFF B, 1976, ANAL BIOCHEM, V73, P236, DOI 10.1016/0003-2697(76)90162-7; Rubins JB, 1998, J LAB CLIN MED, V131, P21, DOI 10.1016/S0022-2143(98)90073-7; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Santos-Sierra S, 2006, J ENDOTOXIN RES, V12, P307, DOI 10.1179/096805106X118762; Scanu AM, 2008, FASEB J, V22, P4044, DOI 10.1096/fj.08-117150; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; SIMON RH, 1995, J LAB CLIN MED, V126, P108; Takashima K, 1997, INFECT IMMUN, V65, P257, DOI 10.1128/IAI.65.1.257-260.1997; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Unterwurzacher I, 2008, CLIN CHEM LAB MED, V46, P1589, DOI 10.1515/CCLM.2008.323; van Leeuwen HJ, 2003, CRIT CARE MED, V31, P1359, DOI 10.1097/01.CCM.0000059724.08290.51; Vermont CL, 2005, CRIT CARE MED, V33, P1610, DOI 10.1097/01.CCM.0000171272.50888.AD; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Winter C, 2007, J IMMUNOL, V178, P5828, DOI 10.4049/jimmunol.178.9.5828; Wu AH, 2004, SHOCK, V21, P210, DOI 10.1097/01.shk.0000111661.09279.82; Yoshimura A, 1999, J IMMUNOL, V163, P1	58	32	33	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2424	2436		10.1096/fj.11-191957	http://dx.doi.org/10.1096/fj.11-191957			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415311				2022-12-28	WOS:000305017200020
J	Krishnaiah, SY; Dodia, C; Feinstein, SI; Fisher, AB				Krishnaiah, Saikumari Y.; Dodia, Chandra; Feinstein, Sheldon I.; Fisher, Aron B.			p67(phox) terminates the phospholipase A(2)-derived signal for activation of NADPH oxidase (NOX2)	FASEB JOURNAL			English	Article						peroxiredoxin 6; reactive oxygen species; protein-protein interactions; pulmonary microvascular endothelium	A(2) ACTIVITY; PEROXIREDOXIN 6; COMPONENT P67(PHOX); ENDOTHELIAL-CELLS; PROTEIN; PHOSPHORYLATION; PEROXIDASE; STRESS; ENZYME	The phospholipase A(2) (PLA(2)) activity of phosphorylated peroxiredoxin 6 (Prdx6) is required for activation of NADPH oxidase (NOX2). We investigated the interaction of Prdx6 with p67(phox) and its effect on NOX2 activity. With the use of specific antibodies, coimmunoprecipitation of p67(phox) and phosphorylated Prdx6 was demonstrated with lysates of mouse pulmonary microvascular endothelial cells (MPMVECs) that were stimulated with angiotensin II; the interaction of p67(phox) with nonphosphorylated Prdx6 was relatively weak. Association of p67(phox) and phosphoPrdx6 in intact MPMVECs after angiotensin II stimulation was demonstrated by proximity ligation assay and was abolished by U0126, a MAP kinase inhibitor. By isothermal titration calorimetry, p67(phox) bound strongly to phosphoPrdx6 but bound poorly to Prdx6; phosphorylated p67(phox) did not bind to either Prdx6 or phosphoPrdx6. PLA(2) activity of recombinant phosphoPrdx6 was decreased by > 98% in the presence of p67(phox); the calculated dissociation constant (K-d) of the p67phox: phosphoPrdx6 complex was 65 nM. PLA(2) activity (MJ33 sensitive) in cell lysates following angiotensin II treatment of MPMVECs was increased by 85% following knockdown of p67(phox) with siRNA. These data indicate that p67(phox) binds to phosphoPrdx6 and inhibits its PLA(2) activity, an interaction that could function to terminate the PLA(2)-mediated NOX2 activation signal.-Krishnaiah, S. Y., Dodia, C., Feinstein, S. I., and Fisher, A. B. p67(phox) terminates the phospholipase A(2)-derived signal for activation of NADPH oxidase (NOX2). FASEB J. 27, 2066-2073 (2013). www.fasebj.org	[Krishnaiah, Saikumari Y.; Dodia, Chandra; Feinstein, Sheldon I.; Fisher, Aron B.] Univ Penn, Inst Environm Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Fisher, AB (corresponding author), Univ Penn, Inst Environm Med, 3620 Hamilton Walk,1 John Morgan Bldg, Philadelphia, PA 19104 USA.	abf@mail.med.upenn.edu	Krishnaiah, Saikumari/I-7140-2016		U.S. National Institutes of Health [HL 105509]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105509] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank David Speicher, Shampa Chatterjee, Luis Ralat, Suiping Zhao, and Sandy Harper for helpful advice, and Yu-Chin Lien for assistance with the Duolink assay. The authors thank Molly McGoey for typing the manuscript. This research has been presented, in part, as a poster at the 2012 Experimental Biology meeting in San Diego, CA, USA. Grant support was provided by HL 105509 from the U.S. National Institutes of Health. The authors declare no conflicts of interest.	Ambruso DR, 2012, BIOCHIM BIOPHYS ACTA, V1823, P306, DOI [10.1016/j.bbamcr.2011.11.014, DOI 10.1016/J.BBAMCR.2011.11.014]; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Chatterjee S, 2011, J BIOL CHEM, V286, P11696, DOI 10.1074/jbc.M110.206623; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Ellison MA, 2012, EUR J IMMUNOL, V42, P1609, DOI 10.1002/eji.201142157; Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200; Fisher AB, 1996, J LIPID RES, V37, P1057; Forbes LV, 1999, BIOCHEM J, V338, P99, DOI 10.1042/0264-6021:3380099; Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI [10.1089/ars.2008.2220, 10.1089/ARS.2008.2220]; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2010, ARTERIOSCL THROM VAS, V30, P653, DOI 10.1161/ATVBAHA.108.181610; Leavey PJ, 2002, J BIOL CHEM, V277, P45181, DOI 10.1074/jbc.M202869200; Lien YC, 2012, ANTIOXID REDOX SIGN, V16, P440, DOI 10.1089/ars.2011.3950; Milovanova T, 2008, BBA-MOL CELL RES, V1783, P1866, DOI 10.1016/j.bbamcr.2008.05.010; Pendyala S, 2009, ANTIOXID REDOX SIGN, V11, P841, DOI [10.1089/ars.2008.2231, 10.1089/ARS.2008.2231]; Rahaman H, 2012, BIOCHEMISTRY-US, V51, P5521, DOI 10.1021/bi300380h; SEGAL AW, 1989, BIOCHEM SOC T, V17, P427, DOI 10.1042/bst0170427; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Wu Y, 2009, BIOCHEM J, V419, P669, DOI 10.1042/BJ20082061; Wu YZ, 2006, J BIOL CHEM, V281, P7515, DOI 10.1074/jbc.M504525200	24	19	19	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2013	27	5					2066	2073		10.1096/fj.12-222133	http://dx.doi.org/10.1096/fj.12-222133			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23401562	Green Published			2022-12-28	WOS:000318226100026
J	Swartz, TD; Sakar, Y; Duca, FA; Covasa, M				Swartz, Timothy D.; Sakar, Yassine; Duca, Frank A.; Covasa, Mihai			Preserved adiposity in the Fischer 344 rat devoid of gut microbiota	FASEB JOURNAL			English	Article						germ-free; nutrient-receptor; FIAF; lipogenesis; metabolism	DIET-INDUCED OBESITY; FATTY-ACID RECEPTOR; ENTEROENDOCRINE CELLS; SECRETION; GPR43; SIZE; METABOLISM; RESISTANCE; GERMFREE; MICE	The gut microbiota is implicated in host metabolism and energy regulation. Germ-free (GF) C57BL/6 mice display decreased adiposity, an effect associated with increased intestinal fasting-induced adipose factor (FIAF) and decreased hepatic lipogenesis. However, whether the altered metabolism observed in the absence of gut microbiota extends to other species, commonly used to examine energy metabolism, is unknown. Thus, we used the GF Fischer 344 rat to examine adiposity and associated alterations in intestinal nutrient chemoreceptors, gut peptide levels, and FIAF expression, as well as markers of hepatic and adipose lipogenesis and adipogenesis. We found that GF rats displayed similar body weights and adiposity relative to controls. GF state was associated with up-regulation of intestinal and hepatic FIAF, decreased expression of hepatic FAS, ACC-1, and SREBP, and increased pAMPK and pACC. However, GF rats displayed reduced adipocyte FIAF, increased lipogenic enzymes, and decreased pAMPK, accompanied by an increase in adipocyte size. These findings show that, despite increased intestinal FIAF and reduced hepatic lipogenesis, adiposity is preserved in the Fisher 344 GF rat, unlike the C57Bl/6J GF mouse, with a shift in increased adipocyte lipogenesis. This also demonstrates that adipose, rather than intestinal, FIAF may have a more prominent role in adiposity.-Swartz, T. D., Sakar, Y., Duca, F. A., Covasa, M. Preserved adiposity in the Fischer 344 rat devoid of gut microbiota. FASEB J. 27, 1701-1710 (2013). www.fasebj.org	[Swartz, Timothy D.; Sakar, Yassine; Duca, Frank A.; Covasa, Mihai] INRA, Ctr Rech Jouy En Josas, UMR 1319, Microbiol Alimentat Serv Sante MICALIS, F-78350 Jouy En Josas, France; [Swartz, Timothy D.; Duca, Frank A.] Univ Paris 06, Doctoral Sch Physiol & Pathophysiol, Paris, France; [Covasa, Mihai] Western Univ Hlth Sci, Coll Osteopath Med, Dept Basic Med Sci, Pomona, CA USA; [Covasa, Mihai] Univ Suceava, Dept Human Hlth & Dev, Suceava, Romania	AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Western University of Health Sciences; Stefan cel Mare University of Suceava	Covasa, M (corresponding author), INRA, Ctr Rech Jouy En Josas, UMR 1319, MICALIS, F-78350 Jouy En Josas, France.	mcovasa@jouy.inra.fr		Swartz, Timothy/0000-0002-9801-8756	Institut National de Recherche Agronomique through a scientific package	Institut National de Recherche Agronomique through a scientific package	The authors thank Fabienne Devime for her technical assistance, Fatima Joly for the husbandry of the Fisher 344 GF rats, and the Animalerie Axenique de Micalis (ANAXEM) team for their assistance in the GF facilities. The study was supported by Institut National de Recherche Agronomique through a scientific package to M. C. The authors declare no conflicts of interest.	Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Cherbuy C, 2010, AM J PHYSIOL-GASTR L, V299, pG348, DOI 10.1152/ajpgi.00384.2009; de La Serre CB, 2010, AM J PHYSIOL-GASTR L, V299, pG440, DOI 10.1152/ajpgi.00098.2010; Duca FA, 2013, INT J OBESITY, V37, P375, DOI 10.1038/ijo.2012.45; Duca FA, 2012, BR J NUTR, P1; Duca FA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039748; Edfalk S, 2008, DIABETES, V57, P2280, DOI 10.2337/db08-0307; Fleissner CK, 2010, BRIT J NUTR, V104, P919, DOI 10.1017/S0007114510001303; Hayes MR, 2009, ENDOCRINOLOGY, V150, P2654, DOI 10.1210/en.2008-1479; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Jernas M, 2006, FASEB J, V20, P1540, DOI 10.1096/fj.05-5678fje; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Karaki S, 2006, CELL TISSUE RES, V324, P353, DOI 10.1007/s00441-005-0140-x; Karaki SI, 2008, J MOL HISTOL, V39, P135, DOI 10.1007/s10735-007-9145-y; KAWAI Y, 1981, MECH AGEING DEV, V16, P149, DOI 10.1016/0047-6374(81)90091-9; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Lin Zhi-jian, 2009, Chinese Medical Sciences Journal, V24, P191; Liou AP, 2011, AM J PHYSIOL-GASTR L, V300, pG538, DOI 10.1152/ajpgi.00342.2010; Liou AP, 2011, GASTROENTEROLOGY, V140, P903, DOI 10.1053/j.gastro.2010.10.012; Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200; Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921; Ruttimann EB, 2010, PHYSIOL BEHAV, V100, P291, DOI 10.1016/j.physbeh.2010.02.022; Samuel BS, 2008, P NATL ACAD SCI USA, V105, P16767, DOI 10.1073/pnas.0808567105; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P515, DOI 10.1007/s00210-007-0250-y; Tazoe H, 2008, J PHYSIOL PHARMACOL, V59, P251; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Williams DL, 2006, DIABETES, V55, P3387, DOI 10.2337/db06-0558; Williams DL, 2009, ENDOCRINOLOGY, V150, P1680, DOI 10.1210/en.2008-1045; WOSTMANN BS, 1983, LAB ANIM SCI, V33, P46	33	12	15	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1701	1710		10.1096/fj.12-221689	http://dx.doi.org/10.1096/fj.12-221689			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23349551				2022-12-28	WOS:000316940800039
J	Valladares, R; Bojilova, L; Potts, AH; Cameron, E; Gardner, C; Lorca, G; Gonzalez, CF				Valladares, Ricardo; Bojilova, Lora; Potts, Anastasia H.; Cameron, Evan; Gardner, Christopher; Lorca, Graciela; Gonzalez, Claudio F.			Lactobacillus johnsonii inhibits indoleamine 2,3-dioxygenase and alters tryptophan metabolite levels in BioBreeding rats	FASEB JOURNAL			English	Article						kynurenine; hydrogen peroxide; intestinal epithelial cell; 5-hydroxytryptamine	INTESTINAL MICROBIOME; NADH OXIDASE; EXPRESSION; CELLS; CONTRIBUTES; RESPONSES; SAMPLES; BRAIN; ONSET; GAMMA	In our previous work, we found that feeding Lactobacillus johnsonii to BioBreeding diabetes-prone (BBDP) rats decreased the incidence of diabetes development. The aim of this study was to investigate host pathways affected by L. johnsonii, with specific focus on the rate-limiting enzyme of tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO). Suspensions of L. johnsonii or an equal volume of vehicle were orally administered to BBDP rats. Tissue IDO was investigated using quantitative RT-PCR and Western blot, whereas tryptophan, kynurenine, and 5-hydroxytryptamine (5-HT) concentrations were quantified by HPLC and ELISA. IDO activity was also investigated using L. johnsonii culture cell-free supernatant (CFS) with affinity-purified IDO and HT-29 intestinal epithelial cells. L. johnsonii feeding resulted in a 17% reduction in serum kynurenine compared with that in vehicle-fed controls, correlating with a 1.4-fold elevation in 5-HT levels. H2O2 produced by L. johnsonii abolished IDO activity in vitro, and L. johnsonii feeding resulted in a 3.9-fold increase in ileum lumen H2O2. L. johnsonii CFS significantly reduced IDO activity in HT-29 intestinal epithelial cells (47% reduction) compared with that in vehicle-treated controls, an effect abolished by catalase treatment. These data support the role of H2O2 in commensal bacteria-host interactions and highlight the influence of commensal bacteria-derived H2O2 on host physiology.-Valladares, R., Bojilova, L., Potts, A. H., Cameron, E., Gardner, C., Lorca, G., Gonzalez, C. F. Lactobacillus johnsonii inhibits indoleamine 2,3-dioxygenase and alters tryptophan metabolite levels in BioBreeding rats. FASEB J. 27, 1711-1720 (2013). www.fasebj.org	[Valladares, Ricardo; Bojilova, Lora; Potts, Anastasia H.; Cameron, Evan; Gardner, Christopher; Lorca, Graciela; Gonzalez, Claudio F.] Univ Florida, Inst Food & Agr Sci, Dept Microbiol & Cell Sci, Genet Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Gonzalez, CF (corresponding author), Univ Florida, Genet Inst 325G, 2033 Mowry Rd,POB 103610, Gainesville, FL 32610 USA.	cfgonzalez@ufl.edu		Gardner, Christopher/0000-0001-6416-8476	University of Florida Opportunity Fund; U.S. National Science Foundation [DGE-0802270]	University of Florida Opportunity Fund; U.S. National Science Foundation(National Science Foundation (NSF))	The authors thank Dr. Yoshitsugu Shiro (RIKEN Center, Hyogo, Japan) for the human IDO cDNA, Beverly Driver for her continuous assistance in the laboratory, and Dr. Sixiue Chen and the Proteomics Core at the Interdisciplinary Center for Biotechnological Research (University of Florida, Gainesville, FL, USA) for their technical assistance with the mass spectrometry work. This work was funded by the University of Florida Opportunity Fund and the U.S. National Science Foundation under grant DGE-0802270. The authors declare no conflicts of interest.	Badawy AAB, 2010, INT J TRYPTOPHAN RES, V3, P175, DOI 10.4137/IJTR.S6225; Bell LV, 2011, PARASITE IMMUNOL, V33, P244, DOI 10.1111/j.1365-3024.2010.01272.x; Boerner BP, 2011, ANN NY ACAD SCI, V1243, P103, DOI 10.1111/j.1749-6632.2011.06340.x; Corona AW, 2013, BRAIN BEHAV IMMUN, V31, P134, DOI 10.1016/j.bbi.2012.08.008; Dai XC, 2010, J HISTOCHEM CYTOCHEM, V58, P17, DOI 10.1369/jhc.2009.953604; Denou E, 2007, J BACTERIOL, V189, P8109, DOI 10.1128/JB.00991-07; Forouhar F, 2007, P NATL ACAD SCI USA, V104, P473, DOI 10.1073/pnas.0610007104; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; GUBERSKI DL, 1993, DIABETOLOGIA, V36, P912, DOI 10.1007/BF02374472; Harrington L, 2008, INFECT IMMUN, V76, P3045, DOI 10.1128/IAI.00193-08; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025792, 10.1371/journal.pone.0014764]; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; Kaszaki J, 2012, J NEURAL TRANSM, V119, P211, DOI 10.1007/s00702-011-0658-x; Kingma SDK, 2011, J NUTR, V141, P1023, DOI 10.3945/jn.110.135517; Kriegel MA, 2011, P NATL ACAD SCI USA, V108, P11548, DOI 10.1073/pnas.1108924108; Kudo Y, 2000, MOL HUM REPROD, V6, P369, DOI 10.1093/molehr/6.4.369; Kumar A, 2007, EMBO J, V26, P4457, DOI 10.1038/sj.emboj.7601867; Lai KK, 2009, APPL ENVIRON MICROB, V75, P5018, DOI 10.1128/AEM.02837-08; Lau K, 2011, J IMMUNOL, V186, P3538, DOI 10.4049/jimmunol.1001864; LEWIS UJ, 1954, J BIOL CHEM, V206, P109; Lin PW, 2009, FREE RADICAL BIO MED, V47, P1205, DOI 10.1016/j.freeradbiomed.2009.07.033; Mandi Y, 2012, J NEURAL TRANSM, V119, P197, DOI 10.1007/s00702-011-0681-y; Marty-Teysset C, 2000, APPL ENVIRON MICROB, V66, P262, DOI 10.1128/AEM.66.1.262-267.2000; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Neu J, 2005, J PEDIATR GASTR NUTR, V40, P589, DOI 10.1097/01.MPG.0000159636.19346.C1; Neu J, 2010, ENDOCRIN METAB CLIN, V39, P563, DOI 10.1016/j.ecl.2010.05.008; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; Poljak A, 2006, ARCH BIOCHEM BIOPHYS, V450, P9, DOI 10.1016/j.abb.2006.03.003; Resta SC, 2009, J PHYSIOL-LONDON, V587, P4169, DOI 10.1113/jphysiol.2009.176370; Rhee SJ, 2005, J IMMUNOL, V175, P1127, DOI 10.4049/jimmunol.175.2.1127; Roesch LFW, 2009, ISME J, V3, P536, DOI 10.1038/ismej.2009.5; Rosell FI, 2011, J BIOL CHEM, V286, P29273, DOI 10.1074/jbc.M111.262139; Salazar A, 2012, HORM BEHAV, V62, P202, DOI 10.1016/j.yhbeh.2012.03.010; Swanson PA, 2011, P NATL ACAD SCI USA, V108, P8803, DOI 10.1073/pnas.1010042108; Terentis AC, 2010, BIOCHEMISTRY-US, V49, P591, DOI 10.1021/bi901546e; Thebault P, 2009, J IMMUNOL, V183, P3099, DOI 10.4049/jimmunol.0803767; Torres MI, 2007, CLIN EXP IMMUNOL, V148, P419, DOI 10.1111/j.1365-2249.2007.03365.x; Valladares R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010507; Visser JTJ, 2010, DIABETOLOGIA, V53, P2621, DOI 10.1007/s00125-010-1903-9; Voltan S, 2008, GASTROENTEROLOGY, V135, P1216, DOI 10.1053/j.gastro.2008.07.007; Wang B, 2011, ENDOCRINOLOGY, V152, P4984, DOI 10.1210/en.2011-0278; WEEKLEY LB, 1984, FOOD CHEM TOXICOL, V22, P65, DOI 10.1016/0278-6915(84)90055-3; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; YOSHIDA R, 1980, ARCH BIOCHEM BIOPHYS, V203, P343, DOI 10.1016/0003-9861(80)90185-X; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082	47	83	88	3	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1711	1720		10.1096/fj.12-223339	http://dx.doi.org/10.1096/fj.12-223339			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303207				2022-12-28	WOS:000316940800040
J	Vines, TH; Andrew, RL; Bock, DG; Franklin, MT; Gilbert, KJ; Kane, NC; Moore, JS; Moyers, BT; Renaut, S; Rennison, DJ; Veen, T; Yeaman, S				Vines, Timothy H.; Andrew, Rose L.; Bock, Dan G.; Franklin, Michelle T.; Gilbert, Kimberly J.; Kane, Nolan C.; Moore, Jean-Sebastien; Moyers, Brook T.; Renaut, Sebastien; Rennison, Diana J.; Veen, Thor; Yeaman, Sam			Mandated data archiving greatly improves access to research data	FASEB JOURNAL			English	Article						science policy; reproducibility; Joint Data Archiving Policy; population genetics; STRUCTURE	AUTHORS	The data underlying scientific papers should be accessible to researchers both now and in the future, but how best can we ensure that these data are available? Here we examine the effectiveness of four approaches to data archiving: no stated archiving policy, recommending (but not requiring) archiving, and two versions of mandating data deposition at acceptance. We control for differences between data types by trying to obtain data from papers that use a single, widespread population genetic analysis, STRUCTURE. At one extreme, we found that mandated data archiving policies that require the inclusion of a data availability statement in the manuscript improve the odds of finding the data online almost 1000-fold compared to having no policy. However, archiving rates at journals with less stringent policies were only very slightly higher than those with no policy at all. We also assessed the effectiveness of asking for data directly from authors and obtained over half of the requested datasets, albeit with similar to 8 d delay and some disagreement with authors. Given the long-term benefits of data accessibility to the academic community, we believe that journal-based mandatory data archiving policies and mandatory data availability statements should be more widely adopted.-Vines, T. H., Andrew, R. L., Bock, D. G., Franklin, M. T., Gilbert, K. J., Kane, N. C., Moore, J-S., Moyers, B. T., Renaut, S., Rennison, D. J., Veen, T., Yeaman, S. Mandated data archiving greatly improves access to research data. FASEB J. 27, 1304-1308 (2013). www.fasebj.org	[Vines, Timothy H.; Andrew, Rose L.; Bock, Dan G.; Franklin, Michelle T.; Gilbert, Kimberly J.; Kane, Nolan C.; Moore, Jean-Sebastien; Moyers, Brook T.; Renaut, Sebastien; Rennison, Diana J.; Veen, Thor; Yeaman, Sam] Univ British Columbia, Biodivers Dept, Vancouver, BC V6T 1Z4, Canada; [Vines, Timothy H.] Editorial Off, Vancouver, BC, Canada; [Franklin, Michelle T.] Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada; [Kane, Nolan C.] Univ Colorado, Dept Ecol & Evolut Biol, Boulder, CO 80309 USA	University of British Columbia; Simon Fraser University; University of Colorado System; University of Colorado Boulder	Vines, TH (corresponding author), Univ British Columbia, Biodivers Dept, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	vines@zoology.ubc.ca	Yeaman, Sam/C-7778-2011; Andrew, Rose/B-5929-2008; Renaut, Sebastien/P-6236-2019; Moyers, Brook T./E-1516-2012; Gilbert, Kimberly/A-2932-2013; KANE, NOLAN/B-7652-2016	Yeaman, Sam/0000-0002-1706-8699; Andrew, Rose/0000-0003-0099-8336; Renaut, Sebastien/0000-0002-8111-5082; Moyers, Brook T./0000-0003-0340-9488; Gilbert, Kimberly/0000-0002-8507-2294; Bock, Dan/0000-0001-7788-1705; Rennison, Diana/0000-0002-5944-0743; KANE, NOLAN/0000-0001-9133-6543; Vines, Timothy/0000-0002-5418-9967				Alsheikh-Ali AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024357; Gilbert KJ, 2012, MOL ECOL, V21, P4925, DOI 10.1111/j.1365-294X.2012.05754.x; Leberg PL, 1999, EVOLUTION, V53, P1961, DOI [10.2307/2640454, 10.1111/j.1558-5646.1999.tb04576.x]; Michener WK, 1997, ECOL APPL, V7, P330, DOI 10.2307/2269427; Peng RD, 2011, SCIENCE, V334, P1226, DOI 10.1126/science.1213847; Piwowar HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018657; Piwowar HA, 2011, NATURE, V473, P285, DOI 10.1038/473285a; Piwowar HA, 2010, J INFORMETR, V4, P148, DOI 10.1016/j.joi.2009.11.010; Pritchard JK, 2000, GENETICS, V155, P945; Savage CJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007078; Vision TJ, 2010, BIOSCIENCE, V60, P330, DOI 10.1525/bio.2010.60.5.2; Whitlock MC, 2010, AM NAT, V175, pE45, DOI 10.1086/650340; Wicherts JM, 2006, AM PSYCHOL, V61, P726, DOI 10.1037/0003-066X.61.7.726; Wolkovich EM, 2012, GLOBAL CHANGE BIOL, V18, P2102, DOI 10.1111/j.1365-2486.2012.02693.x; Wren JD, 2006, EMBO REP, V7, P122, DOI 10.1038/sj.embor.7400631	15	87	88	1	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1304	1308		10.1096/fj.12-218164	http://dx.doi.org/10.1096/fj.12-218164			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23288929	Green Submitted			2022-12-28	WOS:000316940800003
J	van Veenendaal, NR; Ulmer, B; Boskovski, MT; Fang, XF; Khokha, MK; Wendler, CC; Blum, M; Rivkees, SA				van Veenendaal, Nicole R.; Ulmer, Baerbel; Boskovski, Marko T.; Fang, Xiefan; Khokha, Mustafa K.; Wendler, Christopher C.; Blum, Martin; Rivkees, Scott A.			Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos	FASEB JOURNAL			English	Article						thyroid; Graves' disease; methimazole; situs; teratogenicity	THYROID-DYSFUNCTION; ANTITHYROID DRUGS; PREGNANCY; MANAGEMENT; CILIA; HYPERTHYROIDISM; EXPRESSION; HYPOTHYROIDISM; TROPICALIS; MOUSE	Antithyroid medications are the preferred therapy for the treatment of Graves' disease during pregnancy. Propylthiouracil (PTU) is favored over methimazole (MMI) due to potential teratogenic concerns with MMI. This study was to determine the teratogenic potential of MMI and PTU using a validated Xenopus tropicalis embryo model. Embryos were exposed to 1 mM PTU (EC50 = 0.88 mM), 1 mM MMI, or vehicle control (water) from stages 2 to 45. Treated embryos were examined for gross morphological defects, ciliary function, and gene expression by in situ hybridization. Exposure to PTU, but not MMI, led to cardiac and gut looping defects and shortening along the anterior-posterior axis. PTU exposure during gastrulation (stage 8-12.5) was identified as the critical period of exposure leading to left-right (LR) patterning defects. Abnormal cilia polarization, abnormal cilia-driven leftward flow at the gastrocoel roof plate (GRP), and aberrant expression of both Coco and Pitx2c were associated with abnormal LR symmetry observed following PTU exposure. PTU is teratogenic during late blastula, gastrulation, and neurulation; whereas MMI is not. PTU alters ciliary-driven flow and disrupts the normal genetic program involved in LR axis determination. These studies have important implications for women taking PTU during early pregnancy.-Van Veenendaal, N.R., Ulmer, B., Boskovski, M. T., Fang, X., Khokha, M. K., Wendler, C. C., Blum, M., Rivkees, S. A. Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos. FASEB J. 27, 684-691 (2013). www.fasebj.org	[van Veenendaal, Nicole R.; Boskovski, Marko T.; Fang, Xiefan; Khokha, Mustafa K.; Wendler, Christopher C.; Rivkees, Scott A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Boskovski, Marko T.; Khokha, Mustafa K.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Ulmer, Baerbel; Blum, Martin] Univ Hohenheim, Inst Zool, Stuttgart, Germany; [van Veenendaal, Nicole R.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Fang, Xiefan; Wendler, Christopher C.; Rivkees, Scott A.] Univ Florida, Dept Pediat, Gainesville, FL 32610 USA	Yale University; Yale University; University Hohenheim; University of Amsterdam; Academic Medical Center Amsterdam; State University System of Florida; University of Florida	Rivkees, SA (corresponding author), Univ Florida, Coll Med, Dept Pediat, POB 100296, Gainesville, FL 32610 USA.	srivkees@ufl.edu	Ulmer, Bärbel/AAB-9564-2020; Fang, Xiefan/G-1186-2015	Fang, Xiefan/0000-0002-7804-7832	U.S. National Institutes of Health [1R01DE018825, 1R01HD065200]; Deutsche Forschungsgemeinschaft [BL-285/10-1]; Nuffic Dutch Huygens Talent Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD065200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE018825] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Nuffic Dutch Huygens Talent Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by U.S. National Institutes of Health grants 1R01DE018825 (to M. K. K.) and 1R01HD065200 (to S. A. R), by grant BL-285/10-1 from the Deutsche Forschungsgemeinschaft (to M. B.), and by The Nuffic Dutch Huygens Talent Scholarship (to N.R.V.V.). The authors thank Michael Slocum for Xenopus husbandry, Sarah Kirschner for setting up Xenopus matings used in this study, and Isabelle Schneider, Thomas Thumberger, and Peter Walentek for help with GRP and flow analysis.	Abalovich M, 2007, J CLIN ENDOCR METAB, V92, pS1, DOI 10.1210/jc.2007-0141; Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alten L, 2012, DEVELOPMENT, V139, P1276, DOI 10.1242/dev.072728; Antic D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008999; Bahn Rebecca S, 2009, Thyroid, V19, P673, DOI 10.1089/thy.2009.0169; Benavides VC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035213; Beyer T, 2012, CURR BIOL, V22, P33, DOI 10.1016/j.cub.2011.11.027; Blum M, 2007, DIFFERENTIATION, V75, P133, DOI 10.1111/j.1432-0436.2006.00124.x; Blum M, 2009, DEV DYNAM, V238, P1215, DOI 10.1002/dvdy.21855; Braverman L. E., 2003, DIS THYROID; BURROW GN, 1985, NEW ENGL J MED, V313, P562, DOI 10.1056/NEJM198508293130907; Calikoglu AS, 1996, NEUROSCI LETT, V213, P132; Chan GW, 2007, NAT CLIN PRACT ENDOC, V3, P470, DOI 10.1038/ncpendmet0508; Chattaway JM, 2007, ANN PHARMACOTHER, V41, P1018, DOI 10.1345/aph.1H535; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Clementi M, 2010, J CLIN ENDOCR METAB, V95, pE337, DOI 10.1210/jc.2010-0652; Cooper DS, 2005, NEW ENGL J MED, V352, P905, DOI 10.1056/NEJMra042972; Diav-Citrin O, 2002, TERATOLOGY, V65, P38, DOI 10.1002/tera.1095.abs; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fakhro KA, 2011, P NATL ACAD SCI USA, V108, P2915, DOI 10.1073/pnas.1019645108; Fantz CR, 1999, CLIN CHEM, V45, P2250; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; Glinoer D, 1998, THYROID, V8, P859, DOI 10.1089/thy.1998.8.859; GOLDEY ES, 1995, TOXICOL APPL PHARM, V135, P67, DOI 10.1006/taap.1995.1209; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; Kashiwagi K, 2010, EXP ANIM TOKYO, V59, P395, DOI 10.1538/expanim.59.395; Khokha MK, 2002, DEV DYNAM, V225, P499, DOI 10.1002/dvdy.10184; Koren G, 2006, THER DRUG MONIT, V28, P12, DOI 10.1097/01.ftd.0000192135.54477.d9; KREMENTZ ET, 1957, SURGERY, V41, P619; Lenhart KF, 2011, DEVELOPMENT, V138, P4405, DOI 10.1242/dev.071092; Maisonneuve C, 2009, DEVELOPMENT, V136, P3019, DOI 10.1242/dev.038174; Marx H, 2008, BRIT MED J, V336, P663, DOI 10.1136/bmj.39462.709005.AE; Mestman JH, 1998, ENDOCRIN METAB CLIN, V27, P127, DOI 10.1016/S0889-8529(05)70303-0; Mouche I, 2011, METHODS MOL BIOL, V691, P257, DOI 10.1007/978-1-60761-849-2_15; Okosieme OE, 2008, EXPERT OPIN PHARMACO, V9, P2281, DOI [10.1517/14656566.9.13.2281, 10.1517/14656566.9.13.2281 ]; Roti E, 1996, J CLIN ENDOCR METAB, V81, P1679, DOI 10.1210/jc.81.5.1679; Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0; Schweickert A, 2007, CURR BIOL, V17, P60, DOI 10.1016/j.cub.2006.10.067; Schweickert A, 2010, CURR BIOL, V20, P738, DOI 10.1016/j.cub.2010.02.061; Setter PW, 2006, EXP CELL RES, V312, P2880, DOI 10.1016/j.yexcr.2006.05.014; Shi HH, 2010, COMP BIOCHEM PHYS C, V152, P62, DOI 10.1016/j.cbpc.2010.02.013; Shook DR, 2004, DEV BIOL, V270, P163, DOI 10.1016/j.ydbio.2004.02.021; Sive H. L., 2010, EARLY DEV XECOPUS LA; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Song H, 2010, NATURE, V466, P378, DOI 10.1038/nature09129; STANISSTREET M, 1990, TERATOLOGY, V41, P721, DOI 10.1002/tera.1420410609; Stubbs JL, 2008, NAT GENET, V40, P1454, DOI 10.1038/ng.267; Tindall AJ, 2007, BIOL CELL, V99, P151, DOI 10.1042/BC20060074; Vick P, 2009, DEV BIOL, V331, P281, DOI 10.1016/j.ydbio.2009.05.547; Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808; Wheeler GN, 2009, DEV DYNAM, V238, P1287, DOI 10.1002/dvdy.21967; ZOLCINSKI A, 1964, Ginekol Pol, V35, P593	53	13	13	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					684	691		10.1096/fj.12-218073	http://dx.doi.org/10.1096/fj.12-218073			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150524	Green Published			2022-12-28	WOS:000314358000027
J	Zhang, JP; Valianou, M; Simmons, H; Robinson, MK; Lee, HO; Mullins, SR; Marasco, WA; Adams, GP; Weiner, LM; Cheng, JD				Zhang, Jiping; Valianou, Matthildi; Simmons, Heidi; Robinson, Matthew K.; Lee, Hyung-Ok; Mullins, Stefanie R.; Marasco, Wayne A.; Adams, Gregory P.; Weiner, Louis M.; Cheng, Jonathan D.			Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens	FASEB JOURNAL			English	Article						serine protease; single-chain variable fragment	TUMOR STROMAL FIBROBLASTS; SERINE-PROTEASE; EXTRACELLULAR-MATRIX; EPITHELIAL CANCERS; MOLECULAR-CLONING; DIFFERENTIAL EXPRESSION; OVARIAN-CANCER; COLON-CANCER; PHASE-I; CELLS	Fibroblast activation protein (FAP) is a serine protease selectively expressed on tumor stromal fibroblasts in epithelial carcinomas and is important in cancer growth, adhesion, and metastases. As FAP enzymatic activity is a potent therapeutic target, we aimed to identify inhibitory antibodies. Using a competitive inhibition strategy, we used phage display techniques to identify 53 single-chain variable fragments (scFvs) after three rounds of panning against FAP. These scFvs were expressed and characterized for binding to FAP by surface plasmon resonance and flow cytometry. Functional assessment of these antibodies yielded an inhibitory scFv antibody, named E3, which could attenuate 35% of FAP cleavage of the fluorescent substrate Ala-Pro-7-amido-4-trifluoromethylcoumarin compared with nonfunctional scFv control. Furthermore, a mutant E3 scFv was identified by yeast affinity maturation. It had higher affinity (4-fold) and enhanced inhibitory effect on FAP enzyme activity (3-fold) than E3. The application of both inhibitory anti-FAP scFvs significantly affected the formation of 3-dimensional FAP-positive cell matrix, as demonstrated by reducing the fibronectin fiber orientation from 41.18% (negative antibody control) to 34.06% (E3) and 36.15% (mutant E3), respectively. Thus, we have identified and affinity-maturated the first scFv antibody capable of inhibiting FAP function. This scFv antibody has the potential to disrupt the role of FAP in tumor invasion and metastasis.-Zhang, J., Valianou, M., Simmons, H., Robinson, M. K., Lee, H.-O., Mullins, S. R., Marasco, W. A., Adams, G. P., Weiner, L. M., Cheng, J. D. Identification of inhibitory ScFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 27, 581-589 (2013). www.fasebj.org	[Valianou, Matthildi; Lee, Hyung-Ok; Mullins, Stefanie R.; Cheng, Jonathan D.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Zhang, Jiping; Simmons, Heidi; Robinson, Matthew K.; Adams, Gregory P.] Fox Chase Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19111 USA; [Marasco, Wayne A.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Weiner, Louis M.] Georgetown Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute	Cheng, JD (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	j_cheng@fccc.edu	Adams, Gregory/ABE-8245-2020		U.S. National Institutes of Health [CA090468, CA103991-01, CA09035-28]; Frank Strick Foundation; Bernard A. and Rebecca S. Bernard Foundation; NATIONAL CANCER INSTITUTE [K08CA090468, P30CA051008, T32CA009035, R21CA103991] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Frank Strick Foundation; Bernard A. and Rebecca S. Bernard Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by U.S. National Institutes of Health grants CA090468, CA103991-01, and CA09035-28; the Frank Strick Foundation; the Bernard A. and Rebecca S. Bernard Foundation; and an appropriation from the Commonwealth of Pennsylvania and the American Cancer Society.	Adams GP, 2001, CANCER RES, V61, P4750; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Cheng JD, 2005, MOL CANCER THER, V4, P351; Cheng JD, 2002, CANCER RES, V62, P4767; Colby DW, 2004, METHOD ENZYMOL, V388, P348; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Huang Y, 2004, CANCER RES, V64, P2712, DOI 10.1158/0008-5472.CAN-03-3184; IOZZO RV, 1995, LAB INVEST, V73, P157; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Lee HO, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-245; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; LIOTTA LA, 1986, CANCER RES, V46, P1; Niedermeyer J, 1998, EUR J BIOCHEM, V254, P650, DOI 10.1046/j.1432-1327.1998.2540650.x; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; Radisky D, 2002, CANCER INVEST, V20, P139, DOI 10.1081/CNV-120000374; RETTIG WJ, 1993, CANCER RES, V53, P3327; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; RETTIG WJ, 1986, CANCER RES, V46, P6406; Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SCHIER R, 1995, IMMUNOTECHNOLOGY, V1, P73, DOI 10.1016/1380-2933(95)00007-0; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101; Sun SX, 2002, PROTEIN EXPRES PURIF, V24, P274, DOI 10.1006/prep.2001.1572; WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193; Wolf BB, 2008, MINI-REV MED CHEM, V8, P719, DOI 10.2174/138955708784567449; Yuan QA, 2006, MOL CANCER THER, V5, P2096, DOI 10.1158/1535-7163.MCT-06-0115	38	14	19	3	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2013	27	2					581	589		10.1096/fj.12-210377	http://dx.doi.org/10.1096/fj.12-210377			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23104982	Green Published			2022-12-28	WOS:000314358000017
J	Behnke, BJ; Stabley, JN; McCullough, DJ; Davis, RT; Dominguez, JM; Muller-Delp, JM; Delp, MD				Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Dominguez, James M., II; Muller-Delp, Judy M.; Delp, Michael D.			Effects of spaceflight and ground recovery on mesenteric artery and vein constrictor properties in mice	FASEB JOURNAL			English	Article						orthostatic hypotension; microgravity; microcirculation	SIMULATED MICROGRAVITY; ORTHOSTATIC INTOLERANCE; HINDLIMB SUSPENSION; BLOOD-PRESSURE; SMOOTH-MUSCLE; VASOCONSTRICTOR RESPONSIVENESS; RESISTANCE ARTERIES; CA2+ RELEASE; FLOW; RYANODINE	Following exposure to microgravity, there is a reduced ability of astronauts to augment peripheral vascular resistance, often resulting in orthostatic hypotension. The purpose of this study was to test the hypothesis that mesenteric arteries and veins will exhibit diminished vasoconstrictor responses after spaceflight. Mesenteric arteries and veins from female mice flown on the Space Transportation System (STS)-131 (n = 11), STS-133 (n = 6), and STS-135 (n = 3) shuttle missions and respective ground-based control mice (n = 30) were isolated for in vitro experimentation. Vasoconstrictor responses were evoked in arteries via norepinephrine (NE), potassium chloride (KCl), and caffeine, and in veins through NE across a range of intraluminal pressures (2-12 cmH(2)O). Vasoconstriction to NE was also determined in mesenteric arteries at 1, 5, and 7 d postlanding. In arteries, maximal constriction to NE, KCl, and caffeine were reduced immediately following spaceflight and 1 d postflight. Spaceflight also reduced arterial ryanodine receptor-3 mRNA levels. In mesenteric veins, there was diminished constriction to NE after flight. The results indicate that the impaired vasoconstriction following spaceflight occurs through the ryanodine receptor-mediated intracellular Ca2+ release mechanism. Such vascular changes in astronauts could compromise the maintenance of arterial pressure during orthostatic stress.-Behnke, B. J., Stabley, J. N., McCullough, D. J., Davis, R. T., III, Dominguez, J. M., II, Muller-Delp, J. M., Delp, M. D. Effects of spaceflight and ground recovery on mesenteric artery and vein constrictor properties in mice. FASEB J. 27, 399-409 (2013). www.fasebj.org	[Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Dominguez, James M., II; Delp, Michael D.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Dominguez, James M., II; Delp, Michael D.] Univ Florida, Ctr Exercise Sci, Gainesville, FL 32611 USA; [Muller-Delp, Judy M.] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Delp, MD (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, POB 118205, Gainesville, FL 32611 USA.	mdelp@ufl.edu		Delp, Michael/0000-0002-2916-0783; Muller-Delp, Judy/0000-0001-5322-0611; /0000-0002-1825-7846	NASA [NNX08AQ62G, NNX09AP06G]; U.S. National Institutes of Health [AG-31317]; Florida Biomedical Research Program [1BN-02]; Department of Applied Physiology and Kinesiology, University of Florida; NATIONAL INSTITUTE ON AGING [R36AG036816] Funding Source: NIH RePORTER	NASA(National Aeronautics & Space Administration (NASA)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Biomedical Research Program; Department of Applied Physiology and Kinesiology, University of Florida; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	These studies were originally flown on space shuttle mission STS-107, on which the orbiter Columbia tragically disintegrated during its return flight to Earth. This manuscript is dedicated to the STS-107 crew, who were willing to risk their lives to advance our understanding of the effects of microgravity on human health. The authors thank Blaze Emerson for technical assistance and Richard Boyle, Paula Dumars, Marianne Steele, Marilyn Vasquez, and Vera Vizir [U.S. National Aeronautics and Space Administration (NASA) Ames Research Center, Mountain View, CA, USA] for their logistical support. This study was supported by grants from NASA (NNX08AQ62G and NNX09AP06G), the U.S. National Institutes of Health (AG-31317), the Florida Biomedical Research Program (1BN-02), and the Jane Adams Edmonds endowed doctoral fellowship (Department of Applied Physiology and Kinesiology, University of Florida).	Arbeille P, 2008, AM J PHYSIOL-HEART C, V295, pH1846, DOI 10.1152/ajpheart.509.2008; Arbeille P.F., 1996, ACTA ASTRONAUT, V36, P6; Arbeille PP, 2005, J APPL PHYSIOL, V99, P1853, DOI 10.1152/japplphysiol.00331.2005; ARMSTRONG RB, 1987, J APPL PHYSIOL, V62, P1285, DOI 10.1152/jappl.1987.62.3.1285; Baevsky RM, 2007, J APPL PHYSIOL, V103, P156, DOI 10.1152/japplphysiol.00137.2007; Ballard R. W., 1994, FINAL REPORTS US EXP, V1, P374; Behnke BJ, 2001, RESP PHYSIOL, V126, P53, DOI 10.1016/S0034-5687(01)00195-5; Behnke BJ, 2008, J APPL PHYSIOL, V104, P1273, DOI 10.1152/japplphysiol.00954.2006; Behnke BJ, 2010, J APPL PHYSIOL, V108, P14, DOI 10.1152/japplphysiol.00970.2009; Blomqvist C. G., 1983, HDB PHYSL PERIPHERAL, P1027; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Buckey JC, 1996, J APPL PHYSIOL, V81, P7, DOI 10.1152/jappl.1996.81.1.7; BULLARD RW, 1972, ANNU REV PHYSIOL, V34, P205, DOI 10.1146/annurev.ph.34.030172.001225; Callera GE, 1999, GEN PHARMACOL, V33, P457, DOI 10.1016/S0306-3623(99)00042-7; Catterson A.D., 1963, AEROMEDICAL OBSERVAT, P299; Colleran PN, 2008, AM J PHYSIOL-REG I, V294, pR1577, DOI 10.1152/ajpregu.00084.2008; Convertino V. A, 1997, CLIN AUTONOMIC DISOR, V33, P429; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; Dabertrand F, 2012, J APPL PHYSIOL, V112, P471, DOI 10.1152/japplphysiol.00733.2011; Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387; DAVIS MJ, 1992, AM J PHYSIOL, V262, pC1083, DOI 10.1152/ajpcell.1992.262.4.C1083; DELP MD, 1995, J APPL PHYSIOL, V78, P2079, DOI 10.1152/jappl.1995.78.6.2079; DELP MD, 1993, J APPL PHYSIOL, V75, P2620, DOI 10.1152/jappl.1993.75.6.2620; Delp MD, 2000, AM J PHYSIOL-HEART C, V278, pH1866, DOI 10.1152/ajpheart.2000.278.6.H1866; Delp MD, 1999, J APPL PHYSIOL, V86, P1178, DOI 10.1152/jappl.1999.86.4.1178; Donato AJ, 2005, CARDIOVASC RES, V66, P393, DOI 10.1016/j.cardiores.2004.10.023; Dunbar SL, 2000, J APPL PHYSIOL, V89, P2073, DOI 10.1152/jappl.2000.89.5.2073; Ertl AC, 2002, J PHYSIOL-LONDON, V538, P321, DOI 10.1113/jphysiol.2001.012576; Essin K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/135249; FAREH J, 1994, J APPL PHYSIOL, V76, P641, DOI 10.1152/jappl.1994.76.2.641; FENGERGRON J, 1995, J PHYSIOL-LONDON, V488, P753, DOI 10.1113/jphysiol.1995.sp021006; Gashev AA, 2006, AM J PHYSIOL-HEART C, V290, pH2295, DOI 10.1152/ajpheart.00260.2005; Halet G., 1999, AM J PHYSIOL, V277, pC139; Hatton DC, 2002, J APPL PHYSIOL, V92, P13, DOI 10.1152/jappl.2002.92.1.13; KONG JQ, 1994, J PHARMACOL EXP THER, V268, P1153; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710; Levine BD, 1997, CIRCULATION, V96, P517; Lin LJ, 2009, J APPL PHYSIOL, V107, P1710, DOI 10.1152/japplphysiol.00493.2009; Ma J, 1996, J Gravit Physiol, V3, P9; McCurdy MR, 2000, J APPL PHYSIOL, V89, P398, DOI 10.1152/jappl.2000.89.1.398; MCDONALD KS, 1992, J APPL PHYSIOL, V72, P2210, DOI 10.1152/jappl.1992.72.6.2210; Meck JV, 2001, PSYCHOSOM MED, V63, P865, DOI 10.1097/00006842-200111000-00003; Miriel VA, 1999, J PHYSIOL-LONDON, V518, P815, DOI 10.1111/j.1469-7793.1999.0815p.x; Morel J. L., 1997, AM J PHYSIOL, V273, pH2867; MULVAGH SL, 1991, J CLIN PHARMACOL, V31, P1024, DOI 10.1002/j.1552-4604.1991.tb03666.x; Neri G, 2002, AM J PHYSIOL-REG I, V283, pR832, DOI 10.1152/ajpregu.00099.2002; Norsk P, 2006, HYPERTENSION, V47, P69, DOI 10.1161/01.HYP.0000194332.98674.57; Nyhan D, 2002, J APPL PHYSIOL, V92, P33, DOI 10.1152/jappl.2002.92.1.33; OVERTON JM, 1990, J APPL PHYSIOL, V68, P355, DOI 10.1152/jappl.1990.68.1.355; Papadopoulos A, 2003, J APPL PHYSIOL, V94, P439, DOI 10.1152/japplphysiol.00734.2002; Purdy RE, 1998, J APPL PHYSIOL, V85, P1307, DOI 10.1152/jappl.1998.85.4.1307; Rowell L, 1993, HUMAN CARDIOVASCULAR; ROWELL LB, 1972, J APPL PHYSIOL, V32, P213, DOI 10.1152/jappl.1972.32.2.213; Sangha DS, 2000, J APPL PHYSIOL, V88, P507, DOI 10.1152/jappl.2000.88.2.507; SAYET I, 1995, J APPL PHYSIOL, V78, P1882, DOI 10.1152/jappl.1995.78.5.1882; Serova L.V., 1984, PHYSIOLOGIST, V27, pS107; SHOUKAS AA, 1990, AM J PHYSIOL, V259, pH674, DOI 10.1152/ajpheart.1990.259.3.H674; Smimov K. V., 1987, KOS BIOL AVIAK MED, V21, P8; Spier SA, 2004, J PHYSIOL-LONDON, V556, P947, DOI 10.1113/jphysiol.2003.060301; Stabley JN, 2012, J APPL PHYSIOL, V113, P1439, DOI 10.1152/japplphysiol.00772.2012; Steenbergen JF, 1996, J BIOL CHEM, V271, P1821, DOI 10.1074/jbc.271.4.1821; Sun GS, 2010, NUTRITION, V26, P1163, DOI 10.1016/j.nut.2009.09.018; WATANABE J, 1994, CARDIOVASC RES, V28, P480, DOI 10.1093/cvr/28.4.480; WATANABE J, 1993, CIRC RES, V73, P465, DOI 10.1161/01.RES.73.3.465; Watenpaugh D.E., 2011, COMPR PHYSIOL, DOI [10.1002/cphy.cp040129, DOI 10.1002/CPHY.CP040129]; Waters WW, 2002, J APPL PHYSIOL, V92, P586, DOI 10.1152/japplphysiol.00544.2001; White AR, 2010, EUR J APPL PHYSIOL, V110, P395, DOI 10.1007/s00421-010-1514-7; Wilkerson MK, 1999, J APPL PHYSIOL, V87, P2115, DOI 10.1152/jappl.1999.87.6.2115; WOODMAN CR, 1995, J APPL PHYSIOL, V79, P1762, DOI 10.1152/jappl.1995.79.5.1762; Xue JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019775; Zhang LF, 2001, J APPL PHYSIOL, V91, P2415, DOI 10.1152/jappl.2001.91.6.2415; Zheng YM, 2008, J VASC RES, V45, P469, DOI 10.1159/000127438	72	32	36	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					399	409		10.1096/fj.12-218503	http://dx.doi.org/10.1096/fj.12-218503			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23099650	Green Published			2022-12-28	WOS:000313103200038
J	Maamary, PG; Ben Zakour, NL; Cole, JN; Hollands, A; Aziz, RK; Barnett, TC; Cork, AJ; Henningham, A; Sanderson-Smith, M; McArthur, JD; Venturini, C; Gillen, CM; Kirk, JK; Johnson, DR; Taylor, WL; Kaplan, EL; Kotb, M; Nizet, V; Beatson, SA; Walker, MJ				Maamary, Peter G.; Ben Zakour, Nouri L.; Cole, Jason N.; Hollands, Andrew; Aziz, Ramy K.; Barnett, Timothy C.; Cork, Amanda J.; Henningham, Anna; Sanderson-Smith, Martina; McArthur, Jason D.; Venturini, Carola; Gillen, Christine M.; Kirk, Joshua K.; Johnson, Dwight R.; Taylor, William L.; Kaplan, Edward L.; Kotb, Malak; Nizet, Victor; Beatson, Scott A.; Walker, Mark J.			Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone	FASEB JOURNAL			English	Article						Streptococcus pyogenes; virulence factors; reemergent pathogens	PYROGENIC EXOTOXIN; PLASMINOGEN BINDING; MOLECULAR ANALYSIS; M-PROTEIN; IN-VIVO; VIRULENCE; PYOGENES; INFECTIONS; EXPRESSION; SEQUENCE	The past 50 years has witnessed the emergence of new viral and bacterial pathogens with global effect on human health. The hyperinvasive group A Streptococcus (GAS) M1T1 clone, first detected in the mid-1980s in the United States, has since disseminated worldwide and remains a major cause of severe invasive human infections. Although much is understood regarding the capacity of this pathogen to cause disease, much less is known of the precise evolutionary events selecting for its emergence. We used high-throughput technologies to sequence a World Health Organization strain collection of serotype M1 GAS and reconstructed its phylogeny based on the analysis of core genome single-nucleotide polymorphisms. We demonstrate that acquisition of a 36-kb genome segment from serotype M12 GAS and the bacteriophage-encoded DNase Sda1 led to increased virulence of the M1T1 precursor and occurred relatively early in the molecular evolutionary history of this strain. The more recent acquisition of the phage-encoded superantigen SpeA is likely to have provided selection advantage for the global dissemination of the M1T1 clone. This study provides an exemplar for the evolution and emergence of virulent clones from microbial populations existing commensally or causing only superficial infection.-Maamary, P. G., Ben Zakour, N. L., Cole, J. N., Hollands, A., Aziz, R. K., Barnett, T. C., Cork, A. J., Henningham, A., Sanderson-Smith, M., McArthur, J. D., Venturini, C., Gillen, C. M., Kirk, J. K., Johnson, D. R., Taylor, W. L., Kaplan, E. L., Kotb, M., Nizet, V., Beatson, S. A., Walker, M. J. Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. FASEB J. 26, 4675-4684 (2012). www.fasebj.org	[Maamary, Peter G.; Ben Zakour, Nouri L.; Hollands, Andrew; Barnett, Timothy C.; Cork, Amanda J.; Henningham, Anna; Venturini, Carola; Gillen, Christine M.; Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Maamary, Peter G.; Ben Zakour, Nouri L.; Cole, Jason N.; Hollands, Andrew; Barnett, Timothy C.; Cork, Amanda J.; Henningham, Anna; Venturini, Carola; Gillen, Christine M.; Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia; [Maamary, Peter G.; Cole, Jason N.; Hollands, Andrew; Cork, Amanda J.; Henningham, Anna; Sanderson-Smith, Martina; McArthur, Jason D.; Kirk, Joshua K.; Walker, Mark J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia; [Hollands, Andrew] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Nizet, Victor] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Aziz, Ramy K.] Cairo Univ, Fac Pharm, Dept Microbiol & Immunol, Cairo, Egypt; [Aziz, Ramy K.] San Diego State Univ, San Diego, CA 92182 USA; [Johnson, Dwight R.; Kaplan, Edward L.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Johnson, Dwight R.; Kaplan, Edward L.] Univ Minnesota, World Hlth Org Collaborating Ctr Reference & Res, Minneapolis, MN 55455 USA; [Taylor, William L.; Kotb, Malak] Univ Tennessee, Mol Resource Ctr, Memphis, TN USA; [Kotb, Malak] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; [Kotb, Malak] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA	University of Queensland; University of Queensland; University of Wollongong; University of California System; University of California San Diego; University of California System; University of California San Diego; Egyptian Knowledge Bank (EKB); Cairo University; California State University System; San Diego State University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; World Health Organization; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Walker, MJ (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, Cooper Rd, St Lucia, Qld 4072, Australia.	mark.walker@uq.edu.au	Nizet, Victor/AAF-3190-2019; Venturini, Carola/G-6642-2018; Barnett, Timothy/G-2155-2011; Gillen, Christine M/A-2717-2014; Cork, Amanda/C-3830-2012; Walker, Mark J./F-6940-2011; Sanderson-Smith, Martina L/H-9614-2013; Henningham, Anna/C-7355-2017; Sanderson-Smith, Martina/O-9387-2019; ZAKOUR, Nouri L BEN/B-9338-2011; Beatson, Scott/B-6985-2013; Aziz, Ramy/B-2918-2009	Venturini, Carola/0000-0003-2370-8661; Barnett, Timothy/0000-0002-3346-5117; Cork, Amanda/0000-0003-2207-6877; Sanderson-Smith, Martina L/0000-0002-6366-4993; Henningham, Anna/0000-0002-0554-6593; ZAKOUR, Nouri L BEN/0000-0002-6949-1755; Beatson, Scott/0000-0002-1806-3283; Duplancic, Christine/0000-0002-1775-3055; Aziz, Ramy/0000-0002-4448-7100; Walker, Mark/0000-0001-7423-2769; Nizet, Victor/0000-0003-3847-0422	Australian postgraduate award; Australian National Health and Medical Research Council (NHMRC); NHMRC; Medical Research Service, Department of Veterans Affairs; U.S. National Institutes of Health [AI077780]; NHMRC of Australia [573401]; Australian International Science Linkages grant [CG110095]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077780] Funding Source: NIH RePORTER	Australian postgraduate award(Australian Government); Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Service, Department of Veterans Affairs(US Department of Veterans Affairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian International Science Linkages grant(Australian GovernmentDepartment of Industry, Innovation and Science); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	P.M. is the recipient of an Australian postgraduate award. J.C. and A. H. are recipients of Australian National Health and Medical Research Council (NHMRC) Overseas Biomedical Training Fellowships. M. S. S. is the recipient of an NHMRC Career Development Fellowship. This work was funded by Medical Research Service, Department of Veterans Affairs (M. K.), U.S. National Institutes of Health grant AI077780 (V.N., M. W.), NHMRC of Australia grant 573401 (M. W.), and Australian International Science Linkages grant CG110095 (M. W., M. K., V.N.).	Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Aziz RK, 2008, EMERG INFECT DIS, V14, P1511, DOI 10.3201/eid1410.071660; Aziz RK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009798; Aziz RK, 2005, J BACTERIOL, V187, P3311, DOI 10.1128/JB.187.10.3311-3318.2005; Aziz RK, 2004, MOL MICROBIOL, V54, P184, DOI 10.1111/j.1365-2958.2004.04255.x; Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; Baquero F, 2011, J ANTIMICROB CHEMOTH, V66, P1659, DOI 10.1093/jac/dkr214; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; Beres SB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000800; Brosnahan AJ, 2009, J IMMUNOL, V182, P2364, DOI 10.4049/jimmunol.0803283; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Cole JN, 2011, NAT REV MICROBIOL, V9, P724, DOI 10.1038/nrmicro2648; Cole JN, 2010, MBIO, V1, DOI 10.1128/mBio.00191-10; Collin M, 2000, MOL MICROBIOL, V36, P1306, DOI 10.1046/j.1365-2958.2000.01942.x; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; Eschenfeldt William H., 2009, V498, P105, DOI 10.1007/978-1-59745-196-3_7; FALKOW S, 1988, REV INFECT DIS, V10, pS274; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Hollands A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004102; IMANISHI K, 1992, INFECT IMMUN, V60, P5025, DOI 10.1128/IAI.60.12.5025-5029.1992; Johnson DR, 2002, J INFECT DIS, V185, P1586, DOI 10.1086/340576; Johnson JR, 2010, CLIN INFECT DIS, V51, P286, DOI 10.1086/653932; Kansal RG, 2010, J INFECT DIS, V201, P855, DOI 10.1086/651019; KATZ AR, 1992, CLIN INFECT DIS, V14, P298, DOI 10.1093/clinids/14.1.298; KOTB M, 1995, CLIN MICROBIOL REV, V8, P411, DOI 10.1128/CMR.8.3.411; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Maamary PG, 2010, J INNATE IMMUN, V2, P596, DOI 10.1159/000317640; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759; NELSON K, 1991, J EXP MED, V174, P1271, DOI 10.1084/jem.174.5.1271; Posada D, 2009, METHODS MOL BIOL, V537, P93, DOI 10.1007/978-1-59745-251-9_5; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; Rogers S, 2007, J INFECT DIS, V195, P1625, DOI 10.1086/513875; Sanderson-Smith ML, 2008, FASEB J, V22, P2715, DOI 10.1096/fj.07-105643; Sriskandan S, 1999, MOL MICROBIOL, V33, P778, DOI 10.1046/j.1365-2958.1999.01525.x; Sriskandan S, 2001, J INFECT DIS, V184, P166, DOI 10.1086/322018; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Sumby P, 2005, P NATL ACAD SCI USA, V102, P1679, DOI 10.1073/pnas.0406641102; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992; Unnikrishnan M, 2001, MICROB PATHOGENESIS, V31, P109, DOI 10.1006/mpat.2001.0453; Vlaminckx BJM, 2007, INFECT IMMUN, V75, P3673, DOI 10.1128/IAI.01695-06; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612	50	42	42	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4675	4684		10.1096/fj.12-212142	http://dx.doi.org/10.1096/fj.12-212142			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22878963	Green Published			2022-12-28	WOS:000310574200028
J	Sayedyahossein, S; Nini, L; Irvine, TS; Dagnino, L				Sayedyahossein, Samar; Nini, Lylia; Irvine, Timothy S.; Dagnino, Lina			Essential role of integrin-linked kinase in regulation of phagocytosis in keratinocytes	FASEB JOURNAL			English	Article						ILK; epidermis; Rac1; particle engulfment; melanosome	PROTEASE-ACTIVATED RECEPTOR-2; GROWTH-FACTOR; MELANOSOME TRANSFER; ADHESION; RAC1; SKIN; DIFFERENTIATION; MORPHOGENESIS; PROLIFERATION; INACTIVATION	Phagocytic melanosome uptake by epidermal keratinocytes is a central protective mechanism against damage induced by ultraviolet radiation. Phagocytosis requires formation of pseudopodia via actin cytoskeleton rearrangements. Integrin-linked kinase (ILK) is an important modulator of actin cytoskeletal dynamics. We have examined the role of ILK in regulation of phagocytosis, using epidermal keratinocytes isolated from mice with epidermis-restricted Ilk gene inactivation. ILK-deficient cells exhibited severely impaired capacity to engulf fluorescent microspheres in response to stimulation of the keratinocyte growth factor (KGF) receptor or the protease-activated receptor-2. KGF induced ERK phosphorylation in ILK-expressing and ILK-deficient cells, suggesting that ILK is not essential for KGF receptor signaling. In contrast, KGF promoted activation of Rac1 and formation of pseudopodia in ILK-expressing, but not in ILK-deficient cells. Rac1-deficient keratinocytes also showed substantially impaired phagocytic ability, underlining the importance of ILK-dependent Rac1 function for particle engulfment. Finally, cross-modulation of KGF receptors by integrins may be another important element, as integrin beta 1-deficient keratinocytes also fail to show significant phagocytosis in response to KGF. Thus, we have identified a novel signaling pathway essential for phagocytosis in keratinocytes, which involves ILK-dependent activation of Rac1 in response to KGF, resulting in the formation of pseudopodia and particle uptake.-Sayedyahossein, S., Nini, L., Irvine, T. S., and Dagnino, L.. Essential role of integrin-linked kinase in regulation of phagocytosis in keratinocytes. FASEB J. 26, 4218-4229 (2012). www.fasebj.org	[Sayedyahossein, Samar; Nini, Lylia; Irvine, Timothy S.; Dagnino, Lina] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Dagnino, Lina] Univ Western Ontario, Dept Paediat, London, ON N6A 5C1, Canada; [Sayedyahossein, Samar; Nini, Lylia; Irvine, Timothy S.; Dagnino, Lina] Childrens Hlth Res Inst, London, ON, Canada; [Sayedyahossein, Samar; Nini, Lylia; Irvine, Timothy S.; Dagnino, Lina] Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159; Sayedyahossein, Samar/0000-0003-1773-4740	Canadian Institutes of Health Research; Quality of Life Campaign of the Children's Health Research Institute	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Quality of Life Campaign of the Children's Health Research Institute	The authors thank Dr. M. Glogauer (University of Toronto, Toronto, ON, Canada) for his gift of Rac<SUP>f/f</SUP> mice, and Dr. S. Koval and J. Sholdic for expert help with transmission electron microscopy experiments. The authors also thank Karen Nygaard for help with confocal microscopy imaging. Funding to L.D. for this work was provided by the Canadian Institutes of Health Research. S.S. was supported with funds from the Quality of Life Campaign of the Children's Health Research Institute.	Auriemma C, 2010, CELL MOL BIOL LETT, V15, P496, DOI 10.2478/s11658-010-0019-z; Belleudi F, 2011, FASEB J, V25, P170, DOI 10.1096/fj.10-162156; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Botelho RJ, 2011, CURR BIOL, V21, pR533, DOI 10.1016/j.cub.2011.05.053; Boulter E, 2006, FASEB J, V20, P1489, DOI 10.1096/fj.05-4579fje; Byers HR, 2007, J INVEST DERMATOL, V127, P1736, DOI 10.1038/sj.jid.5700760; Cardinali G, 2005, J INVEST DERMATOL, V125, P1190, DOI 10.1111/j.0022-202X.2005.23929.x; Cardinali G, 2008, J INVEST DERMATOL, V128, P558, DOI 10.1038/sj.jid.5701063; Costa C, 2010, THESCIENTIFICWORLDJO, V10, P1826, DOI 10.1100/tsw.2010.178; Dagnino L, 2010, METHODS MOL BIOL, V585, P93, DOI 10.1007/978-1-60761-380-0_8; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Enomoto A, 2011, AM J PATHOL, V178, P679, DOI 10.1016/j.ajpath.2010.10.021; Fens MHAM, 2012, HAEMATOL-HEMATOL J, V97, P500, DOI 10.3324/haematol.2011.048694; Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445; Flannagan RS, 2010, J CELL BIOL, V191, P1205, DOI 10.1083/jcb.201007056; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Guidetti GF, 2009, J THROMB HAEMOST, V7, P1200, DOI 10.1111/j.1538-7836.2009.03444.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Ho E, 2012, MOL BIOL CELL, V23, P492, DOI 10.1091/mbc.E11-07-0596; Ho E, 2009, MOL BIOL CELL, V20, P3033, DOI 10.1091/mbc.E09-01-0050; Ivanova IA, 2007, ONCOGENE, V26, P1147, DOI 10.1038/sj.onc.1209894; Ivanova IA, 2007, CELL CYCLE, V6, P2186, DOI 10.4161/cc.6.17.4650; Judah D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036704; Koivusalo M, 2010, J CELL BIOL, V188, P547, DOI 10.1083/jcb.200908086; Liu E, 2005, MOL CELL BIOL, V25, P11145, DOI 10.1128/MCB.25.24.11145-11155.2005; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; Mao YY, 2012, MOL BIOL CELL, V23, P1104, DOI 10.1091/mbc.E11-10-0840; Nakrieko KA, 2008, MOL BIOL CELL, V19, P1462, DOI 10.1091/mbc.E07-06-0526; Nakrieko KA, 2011, MOL BIOL CELL, V22, P2532, DOI 10.1091/mbc.E11-01-0035; Raghavan S, 2003, DEV CELL, V5, P415, DOI 10.1016/S1534-5807(03)00261-2; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Rooney N, 2011, FEBS LETT, V585, P1663, DOI 10.1016/j.febslet.2011.05.014; Rosenberger G, 2005, J BIOL CHEM, V280, P6879, DOI 10.1074/jbc.M412119200; Sharlow ER, 2000, J CELL SCI, V113, P3093; Siemens N, 2011, J BIOL CHEM, V286, P21612, DOI 10.1074/jbc.M110.202671; Sindrilaru A, 2009, BLOOD, V113, P5266, DOI 10.1182/blood-2008-07-166702; Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Tzircotis G, 2011, J CELL SCI, V124, P2897, DOI 10.1242/jcs.084269; Uliczka F, 2009, CELL MICROBIOL, V11, P1782, DOI 10.1111/j.1462-5822.2009.01371.x; Van den Bossche K, 2006, TRAFFIC, V7, P769, DOI 10.1111/j.1600-0854.2006.00425.x; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; Wang QQ, 2008, J IMMUNOL, V180, P2419, DOI 10.4049/jimmunol.180.4.2419; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Yoshida H, 1996, DEVELOPMENT, V122, P1207; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	47	22	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4218	4229		10.1096/fj.12-207852	http://dx.doi.org/10.1096/fj.12-207852			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22767228				2022-12-28	WOS:000309704000027
J	Vodstrcil, LA; Tare, M; Novak, J; Dragomir, N; Ramirez, RJ; Wlodek, ME; Conrad, KP; Parry, LJ				Vodstrcil, Lenka A.; Tare, Marianne; Novak, Jacqueline; Dragomir, Nicoleta; Ramirez, Rolando J.; Wlodek, Mary E.; Conrad, Kirk P.; Parry, Laura J.			Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow	FASEB JOURNAL			English	Article						RXFP1; extracellular matrix; preeclampsia; vascular smooth muscle	SMOOTH-MUSCLE-CELLS; NONPREGNANT RATS; MYOGENIC REACTIVITY; CONSCIOUS RATS; NITRIC-OXIDE; MATRIX METALLOPROTEINASES; MECHANICAL-PROPERTIES; VASCULAR DYSFUNCTION; RECEPTOR RXFP1; MESSENGER-RNA	Normal pregnancy involves dramatic remodeling of the uterine vasculature, with abnormal vascular adaptations contributing to pregnancy diseases such as preeclampsia. The peptide hormone relaxin is important for the renal and systemic hemodynamic adaptations to pregnancy, and has been shown to increase arterial compliance and outward hypertrophic remodeling. Therefore, we investigated the possibility that relaxin acts on its receptor, RXFP1, to mediate uterine artery compliance in late pregnancy and increase uterine blood flow velocity in rats. RXFP1 was predominantly localized to the tunica media vascular smooth muscle cells in the uterine artery, although receptors were also detected in endothelial cells. Highest expression of Rxfp1 in the uterine artery occurred in estrus and early pregnancy. Isolated uterine arteries from late pregnant rats treated with a monoclonal antibody against circulating relaxin (MCA1) had significantly increased vessel wall stiffness compared with controls, with no reduction in wall thickness. Chronic infusion of relaxin (4 mu g/h, osmotic minipump) for 5 d in nonpregnant rats significantly increased uterine artery blood flow velocity. Overall, these data demonstrate a functional role for relaxin in mediating uterine artery compliance in pregnant rats, which may be necessary to maintain adequate uterine blood flow to the uterus and placenta.-Vodstrcil, L. A., Tare, M., Novak, J., Dragomir, N., Ramirez, R. J., Wlodek, M. E., Conrad, K. P., Parry, L. J. Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow. FASEB J. 26, 4035-4044 (2012). www.fasebj.org	[Vodstrcil, Lenka A.; Parry, Laura J.] Univ Melbourne, Dept Zool, Parkville, Vic 3010, Australia; [Vodstrcil, Lenka A.; Wlodek, Mary E.] Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia; [Dragomir, Nicoleta] Univ Melbourne, Dept Phys, Parkville, Vic 3010, Australia; [Tare, Marianne] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Novak, Jacqueline] Walsh Univ, Div Math & Sci, N Canton, OH USA; [Ramirez, Rolando J.] Univ Akron, Dept Biol, Akron, OH 44325 USA; [Conrad, Kirk P.] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL USA	University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Walsh University; University System of Ohio; University of Akron; State University System of Florida; University of Florida	Parry, LJ (corresponding author), Univ Melbourne, Dept Zool, Gate 12, Parkville, Vic 3010, Australia.	ljparry@unimelb.edu.au	wlodek, Mary/A-8939-2019; Vodstrcil, Lenka/AAC-1896-2019; Vodstrcil, Lenka/AAF-8722-2020; Lostak, Michal/I-6498-2019	wlodek, Mary/0000-0002-8490-9099; Vodstrcil, Lenka/0000-0003-3679-9195; Lostak, Michal/0000-0003-0392-0702; Parry, Laura/0000-0002-6883-3418	National Health and Medical Research Council of Australia (NHMRC); U.S. National Institutes of Health [HL067937]; NH&MRC Dora Lush Postgraduate Scholarship; John and Allan Gilmour Research Award; Albert Shimmin Award (Faculty of Science, University of Melbourne); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NH&MRC Dora Lush Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); John and Allan Gilmour Research Award; Albert Shimmin Award (Faculty of Science, University of Melbourne); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The authors thank Prof. O. David Sherwood (University of Illinois, Urbana, IL, USA) for providing the MCA1, MCAF, and rat RXFP1 antibodies, and for helpful advice with the experimental design. The authors also thank Dr. Elaine Unemori and Dr. Dennis Stewart (Corthera, Inc., San Mateo, CA, USA) for providing the recombinant human relaxin. The authors thank Dr. Jonathan McGuane, Emma Simpson, Kerryn Westcott, Dr. Jill Verlander, and John J. Reho for their valuable contributions to this work. The research was funded by the National Health and Medical Research Council of Australia (NH & MRC; M.E.W., L.J.P., M.T.), and The U.S. National Institutes of Health (HL067937; K.P.C.). L.A.V. received a NH&MRC Dora Lush Postgraduate Scholarship, the John and Allan Gilmour Research Award, and an Albert Shimmin Award (Faculty of Science, University of Melbourne).	Anumba DOC, 2009, EUR J OBSTET GYN R B, V147, P41, DOI 10.1016/j.ejogrb.2009.07.008; Bani D, 1998, HYPERTENSION, V31, P1240, DOI 10.1161/01.HYP.31.6.1240; Bird IM, 2003, AM J PHYSIOL-REG I, V284, pR245, DOI 10.1152/ajpregu.00108.2002; Chan SL, 2011, FASEB J, V25, P3229, DOI 10.1096/fj.10-175471; CIPOLLA M, 1994, AM J OBSTET GYNECOL, V171, P805, DOI 10.1016/0002-9378(94)90102-3; Cipolla MJ, 1997, AM J OBSTET GYNECOL, V177, P215, DOI 10.1016/S0002-9378(97)70464-2; Conrad KP, 2011, CURR HYPERTENS REP, V13, P409, DOI 10.1007/s11906-011-0231-x; Conrad KP, 2011, AM J PHYSIOL-REG I, V301, pR267, DOI 10.1152/ajpregu.00156.2011; Conrad KP, 2011, SEMIN NEPHROL, V31, P15, DOI 10.1016/j.semnephrol.2010.10.003; Conrad KP, 2004, ENDOCRINOLOGY, V145, P3289, DOI 10.1210/en.2003-1612; CRISH JF, 1986, J BIOL CHEM, V261, P1909; Danielson LA, 1999, J CLIN INVEST, V103, P525, DOI 10.1172/JCI5630; Debrah DO, 2006, ENDOCRINOLOGY, V147, P5126, DOI 10.1210/en.2006-0567; Debrah DO, 2011, J APPL PHYSIOL, V111, P260, DOI 10.1152/japplphysiol.00845.2010; Ferreira VM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004845; Fuller R, 2011, REPROD SCI, V18, P723, DOI 10.1177/1933719110396700; Gagnon R, 2003, EUR J OBSTET GYN R B, V110, pS99, DOI 10.1016/S0301-2115(03)00179-9; Granger JP, 2002, MICROCIRCULATION, V9, P147, DOI 10.1038/sj.mn.7800137; GRIENDLING KK, 1985, AM J PHYSIOL, V248, pH658, DOI 10.1152/ajpheart.1985.248.5.H658; GUENTHER AE, 1988, J ANIM SCI, V66, P3144; GUICOLAMM ML, 1988, ENDOCRINOLOGY, V123, P2472, DOI 10.1210/endo-123-5-2472; GUNNERSEN JM, 1995, MOL CELL ENDOCRINOL, V110, P55, DOI 10.1016/0303-7207(95)03516-A; Jacob MP, 2003, BIOMED PHARMACOTHER, V57, P195, DOI 10.1016/S0753-3322(03)00065-9; Jeyabalan A, 2006, J APPL PHYSIOL, V100, P1955, DOI 10.1152/japplphysiol.01330.2005; Jeyabalan A, 2007, ENDOCRINOLOGY, V148, P189, DOI 10.1210/en.2006-0989; Jeyabalan A, 2007, FRONT BIOSCI-LANDMRK, V12, P2425, DOI 10.2741/2244; Kelly B, 1999, FETAL MATERN MED REV, V11, P105; Kelly BA, 2003, MOL HUM REPROD, V9, P351, DOI 10.1093/molehr/gag043; Keyes LE, 1996, J CELL PHYSIOL, V166, P22, DOI 10.1002/(SICI)1097-4652(199601)166:1<22::AID-JCP3>3.0.CO;2-I; Longo M, 2003, AM J OBSTET GYNECOL, V188, P1468, DOI 10.1067/mob.2003.454; Mazzuca MQ, 2010, J PHYSIOL-LONDON, V588, P1997, DOI 10.1113/jphysiol.2010.187849; McGuane JT, 2011, ENDOCRINOLOGY, V152, P2786, DOI 10.1210/en.2010-1126; Novak J, 2001, J CLIN INVEST, V107, P1469, DOI 10.1172/JCI11975; Novak J, 2002, AM J PHYSIOL-REG I, V283, pR349, DOI 10.1152/ajpregu.00635.2001; Novak J, 2002, FASEB J, V16, pA824; Novak J, 2006, FASEB J, V20, P2352, DOI 10.1096/fj.06-6263com; OSOL G, 1993, AM J OBSTET GYNECOL, V168, P697, DOI 10.1016/0002-9378(93)90519-O; Osol G, 2009, PHYSIOLOGY, V24, P58, DOI 10.1152/physiol.00033.2008; Roberts JM, 2005, HYPERTENSION, V46, P1243, DOI 10.1161/01.HYP.0000188408.49896.c5; Scott DJ, 2006, J BIOL CHEM, V281, P34942, DOI 10.1074/jbc.M602728200; SHERWOOD OD, 1980, ENDOCRINOLOGY, V107, P691, DOI 10.1210/endo-107-3-691; Siebel AL, 2003, ENDOCRINOLOGY, V144, P4272, DOI 10.1210/en.2003-0548; STEWART DR, 1990, J CLIN ENDOCR METAB, V70, P1771, DOI 10.1210/jcem-70-6-1771; van der Heijden OWH, 2005, BIOL REPROD, V73, P1289, DOI 10.1095/biolreprod.105.044438; van der Heijden OWH, 2005, BIOL REPROD, V72, P1161, DOI 10.1095/biolreprod.104.033985; Vodstrcil LA, 2007, REPROD FERT DEVELOP, V19, P530, DOI 10.1071/RD07007; Vodstrcil LA, 2010, BIOL REPROD, V83, P825, DOI 10.1095/biolreprod.110.084301; Vodstrcil LA, 2010, BIOL REPROD, V83, P818, DOI 10.1095/biolreprod.110.083931; Wigg SJ, 2004, DIABETOLOGIA, V47, P1038, DOI 10.1007/s00125-004-1411-x; Xu Q, 2010, HYPERTENSION, V55, P1260, DOI 10.1161/HYPERTENSIONAHA.109.149369	50	45	47	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4035	4044		10.1096/fj.12-210567	http://dx.doi.org/10.1096/fj.12-210567			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22744867	Green Published			2022-12-28	WOS:000309704000011
J	Garrido-Gomez, T; Dominguez, F; Quinonero, A; Estella, C; Vilella, F; Pellicer, A; Simon, C				Garrido-Gomez, Tamara; Dominguez, Francisco; Quinonero, Alicia; Estella, Carlos; Vilella, Felipe; Pellicer, Antonio; Simon, Carlos			Annexin A2 is critical for embryo adhesiveness to the human endometrium by RhoA activation through F-actin regulation	FASEB JOURNAL			English	Article						cytoskeleton; implantation; receptivity; epithelial cells	EPITHELIAL RL95-2 CELLS; UTERINE RECEPTIVITY; LIPID RAFTS; TROPHOBLAST; IMPLANTATION; DYNAMICS; BINDING; CYTOSKELETON; MIGRATION; MEMBRANE	Annexin A2 (ANXA2) is present in vivo in the mid-and late-secretory endometria and is mainly localized in the luminal epithelium. Our aim was to evaluate its function in regulating the human implantation process. With an in vitro adhesion model, constructed to evaluate how the mouse embryo and JEG-3 spheroids attach to human endometrial epithelial cells, we demonstrated that ANXA2 inhibition significantly diminishes embryo adhesiveness. ANXA2 is also implicated in endometrial epithelial cell migration and trophoblast outgrowth. ANXA2 was seen to be linked to the RhoA/ROCK pathway and to regulate cell adhesion. We noted that ANXA2 inhibition significantly reduces active RhoA, although RhoA inactivation does not alter the ANXA2 levels. RhoA inactivation and ROCK inhibition also moderate embryo adhesiveness to endometrial epithelial cells. We corroborated that the induction of constitutively active RhoA partially reverses the effects of ANXA2 inhibition on endometrial adhesiveness. These molecules colocalize on the plasma membrane of endometrial epithelial cells, and a large proportion of ANXA2 and RhoA are colocalized in the F-actin networks. The functional effects of ANXA2 inhibition and RhoA/ROCK inactivation are associated with significant alterations in F-actin organization and its depolymerization. ANXA2 may act upstream of the RhoA/ROCK pathway by regulating F-actin remodeling and is a key factor in human endometrial adhesiveness.-Garrido-Gomez, T., Dominguez, F., Quinonero, A., Estella, C., Vilella, F., Pellicer, A., Simon, C. Annexin A2 is critical for embryo adhesiveness to the human endometrium by RhoA activation through F-actin regulation. FASEB J. 26, 3715-3727 (2012). www.fasebj.org	[Garrido-Gomez, Tamara; Dominguez, Francisco; Quinonero, Alicia; Estella, Carlos; Vilella, Felipe; Pellicer, Antonio; Simon, Carlos] Univ Valencia, Fdn Invest Clin Valencia Inst Invest Sanitaria IN, Inst Univ IVI, Fdn IVI, Valencia, Spain	University of Valencia	Simon, C (corresponding author), Univ Valencia, Inst Univ IVI, Fdn IVI, C Catedrat Agustin Escardino 9, Paterna 46980, Valencia, Spain.	carlos.simon@ivi.es	MARTINEZ, ANTONIO PELLICER/C-4832-2015; Simon, Carlos/G-2186-2014; Gomez, Tamara Garrido/B-6551-2017; Pellicer, Antonio/AAA-6005-2020; Dominguez, Francisco/AAA-7260-2020; Vilella, Felipe/C-2970-2018; Estella, Carlos/L-2097-2014	Simon, Carlos/0000-0003-0902-9531; Pellicer, Antonio/0000-0002-8254-863X; Dominguez, Francisco/0000-0002-7620-8081; Estella, Carlos/0000-0003-1551-2327; GARRIDO, TAMARA/0000-0002-6584-4832; Vilella, Felipe/0000-0002-0039-9846				Aplin J D, 2007, Reprod Biomed Online, V14 Spec No 1, P49, DOI 10.1016/S1472-6483(10)61458-7; Babbin BA, 2007, AM J PATHOL, V170, P951, DOI 10.2353/ajpath.2007.060647; Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Burkart A, 2003, J BIOL CHEM, V278, P18360, DOI 10.1074/jbc.M210701200; Dominguez F, 2005, FASEB J, V19, P1056, DOI 10.1096/fj.05-3781hyp; Dominguez F, 2009, HUM REPROD, V24, P2607, DOI 10.1093/humrep/dep230; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fowler PA, 2007, PROTEOMICS, V7, P130, DOI 10.1002/pmic.200600469; Genth H, 2008, INT J BIOCHEM CELL B, V40, P592, DOI 10.1016/j.biocel.2007.12.014; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Grewal S, 2008, P NATL ACAD SCI USA, V105, P16189, DOI 10.1073/pnas.0806219105; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hansen MDH, 2002, J BIOL CHEM, V277, P45371, DOI 10.1074/jbc.M207747200; Hayes MJ, 2006, EMBO J, V25, P1816, DOI 10.1038/sj.emboj.7601078; Heneweer C, 2003, CELLS TISSUES ORGANS, V175, P1, DOI 10.1159/000073432; Heneweer C, 2002, MOL HUM REPROD, V8, P1014, DOI 10.1093/molehr/8.11.1014; HENEWEER C, 2005, J EXP CLIN ASSIST RE, V9, P2; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Horcajadas JA, 2008, J CLIN ENDOCR METAB, V93, P4500, DOI 10.1210/jc.2008-0588; Ihnatovych I, 2009, BIOL REPROD, V81, P222, DOI 10.1095/biolreprod.108.074666; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; JOHN NJ, 1993, IN VITRO CELL DEV-AN, V29A, P461, DOI 10.1007/BF02639380; LINDENBERG S, 1991, DAN MED BULL, V38, P371; Lock FE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031423; Martin JC, 2000, BIOL REPROD, V63, P1370, DOI 10.1095/biolreprod63.5.1370; Mercader A, 2006, METHOD ENZYMOL, V420, P3, DOI 10.1016/S0076-6879(06)20001-6; Murphy CR, 1995, HUM REPROD UPDATE, V1, P567, DOI 10.1093/humupd/1.6.567; Murphy CR, 2000, J REPROD FERTIL, P23; Noyes R W, 1975, Am J Obstet Gynecol, V122, P262; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; Rescher U, 2008, J CELL SCI, V121, P2177, DOI 10.1242/jcs.028415; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Shiokawa S, 2002, J CLIN ENDOCR METAB, V87, P5808, DOI 10.1210/jc.2002-020376; Simon C, 1999, J CLIN ENDOCR METAB, V84, P2638, DOI 10.1210/jc.84.8.2638; Simon C, 2003, TRENDS ENDOCRIN MET, V14, P197, DOI 10.1016/S1043-2760(03)00084-5; Simon C, 2000, J REPROD FERTIL, P43; Simon C, 1999, FERTIL STERIL, V72, P1061, DOI 10.1016/S0015-0282(99)00408-2; Thie M, 1997, MOL HUM REPROD, V3, P275, DOI 10.1093/molehr/3.4.275; THIE M, 1995, EUR J CELL BIOL, V66, P180; VANBLERKOM J, 1981, AM J ANAT, V162, P143, DOI 10.1002/aja.1001620206; Wang DS, 2004, WORLD J GASTROENTERO, V10, P299; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304; Xu BY, 2012, J CELL PHYSIOL, V227, P2722, DOI 10.1002/jcp.23016	47	44	46	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3715	3727		10.1096/fj.12-204008	http://dx.doi.org/10.1096/fj.12-204008			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22645245				2022-12-28	WOS:000308391600013
J	Otero, A; de la Vega, MR; Tanco, S; Lorenzo, J; Aviles, FX; Reverter, D				Otero, Anabel; Rodriguez de la Vega, Monica; Tanco, Sebastian; Lorenzo, Julia; Aviles, Francesc X.; Reverter, David			The novel structure of a cytosolic M14 metallocarboxypeptidase (CCP) from Pseudomonas aeruginosa: a model for mammalian CCPs	FASEB JOURNAL			English	Article						metalloprotease; crystal structure; inhibitor; tubulin	CRYSTAL-STRUCTURE; PROTEIN-STRUCTURE; INHIBITOR; SEQUENCE; COMPLEX; FAMILY	M14 family from Pseudomonas aeruginosa, which belongs to a bacterial clade of carboxypeptidases that are homologous to the recently discovered M14D subfamily of human nonsecretory cytosolic carboxypeptidases (CCPs). CCPs are intracellular peptidases involved, among other roles, in the post-translational modifications of tubulin. Here we report the crystal structure of PaCCP at high resolution (1.6 angstrom). Its 375 residues are folded in a novel beta-sandwich N-terminal domain followed by the classical carboxypeptidase alpha/beta-hydrolase domain, this one in a shorter and more compact form. The former is unique in the whole family and does not have sequential or structural homology with other domains that are usually flanking the latter, like the prodomain of the M14A subfamily or the C-terminal transthyretin/prealbumin-like domains of the M14B subfamily. PaCCP does not display activity against small carboxypeptidase substrates, so in this form it might constitute an inactive precursor of the protease. Structural results derived from cocrystallization with well-known inhibitors of MCPs indicate that the enzyme might only possess C-terminal hydrolase activity against cellular substrates of particular specificity and/or when undergoes structural rearrangements. The derived PaCCP structure allows a first structural insight into the more complex and largely unknown mammalian CCP subfamily.-Otero, A., Rodriguez de la Vega, M., Tanco, S., Lorenzo, J., Aviles, F. X., Reverter, D. The novel structure of a cytosolic M14 metallocarboxypeptidase (CCP) from Pseudomonas aeruginosa: a model for mammalian CCPs. FASEB J. 26, 3754-3764 (2012). www.fasebj.org	[Aviles, Francesc X.] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.	francescxavier.aviles@uab.es; david.reverter@uab.cat	Lorenzo, Julia/E-9015-2011; Aviles, Francesc Xavier/F-3482-2019; Rodriguez de la Vega Otazo, Monica Margarita/H-7008-2015; Tanco, Sebastian Martin/R-2528-2016; Avilés, Francesc Xavier/A-2664-2015; Reverter, David/H-5360-2015	Lorenzo, Julia/0000-0001-5659-6008; Aviles, Francesc Xavier/0000-0002-1399-6789; Rodriguez de la Vega Otazo, Monica Margarita/0000-0002-1061-3471; Tanco, Sebastian Martin/0000-0003-2130-4401; Avilés, Francesc Xavier/0000-0002-1399-6789; Reverter, David/0000-0002-5347-0992	Ministerio de Ciencia e Innovacion (MICINN) of Spain [BFU2008-0364, BIO2010-22321-C02]; European Commission [MIRG-CT-2007-200346, LIVIMODE 241919]	Ministerio de Ciencia e Innovacion (MICINN) of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by grants from the Ministerio de Ciencia e Innovacion (MICINN) of Spain, BFU2008-0364, BIO2010-22321-C02; and by grants from the European Commission, MIRG-CT-2007-200346 and LIVIMODE 241919 (FP7-Health-2009). D. R. acknowledges the Ramon y Cajal program of MICINN.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; Arolas JL, 2007, CURR PHARM DESIGN, V13, P349, DOI 10.2174/138161207780162980; Berezniuk I, 2012, J BIOL CHEM, V287, P6503, DOI 10.1074/jbc.M111.309138; Berezniuk I, 2010, FASEB J, V24, P1813, DOI 10.1096/fj.09-147942; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; Hsieh JM, 2010, P NATL ACAD SCI USA, V107, P17962, DOI 10.1073/pnas.1006687107; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Keil C, 2007, J MOL BIOL, V366, P504, DOI 10.1016/j.jmb.2006.11.025; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; Kimura Y, 2010, J BIOL CHEM, V285, P22934, DOI 10.1074/jbc.C110.128280; Lindner HA, 2003, J BIOL CHEM, V278, P44496, DOI 10.1074/jbc.M304233200; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971; Rogowski K, 2010, CELL, V143, P564, DOI 10.1016/j.cell.2010.10.014; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; Sahab ZJ, 2011, CANCER RES, V71, P1219, DOI 10.1158/0008-5472.CAN-10-2294; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sanglas L, 2008, MOL CELL, V31, P598, DOI 10.1016/j.molcel.2008.05.031; Schrodinger L., 2020, PYMOL MOL GRAPHICS S; Shaya D, 2010, J BIOL CHEM, V285, P20051, DOI 10.1074/jbc.M110.101071; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Winstanley C, 2009, GENOME RES, V19, P12, DOI 10.1101/gr.086082.108; Zuckerkandl E, 1965, EVOLUTIONARY DIVERGE	33	12	12	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3754	3764		10.1096/fj.12-209601	http://dx.doi.org/10.1096/fj.12-209601			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22645247				2022-12-28	WOS:000308391600016
J	Yegutkin, GG; Wieringa, B; Robson, SC; Jalkanen, S				Yegutkin, Gennady G.; Wieringa, Be; Robson, Simon C.; Jalkanen, Sirpa			Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities	FASEB JOURNAL			English	Article						purinergic signaling; human and murine serum; intravascular nucleotide homeostasis; purinergic signaling	EXTRACELLULAR NUCLEOTIDE-METABOLISM; ECTO-ATPASE; ADENOSINE-DIPHOSPHATE; ENDOTHELIAL-CELLS; CD39; PLASMA; ECTONUCLEOTIDASES; INHIBITOR; RECEPTORS; ADENINE	Extracellular ATP and ADP trigger inflammatory, vasodilatatory, and prothrombotic signaling events in the vasculature, and their turnover is governed by networks of membrane-associated enzymes. The contribution of soluble activities to intravascular nucleotide homeostasis remains controversial. By using thin-layer chromatographic assays, we revealed transphosphorylation of [gamma-P-32]ATP and AMP by human and murine sera, which was progressively inhibited by specific adenylate kinase (AK) inhibitor Ap(5)A. This phosphotransfer reaction was diminished markedly in serum from knockout mice lacking the major AK isoform, AK1, and in human serum immunodepleted of AK1. We also showed that similar to 75% ADP in cell-free serum is metabolized via reversible AK1 reaction 2ADP <-> ATP + AMP. The generated ATP and AMP are then metabolized through the coupled nucleotide pyrophosphatase/phosphodiesterase and 5'-nucleotidase/CD73 reactions, respectively. Constitutive presence of another nucleotide-converting enzyme, nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, known as CD39), was ascertained by the relative deficiency of serum from CD39-null mice to dephosphorylate [H-3]ADP and [gamma-P-32]ATP, and also by diminished [H-3]ADP hydrolysis by human serum pretreated with NTPDase1 inhibitors, POM-1 and ARL-67156. In summary, we have identified hitherto unrecognized soluble forms of AK1 and NTPDase1/CD39 that contribute in the active cycling between the principal platelet-recruiting agent ADP and other circulating nucleotides.-Yegutkin, G. G., Wieringa, B., Robson, S. C., Jalkanen, S. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities FASEB J. 26, 3875-3883 (2012). www.fasebj.org	[Yegutkin, Gennady G.; Jalkanen, Sirpa] Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; [Yegutkin, Gennady G.; Jalkanen, Sirpa] Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland; [Wieringa, Be] Radboud Univ Nijmegen, Med Ctr, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; [Robson, Simon C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02215 USA	University of Turku; University of Turku; Radboud University Nijmegen; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Yegutkin, GG (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.	genyeg@utu.fi	Yegutkin, Gennady G./K-3815-2014; Robson, Simon C./AAA-8537-2021; Wieringa, Berend/A-5346-2011	Yegutkin, Gennady G./0000-0001-6684-7982; Wieringa, Berend/0000-0001-9192-8020	Academy of Finland; Sigrid Juselius Foundation; U.S. National Institutes of Health	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the Academy of Finland and the Sigrid Juselius Foundation (G.G.Y. and S.J.) and the U.S. National Institutes of Health (S. C. R.). The authors are grateful to Frank Oerlemans for help in collecting the tissues from AK <SUP>/</SUP> and wild-type AK<SUP>+/+</SUP> mice and to Drs. Keiichi Enjyoji and Guido Beldi (Harvard Medical School, Boston, MA, USA) for supplying plasma samples from CD39-null mice. The authors also thank Sari Maki for technical assistance and Anne Sovikoski-Georgieva for secretarial help.	Banz Y, 2008, BRIT J HAEMATOL, V142, P627, DOI 10.1111/j.1365-2141.2008.07230.x; Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913; Buergler JM, 2005, J THROMB THROMBOLYS, V19, P115, DOI 10.1007/s11239-005-1381-y; Cauwenberghs S, 2006, TRANSFUSION, V46, P1018, DOI 10.1111/j.1537-2995.2006.00837.x; Chalmin F, 2012, IMMUNITY, V36, P362, DOI 10.1016/j.immuni.2011.12.019; Chen BC, 1996, BRIT J PHARMACOL, V119, P1628, DOI 10.1111/j.1476-5381.1996.tb16082.x; Choo HJ, 2008, EXP MOL MED, V40, P220, DOI 10.3858/emm.2008.40.2.220; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Collavin L, 1999, ONCOGENE, V18, P5879, DOI 10.1038/sj.onc.1202970; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Dwyer KM, 2004, J CLIN INVEST, V113, P1440, DOI 10.1172/JCI200419560; Dzeja PP, 2007, MOL SYSTEM BIOENERGE, P265; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Erlinge D, 2008, PURINERG SIGNAL, V4, P1, DOI 10.1007/s11302-007-9078-7; Esch JSA, 1999, BIOCHEMISTRY-US, V38, P2248, DOI 10.1021/bi982426k; Gachet C, 2006, ANNU REV PHARMACOL, V46, P277, DOI 10.1146/annurev.pharmtox.46.120604.141207; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Hart ML, 2010, J IMMUNOL, V184, P4017, DOI 10.4049/jimmunol.0901851; HASLAM RJ, 1967, BIOCHEM J, V103, P773, DOI 10.1042/bj1030773; IRELAND DM, 1966, BIOCHEM J, V99, P283, DOI 10.1042/bj0990283; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Janssen E, 2004, MOL CELL BIOCHEM, V256, P59, DOI 10.1023/B:MCBI.0000009859.15267.db; JORGENSEN S, 1956, ACTA PHARMACOL TOX, V12, P294; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Knowles AF, 2011, PURINERG SIGNAL, V7, P21, DOI 10.1007/s11302-010-9214-7; Levesque SA, 2007, BRIT J PHARMACOL, V152, P141, DOI 10.1038/sj.bjp.0707361; Marcus AJ, 2003, J PHARMACOL EXP THER, V305, P9, DOI 10.1124/jpet.102.043729; Mercier N, 2012, AM J PATHOL, V180, P419, DOI 10.1016/j.ajpath.2011.10.002; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Noma T, 2005, J MED INVESTIG, V52, P127, DOI 10.2152/jmi.52.127; Park W, 1996, J RHEUMATOL, V23, P1233; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robson SC, 2005, SEMIN THROMB HEMOST, V31, P217, DOI 10.1055/s-2005-869527; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; Sorensen CE, 2003, J PHYSIOL-LONDON, V551, P881, DOI 10.1113/jphysiol.2003.049411; Straub A, 2011, ARTERIOSCL THROM VAS, V31, P1607, DOI 10.1161/ATVBAHA.111.226373; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; Wheeler DG, 2012, J MOL CELL CARDIOL, V52, P958, DOI 10.1016/j.yjmcc.2012.01.002; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024; Yegutkin GG, 2007, J PHYSIOL-LONDON, V579, P553, DOI 10.1113/jphysiol.2006.119453; Yegutkin GG, 2006, J BIOL CHEM, V281, P29441, DOI 10.1074/jbc.M602480200; Yegutkin GG, 2011, ANGIOGENESIS, V14, P503, DOI 10.1007/s10456-011-9234-0; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2003, FASEB J, V17, P1328, DOI 10.1096/fj.02-1136fje; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6	55	46	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3875	3883		10.1096/fj.12-205658	http://dx.doi.org/10.1096/fj.12-205658			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22637533	Green Published			2022-12-28	WOS:000308391600027
J	Ripoll, VM; Meadows, NA; Bangert, M; Lee, AW; Kadioglu, A; Cox, RD				Ripoll, Vera M.; Meadows, Nicholas A.; Bangert, Mathieu; Lee, Angela W.; Kadioglu, Aras; Cox, Roger D.			Nicotinamide nucleotide transhydrogenase (NNT) acts as a novel modulator of macrophage inflammatory responses	FASEB JOURNAL			English	Article						mitochondria; reactive oxygen species; S. pneumoniae	OXYGEN SPECIES PRODUCTION; INSULIN-SECRETION; OXIDATIVE STRESS; PNEUMOCOCCAL INFECTION; REACTIVE OXYGEN; STREPTOCOCCUS-PNEUMONIAE; INNATE IMMUNITY; LUNG INFECTION; C57BL/6J MICE; CELL-FUNCTION	Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial redox-driven proton pump that couples the production of NADPH to the mitochondrial metabolic rate. In this study, we demonstrated for the first time that NNT has a significant effect in the modulation of the immune response and host defense against pathogens. We found that NNT mRNA is enriched in immune system-related tissues and regulated during macrophage activation. Overexpression of NNT in a macrophage cell-line resulted in decreased levels of reactive oxygen species (ROS) and nitric oxide upon induction of the macrophage inflammatory responses. These cells failed to fully activate MAPK signaling pathways, resulting in defective secretion of proinflammatory cytokines in response to LPS, and were inefficient in clearance of intracellular bacteria. We have shown that C57BL/6J mice, which have a deletion in the Nnt gene, exhibited greater resistance to acute pulmonary infection with Streptococcus pneumoniae. Macrophages from these mice generated more ROS and established a stronger inflammatory response to this pathogen. Our results demonstrate a novel role for NNT as a regulator of macrophage-mediated inflammatory responses.-Ripoll, V. M., Meadows, N. A., Bangert, M., Lee, A. W., Kadioglu, A., Cox, R. D. Nicotinamide nucleotide transhydrogenase (NNT) acts as a novel modulator of macrophage inflammatory responses. FASEB J. 26, 3550-3562 (2012). www.fasebj.org	[Ripoll, Vera M.; Meadows, Nicholas A.; Lee, Angela W.; Cox, Roger D.] MRC, Mammalian Genet Unit, Harwell OX11 0RD, Oxon, England; [Bangert, Mathieu; Kadioglu, Aras] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Ripoll, VM (corresponding author), MRC, Mammalian Genet Unit, Harwell OX11 0RD, Oxon, England.	v.ripoll@har.mrc.ac.uk	Bangert, Mathieu/K-7233-2019	Cox, Roger/0000-0001-7170-5014; Bangert, Mathieu/0000-0003-1320-8145; Lee, Angela/0000-0002-7591-825X; kadioglu, aras/0000-0003-1137-6321	Medical Research Council [MC_U142661184] Funding Source: Medline; MRC [MC_U142661184] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Ashcroft FM, 2004, REV ENDOCR METAB DIS, V5, P135, DOI 10.1023/B:REMD.0000021435.87776.a7; Cakir Y, 2005, ANTIOXID REDOX SIGN, V7, P726, DOI 10.1089/ars.2005.7.726; Chen J, 2008, ANN NY ACAD SCI, V1150, P157, DOI 10.1196/annals.1447.045; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Emre Y, 2007, BIOCHEM J, V402, P271, DOI 10.1042/BJ20061430; Filippin LI, 2008, CLIN EXP IMMUNOL, V152, P415, DOI 10.1111/j.1365-2249.2008.03634.x; Forman Henry Jay, 2001, Molecular Aspects of Medicine, V22, P189; Freeman H, 2006, CELL METAB, V3, P35, DOI 10.1016/j.cmet.2005.10.008; Freeman H, 2006, BIOCHEM SOC T, V34, P806, DOI 10.1042/BST0340806; Freeman HC, 2006, DIABETES, V55, P2153, DOI 10.2337/db06-0358; Gilgun-Sherki Y, 2004, J NEUROL, V251, P261, DOI 10.1007/s00415-004-0348-9; HOEK JB, 1988, BIOCHEM J, V254, P1; Hollingsworth JW, 2007, IMMUNOGENETICS, V59, P713, DOI 10.1007/s00251-007-0242-6; Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004; Kadioglu A, 2000, INFECT IMMUN, V68, P492, DOI 10.1128/IAI.68.2.492-501.2000; Kadioglu Aras, 2005, Briefings in Functional Genomics & Proteomics, V4, P241, DOI 10.1093/bfgp/4.3.241; Kadioglu A, 2011, J INFECT DIS, V204, P1971, DOI 10.1093/infdis/jir657; Kerr AR, 2002, INFECT IMMUN, V70, P1547, DOI 10.1128/IAI.70.3.1547-1557.2002; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Kolb H, 2005, DIABETOLOGIA, V48, P1038, DOI 10.1007/s00125-005-1764-9; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Liu T, 2000, CELL IMMUNOL, V202, P31, DOI 10.1006/cimm.2000.1644; Marriott HM, 2006, INT J BIOCHEM CELL B, V38, P1848, DOI 10.1016/j.biocel.2006.06.001; Marriott HM, 2004, FASEB J, V18, P1126, DOI 10.1096/fj.03-1450fje; McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PHILLIPS WA, 1990, IMMUNOLOGY, V70, P498; Pi JB, 2009, ENDOCRINOLOGY, V150, P3040, DOI 10.1210/en.2008-1642; Ripoll VM, 2010, J LEUKOCYTE BIOL, V87, P735, DOI 10.1189/jlb.0509359; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Robson-Doucette CA, 2011, DIABETES, V60, P2710, DOI 10.2337/db11-0132; Rousset S, 2006, CYTOKINE, V35, P135, DOI 10.1016/j.cyto.2006.07.012; Shimomura K, 2009, METHOD ENZYMOL, V457, P451, DOI 10.1016/S0076-6879(09)05025-3; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Sweet MJ, 1998, J INTERF CYTOK RES, V18, P263, DOI 10.1089/jir.1998.18.263; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Toye AA, 2005, DIABETOLOGIA, V48, P675, DOI 10.1007/s00125-005-1680-z; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	43	29	29	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3550	3562		10.1096/fj.11-199935	http://dx.doi.org/10.1096/fj.11-199935			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593545				2022-12-28	WOS:000307162800041
J	Faenza, I; Blalock, W; Bavelloni, A; Schoser, B; Fiume, R; Pacella, S; Piazzi, M; D'Angelo, A; Cocco, L				Faenza, Irene; Blalock, William; Bavelloni, Alberto; Schoser, Benedikt; Fiume, Roberta; Pacella, Stephanie; Piazzi, Manuela; D'Angelo, Antonietta; Cocco, Lucio			A role for PLC beta 1 in myotonic dystrophies type 1 and 2	FASEB JOURNAL			English	Article						phospholipase C beta 1; cyclin D3; differentiation	CYCLIN D3; MUSCLE DIFFERENTIATION; NUCLEAR PLC-BETA(1); BINDING PROTEIN; MOLECULAR-BASIS; TRIPLET REPEAT; CELL-CYCLE; CTG REPEAT; EXPANSION; DM1	Phosphoinositide-phospholipase C beta 1 (PLC beta 1) plays a crucial role in the initiation of the genetic program responsible for muscle differentiation. We previously demonstrated that nuclear PLC beta 1 activates the cyclin D3 promoter during the differentiation of myoblasts to myotubes, indicating that PLC beta 1 is essential for cyclin D3 promoter activation and gene transcription, through c-jun/AP1. Myotonic dystrophy (DM) is the most prevalent form of muscular dystrophy in adults. DM type 1 (DM1) and type 2 (DM2) are dominantly inherited multisystem disorders. DM1 is triggered by the pathological expansion of a (CTG)(n) triplet repeat in the gene coding for DMPK, the dystrophia myotonica-protein kinase, whereas a (CCTG)(n) tetranucleotide repeat expansion in the ZNF9 gene, encoding a CCHC-type zinc finger protein, causes DM2. We found that, unlike in normal myotubes, the level of expression of PLC beta 1 in DM1 and DM2 cells was already elevated in proliferating cells. Treatment with insulin induced a dramatic decrease in the amount of PLC beta 1. During differentiation, cyclin D3 and myogenin were elevated in normal myotubes, whereas differentiating DM1 and DM2 cells did not increase these proteins. Forced expression of PLC beta 1 in DM1 and DM2 cells increased the expression of differentiation markers, myogenin and cyclin D3, and enhanced fusion of DM myoblasts. These results highlight again that PLC beta 1 expression is a key player in myoblast differentiation, functioning as a positive regulator in the correction of delayed differentiation of skeletal muscle in DM human myoblasts.-Faenza, I., Blalock, W., Bavelloni, A., Schoser, B., Fiume, R., Pacella, S., Piazzi, M., D'Angelo, A., Cocco, L. A role for PLC beta 1 in myotonic dystrophies type 1 and 2. FASEB J. 26, 3042-3048 (2012). www.fasebj.org	[Faenza, Irene; Fiume, Roberta; Pacella, Stephanie; Piazzi, Manuela; Cocco, Lucio] Univ Bologna, Dept Human Anat, Cellular Signaling Lab, I-40126 Bologna, Italy; [Blalock, William] CNR, IGM, I-40126 Bologna, Italy; [Bavelloni, Alberto] Rizzoli Orthoped Inst, Lab Musculoskeletal Cell Biol, Bologna, Italy; [D'Angelo, Antonietta] Rizzoli Orthoped Inst, Ramses Lab, Bologna, Italy; [Schoser, Benedikt] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; [Pacella, Stephanie] Univ G dAnnunzio, Dept Med & Ageing Sci, Chieti, Italy	University of Bologna; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; University of Munich; G d'Annunzio University of Chieti-Pescara	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, Via Irnerio 48, I-40126 Bologna, Italy.	lucio.cocco@unibo.it	Blalock, William L/C-6959-2019; Piazzi, Manuela/K-2147-2016; Bavelloni, Alberto/E-5726-2019; Faenza, Irene/AAC-4606-2022; Piazzi, Manuela/AAD-5016-2020; Schoser, Benedikt/AAH-6286-2020; Cocco, Lucio/AAI-2206-2020	Blalock, William L/0000-0002-8045-4840; Piazzi, Manuela/0000-0002-9072-2757; Bavelloni, Alberto/0000-0002-6467-1431; Faenza, Irene/0000-0002-5227-3567; Piazzi, Manuela/0000-0002-9072-2757; Cocco, Lucio/0000-0002-9206-8277; FIUME, ROBERTA/0000-0001-7757-4000; Schoser, Benedikt/0000-0002-2757-8131	Deutsche Gesellschaft fur Muskelkranke; German Ministry of Education and Research (BMBF; Bonn, Germany); Italian Ministero dell'Istruzione dell'Universita e della Ricerca (MIUR)-Fondo per gli Investimenti della Ricerca di Base (FIRB); Italian Programma di Ricerca di Rilevante Interesse Nazionale (PRIN)-Cofin	Deutsche Gesellschaft fur Muskelkranke; German Ministry of Education and Research (BMBF; Bonn, Germany)(Federal Ministry of Education & Research (BMBF)); Italian Ministero dell'Istruzione dell'Universita e della Ricerca (MIUR)-Fondo per gli Investimenti della Ricerca di Base (FIRB); Italian Programma di Ricerca di Rilevante Interesse Nazionale (PRIN)-Cofin(Ministry of Education, Universities and Research (MIUR))	This work was supported in part by grants from the Deutsche Gesellschaft fur Muskelkranke (to B. S.). B. S. is member of the German Network on Muscular Dystrophies (MD-NET; 01GM0601). The Muscle Tissue Culture Collection is part of the MD-NET (service structure S1, 01GM0601) funded by the German Ministry of Education and Research (BMBF; Bonn, Germany). The Muscle Tissue Culture Collection is a partner of EuroBioBank (http://www.eurobiobank.org) and Translational Research in Europe-Assessment and Treatment of Neuromuscular Diseases (TREAT-NMD; EC, 6th FP, proposal 036825). The authors thank Julia Emmerich for excellent technical assistance. This work was also supported by the Italian Ministero dell'Istruzione dell'Universita e della Ricerca (MIUR)-Fondo per gli Investimenti della Ricerca di Base (FIRB) and by Italian Programma di Ricerca di Rilevante Interesse Nazionale (PRIN)-Cofin.	BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Cho DH, 2007, BBA-MOL BASIS DIS, V1772, P195, DOI 10.1016/j.bbadis.2006.05.013; Cocco L, 2011, ADV ENZYME REGUL, V51, P2, DOI 10.1016/j.advenzreg.2010.09.015; Cocco L, 2010, ADV ENZYME REGUL, V50, P2, DOI 10.1016/j.advenzreg.2009.10.007; Faenza I, 2003, J CELL PHYSIOL, V195, P446, DOI 10.1002/jcp.10264; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Faenza I, 2007, ENDOCRINOLOGY, V148, P1108, DOI 10.1210/en.2006-1003; Foff EP, 2011, MUSCLE NERVE, V44, P160, DOI 10.1002/mus.22090; Follo MY, 2012, LEUKEMIA, V26, P943, DOI 10.1038/leu.2011.300; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Huichalaf C, 2010, FASEB J, V24, P3706, DOI 10.1096/fj.09-151159; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Loro E, 2010, CELL DEATH DIFFER, V17, P1315, DOI 10.1038/cdd.2010.33; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Malatesta M, 2011, HISTOCHEM CELL BIOL, V135, P419, DOI 10.1007/s00418-011-0797-z; Pelletier R, 2009, NEUROBIOL DIS, V36, P181, DOI 10.1016/j.nbd.2009.07.009; Ramazzotti G, 2008, CELL SIGNAL, V20, P2013, DOI 10.1016/j.cellsig.2008.07.009; Salisbury E, 2008, EXP CELL RES, V314, P2266, DOI 10.1016/j.yexcr.2008.04.018; Schara Ulrike, 2006, Semin Pediatr Neurol, V13, P71; Timchenko NA, 2004, J BIOL CHEM, V279, P13129, DOI 10.1074/jbc.M312923200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Wheeler TM, 2008, NEUROTHERAPEUTICS, V5, P592, DOI 10.1016/j.nurt.2008.08.001	23	14	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3042	3048		10.1096/fj.11-200337	http://dx.doi.org/10.1096/fj.11-200337			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459146				2022-12-28	WOS:000305912500031
J	Li, GH; Li, WX; Mumper, RJ; Nath, A				Li, Guan-Han; Li, Wenxue; Mumper, Russell J.; Nath, Avindra			Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes	FASEB JOURNAL			English	Article						transactivation; uptake; endocytosis; intracellular delivery; hydrophobic peptide	HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING PEPTIDES; HEPARAN-SULFATE PROTEOGLYCANS; FUSION INHIBITOR T-20; DRUG-DELIVERY; LIPID RAFTS; DEPENDENT ENDOCYTOSIS; FUNCTIONAL DOMAINS; PLASMA-MEMBRANE; PROTEIN TAT	Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription (Tat) protein possesses a unique membrane-transduction property. Interestingly, Tat transduction could be dramatically increased 1000-fold based on LTR-transactivation assay when complexed with cationic liposomes (lipo-Tat), compared with Tat alone. Therefore, underlining mechanisms were explored further. Microscopy and flow cytometry showed that this effect was associated with enhanced membrane binding, large particle formation (1-2 mu m) and increased intracellular uptake of Tat fluorescent proteins. Using pharmacological assays and immune colocalizations, it was found that lipid raft-dependent endocytosis and macropinocytosis were major pathways involved in lipo-Tat uptake, and actinfilaments played a major role in intracellular trafficking of lipo-Tat to the nucleus. Furthermore, we found that the Tat hydrophobic domain (aa 36-47) mediated formation of two positively charged molecules into lipo-Tat complexes via hydrophobic bonds, based on LTR-transactivation inhibition assay. Thus, the hydrophobic domain may play an important role in Tat protein uptake and be useful for intracellular delivery of biomacromolecules if coupled together with Tat basic peptide, a cell-penetrating peptide.-Li, G.-H., Li, W., Mumper, R. J., Nath, A. Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes. FASEB J. 26, 2824-2834 (2012). www.fasebj.org	[Li, Guan-Han; Li, Wenxue; Nath, Avindra] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Li, Guan-Han; Li, Wenxue; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA; [Mumper, Russell J.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of North Carolina; University of North Carolina Chapel Hill	Nath, A (corresponding author), NINDS, Sect Infect Nervous Syst, NIH, Bldg 10,7C-103,10 Ctr Dr, Bethesda, MD 20892 USA.	natha@ninds.nih.gov	Li, Guanhan/E-3497-2012	Li, Guan-Han/0000-0002-3403-8491	U.S. National Insitutes of Health [R01NS039253, R01AI058842]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003130, R01NS039253] Funding Source: NIH RePORTER	U.S. National Insitutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by U.S. National Insitutes of Health grants R01NS039253 (A.N.) and R01AI058842 (R.J.M.). The authors thank Yan Huang (A.N. laboratory) and Michael Delannoy (Johns Hopkins Medical Institutions-Microscope Facility, Baltimore, MD, USA) for technical assistance.	Bellino S, 2009, REV RECENT CLIN TRIA, V4, P195, DOI 10.2174/157488709789957529; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bhattacharyya R, 2004, PROTEIN ENG DES SEL, V17, P795, DOI 10.1093/protein/gzh093; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Bohan Cindy A., 1992, Gene Expression, V2, P391; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; Debaisieux S, 2012, TRAFFIC, V13, P355, DOI 10.1111/j.1600-0854.2011.01286.x; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Fong SE, 1997, J VIROL METHODS, V66, P149, DOI 10.1016/S0166-0934(97)00070-0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105; Hoekstra D, 2007, BIOCHEM SOC T, V35, P68, DOI 10.1042/BST0350068; Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767; Huang L, 1995, BIOCHEM BIOPH RES CO, V217, P761, DOI 10.1006/bbrc.1995.2838; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lajoie P, 2007, J CELL MOL MED, V11, P644, DOI 10.1111/j.1582-4934.2007.00083.x; Li WX, 2008, J NEUROSCI, V28, P12190, DOI 10.1523/JNEUROSCI.3019-08.2008; Liu YP, 1996, J BIOL CHEM, V271, P10391, DOI 10.1074/jbc.271.17.10391; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]; Rayne F, 2010, CELL BIOL INT, V34, P409, DOI 10.1042/CBI20090376; Rayne F, 2010, EMBO J, V29, P1348, DOI 10.1038/emboj.2010.32; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rinne J, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-1; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; Ross JL, 2008, CURR OPIN CELL BIOL, V20, P41, DOI 10.1016/j.ceb.2007.11.006; RUBEN S, 1989, J VIROL, V63, P1; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Pappalardo JS, 2009, J CONTROL RELEASE, V134, P41, DOI 10.1016/j.jconrel.2008.11.006; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; Yezid H, 2009, J BIOL CHEM, V284, P22736, DOI 10.1074/jbc.M109.023705; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604	73	19	19	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2824	2834		10.1096/fj.11-203315	http://dx.doi.org/10.1096/fj.11-203315			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22447980	Green Published			2022-12-28	WOS:000305912500011
J	Mima, A; Kitada, M; Geraldes, P; Li, Q; Matsumoto, M; Mizutani, K; Qi, W; Li, CZ; Leitges, M; Rask-Madsen, C; King, GL				Mima, Akira; Kitada, Munehiro; Geraldes, Pedro; Li, Qian; Matsumoto, Motonobu; Mizutani, Koji; Qi, Weier; Li, Chenzhong; Leitges, Michael; Rask-Madsen, Christian; King, George L.			Glomerular VEGF resistance induced by PKC beta/SHP-1 activation and contribution to diabetic nephropathy	FASEB JOURNAL			English	Article						podocyte apoptosis; hyperglycemia; VEGFR-2	KINASE-C-DELTA; ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE; CELL APOPTOSIS; PKC-DELTA; EXPRESSION; GLUCOSE; BETA; DIFFERENTIATION; INHIBITION	This study characterizes the effect of glucose-induced activation of protein kinase C delta (PKC delta) and Src homology-2 domain-containing phosphatase-1 (SHP-1) expression on vascular endothelial growth factor (VEGF) actions in glomerular podocytes in cultures and in glomeruli of diabetic rodents. Elevation of glucose levels induced PKC delta and p38 mitogen-activated protein kinase (p38 MAPK) to increase SHP-1 expression, increased podocyte apoptosis, and inhibited VEGF activation in podocytes and glomerular endothelial cells. The adverse effects of high glucose levels can be negated by molecular inhibitors of PKC delta, p38MAPK, and SHP-1 and only partially reduced by antioxidants and nuclear factor-kappa B (NF-kappa B) inhibitor. Increased PKC delta activation and SHP-1 expression correlated with loss of VEGF signaling and podocyte numbers in the glomeruli of diabetic rats and mice. In contrast, diabetic PKC delta -knockout (Prkcd(-/-)) mice did not exhibit activation of p38 MAPK and SHP-1 or inhibition of VEGF signaling in renal glomeruli. Functionally, diabetic Prkcd(-/-) mice had decreased expressions of TGF beta, VEGF, and extracellular matrix and less albuminuria than diabetic Prkcd(+/+) mice. Hyperglycemia and diabetes can cause glomerular podocyte apoptosis and endothelial dysfunction partly due to increased PKC beta/p38 MAPK activation and the expression of SHP-1 to cause VEGF resistance, independent of NF-kappa B activation.-Mima, A., Kitada, M., Geraldes, P., Li, Q., Matsumoto, M., Mizutani, K., Qi, W., Li, C., Leitges, M., Rask-Madsen, C., King, G. L. Glomerular VEGF resistance induced by PKC delta/SHP-1 activation and contribution to diabetic nephropathy. FASEB J. 26, 2963-2974 (2012). www.fasebj.org	[King, George L.] Harvard Univ, Joslin Diabet Ctr, Div Res, Sch Med,Dianne Nunnally Hoppes Lab Diabet Complic, Boston, MA 02215 USA; [Geraldes, Pedro] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Sherbrooke; University of Oslo	King, GL (corresponding author), Harvard Univ, Joslin Diabet Ctr, Div Res, Sch Med,Dianne Nunnally Hoppes Lab Diabet Complic, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Leitges, Michael/AAN-1953-2021; åå, åç°/AAD-8655-2019	Leitges, Michael/0000-0003-4203-6995; Rask-Madsen, Christian/0000-0002-8548-466X	U.S. National Institutes of Health/National Eye Institute [EY016150]; Manpei Suzuki Diabetes Foundation; Kanzawa Medical Research Foundation; Novartis Foundation, Japan; Diabetes and Endocrinology Research Center [P30DK036836]; NATIONAL EYE INSTITUTE [R01EY016150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Manpei Suzuki Diabetes Foundation; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation); Novartis Foundation, Japan(Novartis); Diabetes and Endocrinology Research Center; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Hillary Keenan for the discussions on the statistical analysis and Ms. Patti Muehter for excellent assistance with manuscript preparation. This work is supported by grants to G. L. K. from the U.S. National Institutes of Health/National Eye Institute (EY016150). A. M. is the recipient of a Research Fellowship (Manpei Suzuki Diabetes Foundation, Kanzawa Medical Research Foundation, Novartis Foundation, Japan). This project has been supported by Diabetes and Endocrinology Research Center grant P30DK036836.	Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520; De Vriese AS, 2001, J AM SOC NEPHROL, V12, P1734, DOI 10.1681/ASN.V1281734; Dubois MJ, 2006, NAT MED, V12, P549, DOI 10.1038/nm1397; ELLIS EN, 1987, KIDNEY INT, V32, P736, DOI 10.1038/ki.1987.268; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Gubler MC, 2003, J AM SOC NEPHROL, V14, pS22, DOI 10.1097/01.ASN.0000067648.75923.68; Hohenstein B, 2006, KIDNEY INT, V69, P1654, DOI 10.1038/sj.ki.5000294; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Kim YH, 2008, DIABETES, V57, P2181, DOI 10.2337/db07-1431; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Ku CH, 2008, DIABETES, V57, P2824, DOI 10.2337/db08-0647; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li XN, 2010, J AM SOC NEPHROL, V21, P1115, DOI 10.1681/ASN.2009070760; Lin CL, 2006, KIDNEY INT, V69, P1593, DOI 10.1038/sj.ki.5000329; Menne J, 2004, DIABETES, V53, P2101, DOI 10.2337/diabetes.53.8.2101; Mima A, 2011, KIDNEY INT, V79, P883, DOI 10.1038/ki.2010.526; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Naruse K, 2006, DIABETES, V55, P691, DOI 10.2337/diabetes.55.03.06.db05-0771; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Quack I., J BIOL CHEM, V15, P12959; Remuzzi G, 2006, J CLIN INVEST, V116, P288, DOI 10.1172/JCI27699; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Schrijvers BF, 2005, HORM METAB RES, V37, P21, DOI 10.1055/s-2005-861027; Shizukuda Y, 1999, CIRCULATION, V100, P1909, DOI 10.1161/01.CIR.100.18.1909; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sison K, 2010, J AM SOC NEPHROL, V21, P1691, DOI 10.1681/ASN.2010030295; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Steffes MW, 2001, KIDNEY INT, V59, P2104, DOI 10.1046/j.1523-1755.2001.0590062104.x; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Tanaka M, 2004, CIRCULATION, V110, pII194, DOI 10.1161/01.CIR.0000138389.22905.62; Toyoda M, 2004, KIDNEY INT, V66, P1107, DOI 10.1111/j.1523-1755.2004.00798.x; TRYGGVASON K, 1975, NEPHRON, V15, P62, DOI 10.1159/000180493; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WEIBEL ER, 1962, J APPL PHYSIOL, V17, P343, DOI 10.1152/jappl.1962.17.2.343; Wilmer WA, 2001, KIDNEY INT, V60, P858, DOI 10.1046/j.1523-1755.2001.060003858.x	39	53	56	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2963	2974		10.1096/fj.11-202994	http://dx.doi.org/10.1096/fj.11-202994			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22499584	Green Published			2022-12-28	WOS:000305912500024
J	Makris, EA; MacBarb, RF; Responte, DJ; Hu, JC; Athanasiou, KA				Makris, Eleftherios A.; MacBarb, Regina F.; Responte, Donald J.; Hu, Jerry C.; Athanasiou, Kyriacos A.			A copper sulfate and hydroxylysine treatment regimen for enhancing collagen cross-linking and biomechanical properties in engineered neocartilage	FASEB JOURNAL			English	Article						articular cartilage regeneration; covalent intermolecular bonds; scaffoldless self-assembly	BOVINE ARTICULAR-CARTILAGE; MECHANICAL-PROPERTIES; LYSYL OXIDASE; CHONDROITINASE-ABC; IN-VITRO; STREPTOCOCCUS FAECALIS; EXTRACELLULAR-MATRIX; CHONDROCYTES; NETWORK; PROTEOGLYCAN	The objective of this study was to improve the biomechanical properties of engineered neotissues through promoting the development of collagen cross-links. It was hypothesized that supplementing medium with copper sulfate and the amino acid hydroxylysine would enhance the activity of lysyl oxidase enzyme to form collagen cross-links, increasing the strength and integrity of the neotissue. Neocartilage constructs were generated using a scaffoldless, self-assembling process and treated with copper sulfate and hydroxylysine, either alone or in combination, following a 2-factor, full-factorial study design. Following a 6-wk culture period, the biomechanical and biochemical properties of the constructs were measured. Results found copper sulfate to significantly increase pyridinoline (PYR) cross-links in all copper sulfate-containing groups over controls. When copper sulfate and hydroxylysine were combined, the result was synergistic, with a 10-fold increase in PYR content over controls. This increase in PYR cross-links manifested in a 3.3-fold significant increase in the tensile properties of the copper sulfate + hydroxylysine group. In addition, an 123% increase over control values was detected in the copper sulfate group in terms of the aggregate modulus. These data elucidate the role of copper sulfate and hydroxylysine toward improving the biomechanical properties of neotissues through collagen cross-linking enhancement.-Makris, E. A., MacBarb, R. F., Responte, D. J., Hu, J. C., Athanasiou, K. A. A copper sulfate and hydroxylysine treatment regimen for enhancing collagen cross-linking and biomechanical properties in engineered neocartilage.	[Makris, Eleftherios A.; MacBarb, Regina F.; Responte, Donald J.; Hu, Jerry C.; Athanasiou, Kyriacos A.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Makris, Eleftherios A.] Univ Thessaly Biomed, Dept Orthoped Surg & Musculoskeletal Trauma, Larisa, Greece	University of California System; University of California Davis	Athanasiou, KA (corresponding author), Univ Calif Davis, Dept Biomed Engn, 1 Shields Ave, Davis, CA 95616 USA.	athanasiou@ucdavis.edu			U.S. National Institutes of Health [R01AR053286]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053286] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was funded by U.S. National Institutes of Health grant R01AR053286. The funding source did not have a role in the collection, analysis, and interpretation of data. The authors declare no conflicts of interest.	Asanbaeva A, 2008, OSTEOARTHR CARTILAGE, V16, P1, DOI 10.1016/j.joca.2007.05.019; Asanbaeva A, 2007, ARTHRITIS RHEUM, V56, P188, DOI 10.1002/art.22298; ATHANASIOU KA, 1995, CLIN ORTHOP RELAT R, P254; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Basser PJ, 1998, ARCH BIOCHEM BIOPHYS, V351, P207, DOI 10.1006/abbi.1997.0507; Bassleer CT, 1998, OSTEOARTHR CARTILAGE, V6, P196, DOI 10.1053/joca.1998.0112; Bastiaansen-Jenniskens YM, 2008, OSTEOARTHR CARTILAGE, V16, P359, DOI 10.1016/j.joca.2007.07.003; Beekman B, 1997, EXP CELL RES, V237, P135, DOI 10.1006/excr.1997.3771; Buckwalter JA, 1998, AAOS INSTR COURS LEC, V47, P477; Chen AC, 2001, J BIOMECH, V34, P1, DOI 10.1016/S0021-9290(00)00170-6; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Dahl SLM, 2005, CELL TRANSPLANT, V14, P861; Eyre DR, 2008, METHODS, V45, P65, DOI 10.1016/j.ymeth.2008.01.002; EYRE DR, 1991, J RHEUMATOL, V18, P49; Ficklin T, 2007, J BIOMECH, V40, P3607, DOI 10.1016/j.jbiomech.2007.06.005; Gabay C, 2011, ARTHRITIS RHEUM-US, V63, P3383, DOI 10.1002/art.30574; Greenwood D., 2003, ANTIBIOT CHEMOTHER, V8, P11; Heraud F, 2002, SCAND J RHEUMATOL, V31, P279, DOI 10.1080/030097402760375179; Hootman JM, 2006, ARTHRITIS RHEUM-US, V54, P226, DOI 10.1002/art.21562; Hu JC, 2006, TISSUE ENG, V12, P969, DOI 10.1089/ten.2006.12.969; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; Khalsa PS, 1997, J BIOMECH, V30, P589, DOI 10.1016/S0021-9290(97)84508-3; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacBarb RF, 2013, ACTA BIOMATER, V9, P4626, DOI 10.1016/j.actbio.2012.09.037; MECHANIC G, 1971, BIOCHEM BIOPH RES CO, V45, P644, DOI 10.1016/0006-291X(71)90465-7; Mow Van C., 1997, P113; MOW VC, 1992, BIOMATERIALS, V13, P67, DOI 10.1016/0142-9612(92)90001-5; Ofek G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002795; OPSAHL W, 1982, J NUTR, V112, P708, DOI 10.1093/jn/112.4.708; Pasqualicchio M, 1996, MEDIAT INFLAMM, V5, P95, DOI 10.1155/S0962935196000154; POLAN CE, 1967, J NUTR, V91, P143, DOI 10.1093/jn/91.2.143; Responte DJ, 2012, FASEB J, V26, P3614, DOI 10.1096/fj.12-207241; Responte DJ, 2012, BIOMATERIALS, V33, P3187, DOI 10.1016/j.biomaterials.2012.01.028; Riesle J, 1998, J CELL BIOCHEM, V71, P313, DOI 10.1002/(SICI)1097-4644(19981201)71:3<313::AID-JCB1>3.0.CO;2-C; Rivard CH, 1996, ANN CHIR, V50, P651; ROSENBLOOM J, 1971, J BIOL CHEM, V246, P1549; Rosenzweig DH, 2012, TISSUE ENG PT A, V18, P2466, DOI [10.1089/ten.tea.2012.0215, 10.1089/ten.TEA.2012.0215]; ROWLEY DA, 1983, ARCH BIOCHEM BIOPHYS, V225, P279, DOI 10.1016/0003-9861(83)90031-0; ROWLEY DA, 1983, CLIN SCI, V64, P649, DOI 10.1042/cs0640649; Royce PM, 2002, CONNECTIVE TISSUE IT; SCARPA M, 1983, J BIOL CHEM, V258, P6695; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SIEGEL RC, 1976, J BIOL CHEM, V251, P5779; Sieibel M. J., 2006, DYNAMICS BONE CARTIL; SINEX FM, 1955, J BIOL CHEM, V216, P245; SMITH WG, 1964, J BIOL CHEM, V239, P1867; Summey BT, 2002, J ORTHOP RES, V20, P76, DOI 10.1016/S0736-0266(01)00064-X; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; TSUNG CM, 1962, J BIOL CHEM, V237, P1194; Wandel S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4675; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Williamson AK, 2003, J ORTHOPAED RES, V21, P872, DOI 10.1016/S0736-0266(03)00030-5; Williamson AK, 2001, J ORTHOPAED RES, V19, P1113, DOI 10.1016/S0736-0266(01)00052-3	53	46	46	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2421	2430		10.1096/fj.12-224030	http://dx.doi.org/10.1096/fj.12-224030			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457219	Green Published			2022-12-28	WOS:000319667600029
J	Kumawat, K; Menzen, MH; Bos, IST; Baarsma, HA; Borger, P; Roth, M; Tamm, M; Halayko, AJ; Simoons, M; Prins, A; Postma, DS; Schmidt, M; Gosens, R				Kumawat, Kuldeep; Menzen, Mark H.; Bos, I. Sophie T.; Baarsma, Hoeke A.; Borger, Pieter; Roth, Michael; Tamm, Michael; Halayko, Andrew J.; Simoons, Mirjam; Prins, Alita; Postma, Dirkje S.; Schmidt, Martina; Gosens, Reinoud			Noncanonical WNT-5A signaling regulates TGF-beta-induced extracellular matrix production by airway smooth muscle cells	FASEB JOURNAL			English	Article						asthma; ECM; frizzled	GROWTH-FACTOR-BETA; ASTHMA; WNT5A; EXPRESSION; CATENIN; PATHWAY; DISEASE; CANCER; PROLIFERATION; FIBROBLASTS	Transforming growth factor beta (TGF-beta), a key mediator of fibrotic responses, is increased in asthma and drives airway remodeling by inducing expression of extracellular matrix (ECM) proteins. We investigated the molecular mechanisms underlying TGF-beta-induced ECM expression by airway smooth muscle cells and demonstrate a novel link between TGF-beta and Wingless/integrase 1 (WNT) signaling in ECM deposition. Airway smooth muscle expresses abundant WNT ligands, with the noncanonical WNT-5A being the most profoundly expressed. Interestingly, WNT-5A shows similar to 2-fold higher abundance in airway smooth muscle cells isolated from individuals with asthma than individuals without asthma. WNT-5A is markedly induced in response to TGF-beta (4 -16-fold; EC50 0.3 ng/ml) and is required for collagen and fibronectin expression by airway smooth muscle. WNT-5A engages noncanonical WNT signaling pathways, as inhibition of Ca2+ and c-Jun N-terminal kinase (JNK) signaling attenuated this TGF-beta response, whereas the canonical WNT antagonist Dickkopf 1 (DKK-1) did not. Accordingly, WNT-5A induced JNK phosphorylation and nuclear translocation of nuclear factor of activated T cells c1 (NFATc1). Furthermore, silencing of the WNT-5A receptors Frizzled 8 (FZD(8)) and RYK attenuated TGF-beta-induced ECM expression. Collectively, these findings demonstrate that noncanonical WNT-5A signaling is activated by and necessary for TGF-beta-induced ECM production by airway smooth muscle cells, which could have significance in asthma pathogenesis.-Kumawat, K., Menzen, M. H.., Bos, I. S. T., Baarsma, H. A., Borger, P., Roth, M., Tamm, M., Halayko, A. J., Simoons, M., Prins, A., Postma, D. S., Schmidt, M., and Gosens, R. Noncanonical WNT-5A signaling regulates TGF-beta-induced extracellular matrix production by airway smooth muscle cells. FASEB J. 27, 1631-1643 (2013). www.fasebj.org	[Kumawat, Kuldeep; Menzen, Mark H.; Bos, I. Sophie T.; Baarsma, Hoeke A.; Simoons, Mirjam; Prins, Alita; Schmidt, Martina; Gosens, Reinoud] Univ Groningen, Univ Med Ctr Groningen, Dept Mol Pharmacol, NL-9713 AV Groningen, Netherlands; [Kumawat, Kuldeep; Menzen, Mark H.; Bos, I. Sophie T.; Baarsma, Hoeke A.; Simoons, Mirjam; Prins, Alita; Postma, Dirkje S.; Schmidt, Martina; Gosens, Reinoud] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & Chron Obstruct Pulm D, NL-9713 AV Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9713 AV Groningen, Netherlands; [Borger, Pieter] Univ Basel, Dept Biomed, Basel, Switzerland; [Roth, Michael; Tamm, Michael] Univ Basel Hosp, Dept Pneumol, CH-4031 Basel, Switzerland; [Roth, Michael; Tamm, Michael] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada	University of Groningen; University of Groningen; University of Groningen; University of Basel; University of Basel; University of Basel; University of Manitoba; University of Manitoba	Kumawat, K (corresponding author), Univ Groningen, Dept Mol Pharmacol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	k.kumawat@rug.nl	Roth, Michael/H-8657-2019; Borger, Pieter (Peter)/HIR-2495-2022; Schmidt, Martina/C-5339-2018	Roth, Michael/0000-0002-8139-2821; Schmidt, Martina/0000-0003-3075-0630; Gosens, Reinoud/0000-0002-5595-152X; Baarsma, Hoeke/0000-0002-0792-0374; Halayko, Andrew/0000-0002-7865-4552	Veni grant from the Dutch Organization for Scientific Research (NWO) [916.86.036]; Rosalind Franklin Fellowship from the University of Groningen; Swiss National Foundation [310030_130740]	Veni grant from the Dutch Organization for Scientific Research (NWO); Rosalind Franklin Fellowship from the University of Groningen; Swiss National Foundation(Swiss National Science Foundation (SNSF))	This work was supported by a Veni grant (916.86.036) from the Dutch Organization for Scientific Research (NWO) to R. G., a Rosalind Franklin Fellowship from the University of Groningen to M. S., and a Swiss National Foundation grant (310030_130740) to M.R.	An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807; Baarsma HA, 2011, AM J PHYSIOL-LUNG C, V301, pL956, DOI 10.1152/ajplung.00123.2011; Baarsma HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025450; Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood-2005-12-5046; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burgess JK, 2009, PHARMACOL THERAPEUT, V122, P19, DOI 10.1016/j.pharmthera.2008.12.002; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dekkers BGJ, 2007, AM J PHYSIOL-LUNG C, V292, pL1405, DOI 10.1152/ajplung.00331.2006; Dekkers Bart G J, 2009, Proc Am Thorac Soc, V6, P683, DOI 10.1513/pats.200907-056DP; Gooch JL, 2004, J BIOL CHEM, V279, P15561, DOI 10.1074/jbc.M308759200; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190; Kawasaki A, 2007, CELL SIGNAL, V19, P2498, DOI 10.1016/j.cellsig.2007.07.023; Keeble TR, 2006, J NEUROSCI, V26, P5840, DOI 10.1523/JNEUROSCI.1175-06.2006; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Komiya Yuko, 2008, Organogenesis, V4, P68; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Leguillette R, 2009, AM J RESP CRIT CARE, V179, P194, DOI 10.1164/rccm.200609-1367OC; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; MacLeod RJ, 2007, AM J PHYSIOL-GASTR L, V293, pG403, DOI 10.1152/ajpgi.00119.2007; McAnulty RJ, 2007, INT J BIOCHEM CELL B, V39, P666, DOI 10.1016/j.biocel.2006.11.005; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Parameswaran K, 2006, CELL BIOCHEM BIOPHYS, V44, P139, DOI 10.1385/CBB:44:1:139; Peradziryi H, 2011, EMBO J, V30, P3729, DOI 10.1038/emboj.2011.236; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Postma Dirkje S, 2006, Proc Am Thorac Soc, V3, P434, DOI 10.1513/pats.200601-006AW; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Ripka S, 2007, CARCINOGENESIS, V28, P1178, DOI 10.1093/carcin/bgl255; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sharma S, 2010, AM J RESP CRIT CARE, V181, P328, DOI 10.1164/rccm.200907-1009OC; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Villar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023914; Vuga LJ, 2009, AM J RESP CELL MOL, V41, P583, DOI 10.1165/rcmb.2008-0201OC; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311	48	85	90	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1631	1643		10.1096/fj.12-217539	http://dx.doi.org/10.1096/fj.12-217539			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23254341				2022-12-28	WOS:000316940800033
J	Li, R; Coulthard, LG; Wu, MCL; Taylor, SM; Woodruff, TM				Li, Rui; Coulthard, Liam G.; Wu, M. C. L.; Taylor, Stephen M.; Woodruff, Trent M.			C5L2: a controversial receptor of complement anaphylatoxin, C5a	FASEB JOURNAL			English	Review							INFLAMMATORY-BOWEL-DISEASE; FORMYL PEPTIDE RECEPTOR; RAT MODEL; SPHINGOSINE 1-PHOSPHATE; ANTAGONIST PROTECTS; EXPERIMENTAL SEPSIS; ALLERGIC-ASTHMA; ACTIVATION; INJURY; PATHOLOGY	C5a is the paramount proinflammatory mediator of the complement cascade, and has been previously thought to act only through a single, G-protein-coupled, C5a receptor (C5aR; also termed CD88). In 2000, a second C5a receptor, C5L2 (previously known as GPR77), was discovered; yet, despite 12 yr of intensive research, its biological, or pathophysiological, function is both enigmatic and controversial. Unlike C5aR, this receptor does not couple to G proteins, and early studies promoted the hypothesis that C5L2 functions as a decoy receptor. However, recent data have provided other evidence for more complicated and conflicting interactions between C5L2 and other inflammatory mediators. C5L2 has been recently demonstrated to physically interact with both C5aR and beta-arrestin to negatively regulate C5aR signaling toward an anti-inflammatory manner, and to reduce pathology, in several disease models in vivo. In direct contrast, other groups have demonstrated that C5L2 stimulation caused release of HMGB1 both in vitro and in vivo, and enhanced pathology in sepsis models, suggesting a clear proinflammatory signaling role. These astoundingly contradictory data challenge our precepts and complicate the foundational bases for the possible targeting of C5L2 as a therapeutic option in inflammatory disease. C5L2 may be the great masquerader in complement biology; its function dependent on the cell type, species, and disease context. Because of these unusual and unforeseen complexities, we present the current state of knowledge on C5L2 structure, expression and, most controversially, its putative functions.-Li, R., Coulthard, L.G., Wu, M. C. L., Taylor, S. M., Woodruff, T. M. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27, 855- 864 (2013). www.fasebj.org	[Li, Rui; Coulthard, Liam G.; Wu, M. C. L.; Taylor, Stephen M.; Woodruff, Trent M.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia	University of Queensland	Woodruff, TM (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	t.woodruff@uq.edu.au	Woodruff, Trent M/B-4861-2009; Coulthard, Liam/I-1980-2016; Woodruff, Trent/AAS-4629-2020	Woodruff, Trent M/0000-0003-1382-911X; Coulthard, Liam/0000-0003-3604-901X; Woodruff, Trent/0000-0003-1382-911X	National Health and Medical Research Council of Australia [APP1021413]; Australian Research Council [FT110100332]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	The authors thank the National Health and Medical Research Council of Australia (project grant APP1021413), and the Australian Research Council (Future Fellowship FT110100332), for supporting their research into C5L2. The authors also thank Prof. Charles Mackay (Monash University, Melbourne, VIC, Australia) and Dr. Peter Monk (University of Sheffield Medical School, Sheffield, UK) for the gift of the mouse and human C5L2 antibodies used in Fig. 2 of this review.	Abe M, 2001, J IMMUNOL, V167, P4651, DOI 10.4049/jimmunol.167.8.4651; Arumugam TV, 2003, KIDNEY INT, V63, P134, DOI 10.1046/j.1523-1755.2003.00737.x; Bachmaier K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030742; Baelder R, 2005, J IMMUNOL, V174, P783, DOI 10.4049/jimmunol.174.2.783; Bamberg CE, 2010, J BIOL CHEM, V285, P7633, DOI 10.1074/jbc.M109.092106; Buck E, 2005, J BIOL CHEM, V280, P4009, DOI 10.1074/jbc.C400500200; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Chen NJ, 2007, NATURE, V446, P203, DOI 10.1038/nature05559; Cui W, 2009, MOL IMMUNOL, V46, P3207, DOI 10.1016/j.molimm.2009.08.013; Cui W, 2009, MOL IMMUNOL, V46, P3086, DOI 10.1016/j.molimm.2009.06.007; Farkas I, 2012, NEUROCHEM INT, V60, P631, DOI 10.1016/j.neuint.2012.02.024; Fisette A, 2013, IMMUNOBIOLOGY, V218, P127, DOI 10.1016/j.imbio.2012.04.001; Flierl MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002560; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Francis K, 2008, J ENDOCRINOL, V199, P417, DOI 10.1677/JOE-08-0110; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; He R, 2001, J IMMUNOL, V166, P4099, DOI 10.4049/jimmunol.166.6.4099; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Jain U, 2013, BRIT J PHARMACOL, V168, P488, DOI 10.1111/j.1476-5381.2012.02183.x; Johswich K, 2009, INFLAMM BOWEL DIS, V15, P1812, DOI 10.1002/ibd.21012; Johswich K, 2006, J BIOL CHEM, V281, P39088, DOI 10.1074/jbc.M609734200; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; Lambrecht BN, 2006, J CLIN INVEST, V116, P628, DOI 10.1172/JCI27876; Liu HB, 2008, PANCREAS, V36, pE10, DOI 10.1097/MPA.0b013e31815f3905; MacLaren R, 2007, BIOCHEM CELL BIOL, V85, P11, DOI 10.1139/O06-207; Manthey HD, 2011, FASEB J, V25, P2447, DOI 10.1096/fj.10-174284; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332; Monkl PN, 2012, IMMUNOBIOLOGY, V217, P1162, DOI 10.1016/j.imbio.2012.08.097; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Pavlovski D, 2012, FASEB J, V26, P3680, DOI 10.1096/fj.11-202382; Peng Q, 2009, J IMMUNOL, V183, P6058, DOI 10.4049/jimmunol.0804186; Proctor LM, 2004, BRIT J PHARMACOL, V142, P756, DOI 10.1038/sj.bjp.0705819; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Raby AC, 2011, EUR J IMMUNOL, V41, P2741, DOI 10.1002/eji.201041350; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Roy C, 2011, AM J PHYSIOL-ENDOC M, V301, pE232, DOI 10.1152/ajpendo.00476.2010; Scola AM, 2007, J BIOL CHEM, V282, P3664, DOI 10.1074/jbc.M609178200; Scola AM, 2009, MOL IMMUNOL, V46, P1149, DOI 10.1016/j.molimm.2008.11.001; Shukla SD, 2008, ALCOHOL CLIN EXP RES, V32, P1525, DOI 10.1111/j.1530-0277.2008.00729.x; van Lith LHC, 2009, J BIOMOL SCREEN, V14, P1067, DOI 10.1177/1087057109341407; van Werkhoven MB, 2013, MOL IMMUNOL, V53, P237, DOI 10.1016/j.molimm.2012.08.013; Wen Yu, 2008, Zhonghua Yi Xue Za Zhi, V88, P114; Woodruff TM, 2004, J SURG RES, V116, P81, DOI 10.1016/j.jss.2003.04.001; Woodruff TM, 2003, J IMMUNOL, V171, P5514, DOI 10.4049/jimmunol.171.10.5514; Woodruff TM, 2002, ARTHRITIS RHEUM-US, V46, P2476, DOI 10.1002/art.10449; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; Woodruff TM, 2011, MOL IMMUNOL, V48, P1631, DOI 10.1016/j.molimm.2011.04.014; Woodruff TM, 2008, J IMMUNOL, V181, P8727, DOI 10.4049/jimmunol.181.12.8727; Zhang X, 2010, J IMMUNOL, V185, P6741, DOI 10.4049/jimmunol.1000892	58	132	139	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					855	864		10.1096/fj.12-220509	http://dx.doi.org/10.1096/fj.12-220509			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23239822				2022-12-28	WOS:000315585200002
J	Yamamoto, K; Troeberg, L; Scilabra, SD; Pelosi, M; Murphy, CL; Strickland, DK; Nagase, H				Yamamoto, Kazuhiro; Troeberg, Linda; Scilabra, Simone D.; Pelosi, Michele; Murphy, Christopher L.; Strickland, Dudley K.; Nagase, Hideaki			LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage	FASEB JOURNAL			English	Article						aggrecanase; protease; chondrocytes; osteoarthritis	RECEPTOR-RELATED PROTEIN-1; HUMAN SYNOVIAL-FLUID; PROTEOLYTIC ACTIVITIES; AGGRECAN FRAGMENTS; IN-VIVO; EXPRESSION; CLEAVAGE; VERSICAN; OSTEOARTHRITIS; DEGRADATION	Aggrecan is a major matrix component of articular cartilage, and its degradation is a crucial event in the development of osteoarthritis (OA). Adamalysin-like metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) is a major aggrecan-degrading enzyme in cartilage, but there is no clear correlation between ADAMTS-5 mRNA levels and OA progression. Here, we report that post-translational endocytosis of ADAMTS-5 by chondrocytes regulates its extracellular activity. We found 2- to 3-fold reduced aggrecanase activity when ADAMTS-5 was incubated with live porcine cartilage, resulting from its rapid endocytic clearance. Studies using receptor-associated protein (RAP), a ligand-binding antagonist for the low-density lipoprotein receptor-related proteins (LRPs), and siRNA-mediated gene silencing revealed that the receptor responsible for ADAMTS-5 clearance is LRP-1. Domain-deletion mutagenesis of ADAMTS-5 identified that the noncatalytic first thrombospondin and spacer domains mediate its endocytosis. The addition of RAP to porcine cartilage explants in culture increased the basal level of aggrecan degradation, as well as ADAMTS-5-induced aggrecan degradation. Notably, LRP-1-mediated endocytosis of ADAMTS-5 is impaired in chondrocytes of OA cartilage, with similar to 90% reduction in protein levels of LRP-1 without changes in its mRNA levels. Thus, LRP-1 dictates physiological and pathological catabolism of aggrecan in cartilage as a key modulator of the extracellular activity of ADAMTS-5.-Yamamoto, K., Troeberg, L., Scilabra, S. D., Pelosi, M., Murphy, C. L., Strickland, D. K., Nagase, H. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. FASEB J. 27, 511-521 (2013). www.fasebj.org	[Yamamoto, Kazuhiro; Troeberg, Linda; Scilabra, Simone D.; Pelosi, Michele; Murphy, Christopher L.; Nagase, Hideaki] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, London W6 8LH, England; [Strickland, Dudley K.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA	University of Oxford; University System of Maryland; University of Maryland Baltimore	Nagase, H (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, Matrix Biol Sect, 65 Aspenlea Rd, London W6 8LH, England.	hideaki.nagase@kennedy.ox.ac.uk	scilabra, simone/AAT-4753-2021; Yamamoto, Kazuhiro/AAD-9650-2019	Scilabra, Simone Dario/0000-0001-7300-6153; /0000-0003-0939-4651	Arthritis Research UK Core Grant; U.S. National Institutes of Health [AR40994, PO1 HL54710, HL54710]; Arthritis Research UK Career Development Fellowship [19466]; Versus Arthritis [19466] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	Arthritis Research UK Core Grant(Versus Arthritis); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arthritis Research UK Career Development Fellowship(Versus Arthritis); Versus Arthritis(Versus Arthritis); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Brendan L. Thoms for help with human chondrocyte culture and the Orthopaedic Surgery Department of Charing Cross Hospital (London, UK) for providing human OA cartilage. Normal human cartilage samples were obtained through the Royal National Orthopaedic Hospital (Stanmore, UK). This work was supported by an Arthritis Research UK Core Grant to the Kennedy Institute of Rheumatology, and U.S. National Institutes of Health grants AR40994 (to H.N.), PO1 HL54710 (to D. K. S.), and HL54710 (to D. K. S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. L. T. is supported by an Arthritis Research UK Career Development Fellowship (grant 19466).	Apte SS, 2009, J BIOL CHEM, V284, P31493, DOI 10.1074/jbc.R109.052340; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; Capehart AA, 2010, ANAT REC, V293, P208, DOI 10.1002/ar.21049; Dupuis LE, 2011, DEV BIOL, V357, P152, DOI 10.1016/j.ydbio.2011.06.041; Fosang AJ, 2008, EUR CELLS MATER, V15, P11, DOI 10.22203/eCM.v015a02; Franken KLMC, 2000, PROTEIN EXPRES PURIF, V18, P95, DOI 10.1006/prep.1999.1162; Fushimi K, 2008, J BIOL CHEM, V283, P6706, DOI 10.1074/jbc.M708647200; Gendron C, 2007, J BIOL CHEM, V282, P18294, DOI 10.1074/jbc.M701523200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Gorovoy M, 2010, J LEUKOCYTE BIOL, V88, P769, DOI 10.1189/jlb.0410220; Hattori N, 2011, J BIOL CHEM, V286, P34298, DOI 10.1074/jbc.M111.254938; Heinegard D, 2011, NAT REV RHEUMATOL, V7, P50, DOI 10.1038/nrrheum.2010.198; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Lim NH, 2010, BIOCHEM J, V431, P113, DOI 10.1042/BJ20100725; Liu Q, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-17; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; McCulloch DR, 2009, DEV CELL, V17, P687, DOI 10.1016/j.devcel.2009.09.008; Murphy G, 2008, NAT CLIN PRACT RHEUM, V4, P128, DOI 10.1038/ncprheum0727; Naito S, 2007, PATHOL INT, V57, P703, DOI 10.1111/j.1440-1827.2007.02167.x; Overton CD, 2007, CIRC RES, V100, P670, DOI 10.1161/01.RES.0000260204.40510.aa; Pratta MA, 2003, J BIOL CHEM, V278, P45539, DOI 10.1074/jbc.M303737200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Selvais C, 2011, FASEB J, V25, P2770, DOI 10.1096/fj.10-169508; Selvais C, 2009, ENDOCRINOLOGY, V150, P3792, DOI 10.1210/en.2009-0015; Sorvillo N, 2012, BLOOD, V119, P3828, DOI 10.1182/blood-2011-09-377754; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Troeberg L, 2008, FASEB J, V22, P3515, DOI 10.1096/fj.08-112680; Troeberg L, 2012, BBA-PROTEINS PROTEOM, V1824, P133, DOI 10.1016/j.bbapap.2011.06.020; Velasco J, 2011, J BIOL CHEM, V286, P26016, DOI 10.1074/jbc.M110.208694; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Walling HW, 2003, OSTEOARTHR CARTILAGE, V11, P854, DOI 10.1016/S1063-4584(03)00170-5; Yu ZX, 2012, J BIOL CHEM, V287, P22988, DOI 10.1074/jbc.M112.348979	41	61	64	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					511	521		10.1096/fj.12-216671	http://dx.doi.org/10.1096/fj.12-216671			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23064555	Green Published			2022-12-28	WOS:000314358000011
J	Tirino, V; Desiderio, V; Paino, F; De Rosa, A; Papaccio, F; La Noce, M; Laino, L; De Francesco, F; Papaccio, G				Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo			Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization	FASEB JOURNAL			English	Review						Tumor initiating cells; sphere formation; chemoresistance; multipotency; stemness; tumorigenicity	EPITHELIAL-MESENCHYMAL TRANSITION; SIDE POPULATION CELLS; INITIATING CELLS; PROSPECTIVE IDENTIFICATION; ALDEHYDE DEHYDROGENASE; PROSTATE-CANCER; HEMATOPOIETIC STEM; LUNG-CANCER; RESISTANCE; CD133	Primary tumors are responsible for 10% of cancer deaths. In most cases, the main cause of mortality is the formation of metastases. Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation. This population is defined as cancer stem cells (CSCs). Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery. CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments. The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay. None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies. This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.-Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., Papaccio, G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 27, 13-24 (2013). www.fasebj.org	[Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; Papaccio, Federica; La Noce, Marcella; De Francesco, Francesco; Papaccio, Gianpaolo] Univ Naples 2, Tissue Engn & Regenerat Med TERM Lab, Canc Stem Cell Eradicat Program, Dept Expt Med,Sect Histol & Embryol, I-80138 Naples, Italy; [De Rosa, Alfredo; Laino, Luigi] Univ Naples 2, Dept Head & Neck Sci, I-80138 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Papaccio, G (corresponding author), Univ Naples 2, Dept Expt Med, Sect Histol & Embryol, TERM & Canc Stem Cell Eradicat Program, 5 Via L Armanni, I-80138 Naples, Italy.	gianpaolo.papaccio@unina2.it	La Noce, Marcella/AAM-1750-2021; LAINO, LUIGI/AAB-8203-2022; desiderio, vincenzo/K-4244-2018; De Francesco, Francesco/D-8080-2016; paino, francesca/AAC-8150-2019; Papaccio, Gianpaolo/B-7150-2014	La Noce, Marcella/0000-0002-8782-3821; LAINO, LUIGI/0000-0003-2372-7109; De Francesco, Francesco/0000-0003-2977-7828; paino, francesca/0000-0002-3186-1888; Papaccio, Gianpaolo/0000-0002-4014-5306; Papaccio, Federica/0000-0002-0302-8696; desiderio, vincenzo/0000-0003-1819-6083; Tirino, Virginia/0000-0003-2731-5718				Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albers AE, 2012, CRIT REV ONCOL HEMAT, V81, P224, DOI 10.1016/j.critrevonc.2011.03.004; Almhanna K, 2011, CURR TREAT OPTION ON, V12, P111, DOI 10.1007/s11864-011-0150-8; Aptsiauri N, 2007, ADV EXP MED BIOL, V601, P123; Awad O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013943; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bapat SA, 2010, REPRODUCTION, V140, P33, DOI 10.1530/REP-09-0389; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Bleau AM, 2009, CELL CYCLE, V8, P2936; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234; Chambers I, 2004, CLONING STEM CELLS, V6, P386, DOI 10.1089/clo.2004.6.386; Chen YC, 2010, ORAL ONCOL, V46, P158, DOI 10.1016/j.oraloncology.2009.11.007; Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004; Clevers H, 2005, NAT GENET, V37, P1027, DOI 10.1038/ng1005-1027; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Corbeil D, 2010, FEBS LETT, V584, P1659, DOI 10.1016/j.febslet.2010.01.050; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dunning NL, 2011, CANCER IMMUNOL IMMUN, V60, P1181, DOI 10.1007/s00262-011-1065-8; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fabian A, 2009, CYTOM PART A, V75A, P67, DOI 10.1002/cyto.a.20690; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gage T, 2010, MLO MED LAB OBS, V32, P34; Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998; Gedye C, 2010, UROL ONCOL-SEMIN ORI, V28, P585, DOI 10.1016/j.urolonc.2009.06.010; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hu ZB, 2010, MOL CANCER THER, V9, P1536, DOI 10.1158/1535-7163.MCT-10-0191; Kelly SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010035; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; LIPINSKI M, 1987, CANCER RES, V47, P183; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu MC, 2009, J CLIN ONCOL, V27, P5153, DOI 10.1200/JCO.2008.20.6664; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Maheswaran S, 2010, CURR OPIN GENET DEV, V20, P96, DOI 10.1016/j.gde.2009.12.002; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Mego M, 2011, INT J CANCER, V129, P417, DOI 10.1002/ijc.25690; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341; Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330; Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Ohi Y, 2011, HISTOPATHOLOGY, V59, P776, DOI 10.1111/j.1365-2559.2011.03884.x; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Ozvegy-Laczka C, 2005, DRUG RESIST UPDATE, V8, P15, DOI 10.1016/j.drup.2005.02.002; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reim F, 2009, CANCER RES, V69, P8058, DOI 10.1158/0008-5472.CAN-09-0834; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Ross JS, 2009, AM J CLIN PATHOL, V132, P237, DOI 10.1309/AJCPJI7DEOLKCS6F; Roy R, 2010, BREAST CANCER RES, V12, pS2, DOI 10.1186/bcr2496; RUSSO JE, 1988, CANCER RES, V48, P2963; Rybak AP, 2011, BBA-MOL CELL RES, V1813, P683, DOI 10.1016/j.bbamcr.2011.01.018; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Singh SK, 2003, CANCER RES, V63, P5821; Steinbach D, 2007, LEUKEMIA, V21, P1172, DOI 10.1038/sj.leu.2404692; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Terry J, 2010, APPL IMMUNOHISTO M M, V18, P159, DOI 10.1097/PAI.0b013e3181b77451; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tirino Virginia, 2012, Methods Mol Biol, V879, P513, DOI 10.1007/978-1-61779-815-3_32; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Tirino V, 2009, EUR J CARDIO-THORAC, V36, P446, DOI 10.1016/j.ejcts.2009.03.063; Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469; Visus C, 2007, CANCER RES, V67, P10538, DOI 10.1158/0008-5472.CAN-07-1346; Vries RGJ, 2010, MOL ONCOL, V4, P373, DOI 10.1016/j.molonc.2010.05.001; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071	95	283	300	6	161	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					13	24		10.1096/fj.12-218222	http://dx.doi.org/10.1096/fj.12-218222			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23024375				2022-12-28	WOS:000313103200003
J	Lomonosova, YN; Shenkman, BS; Nemirovskaya, TL				Lomonosova, Yulia N.; Shenkman, Boris S.; Nemirovskaya, Tatyana L.			Attenuation of unloading-induced rat soleus atrophy with the heat-shock protein inducer 17-(allylamino)17-demethoxygeldanamycin	FASEB JOURNAL			English	Article						musculus soleus atrophy; HSP90/HSP70; E3-ligases; P-p70/S6-kinase	FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE ATROPHY; CHAPERONE MACHINERY; UBIQUITIN LIGASES; IN-VIVO; PATHWAY; EXPRESSION; BINDING; HSP90; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN	We hypothesized that pharmacological induction of HSP70 would attenuate soleus atrophy development under 3 d of rat hindlimb unloading. Male Wistar rats were divided into control (C; n=7), 3-d hindlimb unloading (HUL; n=7), HUL with HSP90 inducer administration, 17-allylamino-17-emethoxygeldanamycin (17-AAG; 60 mg/kg, HUL + 17-AAG, n=8). The relative weight of soleus muscle to body weight [soleus wt (mg)/body wt (g)] in the HUL group was less than that of the C and HUL + 17-AAG groups (P<0.05). We revealed HSP90, HSP70 mRNA decrease in the HUL group (but not the HUL + 17-AAG group) vs. C (P<0.05). The unloading resulted in significant increases of mu-calpain and conjugated ubiquitin (Ub) levels (proteins as well as mRNAs) vs. the C group, whereas 17-AAG administration prevented these alterations (studied by SDS-PAGE and RT-PCR). pFOXO3 protein was decreased in the HUL group vs. C, but not in HUL + 17-AAG. Content of E3-lygase (MuRF-1, MAFbx) mRNA was increased in both suspended groups. In summary, 17-AAG administration attenuates soleus muscle atrophy, mu-calpain, and Ub increases under hindlimb unloading as well as decrease of pFOXO3.-Lomonosova, Y. N., Shenkman, B S., Nemirovskaya, T. L. Attenuation of unloading-induced rat soleus atrophy with the heat-shock protein inducer 17-(allylamino)-17-demethoxygeldanamycin. FASEB J. 26, 4295-4301 (2012). www.fasebj.org	[Nemirovskaya, Tatyana L.] Moscow MV Lomonosov State Univ, Fac Basic Med, Moscow 117191, Russia; [Lomonosova, Yulia N.; Shenkman, Boris S.; Nemirovskaya, Tatyana L.] Russian Acad Sci, Inst Biomed Problems, Moscow, Russia	Lomonosov Moscow State University; Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences	Nemirovskaya, TL (corresponding author), Moscow MV Lomonosov State Univ, Fac Basic Med, Lomonosovsky Pr 31-5, Moscow 117191, Russia.	nemirovskaya@bk.ru	Shenkman, Boris/AAB-1536-2020; Lomonosova, Yulia/ABG-2976-2020	Lomonosova, Yulia/0000-0003-0508-5480	Russian Foundation for Basic Research [RFBR 11-04-00787-a]	Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	This article was supported by Russian Foundation for Basic Research grant RFBR 11-04-00787-a.	Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Cleasby ME, 2007, MOL ENDOCRINOL, V21, P215, DOI 10.1210/me.2006-0154; Egorin MJ, 2001, CANCER CHEMOTH PHARM, V47, P291, DOI 10.1007/s002800000242; Giger JM, 2009, J APPL PHYSIOL, V107, P1204, DOI 10.1152/japplphysiol.00344.2009; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Ishihara A, 2008, J PHYSIOL SCI, V58, P413, DOI 10.2170/physiolsci.RP000808; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Jolly C, 2004, J CELL BIOL, V164, P25, DOI 10.1083/jcb.200306104; Kayani AC, 2008, REJUV RES, V11, P1021, DOI 10.1089/rej.2008.0795; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; McCollum AK, 2008, MOL CANCER THER, V7, P3256, DOI 10.1158/1535-7163.MCT-08-0157; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; MOREY ER, 1979, BIOSCIENCE, V29, P168, DOI 10.2307/1307797; Oishi Y, 2003, JPN J PHYSIOL, V53, P281, DOI 10.2170/jjphysiol.53.281; Pratt WB, 2008, J BIOL CHEM, V283, P22885, DOI 10.1074/jbc.R800023200; Pratt WB, 2010, EXP BIOL MED, V235, P278, DOI 10.1258/ebm.2009.009250; Sakurai T, 2005, FASEB J, V19, P1199, DOI 10.1096/fj.04-3060fje; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163; Shenkman BS, 2008, J MUSCLE RES CELL M, V29, P221, DOI 10.1007/s10974-008-9164-7; Smith IJ, 2007, EXP PHYSIOL, V92, P561, DOI 10.1113/expphysiol.2006.035790; Soti C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/sj.bjp.0706396; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Thomason DB, 1989, AM J PHYSIOL, V257, P300; Waza M, 2006, J MOL MED, V84, P635, DOI 10.1007/s00109-006-0066-0; Yasuhara K, 2011, J APPL PHYSIOL, V111, P1142, DOI 10.1152/japplphysiol.00471.2011	30	24	30	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4295	4301		10.1096/fj.12-204412	http://dx.doi.org/10.1096/fj.12-204412			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751006				2022-12-28	WOS:000309704000034
J	Sanghvi, VR; Steel, LF				Sanghvi, Viraj R.; Steel, Laura F.			RNA silencing as a cellular defense against HIV-1 infection: progress and issues	FASEB JOURNAL			English	Review						antiviral response; TAT; TRBP	IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL NONCODING RNAS; BINDING PROTEIN; GENE-EXPRESSION; MICRORNA EXPRESSION; ANTIVIRAL IMMUNITY; HIV-1-INFECTED CELLS; SUPPRESSOR ACTIVITY; MAMMALIAN-CELLS; TAR ELEMENT	MicroRNAs (miRNAs) are known to have a role in gene regulation that is closely integrated into the pathways that control virtually all fundamental cell processes of growth, differentiation, metabolism, and death. Whether silencing RNAs and the cellular pathways that generate them are also used in antiviral defense in higher eukaryotes, as they are in plants and lower eukaryotes, has been the subject of much study. Results to date point to a complex interplay between viruses and vertebrate host cells that can vary considerably among different viruses. Here, we review current knowledge regarding interactions between HIV-1 and host cell RNA silencing mechanisms. Important questions in this field remain unresolved, including whether HIV-1 itself encodes small silencing RNAs that might either promote or repress its replication, whether host cell miRNAs can directly target viral transcripts or can alter the course of infection indirectly through effects on cellular genes necessary for viral replication, and whether HIV-1 produces proteins or RNAs that suppress the host-silencing pathway. We summarize evidence and controversies related to the potential role of RNA silencing pathways as a defense against HIV-1 infection.-Sanghvi, V. R., Steel, L. F. RNA silencing as a cellular defense against HIV-1 infection: progress and issues. FASEB J. 26, 3937-3945 (2012). www.fasebj.org	[Sanghvi, Viraj R.; Steel, Laura F.] Drexel Univ, Coll Med, Inst Mol Med & Infect Dis, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA	Drexel University	Steel, LF (corresponding author), 245 N 15th St,MS1013A, Philadelphia, PA 19102 USA.	laura.steel@drexelmed.edu		Sanghvi, Viraj/0000-0001-6526-7820	Commonwealth of Pennsylvania Department of Health, Tobacco Formula Funds	Commonwealth of Pennsylvania Department of Health, Tobacco Formula Funds	The authors thank Glenn Rall for his critical reading of the manuscript. Work cited from the authors' laboratory was supported by a grant to L.F.S. from the Commonwealth of Pennsylvania Department of Health, Tobacco Formula Funds.	Ahluwalia JK, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-117; Aliyari R, 2009, IMMUNOL REV, V227, P176, DOI 10.1111/j.1600-065X.2008.00722.x; Althaus CF, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-27; Arvey A, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.24; Barth S, 2008, NUCLEIC ACIDS RES, V36, P666, DOI 10.1093/nar/gkm1080; Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Bennasser Y, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-95; Bennasser Y, 2006, J BIOL CHEM, V281, P27674, DOI 10.1074/jbc.C600072200; Bennasser Yamina, 2004, Retrovirology, V1, P43, DOI 10.1186/1742-4690-1-43; Berkhou B, 2009, FUTURE MICROBIOL, V4, P151, DOI 10.2217/17460913.4.2.151; Bignami F, 2012, BLOOD, V119, P6259, DOI 10.1182/blood-2011-09-379503; Bivalkar-Mehla S, 2011, VIRUS RES, V155, P1, DOI 10.1016/j.virusres.2010.10.003; Boss IW, 2009, TRENDS MICROBIOL, V17, P544, DOI 10.1016/j.tim.2009.09.002; Brown KM, 2005, NAT STRUCT MOL BIOL, V12, P469, DOI 10.1038/nsmb931; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiang K, 2011, FUTURE VIROL, V6, P209, DOI 10.2217/FVL.10.92; Cloonan N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r126; Csorba T, 2009, ADV VIRUS RES, V75, P35, DOI 10.1016/S0065-3527(09)07502-2; Cullen BR, 2006, NAT IMMUNOL, V7, P563, DOI 10.1038/ni1352; Cullen BR, 2011, CURR OPIN VIROL, V1, P211, DOI 10.1016/j.coviro.2011.04.003; Das AT, 2007, J VIROL, V81, P7742, DOI 10.1128/JVI.00392-07; de Vries W, 2008, INT J BIOCHEM CELL B, V40, P2007, DOI 10.1016/j.biocel.2008.04.015; de Vries W, 2009, J GEN VIROL, V90, P1916, DOI 10.1099/vir.0.008284-0; Ding SW, 2010, NAT REV IMMUNOL, V10, P632, DOI 10.1038/nri2824; Eletto D, 2008, J CELL PHYSIOL, V216, P764, DOI 10.1002/jcp.21452; Fabozzi G, 2011, J VIROL, V85, P2512, DOI 10.1128/JVI.01160-10; Gatignol A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-65; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Haasnoot J, 2007, PLOS PATHOG, V3, P794, DOI 10.1371/journal.ppat.0030086; Haasnoot J, 2011, METHODS MOL BIOL, V721, P23, DOI 10.1007/978-1-61779-037-9_2; Hariharan M, 2005, BIOCHEM BIOPH RES CO, V337, P1214, DOI 10.1016/j.bbrc.2005.09.183; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; Hayes AM, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-36; Houzet L, 2011, BBA-GENE REGUL MECH, V1809, P686, DOI 10.1016/j.bbagrm.2011.05.009; Houzet L, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-118; Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639; Imai K, 2005, J BIOL CHEM, V280, P26701, DOI 10.1074/jbc.M503313200; Ji XH, 2008, CURR TOP MICROBIOL, V320, P99; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109; Klase Z, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-63; Klase Z, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-18; Kok KH, 2007, J BIOL CHEM, V282, P17649, DOI 10.1074/jbc.M611768200; Kok KH, 2006, J GEN VIROL, V87, P2639, DOI 10.1099/vir.0.81764-0; Lantermann M, 2007, VIRUS RES, V126, P1, DOI 10.1016/j.virusres.2007.01.009; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lei XF, 2010, VIRULENCE, V1, P433, DOI 10.4161/viru.1.5.12966; Liang DG, 2011, CELL RES, V21, P793, DOI 10.1038/cr.2011.5; Lin J, 2007, J VIROL, V81, P12218, DOI 10.1128/JVI.01390-07; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Nathans R, 2009, MOL CELL, V34, P696, DOI 10.1016/j.molcel.2009.06.003; Omoto S, 2005, J GEN VIROL, V86, P751, DOI 10.1099/vir.0.80449-0; Omoto Shinya, 2004, Retrovirology, V1, P44, DOI 10.1186/1742-4690-1-44; Ott M, 2011, CELL HOST MICROBE, V10, P426, DOI 10.1016/j.chom.2011.11.002; Ouellet DL, 2008, NUCLEIC ACIDS RES, V36, P2353, DOI 10.1093/nar/gkn076; Ouellet DL, 2010, METHODS MOL BIOL, V623, P35, DOI 10.1007/978-1-60761-588-0_3; Parameswaran P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000764; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Qian S, 2009, P NATL ACAD SCI USA, V106, P605, DOI 10.1073/pnas.0806822106; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Sanghvi VR, 2011, J VIROL, V85, P12614, DOI 10.1128/JVI.05240-11; Sanghvi VR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017246; Schnettler E, 2009, EMBO REP, V10, P258, DOI 10.1038/embor.2009.6; Schopman NCT, 2012, NUCLEIC ACIDS RES, V40, P414, DOI 10.1093/nar/gkr719; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243; Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576; Sun GH, 2012, NUCLEIC ACIDS RES, V40, P2181, DOI 10.1093/nar/gkr961; Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263; Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Williams CA, 2005, EXP BIOL MED, V230, P872, DOI 10.1177/153537020523001113; Witwer KW, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-5; Wu QF, 2010, CELL HOST MICROBE, V8, P12, DOI 10.1016/j.chom.2010.06.009; Yeung ML, 2009, NUCLEIC ACIDS RES, V37, P6575, DOI 10.1093/nar/gkp707; Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81	82	12	16	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					3937	3945		10.1096/fj.12-210765	http://dx.doi.org/10.1096/fj.12-210765			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751007				2022-12-28	WOS:000309704000002
J	Huttemann, M; Lee, I; Gao, XF; Pecina, P; Pecinova, A; Liu, J; Aras, S; Sommer, N; Sanderson, TH; Tost, M; Neff, F; Aguilar-Pimentel, JA; Becker, L; Naton, B; Rathkolb, B; Rozman, J; Favor, J; Hans, W; Prehn, C; Puk, O; Schrewe, A; Sun, MX; Hofler, H; Adamski, J; Bekeredjian, R; Graw, J; Adler, T; Busch, DH; Klingenspor, M; Klopstock, T; Ollert, M; Wolf, E; Fuchs, H; Gailus-Durner, V; de Angelis, MH; Weissmann, N; Doan, JW; Bassett, DJP; Grossman, LI				Huettemann, Maik; Lee, Icksoo; Gao, Xiufeng; Pecina, Petr; Pecinova, Alena; Liu, Jenney; Aras, Siddhesh; Sommer, Natascha; Sanderson, Thomas H.; Tost, Monica; Neff, Frauke; Aguilar-Pimentel, Juan Antonio; Becker, Lore; Naton, Beatrix; Rathkolb, Birgit; Rozman, Jan; Favor, Jack; Hans, Wolfgang; Prehn, Cornelia; Puk, Oliver; Schrewe, Anja; Sun, Minxuan; Hoefler, Heinz; Adamski, Jerzy; Bekeredjian, Raffi; Graw, Jochen; Adler, Thure; Busch, Dirk H.; Klingenspor, Martin; Klopstock, Thomas; Ollert, Markus; Wolf, Eckhard; Fuchs, Helmut; Gailus-Durner, Valerie; de Angelis, Martin Hrabe; Weissmann, Norbert; Doan, Jeffrey W.; Bassett, David J. P.; Grossman, Lawrence I.			Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology	FASEB JOURNAL			English	Article						asthma; CCO4-2; COX4-2; COX4i2; inflammation; oxidative phosphorylation	HYPOXIC PULMONARY VASOCONSTRICTION; INFLAMMATORY CELL CHANGES; OXIDATIVE-PHOSPHORYLATION; MURINE MODEL; IN-VIVO; RESPIRATION; OXYGEN; SEX; ATP; MITOCHONDRIA	Cytochrome c oxidase (COX) is the terminal enzyme of the mitochondrial electron transport chain. The purpose of this study was to analyze the function of lung-specific cytochrome c oxidase subunit 4 isoform 2 (COX4i2) in vitro and in COX4i2-knockout mice in vivo. COX was isolated from cow lung and liver as control and functionally analyzed. COX4i2-knockout mice were generated and the effect of the gene knockout was determined, including COX activity, tissue energy levels, noninvasive and invasive lung function, and lung pathology. These studies were complemented by a comprehensive functional screen performed at the German Mouse Clinic (Neuherberg, Germany). We show that isolated cow lung COX containing COX4i2 is about twice as active (88 and 102% increased activity in the presence of allosteric activator ADP and inhibitor ATP, respectively) as liver COX, which lacks COX4i2. In COX4i2-knockout mice, lung COX activity and cellular ATP levels were significantly reduced (-50 and -29%, respectively). Knockout mice showed decreased airway responsiveness (60% reduced P-enh and 58% reduced airway resistance upon challenge with 25 and 100 mg methacholine, respectively), and they developed a lung pathology deteriorating with age that included the appearance of Charcot-Leyden crystals. In addition, there was an interesting sex-specific phenotype, in which the knockout females showed reduced lean mass (-12%), reduced total oxygen consumption rate (-8%), improved glucose tolerance, and reduced grip force (-14%) compared to wild-type females. Our data suggest that high activity lung COX is a central determinant of airway function and is required for maximal airway responsiveness and healthy lung function. Since airway constriction requires energy, we propose a model in which reduced tissue ATP levels explain protection from airway hyperresponsiveness, i.e., absence of COX4i2 leads to reduced lung COX activity and ATP levels, which results in impaired airway constriction and thus reduced airway responsiveness; long-term lung pathology develops in the knockout mice due to impairment of energy-costly lung maintenance processes; and therefore, we propose mitochondrial oxidative phosphorylation as a novel target for the treatment of respiratory diseases, such as asthma.-Huttemann, M., Lee, I., Gao, X., Pecina, P., Pecinova, A., Liu, J., Aras, S., Sommer, N., Sanderson, T. H., Tost, M., Neff, F., Aguilar-Pimentel, J. A., Becker, L., Naton, B., Rathkolb, B., Rozman, J., Favor, J., Hans, W., Prehn, C., Puk, O., Schrewe, A., Sun, M., Hofler, H., Adamski, J., Bekeredjian, R., Graw, J., Adler, T., Busch, D. H., Klingenspor, M., Klopstock, T., Ollert, M., Wolf, E., Fuchs, H., Gailus-Durner, V., Hrabe. de Angelis, M., Weissmann, N., Doan, J. W., Bassett, D. J. P., Grossman, L. I. Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology. FASEB J. 26, 3916-3930 (2012). www.fasebj.org	[Huettemann, Maik; Lee, Icksoo; Pecina, Petr; Pecinova, Alena; Liu, Jenney; Aras, Siddhesh; Doan, Jeffrey W.; Bassett, David J. P.; Grossman, Lawrence I.] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; [Gao, Xiufeng; Bassett, David J. P.] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48201 USA; [Sanderson, Thomas H.] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI 48201 USA; [Sommer, Natascha; Weissmann, Norbert] Univ Giessen, Dept Internal Med 2, Univ Giessen Lung Ctr, D-35390 Giessen, Germany; [Tost, Monica; Neff, Frauke; Hoefler, Heinz] German Res Ctr Environm Hlth, Inst Pathol, Neuherberg, Germany; [Becker, Lore; Naton, Beatrix; Rathkolb, Birgit; Rozman, Jan; Hans, Wolfgang; Prehn, Cornelia; Schrewe, Anja; Adamski, Jerzy; Adler, Thure; Fuchs, Helmut; Gailus-Durner, Valerie; de Angelis, Martin Hrabe] German Res Ctr Environm Hlth, Inst Expt Genet, German Mouse Clin, Neuherberg, Germany; [Favor, Jack] German Res Ctr Environm Hlth, Inst Human Genet, Neuherberg, Germany; [Puk, Oliver; Sun, Minxuan; Graw, Jochen] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany; [Aguilar-Pimentel, Juan Antonio; Ollert, Markus] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Aguilar-Pimentel, Juan Antonio; Ollert, Markus] Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, Munich, Germany; [Hoefler, Heinz] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Klinikum Rechts Isar, Munich, Germany; [Busch, Dirk H.] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Aguilar-Pimentel, Juan Antonio; Ollert, Markus] Tech Univ Munich, Div Environm Dermatol & Allergy, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Becker, Lore; Klopstock, Thomas] Univ Munich, Gene Ctr, Friedrich Baur Inst, Dept Neurol, Munich, Germany; [Rathkolb, Birgit; Wolf, Eckhard] Univ Munich, Gene Ctr, Dept Mol Anim Breeding & Biotechnol, Munich, Germany; [Rozman, Jan; Klingenspor, Martin] Tech Univ Munich, Else Kroner Fresenius Ctr, Dept Mol Nutr Med, Freising Weihenstephan, Germany; [Adamski, Jerzy; de Angelis, Martin Hrabe] Tech Univ Munich, Dept Expt Genet, Freising Weihenstephan, Germany; [Bekeredjian, Raffi] Heidelberg Univ, Otto Meyerhof Zentrum, Dept Med 3, Div Cardiol, Heidelberg, Germany	Wayne State University; Wayne State University; Wayne State University; Justus Liebig University Giessen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; University of Munich; Technical University of Munich; Technical University of Munich; Ruprecht Karls University Heidelberg	Huttemann, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA.	mhuttema@med.wayne.edu	de Angelis, Martin Hrabe/F-5531-2012; Fuchs, Helmut/M-7347-2014; Gailus-Durner, Valerie/M-7337-2014; Becker, Lore/E-3717-2010; Becker, Lore/AAJ-1203-2020; Klingenspor, Martin/K-5033-2019; Pecinová, Alena/A-8695-2010; Puk, Oliver/E-1443-2013; Naton, Beatrix/B-5392-2013; Pecina, Petr/A-9396-2010; Sommer, Natascha/AAD-5406-2020; Rathkolb, Birgit/F-7041-2013; Rozman, Jan/A-2540-2010; Klingenspor, Martin/D-6930-2011; Graw, Jochen/D-9336-2013; Sanderson, Thomas H/K-6656-2012	de Angelis, Martin Hrabe/0000-0002-7898-2353; Fuchs, Helmut/0000-0002-5143-2677; Becker, Lore/0000-0002-6890-4984; Pecinová, Alena/0000-0002-0204-7502; Naton, Beatrix/0000-0002-9453-8877; Pecina, Petr/0000-0003-0641-2834; Rozman, Jan/0000-0002-8035-8904; Klingenspor, Martin/0000-0002-4502-6664; Sanderson, Thomas H/0000-0003-0112-8164; Graw, Jochen/0000-0003-0298-9660; Huttemann, Maik/0000-0001-6310-7081; Adamski, Jerzy/0000-0001-9259-0199; Ollert, Markus W./0000-0002-8055-0103; Wolf, Eckhard/0000-0002-0430-9510; Sommer, Natascha/0000-0002-8915-7762; Weissmann, Norbert/0000-0003-2675-3871; Prehn, Cornelia/0000-0002-1274-4715	Philip Morris USA Inc.; Philip Morris International; U.S. National Institutes of Health (NIH) [GM089900]; NIH [GM48517]; German Federal Ministry of Education and Research (BMBF) [01GS0850, 01GS0851, 01GS0868, 01GS0869, 01GS0854]; EU grant (EU-MODIC) [LSHG-2006-037188]; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048517, R01GM089900] Funding Source: NIH RePORTER	Philip Morris USA Inc.; Philip Morris International; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); EU grant (EU-MODIC); Center for Molecular Medicine and Genetics, Wayne State University School of Medicine; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank R. Seeliger, S. Bothur, R. Fischer, M. Grandl, E. Holupirek, M. Kugler, A. Langer, K. Laube, J. Muller, E. Samson, F. Schleicher, D. Schmidt, W. Schneider, A. E. Schwarz, W. Stettinger, L. Thumann, S. Wittich, and Anja Wohlbier, as well as the German Mouse Clinic (GMC; Neuherberg, Germany) animal caretaker team, M. Huber, B. Schon, H. Marr, A. Miedl, T. Reichelt, M. Gerstlauer, R. Huber, and H. Wenig, for expert technical help. The authors thank Christopher Sinkler (Wayne State University) for conducting quantitative real-time PCR experiments. Research described in this article was supported by Philip Morris USA Inc. and Philip Morris International (M. H.), the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine (M. H.), grant GM089900 from the U.S. National Institutes of Health (NIH; M. H.), and a grant supplement from the NIH (GM48517; L. I. G.). Work performed at the GMC was funded by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD eV) and to the GMC (NGFN-Plus grants 01GS0850, 01GS0851, 01GS0868, 01GS0869, and 01GS0854) as well as by an EU grant (EU-MODIC, LSHG-2006-037188, GMC).	Acin-Perez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021; Acin-Perez R, 2011, CELL METAB, V13, P712, DOI 10.1016/j.cmet.2011.03.024; Ackerman SJ, 2002, J BIOL CHEM, V277, P14859, DOI 10.1074/jbc.M200221200; Alphonse MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001921; Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Bassett D, 2010, J TOXICOL ENV HEAL A, V73, P711, DOI 10.1080/15287391003614018; BASSETT DJP, 1992, AM J PHYSIOL, V263, pL439, DOI 10.1152/ajplung.1992.263.4.L439; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; Birrell MA, 2003, RESPIR RES, V4, DOI 10.1186/rr197; Carey MA, 2007, TRENDS ENDOCRIN MET, V18, P308, DOI 10.1016/j.tem.2007.08.003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corteling Randolph, 2004, BMC Pharmacology, V4, P4, DOI 10.1186/1471-2210-4-4; Dalmonte ME, 2009, J BIOL CHEM, V284, P32331, DOI 10.1074/jbc.M109.050146; DeLorme MP, 2002, J PHARMACOL TOXICOL, V47, P1, DOI 10.1016/S1056-8719(02)00191-0; DeLorme MP, 2002, J TOXICOL ENV HEAL A, V65, P1453, DOI 10.1080/00984100290071432; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; Dudley R, 1998, J EXP BIOL, V201, P1043; FISHER AB, 1973, BIOCHEMISTRY-US, V12, P1438, DOI 10.1021/bi00731a026; Fuchs H, 2011, METHODS, V53, P120, DOI 10.1016/j.ymeth.2010.08.006; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gailus-Durner V, 2005, NAT METHODS, V2, P403, DOI 10.1038/nmeth0605-403; Grossman LI, 1997, BBA-GENE STRUCT EXPR, V1352, P174, DOI 10.1016/S0167-4781(97)00025-0; Hahn YS, 2003, J IMMUNOL, V171, P3170, DOI 10.4049/jimmunol.171.6.3170; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; Holgate ST, 2005, AM J RESP CRIT CARE, V172, P941, DOI 10.1164/rccm.2507007; HOLT PG, 1985, IMMUNOLOGY, V54, P139; Huttemann M, 2007, FEBS J, V274, P5737, DOI 10.1111/j.1742-4658.2007.06093.x; Huttemann M, 2003, MOL REPROD DEV, V66, P8, DOI 10.1002/mrd.10327; Huttemann M, 2003, GENE, V312, P95, DOI 10.1016/S0378-1119(03)00604-8; Huttemann M, 2001, GENE, V267, P111, DOI 10.1016/S0378-1119(01)00385-7; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Kiernan MC, 2004, NEUROMUSCULAR DISORD, V14, P375, DOI 10.1016/j.nmd.2004.02.014; Lee I, 2005, J BIOL CHEM, V280, P6094, DOI 10.1074/jbc.M411335200; Lee I, 2010, BBA-MOL BASIS DIS, V1802, P275, DOI 10.1016/j.bbadis.2009.10.005; Lee I, 2009, METHOD ENZYMOL, V457, P193, DOI 10.1016/S0076-6879(09)05011-3; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.3.CO;2-E; Marin DP, 2010, CELL BIOCHEM FUNCT, V28, P394, DOI 10.1002/cbf.1669; Mason CE, 2010, NUCLEIC ACIDS RES, V38, P2355, DOI 10.1093/nar/gkp1188; Molloy EJ, 2003, BLOOD, V102, P2653, DOI 10.1182/blood-2003-02-0649; Monteseirin J, 2009, J INVEST ALLERG CLIN, V19, P340; Napiwotzki J, 1997, BIOL CHEM, V378, P1013, DOI 10.1515/bchm.1997.378.9.1013; Okuyama K, 2008, CLIN EXP ALLERGY, V38, P1212, DOI 10.1111/j.1365-2222.2008.03015.x; Pacelli C, 2011, MITOCHONDRION, V11, P334, DOI 10.1016/j.mito.2010.12.004; Pecinova A, 2011, MITOCHONDRION, V11, P722, DOI 10.1016/j.mito.2011.05.006; Piccoli C, 2006, BIOCHEM J, V396, P573, DOI 10.1042/BJ20060077; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Roemgens A, 2011, NEUROTOX RES, V20, P1, DOI 10.1007/s12640-010-9213-z; Rosai J., 2004, RJ ROSAI ACKERMANS S, Vninth; Saffar AS, 2007, J IMMUNOL, V178, P2535, DOI 10.4049/jimmunol.178.4.2535; SCHULTHEIS AH, 1994, LUNG, V172, P169; SHANSKE AL, 1993, NEUROMUSCULAR DISORD, V3, P191, DOI 10.1016/0960-8966(93)90058-R; Shteyer E, 2009, AM J HUM GENET, V84, P412, DOI 10.1016/j.ajhg.2009.02.006; Stirone C, 2005, MOL PHARMACOL, V68, P959, DOI 10.1124/mol.105.014662; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Weissmann N, 2004, RESP PHYSIOL NEUROBI, V139, P191, DOI 10.1016/j.resp.2003.10.003; Weissmann N, 2006, P NATL ACAD SCI USA, V103, P19093, DOI 10.1073/pnas.0606728103; WELLER PF, 1984, J BIOL CHEM, V259, P5100; Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Yamano K, 2005, BIOCHEM PHARMACOL, V70, P1487, DOI 10.1016/j.bcp.2005.08.003	67	53	54	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3916	3930		10.1096/fj.11-203273	http://dx.doi.org/10.1096/fj.11-203273			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22730437	Green Published			2022-12-28	WOS:000308391600031
J	Burrack, S; Aberle, D; Burck, J; Ulrich, AS; Meyers, G				Burrack, Sandra; Aberle, Daniel; Buerck, Jochen; Ulrich, Anne S.; Meyers, Gregor			A new type of intracellular retention signal identified in a pestivirus structural glycoprotein	FASEB JOURNAL			English	Article						viral RNase; classical swine fever virus; amphopathic helix; Erns protein; protein sorting; innate immune evasion	VIRAL-DIARRHEA-VIRUS; HEPATITIS-C VIRUS; SWINE-FEVER VIRUS; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; HOG-CHOLERA VIRUS; DOUBLE-STRANDED-RNA; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; NUCLEOTIDE-SEQUENCE	Sorting of membrane proteins into intracellular organelles is crucial for cell function. Viruses exploit intracellular transport and retention systems to concentrate envelope proteins at the site of virus budding. In pestiviruses, a group of important pathogens of pigs and ruminants closely related to human hepatitis C virus, the E-rns protein translated from the viral RNA is secreted from the infected cells and found in the serum of infected animals. Secretion of the protein is regarded as crucial for its function as a viral virulence factor associated with its RNase activity. However, similar to 95% of the E-rns molecules are retained within the infected cell. Fusion of different Erns fragments to the C terminus of CD72 allowed identification of a retention signal within the C-terminal 65 aa of the viral protein. This C-terminal sequence represents its membrane anchor and folds into an amphipathic helix binding in-plane to the membrane surface. Residues L183, I190, and L208 are important for intracellular location of E-rns. Presentation of the retention signal on the cytoplasmic instead of the luminal face of the ER membrane in CD8 alpha fusion proteins still led to retention. Thus, E-rns contains in its C-terminal amphipathic helix an intracellular retention signal that is active on both faces of the membrane.-Burrack, S., Aberle, D., Burck, J., Ulrich, A. S., Meyers, G. A new type of intracellular retention signal identified in a pestivirus structural glycoprotein. FASEB J. 26, 3292-3305 (2012). www.fasebj.org	[Burrack, Sandra; Aberle, Daniel; Meyers, Gregor] Friedrich Loeffler Inst, Inst Immunol, Insel Riems, Germany; [Buerck, Jochen; Ulrich, Anne S.] Karlsruhe Inst Technol, Inst Biol Grenzflachen, Karlsruhe, Germany; [Ulrich, Anne S.] Karlsruhe Inst Technol, Inst Organ Chem, Karlsruhe, Germany	Friedrich Loeffler Institute; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Meyers, G (corresponding author), Friedrich Loeffler Inst, Inst Immunol, Sudufer 10, D-17493 Greifswald, Germany.	gregor.meyers@fli.bund.de	Ulrich, Anne S/H-5519-2013	Ulrich, Anne S/0000-0001-5571-9483	Deutsche Forschungsgemeinschaft [DFG-ME1367/4]; Boehringer Ingelheim Vetmedica GmbH (Ingelheim, Germany)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Boehringer Ingelheim Vetmedica GmbH (Ingelheim, Germany)(Boehringer Ingelheim)	The authors thank Gaby Stooss, Petra Wulle, Maren Ziegler, and Bianca Posselt for excellent technical assistance. The authors are especially grateful to Annette Vogel for help with the FACS analyses. This study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG-ME1367/4) and Boehringer Ingelheim Vetmedica GmbH (Ingelheim, Germany).	Balali-Mood K, 2009, BIOCHEMISTRY-US, V48, P2135, DOI 10.1021/bi8017398; Bintintan I, 2010, J BIOL CHEM, V285, P8572, DOI 10.1074/jbc.M109.083394; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Brass V, 2007, J VIROL, V81, P2745, DOI 10.1128/JVI.01279-06; Brass V, 2010, J VIROL, V84, P11580, DOI 10.1128/JVI.01519-10; Ciczora Y, 2010, J GEN VIROL, V91, P404, DOI 10.1099/vir.0.015339-0; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; Cornell RB, 2006, CURR PROTEIN PEPT SC, V7, P539, DOI 10.2174/138920306779025675; DEMOERLOOZE L, 1993, J GEN VIROL, V74, P1433, DOI 10.1099/0022-1317-74-7-1433; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Fetzer C, 2005, J VIROL, V79, P11901, DOI 10.1128/JVI.79.18.11901-11913.2005; Gouttenoire J, 2010, REV MED VIROL, V20, P117, DOI 10.1002/rmv.640; Gouttenoire J, 2009, J VIROL, V83, P11378, DOI 10.1128/JVI.01122-09; Grummer B, 2001, J GEN VIROL, V82, P2597, DOI 10.1099/0022-1317-82-11-2597; Hausmann Y, 2004, J VIROL, V78, P5507, DOI 10.1128/JVI.78.10.5507-5512.2004; HEINZ FX, 2000, VIRUS TAXONOMY, P859; Heyden ABV, 2011, EMBO J, V30, P3217, DOI 10.1038/emboj.2011.233; Hilton L, 2006, J VIROL, V80, P11723, DOI 10.1128/JVI.01145-06; Hobman TC, 1997, J VIROL, V71, P7670, DOI 10.1128/JVI.71.10.7670-7680.1997; HORIUCHI H, 1988, J BIOCHEM-TOKYO, V103, P408, DOI 10.1093/oxfordjournals.jbchem.a122284; HULST MM, 1994, VIROLOGY, V200, P558, DOI 10.1006/viro.1994.1218; Iqbal M, 2004, J VIROL, V78, P136, DOI 10.1128/JVI.78.1.136-145.2004; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kohl W, 2004, J GEN VIROL, V85, P1101, DOI 10.1099/vir.0.19740-0; Kummerer BM, 1998, J VIROL, V72, P4127; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Lindenbach B., 2011, FIELDS VIROLOGY, V5th ed., P1101; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Magkouras I, 2008, J GEN VIROL, V89, P2501, DOI 10.1099/vir.0.2008/003749-0; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Matzener P, 2009, VIRUS RES, V140, P15, DOI 10.1016/j.virusres.2008.10.015; Meyer C, 2002, J VIROL, V76, P8494, DOI 10.1128/JVI.76.16.8494-8503.2002; Meyers G, 1999, J VIROL, V73, P10224, DOI 10.1128/JVI.73.12.10224-10235.1999; MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9; Meyers G, 1996, J VIROL, V70, P8606, DOI 10.1128/JVI.70.12.8606-8613.1996; Meyers G, 2007, J VIROL, V81, P3327, DOI 10.1128/JVI.02372-06; Moormann RJM, 1996, J VIROL, V70, P763, DOI 10.1128/JVI.70.2.763-770.1996; MOORMANN RJM, 1990, VIROLOGY, V177, P184, DOI 10.1016/0042-6822(90)90472-4; Morikawa K, 2011, J VIRAL HEPATITIS, V18, P305, DOI 10.1111/j.1365-2893.2011.01451.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nair R, 2003, PROTEINS, V53, P917, DOI 10.1002/prot.10507; Nakai K, 2001, J STRUCT BIOL, V134, P103, DOI 10.1006/jsbi.2001.4378; Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pagny S, 1999, J EXP BOT, V50, P157, DOI 10.1093/jexbot/50.331.157; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Picot D, 1997, ADV EXP MED BIOL, V400, P107; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Reimann I, 2007, VIROLOGY, V366, P377, DOI 10.1016/j.virol.2007.05.006; Ronchi P, 2008, J CELL BIOL, V181, P105, DOI 10.1083/jcb.200710093; Ruggli N, 2005, VIROLOGY, V340, P265, DOI 10.1016/j.virol.2005.06.033; RUMENAPF T, 1993, J VIROL, V67, P3288; Sainz IF, 2008, VIROLOGY, V370, P122, DOI 10.1016/j.virol.2007.08.028; Sapay N, 2006, BIOCHEMISTRY-US, V45, P2221, DOI 10.1021/bi0517685; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; Sharpe HJ, 2010, CELL, V142, P158, DOI 10.1016/j.cell.2010.05.037; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Strandberg E, 2004, CONCEPT MAGN RESON A, V23A, P89, DOI 10.1002/cmr.a.20024; Tews BA, 2007, J BIOL CHEM, V282, P32730, DOI 10.1074/jbc.M706803200; Thor F, 2009, TRAFFIC, V10, P1819, DOI 10.1111/j.1600-0854.2009.00989.x; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Wan SZ, 2009, J COMPUT CHEM, V30, P1038, DOI 10.1002/jcc.21130; WEILAND E, 1992, J VIROL, V66, P3677, DOI 10.1128/JVI.66.6.3677-3682.1992; Weiland F, 1999, J GEN VIROL, V80, P1157, DOI 10.1099/0022-1317-80-5-1157; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Widjojoatmodjo MN, 2000, J VIROL, V74, P2973, DOI 10.1128/JVI.74.7.2973-2980.2000; Windisch JM, 1996, J VIROL, V70, P352, DOI 10.1128/JVI.70.1.352-358.1996; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332	76	22	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3292	3305		10.1096/fj.12-207191	http://dx.doi.org/10.1096/fj.12-207191			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22549508				2022-12-28	WOS:000307162800020
J	Sherman, H; Genzer, Y; Cohen, R; Chapnik, N; Madar, Z; Froy, O				Sherman, Hadas; Genzer, Yoni; Cohen, Rotem; Chapnik, Nava; Madar, Zecharia; Froy, Oren			Timed high-fat diet resets circadian metabolism and prevents obesity	FASEB JOURNAL			English	Article						restricted feeding; clock; timing	FOOD-INTAKE; GENE-EXPRESSION; PLASMA LEPTIN; CLOCK GENES; ALPHA; SIRT1; AMPK; ADIPOCYTOKINES; TRANSCRIPTION; RHYTHMS	Disruption of circadian rhythms leads to obesity and metabolic disorders. Timed restricted feeding (RF) provides a time cue and resets the circadian clock, leading to better health. In contrast, a high-fat (HF) diet leads to disrupted circadian expression of metabolic factors and obesity. We tested whether long-term (18 wk) clock resetting by RF can attenuate the disruptive effects of diet-induced obesity. Analyses included liver clock gene expression, locomotor activity, blood glucose, metabolic markers, lipids, and hormones around the circadian cycle for a more accurate assessment. Compared with mice fed the HF diet ad libitum, the timed HF diet restored the expression phase of the clock genes Clock and Cry1 and phase-advanced Per1, Per2, Cry2, Bmal1, Ror alpha, and Rev-erb alpha. Although timed HF-diet-fed mice consumed the same amount of calories as ad libitum low-fat diet-fed mice, they showed 12% reduced body weight, 21% reduced cholesterol levels, and 1.4-fold increased insulin sensitivity. Compared with the HF diet ad libitum, the timed HF diet led to 18% lower body weight, 30% decreased cholesterol levels, 10% reduced TNF-alpha levels, and 3.7-fold improved insulin sensitivity. Timed HF-diet-fed mice exhibited a better satiated and less stressed phenotype of 25% lower ghrelin and 53% lower corticosterone levels compared with mice fed the timed low-fat diet. Taken together, our findings suggest that timing can prevent obesity and rectify the harmful effects of a HF diet.-Sherman, H., Genzer, Y., Cohen, R., Chapnik, N., Madar, Z., Froy, O. Timed high-fat diet resets circadian metabolism and prevents obesity. FASEB J. 26, 3493-3502 (2012). www.fasebj.org	[Sherman, Hadas; Genzer, Yoni; Cohen, Rotem; Chapnik, Nava; Madar, Zecharia; Froy, Oren] Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem	Froy, O (corresponding author), Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel.	froy@agri.huji.ac.il						Ando H, 2005, ENDOCRINOLOGY, V146, P5631, DOI 10.1210/en.2005-0771; Arble DM, 2009, OBESITY, V17, P2100, DOI 10.1038/oby.2009.264; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Barnea M, 2009, ENDOCRINOLOGY, V150, P161, DOI 10.1210/en.2008-0944; Barnea M, 2010, OBESITY, V18, P230, DOI 10.1038/oby.2009.276; Canaple L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052; Cano P, 2009, OBESITY, V17, P1866, DOI 10.1038/oby.2009.200; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cassone VM, 2002, NUTRITION, V18, P814, DOI 10.1016/S0899-9007(02)00937-1; Cha MC, 2000, METABOLISM, V49, P503, DOI 10.1016/S0026-0495(00)80016-5; Dallmann R, 2010, CHRONOBIOL INT, V27, P1317, DOI 10.3109/07420528.2010.489166; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Finger BC, 2011, NEUROSCIENCE, V192, P351, DOI 10.1016/j.neuroscience.2011.06.072; Froy O, 2007, MOL IMMUNOL, V44, P1954, DOI 10.1016/j.molimm.2006.09.026; Froy O, 2010, ENDOCR REV, V31, P1, DOI 10.1210/er.2009-0014; Gomez-Abellan P, 2008, INT J OBESITY, V32, P121, DOI 10.1038/sj.ijo.0803689; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Gutman R, 2011, EXP GERONTOL, V46, P606, DOI 10.1016/j.exger.2011.02.015; Havel PJ, 1999, DIABETES, V48, P334, DOI 10.2337/diabetes.48.2.334; Henry BA, 2008, J NEUROENDOCRINOL, V20, P842, DOI 10.1111/j.1365-2826.2008.1730.x; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kohsaka A, 2007, CELL METAB, V6, P414, DOI 10.1016/j.cmet.2007.09.006; Lamia KA, 2009, SCIENCE, V326, P437, DOI 10.1126/science.1172156; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; Ortolani D, 2011, PHYSIOL BEHAV, V103, P487, DOI 10.1016/j.physbeh.2011.03.028; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Salgado-Delgado R, 2010, ENDOCRINOLOGY, V151, P1019, DOI 10.1210/en.2009-0864; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Sherman H, 2008, MOL IMMUNOL, V45, P3163, DOI 10.1016/j.molimm.2008.03.004; Sherman H, 2011, J CELL MOL MED, V15, P2745, DOI 10.1111/j.1582-4934.2010.01160.x; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Um JH, 2007, J BIOL CHEM, V282, P20794, DOI 10.1074/jbc.C700070200; Xue BZ, 2006, J PHYSIOL-LONDON, V574, P73, DOI 10.1113/jphysiol.2006.113217; Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05-0873	40	237	238	6	65	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3493	3502		10.1096/fj.12-208868	http://dx.doi.org/10.1096/fj.12-208868			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593546				2022-12-28	WOS:000307162800036
J	Onuma, TA; Duan, CM				Onuma, Takeshi A.; Duan, Cunming			Duplicated Kiss1 receptor genes in zebrafish: distinct gene expression patterns, different ligand selectivity, and a novel nuclear isoform with transactivating activity	FASEB JOURNAL			English	Article						alternative splicing; nuclear localization	BINDING PROTEIN-5; GNRH NEURONS; HORMONE; GPR54; KISSPEPTIN; GROWTH; ACTIVATION; IDENTIFICATION; HYPOGONADISM; REGULATOR	The kisspeptin (KISS1) and Kiss1 receptor (Kiss1r) pathway plays a central role in the neuroendocrine control of reproduction. In contrast to humans and mammals that have a single Kiss1 gene and a single Kiss1r gene, multiple Kiss ligand and receptor genes are found in nonmammalian vertebrates. Their functional relationship, however, is poorly understood. Here, we report that the duplicated zebrafish kiss1r genes have evolved a distinct gene expression pattern, different ligand selectivity, and novel nuclear isoforms. While a single kiss1ra mRNA was detected exclusively in the brain, 5 kiss1rb transcripts were found in many peripheral tissues. Functional assays showed that kiss1ra encodes a receptor activated by both Kiss1 and Kiss2, while kiss1rb encodes a receptor that has a preference for Kiss1. The four alternatively spliced kiss1rb mRNAs encoded 4 truncated isoforms, denoted kiss1rb-derived protein (KRBDP) 1-4. When their subcellular localization was examined, KRBDP3 and KRBDP4 were found in the nucleus in cultured mammalian cells and in zebrafish embryos. One-hybrid transcription activation assays revealed that KRBDP3, but not KRBDP4, possesses ligand-independent transactivation activity. These findings highlight how the duplication of Kiss1r genes may facilitate their adaptation of specialized functions. The discovery of a nuclear Kiss1r isoform raises the possibility of novel function of Kiss1r in the nucleus.-Onuma, T. A., Duan, C. Duplicated Kiss1 receptor genes in zebrafish: distinct gene expression patterns, different ligand selectivity, and a novel nuclear isoform with transactivating activity. FASEB J. 26, 2941-2950 (2012). www.fasebj.org	[Onuma, Takeshi A.; Duan, Cunming] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Onuma, Takeshi A/L-2702-2017		National Science Foundation [IOB-0543018, IOS-1051034]; Japan Society for the Promotion of Science [2009159]; Direct For Biological Sciences [1051034] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	The authors thank Andrea Lynema and Sarah Gaubatz (University of Michigan) for proofreading this manuscript. The authors thank Dr. Alfonso Saera-Vila for reading and commenting on an early version of this manuscript. The authors are grateful to Drs. Pamela Mellon, (University of California-San Diego, La Jolla, CA, USA) and Jessica Schwartz (University of Michigan) for providing important reagents. This work was supported in part by National Science Foundation grants IOB-0543018 and IOS-1051034 to C. D. T.A.O. was supported in part by an Oversea Research Fellowship (#2009159) from the Japan Society for the Promotion of Science.	Abraham E, 2008, J NEUROENDOCRINOL, V20, P394, DOI 10.1111/j.1365-2826.2008.01654.x; Abraham E, 2010, ENDOCRINOLOGY, V151, P332, DOI 10.1210/en.2009-0548; Akazome Y, 2010, J FISH BIOL, V76, P161, DOI 10.1111/j.1095-8649.2009.02496.x; Apaja PM, 2006, MOL BIOL CELL, V17, P2243, DOI 10.1091/mbc.E05-09-0875; Biran J, 2008, BIOL REPROD, V79, P776, DOI 10.1095/biolreprod.107.066266; Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Castano JP, 2009, PEPTIDES, V30, P10, DOI 10.1016/j.peptides.2008.07.025; d'Anglemont de Tassigny X, 2007, P NATL ACAD SCI USA, V104, P10714, DOI 10.1073/pnas.0704114104; de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100; Felip A, 2009, MOL CELL ENDOCRINOL, V312, P61, DOI 10.1016/j.mce.2008.11.017; Funes S, 2003, BIOCHEM BIOPH RES CO, V312, P1357, DOI 10.1016/j.bbrc.2003.11.066; Hauge-Evans AC, 2006, DIABETOLOGIA, V49, P2131, DOI 10.1007/s00125-006-0343-z; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; Irwig MS, 2004, NEUROENDOCRINOLOGY, V80, P264, DOI 10.1159/000083140; Kajimura S, 2005, P NATL ACAD SCI USA, V102, P1240, DOI 10.1073/pnas.0407443102; Kitahashi T, 2009, ENDOCRINOLOGY, V150, P821, DOI 10.1210/en.2008-0940; Lapatto R, 2007, ENDOCRINOLOGY, V148, P4927, DOI 10.1210/en.2007-0078; Lee YR, 2009, ENDOCRINOLOGY, V150, P2837, DOI 10.1210/en.2008-1679; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Luan X, 2007, NEUROENDOCRINOLOGY, V86, P77, DOI 10.1159/000107511; Markovic D, 2007, ENDOCRINOLOGY, V148, P3205, DOI 10.1210/en.2007-0095; Markovic D, 2009, CELL MOL LIFE SCI, V66, P3337, DOI 10.1007/s00018-009-0093-4; Matsui H, 2004, BIOCHEM BIOPH RES CO, V320, P383, DOI 10.1016/j.bbrc.2004.05.185; Mayer C, 2011, NAT NEUROSCI, V14, P704, DOI 10.1038/nn.2818; McElvaine AT, 2006, ENDOCRINOLOGY, V147, P1884, DOI 10.1210/en.2005-1488; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Messager S, 2005, P NATL ACAD SCI USA, V102, P1761, DOI 10.1073/pnas.0409330102; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Nakamura Y, 2007, REPROD SCI, V14, P836, DOI 10.1177/1933719107307823; Navarro VM, 2004, J PHYSIOL-LONDON, V561, P379, DOI 10.1113/jphysiol.2004.072298; Oakley AE, 2009, ENDOCR REV, V30, P713, DOI 10.1210/er.2009-0005; Pineda R, 2010, ENDOCRINOLOGY, V151, P722, DOI 10.1210/en.2009-0803; Pisarchik A, 2001, FASEB J, V15, P2754, DOI 10.1096/fj.01-0487fje; Popa SM, 2008, ANNU REV PHYSIOL, V70, P213, DOI 10.1146/annurev.physiol.70.113006.100540; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322; Servili A, 2011, ENDOCRINOLOGY, V152, P1527, DOI 10.1210/en.2010-0948; Silveira LG, 2010, J CLIN ENDOCR METAB, V95, P2276, DOI 10.1210/jc.2009-2421; Sower SA, 2009, GEN COMP ENDOCR, V161, P20, DOI 10.1016/j.ygcen.2008.11.023; Teles MG, 2008, NEW ENGL J MED, V358, P709, DOI 10.1056/NEJMoa073443; Tsutsui K, 2010, J NEUROENDOCRINOL, V22, P716, DOI 10.1111/j.1365-2826.2010.02018.x; van Aerle R, 2008, PEPTIDES, V29, P57, DOI 10.1016/j.peptides.2007.10.018; Wahab F, 2010, HORM METAB RES, V42, P570, DOI 10.1055/s-0030-1252016; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Yi TF, 2010, J BIOL CHEM, V285, P17811, DOI 10.1074/jbc.M110.130740; Zhao Y, 2006, J BIOL CHEM, V281, P14184, DOI 10.1074/jbc.M506941200; Zmijewski MA, 2009, J CELL PHYSIOL, V218, P593, DOI 10.1002/jcp.21632; Zohar Y, 2010, GEN COMP ENDOCR, V165, P438, DOI 10.1016/j.ygcen.2009.04.017	48	21	22	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2941	2950		10.1096/fj.11-201095	http://dx.doi.org/10.1096/fj.11-201095			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22499582	Green Submitted			2022-12-28	WOS:000305912500022
J	Wang, Y; Toh, HC; Chow, P; Chung, AYF; Meyers, DJ; Cole, PA; Ooi, LLPJ; Lee, CGL				Wang, Yu; Toh, Han Chong; Chow, Pierce; Chung, Alexander Y. F.; Meyers, David J.; Cole, Philip A.; Ooi, London L. P. J.; Lee, Caroline G. L.			MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms	FASEB JOURNAL			English	Article						miR-224; histone acetylation; HDAC; EP300	NON-TUMOROUS TISSUES; MICROARRAY ANALYSIS; SUPPRESSOR GENE; HEPATITIS-B; EXPRESSION; CANCER; OVEREXPRESSION; APOPTOSIS; ACETYLATION; CONTRIBUTES	MicroRNA-224 (miR-224) is one of the most commonly up-regulated microRNAs in hepatocellular carcinoma (HCC), which affects crucial cellular processes such as apoptosis and cell proliferation. In this study, we aim to elucidate the molecular mechanism that leads to the overexpression of miR-224 in HCC. We examined the transcript expression of miR-224 and neighboring miR-452 and genes on chromosome Xq28 in tumor and paired adjacent nontumorous tissues from 100 patients with HCC and found that miR-224 is coordinately up-regulated with its neighboring microRNA (miRNA) and genes. This coordinated up-regulation of miRNAs and genes at the Xq28 locus can be mimicked in nontransformed immortalized human liver cells by the introduction of histone deacetylase (HDAC) inhibitors, which resulted in a corresponding increase in histone H3 acetylation in this region. This miR-224-residing locus in Xq28 is reciprocally regulated by HDAC1, HDAC3, and histone acetylase protein, E1A binding protein p300 (EP300). Notably, in HCC tumors that significantly overexpress microRNA-224, EP300 is also overexpressed and displays increased binding to the Xq28 locus. In transformed HCC cells, high miR-224 expression can be attenuated through the inhibition of EP300, using either siRNA or the specific drug C646. In summary, overexpression of EP300 may account, in part, for the up-regulation of miR-224 expression in patients with HCC.-Wang, Y., Toh, H. C., Chow, P., Chung, A. Y. F., Meyers, D. J., Cole, P. A., Ooi, L. L. P. J., Lee, C. G. L. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 26, 3032-3041 (2012). www.fasebj.org	[Wang, Yu; Lee, Caroline G. L.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore; [Wang, Yu; Toh, Han Chong; Lee, Caroline G. L.] Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Med Sci, Singapore, Singapore; [Chow, Pierce; Lee, Caroline G. L.] Duke Natl Univ Singapore, Grad Med Sch Singapore, Singapore, Singapore; [Meyers, David J.; Cole, Philip A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA; [Chow, Pierce; Chung, Alexander Y. F.; Ooi, London L. P. J.] Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; [Ooi, London L. P. J.] Natl Canc Ctr Singapore, Dept Surg Oncol, Singapore, Singapore	National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Singapore General Hospital; National Cancer Centre Singapore (NCCS)	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Lee, Caroline G/M-8918-2019	Lee, Caroline G/0000-0002-4323-3635; Chow, Pierce/0000-0003-0584-2584	National Medical Research Council of Singapore [NMRC/1131/2007]; Biomedical Research Council [BMRC06/1/21/19/449]; Singapore Millennium Foundation; National Cancer Center Singapore; Duke-National University of Singapore Graduate Medical School; U.S. National Institutes of Health	National Medical Research Council of Singapore(National Medical Research Council, Singapore); Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); Singapore Millennium Foundation(Singapore Millennium Foundation); National Cancer Center Singapore; Duke-National University of Singapore Graduate Medical School(National University of Singapore); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work is supported by grants from the National Medical Research Council of Singapore (NMRC/1131/2007), the Biomedical Research Council (BMRC06/1/21/19/449), and the Singapore Millennium Foundation, as well as block funding from National Cancer Center Singapore and Duke-National University of Singapore Graduate Medical School to C. L. This work is also supported by grants from the U.S. National Institutes of Health to P.C. and D.M.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Boyle P, 2008, WORLD CANC REPORT 20; Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Fu XY, 2002, WORLD J GASTROENTERO, V8, P638, DOI 10.3748/wjg.v8.i4.638; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gui J., 2010, CLIN SCI, V120, P183; Huang XH, 2009, HEPATOL RES, V39, P786, DOI 10.1111/j.1872-034X.2009.00502.x; Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Johnsson A, 2009, EMBO REP, V10, P1009, DOI 10.1038/embor.2009.127; Kratz A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-257; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Li M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-5; Li Q, 2010, J GASTROEN HEPATOL, V25, P164, DOI 10.1111/j.1440-1746.2009.05971.x; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Wang Y, 2011, EPIGENOMICS-UK, V3, P235, DOI [10.2217/epi.11.5, 10.2217/EPI.11.5]; Wang Y, 2010, J HEPATOL, V53, P57, DOI 10.1016/j.jhep.2009.12.043; Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840; Yao GD, 2010, MOL ENDOCRINOL, V24, P540, DOI 10.1210/me.2009-0432	32	85	93	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					3032	3041		10.1096/fj.11-201855	http://dx.doi.org/10.1096/fj.11-201855			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459148	Green Published			2022-12-28	WOS:000305912500030
J	Wall, EH; Hewitt, SC; Liu, LW; del Rio, R; Case, LK; Lin, CY; Korach, KS; Teuscher, C				Wall, Emma H.; Hewitt, Sylvia C.; Liu, Liwen; del Rio, Roxana; Case, Laure K.; Lin, Chin-Yo; Korach, Kenneth S.; Teuscher, Cory			Genetic control of estrogen-regulated transcriptional and cellular responses in mouse uterus	FASEB JOURNAL			English	Article						microarray; uterotropic response; phenotypic variation; inheritance; microarray	QUANTITATIVE TRAIT LOCI; RECEPTOR-ALPHA; BONE LOSS; MICE; MECHANISMS; EXPRESSION; MODEL; OSTEOPOROSIS; OVARIECTOMY; DISCOVERY	The uterotropic response of the uterus to 17 beta-estradiol (E-2) is genetically controlled, with marked variation observed depending on the mouse strain studied. Previous genetic studies from our laboratory using inbred mice that are high [C57BL/6J (B6)] or low [C3H/HeJ (C3H)] responders to E-2 led to the identification of quantitative trait (QT) loci associated with phenotypic variation in uterine growth and leukocyte infiltration. The mechanisms underlying differential responsiveness to E-2, and the genes involved, are unknown. Therefore, we used a microarray approach to show association of distinct E-2-regulated transcriptional signatures with genetically controlled high and low responses to E-2 and their segregation in (C57BL/6J x C3H/HeJ) F-1 hybrids. Among the 6664 E-2-regulated transcripts, analysis of cellular functions of those that were strain specific indicated C3H-selective enrichment of apoptosis, consistent with a 7-fold increase in the apoptosis indicator CASP3, and a 2.4-fold decrease in the apoptosis inhibitor Naip1 (Birc1a) in C3H vs. B6 following treatment with E-2. In addition, several differentially expressed transcripts reside within our previously identified QT loci, including the ER alpha-tethering factor Runx1, demonstrated to enhance E-2-mediated transcript regulation. The level of RUNX1 in uterine epithelial cells was shown to be 3.5-fold greater in B6 compared to C3H. Our novel insights into the mechanisms underlying the genetic control of tissue sensitivity to estrogen have great potential to advance understanding of individualized effects in physiological and disease states.-Wall, E. H., Hewitt, S. C., Liu, L., del Rio, R., Case, L. K., Lin, C.-Y., Korach, K. S., Teuscher, C. Genetic control of estrogen-regulated transcriptional and cellular responses in mouse uterus. FASEB J. 27, 1874-1886 (2013). www.fasebj.org	[Wall, Emma H.; del Rio, Roxana; Case, Laure K.; Teuscher, Cory] Univ Vermont, Dept Med, Burlington, VT 05405 USA; [Hewitt, Sylvia C.; Korach, Kenneth S.] NIEHS, Receptor Biol Grp, NIH, Res Triangle Pk, NC 27709 USA; [Liu, Liwen] NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA; [Lin, Chin-Yo; Teuscher, Cory] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	University of Vermont; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Houston System; University of Houston	Teuscher, C (corresponding author), Univ Vermont, Immunobiol Program, C331 Given Med Bldg, Burlington, VT 05405 USA.	c.teuscher@uvm.edu	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Korach, Kenneth/0000-0002-7765-418X; del Rio-Guerra, Roxana/0000-0001-6871-3259; Lin, Chin-Yo/0000-0002-4461-6216	National Center for Research Resources [1S10RR019246]; U.S. National Institutes of Health (NIH) Intramural Research Project [Z01ES70065]; NIH [R01NS36526, R01NS061014, R01NS060901, R01NS069628, R01AI41747]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019246, P20RR021905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZICES102445, ZIAES070065, Z01ES070065, ZICES102546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060901, R01NS061014, R01NS069628, R01NS036526] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); U.S. National Institutes of Health (NIH) Intramural Research Project; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Stephen Grubb (Jackson Laboratory, Bar Harbor, ME, USA) for assistance with the SNP analysis, the U.S. National Institute of Environmental Health Sciences (NIEHS) Microarray Core for microarray analysis of uterine RNA samples, the NIEHS Histology Laboratory for embedding uterine samples, and the NIEHS Comparative Medicine Branch for surgeries. The staff at the Microscopy Imaging Center at the University of Vermont, funded, in part, by the National Center for Research Resources (1S10RR019246), performed staining and imaging of Runx1 and CC3. S.C.H. and K.S.K. were supported by U.S. National Institutes of Health (NIH) Intramural Research Project Z01ES70065. C.T. was supported by NIH Research Projects R01NS36526, R01NS061014, R01NS060901, R01NS069628, and R01AI41747. The authors declare no conflicts of interest.	Abiola O, 2003, NAT REV GENET, V4, P911, DOI 10.1038/nrg1206; Altmae S, 2011, HUM REPROD UPDATE, V17, P813, DOI 10.1093/humupd/dmr034; Andrew Toby, 2004, Curr Osteoporos Rep, V2, P79, DOI 10.1007/s11914-004-0015-1; Beck-Peccoz P, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-9; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BLAIR SM, 1957, ENDOCRINOLOGY, V61, P643, DOI 10.1210/endo-61-6-643; Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307; CLARINGBOLD PJ, 1955, J ENDOCRINOL, V12, P9, DOI 10.1677/joe.0.0120009; CLARK JH, 1994, PHYSL REPROD, V1, P1011; Doll A, 2009, INT J CANCER, V125, P257, DOI 10.1002/ijc.24330; Drasher ML, 1952, J HERED, V46, P190; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Figtree Gemma A, 2009, Recent Pat DNA Gene Seq, V3, P164; Griffith JS, 1997, AM J PATHOL, V150, P2223; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143; Hewitt SC, 2011, ENVIRON HEALTH PERSP, V119, P63, DOI 10.1289/ehp.1002347; Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356; HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; Krausz C, 2007, ARCH ANDROLOGY, V53, P125, DOI 10.1080/01485010701271786; Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819; Loutradis D, 2012, CURR PHARM BIOTECHNO, V13, P417, DOI 10.2174/138920112799361954; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Mather K, 1943, BIOL REV CAMB PHILOS, V18, P32, DOI 10.1111/j.1469-185X.1943.tb00287.x; Meyer MR, 2009, MOL CELL ENDOCRINOL, V308, P9, DOI 10.1016/j.mce.2009.03.009; NAGAI JIRO, 1957, ENDOCRINOL JAPON, V4, P12; Nakai M, 1999, J ANDROL, V20, P626; Nilsen-Hamilton M, 2003, ANN NY ACAD SCI, V995, P94, DOI 10.1111/j.1749-6632.2003.tb03213.x; Padilla-Banks E, 2001, ENVIRON HEALTH PERSP, V109, P821, DOI 10.2307/3454825; Perez MC, 1996, BIOL REPROD, V54, P249, DOI 10.1095/biolreprod54.1.249; Planaguma J, 2005, J PATHOL, V207, P422, DOI 10.1002/path.1853; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Reel JR, 1996, FUND APPL TOXICOL, V34, P288, DOI 10.1006/faat.1996.0198; Richard C, 2003, ENDOCRINOLOGY, V144, P1533, DOI 10.1210/en.2002-0033; Richards JB, 2012, NAT REV GENET, V13, P576, DOI 10.1038/nrg3228; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; Roper RJ, 1999, ENDOCRINOLOGY, V140, P556, DOI 10.1210/en.140.2.556; SILBERBERG M, 1951, P SOC EXP BIOL MED, V76, P161, DOI 10.3181/00379727-76-18423; Simpson E R, 2006, Ernst Schering Found Symp Proc, P45; Spearow JL, 1999, SCIENCE, V285, P1259, DOI 10.1126/science.285.5431.1259; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; TRENTIN JJ, 1950, CANCER RES, V10, P580; Winuthayanon W, 2010, P NATL ACAD SCI USA, V107, P19272, DOI 10.1073/pnas.1013226107; Yin Y, 2008, MOL ENDOCRINOL, V22, P113, DOI 10.1210/me.2007-0295	47	14	14	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2013	27	5					1874	1886		10.1096/fj.12-213462	http://dx.doi.org/10.1096/fj.12-213462			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23371066	Green Published			2022-12-28	WOS:000318226100008
J	Fois, G; Weimer, M; Busch, T; Felder, ET; Oswald, F; von Wichert, G; Seufferlein, T; Dietl, P; Felder, E				Fois, Giorgio; Weimer, Michael; Busch, Tobias; Felder, Erika T.; Oswald, Franz; von Wichert, Goetz; Seufferlein, Thomas; Dietl, Paul; Felder, Edward			Effects of keratin phosphorylation on the mechanical properties of keratin filaments in living cells	FASEB JOURNAL			English	Article						mechanical stress; tension; cytoskeleton; cytoarchitecture	INTERMEDIATE-FILAMENTS; MARKER PROTEIN; NETWORK; STRAIN; ACTIN; CYCLE	Keratin filaments impart resilience against mechanical extension of the cell. Despite the pathophysiological relevance of this function, very little is known about the mechanical properties of intermediate filaments in living cells and how these properties are modulated. We used keratin mutants that mimic or abrogate phosphorylation of keratin 8-serine(431) and keratin 18-serine(52) and investigated their effect on keratin tortuousness after cell stretch release in squamous cell carcinoma cells. Cells transfected with the wild-type keratins were used as controls. We can show that keratin dephosphorylation alters the stretch response of keratin in living cells since keratin tortuousness was abolished when phosphorylation of keratin18-serine(52) was abrogated. Additional experiments demonstrate that keratin tortuousness is not simply caused by a plastic overextension of keratin filaments because tortuousness is reversible and requires an intact actin-myosin system. The role of actin in this process remains unclear, but we suggest anchorage of keratin filaments to actin during stretch that leads to buckling on stretch release. Dephosphorylated keratin18-serine(52) might strengthen the recoil force of keratin filaments and hence explain the abolished buckling. The almost exclusive immunolabeling for phosphorylated keratin18-serine(52) in the cell periphery points at a particular role of the peripheral keratin network in this regard.-Fois, G., Weimer, M., Busch, T., Felder, E. T., Oswald, F., von Wichert, G., Seufferlein, T., Dietl, P., Felder, E. Effects of keratin phosphorylation on the mechanical properties of keratin filaments in living cells. FASEB J. 27, 1322-1329 (2013). www.fasebj.org	[Fois, Giorgio; Weimer, Michael; Felder, Erika T.; Dietl, Paul; Felder, Edward] Univ Ulm, Inst Gen Physiol, D-89081 Ulm, Germany; [Busch, Tobias; Oswald, Franz; von Wichert, Goetz; Seufferlein, Thomas] Univ Med Ctr Ulm, Ctr Internal Med, Dept Internal Med 1, Ulm, Germany	Ulm University; Ulm University	Felder, E (corresponding author), Univ Ulm, Inst Gen Physiol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	edward.felder@uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Oswald, Franz/AAO-9584-2020; Fois, Giorgio/AAD-5657-2022	Fois, Giorgio/0000-0001-5414-1149	Deutsche Forschungsgemeinschaft [DI 1402/1-1, DI1402/3-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Technical assistance by the entire team of the EM-core facility of the University of Ulm and in particular Eberhard Schmid is gratefully acknowledged. The authors also thank Michael Beil for his fruitful comments and helpful discussion. This work was supported by the Deutsche Forschungsgemeinschaft, grants DI 1402/1-1 and DI1402/3-1 (to P.D.).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Busch T, 2012, J CELL SCI, V125, P2148, DOI 10.1242/jcs.080127; CRICK FHC, 1952, NATURE, V170, P882, DOI 10.1038/170882b0; Felder E, 2008, AM J PHYSIOL-LUNG C, V295, pL849, DOI 10.1152/ajplung.00503.2007; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Fuchs J, 2010, NAT METHODS, V7, P627, DOI [10.1038/NMETH.1477, 10.1038/nmeth.1477]; Fudge D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002327; Fudge DS, 2003, BIOPHYS J, V85, P2015, DOI 10.1016/S0006-3495(03)74629-3; Gerstmair A, 2009, J APPL PHYSIOL, V107, P613, DOI 10.1152/japplphysiol.00012.2009; Green KJ, 2005, ADV PROTEIN CHEM, V70, P143, DOI 10.1016/S0065-3233(04)70006-6; Guzman C, 2006, J MOL BIOL, V360, P623, DOI 10.1016/j.jmb.2006.05.030; Harada H, 1998, J ORAL PATHOL MED, V27, P11; Kim S, 2007, GENE DEV, V21, P1581, DOI 10.1101/gad.1552107; Kolsch A, 2010, J CELL SCI, V123, P2266, DOI 10.1242/jcs.068080; Kredel S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004391; Kreplak L, 2005, J MOL BIOL, V354, P569, DOI 10.1016/j.jmb.2005.09.092; Kreplak L, 2007, BIOESSAYS, V29, P26, DOI 10.1002/bies.20514; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Magin TM, 2007, EXP CELL RES, V313, P2021, DOI 10.1016/j.yexcr.2007.03.005; Miklavc P, 2012, J CELL SCI, V125, P2765, DOI 10.1242/jcs.105262; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Omary M B, 1998, Subcell Biochem, V31, P105; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Qin Z, 2010, J BIOMECH, V43, P15, DOI 10.1016/j.jbiomech.2009.09.004; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Russell D, 2004, J CELL SCI, V117, P5233, DOI 10.1242/jcs.01407; SAUK JJ, 1984, J CELL BIOL, V99, P1590, DOI 10.1083/jcb.99.5.1590; Sen-Chowdhry S, 2005, J CARDIOVASC ELECTR, V16, P927, DOI 10.1111/j.1540-8167.2005.40842.x; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; Strnad P, 2002, J CELL SCI, V115, P4133, DOI 10.1242/jcs.00096; Strnad P, 2001, CELL TISSUE RES, V306, P277, DOI 10.1007/s004410100455; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101; Woll S, 2005, EUR J CELL BIOL, V84, P311, DOI 10.1016/j.ejcb.2004.12.004	36	22	24	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1322	1329		10.1096/fj.12-215632	http://dx.doi.org/10.1096/fj.12-215632			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23241311				2022-12-28	WOS:000316940800005
J	Bechara, C; Pallerla, M; Zaltsman, Y; Burlina, F; Alves, ID; Lequin, O; Sagan, S				Bechara, Cherine; Pallerla, Manjula; Zaltsman, Yefim; Burlina, Fabienne; Alves, Isabel D.; Lequin, Olivier; Sagan, Sandrine			Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis	FASEB JOURNAL			English	Article						aggregation; beta strand; beta sheet; alpha helix; membrane translocation	CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAIN; HEPARAN-SULFATE; ANTENNAPEDIA HOMEODOMAIN; SECONDARY STRUCTURE; MEMBRANE INTERACTION; 3RD HELIX; BINDING; INTERNALIZATION; QUANTIFICATION	Deciphering the structural requirements and mechanisms for internalization of cell-penetrating peptides (CPPs) is required to improve their delivery efficiency. Herein, a unique role of tryptophan (Trp) residues in the interaction and structuring of cationic CPP sequences with glycosaminoglycans (GAGs) has been characterized, in relation with cell internalization. Using isothermal titration calorimetry, circular dichroism, NMR, mass spectrometry, and phase-contrast microscopy, we compared the interaction of 7 basic CPPs with 5 classes of GAGs. We found that the affinity of CPPs for GAGs increases linearly with the number of Trp residues, from 30 nM for a penetratin analog with 1 Trp residue to 1.5 nM for a penetratin analog with 6 Trp residues for heparin (HI); peptides with Trp residues adopt a predominantly beta-strand structure in complex with HI and form large, stable beta-sheet aggregates with GAGs; and in the absence of any cytotoxicity effect, the quantity of peptide internalized into CHO cells increased 2 times with 1 Trp residue, 10 times with 2 Trp residues, and 20 times with 3 Trp residues, compared with +6 peptides with no Trp residues. Therefore, Trp residues represent molecular determinants in basic peptide sequences not only for direct membrane translocation but also for efficient endocytosis through GAGs.-Bechara, C., Pallerla, M., Zaltsman, Y., Burlina, F., Alves, I. D., Lequin, O., Sagan S. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. FASEB J. 27, 738-749 (2013). www.fasebj.org	[Bechara, Cherine; Pallerla, Manjula; Zaltsman, Yefim; Burlina, Fabienne; Lequin, Olivier; Sagan, Sandrine] Univ Paris 06, UMR 7203, F-75252 Paris 05, France; [Bechara, Cherine; Pallerla, Manjula; Zaltsman, Yefim; Burlina, Fabienne; Lequin, Olivier; Sagan, Sandrine] CNRS, UMR 7203, Paris, France; [Bechara, Cherine; Pallerla, Manjula; Zaltsman, Yefim; Burlina, Fabienne; Lequin, Olivier; Sagan, Sandrine] ENS, LBM, UMR 7203, F-75230 Paris 05, France; [Alves, Isabel D.] CNRS, UMR 5248, Pessac, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux	Sagan, S (corresponding author), Univ Paris 06, Lab Biomol, ENS, CNRS,UMR 7203, Case Courrier 182,4 Pl Jussieu, F-75252 Paris 05, France.	sandrine.sagan@upmc.fr	Alves, Isabel D/R-9613-2016; QI, DANDAN/GVR-9324-2022; SAGAN, Sandrine/AAA-8537-2022; s, s/GYR-2278-2022; Bechara, Cherine/R-1341-2018; S, SAGAN/I-8132-2013; s, s/HIK-1178-2022; s, s/HHD-0404-2022	Alves, Isabel D/0000-0003-3193-2436; Bechara, Cherine/0000-0002-5539-6327; S, SAGAN/0000-0003-0083-4411; LEQUIN, Olivier/0000-0001-5307-3068; Burlina, Fabienne/0000-0002-6042-680X; Zaltsman, Yefim/0000-0002-2979-8197	Universite Pierre et Marie Curie (UPMC; Universite Paris 6) [ANR-BLAN2010-ParaHP]; Centre National de la Recherche Scientifique (CNRS); French Ministere de l'Enseignement Superieur et de la Recherche; U.S. National Science Foundation [CHE-0755225]; University of Florida	Universite Pierre et Marie Curie (UPMC; Universite Paris 6); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); French Ministere de l'Enseignement Superieur et de la Recherche; U.S. National Science Foundation(National Science Foundation (NSF)); University of Florida(University of Florida)	Support for this research was provided the Universite Pierre et Marie Curie (UPMC; Universite Paris 6), by ANR-BLAN2010-ParaHP (postdoctoral position for M. P.), the Centre National de la Recherche Scientifique (CNRS), and the French Ministere de l'Enseignement Superieur et de la Recherche (Ph.D. fellowship for C. B.). Y.Z. was supported by the U.S. National Science Foundation (grant CHE-0755225, for a fellowship sponsored by the University of Florida).	Alves ID, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024096; Alves ID, 2010, BBA-BIOMEMBRANES, V1798, P2231, DOI 10.1016/j.bbamem.2010.02.009; Aubry S, 2009, FASEB J, V23, P2956, DOI 10.1096/fj.08-127563; Aussedat B, 2006, BBA-BIOMEMBRANES, V1758, P375, DOI 10.1016/j.bbamem.2006.01.012; Balayssac S, 2006, BIOCHEMISTRY-US, V45, P1408, DOI 10.1021/bi0518390; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Binder H, 2003, BIOPHYS J, V85, P982, DOI 10.1016/S0006-3495(03)74537-8; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Burlina F, 2005, ANGEW CHEM INT EDIT, V44, P4244, DOI 10.1002/anie.200500477; Burlina F, 2006, NAT PROTOC, V1, P200, DOI 10.1038/nprot.2006.30; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; Christiaens B, 2004, EUR J BIOCHEM, V271, P1187, DOI 10.1111/j.1432-1033.2004.04022.x; Christiaens B, 2002, EUR J BIOCHEM, V269, P2918, DOI 10.1046/j.1432-1033.2002.02963.x; Delaroche D, 2007, ANAL CHEM, V79, P1932, DOI 10.1021/ac061108l; Delaroche D, 2010, J BIOL CHEM, V285, P7712, DOI 10.1074/jbc.M109.045872; Demeshko S, 2004, J AM CHEM SOC, V126, P4508, DOI 10.1021/ja049458h; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005; Epand RM, 2010, BBA-BIOMEMBRANES, V1798, P1272, DOI 10.1016/j.bbamem.2010.03.012; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784; Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jayaraman G, 2000, FEBS LETT, V482, P154, DOI 10.1016/S0014-5793(00)01964-5; Jean-Francois F, 2007, EUR BIOPHYS J BIOPHY, V36, P1019, DOI 10.1007/s00249-007-0169-8; Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309; JOLIOT AH, 1991, NEW BIOL, V3, P1121; Jones LS, 2004, MOL CELL PROTEOMICS, V3, P746, DOI 10.1074/mcp.R400008-MCP200; Lamaziere A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000201; Lamaziere Antonin, 2009, Commun Integr Biol, V2, P223; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022; Lindberg M, 2003, EUR J BIOCHEM, V270, P3055, DOI 10.1046/j.1432-1033.2003.03685.x; Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Maeda H, 2004, J INCL PHENOM MACRO, V49, P33, DOI 10.1023/B:JIPH.0000031110.42096.d3; Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5; Magzoub M, 2003, BIOPHYS CHEM, V103, P271, DOI 10.1016/S0301-4622(02)00321-6; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; Merabet S, 2009, BIOESSAYS, V31, P500, DOI 10.1002/bies.200800229; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Mulloy B, 1996, BRAZ J MED BIOL RES, V29, P721; Noguchi H, 2003, DIABETES, V52, P1732, DOI 10.2337/diabetes.52.7.1732; Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254; Pasupuleti M, 2009, BBA-GEN SUBJECTS, V1790, P800, DOI 10.1016/j.bbagen.2009.03.029; Persson D, 2001, FEBS LETT, V505, P307, DOI 10.1016/S0014-5793(01)02843-5; Poon GMK, 2007, BIOCHEM SOC T, V35, P788, DOI 10.1042/BST0350788; Ram N, 2008, J BIOL CHEM, V283, P24274, DOI 10.1074/jbc.M709971200; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Rullo A, 2011, BIOPOLYMERS, V95, P722, DOI 10.1002/bip.21641; Rydberg HA, 2012, BIOCHEMISTRY-US, V51, P5531, DOI 10.1021/bi300454k; Sarrazin S, 2010, MOL THER, V18, P1268, DOI 10.1038/mt.2010.78; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Ueda M, 2008, CELL TRANSPLANT, V17, P91, DOI 10.3727/000000008783906892; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Vercauteren D, 2010, MOL THER, V18, P561, DOI 10.1038/mt.2009.281; Verdurmen WPR, 2010, J CONTROL RELEASE, V147, P171, DOI 10.1016/j.jconrel.2010.06.030; Walrant A, 2011, BBA-BIOMEMBRANES, V1808, P382, DOI 10.1016/j.bbamem.2010.09.009; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wittrup A, 2009, J BIOL CHEM, V284, P32959, DOI 10.1074/jbc.M109.036129; Yang H, 2010, J BIOL CHEM, V285, P25666, DOI 10.1074/jbc.M109.089417; Ye J, 2010, J AM CHEM SOC, V132, P980, DOI 10.1021/ja9043196; Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6; Ziegler A, 2008, BIOPHYS J, V94, P2142, DOI 10.1529/biophysj.107.113472; Ziegler A, 2011, BIOCHEMISTRY-US, V50, P4650, DOI 10.1021/bi1019429; Zimmermann P, 1999, FASEB J, V13, pS91	71	88	89	1	62	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					738	749		10.1096/fj.12-216176	http://dx.doi.org/10.1096/fj.12-216176			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23070606				2022-12-28	WOS:000314358000032
J	Modis, K; Coletta, C; Erdelyi, K; Papapetropoulos, A; Szabo, C				Modis, Katalin; Coletta, Ciro; Erdelyi, Katalin; Papapetropoulos, Andreas; Szabo, Csaba			Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics	FASEB JOURNAL			English	Article						gasotransmitter; ATP; hepatocyte	CYSTATHIONINE-BETA-SYNTHASE; H2S; OXIDATION; LIVER; CELLS; ENDOTHELIUM; ADAPTATIONS; INHIBITION; METABOLISM; CYSTEINE	It is well established that exposure of mammalian cells to hydrogen sulfide (H2S) suppresses mitochondrial function by inhibiting cytochrome-c oxidase (CcOX; complex IV). However, recent experimental data show that administration of H2S to mammalian cells can serve as an electron donor and inorganic source of energy. The aim of our study was to investigate the role of endogenously produced H2S in the regulation of mitochondrial electron transport and oxidative phosphorylation in isolated liver mitochondria and in the cultured murine hepatoma cell line Hepa1c1c7. Low concentrations of H2S (0.1-1 mu M) elicited a significant increase in mitochondrial function, while higher concentrations of H2S (3-30 mu M) were inhibitory. The positive bioenergetic effect of H2S required a basal activity of the Krebs cycle and was most pronounced at intermediate concentrations of succinate. 3-mercaptopyruvate (3-MP), the substrate of the mitochondrial enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) stimulated mitochondrial H2S production and enhanced mitochondrial electron transport and cellular bioenergetics at low concentrations (10-100 nM), while at higher concentrations, it inhibited cellular bioenergetics. SiRNA silencing of 3-MST reduced basal bioenergetic parameters and prevented the stimulating effect of 3-MP on mitochondrial bioenergetics. Silencing of sulfide quinone oxidoreductase (SQR) also reduced basal and 3-MP-stimulated bioenergetic parameters. We conclude that an endogenous intramitochondrial H2S-producing pathway, governed by 3-MST, complements and balances the bioenergetic role of Krebs cycle-derived electron donors. This pathway may serve a physiological role in the maintenance of mitochondrial electron transport and cellular bioenergetics.-Modis, K., Coletta, C., Erdelyi, K., Papapetropoulos, A., Szabo, C. Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. FASEB J. 27, 601-611 (2013). www.fasebj.org	[Modis, Katalin; Coletta, Ciro; Erdelyi, Katalin; Papapetropoulos, Andreas; Szabo, Csaba] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Szabo, Csaba] Shriners Burns Hosp Children, Galveston, TX USA	University of Texas System; University of Texas Medical Branch Galveston	Szabo, C (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 601 Harborside Dr, Galveston, TX 77555 USA.	szabocsaba@aol.com	Andreas, Papapetropoulos/AAJ-3089-2020; Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013	Papapetropoulos, Andreas/0000-0002-4253-5930	Shriners of North America [8661]; American Diabetes Association [7-12-BS-184]; University of Texas; American Heart Association	Shriners of North America; American Diabetes Association(American Diabetes Association); University of Texas; American Heart Association(American Heart Association)	This study was supported by a grant from the Shriners of North America (grant 8661) and by a grant from the American Diabetes Association (7-12-BS-184) to C. S. M. K. is supported by a McLaughlin Fellowship of the University of Texas. C. C. is supported by a postdoctoral fellowship of the American Heart Association.	Aslami H, 2009, CURR MED CHEM, V16, P1295, DOI 10.2174/092986709787846631; Banerjee R, 2005, ARCH BIOCHEM BIOPHYS, V433, P144, DOI 10.1016/j.abb.2004.08.037; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; Bouillaud F, 2011, ANTIOXID REDOX SIGN, V15, P379, DOI 10.1089/ars.2010.3678; Chen XL, 2004, J BIOL CHEM, V279, P52082, DOI 10.1074/jbc.C400481200; Coletta C, 2012, P NATL ACAD SCI USA, V109, P9161, DOI 10.1073/pnas.1202916109; Collman J, 2009, P NATL ACAD SCI USA, V106, P22090, DOI 10.1073/pnas.0904082106; Dranka BP, 2010, FREE RADICAL BIO MED, V48, P905, DOI 10.1016/j.freeradbiomed.2010.01.015; Erdelyi K, 2009, FASEB J, V23, P3553, DOI 10.1096/fj.09-133264; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Fu M, 2012, P NATL ACAD SCI USA, V109, P2943, DOI 10.1073/pnas.1115634109; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Grieshaber MK, 1998, ANNU REV PHYSIOL, V60, P33, DOI 10.1146/annurev.physiol.60.1.33; Groeger M, 2012, SHOCK, V38, P367, DOI 10.1097/SHK.0b013e3182651fe6; Kannampuzha JVA, 2009, J RHEUMATOL, V36, P2758, DOI 10.3899/jrheum.090098; KHAN AA, 1990, TOXICOL APPL PHARM, V103, P482, DOI 10.1016/0041-008X(90)90321-K; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Lagoutte E, 2010, BBA-BIOENERGETICS, V1797, P1500, DOI 10.1016/j.bbabio.2010.04.004; Madden JA, 2012, J APPL PHYSIOL, V112, P411, DOI 10.1152/japplphysiol.01049.2011; MARTENSSON J, 1984, FEBS LETT, V176, P334, DOI 10.1016/0014-5793(84)81191-6; Mimoun S, 2012, ANTIOXID REDOX SIGN, V17, P1, DOI 10.1089/ars.2011.4186; Modis K, 2012, BIOCHEM PHARMACOL, V83, P633, DOI 10.1016/j.bcp.2011.12.014; Modis K, 2009, BRIT J PHARMACOL, V158, P1565, DOI 10.1111/j.1476-5381.2009.00432.x; Nagahara N, 1998, HISTOCHEM CELL BIOL, V110, P243, DOI 10.1007/s004180050286; Nelson D.L., 2004, PRINCIPLES BIOCH, V4; NICHOLLS P, 1975, BIOCHEM SOC T, V3, P316, DOI 10.1042/bst0030316; OHTA J, 1989, ACTA MED OKAYAMA, V43, P89; Olson KR, 2012, J COMP PHYSIOL B, V182, P881, DOI 10.1007/s00360-012-0654-y; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Shibuya N, 2009, J BIOCHEM, V146, P623, DOI 10.1093/jb/mvp111; Shibuya N, 2009, ANTIOXID REDOX SIGN, V11, P703, DOI [10.1089/ars.2008.2253, 10.1089/ARS.2008.2253]; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Stachowska E, 2000, FLUORIDE, V33, P115; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Suzuki K, 2011, P NATL ACAD SCI USA, V108, P13829, DOI 10.1073/pnas.1105121108; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Tanizawa K, 2011, J BIOCHEM, V149, P357, DOI 10.1093/jb/mvr018; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Voet D., 2008, INT STUDENT VERSION; Volkel S, 1996, EUR J BIOCHEM, V235, P231, DOI 10.1111/j.1432-1033.1996.00231.x; Wagner F, 2009, CRIT CARE, V13, DOI 10.1186/cc7700; Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011; Wlodek P, 2010, NEPHROLOGY, V15, P755, DOI 10.1111/j.1440-1797.2010.01353.x; Yong R, 2001, COMP BIOCHEM PHYS B, V129, P129, DOI 10.1016/S1096-4959(01)00309-8; Zhao D, 2007, FRONT BIOSCI-LANDMRK, V12, P3774, DOI 10.2741/2351; Zhu AP, 2010, ANAL BIOCHEM, V396, P146, DOI 10.1016/j.ab.2009.09.017	48	208	213	1	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					601	611		10.1096/fj.12-216507	http://dx.doi.org/10.1096/fj.12-216507			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23104984				2022-12-28	WOS:000314358000019
J	Kim, HW; McIntosh, JM				Kim, Hyun-Woo; McIntosh, J. Michael			alpha 6 nAChR subunit residues that confer alpha-conotoxin BuIA selectivity	FASEB JOURNAL			English	Article						nicotinic; Conus; C loop; chimera; channel	NICOTINIC ACETYLCHOLINE-RECEPTORS; PARKINSONS-DISEASE STRIATUM; NIGROSTRIATAL DAMAGE; MOLECULAR-DYNAMICS; MESSENGER-RNAS; MONKEY BRAIN; BINDING; ACHBP; ANTAGONISTS; TARGETS	Nicotinic acetylcholine receptors (nAChRs) containing alpha 6 and/or alpha 4 subunits modulate the release of dopamine. However, few compounds can effectively discriminate between ligand-binding sites that contain alpha 6 vs. alpha 4 nAChR subunits. Using a chimeric (alpha 6/alpha 4) subunit, we showed that alpha-conotoxin BuIA binds the extracellular rat alpha 6 beta 2 vs. alpha 4 beta 2 interface with similar to 60,000-fold selectivity. Chimeras containing residues from the alpha 6 subunit were inserted into the homologous position of the alpha 4 subunit to identify critical sequence segments. The region between residues 184 and 207 in the alpha 6 subunit accounted for the potency difference. Chimeras within this region followed by point mutations were constructed for further definition. alpha 6 Lys185, Thr187, and Ile188 form a triad of key residues that influence BuIA binding; when these 3 alpha 6 residues were inserted into the alpha 4 subunit, there was an similar to 2000-fold increase in toxin potency. We used a crystal structure of BuIA bound to the acetylcholine-binding protein together with the structure of the Torepedo marmorata nAChR to build a homology model of BuIA bound to the interface between alpha 6 and beta 2 subunits. The results indicate that the triad of alpha 6 residues lies outside the C loop and is distantly located from bound BuIA (> 10 angstrom). This suggests that alterations in potency are not caused by the direct interaction between the triad and BuIA. Instead, alterations in C-loop 3-dimensional structure and/or flexibility may account for differential potency. Thr198 and Tyr205 also contributed to BuIA potency. In addition, Thr198 caused BuIA potency differences between the closely related alpha 6 and alpha 3 subunits. Together, the findings provide insight into differences between the alpha 6 and other alpha subunits that may be exploited by alpha-conotoxins to achieve binding selectivity.-Kim, H.-W., McIntosh, J. M. alpha 6 nAChR subunit residues that confer alpha-conotoxin BuIA selectivity. FASEB J. 26, 4102-4110 (2012). www.fasebj.org	[Kim, Hyun-Woo] Pukyong Natl Univ, Dept Marine Biol, Pusan, South Korea; [McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Pukyong National University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kim, HW (corresponding author), Pukyong Natl Univ, Dept Marine Biol, Pusan, South Korea.	kimhw@pkniu.ac.kr			U.S. National Institutes of Health [GM103801, GM84677]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM084677, R01GM103801] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Coordinates for the crystal structure were generously provided by T. Talley (Idaho State University), Albert S. Reger and Choel Kim (Baylor College of Medicine, Houston, TX, USA), and Palmer Taylor (University of California, San Diego, CA, USA). Molecular model was constructed by Myunggi Yi (Pukyong National University). This work was supported by the U.S. National Institutes of Health, grants GM103801 and GM84677.	Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Azam L, 2008, J BIOL CHEM, V283, P11625, DOI 10.1074/jbc.M710288200; Azam L, 2009, ACTA PHARMACOL SIN, V30, P771, DOI 10.1038/aps.2009.47; Bordia T, 2007, MOL PHARMACOL, V72, P52, DOI 10.1124/mol.107.035998; Brunzell DH, 2010, NEUROPSYCHOPHARMACOL, V35, P665, DOI 10.1038/npp.2009.171; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Cheng XL, 2006, PLOS COMPUT BIOL, V2, P1173, DOI 10.1371/journal.pcbi.0020134; Clark RJ, 2010, ANGEW CHEM INT EDIT, V49, P6545, DOI 10.1002/anie.201000620; Dowell C, 2003, J NEUROSCI, V23, P8445; Dutertre S, 2007, EMBO J, V26, P3858, DOI 10.1038/sj.emboj.7601785; Evans NM, 2003, EUR J PHARMACOL, V466, P31, DOI 10.1016/S0014-2999(03)01540-1; Exley R, 2011, P NATL ACAD SCI USA, V108, P7577, DOI 10.1073/pnas.1103000108; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Halai R, 2009, NAT PROD REP, V26, P526, DOI 10.1039/b819311h; Han ZY, 2000, EUR J NEUROSCI, V12, P3664, DOI 10.1046/j.1460-9568.2000.00262.x; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jackson KJ, 2009, J PHARMACOL EXP THER, V331, P547, DOI 10.1124/jpet.109.155457; Kasheverov IE, 2009, CURR PHARM DESIGN, V15, P2430, DOI 10.2174/138161209788682316; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Lai A, 2005, MOL PHARMACOL, V67, P1639, DOI 10.1124/mol.104.006429; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Lewis RJ, 2009, ADV EXP MED BIOL, V655, P44, DOI 10.1007/978-1-4419-1132-2_5; Luo SQ, 2004, BIOCHEMISTRY-US, V43, P6656, DOI 10.1021/bi049906y; Luo SQ, 1998, J NEUROSCI, V18, P8571; Luo SL, 2010, J BIOL CHEM, V285, P12355, DOI 10.1074/jbc.M109.079012; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McCallum SE, 2005, MOL PHARMACOL, V68, P737, DOI 10.1124/mol.105.012773; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; Mordvintsev DY, 2006, J MOL NEUROSCI, V30, P71, DOI 10.1385/JMN:30:1:71; Muttenthaler M, 2010, J AM CHEM SOC, V132, P3514, DOI 10.1021/ja910602h; Olivera BM, 2008, CHANNELS, V2, P143, DOI 10.4161/chan.2.2.6276; Papke RL, 2008, NEUROPHARMACOLOGY, V54, P1189, DOI 10.1016/j.neuropharm.2008.03.010; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Pons S, 2008, J NEUROSCI, V28, P12318, DOI 10.1523/JNEUROSCI.3918-08.2008; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Quik M, 2005, MOL PHARMACOL, V67, P32, DOI 10.1124/mol.104.006015; Quik M, 2004, J NEUROCHEM, V88, P668, DOI 10.1111/j.1471-4159.2004.02177.x; Quik M, 2001, J NEUROSCI, V21, P5494, DOI 10.1523/JNEUROSCI.21-15-05494.2001; Quik M, 2000, J COMP NEUROL, V425, P58, DOI 10.1002/1096-9861(20000911)425:1<58::AID-CNE6>3.0.CO;2-X; Schmidtko A, 2010, LANCET, V375, P1569, DOI 10.1016/S0140-6736(10)60354-6; Shiembob DL, 2006, BIOCHEMISTRY-US, V45, P11200, DOI 10.1021/bi0611715; Talley TT, 2006, J BIOL CHEM, V281, P24678, DOI 10.1074/jbc.M602969200; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Yang KC, 2009, ACTA PHARMACOL SIN, V30, P740, DOI 10.1038/aps.2009.63	53	18	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4102	4110		10.1096/fj.12-204487	http://dx.doi.org/10.1096/fj.12-204487			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751014	Green Published			2022-12-28	WOS:000309704000017
J	Krutskikh, A; Poliandri, A; Cabrera-Sharp, V; Dacheux, JL; Poutanen, M; Huhtaniemi, I				Krutskikh, Anton; Poliandri, Ariel; Cabrera-Sharp, Victoria; Dacheux, Jean Louis; Poutanen, Matti; Huhtaniemi, Ilpo			Epididymal protein Rnase10 is required for post-testicular sperm maturation and male fertility	FASEB JOURNAL			English	Article						capacitation; sperm transport; zona pellucida; fertilization; oviduct	ACROSOME REACTION; MOUSE SPERM; IN-VITRO; ULTRASTRUCTURAL-CHANGES; HAMSTER SPERMATOZOA; REPRODUCTIVE ADAMS; FERTILIZATION; IDENTIFICATION; MICE; EGG	Eutherian spermatozoa are dependent on the environment of the proximal epididymis to complete their maturation; however, no specific epididymal factors that mediate this process have so far been identified. Here, we show that targeted disruption of the novel gene Rnase10 encoding a secreted proximal epididymal protein in the mouse results in a binding defect in spermatozoa and their inability to pass through the uterotubal junction in the female. The failure to gain the site of fertilization in the knockout spermatozoa is associated with a gradual loss of ADAM3 and ADAM6 proteins during epididymal transit. In the distal epididymis, these spermatozoa appear to lack calcium-dependent associations with the immobilizing glutinous extracellular material and are released as single, vigorously motile cells that display no tendency for head-to-head agglutination and lack affinity to the oviductal epithelium. In sperm-egg binding assay, they are unable to establish a tenacious association with the zona pellucida, yet they are capable of fertilization. Furthermore, these sperm show accelerated capacitation resulting in an overall in vitro fertilizing ability superior to that of wild-type sperm. We conclude that the physiological role of sperm adhesiveness is in the mechanism of restricted sperm entry into the oviduct rather than in sperm-egg interaction.-Krutskikh, A., Poliandri, A., Cabrera-Sharp, V., Dacheux, J. L., Poutanen, M., Huhtaniemi, I. Epididymal protein Rnase10 is required for post-testicular sperm maturation and male fertility. FASEB J. 26, 4198-4209 (2012). www.fasebj.org	[Krutskikh, Anton; Poliandri, Ariel; Cabrera-Sharp, Victoria; Huhtaniemi, Ilpo] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England; [Dacheux, Jean Louis] Ctr Natl Rech Sci, Inst Natl Rech Agron, Unite Mixte Rech, Nouzilly, France; [Poutanen, Matti; Huhtaniemi, Ilpo] Univ Turku, Dept Physiol, Turku, Finland; [Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland	Imperial College London; Centre National de la Recherche Scientifique (CNRS); INRAE; University of Turku; University of Turku	Huhtaniemi, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@imperial.ac.uk	Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734	Wellcome Trust [063552, 082101]	Wellcome Trust(Wellcome Trust)	This study was supported by program grants (no. 063552 and 082101) from The Wellcome Trust to I.H.	Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; BEDFORD JM, 1968, AM J ANAT, V123, P329, DOI 10.1002/aja.1001230207; BEDFORD JM, 1983, BIOL REPROD, V28, P108, DOI 10.1095/biolreprod28.1.108; Bedford JM, 2004, BIOL REV, V79, P429, DOI 10.1017/S146479310300633X; BEDFORD JM, 1994, HUM REPROD, V9, P842, DOI 10.1093/oxfordjournals.humrep.a138604; BEDFORD JM, 1972, AM J ANAT, V133, P213, DOI 10.1002/aja.1001330206; BEDFORD JM, 1979, AM J ANAT, V156, P207, DOI 10.1002/aja.1001560204; BEDFORD JM, 1967, J EXP ZOOL, V166, P271, DOI 10.1002/jez.1401660210; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; Castella S, 2004, BIOL REPROD, V71, P1677, DOI 10.1095/biolreprod.104.031666; Castella S, 2004, BIOL REPROD, V70, P319, DOI 10.1095/biolreprod.103.022459; Chabory E, 2009, J CLIN INVEST, V119, P2074, DOI 10.1172/JCI38940; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; CUASNICU PS, 1988, GAMETE RES, V21, P85, DOI 10.1002/mrd.1120210110; CUMMINS JM, 1982, GAMETE RES, V5, P239, DOI 10.1002/mrd.1120050304; Da Ros VG, 2008, DEV BIOL, V320, P12, DOI 10.1016/j.ydbio.2008.03.015; Dacheux JL, 2009, REPROD FERT DEVELOP, V21, P1002, DOI 10.1071/RD09091; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; ELINSON RP, 1989, LIFE SCI R, V45, P251; Florman HM, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P55; Ginzburg AS., 1972, FERTILIZATION FISHES; Han C, 2009, BIOL REPROD, V80, P1001, DOI 10.1095/biolreprod.108.073700; HUNTER RHF, 1976, J ANAT, V122, P43; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Ikawa M, 2011, J BIOL CHEM, V286, P5639, DOI 10.1074/jbc.M110.140152; Inoue N, 2011, P NATL ACAD SCI USA, V108, P20008, DOI 10.1073/pnas.1116965108; Jin M, 2011, P NATL ACAD SCI USA, V108, P4892, DOI 10.1073/pnas.1018202108; Kim E, 2006, J BIOL CHEM, V281, P5634, DOI 10.1074/jbc.M510558200; Kim E, 2005, P NATL ACAD SCI USA, V102, P18028, DOI 10.1073/pnas.0506825102; Kim E, 2004, J REPROD DEVELOP, V50, P571, DOI 10.1262/jrd.50.571; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; Krutskikh A, 2011, ENDOCRINOLOGY, V152, P689, DOI 10.1210/en.2010-0768; LINDER B, 1995, EXP CELL RES, V221, P66, DOI 10.1006/excr.1995.1353; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marcello MR, 2011, J BIOL CHEM, V286, P13060, DOI 10.1074/jbc.M110.175463; Monclus MDLA, 2007, ANAT REC, V290, P814, DOI 10.1002/ar.20555; NAITO K, 1992, HUM REPROD, V7, P281, DOI 10.1093/oxfordjournals.humrep.a137633; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2007, J BIOL CHEM, V282, P17900, DOI 10.1074/jbc.M702268200; Olds P J, 1970, Biol Reprod, V2, P91, DOI 10.1095/biolreprod2.1.91; OLDSCLARKE P, 1992, BIOL REPROD, V47, P621, DOI 10.1095/biolreprod47.4.621; OVERSTREET JW, 1979, J EXP ZOOL, V209, P97, DOI 10.1002/jez.1402090112; Penttinen J, 2003, MOL ENDOCRINOL, V17, P2138, DOI 10.1210/me.2003-0008; QUINN P, 1982, J REPROD FERTIL, V66, P161; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHALGI R, 1992, BIOL REPROD, V46, P419, DOI 10.1095/biolreprod46.3.419; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; SUAREZ SS, 1987, BIOL REPROD, V36, P203, DOI 10.1095/biolreprod36.1.203; Syntin P, 1996, BIOL REPROD, V55, P956, DOI 10.1095/biolreprod55.5.956; Temple-Smith PD, 1998, J REPROD FERTIL, P183; Tokuhiro K, 2012, P NATL ACAD SCI USA, V109, P3850, DOI 10.1073/pnas.1117963109; Ueda Y, 2007, J BIOL CHEM, V282, P30373, DOI 10.1074/jbc.M705601200; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Yamaguchi R, 2008, GENES CELLS, V13, P851, DOI 10.1111/j.1365-2443.2008.01210.x; Yamaguchi R, 2006, BIOL REPROD, V75, P760, DOI 10.1095/biolreprod.106.052977; Yamaguchi R, 2009, BIOL REPROD, V81, P142, DOI 10.1095/biolreprod.108.074021; YANAGIMACHI R, 1970, J ULTRA MOL STRUCT R, V31, P465, DOI 10.1016/S0022-5320(70)90163-2; YANAGIMACHI R, 1984, GAMETE RES, V9, P1, DOI 10.1002/mrd.1120090102; ZHEN HG, 1988, BIOL REPROD, V38, P439, DOI 10.1095/biolreprod38.2.439	59	41	59	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4198	4209		10.1096/fj.12-205211	http://dx.doi.org/10.1096/fj.12-205211			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22750516	Green Submitted, Green Published			2022-12-28	WOS:000309704000025
J	Onate, B; Vilahur, G; Ferrer-Lorente, R; Ybarra, J; Diez-Caballero, A; Ballesta-Lopez, C; Moscatiello, F; Herrero, J; Badimon, L				Onate, Blanca; Vilahur, Gemma; Ferrer-Lorente, Raquel; Ybarra, Juan; Diez-Caballero, Alberto; Ballesta-Lopez, Carlos; Moscatiello, Fabrizio; Herrero, Javier; Badimon, Lina			The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients	FASEB JOURNAL			English	Article						thrombospondin 1; cardiovascular risk factors; hypoxia; proliferation; angiogenesis; differentiation	ENDOTHELIAL PROGENITOR CELLS; CORONARY-ARTERY-DISEASE; STROMAL CELLS; BONE-MARROW; PREADIPOCYTE DIFFERENTIATION; HYPOXIA; TRANSPLANTATION; PROLIFERATION; AGE; THERAPY	It has been demonstrated that the adipose tissue, a highly functional metabolic tissue, is a reservoir of mesenchymal stem cells. The potential use of adipose-derived stem cells (ADSCs) from white adipose tissue (WAT) for organ repair and regeneration has been considered because of their obvious benefits in terms of accessibility and quantity of available sample. However, the functional capability of ADSCs from subjects with different adiposity has not been investigated. It has been our hypothesis that ADSCs from adipose tissue of patients with metabolic syndrome and high adiposity may be functionally impaired. We report that subcutaneous WAT stromal vascular fraction (SVF) from nonobese individuals had a significantly higher number of CD90(+) cells than SVF from obese patients. The isolated ADSCs from WAT of obese patients had reduced differentiation potential and were less proangiogenic. Therefore, ADSCs in adipose tissue of obese patients have lower capacity for spontaneous or therapeutic repair than ADSCs from nonobese metabolically normal individuals.-Onate, B., Vilahur, G., Ferrer-Lorente, R., Ybarra, J., Diez-Caballero, A., Ballesta-Lopez, C., Moscatiello, F., Herrero, J., Badimon, L. The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. FASEB J. 26, 4327-4336 (2012). www.fasebj.org	[Onate, Blanca; Vilahur, Gemma; Ferrer-Lorente, Raquel; Badimon, Lina] Hosp Santa Creu & Sant Pau, Cardiovasc Res Ctr, Barcelona 08025, Spain; [Onate, Blanca; Vilahur, Gemma; Ferrer-Lorente, Raquel; Badimon, Lina] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Ybarra, Juan] Resistencia Insulina SL, Barcelona, Spain; [Diez-Caballero, Alberto] Quirurg Cirujanos Asociados, Barcelona, Spain; [Moscatiello, Fabrizio; Herrero, Javier] Ctr Med Teknon, Dept Plast Surg, Barcelona, Spain; [Ballesta-Lopez, Carlos] Ctr Laparoscop Doctor Ballesta SLU, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC); Hospital of Santa Creu i Sant Pau; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Badimon, L (corresponding author), Hosp Santa Creu & Sant Pau, Cardiovasc Res Ctr CSIC ICCC, Av S Antoni M Claret 167, Barcelona 08025, Spain.	lbadimon@csic-iccc.org	Ferrer-Lorente, Raquel/M-4416-2014; BADIMON, LINA/O-4711-2014; BADIMON, LINA/S-2950-2019	Ferrer-Lorente, Raquel/0000-0002-2052-9011; BADIMON, LINA/0000-0002-9162-2459; 	Instituto Salud Carlos III (Madrid, Spain) [SAF2010/16549, CIBERobn-CB06/03, Retic-TERCEL RD06/0010/0017]; Fundacion Jesus Serra (Barcelona, Spain); Instituto Salud Carlos III; Spanish Ministry of Science and Innovation (MICINN) [RyC-2009-5495]; Instituto Salud Carlos III, MICINN	Instituto Salud Carlos III (Madrid, Spain)(Instituto de Salud Carlos III); Fundacion Jesus Serra (Barcelona, Spain); Instituto Salud Carlos III(Instituto de Salud Carlos III); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto Salud Carlos III, MICINN	This work was supported by grants SAF2010/16549, CIBERobn-CB06/03, and Retic-TERCEL RD06/0010/0017 from Instituto Salud Carlos III (Madrid, Spain) and Fundacion Jesus Serra (Barcelona, Spain). L.B. is the Cardiovascular Research Chair, Universitat Autonoma de Barcelona (Barcelona, Spain). B.O. was the recipient of a predoctoral fellowship from Instituto Salud Carlos III. G.V. is a recipient of a contract from the Spanish Ministry of Science and Innovation (MICINN; RyC-2009-5495). R.F.-L. is a recipient of a Sara Borrell contract from Instituto Salud Carlos III, MICINN. The authors thank Marta Sanchez and Vanesa Rodriguez for their technical support. The authors declare no conflicts of interest.	Casteilla L, 2011, METHODS MOL BIOL, V702, P269, DOI 10.1007/978-1-61737-960-4_20; Casteilla L, 2010, CURR STEM CELL RES T, V5, P141, DOI 10.2174/157488810791268546; Chen JZ, 2004, CLIN SCI, V107, P273, DOI 10.1042/CS20030389; Constantin G, 2009, STEM CELLS, V27, P2624, DOI 10.1002/stem.194; Efimenko A, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-10; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; Fischer LJ, 2009, J SURG RES, V152, P157, DOI 10.1016/j.jss.2008.06.029; Garcia-Diaz DF, 2011, J PHYSIOL BIOCHEM, V67, P453, DOI 10.1007/s13105-011-0081-7; Garcia-Olmo D, 2003, INT J COLORECTAL DIS, V18, P451, DOI 10.1007/s00384-003-0490-3; Garcia-Olmo D, 2009, DIS COLON RECTUM, V52, P79, DOI 10.1007/DCR.0b013e3181973487; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Gonzalez-Rey E, 2010, ANN RHEUM DIS, V69, P241, DOI 10.1136/ard.2008.101881; Grayson WL, 2007, BIOCHEM BIOPH RES CO, V358, P948, DOI 10.1016/j.bbrc.2007.05.054; Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571; Gupta V, 2008, MOL CELL ENDOCRINOL, V296, P32, DOI 10.1016/j.mce.2008.08.019; Heida NM, 2010, J AM COLL CARDIOL, V55, P357, DOI 10.1016/j.jacc.2009.09.031; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071; Isakson P, 2009, DIABETES, V58, P1550, DOI 10.2337/db08-1770; Jurgens WJFM, 2008, CELL TISSUE RES, V332, P415, DOI 10.1007/s00441-007-0555-7; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Kim JH, 2011, EXP DERMATOL, V20, P383, DOI 10.1111/j.1600-0625.2010.01221.x; Lee EY, 2009, WOUND REPAIR REGEN, V17, P540, DOI 10.1111/j.1524-475X.2009.00499.x; Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195; Madonna R, 2011, EUR J CLIN INVEST, V41, P126, DOI 10.1111/j.1365-2362.2010.02384.x; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Permana PA, 2004, AM J PHYSIOL-ENDOC M, V286, pE958, DOI 10.1152/ajpendo.00544.2003; Pilgaard L, 2009, EXP CELL RES, V315, P1937, DOI 10.1016/j.yexcr.2009.01.020; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325; Potier E, 2007, BONE, V40, P1078, DOI 10.1016/j.bone.2006.11.024; Ramis JM, 2002, CELL MOL LIFE SCI, V59, P1960, DOI 10.1007/PL00012518; Ramunni A, 2010, BLOOD PURIFICAT, V29, P383, DOI 10.1159/000314650; Rasmussen JG, 2011, CYTOTHERAPY, V13, P318, DOI 10.3109/14653249.2010.506505; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Riordan NH, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-29; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Schipper BM, 2008, ANN PLAS SURG, V60, P538, DOI 10.1097/SAP.0b013e3181723bbe; Sheng LL, 2011, TOHOKU J EXP MED, V224, P229, DOI 10.1620/tjem.224.229; Tamarat R, 2004, AM J PATHOL, V164, P457, DOI 10.1016/S0002-9440(10)63136-7; Tchoukalova Y, 2007, DIABETOLOGIA, V50, P151, DOI 10.1007/s00125-006-0496-9; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Thangarajah H, 2009, STEM CELLS, V27, P266, DOI 10.1634/stemcells.2008-0276; van Harmelen V, 2003, INT J OBESITY, V27, P889, DOI 10.1038/sj.ijo.0802314; Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Wang MJ, 2006, AM J PHYSIOL-REG I, V291, pR880, DOI 10.1152/ajpregu.00280.2006; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Yang Z, 2010, CLIN EXP HYPERTENS, V32, P444, DOI 10.3109/10641961003686435; Yue WS, 2010, AM J CARDIOL, V106, P1248, DOI 10.1016/j.amjcard.2010.06.045; Zhang DZ, 2007, CHINESE MED J-PEKING, V120, P300, DOI 10.1097/00029330-200702020-00009; Zhu M, 2009, J TISSUE ENG REGEN M, V3, P290, DOI 10.1002/term.165; Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005-0121; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	55	84	86	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4327	4336		10.1096/fj.12-207217	http://dx.doi.org/10.1096/fj.12-207217			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22772162				2022-12-28	WOS:000309704000037
J	Pavlovski, D; Thundyil, J; Monk, PN; Wetsel, RA; Taylor, SM; Woodruff, TM				Pavlovski, Dale; Thundyil, John; Monk, Peter N.; Wetsel, Rick A.; Taylor, Stephen M.; Woodruff, Trent M.			Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis	FASEB JOURNAL			English	Article						neuroinflammation; stroke; cell death; innate immune system; neurodegeneration	DECAY-ACCELERATING FACTOR; CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; RAT MODEL; RECEPTOR ANTAGONIST; ALZHEIMERS-DISEASE; IN-VITRO; STROKE; EXPRESSION; BRAIN	C5a receptors are found in the central nervous system (CNS), on both neurons and glia. However, the origin of the C5a, which activates these receptors, is unclear. In the present study, we show that primary cultured mouse cortical neurons constitutively express C5, the precursor of C5a, and express the classical receptor for C5a, CD88. With cell ischemia caused by 12 h glucose deprivation, or oxygen-glucose deprivation (OGD), neurons demonstrated increased apoptosis, up-regulation of CD88, and increased levels of C5a in the media. Exogenous murine C5a (100 nM) added to the neuronal cultures resulted in apoptosis, without affecting cell necrosis. Pretreatment of the cells with the specific CD88 receptor antagonist PMX53 (100 nM) significantly blocked ischemia-induced apoptosis (similar to 50%), and neurons from CD88(-/-) mice were similarly protected. In a murine model of stroke, using middle cerebral artery occlusion (MCAO), we found that C5a levels in the brain increased; this also occurred in cerebral slice cultures exposed to OGD. CD88(-/-) mice subjected to MCAO had significantly reduced infarct volumes and improved neurological scores. Taken together, our results demonstrate that neurons in the CNS have the capability to generate C5a following ischemic stress, and this has the potential to activate their C5a receptors, with deleterious consequences.-Pavlovski, D., Thundyil, J., Monk, P. N., Wetsel, R. A., Taylor, S. M., Woodruff, T. M. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 26, 3680-3690 (2012). www.fasebj.org	[Pavlovski, Dale; Thundyil, John; Taylor, Stephen M.; Woodruff, Trent M.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Monk, Peter N.] Univ Sheffield, Sch Med, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Wetsel, Rick A.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis, Res Ctr Immunol & Autoimmune Dis, Houston, TX USA	University of Queensland; University of Sheffield; University of Texas System; University of Texas Health Science Center Houston	Woodruff, TM (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	t.woodruff@uq.edu.au	Woodruff, Trent/AAS-4629-2020; Woodruff, Trent M/B-4861-2009; Monk, Peter/C-6155-2008	Woodruff, Trent/0000-0003-1382-911X; Woodruff, Trent M/0000-0003-1382-911X; Monk, Peter/0000-0003-4637-3059	National Health and Medical Research Council of Australia [APP1004455, APP1021413]; Australian Research Council [FT110100332]; British Heart Foundation [PG/09/018/25279] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); British Heart Foundation(British Heart Foundation)	The authors thank Dr. Thiruma Arumugam for his contribution to this study. This study was funded through the support of the National Health and Medical Research Council of Australia (project grants APP1004455 and APP1021413) and the Australian Research Council (Future Fellowship FT110100332 to T. M. W.).	Adams HR, 2003, J HYPERTENS, V21, pS3, DOI 10.1097/00004872-200306005-00002; Agholme L, 2010, J ALZHEIMERS DIS, V20, P1069, DOI 10.3233/JAD-2010-091363; Arumugam TV, 2009, NEUROSCIENCE, V158, P1074, DOI 10.1016/j.neuroscience.2008.07.015; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Benard M, 2008, MOL IMMUNOL, V45, P3767, DOI 10.1016/j.molimm.2008.05.027; Crane JW, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-34; D'Ambrosio AL, 2001, MOL MED, V7, P367, DOI 10.1007/BF03402183; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Fujita H, 1996, GLIA, V18, P269, DOI 10.1002/(SICI)1098-1136(199612)18:4<269::AID-GLIA2>3.0.CO;2-T; Gasque P, 1997, AM J PATHOL, V150, P31; Hollmann TJ, 2008, MOL IMMUNOL, V45, P1907, DOI 10.1016/j.molimm.2007.10.037; Huber-Lang M, 2002, AM J PATHOL, V161, P1849, DOI 10.1016/S0002-9440(10)64461-6; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Humayun S, 2009, J NEUROIMMUNOL, V210, P52, DOI 10.1016/j.jneuroim.2009.01.028; Jacob A, 2010, J NEUROIMMUNOL, V221, P46, DOI 10.1016/j.jneuroim.2010.02.011; Kim DD, 2008, BLOOD, V112, P1109, DOI 10.1182/blood-2008-01-134304; Kim GH, 2008, NEUROSURGERY, V63, P122, DOI 10.1227/01.NEU.0000335079.70222.8D; Malagelada C, 2005, NEUROBIOL DIS, V20, P27, DOI 10.1016/j.nbd.2005.01.028; Manthey HD, 2011, FASEB J, V25, P2447, DOI 10.1096/fj.10-174284; Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Mocco J, 2006, NEUROSURGERY, V59, P28, DOI [10.1227/01.NEU.0000219221.14280.65, 10.1227/01.neu.0000243280.75920.f4]; Nishiura H, 2009, LAB INVEST, V89, P676, DOI 10.1038/labinvest.2009.27; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Okun E, 2007, J NEUROCHEM, V102, P1232, DOI 10.1111/j.1471-4159.2007.04615.x; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Pedersen ED, 2009, SCAND J IMMUNOL, V69, P555, DOI 10.1111/j.1365-3083.2009.02253.x; Ramaglia V, 2009, PROG BRAIN RES, V175, P95, DOI 10.1016/S0079-6123(09)17507-6; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Stahel PF, 1997, AM J PATHOL, V151, P897; Stahel PF, 1997, IMMUNOPHARMACOLOGY, V38, P65, DOI 10.1016/S0162-3109(97)80150-6; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Thomas A, 2000, INT IMMUNOL, V12, P1015, DOI 10.1093/intimm/12.7.1015; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Wang Y, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-24; Woehrl B, 2011, J CLIN INVEST, V121, P3943, DOI 10.1172/JCI57522; Woodruff TM, 2005, J PHARMACOL EXP THER, V314, P811, DOI 10.1124/jpet.105.086835; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y; Woodruff TM, 2008, J IMMUNOL, V181, P8727, DOI 10.4049/jimmunol.181.12.8727; World Health Organization, WHO GLOB INF	50	73	76	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3680	3690		10.1096/fj.11-202382	http://dx.doi.org/10.1096/fj.11-202382			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22651932				2022-12-28	WOS:000308391600010
J	Berghard, A; Hagglund, AC; Bohm, S; Carlsson, L				Berghard, Anna; Hagglund, Anna-Carin; Bohm, Staffan; Carlsson, Leif			Lhx2-dependent specification of olfactory sensory neurons is required for successful integration of olfactory, vomeronasal, and GnRH neurons	FASEB JOURNAL			English	Article						mouse embryo development; gonadotropin-releasing hormone neurons; puberty phenotype	LIM HOMEOBOX GENE; MOLECULAR-BASIS; MOUSE; LHX2; EXPRESSION; CELLS; AXONS; IDENTITY; ORIGIN; BULB	Inactivation of the LIM-homeodomain 2 gene (Lhx2) results in a severe defect in specification of olfactory sensory neurons (OSNs). However, the ramifications of lack of Lhx2-dependent OSN specification for formation of the primary olfactory pathway have not been addressed, since mutant mice die in utero. We have analyzed prenatal and postnatal consequences of conditionally inactivating Lhx2 selectively in OSNs. A cell-autonomous effect is that OSN axons cannot innervate their target, the olfactory bulb. Moreover, the lack of Lhx2 in OSNs causes unpredicted, non-cell-autonomous phenotypes. First, the olfactory bulb shows pronounced hypoplasia in adults, and the data suggest that innervation by correctly specified OSNs is necessary for adult bulb size and organization. Second, absence of an olfactory nerve in the conditional mutant reveals that the vomeronasal nerve is dependent on olfactory nerve formation. Third, the lack of a proper vomeronasal nerve prevents migration of gonadotropin-releasing hormone (GnRH) cells the whole distance to their final positions in the hypothalamus during embryo development. As adults, the conditional mutants do not pass puberty, and these findings support the view of an exclusive nasal origin of GnRH neurons in the mouse. Thus, Lhx2 in OSNs is required for functional development of three separate systems.-Berghard, A., Hagglund, A.-C., Bohm, S., and Carlsson, L. Lhx2-dependent specification of olfactory sensory neurons is required for successful integration of olfactory, vomeronasal, and GnRH neurons. FASEB J. 26, 3464-3472 (2012). www.fasebj.org	[Berghard, Anna; Bohm, Staffan] Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; [Hagglund, Anna-Carin; Carlsson, Leif] Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden	Umea University; Umea University	Berghard, A (corresponding author), Umea Univ, Dept Mol Biol, Byggn 6L, SE-90187 Umea, Sweden.	anna.berghard@molbiol.umu.se			Swedish Research Council FORMAS [221-2006-419]; Swedish Research Council [521-2011-3130]; Swedish Cancer Society; technical-natural science and medical faculties at Umea University	Swedish Research Council FORMAS(Swedish Research CouncilSwedish Research Council Formas); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); technical-natural science and medical faculties at Umea University	The authors thank Dr. V. Vedin for input on experimental procedures, G. Tornqvist (Umea University) for the reelin probe, and the Umea Transgenic Core Facility for animal genotyping service. This study was in part supported by the Swedish Research Council FORMAS (to A.B.; no. 221-2006-419), the Swedish Research Council, (to L.C.; no. 521-2011-3130), the Swedish Cancer Society (to L.C.), and the technical-natural science and medical faculties at Umea University.	Allen Institute for Brain Science, 2009, DEV MOUS BRAIN ATL; BENTLEY D, 1983, NATURE, V304, P62, DOI 10.1038/304062a0; Berghard A, 1996, J NEUROSCI, V16, P909; Bianco SDC, 2009, NAT REV ENDOCRINOL, V5, P569, DOI 10.1038/nrendo.2009.177; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chou SJ, 2009, NAT NEUROSCI, V12, P1381, DOI 10.1038/nn.2427; CUSCHIERI A, 1975, J ANAT, V119, P277; DeMaria S, 2010, J CELL BIOL, V191, P443, DOI 10.1083/jcb.201008163; Forni PE, 2011, J NEUROSCI, V31, P6915, DOI 10.1523/JNEUROSCI.6087-10.2011; GONG QH, 1995, NEURON, V14, P91, DOI 10.1016/0896-6273(95)90243-0; Hagglund AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023387; HINDS JW, 1976, J COMP NEUROL, V169, P15, DOI 10.1002/cne.901690103; Hirata T, 2006, DEVELOPMENT, V133, P1433, DOI 10.1242/dev.02329; Hirota J, 2004, P NATL ACAD SCI USA, V101, P8751, DOI 10.1073/pnas.0400940101; Hirota J, 2007, MOL CELL NEUROSCI, V34, P679, DOI 10.1016/j.mcn.2007.01.014; Kolterud A, 2004, DEVELOPMENT, V131, P5319, DOI 10.1242/dev.01416; Mangale VS, 2008, SCIENCE, V319, P304, DOI 10.1126/science.1151695; Metz H, 2010, ENDOCRINOLOGY, V151, P766, DOI 10.1210/en.2009-0875; Miller AM, 2010, J COMP NEUROL, V518, P4825, DOI 10.1002/cne.22497; Norlin EM, 2005, J NEUROCHEM, V93, P1594, DOI 10.1111/j.1471-4159.2005.03159.x; Packard A, 2011, J COMP NEUROL, V519, P3580, DOI 10.1002/cne.22726; Porter FD, 1997, DEVELOPMENT, V124, P2935; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Saha B, 2007, J NEUROSCI, V27, P2290, DOI 10.1523/JNEUROSCI.5571-06.2007; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Schwarting GA, 2004, EUR J NEUROSCI, V19, P11, DOI 10.1111/j.1460-9568.2004.03094.x; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Takano-Maruyama M, 2010, DEV DYNAM, V239, P1155, DOI 10.1002/dvdy.22273; Tirindelli R, 2009, PHYSIOL REV, V89, P921, DOI 10.1152/physrev.00037.2008; Topaloglu AK, 2010, CURR OPIN OBSTET GYN, V22, P264, DOI 10.1097/GCO.0b013e32833bb425; Tornqvist G, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000904; Tucker ES, 2010, DEVELOPMENT, V137, P2471, DOI 10.1242/dev.049718; Watanabe Y, 2009, J COMP NEUROL, V515, P565, DOI 10.1002/cne.22074; Wierman ME, 2011, FRONT NEUROENDOCRIN, V32, P43, DOI 10.1016/j.yfrne.2010.07.005; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; Yoshida K, 1995, J NEUROSCI, V15, P7769	36	22	22	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3464	3472		10.1096/fj.12-206193	http://dx.doi.org/10.1096/fj.12-206193			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22581782				2022-12-28	WOS:000307162800033
J	Hasegawa, K; Wakino, S; Kimoto, M; Minakuchi, H; Fujimura, K; Hosoya, K; Komatsu, M; Kaneko, Y; Kanda, T; Tokuyama, H; Hayashi, K; Itoh, H				Hasegawa, Kazuhiro; Wakino, Shu; Kimoto, Masumi; Minakuchi, Hitoshi; Fujimura, Keiko; Hosoya, Koji; Komatsu, Motoaki; Kaneko, Yuka; Kanda, Takeshi; Tokuyama, Hirobumi; Hayashi, Koichi; Itoh, Hiroshi			The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice	FASEB JOURNAL			English	Article						beta cells; glucose-stimulated insulin secretion; glucose tolerance; knockout; overexpression	NITRIC-OXIDE SYNTHASE; HIGH-FAT DIET; BETA-CELLS; ENDOTHELIAL-CELLS; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE; ASYMMETRIC DIMETHYLARGININE; UNCOUPLING PROTEIN-2; FACTOR EXPRESSION; OXIDATIVE STRESS; RAT ISLETS	The role of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in glucose metabolism is unknown. Here, we generated DDAH2 transgenic (Tg) mice. These mice had lower plasma glucose levels (60 min: 298 +/- 32 vs. 418 +/- 35 mg/dl; 120 min: 205 +/- 15 vs. 284 +/- 20 mg/dl) and higher insulin levels (15 min: 2.1 +/- 0.2 vs. 1.5 +/- 0.1 ng/ml; 30 min: 1.8 +/- 0.1 vs. 1.5 +/- 0.1 ng/ml) during intraperitoneal glucose tolerance tests when fed a high-fat diet (HFD) compared with HFD-fed wild-type (WT) mice. Glucose-stimulated insulin secretion (GSIS) was increased in Tg islets by 33%. Pancreatic asymmetrical dimethylarginine, nitric oxide, and oxidative stress levels were not correlated with improvements in insulin secretion in Tg mice. Secretagogin, an insulin vesicle docking protein, was up-regulated by 2.7-fold in Tg mice and in pancreatic MIN-6 cells overexpressing DDAH2. GSIS in MIN-6 cells was dependent on DDAH2-induced secretagogin expression. Pancreatic Sirt1, DDAH2, and secretagogin were down-regulated in HFD-fed WT mice by 70, 75, and 85%, respectively. Overexpression of Sirt1 overexpression by 3.9-fold increased DDAH2 and secretagogin expression in MIN-6 cells by 3.2- and 2.5-fold, respectively. DDAH2 overexpression improved GSIS in pancreas-specific Sirt1-deficient mice. In summary, the Sirt1/DDAH2/secretagogin pathway is a novel regulator of GSIS.-Hasegawa, K, Wakino, S., Kimoto, M, Minakuchi, H., Fujimura, K., Hosoya, K., Komatsu, M., Kaneko, Y., Kanda, T., Tokuyama, H., Hayashi, K., Itoh, H. The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice.	[Hasegawa, Kazuhiro; Wakino, Shu; Minakuchi, Hitoshi; Fujimura, Keiko; Hosoya, Koji; Komatsu, Motoaki; Kaneko, Yuka; Kanda, Takeshi; Tokuyama, Hirobumi; Hayashi, Koichi; Itoh, Hiroshi] Keio Univ, Dept Internal Med, Sch Med, Tokyo 1608582, Japan; [Kimoto, Masumi] Okayama Prefectural Univ, Dept Nutr Sci, Okayama, Japan	Keio University; Okayama Prefectural University	Wakino, S (corresponding author), Keio Univ, Dept Internal Med, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	shuwakino@z8.keio.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [22790800]; Grants-in-Aid for Scientific Research [23590683] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank K. Miyashita (Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan) for providing the MIN-6 cells. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant 22790800). Author contributions: H.K., S.W., and H.I. designed the experiments and the study; K.H., H.M., and K.F. collected data or performed the experiments; K.H., S.W., M.K., H.M., K.F., K.H., M.K., Y.K., T.K., H.T., K.H., and H.I. analyzed the data and helped write the manuscript; H.I. supervised all experiments and assisted with preparation of the manuscript; S.W. is the guarantor of this work, had full access to all of the data, and takes responsibility for the integrity and accuracy of the data. The authors declare no conflicts of interest.	Arafat HA, 2007, ENDOCRINOLOGY, V148, P575, DOI 10.1210/en.2006-0970; Bauer MC, 2011, MOL BIOSYST, V7, P2196, DOI 10.1039/c0mb00349b; Boger RH, 2000, J AM COLL CARDIOL, V36, P2287, DOI 10.1016/S0735-1097(00)01013-5; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Brown JM, 2008, CIRCULATION, V118, P1467, DOI 10.1161/CIRCULATIONAHA.108.793182; Chepurny OG, 2010, AM J PHYSIOL-ENDOC M, V298, pE622, DOI 10.1152/ajpendo.00630.2009; Collins SC, 2010, DIABETES, V59, P1192, DOI 10.2337/db09-0791; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Fukui K, 2005, CELL METAB, V2, P373, DOI 10.1016/j.cmet.2005.11.003; Hals IK, 2012, BIOCHEM BIOPH RES CO, V423, P259, DOI 10.1016/j.bbrc.2012.05.101; Hasegawa K, 2008, BIOCHEM BIOPH RES CO, V372, P51, DOI 10.1016/j.bbrc.2008.04.176; Hasegawa K, 2007, CIRC RES, V101, pE2, DOI 10.1161/CIRCRESAHA.107.156901; Hasegawa K, 2006, ARTERIOSCL THROM VAS, V26, P1488, DOI 10.1161/01.ATV.0000219615.88323.b4; Henningsson R, 2002, AM J PHYSIOL-CELL PH, V283, pC296, DOI 10.1152/ajpcell.00537.2001; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Jeong H, 2012, NAT MED, V18, P159, DOI 10.1038/nm.2559; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kang LJ, 2006, CELL METAB, V3, P463, DOI 10.1016/j.cmet.2006.04.012; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Krzyzanowska K, 2008, DIABETES RES CLIN PR, V82, pS122, DOI 10.1016/j.diabres.2008.09.024; Kumar D, 2009, J IMMUNOL, V182, P1011, DOI 10.4049/jimmunol.182.2.1011; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; Lajoix AD, 2001, DIABETES, V50, P1311, DOI 10.2337/diabetes.50.6.1311; Leibiger IB, 2005, CELL METAB, V2, P80, DOI 10.1016/j.cmet.2005.07.006; Leiper J, 2007, NAT MED, V13, P198, DOI 10.1038/nm1543; Liadis N, 2007, DIABETES, V56, P2302, DOI 10.2337/db06-1771; Liew CW, 2010, J CLIN INVEST, V120, P2876, DOI 10.1172/JCI36849; Moeenrezakhanlou A, 2007, J LEUKOCYTE BIOL, V81, P1311, DOI 10.1189/jlb.1106681; Nagamatsu S, 1999, DIABETES, V48, P2367, DOI 10.2337/diabetes.48.12.2367; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qader SS, 2007, AM J PHYSIOL-ENDOC M, V292, pE1447, DOI 10.1152/ajpendo.00172.2006; Ramsey KM, 2008, AGING CELL, V7, P78, DOI 10.1111/j.1474-9726.2007.00355.x; Rogstam A, 2007, BIOCHEM J, V401, P353, DOI 10.1042/BJ20060918; Sauter NS, 2008, ENDOCRINOLOGY, V149, P2208, DOI 10.1210/en.2007-1059; Shankar RR, 2000, DIABETES, V49, P684, DOI 10.2337/diabetes.49.5.684; Sorrenti V, 2006, CURR NEUROVASC RES, V3, P49, DOI 10.2174/156720206775541778; Sydow K, 2003, ATHEROSCLEROSIS SUPP, V4, P41, DOI 10.1016/S1567-5688(03)00033-3; Sydow K, 2008, ARTERIOSCL THROM VAS, V28, P692, DOI 10.1161/ATVBAHA.108.162073; Tanaka M, 2006, J HYPERTENS, V24, P489, DOI 10.1097/01.hjh.0000209985.66853.1e; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Wagner L, 2000, J BIOL CHEM, V275, P24740, DOI 10.1074/jbc.M001974200; Wang D, 2007, CIRC RES, V101, P627, DOI 10.1161/CIRCRESAHA.107.158915; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Xin HY, 2007, THROMB HAEMOSTASIS, V97, P830, DOI 10.1160/TH06-11-0656; Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014; Yuan Q, 2010, CLIN EXP PHARMACOL P, V37, P630, DOI 10.1111/j.1440-1681.2010.05368.x	46	25	25	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2301	2315		10.1096/fj.12-226092	http://dx.doi.org/10.1096/fj.12-226092			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430976				2022-12-28	WOS:000319667600020
J	Taylor, CR; Hanna, M; Behnke, BJ; Stabley, JN; McCullough, DJ; Davis, RT; Ghosh, P; Papadopoulos, A; Muller-Delp, JM; Delp, MD				Taylor, Curtis R.; Hanna, Mina; Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Ghosh, Payal; Papadopoulos, Anthony; Muller-Delp, Judy M.; Delp, Michael D.			Spaceflight-induced alterations in cerebral artery vasoconstrictor, mechanical, and structural properties: implications for elevated cerebral perfusion and intracranial pressure	FASEB JOURNAL			English	Article						microgravity; brain blood flow; hemodynamics	REGIONAL BLOOD-FLOW; HEAD-DOWN-TILT; SIMULATED MICROGRAVITY; HINDLIMB SUSPENSION; MESENTERIC-ARTERY; CO2 REACTIVITY; AUTOREGULATION; RESPONSIVENESS; RESISTANCE; ADAPTATION	Evidence indicates that cerebral blood flow is both increased and diminished in astronauts on return to Earth. Data from ground-based animal models simulating the effects of microgravity have shown that decrements in cerebral perfusion are associated with enhanced vasoconstriction and structural remodeling of cerebral arteries. Based on these results, the purpose of this study was to test the hypothesis that 13 d of spaceflight [Space Transportation System (STS)-135 shuttle mission] enhances myogenic vasoconstriction, increases medial wall thickness, and elicits no change in the mechanical properties of mouse cerebral arteries. Basilar and posterior communicating arteries (PCAs) were isolated from 9-wk-old female C57BL/6 mice for in vitro vascular and mechanical testing. Contrary to that hypothesized, myogenic vasoconstrictor responses were lower and vascular distensibility greater in arteries from spaceflight group (SF) mice (n = 7) relative to ground-based control group (GC) mice (n = 12). Basilar artery maximal diameter was greater in SF mice (SF: 236 +/- 9 mu m and GC: 215 +/- 5 mu m) with no difference in medial wall thickness (SF: 12.4 +/- 1.6 mu m; GC: 12.2 +/- 1.2 mu m). Stiffness of the PCA, as characterized via nanoindentation, was lower in SF mice (SF: 3.4 +/- 0.3 N/m; GC: 5.4 +/- 0.8 N/m). Collectively, spaceflight-induced reductions in myogenic vasoconstriction and stiffness and increases in maximal diameter of cerebral arteries signify that elevations in brain blood flow may occur during spaceflight. Such changes in cerebral vascular control of perfusion could contribute to increases in intracranial pressure and an associated impairment of visual acuity in astronauts during spaceflight.-Taylor, C. R., Hanna, M., Behnke, B. J., Stabley, J. N., McCullough, D. J., Davis III, R. T., Ghosh, P., Papadopoulos, A., Muller-Delp, J. M., Delp, M. D. Spaceflight-induced alterations in cerebral artery vasoconstrictor, mechanical, and structural properties: implications for elevated cerebral perfusion and intracranial pressure.	[Taylor, Curtis R.; Hanna, Mina] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL USA; [Hanna, Mina] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA; [Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Ghosh, Payal; Delp, Michael D.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32610 USA; [Behnke, Bradley J.; Stabley, John N.; McCullough, Danielle J.; Davis, Robert T., III; Ghosh, Payal; Delp, Michael D.] Univ Florida, Ctr Exercise Sci, Gainesville, FL 32611 USA; [Muller-Delp, Judy M.] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL USA; [Papadopoulos, Anthony] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Texas Tech University System; Texas Tech University	Delp, MD (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32610 USA.	mdelp@ufl.edu	Taylor, Curtis/GWR-1891-2022; Taylor, Curtis/J-6236-2013	Taylor, Curtis/0000-0001-9184-5487; /0000-0002-1825-7846; Delp, Michael/0000-0002-2916-0783; Muller-Delp, Judy/0000-0001-5322-0611	NASA [NNX08AQ62G, NNX09AP06G]; U.S. National Institutes of Health [AG-31317]; Florida Biomedical Research Program [1BN-02]; Department of Applied Physiology and Kinesiology, University of Florida	NASA(National Aeronautics & Space Administration (NASA)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Biomedical Research Program; Department of Applied Physiology and Kinesiology, University of Florida	These studies were originally flown on space shuttle mission STS-107, on which the orbiter Columbia tragically disintegrated during its return flight to Earth. This article is dedicated to the STS-107 crew, who were willing to risk their lives to advance our understanding of the effects of microgravity on human health. The authors thank Paula Dumars, Marilyn Vasquez, Vera Vizir, Marianne Steele, Richard Boyle, and Ken Souza [U.S. National Aeronautics and Space Administration (NASA) Ames Research Center, Mountain View, CA, USA] and the Life Sciences staff at NASA Kennedy Space Center (Kennedy Space Center, FL, USA) for logistical support; Thomas Wyrobek, Richard Nay, Lance Kuhn, and Amanda Simpson (Hysitron, Minneapolis, MN, USA) and Donna Ebenstein (Bucknell University, Lewisburg, PA, USA) for assistance with nanoindentation experiments; Dr. Olga Tarasova (Moscow State University, Moscow, Russia) for assistance with the Russian cosmonaut literature; and NASA for providing shuttle CO<INF>2</INF> data from the STS-135 mission. This study was supported by grants from NASA (NNX08AQ62G and NNX09AP06G), U.S. National Institutes of Health (AG-31317), and the Florida Biomedical Research Program (1BN-02) and the Jane Adams Edmonds endowed doctoral fellowship (Department of Applied Physiology and Kinesiology, University of Florida).	Aaslid R, 2006, FRONT NEUROL NEUROSC, V21, P216, DOI 10.1159/000092434; Akhtar R, 2009, J MATER RES, V24, P638, DOI 10.1557/JMR.2009.0130; Arbeille P, 1995, ACTA ASTRONAUT, V36, P753, DOI 10.1016/0094-5765(95)00166-2; Arbeille P, 2001, EUR J APPL PHYSIOL, V86, P157, DOI 10.1007/s004210100473; Arbeille P, 1996, MED SCI SPORT EXER, V28, pS70; BAGIAN JP, 1991, J CLIN PHARMACOL, V31, P1036, DOI 10.1002/j.1552-4604.1991.tb03668.x; Behnke BJ, 2008, J APPL PHYSIOL, V104, P1273, DOI 10.1152/japplphysiol.00954.2006; Behnke BJ, 2013, FASEB J, V27, P399, DOI 10.1096/fj.12-218503; Blaber AP, 2011, STROKE, V42, P1844, DOI 10.1161/STROKEAHA.110.610576; Buckey JC, 1996, J APPL PHYSIOL, V81, P19, DOI 10.1152/jappl.1996.81.1.19; Colleran PN, 2008, AM J PHYSIOL-REG I, V294, pR1577, DOI 10.1152/ajpregu.00084.2008; Colleran PN, 2000, J APPL PHYSIOL, V89, P1046, DOI 10.1152/jappl.2000.89.3.1046; DELP MD, 1993, J APPL PHYSIOL, V75, P2620, DOI 10.1152/jappl.1993.75.6.2620; Delp MD, 2000, AM J PHYSIOL-HEART C, V278, pH1866, DOI 10.1152/ajpheart.2000.278.6.H1866; Delp MD, 1999, J APPL PHYSIOL, V86, P1178, DOI 10.1152/jappl.1999.86.4.1178; DESPLANCHES D, 1987, J APPL PHYSIOL, V63, P1739, DOI 10.1152/jappl.1987.63.5.1739; Dunbar SL, 2000, J APPL PHYSIOL, V89, P2073, DOI 10.1152/jappl.2000.89.5.2073; Ebenstein DM, 2004, J BIOMED MATER RES A, V69A, P222, DOI 10.1002/jbm.a.20096; Ebenstein DM, 2004, J MATER RES, V19, P273, DOI 10.1557/jmr.2004.19.1.273; Ebenstein DM, 2009, J BIOMED MATER RES A, V91A, P1028, DOI 10.1002/jbm.a.32321; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Gashev AA, 2006, AM J PHYSIOL-HEART C, V290, pH2295, DOI 10.1152/ajpheart.00260.2005; Geary GG, 1998, J APPL PHYSIOL, V85, P1615, DOI 10.1152/jappl.1998.85.5.1615; Hargens AR., 1984, PHYSIOLOGIST, V27, pS37; Hatton DC, 2002, J APPL PHYSIOL, V92, P13, DOI 10.1152/jappl.2002.92.1.13; Iwasaki KI, 2007, J PHYSIOL-LONDON, V579, P799, DOI 10.1113/jphysiol.2006.119636; Jain V, 2011, J CEREBR BLOOD F MET, V31, P1504, DOI 10.1038/jcbfm.2011.34; Kondo T, 1999, CHEST, V115, P1402, DOI 10.1378/chest.115.5.1402; Kramer LA, 2012, RADIOLOGY, V263, P819, DOI 10.1148/radiol.12111986; Lakin WD, 2007, AVIAT SPACE ENVIR MD, V78, P932, DOI 10.3357/ASEM.2060.2007; Lin DC, 2008, SOFT MATTER, V4, P669, DOI 10.1039/b714637j; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; Maurel D, 1996, BRAIN RES, V736, P165, DOI 10.1016/0006-8993(96)00676-2; McCurdy MR, 2000, J APPL PHYSIOL, V89, P398, DOI 10.1152/jappl.2000.89.1.398; MCDONALD KS, 1992, J APPL PHYSIOL, V72, P2210, DOI 10.1152/jappl.1992.72.6.2210; MOSKALENKO YE, 1975, AVIAT SPACE ENVIR MD, V46, P1023; NASA, 2012, EVIDENCE REPORT RISK; Oliver WC, 2004, J MATER RES, V19, P3, DOI 10.1557/jmr.2004.19.1.3; OVERTON JM, 1989, J APPL PHYSIOL, V66, P653, DOI 10.1152/jappl.1989.66.2.653; Pourcelot L, 1984, ESA, P119; Powers J, 2004, J APPL PHYSIOL, V97, P1686, DOI 10.1152/japplphysiol.00925.2003; Prisby RD, 2006, J APPL PHYSIOL, V101, P348, DOI 10.1152/japplphysiol.00941.2005; Provost S B, 1992, Physiologist, V35, pS105; Purdy RE, 1998, J APPL PHYSIOL, V85, P1307, DOI 10.1152/jappl.1998.85.4.1307; SANDLER H, 1987, AVIAT SPACE ENVIR MD, V58, P529; Schob OM, 1996, AM J SURG, V172, P248, DOI 10.1016/S0002-9610(96)00101-8; Small SA, 2004, J CLIN INVEST, V114, P1046, DOI 10.1172/JCI200423159; SNEDDON IN, 1948, P CAMB PHILOS SOC, V44, P492, DOI 10.1017/S0305004100024518; Stabley JN, 2012, J APPL PHYSIOL, V113, P1439, DOI 10.1152/japplphysiol.00772.2012; Sun B, 2004, J APPL PHYSIOL, V97, P1022, DOI 10.1152/japplphysiol.00188.2004; Sun GS, 2010, NUTRITION, V26, P1163, DOI 10.1016/j.nut.2009.09.018; Tuday EC, 2007, J APPL PHYSIOL, V102, P853, DOI 10.1152/japplphysiol.00950.2006; Turchaninova V F, 1989, Kosm Biol Aviakosm Med, V23, P19; Ursino M, 1998, AM J PHYSIOL-HEART C, V274, pH1715, DOI 10.1152/ajpheart.1998.274.5.H1715; VASILYEVA TD, 1982, KOSM BIOL AVIAK MED+, V16, P12; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; WATENPAUGH DE, 1996, HDB PHYSIOL SECT 4, V1, P631; Wilkerson MK, 2005, AM J PHYSIOL-HEART C, V288, pH1652, DOI 10.1152/ajpheart.00925.2004; Wilkerson MK, 2002, AM J PHYSIOL-HEART C, V282, pH328, DOI 10.1152/ajpheart.00727.2001; Wilkerson MK, 1999, J APPL PHYSIOL, V87, P2115, DOI 10.1152/jappl.1999.87.6.2115; Willie CK, 2012, J PHYSIOL-LONDON, V590, P3261, DOI 10.1113/jphysiol.2012.228551; Xue JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019775; YARULLIN KK, 1984, KOSM BIOL AVIAK MED+, V18, P22; Yegorov AD., 1982, IZVESTIYA AKAD NAUK, V4, P485; Zhang LN, 2001, J APPL PHYSIOL, V90, P2296, DOI 10.1152/jappl.2001.90.6.2296; Zhang R, 1997, J APPL PHYSIOL, V83, P2139, DOI 10.1152/jappl.1997.83.6.2139; Zuj KA, 2012, AM J PHYSIOL-HEART C, V302, pH2592, DOI 10.1152/ajpheart.00029.2012	67	62	66	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2282	2292		10.1096/fj.12-222687	http://dx.doi.org/10.1096/fj.12-222687			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457215	Green Published			2022-12-28	WOS:000319667600018
J	Gregus, AM; Dumlao, DS; Wei, SC; Norris, PC; Catella, LC; Meyerstein, FG; Buczynski, MW; Steinauer, JJ; Fitzsimmons, BL; Yaksh, TL; Dennis, EA				Gregus, Ann M.; Dumlao, Darren S.; Wei, Spencer C.; Norris, Paul C.; Catella, Laura C.; Meyerstein, Flore G.; Buczynski, Matthew W.; Steinauer, Joanne J.; Fitzsimmons, Bethany L.; Yaksh, Tony L.; Dennis, Edward A.			Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia	FASEB JOURNAL			English	Article						pain; eicosanoid; Aloxe3	POSITIONAL SPECIFICITY; FUNCTIONAL EXPRESSION; SELECTIVE INHIBITORS; GENOMIC STRUCTURE; ARACHIDONIC-ACID; CELL-DEATH; 12-LIPOXYGENASE; LIPOXYGENASE; GENE; CLONING	Previously, we observed significant increases in spinal 12-lipoxygenase (LOX) metabolites, in particular, hepoxilins, which contribute to peripheral inflammation-induced tactile allodynia. However, the enzymatic sources of hepoxilin synthase (HXS) activity in rats remain elusive. Therefore, we overexpressed each of the 6 rat 12/15-LOX enzymes in HEK-293T cells and measured by LC-MS/MS the formation of HXB3, 12-HETE, 8-HETE, and 15-HETE from arachidonic acid (AA) at baseline and in the presence of LOX inhibitors (NDGA, AA-861, CDC, baicalein, and PD146176) vs. vehicle-treated and mock-transfected controls. We detected the following primary intrinsic activities: 12-LOX (Alox12, Alox15), 15-LOX (Alox15b), and HXS (Alox12, Alox15). Similar to human and mouse orthologs, proteins encoded by rat Alox12b and Alox12e possessed minimal 12-LOX activity with AA as substrate, while eLOX3 (encoded by Aloxe3) exhibited HXS without 12-LOX activity when coexpressed with Alox12b or supplemented with 12-HpETE. CDC potently inhibited HXS and 12-LOX activity in vitro (relative IC(50)s: CDC, similar to 0.5 and 0.8 mu M, respectively) and carrageenan-evoked tactile allodynia in vivo. Notably, peripheral inflammation significantly increased spinal eLOX3; intrathecal pretreatment with either siRNA targeting Aloxe3 or an eLOX3-selective antibody attenuated the associated allodynia. These findings implicate spinal eLOX3-mediated hepoxilin synthesis in inflammatory hyperesthesia and underscore the importance of developing more selective 12-LOX/HXS inhibitors.-Gregus, A. M., Dumlao, D. S., Wei, S. C., Norris, P. C., Catella, L. C., Meyerstein, F. G., Buczynski, M. W., Steinauer, J. J., Fitzsimmons, B. L., Yaksh, T. L., Dennis, E. A. Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia. FASEB J. 27, 1939-1949 (2013). www.fasebj.org	[Gregus, Ann M.; Catella, Laura C.; Meyerstein, Flore G.; Steinauer, Joanne J.; Fitzsimmons, Bethany L.; Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Dumlao, Darren S.; Norris, Paul C.; Buczynski, Matthew W.; Dennis, Edward A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Dumlao, Darren S.; Wei, Spencer C.; Yaksh, Tony L.; Dennis, Edward A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Yaksh, TL (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	tyaksh@ucsd.edu; edennis@ucsd.edu	Dennis, Edward A./M-5554-2019; Yaksh, Tony/D-4119-2009	Dennis, Edward A./0000-0003-3738-3140; Norris, Paul/0000-0003-2512-0829	U.S. National Institutes of Health [NS16541, DA02110, GM064611, GM069338]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338, R01GM064611, T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016541, R37NS016541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002110] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Dr. Jing Yang for sharing equipment and Drs. Xiao-Ying Hua, Camilla I. Svensson, and Qinghao Xu for helpful discussions. This work was supported by U.S. National Institutes of Health grants NS16541 and DA02110 (T.L.Y.) and GM064611 and GM069338 (E.A.D.).	Aley KO, 2003, EXP BRAIN RES, V148, P482, DOI 10.1007/s00221-002-1323-2; ASHIDA Y, 1983, PROSTAGLANDINS, V26, P955, DOI 10.1016/0090-6980(83)90157-0; BENDANI MK, 1995, NEUROSCI LETT, V189, P159, DOI 10.1016/0304-3940(95)11482-C; Buczynski MW, 2010, J NEUROCHEM, V114, P981, DOI 10.1111/j.1471-4159.2010.06815.x; Buczynski MW, 2009, J LIPID RES, V50, P1015, DOI 10.1194/jlr.R900004-JLR200; Burger F, 2000, BIOCHEM J, V348, P329, DOI 10.1042/bj3480329; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; Christianson CA, 2010, PAIN, V151, P394, DOI 10.1016/j.pain.2010.07.030; Cornicelli JA, 1999, CURR PHARM DESIGN, V5, P11; Dobrian AD, 2011, PROG LIPID RES, V50, P115, DOI 10.1016/j.plipres.2010.10.005; Epp N, 2007, J CELL BIOL, V177, P173, DOI 10.1083/jcb.200612116; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; Gong YZ, 2008, EUR J PHARMACOL, V600, P18, DOI 10.1016/j.ejphar.2008.10.010; Gregus AM, 2012, P NATL ACAD SCI USA, V109, P6721, DOI 10.1073/pnas.1110460109; Hallenborg P, 2010, MOL CELL BIOL, V30, P4077, DOI 10.1128/MCB.01806-08; Harmon GS, 2010, NAT MED, V16, P313, DOI 10.1038/nm.2101; Ivanov I, 2010, ARCH BIOCHEM BIOPHYS, V503, P161, DOI 10.1016/j.abb.2010.08.016; Jacquot C, 2008, BIOCHEMISTRY-US, V47, P7295, DOI 10.1021/bi800308q; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kawajiri H, 2000, J HISTOCHEM CYTOCHEM, V48, P1411, DOI 10.1177/002215540004801011; Kenyon V, 2011, J MED CHEM, V54, P5485, DOI 10.1021/jm2005089; Krieg P, 1999, FEBS LETT, V446, P142, DOI 10.1016/S0014-5793(99)00196-9; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; Krieg P, 2013, J INVEST DERMATOL, V133, P172, DOI 10.1038/jid.2012.250; Kronke G, 2009, J IMMUNOL, V183, P3383, DOI 10.4049/jimmunol.0900327; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo MC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-29; Malkmus SA, 2004, METH MOLEC MED, P109; McDonnell M, 2001, PROSTAG OTH LIPID M, V63, P93, DOI 10.1016/S0090-6980(00)00100-3; MITA H, 1986, ALLERGY, V41, P493, DOI 10.1111/j.1398-9995.1986.tb00334.x; Moran JL, 2007, J INVEST DERMATOL, V127, P1893, DOI 10.1038/sj.jid.5700825; Mrsny RJ, 2004, P NATL ACAD SCI USA, V101, P7421, DOI 10.1073/pnas.0400832101; Nair DG, 2009, PROSTAG OTH LIPID M, V90, P98, DOI 10.1016/j.prostaglandins.2009.09.006; Nigam S, 2004, J BIOL CHEM, V279, P29023, DOI 10.1074/jbc.M307576200; NIGAM S, 1990, BIOCHEM BIOPH RES CO, V171, P944, DOI 10.1016/0006-291X(90)90775-I; Obrosova IG, 2010, AM J PATHOL, V177, P1436, DOI 10.2353/ajpath.2010.100178; Pace-Asciak CR, 2009, BRIT J PHARMACOL, V158, P972, DOI 10.1111/j.1476-5381.2009.00168.x; Pergola C, 2011, J PHARMACOL EXP THER, V338, P205, DOI 10.1124/jpet.111.180794; Rai G, 2010, J MED CHEM, V53, P7392, DOI 10.1021/jm1008852; Saito O, 2010, BRIT J PHARMACOL, V160, P1754, DOI 10.1111/j.1476-5381.2010.00811.x; SEKIYA K, 1982, BIOCHEM BIOPH RES CO, V105, P1090, DOI 10.1016/0006-291X(82)91081-6; Shen YC, 2003, EUR J PHARMACOL, V465, P171, DOI 10.1016/S0014-2999(03)01378-5; Shibasaki M, 2010, PAIN, V149, P514, DOI 10.1016/j.pain.2010.03.023; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Suk K, 2003, J PHARMACOL EXP THER, V305, P638, DOI 10.1124/jpet.102.047373; Sun D, 1998, CYTOGENET CELL GENET, V81, P79, DOI 10.1159/000014993; Sun DX, 1998, J BIOL CHEM, V273, P33540, DOI 10.1074/jbc.273.50.33540; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Trang T, 2004, EUR J PHARMACOL, V491, P21, DOI 10.1016/j.ejphar.2004.03.022; Wang H, 2004, EUR J NEUROSCI, V20, P2049, DOI 10.1111/j.1460-9568.2004.03650.x; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519; Wu MY, 2012, J CELL BIOCHEM, V113, P2279, DOI 10.1002/jcb.24098; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; Yoo S, 2009, MOL CELLS, V27, P417, DOI 10.1007/s10059-009-0059-2; Yu ZY, 2006, ARCH BIOCHEM BIOPHYS, V455, P188, DOI 10.1016/j.abb.2006.09.002; Yu ZY, 2003, P NATL ACAD SCI USA, V100, P9162, DOI 10.1073/pnas.1633612100	60	30	37	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1939	1949		10.1096/fj.12-217414	http://dx.doi.org/10.1096/fj.12-217414			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23382512	Green Submitted, Green Published			2022-12-28	WOS:000318226100014
J	Berndt, S; Blacher, S; Munaut, C; Detilleux, J; d'Hauterive, SP; Huhtaniemi, I; Evain-Brion, D; Noel, A; Fournier, T; Foidart, JM				Berndt, Sarah; Blacher, Silvia; Munaut, Carine; Detilleux, Julien; d'Hauterive, Sophie Perrier; Huhtaniemi, Ilpo; Evain-Brion, Daniele; Noel, Agnes; Fournier, Thierry; Foidart, Jean-Michel			Hyperglycosylated human chorionic gonadotropin stimulates angiogenesis through TGF-beta receptor activation	FASEB JOURNAL			English	Article						angiostimulation; mural cells; endothelial cells; placenta; choriocarcinoma	GROWTH-FACTOR-BETA; GESTATIONAL TROPHOBLASTIC DISEASES; HUMAN FETOPLACENTAL VASCULOGENESIS; VASCULAR SMOOTH-MUSCLE; INVASIVE TROPHOBLAST; CELL-PROLIFERATION; HCG-BETA; IN-VITRO; ENDOGLIN; EXPRESSION	Embryo implantation requires extensive angiogenesis at the maternal-fetal interface. Hyperglycosylated human chorionic gonadotropin (hCG-H), a trophoblast invasive signal produced by extravillous cytotrophoblasts and by choriocarcinoma, was evaluated for its angiogenic role. hCG-H was purified by HPLC from choriocarcinoma supernatant, and the glycosylation pattern was determined by 2D gel analysis. Angiogenesis models used were aortic ring assay with wild-type and LHCGR-knockout mice, endothelial and mural cell proliferation, and migration assays. The TGF-beta signaling pathway was studied by coimmunoprecipitation, competitive binding, TGF-beta reporter gene assays, and Smad immunoblotting. hCG-H displayed a potent angiogenic effect [3.2-fold increase of number of vessel intersections in wild-type aortic rings (11.406 to 36.964)]. hCG-H-induced angiostimulation was independent of the classic hCG signaling pathway since it persisted in LHCGR-knockout mice [4.73-fold increase of number of vessel intersections (10.826 to 51.288)]. Using TGF-beta signaling inhibitors, T beta-RII was identified as the hCG-H receptor responsible for its angiogenic switch. hCG-H exposure enhanced phosphorylation of Smad 2 in endothelial and mural cells and genomic activation of Smad-responsive elements. Interaction between hCG-H and T beta-RII was demonstrated by coimmunoprecipitation and binding competition with I-125-TGF-beta. This new paracrine interaction between trophoblast and endothelial cells through the hCG-H and the TGF-beta receptor complex plays a key role in angiogenesis associated with placental development and tumorigenesis.-Berndt, S., Blacher, S., Munaut, C., Detilleux, J., Perrier d'Hauterive, S., Huhtaniemi, I., Evain-Brion, D., Noel, A., Fournier, T., Foidart, J.-M. Hyperglycosylated human chorionic gonadotropin stimulates angiogenesis through TGF-beta receptor activation. FASEB J. 27, 1309-1321 (2013). www.fasebj.org	[Berndt, Sarah; Evain-Brion, Daniele; Fournier, Thierry] INSERM, UMRS 767, F-75006 Paris, France; [Berndt, Sarah; Evain-Brion, Daniele; Fournier, Thierry] Univ Paris 05, Paris, France; [Berndt, Sarah; Evain-Brion, Daniele; Fournier, Thierry] PremUP Fondat, Paris, France; [Blacher, Silvia; Munaut, Carine; Detilleux, Julien; Noel, Agnes; Foidart, Jean-Michel] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Liege, Belgium; [d'Hauterive, Sophie Perrier] Univ Liege, Ctr Immunol, Liege, Belgium; [Huhtaniemi, Ilpo] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England; [d'Hauterive, Sophie Perrier; Foidart, Jean-Michel] CHR, Dept Obstet & Gynecol, Liege, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Liege; University of Liege; Imperial College London	Fournier, T (corresponding author), INSERM, U767, 4 Ave Observ, F-75006 Paris, France.	thierry.fournier@parisdescartes.fr	Munaut, Carine/K-8138-2019; Fournier, Thierry C/E-5836-2016	Noel, Agnes/0000-0002-7670-6179; Fournier, Thierry/0000-0002-7515-339X	European 7th Research Framework Programme [HEALTH-2007-2.4.1-6, LSHM-CT-2004-512040]; European Network of Excellence on Embryo Implantation Control (EMBIC); Fonds de la Recherche Scientifique Medicale; Fonds National de la Recherche Scientifique (FNRS; Belgium); Fondation contre le Cancer; Fonds Speciaux Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Frederieq (University of Liege); Direction Generale des Technologies, de la Recherche et de l'Energie (DGTRE) of the Region Wallonne (NEOANGIO); Fonds Social Europeen (FSE); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium); PremUp Fondation; Rotary Foundation	European 7th Research Framework Programme; European Network of Excellence on Embryo Implantation Control (EMBIC); Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Fonds National de la Recherche Scientifique (FNRS; Belgium)(Fonds de la Recherche Scientifique - FNRS); Fondation contre le Cancer; Fonds Speciaux Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Frederieq (University of Liege); Direction Generale des Technologies, de la Recherche et de l'Energie (DGTRE) of the Region Wallonne (NEOANGIO); Fonds Social Europeen (FSE)(European Social Fund (ESF)); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office); PremUp Fondation; Rotary Foundation	The authors thank J. Guibourdenche for the progesterone measurements and F. Olivier, P. Gavitelli, D. Gabriel-Delapierre, L. Volders, M. R. Pignon, F. Bouillenne, A. M. Matton, I. Thamm, and G. Roland for their excellent technical assistance. The authors warmly thank Dr. J. Badet for advice, protocols, and data analyses of <SUP>125</SUP>I-TGF-beta binding experiments; J. Guibourdenche for radioimmunoassay facilities at Assistance Publique-Hopitaux de Paris Cochin Hospital (Paris, France); ZenTech S. A. (Liege Science Park, Angleur, Belgium) for radioactive iodation; and Prof J. Moreau for binding experiment data analysis. This work was supported by grants from the European 7th Research Framework Programme: HEALTH-2007-2.4.1-6, MICROENVIMET; Framework Programme 6-NOE no LSHM-CT-2004-512040; the European Network of Excellence on Embryo Implantation Control (EMBIC); the Fonds de la Recherche Scientifique Medicale; the Fonds National de la Recherche Scientifique (FNRS; Belgium); the Fondation contre le Cancer; the Fonds Speciaux Recherche (University of Liege); the Centre Anticancereux pres l'Universite de Liege; the Fonds Leon Frederieq (University of Liege); the Direction Generale des Technologies, de la Recherche et de l'Energie (DGTRE) of the Region Wallonne (NEOANGIO); the Fonds Social Europeen (FSE); the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium); the PremUp Fondation; and the Rotary Foundation.	ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Berndt S, 2006, FASEB J, V20, P2630, DOI 10.1096/fj.06-5885fje; Berndt S, 2009, J CLIN ENDOCR METAB, V94, P4567, DOI 10.1210/jc.2009-0443; Bersinger NA, 2008, FETAL DIAGN THER, V24, P74, DOI 10.1159/000132412; Birken S, 2003, CLIN CHEM, V49, P144, DOI 10.1373/49.1.144; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Butler SA, 2000, BRIT J CANCER, V82, P1553; Caniggia I, 1997, ENDOCRINOLOGY, V138, P4977, DOI 10.1210/en.138.11.4977; Charnock-Jones DS, 2004, PLACENTA, V25, P103, DOI 10.1016/j.placenta.2003.10.004; Chung IB, 2000, PLACENTA, V21, P320, DOI 10.1053/plac.1999.0481; Cole LA, 2007, PLACENTA, V28, P977, DOI 10.1016/j.placenta.2007.01.011; Cole LA, 2010, PLACENTA, V31, P653, DOI 10.1016/j.placenta.2010.06.005; Cole LA, 1997, CLIN CHEM, V43, P2233; Cole LA, 2008, J REPROD MED, V53, P499; Cole LA, 2006, J REPROD MED, V51, P919; Cole LA, 2006, GYNECOL ONCOL, V102, P145, DOI 10.1016/j.ygyno.2005.12.047; Cole LA, 2006, GYNECOL ONCOL, V102, P151, DOI 10.1016/j.ygyno.2005.12.045; Cole LA, 2012, AM J CANCER RES, V2, P22; Cole LA, 2012, MOL CELL ENDOCRINOL, V349, P232, DOI 10.1016/j.mce.2011.10.029; Cole LA, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-102; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dimitriadis E, 2005, HUM REPROD UPDATE, V11, P613, DOI 10.1093/humupd/dmi023; FEINBERG RF, 1994, J CLIN ENDOCR METAB, V78, P1241, DOI 10.1210/jc.78.5.1241; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; Goumans MJ, 1999, DEVELOPMENT, V126, P3473; Guibourdenche J, 2010, J CLIN ENDOCR METAB, V95, pE240, DOI 10.1210/jc.2010-0138; Hamada AL, 2005, J CLIN ENDOCR METAB, V90, P4873, DOI 10.1210/jc.2004-2458; Handschuh K, 2007, PLACENTA, V28, P175, DOI 10.1016/j.placenta.2006.01.019; Handschuh K, 2007, ENDOCRINOLOGY, V148, P5011, DOI 10.1210/en.2007-0286; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Herrler Andreas, 2003, Reprod Biomed Online, V6, P244; Hungerford JE, 1996, DEV BIOL, V178, P375, DOI 10.1006/dbio.1996.0225; Iles RK, 2010, MOL CELL ENDOCRINOL, V329, P62, DOI 10.1016/j.mce.2010.07.014; Iles RK, 2010, MOL CELL ENDOCRINOL, V329, P1, DOI 10.1016/j.mce.2010.07.024; Ingman WV, 2002, BIOESSAYS, V24, P904, DOI 10.1002/bies.10155; IRVING JA, 1995, EXP CELL RES, V217, P419, DOI 10.1006/excr.1995.1105; Kaufmann P, 2004, PLACENTA, V25, P114, DOI 10.1016/j.placenta.2003.10.009; Khoo NKS, 1998, INT J CANCER, V77, P429, DOI 10.1002/(SICI)1097-0215(19980729)77:3<429::AID-IJC20>3.0.CO;2-1; KORNYEI JL, 1993, BIOL REPROD, V49, P1149, DOI 10.1095/biolreprod49.6.1149; Kovalevskaya G, 2007, MOL CELL ENDOCRINOL, V260, P237, DOI 10.1016/j.mce.2006.02.021; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; MYOKEN Y, 1990, EXP CELL RES, V191, P299, DOI 10.1016/0014-4827(90)90018-6; Orlova VV, 2011, HISTOL HISTOPATHOL, V26, P1219, DOI 10.14670/HH-26.1219; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Sasaki Y, 2008, FERTIL STERIL, V89, P1781, DOI 10.1016/j.fertnstert.2007.03.010; TOTH P, 1994, J CLIN ENDOCR METAB, V79, P307, DOI 10.1210/jc.79.1.307; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172; Zygmunt M, 2003, EUR J OBSTET GYN R B, V110, pS10, DOI 10.1016/S0301-2115(03)00168-4; Zygmunt M, 2002, J CLIN ENDOCR METAB, V87, P5290, DOI 10.1210/jc.2002-020642	54	69	74	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1309	1321		10.1096/fj.12-213686	http://dx.doi.org/10.1096/fj.12-213686			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23233533				2022-12-28	WOS:000316940800004
J	Cieslik, KA; Trial, J; Carlson, S; Taffet, GE; Entman, ML				Cieslik, Katarzyna A.; Trial, JoAnn; Carlson, Signe; Taffet, George E.; Entman, Mark L.			Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels	FASEB JOURNAL			English	Article						mesenchymal stem cell; collagen	MESENCHYMAL STEM-CELLS; HUMAN-SKIN FIBROBLASTS; GROWTH-FACTOR-BETA; TGF-BETA; MYOFIBROBLAST FORMATION; MEDIATED ACTIVATION; PULMONARY-FIBROSIS; SIGNALING PATHWAYS; LUNG FIBROBLASTS; AGING HEART	With age, the collagen content of the heart increases, leading to interstitial fibrosis. We have shown that CD44(pos) fibroblasts derived from aged murine hearts display reduced responsiveness to TGF-beta but, paradoxically, have increased collagen expression in vivo and in vitro. We postulated that this phenomenon was due to the defect in mesenchymal stem cell (MSC) differentiation in a setting of elevated circulating insulin levels and production that we observed in aging mice. We discovered that cultured fibroblasts derived from aged but not young cardiac MSCs of nonhematopoietic lineage displayed increased basal and insulin-induced (1 nM) collagen expression (2-fold), accompanied by increased farnesyltransferase (FTase) and Erk activities. In a quest for a possible mechanism, we found that a chronic pathophysiologic insulin concentration (1 nM) caused abnormal fibroblast differentiation of MSCs isolated from young hearts. Fibroblasts derived from these MSCs responded to insulin by elevating collagen expression as seen in untreated aged fibroblast cultures, suggesting a causal link between increased insulin levels and defective MSC responses. Here we report an insulin-dependent pathway that specifically targets collagen type I transcriptional activation leading to a unique mechanism of fibrosis that is TGF-beta and inflammation-independent in the aged heart.-Cieslik, K. A., Trial, J., Carlson, S., Taffet, G. E., Entman, M. L. Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB J. 27, 1761-1771 (2013). www.fasebj.org	[Cieslik, Katarzyna A.; Trial, JoAnn; Taffet, George E.; Entman, Mark L.] Baylor Coll Med, Div Cardiovasc Sci, Houston, TX 77030 USA; [Cieslik, Katarzyna A.; Trial, JoAnn; Taffet, George E.; Entman, Mark L.] Baylor Coll Med, DeBakey Heart Ctr, Dept Med, Houston, TX 77030 USA; [Carlson, Signe] Univ Washington, Dept Med, Seattle, WA USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; University of Washington; University of Washington Seattle	Cieslik, KA (corresponding author), Baylor Coll Med, Div Cardiovasc Sci, Dept Med, 1 Baylor Plaza,Mail Stn BCM620, Houston, TX 77030 USA.	cieslik@bcm.edu	Cieslik, Katarzyna/AAO-1982-2021	Cieslik, Katarzyna/0000-0002-2167-7921; Trial, JoAnn/0000-0001-7145-7786	U.S. National Institutes of Health [R01HL089792, T32HL07816]; Medallion Foundation; Hankamer Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007816, R01HL022512, R01HL089792] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medallion Foundation; Hankamer Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grants R01HL089792 (M. L. E.) and T32HL07816 (S. C.), a Medallion Foundation grant (J.T.), and the Hankamer Foundation. The authors are grateful to Dr. Heinrich Taegtmeyer for critical reading of this manuscript. The authors also thank Dorellyn B. Lee and Hao Zhang for excellent technical assistance. The authors declare no conflicts of interest.	Barzilai N, 1998, J CLIN INVEST, V101, P1353, DOI 10.1172/JCI485; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Carlson S, 2011, CARDIOVASC RES, V91, P99, DOI 10.1093/cvr/cvr061; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chiao YA, 2012, CARDIOVASC RES, V96, P444, DOI 10.1093/cvr/cvs275; Cieslik KA, 2011, AM J PATHOL, V179, P1792, DOI 10.1016/j.ajpath.2011.06.022; Cieslik KA, 2011, J MOL CELL CARDIOL, V50, P248, DOI 10.1016/j.yjmcc.2010.10.019; Debessa CRG, 2001, MECH AGEING DEV, V122, P1049; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; FRAZE E, 1987, J AM GERIATR SOC, V35, P224, DOI 10.1111/j.1532-5415.1987.tb02313.x; Fukasawa H, 2004, KIDNEY INT, V65, P63, DOI 10.1111/j.1523-1755.2004.00393.x; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; Gagliano N, 2000, J GERONTOL A-BIOL, V55, pB365, DOI 10.1093/gerona/55.8.B365; Gagliano N, 2007, DIGEST DIS, V25, P118, DOI 10.1159/000099475; Glaser J, 2000, GERONTOLOGY, V46, P93, DOI 10.1159/000022141; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone M. L., 2004, DIABETES MELLITUS FU, P422; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; HINTON DE, 1968, J GERONTOL, V23, P205, DOI 10.1093/geronj/23.2.205; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Jones DL, 2011, NAT CELL BIOL, V13, P506, DOI 10.1038/ncb0511-506; Kang HR, 2007, J BIOL CHEM, V282, P7723, DOI 10.1074/jbc.M610764200; KJELLSTROM T, 1984, HORM METAB RES, V16, P168, DOI 10.1055/s-2007-1014734; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Krupsky M, 1996, CONNECT TISSUE RES, V34, P53, DOI 10.3109/03008209609028893; Lakatta EG, 2003, CIRCULATION, V107, P346, DOI 10.1161/01.CIR.0000048893.62841.F7; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC; Mizushige K, 2000, CIRCULATION, V101, P899, DOI 10.1161/01.CIR.101.8.899; Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474-9728.2004.00127.x; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Peyret N, 2000, THESIS WAYNE STATE U; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Shih DTB, 2005, STEM CELLS, V23, P1012, DOI 10.1634/stemcells.2004-0125; Song YX, 1999, FORENSIC SCI INT, V104, P133, DOI 10.1016/S0379-0738(99)00103-6; Spinale FG, 2007, PHYSIOL REV, V87, P1285, DOI 10.1152/physrev.00012.2007; Takeji M, 2006, J BIOL CHEM, V281, P40193, DOI 10.1074/jbc.M602182200; Tang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025320; Teekakirikul P, 2010, J CLIN INVEST, V120, P3520, DOI 10.1172/JCI42028; Watts KL, 2005, AM J RESP CELL MOL, V32, P290, DOI 10.1165/rcmb.2004-0127OC; Xu RH, 2008, CELL STEM CELL, V3, P196, DOI 10.1016/j.stem.2008.07.001; Zhou XP, 2008, P NATL ACAD SCI USA, V105, P17181, DOI 10.1073/pnas.0800846105; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	47	37	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1761	1771		10.1096/fj.12-220145	http://dx.doi.org/10.1096/fj.12-220145			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303205	Green Published			2022-12-28	WOS:000316940800044
J	Flynn, AN; Hoffman, J; Tillu, DV; Sherwood, CL; Zhang, ZY; Patek, R; Asiedu, MNK; Vagner, J; Price, TJ; Boitano, S				Flynn, Andrea N.; Hoffman, Justin; Tillu, Dipti V.; Sherwood, Cara L.; Zhang, Zhenyu; Patek, Renata; Asiedu, Marina N. K.; Vagner, Josef; Price, Theodore J.; Boitano, Scott			Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering	FASEB JOURNAL			English	Article						PAR(2); G-protein coupled receptor; Ca2+ signaling; MAPK; xCELLigence RTCA	RESPONSES IN-VITRO; SIGNALING PATHWAYS; SERINE PROTEASES; INFLAMMATION; MEMBRANE; LIGANDS; HYPERALGESIA; ANTAGONISTS; PEPTIDE; SYSTEM	Protease-activated receptor-2 (PAR(2)) is a G-protein coupled receptor (GPCR) associated with a variety of pathologies. However, the therapeutic potential of PAR(2) is limited by a lack of potent and specific ligands. Following proteolytic cleavage, PAR(2) is activated through a tethered ligand. Hence, we reasoned that lipidation of peptidomimetic ligands could promote membrane targeting and thus significantly improve potency and constructed a series of synthetic tethered ligands (STLs). STLs contained a peptidomimetic PAR(2) agonist (2-aminothiazol-4-yl-LIGRL-NH2) bound to a palmitoyl group (Pam) via polyethylene glycol (PEG) linkers. In a high-throughput physiological assay, these STL agonists displayed EC50 values as low as 1.47 nM, representing a similar to 200 fold improvement over the untethered parent ligand. Similarly, these STL agonists were potent activators of signaling pathways associated with PAR(2): EC50 for Ca2+ response as low as 3.95 nM; EC50 for MAPK response as low as 9.49 nM. Moreover, STLs demonstrated significant improvement in potency in vivo, evoking mechanical allodynia with an EC50 of 14.4 pmol. STLs failed to elicit responses in PAR(2)(-/-) cells at agonist concentrations of >300-fold their EC50 values. Our results demonstrate that the STL approach is a powerful tool for increasing ligand potency at PAR(2) and represent opportunities for drug development at other protease activated receptors and across GPCRs.-Flynn, A. N., Hoffman, J., Tillu, D. V., Sherwood, C. L., Zhang, Z., Patek, R., Asiedu, M. N. K., Vagner, J., Price, T. J., Boitano, S. Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J. 27, 1498-1510 (2013). www.fasebj.org	[Flynn, Andrea N.; Hoffman, Justin; Boitano, Scott] Arizona Hlth Sci Ctr, Dept Physiol, Tucson, AZ 85724 USA; [Flynn, Andrea N.; Hoffman, Justin; Sherwood, Cara L.; Zhang, Zhenyu; Patek, Renata; Vagner, Josef; Price, Theodore J.; Boitano, Scott] Arizona Hlth Sci Ctr, Collaborat Res Inst Bio5, Tucson, AZ 85724 USA; [Flynn, Andrea N.; Hoffman, Justin; Sherwood, Cara L.; Boitano, Scott] Arizona Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Tillu, Dipti V.; Asiedu, Marina N. K.; Price, Theodore J.] Arizona Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ 85724 USA; [Vagner, Josef] Arizona Hlth Sci Ctr, Arizona Canc Ctr, Tucson, AZ 85724 USA	University of Arizona Health Sciences; University of Arizona Health Sciences; University of Arizona Health Sciences; University of Arizona Health Sciences; Arizona Center Cancer Care; University of Arizona Health Sciences	Boitano, S (corresponding author), Arizona Hlth Sci Ctr, Arizona Resp Ctr, Dept Physiol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	sboitano@email.arizona.edu	Price, Theodore/M-3810-2018	Price, Theodore/0000-0002-6971-6221	U.S. National Institutes of Health [NS073664, T32-HL007249, R01NS065926, R01AI083403, ES 04940]; State of Arizona Technology and Research Initiative [Bio5]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694, T32ES007091, P42ES004940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073664, R01NS065926] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); State of Arizona Technology and Research Initiative; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Daniel X. Sherwood for his program that allowed for quick quantification of Ca<SUP>2+</SUP> data, Michael O. Daines for discussion on development and execution of the experiments, Aubrey M. Cunningham for her help with the PAR<INF>2</INF> mice and Terri Boitano for help in editing this manuscript. This work was primarily funded by a multi-PI grant (NS073664 to S. B., J.V., and T.J.P.) and a training grant (T32-HL007249 to A.N.F. and C.L.S.), both from the U.S. National Institutes of Health. Additional support for this work was from the following grants: U.S. National Institutes of Health R01NS065926 (T.J.P.) and R01AI083403 (S. B.; Michael O. Daines, PI), State of Arizona Technology and Research Initiative Fund Awarded through Bio5 (J.V.). Funds to purchase the RTCA were provided through U. S. National Institutes of Health Grant ES 04940 (NIEHS Superfund) and by the State of Arizona Technology and Research Initiative Fund awarded through the Water Sustainability Program. This work is part of a Multi-Principal Investigator group; all PIs contributed equally to this work.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Alier KA, 2008, J PHARMACOL EXP THER, V324, P224, DOI 10.1124/jpet.107.129171; Barry GD, 2010, J MED CHEM, V53, P7428, DOI 10.1021/jm100984y; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Canto I, 2012, MINI-REV MED CHEM, V12, P804, DOI 10.2174/138955712800959116; Cenac N, 2007, J CLIN INVEST, V117, P636, DOI 10.1172/JCI29255; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen CP, 2012, PROTEIN ENG DES SEL, V25, P367, DOI 10.1093/protein/gzs033; Chen HX, 2005, ANAL BIOCHEM, V338, P136, DOI 10.1016/j.ab.2004.11.015; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Dai Y, 2004, J NEUROSCI, V24, P4293, DOI 10.1523/JNEUROSCI.0454-04.2004; Dai Y, 2007, J CLIN INVEST, V117, P1979, DOI 10.1172/JCI30951; Davidson DJ, 2000, AM J PHYSIOL-LUNG C, V279, pL766, DOI 10.1152/ajplung.2000.279.4.L766; DIRKSEN ER, 1995, METHOD CELL BIOL, V47, P65, DOI 10.1016/S0091-679X(08)60792-X; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Flynn AN, 2011, J BIOL CHEM, V286, P19076, DOI 10.1074/jbc.M110.185264; Fortin JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024693; Fortin JP, 2009, P NATL ACAD SCI USA, V106, P8049, DOI 10.1073/pnas.0900149106; Gardell LR, 2008, J PHARMACOL EXP THER, V327, P799, DOI 10.1124/jpet.108.142570; Gough SCL, 2012, DIABETES OBES METAB, V14, P33, DOI 10.1111/j.1463-1326.2012.01576.x; GOZES I, 1995, J PHARMACOL EXP THER, V273, P161; Grant AD, 2007, J PHYSIOL-LONDON, V578, P715, DOI 10.1113/jphysiol.2006.121111; GRUENERT DC, 1995, AM J PHYSIOL-LUNG C, V268, pL347, DOI 10.1152/ajplung.1995.268.3.L347; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Helyes Z, 2010, EUR J PAIN, V14, P351, DOI 10.1016/j.ejpain.2009.07.005; Hollenberg MD, 2008, J PHARMACOL EXP THER, V326, P453, DOI 10.1124/jpet.108.136432; Ibanez-Tallon I, 2012, CURR OPIN NEUROBIOL, V22, P72, DOI 10.1016/j.conb.2011.11.003; Josan JS, 2011, BIOCONJUGATE CHEM, V22, P1270, DOI 10.1021/bc1004284; Josan JS, 2008, INT J PEPT RES THER, V14, P293, DOI 10.1007/s10989-008-9150-3; Kanke T, 2009, BRIT J PHARMACOL, V158, P361, DOI 10.1111/j.1476-5381.2009.00342.x; Kawabata A, 2005, J PHARMACOL SCI, V97, P20, DOI 10.1254/jphs.FMJ04005X4; Kawabata A, 2006, BRIT J PHARMACOL, V148, P54, DOI 10.1038/sj.bjp.0706708; Kawabata A, 2004, J PHARMACOL EXP THER, V309, P1098, DOI 10.1124/jpet.103.061010; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kenakin TP, 2009, NAT REV DRUG DISCOV, V8, P617, DOI 10.1038/nrd2838; Krishnamurthy VM, 2007, J AM CHEM SOC, V129, P1312, DOI 10.1021/ja066780e; Lam DK, 2010, PAIN, V149, P263, DOI 10.1016/j.pain.2010.02.010; Li X, 2011, BIOCHEM SOC T, V39, P1895, DOI 10.1042/BST20110736; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Madsen K, 2007, J MED CHEM, V50, P6126, DOI 10.1021/jm070861j; McGuire JJ, 2004, J PHARMACOL EXP THER, V309, P1124, DOI 10.1124/jpet.103.064584; Means CK, 2011, P NATL ACAD SCI USA, V108, pE1227, DOI 10.1073/pnas.1107182108; O'Callaghan K, 2012, J BIOL CHEM, V287, P12787, DOI 10.1074/jbc.R112.355461; Page K, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-62; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Ramachandran R, 2011, J BIOL CHEM, V286, P24638, DOI 10.1074/jbc.M110.201988; Ramachandran R, 2009, MOL PHARMACOL, V76, P791, DOI 10.1124/mol.109.055509; Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1; Schaffner F, 2009, ARTERIOSCL THROM VAS, V29, P1999, DOI 10.1161/ATVBAHA.108.177428; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Sevigny LM, 2011, P NATL ACAD SCI USA, V108, P8491, DOI 10.1073/pnas.1017091108; Shoichet BK, 2012, TRENDS PHARMACOL SCI, V33, P268, DOI 10.1016/j.tips.2012.03.007; Stallaert W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029420; Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x; Vagner J, 2008, ANGEW CHEM INT EDIT, V47, P1685, DOI 10.1002/anie.200702770; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Xi Biao, 2008, Biotechnology Journal, V3, P484, DOI 10.1002/biot.200800020; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Zhang L, 2012, CURR MED CHEM, V19, P1602	64	21	24	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1498	1510		10.1096/fj.12-217323	http://dx.doi.org/10.1096/fj.12-217323			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23292071	Green Published			2022-12-28	WOS:000316940800022
J	Mika, JT; Birkner, JP; Poolman, B; Kocer, A				Mika, Jacek T.; Birkner, Jan P.; Poolman, Bert; Kocer, Armagan			On the role of individual subunits in MscL gating: "All for one, one for all?"	FASEB JOURNAL			English	Article						DCFBA; electrophysiology; functional reconstitution; heterooligomer formation; mechanosensitive channel; pore diameter	MECHANOSENSITIVE CHANNEL MSCL; ION CHANNELS; MYCOBACTERIUM-TUBERCULOSIS; ESCHERICHIA-COLI; SINGLE RESIDUE; MECHANISM; STATE; HELIX; WATER; GATES	The mechanosensitive channel of large conductance (MscL) is a homopentameric membrane protein that protects bacteria from hypoosmotic stress. Its mechanics are coupled to structural changes in the membrane, yet the molecular mechanism of the transition from closed to open states and the cooperation between subunits are poorly understood. To determine the early stages of channel activation, we have created a chemically addressable heteropentameric MscL, which allows us to selectively trigger only one subunit in the pentameric protein assembly. By employing a liposome leakage assay developed in house, we measured the size-exclusion limits of MscL (G22C(5) homopentamer and WT(4)G22C(1) heteropentamer). Patch-clamp, single-channel conductance recordings were used to electrically characterize the various channel substates. We show that a decrease in the hydrophobicity of a pore residue in only one subunit breaks the energy barrier for gating and increases the pore diameter up to 10 angstrom. A further decrease on the hydrophobicity of the same pore residue in other subunits opens the channel further, up to a diameter of 25 angstrom. However, it is not sufficient for full opening of the channel. This suggests the presence of supplementary mechanisms other than only the hydrophobic gate for MscL opening and closing and/or insufficient expansion of the channel by hydrophobic gating in the absence of applied membrane tension.-Mika, J. T., Birkner, J. P., Poolman, B., Kocer, A. On the role of individual subunits in MscL gating: "All for one, one for all?" FASEB J. 27, 882-892 (2013). www.fasebj.org	[Mika, Jacek T.; Birkner, Jan P.; Poolman, Bert; Kocer, Armagan] Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; [Poolman, Bert] Univ Groningen, Netherlands Prote Ctr, NL-9747 AG Groningen, Netherlands; [Poolman, Bert] Univ Groningen, Zernike Inst Adv Mat, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@rug.nl; a.kocer@rug.nl	Institute, Zernike/W-7033-2019; Birkner, Jan Peter/E-8316-2014; Kocer, A/M-6371-2013	kocer, Armagan/0000-0001-7343-3139; Birkner, Jan Peter/0000-0002-5536-2274	Systems Biology for Microorganisms (SysMo) Consortium via the UK Biotechnology and Biological Sciences Research Council (BBSRC); Ian R. Booth (University of Aberdeen, Aberdeen, UK); Netherlands Organisation for Scientific Research (NWO) [700.56.302]; European Research Council [208814]	Systems Biology for Microorganisms (SysMo) Consortium via the UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ian R. Booth (University of Aberdeen, Aberdeen, UK); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); European Research Council(European Research Council (ERC)European Commission)	The authors acknowledge Ms. Duygu Yilmaz for her work on the experimental design and sample preparation for ESI-MS measurements and Annie van Dam for the ESI-MS analysis. This work was supported by the Systems Biology for Microorganisms (SysMo) Consortium via the UK Biotechnology and Biological Sciences Research Council (BBSRC)-funded KosmoBac program, coordinated by Ian R. Booth (University of Aberdeen, Aberdeen, UK), to J.T.M. and B.P.; a Netherlands Organisation for Scientific Research (NWO) Top-Subsidy grant to B.P. (700.56.302); a NWO-VIDI grant to A.K. (700.57.427), and a European Research Council Ideas Program grant to A. K. (ERC-Starting grant 208814). Author contributions: J.T.M., J.P.B., and A.K. conceived and designed the project; J.P.B. prepared the protein samples and carried out patch-clamp experiments and data analysis; J.T.M. performed the DCFBA experiments and data analysis; A. K. supervised the project and performed patch-clamp data analysis; and J.T.M., J.P.B., A.K., and B.P. discussed the data and wrote the manuscript.	Anishkin A, 2005, J GEN PHYSIOL, V125, P155, DOI 10.1085/jgp.200409118; Anishkin A, 2004, BIOPHYS J, V86, P2883, DOI 10.1016/S0006-3495(04)74340-4; Anishkin A, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/45/454120; Beckstein O, 2004, PHYS BIOL, V1, P42, DOI 10.1088/1478-3967/1/1/005; Beckstein O, 2001, J PHYS CHEM B, V105, P12902, DOI 10.1021/jp012233y; Beckstein O, 2006, PHYS BIOL, V3, P147, DOI 10.1088/1478-3975/3/2/007; Birkner JP, 2012, P NATL ACAD SCI USA, V109, P12944, DOI 10.1073/pnas.1205270109; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Doyle DA, 2004, EUR BIOPHYS J BIOPHY, V33, P175, DOI 10.1007/s00249-003-0382-z; Edwards MD, 2005, NAT STRUCT MOL BIOL, V12, P113, DOI 10.1038/nsmb895; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Iscla I, 2007, BIOPHYS J, V92, P1224, DOI 10.1529/biophysj.106.090316; Kocer A, 2007, NAT PROTOC, V2, P1426, DOI 10.1038/nprot.2007.196; Kung C, 2010, ANNU REV MICROBIOL, V64, P313, DOI 10.1146/annurev.micro.112408.134106; Liu ZF, 2009, NATURE, V461, P120, DOI 10.1038/nature08277; Louhivuori M, 2010, P NATL ACAD SCI USA, V107, P19856, DOI 10.1073/pnas.1001316107; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Roth R, 2008, BIOPHYS J, V94, P4282, DOI 10.1529/biophysj.107.120493; Shapovalov G, 2003, BIOPHYS J, V84, P2357, DOI 10.1016/S0006-3495(03)75041-3; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2004, TRENDS NEUROSCI, V27, P345, DOI 10.1016/j.tins.2004.04.006; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; van den Bogaart G, 2007, BIOPHYS J, V92, P1233, DOI 10.1529/biophysj.106.088708; Vasquez V, 2009, NATURE, V461, P47, DOI 10.1038/461047a; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9; Yoshimura K, 2010, J R SOC INTERFACE, V7, pS307, DOI 10.1098/rsif.2010.0095.focus	35	17	17	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					882	892		10.1096/fj.12-214361	http://dx.doi.org/10.1096/fj.12-214361			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193173				2022-12-28	WOS:000315585200005
J	Huin-Schohn, C; Gueguinou, N; Schenten, V; Bascove, M; Koch, GG; Baatout, S; Tschirhart, E; Frippiat, JP				Huin-Schohn, Cecile; Gueguinou, Nathan; Schenten, Veronique; Bascove, Matthieu; Koch, Guillemette Gauquelin; Baatout, Sarah; Tschirhart, Eric; Frippiat, Jean-Pol			Gravity changes during animal development affect IgM heavy-chain transcription and probably lymphopoiesis	FASEB JOURNAL			English	Article						humoral immune system; antibody; B lymphocyte	NF-KAPPA-B; GENE-EXPRESSION; SHOCK PROTEINS; SPACEFLIGHT; MICROGRAVITY; PATHWAYS; STRESS	Our previous research demonstrated that spaceflight conditions affect antibody production in response to an antigenic stimulation in adult amphibians. Here, we investigated whether antibody synthesis is affected when animal development occurs onboard a space station. To answer this question, embryos of the Iberian ribbed newt, Pleurodeles waltl, were sent to the International Space Station (ISS) before the initiation of immunoglobulin heavy-chain expression. Thus, antibody synthesis began in space. On landing, we determined the effects of spaceflight on P. waltl development and IgM heavy-chain transcription. Results were compared with those obtained using embryos that developed on Earth. We find that IgM heavy-chain transcription is doubled at landing and that spaceflight does not affect P. waltl development and does not induce inflammation. We also recreated the environmental modifications encountered by the embryos during their development onboard the ISS. This strategy allowed us to demonstrate that gravity change is the factor responsible for antibody heavy-chain transcription modifications that are associated with NF-kappa B mRNA level variations. Taken together, and given that the larvae were not immunized, these data suggest a modification of lymphopoiesis when gravity changes occur during ontogeny.-Huin-Schohn, C., Gueguinou, N., Schenten, V., Bascove, M., Koch, G. G., Baatout, S., Tschirhart, E., Frippiat, J.-P. Gravity changes during animal development affect IgM heavy-chain transcription and probably lymphopoiesis. FASEB J. 27, 333-341 (2013). www.fasebj.org	[Frippiat, Jean-Pol] Lorraine Univ, Fac Med Dev & Immunogenet, Dept Dev & Immunogenet, F-54500 Vandoeuvre Les Nancy, France; [Huin-Schohn, Cecile; Gueguinou, Nathan; Tschirhart, Eric] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Koch, Guillemette Gauquelin] French Natl Space Agcy CNES, Paris, France; [Baatout, Sarah] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium; [Baatout, Sarah] Univ Ghent, Dept Mol Biotechnol, B-9000 Ghent, Belgium	Universite de Lorraine; University of Luxembourg; Belgian Nuclear Research Centre (SCK-CEN); Ghent University	Frippiat, JP (corresponding author), Lorraine Univ, Fac Med Dev & Immunogenet, Dept Dev & Immunogenet, JE 2537,9 Ave Foret Haye, F-54500 Vandoeuvre Les Nancy, France.	jean-pol.frippiat@univ-lorraine.fr		Baatout, Sarah/0000-0001-8110-751X; Frippiat, Jean-Pol/0000-0002-4027-6269	CNES; French Ministry of Higher Education and Research; Lorraine area, Lorraine University; ESA/Belspo/PRODEX program; Fonds National de la Recherche of Luxembourg; University of Rochester, Rochester, NY, USA; SCK . CEN; European Space Agency (ESA)	CNES(Centre National D'etudes Spatiales); French Ministry of Higher Education and Research; Lorraine area, Lorraine University; ESA/Belspo/PRODEX program; Fonds National de la Recherche of Luxembourg(Luxembourg National Research Fund); University of Rochester, Rochester, NY, USA; SCK . CEN; European Space Agency (ESA)(European Space Agency)	The authors thank D. Chaput (CNES) for his support during the space mission, J. Robert (University of Rochester, Rochester, NY, USA), for providing the 10A9 hydridoma, M. Beck and F. Mastroleo (SCK . CEN) for their support during the irradiations and RPM experiments, the European Space Agency (ESA) for the spaceflight opportunity, the CNES, the French Ministry of Higher Education and Research, the Lorraine area, Lorraine University, and the ESA/Belspo/PRODEX program for their financial support. C.H.-S. and N.G. were supported by postdoctoral and Ph.D. fellowships from the Fonds National de la Recherche of Luxembourg, V.S. by a CNES postdoctoral fellowship, and M.B. by a Ph.D. fellowship of the French Ministry of Higher Education and Research.	Aimar C, 2000, BIOL REPROD, V63, P551, DOI 10.1095/biolreprod63.2.551; Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Bascove M, 2011, FASEB J, V25, P2947, DOI 10.1096/fj.11-185215; Bascove M, 2009, FASEB J, V23, P1607, DOI 10.1096/fj.08-121327; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; Boudarra N, 2002, DEV COMP IMMUNOL, V26, P659, DOI 10.1016/S0145-305X(02)00014-9; Boxio R, 2005, J APPL PHYSIOL, V98, P905, DOI 10.1152/japplphysiol.00957.2004; Cernysiov V, 2010, INT IMMUNOL, V22, P25, DOI 10.1093/intimm/dxp109; Chouker A, 2002, J APPL PHYSIOL, V92, P1619, DOI 10.1152/japplphysiol.00732.2001; Committee on the Planetary Science Decadal Survey, 2011, VIS VOYAG PLAN SCI D; Cooper MD, 2006, CELL, V124, P815, DOI 10.1016/j.cell.2006.02.001; Courtade M, 2001, INT J RADIAT BIOL, V77, P587, DOI 10.1080/09553000110034621; Cui MA, 2010, FISH SHELLFISH IMMUN, V29, P1060, DOI 10.1016/j.fsi.2010.08.018; Davis TA, 1996, J LEUKOCYTE BIOL, V60, P69, DOI 10.1002/jlb.60.1.69; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dominguez M, 2004, AQUACULTURE, V241, P491, DOI 10.1016/j.aquaculture.2004.06.027; Dournon C, 2003, ADV SPACE B, V9, P101, DOI 10.1016/S1569-2574(03)09005-1; Frippiat C, 2001, IMMUNOGENETICS, V52, P264; Gabriel Martin, 2012, J Exp Zool A Ecol Genet Physiol, V317, P333, DOI 10.1002/jez.1727; GALLIEN L., 1957, BULL BIOL FRANCE ET BELGIQUE, V91, P97; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Gualandris-Parisot Lydie, 2002, Biol Sci Space, V16, P3, DOI 10.2187/bss.16.3; Gueguinou N, 2009, J LEUKOCYTE BIOL, V86, P1027, DOI 10.1189/jlb.0309167; Ishihara A, 2008, J PHYSIOL SCI, V58, P413, DOI 10.2170/physiolsci.RP000808; Kimzey SL, 1977, BIOMEDICAL RESULTS S, P248; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Kumei Yasuhiro, 2002, J Gravit Physiol, V9, pP263; Mussmann R, 1998, EUR J IMMUNOL, V28, P2947, DOI 10.1002/(SICI)1521-4141(199809)28:09<2947::AID-IMMU2947>3.0.CO;2-A; Ortega MT, 2009, J APPL PHYSIOL, V106, P548, DOI 10.1152/japplphysiol.91138.2008; Patterson JS, 2007, EVOL DEV, V9, P525, DOI 10.1111/j.1525-142X.2007.00193.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plett PA, 2004, EXP HEMATOL, V32, P773, DOI 10.1016/j.exphem.2004.03.014; Rupik W, 2011, COMP BIOCHEM PHYS A, V159, P349, DOI 10.1016/j.cbpa.2011.04.002; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Rykova MP, 2008, ACTA ASTRONAUT, V63, P697, DOI 10.1016/j.actaastro.2008.03.016; Schaerlinger B, 2008, MOL IMMUNOL, V45, P776, DOI 10.1016/j.molimm.2007.06.356; Shimada N, 2006, DEV DYNAM, V235, P2686, DOI 10.1002/dvdy.20901; Stowe RP, 1999, J LEUKOCYTE BIOL, V65, P179, DOI 10.1002/jlb.65.2.179; Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vanhavere F, 2001, RADIAT PROT DOSIM, V96, P105, DOI 10.1093/oxfordjournals.rpd.a006563; VOSS EW, 1984, SCIENCE, V225, P214, DOI 10.1126/science.6729476; Yeyati PL, 2007, PLOS GENET, V3, P431, DOI 10.1371/journal.pgen.0030043; Zhang C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000106	46	29	30	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					333	341		10.1096/fj.12-217547	http://dx.doi.org/10.1096/fj.12-217547			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22993194				2022-12-28	WOS:000313103200031
J	Shukla, V; Zheng, YL; Mishra, SK; Amin, ND; Steiner, J; Grant, P; Kesavapany, S; Pant, HC				Shukla, Varsha; Zheng, Ya-Li; Mishra, Santosh K.; Amin, Niranjana D.; Steiner, Joseph; Grant, Philip; Kesavapany, Sashi; Pant, Harish C.			A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice	FASEB JOURNAL			English	Article						Cdk5 hyperphosphorylation; neurodegeneration; therapeutics	CYCLIN-DEPENDENT KINASE-5; INTERMEDIATE-FILAMENT PROTEINS; AMYLOID-PRECURSOR-PROTEIN; PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; SYNAPTIC PLASTICITY; TRANSGENIC MODEL; BETA-SECRETASE; TAU-PROTEIN; MOUSE MODEL	Alzheimer's disease (AD), one of the leading neurodegenerative disorders of older adults, which causes major socioeconomic burdens globally, lacks effective therapeutics without significant side effects. Besides the hallmark pathology of amyloid plaques and neurofibrillary tangles (NFTs), it has been reported that cyclin-dependent kinase 5 (Cdk5), a critical neuronal kinase, is hyperactivated in AD brains and is, in part, responsible for the above pathology. Here we show that a modified truncated 24-aa peptide (TFP5), derived from the Cdk5 activator p35, penetrates the blood-brain barrier after intraperitoneal injections, inhibits abnormal Cdk5 hyperactivity, and significantly rescues AD pathology (up to 70-80%) in 5XFAD AD model mice. The mutant mice, injected with TFP5 exhibit behavioral rescue, whereas no rescue was observed in mutant mice injected with either saline or scrambled peptide. However, TFP5 does not inhibit cell cycle Cdks or normal Cdk5/p35 activity, and thereby has no toxic side effects (even at 200 mg/kg), a common problem in most current therapeutics for AD. In addition, treated mice displayed decreased inflammation, amyloid plaques, NFTs, cell death, and an extended life by 2 mo. These results suggest TFP5 as a potential therapeutic, toxicity-free candidate for AD.-Shukla, V., Zheng, Y.-L., Mishra, S. K., Amin, N. D., Steiner, J., Grant, P., Kesavapany, S., Pant, H. C. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J. 27, 174-186 (2013). www.fasebj.org	[Pant, Harish C.] Natl Inst Neurol Disorders & Stroke, Neurochem Lab, NIH, Bethesda, MD 20892 USA; [Steiner, Joseph] Natl Inst Neurol Disorders & Stroke, Neurotherapeut Dev Unit, Bethesda, MD 20892 USA; [Mishra, Santosh K.] Natl Inst Dent & Craniofacial Res, Mol Genet Unit, Lab Sensory Biol, NIH, Bethesda, MD USA; [Zheng, Ya-Li] Ningxia Peoples Hosp, Dept Nephrol, Yinchuan, Peoples R China; [Kesavapany, Sashi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Neurobiol Program, Singapore 117595, Singapore	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National University of Singapore	Pant, HC (corresponding author), Natl Inst Neurol Disorders & Stroke, Neurochem Lab, NIH, 49 Convent Dr,MSC 4479,Bldg 49,Rm 2A28, Bethesda, MD 20892 USA.	panth@ninds.nih.gov	Mishra, Santosh/S-7516-2017	Mishra, Santosh/0000-0001-8616-2606	U.S. National Institutes of Health (NIH), NINDS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003104, ZIANS003134] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH), NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for the generous gift of Alz-50 antibody. Help from Daniel Abebe (National Institute of Child Health and Human Development, Bethesda, MD, USA) in performing behavior assays is acknowledged. For cell culture studies, rat embryo cortices were provided by Dr. Yanmin Chen [National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA]. This work was supported by the intramural research program of the U.S. National Institutes of Health (NIH), NINDS. A patent application has been filed on behalf of NIH (patent application no. 13/249,003) regarding TFP5 as a potential therapeutic for AD. The authors declare no conflicts of interest. V. S. designed the study, performed the experiments, analyzed the data, and drafted the manuscript; S. K. M. participated in study design and analyzed behavior data; N. D. A. performed the in vitro activity analyses and provided the reagents; P. G. and J. S. contributed to experimental design and reviewed the manuscript; Y. Z. and S. K. performed initial in vitro studies; H. C. P. designed the study, analyzed data, and revised the manuscript.	Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; Bonda DJ, 2010, NEUROPHARMACOLOGY, V59, P290, DOI 10.1016/j.neuropharm.2010.04.005; CORK LC, 1986, J NEUROPATH EXP NEUR, V45, P56, DOI 10.1097/00005072-198601000-00005; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Cruz JC, 2006, J NEUROSCI, V26, P10536, DOI 10.1523/JNEUROSCI.3133-06.2006; Cyr M, 2003, P NATL ACAD SCI USA, V100, P11035, DOI 10.1073/pnas.1831768100; de la Monte S. M., 2000, Journal of Alzheimer's Disease, V2, P261; De Strooper B, 2000, J CELL SCI, V113, P1857; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Fischer A, 2005, NEURON, V48, P825, DOI 10.1016/j.neuron.2005.10.033; Fischer A, 2002, J NEUROSCI, V22, P3700; Giusti-Rodriguez P, 2011, J NEUROSCI, V31, P15751, DOI 10.1523/JNEUROSCI.3588-11.2011; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guan JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025735; Hawash Ammar H., 2007, Biotechnology Journal, V2, P941, DOI 10.1002/biot.200700093; Helal CJ, 2009, BIOORG MED CHEM LETT, V19, P5703, DOI 10.1016/j.bmcl.2009.08.019; Helal CJ, 2004, BIOORG MED CHEM LETT, V14, P5521, DOI 10.1016/j.bmcl.2004.09.006; Ho A, 2001, CANCER RES, V61, P474; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kurt MA, 2003, NEUROBIOL DIS, V14, P89, DOI 10.1016/S0969-9961(03)00084-6; LANGLEY OK, 1988, BRAIN RES, V457, P12, DOI 10.1016/0006-8993(88)90052-2; Lau LF, 2002, J MOL NEUROSCI, V19, P267, DOI 10.1385/JMN:19:3:267; Lau LF, 2003, NEUROSIGNALS, V12, P209, DOI 10.1159/000074622; Lee HP, 2010, EXPERT REV NEUROTHER, V10, P1201, DOI 10.1586/ERN.10.74; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Lopes JP, 2011, PROG NEUROBIOL, V94, P49, DOI 10.1016/j.pneurobio.2011.03.006; Lopez-Tobon A, 2011, REV NEUROSCIENCE, V22, P143, DOI 10.1515/RNS.2011.015; Luque FA, 2009, INT REV NEUROBIOL, V84, P151, DOI 10.1016/S0074-7742(09)00408-5; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; Martins IJ, 2009, J NEUROCHEM, V111, P1275, DOI 10.1111/j.1471-4159.2009.06408.x; Monaco EA, 2005, FRONT BIOSCI-LANDMRK, V10, P143, DOI 10.2741/1516; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ritchie CW, 2004, AM J GERIAT PSYCHIAT, V12, P358, DOI 10.1176/appi.ajgp.12.4.358; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Royce J., PSYCHOL B, V84, P1098; Rudrabhatla P, 2011, FASEB J, V25, P3896, DOI 10.1096/fj.11-181297; Rudrabhatla P, 2010, FASEB J, V24, P4396, DOI 10.1096/fj.10-157859; Sadleir KR, 2012, J BIOL CHEM, V287, P7224, DOI 10.1074/jbc.M111.333914; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shukla V, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/572634; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; Smith Wanli W., 2006, CNS & Neurological Disorders-Drug Targets, V5, P355, DOI 10.2174/187152706784111515; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; Takahashi S, 2010, AM J PATHOL, V176, P320, DOI 10.2353/ajpath.2010.081158; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tsai LH, 2004, BBA-PROTEINS PROTEOM, V1697, P137, DOI 10.1016/j.bbapap.2003.11.019; Tseng HC, 2002, FEBS LETT, V523, P58, DOI 10.1016/S0014-5793(02)02934-4; UEDA K, 1990, J NEUROSCI, V10, P3295; Wen Y, 2008, NEURON, V57, P680, DOI 10.1016/j.neuron.2008.02.024; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zheng YL, 2010, J BIOL CHEM, V285, P34202, DOI 10.1074/jbc.M110.134643; Zheng YL, 2005, EMBO J, V24, P209, DOI 10.1038/sj.emboj.7600441; Zheng YL, 2003, J BIOL CHEM, V278, P24026, DOI 10.1074/jbc.M303079200; Zheng YL, 2002, EUR J BIOCHEM, V269, P4427, DOI 10.1046/j.1432-1033.2002.03133.x	71	86	89	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					174	186		10.1096/fj.12-217497	http://dx.doi.org/10.1096/fj.12-217497			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038754	Green Published			2022-12-28	WOS:000313103200017
J	Laurent-Matha, V; Huesgen, PF; Masson, O; Derocq, D; Prebois, C; Gary-Bobo, M; Lecaille, F; Rebiere, B; Meurice, G; Orear, C; Hollingsworth, RE; Abrahamson, M; Lalmanach, G; Overall, CM; Liaudet-Coopman, E				Laurent-Matha, Valerie; Huesgen, Pitter F.; Masson, Olivier; Derocq, Danielle; Prebois, Christine; Gary-Bobo, Magali; Lecaille, Fabien; Rebiere, Bertrand; Meurice, Guillaume; Orear, Cedric; Hollingsworth, Robert E.; Abrahamson, Magnus; Lalmanach, Gilles; Overall, Christopher M.; Liaudet-Coopman, Emmanuelle			Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment	FASEB JOURNAL			English	Article						cancer; protease web	PROTEASE CLEAVAGE PRODUCTS; CYSTEINE CATHEPSINS; LUNG METASTASIS; TUMOR-GROWTH; N-TERMINOME; D INTERACTS; CELLS; ACTIVATION; RECEPTOR; IDENTIFICATION	The aspartic protease cathepsin D, a poor prognostic indicator of breast cancer, is abundantly secreted as procathepsin D by human breast cancer cells and self-activates at low pH in vitro, giving rise to catalytically active cathepsin D. Due to a lower extracellular pH in tumor microenvironments compared to normal tissues, cathepsin D may cleave pathophysiological substrates contributing to cancer progression. Here, we show by yeast 2-hybrid and degradomics analyses that cystatin C, the most potent natural secreted inhibitor of cysteine cathepsins, both binds to and is a substrate of extracellular procathepsin D. The amount of cystatin C in the extracellular environment is reduced in the secretome of mouse embryonic fibroblasts stably transfected with human cathepsin D. Cathepsin D extensively cleaved cystatin C in vitro at low pH. Cathepsin D secreted by breast cancer cells also processed cystatin C at the pericellular pH of tumors and so enhancing extracellular proteolytic activity of cysteine cathepsins. Thus, tumor derived cathepsin D assists breast cancer progression by reducing cystatin C activity, which, in turn, enhances cysteine cathepsin proteolytic activity, revealing a new link between protease classes in the protease web.-Laurent-Matha, V., Huesgen, P. F., Masson, O., Derocq, D., Prebois, C., Gary-Bobo, M., Lecaille, F., Rebiere, B., Meurice, G., Orear, C., Hollingsworth, R. E., Abrahamson, M., Lalmanach, G., Overall, C. M., Liaudet-Coopman, E. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. FASEB J. 26, 5172-5181 (2012). www.fasebj.org	[Laurent-Matha, Valerie; Masson, Olivier; Derocq, Danielle; Prebois, Christine; Gary-Bobo, Magali; Liaudet-Coopman, Emmanuelle] Univ Montpellier I, INSERM, U896, IRCM, F-34298 Montpellier, France; [Laurent-Matha, Valerie; Masson, Olivier; Derocq, Danielle; Prebois, Christine; Gary-Bobo, Magali; Liaudet-Coopman, Emmanuelle] Ctr Reg Lutte Canc CRLC, Montpellier, France; [Huesgen, Pitter F.; Overall, Christopher M.] Univ British Columbia, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada; [Lecaille, Fabien; Lalmanach, Gilles] Univ Tours, INSERM, U1100, Fac Med, Tours, France; [Rebiere, Bertrand] CNRS, UMR 5237, CRBM, Montpellier, France; [Meurice, Guillaume; Orear, Cedric] Inst Gustave Roussy, Villejuif, France; [Hollingsworth, Robert E.] Medimmune Inc, Oncol Res, Gaithersburg, MD 20878 USA; [Abrahamson, Magnus] Lund Univ, Univ Hosp, Div Clin Chem, Dept Lab Med, Lund, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UNICANCER; Gustave Roussy; AstraZeneca; Medimmune; Lund University; Skane University Hospital	Liaudet-Coopman, E (corresponding author), Univ Montpellier I, INSERM, U896, IRCM, 208 Rue Apothicaires, F-34298 Montpellier, France.	emmanuelle.liaudet-coopman@inserm.fr	Abrahamson, Magnus/CAG-9507-2022; Bonnemaison, Marc/AAD-9243-2021; Huesgen, Pitter/E-9246-2019; Liaudet-Coopman, Emmanuelle/N-4744-2017; Lecaille, Fabien/GRY-5313-2022	Huesgen, Pitter/0000-0002-0335-2242; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Lalmanach, Gilles/0000-0001-8562-4821; Lecaille, Fabien/0000-0003-1060-4222; Rebiere, Bertrand/0000-0002-1767-6547; Valerie, LAURENT-MATHA/0000-0002-3277-7397	INSERM, University of Montpellier I; Agence Nationale de la Recherche (ANR) Jeunes Chercheuses, Jeunes Chercheurs; HEMORES consortium (EU FP6) [LSHC-CT-2007-037665]; Canadian Institutes of Health Research; Michael Smith Research Foundation (University of British Columbia Centre for Blood Research, Vancouver, BC, Canada); British Columbia Proteomics Network	INSERM, University of Montpellier I; Agence Nationale de la Recherche (ANR) Jeunes Chercheuses, Jeunes Chercheurs(French National Research Agency (ANR)); HEMORES consortium (EU FP6); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Research Foundation (University of British Columbia Centre for Blood Research, Vancouver, BC, Canada); British Columbia Proteomics Network	The authors thank Alix Joulin-Giet [Institut National de la Sante et de la Recherche Medicale (INSERM) U1100, Universite Francois Rabelais, Tours, France] for Western blot analysis of cysteine cathepsins. The authors thank Dr. Vladimir Lazar (head of genomic core facilities at Institut Gustave Roussy, Villejuif, France) and the CHEMORES consortium for transcriptomic experiments. The authors thank Simon Thezenas (Centre Regional de Lutte Contre le Cancer Val D'Aurelle Paul Lamarque, Montpellier, France) for statistical analysis, and Dr. Owen Parkes (Romagne, France) for checking the English text. This work was supported by INSERM, University of Montpellier I; Agence Nationale de la Recherche (ANR) Jeunes Chercheuses, Jeunes Chercheurs, which provided a fellowship for V. L. M.; the CHEMORES consortium (EU FP6; grant LSHC-CT-2007-037665); a Canadian Institutes of Health Research grant (C.M.O.); an infrastructure grant from the Michael Smith Research Foundation (University of British Columbia Centre for Blood Research, Vancouver, BC, Canada); and the British Columbia Proteomics Network. C.M.O. holds a Canada Research Chair in Metalloproteinase Proteomics and Systems Biology. INSERM U896 and INSERM U1100 are affiliated with LabEx MabImprove (Tours and Montpellier, France).	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; Beaujouin M, 2010, J CELL SCI, V123, P3336, DOI 10.1242/jcs.070938; Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Brisson L, 2011, ONCOGENE, V30, P2070, DOI 10.1038/onc.2010.574; CAPONY F, 1989, CANCER RES, V49, P3904; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Dean RA, 2007, MOL CELL BIOL, V27, P8454, DOI 10.1128/MCB.00821-07; Dean RA, 2007, MOL CELL PROTEOMICS, V6, P611, DOI 10.1074/mcp.M600341-MCP200; Derocq D, 2012, ONCOGENE, V31, P3202, DOI 10.1038/onc.2011.501; Dunn BM, 2000, BBA-PROTEIN STRUCT M, V1477, P231, DOI 10.1016/S0167-4838(99)00275-7; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Griffiths J R, 2001, Novartis Found Symp, V240, P46; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Keller UAD, 2010, MOL CELL PROTEOMICS, V9, P912, DOI 10.1074/mcp.M000032-MCP201; Kleifeld O, 2011, NAT PROTOC, V6, P1578, DOI 10.1038/nprot.2011.382; Kleifeld O, 2010, NAT BIOTECHNOL, V28, P281, DOI 10.1038/nbt.1611; Kopitz C, 2005, CANCER RES, V65, P8608, DOI 10.1158/0008-5472.CAN-05-1572; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; Laurent-Matha V, 2002, EXP CELL RES, V277, P210, DOI 10.1006/excr.2002.5556; LENARCIC B, 1991, FEBS LETT, V280, P211, DOI 10.1016/0014-5793(91)80295-E; LENARCIC B, 1988, BIOCHEM BIOPH RES CO, V154, P765, DOI 10.1016/0006-291X(88)90206-9; Martino S, 2011, INT J BIOCHEM CELL B, V43, P775, DOI 10.1016/j.biocel.2011.02.001; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Overall CM, 2006, CANCER METAST REV, V25, P69, DOI 10.1007/s10555-006-7890-0; Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Tholen S, 2011, BIOL CHEM, V392, P961, DOI [10.1515/BC-2011-162, 10.1515/BC.2011.162]; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; vanderStappen JWJ, 1996, INT J CANCER, V67, P547, DOI 10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wallin H, 2010, BIOCHIMIE, V92, P1625, DOI 10.1016/j.biochi.2010.08.011; WATABE S, 1983, BIOCHEM BIOPH RES CO, V110, P934, DOI 10.1016/0006-291X(83)91052-5; Wegiel B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007953	44	45	46	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5172	5181		10.1096/fj.12-205229	http://dx.doi.org/10.1096/fj.12-205229			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22898924	Green Submitted			2022-12-28	WOS:000311838300037
J	Ashkenazi, A; Viard, M; Unger, L; Blumenthal, R; Shai, Y				Ashkenazi, Avraham; Viard, Mathias; Unger, Linor; Blumenthal, Robert; Shai, Yechiel			Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1	FASEB JOURNAL			English	Article						viral envelope protein; sphingolipids	IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; CELL-CELL FUSION; ENVELOPE GLYCOPROTEIN; MEDIATED FUSION; COILED-COIL; LIPID RAFTS; GP41; CHOLESTEROL; PEPTIDE	Understanding the structural organization of lipids in the cell and viral membranes is essential for elucidating mechanisms of viral fusion that lead to entry of enveloped viruses into their host cells. The HIV lipidome shows a remarkable enrichment in dihydrosphingomyelin, an unusual sphingolipid formed by a dihydrosphingosine backbone. Here we investigated the ability of dihydrosphingosine to incorporate into the site of membrane fusion mediated by the HIV envelope (Env) protein. Dihydrosphingosine as well as cholesterol, fatty acid, and tocopherol was conjugated to highly conserved, short HIV-1 Env-derived peptides with no antiviral activity otherwise. We showed that dihydrosphingosine exclusively endowed nanomolar antiviral activity to the peptides (IC50 as low as 120 nM) in HIV-1 infection on TZM-bl cells and on Jurkat T cells, as well as in the cell-cell fusion assay. These sphingopeptides were active against enfuvirtide-resistant and wild-type CXCR4 and CCR5 tropic HIV strains. The anti-HIV activity was determined by both the peptides and their dihydrosphingosine conjugate. Moreover, their mode of action involved accumulation in the cells and viruses and binding to membranes enriched in sphingomyelin and cholesterol. The data suggest that sphingopeptides are recruited to the HIV membrane fusion site and provide a general concept in developing inhibitors of sphingolipid-mediated biological systems.-Ashkenazi, A., Viard, M., Unger, L., Blumenthal, R., Shai, Y. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 26, 4628-4636 (2012). www.fasebj.org	[Ashkenazi, Avraham; Unger, Linor; Shai, Yechiel] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Viard, Mathias; Blumenthal, Robert] NCI, Nanobiol Program, Ctr Canc Res, Frederick Natl Lab, Frederick, MD 21701 USA; [Viard, Mathias] SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res Nanobiol Program, Frederick Natl Lab, Frederick, MD USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il		Ashkenazi, Avraham/0000-0002-1253-497X	Israel Science Foundation; Frederick National Laboratory; National Cancer Institute; U.S. National Institutes of Health [HHSN26120080001E]; NATIONAL CANCER INSTITUTE [ZIABC008303] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Frederick National Laboratory(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Batya Zarmi for her valuable help with peptide purification and Winfried Weissenhorn for providing the recent 3-dimensional structure of gp41. This study was supported by the Israel Science Foundation (to Y. S.) and in part by federal funds (to R. B.) from the Frederick National Laboratory, National Cancer Institute, U.S. National Institutes of Health (contract HHSN26120080001E). The content of this publication does not necessarily reflect the views or policies of the U. S. Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. government. Y. S. is the incumbent of the Harold S. and Harriet B. Brady Professorial Chair in Cancer Research.	Ablan S, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-104; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004; BENEFRAIM I, 1993, BIOCHEMISTRY-US, V32, P2371, DOI 10.1021/bi00060a031; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103; Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Chien MP, 2008, FASEB J, V22, P1179, DOI 10.1096/fj.07-9576com; Choi KS, 2005, J VIROL, V79, P9862, DOI 10.1128/JVI.79.15.9862-9871.2005; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Epand RM, 2003, BIOPHYS J, V84, P3102, DOI 10.1016/S0006-3495(03)70035-6; Finnegan CM, 2007, J VIROL, V81, P5294, DOI 10.1128/JVI.02553-06; Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1073/pnas.0402874101; Finzi A, 2010, MOL CELL, V37, P656, DOI 10.1016/j.molcel.2010.02.012; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Garg H, 2007, J BIOL CHEM, V282, P16899, DOI 10.1074/jbc.M701701200; Goni FM, 2006, BBA-BIOMEMBRANES, V1758, P1902, DOI 10.1016/j.bbamem.2006.09.011; Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967; Hetru C, 2000, BIOCHEM J, V345, P653, DOI 10.1042/0264-6021:3450653; Holguin A, 2007, AIDS RES HUM RETROV, V23, P1067, DOI 10.1089/aid.2006.0256; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Kuikka M, 2001, BIOPHYS J, V80, P2327, DOI 10.1016/S0006-3495(01)76203-0; Lev N, 2007, J MOL BIOL, V374, P220, DOI 10.1016/j.jmb.2007.09.008; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Medigeshi GR, 2008, J VIROL, V82, P5212, DOI 10.1128/JVI.00008-08; Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JVI.80.7.3249-3258.2006; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Rawat SS, 2006, GLYCOCONJUGATE J, V23, P189, DOI 10.1007/s10719-006-7924-4; Rawat SS, 2005, BIOSCIENCE REP, V25, P329, DOI 10.1007/s10540-005-2894-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002; Viard M, 2003, GLYCOCONJUGATE J, V20, P213, DOI 10.1023/B:GLYC.0000024253.48791.d9; Vieira CR, 2010, CHEM BIOL, V17, P766, DOI 10.1016/j.chembiol.2010.05.023; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com; Wexler-Cohen Y, 2010, FASEB J, V24, P4196, DOI 10.1096/fj.09-151704; Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331	56	32	33	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4628	4636		10.1096/fj.12-215111	http://dx.doi.org/10.1096/fj.12-215111			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872679	Green Published			2022-12-28	WOS:000310574200024
J	Huang, SK; Scruggs, AM; Donaghy, J; McEachin, RC; Fisher, AS; Richardson, BC; Peters-Golden, M				Huang, Steven K.; Scruggs, Anne M.; Donaghy, Jake; McEachin, Richard C.; Fisher, Aaron S.; Richardson, Bruce C.; Peters-Golden, Marc			Prostaglandin E-2 increases fibroblast gene-specific and global DNA methylation via increased DNA methyltransferase expression	FASEB JOURNAL			English	Article						epigenetics; eicosanoids; macrophage	RECEPTOR-MEDIATED INCREASE; LUNG FIBROBLASTS; E-PROSTANOID-2 RECEPTOR; DE-NOVO; TRANSCRIPTIONAL REGULATION; INHIBITS FIBROBLAST; MAMMALIAN-CELLS; CANCER; GROWTH; CYCLOOXYGENASE-2	Although alterations in DNA methylation patterns have been associated with specific diseases and environmental exposures, the mediators and signaling pathways that direct these changes remain understudied. The bioactive lipid mediator prostaglandin E-2 (PGE(2)) has been shown to exert a myriad of effects on cell survival, proliferation, and differentiation. Here, we report that PGE(2) also signals to increase global DNA methylation and DNA methylation machinery in fibroblasts. HumanMethylation27 BeadChip array analysis of primary fetal (IMR-90) and adult lung fibroblasts identified multiple genes that were hypermethylated in response to PGE(2). PGE(2), compared with nontreated controls, increased expression and activity (EC50 similar to 10(7) M) of one specific isoform of DNA methyltransferase, DNMT3a. Silencing of DNMT3a negated the ability of PGE(2) to increase DNMT activity. The increase in DNMT3a expression was mediated by PGE(2) signaling via its E prostanoid 2 receptor and the second messenger cAMP. PGE(2), compared with the untreated control, increased the expression and activity of Sp1 and Sp3 (EC50 similar to 3 x 10(7) M), transcription factors known to increase DNMT3a expression, and inhibition of these transcription factors abrogated the PGE(2) increase of DNMT3a expression. These findings were specific to fibroblasts, as PGE(2) decreased DNMT1 and DNMT3a expression in RAW macrophages. Taken together, these findings establish that DNA methylation is regulated by a ubiquitous bioactive endogenous mediator. Given that PGE(2) biosynthesis is modulated by environmental toxins, various disease states, and commonly used pharmacological agents, these findings uncover a novel mechanism by which alterations in DNA methylation patterns may arise in association with disease and certain environmental exposures.-Huang, S. K., Scruggs, A. M., Donaghy, J., McEachin, R. C., Fisher, A. S., Richardson, B. C., Peters-Golden, M. Prostaglandin E-2 increases fibroblast gene-specific and global DNA methylation via increased DNA methyltransferase expression. FASEB J. 26, 3703-3714 (2012). www.fasebj.org	[Huang, Steven K.; Scruggs, Anne M.; Donaghy, Jake; Fisher, Aaron S.; Peters-Golden, Marc] Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA; [McEachin, Richard C.] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, Ann Arbor, MI USA; [Richardson, Bruce C.] Univ Michigan, Sch Med, Div Rheumatol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Huang, SK (corresponding author), 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	stehuang@umich.edu			American Thoracic Society Coalition for Pulmonary Fibrosis Foundation; U.S. National Institutes of Health [HL094657, HL094311, AG013283, P30 ES017885]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL094657, R01HL094311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES017885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013283] Funding Source: NIH RePORTER	American Thoracic Society Coalition for Pulmonary Fibrosis Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Drs. Robert Lyons and Susan L. Dagenais for their assistance with the HumanMethylation27 CpG array. This work was funded by a grant from the American Thoracic Society Coalition for Pulmonary Fibrosis Foundation and by grants HL094657 (to S. K. H.), HL094311 (to M.P.-G.), AG013283, and P30 ES017885 from the U.S. National Institutes of Health.	Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Balana C, 2003, CLIN CANCER RES, V9, P1461; Ballestar E, 2006, J IMMUNOL, V176, P7143, DOI 10.4049/jimmunol.176.12.7143; BOROK Z, 1991, AM REV RESPIR DIS, V144, P1080, DOI 10.1164/ajrccm/144.5.1080; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Choung J, 1998, J CELL BIOCHEM, V71, P254, DOI 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.3.CO;2-L; DIBONA GF, 1986, AM J MED, V80, P12, DOI 10.1016/0002-9343(86)90928-9; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; FINE A, 1989, J BIOL CHEM, V264, P16988; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hagood JS, 2005, AM J PATHOL, V167, P365, DOI 10.1016/S0002-9440(10)62982-3; Hata K, 2002, DEVELOPMENT, V129, P1983; Huang S, 2007, AM J PHYSIOL-LUNG C, V292, pL405, DOI 10.1152/ajplung.00232.2006; Huang SK, 2008, AM J RESP CELL MOL, V39, P482, DOI 10.1165/rcmb.2008-0080OC; Huang SK, 2008, AM J RESP CRIT CARE, V177, P66, DOI 10.1164/rccm.200706-963OC; Huang SK, 2010, AM J PATHOL, V177, P2245, DOI 10.2353/ajpath.2010.100446; Huang SK, 2009, FASEB J, V23, P4317, DOI 10.1096/fj.08-128801; Jiang GF, 2008, TOXICOLOGY, V244, P49, DOI 10.1016/j.tox.2007.10.028; Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; Kolodsick JE, 2003, AM J RESP CELL MOL, V29, P537, DOI 10.1165/rcmb.2002-0243OC; Kristensen DM, 2011, ENVIRON HEALTH PERSP, V119, P534, DOI 10.1289/ehp.1002635; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li YP, 2010, EXP GERONTOL, V45, P312, DOI 10.1016/j.exger.2009.12.008; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Liu H, 2007, ONCOGENE, V26, P5900, DOI 10.1038/sj.onc.1210400; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; North ML, 2011, ANN ALLERG ASTHMA IM, V106, P355, DOI 10.1016/j.anai.2011.02.008; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; ROBERT A, 1979, GASTROENTEROLOGY, V77, P433; Sartor MA, 2010, BIOINFORMATICS, V26, P456, DOI 10.1093/bioinformatics/btp683; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Szczeklik W, 2004, J ALLERGY CLIN IMMUN, V114, P248, DOI 10.1016/j.jaci.2004.05.030; Toyota M, 2000, CANCER RES, V60, P4044; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weisenberger DJ, 2002, GENE, V298, P91, DOI 10.1016/S0378-1119(02)00976-9; White ES, 2005, AM J RESP CELL MOL, V32, P135, DOI 10.1165/rcmb.2004-0126OC; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608; Zheng Y, 2009, CANCER RES, V69, P896, DOI 10.1158/0008-5472.CAN-08-2677	53	43	44	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3703	3714		10.1096/fj.11-203323	http://dx.doi.org/10.1096/fj.11-203323			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22645246	Green Published, Green Submitted			2022-12-28	WOS:000308391600012
J	Richards, J; Gumz, ML				Richards, Jacob; Gumz, Michelle L.			Advances in understanding the peripheral circadian clocks	FASEB JOURNAL			English	Review						cardiovascular; metabolism; immune; endocrine; renal	PROTEIN PERIOD 1; BLOOD-PRESSURE; GENE-EXPRESSION; SHIFT WORK; MELATONIN; RHYTHMS; CARDIOMYOCYTE; HYPERTENSION; ENTRAINMENT; CELLS	In the past decade, it has become increasingly evident that the circadian clock system plays an important role in many physiological processes. The circadian clock can be divided into 2 parts: the central clock, residing in the suprachiasmatic nucleus of the hypothalamus, which receives light cues, and the peripheral clocks that reside in various tissues throughout the body. The peripheral clocks play an integral and unique role in each of their respective tissues, driving the circadian expression of specific genes involved in a variety of physiological functions. The goal of this review is to provide an introduction to and overview of the peripheral clocks, including potential mechanisms, targets, and implications for disease states. The peripheral clocks include the cardiovascular, metabolic, endocrine, immune, and reproductive systems.-Richards, J., Gumz, M. L. Advances in understanding the peripheral circadian clocks. FASEB J. 26, 3602-3613 (2012). www.fasebj.org	Univ Florida, Dept Med, Gainesville, FL USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Gumz, ML (corresponding author), 1600 SW Archer Rd,Box 100224, Gainesville, FL 32610 USA.	michelle.gumz@medicine.ufl.edu	Gumz, Michelle/AGX-2097-2022	Gumz, Michelle/0000-0002-1342-0878	U.S. National Institutes of Health (NIH) grant [DK085193]; University of Florida, Division of Nephrology; NIH grant [T32 DK-07518]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007518, K01DK085193] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Florida, Division of Nephrology; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health (NIH) grant DK085193 and University of Florida, Division of Nephrology, funds to M.L.G., and NIH grant T32 DK-07518 to J.R.	Agarwal R, 2010, CLIN J AM SOC NEPHRO, V5, P281, DOI 10.2215/CJN.07011009; Agarwal R, 2010, CURR OPIN NEPHROL HY, V19, P51, DOI 10.1097/MNH.0b013e3283336ddb; Albrecht U, 2004, FRONT BIOSCI-LANDMRK, V9, P48, DOI 10.2741/1196; Alvarez JD, 2008, J BIOL RHYTHM, V23, P26, DOI 10.1177/0748730407311254; Amaral IPG, 2012, AM J PHYSIOL-REG I, V302, pR193, DOI 10.1152/ajpregu.00367.2011; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bass J, 2010, SCIENCE, V330, P1349, DOI 10.1126/science.1195027; Bukowska A, 2011, MED PR, V62, P425; Challet E, 2007, ENDOCRINOLOGY, V148, P5648, DOI 10.1210/en.2007-0804; Chung S, 2011, BBA-MOL BASIS DIS, V1812, P581, DOI 10.1016/j.bbadis.2011.02.003; Costa MJ, 2011, J BIOL CHEM, V286, P9063, DOI 10.1074/jbc.M110.164558; Dallmann R, 2006, J COMP PHYSIOL A, V192, P769, DOI 10.1007/s00359-006-0114-9; Dallmann R, 2012, P NATL ACAD SCI USA, V109, P2625, DOI 10.1073/pnas.1114410109; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Despotovic Nebojsa, 2002, Med Pregl, V55, P419, DOI 10.2298/MPNS0210419D; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Doi M, 2010, NAT MED, V16, P67, DOI 10.1038/nm.2061; Durgan DJ, 2006, J BIOL CHEM, V281, P24254, DOI 10.1074/jbc.M601704200; Durgan DJ, 2010, CIRC RES, V106, P647, DOI 10.1161/CIRCRESAHA.109.209957; Durgan DJ, 2010, CIRC RES, V106, P546, DOI 10.1161/CIRCRESAHA.109.209346; Eckel-Mahan KL, 2012, P NATL ACAD SCI USA, V109, P5541, DOI 10.1073/pnas.1118726109; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Fahrenkrug J, 2006, ENDOCRINOLOGY, V147, P3769, DOI 10.1210/en.2006-0305; FEENER EP, 1995, J CLIN INVEST, V95, P1353, DOI 10.1172/JCI117786; Fortier EE, 2011, J IMMUNOL, V187, P6291, DOI 10.4049/jimmunol.1004030; Fournier S, 2012, AM HEART J, V163, P208, DOI 10.1016/j.ahj.2011.11.006; Franchimont D, 2004, ANN NY ACAD SCI, V1024, P124, DOI 10.1196/annals.1321.009; Fujino Y, 2006, AM J EPIDEMIOL, V164, P128, DOI 10.1093/aje/kwj185; Fukuda M, 2011, AM J PHYSIOL-RENAL, V301, pF953, DOI 10.1152/ajprenal.00167.2011; Gale JE, 2011, J BIOL RHYTHM, V26, P423, DOI 10.1177/0748730411416341; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gumz ML, 2010, BBA-GENE REGUL MECH, V1799, P622, DOI 10.1016/j.bbagrm.2010.09.003; Gumz ML, 2009, J CLIN INVEST, V119, P2423, DOI 10.1172/JCI36908; Guo HG, 2006, J NEUROSCI, V26, P6406, DOI 10.1523/JNEUROSCI.4676-05.2006; Hermida RC, 2010, CHRONOBIOL INT, V27, P1629, DOI 10.3109/07420528.2010.510230; HOSSMANN V, 1980, CARDIOVASC RES, V14, P125, DOI 10.1093/cvr/14.3.125; Imai SI, 2010, BBA-PROTEINS PROTEOM, V1804, P1584, DOI 10.1016/j.bbapap.2009.10.024; Jeyaraj D, 2012, CELL METAB, V15, P311, DOI 10.1016/j.cmet.2012.01.020; Jeyaraj D, 2012, NATURE, V483, P96, DOI 10.1038/nature10852; Jung-Hynes B, 2010, J PINEAL RES, V49, P60, DOI 10.1111/j.1600-079X.2010.00767.x; KANEKO M, 1968, J APPL PHYSIOL, V25, P109, DOI 10.1152/jappl.1968.25.2.109; Klose M, 2011, BIOL REPROD, V84, P124, DOI 10.1095/biolreprod.110.085126; Ko GYP, 2009, J NEUROCHEM, V110, P1150, DOI 10.1111/j.1471-4159.2009.06223.x; Kojima S, 2011, J CELL SCI, V124, P311, DOI 10.1242/jcs.065771; Komoto S, 2012, CHRONOBIOL INT, V29, P66, DOI 10.3109/07420528.2011.636496; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Konturek PC, 2011, J PHYSIOL PHARMACOL, V62, P139; la Fleur SE, 2001, J NEUROENDOCRINOL, V13, P1025, DOI 10.1046/j.1365-2826.2001.00717.x; Lamia KA, 2011, NATURE, V480, P552, DOI 10.1038/nature10700; Larochelle Pierre, 2002, J Clin Hypertens (Greenwich), V4, P3, DOI 10.1111/j.1524-6175.2002.01033.x; Lee HM, 2011, P NATL ACAD SCI USA, V108, P16451, DOI 10.1073/pnas.1107178108; LEE JHW, 2011, J HYDRO-ENVIRON RES, V5, P1, DOI DOI 10.1016/J.JHER.2011.02.001; LeSauter J, 2009, P NATL ACAD SCI USA, V106, P13582, DOI 10.1073/pnas.0906426106; Lieu SJ, 2012, J HYPERTENS, V30, P61, DOI 10.1097/HJH.0b013e32834e1ea3; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Logan RW, 2012, J IMMUNOL, V188, P2583, DOI 10.4049/jimmunol.1102715; Male V, 2012, TRENDS IMMUNOL, V33, P98, DOI 10.1016/j.it.2011.10.002; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Masuda Yoko, 2009, Kobe J Med Sci, V54, pE264; Mazzoccoli G, 2011, J BIOL REG HOMEOS AG, V25, P387; Monk TH, 2000, J BIOL RHYTHM, V15, P86, DOI 10.1177/074873040001500202; Morse D, 2003, MOL ENDOCRINOL, V17, P141, DOI 10.1210/me.2002-0184; Nebzydoski SJ, 2010, VET IMMUNOL IMMUNOP, V138, P183, DOI 10.1016/j.vetimm.2010.07.017; Nikolaeva S, 2012, J AM SOC NEPHROL, V23, P1019, DOI 10.1681/ASN.2011080842; Nishinaga H, 2009, BIOMED RES-TOKYO, V30, P87, DOI 10.2220/biomedres.30.87; PANZA JA, 1991, NEW ENGL J MED, V325, P986, DOI 10.1056/NEJM199110033251402; Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706; Peschke E, 2010, BEST PRACT RES CL EN, V24, P829, DOI 10.1016/j.beem.2010.09.001; Polonia J, 2003, J CARDIOVASC PHARM, V42, P98, DOI 10.1097/00005344-200307000-00015; Prasai MJ, 2011, J CLIN ENDOCR METAB, V96, P913, DOI 10.1210/jc.2010-2449; Radogna F, 2010, BIOCHEM PHARMACOL, V80, P1844, DOI 10.1016/j.bcp.2010.07.041; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Ratajczak CK, 2009, ENDOCRINOLOGY, V150, P1879, DOI 10.1210/en.2008-1021; Reddy AB, 2007, HEPATOLOGY, V45, P1478, DOI 10.1002/hep.21571; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R, 2012, CIRC RES, V110, P105, DOI 10.1161/CIRCRESAHA.111.254284; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Schug TT, 2011, ANN MED, V43, P198, DOI 10.3109/07853890.2010.547211; Sellix MT, 2010, TRENDS ENDOCRIN MET, V21, P628, DOI 10.1016/j.tem.2010.06.002; Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017; Silver AC, 2012, BRAIN BEHAV IMMUN, V26, P407, DOI 10.1016/j.bbi.2011.10.001; Son GH, 2011, FRONT NEUROENDOCRIN, V32, P451, DOI 10.1016/j.yfrne.2011.07.003; Sprouse J, 2010, PSYCHOPHARMACOLOGY, V210, P569, DOI 10.1007/s00213-010-1860-5; Stamenkovic JA, 2012, METABOLISM, V61, P978, DOI 10.1016/j.metabol.2011.11.013; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Stow LR, 2012, HYPERTENSION, V59, P1151, DOI 10.1161/HYPERTENSIONAHA.112.190892; Stow LR, 2011, J AM SOC NEPHROL, V22, P598, DOI 10.1681/ASN.2010080803; Takeda N, 2007, J BIOL CHEM, V282, P32561, DOI 10.1074/jbc.M705692200; Takeda N, 2011, J CARDIOL, V57, P249, DOI 10.1016/j.jjcc.2011.02.006; Tanida M, 2007, NEUROSCI LETT, V413, P177, DOI 10.1016/j.neulet.2006.11.050; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Uzu T, 1999, CIRCULATION, V100, P1635, DOI 10.1161/01.CIR.100.15.1635; Vieira E, 2012, ENDOCRINOLOGY, V153, P592, DOI 10.1210/en.2011-1595; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Virshup DM, 2007, COLD SPRING HARB SYM, V72, P413, DOI 10.1101/sqb.2007.72.048; Wang C, 2011, ENVIRON HEALTH PERSP, V119, P1739, DOI 10.1289/ehp.1103593; Wang NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009; Wang Q, 2010, AM J PHYSIOL-REG I, V299, pR1013, DOI 10.1152/ajpregu.00241.2010; Wu T, 2010, AM J PHYSIOL-REG I, V298, pR635, DOI 10.1152/ajpregu.00578.2009; Zhang EE, 2010, NAT REV MOL CELL BIO, V11, P764, DOI 10.1038/nrm2995; Zhang EE, 2010, NAT MED, V16, P1152, DOI 10.1038/nm.2214; Zhang XP, 2012, NUCLEIC ACIDS RES, V40, P3419, DOI 10.1093/nar/gkr1297; Zhou W, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-141; Zuber AM, 2009, P NATL ACAD SCI USA, V106, P16523, DOI 10.1073/pnas.0904890106	107	119	127	0	52	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3602	3613		10.1096/fj.12-203554	http://dx.doi.org/10.1096/fj.12-203554			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22661008	Green Published			2022-12-28	WOS:000308391600003
J	Ahmed, A; Gaadhe, K; Sharma, GP; Kumar, N; Neculai, M; Hui, R; Mohanty, D; Sharma, P				Ahmed, Anwar; Gaadhe, Kavita; Sharma, Guru Prasad; Kumar, Narendra; Neculai, Mirela; Hui, Raymond; Mohanty, Debasisa; Sharma, Pushkar			Novel insights into the regulation of malarial calcium-dependent protein kinase 1	FASEB JOURNAL			English	Article						autophosphorylation; structure-function	PARASITE PLASMODIUM-FALCIPARUM; CALMODULIN-LIKE DOMAIN; ACTIVATION; SUBSTRATE; MOTILITY; INVASION; COMPLEX	Calcium-dependent protein kinases (CDPKs) are major effectors of calcium signaling in apicomplexan parasites like Toxoplasma and Plasmodium and control important processes of the parasite life cycle. Despite recently reported crystal structures of Toxoplasma gondii (Tg)CDPKs, several important questions about their regulation remain unanswered. Plasmodium falciparum (Pf)CDPK1 has emerged as a key player in the life cycle of the malaria parasite, as it may be involved in the invasion of the host cells. Molecular modeling and site-directed mutagenesis studies on PfCDPK1 suggested that several residues in the regulatory domain play a dual role, as they seem to contribute to the stabilization of both the active and inactive kinase. Mass spectrometry revealed that PfCDPK1 was autophosphorylated at several sites; some of these were placed at strategic locations and therefore were found to be critical for kinase activation. The N-terminal extension of PfCDPK1 was found to be important for PfCDPK1 activation. Unexpectedly, an ATP binding site in the NTE of PfCDPK1 was identified. Our studies highlight several novel features of PfCDPK1 regulation, which may be shared by other members of the CDPK family. These findings may also aid design of inhibitors against these important targets, which are absent from the host.-Ahmed, A., Gaadhe, K., Sharma, G. P., Kumar, N., Neculai, M., Hui, R., Mohanty, D., Sharma, P. Novel insights into the regulation of malarial calcium-dependent protein kinase 1. FASEB J. 26, 3212-3221 (2012). www.fasebj.org	[Ahmed, Anwar; Gaadhe, Kavita; Sharma, Guru Prasad; Sharma, Pushkar] Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India; [Kumar, Narendra; Mohanty, Debasisa] Natl Inst Immunol, Bioinformat Ctr, New Delhi 110067, India; [Neculai, Mirela; Hui, Raymond] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Department of Biotechnology (DBT) India; National Institute of Immunology (NII); University of Toronto; Structural Genomics Consortium	Sharma, P (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India.	pushkar@nii.ac.in	Ahmed, Anwar/ADH-1445-2022; Ahmed, Anwar/AAL-7789-2021; Sharma, Guruprasad/M-5256-2017; Mohanty, Debasisa/A-1428-2009	Ahmed, Anwar/0000-0001-8147-714X; Sharma, Guruprasad/0000-0003-3197-4396; MOHANTY, DEBASISA/0000-0002-3374-0588; Kumar, Narendra/0000-0002-3978-8742	Department of Science and Technology, India; Signalling in Life Cycle Stages of Malaria Parasites (MALSIG) project; European Union under FP7; U.S. National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases [R01AI075459]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI075459] Funding Source: NIH RePORTER	Department of Science and Technology, India(Department of Science & Technology (India)); Signalling in Life Cycle Stages of Malaria Parasites (MALSIG) project; European Union under FP7; U.S. National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	P.S. received a Swarnajayanti Fellowship grant from the Department of Science and Technology, India, and his laboratory is supported by the Signalling in Life Cycle Stages of Malaria Parasites (MALSIG) project funded by the European Union under FP7. This work was also supported in part by U.S. National Institutes of Health grant R01AI075459 from the National Institute of Allergy and Infectious Diseases. The assistance rendered by Shivang Vachharajani, Ashutosh Upadhyay and Sudhir Kumar in generating constructs, protein expression and kinase assays is acknowledged.	Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Doerig C, 2009, PARASITE, V16, P169, DOI 10.1051/parasite/2009163169; Doerig C, 2008, TRENDS PARASITOL, V24, P570, DOI 10.1016/j.pt.2008.08.007; Dvorin JD, 2010, SCIENCE, V328, P910, DOI 10.1126/science.1188191; Fieulaine S, 2002, P NATL ACAD SCI USA, V99, P13437, DOI 10.1073/pnas.192368699; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; Gazarini ML, 2004, BIOCHEM BIOPH RES CO, V321, P138, DOI 10.1016/j.bbrc.2004.06.141; Green JL, 2008, J BIOL CHEM, V283, P30980, DOI 10.1074/jbc.M803129200; Harper JF, 2005, NAT REV MOL CELL BIO, V6, P555, DOI 10.1038/nrm1679; Hegeman AD, 2006, PROTEOMICS, V6, P3649, DOI 10.1002/pmic.200500926; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Kato N, 2008, NAT CHEM BIOL, V4, P347, DOI 10.1038/nchembio.87; Koyama FC, 2009, MOL BIOCHEM PARASIT, V165, P1, DOI 10.1016/j.molbiopara.2009.01.003; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Nagamune Kisaburo, 2008, V47, P70; Ojo KK, 2010, NAT STRUCT MOL BIOL, V17, P602, DOI 10.1038/nsmb.1818; Ranjan R, 2009, J BIOL CHEM, V284, P15267, DOI 10.1074/jbc.M900656200; Rellos P, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000426; Siden-Kiamos I, 2006, MOL MICROBIOL, V60, P1355, DOI 10.1111/j.1365-2958.2006.05189.x; Solyakov L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1558; Treeck M, 2011, CELL HOST MICROBE, V10, P410, DOI 10.1016/j.chom.2011.09.004; Vaid A, 2008, J BIOL CHEM, V283, P5589, DOI 10.1074/jbc.M708465200; Vitart V, 2000, BIOCHEMISTRY-US, V39, P4004, DOI 10.1021/bi992373m; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Wernimont AK, 2011, PROTEINS, V79, P803, DOI 10.1002/prot.22919; Wernimont AK, 2010, NAT STRUCT MOL BIOL, V17, P596, DOI 10.1038/nsmb.1795; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612	28	20	20	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3212	3221		10.1096/fj.12-203877	http://dx.doi.org/10.1096/fj.12-203877			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22539638	Green Published			2022-12-28	WOS:000307162800012
J	Bier, C; Knauer, SK; Wunsch, D; Kunst, L; Scheiding, S; Kaiser, M; Ottmann, C; Kramer, OH; Stauber, RH				Bier, Carolin; Knauer, Shirley K.; Wuensch, Desiree; Kunst, Lena; Scheiding, Sabine; Kaiser, Markus; Ottmann, Christian; Kraemer, Oliver H.; Stauber, Roland H.			Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo	FASEB JOURNAL			English	Article						protein complex stabilizer; chemical biology; protease; dominant negative; protein interaction; threonine aspartase-1	PROTEIN-PROTEIN INTERACTIONS; STABILIZATION; PROTEASES; SURVIVIN; MLL	Taspase1 mediates cleavage of the mixed lineage leukemia (MLL) protein and leukemia-provoking MLL fusions and promotes solid malignancies. Currently, no effective and specific Taspase1 inhibitors are available, precluding its therapeutic exploitation. As the Taspase1 proenzyme is autoproteolytically cleaved and assumed to assemble into an active alpha beta beta alpha heterodimer, we attempted to interfere with its activity by targeting Taspase1's dimerization. Notably, enforced expression of inactive Taspase1 mutants, aiming to inhibit formation of active protease dimers, was not inhibitory. Immunoprecipitation, gel filtration, and in vivo protein interaction assays revealed that active Taspase1 exists predominantly as an alpha beta monomer in living cells, providing an explanation why overexpression of inactive mutants was not trans-dominant. To alternatively test the biological consequences of enforced dimerization, we engineered Taspase1 variants containing the Jun/Fos dimerization motif. In absence of the respective interaction partners, the protease fusions were fully active, while enforcing dimerization by coexpression significantly inhibited processing of several target proteins in living cells. Our study provides the first evidence that Taspase1 is already active as an alpha beta monomer, arguing against heterocomplex formation being required for its pathobiological activity. Thus, it clearly supports strategies aiming to inhibit the cancer-promoting activity of Taspase1 by the identification of chemical decoys enforcing its dimerization.-Bier, C., Knauer, S. K., Wunsch, D., Kunst, L., Scheiding, S., Kaiser, M., Ottmann, C., Kramer, O. H., Stauber, R. H. Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo. FASEB J. 26, 3421-3429 (2012). www.fasebj.org	[Bier, Carolin; Wuensch, Desiree; Stauber, Roland H.] Univ Med Ctr Mainz, Mainz Screening Ctr, D-55101 Mainz, Germany; [Knauer, Shirley K.; Kunst, Lena] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Inst Mol Biol, D-45117 Essen, Germany; [Kaiser, Markus] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Inst Biol Chem, Essen, Germany; [Scheiding, Sabine; Kraemer, Oliver H.] Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Jena, Germany; [Ottmann, Christian] Max Planck Gesell, Chem Genom Ctr, Dortmund, Germany	Johannes Gutenberg University of Mainz; University of Duisburg Essen; University of Duisburg Essen; Friedrich Schiller University of Jena; Max Planck Society	Stauber, RH (corresponding author), Univ Med Ctr Mainz, Mainz Screening Ctr, Langenbeckstr 1, D-55101 Mainz, Germany.	shirley.knauer@uni-due.de; rstauber@uni-mainz.de	Krämer, Oliver H/L-9266-2015; Gül, Désirée/AAB-5965-2022; Knauer, Shirley K/E-7931-2012	Krämer, Oliver H/0000-0003-3973-045X; Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523; Guel, Desiree/0000-0002-2446-5756	German Cancer Aid [FKZ102362]; Fritz Thyssen Foundation; Head and Neck Cancer Foundation; Deutsche Forschungsgemeinschaft [DFG INST371/5-1FUGG]; Inneruniversity and MAIFOR Mainz Support Program	German Cancer Aid(Deutsche Krebshilfe); Fritz Thyssen Foundation; Head and Neck Cancer Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Inneruniversity and MAIFOR Mainz Support Program	The authors thank Sandra Friedl for excellent technical assistance. This study was supported by grants from German Cancer Aid (FKZ102362), the Fritz Thyssen Foundation, the Head and Neck Cancer Foundation, Deutsche Forschungsgemeinschaft (DFG INST371/5-1FUGG), and the Inneruniversity and MAIFOR Mainz Support Program. The authors declare no conflicts of interest.	Arkin MR, 2009, CURR OPIN CHEM BIOL, V13, P284, DOI 10.1016/j.cbpa.2009.05.125; Bier C., 2012, CANCER RES, DOI [10.1158/0008-5472.CAN-12-0150, DOI 10.1158/0008-5472.CAN-12-0150]; Bier C, 2011, TRAFFIC, V12, P703, DOI 10.1111/j.1600-0854.2011.01191.x; Bier C, 2011, J BIOL CHEM, V286, P3007, DOI 10.1074/jbc.M110.161646; Chen DY, 2012, CANCER RES, V72, P736, DOI 10.1158/0008-5472.CAN-11-2584; Chen DY, 2010, CANCER RES, V70, P5358, DOI 10.1158/0008-5472.CAN-10-0027; Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Engels K, 2007, J PATHOL, V211, P532, DOI 10.1002/path.2134; Ginter T, 2012, CELL SIGNAL, V24, P1453, DOI 10.1016/j.cellsig.2012.02.018; Hauske P, 2008, CHEMBIOCHEM, V9, P2920, DOI 10.1002/cbic.200800528; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601; Khan JA, 2005, STRUCTURE, V13, P1443, DOI 10.1016/j.str.2005.07.006; Knauer SK, 2007, CELL CYCLE, V6, P1502; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Knauer SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018253; Knauer SK, 2005, ANAL CHEM, V77, P4815, DOI 10.1021/ac050413o; Knauer SK, 2005, TRAFFIC, V6, P594, DOI 10.1111/j.1600-0854.2005.00298.x; Knauer SK, 2005, MOL CELL BIOL, V25, P2573, DOI 10.1128/MCB.25.7.2573-2582.2005; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Labisso WL, 2012, CELL CYCLE, V11, P1593, DOI 10.4161/cc.20008; Laskowski RA, 2009, FEBS LETT, V583, P1692, DOI 10.1016/j.febslet.2009.03.019; Mitternacht S, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002148; Molzan M, 2010, MOL CELL BIOL, V30, P4698, DOI 10.1128/MCB.01636-09; Ordonez Gonzalo R., 2009, V539, P33, DOI 10.1007/978-1-60327-003-8_2; Ottmann C, 2009, J MOL BIOL, V386, P913, DOI 10.1016/j.jmb.2009.01.005; Pless B, 2011, LEUKEMIA, V25, P663, DOI 10.1038/leu.2010.308; Rose R, 2010, ANGEW CHEM INT EDIT, V49, P4129, DOI 10.1002/anie.200907203; Saunders LP, 2008, MOL CANCER THER, V7, P3352, DOI 10.1158/1535-7163.MCT-08-0463; Schumacher B, 2010, FEBS LETT, V584, P1443, DOI 10.1016/j.febslet.2010.02.065; Shen XY, 2008, P NATL ACAD SCI USA, V105, P18788, DOI 10.1073/pnas.0810104105; Simard JR, 2009, J AM CHEM SOC, V131, P18478, DOI 10.1021/ja907795q; Sperandio O, 2010, DRUG DISCOV TODAY, V15, P220, DOI 10.1016/j.drudis.2009.11.007; Stauber RH, 2012, ONCOTARGET, V3, P31; Tanaka T, 2008, CELL CYCLE, V7, P1569, DOI 10.4161/cc.7.11.6061; Tenzer S, 2011, ACS NANO, V5, P7155, DOI 10.1021/nn201950e; Thiel P, 2012, ANGEW CHEM INT EDIT, V51, P2012, DOI 10.1002/anie.201107616; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Weber L, 2010, EXPERT OPIN THER PAT, V20, P179, DOI 10.1517/13543770903514129; Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017; Zhou HQ, 2006, MOL CELL BIOL, V26, P2728, DOI 10.1128/MCB.26.7.2728-2735.2006; Zinzalla G, 2009, FUTURE MED CHEM, V1, P65, DOI [10.4155/fmc.09.12, 10.4155/FMC.09.12]; Zudaire E, 2011, United States patent US, Patent No. [WO2011/014825 A2, 2011014825]	44	18	18	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3421	3429		10.1096/fj.11-202432	http://dx.doi.org/10.1096/fj.11-202432			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22623586				2022-12-28	WOS:000307162800029
J	Comps-Agrar, L; Kniazeff, J; Brock, C; Trinquet, E; Pin, JP				Comps-Agrar, Laetitia; Kniazeff, Julie; Brock, Carsten; Trinquet, Eric; Pin, Jean-Philippe			Stability of GABA(B) receptor oligomers revealed by dual TR-FRET and drug-induced cell surface targeting	FASEB JOURNAL			English	Article						GPCRs; protein complex dynamics; protein-protein interaction	PROTEIN-COUPLED RECEPTOR; SINGLE-MOLECULE TRACKING; ENDOPLASMIC-RETICULUM; WILD-TYPE; ACTIVATION; SUBUNITS; GB2; HETERODIMERIZATION; TRAFFICKING; TRANSPORT	The function of cell surface proteins likely involves the formation and dissociation of oligomeric complexes. However, the dynamics of this process are unknown. Here we examined this process for the GABA(B) receptors that assemble into oligomers of heterodimers through the association of their GABA(B1) subunit. We report a method to study oligomer dynamics based on a drug-controlled cell surface targeting of intracellularly retained receptors and a parallel measurement of two FRET signals in HEK293 cells. GABA(B1) subunits at the cell surface (4.0 +/- 0.6 a.u.) are labeled with a pair of fluorophores (donor and red acceptor). New receptors are then targeted to the cell surface during 3h treatment with AP21967 such that the number of receptors is doubled (9.1 +/- 0.7 a.u.). After labeling these new receptors with a second acceptor (green), the red FRET remained unchanged (5189 +/- 36 vs. 4783 +/- 32 cps), supporting the stability of the preformed oligomers. However, new oligomers are detected by the green FRET signal indicating both receptor populations are in the same microdomains. As a control, we confirmed the strict stability of the GABA(B) heterodimer itself. Herein, using a novel method to monitor the dynamics of cell surface complexes, we provide evidence for the stability of GABA(B) oligomers.-Comps-Agrar, L., Kniazeff, J., Brock, C., Trinquet, E., Pin, J.-P. Stability of GABA(B) receptor oligomers revealed by dual TR-FRET and drug-induced cell surface targeting. FASEB J. 26, 3430-3439 (2012). www.fasebj.org	[Comps-Agrar, Laetitia; Kniazeff, Julie; Brock, Carsten; Pin, Jean-Philippe] CNRS, Inst Genom Fonct, Dept Mol Pharmacol, UMR 5203,INSERM U661, F-34094 Montpellier 5, France; [Comps-Agrar, Laetitia; Trinquet, Eric] Cisbio Bioassays, Codolet, France; [Comps-Agrar, Laetitia; Kniazeff, Julie; Brock, Carsten; Trinquet, Eric; Pin, Jean-Philippe] Univ Montpellier I, Montpellier, France; [Comps-Agrar, Laetitia; Kniazeff, Julie; Brock, Carsten; Trinquet, Eric; Pin, Jean-Philippe] Univ Montpellier 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier	Kniazeff, J (corresponding author), CNRS, Inst Genom Fonct, Dept Mol Pharmacol, UMR 5203,INSERM U661, 141 Rue Cardonille, F-34094 Montpellier 5, France.	julie.kniazeff@igf.cnrs.fr; jppin@igf.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Kniazeff, Julie/0000-0002-0426-0999; Comps-Agrar, Laetitia/0000-0002-5260-6536	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale; Cisbio Bioassays; French Ministry of Research, Agence Nationale de la Recherche [ANR-06-BLAN-0087, ANR-09-BLAN-0272]; Senomyx (San Diego, CA, USA); Conventions Industrielles de Formation par la Recherche fellowship from Cisbio Bioassays; French government	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)Centre National de la Recherche Scientifique (CNRS)); Cisbio Bioassays; French Ministry of Research, Agence Nationale de la Recherche(French National Research Agency (ANR)); Senomyx (San Diego, CA, USA); Conventions Industrielles de Formation par la Recherche fellowship from Cisbio Bioassays; French government	The authors thank Drs. Sebastien Granier, Damien Maurel, and Gregory Stewart for constructive discussions. Ariad Pharmeceuticals, Inc. (Cambridge, MA, USA) gracefully provided the AP21967. The FRET experiments have been performed using the ARPEGE (Pharmacology Screening-Interactome) platform facility at the Institut de Genomique Fonctionnelle (Montpellier, France). The authors thank the Montpellier RIO Imaging facility of the Institut de Genetique Humaine (Montpellier, France). This work was supported by Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, and Cisbio Bioassays, and by grants from the French Ministry of Research, Agence Nationale de la Recherche (ANR-06-BLAN-0087 and ANR-09-BLAN-0272), and by an unrestricted grant from Senomyx (San Diego, CA, USA). L.C.-A. was supported by a Conventions Industrielles de Formation par la Recherche fellowship from Cisbio Bioassays and the French government. Author contributions: L.C.A. conceived, performed, and analyzed all the experiments and wrote the manuscript; J.K. participated in the experiments and their analysis and wrote the manuscript; C.B. initiated the validation of the drug-induced targeting system on CD4; E.T. and J.P.P. supervised the work; and J.P.P. and J.K. finalized the manuscript.	Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200; Bazin H, 2002, J Biotechnol, V82, P233, DOI 10.1016/S1389-0352(01)00040-X; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carriba P, 2008, NAT METHODS, V5, P727, DOI 10.1038/nmeth.1229; Comps-Agrar L, 2011, EMBO J, V30, P2336, DOI 10.1038/emboj.2011.143; Dorsch S, 2009, NAT METHODS, V6, P225, DOI [10.1038/NMETH.1304, 10.1038/nmeth.1304]; Doumazane E, 2011, FASEB J, V25, P66, DOI 10.1096/fj.10-163147; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Gautier A, 2008, CHEM BIOL, V15, P128, DOI 10.1016/j.chembiol.2008.01.007; Gronemeyer T, 2006, PROTEIN ENG DES SEL, V19, P309, DOI 10.1093/protein/gzl014; Gurevich VV, 2008, TRENDS NEUROSCI, V31, P74, DOI 10.1016/j.tins.2007.11.007; Hansen JL, 2004, J BIOL CHEM, V279, P24108, DOI 10.1074/jbc.M400092200; Hern JA, 2010, P NATL ACAD SCI USA, V107, P2693, DOI 10.1073/pnas.0907915107; Kasai RS, 2011, J CELL BIOL, V192, P463, DOI 10.1083/jcb.201009128; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637; Kusumi A, 2010, FEBS LETT, V584, P1814, DOI 10.1016/j.febslet.2010.02.047; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; Milligan G, 2007, TRENDS PHARMACOL SCI, V28, P615, DOI 10.1016/j.tips.2007.11.001; Pagano A, 2001, J NEUROSCI, V21, P1189; Pin J.-P., 2010, G PROTEIN COUPLED RE, P67; Pisterzi LF, 2010, J BIOL CHEM, V285, P16723, DOI 10.1074/jbc.M109.069443; Pollock R, 2000, P NATL ACAD SCI USA, V97, P13221, DOI 10.1073/pnas.230446297; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Schwenk J, 2010, NATURE, V465, P231, DOI 10.1038/nature08964; Selvin PR, 2002, ANNU REV BIOPH BIOM, V31, P275, DOI 10.1146/annurev.biophys.31.101101.140927; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104	39	26	27	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3430	3439		10.1096/fj.12-203646	http://dx.doi.org/10.1096/fj.12-203646			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22613777				2022-12-28	WOS:000307162800030
J	Nurbaeva, MK; Schmid, E; Szteyn, K; Yang, WT; Viollet, B; Shumilina, E; Lang, F				Nurbaeva, Meerim K.; Schmid, Evi; Szteyn, Kalina; Yang, Wenting; Viollet, Benoit; Shumilina, Ekaterina; Lang, Florian			Enhanced Ca2+ entry and Na+/Ca2+ exchanger activity in dendritic cells from AMP-activated protein kinase-deficient mice	FASEB JOURNAL			English	Article						energy depletion; AMPK; CRAC; store-operated calcium channel; migration; NCX; NKCX	MITOCHONDRIAL CALCIUM UNIPORTER; UBIQUITIN LIGASE NEDD4-2; RENAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; PLASMA-MEMBRANE; NA/CA EXCHANGE; PULMONARY-ARTERY; SKELETAL-MUSCLE; DOWN-REGULATION; CRAC CHANNEL	In dendritic cells (DCs), chemotactic chemokines, such as CXCL12, rapidly increase cytosolic Ca2+ concentrations ([Ca2+](i)) by triggering Ca2+ release from intracellular stores followed by store-operated Ca2+ (SOC) entry. Increase of [Ca2+](i) is blunted and terminated by Ca2+ extrusion, accomplished by K+-independent Na+/Ca2+ exchangers (NCXs) and K+-dependent Na+/Ca2+ exchangers (NCKXs). Increased [Ca2+](i) activates energy-sensing AMP-activated protein kinase (AMPK), which suppresses proinflammatory responses of DCs and macrophages. The present study explored whether AMPK participates in the regulation of DC [Ca2+](i) and migration. DCs were isolated from AMPK alpha 1-deficient (ampk(-/-)) mice and, as control, from their wild-type (ampk(-/-)) littermates. AMPK alpha 1, Orai1-2, STIM1-2, and mitochondrial calcium uniporter protein expression was determined by Western blotting, [Ca2+](i) by Fura-2 fluorescence, SOC entry by inhibition of endosomal Ca2+ ATPase with thapsigargin (1 mu M), Na+/Ca2+ exchanger activity from increase of [Ca2+](i), and respective whole-cell current in patch clamp following removal of extracellular Na+. Migration was quantified utilizing transwell chambers. AMPK alpha 1 protein is expressed in ampk(+/+) DCs but not in ampk(-/-) DCs. CXCL12 (300 ng/ml)-induced increase of [Ca2+](i), SOC entry, Orai 1 protein abundance, NCX, and NCKX were all significantly higher in ampk(-/-) DCs than in ampk(+/+) DCs. NCX and NCKX currents were similarly increased in ampk(-/-) DCs. Moreover, CXCL12 (50 ng/ml)-induced DC migration was enhanced in ampk(-/-) DCs. AMPK thus inhibits SOC entry, Na+/Ca2+ exchangers, and migration of DCs.-Nurbaeva, M. K., Schmid, E., Szteyn, K., Yang, W., Viollet, B., Shumilina, E., Lang, F. Enhanced Ca2+ entry and Na+/Ca2+ exchanger activity in dendritic cells from AMP-activated protein kinase-deficient mice. FASEB J. 26, 3049-3058 (2012). www.fasebj.org	[Nurbaeva, Meerim K.; Schmid, Evi; Szteyn, Kalina; Yang, Wenting; Shumilina, Ekaterina; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Viollet, Benoit] INSERM, Inst Cochin, Dept Genet Dev & Pathol Mol, U567, Paris, France	Eberhard Karls University of Tubingen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Viollet, Benoit/O-6927-2017; Chaube, Balkrishna/F-8879-2012	Viollet, Benoit/0000-0002-0121-0224; Chaube, Balkrishna/0000-0003-4378-7416	Deutsche Forschungsgemeinschaft (DFG) [SFB 766, GRK 1302/1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors gratefully acknowledge the meticulous preparation of the manuscript by L. Subasic and S. Ruebe. This work was supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 766; GRK 1302/1).	Albert AP, 2008, AM J PHYSIOL-LUNG C, V295, pL837, DOI 10.1152/ajplung.90353.2008; Alesutan I, 2011, BIOCHEM BIOPH RES CO, V408, P505, DOI 10.1016/j.bbrc.2011.04.015; Alesutan I, 2011, J MEMBRANE BIOL, V240, P151, DOI 10.1007/s00232-011-9353-y; Alesutan I, 2011, MOL MEMBR BIOL, V28, P79, DOI 10.3109/09687688.2010.520037; Almaca J, 2009, PFLUG ARCH EUR J PHY, V458, P713, DOI 10.1007/s00424-009-0660-4; Alzamora R, 2010, AM J PHYSIOL-RENAL, V299, pF1308, DOI 10.1152/ajprenal.00423.2010; Andersen MN, 2012, TRAFFIC, V13, P143, DOI 10.1111/j.1600-0854.2011.01295.x; Aneiros E, 2005, J IMMUNOL, V174, P119, DOI 10.4049/jimmunol.174.1.119; Bair AM, 2009, J BIOL CHEM, V284, P563, DOI 10.1074/jbc.M803984200; BALASUBRAMANYAM M, 1994, J CLIN INVEST, V94, P2002, DOI 10.1172/JCI117553; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bandyopadhyay BC, 2011, J LEUKOCYTE BIOL, V89, P57, DOI 10.1189/jlb.0610381; Barbet G, 2008, NAT IMMUNOL, V9, P1148, DOI 10.1038/ni.1648; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhalla V, 2006, J BIOL CHEM, V281, P26159, DOI 10.1074/jbc.M606045200; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Canitano A, 2002, ANN NY ACAD SCI, V976, P394; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Connolly SF, 2007, IMMUNOL RES, V39, P115, DOI 10.1007/s12026-007-0076-1; Dallas ML, 2009, ADV EXP MED BIOL, V648, P89, DOI 10.1007/978-90-481-2259-2_10; Dallas ML, 2009, ADV EXP MED BIOL, V648, P57, DOI 10.1007/978-90-481-2259-2_6; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; den Haan JMM, 2000, P NATL ACAD SCI USA, V97, P12950, DOI 10.1073/pnas.97.24.12950; Dreval V, 2005, CELL PHYSIOL BIOCHEM, V16, P119, DOI 10.1159/000087738; Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10-178210; Fahmer M, 2009, IMMUNOL REV, V231, P99, DOI 10.1111/j.1600-065X.2009.00815.x; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Gusarova GA, 2011, MOL CELL BIOL, V31, P3546, DOI 10.1128/MCB.05114-11; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardie DG, 2008, INT J OBESITY, V32, pS7, DOI 10.1038/ijo.2008.116; Heise N, 2011, AM J PHYSIOL-CELL PH, V300, pC1306, DOI 10.1152/ajpcell.00396.2010; Herchuelz A, 2007, ANN NY ACAD SCI, V1099, P456, DOI 10.1196/annals.1387.048; Hirschler-Laszkiewicz I, 2011, J BIOL CHEM, V286, P30636, DOI 10.1074/jbc.M111.238360; Hsu SF, 2001, J IMMUNOL, V166, P6126, DOI 10.4049/jimmunol.166.10.6126; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; Koski GK, 1999, J IMMUNOL, V163, P82; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Kreneisz O, 2009, J PHYSIOL-LONDON, V587, P5819, DOI 10.1113/jphysiol.2009.180372; Lim A, 2009, DIABETES, V58, P2813, DOI 10.2337/db09-0600; Lytton J, 2007, BIOCHEM J, V406, P365, DOI 10.1042/BJ20070619; Mace OJ, 2008, J PHYSIOL-LONDON, V586, P4541, DOI 10.1113/jphysiol.2008.158253; Matzner N, 2008, J IMMUNOL, V181, P6803, DOI 10.4049/jimmunol.181.10.6803; Mungai PT, 2011, MOL CELL BIOL, V31, P3531, DOI 10.1128/MCB.05124-11; Myerburg MM, 2010, AM J RESP CELL MOL, V42, P676, DOI 10.1165/2009-0147OC; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park S, 2009, AM J PHYSIOL-CELL PH, V296, pC106, DOI 10.1152/ajpcell.00114.2008; Partida-Sanchez S, 2004, IMMUNITY, V20, P279, DOI 10.1016/S1074-7613(04)00048-2; Partida-Sanchez S, 2007, J IMMUNOL, V179, P7827, DOI 10.4049/jimmunol.179.11.7827; Peel SE, 2008, AM J RESP CELL MOL, V38, P744, DOI 10.1165/rcmb.2007-0395OC; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Penna A, 2008, NATURE, V456, P116, DOI 10.1038/nature07338; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney JW, 2007, J CELL SCI, V120, P1959, DOI 10.1242/jcs.03462; Reppel M, 2007, ANN NY ACAD SCI, V1099, P361, DOI 10.1196/annals.1387.065; Rotte A, 2010, BIOCHEM BIOPH RES CO, V398, P677, DOI 10.1016/j.bbrc.2010.06.135; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Rumpel E, 2000, BIOPHYS J, V79, P2975, DOI 10.1016/S0006-3495(00)76534-9; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Salter RD, 2009, IMMUNOL REV, V231, P278, DOI 10.1111/j.1600-065X.2009.00806.x; Schmitt R, 1999, AM J PHYSIOL-RENAL, V276, pF367, DOI 10.1152/ajprenal.1999.276.3.F367; Shin DM, 2008, NAT CELL BIOL, V10, P639, DOI 10.1038/ncb0608-639; Shumilina E, 2011, AM J PHYSIOL-CELL PH, V300, pC1205, DOI 10.1152/ajpcell.00039.2011; Shumilina E, 2010, FASEB J, V24, P1989, DOI 10.1096/fj.09-142265; Sidani S, 2009, PFLUG ARCH EUR J PHY, V459, P39, DOI 10.1007/s00424-009-0698-3; Sipido KR, 2007, ANN NY ACAD SCI, V1099, P339, DOI 10.1196/annals.1387.066; Smyth JT, 2010, J CELL MOL MED, V14, P2337, DOI 10.1111/j.1582-4934.2010.01168.x; Sopjani M, 2010, J NEUROCHEM, V113, P1426, DOI 10.1111/j.1471-4159.2010.06678.x; Sopjani M, 2010, MOL MEMBR BIOL, V27, P137, DOI 10.3109/09687681003616870; Staiano RL, 2009, EUR J IMMUNOL, V39, P1405, DOI 10.1002/eji.200838792; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Sumoza-Toledo A, 2011, FASEB J, V25, P3529, DOI 10.1096/fj.10-178483; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Tang C, 2010, PHYSIOL RES, V59, P909, DOI 10.33549/physiolres.931875; Tintinger GR, 2004, BIOCHEM PHARMACOL, V67, P2263, DOI 10.1016/j.bcp.2004.02.029; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Turrell HE, 2011, J MOL CELL CARDIOL, V51, P370, DOI 10.1016/j.yjmcc.2011.06.015; Venetucci LA, 2007, ANN NY ACAD SCI, V1099, P315, DOI 10.1196/annals.1387.033; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Visser F, 2007, PHYSIOLOGY, V22, P185, DOI 10.1152/physiol.00001.2007; Visser F, 2007, J BIOL CHEM, V282, P4453, DOI 10.1074/jbc.M610582200; Walker J, 2005, BIOCHEM J, V385, P485, DOI 10.1042/BJ20040694; Winder WW, 2007, CELL BIOCHEM BIOPHYS, V47, P332, DOI 10.1007/s12013-007-0008-7; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xuan N, 2009, CELL PHYSIOL BIOCHEM, V24, P167, DOI 10.1159/000233243; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Yoshida H, 2012, J MOL CELL CARDIOL, V52, P410, DOI 10.1016/j.yjmcc.2011.08.013; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118; Zhang F, 2009, AM J PHYSIOL-CELL PH, V296, pC346, DOI 10.1152/ajpcell.00444.2008; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	100	27	27	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3049	3058		10.1096/fj.12-204024	http://dx.doi.org/10.1096/fj.12-204024			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22474243				2022-12-28	WOS:000305912500032
J	Lehner, J; Berendt, S; Dorsam, B; Perez, R; Forchhammer, K; Maldener, I				Lehner, Josef; Berendt, Susanne; Doersam, Bastian; Perez, Rebeca; Forchhammer, Karl; Maldener, Iris			Prokaryotic multicellularity: a nanopore array for bacterial cell communication	FASEB JOURNAL			English	Article						cyanobacteria; amidase	SP-STRAIN PCC-7120; HETEROCYST-FORMING CYANOBACTERIUM; INTERCELLULAR MOLECULAR-EXCHANGE; BLUE-GREEN-ALGAE; ANABAENA SP; ESCHERICHIA-COLI; FILAMENT INTEGRITY; NOSTOC-PUNCTIFORME; MUREIN HYDROLASES; PATTERN-FORMATION	The transition from unicellular to multicellular life, which occurred several times during evolution, requires tight interaction and communication of neighboring cells. The multicellular cyanobacterium Nostoc punctiforme ATCC 29133 forms filaments of hundreds of interacting cells exchanging metabolites and signal molecules and is able to differentiate specialized cells in response to environmental stimuli. Mutation of cell wall amidase AmiC2 leads to a severe phenotype with formation of aberrant septa in the distorted filaments, which completely lack cell communication and potential for cell differentiation. Here we demonstrate the function of the amidase AmiC2 in formation of cell-joining structures. The AmiC2 protein localizes to the young septum between cells and shows bona fide amidase activity in vivo and in vitro. Vancomycin staining identified the overall septum morphology in living cells. By electron microscopy of isolated peptidoglycan sacculi, the submicroscopic structure of the cell junctions could be visualized, revealing a novel function for a cell wall amidase: AmiC2 drills holes into the cross-walls, forming an array of similar to 155 nanopores with a diameter of similar to 20 nm each. These nanopores seem to constitute a framework for cell-joining proteins, penetrating the cell wall. The entire array of junctional nanopores appears as a novel bacterial organelle, establishing multicellularity in a filamentous prokaryote.-Lehner, J., Berendt, S., Dorsam, B., Perez, R., Forchhammer, K., Maldener, I. Prokaryotic multicellularity: a nanopore array for bacterial cell communication.	[Lehner, Josef; Berendt, Susanne; Doersam, Bastian; Perez, Rebeca; Forchhammer, Karl; Maldener, Iris] Univ Tubingen, Dept Microbiol Organism Interact, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Forchhammer, K (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	karl.forchhammer@uni-tuebingen.de; iris.maldener@uni-tuebingen.de		Perez, Rebeca/0000-0002-0402-8356	Deutsche Forschungsgemeinschaft [SFB766, GRK1708]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Miguel de Pedro, Klaus Hantke, Markus Kroog, Claudia Menzel, York Stierhof, and Waldemar Vollmer for help and the Deutsche Forschungsgemeinschaft (SFB766) for financial support. R.P. was supported by a grant from Deutsche Forschungsgemeinschaft (GRK1708).	Berendt S, 2012, J BACTERIOL, V194, P5218, DOI 10.1128/JB.00912-12; Bernhardt TG, 2003, MOL MICROBIOL, V48, P1171, DOI 10.1046/j.1365-2958.2003.03511.x; Bonner JT., 2000, 1 SIGNALS EVOLUTION; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; CAIOLA MG, 1985, CYTOBIOS, V42, P171; Daniel RA, 2003, CELL, V113, P767, DOI 10.1016/S0092-8674(03)00421-5; DePedro MA, 1997, J BACTERIOL, V179, P2823, DOI 10.1128/jb.179.9.2823-2834.1997; Drews G., 1982, BIOL CYANOBACTERIA, P333; DUNN JH, 1970, J BACTERIOL, V103, P153, DOI 10.1128/JB.103.1.153-158.1970; Fan Q, 2005, MOL MICROBIOL, V58, P227, DOI 10.1111/j.1365-2958.2005.04818.x; Firczuk M, 2007, FEMS MICROBIOL REV, V31, P676, DOI 10.1111/j.1574-6976.2007.00084.x; Flores E, 2007, J BACTERIOL, V189, P3884, DOI 10.1128/JB.00085-07; Flores E, 2006, TRENDS MICROBIOL, V14, P439, DOI 10.1016/j.tim.2006.08.007; Flores E, 2010, NAT REV MICROBIOL, V8, P39, DOI 10.1038/nrmicro2242; GIDDINGS TH, 1978, CYTOBIOLOGIE, V16, P235; GIDDINGS TH, 1981, ARCH MICROBIOL, V129, P295, DOI 10.1007/BF00414700; Haselkorn R, 2008, MOL MICROBIOL, V70, P783, DOI 10.1111/j.1365-2958.2008.06475.x; Heidrich C, 2002, J BACTERIOL, V184, P6093, DOI 10.1128/JB.184.22.6093-6099.2002; Heidrich C, 2001, MOL MICROBIOL, V41, P167, DOI 10.1046/j.1365-2958.2001.02499.x; Hoiczyk E, 2000, J BACTERIOL, V182, P1191, DOI 10.1128/JB.182.5.1191-1199.2000; Hoiczyk E, 2000, ARCH MICROBIOL, V174, P11, DOI 10.1007/s002030000187; HOLTJE JV, 1995, ARCH MICROBIOL, V164, P243, DOI 10.1007/s002030050261; Jost M., 1965, ARCH MIKROBIOL, V50, P211; Kaplan-Levy RN, 2010, TOP CURR GENET, V21, P5, DOI 10.1007/978-3-642-12422-8_2; Koraimann G, 2003, CELL MOL LIFE SCI, V60, P2371, DOI 10.1007/s00018-003-3056-1; Kumar K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000315; LANG NJ, 1971, PROC R SOC SER B-BIO, V178, P193, DOI 10.1098/rspb.1971.0061; Leganes F, 2005, ARCH MICROBIOL, V184, P234, DOI 10.1007/s00203-005-0046-8; Lehner J, 2011, MOL MICROBIOL, V79, P1655, DOI 10.1111/j.1365-2958.2011.07554.x; Mariscal V, 2011, MOL MICROBIOL, V79, P1077, DOI 10.1111/j.1365-2958.2010.07508.x; Meeks JC, 2002, ARCH MICROBIOL, V178, P395, DOI 10.1007/s00203-002-0476-5; Mella-Herrera RA, 2011, MICROBIOL-SGM, V157, P617, DOI 10.1099/mic.0.046128-0; Merino-Puerto V, 2011, J BACTERIOL, V193, P6815, DOI 10.1128/JB.05995-11; Merino-Puerto V, 2011, MOL MICROBIOL, V82, P87, DOI 10.1111/j.1365-2958.2011.07797.x; Merino-Puerto V, 2010, MOL MICROBIOL, V75, P1159, DOI 10.1111/j.1365-2958.2009.07031.x; Mullineaux CW, 2008, EMBO J, V27, P1299, DOI 10.1038/emboj.2008.66; Nambu T, 1999, J BACTERIOL, V181, P1555, DOI 10.1128/JB.181.5.1555-1561.1999; Nayar AS, 2007, MICROBIOL-SGM, V153, P601, DOI 10.1099/mic.0.2006/002535-0; Palinska KA, 2000, J PHYCOL, V36, P139, DOI 10.1046/j.1529-8817.2000.99040.x; Pinho MG, 2003, MOL MICROBIOL, V50, P871, DOI 10.1046/j.1365-2958.2003.03719.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schneider D, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-39; Tiyanont K, 2006, P NATL ACAD SCI USA, V103, P11033, DOI 10.1073/pnas.0600829103; Weiss DS, 2004, MOL MICROBIOL, V54, P588, DOI 10.1111/j.1365-2958.2004.04283.x; WILDON DC, 1963, ARCH MIKROBIOL, V47, P19, DOI 10.1007/BF00408286; Wilk L, 2011, CELL MICROBIOL, V13, P1744, DOI 10.1111/j.1462-5822.2011.01655.x; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Yoon HS, 1998, SCIENCE, V282, P935, DOI 10.1126/science.282.5390.935; Zhang CC, 2006, MOL MICROBIOL, V59, P367, DOI 10.1111/j.1365-2958.2005.04979.x; Zhu JS, 2001, J BACTERIOL, V183, P6841, DOI 10.1128/JB.183.23.6841-6851.2001	51	44	44	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2293	2300		10.1096/fj.12-225854	http://dx.doi.org/10.1096/fj.12-225854			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23444428				2022-12-28	WOS:000319667600019
J	Nath, AK; Roberts, LD; Liu, Y; Mahon, SB; Kim, S; Ryu, JH; Werdich, A; Januzzi, JL; Boss, GR; Rockwood, GA; MacRae, CA; Brenner, M; Gerszten, RE; Peterson, RT				Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Mahon, Sari B.; Kim, Sonia; Ryu, Justine H.; Werdich, Andreas; Januzzi, James L.; Boss, Gerry R.; Rockwood, Gary A.; MacRae, Calum A.; Brenner, Matthew; Gerszten, Robert E.; Peterson, Randall T.			Chemical and metabolomic screens identify novel biomarkers and antidotes for cyanide exposure	FASEB JOURNAL			English	Article						mitochondria; inosine; zebrafish; riboflavin	CYTOCHROME-C-OXIDASE; LIPID-PEROXIDATION; SMALL MOLECULES; DIFFERENT MODES; INHIBITION; INOSINE; IDENTIFICATION; PARKINSONISM; APOPTOSIS; TOXICITY	Exposure to cyanide causes a spectrum of cardiac, neurological, and metabolic dysfunctions that can be fatal. Improved cyanide antidotes are needed, but the ideal biological pathways to target are not known. To understand better the metabolic effects of cyanide and to discover novel cyanide antidotes, we developed a zebrafish model of cyanide exposure and scaled it for high-throughput chemical screening. In a screen of 3120 small molecules, we discovered 4 novel antidotes that block cyanide toxicity. The most potent antidote was riboflavin. Metabolomic profiling of cyanide-treated zebrafish revealed changes in bile acid and purine metabolism, most notably by an increase in inosine levels. Riboflavin normalizes many of the cyanide-induced neurological and metabolic perturbations in zebrafish. The metabolic effects of cyanide observed in zebrafish were conserved in a rabbit model of cyanide toxicity. Further, humans treated with nitroprusside, a drug that releases nitric oxide and cyanide ions, display increased circulating bile acids and inosine. In summary, riboflavin may be a novel treatment for cyanide toxicity and prophylactic measure during nitroprusside treatment, inosine may serve as a biomarker of cyanide exposure, and metabolites in the bile acid and purine metabolism pathways may shed light on the pathways critical to reversing cyanide toxicity.-Nath, A. K., Roberts, L. D., Liu, Y., Mahon, S. B., Kim, S., Ryu, J. H., Werdich, A., Januzzi, J. L., Boss, G. R., Rockwood, G. A., MacRae, C. A., Brenner, M., Gerszten, R. E., Peterson, R. T. Chemical and metabolomic screens identify novel biomarkers and antidotes for cyanide exposure. FASEB J. 27, 1928-1938 (2013). www.fasebj.org	[Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Kim, Sonia; Ryu, Justine H.; Januzzi, James L.; Gerszten, Robert E.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA; [Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Kim, Sonia; Ryu, Justine H.; Januzzi, James L.; Gerszten, Robert E.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Dept Med, Charlestown, MA USA; [Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Gerszten, Robert E.; Peterson, Randall T.] Broad Inst, Cambridge, MA USA; [Mahon, Sari B.; Brenner, Matthew] Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA; [Werdich, Andreas; MacRae, Calum A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA 02115 USA; [Boss, Gerry R.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Rockwood, Gary A.] USA, Analyt Toxicol Div, Med Res Inst Chem Def, Aberdeen Proving Ground, MD USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California Irvine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Diego; Research Institute of Chemical Defense - China	Nath, AK (corresponding author), Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	anath@cvrc.mgh.harvard.edu; peterson@cvrc.mgh.harvard.edu	Januzzi, James/Y-2436-2019	Peterson, Randall/0000-0003-0727-3469; Werdich, Andreas/0000-0002-1222-1180; Roberts, Lee/0000-0002-1455-5248; Boss, Gerry/0000-0002-9758-8714	U.S. National Institutes of Health (NIH) grant [T32 HL-007208]; NIH Countermeasures Against Chemical Threats (Counter ACT) [U54NS063718, U54NS079201]; CounterACT Program, NIH Office of the Director; National Institute of Allergy and Infectious Diseases, NIH/U.S. Army Medical Research and Materiel Command [Y1-OD-9611-01/A120-B.P2009-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007208, K99HL112724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS063718, U01NS058030, U54NS079201] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Countermeasures Against Chemical Threats (Counter ACT)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CounterACT Program, NIH Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases, NIH/U.S. Army Medical Research and Materiel Command; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funding for this project has been provided by U.S. National Institutes of Health (NIH) grant T32 HL-007208 (A.K.N. and Y.L.) and NIH Countermeasures Against Chemical Threats (Counter ACT) grants U54NS063718 and U54NS079201 (S.B.M. and M.B.) and U54NS079201 (R.T.P). The zebrafish research was supported, in part, by the CounterACT Program, NIH Office of the Director, and the National Institute of Allergy and Infectious Diseases, NIH/U.S. Army Medical Research and Materiel Command interagency agreement no. Y1-OD-9611-01/A120-B.P2009-1 (G.A.R.).	Alcorta Richard, 2004, JEMS, V29, P6; ANTHONY ML, 1994, ARCH TOXICOL, V68, P43; ARDELT BK, 1989, TOXICOLOGY, V56, P147, DOI 10.1016/0300-483X(89)90129-7; Ascherio A, 2009, ARCH NEUROL-CHICAGO, V66, P1460, DOI 10.1001/archneurol.2009.247; Baskin SI, 1999, J APPL TOXICOL, V19, P173, DOI 10.1002/(SICI)1099-1263(199905/06)19:3<173::AID-JAT556>3.0.CO;2-2; Boehnke C, 2004, EUR J NEUROL, V11, P475, DOI 10.1111/j.1468-1331.2004.00813.x; BORGOHAIN R, 1995, CLIN NEUROL NEUROSUR, V97, P213, DOI 10.1016/0303-8467(95)00029-J; Brenner M, 2010, TOXICOL APPL PHARM, V248, P269, DOI 10.1016/j.taap.2010.08.002; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Di Filippo M, 2008, MOVEMENT DISORD, V23, P468, DOI 10.1002/mds.21871; Farthing D, 2006, BIOMARKERS, V11, P449, DOI 10.1080/13547500600800074; GARTLAND KPR, 1989, MOL PHARMACOL, V35, P242; Gracia R, 2004, PHARMACOTHERAPY, V24, P1358, DOI 10.1592/phco.24.14.1358.43149; GRANDAS F, 1989, MOVEMENT DISORD, V4, P188, DOI 10.1002/mds.870040211; HALL A H, 1987, Journal of Emergency Medicine, V5, P115, DOI 10.1016/0736-4679(87)90074-6; HALL AH, 1989, J TOXICOL CLIN EXPER, V9, P3; Houten SM, 2006, EMBO J, V25, P1419, DOI 10.1038/sj.emboj.7601049; Isom GE, 1995, TOXICOL LETT, V82-3, P795, DOI 10.1016/0378-4274(95)03521-4; Jurkowitz MS, 1998, J NEUROCHEM, V71, P535; Katz A, 2003, J PHYSIOL-LONDON, V553, P523, DOI 10.1113/jphysiol.2003.051078; KIMMEL CB, 1974, DEV PSYCHOBIOL, V7, P47, DOI 10.1002/dev.420070109; Kohashi T, 2008, J NEUROSCI, V28, P10641, DOI 10.1523/JNEUROSCI.1435-08.2008; Kokel D, 2010, NAT CHEM BIOL, V6, P231, DOI 10.1038/NCHEMBIO.307; Leavesley HB, 2010, TOXICOL SCI, V115, P569, DOI 10.1093/toxsci/kfq084; Lee QP, 1996, TERATOLOGY, V53, P21, DOI 10.1002/(SICI)1096-9926(199601)53:1<21::AID-TERA3>3.0.CO;2-C; Markowitz CE, 2009, J ALTERN COMPLEM MED, V15, P619, DOI 10.1089/acm.2008.0513; MARRS TC, 1985, HUM TOXICOL, V4, P591, DOI 10.1177/096032718500400605; Mills EM, 1996, J NEUROCHEM, V67, P1039; MULLER U, 1995, BRAIN RES, V678, P265, DOI 10.1016/0006-8993(95)00196-W; Nagahara Noriyuki, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P198, DOI 10.2174/1568008033340162; Nicholls AW, 2000, BIOMARKERS, V5, P410, DOI 10.1080/135475000750052420; Nicholls AW, 2001, CHEM RES TOXICOL, V14, P975, DOI 10.1021/tx000231j; Okolie N. P., 2002, GLOBAL J PURE APPL S, V8, P491; Peal DS, 2011, CIRCULATION, V123, P23, DOI 10.1161/CIRCULATIONAHA.110.003731; Pearce LL, 2003, J BIOL CHEM, V278, P52139, DOI 10.1074/jbc.M310359200; Peterson RT, 2004, METHOD CELL BIOL, V76, P569; Portugues R, 2009, CURR OPIN NEUROBIOL, V19, P644, DOI 10.1016/j.conb.2009.10.007; ROBIN ED, 1992, CHEST, V102, P1842, DOI 10.1378/chest.102.6.1842; ROSENBERG NL, 1989, NEUROLOGY, V39, P142, DOI 10.1212/WNL.39.1.142; ROSENOW F, 1995, ANN NEUROL, V38, P825, DOI 10.1002/ana.410380518; Sachidanandan C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001947; Sauer SW, 2001, ANN EMERG MED, V37, P635, DOI 10.1067/mem.2001.114315; Shaham O, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.50; Shimizu S, 1996, ONCOGENE, V12, P2045; Top H, 2006, NUCL MED COMMUN, V27, P91, DOI 10.1097/00006231-200601000-00013; Unna K, 1942, J PHARMACOL EXP THER, V76, P75; Venglovecz V., 2012, PANCREAPEDIA, DOI [10.3998/panc.2012.8, DOI 10.3998/PANC.2012.8]; VESEY CJ, 1976, BRIT J ANAESTH, V48, P651, DOI 10.1093/bja/48.7.651; Voronina SG, 2004, J BIOL CHEM, V279, P27327, DOI 10.1074/jbc.M311698200; WOODS HG, 1970, BIOCHEM J, V119, P501, DOI 10.1042/bj1190501; Yamada M, 1996, J PHARMACOL TOXICOL, V35, P11, DOI 10.1016/1056-8719(95)00111-5; Zilinski JL, 2012, CRIT CARE, V16, DOI 10.1186/cc11440	53	29	30	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1928	1938		10.1096/fj.12-225037	http://dx.doi.org/10.1096/fj.12-225037			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23345455	Green Published			2022-12-28	WOS:000318226100013
J	Fernandes, ES; Vong, CT; Quek, S; Cheong, J; Awal, S; Gentry, C; Aubdool, AA; Liang, LH; Bodkin, JV; Bevan, S; Heads, R; Brain, SD				Fernandes, Elizabeth S.; Chi Teng Vong; Quek, Samuel; Cheong, Jessica; Awal, Salma; Gentry, Clive; Aubdool, Aisah A.; Liang, Lihuan; Bodkin, Jennifer V.; Bevan, Stuart; Heads, Richard; Brain, Susan D.			Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B-4-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1	FASEB JOURNAL			English	Article						pruritus; inflammation; neutrophils; reactive oxygen species; skin	NEUTROPHIL NADPH OXIDASE; PROTEIN-COUPLED RECEPTOR; P47PHOX PHOSPHORYLATION; ATOPIC-DERMATITIS; TRPA1; B-4; SKIN; INVOLVEMENT; ANTAGONIST; INFLAMMATION	The underlying mechanisms of itch are poorly understood. We have investigated a model involving the chemoattractant leukotriene B-4 (LTB4) that is up-regulated in common skin diseases. Intradermal injection of LTB4 (0.1 nmol/site) into female CD1 mice induced significant scratching movements (used as an itch index) compared with vehicle-injected (0.1% bovine serum albumin-saline) mice. Intraperitoneal transient receptor potential (TRP) channel antagonist treatment significantly inhibited itch as follows: TRP vanilloid 1 (TRPV1) antagonist SB366791 (0.5 mg/kg, by 97%) and the TRP ankyrin 1 (TRPA1) antagonists TCS 5861528 (10 mg/kg; 82%) and HC-030031 (100 mg/kg; 76%). Leukotriene B-4 receptor 2 antagonism by LY255283 (5 mg/kg i.p.; 62%) reduced itch. Neither TRPV1-knockout (TRPV1-KO) nor TRPA1-knockout (TRPA1-KO mice exhibited LTB4-induced itch compared with their wild-type counterparts. The reactive oxygen species scavengers N-acetylcysteine (NAC; 204 mg/kg i.p.;86%) or superoxide dismutase (SOD; 10 mg/kg i.p.; 83%) also inhibited itch. LTB4-induced superoxide release was attenuated by TCS 5861528 (56%) and HC-030031 (66%), NAC (58%), SOD (50%), and LY255283 (59%) but not by the leukotriene B-4 receptor 1 antagonist U-75302 (9 nmol/site) or SB366791. Itch, superoxide, and myeloperoxidase generation were inhibited by the leukocyte migration inhibitor fucoidan (10 mg/kg i.v.) by 80, 61, and 34%, respectively. Myeloperoxidase activity was also reduced by SB366791 (35%) and SOD (28%). TRPV1-KO mice showed impaired myeloperoxidase release, whereas TRPA1-KO mice exhibited diminished production of superoxide. This result provides novel evidence that TRPA1 and TRPV1 contribute to itch via distinct mechanisms.-Fernandes, E. S., Vong, C. T., Quek, S., Cheong, J., Awal, S., Gentry, C., Aubdool, A. A., Liang, L., Bodkin, J. V., Bevan, S., Heads, R., Brain, S. D. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B-4-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. FASEB J. 27, 1664-1673 (2013). www.fasebj.org	[Fernandes, Elizabeth S.] Univ Ceuma, Programa Posgrad Biol Parasitaria, Sao Luis, Brazil; [Chi Teng Vong; Quek, Samuel; Cheong, Jessica; Awal, Salma; Aubdool, Aisah A.; Liang, Lihuan; Bodkin, Jennifer V.; Heads, Richard; Brain, Susan D.] Kings Coll London, Div Cardiovasc, London SE1 9NH, England; [Chi Teng Vong; Quek, Samuel; Cheong, Jessica; Awal, Salma; Aubdool, Aisah A.; Liang, Lihuan; Bodkin, Jennifer V.; Heads, Richard; Brain, Susan D.] Kings Coll London, Ctr Integrat Biomed, British Heart Fdn, Cardiovasc Ctr Excellence, London SE1 9NH, England; [Gentry, Clive; Bevan, Stuart] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 9NH, England	Universidade Ceuma; University of London; King's College London; University of London; King's College London; University College London; University of London; King's College London	Brain, SD (corresponding author), Kings Coll London, Franklin Wilkins Bldg,Waterloo Campus,150 Stamfor, London SE1 9NH, England.	sue.brain@kcl.ac.uk	Fernandes, Elizabeth S./Q-7276-2019; Bevan, Stuart/A-8821-2008; Brain, Susan/L-3681-2013; Fernandes, Elizabeth S/J-9397-2012	Fernandes, Elizabeth S./0000-0002-0567-2514; Vong, Chi Teng/0000-0002-4032-657X; Quek, Samuel/0000-0002-4363-0008; Bevan, Stuart John/0000-0002-8977-1797; Brain, Susan/0000-0002-9684-8342; aubdool, aisah/0000-0003-3087-5150; Aubdool, Dr. Aisah/0000-0002-4712-9421	Arthritis Research UK [19296]; Biotechnology and Biological Sciences Research Council; Capacity Building Award in Integrative Mammalian Biology; Higher Education Funding Council for England; Knowledge Transfer Network; Medical Research Council; Scottish Funding Council; British Heart Foundation 4-Year Ph.D. program; BBSRC [BB/E527098/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E527098/1] Funding Source: researchfish; Versus Arthritis [19296] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Capacity Building Award in Integrative Mammalian Biology; Higher Education Funding Council for England(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); Knowledge Transfer Network; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Funding Council; British Heart Foundation 4-Year Ph.D. program; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Versus Arthritis(Versus Arthritis)	This work was supported by the Arthritis Research UK (grant 19296 to E. S. F.), Biotechnology and Biological Sciences Research Council(A. A. A.), a Capacity Building Award in Integrative Mammalian Biology funded by the Biotechnology and Biological Sciences Research Council, Higher Education Funding Council for England, Knowledge Transfer Network, Medical Research Council, and Scottish Funding Council (L. L.), and British Heart Foundation 4-Year Ph.D. program (J.V.B.). The authors declare no conflicts of interest.	Al-Shabanah OA, 1999, RES COMMUN MOL PATH, V106, P115; Amadesi S, 2006, J PHYSIOL-LONDON, V575, P555, DOI 10.1113/jphysiol.2006.111534; Anand U, 2008, NEUROSCI LETT, V438, P221, DOI 10.1016/j.neulet.2008.04.007; Andersson DA, 2008, J NEUROSCI, V28, P2485, DOI 10.1523/JNEUROSCI.5369-07.2008; Andersson DA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1559; Andoh T, 1998, EUR J PHARMACOL, V353, P93, DOI 10.1016/S0014-2999(98)00440-3; Andoh T, 2001, J INVEST DERMATOL, V117, P1621, DOI 10.1046/j.0022-202x.2001.01585.x; Andoh T, 2011, EXP DERMATOL, V20, P894, DOI 10.1111/j.1600-0625.2011.01346.x; Arruda MA, 2009, FRONT BIOSCI-LANDMRK, V14, P4546, DOI 10.2741/3547; Atoyan R, 2009, J INVEST DERMATOL, V129, P2312, DOI 10.1038/jid.2009.58; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Biro T, 2009, J INVEST DERMATOL, V129, P2096, DOI 10.1038/jid.2009.179; Biro T, 2007, BBA-MOL BASIS DIS, V1772, P1004, DOI 10.1016/j.bbadis.2007.03.002; BRAIN S, 1984, J INVEST DERMATOL, V83, P70, DOI 10.1111/1523-1747.ep12261712; CAMP RDR, 1982, PROSTAGLANDINS, V23, P631, DOI 10.1016/S0090-6980(82)80003-8; Choi JA, 2008, FREE RADICAL BIO MED, V44, P624, DOI 10.1016/j.freeradbiomed.2007.10.041; Costa R, 2008, BRIT J PHARMACOL, V154, P1094, DOI 10.1038/bjp.2008.172; Costa SKP, 2000, EUR J PHARMACOL, V391, P305, DOI 10.1016/S0014-2999(00)00075-3; Davidson S, 2010, TRENDS NEUROSCI, V33, P550, DOI 10.1016/j.tins.2010.09.002; DEMETRI GD, 1991, BLOOD, V78, P2791; Dent G, 1997, BRIT J PHARMACOL, V122, P758, DOI 10.1038/sj.bjp.0701428; Eid SR, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-48; El-Benna J, 2008, SEMIN IMMUNOPATHOL, V30, P279, DOI 10.1007/s00281-008-0118-3; Engel MA, 2012, J GASTROENTEROL, V47, P256, DOI 10.1007/s00535-011-0495-6; Engel MA, 2011, GASTROENTEROLOGY, V141, P1346, DOI 10.1053/j.gastro.2011.07.002; Fernandes ES, 2011, ARTHRITIS RHEUM-US, V63, P819, DOI 10.1002/art.30150; Fernandes ES, 2003, BRIT J PHARMACOL, V139, P973, DOI 10.1038/sj.bjp.0705314; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gaudreault E, 2005, J IMMUNOL, V174, P3617, DOI 10.4049/jimmunol.174.6.3617; Gomides LF, 2012, PHARMACOLOGY, V89, P275, DOI 10.1159/000337378; Gujral JS, 2004, AM J PHYSIOL-GASTR L, V287, pG243, DOI 10.1152/ajpgi.00287.2003; Guzik TJ, 2005, METH MOLEC MED, V108, P73; Hoyer FF, 2012, MOL CELL BIOCHEM, V359, P25, DOI 10.1007/s11010-011-0995-y; HUGHES SR, 1991, BRIT J PHARMACOL, V104, P738, DOI 10.1111/j.1476-5381.1991.tb12497.x; IWAMOTO I, 1993, J IMMUNOL, V151, P2116; Kato S, 2011, J NANOSCI NANOTECHNO, V11, P3814, DOI 10.1166/jnn.2011.4172; Keeble JE, 2009, PAIN, V141, P135, DOI 10.1016/j.pain.2008.10.025; Kim HJ, 2008, BRIT J PHARMACOL, V154, P1073, DOI 10.1038/bjp.2008.220; Liu L, 1997, NEUROSCI LETT, V228, P29, DOI 10.1016/S0304-3940(97)00358-3; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Metz M, 2011, VET DERMATOL, V22, P121, DOI 10.1111/j.1365-3164.2010.00945.x; Pan XQ, 2010, EXP NEUROL, V225, P262, DOI 10.1016/j.expneurol.2010.05.012; Prokopowicz Z, 2012, ARCH IMMUNOL THER EX, V60, P43, DOI 10.1007/s00005-011-0156-8; Puntambekar P, 2005, J NEUROCHEM, V95, P1689, DOI 10.1111/j.1471-4159.2005.03518.x; Rada Balazs, 2008, V15, P164, DOI 10.1159/000136357; Ruan T, 2006, J APPL PHYSIOL, V101, P644, DOI 10.1152/japplphysiol.00192.2006; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; Ryu HC, 2010, J INVEST DERMATOL, V130, P1095, DOI 10.1038/jid.2009.436; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Serezani CHC, 2005, J LEUKOCYTE BIOL, V78, P976, DOI 10.1189/jlb.1004587; Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442; Stander S, 2004, EXP DERMATOL, V13, P129, DOI 10.1111/j.0906-6705.2004.0178.x; Stefanova TH, 2010, Z NATURFORSCH C, V65, P141; Terneus MV, 2008, TOXICOLOGY, V244, P25, DOI 10.1016/j.tox.2007.10.027; Tsuji F, 2010, BIOL PHARM BULL, V33, P1050, DOI 10.1248/bpb.33.1050; Tsukumo Y, 2010, J PHARMACOL SCI, V113, P255, DOI 10.1254/jphs.10050FP; Vigna SR, 2011, PANCREAS, V40, P708, DOI 10.1097/MPA.0b013e318214c8df; Wei H, 2009, ANESTHESIOLOGY, V111, P147, DOI 10.1097/ALN.0b013e3181a1642b; Willemsen MAAP, 2001, EUR J PEDIATR, V160, P711, DOI 10.1007/s004310100838; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhu Y, 2009, INT IMMUNOPHARMACOL, V9, P1332, DOI 10.1016/j.intimp.2009.08.006	63	56	57	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1664	1673		10.1096/fj.12-221218	http://dx.doi.org/10.1096/fj.12-221218			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271050				2022-12-28	WOS:000316940800036
J	Hammadi, M; Oulidi, A; Gackiere, F; Katsogiannou, M; Slomianny, C; Roudbaraki, M; Dewailly, E; Delcourt, P; Lepage, G; Lotteau, S; Ducreux, S; Prevarskaya, N; Van Coppenolle, F				Hammadi, Mehdi; Oulidi, Agathe; Gackiere, Florian; Katsogiannou, Maria; Slomianny, Christian; Roudbaraki, Morad; Dewailly, Etienne; Delcourt, Philippe; Lepage, Gilbert; Lotteau, Sabine; Ducreux, Sylvie; Prevarskaya, Natalia; Van Coppenolle, Fabien			Modulation of ER stress and apoptosis by endoplasmic reticulum calcium leak via translocon during unfolded protein response: involvement of GRP78	FASEB JOURNAL			English	Article						cancer; Bip	STORE-OPERATED CHANNELS; BIP; CHAPERONE; CELLS; COMPONENTS; REGULATOR; DEPLETION; ROLES; PORE	The endoplasmic reticulum (ER) is involved in many cellular functions, including protein folding and Ca2+ homeostasis. The ability of cells to respond to the ER stress is critical for cell survival, and disruption in such regulation can lead to apoptosis. ER stress is accompanied by alterations in Ca2+ homeostasis, and the ER Ca2+ store depletion by itself can induce ER stress and apoptosis. Despite that, the ER Ca2+ leak channels activated in response to the ER stress remain poorly characterized. Here we demonstrate that ER Ca2+ depletion during the ER stress occurs via translocon, the ER protein complex involved in translation. Numerous ER stress inducers stimulate the ER Ca2+ leak that can be prevented by translocon inhibitor, anisomycin. Expression of GRP78, an ER stress marker, increased following treatment with puromycin (a translocon opener) and was suppressed by anisomycin, confirming a primary role of translocon in ER stress induction. Inhibition of ER store depletion by anisomycin significantly reduces apoptosis stimulated by the ER stress inducers. We suggest that translocon opening is physiologically modulated by GRP78, particularly during the ER stress. The ability to modulate the ER Ca2+ permeability and subsequent ER stress can lead to development of a novel therapeutic approach.-Hammadi, M., Oulidi, A., Gackiere, F., Katsogiannou, M., Slomianny, C., Roudbaraki, M., Dewailly, E., Delcourt, P., Lepage, G., Lotteau, S., Ducreux, S., Prevarskaya, N., Van Coppenolle, F. Modulation of ER stress and apoptosis by endoplasmic reticulum calcium leak via translocon during unfolded protein response: involvement of GRP78. FASEB J. 27, 1600-1609 (2013). www.fasebj.org	[Hammadi, Mehdi; Oulidi, Agathe; Slomianny, Christian; Roudbaraki, Morad; Dewailly, Etienne; Delcourt, Philippe; Lepage, Gilbert; Prevarskaya, Natalia] Univ Lille 1, INSERM, U1003, Cellular Physiol Lab, F-59655 Villeneuve Dascq, France; [Gackiere, Florian] Aix Marseille Univ, Inst Neurosci Timone, Marseille, France; [Gackiere, Florian] Aix Marseille Univ, CNRS, UMR 7289, Marseille, France; [Katsogiannou, Maria] Aix Marseille Univ, INSERM, Mol Oncol U1068, Marseille, France; [Katsogiannou, Maria] Aix Marseille Univ, CNRS, UMR 7258, Marseille, France; [Katsogiannou, Maria] Inst J Paoli I Calmettes, CRCM, F-13009 Marseille, France; [Lotteau, Sabine; Ducreux, Sylvie; Van Coppenolle, Fabien] Univ Lyon 1, CNRS, UMR 5534, Ctr Genet & Physiol Mol & Cellulaires, F-69622 Villeurbanne, France; [Lotteau, Sabine; Ducreux, Sylvie; Van Coppenolle, Fabien] Univ Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Van Coppenolle, F (corresponding author), Univ Lyon 1, INSERM, U1060, CarMeN,Equipe 5, 8 Ave Rockefeller, F-69373 Lyon 08, France.	fabien.van-coppenolle@univ-lyon1.fr	Slomianny, Christian/L-8285-2018; DUCREUX, SYLVIE/D-6257-2013	DUCREUX, SYLVIE/0000-0003-3207-9537; Morad, Roudbaraki/0000-0001-5751-3323; Prevarskaya, natacha/0000-0003-0316-197X	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Ligue Nationale Contre le Cancer, Association pour la Recherche contre le Cancer (ARC); Ministere de l'Enseignement Superieur et de la Recherche	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Ligue Nationale Contre le Cancer, Association pour la Recherche contre le Cancer (ARC); Ministere de l'Enseignement Superieur et de la Recherche	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Ligue Nationale Contre le Cancer, Association pour la Recherche contre le Cancer (ARC), and Ministere de l'Enseignement Superieur et de la Recherche. The authors declare no conflicts of interest.	Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Austin RC, 2009, ANTIOXID REDOX SIGN, V11, P2279, DOI [10.1089/ars.2009.2686, 10.1089/ARS.2009.2686]; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; Chami M, 2008, MOL CELL, V32, P641, DOI 10.1016/j.molcel.2008.11.014; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Cunard R, 2011, AM J PHYSIOL-RENAL, V300, pF1054, DOI 10.1152/ajprenal.00021.2011; Erdmann F, 2011, EMBO J, V30, P17, DOI 10.1038/emboj.2010.284; Flourakis M, 2006, FASEB J, V20, P1215, DOI 10.1096/fj.05-5254fje; Fu M, 2011, CELL DEATH DIFFER, V18, P1057, DOI 10.1038/cdd.2010.181; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hegde RS, 2010, CURR OPIN CELL BIOL, V22, P437, DOI 10.1016/j.ceb.2010.05.005; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Hoseki J, 2010, J BIOCHEM, V147, P19, DOI 10.1093/jb/mvp194; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Kaneko M, 2003, LIFE SCI, V74, P199, DOI 10.1016/j.lfs.2003.09.007; Kim SW, 2001, Z NATURFORSCH C, V56, P1169; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Matus S, 2011, CURR OPIN CELL BIOL, V23, P239, DOI 10.1016/j.ceb.2011.01.003; Minamino T, 2010, CIRC RES, V107, P1071, DOI 10.1161/CIRCRESAHA.110.227819; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Parkash J, 2010, LIFE SCI, V87, P587, DOI 10.1016/j.lfs.2010.09.013; Peters LR, 2011, J IMMUNOL, V187, P919, DOI 10.4049/jimmunol.1100690; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Rasheva VI, 2009, APOPTOSIS, V14, P996, DOI 10.1007/s10495-009-0341-y; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Schauble N, 2012, EMBO J, V31, P3282, DOI 10.1038/emboj.2012.189; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Tsai Yien Che, 2010, Genes Cancer, V1, P764; Van Coppenolle F, 2004, J CELL SCI, V117, P4135, DOI 10.1242/jcs.01274; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679	39	129	141	4	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1600	1609		10.1096/fj.12-218875	http://dx.doi.org/10.1096/fj.12-218875			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23322163				2022-12-28	WOS:000316940800030
J	Moghadaszadeh, B; Rider, BE; Lawlor, MW; Childers, MK; Grange, RW; Gupta, K; Boukedes, SS; Owen, CA; Beggs, AH				Moghadaszadeh, Behzad; Rider, Branden E.; Lawlor, Michael W.; Childers, Martin K.; Grange, Robert W.; Gupta, Kushagra; Boukedes, Steve S.; Owen, Caroline A.; Beggs, Alan H.			Selenoprotein N deficiency in mice is associated with abnormal lung development	FASEB JOURNAL			English	Article						selenium; multiminicore myopathy; ryanodine receptor; alveolar enlargement; SEPN1-related myopathy	ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; RYANODINE RECEPTOR-TYPE-1; PULMONARY-EMPHYSEMA; MUSCULAR-DYSTROPHY; FIBER-TYPE; VITAMIN-E; MUSCLE; MUTATIONS; APOPTOSIS	Mutations in the human SEPN1 gene, encoding selenoprotein N (SepN), cause SEPN1-related myopathy (SEPN1-RM) characterized by muscle weakness, spinal rigidity, and respiratory insufficiency. As with other members of the selenoprotein family, selenoprotein N incorporates selenium in the form of selenocysteine (Sec). Most selenoproteins that have been functionally characterized are involved in oxidation-reduction (redox) reactions, with the Sec residue located at their catalytic site. To model SEPN1-RM, we generated a Sepn1-knockout (Sepn1(-/-)) mouse line. Homozygous Sepn1(-/-) mice are fertile, and their weight and lifespan are comparable to wild-type (WT) animals. Under baseline conditions, the muscle histology of Sepn1(-/-) mice remains normal, but subtle core lesions could be detected in skeletal muscle after inducing oxidative stress. Ryanodine receptor (RyR) calcium release channels showed lower sensitivity to caffeine in SepN deficient myofibers, suggesting a possible role of SepN in RyR regulation. SepN deficiency also leads to abnormal lung development characterized by enlarged alveoli, which is associated with decreased tissue elastance and increased quasi-static compliance of Sepn1(-/-) lungs. This finding raises the possibility that the respiratory syndrome observed in patients with SEPN1 mutations may have a primary pulmonary component in addition to the weakness of respiratory muscles.-Moghadaszadeh, B., Rider B. E., Lawlor, M. W., Childers, M. K., Grange, R. W., Gupta, K., Boukedes, S. S., Owen, C. A., Beggs, A. H. Selenoprotein N deficiency in mice is associated with abnormal lung development. FASEB J. 27, 1585-1599 (2013). www.fasebj.org	[Moghadaszadeh, Behzad; Rider, Branden E.; Lawlor, Michael W.; Beggs, Alan H.] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA; [Moghadaszadeh, Behzad; Rider, Branden E.; Lawlor, Michael W.; Beggs, Alan H.] Boston Childrens Hosp, Program Genom, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Gupta, Kushagra; Owen, Caroline A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Boukedes, Steve S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lung Transplant Program, Boston, MA 02115 USA; [Childers, Martin K.] Wake Forest Univ Hlth Sci, Dept Neurol, Winston Salem, NC USA; [Childers, Martin K.] Wake Forest Univ Hlth Sci, Wake Forest Inst Regenerat Med, Winston Salem, NC USA; [Grange, Robert W.] Virginia Polytech Inst & State Univ, Dept Human Nutr Foods & Exercise, Blacksburg, VA 24061 USA; [Owen, Caroline A.] Lovelace Resp Res Inst, Albuquerque, NM USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Virginia Polytechnic Institute & State University; Lovelace Respiratory Research Institute	Beggs, AH (corresponding author), Boston Childrens Hosp, Div Genet, 300 Longwood Ave,CLSB 15026, Boston, MA 02115 USA.	beggs@enders.tch.harvard.edu	Owen, Caroline/H-5925-2013	Grange, Robert/0000-0002-8288-2793; Childers, Martin/0000-0003-4754-0883; Moghadaszadeh, Behzad/0000-0001-9787-0106; Beggs, Alan/0000-0001-8818-0568	Lee and Penny Anderson Family Foundation; U.S. National Institutes of Health [R01 AR044345, K08 AR059750, R21 HL111835, PO1 HL105339]; Muscular Dystrophy Association [MDA 201302]; William Randolph Hearst Foundation; BWH-Lovelace Respiratory Research Consortium; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL095276, R01HL086814, T32HL007633, P01HL105339, R21HL111835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR059750, R01AR044345] Funding Source: NIH RePORTER	Lee and Penny Anderson Family Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); William Randolph Hearst Foundation; BWH-Lovelace Respiratory Research Consortium; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Nicholas Marinakis, Cynthia Hsu, Kiyomi Cho, and Kyle Schoppel for assistance with mouse experiments; Jennifer L. Cusick and Takahiro Nakajima for help with the analysis of lung sections, and Pankaj Agrawal and Vandana Gupta for their critical advice and assistance in performing enzyme and TUNEL assays. The authors also thank Suzanne White and Lena Liu (Histopathology Core Facility, Beth Israel Medical Center, Boston, MA, USA). This work was supported by a generous grant from the Lee and Penny Anderson Family Foundation, and by the U.S. National Institutes of Health, grants R01 AR044345, K08 AR059750, R21 HL111835, and PO1 HL105339; the Muscular Dystrophy Association, grant MDA 201302; the William Randolph Hearst Foundation; and the BWH-Lovelace Respiratory Research Consortium.	Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002-0090OC; Aracena-Parks P, 2006, J BIOL CHEM, V281, P40354, DOI 10.1074/jbc.M600876200; Arbogast S, 2010, ANTIOXID REDOX SIGN, V12, P893, DOI 10.1089/ars.2009.2890; Arbogast S, 2009, ANN NEUROL, V65, P677, DOI 10.1002/ana.21644; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; Boutten A, 2010, EXPERT OPIN THER TAR, V14, P329, DOI 10.1517/14728221003629750; Castets P, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-46; Clarke NF, 2006, ANN NEUROL, V59, P546, DOI 10.1002/ana.20761; Deniziak M, 2007, EXP CELL RES, V313, P156, DOI 10.1016/j.yexcr.2006.10.005; Desrumaux C, 2004, FASEB J, V18, P296, DOI 10.1096/fj.04-2400fje; Dirksen A, 2008, CLIN RESPIR J, V2, P76, DOI 10.1111/j.1752-699X.2008.00088.x; Ferreiro A, 2004, ANN NEUROL, V55, P676, DOI 10.1002/ana.20077; Ferreiro A, 2002, ANN NEUROL, V51, P750, DOI 10.1002/ana.10231; Ferreiro A, 2002, AM J HUM GENET, V71, P739, DOI 10.1086/342719; Fischer BM, 2011, INT J CHRONIC OBSTR, V6, P413, DOI 10.2147/COPD.S10770; Fishman AP., 2008, FISHMANS PULMONARY D; Geraghty P, 2011, INT J CHRONIC OBSTR, V6, P309, DOI 10.2147/COPD.S19599; Grydeland TB, 2010, AM J RESP CRIT CARE, V181, P353, DOI 10.1164/rccm.200907-1008OC; Hadaszadeh BM, 2006, PHYSIOLOGY, V21, P307, DOI 10.1152/physiol.00021.2006; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; Jurynec MJ, 2008, P NATL ACAD SCI USA, V105, P12485, DOI 10.1073/pnas.0806015105; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Koike K, 2010, AM J PHYSIOL-LUNG C, V298, pL784, DOI 10.1152/ajplung.00256.2009; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lawlor MW, 2011, AM J PATHOL, V178, P784, DOI 10.1016/j.ajpath.2010.10.035; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Malhotra D, 2009, AM J RESP CRIT CARE, V180, P1196, DOI 10.1164/rccm.200903-0324OC; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; MENDEZ J, 1960, METABOLISM, V9, P184; Moghadaszadeh B, 2001, NAT GENET, V29, P17, DOI 10.1038/ng713; Neville H., 1973, P 2 INT C MUSCL DIS, V1, P497; Okura Y, 2009, BIOFACTORS, V35, P273, DOI 10.1002/biof.33; PARAIDATHATHU T, 1992, FREE RADICAL BIO MED, V13, P289, DOI 10.1016/0891-5849(92)90176-H; Petit N, 2003, HUM MOL GENET, V12, P1045, DOI 10.1093/hmg/ddg115; Quintero PA, 2010, J IMMUNOL, V184, P1575, DOI 10.4049/jimmunol.0900290; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Ravenscroft G, 2007, CELL MOTIL CYTOSKEL, V64, P727, DOI 10.1002/cm.20223; Rederstorff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023094; ROUND JM, 1980, HISTOCHEM J, V12, P707, DOI 10.1007/BF01012026; Schara U, 2008, EUR J PAEDIATR NEURO, V12, P224, DOI 10.1016/j.ejpn.2007.08.011; Scoto M, 2011, NEUROLOGY, V76, P2073, DOI 10.1212/WNL.0b013e31821f467c; Shchedrina VA, 2010, ANTIOXID REDOX SIGN, V12, P839, DOI 10.1089/ars.2009.2865; Sitia Roberto, 2004, Sci STKE, V2004, ppe27, DOI 10.1126/stke.2392004pe27; Summermatter S, 2012, AM J PHYSIOL-CELL PH, V302, pC88, DOI 10.1152/ajpcell.00190.2011; Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; Treves S, 2008, CURR OPIN PHARMACOL, V8, P319, DOI 10.1016/j.coph.2008.01.005	47	28	30	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1585	1599		10.1096/fj.12-212688	http://dx.doi.org/10.1096/fj.12-212688			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23325319	Green Published			2022-12-28	WOS:000316940800029
J	Strauss, L; Rantakari, P; Sjogren, K; Salminen, A; Lauren, E; Kallio, J; Damdimopoulou, P; Bostrom, M; Bostrom, PJ; Pakarinen, P; Zhang, FP; Kujala, P; Ohlsson, C; Makela, S; Poutanen, M				Strauss, Leena; Rantakari, Pia; Sjogren, Klara; Salminen, Anu; Lauren, Eve; Kallio, Jenny; Damdimopoulou, Pauliina; Bostrom, Minna; Bostrom, Peter J.; Pakarinen, Pirjo; Zhang, FuPing; Kujala, Paula; Ohlsson, Claes; Makela, Sari; Poutanen, Matti			Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1-driven luciferase reporter mouse and human tissue specimens	FASEB JOURNAL			English	Article						aromatase; male urogenital tract; androgen regulation	CYP19 AROMATASE GENE; ESTROGEN-RECEPTOR-ALPHA; TRANSGENIC MICE; TRANSCRIPTIONAL REGULATION; PHYSIOLOGICAL-ROLE; HUMAN SPERM; ER-BETA; EXPRESSION; SPERMATOZOA; DEFICIENCY	The human CYP19A1 gene is expressed in various tissues by the use of tissue-specific promoters, whereas the rodent cyp19a1 gene is expressed mainly in the gonads and brain. We generated a transgenic mouse model containing a > 100-kb 5' region of human CYP19A1 gene connected to a luciferase reporter gene. The luciferase activity in mouse tissues mimicked the CYP19A1 gene expression pattern in humans. Interestingly, the reporter gene activity was 16 and 160 times higher in the urinary bladder and seminal vesicles, respectively, as compared with the activity in the testis. Accordingly, CYP19A1 gene and P450arom protein expression was detected in those human tissues. Moreover, the data revealed that the expression of CYP19A1 gene is driven by promoters PII, I. 4, and I. 3 in the seminal vesicles, and by promoters PII and I. 4 in the urinary bladder. Furthermore, the reporter gene expression in the seminal vesicles was androgen dependent: Castration decreased the expression similar to 20 times, and testosterone treatment restored it to the level of an intact mouse. This reporter mouse model facilitates studies of tissue-specific regulation of the human CYP19A1 gene, and our data provide evidence for seminal vesicles as important sites for estrogen production in males.-Strauss, L., Rantakari, P., Sjogren, K., Salminen, A., Lauren, E., Kallio, J., Damdimopoulou, P., Bostrom, M., Bostrom, P. J., Pakarinen, P., Zhang, F. P., Kujala, P., Ohlsson, C., Makela, S., Poutanen, M. Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1-driven luciferase reporter mouse and human tissue specimens. FASEB J. 27, 1342-1350 (2013). www.fasebj.org	[Strauss, Leena; Rantakari, Pia; Salminen, Anu; Lauren, Eve; Kallio, Jenny; Pakarinen, Pirjo; Zhang, FuPing; Poutanen, Matti] Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; [Strauss, Leena; Rantakari, Pia; Kallio, Jenny; Damdimopoulou, Pauliina; Pakarinen, Pirjo; Zhang, FuPing; Makela, Sari; Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Inst Biomed, FIN-20520 Turku, Finland; [Strauss, Leena] Univ Turku, Electron Microscopy Lab, FIN-20520 Turku, Finland; [Damdimopoulou, Pauliina; Makela, Sari] Univ Turku, FIN-20520 Turku, Finland; [Sjogren, Klara; Ohlsson, Claes; Poutanen, Matti] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden; [Bostrom, Minna; Bostrom, Peter J.] Turku Univ Hosp, Dept Surg, Div Urol, FIN-20520 Turku, Finland; [Kujala, Paula] Tampere Univ Hosp, Dept Pathol, Tampere, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Gothenburg; University of Turku; Tampere University; Tampere University Hospital	Poutanen, M (corresponding author), Univ Turku, Dept Physiol, Inst Biomed, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	matpou@utu.fi	Poutanen, Matti/I-1700-2018; Ohlsson, Claes/AGP-3544-2022; Strauss, Leena/AAY-8824-2021; Ohlsson, Claes/HIR-6959-2022	Poutanen, Matti/0000-0002-8953-1734; Ohlsson, Claes/0000-0002-9633-2805; Ohlsson, Claes/0000-0002-9633-2805; Strauss, Leena/0000-0002-5682-205X; Rantakari, Pia/0000-0003-1638-5075; Bostrom, Peter/0000-0003-3647-0015; Damdimopoulou, Pauliina/0000-0001-8458-0855; Makela, Sari/0000-0002-8698-4076; Sjogren, Klara/0000-0001-5776-7278	European Commission [PIONEER FOOD-CT-2004-513991]; Jalmari and Rauha Ahokas Foundation; Academy of Finland; Sigrid Juselius Foundation; Swedish Research Council	European Commission(European CommissionEuropean Commission Joint Research Centre); Jalmari and Rauha Ahokas Foundation; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission)	The authors thank Katri Hovirinta, Heidi Liljenback, Nina Messner, Erja Mantysalo, Heli Niittymaki, Erica Nyman, Jonna Palmu, Hannele Rekola, and Charlotta Uggla for skillful technical assistance. This work was supported by the European Commission (PIONEER FOOD-CT-2004-513991), the Jalmari and Rauha Ahokas Foundation, the Academy of Finland, the Sigrid Juselius Foundation, and the Swedish Research Council.	Aapro M. S., 2003, BREAST CANC RES T S1, V80, pS13; Aapro MS, 2003, BREAST CANCER RES TR, V80, pS3; Aquila S, 2004, J CLIN ENDOCR METAB, V89, P1443, DOI 10.1210/jc.2003-031681; Aquila S, 2003, HUM REPROD, V18, P1650, DOI 10.1093/humrep/deg340; Balducci L., ONCOLOGY, V24, P741; Barnadas A, 2011, ADV THER, V28, P1045, DOI 10.1007/s12325-011-0075-4; Barnard RJ, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.12.1752; Bianco JJ, 2002, ENDOCRINOLOGY, V143, P4922, DOI 10.1210/en.2002-220493; Bouillon R, 2004, J CLIN ENDOCR METAB, V89, P6025, DOI 10.1210/jc.2004-0602; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1616, DOI 10.1210/jc.77.6.1616; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Cavaco JEB, 2009, SYST BIOL REPROD MED, V55, P137, DOI 10.1080/19396360902855733; Chavalmane AK, 2010, J SEX MED, V7, P2698, DOI 10.1111/j.1743-6109.2010.01811.x; Chow JDY, 2009, J STEROID BIOCHEM, V115, P115, DOI 10.1016/j.jsbmb.2009.03.010; Cunha G R, 1987, Prog Clin Biol Res, V239, P251; Demura M, 2011, LUNG CANCER, V73, P289, DOI 10.1016/j.lungcan.2011.01.003; Demura M, 2008, REPROD SCI, V15, P1044, DOI 10.1177/1933719108322441; Fraser LR, 2006, HUM REPROD, V21, P1184, DOI 10.1093/humrep/dei486; Geisler J, 2011, BRIT J CANCER, V104, P1059, DOI 10.1038/bjc.2011.58; Harada N, 2001, J STEROID BIOCHEM, V79, P151, DOI 10.1016/S0960-0760(01)00153-4; Herrmann BL, 2002, J CLIN ENDOCR METAB, V87, P5476, DOI 10.1210/jc.2002-020498; Hinshelwood MM, 2000, ENDOCRINOLOGY, V141, P2050, DOI 10.1210/en.141.6.2050; IDAOMAR M, 1989, ARCH ANDROLOGY, V22, P197, DOI 10.3109/01485018908986772; JENKINS C, 1993, MOL CELL ENDOCRINOL, V97, pR1, DOI 10.1016/0303-7207(93)90227-B; Jones MEE, 2006, TRENDS ENDOCRIN MET, V17, P53, DOI 10.1016/j.tem.2006.01.004; Kamat A, 2005, ENDOCRINOLOGY, V146, P2481, DOI 10.1210/en.2004-1606; Kamat A, 1999, P NATL ACAD SCI USA, V96, P4575, DOI 10.1073/pnas.96.8.4575; Luboshitzky R, 2002, INT J ANDROL, V25, P345, DOI 10.1046/j.1365-2605.2002.00376.x; Luboshitzky R, 2002, ARCH ANDROLOGY, V48, P225, DOI 10.1080/01485010252869324; Maffei L, 2004, J CLIN ENDOCR METAB, V89, P61, DOI 10.1210/jc.2003-030313; MARTEL C, 1994, MOL CELL ENDOCRINOL, V104, P103, DOI 10.1016/0303-7207(94)90056-6; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Myers RP, 2010, CLIN ANAT, V23, P18, DOI 10.1002/ca.20895; Pradidarcheep W, 2008, AGING MALE, V11, P51, DOI 10.1080/13685530801954026; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Rivest P, 2010, TOXICOL APPL PHARM, V249, P33, DOI 10.1016/j.taap.2010.08.011; Saunders PTK, 2001, MOL HUM REPROD, V7, P227, DOI 10.1093/molehr/7.3.227; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Solakidi S, 2005, HUM REPROD, V20, P3481, DOI 10.1093/humrep/dei267; Streng T, 2002, J UROLOGY, V168, P298, DOI 10.1016/S0022-5347(05)64911-7; Toppari J, 2008, SEX DEV, V2, P260, DOI 10.1159/000152042; Wengstrom Y, 2008, BREAST, V17, P227, DOI 10.1016/j.breast.2007.11.001; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602; Yague JG, 2009, ENDOCRINE, V35, P252, DOI 10.1007/s12020-008-9134-2; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; Zhao H, 2012, ENDOCRINOLOGY, V153, P2701, DOI 10.1210/en.2011-1761; Zhao H, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-37	52	9	9	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1342	1350		10.1096/fj.12-219048	http://dx.doi.org/10.1096/fj.12-219048			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23239821				2022-12-28	WOS:000316940800007
J	Frantz, S; Hofmann, U; Fraccarollo, D; Schafer, A; Kranepuhl, S; Hagedorn, I; Nieswandt, B; Nahrendorf, M; Wagner, H; Bayer, B; Pachel, C; Schon, MP; Kneitz, S; Bobinger, T; Weidemann, F; Ertl, G; Bauersachs, J				Frantz, Stefan; Hofmann, Ulrich; Fraccarollo, Daniela; Schaefer, Andreas; Kranepuhl, Stefanie; Hagedorn, Ina; Nieswandt, Bernhard; Nahrendorf, Matthias; Wagner, Helga; Bayer, Barbara; Pachel, Christina; Schoen, Michael P.; Kneitz, Susanne; Bobinger, Tobias; Weidemann, Frank; Ertl, Georg; Bauersachs, Johann			Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction	FASEB JOURNAL			English	Article						extracellular matrix; ischemia; inflammation	MONOCYTE SUBSETS; MICE; ACTIVATION; EXPRESSION; IMPACT	Myocardial infarction (MI) leads to rapid necrosis of cardiac myocytes. To achieve tissue integrity and function, inflammatory cells are activated, including monocytes/macrophages. However, the effect of monocyte/macrophage recruitment after MI remains poorly defined. After experimental MI, monocytes and macrophages were depleted through serial injections of clodronate-containing liposomes. Monocyte/macrophage infiltration was reduced in the myocardium after MI by active treatment. Mortality was increased due to thromboembolic events in monocyte-and macrophage-depleted animals (92 vs. 33%; P<0.01). Left ventricular thrombi were detectable as early as 24 h after MI; this was reproduced in a genetic model of monocyte/macrophage ablation. A general prothrombotic state, increased infarct expansion, and deficient neovascularization were not observed. Severely compromised extracellular matrix remodeling (collagen I, placebo liposome vs. clodronate liposome, 2.4 +/- 0.2 vs. 0.8 +/- 0.2 arbitrary units; P<0.001) and locally lost integrity of the endocardium after MI are potential mechanisms. Patients with a left ventricular thrombus had a relative decrease of CD14(+) CD16(+) monocyte/macrophage subsets in the peripheral blood after MI (no thrombus vs. thrombus, 14.2 +/- 0.9 vs. 7.80 +/- 0.4%; P<0.05). In summary, monocytes/macrophages are of central importance for healing after MI. Impaired monocyte/macrophage function appears to be an unrecognized new pathophysiological mechanism for left ventricular thrombus development after MI.-Frantz, S., Hofmann, U., Fraccarollo, D., Schafer, A., Kranepuhl, S., Hagedorn, I., Nieswandt, B., Nahrendorf, M., Wagner, H., Bayer, B., Pachel, C., Schon, M.P., Kneitz, S., Bobinger, T., Weidemann, F., Ertl, G., Bauersachs, J. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J. 27, 871-881 (2013). www.fasebj.org	[Frantz, Stefan; Hofmann, Ulrich; Kranepuhl, Stefanie; Wagner, Helga; Bayer, Barbara; Pachel, Christina; Bobinger, Tobias; Weidemann, Frank; Ertl, Georg] Univ Hosp Wurzburg, Dept Internal Med 1, Rudolf Virchow Ctr, Wurzburg, Germany; [Hagedorn, Ina; Nieswandt, Bernhard] Univ Hosp Wurzburg, Rudolf Virchow Ctr, Dept Vasc Med, Wurzburg, Germany; [Frantz, Stefan; Hofmann, Ulrich; Hagedorn, Ina; Nieswandt, Bernhard; Wagner, Helga; Bayer, Barbara; Pachel, Christina; Weidemann, Frank; Ertl, Georg] Univ Wurzburg, Comprehens Heart Failure Ctr, Microarray Core Facil, D-97080 Wurzburg, Germany; [Kneitz, Susanne] Univ Wurzburg, Interdisciplinary Ctr Clin Res, Microarray Core Facil, D-97080 Wurzburg, Germany; [Fraccarollo, Daniela; Schaefer, Andreas; Bauersachs, Johann] Hannover Med Sch, Dept Cardiol & Angiol, D-30623 Hannover, Germany; [Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA; [Schoen, Michael P.] Univ Gottingen, Dept Dermatol Venereol & Allergol, D-37073 Gottingen, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Hannover Medical School; Harvard University; Massachusetts General Hospital; University of Gottingen	Frantz, S (corresponding author), Univ Wurzburg, Dept Internal Med 1, Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	frantz_s@medizin.uni-wuerzburg.de	Schäfer, Andreas/AAQ-9512-2021; Frantz, Stefan/G-1723-2012	Schon, Michael/0000-0002-0698-4130	Bundesministerium fur Bildung und Forschung [BMBF01 EO1004]; Deutsche Forschungsgemeinschaft [SFB688 TP A10]	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Charlotte Dienesch, Benjamin Vogel, Niklas Beyersdorf, Thomas Kerkau, and Jens Biesenbaum for their excellent technical support. This work was supported by grants from the Bundesministerium fur Bildung und Forschung (BMBF01 EO1004; G.E., S.F.) and by the Deutsche Forschungsgemeinschaft (SFB688 TP A10; G.E., S.F.). The authors declare no conflicts of interest.	ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Chiarella F, 1998, AM J CARDIOL, V81, P822, DOI 10.1016/S0002-9149(98)00003-4; Ertl G, 2005, CARDIOVASC RES, V66, P22, DOI 10.1016/j.cardiores.2005.01.011; Esmon CT, 2004, THROMB RES, V114, P321, DOI 10.1016/j.thromres.2004.06.028; Frantz S, 2004, BRIT J PHARMACOL, V141, P9, DOI 10.1038/sj.bjp.0705585; Frantz S, 2009, CARDIOVASC RES, V81, P474, DOI 10.1093/cvr/cvn292; Hofmann U, 2012, CIRCULATION, V125, P1652, DOI 10.1161/CIRCULATIONAHA.111.044164; Hojo Y, 2000, J AM COLL CARDIOL, V35, P968, DOI 10.1016/S0735-1097(99)00632-4; Jugdutt BI, 2002, J AM COLL CARDIOL, V39, P247, DOI 10.1016/S0735-1097(01)01733-8; Kleinbongard P, 2011, HEART FAIL REV, V16, P49, DOI 10.1007/s10741-010-9180-8; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Meier Karen, 2006, Expert Opin Emerg Drugs, V11, P23, DOI 10.1517/14728214.11.1.23; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nosaka M, 2011, J CLIN INVEST, V121, P2911, DOI 10.1172/JCI40782; Tsujioka H, 2009, J AM COLL CARDIOL, V54, P130, DOI 10.1016/j.jacc.2009.04.021; van Amerongen MJ, 2007, AM J PATHOL, V170, P818, DOI 10.2353/ajpath.2007.060547; vanRooijen N, 1997, J LEUKOCYTE BIOL, V62, P702, DOI 10.1002/jlb.62.6.702; Yukami T, 2007, J LEUKOCYTE BIOL, V82, P519, DOI 10.1189/jlb.0307152	19	128	136	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					871	881		10.1096/fj.12-214049	http://dx.doi.org/10.1096/fj.12-214049			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23159933				2022-12-28	WOS:000315585200004
J	McCarthy, C; Duffy, MM; Mooney, D; James, WG; Griffin, MD; Fitzgerald, DJ; Belton, O				McCarthy, Cathal; Duffy, Michelle M.; Mooney, Declan; James, William G.; Griffin, Matthew D.; Fitzgerald, Desmond J.; Belton, Orina			IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis	FASEB JOURNAL			English	Article						M2 macrophages; Ly6C(lo) monocytes; anti-inflammatory; plaque microenvironment	GENE-EXPRESSION; DENDRITIC CELLS; MONOCYTE SUBSETS; T-CELLS; INTERLEUKIN-10; MACROPHAGES; ACTIVATION; MICE; OVEREXPRESSION; RECRUITMENT	Conjugated linoleic acid (CLA) induces regression of preestablished atherosclerosis in the ApoE(-/-) mouse. Understanding the mechanisms involved may help in identifying novel pathways associated with the regression of human disease. Animals were administered a 1% cholesterol diet for 12 wk, with 1% CLA supplementation from wk 8 to 12. ApoE(-/-) mice fed only the 1% cholesterol diet for 12 wk were employed as controls. Transcriptomic analysis of mouse aorta showed that many of the components of the IL-10 signaling pathway were modified during CLA-induced regression. Real-time PCR and Western blot analysis showed increased IL-10 receptor expression, phosphorylation of STAT3, and downstream target gene expression in the aorta, alongside an increase in serum IL-10 (79.8 +/- 22.4 vs. 41.9 +/- 5.5 pg/ml, n=10; P<0.01). CLA -supplementation also increased IL-10 production in bone marrow-derived macrophages (143.6 +/- 28.6 vs. 94 +/- 5.6 pg/ml, n=5; P<0.05). To explore the mechanisms for altered IL-10 production, we examined the profile of monocyte/macrophage phenotype in the vessel wall, bone marrow, and spleen. CLA increased macrophage polarization toward an anti-inflammatory M2 phenotype in vivo, increasing the population of Ly6C(lo) monocytes (29 vs. 77 +/- 14, n=5, P < 0.05) in the aorta. CLA had similar effects on monocytes/macrophages differentiated from marrow-derived progenitor cells and on splenocytes. The induction of IL-10 on CLA supplementation in this model may reflect a systemic alteration toward an anti-inflammatory phenotype, which, in turn promotes increased vascular infiltration by Ly6C(lo) monocytes. These cells may contribute to CLA-induced disease regression.-McCarthy, C., Duffy, M. M., Mooney, D., James, W. G., Griffin, M. D., Fitzgerald, D. J., Belton, O. IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis. FASEB J. 27, 499-510 (2013). www.fasebj.org	[McCarthy, Cathal; Mooney, Declan; James, William G.; Belton, Orina] Univ Coll Dublin, Conway Inst, Sch Biomed & Biomol Sci, Dublin 2, Ireland; [Fitzgerald, Desmond J.] Univ Coll Dublin, Conway Inst, Sch Med & Med Sci, Dublin 2, Ireland; [Duffy, Michelle M.; Griffin, Matthew D.] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Regenerat Med Inst, Galway, Ireland; [Duffy, Michelle M.; Griffin, Matthew D.] Natl Univ Ireland, Sch Med Nursing & Hlth Sci, Galway, Ireland	University College Dublin; University College Dublin; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Belton, O (corresponding author), UCD, UCD Conway Inst, Sch Biomol & Biomed Sci, Dublin 4, Ireland.	orina.belton@ucd.ie	Griffin, Matthew/A-1688-2009	Griffin, Matthew/0000-0002-8701-8056; Belton, Orina/0000-0002-7701-6540	Health Research Board; Science Foundation Ireland	Health Research Board; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	This study was supported by grants from the Health Research Board and Science Foundation Ireland.	Ait-Oufella H, 2006, NAT MED, V12, P178, DOI 10.1038/nm1343; Bassaganya-Riera J, 2004, GASTROENTEROLOGY, V127, P777, DOI 10.1053/j.gastro.2004.06.049; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Choi JH, 2011, IMMUNITY, V35, P819, DOI 10.1016/j.immuni.2011.09.014; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Feig JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028534; Feig JE, 2011, P NATL ACAD SCI USA, V108, P7166, DOI 10.1073/pnas.1016086108; Feig JE, 2011, CIRCULATION, V123, P989, DOI 10.1161/CIRCULATIONAHA.110.984146; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Galkina E, 2006, J EXP MED, V203, P1273, DOI 10.1084/jem.20052205; Han XB, 2010, FASEB J, V24, P2869, DOI 10.1096/fj.09-148155; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Hristov M, 2011, THROMB HAEMOSTASIS, V106, P757, DOI 10.1160/TH11-07-0500; Huebner SM, 2010, J NUTR, V140, P1454, DOI 10.3945/jn.109.120527; Jing L., 2010, J LIPID RES, V51, P1208; Kritchevsky D, 2004, LIPIDS, V39, P611, DOI 10.1007/s11745-004-1273-8; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Lee Y, 2009, J NUTR, V139, P1861, DOI 10.3945/jn.108.100461; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Llodra J, 2004, P NATL ACAD SCI USA, V101, P11779, DOI 10.1073/pnas.0403259101; Loscher CE, 2005, J IMMUNOL, V175, P4990, DOI 10.4049/jimmunol.175.8.4990; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; McClelland S, 2010, ATHEROSCLEROSIS, V211, P96, DOI 10.1016/j.atherosclerosis.2010.02.003; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Mitchell PL, 2008, BIOCHEM CELL BIOL, V86, P293, DOI [10.1139/O08-070, 10.1139/o08-070]; Moloney F, 2007, DIABETES, V56, P574, DOI 10.2337/db06-0384; Moya-Camarena SY, 1999, J LIPID RES, V40, P1426; Murray PJ, 2006, CURR OPIN PHARMACOL, V6, P379, DOI 10.1016/j.coph.2006.01.010; Nagao K, 2003, BIOCHEM BIOPH RES CO, V310, P562, DOI 10.1016/j.bbrc.2003.09.044; Nakajima K, 2011, ARTERIOSCL THROM VAS, V31, P1963, DOI 10.1161/ATVBAHA.111.229443; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; Potteaux S, 2004, ARTERIOSCL THROM VAS, V24, P1474, DOI 10.1161/01.ATV.0000134378.86443.cd; Potteaux S, 2011, J CLIN INVEST, V121, P2025, DOI 10.1172/JCI43802; Reineke U, 1999, J MOL RECOGNIT, V12, P242, DOI 10.1002/(SICI)1099-1352(199907/08)12:4<242::AID-JMR461>3.0.CO;2-1; Robbins CS, 2012, CIRCULATION, V125, P364, DOI 10.1161/CIRCULATIONAHA.111.061986; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Swirski FK, 2009, ARTERIOSCL THROM VAS, V29, P1424, DOI 10.1161/ATVBAHA.108.180521; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Toomey S, 2006, ATHEROSCLEROSIS, V187, P40, DOI 10.1016/j.atherosclerosis.2005.08.024; Trogan E, 2006, P NATL ACAD SCI USA, V103, P3781, DOI 10.1073/pnas.0511043103; van Oostrom AJHHM, 2004, ATHEROSCLEROSIS, V177, P175, DOI 10.1016/j.atherosclerosis.2004.07.004; Wolfs IMJ, 2011, THROMB HAEMOSTASIS, V106, P763, DOI 10.1160/TH11-05-0320	45	48	49	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					499	510		10.1096/fj.12-215442	http://dx.doi.org/10.1096/fj.12-215442			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23070607	Bronze			2022-12-28	WOS:000314358000010
J	Tomas, J; Wrzosek, L; Bouznad, N; Bouet, S; Mayeur, C; Noordine, ML; Honvo-Houeto, E; Langella, P; Thomas, M; Cherbuy, C				Tomas, Julie; Wrzosek, Laura; Bouznad, Nassim; Bouet, Stephan; Mayeur, Camille; Noordine, Marie-Louise; Honvo-Houeto, Edith; Langella, Philippe; Thomas, Muriel; Cherbuy, Claire			Primocolonization is associated with colonic epithelial maturation during conventionalization	FASEB JOURNAL			English	Article						intestine; microbiota; proliferation; germ-free rat; transporters	MICROBIAL DIVERSITY; ESTABLISHMENT; INTESTINE; PROLIFERATION; HOMEOSTASIS; MICROFLORA; SUCCESSION; RECEPTORS; INDUCTION; MUCOSA	Interaction between the gut microbiota and the host starts immediately after birth with the progressive colonization of the sterile intestine. Our aim was to investigate the interactions taking place in the colonic epithelium after the first exposure to gut microbiota. Germ-free (GF) rats were inoculated with two different microbiotas: the first, obtained from suckling rats, was rich in primocolonizing bacteria and the second, obtained from adult rats, was representative of a mature microbiota. Once transferred into GF rats, these two microbiotas evolved such that they converged, and recapitulated the primocolonization pattern, mimicking the chronological scheme of implantation following birth. The two microbiotas induced common responses in the colonic epithelium: a transitory proliferative phase followed by a compensatory phase characterized by increases in the abundance of p21(Cip1) and p27(Kip1) and in the number of goblet cells. The effects of the two microbiotas diverged only through their effects on colonic transporters. Analyses of solute carriers and aquaporins revealed that functional maturation was more pronounced following exposure to adult microbiota than suckling microbiota. The colon matured in parallel with the evolution of the microbiota composition, and we therefore suggest a link between intestinal events regulating homeostasis of the colon and modulation of microbial composition.-Tomas, J., Wrzosek, L., Bouznad, N., Bouet, S., Mayeur, C., Noordine, M.-L., Honvo-Houeto, E., Langella, P., Thomas, M., Cherbuy, C. Primocolonization is associated with colonic epithelial maturation during conventionalization. FASEB J. 27, 645-655 (2013). www.fasebj.org	[Tomas, Julie; Wrzosek, Laura; Mayeur, Camille; Noordine, Marie-Louise; Langella, Philippe; Thomas, Muriel; Cherbuy, Claire] INRA, Commensal & Probiot Host Interact Lab, F-78350 Jouy En Josas, France; [Tomas, Julie; Wrzosek, Laura; Mayeur, Camille; Noordine, Marie-Louise; Langella, Philippe; Thomas, Muriel; Cherbuy, Claire] AgroParisTech, Unite Mixte Rech UMR 1319, Microbiol Alimentat Serv Sante MICALIS, Jouy En Josas, France; [Bouznad, Nassim] Univ Liege, Human Genet Unit, B-4000 Liege, Belgium; [Bouznad, Nassim; Bouet, Stephan] INRA, F-78350 Jouy En Josas, France; [Bouet, Stephan] AgroParisTech, UMR Anim Genet & Integrat Biol 1313, Jouy En Josas, France; [Bouet, Stephan] Commissariat Energie Atom & Energies Alternat CEA, Lab Radiobiol & Genom Studies, DSV, IRCM,SREIT, Jouy En Josas, France; [Honvo-Houeto, Edith] INRA, Genom & Physiol Lactat, F-78350 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay; University of Liege; INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Cherbuy, C (corresponding author), INRA, MICALIS, UMR 1319, F-78350 Jouy En Josas, France.	claire.cherbuy@jouy.inra.fr	Langella, Philippe/N-8368-2017; thomas, muriel/HDO-3887-2022; TOMAS, Julie/AAC-9819-2022; Thomas, Muriel/D-9164-2015	Langella, Philippe/0000-0001-5960-4341; Thomas, Muriel/0000-0002-7608-3274; TOMAS, Julie/0000-0001-9389-0273	Institut National de la Recherche Agronomique (Jouy-en-Josas, France); French Ministry of Education and Research	Institut National de la Recherche Agronomique (Jouy-en-Josas, France); French Ministry of Education and Research	The authors thank Christine Delorme and Sylvie Miquel for fruitful discussions and critical reading of the manuscript, the Animalerie Axenique de MICALIS (ANAXEM) platform [Microbiologie de l'Alimentation au Service de la Sante (MICALIS), Jouy-en-Josas, France] for animal facilities, and Catherine Philippe for SCFA analyses. J.T. was recipient of a Contrat Jeune Scientifique from the Institut National de la Recherche Agronomique (Jouy-en-Josas, France), and L. W. was recipient of a Ph.D. grant from the French Ministry of Education and Research. The authors declare no conflicts of interest.	Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009; Cheesman SE, 2011, P NATL ACAD SCI USA, V108, P4570, DOI 10.1073/pnas.1000072107; Cherbuy C, 2004, EUR J BIOCHEM, V271, P87, DOI 10.1046/j.1432-1033.2003.03908.x; CHERBUY C, 1995, GASTROENTEROLOGY, V109, P1890, DOI 10.1016/0016-5085(95)90756-4; Cherbuy C, 2010, AM J PHYSIOL-GASTR L, V299, pG348, DOI 10.1152/ajpgi.00384.2009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury Shankar R, 2007, BMC Genomics, V8, P215, DOI 10.1186/1471-2164-8-215; Cresci GA, 2010, J GASTROINTEST SURG, V14, P449, DOI 10.1007/s11605-009-1045-x; Danielsen M, 2007, J PROTEOME RES, V6, P2596, DOI 10.1021/pr070038b; Djouzi Z, 1997, J NUTR, V127, P2260, DOI 10.1093/jn/127.11.2260; Drozdowski LA, 2010, WORLD J GASTROENTERO, V16, P787, DOI 10.3748/wjg.v16.i7.787; Duerr CU, 2012, SEMIN IMMUNOL, V24, P25, DOI 10.1016/j.smim.2011.11.002; El Aidy S, 2012, MUCOSAL IMMUNOL, V5, P567, DOI 10.1038/mi.2012.32; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Furet JP, 2009, FEMS MICROBIOL ECOL, V68, P351, DOI 10.1111/j.1574-6941.2009.00671.x; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gillilland MG, 2012, APPL ENVIRON MICROB, V78, P2359, DOI 10.1128/AEM.05239-11; Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802, DOI 10.1128/AEM.63.7.2802-2813.1997; Hopkins MJ, 2005, FEMS MICROBIOL ECOL, V54, P77, DOI 10.1016/j.femsec.2005.03.001; Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105; Joly F, 2009, AM J PHYSIOL-GASTR L, V297, pG116, DOI 10.1152/ajpgi.90657.2008; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Kurokawa K, 2007, DNA RES, V14, P169, DOI 10.1093/dnares/dsm018; Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe; Marchesi JR, 2011, ENVIRON MICROBIOL, V13, P3088, DOI 10.1111/j.1462-2920.2011.02574.x; Marcobal A, 2011, CELL HOST MICROBE, V10, P507, DOI 10.1016/j.chom.2011.10.007; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Preidis GA, 2012, FASEB J, V26, P1960, DOI 10.1096/fj.10-177980; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Rul F, 2011, J BIOL CHEM, V286, P10288, DOI 10.1074/jbc.M110.168666; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Stockinger S, 2011, CELL MOL LIFE SCI, V68, P3699, DOI 10.1007/s00018-011-0831-2; Thiagarajah JR, 2007, GUT, V56, P1529, DOI 10.1136/gut.2006.104620; Thomas M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028789	42	54	57	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					645	655		10.1096/fj.12-216861	http://dx.doi.org/10.1096/fj.12-216861			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118025				2022-12-28	WOS:000314358000023
J	Tang, XN; Zhou, B				Tang, Xiaona; Zhou, Bing			Ferritin is the key to dietary iron absorption and tissue iron detoxification in Drosophila melanogaster	FASEB JOURNAL			English	Article						secretory ferritin; midgut; iron export	SERUM FERRITIN; H-FERRITIN; TRANSGENIC RNAI; LOADED FERRITIN; TASTE BEHAVIOR; MALVOLIO; EXPRESSION; HOMOLOG; METABOLISM; CELLS	Mammalian ferritin is predominantly in the cytosol, with a minor portion found in plasma. In most insects, including Drosophila melanogaster, ferritin belongs to the secretory type. The functional role of secretory ferritin in iron homeostasis remains poorly understood in insects as well as in mammalians. Here we used Drosophila to dissect the involvement of ferritin in insect iron metabolism. Midgut-specific knockdown of ferritin resulted in iron accumulation in the gut but systemic iron deficiency (37% control), accompanied by retarded development and reduced survival (3% survival), and was rescued by dietary iron supplementation (50% survival) or exacerbated by iron depletion (0% survival). These results suggest an essential role of ferritin in removing iron from enterocytes across the basolateral membrane. Expression of wild-type ferritin in the midgut, especially in the iron cell region, could significantly rescue ferritin-null mutants (first-instar larvae rescued up to early adults), indicating iron deficiency as the major cause of early death for ferritin flies. In many nonintestinal tissues, tissue-specific ferritin knockdown also caused local iron accumulation (100% increase) and resulted in severe tissue damage, as evidenced by cell loss. Overall, our study demonstrated Drosophila ferritin is essential to two key aspects of iron homeostasis: dietary iron absorption and tissue iron detoxification.-Tang, X., Zhou, B. Ferritin is the key to dietary iron absorption and tissue iron detoxification in Drosophila melanogaster. FASEB J. 27, 288-298 (2013). www.fasebj.org	[Tang, Xiaona; Zhou, Bing] Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Zhou, B (corresponding author), Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, New Life Sci Bldg,Room 109, Beijing 100084, Peoples R China.	zhoubing@mail.tsinghua.edu.cn			National Basic Research Program of China [2011CB910900]; National Science Foundation of China [30971568, 31123004]	National Basic Research Program of China(National Basic Research Program of China); National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Basic Research Program of China (2011CB910900) and by the National Science Foundation of China (30971568, 31123004). The authors greatly appreciate the kind gifts of fly stocks from Dr. Fanis Missirlis (Queen Mary, University of London, London, UK) and Dr. Craig Montell (Johns Hopkins University School of Medicine, Baltimore, MD, USA). The authors are also grateful to the Bloomington Drosophila Stock Center (Indiana University, Bloomington, IN, USA), the Drosophila Genetic Resource Center (Kyoto Institute of Technology, Kyoto, Japan), the Vienna Drosophila RNAi Center (Vienna, Austria), and the Gene Regulation Laboratory and Tsinghua Fly Center (Tsinghua University) for fly stocks. The authors also thank Dr. Zhihao Wu and Dr. Xiaoxi Wang for helpful discussion.	Andrews NC, 2005, BEST PRACT RES CL HA, V18, P159, DOI 10.1016/j.beha.2004.10.004; AROSIO P, 1977, BRIT J HAEMATOL, V36, P199, DOI 10.1111/j.1365-2141.1977.tb00640.x; Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004; Bettedi L, 2011, J EXP BIOL, V214, P971, DOI 10.1242/jeb.051664; Brenner R, 1997, COMP BIOCHEM PHYS B, V118, P411, DOI 10.1016/S0305-0491(97)00167-3; Coffman LG, 2009, P NATL ACAD SCI USA, V106, P570, DOI 10.1073/pnas.0812010106; D'Souza J, 1999, J EXP BIOL, V202, P1909; Darshan D, 2009, HEPATOLOGY, V50, P852, DOI 10.1002/hep.23058; De Domenico I, 2011, CELL METAB, V13, P57, DOI 10.1016/j.cmet.2010.12.003; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Dunkov BC, 1999, DNA CELL BIOL, V18, P937, DOI 10.1089/104454999314791; Dunkov Boris C, 2002, J Insect Sci, V2, P7; FARGION S, 1988, BLOOD, V71, P753; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Folwell JL, 2006, J EXP BIOL, V209, P1988, DOI 10.1242/jeb.02193; Geiser DL, 2009, COMP BIOCHEM PHYS B, V152, P352, DOI 10.1016/j.cbpb.2009.01.002; Geiser DL, 2006, INSECT BIOCHEM MOLEC, V36, P177, DOI 10.1016/j.ibmb.2005.12.001; Georgieva T, 2002, INSECT BIOCHEM MOLEC, V32, P295, DOI 10.1016/S0965-1748(01)00090-X; Knovich MA, 2009, BLOOD REV, V23, P95, DOI 10.1016/j.blre.2008.08.001; Li JY, 2009, DEV CELL, V16, P35, DOI 10.1016/j.devcel.2008.12.002; Li L, 2010, P NATL ACAD SCI USA, V107, P3505, DOI 10.1073/pnas.0913192107; Li S, 2010, CELL RES, V20, P1148, DOI 10.1038/cr.2010.102; Linder MC, 1996, J GASTROEN HEPATOL, V11, P1033, DOI 10.1111/j.1440-1746.1996.tb00030.x; Martinez-Barnetche J, 2007, INSECT BIOCHEM MOLEC, V37, P532, DOI 10.1016/j.ibmb.2007.02.009; Mehta A, 2009, BIOCHIMIE, V91, P1331, DOI 10.1016/j.biochi.2009.05.003; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Ni JQ, 2011, NAT METHODS, V8, P405, DOI [10.1038/NMETH.1592, 10.1038/nmeth.1592]; NICHOL H, 1990, TISSUE CELL, V22, P767, DOI 10.1016/0040-8166(90)90042-8; Nichol H, 2002, ANNU REV ENTOMOL, V47, P535, DOI 10.1146/annurev.ento.47.091201.145237; Orgad S, 1998, J EXP BIOL, V201, P115; Pham DQD, 2010, BBA-GEN SUBJECTS, V1800, P824, DOI 10.1016/j.bbagen.2010.03.004; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Ruddell RG, 2009, HEPATOLOGY, V49, P887, DOI 10.1002/hep.22716; Todorich B, 2008, J NEUROCHEM, V107, P1495, DOI 10.1111/j.1471-4159.2008.05678.x; UNDERWOOD EM, 1980, DEV BIOL, V74, P286, DOI 10.1016/0012-1606(80)90431-5; Vanoaica L, 2010, CELL METAB, V12, P273, DOI 10.1016/j.cmet.2010.08.003; VANREEN R, 1959, J BIOL CHEM, V234, P1951; Wang T, 2007, J CELL BIOL, V177, P305, DOI 10.1083/jcb.200610081; Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011; Wang XX, 2009, FASEB J, V23, P2650, DOI 10.1096/fj.08-126649; Wu ZH, 2009, HUM MOL GENET, V18, P3659, DOI 10.1093/hmg/ddp314; Zhou GL, 2007, J INSECT PHYSIOL, V53, P1169, DOI 10.1016/j.jinsphys.2007.06.009	43	70	72	2	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2013	27	1					288	298		10.1096/fj.12-213595	http://dx.doi.org/10.1096/fj.12-213595			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23064556				2022-12-28	WOS:000313103200027
J	Uehara, H; Cho, Y; Simonis, J; Cahoon, J; Archer, B; Luo, L; Das, SK; Singh, N; Ambati, J; Ambati, BK				Uehara, Hironori; Cho, YangKyung; Simonis, Jackie; Cahoon, Judd; Archer, Bonnie; Luo, Ling; Das, Subrata K.; Singh, Nirbhai; Ambati, Jayakrishna; Ambati, Balamurali K.			Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR)	FASEB JOURNAL			English	Article						alternative polyadenylation; corneal graft rejection	MESSENGER-RNA POLYADENYLATION; EXTRACELLULAR-MATRIX; ANGIOGENESIS; MECHANISMS; MOUSE; VEGF; MICE; TRANSPLANTATION; METASTASIS; SEQUENCE	The KDR gene, which participates in angiogenesis and lymphangiogenesis, produces two functionally distinct protein products, membrane-bound KDR (mbKDR) and its isoform, soluble KDR (sKDR). Since sKDR does not have a tyrosine kinase domain and does not dimerize, it is principally an antagonist of lymphangiogenesis by sequestering VEGF-C. Alternative polyadenylation of exon 30 or intron 13 leads to the production of mbKDR or sKDR, respectively, yet the regulatory mechanisms are unknown. Here we show that an antisense morpholino oligomer directed against the exon 13-intron 13 junction increases sKDR (suppressing lymphangiogenesis) and decreases mbKDR (inhibiting hemangiogenesis). The latent polyadenylation site in intron 13 of KDR is activated by blocking the upstream 5' splicing site with an antisense morpholino oligomer. Intravitreal morpholino injection suppressed laser choroidal neovascularization while increasing sKDR. In the mouse cornea, subconjunctival injection of the morpholino-inhibited corneal angiogenesis and lymphangiogenesis, and suppressed graft rejection after transplantation. Thus, this morpholino can be used for concurrent suppression of hemangiogenesis and lymphangiogenesis. This study offers new insight into the mechanisms and potential therapeutic modulation of alternative polyadenylation.-Uehara, H., Cho, YK., Simonis, J., Cahoon, J., Archer, B., Luo, L., Das, S. K., Singh, N., Ambati, J., Ambati, B. K. Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). FASEB J. 27, 76-85 (2013). www.fasebj.org	[Uehara, Hironori; Cho, YangKyung; Simonis, Jackie; Cahoon, Judd; Archer, Bonnie; Luo, Ling; Das, Subrata K.; Singh, Nirbhai; Ambati, Balamurali K.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA; [Cho, YangKyung] Catholic Univ Korea, St Vincent Hosp, Suwon, South Korea; [Ambati, Jayakrishna] Univ Kentucky, Coll Med, Dept Ophthalmol & Visual Sci, Lexington, KY USA	Utah System of Higher Education; University of Utah; Catholic University of Korea; University of Kentucky	Ambati, BK (corresponding author), Univ Utah, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.	bala.ambati@utah.edu		DAS, SUBRATA/0000-0001-8608-3270	Research to Prevent Blindness Physician Scientist Award; U.S. Department of Veterans Affairs Merit Award; U.S. National Eye Institute [R01EY017950]; NATIONAL EYE INSTITUTE [P30EY014800, R01EY020672, R01EY017950, R01EY022238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK091317] Funding Source: NIH RePORTER	Research to Prevent Blindness Physician Scientist Award(Research to Prevent Blindness (RPB)); U.S. Department of Veterans Affairs Merit Award(US Department of Veterans Affairs); U.S. National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a Research to Prevent Blindness Physician Scientist Award, a U.S. Department of Veterans Affairs Merit Award, and U.S. National Eye Institute grant R01EY017950.	Abad X, 2008, NUCLEIC ACIDS RES, V36, P2338, DOI 10.1093/nar/gkn068; Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018; An JJ, 2008, CELL, V134, P175, DOI 10.1016/j.cell.2008.05.045; Anderson JR, 2009, PLOS BIOL, V7, P493, DOI 10.1371/journal.pbio.1000074; Andreassi C, 2009, TRENDS CELL BIOL, V19, P465, DOI 10.1016/j.tcb.2009.06.001; Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002; Ebos JML, 2004, MOL CANCER RES, V2, P315; Ferrara N, 2010, MOL BIOL CELL, V21, P687, DOI 10.1091/mbc.E09-07-0590; Fowler MJ, 2008, CLIN DIABETES, V26, P77, DOI [DOI 10.2337/DIACLIN.26.2.77, 10.2337/diaclin.26.2.77]; Fukumura K, 2009, RNA BIOL, V6, P395, DOI 10.4161/rna.6.4.9318; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Hayashi T, 2008, CORNEA, V27, P699, DOI 10.1097/QAI.0b013e31815e722b; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Jain K, 2010, INT J PHARMACEUT, V394, P122, DOI 10.1016/j.ijpharm.2010.04.027; Jearawiriyapaisarn N, 2008, MOL THER, V16, P1624, DOI 10.1038/mt.2008.120; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; Marc RE, 2000, J COMP NEUROL, V425, P560, DOI 10.1002/1096-9861(20001002)425:4<560::AID-CNE7>3.0.CO;2-D; Morcos PA, 2008, BIOTECHNIQUES, V45, P613, DOI 10.2144/000113005; Muro EM, 2008, P NATL ACAD SCI USA, V105, P20286, DOI 10.1073/pnas.0807813105; Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Peterson ML, 2007, IMMUNOL RES, V37, P33, DOI 10.1007/BF02686094; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469; SONODA Y, 1992, TRANSPLANTATION, V54, P694, DOI 10.1097/00007890-199210000-00026; Summerton JE, 2007, CURR TOP MED CHEM, V7, P651, DOI 10.2174/156802607780487740; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Uehara H, 2010, VISION RES, V50, P674, DOI 10.1016/j.visres.2009.12.003; Vorlova S, 2011, MOL CELL, V43, P927, DOI 10.1016/j.molcel.2011.08.009; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Yudin D, 2008, NEURON, V59, P241, DOI 10.1016/j.neuron.2008.05.029	35	22	23	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2013	27	1					76	85		10.1096/fj.12-213835	http://dx.doi.org/10.1096/fj.12-213835			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22997228	Green Published, Bronze			2022-12-28	WOS:000313103200009
J	Richardson, GD; Breault, D; Horrocks, G; Cormack, S; Hole, N; Owens, A				Richardson, Gavin D.; Breault, David; Horrocks, Grace; Cormack, Suzanne; Hole, Nicholas; Owens, Andrew			Telomerase expression in the mammalian heart	FASEB JOURNAL			English	Article						mTert; transgenic; cardiac; stem cell; regeneration	MYOCYTE CELLULAR HYPERPLASIA; ENDOTHELIAL GROWTH-FACTOR; CARDIAC STEM-CELLS; PROGENITOR CELLS; TUMOR-CELLS; PROLIFERATION; FAILURE; DIFFERENTIATION; REGENERATION; CANCER	While the mammalian heart has low, but functionally significant, levels of telomerase expression, the cellular population responsible remains incompletely characterized. This study aimed to identify the cell types responsible for cardiac telomerase activity in neonatal, adult, and cryoinjured adult hearts using transgenic mice expressing green fluorescent protein (GFP), driven by the promoter for murine telomerase reverse transcriptase (mTert), which is a necessary and rate-limiting component of telomerase. A rare population of mTert-GFP-expressing cells was identified that possessed all detectable cardiac telomerase RNA and telomerase activity. It was heterogeneous and included cells coexpressing markers of cardiomyocytic, endothelial, and mesenchymal lineages, putative cardiac stem cell markers, and, interestingly, cardiomyocytes with a differentiated phenotype. Quantification using both flow cytometry and immunofluorescence identified a significant decline in mTert-GFP cells in adult animals compared to neonates (similar to 9- and similar to 20-fold, respectively). Cardiac injury resulted in a similar to 6.45-fold expansion of this population (P<0.005) compared with sham-operated controls. This study identifies the cells responsible for cardiac telomerase activity, demonstrates a significant diminution with age but a marked response to injury, and, given the relationship between telomerase activity and stem cell populations, suggests that they represent a potential target for further investigation of cardiac regenerative potential.-Richardson, G. D., Breault, D., Horrocks, G., Cormack, S., Hole, N., Owens, W. A. Telomerase expression in the mammalian heart. FASEB J. 26, 4832-4840 (2012). www.fasebj.org	[Richardson, Gavin D.; Owens, Andrew] Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Breault, David] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Endocrinol, Boston, MA USA; [Breault, David] Harvard Stem Cell Inst, Cambridge, MA USA; [Horrocks, Grace; Cormack, Suzanne; Hole, Nicholas] Univ Durham, Sch Biol & Biomed Sci, Durham, England; [Owens, Andrew] S Tees Hosp Natl Hlth Serv NHS Fdn Trust, Dept Cardiothorac Surg, Middlesbrough, Cleveland, England	Newcastle University - UK; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Durham University	Richardson, GD (corresponding author), Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	gavin.richardson2@ncl.ac.uk	Richardson, Gavin/M-2128-2019; Breault, David/HDN-6048-2022; Owens, Andrew/K-4776-2012; Owens, W Andrew/AAG-6073-2020	Richardson, Gavin/0000-0002-2310-9987; Owens, Andrew/0000-0001-9836-9209; Owens, W Andrew/0000-0001-9836-9209	British Heart Foundation [PG/06/110/21521]; U.S. National Institutes of Health [R01 DK084056]; Harvard Stem Cell Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084056] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Stem Cell Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the British Heart Foundation, project grant PG/06/110/21521, U.S. National Institutes of Health grant R01 DK084056 (D. T. B), and the Harvard Stem Cell Institute (D. T. B). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2008, J CELL SCI, V121, P1046, DOI 10.1242/jcs.019372; ANVERSA P, 1990, CIRC RES, V67, P871, DOI 10.1161/01.RES.67.4.871; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Blasco MA, 2002, EUR J CANCER, V38, P2222, DOI 10.1016/S0959-8049(02)00450-1; Borges A, 1997, J MOL CELL CARDIOL, V29, P2717, DOI 10.1006/jmcc.1997.0503; Breault DT, 2008, P NATL ACAD SCI USA, V105, P10420, DOI 10.1073/pnas.0804800105; Endl E, 2000, EXP CELL RES, V257, P231, DOI 10.1006/excr.2000.4888; Erusalimsky JD, 2009, EXP PHYSIOL, V94, P299, DOI 10.1113/expphysiol.2008.043133; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; KAJSTURA J, 1994, CIRC RES, V74, P383, DOI 10.1161/01.RES.74.3.383; Kurz David J, 2003, Arterioscler Thromb Vasc Biol, V23, pe54, DOI 10.1161/01.ATV.0000100112.21118.A1; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Leferovich JM, 2001, P NATL ACAD SCI USA, V98, P9830, DOI 10.1073/pnas.181329398; Leri A, 2000, J MOL CELL CARDIOL, V32, P385, DOI 10.1006/jmcc.1999.1084; Leri A, 2003, EMBO J, V22, P131, DOI 10.1093/emboj/cdg013; Leri A, 2001, Ital Heart J, V2 Suppl 3, p12S; Leri A, 2001, P NATL ACAD SCI USA, V98, P8626, DOI 10.1073/pnas.151013298; Liu T, 2006, AM J RESP CELL MOL, V34, P625, DOI 10.1165/rcmb.2005-0252OC; Liu TJ, 2002, AM J RESP CELL MOL, V26, P534, DOI 10.1165/ajrcmb.26.5.4668; Madonna R., EUR HEART J, V32, P1190; MARINO TA, 1991, CIRC RES, V69, P1353, DOI 10.1161/01.RES.69.5.1353; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Montgomery R. K., P NATL ACAD SCI US, V108, P179; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oh H, 2003, P NATL ACAD SCI USA, V100, P5378, DOI 10.1073/pnas.0836098100; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Porrello ER, SCIENCE, V331, P1078; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Tateishi K, 2007, J CELL SCI, V120, P1791, DOI 10.1242/jcs.006122; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Walsh S., CARDIOVASC RES, V86, P365; Wong LSM, 2009, CARDIOVASC RES, V81, P244, DOI 10.1093/cvr/cvn337; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102; Zaccagnini G, 2005, J BIOL CHEM, V280, P14790, DOI 10.1074/jbc.M414644200; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	43	50	51	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					4832	4840		10.1096/fj.12-208843	http://dx.doi.org/10.1096/fj.12-208843			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22919071	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000311838300007
J	Yuki, K; Bu, WM; Xi, J; Sen, M; Shimaoka, M; Eckenhoff, RG				Yuki, Koichi; Bu, Weiming; Xi, Jin; Sen, Mehmet; Shimaoka, Motomu; Eckenhoff, Roderic G.			Isoflurane binds and stabilizes a closed conformation of the leukocyte function-associated antigen-1	FASEB JOURNAL			English	Article						immunomodulation; photolabeling; rigid docking; volatile anesthetics	I-LIKE DOMAIN; STRUCTURAL BASIS; INTEGRIN ALPHA-L-BETA-2; CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; AFFINITY STATES; ADHESION; SUBUNIT; LFA-1; ACTIVATION	We previously demonstrated that isoflurane targets lymphocyte function-associated antigen-1 (LFA-1), a critical adhesion molecule for leukocyte arrest. However, it remains to be determined how isoflurane interacts with the full ectodomain LFA-1 and modulates its conformation and function. Isoflurane binding sites on the full ectodomain LFA-1 were probed by photolabeling using photoactivatable isoflurane (azi-isoflurane). The adducted residues were determined by liquid chromatography/mass spectrometry analysis. Separately, docking simulations were performed to predict binding sites. Point mutations were introduced around isoflurane binding sites. The significance of isoflurane's effect was assessed in both intracellular adhesion molecule-1 (ICAM-1) binding assays and epitope mapping of activation-sensitive antibodies using flow cytometry. Two isoflurane binding sites were identified using photolabeling and were further validated by the docking simulation: one at the hydrophobic pocket in the ICAM-1 binding domain (the alpha I domain); the other at the beta I domain. Mutagenesis of the alpha'1 helix showed that isoflurane binding sites at the beta I domain were significantly important in modulating LFA-1 function and conformation. Epitope mapping using activation-sensitive antibodies suggested that isoflurane stabilized LFA-1 in the closed conformation. This study suggested that isoflurane binds to both the alpha I and beta I domains allosteric to the ICAM-1 binding site, and that isoflurane binding stabilizes LFA-1 in the closed conformation.-Yuki, K., Bu, W., Xi, J., Sen, M., Shimaoka, M., Eckenhof, R. G. Isoflurane binds and stabilizes a closed conformation of the leukocyte function-associated antigen-1. FASEB J. 26, 4408-4417 (2012). www.fasebj.org	[Yuki, Koichi] Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Yuki, Koichi; Sen, Mehmet; Shimaoka, Motomu] Immune Dis Inst, Boston, MA USA; [Bu, Weiming; Xi, Jin; Eckenhoff, Roderic G.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); University of Pennsylvania; Pennsylvania Medicine	Yuki, K (corresponding author), Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.	koichi.yuki@childrens.harvard.edu		Eckenhoff, Roderic/0000-0002-5581-746X	U.S. National Institutes of Health [P01GM55876, K08GM101345]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM055876, K08GM101345] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [24590579] Funding Source: KAKEN	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank W. P. Dailey (University of Pennsylvania) for providing azi-isoflurane, and T. A. Springer (Immune Disease Institute) for providing reagents and insightful comments. This work was supported by grants from the U.S. National Institutes of Health, P01GM55876 (R.G.E.) and K08GM101345 (K.Y.). The authors declare no conflicts of interest.	ARNAOUT MA, 1990, BLOOD, V75, P1037; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; Drbal K, 2001, IMMUNOBIOLOGY, V203, P687, DOI 10.1016/S0171-2985(01)80017-6; Eckenhoff RG, 2010, ACS CHEM NEUROSCI, V1, P139, DOI 10.1021/cn900014m; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Gaillard T, 2007, J MOL BIOL, V374, P231, DOI 10.1016/j.jmb.2007.07.006; Hall RI, 1997, ANESTH ANALG, V85, P766, DOI 10.1097/00000539-199710000-00011; HART TN, 1992, PROTEINS, V13, P206, DOI 10.1002/prot.340130304; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Mobert J, 1999, ANESTHESIOLOGY, V90, P1372, DOI 10.1097/00000542-199905000-00022; Nam K, 2006, PROTEINS, V64, P376, DOI 10.1002/prot.20999; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; Reutershan J, 2006, ANESTHESIOLOGY, V104, P511, DOI 10.1097/00000542-200603000-00019; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SHAYEVITZ JR, 1995, SHOCK, V4, P61, DOI 10.1097/00024382-199507000-00010; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; von Dossow V, 2007, J INT MED RES, V35, P395, DOI 10.1177/147323000703500315; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xie C, 2010, EMBO J, V29, P666, DOI 10.1038/emboj.2009.367; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Yuki K, 2010, ANESTHESIOLOGY, V113, P600, DOI 10.1097/ALN.0b013e3181e89a77; Yuki K, 2008, FASEB J, V22, P4109, DOI 10.1096/fj.08-113324; Zhang HM, 2009, FASEB J, V23, P2735, DOI 10.1096/fj.09-129908	50	28	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4408	4417		10.1096/fj.12-212746	http://dx.doi.org/10.1096/fj.12-212746			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22815384	Green Published			2022-12-28	WOS:000310574200005
J	Coleman, BM; Hanssen, E; Lawson, VA; Hill, AF				Coleman, Bradley M.; Hanssen, Eric; Lawson, Victoria A.; Hill, Andrew F.			Prion-infected cells regulate the release of exosomes with distinct ultrastructural features	FASEB JOURNAL			English	Article						cryo-electron microscopy; tomography; vesicle	PROTEIN; INFECTIVITY; ASSOCIATION; VESICLES; AMPLIFICATION; TRANSMISSION; PROPAGATION; BIOGENESIS; ASSAY; HIV-1	Exosomes are small membrane-bound vesicles released from cells and found in vivo in most biological fluids. Functions reported for exosomes include cell-cell communication, roles in modulating immune responses, and roles in the transfer of pathogens such as prions. Here we investigated the molecular characteristics of the structure of exosomes that harbor prion infectivity to determine the native structure of exosomes and whether infected exosomes have a distinct structure. Cryo-electron tomography revealed the previously unidentified ultrastructural detail of exosomes with high resolution. Exosomes were found to be naturally spherical in shape and to have a diverse population that varies in size and internal structure, such as differences in the number of membrane structures. Exosomes isolated from prion-infected cells contained a significantly different population of exosomes with distinct structural features compared to control vesicles from mock-infected cells. Exosomes are highly structured vesicles that can modify their structure on altering their protein cargo. This finding provides further insight into the role that the exosomal protein cargo plays on influencing the structure of the vesicles as well as highlighting the diversity of exosomes and their relationship to biological processes.-Coleman, B. M., Hanssen, E., Lawson, V. A., Hill, A. F. Prion-infected cells regulate the release of exosomes with distinct ultrastructural features FASEB J. 26, 4160-4173 (2012). www.fasebj.org	[Coleman, Bradley M.; Hill, Andrew F.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; [Coleman, Bradley M.; Lawson, Victoria A.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; [Hanssen, Eric] Univ Melbourne, Electron Microscopy Unit Bio21, Parkville, Vic 3010, Australia; [Lawson, Victoria A.; Hill, Andrew F.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Hill, AF (corresponding author), Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	a.hill@unimelb.edu.au	Hanssen, Eric/A-7217-2013; Hill, Andrew F./GZL-4124-2022; Lawson, Victoria/AAJ-7392-2021; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F/B-4527-2009	Hanssen, Eric/0000-0002-4064-1844; Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Lawson, Victoria/0000-0002-7362-7176	Australian National Health and Medical Research Council (NHMRC) [628946, 400202]; NHMRC Postgraduate Scholarship [628959]; Australian Research Council Future Fellowship [FT100100560]	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Future Fellowship(Australian Research Council)	The authors thank Dr. Percy Chu (Department of Biochemistry and Molecular Biology, The University of Melbourne) for kindly providing mouse brain tissue used in this study, and Dr. David Cullis-Hill (Biopharm Australia, Sydney, NSW, Australia) for kindly providing PPS. This study was funded by grants from the Australian National Health and Medical Research Council (NHMRC; grants 628946 and 400202; www.nhmrc.gov.au). B.M.C. is supported by an NHMRC Postgraduate Scholarship (grant 628959), and A.F.H. is supported by an Australian Research Council (www.arc.gov.au) Future Fellowship (grant FT100100560). A.F.H., B.M.C., and V.A.L. designed research; B.M.C. and E.G. performed research; B.M.C., A.F.H., E.G., and V.A.L. analyzed data; B.M.C. and A.F.H. wrote the paper. The authors declare no conflicts of interest.	Alais S, 2008, BIOL CELL, V100, P603, DOI 10.1042/BC20080025; Arjona A, 2004, P NATL ACAD SCI USA, V101, P8768, DOI 10.1073/pnas.0400158101; Baron GS, 2006, J VIROL, V80, P2106, DOI 10.1128/JVI.80.5.2106-2117.2006; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Bess JW, 1997, VIROLOGY, V230, P134, DOI 10.1006/viro.1997.8499; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Brazier MW, 2006, BRAIN RES BULL, V68, P346, DOI 10.1016/j.brainresbull.2005.09.010; Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007; Castilla J, 2006, METHOD ENZYMOL, V412, P3, DOI 10.1016/s0076-6879(06)12001-7; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Flanagan J, 2003, J GEN VIROL, V84, P1871, DOI 10.1099/vir.0.18944-0; GABIZON R, 1988, J BIOL CHEM, V263, P4950; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haigh CL, 2009, CELL RES, V19, P1062, DOI 10.1038/cr.2009.86; Harrison CF, 2010, J BIOL CHEM, V285, P20213, DOI 10.1074/jbc.M109.093310; Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Larramendy-Gozalo C, 2007, J GEN VIROL, V88, P1062, DOI 10.1099/vir.0.82286-0; Lawson VA, 2008, INT J BIOCHEM CELL B, V40, P2793, DOI 10.1016/j.biocel.2008.05.024; Mahal Sukhvir P., 2008, V459, P49, DOI 10.1007/978-1-59745-234-2_4; Masciopinto F, 2004, EUR J IMMUNOL, V34, P2834, DOI 10.1002/eji.200424887; Mastronarde DN, 1997, J STRUCT BIOL, V120, P343, DOI 10.1006/jsbi.1997.3919; Mattei V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005057; Paquet S, 2007, J GEN VIROL, V88, P706, DOI 10.1099/vir.0.82336-0; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Poliakov A, 2009, PROSTATE, V69, P159, DOI 10.1002/pros.20860; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rasband W., 2006, IMAGEJ; Robertson C, 2006, BLOOD, V107, P3907, DOI 10.1182/blood-2005-02-0802; Schatzl HM, 1997, J VIROL, V71, P8821; Shaw ML, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000085; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Smirnovas V, 2011, NAT STRUCT MOL BIOL, V18, P504, DOI 10.1038/nsmb.2035; Subra C, 2007, BIOCHIMIE, V89, P205, DOI 10.1016/j.biochi.2006.10.014; TATEISHI J, 1979, ANN NEUROL, V5, P581, DOI 10.1002/ana.410050616; Tauro BJ, 2012, METHODS, V56, P293, DOI 10.1016/j.ymeth.2012.01.002; Taylor DR, 2006, MOL MEMBR BIOL, V23, P89, DOI 10.1080/09687860500449994; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tixador P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000859; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vella LJ, 2007, J PATHOL, V211, P582, DOI 10.1002/path.2145; Vella LJ, 2008, VET IMMUNOL IMMUNOP, V124, P385, DOI 10.1016/j.vetimm.2008.04.002; Wang F, 2007, BIOCHEMISTRY-US, V46, P7045, DOI 10.1021/bi700299h; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200	57	111	115	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4160	4173		10.1096/fj.11-202077	http://dx.doi.org/10.1096/fj.11-202077			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22767229				2022-12-28	WOS:000309704000022
J	de Azua, IR; Nakajima, KI; Rossi, M; Cui, YH; Jou, W; Gavrilova, O; Wess, J				de Azua, Inigo Ruiz; Nakajima, Ken-ichiro; Rossi, Mario; Cui, Yinghong; Jou, William; Gavrilova, Oksana; Wess, Juergen			Spinophilin as a novel regulator of M-3 muscarinic receptor-mediated insulin release in vitro and in vivo	FASEB JOURNAL			English	Article						G-protein-coupled receptors; knockout mice; receptor regulation; signal transduction	GLUCAGON-LIKE PEPTIDE-1; ACETYLCHOLINE-RECEPTORS; PROTEIN INTERACTIONS; CELL-SURFACE; SECRETION; INSIGHTS; BINDING; RGS4; BETA-ARRESTIN2; STIMULATION	Spinophilin (SPL), a multidomain scaffolding protein known to modulate the activity of different G-protein-coupled receptors, regulates various central nervous system (CNS) functions. However, little is known about the role of SPL expressed in peripheral cell types including pancreatic beta cells. In this study, we examined the ability of SPL to modulate the activity of beta -cell M-3 muscarinic acetylcholine receptors (M3Rs), which play an important role in facilitating insulin release and maintaining normal blood glucose levels. We demonstrated, by using both in vitro and in vivo approaches (mouse insulinoma cells and SPL-deficient mice), that SPL is a potent negative regulator of M3R-mediated signaling and insulin release. Additional biochemical and biophysical studies, including the use of bioluminescence resonance energy transfer technology, suggested that SPL is able to recruit regulator of G-protein signaling 4 (RGS4) to the M3R signaling complex in an agonist-dependent fashion. Since RGS4 is a member of the RGS family of proteins that act to reduce the lifetime of activated G proteins, these findings support the concept that the inhibitory effects of SPL on M3R activity are mediated by RGS4. These data suggest that SPL or other G-protein-coupled receptor-associated proteins may serve as novel targets for drug therapy aimed at improving beta -cell function for the treatment of type 2 diabetes.-Ruiz de Azua, I., Nakajima, K.-I., Rossi, M., Cui, Y., Jou, W., Gavrilova, O., Wess, J. Spinophilin as a novel regulator of M-3 muscarinic receptor-mediated insulin release in vitro and in vivo. FASEB J. 26, 4275-4286 (2012). www.fasebj.org	[Wess, Juergen] NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; [Jou, William; Gavrilova, Oksana] NIDDK, Mouse Metab Core Facil, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov		Rossi, Mario/0000-0001-7004-0225; Nakajima, Ken-ichiro/0000-0003-1932-418X	U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZICDK070002, ZIADK075021] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by the Intramural Research Program of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The authors thank Dr. Sara McMillin (NIDDK) and Drs. Diaz Gimenez and Vsevolod Gurevich (Vanderbilt University, Nashville, TN, USA) for their help setting up the BRET experiments. Dr. Paul Greengard (Rockefeller University, New York, NY, USA) generously provided the SPL<SUP>-/-</SUP> mice. Finally, the authors thank Drs. Patrick B. Allen (Yale University, New Haven, CT, USA) and Diaz Gimenez and Vsevolod Gurevich (Vanderbilt University), and Qin Wang (University of Alabama, Birmingham, AL, USA) for providing important reagents and plasmids used in this study. The authors declare no conflicts of interest.	Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Arakawa M, 2009, BIOCHEM BIOPH RES CO, V390, P809, DOI 10.1016/j.bbrc.2009.10.054; Balasubramanian R, 2010, BIOCHEM PHARMACOL, V79, P1317, DOI 10.1016/j.bcp.2009.12.026; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Brady AE, 2005, MOL PHARMACOL, V67, P1690, DOI 10.1124/mol.104.005215; Charlton JJ, 2008, NEURON, V58, P238, DOI 10.1016/j.neuron.2008.02.006; de Azua IR, 2010, P NATL ACAD SCI USA, V107, P7999, DOI 10.1073/pnas.1003655107; Doyle ME, 2007, PHARMACOL THERAPEUT, V113, P546, DOI 10.1016/j.pharmthera.2006.11.007; Duttaroy A, 2004, DIABETES, V53, P1714, DOI 10.2337/diabetes.53.7.1714; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; FUKUDO S, 1989, DIABETES, V38, P1433, DOI 10.2337/diabetes.38.11.1433; Gautam D, 2006, CELL METAB, V3, P449, DOI 10.1016/j.cmet.2006.04.009; Gautam D, 2010, ENDOCRINOLOGY, V151, P5185, DOI 10.1210/en.2010-0519; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Hamdan FF, 2005, J BIOMOL SCREEN, V10, P463, DOI 10.1177/1087057105275344; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Ishii M, 2005, BIOCHEM BIOPH RES CO, V338, P839, DOI 10.1016/j.bbrc.2005.10.026; Klewe IV, 2008, NEUROPHARMACOLOGY, V54, P1215, DOI 10.1016/j.neuropharm.2008.03.015; Kocan M, 2011, METHODS MOL BIOL, V746, P357, DOI 10.1007/978-1-61779-126-0_20; Krumins AM, 2004, J BIOL CHEM, V279, P2593, DOI 10.1074/jbc.M311600200; Kurogi M, 2009, NEUROREPORT, V20, P1134, DOI 10.1097/WNR.0b013e32832fd93e; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Luttrell LM, 2010, PHARMACOL REV, V62, P305, DOI 10.1124/pr.109.002436; McMillin SM, 2011, J BIOL CHEM, V286, P28584, DOI 10.1074/jbc.M111.259788; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nag S, 2009, BEHAV BRAIN RES, V197, P457, DOI 10.1016/j.bbr.2008.09.036; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Scarselli M, 2007, J BIOL CHEM, V282, P7385, DOI 10.1074/jbc.M610394200; Sonoda N, 2008, P NATL ACAD SCI USA, V105, P6614, DOI 10.1073/pnas.0710402105; Vishnivetskiy SA, 2011, J BIOL CHEM, V286, P24288, DOI 10.1074/jbc.M110.213835; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wang X, 2007, EMBO J, V26, P2768, DOI 10.1038/sj.emboj.7601701; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 2007, NAT REV DRUG DISCOV, V6, P721, DOI 10.1038/nrd2379; Winzell MS, 2007, PHARMACOL THERAPEUT, V116, P437, DOI 10.1016/j.pharmthera.2007.08.002	42	15	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4275	4286		10.1096/fj.12-204644	http://dx.doi.org/10.1096/fj.12-204644			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22730439	Green Published			2022-12-28	WOS:000309704000032
J	Esselens, C; Sannerud, R; Gallardo, R; Baert, V; Kaden, D; Serneels, L; De Strooper, B; Rousseau, F; Multhaup, G; Schymkowitz, J; Langedijk, JPM; Annaert, W				Esselens, Cary; Sannerud, Ragna; Gallardo, Rodrigo; Baert, Veerle; Kaden, Daniela; Serneels, Lutgarde; De Strooper, Bart; Rousseau, Frederic; Multhaup, Gerd; Schymkowitz, Joost; Langedijk, Johannes P. M.; Annaert, Wim			Peptides based on the presenilin-APP binding domain inhibit APP processing and A beta production through interfering with the APP transmembrane domain	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid precursor protein; Notch-sparing; viral translocation peptide	AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE INHIBITORS; CELL-PENETRATING PEPTIDES; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; INTRAMEMBRANE CLEAVAGE; HIPPOCAMPAL-NEURONS; IN-VITRO; DELIVERY; MUTATIONS	Presenilins (PSENs) form the catalytic component of the gamma-secretase complex, responsible for intramembrane proteolysis of amyloid precursor protein (APP) and Notch, among many other membrane proteins. Previously, we identified a PSEN1-binding domain in APP, encompassing half of the transmembrane domain following the amyloid beta (A beta) sequence. Based on this, we designed peptides mimicking this interaction domain with the aim to selectively block APP processing and A beta generation through interfering with enzyme-substrate binding. We identified a peptide sequence that, when fused to a virally derived translocation peptide, significantly lowered A beta production (IC50: 317 nM) in cell-free and cell-based assays using APP-carboxy terminal fragment as a direct gamma-secretase substrate. Being derived from the APP sequence, this inhibitory peptide did not affect Notch Delta E gamma-cleavage, illustrating specificity and potential therapeutic value. In cell-based assays, the peptide strongly suppressed APP shedding, demonstrating that it exerts the inhibitory effect already upstream of gamma-secretase, most likely through steric hindrance.-Esselens, C., Sannerud, R., Gallardo, R., Baert, V., Kaden, D., Serneels, L., De Strooper, B., Rousseau, F., Multhaup, G., Schymkowitz, J., Langedijk, J. P. M., Annaert, W. Peptides based on the presenilin-APP binding domain inhibit APP processing and A beta production through interfering with the APP transmembrane domain. FASEB J. 26, 3765-3778 (2012). www.fasebj.org	[Serneels, Lutgarde; De Strooper, Bart] Katholieke Univ Leuven, Lab Res Neurodegenerat Dis, Ctr Human Genet, Louvain, Belgium; [Gallardo, Rodrigo; Rousseau, Frederic; Schymkowitz, Joost] Katholieke Univ Leuven, Dept Mol Med, Louvain, Belgium; [Esselens, Cary; Sannerud, Ragna; Baert, Veerle; Serneels, Lutgarde; De Strooper, Bart; Annaert, Wim] Katholieke Univ Leuven VIB, Ctr Biol Dis, Louvain, Belgium; [Gallardo, Rodrigo; Rousseau, Frederic; Schymkowitz, Joost] VIB Switch Lab, Louvain, Belgium; [Kaden, Daniela; Multhaup, Gerd] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany; [Multhaup, Gerd] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Langedijk, Johannes P. M.] Pepscan Therapeut, Lelystad, Netherlands; [Esselens, Cary; Sannerud, Ragna; Baert, Veerle; Annaert, Wim] Katholieke Univ Leuven, Lab Membrane Trafficking, Louvain, Belgium	KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); Free University of Berlin; McGill University; KU Leuven	Annaert, W (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Lab Membrane Trafficking, O& N4,Rm 7-159, B-3000 Louvain, Belgium.	wim.annaert@cme.vib-kuleuven.be	Rousseau, Frederic/J-9044-2016; Sannerud, Ragna/AAA-6497-2021; Schymkowitz, Joost/AAV-3680-2021; de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Schymkowitz, Joost/K-7764-2016	Rousseau, Frederic/0000-0002-9189-7399; De Strooper, Bart/0000-0001-5455-5819; Sannerud, Ragna/0000-0002-6694-3154; Schymkowitz, Joost/0000-0003-2020-0168; Esselens, Cary/0000-0001-8876-634X; Gallardo, Rodrigo/0000-0003-1584-3564; Serneels, Lutgarde/0000-0002-5463-4231	Vlaams Instituut voor Biotechnologie (VIB); Katholieke Universiteit Leuven (KU Leuven-Methusalem); Fonds voor Wetenschappelijk Onderzoek [FWO G.0663.09, G.0.754.10.N]; Stichting Alzheimer Onderzoek (SAO-FRMA/cycle); federal government IAP P7; Alzheimer Association [IIRG-08-91535]; federal government (Belspo)	Vlaams Instituut voor Biotechnologie (VIB); Katholieke Universiteit Leuven (KU Leuven-Methusalem); Fonds voor Wetenschappelijk Onderzoek(FWO); Stichting Alzheimer Onderzoek (SAO-FRMA/cycle); federal government IAP P7; Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); federal government (Belspo)	The work presented here was supported by the Vlaams Instituut voor Biotechnologie (VIB); Katholieke Universiteit Leuven (KU Leuven-Methusalem to B. D. S.); Fonds voor Wetenschappelijk Onderzoek (FWO G.0663.09 and G.0.754.10.N); Stichting Alzheimer Onderzoek (SAO-FRMA/cycle 2010); federal government IAP P7 (2012-2017); and Alzheimer Association (IIRG-08-91535). C. E. is holder of a return fellowship from the federal government (Belspo). The authors thank S. Munck for help with PiMP analysis.	Ahrens T, 2002, J BIOL CHEM, V277, P19455, DOI 10.1074/jbc.M200606200; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Annaert W, 2010, CELL, V141, P1112, DOI 10.1016/j.cell.2010.06.009; Aubele DL, 2011, BIOORG MED CHEM LETT, V21, P5791, DOI 10.1016/j.bmcl.2011.08.008; Auffret A, 2010, REV NEUROSCIENCE, V21, P239; Bakshi P, 2004, J MED CHEM, V47, P6485, DOI 10.1021/jm049566e; Bergmans BA, 2010, LANCET NEUROL, V9, P215, DOI 10.1016/S1474-4422(09)70332-1; Bihel F, 2004, J MED CHEM, V47, P3931, DOI 10.1021/jm049788c; Botev A, 2011, BIOCHEMISTRY-US, V50, P828, DOI 10.1021/bi1014002; Cai B, 2011, EXP NEUROL, V227, P224, DOI 10.1016/j.expneurol.2010.11.009; Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821; Churcher I, 2003, BIOORG MED CHEM LETT, V13, P179, DOI 10.1016/S0960-894X(02)00909-5; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; De Strooper B, 2010, ANNU REV CELL DEV BI, V26, P235, DOI 10.1146/annurev-cellbio-100109-104117; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Dietz Gunnar P. H., 2007, V399, P181, DOI 10.1007/978-1-59745-504-6_13; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esselens C, 2004, J CELL BIOL, V166, P1041, DOI 10.1083/jcb.200406060; Extance A, 2010, NAT REV DRUG DISCOV, V9, P749, DOI 10.1038/nrd3288; FIELDS C G, 1991, Peptide Research, V4, P95; GREENBERG R, 1976, PHARMACOL BIOCHEM BE, V5, P151, DOI 10.1016/0091-3057(76)90345-2; Hashimoto-Torii K, 2008, NEURON, V60, P273, DOI 10.1016/j.neuron.2008.09.026; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Huber O, 1999, J CELL SCI, V112, P4415; Kilic U, 2004, ACTA NEUROPATHOL, V108, P65, DOI 10.1007/s00401-004-0867-6; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kumar-Singh S, 2000, HUM MOL GENET, V9, P2589, DOI 10.1093/hmg/9.18.2589; Langedijk JPM, 2004, MOL DIVERS, V8, P101, DOI 10.1023/B:MODI.0000025653.26130.ce; Langedijk JPM, 2002, J BIOL CHEM, V277, P5308, DOI 10.1074/jbc.M104147200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Monsey J, 2010, J BIOL CHEM, V285, P7035, DOI 10.1074/jbc.M109.096032; Munck S, 2012, J CELL SCI, V125, P2257, DOI 10.1242/jcs.098939; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Panza F, 2010, CNS NEUROSCI THER, V16, P272, DOI 10.1111/j.1755-5949.2010.00164.x; PEREZ F, 1992, J CELL SCI, V102, P717; Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004; Rait A, 2000, BIOCONJUGATE CHEM, V11, P153, DOI 10.1021/bc990106n; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Samson K, 2010, ANN NEUROL, V68, pA11, DOI 10.1002/ana.22249; Sannerud R, 2011, P NATL ACAD SCI USA, V108, pE559, DOI 10.1073/pnas.1100745108; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; Schulz J. G., 2003, J BIOL CHEM, V26, P26; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tolia A, 2006, J BIOL CHEM, V281, P27633, DOI 10.1074/jbc.M604997200; Vaslin A, 2011, J NEUROCHEM, V119, P1243, DOI 10.1111/j.1471-4159.2011.07535.x; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	68	10	10	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3765	3778		10.1096/fj.11-201368	http://dx.doi.org/10.1096/fj.11-201368			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22661005				2022-12-28	WOS:000308391600017
J	Tong, Q; Wang, F; Zhou, HZ; Sun, HL; Song, H; Shu, YY; Gong, Y; Zhang, WT; Cai, TX; Yang, FQ; Tang, J; Jiang, T				Tong, Qiong; Wang, Feng; Zhou, Hong-Zhe; Sun, Han-Li; Song, Hui; Shu, Yu-Yan; Gong, Yong; Zhang, Wen-Ting; Cai, Tan-xi; Yang, Fu-Quan; Tang, Jie; Jiang, Tao			Structural and functional insights into lipid-bound nerve growth factors	FASEB JOURNAL			English	Article						cobra NGF; mouse NGF; lyso-PS; crystal structure	CRYSTAL-STRUCTURE; MAST-CELLS; NEUROTROPHIN RECEPTOR; TRK PROTOONCOGENE; MEMBRANE-BINDING; NGF; ACTIVATION; COMPLEX; SPECIFICITY; EXPRESSION	Nerve growth factor (NGF) is a dimeric molecule that modulates the survival, proliferation, and differentiation of nervous cells and is also known to act on cells of the immune system and endocrine system. NGFs extracted from mouse submaxillary gland and cobra venom have different immunological behaviors, yet the underlying mechanism remains unclear. Here we report the crystal structure of the NGF purified from Chinese cobra Naja naja atra (cNGF), which unexpectedly reveals a 2-tailed lipid molecule that is embedded between the two protomers of the NGF homodimer. In addition, crystallographic analysis indicated that the purified mouse NGF(mNGF) is free from lipid but can bind lysophosphatidylserine (lyso-PS) in the same pocket as cNGF. Bioassays indicated that the binding of lipid molecules to cNGF and mNGF are essential for their mast cell activation activity and abates their p75(NTR) binding capacity. Taken together, these results suggest a new mechanism for the regulation of the function of NGF.-Tong, Q., Wang, F., Zhou, H.-Z., Sun, H.-L., Song, H., Shu, Y.-Y., Gong, Y., Zhang, W.-T., Cai, T.-X., Yang, F.-Q., Tang, J., Jiang, T. Structural and functional insights into lipid-bound nerve growth factors. FASEB J. 26, 3811-3821 (2012). www.fasebj.org	[Tong, Qiong; Wang, Feng; Zhou, Hong-Zhe; Sun, Han-Li; Gong, Yong; Zhang, Wen-Ting; Cai, Tan-xi; Yang, Fu-Quan; Tang, Jie; Jiang, Tao] Inst Biophys, Natl Key Lab Biomacro Mol, Beijing 100101, Peoples R China; [Wang, Feng; Song, Hui] Guangxi Univ Tradit Chinese Med, Nanning, Peoples R China; [Shu, Yu-Yan] Guangxi Univ Tradit Chinese Med, Snake Venom Res Inst, Nanning, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Guangxi University of Chinese Medicine; Guangxi University of Chinese Medicine	Jiang, T (corresponding author), Inst Biophys, Natl Key Lab Biomacro Mol, 15 Datun Rd, Beijing 100101, Peoples R China.	tjiang@ibp.ac.cn			National Natural Science Foundation of China [31021062, 31025009]; National High Technology Research and Development Program of China [2006AA02A319]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	The authors thank Z.-J. Lin for assistance with the design of the project and helpful comments on the manuscript, staff of the Shanghai Synchrotron Radiation Facility (SSRF; Shanghai, China), Beijing Synchrotron Radiation Facility (BSRF; Beijing, China), Super Photon Ring-8 GeV (Spring-8; Koto, Japan) and Diamond Light Source (Chilton, UK) for assistance in data collection, and Y-Y. Chen for assistance with the BIAcore analysis. This research was supported financially by the National Natural Science Foundation of China (grants 31021062, 31025009), and the National High Technology Research and Development Program of China (grant 2006AA02A319).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ANGELETTI RH, 1970, P NATL ACAD SCI USA, V65, P668, DOI 10.1073/pnas.65.3.668; Aurikko JP, 2005, J BIOL CHEM, V280, P33453, DOI 10.1074/jbc.M503189200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banfield MJ, 2001, STRUCTURE, V9, P1191, DOI 10.1016/S0969-2126(01)00681-5; BANKS BEC, 1973, NATURE, V246, P503, DOI 10.1038/246503a0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; Burgi B, 1996, J IMMUNOL, V157, P5582; Butte MJ, 1998, BIOCHEMISTRY-US, V37, P16846, DOI 10.1021/bi981254o; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COHEN S, 1954, P NATL ACAD SCI USA, V40, P1014, DOI 10.1073/pnas.40.10.1014; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Freund-Michel V, 2008, PHARMACOL THERAPEUT, V117, P52, DOI 10.1016/j.pharmthera.2007.07.003; Gong Y, 2008, NATURE, V454, P789, DOI 10.1038/nature07089; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; HEFTI F, 1986, ANN NEUROL, V20, P275, DOI 10.1002/ana.410200302; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Levi-Montalcini R., 1997, SAGA NERVE GROWTH FA, P399; LEVIMONTALCINI R, 1951, J EXP ZOOL, V116, P321, DOI 10.1002/jez.1401160206; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; ROBINSON RC, 1995, BIOCHEMISTRY-US, V34, P4139, DOI 10.1021/bi00013a001; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Tabellini G, 2004, CELL SIGNAL, V16, P1263, DOI 10.1016/j.cellsig.2004.03.018; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Watanabe H, 2004, J BIOL CHEM, V279, P37870, DOI 10.1074/jbc.M402610200; Wehrman T, 2007, NEURON, V53, P25, DOI 10.1016/j.neuron.2006.09.034; Welker P, 1998, IMMUNOLOGY, V94, P310; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; YANKNER BA, 1990, P NATL ACAD SCI USA, V87, P9020, DOI 10.1073/pnas.87.22.9020; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	54	16	16	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3811	3821		10.1096/fj.12-207316	http://dx.doi.org/10.1096/fj.12-207316			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22649032				2022-12-28	WOS:000308391600021
J	Petrik, D; Jiang, YD; Birnbaum, SG; Powell, CM; Kim, MS; Hsieh, J; Eisch, AJ				Petrik, David; Jiang, Yindi; Birnbaum, Shari G.; Powell, Craig M.; Kim, Mi-Sung; Hsieh, Jenny; Eisch, Amelia J.			Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule	FASEB JOURNAL			English	Article						neural stem cells; dendrites; chemical biology; Morris water maze; Mef2	NEURAL STEM-CELL; GENERATED GRANULE CELLS; HIPPOCAMPAL NEUROGENESIS; SYNAPTIC PLASTICITY; TRANSCRIPTION FACTOR; DENTATE GYRUS; PROLIFERATING CELLS; PHYSICAL-ACTIVITY; PROGENITOR CELLS; CHRONIC MORPHINE	Adult neurogenesis occurs throughout life in the mammalian hippocampus and is essential for memory and mood control. There is significant interest in identifying ways to promote neurogenesis and ensure maintenance of these hippocampal functions. Previous work with a synthetic small molecule, isoxazole 9 (Isx-9), highlighted its neuronal-differentiating properties in vitro. However, the ability of Isx-9 to drive neurogenesis in vivo or improve hippocampal function was unknown. Here we show that Isx-9 promotes neurogenesis in vivo, enhancing the proliferation and differentiation of hippocampal subgranular zone (SGZ) neuroblasts, and the dendritic arborization of adult-generated dentate gyrus neurons. Isx-9 also improves hippocampal function, enhancing memory in the Morris water maze. Notably, Isx-9 enhances neurogenesis and memory without detectable increases in cellular or animal activity or vascularization. Molecular exploration of Isx-9-induced regulation of neurogenesis (via FACS and microarray of SGZ stem and progenitor cells) suggested the involvement of the myocyte-enhancer family of proteins (Mef2). Indeed, transgenic-mediated inducible knockout of all brain-enriched Mef2 isoforms (Mef2a/c/d) specifically from neural stem cells and their progeny confirmed Mef2's requirement for Isx-9-induced increase in hippocampal neurogenesis. Thus, Isx-9 enhances hippocampal neurogenesis and memory in vivo, and its effects are reliant on Mef2, revealing a novel cell-intrinsic molecular pathway regulating adult neurogenesis.-Petrik, D., Jiang, Y., Birnbaum, S. G., Powell, C. M., Kim, M.-S., Hsieh, J., Eisch, A. J. Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule. FASEB J. 26, 3148-3162 (2012). www.fasebj.org	[Jiang, Yindi; Kim, Mi-Sung; Hsieh, Jenny] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Petrik, David; Birnbaum, Shari G.; Eisch, Amelia J.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hsieh, J (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jenny.hsieh@utsouthwestern.edu; amelia.eisch@utsouthwestern.edu		Petrik, David/0000-0003-3026-0770; Eisch, Amelia/0000-0001-6476-5385; Powell, Craig/0000-0001-5451-2165	NIH [R01 DA016765, K02 DA023555, R21 DA023701, R01 AG032383]; National Alliance for Research on Schizophrenia and Depression; Welch Foundation [I-1660]; Cancer Prevention and Research Institute of Texas [RP100674]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD069560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH093697, R01MH081164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA023555, R01DA016765, R21DA023701] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Alliance for Research on Schizophrenia and Depression(NARSAD); Welch Foundation(The Welch Foundation); Cancer Prevention and Research Institute of Texas; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Eric N. Olson (University of Texas Southwestern Medical Center) for providing the Mef2a/c/d<SUP>flox/flox</SUP> mice and Paul Worley (Johns Hopkins University, Baltimore, MD, USA) for the anti-Arc antibody. The authors also thank Masahiro Yamaguchi (University of Tokyo, Tokyo, Japan) for providing the initial nestin-GFP breeders that helped establish the colony at University of Texas Southwestern. The authors also thank Haley Speed, Noelle Williams, and Kerstin Ure for helpful comments on the experiments, and the U. S. National Institutes of Health (NIH) Neuroscience Consortium for the microarray help. This work was supported in part by grants from the NIH (R01 DA016765, K02 DA023555, and R21 DA023701 to A.J.E.; R01 AG032383 to J.H.), the National Alliance for Research on Schizophrenia and Depression (Independent Investigator Award to A.J.E.), the Welch Foundation (I-1660 to J.H.), and the Cancer Prevention and Research Institute of Texas (RP100674 to J.H.). The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies. D.P. designed and performed experiments, analyzed data, made figures, and cowrote the manuscript; Y.J. performed experiments and analyzed data; S.B. performed experiments; C.M.P. provided electrophysiological equipment and expertise; M.-S.K. made Mef2a<SUP>flox/flox</SUP> mice;. J.H. and A.J.E. designed experiments and cowrote the manuscript. The authors thank Ami Pettersen, Junie Leblanc, Sohail Kamrudin, and Sean Goetsch for technical assistance and Jose Cabrera for artwork.	Ables JL, 2010, J NEUROSCI, V30, P10484, DOI 10.1523/JNEUROSCI.4721-09.2010; Aboulkassim T, 2011, MOL PHARMACOL, V80, P498, DOI 10.1124/mol.111.071332; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aimone JB, 2011, EUR J NEUROSCI, V33, P1160, DOI 10.1111/j.1460-9568.2011.07615.x; ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; Arguello AA, 2009, NEUROSCIENCE, V159, P1003, DOI 10.1016/j.neuroscience.2009.01.020; Arisi GM, 2007, BRAIN RES, V1165, P126, DOI 10.1016/j.brainres.2007.06.037; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Barbosa AC, 2008, P NATL ACAD SCI USA, V105, P9391, DOI 10.1073/pnas.0802679105; Brewer GJ, 2007, NAT PROTOC, V2, P1490, DOI 10.1038/nprot.2007.207; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chohan MO, 2011, NEUROBIOL AGING, V32, P1420, DOI 10.1016/j.neurobiolaging.2009.08.008; Clark PJ, 2009, HIPPOCAMPUS, V19, P937, DOI 10.1002/hipo.20543; DeCarolis NA, 2010, NEUROPHARMACOLOGY, V58, P884, DOI 10.1016/j.neuropharm.2009.12.013; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Dioum EM, 2011, P NATL ACAD SCI USA, V108, P20713, DOI 10.1073/pnas.1118526109; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Encinas JM, 2012, BEHAV BRAIN RES, V227, P433, DOI 10.1016/j.bbr.2011.10.010; Encinas JM, 2008, METHOD CELL BIOL, V85, P243, DOI 10.1016/S0091-679X(08)85011-X; Ermini FV, 2008, AM J PATHOL, V172, P1520, DOI 10.2353/ajpath.2008.060520; Fabel K, 2008, NEUROMOL MED, V10, P59, DOI 10.1007/s12017-008-8031-4; Farioli-Vecchioli S, 2008, PLOS BIOL, V6, P2188, DOI 10.1371/journal.pbio.0060246; Ge SY, 2007, TRENDS NEUROSCI, V30, P1, DOI 10.1016/j.tins.2006.11.001; Gilley JA, 2011, HIPPOCAMPUS, V21, P33, DOI 10.1002/hipo.20719; Guo WX, 2011, NAT MED, V17, P559, DOI 10.1038/nm.2336; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Halt AR, 2012, EMBO J, V31, P1203, DOI 10.1038/emboj.2011.482; Hawasli AH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005808; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Inoue T, 2007, J NEUROSCI, V27, P5461, DOI 10.1523/JNEUROSCI.4046-06.2007; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; John JPP, 2009, HIPPOCAMPUS, V19, P731, DOI 10.1002/hipo.20553; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kim Y, 2008, J CLIN INVEST, V118, P124, DOI 10.1172/JCI33255; Kohl Z, 2007, BRAIN RES, V1155, P24, DOI 10.1016/j.brainres.2007.04.039; Krampert M, 2010, MOL CELL BIOL, V30, P3685, DOI 10.1128/MCB.00434-09; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kuhn HG, 2007, CURR PHARM BIOTECHNO, V8, P127; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107; Lam BYH, 2007, NEUROSCI LETT, V427, P153, DOI 10.1016/j.neulet.2007.09.030; Lazarov O, 2010, TRENDS NEUROSCI, V33, P569, DOI 10.1016/j.tins.2010.09.003; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mandyam CD, 2007, NEUROSCIENCE, V146, P108, DOI 10.1016/j.neuroscience.2006.12.064; Mandyam CD, 2004, J NEUROSCI RES, V76, P783, DOI 10.1002/jnr.20090; Mandyam CD, 2012, TRENDS NEUROSCI, V35, P250, DOI 10.1016/j.tins.2011.12.005; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murphy GG, 2004, CURR BIOL, V14, P1907, DOI 10.1016/j.cub.2004.10.021; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Perera TD, 2007, J NEUROSCI, V27, P4894, DOI 10.1523/JNEUROSCI.0237-07.2007; Petrik D, 2012, NEUROPHARMACOLOGY, V62, P21, DOI 10.1016/j.neuropharm.2011.09.003; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Rose SPR, 2002, NAT REV NEUROSCI, V3, P975, DOI 10.1038/nrn984; Ross AP, 2009, NEUROBIOL LEARN MEM, V92, P410, DOI 10.1016/j.nlm.2009.05.007; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Samuels BA, 2011, EUR J NEUROSCI, V33, P1152, DOI 10.1111/j.1460-9568.2011.07614.x; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Schneider JW, 2008, NAT CHEM BIOL, V4, P408, DOI 10.1038/nchembio.95; Seki T, 2007, J COMP NEUROL, V502, P275, DOI 10.1002/cne.21301; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tronel S, 2010, P NATL ACAD SCI USA, V107, P7963, DOI 10.1073/pnas.0914613107; Udo H, 2008, J NEUROSCI, V28, P14522, DOI 10.1523/JNEUROSCI.3673-08.2008; Van der Borght K, 2009, HIPPOCAMPUS, V19, P928, DOI 10.1002/hipo.20545; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vetere G, 2011, P NATL ACAD SCI USA, V108, P8456, DOI 10.1073/pnas.1016275108; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wang XK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-360; Wojtowicz JM, 2008, EUR J NEUROSCI, V27, P1494, DOI 10.1111/j.1460-9568.2008.06128.x; Wurdak H, 2010, P NATL ACAD SCI USA, V107, P16542, DOI 10.1073/pnas.1010300107; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Zhang L, 2011, DIFFERENTIATION, V81, P233, DOI 10.1016/j.diff.2011.02.005	93	55	58	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3148	3162		10.1096/fj.11-201426	http://dx.doi.org/10.1096/fj.11-201426			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22542682	Green Published			2022-12-28	WOS:000307162800007
J	Jiang, XY; Du, XD; Tian, YM; Shen, RJ; Sun, CF; Zou, SM				Jiang, Xia-Yun; Du, Xue-Di; Tian, Yu-Mei; Shen, Rui-Jie; Sun, Cheng-Fei; Zou, Shu-Ming			Goldfish transposase Tgf2 presumably from recent horizontal transfer is active	FASEB JOURNAL			English	Article						transposable elements; transposition activity; transgenesis	JAPANESE MEDAKA FISH; AC-LIKE ELEMENT; SLEEPING-BEAUTY; ORYZIAS-LATIPES; GENE-TRANSFER; TOL2 ELEMENT; TC1-LIKE TRANSPOSON; TC1 TRANSPOSON; ZEBRAFISH; GENOME	Hobo/Activator/Tam3 (hAT) superfamily transposons occur in plants and animals and play a role in genomic evolution. Certain hAT transposons are active and have been developed as incisive genetic tools. Active vertebrate elements are rarely discovered; however, Tgf2 transposon was recently discovered in goldfish (Carassius auratus). Here, we found that the endogenous Tgf2 element can transpose in goldfish genome. Seven different goldfish mRNA transcripts, encoding three lengths of Tgf2 transposase, were identified. Tgf2 transposase mRNA was detected in goldfish embryos, mainly in epithelial cells; levels were high in ovaries and mature eggs and in all adult tissues tested. Endogenous Tgf2 transposase mRNA is active in mature eggs and can mediate high rates of transposition (>30%) when injected with donor plasmids harboring a Tgf2 cis-element. When donor plasmid was coinjected with capped Tgf2 transposase mRNA, the insertion rate reached >90% at 1 yr. Nonautonomous copies of the Tgf2 transposon with large-fragment deletions and low levels of point mutations were also detected in common goldfish. Phylogenetic analysis indicates the taxonomic distribution of Tgf2 in goldfish is not due to vertical inheritance. We propose that the goldfish Tgf2 transposon originated by recent horizontal transfer and maintains a highly native activity.-Jiang, X.-Y., Du, X.-D., Tian, Y.-M., Shen, R.-J., Sun, C.-F., Zou, S.-M. Goldfish transposase Tgf2 presumably from recent horizontal transfer is active. FASEB J. 26, 2743-2752 (2012). www.fasebj.org	[Jiang, Xia-Yun; Du, Xue-Di; Tian, Yu-Mei; Shen, Rui-Jie; Sun, Cheng-Fei; Zou, Shu-Ming] Shanghai Ocean Univ, Key Lab Freshwater Aquat Genet Resources, Shanghai 201306, Peoples R China	Shanghai Ocean University	Zou, SM (corresponding author), Shanghai Ocean Univ, Key Lab Freshwater Aquat Genet Resources, Huchenghuan Rd 999, Shanghai 201306, Peoples R China.	smzou@shou.edu.cn	Du, Xuedi/A-4008-2013	Du, Xuedi/0000-0002-6699-1658	National High Technology Research and Development Program of China (863 Program) [2011AA100403, 2009AA10Z105]; Ministry of Agriculture of China [200903045]; Shanghai Educational Committee [08SG50]	National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); Ministry of Agriculture of China(Ministry of Agriculture & Rural Affairs); Shanghai Educational Committee	The authors thank the Center for Applied Aquatic Genomics of the Chinese Academy of Fishery Sciences for assistance in blast whole-genome shotgun sequences for common carp. This work was supported by grants from the National High Technology Research and Development Program of China (863 Program; nos. 2011AA100403, 2009AA10Z105 to S.M.Z.), Special Funding from the Ministry of Agriculture of China (200903045 to S.M.Z.), and the Shu-Guang Project of the Shanghai Educational Committee (08SG50 to S.M.Z.).	Arensburger P, 2011, GENETICS, V188, P45, DOI 10.1534/genetics.111.126813; Asakawa K, 2008, P NATL ACAD SCI USA, V105, P1255, DOI 10.1073/pnas.0704963105; Clark KJ, 2009, NUCLEIC ACIDS RES, V37, P1239, DOI 10.1093/nar/gkn1025; de Boer JG, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-422; Diao XM, 2006, PLOS BIOL, V4, P119, DOI 10.1371/journal.pbio.0040005; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; Faunes F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022569; Feschotte C, 2007, ANNU REV GENET, V41, P331, DOI 10.1146/annurev.genet.40.110405.090448; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; Fujimura K, 2011, AQUACULTURE, V319, P342, DOI 10.1016/j.aquaculture.2011.07.021; Gottgens B, 1999, GENE, V239, P373, DOI 10.1016/S0378-1119(99)00390-X; Halic M, 2009, CELL, V138, P1058, DOI 10.1016/j.cell.2009.08.030; Horie K, 2001, P NATL ACAD SCI USA, V98, P9191, DOI 10.1073/pnas.161071798; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; IZSVAK Z, 1995, MOL GEN GENET, V247, P312, DOI 10.1007/BF00293199; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; Janicki M, 2011, CHROMOSOME RES, V19, P787, DOI 10.1007/s10577-011-9230-7; Jiang XY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026475; Kawakami K, 2004, DEV CELL, V7, P133, DOI 10.1016/j.devcel.2004.06.005; Kawakami K, 2004, GENETICS, V166, P895, DOI 10.1534/genetics.166.2.895; Kawakami K, 1999, GENE, V240, P239, DOI 10.1016/S0378-1119(99)00444-8; Kawakami K, 1998, GENE, V225, P17, DOI 10.1016/S0378-1119(98)00537-X; Kawakami K, 2000, P NATL ACAD SCI USA, V97, P11403, DOI 10.1073/pnas.97.21.11403; Kawakami K, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-S1-S7; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Kempken F, 2001, CHROMOSOMA, V110, P1, DOI 10.1007/s004120000118; Kidwell MG, 2000, TRENDS ECOL EVOL, V15, P95, DOI 10.1016/S0169-5347(99)01817-0; Koga A, 2000, GENETICS, V156, P1243; Koga A, 2000, GENETICS, V155, P273; Koga A, 2002, ZOOL SCI, V19, P1, DOI 10.2108/zsj.19.1; Koga A, 2001, GENES GENET SYST, V76, P1, DOI 10.1266/ggs.76.1; Koga A, 1996, NATURE, V383, P30, DOI 10.1038/383030a0; Koga A, 1999, FEBS LETT, V461, P295, DOI 10.1016/S0014-5793(99)01479-9; Komiyama T, 2009, GENE, V430, P5, DOI 10.1016/j.gene.2008.10.019; Kong J, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq658; Kotani T, 2008, DEV BIOL, V316, P383, DOI 10.1016/j.ydbio.2008.01.043; Liu D, 2009, J MOL EVOL, V69, P395, DOI 10.1007/s00239-009-9295-5; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; Loreto ELS, 2008, HEREDITY, V100, P545, DOI 10.1038/sj.hdy.6801094; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; Miskey C, 2003, NUCLEIC ACIDS RES, V31, P6873, DOI 10.1093/nar/gkg910; Nandi S, 2007, GENETICA, V131, P81, DOI 10.1007/s10709-006-9115-4; Nylander JAA, 2004, SYST BIOL, V53, P47, DOI 10.1080/10635150490264699; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Pace JK, 2008, P NATL ACAD SCI USA, V105, P17023, DOI 10.1073/pnas.0806548105; Parinov S, 2004, DEV DYNAM, V231, P449, DOI 10.1002/dvdy.20157; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; RADICE AD, 1994, MOL GEN GENET, V244, P606, DOI 10.1007/BF00282750; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shibano T, 2007, FEBS LETT, V581, P4333, DOI 10.1016/j.febslet.2007.08.004; Sinzelle L, 2005, GENE, V349, P187, DOI 10.1016/j.gene.2004.12.023; Swofford D.L., 2003, PAUP VERSION 40 B10; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; Venkatesh B, 2001, P NATL ACAD SCI USA, V98, P11382, DOI 10.1073/pnas.201415598; WANG CY, 1983, ACTA ZOOL SINICA, V29, P267; Wu SCY, 2006, P NATL ACAD SCI USA, V103, P15008, DOI 10.1073/pnas.0606979103; Yuan JA, 2010, J EXP ZOOL PART B, V314B, P445, DOI 10.1002/jez.b.21350; Zhang XueYi, 2007, Journal of Shanghai Fisheries University, V16, P513; Zou S., 2011, PROGR AQUACULTURE GE, P188; Zou S., 2010, HEREDITAS, V32, P1; Zou SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007026	65	26	41	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2743	2752		10.1096/fj.11-199273	http://dx.doi.org/10.1096/fj.11-199273			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22441985				2022-12-28	WOS:000305912500004
J	Li, XW; Cudaback, E; Breyer, RM; Montine, KS; Keene, CD; Montine, TJ				Li, Xianwu; Cudaback, Eiron; Breyer, Richard M.; Montine, Kathleen S.; Keene, C. Dirk; Montine, Thomas J.			Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor	FASEB JOURNAL			English	Article						PGE(2); EP1; FP; TP; Parkinson's disease	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TOLL-LIKE RECEPTOR-3; AGED RHESUS-MONKEYS; PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; FACTOR GDNF; INTRAPUTAMENAL INFUSION; IN-VIVO; NEURODEGENERATION; RISK	A major therapeutic target for Parkinson's disease (PD) is providing increased glial-derived neurotrophic factor (GDNF) to dopaminergic neurons. We tested the hypothesis that innate immune activation increases astrocyte GDNF production and that this is regulated by specific eicosanoid receptors. Innate immune-activated primary murine astrocytes were assayed for GDNF expression and secretion. Controls were agent vehicle exposure and wild-type mice. Rank order for up to 10-fold selectively increased GDNF expression was activators of TLR3 > TLR2 or TLR4 > TLR9. TLR3 activator-stimulated GDNF expression was selectively JNK-dependent, followed cyclooxygenase (COX)-2, was coincident with membranous PGE(2) synthase, and was not significantly altered by a nonspecific COX-or a COX-2-selective inhibitor. Specific eicosanoid receptors had opposing effects on TLR3 activator-induced GDNF expression: similar to 60% enhancement by blocking or ablating of PGE(2) receptor subtype 1 (EP1), similar to 30% enhancement by activating PGF(2 alpha) receptor or thromboxane receptor, or similar to 15% enhancement by activating EP4. These results demonstrate functionally antagonistic eicosanoid receptor subtype regulation of innate immunity-induced astrocyte GDNF expression and suggest that selective inhibition of EP1 signaling might be a means to augment astrocyte GDNF secretion in the context of innate immune activation in diseased regions of brain in PD.-Li, X., Cudaback, E., Breyer, R. M., Montine, K. S., Keene, C. D., Montine, T. J. Eicosanoid receptor subtype-mediated opposing regulation of Toll-like receptor-stimulated expression of astrocyte glial-derived neurotrophic factor. FASEB J. 26, 3075-3083 (2012). www.fasebj.org	[Li, Xianwu; Cudaback, Eiron; Montine, Kathleen S.; Keene, C. Dirk; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA; [Breyer, Richard M.] Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37212 USA	University of Washington; University of Washington Seattle; Vanderbilt University	Li, XW (corresponding author), Univ Washington, Dept Pathol, Box 359645, Seattle, WA 98104 USA.	xli@u.washington.edu	Keene, Christopher D/N-1806-2015	Montine, Kathleen/0000-0003-2110-8363; Keene, Christopher/0000-0002-5291-1469	U.S. National Institutes of Health [ES16754, NS62864, AG35681, AG00258, DK37097, GM15431]; Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [RC1AG035681, T32AG000258, Z01AG000258] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Meilany Wijaya for assistance with animal husbandry, Aimee Schantz and Amy Look for administrative support, and Carol Arnold for managerial support. This work was funded by the U.S. National Institutes of Health (ES16754, NS62864, AG35681, AG00258, DK37097, and GM15431) and the Nancy and Buster Alvord Endowment.	Becker C, 2011, EUR J NEUROL, V18, P1336, DOI 10.1111/j.1468-1331.2011.03399.x; Beraud D, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00080; Biju KC, 2010, MOL THER, V18, P1536, DOI 10.1038/mt.2010.107; Bornebroek M, 2007, NEUROEPIDEMIOLOGY, V28, P193, DOI 10.1159/000108110; Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328; Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419; Carpentier PA, 2005, GLIA, V49, P360, DOI 10.1002/glia.20117; Chen HL, 2005, ANN NEUROL, V58, P963, DOI 10.1002/ana.20682; Driver JA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d198; Eberling JL, 2009, HUM GENE THER, V20, P511, DOI 10.1089/hum.2008.201; Emborg ME, 2008, CELL TRANSPLANT, V17, P383; Furuyashiki T, 2011, NAT REV ENDOCRINOL, V7, P163, DOI 10.1038/nrendo.2010.194; Fuxe KG, 2008, BRAIN RES REV, V58, P453, DOI 10.1016/j.brainresrev.2008.04.003; Gagne JJ, 2010, NEUROLOGY, V74, P995, DOI 10.1212/WNL.0b013e3181d5a4a3; Gao XA, 2011, NEUROLOGY, V76, P863, DOI 10.1212/WNL.0b013e31820f2d79; Garbayo E, 2009, J CONTROL RELEASE, V135, P119, DOI 10.1016/j.jconrel.2008.12.010; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Ginsberg SD, 1998, ACTA NEUROPATHOL, V96, P487, DOI 10.1007/s004010050923; Granholm AC, 2000, J NEUROSCI, V20, P3182, DOI 10.1523/JNEUROSCI.20-09-03182.2000; Grondin R, 2003, J NEUROSCI, V23, P1974; Guan Y, 2007, J CLIN INVEST, V117, P2496, DOI 10.1172/JCI29838; Hong Murray, 2008, Expert Rev Neurother, V8, P1125, DOI 10.1586/14737175.8.7.1125; Hovland DN, 2007, TOXICOL PATHOL, V35, P1013, DOI 10.1177/01926230701481899; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Kitaoka S, 2007, J NEUROSCI, V27, P12900, DOI 10.1523/JNEUROSCI.3257-07.2007; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Lau YS, 2011, EUR J NEUROSCI, V33, P1264, DOI 10.1111/j.1460-9568.2011.07626.x; Li XW, 2011, GLIA, V59, P569, DOI 10.1002/glia.21125; Li XZ, 2009, NEUROSCI RES, V65, P252, DOI 10.1016/j.neures.2009.07.007; Lim JE, 2011, AM J PATHOL, V179, P1095, DOI 10.1016/j.ajpath.2011.05.045; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindvall O, 2008, EXP NEUROL, V209, P82, DOI 10.1016/j.expneurol.2007.08.019; Maswood N, 2002, NEUROBIOL AGING, V23, P881, DOI 10.1016/S0197-4580(02)00022-2; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001; Pascual A, 2008, NAT NEUROSCI, V11, P755, DOI 10.1038/nn.2136; Roodveldt C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013481; Ros-Bernal F, 2011, P NATL ACAD SCI USA, V108, P6632, DOI 10.1073/pnas.1017820108; Saito T, 2008, J EXP MED, V205, P1523, DOI 10.1084/jem.20081210; Shie FS, 2005, GLIA, V52, P70, DOI 10.1002/glia.20220; Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551; Slevin JT, 2007, J NEUROSURG, V106, P614, DOI 10.3171/jns.2007.106.4.614; Soeda S, 2008, THROMB HAEMOSTASIS, V100, P1014, DOI 10.1160/TH08-04-0259; Stefanova N, 2011, AM J PATHOL, V179, P954, DOI 10.1016/j.ajpath.2011.04.013; Stone DK, 2009, ANTIOXID REDOX SIGN, V11, P2151, DOI [10.1089/ars.2009.2460, 10.1089/ARS.2009.2460]; Su XM, 2009, HUM GENE THER, V20, P1627, DOI 10.1089/hum.2009.103; Tajiri N, 2010, BRAIN RES, V1310, P200, DOI 10.1016/j.brainres.2009.10.075; Tanaka T, 2008, NEUROSCI LETT, V431, P262, DOI 10.1016/j.neulet.2007.11.051; Tanaka Y, 2009, EUR J NEUROSCI, V30, P2338, DOI 10.1111/j.1460-9568.2009.07021.x; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Thompson LH, 2009, EUR J NEUROSCI, V30, P625, DOI 10.1111/j.1460-9568.2009.06878.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Verity AN, 1999, J NEUROSCI RES, V55, P187, DOI 10.1002/(SICI)1097-4547(19990115)55:2<187::AID-JNR6>3.0.CO;2-T; Verity AN, 1998, J NEUROCHEM, V70, P531; Wu JJ, 2010, NEUROCHEM RES, V35, P495, DOI 10.1007/s11064-009-0086-6; Yang Y, 2009, J GENE MED, V11, P899, DOI 10.1002/jgm.1377; Zigmond MJ, 2009, PARKINSONISM RELAT D, V15, pS42, DOI 10.1016/S1353-8020(09)70778-3	60	12	13	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3075	3083		10.1096/fj.11-200279	http://dx.doi.org/10.1096/fj.11-200279			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22499581	Green Published			2022-12-28	WOS:000305912500035
J	Seffouh, A; Milz, F; Przybylski, C; Laguri, C; Oosterhof, A; Bourcier, S; Sadir, R; Dutkowski, E; Daniel, R; van Kuppevelt, TH; Dierks, T; Lortat-Jacob, H; Vives, RR				Seffouh, Amal; Milz, Fabian; Przybylski, Cedric; Laguri, Cedric; Oosterhof, Arie; Bourcier, Sebastien; Sadir, Rabia; Dutkowski, Elodie; Daniel, Regis; van Kuppevelt, Toin H.; Dierks, Thomas; Lortat-Jacob, Hugues; Vives, Romain R.			HSulf sulfatases catalyze processive and oriented 6-O-desulfation of heparan sulfate that differentially regulates fibroblast growth factor activity	FASEB JOURNAL			English	Article						proteoglycan; glycosaminoglycan; enzymatic mechanism; interaction; structure/function relationships	BINDING; SULF-2; FGF-1; 6-O-ENDOSULFATASES; OLIGOSACCHARIDES; IDENTIFICATION; PROTEOGLYCANS; 6-O-SULFATION; REQUIREMENTS; SEQUENCES	Sulfs are extracellular sulfatases that have emerged recently as critical regulators of heparan sulfate (HS) activities through their ability to catalyze specific 6-O-desulfation of the polysaccharide. Consequently, Sulfs have been involved in many physiological and pathological processes, and notably for Sulf-2, in the development of cancers with poor prognosis. Despite growing interest, little is known about the structure and activity of these enzymes and the way they induce dynamic remodeling of HS 6-O-sulfation status. Here, we have combined an array of analytical approaches, including mass spectrometry, NMR, HS oligosaccharide sequencing, and FACS, to dissect HSulf-2 sulfatase activity, either on a purified octasaccharide used as a mimic of HS functional domains, or on intact cell-surface HS chains. In parallel, we have studied the functional consequences of HSulf-2 activity on fibroblast growth factor (FGF)-induced mitogenesis and found that the enzyme could differentially regulate FGF1 and FGF2 activities. Notably, these data supported the existence of precise 6-O-sulfation patterns for FGF activation and provided new insights into the saccharide structures involved. Altogether, our data bring to light an original processive enzymatic mechanism, by which HSulfs catalyze oriented alteration of HS 6-O-desulfation patterns and direct fine and differential regulation of HS functions.-Seffouh, A., Milz, F., Przybylski, C., Laguri, C., Oosterhof, A., Bourcier, S., Sadir, R., Dutkowski, E., Daniel, R., van Kuppevelt, T. H., Dierks, T., Lortat-Jacob, H., Vives, R. R. HSulf sulfatases catalyze processive and oriented 6-O-desulfation of heparan sulfate that differentially regulates fibroblast growth factor activity.	[Seffouh, Amal; Laguri, Cedric; Bourcier, Sebastien; Sadir, Rabia; Dutkowski, Elodie; Lortat-Jacob, Hugues; Vives, Romain R.] Univ Grenoble 1, CNRS, UMR 5075, Inst Biol Struct Jean Pierre Ebel,Commissariat En, Grenoble, France; [Milz, Fabian; Dierks, Thomas] Univ Bielefeld, Dept Chem, D-33615 Bielefeld, Germany; [Przybylski, Cedric; Daniel, Regis] Univ Evry Val dEssonne, Lab Anal & Modelisat Biol & Environm, CNRS, UMR 8587, Evry, France; [Oosterhof, Arie; van Kuppevelt, Toin H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6525 ED Nijmegen, Netherlands	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of Bielefeld; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; CEA; CY Cergy Paris Universite; Radboud University Nijmegen	Vives, RR (corresponding author), Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble, France.	romain.vives@ibs.fr	Daniel, Regis/S-7890-2016; Dierks, Thomas/A-3596-2012; van Kuppevelt, A.H.M.S.M./L-4463-2015	Daniel, Regis/0000-0003-0725-5439; Dierks, Thomas/0000-0001-6426-1339; laguri, cedric/0000-0002-5429-6914				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chabrol E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050722; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Freeman SD, 2008, DEV BIOL, V320, P436, DOI 10.1016/j.ydbio.2008.05.554; Frese MA, 2009, J BIOL CHEM, V284, P28033, DOI 10.1074/jbc.M109.035808; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hossain MM, 2010, GLYCOBIOLOGY, V20, P175, DOI 10.1093/glycob/cwp159; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Kalus I, 2009, J CELL MOL MED, V13, P4505, DOI 10.1111/j.1582-4934.2008.00558.x; Kudchadkar R, 2008, EXPERT OPIN INV DRUG, V17, P1769, DOI 10.1517/13543784.17.11.1769 ; Lamanna WC, 2008, J BIOL CHEM, V283, P27724, DOI 10.1074/jbc.M802130200; Lamanna WC, 2006, BIOCHEM J, V400, P63, DOI 10.1042/BJ20060848; Lemjabbar-Alaoui H, 2010, ONCOGENE, V29, P635, DOI 10.1038/onc.2009.365; Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4; Lortat-Jacob H, 2009, CURR OPIN STRUC BIOL, V19, P543, DOI 10.1016/j.sbi.2009.09.003; Lum DH, 2007, MOL CELL BIOL, V27, P678, DOI 10.1128/MCB.01279-06; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Ori A, 2008, FRONT BIOSCI-LANDMRK, V13, P4309, DOI 10.2741/3007; Pempe EH, 2012, GLYCOBIOLOGY, V22, P1353, DOI 10.1093/glycob/cws092; Przybylski C, 2010, GLYCOBIOLOGY, V20, P224, DOI 10.1093/glycob/cwp169; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rosen SD, 2010, EXPERT OPIN THER TAR, V14, P935, DOI 10.1517/14728222.2010.504718; Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952; Staples GO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016689; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Yates EA, 1996, CARBOHYD RES, V294, P15	37	42	42	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2431	2439		10.1096/fj.12-226373	http://dx.doi.org/10.1096/fj.12-226373			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457216				2022-12-28	WOS:000319667600030
J	Kim, DH; Wirtz, D				Kim, Dong-Hwee; Wirtz, Denis			Focal adhesion size uniquely predicts cell migration	FASEB JOURNAL			English	Article						motility; mechanosensing; high-throughput phenotyping; systems biology	ACTIN-FILAMENT NETWORKS; ALPHA-ACTININ; MECHANICAL-PROPERTIES; MOTILITY; SUBSTRATE; POLARIZATION; FIBROBLASTS; DYNAMICS; RIGIDITY; BINDING	Focal adhesions are large protein complexes organized at the basal surface of cells, which physically connect the extracellular matrix to the cytoskeleton and have long been speculated to mediate cell migration. However, whether clustering of these molecular components into focal adhesions is actually required for these proteins to regulate cell motility is unclear. Here we use quantitative microscopy to characterize descriptors of focal adhesion and cell motility for mouse embryonic fibroblasts and human fibrosarcoma cells, across a wide range of matrix compliance and following genetic manipulations of focal adhesion proteins (vinculin, talin, zyxin, FAK, and paxilin). This analysis reveals a tight, biphasic gaussian relationship between mean size of focal adhesions (not their number, surface density, or shape) and cell speed. The predictive power of this relationship is comprehensively validated by disrupting nonfocal adhesion proteins (alpha-actinin, F-actin, and myosin II) and subcellular organelles (mitochondria, nuclear DNA, etc.) not known to affect either focal adhesions or cell migration. This study suggests that the mean size of focal adhesions robustly and precisely predicts cell speed independently of focal adhesion surface density and molecular composition.-Kim, D.-H., Wirtz, D. Focal adhesion size uniquely predicts cell migration. FASEB J. 27, 1351-1361 (2013). www.fasebj.org	Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, 3400 N Charles St,NEB Hall Suite 100, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Kim, Dong-Hwee/AAU-4058-2021	Kim, Dong-Hwee/0000-0003-0625-0660	U.S. National Institutes of Health [U54CA143868, R01CA174388]; NATIONAL CANCER INSTITUTE [R01CA174388, U54CA143868] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Sean X. Sun (Johns Hopkins University) for helpful discussions about the interpretation of correlations discussed in this paper. The authors thank G. D. Longmore and Y. Feng (Washington University in St. Louis, School of Medicine, St. Louis, MO, USA) for using their knockdown cells. This work was supported by U.S. National Institutes of Health grants U54CA143868 and R01CA174388. The authors declare no conflicts of interest.	Besser A, 2006, BIOPHYS J, V90, P3469, DOI 10.1529/biophysj.105.074377; BYRNES RW, 1994, RADIAT RES, V137, P162, DOI 10.2307/3578807; Chan CE, 2008, SCIENCE, V322, P1687, DOI 10.1126/science.1163595; Choi CK, 2008, NAT CELL BIOL, V10, P1039, DOI 10.1038/ncb1763; Cloos J, 1999, MUTAGENESIS, V14, P87, DOI 10.1093/mutage/14.1.87; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dumbauld DW, 2010, BIOL CELL, V102, P203, DOI 10.1042/BC20090104; Esue O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004411; Fraley SI, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1711; Fraley SI, 2010, NAT CELL BIOL, V12, P598, DOI 10.1038/ncb2062; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Gallant ND, 2005, MOL BIOL CELL, V16, P4329, DOI 10.1091/mbc.E05-02-0170; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179; Guo WH, 2006, BIOPHYS J, V90, P2213, DOI 10.1529/biophysj.105.070144; Hale CM, 2011, J CELL SCI, V124, P4267, DOI 10.1242/jcs.091231; Hale CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007054; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; ILLC D, 1995, NATURE, V377, P539; Iwanicki MP, 2008, J CELL SCI, V121, P895, DOI 10.1242/jcs.020941; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; Khatau SB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00488; Khatau SB, 2009, P NATL ACAD SCI USA, V106, P19017, DOI 10.1073/pnas.0908686106; Khatiwala CB, 2006, AM J PHYSIOL-CELL PH, V290, pC1640, DOI 10.1152/ajpcell.00455.2005; Kim DH, 2012, SCI REP-UK, V2, DOI 10.1038/srep00555; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee JSH, 2005, MOL BIOL CELL, V16, P871, DOI 10.1091/mbc.e03-12-0910; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lock JG, 2008, SEMIN CANCER BIOL, V18, P65, DOI 10.1016/j.semcancer.2007.10.001; Maheshwari G, 2000, J CELL SCI, V113, P1677; Nagasaki A, 2009, CELL RES, V19, P236, DOI 10.1038/cr.2008.318; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Patla I, 2010, NAT CELL BIOL, V12, P909, DOI 10.1038/ncb2095; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Prager-Khoutorsky M, 2011, NAT CELL BIOL, V13, P1457, DOI 10.1038/ncb2370; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Scales TME, 2011, CURR OPIN CELL BIOL, V23, P562, DOI 10.1016/j.ceb.2011.05.008; Small JV, 1999, FEBS LETT, V452, P96, DOI 10.1016/S0014-5793(99)00530-X; Thompson O, 2010, J CELL SCI, V123, P118, DOI 10.1242/jcs.047902; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; Wakatsuki T, 2001, J CELL SCI, V114, P1025; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Xu WM, 1998, DEVELOPMENT, V125, P327	48	221	225	2	84	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1351	1361		10.1096/fj.12-220160	http://dx.doi.org/10.1096/fj.12-220160			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23254340	Green Published			2022-12-28	WOS:000316940800008
J	Mancarella, S; Potireddy, S; Wang, YJ; Gao, H; Gandhirajan, RK; Autieri, M; Scalia, R; Cheng, ZJ; Wang, H; Madesh, M; Houser, SR; Gill, DL				Mancarella, Salvatore; Potireddy, Santhi; Wang, Youjun; Gao, Hui; Gandhirajan, Rajesh Kumar; Autieri, Michael; Scalia, Rosario; Cheng, Zhongjian; Wang, Hong; Madesh, Muniswamy; Houser, Steven R.; Gill, Donald L.			Targeted STIM deletion impairs calcium homeostasis, NFAT activation, and growth of smooth muscle	FASEB JOURNAL			English	Article						vascular function; gastrointestinal development; Orai channel; transcription factor; mouse knockout	OPERATED CA2+ ENTRY; STROMAL INTERACTION MOLECULE-1; NEOINTIMA FORMATION; CELL PROLIFERATION; I-CRAC; CHANNEL; ORAI; PROTEINS; SIGNALS; INFLUX	The Ca2+ -sensing stromal interaction molecule (STIM) proteins are crucial Ca2+ signal coordinators. Cre-lox technology was used to generate smooth muscle (sm)-targeted STIM1-, STIM2-, and double STIM1/STIM2-knockout (KO) mouse models, which reveal the essential role of STIM proteins in Ca2+ homeostasis and their crucial role in controlling function, growth, and development of smooth muscle cells (SMCs). Compared to Cre(+/-) littermates, sm-STIM1-KO mice showed high mortality (50% by 30 d) and reduced bodyweight. While sm-STIM2-KO was without detectable phenotype, the STIM1/STIM double-KO was perinatally lethal, revealing an essential role of STIM1 partially rescued by STIM2. Vascular and intestinal smooth muscle tissues from sm-STIM1-KO mice developed abnormally with distended, thinned morphology. While depolarization-induced aortic contraction was unchanged in sm-STIM1-KO mice, alpha(1)-adrenergic-mediated contraction was 26% reduced, and store-dependent contraction almost eliminated. Neointimal formation induced by carotid artery ligation was suppressed by 54%, and in vitro PDGF-induced proliferation was greatly reduced (79%) in sm-STIM1-KO. Notably, the Ca2+ store-refilling rate in STIM1- KO SMCs was substantially reduced, and sustained PDGF-induced Ca2+ entry was abolished. This defective Ca2+ homeostasis prevents PDGF-induced NFAT activation in both contractile and proliferating SMCs. We conclude that STIM1-regulated Ca2+ homeostasis is crucial for NFAT-mediated transcriptional control required for induction of SMC proliferation, development, and growth responses to injury.-Mancarella, S., Potireddy, S., Wang, Y., Gao, H., Gandhirajan, K., Autieri, M., Scalia, R., Cheng, Z., Wang, H., Madesh, M., Houser, S. R., Gill, D. L. Targeted STIM deletion impairs calcium homeostasis, NFAT activation, and growth of smooth muscle. FASEB J. 27, 893-906 (2013). www.fasebj.org	[Mancarella, Salvatore; Potireddy, Santhi; Wang, Youjun; Gandhirajan, Rajesh Kumar; Madesh, Muniswamy; Gill, Donald L.] Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; [Gao, Hui; Autieri, Michael; Scalia, Rosario; Houser, Steven R.] Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19140 USA; [Cheng, Zhongjian; Wang, Hong] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA; [Mancarella, Salvatore; Gao, Hui; Autieri, Michael; Scalia, Rosario; Houser, Steven R.; Gill, Donald L.] Temple Univ, Cardiovasc Res Ctr, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mancarella, S (corresponding author), Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA.	mancas@temple.edu; dgill@temple.edu	Wang, Youjun/H-4016-2013	Wang, Youjun/0000-0003-0961-1716; Gandhirajan, Rajesh/0000-0002-0039-771X; Scalia, Rosario/0000-0002-1829-943X	U.S. National Institutes of Health [AI058173]; U.S. National Heart, Blood, and Lung Institute [HL105066]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL105066, R01HL117724, R01HL117654, R01HL141108, R01HL110764, R01HL077288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Heart, Blood, and Lung Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by U.S. National Institutes of Health grant AI058173 (to D.L.G.), and U.S. National Heart, Blood, and Lung Institute postdoctoral fellowship HL105066 (to S.M.). The authors thank Dr. Anjana Rao (La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA) and Dr. Masatsugu Oh-hora (Tokyo Medical and Dental University, Tokyo, Japan) for generously providing the floxed STIM mouse lines.	Aubart FC, 2009, MOL THER, V17, P455, DOI 10.1038/mt.2008.291; Autieri MV, 2002, CIRCULATION, V106, P2218, DOI 10.1161/01.CIR.0000035652.71915.00; Baryshnikov SG, 2009, AM J PHYSIOL-CELL PH, V297, pC1103, DOI 10.1152/ajpcell.00283.2009; Beech DJ, 2007, BIOCHEM SOC T, V35, P890, DOI 10.1042/BST0350890; Beech DJ, 2005, CLIN EXP PHARMACOL P, V32, P597, DOI 10.1111/j.1440-1681.2005.04251.x; Berridge MJ, 2008, J PHYSIOL-LONDON, V586, P5047, DOI 10.1113/jphysiol.2008.160440; Bisaillon JM, 2010, AM J PHYSIOL-CELL PH, V298, pC993, DOI 10.1152/ajpcell.00325.2009; Boeck A, 1997, J ALLERGY CLIN IMMUN, V99, P420, DOI 10.1016/S0091-6749(97)70062-9; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Carrasco S, 2011, ANNU REV BIOCHEM, V80, P973, DOI 10.1146/annurev-biochem-061609-165311; Chen XW, 2011, J MOL CELL CARDIOL, V50, P460, DOI 10.1016/j.yjmcc.2010.11.012; Cheng KT, 2012, P NATL ACAD SCI USA, V109, P14544, DOI 10.1073/pnas.1207354109; Deng XX, 2009, J BIOL CHEM, V284, P22501, DOI 10.1074/jbc.R109.018655; Di Capite J, 2009, CURR BIOL, V19, P853, DOI 10.1016/j.cub.2009.03.063; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Giachini FRC, 2009, HYPERTENSION, V53, P409, DOI 10.1161/HYPERTENSIONAHA.108.124404; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Guo RW, 2009, CARDIOVASC RES, V81, P660, DOI 10.1093/cvr/cvn338; Harmon KJ, 2000, AM J PATHOL, V156, P1741, DOI 10.1016/S0002-9440(10)65045-6; Hewavitharana T, 2008, J BIOL CHEM, V283, P26252, DOI 10.1074/jbc.M802239200; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Hulot JS, 2011, CIRCULATION, V124, P796, DOI 10.1161/CIRCULATIONAHA.111.031229; Kar P, 2012, P NATL ACAD SCI USA, V109, P6969, DOI 10.1073/pnas.1201204109; Kar P, 2012, CURR BIOL, V22, P242, DOI 10.1016/j.cub.2011.12.025; Kumar B, 2006, CIRC RES, V98, P557, DOI 10.1161/01.RES.0000204724.29685.db; Larrieu D, 2005, EXP CELL RES, V310, P166, DOI 10.1016/j.yexcr.2005.07.021; Leung FP, 2008, BRIT J PHARMACOL, V153, P846, DOI 10.1038/sj.bjp.0707455; Lewis RS, 2011, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A003970; Li TY, 2012, MOL CELL BIOL, V32, P3009, DOI 10.1128/MCB.06599-11; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luo X, 2012, J MOL CELL CARDIOL, V52, P136, DOI 10.1016/j.yjmcc.2011.11.003; Mackie AR, 2008, MOL PHARMACOL, V74, P1171, DOI 10.1124/mol.108.049825; Mancarella S, 2011, J BIOL CHEM, V286, P44788, DOI 10.1074/jbc.M111.303081; Mancarella S, 2009, CURR BIOL, V19, pR950, DOI 10.1016/j.cub.2009.08.051; Moller HU, 2012, BRIT J OPHTHALMOL, V96, P1227, DOI 10.1136/bjophthalmol-2011-301462; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Parekh AB, 2011, TRENDS BIOCHEM SCI, V36, P78, DOI 10.1016/j.tibs.2010.07.013; Park CY, 2010, SCIENCE, V330, P101, DOI 10.1126/science.1191027; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Pulver RA, 2004, CIRC RES, V94, P1351, DOI 10.1161/01.RES.0000127618.34500.FD; Ray Jenna Lynn, 2001, Methods in Cell Science, V23, P185; Ray JB, 2008, AM J PHYSIOL-HEART C, V294, pH839, DOI 10.1152/ajpheart.00587.2007; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Rosenberg PB, 2009, J PHYSIOL-LONDON, V587, P3149, DOI 10.1113/jphysiol.2009.172585; Rozenblum GT, 2008, INT J BIOCHEM CELL B, V40, P1990, DOI 10.1016/j.biocel.2007.07.010; Ruusalepp Arno, 2003, Interact Cardiovasc Thorac Surg, V2, P196, DOI 10.1016/S1569-9293(03)00042-2; Soboloff J, 2005, J BIOL CHEM, V280, P39786, DOI 10.1074/jbc.M506064200; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414; Sommerville LJ, 2008, ARTERIOSCL THROM VAS, V28, P47, DOI 10.1161/ATVBAHA.107.156794; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Stiber J, 2008, NAT CELL BIOL, V10, P688, DOI 10.1038/ncb1731; Trebak M, 2012, J PHYSIOL-LONDON, V590, P4201, DOI 10.1113/jphysiol.2012.233353; Varga-Szabo D, 2008, J EXP MED, V205, P1583, DOI 10.1084/jem.20080302; Wamhoff BR, 2006, CIRC RES, V98, P868, DOI 10.1161/01.RES.0000216596.73005.3c; Wang YJ, 2008, CLIN EXP PHARMACOL P, V35, P1127, DOI 10.1111/j.1440-1681.2008.05018.x; Wang YJ, 2010, SCIENCE, V330, P105, DOI 10.1126/science.1191086; Wang YJ, 2009, P NATL ACAD SCI USA, V106, P7391, DOI 10.1073/pnas.0900293106; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; Yoshida T, 2010, J BIOL CHEM, V285, P21175, DOI 10.1074/jbc.M110.112482; Zhang JF, 2006, ARTERIOSCL THROM VAS, V26, pE23, DOI 10.1161/01.ATV.0000202661.61837.93; Zhang SYL, 2011, P NATL ACAD SCI USA, V108, P17838, DOI 10.1073/pnas.1114821108; Zhang W, 2011, CIRC RES, V109, P534, DOI 10.1161/CIRCRESAHA.111.246777	67	55	56	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					893	906		10.1096/fj.12-215293	http://dx.doi.org/10.1096/fj.12-215293			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23159931	Green Published			2022-12-28	WOS:000315585200006
J	Morland, C; Nordengen, K; Larsson, M; Prolo, LM; Farzampour, Z; Reimer, RJ; Gundersen, V				Morland, Cecilie; Nordengen, Kaja; Larsson, Max; Prolo, Laura M.; Farzampour, Zoya; Reimer, Richard J.; Gundersen, Vidar			Vesicular uptake and exocytosis of L-aspartate is independent of sialin	FASEB JOURNAL			English	Article						synaptic transmission; VRAC; excitatory amino acid transporters	RAT CEREBRAL-CORTEX; THREO-BETA-BENZYLOXYASPARTATE; EXCHANGE INHIBITOR KB-R7943; ISCHEMIC CORTICAL PENUMBRA; REGULATED ANION CHANNELS; GAMMA-AMINOBUTYRIC-ACID; METHYL-D-ASPARTATE; L-GLUTAMATE UPTAKE; SYNAPTIC VESICLES; AMINO-ACIDS	The mechanism of release and the role of L-aspartate as a central neurotransmitter are controversial. A vesicular release mechanism for L-aspartate has been difficult to prove, as no vesicular L-aspartate transporter was identified until it was found that sialin could transport L-aspartate and L-glutamate when reconstituted into liposomes. We sought to clarify the release mechanism of L-aspartate and the role of sialin in this process by combining L-aspartate uptake studies in isolated synaptic vesicles with immunocyotchemical investigations of hippocampal slices. We found that radiolabeled L-aspartate was taken up into synaptic vesicles. The vesicular L-aspartate uptake, relative to the L-glutamate uptake, was twice as high in the hippocampus as in the whole brain, the striatum, and the entorhinal and frontal cortices and was not inhibited by L-glutamate. We further show that sialin is not essential for exocytosis of L-aspartate, as there was no difference in ATP-dependent L-aspartate uptake in synaptic vesicles from sialin-knockout and wild-type mice. In addition, expression of sialin in PC12 cells did not result in significant vesicle uptake of L-aspartate, and depolarization-induced depletion of L-aspartate from hippocampal nerve terminals was similar in hippocampal slices from sialin-knockout and wild-type mice. Further, there was no evidence for nonvesicular release of L-aspartate via volume-regulated anion channels or plasma membrane excitatory amino acid transporters. This suggests that L-aspartate is exocytotically released from nerve terminals after vesicular accumulation by a transporter other than sialin.-Morland, C., Nordengen, K., Larsson, M., Prolo, L. M., Farzampour, Z., Reimer, R. J., Gundersen, V. Vesicular uptake and exocytosis of L-aspartate is independent of sialin. FASEB J. 27, 1264-1274 (2013). www.fasebj.org	[Morland, Cecilie; Nordengen, Kaja; Larsson, Max; Gundersen, Vidar] Univ Oslo, Dept Anat, N-0317 Oslo, Norway; [Morland, Cecilie; Nordengen, Kaja; Larsson, Max; Gundersen, Vidar] Univ Oslo, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; [Larsson, Max] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Prolo, Laura M.; Farzampour, Zoya; Reimer, Richard J.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Prolo, Laura M.; Farzampour, Zoya; Reimer, Richard J.] Stanford Univ, Sch Med, Grad Program Neurosci, Stanford, CA 94305 USA; [Gundersen, Vidar] Rikshosp Oslo, Oslo Univ Hosp, Dept Neurol, Oslo, Norway	University of Oslo; University of Oslo; Karolinska Institutet; Stanford University; Stanford University; University of Oslo; National Hospital Norway	Gundersen, V (corresponding author), Univ Oslo, Dept Anat, POB 1105 Blindern, N-0317 Oslo, Norway.	vidar.gundersen@medisin.uio.no	Morland, Cecilie/G-2536-2014	Morland, Cecilie/0000-0002-1776-1821; Larsson, Max/0000-0003-3584-7829; Nordengen, Kaja/0000-0002-5897-6394	Faculty of Medicine, University of Oslo [06/5289]; U. S. National Institute of Neurological Disorders and Stroke [NS050417, NS045634, NS065664]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS065664, R01NS050417, K02NS045634] Funding Source: NIH RePORTER	Faculty of Medicine, University of Oslo; U. S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors are grateful to Inger-Lise Bogen for advice on the vesicular uptake assay and to Anna Torbjorg Bore for technical support. The project was supported by grant 06/5289 from the Faculty of Medicine, University of Oslo, to C. M. and K. N., and awards NS050417 and NS045634 to R. J. R. and NS065664 to L. M. P. from the U. S. National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the U. S. National Institutes of Health. L. M. P. is in the Medical Scientist Training Program at Stanford University School of Medicine.	Aula N, 2004, NEUROBIOL DIS, V15, P251, DOI 10.1016/j.nbd.2003.11.017; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bergersen LH, 2008, NAT PROTOC, V3, P144, DOI 10.1038/nprot.2007.525; Bradford SE, 2004, NEUROSCIENCE, V128, P751, DOI 10.1016/j.neuroscience.2004.06.065; Brustovetsky T, 2011, BRIT J PHARMACOL, V162, P255, DOI 10.1111/j.1476-5381.2010.01054.x; BURKE SP, 1988, J NEUROCHEM, V51, P1541, DOI 10.1111/j.1471-4159.1988.tb01123.x; Cavallero A, 2009, J NEUROCHEM, V110, P924, DOI 10.1111/j.1471-4159.2009.06187.x; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; CHRISTENSEN H, 1991, EUR J PHARM-MOLEC PH, V207, P73, DOI 10.1016/S0922-4106(05)80040-9; CURRAS MC, 1992, MOL PHARMACOL, V41, P520; ERICKSON JD, 1990, BRAIN RES, V516, P155, DOI 10.1016/0006-8993(90)90912-U; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; FLECK MW, 1993, J NEUROSCI, V13, P3944; Fremeau RT, 2004, TRENDS NEUROSCI, V27, P98, DOI 10.1016/j.tins.2003.11.005; Furness DN, 2008, NEUROSCIENCE, V157, P80, DOI 10.1016/j.neuroscience.2008.08.043; FYKSE EM, 1992, NEUROSCI LETT, V135, P125, DOI 10.1016/0304-3940(92)90151-V; FYKSE EM, 1989, J NEUROCHEM, V52, P946, DOI 10.1111/j.1471-4159.1989.tb02546.x; GIRAULT JA, 1986, J NEUROCHEM, V47, P98; Gundersen V, 2008, ACTA NEUROL SCAND, V117, P29, DOI 10.1111/j.1600-0404.2008.01028.x; Gundersen V, 2004, MOL CELL NEUROSCI, V26, P156, DOI 10.1016/j.mcn.2004.01.017; GUNDERSEN V, 1993, NEUROSCIENCE, V57, P97, DOI 10.1016/0306-4522(93)90114-U; Gundersen V, 1998, J NEUROSCI, V18, P6059; Gundersen V, 2000, HAND CHEM N, V18, P45; Gundersen V, 2001, J CEREBR BLOOD F MET, V21, P41, DOI 10.1097/00004647-200101000-00006; GUNDERSEN V, 1991, EUR J NEUROSCI, V3, P1281, DOI 10.1111/j.1460-9568.1991.tb00061.x; Holten AT, 2008, J NEUROCHEM, V104, P1032, DOI 10.1111/j.1471-4159.2007.05065.x; Holten AT, 2008, OPEN NEUROSCI J, V2, P51; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; KADOTA K, 1973, J CELL BIOL, V58, P135, DOI 10.1083/jcb.58.1.135; Kraft R, 2007, BIOCHEM BIOPH RES CO, V361, P230, DOI 10.1016/j.bbrc.2007.07.019; Larsson M, 2005, EUR J NEUROSCI, V21, P2445, DOI 10.1111/j.1460-9568.2005.04081.x; Larsson M, 2012, CEREB CORTEX, V22, P1203, DOI 10.1093/cercor/bhr203; Lewis SM, 1997, NEUROCHEM INT, V31, P581, DOI 10.1016/S0197-0186(97)00014-4; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; Marcaggi P, 2005, NEUROPHARMACOLOGY, V49, P843, DOI 10.1016/j.neuropharm.2005.07.011; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; Miyaji T, 2008, P NATL ACAD SCI USA, V105, P11720, DOI 10.1073/pnas.0804015105; Mongin AA, 2005, AM J PHYSIOL-CELL PH, V288, pC204, DOI 10.1152/ajpcell.00330.2004; Morland C, 2012, NEUROSCI LETT, V527, P100, DOI 10.1016/j.neulet.2012.08.042; Nadler JV, 2011, NEUROCHEM RES, V36, P668, DOI 10.1007/s11064-010-0291-3; NADLER JV, 1990, PROG BRAIN RES, V83, P115; NADLER JV, 1978, J NEUROCHEM, V31, P147, DOI 10.1111/j.1471-4159.1978.tb12442.x; NADLER JV, 1976, NATURE, V260, P538, DOI 10.1038/260538a0; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; Ogita K, 2001, J NEUROCHEM, V77, P34, DOI 10.1046/j.1471-4159.2001.t01-1-00200.x; Omelchenko A, 2003, J PHARMACOL EXP THER, V306, P1050, DOI 10.1124/jpet.103.053389; OTTERSEN OP, 1987, EXP BRAIN RES, V69, P167; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; PAULSEN RE, 1989, J NEUROCHEM, V52, P1823, DOI 10.1111/j.1471-4159.1989.tb07263.x; PETERSON CL, 1995, J NEUROCHEM, V64, P1152; Pezier A, 2009, J NEUROPHYSIOL, V101, P1151, DOI 10.1152/jn.90903.2008; Phillis JW, 2000, BRAIN RES, V884, P155, DOI 10.1016/S0006-8993(00)02938-3; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; Phillis JW, 2000, STROKE, V31, P1462; Phillis JW, 1998, BRAIN RES, V780, P352, DOI 10.1016/S0006-8993(97)01352-8; Phillis JW, 1997, BRAIN RES, V758, P9, DOI 10.1016/S0006-8993(97)00155-8; Prolo LM, 2009, J NEUROSCI, V29, P15355, DOI 10.1523/JNEUROSCI.3005-09.2009; Raiteri L, 2007, J NEUROCHEM, V103, P952, DOI 10.1111/j.1471-4159.2007.04784.x; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; ROISIN MP, 1991, J NEUROSCI METH, V37, P183, DOI 10.1016/0165-0270(91)90129-N; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shimamoto K, 2004, MOL PHARMACOL, V65, P1008, DOI 10.1124/mol.65.4.1008; Sobolevsky AI, 1999, NEUROPHARMACOLOGY, V38, P1235, DOI 10.1016/S0028-3908(99)00040-4; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZERB JC, 1988, J NEUROCHEM, V50, P219, DOI 10.1111/j.1471-4159.1988.tb13252.x; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; Wang LL, 2007, NEUROSCI LETT, V412, P239, DOI 10.1016/j.neulet.2006.11.006; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; Wreden CC, 2005, J BIOL CHEM, V280, P1408, DOI 10.1074/jbc.M411295200; Yarovaya N, 2005, NEUROBIOL DIS, V19, P351, DOI 10.1016/j.nbd.2004.12.020; Zappettini S, 2010, BRIT J PHARMACOL, V161, P1161, DOI 10.1111/j.1476-5381.2010.00958.x; Zhang XY, 2009, BRAIN RES, V1295, P13, DOI 10.1016/j.brainres.2009.07.104; Zhang YH, 2008, EXP NEUROL, V210, P514, DOI 10.1016/j.expneurol.2007.11.027; ZHOU M, 1995, J NEUROCHEM, V64, P1556	80	25	25	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1264	1274		10.1096/fj.12-206300	http://dx.doi.org/10.1096/fj.12-206300			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23221336	Green Published			2022-12-28	WOS:000315585200038
J	Wang, XQ; Cabrera, RM; Li, Y; Miller, DS; Finnell, RH				Wang, Xueqian; Cabrera, Robert M.; Li, Yue; Miller, David S.; Finnell, Richard H.			Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice	FASEB JOURNAL			English	Article						ABC transporters; valproic acid; brain capillaries	CONSTITUTIVE ANDROSTANE RECEPTOR; XENOBIOTIC EFFLUX TRANSPORTERS; RESISTANCE PROTEINS MRP1; MEDIATED UP-REGULATION; FOLIC-ACID; ANTIFOLATE RESISTANCE; EXPRESSION; DEFICIENCY; ACTIVATION; MUTATIONS	Folate deficiency has been associated with many adverse clinical manifestations. The blood-brain barrier (BBB), formed by brain capillary endothelial cells, protects the brain from exposure to neurotoxicants. The function of BBB is modulated by multiple ABC transporters, particularly P-glycoprotein. A proton-coupled folate transporter (PCFT)-deficient mouse has been previously described as a model for systemic folate deficiency. Herein, we demonstrate that exposing mouse brain capillaries to the antiepileptic drug, valproic acid (VPA; 5 mu M), significantly increased P-glycoprotein transport function in the wild-type animals. A ligand to the aryl hydrocarbon receptor, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), produced a similar induction of P-glycoprotein, which tightened the BBB, thereby increasing the neuroprotection. However, VPA- or TCDD-induced P-glycoprotein transport was blocked in the PCFT-nullizygous mice, indicating that multiple neuroprotective mechanisms are compromised under folate-deficient conditions. Brain capillaries from S-folinic acid (SFA; 40 mg/kg)-treated PCFT-nullizygous mice exhibited increased P-glycoprotein transport following VPA exposure. This suggests that SFA supplementation restored the normal BBB function. In addition, we show that tight-junction proteins are disintegrated in the PCFT mutant mice. Taken together, these findings strongly suggest that folate deficiency disrupts the BBB function by targeting the transporter and tight junctions, which may contribute to the development of neurological disorders.-Wang, X., Cabrera, R. M., Li, Y., Miller, D. S., Finnell, R. H. Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. FASEB J. 27, 1167-1175 (2013). www.fasebj.org	[Wang, Xueqian; Cabrera, Robert M.; Finnell, Richard H.] Univ Texas Austin, Dell Pediat Res Inst, Dept Nutr Sci, Austin, TX 78723 USA; [Li, Yue] Univ Texas Austin, Dell Pediat Res Inst, Confocal Microscopy Core, Austin, TX 78723 USA; [Finnell, Richard H.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78723 USA; [Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Finnell, RH (corresponding author), Univ Texas Austin, Dell Pediat Res Inst, Dept Nutr Sci, Austin, TX 78723 USA.	rfinnell@austin.utexas.edu	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754	U.S. National Institutes of Health (NIH) [HD067244, HD072251]; National Institute of Environmental Health Sciences, NIH; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD067244, R21HD072251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080048] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by funds from the U.S. National Institutes of Health (NIH; HD067244 and HD072251). Additional support was provided by the Intramural Research Program of the National Institute of Environmental Health Sciences, NIH. Although the research described in this article has been funded in part by the NIH, it does not necessarily reflect the views of the NIH, and no official endorsement should be inferred. The authors are indebted to Krystal Ogle for the care and well being of the mouse colony.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Assaraf YG, 2006, DRUG RESIST UPDATE, V9, P227, DOI 10.1016/j.drup.2006.09.001; Assaraf YG, 2003, J BIOL CHEM, V278, P6680, DOI 10.1074/jbc.M209186200; Bauer B, 2004, MOL PHARMACOL, V66, P413; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Bednarczyk J, 2011, ACTA NEUROBIOL EXP, V71, P393; Blau N, 2003, NEUROLOGY, V61, P642, DOI 10.1212/01.WNL.0000082726.08631.E7; Blom HJ, 2006, NAT REV NEUROSCI, V7, P724, DOI 10.1038/nrn1986; Cario H, 2009, NEUROLOGY, V73, P2127, DOI 10.1212/WNL.0b013e3181c679df; Carney RM, 2003, PEDIATR NEUROL, V28, P205, DOI 10.1016/S0887-8994(02)00624-0; Cerveny L, 2007, DRUG METAB DISPOS, V35, P1032, DOI 10.1124/dmd.106.014456; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Garcia-Cazorla A, 2008, NEUROLOGY, V70, P1360, DOI 10.1212/01.wnl.0000309223.98616.e4; Goh YI, 2008, J OBSTET GYNAECOL, V28, P3, DOI 10.1080/01443610701814195; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hooijberg JH, 1999, CANCER RES, V59, P2532; Hyland K, 2010, J INHERIT METAB DIS, V33, P563, DOI 10.1007/s10545-010-9159-6; Ifergan I, 2004, J BIOL CHEM, V279, P25527, DOI 10.1074/jbc.M401725200; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Mangold S, 2011, MOL GENET METAB, V104, P369, DOI 10.1016/j.ymgme.2011.06.004; Mercimek-Mahmutoglu S, 2007, TOHOKU J EXP MED, V211, P95, DOI 10.1620/tjem.211.95; Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; Mottino AD, 2000, J PHARMACOL EXP THER, V293, P717; Obican SG, 2010, FASEB J, V24, P4167, DOI 10.1096/fj.10-165084; Perez-Duenas B, 2010, J INHERIT METAB DIS, V33, P795, DOI 10.1007/s10545-010-9196-1; Piedrahita JA, 1999, NAT GENET, V23, P228, DOI 10.1038/13861; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Salojin KV, 2011, BLOOD, V117, P4895, DOI 10.1182/blood-2010-04-279653; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; Steinfeld R, 2009, AM J HUM GENET, V85, P354, DOI 10.1016/j.ajhg.2009.08.005; Takizawa D, 2010, DRUG METAB DISPOS, V38, P1493, DOI 10.1124/dmd.110.032854; Wang XQ, 2011, J CEREBR BLOOD F MET, V31, P1371, DOI 10.1038/jcbfm.2011.44; Wang XQ, 2011, FASEB J, V25, P644, DOI 10.1096/fj.10-169227; Wang XQ, 2010, MOL PHARMACOL, V78, P376, DOI 10.1124/mol.110.063685; Yang HW, 2008, NEUROSCI LETT, V434, P299, DOI 10.1016/j.neulet.2008.01.071; Zhao RB, 2011, ANNU REV NUTR, V31, P177, DOI 10.1146/annurev-nutr-072610-145133; Zhao RB, 2009, J BIOL CHEM, V284, P4267, DOI 10.1074/jbc.M807665200	41	17	17	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1167	1175		10.1096/fj.12-218495	http://dx.doi.org/10.1096/fj.12-218495			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23212123	Green Published			2022-12-28	WOS:000315585200029
J	Gautam, M; Benson, CJ				Gautam, Mamta; Benson, Christopher J.			Acid-sensing ion channels (ASICs) in mouse skeletal muscle afferents are heteromers composed of ASIC1a, ASIC2, and ASIC3 subunits	FASEB JOURNAL			English	Article						sensory neurons; muscle pain; exercise	VANILLOID TYPE-1 RECEPTOR; SENSORY NEURONS; ACTIVATED CURRENTS; PRESSOR REFLEX; PH; CONTRIBUTES; H+; HYPERALGESIA; LACTATE; COMBINATIONS	Acid-sensing ion channels (ASICs) are expressed in skeletal muscle afferents, in which they sense extracellular acidosis and other metabolites released during ischemia and exercise. ASICs are formed as homotrimers or heterotrimers of several isoforms (ASIC1a, ASIC1b, ASIC2a, ASIC2b, and ASIC3), with each channel displaying distinct properties. To dissect the ASIC composition in muscle afferents, we used whole-cell patch-clamp recordings to study the properties of acid-evoked currents (amplitude, pH sensitivity, the kinetics of desensitization and recovery from desensitization, and pharmacological modulation) in isolated, labeled mouse muscle afferents from wild-type (C57BL/6J) and specific ASIC(-/-) mice. We found that ASIC-like currents in wild-type muscle afferents displayed fast desensitization, indicating that they are carried by heteromeric channels. Currents from ASIC1a(-/-) muscle afferents were less pH-sensitive and displayed faster recovery, currents from ASIC2(-/-) mice showed diminished potentiation by zinc, and currents from ASIC3(-/-) mice displayed slower desensitization than those from wild-type mice. Finally, ASIC-like currents were absent from triple-null mice lacking ASIC1a, ASIC2a, and ASIC3. We conclude that ASIC1a, ASIC2a, and ASIC3 heteromers are the principle channels in skeletal muscle afferents. These results will help us understand the role of ASICs in exercise physiology and provide a molecular target for potential drug therapies to treat muscle pain.-Gautam, M., Benson, C. J. Acid-sensing ion channels (ASICs) in mouse skeletal muscle afferents are heteromers composed of ASIC1a, ASIC2, and ASIC3 subunits. FASEB J. 27, 793-802 (2013). www.fasebj.org	[Benson, Christopher J.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Ctr Vet Med, Iowa City, IA USA	University of Iowa	Benson, CJ (corresponding author), Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.	chris-benson@uiowa.edu		Benson, Christopher/0000-0001-6600-8193	U.S. National Institutes of Health National Heart, Lung, and Blood Institute; U.S. Department of Veterans Affairs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107529] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Margaret P. Price and Michael J. Welsh (University of Iowa, Howard Hughes Medical Institute, Iowa City, IA, USA) for providing ASIC double- and triple-null mice and Anne Marie S. Harding for technical support. This work was supported by the U.S. National Institutes of Health National Heart, Lung, and Blood Institute and the U.S. Department of Veterans Affairs.	Alam M, 1937, J PHYSIOL-LONDON, V89, P372, DOI 10.1113/jphysiol.1937.sp003485; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; BANGSBO J, 1993, J PHYSIOL-LONDON, V462, P115, DOI 10.1113/jphysiol.1993.sp019546; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Birdsong WT, 2010, NEURON, V68, P739, DOI 10.1016/j.neuron.2010.09.029; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; COHEN RD, 1983, DIABETES, V32, P181, DOI 10.2337/diab.32.2.181; Connor M, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-31; Deval E, 2008, EMBO J, V27, P3047, DOI 10.1038/emboj.2008.213; Diochot S, 2004, EMBO J, V23, P1516, DOI 10.1038/sj.emboj.7600177; Donier E, 2008, EUR J NEUROSCI, V28, P74, DOI 10.1111/j.1460-9568.2008.06282.x; Gao ZH, 2006, J APPL PHYSIOL, V100, P421, DOI 10.1152/japplphysiol.00659.2005; Gautam M, 2010, NEUROSCIENCE, V170, P893, DOI 10.1016/j.neuroscience.2010.08.003; Hattori T, 2009, CIRC RES, V105, P279, DOI 10.1161/CIRCRESAHA.109.202036; Hayes SG, 2008, AM J PHYSIOL-HEART C, V295, pH1720, DOI 10.1152/ajpheart.00623.2008; Hayes SG, 2007, J PHYSIOL-LONDON, V581, P1271, DOI 10.1113/jphysiol.2007.129197; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Jiang Q, 2011, NEUROSCIENCE, V193, P89, DOI 10.1016/j.neuroscience.2011.07.021; Jiang Q, 2010, NEUROSCIENCE, V169, P574, DOI 10.1016/j.neuroscience.2010.05.043; Kaufman MP, 2002, CLIN AUTON RES, V12, P429, DOI 10.1007/s10286-002-0059-1; Li JH, 2004, J APPL PHYSIOL, V97, P1709, DOI 10.1152/japplphysiol.00389.2004; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Liu JH, 2010, AM J PHYSIOL-HEART C, V299, pH1357, DOI 10.1152/ajpheart.00612.2010; Lu YJ, 2009, NEURON, V64, P885, DOI 10.1016/j.neuron.2009.11.007; Mamet J, 2002, J NEUROSCI, V22, P10662; Mazzuca M, 2007, NAT NEUROSCI, V10, P943, DOI 10.1038/nn1940; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; Molliver DC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-35; Poirot O, 2006, J PHYSIOL-LONDON, V576, P215, DOI 10.1113/jphysiol.2006.113035; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038; Street D, 2001, J PHYSIOL-LONDON, V537, P993; Sugiura T, 2005, J NEUROSCI, V25, P2617, DOI 10.1523/JNEUROSCI.2894-04.2005; Walder RY, 2011, PAIN, V152, P2348, DOI 10.1016/j.pain.2011.06.027; Walder RY, 2010, J PAIN, V11, P210, DOI 10.1016/j.jpain.2009.07.004; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Xing JH, 2008, J PHYSIOL-LONDON, V586, P3245, DOI 10.1113/jphysiol.2008.154450	47	40	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					793	802		10.1096/fj.12-220400	http://dx.doi.org/10.1096/fj.12-220400			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23109675	Green Published			2022-12-28	WOS:000314358000037
J	Menoret, S; Fontaniere, S; Jantz, D; Tesson, L; Thinard, R; Remy, S; Usal, C; Ouisse, LH; Fraichard, A; Anegon, I				Menoret, Severine; Fontaniere, Sandra; Jantz, Derek; Tesson, Laurent; Thinard, Reynald; Remy, Severine; Usal, Claire; Ouisse, Laure-Helene; Fraichard, Alexandre; Anegon, Ignacio			Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases	FASEB JOURNAL			English	Article						rat immunology; transplantation; ZFNs; TALENs	KNOCKOUT RATS; EMBRYO MICROINJECTION; GENE; MECHANISMS; RECOMBINATION; TRANSGENESIS	Despite the recent availability of gene-specific nucleases, such as zinc-finger nucleases (ZFNs) and transcription activator-like nucleases (TALENs), there is still a need for new tools to modify the genome of different species in an efficient, rapid, and less costly manner. One aim of this study was to apply, for the first time, engineered meganucleases to mutate an endogenous gene in animal zygotes. The second aim was to target the mouse and rat recombination activating gene 1 (Rag1) to describe, for the first time, Rag1 knockout immunodeficient rats. We microinjected a plasmid encoding a meganuclease for Rag1 into the pronucleus of mouse and rat zygotes. Mutant animals were detected by PCR sequencing of the targeted sequence. A homozygous RAG1-deficient rat line was generated and immunophenotyped. Meganucleases were efficient, because 3.4 and 0.6% of mouse and rat microinjected zygotes, respectively, generated mutated animals. RAG1-deficient rats showed significantly decreased proportions and numbers of immature and mature T and B lymphocytes and normal NK cells vs. littermate wild-type controls. In summary, we describe the use of engineered meganucleases to inactivate an endogenous gene with efficiencies comparable to those of ZFNs and TALENs. Moreover, we generated an immunodeficient rat line useful for studies in which there is a need for biological parameters to be analyzed in the absence of immune responses.-Menoret, S., Fontaniere, S., Jantz, D., Tesson, L., Thinard, R., Remy, S., Usal, C., Ouisse, L.-H., Fraichard, A., Anegon, A. Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases. FASEB J. 27, 703-711 (2013). www.fasebj.org	[Menoret, Severine; Tesson, Laurent; Thinard, Reynald; Remy, Severine; Usal, Claire; Ouisse, Laure-Helene; Anegon, Ignacio] CNRS, INSERM, UMR 1064, Ctr Res Transplantat & Immunol & Platform Transge, Nantes, France; [Menoret, Severine; Tesson, Laurent; Thinard, Reynald; Remy, Severine; Usal, Claire; Ouisse, Laure-Helene; Anegon, Ignacio] CHU Nantes, ITUN, F-44093 Nantes, France; [Fontaniere, Sandra; Fraichard, Alexandre] genOway, Lyon, France; [Jantz, Derek] Precis Biosci, Durham, NC USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Anegon, I (corresponding author), CHU Nantes, INSERM, UMR 1064, 30 Blvd Jean Monnet, F-44093 Nantes, France.	ignacio.anegon@inserm.fr	Anegon, Ignacio/I-7498-2018; Anegon, Ignacio/I-7760-2018		Region Pays de la Loire; Biogenouest; Infrastructures en Biologie Sante et Agronomie	Region Pays de la Loire(Region Pays de la Loire); Biogenouest; Infrastructures en Biologie Sante et Agronomie	The authors acknowledge E. Corbett (Department of Immunobiology, Yale University, New Haven, CT, USA) for the gift of the anti-RAG1 monoclonal antibody. This work was funded in part by Region Pays de la Loire, Biogenouest, and Infrastructures en Biologie Sante et Agronomie. D.J. is an employee and shareholder of Precision BioSciences, Inc.	Aitman TJ, 2008, NAT GENET, V40, P516, DOI 10.1038/ng.147; Chu XY, 2012, MOL PHARMACOL, V81, P220, DOI 10.1124/mol.111.074179; Cui XX, 2011, NAT BIOTECHNOL, V29, P64, DOI 10.1038/nbt.1731; Daboussi F, 2012, NUCLEIC ACIDS RES, V40, P6367, DOI 10.1093/nar/gks268; De P, 2004, IMMUNOL REV, V200, P70, DOI 10.1111/j.0105-2896.2004.00154.x; de Villartay JP, 2003, NAT REV IMMUNOL, V3, P962, DOI 10.1038/nri1247; DeKelver RC, 2010, GENOME RES, V20, P1133, DOI 10.1101/gr.106773.110; Flisikowska T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021045; Gao HR, 2010, PLANT J, V61, P176, DOI 10.1111/j.1365-313X.2009.04041.x; Geurts AM, 2010, METHODS MOL BIOL, V597, P211, DOI 10.1007/978-1-60327-389-3_15; Geurts AM, 2009, SCIENCE, V325, P433, DOI 10.1126/science.1172447; Grizot S, 2009, NUCLEIC ACIDS RES, V37, P5405, DOI 10.1093/nar/gkp548; Guillot C, 2000, J IMMUNOL, V164, P5258, DOI 10.4049/jimmunol.164.10.5258; Ji YH, 2010, CELL, V141, P419, DOI 10.1016/j.cell.2010.03.010; Mashimo T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008870; Menoret S, 2010, EUR J IMMUNOL, V40, P2932, DOI 10.1002/eji.201040939; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moreno C, 2011, HYPERTENSION, V57, P614, DOI 10.1161/HYPERTENSIONAHA.110.163840; Nguyen TH, 2009, CURR GENE THER, V9, P136, DOI 10.2174/156652309787909481; ONO K, 1972, TRANSPLANTATION, V14, P137; Pattanayak V, 2011, NAT METHODS, V8, P765, DOI 10.1038/nmeth.1670; Petrie-Hanson L, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-8; Redondo P, 2008, NATURE, V456, P107, DOI 10.1038/nature07343; Remy S, 2010, TRANSGENIC RES, V19, P363, DOI 10.1007/s11248-009-9323-7; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Silva G, 2011, CURR GENE THER, V11, P11, DOI 10.2174/156652311794520111; Tesson L, 2011, NAT BIOTECHNOL, V29, P695, DOI 10.1038/nbt.1940; Thermes V, 2002, MECH DEVELOP, V118, P91, DOI 10.1016/S0925-4773(02)00218-6; Tong C, 2010, NATURE, V467, P211, DOI 10.1038/nature09368; Wood AJ, 2011, SCIENCE, V333, P307, DOI 10.1126/science.1207773; Yamamoto S, 2012, TRANSGENIC RES, V21, P743, DOI 10.1007/s11248-011-9564-0	31	73	77	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					703	711		10.1096/fj.12-219907	http://dx.doi.org/10.1096/fj.12-219907			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150522				2022-12-28	WOS:000314358000029
J	Orth, JHC; Fester, I; Siegert, P; Weise, M; Lanner, U; Kamitani, S; Tachibana, T; Wilson, BA; Schlosser, A; Horiguchi, Y; Aktories, K				Orth, Joachim H. C.; Fester, Ines; Siegert, Peter; Weise, Markus; Lanner, Ulrike; Kamitani, Shigeki; Tachibana, Taro; Wilson, Brenda A.; Schlosser, Andreas; Horiguchi, Yasuhiko; Aktories, Klaus			Substrate specificity of Pasteurella multocida toxin for alpha subunits of heterotrimeric G proteins	FASEB JOURNAL			English	Article						PMT; GTPase domain; helical domain; deamidation; oncogene	HELICAL DOMAIN; CRYSTAL-STRUCTURE; MITOGENIC TOXIN; ACTIVATION; CANCER; GTPASE; GROWTH; RHOA; G-ALPHA(13); INVOLVEMENT	Pasteurella multocida is the causative agent of a number of epizootic and zoonotic diseases. Its major virulence factor associated with atrophic rhinitis in animals and dermonecrosis in bite wounds is P. multocida toxin (PMT). PMT stimulates signal transduction pathways downstream of heterotrimeric G proteins, leading to effects such as mitogenicity, blockade of apoptosis, or inhibition of osteoblast differentiation. On the basis of G alpha(i2), it was demonstrated that the toxin deamidates an essential glutamine residue of the G alpha(i2) subunit, leading to constitutive activation of the G protein. Here, we studied the specificity of PMT for its G-protein targets by mass spectrometric analyses and by utilizing a monoclonal antibody, which recognizes specifically G proteins deamidated by PMT. The studies revealed deamidation of 3 of 4 families of heterotrimeric G proteins (G alpha(q/11), G alpha(i1,2,3), and G alpha(12/13) of mouse or human origin) by PMT but not by a catalytic inactive toxin mutant. With the use of G-protein fragments and chimeras of responsive or unresponsive G proteins, the structural basis for the discrimination of heterotrimeric G proteins was studied. Our results elucidate substrate specificity of PMT on the molecular level and provide evidence for the underlying structural reasons of substrate discrimination.-Orth, J. H. C., Fester, I., Siegert, P., Weise, M., Lanner, U., Kamitani, S., Tachibana, T, Wilson, B. A., Schlosser, A., Horiguchi, Y., Aktories, K. Substrate specificity of Pasteurella multocida toxin for alpha subunits of heterotrimeric G proteins. FASEB J. 27, 832-842 (2013). www.fasebj.org	[Orth, Joachim H. C.; Fester, Ines; Siegert, Peter; Weise, Markus; Aktories, Klaus] Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79106 Freiburg, Germany; [Lanner, Ulrike; Schlosser, Andreas] Univ Freiburg, Zentrum Biosyst Anal, D-79106 Freiburg, Germany; [Kamitani, Shigeki; Horiguchi, Yasuhiko] Osaka Univ, Microbial Dis Res Inst, Dept Mol Bacteriol, Suita, Osaka 565, Japan; [Tachibana, Taro] Osaka City Univ, Grad Sch Engn, Dept Bioengn, Osaka, Japan; [Wilson, Brenda A.] Univ Illinois, Dept Microbiol, Urbana, IL USA	University of Freiburg; University of Freiburg; Osaka University; Osaka Metropolitan University; University of Illinois System; University of Illinois Urbana-Champaign	Orth, JHC (corresponding author), Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	joachim.orth@pharmakol.uni-freiburg.de; klaus.aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Kamitani, Shigeki/0000-0002-1268-4652	Deutsche Forschungsgemeinschaft [SFB 746]; U.S. National Institutes of Health [R01-AI-038936]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038396] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was financially supported by the Deutsche Forschungsgemeinschaft, SFB 746 (to J.O. and K. A.), and U.S. National Institutes of Health grant R01-AI-038936 (to B. A. W.). The authors thank Dr. S. Offermanns (Max-Planck-Institut fur Herz- und Lungenforschung, Bad Nauheim, Germany) for the kind gift of G alpha<INF>q/11</INF>-deficient cells and Silke Fieber and Petra Bartholome for excellent technical assistance. The authors thank Dr. Mengfei Ho and Dr. Shuhong Luo (University of Illinois at Urbana-Champaign, Urbana, IL, USA) for construction of the plasmids containing flag-tagged G alpha proteins.	Aminova LR, 2008, PROTEIN SCI, V17, P945, DOI 10.1110/ps.083445408; Aminova LR, 2007, CELL MICROBIOL, V9, P2485, DOI 10.1111/j.1462-5822.2007.00975.x; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; Dohlman HG, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003013; Ehrhardt C., 2006, SIGNAL TRANSDUCT BAN, V6, P179, DOI [10.1002/sita.200500073, DOI 10.1002/SITA.200500073]; Entschladen F, 2011, CELL CYCLE, V10, P1086, DOI 10.4161/cc.10.7.15208; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hildebrand D, 2010, CELL MICROBIOL, V12, P1732, DOI 10.1111/j.1462-5822.2010.01504.x; Kamitani S, 2011, FEBS J, V278, P2702, DOI 10.1111/j.1742-4658.2011.08197.x; Kamitani S, 2010, J BIOL CHEM, V285, P25467, DOI 10.1074/jbc.M110.102285; Kitadokoro K, 2007, P NATL ACAD SCI USA, V104, P5139, DOI 10.1073/pnas.0608197104; Kreutz B, 2007, CELL SIGNAL, V19, P1681, DOI 10.1016/j.cellsig.2007.03.004; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Lax AJ, 2002, TRENDS MICROBIOL, V10, P293, DOI 10.1016/S0966-842X(02)02360-0; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Lutz S, 2007, SCIENCE, V318, P1923, DOI 10.1126/science.1147554; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Orth JHC, 2005, J BIOL CHEM, V280, P36701, DOI 10.1074/jbc.M507203200; Orth JHC, 2004, J BIOL CHEM, V279, P34150, DOI 10.1074/jbc.M405353200; Orth JHC, 2003, BIOCHEMISTRY-US, V42, P4971, DOI 10.1021/bi0272959; Orth JHC, 2008, J BIOL CHEM, V283, P23288, DOI 10.1074/jbc.M803435200; Orth JHC, 2007, CELL SIGNAL, V19, P2174, DOI 10.1016/j.cellsig.2007.06.016; Orth JHC, 2007, J BIOL CHEM, V282, P3050, DOI 10.1074/jbc.M609018200; Orth JHC, 2010, TOXINS, V2, P205, DOI 10.3390/toxins2020205; Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Preuss I, 2010, CELL MICROBIOL, V12, P1174, DOI 10.1111/j.1462-5822.2010.01462.x; Pullinger GD, 2001, INFECT IMMUN, V69, P7839, DOI 10.1128/IAI.69.12.7839-7850.2001; Pullinger Gillian D, 2007, Open Biochem J, V1, P7, DOI 10.2174/1874091X00701010007; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Van Eps N, 2011, P NATL ACAD SCI USA, V108, P9420, DOI 10.1073/pnas.1105810108; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Westfield GH, 2011, P NATL ACAD SCI USA, V108, P16086, DOI 10.1073/pnas.1113645108; Wilson BA, 2000, INFECT IMMUN, V68, P4531, DOI 10.1128/IAI.68.8.4531-4538.2000; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Wilson BA, 2010, FUTURE MICROBIOL, V5, P1185, DOI [10.2217/fmb.10.91, 10.2217/FMB.10.91]; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	52	30	33	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					832	842		10.1096/fj.12-213900	http://dx.doi.org/10.1096/fj.12-213900			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150526	Green Published			2022-12-28	WOS:000314358000041
J	Schmidt-Strassburger, U; Schips, TG; Maier, HJ; Kloiber, K; Mannella, F; Braunstein, KE; Holzmann, K; Ushmorov, A; Liebau, S; Boeckers, TM; Wirth, T				Schmidt-Strassburger, Uta; Schips, Tobias G.; Maier, Harald J.; Kloiber, Katharina; Mannella, Francesca; Braunstein, Kerstin E.; Holzmann, Karlheinz; Ushmorov, Alexey; Liebau, Stefan; Boeckers, Tobias M.; Wirth, Thomas			Expression of constitutively active FoxO3 in murine forebrain leads to a loss of neural progenitors	FASEB JOURNAL			English	Article						adult neurogenesis; apoptosis; Pik3ip1; stem cell	TRANSCRIPTION FACTORS; CELL; BRAIN; CNS; RESTRICTION; DISRUPTION; ACTIVATION; PATHWAYS; PIK3IP1; MICE	Inactivation of FoxO proteins by phosphorylation is the result of a number of stimuli, including the insulin/IGF pathway. We were interested in the consequence of blunting this pathway by employing transgenic mice with tetracycline-controllable conditional expression of a constitutively active allele of FOXO3 under the control of the forebrain-specific CaMKII alpha promoter. Although transgene-expressing mice were viable, brain weight was reduced by 30% in adult animals. Brains showed an isocortex compression with normal cortical layering, and a size reduction in regions known to depend on adult neurogenesis, i.e., the olfactory bulbs and the dentate gyrus. On postnatal activation of the transgene, adult neurogenesis was also severely affected. Investigating the molecular basis of this phenotype, we observed enhanced apoptosis starting from embryonic day E10.5 and a subsequent loss of progenitors in the ventricular/subventricular zones, but not in the isocortex or the striatum of adult mice. The enhanced apoptosis was accompanied by increased expression of PIK3IP1, which we identified as a direct transcriptional target of FOXO3. Transfection of Pik3ip1 into differentiating neural progenitors resulted in a significant reduction of viable cells. We therefore conclude that neural progenitors are particularly vulnerable to FOXO3-induced apoptosis, which is mediated by PIK3IP1, a negative PI3 kinase regulator.-Schmidt-Strassburger, U., Schips, T. G., Maier, H. J., Kloiber, K., Mannella, F., Braunstein, K. E., Holzmann, K., Ushmorov, A., Liebau, S., Boeckers, T. M., Wirth, T. Expression of constitutively active FoxO3 in murine forebrain leads to a loss of neural progenitors. FASEB J. 26, 4990-5001 (2012). www.fasebj.org	[Schmidt-Strassburger, Uta; Schips, Tobias G.; Maier, Harald J.; Kloiber, Katharina; Mannella, Francesca; Ushmorov, Alexey; Wirth, Thomas] Univ Ulm, Inst Physiol Chem, D-89081 Ulm, Germany; [Braunstein, Kerstin E.] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany; [Holzmann, Karlheinz] Univ Ulm, Chip Facil, IZKF, D-89081 Ulm, Germany; [Liebau, Stefan; Boeckers, Tobias M.] Univ Ulm, Inst Anat & Cell Biol, D-89081 Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Wirth, T (corresponding author), Univ Ulm, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.	thomas.wirth@uni-ulm.de	Wirth, Thomas/X-7172-2019; Liebau, Stefan/C-3374-2015; Ushmorov, Alexey/AAI-6445-2020	Liebau, Stefan/0000-0003-0721-8187; Ushmorov, Alexey/0000-0003-3724-7253; Schmidt-Strassburger, Uta/0000-0003-1777-3010	Deutsche Forschungsgemeinschaft, Klinische Forschergruppe 142 [WI-789/3-2]; Rudolf und Clothilde Eberhardt-Stiftung;  [L.SBN.0039]	Deutsche Forschungsgemeinschaft, Klinische Forschergruppe 142; Rudolf und Clothilde Eberhardt-Stiftung; 	The authors are particularly indebted to Nina Ushmorova for her excellent help with all experiments. Also, the authors thank Lucia Flossbach for her help in the initial in vivo analyses, Renate Zienecker and Melanie Gerstenlauer for their excellent histology work, Karin Lanz for the microarray hybridizations, and Katja Fiedler for her help with the FACS analyses. The authors are equally indebted to the animal caretakers Nikolai Derksen and Ralf Bocksrocker. The Bcl11b antibody was a kind gift from Stefan Britsch (Ulm University). The CaMKIIa-tTA; tetO-Cre mice were kindly provided by Ruth Simon (Ulm University), and the Z/AP mice and staining procedures were kindly provided by Martin Wagner, Melanie Guthle, and Ursula Mohnle (Ulm University). This project was supported by the Deutsche Forschungsgemeinschaft (grant WI-789/3-2 to T. W. as part of the Klinische Forschergruppe 142) and an intramural grant (Baustein grant L.SBN.0039 to U. S. S). The Microm HM355S microtome was funded by a grant from the Rudolf und Clothilde Eberhardt-Stiftung to H.J.M.	ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Fasano CA, 2009, GENE DEV, V23, P561, DOI 10.1101/gad.1743709; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; He X, 2008, CANCER RES, V68, P5591, DOI 10.1158/0008-5472.CAN-08-0025; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Katayama K, 2008, ONCOGENE, V27, P1677, DOI 10.1038/sj.onc.1210813; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim MS, 2006, NAT NEUROSCI, V9, P901, DOI 10.1038/nn1731; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Polter A, 2009, BIOL PSYCHIAT, V65, P150, DOI 10.1016/j.biopsych.2008.08.005; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Schips TG, 2011, CARDIOVASC RES, V91, P587, DOI 10.1093/cvr/cvr144; Schuff M, 2010, DEV BIOL, V337, P259, DOI 10.1016/j.ydbio.2009.10.036; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Vue TY, 2007, J COMP NEUROL, V505, P73, DOI 10.1002/cne.21467; Xie LK, 2012, BLOOD, V119, P3503, DOI 10.1182/blood-2011-09-381905; Zheng JY, 2005, AGING CELL, V4, P209, DOI 10.1111/j.1474-9726.2005.00159.x; Zhu ZQ, 2007, BIOCHEM BIOPH RES CO, V358, P66, DOI 10.1016/j.bbrc.2007.04.096	46	24	24	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4990	5001		10.1096/fj.12-208587	http://dx.doi.org/10.1096/fj.12-208587			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22935140				2022-12-28	WOS:000311838300021
J	Quistgaard, EM; Nordlund, P; Low, C				Quistgaard, Esben M.; Nordlund, Par; Low, Christian			High-resolution insights into binding of unfolded polypeptides by the PPIase chaperone SlpA	FASEB JOURNAL			English	Article						protein folding; peptidyl-prolyl cis/trans-isomerase; SlyD-like; crystal structure; ribosome assembly	CRYSTAL-STRUCTURE DETERMINATION; PROLYL ISOMERASE ACTIVITY; OUTER-MEMBRANE PORINS; FOLDING CATALYST SLYD; CIS-TRANS ISOMERASE; TRIGGER FACTOR; PROTEIN; IDENTIFICATION; DOMAIN; NMR	SlpA is a 2-domain protein consisting of an FK506-binding protein (FKBP) domain that harbors the peptidyl-prolyl cis/trans-isomerase (PPIase) active site and a small insert-in-flap (IF) domain that endows the protein with chaperone activity. We have determined the structure of SlpA from Escherichia coli at 1.35-angstrom resolution. The overall structure is similar to other known structures of the FKBP-IF subfamily. However, by serendipity, the linker region of the purification tag binds in the chaperone binding groove of the IF domain, making this the first structure of an FKBP-IF protein in complex with a mimic of an unfolded chaperone substrate. The linker binds by beta-sheet augmentation, thus completing the incomplete beta barrel of the IF domain and shielding a considerable hydrophobic surface area from the solvent. Interestingly, a proline residue in trans configuration appears to be specifically recognized in a small pocket within the binding groove. Hence, the IF domain can preselect and prealign substrates with proline residues, which may explain how it enhances the catalytic efficiency and modulates the specificity of the FKBP domain in addition to its chaperone function. Based on pulldown results, we suggest that SlpA is likely to be involved in ribosome assembly.-Quistgaard, E. M., Nordlund, P., Low, C. High-resolution insights into binding of unfolded polypeptides by the PPIase chaperone SlpA. FASEB J. 26, 4003-4013 (2012). www.fasebj.org	[Quistgaard, Esben M.; Nordlund, Par; Low, Christian] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; [Nordlund, Par] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore	Karolinska Institutet; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Scheeles Vag 2, SE-17177 Stockholm, Sweden.	par.nordlund@ki.se; christian.low@ki.se		Loew, Christian/0000-0003-0764-7483; Quistgaard, Esben/0000-0002-1381-3364	Danish Council for Independent Research (Medical Sciences) [271-09-0187]; European Molecular Biology Organization (EMBO) postdoctoral fellowship; Swedish Research Council; Swedish Cancer Society	Danish Council for Independent Research (Medical Sciences)(Det Frie Forskningsrad (DFF)); European Molecular Biology Organization (EMBO) postdoctoral fellowship; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society)	The authors thank Karthik Maddi for help with crystallization screening and Mirjam Klepsch for critical reading of the manuscript. The crystallographic experiments were carried out at beamline ID14-4 at the European Synchrotron Radiation Facility (Grenoble, France). E.M.Q. was supported by The Danish Council for Independent Research (Medical Sciences; grant 271-09-0187). C.L. was supported by a European Molecular Biology Organization (EMBO) postdoctoral fellowship. This research was supported by grants from the Swedish Research Council and Swedish Cancer Society. E.M.Q. and C.L. designed and performed research; E.M.Q., P.N., and C.L. analyzed data and wrote the manuscript.	Arifuzzaman M, 2006, GENOME RES, V16, P686, DOI 10.1101/gr.4527806; Bartlow P, 2011, PROTEIN EXPRES PURIF, V78, P216, DOI 10.1016/j.pep.2011.04.021; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Cheng TF, 2012, J BIOL INORG CHEM, V17, P331, DOI 10.1007/s00775-011-0855-y; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferguson N, 2003, CURR OPIN STRUC BIOL, V13, P75, DOI 10.1016/S0959-440X(02)00009-X; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Graubner W, 2007, J BIOL CHEM, V282, P7116, DOI 10.1074/jbc.M608235200; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Haupt C, 2011, BIOCHEMISTRY-US, V50, P7321, DOI 10.1021/bi2000627; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Horwich AL, 2009, Q REV BIOPHYS, V42, P83, DOI 10.1017/S0033583509004764; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Hu KF, 2006, BIOCHEMISTRY-US, V45, P11983, DOI 10.1021/bi0607913; Hu PZ, 2009, PLOS BIOL, V7, P929, DOI 10.1371/journal.pbio.1000096; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jahn TR, 2005, FEBS J, V272, P5962, DOI 10.1111/j.1742-4658.2005.05021.x; Jakob RP, 2009, P NATL ACAD SCI USA, V106, P20282, DOI 10.1073/pnas.0909544106; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kahra D, 2011, J MOL BIOL, V411, P781, DOI 10.1016/j.jmb.2011.05.002; Knappe TA, 2007, J MOL BIOL, V368, P1458, DOI 10.1016/j.jmb.2007.02.097; Kovermann M, 2011, BBA-PROTEINS PROTEOM, V1814, P873, DOI 10.1016/j.bbapap.2011.03.016; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; Low C, 2010, J MOL BIOL, V398, P375, DOI 10.1016/j.jmb.2010.03.014; Martinez-Hackert E, 2011, J MOL BIOL, V407, P450, DOI 10.1016/j.jmb.2011.01.027; Martinez-Hackert E, 2009, CELL, V138, P923, DOI 10.1016/j.cell.2009.07.044; Martino L, 2009, FEBS J, V276, P4529, DOI 10.1111/j.1742-4658.2009.07159.x; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Panjikar S, 2005, ACTA CRYSTALLOGR D, V61, P449, DOI 10.1107/S0907444905001307; Ramm K, 2001, J MOL BIOL, V310, P485, DOI 10.1006/jmbi.2001.4747; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; Scholz C, 2006, BIOCHEMISTRY-US, V45, P20, DOI 10.1021/bi051922n; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Steinkellner G, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-32; Suzuki R, 2003, J MOL BIOL, V328, P1149, DOI 10.1016/S0022-2836(03)00379-6; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Weininger U, 2009, J MOL BIOL, V387, P295, DOI 10.1016/j.jmb.2009.01.034; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zoldak G, 2011, J MOL BIOL, V406, P176, DOI 10.1016/j.jmb.2010.12.010	53	8	10	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4003	4013		10.1096/fj.12-208397	http://dx.doi.org/10.1096/fj.12-208397			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22735173				2022-12-28	WOS:000309704000008
J	Stobbe, MD; Houten, SM; van Kampen, AHC; Wanders, RJA; Moerland, PD				Stobbe, Miranda D.; Houten, Sander M.; van Kampen, Antoine H. C.; Wanders, Ronald J. A.; Moerland, Perry D.			Improving the description of metabolic networks: the TCA cycle as example	FASEB JOURNAL			English	Article						pathway database; community effort; curation	ALPHA-KETOGLUTARATE DEHYDROGENASE; SUCCINYL-COA SYNTHETASES; CITRIC-ACID CYCLE; ISOCITRATE DEHYDROGENASE; REDUCTIVE CARBOXYLATION; COMMUNITY APPROACH; RAT-LIVER; RECONSTRUCTION; MITOCHONDRIAL; DATABASES	To collect the ever-increasing yet scattered knowledge on metabolism, multiple pathway databases like the Kyoto Encyclopedia of Genes and Genomes have been created. A complete and accurate description of the metabolic network for human and other organisms is essential to foster new biological discoveries. Previous research has shown, however, that the level of agreement among pathway databases is surprisingly low. We investigated whether the lack of consensus among databases can be explained by an inaccurate representation of the knowledge described in scientific literature. As an example, we focus on the well-known tricarboxylic acid (TCA) cycle and evaluated the description of this pathway as found in a comprehensive selection of 10 human metabolic pathway databases. Remarkably, none of the descriptions given by these databases is entirely correct. Moreover, consensus exists on only 3 reactions. Mistakes in pathway databases might lead to the propagation of incorrect knowledge, misinterpretation of high-throughput molecular data, and poorly designed follow-up experiments. We provide an improved description of the TCA cycle via the community-curated database WikiPathways. We review various initiatives that aim to improve the description of the human metabolic network and discuss the importance of the active involvement of biological experts in these.-Stobbe, M. D., Houten, S. M., van Kampen, A. H. C., Wanders, R. J. A., Moerland, P. D. Improving the description of metabolic networks: the TCA cycle as example. FASEB J. 26, 3625-3636 (2012). www.fasebj.org	[Stobbe, Miranda D.; van Kampen, Antoine H. C.; Moerland, Perry D.] Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1100 DE Amsterdam, Netherlands; [Houten, Sander M.; Wanders, Ronald J. A.] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands; [van Kampen, Antoine H. C.] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands; [van Kampen, Antoine H. C.] Univ Amsterdam, Netherlands Consortium Syst Biol, Amsterdam, Netherlands; [Stobbe, Miranda D.; van Kampen, Antoine H. C.; Moerland, Perry D.] Netherlands Bioinformat Ctr, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Amsterdam	Moerland, PD (corresponding author), Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, POB 22700, NL-1100 DE Amsterdam, Netherlands.	p.d.moerland@amc.uva.nl	Moerland, Perry/AAG-1425-2020; Houten, Sander/Y-3599-2019	Moerland, Perry/0000-0002-2357-3659; Houten, Sander/0000-0002-6167-9147	BioRange program of The Netherlands Bioinformatics Centre (NBIC) [SP1.2.4]; Besluit Subsidies Investeringen Kennisinfrastructuur (BSIK) through The Netherlands Genomics Initiative (NGI) and within the research program of the Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research; Netherlands Organization for Scientific Research [016.086.336]	BioRange program of The Netherlands Bioinformatics Centre (NBIC); Besluit Subsidies Investeringen Kennisinfrastructuur (BSIK) through The Netherlands Genomics Initiative (NGI) and within the research program of the Netherlands Consortium for Systems Biology (NCSB); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This research was performed within the BioRange program (project SP1.2.4) of The Netherlands Bioinformatics Centre (NBIC; http://www.nbic.nl), supported by a Besluit Subsidies Investeringen Kennisinfrastructuur (BSIK) grant through The Netherlands Genomics Initiative (NGI) and within the research program of the Netherlands Consortium for Systems Biology (NCSB), which is part of the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research. S.M.H. was supported by the Netherlands Organization for Scientific Research (VIDI grant 016.086.336).	Antonov AV, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r179; Aral B, 1997, AM J HUM GENET, V61, P1318, DOI 10.1086/301653; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berg JM, 2012, BIOCHEMISTRY; Bierau J, 2007, PHARMACOGENOMICS, V8, P1221, DOI 10.2217/14622416.8.9.1221; Bunik VI, 2008, PROTEINS, V71, P874, DOI 10.1002/prot.21766; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Chindelevitch L, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-1-r6; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; Duarte NC, 2007, P NATL ACAD SCI USA, V104, P1777, DOI 10.1073/pnas.0610772104; FERNANDEZ CA, 1995, J BIOL CHEM, V270, P10037, DOI 10.1074/jbc.270.17.10037; GABRIEL JL, 1986, METABOLISM, V35, P661, DOI 10.1016/0026-0495(86)90175-7; GREKSAK M, 1982, EUR J BIOCHEM, V122, P423, DOI 10.1111/j.1432-1033.1982.tb05897.x; Groth Paul, 2010, Information Services & Use, V30, P51, DOI 10.3233/ISU-2010-0613; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-393; Hartong DT, 2008, NAT GENET, V40, P1230, DOI 10.1038/ng.223; Herrgard MJ, 2008, NAT BIOTECHNOL, V26, P1155, DOI 10.1038/nbt1492; HOEK JB, 1988, BIOCHEM J, V254, P1; HOEK JB, 1980, J BIOL CHEM, V255, P1458; Hoppe A, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-23; Houtkooper RH, 2010, ENDOCR REV, V31, P194, DOI 10.1210/er.2009-0026; Jensen LJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000374; Jerby L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.56; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Karp PD, 2011, ARCH TOXICOL, V85, P1015, DOI 10.1007/s00204-011-0705-2; Kitano H, 2011, NAT CHEM BIOL, V7, P323, DOI 10.1038/nchembio.574; KREBS H. A., 1937, Enzymologia, V4, P148; KREBS HA, 1952, BIOCHEM J, V52, P527, DOI 10.1042/bj0520527; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; LAWSON AM, 1976, CLIN CHEM, V22, P1283; Lee DS, 2008, P NATL ACAD SCI USA, V105, P9880, DOI 10.1073/pnas.0802208105; LIU TC, 1993, P NATL ACAD SCI USA, V90, P5186, DOI 10.1073/pnas.90.11.5186; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; McCartney RG, 1998, J BIOL CHEM, V273, P24158, DOI 10.1074/jbc.273.37.24158; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Mo ML, 2009, TRENDS BIOTECHNOL, V27, P37, DOI 10.1016/j.tibtech.2008.09.007; Morgat A, 2012, NUCLEIC ACIDS RES, V40, pD761, DOI 10.1093/nar/gkr1023; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Oberhardt MA, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.77; Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222; Pico AR, 2008, PLOS BIOL, V6, P1403, DOI 10.1371/journal.pbio.0060184; PLAUT GWE, 1954, J BIOL CHEM, V207, P305; Porcelli AM, 2005, BIOCHEM BIOPH RES CO, V326, P799, DOI 10.1016/j.bbrc.2004.11.105; Radrich K, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-114; RAMAKRISHNA M, 1966, BIOCHEM BIOPH RES CO, V25, P378, DOI 10.1016/0006-291X(66)90215-4; Rey G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000595; Rolfsson O, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-155; Romero P, 2005, GENOME BIOL, V6; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Sheu KFR, 1999, ANN NY ACAD SCI, V893, P61; SIEBERT G, 1957, J BIOL CHEM, V226, P977; Stobbe MD, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-165; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Thiele I, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-8; Thiele I, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.15; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Zelezniak A, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000729	63	18	19	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3625	3636		10.1096/fj.11-203091	http://dx.doi.org/10.1096/fj.11-203091			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22661004				2022-12-28	WOS:000308391600005
J	Schurpf, T; Chen, Q; Liu, JH; Wang, R; Springer, TA; Wang, JH				Schuerpf, Thomas; Chen, Qiang; Liu, Jin-huan; Wang, Rui; Springer, Timothy A.; Wang, Jia-huai			The RGD finger of Del-1 is a unique structural feature critical for integrin binding	FASEB JOURNAL			English	Article						crystal structure; cell adhesion; innate immunity; extracellular matrix protein	DEVELOPMENTAL ENDOTHELIAL LOCUS-1; FACTOR-LIKE DOMAIN; CRYSTAL-STRUCTURE; GROWTH; PROTEIN; ANGIOGENESIS; RECOGNITION; ACTIVATION; INSIGHTS; ALPHA-V-BETA-3	Developmental endothelial cell locus-1 (Del-1) glycoprotein is secreted by endothelial cells and a subset of macrophages. Del-1 plays a regulatory role in vascular remodeling and functions in innate immunity through interaction with integrin alpha(v)beta 3. Del-1 contains 3 epidermal growth factor (EGF)-like repeats and 2 discoidin-like domains. An Arg-Gly-Asp (RGD) motif in the second EGF domain (EGF2) mediates adhesion by endothelial cells and phagocytes. We report the crystal structure of its 3 EGF domains. The RGD motif of EGF2 forms a type II' beta turn at the tip of a long protruding loop, dubbed the RGD finger. Whereas EGF2 and EGF3 constitute a rigid rod via an interdomain calcium ion binding site, the long linker between EGF1 and EGF2 lends considerable flexibility to EGF1. Two unique O-linked glycans and 1 N-linked glycan locate to the opposite side of EGF2 from the RGD motif. These structural features favor integrin binding of the RGD finger. Mutagenesis data confirm the importance of having the RGD motif at the tip of the RGD finger. A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.-Schurpf, T., Chen, Q., Liu, J., Wang, R., Springer, T. A., Wang, J. The RGD finger of Del-1 is a unique structural feature critical for integrin binding. FASEB J. 26, 3412-420 (2012). www.fasebj.org	[Chen, Qiang; Liu, Jin-huan; Wang, Jia-huai] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Wang, Jia-huai] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Schuerpf, Thomas; Wang, Rui; Springer, Timothy A.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Wang, JH (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.	jwang@red.dfci.harvard.edu	Schürpf, Thomas/E-7380-2012; chen, qiang/M-1630-2016	chen, qiang/0000-0002-2398-4482; Schurpf, Thomas/0000-0003-3023-1136	U.S. National Institutes of Health [HL103526]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL103526] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors acknowledge U.S. National Institutes of Health grant HL103526 to T.A.S. and J.-H.W. The authors also thank the staff members at Advanced Photon Source beamlines 24-ID and 19-ID (Argonne National Laboratory, Argonne, IL, USA) for the help in X-ray data collection. Structural data have been deposited in the Protein Data Bank (PDB code 4D90).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Campagne MV, 2007, CELL MICROBIOL, V9, P2095, DOI 10.1111/j.1462-5822.2007.00981.x; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Choi EY, 2008, SCIENCE, V322, P1101, DOI 10.1126/science.1165218; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Cordle J, 2008, J BIOL CHEM, V283, P11785, DOI 10.1074/jbc.M708424200; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan YF, 2008, BRAIN RES, V1219, P1, DOI 10.1016/j.brainres.2008.05.003; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Fujii Y, 2003, J MOL BIOL, V332, P1115, DOI 10.1016/S0022-2836(03)00991-4; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hiruma-Shimizu K, 2010, J AM CHEM SOC, V132, P14857, DOI 10.1021/ja105216u; Ho HKV, 2004, CIRCULATION, V109, P1314, DOI 10.1161/01.CIR.0000118465.36018.2D; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Irjala H, 2003, EUR J IMMUNOL, V33, P815, DOI 10.1002/eji.200323859; Jensen SA, 2009, STRUCTURE, V17, P759, DOI 10.1016/j.str.2009.03.014; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Neutzner M, 2007, CANCER RES, V67, P6777, DOI 10.1158/0008-5472.CAN-07-0165; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Schurpf T, 2011, EMBO J, V30, P4712, DOI 10.1038/emboj.2011.333; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Smagghe BJ, 2010, J BIOL CHEM, V285, P32954, DOI 10.1074/jbc.M110.145177; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Springer TA, 2008, J CELL BIOL, V182, P791, DOI 10.1083/jcb.200801146; Stanley P, 2010, CURR TOP DEV BIOL, V92, P131, DOI 10.1016/S0070-2153(10)92004-8; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Tien AC, 2009, J CELL BIOL, V184, P621, DOI 10.1083/jcb.200811141; Wu Y, 2006, TRENDS CELL BIOL, V16, P189, DOI 10.1016/j.tcb.2006.02.003; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	48	29	33	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3412	3420		10.1096/fj.11-202036	http://dx.doi.org/10.1096/fj.11-202036			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22601780	Green Published			2022-12-28	WOS:000307162800028
J	Bui, C; Barter, MJ; Scott, JL; Xu, YB; Galler, M; Reynard, LN; Rowan, AD; Young, DA				Bui, Catherine; Barter, Matt J.; Scott, Jenny L.; Xu, Yaobo; Galler, Martin; Reynard, Louise N.; Rowan, Andrew D.; Young, David A.			cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis	FASEB JOURNAL			English	Article						transcription; cartilage; collagenase; epigenetic	ENDOCHONDRAL BONE-DEVELOPMENT; GENE-EXPRESSION; DNA METHYLATION; RHEUMATOID-ARTHRITIS; COLLAGENASE EXPRESSION; INFLAMMATORY CYTOKINES; TRANSCRIPTION FACTORS; 13-DEFICIENT MICE; CARTILAGE; PROTEIN	Osteoarthritis is a degenerative joint disease characterized by a progressive and irreversible loss of the articular cartilage, due in main part to the cleavage of type II collagen within the matrix by the enzyme matrix metalloproteinase (MMP)13. Here, we examined the methylation status of MMP13 promoter and report the demethylation of specific CpG dinucleotides within its promoter in osteoarthritic compared to normal cartilage, which correlates with increased MMP13 expression. Of the promoter CpG sites examined, the -104 CpG was consistently demethylated following treatment of human articular chondrocytes with 10 mu M DNA-methyltransferase inhibitor 5-aza-2'-deoxycytidine, again correlating with increased MMP13 expression. Methylation of the -104 CpG site resulted in reduced promoter activity in the chondrosarcoma cell line SW1353 as shown by CpG-free luciferase reporter. Using electrophoretic mobility shift assays, we identified CREB as the regulating factor able to only bind to the MMP13 promoter when the -104 CpG is demethylated, and confirmed this binding by chromatin immunoprecipitation. Finally, we demonstrated that CREB induces MMP13 expression only following treatment of SW1353 with 0.5 mu M Ca2+ ionophore A23187. In summary, the -104 CpG is demethylated in osteoarthritic cartilage, correlating with the elevated MMP13 expression and cartilage destruction, providing a highly novel link between epigenetic status and arthritic disease.-Bui, C., Barter, M. J., Scott, J. L., Xu, Y., Galler, M., Reynard, L. N., Rowan, A. D., Young, D. A. cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. FASEB J. 26, 3000-3011 (2012). www.fasebj.org	[Bui, Catherine; Barter, Matt J.; Scott, Jenny L.; Xu, Yaobo; Galler, Martin; Reynard, Louise N.; Rowan, Andrew D.; Young, David A.] Newcastle Univ, Sch Med, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Young, DA (corresponding author), Newcastle Univ, Sch Med, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	d.a.young@ncl.ac.uk	Young, David/GOV-5677-2022	Young, David/0000-0002-7078-6745; Reynard, Louise/0000-0002-6613-1797	Arthritis Research UK [18726, 19485]; J. G. W. Patterson Foundation; Newcastle University Hospitals Special Trustees, UK; UK National Institute for Health Research Biomedical Research Centre for Aging and Age Related Disease; Northumberland, Tyne; Wear Comprehensive Local Research Network; Versus Arthritis [18746] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); J. G. W. Patterson Foundation; Newcastle University Hospitals Special Trustees, UK; UK National Institute for Health Research Biomedical Research Centre for Aging and Age Related Disease; Northumberland, Tyne; Wear Comprehensive Local Research Network; Versus Arthritis(Versus Arthritis)	The authors thank Maja Klug and Michael Rehli (University Hospital, Regensburg, Germany) for the kind donation of the pCpGL vector. This work was supported by Arthritis Research UK grants 18726 and 19485, the J. G. W. Patterson Foundation, the Newcastle University Hospitals Special Trustees, UK and the UK National Institute for Health Research Biomedical Research Centre for Aging and Age Related Disease award to the Newcastle on Tyne Hospitals National Health Service Foundation Trust. Clinical and translational research in the Musculoskeletal Research Group is supported by the Northumberland, Tyne, and Wear Comprehensive Local Research Network.	Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; Boileau C, 2005, ARTHRITIS RHEUM-US, V52, P488, DOI 10.1002/art.20809; Chan HM, 2001, J CELL SCI, V114, P2363; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dreier R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3117; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258; Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054; Hashimoto K, 2009, ARTHRITIS RHEUM-US, V60, P3303, DOI 10.1002/art.24882; Iliopoulos D, 2007, ANN RHEUM DIS, V66, P1616, DOI 10.1136/ard.2007.069377; Imagawa K, 2011, BIOCHEM BIOPH RES CO, V405, P362, DOI 10.1016/j.bbrc.2011.01.007; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Kasper LH, 2010, EMBO J, V29, P3660, DOI 10.1038/emboj.2010.235; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Li YW, 2011, DEVELOPMENT, V138, P359, DOI 10.1242/dev.052324; Litherland GJ, 2008, J BIOL CHEM, V283, P14221, DOI 10.1074/jbc.M710136200; Little CB, 2009, ARTHRITIS RHEUM-US, V60, P3723, DOI 10.1002/art.25002; Long FX, 2001, DEVELOPMENT, V128, P541; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Matsuo N, 2006, J BIOL CHEM, V281, P5445, DOI 10.1074/jbc.M509923200; McKay JA, 2011, GENES NUTR, V6, P189, DOI 10.1007/s12263-010-0199-1; Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224; Murphy G, 2008, NAT CLIN PRACT RHEUM, V4, P128, DOI 10.1038/ncprheum0727; Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758; Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Ramage L, 2009, SCAND J MED SCI SPOR, V19, P457, DOI 10.1111/j.1600-0838.2009.00912.x; Reynard LN, 2011, HUM MOL GENET, V20, P3450, DOI 10.1093/hmg/ddr253; Roach HI, 2005, ARTHRITIS RHEUM-US, V52, P3110, DOI 10.1002/art.21300; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rowan AD, 2001, ARTHRITIS RHEUM-US, V44, P1620, DOI 10.1002/1529-0131(200107)44:7<1620::AID-ART285>3.0.CO;2-B; Rowan AD, 2007, FRONT BIOSCI-LANDMRK, V12, P536, DOI 10.2741/2080; Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515; Schmucker AC, 2012, J BIOL CHEM, V287, P1189, DOI 10.1074/jbc.M111.264077; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takami N, 2006, ARTHRITIS RHEUM-US, V54, P779, DOI 10.1002/art.21637; Takeda H, 2007, BRAIN RES, V1184, P306, DOI 10.1016/j.brainres.2007.09.055; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wu XL, 2001, J BIOL CHEM, V276, P1735, DOI 10.1074/jbc.M006727200; Yano S, 2003, J IMMUNOL, V171, P2510, DOI 10.4049/jimmunol.171.5.2510; Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702; Young DA, 2002, BIOCHEM J, V364, P89, DOI 10.1042/bj3640089; Zhang Q, 2008, ANN RHEUM DIS, V67, P1633, DOI 10.1136/ard.2007.079574	54	84	86	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					3000	3011		10.1096/fj.12-206367	http://dx.doi.org/10.1096/fj.12-206367			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22505473				2022-12-28	WOS:000305912500027
J	Devalliere, J; Chatelais, M; Fitau, J; Gerard, N; Hulin, P; Velazquez, L; Turner, CE; Charreau, B				Devalliere, Julie; Chatelais, Mathias; Fitau, Juliette; Gerard, Nathalie; Hulin, Philippe; Velazquez, Laura; Turner, Christopher E.; Charreau, Beatrice			LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets alpha-parvin to control cell adhesion and migration	FASEB JOURNAL			English	Article						adaptor protein; integrin-linked kinase; cell motility	ADAPTER PROTEIN; LINKED KINASE; CONSERVED FAMILY; SELF-RENEWAL; ACTIN; ACTIVATION; APS; ILK; MOLECULE; PAXILLIN	Focal adhesion (FA) formation and disassembly play an essential role in adherence and migration of endothelial cells. These processes are highly regulated and involve various signaling molecules that are not yet completely identified. Lnk [Src homology 2-B3 (SH2B3)] belongs to a family of SH2-containing proteins with important adaptor functions. In this study, we showed that Lnk distribution follows that of vinculin, localizing Lnk in FAs. Inhibition of Lnk by RNA interference resulted in decreased spreading, whereas sustained expression dramatically increases the number of focal and cell-matrix adhesions. We demonstrated that Lnk expression impairs FA turnover and cell migration and regulates beta 1-integrin-mediated signaling via Akt and GSK3 beta phosphorylation. Moreover, the alpha-parvin protein was identified as one of the molecular targets of Lnk responsible for impaired FA dynamics and cell migration. Finally, we established the ILK protein as a new molecular partner for Lnk and proposed a model in which Lnk regulates alpha-parvin expression through its interaction with ILK. Collectively, our results underline the adaptor Lnk as a novel and effective key regulator of integrin-mediated signaling controlling endothelial cell adhesion and migration.-Devalliere, J., Chatelais, M., Fitau, J., Gerard, N., Hulin, P., Velazquez, L., Turner, C. E. Charreau, B. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets alpha-parvin to control cell adhesion and migration. FASEB J. 26, 2592-2606 (2012). www.fasebj.org	[Devalliere, Julie; Chatelais, Mathias; Fitau, Juliette; Gerard, Nathalie; Charreau, Beatrice] CHU HoDieu, INSERM, UMR643, F-44093 Nantes 01, France; [Devalliere, Julie; Chatelais, Mathias; Fitau, Juliette; Gerard, Nathalie; Charreau, Beatrice] CHU Nantes, ITERT, Nantes, France; [Hulin, Philippe] Univ Nantes, Cellular & Tissular Imaging Core Facil MicroPICel, Nantes, France; [Velazquez, Laura] Univ Paris 13, INSERM, UMR978, Bobigny, France; [Turner, Christopher E.] Upstate Med Univ, SUNY, Dept Cell & Dev Biol, Syracuse, NY USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Charreau, B (corresponding author), CHU HoDieu, INSERM, UMR643, 30 Bd Jean Monnet, F-44093 Nantes 01, France.	beatrice.charreau@univ-nantes.fr	CHARREAU, Beatrice/AAK-8186-2020	CHARREAU, Beatrice/0000-0001-5870-4615	Xenome, European Commission; Life Sciences, Genomics, and Biotechnology for Health [LSHB-CT-2006-037377]; La Fondation Progreffe; La Fondation Centaure; La Region Pays de la Loire; U.S. National Institutes of Health [RO1-HL-070244]; INSERM; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER	Xenome, European Commission; Life Sciences, Genomics, and Biotechnology for Health(European Commission); La Fondation Progreffe; La Fondation Centaure; La Region Pays de la Loire(Region Pays de la Loire); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank the vector core of the University Hospital of Nantes, supported by the Association Francaise contre les Myopathies (AFM), for providing the adenoviral vectors. This work was supported by Xenome, a European Commission-funded Integrated Project; by Life Sciences, Genomics, and Biotechnology for Health grant LSHB-CT-2006-037377; and by fellowships from La Fondation Progreffe and La Fondation Centaure. J. D. was supported by a grant from La Region Pays de la Loire. C. E. T. was supported by the U.S. National Institutes of Health (RO1-HL-070244). L. V. was supported by an INSERM-Avenir grant.	ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Barres R, 2005, EXP CELL RES, V308, P334, DOI 10.1016/j.yexcr.2005.05.008; Bersenev A, 2008, J CLIN INVEST, V118, P2832, DOI 10.1172/JCI35808; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Boulday G, 2002, TRANSPLANTATION, V74, P1352, DOI 10.1097/00007890-200211150-00026; Boulter E, 2006, FASEB J, V20, P1489, DOI 10.1096/fj.05-4579fje; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Chatelais M, 2011, XENOTRANSPLANTATION, V18, P108, DOI 10.1111/j.1399-3089.2011.00629.x; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Coupel S, 2004, J AM SOC NEPHROL, V15, P2429, DOI 10.1097/01.ASN.0000138237.42675.45; Defilles C, 2009, EXP CELL RES, V315, P1840, DOI 10.1016/j.yexcr.2009.03.014; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Devalliere J, 2011, BIOCHEM PHARMACOL, V82, P1391, DOI 10.1016/j.bcp.2011.06.023; Doyle AD, 2009, J CELL BIOL, V184, P481, DOI 10.1083/jcb.200810041; Eke I, 2010, J CLIN INVEST, V120, P2516, DOI 10.1172/JCI41078; Fitau J, 2006, J BIOL CHEM, V281, P20148, DOI 10.1074/jbc.M510997200; Fukuda K, 2009, MOL CELL, V36, P819, DOI 10.1016/j.molcel.2009.11.028; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 2011, ONCOGENE, V30, P4375, DOI 10.1038/onc.2011.177; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; ILLC D, 1995, NATURE, V377, P539; Iseki M, 2004, MOL CELL BIOL, V24, P2243, DOI 10.1128/MCB.24.6.2243-2250.2004; Jaskolski F, 2005, J NEUROSCI METH, V146, P42, DOI 10.1016/j.jneumeth.2005.01.012; Kamei N, 2010, STEM CELLS, V28, P365, DOI 10.1002/stem.243; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kim H, 2011, FEBS LETT, V585, P18, DOI 10.1016/j.febslet.2010.11.033; Kovacsovics TJ, 1996, BLOOD, V87, P618, DOI 10.1182/blood.V87.2.618.bloodjournal872618; Kubo-Akashi C, 2004, BIOCHEM BIOPH RES CO, V315, P356, DOI 10.1016/j.bbrc.2004.01.060; Kwon SM, 2009, CIRC RES, V104, P969, DOI 10.1161/CIRCRESAHA.108.192856; Lanning NJ, 2011, J CELL SCI, V124, P3095, DOI 10.1242/jcs.081547; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maydan M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012356; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Meder B, 2011, MOL CELL BIOL, V31, P3424, DOI 10.1128/MCB.05269-11; Mitchell RN, 2007, CIRC RES, V100, P967, DOI 10.1161/01.RES.0000261982.76892.09; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Seita J, 2007, P NATL ACAD SCI USA, V104, P2349, DOI 10.1073/pnas.0606238104; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Stanchi F, 2009, J CELL SCI, V122, P1800, DOI 10.1242/jcs.044602; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Takaki S, 2003, J IMMUNOL, V170, P703, DOI 10.4049/jimmunol.170.2.703; Takaki S, 2000, IMMUNITY, V13, P599, DOI 10.1016/S1074-7613(00)00060-1; Takizawa H, 2006, BLOOD, V107, P2968, DOI 10.1182/blood-2005-05-2138; Takizawa H, 2008, EXP HEMATOL, V36, P897, DOI 10.1016/j.exphem.2008.02.004; Takizawa H, 2010, J CLIN INVEST, V120, P179, DOI 10.1172/JCI39503; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858	63	36	37	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2592	2606		10.1096/fj.11-193383	http://dx.doi.org/10.1096/fj.11-193383			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22441983	Green Published			2022-12-28	WOS:000305017200035
J	Krug, S; Kastenmuller, G; Stuckler, F; Rist, MJ; Skurk, T; Sailer, M; Raffler, J; Romisch-Margl, W; Adamski, J; Prehn, C; Frank, T; Engel, KH; Hofmann, T; Luy, B; Zimmermann, R; Moritz, F; Schmitt-Kopplin, P; Krumsiek, J; Kremer, W; Huber, F; Oeh, U; Theis, FJ; Szymczak, W; Hauner, H; Suhre, K; Daniel, H				Krug, Susanne; Kastenmueller, Gabi; Stueckler, Ferdinand; Rist, Manuela J.; Skurk, Thomas; Sailer, Manuela; Raffler, Johannes; Roemisch-Margl, Werner; Adamski, Jerzy; Prehn, Cornelia; Frank, Thomas; Engel, Karl-Heinz; Hofmann, Thomas; Luy, Burkhard; Zimmermann, Ralf; Moritz, Franco; Schmitt-Kopplin, Philippe; Krumsiek, Jan; Kremer, Werner; Huber, Fritz; Oeh, Uwe; Theis, Fabian J.; Szymczak, Wilfried; Hauner, Hans; Suhre, Karsten; Daniel, Hannelore			The dynamic range of the human metabolome revealed by challenges	FASEB JOURNAL			English	Article						clinical study; human physiology; nutrition; systems biology; time-resolved fingerprinting	MASS-SPECTROMETRY; INDIVIDUALITY; BIOMARKERS; URINE; MICE	Metabolic challenge protocols, such as the oral glucose tolerance test, can uncover early alterations in metabolism preceding chronic diseases. Nevertheless, most metabolomics data accessible today reflect the fasting state. To analyze the dynamics of the human metabolome in response to environmental stimuli, we submitted 15 young healthy male volunteers to a highly controlled 4 d challenge protocol, including 36 h fasting, oral glucose and lipid tests, liquid test meals, physical exercise, and cold stress. Blood, urine, exhaled air, and breath condensate samples were analyzed on up to 56 time points by MS-and NMR-based methods, yielding 275 metabolic traits with a focus on lipids and amino acids. Here, we show that physiological challenges increased interindividual variation even in phenotypically similar volunteers, revealing metabotypes not observable in baseline metabolite profiles; volunteer-specific metabolite concentrations were consistently reflected in various biofluids; and readouts from a systematic model of beta-oxidation (e. g., acetylcarnitine/palmitylcarnitine ratio) showed significant and stronger associations with physiological parameters (e. g., fat mass) than absolute metabolite concentrations, indicating that systematic models may aid in understanding individual challenge responses. Due to the multitude of analytical methods, challenges and sample types, our freely available metabolomics data set provides a unique reference for future metabolomics studies and for verification of systems biology models.-Krug, S., Kastenmuller, G., Stuckler, F., Rist, M. J., Skurk, T., Sailer, M., Raffler, J., Romisch-Margl, W., Adamski, J., Prehn, C., Frank, T., Engel, K.-H., Hofmann, T., Luy, B., Zimmermann, R., Moritz, F., Schmitt-Kopplin, P., Krumsiek, J., Kremer, W., Huber, F., Oeh, U., Theis, F. J., Szymczak, W., Hauner, H., Suhre, K., Daniel, H. The dynamic range of the human metabolome revealed by challenges. FASEB J. 26, 2607-2619 (2012). www.fasebj.org	[Krug, Susanne; Skurk, Thomas] Tech Univ Munich, Dept Med Nutr, Res Ctr Nutr & Food Sci, D-85350 Freising Weihenstephan, Germany; [Rist, Manuela J.; Sailer, Manuela; Daniel, Hannelore] Tech Univ Munich, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany; [Frank, Thomas; Engel, Karl-Heinz] Tech Univ Munich, Dept Gen Food Technol, D-85350 Freising Weihenstephan, Germany; [Hofmann, Thomas] Tech Univ Munich, Dept Food Chem & Mol Sensory Sci, D-85350 Freising Weihenstephan, Germany; [Kastenmueller, Gabi; Stueckler, Ferdinand; Raffler, Johannes; Roemisch-Margl, Werner; Krumsiek, Jan; Theis, Fabian J.; Suhre, Karsten] Helmholtz Zentrum Munchen, Inst Bioinformat & Syst Biol, Neuherberg, Germany; [Adamski, Jerzy; Prehn, Cornelia] Helmholtz Zentrum Munchen, Inst Expt Genet, Genome Anal Ctr, Neuherberg, Germany; [Zimmermann, Ralf] Helmholtz Zentrum Munchen, Comprehens Mol Analyt Cooperat Grp, Joint Mass Spectrometry Ctr, Neuherberg, Germany; [Moritz, Franco; Schmitt-Kopplin, Philippe] Helmholtz Zentrum Munchen, Analyt Biogeochem Res Unit, Neuherberg, Germany; [Oeh, Uwe; Szymczak, Wilfried] Helmholtz Zentrum Munchen, Med Radiat Phys & Diagnost Res Unit, Neuherberg, Germany; [Skurk, Thomas; Hauner, Hans] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany; [Theis, Fabian J.] Tech Univ Munich, Dept Math, Munich, Germany; [Suhre, Karsten] Univ Munich, Fac Biol, Planegg Martinsried, Germany; [Luy, Burkhard] Karlsruhe Inst Technol, Inst Organ Chem, Karlsruhe, Germany; [Luy, Burkhard] Karlsruhe Inst Technol, Inst Biol Interfaces 2, Karlsruhe, Germany; [Zimmermann, Ralf] Univ Rostock, Dept Analyt Chem, Rostock, Germany; [Kremer, Werner] LipoFIT Analyt GmbH, Regensburg, Germany; [Kremer, Werner] Univ Regensburg, Inst Biophys & Phys Biochem, D-8400 Regensburg, Germany; [Kremer, Werner] Univ Regensburg, Ctr Magnet Resonance Chem & Biomed, Regensburg, Germany; [Suhre, Karsten] Weill Cornell Med Coll Qatar, Dept Physiol & Biophys, Doha, Qatar	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; University of Munich; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology; University of Rostock; University of Regensburg; University of Regensburg; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Skurk, T (corresponding author), Tech Univ Munich, Else Kroner Fresenius Ctr Nutr Med, Gregor Mendel Str 2, D-85350 Freising Weihenstephan, Germany.	skurk@tum.de	Kastenmüller, Gabi/ABF-5987-2020; Theis, Fabian J/ABD-5212-2021; Daniel, Hannelore/B-8982-2009; Schmitt-Kopplin, Philippe/H-6271-2011; Luy, Burkhard/I-1918-2013; Suhre, Karsten/AAF-1778-2020; Oeh, Uwe/B-8942-2015	Theis, Fabian J/0000-0002-2419-1943; Schmitt-Kopplin, Philippe/0000-0003-0824-2664; Luy, Burkhard/0000-0001-9580-6397; Suhre, Karsten/0000-0001-9638-3912; Adamski, Jerzy/0000-0001-9259-0199; Prehn, Cornelia/0000-0002-1274-4715; Skurk, Thomas/0000-0002-6875-1658; Raffler, Johannes/0000-0003-2495-4020; Kastenmuller, Gabi/0000-0002-2368-7322	Else Kroner-Fresenius-Foundation (Bad Homburg, Germany); Helmholtz Association within Helmholtz Alliance on Systems Biology; German Federal Ministry of Education and Research (BMBF) [0315494A, 03IS2061B]; Studienstiftung des Deutschen Volkes; Deutsche Forschungsgemeinschaft [Graduiertenkolleg 1563]	Else Kroner-Fresenius-Foundation (Bad Homburg, Germany); Helmholtz Association within Helmholtz Alliance on Systems Biology; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Studienstiftung des Deutschen Volkes; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The comprehensiveness of this study became possible by the collaborating work of a consortium of scientists (the Munich Functional Metabolomics Initiative, http://www.mufumet.de). The authors are grateful to Prof. Martin Halle and Dr. Otto Zelger (Center for Prevention and Sports Medicine, Technische Universitat Munchen) for measuring the individual anaerobic threshold. The study was partially funded by the Else Kroner-Fresenius-Foundation (Bad Homburg, Germany), by the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology (project CoReNe), by a grant from the German Federal Ministry of Education and Research (BMBF) for the German Center Diabetes Research (DZD eV), by the BMBF-funded Medizinische Systembiologie-MedSys initiative (subproject SysMBo, project label 0315494A) and BMBF grant 03IS2061B (project Gani_Med). J. K. and F. S. are supported by Ph.D. student fellowships from the Studienstiftung des Deutschen Volkes and J. R. by the Deutsche Forschungsgemeinschaft Graduiertenkolleg 1563. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. Finally, the authors express their appreciation to all volunteers for their participation. Conflicts of interest: W. K. is employed by the University of Regensburg and is cofounder of LipoFIT Analytic GmbH; F. H. is cofounder and chief executive officer of LipoFIT Analytic GmbH. This private company provides fee-for-service NMR measurements. Direct financial benefits did not result from this work. The involvement of LipoFIT Analytic GmbH and the affiliation of F. H. and W. K. to LipoFIT Analytic GmbH do not alter the authors' adherence to all The FASEB Journal policies on sharing data and materials.	Altmaier E, 2008, ENDOCRINOLOGY, V149, P3478, DOI 10.1210/en.2007-1747; Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; Begriche K, 2008, OBESITY, V16, P2053, DOI 10.1038/oby.2008.337; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bogdanov M, 2008, BRAIN, V131, P389, DOI 10.1093/brain/awm304; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; Gall WE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010883; Garrod Archibald E., 2002, Yale Journal of Biology and Medicine, V75, P221; Gowda GAN, 2008, EXPERT REV MOL DIAGN, V8, P617, DOI 10.1586/14737159.8.5.617; Illig T, 2010, NAT GENET, V42, P137, DOI 10.1038/ng.507; Jansson J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006386; Levy PA, 2010, J DEV BEHAV PEDIATR, V31, P622, DOI 10.1097/DBP.0b013e3181eedf01; Lindinger W, 1998, INT J MASS SPECTROM, V173, P191, DOI 10.1016/S0168-1176(97)00281-4; Lucio M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013317; Maher AD, 2007, ANAL CHEM, V79, P5204, DOI 10.1021/ac070212f; Martins A M, 1999, Sao Paulo Med J, V117, P251; Noland RC, 2009, J BIOL CHEM, V284, P22840, DOI 10.1074/jbc.M109.032888; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Rashed MS, 2001, J CHROMATOGR B, V758, P27, DOI 10.1016/S0378-4347(01)00100-1; Romisch-Margl W, 2011, METABOLOMICS, V8, P133, DOI [DOI 10.1007/s11306-011-0293-4, DOI 10.1007/S11306-011-0293-4]; Rubio-Aliaga I, 2011, METABOLOMICS, V7, P375, DOI 10.1007/s11306-010-0255-2; Shaham O, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.50; Suhre K, 2008, NUCLEIC ACIDS RES, V36, pW481, DOI 10.1093/nar/gkn194; Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g; Wopereis S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004525; Zhao XJ, 2010, METABOLOMICS, V6, P362, DOI 10.1007/s11306-010-0203-1	28	231	235	1	83	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2607	2619		10.1096/fj.11-198093	http://dx.doi.org/10.1096/fj.11-198093			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22426117				2022-12-28	WOS:000305017200036
J	Mathews, CK				Mathews, Christopher K.			DNA Synthesis as a Therapeutic Target: The First 65 Years	FASEB JOURNAL			English	Editorial Material							RIBONUCLEOTIDE REDUCTASE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHETASE; MEMORIAL LECTURE; INHIBITION; 5-FLUOROURACIL; CHEMOTHERAPY; POLYMERASE; MECHANISM; SYNTHASE		Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-073744, R01 GM073744] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; BARLOW T, 1983, P NATL ACAD SCI-BIOL, V80, P1492, DOI 10.1073/pnas.80.6.1492; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Chabner B. A., 2011, GOODMAN GILMANS PHAR, P1667; COHEN SS, 1958, P NATL ACAD SCI USA, V44, P1004, DOI 10.1073/pnas.44.10.1004; COHEN SS, 1976, MED BIOL, V54, P299; ELFORD HL, 1979, CANCER RES, V39, P844; ERICKSON JS, 1972, J BIOL CHEM, V247, P5661; Grogan BC, 2011, BIOCHEMISTRY-US, V50, P618, DOI 10.1021/bi102046h; HARTMANN KU, 1961, J BIOL CHEM, V236, P3006; HEIDELBE.C, 1970, CANCER RES, V30, P1549; HITCHING.GH, 1969, CANCER RES, V29, P1895; Hyatt DC, 1997, BIOCHEMISTRY-US, V36, P4585, DOI 10.1021/bi962936j; Liu J, 2002, BBA-MOL BASIS DIS, V1587, P174, DOI 10.1016/S0925-4439(02)00080-7; Marks P. A., 2011, FASEB J, V25, P1786; MATHERLY LH, 1986, CANCER RES, V46, P588; MATHEWS CK, 1963, J BIOL CHEM, V238, P3436; MATHEWS CK, 1963, J BIOL CHEM, V238, P367; MIKITA T, 1994, BIOCHEMISTRY-US, V33, P9195, DOI 10.1021/bi00197a023; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; Mukherjee S., 2012, J POSTGRAD MED ED RE, V46, P112, DOI [10.5005/jp-journals-10028-1025, DOI 10.5005/JP-JOURNALS-10028-1025]; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; OSBORN MJ, 1958, P SOC EXP BIOL MED, V97, P429; Pederson T, 2011, SCIENCE, V332, P423, DOI 10.1126/science.1206460; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; ROSEN B, 1969, J MOL BIOL, V44, P363, DOI 10.1016/0022-2836(69)90181-8; SALSER JS, 1965, CANCER RES, V25, P539; SANTI DV, 1984, FOLATES PTERINS, V1, P345; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Tendian SW, 2000, MOL PHARMACOL, V57, P695, DOI 10.1124/mol.57.4.695; TIDD DM, 1974, CANCER RES, V34, P738; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WERKHEISER W, 1961, J BIOL CHEM, V236, P888	35	9	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2231	2237		10.1096/fj.12-0602ufm	http://dx.doi.org/10.1096/fj.12-0602ufm			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22653564	Green Published			2022-12-28	WOS:000305017200002
J	Cheng, Y; Kawamura, K; Takae, S; Deguchi, M; Yang, Q; Kuo, C; Hsueh, AJW				Cheng, Yuan; Kawamura, Kazuhiro; Takae, Seido; Deguchi, Masashi; Yang, Qing; Kuo, Calvin; Hsueh, Aaron J. W.			Oocyte-derived R-spondin2 promotes ovarian follicle development	FASEB JOURNAL			English	Article						Wnt pathway; follicle development; FSH; ovulation; embryos	WNT SIGNALING PATHWAY; R-SPONDIN; MOUSE OVARIES; BETA-CATENIN; EXPRESSION; MICE; RECEPTORS; GENES; CELLS; NOBOX	R-spondin proteins are adult stem cell growth factors capable of stimulating gut development by activating LGR4, 5, and 6 receptors to promote Wnt signaling. Although multiple Wnt ligands and cognate Frizzled receptors are expressed in the ovary, their physiological roles are unclear. Based on bioinformatic and in situ hybridization analyses, we demonstrated the exclusive expression of R-spondin2 in oocytes of ovarian follicles. In cultured somatic cells from preantral follicles, R-spondin2 treatment (ED50:3 ng/ml) synergized with Wnt3a to stimulate Wnt signaling. In cultured ovarian explants from prepubertal mice containing preantral follicles, treatment with R-spondin2, similar to follicle stimulating hormone, promoted the development of primary follicles to the secondary stage. In vivo administration of an R-spondin agonist stimulated the development of primary follicles to the antral stage in both immature mice and gonadotropin releasing hormone antagonist-treated adult mice. Subsequent treatment with gonadotropins allowed the generation of mature oocytes capable of undergoing early embryonic development and successful pregnancy. Furthermore, R-spondin agonist treatment of immune-deficient mice grafted with human cortical fragments stimulated the development of primary follicles to the secondary stage. Thus, oocyte-derived R-spondin2 is a paracrine factor essential for primary follicle development, and R-spondin agonists could provide a new treatment regimen for infertile women with low responses to the traditional gonadotropin therapy.	[Cheng, Yuan; Takae, Seido; Deguchi, Masashi; Yang, Qing; Kuo, Calvin; Hsueh, Aaron J. W.] Stanford Univ, Sch Med, Program Reprod & Stem Cell Biol, Stanford, CA 94305 USA; [Cheng, Yuan; Kawamura, Kazuhiro; Takae, Seido; Deguchi, Masashi; Yang, Qing; Kuo, Calvin; Hsueh, Aaron J. W.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA; [Cheng, Yuan; Takae, Seido; Deguchi, Masashi; Yang, Qing; Kuo, Calvin; Hsueh, Aaron J. W.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Kawamura, Kazuhiro] Akita Univ, Dept Obstet & Gynecol, Akita 010, Japan	Stanford University; Stanford University; Stanford University; Akita University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, 300 Pasteur Dr,Room A344, Stanford, CA 94305 USA.	aaron.hsueh@stanford.edu		YANG, QING/0000-0002-5910-458X; Kuo, Calvin/0000-0002-7427-5985	U.S. National Institutes of Health National Institute of Child Health and Human Development [R21 HD071259, U54 HD068158]; Japan Ministry of Education, Culture, Sports, Science, and Technology; Developmental Cycle and Epigenome Network [23013004, 24390376]; Naito Foundation; Uehara Memorial Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD068158, R21HD071259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085527] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Developmental Cycle and Epigenome Network; Naito Foundation(Naito Memorial Foundation); Uehara Memorial Foundation(Uehara Memorial Foundation); Mochida Memorial Foundation for Medical and Pharmaceutical Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by funds from the U.S. National Institutes of Health National Institute of Child Health and Human Development (A.H.; R21 HD071259 and U54 HD068158 as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research), the Japan Ministry of Education, Culture, Sports, Science, and Technology (K.K.; Grant-in-Aid for Scientific Research on Priority Area, The Germline: Its Developmental Cycle and Epigenome Network; 23013004 and B: 24390376), the Naito Foundation (K.K.), the Uehara Memorial Foundation (K.K.), and the Mochida Memorial Foundation for Medical and Pharmaceutical Research (K.K.). The authors thank Dr. Nihar Nayak (Stanford University) for help with the in situ hybridization procedure.	Bell SM, 2003, MECH DEVELOP, V120, P597, DOI 10.1016/S0925-4773(03)00021-2; Cadieu E, 2009, SCIENCE, V326, P150, DOI 10.1126/science.1177808; Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Choi YS, 2007, BIOL REPROD, V77, P312, DOI 10.1095/biolreprod.107.060459; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Fan HY, 2010, MOL ENDOCRINOL, V24, P1529, DOI 10.1210/me.2010-0141; Fauser BCJM, 2008, HUM REPROD UPDATE, V14, P1, DOI 10.1093/humupd/dmm034; Harwood BN, 2008, DEV DYNAM, V237, P1099, DOI 10.1002/dvdy.21491; Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kim KA, 2008, MOL BIOL CELL, V19, P2588, DOI 10.1091/mbc.E08-02-0187; Li J, 2010, P NATL ACAD SCI USA, V107, P10280, DOI 10.1073/pnas.1001198107; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McGee EA, 1997, BIOL REPROD, V57, P990, DOI 10.1095/biolreprod57.5.990; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Nayak NR, 2002, J CLIN ENDOCR METAB, V87, P1845, DOI 10.1210/jc.87.4.1845; Ootani A, 2009, NAT MED, V15, P1, DOI 10.1038/nm.1951; Qin YY, 2007, AM J HUM GENET, V81, P576, DOI 10.1086/519496; Rajkovic A, 2004, SCIENCE, V305, P1157, DOI 10.1126/science.1099755; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Sato Y, 2012, MOL ENDOCRINOL, V26, P1158, DOI 10.1210/me.2012-1027; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Tarlatzis BC, 2003, HUM REPROD UPDATE, V9, P61, DOI 10.1093/humupd/dmg007; Van Schoore G, 2005, HISTOCHEM CELL BIOL, V124, P35, DOI 10.1007/s00418-005-0002-3; Wang HX, 2010, BIOL REPROD, V82, P865, DOI 10.1095/biolreprod.109.080903; Wang HX, 2009, MOL HUM REPROD, V15, P11, DOI 10.1093/molehr/gan070; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhao JS, 2007, GASTROENTEROLOGY, V132, P1331, DOI 10.1053/j.gastro.2007.02.001; Zhao JS, 2009, P NATL ACAD SCI USA, V106, P2331, DOI 10.1073/pnas.0805159106	35	35	38	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2175	2184		10.1096/fj.12-223412	http://dx.doi.org/10.1096/fj.12-223412			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23407710	Green Published			2022-12-28	WOS:000319667600009
J	Colletti, E; El Shabrawy, D; Soland, M; Yamagami, T; Mokhtari, S; Osborne, C; Schlauch, K; Zanjani, ED; Porada, CD; Almeida-Porada, G				Colletti, Evan; El Shabrawy, Deena; Soland, Melisa; Yamagami, Takashi; Mokhtari, Saloomeh; Osborne, Craig; Schlauch, Karen; Zanjani, Esmail D.; Porada, Christopher D.; Almeida-Porada, Graca			EphB2 isolates a human marrow stromal cell subpopulation with enhanced ability to contribute to the resident intestinal cellular pool	FASEB JOURNAL			English	Article						crypts of Lieberkiihn; transcriptome; Musashi-1; epithelial; Lgr5; transplant; niche	MESENCHYMAL STEM-CELLS; HUMAN CORD BLOOD; IN-UTERO TRANSPLANTATION; EPITHELIAL-CELLS; GENE-EXPRESSION; HUMAN HEPATOCYTES; SELF-RENEWAL; MICE; ENGRAFTMENT; PROLIFERATION	To identify human bone marrow stromal cell (BMSC) subsets with enhanced ability to engraft/contribute to the resident intestinal cellular pool, we transplanted clonally derived BMSCs into fetal sheep. Analysis at 75 d post-transplantation showed 2 of the 6 clones engrafting the intestine at 4- to 5-fold higher levels (5.03 +/- 0.089 and 5.04 +/- 0.15%, respectively) than the other clones (P<0.01), correlating with the percentage of donor-derived Musashi-1(+) (12.01-14.17 vs. 1.23.8%; P<0.01) or leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5)(+) cells within the intestinal stem cell (ISC) region. Phenotypic and transcriptome analysis determined that the clones with enhanced intestinal contribution expressed high levels of Ephrin type B receptor 2 (EphB2). Intestinal explants demonstrated proliferation of the engrafted cells and ability to generate crypt-like structures in vitro still expressing EphB2. Additional transplants based on BMSC EphB2 expression demonstrated that, at 7 d post-transplant, the EphB2(high) BMSCs engrafted in the ISC region at levels of 2.1 +/- 0.2%, while control EphB2(low) BMSCs engrafted at 0.3 +/- 0.1% (P<0.01). Therefore we identified a marker for isolating and culturing an expandable subpopulation of BMSCs with enhanced intestinal homing and contribution to the ISC region.	[Colletti, Evan; El Shabrawy, Deena; Soland, Melisa; Yamagami, Takashi; Mokhtari, Saloomeh; Zanjani, Esmail D.; Porada, Christopher D.; Almeida-Porada, Graca] Univ Nevada, Dept Anim Biotechnol, Reno, NV 89557 USA; [Osborne, Craig] Univ Nevada, Nevada Genom Ctr, Reno, NV 89557 USA; [Schlauch, Karen] Univ Nevada, Dept Biochem & Mol Biol, Reno, NV 89557 USA; [Schlauch, Karen] Univ Nevada, Nevada Ctr Bioinformat, Reno, NV 89557 USA; [Soland, Melisa; Mokhtari, Saloomeh; Porada, Christopher D.; Almeida-Porada, Graca] Wake Forest Sch Med, Inst Regenerat Med, Winston Salem, NC 27157 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Wake Forest University	Almeida-Porada, G (corresponding author), Wake Forest Sch Med, Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	galmeida@wakehealth.edu		Almeida-Porada, Maria da Graca/0000-0002-6715-865X; soland, Melisa/0000-0001-8217-9734	U.S. National Heart, Lung, and Blood Institute [HL097623, HL073737]; Idea Network of Biological Research Excellence (INBRE) Program of the National Center for Research Resources [P20 RR-016464]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073737, R01HL097623] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Idea Network of Biological Research Excellence (INBRE) Program of the National Center for Research Resources; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Heart, Lung, and Blood Institute grants HL097623 and HL073737 and grant P20 RR-016464 from the Idea Network of Biological Research Excellence (INBRE) Program of the National Center for Research Resources.	Aliotta JM, 2012, STEM CELLS DEV, V21, P1627, DOI 10.1089/scd.2011.0550; Almeida-Porada G, 2005, BRIT J HAEMATOL, V130, P276, DOI 10.1111/j.1365-2141.2005.05588.x; Almeida-Porada G, 2004, BLOOD, V104, P2582, DOI 10.1182/blood-2004-01-0259; Almeida-Porada G, 2002, EXP HEMATOL, V30, P1454, DOI 10.1016/S0301-472X(02)00967-0; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BATMAN PA, 1994, AIDS, V8, P161, DOI 10.1097/00002030-199402000-00003; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Chamberlain J, 2007, HEPATOLOGY, V46, P1935, DOI 10.1002/hep.21899; Clevers H, 2009, EMBO MOL MED, V1, P255, DOI 10.1002/emmm.200900034; Cogle CR, 2007, STEM CELLS, V25, P1881, DOI 10.1634/stemcells.2007-0163; Colletti EJ, 2009, STEM CELL RES, V2, P125, DOI 10.1016/j.scr.2008.08.002; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; Fujiki Y, 2003, TRANSPLANTATION, V75, P916, DOI 10.1097/01.TP.0000057243.12110.7C; Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048; George MD, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-209; Gonzalez MA, 2009, GASTROENTEROLOGY, V136, P978, DOI 10.1053/j.gastro.2008.11.041; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; Gronthos Stan, 2008, V449, P45, DOI 10.1007/978-1-60327-169-1_3; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Hafner C, 2005, WORLD J GASTROENTERO, V11, P4511, DOI 10.3748/wjg.v11.i29.4511; Hafner C, 2005, WORLD J GASTROENTERO, V11, P4024, DOI 10.3748/wjg.v11.i26.4024; Hayashi Y, 2007, PHARMACOLOGY, V80, P193, DOI 10.1159/000104148; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Ishikawa F, 2003, ANN NY ACAD SCI, V996, P174, DOI 10.1111/j.1749-6632.2003.tb03245.x; Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470; Koo BK, 2009, GASTROENTEROLOGY, V137, P145, DOI 10.1053/j.gastro.2009.03.046; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kudo K, 2010, J RADIAT RES, V51, P73, DOI 10.1269/jrr.09091; Lanzoni G, 2008, WORLD J GASTROENTERO, V14, P4616, DOI 10.3748/wjg.14.4616; Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Montgomery RK, 2008, J ANAT, V213, P52, DOI 10.1111/j.1469-7580.2008.00925.x; Mouiseddine M, 2007, BRIT J RADIOL, V80, pS49, DOI 10.1259/bjr/25927054; Nishimura S, 2003, DIGEST DIS SCI, V48, P1523, DOI 10.1023/A:1024763723240; Okamoto R, 2004, J GASTROENTEROL, V39, P1, DOI 10.1007/s00535-003-1259-8; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Peranteau WH, 2009, BIOL BLOOD MARROW TR, V15, P293, DOI 10.1016/j.bbmt.2008.11.034; PIXLEY JS, 1994, PATHOBIOLOGY, V62, P238, DOI 10.1159/000163916; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Rubin JP, 2001, J SURG RES, V95, P188, DOI 10.1006/jsre.2000.6044; Sabatino DE, 2007, MOL THER, V15, P1677, DOI 10.1038/sj.mt.6300219; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schoeberlein A, 2004, STEM CELLS DEV, V13, P677, DOI 10.1089/scd.2004.13.677; Semont A, 2006, ADV EXP MED BIOL, V585, P19; Shaw SWS, 2011, CELL TRANSPLANT, V20, P1015, DOI 10.3727/096368910X543402; SHIELDS LE, 1995, AM J OBSTET GYNECOL, V173, P1157, DOI 10.1016/0002-9378(95)91344-0; Simmons P J, 1994, Prog Clin Biol Res, V389, P271; Sun Y, 2007, BIOCHEM BIOPH RES CO, V357, P1160, DOI 10.1016/j.bbrc.2007.04.087; Swenson ES, 2010, CLIN EXP GASTROENTER, V3, P1; Tarantal AF, 2000, TRANSPLANTATION, V69, P1818, DOI 10.1097/00007890-200005150-00015; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Xiao Yan-ping, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P129; Yabana T, 2009, J PATHOL, V218, P350, DOI 10.1002/path.2535; Zhang J, 2008, J BIOMED SCI, V15, P585, DOI 10.1007/s11373-008-9256-9	63	10	10	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2111	2121		10.1096/fj.12-205054	http://dx.doi.org/10.1096/fj.12-205054			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23413357	Green Published			2022-12-28	WOS:000319667600003
J	Heinemeier, KM; Schjerling, P; Heinemeier, J; Magnusson, SP; Kjaer, M				Heinemeier, Katja Maria; Schjerling, Peter; Heinemeier, Jan; Magnusson, Stig Peter; Kjaer, Michael			Lack of tissue renewal in human adult Achilles tendon is revealed by nuclear bomb C-14	FASEB JOURNAL			English	Article						collagen fibril; turnover; synthesis rate; skeletal muscle; carbon-14	COLLAGEN-SYNTHESIS; TURNOVER; RADIOCARBON; MICRODIALYSIS; TENDINOPATHY; HYPERTROPHY; EXERCISE; AGE	Tendons are often injured and heal poorly. Whether this is caused by a slow tissue turnover is unknown, since existing data provide diverging estimates of tendon protein half-life that range from 2 mo to 200 yr. With the purpose of determining life-long turnover of human tendon tissue, we used the C-14 bomb-pulse method. This method takes advantage of the dramatic increase in atmospheric levels of C-14, produced by nuclear bomb tests in 1955-1963, which is reflected in all living organisms. Levels of C-14 were measured in 28 forensic samples of Achilles tendon core and 4 skeletal muscle samples (donor birth years 1945-1983) with accelerator mass spectrometry (AMS) and compared to known atmospheric levels to estimate tissue turnover. We found that Achilles tendon tissue retained levels of C-14 corresponding to atmospheric levels several decades before tissue sampling, demonstrating a very limited tissue turnover. The tendon concentrations of C-14 approximately reflected the atmospheric levels present during the first 17 yr of life, indicating that the tendon core is formed during height growth and is essentially not renewed thereafter. In contrast, C-14 levels in muscle indicated continuous turnover. Our observation provides a fundamental premise for understanding tendon function and pathology, and likely explains the poor regenerative capacity of tendon tissue.-Heinemeier, K. M., Schjerling, P., Heinemeier, J., Magnusson, S. P., Kjaer, M. Lack of tissue renewal in human adult Achilles tendon is revealed by nuclear bomb C-14. FASEB J. 27, 2074-2079 (2013). www.fasebj.org	[Heinemeier, Katja Maria; Schjerling, Peter; Magnusson, Stig Peter; Kjaer, Michael] Bispebjerg Hosp, Inst Sport Med, Dept Orthoped Surg M, DK-2400 Copenhagen NV, Denmark; [Heinemeier, Katja Maria; Schjerling, Peter; Magnusson, Stig Peter; Kjaer, Michael] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Hlth Aging, DK-1168 Copenhagen, Denmark; [Heinemeier, Jan] Aarhus Univ, Dept Phys & Astron, AMS Dating Ctr 14C, Aarhus, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Aarhus University	Heinemeier, KM (corresponding author), Bispebjerg Hosp, Inst Sport Med, Bldg 8,1 Floor,Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	katjaheinemeier@gmail.com	Magnusson, Peter/AAN-1631-2020; Kjaer, Michael/W-6842-2019; Schjerling, Peter/F-6194-2011; Magnusson, S. Peter/AAD-5903-2022	Kjaer, Michael/0000-0002-4582-8755; Schjerling, Peter/0000-0001-7138-3211; Magnusson, S. Peter/0000-0002-4308-5484	Danish Medical Research Council [11-107595]; Danish Rheumatism Association [A1698]; Weimann Foundation; Lundbeck Foundation; Novo Nordisk Foundation; Nordea Foundation (Healthy Ageing grant); Danish Research Council for Natural Sciences	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Rheumatism Association; Weimann Foundation; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Nordea Foundation (Healthy Ageing grant); Danish Research Council for Natural Sciences(Danish Natural Science Research Council)	The authors are thankful for the reliable and prompt service from Dr. Ugo Zoppi (Accium Biosciences, Seattle, WA, USA) with <SUP>14</SUP>C measurements and for help from Patrick Hanson with tissue sampling and Professor Niels Lynnerup with grant applications. Financial support from the Danish Medical Research Council (11-107595), Danish Rheumatism Association (A1698), Weimann Foundation, Lundbeck Foundation, Novo Nordisk Foundation, Nordea Foundation (Healthy Ageing grant) and the Danish Research Council for Natural Sciences is greatly appreciated. The authors declare no conflicts of interest.	Babraj JA, 2005, AM J PHYSIOL-ENDOC M, V289, pE864, DOI 10.1152/ajpendo.00243.2005; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Couppe C, 2008, J APPL PHYSIOL, V105, P805, DOI 10.1152/japplphysiol.90361.2008; Goodsite ME, 2001, RADIOCARBON, V43, P495; Hedges REM, 2007, AM J PHYS ANTHROPOL, V133, P808, DOI 10.1002/ajpa.20598; Heinemeier KM, 2013, SCAND J MED SCI SPOR, V23, pe150, DOI 10.1111/j.1600-0838.2011.01414.x; Kannus P, 2000, SCAND J MED SCI SPOR, V10, P312, DOI 10.1034/j.1600-0838.2000.010006312.x; Kongsgaard M, 2007, ACTA PHYSIOL, V191, P111, DOI 10.1111/j.1748-1716.2007.01714.x; Kuczmarski RJ., 2000, ADV DATA, P1; Kueppers LM, 2004, OECOLOGIA, V141, P641, DOI 10.1007/s00442-004-1689-x; Kujala UM, 2005, CLIN J SPORT MED, V15, P133, DOI 10.1097/01.jsm.0000165347.55638.23; Langberg H, 2001, J PHYSIOL-LONDON, V534, P297, DOI 10.1111/j.1469-7793.2001.00297.x; Langberg H, 1999, J PHYSIOL-LONDON, V521, P299, DOI 10.1111/j.1469-7793.1999.00299.x; LIBBY WF, 1964, SCIENCE, V146, P1171; Lynnerup N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001529; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Provenzano PP, 2006, MATRIX BIOL, V25, P71, DOI 10.1016/j.matbio.2005.09.005; Riley G, 2008, NAT CLIN PRACT RHEUM, V4, P82, DOI 10.1038/ncprheum0700; Rosager S, 2002, SCAND J MED SCI SPOR, V12, P90, DOI 10.1034/j.1600-0838.2002.120205.x; Spalding KL, 2005, NATURE, V437, P333, DOI 10.1038/437333a; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Sullivan BE, 2009, J APPL PHYSIOL, V106, P468, DOI 10.1152/japplphysiol.91341.2008; Svensson RB, 2011, CONNECT TISSUE RES, V52, P415, DOI 10.3109/03008207.2010.551569; Thorpe CT, 2010, J BIOL CHEM, V285, P15674, DOI 10.1074/jbc.M109.077503; Zoppi U, 2007, RADIOCARBON, V49, P173, DOI 10.1017/S0033822200041990	26	190	191	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2074	2079		10.1096/fj.12-225599	http://dx.doi.org/10.1096/fj.12-225599			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23401563	hybrid, Green Published			2022-12-28	WOS:000318226100027
J	Violante, S; IJlst, L; Brinke, HT; de Almeida, IT; Wanders, RJA; Ventura, FV; Houten, SM				Violante, Sara; IJlst, Lodewijk; Brinke, Heleen te; de Almeida, Isabel Tavares; Wanders, Ronald J. A.; Ventura, Fatima V.; Houten, Sander M.			Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines	FASEB JOURNAL			English	Article						mitochondrial fatty acid beta-oxidation; Acyl-CoA metabolites	RAT-LIVER MITOCHONDRIA; FATTY-ACID OXIDATION; ORGANIC CATION/CARNITINE TRANSPORTER; ADENINE-NUCLEOTIDE TRANSLOCASE; BETA-OXIDATION; COENZYME-A; OCTN2; INHIBITION; DIAGNOSIS; LONG	Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid beta-oxidation disorders (mFAODs). It is generally assumed that this plasma acylcarnitine profile reflects the mitochondrial accumulation of acyl-CoAs. The identity of the enzymes and the mitochondrial and plasmalemmal transporters involved in the synthesis and export of these metabolites have remained undefined. We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts. These cell lines, including mock-transduced controls, were loaded with decanoic acid and carnitine, followed by the measurement of the acylcarnitine profile in the extracellular medium. In control fibroblasts, MCAD knockdown markedly increased the production of octanoylcarnitine (3-fold, P<0.01). OCTN2-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on OCTN2. In contrast, in CPT2- and CACT-deficient cells, the accumulation of octanoylcarnitine in the medium did not significantly increase in the MCAD knockdown. Similar results were obtained using pharmacological inhibition of CPT2 in fibroblasts from MCAD-deficient individuals. This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.	[Violante, Sara; de Almeida, Isabel Tavares; Ventura, Fatima V.] Univ Lisbon, Fac Farm, Metab & Genet Grp, Res Inst Med & Pharmaceut Sci IMed UL, P-1649003 Lisbon, Portugal; [Violante, Sara; IJlst, Lodewijk; Brinke, Heleen te; Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Dept Clin Chem & Pediat, Lab Genet Metab Dis, Amsterdam, Netherlands	Universidade de Lisboa; University of Amsterdam	Ventura, FV (corresponding author), Univ Lisbon, Fac Farm, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal.	fatima.ventura@ff.ul.pt	de Almeida, Isabel Tavares/F-8319-2014; Houten, Sander/Y-3599-2019; iMed.ULisboa, MetGen/B-5293-2014; Ventura, Fátima/F-7211-2015	Houten, Sander/0000-0002-6167-9147; Ventura, Fátima/0000-0002-5699-0387; Tavares de Almeida, Isabel/0000-0002-4024-8305	Fundacao para a Ciencia e Tecnologia (Lisbon, Portugal); Netherlands Organization for Scientific Research (VIDI grant) [016.086.336];  [SFRH/BD/38074/2007]	Fundacao para a Ciencia e Tecnologia (Lisbon, Portugal)(Portuguese Foundation for Science and Technology); Netherlands Organization for Scientific Research (VIDI grant); 	The authors gratefully acknowledge Jos Ruiter for the assistance with the HPLC measurements and helpful discussions and Prof. Marinus Duran for his valuable comments and suggestions throughout the development of the experimental work. Part of this work was financially supported by Fundacao para a Ciencia e Tecnologia (Lisbon, Portugal), by a grant awarded to S.V. (SFRH/BD/38074/2007), and by the Netherlands Organization for Scientific Research (VIDI grant 016.086.336 to S.M.H.).	BELL FP, 1980, ATHEROSCLEROSIS, V37, P21, DOI 10.1016/0021-9150(80)90090-8; Chegary M, 2008, MOL GENET METAB, V93, P403, DOI 10.1016/j.ymgme.2007.11.001; FRITZ IB, 1963, ADV LIPID RES, V1, P285; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; Indiveri C, 2011, MOL ASPECTS MED, V32, P223, DOI 10.1016/j.mam.2011.10.008; JENKINS DL, 1985, J BIOL CHEM, V260, P4748; Longo N, 2006, AM J MED GENET C, V142C, P77, DOI 10.1002/ajmg.c.30087; MALOY SR, 1981, J BIOL CHEM, V256, P3735; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Ohashi R, 2002, J PHARMACOL EXP THER, V302, P1286, DOI 10.1124/jpet.102.036004; Pasquali M, 2006, AM J MED GENET C, V142C, P64, DOI 10.1002/ajmg.c.30086; Pochini L, 2004, BBA-BIOMEMBRANES, V1661, P78, DOI 10.1016/j.bbamem.2003.12.001; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Rinaldo P, 2008, GENET MED, V10, P151, DOI 10.1097/GIM.0b013e3181614289; Schaefer J, 1997, J NEUROL NEUROSUR PS, V62, P169, DOI 10.1136/jnnp.62.2.169; Sim KG, 2002, CLIN CHIM ACTA, V323, P37, DOI 10.1016/S0009-8981(02)00182-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; VAARTJES WJ, 1972, FEBS LETT, V23, P303, DOI 10.1016/0014-5793(72)80302-8; Ventura FV, 2007, BIOCHEM BIOPH RES CO, V352, P873, DOI 10.1016/j.bbrc.2006.11.109; Ventura FV, 2005, MOL GENET METAB, V86, P344, DOI 10.1016/j.ymgme.2005.07.030; Ventura FV, 1998, EUR J BIOCHEM, V253, P614, DOI 10.1046/j.1432-1327.1998.2530614.x; Violante S, 2010, BBA-MOL BASIS DIS, V1802, P728, DOI 10.1016/j.bbadis.2010.06.002; Vreken P, 1999, J INHERIT METAB DIS, V22, P302, DOI 10.1023/A:1005587617745; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	30	42	44	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2013	27	5					2039	2044		10.1096/fj.12-216689	http://dx.doi.org/10.1096/fj.12-216689			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23322164				2022-12-28	WOS:000318226100023
J	Wu, QF; Hwang, CK; Zheng, H; Wagley, Y; Lin, HY; Kim, DK; Law, PY; Loh, HH; Wei, LN				Wu, Qifang; Hwang, Cheol Kyu; Zheng, Hui; Wagley, Yadav; Lin, Hong-Yiou; Kim, Do Kyung; Law, Ping-Yee; Loh, Horace H.; Wei, Li-Na			MicroRNA 339 down-regulates mu-opioid receptor at the post-transcriptional level in response to opioid treatment	FASEB JOURNAL			English	Article						fentanyl; morphine; promoter; UTR	ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; UP-REGULATION; PROMOTER; GENE; TRANSCRIPTION; IDENTIFICATION; INVOLVEMENT; FENTANYL; EXPRESSION	mu-Opioid receptor (MOR) level is directly related to the function of opioid drugs, such as morphine and fentanyl. Although agonist treatment generally does not affect transcription of mor, previous studies suggest that morphine can affect the translation efficiency of MOR transcript via microRNAs (miRNAs). On the basis of miRNA microarray analyses of the hippocampal total RNA isolated from mice chronically treated with mu-opioid agonists, we found a miRNA (miR-339-3p) that was consistently and specifically increased by morphine (2-fold) and by fentanyl (3.8-fold). miR-339-3p bound to the MOR 3'-UTR and specifically suppressed reporter activity. Suppression was blunted by adding miR-339-3p inhibitor or mutating the miR-339-3p target site. In cells endogenously expressing MOR, miR-339-3p inhibited the production of MOR protein by destabilizing MOR mRNA. Up-regulation of miR-339-3p by fentanyl (EC50=0.75 nM) resulted from an increase in primary miRNA transcript. Mapping of the miR-339-3p primary RNA and its promoter revealed that the primary miR-339-3p was embedded in a noncoding 3'-UTR region of an unknown host gene and was coregulated by the host promoter. The identified promoter was activated by opioid agonist treatment (10 nM fentanyl or 10 mu M morphine), a specific effect blocked by the opioid antagonist naloxone (10 mu M). Taken together, these results suggest that miR-339-3p may serve as a negative feedback modulator of MOR signals by regulating intracellular MOR biosynthesis.-Wu, Q., Hwang, C. K., Zheng, H., Wagley, Y., Lin, H.-Y., Kim, D. K., Law, P.-Y., Loh, H. H., Wei, L.-N. MicroRNA 339 downregulates mu opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB J. 27, 522-535 (2013). www.fasebj.org	[Wu, Qifang; Hwang, Cheol Kyu; Zheng, Hui; Wagley, Yadav; Lin, Hong-Yiou; Kim, Do Kyung; Law, Ping-Yee; Loh, Horace H.; Wei, Li-Na] Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hwang, CK (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	hwang025@umn.edu		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	U.S. National Institutes of Health, National Institute of Drug Abuse [DA000564, DA001583, DA011806, DA011190, DA013926]; A&F Stark Fund of the Minnesota Medical Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, R01DA000564, K02DA013926, P50DA011806, R01DA001583, R56DA000564, R37DA001583] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Drug Abuse; A&F Stark Fund of the Minnesota Medical Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Dr. Tracy Kuhlman and Mr. Bradley J. Stish for editorial assistance with the manuscript. This work was supported by the U.S. National Institutes of Health, National Institute of Drug Abuse (grants DA000564, DA001583, DA011806, DA011190, and DA013926); and by the A&F Stark Fund of the Minnesota Medical Foundation. The authors declare no conflicts of interest.	Afify EA, 2002, MOL BRAIN RES, V106, P83, DOI 10.1016/S0169-328X(02)00414-X; Akan P, 2008, GENE, V410, P165, DOI 10.1016/j.gene.2007.12.011; Binyaminy B, 2008, LIFE SCI, V82, P831, DOI 10.1016/j.lfs.2008.01.015; BRODSKY M, 1995, NEUROREPORT, V6, P725, DOI 10.1097/00001756-199503270-00005; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; Chen HC, 1999, NEUROSCIENCE, V92, P1143, DOI 10.1016/S0306-4522(99)00030-5; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010; Huang HY, 2006, NUCLEIC ACIDS RES, V34, pW429, DOI 10.1093/nar/gkl333; Hwang CK, 2007, MOL CELL BIOL, V27, P4720, DOI 10.1128/MCB.00073-07; Hwang CK, 2011, NEUROMETHODS, V60, P49, DOI 10.1007/978-1-61779-179-6_4; Hwang CK, 2010, MOL PHARMACOL, V78, P58, DOI 10.1124/mol.110.064311; Hwang CK, 2009, J CELL MOL MED, V13, P3591, DOI 10.1111/j.1582-4934.2008.00535.x; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Im HJ, 2001, MOL PHARMACOL, V59, P1486, DOI 10.1124/mol.59.6.1486; Jalali A, 2011, J NEUROSCI RES, V89, P299, DOI 10.1002/jnr.22562; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Karaji AG, 2005, INT IMMUNOPHARMACOL, V5, P1019, DOI 10.1016/j.intimp.2005.01.012; Kelkar YD, 2010, GENOME BIOL EVOL, V2, P620, DOI 10.1093/gbe/evq046; Kim CS, 2008, BBA-MOL CELL RES, V1783, P1835, DOI 10.1016/j.bbamcr.2008.06.019; Kim DK, 2011, J NEUROCHEM, V116, P1077, DOI 10.1111/j.1471-4159.2010.07163.x; Koch T, 1997, J NEUROCHEM, V69, P1767; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Law P.-Y., 2011, OPIATE RECEPTORS, V23; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, GENE, V295, P97, DOI 10.1016/S0378-1119(02)00825-9; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Reese MG, 2001, COMPUT CHEM, V26, P51, DOI 10.1016/S0097-8485(01)00099-7; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Solovyev VV, 2010, METHODS MOL BIOL, V674, P57, DOI 10.1007/978-1-60761-854-6_5; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; van Rooij E, 2011, CIRC RES, V108, P219, DOI 10.1161/CIRCRESAHA.110.227496; Wagley Y, 2007, BIOCHEM BIOPH RES CO, V354, P985, DOI 10.1016/j.bbrc.2007.01.083; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wei LN, 2011, ANNU REV PHARMACOL, V51, P75, DOI 10.1146/annurev-pharmtox-010510-100605; Wu H, 2010, BIOSTATISTICS, V11, P499, DOI 10.1093/biostatistics/kxq005; Wu QF, 2005, MOL PHARMACOL, V68, P279, DOI 10.1124/mol.105.012567; Wu QF, 2009, MOL PHARMACOL, V75, P744, DOI 10.1124/mol.108.053462; Wu QF, 2008, FASEB J, V22, P4085, DOI 10.1096/fj.08-108175; Xiong HP, 2009, BIOCHEM BIOPH RES CO, V378, P883, DOI 10.1016/j.bbrc.2008.12.010; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	61	54	60	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					522	535		10.1096/fj.12-213439	http://dx.doi.org/10.1096/fj.12-213439			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085997	Green Published			2022-12-28	WOS:000314358000012
J	Yadaiah, M; Sudhamalla, B; Rao, PN; Roy, KR; Ramakrishna, D; Syed, GH; Ramaiah, KVA; Bhuyan, AK				Yadaiah, Madasu; Sudhamalla, Babu; Rao, P. Nageswara; Roy, Karnati R.; Ramakrishna, Dasari; Syed, Gulam Hussain; Ramaiah, Kolluru V. A.; Bhuyan, Abani K.			Arrested cell proliferation through cysteine protease activity of eukaryotic ribosomal protein S4	FASEB JOURNAL			English	Article						Turner syndrome; human embryonic kidney cells	CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BLEOMYCIN HYDROLASE; ANGSTROM RESOLUTION; EXTRARIBOSOMAL FUNCTIONS; 30S SUBUNIT; RNA; EXPRESSION; DNA; TRANSCRIPTION	S4 is an integral protein of the smaller subunit of cytosolic ribosome. In prokaryotes, it regulates the synthesis of ribosomal proteins by feedback inhibition of the alpha-operon gene expression, and it facilitates ribosomal RNA synthesis by direct binding to RNA polymerase. However, functional roles of S4 in eukaryotes are poorly understood, although its deficiency in humans is thought to produce Turner syndrome. We report here that wheat S4 is a cysteine protease capable of abrogating total protein synthesis in an actively translating cell-free system of rabbit reticulocytes. The translation-blocked medium, imaged by atomic force microscopy, scanning electron microscopy, and transmission electron microscopy, shows dispersed polysomes, and the disbanded polyribosome elements aggregate to form larger bodies. We also show that human embryonic kidney cells transfected with recombinant wheat S4 are unable to grow and proliferate. The mutant S4 protein, where the putative active site residue Cys 41 is replaced by a phenylalanine, can neither suppress protein synthesis nor arrest cell proliferation, suggesting that the observed phenomenon arises from the cysteine protease attribute of S4. The results also inspire many questions concerning in vivo significance of extraribosomal roles of eukaryotic S4 performed through its protease activity.-Yadaiah, M., Sudhamalla, B., Rao, P. N., Roy, K. R., Ramakrishna, D., Hussain Syed, G., Ramaiah, K. V. A., Bhuyan, A. K. Arrested cell proliferation through cysteine protease activity of eukaryotic ribosomal protein S4. FASEB J. 27, 803-810 (2013). www.fasebj.org	[Yadaiah, Madasu; Sudhamalla, Babu; Rao, P. Nageswara; Ramakrishna, Dasari; Bhuyan, Abani K.] Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India; [Roy, Karnati R.; Syed, Gulam Hussain; Ramaiah, Kolluru V. A.; Bhuyan, Abani K.] Univ Hyderabad, Sch Life Sci, Hyderabad 500046, Andhra Pradesh, India	University of Hyderabad; University of Hyderabad	Bhuyan, AK (corresponding author), Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India.	akbsc@uohyd.ernet.in	Syed, Gulam/N-7842-2013; Madasu, Yadaiah/G-5031-2013	Madasu, Yadaiah/0000-0002-3536-6905; Syed, Gulam/0000-0001-8540-6162; Ramaiah, Kolluru/0000-0002-3478-5294	India Council of Scientific and Industrial Research [38(1037)/02/EMR-II]; Department of Biotechnology [BRB/10/622/2008]; Department of Science and Technology (DST) [4/1/2003-SF]; DST Promotion of University Research and Scientific Excellence (PURSE) funds	India Council of Scientific and Industrial Research; Department of Biotechnology; Department of Science and Technology (DST)(Department of Science & Technology (India)); DST Promotion of University Research and Scientific Excellence (PURSE) funds	This research was supported by grants from the India Council of Scientific and Industrial Research [38(1037)/02/EMR-II], the Department of Biotechnology (BRB/10/622/2008), and the Department of Science and Technology (DST; 4/1/2003-SF) to A. K. B. and by DST Promotion of University Research and Scientific Excellence (PURSE) funds to K.R.R.	Adilakshmi T, 2008, NATURE, V455, P1268, DOI 10.1038/nature07298; Armache JP, 2010, P NATL ACAD SCI USA, V107, P19748, DOI 10.1073/pnas.1009999107; Armache JP, 2010, P NATL ACAD SCI USA, V107, P19754, DOI 10.1073/pnas.1010005107; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Becker T, 2012, NATURE, V482, P501, DOI 10.1038/nature10829; BRAUN HP, 1994, BBA-GENE STRUCT EXPR, V1218, P435, DOI 10.1016/0167-4781(94)90200-3; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; DEAN D, 1980, P NATL ACAD SCI-BIOL, V77, P3590, DOI 10.1073/pnas.77.6.3590; Doudna JA, 2002, CELL, V109, P153, DOI 10.1016/S0092-8674(02)00725-0; Flygare J, 2007, BLOOD, V109, P980, DOI 10.1182/blood-2006-07-038232; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; Klinge S, 2011, SCIENCE, V334, P941, DOI 10.1126/science.1211204; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Maisnier-Patin S, 2007, J MOL BIOL, V366, P207, DOI 10.1016/j.jmb.2006.11.047; Mulder AM, 2010, SCIENCE, V330, P673, DOI 10.1126/science.1193220; NOWOTNY V, 1988, BIOCHEMISTRY-US, V27, P7051, DOI 10.1021/bi00418a057; O'Farrell PA, 1999, STRUCT FOLD DES, V7, P619, DOI 10.1016/S0969-2126(99)80083-5; Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200; Rzychon M, 2004, ACTA BIOCHIM POL, V51, P861; Sayers EW, 2000, BIOCHEMISTRY-US, V39, P13602, DOI 10.1021/bi0013391; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schumacher AM, 2006, BIOCHEMISTRY-US, V45, P13614, DOI 10.1021/bi060413y; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; Torres M, 2001, EMBO J, V20, P3811, DOI 10.1093/emboj/20.14.3811; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Yadaiah M, 2012, PROTEIN EXPRES PURIF, V81, P55, DOI 10.1016/j.pep.2011.09.003; YATES JL, 1980, CELL, V21, P517, DOI 10.1016/0092-8674(80)90489-4; YATES JL, 1980, P NATL ACAD SCI-BIOL, V77, P1837, DOI 10.1073/pnas.77.4.1837; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zheng WJ, 1998, MOL CELL BIOL, V18, P3580, DOI 10.1128/MCB.18.6.3580; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485	36	3	3	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2013	27	2					803	810		10.1096/fj.12-217752	http://dx.doi.org/10.1096/fj.12-217752			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118024				2022-12-28	WOS:000314358000038
J	Philip, F; Guo, YJ; Aisiku, O; Scarlata, S				Philip, Finly; Guo, Yuanjian; Aisiku, Omoz; Scarlata, Suzanne			Phospholipase C beta 1 is linked to RNA interference of specific genes through translin-associated factor X	FASEB JOURNAL			English	Article						G protein signaling; RNA transcription; histone H2B	C BETA-1; EXPRESSION; BRAIN; TRAX; MICE; ACTIVATION; COMPLEX; ROLES; MODEL; C3PO	Phospholipase C beta 1 (PLC beta 1) is a G-protein-regulated enzyme whose activity results in proliferative and mitogenic changes in the cell. We have previously found that in solution PLC beta 1 binds to the RNA processing protein translin-associated factor X (TRAX) with nanomolar affinity and that this binding competes with G proteins. Here, we show that endogenous PLC beta 1 and TRAX interact in SK-N-SH cells and also in HEK293 cells induced to overexpress PLC beta 1. In HEK293 cells, TRAX overexpression ablates Ca2+ signals generated by G protein-PLC beta 1 activation. TRAX plays a key role in down-regulation of proteins by small, interfering RNA, and PLC beta 1 overexpression completely reverses the 2- to 4-fold down-regulation of GAPDH by siRNA in HEK293 and HeLa cells as seen by an similar to 4-fold recovery in both the transcript and protein levels. Also, down-regulation of endogenous PLC beta 1 in HEK293 and HeLa cells allows for an similar to 20% increase in siRNA(GAPDH) silencing. While PLC beta 1 overexpression results in a 50% reversal of cell death caused by siRNA(LDH), it does not affect cell survival or silencing of other genes (e. g., cyclophilin, Hsp90, translin). PLC beta 1 overexpression in HEK293 and HeLa cells causes a 30% reduction in the total amount of small RNAs. LDH and GAPDH are part of a complex that promotes H2B synthesis that allows cells to progress through the S phase. We find that PLC beta 1 reverses the cell death and completely rescues H2B levels caused by siRNA knockdown of LDH or GAPDH. Taken together, our study shows a novel role of PLC beta 1 in gene regulation through TRAX association.-Philip, F., Guo, Y., Aisiku, O., Scarlata, S. Phospholipase C beta 1 is linked to RNA interference of specific genes through translin-associated factor X. FASEB J. 26, 4903-4913 (2012). www.fasebj.org	[Philip, Finly; Guo, Yuanjian; Aisiku, Omoz; Scarlata, Suzanne] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Basic Sci Tower T6-146, Stony Brook, NY 11794 USA.	suzanne.scarlata@stonybrook.edu			U.S. National Institutes of Health [GM53132]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful to Loren Runnels (University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA) for the HEK293-TAP-PLC beta 1 cells, to Catherine Berlot (Geisinger Research Center, Danville, PA, USA) for the G alpha<INF>q</INF>(RC) construct, to Izolda Mileva (Stony Brook University) for her assistance in the RT-PCR studies, and to Urszula Golebiewska and Mario Rebecchi (Stony Brook University) for critically reading this paper. This work was supported by U.S. National Institutes of Health grant GM53132.	Aisiku OR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015001; Chennathukuzhi V, 2003, MOL CELL BIOL, V23, P6419, DOI 10.1128/MCB.23.18.6419-6434.2003; Cho YS, 2004, J BIOL CHEM, V279, P31514, DOI 10.1074/jbc.M401442200; Cocco L, 2002, ADV ENZYME REGUL, V42, P181, DOI 10.1016/S0065-2571(01)00030-9; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; Cocco L, 2006, BBA-MOL CELL BIOL L, V1761, P509, DOI 10.1016/j.bbalip.2006.03.001; Dai RP, 2008, J BIOL CHEM, V283, P26894, DOI 10.1074/jbc.M804307200; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Faenza I, 2002, BBA-MOL CELL RES, V1589, P305, DOI 10.1016/S0167-4889(02)00192-1; Follo MY, 2009, J CLIN ONCOL, V27, P782, DOI 10.1200/JCO.2008.19.3748; Guo YJ, 2005, J BIOL CHEM, V280, P1438, DOI 10.1074/jbc.M407593200; Guo YJ, 2011, BIOPHYS J, V100, P1599, DOI 10.1016/j.bpj.2011.02.013; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jaendling A, 2010, BIOCHEM J, V429, P225, DOI 10.1042/BJ20100273; Kawamata T, 2010, TRENDS BIOCHEM SCI, V35, P368, DOI 10.1016/j.tibs.2010.03.009; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LEE YM, 2000, LIFE SCI, V56, P67; Li Z, 2008, BBA-GENE REGUL MECH, V1779, P479, DOI 10.1016/j.bbagrm.2008.03.008; Liu Y, 2009, SCIENCE, V325, P750, DOI 10.1126/science.1176325; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McOmish CE, 2008, HIPPOCAMPUS, V18, P824, DOI 10.1002/hipo.20443; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; Siomi H, 2009, NAT CELL BIOL, V11, P1049, DOI 10.1038/ncb0909-1049; Stein JM, 2006, J NEUROSCI, V26, P2184, DOI 10.1523/JNEUROSCI.4437-05.2006; Suh PG, 2008, BMB REP, V41, P415, DOI 10.5483/BMBRep.2008.41.6.415; Tian Y, 2011, NAT STRUCT MOL BIOL, V18, P658, DOI 10.1038/nsmb.2069; Wang J, 2004, BIOCHEMISTRY-US, V43, P13424, DOI 10.1021/bi048847l; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Yang SC, 2004, J BIOL CHEM, V279, P12605, DOI 10.1074/jbc.M313133200; Ye XC, 2011, NAT STRUCT MOL BIOL, V18, P650, DOI 10.1038/nsmb.2032; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	33	17	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4903	4913		10.1096/fj.12-213934	http://dx.doi.org/10.1096/fj.12-213934			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22889834	Green Published			2022-12-28	WOS:000311838300014
J	Zhou, P; Luo, Y; Liu, X; Fan, L; Lu, Y				Zhou, Peng; Luo, Yi; Liu, Xin; Fan, Lei; Lu, Yi			Down-regulation and CpG island hypermethylation of CRYAA in age-related nuclear cataract	FASEB JOURNAL			English	Article						alpha A-crystallin; bisulfite genomic sequencing; zebularine	ALPHA-B-CRYSTALLIN; C-TERMINAL TRUNCATION; A-CRYSTALLIN; CELL; ZEBULARINE	Age-related cataract (ARC) is the leading cause of blindness among older adults, and the chaperone-like activity of alpha A-crystallin (CRYAA) is considered to be critical for the maintenance of eye lens transparency. To assess the potential contribution of epigenetic regulation of CRYAA genes relevant to ARC pathogenesis, we evaluated DNA methylation, a tissue-specific genetic modulation that affects gene expression. Reverse-transcription PCR and Western blot were used to analyze the expression of CRYAA. Methylation status was analyzed by bisulfite genomic sequencing of the CpG islands in 15 eyes with age-related nuclear cataracts and 15 control eyes. The demethylating agent zebularine was used to investigate the relationship between hypermethylation of the CpG islands and down-expression of CRYAA. The mRNA and protein levels of CRYAA were significantly reduced in the lens epithelia of age-related nuclear cataract cases vs. age-matched controls, which corresponded to hypermethylation of the CpG island of CRYAA promoter. Treatment with a DNA-demethylating agent was associated with restoration of CRYAA expression. Comparing DNA methylation and mRNA and protein levels revealed significant differences between age-related nuclear cataract and control lenses. The evidence presented suggests that CRYAA undergoes epigenetic repression in the lens epithelia in age-related nuclear cataract.-Zhou, P., Luo, Y., Liu, X., Fan, L., Lu, Y. Down-regulation and CpG island hypermethylation of CRYAA in age-related nuclear cataract. FASEB J. 26, 4897-4902 (2012). www.fasebj.org	[Zhou, Peng; Luo, Yi; Liu, Xin; Lu, Yi] Fudan Univ, Eye & Ear Nose & Throat Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China; [Fan, Lei] Fudan Univ, Ctr Canc, Dept Breast Surg, Shanghai 200031, Peoples R China	Fudan University; Fudan University	Lu, Y (corresponding author), Fudan Univ, Eye & Ear Nose & Throat Hosp, Dept Ophthalmol, 83 Fenyang Rd, Shanghai 200031, Peoples R China.	luyi0705@yahoo.com.cn			National Natural Science Foundation of China [81200669, 81102003]; Program of Shanghai Subject Chief Scientist [11XD1401200]; Program of Shanghai 100 Medical Scientist [XBR2011056]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Shanghai Subject Chief Scientist; Program of Shanghai 100 Medical Scientist	This study was supported by grants from the National Natural Science Foundation of China (81200669 and 81102003), Program of Shanghai Subject Chief Scientist (11XD1401200), and Program of Shanghai 100 Medical Scientist (XBR2011056).	Andley UP, 2009, CURR MOL MED, V9, P887, DOI 10.2174/156652409789105598; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; Boyle Daniel L, 2003, BMC Ophthalmol, V3, P3, DOI 10.1186/1471-2415-3-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Chen Y, 2010, J INT MED RES, V38, P1016, DOI 10.1177/147323001003800328; Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449; KUPFER C, 1987, INVEST OPHTH VIS SCI, V28, P1; McCarthy N, 2012, NAT REV CANCER, V12, DOI [10.1038/nrc3222, 10.1038/nrc3227]; Richter GM, 2009, OPHTHALMOLOGY, V116, P2327, DOI 10.1016/j.ophtha.2009.05.040; Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; Su S, 2011, INVEST OPHTH VIS SCI, V52, P4182, DOI 10.1167/iovs.10-7094; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265; Wiggs JL, 2012, INVEST OPHTH VIS SCI, V53, P2467, DOI 10.1167/iovs.12-9483e; You QS, 2011, OPHTHALMOLOGY, V118, P1069, DOI 10.1016/j.ophtha.2010.09.032; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhou P, 2007, CURR EYE RES, V32, P973, DOI 10.1080/02713680701658323; Zhou P, 2012, MOL VIS, V18, P22; Zhou P, 2011, MOL VIS, V17, P2717; Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258	24	49	56	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4897	4902		10.1096/fj.12-213702	http://dx.doi.org/10.1096/fj.12-213702			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22889833				2022-12-28	WOS:000311838300013
J	Hu, XY; Schlanger, R; He, WX; Macklin, WB; Yan, RQ				Hu, Xiangyou; Schlanger, Rita; He, Wanxia; Macklin, Wendy B.; Yan, Riqiang			Reversing hypomyelination in BACE1-null mice with Akt-DD overexpression	FASEB JOURNAL			English	Article						BACE1; Alzheimer's beta-secretase; neuregulin-1; ErbB4; dominant gain of function	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; AXONAL-TRANSPORT; MYELINATION; NEUREGULIN-1; CLEAVAGE; PATHWAY	beta-Site amyloid precursor protein convertase enzyme 1 (BACE1), a type I transmembrane aspartyl protease required to cleave amyloid precursor protein for releasing a toxic amyloid peptide, also cleaves type I and type III neuregulin-1 (Nrg-1). BACE1 deficiency in mice causes hypomyelination during development and impairs remyelination if injured. In BACE1-null mice, the abolished cleavage of neuregulin-1 by BACE1 is speculated to cause reduced myelin sheath thickness in both the central nervous system and peripheral nervous system because reduced cleavage of Nrg-1 correlates with reduced Akt phosphorylation, a downstream signaling molecule of the Nrg-1/ErbB pathway. Here we tested specifically whether increasing Akt activity alone in oligodendrocytes would be sufficient to reverse the hypomyelination phenotype in BACE1-null mice. BACE1-null mice were bred with transgenic mice expressing constitutively active Akt (Akt-DD; mutations with (DT)-T-308 and (DS)-S-473) in oligodendrocytes. Relative to littermate BACE1-null controls, BACE1(-/-)/Akt-DD mice exhibited enhanced expression of myelin basic protein and promoter of proteolipid protein. The elevated expression of myelin proteins correlated with a thicker myelin sheath in optic nerves; comparison of quantified g ratios with statistic significance was used to confirm this reversion. However, it appeared that myelin sheath thickness in the sciatic nerves was not increased in BACE1(-/-)/Akt-DD mice, as the g ratio was not significantly different from the control. Hence, increased Akt activity in BACE1-null myelinating cells only compensates for the loss of BACE1 activity in the central nervous system, which is consistent with the observation that overexpression of Akt-DD in Schwann cells did not induce hypermyelination. Our results suggest that signaling activity other than Akt may also contribute to proper myelination in peripheral nerves.	[Hu, Xiangyou; Schlanger, Rita; He, Wanxia; Yan, Riqiang] Cleveland Clin, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; [Macklin, Wendy B.] Univ Colorado, Denver Hlth Sci Ctr, Dept Cell & Dev Biol, Aurora, CO USA	Cleveland Clinic Foundation; University of Colorado System; University of Colorado Anschutz Medical Campus	Yan, RQ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave NC30, Cleveland, OH 44195 USA.	yanr@ccf.org		Yan, Riqiang/0000-0001-7195-7617	U.S. National Institutes of Health [NS-074256]; National Multiple Sclerosis Society [RG-4012A1/1]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056417, R01NS074256, R01NS025304] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank M. Yin (Electron Microscopy Facility, Cleveland Clinic Foundation, Cleveland, OH, USA) for assistance in electron microscopic analysis. This study was supported by U.S. National Institutes of Health grant NS-074256 (to R.Y.) and National Multiple Sclerosis Society grant RG-4012A1/1 (to R.Y.). The authors declare no conflicts of interests.	Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Barros CS, 2009, DEVELOPMENT, V136, P2717, DOI 10.1242/dev.038679; Brinkmann BG, 2008, NEURON, V59, P581, DOI 10.1016/j.neuron.2008.06.028; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chen S, 2006, J NEUROSCI, V26, P3079, DOI 10.1523/JNEUROSCI.3785-05.2006; Corfas G, 2004, NAT NEUROSCI, V7, P575, DOI 10.1038/nn1258; Cotter L, 2010, SCIENCE, V328, P1415, DOI 10.1126/science.1187735; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Flores AI, 2008, J NEUROSCI, V28, P7174, DOI 10.1523/JNEUROSCI.0150-08.2008; Goebbels S, 2012, EMBO MOL MED, V4, P486, DOI 10.1002/emmm.201200227; Goebbels S, 2010, J NEUROSCI, V30, P8953, DOI 10.1523/JNEUROSCI.0219-10.2010; HAASS C, 1995, ARZNEIMITTEL-FORSCH, V45-1, P398; Hu XY, 2008, FASEB J, V22, P2970, DOI 10.1096/fj.08-106666; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; La Marca R, 2011, NAT NEUROSCI, V14, P857, DOI 10.1038/nn.2849; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Lemke G., 2006, SCI STKE, V2006, pe11; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo XY, 2011, J BIOL CHEM, V286, P23967, DOI 10.1074/jbc.M111.251538; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Macklin WB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3140pe32; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009; Navel KA, 2006, CURR OPIN NEUROBIOL, V16, P492, DOI 10.1016/j.conb.2006.08.008; Newbern J, 2010, SEMIN CELL DEV BIOL, V21, P922, DOI 10.1016/j.semcdb.2010.08.008; Park SK, 2001, DEV NEUROSCI-BASEL, V23, P327, DOI 10.1159/000048716; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Savonenko AV, 2008, P NATL ACAD SCI USA, V105, P5585, DOI 10.1073/pnas.0710373105; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Syed Neeraja, 2010, Mol Cell Pharmacol, V2, P161; Tao YM, 2009, P NATL ACAD SCI USA, V106, P9477, DOI 10.1073/pnas.0901844106; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Taveggia C, 2008, GLIA, V56, P284, DOI 10.1002/glia.20612; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	43	14	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1868	1873		10.1096/fj.12-224212	http://dx.doi.org/10.1096/fj.12-224212			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23335052	Green Published			2022-12-28	WOS:000318226100007
J	Kyle, BD; Hurst, S; Swayze, RD; Sheng, JZ; Braun, AP				Kyle, Barry D.; Hurst, Soleil; Swayze, Richard D.; Sheng, Jianzhong; Braun, Andrew P.			Specific phosphorylation sites underlie the stimulation of a large conductance, Ca2+-activated K+ channel by cGMP-dependent protein kinase	FASEB JOURNAL			English	Article						BK channel; protein kinase G; nitric oxide; smooth muscle; modulation	VASCULAR SMOOTH-MUSCLE; ACTIVATED POTASSIUM CHANNELS; NITRIC-OXIDE; SODIUM-NITROPRUSSIDE; BKCA CHANNELS; CELLS; RECONSTITUTION; ENHANCEMENT; MODULATION; INHIBITION	Smooth muscle contractility and neuronal excitability are regulated by large conductance, Ca2+-activated K+ (BKCa) channels, the activity of which can be increased after modulation by type I cGMP-dependent protein kinase (cGKI) via nitric oxide (NO)/cGMP signaling. Our study focused on identifying key phosphorylation sites within the BKCa channel underlying functional enhancement of channel activity by cGKI. BKCa channel phosphorylation by cGKI alpha was characterized biochemically using radiolabeled ATP, and regulation of channel activity by NO/cGMP signaling was quantified in rat aortic A7r5 smooth muscle cells by cell-attached patch-clamp recording. Serine to alanine substitutions at 3 of 6 putative cGKI phosphorylation sites (Ser691, Ser873, and Ser1112) in the BKCa alpha subunit individually reduced direct channel phosphorylation by 25-60% and blocked BKCa activation by either an NO donor or a membrane-permeable cGMP by 80-100%. Acute inhibition of cGKI prevented stimulus-evoked enhancement of BKCa channel activity. Our data further suggest that augmentation of BKCa activity by NO/cGMP/cGKI signaling requires phosphorylation at all 3 sites and is independent of elevations in [Ca2+](i). Phosphorylation of 3 specific Ser residues within the murine BKCa alpha subunit by cGKI alpha accounts for the enhanced BKCa channel activity induced by elevated [cGMP](i) in situ.	Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Libin Cardiovasc Res Inst, Calgary, AB T2N 4N1, Canada	University of Calgary; Libin Cardiovascular Institute Of Alberta; University of Calgary	Braun, AP (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	abraun@ucalgary.ca		Kyle, Barry/0000-0003-4304-5762	Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada; Kertland Family Fellowship Award; CIHR Rx&D Studentship Award	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Kertland Family Fellowship Award; CIHR Rx&D Studentship Award(Canadian Institutes of Health Research (CIHR))	The authors thank Connie Liao and Dr. Wayne Chen for their assistance with the Fura-2 imaging experiments and Dr. Michael Walsh for his critical reading of the manuscript. Technical advice provided by Cindy Sutherland regarding thin-layer electrophoresis and TLC protocols is appreciated. This work was supported by research funding from the Canadian Institutes of Health Research (CIHR) and Natural Sciences and Engineering Research Council of Canada (to A.P.B.). B.D.K. was supported in part by a Kertland Family Fellowship Award, and R.D.S. was supported in part by a CIHR Rx&D Studentship Award.	Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Brueggemann LI, 2006, J PHARMACOL EXP THER, V317, P488, DOI 10.1124/jpet.105.095067; Brueggemann LI, 2005, AM J PHYSIOL-HEART C, V288, pH923, DOI 10.1152/ajpheart.01126.2003; Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; CREST M, 1993, J PHYSIOL-LONDON, V465, P265, DOI 10.1113/jphysiol.1993.sp019676; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Erxleben C, 2003, P NATL ACAD SCI USA, V100, P2929, DOI 10.1073/pnas.2628046100; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Hanyaloglu AC, 2001, J BIOL CHEM, V276, P18066, DOI 10.1074/jbc.M009275200; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; Klyachko VA, 2001, NEURON, V31, P1015, DOI 10.1016/S0896-6273(01)00449-4; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Lang RJ, 1998, BRIT J PHARMACOL, V123, P505, DOI 10.1038/sj.bjp.0701605; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Lu G, 1998, AM J PHYSIOL-GASTR L, V274, pG848, DOI 10.1152/ajpgi.1998.274.5.G848; MOORE LK, 1995, AM J PHYSIOL-HEART C, V269, pH1481, DOI 10.1152/ajpheart.1995.269.4.H1481; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Nara M, 2000, AM J PHYSIOL-CELL PH, V279, pC1938, DOI 10.1152/ajpcell.2000.279.6.C1938; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; Peng W, 1996, J APPL PHYSIOL, V81, P1264, DOI 10.1152/jappl.1996.81.3.1264; Petkov GV, 2001, J PHYSIOL-LONDON, V537, P443, DOI 10.1111/j.1469-7793.2001.00443.x; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Shipston MJ, 2001, TRENDS CELL BIOL, V11, P353, DOI 10.1016/S0962-8924(01)02068-2; Swayze RD, 2001, J BIOL CHEM, V276, P19729, DOI 10.1074/jbc.M005711200; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Yamakage M, 1996, AM J PHYSIOL-LUNG C, V270, pL338, DOI 10.1152/ajplung.1996.270.3.L338; Yan JS, 2008, MOL CELL PROTEOMICS, V7, P2188, DOI 10.1074/mcp.M800063-MCP200; Yuan P, 2010, SCIENCE, V329, P182, DOI 10.1126/science.1190414; Zhou XB, 2001, J BIOL CHEM, V276, P43239, DOI 10.1074/jbc.M104202200; Zhou XB, 2010, P NATL ACAD SCI USA, V107, P8005, DOI 10.1073/pnas.0912029107	48	34	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2027	2038		10.1096/fj.12-223669	http://dx.doi.org/10.1096/fj.12-223669			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23407708				2022-12-28	WOS:000318226100022
J	Weng, TT; Karmouty-Quintana, H; Garcia-Morales, LJ; Molina, JG; Pedroza, M; Bunge, RR; Bruckner, BA; Loebe, M; Seethamraju, H; Blackburn, MR				Weng, Tingting; Karmouty-Quintana, Harry; Garcia-Morales, Luis J.; Molina, Jose G.; Pedroza, Mesias; Bunge, Raquel R.; Bruckner, Brian A.; Loebe, Matthias; Seethamraju, Harish; Blackburn, Michael R.			Hypoxia-induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease	FASEB JOURNAL			English	Article						COPD; deoxyadenosine; emphysema; adenosine deaminase	ADENOSINE-DEAMINASE DEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; HIF-DEPENDENT INDUCTION; ACTIVATION; PULMONARY; GEMCITABINE; CANCER; INHIBITION; CELLS; CD73	Chronic obstructive pulmonary disease (COPD) is characterized by persistent inflammation and tissue remodeling and is a leading cause of death in the United States. Increased apoptosis of pulmonary epithelial cells is thought to play a role in COPD development and progression. Identification of signaling pathways resulting in increased apoptosis in COPD can be used in the development of novel therapeutic interventions. Deoxyadenosine (dAdo) is a DNA breakdown product that amplifies lymphocyte apoptosis by being phosphorylated to deoxyadenosine triphosphate (dATP). dAdo is maintained at low levels by adenosine deaminase (ADA). This study demonstrated that mice lacking ADA developed COPD manifestations in association with elevated dAdo and dATP levels and increased apoptosis in the lung. Deoxycitidine kinase (DCK), a major enzyme for dAdo phosphorylation, was up-regulated in mouse and human airway epithelial cells in association with air-space enlargement. Hypoxia was identified as a novel regulator of DCK, and inhibition of DCK resulted in diminished dAdo-mediated apoptosis in the lungs. Our results suggest that activating the dAdo-DCK-dATP pathway directly results in increased apoptosis in the lungs of mice with air-space enlargement and suggests a novel therapeutic target for the treatment of COPD.	[Weng, Tingting; Karmouty-Quintana, Harry; Molina, Jose G.; Pedroza, Mesias; Blackburn, Michael R.] Univ Texas Houston, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Garcia-Morales, Luis J.; Bunge, Raquel R.; Bruckner, Brian A.; Loebe, Matthias] Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX 77030 USA; [Bruckner, Brian A.; Loebe, Matthias; Seethamraju, Harish] Methodist Hosp, Methodist JC Walter Jr Transplant Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; The Methodist Hospital System; The Methodist Hospital - Houston	Blackburn, MR (corresponding author), Univ Texas Houston, Sch Med, 6431 Fannin, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	Karmouty-Quintana, Harry/ABC-9144-2020	Karmouty-Quintana, Harry/0000-0003-4753-9823; Blackburn, Michael/0000-0002-1394-9966	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070952, P01HL114457] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL114457, R01 HL070952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2005, ADV IMMUNOL, V86, P1, DOI 10.1016/S0065-2776(04)86001-2; Blackburn MR, 2003, TRENDS PHARMACOL SCI, V24, P66, DOI 10.1016/S0165-6147(02)00045-7; Blackburn MR, 1996, PROG NUCLEIC ACID RE, V55, P195, DOI 10.1016/S0079-6603(08)60194-4; Chen Y, 2012, BIOINFORMATICS, V28, P1, DOI 10.1093/bioinformatics/btr619; COHEN A, 1983, J BIOL CHEM, V258, P2334; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Csapo Z, 2003, BIOCHEM PHARMACOL, V65, P2031, DOI 10.1016/S0006-2952(03)00182-5; Demedts IK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-53; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Ge YB, 2003, J BIOL CHEM, V278, P49901, DOI 10.1074/jbc.M305085200; Geutjes EJ, 2012, BREAST CANCER RES TR, V131, P809, DOI 10.1007/s10549-011-1477-3; Girard N, 2007, B CANCER, V94, pS127; Grenz A, 2011, ANTIOXID REDOX SIGN, V15, P2221, DOI 10.1089/ars.2010.3665; Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617; Hilbig A, 2008, EXPERT REV ANTICANC, V8, P511, DOI 10.1586/14737140.8.4.511; Jiang H, 2010, ACTA BIOCH BIOPH SIN, V42, P483, DOI 10.1093/abbs/gmq041; Joachims ML, 2008, NUCLEOS NUCLEOT NUCL, V27, P816, DOI 10.1080/15257770802146270; Joachims ML, 2008, J IMMUNOL, V181, P8153, DOI 10.4049/jimmunol.181.11.8153; Jones J, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13suppl2/01; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Keszler G, 2004, NUCLEOS NUCLEOT NUCL, V23, P1335, DOI 10.1081/NCN-200027586; Koeppen M, 2011, CURR OPIN ANESTHESIO, V24, P363, DOI 10.1097/ACO.0b013e32834873fd; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Li XB, 2006, MICROVASC RES, V72, P48, DOI 10.1016/j.mvr.2006.04.005; Minet E, 2000, INT J MOL MED, V5, P253; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Robak T, 2005, DRUG AGING, V22, P983, DOI 10.2165/00002512-200522120-00002; Sebastiani V, 2006, CLIN CANCER RES, V12, P2492, DOI 10.1158/1078-0432.CCR-05-2655; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Sigmond J, 2010, ANTI-CANCER DRUG, V21, P591, DOI 10.1097/CAD.0b013e32833a3543; Spasokoukotskaja T, 1998, ADV EXP MED BIOL, V431, P641; SPASOKOUKOTSKAJA T, 1995, EUR J CANCER, V31A, P202, DOI 10.1016/0959-8049(94)00435-8; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Toy G, 2010, P NATL ACAD SCI USA, V107, P5551, DOI 10.1073/pnas.0913900107; Van den Neste E, 2003, BIOCHEM PHARMACOL, V65, P573, DOI 10.1016/S0006-2952(02)01559-9; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Yang MX, 2010, IMMUNOL CELL BIOL, V88, P165, DOI 10.1038/icb.2009.77; Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224; Zhou Y, 2009, PHARMACOL THERAPEUT, V123, P105, DOI 10.1016/j.pharmthera.2009.04.003	46	14	14	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2013	2026		10.1096/fj.12-222067	http://dx.doi.org/10.1096/fj.12-222067			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23392349	Green Published			2022-12-28	WOS:000318226100021
J	Younan, ND; Sarell, CJ; Davies, P; Brown, DR; Viles, JH				Younan, Nadine D.; Sarell, Claire J.; Davies, Paul; Brown, David R.; Viles, John H.			The cellular prion protein traps Alzheimer's A beta in an oligomeric form and disassembles amyloid fibers	FASEB JOURNAL			English	Article						PrP; structure; NMR; electron microscopy; IR; antiparallel beta sheet	DISEASE; TOXICITY; BINDING; IONS; A-BETA(1-42); ASSOCIATION; IMPAIRMENT; PARKINSONS; PLASTICITY; CLEAVAGE	There is now strong evidence to show that the presence of the cellular prion protein (PrPC) mediates amyloid-beta (A beta) neurotoxicity in Alzheimer's disease (AD). Here, we probe the molecular details of the interaction between PrPC and A beta and discover that substoichiometric amounts of PrPC, as little as 1/20, relative to A beta will strongly inhibit amyloid fibril formation. This effect is specific to the unstructured N-terminal domain of PrPC. Electron microscopy indicates PrPC is able to trap A beta in an oligomeric form. Unlike fibers, this oligomeric A beta contains antiparallel beta sheet and binds to a oligomer specific conformational antibody. Our NMR studies show that a specific region of PrPC, notably residues 95-113, binds to A beta oligomers, but only once A beta misfolds. The ability of PrPC to trap and concentrate A beta in an oligomeric form and disassemble mature fibers suggests a mechanism by which PrPC might confer A beta toxicity in AD, as oligomers are thought to be the toxic form of A beta. Identification of a specific recognition site on PrPC that traps A beta in an oligomeric form is potentially a therapeutic target for the treatment of Alzheimer's disease.-Younan, N. D., Sarell, C. J., Davies, P., Brown, D. R., Viles, J. H. The cellular prion protein traps Alzheimer's A beta in an oligomeric form and disassembles amyloid fibers. FASEB J. 27, 1847-1858 (2013). www.fasebj.org	[Younan, Nadine D.; Sarell, Claire J.; Viles, John H.] Univ London, Sch Biol & Chem Sci, London E1 4NS, England; [Davies, Paul; Brown, David R.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of London; University of Bath	Viles, JH (corresponding author), Univ London, Mile End Rd, London E1 4NS, England.	j.viles@qmul.ac.uk		Davies, Paul/0000-0001-8022-2719	Wellcome Trust project [093241/Z/10/Z]; UK Biotechnology and Biological Sciences Research Council Quota studentships; Biotechnology and Biological Sciences Research Council [BB/D005027/1, 978364] Funding Source: researchfish; Medical Research Council [MC_U117533887] Funding Source: researchfish; BBSRC [BB/D005027/1] Funding Source: UKRI; MRC [MC_U117533887] Funding Source: UKRI	Wellcome Trust project(Wellcome Trust); UK Biotechnology and Biological Sciences Research Council Quota studentships(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Wellcome Trust project grant (093241/Z/10/Z) and UK Biotechnology and Biological Sciences Research Council Quota studentships. The authors thank Harold Toms (Queen Mary, University of London) and the UK National Institute for Medical Research for NMR support, and Graham McPhail for assistance with TEM.	Andreetto E, 2010, ANGEW CHEM INT EDIT, V49, P3081, DOI 10.1002/anie.200904902; Balducci C, 2010, P NATL ACAD SCI USA, V107, P2295, DOI 10.1073/pnas.0911829107; Barry AE, 2011, J NEUROSCI, V31, P7259, DOI 10.1523/JNEUROSCI.6500-10.2011; Bate C, 2011, J BIOL CHEM, V286, P37955, DOI 10.1074/jbc.M111.248724; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; Caetano FA, 2011, J NEUROCHEM, V117, P538, DOI 10.1111/j.1471-4159.2011.07225.x; Calella AM, 2010, EMBO MOL MED, V2, P306, DOI 10.1002/emmm.201000082; Calero O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022090; Cerf E, 2009, BIOCHEM J, V421, P415, DOI 10.1042/BJ20090379; Chen SG, 2010, J BIOL CHEM, V285, P26377, DOI 10.1074/jbc.M110.145516; Cisse M, 2011, J NEUROSCI, V31, P10427, DOI 10.1523/JNEUROSCI.1459-11.2011; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P49; Freir DB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1341; Gacia M, 2006, J NEURAL TRANSM, V113, P1747, DOI 10.1007/s00702-006-0540-4; Gimbel DA, 2010, J NEUROSCI, V30, P6367, DOI 10.1523/JNEUROSCI.0395-10.2010; Gunther EC, 2010, J MOL MED, V88, P331, DOI 10.1007/s00109-009-0568-7; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hyeon JW, 2012, BIOCHEM BIOPH RES CO, V424, P214, DOI 10.1016/j.bbrc.2012.06.056; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kessels HW, 2010, NATURE, V466, pE3, DOI 10.1038/nature09217; Khosravani H, 2008, J CELL BIOL, V181, P551, DOI 10.1083/jcb.200711002; Klewpatinond M, 2008, J BIOL CHEM, V283, P1870, DOI 10.1074/jbc.M708472200; Kudo W, 2012, HUM MOL GENET, V21, P1138, DOI 10.1093/hmg/ddr542; Laganowsky A, 2012, SCIENCE, V335, P1228, DOI 10.1126/science.1213151; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; Morales R, 2010, J NEUROSCI, V30, P4528, DOI 10.1523/JNEUROSCI.5924-09.2010; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Nadal RC, 2009, BIOCHEMISTRY-US, V48, P8929, DOI 10.1021/bi9011397; Nieznanski K, 2012, J BIOL CHEM, V287, P33104, DOI 10.1074/jbc.C112.400614; O'Sullivan DBD, 2007, BIOCHEM J, V401, P533, DOI 10.1042/BJ20060668; O'Sullivan DBD, 2009, PROTEIN SCI, V18, P410, DOI 10.1002/pro.44; Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Sarell CJ, 2010, J BIOL CHEM, V285, P41533, DOI 10.1074/jbc.M110.171355; Sarell CJ, 2009, BIOCHEMISTRY-US, V48, P4388, DOI 10.1021/bi900254n; Stanyon HF, 2012, J BIOL CHEM, V287, P28163, DOI 10.1074/jbc.C112.360800; Um JW, 2012, NAT NEUROSCI, V15, P1227, DOI 10.1038/nn.3178; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Viles JH, 2012, COORDIN CHEM REV, V256, P2271, DOI 10.1016/j.ccr.2012.05.003; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Watt NT, 2005, J BIOL CHEM, V280, P35914, DOI 10.1074/jbc.M507327200; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Xue WF, 2009, J BIOL CHEM, V284, P34272, DOI 10.1074/jbc.M109.049809; Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com; You HT, 2012, P NATL ACAD SCI USA, V109, P1737, DOI 10.1073/pnas.1110789109; Younan ND, 2011, J MOL BIOL, V410, P369, DOI 10.1016/j.jmb.2011.05.013; Zou WQ, 2011, J BIOL CHEM, V286, P15095, DOI 10.1074/jbc.M110.199356	54	76	76	0	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1847	1858		10.1096/fj.12-222588	http://dx.doi.org/10.1096/fj.12-222588			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23335053	Green Published, hybrid			2022-12-28	WOS:000318226100005
J	Huang, LS; Berdyshev, E; Mathew, B; Fu, PF; Gorshkova, IA; He, DH; Ma, WL; Noth, I; Ma, SF; Pendyala, S; Reddy, SP; Zhou, T; Zhang, W; Garzon, SA; Garcia, JGN; Natarajan, V				Huang, Long Shuang; Berdyshev, Evgeny; Mathew, Biji; Fu, Panfeng; Gorshkova, Irina A.; He, Donghong; Ma, Wenli; Noth, Imre; Ma, Shwu-Fan; Pendyala, Srikanth; Reddy, Sekhar P.; Zhou, Tong; Zhang, Wei; Garzon, Steven A.; Garcia, Joe G. N.; Natarajan, Viswanathan			Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis	FASEB JOURNAL			English	Article						TGF-beta; S1P; S1P lyase	GROWTH-FACTOR-BETA; VASCULAR LEAK; LUNG INJURY; 1-PHOSPHATE; FIBROBLASTS; MURINE; SPHINGOSINE-1-PHOSPHATE; DIFFERENTIATION; INFLAMMATION; INHIBITION	Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease, wherein transforming growth factor beta (TGF-beta) and sphingosine-1-phosphate (S1P) contribute to the pathogenesis of fibrosis. However, the in vivo contribution of sphingosine kinase (SphK) in fibrotic processes has not been documented. Microarray analysis of blood mononuclear cells from patients with IPF and SphK1- or SphK2-knockdown mice and SphK inhibitor were used to assess the role of SphKs in fibrogenesis. The expression of SphK1/2 negatively correlated with lung function and survival in patients with IPF. Also, the expression of SphK1 was increased in lung tissues from patients with IPF and bleomycin-challenged mice. Knockdown of SphK1, but not SphK2, increased survival and resistance to pulmonary fibrosis in bleomycin-challenged mice. Administration of SphK inhibitor reduced bleomycin-induced mortality and pulmonary fibrosis in mice. Knockdown of SphK1 or treatment with SphK inhibitor attenuated S1P generation and TGF-beta secretion in a bleomycin-induced lung fibrosis mouse model that was accompanied by reduced phosphorylation of Smad2 and MAPKs in lung tissue. In vitro, bleomycin-induced expression of SphK1 in lung fibroblast was found to be TGF-beta dependent. Taken together, these data indicate that SphK1 plays a critical role in the pathology of lung fibrosis and is a novel therapeutic target.-Huang, L. S., Berdyshev, E., Mathew, B., Fu, P., Gorshkova, I. A., He, D., Ma, W., Noth, I., Ma, S.-F., Pendyala, S., Reddy, S. P., Zhou, T., Zhang, W., Garzon, S. A., Garcia, J. G. N., Natarajan, V. Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J. 27, 1749-1760 (2013). www.fasebj.org	[Huang, Long Shuang; Fu, Panfeng; He, Donghong; Ma, Wenli; Pendyala, Srikanth; Natarajan, Viswanathan] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; [Huang, Long Shuang; Berdyshev, Evgeny; Mathew, Biji; Fu, Panfeng; Gorshkova, Irina A.; He, Donghong; Ma, Wenli; Pendyala, Srikanth; Zhou, Tong; Garcia, Joe G. N.; Natarajan, Viswanathan] Univ Illinois, Inst Personalized Resp Med, Chicago, IL 60612 USA; [Berdyshev, Evgeny; Mathew, Biji; Gorshkova, Irina A.; Zhou, Tong; Garcia, Joe G. N.; Natarajan, Viswanathan] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Reddy, Sekhar P.; Zhang, Wei] Univ Illinois, Dept Pediat, Chicago, IL 60612 USA; [Zhang, Wei] Univ Illinois, Inst Human Genet, Chicago, IL 60612 USA; [Garzon, Steven A.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; [Noth, Imre; Ma, Shwu-Fan] Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Natarajan, V (corresponding author), Univ Illinois, Dept Pharmacol, E403 Med Sci Bldg MC868,835 South Wolcott Ave, Chicago, IL 60612 USA.	visnatar@uic.edu	Huang, Longshuang/H-9553-2016; Fu, Panfeng/F-7345-2015	Fu, Panfeng/0000-0001-8813-9258	U.S. National Institutes of Health (NIH) [HL P01 98050, P01 58064, HL66109, ES11863]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL098050, R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by U.S. National Institutes of Health (NIH) grants HL P01 98050 and P01 58064 to V.N. and J.G.N.G, and HL66109 and ES11863 to S.P.R.. The authors thank Dr. Prasad Kanteti for helpful discussion and manuscript preparation. The authors thank Dr. Richard L Proia (NIH/National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA) for providing breeding pairs of the SphK1<SUP>-/-</SUP> and SphK2<SUP>-/-</SUP> mice. The authors declare no conflicts of interest.	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Berdyshev EV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016571; Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812; Chiba Y, 2010, J PHARMACOL SCI, V114, P304, DOI 10.1254/jphs.10202FP; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Dhami R, 2010, CELL PHYSIOL BIOCHEM, V26, P749, DOI 10.1159/000322342; Di AK, 2010, J BIOL CHEM, V285, P15848, DOI 10.1074/jbc.M109.075549; Duan SW, 2008, BIOINFORMATION, V2, P469, DOI 10.6026/97320630002469; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; French KJ, 2006, J PHARMACOL EXP THER, V318, P596, DOI 10.1124/jpet.106.101345; French KJ, 2003, CANCER RES, V63, P5962; Funke M, 2012, AM J RESP CELL MOL, V46, P355, DOI 10.1165/rcmb.2010-0155OC; Gao P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044543; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Ghosh M, 2004, AM J RESP CELL MOL, V30, P91, DOI 10.1165/rcmb.2003-0005OC; Gorshkova I, 2012, J LIPID RES, V53, P1553, DOI 10.1194/jlr.M026039; Hamada K, 2007, CHEST, V131, P650, DOI 10.1378/chest.06-1466; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Huebner RH, 2008, BIOTECHNIQUES, V44, P507, DOI 10.2144/000112729; Inage M, 2009, INT J BIOL SCI, V5, P304; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; Kharel Y, 2012, BIOCHEM J, V447, P149, DOI 10.1042/BJ20120609; Kharel Y, 2011, ANAL BIOCHEM, V411, P230, DOI 10.1016/j.ab.2011.01.003; King TE, 1998, ANN INTERN MED, V129, P806, DOI 10.7326/0003-4819-129-10-199811150-00012; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; LIMPER AH, 1991, CHEST, V99, pS55, DOI 10.1378/chest.99.3_Supplement.55S; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu L, 2009, J ENVIRON PATHOL TOX, V28, P99, DOI 10.1615/JEnvironPatholToxicolOncol.v28.i2.20; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Milara J, 2012, THORAX, V67, P147, DOI 10.1136/thoraxjnl-2011-200026; Mouratis MA, 2011, CURR OPIN PULM MED, V17, P355, DOI 10.1097/MCP.0b013e328349ac2b; Oskouian B, 2007, CELL CYCLE, V6, P522, DOI 10.4161/cc.6.5.3903; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; SAPPINO AP, 1990, LAB INVEST, V63, P144; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Takuwa N, 2010, CARDIOVASC RES, V85, P484, DOI 10.1093/cvr/cvp312; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; Zemann B, 2007, IMMUNOL LETT, V109, P56, DOI 10.1016/j.imlet.2007.01.001	45	70	76	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1749	1760		10.1096/fj.12-219634	http://dx.doi.org/10.1096/fj.12-219634			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23315259	Green Published			2022-12-28	WOS:000316940800043
J	Kim, J; Jia, XM; Buckett, PD; Liu, SH; Lee, CH; Wessling-Resnick, M				Kim, Jonghan; Jia, Xuming; Buckett, Peter D.; Liu, Sihao; Lee, Chih-Hao; Wessling-Resnick, Marianne			Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia	FASEB JOURNAL			English	Article						Belgrade rat; iron overload; divalent metal transporter 1	MICROCYTIC ANEMIA; BETA-THALASSEMIA; LIPID-METABOLISM; FERRITIN; DMT1; RAT; TRANSFERRIN; OVERLOAD; MICE; HYPERGLYCEMIA	Iron loading is associated with altered lipid metabolism, but underlying mechanisms remain unknown. We compared serum iron and triglycerides (TGs) in Belgrade rats, a genetic model of iron-loading anemia. Homozygous b/b rats had greater serum iron (68 vs. 28 mu M; P=0.0004) and TG levels (180 vs. 84 mg/dl; P=0.014) compared to +/b controls. To confirm the association between iron loading and high TGs, Fischer rats were fed chow containing 1% carbonyl iron. Compared to controls pair-fed normal chow, carbonyl iron-fed rats had elevated serum iron (42 vs. 21 mu M; P=0.007) and TGs (190 vs. 115 mg/dl; P=0.009). Despite normal hepatic production and secretion, TG clearance was lower in b/b than +/b rats due to reduced serum lipoprotein lipase (LPL) activity (3.1 vs. 5.0 mM/min; P=0.026). Likewise, LPL was lower in carbonyl iron-fed rats compared to controls (2.4 vs. 3.7 mM/min; P=0.017). Direct addition of iron to serum ex vivo or recombinant LPL in vitro decreased enzymatic activity in a dose-dependent manner. Lowering serum iron in Belgrade rats reduced TG levels (274 to 67 mg/dl, P=0.001). This study explains the relationship between iron status and lipid metabolism and provides mechanistic support for interventions that reduce serum iron levels in individuals at risk for hypertriglyceridemia.-Kim, J., Jia, X., Buckett, P. D., Liu, S., Lee, C.-H., Wessling-Resnick, M. Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia. FASEB J. 27, 1657-1663 (2013). www.fasebj.org	[Kim, Jonghan; Jia, Xuming; Buckett, Peter D.; Liu, Sihao; Lee, Chih-Hao; Wessling-Resnick, Marianne] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	wessling@hsph.harvard.edu	liu, sihao/A-8823-2015	liu, sihao/0000-0002-4188-3693	U.S. National Institutes of Health (NIH) [R01 ES014638, R01 DK064750, RC1 DK086774, R01 DK075046]; NIH Roadmap Fellowship [R90 DK071507]; Yerby Postdoctoral Fellowship at the Harvard School of Public Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075046, RC1DK086774, R01DK064750, P30DK034854, R90DK071507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014638] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Roadmap Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yerby Postdoctoral Fellowship at the Harvard School of Public Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grants from the U.S. National Institutes of Health (NIH) to M.W.-R. (R01 ES014638, R01 DK064750, and RC1 DK086774) and to C.-H. L. (R01 DK075046). J.K. was supported by an NIH Roadmap Fellowship (R90 DK071507) and the Yerby Postdoctoral Fellowship at the Harvard School of Public Health. The authors thank Dr. David E. Cohen and Ms. Yingxia Li (Brigham and Women's Hospital and the Molecular and Cellular Biochemistry Core at the Harvard Digestive Diseases Center, Boston, MA, USA; P30 DK34854) for their help in separating lipid fractions by FPLC for analysis, and Dr. Jorge Plutsky (Joslin Diabetes Center, Boston, MA, USA) for helpful discussion and advice. The authors declare no conflicts of interest.	Al-Quobaili FA, 2004, SAUDI MED J, V25, P871; Beaumont C, 2006, BLOOD, V107, P4168, DOI 10.1182/blood-2005-10-4269; BELLQUINT J, 1981, BIOCHEM BIOPH RES CO, V99, P700, DOI 10.1016/0006-291X(81)91800-3; BOFILL C, 1994, METABOLISM, V43, P614, DOI 10.1016/0026-0495(94)90204-6; Brunet S, 1999, HEPATOLOGY, V29, P1809, DOI 10.1002/hep.510290612; Buckett PD, 2009, AM J PHYSIOL-GASTR L, V296, pG798, DOI 10.1152/ajpgi.90342.2008; Byrne S. L., 2013, ANN REV PHA IN PRESS, V53; Casanova-Esteban P, 2011, METABOLISM, V60, P830, DOI 10.1016/j.metabol.2010.07.035; Chaudhury C, 2006, J NUTR, V136, P2993, DOI 10.1093/jn/136.12.2993; Cherchi G M, 1983, Boll Soc Ital Biol Sper, V59, P1739; Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392; Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010; CUTLER P, 1989, DIABETES, V38, P1207, DOI 10.2337/diabetes.38.10.1207; Davis MR, 2012, GENES NUTR, V7, P415, DOI 10.1007/s12263-011-0278-y; Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978; Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093; GALAN P, 1984, COMP BIOCHEM PHYS B, V77, P647, DOI 10.1016/0305-0491(84)90292-X; Garrick M, 1997, BIOMETALS, V10, P65, DOI 10.1023/A:1018370804882; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hartman C, 2002, J PEDIATR-US, V141, P543, DOI 10.1067/mpd.2002.127498; Heilig E, 2005, AM J PHYSIOL-LUNG C, V288, pL887, DOI 10.1152/ajplung.00382.2004; Holm C, 2000, METH MOL B, V155, P97; Horonchik L, 2008, CHEM BIOL, V15, P647, DOI 10.1016/j.chembiol.2008.05.011; Iolascon A, 2006, BLOOD, V107, P349, DOI 10.1182/blood-2005-06-2477; Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711; JONES AL, 1984, J LIPID RES, V25, P1151; Kim J, 2011, AM J PHYSIOL-LUNG C, V300, pL659, DOI 10.1152/ajplung.00343.2010; LEWIS M, 1971, J LAB CLIN MED, V78, P546; Mateo-Gallego R, 2010, METABOLISM, V59, P154, DOI 10.1016/j.metabol.2009.06.021; Mims MP, 2005, BLOOD, V105, P1337, DOI 10.1182/blood-2004-07-2966; Nasr MR, 2008, J CLIN LIPIDOL, V2, P405, DOI 10.1016/j.jacl.2008.10.008; Papanastasiou DA, 1996, HAEMATOLOGIA, V27, P143; Ramey G, 2007, FEBS LETT, V581, P1053, DOI 10.1016/j.febslet.2007.02.002; Salonen JT, 1998, BRIT MED J, V317, P727, DOI 10.1136/bmj.317.7160.727; Silva M, 2008, NUTR RES, V28, P391, DOI 10.1016/j.nutres.2008.02.009; SLADICSIMIC D, 1969, ANN NY ACAD SCI, V165, P93, DOI 10.1111/j.1749-6632.1969.tb27779.x; Solanas-Barca M, 2009, J CLIN ENDOCR METAB, V94, P4391, DOI 10.1210/jc.2009-0814; Stangl GI, 1998, LIPIDS, V33, P889, DOI 10.1007/s11745-998-0285-8; Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159; Tantawy AAG, 2009, HEMOGLOBIN, V33, P463, DOI 10.3109/03630260903343616; Thompson K, 2006, TOXICOL APPL PHARM, V210, P17, DOI 10.1016/j.taap.2005.05.014; Thompson K, 2007, FASEB J, V21, P223, DOI 10.1096/fj.06-6710com; Thompson K, 2006, J NUTR, V136, P3010, DOI 10.1093/jn/136.12.3010; Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc06-2312; Wlazlo N, 2012, CURR OPIN LIPIDOL, V23, P258, DOI 10.1097/MOL.0b013e328354752d; Yamagishi H, 2000, J NUTR BIOCHEM, V11, P455, DOI 10.1016/S0955-2863(00)00113-3	49	15	15	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1657	1663		10.1096/fj.12-224386	http://dx.doi.org/10.1096/fj.12-224386			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23241313	Green Published			2022-12-28	WOS:000316940800035
J	Radyuk, SN; Klichko, VI; Michalak, K; Orr, WC				Radyuk, Svetlana N.; Klichko, Vladimir I.; Michalak, Katarzyna; Orr, William C.			The effect of peroxiredoxin 4 on fly physiology is a complex interplay of antioxidant and signaling functions	FASEB JOURNAL			English	Article						aging; stress response; signaling pathways; apoptosis	NF-KAPPA-B; ER-OVERLOAD RESPONSE; DROSOPHILA-MELANOGASTER; OXIDATIVE STRESS; GENE FAMILY; CELL-DEATH; IV; EXPRESSION; PROTEIN; OVEREXPRESSION	Peroxiredoxin 4 (Prx4) has been implicated in a wide variety of biological processes, including development, progression of cancer, inflammation, and antioxidant function. The purpose of this study was to provide further insight into its multiple roles at the whole-animal level, using Drosophila. Reduced expression of dPrx4 (up to 90%) resulted in greater sensitivity to oxidative stress, an elevated H2O2 flux, and increases in lipid peroxidation, but no effect on longevity. Overexpression at low levels (<2-fold) gave reduced levels of oxidative damage and tended to show an increase in longevity. Flies expressing dPrx4 globally at high levels (>5-fold) had a dramatically reduced life span (by 20-80%) and increased apoptosis. Analysis of these overexpressors revealed an aberrant redistribution of the dPrx4 protein from the endoplasmic reticulum (ER) to cytosol and hemolymph. In addition to the known proapoptotic effects of the cytosolic form of dPrx4, dPrx4 overexpression triggered an NF-kappa B-mediated proinflammatory response, similar to that observed in cells under ER stress or when microbially challenged. Finally, we provide the first evidence that dPrx4, on secretion into the hemolymph, elicits a JAK/STAT-mediated response. The effects on fly survival and homeostasis appear to represent a combination of differential effects dictated in large part by dPrx4 subcellular and tissue-specific localization.-Radyuk, S. N., Klichko, V. I., Michalak, K., Orr, W. C. The effect of peroxiredoxin 4 on fly physiology is a complex interplay of antioxidant and signaling functions. FASEB J. 27, 1426-1438 (2013). www.fasebj.org	[Radyuk, Svetlana N.; Klichko, Vladimir I.; Michalak, Katarzyna; Orr, William C.] So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Orr, WC (corresponding author), 6501 Airline Rd,Rm 113, Dallas, TX 75275 USA.	borr@smu.edu		Radyuk, Svetlana/0000-0002-3467-5255	National Institute on Aging, U.S. National Institutes of Health [RO1 AG15122, R01 AG032342]; NATIONAL INSTITUTE ON AGING [R01AG015122, R01AG032342] Funding Source: NIH RePORTER	National Institute on Aging, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the grants RO1 AG15122 (W.C.O.) and R01 AG032342 (S.N.R.) from the National Institute on Aging, U.S. National Institutes of Health.	Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Berndt A, 2007, J BIOL CHEM, V282, P13011, DOI 10.1074/jbc.M608872200; Boltz KA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-212; Ding Y, 2010, ANTIOXID REDOX SIGN, V13, P1477, DOI 10.1089/ars.2010.3137; Ekengren S, 2001, BIOCHEM BIOPH RES CO, V284, P998, DOI 10.1006/bbrc.2001.5067; Ekengren S, 2001, CURR BIOL, V11, P1479, DOI 10.1016/S0960-9822(01)00452-3; Giguere P, 2007, FEBS LETT, V581, P3863, DOI 10.1016/j.febslet.2007.07.011; Haridas V, 1998, J IMMUNOL, V161, P1; Iuchi Y, 2009, BIOCHEM J, V419, P149, DOI 10.1042/BJ20081526; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kuang E, 2005, J CELL PHYSIOL, V204, P549, DOI 10.1002/jcp.20340; Landis GN, 2004, P NATL ACAD SCI USA, V101, P7663, DOI 10.1073/pnas.0307605101; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Libert S, 2006, AGING CELL, V5, P533, DOI 10.1111/j.1474-9726.2006.00251.x; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Matsuki S, 2002, REDOX REP, V7, P276, DOI 10.1179/135100002125000785; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Michalak K, 2008, BIOCHEM BIOPH RES CO, V368, P273, DOI 10.1016/j.bbrc.2008.01.052; Okado-Matsumoto A, 2000, J BIOCHEM, V127, P493, DOI 10.1093/oxfordjournals.jbchem.a022632; Orr WC, 2005, J BIOL CHEM, V280, P37331, DOI 10.1074/jbc.M508272200; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Palande K, 2011, J CELL SCI, V124, P3695, DOI 10.1242/jcs.089656; Radyuk SN, 2001, FREE RADICAL BIO MED, V31, P1090, DOI 10.1016/S0891-5849(01)00692-X; Radyuk SN, 2010, FREE RADICAL BIO MED, V49, P1892, DOI 10.1016/j.freeradbiomed.2010.09.014; Radyuk SN, 2010, BBA-GEN SUBJECTS, V1800, P1153, DOI 10.1016/j.bbagen.2010.06.010; Sasagawa I, 2001, EUR J BIOCHEM, V268, P3053, DOI 10.1046/j.1432-1327.2001.02200.x; Shikama N, 1996, GERONTOLOGY, V42, P123; Sowell RA, 2007, J PROTEOME RES, V6, P3637, DOI 10.1021/pr070224h; Stuart LM, 2007, NATURE, V445, P95, DOI 10.1038/nature05380; Tavender TJ, 2008, BIOCHEM J, V411, P191, DOI 10.1042/BJ20071428; Tavender TJ, 2010, EMBO J, V29, P4185, DOI 10.1038/emboj.2010.273; Tavender TJ, 2010, J CELL SCI, V123, P2672, DOI 10.1242/jcs.067843; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Toroser D, 2007, BIOCHEM BIOPH RES CO, V363, P418, DOI 10.1016/j.bbrc.2007.08.193; Wong CM, 2000, ANTIOXID REDOX SIGN, V2, P507, DOI 10.1089/15230860050192288; Zheng A, 2005, P NATL ACAD SCI USA, V102, P12083, DOI 10.1073/pnas.0503374102; Zito E, 2010, MOL CELL, V40, P787, DOI 10.1016/j.molcel.2010.11.010; Zoltowski BD, 2011, NATURE, V480, P396, DOI 10.1038/nature10618	39	26	29	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1426	1438		10.1096/fj.12-214106	http://dx.doi.org/10.1096/fj.12-214106			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271054	Green Published			2022-12-28	WOS:000316940800015
J	Choi, SY; Kim, JY; Kim, HW; Cho, B; Cho, HM; Oppenheim, RW; Kim, H; Rhyu, IJ; Sun, W				Choi, So Yoen; Kim, Joo Yeon; Kim, Hyun-Wook; Cho, Bongki; Cho, Hyo Min; Oppenheim, Ronald W.; Kim, Hyun; Rhyu, Im Joo; Sun, Woong			Drp1-mediated mitochondrial dynamics and survival of developing chick motoneurons during the period of normal programmed cell death	FASEB JOURNAL			English	Article						mitochondria; chick embryo; apoptosis	GROWTH-FACTOR; FISSION; DRP1; MEMBRANE; PHOSPHORYLATION; PROTEIN-1; INCREASES; TRANSPORT; AXONS; MORPHOGENESIS	Mitochondrial morphology is dynamically remodeled by fusion and fission in neurons, and this process is implicated in nervous system development and pathology. However, the mechanism by which mitochondrial dynamics influence neuronal development is less clear. In this study, we found that the length of mitochondria is progressively reduced during normal development of chick embryo motoneurons (MNs), a process partly controlled by a fission-promoting protein, dynamin-related protein 1 (Drp1). Suppression of Drp1 activity by gene electroporation of dominant-negative mutant Drp1 in a subset of developing MNs increased mitochondrial length in vivo, and a greater proportion of Drp1-suppressed MNs underwent programmed cell death (PCD). By contrast, the survival of nontransfected MNs in proximity to the transfected MNs was significantly increased, suggesting that the suppression of Drp1 confers disadvantage during the competition for limited survival signals. Because we also monitored perturbation of neurite outgrowth and mitochondrial membrane depolarization following Drp1 suppression, we suggest that impairments of ATP production and axonal growth may be downstream factors that influence the competition of MNs for survival. Collectively, these results indicate that mitochondrial dynamics are required for normal axonal development and competition-dependent MN PCD.-Choi, S. Y., Kim, J. Y., Kim, H.-W., Cho, B., Cho, H. M., Oppenheim, R. W., Kim, H., Rhyu, I. J., Sun, W. Drp1-mediated mitochondrial dynamics and survival of developing chick motoneurons during the period of normal programmed cell death. FASEB J. 27, 51-62 (2013). www.fasebj.org	[Choi, So Yoen; Kim, Joo Yeon; Kim, Hyun-Wook; Cho, Bongki; Cho, Hyo Min; Kim, Hyun; Rhyu, Im Joo; Sun, Woong] Korea Univ, Coll Med, Dept Anat, Seoul 136705, South Korea; [Oppenheim, Ronald W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA; [Oppenheim, Ronald W.] Wake Forest Univ, Bowman Gray Sch Med, Neurosci Program, Winston Salem, NC 27103 USA	Korea University; Korea University Medicine (KU Medicine); Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Choi, SY (corresponding author), Korea Univ, Coll Med, Dept Anat, Seoul 136705, South Korea.	woongsun@korea.ac.kr	Choi, So Yoen/AAV-1947-2020; Cho, Bongki/ABG-8744-2021	Cho, Bongki/0000-0001-5832-2705; sun, woong/0000-0003-1792-4894; Kim, Hyun/0000-0002-7210-5798; Rhyu, Im Joo/0000-0002-5558-6278	Korean Ministry of Education, Science, and Technology [2010000143, 20100020237, 2010K000803]; U.S. National Institutes of Health (NIH) [NS-069212]; Robert Packard Center for ALS Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS069212] Funding Source: NIH RePORTER	Korean Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Packard Center for ALS Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Korean Ministry of Education, Science, and Technology (2010000143, 20100020237, and 2010K000803; to W. S.), by U.S. National Institutes of Health (NIH) grant NS-069212, and by the Robert Packard Center for ALS Research. The authors thank Dr. Richard J. Youle (NIH, Bethesda, MD, USA) for the mutant Drp1 clone.	Baixauli F, 2011, EMBO J, V30, P1238, DOI 10.1038/emboj.2011.25; Beard E, 2010, J NEUROCHEM, V115, P297, DOI 10.1111/j.1471-4159.2010.06935.x; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800; Caldero J, 1998, J NEUROSCI, V18, P356; Chada SR, 2003, J EXP BIOL, V206, P1985, DOI 10.1242/jeb.00263; Chang KT, 2011, P NATL ACAD SCI USA, V108, P15456, DOI 10.1073/pnas.1106862108; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Cheng AW, 2010, ASN NEURO, V2, P243, DOI 10.1042/AN20100019; Choi SY, 2006, BIOCHEM BIOPH RES CO, V346, P872, DOI 10.1016/j.bbrc.2006.05.207; D'Costa AP, 1998, J NEUROBIOL, V36, P379; de Graaf AO, 2004, EXP CELL RES, V299, P533, DOI 10.1016/j.yexcr.2004.06.024; Dickey AS, 2011, J NEUROSCI, V31, P15716, DOI 10.1523/JNEUROSCI.3159-11.2011; DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Goyal G, 2007, DEV CELL, V12, P807, DOI 10.1016/j.devcel.2007.02.002; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; HAMBURGER V, 1992, DEV DYNAM, V195, P273, DOI 10.1002/dvdy.1001950405; He MD, 2011, TOXICOL APPL PHARM, V253, P38, DOI 10.1016/j.taap.2011.03.008; HOLLYDAY M, 1976, J COMP NEUROL, V170, P311, DOI 10.1002/cne.901700304; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Lee CW, 2008, MOL BIOL CELL, V19, P150, DOI 10.1091/mbc.E07-05-0515; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; LINDAHL PE, 1961, EXP CELL RES, V23, P228, DOI 10.1016/0014-4827(61)90033-7; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MCKAY SE, 1991, J NEUROBIOL, V22, P721, DOI 10.1002/neu.480220707; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; MORRIS RL, 1993, J CELL SCI, V104, P917; Park KS, 2008, J BIOL CHEM, V283, P33347, DOI 10.1074/jbc.M806251200; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257; PILAR G, 1980, J NEUROPHYSIOL, V43, P233, DOI 10.1152/jn.1980.43.1.233; PITTMAN RH, 1978, NATURE, V271, P364, DOI 10.1038/271364a0; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Song WJ, 2011, NAT MED, V17, P377, DOI 10.1038/nm.2313; Steiber Alison, 2004, Molecular Aspects of Medicine, V25, P455, DOI 10.1016/j.mam.2004.06.006; Tada-Oikawa S, 2003, LIFE SCI, V73, P3277, DOI 10.1016/j.lfs.2003.06.013; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Verburg J, 2008, J NEUROSCI, V28, P8306, DOI 10.1523/JNEUROSCI.2614-08.2008; Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018; Wakabayashi J, 2009, J CELL BIOL, V186, P805, DOI 10.1083/jcb.200903065; Wang GY, 2000, J NEUROSCI, V20, P5358, DOI 10.1523/JNEUROSCI.20-14-05358.2000; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107	51	21	22	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					51	62		10.1096/fj.12-211920	http://dx.doi.org/10.1096/fj.12-211920			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22997225	Green Published			2022-12-28	WOS:000313103200007
J	Hu, HM; Chen, YC; Liu, L; Zhang, CG; Wang, W; Gong, K; Huang, Z; Guo, MX; Li, WX; Li, WH				Hu, Hai-Ming; Chen, Yicheng; Liu, Lu; Zhang, Chuan-Geng; Wang, Wei; Gong, Ke; Huang, Zan; Guo, Ming-Xiong; Li, Wen-Xin; Li, Wenhua			C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is associated with tumorigenesis and metastasis	FASEB JOURNAL			English	Article						liver cancer; progression	COMPARATIVE GENOMIC HYBRIDIZATION; HEPATITIS-B-VIRUS; GENE-EXPRESSION; AMPLIFICATION; IMBALANCES; COMPLEX; GROWTH; PROLIFERATION; INHIBITION; INVASION	The genomic amplification of chromosome 1q long arm, the chromosomal region containing C1orf61, is a common event in human cancers. However, the expression pattern of chromosome 1 open reading frame 61 (C1orf61) in hepatocellular carcinoma (HCC) and its effects on HCC progression remain unclear. We have previously reported that C1orf61 is highly up-regulated during human embryogenesis. In this study, we report that C1orf61 expression is associated with the progression of liver disease. We found that C1orf61 is up-regulated in hepatic cirrhosis tissues and is further up-regulated in primary HCC tumors. Moreover, hepatitis B virus (HBV)-positive patients exhibited significantly higher levels of C1orf61 expression than HBV-negative patients. The evaluation of highly malignant HCC cell lines revealed high protein expression levels of C1orf61. Furthermore, the C1orf61 protein was found to be predominantly distributed within the cytoplasm. The ectopic expression of C1orf61 in the nonmalignant L02 cell line promoted cellular proliferation and colony formation in vitro, as well as cell cycle progression via the regulation of the expression of specific cell cycle-related proteins. In addition, the overexpression of C1orf61 in L02 cells facilitated cellular invasion and metastasis. The down-regulation of epithelial markers (E-cadherin and occludin) and the up-regulation of mesenchymal markers (N-cadherin, vimentin, and snail) suggested that the overexpression of C1orf61 induced the epithelial-mesenchymal transition (EMT) that is linked to metastasis. Taken together, our findings demonstrate, for the first time, the roles of C1orf61 in HCC tumorigenesis and metastasis.-Hu, H-M., Chen, Y., Liu, L., Zhang, C-C., Wang, W., Gong, K., Huang, Z., Guo, M-X., Li, W-X., Li, W. C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is associated with tumorigenesis and metastasis. FASEB J. 27, 163-173 (2013). www.fasebj.org	[Hu, Hai-Ming; Chen, Yicheng; Liu, Lu; Zhang, Chuan-Geng; Wang, Wei; Gong, Ke; Huang, Zan; Guo, Ming-Xiong; Li, Wen-Xin; Li, Wenhua] Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China	Wuhan University	Li, WX (corresponding author), Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.	liwxlab@whu.edu.cn; whli@whu.edu.cn		Huang, Zan/0000-0001-5623-6950; Wang, Wei/0000-0001-7429-1013; Liu, Lu/0000-0001-7984-6671	National Basic Research Program of China [2010CB529800]; National Nature Science Foundation of China [81072151, 31271511]; Chinese 111 project [B06018]; Specialized Research Fund for the Doctoral Program of Higher Education of China [200804861004]	National Basic Research Program of China(National Basic Research Program of China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese 111 project(Ministry of Education, China - 111 Project); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by the National Basic Research Program of China (2010CB529800), the National Nature Science Foundation of China (81072151, 31271511), the Chinese 111 project (B06018), and Specialized Research Fund for the Doctoral Program of Higher Education of China grant 200804861004.	Awuah Prince K, 2012, Hepatology, V55, P970, DOI 10.1002/hep.24774; Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08-128702; Berger MF, 2010, GENOME RES, V20, P413, DOI 10.1101/gr.103697.109; Campbell K, 2011, DEV CELL, V21, P1051, DOI 10.1016/j.devcel.2011.10.005; Chen LL, 2010, ACTA PHARMACOL SIN, V31, P1165, DOI 10.1038/aps.2010.94; Chen YN, 2011, FASEB J, V25, P4511, DOI 10.1096/fj.11-187781; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chi F, 2010, BIOCHEM J, V427, P79, DOI 10.1042/BJ20091097; Coulouarn C, 2012, CANCER RES, V72, P2533, DOI 10.1158/0008-5472.CAN-11-3317; Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140; Gong K, 2011, FREE RADICAL BIO MED, V51, P2259, DOI 10.1016/j.freeradbiomed.2011.09.018; Guo H, 2011, CARCINOGENESIS, V32, P1897, DOI 10.1093/carcin/bgr220; Hirsch D, 2012, GENE CHROMOSOME CANC, V51, P490, DOI 10.1002/gcc.21937; Jeannot E, 2012, INT J CANCER, V130, P1347, DOI 10.1002/ijc.26140; Jeffrey PL, 2000, MOL CELL NEUROSCI, V16, P185, DOI 10.1006/mcne.2000.0866; Kaemmerer D, 2011, EUR J NUCL MED MOL I, V38, P1659, DOI 10.1007/s00259-011-1846-5; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karna P, 2012, CARCINOGENESIS, V33, P1769, DOI 10.1093/carcin/bgs200; Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.3.CO;2-K; Kim DI, 2008, CARCINOGENESIS, V29, P1701, DOI 10.1093/carcin/bgn055; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kolupaeva V, 2012, CELL CYCLE, V11, P2557, DOI 10.4161/cc.20944; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Liu L, 2011, INT J CANCER, V128, P1692, DOI 10.1002/ijc.25488; Livraghi T, 2008, HEPATOLOGY, V47, P82, DOI 10.1002/hep.21933; Lou CY, 2004, WORLD J GASTROENTERO, V10, P1462; Lu YJ, 2002, LANCET, V360, P385, DOI 10.1016/S0140-6736(02)09596-X; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Moore MD, 2005, J GENE MED, V7, P918, DOI 10.1002/jgm.739; Luna LEM, 2009, NAT REV GASTRO HEPAT, V6, P679, DOI 10.1038/nrgastro.2009.165; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; Papadopoulou V, 2010, BIOCHEM J, V427, P541, DOI 10.1042/BJ20091578; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Reppe S, 2010, BONE, V46, P604, DOI 10.1016/j.bone.2009.11.007; de Lope CR, 2012, J HEPATOL, V56, pS75, DOI 10.1016/S0168-8278(12)60009-9; Roy SS, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/654698; Serrano I, 2012, ONCOGENE, V31, P1, DOI DOI 10.1038/0NC.2012.30; Shaughnessy J, 2005, HEMATOLOGY, V10, P117, DOI 10.1080/10245330512331390140; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Spano D, 2012, CLIN EXP METASTAS, V29, P381, DOI 10.1007/s10585-012-9457-5; Su YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019412; Tanaka S, 2012, INT J CANCER, V131, P2537, DOI 10.1002/ijc.27575; Tang KH, 2012, HEPATOLOGY, V55, P807, DOI 10.1002/hep.24739; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Wang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036818; Wang SH, 2011, HEPATOLOGY, V53, P1932, DOI 10.1002/hep.24291; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9; Yi H, 2010, FASEB J, V24, P3341, DOI 10.1096/fj.10-158782; Zhang SG, 2010, MOL BIOL REP, V37, P381, DOI 10.1007/s11033-009-9817-7; Zudaire I, 2002, HISTOPATHOLOGY, V40, P547, DOI 10.1046/j.1365-2559.2002.01413.x	54	15	17	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					163	173		10.1096/fj.12-216622	http://dx.doi.org/10.1096/fj.12-216622			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23012322				2022-12-28	WOS:000313103200016
J	Kusuma, S; Zhao, S; Gerecht, S				Kusuma, Sravanti; Zhao, Stephen; Gerecht, Sharon			The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells	FASEB JOURNAL			English	Article						vasculature; collagen I; collagen IV; hypoxia-inducible factors	SMOOTH-MUSCLE-CELLS; STEM-CELLS; INDUCIBLE FACTOR-2-ALPHA; VASCULAR MORPHOGENESIS; MOLECULAR DISTINCTION; COLLAGEN; TISSUE; HIF-2-ALPHA; ARTERIES; KINASE	Extracellular matrix (ECM) production is critical to preserve the function and integrity of mature blood vessels. Toward the engineering of blood vessels, studies have centered on ECM production by supporting cells, whereas few studies implicate endothelial cells (ECs) with ECM synthesis. Here, we elucidate variations between cultured human arterial, venous, and progenitor ECs with respect to ECM deposition assembly, composition, and response to biomolecular and physiological factors. Our studies reveal that progenitor ECs, endothelial colony-forming cells (ECFCs), deposit collagen IV, fibronectin, and laminin that assemble to an organized weblike structure, as confirmed by decellularized cultures. Mature ECs only express these ECM proteins intracellularly. ECFC-derived ECM is abrogated in response to TGF beta signaling inhibition and actin cytoskeleton disruption. Hypoxic (1%) and physiological (5%) O-2 tension stimulate ECM deposition from mature ECs. Interestingly, deposition of collagen I is observed only under 5% O-2 tension. ECM production from all ECs is found to be regulated by hypoxia-inducible factors 1 alpha and 2 alpha but differentially in the different cell lines. Collectively, we suggest that ECM deposition and assembly by ECs is dependent on maturation stage and oxygen supply and that these findings can be harnessed to advance engineered vascular therapeutics.-Kusuma, S., Zhao, S., Gerecht, S. The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells. FASEB J. 26, 4925-4936 (2012). www.fasebj.org	[Kusuma, Sravanti; Zhao, Stephen; Gerecht, Sharon] Johns Hopkins Univ, Dept Chem & Biomol Engn, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD USA; [Kusuma, Sravanti; Zhao, Stephen; Gerecht, Sharon] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD USA; [Kusuma, Sravanti] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Gerecht, S (corresponding author), 3400 N Charles St, Baltimore, MD 21218 USA.	gerecht@jhu.edu	Gerecht, Sharon/A-3388-2010		American Heart Association; U.S. National Institutes of Health (NIH) [F31HL112644]; NIH [R01HL107938]; National Science Foundation [1054415]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL112644, R01HL107938] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Abigail Hielscher and Hasan Erbil Abaci for their assistance and productive discussions and Bradley Isaacs for technical assistance. The research was funded by predoctoral awards from the American Heart Association and the U.S. National Institutes of Health (NIH; grant F31HL112644) to S. K., and by NIH grant R01HL107938, an American Heart Association Scientist Development grant, and National Science Foundation grant 1054415 to S.G.	Abaci HE, 2011, AM J PHYSIOL-CELL PH, V301, pC431, DOI 10.1152/ajpcell.00074.2011; Abaci HE, 2010, AM J PHYSIOL-CELL PH, V298, pC1527, DOI 10.1152/ajpcell.00484.2009; Aitsebaomo J, 2008, CIRC RES, V103, P929, DOI 10.1161/CIRCRESAHA.108.184937; Asahara T, 2011, STEM CELLS, V29, P1650, DOI 10.1002/stem.745; Chapados R, 2006, CIRC RES, V99, P837, DOI 10.1161/01.RES.0000246172.77441.f1; Critser PJ, 2011, CELL PROLIFERAT, V44, P15, DOI 10.1111/j.1365-2184.2010.00719.x; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; Davis GE, 2008, CURR OPIN HEMATOL, V15, P197, DOI 10.1097/MOH.0b013e3282fcc321; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Dickinson LE, 2011, MACROMOL BIOSCI, V11, P36, DOI 10.1002/mabi.201000245; Dickinson LE, 2010, SOFT MATTER, V6, P5109, DOI 10.1039/c0sm00233j; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Gong ZD, 2008, FASEB J, V22, P1635, DOI 10.1096/fj.07-087924; Gui LQ, 2009, TISSUE ENG PT A, V15, P2665, DOI [10.1089/ten.tea.2008.0526, 10.1089/ten.TEA.2008.0526]; Hanjaya-Putra D, 2011, BLOOD, V118, P804, DOI 10.1182/blood-2010-12-327338; Heydarkhan-Hagvall S, 2006, TISSUE ENG, V12, P831, DOI 10.1089/ten.2006.12.831; Hielscher AC, 2012, AM J PHYSIOL-CELL PH, V302, pC1243, DOI 10.1152/ajpcell.00011.2012; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; Ito Y, 2005, J BIOMED MATER RES A, V74A, P659, DOI 10.1002/jbm.a.30360; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jeon H, 1996, BIOSCI BIOTECH BIOCH, V60, P856, DOI 10.1271/bbb.60.856; Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057; Kuruvilla L, 2007, CELL BIOCHEM BIOPHYS, V47, P65, DOI 10.1385/CBB:47:1:65; Kusuma S, 2010, EXPERT REV CARDIOVAS, V8, P1433, DOI [10.1586/erc.10.121, 10.1586/ERC.10.121]; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Li L., 2011, EXP NEUROL, V233, P283; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Mathews A, 2012, J TISSUE ENG REGEN M, V6, P451, DOI 10.1002/term.449; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Nilsson I, 2004, EXP CELL RES, V299, P476, DOI 10.1016/j.yexcr.2004.06.005; Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684; Papadimitrio E., 1993, ENDOTHELIUM-J ENDOTH, V1, P207, DOI [10.3109/10623329309102698, DOI 10.3109/10623329309102698]; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Quint C, 2011, P NATL ACAD SCI USA, V108, P9214, DOI 10.1073/pnas.1019506108; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045; Sansilvestri-Morel P, 2002, CIRCULATION, V106, P479, DOI 10.1161/01.CIR.0000022846.22923.46; Schechner JS, 2003, FASEB J, V17, P2250, DOI 10.1096/fj.03-0257com; Schenke-Layland K, 2004, MATRIX BIOL, V23, P113, DOI 10.1016/j.matbio.2004.03.005; Schmidt CE, 2000, BIOMATERIALS, V21, P2215, DOI 10.1016/S0142-9612(00)00148-4; Silva EA, 2008, P NATL ACAD SCI USA, V105, P14347, DOI 10.1073/pnas.0803873105; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Soucy PA, 2009, MATRIX BIOL, V28, P273, DOI 10.1016/j.matbio.2009.04.005; Stratman AN, 2012, MICROSC MICROANAL, V18, P68, DOI 10.1017/S1431927611012402; Sun GM, 2012, MACROMOL BIOSCI, V12, P21, DOI 10.1002/mabi.201100258; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Torres-Vaazquez J, 2003, CELL TISSUE RES, V314, P43, DOI 10.1007/s00441-003-0771-8; TSENG SCG, 1982, EUR J BIOCHEM, V122, P355, DOI 10.1111/j.1432-1033.1982.tb05888.x; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; Vartanian KB, 2009, J BIOMED MATER RES A, V91A, P528, DOI 10.1002/jbm.a.32225; VILLANUEVA AG, 1991, CIRC RES, V69, P134, DOI 10.1161/01.RES.69.1.134; Vo E, 2010, STEM CELL REV REP, V6, P237, DOI 10.1007/s12015-010-9144-3; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Williams SK, 2011, J BIOMED MATER RES A, V99A, P67, DOI 10.1002/jbm.a.33138; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yang B, 2010, TISSUE ENG PART C-ME, V16, P1201, DOI [10.1089/ten.tec.2009.0311, 10.1089/ten.TEC.2009.0311]; Yoder MC, 2009, J THROMB HAEMOST, V7, P49, DOI 10.1111/j.1538-7836.2009.03407.x; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoneda A, 2007, MOL BIOL CELL, V18, P66, DOI 10.1091/mbc.E06-08-0684; Zeiger AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037904; Zhou M, 2009, ARTIF ORGANS, V33, P230, DOI 10.1111/j.1525-1594.2009.00713.x	70	49	53	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4925	4936		10.1096/fj.12-209296	http://dx.doi.org/10.1096/fj.12-209296			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22919069	Green Published			2022-12-28	WOS:000311838300016
J	Grabias, BM; Konstantopoulos, K				Grabias, Bryan M.; Konstantopoulos, Konstantinos			Epithelial-mesenchymal transition and fibrosis are mutually exclusive reponses in shear-activated proximal tubular epithelial cells	FASEB JOURNAL			English	Article						chronic kidney disease; tubulointerstitial fibrosis; ERK	GROWTH-FACTOR-BETA; DEPENDENT REGULATION; MESOTHELIAL CELLS; STRESS; FIBROBLASTS; EXPRESSION; PODOCYTES; APOPTOSIS; COLLAGEN; INFLAMMATION	Renal fibrosis (RF) is thought to be a direct consequence of dedifferentiation of resident epithelial cells via an epithelial-mesenchymal transition (EMT). Increased glomerular flow is a critical initiator of fibrogenesis. Yet, the responses of proximal tubular epithelial cells (PTECs) to fluid flow remain uncharacterized. Here, we investigate the effects of pathological shear stresses on the development of fibrosis in PTECs. Our data reveal that type I collagen accumulation in shear-activated PTECs is accompanied by a similar to 40-60% decrease in cell motility, thus excluding EMT as a relevant pathological process. In contrast, static incubation of PTECs with TGF beta 1 increases cell motility by similar to 50%, and induces stable expression of key mesenchymal markers, including Snail1, N-cadherin, and vimentin. Ectopic expression of TGF beta 1 in shear-activated PTECs fails to induce EMT-associated changes but abrogates collagen accumulation via SMAD2-dependent mechanisms. Shear-mediated inhibition of EMT occurs via cyclic oscillations in both ERK2 activity and downstream expression of EMT genes. A constitutive ERK2 mutant induces stable expression of Snail1, N-cadherin, and vimentin, and increases cell motility in shear-activated PTECs by 250% without concomitant collagen deposition. Collectively, our data reveal that RF not only occurs without EMT but also that these two responses represent mutually exclusive cell fates.-Grabias, B. M., Konstantopoulos, K. Epithelial-mesenchymal transition and fibrosis are mutually exclusive reponses in shear-activated proximal tubular epithelial cells. FASEB J. 26, 4131-4141 (2012). www.fasebj.org	[Grabias, Bryan M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, New Engn Bldg 114,3400 N Charles St, Baltimore, MD 21218 USA.	konstant@jhu.edu	Konstantopoulos, Konstantinos/A-7045-2011		U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR053358]; Kleberg Foundation award; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053358] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Kleberg Foundation award; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the U.S. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 AR053358, and a Kleberg Foundation award.	Ashall L, 2009, SCIENCE, V324, P242, DOI 10.1126/science.1164860; Bielesz B, 2010, J CLIN INVEST, V120, P4040, DOI 10.1172/JCI43025; Boor P, 2007, NEPHROL DIAL TRANSPL, V22, P1323, DOI 10.1093/ndt/gfl691; Cai ZQ, 2000, AM J PHYSIOL-RENAL, V279, pF270, DOI 10.1152/ajprenal.2000.279.2.F270; Chen YL, 2011, HEPATOLOGY, V53, P1708, DOI 10.1002/hep.24254; Deng C, 2011, J APPL PHYSIOL, V111, P285, DOI 10.1152/japplphysiol.00201.2010; Denton CP, 2007, ARTHRITIS RHEUM-US, V56, P323, DOI 10.1002/art.22289; Ding Z, 2011, TRANSPL IMMUNOL, V25, P34, DOI 10.1016/j.trim.2011.04.001; Docherty NG, 2009, KIDNEY INT, V75, P205, DOI 10.1038/ki.2008.482; Duan Y, 2008, P NATL ACAD SCI USA, V105, P11418, DOI 10.1073/pnas.0804954105; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Essig M, 2001, AM J PHYSIOL-RENAL, V281, pF751, DOI 10.1152/ajprenal.2001.281.4.F751; Fragiadaki M, 2011, MOL BIOL CELL, V22, P1836, DOI 10.1091/mbc.E10-08-0669; Friedrich C, 2006, AM J PHYSIOL-RENAL, V291, pF856, DOI 10.1152/ajprenal.00196.2005; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Herman-Edelstein M, 2011, DIABETES, V60, P1779, DOI 10.2337/db10-1110; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517; Inazaki K, 2004, KIDNEY INT, V66, P597, DOI 10.1111/j.1523-1755.2004.00779.x; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Kuo CC, 2011, J RENIN-ANGIO-ALDO S, V12, P113, DOI 10.1177/1470320310391331; Kuusniemi AM, 2005, KIDNEY INT, V68, P121, DOI 10.1111/j.1523-1755.2005.00386.x; Levin-Salomon V, 2008, J BIOL CHEM, V283, P34500, DOI 10.1074/jbc.M806443200; Levine DZ, 2006, AM J PHYSIOL-REG I, V290, pR975, DOI 10.1152/ajpregu.00693.2005; Li XY, 2011, J CELL BIOL, V195, P729, DOI 10.1083/jcb.201105103; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; Lv ZD, 2012, INT J MOL MED, V29, P373, DOI 10.3892/ijmm.2011.852; Medina C, 2011, J PATHOL, V224, P461, DOI 10.1002/path.2870; Meng XM, 2010, J AM SOC NEPHROL, V21, P1477, DOI 10.1681/ASN.2009121244; Meyer A, 2012, BLOOD, V119, P1064, DOI 10.1182/blood-2011-09-377648; Miravete M, 2011, BIOCHEM BIOPH RES CO, V407, P813, DOI 10.1016/j.bbrc.2011.03.105; OLSON JL, 1982, KIDNEY INT, V22, P112, DOI 10.1038/ki.1982.143; Pang LJ, 2011, EXP CELL RES, V317, P1608, DOI 10.1016/j.yexcr.2011.02.004; Pollack V, 2007, AM J PHYSIOL-RENAL, V293, pF1714, DOI 10.1152/ajprenal.00130.2007; Pozdzik AA, 2008, KIDNEY INT, V73, P595, DOI 10.1038/sj.ki.5002714; RUDBERG S, 1992, KIDNEY INT, V41, P822, DOI 10.1038/ki.1992.126; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Shankaran H, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.90; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; Sun L, 2008, BIOCHEM BIOPH RES CO, V371, P900, DOI 10.1016/j.bbrc.2008.03.114; Takeji M, 2006, J BIOL CHEM, V281, P40193, DOI 10.1074/jbc.M602182200; Wang P, 2011, FASEB J, V25, P3401, DOI 10.1096/fj.11-184861; Wang P, 2010, J BIOL CHEM, V285, P24793, DOI 10.1074/jbc.M110.110320; Waters AM, 2008, J AM SOC NEPHROL, V19, P1139, DOI 10.1681/ASN.2007050596; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13	48	26	28	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4131	4141		10.1096/fj.12-207324	http://dx.doi.org/10.1096/fj.12-207324			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22744866	Green Published			2022-12-28	WOS:000309704000020
J	Jash, S; Adhya, S				Jash, Sukanta; Adhya, Samit			Induction of muscle regeneration by RNA-mediated mitochondrial restoration	FASEB JOURNAL			English	Article						satellite cells; gene delivery; ATP; ROS; myogenesis	SKELETAL-MUSCLE; SATELLITE CELLS; STEM-CELLS; MUTANT MITOCHONDRIA; IN-VIVO; DIFFERENTIATION; RAT; TRANSITIONS; MYOGENESIS; CAPACITY	Skeletal muscle injury is associated with general down-regulation of mitochondrial function. Postinjury regeneration of skeletal muscle occurs through activation, proliferation, and differentiation of resident stem cells, including satellite cells and endothelial precursor cells. We wanted to determine the role of mitochondrial function in the regeneration process. Using a previously described method for complex-mediated delivery to intracellular mitochondria, a combination of polycistronic RNAs encoding the H strand of the rat mitochondrial genome was administered to injured rat quadriceps muscle, resulting in restoration of mitochondrial mRNA levels, organellar translation, and respiratory capacity. Intramuscular ATP levels were elevated on pcRNA treatment of injured muscle; concomitantly, levels of reactive oxygen species in the injured muscle were reduced. These effects combined to produce a notable increase in the rate of wound resolution, accompanied by reduction of fibrosis and acceleration of myogenesis, vasculogenesis, and resumption of muscle contractile function. There was evidence of proliferation of Pax7(+) satellite cells, expression of muscle-specific regulatory factors in a specific time sequence, and formation of new myofibers in the regenerating muscle. RNA-induced wound resolution and satellite cell proliferation were sensitive to mitochondrial inhibitors, indicating the importance of oxidative phosphorylation. These results highlight the activation of endogenous stem cells through mitochondrial restoration as a possible alternative to implantation of cultured stem cells.-Jash, S., Adhya, S. Induction of muscle regeneration by RNA-mediated mitochondrial restoration. FASEB J. 26, 4187-4197 (2012). www.fasebj.org	[Jash, Sukanta; Adhya, Samit] Indian Inst Chem Biol, Genet Engn Lab, CSIR, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, CSIR, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	nilugrandson@gmail.com			Indian Council of Scientific and Industrial Research (CSIR) Suprainstitutional Project [SIP007]	Indian Council of Scientific and Industrial Research (CSIR) Suprainstitutional Project	The authors thank Tapas Chowdury for technical help, Anupam Banerjee for confocal microscopy, Uday Bandyopadhyay for oxygraph measurements, Shymal Roy for FACS analysis, and K. P. Mohanakumar for cryotome sectioning. This study was supported by the Indian Council of Scientific and Industrial Research (CSIR) Suprainstitutional Project SIP007. S.J. was a Senior Research Fellow (CSIR).	Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509; Chen ML, 2009, BLOOD, V114, P4045, DOI 10.1182/blood-2008-08-169474; Chen Q, 2008, AM J PHYSIOL-CELL PH, V294, pC460, DOI 10.1152/ajpcell.00211.2007; Codina Marta, 2010, Curr Cardiol Rep, V12, P199, DOI 10.1007/s11886-010-0098-5; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Cree MG, 2008, AM J SURG, V196, P234, DOI 10.1016/j.amjsurg.2007.09.048; DALBIS A, 1989, DEV BIOL, V135, P320, DOI 10.1016/0012-1606(89)90182-6; Duguez S, 2002, AM J PHYSIOL-ENDOC M, V282, pE802, DOI 10.1152/ajpendo.00343.2001; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Grattagliano I, 2009, WORLD J GASTROENTERO, V15, P4865, DOI 10.3748/wjg.15.4865; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; Ikemoto M, 2007, MOL THER, V15, P2178, DOI 10.1038/sj.mt.6300295; Jash S, 2012, MITOCHONDRION, V12, P262, DOI 10.1016/j.mito.2011.10.001; Jash S, 2011, MITOCHONDRION, V11, P607, DOI 10.1016/j.mito.2011.03.124; KIRKEBY S, 1993, GLYCOCONJUGATE J, V10, P181, DOI 10.1007/BF00737716; Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61; Le Grand F, 2007, CURR OPIN CELL BIOL, V19, P628, DOI 10.1016/j.ceb.2007.09.012; Lonergan T, 2006, J CELL PHYSIOL, V208, P149, DOI 10.1002/jcp.20641; Mahata B, 2005, J BIOL CHEM, V280, P5141, DOI 10.1074/jbc.C400572200; Mahata B, 2006, SCIENCE, V314, P471, DOI 10.1126/science.1129754; Mahato B, 2011, MITOCHONDRION, V11, P564, DOI 10.1016/j.mito.2011.03.006; Mukherjee S, 2008, HUM MOL GENET, V17, P1292, DOI 10.1093/hmg/ddn017; Mukherjee S, 2007, EMBO REP, V8, P589, DOI 10.1038/sj.embor.7400979; Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102; Ramalho-Santos J, 2009, HUM REPROD UPDATE, V15, P553, DOI 10.1093/humupd/dmp016; Rehman J, 2010, J MOL MED, V88, P981, DOI 10.1007/s00109-010-0678-2; Rossi CA, 2011, FASEB J, V25, P2296, DOI 10.1096/fj.10-174755; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Shi M, 2009, STEM CELLS, V27, P949, DOI 10.1002/stem.4	31	16	16	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4187	4197		10.1096/fj.11-203232	http://dx.doi.org/10.1096/fj.11-203232			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751011				2022-12-28	WOS:000309704000024
J	Kim, DG; Choi, JW; Lee, JY; Kim, H; Oh, YS; Lee, JW; Tak, YK; Song, JM; Razin, E; Yun, SH; Kim, S				Kim, Dae Gyu; Choi, Jin Woo; Lee, Jin Young; Kim, Hyerim; Oh, Young Sun; Lee, Jung Weon; Tak, Yu Kyung; Song, Joon Myong; Razin, Ehud; Yun, Seok-Hyun; Kim, Sunghoon			Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration	FASEB JOURNAL			English	Article						metastasis; KRS; phosphorylation; 67LR	PROTEIN-PROTEIN INTERACTIONS; GENE-EXPRESSION; UBIQUITIN LIGASES; CRYSTAL-STRUCTURE; COMPLEX-FORMATION; BINDING PROTEIN; TUMOR-CELLS; RECEPTOR; PHOSPHORYLATION; METASTASIS	Although human lysyl-tRNA synthetase (KRS), an enzyme for protein synthesis, is often highly expressed in various cancer cells, its pathophysiological implications have not been understood. Here we found that KRS induces cancer cell migration through interaction with the 67-kDa laminin receptor (67LR) that is converted from ribosomal subunit p40. On laminin signal, KRS was phosphorylated at the T52 residue by p38MAPK and dissociated from the cytosolic multi-tRNA synthetase complex for membrane translocation. The importance of T52 phosphorylation for membrane translocation of KRS was confirmed by site-directed mutagenesis. In the membrane, turnover of 67LR was controlled by Nedd4-mediated ubiquitination, and KRS inhibited ubiquitin-dependent degradation of 67LR, thereby enhancing laminin-induced cell migration. This work thus unveiled a unique function of KRS in the control of cell migration and its pathological implication in metastasis.- Kim, D. G., Choi, J. W., Lee, J. Y., Kim, H., Oh, Y. S., Lee, J. W., Tak, Y. K., Song, J. M., Razin, E., Yun, S.-H., Kim, S. Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration. FASEB J. 26, 4142-4159 (2012). www.fasebj.org	[Kim, Dae Gyu; Choi, Jin Woo; Lee, Jin Young; Kim, Hyerim; Oh, Young Sun; Lee, Jung Weon; Tak, Yu Kyung; Song, Joon Myong; Kim, Sunghoon] Seoul Natl Univ, Med Bioconvergence Res Ctr, Seoul 151742, South Korea; [Kim, Dae Gyu; Lee, Jin Young; Lee, Jung Weon; Kim, Sunghoon] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Lee, Jung Weon; Tak, Yu Kyung; Song, Joon Myong; Kim, Sunghoon] Seoul Natl Univ, World Class Univ, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea; [Razin, Ehud] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem & Mol Biol, IL-91010 Jerusalem, Israel; [Yun, Seok-Hyun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Hebrew University of Jerusalem; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kim, S (corresponding author), Seoul Natl Univ, Med Bioconvergence Res Ctr, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020; Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012	Lee, Jung Weon/0000-0003-2722-8200; kim, sunghoon/0000-0002-1570-3230	Global Frontier grant from the National Research Foundation [NRF-M1AXA002-2010-0029785]; Acceleration Research grant from the National Research Foundation [R17-2007-020-01000-0]; 21st Frontier Functional Proteomics Research grant from the National Research Foundation [M108KM010027-08K1301-02710]; Ministry of Education, Science, and Technology of Korea	Global Frontier grant from the National Research Foundation; Acceleration Research grant from the National Research Foundation; 21st Frontier Functional Proteomics Research grant from the National Research Foundation; Ministry of Education, Science, and Technology of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by Global Frontier (NRF-M1AXA002-2010-0029785), Acceleration Research (R17-2007-020-01000-0), and 21st Frontier Functional Proteomics Research (M108KM010027-08K1301-02710) grants from the National Research Foundation, funded by the Ministry of Education, Science, and Technology of Korea.	Ardini E, 1998, MOL BIOL EVOL, V15, P1017, DOI 10.1093/oxfordjournals.molbev.a026000; Arif A, 2009, MOL CELL, V35, P164, DOI 10.1016/j.molcel.2009.05.028; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; CASTRONOVO V, 1993, INVAS METAST, V13, P1; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Fujimura Y, 2005, BIOCHEM BIOPH RES CO, V336, P674, DOI 10.1016/j.bbrc.2005.08.146; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Givant-Horwitz V, 2005, CANCER LETT, V223, P1, DOI 10.1016/j.canlet.2004.08.030; Grisaru-Granovsky S, 2005, INT J CANCER, V113, P372, DOI 10.1002/ijc.20607; Guo M, 2008, P NATL ACAD SCI USA, V105, P2331, DOI 10.1073/pnas.0712072105; Guo M, 2010, FEBS LETT, V584, P434, DOI 10.1016/j.febslet.2009.11.064; Halwani R, 2004, J VIROL, V78, P7553, DOI 10.1128/JVI.78.14.7553-7564.2004; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; Han JM, 2008, P NATL ACAD SCI USA, V105, P11206, DOI 10.1073/pnas.0800297105; Han JM, 2006, J BIOL CHEM, V281, P38663, DOI 10.1074/jbc.M605211200; Hippo Y, 2002, CANCER RES, V62, P233; Jamieson KV, 2008, J BIOL CHEM, V283, P3002, DOI 10.1074/jbc.C700206200; Kim G, 2010, BIOCHEM BIOPH RES CO, V397, P100, DOI 10.1016/j.bbrc.2010.05.075; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim S, 2011, NAT REV CANCER, V11, P708, DOI 10.1038/nrc3124; Kim WH, 1998, BRIT J CANCER, V77, P15, DOI 10.1038/bjc.1998.3; Kwon NH, 2011, P NATL ACAD SCI USA, V108, P19635, DOI 10.1073/pnas.1103922108; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Lee Sang Won, 2006, Current Proteomics, V3, P233; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; LIOTTA LA, 1984, CIBA F SYMP, V108, P146; Lukk M, 2010, NAT BIOTECHNOL, V28, P322, DOI 10.1038/nbt0410-322; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Naoghare PK, 2008, ANAL CHEM, V80, P5407, DOI 10.1021/ac800452x; Naoghare PK, 2010, INTEGR BIOL-UK, V2, P46, DOI 10.1039/b916481b; Narumi K, 1999, JPN J CANCER RES, V90, P425, DOI 10.1111/j.1349-7006.1999.tb00765.x; Nelson J, 2008, BIOSCIENCE REP, V28, P33, DOI 10.1042/BSR20070004; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nikles D, 2008, BBA-MOL BASIS DIS, V1782, P335, DOI 10.1016/j.bbadis.2008.02.003; Park SG, 2008, P NATL ACAD SCI USA, V105, P11043, DOI 10.1073/pnas.0802862105; Park SG, 2010, IUBMB LIFE, V62, P296, DOI 10.1002/iub.324; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Park SG, 2005, P NATL ACAD SCI USA, V102, P6356, DOI 10.1073/pnas.0500226102; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Ray PS, 2007, TRENDS BIOCHEM SCI, V32, P158, DOI 10.1016/j.tibs.2007.02.003; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Roesli C, 2009, CANCER RES, V69, P5406, DOI 10.1158/0008-5472.CAN-08-0999; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Suh HN, 2010, AM J PHYSIOL-CELL PH, V298, pC1159, DOI 10.1152/ajpcell.00496.2009; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; WEWER UM, 1987, CANCER RES, V47, P5691; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yan W, 2004, MOL CELL PROTEOMICS, V3, P1039, DOI 10.1074/mcp.D400001-MCP200; Yan W, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r54; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Yannay-Cohen N, 2009, MOL CELL, V34, P603, DOI 10.1016/j.molcel.2009.05.019; Yasuda J, 2003, J VIROL, V77, P9987, DOI 10.1128/JVI.77.18.9987-9992.2003; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200	58	60	63	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4142	4159		10.1096/fj.12-207639	http://dx.doi.org/10.1096/fj.12-207639			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751010				2022-12-28	WOS:000309704000021
J	Yang, SZ; Xie, N; Cui, HC; Banerjee, S; Abraham, E; Thannickal, VJ; Liu, G				Yang, Shanzhong; Xie, Na; Cui, Huachun; Banerjee, Sami; Abraham, Edward; Thannickal, Victor J.; Liu, Gang			RETRACTED: miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis (Retracted article. See vol. 27, pg. 843, 2013)	FASEB JOURNAL			English	Article; Retracted Publication						fibroblasts; RhoA; integrin; alpha(5); contraction; migration	HUMAN LUNG FIBROBLASTS; MESENCHYMAL TRANSITION; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MYOFIBROBLAST DIFFERENTIATION; MICRORNAS; ACTIVATION; BETA; EXPRESSION; TGF-BETA-1	Aberrant expression of miRNAs is closely associated with initiation and progression of pathological processes, including diabetes, cancer, and cardiovascular disease. However, the role of miRNAs in lung fibrosis is not well characterized. We sought to determine the role of miR-31 in regulating the fibrogenic, contractile, and migratory activities of lung fibroblasts and modulating of pulmonary fibrosis in vivo. In vivo lung fibrosis models and ex vivo cell culture systems were employed. Real-time PCR and Western blot analysis were used to determine gene expression levels. miR-31 mimics or inhibitors were transfected into pulmonary fibroblasts. Fibrogenic, contractile, and migratory activities of lung fibroblasts were determined. We found that miR-31 expression is reduced in the lungs of mice with experimental pulmonary fibrosis and in IPF fibroblasts. miR-31 inhibits the profibrotic activity of TGF-beta 1 in normal lung fibroblasts and diminishes the fibrogenic, contractile, and migratory activities of IPF fibroblasts. In these experiments, miR-31 was shown to directly target integrin alpha(5) and RhoA, two proteins that have been shown to regulate activation of fibroblasts. We found that levels of integrin alpha(5) and RhoA are up-regulated in fibrotic mouse lungs. Knockdown of integrin alpha(5) and RhoA attenuated fibrogenic, contractile, and migratory activities of IPF fibroblasts, in a manner similar to that observed with miR-31. We also found that introduction of miR-31 ameliorated experimental lung fibrosis in mice. Our data suggest that miR-31 is an important regulator of the pathological activities of lung fibroblasts and may be a potential target in the development of novel therapies to treat pathological fibrotic disorders, including pulmonary fibrosis.-Yang, S., Xie, N., Cui, H., Banerjee, S., Abraham, E., Thannickal, V. J., Liu, G. miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis. FASEB J. 26, 3790-3799 (2012). www.fasebj.org	[Yang, Shanzhong; Xie, Na; Cui, Huachun; Banerjee, Sami; Thannickal, Victor J.; Liu, Gang] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Abraham, Edward] Wake Forest Sch Med, Winston Salem, NC USA	University of Alabama System; University of Alabama Birmingham; Wake Forest University	Liu, G (corresponding author), Univ Alabama Birmingham, Dept Med, 901 19th St So,BMR 2 233, Birmingham, AL 35294 USA.	gliu@uab.edu		Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	U.S. National Institutes of Health [HL105473, HL097218, HL076206, HL067967, HL10781]; American Heart Association [10SDG4210009]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067967, R21HL097218, R01HL105473, R01HL076206] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grants HL105473, HL097218, and HL076206 (to G. L.); HL067967 and HL10781 (to V.J.T.); and by American Heart Association award 10SDG4210009 (to G. L.). Author contributions: conception and design: G. L.; analysis and interpretation: S.Y., S. B., E. A., and G. L.; drafting the manuscript for important intellectual content: S.Y., N.X., H. C., V.J.T., E. A., and G.L.	Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Cai GQ, 2010, EXP CELL RES, V316, P1600, DOI 10.1016/j.yexcr.2010.01.021; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cutroneo KR, 2007, J CELL PHYSIOL, V211, P585, DOI 10.1002/jcp.20972; Degryse AL, 2011, AM J PHYSIOL-LUNG C, V300, pL887, DOI 10.1152/ajplung.00397.2010; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Gharaee-Kermani M, 2009, CURR MED CHEM, V16, P1400, DOI 10.2174/092986709787846497; Kang HR, 2007, J BIOL CHEM, V282, P7723, DOI 10.1074/jbc.M610764200; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Kondrikov D, 2011, FREE RADICAL BIO MED, V50, P1689, DOI 10.1016/j.freeradbiomed.2011.03.020; Latronico MVG, 2009, NAT REV CARDIOL, V6, P418, DOI 10.1038/nrcardio.2009.56; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P476; Liu G, 2008, FASEB J, V22, P2285, DOI 10.1096/fj.07-101816; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Mishra PK, 2009, J CELL MOL MED, V13, P778, DOI 10.1111/j.1582-4934.2009.00744.x; Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Pandey AK, 2009, CELL PHYSIOL BIOCHEM, V23, P221, DOI 10.1159/000218169; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Patel S, 2005, J AM SOC NEPHROL, V16, P1977, DOI 10.1681/ASN.2004110943; Ramos C, 2001, AM J RESP CELL MOL, V24, P591, DOI 10.1165/ajrcmb.24.5.4333; Sheppard Dean, 2006, Proc Am Thorac Soc, V3, P413, DOI 10.1513/pats.200601-008AW; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Thum T, 2008, CARDIOVASC RES, V79, P562, DOI 10.1093/cvr/cvn137; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tsapara A, 2010, MOL BIOL CELL, V21, P860, DOI 10.1091/mbc.E09-07-0567; Vuga LJ, 2009, AM J RESP CELL MOL, V41, P583, DOI 10.1165/rcmb.2008-0201OC; Watts KL, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-88; White LR, 2007, AM J PHYSIOL-RENAL, V292, pF567, DOI 10.1152/ajprenal.00212.2006; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wu Z, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-1; Xia H, 2008, J EXP MED, V205, P1659, DOI 10.1084/jem.20080001; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yao HW, 2004, LIFE SCI, V76, P29, DOI 10.1016/j.lfs.2004.06.019; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zhou Y, 2010, J BIOL CHEM, V285, P22382, DOI 10.1074/jbc.M110.126227	45	33	37	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3790	3799		10.1096/fj.11-202366	http://dx.doi.org/10.1096/fj.11-202366			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22661007	Green Published			2022-12-28	WOS:000308391600019
J	Cai, QC; Zhao, ZW; Antalis, C; Yan, LB; Del Priore, G; Hamed, AH; Stehman, FB; Schilder, JM; Xu, Y				Cai, Qingchun; Zhao, Zhenwen; Antalis, Caryl; Yan, Libo; Del Priore, Giuseppe; Hamed, Ali Hassan; Stehman, Frederick B.; Schilder, Jeanne M.; Xu, Yan			Elevated and secreted phospolidase A(2) activities as new potential therapeutic targets in human epithelial ovarian cancer	FASEB JOURNAL			English	Article						ascites; migration; autotaxin; methyl arachidonyl fluorophosphonate	LYSOPHOSPHATIDIC ACID PRODUCTION; PHOSPHOLIPASE A(2); CELL-MIGRATION; TUMOR-CELLS; LYSOPHOSPHOLIPIDS; CARCINOMA; INVASION; ENZYMES; GROWTH; PROLIFERATION	Ascites in epithelial ovarian cancer (EOC) promotes tumor development by mechanisms that are incompletely understood. Lysophosphatidic acid (LPA), a major tumor-promoting factor in EOC ascites, is an enzymatic product of autotaxin (ATX) and phospholipase A(2) (PLA(2)) enzymes. The contribution of PLA(2) activities to ovarian tumorigenesis was investigated. The quantitative measurement of PLA(2) activities in ascites and tissues, as well as assay conditions selective for PLA(2) subtypes, were optimized and validated. PLA(2) activities correlated with tumor-promoting activates in cell-based and in vivo assays. High activities consistent with both cytosolic and calcium-independent PLA(2) were found in human EOC ascites for the first time. Elevated PLA(2) and ATX activities were also observed in EOC compared to benign tumors and normal tissues. Cell-free and vesicle-free (S4) human EOC ascites potently promoted proliferation, migration, and invasion of human EOC cells in a PLA(2)-dependent manner. LPA mediated a significant part of the cell-stimulating effects of ascites. S4 ascites stimulated tumorigenesis/metastasis in vivo, and methyl arachidonyl fluorophosphonate was highly effective in inhibiting EOC metastasis in mouse xenograft models. PLA(2) activity was found in conditioned media from both EOC cells and macrophages. Collectively, our work implies that PLA(2) activity is a potential marker and therapeutic target in EOC.- Cai, Q., Zhao, Z., Antalis, C., Yan, L., Del Priore, G., Hamed, A. H., Stehman, F. B., Schilder, J. M., Xu, Y. Elevated and secreted phospholipase A(2) activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J. 26, 3306-3320 (2012). www.fasebj.org	[Cai, Qingchun; Zhao, Zhenwen; Antalis, Caryl; Yan, Libo; Del Priore, Giuseppe; Hamed, Ali Hassan; Stehman, Frederick B.; Schilder, Jeanne M.; Xu, Yan] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Xu, Y (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, 975 W Walnut St,IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.edu	Cai, Qingchun/B-6211-2015; Yan, Libo/H-2328-2012; yan, libo/H-9533-2013	Yan, Libo/0000-0002-4204-3397; Antalis, Caryl/0000-0002-5305-4139	National Cancer Institute [P30 CA082709]; U.S. National Institutes of Health [R01CA95042]; Mary Fendrich Hulman Charitable Trust; NATIONAL CANCER INSTITUTE [P30CA082709, R01CA095042] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Fendrich Hulman Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Lipid analytical work was performed by the Clinical Pharmacology Analytical Core laboratory, a core laboratory of the Indiana University Melvin and Bren Simon Cancer Center, supported by the National Cancer Institute, grant P30 CA082709. This work was supported in part by the U.S. National Institutes of Health, grant R01CA95042 to Y.X., and by the Mary Fendrich Hulman Charitable Trust. The authors report no conflicts of interest.	Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005; Brown DPG, 2007, PROTEOM CLIN APPL, V1, P18, DOI 10.1002/prca.200600171; Burke JE, 2009, J LIPID RES, V50, pS237, DOI 10.1194/jlr.R800033-JLR200; Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9; Colin-Santana CC, 2011, BBA-GEN SUBJECTS, V1810, P1170, DOI 10.1016/j.bbagen.2011.08.016; Cummings BS, 2007, BIOCHEM PHARMACOL, V74, P949, DOI 10.1016/j.bcp.2007.04.021; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goetzl EJ, 2000, ANN NY ACAD SCI, V905, P177; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Iguchi Haruhisa, 2010, Commun Integr Biol, V3, P478, DOI 10.4161/cib.3.5.12693; INOUE S, 1991, J VET MED SCI, V53, P521, DOI 10.1292/jvms.53.521; Iorio E, 2010, CANCER RES, V70, P2126, DOI 10.1158/0008-5472.CAN-09-3833; Kim KS, 2006, CANCER RES, V66, P7983, DOI 10.1158/0008-5472.CAN-05-4381; Kobayashi N, 2009, J BIOL CHEM, V284, P21192, DOI 10.1074/jbc.M109.006163; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li H, 2011, AM J PATHOL, V179, P452, DOI 10.1016/j.ajpath.2011.03.027; Li H, 2010, FASEB J, V24, P4103, DOI 10.1096/fj.10-161356; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Lucas KK, 2005, PROSTAG OTH LIPID M, V77, P235, DOI 10.1016/j.prostaglandins.2005.02.004; Merendino AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009247; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2011, J BIOCHEM, V150, P233, DOI 10.1093/jb/mvr088; Murph MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005583; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Samadi N, 2011, BIOCHIMIE, V93, P61, DOI 10.1016/j.biochi.2010.08.002; Scott KF, 2010, BIOCHIMIE, V92, P601, DOI 10.1016/j.biochi.2010.03.019; Sengupta S, 2007, ONCOGENE, V26, P2894, DOI 10.1038/sj.onc.1210093; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Snider AJ, 2010, AM J PHYSIOL-CELL PH, V298, pC163, DOI 10.1152/ajpcell.00001.2009; Song Y, 2007, BIOCHEM J, V406, P427, DOI 10.1042/BJ20070631; Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y., 2006, CELL SCI REV, V3, P168; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Xu Y, 2009, CANCER TREAT RES, V149, P241, DOI 10.1007/978-0-387-98094-2_12; YU L, 1990, J BIOL CHEM, V265, P2657; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200; Zhao ZW, 2010, J LIPID RES, V51, P652, DOI 10.1194/jlr.D001503; Zhao ZW, 2009, J CHROMATOGR B, V877, P3739, DOI 10.1016/j.jchromb.2009.08.032	46	35	37	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3306	3320		10.1096/fj.12-207597	http://dx.doi.org/10.1096/fj.12-207597			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22767227	Green Published			2022-12-28	WOS:000307162800021
J	Han, RJ; Li, AY; Li, LJ; Kitlinska, JB; Zukowska, Z				Han, Ruijun; Li, Aiyun; Li, Lijun; Kitlinska, Joanna B.; Zukowska, Zofia			Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex- and time-specific manner	FASEB JOURNAL			English	Article						NPY-Y2R; sex differences; metabolic syndrome	ADIPOSE-TISSUE; METABOLIC SYNDROME; FOOD-INTAKE; GROWTH; EXPOSURE; PREGNANCY; INSULIN; WEIGHT; STRESS; CELLS	Neuropeptide Y (NPY) mediates stress-induced obesity in adult male mice by activating its Y2 receptor (Y2R) in visceral adipose tissue (VAT). Here, we studied whether the NPY-Y2R system is also activated by maternal low-protein diet (LPD) and linked to obesity in offspring. Prenatal LPD offspring had lower birth weights compared to normal-protein diet (NPD) offspring. Female prenatal and lactation stress (PLS) offspring from mothers fed an LPD developed abdominal adiposity and glucose intolerance associated with a 5-fold up-regulation of NPY mRNA and a 6-fold up-regulation of Y2R mRNA specifically in VAT, in addition to elevated platelet-rich-plasma (PRP) NPY, compared to control females fed a high-fat diet (HFD). Conversely, PLS male offspring showed lower NPY in PRP, a 10-fold decrease of Y2R mRNA in VAT, lower adiposity, and improved glucose tolerance compared to control males. Interestingly, prenatal LPD offspring cross-fostered to control lactating mothers had completely inverse metabolic and NPY phenotypes. Taken together, these findings suggested that maternal LPD activates the VAT NPY-Y2R system and increases abdominal adiposity and glucose intolerance in a sex-and time-specific fashion, suggesting that the peripheral NPY system is a potential mediator of programming for the offspring's vulnerability to obesity and metabolic syndrome.-Han, R., Li, A., Li, L., Kitlinska, J. B., Zukowska, Z. Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex-and time-specific manner. FASEB J. 26, 3528-3536 (2012). www.fasebj.org	[Han, Ruijun; Zukowska, Zofia] Univ Minnesota, Dept Integrat Biol & Physiol, Stress Physiol Ctr, Minneapolis, MN 55455 USA; [Han, Ruijun; Li, Aiyun; Li, Lijun; Kitlinska, Joanna B.; Zukowska, Zofia] Georgetown Univ, Dept Physiol & Biophys, Washington, DC USA	University of Minnesota System; University of Minnesota Twin Cities; Georgetown University	Han, RJ (corresponding author), Univ Minnesota, Dept Integrat Biol & Physiol, Stress Physiol Ctr, 321 Church St SE, Minneapolis, MN 55455 USA.	rhan@umn.edu	Han, Ruijun/K-6614-2012		U.S. National Institutes of Health [R01HL067357, R37HL055310]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357, R37HL055310] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grants R01HL067357 and R37HL055310 to Z.Z. The authors thank Allison Gurney, Amrutesh Puranik, Dalay Hirsch, Jana Strakova, Jixia Liu, Shuangwei Li, and Allan V. Kalueff for their insightful comments and editing. The authors thank Naz Moaddab for the pilot study reporting that prenatal LPD stress increased anxiety in male offspring, with lower NPY levels in the amygdala. The authors declare no conflicts of interest.	Abe K, 2010, EXP BIOL MED, V235, P1179, DOI 10.1258/ebm.2010.009136; ANGUITA RM, 1993, J NUTR, V123, P1421; Bartness TJ, 2002, J CLIN INVEST, V110, P1235, DOI 10.1172/JCI200217047; Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Costa E, 2009, EXPERT REV NEUROTHER, V9, P87, DOI 10.1586/14737175.9.1.87; Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; Hales CN, 2003, DIABETOLOGIA, V46, P1013, DOI 10.1007/s00125-003-1131-7; Han R, 2007, DIABETOLOGIA, V50, P1960, DOI 10.1007/s00125-007-0752-7; HEYMANN E, 1984, KLIN WOCHENSCHR, V62, P2, DOI 10.1007/BF01725186; Jaquet D, 2000, J CLIN ENDOCR METAB, V85, P1401, DOI 10.1210/jc.85.4.1401; Kalra SP, 2004, NEUROPEPTIDES, V38, P201, DOI 10.1016/j.npep.2004.06.003; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Li LJ, 2011, J CARDIOVASC TRANSL, V4, P351, DOI 10.1007/s12265-011-9271-5; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; Lucas A, 1996, BRIT J NUTR, V76, P605, DOI 10.1079/BJN19960066; LUNDBERG JM, 1990, FUNDAM CLIN PHARM, V4, P373, DOI 10.1111/j.1472-8206.1990.tb00692.x; Mashiko S, 2007, MOL PHARMACOL, V71, P602, DOI 10.1124/mol.106.029991; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Nilsson C, 1996, PEPTIDES, V17, P359, DOI 10.1016/0196-9781(96)00013-7; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Ozanne SE, 2004, CLIN SCI, V106, P141, DOI 10.1042/CS20030278; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V270, pE559, DOI 10.1152/ajpendo.1996.270.4.E559; Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; Pembrey ME, 2010, HUM FERTIL, V13, P268, DOI 10.3109/14647273.2010.524721; Plagemann A, 2002, DIABETES CARE, V25, P16, DOI 10.2337/diacare.25.1.16; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Sainsbury A, 2006, DIABETES, V55, P19; Seckl JR, 2004, EUR J ENDOCRINOL, V151, pU49, DOI 10.1530/eje.0.151u049; Shepherd PR, 1997, BRIT J NUTR, V78, P121, DOI 10.1079/BJN19970124; Shi YC, 2011, OBESITY, V19, P2137, DOI 10.1038/oby.2011.99; Son MY, 2011, J CELL MOL MED, V15, P152, DOI 10.1111/j.1582-4934.2009.00956.x; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; URBAN JH, 1993, ENDOCRINOLOGY, V132, P139, DOI 10.1210/en.132.1.139; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Whitelaw NC, 2008, CURR OPIN GENET DEV, V18, P273, DOI 10.1016/j.gde.2008.07.001; Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07-100735; Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313; Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462; ZukowskaGrojec Z, 1995, ANN NY ACAD SCI, V771, P219, DOI 10.1111/j.1749-6632.1995.tb44683.x	48	29	31	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3528	3536		10.1096/fj.12-203943	http://dx.doi.org/10.1096/fj.12-203943			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22539639	Green Published			2022-12-28	WOS:000307162800039
J	Renga, B; Mencarelli, A; D'Amore, C; Cipriani, S; Baldelli, F; Zampella, A; Distrutti, E; Fiorucci, S				Renga, Barbara; Mencarelli, Andrea; D'Amore, Claudio; Cipriani, Sabrina; Baldelli, Franco; Zampella, Angela; Distrutti, Eleonora; Fiorucci, Stefano			Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition	FASEB JOURNAL			English	Article						nuclear receptors; PEPCK; G6Pase; SHP	SMALL HETERODIMER PARTNER; BILE-ACID; GLUCOSE-HOMEOSTASIS; CARBOHYDRATE-METABOLISM; INSULIN-RESISTANCE; ORPHAN RECEPTOR; DB/DB MICE; FXR; EXPRESSION; GENE	The glucocorticoid receptor (GR) is a master gene orchestrating the activation of gluconeogenic genes in the liver in response to food withdrawal. Mechanisms of GR regulation by other nuclear receptors, however, are poorly defined. Here, we report that the farnesoid X receptor (FXR), a bile acid sensor, activates gluconeogenic pathways in the liver and regulates GR expression and activity. FXR-null mice are hypoglycemic in the unfed state and exhibit both a reduced hepatic production of glucose in response to the pyruvate challenge and a decreased expression of two rate-limiting enzymes involved in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase), along with blunted liver expression of GR. Treating wild-type mice with a semisynthetic FXR ligand (6E-CDCA) increases the liver expression of GR, PEPCK, and G6Pase. This effect was lost in fed animals, as well as in FXR-/- mice. The human and mouse GR promoters contain a conserved FXR-responsive element (an ER-8 sequence) whose activation by FXR ligation leads to GR transcription. GR silencing by siRNA in vitro or its pharmacological antagonism in vivo with mifepristone reverses the effect of FXR activation on expression of gluconeogenic genes. These findings demonstrate that an FXR-GR pathway regulates the activation of hepatic gluconeogenesis in the transition from the unfed to the fed state.-Renga, B., Mencarelli, A., D'Amore, C., Cipriani, S., Baldelli, F., Zampella, A., Distrutti, E., Fiorucci, S. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 26, 3021-3031 (2012). www.fasebj.org	[Renga, Barbara; Mencarelli, Andrea; D'Amore, Claudio; Cipriani, Sabrina; Fiorucci, Stefano] Univ Perugia, Dipartimento Med Clin & Sperimentale, I-06122 Perugia, Italy; [Baldelli, Franco] Univ Perugia, Dipartimento Med & Sci Biochim, I-06122 Perugia, Italy; [Zampella, Angela] Univ Naples Federico II, Dipartimento Chim Sostanze Nat, Naples, Italy; [Distrutti, Eleonora; Fiorucci, Stefano] Osped S Maria Misericordia, Perugia, Italy	University of Perugia; University of Perugia; University of Naples Federico II; Hospital Santa Maria della Misericordia	Renga, B (corresponding author), Univ Perugia, Dipartimento Med Clin & Sperimentale, Via E Pozzo, I-06122 Perugia, Italy.	barbara.renga@unipg.it	Fiorucci, Stefano/I-1251-2012	Zampella, Angela/0000-0002-6170-279X; D'Amore, Claudio/0000-0001-9217-9404				Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; Cariou B, 2005, FEBS LETT, V579, P4076, DOI 10.1016/j.febslet.2005.06.033; Cariou B, 2006, J BIOL CHEM, V281, P11039, DOI 10.1074/jbc.M510258200; Cassuto H, 2005, J BIOL CHEM, V280, P33873, DOI 10.1074/jbc.M504119200; Cipriani S, 2010, J LIPID RES, V51, P771, DOI 10.1194/jlr.M001602; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200; Fiorucci S, 2010, PROG LIPID RES, V49, P171, DOI 10.1016/j.plipres.2009.11.001; Jenson M, 1996, OBES RES, V4, P133, DOI 10.1002/j.1550-8528.1996.tb00525.x; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Liu YJ, 2008, J MOL ENDOCRINOL, V41, P53, DOI 10.1677/JME-08-0004; Liu YJ, 2006, ENDOCRINOLOGY, V147, P5061, DOI 10.1210/en.2006-0243; Liu YJ, 2005, DIABETES, V54, P32, DOI 10.2337/diabetes.54.1.32; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Nehme A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-58; Opherk C, 2004, MOL ENDOCRINOL, V18, P1346, DOI 10.1210/me.2003-0283; Patel R, 2011, J CLIN INVEST, V121, P431, DOI 10.1172/JCI41681; Pellicciari R, 2002, J MED CHEM, V45, P3569, DOI 10.1021/jm025529g; Prawitt J, 2011, DIABETES, V60, P1861, DOI 10.2337/db11-0030; Presul E, 2007, J MOL ENDOCRINOL, V38, P79, DOI 10.1677/jme.1.02183; Renga B, 2010, BBA-MOL BASIS DIS, V1802, P363, DOI 10.1016/j.bbadis.2010.01.002; Renga B, 2009, WORLD J GASTROENTERO, V15, P2097, DOI 10.3748/wjg.15.2097; Sepe V, 2012, J MED CHEM, V55, P84, DOI 10.1021/jm201004p; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; TSAI HJ, 1991, AM J PHYSIOL, V261, pE495, DOI 10.1152/ajpendo.1991.261.4.E495; Turner JD, 2005, J MOL ENDOCRINOL, V35, P283, DOI 10.1677/jme.1.01822; van Dijk TH, 2009, J BIOL CHEM, V284, P10315, DOI 10.1074/jbc.M807317200; Wang L, 2006, MOL ENDOCRINOL, V20, P2671, DOI 10.1210/me.2006-0224; Yabaluri N, 2010, J BIOSCIENCES, V35, P473, DOI 10.1007/s12038-010-0052-0; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Zhang YQ, 2006, P NATL ACAD SCI USA, V103, P1006, DOI 10.1073/pnas.0506982103	36	42	43	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					3021	3031		10.1096/fj.11-195701	http://dx.doi.org/10.1096/fj.11-195701			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22447981				2022-12-28	WOS:000305912500029
J	Getz, GS				Getz, Godfrey S.			Sailing to Byzantium: Eugene P. Kennedy (1919-2011)	FASEB JOURNAL			English	Biographical-Item							BIOSYNTHESIS		Univ Chicago, Dept Pathol & Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Getz, GS (corresponding author), Univ Chicago, Dept Pathol & Biochem & Mol Biol, Chicago, IL 60637 USA.	g-getz@uchicago.edu						Finneran R. B., 1996, COLLECTED POETRY WB; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; KENNEDY EC, PUBLICATION LIST; Kennedy EP, 2001, J BIOL CHEM, V276, P42619, DOI 10.1074/jbc.R100051200; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; KENNEDY EP, 1992, ANNU REV BIOCHEM, V61, P1; KORNBERG A, 1952, FED PROC, V11, P242; Kresge N, 2006, J BIOL CHEM, V281; Wickner WT, 2011, P NATL ACAD SCI USA, V108, P19122, DOI 10.1073/pnas.1117398108; Wickner WT, 2011, P NATL ACAD SCI USA, V108, P17255, DOI 10.1073/pnas.1114405108	11	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2012	26	5					1771	1773		10.1096/fj.12-0502ufm	http://dx.doi.org/10.1096/fj.12-0502ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22547785				2022-12-28	WOS:000303680800002
J	Pogribny, IP; Kutanzi, K; Melnyk, S; de Conti, A; Tryndyak, V; Montgomery, B; Pogribna, M; Muskhelishvili, L; Latendresse, JR; James, SJ; Beland, FA; Rusyn, I				Pogribny, Igor P.; Kutanzi, Kristy; Melnyk, Stepan; de Conti, Aline; Tryndyak, Volodymyr; Montgomery, Beverly; Pogribna, Marta; Muskhelishvili, Levan; Latendresse, John R.; James, S. Jill; Beland, Frederick A.; Rusyn, Ivan			Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury	FASEB JOURNAL			English	Article						strain differences; methyl donor deficiency; gene expression; homocysteinemia; NAFLD	ENDOPLASMIC-RETICULUM STRESS; COULOMETRIC ELECTROCHEMICAL DETECTION; ALCOHOL-FED MICE; FATTY LIVER; GENE-EXPRESSION; INTERSTRAIN DIFFERENCES; COLLABORATIVE CROSS; DISEASE; METHIONINE; HYPERHOMOCYSTEINEMIA	Dysregulation of one-carbon metabolism-related metabolic processes is a major contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). It is well established that genetic and gender-specific variations in one-carbon metabolism contribute to the vulnerability to NAFLD in humans. To examine the role of one-carbon metabolism dysregulation in the pathogenesis and individual susceptibility to NAFLD, we used a "population-based" mouse model where male mice from 7 inbred were fed a choline-and folate-deficient (CFD) diet for 12 wk. Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1 alpha (Mat1a), cystathionine-beta-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed. These changes were strongly associated with interstrain variability in liver injury (steatosis, necrosis, inflammation, and activation of fibrogenesis) and hyperhomocysteinemia. Mechanistically, the decreased expression of Mat1a, Ahcy, and Mthfd1 was linked to a reduced level and promoter binding of transcription factor CCAAT/enhancer binding protein beta (CEBP beta), which directly regulates their transcription. The strain specificity of diet-induced dysregulation of one-carbon metabolism suggests that interstrain variation in the regulation of one-carbon metabolism may contribute to the differential vulnerability to NFLD and that correcting the imbalance may be considered as preventive and treatment strategies for NAFLD.-Pogribny, I. P., Kutanzi, K., Melnyk, S., de Conti, A., Tryndyak, V., Montgomery, B., Pogribna, M., Muskhelishvili, L., Latendresse, J. R., James, S. J., Beland, F. A., Rusyn, I. Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury.	[Pogribny, Igor P.; Kutanzi, Kristy; de Conti, Aline; Tryndyak, Volodymyr; Montgomery, Beverly; Pogribna, Marta; Beland, Frederick A.] US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA; [Muskhelishvili, Levan; Latendresse, John R.] US FDA, Natl Ctr Toxicol Res, Toxicol Pathol Associates, Jefferson, AR 72079 USA; [Melnyk, Stepan; James, S. Jill] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Rusyn, Ivan] Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill	Pogribny, IP (corresponding author), NCTR, Div Biochem Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.	igor.pogribny@fda.hhs.gov	de Conti, Aline/I-1666-2013; Rusyn, Ivan/S-2426-2016	Rusyn, Ivan/0000-0001-9340-7384; Beland, Frederick/0000-0002-2113-6260; Tryndyak, Volodymyr/0000-0002-8319-2954				Adinolfi LE, 2005, HEPATOLOGY, V41, P995, DOI 10.1002/hep.20664; Bravo E, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-60; Buchman AL, 2001, DIGEST DIS SCI, V46, P1, DOI 10.1023/A:1005628121546; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Cheung O, 2010, CURR OPIN GASTROEN, V26, P202, DOI 10.1097/MOG.0b013e328337b0c4; Christensen KE, 2010, J NUTR, V140, P1736, DOI 10.3945/jn.110.124917; Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133; Corbin KD, 2013, FASEB J, V27, P1674, DOI 10.1096/fj.12-219097; Corbin KD, 2012, CURR OPIN GASTROEN, V28, P159, DOI 10.1097/MOG.0b013e32834e7b4b; Daly AK, 2011, EXPERT REV GASTROENT, V5, P253, DOI [10.1586/egh.11.18, 10.1586/EGH.11.18]; Denda A, 2002, JPN J CANCER RES, V93, P125, DOI 10.1111/j.1349-7006.2002.tb01250.x; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feng QP, 2009, J NEUROCHEM, V110, P1806, DOI 10.1111/j.1471-4159.2009.06276.x; Guerrerio AL, 2012, AM J CLIN NUTR, V95, P892, DOI 10.3945/ajcn.111.020156; Harrill AH, 2009, GENOME RES, V19, P1507, DOI 10.1101/gr.090241.108; Harrill AH, 2009, TOXICOL SCI, V110, P235, DOI 10.1093/toxsci/kfp096; Hebbard L, 2011, NAT REV GASTRO HEPAT, V8, P34, DOI 10.1038/nrgastro.2010.191; Henkel AS, 2012, AM J PHYSIOL-GASTR L, V303, pG54, DOI 10.1152/ajpgi.00052.2012; Ikeda R, 2008, INT J BIOCHEM CELL B, V40, P1956, DOI 10.1016/j.biocel.2008.02.004; Ji C, 2008, J GASTROEN HEPATOL, V23, pS16, DOI 10.1111/j.1440-1746.2007.05276.x; Ji C, 2004, WORLD J GASTROENTERO, V10, P1699; Johnson AR, 2010, FASEB J, V24, P2752, DOI 10.1096/fj.09-153718; Kohlmeier M, 2005, P NATL ACAD SCI USA, V102, P16025, DOI 10.1073/pnas.0504285102; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Lubos E, 2007, ANTIOXID REDOX SIGN, V9, P1923, DOI 10.1089/ars.2007.1771; MacFarlane AJ, 2009, J BIOL CHEM, V284, P1533, DOI 10.1074/jbc.M808281200; Maher JJ, 2011, ANTIOXID REDOX SIGN, V15, P535, DOI 10.1089/ars.2010.3749; Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005; Medici V, 2013, MOL NUTR FOOD RES, V57, P596, DOI 10.1002/mnfr.201200077; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Melnyk S, 2000, CLIN CHEM, V46, P265; Molloy Anne M, 2012, Subcell Biochem, V56, P105, DOI 10.1007/978-94-007-2199-9_7; Pagliassotti MJ, 2012, ANNU REV NUTR, V32, P17, DOI 10.1146/annurev-nutr-071811-150644; Pogribny IP, 2012, MOL NUTR FOOD RES, V56, P116, DOI 10.1002/mnfr.201100524; Pogribny IP, 2009, J HEPATOL, V51, P176, DOI 10.1016/j.jhep.2009.03.021; Powell CL, 2005, HEPATOLOGY, V42, P1137, DOI 10.1002/hep.20910; Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200; Robert K, 2005, GASTROENTEROLOGY, V128, P1405, DOI 10.1053/j.gastro.2005.02.034; Roberts A, 2007, MAMM GENOME, V18, P473, DOI 10.1007/s00335-007-9045-1; Rusyn I, 2010, PHARMACOGENOMICS, V11, P1127, DOI [10.2217/pgs.10.100, 10.2217/PGS.10.100]; Shinohara M, 2010, HEPATOLOGY, V51, P796, DOI 10.1002/hep.23391; SHIVAPURKAR N, 1986, J NATL CANCER I, V77, P213; Song JN, 2005, FASEB J, V19, P1266, DOI 10.1096/fj.04-3580com; Soon RK, 2010, GASTROENTEROLOGY, V139, P1730, DOI 10.1053/j.gastro.2010.07.046; Tacke F, 2012, EXPERT REV GASTROENT, V6, P67, DOI [10.1586/egh.11.92, 10.1586/EGH.11.92]; Teng YW, 2011, J BIOL CHEM, V286, P36258, DOI 10.1074/jbc.M111.265348; Threadgill DW, 2012, GENETICS, V190, P291, DOI 10.1534/genetics.111.138032; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Tryndyak V, 2012, FASEB J, V26, P4592, DOI 10.1096/fj.12-209569; Tryndyak VP, 2012, TOXICOL APPL PHARM, V262, P52, DOI 10.1016/j.taap.2012.04.018; Tryndyak VP, 2011, MOL NUTR FOOD RES, V55, P411, DOI 10.1002/mnfr.201000300; Tsuchiya M, 2012, HEPATOLOGY, V56, P130, DOI 10.1002/hep.25641; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045	55	24	24	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2233	2243		10.1096/fj.12-227116	http://dx.doi.org/10.1096/fj.12-227116			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23439872				2022-12-28	WOS:000319667600014
J	Danielson, LS; Park, DS; Rotllan, N; Chamorro-Jorganes, A; Guijarro, MV; Fernandez-Hernando, C; Fishman, GI; Phoon, CKL; Hernando, E				Danielson, Laura S.; Park, David S.; Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Guijarro, Maria V.; Fernandez-Hernando, Carlos; Fishman, Glenn I.; Phoon, Colin K. L.; Hernando, Eva			Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis	FASEB JOURNAL			English	Article						microRNA; mouse model; connexin43; Pten	SMOOTH-MUSCLE-CELLS; CARDIAC-HYPERTROPHY; EXPRESSION; DIFFERENTIATION; MICE; PROLIFERATION; CONDUCTION; MICRORNAS; DELETION	MicroRNA cluster miR-17-92 has been implicated in cardiovascular development and function, yet its precise mechanisms of action in these contexts are uncertain. This study aimed to investigate the role of miR-17-92 in morphogenesis and function of cardiac and smooth muscle tissues. To do so, a mouse model of conditional overexpression of miR-17-92 in cardiac and smooth muscle tissues was generated. Extensive cardiac functional studies identified a dose-dependent induction of dilated, hypertrophic cardiomyopathy, and arrhythmia inducibility in transgenic animals, which correlated with premature mortality (98.3+/-42.5 d, P<0.0001). Expression analyses revealed the abundance of Pten transcript, a known miR-17-92 target, to be inversely correlated with miR-17-92 expression levels and heart size. In addition, we demonstrated through 3'-UTR luciferase assays and expression analyses that Connexin43 (Cx43) is a novel direct target of miR-19a/b and its expression is suppressed in transgenic hearts. Taken together, these data demonstrate that dysregulated expression of miR-17-92 during cardiovascular morphogenesis results in a lethal cardiomyopathy, possibly in part through direct repression of Pten and Cx43. This study highlights the importance of miR-17-92 in both normal and pathological functions of the heart, and provides a model that may serve as a useful platform to test novel antiarrhythmic therapeutics.-Danielson, L. S., Park, D. S., Rotllan, N., Chamorro-Jorganes, A., Guijarro, M. V., Fernandez-Hernando, C., Fishman, G. I., Phoon, C. K. L., Hernando, E. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 27, 1460-1467 (2013). www.fasebj.org	[Danielson, Laura S.; Guijarro, Maria V.; Hernando, Eva] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Park, David S.; Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Fernandez-Hernando, Carlos; Fishman, Glenn I.] NYU, Sch Med, Leon H Charney Div Cardiol, Dept Med, New York, NY 10016 USA; [Phoon, Colin K. L.] NYU, Sch Med, Dept Pediat, Div Pediat Cardiol, New York, NY 10016 USA	New York University; New York University; New York University	Hernando, E (corresponding author), NYU, Sch Med, 550 1st Ave,Smilow 305, New York, NY 10016 USA.	colin.phoon@med.nyu.edu; eva.hernando@med.nyu.edu	Phoon, Colin K/C-9270-2009; Jorganes, Aranzazu Chamorro/N-7774-2019; Chamorro-Jorganes, Aranzazu/B-1871-2019; Rotllan, Noemi/P-1375-2014; Vila, Noemi Rotllan/AAQ-8050-2020	Jorganes, Aranzazu Chamorro/0000-0002-3505-7221; Chamorro-Jorganes, Aranzazu/0000-0002-3505-7221; Rotllan, Noemi/0000-0002-0587-8045; Vila, Noemi Rotllan/0000-0002-0587-8045; Fishman, Glenn/0000-0002-2366-8527; Hernando, Eva/0000-0003-1023-0312; Chamorro Jorganes, Aranzazu/0000-0003-2648-6945	New York University (NYU) Cancer Institute Cancer Center [5P30CA016087-32]; NYU-Health and Hospitals Corp.; Clinical and Translational Science Institute; National Center for Advancing Translational Sciences/U.S. National Institutes of Health (NIH) [UL1 TR000038]; NIH/National Center for Research Resources [1ULIRR029893]; Liddy Shriver Sarcoma Initiative; LMS Direct Research Foundation; Edna's Foundation of Hope; NIH [R01HL82727, S10RR026881, R01HL106063, R01HL107953]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000038] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026881] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107953, R01HL082727, R01HL106063] Funding Source: NIH RePORTER	New York University (NYU) Cancer Institute Cancer Center; NYU-Health and Hospitals Corp.; Clinical and Translational Science Institute; National Center for Advancing Translational Sciences/U.S. National Institutes of Health (NIH); NIH/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Liddy Shriver Sarcoma Initiative; LMS Direct Research Foundation; Edna's Foundation of Hope; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Fang-Yu Liu for technical assistance, and the Experimental Pathology Core resource, partially supported by the New York University (NYU) Cancer Institute Cancer Center, support grant 5P30CA016087-32. This work was partially funded by the NYU-Health and Hospitals Corp. Clinical and Translational Science Institute [which is supported in part by grant UL1 TR000038 from the National Center for Advancing Translational Sciences/U.S. National Institutes of Health (NIH)], NIH/National Center for Research Resources 1ULIRR029893, the Liddy Shriver Sarcoma Initiative, the LMS Direct Research Foundation, Edna's Foundation of Hope to E. H., NIH grants R01HL82727 and S10RR026881 to G. I. F., and NIH grants R01HL106063 and R01HL107953 to C.F.-H. The authors declare no conflicts of interest.	Albinsson S, 2010, ARTERIOSCL THROM VAS, V30, P1118, DOI 10.1161/ATVBAHA.109.200873; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864; Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154; Chen JH, 2012, J MOL CELL CARDIOL, V52, P949, DOI 10.1016/j.yjmcc.2012.01.012; Chen ZX, 2012, J BIOL CHEM, V287, P19018, DOI 10.1074/jbc.M112.351791; Collis LP, 2007, FASEB J, V21, P475, DOI 10.1096/fj.06-6292com; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Danielson LS, 2010, AM J PATHOL, V177, P908, DOI 10.2353/ajpath.2010.091150; Ella L, 2009, CELL DEATH DIFFER, V16, P1590, DOI 10.1038/cdd.2009.153; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736; Lepore JJ, 2005, GENESIS, V41, P179, DOI 10.1002/gene.20112; Liu N, 2008, GENE DEV, V22, P3242, DOI 10.1101/gad.1738708; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Maguire CT, 2003, PHYSIOL GENOMICS, V15, P84, DOI 10.1152/physiolgenomics.00034.2003; Malhowski AJ, 2011, HUM MOL GENET, V20, P1290, DOI 10.1093/hmg/ddq570; Nomura-Kitabayashi A, 2009, AM J PHYSIOL-HEART C, V297, pH1617, DOI 10.1152/ajpheart.00304.2009; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Pullamsetti SS, 2012, AM J RESP CRIT CARE, V185, P409, DOI 10.1164/rccm.201106-1093OC; Tomasoni R, 2011, BIOCHEM SOC T, V39, P466, DOI 10.1042/BST0390466; van Almen GC, 2011, AGING CELL, V10, P769, DOI 10.1111/j.1474-9726.2011.00714.x; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang J, 2012, CELL RES, V22, P516, DOI 10.1038/cr.2011.132; Wang J, 2010, DEV CELL, V19, P903, DOI 10.1016/j.devcel.2010.10.022; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Wilson KD, 2010, CIRC-CARDIOVASC GENE, V3, P426, DOI 10.1161/CIRCGENETICS.109.934281; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	31	88	98	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1460	1467		10.1096/fj.12-221994	http://dx.doi.org/10.1096/fj.12-221994			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271053	Green Published			2022-12-28	WOS:000316940800018
J	Binger, KJ; Ecroyd, H; Yang, S; Carver, JA; Howlett, GJ; Griffin, MDW				Binger, Katrina J.; Ecroyd, Heath; Yang, Shuo; Carver, John A.; Howlett, Geoffrey J.; Griffin, Michael D. W.			Avoiding the oligomeric state: alpha B-crystallin inhibits fragmentation and induces dissociation of apolipoprotein C-II amyloid fibrils	FASEB JOURNAL			English	Article						protein misfolding; aggregation; molecular chaperone; heat-shock protein	HEAT-SHOCK PROTEINS; SEDIMENTATION-VELOCITY ANALYSIS; MOLECULAR CHAPERONE; ALZHEIMERS-DISEASE; A-BETA; SYNUCLEIN; LACTALBUMIN; ASSOCIATION; ELONGATION; PATHWAY	The in vivo aggregation of proteins into amyloid fibrils suggests that cellular mechanisms that normally prevent or reverse this aggregation have failed. The small heat-shock molecular chaperone protein alpha B-crystallin (alpha B-c) inhibits amyloid formation and colocalizes with amyloid plaques; however, the physiological reason for this localization remains unexplored. Here, using apolipoprotein C-II (apoC-II) as a model fibril-forming system, we show that alpha B-c binds directly to mature amyloid fibrils (K-d 5.4 +/- 0.5 mu M). In doing so, alpha B-c stabilized the fibrils from dilution-induced fragmentation, halted elongation of partially formed fibrils, and promoted the dissociation of mature fibrils into soluble monomers. Moreover, in the absence of dilution, the association of alpha B-c with apoC-II fibrils induced a 14-fold increase in average aggregate size, resulting in large fibrillar tangles reminiscent of protein inclusions. We propose that the binding of alpha B-c to fibrils prevents fragmentation and mediates the lateral association of fibrils into large inclusions. We further postulate that transient interactions of apoC-II with alpha B-c induce a fibril-incompetent monomeric apoC-II form, preventing oligomerization and promoting fibril dissociation. This work reveals previously unrecognized mechanisms of alpha B-c chaperone action in amyloid assembly and fibril dynamics, and provides a rationale for the in vivo colocalization of small heat-shock proteins with amyloid deposits.-Binger, K. J., Ecroyd, H., Yang, S., Carver, J. A., Howlett, G. J., Griffin, M. D. W. Avoiding the oligomeric state: alpha B-crystallin inhibits fragmentation and induces dis-sociation of apolipoprotein C-II amyloid fibrils. FASEB J. 27, 1214-1222 (2013). www.fasebj.org	[Binger, Katrina J.; Yang, Shuo; Howlett, Geoffrey J.; Griffin, Michael D. W.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; [Binger, Katrina J.] Commonwealth Sci & Ind Res Org Mol Hlth Technol, Parkville, Vic, Australia; [Ecroyd, Heath] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia; [Ecroyd, Heath] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Carver, John A.] Univ Adelaide, Sch Chem & Phys, Adelaide, SA, Australia	University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Wollongong; University of Wollongong; University of Adelaide	Griffin, MDW (corresponding author), Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, 30 Flemington Rd, Parkville, Vic 3010, Australia.	mgriffin@unimelb.edu.au	Carver, John Adrian/J-3825-2014; Binger, Katrina/G-6640-2018; Ecroyd, Heath/E-7140-2015	Carver, John Adrian/0000-0002-2441-8108; Binger, Katrina/0000-0003-1139-3308; Griffin, Michael/0000-0001-9845-7735; Ecroyd, Heath/0000-0001-7574-0044	Australian Research Council (ARC) [DP0877800]; ARC [DP110103528, FT110100586]; Australian National Health and Medical Research Council [APP1037633]	Australian Research Council (ARC)(Australian Research Council); ARC(Australian Research Council); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by the Australian Research Council (ARC) Discovery Projects funding scheme (DP0877800). M. D. W. G. is the recipient of an ARC Postdoctoral Fellowship (DP110103528). H. E. is the recipient of an ARC Future Fellowship (FT110100586). K. J. B. is the recipient of a Australian National Health and Medical Research Council C. J. Martin Fellowship (APP1037633).	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Balbo A, 2005, PROTEIN PROTEIN INTE; Basha E, 2012, TRENDS BIOCHEM SCI, V37, P106, DOI 10.1016/j.tibs.2011.11.005; Binger KJ, 2008, BIOCHEMISTRY-US, V47, P10208, DOI 10.1021/bi8009339; Binger KJ, 2008, J MOL BIOL, V376, P1116, DOI 10.1016/j.jmb.2007.12.055; Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Ecroyd H, 2009, CELL MOL LIFE SCI, V66, P62, DOI 10.1007/s00018-008-8327-4; Ecroyd H, 2007, BIOCHEM J, V401, P129, DOI 10.1042/BJ20060981; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; Fuxreiter M, 2004, J MOL BIOL, V338, P1015, DOI 10.1016/j.jmb.2004.03.017; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Griffin MDW, 2008, J MOL BIOL, V375, P240, DOI 10.1016/j.jmb.2007.10.038; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hatters DM, 2001, J BIOL CHEM, V276, P33755, DOI 10.1074/jbc.M105285200; Hatters DM, 2000, BIOCHEMISTRY-US, V39, P8276, DOI 10.1021/bi000002w; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Knowles TPJ, 2009, SCIENCE, V326, P1533, DOI 10.1126/science.1178250; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; MacRaild CA, 2003, BIOPHYS J, V84, P2562, DOI 10.1016/S0006-3495(03)75061-9; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; Mok YF, 2006, METHOD ENZYMOL, V413, P199, DOI 10.1016/S0076-6879(06)13011-6; Mok YF, 2011, METHODS, V54, P67, DOI 10.1016/j.ymeth.2010.10.004; Outeiro Tiago Fleming, 2007, Semin Pediatr Neurol, V14, P15, DOI 10.1016/j.spen.2006.11.005; Pountney DL, 2005, NEUROTOX RES, V7, P77, DOI 10.1007/BF03033778; Rekas A, 2004, J MOL BIOL, V340, P1167, DOI 10.1016/j.jmb.2004.05.054; Rekas A, 2007, FEBS J, V274, P6290, DOI 10.1111/j.1742-4658.2007.06144.x; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; Ryan TM, 2008, J BIOL CHEM, V283, P35118, DOI 10.1074/jbc.M804004200; Shammas SL, 2011, BIOPHYS J, V101, P1681, DOI 10.1016/j.bpj.2011.07.056; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; Simon S, 2010, PROTEIN SCI ENG, P457; Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Waudby CA, 2010, BIOPHYS J, V98, P843, DOI 10.1016/j.bpj.2009.10.056; Wilhelmus MMM, 2006, NEUROPATH APPL NEURO, V32, P119, DOI 10.1111/j.1365-2990.2006.00689.x; Wilson LM, 2006, J LIPID RES, V47, P755, DOI 10.1194/jlr.C500022-JLR200	40	40	41	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1214	1222		10.1096/fj.12-220657	http://dx.doi.org/10.1096/fj.12-220657			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23159935				2022-12-28	WOS:000315585200033
J	Lim, J; Iyer, A; Suen, JY; Seow, V; Reid, RC; Brown, L; Fairlie, DP				Lim, Junxian; Iyer, Abishek; Suen, Jacky Y.; Seow, Vernon; Reid, Robert C.; Brown, Lindsay; Fairlie, David P.			C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling	FASEB JOURNAL			English	Article						adipose inflammation; complement; GPCR; metabolism; immunity	ADIPOSE-TISSUE; INSULIN-RESISTANCE; COMPLEMENT; INFLAMMATION; RECEPTOR; CELLS; INFILTRATION; LIPOLYSIS; PATHWAY; C5L2	Mammalian survival depends on metabolizing nutrients, storing energy, and combating infection. Complement activation in blood triggers energy-depleting immune responses to fight infections. Here we identify surprising energy-conserving roles for complement proteins C5a and C3a and their receptors, C5aR and C3aR, roles that are contraindicated in complement biology. Rats fed a high-carbohydrate high-fat diet developed obesity, visceral adiposity, adipose inflammation, glucose/insulin intolerance, and cardiovascular dysfunction that correlated with increased plasma C3a, adipose C5aR, and C3aR. These in vivo changes were dramatically attenuated by receptor-selective antagonists of either C5aR (5 mg/kg/d p.o.) or C3aR (30 mg/kg/d p.o.), which both reduced pro-inflammatory adipokines and altered expression of inflammatory genes in adipose tissue. In vitro C5a and C3a (100 nM) exhibited novel insulin-like effects on 3T3-L1 adipocytes, promoting energy conservation by increasing glucose and fatty acid uptake while inhibiting cAMP signaling and lipolysis, and induced PGE2 release from macrophages, effects all blocked by each respective antagonist (10 mu M). These studies reveal important new links between complement signaling and metabolism, highlight new complement functions on adipocytes and in adipose tissue, demonstrate how aberrant immune responses may exacerbate obesity and metabolic dysfunction, and show that targeting C3aR or C5aR with antagonists is a new strategy for treating metabolic dysfunction.-Lim, J., Iyer, A., Suen, J. Y., Seow, V., Reid, R. C., Brown, L., Fairlie, D. P. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. 27, 822-831 (2013). www.fasebj.org	[Lim, Junxian; Iyer, Abishek; Suen, Jacky Y.; Seow, Vernon; Reid, Robert C.; Brown, Lindsay; Fairlie, David P.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Brown, Lindsay] Univ So Queensland, Fac Sci, Toowoomba, Qld 4350, Australia	University of Queensland; University of Southern Queensland	Brown, L (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	lindsay.brown@usq.edu.au; d.fairlie@imb.uq.edu.au	Reid, Robert/D-8041-2012; Fairlie, David P/F-8865-2014; Iyer, Abishek/C-9767-2017; Lim, Junxian/J-2275-2017; Suen, Jacky/G-4077-2015	Reid, Robert/0000-0002-0829-239X; Fairlie, David P/0000-0002-7856-8566; Iyer, Abishek/0000-0001-9533-5265; Lim, Junxian/0000-0002-8309-0704; Suen, Jacky/0000-0002-0309-2524	Australian Research Council [DP1093245]; Federation Fellowship [FF0668733]; Australian National Health and Medical Research Council [631534]; Senior Principal Research Fellowship [APP1027369]; Institute for Molecular Bioscience; University of Queensland	Australian Research Council(Australian Research Council); Federation Fellowship; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Senior Principal Research Fellowship; Institute for Molecular Bioscience; University of Queensland(University of Queensland)	The authors thank the Australian Research Council (grant DP1093245), Federation Fellowship FF0668733, the Australian National Health and Medical Research Council (grant 631534), and Senior Principal Research Fellowship APP1027369 (to D. F.) for funding, and the Institute for Molecular Bioscience and The University of Queensland for Ph.D. scholarships (to J.L. and V. S.). Author contributions: J.L., A. I., and D. F. wrote the manuscript with important editorial input from L. B.; J.L. and A. I. contributed most research results with help on gene expression and cell regulation from J.S. and V. S., all working in the laboratories of D. F. and L. B.; R. R. synthesized and characterized the key antagonists.; J.L., A. I., L. B., and D. F. designed the experiments. The authors declare no conflicts of interest.	Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Engstrom G, 2005, DIABETOLOGIA, V48, P2525, DOI 10.1007/s00125-005-0021-6; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Iyer A, 2010, BRIT J PHARMACOL, V159, P1408, DOI 10.1111/j.1476-5381.2010.00637.x; Iyer A, 2010, NAT REV ENDOCRINOL, V6, P71, DOI 10.1038/nrendo.2009.264; Jaworski K, 2009, NAT MED, V15, P159, DOI 10.1038/nm.1904; Johswich K, 2006, J BIOL CHEM, V281, P39088, DOI 10.1074/jbc.M609734200; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Laaksonen DE, 2002, DIABETES CARE, V25, P1612, DOI 10.2337/diacare.25.9.1612; Li P, 2010, NATURE, V464, P1287, DOI 10.1038/4641287a; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Mamane Y, 2009, DIABETES, V58, P2006, DOI 10.2337/db09-0323; Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Panchal SK, 2011, J CARDIOVASC PHARM, V57, P611, DOI [10.1097/FJC.0b013e3181feb90a, 10.1097/FJC.0b013e31821b1379]; Phillips CM, 2009, AM J CLIN NUTR, V90, P1665, DOI 10.3945/ajcn.2009.28101; Proctor LM, 2004, BRIT J PHARMACOL, V142, P756, DOI 10.1038/sj.bjp.0705819; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Scola AM, 2007, J BIOL CHEM, V282, P3664, DOI 10.1074/jbc.M609178200; Scully CCG, 2010, J MED CHEM, V53, P4938, DOI 10.1021/jm1003705; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Suen JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013809; Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487; van Lith LHC, 2009, J BIOMOL SCREEN, V14, P1067, DOI 10.1177/1087057109341407; van Oostrom AJHHM, 2007, ATHEROSCLEROSIS, V190, P167, DOI 10.1016/j.atherosclerosis.2006.01.009; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Weyer C, 2000, DIABETES CARE, V23, P779, DOI 10.2337/diacare.23.6.779; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamamoto N, 2010, ANAL BIOCHEM, V404, P238, DOI 10.1016/j.ab.2010.05.012; Yang X, 2009, NAT GENET, V41, P415, DOI 10.1038/ng.325; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang JH, 2007, AM J PHYSIOL-ENDOC M, V292, pE1433, DOI 10.1152/ajpendo.00664.2006	42	88	93	2	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					822	831		10.1096/fj.12-220582	http://dx.doi.org/10.1096/fj.12-220582			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118029				2022-12-28	WOS:000314358000040
J	Liu, CH; Yang, JS; Ren, JQ; Liu, CM; You, ZR; Liu, PK				Liu, Christina H.; Yang, Jinsheng; Ren, Jia Q.; Liu, Charng-Ming; You, Zerong; Liu, Philip K.			MRI reveals differential effects of amphetamine exposure on neuroglia in vivo	FASEB JOURNAL			English	Article						drug delivery; molecular MR imaging; nanomedicine; gliogenesis	BLOOD-BRAIN-BARRIER; FIBRILLARY ACIDIC PROTEIN; GENE-EXPRESSION; SEROTONIN NEUROTOXICITY; MESSENGER-RNA; STEM-CELLS; METHAMPHETAMINE; PROBES; LIVE; DELIVERY	How amphetamine affects the neuroglia in living brains is not well understood. In an effort to elucidate this effect, we investigated neuroglia in response to amphetamine exposure using antisense (AS) or sense (S) phosphorothioate-modified oligodeoxynucleotide (sODN) sequences that correspond to glial fibrillary acidic protein (GFAP) mRNA (AS-gfap or S-gfap, respectively) expression. The control is a random-sequence sODN (Ran). Using cyanine 5.5-super-paramagnetic iron oxide nanoparticle (Cy5.5-SPION) labeling and fluorescent microscopy, we demonstrated that living neural progenitor cells (PC-12.1), as well as the cells in fresh brain slices and intact brains of male C57BL6 mice, exhibited universal uptake of all of the sODNs but rapidly excluded all sODN-Ran and most S-gfap. Moreover, transmission electron microscopy revealed electron-dense nanoparticles only in the neuroglia of normal or transgenic mice [B6;DBA-Tg(Fos-tTA, Fos-EGFP*)1MmayTg(tetO-lacZ,tTA*)1Mmay/J] that had been administered AS-gfap or Cy5.5-SPION-gfap. Subtraction R2* maps from mice with acute and chronic amphetamine exposure demonstrated, validated by postmortem immunohistochemistry, a reduction in striatal neuroglia, with gliogenesis in the subventricular zone and the somatosensory cortex in vivo. The sensitivity of our unique gene transcript targeted MRI was illustrated by a positive linear correlation (r(2) = 1.0) between in vivo MRI signal changes and GFAP mRNA copy numbers determined by ex vivo quantitative RTPCR. The study provides direct evidence for targeting neuroglia by antisense DNA-based SPION-gfap that enables in vivo MRI of inaccessible tissue with PCR sensitivity. The results enable us to conclude that amphetamine induces toxicity to neuroglia in vivo, which may cause remodeling or reconnectivity of neuroglia.-Liu, C. H., Yang, J., Ren, J. Q., Liu, C.-M., You, Z., Liu, P. K. MRI reveals differential effects of amphetamine exposure on neuroglia in vivo. FASEB J. 27, 712-724 (2013). www.fasebj.org	[Liu, Christina H.; Yang, Jinsheng; Ren, Jia Q.; Liu, Charng-Ming; Liu, Philip K.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Liu, PK (corresponding author), CNY149 2301 13th St, Charlestown, MA 02129 USA.	philipl@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X	American Heart Association [2060416]; U.S. National Institutes of Health (NIH) [AT004974, DA026108, DA029889, EB013768, NS045776]; NIH [DK43351, DK57521]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB013768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK057521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA026108, R01DA029889] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Ms. N. Eusemann for help with editing. This project was supported by grants from the American Heart Association (09Grant2060416) and the U.S. National Institutes of Health (NIH; AT004974 to J.Q.R.; DA026108, DA029889, and EB013768 to P. K. L.; and NS045776 to the Massachusetts General Hospital Neuroscience Center). The 9.4-T MR system used for this work was funded in part by an NIH Shared Instrumentation grant awarded to the Athinoula A. Martinos Center for Biomedical Imaging. The authors appreciate the help of M. McKee with TEM, and the availability of the Microscopy Core (which is supported by NIH DK43351 and DK57521). Author contributions: C. H. L. contributed to MRI acquisition and data analysis and wrote the initial draft of the manuscript; J.Y. contributed to qRT-PCR and TaqMan analysis; J.Q.R. established brain slice cultures, delivered SPION-gfap, and contributed to histology and TEM; C.-M. L. synthesized and modified sODN and carried out PC-12.1 culture studies; Z.Y. contributed to immunohistology; P. K. L. coordinated and provided overall oversight for the project, designed and prepared SPION-sODN, carried out time-lapse microscopy, and supervised the various phases of revision of the manuscript.	Armstrong V, 2004, EUR J PHARMACOL, V488, P111, DOI 10.1016/j.ejphar.2004.02.001; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Berman SC, 2011, MAGN RESON MED, V65, P564, DOI 10.1002/mrm.22613; Bowyer JF, 2006, SYNAPSE, V60, P521, DOI 10.1002/syn.20324; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI 10.1111/j.1365-2990.2010.01131.x; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Chadi G, 2009, J MOL HISTOL, V40, P241, DOI 10.1007/s10735-009-9235-0; Fitzgerald ML, 2007, J LIPID RES, V48, P621, DOI 10.1194/jlr.M600449-JLR200; Fornai F, 2004, PSYCHOPHARMACOLOGY, V173, P353, DOI 10.1007/s00213-003-1708-3; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Frey BN, 2006, PROG NEURO-PSYCHOPH, V30, P1231, DOI 10.1016/j.pnpbp.2006.03.016; GYURKO R, 1993, REGUL PEPTIDES, V49, P167, DOI 10.1016/0167-0115(93)90438-E; Huang YN, 2009, TOXICOL APPL PHARM, V240, P315, DOI 10.1016/j.taap.2009.06.021; Ichikawa T, 2002, NEOPLASIA, V4, P523, DOI 10.1038/sj.neo.7900266; Kita T, 2009, INT REV NEUROBIOL, V88, P43, DOI 10.1016/S0074-7742(09)88003-3; Kitamura O, 2010, LEGAL MED-TOKYO, V12, P57, DOI 10.1016/j.legalmed.2009.11.001; Koffie RM, 2011, P NATL ACAD SCI USA, V108, P18837, DOI 10.1073/pnas.1111405108; Krasnova IN, 2005, FASEB J, V19, P851, DOI 10.1096/fj.04-2881fje; Ladenheim B, 2000, MOL PHARMACOL, V58, P1247, DOI 10.1124/mol.58.6.1247; Lee JH, 2010, NATURE, V465, P788, DOI 10.1038/nature09108; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; Liu CH, 2008, FASEB J, V22, P1193, DOI 10.1096/fj.07-9557com; Liu CH, 2007, FASEB J, V21, P3004, DOI 10.1096/fj.07-8203com; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; Liu CH, 2012, FASEB J, V26, P1652, DOI 10.1096/fj.11-199547; Liu CH, 2009, J NEUROSCI, V29, P10663, DOI 10.1523/JNEUROSCI.2167-09.2009; Liu CH, 2009, J NEUROSCI, V29, P3508, DOI 10.1523/JNEUROSCI.5332-08.2009; Liu PK, 2011, METHODS MOL BIOL, V711, P363, DOI 10.1007/978-1-61737-992-5_18; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Malaplate-Armand C, 2005, TOXICOL LETT, V159, P203, DOI 10.1016/j.toxlet.2005.04.005; Malberg JE, 1998, J NEUROSCI, V18, P5086; Mao LM, 2001, DEV BRAIN RES, V130, P41, DOI 10.1016/S0165-3806(01)00195-X; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; Messing A, 1998, AM J PATHOL, V152, P391; MULDOON LL, 1995, AM J PATHOL, V147, P1840; Narita M, 2008, ANN NY ACAD SCI, V1141, P96, DOI 10.1196/annals.1441.032; Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094; ODAWARA T, 1995, NEUROSCI LETT, V192, P145, DOI 10.1016/0304-3940(95)11595-N; PARDRIDGE WM, 1995, P NATL ACAD SCI USA, V92, P5592, DOI 10.1073/pnas.92.12.5592; Paxinos G., 2001, THE MOUSE BRAIN IN S, DOI DOI 10.1084/JEM.20081588; Peleg-Raibstein D, 2008, BEHAV BRAIN RES, V191, P190, DOI 10.1016/j.bbr.2008.03.037; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; ROLLAND B, 1990, DEV BRAIN RES, V56, P144, DOI 10.1016/0165-3806(90)90175-X; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030; Shi NY, 2001, P NATL ACAD SCI USA, V98, P12754, DOI 10.1073/pnas.221450098; Shi NY, 2000, P NATL ACAD SCI USA, V97, P14709, DOI 10.1073/pnas.250332397; SILVER J, 1993, J COMP NEUROL, V328, P415, DOI 10.1002/cne.903280308; Smith MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-409; Strauch RC, 2011, J AM CHEM SOC, V133, P16346, DOI 10.1021/ja206134b; Tanibuchi Y., 2010, GEN HOSP PSYCHIAT, V32; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; Tocharus J, 2010, J PINEAL RES, V48, P347, DOI 10.1111/j.1600-079X.2010.00761.x; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; Winkler J, 2010, CHEMMEDCHEM, V5, P1344, DOI 10.1002/cmdc.201000156	61	10	10	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					712	724		10.1096/fj.12-220061	http://dx.doi.org/10.1096/fj.12-220061			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150521	Green Published			2022-12-28	WOS:000314358000030
J	Yereddi, NR; Cusdin, FS; Namadurai, S; Packman, LC; Monie, TP; Slavny, P; Clare, JJ; Powell, AJ; Jackson, AP				Yereddi, Nikitha R.; Cusdin, Fiona S.; Namadurai, Sivakumar; Packman, Len C.; Monie, Tom P.; Slavny, Peter; Clare, Jeffrey J.; Powell, Andrew J.; Jackson, Antony P.			The immunoglobulin domain of the sodium channel beta 3 subunit contains a surface-localized disulfide bond that is required for homophilic binding	FASEB JOURNAL			English	Article						cell adhesion molecule; evolutionary trace analysis; mass spectrometry	AUXILIARY SUBUNIT; CELL-ADHESION; EXTRACELLULAR DOMAIN; NEURITE OUTGROWTH; MAMMALIAN-CELLS; PROTEIN; EXPRESSION; GLYCOSYLATION; INACTIVATION; MODULATION	The beta subunits of voltage-gated sodium (Na-v) channels possess an extracellular immunoglobulin (Ig) domain that is related to the L1 family of cell-adhesion molecules (CAMs). Here we show that in HEK293 cells, secretion of the free Ig domain of the beta 3 subunit is reduced significantly when it is coexpressed with the full-length beta 3 and beta 1 subunits but not with the beta 2 subunit. Using immunoprecipitation, we show that the beta 3 subunit can mediate trans homophilic-binding via its Ig domain and that the beta 3-Ig domain can associate heterophilically with the beta 1 subunit. Evolutionary tracing analysis and structural modeling identified a cluster of surface-localized amino acids fully conserved between the Ig domains of all known beta 3 and beta 1 sequences. A notable feature of this conserved surface cluster is the presence of two adjacent cysteine residues that previously we have suggested may form a disulfide bond. We now confirm the presence of the disulfide bond in beta 3 using mass spectrometry, and we show that its integrity is essential for the association of the full-length, membrane-anchored beta 3 subunit with itself. However, selective reduction of this surface disulfide bond did not inhibit homophilic binding of the purified beta 3-Ig domain in free solution. Hence, the disulfide bond itself is unlikely to be part of the homophilic binding site. Rather, we suggest that its integrity ensures the Ig domain of the membrane-tethered beta 3 subunit adopts the correct orientation for productive association to occur in vivo.-Yereddi, N. R., Cusdin, F. S., Namadurai, S., Packman, L. C., Monie, T. P., Slavny, P., Clare, J. C., Powell, A. J., Jackson, A. P. The immunoglobulin domain of the sodium channel beta 3 subunit contains a surface-localized disulfide bond that is required for homophilic binding. FASEB J. 27, 568-580 (2013). www.fasebj.org	[Yereddi, Nikitha R.; Cusdin, Fiona S.; Namadurai, Sivakumar; Packman, Len C.; Monie, Tom P.; Slavny, Peter; Jackson, Antony P.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Cusdin, Fiona S.; Clare, Jeffrey J.; Powell, Andrew J.] GlaxoSmithKline, Stevenage, Herts, England	University of Cambridge; GlaxoSmithKline	Jackson, AP (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	apj10@bioc.cam.ac.uk		Powell, Andrew/0000-0003-1540-537X; Monie, Tom/0000-0003-4097-1680; Jackson, Antony Philip/0000-0002-2895-7387; Slavny, Peter/0000-0003-0757-8326	Cambridge University; U.K. Biotechnology and Biological Sciences Research Council; GlaxoSmithKline; Wellcome Trust [WT085090MA]	Cambridge University(University of Cambridge); U.K. Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GlaxoSmithKline(GlaxoSmithKline); Wellcome Trust(Wellcome Trust)	N.R.Y. was supported by funds from Cambridge University. F. S. C. was supported by a Collaborative Awards in Science and Engineering (CASE) studentship from the U.K. Biotechnology and Biological Sciences Research Council and funds from GlaxoSmithKline. T. P. M. was supported by a Wellcome Trust Career Development Award (WT085090MA). The authors thank John McCafferty for helping with Gateway cloning technology and Jamie Ashby for helpful comments.	BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brackenbury W. J., FRONT PHARM, V2, P53; Brackenbury WJ, 2008, J NEUROSCI, V28, P3246, DOI 10.1523/JNEUROSCI.5446-07.2008; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chahine M., FRONT PHARM, V2, P70; Chapple SDJ, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-49; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; Cusdin FS, 2008, TRAFFIC, V9, P17, DOI 10.1111/j.1600-0854.2007.00673.x; Cusdin FS, 2010, J BIOL CHEM, V285, P33404, DOI 10.1074/jbc.M110.114058; Davis TH, 2004, J BIOL CHEM, V279, P51424, DOI 10.1074/jbc.M410830200; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; Gallegos-Perez JL, 2005, ANAL BIOCHEM, V346, P311, DOI 10.1016/j.ab.2005.08.003; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; Hakim P., 2009, ACTA PHYSL OXF, V198, P47; Hakim P, 2008, PROG BIOPHYS MOL BIO, V98, P251, DOI 10.1016/j.pbiomolbio.2009.01.005; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Klaile E, 2009, J CELL BIOL, V187, P553, DOI 10.1083/jcb.200904149; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Maier SKG, 2004, CIRCULATION, V109, P1421, DOI 10.1161/01.CIR.0000121421.61896.24; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; McEwen DP, 2004, J BIOL CHEM, V279, P52744, DOI 10.1074/jbc.M405990200; McEwen DP, 2009, NEUROSCI LETT, V462, P272, DOI 10.1016/j.neulet.2009.07.020; Meadows LS, 2002, J NEUROSCI, V22, P10699; Meadows LS, 2002, NEUROSCIENCE, V114, P745, DOI 10.1016/S0306-4522(02)00242-7; Merrick EC, 2010, PFLUG ARCH EUR J PHY, V460, P743, DOI 10.1007/s00424-009-0739-y; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shah BS, 2001, J PHYSIOL-LONDON, V534, P763, DOI 10.1111/j.1469-7793.2001.t01-1-00763.x; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014; van Gassen KLI, 2009, EPILEPSIA, V50, P957, DOI 10.1111/j.1528-1167.2008.02015.x; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263; Wouters MA, 2007, CURR PROTEIN PEPT SC, V8, P484, DOI 10.2174/138920307782411464; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yu EJ, 2005, BIOCHEM J, V392, P519, DOI 10.1042/BJ20050518; Yu FH, 2003, J NEUROSCI, V23, P7577	50	20	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					568	580		10.1096/fj.12-209445	http://dx.doi.org/10.1096/fj.12-209445			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118027	hybrid, Green Published			2022-12-28	WOS:000314358000016
J	Zhang, HL; He, J; Li, JS; Tian, D; Gu, LB; Zhou, MX				Zhang, Hailong; He, Jing; Li, Jiansha; Tian, Dan; Gu, Lubing; Zhou, Muxiang			Methylation of RASSF1A gene promoter is regulated by p53 and DAXX	FASEB JOURNAL			English	Article						acute lymphoid leukemia; epigenetic gene silencing; protein-DNA binding	ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR RASSF1A; CELL-CYCLE PROGRESSION; WILD-TYPE P53; BINDING PROTEIN; HUMAN CANCERS; APOPTOSIS; MDM2; EXPRESSION; MUTATIONS	Inactivation of the tumor suppressor Ras-association domain family 1 isoform A (RASSF1A) due to epigenetic silencing occurs in a variety of human cancers, and still largely unknown are the regulators and mechanisms underlying RASSF1A gene promoter methylation. Herein, we report that this methylation is regulated by p53 and death-associated protein 6 (DAXX) in acute lymphoblastic leukemia (ALL). We found that p53 bound to the RASSF1A promoter, recruiting DAXX as well as DNA methyltransferase 1 (DNMT1) for DNA methylation, which subsequently resulted in inactivation of RASSF1A in wild-type p53 ALL cells. Although the presence of p53 was required for the recruitment of DAXX and DNMT1 to the RASSF1A promoter, fluctuation in p53 protein levels did not affect the rates of RASSF1A methylation. Conversely, methylation of RASSF1A promoter was critically controlled by DAXX, as the enforced overexpression of DAXX led to enhanced RASSF1A promoter methylation, whereas inhibition of DAXX reduced RASSF1A methylation. Interestingly, we found that the p53/DAXX-mediated RASSF1A methylation regulated murine double minute 2 (MDM2) protein stability in ALL. Our results reveal a novel function for p53 in the methylation of RASSF1A promoter by its interaction with DAXX. Discovery of this mechanism provides new insight into the interactions among the tumor-related factors p53, RASSF1A, DAXX, and MDM2 in cancer pathogenesis.-Zhang, H., He, J., Li, J., Tian, D., Gu, L., Zhou, M. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 27, 232-242 (2013). www.fasebj.org	[Zhang, Hailong; He, Jing; Li, Jiansha; Tian, Dan; Gu, Lubing; Zhou, Muxiang] Emory Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Atlanta, GA 30322 USA	Emory University	Gu, LB (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	lbgu@emory.edu; mzhou@emory.edu			U.S. National Institutes of Health/National Cancer Institute [R01 CA123490, R01 CA143107]; Leukemia and Lymphoma Society [6033-08]; CURE Childhood Cancer; NATIONAL CANCER INSTITUTE [R01CA143107, R01CA123490] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); CURE Childhood Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge support from U.S. National Institutes of Health/National Cancer Institute grants R01 CA123490 and R01 CA143107 (M. Z.), the Leukemia and Lymphoma Society 6033-08 (M. Z.), and CURE Childhood Cancer (M. Z. and L.G.).	Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; Croxton R, 2006, CANCER RES, V66, P9026, DOI 10.1158/0008-5472.CAN-06-1047; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang YS, 2009, BIOCHEM BIOPH RES CO, V386, P762, DOI 10.1016/j.bbrc.2009.06.126; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; King TC, 2000, CANCER-AM CANCER SOC, V89, P769, DOI 10.1002/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Wethkamp N, 2009, J BIOL CHEM, V284, P28783, DOI 10.1074/jbc.M109.041186; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; Zhang XL, 2010, CANCER RES, V70, P9895, DOI 10.1158/0008-5472.CAN-10-1546; Zhou M, 2000, LEUKEMIA, V14, P61, DOI 10.1038/sj.leu.2401619; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	43	30	31	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2013	27	1					232	242		10.1096/fj.12-215491	http://dx.doi.org/10.1096/fj.12-215491			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038753	Green Published			2022-12-28	WOS:000313103200022
J	Itel, F; Al-Samir, S; Oberg, F; Chami, M; Kumar, M; Supuran, CT; Deen, PMT; Meier, W; Hedfalk, K; Gros, G; Endeward, V				Itel, Fabian; Al-Samir, Samer; Oberg, Fredrik; Chami, Mohamed; Kumar, Manish; Supuran, Claudiu T.; Deen, Peter M. T.; Meier, Wolfgang; Hedfalk, Kristina; Gros, Gerolf; Endeward, Volker			CO2 permeability of cell membranes is regulated by membrane cholesterol and protein gas channels	FASEB JOURNAL			English	Article						aquaporin 1; aquaporin Z; phospholipid vesicles; MDCK cells	CARBON-DIOXIDE PERMEABILITY; LIPID BILAYER-MEMBRANES; WATER CHANNEL; EPITHELIAL MEMBRANE; TRANSPORT; AQUAPORIN-1; LIPOSOMES; ANHYDRASE; AMMONIA; BLOOD	Recent observations that some membrane proteins act as gas channels seem surprising in view of the classical concept that membranes generally are highly permeable to gases. Here, we study the gas permeability of membranes for the case of CO2, using a previously established mass spectrometric technique. We first show that biological membranes lacking protein gas channels but containing normal amounts of cholesterol (30-50 mol% of total lipid), e.g., MDCK and tsA201 cells, in fact possess an unexpectedly low CO2 permeability (PCO2) of similar to 0.01 cm/s, which is 2 orders of magnitude lower than the PCO2 of pure planar phospholipid bilayers (similar to 1 cm/s). Phospholipid vesicles enriched with similar amounts of cholesterol also exhibit PCO2 approximate to 0.01 cm/s, identifying cholesterol as the major determinant of membrane PCO2. This is confirmed by the demonstration that MDCK cells depleted of or enriched with membrane cholesterol show dramatic increases or decreases in PCO2, respectively. We demonstrate, furthermore, that reconstitution of human AQP-1 into cholesterol-containing vesicles, as well as expression of human AQP-1 in MDCK cells, leads to drastic increases in PCO2, indicating that gas channels are of high functional significance for gas transfer across membranes of low intrinsic gas permeability.-Itel, F., Al-Samir, S., Oberg, F., Chami, M., Kumar, M., Supuran, C. T., Deen, P. M. T., Meier, W., Hedfalk, K., Gros, G., Endeward, V. CO2 permeability of cell membranes is regulated by membrane cholesterol and protein gas channels. FASEB J. 26, 5182-5191 (2012). www.fasebj.org	[Al-Samir, Samer; Gros, Gerolf; Endeward, Volker] Hannover Med Sch, Zentrum Physiol, Dept Vegetat Physiol, D-30625 Hannover, Germany; [Itel, Fabian; Meier, Wolfgang] Univ Basel, Dept Chem, Basel, Switzerland; [Chami, Mohamed] Univ Basel, Biozentrum, Ctr Cellular Imaging & Nanoanalyt C CINA, Basel, Switzerland; [Oberg, Fredrik; Hedfalk, Kristina] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden; [Kumar, Manish] Penn State Univ, Dept Chem Engn, State Coll, PA USA; [Supuran, Claudiu T.] Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, I-50144 Florence, Italy; [Deen, Peter M. T.] Radboud Univ Nijmegen, Med Ctr, Dept Physiol, NL-6525 ED Nijmegen, Netherlands	Hannover Medical School; University of Basel; University of Basel; University of Gothenburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of Florence; Radboud University Nijmegen	Gros, G (corresponding author), Hannover Med Sch, Zentrum Physiol, Dept Vegetat Physiol, D-30625 Hannover, Germany.	gros.gerolf@mh-hannover.de	Itel, Fabian/AAU-2465-2021; Deen, Peter MT/B-9854-2013; Öberg, Fredrik Kryh/B-1241-2011; Kumar, Manish/C-2346-2008; Hedfalk, Kristina/A-8244-2010; Deen, P.M.T./H-8023-2014; Supuran, Claudiu T/A-5151-2008; Gros, Gerolf/K-8421-2012; Kumar, Manish/ABD-7273-2021	Itel, Fabian/0000-0002-4161-2383; Deen, Peter MT/0000-0002-7868-4655; Öberg, Fredrik Kryh/0000-0002-7089-2118; Deen, P.M.T./0000-0002-7868-4655; Kumar, Manish/0000-0001-5545-3793; Supuran, Claudiu/0000-0003-4262-0323	Deutsche Forschungsgemeinschaft [EN 908/1-1]; National Center of Competence in Nanoscale Science; Netherlands Organization for Scientific research (NWO); VICI [865.07.002]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Center of Competence in Nanoscale Science; Netherlands Organization for Scientific research (NWO)(Netherlands Organization for Scientific Research (NWO)); VICI(Netherlands Organization for Scientific Research (NWO))	The authors thank Prof. Ernst Ungewickell (Medizinische Hochschule Hannover) and Dawid Krenc (Universitat Kiel, Kiel, Germany) for helpful discussions, and Mr. Mark Inglin (University of Basel) for language-editing the manuscript. The authors are indebted to Dr. Aleksandra Rojek (University of Aarhus, Aarhus, Denmark) for the kind gift of the AQP-1 antibody RA3391/2353AP. This work was supported by the Deutsche Forschungsgemeinschaft through grant EN 908/1-1 to V. E., S. A.-S., and G. G.. F. I., W. M., and M. C. gratefully acknowledge the National Center of Competence in Nanoscale Science for financial support and Prof. Henning Stahlberg (University of Basel) for access to the electron microscopy facility. P. M. T. D. is a recipient of a VICI grant of the Netherlands Organization for Scientific research (NWO) and acknowledges VICI grant 865.07.002. Author contributions: V. E. and G. G. conceived the study; V. E. designed the research and performed all mass spectrometric <SUP>18</SUP>O exchange experiments; F. I. and W. M. prepared liposomes and proteoliposomes, as well as AqpZ; S.A.-S. performed all experiments with MDCK and tsA201 cells; F. O. and K. H. contributed hAQP-1 protein; M. C. performed the freeze-fracture studies; P. T. M. D. contributed the pCB6-hAQP-1 expression construct; C. T. S. contributed the extracellular carbonic anhydrase inhibitor; M. K. contributed to lipo- and proteoliposome preparation; G. G. and V. E. wrote the paper; all authors critically commented on the manuscript. The authors declare no conflicts of interest.	AGGERBECK LP, 1986, METHOD ENZYMOL, V128, P457; Antonenko YN, 1997, BIOPHYS J, V72, P2187, DOI 10.1016/S0006-3495(97)78862-3; BATTINO R, 1984, J PHYS CHEM REF DATA, V13, P563, DOI 10.1063/1.555713; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Boron WF, 2011, CHEMPHYSCHEM, V12, P1017, DOI 10.1002/cphc.201100034; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUNCE AS, 1974, BIOCHIM BIOPHYS ACTA, V363, P423, DOI 10.1016/0005-2736(74)90081-9; Christian AE, 1997, J LIPID RES, V38, P2264; CORVERA E, 1992, BIOCHIM BIOPHYS ACTA, V1107, P261, DOI 10.1016/0005-2736(92)90413-G; de Groot Bert L, 2011, Chemphyschem, V12, P1021, DOI 10.1002/cphc.201000974; Duttingdorf HDMZ, 1999, ANAL BIOCHEM, V269, P45, DOI 10.1006/abio.1998.3075; Endeward V, 2006, FASEB J, V20, P1974, DOI 10.1096/fj.04-3300com; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Endeward V, 2008, FASEB J, V22, P64, DOI 10.1096/fj.07-9097com; Endeward V, 2009, J PHYSIOL-LONDON, V587, P1153, DOI 10.1113/jphysiol.2008.165027; Engelman DM, 2005, NATURE, V438, P578, DOI 10.1038/nature04394; FINKELSTEIN A, 1976, J GEN PHYSIOL, V68, P127, DOI 10.1085/jgp.68.2.127; Forster R. E., 1969, NASA, P275; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Geers C, 2000, PHYSIOL REV, V80, P681, DOI 10.1152/physrev.2000.80.2.681; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hasselblatt P, 2000, PFLUG ARCH EUR J PHY, V441, P118, DOI 10.1007/s004240000377; Hill WG, 2000, J BIOL CHEM, V275, P30176, DOI 10.1074/jbc.M003494200; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; Hub JS, 2006, BIOPHYS J, V91, P842, DOI 10.1529/biophysj.106.081406; Hub JS, 2010, J AM CHEM SOC, V132, P13251, DOI 10.1021/ja102133x; ITADA N, 1977, J BIOL CHEM, V252, P3881; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KORN ED, 1969, ANNU REV BIOCHEM, V38, P263, DOI 10.1146/annurev.bi.38.070169.001403; Kumar M, 2007, P NATL ACAD SCI USA, V104, P20719, DOI 10.1073/pnas.0708762104; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Mathai JC, 2009, P NATL ACAD SCI USA, V106, P16633, DOI 10.1073/pnas.0902952106; Missner A, 2008, J BIOL CHEM, V283, P25340, DOI 10.1074/jbc.M800096200; Missner A, 2009, CHEMPHYSCHEM, V10, P1405, DOI 10.1002/cphc.200900270; Moller M, 2005, J BIOL CHEM, V280, P8850, DOI 10.1074/jbc.M413699200; Musa-Aziz R., 2011, FASEB J S, V25, P10405; Musa-Aziz R, 2009, P NATL ACAD SCI USA, V106, P5406, DOI 10.1073/pnas.0813231106; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nejsum LN, 2002, P NATL ACAD SCI USA, V99, P511, DOI 10.1073/pnas.012588099; Nyblom M, 2007, PROTEIN EXPRES PURIF, V56, P110, DOI 10.1016/j.pep.2007.07.007; OBRIEN JS, 1967, J THEOR BIOL, V15, P307, DOI 10.1016/0022-5193(67)90140-3; Overton E., 1901, STUDIEN NARKOSE; Plancon L, 1997, J BIOL CHEM, V272, P16868, DOI 10.1074/jbc.272.27.16868; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SIMON SA, 1980, BIOCHIM BIOPHYS ACTA, V596, P352, DOI 10.1016/0005-2736(80)90122-4; Smith SA, 2004, J THROMB HAEMOST, V2, P1155, DOI 10.1111/j.1538-7836.2004.00772.x; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Trandum C, 2000, BIOPHYS J, V78, P2486, DOI 10.1016/S0006-3495(00)76793-2; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; van Beest M, 2006, BBA-BIOMEMBRANES, V1758, P1126, DOI 10.1016/j.bbamem.2006.03.007; Verkman AS, 2011, J CELL SCI, V124, P2107, DOI 10.1242/jcs.079467; Verkman AS, 2002, J PHYSIOL-LONDON, V542, P31, DOI 10.1113/jphysiol.2002.024398; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; Wang Y, 2007, J STRUCT BIOL, V157, P534, DOI 10.1016/j.jsb.2006.11.008; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILCOCK RJ, 1978, J CHEM THERMODYN, V10, P817, DOI 10.1016/0021-9614(78)90154-4; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686	61	67	67	1	68	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5182	5191		10.1096/fj.12-209916	http://dx.doi.org/10.1096/fj.12-209916			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964306				2022-12-28	WOS:000311838300038
J	Godel, C; Kumar, S; Koutsovoulos, G; Ludin, P; Nilsson, D; Comandatore, F; Wrobel, N; Thompson, M; Schmid, CD; Goto, S; Bringaud, F; Wolstenholme, A; Bandi, C; Epe, C; Kaminsky, R; Blaxter, M; Maser, P				Godel, Christelle; Kumar, Sujai; Koutsovoulos, Georgios; Ludin, Philipp; Nilsson, Daniel; Comandatore, Francesco; Wrobel, Nicola; Thompson, Marian; Schmid, Christoph D.; Goto, Susumu; Bringaud, Frederic; Wolstenholme, Adrian; Bandi, Claudio; Epe, Christian; Kaminsky, Ronald; Blaxter, Mark; Maeser, Pascal			The genome of the heartworm, Dirofilaria immitis, reveals drug and vaccine targets	FASEB JOURNAL			English	Article						comparative genomics; filaria; transposon; Wolbachia	BACTERIAL ENDOSYMBIONTS; CANINE HEARTWORM; WEB SERVER; WOLBACHIA; GENES; RESISTANCE; PREDICTION; SEQUENCE; BIOSYNTHESIS; TETRACYCLINE	The heartworm Dirofilaria immitis is an important parasite of dogs. Transmitted by mosquitoes in warmer climatic zones, it is spreading across southern Europe and the Americas at an alarming pace. There is no vaccine, and chemotherapy is prone to complications. To learn more about this parasite, we have sequenced the genomes of D. immitis and its endosymbiont Wolbachia. We predict 10,179 protein coding genes in the 84.2 Mb of the nuclear genome, and 823 genes in the 0.9-Mb Wolbachia genome. The D. immitis genome harbors neither DNA transposons nor active retrotransposons, and there is very little genetic variation between two sequenced isolates from Europe and the United States. The differential presence of anabolic pathways such as heme and nucleotide biosynthesis hints at the intricate metabolic interrelationship between the heartworm and Wolbachia. Comparing the proteome of D. immitis with other nematodes and with mammalian hosts, we identify families of potential drug targets, immune modulators, and vaccine candidates. This genome sequence will support the development of new tools against dirofilariasis and aid efforts to combat related human pathogens, the causative agents of lymphatic filariasis and river blindness.-Godel, C., Kumar, S., Koutsovoulos, G., Ludin, P., Nilsson, D., Comandatore, F., Wrobel, N., Thompson, M., Schmid, C. D., Goto, S., Bringaud, F., Wolstenholme, A., Bandi, C., Epe, C., Kaminsky, R., Blaxter, M., Maser, P. The genome of the heartworm, Dirofilaria immitis, reveals drug and vaccine targets. FASEB J. 26, 4650-4661 (2012). www.fasebj.org	[Godel, Christelle; Ludin, Philipp; Schmid, Christoph D.; Maeser, Pascal] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Godel, Christelle; Ludin, Philipp; Schmid, Christoph D.; Maeser, Pascal] Univ Basel, Basel, Switzerland; [Godel, Christelle; Kaminsky, Ronald] Novartis Anim Hlth, Ctr Rech Sante Anim, St Aubin, Switzerland; [Kumar, Sujai; Koutsovoulos, Georgios; Blaxter, Mark] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland; [Wrobel, Nicola; Thompson, Marian; Blaxter, Mark] Univ Edinburgh, Sch Biol Sci, GenePool Genom Facil, Edinburgh, Midlothian, Scotland; [Nilsson, Daniel] Karolinska Inst, Dept Mol Med & Surg Sci Life Lab, Solna, Sweden; [Comandatore, Francesco; Bandi, Claudio] Univ Milan, Dipartimento Sci Vet & Sanita Pubbl, Milan, Italy; [Goto, Susumu] Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Uji, Kyoto, Japan; [Bringaud, Frederic] Univ Bordeaux Segalen, Ctr Resonance Magnet Syst Biol, Unite Mixte Rech 5536, Ctr Natl Rech Sci, Bordeaux, France; [Wolstenholme, Adrian] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Wolstenholme, Adrian] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Novartis; University of Edinburgh; University of Edinburgh; Karolinska Institutet; University of Milan; Kyoto University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Maser, P (corresponding author), Swiss Trop & Publ Hlth Inst, Socinstr 57, CH-4002 Basel, Switzerland.	pascal.maeser@unibas.ch	GenePool, The/D-8812-2012; Blaxter, Mark/O-2535-2019; Wolstenholme, Adrian/AAY-1611-2020; Kumar, Sujai/D-1768-2011; Nilsson, Daniel/B-8365-2009; Blaxter, Mark L/B-4113-2010; Bandi, Claudio/J-7835-2018	Wolstenholme, Adrian/0000-0001-7989-3929; Kumar, Sujai/0000-0001-5902-6641; Nilsson, Daniel/0000-0001-5831-385X; Blaxter, Mark L/0000-0003-2861-949X; Bandi, Claudio/0000-0002-0181-4618; Koutsovoulos, Georgios/0000-0003-3406-3715; Maser, Pascal/0000-0003-3122-1941	Novartis; School of Biological Sciences, University of Edinburgh; UK Biotechnology and Biological Sciences Research Council; Swedish Research Council; UK Medical Research Council [G0900740]; UK Natural Environment Research Council [R8/H10/561]; Centre National de Recherche Scientifique; European collaboration Enhanced Protective Immunity Against Filariasis (EPIAF), a focused research project (Specific International Cooperative Action) of the EU [242131]; Swiss National Science Foundation; MRC [G0900740] Funding Source: UKRI; Medical Research Council [G0900740] Funding Source: researchfish	Novartis(Novartis); School of Biological Sciences, University of Edinburgh(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Swedish Research Council(Swedish Research CouncilEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Centre National de Recherche Scientifique; European collaboration Enhanced Protective Immunity Against Filariasis (EPIAF), a focused research project (Specific International Cooperative Action) of the EU; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Claudio and Marco Genchi (University of Milan, Milan, Italy) for providing D. immitis from Pavia, Italy, and Andrew Moorhead (University of Georgia, Athens, GA, USA) for the D. immitis from Athens, GA, USA. D. immitis genomic and RNA sequencing was performed by Fasteris SA (Geneva, Switzerland), and The GenePool Genomics Facility (Edinburgh, UK). The authors are grateful for financial support from the Novartis Fellowship Program (C. G.), the School of Biological Sciences, University of Edinburgh (S. K. and G. K.), the UK Biotechnology and Biological Sciences Research Council (G. K.), the Swedish Research Council (D.N.), the UK Medical Research Council (G0900740; M. B., N.W., and M. T.), the UK Natural Environment Research Council (R8/H10/561; M. B.), the Centre National de Recherche Scientifique (F. B.), the European collaboration Enhanced Protective Immunity Against Filariasis (EPIAF), a focused research project (Specific International Cooperative Action) of the EU (award 242131; M. B.) and the Swiss National Science Foundation (P.M.).	Abbotts R, 2010, CANCER TREAT REV, V36, P425, DOI 10.1016/j.ctrv.2009.12.006; Akhtar LN, 2011, J VIROL, V85, P1912, DOI 10.1128/JVI.01857-10; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; American Heartworm Society, 2010, DIAGN PREV MAN HEART; American Pet Products Association, 2012, APPA NAT PET OWN SUR; Aziz RK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-75; Babayan SA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000525; Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Bandi C, 1999, INT J PARASITOL, V29, P357, DOI 10.1016/S0020-7519(98)00200-8; Bazzocchi C, 2008, INT J PARASITOL, V38, P1401, DOI 10.1016/j.ijpara.2008.03.002; Belanger DH, 2011, J PARASITOL, V97, P602, DOI 10.1645/GE-2679.1; Blaxter M, 2007, CELL HOST MICROBE, V2, P211, DOI 10.1016/j.chom.2007.09.008; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; Borrelli S, 2010, INT J ANTIMICROB AG, V36, P364, DOI 10.1016/j.ijantimicag.2010.06.030; Bourguinat C, 2011, VET PARASITOL, V181, P388, DOI 10.1016/j.vetpar.2011.04.012; Bowman DD, 2009, VET CLIN N AM-SMALL, V39, P1127, DOI 10.1016/j.cvsm.2009.06.003; CAMPBELL WC, 1982, VET RES COMMUN, V5, P251; Cantarel BL, 2008, GENOME RES, V18, P188, DOI 10.1101/gr.6743907; CARLISLE CH, 1984, AUST VET J, V61, P282, DOI 10.1111/j.1751-0813.1984.tb06010.x; Chain PSG, 2009, SCIENCE, V326, P236, DOI 10.1126/science.1180614; Chan DI, 2010, BIOCHEM J, V430, P1, DOI 10.1042/BJ20100462; Chen Nansheng, 2004, Curr Protoc Bioinformatics, VChapter 4, DOI 10.1002/0471250953.bi0410s05; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757; Doyle MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-222; Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114; EICKBUSH TH, 2002, MOBILE DNA, V2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fenn K, 2006, TRENDS PARASITOL, V22, P60, DOI 10.1016/j.pt.2005.12.012; Fenn K, 2004, TRENDS ECOL EVOL, V19, P163, DOI 10.1016/j.tree.2004.01.002; Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121; Ganapathy K, 2011, ARCH BIOCHEM BIOPHYS, V505, P194, DOI 10.1016/j.abb.2010.10.008; Genchi C, 2009, VET PARASITOL, V163, P286, DOI 10.1016/j.vetpar.2009.03.026; Ghedin E, 2007, SCIENCE, V317, P1756, DOI 10.1126/science.1145406; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; GUERRERO J, 1983, AM J VET RES, V44, P2405; Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768; Holman AG, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-243; Hotopp JCD, 2007, SCIENCE, V317, P1753, DOI 10.1126/science.1142490; Hu M, 2003, PARASITOLOGY, V127, P37, DOI 10.1017/S0031182003003275; Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003; Kaminsky R, 2008, NATURE, V452, P176, DOI 10.1038/nature06722; Kapitonov Vladimir V, 2008, Nat Rev Genet, V9, P411, DOI 10.1038/nrg2165-c1; Katz AH, 2003, CURR PHARM DESIGN, V9, P857, DOI 10.2174/1381612033455305; Korf I, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-59; Lamprea-Burgunder E, 2011, DNA RES, V18, P117, DOI 10.1093/dnares/dsr004; Lee ACY, 2010, TRENDS PARASITOL, V26, P168, DOI 10.1016/j.pt.2010.01.003; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Li ZR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001411; Ludin P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017546; Lustigman S, 2002, TRENDS PARASITOL, V18, P135, DOI 10.1016/S1471-4922(01)02211-5; Ma S, 2012, CHEMMEDCHEM, V7, P1161, DOI 10.1002/cmdc.201200156; Maizels RM, 2001, INT J PARASITOL, V31, P889, DOI 10.1016/S0020-7519(01)00213-2; Makepeace BL, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000544; McCall JW, 2005, VET PARASITOL, V133, P197, DOI 10.1016/j.vetpar.2005.04.005; MCCALL JW, 1976, J PARASITOL, V62, P844, DOI 10.2307/3278982; McNulty SN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011029; Mulder NJ, 2008, MOL BIOTECHNOL, V38, P165, DOI 10.1007/s12033-007-9003-x; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Oppenheimer M., 2011, ENZYME RES; Ostlund G, 2010, NUCLEIC ACIDS RES, V38, pD196, DOI 10.1093/nar/gkp931; Parra G, 2007, BIOINFORMATICS, V23, P1061, DOI 10.1093/bioinformatics/btm071; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Robertson G, 2010, NAT METHODS, V7, P909, DOI 10.1038/nmeth.1517; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Sangster NC, 2005, PARASITOLOGY, V131, pS179, DOI 10.1017/S0031182005008656; Segers K, 2011, CHEM BIOL, V18, P685, DOI 10.1016/j.chembiol.2011.04.007; Simpson JT, 2009, GENOME RES, V19, P1117, DOI 10.1101/gr.089532.108; Slatko BE, 2010, SYMBIOSIS, V51, P55, DOI 10.1007/s13199-010-0067-1; Stanke M, 2005, NUCLEIC ACIDS RES, V33, pW465, DOI 10.1093/nar/gki458; Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Traversa D, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-21; Wang JB, 2011, GENOME RES, V21, P1462, DOI 10.1101/gr.121426.111; Williamson Sally M., 2007, Invertebrate Neuroscience, V7, P219, DOI 10.1007/s10158-007-0056-0; World Health Organization, 2008, Weekly Epidemiological Record, V83, P333; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	77	93	101	0	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4650	4661		10.1096/fj.12-205096	http://dx.doi.org/10.1096/fj.12-205096			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22889830	Green Published, hybrid			2022-12-28	WOS:000310574200026
J	Robinson, MW; Alvarado, R; To, J; Hutchinson, AT; Dowdell, SN; Lund, M; Turnbull, L; Whitchurch, CB; O'Brien, BA; Dalton, JP; Donnelly, S				Robinson, Mark W.; Alvarado, Raquel; To, Joyce; Hutchinson, Andrew T.; Dowdell, Stephanie N.; Lund, Maria; Turnbull, Lynne; Whitchurch, Cynthia B.; O'Brien, Bronwyn A.; Dalton, John P.; Donnelly, Sheila			A helminth cathelicidin-like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal vATPase	FASEB JOURNAL			English	Article						trematode; Fasciola hepatica; lysosomal acidification; host defense peptides	ANTIMICROBIAL PEPTIDE LL-37; LIPID RAFTS; CELLS; MEMBRANES; BINDING; CHOLESTEROL; TRAFFICKING; ACTIVATION; PHAGOSOMES; VIRULENCE	We previously reported the identification of a novel family of immunomodulatory proteins, termed helminth defense molecules (HDMs), that are secreted by medically important trematode parasites. Since HDMs share biochemical, structural, and functional characteristics with mammalian cathelicidin-like host defense peptides (HDPs), we proposed that HDMs modulate the immune response via molecular mimicry of host molecules. In the present study, we report the mechanism by which HDMs influence the function of macrophages. We show that the HDM secreted by Fasciola hepatica (FhHDM-1) binds to macrophage plasma membrane lipid rafts via selective interaction with phospholipids and/or cholesterol before being internalized by endocytosis. Following internalization, FhHDM-1 is rapidly processed by lysosomal cathepsin L to release a short C-terminal peptide (containing a conserved amphipathic helix that is a key to HDM function), which then prevents the acidification of the endolysosomal compartments by inhibiting vacuolar ATPase activity. The resulting endolysosomal alkalization impedes macrophage antigen processing and prevents the transport of peptides to the cell surface in conjunction with MHC class II for presentation to CD4(+) T cells. Thus, we have elucidated a novel mechanism by which helminth pathogens alter innate immune cell function to assist their survival in the host.-Robinson, M. W., Alvarado, R., To, J., Hutchinson, A. T., Dowdell, S. N., Lund, M., Turnbull, L., Whitchurch, C. B., O'Brien, B. A., Dalton, J. P., Donnelly, S. A helminth cathelicidin-like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal vATPase. FASEB J. 26, 4614-4627 (2012). www.fasebj.org	[Robinson, Mark W.; Alvarado, Raquel; To, Joyce; Lund, Maria; Turnbull, Lynne; Whitchurch, Cynthia B.; Donnelly, Sheila] Univ Technol Sydney, Ithree Inst, Sydney, NSW 2007, Australia; [Hutchinson, Andrew T.; Dowdell, Stephanie N.; O'Brien, Bronwyn A.] Univ Technol Sydney, Sch Med & Mol Biosci, Sydney, NSW 2007, Australia; [Dalton, John P.] McGill Univ, Inst Parasitol, Quebec City, PQ, Canada	University of Technology Sydney; University of Technology Sydney; McGill University	Robinson, MW (corresponding author), Queens Univ Belfast, Sch Biol Sci, 97 Lisburn Rd, Belfast, Antrim, North Ireland.	mark.robinson@qub.ac.uk	Alvarado, Raquel/J-5073-2019; Donnelly, Sheila/H-7733-2014; Dalton, John/K-4457-2014; Whitchurch, Cynthia/A-5954-2008; Turnbull, Lynne/A-2605-2012	Alvarado, Raquel/0000-0001-7250-2200; Whitchurch, Cynthia/0000-0003-2296-3791; Robinson, Mark/0000-0001-7191-0034; Donnelly, Sheila/0000-0003-2005-3698; To, Joyce/0000-0003-3482-4369; Turnbull, Lynne/0000-0002-9255-9033; Lund, Maria/0000-0001-7360-5041	National Health and Medical Research Council [APP1010197, APP513111]; Tier 1 Canada Research Chair; National Science and Engineering Council (NSERC) Canada	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Tier 1 Canada Research Chair(Canada Research Chairs); National Science and Engineering Council (NSERC) Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by National Health and Medical Research Council Grants APP1010197 and APP513111. J. P. D is supported by a Tier 1 Canada Research Chair and a grant from the National Science and Engineering Council (NSERC) Canada.	Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Doss M, 2010, J LEUKOCYTE BIOL, V87, P79, DOI 10.1189/jlb.0609382; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805; Fjell CD, 2007, BIOINFORMATICS, V23, P1148, DOI 10.1093/bioinformatics/btm068; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Garcia-Marcos M, 2006, BBA-BIOMEMBRANES, V1758, P796, DOI 10.1016/j.bbamem.2006.05.008; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Gustafsson MGL, 2008, BIOPHYS J, V94, P4957, DOI 10.1529/biophysj.107.120345; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harnett W, 2010, NAT REV IMMUNOL, V10, P278, DOI 10.1038/nri2730; Hazlett L, 2011, CELL TISSUE RES, V343, P175, DOI 10.1007/s00441-010-1022-4; Hirsch T, 2008, SHOCK, V30, P117, DOI 10.1097/SHK.0b013e318160de11; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Hutchinson AT, 2010, J IMMUNOL, V185, P4179, DOI 10.4049/jimmunol.1001956; Jenssen H, 2010, METHODS MOL BIOL, V618, P329, DOI 10.1007/978-1-60761-594-1_20; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Kandler K, 2006, INT IMMUNOL, V18, P1729, DOI 10.1093/intimm/dxl107; Kartner N, 2010, J BIOL CHEM, V285, P37476, DOI 10.1074/jbc.M110.123281; Kirikae T, 1998, INFECT IMMUN, V66, P1861, DOI 10.1128/IAI.66.5.1861-1868.1998; Klotz C, 2011, ADV EXP MED BIOL, V712, P208, DOI 10.1007/978-1-4419-8414-2_13; Lajoie P, 2010, INT REV CEL MOL BIO, V282, P135, DOI 10.1016/S1937-6448(10)82003-9; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; Min CK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000209; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Raj PA, 1998, BIOPOLYMERS, V45, P51, DOI 10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y; Risso A, 2000, J LEUKOCYTE BIOL, V68, P785; Robinson MW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002042; Robinson MW, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001012; Luque-Ortega JR, 2008, FASEB J, V22, P1817, DOI 10.1096/fj.07-096081; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Schermelleh L, 2008, SCIENCE, V320, P1332, DOI 10.1126/science.1156947; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288; Seil M, 2010, PHARMACEUTICALS, V3, P3435, DOI 10.3390/ph3113435; Shaw AS, 2006, NAT IMMUNOL, V7, P1139, DOI 10.1038/ni1405; Shui WQ, 2008, P NATL ACAD SCI USA, V105, P16952, DOI 10.1073/pnas.0809218105; Sood R, 2008, BBA-BIOMEMBRANES, V1778, P1460, DOI 10.1016/j.bbamem.2008.02.014; Sood R, 2008, BBA-BIOMEMBRANES, V1778, P983, DOI 10.1016/j.bbamem.2007.11.016; Stack CM, 2008, J BIOL CHEM, V283, P9896, DOI 10.1074/jbc.M708521200; Sun-Wada GH, 2009, J CELL SCI, V122, P2504, DOI 10.1242/jcs.050443; Talloczy Z, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040028; Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; WANG R, 1993, J IMMUNOL, V150, P3832	54	63	63	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4614	4627		10.1096/fj.12-213876	http://dx.doi.org/10.1096/fj.12-213876			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872675	Green Submitted, hybrid			2022-12-28	WOS:000310574200023
J	Balzer, EM; Tong, ZQ; Paul, CD; Hung, WC; Stroka, KM; Boggs, AE; Martin, SS; Konstantopoulos, K				Balzer, Eric M.; Tong, Ziqiu; Paul, Colin D.; Hung, Wei-Chien; Stroka, Kimberly M.; Boggs, Amanda E.; Martin, Stuart S.; Konstantopoulos, Konstantinos			Physical confinement alters tumor cell adhesion and migration phenotypes	FASEB JOURNAL			English	Article						mesenchymal; microtubules; actin; cytoskeleton	MATRIX ADHESIONS; DYNAMICS; ACTIN; MICROTENTACLES; ORGANIZATION; MECHANISM; STIFFNESS; PHOSPHORYLATION; CONTRACTILITY; MICROTUBULES	Cell migration on planar surfaces is driven by cycles of actin protrusion, integrin-mediated adhesion, and myosin-mediated contraction; however, this mechanism may not accurately describe movement in 3-dimensional (3D) space. By subjecting cells to restrictive 3D environments, we demonstrate that physical confinement constitutes a biophysical stimulus that alters cell morphology and suppresses mesenchymal motility in human breast carcinoma (MDA-MB-231). Dorsoventral polarity, stress fibers, and focal adhesions are markedly attenuated by confinement. Inhibitors of myosin, Rho/ROCK, or beta 1-integrins do not impair migration through 3-mu m-wide channels (confinement), even though these treatments repress motility in 50-mu m-wide channels (unconfined migration) by >= 50%. Strikingly, confined migration persists even when F-actin is disrupted, but depends largely on microtubule (MT) dynamics. Interfering with MT polymerization/depolymerization causes confined cells to undergo frequent directional changes, thereby reducing the average net displacement by >= 80% relative to vehicle controls. Live-cell EB1-GFP imaging reveals that confinement redirects MT polymerization toward the leading edge, where MTs continuously impact during advancement of the cell front. These results demonstrate that physical confinement can induce cytoskeletal alterations that reduce the dependence of migrating cells on adhesion-contraction force coupling. This mechanism may explain why integrins can exhibit reduced or altered function during migration in 3D environments.-Balzer, E. M., Tong, Z., Paul, C. D., Hung, W.-C., Stroka, K. M., Boggs, A. E., Martin, S. S., Konstantopoulos, K. Physical confinement alters tumor cell adhesion and migration phenotypes. FASEB J. 26, 4045-4056 (2012). www.fasebj.org	[Balzer, Eric M.; Tong, Ziqiu; Paul, Colin D.; Hung, Wei-Chien; Stroka, Kimberly M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Balzer, Eric M.; Tong, Ziqiu; Paul, Colin D.; Stroka, Kimberly M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Balzer, Eric M.; Tong, Ziqiu; Stroka, Kimberly M.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol, Baltimore, MD 21218 USA; [Boggs, Amanda E.; Martin, Stuart S.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	konstant@jhu.edu	Tong, Ziqiu/AAR-6182-2020; Konstantopoulos, Konstantinos/A-7045-2011	Tong, Ziqiu/0000-0003-4183-1858; 	U.S. National Cancer Institute [T32-CA130840, U54-CA143868, RO1-CA101135]; Kleberg Foundation; NATIONAL CANCER INSTITUTE [P30CA134274, T32CA130840, R01CA101135, U54CA143868] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kleberg Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the U.S. National Cancer Institute (awards T32-CA130840, U54-CA143868, and RO1-CA101135) and the Kleberg Foundation.	Balzer EM, 2010, ONCOGENE, V29, P6402, DOI 10.1038/onc.2010.360; Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Beningo KA, 2004, P NATL ACAD SCI USA, V101, P18024, DOI 10.1073/pnas.0405747102; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Ehrbar M, 2011, BIOPHYS J, V100, P284, DOI 10.1016/j.bpj.2010.11.082; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Faure-Andre G, 2008, SCIENCE, V322, P1705, DOI 10.1126/science.1159894; Fraley SI, 2010, NAT CELL BIOL, V12, P598, DOI 10.1038/ncb2062; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476; Gupton SL, 2006, CELL, V125, P1361, DOI 10.1016/j.cell.2006.05.029; Hawkins RJ, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.058103; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Ilina O, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015010; Irimia D, 2009, INTEGR BIOL, V1, P506, DOI 10.1039/b908595e; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Lakshman N, 2007, CELL MOTIL CYTOSKEL, V64, P434, DOI 10.1002/cm.20194; Liu R, 2012, ANN SURG ONCOL, V19, P199, DOI 10.1245/s10434-011-1871-4; Malawista SE, 1997, P NATL ACAD SCI USA, V94, P11577, DOI 10.1073/pnas.94.21.11577; Matrone MA, 2010, ONCOGENE, V29, P3217, DOI 10.1038/onc.2010.68; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Renkawitz J, 2009, NAT CELL BIOL, V11, P1438, DOI 10.1038/ncb1992; Rolli CG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008726; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stroka KM, 2011, BLOOD, V118, P1632, DOI 10.1182/blood-2010-11-321125; Stroka KM, 2009, CELL MOTIL CYTOSKEL, V66, P328, DOI 10.1002/cm.20363; Tong ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029211; WatermanStorer CM, 1997, CURR BIOL, V7, pR369, DOI 10.1016/S0960-9822(06)00177-1; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607	48	172	175	2	91	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4045	4056		10.1096/fj.12-211441	http://dx.doi.org/10.1096/fj.12-211441			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22707566	Green Published			2022-12-28	WOS:000309704000012
J	Horvat, SJ; Deshpande, DA; Yan, HD; Panettieri, RA; Codina, J; DuBose, TD; Xin, WK; Rich, TC; Penn, RB				Horvat, Sarah J.; Deshpande, Deepak A.; Yan, Huandong; Panettieri, Reynold A.; Codina, Juan; DuBose, Thomas D., Jr.; Xin, Wenkuan; Rich, Thomas C.; Penn, Raymond B.			A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle	FASEB JOURNAL			English	Article						asthma; beta 2-adrenergic receptor; phosphodiesterase; gravin	NUCLEOTIDE-GATED CHANNELS; COUPLED RECEPTORS; ADENYLYL-CYCLASE; CELLS; PKA; PHOSPHODIESTERASE; PHOSPHORYLATION; ACTIVATION; STIMULATION; MECHANISMS	A-kinase anchoring proteins (AKAPs) have emerged as important regulatory molecules that can compartmentalize cAMP signaling transduced by beta 2-adrenergic receptors (beta(2)ARs); such compartmentalization ensures speed and fidelity of cAMP signaling and effects on cell function. This study aimed to assess the role of AKAPs in regulating global and compartmentalized beta(2)AR signaling in human airway smooth muscle (ASM). Transcriptome and proteomic analyses were used to characterize AKAP expression in ASM. Stable expression or injection of peptides AKAP-IS or Ht31 was used to disrupt AKAP-PKA interactions, and global and compartmentalized cAMP accumulation stimulated by beta-agonist was assessed by radioimmunoassay and membrane-delineated flow through cyclic nucleotide-gated channels, respectively. ASM expresses multiple AKAP family members, with gravin and ezrin among the most readily detected. AKAP-PKA disruption had minimal effects on whole-cell cAMP accumulation stimulated by beta-agonist (EC50 and B-max) concentrations, but significantly increased the duration of plasma membrane-delineated cAMP (tau=251 +/- 51 s for scrambled peptide control vs. 399 +/- 79 s for Ht31). Direct PKA inhibition eliminated decay of membrane-delineated cAMP levels. AKAPs coordinate compartmentalized cAMP signaling in ASM cells by regulating multiple elements of beta(2)AR-mediated cAMP accumulation, thereby representing a novel target for manipulating beta 2AR signaling and function in ASM.-Horvat, S. J., Deshpande, D. A., Yan, H., Panettieri, R. A., Codina, J., DuBose Jr., T. D., Xin, W., Rich, T. C., Penn, R. B. A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle. FASEB J. 26, 3670-3679 (2012). www.fasebj.org	[Horvat, Sarah J.; Deshpande, Deepak A.; Yan, Huandong; Penn, Raymond B.] Univ Maryland, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA; [Panettieri, Reynold A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Codina, Juan; DuBose, Thomas D., Jr.; Penn, Raymond B.] Wake Forest Univ Hlth Sci, Dept Internal Med, Winston Salem, NC USA; [Xin, Wenkuan; Rich, Thomas C.] Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; [Xin, Wenkuan; Rich, Thomas C.] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688 USA	University System of Maryland; University of Maryland Baltimore; University of Pennsylvania; Wake Forest University; Wake Forest University School of Medicine; University of South Alabama; University of South Alabama	Penn, RB (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Pulm & Crit Care Med, 20 Penn St,HSF 2 Rm 147, Baltimore, MD 21201 USA.	trich@jaguar1.usouthal.edu; rpenn@medicine.umaryland.edu	panettieri, reynold/AAG-9485-2019		GlaxoSmithKline [P01 H066299, HL58506]; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [T32 AR07592]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058506, R01HL058506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041265] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study reflects equal contributions from the R. B. P. and T. C. R. laboratories and was funded in part by independent investigator grants from GlaxoSmithKline to R. B. P and T.C.R., P01 H066299 (T. C. R.), and HL58506 (R. B. P.). S.J.H. is supported by U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grant T32 AR07592. The authors thank Anna Misior for preliminary transcriptome and proteome analyses. The authors declare no other conflicts of interest.	Alto NM, 2003, P NATL ACAD SCI USA, V100, P4445, DOI 10.1073/pnas.0330734100; Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Billington CK, 1999, AM J RESP CELL MOL, V21, P597, DOI 10.1165/ajrcmb.21.5.3759; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; Billington CK, 2003, RESP RES, V4; Brady JD, 2004, MOL PHARMACOL, V65, P503, DOI 10.1124/mol.65.3.503; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; CARR DW, 1991, J BIOL CHEM, V266, P14188; Chen MH, 2009, CELL SIGNAL, V21, P136, DOI 10.1016/j.cellsig.2008.09.019; Deshpande DA, 2008, FASEB J, V22, P2134, DOI 10.1096/fj.07-102459; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; Hewitt M, 2010, AM J RESP CELL MOL, V42, P243, DOI 10.1165/rcmb.2009-0038OC; Kong KC, 2008, BIOCHEMISTRY-US, V47, P9279, DOI 10.1021/bi801056w; Mauban JRH, 2009, PHYSIOLOGY, V24, P78, DOI 10.1152/physiol.00041.2008; Misior AM, 2008, MOL PHARMACOL, V73, P566, DOI 10.1124/mol.107.040519; Misior AM, 2009, AM J RESP CELL MOL, V41, P24, DOI 10.1165/rcmb.2008-0266OC; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Pascual RM, 2001, AM J PHYSIOL-LUNG C, V281, pL1425, DOI 10.1152/ajplung.2001.281.6.L1425; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Piggott LA, 2006, J GEN PHYSIOL, V128, P3, DOI 10.1085/jgp.200509403; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Rich TC, 2002, ANN BIOMED ENG, V30, P1088, DOI 10.1114/1.1511242; Rich TC, 2001, J GEN PHYSIOL, V118, P63, DOI 10.1085/jgp.118.1.63; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Rich TC, 2007, AM J PHYSIOL-CELL PH, V292, pC319, DOI 10.1152/ajpcell.00121.2006; Sanderson JL, 2011, NEUROSCIENTIST, V17, P321, DOI 10.1177/1073858410384740; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Stangherlin A, 2011, J CARDIOVASC PHARM, V58, P345, DOI 10.1097/FJC.0b013e3182214f2b; Tao Jiangchuan, 2008, J Mol Signal, V3, P19, DOI 10.1186/1750-2187-3-19; Tasken K, 2006, FRONT BIOSCI-LANDMRK, V11, P2929, DOI 10.2741/2022; Tavalin SJ, 2008, J BIOL CHEM, V283, P11445, DOI 10.1074/jbc.M709253200; Terrin A, 2006, J CELL BIOL, V175, P441, DOI 10.1083/jcb.200605050; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Walker JKL, 2011, BRIT J PHARMACOL, V163, P18, DOI 10.1111/j.1476-5381.2010.01178.x; Wang WCH, 2009, P NATL ACAD SCI USA, V106, P15007, DOI 10.1073/pnas.0906034106; Willoughby D, 2006, EMBO J, V25, P2051, DOI 10.1038/sj.emboj.7601113; Xin WK, 2008, J GEN PHYSIOL, V131, P349, DOI 10.1085/jgp.200709881	41	31	31	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3670	3679		10.1096/fj.11-201020	http://dx.doi.org/10.1096/fj.11-201020			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22649031	Green Published			2022-12-28	WOS:000308391600009
J	Barbera-Cremades, M; Baroja-Mazo, A; Gomez, AI; Machado, F; Di Virgilio, F; Pelegrin, P				Barbera-Cremades, Maria; Baroja-Mazo, Alberto; Gomez, Ana I.; Machado, Francisco; Di Virgilio, Francesco; Pelegrin, Pablo			P2X7 receptor-stimulation causes fever via PGE2 and IL-1 beta release	FASEB JOURNAL			English	Article						inflammation; pyrogen; macrophages; purinergic receptors; in vivo bioluminescence	ACTIVATED PROTEIN-KINASE; P2X(7) RECEPTOR; EXTRACELLULAR ATP; ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E-2; MESSENGER-RNA; MOUSE MODEL; INFLAMMATION; CYCLOOXYGENASE-2; MACROPHAGES	Prostaglandins (PGs) are important lipid mediators involved in the development of inflammatory associated pain and fever. PGE2 is a well-established endogenous pyrogen activated by proinflammatory cytokine interleukin (IL)-1 beta. P2X7 receptors (P2X7Rs) expressed by inflammatory cells are stimulated by the danger signal extracellular ATP to activate the inflammasome and release IL-1 beta. Here we show that P2X7R activation is required for the release of PGE2 and other autacoids independent of inflammasome activation, with an ATP EC50 for PGE2 and IL-1 beta release of 1.58 and 1.23 mM, respectively. Furthermore, lack of P2X7R or specific antagonism of P2X7R decreased the febrile response in mice triggered after intraperitoneal LPS or IL-1 beta inoculation. Accordingly, LPS inoculation caused intraperitoneal ATP accumulation. Therefore, P2X7R antagonists emerge as novel therapeutics for the treatment for acute inflammation, pain and fever, with wider anti-inflammatory activity than currently used cyclooxygenase inhibitors.-Barbera-Cremades, M., Baroja-Mazo, A., Gomez, A. I., Machado, F., Di Virgilio, F., Pelegrin, P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1 beta release. FASEB J. 26, 2951-2962 (2012). www.fasebj.org	[Barbera-Cremades, Maria; Baroja-Mazo, Alberto; Gomez, Ana I.; Pelegrin, Pablo] Univ Hosp Virgen, Inflammat & Expt Surg Unit, Arrixaca Fdn Formac Invest Sanit Reg Murcia FFIS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Murcia 30120, Spain; [Machado, Francisco] Univ Hosp Virgen, Dept Gynecol & Obstet, Arrixaca Fdn Formac Invest Sanit Reg Murcia FFIS, Murcia 30120, Spain; [Di Virgilio, Francesco] Univ Ferrara, Sect Gen Pathol, Dept Expt & Diagnost Med, I-44100 Ferrara, Italy	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Ferrara	Pelegrin, P (corresponding author), Univ Hosp Virgen, Inflammat & Expt Surg Unit, Arrixaca Fdn Formac Invest Sanit Reg Murcia FFIS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Carretera Madrid Cartagena S-N, Murcia 30120, Spain.	pablo.pelegrin@ffis.es	Di Virgilio, Francesco/J-3754-2018; Pelegrin, Pablo/M-2007-2014; DI VIRGILIO, Francesco/O-4634-2019; Baroja-Mazo, Alberto/E-6270-2016; Machado, Francisco/B-6098-2011	Di Virgilio, Francesco/0000-0003-3566-1362; Pelegrin, Pablo/0000-0002-9688-1804; DI VIRGILIO, Francesco/0000-0003-3566-1362; Baroja-Mazo, Alberto/0000-0001-5212-5006; Machado, Francisco/0000-0001-9852-8089	Instituto Salud Carlos III-FEDER [EMER07/049, PI09/0120]; Fundacion Seneca [11922/PI/09]; Italian Association for Cancer Research (AIRC)	Instituto Salud Carlos III-FEDER; Fundacion Seneca(Fundacion Seneca); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	The authors thank Francois Rassendren (Institut de Genomique Fonctionnelle, Montpellier, France) for P2X4 deficient mice bone marrow and helpful discussion; Alexij Verkhratsky (University of Manchester, Manchester, UK) for P2X7 receptor-deficient mice used for in vitro experiments; L. Martinez-Alarcon for human blood extraction; G. Lopez-Castejon for help with in vitro culture/stimulation of P2X4-and P2X7-deficient BMDMs; J. Sim for animal handling; M. C. Banos for cellular technical assistance; and V. Mulero for helpful discussion. This work was supported by grants from PN I+D+I 2008-2011-Instituto Salud Carlos III-FEDER (EMER07/049 and PI09/0120), Fundacion Seneca (11922/PI/09), managed by Fundacion Formacion Investigacion Sanitaria Region de Murcia (FFIS), and from the Italian Association for Cancer Research (AIRC). M. B-C. executed and analyzed experiments from all figures. A. B-M. performed flow cytometry experiments with macrophages, and A. I. G. plated human macrophages and performed some of the cell stimulation and IL-1 beta ELISAs. F. M. collected human peritoneal lavage. F. D. V. provided the pmeLUC-HEK probe and helped with in vivo ATP determination experiments. P. P. conceived, designed, and supervised this study, analyzed and interpreted experiments, and wrote the final manuscript with contributions from the other authors.	Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Anrather J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025916; Armstrong S, 2009, J CELL SCI, V122, P136, DOI 10.1242/jcs.031534; Arulkumaran N, 2011, EXPERT OPIN INV DRUG, V20, P897, DOI 10.1517/13543784.2011.578068; Bartfai T, 2010, THESCIENTIFICWORLDJO, V10, P490, DOI 10.1100/tsw.2010.50; Bertolini A, 2002, CURR MED CHEM, V9, P1033, DOI 10.2174/0929867024606650; Brough D, 2003, J IMMUNOL, V170, P3029, DOI 10.4049/jimmunol.170.6.3029; Cao CY, 1996, BRAIN RES, V733, P263, DOI 10.1016/0006-8993(96)00575-6; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Costa HM, 2011, PURINERG SIGNAL, V7, P381, DOI 10.1007/s11302-011-9255-6; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Davidson J, 2001, PFLUG ARCH EUR J PHY, V442, P526; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; Donnelly-Roberts D, 2008, J PHARMACOL EXP THER, V324, P409, DOI 10.1124/jpet.106.105890; Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600; EGUCHI N, 1992, J PHARMACOL EXP THER, V262, P1110; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GOPPELTSTRUEBE M, 1995, PROSTAG LEUKOTR ESS, V52, P213, DOI 10.1016/0952-3278(95)90039-X; Gourine AV, 2005, BRIT J PHARMACOL, V146, P139, DOI 10.1038/sj.bjp.0706287; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Honore P, 2009, BEHAV BRAIN RES, V204, P77, DOI 10.1016/j.bbr.2009.05.018; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Itoh K, 2011, NEUROSCIENCE, V192, P721, DOI 10.1016/j.neuroscience.2011.06.083; Ivanov AI, 2004, FRONT BIOSCI-LANDMRK, V9, P1977, DOI 10.2741/1383; Jiang H, 2007, BRIT J PHARMACOL, V151, P1033, DOI 10.1038/sj.bjp.0707311; Keating C, 2011, J IMMUNOL, V187, P1467, DOI 10.4049/jimmunol.1100423; King BF, 2007, BRIT J PHARMACOL, V151, P565, DOI 10.1038/sj.bjp.0707266; Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019; Lenertz LY, 2011, IMMUNOL RES, V50, P22, DOI 10.1007/s12026-011-8203-4; Li S, 2001, BRAIN RES, V910, P163, DOI 10.1016/S0006-8993(01)02707-X; Lopez-Castejon G, 2010, J IMMUNOL, V185, P2611, DOI 10.4049/jimmunol.1000436; Mackenzie AB, 2005, J BIOL CHEM, V280, P33968, DOI 10.1074/jbc.M502705200; Moore SF, 2009, J IMMUNOL, V183, P3302, DOI 10.4049/jimmunol.0900394; Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720; Nieminen R, 2006, INT IMMUNOPHARMACOL, V6, P987, DOI 10.1016/j.intimp.2006.01.009; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037; Pelegrin P, 2008, J IMMUNOL, V180, P7147, DOI 10.4049/jimmunol.180.11.7147; Pelegrin P, 2011, PROG INFLAMM RES SER, P101, DOI 10.1007/978-3-0348-0148-5_7; Pelegrin P, 2008, DRUG NEWS PERSPECT, V21, P424, DOI 10.1358/dnp.2008.21.8.1265800; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Rainsford K. D., 2007, V42, P3; Riteau N, 2010, AM J RESP CRIT CARE, V182, P774, DOI 10.1164/rccm.201003-0359OC; Roger S, 2010, J BIOL CHEM, V285, P17514, DOI 10.1074/jbc.M109.053082; Royle SJ, 2005, J CELL SCI, V118, P3073, DOI 10.1242/jcs.02451; Sakata D, 2010, J PHARMACOL SCI, V112, P1, DOI 10.1254/jphs.09R03CP; Samad TA, 2002, TRENDS MOL MED, V8, P390, DOI 10.1016/S1471-4914(02)02383-3; Shiratori M, 2010, J NEUROCHEM, V114, P810, DOI 10.1111/j.1471-4159.2010.06809.x; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Ulmann L, 2010, EMBO J, V29, P2290, DOI 10.1038/emboj.2010.126; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xia MS, 2011, GLIA, V59, P664, DOI 10.1002/glia.21138; Yip L, 2009, FASEB J, V23, P1685, DOI 10.1096/fj.08-126458	61	111	112	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2951	2962		10.1096/fj.12-205765	http://dx.doi.org/10.1096/fj.12-205765			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490780				2022-12-28	WOS:000305912500023
J	Guan, XX; Liu, ZS; Liu, HL; Yu, HP; Wang, LE; Sturgis, EM; Li, GJ; Wei, QY				Guan, Xiaoxiang; Liu, Zhensheng; Liu, Hongliang; Yu, Hongping; Wang, Li-E; Sturgis, Erich M.; Li, Guojun; Wei, Qingyi			A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer	FASEB JOURNAL			English	Article						apoptosis; microRNA; genetic susceptibility; polymorphism	SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; GENETIC-VARIANTS; LUNG-CANCER; APOPTOSIS; POLYMORPHISMS; CASPASE-3; EXPRESSION; MICRORNA; PROMOTER	Caspases are important regulators and executioners in the apoptosis pathways and play crucial roles in carcinogenesis. We tested the hypothesis that functional variants of CASP genes are associated with risk of squamous cell carcinoma of the head and neck (SCCHN) and second primary malignancy (SPM). We genotyped 7 selected, potentially functional single nucleotide polymorphisms (SNPs) located in the microRNA binding sites of the 3' untranslational region (UTR; 2 in CASP3, 1 in CASP6, and 4 in CASP7) and evaluated their associations first with risk of SCCHN in 1066 patients with SCCHN and 1074 cancer-free control subjects and then with SPM in 846 patients in the same non-Hispanic white study population. We found that compared with the CASP3 TT genotype of rs1049253, the variant TC/CC genotypes were associated with significantly increased risk of SCCHN (adjusted odds ratio = 1.29 and 95% confidence interval = 1.07-1.56) and SPM (adjusted hazard ratio = 1.79 and 95% CI = 1.02-3.16) and worse SPM-free survival (log-rank P = 0.020), but no associations were found for the other 6 SNPs. We then performed additional experiments to seek functional relevance of the rs1049253 SNP. First, the luciferase activity and miR-885-5p mimic transfection tests suggested that CASP3 was the target of miR-885-5p and that rs1049253T>C resulted in altered regulation of the CASP3 expression. Second, the rs1049253 CC genotype was associated with reduced levels of CASP3 mRNA in peripheral blood mononuclear cells from 118 SCCHN patients and 103 cancer-free control subjects and lower levels of CASP3 protein expression in 11 head and neck cancer cell lines, compared with the TT genotype. Taken together, our data suggest that the miR-885-5p binding site rs1049253T>C SNP in the 3'-UTR of CASP3 modulates CASP3 expression at both mRNA and protein levels and thus contributes to SCCHN susceptibility. Guan, X., Liu, Z., Liu, H., Yu, H., Wang, L.-E., Sturgis, E. M., Li, G., and Wei, Q. A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer. FASEB J. 27, 1404-1412 (2013). www.fasebj.org	[Guan, Xiaoxiang] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210008, Jiangsu, Peoples R China; [Guan, Xiaoxiang; Liu, Zhensheng; Liu, Hongliang; Yu, Hongping; Wang, Li-E; Sturgis, Erich M.; Li, Guojun; Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; [Sturgis, Erich M.; Li, Guojun] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA	Nanjing University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wei, QY (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Box 189,1515 Holcombe Blvd, Houston, TX 77030 USA.	qwei@mdanderson.org	Liu, Hongliang/P-3444-2014	Liu, Hongliang/0000-0001-7639-0904; Guan, Xiaoxiang/0000-0001-6145-0046	U.S. National Institutes of Health [R01 ES 11740, R01 CA 131274, P50 CA 097007, CA 16672]; NATIONAL CANCER INSTITUTE [P50CA097007, R01CA131274, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011740] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was funded by U.S. National Institutes of Health grants R01 ES 11740 and R01 CA 131274 (to Q. W.), P50 CA 097007 (to S. L.), and CA 16672 (to M. D. Anderson Cancer Center). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164; Andersen MH, 2005, NAT REV DRUG DISCOV, V4, P399, DOI 10.1038/nrd1717; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641; Chang SS, 2008, INT J CANCER, V123, P2791, DOI 10.1002/ijc.23831; Chen KX, 2008, CLIN CANCER RES, V14, P6343, DOI 10.1158/1078-0432.CCR-08-1198; Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014; Cho WCS, 2010, BBA-REV CANCER, V1805, P209, DOI 10.1016/j.bbcan.2009.11.003; Danial NN, 2007, CLIN CANCER RES, V13, P7254, DOI 10.1158/1078-0432.CCR-07-1598; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DAY GL, 1994, J NATL CANCER I, V86, P131, DOI 10.1093/jnci/86.2.131; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Do KA, 2004, CANCER-AM CANCER SOC, V101, P2837, DOI 10.1002/cncr.20714; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fujikawa K, 2000, ANTICANCER RES, V20, P1927; Gilbert ES, 2003, RADIAT RES, V159, P161, DOI 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934; Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Isobe N, 2004, ONCOLOGY-BASEL, V66, P201, DOI 10.1159/000077996; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kania J, 2003, DIGEST DIS SCI, V48, P266, DOI 10.1023/A:1021915124064; Kurokawa H, 1999, ONCOL REP, V6, P33; Lan Q, 2007, CARCINOGENESIS, V28, P823, DOI 10.1093/carcin/bgl196; Lee JW, 2006, PATHOLOGY, V38, P358, DOI 10.1080/00313020600820799; Lee WK, 2009, LUNG CANCER, V65, P19, DOI 10.1016/j.lungcan.2008.10.022; Li CY, 2010, CANCER PREV RES, V3, P246, DOI 10.1158/1940-6207.CAPR-08-0228; Liu ZS, 2011, CARCINOGENESIS, V32, P1668, DOI 10.1093/carcin/bgr209; Ng AK, 2008, HEMATOL ONCOL CLIN N, V22, P271, DOI 10.1016/j.hoc.2008.01.007; Park JY, 2006, HUM MOL GENET, V15, P1963, DOI 10.1093/hmg/ddl119; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Sano D, 2011, CLIN CANCER RES, V17, P6658, DOI 10.1158/1078-0432.CCR-11-0046; Song FJ, 2009, CLIN CANCER RES, V15, P6292, DOI 10.1158/1078-0432.CCR-09-0826; Soung YH, 2004, HUM GENET, V115, P112, DOI 10.1007/s00439-004-1129-3; STURGIS EM, 1995, ANN OTO RHINOL LARYN, V104, P946, DOI 10.1177/000348949510401206; Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030; Tormanen-Napankangas U, 2001, INT J CANCER, V93, P192, DOI 10.1002/ijc.1315; Wald AI, 2011, HEAD NECK-J SCI SPEC, V33, P504, DOI 10.1002/hed.21475; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Xu HL, 2009, CANCER EPIDEM BIOMAR, V18, P2114, DOI 10.1158/1055-9965.EPI-09-0152; Zafereo ME, 2009, CARCINOGENESIS, V30, P997, DOI 10.1093/carcin/bgp096; Zeiss CJ, 2003, VET PATHOL, V40, P481, DOI 10.1354/vp.40-5-481	46	29	30	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1404	1412		10.1096/fj.12-223420	http://dx.doi.org/10.1096/fj.12-223420			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271051	Green Published			2022-12-28	WOS:000316940800013
J	van der Vorst, EPC; Vanags, LZ; Dunn, LL; Prosser, HC; Rye, KA; Bursill, CA				van der Vorst, Emiel P. C.; Vanags, Laura Z.; Dunn, Louise L.; Prosser, Hamish C.; Rye, Kerry-Anne; Bursill, Christina A.			High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells	FASEB JOURNAL			English	Article						inflammation; scavenger receptor-B1	APOLIPOPROTEIN-A-I; ANTIINFLAMMATORY PROPERTIES; NEOINTIMAL HYPERPLASIA; ALLOGRAFT VASCULOPATHY; ADHESION MOLECULE-1; ARTERIAL INJURY; CHOLESTEROL; RECEPTORS; INHIBIT; HDL	The inflammatory chemokines CCL2, CCL5, and CX(3)CL1 stimulate vascular smooth muscle cell (SMC) proliferation. High-density lipoproteins (HDLs) exhibit potent cardioprotective and anti-inflammatory properties. We therefore sought to determine the effect of reconstituted HDLs (rHDLs) on SMC chemokine expression and proliferation and elucidate the mechanisms. Preincubation of primary human SMCs with rHDLs containing apolipoprotein (apo) A-I and phosphatidylcholine (20 mu M, final apoA-I concentration), before stimulation with TNF-alpha, inhibited CCL2 (54%), CCL5 (38%), and CX(3)CL1 (33%) protein levels. The chemokine receptors CCR2 (29%) and CX(3)CR1 (22%) were also reduced by rHDLs. Incubation with rHDLs reduced the NF-kappa B subunit p65 in the nucleus (39%) and phosphorylated I kappa B alpha (28%), both regulators of chemokine expression. Furthermore, rHDLs inhibited the upstream signaling proteins phosphoinositide 3-kinase (37%) and phosphorylated Akt (pAkt, 49%). Incubation with rHDLs strikingly suppressed SMC proliferation (84%) and ERK phosphorylation (pERK, 29%). Finally, siRNA knockdown of the scavenger receptor SR-B1 attenuated rHDL-induced inhibition of SMC chemokine expression, p65, and proliferation, indicating that SR-B1 plays a key role in mediating these effects. Thus, rHDLs reduce SMC chemokine expression (via NF-kappa B/pAkt inhibition) and proliferation (via pERK inhibition). This has important implications for preventing the pathogenesis of neointimal hyperplasia, the main cause of early vein graft/stent failure.-Van der Vorst, E. P. C., Vanags, L. Z., Dunn, L. L., Prosser, H. C., Rye, K.-A., Bursill, C. A. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J. 27, 1413-1425 (2013). www.fasebj.org	[van der Vorst, Emiel P. C.; Vanags, Laura Z.; Dunn, Louise L.; Prosser, Hamish C.; Rye, Kerry-Anne; Bursill, Christina A.] Heart Res Inst, Newtown, NSW, Australia; [van der Vorst, Emiel P. C.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands; [Vanags, Laura Z.; Rye, Kerry-Anne; Bursill, Christina A.] Univ Sydney, Sydney Med Sch, Camperdown, NSW, Australia; [Rye, Kerry-Anne] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia	University of Sydney; Heart Research Institute; Maastricht University; University of Sydney; University of Melbourne	Bursill, CA (corresponding author), 7 Eliza St, Sydney, NSW 2042, Australia.	bursillc@hri.org.au		Bursill, Christina/0000-0002-0682-8760	Heart Foundation [CR07S3331]; Bushell Foundation; National Health and Medical Research Council [222722, 537537]	Heart Foundation; Bushell Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by a Heart Foundation Career Development Fellowship (CR07S3331) and a Bushell Foundation grant (to C. A. B), a National Health and Medical Research Council Program grant (222722; to K-A. R), and a National Health and Medical Research Council Early Career Fellowship (537537; to L.L.D).	Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450; Baker PW, 1999, J LIPID RES, V40, P345; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Bursill CA, 2010, ARTERIOSCL THROM VAS, V30, P1773, DOI 10.1161/ATVBAHA.110.211342; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Di Bartolo BA, 2011, ATHEROSCLEROSIS, V217, P395, DOI 10.1016/j.atherosclerosis.2011.04.001; Eefting D, 2009, J VASC SURG, V50, P152, DOI 10.1016/j.jvs.2009.03.027; Feng YM, 2009, BLOOD, V113, P755, DOI 10.1182/blood-2008-06-161794; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Gonzalez-Diez M, 2008, THROMB HAEMOSTASIS, V100, P119, DOI 10.1160/TH07-11-0675; Ibanez B, 2012, ATHEROSCLEROSIS, V220, P72, DOI 10.1016/j.atherosclerosis.2011.10.006; Kovacic JC, 2010, J CLIN INVEST, V120, P303, DOI 10.1172/JCI40364; MATZ CE, 1982, J BIOL CHEM, V257, P4535; McGrath KCY, 2009, ARTERIOSCL THROM VAS, V29, P877, DOI 10.1161/ATVBAHA.109.184663; Mineo C, 2007, TRENDS CARDIOVAS MED, V17, P156, DOI 10.1016/j.tcm.2007.03.005; Murphy AJ, 2013, J PHARMACOL EXP THER, V344, P41, DOI 10.1124/jpet.112.199257; Murphy AJ, 2011, J CLIN INVEST, V121, P4138, DOI 10.1172/JCI57559; Nicholls SJ, 2005, CIRCULATION, V111, P1543, DOI 10.1161/01.CIR.0000159351.95399.50; Rahmani M, 2006, CIRC RES, V99, P801, DOI 10.1161/01.RES.0000246086.93555.f3; Robbesyn F, 2003, FASEB J, V17, P743, DOI 10.1096/fj.02-0240fje; Roque M, 2002, ARTERIOSCL THROM VAS, V22, P554, DOI 10.1161/hq0402.105720; Rye KA, 2009, J LIPID RES, V50, pS195, DOI 10.1194/jlr.R800034-JLR200; Saddar S, 2013, CIRC RES, V112, P140, DOI 10.1161/CIRCRESAHA.112.280081; Scanu A, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2930; Schepers A, 2006, ARTERIOSCL THROM VAS, V26, P2063, DOI 10.1161/01.ATV.0000235694.69719.e2; Schober A, 2004, CIRC RES, V95, P1125, DOI 10.1161/01.RES.0000149518.86865.3e; Schober A, 2008, ARTERIOSCL THROM VAS, V28, P1950, DOI 10.1161/ATVBAHA.107.161224; Seetharam D, 2006, CIRC RES, V98, P63, DOI 10.1161/01.RES.0000199272.59432.5b; Selzman CH, 2002, AM J PHYSIOL-HEART C, V283, pH1455, DOI 10.1152/ajpheart.00188.2002; Seo SM, 2011, HEART, V97, P1943, DOI 10.1136/hrt.2011.225466; Shimizu K, 2009, CIRCULATION, V120, P1800, DOI 10.1161/CIRCULATIONAHA.109.859595; Sviridov D, 2001, BIOCHEM J, V358, P79, DOI 10.1042/0264-6021:3580079; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; Topakian R, 2008, EUR J NEUROL, V15, P179, DOI 10.1111/j.1468-1331.2007.02026.x; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; White GE, 2010, CARDIOVASC RES, V85, P825, DOI 10.1093/cvr/cvp341; Zernecke A, 2006, BLOOD, V107, P4240, DOI 10.1182/blood-2005-09-3922	39	37	37	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1413	1425		10.1096/fj.12-212753	http://dx.doi.org/10.1096/fj.12-212753			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271056				2022-12-28	WOS:000316940800014
J	Camacho-Vanegas, O; Till, J; Miranda-Lorenzo, I; Ozturk, B; Camacho, SC; Martignetti, JA				Camacho-Vanegas, Olga; Till, Jacob; Miranda-Lorenzo, Irene; Ozturk, Berrin; Camacho, Sandra Catalina; Martignetti, John A.			Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors	FASEB JOURNAL			English	Article						Kruppel-like transcription factors; isoforms	PROGRESSION	Alternative splicing represents a unique post-transcriptional mechanism that increases the complexity of the eukaryotic proteome-generating protein isoforms whose functions can be novel, diverse, and/or even antagonistic when compared to its full-length transcript. The KLF family of genes consists of >= 17 members, which are involved in the regulation of numerous critical cellular processes, including differentiation, cell proliferation, growth-related signal transduction, angiogenesis, and apoptosis. Using a strategy based on RT-PCR, selective cloning, and promoter-based assays of cancer-relevant genes, we identify and characterize the existence of multiple biologically active KLF splice forms across the entire family of proteins. We demonstrate biological function for a number of these isoforms. Furthermore, we highlight a possible functional interaction between full-length KLF4 and one of its splice variants in up-regulating cellular proliferation. Taken together, this report identifies for the first time a more complete view of the genomic and proteomic breadth and complexity of the KLF transcription factor family, revealing the existence of highly expressed and biologically active isoforms previously uncharacterized. In essence, knowing that these KLF isoforms exist provides the first step toward understanding the roles of these genes in human health and disease.-Camacho-Vanegas, O., Till, J., Miranda-Lorenzo, I., Ozturk, B., Camacho, S. C., Martignetti, J. A. Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors. FASEB J. 27, 432-436 (2013). www.fasebj.org	[Camacho-Vanegas, Olga; Till, Jacob; Miranda-Lorenzo, Irene; Ozturk, Berrin; Camacho, Sandra Catalina; Martignetti, John A.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Martignetti, John A.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Martignetti, John A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Martignetti, JA (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	john.martignetti@mssm.edu		Till, Jacob/0000-0002-2824-1282				Brosius J, 2005, TRENDS GENET, V21, P287, DOI 10.1016/j.tig.2005.02.014; Bryant Douglas W Jr, 2012, Methods Mol Biol, V883, P97, DOI 10.1007/978-1-61779-839-9_7; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2008, J CLIN INVEST, V118, P2711, DOI 10.1172/JCI34780; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wei DY, 2010, GASTROENTEROLOGY, V139, P2135, DOI 10.1053/j.gastro.2010.08.022	10	15	21	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					432	436		10.1096/fj.12-220319	http://dx.doi.org/10.1096/fj.12-220319			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23134681				2022-12-28	WOS:000314358000004
J	Rines, AK; Burke, MA; Fernandez, RP; Volpert, OV; Ardehali, H				Rines, Amy K.; Burke, Michael A.; Fernandez, Richard P.; Volpert, Olga V.; Ardehali, Hossein			Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of beta-catenin	FASEB JOURNAL			English	Article						SNRK; CacyBP	MOLECULAR-CLONING; EXPRESSION; PATHWAY; TARGET; SNRK; AMPK; IDENTIFICATION; CARCINOMA; SUBFAMILY; FAMILY	Sucrose nonfermenting 1 (Snf1)-related kinase (SNRK) is a serine/threonine kinase with sequence similarity to AMP-activated protein kinase (AMPK); however, its function is not well characterized. We conducted a gene array to determine which genes are regulated by SNRK. The array demonstrated that SNRK overexpression increased the levels of genes involved in cell proliferation, including calcyclin-binding protein (CacyBP), a member of the ubiquitin ligase complex that targets nonphosphorylated beta-catenin for degradation. We confirmed that SNRK increased CacyBP mRNA and protein, and decreased beta-catenin protein in HCT116 and RKO colon cancer cells. Furthermore, SNRK inhibited colon cancer cell proliferation, and CacyBP down-regulation reversed the SNRK-mediated decrease in proliferation and beta-catenin. SNRK overexpression also decreased beta-catenin nuclear localization and target gene transcription, and beta-catenin down-regulation reversed the effects of SNRK knockdown on proliferation. SNRK transcript levels were reduced in human colon tumors compared to normal tissue by 35.82%, and stable knockdown of SNRK increased colon cancer cell tumorigenicity. Our results demonstrate that SNRK is down-regulated in colon cancer and inhibits colon cancer cell proliferation through CacyBP up-regulation and beta-catenin degradation, resulting in reduced proliferation signaling. These findings reveal a novel function for SNRK in the regulation of colon cancer cell proliferation and beta-catenin signaling.-Rines, A. K., Burke, M. A., Fernandez, R. P., Volpert, O. V., Ardehali, H. Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin binding protein-dependent reduction of beta-catenin. FASEB J. 26, 4685-4695 (2012). www.fasebj.org	[Rines, Amy K.; Burke, Michael A.; Fernandez, Richard P.; Ardehali, Hossein] Northwestern Univ, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA; [Volpert, Olga V.] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Feinberg School of Medicine	Ardehali, H (corresponding author), Northwestern Univ, Feinberg Cardiovasc Res Inst, Tarry 14-733,303 E Chicago Ave, Chicago, IL 60611 USA.	h-ardehali@northwestern.edu	Burke, Michael/GSN-3331-2022	Burke, Michael/0000-0003-1491-1131	U.S. National Institutes of Health [K02 HL107448, R01 HL087149, R01 HL104181, P01 HL108795]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087149, K02HL107448, P01HL108795, R01HL104181] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	H.A. is supported by U.S. National Institutes of Health grants K02 HL107448, R01 HL087149, R01 HL104181, P01 HL108795, and the American Heart Association. The authors report no conflicts of interest.	Becker W, 1996, EUR J BIOCHEM, V235, P736, DOI 10.1111/j.1432-1033.1996.00736.x; Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748-1716.2009.01971.x; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; Chen X, 2011, MOL CARCINOGEN, V50, P804, DOI 10.1002/mc.20737; Chun CZ, 2009, BLOOD, V113, P1192, DOI 10.1182/blood-2008-06-162156; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Kertesz N, 2002, GENE, V294, P13, DOI 10.1016/S0378-1119(02)00829-6; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nie F, 2010, INT J ONCOL, V37, P1261, DOI 10.3892/ijo_00000777; Ning XX, 2007, MOL CANCER RES, V5, P1254, DOI 10.1158/1541-7786.MCR-06-0426; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Schneider G, 2011, AMINO ACIDS, V41, P773, DOI 10.1007/s00726-010-0498-2; Sun SR, 2007, BIOCHEM BIOPH RES CO, V356, P864, DOI 10.1016/j.bbrc.2007.03.080; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wong AKF, 2009, CLIN SCI, V116, P607, DOI 10.1042/CS20080066; Yoshida K, 2000, BRAIN RES, V873, P274, DOI 10.1016/S0006-8993(00)02548-8; Zhai HH, 2008, J HISTOCHEM CYTOCHEM, V56, P765, DOI 10.1369/jhc.2008.950519	29	17	18	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2012	26	11					4685	4695		10.1096/fj.12-212282	http://dx.doi.org/10.1096/fj.12-212282			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22874833	Green Published			2022-12-28	WOS:000310574200029
J	Hobbs, CA; Blanchard, MG; Kellenberger, S; Bencharit, S; Cao, R; Kesimer, M; Walton, WG; Redinbo, MR; Stutts, MJ; Tarran, R				Hobbs, Carey A.; Blanchard, Maxime G.; Kellenberger, Stephan; Bencharit, Sompop; Cao, Rui; Kesimer, Mehmet; Walton, William G.; Redinbo, Matthew R.; Stutts, M. Jackson; Tarran, Robert			Identification of SPLUNC1's ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airways	FASEB JOURNAL			English	Article						glycosylation; BPIFA1; PLUNC; LUNX; neutrophil elastase	EPITHELIAL NA+ CHANNEL; SURFACE LIQUID VOLUME; SERINE PROTEASES; ALPHA-SUBUNIT; MEMBRANE TOPOLOGY; SENSORY NEURONS; GAMMA-SUBUNIT; PEPTIDE; PROTEIN; CELLS	The epithelial sodium channel (ENaC) is responsible for Na+ and fluid absorption across colon, kidney, and airway epithelia. We have previously identified SPLUNC1 as an autocrine inhibitor of ENaC. We have now located the ENaC inhibitory domain of SPLUNC1 to SPLUNC1's N terminus, and a peptide corresponding to this domain, G22-A39, inhibited ENaC activity to a similar degree as full-length SPLUNC1 (similar to 2.5 fold). However, G22-A39 had no effect on the structurally related acid-sensing ion channels, indicating specificity for ENaC. G22-A39 preferentially bound to the beta-ENaC subunit in a glycosylation-dependent manner. ENaC hyperactivity is contributory to cystic fibrosis (CF) lung disease. Addition of G22-A39 to CF human bronchial epithelial cultures (HBECs) resulted in an increase in airway surface liquid height from 4.2 +/- 0.6 to 7.9 +/- 0.6 mu m, comparable to heights seen in normal HBECs, even in the presence of neutrophil elastase. Our data also indicate that the ENaC inhibitory domain of SPLUNC1 may be cleaved away from the main molecule by neutrophil elastase, which suggests that it may still be active during inflammation or neutrophilia. Furthermore, the robust inhibition of ENaC by the G22-A39 peptide suggests that this peptide may be suitable for treating CF lung disease.-Hobbs, C. A., Blanchard, M. G., Kellenberger, S., Bencharit, S., Cao, R., Kesimer, M., Walton, W. G., Redinbo, M. R., Stutts, M. J., Tarran, R. Identification of SPLUNC1's ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airways. FASEB J. 26, 4348-4359 (2012). www.fasebj.org	[Hobbs, Carey A.; Cao, Rui; Kesimer, Mehmet; Stutts, M. Jackson; Tarran, Robert] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; [Bencharit, Sompop] Univ N Carolina, Dept Prosthodont, Chapel Hill, NC 27599 USA; [Walton, William G.; Redinbo, Matthew R.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; [Blanchard, Maxime G.; Kellenberger, Stephan] Univ Lausanne, Dept Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Lausanne	Tarran, R (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, 7125 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	robert_tarran@med.unc.edu	Bencharit, Sompop/AAO-8563-2020; , Mehmet Kesimer/AHB-9223-2022		Cystic Fibrosis Foundation Resource Development Program [R026, CFF RDP-R026]; U.S. National Institutes of Health [PPG P01 HL034322, 5 P30 DK 06598808, R01HL103940, R01HL108927]; UNC-Chapel Hill School of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108927, P01HL034322, R01HL103940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK065988] Funding Source: NIH RePORTER	Cystic Fibrosis Foundation Resource Development Program; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC-Chapel Hill School of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Ashley G. Henderson for making the sputum samples available and Dr. Rebecca P. Hughey for helpful discussions on the glycosylation experiments. The authors gratefully acknowledge the technical assistance of Michael Watson, Hong He, and Yan Dang. The authors also thank the University of North Carolina (UNC) Cystic Fibrosis Center Molecular and Cell Culture Cores, as well as the UNC Macromolecular Interactions Facility. Funding was provided by the Cystic Fibrosis Foundation Resource Development Program, grant R026 (CFF RDP-R026); U.S. National Institutes of Health grants PPG P01 HL034322, 5 P30 DK 06598808, R01HL103940, and R01HL108927; and the UNC-Chapel Hill School of Medicine.	Anantharam A, 2006, J PHYSIOL-LONDON, V574, P333, DOI 10.1113/jphysiol.2006.109173; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Bartlett JA, BIOCH SOC T, V39, P1012; Bingle L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-79; Blanchard MG, 2011, PFLUG ARCH EUR J PHY, V461, P123, DOI 10.1007/s00424-010-0884-3; Bray D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-106; Bridges Robert J, 2002, Methods Mol Med, V70, P111; Bruns JB, 2007, J BIOL CHEM, V282, P6153, DOI 10.1074/jbc.M610636200; Buchan DW, NUCL ACIDS RES, V38, pW563; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2008, AM J PHYSIOL-RENAL, V294, pF47, DOI 10.1152/ajprenal.00399.2007; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Diochot S, 2004, EMBO J, V23, P1516, DOI 10.1038/sj.emboj.7600177; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Gally F, 2011, AM J PATHOL, V178, P2159, DOI 10.1016/j.ajpath.2011.01.026; Garcia-Caballero A, 2009, P NATL ACAD SCI USA, V106, P11412, DOI 10.1073/pnas.0903609106; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Haynes J, 2008, AM J PHYSIOL-HEART C, V294, pH379, DOI 10.1152/ajpheart.01068.2007; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kashlan OB, 2011, J BIOL CHEM, V286, P649, DOI 10.1074/jbc.M110.167098; Kashlan OB, 2010, J BIOL CHEM, V285, P35216, DOI 10.1074/jbc.M110.167064; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kesimer M, METHODS MOL BIOL, V842, P67; Kesimer M, 2009, AM J PHYSIOL-LUNG C, V296, pL92, DOI 10.1152/ajplung.90388.2008; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; McGillivary G., PLOS ONE, V5; Poirot O, 2004, J BIOL CHEM, V279, P38448, DOI 10.1074/jbc.M407381200; Randell SH, METHODS MOL BIOL, V742, P285; Ratjen F, 2006, NEW ENGL J MED, V354, P291, DOI 10.1056/NEJMe058293; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rollins BM, CHANNELS AUSTIN, V4, P255; Rossier BC, 2009, ANNU REV PHYSIOL, V71, P361, DOI 10.1146/annurev.physiol.010908.163108; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Roxo-Rosa M, 2006, PROTEOMICS, V6, P2314, DOI 10.1002/pmic.200500273; Sherwood TW, 2009, J NEUROSCI, V29, P14371, DOI 10.1523/JNEUROSCI.2186-09.2009; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tarran R, 2006, J GEN PHYSIOL, V127, P591, DOI 10.1085/jgp.200509468; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Voynow JA, 2008, INT J BIOCHEM CELL B, V40, P1238, DOI 10.1016/j.biocel.2008.03.003; Yan K, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013297.11876.5B; Zhou HD, 2008, MOL CELL BIOCHEM, V309, P191, DOI 10.1007/s11010-007-9659-3	45	9	9	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4348	4359		10.1096/fj.12-207431	http://dx.doi.org/10.1096/fj.12-207431			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22798424	Green Published			2022-12-28	WOS:000309704000039
J	Kerkhofs, S; Dubois, V; De Gendt, K; Helsen, C; Clinckemalie, L; Spans, L; Schuit, F; Boonen, S; Vanderschueren, D; Saunders, PTK; Verhoeven, G; Claessens, F				Kerkhofs, Stefanie; Dubois, Vanessa; De Gendt, Karel; Helsen, Christine; Clinckemalie, Liesbeth; Spans, Lien; Schuit, Frans; Boonen, Steven; Vanderschueren, Dirk; Saunders, Philippa T. K.; Verhoeven, Guido; Claessens, Frank			A role for selective androgen response elements in the development of the epididymis and the androgen control of the 5 alpha reductase II gene	FASEB JOURNAL			English	Article						sperm maturation; male fertility; androgen receptor; binding site; Srd5 alpha 2	DIFFERENTIAL DNA-BINDING; CARBONIC-ANHYDRASE; RECEPTOR-BINDING; EXPRESSION; RAT; KNOCKOUT; MICE; TRANSCRIPTOME; TESTOSTERONE; RECOGNITION	The androgen receptor (AR) recognizes two types of DNA elements that are dimers of 5'-AGAACA-3'-like hexamers, either organized as inverted or direct repeats. We developed a mouse model [(specificity affecting AR knock-in (SPARKI)] in which the AR DNA-binding domain was mutated such that it lost binding to direct repeats but not to inverted elements. The impaired fertility of the male SPARKI mice correlates with the reduced motility of the spermatozoa, a characteristic that is developed during transit through the epididymis. Comparative transcriptome analyses revealed that the expression of 39 genes is changed in SPARKI epididymis. Remarkably, the expression of the steroid 5 alpha-reductase type II (Srd5 alpha 2) gene, which metabolizes testosterone into the more potent dihydrotestosterone, is reduced 4-fold in SPARKI vs. wild type. The comparison of the SPARKI phenotype with that of Srd5 alpha 2-knockout mice shows, however, that the reduced Srd5 alpha 2 expression cannot explain all defects of the SPARKI epididymis. Moreover, we describe three new selective androgen response elements (AREs), which control the androgen responsiveness of the Srd5 alpha 2 gene. We conclude that the SPARKI model can be considered a knockout model for AR functioning via selective AREs and that this has a dramatic effect on sperm maturation in the epididymis.-Kerkhofs, S., Dubois, V., De Gendt, K., Helsen, C., Clinckemalie, L., Spans, L., Schuit, F., Boonen, S., Vanderschueren, D., Saunders, P. T. K., Verhoeven, G., Claessens, F. A role for selective androgen response elements in the development of the epididymis and the androgen control of the 5 alpha reductase II gene. FASEB J. 26, 4360-4372 (2012). www.fasebj.org	[Kerkhofs, Stefanie; Dubois, Vanessa; Helsen, Christine; Clinckemalie, Liesbeth; Spans, Lien; Claessens, Frank] Katholieke Univ Leuven, Mol Endocrinol Lab, Dept Cellular & Mol Med, B-3000 Louvain, Belgium; [De Gendt, Karel; Boonen, Steven; Vanderschueren, Dirk; Verhoeven, Guido] Katholieke Univ Leuven, Div Clin & Expt Endocrinol, B-3000 Louvain, Belgium; [Schuit, Frans] Katholieke Univ Leuven, Dept Cellular & Mol Med, Gene Express Unit, B-3000 Louvain, Belgium; [Saunders, Philippa T. K.] Queens Med Res Inst, MRC, Human Reprod Sci Unit, Edinburgh, Midlothian, Scotland	KU Leuven; KU Leuven; KU Leuven; University of Edinburgh	Claessens, F (corresponding author), Katholieke Univ Leuven, Mol Endocrinol Lab, Dept Cellular & Mol Med, Campus Gasthuisberg O&N1,POB 901,Herestr 49, B-3000 Louvain, Belgium.	frank.claessens@med.kuleuven.be	Claessens, Frank/M-8565-2016; Dubois, Vanessa/ABF-9551-2021; De Gendt, Karel/A-6332-2009; Saunders, Philippa TK/C-7489-2013	Claessens, Frank/0000-0002-8676-7709; Dubois, Vanessa/0000-0001-8894-2980; Saunders, Philippa TK/0000-0001-9051-9380; vanderschueren, dirk/0000-0003-1395-0104; Helsen, Christine/0000-0003-1048-2798	Fonds voor Wetenschappelijk Onderzoek-Vlaanderen; MRC [G1100356, G1002033] Funding Source: UKRI; Medical Research Council [G1002033, G1100356] Funding Source: researchfish	Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. K.D.G. is holder of a postdoctoral fellowship of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. L.C. is holder of a doctoral fellowship of the Agentschap voor Innovatie door Wetenschap en Technologie. V.D. is holder of a doctoral fellowship of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen. S.B. is senior clinical investigator of the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen and holder of the Leuven University Chair in Gerontology and Geriatrics. The authors thank R. Bollen and H. Debruyn for their excellent technical assistance and their colleagues of the Molecular Endocrinology Laboratory for helpful discussions. The authors thank Dr. Diane M. Robins (University of Michigan Medical School, Ann Arbor, MI, USA) for the kind gift of the AR and GR expression plasmids. The authors thank Dr. Carl Spiessens and his coworkers for the help with the sperm analyses. The authors declare no conflicts of interest.	ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Barfield JP, 2005, BIOL REPROD, V72, P1275, DOI 10.1095/biolreprod.104.038448; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Chauvin TR, 2004, BIOL REPROD, V71, P560, DOI 10.1095/biolreprod.103.026302; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; Cooper TG, 2007, ASIAN J ANDROL, V9, P533, DOI 10.1111/j.1745-7262.2007.00285.x; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; DEVOS P, 1993, MOL CELL ENDOCRINOL, V90, pR11, DOI 10.1016/0303-7207(93)90160-L; Ekstedt E, 2004, J MOL HISTOL, V35, P167; Ezer NRB, 2002, ANDROGENIC REGULATIO; Haelens A, 2003, BIOCHEM J, V369, P141, DOI 10.1042/BJ20020912; Helsen C, 2012, MOL CELL ENDOCRINOL, V348, P411, DOI 10.1016/j.mce.2011.07.025; Henderson NA, 2006, J ENDOCRINOL, V190, P779, DOI 10.1677/joe.1.06862; Hermo L., 2002, EPIDIDYMAL CELL TYPE; Hinton BT, 1995, REPROD FERT DEVELOP, V7, P731, DOI 10.1071/RD9950731; Hsia N, 2004, BIOL REPROD, V70, P448, DOI 10.1095/biolreprod.103.021493; Hu SG, 2010, MOL ENDOCRINOL, V24, P2392, DOI 10.1210/me.2010-0226; Itoh M, 1999, J ANDROL, V20, P551; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Jelinsky SA, 2007, BIOL REPROD, V76, P561, DOI 10.1095/biolreprod.106.057323; Jervis KM, 2001, BIOL REPROD, V65, P696, DOI 10.1095/biolreprod65.3.696; Jin Y, 2001, BEST PRACT RES CL EN, V15, P79, DOI 10.1053/beem.2001.0120; Johnston DS, 2005, BIOL REPROD, V73, P404, DOI 10.1095/biolreprod.105.039719; Jones RC, 1999, INT J ANDROL, V22, P57; KAUNISTO K, 1995, BIOL REPROD, V52, P1350, DOI 10.1095/biolreprod52.6.1350; Kobayashi T, 2007, FEBS LETT, V581, P3157, DOI 10.1016/j.febslet.2007.05.081; Krutskikh A, 2011, ENDOCRINOLOGY, V152, P689, DOI 10.1210/en.2010-0768; Mahendroo MS, 2001, ENDOCRINOLOGY, V142, P4652, DOI 10.1210/en.142.11.4652; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Nef S, 2000, GENE DEV, V14, P3075, DOI 10.1101/gad.843800; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; Schauwaers K, 2007, P NATL ACAD SCI USA, V104, P4961, DOI 10.1073/pnas.0610814104; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Snyder EM, 2009, BIOL REPROD, V81, P707, DOI 10.1095/biolreprod.109.079053; Tanner TM, 2010, CELL MOL LIFE SCI, V67, P1919, DOI 10.1007/s00018-010-0302-1; Thimon V, 2007, MOL HUM REPROD, V13, P691, DOI 10.1093/molehr/gam051; TOTH M, 1982, ENDOKRINOLOGIE, V80, P163; TURNER TT, 1995, J ANDROL, V16, P292; Turner TT, 2003, REPRODUCTION, V125, P871, DOI 10.1530/reprod/125.6.871; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Vanderschueren D, 2000, ENDOCRINOLOGY, V141, P1642, DOI 10.1210/en.141.5.1642; Venken K, 2005, J BONE MINER RES, V20, P2138, DOI 10.1359/JBMR.050811; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 2002, J BIOL CHEM, V277, P35191, DOI 10.1074/jbc.M205928200; Wandernoth PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015061; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; World Health Organization (WHO), 2021, WHO LAB MAN EX PROC, V6th, DOI DOI 10.HTTP://WHQLIBD0C.WH0.INT/PUBLICATI0NS/2010/9789241547789_; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; Yeung CH, 2000, BIOL REPROD, V63, P612, DOI 10.1095/biolreprod63.2.612	53	19	19	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4360	4372		10.1096/fj.11-202283	http://dx.doi.org/10.1096/fj.11-202283			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22798427				2022-12-28	WOS:000309704000040
J	Granata, R; Gallo, D; Luque, RM; Baragli, A; Scarlatti, F; Grande, C; Gesmundo, I; Cordoba-Chacon, J; Bergandi, L; Settanni, F; Togliatto, G; Volante, M; Garetto, S; Annunziata, M; Chanclon, B; Gargantini, E; Rocchietto, S; Matera, L; Datta, G; Morino, M; Brizzi, MF; Ong, H; Camussi, G; Castano, JP; Papotti, M; Ghigo, E				Granata, Riccarda; Gallo, Davide; Luque, Raul M.; Baragli, Alessandra; Scarlatti, Francesca; Grande, Cristina; Gesmundo, Iacopo; Cordoba-Chacon, Jose; Bergandi, Loredana; Settanni, Fabio; Togliatto, Gabriele; Volante, Marco; Garetto, Stefano; Annunziata, Marta; Chanclon, Belen; Gargantini, Eleonora; Rocchietto, Stefano; Matera, Lina; Datta, Giacomo; Morino, Mario; Brizzi, Maria Felice; Ong, Huy; Camussi, Giovanni; Castano, Justo P.; Papotti, Mauro; Ghigo, Ezio			Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation	FASEB JOURNAL			English	Article						lipolysis; glucose uptake; PI3K/Akt and AMP-activated protein kinase; sirtuin 1; high-fat diet	HIGH-FAT DIET; ISOPROTERENOL-INDUCED LIPOLYSIS; HORMONE SECRETAGOGUE RECEPTOR; GLUT4 GLUCOSE-TRANSPORTER; PANCREATIC BETA-CELLS; TREATED NEWBORN RATS; WHITE ADIPOSE-TISSUE; UNACYLATED GHRELIN; GENE-EXPRESSION; GASTROINTESTINAL-TRACT	The metabolic actions of the ghrelin gene-derived peptide obestatin are still unclear. We investigated obestatin effects in vitro, on adipocyte function, and in vivo, on insulin resistance and inflammation in mice fed a high-fat diet (HFD). Obestatin effects on apoptosis, differentiation, lipolysis, and glucose uptake were determined in vitro in mouse 3T3-L1 and in human subcutaneous (hSC) and omental (hOM) adipocytes. In vivo, the influence of obestatin on glucose metabolism was assessed in mice fed an HFD for 8 wk. 3T3-L1, hSC, and hOM preadipocytes and adipocytes secreted obestatin and showed specific binding for the hormone. Obestatin prevented apoptosis in 3T3-L1 preadipocytes by increasing phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK)1/2 signaling. In both mice and human adipocytes, obestatin inhibited isoproterenol-induced lipolysis, promoted AMP-activated protein kinase phosphorylation, induced adiponectin, and reduced leptin secretion. Obestatin also enhanced glucose uptake in either the absence or presence of insulin, promoted GLUT4 translocation, and increased Akt phosphorylation and sirtuin 1 (SIRT1) protein expression. Inhibition of SIRT1 by small interfering RNA reduced obestatin-induced glucose uptake. In HFD-fed mice, obestatin reduced insulin resistance, increased insulin secretion from pancreatic islets, and reduced adipocyte apoptosis and inflammation in metabolic tissues. These results provide evidence of a novel role for obestatin in adipocyte function and glucose metabolism and suggest potential therapeutic perspectives in insulin resistance and metabolic dysfunctions.-Granata, R., Gallo, D., Luque, R. M., Baragli, A., Scarlatti, F., Grande, C., Gesmundo, I., Cordoba-Chacon, J., Bergandi, L., Settanni, F., Togliatto, G., Volante, M., Garetto, S., Annunziata, M., Chanclon, B., Gargantini, E., Rocchietto, S., Matera, L., Datta, G., Morino, M., Brizzi, M. F., Ong, H., Camussi, G., Castano, J. P., Papotti, M., Ghigo, E. Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J. 26, 3393-3411 (2012). www.fasebj.org	[Granata, Riccarda; Gallo, Davide; Baragli, Alessandra; Scarlatti, Francesca; Grande, Cristina; Gesmundo, Iacopo; Settanni, Fabio; Annunziata, Marta; Gargantini, Eleonora; Brizzi, Maria Felice] Univ Turin, Lab Mol & Cellular Endocrinol, Dept Internal Med, I-10126 Turin, Italy; [Bergandi, Loredana] Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; [Volante, Marco; Papotti, Mauro] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, I-10126 Turin, Italy; [Rocchietto, Stefano; Datta, Giacomo] Univ Turin, Dept Gen Surg, I-10126 Turin, Italy; [Rocchietto, Stefano; Datta, Giacomo] Univ Turin, Ctr Minimal Invas Surg, I-10126 Turin, Italy; [Morino, Mario] Univ Turin, Dept Plast Surg, I-10126 Turin, Italy; [Luque, Raul M.; Cordoba-Chacon, Jose; Chanclon, Belen; Castano, Justo P.] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Inst Maimonides Invest Biomed Cordoba, Hosp Univ Reina Sofia, Cordoba, Spain; [Luque, Raul M.; Cordoba-Chacon, Jose; Chanclon, Belen; Castano, Justo P.] Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Cordoba, Spain; [Ong, Huy] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	University of Turin; University of Turin; University of Turin; University of Turin; University of Turin; University of Turin; Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Universite de Montreal	Granata, R (corresponding author), Univ Turin, Lab Mol & Cellular Endocrinol, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	riccarda.granata@unito.it	Gesmundo, Iacopo/K-5131-2016; Datta, Giacomo/ABD-6490-2021; Brizzi, Maria Felice/J-7882-2016; Garetto, Stefano/ABD-1709-2020; Raul, Luque Huertas/M-6948-2018; Castaño, Justo P/A-7124-2010; Granata, Riccarda/K-7775-2016; Morino, Mario/AAI-6437-2020; Camussi, Giovanni/J-7624-2016; Bergandi, Loredana/L-2720-2019; Cordoba-Chacon, Jose/AAH-5753-2019; Togliatto, Gabriele/K-5668-2016	Gesmundo, Iacopo/0000-0003-4901-4764; Castaño, Justo P/0000-0002-3145-7287; Granata, Riccarda/0000-0003-4164-7313; Camussi, Giovanni/0000-0003-2795-232X; Bergandi, Loredana/0000-0003-0951-7340; Cordoba-Chacon, Jose/0000-0001-8787-2706; Morino, Mario/0000-0003-4540-1409; Togliatto, Gabriele/0000-0002-3123-7823; Garetto, Stefano/0000-0002-2421-3356; Chanclon Garcia, Belen/0000-0001-7170-9699; Luque, Raul M./0000-0002-7585-1913	Regione Piemonte; Brain Drain University of Turin; Ministro dell'Istruzione, dell'Universita e della Ricerca; Compagnia di San Paolo; Ministerio de Ciencia e Innovacion/Fonds Europeen de Developpement Regional [RYC-2007-00186, BFU2008-01136/BFI]; Instituto de Salud Carlos III [FI06/00804, BFU2010-19300, CTS-5051]; Studio delle Malattie Endocrino Metaboliche Foundation (Turin, Italy)	Regione Piemonte(Regione Piemonte); Brain Drain University of Turin; Ministro dell'Istruzione, dell'Universita e della Ricerca; Compagnia di San Paolo(Compagnia di San Paolo); Ministerio de Ciencia e Innovacion/Fonds Europeen de Developpement Regional; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Studio delle Malattie Endocrino Metaboliche Foundation (Turin, Italy)	The authors thank Amalia Bosia, Stefano Bruschi, Francesco Ferrini, Rhonda Kineman, Roberto Gambino, Fabio Malavasi, Adalberto Merighi, Susanna Romboli, Ana I. Pozo-Salas, Roy G. Smith, Marina Taliano, Letizia Trovato, and Alicia Villa-Osaba for contributing to the study. This work was supported by the following grants: Regione Piemonte 2008, Brain Drain University of Turin 2008, and Ministro dell'Istruzione, dell'Universita e della Ricerca 2009 (to R.G.); Compagnia di San Paolo 2008 (to E.G.); Ministerio de Ciencia e Innovacion/Fonds Europeen de Developpement Regional RYC-2007-00186, BFU2008-01136/BFI (to R.M.L.); Instituto de Salud Carlos III FI06/00804 (to J.C.C.); and BFU2010-19300 and CTS-5051 (to J.P.C.); and by the Studio delle Malattie Endocrino Metaboliche Foundation (Turin, Italy). Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion is an initiative of Instituto de Salud Carlos III.	Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Adeghate E, 2002, J NEUROENDOCRINOL, V14, P555, DOI 10.1046/j.1365-2826.2002.00811.x; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Alloatti G, 2010, AM J PHYSIOL-HEART C, V299, pH470, DOI 10.1152/ajpheart.00800.2009; Ataka K, 2008, AM J PHYSIOL-GASTR L, V294, pG1210, DOI 10.1152/ajpgi.00549.2007; Baragli A, 2011, BBA-MOL CELL BIOL L, V1811, P386, DOI 10.1016/j.bbalip.2011.03.001; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Bonzon-Kulichenko E, 2011, ENDOCRINOLOGY, V152, P1366, DOI 10.1210/en.2010-0858; Bourron O, 2010, DIABETOLOGIA, V53, P768, DOI 10.1007/s00125-009-1639-6; Brunetti L, 2009, PEPTIDES, V30, P1323, DOI 10.1016/j.peptides.2009.04.011; Catalan V, 2007, CLIN ENDOCRINOL, V66, P598, DOI 10.1111/j.1365-2265.2007.02777.x; Challa TD, 2012, J BIOL CHEM, V287, P6421, DOI 10.1074/jbc.M111.310342; Chartrel N, 2007, SCIENCE, V315, DOI 10.1126/science.1135047; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Egerod KL, 2007, MOL ENDOCRINOL, V21, P1685, DOI 10.1210/me.2007-0055; Gaidhu MP, 2010, AM J PHYSIOL-CELL PH, V298, pC961, DOI 10.1152/ajpcell.00547.2009; Giorgino F, 2005, ACTA PHYSIOL SCAND, V183, P13, DOI 10.1111/j.1365-201X.2004.01385.x; Granata R, 2008, DIABETES, V57, P967, DOI 10.2337/db07-1104; Granata R, 2007, ENDOCRINOLOGY, V148, P512, DOI 10.1210/en.2006-0266; Granata R, 2010, J MOL ENDOCRINOL, V45, P107, DOI 10.1677/JME-10-0019; Granata R, 2010, J MOL ENDOCRINOL, V45, P9, DOI 10.1677/JME-09-0141; Gronberg M, 2008, J HISTOCHEM CYTOCHEM, V56, P793, DOI 10.1369/jhc.2008.951145; Gurriaran-Rodriguez U, 2011, J CELL MOL MED, V15, P1927, DOI 10.1111/j.1582-4934.2010.01192.x; Gurriaran-Rodriguez U, 2011, J ENDOCRINOL, V210, pR1, DOI 10.1530/JOE-11-0233; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Holst B, 2007, ENDOCRINOLOGY, V148, P13, DOI 10.1210/en.2006-0933; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Irako T, 2006, DIABETOLOGIA, V49, P1264, DOI 10.1007/s00125-006-0226-3; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kim MS, 2004, MOL ENDOCRINOL, V18, P2291, DOI 10.1210/me.2003-0459; Liang FX, 2009, NAT REV ENDOCRINOL, V5, P367, DOI 10.1038/nrendo.2009.101; Luque RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015767; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miegueu P, 2011, J CELL BIOCHEM, V112, P704, DOI 10.1002/jcb.22983; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Morash MG, 2010, REGUL PEPTIDES, V163, P62, DOI 10.1016/j.regpep.2010.03.010; Muccioli G, 2004, EUR J PHARMACOL, V498, P27, DOI 10.1016/j.ejphar.2004.07.066; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Mulumba M, 2010, MOL ENDOCRINOL, V24, P1615, DOI 10.1210/me.2010-0010; Nishiumi S, 2010, J AGR FOOD CHEM, V58, P12916, DOI 10.1021/jf102840w; Perrini S, 2008, DIABETOLOGIA, V51, P155, DOI 10.1007/s00125-007-0841-7; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Reimer MK, 2002, DIABETES, V51, pS138, DOI 10.2337/diabetes.51.2007.S138; Rodriguez A, 2009, INT J OBESITY, V33, P541, DOI 10.1038/ijo.2009.40; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Seim I, 2011, MOL CELL ENDOCRINOL, V340, P111, DOI 10.1016/j.mce.2011.03.018; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Thompson NM, 2004, ENDOCRINOLOGY, V145, P234, DOI 10.1210/en.2003-0899; Tremblay F, 2007, ENDOCRINOLOGY, V148, P501, DOI 10.1210/en.2006-1275; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Wang ZQ, 2007, METABOLISM, V56, P1635, DOI 10.1016/j.metabol.2007.07.004; Wueest S, 2010, J CLIN INVEST, V120, P191, DOI 10.1172/JCI38388; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Zhang JV, 2008, MOL ENDOCRINOL, V22, P1464, DOI 10.1210/me.2007-0569; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255; Zhao YF, 2006, INT J BIOCHEM CELL B, V38, P804, DOI 10.1016/j.biocel.2005.11.008	59	64	69	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3393	3411		10.1096/fj.11-201343	http://dx.doi.org/10.1096/fj.11-201343			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22601779	Green Submitted			2022-12-28	WOS:000307162800027
J	Huang, Y; Crawford, M; Higuita-Castro, N; Nana-Sinkam, P; Ghadiali, SN				Huang, Yan; Crawford, Melissa; Higuita-Castro, Natalia; Nana-Sinkam, Patrick; Ghadiali, Samir N.			miR-146a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium	FASEB JOURNAL			English	Article						acute respiratory distress syndrome; ventilation-induced lung injury; oscillatory transmural pressure; microRNA; TRAF6; IRAK1; toll-like receptor signaling pathway	INDUCED LUNG INJURY; MECHANICAL VENTILATION; CYTOKINE RELEASE; RAPID CHANGES; EXPRESSION; MICRORNAS; CELLS; LIPOPOLYSACCHARIDE; FLOW; DIFFERENTIATION	Mechanical ventilation generates biophysical forces, including high transmural pressures, which exacerbate lung inflammation. This study sought to determine whether microRNAs (miRNAs) respond to this mechanical force and play a role in regulating mechanically induced inflammation. Primary human small airway epithelial cells (HSAEpCs) were exposed to 12 h of oscillatory pressure and/or the proinflammatory cytokine TNF-alpha. Experiments were also conducted after manipulating miRNA expression and silencing the transcription factor NF-kappa B or toll-like receptor proteins IRAK1 and TRAF6. NF-kappa B activation, IL-6/IL-8/IL-1 beta cytokine secretion, miRNA expression, and IRAK1/TRAF6 protein levels were monitored. A total of 12 h of oscillatory pressure and TNF-alpha resulted in a 5- to 7-fold increase in IL-6/IL-8 cytokine secretion, and oscillatory pressure also resulted in a time-dependent increase in IL-6/IL-8/IL-1 beta cytokine secretion. Pressure and TNF-alpha also resulted in distinct patterns of miRNA expression, with miR-146a being the most deregulated miRNA. Manipulating miR-146a expression altered pressure-induced cytokine secretion. Silencing of IRAK1 or TRAF6, confirmed targets of miR-146a, resulted in a 3-fold decrease in pressure-induced cytokine secretion. Cotransfection experiments demonstrate that miR-146a's regulation of pressure-induced cytokine secretion depends on its targeting of both IRAK1 and TRAF6. MiR-146a is a mechanosensitive miRNA that is rapidly up-regulated by oscillatory pressure and plays an important role in regulating mechanically induced inflammation in lung epithelia.-Huang, Y., Crawford, M., Higuita-Castro, N., Nana-Sinkam, P., Ghadiali, S. N. miR-146a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium. FASEB J. 26, 3351-3364 (2012). www.fasebj.org	[Nana-Sinkam, Patrick] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; [Huang, Yan; Higuita-Castro, Natalia; Ghadiali, Samir N.] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA; [Crawford, Melissa; Nana-Sinkam, Patrick; Ghadiali, Samir N.] Ohio State Univ, Dept Internal Med, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Nana-Sinkam, P (corresponding author), Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	patrick.nana-sinkam@osumc.edu; ghadiali.1@osu.edu	Ghadiali, Samir/AAN-7772-2020; Ghadiali, Samir N./C-5463-2012	Ghadiali, Samir/0000-0002-6845-774X; Ghadiali, Samir N./0000-0002-6845-774X	U.S. National Science Foundation CAREER grant [0852417]; U.S. National Institutes of Health grant [CA150297-01]; American Heart Association postdoctoral fellowship; NATIONAL CANCER INSTITUTE [R21CA150297] Funding Source: NIH RePORTER	U.S. National Science Foundation CAREER grant(National Science Foundation (NSF)); U.S. National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association postdoctoral fellowship(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by U.S. National Science Foundation CAREER grant 0852417 (S.N.G.), U.S. National Institutes of Health grant CA150297-01(S.P.N.) and an American Heart Association postdoctoral fellowship to Y.H. The authors thank the Nucleic Acid Shared Resource (NASR) at the Ohio State University Comprehensive Cancer Center for providing access to the Nanostring nCounter System, and Dr. Carlo Croce for critically reading and reviewing the manuscript.	Antonov AS, 2011, J CELL PHYSIOL, V226, P469, DOI 10.1002/jcp.22356; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042; Brower RG, 2004, NEW ENGL J MED, V351, P327; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Charles PE, 2011, CRIT CARE, V15, DOI 10.1186/cc10330; Cohen TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010385; Curtale G, 2010, BLOOD, V115, P265, DOI 10.1182/blood-2009-06-225987; D'Angelo E, 2008, J APPL PHYSIOL, V104, P41, DOI 10.1152/japplphysiol.00805.2007; Fakler CR, 2000, INFLAMM RES, V49, P63, DOI 10.1007/s000110050560; Ghadiali SN, 2008, RESP PHYSIOL NEUROBI, V163, P232, DOI 10.1016/j.resp.2008.04.008; Ghose J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023837; Guan YJ, 2011, FASEB J, V25, P4457, DOI 10.1096/fj.11-185132; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Halbertsma FJJ, 2005, NETH J MED, V63, P382; Huang Y, 2010, CELL MOL BIOENG, V3, P415, DOI 10.1007/s12195-010-0138-7; Jaecklin T, 2011, AM J PHYSIOL-LUNG C, V300, pL648, DOI 10.1152/ajplung.00305.2010; Jafari B, 2004, RESPIROLOGY, V9, P43, DOI 10.1111/j.1440-1843.2003.00527.x; Kojic N, 2010, BIOPHYS J, V99, P3517, DOI 10.1016/j.bpj.2010.09.044; Kojic N, 2010, FASEB J, V24, P1604, DOI 10.1096/fj.09-145367; Li HH, 2010, ANESTHESIOLOGY, V113, P619, DOI 10.1097/ALN.0b013e3181e89ab2; Li L, 2010, SCAND J IMMUNOL, V71, P227, DOI 10.1111/j.1365-3083.2010.02383.x; Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013; Liu YY, 2009, TRANSL RES, V154, P228, DOI 10.1016/j.trsl.2009.06.006; Luna C, 2009, MOL VIS, V15, P2488; Meltzer S J, 1885, J Physiol, V5, P255; Meltzer SJ, 1909, J EXP MED, V11, P622, DOI 10.1084/jem.11.4.622; Mohamed JS, 2010, J BIOL CHEM, V285, P29336, DOI 10.1074/jbc.M110.101147; Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240; Ni CW, 2011, AM J PHYSIOL-HEART C, V300, pH1762, DOI 10.1152/ajpheart.00829.2010; Nihira K, 2010, CELL DEATH DIFFER, V17, P689, DOI 10.1038/cdd.2009.174; Notter R. H., 2005, LUNG INJURY MECH PAT, V196; Olsen SM, 2011, ANN BIOMED ENG, V39, P688, DOI 10.1007/s10439-010-0203-3; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Pauley KM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2493; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Perry MM, 2009, FEBS LETT, V583, P3349, DOI 10.1016/j.febslet.2009.09.038; Plataki Maria, 2010, Expert Rev Respir Med, V4, P373, DOI 10.1586/ers.10.28; Qin XM, 2010, P NATL ACAD SCI USA, V107, P3240, DOI 10.1073/pnas.0914882107; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Slutsky Arthur S, 2005, Respir Care, V50, P646; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Suarez Y, 2010, J IMMUNOL, V184, P21, DOI 10.4049/jimmunol.0902369; Sun SG, 2011, EMBO REP, V12, P56, DOI 10.1038/embor.2010.172; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thomas M, 2012, ONCOGENE, V31, P918, DOI 10.1038/onc.2011.278; Tschumperlin DJ, 2010, J BIOMECH, V43, P99, DOI 10.1016/j.jbiomech.2009.09.015; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Vaneker M, 2008, ANESTHESIOLOGY, V109, P465, DOI 10.1097/ALN.0b013e318182aef1; Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167, DOI 10.1152/ajplung.1999.277.1.L167; Wang KC, 2010, P NATL ACAD SCI USA, V107, P3234, DOI 10.1073/pnas.0914825107; Weber M, 2010, BIOCHEM BIOPH RES CO, V393, P643, DOI 10.1016/j.bbrc.2010.02.045; Yalcin HC, 2007, J APPL PHYSIOL, V103, P1796, DOI 10.1152/japplphysiol.00164.2007; Zhou J, 2011, P NATL ACAD SCI USA, V108, P10355, DOI 10.1073/pnas.1107052108; Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010	56	56	57	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3351	3364		10.1096/fj.11-199240	http://dx.doi.org/10.1096/fj.11-199240			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593544	Green Published			2022-12-28	WOS:000307162800024
J	Pi, LY; Shenoy, AK; Liu, JW; Kim, S; Nelson, N; Xia, HM; Hauswirth, WW; Petersen, BE; Schultz, GS; Scott, EW				Pi, Liya; Shenoy, Anitha K.; Liu, Jianwen; Kim, Seungbum; Nelson, Nikole; Xia, Huiming; Hauswirth, William W.; Petersen, Bryon E.; Schultz, Gregory S.; Scott, Edward W.			CCN2/CTGF regulates neovessel formation via targeting structurally conserved cystine knot motifs in multiple angiogenic regulators	FASEB JOURNAL			English	Article						retinal neovascularization; tumorigenesis; oxygen-induced retinopathy	TISSUE-GROWTH-FACTOR; OXYGEN-INDUCED RETINOPATHY; CELL-ADHESION; GENE-PRODUCT; MIGRATION; CCN5; CTGF; PROLIFERATION; ACTIVATION; BMP	Blood vessels are formed during development and tissue repair through a plethora of modifiers that coordinate efficient vessel assembly in various cellular settings. Here we used the yeast 2-hybrid approach and demonstrated a broad affinity of connective tissue growth factor (CCN2/CTGF) to C-terminal cystine knot motifs present in key angiogenic regulators Slit3, von Willebrand factor, platelet-derived growth factor-B, and VEGF-A. Biochemical characterization and histological analysis showed close association of CCN2/CTGF with these regulators in murine angiogenesis models: normal retinal development, oxygen-induced retinopathy (OIR), and Lewis lung carcinomas. CCN2/CTGF and Slit3 proteins worked in concert to promote in vitro angiogenesis and downstream Cdc42 activation. A fragment corresponding to the first three modules of CCN2/CTGF retained this broad binding ability and gained a dominant-negative function. Intravitreal injection of this mutant caused a significant reduction in vascular obliteration and retinal neovascularization vs. saline injection in the OIR model. Knocking down CCN2/CTGF expression by short-hairpin RNA or ectopic expression of this mutant greatly decreased tumorigenesis and angiogenesis. These results provided mechanistic insight into the angiogenic action of CCN2/CTGF and demonstrated the therapeutic potential of dominant-negative CCN2/CTGF mutants for antiangiogenesis.-Pi, L., Shenoy, A. K., Liu, J., Kim, S., Nelson, N., Xia, H., Hauswirth, W. W., Petersen, B. E., Schultz, G. S., Scott, E. W. CCN2/CTGF regulates neovessel formation via targeting structurally conserved cystine knot motifs in multiple angiogenic regulators. FASEB J. 26, 3365-3379 (2012). www.fasebj.org	[Pi, Liya; Shenoy, Anitha K.; Kim, Seungbum; Nelson, Nikole; Xia, Huiming; Scott, Edward W.] Univ Florida, Program Stem Cell Biol & Regenerat Med, Gainesville, FL 32610 USA; [Schultz, Gregory S.] Univ Florida, Dept Obstet & Gynecol, Gainesville, FL 32610 USA; [Liu, Jianwen; Hauswirth, William W.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; [Petersen, Bryon E.] Wake Forest Univ, Inst Regenerat Med, Winston Salem, NC 27109 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Wake Forest University	Pi, LY (corresponding author), Univ Florida, Program Stem Cell Biol & Regenerat Med, POB 100232, Gainesville, FL 32610 USA.	lpi@ufl.edu; escott@ufl.edu	Xia, Huiming/F-2713-2012	hauswirth, william/0000-0002-3244-4947	U.S. National Institutes of Health [HL070738, EY018158, T32 DK074367, EY005587, EY021721]; Research to Prevent Blindness, Inc.; NATIONAL CANCER INSTITUTE [T32CA106493] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018158, R01EY005587, P30EY021721] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058614, R01DK065096, T32DK074367] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness, Inc.(Research to Prevent Blindness (RPB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Emina Huang, Long Dang, Robert Fisher, and Tom Shupe for manuscript discussion. The authors also thank Dr. Wen-Yuan Song (University of Florida) for providing the pPC97, pPC96, and pMAL vectors. The authors acknowledge the U.S. National Institutes of Health (grants HL070738 and EY018158 to E.W.S.; T32 DK074367 to L.P.; EY005587 to G.S.S.; and EY021721 to W.W.H.) and Research to Prevent Blindness, Inc. for partial support of this work. W.W.H. and the University of Florida have a financial interest in the use of adeno-associated virus therapies and own equity in a company (AGTC Inc.) that might, in the future, commercialize some aspects of this work. The other authors declare no conflicts of interest.	Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baguma-Nibasheka M, 2008, DEV DYNAM, V237, P485, DOI 10.1002/dvdy.21433; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Dunaway CM, 2011, MOL CELL BIOL, V31, P404, DOI 10.1128/MCB.00667-10; Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456-008-9107-3; Hall-Glenn F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030562; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Holbourn KP, 2011, J BIOL CHEM, V286, P22243, DOI 10.1074/jbc.M111.225755; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Lake AC, 2003, AM J PATHOL, V162, P219, DOI 10.1016/S0002-9440(10)63813-8; Liu HB, 2008, ENDOCRINOLOGY, V149, P1666, DOI 10.1210/en.2007-1415; Liu JM, 2003, MECH DEVELOP, V120, P1059, DOI 10.1016/S0925-4773(03)00161-8; Liu SX, 2011, ARTHRITIS RHEUM-US, V63, P239, DOI 10.1002/art.30074; Loges S, 2009, J THROMB HAEMOST, V7, P21, DOI 10.1111/j.1538-7836.2008.03203.x; Maeda A, 2009, J BIOCHEM, V145, P207, DOI 10.1093/jb/mvn159; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Pi L, 2008, HEPATOLOGY, V47, P996, DOI 10.1002/hep.22079; Pi LY, 2011, INVEST OPHTH VIS SCI, V52, P8701, DOI 10.1167/iovs.11-7870; Pi LY, 2005, GASTROENTEROLOGY, V128, P2077, DOI 10.1053/j.gastro.2005.03.081; Sato T, 2009, BRIT J OPHTHALMOL, V93, P96, DOI 10.1136/bjo.2008.142646; Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002; Shimo T, 2001, ONCOLOGY-BASEL, V61, P315, DOI 10.1159/000055339; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507; STEL HV, 1985, BLOOD, V65, P85; Tanno T, 2007, FEBS LETT, V581, P1022, DOI 10.1016/j.febslet.2007.02.001; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Xu SW, 2009, J CELL COMMUN SIGNAL, V3, P61, DOI 10.1007/s12079-009-0053-7; Yoon PO, 2010, J MOL CELL CARDIOL, V49, P294, DOI 10.1016/j.yjmcc.2010.04.010; Zhang B, 2009, BLOOD, V114, P4300, DOI 10.1182/blood-2008-12-193326	39	40	44	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3365	3379		10.1096/fj.11-200154	http://dx.doi.org/10.1096/fj.11-200154			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22611085	Green Published			2022-12-28	WOS:000307162800025
J	Lee, HD; Koo, BH; Kim, YH; Jeon, OH; Kim, DS				Lee, Hee Doo; Koo, Bon-Hun; Kim, Yeon Hyang; Jeon, Ok-Hee; Kim, Doo-Sik			Exosome release of ADAM15 and the functional implications of human macrophage-derived ADAM15 exosomes	FASEB JOURNAL			English	Article						disintegrin; microvesicles; antitumor immunity	HUMAN ALVEOLAR MACROPHAGES; PROTEIN-KINASE-C; MEMBRANE-VESICLES; TUMORICIDAL PROPERTIES; DISINTEGRIN DOMAIN; CELL-PROLIFERATION; RECEPTOR; DIFFERENTIATION; MECHANISM; ACTIVATION	A disintegrin and metalloproteinase 15 (ADAM15), the only ADAM protein containing an Arg-Gly-Asp (RGD) motif in its disintegrin-like domain, is a widely expressed membrane protein that is involved in tumor progression and suppression. However, the underlying mechanism of ADAM15-mediated tumor suppression is not clearly understood. This study demonstrates that ADAM15 is released as an exosomal component, and ADAM15 exosomes exert tumor suppressive activities. We found that exosomal ADAM15 release is stimulated by phorbol 12-myristate 13-acetate, a typical protein kinase C activator, in various tumor cell types, and this results in a corresponding decrease in plasma membrane-associated ADAM15. Exosomes rich in ADAM15 display enhanced binding affinity for integrin alpha v beta 3 in an RGD-dependent manner and suppress vitronectin-and fibronectin-induced cell adhesion, growth, and migration, as well as in vivo tumor growth. Exosomal ADAM15 is released from human macrophages, and macrophage-derived ADAM15 exosomes have tumor inhibitory effects. This work suggests a primary role of ADAM15 for exosome-mediated tumor suppression, as well as functional significance of exosomal ADAM protein in antitumor immunity.-Lee, H. D., Koo, B.-H., Kim, Y. H., Jeon, O.-H., Kim, D.-S. Exosome release of ADAM15 and the functional implications of human macrophage-derived ADAM15 exosomes. FASEB J. 26, 3084-3095 (2012). www.fasebj.org	[Lee, Hee Doo; Koo, Bon-Hun; Kim, Yeon Hyang; Jeon, Ok-Hee; Kim, Doo-Sik] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea	Yonsei University	Kim, DS (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea.	dskim@yonsei.ac.kr		Lee, Heedoo/0000-0001-7652-3930	National Research Foundation of Korea; Ministry of Education, Science, and Technology [2009-0081760]	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the Future-based Technology Development Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (2009-0081760).	Abache T, 2007, J CELL BIOCHEM, V102, P650, DOI 10.1002/jcb.21318; AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; Anand Paras K, 2010, Commun Integr Biol, V3, P405, DOI 10.4161/cib.3.5.12474; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; BRAUN DP, 1993, CANCER RES, V53, P3362; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Chen Q, 2008, INT J BIOCHEM CELL B, V40, P2164, DOI 10.1016/j.biocel.2008.02.021; Choi SH, 2006, CANCER RES, V66, P7261, DOI 10.1158/0008-5472.CAN-05-4177; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Gutwein P, 2005, CLIN CANCER RES, V11, P2492, DOI 10.1158/1078-0432.CCR-04-1688; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; HIBBS JB, 1982, ADV EXP MED BIOL, V146, P315; Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; LEMARBRE P, 1980, BLOOD, V55, P612; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; Lynch S, 2009, J IMMUNOL, V183, P1884, DOI 10.4049/jimmunol.0900798; Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351; McLane Mary Ann, 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P327, DOI 10.2174/1568006043335880; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; Najy AJ, 2008, J BIOL CHEM, V283, P18393, DOI 10.1074/jbc.M801329200; Najy AJ, 2008, CANCER RES, V68, P1092, DOI 10.1158/0008-5472.CAN-07-2432; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Segura E, 2007, J IMMUNOL, V179, P1489, DOI 10.4049/jimmunol.179.3.1489; SONE S, 1981, CELL IMMUNOL, V57, P42, DOI 10.1016/0008-8749(81)90118-0; SONE S, 1984, CANCER RES, V44, P646; SONE S, 1982, CANCER RES, V42, P2227; Sun CX, 2010, CARDIOVASC RES, V87, P348, DOI 10.1093/cvr/cvq060; Takagi J, 2004, BIOCHEM SOC T, V32, P403, DOI 10.1042/BST0320403; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Toquet C, 2012, INT J CANCER, V130, P278, DOI 10.1002/ijc.25891; Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272; Ungerer C, 2010, BIOCHEM BIOPH RES CO, V401, P363, DOI 10.1016/j.bbrc.2010.09.055; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Kilsdonk JWJ, 2010, EUR J CELL BIOL, V89, P415, DOI 10.1016/j.ejcb.2009.11.026; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Whatling C, 2004, J LIPID RES, V45, P1768, DOI 10.1194/jlr.M400195-JLR200; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wu J, 2008, ONCOL REP, V20, P669, DOI 10.3892/or_00000058; Zeelenberg IS, 2008, CANCER RES, V68, P1228, DOI 10.1158/0008-5472.CAN-07-3163; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	46	35	35	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3084	3095		10.1096/fj.11-201681	http://dx.doi.org/10.1096/fj.11-201681			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22505472				2022-12-28	WOS:000305912500036
J	Naude, PJW; Csaba, N; Eiden, LE; Ait-Ali, D; van der Heide, R; Engelborghs, S; Luiten, PGM; De Deyn, PP; den Boer, JA; Eisel, ULM				Naude, Petrus J. W.; Csaba Nyakas; Eiden, Lee E.; Ait-Ali, Djida; van der Heide, Ragna; Engelborghs, Sebastiaan; Luiten, Paul G. M.; De Deyn, Peter P.; den Boer, Johan A.; Eisel, Ulrich L. M.			Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease	FASEB JOURNAL			English	Article						mild cognitive impairment; TNF-alpha; neurodegeneration	TUMOR-NECROSIS-FACTOR; GELATINASE-ASSOCIATED LIPOCALIN; AMYLOID-BETA; TNF-ALPHA; APOLIPOPROTEIN J; GENE-EXPRESSION; CHOROID-PLEXUS; HIGH-AFFINITY; RECEPTOR; ACTIVATION	Alzheimer's disease (AD) is associated with an altered immune response, resulting in chronic increased inflammatory cytokine production with a prominent role of TNF-alpha. TNF-alpha signals are mediated by two receptors: TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Signaling through TNFR2 is associated with neuroprotection, whereas signaling through TNFR1 is generally proinflammatory and proapoptotic. Here, we have identified a TNF-alpha-induced proinflammatory agent, lipocalin 2 (Lcn2) via gene array in murine primary cortical neurons. Further investigation showed that Lcn2 protein production and secretion were activated solely upon TNFR1 stimulation when primary murine neurons, astrocytes, and microglia were treated with TNFR1 and TNFR2 agonistic antibodies. Lcn2 was found to be significantly decreased in CSF of human patients with mild cognitive impairment and AD and increased in brain regions associated with AD pathology in human postmortem brain tissue. Mechanistic studies in cultures of primary cortical neurons showed that Lcn2 sensitizes nerve cells to beta-amyloid toxicity. Moreover, Lcn2 silences a TNFR2-mediated protective neuronal signaling cascade in neurons, pivotal for TNF-alpha-mediated neuroprotection. The present study introduces Lcn2 as a molecular actor in neuroinflammation in early clinical stages of AD.-Naud, P.J.W., Nyakas, C., Eiden, L. E., Ait-Ali, D., van der Heide, R., Engelborghs, S., Luiten, P. G. M., De Deyn, P. P., den Boer, J.A., Eisel, U. L. M. Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease. FASEB J. 26, 2811-2823 (2012). www.fasebj.org	[Naude, Petrus J. W.; van der Heide, Ragna; Luiten, Paul G. M.; Eisel, Ulrich L. M.] Univ Groningen, Dept Mol Neurobiol, NL-9747 AG Groningen, Netherlands; [Naude, Petrus J. W.; Luiten, Paul G. M.; den Boer, Johan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Biol Psychiat, NL-9747 AG Groningen, Netherlands; [De Deyn, Peter P.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9747 AG Groningen, Netherlands; [De Deyn, Peter P.] Univ Groningen, Univ Med Ctr Groningen, Alzheimer Res Ctr, NL-9747 AG Groningen, Netherlands; [Csaba Nyakas] Semmelweis Univ, Neuropsychopharmacol Res Grp, H-1085 Budapest, Hungary; [Csaba Nyakas] Hungarian Acad Sci, Budapest, Hungary; [Eiden, Lee E.; Ait-Ali, Djida] NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA; [Engelborghs, Sebastiaan; De Deyn, Peter P.] Ziekenhuis Netwerk Antwerpen, Dept Neurol, Antwerp, Belgium; [Engelborghs, Sebastiaan; De Deyn, Peter P.] Ziekenhuis Netwerk Antwerpen, Memory Clin, Antwerp, Belgium; [Engelborghs, Sebastiaan; De Deyn, Peter P.] Univ Antwerp, Inst Born Bunge, Lab Neurochem & Behav, B-2020 Antwerp, Belgium; [Engelborghs, Sebastiaan; De Deyn, Peter P.] Univ Antwerp, Inst Born Bunge, Reference Ctr Biol Markers Dementia, B-2020 Antwerp, Belgium; [Engelborghs, Sebastiaan; De Deyn, Peter P.] Univ Antwerp, Inst Born Bunge, Biobank Antwerp, B-2020 Antwerp, Belgium	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Semmelweis University; Hungarian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Antwerp; University of Antwerp; University of Antwerp	Eisel, ULM (corresponding author), Univ Groningen, Dept Mol Neurobiol, Nijenborgh 7, NL-9747 AG Groningen, Netherlands.	u.l.m.eisel@rug.nl	Naude, Pieter/AAC-2565-2021	Eisel, Ulrich/0000-0003-4178-0384; Eiden, Lee/0000-0001-7524-944X	De Cock Stichting [635155]; European Union [LSHM-CT-2005-018637]; School of Behavioral and Cognitive Neurosciences; NIMH-IRP [Z01-MH002386-23]; Research Foundation Flanders (FWO); Inter-university Poles of Attraction (IAP Network) of the Belgian Federal Science Policy Office [P6/43]; Flemish Government; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002386, Z01MH002386] Funding Source: NIH RePORTER	De Cock Stichting; European Union(European Commission); School of Behavioral and Cognitive Neurosciences; NIMH-IRP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Research Foundation Flanders (FWO)(FWO); Inter-university Poles of Attraction (IAP Network) of the Belgian Federal Science Policy Office; Flemish Government(European Commission); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Dr. Abdel Elkahloun [Manager, National Human Genome Research Institute/National Institute of Mental Health (NIMH)/National Institute of Neurological Disorders and Stroke, U. S. National Institutes of Health (NIH) Microarray Core] for invaluable assistance with microarray analysis and data capture; Babru Samal [NIMH-Intramural Research Program (IRP) Bioinformatics Core Specialist] for help with statistical analysis; David Huddleston (Biologist, Section on Molecular Neuroscience, NIMH-IRP) for processing of RNAs for microarray analysis; Dennis van der Meer and Erin van Buel for helping with cell culture and Western blotting; Dr. Amalia Dolga for assisting with cell culture, treatment, and mRNA isolation; and the Antwerp Biobank at the Institute Born-Bunge of the University of Antwerp for providing the biosamples of control subjects, patients with MCI, and patients with AD. This study was funded by De Cock Stichting (project 635155 to P.J.W.N.) and the European Union (grant FP6 NeuropromMiSe LSHM-CT-2005-018637 to U. L. M. E.) and by a stipend from the School of Behavioral and Cognitive Neurosciences to P.J.W.N. The authors acknowledge the support of NIMH-IRP (project Z01-MH002386-23). In addition, this work was supported by the Research Foundation Flanders (FWO), Inter-university Poles of Attraction (IAP Network P6/43) of the Belgian Federal Science Policy Office, Methusalem excellence grant of the Flemish Government, agreement between Institute Born-Bunge and University of Antwerp, the Medical Research Foundation Antwerp, the Thomas Riellaerts research fund, and Neurosearch Antwerp.	Alvira-Botero Ximena, 2010, Curr Aging Sci, V3, P219; Bolignano D, 2010, J INVEST MED, V58, P569, DOI 10.231/JIM.0b013e3181ccc20c; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Chakrabarty P, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-16; Cheng X, 2010, J ALZHEIMERS DIS, V19, P621, DOI 10.3233/JAD-2010-1253; Choi J, 2011, J NEUROL SCI, V305, P28, DOI 10.1016/j.jns.2011.03.023; Chopra K, 2011, EXPERT OPIN THER TAR, V15, P535, DOI 10.1517/14728222.2011.557363; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Fernandes A, 2011, GLIA, V59, P14, DOI 10.1002/glia.21072; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Granic I, 2010, J ALZHEIMERS DIS, V19, P991, DOI 10.3233/JAD-2010-1297; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Guo H, 2010, DIABETES, V59, P1376, DOI 10.2337/db09-1735; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031; Jin DZ, 2011, MOL CELL BIOCHEM, V351, P165, DOI 10.1007/s11010-011-0724-6; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Laakso MP, 2000, BIOL PSYCHIAT, V47, P1056, DOI 10.1016/S0006-3223(99)00306-6; Lee S, 2007, J IMMUNOL, V179, P3231, DOI 10.4049/jimmunol.179.5.3231; Lee S, 2009, J NEUROSCI, V29, P234, DOI 10.1523/JNEUROSCI.5273-08.2009; Lee YM, 2010, ARCH PHARM RES, V33, P231, DOI 10.1007/s12272-010-0207-4; Li PT, 2007, INT J BIOL SCI, V3, P100; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mak Lok Hang, 2010, J Chem Biol, V3, P157, DOI 10.1007/s12154-010-0041-7; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; Marques F, 2008, J CEREBR BLOOD F MET, V28, P450, DOI 10.1038/sj.jcbfm.9600557; Miharada K, 2008, J CELL PHYSIOL, V215, P526, DOI 10.1002/jcp.21334; Montgomery SL, 2011, AM J PATHOL, V179, P2053, DOI 10.1016/j.ajpath.2011.07.001; Mucha M, 2011, P NATL ACAD SCI USA, V108, P18436, DOI 10.1073/pnas.1107936108; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Nijholt IM, 2011, ADV EXP MED BIOL, V691, P567, DOI 10.1007/978-1-4419-6612-4_59; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Patel JR, 2008, EXP NEUROL, V213, P93, DOI 10.1016/j.expneurol.2008.05.007; Prvulovic D, 2011, CLIN CHEM LAB MED, V49, P367, DOI 10.1515/CCLM.2011.087; Rao JS, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.27; Rathore KI, 2011, J NEUROSCI, V31, P13412, DOI 10.1523/JNEUROSCI.0116-11.2011; Renner NA, 2011, J NEUROVIROL, V17, P146, DOI 10.1007/s13365-010-0017-y; Rosenberg PB, 2006, INT REV PSYCHIATR, V17, P503, DOI 10.1080/02646830500382037; Serot JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS515, DOI 10.2741/1085; Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Veroni C, 2010, MOL CELL NEUROSCI, V45, P234, DOI 10.1016/j.mcn.2010.06.014; Viel JJ, 2001, J NEUROSCI RES, V64, P454, DOI 10.1002/jnr.1097; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang XK, 2007, GENOMICS, V90, P201, DOI 10.1016/j.ygeno.2007.03.007; Wu ZL, 2006, NEUROBIOL AGING, V27, P377, DOI 10.1016/j.neurobiolaging.2005.02.010; Zhao M, 2003, NEUROCHEM RES, V28, P307, DOI 10.1023/A:1022337519035; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	58	122	125	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2811	2823		10.1096/fj.11-202457	http://dx.doi.org/10.1096/fj.11-202457			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22441986	Green Published			2022-12-28	WOS:000305912500010
J	Tsakiri, EN; Sykiotis, GP; Papassideri, IS; Gorgoulis, VG; Bohmann, D; Trougakos, IP				Tsakiri, Eleni N.; Sykiotis, Gerasimos P.; Papassideri, Issidora S.; Gorgoulis, Vassilis G.; Bohmann, Dirk; Trougakos, Ioannis P.			Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress	FASEB JOURNAL			English	Article						antioxidant response elements; gonads; Keap1; Nrf2	EMBRYONIC STEM-CELLS; DAMAGED PROTEINS; 20S PROTEASOME; 26S PROTEASOME; ANTIOXIDANT RESPONSE; HUMAN FIBROBLASTS; LIFE-SPAN; AGE; MELANOGASTER; LONGEVITY	Proteasome is central to proteostasis maintenance, as it degrades both normal and damaged proteins. Herein, we undertook a detailed analysis of proteasome regulation in the in vivo setting of Drosophila melanogaster. We report that a major hallmark of somatic tissues of aging flies is the gradual accumulation of ubiquitinated and carbonylated proteins; these effects correlated with a similar to 50% reduction of proteasome expression and catalytic activities. In contrast, gonads of aging flies were relatively free of proteome oxidative damage and maintained substantial proteasome expression levels and highly active proteasomes. Moreover, gonads of young flies were found to possess more abundant and more active proteasomes than somatic tissues. Exposure of flies to oxidants induced higher proteasome activities specifically in the gonads, which were, independently of age, more resistant than soma to oxidative challenge and, as analyses in reporter transgenic flies showed, retained functional antioxidant responses. Finally, inducible Nrf2 activation in transgenic flies promoted youthful proteasome expression levels in the aged soma, suggesting that age-dependent Nrf2 dysfunction is causative of decreasing somatic proteasome expression during aging. The higher investment in proteostasis maintenance in the gonads plausibly facilitates proteome stability across generations; it also provides evidence in support of the trade-off theories of aging.-Tsakiri, E. N., Sykiotis, G. P., Papassideri, I. S., Gorgoulis, V. G., Bohmann, D., Trougakos, I. P. Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress.	[Tsakiri, Eleni N.; Papassideri, Issidora S.; Trougakos, Ioannis P.] Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece; [Sykiotis, Gerasimos P.] Univ Patras, Sch Med, Dept Internal Med, Div Endocrinol, GR-26110 Patras, Greece; [Gorgoulis, Vassilis G.] Univ Athens, Sch Med, Dept Histol & Embryol, GR-11527 Athens, Greece; [Bohmann, Dirk] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	National & Kapodistrian University of Athens; University of Patras; Athens Medical School; National & Kapodistrian University of Athens; University of Rochester	Trougakos, IP (corresponding author), Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece.	itrougakos@biol.uoa.gr	Sykiotis, Gerasimos P/E-7407-2017; Trougakos, Ioannis/R-6149-2018; Gorgoulis, Vassilis/AAD-3630-2019	Trougakos, Ioannis/0000-0002-6179-2772; Gorgoulis, Vassilis/0000-0001-9001-4112; Sykiotis, Gerasimos/0000-0002-9565-4941; Tsakiri, Eleni/0000-0002-3271-6316	European Union [REGPOT-CT-2011-284460]; NATIONAL INSTITUTE ON AGING [R01AG039753] Funding Source: NIH RePORTER	European Union(European Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Maria Figueiredo-Pereira (Hunter College, City University of New York, New York, NY, USA) for the Drosophila beta 5 proteasome subunit antibody; Eirini Komseli for immunostaining of paraffin-embedded flies; Triantafyllia Ntouroupi for technical support during the early phase of this project; and Marianna Antonelou for helpful suggestions. This work was supported by a European Union FP7 Capacities grant INsPiRE (REGPOT-CT-2011-284460) to I.P.T.	Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924; Bader N, 2007, EXP GERONTOL, V42, P864, DOI 10.1016/j.exger.2007.03.010; Beedholm R, 2004, CELL STRESS CHAPERON, V9, P49, DOI 10.1379/1466-1268(2004)009<0049:MHSSSP>2.0.CO;2; Breusing N, 2008, BIOL CHEM, V389, P203, DOI 10.1515/BC.2008.029; Carnes BA, 2011, BIOGERONTOLOGY, V12, P367, DOI 10.1007/s10522-011-9338-3; Chatterjee N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034063; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6; Cook C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005888; Edelmann MJ, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002031; Erjavec N, 2008, P NATL ACAD SCI USA, V105, P18764, DOI 10.1073/pnas.0804550105; Erjavec N, 2007, P NATL ACAD SCI USA, V104, P10877, DOI 10.1073/pnas.0701634104; Ferguson M, 2005, BIOCHEM J, V390, P501, DOI 10.1042/BJ20042130; Fredriksson A, 2012, AGING CELL, V11, P634, DOI 10.1111/j.1474-9726.2012.00823.x; Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028; Girardot F, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-69; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; Goudeau J, 2010, AGING CELL, V9, P991, DOI 10.1111/j.1474-9726.2010.00625.x; Grimberg KB, 2011, MOL CELL BIOL, V31, P897, DOI 10.1128/MCB.00799-10; Hansen TO, 2012, BIOGERONTOLOGY, V13, P429, DOI 10.1007/s10522-012-9387-2; Hernebring M, 2006, P NATL ACAD SCI USA, V103, P7700, DOI 10.1073/pnas.0510944103; Hubbard VM, 2012, BIOGERONTOLOGY, V13, P21, DOI 10.1007/s10522-011-9331-x; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; Jacobson J, 2010, AGING CELL, V9, P466, DOI 10.1111/j.1474-9726.2010.00573.x; Kim SK, 2007, J EXP BIOL, V210, P1607, DOI 10.1242/jeb.004887; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kucherenko M. M., 2010, J VIS EXP, V46; Kurapati R, 2000, J GERONTOL A-BIOL, V55, pB552, DOI 10.1093/gerona/55.11.B552; Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481; Nickell S, 2009, P NATL ACAD SCI USA, V106, P11943, DOI 10.1073/pnas.0905081106; Petersen A., 2010, CURR GERONTOL GERIAT, DOI [10.1155/2010/, DOI 10.1155/2010]; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickering AM, 2012, PROG MOL BIOL TRANSL, V109, P227, DOI 10.1016/B978-0-12-397863-9.00006-7; Pickering AM, 2010, BIOCHEM J, V432, P585, DOI 10.1042/BJ20100878; Rattan SIS, 2008, BIOL CHEM, V389, P267, DOI 10.1515/BC.2008.030; Rattan SIS, 2006, FREE RADICAL RES, V40, P1230, DOI 10.1080/10715760600911303; Rattan SIS, 2012, BIOGERONTOLOGY, V13, P83, DOI 10.1007/s10522-011-9354-3; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Shenvi SV, 2012, AGING CELL, V11, P297, DOI 10.1111/j.1474-9726.2011.00788.x; Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269; Sohal RS, 2012, FREE RADICAL BIO MED, V52, P539, DOI 10.1016/j.freeradbiomed.2011.10.445; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Tonoki A, 2009, MOL CELL BIOL, V29, P1095, DOI 10.1128/MCB.01227-08; Tower J, 2006, MECH AGEING DEV, V127, P705, DOI 10.1016/j.mad.2006.05.001; Trougakos IP, 1998, J STRUCT BIOL, V123, P97, DOI 10.1006/jsbi.1998.4999; Vernace VA, 2007, FASEB J, V21, P2672, DOI 10.1096/fj.06-6751com; Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216; Vilchez D, 2012, NATURE, V489, P263, DOI 10.1038/nature11315; Vilchez D, 2012, NATURE, V489, P304, DOI 10.1038/nature11468; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wensink M, 2013, BIOGERONTOLOGY, V14, P99, DOI 10.1007/s10522-012-9410-7	54	74	74	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2407	2420		10.1096/fj.12-221408	http://dx.doi.org/10.1096/fj.12-221408			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457214	Green Published, Bronze			2022-12-28	WOS:000319667600028
J	Kim, Y; Cunningham, MA; Mire, J; Tesar, C; Sacchettini, J; Joachimiak, A				Kim, Youngchang; Cunningham, Mark A.; Mire, Joseph; Tesar, Christine; Sacchettini, James; Joachimiak, Andrzej			NDM-1, the ultimate promiscuous enzyme: substrate recognition and catalytic mechanism	FASEB JOURNAL			English	Article						metallo-beta-lactamase; antibiotic resistance; pH dependence	METALLO-BETA-LACTAMASE; ANTIBIOTIC-RESISTANCE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MODEL; ZINC; DIFFRACTION; INSIGHTS; REVEALS	The specter of a return to an era in which infectious disease looms as a significant threat to human health is not just hyperbole; there are serious concerns about the widespread overuse and misuse of antibiotics contributing to increased antibiotic resistance in pathogens. The recent discovery of a new enzyme, first identified in Klebsiella pneumoniae from a patient from New Delhi and denoted as NDM-1, represents an example of extreme promiscuity: It hydrolyzes and inactivates nearly all known beta-lactam-based antibiotics with startling efficiency. NDM-1 can utilize different metal cofactors and seems to exploit an alternative mechanism based on the reaction conditions. Here we report the results of a combined experimental and theoretical study that examines the substrate, metal binding, and catalytic mechanism of the enzyme. We utilize structures obtained through X-ray crystallography, biochemical assays, and numerical simulation to construct a model of the enzyme catalytic pathway. The NDM-1 enzyme interacts with the substrate solely through zinc, or other metals, bound in the active site, explaining the observed lack of specificity against a broad range of beta-lactam antibiotic agents. The zinc ions also serve to activate a water molecule that hydrolyzes the beta-lactam ring through a proton shuttle.-Kim, Y., Cunningham, M. A.; Mire, J., Tesar, C., Sacchettini, J., Joachimiak, A. NDM-1, the ultimate promiscuous enzyme: substrate recognition and catalytic mechanism. FASEB J. 27, 1917-1927 (2013). www.fasebj.org	[Kim, Youngchang; Tesar, Christine; Joachimiak, Andrzej] Argonne Natl Lab, Midwest Ctr Struct Genom, Argonne, IL 60439 USA; [Kim, Youngchang; Tesar, Christine; Joachimiak, Andrzej] Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA; [Cunningham, Mark A.] Univ Texas Pan Amer, Dept Phys & Geol, Edinburg, TX 78539 USA; [Mire, Joseph; Sacchettini, James] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Texas System; University of Texas Rio Grande Valley; Texas A&M University System; Texas A&M University College Station	Joachimiak, A (corresponding author), Argonne Natl Lab, Midwest Ctr Struct Genom, 9700 S Cass Ave, Argonne, IL 60439 USA.	cunningham@utpa.edu; andrzejj@anl.gov		Joachimiak, Andrzej/0000-0003-2535-6209; Kim, Youngchang/0000-0002-1610-4889	U.S. National Institutes of Health [GM094585, GM094568]; U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]; National Science Foundation's FaST program [HRD-0703584]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094585, U01GM094568] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Energy, Office of Biological and Environmental Research(United States Department of Energy (DOE)); National Science Foundation's FaST program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank the members of the Midwest Center for Structural Genomics and the Structural Biology Center at Argonne National Laboratory for their support, specifically Robert Jedrzejczak for cloning the truncated NDM-1 gene. This research has been funded in part by a grant from the U.S. National Institutes of Health GM094585 (A.J.), GM094568 (J.S.), and by the U.S. Department of Energy, Office of Biological and Environmental Research, under contract DE-AC02-06CH11357. M.A.C. has also received support through the National Science Foundation's FaST program (HRD-0703584), administered by the Department of Educational Programs at Argonne National Laboratory. The authors acknowledge the Texas Advanced Computing Center (TACC; http://www.tacc.utexas.edu) at the University of Texas at Austin for providing HPC resources that have contributed to the research results reported within this article. Additional computational resources were provided by the HiPAC cluster at the University of Texas-Pan American. The authors thank Gekleng Chhor for proofreading of the manuscript. The atomic coordinates and structure factors have been deposited to the Protein Data Bank (PDB IDs: 4H0D, 4HL2, 4HL1, 4HKY; http://www.pdb.org).	Badarau A, 2006, BIOCHEMISTRY-US, V45, P10654, DOI 10.1021/bi060934l; Bebrone C, 2008, BIOCHEM J, V414, P151, DOI 10.1042/BJ20080375; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Blakeley MP, 2008, P NATL ACAD SCI USA, V105, P1844, DOI 10.1073/pnas.0711659105; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; BRUNGER A, 1984, CHEM PHYS LETT, V105, P495, DOI 10.1016/0009-2614(84)80098-6; Bush K, 2010, ANTIMICROB AGENTS CH, V54, P969, DOI 10.1128/AAC.01009-09; Carbonell P, 2011, J BIOL CHEM, V286, P43994, DOI 10.1074/jbc.M111.274050; D'Costa VM, 2011, NATURE, V477, P457, DOI 10.1038/nature10388; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Green VL, 2011, ACTA CRYSTALLOGR F, V67, P1160, DOI 10.1107/S1744309111029654; HOOVER WG, 1986, PHYS REV A, V34, P2499, DOI 10.1103/PhysRevA.34.2499; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kendall RA, 2000, COMPUT PHYS COMMUN, V128, P260, DOI 10.1016/S0010-4655(00)00065-5; Khersonsky O, 2010, ANNU REV BIOCHEM, V79, P471, DOI 10.1146/annurev-biochem-030409-143718; Kim Youngchang, 2004, Journal of Structural and Functional Genomics, V5, P111, DOI 10.1023/B:JSFG.0000029206.07778.fc; Kim Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024621; King D, 2011, PROTEIN SCI, V20, P1484, DOI 10.1002/pro.697; King DT, 2012, J AM CHEM SOC, V134, P11362, DOI 10.1021/ja303579d; Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livermore DM, 2009, J ANTIMICROB CHEMOTH, V64, P29, DOI 10.1093/jac/dkp255; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Moellering RC, 2010, NEW ENGL J MED, V363, P2377, DOI 10.1056/NEJMp1011715; Nam H, 2012, SCIENCE, V337, P1101, DOI 10.1126/science.1216861; Page MI, 2008, BIOINORG CHEM APPL, V2008, DOI 10.1155/2008/576297; Park H, 2005, J AM CHEM SOC, V127, P4232, DOI 10.1021/ja042607b; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Riondet C, 1997, BIOTECHNOL TECH, V11, P735, DOI 10.1023/A:1018492217623; Simona F, 2009, J BIOL CHEM, V284, P28164, DOI 10.1074/jbc.M109.049502; Tamilselvi A, 2008, J BIOL INORG CHEM, V13, P1039, DOI 10.1007/s00775-008-0407-2; Thomas PA, 2011, CURR CLIN PATHOL, P1, DOI 10.1007/978-1-60327-154-7_1; Valiev M, 2007, J PHYS CHEM B, V111, P13455, DOI 10.1021/jp074853q; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Walsh TR, 2011, LANCET INFECT DIS, V11, P355, DOI 10.1016/S1473-3099(11)70059-7; Wilks JC, 2007, J BACTERIOL, V189, P5601, DOI 10.1128/JB.00615-07; Xu D, 2007, J AM CHEM SOC, V129, P10814, DOI 10.1021/ja072532m; Yang H, 2012, BIOCHEMISTRY-US, V51, P3839, DOI 10.1021/bi300056y; Zhang HM, 2011, FASEB J, V25, P2574, DOI 10.1096/fj.11-184036	44	88	93	1	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1917	1927		10.1096/fj.12-224014	http://dx.doi.org/10.1096/fj.12-224014			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23363572	Green Published			2022-12-28	WOS:000318226100012
J	Kipari, T; Hadoke, PWF; Iqbal, J; Man, TY; Miller, E; Coutinho, AE; Zhang, ZG; Sullivan, KM; Mitic, T; Livingstone, DEW; Schrecker, C; Samuel, K; White, CI; Bouhlel, MA; Chinetti-Gbaguidi, G; Staels, B; Andrew, R; Walker, BR; Savill, JS; Chapman, KE; Seckl, JR				Kipari, Tiina; Hadoke, Patrick W. F.; Iqbal, Javaid; Man, Tak-Yung; Miller, Eileen; Coutinho, Agnes E.; Zhang, Zhenguang; Sullivan, Katie M.; Mitic, Tijana; Livingstone, Dawn E. W.; Schrecker, Christopher; Samuel, Kay; White, Christopher I.; Bouhlel, M. Amine; Chinetti-Gbaguidi, Giulia; Staels, Bart; Andrew, Ruth; Walker, Brian R.; Savill, John S.; Chapman, Karen E.; Seckl, Jonathan R.			11 beta-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis	FASEB JOURNAL			English	Article						atherogenesis; glucocorticoids; inflammation	INDUCED VISCERAL OBESITY; 11-BETA-HSD1 INHIBITION; APOPTOTIC LEUKOCYTES; COLLAGEN-SYNTHESIS; METABOLIC SYNDROME; CUSHINGS-DISEASE; KNOCKOUT MICE; GLUCOCORTICOIDS; MACROPHAGES; EXPRESSION	11 beta-Hydroxysteroid dehydrogenase type-1 (11 beta-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11 beta-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11 beta-HSD1 deficiency on atherosclerosis and its inflammation, atherosclerosisprone apolipoprotein E-knockout (ApoE-KO) mice were treated with a selective 11 beta-HSD1 inhibitor or crossed with 11 beta-HSD1-KO mice to generate double knockouts (DKOs) and challenged with an atherogenic Western diet. 11 beta-HSD1 inhibition or deficiency attenuated atherosclerosis (74-76%) without deleterious effects on plaque structure. This occurred without affecting plasma lipids or glucose, suggesting independence from classical metabolic risk factors. KO plaques were not more inflamed and indeed had 36% less T-cell infiltration, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower lesional vascular cell adhesion molecule-1 (VCAM-1). Bone marrow (BM) cells are key to the atheroprotection, since transplantation of DKO BM to irradiated ApoE-KO mice reduced atherosclerosis by 51%. 11 beta-HSD1- null macrophages show 76% enhanced cholesterol ester export. Thus, 11 beta-HSD1 deficiency reduces atherosclerosis without exaggerated lesional inflammation independent of metabolic risk factors. Selective 11 beta-HSD1 inhibitors promise novel antiatherosclerosis effects over and above their benefits for metabolic risk factors via effects on BM cells, plausibly macrophages.-Kipari, T., Hadoke, P. W. F., Iqbal, J., Man, T. Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C., Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R., Savill, J. S., Chapman, K. E., Seckl, J. R. 11 beta-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J. 27, 1519-1531 (2013). www.fasebj.org	[Kipari, Tiina; Hadoke, Patrick W. F.; Iqbal, Javaid; Man, Tak-Yung; Miller, Eileen; Coutinho, Agnes E.; Zhang, Zhenguang; Sullivan, Katie M.; Mitic, Tijana; Livingstone, Dawn E. W.; Schrecker, Christopher; White, Christopher I.; Andrew, Ruth; Walker, Brian R.; Chapman, Karen E.; Seckl, Jonathan R.] Univ Edinburgh, British Heart Fdn, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland; [Savill, John S.] Univ Edinburgh, MRC, Ctr Inflammat Res, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland; [Samuel, Kay] Univ Edinburgh, MRC, Ctr Regenerat Med, Edinburgh EH16 4TJ, Midlothian, Scotland; [Bouhlel, M. Amine; Chinetti-Gbaguidi, Giulia; Staels, Bart] Univ Lille 2, Univ Lille Nord France, INSERM, UMR 1011,Inst Pasteur Lille, Lille, France	University of Edinburgh; University of Edinburgh; University of Edinburgh; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Kipari, T (corresponding author), Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, BHF Ctr Cardiovasc Sci, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	tkipari@ed.ac.uk	chinetti, giulia/Q-6901-2016; Staels, Bart/N-9497-2016; Andrew, Ruth/C-2727-2008	chinetti, giulia/0000-0001-8048-8138; Staels, Bart/0000-0002-3784-1503; Andrew, Ruth/0000-0002-6916-2994; Miller, Eileen/0000-0003-1566-8217; Chapman, Karen/0000-0001-7777-6817; Iqbal, Javaid/0000-0002-9729-7503	Wellcome Trust [083184/Z/07/Z]; Medical Research Council [86642]; Society for Endocrinology; British Heart Foundation (BHF), Agence Nationale de la Recherche (AlMHA project); Carnegie Trust; MRC [G9900991, G0800235, G0802069] Funding Source: UKRI; British Heart Foundation [RG/11/4/28734] Funding Source: researchfish; Medical Research Council [G9900991, G0802069, G0800235, MR/K026992/1, G0700704B] Funding Source: researchfish; National Institute for Health Research [CL-2009-04-001] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Society for Endocrinology; British Heart Foundation (BHF), Agence Nationale de la Recherche (AlMHA project)(French National Research Agency (ANR)); Carnegie Trust(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The authors thank Dr. Valerie S. Densmore for generating the original 11 beta-HSD1, ApoE double-knockout line, and Dr. Nicholas Kirkby for help with optical projection tomography. This work was supported by grants from the Wellcome Trust (program grant 083184/Z/07/Z), the Medical Research Council (project grant 86642), the Society for Endocrinology, the British Heart Foundation (BHF), Agence Nationale de la Recherche (AlMHA project), and the Carnegie Trust. The authors acknowledge the support of the BHF Centre of Excellence. Conflict of interest: B. R. W. and J.R.S. hold intellectual property on the concept of 11 beta-HSD1 inhibitors in metabolic and cardiovascular disease.	Alevizaki M, 2007, METABOLISM, V56, P222, DOI 10.1016/j.metabol.2006.09.017; Ayaori M, 2006, ARTERIOSCL THROM VAS, V26, P163, DOI 10.1161/01.ATV.0000193513.29074.52; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo-112-3-931; Cavalcanti DMH, 2007, BRIT J PHARMACOL, V152, P1291, DOI 10.1038/sj.bjp.0707512; Chapman KE, 2009, MOL CELL ENDOCRINOL, V301, P123, DOI 10.1016/j.mce.2008.09.031; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091; Coutinho AE, 2012, ENDOCRINOLOGY, V153, P234, DOI 10.1210/en.2011-1398; Curtiss LK, 2000, ARTERIOSCL THROM VAS, V20, P1852, DOI 10.1161/01.ATV.20.8.1852; CUTRONEO KR, 1975, MOL PHARMACOL, V11, P632; Deuchar G. A., ENDOCRINOLOGY, V152, P236; ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x; Faggiano A, 2003, J CLIN ENDOCR METAB, V88, P2527, DOI 10.1210/jc.2002-021558; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Gilmour JS, 2006, J IMMUNOL, V176, P7605, DOI 10.4049/jimmunol.176.12.7605; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; HADOKE P, 1995, CORONARY ARTERY DIS, V6, P403, DOI 10.1097/00019501-199505000-00008; Hadoke PWF, 2001, CIRCULATION, V104, P2832, DOI 10.1161/hc4801.100077; Hansson G. K., NAT IMMUNOL, V12, P204; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Harris HJ, 2001, ENDOCRINOLOGY, V142, P114, DOI 10.1210/en.142.1.114; Hermanowski-Vosatka A, 2005, J EXP MED, V202, P517, DOI 10.1084/jem.20050119; HOLMAN RL, 1958, LAB INVEST, V7, P42; Kirkby N. S., PLOS ONE, V6; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Liu YQ, 1999, J IMMUNOL, V162, P3639; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; Lloyd DJ, 2009, DIABETES OBES METAB, V11, P688, DOI 10.1111/j.1463-1326.2009.01034.x; LONGENECKER JP, 1984, J CELL BIOL, V98, P534, DOI 10.1083/jcb.98.2.534; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; MEISLER N, 1995, J CELL BIOCHEM, V59, P376, DOI 10.1002/jcb.240590309; Morton NM, 2004, DIABETES, V53, P931, DOI 10.2337/diabetes.53.4.931; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8; Peixoto RADS, 2008, ENDOCRINOLOGY, V149, P1861, DOI 10.1210/en.2007-1028; Poon M, 2001, ATHEROSCLEROSIS, V155, P371, DOI 10.1016/S0021-9150(00)00605-5; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Rigamonti E, 2005, CIRC RES, V97, P682, DOI 10.1161/01.RES.0000184678.43488.9f; Rosenstock J., DIABETES CARE, V33, P1516; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Small GR, 2005, P NATL ACAD SCI USA, V102, P12165, DOI 10.1073/pnas.0500641102; Souverein PC, 2004, HEART, V90, P859, DOI 10.1136/hrt.2003.020180; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Taleb S., CURR OPIN PHARM, V10, P197; Thieringer R, 2001, J IMMUNOL, V167, P30, DOI 10.4049/jimmunol.167.1.30; Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415; Williams H, 2002, ARTERIOSCL THROM VAS, V22, P788, DOI 10.1161/01.ATV.0000014587.66321.B4; Zhang TY, 2005, J IMMUNOL, V174, P879, DOI 10.4049/jimmunol.174.2.879; Zhu Y., BIOCH J, V428, P47	53	37	37	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1519	1531		10.1096/fj.12-219105	http://dx.doi.org/10.1096/fj.12-219105			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303209	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000316940800024
J	Bhutani, N; Decker, MN; Brady, JJ; Bussat, RT; Burns, DM; Corbel, SY; Blau, HM				Bhutani, Nidhi; Decker, Matthew N.; Brady, Jennifer J.; Bussat, Rose T.; Burns, David M.; Corbel, Stephane Y.; Blau, Helen M.			A critical role for AID in the initiation of reprogramming to induced pluripotent stem cells	FASEB JOURNAL			English	Article						activation-induced deaminase; DNA demethylation; early events in iPSC generation	ACTIVE DNA DEMETHYLATION; TET PROTEINS; 5-METHYLCYTOSINE; STATE; 5-HYDROXYMETHYLCYTOSINE; FIBROBLASTS; EXPRESSION; GENERATION; CONVERSION	Mechanistic insights into the reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs) are limited, particularly for early acting molecular regulators. Here we use an acute loss of function approach to demonstrate that activation-induced deaminase (AID) activity is necessary for the initiation of reprogramming to iPSCs. While AID is well known for antibody diversification, it has also recently been shown to have a role in active DNA demethylation in reprogramming toward pluripotency and development. These findings suggested a potential role for AID in iPSC generation, yet, iPSC yield from AID-knockout mouse fibroblasts was similar to that of wild-type (WT) fibroblasts. We reasoned that an acute loss of AID function might reveal effects masked by compensatory mechanisms during development, as reported for other proteins. Accordingly, we induced an acute reduction (> 50%) in AID levels using 4 different shRNAs and determined that reprogramming to iPSCs was significantly impaired by 79 +/- 7%. The deaminase activity of AID was critical, as coexpression of WT but not a catalytic mutant AID rescued reprogramming. Notably, AID was required only during a 72-h time window at the onset of iPSC reprogramming. Our findings show a critical role for AID activity in the initiation of reprogramming to iPSCs.-Bhutani, N., Decker, M. N., Brady, J. J., Bussat, R. T., Burns, D. M., Corbel, S. Y., Blau, H. M. A critical role for AID in the initiation of reprogramming to induced pluripotent stem cells. FASEB J. 27, 1107-1113 (2013). www.fasebj.org	[Bhutani, Nidhi; Decker, Matthew N.; Brady, Jennifer J.; Bussat, Rose T.; Burns, David M.; Corbel, Stephane Y.; Blau, Helen M.] Stanford Univ, Baxter Lab Stem Cell Biol, Inst Stem Cell Biol & Regenerat Med, Dept Microbiol & Immunol,Sch Med, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, 269 Campus Dr, Stanford, CA 94305 USA.	hblau2@stanford.edu			Stanford Bio-X Fellowship; U.S. National Science Foundation; Tumor Biology Training [U.S. NIH T32CA09151]; Baxter Foundation; U.S. National Institutes of Health [HL096113, AG020961, AG09521, HL100397]; California Institute for Regenerative Medicine [RB1-01292]; Stanford Bio-X IIP Award; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096113, U01HL100397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR063963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020961, R01AG009521, R37AG009521] Funding Source: NIH RePORTER	Stanford Bio-X Fellowship; U.S. National Science Foundation(National Science Foundation (NSF)); Tumor Biology Training; Baxter Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Stanford Bio-X IIP Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are very grateful to M. Wernig and S. Marro (Stanford University, Stanford, CA, USA) for iPSC reagents, protocols, guidance, and technical advice throughout this work. The authors thank M. Nussenzweig and D. F. Robbiani (Rockefeller University, New York, NY, USA) for the generous gift of mAIDwt and mAID(E58Q), and T. Honjo (Kyoto University, Kyoto, Japan) for the AID-KO mice. The authors also thank D. Schatz and S. Unniraman (Yale University, New Haven, CT, USA) for the hAID Thy1 construct. The authors are grateful for a Stanford Bio-X Fellowship and U.S. National Science Foundation Graduate Research Fellowship to J.J.B.; the Tumor Biology Training Grant (U.S. NIH T32CA09151) to D. M. B.; support from a Baxter Foundation Award, support from U.S. National Institutes of Health grants HL096113, AG020961, AG09521, and HL100397, California Institute for Regenerative Medicine grant RB1-01292, a Stanford Bio-X IIP Award, and the Baxter Foundation to H. M. B.	Bashir T, 2005, NAT CELL BIOL, V7, P779, DOI 10.1038/ncb0805-779; Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Buganim Y, 2012, CELL, V150, P1209, DOI 10.1016/j.cell.2012.08.023; Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Maekawa M, 2011, NATURE, V474, P225, DOI 10.1038/nature10106; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nabel CS, 2012, NAT CHEM BIOL, V8, P751, DOI [10.1038/NCHEMBIO.1042, 10.1038/nchembio.1042]; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Wernig M, 2008, NAT BIOTECHNOL, V26, P916, DOI 10.1038/nbt1483; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229	33	27	27	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1107	1113		10.1096/fj.12-222125	http://dx.doi.org/10.1096/fj.12-222125			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23212122	Green Published			2022-12-28	WOS:000315585200024
J	Chong, HH; Yao, X; Qiu, ZL; Sun, JP; Zhang, M; Waltersperger, S; Wang, MT; Liu, SL; Cui, S; He, YX				Chong, Huihui; Yao, Xue; Qiu, Zonglin; Sun, Jianping; Zhang, Meng; Waltersperger, Sandro; Wang, Meitian; Liu, Shan-Lu; Cui, Sheng; He, Yuxian			Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1	FASEB JOURNAL			English	Article						M-T hook; crystal structure	IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; CELL-CELL FUSION; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE; CORE STRUCTURE; GP41; ENTRY; DESIGN	Peptides derived from the C-terminal heptad repeat (C peptides) of HIV-1 gp41 are potent inhibitors against virus entry. However, development of a short C peptide possessing high anti-HIV potency is considered a daunting challenge. We recently discovered that the residues Met626 and Thr627 preceding the pocket-binding domain of the C peptide adopt a unique M-T hook structure that is crucial for the design of HIV-1 fusion inhibitors. In this study, we first presented a proof-of-concept prototype that the M-T hook residues can dramatically improve the antiviral activity and thermostability of a short C peptide. We then generated a 24-mer peptide termed MT-SC22EK by incorporating the M-T hook structure to the N terminus of the poorly active short C peptide SC22EK. Amazingly, MT-SC22EK inhibited HIV-1-mediated cell fusion and infection at a level comparable to C34, T1249, SC29EK, and sifuvirtide, and it was highly active against diverse HIV-1 subtypes and variants, including those T20 (enfuvirtide) and SC29EK-resistant viruses. The high-resolution crystal structure of MT-SC22EK reveals the N-terminal M-T hook conformation folded by incorporated Met626 and Thr627 and identifies the C-terminal boundary critical for the anti-HIV activity. Collectively, our studies provide new insights into the mechanisms of HIV-1 fusion and its inhibition.-Chong, H., Yao, X., Qiu, Z., Sun, J., Zhang, M., Waltersperger, S., Wang, M., Liu, S.-L., Cui, S., and He, Y. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 27, 1203-1213 (2013). www.fasebj.org	[Chong, Huihui; Yao, Xue; Qiu, Zonglin; Sun, Jianping; Zhang, Meng; Cui, Sheng; He, Yuxian] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China; [Chong, Huihui; Yao, Xue; Qiu, Zonglin; Sun, Jianping; Zhang, Meng; Cui, Sheng; He, Yuxian] Chinese Acad Med Sci, Inst Pathogen Biol, AIDS Res Ctr, Beijing 100730, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; [Waltersperger, Sandro; Wang, Meitian] Paul Scherrer Inst, Swiss Light Source, Villigen, Switzerland; [Liu, Shan-Lu] Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Pathogen Biology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Pathogen Biology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Missouri System; University of Missouri Columbia	Cui, S (corresponding author), Chinese Acad Med Sci, 9 Dong Dan San Tiao, Beijing 100730, Peoples R China.	cui.sheng@ipb.pumc.edu.cn; yhe@ipb.pumc.edu.cn	Cui, Sheng/AAQ-1721-2020; Liu, Shan-Lu/L-5923-2016; Wang, Meitian/D-3208-2013; Sheng, CUI/M-6405-2013	Liu, Shan-Lu/0000-0003-1620-3817; Sheng, CUI/0000-0001-6329-3582; Wang, Meitian/0000-0002-5340-3036	National Outstanding Youth Award of National Science Foundation of China (NSFC) [81025009]; National 973 Program of China [2010CB530100]; Natural Science Foundation of China [81271830]; Beijing Natural Science Foundation [7122116]	National Outstanding Youth Award of National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National 973 Program of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported by grants from the National Outstanding Youth Award of National Science Foundation of China (NSFC; 81025009), National 973 Program of China (2010CB530100), Natural Science Foundation of China (81271830), and Beijing Natural Science Foundation (7122116). The coordinates and structure factors for SC22EK/T21 and MT-SC22EK/T21 complexes were deposited to the Protein Data Bank (PDB ID: 3VU5, 3VU6; http://www.pdb.org). Author contributions: Y. H. and S. C. conceived and designed the experiments; H. C., X. Y., Z. Q., M. Z., S. W., and M. W. performed the experiments; H. C., S. L., Y. H., and S. C. analyzed the data; Y. H. and S. C. wrote the paper. The authors declare no conflicts of interest.	Ashkenazi A, 2011, BBA-BIOMEMBRANES, V1808, P2352, DOI 10.1016/j.bbamem.2011.06.020; Berkhout B, 2012, CURR OPIN VIROL, V2, P50, DOI 10.1016/j.coviro.2012.01.002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chong HH, 2012, J BIOL CHEM, V287, P34558, DOI 10.1074/jbc.M112.390393; Chong HH, 2012, J BIOL CHEM, V287, P20281, DOI 10.1074/jbc.M112.354126; Chong HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032599; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eggink D, 2008, J VIROL, V82, P6678, DOI 10.1128/JVI.00352-08; Eggink D, 2011, J VIROL, V85, P10785, DOI 10.1128/JVI.05331-11; Eggink D, 2010, CURR PHARM DESIGN, V16, P3716, DOI 10.2174/138161210794079218; Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330; He YX, 2008, P NATL ACAD SCI USA, V105, P16332, DOI 10.1073/pnas.0807335105; He YX, 2008, J VIROL, V82, P6349, DOI 10.1128/JVI.00319-08; He YX, 2008, J BIOL CHEM, V283, P11126, DOI 10.1074/jbc.M800200200; Ingallinella P, 2009, P NATL ACAD SCI USA, V106, P5801, DOI 10.1073/pnas.0901007106; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jin BS, 2000, AIDS RES HUM RETROV, V16, P1797, DOI 10.1089/08892220050195757; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Lalezari JP, 2005, J INFECT DIS, V191, P1155, DOI 10.1086/427993; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Liu ZH, 2011, J BIOL CHEM, V286, P3277, DOI 10.1074/jbc.M110.199323; Naider F, 2009, CURR OPIN STRUC BIOL, V19, P473, DOI 10.1016/j.sbi.2009.07.003; Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08; Nishikawa H, 2008, BIOORGAN MED CHEM, V16, P9184, DOI 10.1016/j.bmc.2008.09.018; Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J; Reeves JD, 2005, J VIROL, V79, P4991, DOI 10.1128/JVI.79.8.4991-4999.2005; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Shimura K, 2010, J BIOL CHEM, V285, P39471, DOI 10.1074/jbc.M110.145789; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Steffen I, 2010, CURR PHARM DESIGN, V16, P1143, DOI 10.2174/138161210790963751; Stoddart CA, 2008, J BIOL CHEM, V283, P34045, DOI 10.1074/jbc.M805536200; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2010, FASEB J, V24, P4196, DOI 10.1096/fj.09-151704; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Xie D, 2010, ANTIMICROB AGENTS CH, V54, P191, DOI 10.1128/AAC.00976-09; Yao X, 2012, J BIOL CHEM, V287, P6788, DOI 10.1074/jbc.M111.317883	44	50	53	1	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1203	1213		10.1096/fj.12-222547	http://dx.doi.org/10.1096/fj.12-222547			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23233535				2022-12-28	WOS:000315585200032
J	Lucas, CD; Allen, KC; Dorward, DA; Hoodless, LJ; Melrose, LA; Marwick, JA; Tucker, CS; Haslett, C; Duffin, R; Rossi, AG				Lucas, Christopher D.; Allen, Keith C.; Dorward, David A.; Hoodless, Laura J.; Melrose, Lauren A.; Marwick, John A.; Tucker, Carl S.; Haslett, Christopher; Duffin, Rodger; Rossi, Adriano G.			Flavones induce neutrophil apoptosis by down-regulation of Mcl-1 via a proteasomal-dependent pathway	FASEB JOURNAL			English	Article						inflammation; resolution; polyphenols	ACUTE LUNG INJURY; PROGRAMMED CELL-DEATH; KAPPA-B PATHWAYS; MACROPHAGE PHAGOCYTOSIS; INFLAMMATION-RESOLUTION; ANTIINFLAMMATORY AGENTS; ENHANCES RESOLUTION; IN-VITRO; INHIBITION; LUTEOLIN	Neutrophil apoptosis and subsequent nonphlogistic clearance by surrounding phagocytes are key to the successful resolution of neutrophilic inflammation, with dysregulated apoptosis reported in multiple human inflammatory diseases. Enhancing neutrophil apoptosis has proresolution and anti-inflammatory effects in preclinical models of inflammation. Here we investigate the ability of the flavones apigenin, luteolin, and wogonin to induce neutrophil apoptosis in vitro and resolve neutrophilic inflammation in vivo. Human neutrophil apoptosis was assessed morphologically and by flow cytometry following incubation with apigenin, luteolin, and wogonin. All three flavones induced timeand concentration-dependent neutrophil apoptosis (apigenin, EC50 = 12.2 mu M; luteolin, EC50 = 14.6 mu M; and wogonin, EC50 = 28.9 mu M). Induction of apoptosis was caspase dependent, as it was blocked by the broad-spectrum caspase inhibitor Q-VD-OPh and was associated with both caspase-3 and caspase-9 activation. Flavone-induced apoptosis was preceded by down-regulation of the prosurvival protein Mcl-1, with proteasomal inhibition preventing flavone-induced Mcl-1 down-regulation and apoptosis. The flavones abrogated the survival effects of mediators that prolong neutrophil life span, including lipoteichoic acid, peptidoglycan, dexamethasone, and granulocyte-macrophage colony stimulating factor, by driving apoptosis. Furthermore, wogonin enhanced resolution of established neutrophilic inflammation in a zebrafish model of sterile tissue injury. Wogonin-induced resolution was dependent on apoptosis in vivo as it was blocked by caspase inhibition. Our data show that the flavones induce neutrophil apoptosis and have potential as neutrophil apoptosis-inducing anti-inflammatory, proresolution agents.-Lucas, C. D., Allen, K. C., Dorward, D. A., Hoodless, L. J., Melrose, L. A., Marwick, J. A., Tucker, C. S., Haslett, C., Duffin, R., Rossi, A. G. Flavones induce neutrophil apoptosis by down-regulation of Mcl-1 via a proteasomal-dependent pathway. FASEB J. 27, 1084-1094 (2013). www.fasebj.org	[Lucas, Christopher D.; Allen, Keith C.; Dorward, David A.; Hoodless, Laura J.; Melrose, Lauren A.; Marwick, John A.; Haslett, Christopher; Duffin, Rodger; Rossi, Adriano G.] Univ Edinburgh, Sch Med, Queens Med Res Inst, MRC,Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Tucker, Carl S.] Univ Edinburgh, Sch Med, Queens Med Res Inst, British Heart Fdn,Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Duffin, Rodger] CXR Biosci Ltd, Dundee, Scotland	University of Edinburgh; University of Edinburgh	Lucas, CD (corresponding author), Univ Edinburgh, Sch Med, Queens Med Res Inst, MRC,Ctr Inflammat Res, 47 Little France Crescent, Edinburgh, Midlothian, Scotland.	clucas@staffmail.ed.ac.uk		Lucas, Christopher/0000-0002-7523-0295; Duffin, Rodger/0000-0002-3425-9745; Hoodless, Laura/0000-0002-9679-0611	Wellcome Trust [WT094415]; UK Medical Research Council [G0601481]; MRC [G0601481, G0901697] Funding Source: UKRI; Medical Research Council [G0901697, G0601481, 1586600] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Dr. Steve Renshaw (University of Sheffield, Sheffield, UK) for use of the transgenic zebrafish used in our in vivo experiments and Fiona Rossi and Shonna Johnston for assistance with flow cytometry. This work was funded by the Wellcome Trust (WT094415) and the UK Medical Research Council (G0601481).	Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Birrell MA, 2005, FASEB J, V19, P840, DOI 10.1096/fj.04-2691fje; Brizuela L, 2010, FASEB J, V24, P3882, DOI 10.1096/fj.10-160838; Chen CY, 2010, J AGR FOOD CHEM, V58, P11653, DOI 10.1021/jf1031668; Chen SR, 2010, BIOL PHARM BULL, V33, P1307, DOI 10.1248/bpb.33.1307; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Derouet M, 2006, J IMMUNOL, V176, P957, DOI 10.4049/jimmunol.176.2.957; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Dorward DA, 2012, PHARMACOL THERAPEUT, V135, P182, DOI 10.1016/j.pharmthera.2012.05.006; Duffin R, 2010, IMMUNOL REV, V236, P28, DOI 10.1111/j.1600-065X.2010.00922.x; Dzhagalov I, 2007, BLOOD, V109, P1620, DOI 10.1182/blood-2006-03-013771; El Kebir D, 2009, AM J RESP CRIT CARE, V180, P311, DOI 10.1164/rccm.200810-1601OC; Fialkow L, 2006, CRIT CARE, V10, DOI 10.1186/cc5090; Fischer CD, 2011, ANTIMICROB AGENTS CH, V55, P338, DOI 10.1128/AAC.01052-10; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Fox S, 2010, J INNATE IMMUN, V2, P216, DOI 10.1159/000284367; Garrison SP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001240; HASLETT C, 1985, AM J PATHOL, V119, P101; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Hideshima T, 2001, CANCER RES, V61, P3071; Huang CH, 2010, J FOOD SCI, V75, pH254, DOI 10.1111/j.1750-3841.2010.01812.x; Jacquemin G, 2010, CELL MOL LIFE SCI, V67, P3115, DOI 10.1007/s00018-010-0407-6; Kato T, 2006, FEBS LETT, V580, P4582, DOI 10.1016/j.febslet.2006.07.034; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Kuo MY, 2011, FOOD CHEM TOXICOL, V49, P2660, DOI 10.1016/j.fct.2011.07.012; Lau GTY, 2010, FOOD CHEM TOXICOL, V48, P3022, DOI 10.1016/j.fct.2010.07.046; Lee JP, 2010, ACTA PHARMACOL SIN, V31, P831, DOI 10.1038/aps.2010.62; Leitch A. E., 2012, CELL DEATH DIFFER, V29, P80; Leitch AE, 2011, J LEUKOCYTE BIOL, V90, P841, DOI 10.1189/jlb.0511222; Leitch AE, 2010, EUR J IMMUNOL, V40, P1127, DOI 10.1002/eji.200939664; Leuenroth SJ, 2000, SURGERY, V128, P171, DOI 10.1067/msy.2000.107609; Lin CL, 2011, CELL DEATH DIFFER, V18, P1651, DOI 10.1038/cdd.2011.80; Loynes CA, 2010, J LEUKOCYTE BIOL, V87, P203, DOI 10.1189/jlb.0409255; Mann GE, 2007, CARDIOVASC RES, V75, P261, DOI 10.1016/j.cardiores.2007.04.004; McCullough ML, 2012, AM J CLIN NUTR, V95, P454, DOI 10.3945/ajcn.111.016634; McGrath EE, 2011, J LEUKOCYTE BIOL, V90, P855, DOI 10.1189/jlb.0211062; Meagher LC, 1996, J IMMUNOL, V156, P4422; Michlewska S, 2009, FASEB J, V23, P844, DOI 10.1096/fj.08-121228; Milan DJ, 2003, CIRCULATION, V107, P1355, DOI 10.1161/01.CIR.0000061912.88753.87; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Munoz LE, 2010, NAT REV RHEUMATOL, V6, P280, DOI 10.1038/nrrheum.2010.46; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; OFLAHERTY JT, 1993, J BIOL CHEM, V268, P14708; Oishi K, 1997, SCAND J IMMUNOL, V45, P21, DOI 10.1046/j.1365-3083.1997.d01-365.x; Qi LL, 2011, EUR J PHARMACOL, V668, P201, DOI 10.1016/j.ejphar.2011.06.020; Raza K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2009; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; Rithidech K. N., 2012, MUTAT RES, V15, P00268; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Rossi L, 2008, NEUROCHEM RES, V33, P2390, DOI 10.1007/s11064-008-9696-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Seki H, 2010, J IMMUNOL, V184, P836, DOI 10.4049/jimmunol.0901809; Serafini M, 2010, P NUTR SOC, V69, P273, DOI 10.1017/S002966511000162X; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Tang YJ, 2010, INFLAMMATION, V33, P180, DOI 10.1007/s10753-009-9172-9; Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023; Walter A, 2010, FASEB J, V24, P3360, DOI 10.1096/fj.09-149419; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Wardle DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015768; Watson RWG, 1996, J IMMUNOL, V156, P3986; Westerfield M., 2007, ZEBRAFISH BOOK GUIDE; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Yamamoto Y, 2009, BRAIN RES, V1295, P218, DOI 10.1016/j.brainres.2009.07.081; Zhu JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035523	70	54	56	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1084	1094		10.1096/fj.12-218990	http://dx.doi.org/10.1096/fj.12-218990			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195034	Green Published, hybrid			2022-12-28	WOS:000315585200022
J	Clark, AA; Liggett, SB; Munger, SD				Clark, Adam A.; Liggett, Stephen B.; Munger, Steven D.			Extraoral bitter taste receptors as mediators of off-target drug effects	FASEB JOURNAL			English	Article						T2R; gastrointestinal system; respiratory system; gustatory system; side effects	CHEMOSENSORY CELLS; FAMILY; SENSITIVITY; GENES; PHENYLTHIOCARBAMIDE; PERCEPTION; EXPRESSION; SECRETION; SACCHARIN; MOUSE	We present a novel hypothesis that could explain many off-target effects of diverse pharmaceuticals. Specifically, we propose that any drug with a bitter taste could have unintended actions in the body through stimulation of extraoral type 2 taste receptors (T2Rs). T2Rs were first identified in the oral cavity, where they function as bitter taste receptors. However, recent findings indicate that they are also expressed outside the gustatory system, including in the gastrointestinal and respiratory systems. T2R ligands include a diverse array of natural and synthetic compounds, many of which are toxins. Notably, many pharmaceuticals taste bitter, with compounds such as chloroquine, haloperidol, erythromycin, procainamide, and ofloxacin known to activate T2Rs. Bitter-tasting compounds can have specific physiological effects in T2R-expressing cells. For example, T2Rs are found in some gastrointestinal endocrine cells, including those that secrete the peptide hormones (e. g., ghrelin and glucagon-like peptide-1) in response to stimulation by bitter-tasting compounds. In the respiratory system, stimulation of T2Rs expressed in respiratory epithelia and smooth muscle has been implicated in protective airway reflexes, ciliary beating, and bronchodilation. If our hypothesis is confirmed, it would offer a new paradigm for understanding the off-target actions of diverse drugs and could reveal potential new therapeutic targets.-Clark, A. A., Liggett, S. B., Munger, S. D. Extraoral bitter taste receptors as mediators of off-target drug effects. FASEB J. 26, 4827-4831 (2012). www.fasebj.org	[Clark, Adam A.; Munger, Steven D.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Clark, Adam A.; Munger, Steven D.] Univ Maryland, Sch Med, Toxicol Program, Baltimore, MD 21201 USA; [Munger, Steven D.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Dept Med, Baltimore, MD 21201 USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Dept Med, Tampa, FL USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Ctr Personalized Med & Genom, Tampa, FL USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Munger, SD (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 20 Penn St,S251, Baltimore, MD 21201 USA.	smung001@umaryland.edu		Liggett, Stephen B./0000-0002-0128-3669	U.S. National Institute on Deafness and Other Communication Disorders [DC-010110]; U.S. National Heart, Lung, and Blood Institute [HL-071609]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010110] Funding Source: NIH RePORTER	U.S. National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Support for this work was provided by the U.S. National Institute on Deafness and Other Communication Disorders, grant DC-010110 (to S. D. M.) and the U.S. National Heart, Lung, and Blood Institute, grant HL-071609 (to S. B. L.). The authors declare no conflicts of interest.	Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; An SS, 2012, AM J PHYSIOL-LUNG C, V303, pL304, DOI 10.1152/ajplung.00126.2012; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Behrens M, 2007, J NEUROSCI, V27, P12630, DOI 10.1523/JNEUROSCI.1168-07.2007; Behrens M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040304; Behrens M, 2011, PHYSIOL BEHAV, V105, P4, DOI 10.1016/j.physbeh.2011.02.010; Behrens M, 2009, J AGR FOOD CHEM, V57, P9860, DOI 10.1021/jf9014334; Brockhoff A, 2007, J AGR FOOD CHEM, V55, P6236, DOI 10.1021/jf070503p; Brockhoff A, 2011, J NEUROSCI, V31, P14775, DOI 10.1523/JNEUROSCI.2923-11.2011; Bufe B, 2005, CURR BIOL, V15, P322, DOI 10.1016/j.cub.2005.01.047; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Conte C, 2003, PHYSIOL GENOMICS, V14, P73, DOI 10.1152/physiolgenomics.00060.2003; Conte C, 2002, CYTOGENET GENOME RES, V98, P45, DOI 10.1159/000068546; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Dotson CD, 2010, CURR OPIN INVEST DR, V11, P447; Dotson CD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003974; Drewnowski A, 2000, AM J CLIN NUTR, V72, P1424; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; Janssen S, 2011, P NATL ACAD SCI USA, V108, P2094, DOI 10.1073/pnas.1011508108; Jeon TI, 2008, J CLIN INVEST, V118, P3693, DOI 10.1172/JCI36461; Kim U, 2005, HUM MUTAT, V26, P199, DOI 10.1002/humu.20203; Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190; Krasteva G, 2011, P NATL ACAD SCI USA, V108, P9478, DOI 10.1073/pnas.1019418108; Kuhn C, 2004, J NEUROSCI, V24, P10260, DOI 10.1523/JNEUROSCI.1225-04.2004; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; Pronin AN, 2007, CURR BIOL, V17, P1403, DOI 10.1016/j.cub.2007.07.046; Sainz E, 2007, BIOCHEM J, V403, P537, DOI 10.1042/BJ20061744; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Shi P, 2003, MOL BIOL EVOL, V20, P805, DOI 10.1093/molbev/msg083; Shi P, 2007, GENOME RES, V17, P166, DOI 10.1101/gr.6040007; Slack JP, 2010, CURR BIOL, V20, P1104, DOI 10.1016/j.cub.2010.04.043; Soranzo N, 2005, CURR BIOL, V15, P1257, DOI 10.1016/j.cub.2005.06.042; Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3; Tizzano M, 2010, P NATL ACAD SCI USA, V107, P3210, DOI 10.1073/pnas.0911934107; Wooding S, 2010, CHEM SENSES, V35, P685, DOI 10.1093/chemse/bjq061; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Yasuoka A, 2009, RESULTS PROBL CELL D, V47, P239, DOI 10.1007/400_2008_6	40	84	88	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4827	4831		10.1096/fj.12-215087	http://dx.doi.org/10.1096/fj.12-215087			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964302	Green Published			2022-12-28	WOS:000311838300006
J	Grosse, J; Wehland, M; Pietsch, J; Schulz, H; Saar, K; Hubner, N; Eilles, C; Bauer, J; Abou-El-Ardat, K; Baatout, S; Ma, X; Infanger, M; Hemmersbach, R; Grimm, D				Grosse, Jirka; Wehland, Markus; Pietsch, Jessica; Schulz, Herbert; Saar, Katrin; Huebner, Norbert; Eilles, Christoph; Bauer, Johann; Abou-El-Ardat, Khalil; Baatout, Sarah; Ma, Xiao; Infanger, Manfred; Hemmersbach, Ruth; Grimm, Daniela			Gravity-sensitive signaling drives 3-dimensional formation of multicellular thyroid cancer spheroids	FASEB JOURNAL			English	Article						gene expression; simulated microgravity; cytokines; neoangiogenesis	NF-KAPPA-B; RANDOM POSITIONING MACHINE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION PATTERNS; SIMULATED MICROGRAVITY; CARCINOMA CELLS; IN-VIVO; EXTRACELLULAR-MATRIX; PROTEIN	This study focused on the effects induced by a random positioning machine (RPM) on FTC-133 thyroid cancer cells and evaluated signaling elements involved in 3-dimensional multicellular tumor spheroid (MCTS) formation. The cells were cultured on the RPM, a device developed to simulate microgravity, and under static 1-g conditions. After 24 h on the RPM, MCTSs swimming in culture supernatants were found, in addition to growth of adherent (AD) cells. Cells grown on the RPM showed higher levels of NF-kappa B p65 protein and apoptosis than 1-g controls, a result also found earlier in endothelial cells. Employing microarray analysis, we found 487 significantly regulated transcripts belonging not only to the apoptosis pathway but also to other biological processes. Selected transcripts were analyzed with quantitative real-time PCR using the same samples. Compared with 1-g IL-6, IL-8, CD44, and OPN were significantly up-regulated in AD cells but not in MCTSs, while ERK1/2, CAV2, TLN1, and CTGF were significantly down-regulated in AD cells. Simultaneously, the expression of ERK2, IL-6, CAV2, TLN1, and CTGF was reduced in MCTSs. IL-6 protein expression and secretion mirrored its gene expression. Thus, we concluded that the signaling elements IL-6, IL-8, OPN, TLN1, and CTGF are involved with NF-kappa B p65 in RPM-dependent thyroid carcinoma cell spheroid formation.-Grosse, J., Wehland, M., Pietsch, J., Schulz, H., Saar, K., Hubner, N., Eilles, C., Bauer, J., Abou-El-Ardat, K., Baatout, S., Ma, X., Infanger, M., Hemmersbach, R., Grimm, D. Gravity-sensitive signaling drives 3-dimensional formation of multicellular thyroid cancer spheroids. FASEB J. 26, 5124-5140 (2012). www.fasebj.org	[Ma, Xiao; Grimm, Daniela] Aarhus Univ, Inst Biomed, DK-8000 Aarhus C, Denmark; [Grosse, Jirka; Eilles, Christoph] Univ Regensburg, Dept Nucl Med, Regensburg, Germany; [Wehland, Markus; Pietsch, Jessica; Infanger, Manfred; Grimm, Daniela] Univ Magdeburg, Clin Plast Aesthet & Hand Surg, D-39106 Magdeburg, Germany; [Schulz, Herbert; Saar, Katrin; Huebner, Norbert] Max Delbruck Ctr Mol Med, Berlin, Germany; [Bauer, Johann] Max Planck Inst Biochem, D-8033 Martinsried, Germany; [Abou-El-Ardat, Khalil; Baatout, Sarah] Belgian Nucl Res Ctr, Studiectr Kernenergie, Ctr Etud Energie Nucl SCK CEN, Mol, Belgium; [Abou-El-Ardat, Khalil; Baatout, Sarah] Univ Ghent, Dept Mol Biotechnol, Ghent, Belgium; [Hemmersbach, Ruth] German Aerosp Ctr, Inst Aerosp Med, Deutsch Zentrum Luft & Raumfahrt DLR, Cologne, Germany	Aarhus University; University of Regensburg; Otto von Guericke University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Belgian Nuclear Research Centre (SCK-CEN); Ghent University; Helmholtz Association; German Aerospace Centre (DLR)	Grimm, D (corresponding author), Aarhus Univ, Inst Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.	daniela.grimm@farm.au.dk		Saar, Kathrin/0000-0002-4483-1557; Grimm, Daniela/0000-0002-4991-3105; Wehland, Markus/0000-0002-8160-859X; Baatout, Sarah/0000-0001-8110-751X	European Space Agency (ESA) [CORA-GBF-2004-003-II, 20507, ESA-CORA-GBF-2010-202, 4000102463, ESA-CORA-GBF-2011-005, 4000104144]; Deutsches Zentrum fur Luft- und Raumfahrt (DLR; German Aerospace Agency) [50WB0824, 50WB1124]; Aarhus University, Denmark; University of Regensburg, Germany	European Space Agency (ESA)(European Space Agency); Deutsches Zentrum fur Luft- und Raumfahrt (DLR; German Aerospace Agency); Aarhus University, Denmark; University of Regensburg, Germany	The authors thank Henriette Dam and Heidi Skou Knudsen for their excellent technical assistance. This study was supported by the European Space Agency (ESA; CORA-GBF-2004-003-II, with contract 20507, ESA-CORA-GBF-2010-202 with contract 4000102463, ESA-CORA-GBF-2011-005 with contract 4000104144; D.G.), the Deutsches Zentrum fur Luft- und Raumfahrt (DLR; German Aerospace Agency; BMWi grants 50WB0824 and 50WB1124; D.G.), Aarhus University, Denmark (D.G.), and the University of Regensburg, Germany (C.E.).	Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battista N, 2012, FASEB J, V26, P1791, DOI 10.1096/fj.11-199406; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergelin N, 2010, ENDOCRINOLOGY, V151, P2994, DOI [10.1210/en.2009-1387, 10.1210//en.2009-1387]; Binder BR, 2002, NEWS PHYSIOL SCI, V17, P56, DOI 10.1152/nips.01369.2001; Boonyaratanakornkit JB, 2005, FASEB J, V19, P2020, DOI 10.1096/fj.05-3778fje; Borst AG, 2009, MICROGRAVITY SCI TEC, V21, P287, DOI 10.1007/s12217-008-9043-2; Caccia D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-278; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Chang TT, 2009, TISSUE ENG PT A, V15, P559, DOI 10.1089/ten.tea.2007.0434; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909; De Winter P, 2008, GROWTH FACTORS, V26, P80, DOI 10.1080/08977190802025602; DUKE PJ, 1993, J CELL BIOCHEM, V51, P274, DOI 10.1002/jcb.240510306; Eberle KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021496; Edwards LA, 2011, JNCI-J NATL CANCER I, V103, P1162, DOI 10.1093/jnci/djr224; Fain JN, 2005, METABOLISM, V54, P220, DOI 10.1016/j.metabol.2004.08.016; Fay WP, 1997, BLOOD, V90, P204; Freeman MR, 2012, ADV EXP MED BIOL, V729, P95, DOI 10.1007/978-1-4614-1222-9_7; Goretzki P E, 1990, Recent Results Cancer Res, V118, P48; Grimm D, 1997, THYROID, V7, P859, DOI 10.1089/thy.1997.7.859; Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01-0673fje; Grimm D, 2011, EXPERT REV PROTEOMIC, V8, P13, DOI 10.1586/EPR.10.105; Grimm D, 2010, TISSUE ENG PT A, V16, P1559, DOI [10.1089/ten.tea.2009.0524, 10.1089/ten.TEA.2009.0524]; Grimm D, 2009, CURR VASC PHARMACOL, V7, P347, DOI 10.2174/157016109788340640; Grimm D, 2009, TISSUE ENG PT A, V15, P2267, DOI 10.1089/ten.tea.2008.0576; Grosse J, 2012, FASEB J, V26, P639, DOI 10.1096/fj.11-194886; Gupta M, 2005, J BIOL CHEM, V280, P8109, DOI 10.1074/jbc.M413697200; Haier J, 1999, CLIN EXP METASTAS, V17, P713, DOI 10.1023/A:1006754829564; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hughes-Fulford M, 2011, FASEB J, V25, P2858, DOI 10.1096/fj.11-0902ufm; Infanger M, 2004, J GRAVIT PHYSL, V11, P169; Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001; Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459; Irby R, 2004, CLIN EXP METASTAS, V21, P515, DOI 10.1007/s10585-004-2873-4; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Jiang CG, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-122; Kim D, 2012, PATHOBIOLOGY, V79, P1, DOI 10.1159/000329472; Kim JY, 2009, CANCER RES TREAT, V41, P29, DOI 10.4143/crt.2009.41.1.29; Konstantinov SM, 2004, ANN NY ACAD SCI, V1030, P103, DOI 10.1196/annals.1329.013; Kossmehl P, 2006, APOPTOSIS, V11, P347, DOI 10.1007/s10495-006-4350-9; Leguy C. A. D., 2011, GRAVITATIONAL SPACE, V25, P36; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Magiera MM, 2004, BIOCHEM J, V382, P803, DOI 10.1042/BJ20040122; Margolis L, 1999, J UROLOGY, V161, P290, DOI 10.1016/S0022-5347(01)62134-7; Marrero B, 2009, IN VITRO CELL DEV-AN, V45, P523, DOI 10.1007/s11626-009-9217-2; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Pardo SJ, 2005, AM J PHYSIOL-CELL PH, V288, pC1211, DOI 10.1152/ajpcell.00222.2004; Pietsch J, 2011, CURR MOL MED, V11, P350, DOI 10.2174/156652411795976600; Pietsch J, 2012, PROTEOMICS, V12, P2539, DOI 10.1002/pmic.201200070; Pietsch J, 2011, PROTEOMICS, V11, P2095, DOI 10.1002/pmic.201000817; Pietsch J, 2010, PROTEOMICS, V10, P904, DOI 10.1002/pmic.200900226; Pullikuth AK, 2007, CELL SIGNAL, V19, P1621, DOI 10.1016/j.cellsig.2007.04.012; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Savage K, 2008, BREAST CANCER RES TR, V110, P245, DOI 10.1007/s10549-007-9718-1; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Schoenberger J, 2008, CURR MED CHEM, V15, P187, DOI 10.2174/092986708783330647; Schwarzenberg M, 1999, ADV SPACE RES, V24, P793, DOI 10.1016/S0273-1177(99)00075-7; Shimizu S, 2007, MOL HUM REPROD, V13, P181, DOI 10.1093/molehr/gal113; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Steffens S, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-25; Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200; Ulbrich C, 2008, J CELL BIOCHEM, V104, P1324, DOI 10.1002/jcb.21710; Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730; Ulbrich C, 2010, CELL PHYSIOL BIOCHEM, V25, P551, DOI 10.1159/000303059; Uva BM, 2002, EUR J HISTOCHEM, V46, P209; van Loon JJWA, 2007, ADV SPACE RES, V39, P1161, DOI 10.1016/j.asr.2007.02.016; Vignoud L, 1997, J CELL SCI, V110, P1421; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Weber GF, 2011, CANCER GENOM PROTEOM, V8, P263; White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243; Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Zhang HJ, 2011, NAT CELL BIOL, V13, P1189, DOI 10.1038/ncb2328; Zhang X, 2008, CHEM ENG J, V135, pS82, DOI 10.1016/j.cej.2007.07.054; Zhu AX, 2009, J CLIN ONCOL, V27, P3027, DOI 10.1200/JCO.2008.20.9908	79	75	78	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5124	5140		10.1096/fj.12-215749	http://dx.doi.org/10.1096/fj.12-215749			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964303				2022-12-28	WOS:000311838300033
J	Jacobs, RA; Siebenmann, C; Hug, M; Toigo, M; Meinild, AK; Lundby, C				Jacobs, Robert A.; Siebenmann, Christoph; Hug, Mike; Toigo, Marco; Meinild, Anne-Kristine; Lundby, Carsten			Twenty-eight days at 3454-m altitude diminishes respiratory capacity but enhances efficiency in human skeletal muscle mitochondria	FASEB JOURNAL			English	Article						acclimatization; exercise; mitochondrial efficiency; respiratory control	OPERATION EVEREST-II; OXIDATIVE DNA-DAMAGE; HYPOXIA; ADAPTATIONS; PHOSPHORYLATION; ACCLIMATIZATION; EXERCISE	Modifications of skeletal muscle mitochondria following exposure to high altitude (HA) are generally studied by morphological examinations and biochemical analysis of expression. The aim of this study was to examine tangible measures of mitochondrial function following a prolonged exposure to HA. For this purpose, skeletal muscle biopsies were obtained from 8 lowland natives at sea level (SL) prior to exposure and again after 28 d of exposure to HA at 3454 m. High-resolution respirometry was performed on the muscle samples comparing respiratory capacity and efficiency. Exercise capacity was assessed at SL and HA. Respirometric analysis revealed that mitochondrial respiratory capacity diminished in complex I-and complex II-specific respiration in addition to a loss of maximal state-3 oxidative phosphorylation capacity from SL to HA, all independent from alterations in mitochondrial content. Leak control coupling, respiratory control ratio, and oligomycin-induced leak respiration, all measures of mitochondrial efficiency, improved in response to HA exposure. SL respiratory capacities correlated with measures of exercise capacity near SL, whereas mitochondrial efficiency correlated best with exercise capacity following HA. This data demonstrate that 1 mo of exposure to HA reduces respiratory capacity in human skeletal muscle; however, the efficiency of electron transport improves.-Jacobs, R. A., Siebenmann, C., Hug, M., Toigo, M., Meinild, A.-K., Lundby, C. Twenty-eight days at 3454-m altitude diminishes respiratory capacity but enhances efficiency in human skeletal muscle mitochondria. FASEB J. 26, 5192-5200 (2012). www.fasebj.org	[Lundby, Carsten] Univ Zurich, ZIHP, Inst Physiol, CH-8057 Zurich, Switzerland; [Jacobs, Robert A.; Siebenmann, Christoph; Toigo, Marco; Lundby, Carsten] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH-8057 Zurich, Switzerland; [Jacobs, Robert A.] Univ Zurich, Vetsuisse Fac, Inst Vet Physiol, CH-8057 Zurich, Switzerland; [Toigo, Marco] ETH, Inst Human Movement Sci, Dept Exercise Physiol, Zurich, Switzerland	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Lundby, C (corresponding author), Univ Zurich, ZIHP, Inst Physiol, Off 23 H 6,Winterthurerstr 190, CH-8057 Zurich, Switzerland.	carsten.lundby@access.uzh.ch	Jacobs, Robert A/G-8439-2015	Jacobs, Robert A/0000-0003-0180-8266; Siebenmann, Christoph/0000-0002-0315-3761				ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; CHANCE B, 1955, J BIOL CHEM, V217, P409; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013; Green H, 2000, J APPL PHYSIOL, V88, P634, DOI 10.1152/jappl.2000.88.2.634; GREEN HJ, 1989, J APPL PHYSIOL, V66, P2454, DOI 10.1152/jappl.1989.66.5.2454; GREEN HJ, 1992, J APPL PHYSIOL, V73, P2701, DOI 10.1152/jappl.1992.73.6.2701; HOCHLI D, 1995, INT J SPORTS MED, V16, P343, DOI 10.1055/s-2007-973017; HOPPELER H, 1990, INT J SPORTS MED, V11, pS3, DOI 10.1055/s-2007-1024846; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; Jacobs RA, 2011, J APPL PHYSIOL, V111, P1422, DOI 10.1152/japplphysiol.00625.2011; Jacobs R. A., 2012, EXP PHYSL IN PRESS; Jacobs RA, 2012, SPORTS MED, V42, P643, DOI 10.2165/11632440-000000000-00000; Kuznetsov AV, 2004, AM J PHYSIOL-HEART C, V286, pH1633, DOI 10.1152/ajpheart.00701.2003; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Levett DZ, 2012, FASEB J, V26, P1431, DOI 10.1096/fj.11-197772; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Lundby C, 2003, TOXICOLOGY, V192, P229, DOI 10.1016/S0300-483X(03)00328-7; MACDOUGALL JD, 1991, ACTA PHYSIOL SCAND, V142, P421, DOI 10.1111/j.1748-1716.1991.tb09176.x; MATHIEU O, 1981, RESP PHYSIOL, V44, P113, DOI 10.1016/0034-5687(81)90079-7; McCarthy J, 2011, J CELL PHYSIOL, V226, P2457, DOI 10.1002/jcp.22592; Mizuno M, 2008, HIGH ALT MED BIOL, V9, P311, DOI 10.1089/ham.2008.1009; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com; Pesta D, 2012, METHODS MOL BIOL, V810, P25, DOI 10.1007/978-1-61779-382-0_3; Pesta D, 2011, AM J PHYSIOL-REG I, V301, pR1078, DOI 10.1152/ajpregu.00285.2011; Ponsot E, 2010, AM J PHYSIOL-REG I, V298, pR558, DOI 10.1152/ajpregu.00216.2009; Rasmussen UF, 2000, ACTA PHYSIOL SCAND, V168, P473, DOI 10.1046/j.1365-201x.2000.00699.x; Robach P, 2012, BRIT J SPORT MED, V46, P822, DOI 10.1136/bjsports-2012-091078; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Vigano A, 2008, PROTEOMICS, V8, P4668, DOI 10.1002/pmic.200800232; WESTERTERP KR, 1992, J APPL PHYSIOL, V73, P1815, DOI 10.1152/jappl.1992.73.5.1815; Yin Y, 2010, J BIOL CHEM, V285, P17038, DOI 10.1074/jbc.M110.104364	37	63	63	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5192	5200		10.1096/fj.12-218206	http://dx.doi.org/10.1096/fj.12-218206			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22968913				2022-12-28	WOS:000311838300039
J	Won, HY; Lee, JY; Shin, DH; Park, JH; Nam, JS; Kim, HC; Kong, G				Won, Hee-Young; Lee, Jeong-Yeon; Shin, Dong-Hui; Park, Ji-Hye; Nam, Jeong-Seok; Kim, Hyoung-Chin; Kong, Gu			Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway	FASEB JOURNAL			English	Article						polycomb; stemness; self-renewal; Jagged-1	POLYCOMB GROUP PROTEINS; SELF-RENEWAL; TUMOR-SUPPRESSOR; PROSTATE-CANCER; SIDE POPULATION; POOR-PROGNOSIS; EXPRESSION; BMI1; TARGET; GENE	Mel-18 has been proposed as a negative regulator of Bmi-1, a cancer stem cell (CSC) marker, but it is still unclear whether Mel-18 is involved in CSC regulation. Here, we examined the effect of Mel-18 on the stemness of human breast CSCs. In Mel-18 small hairpin RNA (shRNA)-transduced MCF-7 cells, side population (SP) cells and breast CSC surface marker (CD44(+)/CD24(-)/ESA(+))-expressing cells, which imply a CSC population, were enriched. Moreover, the self-renewal of CSCs was enhanced by Mel-18 knockdown, as measured by the ability for tumorsphere formation in vitro and tumor-initiating capacity in vivo. Similarly, Mel-18 overexpression inhibited the number and self-renewal activity of breast CSCs in SK-BR-3 cells. Furthermore, our data showed that Mel-18 blockade up-regulated the expression of the Wnt/TCF target Jagged-1, a Notch ligand, and consequently activated the Notch pathway. Pharmacologic inhibition of the Notch and Wnt pathways abrogated Mel-18 knockdown-mediated tumorsphere formation ability. Taken together, our findings suggest that Mel-18 is a novel negative regulator of breast CSCs that inhibits the stem cell population and in vitro and in vivo self-renewal through the inactivation of Wnt-mediated Notch signaling.-Won, H.-Y., Lee, J.-Y., Shin, D.-H., Park, J.-H., Nam, J.-S., Kim, H.-C., Kong, G. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J. 26, 5002-5013 (2012). www.fasebj.org	[Won, Hee-Young; Shin, Dong-Hui; Park, Ji-Hye; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Lee, Jeong-Yeon; Kong, Gu] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea; [Nam, Jeong-Seok] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Tumor Suppressor, Inchon, South Korea; [Kim, Hyoung-Chin] Korea Res Inst Biosci & Biotechnol, Biomed Mouse Resource Ctr, Cheongju, South Korea	Hanyang University; Hanyang University; Gachon University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kong, G (corresponding author), Hanyang Univ, Coll Med, Dept Pathol, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr			National Research Foundation of Korea; Korean Ministry of Education, Science, and Technology (MEST) [2011K000803]; Bio and Medical Technology Development Program of the National Research Foundation; MEST [2011-0027836]	National Research Foundation of Korea(National Research Foundation of Korea); Korean Ministry of Education, Science, and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Bio and Medical Technology Development Program of the National Research Foundation(National Research Foundation of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Research Foundation of Korea, funded by the Korean Ministry of Education, Science, and Technology (MEST; grant 2011K000803) and the Bio and Medical Technology Development Program of the National Research Foundation, funded by MEST (grant 2011-0027836).	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Estrach S, 2006, DEVELOPMENT, V133, P4427, DOI 10.1242/dev.02644; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Kajiume T, 2009, EXP HEMATOL, V37, P857, DOI 10.1016/j.exphem.2009.04.011; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Katoh M, 2006, INT J MOL MED, V17, P681; Kim RJ, 2010, CANCER LETT, V287, P172, DOI 10.1016/j.canlet.2009.06.010; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lin JT, 2010, ANN SURG ONCOL, V17, P2976, DOI 10.1245/s10434-010-1118-9; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005; Nefedova Y, 2008, BLOOD, V111, P2220, DOI 10.1182/blood-2007-07-102632; Pannequin J, 2009, CANCER RES, V69, P6065, DOI 10.1158/0008-5472.CAN-08-2409; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Platet N, 2007, FEBS LETT, V581, P1435, DOI 10.1016/j.febslet.2007.02.071; Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tang B, 2007, CANCER RES, V67, P8643, DOI 10.1158/0008-5472.CAN-07-0982; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wang W, 2009, INT J CANCER, V125, P2836, DOI 10.1002/ijc.24721; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	55	40	44	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5002	5013		10.1096/fj.12-209247	http://dx.doi.org/10.1096/fj.12-209247			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22954590				2022-12-28	WOS:000311838300022
J	Zhang, CK; Huang, VH; Simon, M; Sharma, LK; Fan, WW; Haas, R; Wallace, DC; Bai, YD; Huang, TS				Zhang, Chengkang; Huang, Vincent H.; Simon, Mariella; Sharma, Lokendra K.; Fan, Weiwei; Haas, Richard; Wallace, Douglas C.; Bai, Yidong; Huang, Taosheng			Heteroplasmic mutations of the mitochondrial genome cause paradoxical effects on mitochondrial functions	FASEB JOURNAL			English	Article						ND2; cybrid; nutrients	HEREDITARY-OPTIC-NEUROPATHY; GALACTOSE MEDIUM; DNA; CELLS; DEFECTS; DISEASE; CANCER; DEATH	Mitochondrial genome (mtDNA) mutation causes highly variable clinical features, and its pathogenesis is not fully understood. In this study, we analyzed the heteroplasmic mtDNA mutation C4936T (p.T156I) in ND2 of complex I and the homoplasmic mtDNA mutation A9181G (p.S219G) in ATPase 6 of complex V. Using cybrid technology, we found that in a high-glucose medium in which cultured cells mainly depend on anaerobic glycolysis for energy, the C4936T mutation inhibited cell growth by 50%. Oxygen consumption and reactive oxygen species production were also reduced by 60 and 75%, respectively. Because the subject also had conjunctiva carcinoma, we further tested whether the C4936T mutation was associated with tumor formation. In an anchorage-dependant growth test, we found that only cells with a high level of C4936T mutation formed colonies. In contrast, when the cells grew in a galactose medium in which cells were forced to generate ATP through oxidative phosphorylation, the C4936T mutation protected cells from apoptosis probably caused by the A9181G mutation. Our results suggest that the phenotype caused by mtDNA mutations may depend on the availability of the nutrients. This gene-environment interaction may contribute to the complexity of pathogenesis and clinical phenotypes caused by mtDNA mutation.-Zhang, C., Huang, V. H., Simon, M., Sharma, L. K., Fan, W., Haas, R., Wallace, D. C., Bai, Y., Huang, T. Heteroplasmic mutations of the mitochondrial genome cause paradoxical effects on mitochondrial functions. FASEB J. 26, 4914-4924 (2012). www.fasebj.org	[Zhang, Chengkang; Huang, Vincent H.; Haas, Richard; Huang, Taosheng] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA; [Simon, Mariella; Huang, Taosheng] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA; [Huang, Taosheng] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; [Sharma, Lokendra K.; Bai, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Fan, Weiwei] Salk Inst Biol Studies, Dept Mol & Dev Biol, La Jolla, CA 92037 USA; [Haas, Richard] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Haas, Richard] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Wallace, Douglas C.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wallace, Douglas C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio; Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Huang, TS (corresponding author), Univ Calif Irvine, Dept Pediat, 3113 Gillespie Hall, Irvine, CA 92697 USA.	huangts@uci.edu	Frank, Viki/GXZ-9902-2022; Bai, Yidong/A-4959-2012	Zhang, Chengkang/0000-0002-3746-2095; Huang, Taosheng/0000-0001-6601-6687; Simon, Mariella/0000-0002-8200-3277	Surber Family Foundation; U.S. National Eye Institute [1R01EY018876]; NATIONAL EYE INSTITUTE [R01EY018876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS072777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025223] Funding Source: NIH RePORTER	Surber Family Foundation; U.S. National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank the patients and their families for participating in our study. The authors are grateful to Dr. Ronald Evans (Salk Institute, La Jolla, CA, USA) for access to the Seahorse Oxygen Analyzer. The authors thank Taraneh Esmailpour for her critical reading and for performing a PAGE Blue experiment. This work was supported in part by the Surber Family Foundation. T. H. is also partially supported by U.S. National Eye Institute grant 1R01EY018876. The authors thank the members of the T. H. laboratory for critical reading of this article.	CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; FEIG DI, 1994, CANCER RES, V54, pS1890; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; Hofmann S, 1997, AM J HUM GENET, V60, P1539; Imamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3; MARZUKI S, 1991, HUM GENET, V88, P139; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566; Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Scheffler IE, 2008, MITOCHONDRIA, 2NDEDITION, P1; Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1; Torroni A, 1997, AM J HUM GENET, V60, P1107; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270; Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5	25	9	10	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4914	4924		10.1096/fj.12-206532	http://dx.doi.org/10.1096/fj.12-206532			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22925728	Green Published			2022-12-28	WOS:000311838300015
J	Hald, A; Eickhardt, H; Maerkedahl, RB; Feldborg, CW; Egerod, KL; Engelholm, LH; Laerum, OD; Lund, LR; Rono, B				Hald, Andreas; Eickhardt, Hanne; Maerkedahl, Rasmus Baadsgaard; Feldborg, Christina Winther; Egerod, Kristoffer Lihme; Engelholm, Lars Henning; Laerum, Ole Didrik; Lund, Leif Roge; Rono, Birgitte			Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner	FASEB JOURNAL			English	Article						inflammation; ovariectomy; cancer; squamous cell carcinoma; thrombosis	LEWIS LUNG-CARCINOMA; MATRIX METALLOPROTEINASES; MOUSE SKIN; REDUCED METASTASIS; MAMMARY-CANCER; ACTIVATOR; DEFICIENCY; MICE; FIBRINOGEN; EXPRESSION	Rearrangement of the skin during wound healing depends on plasmin and plasminogen, which serve to degrade fibrin depositions in the provisional matrix and thereby facilitate keratinocyte migration. In the current study, we investigated whether plasmin and plasminogen likewise played a role during the development of skin cancer. To test this, we set up a chemically induced skin tumor model in a cohort of mice and found that skin tumor growth in Plg(-/-) male mice was reduced by 52% compared with wild-type controls. Histological analyses suggested that the growth-restricting effect of plasminogen deficiency was due to thrombosis and lost patency of the tumor vasculature, resulting in tumor necrosis. The connection between plasmin-dependent fibrinolysis, vascular patency, and tumor growth was further substantiated as the effect of plasminogen deficiency on tumor growth could be reverted by superimposing heterozygous fibrinogen deficiency on Plg(-/-) mice. Tumors derived from these Fib(-/-); Plg(-/-) mice displayed a significantly decreased level of tumor thrombosis compared with Plg(-/-) mice. In summary, these data indicate that plasmin-driven fibrinolysis facilitates tumor growth by maintaining patency of the tumor vasculature.-Hald, A., Eickhardt, H., Maerkedahl, R. B., Winther Feldborg, C., Egerod, K. L., Engelholm. L. H., Laerum, O. D., Lund, L. R., Rono, B. Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. FASEB J. 26, 4445-4457 (2012). www.fasebj.org	[Hald, Andreas] Rigshosp, Finsen Lab, Copenhagen Bioctr, DK-2200 Copenhagen, Denmark; [Hald, Andreas; Eickhardt, Hanne; Maerkedahl, Rasmus Baadsgaard; Feldborg, Christina Winther; Lund, Leif Roge; Rono, Birgitte] Univ Copenhagen, Dept Cellular & Mol Med, Fac Hlth Sci, Copenhagen, Denmark; [Egerod, Kristoffer Lihme] Univ Copenhagen, Sect Metab Receptol & Enteroendocrinol, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Hald, Andreas; Engelholm, Lars Henning] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark; [Laerum, Ole Didrik] Univ Bergen, Gade Inst, Haukeland Univ Hosp, Sect Pathol, Bergen, Norway	Rigshospitalet; University of Copenhagen; University of Copenhagen; Novo Nordisk Foundation; University of Copenhagen; University of Copenhagen; University of Bergen; Haukeland University Hospital	Hald, A (corresponding author), Rigshosp, Finsen Lab, Copenhagen Bioctr, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	ahald@finsenlab.dk	Egerod, Kristoffer L/D-9481-2012	Egerod, Kristoffer L/0000-0003-2781-1594; Engelholm, Lars/0000-0002-6616-1232	Lundbeck Foundation; Danish Cancer Society; Cancer Foundation of 1989; Grosserer Alfred Nielsen og Hustrus Fond; Ludvig og Franciska Andersens Legat; Dagmar Marshalls Foundation; Fabrikant Einar Willumsens Mindelegat; Aase og Ejnar Danielsens Fond	Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Cancer Foundation of 1989; Grosserer Alfred Nielsen og Hustrus Fond; Ludvig og Franciska Andersens Legat; Dagmar Marshalls Foundation; Fabrikant Einar Willumsens Mindelegat; Aase og Ejnar Danielsens Fond	The authors acknowledge the following foundations for financial support: Lundbeck Foundation, Danish Cancer Society, Cancer Foundation of 1989, Grosserer Alfred Nielsen og Hustrus Fond, Ludvig og Franciska Andersens Legat, Dagmar Marshalls Foundation, Fabrikant Einar Willumsens Mindelegat, Aase og Ejnar Danielsens Fond. The authors thank Katharina Stegmann, Mette Musfelth Nebbelunde, Agnieszka Ingvorsen, Simone Gress Hansen, and Anne Vive for technical assistance. The authors declare no conflicts of interest.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Azzi L, 2005, J INVEST DERMATOL, V124, P22, DOI 10.1111/j.0022-202X.2004.23545.x; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bezerra JA, 1999, P NATL ACAD SCI USA, V96, P15143, DOI 10.1073/pnas.96.26.15143; Bini A, 1999, BIOCHEMISTRY-US, V38, P13928, DOI 10.1021/bi991096g; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Castellino FJ, 2005, THROMB HAEMOSTASIS, V93, P647, DOI 10.1160/TH04-12-0842; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; De Angelis T, 2002, J INVEST DERMATOL, V118, P759, DOI 10.1046/j.1523-1747.2002.01755.x; DEVRIES TJ, 1995, CANCER RES, V55, P4681; Eichten A, 2007, CANCER RES, V67, P5211, DOI 10.1158/0008-5472.CAN-06-4676; Esmon CT, 2000, HAEMOSTASIS, V30, P34; Frossing S, 2010, EXP DERMATOL, V19, pE234, DOI 10.1111/j.1600-0625.2009.01062.x; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Gong YQ, 2008, J CLIN INVEST, V118, P3012, DOI 10.1172/JCI32750; Green KA, 2008, J INVEST DERMATOL, V128, P2092, DOI 10.1038/jid.2008.54; Hald A, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/157894; Hald A, 2011, DIS MODEL MECH, V4, P212, DOI 10.1242/dmm.005801; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Heissig B, 2007, CELL STEM CELL, V1, P658, DOI 10.1016/j.stem.2007.10.012; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hurtado M, 2007, GUT, V56, P1266, DOI 10.1136/gut.2006.097188; Johansson M, 2008, IMMUNOL REV, V222, P145, DOI 10.1111/j.1600-065X.2008.00600.x; Juncker-Jensen A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016954; Kanda N, 2005, J DERMATOL SCI, V38, P1, DOI 10.1016/j.jdermsci.2004.10.011; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; Lederle W, 2010, CARCINOGENESIS, V31, P1175, DOI 10.1093/carcin/bgp248; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Liu Z, 2005, J CLIN INVEST, V115, P879, DOI 10.1172/JCI200523977; Lund LR, 2006, EMBO J, V25, P2686, DOI 10.1038/sj.emboj.7601173; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Lund LR, 1996, J INVEST DERMATOL, V106, P622, DOI 10.1111/1523-1747.ep12345425; Lund LR, 2000, DEVELOPMENT, V127, P4481; Madsen DH, 2012, J PATHOL, V227, P94, DOI 10.1002/path.3981; McColl BK, 2003, J EXP MED, V198, P863, DOI 10.1084/jem.20030361; McMahon B, 2007, PATHOPHYSIOL HAEMO T, V36, P184, DOI 10.1159/000175156; Mehta R, 2008, HAEMOPHILIA, V14, P1261, DOI 10.1111/j.1365-2516.2008.01825.x; Murray V, 2010, J INTERN MED, V267, P191, DOI 10.1111/j.1365-2796.2009.02205.x; Nozaki S, 2006, ANTI-CANCER DRUG, V17, P1109, DOI 10.1097/01.cad.0000231483.09439.3a; Okaji Y, 2012, EXP HEMATOL, V40, P143, DOI 10.1016/j.exphem.2011.10.008; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Palumbo JS, 2003, BLOOD, V102, P2819, DOI 10.1182/blood-2003-03-0881; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Ploplis VA, 2000, AM J PATHOL, V157, P703, DOI 10.1016/S0002-9440(10)64582-8; Rijken DC, 2009, J THROMB HAEMOST, V7, P4, DOI 10.1111/j.1538-7836.2008.03220.x; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Romer J, 2001, J INVEST DERMATOL, V116, P353, DOI 10.1046/j.1523-1747.2001.01241.x; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shapiro RL, 1996, CANCER RES, V56, P3597; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211; Tjwa M, 2009, J CELL MOL MED, V13, P4587, DOI 10.1111/j.1582-4934.2008.00521.x; Toriseva M, 2009, CELL MOL LIFE SCI, V66, P203, DOI 10.1007/s00018-008-8388-4; Welter M, 2008, J THEOR BIOL, V250, P257, DOI 10.1016/j.jtbi.2007.09.031; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Zalaudek I, 2010, J AM ACAD DERMATOL, V63, P377, DOI 10.1016/j.jaad.2009.11.697	66	3	5	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4445	4457		10.1096/fj.12-208025	http://dx.doi.org/10.1096/fj.12-208025			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22815383				2022-12-28	WOS:000310574200008
J	Rubio, SE; Vega-Flores, G; Martinez, A; Bosch, C; Perez-Mediavilla, A; del Rio, J; Gruart, A; Delgado-Garcia, JM; Soriano, E; Pascual, M				Rubio, Sara E.; Vega-Flores, German; Martinez, Albert; Bosch, Carles; Perez-Mediavilla, Alberto; del Rio, Joaquin; Gruart, Agnes; Maria Delgado-Garcia, Jose; Soriano, Eduardo; Pascual, Marta			Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						&theta rhythm; J20 mice; medial septum	AMYLOID-BETA PATHOLOGY; THETA OSCILLATIONS; CONTAINING NEURONS; GABA(A) RECEPTORS; BASAL FOREBRAIN; DENTATE GYRUS; INTERNEURONS; CALRETININ; MICE; PERFORMANCE	Patients with Alzheimer's disease (AD) display altered functioning of cortical networks, including altered patterns of synchronous activity and a serious deficit in cholinergic septohippocampal (SH) innervation. However, the mechanisms underlying these alterations and the implication of the GABAergic SH component in AD are largely unknown. In addition, the GABAergic septohippocampal pathway (SHP) is believed to regulate synchronous hippocampal activity by controlling the activity of interneurons. Here we show, using well-characterized pathway tracing experiments, that innervation of the GABAergic SHP decreases during normal aging. Furthermore, in an AD mouse model (hAPP(Sw,Ind); J20 mice), the GABAergic SHP shows a dramatic and early onset of this decrease in 8-mo-old mice. This decline is not caused by neuronal loss, but by the reduced number and complexity of GABAergic SH axon terminals. Finally, we demonstrate that hippocampal theta and gamma rhythm power spectra are markedly diminished in 8-mo-old behaving mice expressing mutated hAPP. In addition to the well-known loss of cholinergic input to the hippocampus in AD, these data suggest that the altered patterns of synchronous activity seen in patients with AD could be caused by the loss of GABAergic SH axons, which modulate hippocampal network activities.-Rubio, S. E., Vega-Flores, G., Martinez, A., Bosch, C., Perez-Mediavilla, A., del Rio, J., Gruart, A., Delgado-Garcia, J. M., Soriano, E., Pascual, M. Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease. FASEB J. 26, 4458-4467 (2012). www.fasebj.org	[Rubio, Sara E.; Martinez, Albert; Bosch, Carles; Soriano, Eduardo; Pascual, Marta] Inst Res Biomed, Dev Neurobiol & Regenerat Lab, E-08028 Barcelona, Spain; [Rubio, Sara E.; Martinez, Albert; Bosch, Carles; Soriano, Eduardo; Pascual, Marta] Univ Barcelona, Dept Cell Biol, Barcelona, Spain; [Rubio, Sara E.; Martinez, Albert; Bosch, Carles; Perez-Mediavilla, Alberto; del Rio, Joaquin; Soriano, Eduardo; Pascual, Marta] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Vega-Flores, German; Gruart, Agnes; Maria Delgado-Garcia, Jose] Pablo Olavide Univ, Div Neurosci, Seville, Spain; [Perez-Mediavilla, Alberto; del Rio, Joaquin] Univ Navarra, Ctr Invest Med Aplicada, Div Neurosci, E-31080 Pamplona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; CIBERNED; Universidad Pablo de Olavide; University of Navarra	Pascual, M (corresponding author), Inst Res Biomed, Dev Neurobiol & Regenerat Lab, Baldiri & Reixac 10, E-08028 Barcelona, Spain.	marta.pascual@irbbarcelona.org	Delgado-Garcia, Jose M./V-1567-2019; Vega-Flores, German/AAD-2013-2022; Pascual, Marta/Q-8103-2018; Perez-Mediavilla, Alberto/A-5246-2011; Soriano, Eduardo/AAB-3216-2019; Bosch, Carles/D-7899-2016; Pascual Sánchez, Marta/V-3144-2017	Vega-Flores, German/0000-0001-5605-4567; Pascual, Marta/0000-0002-2621-650X; Perez-Mediavilla, Alberto/0000-0003-1926-0972; Soriano, Eduardo/0000-0002-3204-9285; Bosch, Carles/0000-0003-4179-0451; Pascual Sánchez, Marta/0000-0002-2621-650X; Vega Flores, German/0000-0002-1279-1925; Martinez, Albert/0000-0003-0831-9916; Rubio, Sara E./0000-0002-9719-9719	Ministry of Science and Innovation of Spain [SAF2008-02342, BFU2008-03390, BFU2008-00899]; Union Temporal de Empresas (UTE) project Foundation for Applied Medical Research (FIMA), Spain; Caixa Catalunya-Obra Social Foundation; Ministry of Science and Innovation [BFU2008-3980]; Fondo de Investigaciones Sanitarias, Ministry of Science and Innovation [PI08/1891, PI11/00704]	Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Union Temporal de Empresas (UTE) project Foundation for Applied Medical Research (FIMA), Spain; Caixa Catalunya-Obra Social Foundation; Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fondo de Investigaciones Sanitarias, Ministry of Science and Innovation	The authors thank Natalia Ruiz and Dr. Raudel Sanchez-Campusano for excellent technical support, Tanya Yates for editorial assistance, and the personnel of Advanced Digital Microscopy and Biostatistics and Bioinformatics Facilities at the Institute for Research in Biomedicine for support. This work was supported by the Ministry of Science and Innovation of Spain (SAF2008-02342 to A. P. M., BFU2008-03390 to A. G., and BFU2008-00899 to J. M. D.-G); the Union Temporal de Empresas (UTE) project Foundation for Applied Medical Research (FIMA), Spain (to A. P. M.); the Caixa Catalunya-Obra Social Foundation and the Ministry of Science and Innovation (BFU2008-3980 to E. S.); and Fondo de Investigaciones Sanitarias, Ministry of Science and Innovation (PI08/1891 and PI11/00704 to M. P.).	Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Baglietto-Vargas D, 2010, J ALZHEIMERS DIS, V21, P119, DOI 10.3233/JAD-2010-100066; Hangya B, 2009, J NEUROSCI, V29, P8094, DOI 10.1523/JNEUROSCI.5665-08.2009; Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; Bayer T. A., 2010, INT J ALZHEIMERS DIS, V2010; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; Cardin JA, 2009, NATURE, V459, P663, DOI 10.1038/nature08002; Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8; FISCHER W, 1989, EUR J NEUROSCI, V1, P34, DOI 10.1111/j.1460-9568.1989.tb00772.x; Freund TF, 1997, CAN J PHYSIOL PHARM, V75, P479, DOI 10.1139/y97-033; FREUND TF, 1989, BRAIN RES, V478, P375, DOI 10.1016/0006-8993(89)91520-5; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; GAGE FH, 1984, NEUROBIOL AGING, V5, P43, DOI 10.1016/0197-4580(84)90084-8; GALLAGHER M, 1995, CURR OPIN NEUROBIOL, V5, P161, DOI 10.1016/0959-4388(95)80022-0; GAZTELU JM, 1982, ELECTROEN CLIN NEURO, V54, P375, DOI 10.1016/0013-4694(82)90201-2; Geula C, 2008, J NEUROPATH EXP NEUR, V67, P309, DOI 10.1097/NEN.0b013e31816a1df3; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Gulyas AI, 1996, J NEUROSCI, V16, P3397; GULYAS AI, 1990, NEUROSCIENCE, V37, P31, DOI 10.1016/0306-4522(90)90189-B; Hasselmo ME, 2005, NEURAL NETWORKS, V18, P1172, DOI 10.1016/j.neunet.2005.08.007; Iachini Ina, 2009, Curr Aging Sci, V2, P43; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Lecourtier L, 2011, HIPPOCAMPUS, V21, P1277, DOI 10.1002/hipo.20837; Loerch PM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003329; Matyas F, 2004, HIPPOCAMPUS, V14, P460, DOI 10.1002/hipo.10191; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Mufson EJ, 2003, J CHEM NEUROANAT, V26, P233, DOI 10.1016/S0891-0618(03)00068-1; Muir JL, 1997, PHARMACOL BIOCHEM BE, V56, P687, DOI 10.1016/S0091-3057(96)00431-5; Munera A, 2000, NEUROSCI LETT, V292, P33, DOI 10.1016/S0304-3940(00)01430-0; Newman MC, 2000, AGING NEUROPSYCHOL C, V7, P86, DOI 10.1076/1382-5585(200006)7:2;1-U;FT086; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Pascual M, 2005, HIPPOCAMPUS, V15, P184, DOI 10.1002/hipo.20040; Pascual M, 2004, MOL CELL NEUROSCI, V25, P679, DOI 10.1016/j.mcn.2003.12.009; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pike FG, 2000, J PHYSIOL-LONDON, V529, P205, DOI 10.1111/j.1469-7793.2000.00205.x; Popovic M, 2008, NEUROSCIENCE, V155, P182, DOI 10.1016/j.neuroscience.2008.05.023; Rabinowicz AL, 2000, ALZ DIS ASSOC DIS, V14, P231, DOI 10.1097/00002093-200010000-00008; Ribe EM, 2005, NEUROBIOL DIS, V20, P814, DOI 10.1016/j.nbd.2005.05.027; Rissman RA, 2007, J NEUROCHEM, V103, P1285, DOI 10.1111/j.1471-4159.2007.04832.x; Rissman RA, 2011, J NEUROCHEM, V117, P613, DOI 10.1111/j.1471-4159.2011.07237.x; Rocamora N, 1996, J NEUROSCI, V16, P3991; Schliebs R, 2011, BEHAV BRAIN RES, V221, P555, DOI 10.1016/j.bbr.2010.11.058; Shetty AK, 1998, J COMP NEUROL, V394, P252; STROESSNERJOHNSON HM, 1992, J NEUROSCI, V12, P1936; Takahashi H, 2010, BRAIN STRUCT FUNCT, V214, P145, DOI 10.1007/s00429-010-0242-4; Toth K, 1997, J PHYSIOL-LONDON, V500, P463, DOI 10.1113/jphysiol.1997.sp022033; Vela J, 2003, J NEUROCHEM, V85, P368, DOI 10.1046/j.1471-4159.2003.01681.x; Vertes RP, 2005, HIPPOCAMPUS, V15, P923, DOI 10.1002/hipo.20118; Villette V, 2010, J NEUROSCI, V30, P10991, DOI 10.1523/JNEUROSCI.6284-09.2010; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wilkniss SM, 1997, PSYCHOL AGING, V12, P372, DOI 10.1037/0882-7974.12.2.372; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; Ypsilanti AR, 2008, NEUROBIOL AGING, V29, P1666, DOI 10.1016/j.neurobiolaging.2007.04.001	58	67	68	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4458	4467		10.1096/fj.12-208413	http://dx.doi.org/10.1096/fj.12-208413			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835830				2022-12-28	WOS:000310574200009
J	Foller, M; Jaumann, M; Dettling, J; Saxena, A; Pakladok, T; Munoz, C; Ruth, P; Sopjani, M; Seebohm, G; Ruttiger, L; Knipper, M; Lang, F				Foeller, Michael; Jaumann, Mirko; Dettling, Juliane; Saxena, Ambrish; Pakladok, Tatsiana; Munoz, Carlos; Ruth, Peter; Sopjani, Mentor; Seebohm, Guiscard; Ruettiger, Lukas; Knipper, Marlies; Lang, Florian			AMP-activated protein kinase in BK-channel regulation and protection against hearing loss following acoustic overstimulation	FASEB JOURNAL			English	Article						energy depletion; Ca2+; activated K+ channels; inner ear; acoustic trauma	OUTER HAIR-CELLS; CA2+-ACTIVATED K+ CHANNEL; GUINEA-PIG COCHLEA; GLUCOSE-UPTAKE; POTASSIUM CHANNELS; SKELETAL-MUSCLE; NITRIC-OXIDE; DIFFERENTIAL EXPRESSION; FUNCTIONAL-SIGNIFICANCE; GLUT4 TRANSLOCATION	The energy-sensing AMP-activated serine/threonine protein kinase (AMPK) confers cell survival in part by stimulation of cellular energy production and limitation of cellular energy utilization. AMPK-sensitive functions further include activities of epithelial Na+ channel ENaC and voltage-gated K+ channel KCNE1/KCNQ1. AMPK is activated by an increased cytosolic Ca2+ concentration. The present study explored whether AMPK regulates the Ca2+-sensitive large conductance and voltage-gated potassium (BK) channel. cRNA encoding BK channel was injected into Xenopus oocytes with and without additional injection of wild-type AMPK (AMPK alpha 1 + AMPK beta 1 + AMPK gamma 1), constitutively active AMPK(gamma R70Q), or inactive AMPK(alpha K45R). BK-channel activity was determined utilizing the 2-electrode voltage-clamp. Moreover, BK-channel protein abundance in the cell membrane was determined by confocal immunomicroscopy. As BK channels are expressed in outer hair cells (OHC) of the inner ear and lack of BK channels increases noise vulnerability, OHC BK-channel expression was examined by immunohistochemistry and hearing function analyzed by auditory brain stem response measurements in AMPK alpha 1-deficient mice (ampk(-/-)) and in wild-type mice (ampk(+/+)). As a result, coexpression of AMPK or AMPK(gamma R70Q) but not of AMPK(alpha K45R) significantly enhanced BK-channel-mediated currents and BK-channel protein abundance in the oocyte cell membrane. BK-channel expression in the inner ear was lower in ampk(-/-) mice than in ampk(+/+) mice. The hearing thresholds prior to and immediately after an acoustic overexposure were similar in ampk(-/-) and ampk(+/+) mice. However, the recovery from the acoustic trauma was significantly impaired in ampk(-/-) mice compared to ampk(+/+) mice. In summary, AMPK is a potent regulator of BK channels. It may thus participate in the signaling cascades that protect the inner ear from damage following acoustic overstimulation.-Fuller, M., Jaumann, M., Dettling, J., Saxena, A., Pakladok, T., Munoz, C., Ruth, P., Sopjani, M., Seebohm, G., Ruttiger, L., Knipper, M., Lang, F. AMP-activated protein kinase in BK-channel regulation and protection against hearing loss following acoustic overstimulation. FASEB J. 26, 4243-4253 (2012). www.fasebj.org	[Foeller, Michael; Saxena, Ambrish; Pakladok, Tatsiana; Munoz, Carlos; Sopjani, Mentor; Lang, Florian] Univ Tubingen, Dept Physiol, Tubingen Hearing Res Ctr, D-72076 Tubingen, Germany; [Jaumann, Mirko; Dettling, Juliane; Ruettiger, Lukas; Knipper, Marlies] Univ Tubingen, Dept Otolaryngol, Tubingen Hearing Res Ctr, D-72076 Tubingen, Germany; [Ruth, Peter] Univ Tubingen, Dept Pharmacol & Toxicol, Inst Pharm, D-72076 Tubingen, Germany; [Foeller, Michael] Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Sopjani, Mentor] Univ Pristina, Fac Med, Pristina, Kosovo, Serbia; [Seebohm, Guiscard] Univ Klin Munster, Inst Genet Herzerkrankungen, Munster, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Universiteti i Prishtines; University of Munster	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Tubingen Hearing Res Ctr, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Saxena, Ambrish/AAQ-5984-2020	Sopjani, Mentor/0000-0002-4187-7218	Deutsche Forschungsgemeinschaft; Interdisziplin res Zentrum fur Klinische Forschung of the University of Tubingen (Nachwuchsgruppe)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisziplin res Zentrum fur Klinische Forschung of the University of Tubingen (Nachwuchsgruppe)	The authors gratefully acknowledge the generosity of Benoit Viollet (Institut Cochin, Universite Paris Descartes, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8104, Paris, France), who provided the AMPK alpha 1-deficient mice. The authors acknowledge the experimental support of Ioana Alesutan and Wibke Singer and the technical assistance of E. Faber. The manuscript was meticulously prepared by L. Subasic. Isolated hair cells were kindly provided by J. Engel (University of Tubingen; current address: Saarland University, Homburg/Saar, Germany). This study was supported by the Deutsche Forschungsgemeinschaft and the Interdisziplin res Zentrum fur Klinische Forschung of the University of Tubingen (Nachwuchsgruppe to M.F.).	Albert AP, 2008, AM J PHYSIOL-LUNG C, V295, pL837, DOI 10.1152/ajplung.90353.2008; Alesutan I, 2011, BIOCHEM BIOPH RES CO, V408, P505, DOI 10.1016/j.bbrc.2011.04.015; Alesutan I, 2011, MOL MEMBR BIOL, V28, P79, DOI 10.3109/09687688.2010.520037; Almaca J, 2009, PFLUG ARCH EUR J PHY, V458, P713, DOI 10.1007/s00424-009-0660-4; Andersen MN, 2012, TRAFFIC, V13, P143, DOI 10.1111/j.1600-0854.2011.01295.x; Armstrong CE, 2001, J PHYSIOL-LONDON, V536, P49, DOI 10.1111/j.1469-7793.2001.00049.x; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; Bae HB, 2011, FASEB J, V25, P4358, DOI 10.1096/fj.11-190587; Becker S, 2007, CELL PHYSIOL BIOCHEM, V19, P89, DOI 10.1159/000099197; Berkefeld H, 2010, PHYSIOL REV, V90, P1437, DOI 10.1152/physrev.00049.2009; Bhalla V, 2006, J BIOL CHEM, V281, P26159, DOI 10.1074/jbc.M606045200; Bohmer C, 2010, CELL PHYSIOL BIOCHEM, V25, P723, DOI 10.1159/000315092; BOITEUX A, 1981, PHILOS T ROY SOC B, V293, P5, DOI 10.1098/rstb.1981.0056; Borchert GH, 2011, AM J PHYSIOL-HEART C, V300, pH507, DOI 10.1152/ajpheart.00594.2010; Bortner CD, 2004, PFLUG ARCH EUR J PHY, V448, P313, DOI 10.1007/s00424-004-1266-5; Breen DM, 2008, BIOCHEM BIOPH RES CO, V374, P117, DOI 10.1016/j.bbrc.2008.06.104; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Carling David, 2007, Novartis Found Symp, V286, P72; Dal-Cim T, 2011, NEUROSCIENCE, V183, P212, DOI 10.1016/j.neuroscience.2011.03.022; Dermaku-Sopjani M, 2011, CELL PHYSIOL BIOCHEM, V28, P251, DOI 10.1159/000331737; Dufer M, 2011, DIABETOLOGIA, V54, P423, DOI 10.1007/s00125-010-1936-0; DULON D, 1995, PFLUG ARCH EUR J PHY, V430, P365, DOI 10.1007/BF00373911; Eckey K, 2010, CELL PHYSIOL BIOCHEM, V26, P503, DOI 10.1159/000322318; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; Engel J, 2006, NEUROSCIENCE, V143, P837, DOI 10.1016/j.neuroscience.2006.08.060; Evans AM, 2005, J BIOL CHEM, V280, P41504, DOI 10.1074/jbc.M510040200; Foller M, 2006, CELL PHYSIOL BIOCHEM, V17, P201, DOI 10.1159/000094125; Foller M, 2009, FASEB J, V23, P1072, DOI 10.1096/fj.08-121772; Fraser SA, 2007, BIOCHEM J, V405, P85, DOI 10.1042/BJ20061850; FUCHS PA, 1988, J NEUROSCI, V8, P2460; Grimes WN, 2009, NAT NEUROSCI, V12, P585, DOI 10.1038/nn.2302; Guan F, 2008, ARCH MED RES, V39, P52, DOI 10.1016/j.arcmed.2007.06.022; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hirschler-Laszkiewicz I, 2011, J BIOL CHEM, V286, P30636, DOI 10.1074/jbc.M111.238360; Holtzclaw JD, 2011, CURR OPIN NEPHROL HY, V20, P512, DOI 10.1097/MNH.0b013e3283488889; Horie T, 2008, J CELL PHYSIOL, V215, P733, DOI 10.1002/jcp.21353; Hosseinzadeh Z, 2011, CELL PHYSIOL BIOCHEM, V28, P693, DOI 10.1159/000335763; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P275, DOI 10.1113/jphysiol.1988.sp017120; IKEDA K, 1987, HEARING RES, V26, P117, DOI 10.1016/0378-5955(87)90040-2; Ikematsu N, 2011, P NATL ACAD SCI USA, V108, P18132, DOI 10.1073/pnas.1106201108; Jaumann M, 2012, NAT MED, V18, P252, DOI 10.1038/nm.2634; Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V293, pE286, DOI 10.1152/ajpendo.00693.2006; Jessen N, 2003, J APPL PHYSIOL, V94, P1373, DOI 10.1152/japplphysiol.00250.2002; Kim T, 2009, BIOCHEM BIOPH RES CO, V388, P377, DOI 10.1016/j.bbrc.2009.08.018; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; Knipper M, 2000, J NEUROPHYSIOL, V83, P3101, DOI 10.1152/jn.2000.83.5.3101; Knirsch M, 2007, J NEUROSCI, V27, P6442, DOI 10.1523/JNEUROSCI.5364-06.2007; Kohan AB, 2009, BIOCHEM BIOPH RES CO, V388, P117, DOI 10.1016/j.bbrc.2009.07.130; Kohler R, 2010, PFLUG ARCH EUR J PHY, V459, P969, DOI 10.1007/s00424-010-0819-z; KROS CJ, 1990, J PHYSIOL-LONDON, V421, P263, DOI 10.1113/jphysiol.1990.sp017944; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Lage R, 2010, FASEB J, V24, P2670, DOI 10.1096/fj.09-150672; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LANG F, 1986, AM J PHYSIOL, V250, pF953, DOI 10.1152/ajprenal.1986.250.6.F953; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 2007, AM J PHYSIOL-CELL PH, V293, pC1187, DOI 10.1152/ajpcell.00024.2007; Langer P, 2003, J COMP NEUROL, V455, P198, DOI 10.1002/cne.10471; Lantier L, 2010, FASEB J, V24, P3555, DOI 10.1096/fj.10-155994; Lee US, 2010, TRENDS NEUROSCI, V33, P415, DOI 10.1016/j.tins.2010.06.004; Lei BA, 2005, P NATL ACAD SCI USA, V102, P6966, DOI 10.1073/pnas.0500768102; LEWIS RS, 1983, NATURE, V304, P538, DOI 10.1038/304538a0; Li J, 2004, AM J PHYSIOL-ENDOC M, V287, pE834, DOI 10.1152/ajpendo.00234.2004; Li SJ, 2011, DIABETES-METAB RES, V27, P461, DOI 10.1002/dmrr.1196; Liao YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015601; Lira VA, 2007, AM J PHYSIOL-ENDOC M, V293, pE1062, DOI 10.1152/ajpendo.00045.2007; Liu QQ, 2010, FASEB J, V24, P4229, DOI 10.1096/fj.10-159723; Luiken JJFP, 2004, PFLUG ARCH EUR J PHY, V448, P1, DOI 10.1007/s00424-003-1199-4; Lupescu A, 2009, CELL PHYSIOL BIOCHEM, V23, P211, DOI 10.1159/000204110; Mace OJ, 2008, J PHYSIOL-LONDON, V586, P4541, DOI 10.1113/jphysiol.2008.158253; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; Malerba M, 2010, J BIOL REG HOMEOS AG, V24, P123; Mammano F, 1996, J PHYSIOL-LONDON, V496, P639, DOI 10.1113/jphysiol.1996.sp021715; Mcgee SL, 2008, FRONT BIOSCI-LANDMRK, V13, P3022, DOI 10.2741/2907; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Michna M, 2003, J PHYSIOL-LONDON, V553, P747, DOI 10.1113/jphysiol.2003.053256; Mohamed MR, 2010, CELL PHYSIOL BIOCHEM, V26, P959, DOI 10.1159/000324004; Mounier R, 2009, FASEB J, V23, P2264, DOI 10.1096/fj.08-119057; N'Gouemo P, 2011, EXPERT OPIN THER TAR, V15, P1283, DOI 10.1517/14728222.2011.620607; NAKAZAWA K, 1995, J HISTOCHEM CYTOCHEM, V43, P981, DOI 10.1177/43.10.7560888; Natsuizaka M, 2007, EXP CELL RES, V313, P3337, DOI 10.1016/j.yexcr.2007.06.013; Ningaraj NS, 2009, CANCER BIOL THER, V8, P1924, DOI 10.4161/cbt.8.20.9490; Nurbaeva MK, 2012, FASEB J, V26, P3049, DOI 10.1096/fj.12-204024; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; Oliver D, 2006, J NEUROSCI, V26, P6181, DOI 10.1523/JNEUROSCI.1047-06.2006; Osawa Y, 2011, FASEB J, V25, P1133, DOI 10.1096/fj.10-168351; Ota S, 2009, BIOCHEM BIOPH RES CO, V388, P311, DOI 10.1016/j.bbrc.2009.07.164; Park S, 2009, AM J PHYSIOL-CELL PH, V296, pC106, DOI 10.1152/ajpcell.00114.2008; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Sausbier M, 2007, FASEB J, V21, P812, DOI 10.1096/fj.06-7167com; Schimmang T, 2003, DEVELOPMENT, V130, P4741, DOI 10.1242/dev.00676; Schneider J, 2007, CELL PHYSIOL BIOCHEM, V20, P35, DOI 10.1159/000104151; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Schug N, 2006, EUR J NEUROSCI, V24, P3372, DOI 10.1111/j.1460-9568.2006.05225.x; Shimizu T, 2006, CELL PHYSIOL BIOCHEM, V18, P295, DOI 10.1159/000097607; Skinner LJ, 2003, J NEUROPHYSIOL, V90, P320, DOI 10.1152/jn.01155.2002; Song HY, 2010, BIOCHEM BIOPH RES CO, V396, P961, DOI 10.1016/j.bbrc.2010.05.033; Sopjani M, 2010, MOL MEMBR BIOL, V27, P137, DOI 10.3109/09687681003616870; Spreadbury IC, 2004, HEARING RES, V190, P115, DOI 10.1016/S0378-5955(03)00376-9; Summermatter S, 2008, FASEB J, V22, P774, DOI 10.1096/fj.07-8972com; SUNOSE H, 1993, JPN J PHYSIOL, V43, pS175; Taub M, 2010, BIOCHEM BIOPH RES CO, V393, P339, DOI 10.1016/j.bbrc.2010.02.037; Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546; Thurm H, 2005, J PHYSIOL-LONDON, V569, P137, DOI 10.1113/jphysiol.2005.094680; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Vingtdeux V, 2011, FASEB J, V25, P219, DOI 10.1096/fj.10-167361; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Walker J, 2005, BIOCHEM J, V385, P485, DOI 10.1042/BJ20040694; WANGEMANN P, 1993, HEARING RES, V66, P123, DOI 10.1016/0378-5955(93)90133-L; Winder WW, 2007, CELL BIOCHEM BIOPHYS, V47, P332, DOI 10.1007/s12013-007-0008-7; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wu RS, 2010, KIDNEY INT, V78, P963, DOI 10.1038/ki.2010.325; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Yoshida H, 2012, J MOL CELL CARDIOL, V52, P410, DOI 10.1016/j.yjmcc.2011.08.013; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073; Zygmunt K, 2010, BIOCHEM BIOPH RES CO, V398, P178, DOI 10.1016/j.bbrc.2010.06.048	119	35	35	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4243	4253		10.1096/fj.12-208132	http://dx.doi.org/10.1096/fj.12-208132			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22767231				2022-12-28	WOS:000309704000029
J	Parisi, S; Battista, M; Musto, A; Navarra, A; Tarantino, C; Russo, T				Parisi, Silvia; Battista, Marica; Musto, Anna; Navarra, Angelica; Tarantino, Carolina; Russo, Tommaso			A regulatory loop involving Dies1 and miR-125a controls BMP4 signaling in mouse embryonic stem cells	FASEB JOURNAL			English	Article						differentiation; miRNA gene regulation; signal transduction; transforming growth factor-beta; bone morphogenetic protein 4	BONE MORPHOGENETIC PROTEINS; MICRORNA BIOGENESIS; DNA METHYLATION; SELF-RENEWAL; DIFFERENTIATION; SPECIFICATION; PLURIPOTENCY; INDUCTION; PATHWAY; CLUSTER	Bone morphogenetic protein 4 (BMP4) plays an important role in maintaining embryonic stem cells (ESCs) in the undifferentiated state and in the regulation of lineage commitment. We recently identified a transmembrane protein, named Dies1, the suppression of which by RNA interference blocks mouse ESC differentiation by interfering with the BMP4 signaling. We asked whether modulation of Dies1 levels could be a physiological mechanism to regulate ESC pluripotency and/or differentiation. We demonstrated that miR-125a targets Dies1 and regulates its expression in ESCs. The overexpression of miR-125a impairs differentiation, and this effect is specifically mediated by Dies1 down-regulation and accompanied by a decrease of BMP4 signaling. We also found that Dies1 is associated with BMP4 receptor complex and that BMP4 activates the transcription of miR-125a gene. Therefore, a feedback loop exists that sets ESC sensitivity to BMP4. The analysis of this regulatory mechanism revealed that miR-125a overexpression and the consequent inhibition of the BMP4 signaling arrest the cells in the epiblast stem cell (epiSC) status, due to the concomitant activation of the Nodal/Activin pathway.-Parisi, S., Battista, M., Musto, A., Navarra, A., Tarantino, C., Russo, T. A regulatory loop involving Dies1 and miR-125a controls BMP4 signaling in mouse embryonic stem cells. FASEB J. 26, 3957-3968 (2012). www.fasebj.org	[Parisi, Silvia; Musto, Anna; Navarra, Angelica; Russo, Tommaso] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; [Parisi, Silvia; Battista, Marica; Musto, Anna; Navarra, Angelica; Tarantino, Carolina; Russo, Tommaso] Ceinge Biotecnol Avanzate, Naples, Italy; [Battista, Marica] European Sch Mol Med SEMM, Naples, Italy	University of Naples Federico II; CEINGE Biotecnologie Avanzate	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	tommaso.russo@unina.it	Russo, Tommaso/K-1331-2016	Russo, Tommaso/0000-0003-4426-0106; Tarantino, Carolina/0000-0003-2470-3803	EC-Sirocco Consortium; Associazione Italiana Ricerca sul Cancro; Italian Ministry of Research [PON 01_02782]	EC-Sirocco Consortium; Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Research(Ministry of Education, Universities and Research (MIUR))	The authors are grateful to Antonio Simeone and Dario Acampora for helpful suggestions and to Fabio Formiggini and Daniela Sarnataro for helping in FRET analysis. The authors thank Danila Scarpa for precious assistance and Simona Paladino (Universita Federico II, Naples, Italy) for providing plasmids. This work was supported by grants from EC-Sirocco Consortium, Associazione Italiana Ricerca sul Cancro, and Italian Ministry of Research (PON 01_02782).	Aloia L, 2010, J BIOL CHEM, V285, P7776, DOI 10.1074/jbc.M109.077156; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399; Boissart C, 2012, DEVELOPMENT, V139, P1247, DOI 10.1242/dev.073627; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Bushati N, 2008, CURR OPIN NEUROBIOL, V18, P292, DOI 10.1016/j.conb.2008.07.001; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Galvin KE, 2010, J BIOL CHEM, V285, P19747, DOI 10.1074/jbc.M109.077347; Gritsman K, 2000, DEVELOPMENT, V127, P921; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; Halbrooks Peter J, 2007, J Mol Signal, V2, P4, DOI 10.1186/1750-2187-2-4; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Ji M, 2011, AM J PATHOL, V179, P1645, DOI 10.1016/j.ajpath.2011.06.008; Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Koch CA, 2008, STEM CELLS, V26, P89, DOI 10.1634/stemcells.2007-0151; Lee KL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002130; Lleres D., 2007, CURR PROTOC CYTOM; Ng HH, 2011, NAT CELL BIOL, V13, P490, DOI 10.1038/ncb0511-490; Niwa H, 2009, NATURE, V460, P118, DOI 10.1038/nature08113; Ogawa K, 2007, J CELL SCI, V120, P55, DOI 10.1242/jcs.03296; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Parisi S, 2008, J CELL SCI, V121, P2629, DOI 10.1242/jcs.027599; Parisi S, 2011, VITAM HORM, V87, P381, DOI 10.1016/B978-0-12-386015-6.00037-8; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Rosa A, 2011, EMBO J, V30, P237, DOI 10.1038/emboj.2010.319; Rosa A, 2009, CELL CYCLE, V8, P3513, DOI 10.4161/cc.8.21.9847; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Seuntjens E, 2009, CYTOKINE GROWTH F R, V20, P449, DOI 10.1016/j.cytogfr.2009.10.005; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tarantino C, 2010, FASEB J, V24, P3255, DOI 10.1096/fj.09-152207; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; Wang L, 2011, J EXP MED, V208, P577, DOI 10.1084/jem.20100619; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang YL, 2009, J CELL PHYSIOL, V218, P251, DOI 10.1002/jcp.21607; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhang KJ, 2010, DEVELOPMENT, V137, P2095, DOI 10.1242/dev.049494; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607	48	28	36	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					3957	3968		10.1096/fj.12-211607	http://dx.doi.org/10.1096/fj.12-211607			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751012				2022-12-28	WOS:000309704000004
J	Auffret, J; Viengchareun, S; Carre, N; Denis, RGP; Magnan, C; Marie, PY; Muscat, A; Feve, B; Lombes, M; Binart, N				Auffret, Julien; Viengchareun, Say; Carre, Nadege; Denis, Raphael G. P.; Magnan, Christophe; Marie, Pierre-Yves; Muscat, Adeline; Feve, Bruno; Lombes, Marc; Binart, Nadine			Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity	FASEB JOURNAL			English	Article						thermogenesis; adipocyte	BROWN FAT; TRANSCRIPTIONAL CONTROL; GROWTH-HORMONE; BODY-WEIGHT; TISSUE; WHITE; RELEASE; LEPTIN; GENE; METABOLISM	Stimulating conversion of white fat to metabolically active adipocytes (beige fat) constitutes a promising strategy against weight gain and its deleterious associated-disorders. We provide direct evidence that prolactin (PRL), best known for its actions on the mammary gland, plays a pivotal role in energy balance through the control of adipocyte differentiation and fate. Here we show that lack of prolactin receptor (PRLR) causes resistance to high-fat-diet-induced obesity due to enhanced energy expenditure and increased metabolic rate. Mutant mice displayed reduced fat mass associated with appearance of massive brown-like adipocyte foci in perirenal and subcutaneous but not in gonadal fat depots under a high-fat diet. Positron emission tomography imaging further demonstrated the occurrence of these thermogenic brown fat depots in adult mice, providing additional support for recruitable brown-like adipocytes (beigeing) in white fat depots. Consistent with the activation of brown adipose tissue, PRLR inactivation increases expression of master genes controlling brown adipocyte fate (PRDM16) and mitochondrial function (PGC1 alpha, UCP1). Altered pRb/Foxc2 expression suggests that this PRL-regulated pathway may contribute to beige cell commitment. Together, these results provide direct genetic evidence that PRLR affects energy balance and metabolic adaptation in rodents via effects on brown adipose tissue differentiation and function.-Auffret, J., Viengchareun, S., Carre, N., Denis, R. G. P., Magnan, C., Marie, P.-Y., Muscat, A., Feve, B., Lombes, M., Binart, N. Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J. 26, 3728-3737 (2012). www.fasebj.org	[Auffret, Julien; Viengchareun, Say; Carre, Nadege; Lombes, Marc; Binart, Nadine] INSERM, U693, F-94275 Le Kremlin Bicetre, France; [Auffret, Julien; Viengchareun, Say; Carre, Nadege; Lombes, Marc; Binart, Nadine] Univ Paris 11, Fac Med Paris Sud, UMR S693, Le Kremlin Bicetre, France; [Denis, Raphael G. P.; Magnan, Christophe] Univ Paris Diderot, CNRS, EAC 4413, Equipe Homeostasie Energet & Regulat Nerveuses &, Paris, France; [Marie, Pierre-Yves] CHU Nancy, INSERM, U961, Nancy, France; [Muscat, Adeline; Feve, Bruno] UMR S 938, Fac Med Pierre & Marie Curie, Paris, France; [Lombes, Marc; Binart, Nadine] Hop Bictr, AP HP, Serv Endocrinol & Malad Reprod, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Binart, N (corresponding author), INSERM, U693, F-94275 Le Kremlin Bicetre, France.	nadine.binart@inserm.fr	Lombes, Marc/L-5933-2018; Binart, Nadine/F-2949-2013; Marie, pierre-yves/AAY-6971-2020; Viengchareun, Say/M-6612-2017; magnan, christophe/AAJ-7622-2021; Denis, Raphael/ABE-1758-2020; Viengchareun, Say/GOV-6812-2022	Lombes, Marc/0000-0003-3189-023X; Binart, Nadine/0000-0002-5606-3866; magnan, christophe/0000-0002-7044-2571; Denis, Raphael/0000-0002-7677-7460; Feve, Bruno/0000-0001-6577-9009; viengchareun, say/0000-0003-4280-3250	Region Ile-de-France (CODDIM); Ministere de l'Education Nationale, de la Recherche et de la Technologie, France; Agence Nationale de la Recherche [09-BLAN-0246]; Institut National de la Sante et de la Recherche Medicale; Universite Paris-Sud	Region Ile-de-France (CODDIM)(Region Ile-de-France); Ministere de l'Education Nationale, de la Recherche et de la Technologie, France; Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Paris-Sud	The authors thank Prof. M. Freemark (Duke University Medical Center, Durham, NC, USA) for helpful discussions of the manuscript, P. Letteron (IFR2 Bichat Medical School, Paris, France) for his help with DEXA analysis, and S. Poussier and F. Maskali for the recording and analysis of FDG-PET. The authors are also grateful to Prof. D. Ricquier (Institut Cochin, Paris, France) for UCP1 antibody. Calorimetric studies were performed at the Functional and Physiological Exploration Platform (FPE) of the Unit Biologie Fonctionnelle et Adaptative, Universite Paris Diderot (Sorbonne Paris Cite, Unite de Biologie Fonctionnelle et Adaptative, equipes d'Accueil Conventionnees 4413, Centre National de la Recherche Scientifique). R. G. P. D. received a research fellowship from the Region Ile-de-France (CODDIM). J.A. is the recipient of a doctoral fellowship from the Ministere de l'Education Nationale, de la Recherche et de la Technologie, France. This work was supported by grants from Agence Nationale de la Recherche (09-BLAN-0246), Institut National de la Sante et de la Recherche Medicale, and Universite Paris-Sud.	Ben-Jonathan N, 2008, ENDOCR REV, V29, P1, DOI 10.1210/er.2007-0017; Binart N, 2010, TRENDS ENDOCRIN MET, V21, P362, DOI 10.1016/j.tem.2010.01.008; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Brandebourg TD, 2007, BIOCHEM BIOPH RES CO, V357, P408, DOI 10.1016/j.bbrc.2007.03.168; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carter EA, 2011, LIFE SCI, V89, P78, DOI 10.1016/j.lfs.2011.04.014; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Clevenger CV, 2009, TRENDS ENDOCRIN MET, V20, P223, DOI 10.1016/j.tem.2009.03.001; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Silva CMD, 2011, OBESITY, V19, P800, DOI 10.1038/oby.2010.150; Fleenor D, 2005, ENDOCRINOLOGY, V146, P103, DOI 10.1210/en.2004-0744; Flint DJ, 2006, J ENDOCRINOL, V191, P101, DOI 10.1677/joe.1.06939; Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532; Fueger BJ, 2006, J NUCL MED, V47, P999; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Hugo ER, 2008, J CLIN ENDOCR METAB, V93, P4006, DOI 10.1210/jc.2008-1172; Ishibashi J, 2010, SCIENCE, V328, P1113, DOI 10.1126/science.1190816; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kajimura S, 2010, CELL METAB, V11, P257, DOI 10.1016/j.cmet.2010.03.005; Kok P, 2004, J CLIN ENDOCR METAB, V89, P4445, DOI 10.1210/jc.2003-032184; Kok P, 2006, AM J PHYSIOL-ENDOC M, V291, pE1038, DOI 10.1152/ajpendo.00567.2005; Lee P, 2011, J CLIN ENDOCR METAB, V96, P2450, DOI 10.1210/jc.2011-0487; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lidell ME, 2011, DIABETES, V60, P427, DOI 10.2337/db10-0409; Lisboa PC, 2006, HORM METAB RES, V38, P295, DOI 10.1055/s-2006-925390; Meyre D, 2009, NAT GENET, V41, P157, DOI 10.1038/ng.301; Nanbu-Wakao R, 2000, MOL ENDOCRINOL, V14, P307, DOI 10.1210/me.14.2.307; Nilsson L, 2011, MOL GENET METAB, V102, P78, DOI 10.1016/j.ymgme.2010.08.017; NYBROE O, 1985, GEN COMP ENDOCR, V57, P257, DOI 10.1016/0016-6480(85)90270-9; Ohno H, 2012, CELL METAB, V15, P395, DOI 10.1016/j.cmet.2012.01.019; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Roy AF, 2007, J ENDOCRINOL, V195, P341, DOI 10.1677/JOE-07-0321; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Seale P, 2009, DIABETES, V58, P1482, DOI 10.2337/db09-0622; Toh SY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002890; Vegiopoulos A, 2010, SCIENCE, V328, P1158, DOI 10.1126/science.1186034; Viengchareun S, 2004, J MOL ENDOCRINOL, V33, P679, DOI 10.1677/jme.1.01563; Viengchareun S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001535; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949	47	54	57	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3728	3737		10.1096/fj.12-204958	http://dx.doi.org/10.1096/fj.12-204958			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22637534	Green Submitted			2022-12-28	WOS:000308391600014
J	Pederson, T				Pederson, Thoru			Sense and Antisense in Biotech: The First Antisense DNA Company	FASEB JOURNAL			English	Editorial Material							VIRAL-RNA; INHIBITION; REPLICATION; CELLS		Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; CALVET JP, 1979, P NATL ACAD SCI USA, V76, P755, DOI 10.1073/pnas.76.2.755; Folkman J., 1990, ALZA C SERIES, V3, P141; Pederson T., 2011, BIOGRAPHICAL MEMOIRS; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	7	5	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3594	3601		10.1096/fj.12-0902ufm	http://dx.doi.org/10.1096/fj.12-0902ufm			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22935906				2022-12-28	WOS:000308391600002
J	Responte, DJ; Lee, JK; Hu, JC; Athanasiou, KA				Responte, Donald J.; Lee, Jennifer K.; Hu, Jerry C.; Athanasiou, Kyriacos A.			Biomechanics-driven chondrogenesis: from embryo to adult	FASEB JOURNAL			English	Review						cartilage; tissue engineering; chondrocyte	INTERMITTENT HYDROSTATIC-PRESSURE; BOVINE ARTICULAR-CARTILAGE; CANINE KNEE CARTILAGE; II COLLAGEN; BIOSYNTHETIC RESPONSE; INTRACELLULAR CALCIUM; MECHANICAL-PROPERTIES; EXTRACELLULAR-MATRIX; TISSUE REGENERATION; CONTACT PRESSURES	Biomechanics plays a pivotal role in articular cartilage development, pathophysiology, and regeneration. During embryogenesis and cartilage maturation, mechanical stimuli promote chondrogenesis and limb formation. Mechanical loading, which has been characterized using computer modeling and in vivo studies, is crucial for maintaining the phenotype of cartilage. However, excessive or insufficient loading has deleterious effects and promotes the onset of cartilage degeneration. Informed by the prominent role of biomechanics, mechanical stimuli have been harnessed to enhance redifferentiation of chondrocytes and chondroinduction of other cell types, thus providing new chondrocyte cell sources. Biomechanical stimuli, such as hydrostatic pressure or compression, have been used to enhance the functional properties of neocartilage. By identifying pathways involved in mechanical stimulation, chemical equivalents that mimic mechanical signaling are beginning to offer exciting new methods for improving neocartilage. Harnessing biomechanics to improve differentiation, maintenance, and regeneration is emerging as pivotal toward producing functional neocartilage that could eventually be used to treat cartilage degeneration.-Responte, D. J., Lee, J. K., Hu, J. C., Athanasiou, K. A. Biomechanics-driven chondrogenesis: from embryo to adult. FASEB J. 26, 3614-3624 (2012). www.fasebj.org	[Responte, Donald J.; Lee, Jennifer K.; Hu, Jerry C.; Athanasiou, Kyriacos A.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA	University of California System; University of California Davis	Athanasiou, KA (corresponding author), Univ Calif Davis, Dept Biomed Engn, 1 Shields Ave, Davis, CA 95616 USA.	athanasiou@ucdavis.edu	Hu, Jerry/E-7385-2013	Hu, Jerry/0000-0003-0651-1461	U.S. National Institutes of Health grants [R01 AR053286, R01 AR047839, R01 DE019666, R01 DE015038]; Arthritis Foundation Innovative Research grant; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053286, R01AR047839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015038, R01DE019666] Funding Source: NIH RePORTER	U.S. National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arthritis Foundation Innovative Research grant; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors acknowledge funding support from U.S. National Institutes of Health grants R01 AR053286, R01 AR047839, R01 DE019666, and R01 DE015038, and an Arthritis Foundation Innovative Research grant.	Abusara Z, 2011, J BIOMECH, V44, P930, DOI 10.1016/j.jbiomech.2010.11.031; AFOKE NYP, 1987, J BONE JOINT SURG BR, V69, P536, DOI 10.1302/0301-620X.69B4.3611154; Andriacchi TP, 2006, CURR OPIN RHEUMATOL, V18, P514, DOI 10.1097/01.bor.0000240365.16842.4e; Angele P, 2003, J ORTHOPAED RES, V21, P451, DOI 10.1016/S0736-0266(02)00230-9; Bachrach NM, 1995, J BIOMECH, V28, P1561, DOI 10.1016/0021-9290(95)00103-4; BEHRENS F, 1989, J ORTHOPAED RES, V7, P335, DOI 10.1002/jor.1100070305; BRANDT KD, 1991, ARTHRITIS RHEUM-US, V34, P1560; Brommer H, 2005, EQUINE VET J, V37, P148, DOI 10.2746/0425164054223769; Browning JA, 1999, ACTA PHYSIOL SCAND, V166, P39; Browning JA, 2004, BIORHEOLOGY, V41, P299; BURTONWURSTER N, 1993, J ORTHOPAED RES, V11, P717, DOI 10.1002/jor.1100110514; Carter DR, 2003, PHILOS T ROY SOC B, V358, P1461, DOI 10.1098/rstb.2003.1346; CARTER DR, 1987, CLIN ORTHOP RELAT R, P237; CARTER DR, 1988, J ORTHOPAED RES, V6, P148, DOI 10.1002/jor.1100060120; CARTER DR, 1988, J ORTHOPAED RES, V6, P804, DOI 10.1002/jor.1100060604; Carver SE, 1999, BIOTECHNOL BIOENG, V62, P166, DOI 10.1002/(SICI)1097-0290(19990120)62:2<166::AID-BIT6>3.3.CO;2-B; Chen AC, 2001, J BIOMECH, V34, P1, DOI 10.1016/S0021-9290(00)00170-6; Chiang HS, 2011, TISSUE ENG PT A, V17, P2919, DOI 10.1089/ten.tea.2010.0732; Crawford-Young SJ, 2006, INT J DEV BIOL, V50, P183, DOI 10.1387/ijdb.052077sc; D'Andrea P, 2000, BIORHEOLOGY, V37, P75; Darling EM, 2005, J ORTHOP RES, V23, P425, DOI 10.1016/j.orthres.2004.08.008; Darling EM, 2009, CELL MOL BIOENG, V2, P395, DOI 10.1007/s12195-009-0077-3; Das RHJ, 2008, OSTEOARTHR CARTILAGE, V16, P385, DOI 10.1016/j.joca.2007.07.014; Demarteau O, 2003, BIOCHEM BIOPH RES CO, V310, P580, DOI 10.1016/j.bbrc.2003.09.099; Doehring LC, 2010, AM J PATHOL, V177, P473, DOI 10.2353/ajpath.2010.090758; Domm C, 2000, ORTHOPADE, V29, P91; Eckstein F, 2001, ANAT EMBRYOL, V203, P147, DOI 10.1007/s004290000154; Edlich M, 2001, J BIOMECH, V34, P59, DOI 10.1016/S0021-9290(00)00158-5; Elder BD, 2009, TISSUE ENG PART B-RE, V15, P43, DOI 10.1089/ten.teb.2008.0435; Elder SH, 2005, BIOMECH MODEL MECHAN, V3, P141, DOI 10.1007/s10237-004-0058-3; Elder SH, 2000, J ORTHOPAED RES, V18, P78, DOI 10.1002/jor.1100180112; Elder SH, 2006, J ORTHOP RES, V24, P740, DOI 10.1002/jor.20086; Evans ND, 2009, EUR CELLS MATER, V18, P1; Foty RA, 2005, DEV BIOL, V278, P255, DOI 10.1016/j.ydbio.2004.11.012; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; HALL BK, 1990, J MORPHOL, V206, P45, DOI 10.1002/jmor.1052060105; Heyland J, 2006, BIOTECHNOL LETT, V28, P1641, DOI 10.1007/s10529-006-9144-1; HODGE WA, 1989, J BONE JOINT SURG AM, V71A, P1378, DOI 10.2106/00004623-198971090-00015; Hu J. C., 2003, HDB HISTOLOGY METHOD; Hu JC, 2006, TISSUE ENG, V12, P1337, DOI 10.1089/ten.2006.12.1337; Huang CYC, 2004, STEM CELLS, V22, P313, DOI 10.1634/stemcells.22-3-313; Jin M, 2001, ARCH BIOCHEM BIOPHYS, V395, P41, DOI 10.1006/abbi.2001.2543; Juang YM, 2010, BIOMED CHROMATOGR, V24, P1273, DOI 10.1002/bmc.1436; Kawanishi M, 2007, TISSUE ENG, V13, P957, DOI 10.1089/ten.2006.0176; Kelly DJ, 2005, J BIOMECH, V38, P1413, DOI 10.1016/j.jbiomech.2004.06.026; Kim E, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000938; Klein TJ, 2007, J BIOMECH, V40, P182, DOI 10.1016/j.jbiomech.2005.11.002; Knight MM, 2006, J BIOMECH, V39, P1547, DOI 10.1016/j.jbiomech.2005.04.006; Korhonen RK, 2006, BIOMECH MODEL MECHAN, V5, P150, DOI 10.1007/s10237-006-0021-6; Krieg M, 2008, NAT CELL BIOL, V10, P429, DOI 10.1038/ncb1705; Kunitomo T, 2009, J ORTHOP SCI, V14, P776, DOI 10.1007/s00776-009-1393-0; Lee CR, 2003, J BIOMED MATER RES A, V64A, P560, DOI 10.1002/jbm.a.10443; Lefebvre V, 2010, CURR TOP DEV BIOL, V90, P291, DOI 10.1016/S0070-2153(10)90008-2; LeRoux MA, 2000, J ORTHOP RES, V18, P383, DOI 10.1002/jor.1100180309; Li GA, 2005, AM J SPORT MED, V33, P102, DOI 10.1177/0363546504265577; Mahmoodian R, 2011, OSTEOARTHR CARTILAGE, V19, P1199, DOI 10.1016/j.joca.2011.07.013; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Mikic B, 2004, ANN BIOMED ENG, V32, P18, DOI 10.1023/B:ABME.0000007787.39262.a7; Mizuno S, 2005, AM J PHYSIOL-CELL PH, V288, pC329, DOI 10.1152/ajpcell.00131.2004; Moukoko D, 2010, ORTHOP TRAUMATOL-SUR, V96, P833, DOI 10.1016/j.otsr.2010.07.006; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Natoli R. M., 2002, ARTHR RHEUM, V62, P1097; Natoli RM, 2008, ANN BIOMED ENG, V36, P780, DOI 10.1007/s10439-008-9472-5; Nowlan NC, 2007, ANN NY ACAD SCI, V1101, P389, DOI 10.1196/annals.1389.003; Nowlan NC, 2010, BIRTH DEFECTS RES C, V90, P203, DOI 10.1002/bdrc.20184; Ofek G, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3127262; Ongaro A, 2011, BIOELECTROMAGNETICS, V32, P543, DOI 10.1002/bem.20663; Oswald ES, 2011, TISSUE ENG PART C-ME, V17, P1041, DOI 10.1089/ten.tec.2011.0212; PALMOSKI MJ, 1981, ARTHRITIS RHEUM, V24, P1329, DOI 10.1002/art.1780241101; PALMOSKI MJ, 1980, ARTHRITIS RHEUM, V23, P325, DOI 10.1002/art.1780230310; Park S, 2004, OSTEOARTHR CARTILAGE, V12, P65, DOI 10.1016/j.joca.2003.08.005; Pillarisetti A, 2011, CELL REPROGRAM, V13, P371, DOI 10.1089/cell.2011.0028; Roddy KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017526; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; SALTER RB, 1980, J BONE JOINT SURG AM, V62, P1232, DOI 10.2106/00004623-198062080-00002; Schinagl RM, 1997, J ORTHOPAED RES, V15, P499, DOI 10.1002/jor.1100150404; Setton LA, 1997, OSTEOARTHR CARTILAGE, V5, P1, DOI 10.1016/S1063-4584(97)80027-1; Shakibaei M, 2001, J BIOL CHEM, V276, P13289, DOI 10.1074/jbc.M010859200; Singh M, 2011, J BIOMED MATER RES A, V98A, P412, DOI 10.1002/jbm.a.33129; Smith RL, 1995, J ORTHOPAED RES, V13, P824, DOI 10.1002/jor.1100130604; Smith RL, 2000, J REHABIL RES DEV, V37, P153; Solem RC, 2011, DEV BIOL, V356, P28, DOI 10.1016/j.ydbio.2011.05.003; STEINBERG MS, 1970, J EXP ZOOL, V173, P395, DOI 10.1002/jez.1401730406; Takahashi I, 1998, J CELL SCI, V111, P2067; Takahashi K, 1998, ANN RHEUM DIS, V57, P231, DOI 10.1136/ard.57.4.231; TAYLOR DJ, 1985, BIOCHEM J, V225, P315, DOI 10.1042/bj2250315; Tew SR, 2009, AM J PHYSIOL-CELL PH, V297, pC898, DOI 10.1152/ajpcell.00571.2008; Toyoda T, 2003, ARTHRITIS RHEUM, V48, P2865, DOI 10.1002/art.11250; VENN M, 1977, ANN RHEUM DIS, V36, P121, DOI 10.1136/ard.36.2.121; Wada N, 2011, DEV DYNAM, V240, P969, DOI 10.1002/dvdy.22552; Waldman SD, 2006, OSTEOARTHR CARTILAGE, V14, P323, DOI 10.1016/j.joca.2005.10.007; Waldman SD, 2003, J ORTHOP RES, V21, P590, DOI 10.1016/S0736-0266(03)00009-3; WATERS RL, 1988, J ORTHOPAED RES, V6, P215, DOI 10.1002/jor.1100060208; Williamson AK, 2003, J ORTHOPAED RES, V21, P872, DOI 10.1016/S0736-0266(03)00030-5; Yamashita A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010998; Yao H, 2007, J BIOMECH, V40, P2071, DOI 10.1016/j.jbiomech.2006.10.001; Yellowley CE, 2002, J CELL BIOCHEM, V86, P290, DOI 10.1002/jcb.10217; Zoldan J, 2011, BIOMATERIALS, V32, P9612, DOI 10.1016/j.biomaterials.2011.09.012	98	53	55	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3614	3624		10.1096/fj.12-207241	http://dx.doi.org/10.1096/fj.12-207241			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22673579	Green Published			2022-12-28	WOS:000308391600004
J	Xiong, FX; Xiao, DL; Zhang, LB				Xiong, Fuxia; Xiao, Daliao; Zhang, Lubo			Norepinephrine causes epigenetic repression of PKC epsilon gene in rodent hearts by activating Nox1-dependent reactive oxygen species production	FASEB JOURNAL			English	Article						ischemic heart disease; sympathetic activity; oxidative stress; promoter methylation	KINASE-C-EPSILON; SMOOTH-MUSCLE-CELLS; NADPH OXIDASE; RAT HEARTS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; NAD(P)H OXIDASE; DELTA-PKC; NOX4; EXPOSURE	Heart disease is the leading cause of death in the United States. Recent studies demonstrate that fetal programming of PKC epsilon gene repression results in ischemia-sensitive phenotype in the heart. The present study tests the hypothesis that increased norepinephrine causes epigenetic repression of PKC epsilon gene in the heart via Nox1-dependent reactive oxygen species (ROS) production. Prolonged norepinephrine treatment increased ROS production in fetal rat hearts and embryonic ventricular myocyte H9c2 cells via a selective increase in Nox1 expression. Norepinephrine-induced ROS resulted in an increase in PKC epsilon promoter methylation at Egr-1 and Sp-1 binding sites, leading to PKC epsilon gene repression. N-acetylcysteine, diphenyleneiodonium, and apocynin blocked norepinephrine-induced ROS production and the promoter methylation, and also restored PKC epsilon mRNA and protein to control levels in vivo in fetal hearts and in vitro in embryonic myocyte cells. Accordingly, norepinephrine-induced ROS production, promoter methylation, and PKC epsilon gene repression were completely abrogated by knockdown of Nox1 in cardiomyocytes. These findings provide evidence of a novel interaction between elevated norepinephrine and epigenetic repression of PKC epsilon gene in the heart mediated by Nox1-dependent oxidative stress and suggest new insights of molecular mechanisms linking the heightened sympathetic activity to aberrant cardioprotection and increased ischemic vulnerability in the heart.-Xiong, F., Xiao, D., Zhang, L. Norepinephrine causes epigenetic repression of PKC epsilon gene in rodent hearts by activating Nox1-dependent reactive oxygen species production. FASEB J. 26, 2753-2763 (2012). www.fasebj.org	[Xiong, Fuxia; Xiao, Daliao; Zhang, Lubo] Loma Linda Univ, Dept Basic Sci, Div Pharmacol, Ctr Perinatal Biol,Sch Med, Loma Linda, CA 92350 USA	Loma Linda University	Zhang, LB (corresponding author), Loma Linda Univ, Dept Basic Sci, Div Pharmacol, Ctr Perinatal Biol,Sch Med, Loma Linda, CA 92350 USA.	lzhang@llu.edu	Xiao, DaLiao/AAY-1800-2020	Xiao, DaLiao/0000-0003-0147-2758; Zhang, Lubo/0000-0002-9386-8938	U.S. National Institutes of Health [HL82779, HL83966, HL110125, DA032510]; California Tobacco-Related Disease Research Program [18KT-0024]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083966, R01HL110125, R01HL082779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA032510] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Tobacco-Related Disease Research Program(University of California System); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by U.S. National Institutes of Health grants HL82779 (L.Z.), HL83966 (L.Z.), HL110125 (L.Z.), and DA032510 (D. X.), and by California Tobacco-Related Disease Research Program Award 18KT-0024 (D. X.). The authors declare no conflicts of interest.	Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70; Ago T, 2010, CIRC RES, V106, P1253, DOI 10.1161/CIRCRESAHA.109.213116; BARKER DJP, 1986, LANCET, V1, P1077; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Block K, 2009, P NATL ACAD SCI USA, V106, P14385, DOI 10.1073/pnas.0906805106; Borchi E, 2009, J CELL MOL MED, V13, P2724, DOI 10.1111/j.1582-4934.2008.00485.x; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Csont T, 2007, CARDIOVASC RES, V76, P100, DOI 10.1016/j.cardiores.2007.06.006; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Gray MO, 2004, J BIOL CHEM, V279, P3596, DOI 10.1074/jbc.M311459200; Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c; Kuroda J, 2005, GENES CELLS, V10, P1139, DOI 10.1111/j.1365-2443.2005.00907.x; Kuroda J, 2010, P NATL ACAD SCI USA, V107, P15565, DOI 10.1073/pnas.1002178107; Kuznetsov AV, 2011, ANAL BIOANAL CHEM, V400, P2383, DOI 10.1007/s00216-011-4764-2; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lawrence J, 2008, J PHARMACOL EXP THER, V324, P331, DOI 10.1124/jpet.107.132175; Lawrence J, 2011, CARDIOVASC RES, V89, P89, DOI 10.1093/cvr/cvq270; Liang CS, 2000, CIRCULATION, V102, P96, DOI 10.1161/01.CIR.102.1.96; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Looi YH, 2008, HYPERTENSION, V51, P319, DOI 10.1161/HYPERTENSIONAHA.107.101980; Malpas SC, 2010, PHYSIOL REV, V90, P513, DOI 10.1152/physrev.00007.2009; Matsuno K, 2005, CIRCULATION, V112, P2677, DOI 10.1161/CIRCULATIONAHA.105.573709; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Meyer K, 2009, J MOL CELL CARDIOL, V47, P504, DOI 10.1016/j.yjmcc.2009.06.004; Meyer KD, 2009, AM J PHYSIOL-HEART C, V296, pH1566, DOI 10.1152/ajpheart.00898.2008; Murdoch CE, 2006, CARDIOVASC RES, V71, P208, DOI 10.1016/j.cardiores.2006.03.016; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; Nisimoto Y, 2008, BIOCHEM J, V415, P57, DOI 10.1042/BJ20080300; Patterson AJ, 2012, CARDIOVASC RES, V93, P302, DOI 10.1093/cvr/cvr322; Patterson AJ, 2010, CIRC RES, V107, P365, DOI 10.1161/CIRCRESAHA.110.221259; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Van Buul JD, 2005, ANTIOXID REDOX SIGN, V7, P308, DOI 10.1089/ars.2005.7.308; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Xue Q, 2009, J PHARMACOL EXP THER, V330, P624, DOI 10.1124/jpet.109.153239; Zhang HT, 2009, BIOL REPROD, V80, P440, DOI 10.1095/biolreprod.108.072983	38	54	54	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2753	2763		10.1096/fj.11-199422	http://dx.doi.org/10.1096/fj.11-199422			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22441984	Green Published			2022-12-28	WOS:000305912500005
J	Tong, C; Morrison, A; Mattison, S; Qian, S; Bryniarski, M; Rankin, B; Wang, J; Thomas, DP; Li, J				Tong, Chao; Morrison, Alex; Mattison, Samantha; Qian, Su; Bryniarski, Mark; Rankin, Bethany; Wang, Jun; Thomas, D. Paul; Li, Ji			Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress	FASEB JOURNAL			English	Article						Sirtuin 1; sumoylation; myocardial infarction	ACTIVATED PROTEIN-KINASE; SMALL-MOLECULE ACTIVATORS; CARDIAC DYSFUNCTION; CALORIE RESTRICTION; MUTANT MICE; SUMOYLATION; DEACETYLASE; COMPLEX; AMPK; RESVERATROL	A longevity gene, sirtuin 1 (SIRT1), can attenuate age-dependent induction of left ventricular dysfunction. This study aimed to characterize the role of SIRT1 in the tolerance of aged heart to ischemic insults. Male C57BL/6 young (4-6 mo) and aged (24-26 mo) mice were used to determine the role of SIRT1 in myocardial ischemia/reperfusion (I/R) tolerance. SIRT1 localization was assessed by confocal microscopy. Immunoblotting was used to evaluate SIRT1 expression and translocation. The results demonstrated that SIRT1 is expressed predominantly as a sumoylated form in cardiomyocyte nuclei. Moreover, cardiac overexpression of desumoylase, sentrin-specific protease 2 (SENP2), significantly reduces nuclear sumoylated SIRT1 levels (P<0.05). Interestingly, I/R stress leads to desumoylation and translocation of nuclear SIRT1 into the cytoplasm in aged but not in young hearts. SIRT1 activity in ischemic young hearts was 3.2-fold higher than that seen in ischemic aged hearts, which suggests that aging causes impaired nucleocytoplasmic shuttling and activation of SIRT1 during ischemic stress. The infarct size in aged and Sirt1(+/-) knockout hearts was higher than that observed in young and Sirt1(+/+) WT littermate hearts, respectively (all P<0.05). SIRT1 agonist, SRT1720, reduced myocardial infarction in both aged and Sirt1(+/-) hearts. Therefore, impaired cardiac SIRT1 activity plays a critical role in the observed increase in susceptibility of the aged heart to I/R injury. SIRT1 agonist can restore this aging-related loss of cardioprotection.Tong, C., Morrison, A., Mattison, S., Qian, S., Bryniarski, M., Rankin, B., Wang, J., Thomas, D.P., Li, J. Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress.	[Tong, Chao; Morrison, Alex; Mattison, Samantha; Bryniarski, Mark; Rankin, Bethany; Li, Ji] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA; [Qian, Su] SUNY Buffalo, Dept Biostat, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA; [Wang, Jun] Texas Heart Inst, Basic Res Labs, Dept Stem Cell Engn, Houston, TX 77025 USA; [Thomas, D. Paul] Univ Wyoming, Div Kinesiol & Hlth, Laramie, WY 82071 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Texas Heart Institute; University of Wyoming	Li, J (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Pharmacol & Toxicol, 615 Biomed Res Bldg,3435 Main St, Buffalo, NY 14214 USA.	jli23@buffalo.edu	Tong, Chao/AAM-2225-2020	Tong, Chao/0000-0003-0828-2674	National Institute on Aging of the U.S. National Institutes of Health [AG 028163]; American Heart Association [SDG0835169N, 12GRNT11620029]; American Diabetes Association [11-BS-92]; NATIONAL INSTITUTE ON AGING [R03AG028163] Funding Source: NIH RePORTER	National Institute on Aging of the U.S. National Institutes of Health; American Heart Association(American Heart Association); American Diabetes Association(American Diabetes Association); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants awarded by the National Institute on Aging of the U.S. National Institutes of Health (AG 028163; J.L.), the American Heart Association (SDG0835169N and 12GRNT11620029; J.L.), and the American Diabetes Association (Basic Science grant 11-BS-92; J.L.).	Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Azhar G, 1999, EXP GERONTOL, V34, P699, DOI 10.1016/S0531-5565(99)00031-5; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Cai Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010729; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Fukuda I, 2009, CHEM BIOL, V16, P133, DOI 10.1016/j.chembiol.2009.01.009; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim EY, 2012, J MOL CELL CARDIOL, V52, P638, DOI 10.1016/j.yjmcc.2011.11.011; Li F, 2008, MECH AGEING DEV, V129, P515, DOI 10.1016/j.mad.2008.04.007; Lin JF, 2008, LIFE SCI, V83, P313, DOI 10.1016/j.lfs.2008.06.016; Ma H, 2010, CIRCULATION, V122, P282, DOI 10.1161/CIRCULATIONAHA.110.953208; Mathers C, 2008, GLOBAL BURDEN OF DISEASE: 2004 UPDATE, P1; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Morrison A, 2011, AM J PHYSIOL-HEART C, V301, pH895, DOI 10.1152/ajpheart.00137.2011; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131; Smith JJ, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-31; Stade K, 2002, J BIOL CHEM, V277, P49554, DOI 10.1074/jbc.M207991200; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tong C, 2010, J DIABETES, V2, P267, DOI 10.1111/j.1753-0407.2010.00088.x; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang J, 2011, J THROMB HAEMOST, V9, P1308, DOI 10.1111/j.1538-7836.2011.04331.x; Wang JY, 2010, FASEB J, V24, P2066, DOI 10.1096/fj.09-142315; Wang J, 2010, CIRC RES, V107, P19, DOI 10.1161/CIRCRESAHA.110.220491; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wei F, 2007, J BIOL CHEM, V282, P21551, DOI 10.1074/jbc.M611041200; Xie ZL, 2000, JPN J PHYSIOL, V50, P159, DOI 10.2170/jjphysiol.50.159; Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013; Yang TL, 2006, AAPS J, V8, pE632, DOI 10.1208/aapsj080472; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeung ED, 2012, PROSTATE, V72, P165, DOI 10.1002/pros.21417; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	48	96	99	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4332	4342		10.1096/fj.12-216473	http://dx.doi.org/10.1096/fj.12-216473			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23024374	Green Published			2022-12-28	WOS:000329937500002
J	Lai, SC; Nakayama, Y; Sequeira, JM; Wlodarczyk, BJ; Cabrera, RM; Finnell, RH; Bottiglieri, T; Quadros, EV				Lai, Shao-Chiang; Nakayama, Yasumi; Sequeira, Jeffrey M.; Wlodarczyk, Bogdan J.; Cabrera, Robert M.; Finnell, Richard H.; Bottiglieri, Teodoro; Quadros, Edward V.			The transcobalamin receptor knockout mouse: a model for vitamin B-12 deficiency in the central nervous system	FASEB JOURNAL			English	Article						cellular uptake; nullizygous; methylmalonic acid; homocysteine; CD320	CYSTATHIONINE BETA-SYNTHASE; LIQUID-CHROMATOGRAPHY; GENE; METABOLISM; PROTEIN; MEGALIN; BRAIN; MICE	The membrane receptor (TCblR/CD320) for transcobalamin (TC)-bound cobalamin (Cbl) facilitates the cellular uptake of Cbl. A genetically modified mouse model involving ablation of the CD320 gene was generated to study the effects on cobalamin homeostasis. The nonlethal nature of this knockout and the lack of systemic cobalamin deficiency point to other mechanisms for cellular Cbl uptake in the mouse. However, severe cobalamin depletion in the central nervous system (CNS) after birth (P<0.01) indicates that TCblR is the only receptor responsible for Cbl uptake in the CNS. Metabolic Cbl deficiency in the brain was evident from the increased methylmalonic acid (P<0.01-0.04), homocysteine (P<0.01), cystathionine (P<0.01), and the decreased S-adenosylmethionine/S-adenosyl homocysteine ratio (P<0.01). The CNS pathology of Cbl deficiency seen in humans may not manifest in this mouse model; however, it does provide a model with which to evaluate metabolic pathways and genes affected.-Lai, S.-C., Nakayama, Y., Sequeira, J. M., Wlodarczyk, B. J., Cabrera, R. M., Finnell, R. H., Bottiglieri, T., Quadros, E. V. The transcobalamin receptor knockout mouse: a model for vitamin B-12 deficiency in the central nervous system.	[Lai, Shao-Chiang; Quadros, Edward V.] Suny Downstate Med Ctr, Sch Grad Studies, Brooklyn, NY 11203 USA; [Nakayama, Yasumi; Sequeira, Jeffrey M.; Quadros, Edward V.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Quadros, Edward V.] Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA; [Wlodarczyk, Bogdan J.; Cabrera, Robert M.; Finnell, Richard H.] Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78712 USA; [Bottiglieri, Teodoro] Baylor Res Inst, Inst Metab Dis, Dallas, TX USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Austin; Baylor Scott & White Health; Baylor University Medical Center	Quadros, EV (corresponding author), Suny Downstate Med Ctr, Box 20,450 Clarkson Ave, Brooklyn, NY 11203 USA.	edward.quadros@downstate.edu	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754; Wlodarczyk, Bogdan J./0000-0001-5249-5832	U.S. National Institutes of Health [DK064732, HD067244]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD067244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK064732, R01DK064732] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants DK064732 (E.V.Q.) and HD067244 (R.H.F.). The authors are most thankful to Dr. Erland Arning for his contributions to the analysis of metabolites.	ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; AWATA S, 1995, BIOCHEM MOL BIOL INT, V35, P1331; Cannata J. J., J BIOL CHEM, V240, P3249; CHANARIN I, 1985, BLOOD, V66, P479; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; Ducros V, 2006, CLIN CHEM LAB MED, V44, P987, DOI 10.1515/CCLM.2006.178; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Fasching C, 2010, METHODS MOL BIOL, V603, P371, DOI 10.1007/978-1-60761-459-3_36; Fernandez-Roig S, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-41; Hygum K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020638; Inoue-Choi M, 2012, INT J MOL EPIDEMIOL, V3, P160; JACOB E, 1975, J LAB CLIN MED, V86, P505; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; LINDEMANS J, 1982, BIOCHIM BIOPHYS ACTA, V720, P203, DOI 10.1016/0167-4889(82)90013-1; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; Oh RC, 2003, AM FAM PHYSICIAN, V67, P979; Quadros E. V., 2000, Modern analytical methodologies in fat- and water-soluble vitamins., P313; Quadros EV, 2010, BRIT J HAEMATOL, V148, P195, DOI 10.1111/j.1365-2141.2009.07937.x; Quadros EV, 2009, BLOOD, V113, P186, DOI 10.1182/blood-2008-05-158949; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Rothenberg SP, 1997, METHOD ENZYMOL, V281, P261; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Verroust PJ, 2002, NEPHROL DIAL TRANSPL, V17, P1867, DOI 10.1093/ndt/17.11.1867; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yuan C, 2012, ANAL BIOANAL CHEM, V404, P133, DOI 10.1007/s00216-012-6099-z	25	26	28	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2468	2475		10.1096/fj.12-219055	http://dx.doi.org/10.1096/fj.12-219055			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430977	Green Published			2022-12-28	WOS:000319667600034
J	Pierzchalski, K; Yu, JS; Norman, V; Kane, MA				Pierzchalski, Keely; Yu, Jianshi; Norman, Victoria; Kane, Maureen A.			CrbpI regulates mammary retinoic acid homeostasis and the mammary microenvironment	FASEB JOURNAL			English	Article						vitamin A; breast cancer; Rbp1; retinoids	ADENOMATOUS POLYPOSIS-COLI; BINDING-PROTEIN-I; BREAST-CANCER; OXIDATIVE STRESS; LIGAND-BINDING; DIFFERENTIAL RECOGNITION; 9-CIS-RETINOIC ACID; MATRIX-HOMEOSTASIS; CELLULAR UPTAKE; HOLO-CRBP	Cellular retinol-binding protein, type I (CrbpI), encoded by retinol-binding protein, type 1 (Rbp1), is a chaperone of vitamin A (retinol) that is epigenetically silenced in similar to 25% of human breast cancers. CrbpI delivers vitamin A to enzymes for metabolism into an active metabolite, all-trans retinoic acid (atRA), where atRA is essential to cell proliferation, apoptosis, differentiation, and migration. Here, we show the effect of CrbpI loss on mammary atRA homeostasis using the Rbp1(-/-) mouse model. Rbp1(-/-) mouse mammary tissue has disrupted retinoid homeostasis that results in 40% depleted endogenous atRA. CrbpI loss and atRA depletion precede defects in atRA biosynthesis enzyme expression. Compensation by CrbpIII as a retinoid chaperone does not functionally replace CrbpI. Mammary subcellular fractions isolated from Rbp1(-/-) mice have altered retinol dehydrogenase/reductase (Rdh) enzyme activity that results in 24-42% less atRA production. Rbp1(-/-) mammary tissue has epithelial hyperplasia, stromal hypercellularity, increased collagen, and increased oxidative stress characteristic of atRA deficiency and early tissue dysfunction that precedes tumor formation. Consistent with the findings from the Rbp1(-/-) mouse, tumorigenic epithelial cells lacking CrbpI expression produce 51% less atRA. Together, these data show that CrbpI loss disrupts atRA homeostasis in mammary tissue, resulting in microenvironmental defects similar to those observed at the early stages of tumorigenesis.-Pierzchalski, K., Yu, J., Norman, V., Kane, M. A. CrbpI regulates mammary retinoic acid homeostasis and the mammary microenvironment. FASEB J. 27, 1904-1916 (2013). www.fasebj.org	[Pierzchalski, Keely; Yu, Jianshi; Kane, Maureen A.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Norman, Victoria] Bryn Mawr Sch, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore	Kane, MA (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St,PH 723N, Baltimore, MD 21201 USA.	mkane@rx.umaryland.edu		Norman, Victoria/0000-0002-7093-607X; Pierzchalski, Keely/0000-0002-2456-0382	University of Maryland, Department of Pharmaceutical Sciences New Faculty Start-Up funds	University of Maryland, Department of Pharmaceutical Sciences New Faculty Start-Up funds	This work was supported by University of Maryland, Department of Pharmaceutical Sciences New Faculty Start-Up funds. The authors are very grateful to Norbert Ghyselinck and Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Institut National de la Sante et de la Recherche Medicale, Illkirch, France) for the Rbp1<SUP>-/-</SUP> mice. The authors thank Elizabeth Smith (Center for Vascular and Inflammatory Diseases Histology Core, University of Maryland School of Medicine) for mammary histology.	Aiello EJ, 2005, CANCER EPIDEM BIOMAR, V14, P662, DOI 10.1158/1055-9965.EPI-04-0327; American Cancer Society, 2009, BREAST CANC SOURCEBO; Arapshian A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-13; Ashique AM, 2012, GENESIS, V50, P415, DOI 10.1002/dvg.22002; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; Boyd N F, 2001, Curr Oncol Rep, V3, P314, DOI 10.1007/s11912-001-0083-7; Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301; Caren H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-66; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen N, 2008, J BIOL CHEM, V283, P20841, DOI 10.1074/jbc.M802314200; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Chiu HJ, 2008, FASEB J, V22, P3878, DOI 10.1096/fj.08-112375; CHOPRA DP, 1976, J NATL CANCER I, V56, P583, DOI 10.1093/jnci/56.3.583; Cichon MA, 2010, J MAMMARY GLAND BIOL, V15, P389, DOI 10.1007/s10911-010-9195-8; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; Esteller M, 2002, CANCER RES, V62, P5902; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004; Feng L, 2010, DEV BIOL, V338, P1, DOI 10.1016/j.ydbio.2009.10.029; Fleming JM, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-46; Folli C, 2002, J BIOL CHEM, V277, P41970, DOI 10.1074/jbc.M207124200; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157; Gallego O, 2006, BIOCHEM J, V399, P101, DOI 10.1042/BJ20051988; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; HARRISON EH, 1987, J LIPID RES, V28, P973; HERR F, 1992, FASEB J, V6, pA1783; JAMISON RS, 1994, BIOCHEMISTRY-US, V33, P2873, DOI 10.1021/bi00176a017; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kane MA, 2011, MOL CELL BIOL, V31, P3277, DOI 10.1128/MCB.05516-11; Kane MA, 2011, BBA-GEN SUBJECTS, V1810, P514, DOI 10.1016/j.bbagen.2011.02.009; Kane MA, 2010, P NATL ACAD SCI USA, V107, P21884, DOI 10.1073/pnas.1008859107; Kane MA, 2010, METHODS MOL BIOL, V652, P1, DOI 10.1007/978-1-60327-325-1_1; Kane MA, 2010, FASEB J, V24, P823, DOI 10.1096/fj.09-141572; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Kupumbati TS, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-12; Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r; Lee SA, 2007, J BIOL CHEM, V282, P35621, DOI 10.1074/jbc.M706372200; Lei Z, 2003, BIOCHEMISTRY-US, V42, P4190, DOI 10.1021/bi026948i; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; Liden M, 2006, J BIOL CHEM, V281, P13001, DOI 10.1074/jbc.R500027200; Lim R, 2011, BIOCHEM BIOPH RES CO, V406, P408, DOI 10.1016/j.bbrc.2011.02.056; Lotan R, 2005, JNCI-J NATL CANCER I, V97, P3, DOI 10.1093/jnci/dji031; Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Malins DC, 2006, CELL CYCLE, V5, P1629, DOI 10.4161/cc.5.15.3098; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Markova NG, 2006, J INVEST DERMATOL, V126, P2019, DOI 10.1038/sj.jid.5700347; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048; McArthur MJ, 1999, J LIPID RES, V40, P1371; Mic FA, 2002, DEVELOPMENT, V129, P2271; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; Napoli JL, 2000, NUTR REV, V58, P230, DOI 10.1111/j.1753-4887.2000.tb01870.x; Napoli JL, 2012, BBA-MOL CELL BIOL L, V1821, P152, DOI 10.1016/j.bbalip.2011.05.004; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ONG DE, 1988, J BIOL CHEM, V263, P5789; Parmar H, 2004, ENDOCR-RELAT CANCER, V11, P437, DOI 10.1677/erc.1.00659; PEEHL DM, 1993, PROSTATE, V23, P69, DOI 10.1002/pros.2990230107; Penzes P, 1999, BIOCHEMISTRY-US, V38, P2088, DOI 10.1021/bi982228t; Piantedosi R, 2005, J BIOL CHEM, V280, P24286, DOI 10.1074/jbc.M503906200; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Rexer BN, 2001, CANCER RES, V61, P7065; RONG D, 1994, BBA-PROTEIN STRUCT M, V1208, P136, DOI 10.1016/0167-4838(94)90170-8; ROSS AC, 1982, J LIPID RES, V23, P133; Sandell LL, 2007, GENE DEV, V21, P1113, DOI 10.1101/gad.1533407; Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200; Shih MYS, 2009, J BIOL CHEM, V284, P4292, DOI 10.1074/jbc.M807503200; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Singh R, 2007, J BACTERIOL, V189, P6665, DOI 10.1128/JB.00555-07; Sun FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034525; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang C, 2011, J BIOL CHEM, V286, P6542, DOI 10.1074/jbc.M110.198382; Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570; Williams JA, 2010, J BIOL CHEM, V285, P36674, DOI 10.1074/jbc.M110.151878; Williams JA, 2009, DEV BIOL, V328, P315, DOI 10.1016/j.ydbio.2009.01.031; Zhang M, 2007, FASEB J, V21, P2886, DOI 10.1096/fj.06-7964com; Zizola CF, 2008, AM J PHYSIOL-ENDOC M, V295, pE1358, DOI 10.1152/ajpendo.90464.2008	92	26	26	3	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1904	1916		10.1096/fj.12-219410	http://dx.doi.org/10.1096/fj.12-219410			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23362116				2022-12-28	WOS:000318226100011
J	Ruud, J; Wilhelms, DB; Nilsson, A; Eskilsson, A; Tang, YJ; Strohle, P; Caesar, R; Schwaninger, M; Wunderlich, T; Backhed, F; Engblom, D; Blomqvist, A				Ruud, Johan; Wilhelms, Daniel Bjork; Nilsson, Anna; Eskilsson, Anna; Tang, Yan-Juan; Stroehle, Peter; Caesar, Robert; Schwaninger, Markus; Wunderlich, Thomas; Backhed, Fredrik; Engblom, David; Blomqvist, Anders			Inflammation- and tumor-induced anorexia and weight loss require MyD88 in hematopoietic/myeloid cells but not in brain endothelial or neural cells	FASEB JOURNAL			English	Article						lipopolysaccharide; methylcholanthrene-induced sarcoma; food intake; chimeric mice; Cre-LoxP; inducible cell-specific deletion	LIPOPOLYSACCHARIDE-INDUCED ANOREXIA; NECROSIS-FACTOR; NERVOUS-SYSTEM; CYTOKINE; GENE; EXPRESSION; RECEPTOR; MICE; CNS; CYCLOOXYGENASE-2	Loss of appetite is a hallmark of inflammatory diseases. The underlying mechanisms remain undefined, but it is known that myeloid differentiation primary response gene 88 (MyD88), an adaptor protein critical for Toll-like and IL-1 receptor family signaling, is involved. Here we addressed the question of determining in which cells the MyD88 signaling that results in anorexia development occurs by using chimeric mice and animals with cell-specific deletions. We found that MyD88-knockout mice, which are resistant to bacterial lipopolysaccharide (LPS)-induced anorexia, displayed anorexia when transplanted with wild-type bone marrow cells. Furthermore, mice with a targeted deletion of MyD88 in hematopoietic or myeloid cells were largely protected against LPS-induced anorexia and displayed attenuated weight loss, whereas mice with MyD88 deletion in hepatocytes or in neural cells or the cerebrovascular endothelium developed anorexia and weight loss of similar magnitude as wild-type mice. Furthermore, in a model for cancer-induced anorexia-cachexia, deletion of MyD88 in hematopoietic cells attenuated the anorexia and protected against body weight loss. These findings demonstrate that MyD88-dependent signaling within the brain is not required for eliciting inflammation-induced anorexia. Instead, we identify MyD88 signaling in hematopoietic/myeloid cells as a critical component for acute inflammatory-driven anorexia, as well as for chronic anorexia and weight loss associated with malignant disease.	[Ruud, Johan; Wilhelms, Daniel Bjork; Nilsson, Anna; Eskilsson, Anna; Tang, Yan-Juan; Engblom, David; Blomqvist, Anders] Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Stroehle, Peter; Wunderlich, Thomas] Univ Cologne, Inst Genet, Ctr Mol Med, Dept Mouse Genet & Metab, Cologne, Germany; [Stroehle, Peter; Wunderlich, Thomas] Max Planck Inst Neurol Res, D-50931 Cologne, Germany; [Caesar, Robert; Backhed, Fredrik] Univ Gothenburg, Dept Mol & Clin Med, Wallenberg Lab, Sahlgrenska Ctr Cardiovasc & Metab Res, Gothenburg, Sweden; [Schwaninger, Markus] Med Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany	Linkoping University; University of Cologne; Max Planck Society; University of Gothenburg; University of Lubeck	Blomqvist, A (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden.	anders.blomqvist@liu.se	Backhed, Fredrik/ABE-6613-2020; Caesar, Robert/AAX-3205-2020; Ruud, Johan/W-7407-2019; Blomqvist, Anders/K-3990-2019	Backhed, Fredrik/0000-0002-4871-8818; Blomqvist, Anders/0000-0002-6928-4473; Bjork Wilhelms, Daniel/0000-0001-6347-3970; Schwaninger, Markus/0000-0002-4510-9718; Eskilsson, Anna/0000-0002-6131-0403	Swedish Research Council [7879, 20725, 21677]; Swedish Cancer Foundation [100533]; Swedish Brain Foundation; Gustav V:s 80-ars fond; European Research Council [260820]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Swedish Brain Foundation; Gustav V:s 80-ars fond; European Research Council(European Research Council (ERC)European Commission)	The authors thank Maarit Jaarola for technical assistance. This work was supported by grants from the Swedish Research Council (7879), the Swedish Cancer Foundation (100533), the Swedish Brain Foundation, and the Gustav V:s 80-ars fond to A.B.; and the Swedish Research Council (20725 and 21677), the Swedish Brain Foundation, and the European Research Council (starting grant 260820) to D.E.	Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Chakravarty S, 2005, J NEUROSCI, V25, P1788, DOI 10.1523/jneurosci.4268-04.2005; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Eigenbrod T, 2008, J IMMUNOL, V181, P8194, DOI 10.4049/jimmunol.181.12.8194; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; Engstrom L, 2012, ENDOCRINOLOGY, V153, P4849, DOI 10.1210/en.2012-1375; Erdmann G, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-63; Gosselin D, 2008, MOL PSYCHIATR, V13, P480, DOI 10.1038/sj.mp.4002122; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Johnson PM, 2002, AM J PHYSIOL-ENDOC M, V282, pE650, DOI 10.1152/ajpendo.00388.2001; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; Kent S, 1996, NEUROSCI BIOBEHAV R, V20, P171, DOI 10.1016/0149-7634(95)00037-F; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Kranc KR, 2009, CELL STEM CELL, V5, P659, DOI 10.1016/j.stem.2009.11.001; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lang MF, 2011, J NEUROENDOCRINOL, V23, P1194, DOI 10.1111/j.1365-2826.2011.02216.x; Langhans W, 2007, P NUTR SOC, V66, P321, DOI 10.1017/S0029665107005587; Laye S, 2000, AM J PHYSIOL-REG I, V279, pR93, DOI 10.1152/ajpregu.2000.279.1.R93; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Lugarini F, 2002, AM J PHYSIOL-REG I, V283, pR862, DOI 10.1152/ajpregu.00200.2002; LUNDHOLM K, 1978, CANCER-AM CANCER SOC, V42, P453, DOI 10.1002/1097-0142(197808)42:2<453::AID-CNCR2820420212>3.0.CO;2-T; Marks DL, 2001, CANCER RES, V61, P1432; Ogimoto K, 2006, ENDOCRINOLOGY, V147, P4445, DOI 10.1210/en.2006-0465; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Ransohoff RM, 2007, NAT NEUROSCI, V10, P1507, DOI 10.1038/nn1207-1507; Ridder DA, 2011, J EXP MED, V208, P2615, DOI 10.1084/jem.20110398; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Ruud J, 2013, BRAIN BEHAV IMMUN, V29, P124, DOI 10.1016/j.bbi.2012.12.020; Ruud J, 2010, BRAIN BEHAV IMMUN, V24, P554, DOI 10.1016/j.bbi.2010.01.006; Schilte MN, 2009, PERITON DIALYSIS INT, V29, P605; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; von Meyenburg C, 2004, AM J PHYSIOL-REG I, V287, pR298, DOI 10.1152/ajpregu.00659.2003; Wang WH, 2001, CANCER RES, V61, P4707; Wisse BE, 2007, ENDOCRINOLOGY, V148, P5230, DOI 10.1210/en.2007-0394; Yamawaki Y, 2010, AM J PHYSIOL-REG I, V298, pR403, DOI 10.1152/ajpregu.00395.2009	40	22	22	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1973	1980		10.1096/fj.12-225433	http://dx.doi.org/10.1096/fj.12-225433			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23395911				2022-12-28	WOS:000318226100017
J	Iolyeva, M; Karaman, S; Willrodt, AH; Weingartner, S; Vigl, B; Halin, C				Iolyeva, Maria; Karaman, Sinem; Willrodt, Ann-Helen; Weingartner, Stephanie; Vigl, Benjamin; Halin, Cornelia			Novel role for ALCAM in lymphatic network formation and function	FASEB JOURNAL			English	Article						adhesion molecule; lymphangiogenesis; dendritic; cell migration	CELL-ADHESION MOLECULE; ANGIOGENESIS; TRAFFICKING; VASCULATURE; MIGRATION; JUNCTIONS; CD6; LYMPHANGIOGENESIS; ANGIOPOIETIN-2; IDENTIFICATION	Adhesion molecules play an important role in vascular biology because they mediate vascular stability, permeability, and leukocyte trafficking to and from tissues. Performing microarray analyses, we have recently identified activated leukocyte cell adhesion molecule (ALCAM) as an inflammation-induced gene in lymphatic endothelial cells (LECs). ALCAM belongs to the immunoglobulin superfamily and engages in homophilic as well as heterophilic interactions. In this study, we found ALCAM to be expressed at the protein level in human and murine lymphatic and blood vascular endothelial cells in vitro and in the vasculature of human and murine tissues in vivo. Functional in vitro experiments revealed that ALCAM mediates adhesive interactions, migration, and tube formation in LECs, suggesting a role for ALCAM in lymphatic vessel (LV) stability and in lymphangiogenesis. Furthermore, ALCAM supported dendritic cell (DC) adhesion to lymphatic endothelium. In agreement with these findings, experiments performed in ALCAM(-/-) mice detected reduced LEC numbers in various tissues and defects in the formation of an organized LV network. Moreover, DC migration from lung to draining lymph nodes was compromised in ALCAM(-/-) mice. Collectively, our data reveal a novel role for ALCAM in stabilizing LEC-LEC interactions and in the organization and function of the LV network.-Iolyeva, M., Karaman, S., Willrodt, A.-H., Weingartner, S., Vigl, B., Halin, C. Novel role for ALCAM in lymphatic network formation and function. FASEB J. 27, 978-990 (2013). www.fasebj.org	[Iolyeva, Maria; Karaman, Sinem; Willrodt, Ann-Helen; Weingartner, Stephanie; Vigl, Benjamin; Halin, Cornelia] ETH, Inst Pharmaceut Sci, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Halin, C (corresponding author), ETH, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H413, CH-8093 Zurich, Switzerland.	cornelia.halin@pharma.ethz.ch	Karaman, Sinem/C-4428-2017	Karaman, Sinem/0000-0002-0719-1773; Halin, Cornelia/0000-0002-7899-2850; Weingartner, Sebastian/0000-0002-0739-6306	Swiss National Fund [310030_138330]; Prof. Dr. Max Cloetta Foundation; ETH Zurich [0-20566_09]	Swiss National Fund(Swiss National Science Foundation (SNSF)); Prof. Dr. Max Cloetta Foundation; ETH Zurich(ETH Zurich)	The authors thank Csaba Balazs (ETH Zurich) for developing the ImageJ-based script used for image quantification and Simone Haener (ETH Zurich) for excellent technical support. Furthermore, the authors thank Joshua Weiner (University of Iowa, Iowa City, IA, USA) for providing tissue samples of ALCAM<SUP>-/-</SUP> and control mice in the beginning of the project. C.H, gratefully acknowledges financial support from the Swiss National Fund (grant 310030_138330), the Prof. Dr. Max Cloetta Foundation, and ETH Zurich (project grant 0-20566_09). M.I. designed research, performed research, analyzed data, and wrote the paper; S.K., A.H.W., and S.W. performed research and analyzed and discussed data; C.H. designed research, analyzed data, and wrote the paper. The authors declare no conflicts of interest.	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Bazigou E, 2011, J CLIN INVEST, V121, P2984, DOI 10.1172/JCI58050; Buhusi M, 2009, J NEUROSCI, V29, P15630, DOI 10.1523/JNEUROSCI.2215-09.2009; Delgado VMC, 2011, FASEB J, V25, P242, DOI 10.1096/fj.09-144907; Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551; Cueni LN, 2009, EXP CELL RES, V315, P1715, DOI 10.1016/j.yexcr.2009.02.021; Dellinger M, 2008, DEV BIOL, V319, P309, DOI 10.1016/j.ydbio.2008.04.024; Forster R, 2012, TRENDS IMMUNOL, V33, P271, DOI 10.1016/j.it.2012.02.007; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Garmy-Susini B, 2010, CANCER RES, V70, P3042, DOI 10.1158/0008-5472.CAN-09-3761; Garrido-Urbani S, 2008, BIOCHEM SOC T, V36, P203, DOI 10.1042/BST0360203; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Halin C, 2008, METHOD ENZYMOL, V445, P1, DOI 10.1016/S0076-6879(08)03001-2; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Ikeda K, 2004, J BIOL CHEM, V279, P55315, DOI 10.1074/jbc.M407776200; Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200; Jakubzick C, 2010, METHODS MOL BIOL, V595, P371, DOI 10.1007/978-1-60761-421-0_24; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Maddaluno L, 2009, J EXP MED, V206, P623, DOI 10.1084/jem.20081211; Makinen T, 2005, GENE DEV, V19, P397, DOI 10.1101/gad.330105; Masedunskas A, 2006, FEBS LETT, V580, P2637, DOI 10.1016/j.febslet.2006.04.013; Mirza M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037523; Ofori-Acquah SF, 2008, MICROVASC RES, V75, P391, DOI 10.1016/j.mvr.2007.10.006; Ofori-Acquah SF, 2008, TRANSL RES, V151, P122, DOI 10.1016/j.trsl.2007.09.006; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; Pfeiffer F, 2008, EUR J IMMUNOL, V38, P2142, DOI 10.1002/eji.200838140; Pflicke H, 2009, J EXP MED, V206, P2925, DOI 10.1084/jem.20091739; Schliemann C, 2010, BLOOD, V115, P736, DOI 10.1182/blood-2009-08-239004; Schulte-Merker S, 2011, J CELL BIOL, V193, P607, DOI 10.1083/jcb.201012094; Singer NG, 2002, INT IMMUNOL, V14, P585, DOI 10.1093/intimm/dxf025; Swart GWM, 2005, CANCER METAST REV, V24, P223, DOI 10.1007/s10555-005-1573-0; van Kempen LCLT, 2001, J BIOL CHEM, V276, P25783, DOI 10.1074/jbc.M011272200; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7; Vestweber D, 2012, ANN NY ACAD SCI, V1257, P184, DOI 10.1111/j.1749-6632.2012.06558.x; Vigl B, 2011, BLOOD, V118, P205, DOI 10.1182/blood-2010-12-326447; Vigl B, 2009, EXP CELL RES, V315, P336, DOI 10.1016/j.yexcr.2008.10.020; Weidle Ulrich H., 2010, Cancer Genomics & Proteomics, V7, P231; Weiner JA, 2004, MOL CELL NEUROSCI, V27, P59, DOI 10.1016/j.mcn.2004.06.005; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Zimmerman AW, 2006, BLOOD, V107, P3212, DOI 10.1182/blood-2005-09-3881	43	36	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					978	990		10.1096/fj.12-217844	http://dx.doi.org/10.1096/fj.12-217844			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23169771				2022-12-28	WOS:000315585200013
J	Li, XW; Liu, XY; Cui, L; Brunson, C; Zhao, W; Bhat, NR; Zhang, N; Wen, XJ				Li, Xiaowei; Liu, Xiaoyan; Cui, Lin; Brunson, Christopher; Zhao, Wen; Bhat, Narayan R.; Zhang, Ning; Wen, Xuejun			Engineering an in situ crosslinkable hydrogel for enhanced remyelination	FASEB JOURNAL			English	Article						biomaterials; oligodendrocyte progenitor cells; transplantation; spinal cord regeneration	SPINAL-CORD-INJURY; OLIGODENDROCYTE PRECURSOR CELLS; MULTIPLE-SCLEROSIS; STEM-CELLS; MYELIN REGENERATION; NEURAL PRECURSORS; PROGENITOR CELLS; VIRAL MODEL; DIFFERENTIATION; DEMYELINATION	Remyelination has to occur to fully regenerate injured spinal cords or brain tissues. A growing body of evidence has suggested that exogenous cell transplantation is one promising strategy to promote remyelination. However, direct injection of neural stem cells or oligodendrocyte progenitor cells (OPCs) to the lesion site may not be an optimal therapeutic strategy due to poor viability and functionality of transplanted cells resulted from the local hostile tissue environment. The overall objective of this study was to engineer an injectable biocompatible hydrogel system as a supportive niche to provide a regeneration permissive microenvironment for transplanted OPCs to survive, functionally differentiate, and remyelinate central nervous system (CNS) lesions. A highly biocompatible hydrogel, based on thiol-functionalized hyaluronic acid and thiol-functionalized gelatin, which can be crosslinked by poly-(ethylene glycol) diacrylate (PEGDA), was used. These hydrogels were optimized first regarding cell adhesive properties and mechanical properties to best support the growth properties of OPCs in culture. Transplanted OPCs with the hydrogels optimized in vitro exhibited enhanced survival and oligodendrogenic differentiation and were able to remyelinate demyelinated axons inside ethidium bromide (EB) demyelination lesion in adult spinal cord. This study provides a new possible therapeutic approach to treat CNS injuries in which cell therapies may be essential.-Li, X., Liu, X., Cui, L., Brunson, C., Zhao, W., Bhat, N. R., Zhang, N., Wen, X. Engineering an in situ crosslinkable hydrogel for enhanced remyelination. FASEB J. 27, 1127-1136 (2013). www.fasebj.org	[Li, Xiaowei; Liu, Xiaoyan; Cui, Lin; Zhao, Wen; Zhang, Ning; Wen, Xuejun] Clemson Univ, Dept Bioengn, Clemson MUSC Bioengn Program, Charleston, SC 29425 USA; [Brunson, Christopher] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; [Zhao, Wen] Beijing Aerosp Gen Hosp, Dept Orthoped Surg, Beijing, Peoples R China; [Bhat, Narayan R.; Wen, Xuejun] Med Univ S Carolina, Inst Neurosci, Charleston, SC 29425 USA; [Zhang, Ning] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Wen, Xuejun] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Wen, Xuejun] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA; [Wen, Xuejun] Tongji Univ, Inst Adv Mat & Nano Biomed iNANO, Shanghai 200092, Peoples R China	Clemson University; Medical University of South Carolina; Stanford University; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Tongji University	Zhang, N (corresponding author), Clemson Univ, Dept Bioengn, Clemson MUSC Bioengn Program, 68 President St,BEB 313, Charleston, SC 29425 USA.	nzhang@clemson.edu; xjwen@clemson.edu	Li, Xiaowei/E-4973-2014	Li, Xiaowei/0000-0001-6237-599X	U.S. National Institutes of Health [R01-NS050243]; National Science Foundation [0748129]; American Heart Association [10PRE4280017]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050243] Funding Source: NIH RePORTER; Directorate For Engineering [1346387] Funding Source: National Science Foundation	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Directorate For Engineering(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported by U.S. National Institutes of Health grant R01-NS050243, National Science Foundation grant 0748129, and American Heart Association grant 10PRE4280017.	Aharonowiz M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003145; Ben-Hur T, 2008, ANN NY ACAD SCI, V1142, P218, DOI 10.1196/annals.1444.014; Boudou T, 2006, BIORHEOLOGY, V43, P721; Cao QL, 2010, J NEUROSCI, V30, P2989, DOI 10.1523/JNEUROSCI.3174-09.2010; Carbajal KS, 2011, GLIA, V59, P1813, DOI 10.1002/glia.21225; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Cushing MC, 2007, SCIENCE, V316, P1133, DOI 10.1126/science.1140171; Deverman BE, 2012, J NEUROSCI, V32, P2100, DOI 10.1523/JNEUROSCI.3803-11.2012; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Einstein O, 2009, J NEUROSCI, V29, P15694, DOI 10.1523/JNEUROSCI.3364-09.2009; Ghosh K, 2005, BIOMACROMOLECULES, V6, P2857, DOI 10.1021/bm050361c; Gordon D, 2010, J NEUROPATH EXP NEUR, V69, P1087, DOI 10.1097/NEN.0b013e3181f97392; Habib M, 2011, BIOMATERIALS, V32, P7514, DOI 10.1016/j.biomaterials.2011.06.049; Hur EM, 2011, P NATL ACAD SCI USA, V108, P5057, DOI 10.1073/pnas.1011258108; Jadasz JJ, 2012, CELL TISSUE RES, V349, P331, DOI 10.1007/s00441-012-1331-x; Kotter MR, 2011, BRAIN, V134, P1882, DOI 10.1093/brain/awr014; Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096; Liu ZQ, 2012, BIOMATERIALS, V33, P3093, DOI 10.1016/j.biomaterials.2011.12.044; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mahoney MJ, 2006, BIOMATERIALS, V27, P2265, DOI 10.1016/j.biomaterials.2005.11.007; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; Marklein RA, 2010, ADV MATER, V22, P175, DOI 10.1002/adma.200901055; Park H, 2009, J BIOMED MATER RES A, V88A, P889, DOI 10.1002/jbm.a.31948; Sasaki M, 2011, EXP NEUROL, V229, P88, DOI 10.1016/j.expneurol.2011.01.010; Sirn FJ, 2006, ANN NEUROL, V59, P763, DOI 10.1002/ana.20812; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; Tsuji O, 2010, P NATL ACAD SCI USA, V107, P12704, DOI 10.1073/pnas.0910106107; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Uemura M, 2010, J NEUROSCI RES, V88, P542, DOI 10.1002/jnr.22223; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L; Yang JX, 2009, J NEUROL SCI, V276, P1, DOI 10.1016/j.jns.2008.08.020; Zawadzka M, 2007, CURR OPIN NEUROL, V20, P294, DOI 10.1097/WCO.0b013e32813aee7f; Zhong J, 2010, NEUROREHAB NEURAL RE, V24, P636, DOI 10.1177/1545968310361958	36	36	38	5	87	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1127	1136		10.1096/fj.12-211151	http://dx.doi.org/10.1096/fj.12-211151			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23239823	Green Published			2022-12-28	WOS:000315585200026
J	Kraft, AW; Hu, XY; Yoon, H; Yan, P; Xiao, QL; Wang, Y; Gil, SC; Brown, J; Wilhelmsson, U; Restivo, JL; Cirrito, JR; Holtzman, DM; Kim, J; Pekny, M; Lee, JM				Kraft, Andrew W.; Hu, Xiaoyan; Yoon, Hyejin; Yan, Ping; Xiao, Qingli; Wang, Yan; Gil, So Chon; Brown, Jennifer; Wilhelmsson, Ulrika; Restivo, Jessica L.; Cirrito, John R.; Holtzman, David M.; Kim, Jungsu; Pekny, Milos; Lee, Jin-Moo			Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice	FASEB JOURNAL			English	Article						Alzheimer's disease; GFAP; astrogliosis; intermediate filaments; vimentin	FIBRILLARY ACIDIC PROTEIN; AMYLOID-BETA-PROTEIN; INTERMEDIATE-FILAMENTS; ALZHEIMERS-DISEASE; A-BETA; REACTIVE ASTROCYTES; MICROGLIAL CELLS; DRIVING-FORCE; MOUSE MODEL; IN-VITRO	The accumulation of aggregated amyloid-beta (A beta) in amyloid plaques is a neuropathological hallmark of Alzheimer's disease (AD). Reactive astrocytes are intimately associated with amyloid plaques; however, their role in AD pathogenesis is unclear. We deleted the genes encoding two intermediate filament proteins required for astrocyte activation-glial fibrillary acid protein (Gfap) and vimentin (Vim)-in transgenic mice expressing mutant human amyloid precursor protein and presenilin-1 (APP/PS1). The gene deletions increased amyloid plaque load: APP/PS1 Gfap(-/-) Vim(-/-) mice had twice the plaque load of APP/PS1 Gfap(+/+) Vim(+/+) mice at 8 and 12 mo of age. APP expression and soluble and interstitial fluid A beta levels were unchanged, suggesting that the deletions had no effect on APP processing or A beta generation. Astrocyte morphology was markedly altered by the deletions: wild-type astrocytes had hypertrophied processes that surrounded and infiltrated plaques, whereas Gfap(-/-) Vim(-/-) astrocytes had little process hypertrophy and lacked contact with adjacent plaques. Moreover, Gfap and Vim gene deletion resulted in a marked increase in dystrophic neurites (2- to 3-fold higher than APP/PS1 Gfap(+/+) Vim(+/+) mice), even after normalization for amyloid load. These results suggest that astrocyte activation limits plaque growth and attenuates plaque-related dystrophic neurites. These activities may require intimate contact between astrocyte and plaque.-Kraft, A. W., Hu, X., Yoon, H., Yan, P., Xiao, Q., Wang, Y., Gil, S. C., Brown, J., Wilhelmsson, U., Restivo, J. L., Cirrito, J. R., Holtzman, D. M., Kim, J., Pekny, M., Lee, J.-M. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 27, 187-198 (2013). www.fasebj.org	[Kraft, Andrew W.; Hu, Xiaoyan; Yoon, Hyejin; Yan, Ping; Xiao, Qingli; Wang, Yan; Gil, So Chon; Brown, Jennifer; Restivo, Jessica L.; Cirrito, John R.; Holtzman, David M.; Kim, Jungsu; Lee, Jin-Moo] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Hope Ctr Neurol Disorders,Dept Neurol, St Louis, MO 63124 USA; [Wilhelmsson, Ulrika; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden	Washington University (WUSTL); University of Gothenburg	Lee, JM (corresponding author), Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Hope Ctr Neurol Disorders,Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63124 USA.	leejm@wustl.edu	Yoon, Hyejin/AAI-8641-2021; Lee, Jin-Moo/K-2024-2015; Kim, Jungsu/F-2457-2012	Lee, Jin-Moo/0000-0002-3979-0906; Kim, Jungsu/0000-0002-6931-8581; Wilhelmsson, Ulrika/0000-0003-3227-2687	U.S. National Institutes of Health [R01 NS48283, R01 NS67905, P01 NS32636, R37 AG13956, P30NS69329]; Swedish Medical Research Council [11548]; ALF Goteborg; Sten A. Olsson Foundation for Research and Culture; Nano-Net COST Action [BM1002]; EU [237956, 279017]; Frimurare Foundation; Wilhelm and Martina Lundgren's Research Foundation; Hjarnfonden; AFA Insurance; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS032636, R01NS048283, P30NS069329, R01NS067905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG013956] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); ALF Goteborg; Sten A. Olsson Foundation for Research and Culture; Nano-Net COST Action(European Cooperation in Science and Technology (COST)); EU(European Commission); Frimurare Foundation; Wilhelm and Martina Lundgren's Research Foundation; Hjarnfonden; AFA Insurance; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Alec Zhu for help with PCR, histology, and writing of the manuscript. This work was supported by U.S. National Institutes of Health grants R01 NS48283, R01 NS67905, and P01 NS32636 (to J.-M. L.); R37 AG13956 (to D. M. H.); and P30NS69329 (to J. K.); and grants from the Swedish Medical Research Council (11548), ALF Goteborg, Sten A. Olsson Foundation for Research and Culture, Nano-Net COST Action (BM1002), the EU FP 7 Programs EduGlia (237956) and TargetBraIn (279017), the Frimurare Foundation, Wilhelm and Martina Lundgren's Research Foundation, Hjarnfonden, and AFA Insurance (to M. P.).	Allen NJ, 2009, NATURE, V457, P675, DOI 10.1038/457675a; Askarova S, 2011, NEUROSCIENCE, V199, P375, DOI 10.1016/j.neuroscience.2011.09.038; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Bolmont T, 2008, J NEUROSCI, V28, P4283, DOI 10.1523/JNEUROSCI.4814-07.2008; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Burbach GJ, 2004, J NEUROSCI, V24, P2421, DOI 10.1523/JNEUROSCI.5599-03.2004; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chakrabarty P, 2010, J IMMUNOL, V184, P5333, DOI 10.4049/jimmunol.0903382; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Cirrito JR, 2003, J NEUROSCI, V23, P8844; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DiCarlo G, 2001, NEUROBIOL AGING, V22, P1007, DOI 10.1016/S0197-4580(01)00292-5; Ding M, 1998, MOL BRAIN RES, V62, P77, DOI 10.1016/S0169-328X(98)00240-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Grimwood S, 2005, NEUROPHARMACOLOGY, V48, P1002, DOI 10.1016/j.neuropharm.2005.01.016; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hu XY, 2007, EMBO J, V26, P2755, DOI 10.1038/sj.emboj.7601707; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Jing RF, 2007, J CELL SCI, V120, P1267, DOI 10.1242/jcs.03423; Kato S, 1998, PATHOL INT, V48, P332, DOI 10.1111/j.1440-1827.1998.tb03915.x; Kim J, 2009, NEURON, V64, P632, DOI 10.1016/j.neuron.2009.11.013; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Lepekhin EA, 2001, J NEUROCHEM, V79, P617, DOI 10.1046/j.1471-4159.2001.00595.x; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Lu YB, 2011, FASEB J, V25, P624, DOI 10.1096/fj.10-163790; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Mandrekar S, 2009, J NEUROSCI, V29, P4252, DOI 10.1523/JNEUROSCI.5572-08.2009; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398; Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2007, EXP CELL RES, V313, P2244, DOI 10.1016/j.yexcr.2007.04.023; Potokar M, 2007, TRAFFIC, V8, P12, DOI 10.1111/j.1600-0854.2006.00509.x; Potokar M, 2010, GLIA, V58, P1208, DOI 10.1002/glia.21000; Szapacs ME, 2004, NEUROBIOL DIS, V16, P572, DOI 10.1016/j.nbd.2004.04.010; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Vardjan N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-144; Wegiel J, 2001, NEUROBIOL AGING, V22, P49, DOI 10.1016/S0197-4580(00)00181-0; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Weisman D, 2006, VITAM HORM, V74, P505, DOI 10.1016/S0083-6729(06)74020-1; Widestrand A, 2007, STEM CELLS, V25, P2619, DOI 10.1634/stemcells.2007-0122; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Wilhelmsson U, 2012, STEM CELLS, V30, P2320, DOI 10.1002/stem.1196; WISNIEWSKI HM, 1991, NEUROBIOL AGING, V12, P593, DOI 10.1016/0197-4580(91)90091-W; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamaguchi H, 1998, ACTA NEUROPATHOL, V95, P217, DOI 10.1007/s004010050790; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; Yin KJ, 2006, J NEUROSCI, V26, P10939, DOI 10.1523/JNEUROSCI.2085-06.2006; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	65	205	211	0	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					187	198		10.1096/fj.12-208660	http://dx.doi.org/10.1096/fj.12-208660			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038755	Green Published			2022-12-28	WOS:000313103200018
J	Ayroldi, E; Cannarile, L; Migliorati, G; Nocentini, G; Delfino, DV; Riccardi, C				Ayroldi, Emira; Cannarile, Lorenza; Migliorati, Graziella; Nocentini, Giuseppe; Delfino, Domenico V.; Riccardi, Carlo			Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways	FASEB JOURNAL			English	Review						gene regulation; inhibition of Ras/ERK pathways; GILZ; MKP-1; Anx-1	INDUCED LEUCINE-ZIPPER; NF-KAPPA-B; DUAL-SPECIFICITY PHOSPHATASE-1; ACTIVATED PROTEIN-KINASES; LYMPHOBLASTIC-LEUKEMIA CELLS; HORMONE-INDUCED GENE; TAT-ANNEXIN PROTEIN; ADAPTER PROTEIN; P38 MAPK; TRANSDUCTION PATHWAYS	Glucocorticoids (GCs) are steroid hormones produced by the adrenal gland and regulated by the hypothalamus-pituitary-adrenal axis. GCs mediate effects that mostly result in transcriptional regulation of glucocorticoid receptor target genes. Mitogen-activated protein kinases (MAPKs) comprise a family of signaling proteins that convert extracellular stimuli into the activation of intracellular transduction pathways via phosphorylation of a cascade of substrates. They modulate a variety of physiological cell processes, such as proliferation, apoptosis, and development. However, when MAPKs are improperly activated by proinflammatory and/or extracellular stress stimuli, they contribute to the regulation of proinflammatory transcription factors, thus perpetuating activation of the inflammatory cascade. One of the mechanisms by which GCs exert their anti-inflammatory effects is negative interference with MAPK signaling pathways. Several functional interactions between GCs and MAPK signaling have been discovered and studied. Some of these interactions involve the GC-mediated up-regulation of proteins that in turn interfere with the activation of MAPK, such as glucocorticoid-induced-leucine zipper, MAPK phosphatase-1, and annexin-1. Other mechanisms include activated GR directly interacting with components of the MAPK pathway and negatively regulating their activation. The multiple interactions between GCs and MAPK pathways and their potential biological relevance in mediating the anti-inflammatory effects of GCs are reviewed.-Ayroldi, E., Cannarile, L., Migliorati, G., Nocentini, G., Delfino, D. V., Riccardi, C. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J. 26, 4805-4820 (2012). www.fasebj.org	[Ayroldi, Emira; Cannarile, Lorenza; Migliorati, Graziella; Nocentini, Giuseppe; Delfino, Domenico V.; Riccardi, Carlo] Univ Perugia, Dept Clin & Expt Med, Pharmacol Sect, I-06122 Perugia, Italy	University of Perugia	Ayroldi, E (corresponding author), Univ Perugia, Dept Clin & Expt Med, Pharmacol Sect, Via Giochetto, I-06122 Perugia, Italy.	ayroldi@unipg.it	Nocentini, Giuseppe/B-9412-2013; Riccardi, Carlo/N-4610-2014; Delfino, Domenico/AAB-5124-2020; Nocentini, Giuseppe/GZB-0146-2022	Nocentini, Giuseppe/0000-0002-5209-0488; Riccardi, Carlo/0000-0001-9257-3997; Ayroldi, Emira/0000-0002-9073-7297; MIGLIORATI, Graziella/0000-0002-9475-6399	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy; Fondo per gli Investimenti della Ricerca di Base (FIRB) (Italy) [RBPR05NWWC]	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy(Fondazione AIRC per la ricerca sul cancro); Fondo per gli Investimenti della Ricerca di Base (FIRB) (Italy)(Ministry of Education, Universities and Research (MIUR))	This work is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy, and by a network Fondo per gli Investimenti della Ricerca di Base (FIRB) grant, protocol RBPR05NWWC "CHEM-PROFARMA-NET" (Italy).	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Abramson J, 2002, IMMUNOL LETT, V82, P23, DOI 10.1016/S0165-2478(02)00013-5; Aeberli D, 2006, FEBS LETT, V580, P974, DOI 10.1016/j.febslet.2006.01.027; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alldridge LC, 2003, EXP CELL RES, V290, P93, DOI 10.1016/S0014-4827(03)00310-0; Alldridge LC, 1999, J BIOL CHEM, V274, P37620, DOI 10.1074/jbc.274.53.37620; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003-0213; Beaulieu E, 2010, ARTHRITIS RHEUM-US, V62, P2651, DOI 10.1002/art.27566; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bruscoli S, 2006, EUR J PHARMACOL, V529, P63, DOI 10.1016/j.ejphar.2005.10.053; Bruscoli S, 2012, J BIOL CHEM, V287, P1242, DOI 10.1074/jbc.M111.316372; Bruscoli S, 2010, J BIOL CHEM, V285, P10385, DOI 10.1074/jbc.M109.070136; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cannarile L, 2006, BLOOD, V107, P1039, DOI 10.1182/blood-2005-05-2183; Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798; Cannarile L, 2009, GASTROENTEROLOGY, V136, P530, DOI 10.1053/j.gastro.2008.09.024; Cavet ME, 2010, MOL VIS, V16, P1791; Chen LY, 2009, J IMMUNOL, V182, P2518, DOI 10.4049/jimmunol.0713933; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013; Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471-4892(03)00073-0; Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood-2005-07-2760; Conradie MM, 2011, CALCIFIED TISSUE INT, V89, P221, DOI 10.1007/s00223-011-9509-x; Crawford TQ, 2011, J VIROL, V85, P12343, DOI 10.1128/JVI.05682-11; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; D'Acquisto F, 2008, BRIT J PHARMACOL, V155, P152, DOI 10.1038/bjp.2008.252; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Delfino DV, 2011, CELL DEATH DIFFER, V18, P183, DOI 10.1038/cdd.2010.86; Delfino DV, 2006, INT IMMUNOPHARMACOL, V6, P1126, DOI 10.1016/j.intimp.2006.02.001; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Denayer E, 2008, J MED GENET, V45, P695, DOI 10.1136/jmg.2007.055772; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Marco B, 2007, NUCLEIC ACIDS RES, V35, P517, DOI 10.1093/nar/gkl1080; Esposito E, 2012, NEUROTHERAPEUTICS, V9, P210, DOI 10.1007/s13311-011-0084-7; Fan WJ, 2009, LIFE SCI, V84, P838, DOI 10.1016/j.lfs.2009.03.014; Ferlazzo V, 2003, INT IMMUNOPHARMACOL, V3, P1363, DOI 10.1016/S1567-5769(03)00133-4; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Franks AL, 2012, ANTICANCER RES, V32, P1119; Furst R, 2008, ENDOCRINOLOGY, V149, P3635, DOI 10.1210/en.2007-1524; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Gorelik G, 2010, AUTOIMMUNITY, V43, P17, DOI 10.3109/08916930903374832; Gravallese EM, 2000, ARTHRITIS RHEUM-US, V43, P2143, DOI 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.3.CO;2-J; Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472; Grugan KD, 2008, J STEROID BIOCHEM, V110, P244, DOI 10.1016/j.jsbmb.2007.11.003; Gupta V, 2007, INVEST OPHTH VIS SCI, V48, P1724, DOI 10.1167/iovs.06-0889; Gutierrez-Mecinas M, 2011, P NATL ACAD SCI USA, V108, P13806, DOI 10.1073/pnas.1104383108; He LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031717; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Hiragun T, 2005, MOL PHARMACOL, V67, P598, DOI 10.1124/mol.104.008607; Hiragun T, 2006, J IMMUNOL, V177, P2047, DOI 10.4049/jimmunol.177.4.2047; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Horsch K, 2007, MOL ENDOCRINOL, V21, P2929, DOI 10.1210/me.2007-0153; Huang J, 2011, J CHEMOTHERAPY, V23, P221, DOI 10.1179/joc.2011.23.4.221; Huang PY, 2010, PROTEIN CELL, V1, P218, DOI 10.1007/s13238-010-0019-9; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Hulley PA, 2002, BONE, V31, P220, DOI 10.1016/S8756-3282(02)00807-4; Huo YQ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-49; Joha S, 2012, ONCOGENE, V31, P1419, DOI 10.1038/onc.2011.328; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kang BN, 2008, AM J PHYSIOL-LUNG C, V295, pL186, DOI 10.1152/ajplung.00352.2007; Kang YJ, 2008, J IMMUNOL, V180, P5075, DOI 10.4049/jimmunol.180.7.5075; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Keeton AB, 2004, BBA-GENE STRUCT EXPR, V1679, P248, DOI 10.1016/j.bbaexp.2004.07.002; Kharwanlang B, 2011, INDIAN J BIOCHEM BIO, V48, P236; King EM, 2009, J BIOL CHEM, V284, P26803, DOI 10.1074/jbc.M109.028381; Kofler R, 2000, HISTOCHEM CELL BIOL, V114, P1; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Komatsu K., 2008, BIOCHEM BIOPH RES CO, V377, P763; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Krens SFG, 2006, FEBS LETT, V580, P4984, DOI 10.1016/j.febslet.2006.08.025; Krzysiek R, 2010, TRANSPL P, V42, P3331, DOI 10.1016/j.transproceed.2010.07.038; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lang R, 2006, J IMMUNOL, V177, P7497, DOI 10.4049/jimmunol.177.11.7497; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee SM, 2011, CELL IMMUNOL, V271, P157, DOI 10.1016/j.cellimm.2011.06.019; Lee SH, 2012, BIOCHEM BIOPH RES CO, V417, P1024, DOI 10.1016/j.bbrc.2011.12.084; Lee SH, 2011, BMB REP, V44, P484, DOI 10.5483/BMBRep.2011.44.7.484; Leis H, 2004, MOL ENDOCRINOL, V18, P303, DOI 10.1210/me.2003-0350; Li Jian-Ping, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P391; Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281-003-0125-3; Lin YM, 2008, EUR J PHARMACOL, V593, P1, DOI 10.1016/j.ejphar.2008.06.111; Liu XW, 2012, NAT IMMUNOL, V13, P457, DOI 10.1038/ni.2258; Lowenberg M, 2007, TRENDS MOL MED, V13, P158, DOI 10.1016/j.molmed.2007.02.001; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Maier JV, 2007, MOL ENDOCRINOL, V21, P2663, DOI 10.1210/me.2007-0067; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Mitsuyama K, 2006, INT J MOL MED, V17, P449; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; O'Reilly LA, 2009, J IMMUNOL, V183, P261, DOI 10.4049/jimmunol.0803853; Osborne JK, 2012, CELL RES, V22, P14, DOI 10.1038/cr.2011.193; Palma Linda, 2011, BMC Pharmacology, V11, P8, DOI 10.1186/1471-2210-11-8; Pan WW, 2010, J BIOL CHEM, V285, P34348, DOI 10.1074/jbc.M110.109165; PARENTE L, 1994, TRENDS PHARMACOL SCI, V15, P362, DOI 10.1016/0165-6147(94)90154-6; Park SK, 2009, MOL IMMUNOL, V46, P2133, DOI 10.1016/j.molimm.2009.03.013; Park SK, 2009, MOL IMMUNOL, V46, P492, DOI 10.1016/j.molimm.2008.10.011; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Piette C, 2009, J BIOL CHEM, V284, P32483, DOI 10.1074/jbc.M109.014589; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Pozzesi N, 2007, J CHEMOTHERAPY, V19, P562, DOI 10.1179/joc.2007.19.5.562; Quante T, 2008, AM J RESP CELL MOL, V39, P208, DOI 10.1165/rcmb.2007-0014OC; Redjimi N, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-83; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Riccardi C, 2001, ADV EXP MED BIOL, V495, P31; Riccardi C, 2000, THERAPIE, V55, P165; Riccardi C, 1999, CELL DEATH DIFFER, V6, P1182, DOI 10.1038/sj.cdd.4400609; Romero Y, 2012, SEX DEV, V6, P169, DOI 10.1159/000338415; Roviezzo F, 2002, J PHYSIOL PHARMACOL, V53, P541; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shipp LE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013754; Simons SS, 2008, BIOESSAYS, V30, P744, DOI 10.1002/bies.20792; SOLITO E, 1994, BRIT J PHARMACOL, V112, P347, DOI 10.1111/j.1476-5381.1994.tb13075.x; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Streetz K, 2001, J IMMUNOL, V167, P514, DOI 10.4049/jimmunol.167.1.514; Tagoe CE, 2008, J IMMUNOL, V181, P2813, DOI 10.4049/jimmunol.181.4.2813; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Vandevyver S, 2012, J CLIN INVEST, V122, P2130, DOI 10.1172/JCI60006; Vogt A, 2008, MOL CANCER THER, V7, P330, DOI 10.1158/1535-7163.MCT-07-2165; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang XX, 2008, LIFE SCI, V83, P671, DOI 10.1016/j.lfs.2008.09.003; Wang XX, 2007, J IMMUNOL, V178, P5312, DOI 10.4049/jimmunol.178.8.5312; WEINSTOCK RS, 1992, ENDOCRINOLOGY, V130, P616, DOI 10.1210/en.130.2.616; Widen C, 2000, J BIOL CHEM, V275, P39296, DOI 10.1074/jbc.M006943200; Wu W, 2005, J BIOL CHEM, V280, P4117, DOI 10.1074/jbc.M411200200; Xiao L, 2010, MOL ENDOCRINOL, V24, P497, DOI 10.1210/me.2009-0422; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Yamasaki S, 2004, SEMIN IMMUNOL, V16, P421, DOI 10.1016/j.smim.2004.08.021; Yang NL, 2008, J CELL BIOCHEM, V103, P1760, DOI 10.1002/jcb.21562; Yang YH, 2006, J IMMUNOL, V177, P8148, DOI 10.4049/jimmunol.177.11.8148; Yang YH, 2009, J IMMUNOL, V183, P1435, DOI 10.4049/jimmunol.0804000; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhu Q. Y., 2010, J IMMUNOL, V185, P7435	158	120	125	2	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					4805	4820		10.1096/fj.12-216382	http://dx.doi.org/10.1096/fj.12-216382			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22954589				2022-12-28	WOS:000311838300004
J	Bettayeb, K; Oumata, N; Zhang, YY; Luo, WJ; Bustos, V; Galons, H; Greengard, P; Meijer, L; Flajolet, M				Bettayeb, Karima; Oumata, Nassima; Zhang, Yuanyuan; Luo, Wenjie; Bustos, Victor; Galons, Herve; Greengard, Paul; Meijer, Laurent; Flajolet, Marc			Small-molecule inducers of A beta-42 peptide production share a common mechanism of action	FASEB JOURNAL			English	Article						Aftin; Alzheimer's disease; amyloid-beta; trafficking; VDAC1; lipid rafts	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA; LIPID RAFTS; GAMMA-SECRETASE; SENILE PLAQUES; IN-VIVO; PROTEIN; BRAIN; IDENTIFICATION; MUTATIONS	The pathways leading specifically to the toxic A beta 42 peptide production, a key event in Alzheimer's disease (AD), are unknown. While searching for pathways that mediate pathological increases of A beta 42, we identified Aftin-4, a new compound that selectively and potently increases A beta 42 compared to DMSO (N2a cells: 7-fold; primary neurons: 4-fold; brain lysates: 2-fold) with an EC50 of 30 mu M. These results were confirmed by ELISA and IP-WB. Using affinity chromatography and mass spectrometry, we identified 3 proteins (VDAC1, prohibitin, and mitofilin) relevant to AD that interact with Aftin-4, but not with a structurally similar but inactive molecule. Electron microscopy studies demonstrated that Aftin-4 induces a reversible mitochondrial phenotype reminiscent of the one observed in AD brains. Sucrose gradient fractionation showed that Aftin-4 perturbs the subcellular localization of gamma-secretase components and could, therefore, modify gamma-secretase specificity by locally altering its membrane environment. Remarkably, Aftin-4 shares all these properties with two other "AD accelerator" compounds. In summary, treatment with three A beta 42 raising agents induced similar biochemical alterations that lead to comparable cellular phenotypes in vitro, suggesting a common mechanism of action involving three structural cellular targets.-Bettayeb, K., Oumata, N., Zhang, Y., Luo, W., Bustos, V., Galons, H., Greengard, P., Meijer, L., Flajolet, M. Small-molecule inducers of A beta-42 peptide production share a common mechanism of action. FASEB J. 26, 5115-5123 (2012). www.fasebj.org	[Bettayeb, Karima; Zhang, Yuanyuan; Luo, Wenjie; Bustos, Victor; Greengard, Paul; Flajolet, Marc] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA; [Oumata, Nassima; Galons, Herve] Univ Paris 05, CNRS, UMR, Lab Pharmacochim, Paris, France; [Meijer, Laurent] CNRS, Stn Biol Roscoff, USR 3151, Roscoff, France	Rockefeller University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Flajolet, M (corresponding author), Rockefeller Univ, Lab Mol & Cellular Neurosci, 1230 York Ave, New York, NY 10021 USA.	flajolm@rockefeller.edu	MEIJER, Laurent/ABE-7465-2021; Luo, Wenjie/ABF-8451-2020	Zhang, Yuanyuan/0000-0001-9230-7314; Greengard, Paul/0000-0002-4437-0893	U.S. National Institutes of Health [AG/NIA: AG-09464]; Fisher Center for Alzheimer's Research Foundation; Fonds Unique Interministeriel (FUI) PHARMASEA project; CRITT-Sante Bretagne; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fisher Center for Alzheimer's Research Foundation; Fonds Unique Interministeriel (FUI) PHARMASEA project; CRITT-Sante Bretagne; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Drs. J. P. Roussarie, G. He, and F. Gorelick for their critical reading of the manuscript; to Drs. K. Uryu and E. Sphicas for their help regarding the electron microscopy; and to Drs. F. Mikhail, A. Starkov, and C. Chinopoulos for their helpful discussions and advice regarding mitochondrial experiments. The authors thank Angie Lin for her technical assistance. This work was supported, in part, by grants from the U.S. National Institutes of Health (AG/NIA: AG-09464; P.G.) and the Fisher Center for Alzheimer's Research Foundation. The authors also acknowledge support from the Fonds Unique Interministeriel (FUI) PHARMASEA project (L.M. and H.G.) and CRITT-Sante Bretagne (L.M.).	Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; COATES PM, 1995, AM J HUM GENET, V57, P233; Cuadrado-Tejedor M, 2011, J ALZHEIMERS DIS, V23, P195, DOI 10.3233/JAD-2010-100966; Czech C, 2007, J NEUROCHEM, V101, P929, DOI 10.1111/j.1471-4159.2007.04467.x; Eckert GP, 2012, MOL NEUROBIOL, V46, P136, DOI 10.1007/s12035-012-8271-z; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Flajolet M, 2007, P NATL ACAD SCI USA, V104, P4159, DOI 10.1073/pnas.0611236104; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Hur JY, 2012, J BIOL CHEM, V287, P11991, DOI 10.1074/jbc.M111.246074; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Jae-Kyung M, 2003, CELL MOL BIOL, V49, P739; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kuperstein I, 2010, EMBO J, V29, P3408, DOI 10.1038/emboj.2010.211; Martin V, 2010, J ALZHEIMERS DIS, V19, P489, DOI 10.3233/JAD-2010-1242; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Mielenz D, 2005, J IMMUNOL, V174, P3508, DOI 10.4049/jimmunol.174.6.3508; Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352; O'Connell K, 2009, PROTEOMICS, V9, P5509, DOI 10.1002/pmic.200900472; Oumata N, 2008, J MED CHEM, V51, P5229, DOI 10.1021/jm800109e; Perez-Gracia E, 2008, ACTA NEUROPATHOL, V116, P261, DOI 10.1007/s00401-008-0370-6; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016; Selkoe DJ, 2000, NEUROL CLIN, V18, P903, DOI 10.1016/S0733-8619(05)70232-2; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Sultana R, 2006, NEUROBIOL DIS, V22, P76, DOI 10.1016/j.nbd.2005.10.004; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Tian Y, 2011, FASEB J, V25, P1934, DOI 10.1096/fj.10-175158; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Wang QS, 2008, NEUROCHEM RES, V33, P1776, DOI 10.1007/s11064-008-9628-6; Williamson R, 2011, CURR ALZHEIMER RES, V8, P213, DOI 10.2174/156720511795256008; Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998; Zhu L, 2011, J ALZHEIMERS DIS, V23, P641, DOI 10.3233/JAD-2010-101389	42	18	20	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5115	5123		10.1096/fj.12-212985	http://dx.doi.org/10.1096/fj.12-212985			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22972917	Green Published			2022-12-28	WOS:000311838300032
J	Faryna, M; Konermann, C; Aulmann, S; Bermejo, JL; Brugger, M; Diederichs, S; Rom, J; Weichenhan, D; Claus, R; Rehli, M; Schirmacher, P; Sinn, HP; Plass, C; Gerhauser, C				Faryna, Marta; Konermann, Carolin; Aulmann, Sebastian; Bermejo, Justo Lorenzo; Brugger, Markus; Diederichs, Sven; Rom, Joachim; Weichenhan, Dieter; Claus, Rainer; Rehli, Michael; Schirmacher, Peter; Sinn, Hans-Peter; Plass, Christoph; Gerhauser, Clarissa			Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis	FASEB JOURNAL			English	Article						estrogen receptor-positive; EpiTyper MassArray; CpG island array; methyl-CpG immunoprecipitation; DMR; ductal carcinoma in situ	CARCINOMA IN-SITU; DNA METHYLATION; PROMOTER HYPERMETHYLATION; PROTOCADHERIN PCDH10; RECEPTOR STATUS; EARLY EVENT; FREQUENT; SUPPRESSOR; PATTERNS; EXPRESSION	Aberrant DNA methylation constitutes a well-established epigenetic marker for breast cancer. Changes in methylation early in cancer development may be clinically relevant for cancer detection and prognosis-based therapeutic decisions. In the present study, a combination of methyl-CpG immunoprecipitation (MCIp) and human CpG island (CGI) arrays was applied to compare genome-wide DNA methylation profiles in 10 low-grade in situ and invasive breast cancers against 10 normal breast samples. In total, 214 CGIs were found to be hypermethylated in >= 6 of 10 tumors. Functional term enrichment analyses revealed an overrepresentation of homeobox genes and genes involved in transcription and regulation of transcription. Significant hypermethylation of 11 selected genes in tumor vs. normal tissue was validated in two independent sample sets (45 tumors and 11 controls, 43 tumors and 8 controls) using quantitative EpiTyper technology. In tumors, median methylation levels of BCAN, HOXD1, KCTD8, KLF11, NXPH1, POU4F1, SIM1, and TCF7L1 were >= 30% higher than in normal samples, representing potential biomarkers for tumor diagnosis. Using the 90th percentile of methylation levels in normal tissue as cutoff value, 62-92% of in situ samples (n = 13), 72-97% of invasive samples from the first validation set (n = 32), and 86-100% of invasive samples from the second validation set (n = 43) were classified as hypermethylated. Hypermethylation of KLF11 and SIM1 might also be associated with increased risk of developing metastases. In summary, early methylation changes are frequent in the low-grade pathway of breast cancer and may be useful in the development of differential diagnostic and possibly also prognostic markers.-Faryna, M., Konermann, C., Aulmann, S., Bermejo, J. L., Brugger, M., Diederichs, S., Rom, J., Weichenhan, D., Claus, R., Rehli, M., Schirmacher, P., Sinn, H.-P., Plass, C., Gerhauser, C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26, 4937-4950 (2012). www.fasebj.org	[Faryna, Marta; Konermann, Carolin; Weichenhan, Dieter; Claus, Rainer; Plass, Christoph; Gerhauser, Clarissa] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany; [Diederichs, Sven] German Canc Res Ctr, Helmholtz Univ Grp Mol RNA Biol & Canc, D-69120 Heidelberg, Germany; [Konermann, Carolin; Aulmann, Sebastian; Diederichs, Sven; Schirmacher, Peter; Sinn, Hans-Peter] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Bermejo, Justo Lorenzo; Brugger, Markus] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany; [Rom, Joachim] Univ Heidelberg Hosp, Dept Gynecol & Obstet, Heidelberg, Germany; [Claus, Rainer] Univ Freiburg, Med Ctr, Div Hematol & Oncol, Dept Med, D-79106 Freiburg, Germany; [Rehli, Michael] Univ Hosp Regensburg, Dept Hematol & Oncol, Regensburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Freiburg; University of Regensburg	Gerhauser, C (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	c.gerhauser@dkfz-heidelberg.de	Claus, Rainer/AAZ-5606-2020; Plass, Christoph/H-7192-2014; Sinn, Hans-Peter/C-5661-2008; Rehli, Michael/E-9093-2011; Diederichs, Sven/J-6237-2012	Claus, Rainer/0000-0003-2617-8766; Sinn, Hans-Peter/0000-0003-2836-6699; Rehli, Michael/0000-0003-3992-932X; Diederichs, Sven/0000-0001-7901-4752; Gerhauser, Clarissa/0000-0002-5792-3901	FRONTIER Innovation Fund, Excellence Initiative of Heidelberg University; Deutsche Forschungsgemeinschaft (DFG) [SFB/TRR77, CL 427/2-1]; Helmholtz Society [VH-NG-504]; German Research Foundation [DFG Transregio TRR77, TP B03]; Marie Curie Program of the European Commission	FRONTIER Innovation Fund, Excellence Initiative of Heidelberg University; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Helmholtz Society(Helmholtz Association); German Research Foundation(German Research Foundation (DFG)); Marie Curie Program of the European Commission(European Commission)	The authors thank Manuela Zucknick for statistical support in array analysis and Julia Strathmann for providing DNA from MCF7 cells. The authors thank Oliver Mucke, Sandra Hahn, and Tina Philipp for excellent technical assistance. This project was funded by the FRONTIER Innovation Fund as part of the Excellence Initiative of Heidelberg University. J.L.B. and M. B. were supported by a grant of the Deutsche Forschungsgemeinschaft (DFG; SFB/TRR77, project Z2). Research in the S. D. laboratory is supported by the Helmholtz Society (VH-NG-504), the German Research Foundation (DFG Transregio TRR77, TP B03) and the Marie Curie Program of the European Commission. R. C. was supported by a DFG grant (CL 427/2-1). The authors declare no conflicts of interest.	Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721; Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801; Dedeurwaerder S, 2011, CURR OPIN ONCOL, V23, P559, DOI 10.1097/CCO.0b013e32834bd481; Deli T, 2007, INT J CANCER, V121, P55, DOI 10.1002/ijc.22621; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Ferlay J, 2010, GLOBOCAN 2008 V1 2 C; Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008; Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376; Goeppert B, 2010, HEPATOLOGY, V52, P2023, DOI 10.1002/hep.23939; Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026; Holleczek B, 2011, CANCER EPIDEMIOL, V35, P399, DOI 10.1016/j.canep.2011.01.008; Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590; Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002; Killian JK, 2011, AM J PATHOL, V179, P55, DOI 10.1016/j.ajpath.2011.03.022; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351; Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Narayan G, 2011, GENE CHROMOSOME CANC, V50, P1043, DOI 10.1002/gcc.20922; Narayan G, 2009, GENE CHROMOSOME CANC, V48, P983, DOI 10.1002/gcc.20703; Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314; Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6; Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011; Schilling E, 2009, GENOME RES, V19, P2028, DOI 10.1101/gr.095562.109; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; VOLLENWEIDERZERARGUI L, 1986, CANCER-AM CANCER SOC, V57, P1171, DOI 10.1002/1097-0142(19860315)57:6<1171::AID-CNCR2820570618>3.0.CO;2-X; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050	58	69	73	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4937	4950		10.1096/fj.12-209502	http://dx.doi.org/10.1096/fj.12-209502			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22930747	Green Submitted			2022-12-28	WOS:000311838300017
J	Pomerantz, Y; Elbaz, J; Ben-Eliezer, I; Reizel, Y; David, Y; Galiani, D; Nevo, N; Navon, A; Dekel, N				Pomerantz, Yael; Elbaz, Judith; Ben-Eliezer, Inbal; Reizel, Yitzhak; David, Yael; Galiani, Dalia; Nevo, Nava; Navon, Ami; Dekel, Nava			From ubiquitin-proteasomal degradation to CDK1 inactivation: requirements for the first polar body extrusion in mouse oocytes	FASEB JOURNAL			English	Article						meiosis; PLK1; MEK1/2; chromosome segregation; cell division	SISTER-CHROMATID SEPARATION; MATURATION-PROMOTING FACTOR; CHROMOSOME SEGREGATION; MEIOTIC MATURATION; MEIOSIS-I; KINASE 1; ASYMMETRIC DIVISION; SPINDLE MIDZONE; ACTIVATION; INHIBITION	Completion of the first meiotic division, manifested by extrusion of the first polar body (PBI), depends on proteasomal degradation of cyclin B1 and securin and the subsequent respective CDK1 inactivation and chromosome segregation. We aimed at identifying the polyubiquitin signal that mediates proteasomal action and at a better characterization of the role of CDK1 inactivation at this stage of meiosis. Microinjections of mutated ubiquitin proteins into mouse oocytes revealed that interference with lysine-11 polyubiquitin chains abrogated chromosome segregation and reduced PBI extrusion by 63% as compared to WT ubiquitin-injected controls. Inactivation of CDK1 in oocytes arrested at first metaphase by a proteasome inhibitor fully rescued PBI extrusion. However, removal of CDK1 inhibition failed to allow progression to the second metaphase, rather, inducing PBI reengulfment in 62% of the oocytes. Inhibition of either PLK1 or MEK1/2 during the first anaphase changed spindle dimensions. The PLK1 inhibitor also blocked PBI emission and prevented RhoA translocation. Our results identified lysine-11 rather than the canonic lysine-48 ubiquitin chains as the degradation signal in oocytes resuming meiosis, further disclosing that CDK1 inactivation is necessary and sufficient for PBI emission. This information significantly contributes to our understanding of faulty chromosome segregation that may lead to aneuploidy.-Pomerantz, Y., Elbaz, J., Ben-Eliezer, I., Reizel, Y., David, Y., Galiani, D., Nevo, N., Navon, A., Dekel, N. From ubiquitin-proteasomal degradation to CDK1 inactivation: requirements for the first polar body extrusion in mouse oocytes. FASEB J. 26, 4495-4505 (2012). www.fasebj.org	[Pomerantz, Yael; Elbaz, Judith; Ben-Eliezer, Inbal; Reizel, Yitzhak; David, Yael; Galiani, Dalia; Nevo, Nava; Navon, Ami; Dekel, Nava] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dekel, N (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	nava.dekel@weizmann.ac.il	DEKEL, NAVA/R-8817-2019		Dwek Fund for Biomedical Research	Dwek Fund for Biomedical Research	The authors thank Dr. Edna Schechtman for statistical analysis. This study was supported by the Dwek Fund for Biomedical Research. N. D. is the incumbent of the Philip M. Klutznick Professorial Chair in Developmental Biology.	Araki K, 1996, BIOL REPROD, V55, P1315, DOI 10.1095/biolreprod55.6.1315; Azoury J, 2008, CURR BIOL, V18, P1514, DOI 10.1016/j.cub.2008.08.044; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Berkers CR, 2005, NAT METHODS, V2, P357, DOI 10.1038/nmeth759; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Brunet S, 1999, J CELL BIOL, V146, P1, DOI 10.1083/jcb.146.1.1; Brunet S, 2011, HUM REPROD UPDATE, V17, P68, DOI 10.1093/humupd/dmq044; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chiang T, 2011, BIOL REPROD, V85, P1279, DOI 10.1095/biolreprod.111.094094; CHOI T, 1991, DEVELOPMENT, V113, P789; Choi TS, 1996, P NATL ACAD SCI USA, V93, P7032, DOI 10.1073/pnas.93.14.7032; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; D'Avino PP, 2009, NAT CELL BIOL, V11, P112, DOI 10.1038/ncb0209-112; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; David Y, 2010, J BIOL CHEM, V285, P8595, DOI 10.1074/jbc.M109.089003; Dumont J, 2007, DEV BIOL, V301, P254, DOI 10.1016/j.ydbio.2006.08.044; Dumont J, 2012, TRENDS CELL BIOL, V22, P241, DOI 10.1016/j.tcb.2012.02.007; Dumont J, 2010, NAT CELL BIOL, V12, P894, DOI 10.1038/ncb2093; Dupre A., 2011, J SIGNAL TRANSDUCT, V2011; Elbaz J, 2010, ENDOCRINOLOGY, V151, P755, DOI 10.1210/en.2009-0830; EPPIG JJ, 1993, METHOD ENZYMOL, V225, P77; Erpapazoglou Z, 2012, MOL BIOL CELL, V23, P2170, DOI 10.1091/mbc.E11-10-0891; Garnett MJ, 2009, NAT CELL BIOL, V11, P1363, DOI 10.1038/ncb1983; Gaudet S, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-55; Gorr IH, 2005, MOL CELL, V19, P135, DOI 10.1016/j.molcel.2005.05.022; Gorr IH, 2006, NAT CELL BIOL, V8, P1035, DOI 10.1038/ncb1467; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; HAMPL A, 1995, DEVELOPMENT, V121, P925; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Herbert M, 2003, NAT CELL BIOL, V5, P1023, DOI 10.1038/ncb1062; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holland AJ, 2006, J CELL SCI, V119, P3325, DOI 10.1242/jcs.03083; Holt JE, 2009, MOL HUM REPROD, V15, P139, DOI 10.1093/molehr/gap007; Homer HA, 2005, REPRODUCTION, V130, P829, DOI 10.1530/rep.1.00856; Huang XX, 2009, MOL CELL BIOL, V29, P1498, DOI 10.1128/MCB.01778-08; Huang XX, 2005, MOL BIOL CELL, V16, P4725, DOI 10.1091/mbc.E05-03-0190; Hunt PA, 1998, J ASSIST REPROD GEN, V15, P246, DOI 10.1023/A:1022580024402; Jin LY, 2008, CELL, V133, P653, DOI 10.1016/j.cell.2008.04.012; Jones KT, 2011, RESULTS PROBL CELL D, V53, P343, DOI 10.1007/978-3-642-19065-0_15; Josefsberg LBY, 2000, BIOL REPROD, V62, P1270, DOI 10.1095/biolreprod62.5.1270; Josefsberg LBY, 2003, BIOL REPROD, V68, P1282, DOI 10.1095/biolreprod.102.006882; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kravtsova-Ivantsiv Y, 2012, J CELL SCI, V125, P539, DOI 10.1242/jcs.093567; Kudo NR, 2006, CELL, V126, P135, DOI 10.1016/j.cell.2006.05.033; Kudo NR, 2009, J CELL SCI, V122, P2686, DOI 10.1242/jcs.035287; Lefebvre C, 2002, J CELL BIOL, V157, P603, DOI 10.1083/jcb.200202052; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Li M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007701; Lightcap ES, 2000, CLIN CHEM, V46, P673; Lin Sheng-Li, 2010, Front Biosci (Elite Ed), V2, P1254; Martinez-Forero I, 2009, CLIN CANCER RES, V15, P6751, DOI 10.1158/1078-0432.CCR-09-1225; Monen J, 2005, NAT CELL BIOL, V7, P1248, DOI 10.1038/ncb1331; Mtango NR, 2012, J CELL PHYSIOL, V227, P2022, DOI 10.1002/jcp.22931; Mtango NR, 2012, J CELL PHYSIOL, V227, P1592, DOI 10.1002/jcp.22876; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Otsuki J, 2009, REPROD BIOMED ONLINE, V18, P522, DOI 10.1016/S1472-6483(10)60129-0; Pahlavan G, 2000, DEV BIOL, V220, P392, DOI 10.1006/dbio.2000.9656; Panier S, 2009, DNA REPAIR, V8, P436, DOI 10.1016/j.dnarep.2009.01.013; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Phu LL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003756; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Potapova TA, 2009, MOL BIOL CELL, V20, P1737, DOI 10.1091/mbc.E08-07-0771; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Schindler K, 2011, RESULTS PROBL CELL D, V53, P309, DOI 10.1007/978-3-642-19065-0_14; SCHULTZ RM, 1983, DEV BIOL, V95, P294, DOI 10.1016/0012-1606(83)90030-1; Sharif B, 2010, J CELL SCI, V123, P4292, DOI 10.1242/jcs.067447; Skoufias DA, 2007, J CELL BIOL, V179, P671, DOI 10.1083/jcb.200704117; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Terret ME, 2003, CURR BIOL, V13, P1797, DOI 10.1016/j.cub.2003.09.032; Tong C, 2003, CELL RES, V13, P375, DOI 10.1038/sj.cr.7290183; Tong C, 2002, BIOL REPROD, V67, P546, DOI 10.1095/biolreprod67.2.546; Verlhac MH, 2000, CURR BIOL, V10, P1303, DOI 10.1016/S0960-9822(00)00753-3; Wang Y, 2008, MECH DEVELOP, V125, P142, DOI 10.1016/j.mod.2007.09.008; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Wei L, 2010, CELL CYCLE, V9, P1112, DOI 10.4161/cc.9.6.10957; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Williamson A, 2009, P NATL ACAD SCI USA, V106, P18213, DOI 10.1073/pnas.0907887106; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Woolner S, 2008, J CELL BIOL, V182, P77, DOI 10.1083/jcb.200804062; Wu T, 2010, P NATL ACAD SCI USA, V107, P1355, DOI 10.1073/pnas.0912802107; Xiong B, 2007, CELL CYCLE, V6, P1522; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	87	12	14	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4495	4505		10.1096/fj.12-209866	http://dx.doi.org/10.1096/fj.12-209866			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859367				2022-12-28	WOS:000310574200012
J	Rajshankar, D; Downey, GP; McCulloch, CA				Rajshankar, Dhaarmini; Downey, Gregory P.; McCulloch, Christopher A.			IL-1 beta enhances cell adhesion to degraded fibronectin	FASEB JOURNAL			English	Article						integrins; talins; kindlins; MMP	TYROSINE PHOSPHATASE-ALPHA; HUMAN PERIODONTAL-LIGAMENT; LINK FOCAL ADHESIONS; MATRIX METALLOPROTEINASES; ENDOPLASMIC-RETICULUM; GINGIVAL FIBROBLASTS; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INTERLEUKIN-1	IL-1 beta is a prominent proinflammatory cytokine that mediates degradation of extracellular matrix proteins through increased expression of matrix metalloproteinases, which involves a signaling pathway in adherent cells that is restricted by focal adhesions. Currently, the mechanism by which IL-1 beta affects cell adhesion to matrix proteins is not defined, and it is not known whether degraded matrix proteins affect IL-1 beta signaling. We examined adhesion-related IL-1 beta signaling in fibroblasts attaching to native or MMP3-degraded fibronectin. IL-1 beta increased cell attachment, resistance to shear force and the numbers of focal adhesions containing activated beta(1) integrins. IL-1 beta-enhanced attachment required FAK, kindlins 1/2, and talin. MMP3-degraded fibronectin-inhibited IL-1 beta-enhanced cell adhesion and promoted spontaneous ERK activation that was independent of IL-1 beta treatment. We conclude that IL-1 beta enhances the adhesion of anchorage-dependent cells to MMP3-degraded fibronectin, which, in turn, is associated with deregulated cellular responses to IL-1 beta. These data point to a novel role of IL-1 beta as a proadhesive signaling molecule in inflammation that employs kindlins and talin to regulate adhesion.-Rajshankar, D., Downey, G. P., McCulloch, C. A. IL-1 beta enhances cell adhesion to degraded fibronectin. FASEB J. 26, 4429-4444 (2012). www.fasebj.org	[Rajshankar, Dhaarmini; McCulloch, Christopher A.] Univ Toronto, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada; [Downey, Gregory P.] Natl Jewish Hlth, Dept Med, Div Pulm & Crit Care Med, Denver, CO USA; [Downey, Gregory P.] Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Downey, Gregory P.] Univ Colorado, Integrated Dept Immunol, Aurora, CO USA	University of Toronto; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	McCulloch, CA (corresponding author), Univ Toronto, Matrix Dynam Grp, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca		Downey, Gregory P/0000-0003-3253-5862	Canadian Institutes of Health Research [MOP 84254]; Canada Research Chair (Tier 1); U.S. National Institutes of Health [HL090669]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090669] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair (Tier 1)(Canada Research Chairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study is supported by Canadian Institutes of Health Research operating grant MOP 84254 to C. A. M., who is also supported by a Canada Research Chair (Tier 1). This work was also supported, in part, by U.S. National Institutes of Health grant HL090669 (to G. P. D.).	Abreu MTH, 2006, J CELL PHYSIOL, V207, P132, DOI 10.1002/jcp.20544; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Bhide VM, 2005, J BIOL CHEM, V280, P23103, DOI 10.1074/jbc.M410060200; Boch JA, 2001, J DENT RES, V80, P400, DOI 10.1177/00220345010800020101; Bolcato-Bellemin AL, 2000, J DENT RES, V79, P1712, DOI 10.1177/00220345000790091201; Boyle DL, 1997, ARTHRITIS RHEUM, V40, P1772, DOI 10.1002/art.1780401008; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Calderwood DA, 2004, BIOCHEM SOC T, V32, P434, DOI 10.1042/BST0320434; Chong SAC, 2007, J BIOL CHEM, V282, P8510, DOI 10.1074/jbc.M609859200; Chung Kian F., 2005, Current Drug Targets - Inflammation and Allergy, V4, P619, DOI 10.2174/156801005774912806; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; FORSYTH KD, 1990, J PATHOL, V161, P313, DOI 10.1002/path.1711610407; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Glogauer M, 1998, PFLUG ARCH EUR J PHY, V435, P320; HAKKINEN L, 1994, BBA-MOL CELL RES, V1224, P33, DOI 10.1016/0167-4889(94)90110-4; Han YP, 2006, J GASTROEN HEPATOL, V21, pS88, DOI 10.1111/j.1440-1746.2006.04586.x; Heng ECK, 2006, J CELL BIOCHEM, V98, P409, DOI 10.1002/jcb.20810; Humphries Martin J., 2009, V522, P203, DOI 10.1007/978-1-59745-413-1_14; Ithychanda SS, 2009, J BIOL CHEM, V284, P4713, DOI 10.1074/jbc.M807719200; Kim C., 2012, ANNU REV CELL DEV BI, V3, P67; Kim H, 2010, EXP CELL RES, V316, P1829, DOI 10.1016/j.yexcr.2010.02.007; Kim H, 2010, AM J PHYSIOL-CELL PH, V298, pC221, DOI 10.1152/ajpcell.00323.2009; Lallier TE, 2005, J PERIODONTOL, V76, P1044, DOI 10.1902/jop.2005.76.7.1044; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Le Maitre CL, 2007, BIOCHEM SOC T, V35, P652, DOI 10.1042/BST0350652; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207; McCulloch CA, 2006, NAT REV DRUG DISCOV, V5, P864, DOI 10.1038/nrd2109; Meves A, 2009, TRENDS CELL BIOL, V19, P504, DOI 10.1016/j.tcb.2009.07.006; Montanez E, 2008, GENE DEV, V22, P1325, DOI 10.1101/gad.469408; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Phares DJ, 2000, J FLUID MECH, V418, P351, DOI 10.1017/S002211200000121X; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Rescorla F. J., CELL SIGNAL, V24, P393; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Szabo K.A., 2004, CLIN APPL IMMUNOL RE, V4, P295, DOI DOI 10.1016/J.CAIR.2004.02.001; Szabo K. A., 2004, CLIN APPL IMMUNOL RE, V4, P319; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Thomas P., CLIN EXP METASTASIS, V28, P923; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; van der Pauw MTM, 2002, J PERIODONTAL RES, V37, P317, DOI 10.1034/j.1600-0765.2002.00349.x; Wang Q, 2005, J BIOL CHEM, V280, P8397, DOI 10.1074/jbc.M410462200; Wang Q, 2006, J BIOL CHEM, V281, P31093, DOI 10.1074/jbc.M606392200; Wang Qin, 2003, FASEB Journal, V17, P1898; Wang Q, 2011, FASEB J, V25, P3448, DOI 10.1096/fj.11-183459; Wang Q, 2010, J BIOL CHEM, V285, P22308, DOI 10.1074/jbc.M110.102426; Wang Q, 2009, J BIOL CHEM, V284, P20763, DOI 10.1074/jbc.M808828200; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zhang H., NEUROTHERAPEUTICS, V8, P206; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	63	20	20	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4429	4444		10.1096/fj.12-207381	http://dx.doi.org/10.1096/fj.12-207381			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22829527	Green Published			2022-12-28	WOS:000310574200007
J	Roudier, E; Forn, P; Perry, ME; Birot, O				Roudier, Emilie; Forn, Paul; Perry, Mary Ellen; Birot, Olivier			Murine double minute-2 expression is required for capillary maintenance and exercise-induced angiogenesis in skeletal muscle	FASEB JOURNAL			English	Article						VEGF-A; endothelial cell; p53; physiology	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FACTOR MESSENGER-RNA; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; MDM2; P53; HDM2; UBIQUITINATION; STABILIZATION; INHIBITION	Exercise-induced angiogenesis is a key determinant of skeletal muscle function. Here, we investigated whether the E3 ubiquitin ligase murine double minute-2 (Mdm2) exerts a proangiogenic function in exercised skeletal muscle. Mdm2 hypomorphic (Mdm2(Puro/Delta 7-9)) mice have a 60% reduction in Mdm2 expression compared with that in wild-type animals. Capillary staining on muscle sections from Mdm2(Puro/Delta 7-9) sedentary mice with a wild-type or knockout background for p53 revealed that deficiency in Mdm2 resulted in 20% capillary regression independently of p53 status. In response to one bout of exercise, protein expression of the proangiogenic vascular endothelial growth factor-A (VEGF-A) was increased by 64% in muscle from wild-type animals, and endothelial cell outgrowth from exercised muscle biopsy samples cultured in a 3-dimensional collagen gel was enhanced by 37%. These proangiogenic responses to exercise were impaired in exercised Mdm2(Puro/Delta 7-9) mice. Prolonged exercise training resulted in increased Mdm2 protein expression (+49%) and capillarization (+24%) in wildtype muscles. However, exercise training-induced angiogenesis was abolished in Mdm2(Puro/Delta 7-9) mice. Finally, exercise training restored Mdm2, VEGF-A, and capillarization levels in skeletal muscles from obese Zucker diabetic fatty rats compared with those in healthy animals. Our results define Mdm2 as a crucial regulator of capillary maintenance and exercise-induced angiogenesis in skeletal muscle.-Roudier, E., Forn, P., Perry, M. E., Birot, O. Murine double minute-2 expression is required for capillary maintenance and exercise-induced angiogenesis in skeletal muscle. FASEB J. 26, 4530-4539 (2012). www.fasebj.org	[Birot, Olivier] York Univ, Fac Hlth, Norman Bethune Coll, Angiogenesis Res Grp, Toronto, ON M3J 1P3, Canada; [Roudier, Emilie; Birot, Olivier] Univ Montreal, Dept Kinesiol, Montreal, PQ, Canada; [Perry, Mary Ellen] NCI, Lab Prot Dynam & Signaling, US Natl Inst Hlth, Frederick, MD 21701 USA	York University - Canada; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birot, O (corresponding author), York Univ, Fac Hlth, Norman Bethune Coll, Angiogenesis Res Grp, Room 353,4700 Keele St, Toronto, ON M3J 1P3, Canada.	birot@yorku.ca			Natural Sciences and Engineering Research Council of Canada (NSERC) [341258]; NIH, National Cancer Institute, Center for Cancer Research	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Nicole Morris [National Cancer Institute, U.S. National Institutes of Health (NIH)] for maintaining the Mdm2<SUP>puro/Delta 7-9</SUP> mice, and Dr. Raynald Bergeron (University of Montreal) for his help in the ZDF mouse conditioning. This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC discovery grant 341258 to O.B.) and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (M. E. P.). E. R. and O.B. conceived the study; E. R., M. E. P., and O.B. designed experiments; E. R., P. F., and O.B. performed experiments and analyzed data; M. E. P. supplied Mdm2<SUP>puro/Delta 7-9</SUP> mice; E. R., M. E. P., and O.B. participated in the redaction of the manuscript.	Alam H, 2009, ENDOCRINOLOGY, V150, P915, DOI 10.1210/en.2008-0850; Assadin S, 2008, EXPERT OPIN BIOL TH, V8, P941, DOI [10.1517/14712590802184482, 10.1517/14712598.8.7.941 ]; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Birot OJG, 2003, J PHYSIOL-LONDON, V552, P213, DOI 10.1113/jphysiol.2003.043026; Bloor Colin M., 2005, Angiogenesis, V8, P263, DOI 10.1007/s10456-005-9013-x; Bouvet M, 1998, CANCER RES, V58, P2288; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Carroll VA, 2008, CANCER RES, V68, P545, DOI 10.1158/0008-5472.CAN-06-4738; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Egginton S, 2009, PFLUG ARCH EUR J PHY, V457, P963, DOI 10.1007/s00424-008-0563-9; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gustafsson T, 2001, FRONT BIOSCI-LANDMRK, V6, pD75, DOI 10.2741/gustafss; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; Hohberg M, 2011, J CELL PHYSIOL, V226, P350, DOI 10.1002/jcp.22340; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196; Malek MH, 2009, EXP PHYSIOL, V94, P749, DOI 10.1113/expphysiol.2008.045989; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Milkiewicz M, 2011, AM J PATHOL, V178, P935, DOI 10.1016/j.ajpath.2010.10.042; Millard M, 2011, CURR PHARM DESIGN, V17, P536, DOI 10.2174/138161211795222649; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Olfert IM, 2010, AM J PHYSIOL-REG I, V299, pR1059, DOI 10.1152/ajpregu.00347.2010; Olfert IM, 2009, J PHYSIOL-LONDON, V587, P1755, DOI 10.1113/jphysiol.2008.164384; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310; Perry ME, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000968; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Qin G., 2006, P NATL ACAD SCI USA, V103, P11015; Ravi R, 2000, GENE DEV, V14, P34; Roudier E, 2010, J PHYSIOL-LONDON, V588, P4579, DOI 10.1113/jphysiol.2010.193243; Roudier E, 2009, J PHYSIOL-LONDON, V587, P4105, DOI 10.1113/jphysiol.2009.175554; Secchiero P, 2007, CIRC RES, V100, P61, DOI 10.1161/01.RES.0000253975.76198.ff; Shangary S, 2008, CLIN CANCER RES, V14, P5318, DOI 10.1158/1078-0432.CCR-07-5136; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Su F, 2010, ONCOGENE, V29, P421, DOI 10.1038/onc.2009.326; Teodoro JG, 2007, J MOL MED-JMM, V85, P1175, DOI 10.1007/s00109-007-0221-2; Uguccioni G, 2011, AM J PHYSIOL-ENDOC M, V300, pE361, DOI 10.1152/ajpendo.00292.2010; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wang ZF, 2010, PROTEIN CELL, V1, P1063, DOI 10.1007/s13238-010-0140-9; Yang HT, 2008, J PHYSIOL PHARMACOL, V59, P57; Yoshioka Y, 2012, J SURG RES, V174, P291, DOI 10.1016/j.jss.2010.12.028; Zhang LL, 2000, CANCER RES, V60, P3655; Zhang XF, 2009, FASEB J, V23, P3368, DOI 10.1096/fj.09-131649; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11	54	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4530	4539		10.1096/fj.12-212720	http://dx.doi.org/10.1096/fj.12-212720			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835827	Green Published			2022-12-28	WOS:000310574200015
J	Zhou, DQ; Samovski, D; Okunade, AL; Stahl, PD; Abumrad, NA; Su, X				Zhou, Dequan; Samovski, Dmitri; Okunade, Adewole L.; Stahl, Philip D.; Abumrad, Nada A.; Su, Xiong			CD36 level and trafficking are determinants of lipolysis in adipocytes	FASEB JOURNAL			English	Article						triacylglycerol; lipid metabolism; protein kinase A; adipose triacylglycerol lipase; hormone-sensitive lipase	FATTY-ACID UPTAKE; ADIPOSE-TISSUE; LIPID-METABOLISM; PLASMA-MEMBRANE; INSULIN ACTION; MUSCLE; CALCIUM; PROTEIN; OBESITY; STORAGE	CD36 has been linked to the etiology of insulin resistance and inflammation. We explored its function in regulating adipose tissue lipolysis, which influences fat accumulation by liver and muscle and overall metabolism. Knockdown of CD36 in differentiated 3T3-L1 adipocytes decreased lipolysis in response to 10 mu M of the beta-adrenergic agonist isoproterenol (by 42%), 10 mu M of the adenyl cyclase activator forskolin (by 32%), and 500 mu M of the phosphodiesterase (PDE) inhibitor isobutylmethylxanthine (by 33%). All three treatments in the knockdown adipocytes were associated with significant decreases of cAMP levels and of the hormone-sensitive lipase (HSL) and perilipin phosphorylation. An important role for PDE was supported by the lack of inhibition of the lipolysis induced by the poorly hydrolyzable dibutyryl cAMP analog. An additional contributory mechanism was diminished activation of the Src-ERK1/2 pathway. Regulation of lipolysis and lipolytic signaling by CD36 was reproduced with adipose tissue from CD36(-/-) mice. The importance of surface CD36 in this regulation was suggested by the finding that the plasma membrane-impermeable CD36 inhibitor sulfo-N-succinimidyl oleate (20 mu M) decreased lipolysis. Interestingly, isoproterenol induced CD36 internalization, and this process was blocked by HSL inhibition, suggesting feedback regulation of adipocyte lipolysis via CD36 trafficking.-Zhou, D., Samovski, D., Okunade, A. L., Stahl, P. D., Abumrad, N. A., Su, X.. CD36 level and trafficking are determinants of lipolysis in adipocytes. FASEB J. 26, 4733-4742 (2012). www.fasebj.org	[Zhou, Dequan; Okunade, Adewole L.; Abumrad, Nada A.; Su, Xiong] Washington Univ, Sch Med, Dept Internal Med, Ctr Human Nutr, St Louis, MO 63110 USA; [Samovski, Dmitri; Stahl, Philip D.; Abumrad, Nada A.; Su, Xiong] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Su, X (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Ctr Human Nutr, Campus Box 8031,660 S Euclid Ave, St Louis, MO 63110 USA.	xsu@wustl.edu	Samovski, Dmitri/K-3705-2019; Samovski, Dmitri/AAQ-2014-2020; zhou, dequan/J-9937-2012	Samovski, Dmitri/0000-0002-6860-6688; zhou, dequan/0000-0002-2662-2882	American Heart Association [835140N]; U.S. National Institutes of Health [DK33301, DK56351]; Nutrition Obesity Research Center [P30DK56341]; Adipocyte Biology and Molecular Nutrition Core at Washington University School of Medicine; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK033301] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nutrition Obesity Research Center; Adipocyte Biology and Molecular Nutrition Core at Washington University School of Medicine; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a Scientist Development grant from the American Heart Association (835140N to X. S.) and by U.S. National Institutes of Health grants DK33301 and DK56351. This work was also supported by the core services of the Nutrition Obesity Research Center (P30DK56341) and, in particular, the Adipocyte Biology and Molecular Nutrition Core at Washington University School of Medicine.	Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Ali AH, 2011, DIABETES, V60, P2300, DOI 10.2337/db11-0219; Bastie CC, 2004, DIABETES, V53, P2209, DOI 10.2337/diabetes.53.9.2209; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 2006, INT J OBESITY, V30, P877, DOI 10.1038/sj.ijo.0803212; Carmen GY, 2006, CELL SIGNAL, V18, P401, DOI 10.1016/j.cellsig.2005.08.009; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Ducharme NA, 2008, ENDOCRINOLOGY, V149, P942, DOI 10.1210/en.2007-1713; Duncan RE, 2007, ANNU REV NUTR, V27, P79, DOI 10.1146/annurev.nutr.27.061406.093734; El-Yassimi A, 2008, J BIOL CHEM, V283, P12949, DOI 10.1074/jbc.M707478200; Fabbrini E, 2009, P NATL ACAD SCI USA, V106, P15430, DOI 10.1073/pnas.0904944106; Glatz JFC, 2002, CURR OPIN CLIN NUTR, V5, P365, DOI 10.1097/00075197-200207000-00003; GLENN KC, 1992, ENDOCRINOLOGY, V131, P1115, DOI 10.1210/en.131.3.1115; Gruarin P, 2000, BIOCHEM BIOPH RES CO, V275, P446, DOI 10.1006/bbrc.2000.3333; Guo L, 2010, J BIOL CHEM, V285, P25438, DOI 10.1074/jbc.M110.119933; Hajri T, 2001, J BIOL CHEM, V276, P23661, DOI 10.1074/jbc.M100942200; Hajri T, 2007, DIABETES, V56, P1872, DOI 10.2337/db06-1699; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Hwang HH, 2011, MOL CELLS, V31, P239, DOI 10.1007/s10059-011-0026-6; JAMES DE, 1985, DIABETES, V34, P1049, DOI 10.2337/diabetes.34.10.1049; Koutsari C, 2011, DIABETES, V60, P2032, DOI 10.2337/db11-0154; Kuda O, 2011, J BIOL CHEM, V286, P17785, DOI 10.1074/jbc.M111.232975; Lafontan M, 2008, INT J OBESITY, V32, pS39, DOI 10.1038/ijo.2008.237; Lafontan M, 2012, AM J PHYSIOL-CELL PH, V302, pC327, DOI 10.1152/ajpcell.00168.2011; Lafontan M, 2009, PROG LIPID RES, V48, P275, DOI 10.1016/j.plipres.2009.05.001; Liu YQ, 2010, AM J PHYSIOL-CELL PH, V298, pC921, DOI 10.1152/ajpcell.00541.2009; McGarrigle Deirdre, 2007, Sci STKE, V2007, ppe35, DOI 10.1126/stke.3922007pe35; Nishiumi S, 2007, BIOSCI BIOTECH BIOCH, V71, P2343, DOI 10.1271/bbb.70342; Roberts LD, 2009, PHYSIOL GENOMICS, V39, P109, DOI 10.1152/physiolgenomics.90365.2008; Robidoux J, 2006, J BIOL CHEM, V281, P37794, DOI 10.1074/jbc.M605572200; Rodriguez-Cuenca S, 2012, MOL CELL BIOL, V32, P1555, DOI 10.1128/MCB.06154-11; Samovski D, 2012, J LIPID RES, V53, P709, DOI 10.1194/jlr.M023424; Silverstein Roy L, 2010, Trans Am Clin Climatol Assoc, V121, P206; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Smith J, 2008, WESTERN HUM REV, V62, P36; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Su X, 2009, TRENDS ENDOCRIN MET, V20, P72, DOI 10.1016/j.tem.2008.11.001; Thi TTT, 2011, J BIOL CHEM, V286, P25201, DOI 10.1074/jbc.M111.233551; Wang YX, 2003, OBES RES, V11, P930, DOI 10.1038/oby.2003.128; Xue BZ, 2001, FASEB J, V15, P2527, DOI 10.1096/fj.01-0278fje; Yin J, 2009, AM J PHYSIOL-ENDOC M, V296, pE333, DOI 10.1152/ajpendo.90760.2008; Zhou LB, 2011, BBA-MOL BASIS DIS, V1812, P527, DOI 10.1016/j.bbadis.2010.10.001	46	45	51	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4733	4742		10.1096/fj.12-206862	http://dx.doi.org/10.1096/fj.12-206862			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22815385	Green Published			2022-12-28	WOS:000310574200033
J	Yang, JC; Xu, XL				Yang, Jingchun; Xu, Xiaolei			alpha-Actinin2 is required for the lateral alignment of Z discs and ventricular chamber enlargement during zebrafish cardiogenesis	FASEB JOURNAL			English	Article						cardiac contraction; mechanical force; cardiomyocyte; myofibrillogenesis	ALPHA-ACTININ; HYPERTROPHIC CARDIOMYOPATHY; SEVERE FORM; PROTEINS; MYOFIBRILLOGENESIS; EXPRESSION; TITIN; DEPLETION; CYPHER; MUTATIONS	alpha-Actinin2 (Actn2) is a predominant protein in the sarcomere Z disc whose mutation can lead to cardiomyopathy. However, the function of Actn2 in Z-disc assembly and cardiomyopathy in vertebrates remains elusive. We leveraged genetic tools in zebrafish embryos to elucidate the function of Actn2. We identified a single Actn2 homologue expressed in the zebrafish heart and conducted loss-of-function studies by antisense morpholino technology. Although zebrafish Actn2 assembles early into the Z disc, depletion of actn2 did not affect the early steps of sarcomere assembly. Instead, Actn2 is required for Z bodies to register laterally, forming well-aligned Z discs. Presumably as a consequence to this structural defect in the sarcomere, the depletion of Actn2 resulted in reduced cardiac function, primarily characterized as a reduced end-diastolic diameter. The depletion of actn2 also significantly reduced the ventricle chamber size, due to both reduced cardiomyocyte (CM) size and CM number. Interestingly, reduced CM size can be rescued by the cessation of heart contractions. The genetic studies of zebrafish uncovered a function for actn2 in lateral registration of Z body. In actn2 morphant fish, the Z-disc defect sequentially affects cardiac function, which leads to morphological changes in the ventricle through a mechanical force-dependent mechanism.-Yang, J., Xu, X. alpha-Actinin2 is required for the lateral alignment of Z discs and ventricular chamber enlargement during zebrafish cardiogenesis. FASEB J. 26, 4230-4242 (2012). www.fasebj.org	[Yang, Jingchun; Xu, Xiaolei] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Div Cardiovasc Dis,Dept Med, Rochester, MN 55905 USA	Mayo Clinic	Xu, XL (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Div Cardiovasc Dis,Dept Med, 200 1st St SW, Rochester, MN 55905 USA.	xu.xiaolei@mayo.edu		Yang, Jingchun/0000-0002-9122-2367	Mayo Foundation; U.S. National Institutes of Health grant [HL81753]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081753] Funding Source: NIH RePORTER	Mayo Foundation; U.S. National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Yu-huan Shih (Mayo Clinic College of Medicine) for his contributions in conducting the RT-PCR experiments. The authors thank Dr. Chi-Bin Chien (University of Utah, Salt Lake City, UT, USA) for sharing the following plasmids: p5E-MCS, pME-megfp, p3E-poly(A), and pDestTol2pA. The authors thank Dr. Carol Gregorio (University of Arizona, Tucson, AZ, USA) and Dr. Joseph Sanger (SUNY Upstate Medical University, Syracuse, NY, USA) for sharing the LASP2 and MYOTILIN cDNAs, respectively. The authors also thank Beninio Jomok for his help with zebrafish husbandry. This study was supported by the Mayo Foundation and by a U.S. National Institutes of Health grant (HL81753) to X.X. The authors declare no conflicts of interest.	Auman HJ, 2007, PLOS BIOL, V5, P604, DOI 10.1371/journal.pbio.0050053; Bartman T, 2005, DEV DYNAM, V233, P373, DOI 10.1002/dvdy.20367; Bartman T, 2004, PLOS BIOL, V2, P673, DOI 10.1371/journal.pbio.0020129; Chen ZY, 2008, CARDIOVASC RES, V79, P97, DOI 10.1093/cvr/cvn073; Chiu C, 2010, J AM COLL CARDIOL, V55, P1127, DOI 10.1016/j.jacc.2009.11.016; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; Du AP, 2008, DEV BIOL, V318, P236, DOI 10.1016/j.ydbio.2008.03.011; Frank D, 2006, J MOL MED, V84, P446, DOI 10.1007/s00109-005-0033-1; Freeman JLR, 2000, FEBS LETT, V473, P280, DOI 10.1016/S0014-5793(00)01543-X; Garvey SM, 2006, HUM MOL GENET, V15, P2348, DOI 10.1093/hmg/ddl160; Gupta V, 2012, FASEB J, V26, P1892, DOI 10.1096/fj.11-194548; Hassel D, 2009, NAT MED, V15, P1281, DOI 10.1038/nm.2037; Holterhoff CK, 2009, DEV DYNAM, V238, P2936, DOI 10.1002/dvdy.22123; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282; Huang W, 2009, DEV BIOL, V331, P237, DOI 10.1016/j.ydbio.2009.04.039; Jani K, 2007, J CELL BIOL, V179, P1583, DOI 10.1083/jcb.200707045; Jou CJ, 2010, CELL PHYSIOL BIOCHEM, V25, P419, DOI 10.1159/000303046; Keren A, 2008, NAT CLIN PRACT CARD, V5, P158, DOI 10.1038/ncpcardio1110; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343; Lange S, 2006, TRENDS CELL BIOL, V16, P11, DOI 10.1016/j.tcb.2005.11.007; Lin YF, 2012, DEV BIOL, V362, P242, DOI 10.1016/j.ydbio.2011.12.005; Linke WA, 2008, CARDIOVASC RES, V77, P637, DOI 10.1016/j.cardiores.2007.03.029; Luther PK, 2009, J MUSCLE RES CELL M, V30, P171, DOI 10.1007/s10974-009-9189-6; Mills MA, 2001, HUM MOL GENET, V10, P1335, DOI 10.1093/hmg/10.13.1335; Moncman CL, 2002, EXP CELL RES, V273, P204, DOI 10.1006/excr.2001.5423; Morimoto S, 2008, CARDIOVASC RES, V77, P659, DOI 10.1093/cvr/cvm084; Moulder GL, 2010, J MOL BIOL, V403, P516, DOI 10.1016/j.jmb.2010.08.055; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Poss KD, 2002, DEVELOPMENT, V129, P5141; Pyle WG, 2004, CIRC RES, V94, P296, DOI 10.1161/01.RES.0000116143.74830.A9; ROULIER EM, 1992, J CELL BIOL, V116, P911, DOI 10.1083/jcb.116.4.911; Sanger JW, 2009, CELL MOTIL CYTOSKEL, V66, P556, DOI 10.1002/cm.20365; Seeley M, 2007, CIRC RES, V100, P238, DOI 10.1161/01.RES.0000255758.69821.b5; Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875; Sjoblom B, 2008, CELL MOL LIFE SCI, V65, P2688, DOI 10.1007/s00018-008-8080-8; Stout AL, 2008, CELL MOTIL CYTOSKEL, V65, P353, DOI 10.1002/cm.20265; Sun XJ, 2008, CIRC RES, V102, P831, DOI 10.1161/CIRCRESAHA.107.166488; Sun XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006596; van der Meer DLM, 2006, DEV BIOL, V299, P356, DOI 10.1016/j.ydbio.2006.07.032; Wang J, 2005, CELL MOTIL CYTOSKEL, V61, P34, DOI 10.1002/cm.20063; Xu XL, 2002, NAT GENET, V30, P205, DOI 10.1038/ng816; Yang JC, 2012, JOVE-J VIS EXP, DOI 10.3791/3510; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhang RL, 2009, HUM MOL GENET, V18, P4130, DOI 10.1093/hmg/ddp362; Zhang RL, 2009, DEV DYNAM, V238, P1564, DOI 10.1002/dvdy.21929; Zheng M, 2009, HUM MOL GENET, V18, P701, DOI 10.1093/hmg/ddn400; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	52	27	28	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4230	4242		10.1096/fj.12-207969	http://dx.doi.org/10.1096/fj.12-207969			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22767232	Bronze, Green Published			2022-12-28	WOS:000309704000028
J	Slominski, AT; Kim, TK; Shehabi, HZ; Semak, I; Tang, EKY; Nguyen, MN; Benson, HAE; Korik, E; Janjetovic, Z; Chen, JJ; Yates, CR; Postlethwaite, A; Li, W; Tuckey, RC				Slominski, Andrzej T.; Kim, Tae-Kang; Shehabi, Haleem Z.; Semak, Igor; Tang, Edith K. Y.; Nguyen, Minh N.; Benson, Heather A. E.; Korik, Elena; Janjetovic, Zorica; Chen, Jianjun; Yates, Charles R.; Postlethwaite, Arnold; Li, Wei; Tuckey, Robert C.			In vivo evidence for a novel pathway of vitamin D-3 metabolism initiated by P450scc and modified by CYP27B1	FASEB JOURNAL			English	Article						20-hydroxyvitamin D; CYP11A1; placenta; adrenals; keratinocytes	KAPPA-B ACTIVITY; CYTOCHROME P450SCC; INHIBITS PROLIFERATION; 7-DEHYDROCHOLESTEROL; PRODUCT; SKIN; D-3; D3; TRANSFORMATION; HYDROXYLATION	We define previously unrecognized in vivo pathways of vitamin D-3 (D3) metabolism generating novel D3-hydroxyderivatives different from 25-hydroxyvitamin D-3 [25(OH)D3] and 1,25(OH)(2)D3. Their novel products include 20-hydroxyvitamin D-3 [20(OH) D3], 22(OH)D3, 20,23(OH)(2)D3, 20,22(OH)(2)D3, 1,20(OH)(2)D3, 1,20,23(OH)(3)D3, and 17,20,23(OH)(3)D3 and were produced by placenta, adrenal glands, and epidermal keratinocytes. We detected the predominant metabolite [20(OH)D3] in human serum with a relative concentration similar to 20 times lower than 25(OH)D3. Use of inhibitors and studies performed with isolated mitochondria and purified enzymes demonstrated involvement of the steroidogenic enzyme cytochrome P450scc (CYP11A1) as well as CYP27B1 (1 alpha-hydroxylase). In placenta and adrenal glands with high CYP11A1 expression, the predominant pathway was D3 -> 20(OH) D3 -> 20,23(OH)(2)D3 -> 17,20,23(OH)(3)D3 with further 1 alpha-hydroxylation, and minor pathways were D3 v 25(OH) D3 -> 1,25(OH)(2)D3 and D3 -> 22(OH) D3 -> 20,22(OH)(2)D3. In epidermal keratinocytes, we observed higher proportions of 22(OH)D3 and 20,22(OH)(2)D3. We also detected endogenous production of 20(OH)D3, 22(OH) D3, 20,23(OH)(2)D3, 20,22(OH)(2)D3, and 17,20,23(OH)(3)D3 by immortalized human keratinocytes. Thus, we provide in vivo evidence for novel pathways of D3 metabolism initiated by CYP11A1, with the product profile showing organ/cell type specificity and being modified by CYP27B1 activity. These findings define the pathway intermediates as natural products/endogenous bioregulators and break the current dogma that vitamin D is solely activated through the sequence D3 -> 25(OH)D3 -> 1,25(OH)(2)D3.-Slominski, A. T., Kim, T.-K., Shehabi, H. Z., Semak, I., Tang, E. K. Y., Nguyen, M. N., Benson, H. A. E., Korik, E., Janjetovic, Z., Chen, J., Yates, C. R., Postlethwaite, A., Li, W., Tuckey, R. C. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26, 3901-3915 (2012). www.fasebj.org	[Slominski, Andrzej T.; Postlethwaite, Arnold] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA; [Chen, Jianjun; Yates, Charles R.; Li, Wei] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Shehabi, Haleem Z.; Benson, Heather A. E.] Curtin Univ Technol, Sch Pharm, Curtin Hlth Innovat Res Inst, Perth, WA, Australia; [Semak, Igor; Korik, Elena] Belarusian State Univ, Dept Biochem, Minsk 220050, BELARUS; [Tang, Edith K. Y.; Nguyen, Minh N.; Tuckey, Robert C.] Univ Western Australia, Sch Chem & Biochem, Crawley, WA, Australia; [Slominski, Andrzej T.; Kim, Tae-Kang; Janjetovic, Zorica] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Curtin University; Belarusian State University; University of Western Australia; University of Tennessee System; University of Tennessee Health Science Center	Slominski, AT (corresponding author), Dept Pathol, 930 Madison Ave,RM525, Memphis, TN 38163 USA.	aslominski@uthsc.edu	Semak, Igor/AAT-9273-2020; Tuckey, Robert/H-5983-2014	Semak, Igor/0000-0001-9430-8492; Korik, Elena/0000-0002-7888-4518; Slominski, Andrzej/0000-0001-8963-3995; Li, Wei/0000-0002-9522-4474; Tuckey, Robert/0000-0002-5022-4729	U.S. National Institutes of Health (NIH) [R01AR052190]; University of Western Australia; College of Pharmacy at the University of Tennessee Health Science Center; Curtin University of Perth; NIH [1R01AR056666-01A2]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056666, R01AR052190] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Western Australia; College of Pharmacy at the University of Tennessee Health Science Center; Curtin University of Perth; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Drs. D. D. Bikle, T. C. Chen, and H. F. DeLuca for valuable information on vitamin D<INF>3</INF> metabolism in placenta and adrenal glands. The project was supported by U.S. National Institutes of Health (NIH) grant R01AR052190 to A. S., by the University of Western Australia, by the College of Pharmacy at the University of Tennessee Health Science Center, and by Curtin University of Perth. Additional partial support was also obtained from NIH grant 1R01AR056666-01A2 to A.S.	Bikle DD, 2008, J INVEST DERMATOL, V128, P2357, DOI 10.1038/jid.2008.249; Bikle DD, 2011, MOL CELL ENDOCRINOL, V347, P80, DOI 10.1016/j.mce.2011.05.017; Guryev O, 2003, P NATL ACAD SCI USA, V100, P14754, DOI 10.1073/pnas.2336107100; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; HOLICK MF, 1995, P NATL ACAD SCI USA, V92, P3124, DOI 10.1073/pnas.92.8.3124; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Janjetovic Z, 2011, BRIT J CANCER, V105, P1874, DOI 10.1038/bjc.2011.458; Janjetovic Z, 2010, J CELL PHYSIOL, V223, P36, DOI 10.1002/jcp.21992; Janjetovic Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005988; Kubodera N, 2009, MINI-REV MED CHEM, V9, P1416, DOI 10.2174/138955709789957486; Li W, 2010, STEROIDS, V75, P926, DOI 10.1016/j.steroids.2010.05.021; Nguyen MN, 2009, DRUG METAB DISPOS, V37, P761, DOI 10.1124/dmd.108.025619; Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318; PONCHON G, 1969, J CLIN INVEST, V48, P2032, DOI 10.1172/JCI106168; SEINO Y, 1987, BONE MINER, V2, P479; Slominski A, 2005, FEBS J, V272, P4080, DOI 10.1111/j.1742-4658.2005.04819.x; Slominski A, 2004, EUR J BIOCHEM, V271, P4178, DOI 10.1111/j.1432-1033.2004.04356.x; Slominski A, 2006, FEBS J, V273, P2891, DOI 10.1111/j.1742-4658.2006.05302.x; Slominski Andrzej, 2008, Drug Discov Today Dis Mech, V5, P137; Slominski AT, 2011, J INVEST DERMATOL, V131, P1167, DOI 10.1038/jid.2010.425; Slominski AT, 2011, AM J PHYSIOL-CELL PH, V300, pC526, DOI 10.1152/ajpcell.00203.2010; Slominski AT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009907; Slominski AT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004309; Strushkevich N, 2011, P NATL ACAD SCI USA, V108, P10139, DOI 10.1073/pnas.1019441108; Tang EKY, 2010, DRUG METAB DISPOS, V38, P1553, DOI 10.1124/dmd.110.034389; Tang EKY, 2010, J STEROID BIOCHEM, V119, P171, DOI 10.1016/j.jsbmb.2010.02.022; TUCKER G, 1973, ARCH BIOCHEM BIOPHYS, V155, P47, DOI 10.1016/S0003-9861(73)80008-6; Tuckey RC, 2005, PLACENTA, V26, P273, DOI 10.1016/j.placenta.2004.06.012; Tuckey RC, 1999, EUR J BIOCHEM, V263, P319, DOI 10.1046/j.1432-1327.1999.00483.x; Tuckey RC, 2008, FEBS J, V275, P2585, DOI 10.1111/j.1742-4658.2008.06406.x; Tuckey RC, 2012, DRUG METAB DISPOS, V40, P436, DOI 10.1124/dmd.111.042515; Tuckey RC, 2011, DRUG METAB DISPOS, V39, P1577, DOI 10.1124/dmd.111.040071; Tuckey RC, 2008, J STEROID BIOCHEM, V112, P213, DOI 10.1016/j.jsbmb.2008.10.005; Wang J, 2012, ANTICANCER RES, V32, P739; Yamamoto K, 2005, J BIOL CHEM, V280, P30511, DOI 10.1074/jbc.M505244200; Zbytek B, 2008, J INVEST DERMATOL, V128, P2271, DOI 10.1038/jid.2008.62; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4; Zmijewski MA, 2011, STEROIDS, V76, P193, DOI 10.1016/j.steroids.2010.10.009; Zmijewski MA, 2009, STEROIDS, V74, P218, DOI 10.1016/j.steroids.2008.10.017	39	213	216	2	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3901	3915		10.1096/fj.12-208975	http://dx.doi.org/10.1096/fj.12-208975			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22683847	Green Published			2022-12-28	WOS:000308391600030
J	Stehberg, J; Moraga-Amaro, R; Salazar, C; Becerra, A; Echeverria, C; Orellana, JA; Bultynck, G; Ponsaerts, R; Leybaert, L; Simon, F; Saez, JC; Retamal, MA				Stehberg, Jimmy; Moraga-Amaro, Rodrigo; Salazar, Christian; Becerra, Alvaro; Echeverria, Cesar; Orellana, Juan A.; Bultynck, Geert; Ponsaerts, Raf; Leybaert, Luc; Simon, Felipe; Saez, Juan C.; Retamal, Mauricio A.			Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala	FASEB JOURNAL			English	Article						astrocyte; amnesia; gliotransmitters; learning	GAP-JUNCTION HEMICHANNELS; LONG-TERM POTENTIATION; GLUTAMATE RELEASE; GLIAL-CELLS; ASTROCYTES; EXPRESSION; CHANNEL; NETWORKS; PANNEXIN; BLOCKERS	Recent in vitro evidence indicates that astrocytes can modulate synaptic plasticity by releasing neuroactive substances (gliotransmitters). However, whether gliotransmitter release from astrocytes is necessary for higher brain function in vivo, particularly for memory, as well as the contribution of connexin (Cx) hemichannels to gliotransmitter release, remain elusive. Here, we microinfused into the rat basolateral amygdala (BLA) TAT-Cx43L2, a peptide that selectively inhibits Cx43-hemichannel opening while maintaining synaptic transmission or interastrocyte gap junctional communication. In vivo blockade of Cx43 hemichannels during memory consolidation induced amnesia for auditory fear conditioning, as assessed 24 h after training, without affecting short-term memory, locomotion, or shock reactivity. The amnesic effect was transitory, specific for memory consolidation, and was confirmed after microinfusion of Gap27, another Cx43-hemichannel blocker. Learning capacity was recovered after coinfusion of TAT-Cx43L2 and a mixture of putative gliotransmitters (glutamate, glutamine, lactate, D-serine, glycine, and ATP). We propose that gliotransmitter release from astrocytes through Cx43 hemichannels is necessary for fear memory consolidation at the BLA. Thus, the present study is the first to demonstrate a physiological role for astroglial Cx43 hemichannels in brain function, making these channels a novel pharmacological target for the treatment of psychiatric disorders, including post-traumatic stress disorder.-Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverria, C., Orellana, J. A., Bultynck, G., Ponsaerts, R., Leybaert, L., Simon, F., Saez, J. C., Retamal, M. A. Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. FASEB J. 26, 3649-3657 (2012). www.fasebj.org.	[Stehberg, Jimmy; Moraga-Amaro, Rodrigo; Salazar, Christian] Univ Andres Bello, Fac Ciencias Biol, Dept Ciencias Biol, Neurobiol Lab, Santiago, Chile; [Becerra, Alvaro; Echeverria, Cesar; Simon, Felipe] Univ Andres Bello, Fac Ciencias Biol, Dept Ciencias Biol, Lab Fisiopatol Integrat, Santiago, Chile; [Stehberg, Jimmy] Univ Andres Bello, Ctr Invest Biomed, Santiago, Chile; [Saez, Juan C.] Pontificia Univ Catolica Chile, Dept Fisiol, Santiago, Chile; [Bultynck, Geert; Ponsaerts, Raf] Katholieke Univ Leuven, Dept Cell & Mol Med, Lab Mol & Cellular Signaling, Louvain, Belgium; [Leybaert, Luc] Univ Ghent, Fac Med & Hlth Sci, Dept Basic Med Sci, B-9000 Ghent, Belgium; [Saez, Juan C.] Ctr Interdiciplinario Neurociencias Valparaiso, Inst Milenio, Valparaiso, Chile; [Retamal, Mauricio A.] Clin Alemana Univ Desarrollo, Fac Med, Dept Fisiol, Santiago, Chile; [Simon, Felipe] Millennium Inst Immunol & Immunotherapy, Santiago, Chile	Universidad Andres Bello; Universidad Andres Bello; Universidad Andres Bello; Pontificia Universidad Catolica de Chile; KU Leuven; Ghent University; Universidad del Desarrollo	Stehberg, J (corresponding author), Univ Andres Bello, Fac Ciencias Biol, Dept Ciencias Biol, Neurobiol Lab, Santiago, Chile.	jstehberg@unab.cl	Orellana, Juan A./F-6148-2012; Echeverría, César/AAH-4994-2019; Leybaert, Luc/F-4079-2015	Echeverría, César/0000-0001-5431-7183; Leybaert, Luc/0000-0001-6452-6982; Orellana, Juan Andres/0000-0003-4076-207X; Bultynck, Geert/0000-0002-5968-4828; Retamal, Mauricio A./0000-0003-2562-6686; Simon, Felipe/0000-0002-2653-9798	Universidad Andres Bello [(UNAB) AR-05-09, UNAB AR-01-10, UNAB DI-02-11/N, UNAB DI-33-11/R]; Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [1121078]; Fondo de Fomento al Desarrollo Cientifico y Tecnologico (FONDEF) [D07I1086]; FONDECYT [1120214, 1070591]; Millennium Institute on Immunology and Immunotherapy [P09-016-F]; Research Council of the Katholieke Universiteit Leuven (Leuven, Belgium) [GOA/09/012]; Interuniversity Attraction Poles Program Belgian Science Policy [P6/28, P6/31, P7]; Research Foundation-Flanders (FWO) [G.0298.11]; FWO; Anillo [ACT71]	Universidad Andres Bello; Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Fondo de Fomento al Desarrollo Cientifico y Tecnologico (FONDEF)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDEF); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Millennium Institute on Immunology and Immunotherapy; Research Council of the Katholieke Universiteit Leuven (Leuven, Belgium); Interuniversity Attraction Poles Program Belgian Science Policy(Belgian Federal Science Policy Office); Research Foundation-Flanders (FWO)(FWO); FWO(FWO); Anillo(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT PIA/ANILLOS)	The authors thank Dr. Gabriel Leon, Juan Pablo Morales Montenegro, Juan Pablo Donoso Ramos, Mar a Viviana Moreno, Gabriela Andaur, Francia Quintana, Raul Galarce and Fernando Bustos for technical assistance. This work was partially supported by grants Universidad Andres Bello (UNAB) AR-05-09 (J.S.), UNAB AR-01-10 (J.S.), UNAB DI-02-11/N (J.S.), UNAB DI-33-11/R (F. S.), Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) 1121078 (F. S.), Fondo de Fomento al Desarrollo Cientifico y Tecnologico (FONDEF) D07I1086 (J.C.S.), FONDECYT 1120214 (M. A. R), FONDECYT 1070591, Millennium Institute on Immunology and Immunotherapy P09-016-F (F. S.), and Anillo ACT71 (J.C.S.), by the Research Council of the Katholieke Universiteit Leuven (Leuven, Belgium) via the Concerted Actions program GOA/09/012 (G. B.), and by the Interuniversity Attraction Poles Program Belgian Science Policy P6/28 (G. B.) and P6/31 and P7 (L. L.) and by the Research Foundation-Flanders (FWO) through research grant G.0298.11 (G. B. and L. L.) and the FWO-sponsored Cx/Panx research network.	Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Bonansco C, 2011, EUR J NEUROSCI, V33, P1483, DOI 10.1111/j.1460-9568.2011.07631.x; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Domingues AMD, 2010, NEUROCHEM INT, V57, P359, DOI 10.1016/j.neuint.2010.03.024; Evans WH, 2007, CELL COMMUN ADHES, V14, P265, DOI 10.1080/15419060801891034; Florian C, 2011, J NEUROSCI, V31, P6956, DOI 10.1523/JNEUROSCI.5761-10.2011; Frisch C, 2003, EUR J NEUROSCI, V18, P2313, DOI 10.1046/j.1460-9568.2003.02971.x; Garre JM, 2010, P NATL ACAD SCI USA, V107, P22659, DOI 10.1073/pnas.1013793107; Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00-0594fje; Giaume C, 2010, NAT REV NEUROSCI, V11, P87, DOI 10.1038/nrn2757; Gorg B, 2010, GLIA, V58, P691, DOI 10.1002/glia.20955; Gosejacob D, 2011, GLIA, V59, P511, DOI 10.1002/glia.21120; Gourine AV, 2010, SCIENCE, V329, P571, DOI 10.1126/science.1190721; GUTNICK MJ, 1981, BRAIN RES, V213, P486, DOI 10.1016/0006-8993(81)90259-6; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Iglesias R, 2009, J NEUROSCI, V29, P7092, DOI 10.1523/JNEUROSCI.6062-08.2009; Iwabuchi S, 2011, NEUROCHEM INT, V58, P376, DOI 10.1016/j.neuint.2010.12.013; Jiang S, 2011, BRAIN RES, V1392, P8, DOI 10.1016/j.brainres.2011.03.056; Juszczak GR, 2009, PROG NEURO-PSYCHOPH, V33, P181, DOI 10.1016/j.pnpbp.2008.12.014; Koulakoff A, 2008, GLIA, V56, P1299, DOI 10.1002/glia.20698; LeDoux J, 2007, CURR BIOL, V17, pR868, DOI 10.1016/j.cub.2007.08.005; Lee S, 2010, SCIENCE, V330, P790, DOI 10.1126/science.1184334; Nagy JI, 2001, J COMP NEUROL, V441, P302, DOI 10.1002/cne.1414; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; Orellana JA, 2010, GLIA, V58, P329, DOI 10.1002/glia.20926; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640; Perea G, 2010, BRAIN RES REV, V63, P93, DOI 10.1016/j.brainresrev.2009.10.005; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Ponsaerts R, 2012, BIOL CELL, V104, P367, DOI 10.1111/boc.201100079; Ponsaerts R, 2010, FASEB J, V24, P4378, DOI 10.1096/fj.09-153007; Rash JE, 2001, CELL COMMUN ADHES, V8, P315, DOI 10.3109/15419060109080745; Rash JE, 2001, J NEUROSCI, V21, P1983, DOI 10.1523/JNEUROSCI.21-06-01983.2001; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Rudkouskaya A, 2008, J NEUROCHEM, V105, P2260, DOI 10.1111/j.1471-4159.2008.05312.x; Saez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365-201X.2003.01196.x; Saez JC, 2010, EXP CELL RES, V316, P2377, DOI 10.1016/j.yexcr.2010.05.026; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Welsh DK, 1996, BRAIN RES, V706, P30, DOI 10.1016/0006-8993(95)01172-2; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003	46	162	170	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3649	3657		10.1096/fj.11-198416	http://dx.doi.org/10.1096/fj.11-198416			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22665389				2022-12-28	WOS:000308391600007
J	Bulmer, JN; Innes, BA; Levey, J; Robson, SC; Lash, GE				Bulmer, Judith N.; Innes, Barbara A.; Levey, Joanne; Robson, Stephen C.; Lash, Gendie E.			The role of vascular smooth muscle cell apoptosis and migration during uterine spiral artery remodeling in normal human pregnancy	FASEB JOURNAL			English	Article						trophoblast; protease; angiogenic growth factor	NATURAL-KILLER-CELLS; EXTRAVILLOUS TROPHOBLAST; UTEROPLACENTAL ARTERIES; GROWTH-FACTORS; PLACENTAL BED; GUINEA-PIG; LIGAND; TRANSFORMATION; EXPRESSION; CYTOKINE	During human uterine spiral artery (SpA) remodeling, vascular smooth muscle cells (VSMCs) are lost and replaced by fibrinoid, incorporating extravillous trophoblast (EVT) cells. The aim of the current study was to determine the relative contributions of apoptosis and migration to VSMC loss during SpA remodeling. Immunohistochemistry (Apoptag, active caspase 3, lamin) of placental bed biopsies (8-20 wk gestation) demonstrated apoptotic cells in all samples; double immunolabeling identified these as trophoblasts, leukocytes, and endothelial cells. In total, 294 SpAs were studied, and only one apoptotic VSMC was identified. H-caldesmon-immunopositive VSMCs were observed surrounding and separate from SpA walls in partially remodeled vessels; the highest level of VSMC migration was observed in vessels with associated EVT cells (number of migrated cells 6.4 +/- 1.2; distance migrated 3.5 +/- 0.3 pixels) compared with those without (number of migrated cells 3.6 +/- 0.5, P<0.001; distance migrated 2.8 +/- 0.1 pixels, P<0.0001). VEGF-A, VEGF-C, TGF-beta 1, and Ang-2 all stimulated human aorta VSMC invasion in vitro, although EVT cell culture supernatants did not. In summary, apoptosis is unlikely to play a major role in loss of VSMCs from SpAs during remodeling in normal pregnancy, but VSMCs appear to migrate away from the wall of the SpA, an effect enhanced by the presence of EVT cells.-Bulmer, J. N., Innes, B. A., Levey, J., Robson, S. C., Lash, G. E. The role of vascular smooth muscle cell apoptosis and migration during uterine spiral artery remodeling in normal human pregnancy. FASEB J. 26, 2975-2985 (2012). www.fasebj.org	[Bulmer, Judith N.; Innes, Barbara A.; Levey, Joanne; Robson, Stephen C.; Lash, Gendie E.] Newcastle Univ, Inst Cellular Med, Reprod & Vasc Biol Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Lash, GE (corresponding author), Newcastle Univ, Inst Cellular Med, Reprod & Vasc Biol Grp, 3rd Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.e.lash@ncl.ac.uk	Lash, Gendie/AAI-4116-2021	Lash, Gendie/0000-0002-3606-1361	Wellcome Trust [069939]; UK Biotechnology and Biological Sciences Research Council [BB/E016790/1]; BBSRC [BB/E016790/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E016790/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors acknowledge the staff at the Royal Victoria Infirmary (Newcastle upon Tyne, UK) for their assistance in sample collection. This project was supported by funding from The Wellcome Trust (069939) and from the UK Biotechnology and Biological Sciences Research Council (BB/E016790/1).	Ball E, 2006, J PATHOL, V208, P535, DOI 10.1002/path.1927; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Gerthoffer WT, 2007, CIRC RES, V100, P607, DOI 10.1161/01.RES.0000258492.96097.47; Harris LK, 2006, AM J PATHOL, V169, P1863, DOI 10.2353/ajpath.2006.060265; Harris LK, 2010, AM J PATHOL, V177, P2103, DOI 10.2353/ajpath.2010.100182; Keogh RJ, 2007, CIRC RES, V100, P834, DOI 10.1161/01.RES.0000261352.81736.37; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Kim YM, 2003, AM J OBSTET GYNECOL, V189, P1063, DOI 10.1067/S0002-9378(03)00838-X; Korshunov VA, 2008, CURR OPIN HEMATOL, V15, P250, DOI 10.1097/MOH.0b013e3282f97d71; Lash GE, 2007, PLACENTA, V28, P390, DOI 10.1016/j.placenta.2006.06.001; Lash GE, 2010, PLACENTA, V31, pS87, DOI 10.1016/j.placenta.2009.12.022; Lash GE, 2010, PLACENTA, V31, P545, DOI 10.1016/j.placenta.2010.02.020; Lash GE, 2011, HUM REPROD, V26, P2289, DOI 10.1093/humrep/der198; Lash GE, 2006, J LEUKOCYTE BIOL, V80, P572, DOI 10.1189/jlb.0406250; Loro LL, 2003, J ORAL PATHOL MED, V32, P125, DOI 10.1034/j.1600-0714.2003.00052.x; NANAEV A, 1995, CELL TISSUE RES, V282, P407, DOI 10.1007/s004410050492; Nanaev AK, 2000, PLACENTA, V21, P306, DOI 10.1053/plac.1999.0490; Naruse K, 2009, HUM REPROD, V24, P553, DOI 10.1093/humrep/den408; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; Pongcharoen S, 2004, PLACENTA, V25, P321, DOI 10.1016/j.placenta.2003.08.020; Rakesh K, 2005, INT IMMUNOPHARMACOL, V5, P1487, DOI 10.1016/j.intimp.2005.05.003; Red-Horse K, 2006, J CLIN INVEST, V116, P2643, DOI 10.1172/JC127306; Robson SC, 2002, AM J OBSTET GYNECOL, V187, P1349, DOI 10.1067/mob.2002.126866; Smith SD, 2009, AM J PATHOL, V174, P1959, DOI 10.2353/ajpath.2009.080995; Stadelmann C, 2000, CELL TISSUE RES, V301, P19, DOI 10.1007/s004410000203; Tarrade A, 2001, LAB INVEST, V81, P1199, DOI 10.1038/labinvest.3780334; Vassiliadou N, 1998, BIOL REPROD, V58, P982, DOI 10.1095/biolreprod58.4.982; Whitley GSJ, 2010, PLACENTA, V31, P465, DOI 10.1016/j.placenta.2010.03.002; Whitley GSJ, 2009, J ANAT, V215, P21, DOI 10.1111/j.1469-7580.2008.01039.x	30	52	53	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2975	2985		10.1096/fj.12-203679	http://dx.doi.org/10.1096/fj.12-203679			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22499583				2022-12-28	WOS:000305912500025
J	Matusali, G; Tchidjou, HK; Pontrelli, G; Bernardi, S; D'Ettorre, G; Vullo, V; Buonomini, AR; Andreoni, M; Santoni, A; Cerboni, C; Doria, M				Matusali, Giulia; Tchidjou, Hyppolite Kuekou; Pontrelli, Giuseppe; Bernardi, Stefania; D'Ettorre, Gabriella; Vullo, Vincenzo; Buonomini, Anna Rita; Andreoni, Massimo; Santoni, Angela; Cerboni, Cristina; Doria, Margherita			Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells	FASEB JOURNAL			English	Article						immune evasion; MICA/B; ULBP; shedding	MHC CLASS-I; NATURAL-KILLER CYTOTOXICITY; BLOOD MONONUCLEAR-CELLS; DOWN-REGULATION; MATRIX METALLOPROTEINASES; ACTIVATING RECEPTORS; T-LYMPHOCYTES; MIC LIGANDS; MOLECULES; MECHANISM	In humans, the interaction of the natural killer group 2 member D (NKG2D)-activating receptor on natural killer (NK) and CD8(+) T cells with its major histocompatibility complex class I-related chain (MIC) and UL16 binding protein (ULBP) ligands (NKG2DLs) promotes recognition and elimination of stressed cells, such as tumor or infected cells. Here, we investigated the capacity of HIV-1 to modulate NKG2DL expression and escape NGK2D-mediated immunosurveillance. In CD4(+) T lymphocytes, both cell surface expression and release of MICA, MICB, and ULBP2 were up-regulated >2-fold by HIV-1 infection. In HIV-infected CD4(+) T lymphocytes or Jurkat T-cell lines, increased shedding of soluble NKG2DLs (sNKG2DLs) was impaired by a matrix metalloproteinase inhibitor (MMPI). Moreover, naive HIV+ patients displayed increased plasma sMICA and sULBP2 levels and reduced NKG2D expression on NK and CD8(+) T cells compared to patients receiving highly active antiretroviral therapy (HAART) or healthy donors. In individual patients, HAART uptake resulted in the drop of sNKG2DL and recovery of NKG2D expression. Finally, sNKG2DLs in patients' plasma down-regulated NKG2D on NK and CD8(+) T cells and impaired NKG2D-mediated cytotoxicity of NK cells. Thus, NKG2D detuning by sNKG2DLs may promote HIV-1 immune evasion and compromise host resistance to opportunistic infections, but HAART and MMPI have the potential to avoid such immune dysfunction.-Matusali, G., Tchidjou, H. K., Pontrelli, G., Bernardi, S., D'Ettorre, G., Vullo, V., Buonomini, A. R., Andreoni, M., Santoni, A., Cerboni, C., Doria, M. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.	[Matusali, Giulia; Doria, Margherita] Bambino Gesu Pediat Hosp, Lab Immunoinfectivol, IRCCS, I-00165 Rome, Italy; [Tchidjou, Hyppolite Kuekou; Pontrelli, Giuseppe; Bernardi, Stefania] Bambino Gesu Pediat Hosp, Lab Immunoinfectivol, Univ Dept Pediat DPUO, I-00165 Rome, Italy; [D'Ettorre, Gabriella; Vullo, Vincenzo] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dept Publ Hlth & Infect Dis, Rome, Italy; [Santoni, Angela; Cerboni, Cristina] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dept Mol Med, Rome, Italy; [Buonomini, Anna Rita; Andreoni, Massimo] Univ Roma Tor Vergata, Dept Clin Infect Dis, Rome, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; Fondazione Cenci Bolognetti; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; University of Rome Tor Vergata	Doria, M (corresponding author), Bambino Gesu Pediat Hosp, Lab Immunoinfectivol, Piazza S Onofrio 4, I-00165 Rome, Italy.	doria@uniroma2.it	Bernardi, stefania/AAA-2803-2020; matusali, giulia/N-7201-2015; Andreoni, Masimo/AAL-2214-2020; Buonomini, Anna Rita/AAC-7325-2022; d'Ettorre, Gabriella/K-4511-2016; Doria, Margherita/K-3157-2016; Pontrelli, Giuseppe/AAB-5268-2020; santoni, angela/K-8997-2016	matusali, giulia/0000-0002-2948-4243; Buonomini, Anna Rita/0000-0001-7503-2742; Doria, Margherita/0000-0001-5533-0304; Pontrelli, Giuseppe/0000-0001-7831-8383; santoni, angela/0000-0003-1206-7731; Andreoni, Massimo/0000-0002-3205-9758; d'Ettorre, Gabriella/0000-0002-3571-5677; tchidjou kuekou, hyppolite/0000-0001-9573-3845; Bernardi, Stefania/0000-0001-5672-0881	Italian Ministry of Health, Programma Nazionale di Ricerca sull'AIDS; Istituto Superiore di Sanita; Ricerca Corrente	Italian Ministry of Health, Programma Nazionale di Ricerca sull'AIDS; Istituto Superiore di Sanita; Ricerca Corrente(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Corrente (MOH-RC))	The authors thank Marina Potesta for technical work. The authors are grateful to Gabriella Palmieri, Alessandra Zingoni, and Alessandra Soriani for helpful discussions; to Mark Harris for providing anti-Nef mAb; and to Maria Luisa Romiti for help with statistics. The work was supported by grants of the Italian Ministry of Health, Programma Nazionale di Ricerca sull'AIDS, in collaboration with Istituto Superiore di Sanita and Ricerca Corrente, cofunded by the Italian 5 x 1000 contribution to M.D. The authors declare no conflicts of interest.	Alter G, 2009, J INTERN MED, V265, P29, DOI 10.1111/j.1365-2796.2008.02045.x; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Cerboni C, 2007, J GEN VIROL, V88, P242, DOI 10.1099/vir.0.82125-0; Cerboni C, 2009, BLOOD, V113, P2955, DOI 10.1182/blood-2008-06-165944; Champsaur M, 2010, IMMUNOL REV, V235, P267, DOI 10.1111/j.0105-2896.2010.00893.x; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Conry SJ, 2009, J VIROL, V83, P11175, DOI 10.1128/JVI.00753-09; Diermayr S, 2008, BLOOD, V111, P1428, DOI 10.1182/blood-2007-07-101311; Doubrovina ES, 2003, J IMMUNOL, V171, P6891, DOI 10.4049/jimmunol.171.12.6891; Duan XH, 2011, MED ONCOL, V28, P466, DOI 10.1007/s12032-010-9480-9; Epling-Burnette PK, 2007, BLOOD, V109, P4816, DOI 10.1182/blood-2006-07-035519; Fausther-Bovendo H, 2009, AIDS, V23, P1077, DOI 10.1097/QAD.0b013e32832cb26b; Fu GF, 2010, CELL IMMUNOL, V265, P37, DOI 10.1016/j.cellimm.2010.06.011; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Jinushi M, 2003, J IMMUNOL, V171, P5423, DOI 10.4049/jimmunol.171.10.5423; Landi A, 2011, CURR HIV RES, V9, P496, DOI 10.2174/157016211798842116; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Latronico T, 2007, AIDS, V21, P677, DOI 10.1097/QAD.0b013e328018751d; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Liuzzi GM, 2004, BRAIN, V127, P398, DOI 10.1093/brain/awh049; Mastroianni CM, 2007, TRENDS MOL MED, V13, P449, DOI 10.1016/j.molmed.2007.09.001; Matusali G, 2012, J VIROL, V86, P4496, DOI 10.1128/JVI.05788-11; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Mincheva-Nilsson L, 2006, J IMMUNOL, V176, P3585, DOI 10.4049/jimmunol.176.6.3585; Nolting A, 2010, VIROLOGY, V406, P12, DOI 10.1016/j.virol.2010.05.014; Norman JM, 2011, NAT IMMUNOL, V12, P975, DOI 10.1038/ni.2087; Nowbakht P, 2005, BLOOD, V105, P3615, DOI 10.1182/blood-2004-07-2585; Raffaghello L, 2004, NEOPLASIA, V6, P558, DOI 10.1593/neo.04316; Richard J, 2010, BLOOD, V115, P1354, DOI 10.1182/blood-2009-08-237370; Rognvaldsson T, 2007, EXPERT REV MOL DIAGN, V7, P435, DOI 10.1586/14737159.7.4.435; Salih HR, 2008, FRONT BIOSCI, V13, P3448; Salih HR, 2006, HUM IMMUNOL, V67, P188, DOI 10.1016/j.humimm.2006.02.008; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Shafi S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002922; Shah AH, 2010, CELL HOST MICROBE, V8, P397, DOI 10.1016/j.chom.2010.10.008; Stephens HAF, 2001, TRENDS IMMUNOL, V22, P378, DOI 10.1016/S1471-4906(01)01960-3; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; VULCANO M, 1993, IMMUNOL LETT, V36, P153, DOI 10.1016/0165-2478(93)90047-6; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Ward J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000613; Webster NL, 2006, J LEUKOCYTE BIOL, V80, P1052, DOI 10.1189/jlb.0306152; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720	46	55	60	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2440	2450		10.1096/fj.12-223057	http://dx.doi.org/10.1096/fj.12-223057			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23395909				2022-12-28	WOS:000319667600031
J	Miyahara, T; Runge, S; Chatterjee, A; Chen, M; Mottola, G; Fitzgerald, JM; Serhan, CN; Conte, MS				Miyahara, Takuya; Runge, Sara; Chatterjee, Anuran; Chen, Mian; Mottola, Giorgio; Fitzgerald, Jonathan M.; Serhan, Charles N.; Conte, Michael S.			D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury	FASEB JOURNAL			English	Article						inflammation; intracellular signaling; resolvin	DOCOSAHEXAENOIC ACID; ANTIINFLAMMATORY PROPERTIES; HUMAN PHAGOCYTES; INFLAMMATION; RESOLUTION; E1; OMEGA-3-FATTY-ACIDS; MEDIATORS; RECEPTOR; LIPOXIN	Recent evidence suggests that specialized lipid mediators derived from polyunsaturated fatty acids control resolution of inflammation, but little is known about resolution pathways in vascular injury. We sought to determine the actions of D-series resolvin (RvD) on vascular smooth muscle cell (VSMC) phenotype and vascular injury. Human VSMCs were treated with RvD1 and RvD2, and phenotype was assessed by proliferation, migration, monocyte adhesion, superoxide production, and gene expression assays. A rabbit model of arterial angioplasty with local delivery of RvD2 (10 nM vs. vehicle control) was employed to examine effects on vascular injury in vivo. Local generation of proresolving lipid mediators (LC-MS/MS) and expression of RvD receptors in the vessel wall were assessed. RvD1 and RvD2 produced dose-dependent inhibition of VSMC proliferation, migration, monocyte adhesion, superoxide production, and proinflammatory gene expression (IC50 approximate to 0.1-1 nM). In balloon-injured rabbit arteries, cell proliferation (51%) and leukocyte recruitment (41%) were reduced at 3 d, and neointimal hyperplasia was attenuated (29%) at 28 d by RvD2. We demonstrate endogenous biosynthesis of proresolving lipid mediators and expression of receptors for RvD1 in the artery wall. RvDs broadly reduce VSMC responses and modulate vascular injury, suggesting that local activation of resolution mechanisms expedites vascular homeostasis.-Miyahara, T., Runge, S., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J. M., Serhan, C. N., Conte, M. S. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury.	[Miyahara, Takuya; Runge, Sara; Chatterjee, Anuran; Chen, Mian; Mottola, Giorgio; Conte, Michael S.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA; [Fitzgerald, Jonathan M.; Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; [Fitzgerald, Jonathan M.; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Conte, MS (corresponding author), Univ Calif San Francisco, Div Vasc & Endovasc Surg, Lab Accelerated Vasc Res, 400 Parnassus Ave,Ste A581, San Francisco, CA 94143 USA.	michael.conte@ucsfmedctr.org	Mottola, Giorgio/AAO-4375-2021	Mottola, Giorgio/0000-0003-0670-8619	Foundation for Accelerated Vascular Research (Vascular Cures); U.S. National Institutes of Health [1P01GM095467, F32 HL 104851-2]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL104851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER	Foundation for Accelerated Vascular Research (Vascular Cures); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Rong Wang for critical review of the manuscript. This work was supported in part by funding from the Foundation for Accelerated Vascular Research (Vascular Cures), and U.S. National Institutes of Health grants 1P01GM095467 (C.N.S.), and F32 HL 104851-2 (S.R.). C.N.S. is an inventor on patents (resolvins) assigned to Brigham and Women's Hospital (BWH) and licensed to Resolvyx Pharmaceuticals (Cambridge, MA, USA). C.N.S. is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. C.N.S.'s interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies.	Aoki H, 2008, BIOCHEM BIOPH RES CO, V367, P509, DOI 10.1016/j.bbrc.2008.01.012; Aoki H, 2010, BIOCHEM BIOPH RES CO, V400, P128, DOI 10.1016/j.bbrc.2010.08.025; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bento AF, 2011, J IMMUNOL, V187, P1957, DOI 10.4049/jimmunol.1101305; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Conte MS, 2006, J VASC SURG, V43, P742, DOI 10.1016/j.jvs.2005.12.058; CONTE MS, 1994, CIRCULATION, V89, P2161, DOI 10.1161/01.CIR.89.5.2161; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; DECATERINA R, 1995, PROSTAG LEUKOTR ESS, V52, P191, DOI 10.1016/0952-3278(95)90021-7; Filion KB, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-24; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Ho KJ, 2008, AM J PHYSIOL-HEART C, V295, pH1132, DOI 10.1152/ajpheart.00079.2008; Ho KJ, 2010, AM J PATHOL, V177, P2116, DOI 10.2353/ajpath.2010.091082; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LoGerfo F, 2006, J VASC SURG, V43, P750; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMahon B, 2000, J BIOL CHEM, V275, P27566; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Norling LV, 2012, ARTERIOSCL THROM VAS, V32, P1970, DOI 10.1161/ATVBAHA.112.249508; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Qu XL, 2012, J PATHOL, V228, P506, DOI 10.1002/path.4050; Rocha-Singh KJ, 2007, CATHETER CARDIO INTE, V69, P910, DOI 10.1002/ccd.21104; Rodgers K, 2005, AM J PATHOL, V167, P683, DOI 10.1016/S0002-9440(10)62043-3; Schillinger M, 2007, CIRCULATION, V115, P2745, DOI 10.1161/CIRCULATIONAHA.107.688341; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Spite M, 2009, BRIT J PHARMACOL, V158, P1062, DOI 10.1111/j.1476-5381.2009.00234.x; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Wang GJ, 2005, ARTERIOSCL THROM VAS, V25, P2081, DOI 10.1161/01.ATV.0000183885.66153.8a	44	90	94	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2220	2232		10.1096/fj.12-225615	http://dx.doi.org/10.1096/fj.12-225615			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23407709	Green Published			2022-12-28	WOS:000319667600013
J	Tilan, JU; Everhart, LM; Abe, K; Kuo-Bonde, L; Chalothorn, D; Kitlinska, J; Burnett, MS; Epstein, SE; Faber, JE; Zukowska, Z				Tilan, Jason U.; Everhart, Lindsay M.; Abe, Ken; Kuo-Bonde, Lydia; Chalothorn, Dan; Kitlinska, Joanna; Burnett, Mary Susan; Epstein, Stephen E.; Faber, James E.; Zukowska, Zofia			Platelet neuropeptide Y is critical for ischemic revascularization in mice	FASEB JOURNAL			English	Article						angiogenesis; NPY	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; IMMUNOREACTIVE-NEUROPEPTIDE; DIFFERENTIAL RELEASE; INDUCED ANGIOGENESIS; HINDLIMB ISCHEMIA; RABBIT HINDLIMB; ALPHA-GRANULES; MOUSE STRAINS; NITRIC-OXIDE	We previously reported that the sympathetic neurotransmitter neuropeptide Y (NPY) is potently angiogenic, primarily through its Y2 receptor, and that endogenous NPY is crucial for capillary angiogenesis in rodent hindlimb ischemia. Here we sought to identify the source of NPY responsible for revascularization and its mechanisms of action. At d 3, NPY-/- mice demonstrated delayed recovery of blood flow and limb function, consistent with impaired collateral conductance, while ischemic capillary angiogenesis was reduced (similar to 70%) at d 14. This biphasic temporal response was confirmed by 2 peaks of NPY activation in rats: a transient early increase in neuronally derived plasma NPY and increase in platelet NPY during late-phase recovery. Compared to NPY-null platelets, collagen-activated NPY-rich platelets were more mitogenic (similar to 2-fold vs. similar to 1.6-fold increase) for human microvascular endothelial cells, and Y2/Y5 receptor antagonists ablated this difference in proliferation. In NPY+/+ mice, ischemic angiogenesis was prevented by platelet depletion and then restored by transfusion of platelets from NPY+/+ mice, but not NPY-/- mice. In thrombocytopenic NPY-/- mice, transfusion of wild-type platelets fully restored ischemia-induced angiogenesis. These findings suggest that neuronally derived NPY accelerates the early response to femoral artery ligation by promoting collateral conductance, while platelet-derived NPY is critical for sustained capillary angiogenesis.-Tilan, J. U., Everhart, L. M., Abe, K., Kuo-Bonde, L., Chalothorn, D., Kitlinska, J., Burnett, M. S., Epstein, S. E., Faber, J. E., Zukowska, Z. Platelet neuropeptide Y is critical for ischemic revascularization in mice.	[Tilan, Jason U.; Everhart, Lindsay M.; Abe, Ken; Kuo-Bonde, Lydia; Kitlinska, Joanna; Zukowska, Zofia] Georgetown Univ, Dept Physiol & Biophys, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Tilan, Jason U.] Georgetown Univ, Dept Nursing, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Kitlinska, Joanna] Georgetown Univ, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA; [Chalothorn, Dan; Faber, James E.] Univ N Carolina, Dept Physiol, Chapel Hill, NC USA; [Burnett, Mary Susan; Epstein, Stephen E.] MedStar Hlth Res Inst, Cardiovasc Res Inst, Washington, DC USA; [Zukowska, Zofia] Univ Minnesota, Sch Med, Dept Integrat Biol & Physiol, Minneapolis, MN 55455 USA	Georgetown University; Georgetown University; Georgetown University; University of North Carolina; University of North Carolina Chapel Hill; MedStar Health Research Institute; University of Minnesota System; University of Minnesota Twin Cities	Tilan, JU (corresponding author), Georgetown Univ, Dept Nursing, Sch Nursing & Hlth Studies, 3700 Reservoir Rd NW,St Marys Hall 427E, Washington, DC 20057 USA.	jut@georgetown.edu			U.S. National Institutes of Health (NIH) [HL067357, HL055310, CA123211]; NATIONAL CANCER INSTITUTE [R01CA123211] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055310, R01HL067357, R01HL055310] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health (NIH) grants HL067357 and HL055310 to Z.Z. and, in part, CA123211 to J.K. The authors thank Anton Wellstein, Thomas G. Sherman, and Allan V. Kalueff for their insightful comments and editing. The authors declare no conflicts of interest.	Amano H, 2005, CIRC RES, V97, P337, DOI 10.1161/01.RES.0000179534.17668.f8; Andre P, 2011, BLOOD, V118, P5000, DOI 10.1182/blood-2011-06-360743; Brenes RA, 2012, J VASC SURG, V56, P1669, DOI 10.1016/j.jvs.2012.04.067; BRUNNER G, 1993, BLOOD, V81, P631; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chalothorn D, 2005, AM J PHYSIOL-HEART C, V289, pH947, DOI 10.1152/ajpheart.00952.2004; Chalothorn D, 2007, PHYSIOL GENOMICS, V30, P179, DOI 10.1152/physiolgenomics.00047.2007; Cruze CA, 2007, PEPTIDES, V28, P269, DOI 10.1016/j.peptides.2006.09.026; Ekstrand AJ, 2003, P NATL ACAD SCI USA, V100, P6033, DOI 10.1073/pnas.1135965100; Epstein SE, 2004, CIRCULATION, V109, P2826, DOI 10.1161/01.CIR.0000132468.82942.F5; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; Ferreira R, 2010, J BIOL CHEM, V285, P41921, DOI 10.1074/jbc.M110.164020; Hancock V., 1993, BRIT J HAEMATOL, V85, P694; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; Hershey JC, 2001, CARDIOVASC RES, V49, P618, DOI 10.1016/S0008-6363(00)00232-7; Herzog H, 2003, EUR J PHARMACOL, V480, P21, DOI 10.1016/j.ejphar.2003.08.089; Hoefer IE, 2005, ATHEROSCLEROSIS, V181, P285, DOI 10.1016/j.atherosclerosis.2005.01.047; Holler J, 2008, J IMMUNOL, V181, P6906, DOI 10.4049/jimmunol.181.10.6906; Hu ZW, 1999, J PHARMACOL EXP THER, V290, P28; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Kitlinska J, 2002, PEPTIDES, V23, P71, DOI 10.1016/S0196-9781(01)00581-2; Klement GL, 2009, BLOOD, V113, P2835, DOI 10.1182/blood-2008-06-159541; Kondoh K, 2004, CARDIOVASC RES, V61, P132, DOI 10.1016/j.cardiores.2003.10.003; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Li LJ, 2011, J CARDIOVASC TRANSL, V4, P351, DOI 10.1007/s12265-011-9271-5; Li LJ, 2003, ARTERIOSCL THROM VAS, V23, P1204, DOI 10.1161/01.ATV.0000071349.30914.25; Lu C, 2010, ONCOGENE, V29, P5630, DOI 10.1038/onc.2010.301; Lu CY, 2011, J BIOL CHEM, V286, P27494, DOI 10.1074/jbc.M111.224089; LUNDBERG JM, 1986, NEUROSCI LETT, V63, P96, DOI 10.1016/0304-3940(86)90020-0; Ma L, 2005, P NATL ACAD SCI USA, V102, P216, DOI 10.1073/pnas.0406682102; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762; MYERS AK, 1993, REGUL PEPTIDES, V47, P239, DOI 10.1016/0167-0115(93)90391-K; MYERS AK, 1988, BIOCHEM BIOPH RES CO, V155, P118, DOI 10.1016/S0006-291X(88)81057-X; Pinedo HM, 1998, LANCET, V352, P1775, DOI 10.1016/S0140-6736(98)05095-8; Pintucci G, 2002, THROMB HAEMOSTASIS, V88, P834, DOI 10.1055/s-0037-1613311; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Robich MP, 2010, J MOL CELL CARDIOL, V49, P1022, DOI 10.1016/j.yjmcc.2010.08.022; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; SCHAPER W, 2004, ARTERIOGENESIS; Schaper W, 2009, BASIC RES CARDIOL, V104, P5, DOI 10.1007/s00395-008-0760-x; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; SCHWARZ H, 1994, J NEUROIMMUNOL, V51, P53, DOI 10.1016/0165-5728(94)90128-7; Sehgal S, 2007, J THROMB HAEMOST, V5, P2009, DOI 10.1111/j.1538-7836.2007.02698.x; Sirois MG, 1997, CIRCULATION, V96, P1291, DOI 10.1161/01.CIR.96.4.1291; Stabile E, 2003, CIRCULATION, V108, P205, DOI 10.1161/01.CIR.0000079225.50817.71; Tan YH, 2007, CARDIOVASC RES, V73, P823, DOI 10.1016/j.cardiores.2006.12.015; Tirziu D, 2005, CIRCULATION, V112, P2501, DOI 10.1161/CIRCULATIONAHA.105.542829; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Tritsaris K, 2007, P NATL ACAD SCI USA, V104, P15364, DOI 10.1073/pnas.0707302104; Troidl K, 2010, J CARDIOVASC PHARM, V55, P153, DOI 10.1097/FJC.0b013e3181c9556f; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; WAHLESTEDT C, 1990, AM J PHYSIOL, V258, pR736, DOI 10.1152/ajpregu.1990.258.3.R736; Wartiovaara U, 1998, THROMB HAEMOSTASIS, V80, P171, DOI 10.1055/s-0037-1615158; Westfall TC, 2004, HANDB EXP PHARM, V162, P137; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1988, SYNAPSE, V2, P293, DOI 10.1002/syn.890020319	67	15	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2244	2255		10.1096/fj.12-213546	http://dx.doi.org/10.1096/fj.12-213546			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457218	Green Published			2022-12-28	WOS:000319667600015
J	Damm, TB; Richard, S; Tanner, S; Wyss, F; Egli, M; Franco-Obregon, A				Damm, Tatiana Benavides; Richard, Stephane; Tanner, Samuel; Wyss, Fabienne; Egli, Marcel; Franco-Obregon, Alfredo			Calcium-dependent deceleration of the cell cycle in muscle cells by simulated microgravity	FASEB JOURNAL			English	Article						mechanotransduction; transient receptor potential canonical type 1; TRPC1; insulin-like growth factor 1; IGF-1	CAPACITATIVE CA2+ ENTRY; SKELETAL-MUSCLE; GROWTH-FACTOR; MECHANICAL SIGNALS; C2C12 MYOBLASTS; CATION CHANNEL; IN-VIVO; DIFFERENTIATION; EXPRESSION; TRPC1	Of all our mechanosensitive tissues, skeletal muscle is the most developmentally responsive to physical activity. Conversely, restricted mobility due to injury or disease results in muscle atrophy. Gravitational force is another form of mechanical input with profound developmental consequences. The mechanical unloading resulting from the reduced gravitational force experienced during spaceflight results in oxidative muscle loss. We examined the early stages of myogenesis under conditions of simulated microgravity (SM). C2C12 mouse myoblasts in SM proliferated more slowly (2.23 x less) as a result of their being retained longer within the G(2)/M phase of the cell cycle (2.10 x more) relative to control myoblasts at terrestrial gravity. Blocking calcium entry via TRP channels with SKF-96365 (10-20 mu M) accumulated myoblasts within the G(2)/M phase of the cell cycle and retarded their proliferation. On the genetic level, SM resulted in the reduced expression of TRPC1 and IGF-1 isoforms, transcriptional events regulated by calcium downstream of mechanical input. A decrease in TRPC1-mediated calcium entry thus appears to be a pivotal event in the muscle atrophy brought on by gravitational mechanical unloading. Hence, relieving the constant force of gravity on cells might prove one valid experimental approach to expose the underlying mechanisms modulating mechanically regulated developmental programs.	[Damm, Tatiana Benavides; Richard, Stephane; Tanner, Samuel; Wyss, Fabienne; Egli, Marcel; Franco-Obregon, Alfredo] Swiss Fed Inst Technol, Space Biol Grp, CH-8005 Zurich, Switzerland; [Franco-Obregon, Alfredo] Swiss Fed Inst Technol, Rehabil & Regenerat Strategies Grp, CH-8005 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Franco-Obregon, A (corresponding author), Swiss Fed Inst Technol, Space Biol Grp, Rehabil & Regenerat Strategies Grp, Technopk Str 1, CH-8005 Zurich, Switzerland.	franco@spacebiol.ethz.ch	Franco-Obregon, Alfredo/F-3056-2019	Franco-Obregon, Alfredo/0000-0002-2514-1083; Benavides, Tatiana/0000-0002-0992-5240	European Space Agency	European Space Agency(European Space AgencyEuropean Commission)	The authors gratefully acknowledge the technical assistance of Dr. Malgorzata Kisielow and Ms. Anette Schutz (Flow Cytometry Laboratory, ETH Zurich) and of Krzysztof Krawczyk. The authors also thank Prof. Dr. Ralph Muller for insightful comments. This work was supported by the European Space Agency.	Alfieri CM, 2007, AM J PHYSIOL-CELL PH, V292, pC1887, DOI 10.1152/ajpcell.00506.2006; Armand AS, 2008, J BIOL CHEM, V283, P29004, DOI 10.1074/jbc.M801297200; Arnaudeau S, 2006, J CELL PHYSIOL, V208, P435, DOI 10.1002/jcp.20679; Bajotto G, 2006, J NUTR SCI VITAMINOL, V52, P233, DOI 10.3177/jnsv.52.233; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Batchelor CL, 2006, TRENDS CELL BIOL, V16, P198, DOI 10.1016/j.tcb.2006.02.001; Bidaud I, 2006, J MUSCLE RES CELL M, V27, P75, DOI 10.1007/s10974-006-9058-5; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Bomben VC, 2010, GLIA, V58, P1145, DOI 10.1002/glia.20994; Borst AG, 2009, MICROGRAVITY SCI TEC, V21, P287, DOI 10.1007/s12217-008-9043-2; Chang KC, 2007, ANIMAL, V1, P681, DOI 10.1017/S1751731107702070; Cheema U, 2005, J CELL PHYSIOL, V202, P67, DOI 10.1002/jcp.20107; Chu Lily, 2005, V308, P107; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Darbellay B, 2009, J BIOL CHEM, V284, P5370, DOI 10.1074/jbc.M806726200; Ducret T, 2006, J PHYSIOL-LONDON, V575, P913, DOI 10.1113/jphysiol.2006.115154; Fitts RH, 2001, J EXP BIOL, V204, P3201; Formigli L, 2009, J CELL SCI, V122, P1322, DOI 10.1242/jcs.035402; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; Goldspink G, 2002, BIOCHEM SOC T, V30, P285, DOI 10.1042/bst0300285; Goldspink G, 2005, PHYSIOLOGY, V20, P232, DOI 10.1152/physiol.00004.2005; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Guo RW, 2012, CARDIOVASC RES, V93, P360, DOI 10.1093/cvr/cvr307; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hiani YEL, 2009, CELL PHYSIOL BIOCHEM, V23, P335, DOI 10.1159/000218179; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Hruz T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-156; Iida K, 2004, J PHYSIOL-LONDON, V560, P341, DOI 10.1113/jphysiol.2004.069500; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Iwata Y, 2003, J CELL BIOL, V161, P957, DOI 10.1083/jcb.200301101; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Ju YK, 2003, J CELL PHYSIOL, V197, P53, DOI 10.1002/jcp.10347; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; Kook SH, 2008, MOL CELLS, V25, P479; Kumar B, 2006, CIRC RES, V98, P557, DOI 10.1161/01.RES.0000204724.29685.db; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; Kurth F, 2012, CURR OPIN CHEM BIOL, V16, P400, DOI 10.1016/j.cbpa.2012.03.014; Louis M, 2008, J CELL SCI, V121, P3951, DOI 10.1242/jcs.037218; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Morales S, 2007, AM J PHYSIOL-CELL PH, V292, pC553, DOI 10.1152/ajpcell.00096.2006; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Narici MV, 2011, EUR J APPL PHYSIOL, V111, P403, DOI 10.1007/s00421-010-1556-x; Patel A, 2010, PFLUG ARCH EUR J PHY, V460, P571, DOI 10.1007/s00424-010-0847-8; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; Philippou A, 2007, IN VIVO, V21, P45; Rolland JF, 2006, NEUROBIOL DIS, V24, P466, DOI 10.1016/j.nbd.2006.08.010; Rotwein P, 2003, GROWTH HORM IGF RES, V13, P303, DOI 10.1016/j.ghir.2003.09.001; Santella L, 2005, CELL MOL LIFE SCI, V62, P2405, DOI 10.1007/s00018-005-5083-6; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Stiber J, 2008, NAT CELL BIOL, V10, P688, DOI 10.1038/ncb1731; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Tajeddine N, 2012, J BIOL CHEM, V287, P16146, DOI 10.1074/jbc.M112.340034; van Loon JJWA, 2007, ADV SPACE RES, V39, P1161, DOI 10.1016/j.asr.2007.02.016; Vandebrouck A, 2007, FASEB J, V21, P608, DOI 10.1096/fj.06-6683com; Vandenburgh H, 1999, FASEB J, V13, P1031, DOI 10.1096/fasebj.13.9.1031; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Xiao R, 2010, CURR BIOL, V20, pR936, DOI 10.1016/j.cub.2010.09.053; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; YIP DK, 1972, IN VITRO CELL DEV B, V7, P323	67	26	27	2	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2045	2054		10.1096/fj.12-218693	http://dx.doi.org/10.1096/fj.12-218693			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23363573				2022-12-28	WOS:000318226100024
J	Kanasaki, K; Yu, WQ; von Bodungen, M; Larigakis, JD; Kanasaki, M; de la Pena, FA; Kalluri, R; Hill, WG				Kanasaki, Keizo; Yu, Weiqun; von Bodungen, Maximilian; Larigakis, John D.; Kanasaki, Megumi; de la Pena, Francisco Ayala; Kalluri, Raghu; Hill, Warren G.			Loss of beta 1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype	FASEB JOURNAL			English	Article						micturition; voiding dysfunction; mechanotransduction; urinary tract	URINARY-BLADDER; CONDITIONAL DELETION; INTEGRIN; EXPRESSION; RECEPTORS; MATRIX; ABLATION; CHANNELS; BARRIER; REVEAL	Bladder urothelium senses and communicates information about bladder fullness. However, the mechanoreceptors that respond to tissue stretch are poorly defined. Integrins are mechanotransducers in other tissues. Therefore, we eliminated beta 1-integrin selectively in urothelium of mice using Cre-LoxP targeted gene deletion. beta 1-Integrin localized to basal/intermediate urothelial cells by confocal microscopy. beta 1-Integrin conditional-knockout (beta 1-cKO) mice lacking urothelial beta 1-integrin exhibited down-regulation and mislocalization of alpha 3- and alpha 5-integrins by immunohistochemistry but, surprisingly, had normal morphology, permeability, and transepithelial resistance when compared with Cre-negative littermate controls. beta 1-cKO mice were incontinent, as judged by random urine leakage on filter paper (4-fold higher spotting, P<0.01; 2.5-fold higher urine area percentage, P<0.05). Urodynamic function assessed by cystometry revealed bladder overfilling with 80% longer intercontractile intervals (P<0.05) and detrusor hyperactivity (3-fold more prevoid contractions, P<0.05), but smooth muscle contractility remained intact. ATP secretion into the lumen was elevated (49 vs. 22 nM, P<0.05), indicating abnormal filling-induced purinergic signaling, and short-circuit currents (measured in Ussing chambers) revealed 2-fold higher stretch-activated ion channel conductances in response to hydrostatic pressure of 1 cmH(2)O (P<0.05). We conclude that loss of integrin signaling from urothelium results in incontinence and overactive bladder due to abnormal mechanotransduction; more broadly, our findings indicate that urothelium itself directly modulates voiding.-Kanasaki, K., Yu, W., von Bodungen, M., Larigakis, J. D., Kanasaki, M., Ayala de la Pena, F., Kalluri, R., Hill, W.G. Loss of beta 1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J. 27, 1950-1961 (2013). www.fasebj.org	[Kanasaki, Keizo; Kanasaki, Megumi; de la Pena, Francisco Ayala; Kalluri, Raghu; Hill, Warren G.] Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA; [Yu, Weiqun; von Bodungen, Maximilian; Larigakis, John D.] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; [Yu, Weiqun; von Bodungen, Maximilian; Larigakis, John D.; Hill, Warren G.] Beth Israel Deaconess Med Ctr, Dept Med, Lab Voiding Dysfunct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hill, WG (corresponding author), Beth Israel Deaconess Med Ctr, RN349,99 Brookline Ave, Boston, MA 02215 USA.	whill@bidmc.harvard.edu	Hill, Warren/AAM-1917-2020; Ayala, Francisco/C-5280-2011; Kalluri, Raghu/E-2677-2015	Hill, Warren/0000-0002-2772-7264; Ayala, Francisco/0000-0001-6311-920X; Kalluri, Raghu/0000-0002-2190-547X	U.S. National Institute of Diabetes and Digestive and Kidney Diseases grant [DK083299]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083299] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Diseases grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The project described was supported by U.S. National Institute of Diabetes and Digestive and Kidney Diseases grant DK083299 to W.G.H. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. National Institutes of Health.	Acharya P, 2004, AM J PHYSIOL-RENAL, V287, pF305, DOI 10.1152/ajprenal.00341.2003; Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Apodaca G, 2007, KIDNEY INT, V72, P1057, DOI 10.1038/sj.ki.5002439; Apodaca G, 2003, AM J PHYSIOL-RENAL, V284, pF966, DOI 10.1152/ajprenal.00359.2002; Arcangeli A, 2006, TRENDS CELL BIOL, V16, P631, DOI 10.1016/j.tcb.2006.10.003; Becchetti A, 2010, INT REV CEL MOL BIO, V279, P135, DOI 10.1016/S1937-6448(10)79005-5; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Birder LA, 2010, AUTON NEUROSCI-BASIC, V153, P33, DOI 10.1016/j.autneu.2009.07.005; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Cockayne DA, 2005, J PHYSIOL-LONDON, V567, P621, DOI 10.1113/jphysiol.2005.088435; de Groat WC, 2004, UROLOGY, V64, P7, DOI 10.1016/j.urology.2004.08.063; de Groat William C, 2009, Handb Exp Pharmacol, P91, DOI 10.1007/978-3-540-79090-7_4; de la Pena FA, 2011, J BIOL CHEM, V286, P20778, DOI 10.1074/jbc.M110.198069; DEBOER WI, 1994, AM J PATHOL, V145, P1199; Elneil S, 2001, PHARMACOLOGY, V63, P120, DOI 10.1159/000056122; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Gevaert T, 2007, J CLIN INVEST, V117, P3453, DOI 10.1172/JCI31766; Hill WG, 2008, AM J PHYSIOL-RENAL, V294, pF919, DOI 10.1152/ajprenal.00265.2007; Jones RG, 2006, J CELL BIOL, V175, P505, DOI 10.1083/jcb.200602160; Kanasaki K, 2008, DEV BIOL, V313, P584, DOI 10.1016/j.ydbio.2007.10.047; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Khandelwal P, 2010, EMBO J, V29, P1961, DOI 10.1038/emboj.2010.91; Lavelle J, 2002, AM J PHYSIOL-RENAL, V283, pF242, DOI 10.1152/ajprenal.00307.2001; Lee HY, 2000, J UROLOGY, V163, P2002, DOI 10.1016/S0022-5347(05)67618-5; Lewis SA, 2006, AM J PHYSIOL-RENAL, V291, pF332, DOI 10.1152/ajprenal.00340.2005; LIEBERT M, 1994, AM J PATHOL, V144, P787; LIEBERT M, 1994, AM J PATHOL, V144, P1016; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; Puklin-Faucher E, 2009, J CELL SCI, V122, P179, DOI 10.1242/jcs.042127; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Simirskii VN, 2007, DEV BIOL, V306, P658, DOI 10.1016/j.ydbio.2007.04.004; SOUTHGATE J, 1995, CELL ADHES COMMUN, V3, P231, DOI 10.3109/15419069509081289; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Truschel ST, 2002, MOL BIOL CELL, V13, P830, DOI 10.1091/mbc.01-09-0435; Vlaskovska M, 2001, J NEUROSCI, V21, P5670, DOI 10.1523/JNEUROSCI.21-15-05670.2001; Wang ECY, 2003, AM J PHYSIOL-RENAL, V285, pF651, DOI 10.1152/ajprenal.00403.2002; Wilson CB, 1996, WORLD J UROL, V14, pS30; Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73; Yu WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018704; Yu WQ, 2011, AM J PHYSIOL-RENAL, V300, pF49, DOI 10.1152/ajprenal.00349.2010; Yu WQ, 2009, MOL BIOL CELL, V20, P282, DOI 10.1091/mbc.E08-04-0439	43	30	32	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1950	1961		10.1096/fj.12-223404	http://dx.doi.org/10.1096/fj.12-223404			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23395910	Green Published			2022-12-28	WOS:000318226100015
J	Shan, TZ; Liang, XR; Bi, PP; Kuang, SH				Shan, Tizhong; Liang, Xinrong; Bi, Pengpeng; Kuang, Shihuan			Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1 alpha-Fndc5 pathway in muscle	FASEB JOURNAL			English	Article						irisin; UCP1	SKELETAL-MUSCLE; ADIPOCYTE PROGENITORS; INDUCED OBESITY; SELF-RENEWAL; FAT; ADIPOGENESIS; INHIBITION; DIFFERENTIATION; EXPRESSION; PROMOTES	Myostatin (Mstn) is predominantly expressed in skeletal muscles and plays important roles in regulating muscle growth and development, as well as fat deposition. Mstn-knockout (Mstn(-/-)) mice exhibit increased muscle mass due to both hypertrophy and hyperplasia, and leaner body composition due to reduced fat mass. Here, we show that white adipose tissue (WAT) of Mstn(-/-) develops characteristics of brown adipose tissue (BAT) with dramatically increased expression of BAT signature genes, including Ucp1 and Pgc1 alpha, and beige adipocyte markers Tmem26 and CD137. Strikingly, the observed browning phenotype is non-cell autonomous and is instead driven by the newly defined myokine irisin (Fndc5) secreted from Mstn(-/-) skeletal muscle. Within the muscle, Mstn(-/-) leads to increased expression of AMPK and its phosphorylation, which subsequently activates PGC1 alpha and Fndc5. Together, our study defines a paradigm of muscle-fat crosstalk mediated by Fndc5, which is up-regulated and secreted from muscle to induce beige cell markers and the browning of WAT in Mstn(-/-) mice. These results suggest that targeting muscle Mstn and its downstream signaling represents a therapeutic approach to treat obesity and type 2 diabetes.	[Shan, Tizhong; Liang, Xinrong; Bi, Pengpeng; Kuang, Shihuan] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; [Kuang, Shihuan] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kuang, SH (corresponding author), 174B Smith Hall,901 West State St, W Lafayette, IN 47907 USA.	skuang@purdue.edu	Shan, Tizhong/G-1947-2015; Bi, Pengpeng/P-4936-2016	Bi, Pengpeng/0000-0002-9871-6773; Kuang, Shihuan/0000-0001-9180-3180	Muscular Dystrophy Association; U.S. National Institutes of Health; U.S. Department of Agriculture; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060652] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Agriculture(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This project is partially supported by funding from the Muscular Dystrophy Association, the U.S. National Institutes of Health, and the U.S. Department of Agriculture to S.K. The authors thank Yong-Soo Kim (University of Hawaii, Manoa, HI, USA) for providing anti-Mstn and ActRIIB. The authors are grateful to Jun Wu and Pengpeng Zhang for mouse colony and technical support. The authors declare no conflicts of interests.	Argiles JM, 2012, DRUG DISCOV TODAY, V17, P702, DOI 10.1016/j.drudis.2012.02.001; Artaza JN, 2005, ENDOCRINOLOGY, V146, P3547, DOI 10.1210/en.2005-0362; Bernardo BL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011307; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cao L, 2011, CELL METAB, V14, P324, DOI 10.1016/j.cmet.2011.06.020; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Fournier B, 2012, MOL CELL BIOL, V32, P2871, DOI 10.1128/MCB.06575-11; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Glass DJ, 2010, CURR TOP MICROBIOL, V346, P267, DOI 10.1007/82_2010_78; Guo TQ, 2012, DIABETES, V61, P2414, DOI 10.2337/db11-0915; Guo TQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004937; Hennebry A, 2009, AM J PHYSIOL-CELL PH, V296, pC525, DOI 10.1152/ajpcell.00259.2007; Jorgensen SB, 2006, J PHYSIOL-LONDON, V574, P17, DOI 10.1113/jphysiol.2006.109942; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Kelly DP, 2012, SCIENCE, V336, P42, DOI 10.1126/science.1221688; Kim WK, 2012, INT J BIOCHEM CELL B, V44, P327, DOI 10.1016/j.biocel.2011.11.004; Koncarevic A, 2012, ENDOCRINOLOGY, V153, P3133, DOI 10.1210/en.2012-1016; LeBrasseur NK, 2012, DIABETOLOGIA, V55, P13, DOI 10.1007/s00125-011-2361-8; LeBrasseur NK, 2009, J GERONTOL A-BIOL, V64, P940, DOI 10.1093/gerona/glp068; Lee-Young RS, 2009, J APPL PHYSIOL, V107, P283, DOI 10.1152/japplphysiol.91208.2008; Liu WY, 2012, DEVELOPMENT, V139, P2857, DOI 10.1242/dev.079665; Liu WY, 2012, DEV BIOL, V361, P27, DOI 10.1016/j.ydbio.2011.10.011; Madsen L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011391; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Mehran AE, 2012, CELL METAB, V16, P723, DOI 10.1016/j.cmet.2012.10.019; Murphy KT, 2010, FASEB J, V24, P4433, DOI 10.1096/fj.10-159608; Ohno H, 2012, CELL METAB, V15, P395, DOI 10.1016/j.cmet.2012.01.019; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Powelka AM, 2006, J CLIN INVEST, V116, P125, DOI 10.1172/JCI26040; Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Shan TZ, 2013, FASEB J, V27, P277, DOI 10.1096/fj.12-211516; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Tsurutani Y, 2009, DIABETES, V58, pA436; Walden TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011; Wang M, 2012, BIOCHEM BIOPH RES CO, V426, P83, DOI 10.1016/j.bbrc.2012.08.040; Wen YF, 2012, MOL CELL BIOL, V32, P2300, DOI 10.1128/MCB.06753-11; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Yadav Hariom, 2012, Front Endocrinol (Lausanne), V3, P35, DOI 10.3389/fendo.2012.00035; Yadav H, 2011, CELL METAB, V14, P67, DOI 10.1016/j.cmet.2011.04.013; Zhang C, 2012, DIABETOLOGIA, V55, P183, DOI 10.1007/s00125-011-2304-4; Zhang C, 2011, DIABETOLOGIA, V54, P1491, DOI 10.1007/s00125-011-2079-7	50	225	244	2	101	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1981	1989		10.1096/fj.12-225755	http://dx.doi.org/10.1096/fj.12-225755			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23362117	Green Published			2022-12-28	WOS:000318226100018
J	Deepa, SS; Pulliam, D; Hill, S; Shi, Y; Walsh, ME; Salmon, A; Sloane, L; Zhang, N; Zeviani, M; Viscomi, C; Musi, N; Van Remmen, H				Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Shi, Yun; Walsh, Michael E.; Salmon, Adam; Sloane, Lauren; Zhang, Ning; Zeviani, Massimo; Viscomi, Carlo; Musi, Nicolas; Van Remmen, Holly			Improved insulin sensitivity associated with reduced mitochondrial complex IV assembly and activity	FASEB JOURNAL			English	Article						fatty acid oxidation; PGC-1 alpha; longevity; Surf1	CYTOCHROME-C-OXIDASE; ACTIVATED RECEPTOR-ALPHA; FATTY-ACID OXIDATION; ADIPOSE-TISSUE; LIFE-SPAN; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; GROWTH-HORMONE; KNOCKOUT MICE; UP-REGULATION	Mice lacking Surf1, a complex IV assembly protein, have similar to 50-70% reduction in cytochrome c oxidase activity in all tissues yet a paradoxical increase in lifespan. Here we report that Surf1(-/-) mice have lower body (15%) and fat (20%) mass, in association with reduced lipid storage, smaller adipocytes, and elevated indicators of fatty acid oxidation in white adipose tissue (WAT) compared with control mice. The respiratory quotient in the Surf1(-/-) mice was significantly lower than in the control animals (0.83-0.93 vs. 0.90-0.98), consistent with enhanced fat utilization in Surf1(-/-) mice. Elevated fat utilization was associated with increased insulin sensitivity measured as insulin-stimulated glucose uptake, as well as an increase in insulin receptor levels (similar to 2-fold) and glucose transporter type 4 (GLUT4; similar to 1.3-fold) levels in WAT in the Surf1(-/-) mice. The expression of peroxisome proliferator-activated receptor gamma-coactivator 1-alpha (PGC-1 alpha) mRNA and protein was up-regulated by 2.5- and 1.9-fold, respectively, in WAT from Surf1(-/-) mice, and the expression of PGC-1 alpha target genes and markers of mitochondrial biogenesis was elevated. Together, these findings point to a novel and unexpected link between reduced mitochondrial complex IV activity, enhanced insulin sensitivity, and increased mitochondrial biogenesis that may contribute to the increased longevity in the Surf1(-/-) mice.-Deepa, S. S., Pulliam, D., Hill, S., Shi, Y., Walsh, M. E., Salmon, A., Sloane, L., Zhang, N., Zeviani, M., Viscomi, C., Musi, N., Van Remmen, H. Improved insulin sensitivity associated with reduced mitochondrial complex IV assembly and activity. FASEB J. 27, 1371-1380 (2013). www.fasebj.org	[Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Shi, Yun; Walsh, Michael E.; Salmon, Adam; Sloane, Lauren; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA; [Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Walsh, Michael E.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA; [Zhang, Ning; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78245 USA; [Salmon, Adam; Musi, Nicolas; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA; [Zeviani, Massimo; Viscomi, Carlo] Ist Ricovero & Cura Carattere Sci, Fdn Ist Neurol Carlo Besta, Unit Mol Neurogenet, Milan, Italy	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Neurologico Besta	Van Remmen, H (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,Mail Code 5566, San Antonio, TX 78245 USA.	vanremmen@uthscsa.edu	Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021; viscomi, Carlo/R-1940-2016	Zeviani, Massimo/0000-0002-9067-5508; Viscomi, Carlo/0000-0001-6050-0566; Deepa, Sathyaseelan/0000-0002-3669-4820	Ellison Medical Foundation; Telethon grant [GPP10005]; Italian Ministry of Health [GR2010-2306756]	Ellison Medical Foundation(Lawrence Ellison Foundation); Telethon grant(Fondazione Telethon); Italian Ministry of Health(Ministry of Health, Italy)	The authors thank Yuhong Liu, Li Yan, Marian Sabia, Amanda Jernigan, and Barbara Hunter for technical support. This work was supported by an Ellison Medical Foundation Senior Scholar award to H. V. R. Telethon grant GPP10005 to M.Z. and Italian Ministry of Health grant GR2010-2306756 to C.V. are also acknowledged. The authors report no conflicts of interest.	Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; CAHILL GF, 1960, J BIOL CHEM, V235, P1246; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; Copeland JM, 2009, CURR BIOL, V19, P1591, DOI 10.1016/j.cub.2009.08.016; Dell'Agnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dominici FP, 2002, J ENDOCRINOL, V173, P81, DOI 10.1677/joe.0.1730081; Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; FOUCHEREAUPERON M, 1980, BIOCHIM BIOPHYS ACTA, V631, P451, DOI 10.1016/0304-4165(80)90021-5; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; Gnudi L, 1996, P NUTR SOC, V55, P191, DOI 10.1079/PNS19960020; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hughes BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026116; Jang YC, 2010, FASEB J, V24, P1376, DOI 10.1096/fj.09-146308; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; Kenyon C, 2011, PHILOS T R SOC B, V366, P9, DOI 10.1098/rstb.2010.0276; Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004; Lapointe J, 2008, J BIOL CHEM, V283, P26217, DOI 10.1074/jbc.M803287200; Lee SJ, 2010, CURR BIOL, V20, P2131, DOI 10.1016/j.cub.2010.10.057; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221; Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050; Park SH, 2002, J APPL PHYSIOL, V92, P2475, DOI 10.1152/japplphysiol.00071.2002; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Rasmussen BB, 1999, ANNU REV NUTR, V19, P463, DOI 10.1146/annurev.nutr.19.1.463; RODBELL M, 1964, J BIOL CHEM, V239, P375; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; Toh SY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002890; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011; Wang ZH, 2006, J GERONTOL A-BIOL, V61, P323, DOI 10.1093/gerona/61.4.323; Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106; WONG A, 1995, GENETICS, V139, P1247; Wredenberg A, 2006, BIOCHEM BIOPH RES CO, V350, P202, DOI 10.1016/j.bbrc.2006.09.029; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	47	25	25	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1371	1380		10.1096/fj.12-221879	http://dx.doi.org/10.1096/fj.12-221879			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23241310				2022-12-28	WOS:000316940800010
J	Jinwal, UK; Akoury, E; Abisambra, JF; O'Leary, JC; Thompson, AD; Blair, LJ; Jin, Y; Bacon, J; Nordhues, BA; Cockman, M; Zhang, J; Li, PF; Zhang, B; Borysov, S; Uversky, VN; Biernat, J; Mandelkow, E; Gestwicki, JE; Zweckstetter, M; Dickey, CA				Jinwal, Umesh K.; Akoury, Elias; Abisambra, Jose F.; O'Leary, John C., III; Thompson, Andrea D.; Blair, Laura J.; Jin, Ying; Bacon, Justin; Nordhues, Bryce A.; Cockman, Matthew; Zhang, Juan; Li, Pengfei; Zhang, Bo; Borysov, Sergiy; Uversky, Vladimir N.; Biernat, Jacek; Mandelkow, Eckhard; Gestwicki, Jason E.; Zweckstetter, Markus; Dickey, Chad A.			Imbalance of Hsp70 family variants fosters tau accumulation	FASEB JOURNAL			English	Article						chaperones; CHIP; Hsc70; Hsp72; Alzheimer's	PAIRED HELICAL FILAMENTS; BETA-STRUCTURE; MOLECULAR CHAPERONE; TRANSGENIC MICE; PROTEIN; AGGREGATION; CHIP; NEURONS; STRESS; MICROTUBULES	Dysfunctional tau accumulation is a major contributing factor in tauopathies, and the heat-shock protein 70 (Hsp70) seems to play an important role in this accumulation. Several reports suggest that Hsp70 proteins can cause tau degradation to be accelerated or slowed, but how these opposing activities are controlled is unclear. Here we demonstrate that highly homologous variants in the Hsp70 family can have opposing effects on tau clearance kinetics. When overexpressed in a tetracycline (Tet)-based protein chase model, constitutive heat shock cognate 70 (Hsc70) and inducible Hsp72 slowed or accelerated tau clearance, respectively. Tau synergized with Hsc70, but not Hsp72, to promote microtubule assembly at nearly twice the rate of either Hsp70 homologue in reconstituted, ATP-regenerating Xenopus extracts supplemented with rhodamine-labeled tubulin and human recombinant Hsp72 and Hsc70. Nuclear magnetic resonance spectroscopy with human recombinant protein revealed that Hsp72 had greater affinity for tau than Hsc70 (I/I-0 ratio difference of 0.3), but Hsc70 was 30 times more abundant than Hsp72 in human and mouse brain tissue. This indicates that the predominant Hsp70 variant in the brain is Hsc70, suggesting that the brain environment primarily supports slower tau clearance. Despite its capacity to clear tau, Hsp72 was not induced in the Alzheimer's disease brain, suggesting a mechanism for age-associated onset of the disease. Through the use of chimeras that blended the domains of Hsp72 and Hsc70, we determined that the reason for these differences between Hsc70 and Hsp72 with regard to tau clearance kinetics lies within their C-terminal domains, which are essential for their interactions with substrates and cochaperones. Hsp72 but not Hsc70 in the presence of tau was able to recruit the cochaperone ubiquitin ligase CHIP, which is known to facilitate the ubiquitination of tau, describing a possible mechanism of how the C-termini of these homologous Hsp70 variants can differentially regulate tau triage. Thus, efforts to promote Hsp72 expression and inhibit Hsc70 could be therapeutically relevant for tauopathies.-Jinwal, U. K., Akoury, E., Abisambra, J. F., O'Leary, J. C., III, Thompson, A. D., Blair, L. J., Jin, Y., Bacon, J., Nordhues, B. A., Cockman, M., Zhang, J., Li, P., Zhang, B., Borysov, S., Uversky, V. N., Biernat, J., Mandelkow, E., Gestwicki, J. E., Zweckstetter, M., Dickey, C. A. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J. 27, 1450-1459 (2013). www.fasebj.org	[Jinwal, Umesh K.; Zhang, Juan] Univ S Florida, Hlth Byrd Alzheimers Inst, Dept Pharmaceut Sci, Tampa, FL 33613 USA; [Abisambra, Jose F.; O'Leary, John C., III; Blair, Laura J.; Jin, Ying; Bacon, Justin; Nordhues, Bryce A.; Cockman, Matthew; Li, Pengfei; Zhang, Bo; Borysov, Sergiy; Uversky, Vladimir N.; Dickey, Chad A.] Univ S Florida, Hlth Byrd Alzheimers Inst, Dept Mol Med, Tampa, FL 33613 USA; [Akoury, Elias; Zweckstetter, Markus] Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; [Thompson, Andrea D.; Gestwicki, Jason E.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Uversky, Vladimir N.] Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142292, Russia; [Biernat, Jacek; Mandelkow, Eckhard] Deutsch Elektronen Synchrotron DESY, Max Planck Unit Struct Mol Biol, Hamburg, Germany; [Biernat, Jacek; Mandelkow, Eckhard] German Ctr Neurodegenerat Dis DZNE, CAESAR, Bonn, Germany; [Zweckstetter, Markus] DZNE, Gottingen, Germany	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Max Planck Society; University of Michigan System; University of Michigan; Russian Academy of Sciences; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Center of Advanced European Studies & Research (CAESAR); Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Dickey, CA (corresponding author), Univ S Florida, 4001 E Fletcher Ave,Room 325, Tampa, FL 33613 USA.	cdickey@health.usf.edu	Abisambra, Joe/AAP-3269-2020; Uversky, Vladimir N./F-4515-2011; Thompson, Andrea/AAQ-5735-2020; Akoury, Elias/AAG-2881-2019; Abisambra, Jose/V-6860-2019	Uversky, Vladimir N./0000-0002-4037-5857; Akoury, Elias/0000-0001-5202-8935; Abisambra, Jose/0000-0001-6341-679X; Blair, Laura/0000-0002-4981-5564; Thompson, Andrea/0000-0001-8798-2024; Zweckstetter, Markus/0000-0002-2536-6581	U.S. National Institutes of Health (NIH)/National Institute on Aging (NIA) [R00AG031291]; NIH/National Institute of Neurological Disorders and Stroke (NINDS) [R01NS073899]; Alzheimer's Association; CurePSP; NIH/NINDS [NS059690]; NIH/NIA [P50 AG16573]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059690, R01NS073899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG042813, R00AG031291, P50AG016573] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001637] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute on Aging (NIA); NIH/National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Alzheimer's Association(Alzheimer's Association); CurePSP; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	C.A.D. was supported by grants from the U.S. National Institutes of Health (NIH)/National Institute on Aging (NIA; R00AG031291), NIH/National Institute of Neurological Disorders and Stroke (NINDS; R01NS073899), the Alzheimer's Association, and CurePSP. U.K.J. was supported by the Alzheimer's Association. J.E.G. was supported by NIH/NINDS (NS059690) and the Alzheimer's Association. Funding for the University of California at Irvine Alzheimer's Disease Research Center (UCI-ADRC; Irvine, CA, USA) was provided by NIH/NIA grant P50 AG16573. The authors declare no conflicts of interest.	Abisambra JF, 2010, J NEUROSCI, V30, P15374, DOI 10.1523/JNEUROSCI.3155-10.2010; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BLACK MM, 1991, J NEUROSCI, V11, P1163; BRION JP, 1994, NEUROSCIENCE, V63, P895, DOI 10.1016/0306-4522(94)90533-9; Budde PP, 2006, METHODS, V38, P29, DOI 10.1016/j.ymeth.2005.07.008; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Dickey C, 2009, AM J PATHOL, V174, P228, DOI 10.2353/ajpath.2009.080764; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dickey CA, 2006, FASEB J, V20, P753, DOI 10.1096/fj.05-5343fje; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Dolan PJ, 2010, J BIOL CHEM, V285, P21978, DOI 10.1074/jbc.M110.110940; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Eisenberg D, 2006, ACCOUNTS CHEM RES, V39, P568, DOI 10.1021/ar0500618; FAWCETT TW, 1994, J BIOL CHEM, V269, P32272; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; Goldschmidt L, 2010, P NATL ACAD SCI USA, V107, P3487, DOI 10.1073/pnas.0915166107; HAMMOND GL, 1982, P NATL ACAD SCI-BIOL, V79, P3485, DOI 10.1073/pnas.79.11.3485; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; Jinwal UK, 2010, J BIOL CHEM, V285, P16798, DOI 10.1074/jbc.M110.113753; Jinwal UK, 2010, J NEUROSCI, V30, P591, DOI 10.1523/JNEUROSCI.4815-09.2010; Jinwal UK, 2009, J NEUROSCI, V29, P12079, DOI 10.1523/JNEUROSCI.3345-09.2009; Jo H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010318; Koren J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035566; MATTSON MP, 1992, BRAIN RES, V582, P107, DOI 10.1016/0006-8993(92)90323-2; Mukrasch MD, 2005, J BIOL CHEM, V280, P24978, DOI 10.1074/jbc.M501565200; O'Leary JC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-45; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Ricci Laura, 2008, Curr Chem Genomics, V2, P90, DOI 10.2174/1875397300802010090; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Sarkar M, 2008, J NEUROSCI RES, V86, P2763, DOI 10.1002/jnr.21721; Song YT, 2005, EUKARYOT CELL, V4, P289, DOI 10.1128/EC.4.2.289-297.2005; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	46	87	90	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1450	1459		10.1096/fj.12-220889	http://dx.doi.org/10.1096/fj.12-220889			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271055	Green Submitted, Green Published			2022-12-28	WOS:000316940800017
J	Gracia, E; Farre, D; Cortes, A; Ferrer-Costa, C; Orozco, M; Mallol, J; Lluis, C; Canela, EI; McCormick, PJ; Franco, R; Fanelli, F; Casado, V				Gracia, Eduard; Farre, Daniel; Cortes, Antoni; Ferrer-Costa, Carles; Orozco, Modesto; Mallol, Josefa; Lluis, Carme; Canela, Enric I.; McCormick, Peter J.; Franco, Rafael; Fanelli, Francesca; Casado, Vicent			The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors	FASEB JOURNAL			English	Article						multifunctional proteins; protein-protein interaction; enzyme mutants; in silico docking; immunological synapse	DIPEPTIDYL-PEPTIDASE-IV; T-CELL-ACTIVATION; QUATERNARY STRUCTURE PREDICTIONS; OVARIAN-CARCINOMA CELLS; MOLECULAR-DYNAMICS; CONFORMATIONAL-CHANGE; CRYSTAL-STRUCTURE; PROTEIN-DOCKING; A(1) RECEPTORS; PIG BRAIN	The enzyme adenosine deaminase (ADA) is a multifunctional protein that can both degrade adenosine and bind extracellularly to adenosine receptors, acting as an allosteric modulator regulating the hormonal effects of adenosine. The molecular regions of ADA responsible for the latter are unknown. In this work, alanine scanning mutagenesis of various ADA amino acid stretches, selected through in silico docking experiments, allowed us to identify regions of the enzyme responsible for modulating both its catalytic activity and its ability to modulate agonist binding to A(1) and A(2A) adenosine receptors (A(1)R and A(2A)R). The combination of computational and in vitro experiments show that the structural gate to the catalytic site; i.e., the alpha-1 helix containing residues L58-I72 and the loop containing residues A184-I188 of ADA, were important to maintain both the catalytic efficiency of the enzyme and its action as an allosteric modulator of the adenosine receptors. These data are consistent with a predicted supramolecular assembly, in which ADA bridges A(2A)R and CD26 and are in line with the notion that the interaction of ADA with adenosine receptors has an important role in the immunosynapse. We propose that it is the ADA open form, but not the closed one, that is responsible for the functional interaction with A1R and A(2A)R.-Gracia, E., Farre, D., Cortes, A., Ferrer-Costa, C., Orozco, M., Mallol, J., Lluis, C., Canela, E. I., McCormick, P. J., Franco, R., Fanelli, F., Casado, V. The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB J. 27, 1048-1061 (2013). www.fasebj.org	[Gracia, Eduard; Farre, Daniel; Cortes, Antoni; Mallol, Josefa; Lluis, Carme; Canela, Enric I.; McCormick, Peter J.; Casado, Vicent] Univ Barcelona, Fac Biol, Mol Neurobiol Lab, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08028 Barcelona, Spain; [Gracia, Eduard; Farre, Daniel; Cortes, Antoni; Orozco, Modesto; Mallol, Josefa; Lluis, Carme; Canela, Enric I.; McCormick, Peter J.; Franco, Rafael; Casado, Vicent] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; [Ferrer-Costa, Carles; Orozco, Modesto] Inst Res Biomed, Joint Inst Res Biomed Barcelona Comp Ctr IRB BSC, Modena, Italy; [Fanelli, Francesca] Dulbecco Telethon Inst, Modena, Italy; [Fanelli, Francesca] Univ Modena, Dept Chem, I-41100 Modena, Italy	CIBERNED; University of Barcelona; University of Barcelona; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Universita di Modena e Reggio Emilia	Casado, V (corresponding author), Univ Barcelona, Fac Biol, Mol Neurobiol Lab, Dept Biochem & Mol Biol, Av Diagonal 643, E-08028 Barcelona, Spain.	vcasado@ub.edu	McCormick, Peter/E-7387-2012; Franco, Rafael/C-3694-2015; Fanelli, Francesca/O-8807-2014; Casadó, Vicent/K-1660-2014; Mallol, Josefa/I-4194-2015; Canela, Enric I./M-8726-2013	McCormick, Peter/0000-0002-2225-5181; Franco, Rafael/0000-0003-2549-4919; Fanelli, Francesca/0000-0002-7620-6895; Casadó, Vicent/0000-0002-1764-3825; Mallol, Josefa/0000-0002-2479-4162; Canela, Enric I./0000-0003-4992-7440; Orozco Lopez, Modesto/0000-0002-8608-3278	Spanish Ministerio de Ciencia y Tecnologia [SAF2010-18472, SAF2011-23813, SAF2008-3229-E/]; Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) [PI2011/02-7]; FIPSE [36750/08]; Telethon-Italy [S00068TELU]	Spanish Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); FIPSE; Telethon-Italy(Fondazione Telethon)	The authors acknowledge the technical help obtained from Jasmina Jimenez (Laboratory of Molecular Neurobiology, University of Barcelona) and Francesco Raimondi (University of Modena and Reggio Emilia). This study was supported by grants from the Spanish Ministerio de Ciencia y Tecnologia (SAF2010-18472, SAF2011-23813 and SAF2008-3229-E/ within the frame of the Era-NET Neuron program), grant for collaborative projects PI2011/02-7 from the Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), and by FIPSE (a non- profit foundation including the Spanish Ministry of Health, Abbott Laboratories, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, and Roche) grant 36750/08. This study was also supported by Telethon-Italy grant S00068TELU (to F.F.). P.J.M. is a Ramon y Cajal Fellow.	Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; Canals M, 2003, J BIOL CHEM, V278, P46741, DOI 10.1074/jbc.M306451200; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; Casciari D, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-340; Casciari D, 2008, J CHEM INF MODEL, V48, P1669, DOI 10.1021/ci800048d; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Cheng TMK, 2007, PROTEINS, V68, P503, DOI 10.1002/prot.21419; Cieplak P, 1996, J MOL RECOGNIT, V9, P103, DOI 10.1002/(SICI)1099-1352(199603)9:2<103::AID-JMR246>3.0.CO;2-A; Ciruela F, 1996, FEBS LETT, V380, P219, DOI 10.1016/0014-5793(96)00023-3; Climent N, 2009, IMMUNOL CELL BIOL, V87, P634, DOI 10.1038/icb.2009.53; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; Dong R P, 1996, Hum Cell, V9, P153; Dong RP, 1997, J IMMUNOL, V159, P6070; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Fanelli F, 2007, MOL CELL ENDOCRINOL, V260, P59, DOI 10.1016/j.mce.2005.12.054; Fanelli F, 2011, BBA-BIOMEMBRANES, V1808, P1256, DOI 10.1016/j.bbamem.2010.08.006; Fanelli F, 2011, CELL MOL LIFE SCI, V68, P3109, DOI 10.1007/s00018-010-0615-0; Fernandez-Recio J, 2005, PROTEINS, V58, P134, DOI 10.1002/prot.20285; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gracia E, 2008, J NEUROCHEM, V107, P161, DOI 10.1111/j.1471-4159.2008.05602.x; Gracia E, 2011, BIOCHEM J, V435, P701, DOI 10.1042/BJ20101749; Harris R, 2008, PROTEINS, V70, P1506, DOI 10.1002/prot.21645; Havre PA, 2008, FRONT BIOSCI-LANDMRK, V13, P1634, DOI 10.2741/2787; Herrera C, 2001, MOL PHARMACOL, V59, P127, DOI 10.1124/mol.59.1.127; Hershfield MS, 2003, CURR OPIN IMMUNOL, V15, P571, DOI 10.1016/S0952-7915(03)00104-3; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; Hino T, 2012, NATURE, V482, P237, DOI 10.1038/nature10750; Kajiyama H, 2003, CANCER RES, V63, P2278; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; Kameoka J, 2006, LEUKEMIA LYMPHOMA, V47, P2181, DOI 10.1080/10428190600773396; Kikkawa F, 2003, INT J CANCER, V105, P779, DOI 10.1002/ijc.11177; Kinoshita T, 2005, BIOCHEMISTRY-US, V44, P10562, DOI 10.1021/bi050529e; Kinoshita T, 2003, ACTA CRYSTALLOGR D, V59, P299, DOI 10.1107/S090744490202190X; Kinoshita T, 2008, BIOCHEM BIOPH RES CO, V373, P53, DOI 10.1016/j.bbrc.2008.05.180; Larson ET, 2008, J MOL BIOL, V381, P975, DOI 10.1016/j.jmb.2008.06.048; Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136; Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D; Martinez-Navio JM, 2011, J LEUKOCYTE BIOL, V89, P127, DOI 10.1189/jlb.1009696; Martinez-Navio JM, 2009, IMMUNOLOGY, V128, P393, DOI 10.1111/j.1365-2567.2009.03121.x; Meyer T, 2010, STRUCTURE, V18, P1399, DOI 10.1016/j.str.2010.07.013; Pacheco R, 2005, P NATL ACAD SCI USA, V102, P9583, DOI 10.1073/pnas.0501050102; PETERSEN MB, 1987, J MED GENET, V24, P93, DOI 10.1136/jmg.24.2.93; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Resta R, 1997, IMMUNOL TODAY, V18, P371, DOI 10.1016/S0167-5699(97)01047-5; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Richard E, 2002, J BIOL CHEM, V277, P19720, DOI 10.1074/jbc.M111901200; Rueda M, 2007, P NATL ACAD SCI USA, V104, P796, DOI 10.1073/pnas.0605534104; Ruiz MA, 2000, J NEUROCHEM, V75, P656, DOI 10.1046/j.1471-4159.2000.0750656.x; Saura C, 1996, J NEUROCHEM, V66, P1675; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sun WC, 2005, ACTA PHARMACOL SIN, V26, P160, DOI 10.1111/j.1745-7254.2005.00524.x; Terasaka T, 2004, J AM CHEM SOC, V126, P34, DOI 10.1021/ja038606l; Torvinen M, 2002, NEUROSCIENCE, V113, P709, DOI 10.1016/S0306-4522(02)00058-1; van Gunsteren W F, 1987, J Comput Aided Mol Des, V1, P171; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; WILSON DK, 1993, BIOCHEMISTRY-US, V32, P1689, DOI 10.1021/bi00058a001; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YORK DM, 1994, P NATL ACAD SCI USA, V91, P8715, DOI 10.1073/pnas.91.18.8715	64	27	33	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1048	1061		10.1096/fj.12-212621	http://dx.doi.org/10.1096/fj.12-212621			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193172				2022-12-28	WOS:000315585200019
J	Okumura-Noji, K; Miura, Y; Lu, R; Asai, K; Ohta, N; Brindley, PJ; Yokoyama, S				Okumura-Noji, Kuniko; Miura, Yutaka; Lu, Rui; Asai, Kiyofumi; Ohta, Nobuo; Brindley, Paul J.; Yokoyama, Shinji			CD36-related protein in Schistosoma japonicum: candidate mediator of selective cholesteryl ester uptake from high-density lipoprotein for egg maturation	FASEB JOURNAL			English	Article						CETP deficiency; miracidium; CETP; embryonation; hepatic granulomatosis; HDL	SCAVENGER RECEPTOR; HUMAN PLASMA; SR-BI; DEFICIENCY; IDENTIFICATION; DATABASE; BINDING; GENE; HYPERALPHALIPOPROTEINEMIA; PURIFICATION	Familial cholesteryl ester transfer protein (CETP) deficiency is more common in some East Asian populations than elsewhere, suggesting the possibility of a selective advantage of this genetic defect against regional infectious diseases. Historically, infection with the Asian blood fluke Schistosoma japonicum has been endemic in these regions, including Japan. We previously reported that eggs of S. japonicum require cholesteryl ester uptake from normal high-density lipoprotein (HDL) but not from CETP-deficient HDL for their maturation to miracidia, a critical step of the hepatic pathogenesis of schistosomiasis. Herein we show that cholesteryl ester uptake is selective from HDL, and identified CD36-related protein (CD36RP) as a candidate to mediate the reaction. CD36RP was cloned from the adult and the egg developmental stages of S. japonicum, with 1880 bp encoding 506 amino acid residues exhibiting the CD36 domains and two transmembrane regions. Using antibodies against recombinant peptides representing the potential extracellular domains of CD36RP, Western blotting detected a protein with a molecular mass of 82 kDa in the particulate fraction of the adult parasite cells, which was reduced to 62 kDa after N-glycanase treatment. The extracellular domain peptide bound human HDL, as established by immunoblots following nondenaturing gel electrophoresis. Antibodies against the extracellular domain suppressed HDL cholesteryl ester uptake and maturation of the eggs in vitro. CD36RP is a candidate receptor on eggs of S. japonicum that facilitates uptake of HDL cholesteryl ester necessary for egg embryonation and maturation.-Okumura-Noji, K., Miura, Y., Lu, R., Asai, K., Ohta, N., Brindley, P. J., Yokoyama, S. CD36-related protein in Schistosoma japonicum: candidate mediator of selective cholesteryl ester uptake from high-density lipoprotein for egg maturation. FASEB J. 27, 1236-1244 (2013). www.fasebj.org	[Okumura-Noji, Kuniko; Lu, Rui; Yokoyama, Shinji] Chubu Univ, Nutr Hlth Sci Res Ctr, Kasugai, Aichi 4878501, Japan; [Okumura-Noji, Kuniko; Lu, Rui; Yokoyama, Shinji] Chubu Univ, Dept Food & Nutr Sci, Kasugai, Aichi 4878501, Japan; [Okumura-Noji, Kuniko; Yokoyama, Shinji] Nagoya City Univ, Grad Sch Med Sci, Dept Biochem, Nagoya, Aichi, Japan; [Miura, Yutaka; Asai, Kiyofumi] Nagoya City Univ, Grad Sch Med Sci, Dept Neurosci, Nagoya, Aichi, Japan; [Ohta, Nobuo] Nagoya City Univ, Grad Sch Med Sci, Dept Parasitol, Nagoya, Aichi, Japan; [Ohta, Nobuo] Tokyo Med & Dent Univ, Dept Environm Parasitol, Tokyo, Japan; [Brindley, Paul J.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA	Chubu University; Chubu University; Nagoya City University; Nagoya City University; Nagoya City University; Tokyo Medical & Dental University (TMDU); George Washington University	Yokoyama, S (corresponding author), Chubu Univ, Nutr Hlth Sci Res Ctr, Kasugai, Aichi 4878501, Japan.	syokoyam@med.nagoya-cu.ac.jp	Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251; Brindley, Paul J./0000-0003-1765-0002	MEXT-Supported Program for the Strategic Research Foundation at Private Universities (Japan)	MEXT-Supported Program for the Strategic Research Foundation at Private Universities (Japan)	This work was supported in part by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities (Japan).	Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BISGAIER CL, 1991, J LIPID RES, V32, P21; Chiba H, 1997, J LIPID RES, V38, P1204; EISENBERG S, 1972, BIOCHIM BIOPHYS ACTA, V260, P329, DOI 10.1016/0005-2760(72)90045-8; Fan J., 2003, INT J BIOCHEM CELL B, V1507, P1; Fan JJ, 1998, BIOCHEM BIOPH RES CO, V252, P348, DOI 10.1006/bbrc.1998.9491; FURLONG ST, 1995, J LIPID RES, V36, P1; Gray Darren J, 2011, BMJ, V342, pd2651, DOI 10.1136/bmj.d2651; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HIRANO K, 1993, ATHEROSCLEROSIS, V100, P85, DOI 10.1016/0021-9150(93)90070-B; Hirano K, 1997, ARTERIOSCL THROM VAS, V17, P1053, DOI 10.1161/01.ATV.17.6.1053; Hui Shu-Ping, 1997, Hokkaido Journal of Medical Science, V72, P319; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; OHNISHI T, 1990, J LIPID RES, V31, P397; Okumura-Noji K, 2001, BIOCHEM BIOPH RES CO, V286, P305, DOI 10.1006/bbrc.2001.5386; OWHASHI M, 1981, INT ARCH ALLER A IMM, V64, P146; Rinaldi G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002820; ROGERS MV, 1990, MOL BIOCHEM PARASIT, V41, P93, DOI 10.1016/0166-6851(90)90100-Z; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Rost B, 1996, METHOD ENZYMOL, V266, P525; Shao HG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002871; Song GJ, 1997, MOL CELLS, V7, P615; Taylor SM, 2012, LANCET INFECT DIS, V12, P457, DOI 10.1016/S1473-3099(12)70055-5; Vinals M, 2003, J BIOL CHEM, V278, P5325, DOI 10.1074/jbc.M211073200; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; XU XF, 1992, EUR J CELL BIOL, V57, P229; Yang SH, 2010, MOL BIOCHEM PARASIT, V174, P109, DOI 10.1016/j.molbiopara.2010.07.007; Zhang R, 2000, Parasitol Int, V48, P232; Zhang RL, 2001, INFECT IMMUN, V69, P386, DOI 10.1128/IAI.69.1.386-391.2001	33	9	9	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1236	1244		10.1096/fj.12-219816	http://dx.doi.org/10.1096/fj.12-219816			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195036				2022-12-28	WOS:000315585200035
J	De Franceschi, L; Franco, RS; Bertoldi, M; Brugnara, C; Matte, A; Siciliano, A; Wieschhaus, AJ; Chishti, AH; Joiner, CH				De Franceschi, Lucia; Franco, Robert S.; Bertoldi, Mariarita; Brugnara, Carlo; Matte, Alessandro; Siciliano, Angela; Wieschhaus, Adam J.; Chishti, Athar H.; Joiner, Clinton H.			Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease	FASEB JOURNAL			English	Article						peroxiredoxin-2; BDA-410; protease	K-CA CHANNEL; DEPENDENT ACTIVATION; KCL COTRANSPORT; PROTEIN-KINASE; BLOOD-CELLS; INTERMEDIATE CONDUCTANCE; DENSE CELLS; IN-VITRO; SAD MICE; MEMBRANE	Sickle cell disease (SCD) is a globally distributed hereditary red blood cell (RBC) disorder. One of the hallmarks of SCD is the presence of circulating dense RBCs, which are important in SCD-related clinical manifestations. In human dense sickle cells, we found reduced calpastatin activity and protein expression compared to either healthy RBCs or unfractionated sickle cells, suggesting an imbalance between activator and inhibitor of calpain-1 in favor of activator in dense sickle cells. Calpain-1 is a nonlysosomal cysteine proteinase that modulates multiple cell functions through the selective cleavage of proteins. To investigate the relevance of this observation in vivo, we evaluated the effects of the orally active inhibitor of calpain-1, BDA-410 (30 mg/kg/d), on RBCs from SAD mice, a mouse model for SCD. In SAD mice, BDA-410 improved RBC morphology, reduced RBC density (D-20; from 1106 +/- 0.001 to 1100 +/- 0.001 g/ml; P<0.05) and increased RBC-K+ content (from 364 +/- 10 to 429 +/- 12.3 mmol/kg Hb; P<0.05), markedly reduced the activity of the Ca2+-activated K+ channel (Gardos channel), and decreased membrane association of peroxiredoxin-2. The inhibitory effect of calphostin C, a specific inhibitor of protein kinase C (PKC), on the Gardos channel was eliminated after BDA-410 treatment, which suggests that calpain-1 inhibition affects the PKC-dependent fraction of the Gardos channel. BDA-410 prevented hypoxia-induced RBC dehydration and K+ loss in SAD mice. These data suggest a potential role of BDA-410 as a novel therapeutic agent for treatment of SCD.-De Franceschi, L., Franco, R. S., Bertoldi, M., Brugnara, C., Matte, A., Siciliano, A., Wieschhaus, A.J., Chishti, A. H., Joiner, C. H. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB J. 27, 750-759 (2013). www.fasebj.org	[De Franceschi, Lucia; Matte, Alessandro; Siciliano, Angela] Univ Verona, Dept Med, Sect Internal Med, I-37134 Verona, Italy; [Bertoldi, Mariarita] Univ Verona, Dept Life & Reprod Sci, Biochem Sect, I-37134 Verona, Italy; [Franco, Robert S.; Joiner, Clinton H.] Univ Cincinnati, Coll Med, Div Hematol Oncol, Cincinnati, OH USA; [Franco, Robert S.; Joiner, Clinton H.] Childrens Hosp, Ctr Comprehens Sickle Cell, Cincinnati, OH 45229 USA; [Brugnara, Carlo] Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, Boston, MA 02115 USA; [Brugnara, Carlo] Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Wieschhaus, Adam J.; Chishti, Athar H.] Tufts Univ, Sch Med, Dept Mol Physiol & Pharmacol, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA	University of Verona; University of Verona; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Tufts University	De Franceschi, L (corresponding author), Univ Verona, Dept Med, Ple L Scuro 10, I-37134 Verona, Italy.	lucia.defranceschi@univr.it	Bertoldi, Mariarita/F-1154-2010; Matte, Alessandro/AAB-3496-2022; DE FRANCESCHI, Lucia/AAB-8652-2022	Bertoldi, Mariarita/0000-0002-2337-9928; DE FRANCESCHI, Lucia/0000-0001-7093-777X	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR); University of Verona; U.S. National Institutes of Health [HL089517, HL095050]; Tufts Collaborates grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095050, R01HL089517] Funding Source: NIH RePORTER	Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); University of Verona; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tufts Collaborates grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by ex-40% Ministro dell'Istruzione, dell'Universita e della Ricerca (MIUR), University of Verona, to L. D. F. and by U.S. National Institutes of Health grants HL089517 and HL095050 and a Tufts Collaborates grant to A. H. C. The authors are grateful to Drs. Narihiko Yoshii and Hiroshi Kinoshita. A. H. C. proposed the evaluation of BDA-410 in SCD mice. A. H. C. and C.H.J. served as equal senior authors of the manuscript.	AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; Bennekou F, 2001, BLOOD, V97, P1451, DOI 10.1182/blood.V97.5.1451; Biondani A, 2008, PROTEOM CLIN APPL, V2, P706, DOI 10.1002/prca.200780058; BOIVIN P, 1990, INT J BIOCHEM, V22, P1479, DOI 10.1016/0020-711X(90)90240-4; BRUGNARA C, 1989, BLOOD, V74, P487; Ciana A, 2004, BIOELECTROCHEMISTRY, V62, P169, DOI 10.1016/j.bioelechem.2003.07.004; De Franceschi L, 2004, HAEMATOLOGICA, V89, P348; de Franceschi L, 2003, BLOOD, V102, P1087, DOI 10.1182/blood-2002-07-2135; De Franceschi L, 1999, BLOOD, V94, P4307, DOI 10.1182/blood.V94.12.4307.424k39_4307_4313; De Franceschi L, 2011, HAEMATOL-HEMATOL J, V96, P1595, DOI 10.3324/haematol.2011.043612; De Franceschi L, 2011, SEMIN THROMB HEMOST, V37, P226, DOI 10.1055/s-0031-1273087; De Franceschi L, 2008, PROTEOMICS, V8, P4695, DOI 10.1002/pmic.200700596; DEFRANCESCHI L, 1995, AM J PHYSIOL-CELL PH, V269, pC899, DOI 10.1152/ajpcell.1995.269.4.C899; duVerle DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019035; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fathallah H, 1997, AM J PHYSIOL-CELL PH, V273, pC1206, DOI 10.1152/ajpcell.1997.273.4.C1206; Franco RS, 2000, BLOOD, V96, P3610, DOI 10.1182/blood.V96.10.3610.h8003610_3610_3617; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Hanna RA, 2008, NATURE, V456, P409, DOI 10.1038/nature07451; Hebbel RP, 2008, TRANSFUS CLIN BIOL, V15, P14, DOI 10.1016/j.tracli.2008.03.011; Hebbel RP, 2010, BLOOD, V115, P2483, DOI 10.1182/blood-2009-02-204990; Joiner CH, 2004, BLOOD, V104, P2954, DOI 10.1182/blood-2004-01-0112; Joiner CH, 2007, BLOOD, V109, P1728, DOI 10.1182/blood-2006-04-018630; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Kuchay SM, 2007, MOL CELL BIOL, V27, P6038, DOI 10.1128/MCB.00522-07; Li XR, 2007, MOL BIOCHEM PARASIT, V155, P26, DOI 10.1016/j.molbiopara.2007.05.004; Matarrese P, 2005, FASEB J, V19, P416, DOI 10.1096/fj.04-2450fje; Matte A, 2010, FREE RADICAL BIO MED, V49, P457, DOI 10.1016/j.freeradbiomed.2010.05.003; McGoron AJ, 2000, BLOOD, V95, P2164, DOI 10.1182/blood.V95.6.2164; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Melloni E, 2000, BIOCHEM BIOPH RES CO, V272, P472, DOI 10.1006/bbrc.2000.2796; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; Moon JC, 2005, J BIOL CHEM, V280, P28775, DOI 10.1074/jbc.M505362200; Moore RB, 1997, AM J HEMATOL, V56, P100, DOI 10.1002/(SICI)1096-8652(199710)56:2<100::AID-AJH5>3.3.CO;2-M; MOORE RB, 1991, J BIOL CHEM, V266, P18964; OLORUNSOGO OO, 1990, BIOSCIENCE REP, V10, P281, DOI 10.1007/BF01117244; PONTREMOLI S, 1988, BIOCHEM BIOPH RES CO, V151, P590, DOI 10.1016/0006-291X(88)90635-3; Rivera A, 2002, BLOOD, V99, P357, DOI 10.1182/blood.V99.1.357; Rivera A, 1999, AM J PHYSIOL-CELL PH, V277, pC746, DOI 10.1152/ajpcell.1999.277.4.C746; Sabaa N, 2008, J CLIN INVEST, V118, P1924, DOI 10.1172/JCI33308; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; Siciliano A, 2011, HAEMATOL-HEMATOL J, V96, P24, DOI 10.3324/haematol.2010.028506; Solovey AA, 2001, BLOOD, V97, P1937, DOI 10.1182/blood.V97.7.1937; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Stocker JW, 2003, BLOOD, V101, P2412, DOI 10.1182/blood-2002-05-1433; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Trinchese F, 2008, J CLIN INVEST, V118, P2796, DOI 10.1172/JCI34254; WANG KKW, 1989, J MEMBRANE BIOL, V112, P233, DOI 10.1007/BF01870954; Wieschhaus A, 2012, BIOCHEM J, V448, P141, DOI 10.1042/BJ20121008; Woycechowsky KJ, 2003, BIOCHEMISTRY-US, V42, P5387, DOI 10.1021/bi026993q; Yan Y, 2009, CELL, V138, P1209, DOI 10.1016/j.cell.2009.06.042; Yasin Z, 2003, BLOOD, V102, P365, DOI 10.1182/blood-2002-11-3416	59	24	24	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					750	759		10.1096/fj.12-217836	http://dx.doi.org/10.1096/fj.12-217836			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085996	Green Published			2022-12-28	WOS:000314358000033
J	Thaler, R; Zwerina, J; Rumpler, M; Spitzer, S; Gamsjaeger, S; Paschalis, EP; Klaushofer, K; Varga, F				Thaler, Roman; Zwerina, Jochen; Rumpler, Monika; Spitzer, Silvia; Gamsjaeger, Sonja; Paschalis, Eleftherios P.; Klaushofer, Klaus; Varga, Franz			Homocysteine induces serum amyloid A3 in osteoblasts via unlocking RGD-motifs in collagen	FASEB JOURNAL			English	Article						bone; extracellular matrix; Saa3; MC3T3-E1 cells	ACUTE MYOCARDIAL-INFARCTION; NF-KAPPA-B; BETA-CATENIN; ACUTE-PHASE; TYROSINE PHOSPHORYLATION; RHEUMATOID-ARTHRITIS; DIETARY-CHOLESTEROL; PLASMA HOMOCYSTEINE; ALZHEIMERS-DISEASE; AA-AMYLOIDOSIS	Hyperhomocysteinemia is a risk factor for osteoporotic fractures. Homocysteine (Hcys) inhibits collagen cross-linking and consequently decreases bone extracellular matrix (ECM) quality. Serum amyloid A (A-SAA), an acute-phase protein family, plays an important role in chronic and inflammatory diseases and up-regulates MMP13, which plays an important role in bone development and remodeling. Here, we investigate the effect of Hcys on expression of SAA3, a member of the A-SAA gene family, in osteoblasts characterizing underlying mechanisms and possible consequences on bone metabolism. MC3T3-E1 osteoblast-like cells were cultured up to 21 d with Hcys (low millimolar range) or reseeded onto ECM resulting from untreated or Hcys-treated MC3T3-E1 cells. Fourier-transformed infrared spectroscopy and a discriminative antibody were used to characterize the resulting ECM. Gene expression and signaling pathways were analyzed by gene chip, quantitative RT-PCR, and immunoblotting. Transcriptional regulation of Saa3 was studied by promoter transfection assays, chromatin immunoprecipitation, and immunofluorescence microscopy. Hcys treatment resulted in reduced collagen cross-linking, uncovering of RGD-motifs, and activation of the PTK2-PXN-CTNNB1 pathway followed by RELA activation. These signaling events led to increased SAA3 expression followed by the production of MMP13 and several chemokines, including Ccl5, Ccl2, Cxcl10, and Il6. Our data suggest Saa3 as link between hyperhomocysteinemia and development of osteoporosis.-Thaler, R., Zwerina, J., Rumpler, M., Spitzer, S., Gamsjaeger, S., Paschalis, E. P., Klaushofer, K., Varga, F. Homocysteine induces serum amyloid A3 in osteoblasts via unlocking RGD motifs in collagen. FASEB J. 27, 446-463 (2013). www.fasebj.org	Hanusch Hosp, Ludwig Boltzmann Inst Osteol, Wiener Gebietskrankenkasse WGKK, A-1140 Vienna, Austria; Hanusch Hosp, Dept Med 1, Allgemeine Unfallversicherungsanstalt AUVA Trauma, A-1140 Vienna, Austria	Ludwig Boltzmann Institute; WGKK - Hanusch Hospital; WGKK - Hanusch Hospital	Varga, F (corresponding author), Hanusch Hosp, Dept Med 1, Ludwig Boltzmann Inst Osteol, Heinrich Collin Str 30, A-1140 Vienna, Austria.	franz.varga@osteologie.at	/AAC-1939-2021; Gamsjaeger, Sonja/AAD-3956-2019; Gamsjaeger, Sonja/AAB-6636-2021	Gamsjaeger, Sonja/0000-0002-9543-6530; Gamsjaeger, Sonja/0000-0002-9543-6530	Fonds zur Forderung der Wissenschaftlichen Forschung (FWF; The Austrian Science Fund) [P20646-B11]; Wiener Gebietskrankenkasse (WGKK; Social Health Insurance Vienna); Allgemeine Unfallversicherungsanstalt (AUVA; Austrian Social Insurance for Occupational Risks); Austrian Science Fund (FWF) [P 24370] Funding Source: researchfish	Fonds zur Forderung der Wissenschaftlichen Forschung (FWF; The Austrian Science Fund)(Austrian Science Fund (FWF)); Wiener Gebietskrankenkasse (WGKK; Social Health Insurance Vienna); Allgemeine Unfallversicherungsanstalt (AUVA; Austrian Social Insurance for Occupational Risks); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This study was supported by the Fonds zur Forderung der Wissenschaftlichen Forschung (FWF; The Austrian Science Fund) Project P20646-B11, the Wiener Gebietskrankenkasse (WGKK; Social Health Insurance Vienna), and the Allgemeine Unfallversicherungsanstalt (AUVA; Austrian Social Insurance for Occupational Risks). The authors thank E. Schiemel and K. Schiemel for carefully reading the manuscript. The authors declare no conflicts of interest.	BIRAN H, 1986, J CLIN PATHOL, V39, P794, DOI 10.1136/jcp.39.7.794; Blouin S, 2009, BONE, V44, P959, DOI 10.1016/j.bone.2008.12.023; Brustolin S, 2010, BRAZ J MED BIOL RES, V43, P1, DOI 10.1590/S0100-879X2009007500021; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chiba T, 2009, J LIPID RES, V50, P1353, DOI 10.1194/jlr.M900089-JLR200; Chung TF, 2000, AMYLOID, V7, P105, DOI 10.3109/13506120009146246; Connolly M, 2011, ANN RHEUM DIS, V70, P1296, DOI 10.1136/ard.2010.142240; Cunnane G, 2001, CURR OPIN RHEUMATOL, V13, P67, DOI 10.1097/00002281-200101000-00011; Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007; Dionisio N, 2010, CURR MED CHEM, V17, P3109, DOI 10.2174/092986710791959783; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; Fasshauer M, 2004, J ENDOCRINOL, V183, P561, DOI 10.1677/joe.1.05699; Fornoni A, 2008, DIABETOLOGIA, V51, P298, DOI 10.1007/s00125-007-0889-4; Fratzl-Zelman N, 2003, CELL BIOL INT, V27, P459, DOI 10.1016/S1065-6995(03)00037-4; Gjesdal CG, 2007, J BONE MINER RES, V22, P747, DOI 10.1359/JBMR.070210; Gruys E, 1996, LAB ANIM, V30, P28, DOI 10.1258/002367796780745018; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Johnson BD, 2004, CIRCULATION, V109, P726, DOI 10.1161/01.CIR.0000115516.54550.B1; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Katayama T, 2007, INT HEART J, V48, P45, DOI 10.1536/ihj.48.45; Kelley BP, 2011, J BONE MINER RES, V26, P666, DOI 10.1002/jbmr.250; Kim CG, 2011, BIOCHEM BIOPH RES CO, V410, P637, DOI 10.1016/j.bbrc.2011.06.044; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; Klamer G, 2010, CURR MED CHEM, V17, P2873, DOI 10.2174/092986710792065090; KLUVEBECKERMAN B, 1991, DNA CELL BIOL, V10, P651, DOI 10.1089/dna.1991.10.651; Kovacevic A, 2008, J CELL BIOCHEM, V103, P994, DOI 10.1002/jcb.21472; Kumon Y, 1997, J RHEUMATOL, V24, P14; Lewis KE, 2004, CIRCULATION, V110, P540, DOI 10.1161/01.CIR.0000136819.93989.E1; LI XX, 1991, J BIOL CHEM, V266, P15192; Li YT, 2006, PROTEOMICS, V6, P3426, DOI 10.1002/pmic.200500472; Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154-006-9001-5; Liu YC, 2010, J CELL BIOCHEM, V111, P402, DOI 10.1002/jcb.22714; Ludlage E, 2005, VET PATHOL, V42, P117, DOI 10.1354/vp.42-2-117; Maier W, 2005, CIRCULATION, V111, P1355, DOI 10.1161/01.CIR.0000158479.58589.0A; Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x; Marzocco S, 2004, LIFE SCI, V75, P1491, DOI 10.1016/j.lfs.2004.03.013; Mauney JR, 2006, J BIOMED MATER RES A, V79A, P464, DOI 10.1002/jbm.a.30876; McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1992, P NATL ACAD SCI USA, V89, P7949, DOI 10.1073/pnas.89.17.7949; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Moran AE, 2005, CANCER RES, V65, P1097; Morrison C, 2011, J BIOL CHEM, V286, P34271, DOI 10.1074/jbc.M111.222513; Paschalis EP, 2001, J BONE MINER RES, V16, P1821, DOI 10.1359/jbmr.2001.16.10.1821; Peperkamp NHMT, 1997, VET PATHOL, V34, P271, DOI 10.1177/030098589703400402; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raisz LG, 2004, NEW ENGL J MED, V350, P2089, DOI 10.1056/NEJMe048030; Rauner M, 2012, J BONE MINER RES, V27, P575, DOI 10.1002/jbmr.1488; Reigstad CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005842; Robich MP, 2010, CIRCULATION, V122, pS142, DOI 10.1161/CIRCULATIONAHA.109.920132; Rucker RB, 1998, AM J CLIN NUTR, V67, p996S, DOI 10.1093/ajcn/67.5.996S; RYGG M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P402, DOI 10.1016/0167-4781(93)90007-Z; Scheja L, 2008, EXP DIABETES RES, DOI 10.1155/2008/230837; SHIMIZU H, 1994, GENE, V149, P305; Sommer G, 2008, J CELL BIOCHEM, V104, P2241, DOI 10.1002/jcb.21782; Subramanian S, 2008, ARTERIOSCL THROM VAS, V28, P685, DOI 10.1161/ATVBAHA.107.157685; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003; Taubenberger AV, 2010, BIOMATERIALS, V31, P2827, DOI 10.1016/j.biomaterials.2009.12.051; Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181; Thaler R, 2010, BONE, V46, P703, DOI 10.1016/j.bone.2009.10.038; Thorn CF, 2003, EUR J IMMUNOL, V33, P2630, DOI 10.1002/eji.200323985; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Vallon R, 2001, J IMMUNOL, V166, P2801, DOI 10.4049/jimmunol.166.4.2801; Van Dam F, 2009, ARCH GERONTOL GERIAT, V48, P425, DOI 10.1016/j.archger.2008.03.009; Villa P, 2007, CLIN CHEM LAB MED, V45, P130, DOI 10.1515/CCLM.2007.067; WESTERMARK GT, 1990, AM J PATHOL, V137, P377; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yamada T, 2000, SCAND J IMMUNOL, V52, P7; Zerega B, 2004, MATRIX BIOL, V23, P35, DOI 10.1016/j.matbio.2004.02.002; Zhang B, 2008, J HERED, V99, P355, DOI 10.1093/jhered/esn015; Zhang H, 2006, J BIOMED MATER RES A, V76A, P120, DOI 10.1002/jbm.a.30491	72	18	19	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					446	463		10.1096/fj.12-208058	http://dx.doi.org/10.1096/fj.12-208058			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085993				2022-12-28	WOS:000314358000006
J	Wong, EWP; Lee, WM; Cheng, CY				Wong, Elissa W. P.; Lee, Will M.; Cheng, C. Yan			Secreted Frizzled-related protein 1 (sFRP1) regulates spermatid adhesion in the testis via dephosphorylation of focal adhesion kinase and the nectin-3 adhesion protein complex	FASEB JOURNAL			English	Article						spermatogenesis; seminiferous epithelial cycle; apical ectoplasmic specialization	ANCHORING JUNCTION DYNAMICS; SEMINIFEROUS EPITHELIUM; SERTOLI-CELLS; WNT ANTAGONIST; ECTOPLASMIC SPECIALIZATION; TUBULOBULBAR COMPLEXES; SIGNALING PATHWAY; BARRIER DYNAMICS; BREAST-CANCER; GERM-CELLS	Development of spermatozoa in adult mammalian testis during spermatogenesis involves extensive cell migration and differentiation. Spermatogonia that reside at the basal compartment of the seminiferous epithelium differentiate into more advanced germ cell types that migrate toward the apical compartment until elongated spermatids are released into the tubule lumen during spermiation. Apical ectoplasmic specialization (ES; a testis-specific anchoring junction) is the only cell junction that anchors and maintains the polarity of elongating/elongated spermatids (step 8-19 spermatids) in the epithelium. Little is known regarding the signaling pathways that trigger the disassembly of the apical ES at spermiation. Here, we show that secreted Frizzled-related protein 1 (sFRP1), a putative tumor suppressor gene that is frequently down-regulated in multiple carcinomas, is a crucial regulatory protein for spermiation. The expression of sFRP1 is tightly regulated in adult rat testis to control spermatid adhesion and sperm release at spermiation. Downregulation of sFRP1 during testicular development was found to coincide with the onset of the first wave of spermiation at approximately age 45 d postpartum, implying that sFRP1 might be correlated with elongated spermatid adhesion conferred by the apical ES before spermiation. Indeed, administration of sFRP1 recombinant protein to the testis in vivo delayed spermiation, which was accompanied by down-regulation of phosphorylated (p)-focal adhesion kinase (FAK)-Tyr(397) and retention of nectin-3 adhesion protein at the apical ES. To further investigate the functional relationship between p-FAK-Tyr(397) and localization of nectin-3, we overexpressed sFRP1 using lentiviral vectors in the Sertoli-germ cell coculture system. Consistent with the in vivo findings, overexpression of sFRP1 induced down-regulation of p-FAK-Tyr(397), leading to a decline in phosphorylation of nectin-3. In summary, this report highlights the critical role of sFRP1 in regulating spermiation via its effects on the FAK signaling and retention of nectin-3 adhesion complex at the apical ES.-Wong, E. W. P., Lee, W. M., Cheng, C. Y. Secreted Frizzled-related protein 1 (sFRP1) regulates spermatid adhesion in the testis via dephosphorylation of focal adhesion kinase and the nectin-3 adhesion protein complex. FASEB J. 27, 464-477 (2013). www.fasebj.org	[Wong, Elissa W. P.; Cheng, C. Yan] Rockefeller Univ, Populat Council, Ctr Biomed Res, New York, NY 10021 USA; [Lee, Will M.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China	Population Council; Rockefeller University; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USA.	y-cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	U.S. National Institutes of Health (National Institute of Child Health and Human Development) [R01-HD-056034, U54-HD-029990]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990, R01HD056034] Funding Source: NIH RePORTER	U.S. National Institutes of Health (National Institute of Child Health and Human Development)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Dr. Naama Kanarek for helpful discussion on the production of lentiviral vectors. The authors also appreciate the generous gifts of gag-pol and pMD.G plasmids from Prof. Yinon Ben-Neriah and Dr. Naama Kanarek (Hebrew University of Jerusalem, Jerusalem, Israel). This work was supported by grants from the U.S. National Institutes of Health (National Institute of Child Health and Human Development, R01-HD-056034 to C.Y.C; U54-HD-029990 Project 5 to C.Y.C.).	Amin N, 2012, FRONT BIOSCI-LANDMRK, V17, P784, DOI 10.2741/3957; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Ashton GH, 2010, DEV CELL, V19, P259, DOI 10.1016/j.devcel.2010.07.015; Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Beardsley A, 2006, J ENDOCRINOL, V190, P759, DOI 10.1677/joe.1.06867; Berndt T, 2007, ANNU REV PHYSIOL, V69, P341, DOI 10.1146/annurev.physiol.69.040705.141729; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; BROKELMANN J, 1963, Z ZELLFORSCH MIK ANA, V59, P820, DOI 10.1007/BF00362263; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Cheng C Yan, 2011, Spermatogenesis, V1, P291; Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790; Cheng CY, 2010, NAT REV ENDOCRINOL, V6, P380, DOI 10.1038/nrendo.2010.71; CHENG CY, 1989, J BIOL CHEM, V264, P21386; Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008; Cheshenko N, 2005, J BIOL CHEM, V280, P31116, DOI 10.1074/jbc.M503518200; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; Denison FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028306; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Findley MK, 2009, IUBMB LIFE, V61, P431, DOI 10.1002/iub.175; Froment P, 2007, J ENDOCRINOL, V194, P557, DOI 10.1677/JOE-07-0258; GALDIERI M, 1981, J ANDROL, V2, P249; Galen B, 2006, J VIROL, V80, P12209, DOI 10.1128/JVI.01503-06; Green KJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000125; Han XZ, 2004, J BIOL CHEM, V279, P2832, DOI 10.1074/jbc.M308102200; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Ikawa M, 2002, P NATL ACAD SCI USA, V99, P7524, DOI 10.1073/pnas.072207299; Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kele J, 2012, STEM CELLS, V30, P865, DOI 10.1002/stem.1049; Leithe E, 2012, BBA-BIOMEMBRANES, V1818, P1870, DOI 10.1016/j.bbamem.2011.09.029; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li MWM, 2006, J ENDOCRINOL, V190, P313, DOI 10.1677/joe.1.06781; Li MWM, 2009, INT J BIOCHEM CELL B, V41, P2302, DOI 10.1016/j.biocel.2009.05.016; Lie PPY, 2012, P NATL ACAD SCI USA, V109, P12562, DOI 10.1073/pnas.1202316109; Lie PPY, 2010, P NATL ACAD SCI USA, V107, P11411, DOI 10.1073/pnas.1001823107; Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Mruk DD, 2011, METHODS MOL BIOL, V763, P237, DOI 10.1007/978-1-61779-191-8_16; O'Donnell Liza, 2011, Spermatogenesis, V1, P14; ODonnell L, 1996, BIOL REPROD, V55, P895, DOI 10.1095/biolreprod55.4.895; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Polakis P, 2012, COLD SPRING HARB PER, V4; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Rainey MA, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-37; RUSSELL L, 1976, ANAT REC, V185, P259, DOI 10.1002/ar.1091850302; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; Satoh W, 2008, GENESIS, V46, P92, DOI 10.1002/dvg.20369; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; Stiles KM, 2008, VIROLOGY, V373, P98, DOI 10.1016/j.virol.2007.11.012; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Vaid KS, 2007, J CELL PHYSIOL, V210, P644, DOI 10.1002/jcp.20855; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Warr N, 2009, DEV BIOL, V326, P273, DOI 10.1016/j.ydbio.2008.11.023; Wong CH, 2005, ENDOCRINOLOGY, V146, P1192, DOI 10.1210/en.2004-1275; Wong EWP, 2008, P NATL ACAD SCI USA, V105, P9657, DOI 10.1073/pnas.0801527105; Wong EWP, 2011, TRENDS PHARMACOL SCI, V32, P290, DOI 10.1016/j.tips.2011.01.001; Wong EWP, 2010, P NATL ACAD SCI USA, V107, P11399, DOI 10.1073/pnas.1001077107; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xia WL, 2006, J BIOL CHEM, V281, P16799, DOI 10.1074/jbc.M601618200; Xia WL, 2005, DEV BIOL, V280, P321, DOI 10.1016/j.ydbio.2004.12.036; Young J'nelle S, 2012, Spermatogenesis, V2, P63; Young JS, 2009, BIOL REPROD, V80, P162, DOI 10.1095/biolreprod.108.070623; Young JS, 2009, BIOL REPROD, V80, P153, DOI 10.1095/biolreprod.108.070615; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103	73	15	15	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					464	477		10.1096/fj.12-212514	http://dx.doi.org/10.1096/fj.12-212514			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23073828	Green Published			2022-12-28	WOS:000314358000007
J	Tryndyak, V; de Conti, A; Kobets, T; Kutanzi, K; Koturbash, I; Han, T; Fuscoe, JC; Latendresse, JR; Melnyk, S; Shymonyak, S; Collins, L; Ross, SA; Rusyn, I; Beland, FA; Pogribny, IP				Tryndyak, Volodymyr; de Conti, Aline; Kobets, Tetyana; Kutanzi, Kristy; Koturbash, Igor; Han, Tao; Fuscoe, James C.; Latendresse, John R.; Melnyk, Stepan; Shymonyak, Svitlana; Collins, Leonard; Ross, Sharon A.; Rusyn, Ivan; Beland, Frederick A.; Pogribny, Igor P.			Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism	FASEB JOURNAL			English	Article						nonalcoholic fatty liver; interindividual; oxidative stress	ELEMENT-BINDING PROTEIN; PPAR-ALPHA; OXIDATIVE STRESS; HEPATIC STEATOSIS; EXPRESSION; CHREBP; CYTOCHROME-P450; SUSCEPTIBILITY; PROGRESSION; DIVERSITY	Nonalcoholic fatty liver disease (NAFLD) is a major health problem and a leading cause of chronic liver disease in the United States and developed countries. In humans, genetic factors greatly influence individual susceptibility to NAFLD. The goals of this study were to compare the magnitude of interindividual differences in the severity of liver injury induced by methyl-donor deficiency among individual inbred strains of mice and to investigate the underlying mechanisms associated with the variability. Feeding mice a choline-and folate-deficient diet for 12 wk caused liver injury similar to NAFLD. The magnitude of liver injury varied among the strains, with the order of sensitivity being A/J approximate to C57BL/6J approximate to C3H/HeJ < 129S1/SvImJ approximate to CAST/EiJ < PWK/PhJ < WSB/EiJ. The interstrain variability in severity of NAFLD liver damage was associated with dysregulation of genes involved in lipid metabolism, primarily with a down-regulation of the peroxisome proliferator receptor alpha (PPAR alpha)-regulated lipid catabolic pathway genes. Markers of oxidative stress and oxidative stress-induced DNA damage were also elevated in the livers but were not correlated with severity of liver damage. These findings suggest that the PPAR alpha-regulated metabolism network is one of the key mechanisms determining interstrain susceptibility and severity of NAFLD in mice.-Tryndyak, V., de Conti, A., Kobets, T., Kutanzi, K., Koturbash, I., Han, T., Fuscoe, J. C., Latendresse, J. R., Melnyk, S., Shymonyak, S., Collins, L., Ross, S. A., Rusyn, I., Beland, F. A., Pogribny, I. P. Interstrain differences in the severity of liver injury induced by a choline-and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism. FASEB J. 26, 4592-4602 (2012). www.fasebj.org	[Tryndyak, Volodymyr; Kobets, Tetyana; Kutanzi, Kristy; Koturbash, Igor; Beland, Frederick A.; Pogribny, Igor P.] US FDA, NCTR, Div Biochem Toxicol, Jefferson, AR 72079 USA; [Han, Tao; Fuscoe, James C.] US FDA, NCTR, Div Syst Biol, Jefferson, AR 72079 USA; [Latendresse, John R.] US FDA, NCTR, Toxicol Pathol Associates, Jefferson, AR 72079 USA; [de Conti, Aline] Univ Sao Paulo, Lab Diet Nutr & Canc, Sao Paulo, Brazil; [Kobets, Tetyana; Shymonyak, Svitlana; Collins, Leonard; Rusyn, Ivan] Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC USA; [Melnyk, Stepan] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Ross, Sharon A.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Universidade de Sao Paulo; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pogribny, IP (corresponding author), US FDA, NCTR, Div Biochem Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.	igor.pogribny@fda.hhs.gov	Rusyn, Ivan/S-2426-2016; de Conti, Aline/I-1666-2013	Kobets, Tetyana/0000-0002-8207-5035; Beland, Frederick/0000-0002-2113-6260; Rusyn, Ivan/0000-0001-9340-7384; Tryndyak, Volodymyr/0000-0002-8319-2954	NIEHS NIH HHS [P30 ES010126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelmegeed MA, 2011, J NUTR, V141, P603, DOI 10.3945/jn.110.135210; Benhamed F, 2012, J CLIN INVEST, V122, P2176, DOI 10.1172/JCI41636; Buechler C, 2011, CURR DRUG METAB, V12, P24, DOI 10.2174/138920011794520035; Chalasani N, 2010, GASTROENTEROLOGY, V139, P1567, DOI 10.1053/j.gastro.2010.07.057; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; Daly AK, 2011, EXPERT REV GASTROENT, V5, P253, DOI [10.1586/egh.11.18, 10.1586/EGH.11.18]; Di Rosa M, 2012, J MOL MED, V90, P105, DOI 10.1007/s00109-011-0803-x; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fang H, 2009, METHODS MOL BIOL, V563, P379, DOI 10.1007/978-1-60761-175-2_20; Fischer M, 2003, J BIOL CHEM, V278, P27997, DOI 10.1074/jbc.M302140200; Fisher CD, 2008, ARCH TOXICOL, V82, P959, DOI 10.1007/s00204-008-0312-z; Franco R., 2007, Archives of Physiology and Biochemistry, V113, P234, DOI 10.1080/13813450701661198; Guillen N, 2009, PHYSIOL GENOMICS, V37, P187, DOI 10.1152/physiolgenomics.90339.2008; Harrill AH, 2009, TOXICOL SCI, V110, P235, DOI 10.1093/toxsci/kfp096; Hebbard L, 2011, NAT REV GASTRO HEPAT, V8, P34, DOI 10.1038/nrgastro.2010.191; Hernaez R, 2012, GASTROENT HEPAT-BARC, V35, P32, DOI 10.1016/j.gastrohep.2011.08.002; Hill-Baskin AE, 2009, HUM MOL GENET, V18, P2975, DOI 10.1093/hmg/ddp236; Hooper AJ, 2011, J LIPID RES, V52, P593, DOI 10.1194/jlr.R008896; Huang JS, 2012, FASEB J, V26, P628, DOI 10.1096/fj.11-194019; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307; Gomez-Lechon MJ, 2009, CURR DRUG METAB, V10, P692, DOI 10.2174/138920009789895543; Klein K, 2012, CLIN PHARMACOL THER, V91, P1044, DOI 10.1038/clpt.2011.336; Koek GH, 2011, CLIN CHIM ACTA, V412, P1297, DOI 10.1016/j.cca.2011.04.013; Koh KH, 2011, DRUG METAB DISPOS, V39, P165, DOI 10.1124/dmd.110.035790; Maher JJ, 2011, ANTIOXID REDOX SIGN, V15, P535, DOI 10.1089/ars.2010.3749; Marra F, 2008, TRENDS MOL MED, V14, P72, DOI 10.1016/j.molmed.2007.12.003; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Nakajima T, 2004, HEPATOLOGY, V40, P972, DOI 10.1002/hep.20399; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nishikawa S, 2012, TOXICOL PATHOL, V40, P71, DOI 10.1177/0192623311422078; Pogribny IP, 2009, J HEPATOL, V51, P176, DOI 10.1016/j.jhep.2009.03.021; Powell CL, 2006, TOXICOL SCI, V93, P213, DOI 10.1093/toxsci/kfl030; Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002; Pyper Sean R, 2010, Nucl Recept Signal, V8, pe002, DOI 10.1621/nrs.08002; Rolo AP, 2012, FREE RADICAL BIO MED, V52, P59, DOI 10.1016/j.freeradbiomed.2011.10.003; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Speliotes EK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001324; Spiekerkoetter U, 2010, J INHERIT METAB DIS, V33, P539, DOI 10.1007/s10545-010-9121-7; Tolwani RJ, 2005, PLOS GENET, V1, P205, DOI 10.1371/journal.pgen.0010023; Uyeda K, 2006, CELL METAB, V4, P107, DOI 10.1016/j.cmet.2006.06.008; van der Meer DLM, 2010, NUCLEIC ACIDS RES, V38, P2839, DOI 10.1093/nar/gkq012; Vluggens A, 2010, LAB INVEST, V90, P696, DOI 10.1038/labinvest.2010.46; Yamazaki Y, 2008, J GASTROEN HEPATOL, V23, P276, DOI 10.1111/j.1440-1746.2007.05150.x; Yang HN, 2011, NAT GENET, V43, P648, DOI 10.1038/ng.847	45	35	36	2	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4592	4602		10.1096/fj.12-209569	http://dx.doi.org/10.1096/fj.12-209569			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872676	Green Published			2022-12-28	WOS:000310574200021
J	Zhang, X; Zhang, Y; Tao, B; Wang, D; Cheng, HQ; Wang, K; Zhou, R; Xie, QM; Ke, YH				Zhang, Xue; Zhang, Yun; Tao, Bo; Wang, Di; Cheng, Hongqiang; Wang, Kai; Zhou, Ren; Xie, Qiangmin; Ke, Yuehai			Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2/STAT6 pathway	FASEB JOURNAL			English	Article						airway inflammatory diseases; airway epithelial cells; Muc5ac; IL-13; SOCS3	EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; AIRWAY; IL-13; RECEPTOR; MUCUS; METAPLASIA; CYTOKINE; ASTHMA	Goblet cell hyperplasia (GCH) and mucous hypersecretion are common pathological features of chronic pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Despite numerous studies, the molecular basis for this condition remains elusive. Gab2 is a member of the Dos/Gab subfamily scaffolding molecules and plays important roles in regulating growth, differentiation, and inflammation. We found that an elevated level of Gab2 correlates with upregulated mucus in airway epithelia from patients with lung cancer or COPD, suggesting the potential involvement of Gab2 in pathological lesions in lungs. Knockdown of Gab2 in human airway epithelial cells in vitro decreases IL-13-induced expression of mucin genes. To address the in vivo role of Gab2 in lungs, Gab2-knockout (Gab2(-/-)) mice were sensitized and challenged with ovalbumin (OVA). Further analysis of lungs in an OVA-induced allergy model suggested that GCH and mucus production are remarkably reduced in Gab2-/- mice. Mechanistically, Gab2 positively regulates IL-13-induced activation of TYK2/STAT6 by decreasing SOCS3-mediated degradation of TYK2. Together, we define a novel role for Gab2 in mediating mucin gene expression and GCH; these findings have important implications for the pathogenesis and therapy of airway inflammatory diseases.-Zhang, X., Zhang, Y., Tao, B., Wang, D., Cheng, H., Wang, K., Zhou, R., Xie, Q., Ke, Y. Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2/STAT6 pathway. FASEB J. 26, 4603-4613 (2012). www.fasebj.org	[Zhang, Xue; Zhang, Yun; Tao, Bo; Cheng, Hongqiang; Zhou, Ren; Ke, Yuehai] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Xue; Zhang, Yun; Tao, Bo; Cheng, Hongqiang; Zhou, Ren; Ke, Yuehai] Zhejiang Univ, Sch Med, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Di] Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Kai] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou 310058, Zhejiang, Peoples R China; [Xie, Qiangmin] Zhejiang Univ, Sch Med, Inst Resp Dis, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Ke, YH (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, POB 59,866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	yke@zju.edu.cn	Xie, Qiang-min/AAV-7711-2021	Xie, qiang-min/0000-0002-7975-9962; Cheng, Hongqiang/0000-0001-9662-1570	National Natural Science Foundation of China [30871291, 30971504, 30900849, 81170026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China grants 30871291 and 30971504 (to Y. K.), 30900849 (to X. Z.), and 81170026 (to K. W).	Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Curran DR, 2010, AM J RESP CELL MOL, V42, P268, DOI 10.1165/rcmb.2009-0151TR; Dail M, 2010, P NATL ACAD SCI USA, V107, P5106, DOI 10.1073/pnas.1001064107; Elias JA, 2011, AM J RESP CRIT CARE, V183, P957, DOI 10.1164/rccm.201101-0080ED; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Kanoh S, 2011, CLIN EXP ALLERGY, V41, P1747, DOI 10.1111/j.1365-2222.2011.03852.x; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kioi M, 2006, FASEB J, V20, P2378, DOI 10.1096/fj.06-5995fje; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee AW, 2011, MOL CELL BIOL, V31, P4563, DOI 10.1128/MCB.05706-11; Lemarie CA, 2011, ARTERIOSCL THROM VAS, V31, P956, DOI 10.1161/ATVBAHA.111.225987; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Long AJ, 2006, AM J RESP CELL MOL, V35, P357, DOI 10.1165/rcmb.2005-0451OC; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Ni S, 2007, MOL CELL BIOL, V27, P3708, DOI 10.1128/MCB.01838-06; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Raiford KL, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-118; Rogers DF, 2001, RESP PHYSIOL, V125, P129, DOI 10.1016/S0034-5687(00)00209-7; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; Seiden-Long I, 2008, CARCINOGENESIS, V29, P647, DOI 10.1093/carcin/bgn009; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Sithanandam G, 2005, AM J RESP CELL MOL, V33, P490, DOI 10.1165/rcmb.2005-0049OC; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tesfaigzi Y, 2008, CURR MOL MED, V8, P408, DOI 10.2174/156652408785160961; Thai P, 2005, AM J RESP CELL MOL, V33, P523, DOI 10.1165/rcmb.2004-0220RC; Thai P, 2008, ANNU REV PHYSIOL, V70, P405, DOI 10.1146/annurev.physiol.70.113006.100441; Tyner JW, 2006, J CLIN INVEST, V116, P309, DOI 10.1172/JCI25167; Vaughan TY, 2011, AM J BLOOD RES, V1, P130; Vestbo J, 2002, NOVART FDN SYMP, V248, P3; Vestbo J., 2002, NOVART FDN SYMP, V248, P277; Vestbo J, 2002, NOVART FDN SYMP, V248, P12; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Xie ZH, 2002, J IMMUNOL, V168, P4682, DOI 10.4049/jimmunol.168.9.4682; Xu XL, 2011, INT J BIOL SCI, V7, P496, DOI 10.7150/ijbs.7.496; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Yoshisue H, 2004, BIOSCI BIOTECH BIOCH, V68, P2024, DOI 10.1271/bbb.68.2024; Zhong J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017764; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578	54	14	23	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4603	4613		10.1096/fj.12-211755	http://dx.doi.org/10.1096/fj.12-211755			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859374				2022-12-28	WOS:000310574200022
J	Huitema, LFA; Renn, J; Logister, I; Gray, JK; Waltz, SE; Flik, G; Schulte-Merker, S				Huitema, Leonie F. A.; Renn, Joerg; Logister, Ive; Gray, Jerilyn K.; Waltz, Susan E.; Flik, Gert; Schulte-Merker, Stefan			Macrophage-stimulating protein and calcium homeostasis in zebrafish	FASEB JOURNAL			English	Article						msp; ron; mineralization; bone; osteogenesis; stanniocalcin	RECEPTOR TYROSINE KINASE; BONE-RESORPTION; GENE-PRODUCT; GROWTH; EXPRESSION; IDENTIFICATION; OSTEOBLASTS; ACTIVATION; RON; STANNIOCALCIN	To systematically identify novel gene functions essential for osteogenesis and skeletal mineralization, we performed a forward genetic mutagenesis screen in zebrafish and isolated a mutant that showed delayed skeletal mineralization. Analysis of the mutant phenotype in an osterix:nuclear-GFP transgenic background demonstrated that mutants contain osterix-expressing osteoblasts comparable to wild-type embryos. Positional cloning revealed a premature stop mutation in the macrophage-stimulating protein (msp) gene, predicted to result in a biologically inactive protein. Analysis of the embryonic expression pattern for the receptor for Msp, Ron, shows specific expression in the corpuscles of Stannius, a teleost-specific organ that produces stanniocalcin, a pivotal hormone in fish calcium homeostasis. Knockdown of Ron resulted in identical phenotypes as observed in msp mutants. Msp mutant embryos could be rescued by excess calcium. Consistent with a role for Msp/Ron in calcium homeostasis, calcium-regulating factors, such as pth1, pth2, stc1l, and trpv5/6 were significantly affected in msp mutant larvae. While Msp and Ron have previously been shown to play a critical role in a wide variety of biological processes, we introduce here the Msp/Ron signaling axis as a previously unappreciated player in calcium homeostasis and embryonic skeletal mineralization.-Huitema, L. F. A., Renn, J., Logister, I., Gray, J. K., Waltz, S. E., Flik, G., Schulte-Merker, S. Macrophage stimulating protein and calcium homeostasis in zebrafish. FASEB J. 26, 4092-4101 (2012). www.fasebj.org	[Huitema, Leonie F. A.; Logister, Ive; Schulte-Merker, Stefan] Royal Netherlands Acad Arts & Sci KNAW, Hubrecht Inst, Utrecht, Netherlands; [Huitema, Leonie F. A.; Logister, Ive; Schulte-Merker, Stefan] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands; [Huitema, Leonie F. A.; Logister, Ive; Schulte-Merker, Stefan] Ctr Biomed Genet, Utrecht, Netherlands; [Schulte-Merker, Stefan] Wageningen Univ, Expt Zool Grp, Wageningen, Netherlands; [Renn, Joerg] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Gray, Jerilyn K.; Waltz, Susan E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA; [Gray, Jerilyn K.; Waltz, Susan E.] Vet Hosp Med Ctr, Cincinnati, OH USA; [Flik, Gert] Radboud Univ Nijmegen, Inst Water & Wetland Res, Dept Anim Physiol, NL-6525 ED Nijmegen, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Wageningen University & Research; National University of Singapore; University System of Ohio; University of Cincinnati; Radboud University Nijmegen	Schulte-Merker, S (corresponding author), KNAW, Hubrecht Inst, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	s.schulte@hubrecht.eu	Flik, Gert/C-8229-2011	Flik, Gert/0000-0001-9285-7957; Waltz, Susan/0000-0003-3572-4642	Smart Mix Programme of the Netherlands Ministry of Economic Affairs; Netherlands Ministry of Education, Culture, and Science; NATIONAL CANCER INSTITUTE [R01CA125379] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	Smart Mix Programme of the Netherlands Ministry of Economic Affairs(Ministry of Economic Affairs, Netherlands); Netherlands Ministry of Education, Culture, and Science; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank the Tubingen 2000 screen consortium members for identifying the msp<SUP>t34230</SUP> mutant phenotype; this mutant was identified while S.S.-M. was working at Exelixis Deutschland GmbH (Tubingen, Germany). Many thanks also go to C. Hammond and J. Vanoevelen for editorial review and W. Atsma for calcium measurements. The authors acknowledge the Hubrecht Institute Imaging Center for expert advice on imaging. All members of the S.S.-M. laboratory are acknowledged for comments and scientific discussions. S.S.-M. gratefully recognizes the support of the Smart Mix Programme of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of Education, Culture, and Science.	Bassett DI, 2003, DEV GENES EVOL, V213, P360, DOI 10.1007/s00427-003-0339-3; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; Brand Michael, 2002, P7; Bushinsky DA, 2010, CLIN J AM SOC NEPHRO, V5, pS12, DOI 10.2215/CJN.05970809; FLIK G, 1995, FISH PHYSIOL, V14, P317; Flik Gert, 1995, Biochemistry and Molecular Biology of Fishes, V5, P251; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gerritsen ME, 2005, VITAM HORM, V70, P105, DOI 10.1016/S0083-6729(05)70004-2; Guerreiro PM, 2004, J EXP BIOL, V207, P645, DOI 10.1242/jeb.00765; Haffter P, 1996, DEVELOPMENT, V123, P1; Hammond CL, 2009, DEVELOPMENT, V136, P3991, DOI 10.1242/dev.042150; Hogan BM, 2009, NAT GENET, V41, P396, DOI 10.1038/ng.321; Hogan BM, 2005, ENDOCRINOLOGY, V146, P547, DOI 10.1210/en.2004-0296; Hoshijima K, 2007, J ENDOCRINOL, V193, P481, DOI 10.1677/JOE-07-0003; Inohaya K, 2007, DEV DYNAM, V236, P3031, DOI 10.1002/dvdy.21329; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437; Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lafont AG, 2011, J BONE MINER RES, V26, P1072, DOI 10.1002/jbmr.301; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; Mundy GR, 1999, CLIN CHEM, V45, P1347; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Ober EA, 2006, NATURE, V442, P688, DOI 10.1038/nature04888; Postlethwait JH, 2007, J EXP ZOOL PART B, V308B, P563, DOI 10.1002/jez.b.21137; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schulte-Merker S., 2002, ZEBRAFISH PRACTICAL, P41; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; Spoorendonk KM, 2010, J APPL ICHTHYOL, V26, P219, DOI 10.1111/j.1439-0426.2010.01409.x; Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tseng DY, 2009, AM J PHYSIOL-REG I, V296, pR549, DOI 10.1152/ajpregu.90742.2008; Vanoevelen J, 2011, FASEB J, V25, P3197, DOI 10.1096/fj.11-183145; Varsamos S, 2005, COMP BIOCHEM PHYS A, V141, P401, DOI 10.1016/j.cbpb.2005.01.013; Varsamos S, 2002, ANAT EMBRYOL, V205, P203, DOI 10.1007/s00429-002-0231-3; WAGNER GF, 1991, MOL CELL ENDOCRINOL, V79, P129, DOI 10.1016/0303-7207(91)90103-Y; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; Willett CE, 1997, DEV BIOL, V182, P331, DOI 10.1006/dbio.1996.8446	46	15	16	0	103	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4092	4101		10.1096/fj.11-202663	http://dx.doi.org/10.1096/fj.11-202663			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22787265	Green Published			2022-12-28	WOS:000309704000016
J	van Weeghel, M; te Brinke, H; van Lenthe, H; Kulik, W; Minkler, PE; Stoll, MSK; Sass, JO; Janssen, U; Stoffel, W; Schwab, KO; Wanders, RJA; Hoppel, CL; Houten, SM				van Weeghel, Michel; te Brinke, Heleen; van Lenthe, Henk; Kulik, Wim; Minkler, Paul E.; Stoll, Maria S. K.; Sass, Joern Oliver; Janssen, Uwe; Stoffel, Wilhelm; Schwab, K. Otfried; Wanders, Ronald J. A.; Hoppel, Charles L.; Houten, Sander M.			Functional redundancy of mitochondrial enoyl-CoA isomerases in the oxidation of unsaturated fatty acids	FASEB JOURNAL			English	Article						mouse models; inherited metabolic disease	TANDEM MASS-SPECTROMETRY; BETA-OXIDATION; RAT-LIVER; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 3-HYDROXYACYL-COA DEHYDROGENASE; 2-ENOYL-COA HYDRATASE; ZELLWEGER SYNDROME; ENZYME; MOUSE; FIBROBLASTS	Mitochondrial enoyl-CoA isomerase (ECI1) is an auxiliary enzyme involved in unsaturated fatty acid oxidation. In contrast to most of the other enzymes involved in fatty acid oxidation, a deficiency of ECI1 has yet to be identified in humans. We used wild-type (WT) and Eci1-deficient knockout (KO) mice to explore a potential presentation of human ECI1 deficiency. Upon food withdrawal, Eci1-deficient mice displayed normal blood beta-hydroxybutyrate levels (WT 1.09 mM vs. KO 1.10 mM), a trend to lower blood glucose levels (WT 4.58 mM vs. KO 3.87 mM, P=0.09) and elevated blood levels of unsaturated acylcarnitines, in particular C12:1 acylcarnitine (WT 0.03 mu M vs. KO 0.09 mu M, P<0.01). Feeding an olive oil-rich diet induced an even greater increase in C12: 1 acylcarnitine levels (WT 0.01 mu M vs. KO 0.04 mu M, P<0.01). Overall, the phenotypic presentation of Eci1-deficient mice is mild, possibly caused by the presence of a second enoyl-CoA isomerase (Eci2) in mitochondria. Knockdown of Eci2 in Eci1-deficient fibroblasts caused a more pronounced accumulation of C12: 1 acylcarnitine on incubation with unsaturated fatty acids (12-fold, P<0.05). We conclude that Eci2 compensates for Eci1 deficiency explaining the mild phenotype of Eci1-deficient mice. Hypoglycemia and accumulation of C12: 1 acylcarnitine might be diagnostic markers to identify ECI1 deficiency in humans.-van Weeghel, M., te Brinke, H., van Lenthe, H., Kulik, W., Minkler, P. E., Stoll, M. S. K., Sass, J. O., Janssen, U., Stoffel, W., Schwab, O. K., Wanders, R. J. A., Hoppel, C. L., Houten, S. M. Functional redundancy of mitochondrial enoyl-CoA isomerases in the oxidation of unsaturated fatty acids. FASEB J. 26, 4316-4326 (2012). www.fasebj.org	[van Weeghel, Michel; te Brinke, Heleen; van Lenthe, Henk; Kulik, Wim; Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis,Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; [Minkler, Paul E.; Stoll, Maria S. K.; Hoppel, Charles L.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Hoppel, Charles L.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; [Sass, Joern Oliver; Schwab, K. Otfried] Ctr Childrens Hosp Freiburg, Freiburg, Germany; [Sass, Joern Oliver] Univ Childrens Hosp Zurich, Dept Clin Chem & Biochem, Zurich, Switzerland; [Janssen, Uwe] Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; [Stoffel, Wilhelm] Univ Cologne, Inst Biochem, Ctr Mol Med Cologne, Cluster Excellence Cellular Stress Response Aging, Cologne, Germany	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Case Western Reserve University; Case Western Reserve University; University Children's Hospital Zurich; Miltenyi Biotec; University of Cologne	Houten, SM (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.m.houten@amc.uva.nl	Houten, Sander/Y-3599-2019; van Weeghel, Michel/A-2766-2010	Houten, Sander/0000-0002-6167-9147; van Weeghel, Michel/0000-0002-4916-2866	Netherlands Organization for Scientific Research (VIDI) [016.086.336]; Ter Meulen Fund, Royal Netherlands Academy of Arts and Sciences, The Netherlands	Netherlands Organization for Scientific Research (VIDI)(Netherlands Organization for Scientific Research (NWO)); Ter Meulen Fund, Royal Netherlands Academy of Arts and Sciences, The Netherlands	The authors thank Dr. H. Schulz (Department of Chemistry, City College and Graduate School of the City University of New York, New York, NY, USA) for the generous gift of the polyclonal mouse Eci1 and Eci2 antibody, Dr. C. Argmann for critically reading the manuscript, W. Smit for the analysis of the fatty acid composition of the diet, and the employees of the Animal Research Institute (Amsterdam, The Netherlands) for technical assistance. This work was supported by the Netherlands Organization for Scientific Research (VIDI; grant 016.086.336 to S.M.H.) and the Ter Meulen Fund, Royal Netherlands Academy of Arts and Sciences, The Netherlands (to M.V.W.).	Bakermans AJ, 2011, CIRC-CARDIOVASC IMAG, V4, P558, DOI 10.1161/CIRCIMAGING.111.963751; Bergmeyer H. U., 1986, METHODS ENZYMATIC AN, V2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDEL K, 1967, BIOCHIM BIOPHYS ACTA, V137, P98, DOI 10.1016/0005-2760(67)90012-4; Chegary M, 2009, BBA-MOL CELL BIOL L, V1791, P806, DOI 10.1016/j.bbalip.2009.05.006; Cox KB, 2001, HUM MOL GENET, V10, P2069, DOI 10.1093/hmg/10.19.2069; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Ijlst L, 1998, J CLIN INVEST, V102, P527, DOI 10.1172/JCI2927; Janssen U, 2002, J BIOL CHEM, V277, P19579, DOI 10.1074/jbc.M110993200; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; Miinalainen IJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000543; Minkler P. E., 2011, J AM SOC MASS SPE S1, V22, P69; Minkler PE, 2008, CLIN CHEM, V54, P1451, DOI 10.1373/clinchem.2007.099226; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; Ofman R, 2006, BIOCHEM J, V393, P537, DOI 10.1042/BJ20050893; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; Stoffel W, 1964, Hoppe Seylers Z Physiol Chem, V339, P167, DOI 10.1515/bchm2.1964.339.1.167; van Vlies N, 2007, MOL GENET METAB, V90, P24, DOI 10.1016/j.ymgme.2006.07.006; Ventura FV, 1999, CLIN CHIM ACTA, V281, P1, DOI 10.1016/S0009-8981(98)00188-0; Vreken P, 1999, J INHERIT METAB DIS, V22, P302, DOI 10.1023/A:1005587617745; WANDERS RJA, 1984, BIOCHEM BIOPH RES CO, V123, P1054, DOI 10.1016/S0006-291X(84)80240-5; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200	32	33	33	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4316	4326		10.1096/fj.12-206326	http://dx.doi.org/10.1096/fj.12-206326			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22782973				2022-12-28	WOS:000309704000036
J	Chiaverini, C; Sillard, L; Flori, E; Ito, S; Briganti, S; Wakamatsu, K; Fontas, E; Berard, E; Cailliez, M; Cochat, P; Foulard, M; Guest, G; Niaudet, P; Picardo, M; Bernard, FX; Antignac, C; Ortonne, JP; Ballotti, R				Chiaverini, Christine; Sillard, Laura; Flori, Enrica; Ito, Shosuke; Briganti, Stefania; Wakamatsu, Kazumasa; Fontas, Eric; Berard, Etienne; Cailliez, Mathilde; Cochat, Pierre; Foulard, Michel; Guest, Genevieve; Niaudet, Patrick; Picardo, Mauro; Bernard, Francois-Xavier; Antignac, Corinne; Ortonne, Jean Paul; Ballotti, Robert			Cystinosin is a melanosomal protein that regulates melanin synthesis	FASEB JOURNAL			English	Article						pigmentation; melanocyte; melanogenesis; tyrosinase; cystinosis	HUMAN HAIR MELANINS; NEPHROPATHIC CYSTINOSIS; CYCLIC-AMP; EPITHELIAL-CELLS; CTNS MUTATIONS; TYROSINASE; MELANOGENESIS; PIGMENTATION; TRAFFICKING; PHEOMELANIN	Cystinosis is a rare autosomal recessive disease characterized by cystine crystal accumulation leading to multiorgan dysfunctions and caused by mutation in CTNS. CTNS encodes cystinosin, a cystine/H+ symporter that exports cystine out of the lysosomes. Patients with cystinosis frequently exhibit blond hair and fair complexion, suggesting an alteration in melanogenesis. However, the pigmentation singularities of these patients have not been studied, and the role of cystinosin in melanogenesis has remained unknown. In our study, a clinical evaluation of 27 patients with cystinosis showed that 44% had a cutaneous pigmentation dilution compared to their relatives. Analysis of the hair melanin content in these patients by HPLC demonstrated a 50% decrease in eumelanin (4360 vs. 9360 ng/mg), and a 2-fold increase in pheomelanin (53 vs. 20 ng/mg), the yellow/red pigments. Cystinosin-deficient mice also showed a 4-fold increase in hair pheomelanin content. In vitro studies showed that cystinosin was located at melanosomes. CTNS silencing led to a 75% reduction of melanin synthesis that was caused by a degradation of tyrosinase by lysosomal proteases. Our results objectify the pigmentation defect in patients with cystinosis. We also identify the role of CTNS in melanogenesis and add a new gene to the list of the genes involved in the control of skin and hair pigmentation.-Chiaverini, C., Sillard, L., Flori, E., Ito, S., Briganti, S., Wakamatsu, K., Fontas, E., Berard, E., Cailliez, M., Cochat, P., Foulard, M., Guest, G., Niaudet, P., Picardo, M., Bernard, F.-X., Antignac, C., Ortonne, J. P., Ballotti, R. Cystinosin is a melanosomal protein that regulates melanin synthesis. FASEB J. 26, 3779-3789 (2012). www.fasebj.org	[Chiaverini, Christine; Sillard, Laura; Ortonne, Jean Paul; Ballotti, Robert] CHU NICE, Dept Dermatol, F-06202 Nice 3, France; [Chiaverini, Christine; Flori, Enrica; Ortonne, Jean Paul; Ballotti, Robert] Ctr Mediterraneen Med Mol, INSERM, U1065, Equipe 1, Nice, France; [Berard, Etienne] CHU Nice, Dept Clin Res, Nice, France; [Fontas, Eric; Berard, Etienne] CHU Nice, Dept Paediat Nephrol, Nice, France; [Ortonne, Jean Paul; Ballotti, Robert] Med Univ Nice Sophia Antipolis, Unit Format & Rech, Nice, France; [Flori, Enrica; Briganti, Stefania; Picardo, Mauro] Ist Ricovero Cura Carattere Sci IRCSS, San Gallicano Dermatol Inst, Lab Cutaneous Physiopathol, Rome, Italy; [Briganti, Stefania] Ist Ricovero Cura Carattere Sci IRCSS, San Gallicano Dermatol Inst, Integrated Ctr Metabol Res, Rome, Italy; [Ito, Shosuke; Wakamatsu, Kazumasa] Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Aichi, Japan; [Cailliez, Mathilde] Assistance Publ Hop Marseille, Dept Paediat Nephrol, Marseille, France; [Cochat, Pierre] CHU Lyon, Ctr Reference Malad Renales Rares, Bron, France; [Foulard, Michel] CHU Lille, F-59037 Lille, France; [Guest, Genevieve; Niaudet, Patrick] Univ Paris Descartes Sorbonne Paris Cite, AP HP, Dept Paediat Nephrol, Paris, France; [Antignac, Corinne] Univ Paris Descartes Sorbonne Paris Cite, INSERM, U983, Hop Necker Enfants Malades,Inst Imagine, Paris, France; [Bernard, Francois-Xavier] BIOalternat SAS, Gencay, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Fujita Health University; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Lyon; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ballotti, R (corresponding author), CHU NICE, Dept Dermatol, F-06202 Nice 3, France.	ballotti@unice.fr	BALLOTTI, Robert/F-8825-2013; Flori, Enrica/H-4417-2014; Briganti, Stefania/AAY-2136-2021; briganti, stefania/J-3185-2016; Wakamatsu, Kazumasa/AAZ-5877-2020; ANTIGNAC, Corinne/H-8945-2017; Picardo, Mauro/A-6978-2011	Flori, Enrica/0000-0002-9275-1041; Briganti, Stefania/0000-0003-2000-006X; briganti, stefania/0000-0003-2000-006X; Wakamatsu, Kazumasa/0000-0003-1748-9001; ANTIGNAC, Corinne/0000-0002-9934-4940; BALLOTTI, Robert/0000-0002-7322-4908; Ito, Shosuke/0000-0001-9182-5144; Picardo, Mauro/0000-0003-4899-6639	Cystinosin Research Foundation	Cystinosin Research Foundation	This work was supported by the Cystinosin Research Foundation (http://www.natalieswish.org). The authors are also indebted to the patients for their invaluable help in this research program. This work has been possible thanks to the expert technical help of Mansour Djedaini, Patricia Abbe, Karine Bille, Anne Pierron, and Genevieve Gozzerino. Electron microscopy experiments were performed by Sandra Lacas-Gervais (Centre Commun de Microscopie Appliquee, Universite de Nice Sophia-Antipolis). The authors are indebted to Dr Philippe Eckart (Department of Paediatry, Centre Hospitalier Universitaire Caen, Caen, France) for patient inclusion.	Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251; Anikster Y, 1999, HUM MUTAT, V14, P454, DOI 10.1002/(SICI)1098-1004(199912)14:6<454::AID-HUMU2>3.0.CO;2-H; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cheli Y, 2009, J BIOL CHEM, V284, P18699, DOI 10.1074/jbc.M109.005819; Chen K, 2004, PIGM CELL RES, V17, P36, DOI 10.1046/j.1600-0749.2003.00106.x; Cherqui S, 2002, MOL CELL BIOL, V22, P7622, DOI 10.1128/MCB.22.21.7622-7632.2002; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Forestier L, 1999, AM J HUM GENET, V65, P353, DOI 10.1086/302509; Fujita H, 2009, J INVEST DERMATOL, V129, P1489, DOI 10.1038/jid.2008.376; Gahl WA, 2002, NEW ENGL J MED, V347, P111, DOI 10.1056/NEJMra020552; Guillet G, 1998, LANCET, V352, P1444, DOI 10.1016/S0140-6736(05)61267-6; Halaban R, 2002, J BIOL CHEM, V277, P14821, DOI 10.1074/jbc.M111497200; Haq MR, 2002, J AM SOC NEPHROL, V13, P2046, DOI 10.1097/01.ASN.0000022012.95680.BA; Ito S, 2003, PIGM CELL RES, V16, P230, DOI 10.1034/j.1600-0749.2003.00037.x; Ito S, 2011, PIGM CELL MELANOMA R, V24, P605, DOI 10.1111/j.1755-148X.2011.00864.x; Ito S, 2011, PIGM CELL MELANOMA R, V24, P63, DOI 10.1111/j.1755-148X.2010.00755.x; Kalatzis V, 2004, HUM MOL GENET, V13, P1361, DOI 10.1093/hmg/ddh152; Kalatzis V, 2003, PEDIATR NEPHROL, V18, P207, DOI 10.1007/s00467-003-1077-5; Kalatzis V, 2001, EMBO J, V20, P5940, DOI 10.1093/emboj/20.21.5940; Kumar A, 2010, J BIOSCIENCES, V35, P21, DOI 10.1007/s12038-010-0004-8; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; Nevo N, 2010, NEPHROL DIAL TRANSPL, V25, P1059, DOI 10.1093/ndt/gfp553; Nordlund J. J., 1998, PIGMENTARY SYSTEM; Park M, 2002, J AM SOC NEPHROL, V13, P2878, DOI 10.1097/01.ASN.0000036867.49866.59; Park MA, 2006, J AM SOC NEPHROL, V17, P3167, DOI 10.1681/ASN.2006050474; Passeron T, 2004, FASEB J, V18, P989, DOI 10.1096/fj.03-1240fje; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Sturm RA, 2009, HUM MOL GENET, V18, pR9, DOI 10.1093/hmg/ddp003; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; Toyofuku K, 2002, PIGM CELL RES, V15, P217, DOI 10.1034/j.1600-0749.2002.02007.x; Tsilou ET, 2006, OPHTHALMOLOGY, V113, P1002, DOI 10.1016/j.ophtha.2005.12.026; Wakamatsu K, 2002, PIGM CELL RES, V15, P225, DOI 10.1034/j.1600-0749.2002.02009.x; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WONG VG, 1970, INVEST OPHTH VISUAL, V9, P83	38	34	36	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3779	3789		10.1096/fj.11-201376	http://dx.doi.org/10.1096/fj.11-201376			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22649030				2022-12-28	WOS:000308391600018
J	Jiang, XY; Yan, J; West, AA; Perry, CA; Malysheva, OV; Devapatla, S; Pressman, E; Vermeylen, F; Caudill, MA				Jiang, Xinyin; Yan, Jian; West, Allyson A.; Perry, Cydne A.; Malysheva, Olga V.; Devapatla, Srisatish; Pressman, Eva; Vermeylen, Francoise; Caudill, Marie A.			Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans	FASEB JOURNAL			English	Article						methyl donor; prenatal nutrition; DNA methylation; HPA axis	CORTICOTROPIN-RELEASING HORMONE; DNA METHYLATION; PRENATAL EXPOSURE; BLOOD-PRESSURE; STRESS; EXPRESSION; RESPONSES; RESTRICTION; DISORDERS; PREGNANCY	The in utero availability of methyl donors, such as choline, may modify fetal epigenetic marks and lead to sustainable functional alterations throughout the life course. The hypothalamic-pituitary-adrenal (HPA) axis regulates cortisol production and is sensitive to perinatal epigenetic programming. As an extension of a 12-wk dose-response choline feeding study conducted in third-trimester pregnant women, we investigated the effect of maternal choline intake (930 vs. 480 mg/d) on the epigenetic state of cortisol-regulating genes, and their expression, in placenta and cord venous blood. The higher maternal choline intake yielded higher placental promoter methylation of the cortisol-regulating genes, corticotropin releasing hormone (CRH; P = 0.05) and glucocorticoid receptor (NR3C1; P = 0.002); lower placental CRH transcript abundance (P = 0.04); lower cord blood leukocyte promoter methylation of CRH (P = 0.05) and NR3C1 (P = 0.04); and 33% lower (P = 0.07) cord plasma cortisol. In addition, placental global DNA methylation and dimethylated histone H3 at lysine 9 (H3K9me2) were higher (P = 0.02) in the 930 mg choline/d group, as was the expression of select placental methyltransferases. These data collectively suggest that maternal choline intake in humans modulates the epigenetic state of genes that regulate fetal HPA axis reactivity as well as the epigenomic status of fetal derived tissues.-Jiang, X., Yan, J., West, A. A., Perry, C. A., Malysheva, O. V., Devapatla, S., Pressman, E., Vermeylen, F., Caudill, M. A. Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans. FASEB J. 26, 3563-3574 (2012). www.fasebj.org	[Jiang, Xinyin; Yan, Jian; West, Allyson A.; Perry, Cydne A.; Malysheva, Olga V.; Caudill, Marie A.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; [Devapatla, Srisatish] Cornell Univ, Cornell Stat Consulting Unit, Ithaca, NY 14853 USA; [Pressman, Eva] Univ Rochester, Med Ctr, Dept Obstet & Gynecol, Rochester, NY 14642 USA; [Vermeylen, Francoise] Cayuga Med Ctr, Dept Pediat, Ithaca, NY USA	Cornell University; Cornell University; University of Rochester	Caudill, MA (corresponding author), Cornell Univ, Div Nutr Sci & Genom, 228 Savage Hall, Ithaca, NY 14853 USA.	mac379@cornell.edu	Jiang, Xinyin/I-5096-2014; Pressman, Eva K/AAG-5564-2020	Jiang, Xinyin/0000-0001-6090-371X; Pressman, Eva K/0000-0002-2556-9290	Egg Checkoff, through the Egg Nutrition Center; Beef Checkoff, through the National Cattlemen's Beef Association; Nebraska Beef Council; U.S. Department of Agriculture Cooperative State Research, Education and Extension Service (CSREES) [00444528]; Affinito-Stewart Grants Program, through the President's Council of Cornell Women	Egg Checkoff, through the Egg Nutrition Center; Beef Checkoff, through the National Cattlemen's Beef Association; Nebraska Beef Council; U.S. Department of Agriculture Cooperative State Research, Education and Extension Service (CSREES)(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); Affinito-Stewart Grants Program, through the President's Council of Cornell Women	This work was funded by the Egg Checkoff, through the Egg Nutrition Center; the Beef Checkoff, through the National Cattlemen's Beef Association and the Nebraska Beef Council; the U.S. Department of Agriculture Cooperative State Research, Education and Extension Service (CSREES), special research grant 00444528; and the Affinito-Stewart Grants Program, through the President's Council of Cornell Women. The funding sources had no role in the study design, interpretation of the data, and/or publication of the results.	Davison JM, 2009, J BIOL CHEM, V284, P1982, DOI 10.1074/jbc.M807651200; Gitau R, 2001, EUR J OBSTET GYN R B, V98, P14, DOI 10.1016/S0301-2115(01)00298-6; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; Hartmer R, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng047; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Kim JK, 2005, BIOSCI BIOTECH BIOCH, V69, P1331, DOI 10.1271/bbb.69.1331; King BR, 2001, PEPTIDES, V22, P1939, DOI 10.1016/S0196-9781(01)00485-5; Kovacheva VP, 2009, FASEB J, V23, P1054, DOI 10.1096/fj.08-122168; KRAUER F, 1973, ARCH GYNAKOL, V215, P343, DOI 10.1007/BF00673077; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; Levitt NS, 2000, J CLIN ENDOCR METAB, V85, P4611, DOI 10.1210/jc.85.12.4611; Li F, 2008, MOL GENET METAB, V94, P326, DOI 10.1016/j.ymgme.2008.03.013; Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marchetti B, 2001, BRAIN RES REV, V37, P259, DOI 10.1016/S0165-0173(01)00130-8; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Mehedint MG, 2010, P NATL ACAD SCI USA, V107, P12834, DOI 10.1073/pnas.0914328107; Mehedint MG, 2010, FASEB J, V24, P184, DOI 10.1096/fj.09-140145; Mueller BR, 2008, J NEUROSCI, V28, P9055, DOI 10.1523/JNEUROSCI.1424-08.2008; Murrell A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001849; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; Novakovic B, 2010, J BIOL CHEM, V285, P9583, DOI 10.1074/jbc.M109.064956; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Shin W, 2010, J NUTR, V140, P975, DOI 10.3945/jn.110.121186; Smith R, 2007, NEW ENGL J MED, V356, P271, DOI 10.1056/NEJMra061360; Song LG, 2005, ANAL CHEM, V77, P504, DOI 10.1021/ac0489420; Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Wadhwa PD, 2004, AM J OBSTET GYNECOL, V191, P1063, DOI 10.1016/j.ajog.2004.06.070; Wadhwa PD, 2002, REGUL PEPTIDES, V108, P149, DOI 10.1016/S0167-0115(02)00102-7; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Yan J, 2012, AM J CLIN NUTR, V95, P1060, DOI 10.3945/ajcn.111.022772	34	143	143	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3563	3574		10.1096/fj.12-207894	http://dx.doi.org/10.1096/fj.12-207894			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22549509				2022-12-28	WOS:000307162800042
J	Tota, B; Gentile, S; Pasqua, T; Bassino, E; Koshimizu, H; Cawley, NX; Cerra, MC; Loh, YP; Angelone, T				Tota, Bruno; Gentile, Stefano; Pasqua, Teresa; Bassino, Eleonora; Koshimizu, Hisatsugu; Cawley, Niamh X.; Cerra, Maria C.; Loh, Y. Peng; Angelone, Tommaso			The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac beta-adrenergic-like inotropes	FASEB JOURNAL			English	Article						heart; adenylate cyclase; PKA	RAT-HEART; NATRIURETIC PEPTIDES; MYOCARDIAL PRODUCTION; TARGETED ABLATION; PROGNOSTIC VALUE; NITRIC-OXIDE; RECEPTOR; FAILURE; CELLS; PHEOCHROMOCYTOMA	Three forms of serpinin peptides, serpinin (Ala26Leu), pyroglutaminated (pGlu)-serpinin (pGlu23Leu), and serpinin-Arg-Arg-Gly (Ala29Gly), are derived from cleavage at pairs of basic residues in the highly conserved C terminus of chromogranin A (CgA). Serpinin induces PN-1 expression in neuroendocrine cells to up-regulate granule biogenesis via a cAMP-protein kinase A-Sp1 pathway, while pGlu-serpinin inhibits cell death. The aim of this study was to test the hypothesis that serpinin peptides are produced in the heart and act as novel beta-adrenergic-like cardiac modulators. We detected serpinin peptides in the rat heart by HPLC and ELISA methods. The peptides included predominantly Ala29Gly and pGlu-serpinin and a small amount of serpinin. Using the Langendorff perfused rat heart to evaluate the hemodynamic changes, we found that serpinin and pGlu-serpinin exert dose-dependent positive inotropic and lusitropic effects at 11-165 nM, within the first 5 min after administration. The pGlu-serpinin-induced contractility is more potent than that of serpinin, starting from 1 nM. Using the isolated rat papillary muscle preparation to measure contractility in terms of tension development and muscle length, we further corroborated the pGlu-serpinin-induced positive inotropism. Ala29Gly was unable to affect myocardial performance. Both pGlu-serpinin and serpinin act through a beta 1-adrenergic receptor/adenylate cyclase/cAMP/PKA pathway, indicating that, contrary to the beta-blocking profile of the other CgA-derived cardiosuppressive peptides, vasostatin-1 and catestatin, these two C-terminal peptides act as beta-adrenergic-like agonists. In cardiac tissue extracts, pGlu-serpinin increased intracellular cAMP levels and phosphorylation of phospholamban (PLN) Ser16, ERK1/2, and GSK-3 beta. Serpinin and pGlu-serpinin peptides emerge as novel beta-adrenergic inotropic and lusitropic modulators, suggesting that CgA and the other derived cardioactive peptides can play a key role in how the myocardium orchestrates its complex response to sympathochromaffin stimulation.-Tota, B., Gentile, S., Pasqua, T., Bassino, E., Koshimizu, H., Cawley, N. X., Cerra, M. C., Loh, Y. P., Angelone, T. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac beta-adrenergic-like inotropes. FASEB J. 26, 2888-2898 (2012). www.fasebj.org	[Tota, Bruno; Gentile, Stefano; Pasqua, Teresa; Cerra, Maria C.; Angelone, Tommaso] Univ Calabria, Dept Cell Biol, Arcavacata Di Rende, Italy; [Cerra, Maria C.] Univ Calabria, Dept Pharmacobiol, Arcavacata Di Rende, Italy; [Bassino, Eleonora] Univ Turin, Dept Anim & Human Biol, Turin, Italy; [Koshimizu, Hisatsugu; Cawley, Niamh X.; Loh, Y. Peng] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cellular Neurobiol Sect, NIH, Bethesda, MD USA	University of Calabria; University of Calabria; University of Turin; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Loh, YP (corresponding author), NICHD, NIH, Bldg 49,Rm 5A2249,Convent Dr, Bethesda, MD 20892 USA.	lohp@mail.nih.gov; t.angelone@unical.it	Koshimizu, Hisatsugu/AAD-2428-2019; Bassino, Eleonora/X-1370-2019; Angelone, Tommaso/AAM-1230-2020	Koshimizu, Hisatsugu/0000-0002-8619-6678; Angelone, Tommaso/0000-0001-7797-7862; Cerra, Maria Carmela/0000-0002-2091-928X	Ministero dell'Universita e Ricerca Scientifica e Tecnologica; Italian National Institute of Cardiovascular Research (INRC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.S. National Institutes of Health); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER	Ministero dell'Universita e Ricerca Scientifica e Tecnologica(Ministry of Education, Universities and Research (MIUR)); Italian National Institute of Cardiovascular Research (INRC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.S. National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Dr. G. Mengozzi and M. Lucchiari (Dipartimento di Diagnostica di Laboratorio, Azienda Ospedaliera Universitaria San Giovanni Battista di Torino, Turin, Italy) for their precious support in NE detection. The authors also thank Prof. Alan Kopin and Mr. Benjamin Harwood (Molecular Pharmacology Research Center, Tufts Medical Center, Boston, MA, USA) for their help with the GPCR signaling assays. This research was supported by grants from Ministero dell'Universita e Ricerca Scientifica e Tecnologica (ex60%), the Italian National Institute of Cardiovascular Research (INRC), and the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.S. National Institutes of Health). The authors declare no conflicts of interest.	Al-Fulaij MA, 2007, J PHARMACOL EXP THER, V321, P298, DOI 10.1124/jpet.106.116384; Angelone T, 2008, ENDOCRINOLOGY, V149, P4780, DOI 10.1210/en.2008-0318; Bassino E, 2011, CARDIOVASC RES, V91, P617, DOI 10.1093/cvr/cvr129; Biswas N, 2010, CELL TISSUE RES, V342, P353, DOI 10.1007/s00441-010-1059-4; Bott-Flugel L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018048; Cappello S, 2007, AM J PHYSIOL-HEART C, V293, pH719, DOI 10.1152/ajpheart.01352.2006; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Cerra MC, 2008, FASEB J, V22, P3992, DOI 10.1096/fj.08-110239; CHAHINE R, 1994, CAN J PHYSIOL PHARM, V72, P595, DOI 10.1139/y94-085; Das A, 2009, AM J PHYSIOL-HEART C, V296, pH1236, DOI 10.1152/ajpheart.00100.2009; De Arcangelis V, 2010, MOL PHARMACOL, V78, P340, DOI 10.1124/mol.110.064444; Fortin JP, 2009, P NATL ACAD SCI USA, V106, P8049, DOI 10.1073/pnas.0900149106; Gallo MP, 2007, AM J PHYSIOL-HEART C, V292, pH2906, DOI 10.1152/ajpheart.01253.2006; Gao YS, 2012, J CARDIOVASC PHARM, V59, P16, DOI 10.1097/FJC.0b013e3182073e27; Gayen JR, 2010, CIRC-CARDIOVASC GENE, V3, P414, DOI 10.1161/CIRCGENETICS.109.924050; Glattard E, 2006, FEBS J, V273, P3311, DOI 10.1111/j.1742-4658.2006.05334.x; Gonzalez-Munoz C, 2011, LIFE SCI, V88, P1095, DOI 10.1016/j.lfs.2011.04.015; He Q, 2010, AM J PHYSIOL-HEART C, V298, pH136, DOI 10.1152/ajpheart.00251.2009; Hearn MG, 2002, P NATL ACAD SCI USA, V99, P14554, DOI 10.1073/pnas.202498299; Helle KB, 2007, CELL MOL LIFE SCI, V64, P2863, DOI 10.1007/s00018-007-7254-0; Hook V, 2010, AAPS J, V12, P635, DOI 10.1208/s12248-010-9223-z; Jansson AM, 2009, EUR HEART J, V30, P25, DOI 10.1093/eurheartj/ehn513; KATZ AM, 1990, EUR HEART J, V11, P27, DOI 10.1093/eurheartj/11.suppl_A.27; Koshimizu H, 2011, J MOL NEUROSCI, V45, P294, DOI 10.1007/s12031-011-9521-7; Koshimizu H, 2011, MOL ENDOCRINOL, V25, P732, DOI 10.1210/me.2010-0124; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Mattiazzi A, 2007, CARDIOVASC RES, V73, P648, DOI 10.1016/j.cardiores.2006.12.002; Mazza R, 2010, REGUL PEPTIDES, V165, P86, DOI 10.1016/j.regpep.2010.05.005; Mohammadi K, 2003, J CARDIOVASC PHARM, V41, P609, DOI 10.1097/00005344-200304000-00014; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Penna C, 2009, BBA-BIOENERGETICS, V1787, P794, DOI 10.1016/j.bbabio.2009.03.013; Pieroni M, 2007, EUR HEART J, V28, P1117, DOI 10.1093/eurheartj/ehm022; Rosjo H, 2010, EUR J HEART FAIL, V12, P549, DOI 10.1093/eurjhf/hfq055; Satoh K, 2011, J BIOL CHEM, V286, P20591, DOI 10.1074/jbc.M110.204685; STEINER HJ, 1990, J HISTOCHEM CYTOCHEM, V38, P845, DOI 10.1177/38.6.2139887; Stridsberg M, 1997, EUR J ENDOCRINOL, V136, P67, DOI 10.1530/eje.0.1360067; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Tota B, 2010, J EXP BIOL, V213, P3081, DOI 10.1242/jeb.027391; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Zaric V, 2004, J GENE MED, V6, P176, DOI 10.1002/jgm.484	40	34	38	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2888	2898		10.1096/fj.11-201111	http://dx.doi.org/10.1096/fj.11-201111			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459152	Green Published			2022-12-28	WOS:000305912500017
J	Wu, H; Downs, D; Ghosh, K; Ghosh, AK; Staib, P; Monod, M; Tang, J				Wu, Hao; Downs, Deborah; Ghosh, Koena; Ghosh, Arun K.; Staib, Peter; Monod, Michel; Tang, Jordan			Candida albicans secreted aspartic proteases 4-6 induce apoptosis of epithelial cells by a novel Trojan horse mechanism	FASEB JOURNAL			English	Article						virulence factors; integrins; infectious diseases; lysosome membrane	PROTEINASE GENE FAMILY; CRYSTAL-STRUCTURE; VIRULENCE; EXPRESSION; DEGRADATION; ACTIVATION; INHIBITORS; SAP6; EPIDEMIOLOGY; INFECTIONS	Systemic infection by the pathogenic yeast Candida albicans produces high mortality in immune- compromised people. Such infection starts with the penetration of the organism at the mucosal surfaces, facilitated by the secreted aspartic proteases (Saps) 4, 5, and 6. The functional mechanism of these virulence factors is unclear. We discovered that Saps 4-6 each contains amino acid motifs RGD/KGD to bind integrins on epithelial cell A549 and are internalized to endosomes and lysosomes. These processes are inhibited by RGD-containing peptides or by substituting RGD motifs of these Saps. The internalization of Saps 4-6 results in partial permeabilization of lysosomal membranes, measured by the redistribution of the lysosomal tropic dye acridine orange to the cytosol, and the triggering of apoptosis via caspase activation. Sap 2 and mutated Saps 4-6 contain no RGD motif, are ineffective in these processes, and a proteolytic inhibitor abolished Sap 4 activity in lysosome permeabilization. Same results were also seen for human tongue keratinocyte SCC-15 cells. Mucosal lesions from this fundamental new mechanism may permit C. albicans to enter the body and may be used to attack cells in immune defense during systemic infections. RGD-motif may also be incorporated in Sap inhibitors for Candidiasis drugs targeting to lysosomes.	[Wu, Hao; Downs, Deborah; Tang, Jordan] Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; [Ghosh, Koena; Ghosh, Arun K.] Purdue Univ, Dept Chem & Med Chem, W Lafayette, IN 47907 USA; [Staib, Peter] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany; [Monod, Michel] CHU Vaudois, Lab Mycol, CH-1011 Lausanne, Switzerland	Oklahoma Medical Research Foundation; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Hans Knoll Institute (HKI); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Tang, J (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jordan-tang@omrf.org			NIAID NIH HHS [R01 AI094335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI094335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht A, 2006, J BIOL CHEM, V281, P688, DOI 10.1074/jbc.M509297200; ALJANABI J, 1972, J BIOL CHEM, V247, P4628; Aoki W, 2011, J BIOCHEM, V150, P431, DOI 10.1093/jb/mvr073; Arthur PG, 2008, FREE RADICAL BIO MED, V44, P24, DOI 10.1016/j.freeradbiomed.2007.09.003; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; Borelli C, 2008, PROTEINS, V72, P1308, DOI 10.1002/prot.22021; Borelli C, 2007, PROTEINS, V68, P738, DOI 10.1002/prot.21425; Borg-von Zepelin M, 1998, MOL MICROBIOL, V28, P543, DOI 10.1046/j.1365-2958.1998.00815.x; Borg-von Zepelin M, 1999, J INVEST DERMATOL, V113, P747, DOI 10.1046/j.1523-1747.1999.00747.x; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Colina AR, 1996, INFECT IMMUN, V64, P4514, DOI 10.1128/IAI.64.11.4514-4519.1996; Correia A, 2010, INFECT IMMUN, V78, P4839, DOI 10.1128/IAI.00248-10; CUTFIELD SM, 1995, STRUCTURE, V3, P1261, DOI 10.1016/S0969-2126(01)00261-1; De Bernardis F, 1999, J INFECT DIS, V179, P201, DOI 10.1086/314546; Doulias PT, 2007, FREE RADICAL BIO MED, V42, P567, DOI 10.1016/j.freeradbiomed.2006.11.022; Eggimann P, 2003, LANCET INFECT DIS, V3, P685, DOI 10.1016/S1473-3099(03)00801-6; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gasparoto TH, 2004, FEMS IMMUNOL MED MIC, V42, P219, DOI 10.1016/j.femsim.2004.05.006; Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Hauck CR, 2006, EUR J CELL BIOL, V85, P235, DOI 10.1016/j.ejcb.2005.08.002; Hernandez-Canaveral I, 2009, MEM I OSWALDO CRUZ, V104, P858, DOI 10.1590/S0074-02762009000600006; Hube B, 1997, INFECT IMMUN, V65, P3529, DOI 10.1128/IAI.65.9.3529-3538.1997; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; KAMINISHI H, 1995, INFECT IMMUN, V63, P984, DOI 10.1128/IAI.63.3.984-988.1995; Laforge M, 2007, J VIROL, V81, P11426, DOI 10.1128/JVI.00597-07; Lermann U, 2008, MICROBIOL-SGM, V154, P3281, DOI 10.1099/mic.0.2008/022525-0; Monod M, 2010, METH PRIN MED CHEM, V45, P573; Morschhauser J, 1997, FEMS MICROBIOL LETT, V153, P349, DOI 10.1016/S0378-1097(97)00273-5; Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003; Naglik JR, 1999, INFECT IMMUN, V67, P2482, DOI 10.1128/IAI.67.5.2482-2490.1999; Naglik JR, 2008, MICROBIOL-SGM, V154, P3266, DOI 10.1099/mic.0.2008/022293-0; Prince LR, 2008, J IMMUNOL, V180, P3502, DOI 10.4049/jimmunol.180.5.3502; RUCHEL R, 1981, BIOCHIM BIOPHYS ACTA, V659, P99, DOI 10.1016/0005-2744(81)90274-6; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sanglard D, 1997, INFECT IMMUN, V65, P3539, DOI 10.1128/IAI.65.9.3539-3546.1997; Shi F, 2008, J CELL SCI, V121, P2360, DOI 10.1242/jcs.014977; Staib F, 1965, Sabouraudia, V4, P187; Staib P, 2000, P NATL ACAD SCI USA, V97, P6102, DOI 10.1073/pnas.110031497; Staib P, 2008, ANTIMICROB AGENTS CH, V52, P146, DOI 10.1128/AAC.01072-07; Villar CC, 2007, INFECT IMMUN, V75, P2126, DOI 10.1128/IAI.00054-07; Villar CC, 2010, MOL ORAL MICROBIOL, V25, P215, DOI 10.1111/j.2041-1014.2010.00577.x; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	43	47	49	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2132	2144		10.1096/fj.12-214353	http://dx.doi.org/10.1096/fj.12-214353			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430844	Green Published			2022-12-28	WOS:000319667600005
J	Moison, C; Senamaud-Beaufort, C; Fourriere, L; Champion, C; Ceccaldi, A; Lacomme, S; Daunay, A; Tost, J; Arimondo, PB; Guieysse-Peugeot, AL				Moison, Celine; Senamaud-Beaufort, Catherine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre; Lacomme, Stephanie; Daunay, Antoine; Tost, Joerg; Arimondo, Paola B.; Guieysse-Peugeot, Anne-Laure			DNA methylation associated with polycomb repression in retinoic acid receptor beta silencing	FASEB JOURNAL			English	Article						prostate cancer; epigenetic silencing; tumor supressor gene; DNA hypermethylation; EZH2	BREAST-CANCER CELLS; GROUP PROTEIN EZH2; PROSTATE-CANCER; TARGET GENES; CARCINOMA-CELLS; GROWTH ARREST; EXPRESSION; CHROMATIN; ISOFORM; HYPERMETHYLATION	Retinoic acid receptor beta 2 (RAR beta 2) is a tumor suppressor gene whose loss of expression is recurrent in prostate cancers. Here we studied the epigenetic mechanisms leading to its stable silencing. First, we characterized all RAR beta isoforms in 6 human tumor cell lines (prostate DU145, LNCaP, PC3, lung A549, breast Hs578T, and colon HCT116) by RT-PCR and Western blot. We excluded loss of heterozygosity (2D-FISH) and loss of RARa expression, an upstream regulator, as origin of RAR beta 2 silencing. All data concluded to an epigenetic silencing. In agreement, a DNA methylation inhibitor restored its expression. Second RAR beta 2 loss of expression was found associated with different epigenetic profiles in LNCaP and DU145 cells. According to bisulfite sequencing and ChIP analysis, we observed heavy methylation (97%) of the RAR beta 2 promoter with repressive histone mark H3K9me3 in LNCaP. While DNA methylation and polycomb repression are described to be mutually exclusive at CpG-rich promoters, we observed that in DU145, moderate DNA methylation (36%) and H3K9me3 mark were present concomitantly with H3K27me3, a signature of polycomb repression. In summary, we provide new insights on how the RAR beta 2 promoter is silenced, reveal the existence of two distinct repressive chromatin profiles at the same locus, and support a polycomb-mediated epigenetic repression process in prostate cancer.-Moison, C., Senamaud-Beaufort, C., Fourriere, L., Champion, C., Ceccaldi, A., Lacomme, S., Daunay, A., Tost, J. Arimondo, P. B., Guieysse-Peugeot, A.-L. DNA methylation associated with polycomb repression in retinoic acid receptor beta silencing. FASEB J. 27, 1468-1478 (2013). www.fasebj.org	[Moison, Celine; Arimondo, Paola B.] CRDPF, CNRS Pierre Fabre, USR ETaC 3388, F-31100 Toulouse, France; [Moison, Celine; Senamaud-Beaufort, Catherine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre; Guieysse-Peugeot, Anne-Laure] Museum Natl Hist Nat, CNRS, UMR7196, Paris, France; [Moison, Celine; Senamaud-Beaufort, Catherine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre; Guieysse-Peugeot, Anne-Laure] INSERM, U565, Paris, France; [Moison, Celine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre] Univ Paris 06, Paris, France; [Lacomme, Stephanie] Hop Cent, Ctr Ressources Biol, Serv Anat & Cytol Pathol, Nancy, France; [Daunay, Antoine; Tost, Joerg] Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, Lab Funct Genom, F-75010 Paris, France; [Tost, Joerg] Commissariat Energie Atom & Energies Alternat CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet, Evry, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Nancy; Foundation Jean Dausset-CEPH; CEA; UDICE-French Research Universities; Universite Paris Saclay	Arimondo, PB (corresponding author), CRDPF, CNRS Pierre Fabre, USR ETaC 3388, 3 Ave Hubert Curien, F-31100 Toulouse, France.	paola.arimondo@etac.cnrs.fr; guieysse@mnhn.fr	Arimondo, Paola B/R-9095-2017; Tost, Joerg/H-7129-2019	Arimondo, Paola B/0000-0001-5175-4396; Tost, Joerg/0000-0002-2683-0817	Agence Nationale de la Recherche [ANR-06 JCJCJ-0080]; Ministry of Education, Research, and Technology; Institut National de la Sante et de la Recherche Medicale-Centre National de la Recherche Scientifique Bourse de Doctorat pour Ingenieurs; ARC	Agence Nationale de la Recherche(French National Research Agency (ANR)); Ministry of Education, Research, and Technology; Institut National de la Sante et de la Recherche Medicale-Centre National de la Recherche Scientifique Bourse de Doctorat pour Ingenieurs; ARC(Australian Research Council)	The authors acknowledge the Service d'Anatomie et Cytologie Pathologiques des Hopitaux de Toulouse for the tumor samples. The authors thank Helene Gondelle and Jean Ollion for technical help in FISH experiments and Laurent Lacroix, Christophe Escude, Loic Ponger, and Pierre-Antoine Defossez for helpful discussions. This work was supported by Agence Nationale de la Recherche (ANR-06 JCJCJ-0080) and Region Midi-Pyrenees. C. M. was the recipient of a Ministry of Education, Research, and Technology fellowship, C. C. of an Institut National de la Sante et de la Recherche Medicale-Centre National de la Recherche Scientifique Bourse de Doctorat pour Ingenieurs, and A.C. of an ARC fellowship. The authors declare no conflicts of interest.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Berezovska OP, 2006, CELL CYCLE, V5, P1886; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gillespie RF, 2007, J MOL BIOL, V372, P298, DOI 10.1016/j.jmb.2007.06.079; HOULE B, 1994, CANCER RES, V54, P365; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Kanhere A, 2010, MOL CELL, V38, P675, DOI 10.1016/j.molcel.2010.03.019; Karamouzis MV, 2007, CELL ONCOL, V29, P183; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LaTulippe E, 2002, CANCER RES, V62, P4499; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Liu Y, 1996, MOL CELL BIOL, V16, P1138; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Peng XJ, 2004, CANCER RES, V64, P8911, DOI 10.1158/0008-5472.CAN-04-1810; Petty WJ, 2005, J NATL CANCER I, V97, P1645, DOI 10.1093/jnci/dji371; Poulain S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-423; Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sun J., 2010, MED ONCOL, P1311; Swift ME, 2006, J CELL PHYSIOL, V209, P718, DOI 10.1002/jcp.20788; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Toulouse A, 1996, BBA-GENE STRUCT EXPR, V1309, P1, DOI 10.1016/S0167-4781(96)00126-1; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	61	28	30	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1468	1478		10.1096/fj.12-210971	http://dx.doi.org/10.1096/fj.12-210971			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23299856	Bronze			2022-12-28	WOS:000316940800019
J	Eltit, JM; Ding, XD; Pessah, IN; Allen, PD; Lopez, JR				Eltit, Jose M.; Ding, Xudong; Pessah, Isaac N.; Allen, Paul D.; Lopez, Jose R.			Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia	FASEB JOURNAL			English	Article						skeletal muscle; dantrolene	CELL BOUNDARY THEOREM; CA2+ RELEASE CHANNELS; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; FUNCTIONAL-CHARACTERIZATION; DANTROLENE INHIBITION; CALCIUM-CONCENTRATION; MG2+ INHIBITION; CYTOSOLIC CA2+	Malignant hyperthermia (MH) susceptibility has been attributed to a leaky sarcoplasmic reticulum (SR) caused by missense mutations in RYR1 or CACNA1S, and the MH crisis has been attributed solely to massive self-sustaining release of Ca2+ from SR stores elicited by triggering agents. Here, we show in muscle cells from MH-RyR1(R163C) knock-in mice that increased passive SR Ca2+ leak causes an enlarged basal influx of sarcolemmal Ca2+ that results in chronically elevated myoplasmic free Ca2+ concentration ([Ca2+](i)) at rest. We discovered that Gd+3 and GsMTx-4 were more effective than BTP2 or expression of the dominant-negative Orai1(E190Q) in reducing both Ca2+ entry and [Ca2+](i), implicating a non-STIM1/Orai1 SOCE pathway in resetting resting [Ca2+](i). Indeed, two nonselective cationic channels, TRPC3 and TRPC6, are overexpressed, and [Na](i) is chronically elevated in MH-RyR1(R163C) muscle cells. [Ca2+](i) and [Na+](i) are persistently elevated in vivo and further increased by halothane in MH-RyR1(R163C/WT) muscle. These increases are markedly attenuated by local perfusion of Gd+3 or GsMTx- 4 and completely suppressed by dantrolene. These results contribute a new paradigm for understanding MH pathophysiology by demonstrating that nonselective sarcolemmal cation channel activity plays a critical role in causing myoplasmic Ca2+ and Na+ overload both at rest and during the MH crisis.-Eltit, J. M., Ding, X., Pessah, I. N., Allen, P. D., Lopez, J. R. Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia. FASEB J. 27, 991-1000 (2013). www.fasebj.org	[Eltit, Jose M.] Virginia Commonwealth Univ, Dept Physiol & Biophys, Richmond, VA USA; [Ding, Xudong; Allen, Paul D.; Lopez, Jose R.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Pessah, Isaac N.; Lopez, Jose R.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	Virginia Commonwealth University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis	Lopez, JR (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.	jrlopez@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. National Institutes of Health [AR052534]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR052354] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. National Institutes of Health; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grant AR052534 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. National Institutes of Health, to P.D.A and I.N.P. The authors declare no conflicts of interest.	Allen DG, 2004, CLIN EXP PHARMACOL P, V31, P485, DOI 10.1111/j.1440-1681.2004.04032.x; ALLEN PD, 1992, ANESTHESIOLOGY, V76, P132, DOI 10.1097/00000542-199201000-00019; Barrientos GC, 2012, J BIOL CHEM, V287, P2863, DOI 10.1074/jbc.M111.307926; Brini M, 2005, J BIOL CHEM, V280, P15380, DOI 10.1074/jbc.M410421200; Carpenter D, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-104; Chelu MG, 2006, FASEB J, V20, P329, DOI 10.1096/fj.05-4497fje; Cherednichenko G, 2008, MOL PHARMACOL, V73, P1203, DOI 10.1124/mol.107.043299; DUNN JF, 1993, J NEUROL SCI, V114, P76, DOI 10.1016/0022-510X(93)90052-Z; Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042; Eltit JM, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.N110.107300; Eltit JM, 2010, J BIOL CHEM, V285, P13781, DOI 10.1074/jbc.M110.107300; Eltit JM, 2012, P NATL ACAD SCI USA, V109, P7923, DOI 10.1073/pnas.1119207109; Eltit JM, 2011, P NATL ACAD SCI USA, V108, P7046, DOI 10.1073/pnas.1018380108; Feng W, 2011, MOL PHARMACOL, V79, P420, DOI 10.1124/mol.110.067959; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; Giulivi C, 2011, J BIOL CHEM, V286, P99, DOI 10.1074/jbc.M110.153247; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; KAUSCH K, 1991, GENOMICS, V10, P765, DOI 10.1016/0888-7543(91)90461-M; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Laver DR, 1997, BIOPHYS J, V73, P1913, DOI 10.1016/S0006-3495(97)78222-5; Laver DR, 2004, J GEN PHYSIOL, V124, P741, DOI 10.1085/jgp.200409092; Li HL, 2010, J BIOL CHEM, V285, P39171, DOI 10.1074/jbc.M110.149690; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Lopez J. R., 1993, Acta Anaesthesiologica Italica, V44, P277; LOPEZ JR, 1988, MUSCLE NERVE, V11, P82; LOPEZ JR, 1987, CELL CALCIUM, V8, P385, DOI 10.1016/0143-4160(87)90013-3; LOPEZ JR, 1992, ANESTHESIOLOGY, V76, P711, DOI 10.1097/00000542-199205000-00008; LOPEZ JR, 1986, MUSCLE NERVE, V9, P85; LOPEZ JR, 1985, MUSCLE NERVE, V8, P355, DOI 10.1002/mus.880080502; LOPEZ JR, 1983, BIOPHYS J, V43, P1, DOI 10.1016/S0006-3495(83)84316-1; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NELSON TE, 1983, J CLIN INVEST, V72, P862, DOI 10.1172/JCI111057; Nelson Thomas E., 2002, Current Molecular Medicine (Hilversum), V2, P347, DOI 10.2174/1566524023362429; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; Ostrow KL, 2003, TOXICON, V42, P263, DOI 10.1016/S0041-0101(03)00141-7; Owen VJ, 1997, AM J PHYSIOL-CELL PH, V272, pC203, DOI 10.1152/ajpcell.1997.272.1.C203; Pessah IN, 1996, ANESTHESIOLOGY, V84, P1275, DOI 10.1097/00000542-199606000-00001; Pirone A, 2010, AM J PHYSIOL-CELL PH, V299, pC1345, DOI 10.1152/ajpcell.00008.2010; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rios E, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.L110.107300; Rios E, 2010, J PHYSIOL SCI, V60, P81, DOI 10.1007/s12576-009-0069-z; Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Weiss RG, 2004, AM J PHYSIOL-CELL PH, V287, pC1094, DOI 10.1152/ajpcell.00173.2004; Whitehead NP, 2006, NEUROMUSCULAR DISORD, V16, P845, DOI 10.1016/j.nmd.2006.07.024; Yang TZ, 2006, ANESTHESIOLOGY, V105, P1164, DOI 10.1097/00000542-200612000-00016; Yang TZ, 2007, AM J PHYSIOL-CELL PH, V292, pC1591, DOI 10.1152/ajpcell.00133.2006; Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yeung EW, 2003, J APPL PHYSIOL, V94, P2475, DOI 10.1152/japplphysiol.01128.2002; Yuan JP, 2007, NAT CELL BIOL, V9, P636, DOI 10.1038/ncb1590; Yuen B, 2012, FASEB J, V26, P1311, DOI 10.1096/fj.11-197582; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zhao XL, 2006, J BIOL CHEM, V281, P33477, DOI 10.1074/jbc.M602306200; Zhou JS, 2005, J GEN PHYSIOL, V126, P301, DOI 10.1085/jgp.200509353; Zhou JS, 2004, J GEN PHYSIOL, V124, P409, DOI 10.1085/jgp.200409105; Zitt C, 2004, J BIOL CHEM, V279, P12427, DOI 10.1074/jbc.M309297200	63	58	58	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					991	1000		10.1096/fj.12-218354	http://dx.doi.org/10.1096/fj.12-218354			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23159934	Green Published			2022-12-28	WOS:000315585200014
J	Jang, E; Lee, S; Kim, JH; Kim, JH; Seo, JW; Lee, WH; Mori, K; Nakao, K; Suk, K				Jang, Eunha; Lee, Shinrye; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Jung-Wan; Lee, Won-Ha; Mori, Kiyoshi; Nakao, Kazuwa; Suk, Kyoungho			Secreted protein lipocalin-2 promotes microglial M1 polarization	FASEB JOURNAL			English	Article						neuroinflammation; central nervous system; innate immunity; brain	GELATINASE-ASSOCIATED LIPOCALIN; BLOOD-DERIVED MACROPHAGES; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; INFLAMMATORY RESPONSE; TUMOR-DEVELOPMENT; EPITHELIAL-CELLS; ANIMAL-MODELS; LIPOPOLYSACCHARIDE; DISEASE	Activated macrophages are classified into two different forms: classically activated (M1) or alternatively activated (M2) macrophages. The presence of M1/M2 phenotypic polarization has also been suggested for microglia. Here, we report that the secreted protein lipocalin 2 (LCN2) amplifies M1 polarization of activated microglia. LCN2 protein (EC50 1 mu g/ml), but not glutathione S-transferase used as a control, increased the M1-related gene expression in cultured mouse microglial cells after 8-24 h. LCN2 was secreted from M1-polarized, but not M2-polarized, microglia. LCN2 inhibited phosphorylation of STAT6 in IL-4-stimulated microglia, suggesting LCN2 suppression of the canonical M2 signaling. In the lipopolysaccharide (LPS)-induced mouse neuroinflammation model, the expression of LCN2 was notably increased in microglia. Primary microglial cultures derived from LCN2-deficient mice showed a suppressed M1 response and enhanced M2 response. Mice lacking LCN2 showed a markedly reduced M1-related gene expression in microglia after LPS injection, which was consistent with the results of histological analysis. Neuroinflammation-associated impairment in motor behavior and cognitive function was also attenuated in the LCN2-deficient mice, as determined by the rotarod performance test, fatigue test, open-field test, and object recognition task. These findings suggest that LCN2 is an M1-amplifier in brain microglial cells.-Jang, E., Lee, S., Kim, J.-H., Kim, J.-H., Seo, J.-W., Lee, W.-H., Mori, K., Nakao, K., Suk, K. Secreted protein lipocalin-2 promotes microglial M1 polarization. FASEB J. 27, 1176-1190 (2013). www.fasebj.org	[Jang, Eunha; Lee, Shinrye; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Jung-Wan; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst,CMRI, Taegu 700422, South Korea; [Lee, Won-Ha] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Taegu 700422, South Korea; [Mori, Kiyoshi; Nakao, Kazuwa] Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan	Kyungpook National University; Kyungpook National University; Kyoto University	Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, 680 Gukchaebosang St, Taegu 700422, South Korea.	ksuk@knu.ac.kr	Mori, Kiyoshi/N-1267-2014	Mori, Kiyoshi/0000-0002-7285-8351	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of the Korean government [2012-0009328, 200804090]; Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A111345]	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of the Korean government(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	The authors thank Dr. Shizuo Akira (Osaka University, Osaka, Japan) for generously providing the LCN2-deficient mice. This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Education, Science and Technology (MEST) of the Korean government (2012-0009328, 200804090). This study was also supported by a grant of the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A111345).	Berard JL, 2012, GLIA, V60, P1145, DOI 10.1002/glia.22342; Bolignano D, 2008, AM J KIDNEY DIS, V52, P595, DOI 10.1053/j.ajkd.2008.01.020; Bonow RH, 2009, PHARMACOGENOMICS J, V9, P116, DOI 10.1038/tpj.2008.15; Bruce-Keller AJ, 2001, J NEUROCHEM, V78, P1315, DOI 10.1046/j.1471-4159.2001.00511.x; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Choi J, 2011, J NEUROL SCI, V305, P28, DOI 10.1016/j.jns.2011.03.023; Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Dirscherl K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-3; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Ip JPK, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-124; Jack CS, 2007, J NEUROPATH EXP NEUR, V66, P848, DOI 10.1097/nen.0b013e3181492a7; Kehrer JP, 2010, CELL BIOL TOXICOL, V26, P83, DOI 10.1007/s10565-009-9119-9; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee S, 2007, J IMMUNOL, V179, P3231, DOI 10.4049/jimmunol.179.5.3231; Lee S, 2012, J BIOL CHEM, V287, P9414, DOI 10.1074/jbc.M111.330662; Lee S, 2011, J BIOL CHEM, V286, P43855, DOI 10.1074/jbc.M111.299248; Lee S, 2009, J NEUROSCI, V29, P234, DOI 10.1523/JNEUROSCI.5273-08.2009; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li MQ, 2007, IMMUNOL LETT, V109, P129, DOI 10.1016/j.imlet.2007.02.002; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; MEHEUS LA, 1993, J IMMUNOL, V151, P1535; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nairz M, 2009, BLOOD, V114, P3642, DOI 10.1182/blood-2009-05-223354; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Park SY, 2002, MOL BRAIN RES, V107, P9, DOI 10.1016/S0169-328X(02)00421-7; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006; Rathore KI, 2011, J NEUROSCI, V31, P13412, DOI 10.1523/JNEUROSCI.0116-11.2011; Sargsyan SA, 2005, GLIA, V51, P241, DOI 10.1002/glia.20210; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Schefer V, 1996, EXP GERONTOL, V31, P387, DOI 10.1016/0531-5565(95)02032-2; Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409; Schmidt-Ott KM, 2006, CURR OPIN NEPHROL HY, V15, P442, DOI 10.1097/01.mnh.0000232886.81142.58; Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164; Shah VB, 2008, J IMMUNOL, V180, P2777, DOI 10.4049/jimmunol.180.5.2777; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Suh HS, 2009, VIROLOGY, V392, P246, DOI 10.1016/j.virol.2009.07.001; Sunil VR, 2007, EXP MOL PATHOL, V83, P177, DOI 10.1016/j.yexmp.2007.03.004; Vegeto E, 2006, ENDOCRINOLOGY, V147, P2263, DOI 10.1210/en.2005-1330; Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	66	129	131	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1176	1190		10.1096/fj.12-222257	http://dx.doi.org/10.1096/fj.12-222257			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23207546				2022-12-28	WOS:000315585200030
J	Nair, P; Vilcek, J				Nair, Prashant; Vilcek, Jan			Foreign minds, fenceless imagination: The 2013 Vilcek Foundation Prizes	FASEB JOURNAL			English	Editorial Material							BORRELIA-BURGDORFERI; DNA METHYLATION; MICE; GENE; OSPA		[Nair, Prashant] Proceedings Natl Acad Sci USA, Washington, DC USA; [Vilcek, Jan] NYU, Langone Med Ctr, Sch Med, Dept Microbiol, New York, NY 10016 USA	National Academies of Sciences, Engineering & Medicine; New York University; NYU Langone Medical Center	Vilcek, J (corresponding author), NYU, Langone Med Ctr, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	jan.vilcek@nyumc.org						Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418; FLAVELL RA, 1974, J MOL BIOL, V89, P255, DOI 10.1016/0022-2836(74)90517-8; FLAVELL RA, 1970, BIOCHEM J, V116, P155, DOI 10.1042/bj1160155; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; Legrand N, 2009, CELL HOST MICROBE, V6, P5, DOI 10.1016/j.chom.2009.06.006; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Nair Prashant, 2012, FASEB J, V26, P1361, DOI 10.1096/fj.12-0402ufm; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rathinam C, 2011, BLOOD, V118, P3119, DOI 10.1182/blood-2010-12-326926; Rongvaux A, 2011, P NATL ACAD SCI USA, V108, P2378, DOI 10.1073/pnas.1019524108; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Superville D., 2011, HUFF POST TECH  1021; U.S. Census Bureau, 2010, FOR BORN; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; Vilcek J, 2006, FASEB J, V20, P1281, DOI 10.1096/fj.06-0702ufm	23	2	2	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					845	852		10.1096/fj.13-0301ufm	http://dx.doi.org/10.1096/fj.13-0301ufm			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23450005				2022-12-28	WOS:000315585200001
J	Hamill, KJ; Hopkinson, SB; Skalli, O; Jones, JCR				Hamill, Kevin J.; Hopkinson, Susan B.; Skalli, Omar; Jones, Jonathan C. R.			Actinin-4 in keratinocytes regulates motility via an effect on lamellipodia stability and matrix adhesions	FASEB JOURNAL			English	Article						focal contact; hemidesmosome; laminin; integrin	BULLOUS-PEMPHIGOID ANTIGEN; ALPHA-ACTININ; CELL MOTILITY; COFILIN PHOSPHORYLATION; FOCAL ADHESIONS; DEPOLYMERIZING FACTOR; GENE AMPLIFICATION; BETA-4 INTEGRIN; PROTEIN-KINASE; DYNAMICS	During wound repair, epidermal cells at the edge of an injury establish front-rear polarity through orchestrated changes in their cytoskeleton and adhesion structures. The polarity and directed migration of such cells is determined by the assembly, extension, and stabilization of a lamellipodium. Actinin-4 associates with lamellipodia and has been implicated in regulating lamellipodial structure, function and assembly. To study the functions of actinin-4 in human keratinocytes, we used shRNA to generate knockdown cells and compared their motility behavior and matrix adhesion assembly to scrambled shRNA treated control keratinocytes. Actinin-4 knockdown keratinocytes lack polarity, assemble multiple lamellipodia with a 2 x increased area over controls, display reduced activity of the actin remodeling protein cofilin, and fail to migrate in a directional manner. This motility defect is rescued by plating knockdown cells on preformed laminin-332 matrix. In actinin-4-knockdown keratinocytes, focal contact area is increased by 25%, and hemidesmosome proteins are mislocalized. Specifically, alpha 6 beta 4 integrin localizes to large lamellipodial extensions, displays reduced dynamics, and fails to recruit its bullous pemphigoid antigen binding partners. Together, our data indicate a role for actinin-4 in regulating the steering mechanism of keratinocytes via profound effects on their matrix adhesion sites.-Hamill, K. J., Hopkinson, S. B., Skalli, O., Jones, J. C. R. Actinin-4 in keratinocytes regulates motility via an effect on lamellipodia stability and matrix adhesions. FASEB J. 27, 546-556 (2013). www.fasebj.org	[Hamill, Kevin J.; Hopkinson, Susan B.; Jones, Jonathan C. R.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Skalli, Omar] Univ Memphis, Dept Biol Sci, Memphis, TN 38152 USA	Northwestern University; Feinberg School of Medicine; University of Memphis	Jones, JCR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-jones3@northwestern.edu	Hamill, Kevin/ABF-9727-2020; Skalli, Omar/D-4980-2013; Jones, Jonathan C R/T-9467-2017	Hamill, Kevin/0000-0002-7852-1944; Jones, Jonathan C R/0000-0002-1496-4922	Dermatology Foundation; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases [K99AR060242, R01AR054184]; Cancer Center Support grant [NCI CA060553];  [NCI CCSG P30 CA060553]; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K99AR060242, P30AR057216, R01AR054184] Funding Source: NIH RePORTER	Dermatology Foundation; U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Cancer Center Support grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	A Dermatology Foundation Career Development Award (to K.J.H.), as well as grants K99AR060242 (K.J.H.), and R01AR054184 (J.C.R.J.) from the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases supported this project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Arthritis and Musculoskeletal and Skin Diseases or the U. S. National Institutes of Health. Imaging work was performed at the Northwestern University Cell Imaging Facility, generously supported by grant NCI CCSG P30 CA060553, awarded to the Robert H. Lurie Comprehensive Cancer Center. FACS analyses were performed at the Northwestern University Flow Cytometry Facility, supported by a Cancer Center Support grant (NCI CA060553).	AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Barbolina MV, 2008, LAB INVEST, V88, P602, DOI 10.1038/labinvest.2008.25; BARON MD, 1987, J BIOL CHEM, V262, P17623; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; Galler AB, 2006, HISTOCHEM CELL BIOL, V125, P457, DOI 10.1007/s00418-005-0091-z; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Gonzalez AM, 2001, J CELL SCI, V114, P4197; Hamill KJ, 2009, MOL BIOL CELL, V20, P2954, DOI 10.1091/mbc.E09-01-0051; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO T, 1993, J INVEST DERMATOL, V100, P310, DOI 10.1111/1523-1747.ep12469916; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; Jovceva E, 2007, J CELL SCI, V120, P1888, DOI 10.1242/jcs.004366; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; KLATTE DH, 1994, J INVEST DERMATOL, V102, P39, DOI 10.1111/1523-1747.ep12371728; Kligys K, 2007, J BIOL CHEM, V282, P32520, DOI 10.1074/jbc.M707041200; Koizumi T, 2010, UROLOGY, V75, P357, DOI 10.1016/j.urology.2009.09.037; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; LANGHOFER M, 1993, J CELL SCI, V105, P753; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Ozawa T, 2011, MED MOL MORPHOL, V44, P27, DOI 10.1007/s00795-010-0502-7; Ozawa T, 2010, J INVEST DERMATOL, V130, P1624, DOI 10.1038/jid.2009.439; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pullar CE, 2006, MOL BIOL CELL, V17, P4925, DOI 10.1091/mbc.E06-05-0433; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Schafer C, 2010, CELL ADHES MIGR, V4, P215, DOI 10.4161/cam.4.2.10745; Sehgal BU, 2006, J BIOL CHEM, V281, P35487, DOI 10.1074/jbc.M606317200; Sen S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008427; Shao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013921; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Tsuruta D, 2003, CELL MOTIL CYTOSKEL, V54, P122, DOI 10.1002/cm.10089; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; Tsuruta D, 2011, J DERMATOL SCI, V62, P1, DOI 10.1016/j.jdermsci.2011.01.005; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Xia N, 2008, FASEB J, V22, P1649, DOI 10.1096/fj.07-090571; Yamada S, 2010, INT J ORAL MAX SURG, V39, P61, DOI 10.1016/j.ijom.2009.10.003; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamamoto S, 2007, MODERN PATHOL, V20, P1278, DOI 10.1038/modpathol.3800966; Yamamoto S, 2012, HISTOPATHOLOGY, V60, P1073, DOI 10.1111/j.1365-2559.2011.04163.x; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	59	26	26	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					546	556		10.1096/fj.12-217406	http://dx.doi.org/10.1096/fj.12-217406			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085994	Green Published			2022-12-28	WOS:000314358000014
J	He, LH; Kota, P; Aleksandrov, AA; Cui, LY; Jensen, T; Dokholyan, NV; Riordan, JR				He, Lihua; Kota, Pradeep; Aleksandrov, Andrei A.; Cui, Liying; Jensen, Tim; Dokholyan, Nikolay V.; Riordan, John R.			Correctors of Delta F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein	FASEB JOURNAL			English	Article						cystic fibrosis; VX-809; domain interactions; molecular docking; anion channel; ABC transporter	TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE-ASSOCIATED MUTATIONS; CYTOPLASMIC LOOP; CHANNEL FUNCTION; IN-VITRO; RESCUE; POTENTIATOR; CYANOQUINOLINES; DEFECTS	Most cystic fibrosis is caused by the deletion of a single amino acid (F508) from CFTR and the resulting misfolding and destabilization of the protein. Compounds identified by high-throughput screening to improve Delta F508 CFTR maturation have already entered clinical trials, and it is important to understand their mechanisms of action to further improve their efficacy. Here, we showed that several of these compounds, including the investigational drug VX-809, caused a much greater increase (5- to 10-fold) in maturation at 27 than at 37 degrees C (<2-fold), and the mature product remained short-lived (T-1/2 similar to 4.5 h) and thermally unstable, even though its overall conformational state was similar to wild type, as judged by resistance to proteolysis and interdomain cross-linking. Consistent with its inability to restore thermodynamic stability, VX-809 stimulated maturation 2-5-fold beyond that caused by several different stabilizing modifications of NBD1 and the NBD1/CL4 interface. The compound also promoted maturation of several disease-associated processing mutants on the CL4 side of this interface. Although these effects may reflect an interaction of VX-809 with this interface, an interpretation supported by computational docking, it also rescued maturation of mutants in other cytoplasmic loops, either by allosteric effects or via additional sites of action. In addition to revealing the capabilities and some of the limitations of this important investigational drug, these findings clearly demonstrate that Delta F508 CFTR can be completely assembled and evade cellular quality control systems, while remaining thermodynamically unstable. He, L., Kota, P., Aleksandrov, A. A., Cui, L., Jensen, T., Dokholyan, N. V., Riordan, J. R. Correctors of Delta F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27, 536-545 (2013). www.fasebj.org	[He, Lihua; Kota, Pradeep; Aleksandrov, Andrei A.; Cui, Liying; Jensen, Tim; Dokholyan, Nikolay V.; Riordan, John R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [He, Lihua; Aleksandrov, Andrei A.; Cui, Liying; Jensen, Tim; Riordan, John R.] Univ N Carolina, Cyst Fibrosis Treatment & Res Ctr, Chapel Hill, NC 27599 USA; [Kota, Pradeep; Dokholyan, Nikolay V.] Univ N Carolina, Mol & Cellular Biophys Program, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Riordan, JR (corresponding author), Univ N Carolina, Cyst Fibrosis Treatment & Res Ctr, Dept Biochem & Biophys, 6103 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	jack_riordan@med.unc.edu	Dokholyan, Nikolay/D-8081-2018	Dokholyan, Nikolay/0000-0002-8225-4025	U.S. National Institutes of Health [DK051619, GM080742]; Cystic Fibrosis Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL110873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051870, R01DK051619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080742] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the U.S. National Institutes of Health to J.R.R. (DK051619) and N.V.D. (GM080742) and from the Cystic Fibrosis Foundation.	Aleksandrov AA, 2012, J MOL BIOL, V419, P41, DOI 10.1016/j.jmb.2012.03.001; Aleksandrov AA, 2010, J MOL BIOL, V401, P194, DOI 10.1016/j.jmb.2010.06.019; Alexander C, 2009, BIOCHEMISTRY-US, V48, P10078, DOI 10.1021/bi901314c; Bartlett JR, 2009, JAMA-J AM MED ASSOC, V302, P1076, DOI 10.1001/jama.2009.1295; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; Cutting GR, 2010, ANN NY ACAD SCI, V1214, P57, DOI 10.1111/j.1749-6632.2010.05879.x; Dalton J, 2012, J CHEM INF MODEL, V52, P1842, DOI 10.1021/ci2005884; deCarvalho ACV, 2002, J BIOL CHEM, V277, P35896, DOI 10.1074/jbc.M205644200; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Ding F, 2010, J CHEM INF MODEL, V50, P1623, DOI 10.1021/ci100218t; Dorfman R, 2009, HUM GENET, V126, P763, DOI 10.1007/s00439-009-0724-8; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; He LH, 2008, J BIOL CHEM, V283, P26383, DOI 10.1074/jbc.M803894200; He LH, 2010, FASEB J, V24, P3103, DOI 10.1096/fj.09-141788; Hoelen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015458; Kalid O, 2010, J COMPUT AID MOL DES, V24, P971, DOI 10.1007/s10822-010-9390-0; Knapp JM, 2012, J MED CHEM, V55, P1242, DOI 10.1021/jm201372q; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Liu X., 2012, BIOCHEMISTR IN PRESS; Liu XH, 2012, BIOCHEMISTRY-US, V51, P5113, DOI 10.1021/bi300018e; Loo TW, 2010, BIOCHEMISTRY-US, V49, P6352, DOI 10.1021/bi100807h; Lukacs GL, 2012, TRENDS MOL MED, V18, P81, DOI 10.1016/j.molmed.2011.10.003; Mendoza JL, 2012, CELL, V148, P164, DOI 10.1016/j.cell.2011.11.023; Mickle JE, 2000, MED CLIN N AM, V84, P597, DOI 10.1016/S0025-7125(05)70243-1; MITTRE H, 1995, J MED GENET, V32, P577, DOI 10.1136/jmg.32.7.577; Mornon JP, 2009, CELL MOL LIFE SCI, V66, P3469, DOI 10.1007/s00018-009-0133-0; Protasevich I, 2010, PROTEIN SCI, V19, P1917, DOI 10.1002/pro.479; Phuan PW, 2011, MOL PHARMACOL, V80, P683, DOI 10.1124/mol.111.073056; Rabeh WM, 2012, CELL, V148, P150, DOI 10.1016/j.cell.2011.11.024; Schultz BD, 1999, J MEMBRANE BIOL, V170, P51, DOI 10.1007/s002329900537; Scotet Virginie, 2003, Hum Mutat, V22, P105, DOI 10.1002/humu.9158; Seibert FS, 1996, J BIOL CHEM, V271, P27493, DOI 10.1074/jbc.271.44.27493; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Thibodeau PH, 2010, J BIOL CHEM, V285, P35825, DOI 10.1074/jbc.M110.131623; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; Wang W, 2011, J BIOL CHEM, V286, P41937, DOI 10.1074/jbc.M111.296061; Wang XD, 2008, TRAFFIC, V9, P1878, DOI 10.1111/j.1600-0854.2008.00806.x; Yin S, 2008, J CHEM INF MODEL, V48, P1656, DOI 10.1021/ci8001167; Yu HH, 2012, J CYST FIBROS, V11, P237, DOI 10.1016/j.jcf.2011.12.005; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	44	101	103	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					536	545		10.1096/fj.12-216119	http://dx.doi.org/10.1096/fj.12-216119			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23104983	Green Published			2022-12-28	WOS:000314358000013
J	Khidhir, KG; Woodward, DF; Farjo, NP; Farjo, BK; Tang, ES; Wang, JW; Picksley, SM; Randall, VA				Khidhir, Karzan G.; Woodward, David F.; Farjo, Nilofer P.; Farjo, Bessam K.; Tang, Elaine S.; Wang, Jenny W.; Picksley, Steven M.; Randall, Valerie A.			The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias	FASEB JOURNAL			English	Article						hair follicle; hair growth; balding; prostaglandins; human organ culture	HAIR-GROWTH; PHARMACOLOGICAL CHARACTERIZATION; FP-RECEPTOR; PATTERN; INDUCTION; AREATA; MEN; PROSTAGLANDIN-F2-ALPHA; IDENTIFICATION; REGENERATION	Balding causes widespread psychological distress but is poorly controlled. The commonest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair. We hypothesized that another serendipitous discovery, increased eyelash growth side-effects of prostamide F-2 alpha-related eyedrops for glaucoma, may be relevant for scalp alopecias. Eyelash hairs and follicles are highly specialized and remain unaffected by androgens that inhibit scalp follicles and stimulate many others. Therefore, we investigated whether non-eyelash follicles could respond to bimatoprost, a prostamide F-2 alpha analog recently licensed for eyelash hypotrichosis. Bimatoprost, at pharmacologically selective concentrations, increased hair synthesis in scalp follicle organ culture and advanced mouse pelage hair regrowth in vivo compared to vehicle alone. A prostamide receptor antagonist blocked isolated follicle growth, confirming a direct, receptor-mediated mechanism within follicles; RT-PCR analysis identified 3 relevant receptor genes in scalp follicles in vivo. Receptors were located in the key follicle regulator, the dermal papilla, by analyzing individual follicular structures and immunohistochemistry. Thus, bimatoprost stimulates human scalp follicles in culture and rodent pelage follicles in vivo, mirroring eyelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo. This highlights a new follicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approach for scalp alopecias.-Khidhir, K. G., Woodward, D. F., Farjo, N. P., Farjo, B. K., Tang, E. S., Wang, J. W., Picksley, S. M., and Randall, V. A. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J. 27, 557-567 (2013). www.fasebj.org	[Khidhir, Karzan G.; Picksley, Steven M.; Randall, Valerie A.] Univ Bradford, Ctr Skin Sci, Bradford BD7 1DP, W Yorkshire, England; [Woodward, David F.; Tang, Elaine S.; Wang, Jenny W.] Allergan, Irvine, CA USA; [Farjo, Nilofer P.; Farjo, Bessam K.] Farjo Med Ctr, Manchester, Lancs, England	University of Bradford; AbbVie; Allergan	Randall, VA (corresponding author), Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England.	v.a.randall@bradford.ac.uk			Ministry of Higher Education and Scientific Research, Kurdistan, Iraq; Allergan, Inc.	Ministry of Higher Education and Scientific Research, Kurdistan, Iraq; Allergan, Inc.(AbbVieAllergan)	The authors gratefully acknowledge a Research Scholarship from the Ministry of Higher Education and Scientific Research, Kurdistan, Iraq, to support K. G. K. The authors also thank Allergan, Inc. (Irvine, CA, USA) for gifts of bimatoprost and AGN 211336. One of the authors of this article (V. A. R.) has informed The FASEB Journal that she has been asked to be an expert witness for Allergan and their coplaintiff Duke University in a legal matter. V. A. R. has acted as a consultant for Allergan, Inc., and has received unrestricted grants from Allergan, Inc., to support her research. E. S. T., J.W.W., and D. F. W. are Allergan employees.	CASH TF, 1993, J AM ACAD DERMATOL, V29, P568, DOI 10.1016/0190-9622(93)70223-G; Chuong CM, 2012, PHYSIOLOGY, V27, P61, DOI 10.1152/physiol.00028.2011; Colombe L, 2008, EXP DERMATOL, V17, P63, DOI 10.1111/j.1600-0625.2007.00639.x; Colombe L, 2007, EXP DERMATOL, V16, P762, DOI 10.1111/j.1600-0625.2007.00586.x; Curran MP, 2009, DRUG AGING, V26, P1049, DOI 10.2165/11203210-000000000-00000; Garg S, 2009, SEMIN CUTAN MED SURG, V28, P15, DOI 10.1016/j.sder.2008.12.002; Girman CJ, 1998, DERMATOLOGY, V197, P223, DOI 10.1159/000018001; Gulec AT, 2004, INT J DERMATOL, V43, P352, DOI 10.1111/j.1365-4632.2004.02028.x; HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708, DOI 10.1111/j.1749-6632.1951.tb31971.x; Higgins CA, 2009, EXP DERMATOL, V18, P793, DOI 10.1111/j.1600-0625.2008.00833.x; Inui S, 2003, J INVEST DERM SYMP P, V8, P69, DOI 10.1046/j.1523-1747.2003.12174.x; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; JAHODA CAB, 1992, DEVELOPMENT, V115, P1103; Jansen VAA, 2006, NATURE, V440, P663, DOI 10.1038/nature04387; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; KEOGH EV, 1965, NATURE, V207, P877, DOI 10.1038/207877a0; KLIGMAN AM, 1959, J INVEST DERMATOL, V33, P307, DOI 10.1038/jid.1959.156; LEE PY, 1988, INVEST OPHTH VIS SCI, V29, P1474; Liang Y, 2008, BRIT J PHARMACOL, V154, P1079, DOI 10.1038/bjp.2008.142; Liang YB, 2003, J BIOL CHEM, V278, P27267, DOI 10.1074/jbc.M301009200; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; McCarey BE, 2004, OPHTHALMOLOGY, V111, P1480, DOI 10.1016/j.ophtha.2003.11.013; Messenger AG, 2004, BRIT J DERMATOL, V150, P186, DOI 10.1111/j.1365-2133.2004.05785.x; Michelet JF, 1997, J INVEST DERMATOL, V108, P205, DOI 10.1111/1523-1747.ep12334249; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Ota T, 2005, INVEST OPHTH VIS SCI, V46, P4159, DOI 10.1167/iovs.05-0494; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Piraccini BM, 2006, CURR DRUG SAF, V1, P301, DOI 10.2174/157488606777934477; Plikus MV, 2008, J INVEST DERMATOL, V128, P1071, DOI 10.1038/sj.jid.5701180; Plikus MV, 2011, SCIENCE, V332, P586, DOI 10.1126/science.1201647; Randall VA, 2001, LANCET, V358, P1922, DOI 10.1016/S0140-6736(01)06943-4; Randall VA, 2008, J ENDOCRINOL, V197, P11, DOI 10.1677/JOE-07-0522; Randall VA, 2008, DERMATOL THER, V21, P314, DOI 10.1111/j.1529-8019.2008.00214.x; Randall VA, 2007, SEMIN CELL DEV BIOL, V18, P274, DOI 10.1016/j.semcdb.2007.02.004; Rendl M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/journal.pbio.0030331; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Rogers NE, 2008, J AM ACAD DERMATOL, V59, P547, DOI 10.1016/j.jaad.2008.07.001; SAITOH M, 1970, J INVEST DERMATOL, V54, P65, DOI 10.1111/1523-1747.ep12551679; Shorter K, 2008, FASEB J, V22, P1725, DOI 10.1096/fj.07-099424; Sotiropoulou PA, 2010, NAT CELL BIOL, V12, P572, DOI 10.1038/ncb2059; Tauchi M, 2010, BRIT J DERMATOL, V162, P1186, DOI 10.1111/j.1365-2133.2010.09685.x; Thibaut S, 2010, BRIT J DERMATOL, V162, P304, DOI 10.1111/j.1365-2133.2009.09487.x; Trueb R M, 2010, Skin Therapy Lett, V15, P5; Whiting DA, 2003, EUR J DERMATOL, V13, P150; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4; Woodward DF, 2008, PHARMACOL THERAPEUT, V120, P71, DOI 10.1016/j.pharmthera.2008.08.001; Woodward DF, 2003, J PHARMACOL EXP THER, V305, P772, DOI 10.1124/jpet.102.047837; Woodward FD, 2010, CELL BIO RES PROG, P65	48	35	41	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					557	567		10.1096/fj.12-218156	http://dx.doi.org/10.1096/fj.12-218156			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23104985	Green Published, hybrid			2022-12-28	WOS:000314358000015
J	Niculescu, MD; Lupu, DS; Craciunescu, CN				Niculescu, Mihai D.; Lupu, Daniel S.; Craciunescu, Corneliu N.			Perinatal manipulation of alpha-linolenic acid intake induces epigenetic changes in maternal and offspring livers	FASEB JOURNAL			English	Article						Fads2; flaxseed oil; polyunsaturated fatty acids; DNA methylation; postnatal development	FATTY-ACID; PRETERM INFANTS; DOCOSAHEXAENOIC ACID; DNA METHYLATION; KAPPA-B; GROWTH; N-3; SUPPLEMENTATION; EXPRESSION; LACTATION	Previous studies indicated that the intake of alpha-linolenic acid (ALA) can alter the concentration of both omega-6 and omega-3 fatty acids in both mother and offspring, with consequences on postnatal brain development. This study describes the association between maternal ALA availability during gestation and lactation, and alterations in the Fads2 DNA methylation in both maternal and offspring livers, at the end of lactation period. Both Fads2 promoter and intron 1 DNA methylation were increased in the groups receiving postnatal flaxseed oil containing 50% ALA (mothers or pups), while bivariate analysis indicated a significant association of the Fads2 epigenetic status in the liver between each mother and its offspring. In addition, Fads2 expression was negatively correlated with promoter methylation at the individual level in maternal livers (P<0.05). This study also indicated that the interplay between ALA availability during gestation and lactation can differentially alter the expression of desaturases and elongases involved in omega-6 and omega-3 metabolic pathways. In summary, when considering the perinatal dietary ALA requirements in mice, both gestation and lactation periods should be considered as having distinct roles in modulating the metabolism of omega-6 and omega-3 fatty acids in maternal mouse livers.-Niculescu, M. D., Lupu, D. S., Craciunescu, C. N. Perinatal manipulation of alpha-linolenic acid intake induces epigenetic changes in maternal and offspring livers. FASEB J. 27, 350-358 (2013). www.fasebj.org	[Niculescu, Mihai D.; Lupu, Daniel S.] Univ N Carolina, Inst Nutr Res, Kannapolis, NC 28081 USA; [Niculescu, Mihai D.; Lupu, Daniel S.; Craciunescu, Corneliu N.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina; University of North Carolina Chapel Hill	Niculescu, MD (corresponding author), Univ N Carolina, Inst Nutr Res, 500 Laureate Way, Kannapolis, NC 28081 USA.	mihai_niculescu@unc.edu	LUPU, DANIEL/A-6004-2011; LUPU, DANIEL/K-1990-2014	LUPU, DANIEL/0000-0001-8174-5482	University of North Carolina Center for Excellence in Children's Nutrition; Mead Johnson Nutrition	University of North Carolina Center for Excellence in Children's Nutrition; Mead Johnson Nutrition	This work was partially funded by a grant to M. D. N. from the University of North Carolina Center for Excellence in Children's Nutrition, sponsored by Mead Johnson Nutrition.	Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; CARLSON SE, 1992, LIPIDS, V27, P901, DOI 10.1007/BF02535870; Carlson SE, 1996, AM J CLIN NUTR, V63, P687, DOI 10.1093/ajcn/63.5.687; Childs CE, 2012, PROSTAG LEUKOTR ESS, V86, P141, DOI 10.1016/j.plefa.2012.03.007; Clandinin MT, 2005, J PEDIATR-US, V146, P461, DOI 10.1016/j.jpeds.2004.11.030; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; Deckelbaum RJ, 2012, J NUTR, V142, p641S, DOI 10.3945/jn.111.149831; Devlin AM, 2007, J BIOL CHEM, V282, P37082, DOI 10.1074/jbc.M704256200; Fewtrell MS, 2004, J PEDIATR-US, V144, P471, DOI 10.1016/j.jpeds.2004.01.034; Garrel C, 2012, INT J BIOCHEM CELL B, V44, P123, DOI 10.1016/j.biocel.2011.10.007; Gibson RA, 2011, NESTLE NUTR WORKS SE, V67, P197, DOI 10.1159/000325585; Gibson RA, 2011, MATERN CHILD NUTR, V7, P17, DOI 10.1111/j.1740-8709.2011.00299.x; Giegerich R, 1996, Proc Int Conf Intell Syst Mol Biol, V4, P68; Grayson C, 2005, J BIOL CHEM, V280, P32521, DOI 10.1074/jbc.M503411200; Gregory MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029662; Guillou H, 2004, J LIPID RES, V45, P32, DOI 10.1194/jlr.M300339-JLR200; Guillou H, 2010, PROG LIPID RES, V49, P186, DOI 10.1016/j.plipres.2009.12.002; Harauma A, 2010, LIPIDS, V45, P659, DOI 10.1007/s11745-010-3443-y; Innis SM, 2003, J PEDIATR-US, V143, pS1, DOI 10.1067/S0022-3476(03)00396-2; Innis SM, 2002, J PEDIATR-US, V140, P547, DOI 10.1067/mpd.2002.123282; Jordan RG, 2010, J MIDWIFERY WOM HEAL, V55, P520, DOI 10.1016/j.jmwh.2010.02.018; Jump DB, 2008, CURR OPIN LIPIDOL, V19, P242, DOI 10.1097/MOL.0b013e3282ffaf6a; Jump DB, 2011, CURR OPIN CLIN NUTR, V14, P115, DOI 10.1097/MCO.0b013e328342991c; LANDS WEM, 1990, LIPIDS, V25, P505, DOI 10.1007/BF02537156; Makrides M, 2011, MATERN CHILD NUTR, V7, P80, DOI 10.1111/j.1740-8709.2011.00304.x; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739; Mehedint MG, 2010, FASEB J, V24, P184, DOI 10.1096/fj.09-140145; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Muhlhausler BS, 2011, PROSTAG LEUKOTR ESS, V85, P83, DOI 10.1016/j.plefa.2011.04.027; Muhlhausler Beverly Sara, 2011, Frontiers in Genetics, V2, P48, DOI 10.3389/fgene.2011.00048; Niculescu MD, 2011, INT J DEV NEUROSCI, V29, P795, DOI 10.1016/j.ijdevneu.2011.09.006; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; Ren J, 2007, J AGR FOOD CHEM, V55, P5073, DOI 10.1021/jf0702693; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002; Torchetti EM, 2010, MITOCHONDRION, V10, P263, DOI 10.1016/j.mito.2009.12.149; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Wang Y, 2005, J LIPID RES, V46, P706, DOI 10.1194/jlr.M400335-JLR200	39	59	63	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					350	358		10.1096/fj.12-210724	http://dx.doi.org/10.1096/fj.12-210724			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22997227				2022-12-28	WOS:000313103200033
J	Uemura, Y; Shibata, R; Ohashi, K; Enomoto, T; Kambara, T; Yamamoto, T; Ogura, Y; Yuasa, D; Joki, Y; Matsuo, K; Miyabe, M; Kataoka, Y; Murohara, T; Ouchi, N				Uemura, Yusuke; Shibata, Rei; Ohashi, Koji; Enomoto, Takashi; Kambara, Takahiro; Yamamoto, Takashi; Ogura, Yasuhiro; Yuasa, Daisuke; Joki, Yusuke; Matsuo, Kazuhiro; Miyabe, Megumi; Kataoka, Yoshiyuki; Murohara, Toyoaki; Ouchi, Noriyuki			Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation	FASEB JOURNAL			English	Article						adipocytokine; vascular remodeling; cAMP	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR; ISCHEMIA-REPERFUSION; INSULIN-RESISTANCE; BINDING PROTEIN; ADIPONECTIN; OBESITY; RESTENOSIS; INHIBITION	Obesity is closely associated with the progression of vascular disorders, including atherosclerosis and postangioplasty restenosis. C1q/TNF-related protein (CTRP) 9 is an adipocytokine that is down-regulated in obese mice. Here we investigated whether CTRP9 modulates neointimal hyperplasia and vascular smooth muscle cell (VSMC) proliferation in vivo and in vitro. Left femoral arteries of wild-type (WT) mice were injured by a steel wire. An adenoviral vector expressing CTRP9 (Ad-CTRP9) or beta-galactosidase as a control was intravenously injected into WT mice 3 d before vascular injury. Delivery of Ad-CTRP9 significantly attenuated the neointimal thickening and the number of bromode-oxyuridine-positive proliferating cells in the injured arteries compared with that of control. Treatment of VSMCs with CTRP9 protein attenuated the proliferative and chemotactic activities induced by growth factors including platelet-derived growth factor (PDGF)BB, and suppressed PDGF-BB-stimulated phosphorylation of ERK. CTRP9 treatment dose-dependently increased cAMP levels in VSMCs. Blockade of cAMP-PKA pathway reversed the inhibitory effect of CTRP9 on DNA synthesis and ERK phosphorylation in response to PDGF-BB. The present data indicate that CTRP9 functions to attenuate neointimal formation following vascular injury through its ability to inhibit VSMC growth via cAMP-dependent mechanism, suggesting that the therapeutic approaches to enhance CTRP9 production could be valuable for prevention of vascular restenosis after angioplasty.-Uemura, Y., Shibata, R., Ohashi, K., Enomoto, T., Kambara, T., Yamamoto, T., Ogura, Y., Yuasa, D., Joki, Y., Matsuo, K., Miyabe, M., Kataoka, Y., Murohara, T., Ouchi, N. Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation. FASEB J. 27, 25-33 (2013). www.fasebj.org	[Uemura, Yusuke; Shibata, Rei; Enomoto, Takashi; Kambara, Takahiro; Yamamoto, Takashi; Ogura, Yasuhiro; Yuasa, Daisuke; Joki, Yusuke; Matsuo, Kazuhiro; Miyabe, Megumi; Kataoka, Yoshiyuki; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan; [Ohashi, Koji; Ouchi, Noriyuki] Nagoya Univ, Grad Sch Med, Dept Mol Cardiol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Shibata, R (corresponding author), Nagoya Univ, Grad Sch Med, Dept Mol Cardiol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	rshibata@med.nagoya-u.ac.jp; nouchi@med.nagoya-u.ac.jp	OUCHI, Noriyuki/I-7306-2014; Murohara, Toyoaki/M-4958-2014; OHASHI, Koji/I-7307-2014	Enomoto, Takashi/0000-0002-7370-8013	Japan Society for the Promotion of Science; Senshin Medical Research Foundation; Japan Research Foundation for Clinical Pharmacology; Takeda Science Foundation; Japan Ministry of Education, Culture, Sports, Science, and Technology; Uehara Memorial Foundation; Japan Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology; Japan Heart Foundation; Astellas/Pfizer Grant for Research on Atherosclerosis Update	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Senshin Medical Research Foundation(SENSHIN Medical Research Foundation); Japan Research Foundation for Clinical Pharmacology; Takeda Science Foundation(Takeda Science Foundation (TSF)); Japan Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Japan Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology; Japan Heart Foundation; Astellas/Pfizer Grant for Research on Atherosclerosis Update	This work was supported by a Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research and grants from the Senshin Medical Research Foundation, the Japan Research Foundation for Clinical Pharmacology, and the Takeda Science Foundation to N.O.; R. S. was supported by a Japan Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Young Scientists (B), the Uehara Memorial Foundation, a Japan Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology, and a Japan Heart Foundation and Astellas/Pfizer Grant for Research on Atherosclerosis Update. The authors gratefully acknowledge the technical assistance of Yoko Inoue and Miho Sakai.	Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cospedal R., 1999, BIOCH J 2, V342, P407; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Gennaro G, 2004, CIRCULATION, V110, P3367, DOI 10.1161/01.CIR.0000147773.86866.CD; Giasson E, 1997, J BIOL CHEM, V272, P26879, DOI 10.1074/jbc.272.43.26879; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Indolfi C, 2002, CIRC RES, V91, P1190, DOI 10.1161/01.RES.0000046233.94299.D6; Indolfi C, 1997, NAT MED, V3, P775, DOI 10.1038/nm0797-775; Iwakura A, 2003, CIRCULATION, V108, P3115, DOI 10.1161/01.CIR.0000106906.56972.83; Iwashima Y, 2004, HYPERTENSION, V43, P1318, DOI 10.1161/01.HYP.0000129281.03801.4b; Kambara T, 2012, J BIOL CHEM, V287, P18965, DOI 10.1074/jbc.M112.357939; Kawabe J, 2010, ARTERIOSCL THROM VAS, V30, P464, DOI 10.1161/ATVBAHA.109.193730; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Matsuzawa Y, 2006, NAT CLIN PRACT CARD, V3, P35, DOI 10.1038/ncpcardio0380; Mii S, 1996, AM J PHYSIOL-HEART C, V270, pH142, DOI 10.1152/ajpheart.1996.270.1.H142; Miyake H, 2011, CIRC RES, V108, P1170, DOI 10.1161/CIRCRESAHA.110.236174; Nielsen S, 1997, CURR OPIN LIPIDOL, V8, P200, DOI 10.1097/00041433-199708000-00002; Nikolsky E, 2005, AM J CARDIOL, V95, P709, DOI 10.1016/j.amjcard.2004.11.020; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Rana JS, 2005, AM HEART J, V150, P821, DOI 10.1016/j.ahj.2004.11.022; ROSS R, 1995, ANN NY ACAD SCI, V748, P1; Ross R., 1995, ANN NY ACAD SCI, V748, P4; Rossi F, 2009, ATHEROSCLEROSIS, V203, P97, DOI 10.1016/j.atherosclerosis.2008.06.015; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295; Takaoka M, 2009, CIRC RES, V105, P906, DOI 10.1161/CIRCRESAHA.109.199653; Tao L, 2007, CIRCULATION, V115, P1408, DOI 10.1161/CIRCULATIONAHA.106.666941; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; Wong GW, 2009, FASEB J, V23, P241, DOI 10.1096/fj.08-114991; Wong GW, 2008, BIOCHEM J, V416, P161, DOI 10.1042/BJ20081240; Wong GW, 2004, P NATL ACAD SCI USA, V101, P10302, DOI 10.1073/pnas.0403760101; Wu YJ, 2006, CIRC RES, V98, P1141, DOI 10.1161/01.RES.0000219905.16312.28; Zheng QJ, 2011, ARTERIOSCL THROM VAS, V31, P2616, DOI 10.1161/ATVBAHA.111.231050	44	84	90	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					25	33		10.1096/fj.12-213744	http://dx.doi.org/10.1096/fj.12-213744			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22972916				2022-12-28	WOS:000313103200004
J	Andrieu, G; Quaranta, M; Leprince, C; Hatzoglou, A				Andrieu, Guillaume; Quaranta, Muriel; Leprince, Corinne; Hatzoglou, Anastassia			The GTPase Gem and its partner Kif9 are required for chromosome alignment, spindle length control, and mitotic progression	FASEB JOURNAL			English	Article						cell division; cytoskeleton; microtubules; prometaphase	KINESIN-LIKE PROTEIN; BINDING PROTEINS; MICROTUBULE DYNAMICS; RAS FAMILY; RGK FAMILY; INTERACTS; MEMBER; PATHWAY; REORGANIZATION; ACTIVATION	Within the Ras superfamily, Gem is a small GTP-binding protein that plays a role in regulating Ca2+ channels and cytoskeletal remodeling in interphase cells. Here, we report for the first time that Gem is a spindle-associated protein and is required for proper mitotic progression. Functionally, loss of Gem leads to misaligned chromosomes and prometaphase delay. On the basis of different experimental approaches, we demonstrate that loss of Gem by RNA interference induces spindle elongation, while its enforced expression results in spindle shortening. The spindle length phenotype is generated through deregulation of spindle dynamics on Gem depletion and requires the expression of its downstream effector, the kinesin Kif9. Loss of Kif9 induces spindle abnormalities similar to those observed when Gem expression is repressed by siRNA. We further identify Kif9 as a new regulator of spindle dynamics. Kif9 depletion increases the steady-state levels of spindle alpha-tubulin by increasing the rate of microtubule polymerization. Overall, this study demonstrates a novel mechanism by which Gem contributes to the mitotic progression by maintaining correct spindle length through the kinesin Kif9.-Andrieu, G., Quaranta, M., Leprince, C., Hatzoglou, A. The GTPase Gem and its partner Kif9 are required for chromosome alignment, spindle length control, and mitotic progression. FASEB J. 26, 5025-5034 (2012). www.fasebj.org	[Andrieu, Guillaume; Hatzoglou, Anastassia] CNRS UMR 5089, IPBS, Toulouse, France; [Andrieu, Guillaume; Quaranta, Muriel; Leprince, Corinne; Hatzoglou, Anastassia] CNRS UMR 5089, Lab Biol Cellulaire & Mol Controle Proliferat, Toulouse, France; [Andrieu, Guillaume; Quaranta, Muriel; Hatzoglou, Anastassia] Univ Toulouse 3, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Hatzoglou, A (corresponding author), CNRS UMR 5089, IPBS, 205 Route Narbonne,BP 64182, Toulouse, France.	anastassia.hatzoglou@ipbs.fr	Leprince, Corinne/M-7109-2018	Leprince, Corinne/0000-0002-4462-5737; Andrieu, Guillaume/0000-0003-0289-4952	Ligue Nationale Contre le Cancer; Universite de Toulouse, UPS; Ministere de l'Education Nationale	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Universite de Toulouse, UPS; Ministere de l'Education Nationale	The authors thank Dr. J. Goetz (Hopital de Strasbourg, Strasbourg, France) for CREST serum; N. Galjart (Erasmus Medical Center, Rotterdam, The Netherlands) for EB3-GFP plasmid; A. Ledoux, B. Caussares, and I. Dais for their contribution; and the Toulouse Reseau Imagerie-Laboratoire de Biologie Cellulaire et Moleculaire du Controle de la Proliferation (TRI-LBCMCP) microscopy facilities [Universite Paul Sabatier (UPS), Toulouse, France]. This work was supported by grants from Ligue Nationale Contre le Cancer and Universite de Toulouse, UPS, to A. H. G. A. was supported by a Ph.D. fellowship from Ministere de l'Education Nationale.	Aresta S, 2002, BIOCHEM J, V367, P57, DOI 10.1042/BJ20020829; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Birk M, 2012, INT J CANCER, V130, P798, DOI 10.1002/ijc.26036; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cornfine S, 2011, MOL BIOL CELL, V22, P202, DOI 10.1091/mbc.E10-05-0394; Correll RN, 2008, CELL SIGNAL, V20, P292, DOI 10.1016/j.cellsig.2007.10.028; Demonchy R, 2009, J CELL BIOL, V187, P615, DOI 10.1083/jcb.200903139; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Ems-McClung SC, 2010, SEMIN CELL DEV BIOL, V21, P276, DOI 10.1016/j.semcdb.2010.01.016; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Goshima G, 2010, ANNU REV CELL DEV BI, V26, P21, DOI 10.1146/annurev-cellbio-100109-104006; Hatzoglou A, 2007, MOL BIOL CELL, V18, P1242, DOI 10.1091/mbc.E06-06-0510; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jang CY, 2008, J CELL BIOL, V181, P255, DOI 10.1083/jcb.200711032; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kunda P, 2009, TRENDS CELL BIOL, V19, P174, DOI 10.1016/j.tcb.2009.01.006; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Leone A, 2001, ONCOGENE, V20, P3217, DOI 10.1038/sj.onc.1204420; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Mazumdar M, 2005, TRENDS CELL BIOL, V15, P349, DOI 10.1016/j.tcb.2005.05.006; Narumiya S, 2006, CURR OPIN CELL BIOL, V18, P199, DOI 10.1016/j.ceb.2006.02.002; Oyama F, 2004, J BIOL CHEM, V279, P27272, DOI 10.1074/jbc.M401634200; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Tikhonenko I, 2009, EUKARYOT CELL, V8, P723, DOI 10.1128/EC.00018-09; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Vassilev LT, 2006, CELL CYCLE, V5, P2555, DOI 10.4161/cc.5.22.3463; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Yokoyama R, 2004, P NATL ACAD SCI USA, V101, P17398, DOI 10.1073/pnas.0406817101; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; Zhu M, 2008, J BIOL CHEM, V283, P18916, DOI 10.1074/jbc.M710591200	39	15	15	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5025	5034		10.1096/fj.12-209460	http://dx.doi.org/10.1096/fj.12-209460			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964304				2022-12-28	WOS:000311838300024
J	Schreiter, A; Gore, C; Labuz, D; Fournie-Zaluski, MC; Roques, BP; Stein, C; Machelska, H				Schreiter, Anja; Gore, Carmen; Labuz, Dominika; Fournie-Zaluski, Marie-Claude; Roques, Bernard P.; Stein, Christoph; Machelska, Halina			Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue	FASEB JOURNAL			English	Article						immune cells; sensory nerves; analgesia	NEUTRAL ENDOPEPTIDASE ENKEPHALINASE; RECEPTORS MEDIATING ANTINOCICEPTION; INFLAMMATORY PAIN; DEGRADING ENZYMES; SYNOVIAL-FLUID; BETA-ENDORPHIN; SPINAL-CORD; RAT-BRAIN; NEUROGENIC INFLAMMATION; CATABOLIZING ENZYMES	Inflammatory pain can be controlled by endogenous opioid peptides. Here we blocked the degradation of opioids in peripheral injured tissue to locally augment this physiological system. In rats with hindpaw inflammation, inhibitors of aminopeptidase N (APN; bestatin) or neutral endopeptidase (NEP; thiorphan), and a dual inhibitor, NH2-CH-Ph-P(O)(OH)CH2-CH-CH2Ph(p-Ph)-CONH-CH-CH3-COOH (P8B), were applied to injured paws. Combined bestatin (1.25-5 mg)/thiorphan (0.2-0.8 mg) or P8B (0.0625-1 mg) alone elevated mechanical nociceptive thresholds to 307 and 227% of vehicle-treated controls, respectively. This analgesia was abolished by antibodies to methionine-enkephalin, leucine-enkephalin, and dynorphin A 1-17, by peripherally restricted and by selective mu-, delta-, and kappa-opioid receptor antagonists. Flow cytometry and photospectrometry revealed expression and metabolic activity of APN and NEP on macrophages, granulocytes, and sciatic nerves from inflamed tissue. Radioimmunoassays showed that inhibition of leukocytic APN and NEP by bestatin (5-500 mu M)/thiorphan (1-100 mu M) combinations or by P8B (1-100 mu M) prevented the degradation of enkephalins. Blockade of neuronal peptidases by bestatin (0.5-10 mM)/thiorphan (0.1-5 mM) or by P8B (0.1-10 mM) additionally hindered dynorphin A 1-17 catabolism. Thus, leukocytes and peripheral nerves are important sources of APN and NEP in inflamed tissue, and their blockade promotes peripheral opioid analgesia.-Schreiter, A., Gore, C., Labuz, D., Fournie-Zaluski, M.-C., Roques, B. P., Stein, C., Machelska, H. Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue. FASEB J. 26, 5161-5171 (2012). www.fasebj.org	[Schreiter, Anja; Gore, Carmen; Labuz, Dominika; Stein, Christoph; Machelska, Halina] Charite, Klin Anesthesiol & Operat Intensivmed, Free Univ Berlin, D-12203 Berlin, Germany; [Fournie-Zaluski, Marie-Claude; Roques, Bernard P.] Pharmaleads SAS, Paris, France; [Roques, Bernard P.] Univ Paris 05, Paris, France	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UDICE-French Research Universities; Universite Paris Cite	Machelska, H (corresponding author), Charite, Klin Anesthesiol & Operat Intensivmed, Free Univ Berlin, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany.	halina.machelska@charite.de		Stein, Christoph/0000-0001-5240-6836; Machelska, Halina/0000-0001-6315-2958	Deutsche Forschungsgemeinschaft [MA 2437/2-1, STE 477/9-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study was supported by Deutsche Forschungsgemeinschaft grants MA 2437/2-1 (H.M.) and STE 477/9-1 (C.S.). The authors declare no conflicts of interest.	Akil H, 1998, DRUG ALCOHOL DEPEN, V51, P127, DOI 10.1016/S0376-8716(98)00071-4; Balog T, 1999, IMMUNOPHARMACOLOGY, V41, P11, DOI 10.1016/S0162-3109(98)00050-2; Balog T, 2001, INT IMMUNOPHARMACOL, V1, P569, DOI 10.1016/S1567-5769(00)00031-X; BARNES K, 1991, NEUROSCIENCE, V44, P245, DOI 10.1016/0306-4522(91)90265-P; BOURGOIN S, 1986, J PHARMACOL EXP THER, V238, P360; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; CADONI A, 1993, J NEUROIMMUNOL, V45, P61, DOI 10.1016/0165-5728(93)90164-T; Catheline G, 1998, EUR J PHARMACOL, V357, P171, DOI 10.1016/S0014-2999(98)00597-4; Chen HX, 2000, J MED CHEM, V43, P1398, DOI 10.1021/jm990483l; Chen HX, 1998, P NATL ACAD SCI USA, V95, P12028, DOI 10.1073/pnas.95.20.12028; Coudore-Civiale MA, 2001, BRIT J PHARMACOL, V133, P179, DOI 10.1038/sj.bjp.0704059; Fischer HS, 2002, J MOL NEUROSCI, V18, P129, DOI 10.1385/JMN:18:1-2:129; FOURNIEZALUSKI MC, 1984, EUR J PHARMACOL, V102, P525, DOI 10.1016/0014-2999(84)90575-2; GRAF L, 1985, NEUROPEPTIDES, V6, P13, DOI 10.1016/0143-4179(85)90126-X; HASSAN AHS, 1992, NEUROSCI LETT, V140, P85, DOI 10.1016/0304-3940(92)90688-4; Heinl C, 2011, J NEUROSCI, V31, P16748, DOI 10.1523/JNEUROSCI.3491-11.2011; HERSH LB, 1985, J NEUROCHEM, V44, P1427, DOI 10.1111/j.1471-4159.1985.tb08779.x; HERSH LB, 1984, J NEUROCHEM, V43, P487, DOI 10.1111/j.1471-4159.1984.tb00925.x; IWAMOTO I, 1991, J LEUKOCYTE BIOL, V49, P116, DOI 10.1002/jlb.49.2.116; Kramer HH, 2009, NEUROBIOL DIS, V35, P177, DOI 10.1016/j.nbd.2008.11.002; Kramer HH, 2005, EXP NEUROL, V195, P179, DOI 10.1016/j.expneurol.2005.04.015; Labuz D, 2006, J NEUROSCI, V26, P4350, DOI 10.1523/JNEUROSCI.4349-05.2006; Le Guen S, 2003, PAIN, V104, P139, DOI 10.1016/S0304-3959(02)00486-4; LEE SH, 1994, EUR J PHARMACOL, V264, P61, DOI 10.1016/0014-2999(94)90636-X; Lendeckel U, 2000, ADV EXP MED BIOL, V477, P1; Likar R, 2007, CLIN J PAIN, V23, P136, DOI 10.1097/01.ajp.0000210954.93878.0d; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; MALDONADO R, 1994, PAIN, V58, P77, DOI 10.1016/0304-3959(94)90186-4; MATUCCICERINIC M, 1993, RHEUMATOL INT, V13, P1, DOI 10.1007/BF00290326; Mentlein R, 1996, PEPTIDES, V17, P709, DOI 10.1016/0196-9781(96)00066-6; Meynadier J., 1988, PAIN CLINIC, V2, P201; MILLER BC, 1994, REGUL PEPTIDES, V50, P87, DOI 10.1016/0167-0115(94)90194-5; Noble F, 2001, NEUROSCIENCE, V105, P479, DOI 10.1016/S0306-4522(01)00185-3; NOBLE F, 1992, J PHARMACOL EXP THER, V261, P181; Noble F, 2008, PSYCHOPHARMACOLOGY, V196, P327, DOI 10.1007/s00213-007-0964-z; Noble F, 2007, EXPERT OPIN THER TAR, V11, P145, DOI 10.1517/14728222.11.2.145; PARSONS CG, 1990, J PHARMACOL EXP THER, V255, P795; RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001; RIEMANN D, 1993, IMMUNOBIOLOGY, V187, P24, DOI 10.1016/S0171-2985(11)80243-3; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Roques BP, 2012, NAT REV DRUG DISCOV, V11, P292, DOI 10.1038/nrd3673; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; Rougeot C, 2003, P NATL ACAD SCI USA, V100, P8549, DOI 10.1073/pnas.1431850100; SAFAVI A, 1995, J NEUROCHEM, V65, P389; Saria A, 1997, NEUROSCI LETT, V234, P27, DOI 10.1016/S0304-3940(97)00660-5; Simonini G, 2005, RHEUMATOL INT, V25, P336, DOI 10.1007/s00296-004-0447-z; Song BB, 2003, J NEUROSCI, V23, P1847; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1988, PHARMACOL BIOCHEM BE, V31, P445, DOI 10.1016/0091-3057(88)90372-3; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; Stein C, 2011, PHARMACOL REV, V63, P860, DOI 10.1124/pr.110.003145; Thibault K, 2008, EUR J PHARMACOL, V600, P71, DOI 10.1016/j.ejphar.2008.10.004; Thiele DL, 1998, ADV EXP MED BIOL, V437, P291; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; van Rijn RM, 2010, CURR OPIN PHARMACOL, V10, P73, DOI 10.1016/j.coph.2009.09.007; VANVELDHOVEN P, 1982, FEBS LETT, V138, P76, DOI 10.1016/0014-5793(82)80398-0; WAKSMAN G, 1986, P NATL ACAD SCI USA, V83, P1523, DOI 10.1073/pnas.83.5.1523; Woodcock J, 2009, NEW ENGL J MED, V361, P2105, DOI 10.1056/NEJMp0908913; YAKSH TL, 1991, J PHARMACOL EXP THER, V256, P1033; Zollner C, 2008, J CLIN INVEST, V118, P1065, DOI 10.1172/JCI25911	62	55	55	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5161	5171		10.1096/fj.12-208678	http://dx.doi.org/10.1096/fj.12-208678			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22923332				2022-12-28	WOS:000311838300036
J	Hayashi, T; Morishita, Y; Khattree, R; Misumi, M; Sasaki, K; Hayashi, I; Yoshida, K; Kajimura, J; Kyoizumi, S; Imai, K; Kusunoki, Y; Nakachi, K				Hayashi, Tomonori; Morishita, Yukari; Khattree, Ravindra; Misumi, Munechika; Sasaki, Keiko; Hayashi, Ikue; Yoshida, Kengo; Kajimura, Junko; Kyoizumi, Seishi; Imai, Kazue; Kusunoki, Yoichiro; Nakachi, Kei			Evaluation of systemic markers of inflammation in atomic-bomb survivors with special reference to radiation and age effects	FASEB JOURNAL			English	Article						reactive oxygen species; cytokines; immunosenescence	NF-KAPPA-B; C-REACTIVE PROTEIN; OXIDATIVE STRESS; CELL-DEATH; T-CELLS; CANCER; INTERLEUKIN-6; MORTALITY; OXYGEN; DYSFUNCTION	Past exposure to atomic bomb (A-bomb) radiation has exerted various long-lasting deleterious effects on the health of survivors. Some of these effects are seen even after >60 yr. In this study, we evaluated the subclinical inflammatory status of 442 A-bomb survivors, in terms of 8 inflammation-related cytokines or markers, comprised of plasma levels of reactive oxygen species (ROS), interleukin (IL)-6, tumor necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), IL-4, IL-10, and immunoglobulins, and erythrocyte sedimentation rate (ESR). The effects of past radiation exposure and natural aging on these markers were individually assessed and compared. Next, to assess the biologically significant relationship between inflammation and radiation exposure or aging, which was masked by the interrelationship of those cytokines/markers, we used multivariate statistical analyses and evaluated the systemic markers of inflammation as scores being calculated by linear combinations of selected cytokines and markers. Our results indicate that a linear combination of ROS, IL-6, CRP, and ESR generated a score that was the most indicative of inflammation and revealed clear dependences on radiation dose and aging that were found to be statistically significant. The results suggest that collectively, radiation exposure, in conjunction with natural aging, may enhance the persistent inflammatory status of A-bomb survivors.-Hayashi, T., Morishita, Y., Khattree, R., Misumi, M., Sasaki, K., Hayashi, I., Yoshida, K., Kajimura, J., Kyoizumi, S., Imai, K., Kusunoki, Y., Nakachi, K. Evaluation of systemic markers of inflammation in atomic-bomb survivors with special reference to radiation and age effects. FASEB J. 26, 4765-4773 (2012). www.fasebj.org	[Hayashi, Tomonori; Morishita, Yukari; Sasaki, Keiko; Yoshida, Kengo; Kajimura, Junko; Kyoizumi, Seishi; Imai, Kazue; Kusunoki, Yoichiro; Nakachi, Kei] Radiat Effects Res Fdn, Dept Radiobiol Mol Epidemiol, Hiroshima 7320815, Japan; [Khattree, Ravindra] Radiat Effects Res Fdn, Dept Stat, Hiroshima 7320815, Japan; [Misumi, Munechika] Oakland Univ, Dept Math & Stat, Rochester, MI 48063 USA; [Hayashi, Ikue] Hiroshima Univ, Cent Res Lab, Fac Dent, Hiroshima, Japan	Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Oakland University; Hiroshima University	Hayashi, T (corresponding author), Radiat Effects Res Fdn, Dept Radiobiol Mol Epidemiol, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.	tomo@rerf.or.jp		Misumi, Munechika/0000-0003-2698-4880	Japanese Ministry of Health, Labor, and Welfare; U.S. Department of Energy (DOE); DOE [DE-HS0000031]; Japanese Ministry of Education, Culture, Sports Science, and Technology; U.S. National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200900059C]	Japanese Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); U.S. Department of Energy (DOE)(United States Department of Energy (DOE)); DOE(United States Department of Energy (DOE)); Japanese Ministry of Education, Culture, Sports Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); U.S. National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Radiation Effects Research Foundation (RERF; Hiroshima and Nagasaki, Japan) is a private, nonprofit foundation funded by the Japanese Ministry of Health, Labor, and Welfare and the U.S. Department of Energy (DOE), the latter in part through DOE award DE-HS0000031 to the National Academy of Sciences. This was based on RERF Research Protocols 1-93, 4-02, and 3-09 and was supported in part by grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports Science, and Technology; the Japanese Ministry of Health, Labor, and Welfare; and the U.S. National Institute of Allergy and Infectious Diseases (NIAID; contract HHSN272200900059C). The views of the authors do not necessarily reflect those of the two governments.	Ballou SP, 1996, AGE AGEING, V25, P224, DOI 10.1093/ageing/25.3.224; Bishop Y. M., 2007, DISCRETE MULTIVARIAT; Bretz WA, 2005, J AM GERIATR SOC, V53, P1532, DOI 10.1111/j.1532-5415.2005.53468.x; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Cesselli D, 2001, CIRC RES, V89, P279, DOI 10.1161/hh1501.094115; Chung J, 2008, BIOTECHNOL LETT, V30, P1553, DOI 10.1007/s10529-008-9744-z; Cubbon RM, 2009, CLIN SCI, V117, P173, DOI 10.1042/CS20080263; Cullings HM, 2006, RADIAT RES, V166, P219, DOI 10.1667/RR3546.1; DINARELLO CA, 1991, BLOOD, V77, P1627; Dobbs RJ, 1999, ACTA NEUROL SCAND, V100, P34, DOI 10.1111/j.1600-0404.1999.tb00721.x; Douple EB, 2011, DISASTER MED PUBLIC, V5, pS122, DOI 10.1001/dmp.2011.21; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Ferrari R, 2004, CURR PHARM DESIGN, V10, P1699, DOI 10.2174/1381612043384718; FEY GH, 1991, BIOCHIMIE, V73, P47, DOI 10.1016/0300-9084(91)90073-A; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hayashi I, 2007, MUTAT RES-GEN TOX EN, V631, P55, DOI 10.1016/j.mrgentox.2007.04.006; Hayashi T, 2005, AM J MED, V118, P83, DOI 10.1016/j.amjmed.2004.06.045; Hayashi T, 2003, INT J RADIAT BIOL, V79, P129, DOI 10.1080/0955300021000038662; Kanayama A, 2007, J LEUKOCYTE BIOL, V82, P1344, DOI 10.1189/jlb.0407259; Khattree R., 2000, MULTIVARIATE DATA RE; Khattree R, 1999, APPL MULTIVARIATE ST; KODAMA K, 1990, JPN CIRC J, V54, P414, DOI 10.1253/jcj.54.414; Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009; Kusunoki Y, 1999, RADIAT RES, V152, P539, DOI 10.2307/3580151; Kusunoki Y, 1998, RADIAT RES, V150, P227, DOI 10.2307/3579858; Kusunoki Y, 2002, RADIAT RES, V158, P715, DOI 10.1667/0033-7587(2002)158[0715:TCOABS]2.0.CO;2; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004; LU ZY, 1995, BLOOD, V86, P3123; Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003; Mantovani G, 2002, INT J CANCER, V98, P84, DOI 10.1002/ijc.10143; Neriishi K, 2001, INT J RADIAT BIOL, V77, P475, DOI 10.1080/09553000010024911; Ozasa K, 2012, RADIAT RES, V177, P229, DOI 10.1667/RR2629.1; Pannen B H, 1995, New Horiz, V3, P183; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Papadaki HA, 2001, INT J HEMATOL, V73, P339, DOI 10.1007/BF02981959; Pedersen BK, 2003, SCAND J MED SCI SPOR, V13, P56, DOI 10.1034/j.1600-0838.2003.20218.x; Peters T, 2009, MECH AGEING DEV, V130, P564, DOI 10.1016/j.mad.2009.07.003; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X; Roxburgh CSD, 2010, FUTURE ONCOL, V6, P149, DOI 10.2217/FON.09.136; Sharp GB, 2003, INT J CANCER, V103, P531, DOI 10.1002/ijc.10862; Solana R, 2000, VACCINE, V18, P1613, DOI 10.1016/S0264-410X(99)00495-8; Sone H, 2010, REDOX REP, V15, P98, DOI 10.1179/174329210X12650506623843; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Ungvari Z, 2004, HERZ, V29, P733, DOI 10.1007/s00059-004-2625-x; VanderMeide PH, 1996, BIOTHERAPY, V8, P243, DOI 10.1007/BF01877210; Willcox JK, 2004, CRIT REV FOOD SCI, V44, P275, DOI 10.1080/10408690490468489; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003	57	30	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4765	4773		10.1096/fj.12-215228	http://dx.doi.org/10.1096/fj.12-215228			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872680	Green Published			2022-12-28	WOS:000310574200036
J	Koziol, A; Gonzalo, P; Mota, A; Pollan, A; Lorenzo, C; Colome, N; Montaner, D; Dopazo, J; Arribas, J; Canals, F; Arroyo, AG				Koziol, Agnieszka; Gonzalo, Pilar; Mota, Alba; Pollan, Angela; Lorenzo, Cristina; Colome, Nuria; Montaner, David; Dopazo, Joaquin; Arribas, Joaquin; Canals, Francesc; Arroyo, Alicia G.			The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; degradome; inflammation; SILAC	TYPE-1 MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; MEMBRANE; ANGIOGENESIS; PROTEOMICS; PHARMACOPROTEOMICS; IDENTIFICATION; EXPRESSION; INHIBITOR; RELEASE	The mechanism by which proteolytic events translate into biological responses is not well understood. To explore the link of pericellular proteolysis to events relevant to capillary sprouting within the inflammatory context, we aimed at the identification of the collection of substrates of the protease MT1-MMP in endothelial tip cells induced by inflammatory stimuli. We applied quantitative proteomics to endothelial cells (ECs) derived from wild-type and MT1-MMP-null mice to identify the substrate repertoire of this protease in TNF-alpha-activated ECs. Bioinformatics analysis revealed a combinatorial MT1-MMP proteolytic program, in which combined rather than single substrate processing would determine biological decisions by activated ECs, including chemotaxis, cell motility and adhesion, and vasculature development. MT1-MMP-deficient ECs inefficiently processed several of these substrates (TSP1, CYR61, NID1, and SEM3C), validating the model. This novel concept of MT1-MMP-driven combinatorial proteolysis in angiogenesis might be extendable to proteo-lytic actions in other cellular contexts.-Koziol, A., Gonzalo, P., Mota, A., Pollon, A., Lorenzo, C., Colome, N., Montaner, D., Dopazo, J., Arribas, J., Canals, F., Arroyo, A. G. The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 26, 4481-4494 (2012). www.fasebj.org	[Arroyo, Alicia G.] CNIC, Matrix Metalloproteinases Lab, Vasc Biol Dept, Madrid 28029, Spain; [Colome, Nuria; Arribas, Joaquin; Canals, Francesc] Vall dHebron Univ Hosp Res Inst, Vall dHebron Inst Oncol, Prote Lab, Barcelona, Spain; [Colome, Nuria; Arribas, Joaquin; Canals, Francesc] Vall dHebron Univ Hosp Res Inst, Vall dHebron Inst Oncol, Med Oncol Res Program, Barcelona, Spain; [Montaner, David; Dopazo, Joaquin] Ctr Invest Principe Felipe, Bioinformat Dept, Valencia, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut d'Oncologia (VHIO); Prince Felipe Research Center	Arroyo, AG (corresponding author), CNIC, Matrix Metalloproteinases Lab, Vasc Biol Dept, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	agarroyo@cnic.es	Arroyo, Alicia G./L-2796-2014; Dopazo, Joaquin/A-9270-2014; Arroyo, Alicia G/M-2507-2018; Arribas, Joaquin/M-4482-2014; Jimenez, Alba Mota/M-5710-2014; Montaner, David/A-9362-2014	Arroyo, Alicia G./0000-0002-1536-3846; Dopazo, Joaquin/0000-0003-3318-120X; Arroyo, Alicia G/0000-0002-1536-3846; Arribas, Joaquin/0000-0002-0504-0664; Jimenez, Alba Mota/0000-0001-9148-3965; Gonzalo, Pilar/0000-0001-8811-8369; Montaner, David/0000-0002-2484-3278	Spanish Ministry of Economy and Competitivity (MINECO) [SAF2008-02104, SAF2011-25619, RD06/0014/1016]; Fundacion Genoma Espana; Formacion de Profesorado Universitario; Fondo de Investigacion Sanitaria contract from the former Ministry of Science and Innovation (MICINN); Instituto Nacional de Bioinformatica (MICINN); MINECO; Pro-CNIC Foundation	Spanish Ministry of Economy and Competitivity (MINECO)(Spanish Government); Fundacion Genoma Espana; Formacion de Profesorado Universitario(Spanish Government); Fondo de Investigacion Sanitaria contract from the former Ministry of Science and Innovation (MICINN); Instituto Nacional de Bioinformatica (MICINN)(Ministry of Science and Innovation, Spain (MICINN)); MINECO(Spanish Government); Pro-CNIC Foundation	The authors thank Suneel S. Apte (Lerner Research Institute, Cleveland, OH, USA) and Karl Tryggvason (Karolinska Institute, Stockholm, Sweden) for MT1-MMP-null mice, R. Alvarez and A. Dopazo for microarray analysis, A. Luque for help in EC immortalization, J. Vazquez for critical reading of the manuscript, and S. Bartlett for English editing. This work was supported by grants from the Spanish Ministry of Economy and Competitivity (MINECO; SAF2008-02104, SAF2011-25619 and RD06/0014/1016) and the Fundacion Genoma Espana to A. G. A. A. K. is funded by a Formacion de Profesorado Universitario fellowship and P. G. by a Fondo de Investigacion Sanitaria contract from the former Ministry of Science and Innovation (MICINN). The Vall d'Hebron Institute of Oncology Proteomics Laboratory is a member of the ProteoRed-Instituto de Salud Carlos III network (MICINN). Work at the Centro de Investigacion Principe Felipe was partly supported by the Instituto Nacional de Bioinformatica (MICINN). The CNIC is supported by the MINECO and the Pro-CNIC Foundation. A. K. and P. G. designed and performed research, data analysis and interpretation, and contributed to the manuscript; A. M., A. P., C. L., and N. C. performed specific assays; D. M. and J. D. helped with bioinformatics analysis; J. A. and F. C. provided conceptual and technical support in proteomics analysis; and A. G. A. designed and supervised research and wrote the paper. Data presented are under patent application review.	Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Arroyo AG, 2010, CARDIOVASC RES, V86, P226, DOI 10.1093/cvr/cvq049; Basile JR, 2007, J BIOL CHEM, V282, P6899, DOI 10.1074/jbc.M609570200; Beck M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.82; Butler GS, 2007, CURR PHARM DESIGN, V13, P263, DOI 10.2174/138161207779313524; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Conn EM, 2008, J BIOL CHEM, V283, P26518, DOI 10.1074/jbc.M803337200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; De Smet F, 2009, ARTERIOSCL THROM VAS, V29, P639, DOI 10.1161/ATVBAHA.109.185165; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Doucet A, 2008, MOL CELL PROTEOMICS, V7, P1925, DOI 10.1074/mcp.R800012-MCP200; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Esselens C, 2010, J BIOL CHEM, V285, P2463, DOI 10.1074/jbc.M109.055129; Galvez BG, 2005, J BIOL CHEM, V280, P1292, DOI 10.1074/jbc.M408673200; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Hasan A, 2011, J BIOL CHEM, V286, P9542, DOI 10.1074/jbc.M110.198689; Hawinkels L. J., 2010, CANCER RES, V70, P4141; Ho MSP, 2008, MICROSC RES TECHNIQ, V71, P387, DOI 10.1002/jemt.20567; Huang DW, 2008, BIOINFORMATION, V2, P428; Hwang IK, 2004, BBA-PROTEINS PROTEOM, V1702, P79, DOI 10.1016/j.bbapap.2004.08.001; Iruela-Arispe ML, 2004, INT J BIOCHEM CELL B, V36, P1070, DOI 10.1016/j.biocel.2004.01.025; Karagiannis ED, 2006, J THEOR BIOL, V238, P124, DOI 10.1016/j.jtbi.2005.05.020; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Kubota Satoshi, 2007, Angiogenesis, V10, P1, DOI 10.1007/s10456-006-9058-5; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Ligresti G, 2011, ARTERIOSCL THROM VAS, V31, P1151, DOI 10.1161/ATVBAHA.111.223917; Medina I, 2010, NUCLEIC ACIDS RES, V38, pW210, DOI 10.1093/nar/gkq388; Oblander SA, 2005, DEV BIOL, V277, P255, DOI 10.1016/j.ydbio.2004.09.033; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597; Strasser GA, 2010, BLOOD, V115, P5102, DOI 10.1182/blood-2009-07-230284; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Yana I, 2007, J CELL SCI, V120, P1607, DOI 10.1242/jcs.000679; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	37	22	26	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4481	4494		10.1096/fj.12-205906	http://dx.doi.org/10.1096/fj.12-205906			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859368				2022-12-28	WOS:000310574200011
J	Camargo, N; Brouwers, JF; Loos, M; Gutmann, DH; Smit, AB; Verheijen, MHG				Camargo, Nutabi; Brouwers, Jos F.; Loos, Maarten; Gutmann, David H.; Smit, August B.; Verheijen, Mark H. G.			High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism	FASEB JOURNAL			English	Article						brain; glia; Huntington; SREBP; dyskinesia	ELEMENT-BINDING PROTEIN-1; CHOLESTEROL-METABOLISM; BRAIN; NEURONS; ACIDS; CELLS; MICE; INCREASES; INTEGRITY; GENETICS	The mammalian CNS is considered to be autonomous in lipid metabolism. Glial cells, in particular astrocytes, have been shown to be highly active in lipid synthesis and secretion. To determine the importance of astrocytes as lipid providers in the brain, we generated mice in which the sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) was deleted from astrocytes using cre/lox technology. SCAP mutant mice showed microcephaly, without effects on astrocyte survival. SCAP deletion in astrocytes led to a loss of cholesterol and fatty acid synthesis pathways. SCAP mutants showed progressive motor deficits, dyskinesia, and reduced anxiety. Interestingly, SCAP mutants showed changes in brain sterol and fatty acid profiles that were concordant with reduced lipid synthesis as well as with increased uptake of dietary lipids. Accordingly, a high-fat diet rich in cholesterol and monounsaturated fatty acids, but not a fish oil diet rich in polyunsaturated fatty acids, improved motor deficits and survival of the mutant mice. These observations establish a critical role for astrocytes in brain lipid metabolism and demonstrate that dietary lipids can rescue astrocyte-mediated lipid deficiency. The ability to correct these neurological deficits suggests that lipid supplementation may serve as a treatment for brain disorders associated with defective astrocyte lipid synthesis.-Camargo, N., Brouwers, J. F., Loos, M., Gutmann, D. H., Smit, A. B., Verheijen, M. H. G. High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J. 26, 4302-4315 (2012). www.fasebj.org	[Camargo, Nutabi; Loos, Maarten; Smit, August B.; Verheijen, Mark H. G.] Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Ctr Neurogen & Cognit Res, NL-1081 HV Amsterdam, Netherlands; [Brouwers, Jos F.] Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, Utrecht, Netherlands; [Gutmann, David H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Vrije Universiteit Amsterdam; Utrecht University; Washington University (WUSTL)	Verheijen, MHG (corresponding author), Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Ctr Neurogen & Cognit Res, De Boelelaan,Neurosci Campus Amsterdam, NL-1081 HV Amsterdam, Netherlands.	mark.verheijen@vu.nl	Verheijen, Mark/GQY-5157-2022; Verheijen, Mark/AAD-8112-2019; Brouwers, Jos F/AAH-1444-2019; Loos, Maarten/A-2768-2012	Verheijen, Mark/0000-0002-3739-3755; Brouwers, Jos F/0000-0003-2924-3279; Loos, Maarten/0000-0003-1629-2928; Gutmann, David/0000-0002-3127-5045	Marie Curie Foundation Host Fellowship [EST-2005-020919]; Center for Medical Systems Biology	Marie Curie Foundation Host Fellowship(European Commission); Center for Medical Systems Biology	The authors thank A. Goudriaan for contributions to SREBP2 antibody generation and Western blotting, R. Vrooman and G. Stam for contributions to pilot experiments, H. Shimano (Vrije Universiteit, Amsterdam, The Netherlands) for kindly providing SREBP antibodies, and T. Rhys and M. Tijssen for expert advice on motor deficits. This work was supported by Marie Curie Foundation Host Fellowship EST-2005-020919 (to N.C.) and by the Center for Medical Systems Biology (to A.B.S.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bazan NG, 2003, J LIPID RES, V44, P2221, DOI 10.1194/jlr.R300013-JLR200; Bjorkhem I, 2010, J LIPID RES, V51, P2489, DOI 10.1194/jlr.R006338; Blakeley J, 2002, ADV NEUROL, V89, P401; Bottelbergs A, 2010, GLIA, V58, P1532, DOI 10.1002/glia.21027; Camargo N, 2009, FEBS J, V276, P628, DOI 10.1111/j.1742-4658.2008.06808.x; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chrast R, 2011, J LIPID RES, V52, P419, DOI 10.1194/jlr.R009761; Devanagondi R, 2007, NEUROBIOL DIS, V27, P249, DOI 10.1016/j.nbd.2007.05.001; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Dorst J, 2011, J NEUROL, V258, P613, DOI 10.1007/s00415-010-5805-z; Dulawa SC, 2005, NEUROSCI BIOBEHAV R, V29, P771, DOI 10.1016/j.neubiorev.2005.03.017; Dupuis L, 2004, P NATL ACAD SCI USA, V101, P11159, DOI 10.1073/pnas.0402026101; Edmond J, 2001, J MOL NEUROSCI, V16, P181, DOI 10.1385/JMN:16:2-3:181; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Funfschilling U, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-1; GREEN P, 1993, J LIPID RES, V34, P2099; Harvey RJ, 2008, TRENDS GENET, V24, P439, DOI 10.1016/j.tig.2008.06.005; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Karasinska JM, 2011, NAT REV NEUROL, V7, P561, DOI 10.1038/nrneurol.2011.132; Karasinska JM, 2009, J NEUROSCI, V29, P3579, DOI 10.1523/JNEUROSCI.4741-08.2009; Komine O, 2007, DEV BIOL, V311, P238, DOI 10.1016/j.ydbio.2007.08.042; Loos M, 2009, GENES BRAIN BEHAV, V8, P817, DOI 10.1111/j.1601-183X.2009.00528.x; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Mitchell RW, 2009, J NEUROCHEM, V110, P1049, DOI 10.1111/j.1471-4159.2009.06199.x; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Moore SA, 2001, J MOL NEUROSCI, V16, P195, DOI 10.1385/JMN:16:2-3:195; Mutka AL, 2010, CURR OPIN LIPIDOL, V21, P93, DOI 10.1097/MOL.0b013e32833538b7; Nguyen HP, 2006, HUM MOL GENET, V15, P3177, DOI 10.1093/hmg/ddl394; Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002; Porter FD, 2000, MOL GENET METAB, V71, P163, DOI 10.1006/mgme.2000.3069; Rapoport SI, 2007, PROSTAG LEUKOTR ESS, V77, P251, DOI 10.1016/j.plefa.2007.10.023; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Saito K, 2009, P NATL ACAD SCI USA, V106, P8350, DOI 10.1073/pnas.0903541106; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Spencer BJ, 2007, P NATL ACAD SCI USA, V104, P7594, DOI 10.1073/pnas.0702170104; Sprecher H, 2001, J MOL NEUROSCI, V16, P215; Sudarov A, 2007, NEURAL DEV, V2, DOI 10.1186/1749-8104-2-26; Tabernero A, 2002, J BIOL CHEM, V277, P4240, DOI 10.1074/jbc.M108760200; Tabernero A, 2001, J NEUROCHEM, V79, P606, DOI 10.1046/j.1471-4159.2001.00598.x; Valenza M, 2005, J NEUROSCI, V25, P9932, DOI 10.1523/JNEUROSCI.3355-05.2005; Valenza M., 2011, J NEUROSCI, V30, P10844; van Rootselaar Anne-Fleur, 2009, Pract Neurol, V9, P102, DOI 10.1136/jnnp.2009.172213; Van Veldhoven PP, 2010, J LIPID RES, V51, P2863, DOI 10.1194/jlr.R005959; Verheijen MHG, 2009, P NATL ACAD SCI USA, V106, P21383, DOI 10.1073/pnas.0905633106; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	50	51	51	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4302	4315		10.1096/fj.12-205807	http://dx.doi.org/10.1096/fj.12-205807			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751013				2022-12-28	WOS:000309704000035
J	Fadri-Moskwik, M; Weiderhold, KN; Deeraksa, A; Chuang, C; Pan, J; Lin, SH; Yu-Lee, LY				Fadri-Moskwik, Maria; Weiderhold, Kimberly N.; Deeraksa, Arpaporn; Chuang, Carol; Pan, Jing; Lin, Sue-Hwa; Yu-Lee, Li-Yuan			Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells	FASEB JOURNAL			English	Article						HDAC3; mitotic spindle; kinetochore-microtubule attachment; post-translational modification	CHROMOSOMAL PASSENGER COMPLEX; HISTONE DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITOR; MITOTIC SPINDLE; LYSINE ACETYLATION; PROTEIN COMPLEXES; KINASE-ACTIVITY; KINETOCHORE; PHOSPHORYLATION; MICROTUBULES	Protein acetylation has been implicated in playing an important role during mitotic progression. Aurora B kinase is known to play a critical role in mitosis. However, whether Aurora B is regulated by acetylation is not known. Using IP with an anti-acetyl lysine antibody, we identified Aurora B as an acetylated protein in PC3 prostate cancer cells. Knockdown of HDAC3 or inhibiting HDAC3 deacetylase activity led to a significant increase (P < 0.01 and P < 0.05, respectively) in Aurora B acetylation as compared to siLuc or vehicle-treated controls. Increased Aurora B acetylation is correlated with a 30% reduction in Aurora B kinase activity in vitro and resulted in significant defects in Aurora B-dependent mitotic processes, including kinetochore-microtubule attachment and chromosome congression. Furthermore, Aurora B transiently interacts with HDAC3 at the kinetochore-microtubule interface of congressing chromosomes during prometaphase. This window of interaction corresponded with a transient but significant reduction (P=0.02) in Aurora B acetylation during early mitosis. Together, these results indicate that Aurora B is more active in its deacetylated state and further suggest a new mechanism by which dynamic acetylation/deacetylation acts as a rheostat to fine-tune Aurora B activity during mitotic progression.-Fadri-Moskwik, M., Weiderhold, K. N., Deeraksa, A., Chuang, C., Pan, J., Lin, S.-H., Yu-Lee, L.-Y. Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J. 26, 4057-4067 (2012). www.fasebj.org	[Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, IAR Sect, Houston, TX 77030 USA; [Weiderhold, Kimberly N.; Yu-Lee, Li-Yuan] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; [Chuang, Carol; Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Yu-Lee, LY (corresponding author), Baylor Coll Med, Dept Med, IAR Sect, 1 Baylor Plaza, Houston, TX 77030 USA.	yulee@bcm.edu			U.S. National Institutes of Health (NIH) [IRACDA K12-GM084897, NRSA F31-GM084695]; NIH [T32-AI07495, T32-DK07696, CA111479, DK53176, AI071130]; U.S. Department of Defense [PC080847, PC093132]; Dan L. Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE [R01CA111479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007495, U19AI071130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696, R01DK053176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM084695, K12GM084897] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense(United States Department of Defense); Dan L. Duncan Cancer Center; Alkek Award in Experimental Therapeutics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health (NIH) fellowships (IRACDA K12-GM084897 to M.F.-M.; NRSA F31-GM084695 to K.N.W.); NIH training grants (T32-AI07495 to M.F.-M and A.D.; T32-DK07696 to A.D. and C.C.); grants from the NIH (CA111479 to S.-H.L.; DK53176, AI071130 to L.-Y.Y.-L.), the U.S. Department of Defense (PC080847, PC093132 to S.-H.L.), and the Dan L. Duncan Cancer Center (L.-Y.Y.-L. and S.-H.L.); and an Alkek Award in Experimental Therapeutics (L.-Y.Y.-L. and S.-H.L.).	Alexander J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001796; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; BRINKLEY BR, 1975, ANN NY ACAD SCI, V253, P428, DOI 10.1111/j.1749-6632.1975.tb19218.x; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chuang C., 2012, METHODS MOL IN PRESS; Chuang C, 2010, J PROTEOME RES, V9, P4554, DOI 10.1021/pr100281h; Cimini D, 2003, J CELL SCI, V116, P4213, DOI 10.1242/jcs.00716; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Dowling M, 2005, CANCER BIOL THER, V4, P197, DOI 10.4161/cbt.4.2.1441; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Fernandez-Miranda G, 2010, J CELL SCI, V123, P2823, DOI 10.1242/jcs.065565; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Hutchins JRA, 2010, SCIENCE, V328, P593, DOI 10.1126/science.1181348; Ishii S, 2008, P NATL ACAD SCI USA, V105, P4179, DOI 10.1073/pnas.0710140105; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kim GW, 2011, TRENDS BIOCHEM SCI, V36, P211, DOI 10.1016/j.tibs.2010.10.001; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Klein UR, 2009, MOL BIOL CELL, V20, P410, DOI 10.1091/mbc.E08-05-0511; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; Kurasawa Y, 2010, MOL BIOL CELL, V21, P1188, DOI 10.1091/mbc.E09-11-0950; Lampson MA, 2011, TRENDS CELL BIOL, V21, P133, DOI 10.1016/j.tcb.2010.10.007; Le Breton M, 2005, BIOCHIMIE, V87, P805, DOI 10.1016/j.biochi.2005.04.014; Li Y, 2006, GENE DEV, V20, P2566, DOI 10.1101/gad.1455006; Ma Y, 2008, CELL MOL LIFE SCI, V65, P3100, DOI 10.1007/s00018-008-8237-5; Maerki S, 2009, J CELL BIOL, V187, P791, DOI 10.1083/jcb.200906117; Magnaghi-Jaulin L, 2007, CANCER RES, V67, P6360, DOI 10.1158/0008-5472.CAN-06-3012; Malik R, 2009, J PROTEOME RES, V8, P4553, DOI 10.1021/pr9003773; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Merbl Y, 2009, P NATL ACAD SCI USA, V106, P2543, DOI 10.1073/pnas.0812892106; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Muller S, 2010, CURR CANCER DRUG TAR, V10, P210, DOI 10.2174/156800910791054149; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Nezi L., 2009, CURR OPIN CELL BIOL, V21, P1; Nishino M, 2006, CURR BIOL, V16, P1414, DOI 10.1016/j.cub.2006.05.052; Robbins AR, 2005, CELL CYCLE, V4, P717, DOI 10.4161/cc.4.5.1690; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; Slattery SD, 2008, CELL CYCLE, V7, P787, DOI 10.4161/cc.7.6.5563; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Tan L, 2011, P NATL ACAD SCI USA, V108, P16675, DOI 10.1073/pnas.1106748108; Tanenbaum ME, 2011, CHROMOSOMA, V120, P599, DOI 10.1007/s00412-011-0334-9; Tseng BS, 2010, DEV CELL, V18, P903, DOI 10.1016/j.devcel.2010.05.018; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang EX, 2011, J CELL BIOL, V194, P538, DOI 10.1083/jcb.201103044; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Warrener R, 2010, MOL PHARMACOL, V78, P384, DOI 10.1124/mol.109.062976; Wheatley SP, 2007, CELL CYCLE, V6, P1220, DOI 10.4161/cc.6.10.4179; Xu ZJ, 2009, J CELL BIOL, V187, P637, DOI 10.1083/jcb.200906053; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	67	25	25	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4057	4067		10.1096/fj.12-206656	http://dx.doi.org/10.1096/fj.12-206656			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751009	Green Published			2022-12-28	WOS:000309704000013
J	Perez-Aso, M; Chiriboga, L; Cronstein, BN				Perez-Aso, Miguel; Chiriboga, Luis; Cronstein, Bruce N.			Pharmacological blockade of adenosine A(2A) receptors diminishes scarring	FASEB JOURNAL			English	Article						ZM241385; collagen; splinted wounds	ENDOTHELIAL GROWTH-FACTOR; DERMAL FIBROSIS; MYOFIBROBLAST DIFFERENTIATION; MURINE MODEL; FACTOR-BETA; EXPRESSION; COLLAGEN; ANGIOGENESIS; AGONISTS; PLASMINOGEN	Adenosine A2A receptor (A(2A)R) stimulation promotes wound healing and is required for the development of fibrosis in murine models of scleroderma and cirrhosis. Nonetheless, the role of A2AR in the formation of scars following skin trauma has not been explored. Here, we examined the effect of pharmacological blockade of A2AR, with the selective adenosine A(2A)R-antagonist ZM241385 (2.5 mg/ml), in a murine model of scarring that mimics human scarring. We found that application of the selective adenosine A(2A)R antagonist ZM241385 decreased scar size and enhanced the tensile strength of the scar. Within the scar itself, collagen alignment and composition (marked reduction in collagen 3), but not periostin, biglycan, or fibronectin accumulation, was improved by application of ZM241385. Moreover, A(2A)R blockade reduced the number of myofibroblasts and angiogenesis but not macrophage infiltration in the scar. Taken together, our work strongly suggests that pharmacological A(2A)R blockade can be used to diminish scarring while improving the collagen composition and tensile strength of the healed wound.-Perez-Aso, M., Chiriboga, L., Cronstein, B. N. Pharmacological blockade of adenosine A(2A) receptors diminishes scarring. FASEB J. 26, 4254-4263 (2012). www.fasebj.org	[Perez-Aso, Miguel; Cronstein, Bruce N.] NYU, Sch Med, Dept Med, Div Translat Med, New York, NY 10016 USA; [Chiriboga, Luis] NYU, Sch Med, Expt Pathol Core Lab, New York, NY 10016 USA	New York University; New York University	Cronstein, BN (corresponding author), NYU, Sch Med, Dept Med, Div Translat Med, 550 1st Ave,MSB255, New York, NY 10016 USA.	bruce.cronstein@nyumc.org	Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383; Chiriboga, Luis/0000-0002-2028-6873	U.S. National Institutes of Health [AR56672, AR56672S1, AR54897]; NYU-Health and Hospitals Corp. Clinical and Translational Science Institute [UL1TR000038]; NYU Cancer Institute Center [5P30CA0016087-33]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054897, R01AR056672, R56AR056672] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU-Health and Hospitals Corp. Clinical and Translational Science Institute; NYU Cancer Institute Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank the Histopathology Core of the New York University (NYU) Langone Medical Center. This work was supported by grants from the U.S. National Institutes of Health (AR56672, AR56672S1, and AR54897) and the NYU-Health and Hospitals Corp. Clinical and Translational Science Institute (UL1TR000038), and by the NYU Cancer Institute Center support grant (U.S. National Cancer Institute grant 5P30CA0016087-33). B.N.C. holds patents on use of A<INF>2A</INF>R agonists to promote wound healing and use of A<INF>2A</INF>R antagonists to inhibit fibrosis, use of adenosine A1 receptor antagonists to treat osteoporosis and other diseases of bone, use of adenosine A1 and A<INF>2B</INF>R antagonists to treat fatty liver, and use of A<INF>2A</INF>R agonists to prevent prosthesis loosening. B.N.C. is a consultant for Bristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, Data and Safety Monitoring Board), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, and Medivector.	Aarabi S, 2007, FASEB J, V21, P3250, DOI 10.1096/fj.07-8218com; Abe K, 2000, NEPHROL DIAL TRANSPL, V15, P529, DOI 10.1093/ndt/15.4.529; Barnes JL, 2011, KIDNEY INT, V79, P944, DOI 10.1038/ki.2010.516; Bellemare J, 2005, J PATHOL, V206, P1, DOI 10.1002/path.1737; Bloch W, 2000, FASEB J, V14, P2373; Cha JS, 2007, CLIN DERMATOL, V25, P73, DOI 10.1016/j.clindermatol.2006.10.002; Chan ESL, 2006, ARTHRITIS RHEUM-US, V54, P2632, DOI 10.1002/art.21974; Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; DAYAN D, 1989, HISTOCHEMISTRY, V93, P27, DOI 10.1007/BF00266843; Desai A, 2005, MOL PHARMACOL, V67, P1406, DOI 10.1124/mol.104.007807; Di Gregorio GB, 2005, DIABETES, V54, P2305, DOI 10.2337/diabetes.54.8.2305; EHRLICH HP, 1994, AM J PATHOL, V145, P105; Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841; Feoktistov Igor, 2009, Handb Exp Pharmacol, P383, DOI 10.1007/978-3-540-89615-9_13; Fernandez P, 2008, AM J PATHOL, V172, P1675, DOI 10.2353/ajpath.2008.070952; Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067-1927.2004.12404.x; GHAHARY A, 1993, J LAB CLIN MED, V122, P465; Gibson SE, 2006, ARCH PATHOL LAB MED, V130, P209; Gira AK, 2004, J AM ACAD DERMATOL, V50, P850, DOI 10.1016/j.jaad.2003.11.061; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; IHARA S, 1990, DEVELOPMENT, V110, P671; JUNQUEIRA LCU, 1979, CELL TISSUE RES, V202, P453, DOI 10.1007/BF00220437; Kiernan J.A., 1999, HISTOLOGICAL HISTOCH, V3rd ed; Kozma EM, 2000, MOL CELL BIOCHEM, V203, P103, DOI 10.1023/A:1007012321333; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; MADDEN JW, 1968, SURGERY, V64, P288; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; MONTES GS, 1980, HISTOCHEMISTRY, V65, P131, DOI 10.1007/BF00493161; Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002-9440(10)63749-2; Montesinos MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002-9440(10)61151-0; Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; PIERCE GF, 1995, ANNU REV MED, V46, P467; Poucher SM, 1996, J PHARM PHARMACOL, V48, P601, DOI 10.1111/j.2042-7158.1996.tb05981.x; POUCHER SM, 1995, BRIT J PHARMACOL, V115, P1096, DOI 10.1111/j.1476-5381.1995.tb15923.x; Rhett JM, 2008, TRENDS BIOTECHNOL, V26, P173, DOI 10.1016/j.tibtech.2007.12.007; Romer J, 1996, NAT MED, V2, P725, DOI 10.1038/nm0796-725a; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Sheridan RL, 2004, J AM COLL SURGEONS, V198, P243, DOI 10.1016/j.jamcollsurg.2003.11.007; Sidgwick GP, 2012, J EUR ACAD DERMATOL, V26, P141, DOI 10.1111/j.1468-3083.2011.04200.x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002-9610(98)00184-6; Tredget EE, 1998, PLAST RECONSTR SURG, V102, P1317, DOI 10.1097/00006534-199810000-00001; Valls MD, 2009, BIOCHEM PHARMACOL, V77, P1117, DOI 10.1016/j.bcp.2008.11.002; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wetterau M, 2011, WOUND REPAIR REGEN, V19, P481, DOI 10.1111/j.1524-475X.2011.00697.x; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; Wilgus TA, 2008, LAB INVEST, V88, P579, DOI 10.1038/labinvest.2008.36; Wu YD, 2004, AM J PHYSIOL-CELL PH, V286, pC905, DOI 10.1152/ajpcell.00200.2003; Yates CC, 2010, AM J PATHOL, V176, P1743, DOI 10.2353/ajpath.2010.090564	57	30	31	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4254	4263		10.1096/fj.12-209627	http://dx.doi.org/10.1096/fj.12-209627			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22767233	Green Published			2022-12-28	WOS:000309704000030
J	Delezie, J; Dumont, S; Dardente, H; Oudart, H; Grechez-Cassiau, A; Klosen, P; Teboul, M; Delaunay, F; Pevet, P; Challet, E				Delezie, Julien; Dumont, Stephanie; Dardente, Hugues; Oudart, Hugues; Grechez-Cassiau, Aline; Klosen, Paul; Teboul, Michele; Delaunay, Franck; Pevet, Paul; Challet, Etienne			The nuclear receptor REV-ERB alpha is required for the daily balance of carbohydrate and lipid metabolism	FASEB JOURNAL			English	Article						circadian; obesity; hyperglycemia; respiratory quotient; lipoprotein lipase	LIPOPROTEIN-LIPASE ACTIVITY; SKELETAL-MUSCLE; CIRCADIAN TRANSCRIPTION; INSULIN-RESISTANCE; GENE-EXPRESSION; PPAR-ALPHA; CLOCK; MICE; COMPONENTS; RHYTHMS	Mutations of clock genes can lead to diabetes and obesity. REV-ERB alpha, a nuclear receptor involved in the circadian clockwork, has been shown to control lipid metabolism. To gain insight into the role of REV-ERB alpha in energy homeostasis in vivo, we explored daily metabolism of carbohydrates and lipids in chow-fed, unfed, or high-fat-fed Rev-erb alpha(-/-) mice and their wild-type littermates. Chow-fed Rev-erb alpha(-/-) mice displayed increased adiposity (2.5-fold) and mild hyperglycemia (similar to 10%) without insulin resistance. Indirect calorimetry indicates that chow-fed Rev-erb alpha(-/-) mice utilize more fatty acids during daytime. A 24-h nonfeeding period in Rev-erb alpha(-/-) animals favors further fatty acid mobilization at the expense of glycogen utilization and gluconeogenesis, without triggering hypoglycemia and hypothermia. High-fat feeding in Rev-erb alpha(-/-) mice amplified metabolic disturbances, including expression of lipogenic factors. Lipoprotein lipase (Lpl) gene, critical in lipid utilization/storage, is triggered in liver at night and constitutively up-regulated (similar to 2-fold) in muscle and adipose tissue of Rev-erb alpha(-/-) mice. We show that CLOCK, up-regulated (2-fold) at night in Rev-erb alpha(-/-) mice, can transactivate Lpl. Thus, overexpression of Lpl facilitates muscle fatty acid utilization and contributes to fat overload. This study demonstrates the importance of clock-driven Lpl expression in energy balance and highlights circadian disruption as a potential cause for the metabolic syndrome.-Delezie, J., Dumont, S., Dardente, H., Oudart, H., Grechez-Cassiau, A., Klosen, P., Teboul, M., Delaunay, F., Pevet, P., Challet, E. The nuclear receptor REV-ERB alpha is required for the daily balance of carbohydrate and lipid metabolism. FASEBJ. 26, 3321-3335 (2012). www.fasebj.org	[Challet, Etienne] Univ Strasbourg, Dept Neurobiol Rhythms, Inst Cellular & Integrat Neurosci, CNRS,UPR3212, F-67084 Strasbourg, France; [Oudart, Hugues] Univ Strasbourg, Dept Ecol Physiol & Ethol, Hubert Curien Multidisciplinary Inst, F-67084 Strasbourg, France; [Dardente, Hugues] Univ Tours, French Inst Horse & Equitat, Nouzilly, France; [Grechez-Cassiau, Aline; Teboul, Michele; Delaunay, Franck] Univ Nice, Valrose Inst Biol, Nice, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Tours; UDICE-French Research Universities; Universite Cote d'Azur	Challet, E (corresponding author), Univ Strasbourg, Dept Neurobiol Rhythms, Inst Cellular & Integrat Neurosci, CNRS,UPR3212, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	challet@inci-cnrs.unistra.fr	DARDENTE, Hugues/ABI-5590-2020; Challet, Etienne/ABF-7553-2020	DARDENTE, Hugues/0000-0001-7209-5940; Challet, Etienne/0000-0001-9416-9496; Delaunay, Franck/0000-0003-4927-1701; Teboul, Michele/0000-0002-3418-4384; Delezie, Julien/0000-0002-1350-8423; Klosen, Paul/0000-0001-9724-5044	French Ministry of National Education and Research; Centre National de la Recherche Scientifique, CNRS; Agence Nationale pour la Recherche Jeunes Chercheurs/Jeunes Chercheuses [ANR-07-JCJC-0111]; University of Nice Sophia-Antipolis; CNRS; European Commission (integrated project CRESCENDO) [LSHM-CT-2005-018652]; University of Strasbourg	French Ministry of National Education and Research; Centre National de la Recherche Scientifique, CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale pour la Recherche Jeunes Chercheurs/Jeunes Chercheuses(French National Research Agency (ANR)); University of Nice Sophia-Antipolis; CNRS(Centre National de la Recherche Scientifique (CNRS)); European Commission (integrated project CRESCENDO); University of Strasbourg	The authors thank Dr. Andre Malan for statistical advice. The authors are grateful to Laurence Huck and Dr. Sophie Reibel-Foisset for animal care and Sophie Brangolo, Marion Grandjean, and Sylviane Gourmelen for helpful technical assistance. The authors are indebted to the Mouse Clinical Institute (MCI; Strasbourg, France) for the clamp study. The authors also thank Prof. Ueli Schibler (University of Geneva, Geneva, Switzerland) for kindly providing the founder Reverb alpha<SUP>+/-</SUP> mice. J.D. is supported by a doctoral fellowship from the French Ministry of National Education and Research, and E.C. is supported by Centre National de la Recherche Scientifique, CNRS), University of Strasbourg, and Agence Nationale pour la Recherche Jeunes Chercheurs/Jeunes Chercheuses (ANR-07-JCJC-0111). A.G.C., M.T., and F.D. are supported by the University of Nice Sophia-Antipolis, CNRS, and the European Commission (integrated project CRESCENDO LSHM-CT-2005-018652).	Andrews JL, 2010, P NATL ACAD SCI USA, V107, P19090, DOI 10.1073/pnas.1014523107; Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006; Bey L, 1998, GENE, V209, P31, DOI 10.1016/S0378-1119(98)00003-1; Crumbley C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017290; Dallmann R, 2010, CHRONOBIOL INT, V27, P1317, DOI 10.3109/07420528.2010.489166; Dardente H, 2009, COMP BIOCHEM PHYS A, V153, P391, DOI 10.1016/j.cbpa.2009.03.016; Delezie J, 2011, ANN NY ACAD SCI, V1243, P30, DOI 10.1111/j.1749-6632.2011.06246.x; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Duez H, 2008, GASTROENTEROLOGY, V135, P689, DOI 10.1053/j.gastro.2008.05.035; Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125; Fergani A, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-26; FERRARO RT, 1993, J CLIN INVEST, V92, P441, DOI 10.1172/JCI116586; Froy O, 2010, ENDOCR REV, V31, P1, DOI 10.1210/er.2009-0014; Gachon F, 2011, P NATL ACAD SCI USA, V108, P4794, DOI 10.1073/pnas.1002862108; Gallou-Kabani C, 2007, OBESITY, V15, P1996, DOI 10.1038/oby.2007.238; Gimble JM, 2009, J APPL PHYSIOL, V107, P1629, DOI 10.1152/japplphysiol.00090.2009; Goldberg IJ, 2009, J LIPID RES, V50, pS86, DOI 10.1194/jlr.R800085-JLR200; Gonzales AM, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-22; Guillaumond F, 2005, J BIOL RHYTHM, V20, P391, DOI 10.1177/0748730405277232; Heikkinen S, 2007, CURR PROTOC MOL BIOL, DOI DOI 10.1002/0471142727.MB29B03S77; Hensley LL, 2003, J BIOL CHEM, V278, P32702, DOI 10.1074/jbc.M304200200; Hughes ME, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000442; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Jensen DR, 2008, J LIPID RES, V49, P870, DOI 10.1194/jlr.M700519-JLR200; Kalsbeek A, 2010, TRENDS ENDOCRIN MET, V21, P402, DOI 10.1016/j.tem.2010.02.005; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Kohsaka A, 2007, CELL METAB, V6, P414, DOI 10.1016/j.cmet.2007.09.006; Lau P, 2008, J BIOL CHEM, V283, P18411, DOI 10.1074/jbc.M710526200; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; Le Martelot G, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000181; Manttari Satu, 2005, BMC Physiol, V5, P4, DOI 10.1186/1472-6793-5-4; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Mendoza J, 2008, J PHYSIOL-LONDON, V586, P5901, DOI 10.1113/jphysiol.2008.159566; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; MURAT JC, 1974, CLIN CHEM, V20, P1576; Nader N, 2009, FASEB J, V23, P1572, DOI 10.1096/fj.08-117697; Ortega FJ, 2010, OBESITY, V18, P13, DOI 10.1038/oby.2009.202; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pircher P, 2005, AM J PHYSIOL-REG I, V288, pR482, DOI 10.1152/ajpregu.00690.2003; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Raspe E, 2002, J LIPID RES, V43, P2172, DOI 10.1194/jlr.M200386-JLR200; Schmutz I, 2010, GENE DEV, V24, P345, DOI 10.1101/gad.564110; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schutz Y, 2004, INT J OBESITY, V28, pS3, DOI 10.1038/sj.ijo.0802852; Shibata S, 2010, ADV DRUG DELIVER REV, V62, P918, DOI 10.1016/j.addr.2010.06.003; STAELS B, 1992, DEVELOPMENT, V115, P1035; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Triqueneaux G, 2004, J MOL ENDOCRINOL, V33, P585, DOI 10.1677/jme.1.01554; Tsutsumi K, 2002, BIOL PHARM BULL, V25, P1360, DOI 10.1248/bpb.25.1360; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Vieira E, 2012, ENDOCRINOLOGY, V153, P592, DOI 10.1210/en.2011-1595; Voshol PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/diabetes.50.11.2585; Wang J, 2008, MOL CELL BIOL, V28, P2213, DOI 10.1128/MCB.01608-07; Wu N, 2009, GENE DEV, V23, P2201, DOI 10.1101/gad.1825809; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179; Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05-0873	61	149	154	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3321	3335		10.1096/fj.12-208751	http://dx.doi.org/10.1096/fj.12-208751			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22562834				2022-12-28	WOS:000307162800022
J	Gong, JL; Hoyos, B; Acin-Perez, R; Vinogradov, V; Shabrova, E; Zhao, F; Leitges, M; Fischman, D; Manfredi, G; Hammerling, U				Gong, Jianli; Hoyos, Beatrice; Acin-Perez, Rebeca; Vinogradov, Valerie; Shabrova, Elena; Zhao, Feng; Leitges, Michael; Fischman, Donald; Manfredi, Giovanni; Hammerling, Ulrich			Two protein kinase C isoforms, delta and epsilon, regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex	FASEB JOURNAL			English	Article						mitochondrial energy metabolism; retinoids; vitamin A physiology; redox biology; respiration; signal transduction	RETINOL-BINDING-PROTEIN; OXIDASE SUBUNIT-IV; CYTOCHROME-C; PKC-DELTA; OXIDATIVE-PHOSPHORYLATION; INSULIN SENSITIVITY; RETRO-RETINOIDS; GENE-EXPRESSION; VITAMIN-A; ACTIVATION	Energy production in mitochondria is a multistep process that requires coordination of several subsystems. While reversible phosphorylation is emerging as the principal tool, it is still unclear how this signal network senses the workloads of processes as different as fuel procurement, catabolism in the Krebs cycle, and stepwise oxidation of reducing equivalents in the electron transfer chain. We previously proposed that mitochondria use oxidized cytochrome c in concert with retinol to activate protein kinase C delta, thereby linking a prominent kinase network to the redox balance of the ETC. Here, we show that activation of PKC epsilon in mitochondria also requires retinol as a cofactor, implying a redox-mechanism. Whereas activated PKC delta transmits a stimulatory signal to the pyruvate dehdyrogenase complex (PDHC), PKC epsilon opposes this signal and inhibits the PDHC. Our results suggest that the balance between PKC delta and epsilon is of paramount importance not only for flux of fuel entering the Krebs cycle but for overall energy homeostasis. We observed that the synthetic retinoid fenretinide substituted for the retinol cofactor function but, on chronic use, distorted this signal balance, leading to predominance of PKC epsilon over PKC delta. The suppression of the PDHC might explain the proapoptotic effect of fenretinide on tumor cells, as well as the diminished adiposity observed in experimental animals and humans. Furthermore, a disturbed balance between PKC delta and PKC epsilon might underlie the injury inflicted on the ischemic myocardium during reperfusion.-Gong, J., Hoyos, B., Acin-Perez, R., Vinogradov, V., Shabrova, E., Zhao, F., Leitges, M., Fischman, D., Manfredi, G., Hammerling, U. Two protein kinase C isoforms, delta and epsilon, regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex. FASEB J. 26, 3537-3549 (2012). www.fasebj.org	[Gong, Jianli; Hoyos, Beatrice; Vinogradov, Valerie; Shabrova, Elena; Zhao, Feng; Hammerling, Ulrich] Sloan Kettering Inst Canc Res, Program Immunol, New York, NY 10065 USA; [Acin-Perez, Rebeca; Manfredi, Giovanni] Weill Cornell Med Sch, Dept Neurol & Neurosci, New York, NY USA; [Fischman, Donald] Weill Cornell Med Sch, Dept Cell Biol & Dev Biol, New York, NY USA; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway	Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Oslo	Hammerling, U (corresponding author), Sloan Kettering Inst Canc Res, Program Immunol, New York, NY 10065 USA.	u-hammerling@ski.mskcc.org	Leitges, Michael/AAN-1953-2021; Acin-Perez, Rebeca/H-6160-2015; Acin-Perez, Rebeca/AAU-4913-2020	Acin-Perez, Rebeca/0000-0001-9553-8337; Acin-Perez, Rebeca/0000-0001-9553-8337; Leitges, Michael/0000-0003-4203-6995	U.S. National Institutes of Health [K-089348, GM-088999]; Muscular Dystrophy Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088999] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors acknowledge the generous gifts by Dr. P. Parker (Cancer Research UK London Institute, London, UK) of the PKC epsilon<SUP>-/-</SUP> and the PKC epsilon-overexpressing cell lines, and by Dr. U. Kikkawa (Biosignal Research Centre, Kobe University, Kobe, Japan) of the PKC delta Y332F mutant cell line. The authors also thank Dr. Gavril Pasternak and Dr. Richard Kolesnick for their advice on binding affinity measurements. This work was supported by grants from the U.S. National Institutes of Health, DK-089348 (to U. H.) and GM-088999 (to G. M.), and from the Muscular Dystrophy Association. Author contributions: G. M. and U. H. designed research; J.G., B. H., R. A-P., F.Z., E. S., and V. V. performed research; M. L. provided research materials; D. F., G. M., and UH wrote the article. The authors declare no conflicts of interest.	Acin-Perez R, 2010, FASEB J, V24, P5033, DOI 10.1096/fj.10-166934; Acin-Perez R, 2010, FASEB J, V24, P627, DOI 10.1096/fj.09-142281; Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; Barnett M, 2008, EXP EYE RES, V86, P226, DOI 10.1016/j.exer.2007.10.012; Berry DC, 2011, P NATL ACAD SCI USA, V108, P4340, DOI 10.1073/pnas.1011115108; Bezy O, 2011, J CLIN INVEST, V121, P2504, DOI 10.1172/JCI46045; Blaner WS, 2007, CELL METAB, V5, P164, DOI 10.1016/j.cmet.2007.02.006; Bouillet P, 1997, MECH DEVELOP, V63, P173, DOI 10.1016/S0925-4773(97)00039-7; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Budas GR, 2007, PHARMACOL RES, V55, P523, DOI 10.1016/j.phrs.2007.04.005; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Chen YQ, 1999, CANCER RES, V59, P3985; Chiu HJ, 2008, FASEB J, V22, P3878, DOI 10.1096/fj.08-112375; Churchill EN, 2005, CIRC RES, V97, P78, DOI 10.1161/01.RES.0000173896.32522.6e; D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Frangioudakis G, 2009, DIABETOLOGIA, V52, P2616, DOI 10.1007/s00125-009-1543-0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Guo DH, 2007, AM J PHYSIOL-HEART C, V293, pH2219, DOI 10.1152/ajpheart.01306.2006; Hail N, 2006, APOPTOSIS, V11, P1677, DOI 10.1007/s10495-006-9289-3; Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; Hayden MR, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-4; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Hoyos B, 2005, J BIOL CHEM, V280, P6872, DOI 10.1074/jbc.M412695200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Hoyos B., 2011, BIOCHIM BIOPHYS ACTA, V1821, P241; Hu YY, 2007, CELL SIGNAL, V19, P410, DOI 10.1016/j.cellsig.2006.07.017; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Imam A, 2001, FASEB J, V15, P28; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Johansson H, 2008, CANCER RES, V68, P9512, DOI 10.1158/0008-5472.CAN-08-0553; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; Korichneva I, 2003, J PHARMACOL EXP THER, V305, P426, DOI 10.1124/jpet.103.048900; Korichneva I, 1999, J CELL SCI, V112, P2521; Kurie JM, 2000, CLIN CANCER RES, V6, P2973; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leitges M, 2001, J CLIN INVEST, V108, P1505; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Mayr M, 2009, J MOL CELL CARDIOL, V46, P268, DOI 10.1016/j.yjmcc.2008.10.008; Morita M, 2008, J BIOCHEM, V143, P31, DOI 10.1093/jb/mvm190; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; Nowak G, 2011, AM J PHYSIOL-RENAL, V301, pF197, DOI 10.1152/ajprenal.00364.2010; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3888, DOI 10.1021/bi00468a014; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Ogbi M, 2006, BIOCHEM J, V393, P191, DOI 10.1042/BJ20050757; Pagliarini DJ, 2005, MOL CELL, V19, P197, DOI 10.1016/j.molcel.2005.06.008; Palaniyandi SS, 2009, CARDIOVASC RES, V82, P229, DOI 10.1093/cvr/cvp001; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Preitner F, 2009, AM J PHYSIOL-ENDOC M, V297, pE1420, DOI 10.1152/ajpendo.00362.2009; Ranieri SC, 2010, P NATL ACAD SCI USA, V107, P13420, DOI 10.1073/pnas.1008647107; Salvi M, 2005, FREE RADICAL BIO MED, V38, P1267, DOI 10.1016/j.freeradbiomed.2005.02.006; Sapin V, 2000, MECH DEVELOP, V92, P295, DOI 10.1016/S0925-4773(00)00241-0; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Yin XL, 2009, CELL PHYSIOL BIOCHEM, V24, P219, DOI 10.1159/000233248; Zhao F, 2011, ANTIOXID REDOX SIGN, V14, P757, DOI 10.1089/ars.2010.3773	71	15	15	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3537	3549		10.1096/fj.11-197376	http://dx.doi.org/10.1096/fj.11-197376			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22573912	Green Published			2022-12-28	WOS:000307162800040
J	Bett, C; Fernandez-Borges, N; Kurt, TD; Lucero, M; Nilsson, KPR; Castilla, J; Sigurdson, CJ				Bett, Cyrus; Fernandez-Borges, Natalia; Kurt, Timothy D.; Lucero, Melanie; Nilsson, K. Peter R.; Castilla, Joaquin; Sigurdson, Christina J.			Structure of the beta 2-alpha 2 loop and interspecies prion transmission	FASEB JOURNAL			English	Article						amyloid; TSE; transmissible spongiform encephalopathy; neurodegeneration	CREUTZFELDT-JAKOB-DISEASE; SPONGIFORM ENCEPHALOPATHY; NMR STRUCTURE; AMINO-ACID; IN-VITRO; SPECIES BARRIER; PROTEIN; PRP; VARIANT; PROPAGATION	Prions are misfolded, aggregated conformers of the prion protein that can be transmitted between species. The precise determinants of interspecies transmission remain unclear, although structural similarity between the infectious prion and host prion protein is required for efficient conversion to the misfolded conformer. The beta 2-alpha 2 loop region of endogenous prion protein, PrPC, has been implicated in barriers to prion transmission. We recently discovered that conversion was efficient when incoming and host prion proteins had similar beta 2-alpha 2 loop structures; however, the roles of primary vs. secondary structural homology could not be distinguished. Here we uncouple the effect of primary and secondary structural homology of the beta 2-alpha 2 loop on prion conversion. We inoculated prions from animals having a disordered or an ordered beta 2-alpha 2 loop into mice having a disordered loop or an ordered loop due to a single residue substitution (D167S). We found that prion conversion was driven by a homologous primary structure and occurred independently of a homologous secondary structure. Similarly, cell-free conversion using PrPC from mice with disordered or ordered loops and prions from 5 species correlated with primary but not secondary structural homology of the loop. Thus, our findings support a model in which efficient interspecies prion conversion is determined by small stretches of the primary sequence rather than the secondary structure of PrP.-Bett, C., Fernandez-Borges, N., Kurt, T. D., Lucero, M., Nilsson, K. P. R., Castilla, J., Sigurdson, C. J. Structure of the beta 2-alpha 2 loop and interspecies prion transmission. FASEB J. 26, 2868-2876 (2012). www.fasebj.org	[Bett, Cyrus; Kurt, Timothy D.; Lucero, Melanie; Sigurdson, Christina J.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Bett, Cyrus; Kurt, Timothy D.; Lucero, Melanie; Sigurdson, Christina J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Fernandez-Borges, Natalia; Castilla, Joaquin] Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain; [Nilsson, K. Peter R.] Linkoping Univ, Dept Phys Chem & Biol, Linkoping, Sweden; [Castilla, Joaquin] Basque Fdn Sci IkerBasque, Bilbao, Spain; [Sigurdson, Christina J.] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; CIC bioGUNE; Linkoping University; Basque Foundation for Science; University of California System; University of California Davis	Sigurdson, CJ (corresponding author), Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.	csigurdson@ucsd.edu	Castilla, Joaquin/D-5261-2011; Castilla, Joaquín/J-8414-2019; Fernández-Borges, Natalia/H-1875-2012	Castilla, Joaquin/0000-0002-2216-1361; Castilla, Joaquín/0000-0002-2216-1361; Fernandez-Borges, Natalia/0000-0001-6274-0096	U.S. National Institutes of Health [NS055116, NS069566, U54AI0359]; national grant from Spain [AGL2009-11553-C02-01]; Basque government grant [PI2010-18]; IKERBasque Foundation; Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country; Innovation Technology Department of Bizkaia County; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS069566, R01NS076896, R21NS055116] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); national grant from Spain; Basque government grant(Basque Government); IKERBasque Foundation; Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country; Innovation Technology Department of Bizkaia County; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Adriano Aguzzi (Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland) and Dr. Charles Weissmann (The Scripps Research Institute Florida, Jupiter, FL, USA) for kindly providing the anti-PrP POM antibodies and the CAD-RML cells, respectively; Mona Farahi, Rozalyn Simon, and Karin Magnusson for excellent technical support; and Drs. David Eisenberg and Michael Sawaya for helpful discussions. The authors also thank the animal caretakers at the University of California, San Diego, and CIC bioGUNE and Drs. Jean E. Jewell (University ofWyoming, Laramie, WY, USA) and Tomas Mayoral (Central Veterinary Laboratory, Madrid, Spain) for the CWD and BSE brain samples. This study was supported by the U.S. National Institutes of Health (NS055116, NS069566, and U54AI0359; C.J.S.); a national grant from Spain (AGL2009-11553-C02-01); a Basque government grant (PI2010-18); the IKERBasque Foundation; the Department of Industry, Tourism, and Trade of the Government of the Autonomous Community of the Basque Country (Etortek Research Programs 2011/2013); the Innovation Technology Department of Bizkaia County; and an Institutional Grant for Younger Researchers from the Swedish Foundation for International Cooperation in Research and Higher Education (STINT; C.J.S., K.P.R.N.).	Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Bett C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002522; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bruce KL, 2011, SEMIN CELL DEV BIOL, V22, P444, DOI 10.1016/j.semcdb.2011.03.005; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2008, EMBO J, V27, P2557, DOI 10.1038/emboj.2008.181; Castilla J, 2008, CELL, V134, P757, DOI 10.1016/j.cell.2008.07.030; Castilla J, 2006, METHOD ENZYMOL, V412, P3, DOI 10.1016/s0076-6879(06)12001-7; Chang HY, 2008, P NATL ACAD SCI USA, V105, P13345, DOI 10.1073/pnas.0802215105; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Christen B, 2008, J MOL BIOL, V383, P306, DOI 10.1016/j.jmb.2008.08.045; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Ding L, 2000, SYNTHETIC MET, V110, P133, DOI 10.1016/S0379-6779(99)00284-2; Gossert AD, 2005, P NATL ACAD SCI USA, V102, P646, DOI 10.1073/pnas.0409008102; Green KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000139; Ho HA, 2002, ANGEW CHEM INT EDIT, V41, P1548, DOI 10.1002/1521-3773(20020503)41:9<1548::AID-ANIE1548>3.0.CO;2-I; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KIRKWOOD JK, 1993, VET REC, V133, P360, DOI 10.1136/vr.133.15.360; KIRKWOOD JK, 1994, VET REC, V135, P296, DOI 10.1136/vr.135.13.296; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Kurt TD, 2011, J VIROL, V85, P8528, DOI 10.1128/JVI.00809-11; Kurt TD, 2009, VIROLOGY, V387, P235, DOI 10.1016/j.virol.2009.02.025; Lau AL, 2007, P NATL ACAD SCI USA, V104, P11551, DOI 10.1073/pnas.0704260104; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Perez DR, 2010, J MOL BIOL, V400, P121, DOI 10.1016/j.jmb.2010.04.066; Piening N, 2006, J BIOL CHEM, V281, P9373, DOI 10.1074/jbc.M512239200; Polymenidou M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003872; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Qi YP, 1997, J NEUROSCI, V17, P1217; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Ryder SJ, 2001, VET REC, V148, P437, DOI 10.1136/vr.148.14.437; Saa Paula, 2004, V299, P53; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Schatzl HM, 1997, J MOL BIOL, V265, P257, DOI 10.1006/jmbi.1996.0791; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; Scott MR, 1997, P NATL ACAD SCI USA, V94, P14279, DOI 10.1073/pnas.94.26.14279; Sigurdson CJ, 2007, NAT METHODS, V4, P1023, DOI 10.1038/nmeth1131; Sigurdson CJ, 2006, J VIROL, V80, P12303, DOI 10.1128/JVI.01120-06; Sigurdson CJ, 2011, J NEUROSCI, V31, P13840, DOI 10.1523/JNEUROSCI.3504-11.2011; Sigurdson CJ, 2010, J CLIN INVEST, V120, P2590, DOI 10.1172/JCI42051; Tessier PM, 2007, NATURE, V447, P556, DOI 10.1038/nature05848; Verges KJ, 2011, NAT STRUCT MOL BIOL, V18, P493, DOI 10.1038/nsmb.2030; Vorberg I, 2003, J VIROL, V77, P2003, DOI 10.1128/JVI.77.3.2003-2009.2003; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wiltzius JJW, 2009, NAT STRUCT MOL BIOL, V16, P973, DOI 10.1038/nsmb.1643	53	27	27	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2868	2876		10.1096/fj.11-200923	http://dx.doi.org/10.1096/fj.11-200923			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490928	Green Published			2022-12-28	WOS:000305912500015
J	Erener, S; Mirsaidi, A; Hesse, M; Tiaden, AN; Ellingsgaard, H; Kostadinova, R; Donath, MY; Richards, PJ; Hottiger, MO				Erener, Sueheda; Mirsaidi, Ali; Hesse, Mareike; Tiaden, Andre N.; Ellingsgaard, Helga; Kostadinova, Radina; Donath, Marc Y.; Richards, Peter J.; Hottiger, Michael O.			ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation	FASEB JOURNAL			English	Article						adipogenesis; ADP-ribosylation; liver; PARP-1	POLY(ADP-RIBOSE) POLYMERASE; ADIPOSE-TISSUE; ADP-RIBOSYLATION; GENE-EXPRESSION; TELOMERE LENGTH; PPAR-GAMMA; LIVER; INFLAMMATION; OBESITY; CELLS	ADP-ribosyltransferase Diphtheria toxin-like 1 [ARTD1; formerly called poly-ADP-ribose polymerase 1 (PARP1)] is a chromatin-associated enzyme involved in regulating metabolic homeostasis. The liver is at the core of glucose and lipid metabolism and is significantly affected by obesity and the metabolic syndrome. Here, we show that when fed a high-fat diet (HFD), mice lacking ARTD1 developed exacerbated hepatic steatosis. ARTD1(-/-) mice had a 19% higher liver weight than wild-type (WT) animals and exhibited a significantly increased serum concentration of cholesterol (38%) and impaired glucose tolerance. In addition, adipocyte function and size were significantly reduced in ARTD1(-/-) mice fed an HFD (7794 mu m(2) for WT and 5579 mu m(2) for ARTD1(-/-) mice). The significantly reduced adipogenic differentiation of adipose-derived stromal cells (ASCs) isolated from ARTD1(-/-) mice (28 vs. 11% Oil red O-positive cells in WT and ARTD1(-/-) ASCs, respectively) suggested that impaired adipogenesis as the underlying cause for this adipose tissue malfunction. This function of ARTD1 was specific for adipogenesis, since osteogenic differentiation was not affected by the ARTD1 deletion. In summary, we show that ARTD1(-/-) mice fed an HFD display impaired adipogenesis and show exacerbated hepatic steatosis, which can have important implications for nonalcoholic fatty liver disease.-Erener, S., Mirsaidi, A., Hesse, M., Tiaden, A. N., Ellingsgaard, H., Kostadinova, R., Donath, M. Y., Richards, P. J., Hottiger, M. O. ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation. FASEB J. 26, 2631-2638 (2012). www.fasebj.org	[Erener, Sueheda; Hesse, Mareike; Kostadinova, Radina; Hottiger, Michael O.] Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; [Erener, Sueheda; Hesse, Mareike] Univ Zurich, Life Sci Zurich Grad Sch, Mol Life Sci Program, CH-8057 Zurich, Switzerland; [Mirsaidi, Ali; Tiaden, Andre N.; Richards, Peter J.] Univ Zurich, Competence Ctr Appl Biotechnol & Mol Med, Bone & Stem Cell Res Grp, CH-8057 Zurich, Switzerland; [Mirsaidi, Ali; Richards, Peter J.; Hottiger, Michael O.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Inst Physiol, CH-8057 Zurich, Switzerland; [Ellingsgaard, Helga; Donath, Marc Y.] Univ Basel Hosp, Clin Endocrinol Diabet & Metab, CH-4031 Basel, Switzerland	University of Zurich; University of Zurich; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Basel	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hottiger@vetbio.uzh.ch	Lehmann, Mareike/S-8727-2019; Hottiger, Michael O./J-7747-2013; Ellingsgaard, Helga/AAD-5705-2022	Lehmann, Mareike/0000-0002-8601-8206; Hottiger, Michael O./0000-0002-7323-2270; Ellingsgaard, Helga/0000-0002-9105-5247	University of Zurich; Swiss National Science Foundation [31-122421, 310030B-138667]; Kanton of Zurich	University of Zurich; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Kanton of Zurich	The authors thank I. Mittner and M. Wanner (University of Zurich) for FFA measurements. F. Freimoser (University of Zurich) provided editorial assistance and critical input during the writing. This work was supported in part by the University Research Priority Program, Integrative Human Physiology, at the University of Zurich; a Forschungskredit of the University of Zurich (to M. H.); Swiss National Science Foundation grants 31-122421 and 310030B-138667; and the Kanton of Zurich (to M. O. H.). The authors declare no conflicts of interest. Author contributions: S. E., A. M., M. H., P. J. R., R. K., M. Y. D., and M. O. H. designed the experiments; S. E., A. M., M. H., A. N. T., and H. E. performed the experiments; P. J. R. and M. O. H. supervised the study; M. O. H., S. E., and P. J. R. wrote and edited the manuscript.	Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Bai P, 2011, CELL METAB, V13, P450, DOI 10.1016/j.cmet.2011.03.013; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; Bluhre M, 2009, EXP CLIN ENDOCR DIAB, V117, P241, DOI 10.1055/s-0029-1192044; Cortez-Pinto H, 1999, CLIN NUTR, V18, P353, DOI 10.1016/S0261-5614(99)80015-6; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Devalaraja-Narashimha K, 2010, J ENDOCRINOL, V205, P242, DOI 10.1677/JOE-09-0402; di Fagagna FD, 1999, NAT GENET, V23, P76; Erener S, 2012, MOL ENDOCRINOL, V26, P79, DOI 10.1210/me.2011-1163; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; Messner S, 2011, TRENDS CELL BIOL, V21, P534, DOI 10.1016/j.tcb.2011.06.001; Mirsaidi A, 2012, J TISSUE ENG REGEN M, V6, P378, DOI 10.1002/term.440; Nguyen P, 2008, J ANIM PHYSIOL AN N, V92, P272, DOI 10.1111/j.1439-0396.2007.00752.x; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Samuel VT, 2010, LANCET, V375, P2267, DOI 10.1016/S0140-6736(10)60408-4; Sethi JK, 2007, J LIPID RES, V48, P1253, DOI 10.1194/jlr.R700005-JLR200; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wang F, 2009, MOL BIOL CELL, V20, P801, DOI 10.1091/mbc.E08-06-0647; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	32	39	39	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2631	2638		10.1096/fj.11-200212	http://dx.doi.org/10.1096/fj.11-200212			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22426118				2022-12-28	WOS:000305017200038
J	Lu, D; Soleymani, S; Madakshire, R; Insel, PA				Lu, David; Soleymani, Sahar; Madakshire, Rohit; Insel, Paul A.			ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y(2) receptors	FASEB JOURNAL			English	Article						cardiac fibrosis; purinergic signaling; extracellular matrix; alpha-smooth muscle actin; MAPK/ERK activation	PANNEXIN 1 CHANNELS; FIND-ME SIGNAL; EXTRACELLULAR ATP; TGF-BETA; NUCLEOTIDE RECEPTORS; GROWTH-FACTOR; HEART; EXPRESSION; INHIBITION; ASTROCYTES	Cardiac fibroblasts (CFs) play an essential role in remodeling of the cardiac extracellular matrix. Extracellular nucleotide signaling may provoke a profibrotic response in CFs. We tested the hypothesis that physical perturbations release ATP from CFs and that ATP participates in profibrotic signaling. ATP release was abolished by the channel inhibitor carbenoxolone and inhibited by knockdown of either connexin (Cx)43 or Cx45 (47 and 35%, respectively), implying that hypotonic stimulation induces ATP release via Cx43 and Cx45 hemichannels, although pannexin 1 may also play a role. ATP released by hypotonic stimulation rapidly (<10 min) increased phosphorylated ERK by 5-8 fold, an effect largely eliminated by P2Y(2) receptor knockdown or ATP hydrolysis with apyrase. ATP stimulation of P2Y(2) receptors increased alpha-smooth muscle actin (alpha-SMA) production, and in an ERK-dependent manner, ATP increased collagen accumulation by 60% and mRNA expression of profibrotic markers: plasminogen activator inhibitor-1 and monocyte chemotactic protein-1 by 4.5- and 4.0-fold, respectively. Apyrase treatment substantially reduced the basal profibrotic phenotype, decreasing collagen and alpha-SMA content and increasing matrix metalloproteinase expression. Thus, ATP release activates P2Y(2) receptors to mediate profibrotic responses in CFs, implying that nucleotide release under both basal and activated states is likely an important mechanism for fibroblast homeostasis.-Lu, D., Soleymani, S., Madakshire, R., Insel, P. A. ATP released from cardiac fibroblasts via connexin hemichannels activates profibrotic P2Y(2) receptors. FASEB J. 26, 2580-2591 (2012). www.fasebj.org	[Lu, David; Soleymani, Sahar; Madakshire, Rohit; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, BSB 3076,9500 Gilman Dr 0636, La Jolla, CA 92093 USA.	pinsel@ucsd.edu			U.S. National Institutes of Health (NIH); Ellison Medical Research Foundation; University of California-San Diego Academic Senate; NIH [1T32HL098062-01A1]; National Research Service [1F31AG039992-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL098062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F31AG039992] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Research Foundation(Lawrence Ellison Foundation); University of California-San Diego Academic Senate; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Research Service; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Nakon Aroonsakool for assistance in the isolation of rat CFs and Eveline Sun Arnold for assistance with confocal microscopy. This work was supported by research grants from the U.S. National Institutes of Health (NIH) and the Ellison Medical Research Foundation and support from the University of California-San Diego Academic Senate (to P. A. I.). D. L. was supported by NIH training grant 1T32HL098062-01A1 and National Research Service Award 1F31AG039992-01. The authors declare no conflicts of interests.	Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Anselmi F, 2008, P NATL ACAD SCI USA, V105, P18770, DOI [10.1073/pnas.0800793105, 10.1073/pnas.080079310S]; Barbe MT, 2006, PHYSIOLOGY, V21, P103, DOI 10.1152/physiol.00048.2005; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Beyer EC, 2001, CELL COMMUN ADHES, V8, P199, DOI 10.3109/15419060109080723; Braun OO, 2010, J MOL CELL CARDIOL, V49, P362, DOI 10.1016/j.yjmcc.2010.05.001; Camelliti P, 2005, CARDIOVASC RES, V65, P40, DOI 10.1016/j.cardiores.2004.08.020; Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; Corriden R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3104re1; D'hondt C, 2009, BIOESSAYS, V31, P953, DOI 10.1002/bies.200800236; Dewald O, 2005, CIRC RES, V96, P881, DOI 10.1161/01.RES.0000163017.13772.3a; Dranoff JA, 2004, AM J PHYSIOL-GASTR L, V287, pG417, DOI 10.1152/ajpgi.00294.2003; Dubyak GR, 2009, AM J PHYSIOL-CELL PH, V296, pC235, DOI 10.1152/ajpcell.00639.2008; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Erlinge D, 2008, PURINERG SIGNAL, V4, P1, DOI 10.1007/s11302-007-9078-7; Espira L, 2009, CAN J PHYSIOL PHARM, V87, P996, DOI 10.1139/Y09-105; Ghosh AK, 2012, J CELL PHYSIOL, V227, P493, DOI 10.1002/jcp.22783; Gunduz D, 2006, CARDIOVASC RES, V71, P764, DOI 10.1016/j.cardiores.2006.06.011; Iglesias R, 2008, AM J PHYSIOL-CELL PH, V295, pC752, DOI 10.1152/ajpcell.00228.2008; Iglesias R, 2009, J NEUROSCI, V29, P7092, DOI 10.1523/JNEUROSCI.6062-08.2009; Johansen D, 2011, CELL PHYSIOL BIOCHEM, V28, P103, DOI 10.1159/000331719; Kakkar R, 2010, CIRC RES, V106, P47, DOI 10.1161/CIRCRESAHA.109.207456; Khan R, 2006, IMMUNOLOGY, V118, P10, DOI 10.1111/j.1365-2567.2006.02336.x; LaFramboise WA, 2007, AM J PHYSIOL-CELL PH, V292, pC1799, DOI 10.1152/ajpcell.00166.2006; Lal H, 2009, FRONT BIOSCI-LANDMRK, V14, P2307, DOI 10.2741/3381; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Lugo-Garcia L, 2007, EUR J PHARMACOL, V568, P54, DOI 10.1016/j.ejphar.2007.04.012; Manso AM, 2009, J INVEST MED, V57, P856, DOI 10.2310/JIM.0b013e3181c5e61f; Martinez AD, 2002, CIRC RES, V90, P1100, DOI 10.1161/01.RES.0000019580.64013.31; McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491; Missan S, 2011, CARDIOVASC RES, V91, P429, DOI 10.1093/cvr/cvr074; Montalbetti N, 2011, J BIOL CHEM, V286, P38397, DOI 10.1074/jbc.M111.221713; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nishida M, 2008, EMBO J, V27, P3104, DOI 10.1038/emboj.2008.237; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ratchford AM, 2010, J BIOL CHEM, V285, P7545, DOI 10.1074/jbc.M109.078170; Riteau N, 2010, AM J RESP CRIT CARE, V182, P774, DOI 10.1164/rccm.201003-0359OC; Schock SC, 2008, BIOCHEM BIOPH RES CO, V368, P138, DOI 10.1016/j.bbrc.2008.01.054; Shestopalov VI, 2008, CELL MOL LIFE SCI, V65, P376, DOI 10.1007/s00018-007-7200-1; Silverman W, 2008, AM J PHYSIOL-CELL PH, V295, pC761, DOI 10.1152/ajpcell.00227.2008; Sobel BE, 2006, LIFE SCI, V79, P1600, DOI 10.1016/j.lfs.2006.05.011; Souders CA, 2009, CIRC RES, V105, P1164, DOI 10.1161/CIRCRESAHA.109.209809; Srinivas M, 2006, J GEN PHYSIOL, V127, P67, DOI 10.1085/jgp.200509397; Stenmark KR, 2002, CHEST, V122, p326S, DOI 10.1378/chest.122.6_suppl.326S; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; van den Borne SWM, 2010, NAT REV CARDIOL, V7, P30, DOI 10.1038/nrcardio.2009.199; van der Vliet A, 2011, SUBCELL BIOCHEM, V55, P139, DOI 10.1007/978-94-007-1217-1_6; Vasquez C, 2010, CIRC RES, V107, P1011, DOI 10.1161/CIRCRESAHA.110.227421; Verma SK, 2011, CARDIOVASC RES, V90, P88, DOI 10.1093/cvr/cvq385; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yamamoto K, 2011, J CELL SCI, V124, P3477, DOI 10.1242/jcs.087221; Yang LL, 2004, J CELL BIOCHEM, V91, P938, DOI 10.1002/jcb.10774; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Ye ZC, 2009, GLIA, V57, P258, DOI 10.1002/glia.20754; Yokoyama U, 2008, P NATL ACAD SCI USA, V105, P6386, DOI 10.1073/pnas.0801490105; Zeisberg EM, 2010, CIRC RES, V107, P1304, DOI 10.1161/CIRCRESAHA.110.231910; Zhang Y, 2010, AM J PHYSIOL-HEART C, V298, pH477, DOI 10.1152/ajpheart.00806.2009	64	70	70	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2580	2591		10.1096/fj.12-204677	http://dx.doi.org/10.1096/fj.12-204677			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22415310	Green Published			2022-12-28	WOS:000305017200034
J	Villar, VAM; Armando, I; Sanada, H; Frazer, LC; Russo, CM; Notario, PM; Lee, H; Comisky, L; Russell, HA; Yang, Y; Jurgens, JA; Jose, PA; Jones, JE				Villar, Van Anthony M.; Armando, Ines; Sanada, Hironobu; Frazer, Lauren C.; Russo, Christen M.; Notario, Patricia M.; Lee, Hewang; Comisky, Lauren; Russell, Holly Ann; Yang, Yu; Jurgens, Julie A.; Jose, Pedro A.; Jones, John E.			Novel role of sorting nexin 5 in renal D-1 dopamine receptor trafficking and function: implications for hypertension	FASEB JOURNAL			English	Article						GRK4; cAMP; natriuresis; kidney; receptor trafficking	PROTEIN-COUPLED RECEPTOR; AGONIST-INDUCED DESENSITIZATION; KINASE 4; INTRARENAL DOPAMINE; D1; PHOSPHORYLATION; IDENTIFICATION; CELLS; RESPONSIVENESS; ENDOCYTOSIS	The D-1 dopamine receptor (D1R) is widely expressed in the kidney and plays a crucial role in blood pressure regulation. Although much is known about D1R desensitization, especially through G-protein-coupled receptor kinase 4 (GRK4), comparatively little is known about other aspects of D1R trafficking and the proteins involved in the process. We now report the discovery of a dynamic interaction between sorting nexin 5 (SNX5), a component of the mammalian retromer, and D1R in human renal epithelial cells. We show that internalization of agonist-activated D1R is regulated by both SNX5 and GRK4, and that SNX5 is critical to the recycling of the receptor to the plasma membrane. SNX5 depletion increases agonist-activated D1R phosphorylation (>50% at basal condition), prevents D1R internalization and cAMP response, and delays receptor recycling compared to mock siRNA-transfected controls. Moreover, renal restricted subcapsular infusion of Snx5-specific siRNA (vs. mock siRNA) decreases sodium excretion (Delta = -0.2 +/- 0.005 mEq/mg creatinine) and further elevates the systolic blood pressure (Delta = 48 +/- 5 mm Hg) in spontaneously hypertensive rats, indicating that SNX5 depletion impairs renal D1R function. These studies demonstrate an essential role for SNX5 in regulating D1R function, which may have important diagnostic, prognostic, and therapeutic implications in the management of essential hypertension.-Villar, V. A. M., Armando, I., Sanada, H., Frazer, L. C., Russo, C. M., Notario, P. M., Lee, H., Comisky, L., Russell, H. A., Yang, Y., Jurgens, J. A., Jose, P. A., Jones, J. E. Novel role of sorting nexin 5 in renal D-1 dopamine receptor trafficking and function: implications for hypertension. FASEB J. 27, 1808-1819 (2013). www.fasebj.org	[Villar, Van Anthony M.; Armando, Ines; Lee, Hewang; Yang, Yu; Jurgens, Julie A.; Jose, Pedro A.; Jones, John E.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Villar, Van Anthony M.; Armando, Ines; Frazer, Lauren C.; Russo, Christen M.; Notario, Patricia M.; Lee, Hewang; Comisky, Lauren; Russell, Holly Ann; Jose, Pedro A.; Jones, John E.] Georgetown Univ, Sch Med, Dept Pediat, Washington, DC 20007 USA; [Sanada, Hironobu] Fukushima Med Univ, Sch Med, Dept Internal Med 3, Fukushima, Japan	University System of Maryland; University of Maryland Baltimore; Georgetown University; Fukushima Medical University	Villar, VAM (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Nephrol, 20 Penn St,Ste S003C, Baltimore, MD 21201 USA.	vvillar@medicine.umaryland.edu		Frazer, Lauren/0000-0003-2366-7409; Lee, Hewang/0000-0003-1338-2573	U.S. National Institutes of Health (NIH) [R37HL023081, R01HL092196]; NIH National Center for Research Resources [UL1RR031988, KL2 RR031987]; Lombardi Comprehensive Cancer Center Microscopy and Imaging Shared Resource [P30CA51008, S10RR15768]	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Lombardi Comprehensive Cancer Center Microscopy and Imaging Shared Resource	The authors are grateful to Dr. Robin A. Felder (Department of Pathology, The University of Virginia School of Medicine, Charlottesville, VA, USA) for providing the immortalized human renal proximal tubule cells and to Dr. Xiaoyan Wang for validating the in-house rabbit polyclonal anti-D<INF>1</INF>R Ab (clone 408) that was used in this work. These experiments were supported, in part, by grants R37HL023081 and R01HL092196 from the U.S. National Institutes of Health (NIH); by trants UL1RR031988 and KL2 RR031987 from the NIH National Center for Research Resources; and by the Lombardi Comprehensive Cancer Center Microscopy and Imaging Shared Resource, grants P30CA51008 and S10RR15768.	Albrecht FE, 1996, J CLIN INVEST, V97, P2283, DOI 10.1172/JCI118670; Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; Banday AA, 2008, CURR HYPERTENS REP, V10, P268, DOI 10.1007/s11906-008-0051-9; Brana C, 1996, J COMP NEUROL, V370, P23, DOI 10.1002/(SICI)1096-9861(19960617)370:1<23::AID-CNE3>3.0.CO;2-N; Brismar H, 2006, PFLUG ARCH EUR J PHY, V451, P793, DOI 10.1007/s00424-005-1510-7; Brismar H, 1998, P NATL ACAD SCI USA, V95, P5573, DOI 10.1073/pnas.95.10.5573; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Costa MZD, 2006, APPL IMMUNOHISTO M M, V14, P348; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; Felder RA, 2002, P NATL ACAD SCI USA, V99, P3872, DOI 10.1073/pnas.062694599; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Guo Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029204; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; He Y, 2009, NEUROSCI BULL, V25, P43, DOI 10.1007/s12264-009-0107-0; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Jiang D, 1999, MOL PHARMACOL, V56, P675; Jose PA, 2010, BBA-MOL BASIS DIS, V1802, P1259, DOI 10.1016/j.bbadis.2010.02.004; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kong MMC, 2007, MOL PHARMACOL, V72, P1157, DOI 10.1124/mol.107.034769; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li HW, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2943286; Marchese A, 2008, ANNU REV PHARMACOL, V48, P601, DOI 10.1146/annurev.pharmtox.48.113006.094646; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Rankin ML, 2006, MOL PHARMACOL, V69, P759, DOI 10.1124/mol.105.019901; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Sanada H, 2006, HYPERTENSION, V47, P1131, DOI 10.1161/01.HYP.0000222004.74872.17; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Sun YS, 2011, NAT PROTOC, V6, P1324, DOI 10.1038/nprot.2011.364; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Trivedi M, 2004, AM J PHYSIOL-RENAL, V287, pF921, DOI 10.1152/ajprenal.00023.2004; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Villar VM, 2009, J BIOL CHEM, V284, P21425, DOI 10.1074/jbc.M109.003665; Wassmer T, 2007, J CELL SCI, V120, P45, DOI 10.1242/jcs.03302; Watanabe H, 2002, KIDNEY INT, V62, P790, DOI 10.1046/j.1523-1755.2002.00525.x; Yatabe J, 2008, HYPERTENS RES, V31, P1455, DOI 10.1291/hypres.31.1455; Yoneda M, 2005, HYPERTENSION, V46, P58, DOI 10.1161/01.HYP.0000171587.44736.ba; Yoo KW, 2006, FEBS LETT, V580, P4409, DOI 10.1016/j.febslet.2006.07.009; Yu PY, 2011, FREE RADICAL BIO MED, V50, P832, DOI 10.1016/j.freeradbiomed.2010.12.027; Yu PY, 2004, KIDNEY INT, V66, P2167, DOI 10.1111/j.1523-1755.2004.66007.x; Zhang MZ, 2011, J CLIN INVEST, V121, P2845, DOI 10.1172/JCI57324	54	30	30	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1808	1819		10.1096/fj.12-208439	http://dx.doi.org/10.1096/fj.12-208439			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23195037	Green Published			2022-12-28	WOS:000318226100002
J	Coomans, CP; van den Berg, SAA; Houben, T; van Klinken, JB; van den Berg, R; Pronk, ACM; Havekes, LM; Romijn, JA; van Dijk, KW; Biermasz, NR; Meijer, JH				Coomans, Claudia P.; van den Berg, Sjoerd A. A.; Houben, Thijs; van Klinken, Jan-Bert; van den Berg, Rosa; Pronk, Amanda C. M.; Havekes, Louis M.; Romijn, Johannes A.; van Dijk, Ko Willems; Biermasz, Nienke R.; Meijer, Johanna H.			Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity	FASEB JOURNAL			English	Article						constant light; SCN; multiunit activity; electrophysiology	HUMAN SKELETAL-MUSCLE; SUPRACHIASMATIC NUCLEUS; MAMMALIAN CLOCK; DAILY RHYTHM; RAT; TIME; DISTURBANCES; DISRUPTION; EXPRESSION; COMPONENTS	Circadian rhythm disturbances are observed in, e. g., aging and neurodegenerative diseases and are associated with an increased incidence of obesity and diabetes. We subjected male C57Bl/6J mice to constant light [12-h light-light (LL) cycle] to examine the effects of a disturbed circadian rhythm on energy metabolism and insulin sensitivity. In vivo electrophysiological recordings in the central pacemaker of the suprachiasmatic nuclei (SCN) revealed an immediate reduction in rhythm amplitude, stabilizing at 44% of normal amplitude values after 4 d LL. Food intake was increased (+26%) and energy expenditure decreased (-13%), and we observed immediate body weight gain (d 4: +2.4%, d 14: +5.0%). Mixed model analysis revealed that weight gain developed more rapidly in response to LL as compared to high fat. After 4 wk in LL, the circadian pattern in feeding and energy expenditure was completely lost, despite continuing low-amplitude rhythms in the SCN and in behavior, whereas weight gain had stabilized. Hyperinsulinemic-euglycemic clamp analysis revealed complete abolishment of normal circadian variation in insulin sensitivity in LL. In conclusion, a reduction in amplitude of the SCN, to values previously observed in aged mice, is sufficient to induce a complete loss of circadian rhythms in energy metabolism and insulin sensitivity.-Coomans, C. P., van den Berg, S. A. A., Houben, T., van Klinken, J.-B., van den Berg, R., Pronk, A. C. M., Havekes, L. M., Romijn, J. A., Willems van Dijk, K., Biermasz, N. R., Meijer, J. H. Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity. FASEB J. 27, 1721-1732 (2013). www.fasebj.org	[Coomans, Claudia P.; Meijer, Johanna H.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [Coomans, Claudia P.; Romijn, Johannes A.; Biermasz, Nienke R.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Disorders, NL-2300 RC Leiden, Netherlands; [van den Berg, Sjoerd A. A.; Houben, Thijs; van Klinken, Jan-Bert; van den Berg, Rosa; Pronk, Amanda C. M.; Havekes, Louis M.; van Dijk, Ko Willems] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; [Havekes, Louis M.] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; [Havekes, Louis M.] Netherlands Org Appl Sci Res, Gaubius Lab, Leiden, Netherlands; [Romijn, Johannes A.] Amsterdam Med Ctr, Dept Med, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; University of Amsterdam; Academic Medical Center Amsterdam	Coomans, CP (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Neurophysiol Lab, Bldg 2,Room T5-32,Einthovenweg 20,POB 9600, NL-2300 RC Leiden, Netherlands.	c.p.coomans@lumc.nl	van der Heijde, Désirée/I-6774-2019; van Dijk, Ko Willems/A-1798-2008; van den Berg, Sjoerd A/R-9541-2018; Biermasz, Nienke/ABE-9436-2021; van Dijk, Ko Willems/AAT-4681-2021; Coomans, Claudia/A-4458-2013	van der Heijde, Désirée/0000-0002-5781-158X; van Dijk, Ko Willems/0000-0002-2172-7394; Biermasz, Nienke/0000-0001-5817-3594; van Dijk, Ko Willems/0000-0002-2172-7394; Coomans, Claudia/0000-0003-0883-458X; van den Berg, Sjoerd/0000-0001-5937-7505; van den Berg, Sjoerd/0000-0001-8967-376X	TI Pharma (TIP project) [T2-105]; Netherlands Heart Foundation (NHS project) [2007B81]; Dutch Diabetes Research Foundation (DFN project) [2007.00.010]; Center of Medical Systems Biology (CMSB project); Netherlands Consortium for Systems Biology (NCSB project) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO); Dutch Organization for Scientific Research [90700195]; NWO ZonMW (Top Go grant) [81802016]	TI Pharma (TIP project); Netherlands Heart Foundation (NHS project); Dutch Diabetes Research Foundation (DFN project); Center of Medical Systems Biology (CMSB project); Netherlands Consortium for Systems Biology (NCSB project) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO); Dutch Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NWO ZonMW (Top Go grant)	The authors thank H. Duindam [Department of Molecular Cell Biology, Leiden University Medical Center (LUMC), Leiden, the Netherlands] and H. E. Auvinen (Department of Endocrinology, LUMC) for excellent technical support. This work was supported by grants from TI Pharma (TIP project T2-105, to J.A.R. and L. M. H.), the Netherlands Heart Foundation (NHS project 2007B81, to J.A.R.), the Dutch Diabetes Research Foundation (DFN project 2007.00.010, to J.A.R.), the Center of Medical Systems Biology (CMSB project, to K. W. V. D.), the Netherlands Consortium for Systems Biology (NCSB project, to K. W. V. D.) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO), the Dutch Organization for Scientific Research (Clinical Fellows 90700195, to N.R.B.), and NWO ZonMW (Top Go grant 81802016, to J.H.M.). The authors report no conflicts of interest.	Ancoli-Israel S, 2002, J AM GERIATR SOC, V50, P282, DOI 10.1046/j.1532-5415.2002.50060.x; ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Buijs RM, 2006, PROG BRAIN RES, V153, P341, DOI 10.1016/S0079-6123(06)53020-1; Cailotto C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005650; Chen RM, 2008, J NEUROSCI, V28, P11839, DOI 10.1523/JNEUROSCI.2191-08.2008; Claustrat B, 2008, HORM METAB RES, V40, P398, DOI 10.1055/s-2008-1065330; Colwell CS, 2011, NAT REV NEUROSCI, V12, P553, DOI 10.1038/nrn3086; Coomans CP, 2013, DIABETES, V62, P1102, DOI 10.2337/db12-0507; Copertaro Alfredo, 2009, Recenti Progressi in Medicina, V100, P502; Corpeleijn E, 2008, OBESITY, V16, P1025, DOI 10.1038/oby.2008.24; Dalm S, 2005, NEUROENDOCRINOLOGY, V81, P372, DOI 10.1159/000089555; Dijk DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030037; DORRSCHEIDT GJ, 1975, J MATH BIOL, V2, P107; Ekmekcioglu C, 2011, OBES REV, V12, P14, DOI 10.1111/j.1467-789X.2010.00716.x; Fonken LK, 2010, P NATL ACAD SCI USA, V107, P18664, DOI 10.1073/pnas.1008734107; Fonken LK, 2009, BEHAV BRAIN RES, V205, P349, DOI 10.1016/j.bbr.2009.07.001; Foster RG, 2007, CURR BIOL, V17, pR746, DOI 10.1016/j.cub.2007.07.007; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; FUKUDA H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P261, DOI 10.1016/0005-2760(91)90168-H; Gale JE, 2011, J BIOL RHYTHM, V26, P423, DOI 10.1177/0748730411416341; GROOS GA, 1985, ANN NY ACAD SCI, V453, P134, DOI 10.1111/j.1749-6632.1985.tb11806.x; Jud C, 2005, BIOL PROCED ONLINE, V7, P101, DOI 10.1251/bpo109; Kalsbeek A, 2012, MOL CELL ENDOCRINOL, V349, P20, DOI 10.1016/j.mce.2011.06.042; Kalsbeek A, 2003, J NEUROENDOCRINOL, V15, P1144, DOI 10.1111/j.1365-2826.2003.01112.x; Kalsbeek A, 2001, ENDOCRINOLOGY, V142, P2677, DOI 10.1210/en.142.6.2677; Kalsbeek A, 2011, FEBS LETT, V585, P1412, DOI 10.1016/j.febslet.2011.03.021; Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012; Karlsson BH, 2003, INT ARCH OCC ENV HEA, V76, P424, DOI 10.1007/s00420-003-0440-y; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Klarsfeld A, 1998, J BIOL RHYTHM, V13, P471, DOI 10.1177/074873098129000309; Kohsaka A, 2007, TRENDS ENDOCRIN MET, V18, P4, DOI 10.1016/j.tem.2006.11.005; la Fleur SE, 2001, DIABETES, V50, P1237, DOI 10.2337/diabetes.50.6.1237; LEIGHTON B, 1988, AM J PHYSIOL, V255, pE41, DOI 10.1152/ajpendo.1988.255.1.E41; Meijer JH, 1996, PROG BRAIN RES, V111, P175, DOI 10.1016/S0079-6123(08)60407-0; Nakamura TJ, 2011, J NEUROSCI, V31, P10201, DOI 10.1523/JNEUROSCI.0451-11.2011; Ohta H, 2005, NAT NEUROSCI, V8, P267, DOI 10.1038/nn1395; Ohta H, 2006, PEDIATR RES, V60, P304, DOI 10.1203/01.pdr.0000233114.18403.66; Rimmer DW, 2000, AM J PHYSIOL-REG I, V279, pR1574, DOI 10.1152/ajpregu.2000.279.5.R1574; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Ruiter M, 2003, DIABETES, V52, P1709, DOI 10.2337/diabetes.52.7.1709; Scheer FAJL, 2003, BIOL CHEM, V384, P697, DOI 10.1515/BC.2003.078; Scheer FAJL, 2001, AM J PHYSIOL-HEART C, V280, pH1391, DOI 10.1152/ajpheart.2001.280.3.H1391; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; van Oosterhout F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039693; Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1; VanSomeren EJW, 1997, J BIOL RHYTHM, V12, P146, DOI 10.1177/074873049701200206; Vinogradova IA, 2009, AGING-US, V1, P855, DOI 10.18632/aging.100092; Wagner, 1999, Curr Treat Options Neurol, V1, P299, DOI 10.1007/s11940-999-0020-x; Wideman CH, 2009, NUTR NEUROSCI, V12, P233, DOI 10.1179/147683009X423436; Wong H, 2010, INT J NURS STUD, V47, P1021, DOI 10.1016/j.ijnurstu.2010.01.001; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zambon AC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r61	53	168	170	3	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1721	1732		10.1096/fj.12-210898	http://dx.doi.org/10.1096/fj.12-210898			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303208				2022-12-28	WOS:000316940800041
J	Sorli, SC; Colie, S; Albinet, V; Dubrac, A; Touriol, C; Guilbaud, N; Bedia, C; Fabrias, G; Casas, J; Segui, B; Levade, T; Andrieu-Abadie, N				Sorli, Sonia-Caroline; Colie, Sandra; Albinet, Virginie; Dubrac, Alexandre; Touriol, Christian; Guilbaud, Nicolas; Bedia, Carmen; Fabrias, Gemma; Casas, Josefina; Segui, Bruno; Levade, Thierry; Andrieu-Abadie, Nathalie			The nonlysosomal beta-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells	FASEB JOURNAL			English	Article						glycosylceramidase; unfolded protein response; cancer cell death; glucosylceramide	KLOTHO-RELATED PROTEIN; GLUCOSYLCERAMIDE SYNTHASE; ER STRESS; GAUCHER-DISEASE; DRUG-RESISTANCE; CERAMIDE; CANCER; SPHINGOLIPIDS; GLYCOSPHINGOLIPIDS; METABOLISM	Glycosphingolipids, which are abundant at the surface of melanoma cells, play crucial roles in tumor progression. We investigated whether a newly described glycosphingolipid hydrolase, encoded by the GBA2 gene, can modulate human melanoma cell growth and death. GBA2 expression was quantified on melanoma cells by RT-qPCR. The antiproliferative effects of GBA2 were assessed in tumor cells expressing inducible GBA2 and in established melanoma xenografts. As a control an inducible catalytically inactive GBA2 mutant was generated. Sphingolipid levels were monitored by mass spectrometry; unfolded protein response (UPR) and apoptosis were assessed by Western blot and flow cytometry analyses, respectively. We report that GBA2 is down-regulated in melanoma; inducible expression of GBA2 affects endogenous sphingolipid metabolism by promoting glucosylceramide degradation (decrease by 78%) and ceramide generation; this is followed by a UPR that causes apoptosis, subsequent decreased anchorage-independent cell growth, and reduced in vivo tumor growth (by 40%); and all these events are abrogated when expressing a catalytically inactive GBA2. This study documents for the first time the antitumor activity of GBA2 and provides evidence for the role of nonlysosomal glucosylceramide breakdown as a source of bioactive ceramide and a mechanistic link between glycolipid catabolism and the UPR/death response of melanoma cells.-Sorli, S.-C., Colie, S., Albinet, V., Dubrac, A., Touriol, C., Guilbaud, N., Bedia, C., Fabrias, G., Casas, J., Segui, B., Levade, T., Andrieu-Abadie, N. The nonlysosomal beta-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 27, 489-498 (2013). www.fasebj.org	[Sorli, Sonia-Caroline; Colie, Sandra; Albinet, Virginie; Dubrac, Alexandre; Touriol, Christian; Segui, Bruno; Levade, Thierry; Andrieu-Abadie, Nathalie] Ctr Rech Cancerol Toulouse, Unite Mixte Rech UMR 1037, INSERM, Toulouse, France; [Sorli, Sonia-Caroline; Colie, Sandra; Albinet, Virginie; Dubrac, Alexandre; Touriol, Christian; Segui, Bruno; Levade, Thierry; Andrieu-Abadie, Nathalie] Univ Toulouse 3, F-31062 Toulouse, France; [Guilbaud, Nicolas] Inst Rech Pierre Fabre, Ctr Rech Oncol Expt, Toulouse, France; [Bedia, Carmen; Fabrias, Gemma; Casas, Josefina] CSIC, IQAC, Dept Biomed Chem, Barcelona, Spain; [Levade, Thierry] Ctr Hosp Univ Toulouse, Lab Biochim Metab, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC); CHU de Toulouse	Andrieu-Abadie, N (corresponding author), CHU Rangueil, Ctr Rech Cancerol Toulouse, UMR1037, INSERM, BP84225, F-31432 Toulouse 4, France.	thierry.levade@inserm.fr; andrieu@inserm.fr	Ségui, Bruno/O-8957-2014; Dubrac, Alexandre/AAQ-9515-2021; TOURIOL, Christian/O-8949-2014; Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013; Bedia, Carmen/D-3827-2013; Bedia, Carmen/H-9185-2015; Casas, Josefina/L-7934-2014	Ségui, Bruno/0000-0002-6119-1889; Dubrac, Alexandre/0000-0002-3829-2577; TOURIOL, Christian/0000-0003-1219-4693; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Bedia, Carmen/0000-0003-4584-5843; Fabrias, Gemma/0000-0001-7162-3772	Institut National de la Sante et de la Recherche Medicale (INSERM); Paul Sabatier University; Pierre-Fabre Dermo-Cosmetique; Centre Europeen de Recherche sur la Peau (Toulouse, France); Generalitat de Catalunya [2009SGR-1072]	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Paul Sabatier University; Pierre-Fabre Dermo-Cosmetique; Centre Europeen de Recherche sur la Peau (Toulouse, France); Generalitat de Catalunya(Generalitat de Catalunya)	The authors thank N. Therville, S. Carpentier, and the staff of the animal facilities and the Plateforme d'Experimentation Fonctionnelle (S. Le Gonidec, A. Desquesnes, and A. Estival) for technical assistance. This project was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Paul Sabatier University, Pierre-Fabre Dermo-Cosmetique, Centre Europeen de Recherche sur la Peau (Toulouse, France), and Generalitat de Catalunya (grant 2009SGR-1072). The authors declare no conflicts of interest.	Bedia C, 2011, J BIOL CHEM, V286, P28200, DOI 10.1074/jbc.M110.216382; Beutler E., 2001, METABOLIC MOL BASES, VIII, P3635; Boot RG, 2007, J BIOL CHEM, V282, P1305, DOI 10.1074/jbc.M610544200; Boslem E, 2011, BIOCHEM J, V435, P267, DOI 10.1042/BJ20101867; Cobucci-Ponzano B, 2010, J BIOL CHEM, V285, P20691, DOI 10.1074/jbc.M109.086470; Colie S, 2009, CANCER RES, V69, P9346, DOI 10.1158/0008-5472.CAN-09-2198; Deng W, 2002, GLYCOBIOLOGY, V12, P145, DOI 10.1093/glycob/12.3.145; Deng W, 2000, J NATL CANCER I, V92, P912, DOI 10.1093/jnci/92.11.912; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329; Gouaze-Andersson V, 2006, BBA-BIOMEMBRANES, V1758, P2096, DOI 10.1016/j.bbamem.2006.08.012; Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106; Hakomori S, 2010, FEBS LETT, V584, P1901, DOI 10.1016/j.febslet.2009.10.065; Halter D, 2007, J CELL BIOL, V179, P101, DOI 10.1083/jcb.200704091; Hayashi Y, 2007, J BIOL CHEM, V282, P30889, DOI 10.1074/jbc.M700832200; Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200; KOBAYASHI T, 1981, J BIOL CHEM, V256, P7768; Kuphal S, 2009, J PATHOL, V219, P400, DOI 10.1002/path.2617; Lahiri S, 2007, CELL MOL LIFE SCI, V64, P2270, DOI 10.1007/s00018-007-7076-0; Landgren O, 2007, ARCH INTERN MED, V167, P1189, DOI 10.1001/archinte.167.11.1189; Lepine S, 2011, CELL DEATH DIFFER, V18, P350, DOI 10.1038/cdd.2010.104; Liu YY, 2011, CANCER RES, V71, P2276, DOI 10.1158/0008-5472.CAN-10-3107; Lo ASY, 2010, CLIN CANCER RES, V16, P2769, DOI 10.1158/1078-0432.CCR-10-0043; Morales A, 2007, APOPTOSIS, V12, P923, DOI 10.1007/s10495-007-0721-0; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ponnusamy S, 2010, FUTURE ONCOL, V6, P1603, DOI 10.2217/FON.10.116; PORTOUKALIAN J, 1979, EUR J BIOCHEM, V94, P19, DOI 10.1111/j.1432-1033.1979.tb12866.x; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Salma Y, 2009, BIOCHEM PHARMACOL, V78, P477, DOI 10.1016/j.bcp.2009.05.002; Sauane M, 2010, J CELL PHYSIOL, V222, P546, DOI 10.1002/jcp.21969; Segui B, 2006, BBA-BIOMEMBRANES, V1758, P2104, DOI 10.1016/j.bbamem.2006.05.024; Senkal CE, 2011, J BIOL CHEM, V286, P42446, DOI 10.1074/jbc.M111.287383; Sietsma H, 2000, CLIN CANCER RES, V6, P942; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Taddei TH, 2009, AM J HEMATOL, V84, P208, DOI 10.1002/ajh.21362; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Weiss M, 2003, CANCER RES, V63, P3654; Yahata K, 2000, J MOL MED, V78, P389, DOI 10.1007/s001090000131; Yildiz Y, 2006, J CLIN INVEST, V116, P2985, DOI 10.1172/JCI29224	45	31	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2013	27	2					489	498		10.1096/fj.12-215152	http://dx.doi.org/10.1096/fj.12-215152			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23073830				2022-12-28	WOS:000314358000009
J	Dieterich, LC; Schiller, P; Huang, H; Wawrousek, EF; Loskog, A; Wanders, A; Moons, L; Dimberg, A				Dieterich, Lothar C.; Schiller, Petter; Huang, Hua; Wawrousek, Eric F.; Loskog, Angelica; Wanders, Alkwin; Moons, Lieve; Dimberg, Anna			alpha B-Crystallin regulates expansion of CD11b(+)Gr-1(+) immature myeloid cells during tumor progression	FASEB JOURNAL			English	Article						heat-shock protein B5; inflammation; cancer; myelopoiesis	HEAT-SHOCK PROTEINS; SUPPRESSOR-CELLS; IMMUNE-RESPONSES; CANCER; INFLAMMATION; EXPRESSION; HSP27; HYPERPROLIFERATION; DIFFERENTIATION; ANGIOGENESIS	The molecular chaperone alpha B-crystallin has emerged as a target for cancer therapy due to its expression in human tumors and its role in regulating tumor angiogenesis. alpha B-crystallin also reduces neuroinflammation, but its role in other inflammatory conditions has not been investigated. Here, we examined whether alpha B-crystallin regulates inflammation associated with tumors and ischemia. We found that CD45(+) leukocyte infiltration is 3-fold increased in tumors and ischemic myocardium in alpha B-crystallin-deficient mice. Notably, alpha B-crystallin is prominently expressed in CD11b(+) Gr-1(+) immature myeloid cells (IMCs), known as regulators of angiogenesis and immune responses, while lymphocytes and mature granulocytes show low alpha B-crystallin expression. alpha B-Crystallin deficiency results in a 3-fold higher accumulation of CD11b(+) Gr-1(+) IMCs in tumors and a significant rise in CD11b(+) Gr-1(+) IMCs in spleen and bone marrow. Similarly, we noted a 2-fold increase in CD11b(+) Gr-1(+) IMCs in chronically inflamed livers in alpha B-crystallin-deficient mice. The effect of alpha B-crystallin on IMC accumulation is limited to pathological conditions, as CD11b(+) Gr-1(+) IMCs are not elevated in naive mice. Through ex vivo differentiation of CD11b(+) Gr-1(+) cells, we provide evidence that alpha B-crystallin regulates systemic expansion of IMCs through a cell-intrinsic mechanism. Our study suggests a key role of alpha B-crystallin in limiting expansion of CD11b(+) Gr-1(+) IMCs in diverse pathological conditions.-Dieterich, L. C., Schiller, P., Huang, H., Wawrousek, E. F., Loskog, A., Wanders, A., Moons, L., Dimberg, A. alpha B-Crystallin regulates expansion of CD11b(+) Gr-1(+) immature myeloid cells during tumor progression. FASEB J. 27, 151-162 (2013). www.fasebj.org	[Dieterich, Lothar C.; Schiller, Petter; Huang, Hua; Loskog, Angelica; Wanders, Alkwin; Dimberg, Anna] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden; [Wawrousek, Eric F.] NEI, NIH, Bethesda, MD 20892 USA; [Moons, Lieve] Katholieke Univ Leuven, Dept Biol, Anim Physiol & Neurobiol Sect, Louvain, Belgium	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); KU Leuven	Dimberg, A (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.	anna.dimberg@igp.uu.se	Wawrousek, Eric/A-4547-2008	Dieterich, Lothar/0000-0001-7908-5710; Dimberg, Anna/0000-0003-4422-9125; Loskog, Angelica/0000-0001-8583-6138; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Schiller, Petter/0000-0002-1790-3711	NATIONAL EYE INSTITUTE [ZICEY000458] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adhikari AS, 2011, BBA-MOL CELL RES, V1813, P1532, DOI 10.1016/j.bbamcr.2011.04.009; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Arac A, 2011, P NATL ACAD SCI USA, V108, P13287, DOI 10.1073/pnas.1107368108; Arrigo AP, 2007, FEBS LETT, V581, P3665, DOI 10.1016/j.febslet.2007.04.033; Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200; Benjamin IJ, 2007, AM J PHYSIOL-HEART C, V293, pH3201, DOI 10.1152/ajpheart.01363.2006; Boslooper K, 2008, PATHOLOGY, V40, P500, DOI 10.1080/00313020802198010; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Chin D, 2005, LARYNGOSCOPE, V115, P1239, DOI 10.1097/01.MLG.0000164715.86240.55; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092; De Wilde V, 2009, AM J TRANSPLANT, V9, P2034, DOI 10.1111/j.1600-6143.2009.02757.x; Dieterich L. C., 2012, CURR ANGIOGEN, V1, P39; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Dugast AS, 2008, J IMMUNOL, V180, P7898, DOI 10.4049/jimmunol.180.12.7898; Evert M, 2002, CARCINOGENESIS, V23, P697, DOI 10.1093/carcin/23.5.697; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Ho PY, 2013, UROL ONCOL-SEMIN ORI, V31, P1367, DOI 10.1016/j.urolonc.2012.01.015; Ioannou M, 2012, J IMMUNOL, V188, P1136, DOI 10.4049/jimmunol.1101816; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Moline-Velazquez V, 2011, BRAIN PATHOL, V21, P678, DOI 10.1111/j.1750-3639.2011.00495.x; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935; Parcellier A, 2005, ANTIOXID REDOX SIGN, V7, P404, DOI 10.1089/ars.2005.7.404; Ria R, 2009, CLIN CANCER RES, V15, P5369, DOI 10.1158/1078-0432.CCR-09-0040; Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691; Ruan Q, 2011, MOL CANCER RES, V9, P1632, DOI 10.1158/1541-7786.MCR-11-0327; Sander LE, 2010, J EXP MED, V207, P1453, DOI 10.1084/jem.20091474; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004; van Noort JM, 2012, INT J BIOCHEM CELL B, V44, P1670, DOI 10.1016/j.biocel.2011.12.010; van Noort JM, 2010, J NEUROPATH EXP NEUR, V69, P694, DOI 10.1097/NEN.0b013e3181e4939c; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Yin BJ, 2010, J IMMUNOL, V185, P5828, DOI 10.4049/jimmunol.0903636	50	3	3	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					151	162		10.1096/fj.12-213017	http://dx.doi.org/10.1096/fj.12-213017			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23033322	Green Published, Green Accepted			2022-12-28	WOS:000313103200015
J	Goosen, P; Swart, AC; Storbeck, KH; Swart, P				Goosen, Pierre; Swart, Amanda C.; Storbeck, Karl-Heinz; Swart, Pieter			Allosteric interaction between 3 beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase and cytochrome b(5) influences cofactor binding	FASEB JOURNAL			English	Article						adrenal steroidogenesis; dehydroepiandrosterone; androstenedione; UPLC-MS/MS; FRET; NAD(+)	PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; BETA-HYDROXYSTEROID DEHYDROGENASE; STEROID 5->4-ENE-ISOMERASE; 17,20-LYASE ACTIVITY; MOLECULAR-BIOLOGY; ADRENAL-CORTEX; PURIFICATION; EXPRESSION; P450C17; STEROIDOGENESIS	The biosynthesis of steroid hormones, essential to the survival of all mammals, is dependent on the activity of 3 beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase (3 beta HSD). 3 beta HSD activity is, in turn, influenced by cytochrome-b(5) (Cyt-b(5)). However, the mechanism through which this occurs is unknown. In this study, we investigated this mechanism by evaluating the influence of Cyt-b(5) on the dehydrogenase and isomerase activities of 3 beta HSD. Capra hircus 3 beta HSD was overexpressed in SF-9 cells, using a baculovirus expression system, and purified. Substrate and cofactor kinetics were determined spectrophotometrically in the presence and absence of purified Ovis aries liver Cyt-b(5). Nonspecific enzyme activity was evaluated by zero-enzyme, -substrate, and -cofactor blanks. Fusion proteins, 3 beta HSD-eCFP, and Cyt-b(5)-eYFP were subsequently coexpressed in COS-1 cells and analyzed for FRET. A CFP-YFP fusion protein served as positive control, while coexpression of 3 beta HSD-eCFP and cytochrome P450 17 alpha-hydroxylase/17,20 lyase-eYFP (CYP17A1-eYFP) served as negative control. Results showed Cyt-b(5) to decrease the K-m,K-NAD+ value of 3 beta HSD approximate to 3.5-fold while increasing the V-max,V-app of the dehydrogenase reaction approximate to 17%. FRET analysis showed COS-1 cells coexpressing 3 beta HSD-eCFP and Cyt-b(5)-eYFP to exhibit a FRET signal approximate to 9-fold greater than that of the negative control. These results indicate that Cyt-b(5) augments 3 beta HSD activity via an allosteric mechanism by increasing the affinity of the enzyme toward NAD(+).-Goosen, P., Swart, A. C., Storbeck, K.-H., Swart, P. Allosteric interaction between 3 beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase and cytochrome b(5) influences cofactor binding. FASEB J. 27, 322-332 (2013). www.fasebj.org	[Goosen, Pierre; Swart, Amanda C.; Storbeck, Karl-Heinz; Swart, Pieter] Univ Stellenbosch, Dept Biochem, ZA-7602 Stellenbosch, South Africa	Stellenbosch University	Swart, P (corresponding author), Unvers Stellenbosch, Private Bag X1, ZA-7602 Stellenbosch, South Africa.	pswart@sun.ac.za	Storbeck, Karl/AAF-5126-2020; Swart, Pieter/J-3856-2015; Swart, Amanda C/O-5939-2017	Swart, Pieter/0000-0001-8610-4799; Swart, Amanda C/0000-0001-7529-8989; Storbeck, Karl-Heinz/0000-0003-1669-6383	South Africa National Research Foundation; Harry Crossly Foundation; Claude Leon Foundation; University of Stellenbosch	South Africa National Research Foundation(National Research Foundation - South Africa); Harry Crossly Foundation; Claude Leon Foundation; University of Stellenbosch	The authors thank James L. Thomas (Division of Basic Medical Sciences, Department of Obstetics-Gynecology, Mercer University School of Medicine, Macon, GA, USA) for technical assistance in the expression and purification of 3 beta HSD, and Jacky Snoep (Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa) for fruitful discussions. The plasmids containing the eCFP-GR and eYFP-GR constructs were a generous gift from Ann Louw (Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa). The Cer-5-Ven plasmid containing both CFP and YFP was a generous gift from Ammasi Periasamy (W. M. Keck Center for Cellular Imaging, Department of Biology, University of Virginia, Charlottesville, VA, USA). The authors thank Patricia Storbeck for assistance in the preparation of the colocalization SDS-PAGE figures. This work was financially supported by the South Africa National Research Foundation, the Harry Crossly Foundation, the Claude Leon Foundation, and the University of Stellenbosch.	Agarwal AK, 2005, ENDOCRINOLOGY, V146, P2531, DOI 10.1210/en.2005-0061; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; BRETON R, 1994, J STEROID BIOCHEM, V50, P275, DOI 10.1016/0960-0760(94)90132-5; Burger HG, 2002, FERTIL STERIL, V77, pS3; Chapman JC, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-11; Cherradi N, 1995, J STEROID BIOCHEM, V55, P507, DOI 10.1016/0960-0760(95)00199-9; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; Dharia S, 2004, BIOL REPROD, V71, P83, DOI 10.1095/biolreprod.103.026732; Fluck CE, 2003, J CLIN ENDOCR METAB, V88, P3762, DOI 10.1210/jc.2003-030143; GEORGIADIS EI, 1992, HORM METAB RES, V24, P488, DOI 10.1055/s-2007-1003369; Goosen P, 2011, J STEROID BIOCHEM, V127, P238, DOI 10.1016/j.jsbmb.2011.09.001; Goosen P, 2010, MOL CELL ENDOCRINOL, V315, P182, DOI 10.1016/j.mce.2009.07.026; KATAGIRI M, 1982, BIOCHEM BIOPH RES CO, V108, P379, DOI 10.1016/0006-291X(82)91877-0; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; Lombard N, 2002, ENDOCR RES, V28, P485, DOI 10.1081/ERC-120016827; Miller WL, 2011, ENDOCR REV, V32, P81, DOI 10.1210/er.2010-0013; Nakamura Y, 2011, J STEROID BIOCHEM, V123, P122, DOI 10.1016/j.jsbmb.2010.12.001; NASH WE, 1994, J STEROID BIOCHEM, V50, P235, DOI 10.1016/0960-0760(94)90127-9; Nguyen PTT, 2012, J STEROID BIOCHEM, V128, P12, DOI 10.1016/j.jsbmb.2011.10.003; Pandey AV, 2005, J BIOL CHEM, V280, P13265, DOI 10.1074/jbc.M414673200; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Piltonen T, 2002, HUM REPROD, V17, P620, DOI 10.1093/humrep/17.3.620; Rainey WE, 2008, J STEROID BIOCHEM, V108, P281, DOI 10.1016/j.jsbmb.2007.09.015; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; Storbeck KH, 2008, ANAL BIOCHEM, V372, P11, DOI 10.1016/j.ab.2007.09.036; Storbeck KH, 2007, DRUG METAB REV, V39, P467, DOI 10.1080/03602530701468649; Suzuki T, 2000, CLIN ENDOCRINOL, V53, P739, DOI 10.1046/j.1365-2265.2000.01144.x; Swart P, 2003, ARCH BIOCHEM BIOPHYS, V409, P145, DOI 10.1016/S0003-9861(02)00547-7; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; Thomas JL, 2003, J BIOL CHEM, V278, P35483, DOI 10.1074/jbc.M304752200; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; THOMAS JL, 1995, J BIOL CHEM, V270, P21003, DOI 10.1074/jbc.270.36.21003; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; Van L., 1991, BIOCHEMISTRY-US, V36, P8861; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Zhou M, 1996, J CRYST GROWTH, V168, P142, DOI 10.1016/0022-0248(96)00372-7	38	4	4	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					322	332		10.1096/fj.12-213736	http://dx.doi.org/10.1096/fj.12-213736			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22982379				2022-12-28	WOS:000313103200030
J	Shan, TZ; Liu, WY; Kuang, SH				Shan, Tizhong; Liu, Weiyi; Kuang, Shihuan			Fatty acid binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues	FASEB JOURNAL			English	Article						mouse; stromal vascular fraction	COMMITTED PREADIPOCYTES; STEM-CELLS; DISTINCT; IDENTIFICATION; ADIPOGENESIS; COMMITMENT; RESPONSES; RECEPTOR; ROLES; OBESE	Adipose tissues regulate metabolism, reproduction, and life span. The development and growth of adipose tissue are due to increases of both adipocyte cell size and cell number; the latter is mediated by adipocyte progenitors. Various markers have been used to identify either adipocyte progenitors or mature adipocytes. The fatty acid binding protein 4 (FABP4), commonly known as adipocyte protein 2 (aP2), has been extensively used as a marker for differentiated adipocytes. However, whether aP2 is expressed in adipogenic progenitors is controversial. Using Cre/LoxP-based cell lineage tracing in mice, we have identified a population of aP2-expressing progenitors in the stromal vascular fraction (SVF) of both white and brown adipose tissues. The aP2-lineage progenitors reside in the adipose stem cell niche and express adipocyte progenitor markers, including CD34, Sca1, Dlk1, and PDGFR alpha. When isolated and grown in culture, the aP2-expressing SVF cells proliferate and differentiate into adipocytes upon induction. Conversely, ablation of the aP2 lineage greatly reduces the adipogenic potential of SVF cells. When grafted into wild-type mice, the aP2-lineage progenitors give rise to adipose depots in recipient mice. Therefore, the expression of aP2 is not limited to mature adipocytes, but also marks a pool of undifferentiated progenitors associated with the vasculature of adipose tissues. Our finding adds to the repertoire of adipose progenitor markers and points to a new regulator of adipose plasticity.-Shan, T., Liu, W., Kuang, S. Fatty acid-binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues. FASEB J. 27, 277-287 (2013). www.fasebj.org	[Shan, Tizhong; Liu, Weiyi; Kuang, Shihuan] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; [Kuang, Shihuan] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kuang, SH (corresponding author), Purdue Univ, Dept Anim Sci, 174B Smith Hall,901 W State St, W Lafayette, IN 47907 USA.	skuang@purdue.edu	liu, weiyi/B-2053-2014; Shan, Tizhong/G-1947-2015; liu, weiyi/G-2730-2012	Kuang, Shihuan/0000-0001-9180-3180	Muscular Dystrophy Association; U.S. National Institutes of Health; U.S. Department of Agriculture; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060652] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Agriculture(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Pengpeng Bi for comments on the manuscript, and Jun Wu for mouse colony support. The project is partially supported by funding from the Muscular Dystrophy Association, the U.S. National Institutes of Health, and the U.S. Department of Agriculture to S.K. The authors declare no conflict of interests.	Agardh HE, 2011, J INTERN MED, V269, P200, DOI 10.1111/j.1365-2796.2010.02304.x; Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543; Cataltepe O, 2012, NEUROPATH APPL NEURO, V38, P400, DOI 10.1111/j.1365-2990.2011.01237.x; Cawthorn WP, 2012, J LIPID RES, V53, P227, DOI 10.1194/jlr.R021089; Crisan M, 2008, STEM CELLS, V26, P2425, DOI 10.1634/stemcells.2008-0325; Daquinag AC, 2011, CELL STEM CELL, V9, P74, DOI 10.1016/j.stem.2011.05.017; Di Rocco G, 2006, J CELL SCI, V119, P2945, DOI 10.1242/jcs.03029; Elmasri H, 2009, FASEB J, V23, P3865, DOI 10.1096/fj.09-134882; Gupta RK, 2012, CELL METAB, V15, P230, DOI 10.1016/j.cmet.2012.01.010; Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Hui XY, 2010, J BIOL CHEM, V285, P10273, DOI 10.1074/jbc.M109.097907; Tran KV, 2012, CELL METAB, V15, P222, DOI 10.1016/j.cmet.2012.01.008; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Lee K, 2003, J CLIN INVEST, V111, P453, DOI 10.1172/JCI15924; Liu WY, 2012, DEV BIOL, V361, P27, DOI 10.1016/j.ydbio.2011.10.011; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Makowski L, 2005, J BIOL CHEM, V280, P12888, DOI 10.1074/jbc.M413788200; Mussig K, 2012, CLIN ENDOCRINOL, V77, P139, DOI 10.1111/j.1365-2265.2012.04343.x; Poulos SP, 2010, EXP BIOL MED, V235, P1185, DOI 10.1258/ebm.2010.010063; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Russell AP, 2012, INT J OBESITY, V36, P155, DOI 10.1038/ijo.2011.85; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Shan T, 2010, J ANIM SCI, V88, P3909, DOI 10.2527/jas.2010-2880; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Suga H, 2009, STEM CELLS DEV, V18, P1201, DOI 10.1089/scd.2009.0003; Sul HS, 2009, MOL ENDOCRINOL, V23, P1717, DOI 10.1210/me.2009-0160; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Tchoukalova YD, 2004, AM J PHYSIOL-REG I, V287, pR1132, DOI 10.1152/ajpregu.00337.2004; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Urs S, 2006, TRANSGENIC RES, V15, P647, DOI 10.1007/s11248-006-9000-z; Walden TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011; Yamamoto Y, 2010, OBESITY, V18, P872, DOI 10.1038/oby.2009.512; Zeve D, 2009, CELL STEM CELL, V5, P472, DOI 10.1016/j.stem.2009.10.014	38	125	132	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					277	287		10.1096/fj.12-211516	http://dx.doi.org/10.1096/fj.12-211516			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047894	Green Published			2022-12-28	WOS:000313103200026
J	Aratake, Y; Okuno, T; Matsunobu, T; Saeki, K; Takayanagi, R; Furuya, S; Yokomizo, T				Aratake, Yoshifusa; Okuno, Toshiaki; Matsunobu, Takehiko; Saeki, Kazuko; Takayanagi, Ryoichi; Furuya, Sonoko; Yokomizo, Takehiko			Helix 8 of leukotriene B-4 receptor 1 inhibits ligand-induced internalization	FASEB JOURNAL			English	Article						GPCR; BLT1; endocytosis; phosphorylation	PROTEIN-COUPLED RECEPTOR; AGONIST-INDUCED INTERNALIZATION; ACTIVATING-FACTOR RECEPTOR; CRYSTAL-STRUCTURE; CIRCULAR-DICHROISM; C-TERMINUS; PHOSPHORYLATION; TRAFFICKING; NMR; ENDOCYTOSIS	Recent crystallographic studies revealed that G-protein-coupled receptors (GPCRs) possess a putative cytoplasmic helical domain, termed helix 8, at the proximal region of the C-terminal tail. However, the significance of helix 8 in GPCR functions and signaling is not fully understood. Helix 8 mutants of leukotriene B-4 receptor type 1 (BLT1) exhibit prolonged activation after ligand stimulation, suggesting some regulatory roles of helix 8 in GPCR signaling. Here, we report the inhibitory role of BLT1 helix 8 on ligand-dependent internalization using BLT1 and platelet- activating factor receptor as model GPCRs. Mutating the dileucine motif in helix 8 of BLT1 to alanines (BLT1 LLAA) enhanced LTB4-dependent internalization of BLT1, whereas wild-type (WT) BLT1 exhibited minimal internalization. Mutational studies revealed that phosphorylation of 5 serine/threonine residues between amino acids 308 and 319 of BLT1 was responsible for enhanced ligand-dependent internalization of BLT1 LLAA. BLT1 LLAA showed enhanced basal and ligand-dependent phosphorylation compared to WT BLT1. Taken together, helix 8 of BLT1 inhibits receptor internalization by suppressing the excessive phosphorylation of the C-terminal tail.-Aratake, Y., Okuno, T., Matsunobu, T., Saeki, K., Takayanagi, R., Furuya, S., Yokomizo, T. Helix 8 of leukotriene B4 receptor 1 inhibits ligand-induced internalization. FASEB J. 26, 4068-4078 (2012). www.fasebj.org	[Yokomizo, Takehiko] Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Fukuoka 8128582, Japan; [Aratake, Yoshifusa; Takayanagi, Ryoichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 8128582, Japan; [Furuya, Sonoko] Natl Inst Physiol Sci, Support Ctr Brain Res, Sect Brain Struct Informat, Aichi, Japan	Kyushu University; Kyushu University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Yokomizo, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	yokomizo-tky@umin.ac.jp	Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553	Ministry of Education, Culture, Sports, Science, and Technology of Japan [21390083, 22116001, 22116002, 22790296, 24102522]; Mochida Memorial Foundation; Takeda Science Foundation; Senshin Medial Research Foundation; Kowa Life Science Foundation; Inamori Foundation; Japan Society for the Promotion of Science (Global COE program)	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mochida Memorial Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Senshin Medial Research Foundation; Kowa Life Science Foundation; Inamori Foundation; Japan Society for the Promotion of Science (Global COE program)	The authors thank the Support Center for Education and Research, Graduate School of Medical Sciences, Kyushu University for technical support; F. Sasaki, M. Minami, K. Moroishi, and N. Onohara for technical assistance; and all of their laboratory members for valuable advice and discussions. This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (21390083, 22116001, and 22116002 to T. Y.; 22790296 and 24102522 to T.O.), and grants from the Mochida Memorial Foundation, the Takeda Science Foundation, the Senshin Medial Research Foundation, the Kowa Life Science Foundation, and the Inamori Foundation (to T.O.), and Japan Society for the Promotion of Science (Global COE program; to T.Y.).	Ahn KH, 2010, BIOCHEMISTRY-US, V49, P502, DOI 10.1021/bi901619r; Anavi-Goffer S, 2007, J BIOL CHEM, V282, P25100, DOI 10.1074/jbc.M703388200; Awwad HO, 2010, EUR J PHARMACOL, V635, P9, DOI 10.1016/j.ejphar.2010.02.033; Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Chen ZG, 2004, MOL PHARMACOL, V66, P377; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Choi G, 2005, BBA-BIOMEMBRANES, V1668, P1, DOI 10.1016/j.bbamem.2004.10.011; Choi G, 2002, J PEPT RES, V60, P169, DOI 10.1034/j.1399-3011.2002.21012.x; D'Amelio N, 2003, BIOPOLYMERS, V70, P134, DOI 10.1002/bip.10426; Delos Santos NM, 2006, J BIOL CHEM, V281, P12896, DOI 10.1074/jbc.M508500200; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iizuka Y, 2010, FASEB J, V24, P4678, DOI 10.1096/fj.10-165050; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Katragadda M, 2004, BBA-BIOMEMBRANES, V1663, P74, DOI 10.1016/j.bbamem.2004.01.012; Kuramasu A, 2011, CELL SIGNAL, V23, P1843, DOI 10.1016/j.cellsig.2011.06.021; Kuwasako K, 2011, PEPTIDES, V32, P144, DOI 10.1016/j.peptides.2010.10.005; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Moskowitz HS, 2003, MOL BIOL CELL, V14, P4437, DOI 10.1091/mbc.e03-04-0230; Mukhopadhyay S, 1999, BIOCHEMISTRY-US, V38, P3447, DOI 10.1021/bi981767v; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; Nakamura M, 2011, CHEM REV, V111, P6231, DOI 10.1021/cr100392s; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parhamifar L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014439; Piserchio A, 2005, BIOPOLYMERS, V80, P367, DOI 10.1002/bip.20220; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Reid HM, 2010, J BIOL CHEM, V285, P18709, DOI 10.1074/jbc.M110.106476; Serezani CH, 2009, BLOOD, V114, P3316, DOI 10.1182/blood-2009-01-199919; Suvorova ES, 2008, BBA-MOL CELL RES, V1783, P1261, DOI 10.1016/j.bbamcr.2008.02.004; Suvorova ES, 2009, BBA-MOL CELL RES, V1793, P406, DOI 10.1016/j.bbamcr.2008.09.011; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Yasuda D, 2009, FASEB J, V23, P1470, DOI 10.1096/fj.08-125385; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	48	17	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4068	4078		10.1096/fj.12-212050	http://dx.doi.org/10.1096/fj.12-212050			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22707565	Green Accepted			2022-12-28	WOS:000309704000014
J	Gjorlund, MD; Nielsen, J; Pankratova, S; Li, SZ; Korshunova, I; Bock, E; Berezin, V				Gjorlund, Michelle D.; Nielsen, Janne; Pankratova, Stanislava; Li, Shizhong; Korshunova, Irina; Bock, Elisabeth; Berezin, Vladimir			Neuroligin-1 induces neurite outgrowth through interaction with neurexin-1 beta and activation of fibroblast growth factor receptor-1	FASEB JOURNAL			English	Article						synaptic cell adhesion molecules; neuritogenesis; hippocampal neurons	CELL-ADHESION MOLECULES; FGF-RECEPTOR; BETA-NEUREXINS; STRUCTURAL BASIS; NEURONAL SURVIVAL; CRYSTAL-STRUCTURE; SURFACE PROTEINS; N-CADHERIN; BINDING; EXPRESSION	Neurexin-1 (NRXN1) and neuroligin-1 (NLGN1) are synaptic cell adhesion molecules that connect pre- and postsynaptic neurons at synapses and mediate signaling across the synapse, which modulates synaptic activity and determines the properties of neuronal networks. Defects in the genes encoding NLGN1 have been linked to cognitive diseases such as autism. The roles of both NRXN1 and NLGN1 during synaptogenesis have been studied extensively, but little is known about the role of these molecules in neuritogenesis, which eventually results in neuronal circuitry formation. The present study investigated the neuritogenic effect of NLGN1 in cultures of hippocampal neurons. Our results show that NLGN1, both in soluble and membrane-bound forms, induces neurite outgrowth that depends on the interaction with NRXN1 beta and on activation of fibroblast growth factor receptor-1. In addition, we demonstrate that a synthetic peptide, termed neurolide, which is modeled after a part of the binding interface of NLGN1 for NRXN1 beta, can bind to NRXN1 beta and mimic the biological properties of NLGN1 in vitro.-Gjorlund, M. D., Nielsen, J., Pankratova, S., Li, S., Korshunova, I., Bock, B., Berezin, V. Neuroligin-1 induces neurite outgrowth through interaction with neurexin-1 beta and activation of fibroblast growth factor receptor-1. FASEB J. 26, 4174-4186 (2012). www.fasebj.org	[Gjorlund, Michelle D.; Nielsen, Janne; Pankratova, Stanislava; Li, Shizhong; Korshunova, Irina; Bock, Elisabeth; Berezin, Vladimir] Univ Copenhagen, Dept Neurosci & Pharmacol, Fac Hlth Sci, Prot Lab, DK-2200 Copenhagen, Denmark	University of Copenhagen	Berezin, V (corresponding author), Univ Copenhagen, Dept Neurosci & Pharmacol, Fac Hlth Sci, Prot Lab, Blegdamsvej 3B,Bldg 24-2, DK-2200 Copenhagen, Denmark.	berezin@sund.ku.dk	Nielsen, Janne/J-5987-2014	Nielsen, Janne/0000-0001-8521-7353; Korshunova, Irina/0000-0003-1921-6170; Pankratova, Stanislava/0000-0002-5406-5163	7FP European Union collaborative project MemStick [201600]; Lundbeck Foundation; Danish Research Councils; Lundbeck Foundation [R44-2009-4226] Funding Source: researchfish	7FP European Union collaborative project MemStick; Lundbeck Foundation(Lundbeckfonden); Danish Research Councils(Det Frie Forskningsrad (DFF)); Lundbeck Foundation(Lundbeckfonden)	This study was supported by the 7FP European Union collaborative project MemStick (grant agreement 201600), the Lundbeck Foundation, and the Danish Research Councils.	Arac D, 2007, NEURON, V56, P992, DOI 10.1016/j.neuron.2007.12.002; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Blundell J, 2010, J NEUROSCI, V30, P2115, DOI 10.1523/JNEUROSCI.4517-09.2010; Boucard AA, 2005, NEURON, V48, P229, DOI 10.1016/j.neuron.2005.08.026; Budreck EC, 2007, EUR J NEUROSCI, V26, P1738, DOI 10.1111/j.1460-9568.2007.05842.x; Chih B, 2006, NEURON, V51, P171, DOI 10.1016/j.neuron.2006.06.005; Chubykin AA, 2007, NEURON, V54, P919, DOI 10.1016/j.neuron.2007.05.029; Dean C, 2006, TRENDS NEUROSCI, V29, P21, DOI 10.1016/j.tins.2005.11.003; Dong HH, 2004, J NEUROSCI, V24, P8950, DOI 10.1523/JNEUROSCI.2106-04.2004; Dvir H, 2010, CHEM-BIOL INTERACT, V187, P10, DOI 10.1016/j.cbi.2010.01.042; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gilbert M, 2001, GLIA, V34, P151, DOI 10.1002/glia.1050; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Hansen SM, 2008, CELL MOL LIFE SCI, V65, P3809, DOI 10.1007/s00018-008-8290-0; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hoon M, 2011, P NATL ACAD SCI USA, V108, P3053, DOI 10.1073/pnas.1006946108; Hu YL, 2009, J BIOL CHEM, V284, P29905, DOI 10.1074/jbc.M109.049155; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Karaulanov EE, 2006, EMBO REP, V7, P283, DOI 10.1038/sj.embor.7400614; Kim J, 2008, P NATL ACAD SCI USA, V105, P9087, DOI 10.1073/pnas.0803448105; Kirschbaum K, 2009, J BIOL CHEM, V284, P28533, DOI 10.1074/jbc.M109.004440; Kiselyov VV, 2006, PROTEIN SCI, V15, P2318, DOI 10.1110/ps.062206106; Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969-2126(03)00096-0; Koehnke J, 2008, P NATL ACAD SCI USA, V105, P1873, DOI 10.1073/pnas.0711701105; Kohler LB, 2010, J NEUROSCI RES, V88, P2165, DOI 10.1002/jnr.22380; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kulahin N, 2008, MOL CELL NEUROSCI, V37, P528, DOI 10.1016/j.mcn.2007.12.001; Lise MF, 2006, CELL MOL LIFE SCI, V63, P1833, DOI 10.1007/s00018-006-6061-3; Maar TE, 1997, J NEUROSCI RES, V47, P163; Missler M, 1998, J NEUROCHEM, V71, P1339; Neiiendam JL, 2004, J NEUROCHEM, V91, P920, DOI 10.1111/j.1471-4159.2004.02779.x; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Olsen SK, 2006, GENE DEV, V20, P185, DOI 10.1101/gad.1365406; Owczarek S, 2010, FASEB J, V24, P1139, DOI 10.1096/fj.09-140509; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wittenmayer N, 2009, P NATL ACAD SCI USA, V106, P13564, DOI 10.1073/pnas.0905819106; Zhang Y, 2001, FEBS LETT, V497, P99, DOI 10.1016/S0014-5793(01)02450-4	47	36	36	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4174	4186		10.1096/fj.11-202242	http://dx.doi.org/10.1096/fj.11-202242			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22750515				2022-12-28	WOS:000309704000023
J	Bechtel, M; Keller, MV; Bloch, W; Sasaki, T; Boukamp, P; Zaucke, F; Paulsson, M; Nischt, R				Bechtel, Manuela; Keller, Manuel V.; Bloch, Wilhelm; Sasaki, Takako; Boukamp, Petra; Zaucke, Frank; Paulsson, Mats; Nischt, Roswitha			Different domains in nidogen-1 and nidogen-2 drive basement membrane formation in skin organotypic cocultures	FASEB JOURNAL			English	Article						3-dimensional coculture system; laminin-collagen connecting activity	LAMININ GAMMA-1 CHAIN; COLLAGEN TYPE-IV; EPITHELIAL MORPHOGENESIS; MOUSE NIDOGEN-2; BINDING-SITE; KERATINOCYTES; COMPONENTS; PROTEIN; CELLS; MICE	Nidogen-1 and nidogen-2 are homologous proteins found in all basement membranes (BMs). They show comparable binding activities in vitro and partially redundant functions in vivo. Previously, we showed that in skin organotypic cocultures, BM formation was prevented in the absence of nidogens and that either nidogen was able to rescue this failure. We now dissected the two nidogens to identify the domains required for BM deposition. For that purpose, HaCaT cells were grown on collagen matrices containing nidogen-deficient, murine fibroblasts. After addition of nidogen-1 or nidogen-2 protein fragments comprising different binding domains, BM deposition was analyzed by immunofluorescence and electron microscopy. We could demonstrate that the rod-G3 domain of nidogen-2 was sufficient to achieve deposition of BM components at the epidermal-collagen interface. In contrast, for nidogen-1, both the G2 and G3 domains were required. Immunoblot analysis confirmed that all BM components were present in comparable amounts under all culture conditions. This finding demonstrates that nidogens, although homologous proteins, exert their effect on BM assembly through different binding domains, which may in turn result in alterations of BM structure and functions, thus providing an explanation for the phenotypical differences observed between nidogen-1 and -2 deficient mice.-Bechtel, M., Keller, M. V., Bloch, W., Sasaki, T., Boukamp, P., Zaucke, F., Paulsson, M., Nischt, R. Different domains in nidogen-1 and nidogen-2 drive basement membrane formation in skin organotypic cocultures. FASEB J. 26, 3637-3648 (2012). www.fasebj.org	[Bechtel, Manuela; Nischt, Roswitha] Univ Hosp Cologne, Dept Dermatol, D-50937 Cologne, Germany; [Keller, Manuel V.; Zaucke, Frank; Paulsson, Mats] Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; [Zaucke, Frank] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Bloch, Wilhelm] German Sport Univ Cologne, Inst Cardiol & Sport Med, Dept Mol & Cellular Sport Med, Cologne, Germany; [Sasaki, Takako] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Dept Expt Med 1, D-91054 Erlangen, Germany; [Boukamp, Petra] German Canc Res Ctr, Div Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	University of Cologne; University of Cologne; University of Cologne; German Sport University Cologne; University of Erlangen Nuremberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Nischt, R (corresponding author), Univ Hosp Cologne, Dept Dermatol, KerpenerStr 62, D-50937 Cologne, Germany.	roswitha.nischt@uni-koeln.de	Zaucke, Frank/AAT-2688-2021; Zaucke, Frank/E-2077-2012		Deutsche Forschungsgemeinschaft [SFB 829]; Baden-Wurttemberg Stiftung: Adult Stem Cells [P-LS-ASII/35]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Baden-Wurttemberg Stiftung: Adult Stem Cells	The authors thank Marion Reibetanz and Isabell Koxholt (Department of Dermatology) for excellent technical assistance. The authors thank all colleagues listed in Materials and Methods for providing antibodies, plasmids, and cells expressing recombinant proteins. This work was supported by the Deutsche Forschungsgemeinschaft through the SFB 829 at the University of Cologne (to R.N. and W. B.) and the Baden-Wurttemberg Stiftung: Adult Stem Cells (P-LS-ASII/35 to P.B.).	AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; Aumailley M, 1999, MATRIX BIOL, V18, P19, DOI 10.1016/S0945-053X(98)00004-3; Aumailley M, 2003, MATRIX BIOL, V22, P49, DOI 10.1016/S0945-053X(03)00013-1; Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005; Baranowsky A, 2010, MATRIX BIOL, V29, P15, DOI 10.1016/j.matbio.2009.09.004; Berthod F, 2001, MATRIX BIOL, V20, P463, DOI 10.1016/S0945-053X(01)00162-7; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; BREITKREUTZ D, 1993, DIFFERENTIATION, V54, P201, DOI 10.1111/j.1432-0436.1993.tb01602.x; Breitkreutz D, 2004, J CELL SCI, V117, P2611, DOI 10.1242/jcs.01127; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; El Ghalbzouri A, 2005, J INVEST DERMATOL, V124, P79, DOI 10.1111/j.0022-202X.2004.23549.x; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Ho MSP, 2008, MICROSC RES TECHNIQ, V71, P387, DOI 10.1002/jemt.20567; Hopf M, 2001, NAT STRUCT BIOL, V8, P634, DOI 10.1038/89683; Kadoya Y, 1997, DEVELOPMENT, V124, P683; Koch M, 2006, J BIOL CHEM, V281, P21546, DOI 10.1074/jbc.M604131200; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kvasankul M., 2001, EMBO J, V20, P5342; Li A, 2004, J CLIN INVEST, V113, P390, DOI 10.1172/JCI.200419140; Limat A, 1996, EUR J CELL BIOL, V69, P245; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Mokkapati S, 2008, J INVEST DERMATOL, V128, P2259, DOI 10.1038/jid.2008.65; Mokkapati S, 2011, J BIOL CHEM, V286, P1911, DOI 10.1074/jbc.M110.149864; Murshed M, 2000, MOL CELL BIOL, V20, P7007, DOI 10.1128/MCB.20.18.7007-7012.2000; NAKAE H, 1993, EUR J BIOCHEM, V213, P11, DOI 10.1111/j.1432-1033.1993.tb17729.x; Nischt R, 2007, J INVEST DERMATOL, V127, P545, DOI 10.1038/sj.jid.5700562; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Schymeinsky J, 2002, MOL CELL BIOL, V22, P6820, DOI 10.1128/MCB.22.19.6820-6830.2002; Sher I, 2006, J BIOL CHEM, V281, P5178, DOI 10.1074/jbc.M509500200; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Takagi J, 2003, NATURE, V424, P969, DOI 10.1038/nature01873; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vasudevan A, 2010, HIPPOCAMPUS, V20, P608, DOI 10.1002/hipo.20660; Willem M, 2002, DEVELOPMENT, V129, P2711	42	20	20	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3637	3648		10.1096/fj.11-194597	http://dx.doi.org/10.1096/fj.11-194597			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22623588				2022-12-28	WOS:000308391600006
J	Emery, AC; Eiden, LE				Emery, Andrew C.; Eiden, Lee E.			Signaling through the neuropeptide GPCR PAC(1) induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor	FASEB JOURNAL			English	Article						adenylate cyclase; neurite; Neuroscreen-1; PC12; signal transduction	CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-KINASE-A; NERVE GROWTH-FACTOR; VASOACTIVE-INTESTINAL-PEPTIDE; PC12 CELLS; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; RAP1 ACTIVATION; GENE-EXPRESSION; CYCLIC-AMP	Both cAMP and ERK are necessary for neuroendocrine cell neuritogenesis, and pituitary adenylate cyclase-activating polypeptide (PACAP) activates each. It is important to know whether cAMP and ERK are arranged in a novel, linear pathway or in two parallel pathways using known signaling mechanisms. Native cellular responses [cAMP elevation, ERK phosphorylation, cAMP responsive element binding (CREB) phosphorylation, and neuritogenesis] and promoter-reporter gene activation after treatment with forskolin, cAMP analogs, and PACAP were measured in Neuroscreen-1 (NS-1) cells, a PC12 variant enabling simultaneous morphological, molecular biological, and biochemical analysis. Forskolin (25 mu M) and cAMP analogs (8-bromo-cAMP, dibutyryl-cAMP, and 8-chlorophenylthio-cAMP) stimulated ERK phosphorylation and neuritogenesis in NS-1 cells. Both ERK phosphorylation and neuritogenesis were MEK dependent (blocked by 10 mu M U0126) and PKA independent (insensitive to 30 mu M H-89 or 100 nM myristoylated protein kinase A inhibitor). CREB phosphorylation induced by PACAP was blocked by H-89. The exchange protein activated by cAMP (Epac)-selective 8-(4-chlorophenylthio)-2'-O-Me-cAMP (100-500 mu M) activated Rap1 without affecting the other cAMP-dependent processes. Thus, PACAP-38 potently stimulated two distinct and independent cAMP pathways leading to CREB or ERK activation in NS-1 cells. Drug concentrations for appropriate effect were derived from control data for all compounds. In summary, a novel PKA- and Epac-independent signaling pathway: PACAP -> adenylate cyclase -> cAMP -> ERK -> neuritogenesis has been identified.-Emery, A. C., Eiden, L. E. Signaling through the neuropeptide GPCR PAC(1) induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor. FASEB J. 26, 3199-3211 (2012). www.fasebj.org	[Emery, Andrew C.; Eiden, Lee E.] NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Eiden, LE (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, 49 Convent Dr,Bldg 49,Rm 5A-38, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov		Eiden, Lee/0000-0001-7524-944X; Emery, Andrew/0000-0002-6760-2570	NIMH Intramural Research Project [1-Z01-MH002386]; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002386, Z01MH002386] Funding Source: NIH RePORTER	NIMH Intramural Research Project; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Dr. Tomris Mustafa [U.S. National Institute of Mental Health (NIMH)] and Dr. Tamas Balla (Eunice Kennedy Shriver National Institute of Child Health and Human Development) for their helpful suggestions and feedback about this manuscript. All work performed was supported by NIMH Intramural Research Project 1-Z01-MH002386. The authors declare no conflicts of interest.	Abad C, 2001, J IMMUNOL, V167, P3182, DOI 10.4049/jimmunol.167.6.3182; Armstrong BD, 2008, NEUROSCIENCE, V151, P63, DOI 10.1016/j.neuroscience.2007.09.084; Bers DM, 2007, J PHYSIOL-LONDON, V583, P415, DOI 10.1113/jphysiol.2007.140764; Burgun C, 2000, FEBS LETT, V484, P189, DOI 10.1016/S0014-5793(00)02153-0; Cheadle C, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-43; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Cibelli G, 2001, EUR J NEUROSCI, V13, P1339, DOI 10.1046/j.0953-816x.2001.01510.x; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gerdin Matthew J, 2007, Sci STKE, V2007, ppe15; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Grumolato L, 2003, ENDOCRINOLOGY, V144, P2368, DOI 10.1210/en.2002-0106; Grumolato L, 2003, EUR J NEUROSCI, V17, P71, DOI 10.1046/j.1460-9568.2003.02426.x; Guirland C, 2003, J NEUROSCI, V23, P2274; Gutkind J S, 2000, Sci STKE, V2000, pre1, DOI 10.1126/stke.2000.40.re1; Hamelink C, 2002, J NEUROSCI, V22, P5310; Hammack SE, 2009, PSYCHONEUROENDOCRINO, V34, P833, DOI 10.1016/j.psyneuen.2008.12.013; Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498; Holighaus Y, 2012, J MOL NEUROSCI, V46, P75, DOI 10.1007/s12031-011-9653-9; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kim HS, 2006, EXP MOL MED, V38, P85, DOI 10.1038/emm.2006.10; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; Lelievre V, 2008, DEV BIOL, V313, P359, DOI 10.1016/j.ydbio.2007.10.031; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9; Macdonald DS, 2005, J NEUROSCI, V25, P11374, DOI 10.1523/JNEUROSCI.3871-05.2005; Monaghan TK, 2008, J NEUROCHEM, V104, P74, DOI 10.1111/j.1471-4159.2007.05018.x; Nijholt IM, 2008, CELL SIGNAL, V20, P1715, DOI 10.1016/j.cellsig.2008.05.001; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Radio NM, 2008, TOXICOL SCI, V105, P106, DOI 10.1093/toxsci/kfn114; Ravni A, 2008, MOL PHARMACOL, V73, P1688, DOI 10.1124/mol.107.044792; Roscioni SS, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-88; Samal BB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.131pt4; Ster J, 2007, P NATL ACAD SCI USA, V104, P2519, DOI 10.1073/pnas.0611031104; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stroth N, 2011, J NEUROENDOCRINOL, V23, P944, DOI 10.1111/j.1365-2826.2011.02202.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tan YV, 2009, P NATL ACAD SCI USA, V106, P2012, DOI 10.1073/pnas.0812257106; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Waschek JA, 2006, ANN NY ACAD SCI, V1070, P120, DOI 10.1196/annals.1317.089; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	56	51	52	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3199	3211		10.1096/fj.11-203042	http://dx.doi.org/10.1096/fj.11-203042			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22532442	Green Published			2022-12-28	WOS:000307162800011
J	Lohman, RJ; Cotterell, AJ; Barry, GD; Liu, LG; Suen, JY; Vesey, DA; Fairlie, DP				Lohman, Rink-Jan; Cotterell, Adam J.; Barry, Grant D.; Liu, Ligong; Suen, Jacky Y.; Vesey, David A.; Fairlie, David P.			An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats	FASEB JOURNAL			English	Article						joint inflammation; beta-tryptase	IN-VIVO; INFLAMMATORY ARTHRITIS; RHEUMATOID-ARTHRITIS; SYNOVIAL FIBROBLASTS; EXPERIMENTAL COLITIS; CATHEPSIN S; EXPRESSION; TRYPTASE; AGONISTS; TRYPSIN	Multiple serine proteases exert proinflammatory actions by signaling through protease-activated receptor-2 (PAR2) on the cell surface. Although inhibitors of individual proteases are anti-inflammatory, we sought to discover whether the first potent antagonist of their common target PAR2 might be beneficial in treating chronic arthritis-like inflammatory disease. Using a fluorescence assay, a novel compound, GB88, was shown to antagonize PAR2-induced intracellular Ca2+ release in human monocyte-derived macrophages, being 1000 times more potent than a control compound, ENMD-1068 (IC50 1.6 +/- 0.5 mu M vs. 1.2 +/- 0.4 mM, respectively). In Wistar rats, GB88 was orally bioavailable (F=55%, T-max 4 h, C-max 1.7 mu M, 10 mg/kg). GB88 inhibited the acute paw edema induced in Wistar rats by intraplantar lambda-carrageenan or PAR2 agonists 2-furoyl-LIGRLO-NH2 or mast cell beta-tryptase, without inhibiting proteolytic activity of tryptase in vitro. In the chronic collagen-induced model of arthritis in rats, GB88 (10 mg/kg) was disease modifying and ameliorated pathological and histopathological changes (edema, pannus formation, synovial hyperplasia, collagen degradation, macrophage invasion, mast cell degranulation) compared to untreated arthritic controls. The results suggest that an orally active PAR2 antagonist is effective in treating chronic arthritis in rats through inhibiting macrophage infiltration, mast cell degranulation, and beta-tryptase-PAR2 signaling in joint inflammation.-Lohman, R.-J., Cotterell, A. J., Barry, G. D., Liu, L., Suen, J. Y., Vesey, D. A., Fairlie, D. P. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J. 26, 2877-2887 (2012). www.fasebj.org	[Lohman, Rink-Jan; Cotterell, Adam J.; Barry, Grant D.; Liu, Ligong; Suen, Jacky Y.; Fairlie, David P.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Vesey, David A.] Univ Queensland, Dept Med, Princess Alexandra Hosp, Ctr Kidney Dis Res, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.fairlie@imb.uq.edu.au	liu, ligong/B-1690-2010; Suen, Jacky/G-4077-2015; Fairlie, David P/F-8865-2014; Vesey, David A/C-2253-2011; Lohman, Rink-Jan/F-5733-2011	liu, ligong/0000-0002-2693-1896; Suen, Jacky/0000-0002-0309-2524; Fairlie, David P/0000-0002-7856-8566; Vesey, David A/0000-0002-2856-6650; Lohman, Rink-Jan/0000-0001-6387-0992	Australian National Health and Medical Research Council [569595, APP1000745]; Australian Research Council [DP1093245]; ARC [FF668733]; NHMRC [APP1027369]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); ARC(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank the Australian National Health and Medical Research Council (grants 569595, APP1000745) and the Australian Research Council (grant DP1093245) for support, including an ARC Federation Fellowship (FF668733) and an NHMRC Senior Principal Research Fellowship (APP1027369) to D. P. F. The authors declare no conflicts of interest.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Al-Ani B, 2002, J PHARMACOL EXP THER, V300, P702, DOI 10.1124/jpet.300.2.702; Alshurafa Hashem N., 2004, BMC Pharmacology, V4, P12, DOI 10.1186/1471-2210-4-12; Amiable N, 2009, BONE, V44, P1143, DOI 10.1016/j.bone.2009.02.015; Barry GD, 2006, CURR MED CHEM, V13, P243, DOI 10.2174/092986706775476070; Barry GD, 2010, J MED CHEM, V53, P7428, DOI 10.1021/jm100984y; Baugh M, 2011, J AUTOIMMUN, V36, P201, DOI 10.1016/j.jaut.2011.01.003; Boileau C, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2329; Bunnett NW, 2006, SEMIN THROMB HEMOST, V32, P39, DOI 10.1055/s-2006-939553; Busso N, 2007, ARTHRITIS RHEUM, V56, P101, DOI 10.1002/art.22312; Cattaruzza F, 2011, GASTROENTEROLOGY, V141, P1864, DOI 10.1053/j.gastro.2011.07.035; Cho EY, 2011, INT IMMUNOPHARMACOL, V11, P412, DOI 10.1016/j.intimp.2010.12.008; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Costa R, 2008, BRIT J PHARMACOL, V154, P1094, DOI 10.1038/bjp.2008.172; Cudic M, 2009, CURR PROTEIN PEPT SC, V10, P297, DOI 10.2174/138920309788922207; Ferrell WR, 2010, ANN RHEUM DIS, V69, P2051, DOI 10.1136/ard.2010.130336; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Flick MJ, 2007, J CLIN INVEST, V117, P3224, DOI 10.1172/JCI30134; Huang TY, 2009, TOXICOL APPL PHARM, V237, P69, DOI 10.1016/j.taap.2009.02.026; INO Y, 1987, GEN PHARMACOL, V18, P513, DOI 10.1016/0306-3623(87)90072-3; Isozaki Y, 2006, SCAND J GASTROENTERO, V41, P944, DOI 10.1080/00365520500529470; Johansson U, 2005, J LEUKOCYTE BIOL, V78, P967, DOI 10.1189/jlb.0704422; Kang OH, 2003, CELL BIOCHEM FUNCT, V21, P161, DOI 10.1002/cbf.1014; Kanke T, 2009, BRIT J PHARMACOL, V158, P361, DOI 10.1111/j.1476-5381.2009.00342.x; Kawabata A, 2008, BRIT J PHARMACOL, V153, pS230, DOI 10.1038/sj.bjp.0707491; Kawabata A, 2002, PEPTIDES, V23, P1181, DOI 10.1016/S0196-9781(02)00053-0; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807; Kelso EB, 2007, ARTHRITIS RHEUM, V56, P765, DOI 10.1002/art.22423; Lam DK, 2010, PAIN, V149, P263, DOI 10.1016/j.pain.2010.02.010; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165; Lohman RJ, 2008, NEUROBIOL DIS, V30, P84, DOI 10.1016/j.nbd.2007.12.010; Lohman RJ, 2012, J PHARMACOL EXP THER, V340, P256, DOI 10.1124/jpet.111.187062; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McIntosh KA, 2007, CURR OPIN PHARMACOL, V7, P334, DOI 10.1016/j.coph.2007.01.002; Mei H, 2006, AAPS J, V8, pE493, DOI 10.1208/aapsj080358; Moore CS, 2012, AM J PATHOL, V180, P12, DOI 10.1016/j.ajpath.2011.09.008; MORRIS R, 1994, ANN RHEUM DIS, V53, P72, DOI 10.1136/ard.53.1.72; Nakano S, 2007, CLIN RHEUMATOL, V26, P1284, DOI 10.1007/s10067-006-0495-8; Nishikawa M, 2003, ARTHRITIS RHEUM-US, V48, P2670, DOI 10.1002/art.11227; Palmer HS, 2007, ARTHRITIS RHEUM-US, V56, P3532, DOI 10.1002/art.22936; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Pimentel TA, 2011, LAB INVEST, V91, P33, DOI 10.1038/labinvest.2010.140; Sawamukai N, 2010, ARTHRITIS RHEUM-US, V62, P952, DOI 10.1002/art.27331; Sharma A, 2005, AM J PHYSIOL-GASTR L, V288, pG388, DOI 10.1152/ajpgi.00341.2004; Shin K, 2009, J IMMUNOL, V182, P647, DOI 10.4049/jimmunol.182.1.647; Shpacovitch VM, 2004, J LEUKOCYTE BIOL, V76, P388, DOI 10.1189/jlb.0503221; Singh VP, 2007, GUT, V56, P958, DOI 10.1136/gut.2006.094268; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x; Teronen O, 1996, J ORAL PATHOL MED, V25, P376, DOI 10.1111/j.1600-0714.1996.tb00282.x; Thrivikraman KV, 2002, BRAIN RES PROTOC, V10, P84, DOI 10.1016/S1385-299X(02)00185-X; van Raay L, 2009, J NEUROSCI METH, V179, P184, DOI 10.1016/j.jneumeth.2009.01.024; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Wang JR, 2010, INT J RADIAT ONCOL, V77, P1206, DOI 10.1016/j.ijrobp.2009.12.075; Woodruff TM, 2002, ARTHRITIS RHEUM-US, V46, P2476, DOI 10.1002/art.10449; Woolley DE, 2003, NEW ENGL J MED, V348, P1709, DOI 10.1056/NEJMcibr023206; Xue ML, 2012, ARTHRITIS RHEUM-US, V64, P88, DOI 10.1002/art.33323	61	79	81	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2877	2887		10.1096/fj.11-201004	http://dx.doi.org/10.1096/fj.11-201004			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22467762				2022-12-28	WOS:000305912500016
J	Bossenmeyer-Pourie, C; Pourie, G; Koziel, V; Helle, D; Jeannesson, E; Gueant, JL; Beck, B				Bossenmeyer-Pourie, Carine; Pourie, Gregory; Koziel, Violette; Helle, Deborah; Jeannesson, Elise; Gueant, Jean-Louis; Beck, Bernard			Early methyl donor deficiency produces severe gastritis in mothers and offspring through N-homocysteinylation of cytoskeleton proteins, cellular stress, and inflammation	FASEB JOURNAL			English	Article						E-cadherin; actin; oxidative stress; NF-kappa B pathway; apoptosis	FACTOR-KAPPA-B; SMOOTH-MUSCLE-CELLS; INSULIN-RESISTANCE; E-CADHERIN; IN-VITRO; ELDERLY POPULATION; ATROPHIC GASTRITIS; FOLATE-DEFICIENCY; TREFOIL FACTOR-1; OXIDATIVE STRESS	We examined the gastric mucosa structure and inflammatory status in control well-nourished Wistar dams and in Wistar dams deprived of choline, folate, and vitamin B-12 during gestation and suckling periods, and in their offspring just before birth and at weaning. In this model of methyl donor deficiency (MDD), structural protein (E-cadherin and actin) N-homocysteinylation was measured through immunoprecipitation and proximity ligation assays. Cellular stress, inflammation, and apoptosis were estimated by the analysis of the NF-kappa B pathway, and the expression of superoxide dismutase, cyclooxygenase-2, tumor necrosis factor alpha, caspases 3 and 9, and TUNEL assay. Aberrant gastric mucosa formation and signs of surface layer erosion were detected in MDD fetuses and weanlings. E-cadherin and actin were N-homocysteinylated (+215 and +249% vs. controls, respectively; P< 0.001). Expression of beta-catenin staining drastically decreased (-98%; P<0.01). NF-kappa B pathway was activated (+124%; P<0.01). Expressions of all inflammatory factors (+70%; P<0.01), superoxide dismutase (+55%; P<0.01), and caspases (+104%; P<0.01) were markedly increased. These changes were also observed in dams, to a lesser extent. Early MDD induced gastric mucosa injury similar to atrophic gastritis through structural protein N-homocysteinylation, marked inflammation, and apoptosis, despite activation of repair machinery.	[Bossenmeyer-Pourie, Carine; Pourie, Gregory; Koziel, Violette; Helle, Deborah; Jeannesson, Elise; Gueant, Jean-Louis; Beck, Bernard] INSERM, Nutr Genet & Exposit Risques Environm U954, Vandoeuvre Les Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Beck, B (corresponding author), Fac Med, INSERM, U954, BP 184, F-54505 Vandoeuvre Les Nancy, France.	bernard.beck@inserm.fr	Bossenmeyer-Pourié, Carine/F-7695-2019	Bossenmeyer-Pourié, Carine/0000-0003-3831-4809				AimoneGastin I, 1997, GUT, V41, P475, DOI 10.1136/gut.41.4.475; Akchiche N, 2012, FASEB J, V26, P3980, DOI 10.1096/fj.12-205757; Bai YP, 2007, BIOCHEM BIOPH RES CO, V360, P20, DOI 10.1016/j.bbrc.2007.05.222; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Blaise S, 2005, PEDIATR RES, V57, P777, DOI 10.1203/01.PDR.0000161406.19231.98; Blaise SA, 2007, AM J PATHOL, V170, P667, DOI 10.2353/ajpath.2007.060339; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Bossenmeyer-Pourie C, 2010, AM J PATHOL, V176, P270, DOI 10.2353/ajpath.2010.090153; Cheung GTY, 2008, CAN J PHYSIOL PHARM, V86, P88, DOI [10.1139/Y08-002, 10.1139/y08-002]; Contasta I, 1999, CANCER BIOTHER RADIO, V14, P465, DOI 10.1089/cbr.1999.14.465; Dholakia KR, 2005, WORLD J GASTROENTERO, V11, P7078, DOI 10.3748/wjg.v11.i45.7078; Ducros V, 2006, CLIN CHEM LAB MED, V44, P987, DOI 10.1515/CCLM.2006.178; Durer U, 2007, CELL PHYSIOL BIOCHEM, V20, P329, DOI 10.1159/000107519; Eida M., 2002, GASTROINTEST ONCOL, V4, P203; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Giraud AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1, DOI 10.1152/ajpgi.00382.2006; Gori AM, 2007, CLIN CHEM LAB MED, V45, P1728, DOI 10.1515/CCLM.2007.347; Hanby AM, 1996, AM J PATHOL, V148, P723; Herrmann W, 2001, CLIN CHEM, V47, P1094; Howell JM, 2006, PROTEOMICS, V6, P2050, DOI 10.1002/pmic.200500517; Huerta JM, 2004, FREE RADICAL RES, V38, P1215, DOI 10.1080/10715760400017269; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2009, FASEB J, V23, P1721, DOI 10.1096/fj.08-127548; Karam SM, 2004, GUT, V53, P1408, DOI 10.1136/gut.2003.031963; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; Lee JE, 2010, AM J CLIN NUTR, V91, P1303, DOI 10.3945/ajcn.2009.28456; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; MAGNUSSON I, 1985, Scandinavian Journal of Gastroenterology, V20, P623, DOI 10.3109/00365528509089707; Maloney CA, 2007, BRIT J NUTR, V97, P1090, DOI 10.1017/S0007114507670834; Martos R, 2006, METABOLISM, V55, P72, DOI 10.1016/j.metabol.2005.07.008; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Milman N, 2006, EUR J HAEMATOL, V76, P521, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2550.x; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; MONGIN M, 1993, ANN GASTROENT HEPATO, V29, P42; Moriyama N, 2001, J LAB CLIN MED, V138, P236, DOI 10.1067/mlc.2001.118177; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; NEWBERNE PM, 1973, NATURE, V242, P263, DOI 10.1038/242263b0; Obeid R, 2005, CLIN CHEM LAB MED, V43, P1052, DOI 10.1515/CCLM.2005.184; Paoli P, 2010, J MOL BIOL, V400, P889, DOI 10.1016/j.jmb.2010.05.039; Perla-Kajan J, 2007, AMINO ACIDS, V32, P561, DOI 10.1007/s00726-006-0432-9; Perna AF, 2003, AMINO ACIDS, V25, P409, DOI 10.1007/s00726-003-0026-8; Peyrin-Biroulet L, 2007, AM J GASTROENTEROL, V102, P1108, DOI 10.1111/j.1572-0241.2007.01170.x; Roubenoff R, 1997, ARTHRITIS RHEUM, V40, P718, DOI 10.1002/art.1780400418; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Sibrian-Vazquez M, 2010, P NATL ACAD SCI USA, V107, P551, DOI 10.1073/pnas.0909737107; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Sipponen P, 2003, SCAND J GASTROENTERO, V38, P1209, DOI 10.1080/00365520310007224; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stabler SP, 2004, ANNU REV NUTR, V24, P299, DOI 10.1146/annurev.nutr.24.012003.132440; Stroylova YY, 2011, BBA-PROTEINS PROTEOM, V1814, P1234, DOI 10.1016/j.bbapap.2011.05.017; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Takahashi S, 1998, AM J PHYSIOL-GASTR L, V275, pG1137, DOI 10.1152/ajpgi.1998.275.5.G1137; Tarnawski AS, 2005, DIGEST DIS SCI, V50, pS24, DOI 10.1007/s10620-005-2803-6; Testino G, 1993, Ann Ital Med Int, V8, P86; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Wallace JL, 2005, BRIT J PHARMACOL, V145, P275, DOI 10.1038/sj.bjp.0706201; Wallace JL, 2001, EXP BIOL MED, V226, P1003, DOI 10.1177/153537020122601107; Wang GP, 2000, BIOCHEM J, V352, P817, DOI 10.1042/0264-6021:3520817; Weinberg JB, 2000, IMMUNOL RES, V22, P319, DOI 10.1385/IR:22:2-3:319; Wu N, 2009, AM J PHYSIOL-REG I, V297, pR1086, DOI 10.1152/ajpregu.00293.2009; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Zeisel SH, 2009, AM J CLIN NUTR, V89, p673S, DOI 10.3945/ajcn.2008.26811D; Zeng XK, 2005, ACTA PHARMACOL SIN, V26, P85, DOI 10.1111/j.1745-7254.2005.00005.x; Zhang L, 2006, CELL BIOL INT, V30, P592, DOI 10.1016/j.cellbi.2006.03.007	67	18	19	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2185	2197		10.1096/fj.12-224642	http://dx.doi.org/10.1096/fj.12-224642			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23401564				2022-12-28	WOS:000319667600010
J	Cotella, D; Hernandez-Enriquez, B; Duan, ZB; Wu, XL; Gazula, VR; Brown, MR; Kaczmarek, LK; Sesti, F				Cotella, Diego; Hernandez-Enriquez, Berenice; Duan, Zhibing; Wu, Xilong; Gazula, Valeswara-Rao; Brown, Maile R.; Kaczmarek, Leonard K.; Sesti, Federico			An evolutionarily conserved mode of modulation of Shaw-like K+ channels	FASEB JOURNAL			English	Article						acid phosphatase; neuronal adaptation; C. elegans	PROSTATIC ACID-PHOSPHATASE; POTASSIUM CHANNEL; MICE LACKING; ETHANOL TOLERANCE; AUDITORY NEURONS; KV3.1; RESPONSES; PHOSPHORYLATION; IDENTIFICATION; STIMULATION	Voltage-gated K+ channels of the Shaw family (also known as the KCNC or Kv3 family) play pivotal roles in mammalian brains, and genetic or pharmacological disruption of their activities in mice results in a spectrum of behavioral defects. We have used the model system of Caenorhabditis elegans to elucidate conserved molecular mechanisms that regulate these channels. We have now found that the C. elegans Shaw channel KHT-1, and its mammalian homologue, murine Kv3.1b, are both modulated by acid phosphatases. Thus, the C. elegans phosphatase ACP-2 is stably associated with KHT-1, while its mammalian homolog, prostatic acid phosphatase (PAP; also known as ACPP-201) stably associates with murine Kv3.1b K+ channels in vitro and in vivo. In biochemical experiments both phosphatases were able to reverse phosphorylation of their associated channel. The effect of phosphorylation on both channels is to produce a decrease in current amplitude and electrophysiological analyses demonstrated that dephosphorylation reversed the effects of phosphorylation on the magnitude of the macroscopic currents. ACP-2 and KHT-1 were colocalized in the nervous system of C. elegans and, in the mouse nervous system, PAP and Kv3.1b were colocalized in subsets of neurons, including in the brain stem and the ventricular zone. Taken together, this body of evidence suggests that acid phosphatases are general regulatory partners of Shaw-like K+ channels.-Cotella, D., Hernandez-Enriquez, B., Duan, Z., Wu, X., Gazula, V.-R., Brown, M. R., Kaczmarek, L. K., and Sesti, F. An evolutionarily conserved mode of modulation of Shaw-like K+ channels. FASEB J. 27, 1381-1393 (2013). www.fasebj.org	[Cotella, Diego; Hernandez-Enriquez, Berenice; Duan, Zhibing; Wu, Xilong; Sesti, Federico] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Gazula, Valeswara-Rao; Brown, Maile R.; Kaczmarek, Leonard K.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA.	sestife@umdnj.edu	cotella, diego/J-8422-2019	cotella, diego/0000-0003-2714-4744	U.S. National Institutes of Health [DC 01919]; National Science Foundation [0842708, 1026958]; American Heart Association [09GRNT2250529]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); American Heart Association(American Heart Association); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	The authors thank the C. elegans Gene Knockout Consortium (University of British Columbia, Vancouver, BC, Canada) for the F14E5.4-KO (RB1704) strain, Dr. Shuang Liu for critical reading of the manuscript, and Dr. Costantino Vetriani for help with phylogenic calculations. The Kv3.1b cDNA was a gift from Dr. Geoffrey Abbott (University of California-Irvine, Irvine, CA, USA). This work was supported by a U.S. National Institutes of Health grant (DC 01919) to L. K. and two National Science Foundation grants (0842708 and 1026958) and an American Heart Association grant (09GRNT2250529) to F.S.	Aumuller G, 1999, UROLOGY, V53, P1041, DOI 10.1016/S0090-4295(98)00631-1; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Cai SQ, 2009, EMBO J, V28, P1601, DOI 10.1038/emboj.2009.112; Cai SQ, 2005, NAT NEUROSCI, V8, P1503, DOI 10.1038/nn1557; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cowmeadow RB, 2006, ALCOHOL CLIN EXP RES, V30, P745, DOI 10.1111/j.1530-0277.2006.00087.x; Cowmeadow RB, 2005, ALCOHOL CLIN EXP RES, V29, P1777, DOI 10.1097/01.alc.0000183232.56788.62; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; Deschaux O, 1997, NEUROSCI LETT, V227, P57, DOI 10.1016/S0304-3940(97)00301-7; Engel JE, 1998, J NEUROSCI, V18, P2254; Espinosa F, 2001, J NEUROSCI, V21, P6657, DOI 10.1523/JNEUROSCI.21-17-06657.2001; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Graddis TJ, 2011, INT J CLIN EXP PATHO, V4, P295; Hassan MI, 2010, EXPERT REV ANTICANC, V10, P1055, DOI 10.1586/ERA.10.46; Ho CS, 1997, P NATL ACAD SCI USA, V94, P1533, DOI 10.1073/pnas.94.4.1533; ITO K, 1987, BRAIN RES, V409, P97, DOI 10.1016/0006-8993(87)90745-1; Joho RH, 2006, EUR J NEUROSCI, V23, P1567, DOI 10.1111/j.1460-9568.2006.04672.x; Kanda VA, 2011, BIOPHYS J, V101, P1354, DOI 10.1016/j.bpj.2011.08.015; Kanda VA, 2011, BIOPHYS J, V101, P1364, DOI 10.1016/j.bpj.2011.08.014; KANEMASA T, 1995, J NEUROPHYSIOL, V74, P207, DOI 10.1152/jn.1995.74.1.207; Keller C. C., 2005, INT WORM M, V539A; LEDEBUR IX, 1966, ELECTROEN CLIN NEURO, V20, P370, DOI 10.1016/0013-4694(66)90005-8; Lewis A, 2004, J BIOL CHEM, V279, P7884, DOI 10.1074/jbc.M310501200; Macica CM, 2003, J NEUROSCI, V23, P1133, DOI 10.1523/JNEUROSCI.23-04-01133.2003; Mason P, 2005, J COMP NEUROL, V493, P2, DOI 10.1002/cne.20751; Matsukawa H, 2003, J NEUROSCI, V23, P7677; Pietrzykowski AZ, 2004, J NEUROSCI, V24, P8322, DOI 10.1523/JNEUROSCI.1536-04.2004; Pravetoni M, 2008, GENES BRAIN BEHAV, V7, P523, DOI 10.1111/j.1601-183X.2008.00388.x; Quessy S, 2004, EXP BRAIN RES, V156, P342, DOI 10.1007/s00221-003-1787-8; Quintero IB, 2007, CANCER RES, V67, P6549, DOI 10.1158/0008-5472.CAN-07-1651; RANKIN CH, 1990, BEHAV BRAIN RES, V37, P89, DOI 10.1016/0166-4328(90)90074-O; RISLEY JM, 1987, ARCH BIOCHEM BIOPHYS, V258, P404, DOI 10.1016/0003-9861(87)90361-4; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Santi CM, 2006, J NEUROSCI, V26, P5059, DOI 10.1523/JNEUROSCI.3372-05.2006; Song P, 2005, NAT NEUROSCI, V8, P1335, DOI 10.1038/nn1533; Song P, 2006, J BIOL CHEM, V281, P15582, DOI 10.1074/jbc.M512866200; Taylor-Blake B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008674; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; von Hehn CAA, 2004, J NEUROSCI, V24, P1936, DOI 10.1523/JNEUROSCI.4554-03.2004; Wang Y, 2007, BIOPHYS J, V93, P3083, DOI 10.1529/biophysj.107.110320; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891	42	7	9	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1381	1393		10.1096/fj.12-222778	http://dx.doi.org/10.1096/fj.12-222778			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23233530	Green Published			2022-12-28	WOS:000316940800011
J	Jastrzebska, B; Orban, T; Golczak, M; Engel, A; Palczewski, K				Jastrzebska, Beata; Orban, Tivadar; Golczak, Marcin; Engel, Andreas; Palczewski, Krzysztof			Asymmetry of the rhodopsin dimer in complex with transducin	FASEB JOURNAL			English	Article						G-protein-coupled receptor; heterotrimeric G protein; retinoids; retinal isomerization; membrane protein	PROTEIN-COUPLED RECEPTOR; CRYSTAL-STRUCTURE; VISUAL CYCLE; ACTIVATION; OPSIN; SITE; HETERODIMERIZATION; INTERMEDIATE; DYNAMICS; ARRESTIN	A large body of evidence for G-protein-coupled receptor (GPCR) oligomerization has accumulated over the past 2 decades. The smallest of these oligomers in vivo most likely is a dimer that buries 1000-angstrom(2) intramolecular surfaces and on stimulation forms a complex with heterotrimeric G protein in 2:1 stoichiometry. However, it is unclear whether each of the monomers adopts the same or a different conformation and function after activation of this dimer. With bovine rhodopsin (Rho) and its cognate bovine G-protein transducin (G(t)) as a model system, we used the retinoid chromophores 11-cis-retinal and 9-cis-retinal to monitor each monomer of the dimeric GPCR within a stable complex with nucleotide-free Gt. We found that only 50% of Rho* in the Rho*-G(t) complex is trapped in a Meta II conformation, while 50% evolves toward an opsin conformation and can be regenerated with 9-cis-retinal. We also found that all-trans-retinal can regenerate chromophore-depleted Rho* e complexed with Gt and FAK*TSA peptide containing Lys(296) with the attached all-trans retinoid (m/z of 934.5[MH](+)) was identified by mass spectrometry. Thus, our study shows that each of the monomers contributes unequally to the pentameric (2:1:1:1) complex of Rho dimer and Gt heterotrimer, validating the oligomeric structure of the complex and the asymmetry of the GPCR dimer, and revealing its structural/functional signature. This study provides a clear functional distinction between monomers of family A GPCRs in their oligomeric form.-Jastrzebska, B., Orban, T., Golczak, M., Engel, A., Palczewski, K. Asymmetry of the rhodopsin dimer in complex with transducin. FASEB J. 27, 1572-1584 (2013). www.fasebj.org	[Jastrzebska, Beata; Orban, Tivadar; Golczak, Marcin; Engel, Andreas; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Jastrzebska, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	bxj27@case.edu; kxp65@case.edu			U.S. National Institutes of Health [EY008061, EY019478]; NATIONAL EYE INSTITUTE [R01EY019478, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094598] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Leslie T. Webster, Jr. and members of the K. P. laboratory for helpful comments on this manuscript. This work was supported by U.S. National Institutes of Health grants EY008061 and EY019478. K. P. is John Hord Professor of Pharmacology.	ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BOWNDS D, 1965, NATURE, V205, P254, DOI 10.1038/205254a0; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Choe HW, 2011, NATURE, V471, P651, DOI 10.1038/nature09789; Damian M, 2006, EMBO J, V25, P5693, DOI 10.1038/sj.emboj.7601449; Deupi X, 2012, P NATL ACAD SCI USA, V109, P119, DOI 10.1073/pnas.1114089108; Fanelli F, 2008, FEBS LETT, V582, P991, DOI 10.1016/j.febslet.2008.02.041; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filizola M, 2006, J COMPUT AID MOL DES, V20, P405, DOI 10.1007/s10822-006-9053-3; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Goc A, 2008, BIOCHEMISTRY-US, V47, P12409, DOI 10.1021/bi8015444; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Han Y, 2009, NAT CHEM BIOL, V5, P688, DOI 10.1038/nchembio.199; Heck M, 2003, VISION RES, V43, P3003, DOI 10.1016/j.visres.2003.08.011; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Ianoul A, 2005, NAT CHEM BIOL, V1, P196, DOI 10.1038/nchembio726; Jastrzebska B, 2011, J STRUCT BIOL, V176, P387, DOI 10.1016/j.jsb.2011.08.016; Jastrzebska B, 2011, J BIOL CHEM, V286, P18930, DOI 10.1074/jbc.M111.234583; Jastrzebska B, 2009, FASEB J, V23, P371, DOI 10.1096/fj.07-114835; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; Kniazeff J, 2011, PHARMACOL THERAPEUT, V130, P9, DOI 10.1016/j.pharmthera.2011.01.006; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; KROPF A, 1970, PHOTOCHEM PHOTOBIOL, V12, P249, DOI 10.1111/j.1751-1097.1970.tb06057.x; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lambert NA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115pe12; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lebon G, 2012, CURR OPIN STRUC BIOL, V22, P482, DOI 10.1016/j.sbi.2012.03.007; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lodowski DT, 2006, J BIOL CHEM, V281, P16785, DOI 10.1074/jbc.M601327200; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Maurice P, 2011, TRENDS PHARMACOL SCI, V32, P514, DOI 10.1016/j.tips.2011.05.006; Modzelewska A, 2006, CELL BIOCHEM BIOPHYS, V46, P1, DOI 10.1385/CBB:46:1:1; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; Nakamichi H, 2006, P NATL ACAD SCI USA, V103, P12729, DOI 10.1073/pnas.0601765103; Neri M, 2010, BIOCHEMISTRY-US, V49, P4827, DOI 10.1021/bi100478j; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Okada Tetsuji, 2006, P243; Orban T, 2012, STRUCTURE, V20, P826, DOI 10.1016/j.str.2012.03.017; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Palczewski K, 2010, TRENDS BIOCHEM SCI, V35, P595, DOI 10.1016/j.tibs.2010.05.002; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; Park PSH, 2008, ANNU REV PHARMACOL, V48, P107, DOI 10.1146/annurev.pharmtox.48.113006.094630; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rivero-Muller A, 2010, P NATL ACAD SCI USA, V107, P2319, DOI 10.1073/pnas.0906695106; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Singh P, 2008, J BIOL CHEM, V283, P14053, DOI 10.1074/jbc.M708974200; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vahedi-Faridi A, 2013, MICROSCOPY-JPN, V62, P95, DOI 10.1093/jmicro/dfs091; Van Hooser JP, 2000, METHOD ENZYMOL, V316, P565; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1957, NATURE, V180, P278, DOI 10.1038/180278a0; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200; Zhang N, 2013, J CLIN INVEST, V123, P121, DOI 10.1172/JCI66176	71	54	57	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1572	1584		10.1096/fj.12-225383	http://dx.doi.org/10.1096/fj.12-225383			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303210	Green Published			2022-12-28	WOS:000316940800028
J	Sauvat, F; Bouilly, J; Capito, C; Lefevre, A; Blachere, T; Borenstein, N; Sarnacki, S; Dandolo, L; Binart, N				Sauvat, Frederique; Bouilly, Justine; Capito, Carmen; Lefevre, Annick; Blachere, Thierry; Borenstein, Nicolas; Sarnacki, Sabine; Dandolo, Luisa; Binart, Nadine			Ovarian function is restored after grafting of cryopreserved immature ovary in ewes	FASEB JOURNAL			English	Article						epigenetics; puberty; fertility preservation; cancer	BECKWITH-WIEDEMANN-SYNDROME; ASSISTED REPRODUCTIVE TECHNOLOGY; IN-VITRO FERTILIZATION; TISSUE CRYOPRESERVATION; FERTILITY PRESERVATION; SYNDROME BORN; TRANSPLANTATION; SHEEP; PREGNANCIES; AUTOGRAFTS	As a result of advances in medical treatment, almost 80% of children who are diagnosed with cancer survive long-term. The adverse consequences of cancer treatments include impaired puberty and fertility. In prepubertal girls, the only therapeutic option is the cryopreservation of an ovary. To date, a dozen births have been reported after reimplantation of cryopreserved mature ovaries. To analyze ovarian function after immature grafts, we performed ovarian grafting in a ewe model. Fresh or cryopreserved ovaries from immature ewes were autografted in prepubertal or adult ewes. Cyclic hormonal activity was recovered 3 mo after grafting. Histological analysis demonstrated the presence of all follicle populations and corpora lutea not affected by cryopreservation. After 3 reproductive seasons, births had been observed in all groups, and the follicle-stimulating hormone status was under the limit, which indicated an exhausted ovary. As an indicator of potential imprinting default, the methylation status of the Igf2r gene was analyzed and did not show significant alteration compared with that of non-manipulated animals. Taken together, these results demonstrate that immature ovarian grafting is able to restore spontaneous puberty and fertility and could guide the reimplantation of immature cortex in women.-Sauvat, F., Bouilly, J., Capito, C., Lefevre, A., Blachere, T., Borenstein, N., Sarnacki, S., Dandolo, L., Binart, N. Ovarian function is restored after grafting of cryopreserved immature ovary in ewes. FASEB J. 27, 1511-1518 (2013). www.fasebj.org	[Sauvat, Frederique; Bouilly, Justine; Binart, Nadine] INSERM, U693, F-94276 Le Kremlin Bicetre, France; [Sauvat, Frederique; Bouilly, Justine; Binart, Nadine] Univ Paris 11, Fac Med Paris Sud, UMR S693, Le Kremlin Bicetre, France; [Capito, Carmen; Sarnacki, Sabine] Assistance Publ Hop Paris, Paris, France; [Capito, Carmen; Dandolo, Luisa] Univ Paris 05, Paris, France; [Lefevre, Annick; Blachere, Thierry] INSERM, U846, F-69008 Lyon, France; [Borenstein, Nicolas; Sarnacki, Sabine] Inst Mutualiste Montsouris IMM Rech Paris, Paris, France; [Dandolo, Luisa] Inst Cochin, CNRS, UMR 8104, INSERM,U1016, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Binart, N (corresponding author), INSERM, U693, F-94276 Le Kremlin Bicetre, France.	nadine.binart@inserm.fr	Binart, Nadine/F-2949-2013; Sarnacki, Sabine/I-2692-2017	Binart, Nadine/0000-0002-5606-3866; Sarnacki, Sabine/0000-0003-4304-5578	Fondation pour l'Avenir; Agence de Biomedecine; Institut National de la Sante et de la Recherche Medicale-Assistance Publique-Hopitaux de Paris Interface	Fondation pour l'Avenir; Agence de Biomedecine; Institut National de la Sante et de la Recherche Medicale-Assistance Publique-Hopitaux de Paris Interface	The authors thank C. Poirot and F. Jaubert for helpful discussions and A. L. Laine for FSH measurement. This work was supported by the Fondation pour l'Avenir and the Agence de Biomedecine. N.B. was awarded an Institut National de la Sante et de la Recherche Medicale-Assistance Publique-Hopitaux de Paris Interface contract.	Andersen CY, 2008, HUM REPROD, V23, P2266, DOI 10.1093/humrep/den244; Arav A, 2005, HUM REPROD, V20, P3554, DOI 10.1093/humrep/dei278; Arnaud Philippe, 2005, Birth Defects Res C Embryo Today, V75, P81, DOI 10.1002/bdrc.20039; Azzi S, 2009, HUM MOL GENET, V18, P4724, DOI 10.1093/hmg/ddp435; Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; Bedaiwy MA, 2003, FERTIL STERIL, V79, P594, DOI 10.1016/S0015-0282(02)04842-2; BenEzra D, 2005, BRIT J OPHTHALMOL, V89, P393, DOI 10.1136/bjo.2004.056739; Chang AS, 2005, FERTIL STERIL, V83, P349, DOI 10.1016/j.fertnstert.2004.07.964; Courbiere B, 2009, FERTIL STERIL, V91, P2697, DOI 10.1016/j.fertnstert.2008.03.012; DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031; Demeestere I, 2007, ONCOLOGIST, V12, P1437, DOI 10.1634/theoncologist.12-12-1437; Denschlag D, 2005, FERTIL STERIL, V83, P501, DOI 10.1016/j.fertnstert.2004.07.958; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Donnez J, 2006, HUM REPROD UPDATE, V12, P519, DOI 10.1093/humupd/dml032; Donnez J, 2011, ANN MED, V43, P437, DOI 10.3109/07853890.2010.546807; Donnez J, 2010, CLIN OBSTET GYNECOL, V53, P787, DOI 10.1097/GRF.0b013e3181f97a55; Donnez J, 2010, BEST PRACT RES CL OB, V24, P87, DOI 10.1016/j.bpobgyn.2009.09.003; Ernst E, 2010, HUM REPROD, V25, P1280, DOI 10.1093/humrep/deq033; Gicquel C, 2003, AM J HUM GENET, V72, P1338, DOI 10.1086/374824; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; Imhof M, 2006, FERTIL STERIL, V85, P1208, DOI 10.1016/j.fertnstert.2005.11.030; Jadoul P, 2010, HUM REPROD UPDATE, V16, P617, DOI 10.1093/humupd/dmq010; Linet MS, 1999, JNCI-J NATL CANCER I, V91, P1051, DOI 10.1093/jnci/91.12.1051; Liu J, 2002, HUM REPROD, V17, P605, DOI 10.1093/humrep/17.3.605; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; Ludwig M, 2005, J MED GENET, V42, P289, DOI 10.1136/jmg.2004.026930; Maher ER, 2003, J MED GENET, V40, P62, DOI 10.1136/jmg.40.1.62; Meirow D, 1999, FERTIL STERIL, V71, P948, DOI 10.1016/S0015-0282(99)00067-9; Meirow D, 2005, NEW ENGL J MED, V353, P318, DOI 10.1056/NEJMc055237; MUSSETT MV, 1961, J REPROD FERTIL, V2, P80, DOI 10.1530/jrf.0.0020080; Nativio R, 2011, HUM MOL GENET, V20, P1363, DOI 10.1093/hmg/ddr018; Niemitz EL, 2004, AM J HUM GENET, V74, P599, DOI 10.1086/382897; Paoloni-Giacobino A, 2007, PEDIATR RES, V61, p51R, DOI 10.1203/pdr.0b013e318039d978; Poirot C, 2005, Gynecol Obstet Fertil, V33, P799, DOI 10.1016/j.gyobfe.2005.07.032; Poirot C, 2012, LANCET, V379, P588, DOI 10.1016/S0140-6736(11)61781-9; Poirot CJ, 2007, PEDIATR BLOOD CANCER, V49, P74, DOI 10.1002/pbc.21027; Revel A, 2004, FERTIL STERIL, V82, P1714, DOI 10.1016/j.fertnstert.2004.06.046; Rodriguez-Wallberg KA, 2012, BEST PRACT RES CL OB, V26, P391, DOI 10.1016/j.bpobgyn.2012.01.001; Rossignol S, 2006, J MED GENET, V43, P902, DOI 10.1136/jmg.2006.042135; Roux C, 2010, FERTIL STERIL, V93, DOI 10.1016/j.fertnstert.2009.12.022; Salle B, 2003, FERTIL STERIL, V80, P172, DOI 10.1016/S0015-0282(03)00554-5; Salle B, 2002, FERTIL STERIL, V77, P403, DOI 10.1016/S0015-0282(01)02960-0; Sauvat F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001972; Schmidt KT, 2010, BJOG-INT J OBSTET GY, V117, P163, DOI 10.1111/j.1471-0528.2009.02408.x; Shaw JM, 2000, MOL CELL ENDOCRINOL, V161, P103, DOI 10.1016/S0303-7207(99)00230-0; Shaw JM, 2002, SEMIN REPROD MED, V20, P51, DOI 10.1055/s-2002-24950; Silber SJ, 2012, MOL HUM REPROD, V18, P59, DOI 10.1093/molehr/gar082; Tierling S, 2010, J MED GENET, V47, P371, DOI 10.1136/jmg.2009.073189; Wang HB, 2002, AM J OBSTET GYNECOL, V187, P370, DOI 10.1067/mob.2002.123606; Wilkins-Haug L, 2008, CLIN OBSTET GYNECOL, V51, P96, DOI 10.1097/GRF.0b013e318161d25a; Young LE, 2003, MECH DEVELOP, V120, P1433, DOI 10.1016/j.mod.2003.09.006; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	52	11	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1511	1518		10.1096/fj.12-218297	http://dx.doi.org/10.1096/fj.12-218297			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271057				2022-12-28	WOS:000316940800023
J	Fang, L; Du, WW; Yang, XL; Chen, K; Ghanekar, A; Levy, G; Yang, WN; Yee, AJ; Lu, WY; Xuan, JW; Gao, ZL; Xie, F; He, CY; Deng, ZQ; Yang, BB				Fang, Ling; Du, William W.; Yang, Xiangling; Chen, Kui; Ghanekar, Anand; Levy, Gary; Yang, Weining; Yee, Albert J.; Lu, Wei-Yang; Xuan, Jim W.; Gao, Zhongli; Xie, Feng; He, Chengyan; Deng, Zhaoqun; Yang, Burton B.			Versican 3 '-untranslated region (3 '-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity	FASEB JOURNAL			English	Article						microRNA; transgenic mice; noncoding RNA	PROMOTES TUMOR-GROWTH; OSTEOBLAST DIFFERENTIATION; CELL-PROLIFERATION; ISOFORM EXPRESSION; MICRORNA FUNCTIONS; BREAST-CANCER; G3 DOMAIN; PG-M; PROTEOGLYCAN; ANGIOGENESIS	This study was designed to explore the role of versican in the development of hepatocellular carcinoma (HCC). Ectopic expression of the versican 3'-untranslated region (3'-UTR) was studied as a competitive endogenous RNA for regulating miRNA functions. We used this approach to modulate the expression of versican and its related proteins in 3'-UTR transgenic mice and in the liver cancer cell line HepG2, stably transfected with the 3'-UTR or a control vector. We demonstrated that transgenic mice expressing the versican 3'-UTR developed HCC and increased expression of versican isoforms V0 and V1. HepG2 cells transfected with versican 3'-UTR displayed increased proliferation, survival, migration, invasion, colony formation, and enhanced endothelial cell growth, but decreased apoptosis. We found that versican 3'-UTR could bind to miRNAs miR-133a, miR-199a*, miR-144, and miR-431 and also interacted with CD34 and fibronectin. As a consequence, expression of versican, CD34, and fibronectin was up-regulated by ectopic transfection of the versican 3'-UTR, which was confirmed in HepG2 cells and in transgenic mice as compared with wild-type controls. Transfection with siRNAs targeting the versican 3'-UTR abolished the effects of the 3'-UTR. Taken together, these results demonstrate that versican V0 and V1 isoforms play important roles in HCC development and that versican mRNAs compete with endogenous RNAs in regulating miRNA functions.-Fang, L., Du, W. W., Yang, X., Chen, K., Ghanekar, A., Levy, G., Yang, W., Yee, A. J., Lu, W.-Y., Xuan, J. W., Gao, Z., Xie, F., He, C., Deng, Z., Yang, B. B. Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J. 27, 907-919 (2013). www.fasebj.org	[Fang, Ling; Du, William W.; Yang, Xiangling; Yang, Weining; Yee, Albert J.; Deng, Zhaoqun; Yang, Burton B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Fang, Ling; Du, William W.; Yang, Xiangling; Deng, Zhaoqun; Yang, Burton B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Ghanekar, Anand] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Levy, Gary] Univ Toronto, Inst Transplantat, Toronto, ON, Canada; [Chen, Kui; Ghanekar, Anand] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada; [Lu, Wei-Yang] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Xuan, Jim W.] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada; [Gao, Zhongli; Xie, Feng; He, Chengyan] Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Western University (University of Western Ontario); Western University (University of Western Ontario); Jilin University	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	byang@sri.utoronto.ca	Lu, Wei-Yang/K-4404-2013	Yang, Xiangling/0000-0002-5881-4299	Natural Sciences and Engineering Research Council of Canada (NSERC) [227937-2012]; Heart and Stroke Foundation of Ontario [CI 7418]; NSERC	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC; 227937-2012) to B.B.Y., who is the recipient of a Career Investigator award (CI 7418) from the Heart and Stroke Foundation of Ontario. W.Y. was a recipient of an NSERC Undergraduate Summer Research award.	Arslan F, 2007, BRIT J CANCER, V96, P1560, DOI 10.1038/sj.bjc.6603766; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Kahai S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007535; LaPierre DP, 2007, CANCER RES, V67, P4742, DOI 10.1158/0008-5472.CAN-06-3610; Lee D. Y., PLOS ONE, V5; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Lee SC, 2011, FEBS LETT, V585, P2610, DOI 10.1016/j.febslet.2011.07.016; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lin HM, 2007, ONCOL REP, V17, P1541; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; Miquel-Serra L, 2006, LAB INVEST, V86, P889, DOI 10.1038/labinvest.3700449; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Seitz H, 2009, CURR BIOL, V19, P870, DOI 10.1016/j.cub.2009.03.059; Serra M, 2005, INT J CANCER, V114, P879, DOI 10.1002/ijc.20813; Setoguchi T., CANC SCI, V102, P883; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Shatseva T, 2011, J CELL SCI, V124, P2826, DOI 10.1242/jcs.077529; Sheng W, 2006, MOL BIOL CELL, V17, P2009, DOI 10.1091/mbc.E05-10-0951; Sheng W, 2005, MOL BIOL CELL, V16, P1330, DOI 10.1091/mbc.e04-04-0295; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Swami M, 2010, NAT REV CANCER, V10, P535, DOI 10.1038/nrc2898; Tarantino C, 2010, FASEB J, V24, P3255, DOI 10.1096/fj.09-152207; YAMAGATA M, 1993, J CELL SCI, V106, P55; Yang XL, 2012, CELL CYCLE, V11, P3097, DOI 10.4161/cc.21503; Ye WB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001719; Yee AJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1751; Zeng Y, 2004, NUCLEIC ACIDS RES, V32, P4776, DOI 10.1093/nar/gkh824; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	42	102	110	0	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					907	919		10.1096/fj.12-220905	http://dx.doi.org/10.1096/fj.12-220905			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23180826				2022-12-28	WOS:000315585200007
J	Mok, KW; Mruk, DD; Lee, WM; Cheng, CY				Mok, Ka-Wai; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Rictor/mTORC2 regulates blood-testis barrier dynamics via its effects on gap junction communications and actin filament network	FASEB JOURNAL			English	Article						spermatogenesis; seminiferous epithelial cycle; Sertoli cell; ectoplasmic specialization	ADHERENS JUNCTIONS; MAMMALIAN TARGET; CADMIUM CHLORIDE; TIGHT JUNCTIONS; PROTEIN COMPLEX; SERTOLI-CELLS; MTOR; CYTOSKELETON; CONNEXIN-43; TGF-BETA-3	In the mammalian testis, coexisting tight junctions (TJs), basal ectoplasmic specializations, and gap junctions (GJs), together with desmosomes near the basement membrane, constitute the blood-testis barrier (BTB). The most notable feature of the BTB, however, is the extensive network of actin filament bundles, which makes it one of the tightest blood-tissue barriers. The BTB undergoes restructuring to facilitate the transit of preleptotene spermatocytes at stage VIII-IX of the epithelial cycle. Thus, the F-actin network at the BTB undergoes cyclic reorganization via a yet-to-be explored mechanism. Rictor, the key component of mTORC2 that is known to regulate actin cytoskeleton, was shown to express stage-specifically at the BTB in the seminiferous epithelium. Its expression was down-regulated at the BTB in stage VIII-IX tubules, coinciding with BTB restructuring at these stages. Using an in vivo model, a down-regulation of rictor at the BTB was also detected during adjudin-induced BTB disruption, illustrating rictor expression is positively correlated with the status of the BTB integrity. Indeed, the knockdown of rictor by RNAi was found to perturb the Sertoli cell TJ-barrier function in vitro and the BTB integrity in vivo. This loss of barrier function was accompanied by changes in F-actin organization at the Sertoli cell BTB in vitro and in vivo, associated with a loss of interaction between actin and alpha-catenin or ZO-1. Rictor knockdown by RNAi was also found to impede Sertoli cell-cell GJ communication, disrupting protein distribution (e. g., occludin, ZO-1) at the BTB, illustrating that rictor is a crucial BTB regulator.-Mok, K., Mruk, D. D., Lee, W. M., Cheng, C. Y. Rictor/mTORC2 regulates blood-testis barrier dynamics via its effects on gap junction communications and actin filament network. FASEB J. 27, 1137-1152 (2013). www.fasebj.org	[Mok, Ka-Wai; Mruk, Dolores D.; Cheng, C. Yan] Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, New York, NY 10065 USA; [Mok, Ka-Wai; Lee, Will M.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USA.	hrszlwm@hku.hk; y-cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	U.S. National Institutes of Health (National Institute of Child Health and Human Development) [R01 HD056034, U54 HD029990, R03 HD061401]; University of Hong Kong Committee on Research and Conference Grants; University of Hong Kong; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD056034, U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD061401] Funding Source: NIH RePORTER	U.S. National Institutes of Health (National Institute of Child Health and Human Development)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); University of Hong Kong Committee on Research and Conference Grants; University of Hong Kong(University of Hong Kong); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grants from the U.S. National Institutes of Health (National Institute of Child Health and Human Development, R01 HD056034 to C. Y. C.; U54 HD029990, Project 5, to C. Y. C.; R03 HD061401 to D. D. M.), and University of Hong Kong Committee on Research and Conference Grants seed funding to W. M. L. K. W. M. was supported by a University of Hong Kong Postgraduate Student Research award while all the experiments reported herein were conducted in the laboratory of C. Y. C. in New York.	Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790; Cheng CY, 2010, NAT REV ENDOCRINOL, V6, P380, DOI 10.1038/nrendo.2010.71; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Das G, 2011, MOL CARCINOGEN, V50, P412, DOI 10.1002/mc.20723; Ezan P, 2012, J CEREBR BLOOD F MET, V32, P1457, DOI 10.1038/jcbfm.2012.45; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Grima J, 1998, J BIOL CHEM, V273, P21040, DOI 10.1074/jbc.273.33.21040; Hagan GN, 2008, MOL CELL BIOL, V28, P4215, DOI 10.1128/MCB.00867-07; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Huang SH, 2003, J CELL BIOCHEM, V90, P33, DOI 10.1002/jcb.10610; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; JANECKI A, 1992, TOXICOL APPL PHARM, V112, P51, DOI 10.1016/0041-008X(92)90278-Z; Jin EJ, 2008, J CELL PHYSIOL, V214, P345, DOI 10.1002/jcp.21202; Joung SM, 2011, J IMMUNOL, V186, P499, DOI 10.4049/jimmunol.0903534; Lee NPY, 2003, BIOL REPROD, V68, P489, DOI 10.1095/biolreprod.102.005793; Lee NPY, 2004, J ANDROL, V25, P200; Li MWM, 2013, ADV EXP MED BIOL, V763, P260; Li MWM, 2010, P NATL ACAD SCI USA, V107, P17998, DOI 10.1073/pnas.1007047107; Li MWM, 2009, P NATL ACAD SCI USA, V106, P10213, DOI 10.1073/pnas.0901700106; Lie PPY, 2011, FASEB J, V25, P1244, DOI 10.1096/fj.10-169995; Lie PPY, 2010, P NATL ACAD SCI USA, V107, P11411, DOI 10.1073/pnas.1001823107; Lie PPY, 2010, INT J BIOCHEM CELL B, V42, P975, DOI 10.1016/j.biocel.2010.02.010; Lie PPY, 2009, FASEB J, V23, P2555, DOI 10.1096/fj.06-070573; Mahajan K., 2010, J CELL PHYSL, V227, P3178; Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014; Mok KW, 2012, INT J ANDROL, V35, P86, DOI 10.1111/j.1365-2605.2011.01183.x; Mok KW, 2012, ENDOCRINOLOGY, V153, P5036, DOI 10.1210/en.2012-1665; Mruk DD, 2011, METHODS MOL BIOL, V763, P237, DOI 10.1007/978-1-61779-191-8_16; Nagasawa K, 2006, J CELL PHYSIOL, V208, P123, DOI 10.1002/jcp.20647; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; PINEAU C, 1993, J ANDROL, V14, P87; Pointis G, 2010, PHILOS T R SOC B, V365, P1607, DOI 10.1098/rstb.2009.0114; Putnam AJ, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-10; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; SETCHELL BP, 1970, J ENDOCRINOL, V47, P81, DOI 10.1677/joe.0.0470081; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Vollenbroker B, 2009, AM J PHYSIOL-RENAL, V296, pF418, DOI 10.1152/ajprenal.90319.2008; Wong CH, 2004, J CELL SCI, V117, P783, DOI 10.1242/jcs.00900; Wong EWP, 2010, P NATL ACAD SCI USA, V107, P11399, DOI 10.1073/pnas.1001077107; Xia WL, 2009, DEV BIOL, V327, P48, DOI 10.1016/j.ydbio.2008.11.028; Zhou HY, 2010, CURR PROTEIN PEPT SC, V11, P409, DOI 10.2174/138920310791824093	47	61	64	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1137	1152		10.1096/fj.12-212977	http://dx.doi.org/10.1096/fj.12-212977			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23288930	Green Published			2022-12-28	WOS:000315585200027
J	Bernal, AJ; Dolinoy, DC; Huang, D; Skaar, DA; Weinhouse, C; Jirtle, RL				Bernal, Autumn J.; Dolinoy, Dana C.; Huang, Dale; Skaar, David A.; Weinhouse, Caren; Jirtle, Randy L.			Adaptive radiation-induced epigenetic alterations mitigated by antioxidants	FASEB JOURNAL			English	Article						agouti mice; DNA methylation; hormesis; reactive oxygen species	EFFECTS IN-VIVO; IONIZING-RADIATION; DNA METHYLATION; IRRADIATION; YELLOW; EXPRESSION; EFFECTORS; PATTERNS; EXPOSURE; OBESITY	Humans are exposed to low-dose ionizing radiation (LDIR) from a number of environmental and medical sources. In addition to inducing genetic mutations, there is concern that LDIR may also alter the epigenome. Such heritable effects early in life can either be positively adaptive or result in the enhanced formation of diseases, including cancer, diabetes, and obesity. Herein, we show that LDIR significantly increased DNA methylation at the viable yellow agouti (A(vy)) locus in a sex-specific manner (P=0.004). Average DNA methylation was significantly increased in male offspring exposed to doses between 0.7 and 7.6 cGy, with maximum effects at 1.4 and 3.0 cGy (P<0.01). Offspring coat color was concomitantly shifted toward pseudoagouti (P<0.01). Maternal dietary antioxidant supplementation mitigated both the DNA methylation changes and coat color shift in the irradiated offspring. Thus, LDIR exposure during gestation elicits epigenetic alterations that lead to positive adaptive phenotypic changes that are negated with antioxidants, indicating they are mediated in part by oxidative stress. These findings provide evidence that in the isogenic A(vy) mouse model, epigenetic alterations resulting from LDIR play a role in radiation hormesis, bringing into question the assumption that every dose of radiation is harmful.-Bernal, A. J., Dolinoy, D. C., Huang, D., Skaar, D. A., Weinhouse, C., Jirtle, R. J. Adaptive radiation-induced epigenetic alterations mitigated by antioxidants. FASEB J. 27, 665-671 (2013). www.fasebj.org	[Bernal, Autumn J.; Huang, Dale; Skaar, David A.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA; [Dolinoy, Dana C.; Weinhouse, Caren] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Jirtle, Randy L.] Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	Duke University; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Jirtle, RL (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	jirtle@geneimprint.com		Weinhouse, Caren/0000-0002-1257-7267	U.S. Department of Energy [DE-FG02-10ER64931]; Ester B. O'Keeffe Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES017885, T32ES007062] Funding Source: NIH RePORTER	U.S. Department of Energy(United States Department of Energy (DOE)); Ester B. O'Keeffe Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Susan K. Murphy for critically reading this manuscript, Theodore Slotkin for assisting with statistical analysis, and Christopher Faulk for agouti mouse photography. The authors also thank Greta Toncheva and the Duke Radiation Dosimetry Laboratory for assistance in determining the intrauterine radiation doses. Financial support from the U.S. Department of Energy (grant DE-FG02-10ER64931) and the Ester B. O'Keeffe Foundation is gratefully acknowledged. The authors declare no conflicts of interest.	Akiba S, 2012, J RADIOL PROT, V32, P1, DOI 10.1088/0952-4746/32/1/1; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bairati I, 2005, JNCI-J NATL CANCER I, V97, P481, DOI 10.1093/jnci/dji095; Calabrese E, 2011, P NATL ACAD SCI USA, V108, P19447, DOI 10.1073/pnas.1117296108; Calabrese EJ, 2009, ARCH TOXICOL, V83, P203, DOI 10.1007/s00204-009-0412-4; Calabrese EJ, 2002, HUM EXP TOXICOL, V21, P91, DOI 10.1191/0960327102ht217oa; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2010, EPIGENETICS-US, V5, P637, DOI 10.4161/epi.5.7.12892; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Ilnytskyy Y, 2009, ENVIRON MOL MUTAGEN, V50, P105, DOI 10.1002/em.20440; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kaminen-Ahola N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000811; Koturbash I, 2006, ONCOGENE, V25, P4267, DOI 10.1038/sj.onc.1209467; Koturbash I, 2008, MUTAT RES-FUND MOL M, V642, P28, DOI 10.1016/j.mrfmmm.2008.04.002; Koturbash I, 2007, CARCINOGENESIS, V28, P1831, DOI 10.1093/carcin/bgm053; Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P114, DOI 10.1016/j.mrgentox.2010.05.007; Kovalchuk O, 2004, MUTAT RES-FUND MOL M, V548, P75, DOI 10.1016/j.mrfmmm.2003.12.016; Morgan HD, 2008, BIOL REPROD, V79, P618, DOI 10.1095/biolreprod.108.068213; Nandakumar V, 2011, CARCINOGENESIS, V32, P597, DOI 10.1093/carcin/bgq282; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Rugo RE, 2011, ONCOGENE, V30, P751, DOI 10.1038/onc.2010.480; Saenko V, 2011, CLIN ONCOL-UK, V23, P234, DOI 10.1016/j.clon.2011.01.502; Sanders CL, 2009, RAD HORMESIS LINEAR; Schauer DA, 2009, HEALTH PHYS, V97, P1, DOI 10.1097/01.HP.0000356672.44380.b7; Tawa R, 1998, J RADIAT RES, V39, P271, DOI 10.1269/jrr.39.271; Vaiserman AM, 2011, AGEING RES REV, V10, P413, DOI 10.1016/j.arr.2011.01.004; Wambi CO, 2009, RADIAT RES, V172, P175, DOI 10.1667/RR1589.1; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Williams G, 2000, P NUTR SOC, V59, P385, DOI 10.1017/S0029665100000434; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666	35	75	84	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					665	671		10.1096/fj.12-220350	http://dx.doi.org/10.1096/fj.12-220350			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118028	Green Published, Green Submitted			2022-12-28	WOS:000314358000025
J	Barroso, R; Munoz, LM; Barrondo, S; Vega, B; Holgado, BL; Lucas, P; Baillo, A; Salles, J; Rodriguez-Frade, JM; Mellado, M				Barroso, Ruben; Martinez Munoz, Laura; Barrondo, Sergio; Vega, Beatriz; Holgado, Borja L.; Lucas, Pilar; Baillo, Amparo; Salles, Joan; Rodriguez-Frade, Jose M.; Mellado, Mario			EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5	FASEB JOURNAL			English	Article						modulation of the B-cell response; binding affinity; G alpha(i) activation	B-CELL MIGRATION; CHEMOKINE RECEPTOR; QUANTITATIVE ASSESSMENT; CONFORMATIONAL-CHANGES; OPIOID RECEPTORS; LIVING CELLS; LIGAND; HOMODIMERS; REVEALS; CCR5	B-cell movement into lymphoid follicles depends on the expression of the chemokine receptor CXCR5 and the recently reported Epstein-Barr virus-induced receptor 2 (EBI2). In cooperation with CXCR5, EBI2 helps to position activated B cells in the follicle, although the mechanism is poorly understood. Using human HEK293T cells and fluorescence resonance energy transfer (FRET) techniques, we demonstrate that CXCR5 and EBI2 form homo- and heterodimers. EBI2 expression modulated CXCR5 homodimeric complexes, as indicated by the FRET50 value (CXCR5 homodimer, 0.9851 +/- 0.0784; CXCR5 homodimer+EBI2, 1.7320 +/- 0.4905; P<0.05). HEK293T cells expressing CXCR5/EBI2 and primary activated murine B cells both down-modulated CXCR5-mediated responses, such as Ca2+ flux, cell migration, and MAPK activation; this modulation did not occur when primary B cells were obtained from EBI2(-/-) mice. The mechanism involves a reduction in binding affinity of the ligand (CXCL13) for CXCR5 (K-D: 5.05 x 10(-8) M for CXCR5 alone vs. 1.49 x 10(-7) M for CXCR5/EBI2) and in the efficacy (E-max) of G-protein activation in CXCR5/EBI2-coexpressing cells (42.33 +/- 4.3%; P<0.05). These findings identify CXCR5/EBI2 heterodimers as functional units that contribute to the plasticity of CXCL13-mediated B-cell responses.-Barroso, R., Munoz, L. Martinez., Barrondo, S., Vega, B., Holgado, B. L., Lucas, P., Baillo, A., Salles, J., Rodriguez-Frade J. M., Mellado, M. EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5. FASEB J. 26, 4841-4854 (2012). www.fasebj.org	[Barroso, Ruben; Martinez Munoz, Laura; Vega, Beatriz; Holgado, Borja L.; Lucas, Pilar; Rodriguez-Frade, Jose M.; Mellado, Mario] Univ Autonoma Madrid, CSIC, CNB, Dept Immunol & Oncol, E-28049 Madrid, Spain; [Baillo, Amparo] Univ Autonoma Madrid, Dept Math, E-28049 Madrid, Spain; [Barrondo, Sergio; Salles, Joan] UPV, EHU, Univ Basque Country, Fac Pharm,Dept Pharmacol, Vitoria, Spain; [Barrondo, Sergio; Salles, Joan] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; University of Basque Country; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM	Mellado, M (corresponding author), Univ Autonoma Madrid, CSIC, CNB, Dept Immunol & Oncol, Darwin 3, E-28049 Madrid, Spain.	mmellado@cnb.csic.es	Barrondo, Sergio/F-2470-2016; Sallés, Joan/ABE-1959-2021; Sallés, Joan/A-7141-2015; Baíllo, Amparo/L-2386-2013; Martínez-Muñoz, Laura/C-2719-2017; Mellado, Mario/M-9893-2014; Sallés, Joan/ABE-2123-2021; Frade, Jose Miguel Rodriguez/K-4266-2014	Barrondo, Sergio/0000-0001-8159-4872; Sallés, Joan/0000-0001-6727-2674; Baíllo, Amparo/0000-0003-1644-3992; Martínez-Muñoz, Laura/0000-0003-3098-279X; Mellado, Mario/0000-0001-6325-1630; Sallés, Joan/0000-0001-6727-2674; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Barroso, Ruben/0000-0003-3737-5538	Spanish Ministry of Science and Innovation [SAF 2008-03388, SAF 2011-27370, MTM2010-17366]; RETICS Program [RD08/0075/0010]; Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental; Basque Government [GIC10/147]; European Union [223404]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); RETICS Program; Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental(Instituto de Salud Carlos III); Basque Government(Basque Government); European Union(European Commission)	The authors thank Dr. R. Brink (Garvan Institute of Medical Research, Darlinghurst, NSW, Australia) for the gift of EBI2<SUP>-/-</SUP> mice, L. Gomez for animal handling, and C. Bastos and C. Mark for secretarial and editorial assistance, respectively. This work was supported in part by grants from the Spanish Ministry of Science and Innovation (SAF 2008-03388 and SAF 2011-27370 to M. M.; MTM2010-17366 to A. B.), the RETICS Program (RD08/0075/0010; RIER to M. M.), the Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental (to J.S.), the Basque Government (GIC10/147 to J.S.), and the European Union (FP7-integrated project Masterswitch 223404 to M.M.).	Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Audet N, 2008, J BIOL CHEM, V283, P15078, DOI 10.1074/jbc.M707941200; Barrondo S, 2009, NEUROPHARMACOLOGY, V56, P455, DOI 10.1016/j.neuropharm.2008.09.018; Berglund MM, 2003, J PHARMACOL EXP THER, V307, P1120, DOI 10.1124/jpet.103.055673; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Canals M, 2003, J BIOL CHEM, V278, P46741, DOI 10.1074/jbc.M306451200; Chabre M, 2009, TRENDS PHARMACOL SCI, V30, P182, DOI 10.1016/j.tips.2009.01.003; Chakera A, 2008, MOL PHARMACOL, V73, P1362, DOI 10.1124/mol.107.040915; Chen CG, 2004, EUR J PHARMACOL, V483, P175, DOI 10.1016/j.ejphar.2003.10.033; Contento RL, 2008, P NATL ACAD SCI USA, V105, P10101, DOI 10.1073/pnas.0804286105; Cyster JG, 2010, NAT IMMUNOL, V11, P989, DOI 10.1038/ni.1946; Gatto D, 2011, J IMMUNOL, V187, P4621, DOI 10.4049/jimmunol.1101542; Gatto D, 2009, IMMUNITY, V31, P259, DOI 10.1016/j.immuni.2009.06.016; Han Y, 2009, NAT CHEM BIOL, V5, P688, DOI 10.1038/nchembio.199; Hannedouche S, 2011, NATURE, V475, P524, DOI 10.1038/nature10280; Heinig M, 2010, NATURE, V467, P460, DOI 10.1038/nature09386; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Katakai T, 2008, J IMMUNOL, V181, P6189, DOI 10.4049/jimmunol.181.9.6189; Kelly LM, 2011, J IMMUNOL, V187, P3026, DOI 10.4049/jimmunol.1101262; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Levoye A, 2006, EMBO J, V25, P3012, DOI 10.1038/sj.emboj.7601193; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Liu CL, 2011, NATURE, V475, P519, DOI 10.1038/nature10226; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Munoz LM, 2009, J IMMUNOL, V183, P7337, DOI 10.4049/jimmunol.0901802; Mellado M., 2008, CURR PROTOC PHARM, V12, P11; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Mueller SN, 2009, NAT REV IMMUNOL, V9, P618, DOI 10.1038/nri2588; Muller G, 2001, BIOL CHEM, V382, P1387, DOI 10.1515/BC.2001.171; Okada T, 2005, PLOS BIOL, V3, P1047, DOI 10.1371/journal.pbio.0030150; Pello OM, 2008, EUR J IMMUNOL, V38, P537, DOI 10.1002/eji.200737630; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Pereira JP, 2009, NATURE, V460, P1122, DOI 10.1038/nature08226; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Poncelet P, 1993, METHODS IMMUNOLOGICA, P388; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Rosenkilde MM, 2006, J BIOL CHEM, V281, P13199, DOI 10.1074/jbc.M602245200; Sakai T, 2010, MOL BIOL EVOL, V27, P1097, DOI 10.1093/molbev/msp319; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Smith N. J., PHARM REV, V62, P701; Szabo I, 2003, J LEUKOCYTE BIOL, V74, P1074, DOI 10.1189/jlb.0203067; Vega B, 2011, J LEUKOCYTE BIOL, V90, P399, DOI 10.1189/jlb.1010565; Wilson S, 2005, J BIOL CHEM, V280, P28663, DOI 10.1074/jbc.M413475200; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Zhu WZ, 2005, CIRC RES, V97, P244, DOI 10.1161/01.RES.0000176764.38934.86; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1	52	31	33	3	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4841	4854		10.1096/fj.12-208876	http://dx.doi.org/10.1096/fj.12-208876			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22913878				2022-12-28	WOS:000311838300008
J	Fridolfsson, HN; Kawaraguchi, Y; Ali, SS; Panneerselvam, M; Niesman, IR; Finley, JC; Kellerhals, SE; Migita, MY; Okada, H; Moreno, AL; Jennings, M; Kidd, MW; Bonds, JA; Balijepalli, RC; Ross, RS; Patel, PM; Miyanohara, A; Chen, Q; Lesnefsky, EJ; Head, BP; Roth, DM; Insel, PA; Patel, HH				Fridolfsson, Heidi N.; Kawaraguchi, Yoshitaka; Ali, Sameh S.; Panneerselvam, Mathivadhani; Niesman, Ingrid R.; Finley, J. Cameron; Kellerhals, Sarah E.; Migita, Michael Y.; Okada, Hideshi; Moreno, Ana L.; Jennings, Michelle; Kidd, Michael W.; Bonds, Jacqueline A.; Balijepalli, Ravi C.; Ross, Robert S.; Patel, Piyush M.; Miyanohara, Atsushi; Chen, Qun; Lesnefsky, Edward J.; Head, Brian P.; Roth, David M.; Insel, Paul A.; Patel, Hemal H.			Mitochondria-localized caveolin in adaptation to cellular stress and injury	FASEB JOURNAL			English	Article						cardiac protection; cancer biology; gene transfer; reactive oxygen species; respiratory function	CARDIAC-SPECIFIC OVEREXPRESSION; PERMEABILITY TRANSITION; PULMONARY-HYPERTENSION; MYOCARDIAL-INFARCTION; ELECTRON-TRANSPORT; REPERFUSION INJURY; CAT MYOCARDIUM; PROTECTION; ISCHEMIA; MUSCLE	We show here that the apposition of plasmamembrane caveolae and mitochondria (first noted in electron micrographs >50 yr ago) and caveolae-mitochondria interaction regulates adaptation to cellular stress by modulating the structure and function of mitochondria. In C57Bl/6 mice engineered to overexpress caveolin specifically in cardiac myocytes (Cav-3 OE), localization of caveolin to mitochondria increases membrane rigidity (4.2%; P<0.05), tolerance to calcium, and respiratory function (72% increase in state 3 and 23% increase in complex IV activity; P<0.05), while reducing stress-induced generation of reactive oxygen species (by 20% in cellular superoxide and 41 and 28% in mitochondrial superoxide under states 4 and 3, respectively; P<0.05) in Cav-3 OE vs. TGneg. By contrast, mitochondrial function is abnormal in caveolin-knockout mice and Caenorhabditis elegans with null mutations in caveolin (60% increase free radical in Cav-2 C. elegans mutants; P<0.05). In human colon cancer cells, mitochondria with increased caveolin have a 30% decrease in apoptotic stress (P<0.05), but cells with disrupted mitochondria-caveolin interaction have a 30% increase in stress response (P<0.05). Targeted gene transfer of caveolin to mitochondria in C57Bl/6 mice increases cardiac mitochondria tolerance to calcium, enhances respiratory function (increases of 90% state 4, 220% state 3, 88% complex IV activity; P<0.05), and decreases (by 33%) cardiac damage (P<0.05). Physical association and apparently the transfer of caveolin between caveolae and mitochondria is thus a conserved cellular response that confers protection from cellular damage in a variety of tissues and settings.-Fridolfsson, H. N., Kawaraguchi, Y., Ali, S. S., Panneerselvam, M., Niesman, I. R., Finley, J. C., Kellerhals, S. E., Migita, M. Y., Okada, H., Moreno, A. L., Jennings, M., Kidd, M. W., Bonds, J. A., Balijepalli, R. C., Ross, R. S., Patel, P. M., Miyanohara, A., Chen, Q., Lesnefsky, E. J., Head, B. P., Roth, D. M., Insel, P. A., Patel, H. H. Mitochondria-localized caveolin in adaptation to cellular stress and injury. FASEB J. 26, 4637-4649 (2012). www.fasebj.org	[Fridolfsson, Heidi N.; Kawaraguchi, Yoshitaka; Ali, Sameh S.; Panneerselvam, Mathivadhani; Niesman, Ingrid R.; Finley, J. Cameron; Kellerhals, Sarah E.; Migita, Michael Y.; Moreno, Ana L.; Jennings, Michelle; Kidd, Michael W.; Bonds, Jacqueline A.; Patel, Piyush M.; Head, Brian P.; Roth, David M.; Patel, Hemal H.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Okada, Hideshi; Ross, Robert S.; Miyanohara, Atsushi; Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Ali, Sameh S.] Helmy Inst Med Sci, Ctr Aging & Associated Dis, Zewail City, Egypt; [Migita, Michael Y.; Okada, Hideshi; Ross, Robert S.; Patel, Piyush M.; Head, Brian P.; Roth, David M.; Patel, Hemal H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Balijepalli, Ravi C.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; [Chen, Qun; Lesnefsky, Edward J.] McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Chen, Qun] Virginia Commonwealth Univ, Richmond, VA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Egyptian Knowledge Bank (EKB); Zewail City of Science & Technology; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Wisconsin System; University of Wisconsin Madison; Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Patel, HH (corresponding author), Univ Calif San Diego, Dept Anesthesiol, VASDHS 9125,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	hepatel@ucsd.edu	Chen, Qun/HGD-0868-2022; Ross, Robert/ABE-1109-2020; Patel, Hemal/C-7325-2019	Ross, Robert/0000-0003-2195-8982; Ali, Sameh Saad/0000-0002-0339-6106; Okada, Hideshi/0000-0002-7775-4308; Niesman, Ingrid/0000-0001-9767-6629; Patel, Hemal/0000-0001-6722-9625	AP Giannini Foundation; U.S. National Institutes of Heath [HL091071, HL107200, 3R01HL91071, GM066232, HL081400, HL46345, HL088390, HL103566, HL105713]; Veterans Affairs [BX000783]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091071, R01HL081400, R01HL107200, R01HL105713, R01HL088390, P01HL046345, P01HL066941, R01HL103566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R01GM066232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073653] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000783] Funding Source: NIH RePORTER	AP Giannini Foundation; U.S. National Institutes of Heath(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by grants from the AP Giannini Foundation (H. N. F.); U.S. National Institutes of Heath grants HL091071 (H. H. P.), HL107200 (H. H. P. and D. M. R.), ARRA Supplement 3R01HL91071 (H. H. P.), GM066232 (P. A. I.), HL081400 (D. M. R.), HL46345 (R. S. R.), HL088390 (R. S. R.), HL103566 (R. S. R.), and HL105713 (R. C. B.); and Veterans Affairs merit grant BX000783 (D. M. R.). Author contributions: H. N. F., Y. K., D. M. R., P. A. I, and H. H. P planned the majority of experiments and wrote the paper; S. S. A., M. W. K., M. Y. M., and A. L. M contributed to the design and interpretation of EPR and mitochondrial assays and performed calcium swelling assays; M. P. and M. J performed in vivo ischemia reperfusion and preconditioning experiments and cell-based ROS assays; I. R. N. performed all electron and immunoelectron microscopy; H. N. F., J. C. F., and S. K. created purified mitochondria and performed mitochondrial assays, membrane fluidity EPR studies, and C. elegans studies; Y. K. and I. R. N. performed all studies with HT29 and HCT116 cells; Y. K., H. O., and A. M designed, generated, and performed experiments with the AAV vector; R. C. B., R. S. R., and P. M. P. contributed to the discussion; Q. C. and E. J. L. performed SSM and IFM experiments and helped revise drafts of the manuscripts; B. P. H, P. A. I, and H. H. P made the initial connection and analysis of the association of caveolae and mitochondria.	Albert DA, 2011, ARTHRIT CARE RES, V63, P1497, DOI 10.1002/acr.20592; Ali SS, 2010, J BIOL CHEM, V285, P32522, DOI 10.1074/jbc.M110.155432; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Asterholm IW, 2012, CELL METAB, V15, P171, DOI 10.1016/j.cmet.2012.01.004; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Bish LT, 2008, HUM GENE THER, V19, P1359, DOI 10.1089/hum.2008.123; Bosch M, 2011, CURR BIOL, V21, P681, DOI 10.1016/j.cub.2011.03.030; BRENNER S, 1974, GENETICS, V77, P71; Chen Q, 2006, J PHARMACOL EXP THER, V319, P1405, DOI 10.1124/jpet.106.110262; Corti O, 2011, PHYSIOL REV, V91, P1161, DOI 10.1152/physrev.00022.2010; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Engin AB, 2012, EXP TOXICOL PATHOL, V64, P481, DOI 10.1016/j.etp.2010.11.002; FAWCETT DW, 1969, J CELL BIOL, V42, P1, DOI 10.1083/jcb.42.1.1; Fryer RM, 2000, AM J PHYSIOL-HEART C, V278, pH305, DOI 10.1152/ajpheart.2000.278.1.H305; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; Gabbita SP, 1998, BBA-BIOMEMBRANES, V1372, P163, DOI 10.1016/S0005-2736(98)00040-6; GABELLA G, 1978, CELL TISSUE RES, V190, P255; GABELLA G, 1978, J ULTRA MOL STRUCT R, V65, P135, DOI 10.1016/S0022-5320(78)90051-5; Garlid KD, 2009, J MOL CELL CARDIOL, V46, P858, DOI 10.1016/j.yjmcc.2008.11.019; Ge ZD, 2010, ANESTHESIOLOGY, V112, P73, DOI 10.1097/ALN.0b013e3181c4a607; Gherghiceanu M, 2007, J CELL MOL MED, V11, P1416, DOI 10.1111/j.1582-4934.2007.00166.x; Hagiwara Y, 2000, HUM MOL GENET, V9, P3047, DOI 10.1093/hmg/9.20.3047; Head BP, 2007, TRENDS CELL BIOL, V17, P51, DOI 10.1016/j.tcb.2006.11.008; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Horikawa YT, 2008, J MOL CELL CARDIOL, V44, P123, DOI 10.1016/j.yjmcc.2007.10.003; Horikawa YT, 2011, J AM COLL CARDIOL, V57, P2273, DOI 10.1016/j.jacc.2010.12.032; Hutchinson TE, 2009, CELL PHYSIOL BIOCHEM, V24, P471, DOI 10.1159/000257487; Insel PA, 2009, CURR OPIN NEPHROL HY, V18, P50, DOI 10.1097/MNH.0b013e3283186f82; Jasmin JF, 2004, CARDIOVASC RES, V63, P747, DOI 10.1016/j.cardiores.2004.05.018; JENNINGS RB, 1976, CIRC RES, V38, P80; Kamp DW, 2011, ONCOLOGY-NY, V25, P400; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kirkham M, 2008, J CELL SCI, V121, P2075, DOI 10.1242/jcs.024588; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; MCNUTT NS, 1969, J CELL BIOL, V42, P46, DOI 10.1083/jcb.42.1.46; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; PALADE GE, 1955, J BIOPHYS BIOCHEM CY, V1, P59, DOI 10.1083/jcb.1.1.59; PALADE GE, 1953, J APPL PHYS, V24, P1424; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Park DS, 2002, AM J PATHOL, V160, P2207, DOI 10.1016/S0002-9440(10)61168-6; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patel HH, 2007, FASEB J, V21, P1565, DOI 10.1096/fj.06-7719com; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x; Quinlan CL, 2008, AM J PHYSIOL-HEART C, V295, pH953, DOI 10.1152/ajpheart.00520.2008; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Roy UKB, 2008, MOL CARCINOGEN, V47, P947, DOI 10.1002/mc.20451; STONE D, 1989, J MOL CELL CARDIOL, V21, P963, DOI 10.1016/0022-2828(89)90795-5; Sun JH, 2012, ANTIOXID REDOX SIGN, V16, P45, DOI 10.1089/ars.2010.3844; Tsutsumi YM, 2008, CIRCULATION, V118, P1979, DOI 10.1161/CIRCULATIONAHA.108.788331; Tsutsumi YM, 2010, ANESTHESIOLOGY, V112, P1136, DOI 10.1097/ALN.0b013e3181d3d624; Tsutsumi YM, 2006, ANESTHESIOLOGY, V104, P495, DOI 10.1097/00000542-200603000-00017; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Witte ME, 2010, MITOCHONDRION, V10, P411, DOI 10.1016/j.mito.2010.05.014; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	59	75	79	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4637	4649		10.1096/fj.12-215798	http://dx.doi.org/10.1096/fj.12-215798			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859372	Green Published			2022-12-28	WOS:000310574200025
J	Hashimoto, Y; Muramatsu, K; Kunii, M; Yoshimura, S; Yamada, M; Sato, T; Ishida, Y; Harada, R; Harada, A				Hashimoto, Yukiko; Muramatsu, Kazuhiro; Kunii, Masataka; Yoshimura, Shin-ichiro; Yamada, Minami; Sato, Takashi; Ishida, Yasumasa; Harada, Reiko; Harada, Akihiro			Uncovering genes required for neuronal morphology by morphology-based gene trap screening with a revertible retrovirus vector	FASEB JOURNAL			English	Article						PC12; synaptic vesicles	PROTEIN; CELLS; LOCALIZATION; MUTAGENESIS; DISRUPTION; POLARITY	The molecular mechanisms of neuronal morphology and synaptic vesicle transport have been largely elusive, and only a few of the molecules involved in these processes have been identified. Here, we developed a novel morphology-based gene trap method, which is theoretically applicable to all cell lines, to easily and rapidly identify the responsible genes. Using this method, we selected several gene-trapped clones of rat pheochromocytoma PC12 cells, which displayed abnormal morphology and distribution of synaptic vesicle-like microvesicles (SLMVs). We identified several genes responsible for the phenotypes and analyzed three genes in more detail. The first gene was BTB/POZ domain-containing protein 9 (Btbd9), which is associated with restless legs syndrome. The second gene was cytokine receptor-like factor 3 (Crlf3), whose involvement in the nervous system remains unknown. The third gene was single-stranded DNA-binding protein 3 (Ssbp3), a gene known to regulate head morphogenesis. These results suggest that Btbd9, Crlf3, and Ssbp3 regulate neuronal morphology and the biogenesis/transport of synaptic vesicles. Because our novel morphology-based gene trap method is generally applicable, this method is promising for uncovering novel genes involved in the function of interest in any cell lines.-Hashimoto, Y., Muramatsu, K., Kunii, M., Yoshimura, S., Yamada, M., Sato, T., Ishida, Y., Harada, R., Harada, A. Uncovering genes required for neuronal morphology by morphology-based gene trap screening with a revertible retrovirus vector. FASEB J. 26, 4662-4674 (2012). www.fasebj.org	[Kunii, Masataka; Yoshimura, Shin-ichiro; Harada, Reiko; Harada, Akihiro] Osaka Univ, Grad Sch Med, Dept Cell Biol, Osaka 5650871, Japan; [Hashimoto, Yukiko; Muramatsu, Kazuhiro; Yamada, Minami; Sato, Takashi; Harada, Akihiro] Gunma Univ, Grad Sch Med, Inst Mol & Cellular Regulat, Gunma, Japan; [Hashimoto, Yukiko] Gunma Univ, Grad Sch Med, Dept Neurol, Gunma, Japan; [Muramatsu, Kazuhiro] Gunma Univ, Grad Sch Med, Dept Pediat, Gunma, Japan; [Ishida, Yasumasa] Nara Inst Sci & Technol, Div Gene Funct Anim, Grad Sch Biol Sci, Nara, Japan; [Harada, Reiko] Takarazuka Univ Med & Hlth Care, Dept Judo Therapy, Takarazuka, Hyogo, Japan	Osaka University; Gunma University; Gunma University; Gunma University; Nara Institute of Science & Technology	Harada, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol, Osaka 5650871, Japan.	aharada@acb.med.osaka-u.ac.jp	Muramatsu, Kazuhiro/AAA-6350-2021	Muramatsu, Kazuhiro/0000-0001-9256-5591	Ministry of Education, Culture, Sports, Science, and Technology, Japan [21390050, 21590210]; Kato Memorial Bioscience Foundation; Mishima Kaiun Memorial Foundation	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kato Memorial Bioscience Foundation; Mishima Kaiun Memorial Foundation(Mishima Kaiun Memorial Foundation)	The authors thank M. Takano, A. Goto, H. Togawa, and A. Watanabe for assistance with cell culture and immunostaining. The funding for the open access charge was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan [Grant-in-Aid for Scientific Research (B) 21390050 to A.H.; Grant-in-Aid for Scientific Research (C) 21590210 to R.H.]; grants from Kato Memorial Bioscience Foundation to T. S.; and grants from the Mishima Kaiun Memorial Foundation to R.H.	ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Araki K, 1999, CELL MOL BIOL, V45, P737; Barnes AP, 2009, ANNU REV NEUROSCI, V32, P347, DOI 10.1146/annurev.neuro.31.060407.125536; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Fei H, 2008, TRAFFIC, V9, P1425, DOI 10.1111/j.1600-0854.2008.00771.x; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Horn C, 2007, NAT GENET, V39, P933, DOI 10.1038/ng0807-933; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Judge DP, 2004, J CLIN INVEST, V114, P172, DOI 10.1172/JCI200420641; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; Nishioka N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/dev.01844; Rasband MN, 2010, NAT REV NEUROSCI, V11, P552, DOI 10.1038/nrn2852; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Sato T, 2007, NATURE, V448, P366, DOI 10.1038/nature05929; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Stefansson H, 2007, NEW ENGL J MED, V357, P639, DOI 10.1056/NEJMoa072743; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099; Yamamura K, 2008, CANCER SCI, V99, P1, DOI 10.1111/j.1349-7006.2007.00611.x; Yusa K, 2004, NATURE, V429, P896, DOI 10.1038/nature02646	29	12	12	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4662	4674		10.1096/fj.12-207530	http://dx.doi.org/10.1096/fj.12-207530			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22874834	Green Published, hybrid			2022-12-28	WOS:000310574200027
J	Yang, CZ; Matro, JC; Huntoon, KM; Ye, DY; Huynh, TT; Fliedner, SMJ; Breza, J; Zhuang, ZP; Pacak, K				Yang, Chunzhang; Matro, Joey C.; Huntoon, Kristin M.; Ye, Donald Y.; Huynh, Thanh T.; Fliedner, Stephanie M. J.; Breza, Jan; Zhuang, Zhengping; Pacak, Karel			Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function	FASEB JOURNAL			English	Article						pheochromocytoma; paraganglioma; succinate dehydrogenase subunit B; histone deacetylase inhibitor	SUCCINATE-DEHYDROGENASE; QUALITY-CONTROL; GERMLINE SDHB; IN-VIVO; PHEOCHROMOCYTOMA; PARAGANGLIOMA; SUBUNIT; HYPOXIA; CHAPERONES; INSERTION	Mutations of succinate dehydrogenase subunit B (SDHB) play a crucial role in the pathogenesis of the most aggressive and metastatic pheochromocytomas (PHEOs) and paragangliomas (PGLs). Although a variety of missense mutations in the coding sequence of the SDHB gene have been found in PHEOs and PGLs, it has been unclear whether these mutations impair mRNA expression, protein stability, subcellular localization, or intrinsic protein function. RT-PCR and Western blot analysis of SDHB mRNA and protein expression from SDHB-related PHEOs and PGLs demonstrated intact mRNA expression but significantly reduced protein expression compared to non-SDHB PHEOs and PGLs. A pulse-chase assay of common SDHB missense mutations in transfected HeLa cell lines demonstrated that the loss of SDHB function was due to a reduction in mutant protein half-life, whereas colocalization of SDHB with mitochondria and immunoprecipitation with SDHA demonstrated intact subcellular localization and complex formation. The half-life of the SDHB protein increased after treatment with histone deacetylase inhibitors (HDACis), implicating the protein quality control machinery in the degradation of mutant SDHB protein. These findings provide the first direct mechanism of functional loss resulting from SDHBmutations and suggest that reducing protein degradation with HDACis may serve as a novel therapeutic paradigm for preventing the development of SDHB-related tumors.-Yang, C., Matro, J. C., Huntoon, K. M., Ye, D. Y., Huynh, T. T., Fliedner, S. M. J., Breza, J., Zhuang, Z., Pacak, K. Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J. 26, 4506-4516 (2012). www.fasebj.org	[Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, CRC, Bethesda, MD 20892 USA; [Zhuang, Zhengping] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; [Breza, Jan] Comenius Univ, Sch Med, Dept Urol, Bratislava, Slovakia	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Comenius University Bratislava	Pacak, K (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, CRC, Bldg 10,Rm 1E-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov; karel@mail.nih.gov	Fliedner, Stephanie MJ/D-3406-2012	Yang, Chunzhang/0000-0001-6433-0867; Fliedner, Stephanie/0000-0001-5515-8196; Huntoon, Kristin/0000-0002-7211-8986	Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke at the U. S. National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003053, ZIANS003052] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Neurological Disorders and Stroke at the U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke at the U. S. National Institutes of Health.	Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2011, ENDOCR-RELAT CANCER, V18, P73, DOI 10.1677/ERC-10-0113; Baysal BE, 2003, TRENDS ENDOCRIN MET, V14, P453, DOI 10.1016/j.tem.2003.08.004; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; CHEN F, 1995, CANCER RES, V55, P4804; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Delellis RA, 2004, TUMORS ENDOCRINE ORG; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P423, DOI 10.1677/erc.1.00829; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Favier J, 2010, BEST PRACT RES CL EN, V24, P957, DOI 10.1016/j.beem.2010.10.004; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Fliedner SMJ, 2010, CELL TISSUE RES, V340, P607, DOI 10.1007/s00441-010-0965-9; Furuta M, 2004, ONCOGENE, V23, P6806, DOI 10.1038/sj.onc.1207770; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gill AJ, 2011, NEW ENGL J MED, V364, P885, DOI 10.1056/NEJMc1012357; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Henderson A, 2009, FAM CANCER, V8, P257, DOI 10.1007/s10689-009-9234-z; Hensen EF, 2011, FAM CANCER, V10, P355, DOI 10.1007/s10689-010-9402-1; Huang H, 2008, CANCER-AM CANCER SOC, V113, P2020, DOI 10.1002/cncr.23812; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Lu J, 2010, P NATL ACAD SCI USA, V107, P21665, DOI 10.1073/pnas.1014376107; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Pawlu C, 2005, FAM CANCER, V4, P49, DOI 10.1007/s10689-004-4227-4; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Ricketts CJ, 2010, HUM MUTAT, V31, P41, DOI 10.1002/humu.21136; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Tormos KV, 2010, J CELL MOL MED, V14, P795, DOI 10.1111/j.1582-4934.2010.01031.x; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Van Nederveen FH, 2006, ANN NY ACAD SCI, V1073, P177, DOI 10.1196/annals.1353.018; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Yang CZ, 2011, P NATL ACAD SCI USA, V108, P4980, DOI 10.1073/pnas.1102198108; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; ZHUANG Z, 1988, FEBS LETT, V238, P185, DOI 10.1016/0014-5793(88)80253-9; Zhuang Z., 2001, J NEUROSURG, V115, P789; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	58	39	40	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4506	4516		10.1096/fj.12-210146	http://dx.doi.org/10.1096/fj.12-210146			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835832	Green Published			2022-12-28	WOS:000310574200013
J	Barton, ER; Park, S; James, JK; Makarewich, CA; Philippou, A; Eletto, D; Lei, HQ; Brisson, B; Ostrovsky, O; Li, ZH; Argon, Y				Barton, Elisabeth R.; Park, SooHyun; James, Jose K.; Makarewich, Catherine A.; Philippou, Anastassios; Eletto, Davide; Lei, Hanqin; Brisson, Becky; Ostrovsky, Olga; Li, Zihai; Argon, Yair			Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production	FASEB JOURNAL			English	Article						chaperones; endocrine growth control; glucose homeostasis; glucose regulated protein 94; IGFs	FACTOR-BINDING PROTEIN-1; TOLL-LIKE RECEPTORS; (IGF)-I E-PEPTIDES; FACTOR-I; SKELETAL-MUSCLE; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; CHAPERONE ACTIVITY; GENE-EXPRESSION; TRANSGENIC MICE	Insulin-like growth factors (IGFs) are critical for development and growth of skeletal muscles, but because several tissues produce IGFs, it is not clear which source is necessary or sufficient for muscle growth. Because it is critical for production of both IGF-I and IGF-II, we ablated glucose-regulated protein 94 (GRP94) in murine striated muscle to test the necessity of local IGFs for normal muscle growth. These mice exhibited smaller skeletal muscles with diminished IGF contents but with normal contractile function and no apparent endoplasmic reticulum stress response. This result shows that muscles rely on GRP94 primarily to support local production of IGFs, a pool that is necessary for normal muscle growth. In addition, body weights were similar to 30% smaller than those of litter-mate controls, and circulating IGF-I also decreased significantly, yet glucose homeostasis was maintained with little disruption to the growth hormone pathway. The growth defect was complemented on administration of recombinant IGF-I. Thus, unlike liver production of IGF-I, muscle IGF-I is necessary not only locally but also globally for whole-body growth.-Barton, E. R., Park, S., James, J. K., Makarewich, C. A., Philippou, A., Eletto, D., Lei, H., Brisson, B., Ostrovsky, O., Li, Z., Argon, Y. Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production. FASEB J. 26, 3691-3702 (2012). www.fasebj.org	[Barton, Elisabeth R.; Park, SooHyun; Philippou, Anastassios; Lei, Hanqin; Brisson, Becky] Univ Penn, Dept Anat & Cell Biol, Sch Dent Med, Philadelphia, PA 19104 USA; [James, Jose K.; Makarewich, Catherine A.; Eletto, Davide; Ostrovsky, Olga; Argon, Yair] Univ Penn, Div Cellular Pathol, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Barton, Elisabeth R.; Philippou, Anastassios; Brisson, Becky; Argon, Yair] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; [Li, Zihai] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Medical University of South Carolina	Argon, Y (corresponding author), 816B ARC,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	yargon@mail.med.upenn.edu	Philippou, Anastassios/H-2748-2019; Ostrovsky, Olga/AAZ-9351-2021	Philippou, Anastassios/0000-0003-0047-3003; park, soohyun/0000-0001-9847-9985	U.S. National Institutes of Health [AG18001, GM04788, AR057363, AR052646, AI070603, AI077283]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077283, R01AI070603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646, R01AR057363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008339, R01GM077480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018001] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to the technical expertise provided by Jalpa Modi in mouse husbandry, Magdalena Sikora and Zuozhen Tian in muscle functional measurements and glucose clearance tests, and Monjir Bakshi in muscle primary cultures. The authors also thank Dr. Yina Dong for help with the quantitation of GRP94 deletion, and Dr. Beth McNally (University of Chicago, Chicago, IL, USA) for the gift of antibodies. IPLEX was provided by David Green (Insmed Inc., Monmouth Junction, NJ, USA). This work was supported by U.S. National Institutes of Health grants AG18001 and GM04788 (Y.A.), AR057363 and AR052646 (E. R. B), and AI070603 and AI077283 (Z.L.). O.O. was a fellow of the Arthritis Foundation. The authors declare no conflicts of interest. Author contributions: Y.A., E. R. B., S. P., and Z.L. conceived or designed the experiments and wrote the manuscript; S. P., J.K.J., C. A. M., A. P., D. E., H. L., B. B., and O.O. performed the experiments; E. R. B., S. P., J.K.J., and Y.A. analyzed the data.	Adams GR, 1998, J APPL PHYSIOL, V84, P1716, DOI 10.1152/jappl.1998.84.5.1716; Barton ER, 2010, J APPL PHYSIOL, V108, P1069, DOI 10.1152/japplphysiol.01308.2009; Barton ER, 2006, J APPL PHYSIOL, V100, P1778, DOI 10.1152/japplphysiol.01405.2005; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Biswas C, 2007, BIOCHEM J, V405, P233, DOI 10.1042/BJ20061867; BORGES JLC, 1984, J CLIN ENDOCR METAB, V59, P1; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; CALA SE, 1994, J BIOL CHEM, V269, P5926; Chin ER, 2003, J PHYSIOL-LONDON, V547, P649, DOI 10.1113/jphysiol.2002.024760; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Datta K, 2009, J BIOL CHEM, V284, P29666, DOI 10.1074/jbc.M109.034041; Eletto D, 2010, SEMIN CELL DEV BIOL, V21, P479, DOI 10.1016/j.semcdb.2010.03.004; Elis S, 2011, AGING CELL, V10, P547, DOI 10.1111/j.1474-9726.2011.00683.x; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Govoni KE, 2007, PHYSIOL GENOMICS, V30, P354, DOI 10.1152/physiolgenomics.00022.2007; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Marchand A, 2006, J BIOL CHEM, V281, P19124, DOI 10.1074/jbc.M602157200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Murphy RM, 2009, J PHYSIOL-LONDON, V587, P443, DOI 10.1113/jphysiol.2008.163162; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nishimura M, 2005, BIOL PHARM BULL, V28, P886, DOI 10.1248/bpb.28.886; Novosyadlyy R, 2008, CELL DEATH DIFFER, V15, P1304, DOI 10.1038/cdd.2008.52; Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009-0010; Ostrovsky O, 2010, BBA-MOL CELL RES, V1803, P333, DOI 10.1016/j.bbamcr.2009.11.005; Ostrovsky O, 2009, P NATL ACAD SCI USA, V106, P11600, DOI 10.1073/pnas.0902626106; Ostrovsky O, 2009, MOL BIOL CELL, V20, P1855, DOI 10.1091/mbc.E08-04-0346; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; Pfeffer LA, 2009, MOL BIOL CELL, V20, P3810, DOI 10.1091/mbc.E08-12-1202; POWELL DR, 1991, J BIOL CHEM, V266, P18868; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Rosenfeld RG, 1996, HORM RES, V46, P170, DOI 10.1159/000185018; Rotwein P, 2010, PEDIATR NEPHROL, V25, P651, DOI 10.1007/s00467-009-1258-y; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395, DOI 10.1152/ajpcell.1999.276.2.C395; Shefer Gabi, 2005, Methods Mol Biol, V290, P281; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; TURNER JD, 1988, AM J PHYSIOL, V255, pE513, DOI 10.1152/ajpendo.1988.255.4.E513; VAN PN, 1989, J BIOL CHEM, V264, P17494; Vitadello M, 1998, BIOCHEM J, V332, P351, DOI 10.1042/bj3320351; Vitadello M, 2003, FASEB J, V17, P923, DOI 10.1096/fj.02-0644fje; Wallenius K, 2001, ENDOCRINOLOGY, V142, P4762, DOI 10.1210/en.142.11.4762; Wanderling S, 2007, MOL BIOL CELL, V18, P3764, DOI 10.1091/mbc.E07-03-0275; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110; Yang CQ, 1996, ENDOCRINOLOGY, V137, P2766, DOI 10.1210/en.137.7.2766; Yang Y, 2005, MOL CELLS, V20, P173; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005	54	54	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3691	3702		10.1096/fj.11-203026	http://dx.doi.org/10.1096/fj.11-203026			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22649033	Green Published			2022-12-28	WOS:000308391600011
J	Kurusu, S; Sapirstein, A; Bonventre, JV				Kurusu, Shiro; Sapirstein, Adam; Bonventre, Joseph V.			Group IVA phospholipase A(2) optimizes ovulation and fertilization in rodents through induction of and metabolic coupling with prostaglandin endoperoxide synthase 2	FASEB JOURNAL			English	Article						PLA(2) isoforms; prostaglandin E-2; preovulatory follicle; female reproduction	HUMAN CHORIONIC-GONADOTROPIN; CYCLOOXYGENASE-2 EXPRESSION; ARACHIDONIC-ACID; GRANULOSA-CELLS; EICOSANOID GENERATION; FEEDBACK-CONTROL; GENE DISRUPTION; MICE LACKING; H SYNTHASE; E-2	Female mice lacking group IVA phospholipase A(2) (Pla2g4a(-/-)) have a smaller litter size, which is due, in part, to defective implantation. We examined PLA(2)G4A dependence of the processes of ovulation and fertilization. Following induction of ovulation by equine chorionic gonadotropin (eCG)/human CG (hCG) treatment and mating, ovulation and fertilization rates were reduced significantly in Pla2g4a(-/-) mice as compared to wild-type littermates. Human CG triggered robust ovarian prostaglandin (PG) E-2 production in the preovulatory period that was significantly attenuated in Pla2g4a(-/-) mice. Human CG transiently enhanced ovarian expression of PLA(2)G4A and prostaglandin endoperoxide synthase 2 (PTGS2) in wild-type mice. This PTGS2 induction was decreased in Pla2g4a(-/-) mice and also in immature rats treated with the PLA(2)G4A inhibitor, archidonyl trifluoromethyl ketone. A close spatiotemporal association of PLA(2)G4A with PTGS2 was found in mouse and rat preovulatory follicles examined by immunohistochemistry. Less association was observed with 4 other forms of PLA(2). Our data strongly suggest that PLA(2)G4A amplifies hCG induction of PTGS2 and colocalizes with the induced PTGS2, thus contributing to robust PG production required for optimal ovulation and fertilization in rodents.-Kurusu, S., Sapirstein, A., Bonventre, J. V. Group IVA phospholipase A(2) optimizes ovulation and fertilization in rodents through induction of and metabolic coupling with prostaglandin endoperoxide synthase 2. FASEB J. 26, 3800-3810 (2012). www.fasebj.org	[Kurusu, Shiro; Bonventre, Joseph V.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Sapirstein, Adam] Harvard Univ, Sch Med, Dept Anesthesia & Crit Care, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Bonventre, Joseph V.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [Kurusu, Shiro] Kitasato Univ, Sch Vet Med, Vet Physiol Lab, Towada, Aomori 034, Japan; [Sapirstein, Adam] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Bonventre, Joseph V.] Harvard Stem Cell Inst, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Kitasato University; Johns Hopkins University; Harvard University	Bonventre, JV (corresponding author), Harvard Inst Med, Div Renal, 4 Blackfan Cir,Rm 576, Boston, MA 02115 USA.	joseph_bonventre@hms.harvard.edu			U.S. National Institute of Health [DK39773, DK38452]; Japanese Society for the Promotion of Science; Kieikai Research Foundation; Nakayama Foundation for Human Science; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R01DK039773, R37DK039773] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kieikai Research Foundation(Kieikai Research Foundation); Nakayama Foundation for Human Science; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors greatly thank E. O'Leary and X.-M. Sun and other members of the J.V.B. laboratory for technical assistance and useful suggestions; H. Satoh and M. Jinno for experimental help; Dr. M. Kawaminami (Kitasato University, Towada, Japan) for supplying experimental materials; Drs. A. Cybulsky (McGill University, Montreal, QC, Canada), K. Nomura (Shionogi Research Laboratories, Osaka, Japan), and I. Kudo (Showa University, Tokyo, Japan) and Wyeth Co. (Cambridge, MA, USA) for antibodies; and M. Nakata for assistance with manuscript preparation. The work with mice was supported by U.S. National Institute of Health grants DK39773 and DK38452 (to J.V.B.) and that with rats was by grants-in-aid for scientific research from the Japanese Society for the Promotion of Science and the Kieikai Research Foundation (to S. K.). S. K. received a fellowship for studies abroad from the Nakayama Foundation for Human Science. The authors declare no conflicts of interest.	Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brown N, 2009, BIOL REPROD, V81, P1131, DOI 10.1095/biolreprod.109.079061; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Diouf MN, 2006, BIOL REPROD, V74, P1096, DOI 10.1095/biolreprod.105.048579; Duffy DM, 2005, J CLIN ENDOCR METAB, V90, P5858, DOI 10.1210/jc.2005-0980; Espey LL, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P425; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Funk CD, 2009, REPROD ENDOCRINOLOGY, P121; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; Halliwell R. J. A., 2004, PROSTAGLANDIN LEUKOT, V70, P140; Henderson WR, 2007, J EXP MED, V204, P865, DOI 10.1084/jem.20070029; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Inoue H, 2000, J BIOL CHEM, V275, P28028; Ishiguro Y, 1999, CARCINOGENESIS, V20, P1063, DOI 10.1093/carcin/20.6.1063; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kishimoto K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-42; Kita Y, 2006, BBA-MOL CELL BIOL L, V1761, P1317, DOI 10.1016/j.bbalip.2006.08.001; Kol S, 1997, ENDOCRINOLOGY, V138, P322, DOI 10.1210/en.138.1.322; Kurusu S, 1998, PROSTAG LEUKOTR ESS, V58, P405, DOI 10.1016/S0952-3278(98)90161-2; Kurusu S, 2001, ENDOCRINE, V14, P337, DOI 10.1385/ENDO:14:3:337; Kurusu S, 2007, PROSTAG OTH LIPID M, V83, P139, DOI 10.1016/j.prostaglandins.2006.10.008; Kurusu S, 2011, BIOCHEM J, V439, P403, DOI 10.1042/BJ20102167; Kurusu S, 2009, REPRODUCTION, V137, P59, DOI 10.1530/REP-08-0257; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lappas M, 2004, PROSTAG LEUKOTR ESS, V70, P87, DOI 10.1016/j.plefa.2003.04.001; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Mendonca LLF, 2000, RHEUMATOLOGY, V39, P880, DOI 10.1093/rheumatology/39.8.880; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murakami M, 2011, PROG LIPID RES, V50, P152, DOI 10.1016/j.plipres.2010.12.001; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NOMURA K, 1994, ENDOCRINOLOGY, V135, P603, DOI 10.1210/en.135.2.603; OCHIAI K, 1983, ENDOCRINOLOGY, V112, P1687, DOI 10.1210/endo-112-5-1687; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Sapirstein A, 2005, AM J PHYSIOL-REG I, V288, pR1774, DOI 10.1152/ajpregu.00815.2004; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Sato H, 2010, J CLIN INVEST, V120, P1400, DOI 10.1172/JCI40493; Sheldrick ELR, 2007, BIOCHEM J, V406, P175, DOI 10.1042/BJ20070089; SHERWOOD OD, 1985, ENDOCRINOLOGY, V116, P2554, DOI 10.1210/endo-116-6-2554; Sirois J, 2004, HUM REPROD UPDATE, V10, P373, DOI 10.1093/humupd/dmh032; SIROIS J, 1992, J BIOL CHEM, V267, P11586; Song H, 2002, DEVELOPMENT, V129, P2879; Stavreus-Evers A, 2005, FERTIL STERIL, V83, P156, DOI 10.1016/j.fertnstert.2004.06.057; Takahashi T, 2006, J BIOL CHEM, V281, P37117, DOI 10.1074/jbc.M608202200; Tilley SL, 1999, J CLIN INVEST, V103, P1539, DOI 10.1172/JCI6579; Tokuyama Osamu, 2003, Osaka City Medical Journal, V49, P39; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269	57	14	14	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3800	3810		10.1096/fj.12-203968	http://dx.doi.org/10.1096/fj.12-203968			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22673578	Green Published			2022-12-28	WOS:000308391600020
J	Tian, XY; Tian, YF; Sarich, N; Wu, TH; Birukova, AA				Tian, Xinyong; Tian, Yufeng; Sarich, Nicolene; Wu, Tinghuai; Birukova, Anna A.			Novel role of stathmin in microtubule-dependent control of endothelial permeability	FASEB JOURNAL			English	Article						dynamics; cytoskeleton; lung; Rho GTPase; GEF-H1	BARRIER ENHANCEMENT; PROTEIN-KINASE; RHO-KINASE; IN-VITRO; GEF-H1; DYNAMICS; MYOSIN; PHOSPHORYLATION; PHOSPHATASE	Microtubule (MT) dynamics in vascular endothelium are modulated by vasoactive mediators and are critically involved in the control of endothelial cell (EC) permeability via Rho GTPase-dependent crosstalk with the actin cytoskeleton. However, the role of regulators in MT stability in these mechanisms remains unclear. This study investigated the involvement of the MT-associated protein stathmin in the mediation of agonist-induced permeability in EC cultures and vascular leak in vivo. Thrombin treatment of human pulmonary ECs induced rapid dephosphorylation and activation of stathmin. Inhibition of stathmin activity by small interfering RNA-based knockdown or cAMP-mediated phosphorylation abrogated thrombin-induced F-actin remodeling and Rho-dependent EC hyperpermeability, while expression of a phosphorylation-deficient stathmin mutant exacerbated thrombin-induced EC barrier disruption. Stathmin suppression preserved the MT network against thrombin-induced MT disassembly and release of Rho-specific guanine nucleotide exchange factor, GEF-H1. The protective effects of stathmin knockdown were observed in vivo in the mouse 2-hit model of ventilator-induced lung injury and were linked to MT stabilization and down-regulation of Rho signaling in the lung. These results demonstrate the mechanism of stathmin-dependent control of MT dynamics, Rho signaling, and permeability and suggest novel potential pharmacological interventions in the prevention of increased vascular leak via modulation of stathmin activity.-Tian, X., Tian, Y., Sarich, N., Wu, T., Birukova, A. A. Novel role of stathmin in microtubule-dependent control of endothelial permeability. FASEB J. 26, 3862-3874 (2012). www.fasebj.org	[Birukova, Anna A.] Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med,Off N 611, Chicago, IL 60637 USA	University of Chicago	Birukova, AA (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med,Off N 611, 5841 S Maryland Ave, Chicago, IL 60637 USA.	abirukov@medicine.bsd.uchicago.edu			U.S. National Heart, Lung, and Blood Institute [HL-089257, HL-107920]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089257, R01HL107920] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Katherine Higginbotham for invaluable assistance with editing and proofreading the manuscript. This work was aupported by U.S. National Heart, Lung, and Blood Institute grants HL-089257 and HL-107920	Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005; Birukova AA, 2005, J CELL PHYSIOL, V204, P934, DOI 10.1002/jcp.20359; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009; Birukova AA, 2010, TRANSL RES, V155, P44, DOI 10.1016/j.trsl.2009.09.002; Birukova AA, 2010, MICROVASC RES, V79, P128, DOI 10.1016/j.mvr.2009.11.007; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chen PW, 2010, J BIOL CHEM, V285, P10053, DOI 10.1074/jbc.M109.044420; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Giampietro C, 2005, ENDOCRINOLOGY, V146, P1825, DOI 10.1210/en.2004-0972; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com; Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200; Komarova Y, 2009, J CELL BIOL, V184, P691, DOI 10.1083/jcb.200807179; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Manna T, 2009, J BIOL CHEM, V284, P15640, DOI 10.1074/jbc.M900343200; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; Singleton PA, 2009, CIRC RES, V104, P978, DOI 10.1161/CIRCRESAHA.108.193367; Thomas M, 2005, P NATL ACAD SCI USA, V102, P5679, DOI 10.1073/pnas.0502067102; Thomas M, 2005, PHARM RES-DORDR, V22, P373, DOI 10.1007/s11095-004-1874-y; Verin AD, 1998, AM J PHYSIOL-LUNG C, V275, pL788, DOI 10.1152/ajplung.1998.275.4.L788; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Xing JJ, 2010, MICROVASC RES, V79, P56, DOI 10.1016/j.mvr.2009.11.006	35	23	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3862	3874		10.1096/fj.12-207746	http://dx.doi.org/10.1096/fj.12-207746			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22700873	Green Published			2022-12-28	WOS:000308391600026
J	Gilbert, NC; Rui, Z; Neau, DB; Waight, MT; Bartlett, SG; Boeglin, WE; Brash, AR; Newcomer, ME				Gilbert, Nathaniel C.; Rui, Zhe; Neau, David B.; Waight, Maria T.; Bartlett, Sue G.; Boeglin, William E.; Brash, Alan R.; Newcomer, Marcia E.			Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663	FASEB JOURNAL			English	Article						leukotrienes; crystal structure; crystallography; eicosanoids	ARACHIDONIC-ACID; LEUKOTRIENE BIOSYNTHESIS; CRYSTAL-STRUCTURE; HUMAN PLATELETS; PROTEIN; ACTIVATION; MODEL; 8R-LIPOXYGENASE; LIPOXYGENASES; INFLAMMATION	The enzyme 5-lipoxygenase (5-LOX) initiates biosynthesis of the proinflammatory leukotriene lipid mediators and, together with 15-LOX, is also required for synthesis of the anti-inflammatory lipoxins. The catalytic activity of 5-LOX is regulated through multiple mechanisms, including Ca2+-targeted membrane binding and phosphorylation at specific serine residues. To investigate the consequences of phosphorylation at S663, we mutated the residue to the phosphorylation mimic Asp, providing a homogenous preparation suitable for catalytic and structural studies. The S663D enzyme exhibits robust 15-LOX activity, as determined by spectrophotometric and HPLC analyses, with only traces of 5-LOX activity remaining; synthesis of the anti-inflammatory lipoxin A(4) from arachidonic acid is also detected. The crystal structure of the S663D mutant in the absence and presence of arachidonic acid (in the context of the previously reported Stable-5-LOX) reveals substantial remodeling of helices that define the active site so that the once fully encapsulated catalytic machinery is solvent accessible. Our results suggest that phosphorylation of 5-LOX at S663 could not only down-regulate leukotriene synthesis but also stimulate lipoxin production in inflammatory cells that do not express 15-LOX, thus redirecting lipid mediator biosynthesis to the production of proresolving mediators of inflammation.-Gilbert, N. C., Rui, Z., Neau, D. B., Waight, M. T., Bartlett, S. G., Boeglin, W. E., Brash, A. R., Newcomer, M. E. Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663. FASEB J. 26, 3222-3229 (2012). www.fasebj.org	[Gilbert, Nathaniel C.; Rui, Zhe; Waight, Maria T.; Bartlett, Sue G.; Newcomer, Marcia E.] Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; [Neau, David B.] Argonne Natl Lab, NE Collaborat Access Team, Argonne, IL 60439 USA; [Boeglin, William E.; Brash, Alan R.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; [Boeglin, William E.; Brash, Alan R.] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN USA	Louisiana State University System; Louisiana State University; United States Department of Energy (DOE); Argonne National Laboratory; Vanderbilt University; Vanderbilt University	Newcomer, ME (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	newcomer@lsu.edu	Gilbert, Nathaniel/I-8223-2018; Rui, Zhe/D-9541-2013	Rui, Zhe/0000-0001-8113-2694; Gilbert, Nathaniel/0000-0002-6706-811X	American Heart Association [08553920E]; National Science Foundation [MCB 0818387]; U.S. National Institutes of Health (NIH) [HL 107887]; NIH [GM-15431]; Louisiana Governors' Biotechnology Initiative; National Center for Research Resources [5P41RR015301-10]; National Institute of General Medical Sciences from the NIH [8 P41 GM103403-10]; U.S. DOE [DE-AC02-06CH11357]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431, P41GM103403] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Science Foundation(National Science Foundation (NSF)); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Governors' Biotechnology Initiative; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences from the NIH; U.S. DOE(United States Department of Energy (DOE)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded in part by grants from the American Heart Association (08553920E), the National Science Foundation (MCB 0818387), and the U.S. National Institutes of Health (NIH; HL 107887) to M.E.N. and from the NIH (GM-15431) to A.R.B. Preliminary work was performed at the Center for Advanced Microstructures and Devices (Baton Rouge), funded in part by the Louisiana Governors' Biotechnology Initiative. The work includes research conducted at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines, which are supported by grants from the National Center for Research Resources (5P41RR015301-10) and the National Institute of General Medical Sciences (8 P41 GM103403-10) from the NIH. Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under contract DE-AC02-06CH11357. Coordinates and structure factors have been deposited in the Protein Data Bank (3V92, S663A-Stable-5-LOX; 3V98, S663D-Stable-5-LOX; 3V99, S663D-Stable-5-LOX with AA).	AHARONY D, 1986, J BIOL CHEM, V261, P1512; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Borngraber S, 1998, PROTEIN EXPRES PURIF, V14, P237, DOI 10.1006/prep.1998.0963; Boutaud O, 1999, J BIOL CHEM, V274, P33764, DOI 10.1074/jbc.274.47.33764; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Choi J, 2008, PROTEINS, V70, P1023, DOI 10.1002/prot.21590; Coffa G, 2005, BIOCHEM BIOPH RES CO, V338, P87, DOI 10.1016/j.bbrc.2005.07.185; DeLano W.L, PYMOL MOL GRAPHICS S; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EDENIUS C, 1991, ADV PROSTAG THROMB L, V21, P97; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans JF, 2008, TRENDS PHARMACOL SCI, V29, P72, DOI 10.1016/j.tips.2007.11.006; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; Flamand N, 2009, J BIOL CHEM, V284, P306, DOI 10.1074/jbc.M805593200; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Gilbert NC, 2011, SCIENCE, V331, P217, DOI 10.1126/science.1197203; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Lee YH, 1997, NAT STRUCT BIOL, V4, P615, DOI 10.1038/nsb0897-615; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; Luo M, 2005, J BIOL CHEM, V280, P40609, DOI 10.1074/jbc.M507045200; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Neau DB, 2009, BIOCHEMISTRY-US, V48, P7906, DOI 10.1021/bi900084m; Oldham ML, 2005, J BIOL CHEM, V280, P39545, DOI 10.1074/jbc.M506675200; Pergola C, 2008, P NATL ACAD SCI USA, V105, P19881, DOI 10.1073/pnas.0809120105; Radmark O, 2010, BIOCHEM BIOPH RES CO, V396, P105, DOI 10.1016/j.bbrc.2010.02.173; Radmark O, 2009, J LIPID RES, V50, pS40, DOI 10.1194/jlr.R800062-JLR200; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Vliegenthart J. F. G., 1982, FREE RADICAL BIO MED, P29; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2003, ADV EXP MED BIOL, V525, P129; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701; Yamada T, 2011, FASEB J, V25, P561, DOI 10.1096/fj.10-170027; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Youn B, 2006, PROTEINS, V65, P1008, DOI 10.1002/prot.21182; Zwart Peter H., 2008, V426, P419, DOI 10.1007/978-1-60327-058-8_28	43	96	99	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3222	3229		10.1096/fj.12-205286	http://dx.doi.org/10.1096/fj.12-205286			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22516296	Green Published, Green Submitted			2022-12-28	WOS:000307162800013
J	Haselkorn, R				Haselkorn, Robert			Maria Irene Baldi (1937-2012) from Light Chains to Xenopus	FASEB JOURNAL			English	Biographical-Item									Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Haselkorn, R (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA.	rh01@uchicago.edu							0	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2721	2722		10.1096/fj.12-0701ufm	http://dx.doi.org/10.1096/fj.12-0701ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22745223				2022-12-28	WOS:000305912500001
J	Smith, HK; Gavins, FNE				Smith, Helen K.; Gavins, Felicity N. E.			The potential of stem cell therapy for stroke: is PISCES the sign?	FASEB JOURNAL			English	Review						ischemic stroke; cell transplantation; cytokines; in vivo imaging	CEREBRAL-ARTERY OCCLUSION; MARROW STROMAL CELLS; PROMOTES FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; IN-VITRO; INTRACEREBRAL HEMORRHAGE; BRAIN-INJURY; NEUROTROPHIC FACTORS; CLINICAL-TRIALS; GROWTH-FACTORS	Substantial developments in the field of stem cell research point toward novel therapies for the treatment of diseases such as stroke. This review covers the establishment of tissue damage in stroke and the status of current therapies. We evaluate stem cell therapy with respect to other treatments, including clinical, preclinical, and failed, and provide a comprehensive account of stem cell clinical trials for stroke therapy currently underway. Finally, we describe mechanisms through which stem cells improve outcome in experimental stroke as well as potential pitfalls this basic research has identified.-Smith, H. K., and Gavins, F. N. E. The potential of stem cell therapy for stroke: is PISCES the sign? FASEB J. 26, 2239-2252 (2012). www.fasebj.org	[Gavins, Felicity N. E.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Wolfson Neurosci Labs, Dept Med, London W12 0NN, England	Imperial College London	Gavins, FNE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Wolfson Neurosci Labs, Dept Med, Hammersmith Hosp Campus,Burlington Danes Bldg,Du, London W12 0NN, England.	f.gavins@imperial.ac.uk	Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423	Biotechnology and Biological Sciences Research Council (BBSRC); BBSRC [BB/E52708X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	F.G. is funded by the Biotechnology and Biological Sciences Research Council (BBSRC). H. K. S. is funded by a BBSRC Integrative Mammalian Biology Fund studentship.	Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Albers GW, 2003, LANCET, V362, P1691; Ardehali MR, 2003, ACTA NEUROL SCAND, V107, P267, DOI 10.1034/j.1600-0404.2003.00010.x; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285; Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0; Butz M, 2009, FRONT COMPUT NEUROSC, V3, DOI 10.3389/neuro.10.010.2009; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen SJ, 2010, STEM CELLS DEV, V19, P1757, DOI 10.1089/scd.2009.0452; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Erlandsson A, 2011, EXP NEUROL, V230, P48, DOI 10.1016/j.expneurol.2010.05.018; Frangioni JV, 2004, CIRCULATION, V110, P3378, DOI 10.1161/01.CIR.0000149840.46523.FC; Gavins FNE, 2007, FASEB J, V21, P1751, DOI 10.1096/fj.06-7842com; Green AR, 2003, TRENDS PHARMACOL SCI, V24, P402, DOI 10.1016/S0165-6147(03)00192-5; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Hermann DM, 2008, STROKE, V39, pE182, DOI 10.1161/STROKEAHA.108.532374; Holloway PM, 2011, TRENDS PHARMACOL SCI, V32, P90, DOI 10.1016/j.tips.2010.11.010; Honmou O, 2011, BRAIN, V134, P1790, DOI 10.1093/brain/awr063; Ikegame Y, 2011, CYTOTHERAPY, V13, P675, DOI 10.3109/14653249.2010.549122; Jang KS, 2010, J KOREAN NEUROSURG S, V48, P391, DOI 10.3340/jkns.2010.48.5.391; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Jiang LX, 2008, CURR NEUROVASC RES, V5, P118, DOI 10.2174/156720208784310259; Jiang M, 2011, MOL CELL BIOCHEM, V354, P67, DOI 10.1007/s11010-011-0806-5; Jin G, 2008, NEUROL RES, V30, P731, DOI 10.1179/174313208X305418; Kalista T, 2011, CELL STEM CELL, V8, P360, DOI 10.1016/j.stem.2011.02.018; Kawai H, 2010, J CEREBR BLOOD F MET, V30, P1487, DOI 10.1038/jcbfm.2010.32; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kim JM, 2007, BRAIN RES, V1183, P43, DOI 10.1016/j.brainres.2007.09.005; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600-0463.2005.apm_3061.x; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Lanfranconi S, 2011, J CELL MOL MED, V15, P1645, DOI 10.1111/j.1582-4934.2009.00987.x; Lee HJ, 2007, STEM CELLS, V25, P1204, DOI 10.1634/stemcells.2006-0409; Li J, 2011, J CEREBR BLOOD F MET, V31, P413, DOI 10.1038/jcbfm.2010.181; Li XL, 2010, J NEUROCHEM, V113, P1012, DOI 10.1111/j.1471-4159.2010.06667.x; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Liu N, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-105; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Loffredo FS, 2011, CELL STEM CELL, V8, P389, DOI 10.1016/j.stem.2011.02.002; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Lundberg J., 2011, CELL TRANSPLANT; Lyden P, 2002, STROKE, V33, P122, DOI 10.1161/hs0102.101478; Mackie AR, 2011, TEX HEART I J, V38, P474; Manev H, 2001, EUR J PHARMACOL, V411, P67, DOI 10.1016/S0014-2999(00)00904-3; Martino G, 2011, BRAIN, V134, P1585, DOI 10.1093/brain/awr115; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Modo M, 2002, NEUROIMAGE, V17, P803, DOI 10.1006/nimg.2002.1194; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nan ZH, 2005, ANN NY ACAD SCI, V1049, P84, DOI 10.1196/annals.1334.009; NEIMAN P, 1974, ANNU REV MED, V25, P179, DOI 10.1146/annurev.me.25.020174.001143; Novak K, 2010, CELL, V140, P10, DOI 10.1016/j.cell.2009.12.039; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684; Palladino M, 2011, MOL THER, V19, P658, DOI 10.1038/mt.2010.292; Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043; Pastori C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002754; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA; Prockop DJ, 2007, CLIN PHARMACOL THER, V82, P241, DOI 10.1038/sj.clpt.6100313; Reichel CA, 2009, ARTERIOSCL THROM VAS, V29, P1787, DOI 10.1161/ATVBAHA.109.193268; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rodriguez-Lozano FJ, 2011, INT ENDOD J, V44, P800, DOI 10.1111/j.1365-2591.2011.01877.x; Sabe H, 2011, J BIOCHEM, V149, P633, DOI 10.1093/jb/mvr044; Saino O, 2010, J NEUROSCI RES, V88, P2385, DOI 10.1002/jnr.22410; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Shang JW, 2011, J NEUROSCI RES, V89, P86, DOI 10.1002/jnr.22524; Sharma S, 2010, J NEUROSCI RES, V88, P2869, DOI 10.1002/jnr.22452; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Shirakura M, 2004, GENE THER, V11, P784, DOI 10.1038/sj.gt.3302224; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Straface G, 2009, J CELL MOL MED, V13, P2424, DOI 10.1111/j.1582-4934.2008.00440.x; Sugiyama M, 2011, TISSUE ENG PT A, V17, P1303, DOI [10.1089/ten.tea.2010.0306, 10.1089/ten.TEA.2010.0306]; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tamaki S, 2002, J NEUROSCI RES, V69, P976, DOI 10.1002/jnr.10412; Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146; U.S. National Institutes of Health, 2009, SUMM FY 2010 PRES BU; U.S. National Institutes of Health, 2011, EST FUND VAR RES CON; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; UK Office for National Statistics, 2009, MORT STAT DEATHS REG; United Kingdom Stem Cell Initiative, 2005, REP REC; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; Wei L, 2005, NEUROBIOL DIS, V19, P183, DOI 10.1016/j.nbd.2004.12.016; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wu JC, 2003, CIRCULATION, V108, P1302, DOI 10.1161/01.CIR.0000091252.20010.6E; Yamashita T, 2009, CELL TRANSPLANT, V18, P999, DOI 10.3727/096368909X471233; Yang YC, 2011, CURR NEUROVASC RES, V8, P1, DOI 10.2174/156720211794520215; Zhang Hui, 2004, Chin J Traumatol, V7, P3; Zhang RL, 1996, J CEREBR BLOOD F MET, V16, P1126, DOI 10.1097/00004647-199611000-00006; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	112	33	33	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2012	26	6					2239	2252		10.1096/fj.11-195719	http://dx.doi.org/10.1096/fj.11-195719			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22426119				2022-12-28	WOS:000305017200004
J	Chorny, M; Fishbein, I; Tengood, JE; Adamo, RF; Alferiev, IS; Levy, RJ				Chorny, Michael; Fishbein, Ilia; Tengood, Jillian E.; Adamo, Richard F.; Alferiev, Ivan S.; Levy, Robert J.			Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors	FASEB JOURNAL			English	Article						physical targeting; in-stent restenosis; rat model	LOCAL-DELIVERY; VIRAL VECTORS; THERAPY; ENCAPSULATION; RESTENOSIS; SURFACES; CELLS; OXIDE	Gene therapeutic strategies have shown promise in treating vascular disease. However, their translation into clinical use requires pharmaceutical carriers enabling effective, site-specific delivery as well as providing sustained transgene expression in blood vessels. While replication-deficient adenovirus (Ad) offers several important advantages as a vector for vascular gene therapy, its clinical applicability is limited by rapid inactivation, suboptimal transduction efficiency in vascular cells, and serious systemic adverse effects. We hypothesized that novel zinc oleate-based magnetic nanoparticles (MNPs) loaded with Ad would enable effective arterial cell transduction by shifting vector processing to an alternative pathway, protect Ad from inactivation by neutralizing factors, and allow site-specific gene transfer to arteries treated with stent angioplasty using a 2-source magnetic guidance strategy. Ad-loaded MNPs effectively transduced cultured endothelial and smooth muscle cells under magnetic conditions compared to controls and retained capacity for gene transfer after exposure to neutralizing antibodies and lithium iodide, a lytic agent causing disruption of free Ad. Localized arterial gene expression significantly stronger than in control animal groups was demonstrated after magnetically guided MNP delivery in a rat stenting model 2 and 9 d post-treatment, confirming feasibility of using Ad-loaded MNPs to achieve site-specific transduction in stented blood vessels. In conclusion, Ad-loaded MNPs formed by controlled precipitation of zinc oleate represent a novel delivery system, well-suited for efficient, magnetically targeted vascular gene transfer.-Chorny, M., Fishbein, I., Tengood, J. E., Adamo, R. F., Alferiev, I. S., Levy, R. J. Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors.	[Chorny, Michael; Fishbein, Ilia; Tengood, Jillian E.; Adamo, Richard F.; Alferiev, Ivan S.; Levy, Robert J.] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Chorny, M (corresponding author), Childrens Hosp Philadelphia, Abramson Res Bldg,Ste 702,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	chorny@email.chop.edu	Chorny, Michael/O-1313-2017		American Heart Association; U.S. National Heart, Lung, and Blood Institute [HL 094816]; William J. Rashkind Endowment of The Children's Hospital of Philadelphia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007915, R21HL094816] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); William J. Rashkind Endowment of The Children's Hospital of Philadelphia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Gary Friedman (Drexel University, Philadelphia, PA, USA) for advising on the magnetic delivery strategy, and NuMED, Inc. (New York, NY, USA) for providing rat angioplasty catheters. This research was supported in part by American Heart Association Scientist Development grants (I.F. and M.C.), U.S. National Heart, Lung, and Blood Institute grant HL 094816 (R.J.L.), and The William J. Rashkind Endowment of The Children's Hospital of Philadelphia.	Alfonso F, 2010, J AM COLL CARDIOL, V55, P2717, DOI 10.1016/j.jacc.2010.03.026; Aminian A, 2009, CATHETER CARDIO INTE, V74, P108, DOI 10.1002/ccd.21938; Barman S, 2006, J PHYS CHEM B, V110, P651, DOI 10.1021/jp055814m; Beer SJ, 1998, GENE THER, V5, P740, DOI 10.1038/sj.gt.3300647; Beringer G. M., 1890, PHARM J T, V20, P676; Bryan NS, 2007, FREE RADICAL BIO MED, V43, P645, DOI 10.1016/j.freeradbiomed.2007.04.026; Carpi F, 2009, EXPERT REV MED DEVIC, V6, P487, DOI [10.1586/erd.09.32, 10.1586/ERD.09.32]; Chorny M., 2012, METHODIST DEBAKEY CA, V8, P25; Chorny M, 2006, MOL THER, V14, P382, DOI 10.1016/j.ymthe.2006.03.023; Chorny M, 2010, J CONTROL RELEASE, V146, P144, DOI 10.1016/j.jconrel.2010.05.003; Chorny M, 2010, P NATL ACAD SCI USA, V107, P8346, DOI 10.1073/pnas.0909506107; Coughlan L., 2012, VIRUSES, V2, P2290; Coughlan L, 2012, HUM GENE THER, V23, P960, DOI 10.1089/hum.2011.218; Di Paolo NC, 2009, CURR OPIN MOL THER, V11, P523; Duffy MR, 2012, NANOMEDICINE-UK, V7, P271, DOI [10.2217/nnm.11.186, 10.2217/NNM.11.186]; Eide DJ, 2006, BBA-MOL CELL RES, V1763, P711, DOI 10.1016/j.bbamcr.2006.03.005; Fishbein I, 2008, CIRCULATION, V117, P2096, DOI 10.1161/CIRCULATIONAHA.107.746412; Fishbein I, 2010, CURR OPIN DRUG DISC, V13, P203; Gruchala M, 2004, CURR PHARM DESIGN, V10, P407, DOI 10.2174/1381612043453379; Kempe H, 2011, EXPERT REV MED DEVIC, V8, P291, DOI [10.1586/ERD.10.94, 10.1586/erd.10.94]; Lee DS, 2009, BIOCHEM BIOPH RES CO, V378, P640, DOI 10.1016/j.bbrc.2008.11.096; Li QG, 1997, ARCH VIROL, V142, P1307, DOI 10.1007/s007050050162; Mok H, 2007, PHARM RES, V24, P2263, DOI 10.1007/s11095-007-9441-y; Naseem Khalid M., 2005, Molecular Aspects of Medicine, V26, P33, DOI 10.1016/j.mam.2004.09.003; NEURATH AR, 1970, J VIROL, V5, P173, DOI 10.1128/JVI.5.2.173-178.1970; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Pandori MW, 2005, GENE THER, V12, P521, DOI 10.1038/sj.gt.3302420; Pfeifer A, 2012, PHARM RES-DORDR, V29, P1161, DOI 10.1007/s11095-012-0736-2; Polyak B, 2008, P NATL ACAD SCI USA, V105, P698, DOI 10.1073/pnas.0708338105; Ridgway JP, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-71; Rissanen TT, 2007, MOL THER, V15, P1233, DOI 10.1038/sj.mt.6300175; Seymour LW, 2011, HUM GENE THER, V22, P1041, DOI 10.1089/hum.2011.2517; Shayakhmetov DM, 2005, J VIROL, V79, P7478, DOI 10.1128/JVI.79.12.7478-7491.2005; Singh R, 2009, TRENDS BIOTECHNOL, V27, P220, DOI 10.1016/j.tibtech.2009.01.003; Talsma H, 1997, INT J PHARMACEUT, V157, P233, DOI 10.1016/S0378-5173(97)00244-5; Tresilwised N, 2012, BIOMATERIALS, V33, P256, DOI 10.1016/j.biomaterials.2011.09.028; Turner P, 2007, BIOTECHNOL PROGR, V23, P423, DOI 10.1021/bp0600177; van Beusekom HM, 2007, NETH HEART J, V15, P395, DOI 10.1007/BF03086022; Volpers C, 2004, J GENE MED, V6, pS164, DOI 10.1002/jgm.496; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; Williams PD, 2010, VIRUSES-BASEL, V2, P334, DOI 10.3390/v2020334; Wolfrum C, 2000, EUR J LIPID SCI TECH, V102, P746, DOI 10.1002/1438-9312(200012)102:12<746::AID-EJLT746>3.0.CO;2-R; Yellen BB, 2005, J MAGN MAGN MATER, V293, P647, DOI 10.1016/j.jmmm.2005.01.083	43	29	29	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2198	2206		10.1096/fj.12-224659	http://dx.doi.org/10.1096/fj.12-224659			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23407712	Green Published			2022-12-28	WOS:000319667600011
J	Ma, L; Huang, DW; Cuomo, CA; Sykes, S; Fantoni, G; Das, B; Sherman, BT; Yang, J; Huber, C; Xia, Y; Davey, E; Kutty, G; Bishop, L; Sassi, M; Lempicki, RA; Kovacs, JA				Ma, Liang; Huang, Da-Wei; Cuomo, Christina A.; Sykes, Sean; Fantoni, Giovanna; Das, Biswajit; Sherman, Brad T.; Yang, Jun; Huber, Charles; Xia, Yun; Davey, Emma; Kutty, Geetha; Bishop, Lisa; Sassi, Monica; Lempicki, Richard A.; Kovacs, Joseph A.			Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis	FASEB JOURNAL			English	Article						inverted repeats; DNA replication; pneumonia	F SP. HOMINIS; DNA-SEQUENCES; GENETIC-DIVERGENCE; TANDEM REPEATS; SP CARINII; EVOLUTION; MICE; FUNGI; CHAIN; IDENTIFICATION	Pneumocystis jirovecii is an important opportunistic pathogen associated with AIDS and other immunodeficient conditions. Currently, very little is known about its nuclear and mitochondrial genomes. In this study, we sequenced the complete mitochondrial genome (mtDNA) of this organism and its closely related species Pneumocystis carinii and Pneumocystis murina by a combination of sequencing technologies. Our study shows that P. carinii and P. murina mtDNA share a nearly identical number and order of genes in a linear configuration, whereas P. jirovecii has a circular mtDNA containing nearly the same set of genes but in a different order. Detailed studies of the mtDNA terminal structures of P. murina and P. carinii suggest a unique replication mechanism for linear mtDNA. Phylogenetic analysis supports a close association of Pneumocystis species with Taphrina, Saitoella, and Schizosaccharomyces, and divergence within Pneumocystis species, with P. murina and P. carinii being more closely related to each other than either is to P. jirovecii. Comparative analysis of four complete P. jirovecii mtDNA sequences in this study and previously reported mtDNA sequences for diagnosing and genotyping suggests that the current diagnostic and typing methods can be improved using the complete mtDNA data. The availability of the complete P. jirovecii mtDNA also opens the possibility of identifying new therapeutic targets.-Ma, L., Huang, D. W., Cuomo, C. A., Sykes, S., Fantoni, G., Das, B., Sherman, B. T., Yang, J., Huber, C., Xia, Y., Davey, E., Kutty, G., Bishop, L., Sassi, M., Lempicki, R. A., Kovacs, J. A. Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB J. 27, 1962-1972 (2013). www.fasebj.org	[Ma, Liang; Fantoni, Giovanna; Xia, Yun; Davey, Emma; Kutty, Geetha; Bishop, Lisa; Sassi, Monica; Kovacs, Joseph A.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; [Huber, Charles] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Huang, Da-Wei; Das, Biswajit; Sherman, Brad T.; Yang, Jun; Lempicki, Richard A.] Sci Applicat Int Corp Frederick, Lab Immunopathogenesis & Bioinformat, Clin Serv Program, Frederick, MD USA; [Cuomo, Christina A.; Sykes, Sean] MIT, Broad Inst, Cambridge, MA 02139 USA; [Cuomo, Christina A.; Sykes, Sean] Harvard Univ, Cambridge, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Science Applications International Corporation (SAIC); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Ma, L (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr, Bethesda, MD 20892 USA.	mal3@mail.nih.gov	Lempicki, Richard A/E-1844-2012; Cuomo, Christina/L-2222-2019; Kovacs, Joseph/AAU-6105-2021	Lempicki, Richard A/0000-0002-7059-409X; Cuomo, Christina/0000-0002-5778-960X; Kovacs, Joseph/0000-0002-5191-9880; Sykes, Sean/0000-0001-8344-5176; Ma, Liang/0000-0002-6078-5730	Intramural Research Program of the U.S. National Institutes of Health Clinical Center; National Institute of Allergy and Infectious Diseases [NOI-CO-56000]; National Human Genome Research Institute [U54HG003067]; Chongqing Medical University (Chongqing, China); NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL000192] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health Clinical Center; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Chongqing Medical University (Chongqing, China); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CLINICAL CENTER	This work was supported by the Intramural Research Program of the U.S. National Institutes of Health Clinical Center; the National Institute of Allergy and Infectious Diseases (contract NOI-CO-56000); and the National Human Genome Research Institute (grant U54HG003067). Y.X. was supported by a scholarship from Chongqing Medical University (Chongqing, China). The authors declare no conflicts of interests. The authors thank Rene Costello and Howard Mostowski for their support of the animal studies.	BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; Ben Beard C, 2004, EMERG INFECT DIS, V10, P1729, DOI 10.3201/eid1010.030981; Bishop LR, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-39; Bullerwell CE, 2003, NUCLEIC ACIDS RES, V31, P759, DOI 10.1093/nar/gkg134; DINOUEL N, 1993, MOL CELL BIOL, V13, P2315, DOI 10.1128/MCB.13.4.2315; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; Gianella S, 2010, TRANSPL INFECT DIS, V12, P1, DOI 10.1111/j.1399-3062.2009.00447.x; Helweg-Larsen J, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-28; Hunter JAC, 1996, J EUKARYOT MICROBIOL, V43, pS24, DOI 10.1111/j.1550-7408.1996.tb04962.x; James TY, 2006, NATURE, V443, P818, DOI 10.1038/nature05110; Keely SP, 2004, MICROBIOL-SGM, V150, P1153, DOI 10.1099/mic.0.26921-0; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kosa P, 2006, NUCLEIC ACIDS RES, V34, P2472, DOI 10.1093/nar/gkl327; KOVACS JA, 1988, J IMMUNOL, V140, P2023; Kovacs JA, 2009, JAMA-J AM MED ASSOC, V301, P2578, DOI 10.1001/jama.2009.880; Larsen HH, 2002, J CLIN MICROBIOL, V40, P2989, DOI 10.1128/JCM.40.8.2989-2993.2002; Lee CH, 1998, J CLIN MICROBIOL, V36, P734, DOI 10.1128/JCM.36.3.734-741.1998; Liu Y, 2009, MOL BIOL EVOL, V26, P27, DOI 10.1093/molbev/msn221; Ma L, 2003, J MED MICROBIOL, V52, P955, DOI 10.1099/jmm.0.05131-0; Ma L, 2002, J INFECT DIS, V186, P1647, DOI 10.1086/345721; Ma L, 2001, J INFECT DIS, V184, P1358, DOI 10.1086/324208; MacCallum I, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-r103; Martins VD, 2011, J BIOENERG BIOMEMBR, V43, P81, DOI 10.1007/s10863-011-9331-1; Maskell NA, 2003, THORAX, V58, P594, DOI 10.1136/thorax.58.7.594; MORIN GB, 1986, CELL, V46, P873, DOI 10.1016/0092-8674(86)90069-3; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; Perez-Brocal V, 2010, GENOME BIOL EVOL, V2, P257, DOI 10.1093/gbe/evq015; Redhead S, 2006, J EUKARYOT MICROBIOL, V53, P2, DOI 10.1111/j.1550-7408.2005.00072.x; Rodova M, 2003, MOL BIOL EVOL, V20, P1669, DOI 10.1093/molbev/msg191; Schattner P, 2005, NUCLEIC ACIDS RES, V33, pW686, DOI 10.1093/nar/gki366; Sesterhenn TM, 2010, MOL GENET GENOMICS, V283, P63, DOI 10.1007/s00438-009-0498-7; Shingu-Vazquez M, 2011, EUKARYOT CELL, V10, P1376, DOI 10.1128/EC.05184-11; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Stiller JW, 1999, MOL BIOL EVOL, V16, P1270, DOI 10.1093/oxfordjournals.molbev.a026217; Talavera G, 2007, SYST BIOL, V56, P564, DOI 10.1080/10635150701472164; Tsolaki AG, 1998, J CLIN MICROBIOL, V36, P90, DOI 10.1128/JCM.36.1.90-93.1998; Valach M, 2011, NUCLEIC ACIDS RES, V39, P4202, DOI 10.1093/nar/gkq1345; Vestereng VH, 2004, J INFECT DIS, V189, P1540, DOI 10.1086/382486; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6; Wakefield AE, 1996, J CLIN MICROBIOL, V34, P1754, DOI 10.1128/JCM.34.7.1754-1759.1996; Walker DJ, 1998, J INFECT DIS, V178, P1767, DOI 10.1086/314509; Weniger T, 2010, NUCLEIC ACIDS RES, V38, pW326, DOI 10.1093/nar/gkq351; Xu Z, 2003, GENETICS, V163, P1299	44	30	34	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1962	1972		10.1096/fj.12-224444	http://dx.doi.org/10.1096/fj.12-224444			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23392351	Green Published			2022-12-28	WOS:000318226100016
J	Long, XG; Li, Y; Qi, YM; Xu, J; Wang, ZL; Zhang, XM; Zhang, DD; Zhang, L; Huang, JQ				Long, Xigui; Li, Ying; Qi, Yiming; Xu, Juan; Wang, Zilian; Zhang, Ximeng; Zhang, Duoduo; Zhang, Lin; Huang, Junqi			XAF1 contributes to dengue virus-induced apoptosis in vascular endothelial cells	FASEB JOURNAL			English	Article						XIAP; VECs	X-LINKED INHIBITOR; COLON-CANCER; KAPPA-B; INFECTION; GENE; EXPRESSION; PATHWAY; TRAIL; ALPHA; XIAP	The mechanism of vascular leakage in severe dengue infection remains unclear. Here, we used primary human umbilical vein endothelial cells (HUVECs) and the EA.hy926 cell line to study the molecular events that occur after dengue virus serotype 2 (DENV2) infection. DENV2-induced apoptosis was confirmed using nuclear staining, TUNEL assay, and electron microscopy. A genome-wide transcriptome analysis was performed using a microarray of DENV2-infected HUVECs. Notably, interferon-inducible genes were differentially expressed after DENV2 infection. Prominent among these genes was the X chromosome-linked inhibitor of apoptosis protein (XIAP)-associated factor 1 (XAF1; up-regulated 1.2-fold in the microarray analysis and similar to 8-fold by qRT-PCR after DENV2 infection). XAF1 protein levels were up-regulated after DENV2 infection in both HUVECs and EA.hy926 cells. Evidence indicated interaction between XAF1 and XIAP during DENV2 infection based on their cellular localization, as observed by confocal microscopy and the coimmunoprecipitation of XIAP with an anti-XAF1 antibody. Next, recombinant EA.hy926 cell lines in which XAF1 was either knocked down or overexpressed were constructed. The expression levels of the apoptosis-related genes caspase 3, caspase 8, caspase 9, and poly-(ADP-ribose) polymerase (PARP) were down-regulated in the XAF1 knockdown (24-48 h postinfection) but were up-regulated in XAF1 overexpressing cells (36 h postinfection). This is the first study of the role of XAF1 in promoting apoptosis in vascular endothelial cells after DENV2 infection.-Long, X., Li, Y., Qi, Y., Xu, J., Wang, Z., Zhang, X., Zhang, D., Zhang, L., Huang, J. XAF1 contributes to dengue virus-induced apoptosis in vascular endothelial cells. FASEB J. 27, 1062-1073 (2013). www.fasebj.org	[Long, Xigui; Li, Ying; Qi, Yiming; Xu, Juan; Zhang, Ximeng; Zhang, Duoduo; Zhang, Lin; Huang, Junqi] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Immunol, Guangzhou 510080, Guangdong, Peoples R China; [Wang, Zilian] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Long, Xigui; Li, Ying; Qi, Yiming; Xu, Juan; Zhang, Ximeng; Zhang, Duoduo; Zhang, Lin; Huang, Junqi] Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Huang, JQ (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Inst Immunol, Guangzhou 510080, Guangdong, Peoples R China.	huangjunqi1410@163.com	Zhang, Duo/GYU-8678-2022; ZHANG, LIN/GYD-9123-2022; zhan, lin/AAP-5149-2020		National Natural Science Foundation of China [30872350]; Natural Science Foundation of Guangdong Province [81510008901000017, S2012010009050]; Guangdong Province Scientific Technology Project [2010B050700008, 2011B040300022]; Guangzhou City Scientific Technology Project [2011J4100084, 2008Z1-E221]; Fundamental Research Funds for the Central Universities [10YKPY31]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Province Scientific Technology Project; Guangzhou City Scientific Technology Project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The authors thank Yimin Jiang (Guangzhou Center for Disease Control and Prevention, Guangzhou, China) for providing the clinical DENV2 strain of Guangzhou (06/GZ/D2-156). This work was supported by the National Natural Science Foundation of China (30872350), the Natural Science Foundation of Guangdong Province (81510008901000017, S2012010009050), the Guangdong Province Scientific Technology Project (2010B050700008, 2011B040300022), the Guangzhou City Scientific Technology Project (2011J4100084, 2008Z1-E221), and the Fundamental Research Funds for the Central Universities (10YKPY31). The authors declare no conflicts of interest.	Arevalo MT, 2009, J MED VIROL, V81, P519, DOI 10.1002/jmv.21408; Avirutnan P, 1998, J IMMUNOL, V161, P6338; Byun DS, 2003, CANCER RES, V63, P7068; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Dalrymple N, 2011, J VIROL, V85, P9478, DOI 10.1128/JVI.05008-11; Delong MJ, 1998, ANN NY ACAD SCI, V842, P82, DOI 10.1111/j.1749-6632.1998.tb09635.x; Despres P, 1998, J VIROL, V72, P823; Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000; Giovannetti A, 2008, CURR PHARM DESIGN, V14, P253; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Jimenez-Marin Angeles, 2009, BMC Proc, V3 Suppl 4, pS6, DOI 10.1186/1753-6561-3-S4-S6; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee MG, 2006, CURR CLIN PHARMACOL, V1, P193, DOI 10.2174/157488406776872569; Liao HW, 2010, J MED VIROL, V82, P1392, DOI 10.1002/jmv.21815; Liew KJL, 2004, J MED VIROL, V72, P597, DOI 10.1002/jmv.20034; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu P, 2009, J INFECT DIS, V200, P191, DOI 10.1086/599795; Lovering RC, 2008, IMMUNOLOGY, V125, P154, DOI 10.1111/j.1365-2567.2008.02940.x; Marianneau Philippe, 1998, Acta Cientifica Venezolana, V49, P13; Micali OC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-52; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Morishita R, 2004, CURR GENE THER, V4, P199; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Nathan MB, 2006, RECENT EPIDEMIOLOGIC; Patel A, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-3; Pfeffer LM, 2011, J INTERF CYTOK RES, V31, P553, DOI 10.1089/jir.2011.0028; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; Straszewski-Chavez SL, 2007, J BIOL CHEM, V282, P13059, DOI 10.1074/jbc.M609038200; Sun YW, 2008, CANCER LETT, V260, P62, DOI 10.1016/j.canlet.2007.10.014; Sutejo R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033732; Tu SP, 2009, INT J CANCER, V125, P688, DOI 10.1002/ijc.24282; Wang JD, 2006, J BIOL CHEM, V281, P2451, DOI 10.1074/jbc.M505890200; Warke RV, 2008, J VIROL, V82, P555, DOI 10.1128/JVI.01694-06; Warke RV, 2003, J VIROL, V77, P11822, DOI 10.1128/JVI.77.21.11822-11832.2003; Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2; Yu LF, 2007, CANCER-AM CANCER SOC, V109, P1996, DOI 10.1002/cncr.22624; Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050	40	23	27	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1062	1073		10.1096/fj.12-213967	http://dx.doi.org/10.1096/fj.12-213967			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23207547				2022-12-28	WOS:000315585200020
J	Shelton, P; Jaiswal, AK				Shelton, Phillip; Jaiswal, Anil K.			The transcription factor NF-E2-related Factor 2 (Nrf2): a protooncogene?	FASEB JOURNAL			English	Review						cancer; signal transduction; oxidative stress; chemoprevention; targeted therapy	ANTIOXIDANT-RESPONSE ELEMENT; PPAR-GAMMA EXPRESSION; OXIDATIVE STRESS; NUCLEAR EXPORT; HEME OXYGENASE-1; MEDIATED EXPRESSION; ANTICANCER DRUGS; GENE-EXPRESSION; ENZYME GENES; DLG MOTIFS	The transcription factor Nrf2 is responsible for regulating a battery of antioxidant and cellular protective genes, primarily in response to oxidative stress. A member of the cap 'n' collar family of transcription factors, Nrf2 activation is tightly controlled by a series of signaling events. These events can be separated into the basal state, a preinduction response, gene induction, and finally a postinduction response, culminating in the restoration of redox homeostasis. However, despite the immensely intricate level of control the cellular environment imposes on Nrf2 activity, there are many opportunities for perturbations to arise in the signaling events that favor carcinogenesis and, therefore, implicate Nrf2 as both a tumor suppressor and a protooncogene. Herein, we highlight the ways in which Nrf2 is regulated, and discuss some of the Nrf2-inducible antioxidant (NQO1, NQO2, HO-1, GCLC), antiapoptotic (Bcl-2), metabolic (G6PD, TKT, PPAR gamma), and drug efflux transporter (ABCG2, MRP3, MRP4) genes. In addition, we focus on how Nrf2 functions as a tumor suppressor under normal conditions and how its ability to detoxify the cellular environment makes it an attractive target for other oncogenes either via stabilization or degradation of the transcription factor. Finally, we discuss some of the ways in which Nrf2 is being considered as a therapeutic target for cancer treatment.-Shelton, P., Jaiswal, A. K. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J. 27, 414-423 (2013). www.fasebj.org	[Shelton, Phillip; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Jaiswal, AK (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, Mol & Mechanist Grad Program, 655 W Baltimore St, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			U.S. National Institutes of Health (NIH) [RO1GM047466, RO1ES012265]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health (NIH) grants RO1GM047466 and RO1ES012265. The helpful suggestions from Dr. Suresh Niture (University of Maryland, Baltimore) are greatly appreciated.	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bauer AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026590; Bishop J. M., 1988, J CELL PHYSL, V129, P1; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hernandez F, 2010, MOL CELL BIOCHEM, V344, P211, DOI 10.1007/s11010-010-0544-0; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kaspar JW, 2012, J CELL SCI, V125, P1027, DOI 10.1242/jcs.097295; Kaspar JW, 2011, FASEB J, V25, P1076, DOI 10.1096/fj.10-171553; Kaspar JW, 2010, J BIOL CHEM, V285, P153, DOI 10.1074/jbc.M109.040022; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231; Kim YJ, 2007, CANCER RES, V67, P546, DOI 10.1158/0008-5472.CAN-06-2401; Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Lim JH, 2008, PHARMACOL RES, V57, P325, DOI 10.1016/j.phrs.2008.03.004; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Ma Q, 2012, PHARMACOL REV, V64, P1055, DOI 10.1124/pr.110.004333; Maher JM, 2007, HEPATOLOGY, V46, P1597, DOI 10.1002/hep.21831; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694; Niture SK, 2011, J BIOL CHEM, V286, P28821, DOI 10.1074/jbc.M111.255042; Niture SK, 2009, J CELL SCI, V122, P4452, DOI 10.1242/jcs.058537; Ohnuma T, 2011, BIOCHEM BIOPH RES CO, V413, P623, DOI 10.1016/j.bbrc.2011.09.014; Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Perera RM, 2011, NATURE, V475, P43, DOI 10.1038/475043a; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sankaranarayanan K, 2004, J BIOL CHEM, V279, P50810, DOI 10.1074/jbc.M404984200; Satoh H, 2010, CARCINOGENESIS, V31, P1833, DOI 10.1093/carcin/bgq105; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07; Tudek B, 2010, AM J TRANSL RES, V2, P254; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vollrath V, 2006, BIOCHEM J, V395, P599, DOI 10.1042/BJ20051518; Wang W, 2006, FREE RADICAL BIO MED, V40, P1119, DOI 10.1016/j.freeradbiomed.2005.10.063; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wu RP, 2010, P NATL ACAD SCI USA, V107, P7479, DOI 10.1073/pnas.1002890107; Xu ZR, 2005, P NATL ACAD SCI USA, V102, P4120, DOI 10.1073/pnas.0500660102; Zhan LJ, 2012, FREE RADICAL BIO MED, V53, P758, DOI 10.1016/j.freeradbiomed.2012.05.041; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	98	144	152	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					414	423		10.1096/fj.12-217257	http://dx.doi.org/10.1096/fj.12-217257			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23109674	Green Published			2022-12-28	WOS:000314358000002
J	Dottorini, T; Persampieri, T; Palladino, P; Baker, DA; Spaccapelo, R; Senin, N; Crisanti, A				Dottorini, Tania; Persampieri, Tania; Palladino, Pietro; Baker, Dean A.; Spaccapelo, Roberta; Senin, Nicola; Crisanti, Andrea			Regulation of Anopheles gambiae male accessory gland genes influences postmating response in female	FASEB JOURNAL			English	Article						reproductive biology; malaria; vector control; fertility; heat-shock factor	SEMINAL FLUID PROTEINS; MOLECULAR POPULATION-GENETICS; DROSOPHILA-MELANOGASTER; SEX-PEPTIDE; SPERM STORAGE; REPRODUCTIVE-BEHAVIOR; PROTEASE INHIBITOR; ECTOPIC EXPRESSION; IMMUNE-RESPONSE; MALARIA VECTOR	In Drosophila, the accessory gland proteins (Acps) secreted from the male accessory glands (MAGs) and transferred along with sperm into the female reproductive tract have been implicated in triggering postmating behavioral changes, including refractoriness to subsequent mating and propensity to egg laying. Recently, Acps have been found also in Anopheles, suggesting similar functions. Understanding the mechanisms underlying transcriptional regulation of Acps and their functional role in modulating Anopheles postmating behavior may lead to the identification of novel vector control strategies to reduce mosquito populations. We identified heat-shock factor (HSF) binding sites within the Acp promoters of male Anopheles gambiae and discovered three distinct Hsf isoforms; one being significantly up-regulated in the MAGs after mating. Through genome-wide transcription analysis of Hsf-silenced males, we observed significant down-regulation in 50% of the Acp genes if compared to control males treated with a construct directed against an unrelated bacterial sequence. Treated males retained normal life span and reproductive behavior compared to control males. However, mated wild-type females showed a similar to 46% reduction of egg deposition rate and a similar to 23% reduction of hatching rate (similar to 58% combined reduction of progeny). Our results highlight an unsuspected role of HSF in regulating Acp transcription in A. gambiae and provide evidence that Acp down-regulation in males leads a significant reduction of progeny, thus opening new avenues toward the development of novel vector control strategies.-Dottorini, T., Persampieri, T., Palladino, P., Baker, D. A., Spaccapelo, R., Senin, N., Crisanti, A. Regulation of Anopheles gambiae male accessory gland genes influences postmating response in female. FASEB J. 27, 86-97 (2013). www.fasebj.org	[Dottorini, Tania; Persampieri, Tania; Palladino, Pietro; Spaccapelo, Roberta; Crisanti, Andrea] Univ Perugia, Dept Expt Med, I-06100 Perugia, Italy; [Senin, Nicola] Univ Perugia, Dept Ind Engn, I-06100 Perugia, Italy; [Crisanti, Andrea] Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, SAF, London SW7 2AZ, England; [Baker, Dean A.] Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Perugia; University of Perugia; Imperial College London; University of Cambridge	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, SAF, S Kensington Campus, London SW7 2AZ, England.	acrs@imperial.ac.uk	senin, nicola/B-5292-2016	senin, nicola/0000-0002-9556-0363; Spaccapelo, Roberta/0000-0003-2100-6172; Dottorini, Tania/0000-0001-7733-906X; Crisanti, Andrea/0000-0002-2406-4426	European Union [PIEF-GA-2010-273268, IAPP-218164]; BBSRC [BB/E021794/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E021794/1] Funding Source: researchfish	European Union(European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Alessandro Trusso for 3'-RACE analysis and sequencing of HSF1, HSF2, and HSF3 and for preparing the RNA samples for microarray analysis; as well as Elena Levashina, Manlio DiCristina, Nikolai Windbichler, and Tony Nolan for the insight and suggestions. The authors thank the anonymous reviewers for the constructive and insightful comments that helped to improve the manuscript. This work was supported by the European Union, (PIEF-GA-2010-273268), programs Vectrap and FIGHTMAL (IAPP-218164). The authors declare no conflicts of interest.	Adams EM, 2007, J INSECT PHYSIOL, V53, P319, DOI 10.1016/j.jinsphys.2006.12.003; AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Andres JA, 2006, MOL BIOL EVOL, V23, P1574, DOI 10.1093/molbev/msl020; Avila FW, 2011, ANNU REV ENTOMOL, V56, P21, DOI 10.1146/annurev-ento-120709-144823; Baer B, 2009, PROTEOMICS, V9, P2085, DOI 10.1002/pmic.200800708; Baker DA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-296; Begun DJ, 2006, GENETICS, V172, P1675, DOI 10.1534/genetics.105.050336; Begun DJ, 2005, MOL BIOL EVOL, V22, P2010, DOI 10.1093/molbev/msi201; Begun DJ, 2000, GENETICS, V156, P1879; Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Braswell WE, 2006, GENOME, V49, P1069, DOI 10.1139/G06-061; Carvalho GB, 2006, CURR BIOL, V16, P692, DOI 10.1016/j.cub.2006.02.064; Chapman T, 2003, P NATL ACAD SCI USA, V100, P9923, DOI 10.1073/pnas.1631635100; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; CLARK AG, 1995, GENETICS, V139, P189; Collins AM, 2006, INSECT MOL BIOL, V15, P541, DOI 10.1111/j.1365-2583.2006.00674.x; Dai ZM, 2012, NUCLEIC ACIDS RES, V40, P27, DOI 10.1093/nar/gkr689; Davies SJ, 2006, INSECT BIOCHEM MOLEC, V36, P846, DOI 10.1016/j.ibmb.2006.08.009; Domanitskaya EV, 2007, FEBS J, V274, P5659, DOI 10.1111/j.1742-4658.2007.06088.x; Dottorini T, 2007, P NATL ACAD SCI USA, V104, P16215, DOI 10.1073/pnas.0703904104; Dottorini T, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-34; EBERHARD WG, 1995, TRENDS ECOL EVOL, V10, P493, DOI 10.1016/S0169-5347(00)89205-8; Findlay GD, 2008, PLOS BIOL, V6, P1417, DOI 10.1371/journal.pbio.0060178; Fiumera AC, 2005, GENETICS, V169, P243, DOI 10.1534/genetics.104.032870; Fiumera AC, 2007, GENETICS, V176, P1245, DOI 10.1534/genetics.106.064915; Hasemeyer M, 2009, NEURON, V61, P511, DOI 10.1016/j.neuron.2009.01.009; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; Heifetz Y, 2005, P NATL ACAD SCI USA, V102, P743, DOI 10.1073/pnas.0407692102; Heifetz Y, 2000, CURR BIOL, V10, P99, DOI 10.1016/S0960-9822(00)00288-8; Hershberg R, 2005, TRENDS GENET, V21, P138, DOI 10.1016/j.tig.2005.01.003; HIHARA F, 1981, ZOOL MAG, V90, P303; Holloway AK, 2004, MOL BIOL EVOL, V21, P1625, DOI 10.1093/molbev/msh195; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; Kapelnikov A, 2008, P NATL ACAD SCI USA, V105, P13912, DOI 10.1073/pnas.0710997105; Kern AD, 2004, GENETICS, V167, P725, DOI 10.1534/genetics.103.020883; Liu HF, 2003, P NATL ACAD SCI USA, V100, P9929, DOI 10.1073/pnas.1631700100; Lung O, 2002, GENETICS, V160, P211; Lung O, 2001, INSECT BIOCHEM MOLEC, V31, P543, DOI 10.1016/S0965-1748(00)00154-5; Magnusson K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021572; Marshall OJ, 2004, BIOINFORMATICS, V20, P2471, DOI 10.1093/bioinformatics/bth254; McGraw LA, 2008, GENETICS, V179, P1395, DOI 10.1534/genetics.108.086934; Mueller JL, 2008, GENETICS, V178, P1605, DOI 10.1534/genetics.107.083766; Mueller JL, 2007, GENETICS, V175, P777, DOI 10.1534/genetics.106.065318; Mueller JL, 2005, GENETICS, V171, P131, DOI 10.1534/genetics.105.043844; Mueller JL, 2004, P NATL ACAD SCI USA, V101, P13542, DOI 10.1073/pnas.0405579101; Neubaum DM, 1999, GENETICS, V153, P845; OSBOURN AE, 2009, OPERONS CELL MOL LIF, DOI DOI 10.1007/S00018-009-0114-3; Parthasarathy R, 2009, MECH DEVELOP, V126, P563, DOI 10.1016/j.mod.2009.03.005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ram KR, 2007, PLOS GENET, V3, P2428, DOI 10.1371/journal.pgen.0030238; Ram KR, 2007, INTEGR COMP BIOL, V47, P427, DOI 10.1093/icb/icm046; Ram KR, 2009, P NATL ACAD SCI USA, V106, P15384, DOI 10.1073/pnas.0902923106; Ram KR, 2005, INSECT BIOCHEM MOLEC, V35, P1059, DOI 10.1016/j.ibmb.2005.05.001; Rexhepaj A, 2003, EUR J BIOCHEM, V270, P4306, DOI 10.1046/j.1432-1033.2003.03823.x; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Rogers DW, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000272; Rogers DW, 2008, P NATL ACAD SCI USA, V105, P19390, DOI 10.1073/pnas.0809723105; Santos SD, 2004, NEUROSCIENCE, V126, P657, DOI 10.1016/j.neuroscience.2004.03.023; Sirot LK, 2008, INSECT BIOCHEM MOLEC, V38, P176, DOI 10.1016/j.ibmb.2007.10.007; Soller M, 1999, DEV BIOL, V208, P337, DOI 10.1006/dbio.1999.9210; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P7375, DOI 10.1073/pnas.131568198; Takemori N, 2009, PROTEOMICS, V9, P2484, DOI 10.1002/pmic.200800795; Thailayil J, 2011, P NATL ACAD SCI USA, V108, P13677, DOI 10.1073/pnas.1104738108; Tram U, 1999, GENETICS, V153, P837; Voordouw MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-103; Wagstaff BJ, 2005, GENETICS, V171, P1083, DOI 10.1534/genetics.105.043372; Wagstaff BJ, 2005, MOL BIOL EVOL, V22, P818, DOI 10.1093/molbev/msi067; Walker MJ, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-9; Walters JR, 2010, MOL BIOL EVOL, V27, P2000, DOI 10.1093/molbev/msq092; Walters JR, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-592; Wang GH, 2004, GENESIS, V38, P66, DOI 10.1002/gene.20005; Wong A, 2008, GENETICS, V180, P921, DOI 10.1534/genetics.108.092106; Xue L, 2000, P NATL ACAD SCI USA, V97, P3272, DOI 10.1073/pnas.060018897; Yang CH, 2009, NEURON, V61, P519, DOI 10.1016/j.neuron.2008.12.021; Yapici N, 2008, NATURE, V451, P33, DOI 10.1038/nature06483	78	12	12	1	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					86	97		10.1096/fj.12-219444	http://dx.doi.org/10.1096/fj.12-219444			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22997226	Bronze			2022-12-28	WOS:000313103200010
J	Jensen, K; Nizamutdinov, D; Guerrier, M; Afroze, S; Dostal, D; Glaser, S				Jensen, Kendal; Nizamutdinov, Damir; Guerrier, Micheleine; Afroze, Syeda; Dostal, David; Glaser, Shannon			General mechanisms of nicotine-induced fibrogenesis	FASEB JOURNAL			English	Review						cigarette smoking; fibroblast; reactive oxygen species; collagen; NRT	TO-MYOFIBROBLAST TRANSDIFFERENTIATION; MURINE PERITONEAL-MACROPHAGES; INDUCED OXIDATIVE STRESS; ACETYLCHOLINE-RECEPTORS; CIGARETTE-SMOKING; REPLACEMENT THERAPY; EPITHELIAL-CELLS; DNA-DAMAGE; CYTOCHROME-P450 2E1; ENHANCES EXPRESSION	Cigarette smoking contributes to the development of cancer, and pathogenesis of other diseases. Many chemicals have been identified in cigarettes that have potent biological properties. Nicotine is especially known for its role in addiction and plays a role in other physiological effects of smoking and tobacco use. Recent studies have provided compelling evidence that, in addition to promoting cancer, nicotine also plays a pathogenic role in systems, such as the lung, kidney, heart, and liver. In many organ systems, nicotine modulates fibrosis by altering the functions of fibroblasts. Understanding the processes modulated by nicotine holds therapeutic potential and may guide future clinical and research decisions. This review discusses the role of nicotine in the general fibrogenic process that governs fibrosis and fibrosis-related diseases, focusing on the cellular mechanisms that have implications in multiple organ systems. Potential research directions for the management of nicotine-induced fibrosis, and potential clinical considerations with regard to nicotine-replacement therapy (NRT) are presented.-Jensen, K., Nizamutdinov, D., Guerrier, M., Afroze, S., Dostal, D., Glaser, S. General mechanisms of nicotine-induced fibrogenesis. FASEB J. 26, 4778-4787 (2012). www.fasebj.org	[Jensen, Kendal; Guerrier, Micheleine; Afroze, Syeda; Glaser, Shannon] Cent Texas Vet Hlth Care Syst, Texas A&M Hlth Sci Ctr, Dept Internal Med, Div Gastroenterol, Temple, TX 76504 USA; [Nizamutdinov, Damir; Dostal, David] Cent Texas Vet Hlth Care Syst, Texas A&M Hlth Sci Ctr, Dept Internal Med, Div Mol Cardiol, Temple, TX 76504 USA; [Glaser, Shannon] Scott & White Healthcare Digest Dis Res Ctr, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Glaser, S (corresponding author), Cent Texas Vet Hlth Care Syst, Texas A&M Hlth Sci Ctr, Dept Med, VA Bldg 205,1901 S 1st St, Temple, TX 76504 USA.	sglaser@medicine.tamhsc.edu			Scott and White Hospital, Department of Internal Medicine; Scott and White Research Advancement award; U.S. Department of Veteran's Affairs Career Development Award-2; U.S. National Institutes of Health [DK081442]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081442] Funding Source: NIH RePORTER	Scott and White Hospital, Department of Internal Medicine; Scott and White Research Advancement award; U.S. Department of Veteran's Affairs Career Development Award-2; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Portions of this work were supported by the Scott and White Hospital, Department of Internal Medicine; a Scott and White Research Advancement award; a U.S. Department of Veteran's Affairs Career Development Award-2; and a U.S. National Institutes of Health RO1 grant (DK081442) to S. G. The authors thank Dr. Gianfranco Alpini for his kind suggestions and comments on the manuscript.	Aicher A, 2003, CIRCULATION, V107, P604, DOI 10.1161/01.CIR.0000047279.42427.6D; Arany I, 2012, AM J PHYSIOL-RENAL, V302, pF722, DOI 10.1152/ajprenal.00338.2011; Arany I, 2011, AM J PHYSIOL-RENAL, V301, pF125, DOI 10.1152/ajprenal.00041.2011; Armstrong LW, 1996, AM J RESP CRIT CARE, V154, P1520, DOI 10.1164/ajrccm.154.5.8912774; Ashakumary L, 1996, PHARMACOLOGY, V52, P153, DOI 10.1159/000139379; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Biondo-Simões Maria de Lourdes Pessole, 2009, Rev. Col. Bras. Cir., V36, P425; Cahill K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub5; Caldeira EJ, 2007, ARCH ORAL BIOL, V52, P83, DOI 10.1016/j.archoralbio.2006.07.008; Cardenas L, 2002, J PHARMACOL EXP THER, V302, P1265, DOI 10.1124/jpet.302.3.1265; Ciobica A, 2009, Rev Med Chir Soc Med Nat Iasi, V113, P832; Costa F, 2009, LIFE SCI, V84, P785, DOI 10.1016/j.lfs.2009.03.002; Dey SK, 2010, B ENVIRON CONTAM TOX, V84, P385, DOI 10.1007/s00128-010-9948-5; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Ejaz S, 2005, ENVIRON TOXICOL PHAR, V20, P335, DOI 10.1016/j.etap.2005.03.011; Carvalho CAF, 2012, MICROSC RES TECHNIQ, V75, P46, DOI 10.1002/jemt.21023; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Galatz LM, 2006, J BONE JOINT SURG AM, V88A, P2027, DOI 10.2106/JBJS.E.00899; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Goette A, 2007, HEART, V93, P1056, DOI 10.1136/hrt.2005.087171; Grief SN, 2011, PRIMARY CARE, V38, P23, DOI 10.1016/j.pop.2010.11.003; Haass M, 1997, CARDIOVASC DRUG THER, V10, P657, DOI 10.1007/BF00053022; Hayashi H, 2003, AM J PHYSIOL-HEART C, V285, pH2091, DOI 10.1152/ajpheart.00371.2003; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Helen A, 2000, TOXICOL LETT, V116, P61, DOI 10.1016/S0378-4274(00)00208-3; Helen A, 2003, PHARMACOLOGY, V67, P113, DOI 10.1159/000067796; Hemnani T, 1998, Indian J Physiol Pharmacol, V42, P440; Hua P, 2010, AM J PHYSIOL-RENAL, V299, pF732, DOI 10.1152/ajprenal.00293.2010; HUCKER HB, 1960, J PHARMACOL EXP THER, V129, P94; Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3; Husain K, 2001, ALCOHOL, V25, P89, DOI 10.1016/S0741-8329(01)00176-8; Jaimes EA, 2007, AM J PHYSIOL-HEART C, V292, pH76, DOI 10.1152/ajpheart.00693.2006; Jain M, 2006, EXPERT OPIN PHARMACO, V7, P1487, DOI 10.1517/14656566.7.11.1487; Jensen K, 2012, AM J PHYSIOL-GASTR L, V302, pG473, DOI 10.1152/ajpgi.00482.2011; Kashiwagi Y, 2012, ARCH ORAL BIOL, V57, P483, DOI 10.1016/j.archoralbio.2011.10.007; Kisseleva T, 2008, EXP BIOL MED, V233, P109, DOI 10.3181/0707-MR-190; Krebs M, 2010, EXP LUNG RES, V36, P390, DOI 10.3109/01902141003714023; Lafyatis Robert, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P395; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; Mahapatra SK, 2009, EUR J PHARMACOL, V623, P132, DOI 10.1016/j.ejphar.2009.09.019; Mahapatra SK, 2009, OXID MED CELL LONGEV, V2, P222, DOI 10.4161/oxim.2.4.9000; Mahapatra SK, 2009, TOXICOL MECH METHOD, V19, P100, DOI 10.1080/15376510802255184; Mariolis P., 2006, Morbidity and Mortality Weekly Report, V55, P1145; Millar NS, 2008, MOL MEMBR BIOL, V25, P279, DOI 10.1080/09687680802035675; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Molyneux AN, 2004, BRIT MED J, V328, P454, DOI 10.1136/bmj.328.7437.454; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; Muriel P, 2009, HEPATOL INT, V3, P526, DOI 10.1007/s12072-009-9158-6; Murray RP, 2009, NICOTINE TOB RES, V11, P1076, DOI 10.1093/ntr/ntp104; Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nouri-Shirazi M, 2003, IMMUNOLOGY, V109, P365, DOI 10.1046/j.1365-2567.2003.01655.x; NOWAK D, 1990, EXP PATHOL-JENA, V39, P37; Prabhulkar S, 2010, BIOSENS BIOELECTRON, V26, P1743, DOI 10.1016/j.bios.2010.08.029; Rehan VK, 2007, LUNG, V185, P151, DOI 10.1007/s00408-007-9007-0; Rehan VK, 2007, AM J PHYSIOL-LUNG C, V292, pL323, DOI 10.1152/ajplung.00071.2006; Rehan VK, 2005, AM J PHYSIOL-LUNG C, V289, pL667, DOI 10.1152/ajplung.00358.2004; Roomans G. M., 2002, Journal of Submicroscopic Cytology and Pathology, V34, P381; RYDER MI, 1994, EXP LUNG RES, V20, P283, DOI 10.3109/01902149409064388; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Sekhon HS, 2002, AM J RESP CELL MOL, V26, P31, DOI 10.1165/ajrcmb.26.1.4170; SEOW WK, 1994, INFLAMMATION, V18, P119, DOI 10.1007/BF01534553; Shan HL, 2009, CARDIOVASC RES, V83, P465, DOI 10.1093/cvr/cvp130; Sharafkhaneh Amir, 2008, Proc Am Thorac Soc, V5, P475, DOI 10.1513/pats.200708-126ET; Shieh DH, 2004, J ORAL PATHOL MED, V33, P581, DOI 10.1111/j.1600-0714.2004.00229.x; Shin VY, 2010, CANCER LETT, V292, P237, DOI 10.1016/j.canlet.2009.12.011; Soeda J, 2012, BIOCHEM BIOPH RES CO, V417, P17, DOI 10.1016/j.bbrc.2011.10.151; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; Sudheer AR, 2008, TOXICOLOGY, V243, P317, DOI 10.1016/j.tox.2007.10.016; Sudheer AR, 2007, TOXICOL IN VITRO, V21, P576, DOI 10.1016/j.tiv.2006.11.006; Takeuchi H, 2010, J DENT RES, V89, P34, DOI 10.1177/0022034509353403; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Tsai JR, 2006, DNA CELL BIOL, V25, P312, DOI 10.1089/dna.2006.25.312; Wong HPS, 2007, TOXICOL SCI, V97, P279, DOI 10.1093/toxsci/kfm060; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yamano S, 2010, CLIN ORAL IMPLAN RES, V21, P1353, DOI 10.1111/j.1600-0501.2010.01955.x; Yanagita M, 2012, CELL IMMUNOL, V274, P26, DOI 10.1016/j.cellimm.2012.02.007; Yang IA, 2011, EXPERT OPIN THER TAR, V15, P439, DOI 10.1517/14728222.2011.555400; Yashima M, 2000, AM J PHYSIOL-HEART C, V278, pH2124, DOI 10.1152/ajpheart.2000.278.6.H2124; Zhang SL, 2001, ATHEROSCLEROSIS, V154, P277, DOI 10.1016/S0021-9150(00)00475-5; Zhou YO, 2012, RHEUMATOL INT, V32, P97, DOI 10.1007/s00296-010-1549-4; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	84	55	56	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4778	4787		10.1096/fj.12-206458	http://dx.doi.org/10.1096/fj.12-206458			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22906950	Green Published			2022-12-28	WOS:000311838300002
J	Mendes-da-Cruz, DA; Stimamiglio, MA; Munoz, JJ; Alfaro, D; Terra-Granado, E; Garcia-Ceca, J; Alonso-Colmenar, LM; Savino, W; Zapata, AG				Mendes-da-Cruz, Daniella Areas; Augusto Stimamiglio, Marco; Jose Munoz, Juan; Alfaro, David; Terra-Granado, Eugenia; Garcia-Ceca, Javier; Miguel Alonso-Colmenar, Luis; Savino, Wilson; Zapata, Agustin G.			Developing T-cell migration: role of semaphorins and ephrins	FASEB JOURNAL			English	Review						thymus; thymic epithelial cells; thymocyte migration; neuropilins; ephs	HUMAN THYMOCYTE MIGRATION; HEMATOPOIETIC PROGENITORS; AXON GUIDANCE; EPH; RECEPTOR; THYMUS; EXPRESSION; ADHESION; NEUROPILIN-1; FAMILY	Cell migration is a crucial event for normal T-cell development, and various ligand/receptor pairs have been implicated. Most of them, including chemokines and extracellular matrix proteins, have attractant properties on thymocytes. We discuss herein two further groups of ligand/receptor pairs, semaphorins/neuropilins and ephs/ephrins, which are constitutively expressed by thymocytes and thymic microenvironmental cells. Evidence shows that the corresponding interactions are relevant for developing T-cell migration, including the entry of bone marrow progenitor cells, migration of CD4/CD8-defined thymocyte subpopulations triggered by chemokines and/or extracellular matrix proteins, and thymocyte export. Conceptually, the data summarized here show that thymocyte migration results from a complex network of molecular interactions, which generate not only attraction, but also repulsion of migrating T-cell precursors.-Mendes-da-Cruz, D. A., Stimamiglio, M. A., Munoz, J. J., Alfaro, D., Terra-Granado, E., Garcia-Ceca, J., Alonso-Colmenar, L. M., Savino, W., Zapata, A. G. Developing T-cell migration: role of semaphorins and ephrins. FASEB J. 26, 4390-4399 (2012). www.fasebj.org	[Mendes-da-Cruz, Daniella Areas; Augusto Stimamiglio, Marco; Terra-Granado, Eugenia; Savino, Wilson] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Thymus Res, BR-21040360 Rio De Janeiro, Brazil; [Augusto Stimamiglio, Marco] Fundacao Oswaldo Cruz, Carlos Chagas Inst, Lab Regulat Gene Express, Curitiba, Parana, Brazil; [Augusto Stimamiglio, Marco; Alfaro, David; Terra-Granado, Eugenia; Garcia-Ceca, Javier; Zapata, Agustin G.] Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain; [Jose Munoz, Juan; Miguel Alonso-Colmenar, Luis; Zapata, Agustin G.] Univ Complutense, Ctr Cytometry & Fluorescence Microscopy, E-28040 Madrid, Spain; [Terra-Granado, Eugenia] Natl Canc Inst, Res Ctr, Pediat Hematol & Oncol Program, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Complutense University of Madrid; Complutense University of Madrid; National Cancer Institute (Inca)	Mendes-da-Cruz, DA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Thymus Res, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.	savino@fiocruz.br	García-Ceca, Javier/J-1803-2016; Mendes-da-Cruz, Daniella/AAN-6644-2020; Stimamiglio, Marco Augusto A/D-6239-2013; Sánchez, David Alfaro/E-5155-2016; Alonso-Colmenar, Luis Miguel/K-6957-2018; Stimamiglio, Marco Augusto/AAA-8129-2019; Mendes-da-Cruz, Daniella A/E-7875-2016	García-Ceca, Javier/0000-0002-0940-455X; Mendes-da-Cruz, Daniella/0000-0003-3697-1506; Stimamiglio, Marco Augusto A/0000-0001-8537-2812; Sánchez, David Alfaro/0000-0003-2139-9818; Alonso-Colmenar, Luis Miguel/0000-0003-3869-6309; Stimamiglio, Marco Augusto/0000-0001-8537-2812; Mendes-da-Cruz, Daniella A/0000-0003-3697-1506; Terra-Granado, Eugenia/0000-0002-3616-140X; Zapata, Agustin G/0000-0003-0576-2672	Spanish Ministry of Education and Science [BFU 2007-65520, BFU 2010-18250]; Spanish Ministry of Health and Consumption [RD06/0010/0003]; CELLCAM-CM from the regional government of Madrid [S-BIO/0204/2006, GR74/910552/2007, S2010/BMD-2420]; Oswaldo Cruz Foundation (Fiocruz); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) of Brazil	Spanish Ministry of Education and Science(Spanish Government); Spanish Ministry of Health and Consumption(Spanish Government); CELLCAM-CM from the regional government of Madrid; Oswaldo Cruz Foundation (Fiocruz); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) of Brazil(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	This work was supported by grants BFU 2007-65520 and BFU 2010-18250 from the Spanish Ministry of Education and Science; RD06/0010/0003 from the Spanish Ministry of Health and Consumption; S-BIO/0204/2006, GR74/910552/2007, and S2010/BMD-2420 CELLCAM-CM from the regional government of Madrid; and also the Oswaldo Cruz Foundation (Fiocruz), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) of Brazil.	Aasheim HC, 2005, BLOOD, V105, P2869, DOI 10.1182/blood-2004-08-2981; Alfaro D, 2008, IMMUNOLOGY, V125, P131, DOI 10.1111/j.1365-2567.2008.02828.x; Alfaro D, 2007, EUR J IMMUNOL, V37, P2596, DOI 10.1002/eji.200737097; Alfaro D, 2011, IMMUNOL CELL BIOL, V89, P844, DOI 10.1038/icb.2010.172; Alonso LM, 2009, LEUKEMIA RES, V33, P395, DOI 10.1016/j.leukres.2008.08.010; Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Castellani V, 2002, CURR OPIN NEUROBIOL, V12, P532, DOI 10.1016/S0959-4388(02)00357-4; Cejalvo T., 2011, THESIS COMPLUTENSE U; Chan B, 2009, THROMB RES, V123, P745, DOI 10.1016/j.thromres.2008.07.010; Choi YI, 2008, IMMUNITY, V29, P888, DOI 10.1016/j.immuni.2008.10.008; Corbel C, 2007, DEV COMP IMMUNOL, V31, P1082, DOI 10.1016/j.dci.2007.01.009; de Saint-Vis B, 2003, BLOOD, V102, P4431, DOI 10.1182/blood-2003-02-0500; de Wit J, 2003, PROG NEUROBIOL, V71, P249, DOI 10.1016/j.pneurobio.2003.06.001; Drake PM, 2009, P NATL ACAD SCI USA, V106, P11995, DOI 10.1073/pnas.0905188106; Ehrlich LIR, 2009, IMMUNITY, V31, P986, DOI 10.1016/j.immuni.2009.09.020; Foster KE, 2010, P NATL ACAD SCI USA, V107, P13414, DOI 10.1073/pnas.1003747107; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Freywald A, 2006, J IMMUNOL, V176, P4066, DOI 10.4049/jimmunol.176.7.4066; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; Garcia F, 2012, J LEUKOCYTE BIOL, V91, P7, DOI 10.1189/jlb.0111031; Garcia-Ceca J, 2009, INT J DEV BIOL, V53, P971, DOI 10.1387/ijdb.082702jg; Geretti E, 2008, ANGIOGENESIS, V11, P31, DOI 10.1007/s10456-008-9097-1; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Gossens K, 2009, J EXP MED, V206, P761, DOI 10.1084/jem.20082502; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Ikegami R, 2004, DEV CELL, V6, P383, DOI 10.1016/S1534-5807(04)00057-7; Ivanov AI, 2006, IUBMB LIFE, V58, P389, DOI 10.1080/15216540600756004; Jenkinson WE, 2007, EUR J IMMUNOL, V37, P2090, DOI 10.1002/eji.200737212; Karjalainen K, 2011, BLOOD, V117, P920, DOI 10.1182/blood-2010-05-282921; Kawakami N, 1999, J IMMUNOL, V163, P3211; Khounlotham M, 2009, J INFECT DIS, V199, P1797, DOI 10.1086/599096; Kitamura T, 2008, AM J PHYSIOL-CELL PH, V294, pC189, DOI 10.1152/ajpcell.00314.2007; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Krueger A, 2010, BLOOD, V115, P1906, DOI 10.1182/blood-2009-07-235721; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Lackmann M, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.115re2; Lange C, 1998, GENOMICS, V51, P340, DOI 10.1006/geno.1998.5256; Le Borgne M, 2009, NAT IMMUNOL, V10, P823, DOI 10.1038/ni.1761; Lei Y, 2009, EUR J IMMUNOL, V39, P2695, DOI 10.1002/eji.200939630; Lepelletier Y, 2007, P NATL ACAD SCI USA, V104, P5545, DOI 10.1073/pnas.0700705104; Lin KT, 2008, J BIOL CHEM, V283, P28969, DOI 10.1074/jbc.M804401200; Liu CL, 2006, BLOOD, V108, P2531, DOI 10.1182/blood-2006-05-024190; Mendes-Da-Cruz DA, 2008, J IMMUNOL, V180, P4639, DOI 10.4049/jimmunol.180.7.4639; Mendes-da-Cruz DA, 2009, ANN NY ACAD SCI, V1153, P20, DOI 10.1111/j.1749-6632.2008.03980.x; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Milpied P, 2011, BLOOD, V118, P2993, DOI 10.1182/blood-2011-01-329268; Milpied P, 2009, EUR J IMMUNOL, V39, P1466, DOI 10.1002/eji.200839040; Mine T, 2000, TISSUE ANTIGENS, V55, P429, DOI 10.1034/j.1399-0039.2000.550505.x; Munoz JJ, 2002, J IMMUNOL, V169, P177, DOI 10.4049/jimmunol.169.1.177; Munoz JJ, 2009, INMUNOLOGIA, V28, P19, DOI [10.1016/S0213-9626(09)70024-1, DOI 10.1016/S0213-9626(09)70024-1]; Munoz JJ, 2006, J IMMUNOL, V177, P804, DOI 10.4049/jimmunol.177.2.804; Nakao F, 2007, GENETICS, V176, P1591, DOI 10.1534/genetics.106.067116; Naska S, 2010, MOL CELL NEUROSCI, V45, P108, DOI 10.1016/j.mcn.2010.05.015; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Odaka C, 2006, CELL TISSUE RES, V325, P13, DOI 10.1007/s00441-005-0139-3; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Poliakov A, 2008, J CELL BIOL, V183, P933, DOI 10.1083/jcb.200807151; Prevost N, 2005, P NATL ACAD SCI USA, V102, P9820, DOI 10.1073/pnas.0404065102; Prockop Susan E, 2004, Clin Dev Immunol, V11, P135, DOI 10.1080/10446670410001722212; Saran N, 2010, BLOOD, V115, P1137, DOI 10.1182/blood-2009-07-230821; Scimone ML, 2006, P NATL ACAD SCI USA, V103, P7006, DOI 10.1073/pnas.0602024103; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Sharfe N, 2008, MOL IMMUNOL, V45, P1208, DOI 10.1016/j.molimm.2007.09.019; Stimamiglio MA, 2010, J LEUKOCYTE BIOL, V88, P483, DOI 10.1189/jlb.0210079; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; Takahashi K, 2008, DEV DYNAM, V237, P1699, DOI 10.1002/dvdy.21556; Takamatsu H, 2012, TRENDS IMMUNOL, V33, P127, DOI 10.1016/j.it.2012.01.008; Trinidad EM, 2010, CELL ADHES MIGR, V4, P363, DOI 10.4161/cam.4.3.11586; Trinidad EM, 2009, BLOOD, V114, P5081, DOI 10.1182/blood-2009-03-210617; Vincent P, 2005, J IMMUNOL, V175, P7650, DOI 10.4049/jimmunol.175.11.7650; Wada K, 1996, CELL IMMUNOL, V170, P11, DOI 10.1006/cimm.1996.0128; Wang LH, 1997, J NEUROCHEM, V69, P2261; Witt CM, 2005, PLOS BIOL, V3, P1062, DOI 10.1371/journal.pbio.0030160; Yamada A, 1999, J IMMUNOL, V162, P4094; Yamamoto T, 2010, INT J RADIAT ONCOL, V77, P235, DOI 10.1016/j.ijrobp.2009.11.005; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211; Yuan L, 2002, DEVELOPMENT, V129, P4797; Zlotoff DA, 2010, BLOOD, V115, P1897, DOI 10.1182/blood-2009-08-237784	82	14	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4390	4399		10.1096/fj.11-202952	http://dx.doi.org/10.1096/fj.11-202952			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22815386				2022-12-28	WOS:000310574200003
J	Waltereit, R; Leimer, U; Halbach, OVU; Panke, J; Holter, SM; Garrett, L; Wittig, K; Schneider, M; Schmitt, C; Calzada-Wack, J; Neff, F; Becker, L; Prehn, C; Kutscherjawy, S; Endris, V; Bacon, C; Fuchs, H; Gailus-Durner, V; Berger, S; Schonig, K; Adamski, J; Klopstock, T; Esposito, I; Wurst, W; de Angelis, MH; Rappold, G; Wieland, T; Bartsch, D				Waltereit, Robert; Leimer, Uwe; Halbach, Oliver von Bohlen Und; Panke, Jutta; Hoelter, Sabine M.; Garrett, Lillian; Wittig, Karola; Schneider, Miriam; Schmitt, Camie; Calzada-Wack, Julia; Neff, Frauke; Becker, Lore; Prehn, Cornelia; Kutscherjawy, Sergej; Endris, Volker; Bacon, Claire; Fuchs, Helmut; Gailus-Durner, Valerie; Berger, Stefan; Schoenig, Kai; Adamski, Jerzy; Klopstock, Thomas; Esposito, Irene; Wurst, Wolfgang; de Angelis, Martin Hrabe; Rappold, Gudrun; Wieland, Thomas; Bartsch, Dusan			Srgap3(-/-) mice present a neurodevelopmental disorder with schizophrenia-related intermediate phenotypes	FASEB JOURNAL			English	Article						intellectual disability; hydrocephalus; knockout mouse; RHO proteins; polygenetic disease	NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; MEMORY; RAC; EXPRESSION; PATHOLOGY; SPINES; GENE; METAANALYSIS; MAINTENANCE	Mutations in the SRGAP3 gene residing on chromosome 3p25 have previously been associated with intellectual disability. Genome-wide association studies have also revealed SRGAP3, together with genes from the same cellular network, as risk genes for schizophrenia. SRGAP3 regulates cytoskeletal dynamics through the RHO protein RAC1. RHO proteins are known to be involved in cytoskeletal reorganization during brain development to control processes such as synaptic plasticity. To elucidate the importance of SRGAP3 in brain development, we generated Srgap3-knockout mice. Ten percent of these mice developed a hydrocephalus and died before adulthood. Surviving mice showed various neuroanatomical changes, including enlarged lateral ventricles, white matter tracts, and dendritic spines together with molecular changes, including an increased basal activity of RAC1. Srgap3(-/-) mice additionally exhibited a complex behavioral phenotype. Behavioral studies revealed an impaired spontaneous alternation and social behavior, while long-term memory was unchanged. The animals also had tics. Lower locomotor activity was observed in male Srgap3(-/-) only. Srgap3(-/-) mice showed increased methylphenidate stimulation in males and an impaired prepulse inhibition in females. Together, the results show neurodevelopmental aberration in Srgap3(-/-) mice, with many of the observed phenotypes matching several schizophrenia-related intermediate phenotypes. Mutations of SRGAP3 may thus contribute to various neurodevelopmental disorders.-Waltereit, R., Leimer, U., von Bohlen und Halbach, O., Panke, J., Holter, S. M., Garrett, L., Wittig, K., Schneider, M., Schmitt, C., Calzada-Wack, J., Neff, F., Becker, L., Prehn, C., Kutscherjawy, S., Endris, V., Bacon, C., Fuchs, H., Gailus-Durner, V., Berger, S., Schonig, K., Adamski, J., Klopstock, T., Esposito, I., Wurst, W., Hrabe. de Angelis, M., Rappold, G., Wieland, T., Bartsch, D. Srgap3(-/-) mice present a neurodevelopmental disorder with schizophrenia-related intermediate phenotypes. FASEB J. 26, 4418-4428 (2012). www.fasebj.org	[Waltereit, Robert] Heidelberg Univ, Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany; [Waltereit, Robert] Cent Inst Mental Hlth, Dept Psychiat, D-6800 Mannheim, Germany; [Schneider, Miriam] Cent Inst Mental Hlth, Inst Psychopharmacol, D-6800 Mannheim, Germany; [Wittig, Karola; Wieland, Thomas] Heidelberg Univ, Med Fac Mannheim, Inst Expt & Clin Pharmacol & Toxicol, D-68159 Mannheim, Germany; [Halbach, Oliver von Bohlen Und] Ernst Moritz Arndt Univ Greifswald, Inst Anat & Cell Biol, Greifswald, Germany; [Hoelter, Sabine M.; Garrett, Lillian] Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany; [Calzada-Wack, Julia; Neff, Frauke] Helmholtz Zentrum Munchen, Inst Pathol, Neuherberg, Germany; [Becker, Lore; Prehn, Cornelia; Fuchs, Helmut; Gailus-Durner, Valerie; Adamski, Jerzy; de Angelis, Martin Hrabe] Helmholtz Zentrum Munchen, Inst Expt Genet, German Mouse Clin, Neuherberg, Germany; [Becker, Lore; Klopstock, Thomas] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany; [Endris, Volker; Bacon, Claire; Rappold, Gudrun] Heidelberg Univ, Dept Human Mol Genet, Heidelberg, Germany; [Esposito, Irene] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Munich, Germany; [Wurst, Wolfgang] Max Planck Inst Psychiat, D-8000 Munich, Germany; [Wurst, Wolfgang] Deutsch Zentrum Neurodegenerat Erkrankungen, Munich, Germany; [Wurst, Wolfgang] Tech Univ Munich, Lehrstuhl Entwicklungsgenet, Freising Weihenstephan, Germany; [de Angelis, Martin Hrabe] Tech Univ Munich, Lehrstuhl Expt Genet, Freising Weihenstephan, Germany	Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Central Institute of Mental Health; Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Ernst Moritz Arndt Universitat Greifswald; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Ruprecht Karls University Heidelberg; Technical University of Munich; Max Planck Society; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Technical University of Munich; Technical University of Munich	Bartsch, D (corresponding author), Heidelberg Univ, Cent Inst Mental Hlth, Dept Mol Biol, J 5, D-68159 Mannheim, Germany.	dusan.bartsch@zi-mannheim.de	Wieland, Thomas/G-1772-2012; Wieland, Thomas/Q-1506-2019; Becker, Lore/AAJ-1203-2020; Becker, Lore/E-3717-2010; Fuchs, Helmut/M-7347-2014; von Bohlen und Halbach, Oliver/A-1060-2008; Hölter, Sabine M./N-5868-2014; de Angelis, Martin Hrabe/F-5531-2012; Cabrera, Mariel/GMX-2706-2022; von Bohlen und Halbach, Oliver/R-3464-2019; Gailus-Durner, Valerie/M-7337-2014	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Becker, Lore/0000-0002-6890-4984; Fuchs, Helmut/0000-0002-5143-2677; Hölter, Sabine M./0000-0003-4878-5241; de Angelis, Martin Hrabe/0000-0002-7898-2353; von Bohlen und Halbach, Oliver/0000-0002-6265-9156; Garrett, Lillian/0000-0003-4880-7076; Adamski, Jerzy/0000-0001-9259-0199; Wurst, Wolfgang/0000-0003-4422-7410; Prehn, Cornelia/0000-0002-1274-4715; Calzada, Julia/0000-0003-0816-9305; von Bohlen und Halbach, Oliver/0000-0002-2613-2517	EU [HEALTH-F2-2007-201714 DEVANX, LSHG-2006-037188]; Bundesministerium fur Bildung und Forschung (BMBF) Bernstein Center for Computational Neuroscience Heidelberg/Mannheim grant [01GQ1003A]; BMBF NGFN-Plus grant [01GS0851]; Deutsche Forshungsgemeinschaft [BO 1971/5-1]; BMBF NGFN-Plus [01GS0851, 01GS0850]	EU(European Commission); Bundesministerium fur Bildung und Forschung (BMBF) Bernstein Center for Computational Neuroscience Heidelberg/Mannheim grant(Federal Ministry of Education & Research (BMBF)); BMBF NGFN-Plus grant(Federal Ministry of Education & Research (BMBF)); Deutsche Forshungsgemeinschaft(German Research Foundation (DFG)); BMBF NGFN-Plus(Federal Ministry of Education & Research (BMBF))	The authors thank Drs. Birgit Rathkolb and Eckhard Wolf for the clinical chemistry screening and Drs. Jan Rozman and Martin Klingenspor for the energy metabolism screening; Dr. Vera Baier and Stefano Clementi for help with initial experiments; Lena Wendler, Ariana Frommig, Elke Hermann, Waltraut Stettinger, Albert Langer, Maria Kugler, Tamara Halex, Sabine Holthaus, Katrin Laube, Jacqueline Muller, Elenore Samson, Waldemar Schneider, and Lucie Thurmann for excellent technical support; and finally the Central Institute of Mental Health and German Mouse Clinic animal caretaker teams. The authors thank Dr. Beatrix Naton for excellent administrative support. The authors also thank the members of the German Mouse Clinic for comprehensive phenotyping of the Srgap3<SUP>-/-</SUP> mice and fruitful discussions. The work was supported by EU HEALTH-F2-2007-201714 DEVANX, Bundesministerium fur Bildung und Forschung (BMBF) Bernstein Center for Computational Neuroscience Heidelberg/Mannheim grant 01GQ1003A and BMBF NGFN-Plus grant 01GS0851 to D.B.; Deutsche Forshungsgemeinschaft grant BO 1971/5-1 to O.V.B.U.H; BMBF NGFN-Plus grants 01GS0850 to S.M.H, L.G., J.C.-W., F.N., C.P., J.A., I.E., H.F., V.G.-D., W.W. and M.H.D.A. and 01GS0851 to L.B. and T.K.; and EU grant LSHG-2006-037188 to the German Mouse Clinic.	Addington AM, 2009, CURR PSYCHIAT REP, V11, P156, DOI 10.1007/s11920-009-0024-y; Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Arguello PA, 2010, SCHIZOPHRENIA BULL, V36, P289, DOI 10.1093/schbul/sbp153; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Bacon C, 2009, J COMP NEUROL, V513, P224, DOI 10.1002/cne.21955; Benard V, 2002, METHOD ENZYMOL, V345, P349; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Blanpied TA, 2004, BIOL PSYCHIAT, V55, P1121, DOI 10.1016/j.biopsych.2003.10.006; Calabrese B, 2006, PHYSIOLOGY, V21, P38, DOI 10.1152/physiol.00042.2005; Carlisle HJ, 2005, TRENDS NEUROSCI, V28, P182, DOI 10.1016/j.tins.2005.01.008; Carlson BR, 2011, J NEUROSCI, V31, P2447, DOI 10.1523/JNEUROSCI.4433-10.2011; Chen L, 2007, J NEUROSCI, V27, P3884, DOI 10.1523/JNEUROSCI.3509-06.2007; Chen YJJ, 2008, J NEUROSCI, V28, P6872, DOI 10.1523/JNEUROSCI.1815-08.2008; Cook EH, 2008, NATURE, V455, P919, DOI 10.1038/nature07458; Deussing JM, 2010, J NEUROSCI, V30, P9103, DOI 10.1523/JNEUROSCI.1049-10.2010; Endris V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/pnas.162241099; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; Gailus-Durner V, 2005, NAT METHODS, V2, P403, DOI 10.1038/nmeth0605-403; Gailus-Durner Valerie, 2009, V530, P463, DOI 10.1007/978-1-59745-471-1_25; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Guilmatre A, 2009, ARCH GEN PSYCHIAT, V66, P947, DOI 10.1001/archgenpsychiatry.2009.80; Halpain S, 2005, PROG BRAIN RES, V147, P29, DOI 10.1016/S0079-6123(04)47003-4; Hamdan FF, 2009, ARCH NEUROL-CHICAGO, V66, P675, DOI 10.1001/archneurol.2009.65; Hayashi-Takagi A, 2010, NAT NEUROSCI, V13, P327, DOI 10.1038/nn.2487; Joyner AL, 2000, GENE TARGETING PRACT; Kassai H, 2008, EUR J NEUROSCI, V28, P257, DOI 10.1111/j.1460-9568.2008.06343.x; Ko YH, 2007, PSYCHONEUROENDOCRINO, V32, P385, DOI 10.1016/j.psyneuen.2007.02.002; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Lewis CM, 2003, AM J HUM GENET, V73, P34, DOI 10.1086/376549; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Mata I, 2009, BIOL PSYCHIAT, V65, P535, DOI 10.1016/j.biopsych.2008.10.020; Mitchell KJ, 2010, CURR OPIN NEUROBIOL, V21, P1; Mohl M, 2006, N-S ARCH PHARMACOL, V373, P333, DOI 10.1007/s00210-006-0083-0; Morrow EM, 2010, J AM ACAD CHILD PSY, V49, P1091, DOI 10.1016/j.jaac.2010.08.009; MOWREY PN, 1993, AM J MED GENET, V46, P623, DOI 10.1002/ajmg.1320460604; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI 10.1038/nn.2647; O'Tuathaigh CMP, 2010, SCHIZOPHRENIA BULL, V36, P271, DOI 10.1093/schbul/sbp125; Oh D, 2010, J NEUROSCI, V30, P14134, DOI 10.1523/JNEUROSCI.1711-10.2010; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Ramakers GJA, 2000, AM J MED GENET, V94, P367, DOI 10.1002/1096-8628(20001023)94:5<367::AID-AJMG4>3.0.CO;2-I; Ramakers GJA, 2002, TRENDS NEUROSCI, V25, P191, DOI 10.1016/S0166-2236(00)02118-4; Ramon-Moliner E, 1970, GOLGI COX TECHNIQUE; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Schneider I, 2006, J NEUROSCI METH, V157, P82, DOI 10.1016/j.jneumeth.2006.04.002; Schneider M, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-105; SCHURR PH, 1953, J NEUROSURG, V10, P515, DOI 10.3171/jns.1953.10.5.0515; Schwartz M, 2004, J CELL SCI, V117, P5457, DOI 10.1242/jcs.01582; Sebat J, 2009, TRENDS GENET, V25, P528, DOI 10.1016/j.tig.2009.10.004; Shen SB, 2008, J NEUROSCI, V28, P10893, DOI 10.1523/JNEUROSCI.3299-08.2008; Shprecher D, 2009, MOVEMENT DISORD, V24, P15, DOI 10.1002/mds.22378; Shuib S, 2009, AM J MED GENET A, V149A, P2099, DOI 10.1002/ajmg.a.32824; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Steen RG, 2006, BRIT J PSYCHIAT, V188, P510, DOI 10.1192/bjp.188.6.510; Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229; Sweatt JD, 2003, MECH MEMORY; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Van Aelst L, 2004, CURR OPIN NEUROBIOL, V14, P297, DOI 10.1016/j.conb.2004.05.012; van den Buuse M, 2010, SCHIZOPHRENIA BULL, V36, P246, DOI 10.1093/schbul/sbp132; van Spronsen M, 2010, CURR NEUROL NEUROSCI, V10, P207, DOI 10.1007/s11910-010-0104-8; von Bohlen und Halbach O, 2008, NEUROBIOL AGING, V29, P1247, DOI 10.1016/j.neurobiolaging.2007.02.028; von Bohlen und Halbach O, 2006, J NEUROSCI RES, V83, P525, DOI 10.1002/jnr.20759; Waltereit R, 2006, J NEUROCHEM, V96, P407, DOI 10.1111/j.1471-4159.2005.03538.x; Waltereit R, 2008, GENE EXPR PATTERNS, V8, P307, DOI 10.1016/j.gep.2008.01.006; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Zhang J, 2006, J NEUROL, V253, P1255, DOI 10.1007/s00415-006-0245-5	68	35	35	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4418	4428		10.1096/fj.11-202317	http://dx.doi.org/10.1096/fj.11-202317			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22820399				2022-12-28	WOS:000310574200006
J	Wiemuth, D; Sahin, H; Falkenburger, BH; Lefevre, CMT; Wasmuth, HE; Grunder, S				Wiemuth, Dominik; Sahin, Hacer; Falkenburger, Bjoern H.; Lefevre, Catherine M. T.; Wasmuth, Hermann E.; Gruender, Stefan			BASIC-a bile acid-sensitive ion channel highly expressed in bile ducts	FASEB JOURNAL			English	Article						BLINaC; cholangiocyte; ENaC	3 HOMOLOGOUS SUBUNITS; NA+ CHANNEL; LARGE-CONDUCTANCE; FUNCTIONAL EXPRESSION; SODIUM-CHANNEL; K+ CHANNELS; INTESTINE; CLONING; CELLS; RAT	Brain liver intestine Na+ channel (BLINaC) is an ion channel of the DEG/ENaC gene family of unknown function. BLINaC from rats (rBLINaC) and humans (INaC) is inactive at rest, and its mode of activation has remained unclear. Here, we show that the BLINaC protein localizes to cholangiocytes, epithelial cells that line bile ducts. Moreover, we provide evidence that rBLINaC and INaC are robustly activated by bile acids, in particular chenodeoxycholic acid and hyodeoxycholic acid (EC50 =2.1 +/- 0.05 mM). Thus, BLINaC appears to be an epithelial cation channel of bile ducts sensitive to physiological concentrations of bile acids. BLINaC is related to acid-sensing ion channels (ASICs) and to the epithelial Na+ channel (ENaC) and shares ligand activation with ASICs and epithelial localization with ENaC. Therefore, based on the close homology of BLINaC to ASICs and its activation by bile acids, we propose to rename BLINaC bile acid-sensitive ion channel (BASIC).-Wiemuth, D., Sahin, H., Falkenburger, B. H., Lefevre, C. M. T., Wasmuth, H. E., Grunder, S. BASIC-a bile acid-sensitive ion channel highly expressed in bile ducts. FASEB J. 26, 4122-4130 (2012). www.fasebj.org	[Wiemuth, Dominik; Lefevre, Catherine M. T.; Gruender, Stefan] Rhein Westfal TH Aachen, Dept Physiol, D-52074 Aachen, Germany; [Sahin, Hacer; Wasmuth, Hermann E.] Rhein Westfal TH Aachen, Dept Med 3, D-52074 Aachen, Germany; [Falkenburger, Bjoern H.] Rhein Westfal TH Aachen, Dept Neurol, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University	Wiemuth, D (corresponding author), Rhein Westfal TH Aachen, Dept Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.	dwiemuth@ukaachen.de; sgruender@ukaachen.de	Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Falkenburger, Bjoern/0000-0002-2387-526X	START program of the Faculty of Medicine of Rheinisch-Westfaelische Technische Hochschule (RWTH) Aachen University; Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at RWTH Aachen University [N5-1, N6]; Deutsche Forschungsgemeinschaft [WA 2557/2-1, SFB-TRR57]; Else Kroner-Fresenius-Stiftung	START program of the Faculty of Medicine of Rheinisch-Westfaelische Technische Hochschule (RWTH) Aachen University; Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at RWTH Aachen University; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else Kroner-Fresenius-Stiftung	The authors thank H. Kalbacher for helpful discussions, M. Pusch for comments on the manuscript, and A. Oslender-Bujotzek, S. Lenz, and S. Hamm for expert technical assistance. This project was supported by the START program of the Faculty of Medicine of Rheinisch-Westfaelische Technische Hochschule (RWTH) Aachen University (D.W.). B.H.F. and S.G. are supported by a grant from the Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at RWTH Aachen University (projects N5-1 and N6); H.E.W. is supported by the Deutsche Forschungsgemeinschaft (WA 2557/2-1, SFB-TRR57) and the Else Kroner-Fresenius-Stiftung.	Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Bukiya AN, 2007, MOL PHARMACOL, V72, P359, DOI 10.1124/mol.107.034330; Bukiya AN, 2011, P NATL ACAD SCI USA, V108, P20207, DOI 10.1073/pnas.1112901108; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; COHN JA, 1993, GASTROENTEROLOGY, V105, P1857, DOI 10.1016/0016-5085(93)91085-V; Dopico AM, 2002, J GEN PHYSIOL, V119, P251, DOI 10.1085/jgp.119.3.251; Durrnagel S, 2010, J BIOL CHEM, V285, P11958, DOI 10.1074/jbc.M109.059998; FISHER MM, 1973, CAN MED ASSOC J, V109, P190; Golubovic A, 2007, J BIOL CHEM, V282, P35098, DOI 10.1074/jbc.M706849200; Grunder S, 2000, NEUROREPORT, V11, P1607; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Grunder Stefan, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P73; HASLEWOOD GA, 1971, BIOCHEM J, V123, P15, DOI 10.1042/bj1230015; Hofmann AF, 2008, CELL MOL LIFE SCI, V65, P2461, DOI 10.1007/s00018-008-7568-6; Hofmann AF, 2009, HEPATOLOGY, V49, P1403, DOI 10.1002/hep.22789; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; PAUMGART.G, 1971, N-S ARCH PHARMAKOL, V270, P98, DOI 10.1007/BF00997305; Qiao X, 2011, J CHROMATOGR A, V1218, P107, DOI 10.1016/j.chroma.2010.10.116; Sakai H, 1999, J PHYSIOL-LONDON, V519, P323, DOI 10.1111/j.1469-7793.1999.0323m.x; SAKAKURA H, 1993, J CHROMATOGR-BIOMED, V621, P123, DOI 10.1016/0378-4347(93)80087-K; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Springauf A, 2010, J PHYSIOL-LONDON, V588, P809, DOI 10.1113/jphysiol.2009.182931; Talalay P., 1963, ENZYMES, V7, P177; Voronina SG, 2005, J BIOL CHEM, V280, P1764, DOI 10.1074/jbc.M410230200; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wiemuth D, 2011, MOL PHARMACOL, V80, P911, DOI 10.1124/mol.111.073726; Wiemuth D, 2010, J BIOL CHEM, V285, P30404, DOI 10.1074/jbc.M110.153064	31	31	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4122	4130		10.1096/fj.12-207043	http://dx.doi.org/10.1096/fj.12-207043			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22735174				2022-12-28	WOS:000309704000019
J	Guo, BY; Chatterjee, S; Li, LF; Kim, JM; Lee, J; Yechoor, VK; Minze, LJ; Hsueh, W; Ma, K				Guo, Bingyan; Chatterjee, Somik; Li, Lifei; Kim, Ji M.; Lee, Jeongkyung; Yechoor, Vijay K.; Minze, Laurie J.; Hsueh, Willa; Ma, Ke			The clock gene, brain and muscle Arnt-like 1, regulates adipogenesis via Wnt signaling pathway	FASEB JOURNAL			English	Article						circadian rhythm; adipocyte development; obesity	MOLECULAR CLOCK; ADIPOCYTE; RECEPTOR; TRANSCRIPTION; COMPONENT; CATENIN; BMAL1; SUSCEPTIBILITY; ACTIVATION; EXPRESSION	Circadian clocks in adipose tissue are known to regulate adipocyte biology. Although circadian dysregulation is associated with development of obesity, the underlying mechanism has not been established. Here we report that disruption of the clock gene, brain and muscle Arnt-like 1 (Bmall), in mice led to increased adipogenesis, adipocyte hypertrophy, and obesity, compared to wild-type (WT) mice. This is due to its cell-autonomous effect, as Bmall deficiency in embryonic fibroblasts, as well as stable shRNA knockdown (KD) in 3T3-L1 preadipocyte and C3H10T1/2 mesenchymal stem cells, promoted adipogenic differentiation. We demonstrate that attenuation of Bmall function resulted in down-regulation of genes in the canonical Wnt pathway, known to suppress adipogenesis. Promoters of these genes (Wnt10a, beta-catenin, Dishevelled2, TCF3) displayed Bmall occupancy, indicating direct circadian regulation by Bmall. As a result, Wnt signaling activity was attenuated by Bmall KD and augmented by its overexpression. Furthermore, stabilizing beta-catenin through Wnt ligand or GSK-3 beta inhibition achieved partial restoration of blunted Wnt activity and suppression of increased adipogenesis induced by Bmall KD. Taken together, our study demonstrates that Bmall is a critical negative regulator of adipocyte development through transcriptional control of components of the canonical Wnt signaling cascade, and provides a mechanistic link between circadian disruption and obesity.-Guo, B., Chatterjee, S., Li, L., Kim, J. M., Lee, J., Yechoor, V. K., Minze, L. J., Hsueh, W., Ma, K. The clock gene, brain and muscle Arnt-like 1, regulates adipogenesis via Wnt signaling pathway. FASEB J. 26, 3453-3463 (2012). www.fasebj.org	[Guo, Bingyan; Chatterjee, Somik; Li, Lifei; Kim, Ji M.; Minze, Laurie J.; Hsueh, Willa; Ma, Ke] Methodist Hosp, Ctr Diabet Res, Dept Med, Res Inst, Houston, TX 77030 USA; [Guo, Bingyan] Hebei Med Univ, Affiliated Hosp 2, Dept Cardiovasc Med, Shijiazhuang, Hebei, Peoples R China; [Lee, Jeongkyung; Yechoor, Vijay K.] Baylor Coll Med, Dept Med, Diabet & Endocrinol Res Ctr, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston; Hebei Medical University; Baylor College of Medicine	Ma, K (corresponding author), Methodist Hosp, Ctr Diabet Res, Dept Med, Res Inst, Houston, TX 77030 USA.	kma@tmhs.org	Chatterjee, Somik/P-1581-2016; Yechoor, Vijay/AAX-3244-2021	Chatterjee, Somik/0000-0001-6869-4019; 	The Methodist Hospital Research Institute (TMHRI); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK089061] Funding Source: NIH RePORTER	The Methodist Hospital Research Institute (TMHRI); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank The Methodist Hospital Research Institute (TMHRI) for funding support and the Center for Diabetes Research for technical assistance. The authors also thank Dr. David D. Moore (Baylor College of Medicine, Houston, TX, USA) and Dr. Tuo Deng (TMHRI, Houston, TX, USA) for insightful discussions and for reagents.	Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bass J., SCIENCE NEW YORK, V330, P1349; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bowers RR, 2008, CELL CYCLE, V7, P1191, DOI 10.4161/cc.7.9.5815; Bowers RR, 2007, CELL CYCLE, V6, P385, DOI 10.4161/cc.6.4.3804; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Chalmers JA, 2008, AM J PHYSIOL-REG I, V295, pR1529, DOI 10.1152/ajpregu.90572.2008; Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743; Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gachon F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015; Gavrila A, 2003, J CLIN ENDOCR METAB, V88, P2838, DOI 10.1210/jc.2002-021721; Gimble JM, 2011, CURR OPIN CLIN NUTR, V14, P554, DOI 10.1097/MCO.0b013e32834ad94b; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Grimaldi B, 2010, CELL METAB, V12, P509, DOI 10.1016/j.cmet.2010.10.005; Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007; Janich P, 2011, NATURE, V480, P209, DOI 10.1038/nature10649; Jefcoate Colin R., 2008, V456, P173, DOI 10.1007/978-1-59745-245-8_13; Kalsbeek A, 2001, ENDOCRINOLOGY, V142, P2677, DOI 10.1210/en.142.6.2677; Karatsoreos IN, 2011, P NATL ACAD SCI USA, V108, P1657, DOI 10.1073/pnas.1018375108; Kawai M, 2007, BIOCHEM BIOPH RES CO, V363, P276, DOI 10.1016/j.bbrc.2007.08.088; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Ma K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006843; Otway DT, 2009, CHRONOBIOL INT, V26, P1340, DOI 10.3109/07420520903412368; Pan A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001141; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Parkes KR, 2002, SCAND J WORK ENV HEA, V28, P64, DOI 10.5271/sjweh.648; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rey G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000595; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; Shimba S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025231; Sookoian S, 2008, AM J CLIN NUTR, V87, P1606, DOI 10.1093/ajcn/87.6.1606; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang J, 2008, MOL CELL BIOL, V28, P2213, DOI 10.1128/MCB.01608-07; Woon PY, 2007, P NATL ACAD SCI USA, V104, P14412, DOI 10.1073/pnas.0703247104; Wu XY, 2007, OBESITY, V15, P2560, DOI 10.1038/oby.2007.308; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	47	113	116	5	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3453	3463		10.1096/fj.12-205781	http://dx.doi.org/10.1096/fj.12-205781			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22611086	Green Published			2022-12-28	WOS:000307162800032
J	Heinis, M; Soggia, A; Bechetoille, C; Simon, MT; Peyssonnaux, C; Rustin, P; Scharfmann, R; Duvillie, B				Heinis, Mylene; Soggia, Andrea; Bechetoille, Camille; Simon, Marie-Therese; Peyssonnaux, Carole; Rustin, Pierre; Scharfmann, Raphael; Duvillie, Bertrand			HIF1 alpha and pancreatic beta-cell development	FASEB JOURNAL			English	Article						oxygen tension; pVHL; pancreas; development	LINDAU TUMOR-SUPPRESSOR; OXYGEN-TENSION; EMBRYONIC-DEVELOPMENT; HYPOXIC RESPONSE; IN-VITRO; DIFFERENTIATION; MESENCHYME; ENDOCRINE; HIF-1-ALPHA; METABOLISM	During early embryogenesis, the pancreas shows a paucity of blood flow, and oxygen tension, the partial pressure of oxygen (pO(2)), is low. Later, the blood flow increases as beta-cell differentiation occurs. We have previously reported that pO(2) controls beta-cell development in rats. Here, we checked that hypoxia inducible factor 1 alpha (HIF1 alpha) is essential for this control. First, we demonstrated that the effect of pO(2) on beta-cell differentiation in vitro was independent of epitheliomesenchymal interactions and that neither oxidative nor energetic stress occurred. Second, the effect of pO(2) on pancreas development was shown to be conserved among species, since increasing pO(2) to 21 vs. 3% also induced beta-cell differentiation in mouse (7-fold, P<0.001) and human fetal pancreas. Third, the effect of hypoxia was mediated by HIF1 alpha, since the addition of an HIF1 alpha inhibitor at 3% O-2 increased the number of NGN3-expressing progenitors as compared to nontreated controls (9.2-fold, P<0.001). In contrast, when we stabilized HIF1 alpha by deleting ex vivo the gene encoding pVHL in E13.5 pancreas from Vhl floxed mice, Ngn3 expression and beta-cell development decreased in such Vhl-deleted pancreas compared to controls (2.5 fold, P<0.05, and 6.6-fold, P<0.001, respectively). Taken together, these data demonstrate that HIF1 alpha exerts a negative control over beta-cell differentiation.-Heinis, M., Soggia, A., Bechetoille, C., Simon, M.-T., Peyssonnaux, C., Rustin, P., Scharfmann, R., Duvillie, B. HIF1 alpha and pancreatic beta-cell development. FASEB J. 26, 2734-2742 (2012). www.fasebj.org	[Heinis, Mylene; Soggia, Andrea; Bechetoille, Camille; Simon, Marie-Therese; Scharfmann, Raphael; Duvillie, Bertrand] Univ Paris 05, INSERM, Fac Med, Res Ctr Growth & Signalling,U845, Paris, France; [Peyssonnaux, Carole] Univ Paris 05, Ctr Natl Rech Sci, Inst Cochin, Unite Mixte Rech UMR 8104, Paris, France; [Peyssonnaux, Carole] INSERM, U1016, F-75015 Paris, France; [Rustin, Pierre] INSERM, U676, F-75015 Paris, France; [Rustin, Pierre] Univ Paris 07, Fac Med Denis Diderot, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Duvillie, B (corresponding author), INSERM, Fac Necker, U845, 156 Rue Vaugirard, F-75015 Paris, France.	bertrand.duvillie@inserm.fr	scharfmann, raphael/L-3296-2017; Peyssonnaux, Carole/GLU-5786-2022; Duvillie, Bertrand/N-4343-2018; Peyssonnaux, Carole/L-4057-2017	Peyssonnaux, Carole/0000-0002-1392-8225; Duvillie, Bertrand/0000-0003-0551-8100; Scharfmann, Raphael/0000-0001-7619-337X	French Ministry of Research and Technology; U.S. National Institutes of Health beta-Cell Biology Consortium; 6th European Union Framework Program beta-Cell Therapy Integrated Project; bilateral program Bundesministerium fur Bildung und Forschung L'Agence Nationale de la Recherche; European Foundation; Societe Francophone du Diabete/Association Francaise des Diabetiques	French Ministry of Research and Technology; U.S. National Institutes of Health beta-Cell Biology Consortium; 6th European Union Framework Program beta-Cell Therapy Integrated Project; bilateral program Bundesministerium fur Bildung und Forschung L'Agence Nationale de la Recherche(French National Research Agency (ANR)); European Foundation(European Science Foundation (ESF)); Societe Francophone du Diabete/Association Francaise des Diabetiques	The authors thank Genethon (Evry, France) for providing Ade-GFP-Cre ref.pG3.42155 and Dr. Sylvie Fabrega for the virus amplification. The authors thank Dr. Susan Saint-Just for correcting the English of the manuscript. M. H. and A. S. received support from the French Ministry of Research and Technology. This study received support from the U.S. National Institutes of Health beta-Cell Biology Consortium, the 6th European Union Framework Program beta-Cell Therapy Integrated Project, the bilateral program Bundesministerium fur Bildung und Forschung L'Agence Nationale de la Recherche, European Foundation for the Study of Diabetes/NovoNordisk/Juvenile Diabetes Research Foundation, and Societe Francophone du Diabete/Association Francaise des Diabetiques. Author contributions: M. H. performed research and analyzed data; A. S., C. B., and M.-T.S., performed research; C. P. provided the transgenic mice and proofread the manuscript; P. R. performed research and proofread the manuscript; R. S. designed research and corrected the manuscript; B. D. designed and performed research, analyzed data, and wrote the manuscript.	Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Attali M, 2007, DIABETES, V56, P1248, DOI 10.2337/db06-1307; Benit P, 2006, CLIN CHIM ACTA, V374, P81, DOI 10.1016/j.cca.2006.05.034; Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038-9047.2004; Boutin AT, 2008, CELL, V133, P223, DOI 10.1016/j.cell.2008.02.038; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Cantley J., DIABETES OBES METAB, V12, P159; Cantley J, 2009, J CLIN INVEST, V119, P125, DOI 10.1172/JCI26934; Cejudo-Martin P, 2005, DEV CELL, V9, P575, DOI 10.1016/j.devcel.2005.10.001; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Cheng K, 2010, J CLIN INVEST, V120, P2171, DOI 10.1172/JCI35846; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Duvillie B, 2006, DIABETES, V55, P582, DOI 10.2337/diabetes.55.03.06.db05-0839; Fraker CA, 2007, STEM CELLS, V25, P3155, DOI 10.1634/stemcells.2007-0445; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; GOLOSOW N, 1962, DEV BIOL, V4, P242, DOI 10.1016/0012-1606(62)90042-8; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Guillemain G, 2007, J BIOL CHEM, V282, P15228, DOI 10.1074/jbc.M610986200; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Heinis M, 2010, HORM RES PAEDIAT, V74, P77, DOI 10.1159/000314894; Heinis M, 2010, DIABETES, V59, P662, DOI 10.2337/db09-0891; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li C, 2011, J CELL PHYSIOL, V226, P2429, DOI 10.1002/jcp.22591; Lin Q, 2006, J BIOL CHEM, V281, P30678, DOI 10.1074/jbc.C600120200; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miralles F, 1999, DEV DYNAM, V214, P116, DOI 10.1002/(SICI)1097-0177(199902)214:2<116::AID-AJA2>3.0.CO;2-M; Miralles F, 1998, DEVELOPMENT, V125, P1017; Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023; Puri S, 2009, DIABETES, V58, P433, DOI 10.2337/db08-0749; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; Scharfmann R, 2000, DIABETOLOGIA, V43, P1083, DOI 10.1007/s001250051498; Schipani E, 2001, GENE DEV, V15, P2865; Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949; Shah SR, 2011, DEV BIOL, V349, P342, DOI 10.1016/j.ydbio.2010.10.033; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; YOCHIM JM, 1968, ENDOCRINOLOGY, V83, P706, DOI 10.1210/endo-83-4-706; Zehetner J, 2008, GENE DEV, V22, P3135, DOI 10.1101/gad.496908	47	13	14	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2734	2742		10.1096/fj.11-199224	http://dx.doi.org/10.1096/fj.11-199224			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22426121	Green Published			2022-12-28	WOS:000305912500003
J	Romaniuk, MA; Croci, DO; Lapponi, MJ; Tribulatti, MV; Negrotto, S; Poirier, F; Campetella, O; Rabinovich, GA; Schattner, M				Romaniuk, Maria A.; Croci, Diego O.; Lapponi, Maria J.; Tribulatti, Maria V.; Negrotto, Soledad; Poirier, Francoise; Campetella, Oscar; Rabinovich, Gabriel A.; Schattner, Mirta			Binding of galectin-1 to alpha(IIb)beta(3) integrin triggers "outside-in" signals, stimulates platelet activation, and controls primary hemostasis	FASEB JOURNAL			English	Article						inflammation; glycobiology	TYROSINE PHOSPHORYLATION; PROTEIN; CELLS; INFLAMMATION; AGGREGATION; PATHWAY; LECTIN	Understanding noncanonical mechanisms of platelet activation represents an important challenge for the identification of novel therapeutic targets in bleeding disorders, thrombosis, and cancer. We previously reported that galectin-1 (Gal-1), a beta-galactoside-binding protein, triggers platelet activation in vitro. Here we investigated the molecular mechanisms underlying this function and the physiological relevance of endogenous Gal-1 in hemostasis. Mass spectrometry analysis, as well as studies using blocking antibodies against the anti-alpha(IIb) subunit of alpha(IIb)beta(3) integrin or platelets from patients with Glanzmann's thrombasthenia syndrome (alpha(IIb)beta(3) deficiency), identified this integrin as a functional Gal-1 receptor in platelets. Binding of Gal-1 to platelets triggered the phosphorylation of beta(3)-integrin, Syk, MAPKs, PI3K, PLC gamma 2, thromboxane (TXA(2)) release, and Ca2+ mobilization. Not only soluble but also immobilized Gal-1 promoted platelet activation. Gal-1-deficient (Lgals1(-/-)) mice showed increased bleeding time (P<0.0002, knockout vs. wild type), which was not associated with an abnormal platelet count. Lgals1(-/-) platelets exhibited normal aggregation to PAR4, ADP, arachidonic acid, or collagen but abnormal ATP release at low collagen concentrations. Impaired spreading on fibrinogen and clot retraction with normal levels of alpha(IIb)beta(3) was also observed in Lgals1(-/-) platelets, indicating a failure in the "outside-in" signaling through this integrin. This study identifies a noncanonical mechanism, based on galectin-integrin interactions, for regulating platelet activation.-Romaniuk, M. A., Croci, D. O., Lapponi, M. J., Tribulatti, M. V., Negrotto, S., Poirier, F., Campetella, O., Rabinovich, G. A., Schattner, M. Binding of galectin-1 to alpha(IIb)beta(3) integrin triggers "outside-in" signals, stimulates platelet activation, and controls primary hemostasis. FASEB J. 26, 2788-2798 (2012). www.fasebj.org	[Croci, Diego O.; Rabinovich, Gabriel A.] Natl Univ San Martin, Consejo Nacl Invest Cient & Tecn CONICET, Inst Biol & Expt Med IBYME, Immunopathol Lab, Buenos Aires, DF, Argentina; [Romaniuk, Maria A.; Lapponi, Maria J.; Negrotto, Soledad; Schattner, Mirta] Natl Univ San Martin, Consejo Nacl Invest Cient & Tecn CONICET, Natl Acad Med, Lab Expt Thrombosis,Inst Expt Med IMEX, Buenos Aires, DF, Argentina; [Lapponi, Maria J.; Campetella, Oscar] Natl Univ San Martin, Consejo Nacl Invest Cient & Tecn CONICET, Inst Biotechnol Invest, Inst Technol Chascomus, Buenos Aires, DF, Argentina; [Poirier, Francoise] Paris Diderot Univ, Inst Jacques Monod, CNRS, UMR 7592, Paris, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Buenos Aires National Academy of Medicine; IMEX - Instituto de Medicina Experimental; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Rabinovich, GA (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	gabriel.r@ibyme.conicet.gov.ar; mschattner@hematologia.anm.edu.ar	Croci, Diego/AAJ-5709-2021	Croci, Diego/0000-0002-8623-0645; Campetella, Oscar/0000-0002-7018-375X; Tribulatti, Maria Virginia/0000-0003-0507-065X	Argentinean National Agency for Science and Technology [PICTs 1990, 0369, 870]; Aniara; University of Buenos Aires; Mizutani Foundation for Glycoscience; National Multiple Sclerosis Society; Sales Foundation	Argentinean National Agency for Science and Technology; Aniara; University of Buenos Aires(University of Buenos Aires); Mizutani Foundation for Glycoscience; National Multiple Sclerosis Society(National Multiple Sclerosis Society); Sales Foundation	The authors thank Juan Stupirsky and Claudia Gatto for technical support. This work was supported by grants from the Argentinean National Agency for Science and Technology (PICTs 1990, 0369 and 870 to M. S., O.C. and G. A. R., respectively) and grants from Aniara (to M. S.), the University of Buenos Aires (to G. A. R.), the Mizutani Foundation for Glycoscience (to G. A. R.), the National Multiple Sclerosis Society (to G. A. R.), and the Sales Foundation (to G. A. R). Author contributions: M. A. R. performed the experiments, analyzed data, and wrote the paper; D.O.C., M.J.L., and S.N. contributed to production of recombinant Gal-1 and performed animal studies; M. V. T. contributed to mass spectrometry experiments; F. P. provided Lgals1 <SUP>/</SUP> mice and intellectual insights; O.C. critically reviewed the manuscript; G. A. R. and M. S. designed the experiments, analyzed data, and wrote the paper.	Abrams CS, 2005, CURR OPIN HEMATOL, V12, P401, DOI 10.1097/01.moh.0000176681.18710.e3; Al-Ansari S, 2009, TRENDS CARDIOVAS MED, V19, P164, DOI 10.1016/j.tcm.2009.10.001; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; BRASS LF, 1986, J BIOL CHEM, V261, P6838; Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; Chellan B, 2007, EXP MOL PATHOL, V83, P399, DOI 10.1016/j.yexmp.2007.04.004; Coller BS, 2008, BLOOD, V112, P3011, DOI 10.1182/blood-2008-06-077891; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Dhirapong A, 2009, AUTOIMMUN REV, V8, P360, DOI 10.1016/j.autrev.2008.11.009; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Goschnick MW, 2006, BLOOD, V108, P1911, DOI 10.1182/blood-2006-02-004267; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HUANG EM, 1981, BLOOD, V57, P685; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Jones CI, 2009, FEBS LETT, V583, P3618, DOI 10.1016/j.febslet.2009.10.037; Jurk K, 2005, SEMIN THROMB HEMOST, V31, P381, DOI 10.1055/s-2005-916671; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Lemkes BA, 2010, J THROMB HAEMOST, V8, P1663, DOI 10.1111/j.1538-7836.2010.03910.x; LEVYTOLEDANO S, 1982, BLOOD, V59, P1078; Li ZY, 2010, ARTERIOSCL THROM VAS, V30, P2341, DOI 10.1161/ATVBAHA.110.207522; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Liu XJ, 2009, J PROTEOME RES, V8, P1255, DOI 10.1021/pr800850a; Ma YQ, 2007, J THROMB HAEMOST, V5, P1345, DOI 10.1111/j.1538-7836.2007.02537.x; Malaver E, 2009, J THROMB HAEMOST, V7, P1333, DOI 10.1111/j.1538-7836.2009.03492.x; Malik RKJ, 2009, GLYCOBIOLOGY, V19, P1402, DOI 10.1093/glycob/cwp077; Moiseeva EP, 2000, CARDIOVASC RES, V45, P493, DOI 10.1016/S0008-6363(99)00276-X; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pacienza N, 2008, FASEB J, V22, P1113, DOI 10.1096/fj.07-9524com; Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785; Payrastre B, 2000, BIOCHEM PHARMACOL, V60, P1069, DOI 10.1016/S0006-2952(00)00417-2; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Prasad KSS, 2003, P NATL ACAD SCI USA, V100, P12367, DOI 10.1073/pnas.2032886100; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Romaniuk M. A., BIOCH J, V432, P535; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Ten Cate H, 2007, PATHOPHYSIOL HAEMO T, V36, P122, DOI 10.1159/000175150; Thijssen VL, 2008, AM J PATHOL, V172, P545, DOI 10.2353/ajpath.2008.070938; Torti M, 1999, THROMB HAEMOSTASIS, V81, P124; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Varga-Szabo D, 2009, J THROMB HAEMOST, V7, P1057, DOI 10.1111/j.1538-7836.2009.03455.x; Wagner DD, 2005, ARTERIOSCL THROM VAS, V25, P1321, DOI 10.1161/01.ATV.0000166521.90532.44; Watanabe M, 2011, ONCOL REP, V25, P1217, DOI 10.3892/or.2011.1198; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719	48	30	30	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2788	2798		10.1096/fj.11-197541	http://dx.doi.org/10.1096/fj.11-197541			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22456341				2022-12-28	WOS:000305912500008
J	Schyr, RBH; Shabtai, Y; Shashikant, CS; Fainsod, A				Schyr, Rachel Ben-Haroush; Shabtai, Yehuda; Shashikant, Cooduvalli S.; Fainsod, Abraham			Cdx1 is essential for the initiation of HoxC8 expression during early embryogenesis	FASEB JOURNAL			English	Article						gene regulation; gastrulation; Xenopus; chromatin immunoprecipitation; mouse; colinearity	MOUSE EMBRYONIC-DEVELOPMENT; ANTERIOR-POSTERIOR AXIS; HOMEOBOX GENE; XENOPUS-LAEVIS; RETINOIC ACID; CAUDAL GENES; POSITIONAL INFORMATION; OVERLAPPING FUNCTIONS; TEMPORAL COLINEARITY; EARLY ENHANCER	The Hox genes pattern the anterior-posterior axis in developing embryos through tightly regulated, partially overlapping, temporal and spatial expression domains. Initial regulation of Hox expression is important to establish these overlapping transcription domains. The Cdx homeodomain factors have been proposed as Hox regulators, but their precise role and mechanism during this regulatory interaction remain unclear. In Xenopus embryos, HoxC8 transcripts begin to accumulate during mid/late gastrula. Cdx1 overexpression and knockdown lead to precocious or slower HoxC8 expression, respectively. The mouse HoxC8 early enhancer when introduced into Xenopus embryos recapitulates the endogenous XHoxC8 temporal expression pattern and shows the same responsiveness to Cdx1 regulation. Three pairs of conserved Cdx binding sites were identified within the HoxC8 early enhancer. We demonstrate that Cdx1 binds directly these responsive elements during embryogenesis, as part of the mechanism for the timely activation of HoxC8 expression. We define the function and mechanism of Cdx1 regulation on HoxC8 expression and suggest the possibility that the temporal changes in Cdx activity levels during gastrulation, combined with differential DNA binding affinity, might play a role in the establishment of Hox sequential activation.-Ben-Haroush Schyr, R., Shabtai, Y., Shashikant, C. S., Fainsod, A. Cdx1 is essential for the initiation of HoxC8 expression during early embryogenesis. FASEB J. 26, 2674-2684 (2012). www.fasebj.org	[Schyr, Rachel Ben-Haroush; Shabtai, Yehuda; Fainsod, Abraham] Hebrew Univ Jerusalem, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Fac Med, IL-91120 Jerusalem, Israel; [Shashikant, Cooduvalli S.] Penn State Univ, Dept Dairy & Anim Sci, Coll Agr Sci, University Pk, PA 16802 USA	Hebrew University of Jerusalem; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Fainsod, A (corresponding author), Hebrew Univ Jerusalem, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Fac Med, POB 12272, IL-91120 Jerusalem, Israel.	abrahamf@ekmd.huji.ac.il	Fainsod, Abraham/AAE-5633-2019	Shabtai, Yehuda/0000-0002-2415-4421; Schyr, Rachel/0000-0002-4894-7979	U.S.-Israel Binational Science Foundation; March of Dimes Birth Defects Foundation; Canadian Friends of Hebrew University; Wolfson Family Chair in Genetics	U.S.-Israel Binational Science Foundation(US-Israel Binational Science Foundation); March of Dimes Birth Defects Foundation(March of Dimes); Canadian Friends of Hebrew University; Wolfson Family Chair in Genetics	The authors thank Y. Dor, G. Pillemer, and Z. Paroush for critically reading this manuscript and F. H. Ruddle for fruitful discussions during the course of this research. This work was funded, in part, by grants from the U.S.-Israel Binational Science Foundation, the March of Dimes Birth Defects Foundation, the Canadian Friends of the Hebrew University, and the Wolfson Family Chair in Genetics to A. F.	Alexander T, 2009, ANNU REV CELL DEV BI, V25, P431, DOI 10.1146/annurev.cellbio.042308.113423; ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Belting HG, 1998, J EXP ZOOL, V282, P196, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;196::AID-JEZ22&gt;3.0.CO;2-R; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; Cao Y, 2004, J BIOL CHEM, V279, P43735, DOI 10.1074/jbc.M407544200; Chambeyron S, 2005, DEVELOPMENT, V132, P2215, DOI 10.1242/dev.01813; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Charite J, 1998, DEVELOPMENT, V125, P4349; Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Crawford M, 2003, J EXP ZOOL PART B, V295B, P1, DOI 10.1002/jez.b.00002; Davidson AJ, 2006, DEV BIOL, V292, P506, DOI 10.1016/j.ydbio.2006.01.003; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897; DUBOULE D, 1994, DEVELOPMENT, P135; Epstein M, 1997, DEVELOPMENT, V124, P3805; Faas L, 2009, DEV DYNAM, V238, P835, DOI 10.1002/dvdy.21901; Forlani S, 2003, DEVELOPMENT, V130, P3807, DOI 10.1242/dev.00573; FRUMKIN A, 1993, DEVELOPMENT, V118, P553; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; Gaunt SJ, 2004, INT J DEV BIOL, V48, P613, DOI 10.1387/ijdb.041829sg; GAUNT SJ, 1994, DEV DYNAM, V199, P229, DOI 10.1002/aja.1001990307; Gaunt SJ, 1996, DEV DYNAM, V207, P270, DOI 10.1002/(SICI)1097-0177(199611)207:3<270::AID-AJA4>3.0.CO;2-E; Gaunt SJ, 2008, DEVELOPMENT, V135, P2511, DOI 10.1242/dev.015909; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Iimura T, 2006, NATURE, V442, P568, DOI 10.1038/nature04838; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; Juan AH, 2003, DEVELOPMENT, V130, P4823, DOI 10.1242/dev.00672; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Levy V, 2002, DEV BIOL, V248, P40, DOI 10.1006/dbio.2002.0705; Lohnes D, 2003, BIOESSAYS, V25, P971, DOI 10.1002/bies.10340; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; Marom K, 1997, MECH DEVELOP, V64, P41, DOI 10.1016/S0925-4773(97)00043-9; MEYER BI, 1993, DEVELOPMENT, V117, P191; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; Pillemer G, 1998, MECH DEVELOP, V71, P193, DOI 10.1016/S0925-4773(97)00193-7; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Rousso SZ, 2011, DEV DYNAM, V240, P796, DOI 10.1002/dvdy.22588; Shashikant CS, 1995, DEVELOPMENT, V121, P4339; Shashikant CS, 1996, P NATL ACAD SCI USA, V93, P12364, DOI 10.1073/pnas.93.22.12364; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Stern CD, 2006, INT J DEV BIOL, V50, P3, DOI 10.1387/ijdb.052095cs; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; van den Akker E, 2002, DEVELOPMENT, V129, P2181; van Nes J, 2006, DEVELOPMENT, V133, P419, DOI 10.1242/dev.02216; Wacker SA, 2004, DEV BIOL, V268, P207, DOI 10.1016/j.ydbio.2003.12.022; Wacker SA, 2004, DEV BIOL, V266, P123, DOI 10.1016/j.ydbio.2003.10.011; Wang WCH, 2004, J EXP ZOOL PART B, V302B, P436, DOI 10.1002/jez.b.21009; Young T, 2009, CURR TOP DEV BIOL, V88, P235, DOI 10.1016/S0070-2153(09)88008-3	57	8	8	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2674	2684		10.1096/fj.11-191403	http://dx.doi.org/10.1096/fj.11-191403			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22426122	Bronze			2022-12-28	WOS:000305017200043
J	Chung, YL				Chung, Yih-Lin			Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen	FASEB JOURNAL			English	Article						tumor suppressor; promyelocytic leukemia protein; synthetic lethality	PROMYELOCYTIC LEUKEMIA PROTEIN; ALPHA-INDUCED APOPTOSIS; PML NUCLEAR-BODIES; HEPATOCELLULAR-CARCINOMA; CLASS-I; SYNTHETIC LETHALITY; SUPPRESSOR PML; TARGETS; INCREASE; PATHWAYS	Hepatitis B virus (HBV) is implicated in liver cancer. The aim of this study was to find out whether HBV or its components [HBV surface antigen (HBsAg), HBV core protein (HBc), and HBV X protein (HBx)] could interfere with the host DNA damage response and repair pathway. The full HBV genome or individual HBV open-reading frame (ORF) was introduced into HepG2 cells to examine the effect on host genomic stability, DNA repair efficacy in response to double-strand DNA damage, and DNA damage-induced cell death. Responses to apoptosis induction in the HBV ORF-transfected HepG2 cells were also compared with those in HBV-positive and HBV-negative human hepatocellular carcinoma (HCC) cells. In the absence of HBV replication, accumulation of HBsAg in liver cells without other HBV proteins enhanced DNA repair protein and tumor suppressor promyelocytic leukemia (PML) degradation, which resulted in resistance to apoptosis induction and deficient double-strand DNA repair. However, HBsAg-positive cells exhibited increased cell death with exposure to the poly(ADP-ribose) polymerase inhibitor that blocks single-strand DNA repair. These results indicate that suppression of PML by HBsAg disrupts cellular mechanisms that respond to double-strand DNA damage for DNA repair or apoptosis induction, which may facilitate hepatocarcinogenesis and open up a synthetic lethality strategy for HBsAg-positive HCC treatment.-Chung, Y.-L. Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen.	Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei 112, Taiwan		Chung, YL (corresponding author), Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, 125 Lih Der Rd, Taipei 112, Taiwan.	ylchung@kfsyscc.org			National Science Council in Taiwan [97-2320-B-368-001-MY2, 100-2320-B-368-001-MY3]	National Science Council in Taiwan(Ministry of Science and Technology, Taiwan)	This research was supported by the National Science Council in Taiwan (grants 97-2320-B-368-001-MY2 and 100-2320-B-368-001-MY3 to Y.C.).	Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartoszewski R, 2011, J BIOL CHEM, V286, P41862, DOI 10.1074/jbc.M111.304956; Basu B, 2012, CURR OPIN ONCOL, V24, P316, DOI 10.1097/CCO.0b013e32835280c6; Boichuk S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025814; Borden KLB, 2009, FRONT BIOSCI-LANDMRK, V14, P497, DOI 10.2741/3258; Chalmers AJ, 2010, SEMIN RADIAT ONCOL, V20, P274, DOI 10.1016/j.semradonc.2010.06.001; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Chen YY, 2006, CELL MOL IMMUNOL, V3, P373; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; Chou YC, 2005, J VIROL, V79, P1813, DOI 10.1128/JVI.79.3.1813-1823.2005; Chung YL, 2009, MOL CANCER RES, V7, P1672, DOI 10.1158/1541-7786.MCR-09-0112; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Damia G, 2007, EUR J CANCER, V43, P1791, DOI 10.1016/j.ejca.2007.05.003; de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; Du J, 2009, CELL DEATH DIFFER, V16, P219, DOI 10.1038/cdd.2008.144; Geng X, 2012, P NATL ACAD SCI USA, V109, P18465, DOI 10.1073/pnas.1204652109; Geoffroy MC, 2011, J INTERF CYTOK RES, V31, P145, DOI 10.1089/jir.2010.0111; Giorgi C, 2010, SCIENCE, V330, P1247, DOI 10.1126/science.1189157; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Herzer K, 2009, CANCER RES, V69, P855, DOI 10.1158/0008-5472.CAN-08-2831; Hoofnagle JH, 2009, HEPATOLOGY, V49, pS156, DOI 10.1002/hep.22945; Ibarra RA, 2012, ACTA ONCOL, V51, P575, DOI 10.3109/0284186X.2011.652736; Iglehart JD, 2009, NEW ENGL J MED, V361, P189, DOI 10.1056/NEJMe0903044; Jalal S, 2011, CLIN CANCER RES, V17, P6973, DOI 10.1158/1078-0432.CCR-11-0761; Kasparek TR, 2011, SEMIN CELL DEV BIOL, V22, P886, DOI 10.1016/j.semcdb.2011.10.007; Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559; Kuribayashi K, 2011, CELL CYCLE, V10, P2380, DOI 10.4161/cc.10.14.16588; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; Liu M, 2012, HEPATOLOGY, V55, P1754, DOI 10.1002/hep.25584; Liu YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036914; Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005; Na B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026240; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; Tavalai N, 2009, VIRUSES-BASEL, V1, P1240, DOI 10.3390/v1031240; Tsai HW, 2011, CANCER-AM CANCER SOC, V117, P2951, DOI 10.1002/cncr.25837; Tsai WL, 2010, ONCOGENE, V29, P2309, DOI 10.1038/onc.2010.36; Tseng TC, 2012, GASTROENTEROLOGY, V142, P1140, DOI 10.1053/j.gastro.2012.02.007; Turnell AS, 2012, J GEN VIROL, V93, P2076, DOI 10.1099/vir.0.044412-0; Varadaraj A, 2007, J PATHOL, V211, P471, DOI 10.1002/path.2126; Xia M, 2007, TISSUE ANTIGENS, V70, P272, DOI 10.1111/j.1399-0039.2007.00892.x; Yeung PL, 2012, J CELL BIOCHEM, V113, P1787, DOI 10.1002/jcb.24050; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200; Yoon GS, 2001, J KOREAN MED SCI, V16, P433, DOI 10.3346/jkms.2001.16.4.433; Yue XT, 2012, GASTROENTEROLOGY, V142, P1559, DOI 10.1053/j.gastro.2012.02.049; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zheng YY, 2007, HEPATOLOGY, V45, P16, DOI 10.1002/hep.21445	51	18	18	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2316	2327		10.1096/fj.12-226639	http://dx.doi.org/10.1096/fj.12-226639			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23444429				2022-12-28	WOS:000319667600021
J	Wan, E; Kushner, JS; Zakharov, S; Nui, XW; Chudasama, N; Kelly, C; Waase, M; Doshi, D; Liu, GX; Iwata, S; Shiomi, T; Katchman, A; D'Armiento, J; Homma, S; Marx, SO				Wan, Elaine; Kushner, Jared S.; Zakharov, Sergey; Nui, Xiao-wei; Chudasama, Neelesh; Kelly, Christopher; Waase, Marc; Doshi, Darshan; Liu, Guoxia; Iwata, Shinichi; Shiomi, Takayuki; Katchman, Alexander; D'Armiento, Jeanine; Homma, Shunichi; Marx, Steven O.			Reduced vascular smooth muscle BK channel current underlies heart failure-induced vasoconstriction in mice	FASEB JOURNAL			English	Article						calcium; myogenic tone; membrane potential	CA2+-ACTIVATED K+ CHANNELS; LARGE-CONDUCTANCE; MYOGENIC CONSTRICTION; CORONARY-ARTERY; BETA-1 SUBUNIT; MYOCARDIAL-ISCHEMIA; INDUCED CONTRACTION; MESENTERIC-ARTERY; BLOOD-PRESSURE; WALL CA2+	Excessively increased peripheral vasoconstriction is a hallmark of heart failure (HF). Here, we show that in mice with systolic HF post-myocardial infarction, the myogenic tone of third-order mesenteric resistance vessels is increased, the vascular smooth muscle (VSM) membrane potential is depolarized by similar to 20 mV, and vessel wall intracellular [Ca2+] is elevated relative to that in sham-operated control mice. Despite the increased [Ca2+], the frequency and amplitude of spontaneous transient outward currents (STOCs), mediated by large conductance, Ca2+-activated BK channels, were reduced by nearly 80% (P<0.01) and 25% (P<0.05), respectively, in HF. The expression of the BK alpha and beta 1 subunits was reduced in HF mice compared to controls (65 and 82% lower, respectively, P<0.01). Consistent with the importance of a reduction in BK channel expression and function in mediating the HF-induced increase in myogenic tone are two further findings: a blunting of paxilline-induced increase in myogenic tone in HF mice compared to controls (0.9 vs. 10.9%, respectively), and that HF does not alter the increased myogenic tone of BK beta 1-null mice. These findings identify electrical dysregulation within VSM, specifically the reduction of BK currents, as a key molecular mechanism sensitizing resistance vessels to pressure-induced vasoconstriction in systolic HF.	[Wan, Elaine; Kushner, Jared S.; Zakharov, Sergey; Nui, Xiao-wei; Chudasama, Neelesh; Kelly, Christopher; Waase, Marc; Doshi, Darshan; Liu, Guoxia; Iwata, Shinichi; Katchman, Alexander; Homma, Shunichi; Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Div Cardiol, New York, NY USA; [Shiomi, Takayuki; D'Armiento, Jeanine] Columbia Univ, Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY USA; [Marx, Steven O.] Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA	Columbia University; Columbia University; Columbia University	Marx, SO (corresponding author), Columbia Univ Coll Phys & Surg, PH Ctr 3, 630 W 168th St, New York, NY 10032 USA.	sm460@columbia.edu	Shiomi, Takayuki/A-2228-2014; Zakharov, Sergey/O-2896-2019; Zakharov, Sergey/L-8511-2014	Shiomi, Takayuki/0000-0002-4250-1204; Zakharov, Sergey/0000-0001-9864-8304; Zakharov, Sergey/0000-0001-9864-8304; Kushner, Jared S./0000-0003-4821-0990	U.S. National Heart, Lung, and Blood Institute (NHLBI) [P01 HL081172]; NHLBI [T32HL007854]; Howard Hughes Medical Institute Medical Research Fellowship; Arlene and Arnold Goldstein Family Foundation; Lewis Katz Cardiovascular Research Prize; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007854, P01HL081172] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute Medical Research Fellowship(Howard Hughes Medical Institute); Arlene and Arnold Goldstein Family Foundation; Lewis Katz Cardiovascular Research Prize; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. George Osol, Dr. Natalia Gokina, and Dr. Mark Nelson (University of Vermont, Burlington, VT, USA), as well as their laboratories. These studies were supported by U.S. National Heart, Lung, and Blood Institute (NHLBI) grant P01 HL081172 (S.O.M. and J.M.D.), NHLBI grant T32HL007854 (E.W.), a Howard Hughes Medical Institute Medical Research Fellowship (J.K.), the Arlene and Arnold Goldstein Family Foundation, and the Lewis Katz Cardiovascular Research Prize. The authors declare no conflicts of interest.	Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Ambroisine ML, 2007, CIRCULATION, V116, P2435, DOI 10.1161/CIRCULATIONAHA.107.722009; Bagi Z, 2005, ARTERIOSCL THROM VAS, V25, P1610, DOI 10.1161/01.ATV.0000172688.26838.9f; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; CHRISTENSEN KL, 1993, J VASC RES, V30, P73, DOI 10.1159/000158978; Dong L, 2008, J CEREBR BLOOD F MET, V28, P377, DOI 10.1038/sj.jcbfm.9600536; Dong L, 2009, CLIN EXP PHARMACOL P, V36, pe57, DOI 10.1111/j.1440-1681.2009.05222.x; Duncker DJ, 2008, MED BIOL ENG COMPUT, V46, P485, DOI 10.1007/s11517-008-0315-1; Earley S, 2010, CLIN SCI, V119, P19, DOI 10.1042/CS20090641; Emter CA, 2011, AM J PHYSIOL-HEART C, V301, pH1687, DOI 10.1152/ajpheart.00610.2011; Fernandez-Tenorio M, 2011, CIRC RES, V108, P1348, DOI 10.1161/CIRCRESAHA.111.240127; Gschwend S, 2003, BRIT J PHARMACOL, V139, P1317, DOI 10.1038/sj.bjp.0705367; Gschwend S, 2003, EUR J HEART FAIL, V5, P147, DOI 10.1016/S1388-9842(02)00248-9; Hannah RM, 2011, J CEREBR BLOOD F MET, V31, P1175, DOI 10.1038/jcbfm.2010.214; Hill MA, 2006, CLIN HEMORHEOL MICRO, V34, P67; Hill MA, 2009, TRENDS PHARMACOL SCI, V30, P363, DOI 10.1016/j.tips.2009.04.008; Hoefer J, 2010, CIRC RES, V107, P923, DOI 10.1161/CIRCRESAHA.110.226464; KATZ SD, 1992, J AM COLL CARDIOL, V19, P918, DOI 10.1016/0735-1097(92)90271-N; Kim N, 2003, CIRC RES, V93, P541, DOI 10.1161/01.RES.0000090087.66390.F2; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Kotecha N, 2005, AM J PHYSIOL-HEART C, V289, pH1326, DOI 10.1152/ajpheart.00323.2005; Lagaud GJL, 2001, J VASC RES, V38, P578, DOI 10.1159/000051094; Liu YP, 2009, BASIC RES CARDIOL, V104, P211, DOI 10.1007/s00395-009-0775-y; Lohn M, 2001, J APPL PHYSIOL, V91, P1350, DOI 10.1152/jappl.2001.91.3.1350; Lu T, 2008, BIOPHYS J, V95, P5165, DOI 10.1529/biophysj.108.138339; McCarron JG, 1997, J PHYSIOL-LONDON, V498, P371, DOI 10.1113/jphysiol.1997.sp021864; McGahon MK, 2007, CIRC RES, V100, P703, DOI 10.1161/01.RES.0000260182.36481.c9; McGahon Mary K, 2007, Channels (Austin), V1, P141; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Mita M, 2002, BIOCHEM J, V364, P431, DOI 10.1042/BJ20020191; Moosmang S, 2003, EMBO J, V22, P6027, DOI 10.1093/emboj/cdg583; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nieves-Cintron M, 2008, P NATL ACAD SCI USA, V105, P15623, DOI 10.1073/pnas.0808759105; Nieves-Cintron M, 2007, J BIOL CHEM, V282, P3231, DOI 10.1074/jbc.M608822200; OSOL G, 1993, AM J OBSTET GYNECOL, V168, P268, DOI 10.1016/S0002-9378(12)90924-2; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Phillips SA, 2005, AM J PHYSIOL-REG I, V288, pR522, DOI 10.1152/ajpregu.00655.2004; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Sakamoto K, 2003, J PHARMACOL SCI, V92, P56; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Sorop O, 2008, CIRC RES, V102, P795, DOI 10.1161/CIRCRESAHA.108.172528; Tomaselli GF, 2004, CIRC RES, V95, P754, DOI 10.1161/01.RES.0000145047.14691.db; Urban NH, 2003, AM J PHYSIOL-CELL PH, V285, pC1377, DOI 10.1152/ajpcell.00501.2002; van den Heuvel AFM, 2002, CARDIOVASC RES, V55, P97, DOI 10.1016/S0008-6363(02)00331-0; van den Heuvel AFM, 2000, J AM COLL CARDIOL, V35, P19, DOI 10.1016/S0735-1097(99)00499-4; van Veldhuisen DJ, 1998, J CARDIOVASC PHARM, V32, pS46, DOI 10.1097/00005344-199800003-00008; Xu H, 2011, AM J PHYSIOL-HEART C, V300, pH476, DOI 10.1152/ajpheart.00975.2010; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Xu Y, 2007, EUR J HEART FAIL, V9, P144, DOI 10.1016/j.ejheart.2006.05.003; Xu Y, 2009, EUR J HEART FAIL, V11, P246, DOI 10.1093/eurjhf/hfn027; ZELIS R, 1982, PROG CARDIOVASC DIS, V24, P437, DOI 10.1016/0033-0620(82)90012-3	53	19	19	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1859	1867		10.1096/fj.12-223511	http://dx.doi.org/10.1096/fj.12-223511			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23325318	Green Published, Bronze			2022-12-28	WOS:000318226100006
J	Avraham, T; Zampell, JC; Yan, A; Elhadad, S; Weitman, ES; Rockson, SG; Bromberg, J; Mehrara, BJ				Avraham, Tomer; Zampell, Jamie C.; Yan, Alan; Elhadad, Sonia; Weitman, Evan S.; Rockson, Stanley G.; Bromberg, Jacqueline; Mehrara, Babak J.			Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema	FASEB JOURNAL			English	Article						inflammation; lymphangiogenesis; lymphatic endothelial cell	VEGF-C; FILARIAL LYMPHEDEMA; BREAST-CARCINOMA; WOUND REPAIR; LYMPHANGIOGENESIS; INFLAMMATION; REGENERATION; EXPRESSION; CANCER; SKIN	Lymphedema is a dreaded complication of cancer treatment. However, despite the fact that > 5 million Americans are affected by this disorder, the development of effective treatments is limited by the fact that the pathology of lymphedema remains unknown. The purpose of these studies was to determine the role of inflammatory responses in lymphedema pathology. Using mouse models of lymphedema, as well as clinical lymphedema specimens, we show that lymphatic stasis results in a CD4+ T-cell inflammation and T-helper 2 (Th2) differentiation. Using mice deficient in T cells or CD4+ cells, we show that this inflammatory response is necessary for the pathological changes of lymphedema, including fibrosis, adipose deposition, and lymphatic dysfunction. Further, we show that inhibition of Th2 differentiation using interleukin-4 (IL-4) or IL-13 blockade prevents initiation and progression of lymphedema by decreasing tissue fibrosis and significantly improving lymphatic function, independent of lymphangiogenic growth factors. We show that CD4+ inflammation is a critical regulator of tissue fibrosis and lymphatic dysfunction in lymphedema and that inhibition of Th2 differentiation markedly improves lymphatic function independent of lymphangiogenic cytokine expression. Notably, preventing and/or reversing the development of pathological tissue changes that occur in lymphedema may be a viable treatment strategy for this disorder.-Avraham, T., Zampell, J. C., Yan, A., Elhadad, S., Weitman, E. S., Rockson, S. G., Bromberg, J., Mehrara, B. J. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 27, 1114-1126 (2013). www.fasebj.org	[Avraham, Tomer; Zampell, Jamie C.; Yan, Alan; Elhadad, Sonia; Weitman, Evan S.; Mehrara, Babak J.] Mem Sloan Kettering Canc Ctr, Dept Surg, Div Plast & Reconstruct Surg, New York, NY 10021 USA; [Bromberg, Jacqueline] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Rockson, Stanley G.] Stanford Univ, Med Ctr, Dept Med, Div Cardiol, Stanford, CA 94305 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Stanford University	Mehrara, BJ (corresponding author), FACS, 1275 York Ave,Rm MRI 1005, New York, NY 10065 USA.	mehrarab@mskcc.org	Elhadad, Sonia/GRF-6466-2022	Elhadad, Sonia/0000-0002-0139-6487; rockson, stanley/0000-0003-1253-474X	Plastic Surgery Educational Foundation; The Society of Memorial Sloan-Kettering Cancer Center; T32 Surgical Oncology Training [NIH T32 CA 009501]; U.S. Department of Defense [BC103691]; National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH) [R01HL111130]; NIH [R24 CA83084, P30 CA08748]; NATIONAL CANCER INSTITUTE [R24CA083084, P30CA008748, T32CA009501] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111130] Funding Source: NIH RePORTER	Plastic Surgery Educational Foundation; The Society of Memorial Sloan-Kettering Cancer Center; T32 Surgical Oncology Training; U.S. Department of Defense(United States Department of Defense); National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Ronald DeMatteo (Memorial SloanKettering Cancer Center) for his helpful advice regarding planning and execution of the experiments. This work was funded, in part, by the Plastic Surgery Educational Foundation and The Society of Memorial Sloan-Kettering Cancer Center grants to B.J.M. T. A. was funded in part by a fellowship grant from the Plastic Surgery Educational Foundation. T.A., J.Z., and E. W. were also supported by T32 Surgical Oncology Training Grant NIH T32 CA 009501. J.Z. was also partially supported from a grant (BC103691) from the U.S. Department of Defense. Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH) under award R01HL111130. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Technical services provided by the MSKCC Small-Animal Imaging Core Facility, supported, in part, by NIH Small- Animal Imaging Research Program (SAIRP) grant R24 CA83084 and NIH Center grant P30 CA08748, are gratefully acknowledged.	ABOULENEIN A, 1984, SURGERY, V95, P562; Avraham T, 2010, AM J PATHOL, V177, P3202, DOI 10.2353/ajpath.2010.100594; Avraham T, 2010, AM J PHYSIOL-CELL PH, V299, pC589, DOI 10.1152/ajpcell.00535.2009; Avraham T, 2009, PLAST RECONSTR SURG, V124, P438, DOI 10.1097/PRS.0b013e3181adcf4b; Beesley V, 2007, CANCER, V109, P2607, DOI 10.1002/cncr.22684; Bennuru S, 2010, AM J TROP MED HYG, V83, P884, DOI 10.4269/ajtmh.2010.10-0039; Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262; Clavin NW, 2008, AM J PHYSIOL-HEART C, V295, pH2113, DOI 10.1152/ajpheart.00879.2008; Foldi E, 2000, LYMPHOLOGY, V33, P19; GALKOWSKA H, 1986, LYMPHOLOGY, V19, P139; Goldman J, 2005, CIRC RES, V96, P1193, DOI 10.1161/01.RES.0000168918.27576.78; Goldman J, 2007, FASEB J, V21, P1003, DOI 10.1096/fj.06-6656com; Gu Y, 2008, CLIN EXP METASTAS, V25, P717, DOI 10.1007/s10585-008-9180-4; Hinrichs CS, 2004, ANN SURG ONCOL, V11, P573, DOI 10.1245/ASO.2004.04.017; Karlsen TV, 2006, J PHYSIOL-LONDON, V574, P583, DOI 10.1113/jphysiol.2006.108308; Kataru RP, 2011, IMMUNITY, V34, P96, DOI 10.1016/j.immuni.2010.12.016; Mankan AK, 2011, EXPERT OPIN INV DRUG, V20, P1263, DOI 10.1517/13543784.2011.601739; Nakamura K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008380; Neurath MF, 2011, CYTOKINE GROWTH F R, V22, P83, DOI 10.1016/j.cytogfr.2011.02.003; Oka M, 2008, BLOOD, V111, P4571, DOI 10.1182/blood-2007-10-120337; OLSZEWSKI WL, 1993, TROP MED PARASITOL, V44, P40; OLSZEWSKI WL, 1992, LYMPHOLOGY, V25, P166; Petrek JA, 1998, CANCER-AM CANCER SOC, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; Pyszel A, 2006, LYMPHOLOGY, V39, P185; Rockson SG, 2008, ANN NY ACAD SCI, V1131, P147, DOI 10.1196/annals.1413.014; ROMANI L, 1992, J EXP MED, V176, P19, DOI 10.1084/jem.176.1.19; Rossi A, 2007, LYMPHOLOGY, V40, P102; Rutkowski JM, 2006, MICROVASC RES, V72, P161, DOI 10.1016/j.mvr.2006.05.009; Rutkowski JM, 2010, AM J PATHOL, V176, P1122, DOI 10.2353/ajpath.2010.090733; SCHRIER DJ, 1983, AM REV RESPIR DIS, V127, P614, DOI 10.1164/arrd.1983.127.5.614; Suami H, 2007, PLAST RECONSTR SURG, V120, P982, DOI 10.1097/01.prs.0000277995.25009.3e; Tabibiazar R, 2006, PLOS MED, V3, P1114, DOI 10.1371/journal.pmed.0030254; Tammela T, 2007, NAT MED, V13, P1458, DOI 10.1038/nm1689; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Xu JG, 2006, AM J PHYSIOL-LUNG C, V291, pL658, DOI 10.1152/ajplung.00006.2006; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Yoshizaki A, 2008, AM J PATHOL, V172, P1650, DOI 10.2353/ajpath.2008.071049; Zampell JC, 2012, FASEB J, V26, P1027, DOI 10.1096/fj.11-195321; Zampell JC, 2012, AM J PHYSIOL-CELL PH, V302, pC709, DOI 10.1152/ajpcell.00284.2011; Zampell JC, 2012, AM J PHYSIOL-CELL PH, V302, pC392, DOI 10.1152/ajpcell.00306.2011; Zampell JC, 2011, AM J PHYSIOL-CELL PH, V300, pC1107, DOI 10.1152/ajpcell.00378.2010	42	128	135	4	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1114	1126		10.1096/fj.12-222695	http://dx.doi.org/10.1096/fj.12-222695			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193171	Green Published			2022-12-28	WOS:000315585200025
J	Roux, J; McNicholas, CM; Carles, M; Goolaerts, A; Houseman, BT; Dickinson, DA; Iles, KE; Ware, LB; Matthay, MA; Pittet, JF				Roux, Jeremie; McNicholas, Carmel M.; Carles, Michel; Goolaerts, Arnaud; Houseman, Benjamin T.; Dickinson, Dale A.; Iles, Karen E.; Ware, Lorraine B.; Matthay, Michael A.; Pittet, Jean-Franois			IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport via a GRK2/PI3K-dependent mechanism	FASEB JOURNAL			English	Article						beta(2) adrenergic receptor; acute lung injury	RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; CONTROLLED CLINICAL-TRIAL; BETA-ADRENERGIC AGONISTS; PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; LIQUID CLEARANCE; II CELLS; PULMONARY-EDEMA; DECREASES EXPRESSION	Patients with acute lung injury (ALI) who retain maximal alveolar fluid clearance (AFC) have better clinical outcomes. Experimental and small clinical studies have shown that beta(2)-adrenergic receptor (beta(2)AR) agonists enhance AFC via a cAMP-dependent mechanism. However, two multicenter phase 3 clinical trials failed to show that beta(2)AR agonists provide a survival advantage in patients with ALI. We hypothesized that IL-8, an important mediator of ALI, directly antagonizes the alveolar epithelial response to beta(2)AR agonists. Short-circuit current and whole-cell patch-clamping experiments revealed that IL-8 or its rat analog CINC-1 decreases by 50% beta(2)AR agonist-stimulated vectorial Cl- and net fluid transport across rat and human alveolar epithelial type II cells via a reduction in the cystic fibrosis transmembrane conductance regulator activity and biosynthesis. This reduction was mediated by heterologous beta(2)AR desensitization and down-regulation (50%) via the G-protein-coupled receptor kinase 2 (GRK2)/PI3K signaling pathway. Inhibition of CINC-1 restored beta(2)AR agonist- stimulated AFC in an experimental model of ALI in rats. Finally, consistent with the experimental results, high pulmonary edema fluid levels of IL-8 (>4000 pg/ml) were associated with impaired AFC in patients with ALI. These results demonstrate a novel role for IL-8 in inhibiting beta(2)AR agonist- stimulated alveolar epithelial fluid transport via GRK2/PI3K-dependent mechanisms.-Roux, J., McNicholas, C. M., Carles, M., Goolaerts, A., Houseman, B. T., Dickinson, D. A., Iles, K. E., Ware, L. B., Matthay, M. A., Pittet, J.-F. IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport via a GRK2/PI3K-dependent mechanism. FASEB J. 27, 1095-1106 (2013). www.fasebj.org	[Roux, Jeremie; Carles, Michel; Goolaerts, Arnaud; Houseman, Benjamin T.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Houseman, Benjamin T.] Univ Calif San Francisco, Dept Cellular Pharmacol, San Francisco, CA 94143 USA; [Matthay, Michael A.; Pittet, Jean-Franois] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Iles, Karen E.; Pittet, Jean-Franois] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35249 USA; [McNicholas, Carmel M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35249 USA; [Dickinson, Dale A.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35249 USA; [Ware, Lorraine B.] Vanderbilt Univ, Dept Med, Nashville, TN USA; [Ware, Lorraine B.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Vanderbilt University	Pittet, JF (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 619 South 19th St,JT926, Birmingham, AL 35249 USA.	pittetj@uab.edu	Carles, Michel/CAH-0065-2022; Roux, Jeremie/A-9746-2013; Ware, Lorraine/AAJ-9307-2021	Roux, Jeremie/0000-0001-5712-8660; Ware, Lorraine/0000-0002-9429-4702; McNicholas-Bevensee, Carmel/0000-0002-7013-8764; CARLES, MICHEL/0000-0001-5485-1511	U.S. National Institutes of Health [GM-62188, HL-51854, HL-51856]; American Lung Association Senior Research Training Fellowship [T32 GM008440]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051856, R01HL051856, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188, T32GM008440] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association Senior Research Training Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank G. Stanley McKnight (University of Washington, Seattle, WA, USA; CFTR promoter luciferase constructs) and Alan S. Verkman (University of California, San Francisco, CA, USA; CFTR inhibitor, CFTRinh-172) for their generous gifts. This work was primarily supported by U.S. National Institutes of Health grants GM-62188 (J.F.P.), HL-51854 and and HL-51856 (M.A.M.), and T32 GM008440 (J.R.) an American Lung Association Senior Research Training Fellowship (J.R.).	Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; Amat M, 2000, CRIT CARE MED, V28, P57, DOI 10.1097/00003246-200001000-00009; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; Banday AA, 2007, AM J PHYSIOL-RENAL, V293, pF877, DOI 10.1152/ajprenal.00184.2007; Batra S, 2012, J IMMUNOL, V188, P3458, DOI 10.4049/jimmunol.1101985; BERTHIAUME Y, 1991, J APPL PHYSIOL, V70, P2490, DOI 10.1152/jappl.1991.70.6.2490; BERTHIAUME Y, 1987, J CLIN INVEST, V79, P335, DOI 10.1172/JCI112817; Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743; Craig TR, 2010, CRIT CARE MED, V38, P114, DOI 10.1097/CCM.0b013e3181b43050; Davis IC, 2007, AM J PHYSIOL-LUNG C, V293, pL281, DOI 10.1152/ajplung.00458.2006; De Perrot M, 2002, AM J RESP CRIT CARE, V165, P211, DOI 10.1164/ajrccm.165.2.2011151; DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Fang X, 2002, J GEN PHYSIOL, V119, P199, DOI 10.1085/jgp.119.2.199; Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005; Fang XH, 2004, AM J PHYSIOL-LUNG C, V287, pL104, DOI 10.1152/ajplung.00176.2003; Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200; Gregg CJ, 2010, ANESTH ANALG, V111, P870, DOI 10.1213/ANE.0b013e3181ee8312; Jiang X, 2001, J MEMBRANE BIOL, V181, P195, DOI 10.1007/s00232-001-0022-4; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Kurdowska A, 1996, J IMMUNOL, V157, P2699; Laffon M, 1999, AM J RESP CRIT CARE, V160, P1443, DOI 10.1164/ajrccm.160.5.9901097; Lee JW, 2007, J BIOL CHEM, V282, P24109, DOI 10.1074/jbc.M700821200; Maron MB, 2006, AM J PHYSIOL-LUNG C, V291, pL252, DOI 10.1152/ajplung.00022.2006; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; Modelska K, 1999, AM J RESP CRIT CARE, V160, P1450, DOI 10.1164/ajrccm.160.5.9901096; Mutlu GM, 2008, AM J RESP CELL MOL, V38, P127, DOI 10.1165/rcmb.2007-0198TR; Nielsen VG, 1998, AM J PHYSIOL-LUNG C, V275, pL1127, DOI 10.1152/ajplung.1998.275.6.L1127; Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC; Perrino C, 2005, CIRCULATION, V111, P2579, DOI 10.1161/CIRCULATIONAHA.104.508796; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; PITTET JF, 1994, J CLIN INVEST, V94, P663, DOI 10.1172/JCI117383; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200; Roux J, 2010, J BIOL CHEM, V285, P4278, DOI 10.1074/jbc.M109.036731; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sakuma T, 1997, AM J RESP CRIT CARE, V155, P506, DOI 10.1164/ajrccm.155.2.9032186; Sakuma T, 2006, CRIT CARE MED, V34, P676, DOI 10.1097/01.CCM.0000201403.70636.0F; Sakuma T, 2001, J APPL PHYSIOL, V90, P10, DOI 10.1152/jappl.2001.90.1.10; Sartori C, 2002, J APPL PHYSIOL, V93, P1875, DOI 10.1152/japplphysiol.00275.2002; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Song WF, 2007, AM J PHYSIOL-LUNG C, V293, pL855, DOI 10.1152/ajplung.00305.2007; Su X, 2006, AM J PHYSIOL-LUNG C, V290, pL769, DOI 10.1152/ajplung.00334.2005; TIBALLI RN, 1995, J CLIN MICROBIOL, V33, P915, DOI 10.1128/JCM.33.4.915-917.1995; Tsai WC, 1998, J IMMUNOL, V161, P2435; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	57	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1095	1106		10.1096/fj.12-219295	http://dx.doi.org/10.1096/fj.12-219295			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23221335	Green Submitted, Green Published			2022-12-28	WOS:000315585200023
J	Gundelach, JH; Madhavan, AA; Wettstein, PJ; Bram, RJ				Gundelach, Justin H.; Madhavan, Ajay A.; Wettstein, Peter J.; Bram, Richard J.			The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism	FASEB JOURNAL			English	Article						CD69; chemotherapy; immune suppression; IL-2	IRON CHELATORS; ANTITUMOR-ACTIVITY; IN-VITRO; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAYS; RECEPTOR; INTERLEUKIN-2; LYMPHOCYTE; EXPRESSION; MURINE	The di-2-pyridylketone thiosemicarbazone Dp44mT is a metal-chelating compound that has been demonstrated to have potent activity as an anticancer agent. Here we report that it also has a dramatic inhibitory effect on T-cell activation in vitro. We found that 10 nM Dp44mT (IC50 3.2 nM) prevented the up-regulation of surface CD25, and completely suppressed the activation and proliferation of splenic T cells isolated from Mus musculus that were stimulated with either T-cell receptor (TCR) cross-linking antibodies or phorbol ester plus ionomycin. In contrast, Dp44mT had no adverse effects on the survival of resting T cells. In addition, T cells stimulated in the presence of Dp44mT maintained the ability to up-regulate CD69 surface expression and secrete interleukin-2. Consistent with these observations, Dp44mT did not inhibit multiple canonical signals downstream of the TCR, including the nuclear factor of activated T cells. The effects of Dp44mT were easily mitigated by addition of nontoxic copper chelators or N-acetylcysteine, indicating a role for copper and reactive oxygen species in its actions. Together, these findings suggest that Dp44mT may serve as a potent immunosuppressive agent that could complicate its use as a cancer therapeutic agent, but might have utility in the treatment of autoimmunity.-Gundelach, J. H., Madhavan, A. A., Wettstein, P. J., Bram, R. J. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. FASEB J. 27, 782-792 (2013). www.fasebj.org	[Gundelach, Justin H.; Madhavan, Ajay A.; Bram, Richard J.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Gundelach, Justin H.; Madhavan, Ajay A.; Bram, Richard J.] Mayo Clin, Dept Pediat & Adolescent Med, Coll Med, Rochester, MN 55905 USA; [Gundelach, Justin H.] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Rochester, MN 55905 USA; [Wettstein, Peter J.; Bram, Richard J.] Mayo Clin, Dept Immunol, Coll Med, Rochester, MN 55905 USA; [Wettstein, Peter J.] Mayo Clin, Dept Surg, Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Bram, RJ (corresponding author), Mayo Clin, 533 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	bramr@mayo.edu		Gundelach, Justin/0000-0001-7347-0511	Stanley and Belle Bestor Fund	Stanley and Belle Bestor Fund	The authors thank the laboratories of Dr. Karen Hedin and Dr. Virginia Shapiro (Department of Immunology, Mayo Clinic, Rochester, MN, USA) for kindly providing the luciferase reporter constructs used in this work. This work was supported by a grant from the Stanley and Belle Bestor Fund. The authors declare no conflicts of interest.	ABRAHAM RT, 1986, J IMMUNOPHARMACOL, V8, P165; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; Barbarulo A, 2011, J IMMUNOL, V186, P6199, DOI 10.4049/jimmunol.1002136; BISMUTH G, 1985, EUR J IMMUNOL, V15, P723, DOI 10.1002/eji.1830150716; Brewer GJ, 2008, CURR OPIN CLIN NUTR, V11, P727, DOI 10.1097/MCO.0b013e328314b678; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chatterjee S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007048; Chen CL, 1996, J NATL CANCER I, V88, P1840, DOI 10.1093/jnci/88.24.1840; Debebe Z, 2011, MOL PHARMACOL, V79, P185, DOI 10.1124/mol.110.069062; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; Emens LA, 2005, CANCER RES, V65, P8059, DOI 10.1158/0008-5472.CAN-05-1797; FIDELUS RK, 1988, CELL IMMUNOL, V113, P175, DOI 10.1016/0008-8749(88)90015-9; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; Hopkins RG, 1999, J NUTR, V129, P596, DOI 10.1093/jn/129.3.596; Horvathova M, 2010, HEMATOLOGY, V15, P96, DOI 10.1179/102453310X12583347009810; Kaminski MM, 2012, BBA-MOL CELL RES, V1823, P1041, DOI 10.1016/j.bbamcr.2012.03.003; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; Khwaja SS, 2010, J CLIN INVEST, V120, P2537, DOI 10.1172/JCI41277; Kovacevic Z, 2011, CURR TOP MED CHEM, V11, P483, DOI 10.2174/156802611794785190; Kuvibidila SR, 1998, J NUTR, V128, P1077, DOI 10.1093/jn/128.7.1077; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; LARSEN CS, 1989, SCAND J IMMUNOL, V30, P285, DOI 10.1111/j.1365-3083.1989.tb01213.x; Leanderson P, 1996, CARCINOGENESIS, V17, P545, DOI 10.1093/carcin/17.3.545; LIPKOWITZ S, 1984, J IMMUNOL, V132, P31; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008-5472.CAN-11-1218; MacGregor HJ, 2011, CYTOKINE, V56, P669, DOI 10.1016/j.cyto.2011.08.025; Marie-Cardine A, 1999, CELL SIGNAL, V11, P705, DOI 10.1016/S0898-6568(99)00047-9; MIYAWAKI T, 1982, J IMMUNOL, V129, P2474; Norris RE, 2010, CANCER CHEMOTH PHARM, V65, P1125, DOI 10.1007/s00280-009-1120-8; Noulsri E, 2009, AM J HEMATOL, V84, P170, DOI 10.1002/ajh.21350; Nowak AK, 2003, CANCER RES, V63, P4490; Patwardhan RS, 2011, BIOCHEM PHARMACOL, V82, P642, DOI 10.1016/j.bcp.2011.06.024; Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008-5472.CAN-08-1437; Rhee YS, 2002, CLIN EXP IMMUNOL, V127, P463, DOI 10.1046/j.1365-2249.2002.01697.x; Romagnani S, 2006, CLIN EXP ALLERGY, V36, P1357, DOI 10.1111/j.1365-2222.2006.02606.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Siegel J N, 1991, Semin Immunol, V3, P325; Song PH, 2004, ACTA BIOCH BIOPH SIN, V36, P123, DOI 10.1093/abbs/36.2.123; Tatla S, 1999, FREE RADICAL BIO MED, V26, P14, DOI 10.1016/S0891-5849(98)00133-6; TSURUO T, 1981, CANCER RES, V41, P1967; Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103; Williams MS, 2004, FREE RADICAL BIO MED, V37, P1144, DOI 10.1016/j.freeradbiomed.2004.05.029; Xiao Y, 2008, INT J ONCOL, V33, P1073, DOI 10.3892/ijo_00000096; Xiao Y, 2010, INT J ONCOL, V37, P81, DOI 10.3892/ijo_00000655; Yu Y, 2012, CURR MED CHEM, V19, P2689, DOI 10.2174/092986712800609706; Yuan J, 2004, BLOOD, V104, P1450, DOI 10.1182/blood-2004-03-0868; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	50	7	8	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					782	792		10.1096/fj.12-215756	http://dx.doi.org/10.1096/fj.12-215756			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23134680				2022-12-28	WOS:000314358000036
J	Karpinich, NO; Kechele, DO; Espenschied, ST; Willcockson, HH; Fedoriw, Y; Caron, KM				Karpinich, Natalie O.; Kechele, Daniel O.; Espenschied, Scott T.; Willcockson, Helen H.; Fedoriw, Yuri; Caron, Kathleen M.			Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis	FASEB JOURNAL			English	Article						cancer; endothelial cells; metastasis; mouse models	GROWTH-FACTOR-C; VEGF-D PROMOTES; MOLECULAR-MECHANISMS; PEPTIDE RECEPTORS; METASTASIS; ANGIOGENESIS; MACROPHAGES; EXPRESSION; CELLS; CANCER	Adrenomedullin (AM) is a potent lymphangiogenic factor that promotes lymphatic endothelial cell (LEC) proliferation through a pharmacologically tractable G-protein-coupled receptor. Numerous types of human cancers have increased levels of AM; however, the functional consequences of this fact have not been characterized. Therefore, we evaluated whether modulating adrenomedullin (Adm) gene dosage within tumor cells affects lymphangiogenesis. Murine Lewis lung carcinoma (LLC) cells that overexpress or underexpress Adm were injected subcutaneously into C57BL/6 mice, and tumors were evaluated for growth and vascularization. A dosage range from similar to 10 to 200% of wild-type Adm expression did not affect LLC proliferation in vitro or in vivo, nor did it affect angiogenesis. Notably, the dosage of Adm markedly and significantly influenced tumor lymphangiogenesis. Reduced Adm expression in tumors decreased the proliferation of LECs and the number of lymphatic vessels, while elevated tumor Adm expression led to enlarged lymphatic vessels. Moreover, overexpression of Adm in tumors induced sentinel lymph node lymphangiogenesis and led to an increased incidence of Ki67-positive foci within the lung. These data show that tumor-secreted AM is a critical factor for driving both tumor and lymph node lymphangiogenesis. Thus, pharmacological targeting of AM signaling may provide a new avenue for inhibition of tumor lymphangiogenesis.-Karpinich, N. O., Kechele, D. O., Espenschied, S. T., Willcockson, H. H., Fedoriw, Y., Caron, K. M. Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis. FASEB J. 27, 590-600 (2013). www.fasebj.org	[Karpinich, Natalie O.; Kechele, Daniel O.; Espenschied, Scott T.; Willcockson, Helen H.; Caron, Kathleen M.] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; [Fedoriw, Yuri] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Caron, Kathleen M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Caron, KM (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, 111 Mason Farm Rd,CB 7545,6330 MBRB, Chapel Hill, NC 27599 USA.	kathleen_caron@med.unc.edu	Espenschied, Scott T./AAO-2900-2020; , Histology Research Core Facility/ABF-6317-2021	Caron, Kathleen/0000-0002-7033-9232; Espenschied, Scott T./0000-0001-8885-7532; Kechele, Daniel/0000-0001-5377-1392	UNC-CH University Cancer Research Innovation Award; U.S. National Institutes of Health, National Heart, Lung, and Blood Institute [HL091973]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091973] Funding Source: NIH RePORTER	UNC-CH University Cancer Research Innovation Award; U.S. National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Kirk McNaughton [University of North Carolina at Chapel Hill (UNC-CH) Histology Research Core] for assistance with tissue sectioning. This work was supported by a UNC-CH University Cancer Research Innovation Award and U.S. National Institutes of Health, National Heart, Lung, and Blood Institute grant HL091973 to K. M. C. The authors declare no conflicts of interest.	Albrecht I, 2011, INT J DEV BIOL, V55, P483, DOI 10.1387/ijdb.103226ia; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Chen PW, 2011, CLIN CANCER RES, V17, P7230, DOI 10.1158/1078-0432.CCR-11-1354; Clasper S, 2008, CANCER RES, V68, P7293, DOI 10.1158/0008-5472.CAN-07-6506; Doods H, 2007, TRENDS PHARMACOL SCI, V28, P580, DOI 10.1016/j.tips.2007.10.005; Dunworth WP, 2008, PEPTIDES, V29, P2243, DOI 10.1016/j.peptides.2008.09.009; Dunworth WP, 2009, ARTERIOSCL THROM VAS, V29, P650, DOI 10.1161/ATVBAHA.109.185066; Fagiani E, 2011, CANCER RES, V71, P5717, DOI 10.1158/0008-5472.CAN-10-4635; Fritz-Six KL, 2008, J CLIN INVEST, V118, P40, DOI 10.1172/JCI33302; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; Hay DL, 2011, ENDOCR-RELAT CANCER, V18, pC1, DOI 10.1677/ERC-10-0244; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Holopainen T, 2012, J NATL CANCER I, V104, P461, DOI 10.1093/jnci/djs009; Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9; Ji RC, 2009, HISTOL HISTOPATHOL, V24, P377, DOI 10.14670/HH-24.377; Jin DH, 2008, CARDIOVASC RES, V80, P339, DOI 10.1093/cvr/cvn228; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Karpanen T, 2001, CANCER RES, V61, P1786; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Martinez A, 2002, J NATL CANCER I, V94, P1226; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Nagaya N, 2005, AM J PHYSIOL-REG I, V288, pR1432, DOI 10.1152/ajpregu.00662.2004; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Ramachandran V, 2007, CANCER RES, V67, P2666, DOI 10.1158/0008-5472.CAN-06-3362; Ribatti D, 2005, PEPTIDES, V26, P1670, DOI 10.1016/j.peptides.2005.02.017; Roesli C, 2008, FASEB J, V22, P1933, DOI 10.1096/fj.07-100529; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Schulz P, 2011, FASEB J, V25, P3325, DOI 10.1096/fj.11-182287; Sharpe J, 2002, SCIENCE, V296, P541, DOI 10.1126/science.1068206; Shields JD, 2007, ONCOGENE, V26, P2997, DOI 10.1038/sj.onc.1210114; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; SUGIURA K, 1955, CANCER RES, V15, P38; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Thouennon E, 2010, ENDOCR-RELAT CANCER, V17, P637, DOI 10.1677/ERC-10-0109; Wallgard E, 2008, ARTERIOSCL THROM VAS, V28, P1469, DOI 10.1161/ATVBAHA.108.165738; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Zhao B, 2011, J HEPATO-BIL-PAN SCI, V18, P821, DOI 10.1007/s00534-011-0395-4; Zudaire E, 2003, REGUL PEPTIDES, V112, P175, DOI 10.1016/S0167-0115(03)00037-5	51	27	27	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					590	600		10.1096/fj.12-214080	http://dx.doi.org/10.1096/fj.12-214080			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23099649	Green Published			2022-12-28	WOS:000314358000018
J	Maingat, FG; Polyak, MJ; Paul, AM; Vivithanaporn, P; Noorbakhsh, F; Ahboucha, S; Baker, GB; Pearson, K; Power, C				Maingat, Ferdinand G.; Polyak, Maria J.; Paul, Amber M.; Vivithanaporn, Pornpun; Noorbakhsh, Farshid; Ahboucha, Samir; Baker, Glen B.; Pearson, Keir; Power, Christopher			Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence	FASEB JOURNAL			English	Article						FIV; inflammation; glia; neuron	FELINE-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; NEUROACTIVE STEROIDS; LENTIVIRUS INFECTION; NEURONAL INJURY; NEUROCOGNITIVE IMPAIRMENT; DEHYDROEPIANDROSTERONE; RECEPTOR; ACTIVATION; HORMONE	Neurosteroids are cholesterol-derived molecules synthesized within the brain, which exert trophic and protective actions. Infection by human and feline immunodeficiency viruses (HIV and FIV, respectively) causes neuroinflammation and neurodegeneration, leading to neurological deficits. Secretion of neuroinflammatory host and viral factors by glia and infiltrating leukocytes mediates the principal neuropathogenic mechanisms during lentivirus infections, although the effect of neurosteroids on these processes is unknown. We investigated the interactions between neurosteroid-mediated effects and lentivirus infection outcomes. Analyses of HIV-infected (HIV+) and uninfected human brains disclosed a reduction in neurosteroid synthesis enzyme expression. Human neurons exposed to supernatants from HIV+ macrophages exhibited suppressed enzyme expression without reduced cellular viability. HIV+ human macrophages treated with sulfated dehydroepiandrosterone (DHEA-S) showed suppression of inflammatory gene (IL-1 beta, IL-6, TNF-alpha) expression. FIV-infected (FIV+) animals treated daily with 15 mg/kg body weight. DHEA-S treatment reduced inflammatory gene transcripts (IL-1 beta, TNF-alpha, CD3 epsilon, GFAP) in brain compared to vehicle-(beta-cyclodextrin)-treated FIV+ animals similar to levels found in vehicle-treated FIV- animals. DHEA-S treatment also increased CD4(+) T-cell levels and prevented neurobehavioral deficits and neuronal loss among FIV+ animals, compared to vehicle-treated FIV+ animals. Reduced neuronal neurosteroid synthesis was evident in lentivirus infections, but treatment with DHEA-S limited neuroinflammation and prevented neurobehavioral deficits. Neurosteroid-derived therapies could be effective in the treatment of virus-or inflammation-mediated neurodegeneration.-Maingat, F. G., Polyak, M. J., Paul, A. M., Vivithanaporn, P., Noorbakhsh, F., Ahboucha S., Baker, G. B., Pearson, K., Power, C. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB J. 27, 725-737 (2013). www.fasebj.org	[Maingat, Ferdinand G.; Polyak, Maria J.; Paul, Amber M.; Vivithanaporn, Pornpun; Noorbakhsh, Farshid; Power, Christopher] Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; [Baker, Glen B.; Power, Christopher] Univ Alberta, Dept Psychiat, Edmonton, AB T6G 2S2, Canada; [Pearson, Keir] Univ Alberta, Dept Physiol, Edmonton, AB T6G 2S2, Canada; [Vivithanaporn, Pornpun] Mahidol Univ, Fac Sci, Dept Pharmacol, Bangkok 10400, Thailand; [Ahboucha, Samir] Univ Cadi Ayyad, Fac Sci, Dept Pharmacol & Environm, Marrakech, Morocco	University of Alberta; University of Alberta; University of Alberta; Mahidol University; Cadi Ayyad University of Marrakech	Power, C (corresponding author), Univ Alberta, Dept Med, Heritage Med Res Ctr 6 11, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca	AHBOUCHA, Samir/AAE-4294-2020	Power, Christopher/0000-0002-5131-9711; Paul, Amber/0000-0002-1657-3618	Alberta Innovates-Health Solutions; Canadian Institutes of Health Research	Alberta Innovates-Health Solutions; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	C.P. holds a Canada Research Chair (CRC; tier 1) in Neurological Infection and Immunity and is an Alberta Innovates-Health Solutions Senior Scholar. P. V. holds a fellowship from Alberta Innovates-Health Solutions. These studies were supported by the Canadian Institutes of Health Research (C. P., G. B. B.). The authors thank Dr. Synthia Mellon (University of California, San Francisco, CA, USA) for generously providing antibodies for these studies and helpful discussions. The authors are grateful to Ms. Gail Rauw for her expert technical assistance in assaying levels of the neurosteroids. The authors declare no conflicts of interest.	Abrams DI, 2007, AIDS RES HUM RETROV, V23, P77, DOI [10.1089/aid.2006.0107, 10.1089/aid.2006.0170]; Afkhami-Goli A, 2007, J IMMUNOL, V179, P5493, DOI 10.4049/jimmunol.179.8.5493; Ahboucha S, 2008, NEUROGASTROENT MOTIL, V20, P671, DOI 10.1111/j.1365-2982.2007.01080.x; Ahboucha S, 2007, METAB BRAIN DIS, V22, P291, DOI 10.1007/s11011-007-9065-2; Barger SW, 2000, J NEUROSCI RES, V62, P503, DOI 10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BENDINELLI M, 1995, CLIN MICROBIOL REV, V8, P87, DOI 10.1128/CMR.8.1.87; Bhat RK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019176; BLACK SM, 1993, ENDOCRINOLOGY, V132, P539, DOI 10.1210/en.132.2.539; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; Borjabad A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002213; Boven LA, 2007, J NEUROVIROL, V13, P173, DOI 10.1080/13550280701258399; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Dong LY, 2009, J PHARMACOL EXP THER, V330, P494, DOI 10.1124/jpet.109.154294; Dubrovsky B, 2006, PHARMACOL BIOCHEM BE, V84, P644, DOI 10.1016/j.pbb.2006.06.016; Dubrovsky BO, 2005, PROG NEURO-PSYCHOPH, V29, P169, DOI 10.1016/j.pnpbp.2004.11.001; Epstein LG, 1999, J LEUKOCYTE BIOL, V65, P453, DOI 10.1002/jlb.65.4.453; Eser D, 2006, PHARMACOL BIOCHEM BE, V84, P656, DOI 10.1016/j.pbb.2006.05.020; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Johnston J, 1999, J VIROL, V73, P2491, DOI 10.1128/JVI.73.3.2491-2498.1999; Johnston JB, 2002, J NEUROVIROL, V8, P420, DOI 10.1080/13550280260422721; KALIMI M, 1994, MOL CELL BIOCHEM, V131, P99, DOI 10.1007/BF00925945; Kennedy JM, 2004, AIDS, V18, P1241, DOI 10.1097/00002030-200406180-00002; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; Le Melledo JM, 2002, J PSYCHIATR NEUROSCI, V27, P161; LEVINE MS, 1987, NEUROBIOL AGING, V8, P253, DOI 10.1016/0197-4580(87)90010-8; Lombardi G, 2001, BRIT J PHARMACOL, V133, P936, DOI 10.1038/sj.bjp.0704134; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Luchetti S, 2011, NEUROSCIENCE, V191, P6, DOI 10.1016/j.neuroscience.2011.04.010; MacKenzie EM, 2007, CELL MOL NEUROBIOL, V27, P541, DOI 10.1007/s10571-006-9086-0; Maingat F, 2011, FASEB J, V25, P2211, DOI 10.1096/fj.10-175992; Maingat F, 2009, J NEUROSCI, V29, P8429, DOI 10.1523/JNEUROSCI.5818-08.2009; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Maninger N, 2009, FRONT NEUROENDOCRIN, V30, P65, DOI 10.1016/j.yfrne.2008.11.002; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Maurice T, 2001, BRAIN RES REV, V37, P116, DOI 10.1016/S0165-0173(01)00112-6; McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4; McVea DA, 2006, J NEUROSCI, V26, P1175, DOI 10.1523/JNEUROSCI.4458-05.2006; Mellon SH, 2002, ENDOCR RES, V28, P463, DOI 10.1081/ERC-120016823; Mellon SH, 2002, TRENDS ENDOCRIN MET, V13, P35, DOI 10.1016/S1043-2760(01)00503-3; Mellon SH, 2007, PHARMACOL THERAPEUT, V116, P107, DOI 10.1016/j.pharmthera.2007.04.011; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Nigam R, 2010, ARCH DERMATOL RES, V302, P507, DOI 10.1007/s00403-010-1052-5; Noorbakhsh F, 2005, J IMMUNOL, V174, P7320, DOI 10.4049/jimmunol.174.11.7320; Noorbakhsh F, 2006, VIROLOGY, V348, P260, DOI 10.1016/j.virol.2005.10.044; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; PARKCHUNG MJ, 1994, MOL PHARMACOL, V46, P146; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pedersen NC, 2003, VET IMMUNOL IMMUNOP, V94, P133, DOI 10.1016/S0165-2427(03)00081-3; Piketty C, 2001, CLIN ENDOCRINOL, V55, P325, DOI 10.1046/j.1365-2265.2001.01310.x; Poli A, 1999, J NEUROVIROL, V5, P465, DOI 10.3109/13550289909045375; Power C, 1997, NEUROSCIENCE, V77, P1175, DOI 10.1016/S0306-4522(96)00531-3; Power C, 1998, J VIROL, V72, P9109, DOI 10.1128/JVI.72.11.9109-9115.1998; Power C, 1998, J VIROL, V72, P9045, DOI 10.1128/JVI.72.11.9045-9053.1998; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Power C, 2009, CAN J NEUROL SCI, V36, P285, DOI 10.1017/S0317167100007009; Rackstraw S, 2011, PSYCHOL HEALTH MED, V16, P548, DOI 10.1080/13548506.2011.579992; Ritsner MS, 2011, NEUROSCIENCE, V191, P91, DOI 10.1016/j.neuroscience.2011.04.017; Ritsner MS, 2010, J PSYCHIATR RES, V44, P75, DOI 10.1016/j.jpsychires.2009.07.002; Roy A, 2007, J VIROL, V81, P7993, DOI 10.1128/JVI.00710-07; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Schule C, 2011, NEUROSCIENCE, V191, P55, DOI 10.1016/j.neuroscience.2011.03.025; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; Scott-Sheldon L. A., 2008, HEALTH PSYCHOL, V27, P129; Strous RD, 2006, EUR NEUROPSYCHOPHARM, V16, P155, DOI 10.1016/j.euroneuro.2005.09.005; Traish AM, 2011, J SEX MED, V8, P2960, DOI 10.1111/j.1743-6109.2011.02523.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsutsui S, 2008, FASEB J, V22, P786, DOI 10.1096/fj.07-9002com; van Marle G, 2005, J NEUROVIROL, V11, P107, DOI 10.1080/13550280590922838; WARNER M, 1995, FRONT NEUROENDOCRIN, V16, P224, DOI 10.1006/frne.1995.1008; Weaver CE, 1997, P NATL ACAD SCI USA, V94, P10450, DOI 10.1073/pnas.94.19.10450; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wetzel CHR, 1998, MOL ENDOCRINOL, V12, P1441, DOI 10.1210/me.12.9.1441; Wright E, 2011, CURR OPIN HIV AIDS, V6, P303, DOI 10.1097/COH.0b013e3283477c46; WU FS, 1991, MOL PHARMACOL, V40, P333; Zhu Y, 2005, J IMMUNOL, V175, P1118, DOI 10.4049/jimmunol.175.2.1118; Zhu Y, 2009, FASEB J, V23, P2928, DOI 10.1096/fj.08-128819; Zink MC, 2006, CURR HIV RES, V4, P293	82	28	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					725	737		10.1096/fj.12-215079	http://dx.doi.org/10.1096/fj.12-215079			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150523				2022-12-28	WOS:000314358000031
J	Rochelle, T; Daubon, T; Van Troys, M; Harnois, T; Waterschoot, D; Ampe, C; Roy, L; Bourmeyster, N; Constantin, B				Rochelle, Tristan; Daubon, Thomas; Van Troys, Marleen; Harnois, Thomas; Waterschoot, Davy; Ampe, Christophe; Roy, Lydia; Bourmeyster, Nicolas; Constantin, Bruno			p210(bcr-abl) induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1	FASEB JOURNAL			English	Article						isoform selectivity; cell migration; GTPases; actin-binding proteins; signalplex; leukemia	TUMOR-CELL INVASION; ACTIN-DEPOLYMERIZING FACTOR; BCR-ABL ONCOGENE; CHEMOTACTIC RESPONSE; RHO-GTPASES; LIM-KINASE; MIGRATION; COFILIN; BCR/ABL; PHOSPHORYLATION	We previously demonstrated that the BcrAbl oncogene, p210(bcr-abl), through its unique GEF domain, specifically activates RhoA and induces spontaneous amoeboid motility. We intend to study the pathways downstream RhoA controlling amoeboid motility. Mouse prolymphoblastic cells (Ba/F3 cell line) expressing different forms of Bcr-Abl were embedded in 3-dimensional (3D) Matrigel to study motility and explore the effects of inhibiting Rho pathway (inhibitors and siRNAs). The phosphorylation levels of cofilin-1 and destrin were analyzed by 2-dimensional electrophoresis. Composition of Bcr-Abl signalplex in different conditions was determined by coimmunoprecipitation. Ba/F3p190 and Ba/F3 expressing a mutant form of p210(bcr-abl) (unable to activate RhoA) cells presented a spontaneous motility, but not an amoeboid type. p210(bcr-abl)-induced amoeboid motility in a 3D matrix requires isoform-specific RhoA/ROCK-1/destrin signaling. Next to the conventional Rho/ROCK/MLC/myosin pathway, this pathway is a crucial determinant for amoeboid motility, specific for the destrin isoform (and not its coexpressed homologue cofilin-1). Also, the presence of destrin (and not cofilin-1) in the p210(bcr-abl) complex is dependent on ROCK1, and this signalplex is required for amoeboid motility. This underscores isoform-specific function within the ADF/cofilin family and provides new insight into Bcr-Abl signaling to amoeboid motility and possible impact on understanding chronic myeloid leukemia progression.-Rochelle, T., Daubon, T., Van Troys, M., Harnois, T., Waterschoot, D., Ampe, C., Roy, L., Bourmeyster, N., Constantin, B. p210(bcr-abl) induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1. FASEB J. 27, 123-134 (2013). www.fasebj.org	[Rochelle, Tristan; Daubon, Thomas; Roy, Lydia; Bourmeyster, Nicolas; Constantin, Bruno] Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France; [Harnois, Thomas; Bourmeyster, Nicolas] Univ Poitiers, Plateforme Prote ProteomeUP, F-86022 Poitiers, France; [Van Troys, Marleen; Waterschoot, Davy; Ampe, Christophe] Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; [Van Troys, Marleen; Waterschoot, Davy; Ampe, Christophe] Univ Ghent VIB, Dept Med Prot Res, B-9052 Ghent, Belgium; [Harnois, Thomas; Roy, Lydia; Bourmeyster, Nicolas] Ctr Hosp Univ Poitiers, Poitiers, France; [Roy, Lydia] INSERM, CIC 802, Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Universite de Poitiers; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Bourmeyster, N (corresponding author), Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, Batiment B36,1 Rue Georges Bonnet, F-86022 Poitiers, France.	n.bourmeyster@chu-poitiers.fr	Constantin, Bruno/AAH-6463-2021	Constantin, Bruno/0000-0003-1668-581X; DAUBON, Thomas/0000-0002-0319-7617; Bourmeyster, Nicolas/0000-0002-9563-5142; Van Troys, Marleen/0000-0003-4283-8103	Ligue Nationale Contre le Cancer (Vienne, Charente-Maritime, Deux-Sevres, Loir-et-Cher); Sport et Collection; Association Pictave pour l'Etude des Maladies du SAng (APEMSA)	Ligue Nationale Contre le Cancer (Vienne, Charente-Maritime, Deux-Sevres, Loir-et-Cher); Sport et Collection; Association Pictave pour l'Etude des Maladies du SAng (APEMSA)	The authors thank Nathalie Piccirilli for efficient technical help with cell cultures and Anne Cantereau for the microscopy platform ImageUP. This work was realized using grants from the Ligue Nationale Contre le Cancer (Vienne, Charente-Maritime, Deux-Sevres, Loir-et-Cher), Sport et Collection, and Association Pictave pour l'Etude des Maladies du SAng (APEMSA). The authors declare no conflicts of interest.	Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Chang YC, 2009, ONCOGENE, V28, P4105, DOI 10.1038/onc.2009.260; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Daubon T, 2008, ONCOGENE, V27, P2673, DOI 10.1038/sj.onc.1210933; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Fierro FA, 2008, J MOL BIOL, V377, P1082, DOI 10.1016/j.jmb.2008.01.085; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gorlich A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026789; Gurniak CB, 2005, DEV BIOL, V278, P231, DOI 10.1016/j.ydbio.2004.11.010; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Hirayama A, 2007, J LEUKOCYTE BIOL, V81, P720, DOI 10.1189/jlb.0506314; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klemke M, 2010, EMBO J, V29, P2915, DOI 10.1038/emboj.2010.153; Kuure S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001176; Kuzelova Katerina, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P261, DOI 10.2174/187152908786786241; Ladwein M, 2008, FEBS LETT, V582, P2066, DOI 10.1016/j.febslet.2008.04.033; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Lammermann T, 2009, CURR OPIN CELL BIOL, V21, P636, DOI 10.1016/j.ceb.2009.05.003; Lee CF, 2010, PROTEOMICS, V10, P3321, DOI 10.1002/pmic.201000176; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; Noma K, 2008, J CLIN INVEST, V118, P1632, DOI 10.1172/JCI29226; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Pellegrin S, 2007, J CELL SCI, V120, P3491, DOI 10.1242/jcs.018473; Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1999, BLOOD, V94, P4233; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Shi JJ, 2011, PEDIATR CARDIOL, V32, P297, DOI 10.1007/s00246-011-9920-0; Sixt M, 2011, METHODS MOL BIOL, V769, P149, DOI 10.1007/978-1-61779-207-6_11; Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015; Torka R, 2006, EXP CELL RES, V312, P3857, DOI 10.1016/j.yexcr.2006.08.025; Unwin RD, 2005, J BIOL CHEM, V280, P6316, DOI 10.1074/jbc.M410598200; Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Wen ZX, 2007, J CELL BIOL, V178, P107, DOI 10.1083/jcb.200703055; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Wolf K, 2003, BLOOD, V102, P3262, DOI 10.1182/blood-2002-12-3791; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280; Yoshida K, 2006, J CELL SCI, V119, P3833, DOI 10.1242/jcs.03152	58	12	12	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					123	134		10.1096/fj.12-205112	http://dx.doi.org/10.1096/fj.12-205112			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047898				2022-12-28	WOS:000313103200013
J	Chang, Y; Al-Alwan, L; Risse, PA; Halayko, AJ; Martin, JG; Baglole, CJ; Eidelman, DH; Hamid, Q				Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Halayko, Andrew J.; Martin, James G.; Baglole, Carolyn J.; Eidelman, David H.; Hamid, Qutayba			Th17-associated cytokines promote human airway smooth muscle cell proliferation	FASEB JOURNAL			English	Article						asthma; apoptosis; ERK; NF-kappa B	INTERLEUKIN-17; ACTIVATION; RECEPTOR; GROWTH; ROLES; INFLAMMATION; RECRUITMENT; NEUTROPHIL; EXPRESSION; INDUCTION	Increased airway smooth muscle (ASM) mass is a hallmark of airway remodeling in severe asthma. Th17-associated cytokines, particularly IL-17A, IL-17F, and IL-22, have been postulated to play a role in the pathogenesis of asthma. To investigate the in vitro effect of Th17 cytokines on the proliferation and survival of airway smooth muscle cells (ASMCs), human ASMCs from asthmatic and nonasthmatic subjects were incubated with IL-17A, IL-17F, or IL-22. The aforementioned cytokines demonstrated an ability to promote proliferation and survival of ASMCs from asthmatic and nonasthmatic subjects, which were mediated by selective activation of their corresponding receptors on ASMCs, including IL-17RA, IL-17RC, or IL-22R1, respectively. IL-17A and IL-17F-induced proliferation of ASMCs was dependent on ERK1/2 MAPK pathway, while IL-22-induced proliferation involved both ERK1/2 MAPK and NF-kappa B pathways. The involvement of signaling pathways was further confirmed by the inhibition of proliferation by knockdown of ERK1/2 MAPK or NF-kappa B p65 expression with pathway-specific siRNA. Together, our results show that Th17-associated cytokines promote proliferation and reduce the apoptotic rate of human ASMCs, raising the possibility that Th17 cytokines may contribute to increasing airway smooth muscle mass and airway remodeling in asthma.-Chang, Y., Al-Alwan, L., Risse, P.-A., Halayko, A. J., Martin, J. G.. Baglole, C. J., Eidelman, D. H., Hamid, Q. Th17-associated cytokines promote human airway smooth muscle cell proliferation. FASEB J. 26, 5152-5160 (2012). www.fasebj.org	[Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Martin, James G.; Baglole, Carolyn J.; Eidelman, David H.; Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; [Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Martin, James G.; Baglole, Carolyn J.; Eidelman, David H.; Hamid, Qutayba] McGill Univ, Dept Med, Div Resp, Montreal, PQ H2X 2P2, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Resp Hosp, Winnipeg, MB, Canada	McGill University; McGill University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 Rue St Urbain, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Chang, Ying/I-1362-2012	Halayko, Andrew/0000-0002-7865-4552; Martin, James/0000-0001-7574-5363	Canadian Institutes of Health Research; Costello Memorial Fund; McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Costello Memorial Fund; McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec	This work was supported by the Canadian Institutes of Health Research, the Costello Memorial Fund, and the McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec.	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Chang SH, 2009, CYTOKINE, V46, P7, DOI 10.1016/j.cyto.2008.12.024; Chang Y, 2011, J ALLERGY CLIN IMMUN, V127, P1046, DOI 10.1016/j.jaci.2010.12.1117; Dragon S, 2008, MOL IMMUNOL, V45, P160, DOI 10.1016/j.molimm.2007.04.027; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Girodet PO, 2011, PHARMACOL THERAPEUT, V130, P325, DOI 10.1016/j.pharmthera.2011.02.001; Gosens R, 2002, BRIT J PHARMACOL, V137, P459, DOI 10.1038/sj.bjp.0704889; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; Halwani R, 2011, J IMMUNOL, V186, P4156, DOI 10.4049/jimmunol.1001210; Hirota JA, 2011, AM J RESP CELL MOL, V45, P566, DOI 10.1165/rcmb.2010-0277OC; Hirst SJ, 1996, AM J PHYSIOL-LUNG C, V270, pL415, DOI 10.1152/ajplung.1996.270.3.L415; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Joubert P, 2005, J ALLERGY CLIN IMMUN, V116, P713, DOI 10.1016/j.jaci.2005.05.042; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Kuestner RE, 2007, J IMMUNOL, V179, P5462, DOI 10.4049/jimmunol.179.8.5462; Kuma Y., 2005, J BIOL CHEM, V280, P19472; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Linden A, 2006, PULM PHARMACOL THER, V19, P47, DOI 10.1016/j.pupt.2005.02.004; Linden A, 2001, INT ARCH ALLERGY IMM, V126, P179, DOI 10.1159/000049511; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Robins S, 2011, AM J RESP CELL MOL, V45, P984, DOI 10.1165/rcmb.2010-0450OC; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Seidel P, 2009, AM J PHYSIOL-LUNG C, V297, pL326, DOI 10.1152/ajplung.90624.2008; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Silverpil E, 2011, INFLAMMATION, V34, P1, DOI 10.1007/s10753-010-9201-8; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Sumi Yuki, 2007, Allergol Int, V56, P341, DOI 10.2332/allergolint.R-07-153; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Wolk K, 2010, SEMIN IMMUNOPATHOL, V32, P17, DOI 10.1007/s00281-009-0188-x; Xie SP, 2007, AM J PHYSIOL-LUNG C, V293, pL245, DOI 10.1152/ajplung.00068.2007; Ying-Fang S, 2007, INDIAN J MED RES, V126, P139; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zrioual S, 2008, J IMMUNOL, V180, P655, DOI 10.4049/jimmunol.180.1.655	40	92	99	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5152	5160		10.1096/fj.12-208033	http://dx.doi.org/10.1096/fj.12-208033			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22898922				2022-12-28	WOS:000311838300035
J	Sandoval-Guzman, T; Gongrich, C; Moliner, A; Guo, TQ; Wu, HY; Broberger, C; Ibanez, CF				Sandoval-Guzman, Tatiana; Gongrich, Christina; Moliner, Annalena; Guo, Tingqing; Wu, Haiya; Broberger, Christian; Ibanez, Carlos F.			Neuroendocrine control of female reproductive function by the activin receptor ALK7	FASEB JOURNAL			English	Article						ovary; pituitary; hypothalamus; NPY; PCOS	HORMONE-RELEASING HORMONE; FOLLICLE-STIMULATING-HORMONE; NEUROPEPTIDE-Y; GENE-EXPRESSION; INHIBIN/ACTIVIN SUBUNITS; ARCUATE NUCLEUS; ADIPOSE-TISSUE; HYPOTHALAMUS; MODULATION; INHIBIN	Activins are critical components of the signaling network that controls female reproduction. However, their roles in hypothalamus, and the specific functions of their different receptors, have not been elucidated. Here, we investigated the expression and function of the activin receptor ALK7 in the female reproductive axis using Alk7-knockout mice. ALK7 was found in subsets of SF1-expressing granulosa cells in the ovary, FSH gonadotrophs in the pituitary, and NPY-expressing neurons in the arcuate nucleus of the hypothalamus. Alk7-knockout females showed delayed onset of puberty and abnormal estrous cyclicity, had abnormal diestrous levels of FSH and LH in serum, and their ovaries showed premature depletion of follicles, oocyte degeneration, and impaired responses to exogenous gonadotropins. In the arcuate nucleus, mutant mice showed reduced expression of Npy mRNA and lower numbers of Npy-expressing neurons than wildtype controls. Alk7 knockouts showed a selective loss of arcuate NPY/AgRP innervation in the medial preoptic area, a key central regulator of reproduction. These results indicate that ALK7 is an important regulator of female reproductive function and reveal a new role for activin signaling in the control of hypothalamic gene expression and wiring. Alk7 gene variants may contribute to female reproductive disorders in humans, such as polycystic ovary syndrome.-Sandoval-Guzman, T., Gongrich, C., Moliner, A., Guo, T., Wu, H., Broberger, C., Ibanez, C. F. Neuroendocrine control of female reproductive function by the activin receptor ALK7. FASEB J. 26, 4966-4976 (2012). www.fasebj.org	[Sandoval-Guzman, Tatiana; Gongrich, Christina; Moliner, Annalena; Guo, Tingqing; Wu, Haiya; Broberger, Christian; Ibanez, Carlos F.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Stockholm, Sweden.	carlos.ibanez@ki.se	Sandoval-Guzman, Tatiana/P-3795-2018; Sandoval-Guzmán, Tatiana/B-8172-2017; Sandoval-Guzmán, Tatiana/P-2473-2019	Sandoval-Guzmán, Tatiana/0000-0003-1802-5145; Sandoval-Guzmán, Tatiana/0000-0003-1802-5145; Gongrich, Christina/0000-0003-4495-1476	Swedish Research Council; Swedish Cancer Society; European Research Council; Novo Nordisk Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); European Research Council(European Research Council (ERC)European Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	This work was supported by grants from the Swedish Research Council, the Swedish Cancer Society, and the European Research Council to C. F. I.; and the Swedish Research Council, Novo Nordisk Foundation, and European Research Council to C.B.	Andersson O, 2008, P NATL ACAD SCI USA, V105, P7252, DOI 10.1073/pnas.0800272105; Andersson O, 2007, DEV BIOL, V311, P500, DOI 10.1016/j.ydbio.2007.08.060; Andersson O, 2006, EMBO REP, V7, P831, DOI 10.1038/sj.embor.7400752; Andersson O, 2006, DEV BIOL, V293, P370, DOI 10.1016/j.ydbio.2006.02.002; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; Bernard DJ, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-52; Bertolino P, 2008, P NATL ACAD SCI USA, V105, P7246, DOI 10.1073/pnas.0801285105; BILEZIKJIAN LM, 1993, ENDOCRINOLOGY, V133, P2554, DOI 10.1210/en.133.6.2554; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Bristol-Gould SK, 2006, DEV BIOL, V298, P132, DOI 10.1016/j.ydbio.2006.06.025; Broberger C, 1998, J COMP NEUROL, V402, P460; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; Burger LL, 2007, AM J PHYSIOL-ENDOC M, V293, pE277, DOI 10.1152/ajpendo.00447.2006; Calogero AE, 1998, J ENDOCRINOL, V156, P269, DOI 10.1677/joe.0.1560269; Campbell RE, 2001, NEUROENDOCRINOLOGY, V74, P106, DOI 10.1159/000054676; Cho BN, 2001, ENDOCRINOLOGY, V142, P4994, DOI 10.1210/en.142.11.4994; CROWLEY WR, 1987, ENDOCRINOLOGY, V120, P941, DOI 10.1210/endo-120-3-941; CROWLEY WR, 1987, NEUROENDOCRINOLOGY, V46, P97, DOI 10.1159/000124804; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ewens KG, 2010, J CLIN ENDOCR METAB, V95, P2306, DOI 10.1210/jc.2009-2703; Furuta C, 2008, ENDOCRINE, V33, P126, DOI 10.1007/s12020-008-9073-y; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; GONZALEZMANCHON C, 1991, NEUROENDOCRINOLOGY, V54, P373, DOI 10.1159/000125916; Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Hoggard N, 2009, J MOL ENDOCRINOL, V43, P171, DOI 10.1677/JME-09-0046; Jornvall H, 2004, MOL CELL BIOL, V24, P9383, DOI 10.1128/MCB.24.21.9383-9389.2004; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Kupershmidt L, 2007, J NEUROCHEM, V103, P962, DOI 10.1111/j.1471-4159.2007.04785.x; Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382; LI SY, 1994, MOL BRAIN RES, V26, P69, DOI 10.1016/0169-328X(94)90075-2; Lorentzon M, 1996, EXP NEUROL, V142, P351, DOI 10.1006/exnr.1996.0204; MATSUO H, 1971, BIOCHEM BIOPH RES CO, V43, P1334, DOI 10.1016/S0006-291X(71)80019-0; McGinnis MY, 1996, PHYSIOL BEHAV, V60, P783; Murata T, 1997, ENDOCR J, V44, P35, DOI 10.1507/endocrj.44.35; Nakane P. K., 1970, CLASSIFICATIONS ANTE, V18, P9; Pangas SA, 2007, MOL ENDOCRINOL, V21, P2458, DOI 10.1210/me.2007-0146; Paxinos G, 2004, MOUSE BRAIN STEREOTA; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PLOTSKY PM, 1991, ENDOCRINOLOGY, V128, P2520, DOI 10.1210/endo-128-5-2520; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; SCHWARTZ MW, 1991, ENDOCRINOLOGY, V128, P2645, DOI 10.1210/endo-128-5-2645; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shoji-Kasai Y, 2007, J CELL SCI, V120, P3830, DOI 10.1242/jcs.012450; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thackray VG, 2008, ENDOCRINOLOGY, V149, P1091, DOI 10.1210/en.2007-1498; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Turi GF, 2003, ENDOCRINOLOGY, V144, P4967, DOI 10.1210/en.2003-0470; Urban JH, 1996, NEUROENDOCRINOLOGY, V63, P112, DOI 10.1159/000126947; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Wang H, 2006, MOL ENDOCRINOL, V20, P2469, DOI 10.1210/me.2005-0446; Weng Q, 2006, J REPROD DEVELOP, V52, P607, DOI 10.1262/jrd.18026; Wilson ME, 1998, BIOL REPROD, V59, P278, DOI 10.1095/biolreprod59.2.278; WOLLER MJ, 1991, ENDOCRINOLOGY, V128, P1144, DOI 10.1210/endo-128-2-1144; Xu GX, 2004, J CLIN ENDOCR METAB, V89, P5523, DOI 10.1210/jc.2004-0893; Xu M, 2000, NEUROENDOCRINOLOGY, V72, P263, DOI 10.1159/000054595	62	20	22	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4966	4976		10.1096/fj.11-199059	http://dx.doi.org/10.1096/fj.11-199059			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22954591				2022-12-28	WOS:000311838300019
J	Gallo, LA; Tran, M; Moritz, KM; Jefferies, AJ; Wlodek, ME				Gallo, Linda A.; Tran, Melanie; Moritz, Karen M.; Jefferies, Andrew J.; Wlodek, Mary E.			Pregnancy in aged rats that were born small: cardiorenal and metabolic adaptations and second-generation fetal growth	FASEB JOURNAL			English	Article						growth restriction; maternal age; gestational; blood pressure; glucose tolerance	MATERNAL PROTEIN RESTRICTION; REDUCING LITTER SIZE; UTEROPLACENTAL INSUFFICIENCY; BLOOD-PRESSURE; GLUCOSE-TOLERANCE; BARKER HYPOTHESIS; PRENATAL EXPOSURE; UTERINE ARTERY; RENAL-FUNCTION; BIRTH-WEIGHT	Uteroplacental insufficiency is associated with adult cardiorenal and metabolic diseases, particularly in males. Pregnancy is the greatest physiological challenge facing women, and those born small are at increased risk of gestational hypertension and diabetes and delivering smaller babies. Increased maternal age is associated with exacerbated pregnancy complications. We hypothesized that pregnancy in aged, growth-restricted females unmasks an underlying predisposition to cardiorenal and metabolic dysfunction and compromises fetal growth. Uteroplacental insufficiency was induced by bilateral uterine vessel ligation (restricted group) or sham surgery (control group) on d 18 of gestation in Wistar Kyoto rats. At 12 mo, growth-restricted F1 female offspring were mated with a normal male. F1 restricted females had elevated systolic blood pressure, before and during pregnancy (+10 mmHg) but normal renal and metabolic pregnancy adaptations. F2 fetal weight was not different between groups. In control and restricted females, advanced maternal age (12 vs. 4 mo) was associated with a reduction in the hypoglycemic response to pregnancy and reduced F2 fetal litter size and body weight. Aged rats born small exhibited mostly normal pregnancy adaptations, although they had elevated blood pressure. Advanced maternal age was associated with poorer fetal outcomes that were not exacerbated by low maternal birth weight.-Gallo, L. A., Tran, M., Moritz, K. M., Jefferies, A. J., Wlodek, M. E. Pregnancy in aged rats that were born small: cardiorenal and metabolic adaptations and second-generation fetal growth. FASEB J. 26, 4337-4347 (2012). www.fasebj.org	[Gallo, Linda A.; Tran, Melanie; Jefferies, Andrew J.; Wlodek, Mary E.] Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia; [Moritz, Karen M.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia	University of Melbourne; University of Queensland	Wlodek, ME (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.	m.wlodek@unimelb.edu.au	Dalton-O'Reilly, Jessica/AAM-8569-2021; wlodek, Mary/A-8939-2019; Gallo, Linda A/M-3197-2014; Moritz, Karen/G-2508-2015	wlodek, Mary/0000-0002-8490-9099; Gallo, Linda A/0000-0002-0471-8517; Moritz, Karen/0000-0002-8085-0034; Tran, Melanie/0000-0003-1427-841X	National Health and Medical Research Council of Australia [400004]; Heart Foundation of Australia [G 08M 3698]; March of Dimes Birth Defects Foundation, USA [6-FY08-269]; National Heart Foundation Biomedical Scholarship; University of Melbourne Faculty Research Scholarship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation of Australia(National Heart Foundation of Australia); March of Dimes Birth Defects Foundation, USA(March of Dimes); National Heart Foundation Biomedical Scholarship; University of Melbourne Faculty Research Scholarship	The authors acknowledge the technical assistance of Kerryn Westcott and Jordanna Master. This work was funded by the National Health and Medical Research Council of Australia (grant 400004), the Heart Foundation of Australia (G 08M 3698), and the March of Dimes Birth Defects Foundation, USA (grant 6-FY08-269). L.A.G. was supported by a National Heart Foundation Biomedical Scholarship and a University of Melbourne Faculty Research Scholarship.	BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Black MJ, 2012, AM J PHYSIOL-REG I, V302, pR1101, DOI 10.1152/ajpregu.00030.2012; Blondeau B, 1999, ENDOCRINOLOGY, V140, P4208, DOI 10.1210/en.140.9.4208; Caluwaerts S, 2006, METABOLISM, V55, P409, DOI 10.1016/j.metabol.2005.10.001; Gallo LA, 2012, CELL TISSUE RES, V349, P863, DOI 10.1007/s00441-012-1411-y; Gallo LA, 2012, HYPERTENSION, V60, P206, DOI 10.1161/HYPERTENSIONAHA.112.195578; Gallo LA, 2012, J PHYSIOL-LONDON, V590, P617, DOI 10.1113/jphysiol.2011.219147; Haavaldsen C, 2011, BJOG-INT J OBSTET GY, V118, P1470, DOI 10.1111/j.1471-0528.2011.03053.x; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Harrison M, 2009, BRIT J NUTR, V101, P1020, DOI 10.1017/S0007114508057607; Heffner LJ, 2004, NEW ENGL J MED, V351, P1927, DOI 10.1056/NEJMp048087; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Henriksen T, 2002, ACTA OBSTET GYN SCAN, V81, P112, DOI 10.1034/j.1600-0412.2002.810204.x; Hoppe CC, 2009, PHYSIOL RES, V58, P69, DOI 10.33549/physiolres.931390; Hoy WE, 1999, KIDNEY INT, V56, P1072, DOI 10.1046/j.1523-1755.1999.00633.x; Huang L, 2008, CAN MED ASSOC J, V178, P165, DOI 10.1503/cmaj.070150; Klebanoff MA, 1999, ARCH INTERN MED, V159, P1607, DOI 10.1001/archinte.159.14.1607; Laker RC, 2011, AM J PHYSIOL-ENDOC M, V301, pE931, DOI 10.1152/ajpendo.00114.2011; Langley-Evans SC, 2005, MATERN CHILD NUTR, V1, P142, DOI 10.1111/j.1740-8709.2005.00015.x; Mazzuca MQ, 2010, J PHYSIOL-LONDON, V588, P1997, DOI 10.1113/jphysiol.2010.187849; Mook-Kanamori DO, 2010, JAMA-J AM MED ASSOC, V303, P527, DOI 10.1001/jama.2010.78; Moritz KM, 2009, J PHYSIOL-LONDON, V587, P2635, DOI 10.1113/jphysiol.2009.170407; Nicolaides KH, 2005, SEMIN PERINATOL, V29, P190, DOI 10.1053/j.semperi.2005.06.001; Nybo, 2000, West J Med, V173, P331, DOI 10.1136/ewjm.173.5.331; O'Dowd R, 2008, AM J PHYSIOL-REG I, V294, pR539, DOI 10.1152/ajpregu.00628.2007; Odibo AO, 2006, AM J PERINAT, V23, P325, DOI 10.1055/s-2006-947164; Ojeda NB, 2007, HYPERTENSION, V50, P679, DOI 10.1161/HYPERTENSIONAHA.107.091785; Paulson RJ, 2002, JAMA-J AM MED ASSOC, V288, P2320, DOI 10.1001/jama.288.18.2320; Plagemann A, 2000, J NUTR, V130, P2582, DOI 10.1093/jn/130.10.2582; REFSAL KR, 1984, DOMEST ANIM ENDOCRIN, V1, P225, DOI 10.1016/0739-7240(84)90003-1; Roseboom TJ, 2001, MOL CELL ENDOCRINOL, V185, P93, DOI 10.1016/S0303-7207(01)00721-3; Schreuder MF, 2007, J PHYSIOL BIOCHEM, V63, P213, DOI 10.1007/BF03165784; Schreuder M, 2006, KIDNEY BLOOD PRESS R, V29, P108, DOI 10.1159/000094538; Seghieri G, 2002, DIABETES CARE, V25, P1761, DOI 10.2337/diacare.25.10.1761; Siebel AL, 2008, ENDOCRINOLOGY, V149, P3067, DOI 10.1210/en.2008-0128; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Taricco E, 2003, PLACENTA, V24, P343, DOI 10.1053/plac.2002.0913; Toner JP, 2002, FERTIL STERIL, V78, P1038, DOI 10.1016/S0015-0282(02)03371-X; Torgersen CKL, 2006, CRIT CARE NURS Q, V29, P2, DOI 10.1097/00002727-200601000-00002; Torrens C, 2008, BRIT J NUTR, V100, P760, DOI 10.1017/S0007114508921747; van der Heijden OWH, 2004, J SOC GYNECOL INVEST, V11, P304, DOI 10.1016/j.jsgi.2004.02.004; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Wadley GD, 2008, AM J PHYSIOL-ENDOC M, V294, pE861, DOI 10.1152/ajpendo.00037.2008; White SL, 2009, AM J KIDNEY DIS, V54, P248, DOI 10.1053/j.ajkd.2008.12.042; Wight E, 2000, J SOC GYNECOL INVEST, V7, P106, DOI 10.1016/S1071-5576(00)00036-8; Wlodek ME, 2008, KIDNEY INT, V74, P187, DOI 10.1038/ki.2008.153; Wlodek ME, 2007, J AM SOC NEPHROL, V18, P1688, DOI 10.1681/ASN.2007010015; Wu G, 2006, J ANIM SCI, V84, P2316, DOI 10.2527/jas.2006-156; Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462	50	21	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4337	4347		10.1096/fj.12-210401	http://dx.doi.org/10.1096/fj.12-210401			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22772163	Bronze			2022-12-28	WOS:000309704000038
J	Kerroch, M; Guerrot, D; Vandermeersch, S; Placier, S; Mesnard, L; Jouanneau, C; Rondeau, E; Ronco, P; Boffa, JJ; Chatziantoniou, C; Dussaule, JC				Kerroch, Monique; Guerrot, Dominique; Vandermeersch, Sophie; Placier, Sandrine; Mesnard, Laurent; Jouanneau, Chantal; Rondeau, Eric; Ronco, Pierre; Boffa, Jean-Jacques; Chatziantoniou, Christos; Dussaule, Jean-Claude			Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis	FASEB JOURNAL			English	Article						renal fibrosis; prevention of chronic kidney disease; renal pharmacogenetics; renal inflammation	TYROSINE KINASE; CELL-MIGRATION; MATRIX ACCUMULATION; GLOMERULAR INJURY; GROWTH; DDR1; ACTIVATION; INFLAMMATION; MACROPHAGES; SUPPRESSION	This study investigated the role of discoidin domain receptor 1 (DDR1), a collagen receptor that displays tyrosine-kinase activity, in the development of glomerulonephritis. Crescentic glomerulonephritis was induced in DDR1-deficient mice and their wild-type (WT) littermates as controls, by injection of alloimmune sheep nephrotoxic serum (NTS). Histological, functional and transcriptomic studies were performed. Glomerulonephritis produced a 17-fold increase of DDR1 expression, predominantly in glomeruli. DDR1 deletion protected NTS-treated mice against glomerular disease (proteinuria/creatininuria 5.5 +/- 1.1 vs. 13.2 +/- 0.8 g/mmol in WT, crescents 12 +/- 2 vs. 24 +/- 2% of glomeruli, urea 16 +/- 2 vs. 28 +/- 5 mM), hypertension (123 +/- 11 vs. 157 +/- 8 mmHg), and premature death (70 vs. 10% survival) (all P < 0.05). Reciprocal stimulation between DDR1 and interleukin-1b expression in vivo and in cultured podocytes suggested a positive feedback loop between DDR1 and inflammation. In NTStreated WT mice, administration of DDR1-specific antisense oligodeoxynucleotides decreased DDR1 expression (-56%) and protected renal function and structure, including nephrin expression (4.2 +/- 1.4 vs. 0.9 +/- 0.4 arbitrary units, P < 0.05), compared to control mice receiving scrambled oligodeoxynucleotides. The therapeutic potential of this approach was reinforced by the observation of increased DDR1 expression in glomeruli of patients with lupus nephritis and Goodpasture's syndrome. These results prompt further interest in DDR1 blockade strategies, especially in the treatment of glomerulonephritis.-Kerroch, M., Guerrot, D., Vandermeersch, S., Placier, S., Mesnard, L., Jouanneau, C., Rondeau, E., Ronco, P., Boffa, J.-J., Chatziantoniou, C., Dussaule, J.-C. Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis. FASEB J. 26, 4079-4091 (2012). www.fasebj.org	[Kerroch, Monique; Guerrot, Dominique; Vandermeersch, Sophie; Placier, Sandrine; Mesnard, Laurent; Jouanneau, Chantal; Rondeau, Eric; Ronco, Pierre; Boffa, Jean-Jacques; Chatziantoniou, Christos; Dussaule, Jean-Claude] Hop Tenon, AP HP, INSERM UMR S 702, F-75020 Paris, France; [Ronco, Pierre; Boffa, Jean-Jacques] Hop Tenon, AP HP, Serv Nephrol & Dialyses, F-75020 Paris, France; [Kerroch, Monique; Guerrot, Dominique; Vandermeersch, Sophie; Placier, Sandrine; Mesnard, Laurent; Jouanneau, Chantal; Rondeau, Eric; Ronco, Pierre; Boffa, Jean-Jacques; Chatziantoniou, Christos; Dussaule, Jean-Claude] Univ Paris 06, Paris, France; [Dussaule, Jean-Claude] St Antoine Hosp, AP HP, Dept Physiol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Dussaule, JC (corresponding author), Hop Tenon, AP HP, INSERM UMR S 702, F-75020 Paris, France.	jean-claude.dussaule@sat.aphp.fr	Guerrot, Dominique/N-7769-2019; Chatziantoniou, Christos/L-2501-2016; Ronco, Pierre/AAC-8390-2022	Guerrot, Dominique/0000-0002-5953-5785; VANDERMEERSCH, sophie/0000-0001-6021-1334; Guerrot, Dominique/0000-0001-9562-530X	Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Pierre et Marie Curie Paris 6 University; Societe Francaise de Nephrologie; INSERM	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Pierre et Marie Curie Paris 6 University; Societe Francaise de Nephrologie; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	The authors are grateful to Dr. Carlo Alfieri for the outstanding quality of his technical contribution. The authors thank Dr. Yi Chun Xu-Dubois for technical advice. This work was funded by Institut National de la Sante et de la Recherche Medicale (INSERM) and Universite Pierre et Marie Curie Paris 6 University. M.K. was supported by the Societe Francaise de Nephrologie and D.G. by INSERM. Transgenic mice were a legacy of Dr. Wolfgang F. Vogel (University of Toronto, Toronto, ON, Canada). The podocyte cell line was a gift of Dr. P. Mundel (Mount Sinai School of Medicine, New York, NY, USA).	Agarwal G, 2007, J MOL BIOL, V367, P443, DOI 10.1016/j.jmb.2006.12.073; Avivi-Green C, 2006, AM J RESP CRIT CARE, V174, P420, DOI 10.1164/rccm.200603-333OC; Bollee G, 2011, NAT MED, V17, P1242, DOI 10.1038/nm.2491; Bruggeman LA, 2011, LAB INVEST, V91, P413, DOI 10.1038/labinvest.2010.199; Burt D, 2007, AM J PATHOL, V171, P1789, DOI 10.2353/ajpath.2007.070398; Curat CA, 2002, J AM SOC NEPHROL, V13, P2648, DOI 10.1097/01.ASN.0000032419.13208.0C; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014; Feng LL, 2000, J CLIN INVEST, V105, P341, DOI 10.1172/JCI2869; Flamant M, 2006, J AM SOC NEPHROL, V17, P3374, DOI 10.1681/ASN.2006060677; Flynn LA, 2010, J MOL BIOL, V395, P533, DOI 10.1016/j.jmb.2009.10.073; Franco C, 2008, CIRC RES, V102, P1202, DOI 10.1161/CIRCRESAHA.107.170662; Franco C, 2010, CIRC RES, V106, P1775, DOI 10.1161/CIRCRESAHA.109.213637; Franco C, 2009, CIRC RES, V105, P1141, DOI 10.1161/CIRCRESAHA.109.207357; Gross O, 2004, KIDNEY INT, V66, P102, DOI 10.1111/j.1523-1755.2004.00712.x; Gross O, 2010, MATRIX BIOL, V29, P346, DOI 10.1016/j.matbio.2010.03.002; Guerrot D, 2011, AM J PATHOL, V179, P83, DOI 10.1016/j.ajpath.2011.03.023; Hachehouche LN, 2010, MOL IMMUNOL, V47, P1866, DOI 10.1016/j.molimm.2010.02.023; Hertig A, 2003, FASEB J, V17, P1904, DOI 10.1096/fj.03-0084fje; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje; Kitching AR, 2003, J AM SOC NEPHROL, V14, P1487, DOI 10.1097/01.ASN.0000065550.13931.00; Klein J, 2010, J AM SOC NEPHROL, V21, P1157, DOI 10.1681/ASN.2009090887; LENDRUM AC, 1962, J CLIN PATHOL, V15, P401, DOI 10.1136/jcp.15.5.401; Marshall CB, 2011, AM J PHYSIOL-RENAL, V300, pF1026, DOI 10.1152/ajprenal.00187.2010; Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332; Mesnard L, 2009, J AM SOC NEPHROL, V20, P1282, DOI 10.1681/ASN.2008040433; Mukai E, 2004, ATHEROSCLEROSIS, V176, P289, DOI 10.1016/j.atherosclerosis.2004.03.028; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Park HS, 2007, ONCOL REP, V18, P1435; Roig B, 2010, BRAIN RES, V1336, P22, DOI 10.1016/j.brainres.2010.03.099; Ronco P, 2008, KIDNEY INT, V74, P873, DOI 10.1038/ki.2008.349; Ruiz PA, 2011, J BIOL CHEM, V286, P12912, DOI 10.1074/jbc.M110.143693; Seo MC, 2008, J NEUROSCI RES, V86, P1087, DOI 10.1002/jnr.21552; Sheryanna A, 2007, J AM SOC NEPHROL, V18, P1167, DOI 10.1681/ASN.2006010050; Singh SKS, 2011, CURR OPIN NEPHROL HY, V20, P258, DOI 10.1097/MNH.0b013e32834583ec; Takano Y, 2007, FEBS LETT, V581, P421, DOI 10.1016/j.febslet.2006.12.051; Timoshanko JR, 2004, AM J PATHOL, V164, P1967, DOI 10.1016/S0002-9440(10)63757-1; Tipping PG, 2005, NEPHRON EXP NEPHROL, V101, pE173, DOI 10.1159/000088165; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Vogel WF, 2006, CELL SIGNAL, V18, P1108, DOI 10.1016/j.cellsig.2006.02.012; zum Gottesberge AMM, 2008, LAB INVEST, V88, P27, DOI 10.1038/labinvest.3700692	45	52	58	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4079	4091		10.1096/fj.11-194902	http://dx.doi.org/10.1096/fj.11-194902			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22751008				2022-12-28	WOS:000309704000015
J	Li, TF; Bourgeois, JP; Celli, S; Glacial, F; Le Sourd, AM; Mecheri, S; Weksler, B; Romero, I; Couraud, PO; Rougeon, F; Lafaye, P				Li, Tengfei; Bourgeois, Jean-Pierre; Celli, Susanna; Glacial, Fabienne; Le Sourd, Anne-Marie; Mecheri, Salah; Weksler, Babette; Romero, Ignacio; Couraud, Pierre-Olivier; Rougeon, Francois; Lafaye, Pierre			Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging	FASEB JOURNAL			English	Article						intrabodies; central nervous system; BBB; camelids; fluobodies; nanobodies	SINGLE-DOMAIN ANTIBODY; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; INTRABODIES; FRAGMENTS; DELIVERY; EXPRESSION; TRANSPORT; PEPTIDE; TRANSDUCTION	Antibodies normally do not cross the blood-brain barrier (BBB) and cannot bind an intracellular cerebral antigen. We demonstrate here for the first time that a new class of antibodies can cross the BBB without treatment. Camelids produce native homodimeric heavy-chain antibodies, the paratope being composed of a single-variable domain called VHH. Here, we used recombinant VHH directed against human glial fibrillary acidic protein (GFAP), a specific marker of astrocytes. Only basic VHHs (e.g., pI=9.4) were able to cross the BBB in vitro (7.8 vs. 0% for VHH with pI=7.7). By intracarotid and intravenous injections into live mice, we showed that these basic VHHs are able to cross the BBB in vivo, diffuse into the brain tissue, penetrate into astrocytes, and specifically label GFAP. To analyze their ability to be used as a specific transporter, we then expressed a recombinant fusion protein VHH-green fluorescent protein (GFP). These "fluobodies" specifically labeled GFAP on murine brain sections, and a basic variant (pI=9.3) of the fusion protein VHH-GFP was able to cross the BBB and to label astrocytes in vivo. The potential of VHHs as diagnostic or therapeutic agents in the central nervous system now deserves attention. Li, T., Bourgeois, J.-P., Celli, S., Glacial, F., Le Sourd, A.-M., Mecheri, S., Weksler, B., Romero, I., Couraud, P.-O., Rougeon, F., and Lafaye, P. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 26, 3969-3979 (2012). www.fasebj.org	[Bourgeois, Jean-Pierre; Le Sourd, Anne-Marie] Inst Pasteur, Unite Genes Synapses & Cognit, CNRS, URA 2182, F-75724 Paris 15, France; [Celli, Susanna] Inst Pasteur, Unite Dynam Reponses Immunes, INSERM, U668, F-75724 Paris 15, France; [Mecheri, Salah] Inst Pasteur, CNRS, U2581, Unite Biol Interact Hote Parasites, F-75724 Paris 15, France; [Rougeon, Francois] Inst Pasteur, Unite Genet & Biochim Dev, F-75724 Paris 15, France; [Glacial, Fabienne; Couraud, Pierre-Olivier] Inst Cochin, U1016, INSERM, Paris, France; [Glacial, Fabienne; Couraud, Pierre-Olivier] CNRS, UMR 8104, Paris, France; [Glacial, Fabienne; Couraud, Pierre-Olivier] Univ Paris 05, Paris, France; [Weksler, Babette] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA; [Romero, Ignacio] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Cornell University; Open University - UK	Lafaye, P (corresponding author), Inst Pasteur, PF Prod Prot Recombinantes & Anticorps, 25 Rue Dr Roux, F-75724 Paris 15, France.	plafaye@pasteur.fr	Mecheri, Salah/M-8315-2013; Celli, Susanna/M-7138-2014	Romero, Ignacio/0000-0002-0322-9180				Abulrob A, 2005, J NEUROCHEM, V95, P1201, DOI 10.1111/j.1471-4159.2005.03463.x; Achour I, 2008, J IMMUNOL, V181, P2001, DOI 10.4049/jimmunol.181.3.2001; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; Beghdadi W, 2008, J EXP MED, V205, P395, DOI 10.1084/jem.20071548; Beghdadi W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006004; Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Cao GD, 2002, J NEUROSCI, V22, P5423; Demangel C, 1996, MOL IMMUNOL, V33, P909, DOI 10.1016/S0161-5890(96)00058-2; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Doyle PJ, 2009, J BIOL CHEM, V284, P35029, DOI 10.1074/jbc.M109.045047; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Jones DR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009804; Kvam E, 2010, PROTEIN ENG DES SEL, V23, P489, DOI 10.1093/protein/gzq022; Lafaye P, 2009, MOL IMMUNOL, V46, P695, DOI 10.1016/j.molimm.2008.09.008; Luissint AC, 2012, J CEREBR BLOOD F MET, V32, P860, DOI 10.1038/jcbfm.2011.202; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; Olichon A, 2007, J BIOL CHEM, V282, P36314, DOI 10.1074/jbc.M704908200; PARDRIDGE WM, 1995, J PHARM SCI-US, V84, P943, DOI 10.1002/jps.2600840808; Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7; Perruchini C, 2009, ACTA NEUROPATHOL, V118, P685, DOI 10.1007/s00401-009-0572-6; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; RAPOPORT SI, 1980, AM J PHYSIOL, V238, pR421, DOI 10.1152/ajpregu.1980.238.5.R421; Rapoport SI, 2000, CELL MOL NEUROBIOL, V20, P217, DOI 10.1023/A:1007049806660; Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Rutgers KS, 2011, NEUROSCIENCE, V190, P37, DOI 10.1016/j.neuroscience.2011.05.076; Schwalbach G, 2000, PROTEIN EXPRES PURIF, V18, P121, DOI 10.1006/prep.1999.1185; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Serruys B, 2009, HEPATOLOGY, V49, P39, DOI 10.1002/hep.22609; Stocks M, 2005, CURR OPIN CHEM BIOL, V9, P359, DOI 10.1016/j.cbpa.2005.06.003; Tanaka T, 2003, EMBO J, V22, P1025, DOI 10.1093/emboj/cdg106; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; VORBRODT AW, 1989, J NEUROCYTOL, V18, P359, DOI 10.1007/BF01190839; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795	45	121	135	3	65	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					3969	3979		10.1096/fj.11-201384	http://dx.doi.org/10.1096/fj.11-201384			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22730440				2022-12-28	WOS:000309704000005
J	Saqui-Salces, M; Dowdle, WE; Reiter, JF; Merchant, JL				Saqui-Salces, Milena; Dowdle, William E.; Reiter, Jeremy F.; Merchant, Juanita L.			A high-fat diet regulates gastrin and acid secretion through primary cilia	FASEB JOURNAL			English	Article						gastric hyperplasia; endocrine cell; chemosensing; somatostatin; ghrelin	POLYCYSTIC KIDNEY-DISEASE; SONIC HEDGEHOG; FOOD-INTAKE; SOMATOSTATIN RECEPTOR-3; SYNERGISTIC INTERACTION; ATROPHIC GASTRITIS; GHRELIN SECRETION; GENE-EXPRESSION; MOUSE STOMACH; LEAN MICE	The role of primary cilia in the gastrointestinal tract has not been examined. Here we report the presence of primary cilia on gastric endocrine cells producing gastrin, ghrelin, and somatostatin (Sst), hormones regulated by food intake. During eating, cilia in the gastric antrum decreased, whereas gastric acid and circulating gastrin increased. Mice fed high-fat chow showed a delayed decrease in antral cilia, increased plasma gastrin, and gastric acidity. Mice fed high-fat chow for 3 wk showed lower cilia numbers and acid but higher gastrin levels than mice fed a standard diet, suggesting that fat affects gastric physiology. Ex vivo experiments showed that cilia in the corpus responded to acid and distension, whereas cilia in the antrum responded to food. To analyze the role of gastric cilia, we conditionally deleted the intraflagellar transport protein Ift88 (Ift88(-/fl)). In fed Ift88(-/fl) mice, gastrin levels were higher, and gastric acidity was lower. Moreover, gastrin and Sst gene expression did not change in response to food as in controls. At 8 mo, Ift88(-/fl) mice developed foveolar hyperplasia, hypergastrinemia, and hypochlorhydria associated with endocrine dysfunction. Our results show that components of food (fat) are sensed by antral cilia on endocrine cells, which modulates gastrin secretion and gastric acidity.-Saqui-Salces, M., Dowdle, W. E., Reiter, J. F., Merchant, J. L. A high-fat diet regulates gastrin and acid secretion through primary cilia. FASEB J. 26, 3127-3139 (2012). www.fasebj.org	[Saqui-Salces, Milena; Merchant, Juanita L.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Merchant, Juanita L.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Dowdle, William E.; Reiter, Jeremy F.] Univ Calif San Francisco, Dept Biochem & Biophys, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Merchant, JL (corresponding author), Univ Michigan, Dept Internal Med & Mol & Integrat Physiol, 109 Zina Pitcher Pl,BSRB,Rm 2051, Ann Arbor, MI 48109 USA.	merchanj@umich.edu	Merchant, Juanita/AAF-8277-2019; Dowdle, William/F-3424-2011	Merchant, Juanita/0000-0002-6559-8184; Saqui-Salces, Milena/0000-0001-5848-0092	U.S. National Institutes of Health [P01-DK62041, R01-AR054396, R01-GM095941]; California Institute for Regenerative Medicine [TG2-01153]; Burroughs Wellcome Fund; Packard Foundation; Sandler Family Supporting Foundation; Helmsley Charitable Trust; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062041, P30DK074038, R37DK045729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095941] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Packard Foundation(The David & Lucile Packard Foundation); Sandler Family Supporting Foundation; Helmsley Charitable Trust; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Linda C. Samuelson for her critical comments on the preparation of this manuscript. The research was made possible by grants from the U.S. National Institutes of Health (P01-DK62041 to J.L.M.; R01-AR054396, and R01-GM095941 to J.F.R.) and from the California Institute for Regenerative Medicine (TG2-01153), the Burroughs Wellcome Fund, the Packard Foundation, the Sandler Family Supporting Foundation, and the Helmsley Charitable Trust (to J.F.R.).	Al Massadi O, 2010, J ENDOCRINOL INVEST, V33, P599, DOI 10.1007/BF03346655; BACHWICH D, 1992, MOL ENDOCRINOL, V6, P1175, DOI 10.1210/me.6.8.1175; Baly C, 2007, BRAIN RES, V1129, P130, DOI 10.1016/j.brainres.2006.10.030; Barrachina MD, 1997, AM J PHYSIOL-REG I, V272, pR1007, DOI 10.1152/ajpregu.1997.272.3.R1007; Barrachina MD, 1997, P NATL ACAD SCI USA, V94, P10455, DOI 10.1073/pnas.94.19.10455; Bewick GA, 2009, DIABETES, V58, P840, DOI 10.2337/db08-1428; Boushey RP, 2003, GASTROENTEROLOGY, V125, P1164, DOI 10.1016/S0016-5085(03)01195-8; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; Caspary T, 2007, DEV CELL, V12, P767, DOI 10.1016/j.devcel.2007.03.004; Dezaki K, 2011, DIABETES, V60, P2315, DOI 10.2337/db11-0368; Dixit D, 2006, AM J PHYSIOL-GASTR L, V291, pG1129, DOI 10.1152/ajpgi.00518.2005; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Girard D, 2011, NAT REV ENDOCRINOL, V7, P77, DOI 10.1038/nrendo.2010.210; Gomez G, 1996, REGUL PEPTIDES, V67, P55, DOI 10.1016/S0167-0115(96)00107-3; Grossini E, 2011, J APPL PHYSIOL, V110, P95, DOI 10.1152/japplphysiol.00625.2010; Guo DF, 2011, TRENDS ENDOCRIN MET, V22, P286, DOI 10.1016/j.tem.2011.02.009; Haid D, 2011, J MOL HISTOL, V42, P355, DOI 10.1007/s10735-011-9339-1; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Hashimoto K, 1999, ARCH HISTOL CYTOL, V62, P181, DOI 10.1679/aohc.62.181; Hass N, 2010, CELL TISSUE RES, V339, P493, DOI 10.1007/s00441-009-0907-6; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Hildebrand P, 2001, GUT, V49, P23, DOI 10.1136/gut.49.1.23; Howard TA, 1996, J ANAT, V189, P303; Iwakura H, 2010, ENDOCRINOLOGY, V151, P2940, DOI 10.1210/en.2010-0090; Iwanaga T, 2011, BIOMED RES-TOKYO, V32, P73, DOI 10.2220/biomedres.32.73; Jackson K, 2011, DIGEST DIS SCI, V56, P125, DOI 10.1007/s10620-010-1422-z; Judd LM, 2005, J GASTROEN HEPATOL, V20, P1266, DOI 10.1111/j.1440-1746.2005.03867.x; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; Kentish S, 2012, J PHYSIOL-LONDON, V590, P209, DOI 10.1113/jphysiol.2011.222158; Kidd M, 2009, GASTROENTEROLOGY, V137, P231, DOI 10.1053/j.gastro.2009.01.005; KORMAN MG, 1971, GUT, V12, P619, DOI 10.1136/gut.12.8.619; LeSauter J, 2009, P NATL ACAD SCI USA, V106, P13582, DOI 10.1073/pnas.0906426106; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; MANELA FD, 1992, LIFE SCI, V51, P1363, DOI 10.1016/0024-3205(92)90636-4; MCINTOSH C, 1978, GUT, V19, P655, DOI 10.1136/gut.19.7.655; Mensah-Osman E, 2008, AM J PHYSIOL-GASTR L, V295, pG843, DOI 10.1152/ajpgi.00607.2007; Mensah-Osman E, 2008, REGUL PEPTIDES, V151, P115, DOI 10.1016/j.regpep.2008.03.009; Pashankar DS, 2001, J PEDIATR GASTR NUTR, V33, P537, DOI 10.1097/00005176-200111000-00005; Perez-Tilve D, 2011, FASEB J, V25, P2814, DOI 10.1096/fj.11-183632; Rau T, 2005, J PATHOL, V206, P383, DOI 10.1002/path.1795; SAKAI N, 1989, Auris Nasus Larynx, V16, P177; SANDVIK AK, 1995, AM J PHYSIOL-GASTR L, V269, pG542, DOI 10.1152/ajpgi.1995.269.4.G542; Saqui-Salces M, 2011, HISTOCHEM CELL BIOL, V136, P191, DOI 10.1007/s00418-011-0831-1; Satir P, 2010, J CELL SCI, V123, P499, DOI 10.1242/jcs.050377; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seoane LM, 2007, J ENDOCRINOL INVEST, V30, pRC22, DOI 10.1007/BF03350806; Shinozaki K, 2010, NUTR CANCER, V62, P1067, DOI 10.1080/01635581.2010.492086; Silva AP, 2005, EUR J ENDOCRINOL, V152, P887, DOI 10.1530/eje.1.01914; Singh P, 2000, CURR OPIN GASTROEN, V16, P68, DOI 10.1097/00001574-200001000-00013; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Steiger A, 2011, MOL CELL ENDOCRINOL, V340, P88, DOI 10.1016/j.mce.2011.02.013; Takaishi S, 2011, AM J PHYSIOL-GASTR L, V300, pG334, DOI 10.1152/ajpgi.00134.2010; TAUPIN DR, 1995, PEPTIDES, V16, P1001, DOI 10.1016/0196-9781(95)00070-Z; Tellez N, 2011, ENDOCRINOLOGY, V152, P2580, DOI 10.1210/en.2011-0066; Tennant SM, 2008, INFECT IMMUN, V76, P639, DOI 10.1128/IAI.01138-07; Ueno H, 2005, REGUL PEPTIDES, V126, P11, DOI 10.1016/j.regpep.2004.08.007; UVNASMOBERG K, 1984, SCAND J GASTROENTERO, V19, P131; UVNASWALLENSTEN K, 1980, ACTA PHYSIOL SCAND, V110, P391, DOI 10.1111/j.1748-1716.1980.tb06686.x; VALENZUELA JE, 1976, GASTROENTEROLOGY, V71, P409; Vesper BJ, 2009, CURR DRUG METAB, V10, P84, DOI 10.2174/138920009787048392; Waghray M, 2010, GASTROENTEROLOGY, V138, P562, DOI 10.1053/j.gastro.2009.10.043; WALSH JH, 1975, NEW ENGL J MED, V292, P1324, DOI 10.1056/NEJM197506192922505; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Waters AM, 2011, PEDIATR NEPHROL, V26, P1039, DOI 10.1007/s00467-010-1731-7; WU V, 1991, GASTROENTEROLOGY, V101, P1552, DOI 10.1016/0016-5085(91)90391-W; Xia Q, 2004, REGUL PEPTIDES, V122, P173, DOI 10.1016/j.regpep.2004.06.016; Xiao C, 2010, GASTROENTEROLOGY, V138, P550, DOI 10.1053/j.gastro.2009.11.002; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zavros Y, 1998, AM J PHYSIOL-GASTR L, V274, pG742, DOI 10.1152/ajpgi.1998.274.4.G742; Zavros Y, 2003, P NATL ACAD SCI USA, V100, P12944, DOI 10.1073/pnas.2135193100; Zavros Y, 2005, ONCOGENE, V24, P2354, DOI 10.1038/sj.onc.1208407; Zavros Y, 1997, J PHYSIOL-LONDON, V505, P811, DOI 10.1111/j.1469-7793.1997.811ba.x	73	38	38	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3127	3139		10.1096/fj.11-197426	http://dx.doi.org/10.1096/fj.11-197426			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22516298	Green Published, Green Submitted			2022-12-28	WOS:000307162800005
J	Teijeira, A; Palazon, A; Garasa, S; Marre, D; Auba, C; Rogel, A; Murillo, O; Martinez-Forero, I; Lang, F; Melero, I; Rouzaut, A				Teijeira, Alvaro; Palazon, Asis; Garasa, Saray; Marre, Diego; Auba, Cristina; Rogel, Anne; Murillo, Ohiana; Martinez-Forero, Ivan; Lang, Francois; Melero, Ignacio; Rouzaut, Ana			CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells	FASEB JOURNAL			English	Article						antigen-presenting cells; TNF-alpha receptor family; transmigration through lymphatic capillaries	MONOCLONAL-ANTIBODIES; TUMOR-IMMUNITY; T-LYMPHOCYTES; VESSEL WALLS; 4-1BB CD137; INFLAMMATION; EXPRESSION; CANCER; LIGAND; MICE	CD137/TNFR9/41BB was originally described as a surface molecule present on activated T and NK cells. However, its expression is broader among leukocytes, and it is also detected on hypoxic endothelial cells and inflamed blood vessels, as well as in atherosclerotic lesions. Here, we demonstrate that lymphatic endothelial cells (LECs) up-regulate CD137 expression from undetectable baseline levels on stimulation with TNF-alpha, LPS, and IL-1 beta. CD137 cross-linking with an agonistic mAb results in NF-kappa B nuclear translocation, followed by up-regulation of VCAM and a 3-fold increase in the production of the chemokine CCL21. Accordingly, there is a 50% increase in CCR7-dependent migration toward conditioned medium from activated LECs on CD137 cross-linking with the agonistic mAb or the natural ligand (CD137L). Such an enhancement of cell migration is also observed with monocyte-derived dendritic cells transmigrating across CD137-activated LEC monolayers. Using explanted human dermal tissue, we found that inflamed skin contains abundant CD137(+) lymphatic vessels and that ex vivo incubation of explanted human dermis with TNF-alpha induces CD137 expression in lymphatic capillaries. More interestingly, treatment with CD137 agonistic antibody induces CCL21 expression and DC accumulation close to lymphatic vessels. Collectively, our results demonstrate that the inflammatory function of lymphatic vessels can be regulated by CD137.-Teijeira, A., Palazon, A., Garasa, S., Marre, D., Auba, C., Rogel, A., Murillo, O., Martinez-Forero, I., Lang, F., Melero, I., Rouzaut, A. CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J. 26, 3380-3392 (2012). www.fasebj.org	[Teijeira, Alvaro; Garasa, Saray; Rouzaut, Ana] Univ Navarra, Ctr Appl Med Res, Dept Oncol, Pamplona 31008, Spain; [Palazon, Asis; Murillo, Ohiana; Martinez-Forero, Ivan; Melero, Ignacio] Univ Navarra, Hepathol & Gene Therapy Unit, Ctr Appl Med Res, Pamplona 31008, Spain; [Marre, Diego; Auba, Cristina] Univ Navarra, Dept Plast Surg, Univ Navarra Clin, Pamplona 31008, Spain; [Rogel, Anne; Lang, Francois] Univ Nantes, Inst Rech Therapeut, Nantes, France	University of Navarra; University of Navarra; University of Navarra; Nantes Universite	Rouzaut, A (corresponding author), Univ Navarra, Ctr Appl Med Res, Dept Oncol, Pio XII 55, Pamplona 31008, Spain.	arouzaut@unav.es	Rouzaut, Ana/I-2576-2017; Murillo, Oihana/S-4162-2018; Auba, Cristina/I-1878-2017; Melero, Ignacio/T-7600-2019; Palazon, Asis/ABI-1748-2020; Garasa, Saray/J-6602-2017; Teijeira, Alvaro/I-6903-2017; LANG, François/K-7403-2015	Rouzaut, Ana/0000-0003-3226-9162; Murillo, Oihana/0000-0003-3963-7394; Auba, Cristina/0000-0002-8939-029X; Melero, Ignacio/0000-0002-1360-348X; Palazon, Asis/0000-0002-7172-7229; Garasa, Saray/0000-0001-5192-2599; Teijeira, Alvaro/0000-0002-7339-4464; LANG, François/0000-0002-0762-4647; Rogel, Anne/0000-0002-8788-566X	Ministerio de Educacion y Ciencia/Ministerio de Ciencia e Innovacion [SAF2011-22831]; European Commission VII framework program (ENCITE); SUDOE-IMMUNONET; UTE for Project FIMA; Spanish Ministry of Education (FPU); Ministry of Health (FIS)	Ministerio de Educacion y Ciencia/Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Commission VII framework program (ENCITE)(European Commission); SUDOE-IMMUNONET; UTE for Project FIMA; Spanish Ministry of Education (FPU)(Spanish Government); Ministry of Health (FIS)(Instituto de Salud Carlos III)	Financial support was from the Ministerio de Educacion y Ciencia/Ministerio de Ciencia e Innovacion (SAF2011-22831), European Commission VII framework program (ENCITE), SUDOE-IMMUNONET, and UTE for Project FIMA. A.T. has a scholarship from the Spanish Ministry of Education (FPU) and A.P. from the Ministry of Health (FIS). I.M. has received consultant honoraria and reagents from Brystol-Myers Squibb. The remaining authors declare no conflicts of interest.	Alvarez D, 2008, IMMUNITY, V29, P325, DOI 10.1016/j.immuni.2008.08.006; Angeli Veronique, 2006, Lymphatic Research and Biology, V4, P217, DOI 10.1089/lrb.2006.4406; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Broll K, 2001, AM J CLIN PATHOL, V115, P543, DOI 10.1309/E343-KMYX-W3Y2-10KY; Choi BK, 2010, J IMMUNOL, V185, P1404, DOI 10.4049/jimmunol.1000850; Clasper S, 2008, CANCER RES, V68, P7293, DOI 10.1158/0008-5472.CAN-07-6506; Drenkard D, 2007, FASEB J, V21, P456, DOI 10.1096/fj.05-4739com; Dubrot J, 2010, CANCER IMMUNOL IMMUN, V59, P1223, DOI 10.1007/s00262-010-0846-9; Irigoyen M, 2007, BBA-MOL CELL RES, V1773, P880, DOI 10.1016/j.bbamcr.2007.03.001; Jeon HJ, 2010, CIRCULATION, V121, P1124, DOI 10.1161/CIRCULATIONAHA.109.882704; Johnson LA, 2008, ANN NY ACAD SCI, V1131, P119, DOI 10.1196/annals.1413.011; Johnson LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759; Johnson LA, 2010, INT IMMUNOL, V22, P839, DOI 10.1093/intimm/dxq435; Kim YJ, 2002, J HEMATOTH STEM CELL, V11, P895, DOI 10.1089/152581602321080556; Kwon B, 2003, EXP MOL MED, V35, P8, DOI 10.1038/emm.2003.2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; Laderach D, 2003, CELL IMMUNOL, V226, P37, DOI 10.1016/j.cellimm.2003.11.003; Lee SW, 2009, J IMMUNOL, V182, P6753, DOI 10.4049/jimmunol.0803241; Lynch DH, 2008, IMMUNOL REV, V222, P277, DOI 10.1111/j.1600-065X.2008.00621.x; McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Melero I, 2008, TRENDS PHARMACOL SCI, V29, P383, DOI 10.1016/j.tips.2008.05.005; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; Meyer TPH, 2005, J IMMUNOL METHODS, V307, P150, DOI 10.1016/j.jim.2005.10.004; Nam KO, 2005, CURR CANCER DRUG TAR, V5, P357, DOI 10.2174/1568009054629681; Niu LG, 2007, J IMMUNOL, V178, P4194, DOI 10.4049/jimmunol.178.7.4194; Olofsson PS, 2008, CIRCULATION, V117, P1292, DOI 10.1161/CIRCULATIONAHA.107.699173; Palazon A, 2011, CANCER RES, V71, P801, DOI 10.1158/0008-5472.CAN-10-1733; Pflicke H, 2009, J EXP MED, V206, P2925, DOI 10.1084/jem.20091739; Rabu C, 2005, J BIOL CHEM, V280, P41472, DOI 10.1074/jbc.M506881200; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Rouzaut A, 2010, EUR J IMMUNOL, V40, P3054, DOI 10.1002/eji.201040523; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Shao Z, 2011, J LEUKOCYTE BIOL, V89, P21, DOI 10.1189/jlb.0510315; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Tal O, 2011, J EXP MED, V208, P2141, DOI 10.1084/jem.20102392; Tirapu I, 2004, INT J CANCER, V110, P51, DOI 10.1002/ijc.20093; Vogel JD, 2004, GASTROENTEROLOGY, V126, P63, DOI 10.1053/j.gastro.2003.10.046; vonKempis J, 1997, OSTEOARTHR CARTILAGE, V5, P394, DOI 10.1016/S1063-4584(97)80044-1; Wan YL, 2004, WORLD J GASTROENTERO, V10, P195; Wang C, 2009, IMMUNOL REV, V229, P192, DOI 10.1111/j.1600-065X.2009.00765.x; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897; Wilcox RA, 2004, BLOOD, V103, P177, DOI 10.1182/blood-2003-06-2184	49	34	35	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3380	3392		10.1096/fj.11-201061	http://dx.doi.org/10.1096/fj.11-201061			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593548				2022-12-28	WOS:000307162800026
J	Vila-Bedmar, R; Garcia-Guerra, L; Nieto-Vazquez, I; Mayor, F; Lorenzo, M; Murga, C; Fernandez-Veledo, S				Vila-Bedmar, Rocio; Garcia-Guerra, Lucia; Nieto-Vazquez, Iria; Mayor, Federico, Jr.; Lorenzo, Margarita; Murga, Cristina; Fernandez-Veledo, Sonia			GRK2 contribution to the regulation of energy expenditure and brown fat function	FASEB JOURNAL			English	Article						brown adipose tissue; thermogenesis; cold exposure; obesity	ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL UNCOUPLING PROTEIN; DIET-INDUCED OBESITY; ADIPOSE-TISSUE; ADAPTIVE THERMOGENESIS; INSULIN-RESISTANCE; ACID-METABOLISM; ADULT HUMANS; 2 PLAYS; RECEPTOR	Obesity is a major health problem and an important risk factor for the development of multiple disorders. Previous studies in our laboratory have revealed that down-regulation of GRK2 decreases age-related adiposity, but the physiological and molecular mechanisms underlying this outcome remain unclear. We evaluate whether the lean phenotype results from a direct effect of GRK2 on energy homeostasis. The study of white adipose tissue (WAT) in wild-type (WT) and GRK2(+/-) littermates showed a reduced expression of lipogenic enzymes and enhanced lipolytic rate in adult GRK2(+/-) mice. Moreover, hemizygous mice display higher energy expenditure and lower respiratory exchange ratio. Analysis of brown adipose tissue (BAT) from adult GRK2(+/-) mice showed a less deteriorated morphology associated with age compared to WT, which is correlated with a higher basal core temperature. BAT from young GRK2(+/-) mice showed an increase in gene expression of thermogenesis-related genes. Accordingly, hemizygous mice displayed better thermogenic capacity and exhibited a more oxidative phenotype in both BAT and WAT than WT littermates. Overexpression of GRK2 in brown adipocytes corroborated the negative effect of this kinase in BAT function and differentiation. Collectively, our data point to GRK2 inhibition as a potential tool for the enhancement of brown fat activity, which may have important therapeutic implications for the treatment of obesity and associated metabolic disorders.-Vila-Bedmar, R., Garcia-Guerra, L., Nieto-Vazquez, I., Mayor, F., Jr., Lorenzo, M., Murga, C., Fernandez-Veledo, S. GRK2 contribution to the regulation of energy expenditure and brown fat function. FASEB J. 26, 3503-3514 (2012). www.fasebj.org	[Fernandez-Veledo, Sonia] Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, Res Unit, IISPV,CIBERDEM, Tarragona 43007, Spain; [Garcia-Guerra, Lucia] UAM, CSIC, Inst Invest Biomed Alberto Sols, CIBER Enfermedades Neurodegenerat CIBERNED, Madrid, Spain; [Vila-Bedmar, Rocio; Mayor, Federico, Jr.; Murga, Cristina] Inst Invest Sanitaria IIS La Princesa, Madrid, Spain; [Vila-Bedmar, Rocio; Mayor, Federico, Jr.; Murga, Cristina] UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Vila-Bedmar, Rocio; Mayor, Federico, Jr.; Murga, Cristina] UAM, CSIC, Dept Biol Mol, Madrid, Spain; [Vila-Bedmar, Rocio; Garcia-Guerra, Lucia; Nieto-Vazquez, Iria; Lorenzo, Margarita; Fernandez-Veledo, Sonia] Univ Complutense, Dept Biochem & Mol Biol 2, Sch Pharm, Ctr Invest Biomed Red CIBER Diabet & Enfermedades, E-28040 Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Universitat Rovira i Virgili; Hospital Universitari De Tarragona Joan XXIII; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Autonomous University of Madrid; CIBERNED; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Complutense University of Madrid	Fernandez-Veledo, S (corresponding author), Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, Res Unit, IISPV,CIBERDEM, C-O Dr Mallafre Guasch 4, Tarragona 43007, Spain.	sonia.fernandezveledo@gmail.com	Mayor, Federico/N-7644-2016; Bedmar, Rocio Vila/R-9140-2018; Fernández-Veledo, Sonia/V-4625-2018; Murga, Cristina/E-1965-2014	Bedmar, Rocio Vila/0000-0002-0973-5156; Fernández-Veledo, Sonia/0000-0003-2906-3788; Murga, Cristina/0000-0002-8964-4077; Garcia, Lucia/0000-0002-8321-3137; Mayor Menendez, Federico/0000-0003-1434-8449	Ministerio de Educacion y Ciencia [SAF2008-00552, BFU2008-04043]; Fundacion Ramon Areces, Comunidad de Madrid [S-SAL-0159-2006]; Ministerio Sanidad y Consumo-Instituto Carlos III via The Cardiovascular Network (RECAVA) [RD06-0014/0037, PS09/0128]; Fondo de Investigacion Sanitaria (FIS) Miguel Servet [CP10/00438]; European Regional Development Fund (ERDF)	Ministerio de Educacion y Ciencia(Spanish Government); Fundacion Ramon Areces, Comunidad de Madrid(Comunidad de Madrid); Ministerio Sanidad y Consumo-Instituto Carlos III via The Cardiovascular Network (RECAVA); Fondo de Investigacion Sanitaria (FIS) Miguel Servet; European Regional Development Fund (ERDF)(European Commission)	This work was funded by grants from Ministerio de Educacion y Ciencia (SAF2008-00552 to F. M. and BFU2008-04043 to S. F. V.), Fundacion Ramon Areces, Comunidad de Madrid (S-SAL-0159-2006), and Ministerio Sanidad y Consumo-Instituto Carlos III via The Cardiovascular Network (RECAVA, RD06-0014/0037 to F. M. and PS09/0128 to C. M.). S. F. V. is supported by a fellowship from the Fondo de Investigacion Sanitaria (FIS) Miguel Servet CP10/00438, cofinanced by the European Regional Development Fund (ERDF). R. B. V. designed and conducted experiments, interpreted data, prepared figures, and drafted and revised the manuscript; L. G. G. conducted experiments and prepared figures; I.N.V. designed experiments and analyzed results; F. M. conceived and designed experiments, analyzed results, performed critical revision, and approved the final manuscript; M. L. conceived and designed experiments and interpreted and revised results; C. M. analyzed and interpreted data and prepared, revised, and approved the final manuscript; S. F. V. conceived and designed experiments, analyzed and interpreted results, and drafted, revised, and approved the final manuscript. The authors declare no conflicts of interest.	Anis Y, 2004, DIABETOLOGIA, V47, P1232, DOI 10.1007/s00125-004-1444-1; Atgie C, 1997, AM J PHYSIOL-CELL PH, V273, pC1136, DOI 10.1152/ajpcell.1997.273.4.C1136; Barroso E, 2011, ENDOCRINOLOGY, V152, P1848, DOI 10.1210/en.2010-1468; BIANCO AC, 1987, AM J PHYSIOL, V253, pE255, DOI 10.1152/ajpendo.1987.253.3.E255; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brinks H, 2011, FUTUR CARDIOL, V7, P547, DOI [10.2217/FCA.11.36, 10.2217/fca.11.36]; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2010, INT J OBESITY, V34, pS7, DOI 10.1038/ijo.2010.177; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Carpentier AC, 2008, DIABETES METAB, V34, P97, DOI 10.1016/j.diabet.2007.10.009; CARVALHO SD, 1991, ENDOCRINOLOGY, V128, P2149, DOI 10.1210/endo-128-4-2149; Christoffolete MA, 2004, DIABETES, V53, P577, DOI 10.2337/diabetes.53.3.577; Cipolletta E, 2009, CARDIOVASC RES, V84, P407, DOI 10.1093/cvr/cvp252; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Collins S, 2010, INT J OBESITY, V34, pS28, DOI 10.1038/ijo.2010.180; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; de Jesus LA, 2001, J CLIN INVEST, V108, P1379, DOI 10.1172/JCI200113803; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Florez-Duquet M, 1998, PHYSIOL REV, V78, P339, DOI 10.1152/physrev.1998.78.2.339; Garcia-Guerra L, 2010, DIABETES, V59, P2407, DOI 10.2337/db10-0771; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Gray SL, 2006, ENDOCRINOLOGY, V147, P5708, DOI 10.1210/en.2006-0684; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Hall JA, 2010, ENDOCRINOLOGY, V151, P4573, DOI 10.1210/en.2010-0511; Harvey A. N., 2011, CURR MOL PHARM; Hernandez A, 1996, MOL CELL ENDOCRINOL, V121, P37, DOI 10.1016/0303-7207(96)03849-X; Hutchinson DS, 2005, DIABETOLOGIA, V48, P2386, DOI 10.1007/s00125-005-1936-7; Jimenez-Sainz MC, 2006, MOL BIOL CELL, V17, P25, DOI 10.1091/mbc.e05-05-0399; Kolditz CI, 2010, CURR OPIN CLIN NUTR, V13, P377, DOI 10.1097/MCO.0b013e32833bed6a; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Lopez M, 2010, NAT MED, V16, P1001, DOI 10.1038/nm.2207; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Mayor Federico Jr., 2011, Archives of Physiology and Biochemistry, V117, P125, DOI 10.3109/13813455.2011.584693; McDonald RB, 1999, J BIOENERG BIOMEMBR, V31, P507, DOI 10.1023/A:1005404708710; Mulligan JD, 2007, J PHYSIOL-LONDON, V580, P677, DOI 10.1113/jphysiol.2007.128652; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Nedergaard J, 2010, CELL METAB, V11, P268, DOI 10.1016/j.cmet.2010.03.007; Peregrin S, 2006, CURR BIOL, V16, P2042, DOI 10.1016/j.cub.2006.08.083; Perwitz N, 2010, DIABETES OBES METAB, V12, P158, DOI 10.1111/j.1463-1326.2009.01133.x; Petrovic N, 2008, AM J PHYSIOL-ENDOC M, V295, pE287, DOI 10.1152/ajpendo.00035.2008; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Qi JZ, 2008, EMBO J, V27, P1537, DOI 10.1038/emboj.2008.92; Ribas C, 2007, BBA-BIOMEMBRANES, V1768, P913, DOI 10.1016/j.bbamem.2006.09.019; Ricquier D, 2005, P NUTR SOC, V64, P47, DOI 10.1079/PNS2004408; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Sabio G, 2010, GENE DEV, V24, P256, DOI 10.1101/gad.1878510; Sell H, 2004, INT J BIOCHEM CELL B, V36, P2098, DOI 10.1016/j.biocel.2004.04.003; Shahid G, 2007, J BIOL CHEM, V282, P20612, DOI 10.1074/jbc.M700744200; Silva JE, 2008, THYROID, V18, P157, DOI 10.1089/thy.2007.0252; St-Onge MP, 2005, CURR OPIN CLIN NUTR, V8, P523; Tabbi-Anneni I, 2010, AM J PHYSIOL-ENDOC M, V298, pE961, DOI 10.1152/ajpendo.00655.2009; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Usui I, 2004, EMBO J, V23, P2821, DOI 10.1038/sj.emboj.7600297; Valle A, 2008, REJUV RES, V11, P597, DOI 10.1089/rej.2007.0626; Vila-Bedmar Rocio, 2011, Archives of Physiology and Biochemistry, V117, P195, DOI 10.3109/13813455.2011.560951; Vila-Bedmar R, 2010, ENDOCRINOLOGY, V151, P980, DOI 10.1210/en.2009-0810; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Weiser M, 1997, J CLIN PHARMACOL, V37, P453, DOI 10.1002/j.1552-4604.1997.tb04323.x; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546	61	24	24	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3503	3514		10.1096/fj.11-202267	http://dx.doi.org/10.1096/fj.11-202267			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22516294				2022-12-28	WOS:000307162800037
J	Gomes, AV; Waddell, DS; Siu, R; Stein, M; Dewey, S; Furlow, JD; Bodine, SC				Gomes, Aldrin V.; Waddell, Dave S.; Siu, Rylie; Stein, Matthew; Dewey, Shannamar; Furlow, J. David; Bodine, Sue C.			Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation	FASEB JOURNAL			English	Article						E3 ubiquitin ligase; ubiquitin proteasome system; MAFbx; muscle atrophy	UBIQUITIN-DEPENDENT PROTEOLYSIS; RAT SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; IN-VIVO; ACTIVATION; ATROPHY; PATHWAY; SEPSIS; GLUCOCORTICOIDS; DEGRADATION	Deletion of muscle RING finger 1 (MuRF1), an E3 ubiquitin ligase, leads to sparing of muscle mass following denervation. The purpose of this study was to test the hypothesis that muscle sparing in mice with a deletion of MuRF1 is due to the selective inhibition of the ubiquitin proteasome system. Activities of the 20S and 26S proteasomes, calpain and cathepsin L, were measured in the triceps surae muscles of wild-type (WT) and MuRF1-knockout (KO) mice at 3 and 14 d following denervation. In addition, fractional protein synthesis rates and differential gene expression were measured in WT and KO muscle. The major finding was that 20S and 26S proteasome activities were significantly elevated (1.5- to 2.5-fold) after 14 d of denervation in both WT and KO mice relative to control, but interestingly, the activities of both the 20S and 26S proteasome were significantly higher in KO than WT mice. Further, mRNA expression of MAFbx was elevated after 14 d of denervation in KO, but not WT, mice. These data challenge the conventional dogma that MuRF1 is controlling the degradation of only contractile proteins and suggest a role for MuRF1 in the global control of the ubiquitin proteasome system and protein turnover.-Gomes, A. V., Waddell, D. S., Siu, R., Stein, M., Dewey, S., Furlow, J. D., Bodine, S. C. Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J. 26, 2986-2999 (2012). www.fasebj.org	[Gomes, Aldrin V.; Bodine, Sue C.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA; [Waddell, Dave S.] Univ N Florida, Dept Biol, Jacksonville, FL USA; [Gomes, Aldrin V.; Siu, Rylie; Stein, Matthew; Dewey, Shannamar; Furlow, J. David; Bodine, Sue C.] Univ Calif Davis, Dept Neurobiol Physiol & Behav, Davis, CA 95616 USA	University of California System; University of California Davis; State University System of Florida; University of North Florida; University of California System; University of California Davis	Gomes, AV (corresponding author), Univ Calif Davis, Dept Neurobiol Physiol & Behav, 196 Briggs Hall,1 Shields Ave, Davis, CA 95616 USA.	avgomes@ucdavis.edu; scbodine@ucdavis.edu	Waddell, David/AAG-3774-2020; Waddell, David/J-7435-2015; Gomes, Aldrin V/I-6529-2018	Waddell, David/0000-0001-6749-4461; Waddell, David/0000-0001-6749-4461; Gomes, Aldrin V/0000-0002-9819-3036; Bodine, Sue/0000-0002-5742-9145	Muscular Dystrophy Association; U.S. National Institutes of Health [DK75801, HL096819]; Howard Hughes Medical Institute; Kirchstein National Research Service Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075801] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Kirchstein National Research Service Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank their colleagues at the University of California, Davis, for support and technical expertise. This research was supported by grants from the Muscular Dystrophy Association (S. C. B.) and the U.S. National Institutes of Health (DK75801 to S. C. B. and J.D.F.; HL096819 to A. V. G.), and partly supported by a Howard Hughes Medical Institute basic science research training program (S. D.), and a Kirchstein National Research Service Award (D.S.W.).	Anderson SR, 2008, METABOLISM, V57, P347, DOI 10.1016/j.metabol.2007.10.009; Argadine H. M., AM J PHYSL CELL PHYS, V300, pC318; Baehr LM, 2011, J PHYSIOL-LONDON, V589, P4759, DOI 10.1113/jphysiol.2011.212845; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Batt J, 2005, FASEB J, V19, P115, DOI 10.1096/fj.04-3640fje; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Chrysis D, 1999, ENDOCRINOLOGY, V140, P5635, DOI 10.1210/en.140.12.5635; Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052; Combaret L, 2005, AM J PHYSIOL-ENDOC M, V288, pE693, DOI 10.1152/ajpendo.00281.2004; Dewey S, 2010, J MOL CELL CARDIOL, V49, P1, DOI 10.1016/j.yjmcc.2010.03.024; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Drews O, 2010, CIRC RES, V107, P1094, DOI 10.1161/CIRCRESAHA.110.222364; Dufner DA, 2005, AM J PHYSIOL-ENDOC M, V288, pE1277, DOI 10.1152/ajpendo.00580.2004; Gomes AV, 2009, MOL CELL PROTEOMICS, V8, P302, DOI 10.1074/mcp.M800058-MCP200; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hirner S, 2008, J MOL BIOL, V379, P666, DOI 10.1016/j.jmb.2008.03.049; Ikemoto M, 2001, FASEB J, V15, P1279, DOI 10.1096/fj.00-0629fje; Kline WO, 2007, J APPL PHYSIOL, V102, P740, DOI 10.1152/japplphysiol.00873.2006; Koncarevic A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com; Koyama S, 2008, J MOL BIOL, V376, P1224, DOI 10.1016/j.jmb.2007.11.049; Labeit S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/693741; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li J, 2011, FASEB J, V25, P883, DOI 10.1096/fj.10-160895; Lorite MJ, 2001, BRIT J CANCER, V85, P297, DOI 10.1054/bjoc.2001.1879; McCabe BJ, 2006, ANAL BIOCHEM, V350, P171, DOI 10.1016/j.ab.2006.01.020; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Ochala J, 2011, J PHYSIOL-LONDON, V589, P2007, DOI 10.1113/jphysiol.2010.202044; Plant PJ, 2010, AM J RESP CELL MOL, V42, P461, DOI 10.1165/rcmb.2008-0382OC; Polge C, 2011, FASEB J, V25, P3790, DOI 10.1096/fj.11-180968; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Sundaram P, 2009, AM J PHYSIOL-ENDOC M, V297, pE1283, DOI 10.1152/ajpendo.00409.2009; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; TEMPARIS S, 1994, CANCER RES, V54, P5568; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; Yewdell JW, 2005, P NATL ACAD SCI USA, V102, P9089, DOI 10.1073/pnas.0504018102	39	82	83	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2986	2999		10.1096/fj.12-204495	http://dx.doi.org/10.1096/fj.12-204495			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22508689	Green Published			2022-12-28	WOS:000305912500026
J	Mutoh, T; Kawamura, N; Hirabayashi, Y; Shima, S; Miyashita, T; Ito, S; Asakura, K; Araki, W; Cazzaniga, E; Muto, E; Masserini, M				Mutoh, Tatsuro; Kawamura, Naoki; Hirabayashi, Yoshio; Shima, Sayuri; Miyashita, Tadayuki; Ito, Shinji; Asakura, Kunihiko; Araki, Wataru; Cazzaniga, Emanuela; Muto, Eri; Masserini, Massimo			Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis	FASEB JOURNAL			English	Article						gangliosides; glucosylceramide; glucosylceramide synthase; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; NERVE GROWTH-FACTOR; GAMMA-SECRETASE CLEAVAGE; DENSITY MEMBRANE DOMAIN; NEUROTROPHIN RECEPTOR; ALZHEIMERS-DISEASE; TRANSGENIC MICE; BETA-PROTEIN; INTRACELLULAR DOMAIN; GM1 GANGLIOSIDE	Mutations in the presenilin 1 (PS1) gene are associated with early onset familial Alzheimer's disease (FAD). In this study, we found that the expression of mutant-PS1 in stable transfectants of SH-SY5Y neuroblastoma cells results in a reduction of the biosynthesis and steady-state levels of glucosylceramide. As an in vivo corroboration of these data, there was a significant reduction of brain glucosylceramide and gangliosides in an animal model of FAD. In mutant-PS1-transfectants (I143T, G384A), immunocytochemistry disclosed a remarkable reduction of glucosylceramide synthase (GlcT-1)-like immunoreactivity in the cells when compared with those of mock-and wild-PS1 transfectants. Immunoprecipitation of GlcT-1 protein from mutant-PS1 transfectants demonstrated a marked reduction in GlcT-1 protein, but there was no reduction in the levels of GlcT-1 mRNA. Both coprecipitation and gamma-secretase inhibition experiments suggest that mutant-PS1 seems to form a complex with GlcT-1 protein and to be involved in GlcT-1 degradation, which was never found in other cell types. Thus, mutations in the PS1 gene result in profound glycosphingolipids abnormalities by abnormal molecular interaction with GlcT-1.-Mutoh, T., Kawamura, N., Hirabaysshi, Y., Shima, S., Miyashita, T., Ito, S., Asakura, K., Araki, W., Cazzaniga, E., Muto, E., Masserini, M. Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis. FASEB J. 26, 3065-3074 (2012). www.fasebj.org	[Mutoh, Tatsuro; Kawamura, Naoki; Shima, Sayuri; Miyashita, Tadayuki; Ito, Shinji; Asakura, Kunihiko; Muto, Eri] Fujita Hlth Univ, Sch Med, Dept Neurol, Toyoake, Aichi 4701192, Japan; [Hirabayashi, Yoshio] RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama, Japan; [Araki, Wataru] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Demyelinating Dis & Aging, Tokyo, Japan; [Cazzaniga, Emanuela; Masserini, Massimo] Univ Milano Bicocca, Dept Expt Med, Monza, Italy	Fujita Health University; RIKEN; National Center for Neurology & Psychiatry - Japan; University of Milano-Bicocca	Mutoh, T (corresponding author), Fujita Hlth Univ, Sch Med, Dept Neurol, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	tmutoh@fujita-hu.ac.jp	Araki, Wataru/G-7913-2014; Mutoh, Tatsuro/H-4317-2019	Araki, Wataru/0000-0001-8467-6937; Mutoh, Tatsuro/0000-0001-7712-8481; Hirabayashi, Yoshio/0000-0002-5774-7354	Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The present study was partly supported by a grant-in-aid on COE, high-tech research, and priority area on functional glycomics from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T. M). The authors thank Dr. John Kasik (Santa Maria, CA, USA) for critical review of the present manuscript and also Dr. A. Takashima (RIKEN, Saitama, Japan) for providing the anti-PS1-CTF (#312) antibody. The authors are grateful to C. Nishikawa (Department of Neurology, Fujita Health University School of Medicine, Toyoake, Japan) and Dr. A. Tokuda (Fukui Rehabilitation Hospital, Fukui, Japan) for technical assistance. The authors also thank Dr. T. Tabira (Juntendo University School of Medicine, Tokyo, Japan) for support and encouragement of this work. The authors declare no conflicts of interest.	Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell WA, 2003, J NEUROCHEM, V85, P1563, DOI 10.1046/j.1471-4159.2003.01799.x; Capsoni S, 2000, P NATL ACAD SCI USA, V97, P6826, DOI 10.1073/pnas.97.12.6826; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CRINO PB, 1989, ARCH NEUROL-CHICAGO, V46, P398, DOI 10.1001/archneur.1989.00520400054019; DALIA A, 1993, J NEUROSCI, V13, P3104; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GIGLIONI A, 1990, BIOCHEM INT, V22, P85; Gottfries C G, 1996, Int Psychogeriatr, V8, P365, DOI 10.1017/S1041610296002736; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hamano T, 2005, MOL BRAIN RES, V137, P70, DOI 10.1016/j.molbrainres.2005.02.018; HINDMAN J, 1972, CLIN CHEM, V18, P971; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kirschenbaum F, 2001, J BIOL CHEM, V276, P30701, DOI 10.1074/jbc.M102849200; KRACUN I, 1992, NEUROCHEM INT, V20, P433, DOI 10.1016/0197-0186(92)90058-Y; LAZZARO A, 1994, EXP NEUROL, V125, P278, DOI 10.1006/exnr.1994.1030; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marks N, 2008, BRAIN RES, V1191, P136, DOI 10.1016/j.brainres.2007.10.066; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MUTOH T, 1984, CLIN CHIM ACTA, V140, P223; MUTOH T, 1993, J NEUROCHEM, V60, P1540, DOI 10.1111/j.1471-4159.1993.tb03319.x; Mutoh T, 2000, NEUROCHEM RES, V25, P239, DOI 10.1023/A:1007575504321; MUTOH T, 1986, NEUROLOGY, V36, P54, DOI 10.1212/WNL.36.1.54; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Mutoh T, 2002, NEUROCHEM RES, V27, P801, DOI 10.1023/A:1020209008169; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; Rossner S, 1998, PROG NEUROBIOL, V56, P541, DOI 10.1016/S0301-0082(98)00044-6; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SVENNERHOLM L, 1994, J NEUROCHEM, V62, P1039; Tamboli IY, 2005, J BIOL CHEM, V280, P28110, DOI 10.1074/jbc.M414525200; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Wu GS, 2001, J NEUROCHEM, V76, P690, DOI 10.1046/j.1471-4159.2001.00036.x; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	50	7	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					3065	3074		10.1096/fj.11-198630	http://dx.doi.org/10.1096/fj.11-198630			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22508690				2022-12-28	WOS:000305912500034
J	Yao, HH; Duan, M; Yang, L; Buch, S				Yao, Honghong; Duan, Ming; Yang, Lu; Buch, Shilpa			Nonmuscle myosin light-chain kinase mediates microglial migration induced by HIV Tat: Involvement of beta 1 integrins	FASEB JOURNAL			English	Article						neuroinflammation; nmMYLK	IN-VIVO; ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; EXTRACELLULAR-MATRIX; BARRIER DYSFUNCTION; INTEGRIN REGULATION; ACTIVATION; PROTEIN; PHOSPHORYLATION; ATP	One of the hallmark features of HIV-associated neurological disease is increased activation and migration of microglia. HIV transactivator of transcription (Tat) is released from infected cells and has the ability to recruit microglia. The purpose of this study was to investigate molecular mechanisms by which recombinant Tat(1-72), but not heated-inactive Tat(1-72), induces migration of rat primary microglia. Using primary microglia in Boyden chambers, we demonstrated the role of nonmuscle myosin light-chain kinase (nmMYLK) in Tat(1-72) (14.4 nM)-mediated increased microglial migration (up to 171.85%). These findings were validated using microglia isolated from wild-type (WT) or nmMYLK(-/-) mice in Dunn chamber assays. Tat(1-72)-mediated activation of nmMYLK resulted in "inside-out" activation of beta 1 integrin, followed by "outside-in" activation of c-Src, Pyk2, and Cdc42-GTP (using GLISA in primary and nmMYLK(-/-) microglia) and, subsequently, actin polymerization (flow cytometry and Western blot assays). In vivo corroboration of these findings demonstrated decreased migration of nmMYLK(-/-) microglia (2 x 10(5) cells transplanted into corpus callosum) compared with WT microglia toward microinjected Tat(1-72) (2 mu g/mouse) in hippocampus. Up-regulation of nmMYLK in microglia was also detected in sections of basal ganglia from humans with HIV-encephalitis compared with uninfected controls. nmMYLK is thus critical for eliciting microglial migration during the innate immune response.-Yao, H., Duan, M., Yang, L., Buch, S. Nonmuscle myosin lightchain kinase mediates microglial migration induced by HIV Tat: Involvement of beta 1 integrins. FASEB J. 27, 1532-1548 (2013). www.fasebj.org	[Yao, Honghong; Yang, Lu; Buch, Shilpa] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Duan, Ming] Jilin Univ, Minist Educ, Key Lab Zoonosis Res, Changchun 130023, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; Jilin University	Buch, S (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr,DRC 8011, Omaha, NE 68198 USA.	sbuch@unmc.edu	duan, ming/M-9892-2016	Buch, Shilpa/0000-0002-3103-6685	U.S. National Institutes of Health [MH-068212, DA020392, DA023397, DA024442, DA030285]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH068212, P30MH062261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA020392, R21DA023397, R01DA024442, R21DA030285] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Yaman Lu for technical support. This work was supported by grants MH-068212, DA020392, DA023397, and DA024442 (S.B.), and DA030285 (H.Y.) from the U.S. National Institutes of Health. The authors declare no conflicts of interest.	ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0; Eugenin EA, 2005, GLIA, V49, P501, DOI 10.1002/glia.20137; Eugenin EA, 2007, P NATL ACAD SCI USA, V104, P3438, DOI 10.1073/pnas.0611699104; Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481-011-9291-6; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Graham WV, 2006, J BIOL CHEM, V281, P26205, DOI 10.1074/jbc.M602164200; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hixenbaugh EA, 1997, AM J PHYSIOL-HEART C, V273, pH981, DOI 10.1152/ajpheart.1997.273.2.H981; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4; Kurpius D, 2006, GLIA, V54, P58, DOI 10.1002/glia.20355; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; Lu SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023915; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Ma TY, 2005, AM J PHYSIOL-GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004; Miao HX, 2010, INVEST OPHTH VIS SCI, V51, P4096, DOI 10.1167/iovs.10-5177; Miller AM, 2009, GLIA, V57, P875, DOI 10.1002/glia.20813; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Milner R, 2002, J NEUROSCI, V22, P1562, DOI 10.1523/JNEUROSCI.22-05-01562.2002; Minghetti L, 2004, NEUROCHEM RES, V29, P965, DOI 10.1023/B:NERE.0000021241.90133.89; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; MOY AB, 1993, J CLIN INVEST, V92, P1198, DOI 10.1172/JCI116690; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Peng FW, 2008, EUR J NEUROSCI, V28, P1255, DOI 10.1111/j.1460-9568.2008.06444.x; Ranaivo HR, 2007, AM J PATHOL, V170, P439, DOI 10.2353/ajpath.2007.060219; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Reynoso R, 2007, SHOCK, V28, P589, DOI 10.1097/SHK.0b013c31804d415f; Rostasy KM, 2005, NEUROPEDIATRICS, V36, P230, DOI 10.1055/s-2005-865864; Rumbaugh J, 2006, FASEB J, V20, P1736, DOI 10.1096/fj.05-5619fje; Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009; Saito H, 1998, J IMMUNOL, V161, P1533; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; Smith L, 2002, J BIOL CHEM, V277, P35597, DOI 10.1074/jbc.M206483200; STULL JT, 1988, AM J MED SCI, V296, P241, DOI 10.1016/S0002-9629(15)40865-1; Sun CX, 2011, CIRCULATION, V124, P48, DOI 10.1161/CIRCULATIONAHA.110.988915; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x; Toschi E, 2006, MOL BIOL CELL, V17, P1985, DOI 10.1091/mbc.E05-08-0717; Totani L, 2006, BIOCHEM J, V396, P89, DOI 10.1042/BJ20051924; Urbinati C, 2005, ARTERIOSCL THROM VAS, V25, P2315, DOI 10.1161/01.ATV.0000186182.14908.7b; Urbinati C, 2009, BLOOD, V114, P3335, DOI 10.1182/blood-2009-01-198945; Van Grol J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011733; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb SE, 1996, J CELL SCI, V109, P793; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628; Yao HH, 2009, J NEUROSCI, V29, P1657, DOI 10.1523/JNEUROSCI.2781-08.2009; Zhou F, 2008, J CELL MOL MED, V12, P1559, DOI 10.1111/j.1582-4934.2007.00144.x	64	13	13	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1532	1548		10.1096/fj.12-219600	http://dx.doi.org/10.1096/fj.12-219600			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23292072	Green Published			2022-12-28	WOS:000316940800025
J	Choi, YJ; Jung, J; Chung, HK; Im, E; Rhee, SH				Choi, Yoon Jeong; Jung, Jane; Chung, Hyo Kyun; Im, Eunok; Rhee, Sang Hoon			PTEN regulates TLR5-induced intestinal inflammation by controlling Mal/TIRAP recruitment	FASEB JOURNAL			English	Article						flagellin; inflammatory bowel disease; interleukin 10; epithelial cells	DOMAIN-CONTAINING ADAPTER; TOLL-LIKE RECEPTOR-4; BACTERIAL FLAGELLIN; TOLL-LIKE-RECEPTOR-5 ENGAGEMENT; GENE-EXPRESSION; CUTTING EDGE; ACTIVATION; TLR5; IMMUNITY; CELLS	Defective IL-10 allele is a risk factor for intestinal inflammation. Indeed, IL-10(-/-) mice are predisposed to spontaneous colitis in the presence of intestinal microbiota, indicating that microbial factors contribute to developing intestinal inflammation. By recognizing flagellin, TLR5 plays a quintessential role in microbial recognition in intestinal epithelial cells. Here, we treated flagellin (1.0 mu g/mouse/d) in mouse colon and found that it elicited colonic inflammation in IL-10(-/-) mice, characterized with tissue hypertrophy, inflamed epithelium, and enhanced cytokine production in the colon (MPO, KC, IL-6; >= 2-fold; P < 0.05). These inflammatory effects were dramatically inhibited in TLR5(-/-); IL-10(-/-) mice. Intestinal epithelium specific PTEN deletion significantly attenuated flagellin-promoted colonic inflammation in IL-10(-/-) mice. As a molecular mechanism that PTEN deletion inhibited TLR5-elicited responses, we hypothesized that PTEN regulated TLR5-induced responses by controlling the involvement of Mal in TLR5 engagement. Mal interacted with TLR5 on flagellin, and Mal deficiency inhibited flagellin-induced responses in intestinal epithelial cells. Similarly, Mal(-/-); IL-10(-/-) mice showed reduced flagellin-promoted responses. Furthermore, PTEN deletion disrupted Mal-TLR5 interaction, resulting in diminished TLR5-induced responses. PTEN deletion impeded Mal localization at the plasma membrane and suppressed Mal-TLR5 interaction. These results suggest that, by controlling Mal recruitment, PTEN regulates TLR5-induced inflammatory responses.-Choi, Y. J., Jung, J., Chung, H. K., Im, E., Rhee, S. H. PTEN regulates TLR5-induced intestinal inflammation by controlling Mal/TIRAP recruitment. FASEB J. 27, 243-254 (2013). www.fasebj.org	[Choi, Yoon Jeong; Jung, Jane; Chung, Hyo Kyun; Rhee, Sang Hoon] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA; [Im, Eunok] Pusan Natl Univ, Sch Pharm, Pusan, South Korea	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pusan National University	Rhee, SH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, MRL1240,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	shrhee@mednet.ucla.edu	Lee, Kee-Joon/AAA-4090-2022		U.S. National Institutes of Health [DK079015]; National Research Foundation (NRF) of Korea; Ministry of Education, Science and Technology [2012R1A1A1042566]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK079015] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Ruslan M. Medzhitov (Yale University, New Haven, CT, USA) for Mal (TIRAP)<SUP>-/-</SUP> mice, Dr. Vivek M. Rangnekar (University of Kentucky, Lexington, KY, USA) for PTEN-GFP construct, and Dr. Hong Wu (University of California-Los Angeles, Los Angeles, CA, USA) for MEF-PTEN<SUP>-/-</SUP> and MEF-PTEN<SUP>+/+</SUP> cells. This work was supported by the U.S. National Institutes of Health (DK079015, S. H. R.) and by the Basic Science Research Program through the National Research Foundation (NRF) of Korea, funded by the Ministry of Education, Science and Technology (2012R1A1A1042566; E. I.). The authors declare no conflicts of interest.	Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Blohmke CJ, 2008, J IMMUNOL, V180, P7764, DOI 10.4049/jimmunol.180.11.7764; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Carvalho FA, 2008, INFLAMM BOWEL DIS, V14, P1051, DOI 10.1002/ibd.20423; Choi YJ, 2010, J BIOL CHEM, V285, P37570, DOI 10.1074/jbc.M110.158394; Choi YJ, 2010, J BIOL CHEM, V285, P21382, DOI 10.1074/jbc.M110.115022; CROHN BB, 1958, JAMA-J AM MED ASSOC, V166, P1479, DOI 10.1001/jama.1958.62990120019013; Feuillet V, 2006, P NATL ACAD SCI USA, V103, P12487, DOI 10.1073/pnas.0605200103; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Hakelien AM, 2002, NAT BIOTECHNOL, V20, P460, DOI 10.1038/nbt0502-460; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100; Im E, 2009, J NUTR, V139, P1848, DOI 10.3945/jn.109.108613; Jiang BH, 2009, ADV CANCER RES, V102, P19, DOI 10.1016/S0065-230X(09)02002-8; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Langlois MJ, 2009, FASEB J, V23, P1835, DOI 10.1096/fj.08-123125; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Letran SE, 2011, J IMMUNOL, V186, P5406, DOI 10.4049/jimmunol.1003576; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lodes MJ, 2004, J CLIN INVEST, V113, P1296, DOI 10.1172/JCI200420295; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Miao EA, 2007, SEMIN IMMUNOPATHOL, V29, P275, DOI 10.1007/s00281-007-0078-z; Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Rhee SH, 2008, GASTROENTEROLOGY, V135, P518, DOI 10.1053/j.gastro.2008.04.022; Rhee SH, 2006, J BIOL CHEM, V281, P18560, DOI 10.1074/jbc.M513861200; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rhee SH, 2005, P NATL ACAD SCI USA, V102, P13610, DOI 10.1073/pnas.0502174102; Rhee SH, 2004, J BIOL CHEM, V279, P25179, DOI 10.1074/jbc.M400967200; Schaefer TM, 2004, IMMUNOLOGY, V112, P428, DOI 10.1111/j.1365-2567.2004.01898.x; Song XY, 2011, NAT IMMUNOL, V12, P1151, DOI 10.1038/ni.2155; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Vijay-Kumar M, 2007, J CLIN INVEST, V117, P3909, DOI 10.1172/JCI33084; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986	45	27	28	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					243	254		10.1096/fj.12-217596	http://dx.doi.org/10.1096/fj.12-217596			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038756	Green Published			2022-12-28	WOS:000313103200023
J	Lang, F; Shumilina, E				Lang, Florian; Shumilina, Ekaterina			Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1	FASEB JOURNAL			English	Review						Na+ channels; K+ channels; Ca2+ channels; Cl- channels; ENaC; Orai1	EPITHELIAL SODIUM-CHANNEL; ALDOSTERONE-INDUCED KINASE; UBIQUITIN LIGASE NEDD4-2; MEDULLARY K+ CHANNEL; KCNQ1 POTASSIUM CHANNEL; XENOPUS-LAEVIS OOCYTES; NA+ CHANNEL; PROTEIN-KINASE; DEPENDENT KINASE; PLASMA-MEMBRANE	The ubiquitously expressed serum-and glucocorticoid-inducible kinase-1 (SGK1) is genomically regulated by cell stress (including cell shrinkage) and several hormones (including gluco-and mineralo-corticoids). SGK1 is activated by insulin and growth factors through PI3K and 3-phosphoinositide-dependent kinase PDK1. SGK1 activates a wide variety of ion channels (e. g., ENaC, SCN5A, TRPV4-6, ROMK, Kv1.3, Kv1.5, Kv4.3, KCNE1/KCNQ1, KCNQ4, ASIC1, GluR6, ClCKa/barttin, ClC2, CFTR, and Orai/STIM), which participate in the regulation of transport, hormone release, neuroexcitability, inflammation, cell proliferation, and apoptosis. SGK1-sensitive ion channels participate in the regulation of renal Na+ retention and K+ elimination, blood pressure, gastric acid secretion, cardiac action potential, hemostasis, and neuroexcitability. A common (similar to 3-5% prevalence in Caucasians and similar to 10% in Africans) SGK1 gene variant is associated with increased blood pressure and body weight as well as increased prevalence of type II diabetes and stroke. SGK1 further contributes to the pathophysiology of allergy, peptic ulcer, fibrosing disease, ischemia, tumor growth, and neurodegeneration. The effect of SGK1 on channel activity is modest, and the channels do not require SGK1 for basic function. SGK1-dependent ion channel regulation may thus become pathophysiologically relevant primarily after excessive (pathological) expression. Therefore, SGK1 may be considered an attractive therapeutic target despite its broad range of functions.-Lang, F., Shumilina, E. Regulation of ion channels by the serum-and glucocorticoid-inducible kinase SGK1. FASEB J. 27, 3-12 (2013). www.fasebj.org	[Lang, Florian; Shumilina, Ekaterina] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de						Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Ali S, 2001, CELL PHYSIOL BIOCHEM, V11, P135, DOI 10.1159/000047801; Aronzon A, 2003, OTOL NEUROTOL, V24, P465, DOI 10.1097/00129492-200305000-00018; Arteaga MF, 2008, P NATL ACAD SCI USA, V105, P4459, DOI 10.1073/pnas.0800958105; Asher C, 2003, BBA-BIOMEMBRANES, V1612, P59, DOI 10.1016/S0005-2736(03)00083-X; Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Baltaev R, 2005, PFLUG ARCH EUR J PHY, V450, P26, DOI 10.1007/s00424-004-1369-z; BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27; Bergler T, 2008, KIDNEY INT, V74, P1170, DOI 10.1038/ki.2008.312; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; Bhalla V, 2006, J BIOL CHEM, V281, P26159, DOI 10.1074/jbc.M606045200; Boehmer C, 2007, FEBS LETT, V581, P5586, DOI 10.1016/j.febslet.2007.11.006; Boehmer C, 2003, CARDIOVASC RES, V57, P1079, DOI 10.1016/S0008-6363(02)00837-4; Boehmer C, 2008, CELL PHYSIOL BIOCHEM, V22, P591, DOI 10.1159/000185543; Bohmer C, 2000, CELL PHYSIOL BIOCHEM, V10, P187, DOI 10.1159/000016349; Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood-2011-06-359976; Boyd C, 2005, AM J PHYSIOL-RENAL, V288, pF505, DOI 10.1152/ajprenal.00242.2004; Burton TJ, 2009, EUR J PHARMACOL, V613, P176, DOI 10.1016/j.ejphar.2009.04.005; Busjahn A, 2004, CELL PHYSIOL BIOCHEM, V14, P135, DOI 10.1159/000078105; Busjahn A, 2003, CELL PHYSIOL BIOCHEM, V13, P51, DOI 10.1159/000070249; Busjahn A, 2002, HYPERTENSION, V40, P256, DOI 10.1161/01.HYP.0000030153.19366.26; Caohuy H, 2009, J BIOL CHEM, V284, P25241, DOI 10.1074/jbc.M109.035345; Chandran S, 2011, J BIOL CHEM, V286, P37830, DOI 10.1074/jbc.M111.293233; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Dahlberg J, 2011, J HYPERTENS, V29, P884, DOI 10.1097/HJH.0b013e3283455117; de la Rosa DA, 2004, J GEN PHYSIOL, V124, P395, DOI 10.1085/jgp.200409120; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Deng W, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-29; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Diakov A, 2010, CELL PHYSIOL BIOCHEM, V26, P913, DOI 10.1159/000324000; Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Edinger RS, 2009, J BIOL CHEM, V284, P150, DOI 10.1074/jbc.M807358200; Embark HM, 2004, KIDNEY INT, V66, P1918, DOI 10.1111/j.1523-1755.2004.00966.x; Embark HM, 2004, CELL PHYSIOL BIOCHEM, V14, P203, DOI 10.1159/000080329; Embark HM, 2003, PFLUG ARCH EUR J PHY, V445, P601, DOI 10.1007/s00424-002-0982-y; Eylenstein A, 2012, J BIOL CHEM, V287, P2719, DOI 10.1074/jbc.M111.275925; Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10-178210; Fahmer M, 2009, IMMUNOL REV, V231, P99, DOI 10.1111/j.1600-065X.2009.00815.x; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Faresse N, 2012, AM J PHYSIOL-RENAL, V302, pF977, DOI 10.1152/ajprenal.00535.2011; Fejes-Toth G, 2008, AM J PHYSIOL-RENAL, V294, pF1298, DOI 10.1152/ajprenal.00579.2007; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Flores SY, 2005, J AM SOC NEPHROL, V16, P2279, DOI 10.1681/ASN.2004100828; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Gamper N, 2002, PFLUG ARCH EUR J PHY, V443, P625, DOI 10.1007/s00424-001-0741-5; Gehring EM, 2009, BIOCHEM BIOPH RES CO, V390, P952, DOI 10.1016/j.bbrc.2009.10.084; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hallows KR, 2010, J BIOL CHEM, V285, P21671, DOI 10.1074/jbc.M109.084731; Heise CJ, 2010, J BIOL CHEM, V285, P25161, DOI 10.1074/jbc.M110.103432; Helms MN, 2005, AM J PHYSIOL-CELL PH, V289, pC717, DOI 10.1152/ajpcell.00006.2005; Helms MN, 2003, AM J PHYSIOL-RENAL, V284, pF480, DOI 10.1152/ajprenal.00299.2002; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Hewavitharana T, 2007, CELL CALCIUM, V42, P173, DOI 10.1016/j.ceca.2007.03.009; Hillman TM, 2003, LARYNGOSCOPE, V113, P1903, DOI 10.1097/00005537-200311000-00008; Hills CE, 2008, J ENDOCRINOL, V199, P343, DOI 10.1677/JOE-08-0295; Hougaard C, 2004, BBA-BIOMEMBRANES, V1660, P1, DOI 10.1016/j.bbamem.2003.11.015; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Jespersen T, 2005, PHYSIOLOGY, V20, P408, DOI 10.1152/physiol.00031.2005; Jespersen T, 2007, CARDIOVASC RES, V74, P64, DOI 10.1016/j.cardiores.2007.01.008; Ji W, 2008, P NATL ACAD SCI USA, V105, P13668, DOI 10.1073/pnas.0806499105; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Ke Y, 2010, AM J PHYSIOL-RENAL, V298, pF1445, DOI 10.1152/ajprenal.00257.2009; Keil JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013465; Kim SH, 2009, AM J PHYSIOL-CELL PH, V296, pC544, DOI 10.1152/ajpcell.00338.2008; Klaus F, 2009, BIOCHEM BIOPH RES CO, V381, P407, DOI 10.1016/j.bbrc.2009.02.053; Krueger B, 2009, CELL PHYSIOL BIOCHEM, V24, P605, DOI 10.1159/000257516; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lang F, 2000, P NATL ACAD SCI USA, V97, P8157, DOI 10.1073/pnas.97.14.8157; Lang F, 2007, AM J PHYSIOL-CELL PH, V293, pC1187, DOI 10.1152/ajpcell.00024.2007; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2012, CLIN EXP NEPHROL, V16, P73, DOI 10.1007/s10157-011-0488-z; Lang F, 2010, J PHYSIOL-LONDON, V588, P3349, DOI 10.1113/jphysiol.2010.190926; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807; Lang F, 2009, CURR OPIN NEPHROL HY, V18, P439, DOI 10.1097/MNH.0b013e32832f125e; Laufer J, 2009, CELL PHYSIOL BIOCHEM, V23, P25, DOI 10.1159/000204077; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Liang XB, 2006, J BIOL CHEM, V281, P16323, DOI 10.1074/jbc.M601360200; Liang XB, 2010, MOL BIOL CELL, V21, P2024, DOI 10.1091/mbc.E10-01-0042; Lin DH, 2012, AM J PHYSIOL-RENAL, V303, pF110, DOI 10.1152/ajprenal.00676.2011; Lu M, 2011, J BIOL CHEM, V286, P30647, DOI 10.1074/jbc.M111.257592; Lu M, 2010, J AM SOC NEPHROL, V21, P811, DOI 10.1681/ASN.2009111168; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Marcotti W, 1999, J PHYSIOL-LONDON, V520, P653, DOI 10.1111/j.1469-7793.1999.00653.x; Menniti M, 2010, CELL PHYSIOL BIOCHEM, V26, P587, DOI 10.1159/000322326; Mignen O, 2008, J PHYSIOL-LONDON, V586, P419, DOI 10.1113/jphysiol.2007.147249; Nagaki K, 2006, BIOCHEMISTRY-US, V45, P6733, DOI 10.1021/bi052640q; Naray-Fejes-Toth A, 2004, MOL CELL ENDOCRINOL, V217, P197, DOI 10.1016/j.mce.2003.10.043; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Naray-Fejes-Toth A, 2008, AM J PHYSIOL-RENAL, V295, pF18, DOI 10.1152/ajprenal.00573.2007; Palmada M, 2005, CELL PHYSIOL BIOCHEM, V15, P175, DOI 10.1159/000083650; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Palmada M, 2003, BIOCHEM BIOPH RES CO, V311, P629, DOI 10.1016/j.bbrc.2003.10.037; Palmada M, 2003, BIOCHEM BIOPH RES CO, V307, P967, DOI 10.1016/S0006-291X(03)01301-9; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Pavlov TS, 2010, PPAR RES, V2010, DOI 10.1155/2010/703735; Pearce D, 2003, CELL PHYSIOL BIOCHEM, V13, P13, DOI 10.1159/000070245; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Penna A, 2008, NATURE, V456, P116, DOI 10.1038/nature07338; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Rao AD, 2013, J HUM HYPERTENS, V27, P176, DOI 10.1038/jhh.2012.22; Reisenauer MR, 2010, AM J PHYSIOL-RENAL, V299, pF63, DOI 10.1152/ajprenal.00105.2010; Reisenauer MR, 2009, J BIOL CHEM, V284, P35659, DOI 10.1074/jbc.M109.038448; Renauld S, 2010, J MEMBRANE BIOL, V236, P259, DOI 10.1007/s00232-010-9297-7; Resch M, 2010, HIGH PERFORMANCE COMPUTING IN SCIENCE AND ENGINEERING '09, P1; Ring AM, 2007, P NATL ACAD SCI USA, V104, P4025, DOI 10.1073/pnas.0611728104; Ronchi CL, 2012, NEOPLASIA, V14, P206, DOI 10.1593/neo.111758; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Rotte A, 2009, CELL PHYSIOL BIOCHEM, V23, P133, DOI 10.1159/000204102; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Sato JD, 2007, CELL PHYSIOL BIOCHEM, V20, P91, DOI 10.1159/000104157; Schindl R, 2009, CELL CALCIUM, V46, P227, DOI 10.1016/j.ceca.2009.08.003; Schwab M, 2008, CELL PHYSIOL BIOCHEM, V21, P151, DOI 10.1159/000113757; Seebohm G, 2005, CELL PHYSIOL BIOCHEM, V16, P255, DOI 10.1159/000089851; Seebohm G, 2008, CIRC RES, V103, P1451, DOI 10.1161/CIRCRESAHA.108.177360; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Shaw JR, 2008, CELL PHYSIOL BIOCHEM, V22, P69, DOI 10.1159/000149784; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Shin SH, 2012, CELL SIGNAL, V24, P641, DOI 10.1016/j.cellsig.2011.11.002; Shisheva A, 2008, CELL BIOL INT, V32, P591, DOI 10.1016/j.cellbi.2008.01.006; Shulman A, 2000, Int Tinnitus J, V6, P10; Shumilina E, 2005, J CELL PHYSIOL, V204, P87, DOI 10.1002/jcp.20267; Shumilina E, 2010, CELL PHYSIOL BIOCHEM, V26, P699, DOI 10.1159/000322337; Smyth JT, 2010, J CELL MOL MED, V14, P2337, DOI 10.1111/j.1582-4934.2010.01168.x; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Sobiesiak M, 2009, J IMMUNOL, V183, P4395, DOI 10.4049/jimmunol.0803017; Sopjani M, 2010, J MEMBRANE BIOL, V233, P35, DOI 10.1007/s00232-009-9222-0; Soundararajan R, 2012, MOL CELL ENDOCRINOL, V350, P242, DOI 10.1016/j.mce.2011.11.003; Soundararajan R, 2010, J BIOL CHEM, V285, P39905, DOI 10.1074/jbc.M110.161133; Soundararajan R, 2009, P NATL ACAD SCI USA, V106, P7804, DOI 10.1073/pnas.0809892106; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strutz-Seebohm N, 2005, J PHYSIOL-LONDON, V565, P391, DOI 10.1113/jphysiol.2004.079624; Strutz-Seebohm N, 2009, CHANNELS, V3, P88, DOI 10.4161/chan.3.2.8086; Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Thomas SV, 2011, J BIOL CHEM, V286, P32074, DOI 10.1074/jbc.M111.278283; Ullrich S, 2005, DIABETES, V54, P1090, DOI 10.2337/diabetes.54.4.1090; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Vallon V, 2006, J MOL MED, V84, P396, DOI 10.1007/s00109-005-0027-z; Verma P, 2010, CHANNELS, V4, P319, DOI 10.4161/chan.4.4.12905; Verrey F, 2003, CELL PHYSIOL BIOCHEM, V13, P21, DOI 10.1159/000070246; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wagner CA, 2000, J PHYSIOL-LONDON, V526, P35, DOI 10.1111/j.1469-7793.2000.00035.x; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wald H, 1998, AM J PHYSIOL-RENAL, V275, pF239, DOI 10.1152/ajprenal.1998.275.2.F239; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Wang GX, 2004, AM J PHYSIOL-HEART C, V287, pH533, DOI 10.1152/ajpheart.00228.2003; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wang K, 2010, CELL PHYSIOL BIOCHEM, V25, P271, DOI 10.1159/000276561; Wang WH, 1999, AM J PHYSIOL-RENAL, V277, pF826, DOI 10.1152/ajprenal.1999.277.6.F826; Warntges S, 2002, PFLUG ARCH EUR J PHY, V443, P617, DOI 10.1007/s00424-001-0737-1; Warntges S, 2002, CELL PHYSIOL BIOCHEM, V12, P135, DOI 10.1159/000063790; Watt GB, 2012, BRIT J PHARMACOL, V166, P1272, DOI 10.1111/j.1476-5381.2012.01860.x; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Wesch D, 2010, AM J PHYSIOL-CELL PH, V299, pC779, DOI 10.1152/ajpcell.00184.2010; Wielputz MO, 2007, J BIOL CHEM, V282, P28264, DOI 10.1074/jbc.M702168200; Wiemuth D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012163; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Yue P, 2011, KIDNEY INT, V79, P423, DOI 10.1038/ki.2010.380; Yue P, 2009, P NATL ACAD SCI USA, V106, P15061, DOI 10.1073/pnas.0907855106; Yun CC, 2003, CELL PHYSIOL BIOCHEM, V13, P29, DOI 10.1159/000070247; Yun CC, 2002, J AM SOC NEPHROL, V13, P2823, DOI 10.1097/01.ASN.0000035085.54451.81; Zhang LP, 2005, CANCER RES, V65, P457; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhang WZ, 2007, J CLIN INVEST, V117, P773, DOI 10.1172/JCI29850; Zhong SX, 2009, ACTA OTO-LARYNGOL, V129, P935, DOI 10.1080/00016480802552501; Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200; Zhu T, 2012, INJURY, V43, P1277, DOI 10.1016/j.injury.2012.04.004	180	122	130	0	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					3	12		10.1096/fj.12-218230	http://dx.doi.org/10.1096/fj.12-218230			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23012321				2022-12-28	WOS:000313103200002
J	Hochrath, K; Krawczyk, M; Goebel, R; Langhirt, M; Rathkolb, B; Micklich, K; Rozman, J; Horsch, M; Beckers, J; Klingenspor, M; Fuchs, H; Gailus-Durner, V; Wolf, E; Acalovschi, M; Volmer, DA; de Angelis, MH; Lammert, F				Hochrath, Katrin; Krawczyk, Marcin; Goebel, Reinhild; Langhirt, Miriam; Rathkolb, Birgit; Micklich, Kateryna; Rozman, Jan; Horsch, Marion; Beckers, Johannes; Klingenspor, Martin; Fuchs, Helmut; Gailus-Durner, Valerie; Wolf, Eckhard; Acalovschi, Monica; Volmer, Dietrich A.; de Angelis, Martin Hrabe; Lammert, Frank			The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis	FASEB JOURNAL			English	Article						ATP-binding cassette transporter; chronic cholangitis; liver fibrosis; liver receptor homolog	INTRAHEPATIC CHOLESTASIS; INSULIN-RESISTANCE; TRANSFER PROTEIN; GALLSTONE RISK; LIVER-INJURY; BILE-ACIDS; GENE; MICE; EXPRESSION; FIBROSIS	The hepatic phosphatidylcholine (PC) transporter ATP-binding cassette (ABC) B4 flops PC from hepatocytes into bile, and its dysfunction causes chronic cholestasis and fibrosis. Because a nuclear receptor-dependent PC pathway has been determined to exert antidiabetic effects, we now analyzed the role of ABCB4 in glucose metabolism. We bred congenic Abcb4-knockout (Abcb4(-/-)) mice on the fibrosis-susceptible BALB/cJ background. Knockout mice and wild-type controls were phenotyped by measuring plasma glucose concentrations, intraperitoneal glucose tolerance, hepatic RNA expression profiles, and liver histology. In addition, 4 procholestatic ABCB4 gene variants were correlated with blood glucose levels in 682 individuals from 2 independent European cohorts. Systemic glucose levels differ significantly between Abcb4(-/-) mice and wild-type controls, and knockout mice display improved glucose tolerance with significantly lower area under the curve values on intraperitoneal glucose challenge. Of note, hepatic expression of the antidiabetic nuclear receptor 5A2 (LRH-1) is induced consistently in Abcb4(-/-) mice, and its specific rare PC ligands are detected in liver by mass spectrometry imaging. In humans, serum glucose levels are associated significantly with the common ABCB4 variant c.711A>T. In summary, ABCB4 might play a critical role in glucose homeostasis in mice and humans. We speculate that the effects could be mediated via LRH-1-dependent PC pathways.-Hochrath, K., Krawczyk, M., Goebel, R., Langhirt, M., Rathkolb, B., Micklich, K., Rozman, J., Horsch, M., Beckers, J., Klingenspor, M., Fuchs, H., Gailus- Durner, V., Wolf, E., Acalovschi, M., Volmer, D. A., Hrabe. de Angelis, M., Lammert, F. The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis. FASEB J. 26, 5081-5091 (2012). www.fasebj.org	[Hochrath, Katrin; Krawczyk, Marcin; Goebel, Reinhild; Langhirt, Miriam; Lammert, Frank] Univ Saarland, Med Ctr, Dept Med 2, D-66421 Homburg, Germany; [Rathkolb, Birgit; Micklich, Kateryna; Wolf, Eckhard] Univ Munich, Inst Mol Anim Breeding & Biotechnol, Munich, Germany; [Rathkolb, Birgit; Micklich, Kateryna; Rozman, Jan; Horsch, Marion; Beckers, Johannes; Fuchs, Helmut; Gailus-Durner, Valerie; de Angelis, Martin Hrabe] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Expt Genet, German Mouse Clin, Neuherberg, Germany; [Rozman, Jan; Klingenspor, Martin] Tech Univ Munich, Dept Mol Nutr Med, Else Kroner Fresenius Ctr, Freising Weihenstephan, Germany; [Rozman, Jan; Beckers, Johannes] Tech Univ Munich, Zent Inst Ernahrungs & Lebensmittelforsch ZIEL, Res Ctr Nutr & Food Sci, Freising Weihenstephan, Germany; [Beckers, Johannes] Tech Univ Munich, Dept Expt Genet, Freising Weihenstephan, Germany; [Acalovschi, Monica; de Angelis, Martin Hrabe] Iuliu Hatieganu Univ Med & Pharm, Dept Med 3, Cluj Napoca, Romania; [Volmer, Dietrich A.] Univ Saarland, Inst Bioanalyt Chem, D-6600 Saarbrucken, Germany; [de Angelis, Martin Hrabe] German Ctr Diabet Res, Neuherberg, Germany	Saarland University; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; Technical University of Munich; Iuliu Hatieganu University of Medicine & Pharmacy; Regional Institute of Gastroenterology & Hepatology; Saarland University	Lammert, F (corresponding author), Univ Saarland, Med Ctr, Dept Med 2, Kirrberger Str 100, D-66421 Homburg, Germany.	frank.lammert@uks.eu	Rathkolb, Birgit/F-7041-2013; Klingenspor, Martin/D-6930-2011; Beckers, Johannes/K-7237-2012; Krawczyk, Marcin/AAG-4356-2020; Gailus-Durner, Valerie/M-7337-2014; Klingenspor, Martin/K-5033-2019; Fuchs, Helmut/M-7347-2014; Rozman, Jan/A-2540-2010; Volmer, Dietrich/G-7900-2012; de Angelis, Martin Hrabe/F-5531-2012	Klingenspor, Martin/0000-0002-4502-6664; Beckers, Johannes/0000-0001-7874-3822; Krawczyk, Marcin/0000-0002-0113-0777; Fuchs, Helmut/0000-0002-5143-2677; Rozman, Jan/0000-0002-8035-8904; Volmer, Dietrich/0000-0003-2820-1480; de Angelis, Martin Hrabe/0000-0002-7898-2353; Wolf, Eckhard/0000-0002-0430-9510	Deutsche Forschungsgemeinschaft [SFB/TRR57 TP01]; German Federal Ministry of Education and Research [01GS0851, 01GS0850, 01GS0869, 01KX1012]; European Union [EUMODIC LSHG-2006-037188, 211404]; Alfried Krupp von Bohlen and Halbach-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); Alfried Krupp von Bohlen and Halbach-Stiftung	The authors thank all patients for participating in this study and providing blood samples. The authors also thank the technicians, especially Annika Bohner for setting up cell culture experiments, and Sandra Geissler, Elfi Holupirek, Ann-Elisabeth Schwarz, and Reinhard Seeliger, as well as the animal caretaker team of the German Mouse Clinic (Michael Gerstlauer, Manuela Huber, Renate Huber, Heidi Marr, Annica Miedl, Tina Reichelt, Boris Schn, and Horst Wenig), for technical assistance in mouse phenotyping. The authors also thank Christine Gau for help with statistical analyses. This study was supported by Deutsche Forschungsgemeinschaft (SFB/TRR57 TP01 to F. L.), by a grant from the German Federal Ministry of Education and Research to the German Center for Diabetes Research, NGFN-Plus (01GS0851 to E. W., 01GS0850 to M. H. A., and 01GS0869 to M. K.), and Infrafrontier (01KX1012). The German Mouse Clinic received funding from the European Union (EUMODIC LSHG-2006-037188 and Infrafrontier Contract No. 211404). D. A. V. acknowledges research support by the Alfried Krupp von Bohlen and Halbach-Stiftung. The results of this article were included, in part, in an oral presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, November 3, 2009, and were published in abstract form in Hepatology [2009; 50(Suppl. 4), A232].	Acalovschi M, 2009, LIPIDS, V44, P521, DOI 10.1007/s11745-009-3300-z; Baghdasaryan A, 2008, LIVER INT, V28, P948, DOI 10.1111/j.1478-3231.2008.01758.x; Baghy K, 2011, LAB INVEST, V91, P439, DOI 10.1038/labinvest.2010.172; Biddinger SB, 2008, NAT MED, V14, P778, DOI 10.1038/nm1785; Borkham-Kamphorst E, 2011, LIVER INT, V31, P656, DOI 10.1111/j.1478-3231.2011.02495.x; Carey M C, 1992, Prog Liver Dis, V10, P139; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dooley S, 2008, GASTROENTEROLOGY, V135, P642, DOI 10.1053/j.gastro.2008.04.038; Elferink RPJO, 2006, GASTROENTEROLOGY, V130, P908, DOI 10.1053/j.gastro.2005.08.052; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Fickert P, 2004, GASTROENTEROLOGY, V127, P261, DOI 10.1053/j.gastro.2004.04.009; Forman BM, 2005, CELL METAB, V1, P153, DOI 10.1016/j.cmet.2005.02.006; Gailus-Durner V, 2005, NAT METHODS, V2, P403, DOI 10.1038/nmeth0605-403; Grunhage F, 2007, HEPATOLOGY, V46, P793, DOI 10.1002/hep.21847; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599; Hillebrandt S, 2002, GASTROENTEROLOGY, V123, P2041, DOI 10.1053/gast.2002.37069; Hohenester Simon, 2011, Hepatology, V54, P2265, DOI 10.1002/hep.24697; Horsch M, 2008, PROTEOMICS, V8, P1248, DOI 10.1002/pmic.200700725; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Iyengar SK, 2007, DIABETES, V56, P1577, DOI 10.2337/db06-1154; JAMALL IS, 1981, ANAL BIOCHEM, V112, P70, DOI 10.1016/0003-2697(81)90261-X; Jung C, 2007, J PEDIATR GASTR NUTR, V44, P453, DOI 10.1097/MPG.0b013e318036a569; Keitel V, 2012, HEPATOBILIARY TRANSP, P117; Kovacs P, 2008, J HEPATOL, V48, P116, DOI 10.1016/j.jhep.2007.07.027; Krawczyk M, 2011, J PHYSIOL PHARMACOL, V62, P369; Krawczyk M, 2011, SEMIN LIVER DIS, V31, P157, DOI 10.1055/s-0031-1276645; Krawczyk M, 2010, J GASTROINTEST LIVER, V19, P273; Lammert F, 2004, HEPATOLOGY, V39, P117, DOI 10.1002/hep.20022; Lang C, 2007, PHARMACOGENET GENOM, V17, P47, DOI 10.1097/01.fpc.0000230418.28091.76; Lee JM, 2011, NATURE, V474, P506, DOI 10.1038/nature10111; Lee YK, 2008, MOL ENDOCRINOL, V22, P1345, DOI 10.1210/me.2007-0565; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mochizuki H, 1998, GENE, V213, P149, DOI 10.1016/S0378-1119(98)00193-0; Moles A, 2012, J BIOL CHEM, V287, P1178, DOI 10.1074/jbc.M111.272393; Mullenbach R, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e70; Mullenbach R., 2011, J LIPIDS; Oosterveer MH, 2012, J CLIN INVEST, V122, P2817, DOI 10.1172/JCI62368; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Perez-Carreon J. I., 2010, INT J BIOCHEM CELL B, V42, P287; Popov Y, 2005, J HEPATOL, V43, P1045, DOI 10.1016/j.jhep.2005.06.025; PROCHAZKA M, 1995, DIABETOLOGIA, V38, P461, DOI 10.1007/s001250050306; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Rosmorduc O, 2003, GASTROENTEROLOGY, V125, P452, DOI 10.1016/S0016-5085(03)00898-9; Rosmorduc O, 2001, GASTROENTEROLOGY, V120, P1459, DOI 10.1053/gast.2001.23947; Scapa EF, 2008, FASEB J, V22, P2579, DOI 10.1096/fj.07-105395; Shishova EY, 2011, HEPATOLOGY, V54, P664, DOI 10.1002/hep.24393; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vacca M, 2007, CURR MED CHEM, V14, P2081; Varela-Rey M, 2010, HEPATOLOGY, V52, P105, DOI 10.1002/hep.23639; Wasmuth HE, 2007, GUT, V56, P265, DOI 10.1136/gut.2006.092742; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Wopereis S, 2012, PHYSIOL GENOMICS, V44, P293, DOI 10.1152/physiolgenomics.00072.2011	55	20	21	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5081	5091		10.1096/fj.12-209379	http://dx.doi.org/10.1096/fj.12-209379			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22982378				2022-12-28	WOS:000311838300029
J	Degen, J; Dublin, P; Zhang, J; Dobrowolski, R; Jokwitz, M; KarramO, K; Trotter, J; Jabs, R; Willecke, K; Steinhauser, C; Theis, M				Degen, Joachim; Dublin, Pavel; Zhang, Jiong; Dobrowolski, Radoslaw; Jokwitz, Melanie; KarramO, Khalad; Trotter, Jacqueline; Jabs, Ronald; Willecke, Klaus; Steinhaeuser, Christian; Theis, Martin			Dual reporter approaches for identification of Cre efficacy and astrocyte heterogeneity	FASEB JOURNAL			English	Article						conditional knock-in; connexin; Gap junctions; GFAP	MOUSE CORTICAL ASTROCYTES; GLUTAMATE TRANSPORTERS; CONNEXIN EXPRESSION; ALZHEIMERS-DISEASE; GENE-EXPRESSION; AMYLOID PLAQUES; TRANSGENIC MICE; P2X RECEPTOR; RECOMBINATION; CELLS	Gene inactivation reporters are powerful tools to circumvent limitations of the widely used Cre/loxP system of conditional mutagenesis. With new conditional transgenic mouse lines expressing the enhanced cyan fluorescent protein (ECFP) instead of connexin43 (Cx43) after Cre-mediated recombination, we demonstrate dual reporter approaches to simultaneously examine astrocyte subpopulations expressing different connexins, identify compensatory up-regulation within gene families, and quantify Cre-mediated deletion at the allelic level. Analysis of a newly generated Cx43 knock-in ECFP mouse revealed an unexpected heterogeneity of Cx43-expressing astrocytes across brain areas.-Degen, J., Dublin, P., Zhang, J., Dobrowolski, R., Jokwitz, M., Karram, K., Trotter, J., Jabs, R., Willecke, K., Steinh user, C., Theis, M. Dual reporter approaches for identification of Cre efficacy and astrocyte heterogeneity. FASEB J. 26, 4576-4583 (2012). www.fasebj.org	[Dublin, Pavel; Zhang, Jiong; Jabs, Ronald; Steinhaeuser, Christian; Theis, Martin] Univ Bonn, Inst Cellular Neurosci, Fac Med, D-53105 Bonn, Germany; [Degen, Joachim; Dobrowolski, Radoslaw; Jokwitz, Melanie; Willecke, Klaus] Univ Bonn, Life & Med Sci Inst, Fac Med, D-53105 Bonn, Germany; [KarramO, Khalad] Johannes Gutenberg Univ Mainz, Inst Mol Med, Mainz, Germany; [KarramO, Khalad; Trotter, Jacqueline] Johannes Gutenberg Univ Mainz, Dept Biol, Mainz, Germany	University of Bonn; University of Bonn; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Steinhauser, C (corresponding author), Univ Bonn, Inst Cellular Neurosci, Fac Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.	christian.steinhaeuser@ukb.uni-bonn.de; martin.theis@ukb.uni-bonn.de	Jabs, Ronald/C-5132-2008	Jabs, Ronald/0000-0001-6612-7678; Dobrowolski, Radek/0000-0002-1805-5806; Zhang, Jiong/0000-0001-8709-1141	German Research Foundation [Wi 270/29-1, 31-1, SFB 645/B2, SFB/TR3 C1, C9, SPP1172 SE 774/3]; European Community [FP7-202167];  [SFB/TR3 N01];  [SPP1172 TH 1350/1-1]	German Research Foundation(German Research Foundation (DFG)); European Community(European Commission); ; 	The authors thank Joana Fischer, Lukas Kunz, and Ina Fiedler for excellent technical assistance. This work was supported by German Research Foundation grants Wi 270/29-1, 31-1, SFB 645/B2 to K. W.; SFB/TR3 C1, C9, SPP1172 SE 774/3 to C. S.; and SFB/TR3 N01, C9, SPP1172 TH 1350/1-1 to M. T.; and by European Community grant FP7-202167 to C. S. and M. T.	Barrow J, 2005, Organogenesis, V2, P22; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Bedner P, 2012, BBA-BIOMEMBRANES, V1818, P1971, DOI 10.1016/j.bbamem.2011.10.016; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chokalingam K, 2009, TISSUE ENG PT A, V15, P2807, DOI 10.1089/ten.TEA.2008.0560; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Dobrowolski R, 2008, HUM MOL GENET, V17, P539, DOI 10.1093/hmg/ddm329; Eckardt D, 2004, GENESIS, V38, P159, DOI 10.1002/gene.20011; Giaume C, 2010, BRAIN RES REV, V63, P160, DOI 10.1016/j.brainresrev.2009.11.005; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Gosejacob D, 2011, GLIA, V59, P511, DOI 10.1002/glia.21120; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Hirrlinger PG, 2006, GLIA, V54, P11, DOI 10.1002/glia.20342; Houades V, 2008, J NEUROSCI, V28, P5207, DOI 10.1523/JNEUROSCI.5100-07.2008; Jabs R, 2007, GLIA, V55, P1648, DOI 10.1002/glia.20580; Karram K, 2008, GENESIS, V46, P743, DOI 10.1002/dvg.20440; Korets-Smith E, 2004, GENESIS, V40, P131, DOI 10.1002/gene.20074; Koulakoff A, 2008, GLIA, V56, P1299, DOI 10.1002/glia.20698; Koulakoff A, 2012, BBA-BIOMEMBRANES, V1818, P2048, DOI 10.1016/j.bbamem.2011.10.001; Kunze A, 2009, P NATL ACAD SCI USA, V106, P11336, DOI 10.1073/pnas.0813160106; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Lalo U, 2008, J NEUROSCI, V28, P5473, DOI 10.1523/JNEUROSCI.1149-08.2008; Matthias K, 2003, J NEUROSCI, V23, P1750; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Mei X, 2010, NEUROSCIENCE, V171, P92, DOI 10.1016/j.neuroscience.2010.08.001; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Requardt RP, 2009, GLIA, V57, P680, DOI 10.1002/glia.20796; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Roux L, 2011, P NATL ACAD SCI USA, V108, P18442, DOI 10.1073/pnas.1107386108; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Schnutgen F, 2003, NAT BIOTECHNOL, V21, P562, DOI 10.1038/nbt811; Theis M, 2003, J NEUROSCI, V23, P766; Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526-968X(200101)29:1<1::AID-GENE1000>3.0.CO;2-0; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Wallraff A, 2006, J NEUROSCI, V26, P5438, DOI 10.1523/JNEUROSCI.0037-06.2006; Zhang CK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007151; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	41	23	23	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2012	26	11					4576	4583		10.1096/fj.12-207183	http://dx.doi.org/10.1096/fj.12-207183			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859373				2022-12-28	WOS:000310574200019
J	Salhi, A; Centeno, G; Firsov, D; Crambert, G				Salhi, Amel; Centeno, Gabriel; Firsov, Dmitri; Crambert, Gilles			Circadian expression of H,K-ATPase type 2 contributes to the stability of plasma K+ levels	FASEB JOURNAL			English	Article						diurnal variation; potassium balance; electrolyte; epithelial ion transport	PROTEIN PERIOD 1; TIMING SYSTEM; POTASSIUM; CLOCK; ATPASE; SECRETION; EXCRETION; NEPHRON; MICE	Maintenance by the kidney of stable plasma K+ values is crucial, as plasma K+ controls muscle and nerve activity. Since renal K+ excretion is regulated by the circadian clock, we aimed to identify the ion transporters involved in this process. In control mice, the renal mRNA expression of H, K-ATPase type 2 (HKA2) is 25% higher during rest compared to the activity period. Conversely, under dietary K+ restriction, HKA2 expression is similar to 40% higher during the activity period. This reversal suggests that HKA2 contributes to the circadian regulation of K+ homeostasis. Compared to their wild-type (WT) littermates, HKA2-null mice fed a normal diet have 2-fold higher K+ renal excretion during rest. Under K+ restriction, their urinary K+ loss is 40% higher during the activity period. This inability to excrete K+ "on time" is reflected in plasma K+ values, which vary by 12% between activity and rest periods in HKA2-null mice but remain stable in WT mice. Analysis of the circadian expression of HKA2 regulators suggests that Nrf2, but not progesterone, contributes to its rhythmicity. Therefore, HKA2 acts to maintain the circadian rhythm of urinary K+ excretion and preserve stable plasma K+ values throughout the day.-Salhi, A., Centeno, G., Firsov, D., Crambert, G. Circadian expression of H, K-ATPase type 2 contributes to the stability of plasma K+ levels. FASEB J. 26, 2859-2867 (2012). www.fasebj.org	[Salhi, Amel; Crambert, Gilles] Univ Paris 06, INSERM, CNRS,UMRS 872,Equipe 3, Lab Genom Physiol & Physiopathol Renales ERL Pari, F-75252 Paris 05, France; [Centeno, Gabriel; Firsov, Dmitri] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Lausanne	Crambert, G (corresponding author), Ctr Rech Cordeliers Genom Physiol & Physiopathol, UMRS 872, ERL 7226, Equipe 3, 15 Rue Ecole Med, F-75270 Paris, France.	gilles.crambert@crc.jussieu.fr	Crambert, Gilles/ABF-2753-2020	Crambert, Gilles/0000-0001-7065-9124	French Society of Nephrology; Transatlantic Network on Hypertension of the Leducq Fondation	French Society of Nephrology; Transatlantic Network on Hypertension of the Leducq Fondation	The authors thank Dr. Nikolai N. Modyanov (University of Toledo, Toledo, OH, USA) for his generous gift of anti-HKA2 antibody. The authors thank Alain Doucet and Aurelie Edwards for helpful reading of the manuscript and fruitful discussion and Lydie Cheval for technical help. This study was supported by grants from the French Society of Nephrology (G. C. and A. S.) and by the program of the Transatlantic Network on Hypertension of the Leducq Fondation (G. C.). The authors declare no conflicts of interest.	Azroyan A, 2012, AM J PHYSIOL-RENAL, V302, pF1180, DOI 10.1152/ajprenal.00403.2011; Babilonia E, 2005, J BIOL CHEM, V280, P10790, DOI 10.1074/jbc.M414610200; Codina J, 2005, AM J PHYSIOL-CELL PH, V288, pC1279, DOI 10.1152/ajpcell.00463.2004; Codina J, 2011, AM J PHYSIOL-RENAL, V301, pF536, DOI 10.1152/ajprenal.00220.2011; DALTON PL, 1989, AM J PHYSIOL, V256, pR510, DOI 10.1152/ajpregu.1989.256.2.R510; DeBruyne JP, 2007, NAT NEUROSCI, V10, P543, DOI 10.1038/nn1884; DeBruyne JP, 2006, NEURON, V50, P465, DOI 10.1016/j.neuron.2006.03.041; El Moghrabi S, 2010, P NATL ACAD SCI USA, V107, P13526, DOI 10.1073/pnas.0913070107; Elabida B, 2011, KIDNEY INT, V80, P256, DOI 10.1038/ki.2011.15; Fila M, 2011, J PHYSIOL-LONDON, V589, P3611, DOI 10.1113/jphysiol.2011.209692; Firsov D, 2012, MOL CELL ENDOCRINOL, V349, P51, DOI 10.1016/j.mce.2011.06.037; Giebisch G, 2007, KIDNEY INT, V72, P397, DOI 10.1038/sj.ki.5002288; Grimont A, 2009, FEBS LETT, V583, P1644, DOI 10.1016/j.febslet.2009.04.032; Gumz ML, 2010, BBA-GENE REGUL MECH, V1799, P622, DOI 10.1016/j.bbagrm.2010.09.003; Gumz ML, 2009, J CLIN INVEST, V119, P2423, DOI 10.1172/JCI36908; Lee CB, 2012, J NEPHROL, V25, P225, DOI 10.5301/JN.2011.8448; Lynch IJ, 2008, AM J PHYSIOL-RENAL, V294, pF621, DOI 10.1152/ajprenal.00412.2007; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; MOOREEDE MC, 1977, AM J PHYSIOL, V233, pR230, DOI 10.1152/ajpregu.1977.233.5.R230; MOOREEDE MC, 1986, AM J PHYSIOL, V250, pR737, DOI 10.1152/ajpregu.1986.250.5.R737; MOOREEDE MC, 1977, AM J PHYSIOL, V232, pF128, DOI 10.1152/ajprenal.1977.232.2.F128; Nikolaeva S, 2012, J AM SOC NEPHROL, V23, P1019, DOI 10.1681/ASN.2011080842; Pestov NB, 2006, AM J PHYSIOL-CELL PH, V291, pC366, DOI 10.1152/ajpcell.00042.2006; RABINOWITZ L, 1987, AM J PHYSIOL, V253, pF1178; RABINOWITZ L, 1986, AM J PHYSIOL, V250, pF930, DOI 10.1152/ajprenal.1986.250.5.F930; Wang W. H., 2008, PFLUGERS ARCH, V458, P157; Wang WH, 2006, AM J PHYSIOL-RENAL, V290, pF14, DOI 10.1152/ajprenal.00093.2005; Wu T, 2010, AM J PHYSIOL-REG I, V298, pR635, DOI 10.1152/ajpregu.00578.2009; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Zuber AM, 2009, P NATL ACAD SCI USA, V106, P16523, DOI 10.1073/pnas.0904890106	30	21	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2859	2867		10.1096/fj.11-199711	http://dx.doi.org/10.1096/fj.11-199711			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459151				2022-12-28	WOS:000305912500014
J	Vella, LJ; Cappai, R				Vella, Laura J.; Cappai, Roberto			Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments	FASEB JOURNAL			English	Article						Alzheimer's disease; alpha-secretase; beta-secretase; developmental regulation	ALZHEIMERS-DISEASE; KINASE-C; ALPHA-SECRETASE; BETA-SECRETASE; RETINOIC ACID; BINDING DOMAIN; SOLUBLE FORM; EXPRESSION; APP; RAT	Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system. The proteolytic processing of the amyloid precursor protein (APP) into the beta-amyloid (A beta) peptide is a central event in AD. While the pathway that generates A beta is well described, many questions remain concerning general APP metabolism and its metabolites. It is becoming clear that the amino-terminal region of APP can be processed to release small N-terminal fragments (NTFs). The purpose of this study was to investigate the occurrence and generation of APP NTFs in vivo and in cell culture (SH-SY5Y) in order to delineate the cellular pathways implicated in their generation. We were able to detect 17- to 28-kDa APP NTFs in human and mouse brain tissue that are distinct from N-APP fragments previously reported. We show that the 17- to 28-kDa APP NTFs were highly expressed in mice from the age of 2 wk to adulthood. SH-SY5Y studies indicate the generation of APP NTFs involves a novel APP processing pathway, regulated by protein kinase C, but independent of alpha-secretase or beta-secretase 1 (BACE) activity. These results identify a novel, developmentally regulated APP processing pathway that may play an important role in the physiological function of APP.-Vella, L. J., Cappai, R. Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J. 26, 2930-2940 (2012). www.fasebj.org	[Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia	University of Melbourne; University of Melbourne	Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Vella, laura/N-2733-2017; Cappai, Roberto/B-3347-2010	Vella, laura/0000-0002-1869-6291; Cappai, Roberto/0000-0002-9505-8496	Alzheimer's Australia Research Viertel Fellowship; NHMRC; Australian Research Council	Alzheimer's Australia Research Viertel Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	The authors thank Giuseppe Ciccotosto and Andrea Connor (Department of Pathology, University of Melbourne) for assistance in providing the mouse and human brain tissue respectively. We thank the National Neural Tissue Resource Centre for the human brain tissues. L.J.V. is an Alzheimer's Australia Research Viertel Fellowship recipient. R. C. is an Australia National Health and Medical Research Council (NHMRC) Senior Research Fellow. Funding was provided by the NHMRC and the Australian Research Council to R.C.	ARAI H, 1994, BRAIN RES, V642, P132, DOI 10.1016/0006-8993(94)90914-8; Arai Y, 1997, BRAIN DEV-JPN, V19, P290, DOI 10.1016/S0387-7604(97)00559-7; Argellati F, 2009, FASEB J, V23, P1246, DOI 10.1096/fj.08-119263; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chen ST, 1997, NEUROREPORT, V8, P713, DOI 10.1097/00001756-199702100-00027; CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P; Constantinescu R, 2007, J NEURAL TRANSM-SUPP, P17; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Dahms SO, 2010, P NATL ACAD SCI USA, V107, P5381, DOI 10.1073/pnas.0911326107; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; De Chiara G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013989; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; Esh C, 2005, BIOCHEMISTRY-US, V44, P13807, DOI 10.1021/bi051213+; Fahrenholz F, 2010, NEURODEGENER DIS, V7, P190, DOI 10.1159/000295662; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Govoni S, 1996, ANN NY ACAD SCI, V777, P332, DOI 10.1111/j.1749-6632.1996.tb34442.x; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAYASHI Y, 1994, BIOCHEM BIOPH RES CO, V205, P936, DOI 10.1006/bbrc.1994.2755; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Hoe HS, 2009, J NEUROSCI, V29, P7459, DOI 10.1523/JNEUROSCI.4872-08.2009; Holback S, 2005, J NEUROCHEM, V95, P1059, DOI 10.1111/j.1471-4159.2005.03440.x; Hoshino M, 2003, NEUROSCI LETT, V353, P135, DOI 10.1016/j.neulet.2003.09.030; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; Jacobsen KT, 2010, J BIOL CHEM, V285, P10223, DOI 10.1074/jbc.M109.038224; Jefferson T, 2011, J BIOL CHEM, V286, P27741, DOI 10.1074/jbc.M111.252718; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Kaden D, 2008, J BIOL CHEM, V283, P7271, DOI 10.1074/jbc.M708046200; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kuhn PH, 2010, EMBO J, V29, P3020, DOI 10.1038/emboj.2010.167; Lane RF, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-62; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Lichtenthaler SF, 2011, J NEUROCHEM, V116, P10, DOI 10.1111/j.1471-4159.2010.07081.x; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; Lopez-Andreo MJ, 2005, BIOCHEMISTRY-US, V44, P11353, DOI 10.1021/bi0504862; Lyckman AW, 1998, J BIOL CHEM, V273, P11100, DOI 10.1074/jbc.273.18.11100; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mok SS, 1997, FEBS LETT, V415, P303, DOI 10.1016/S0014-5793(97)01146-0; Mok SS, 1997, BIOCHEMISTRY-US, V36, P156, DOI 10.1021/bi961848w; Morimoto T, 1998, J NEUROSCI, V18, P9386; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; Needham BE, 2008, J PATHOL, V215, P155, DOI 10.1002/path.2343; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; NORDSTEDT C, 1994, J BIOL CHEM, V269, P9805; Ohsawa I, 1999, EUR J NEUROSCI, V11, P1907, DOI 10.1046/j.1460-9568.1999.00601.x; Ohsawa I, 2001, J NEUROCHEM, V76, P1411, DOI 10.1046/j.1471-4159.2001.00144.x; OHTA M, 1993, DEV BRAIN RES, V75, P151, DOI 10.1016/0165-3806(93)90019-7; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Portelius E, 2010, EXP NEUROL, V223, P351, DOI 10.1016/j.expneurol.2009.06.011; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Ruiz-Leon Y, 2001, J NEUROCHEM, V79, P278, DOI 10.1046/j.1471-4159.2001.00547.x; SALBAUM JM, 1994, J EXP ZOOL, V269, P116, DOI 10.1002/jez.1402690205; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; SMALL DH, 1994, J NEUROSCI, V14, P2117; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; vanSetten GB, 1996, INVEST OPHTH VIS SCI, V37, P2585; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Yasuoka K, 2004, J ANAT, V205, P135, DOI 10.1111/j.0021-8782.2004.00320.x	75	20	21	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2930	2940		10.1096/fj.11-200295	http://dx.doi.org/10.1096/fj.11-200295			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490781				2022-12-28	WOS:000305912500021
J	Verheggen, RJHM; Jones, H; Nyakayiru, J; Thompson, A; Groothuis, JT; Atkinson, G; Hopman, MTE; Thijssen, DHJ				Verheggen, Rebecca J. H. M.; Jones, Helen; Nyakayiru, Jean; Thompson, Andrew; Groothuis, Jan T.; Atkinson, Greg; Hopman, Maria T. E.; Thijssen, Dick H. J.			Complete absence of evening melatonin increase in tetraplegics	FASEB JOURNAL			English	Article						sleep quality; paraplegia; pineal gland	HUMAN CIRCADIAN-RHYTHMS; SLEEP QUALITY INDEX; SPINAL-CORD-INJURY; VALIDITY; PHASE; LESIONS; SERUM	Individuals with a spinal cord injury (SCI), especially with tetraplegia, experience poor sleep quality, and this may be related to impaired control of circadian rhythmicity. Here, we examined the evening onset of melatonin secretion, an important hormone for the initiation of sleep, in people with a complete cervical (tetraplegia) and thoracic (paraplegia) SCI, and age- and sex-matched able-bodied control participants. Multiple samples of salivary melatonin were obtained during the evening hours and analyzed by ELISA methods in 10 control partcipants, 9 individuals with paraplegia, and 6 individuals with tetraplegia. Sleep quality was assessed using questionnaires. Interactive effects of group and time were found for melatonin levels (P=0.022). In the control and paraplegia groups, the mean melatonin level increased significantly from 2.59 +/- 1.04 and 4.28 +/- 3.28 pg/ml at 7 PM to 10.62 +/- 4.59 and 13.10 +/- 7.39 pg/ml at 11 PM, respectively (P<0.001). In the tetraplegia group, melatonin level was 5.25 +/- 3.72 at 7 PM but only 2.41 +/- 1.25 pg/ml at 11 PM (P>0.05). Decreased sleep quality was more prevalent in individuals with tetraplegia (83%) and paraplegia (75%) compared with controls (20%; P=0.02). Unlike in the control and paraplegia groups, the evening increase in melatonin concentration was completely absent in the tetraplegia group. This provides biological insight into sleep regulation in humans and provides better understanding of the poor sleep quality in people with tetraplegia.-Verheggen, R. J., Jones, H., Nyakayiru, J., Thompson, A., Groothuis, J. T., Atkinson, G., Hopman, M. T., Thijssen, D. H. Complete absence of evening melatonin increase in tetraplegics. FASEB J. 26, 3059-3064 (2012). www.fasebj.org	[Verheggen, Rebecca J. H. M.; Nyakayiru, Jean; Groothuis, Jan T.; Hopman, Maria T. E.; Thijssen, Dick H. J.] Radboud Univ Nijmegen, Med Ctr, Dept Physiol, NL-6525 EZ Nijmegen, Netherlands; [Jones, Helen; Thompson, Andrew; Atkinson, Greg; Thijssen, Dick H. J.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool L3 5UX, Merseyside, England; [Groothuis, Jan T.] St Maartens Clin, Dept Rehabil, Nijmegen, Netherlands	Radboud University Nijmegen; Liverpool John Moores University; Sint Maartens Clinic	Thijssen, DHJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Physiol, Geert Grootepl Noord 21, NL-6525 EZ Nijmegen, Netherlands.	d.thijssen@fysiol.umcn.nl	Atkinson, Greg/ABA-2278-2021; Nyakayiru, Jean/O-9191-2018; Verheggen, Rebecca/G-6182-2016; Groothuis, Jan T/D-3439-2009; Thijssen, Dick HJ/E-8731-2016; Hopman, Maria/A-4205-2014; Thijssen, Dick/D-3430-2009	Nyakayiru, Jean/0000-0001-6596-7106; Groothuis, Jan T/0000-0003-3436-2475; Thijssen, Dick HJ/0000-0002-7707-5567; Atkinson, Greg/0000-0002-5459-9042	Het Dwarslaesie Fonds (Dutch Spinal Cord Injury Foundation); Netherlands Heart Foundation [2009T064]	Het Dwarslaesie Fonds (Dutch Spinal Cord Injury Foundation); Netherlands Heart Foundation(Netherlands Heart Foundation)	This study was financially supported by Het Dwarslaesie Fonds (Dutch Spinal Cord Injury Foundation). D.H.J.T. was financially supported by the Netherlands Heart Foundation (2009T064). Author contributions were as follows: D.H.J.T., M. T. E. H., J.T.G., and H.J. designed the study; R.J.H.M.V. and J.N. performed the data collection; R.J.H.M.V., J.N., G. A., and A. T. performed the data (biochemical) analysis and statistical analysis; R.J.H.M.V., J.N., D.H.J.T., and H.J. drafted the manuscript; and all authors have critically revised the manuscript.	Arendt J, 2005, SLEEP MED REV, V9, P25, DOI 10.1016/j.smrv.2004.05.002; Atkinson G, 2003, SPORTS MED, V33, P809, DOI 10.2165/00007256-200333110-00003; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Benloucif S, 2008, J CLIN SLEEP MED, V4, P66; Biering-Sorensen F, 2001, SPINAL CORD, V39, P505, DOI 10.1038/sj.sc.3101197; Burgess HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003055; Burns SP, 2000, ARCH PHYS MED REHAB, V81, P1334, DOI 10.1053/apmr.2000.9398; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Claustrat B, 2005, SLEEP MED REV, V9, P11, DOI 10.1016/j.smrv.2004.08.001; Fruin ML, 2004, MED SCI SPORT EXER, V36, P1063, DOI 10.1249/01.MSS.0000128144.91337.38; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Keijzer H, 2011, CLIN CHIM ACTA, V412, P1616, DOI 10.1016/j.cca.2011.05.014; King GA, 2004, MED SCI SPORT EXER, V36, P1244, DOI 10.1249/01.MSS.0000132379.09364.F8; KNEISLEY LW, 1978, J NEURAL TRANSM, P311; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; LI Y, 1989, CLIN ENDOCRINOL, V30, P47, DOI 10.1111/j.1365-2265.1989.tb03726.x; LYNCH HJ, 1973, P NATL ACAD SCI USA, V70, P1704, DOI 10.1073/pnas.70.6.1704; Malavolti M, 2007, NUTR METAB CARDIOVAS, V17, P338, DOI 10.1016/j.numecd.2005.12.009; Marino RJ., 2003, J SPINAL CORD MED S1, V26, pS50, DOI [10.1080/10790268.2003.11754575, DOI 10.1080/10790268.2003.11754575]; Nagtegaal E, 1998, THER DRUG MONIT, V20, P181, DOI 10.1097/00007691-199804000-00008; Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001; Pandi-Perumal SR, 2007, PROG NEURO-PSYCHOPH, V31, P1, DOI 10.1016/j.pnpbp.2006.06.020; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Sletten TL, 2010, FRONT NEUROL, V1, P1; Spira AP, 2012, J GERONTOL A-BIOL, V67, P433, DOI 10.1093/gerona/glr172; Thijssen DHJ, 2011, CHRONOBIOL INT, V28, P146, DOI 10.3109/07420528.2010.540364; Waterhouse J, 2005, CHRONOBIOL INT, V22, P207, DOI 10.1081/CBI-200053477; Weiss AR, 2010, J CLIN SLEEP MED, V6, P336; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189	33	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3059	3064		10.1096/fj.12-205401	http://dx.doi.org/10.1096/fj.12-205401			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22474242	Bronze			2022-12-28	WOS:000305912500033
J	Saito, A; Ochiai, H; Okada, S; Miyata, N; Azuma, T				Saito, Akiko; Ochiai, Hiromi; Okada, Shoko; Miyata, Naoteru; Azuma, Toshifumi			Suppression of Lefty expression in induced pluripotent cancer cells	FASEB JOURNAL			English	Article						DNA methylation; TGF beta; Ras-MAPK signaling	EMBRYONIC STEM-CELLS; METASTATIC TUMOR-CELLS; TGF-BETA; PANCREATIC-CANCER; DEFINED FACTORS; EPIGENETICS; LINE; MICROENVIRONMENT; PATHWAYS; LINKING	Cancer and stem cells share the ability to silence tumor suppressors. We focused on Lefty, which encodes one of the most abundant tumor suppressors in embryonic stem (ES) cells and is not expressed in somatic cancer cells. We found that transforming growth factor beta (TGF-beta) induced demethylation of the Lefty B cytosine-phosphate-guanine (CpG) island and increased Lefty expression (10-200 times) in human pancreatic cancer cells and human liver cancer cells (PLC/PRF/5 and HLF). Expression of Cripto, another important factor in Nodal-Lefty signaling, was not increased after adding TGF-beta. We generated reprogrammed cancer cells that revealed high expression of immature marker proteins, high proliferation, and the potential to express morphological patterns of ectoderm, mesoderm, and endoderm, suggesting that these cells may have cancer stem cell-like phenotypes. We investigated Lefty and found that reprogrammed human liver cancer cells (induced pluripotent cancer cells) displayed a much lower ability to express Lefty, although less Lefty B CpG methylation was also observed. We also found that a MEK inhibitor dramatically enhanced Lefty expression in human pancreatic cancers with mutated ras, whereas Lefty B CpG methylation was not decreased. These observations indicate that despite the demethylation of DNA strands in promoter regions of pluripotency-associated genes, including Lefty gene, Lefty expression was not induced well in reprogrammed cells. Of note was the fact that Lefty is abundantly expressed in human ES cells but not in induced pluripotent stem (iPS) cells. We thus think that reprogrammed cancer cells share the mechanism for expression of Lefty with iPS cells. This shared mechanism may contribute to the cancerous transformation of iPS cells.	[Saito, Akiko; Ochiai, Hiromi; Okada, Shoko; Azuma, Toshifumi] Tokyo Dent Coll, Dept Biochem, Chiba 2618502, Japan; [Ochiai, Hiromi; Azuma, Toshifumi] Tokyo Dent Coll, Oral Hlth Sci Ctr Hrc8, Chiba 2618502, Japan; [Miyata, Naoteru] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan	Tokyo Dental College; Tokyo Dental College; Keio University	Azuma, T (corresponding author), Tokyo Dent Coll, Dept Biochem, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.	tazuma@tdc.ac.jp						Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; Barroso-delJesus A, 2011, FASEB J, V25, P1497, DOI 10.1096/fj.10-172221; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bilic J, 2012, STEM CELLS, V30, P33, DOI 10.1002/stem.700; Brait M, 2011, TOXICOL MECH METHOD, V21, P275, DOI 10.3109/15376516.2011.562671; Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08; Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI 10.2217/EPI.09.25; DAEMER RJ, 1980, INFECT IMMUN, V30, P607; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Falzacappa MVV, 2012, FEBS J, V279, P3559, DOI 10.1111/j.1742-4658.2012.08727.x; Furukawa T, 2009, CLIN GASTROENTEROL H, V7, pS35, DOI 10.1016/j.cgh.2009.07.035; Gouas DA, 2010, CARCINOGENESIS, V31, P1475, DOI 10.1093/carcin/bgq118; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Joan M., 2008, CELL, V134, P215; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Malchenko S, 2010, J CELL PHYSIOL, V225, P390, DOI 10.1002/jcp.22280; MARION PL, 1979, J VIROL, V32, P796, DOI 10.1128/JVI.32.3.796-802.1979; Miyata N, 2012, PANCREAS, V41, P745, DOI 10.1097/MPA.0b013e31823b66d3; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; MOTOO Y, 1986, BIOCHEM BIOPH RES CO, V135, P262, DOI 10.1016/0006-291X(86)90971-X; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Schmelzer E, 2006, STEM CELLS, V24, P1852, DOI 10.1634/stemcells.2006-0036; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; SUMI S, 1994, PANCREAS, V9, P657, DOI 10.1097/00006676-199409000-00018; Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312; Tabibzadeh S, 2006, STEM CELLS, V24, P1998, DOI 10.1634/stemcells.2006-0075; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24; Tysnes BB, 2010, NEOPLASIA, V12, P506, DOI 10.1593/neo.10290; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yajima T, 2009, INT J ONCOL, V35, P273, DOI 10.3892/ijo_00000337	48	16	16	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2165	2174		10.1096/fj.12-221432	http://dx.doi.org/10.1096/fj.12-221432			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23407711				2022-12-28	WOS:000319667600008
J	van Putten, M; Hulsker, M; Young, C; Nadarajah, VD; Heemskerk, H; van der Weerd, L; 't Hoen, PAC; van Ommen, GJB; Aartsma-Rus, AM				van Putten, Maaike; Hulsker, Margriet; Young, Courtney; Nadarajah, Vishna D.; Heemskerk, Hans; van der Weerd, Louise; 't Hoen, Peter A. C.; van Ommen, Gert-Jan B.; Aartsma-Rus, Annemieke M.			Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; Becker muscular dystrophy; biomarkers; cardiomyopathy; mouse models	DUCHENNE MUSCULAR-DYSTROPHY; FULL-LENGTH; GENE-THERAPY; MDX MOUSE; DEFICIENT MICE; UTROPHIN; SKELETAL; EXPRESSION; RESCUE; MODEL	Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by the lack of functional dystrophin. There is no cure, but several clinical trials aimed to restore the synthesis of functional dystrophin are underway. The dystrophin levels needed for improvement of muscle pathology, function, and overall vitality are not known. Here, we describe the mdx/utrn(-/-)/Xist(Delta hs) mouse model, which expresses a range of low dystrophin levels, depending on the degree of skewing of X inactivation in a utrophin-negative background. Mdx/utrn(-/-) mice develop severe muscle weakness, kyphosis, respiratory and heart failure, and premature death closely resembling DMD pathology. We show that at dystrophin levels < 4%, survival and motor function in these animals are greatly improved. In mice expressing >4% dystrophin, histopathology is ameliorated, as well. These findings suggest that the dystrophin levels needed to benefit vitality and functioning of patients with DMD might be lower than those needed for full protection against muscle damage.	[van Putten, Maaike; Hulsker, Margriet; Young, Courtney; Nadarajah, Vishna D.; Heemskerk, Hans; van der Weerd, Louise; 't Hoen, Peter A. C.; van Ommen, Gert-Jan B.; Aartsma-Rus, Annemieke M.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; [van der Weerd, Louise] Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Aartsma-Rus, AM (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, POB 9600, NL-2300 RC Leiden, Netherlands.	a.m.rus@lumc.nl	Hoen, Peter A 't/D-3950-2018; van der Weerd, Louise/B-5421-2014	Hoen, Peter A 't/0000-0003-4450-3112; van der Weerd, Louise/0000-0002-5997-2125; V Nadarajah, Vishna Devi/0000-0002-7126-7189; van Putten, Maaike/0000-0002-0683-8897; Aartsma-Rus, Annemieke/0000-0003-1565-654X	Sixth Framework Programme [LSHM-CT-2006-036825]; Dutch Organization for Scientific Research (NWO/ZonMW) [43200002]; Dutch Duchenne Parent Project	Sixth Framework Programme(European Commission); Dutch Organization for Scientific Research (NWO/ZonMW)(Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development); Dutch Duchenne Parent Project	The authors thank Prof. Neil Brockdorff and Dr. Tatyana Nesterova (Medical Research Council Clinical Sciences Center, London, UK; current affiliation: Department of Biochemistry, University of Oxford, Oxford, UK) for providing the Xist<SUP>Delta hs</SUP> embryos and help with genotyping the mice, respectively, and Prof. Kay Davies (Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK) for providing the mdx/utrn<SUP>-/-</SUP> mouse. The authors are grateful to Maarten van Iterson and Jelle Goeman for their help with statistical analyses. This work was supported by the Sixth Framework Programme-funded TREAT-NMD network of excellence (LSHM-CT-2006-036825), the Dutch Organization for Scientific Research (NWO/ZonMW, grant 43200002), and the Dutch Duchenne Parent Project and used the infrastructure of the Center for Biomedical Genetics (Utrecht, The Netherlands) and the Center for Medical Systems Biology (Leiden, The Netherlands). The authors declare no conflicts of interest.	Bowles DE, 2012, MOL THER, V20, P443, DOI 10.1038/mt.2011.237; Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Crisp A, 2011, HUM MOL GENET, V20, P413, DOI 10.1093/hmg/ddq477; DANKO I, 1992, PEDIATR RES, V32, P128, DOI 10.1203/00006450-199207000-00025; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Goyenvalle A, 2012, HUM MOL GENET, V21, P2559, DOI 10.1093/hmg/dds082; Goyenvalle A, 2010, MOL THER, V18, P198, DOI 10.1038/mt.2009.248; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Hauser MA, 1997, NEUROMUSCULAR DISORD, V7, P277, DOI 10.1016/S0960-8966(97)00052-7; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1990, J NEUROPATH EXP NEUR, V49, P96, DOI 10.1097/00005072-199003000-00002; Kawano R, 2008, MOL THER, V16, P825, DOI 10.1038/mt.2008.23; Kohler M, 2009, J NEUROL NEUROSUR PS, V80, P320, DOI 10.1136/jnnp.2007.141721; Li DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015286; Malik V, 2010, ANN NEUROL, V67, P771, DOI 10.1002/ana.22024; Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4; Nadarajah VD, 2011, NEUROMUSCULAR DISORD, V21, P569, DOI 10.1016/j.nmd.2011.05.011; Neri M, 2007, NEUROMUSCULAR DISORD, V17, P913, DOI 10.1016/j.nmd.2007.07.005; Newall AET, 2001, HUM MOL GENET, V10, P581, DOI 10.1093/hmg/10.6.581; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Rafael JA, 1999, MUSCLE NERVE, V22, P517, DOI 10.1002/(SICI)1097-4598(199904)22:4<517::AID-MUS14>3.0.CO;2-6; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Saito T, 2009, BRAIN DEV-JPN, V31, P612, DOI 10.1016/j.braindev.2008.09.008; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Skuk D, 2006, J NEUROPATH EXP NEUR, V65, P371, DOI 10.1097/01.jnen.0000218443.45782.81; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; 't Hoen PAC, 2008, J BIOL CHEM, V283, P5899, DOI 10.1074/jbc.M709410200; van Putten M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031937; van Putten M, 2012, NEUROMUSCULAR DISORD, V22, P406, DOI 10.1016/j.nmd.2011.10.011; van Putten M, 2010, NEUROMUSCULAR DISORD, V20, P273, DOI 10.1016/j.nmd.2010.02.004; Verhaart IEC, 2012, NEUROMUSCULAR DISORD, V22, P418, DOI 10.1016/j.nmd.2011.10.025; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245	34	69	76	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2484	2495		10.1096/fj.12-224170	http://dx.doi.org/10.1096/fj.12-224170			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23460734	Green Published			2022-12-28	WOS:000319667600036
J	Madaro, L; Marrocco, V; Carnio, S; Sandri, M; Bouche, M				Madaro, Luca; Marrocco, Valeria; Carnio, Silvia; Sandri, Marco; Bouche, Marina			Intracellular signaling in ER stress-induced autophagy in skeletal muscle cells	FASEB JOURNAL			English	Article						protein kinase C theta; muscle atrophy autophagosome; CHOP	ENDOPLASMIC-RETICULUM STRESS; KINASE-C-THETA; PKC-THETA; ACTIVATION; EXPRESSION; FOXO3; PATHWAYS; SURVIVAL; DELTA; MODEL	Skeletal muscle remodeling in response to muscle disuse and unloading is known to be associated with so-called ER stress, which, in turn, activates autophagy and contributes to muscle atrophy. Different molecules are involved in ER stress-induced autophagy, among which PKC theta has recently been described. In this study, we dissected both in vitro and in vivo ER stress-induced autophagy pathways in muscle. Using C2C12 muscle cells in culture, we demonstrated that PKC activation induced autophagy in the absence of ER stress. We further demonstrated that PKC theta was strongly activated in cultured myoblasts and myotubes during ER stress induced by different stimuli, such as TG or TN treatment, and that it localized into Lc3-positive autophagic dots upon TG treatment. Neither Akt dephosphorylation nor Foxo or GSK3 beta activation was observed in these conditions. Moreover, PKC theta inhibition in myoblasts and myotubes prevented ER stress-induced Lc3 activation and autophagic dot formation, but not ER stress. In vivo, lack of PKC theta prevented both food deprivation- and immobilization-induced autophagy and muscle atrophy, irrespective of Akt pathway inhibition. Taken together, these results demonstrate that PKC theta functions as an ER stress sensor in skeletal muscle, required for ER-stress-dependent autophagy activation, and can be proposed as a novel molecular target to maintain muscle homeostasis in response to external stimuli, such as disuse and unloading, still allowing intracellular clearance.	[Madaro, Luca; Marrocco, Valeria; Bouche, Marina] Univ Roma La Sapienza, Unit Histol, Dept Anat Histol Forensis Med & Orthoped, I-00161 Rome, Italy; [Madaro, Luca; Marrocco, Valeria; Sandri, Marco; Bouche, Marina] Univ Roma La Sapienza, Interuniv Inst Myol, I-00161 Rome, Italy; [Carnio, Silvia] Venetian Inst Mol Med, Dulbecco Telethon Inst, Padua, Italy; [Sandri, Marco] Univ Padua, Dept Biomed Sci, Padua, Italy	Sapienza University Rome; Sapienza University Rome; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; University of Padua	Bouche, M (corresponding author), Univ Roma La Sapienza, Unit Histol, DAHFMO, Via A Scarpa 14, I-00161 Rome, Italy.	marina.bouche@uniroma1.it	Madaro, Luca/ABE-4683-2021; Madaro, Luca/K-4629-2016	Madaro, Luca/0000-0003-0839-5724; Madaro, Luca/0000-0003-0839-5724; Bouche, Marina/0000-0002-0938-5360	Italian Ministry for University and Research; Sapienza University of Rome; French Association against Myopathies (AFM); Duchenne Parent Project (The Netherlands) Fellowship; Fondazione Telethon Funding Source: Custom	Italian Ministry for University and Research(Ministry of Education, Universities and Research (MIUR)); Sapienza University of Rome; French Association against Myopathies (AFM)(Association Francaise contre les Myopathies); Duchenne Parent Project (The Netherlands) Fellowship(Netherlands Government); Fondazione Telethon(Fondazione Telethon)	The authors thank Prof. D. A. Littman (New York University, New York, NY, USA) for providing the PKC theta mutant mice and Dr. M. Brown (Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA) for providing the C20 inhibitor. The authors also thank Dr. F. Padula and Dr. P. Fiore for support in cytofluorimetric analysis. This work was supported by the Italian Ministry for University and Research, by the Sapienza University of Rome, and by the French Association against Myopathies (AFM). L.M. is the recipient of a Duchenne Parent Project (The Netherlands) Fellowship.	Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Cywin CL, 2007, BIOORG MED CHEM LETT, V17, P225, DOI 10.1016/j.bmcl.2006.09.056; D'Andrea M, 2006, J CELL PHYSIOL, V207, P379, DOI 10.1002/jcp.20585; Fouillet A, 2012, AUTOPHAGY, V8, P915, DOI 10.4161/auto.19716; Greene MW, 2010, J BIOL CHEM, V285, P42115, DOI 10.1074/jbc.M110.168575; Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Madaro L, 2008, BASIC APPL MYOL, V18, P149; Madaro L, 2011, MOL BIOL CELL, V22, P1409, DOI 10.1091/mbc.E10-10-0821; Madaro L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031515; Maioli E, 2012, SCI WORLD J, DOI 10.1100/2012/350826; Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Messina G, 2010, CELL, V140, P554, DOI 10.1016/j.cell.2010.01.027; Nascimbeni AC, 2012, CELL DEATH DIFFER, V19, P1698, DOI 10.1038/cdd.2012.52; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Paoletti R, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.24; Paul PK, 2011, AUTOPHAGY, V7, P555, DOI 10.4161/auto.7.5.15102; Qi X, 2007, J MOL CELL CARDIOL, V43, P420, DOI 10.1016/j.yjmcc.2007.07.061; Rayavarapu S, 2012, CURR RHEUMATOL REP, V14, P238, DOI 10.1007/s11926-012-0247-5; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Sakaki K, 2008, J BIOL CHEM, V283, P15370, DOI 10.1074/jbc.M710209200; Sandri M, 2010, FEBS LETT, V584, P1411, DOI 10.1016/j.febslet.2010.01.056; Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4; Serra C, 2003, J CELL PHYSIOL, V196, P89, DOI 10.1002/jcp.10278; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tokugawa S, 2009, NEUROPATHOLOGY, V29, P211, DOI 10.1111/j.1440-1789.2008.00967.x; Zappelli F, 1996, DEV BIOL, V180, P156, DOI 10.1006/dbio.1996.0292; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	33	44	45	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1990	2000		10.1096/fj.12-215475	http://dx.doi.org/10.1096/fj.12-215475			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23388382				2022-12-28	WOS:000318226100019
J	Lima, TB; Pinto, MFS; Ribeiro, SM; de Lima, LA; Viana, JC; Gomes, N; Candido, ED; Dias, SC; Franco, OL				Lima, Thais Bergamin; Soares Pinto, Michelle Flaviane; Ribeiro, Suzana Meira; de Lima, Loiane Alves; Viana, Juliana Canado; Gomes Junior, Nelson; Candido, Elizabete de Souza; Dias, Simoni Campos; Franco, Octavio Luiz			Bacterial resistance mechanism: what proteomics can elucidate	FASEB JOURNAL			English	Review						antibiotic; action mechanism	OUTER-MEMBRANE PROTEIN; 2-COMPONENT REGULATORY SYSTEM; STAPHYLOCOCCUS-AUREUS STRAINS; BETA-LACTAM RESISTANCE; ACINETOBACTER-BAUMANNII; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; POLYMYXIN-B	Antibiotics are important therapeutic agents commonly used for the control of bacterial infectious diseases; however, resistance to antibiotics has become a global public health problem. Therefore, effective therapy in the treatment of resistant bacteria is necessary and, to achieve this, a detailed understanding of mechanisms that underlie drug resistance must be sought. To fill the multiple gaps that remain in understanding bacterial resistance, proteomic tools have been used to study bacterial physiology in response to antibiotic stress. In general, the global analysis of changes in the protein composition of bacterial cells in response to treatment with antibiotic agents has made it possible to construct a database of proteins involved in the process of resistance to drugs with similar mechanisms of action. In the past few years, progress in using proteomic tools has provided the most realistic picture of the infective process, since these tools detect the end products of gene biosynthetic pathways, which may eventually determine a biological phenotype. In most bacterial species, alterations occur in energy and nitrogen metabolism regulation; glucan biosynthesis is up-regulated; amino acid, protein, and nucleotide synthesis is affected; and various proteins show a stress response after exposing these microorganisms to antibiotics. These issues have been useful in identifying targets for the development of novel antibiotics and also in understanding, at the molecular level, how bacteria resist antibiotics.-Lima, T. B., Pinto, M. F. S., Ribeiro, S. M., de Lima, L. A., Viana, J. C., Junior, N. G., Candido, E. D., Dias, S. C., and Franco, O. L. Bacterial resistance mechanism: what proteomics can elucidate. FASEB J. 27, 1291-1303 (2013). www.fasebj.org	[Lima, Thais Bergamin; Soares Pinto, Michelle Flaviane; Ribeiro, Suzana Meira; de Lima, Loiane Alves; Viana, Juliana Canado; Gomes Junior, Nelson; Candido, Elizabete de Souza; Dias, Simoni Campos; Franco, Octavio Luiz] Univ Catol Brasilia, Ctr Analises Proteom & Bio quim, Posgrad Ciencias Genom & Biotecnol, BR-70790160 Brasilia, DF, Brazil		Franco, OL (corresponding author), Univ Catol Brasilia, Ctr Analises Proteom & Bio quim, Posgrad Ciencias Genom & Biotecnol, Campus Avancado Asa Norte SGAN 916 11 Ave W5, BR-70790160 Brasilia, DF, Brazil.	ocfranco@gmail.com	Franco, Octavio L/T-3020-2017; Ribeiro, Suzana Meira/T-5836-2017; Cândido, Elizabete/F-3347-2019; Oliveira-Júnior, Nelson/M-5794-2014	Ribeiro, Suzana Meira/0000-0003-1781-3289; Cândido, Elizabete/0000-0002-3126-029X; Oliveira-Júnior, Nelson/0000-0001-9437-6778; Franco, Octavio/0000-0001-9546-0525				Amini S, 2011, CURR OPIN MICROBIOL, V14, P513, DOI 10.1016/j.mib.2011.07.017; Barman S, 2010, INT J ANTIMICROB AG, V36, P348, DOI 10.1016/j.ijantimicag.2010.06.037; Barroso DE, 2012, PEDIATR INFECT DIS J, V31, P30, DOI 10.1097/INF.0b013e31822f8a92; Beceiro A, 2011, ANTIMICROB AGENTS CH, V55, P3370, DOI 10.1128/AAC.00079-11; Beck M, 2009, NAT METHODS, V6, P817, DOI [10.1038/NMETH.1390, 10.1038/nmeth.1390]; Biot FV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016892; Bishop RE, 2005, MOL MICROBIOL, V57, P900, DOI 10.1111/j.1365-2958.2005.04711.x; Bush K, 2012, REV SCI TECH OIE, V31, P43; Cajal Y, 1996, BIOCHEMISTRY-US, V35, P5684, DOI 10.1021/bi952703c; Candido ED, 2011, FASEB J, V25, P3290, DOI 10.1096/fj.11-184291; Cash P, 1999, ELECTROPHORESIS, V20, P2259, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2259::AID-ELPS2259>3.0.CO;2-F; Catel-Ferreira M, 2011, J ANTIMICROB CHEMOTH, V66, P2053, DOI 10.1093/jac/dkr267; Cavallo JD, 2002, J ANTIMICROB CHEMOTH, V50, P1039, DOI 10.1093/jac/dkf186; Chaussee MA, 2006, J ANTIMICROB CHEMOTH, V58, P752, DOI 10.1093/jac/dkl319; Chiu Y, 2011, J APPL MICROBIOL, V110, P80, DOI 10.1111/j.1365-2672.2010.04856.x; Coldham NG, 2006, J ANTIMICROB CHEMOTH, V58, P1145, DOI 10.1093/jac/dkl413; Cox G, 2012, P NATL ACAD SCI USA, V109, P2102, DOI 10.1073/pnas.1117275109; da Silva LV, 2011, MEM I OSWALDO CRUZ, V106, P44, DOI 10.1590/S0074-02762011000100007; del Castillo E, 2011, J PROTEOMICS, V74, P35, DOI 10.1016/j.jprot.2010.07.011; Diaz-Mejia JJ, 2009, FEMS MICROBIOL REV, V33, P66, DOI 10.1111/j.1574-6976.2008.00141.x; dos Santos KV, 2010, RES MICROBIOL, V161, P268, DOI 10.1016/j.resmic.2010.03.006; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Drummelsmith J, 2007, J PROTEOME RES, V6, P4690, DOI 10.1021/pr070521m; Dueger EL, 2008, INT J INFECT DIS, V12, P289, DOI 10.1016/j.ijid.2007.09.001; Duthie SJ, 2004, P NUTR SOC, V63, P571, DOI 10.1079/PNS2004; Eirich J, 2011, J AM CHEM SOC, V133, P12144, DOI 10.1021/ja2039979; Fehri LF, 2005, ANTIMICROB AGENTS CH, V49, P4154, DOI 10.1128/AAC.49.10.4154-4165.2005; Fenollar F, 2009, INT J ANTIMICROB AG, V34, P255, DOI 10.1016/j.ijantimicag.2009.02.014; Fernandez L, 2013, ANTIMICROB AGENTS CH, V57, P110, DOI 10.1128/AAC.01583-12; Fernandez L, 2010, ANTIMICROB AGENTS CH, V54, P3372, DOI 10.1128/AAC.00242-10; Fernandez-Reyes M, 2009, PROTEOMICS, V9, P1632, DOI 10.1002/pmic.200800434; Fernando D, 2012, J ANTIMICROB CHEMOTH, V67, P569, DOI 10.1093/jac/dkr519; Fischer A, 2011, J ANTIMICROB CHEMOTH, V66, P1696, DOI 10.1093/jac/dkr195; Gan HM, 2012, J BACTERIOL, V194, P5979, DOI 10.1128/JB.01466-12; Giedraitiene A, 2011, MEDICINA-LITHUANIA, V47, P137, DOI 10.3390/medicina47030019; Gliniewicz K, 2012, J FISH DIS, V35, P529, DOI 10.1111/j.1365-2761.2012.01378.x; Grundmann H, 2011, DRUG RESIST UPDATE, V14, P79, DOI 10.1016/j.drup.2011.02.007; Hachmann AB, 2009, ANTIMICROB AGENTS CH, V53, P1598, DOI 10.1128/AAC.01329-08; He GX, 2011, ARCH MICROBIOL, V193, P759, DOI 10.1007/s00203-011-0738-1; Ho PL, 2009, DIAGN MICR INFEC DIS, V64, P131, DOI 10.1016/j.diagmicrobio.2009.01.030; Hong HJ, 2008, ADV EXP MED BIOL, V631, P200; Hornsey M, 2011, J ANTIMICROB CHEMOTH, V66, P1499, DOI 10.1093/jac/dkr168; Hu LF, 2011, INT J ANTIMICROB AG, V37, P230, DOI 10.1016/j.ijantimicag.2010.10.025; Otero-Gonzalez AJ, 2010, FASEB J, V24, P1320, DOI 10.1096/fj.09-143388; Jung D, 2008, CHEM PHYS LIPIDS, V154, P120, DOI 10.1016/j.chemphyslip.2008.04.004; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; Kim HS, 2012, BIOCHEMISTRY-US, V51, P4188, DOI 10.1021/bi300379y; Kirby A, 2011, INFECTION, V39, P277, DOI 10.1007/s15010-011-0103-y; Koser CU, 2010, ANTIMICROB AGENTS CH, V54, P4522, DOI [10.1128/AAC.00876-10, 10.1128/AAC.00422-10]; Koskiniemi S, 2011, MOL MICROBIOL, V80, P1464, DOI 10.1111/j.1365-2958.2011.07657.x; Lee JH, 2012, MED RES REV, V32, P216, DOI 10.1002/med.20210; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086/491709; Li HL, 2007, COMPUTER, V40, P6; Li XZ, 2009, DRUGS, V69, P1555, DOI 10.2165/11317030-000000000-00000; Liu C, 2003, ANTIMICROB AGENTS CH, V47, P3040, DOI 10.1128/AAC.47.10.3040-3045.2003; Loutet Slade A, 2011, Front Cell Infect Microbiol, V1, P6, DOI [10.3389/fmicb.2011.00159, 10.3389/fcimb.2011.00006]; Maria-Neto S, 2012, ANTIMICROB AGENTS CH, V56, P1714, DOI 10.1128/AAC.05558-11; Mikami Y, 2011, J PHARMACOL SCI, V117, P204, DOI 10.1254/jphs.11052SC; Monsieurs P, 2005, J MOL EVOL, V60, P462, DOI 10.1007/s00239-004-0212-7; Monteiro R, 2012, J PROTEOMICS, V75, P2892, DOI 10.1016/j.jprot.2011.12.036; MOORE RA, 1986, ANTIMICROB AGENTS CH, V30, P923, DOI 10.1128/AAC.30.6.923; Morar M, 2010, ANNU REV GENET, V44, P25, DOI 10.1146/annurev-genet-102209-163517; Muller MM, 2011, APPL MICROBIOL BIOT, V89, P585, DOI 10.1007/s00253-010-2901-z; Nanduri B, 2005, PROTEOMICS, V5, P4852, DOI 10.1002/pmic.200500112; Neri A, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-246; Oh JT, 1998, BBA-BIOMEMBRANES, V1415, P235, DOI 10.1016/S0005-2736(98)00195-3; Okamoto S, 2007, MOL MICROBIOL, V63, P1096, DOI 10.1111/j.1365-2958.2006.05585.x; OZAKI M, 1969, NATURE, V222, P333, DOI 10.1038/222333a0; Pages JM, 2008, NAT REV MICROBIOL, V6, P893, DOI 10.1038/nrmicro1994; PARENTI F, 1978, J ANTIBIOT, V31, P276, DOI 10.7164/antibiotics.31.276; Peng XX, 2005, J PROTEOME RES, V4, P2257, DOI 10.1021/pr050159g; Pinto L, 2010, J PROTEOMICS, V73, P1535, DOI 10.1016/j.jprot.2010.03.009; Poutanen M, 2009, J PROTEOME RES, V8, P246, DOI 10.1021/pr800384j; Raynaud C, 2005, MICROBIOL-SGM, V151, P3769, DOI 10.1099/mic.0.28066-0; Reeks BY, 2005, CAN J VET RES, V69, P1; Rosales-Reyes R, 2012, MICROBIOL-SGM, V158, P2315, DOI 10.1099/mic.0.060988-0; Rubinchik E, 2011, ANTIMICROB AGENTS CH, V55, P2743, DOI 10.1128/AAC.00170-11; Saar-Dover R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002891; Sandalakis V, 2012, J PROTEOME RES, V11, P2374, DOI 10.1021/pr201122w; Sharma P, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-59; Shimada T, 2009, J BACTERIOL, V191, P4562, DOI 10.1128/JB.00108-09; Sparbier K, 2012, J CLIN MICROBIOL, V50, P927, DOI 10.1128/JCM.05737-11; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P354, DOI 10.1128/AAC.37.2.354; van Hal SJ, 2011, EUR J CLIN MICROBIOL, V30, P603, DOI 10.1007/s10096-010-1128-3; Varhimo E, 2008, ENVIRON MICROBIOL, V10, P2179, DOI 10.1111/j.1462-2920.2008.01634.x; Vijayakumar SRV, 2004, J BACTERIOL, V186, P8499, DOI 10.1128/JB.186.24.8499-8507.2004; Vranakis I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033599; Vranakis I, 2011, J PROTEOME RES, V10, P756, DOI 10.1021/pr100906v; Vranakis I, 2010, MICROB DRUG RESIST, V16, P111, DOI 10.1089/mdr.2010.0015; Wang XS, 2010, J PROTEOME RES, V9, P1772, DOI 10.1021/pr901216e; Wecke T, 2009, ANTIMICROB AGENTS CH, V53, P1619, DOI 10.1128/AAC.01046-08; Xaplanteri MA, 2003, NUCLEIC ACIDS RES, V31, P5074, DOI 10.1093/nar/gkg686; Xiong XP, 2010, MAR BIOTECHNOL, V12, P686, DOI 10.1007/s10126-009-9256-4; Yamade M, 2011, J GASTROEN HEPATOL, V26, P1457, DOI 10.1111/j.1440-1746.2011.06815.x; Yang LA, 2011, J MICROBIOL, V49, P107, DOI 10.1007/s12275-011-0186-2; Yekutiel A, 2004, ANTIMICROB AGENTS CH, V48, P3279, DOI 10.1128/AAC.48.9.3279-3283.2004; Yun SH, 2006, CURR MICROBIOL, V53, P95, DOI 10.1007/s00284-005-0234-4; Yun SH, 2008, J MICROBIOL, V46, P720, DOI 10.1007/s12275-008-0202-3; Zhanel GG, 2008, EXPERT REV ANTI-INFE, V6, P67, DOI 10.1586/14787210.6.1.67; Zhang B, 2012, MICROB PATHOGENESIS, V52, P117, DOI 10.1016/j.micpath.2011.11.002; Zucca M, 2011, MINI-REV MED CHEM, V11, P888, DOI 10.2174/138955711796575498	102	52	54	1	91	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1291	1303		10.1096/fj.12-221127	http://dx.doi.org/10.1096/fj.12-221127			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23349550				2022-12-28	WOS:000316940800002
J	Thompson, KE; Korbmacher, JP; Hecht, E; Hobi, N; Wittekindt, OH; Dietl, P; Kranz, C; Frick, M				Thompson, Kristin E.; Korbmacher, Jonas P.; Hecht, Elena; Hobi, Nina; Wittekindt, Oliver H.; Dietl, Paul; Kranz, Christine; Frick, Manfred			Fusion-activated cation entry (FACE) via P2X(4) couples surfactant secretion and alveolar fluid transport	FASEB JOURNAL			English	Article						exocytosis; ATII cell; lamellar body; transepithelial ion transport; purinergic	CELLS IN-VITRO; AIR-LIQUID INTERFACE; II CELLS; EPITHELIAL-CELLS; RECEPTOR CHANNELS; RECENT PROGRESS; LUNG FUNCTIONS; ION-TRANSPORT; BALB/C MICE; EXOCYTOSIS	Two fundamental mechanisms within alveoli are essential for lung function: regulated fluid transport and secretion of surfactant. Surfactant is secreted via exocytosis of lamellar bodies (LBs) in alveolar type II (ATII) cells. We recently reported that LB exocytosis results in fusion-activated cation entry (FACE) via P2X(4) receptors on LBs. We propose that FACE, in addition to facilitating surfactant secretion, modulates alveolar fluid transport. Correlative fluorescence and atomic force microscopy revealed that FACE-dependent water influx correlated with individual fusion events in rat primary ATII cells. Moreover, ATII cell monolayers grown at air-liquid interface exhibited increases in short-circuit current (I-sc) on stimulation with ATP or UTP. Both are potent agonists for LB exocytosis, but only ATP activates FACE. ATP, not UTP, elicited additional fusion-dependent increases in Isc. Overexpressing dominant-negative P2X(4) abrogated this effect by similar to 50%, whereas potentiating P2X(4) lead to similar to 80% increase in I-sc. Finally, we monitored changes in alveolar surface liquid (ASL) on ATII monolayers by confocal microscopy. Only stimulation with ATP, not UTP, led to a significant, fusion-dependent, 20% decrease in ASL, indicating apical-to-basolateral fluid transport across ATII monolayers. Our data support the first direct link between LB exocytosis, regulation of surfactant secretion, and transalveolar fluid resorption via FACE.-Thompson, K. E., Korbmacher, J. P., Hecht, E., Hobi, N., Wittekindt, O. H., Dietl, P., Kranz, C., Frick, M. Fusion-activated cation entry (FACE) via P2X(4) couples surfactant secretion and alveolar fluid transport. FASEB J. 27, 1772-1783 (2013). www.fasebj.org	[Thompson, Kristin E.; Korbmacher, Jonas P.; Hecht, Elena; Hobi, Nina; Wittekindt, Oliver H.; Dietl, Paul; Frick, Manfred] Univ Ulm, Inst Gen Physiol, D-89081 Ulm, Germany; [Kranz, Christine] Univ Ulm, Inst Analyt & Bioanalyt Chem, D-89081 Ulm, Germany	Ulm University; Ulm University	Frick, M (corresponding author), Univ Ulm, Inst Gen Physiol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	manfred.frick@uni-ulm.de	Kranz, Christine/F-3838-2014; Frick, Manfred/E-1374-2012	Kranz, Christine/0000-0002-6001-0580; Frick, Manfred/0000-0002-4763-1104; Korbmacher, Jonas/0000-0002-0454-8407	Deutsche Forschungsgemeinschaft (DFG) [D-1402/1-1, D-1422/3-1]; BiU grant [D.5006]; Landesstiftung Baden-Wurtemberg grant [P-LS-Biomat/03]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); BiU grant; Landesstiftung Baden-Wurtemberg grant	The authors thank M. Timmler and T. Felder for technical assistance, in particular for primary alveolar type II cell isolation; and S. Britsch and C. Wiegreffe for access to and support for the Leica SP5 confocal microscope. The authors are especially grateful to F. Wagner and P. Radermacher for their help with the in situ compliance measurements. The authors declare no conflicts of interest. This work was supported by Deutsche Forschungsgemeinschaft (DFG) grants D-1402/1-1 and D-1422/3-1, BiU grant D.5006, and Landesstiftung Baden-Wurtemberg grant P-LS-Biomat/03. K. T. and M. F. designed the study; K. T., J. K., E. H., N. H., O. H. W., and M. F. performed experiments and analyzed data; all authors wrote the manuscript.	Altamirano J, 1998, J GEN PHYSIOL, V112, P145, DOI 10.1085/jgp.112.2.145; Ameen NA, 2003, AM J PHYSIOL-CELL PH, V284, pC429, DOI 10.1152/ajpcell.00261.2002; BASTACKY J, 1995, J APPL PHYSIOL, V79, P1615, DOI 10.1152/jappl.1995.79.5.1615; Berthiaume Y, 2007, RESP PHYSIOL NEUROBI, V159, P350, DOI 10.1016/j.resp.2007.05.010; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Bove PF, 2010, J BIOL CHEM, V285, P34939, DOI 10.1074/jbc.M110.162933; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; CLEMENTS JA, 1961, J APPL PHYSIOL, V16, P444, DOI 10.1152/jappl.1961.16.3.444; Davis IC, 2004, AM J PHYSIOL-LUNG C, V286, pL112, DOI 10.1152/ajplung.00218.2003; Dietl P, 2005, ANNU REV PHYSIOL, V67, P595, DOI 10.1146/annurev.physiol.67.040403.102553; Dietl P, 2004, BIOL NEONATE, V85, P299, DOI 10.1159/000078176; Dietl P, 2001, NEWS PHYSIOL SCI, V16, P239; Dietl P, 2012, CELL CALCIUM, V52, P296, DOI 10.1016/j.ceca.2012.04.010; Dobbs LG, 2007, RESP PHYSIOL NEUROBI, V159, P283, DOI 10.1016/j.resp.2007.06.011; Dobbs LG, 1997, AM J PHYSIOL-LUNG C, V273, pL347, DOI 10.1152/ajplung.1997.273.2.L347; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; Edwards YS, 2001, COMP BIOCHEM PHYS A, V129, P245, DOI 10.1016/S1095-6433(01)00321-X; Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005; Folkesson HG, 2006, AM J RESP CELL MOL, V35, P10, DOI 10.1165/rcmb.2006-0080SF; Frick M, 2001, AM J RESP CELL MOL, V25, P306, DOI 10.1165/ajrcmb.25.3.4493; Haller T, 1999, AM J PHYSIOL-LUNG C, V277, pL893, DOI 10.1152/ajplung.1999.277.5.L893; Haller T, 2004, AM J PHYSIOL-LUNG C, V286, pL1009, DOI 10.1152/ajplung.00342.2003; Haller T, 1998, P NATL ACAD SCI USA, V95, P1579, DOI 10.1073/pnas.95.4.1579; Hecht E, 2012, ANAL CHEM, V84, P5716, DOI 10.1021/ac300775j; Hollenhorst MI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/174306; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Ito Y, 2011, AM J RESP CELL MOL, V45, P938, DOI 10.1165/rcmb.2011-0052OC; Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7; Kemp PJ, 2004, AM J PHYSIOL-LUNG C, V287, pL460, DOI 10.1152/ajplung.00191.2004; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Mason RJ, 2002, AM J PHYSIOL-LUNG C, V282, pL249, DOI 10.1152/ajplung.00027.2001; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Miklavc P, 2012, J CELL SCI, V125, P2765, DOI 10.1242/jcs.105262; Miklavc P, 2011, P NATL ACAD SCI USA, V108, P14503, DOI 10.1073/pnas.1101039108; Miklavc P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010982; Mishra A, 2011, J CELL SCI, V124, P657, DOI 10.1242/jcs.066977; Mizgerd JP, 2004, AM J PHYSIOL-LUNG C, V286, pL1302, DOI 10.1152/ajplung.00353.2003; Moschos SA, 2011, MOL THER, V19, P2163, DOI 10.1038/mt.2011.206; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Patel AS, 2005, AM J PHYSIOL-LUNG C, V289, pL489, DOI 10.1152/ajplung.00074.2005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ravasio A, 2011, AM J PHYSIOL-CELL PH, V300, pC1456, DOI 10.1152/ajpcell.00427.2010; Rich PB, 2003, J TRAUMA, V55, P290, DOI 10.1097/01.TA.0000078882.11919.AF; SHANNON JM, 1992, AM J PHYSIOL, V262, pL427, DOI 10.1152/ajplung.1992.262.4.L427; Silberberg SD, 2005, J GEN PHYSIOL, V125, P347, DOI 10.1085/jgp.200409221; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tarran R, 2002, J GEN PHYSIOL, V120, P407, DOI 10.1085/jgp.20028599; Tarran Robert, 2004, Proc Am Thorac Soc, V1, P42, DOI 10.1513/pats.2306014; Wang JR, 2007, AM J RESP CELL MOL, V36, P661, DOI 10.1165/rcmb.2006-0410OC; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wemhoner A, 2006, J BIOMOL SCREEN, V11, P286, DOI 10.1177/1087057105285284; Wirtz HR, 2000, RESP PHYSIOL, V119, P1, DOI 10.1016/S0034-5687(99)00092-4; Wolk KE, 2008, AM J RESP CRIT CARE, V178, P969, DOI 10.1164/rccm.200803-455OC; Worthington EN, 2011, METHODS MOL BIOL, V742, P77, DOI 10.1007/978-1-61779-120-8_5; Yang CX, 2009, AM J PHYSIOL-LUNG C, V297, pL439, DOI 10.1152/ajplung.90268.2008	58	28	28	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1772	1783		10.1096/fj.12-220533	http://dx.doi.org/10.1096/fj.12-220533			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23307836				2022-12-28	WOS:000316940800045
J	Hendrix, S; Kramer, P; Pehl, D; Warnke, K; Boato, F; Nelissen, S; Lemmens, E; Pejler, G; Metz, M; Siebenhaar, F; Maurer, M				Hendrix, Sven; Kramer, Peter; Pehl, Debora; Warnke, Katharina; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi; Pejler, Gunnar; Metz, Martin; Siebenhaar, Frank; Maurer, Marcus			Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4	FASEB JOURNAL			English	Article						entorhinal cortex lesion; mMCP-4; protease; T cells	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-ISCHEMIA; EARLY RESPONDERS; MICE; ACTIVATION; PROTEASES; BIOLOGY; MOUSE	Mast cells (MCs) are found abundantly in the brain and the meninges and play a complex role in neuroinflammatory diseases, such as stroke and multiple sclerosis. Here, we show that MC-deficient Kit(W)/Kit(W-v) mice display increased neurodegeneration in the lesion area after brain trauma. Furthermore, MC-deficient mice display significantly more brain inflammation, namely an increased presence of macrophages/microglia, as well as dramatically increased T-cell infiltration at days 4 and 14 after injury, combined with increased astrogliosis at day 14 following injury. The number of proliferating Ki67(+) macrophages/microglia and astrocytes around the lesion area is more than doubled in these MC-deficient mice. In parallel, MC-deficient Kit(W-sh/W-sh) mice display increased presence of macrophages/microglia at day 4, and persistent astrogliosis at day 4 and 14 after brain trauma. Further analysis of mice deficient in one of the most relevant MC proteases, i.e., mouse mast cell protease 4 (mMCP-4), revealed that astrogliosis and T-cell infiltration are significantly increased in mMCP-4-knockout mice. Finally, treatment with an inhibitor of mMCP-4 significantly increased macrophage/microglia numbers and astrogliosis. These data suggest that MCs exert protective functions after trauma, at least in part via mMCP-4, by suppressing exacerbated inflammation via their proteases.-Hendrix, S., Kramer, P., Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., Maurer, M. Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. FASEB J. 27, 920-929 (2013). www.fasebj.org	[Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Dept Morphol, Diepenbeek, Belgium; [Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium; [Kramer, Peter; Pehl, Debora; Warnke, Katharina] Charite, Ctr Anat Cell Biol & Neurobiol, D-13353 Berlin, Germany; [Metz, Martin; Siebenhaar, Frank; Maurer, Marcus] Charite, Dept Dermatol, D-13353 Berlin, Germany; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Hasselt University; Hasselt University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Swedish University of Agricultural Sciences	Hendrix, S (corresponding author), Dept Morphol, Agoralaan Gebouw D, BE-3590 Diepenbeek, Belgium.	sven.hendrix@uhasselt.be	Metz, Martin/B-8799-2009; Hendrix, Sven/F-4059-2010; Maurer, Marcus/ABG-2174-2020; Metz, Martin/M-5237-2013	Metz, Martin/0000-0002-4070-9976; Hendrix, Sven/0000-0003-2344-7369; Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Boato, Francesco/0000-0001-9741-8021; Lemmens, Evi/0000-0001-6044-5659; Siebenhaar, Frank/0000-0003-4532-1644; Kramer, Peter/0000-0003-4780-5271	Deutsche Forschungsgemeinschaft [SPP1394]; Fonds Wetenschappelijk Onderzoek-Vlaanderen [G.0834.11N, G.0389.12]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fonds Wetenschappelijk Onderzoek-Vlaanderen(FWO)	The authors are indebted to Doreen Ludecke and Julia Konig for their engaged and skillful technical assistance, to Nathalie Geurts for performing the FACS analyses and to Dearbhaile Dooley for editing the text. P.K. was a member of GRK1258. This study was supported in part by grants from Deutsche Forschungsgemeinschaft (SPP1394) and from Fonds Wetenschappelijk Onderzoek-Vlaanderen (G.0834.11N, G.0389.12) to S.H. The authors declare no conflicts of interests.	Bennett JL, 2009, J IMMUNOL, V182, P5507, DOI 10.4049/jimmunol.0801485; Berghmans N, 2011, J INTERF CYTOK RES, V31, P575, DOI 10.1089/jir.2010.0137; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Brown MA, 2002, MOL IMMUNOL, V38, P1373, DOI 10.1016/S0161-5890(02)00091-3; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; DROPP JJ, 1972, ANAT REC, V174, P227, DOI 10.1002/ar.1091740207; Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hendrix S, 2006, NEUROSCI LETT, V392, P174, DOI 10.1016/j.neulet.2005.09.029; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Kwidzinski E, 2003, J NEURAL TRANSM-SUPP, P29, DOI 10.1007/978-3-7091-0643-3_2; Li HM, 2011, J IMMUNOL, V187, P274, DOI 10.4049/jimmunol.1003603; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Manni L, 1998, INT J DEV NEUROSCI, V16, P1, DOI 10.1016/S0736-5748(98)00003-3; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; Robbie-Ryan M, 2003, J IMMUNOL, V170, P1630, DOI 10.4049/jimmunol.170.4.1630; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Skaper SD, 2001, J NEUROCHEM, V76, P47, DOI 10.1046/j.1471-4159.2001.00008.x; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Strbian D, 2007, J CEREBR BLOOD F MET, V27, P795, DOI 10.1038/sj.jcbfm.9600387; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Taiwo OB, 2005, PAIN, V114, P131, DOI 10.1016/j.pain.2004.12.002; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Waskow C, 2004, BLOOD, V104, P1688, DOI 10.1182/blood-2004-04-1247; Zappulla JP, 2002, J NEUROIMMUNOL, V131, P5, DOI 10.1016/S0165-5728(02)00250-3; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	38	42	44	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					920	929		10.1096/fj.12-204800	http://dx.doi.org/10.1096/fj.12-204800			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193170				2022-12-28	WOS:000315585200008
J	Kenche, H; Baty, CJ; Vedagiri, K; Shapiro, SD; Blumental-Perry, A				Kenche, Harshavardhan; Baty, Catherine J.; Vedagiri, Kokilavani; Shapiro, Steven D.; Blumental-Perry, Anna			Cigarette smoking affects oxidative protein folding in endoplasmic reticulum by modifying protein disulfide isomerase	FASEB JOURNAL			English	Article						COPD; ER stress response	OBSTRUCTIVE PULMONARY-DISEASE; ER STRESS; MOLECULAR CHAPERONE; BOND FORMATION; HUMAN LUNG; AUTOPHAGY; CELLS; TRANSCRIPTION; GLUTATHIONE; EXPRESSION	The endoplasmic reticulum (ER) stress response (ERSR) and associated protein aggregation, is under investigation for its role in human diseases, including chronic obstructive pulmonary disease (COPD) where cigarette smoking (CS) is a risk factor for disease development. Our hypothesis states that CS-associated oxidative stress interferes with oxidative protein folding in the ER and elicits ERSR. We investigated ERSR induction following acute CS exposure and delineated mechanisms of CS-induced ERSR. Lung lysates from mice exposed or not to one cigarette were tested for activation of the ERSR. Up to 4-fold increase in phosphorylation of eIF2 alpha and nuclear form of ATF6 was detected in CS-exposed animals. CS affected the formation of disulfide bonds through excessive posttranslational oxidation of protein disulfide isomerase (PDI). Increased amounts of complexes between PDI and its client proteins persisted in CS-exposed samples. BiP was not a constituent of these complexes, demonstrating the specificity of the early effects of CS exposure on ER. Disturbances in protein folding were accompanied by changes in the organization of ER network and ER exit sites. Our results provide evidence that ERSR is induced early in response to CS exposure and identifies the first known ER-resident target of CS PDI, demonstrating that CS affects oxidative protein folding.-Kenche, H., Baty, C. J., Vedagiri, K., Shapiro, S. D., Blumental-Perry, A. Cigarette smoking affects oxidative protein folding in endoplasmic reticulum by modifying protein disulfide isomerase. FASEB J. 27, 965-977 (2013). www.fasebj.org	[Kenche, Harshavardhan; Vedagiri, Kokilavani; Blumental-Perry, Anna] Mem Hlth Univ Med Ctr, Anderson Canc Inst, Savannah, GA 31405 USA; [Blumental-Perry, Anna] Mercer Univ, Sch Med, Dept Biomed Sci, Savannah, GA USA; [Baty, Catherine J.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA; [Shapiro, Steven D.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA	Mercer University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Blumental-Perry, A (corresponding author), Mem Hlth Univ Med Ctr, Anderson Canc Inst, Hoskins Res Bldg,4700 Waters Ave, Savannah, GA 31405 USA.	perry_a@mercer.edu			ATS/Alpha-1 Foundation; Flight Attendant Medical Research Institute [092207]; Curtis and Elizabeth Anderson Cancer Institute	ATS/Alpha-1 Foundation; Flight Attendant Medical Research Institute; Curtis and Elizabeth Anderson Cancer Institute	The authors thank Celia Reynolds for editorial and technical help, Jenny Karlsson for help with live imaging, and Jeremy Brown for help with the ImageJ macro for analysis of intensity of IHC staining. This research was funded by an ATS/Alpha-1 Foundation partnership grant in alpha 1-antitrypsin deficiency (A.B.-P.), a Flight Attendant Medical Research Institute Young Clinical Scientist Award (grant 092207; A.B.-P.), and by the Welcome Fund from the Curtis and Elizabeth Anderson Cancer Institute.	Aksoy R. J., 2011, AM J RESP CRIT CARE, V183, pA4094; An CH, 2012, AM J PHYSIOL-LUNG C, V303, pL748, DOI 10.1152/ajplung.00102.2012; Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974; Aoshiba K, 2003, INHAL TOXICOL, V15, P1029, DOI 10.1080/08958370390226431; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bernales S, 2007, AUTOPHAGY, V3, P285, DOI 10.4161/auto.3930; Bezemer GFG, 2012, PHARMACOL REV, V64, P337, DOI 10.1124/pr.111.004622; Biswas SK, 2009, MOL ASPECTS MED, V30, P60, DOI 10.1016/j.mam.2008.07.001; Blumental-Perry A, 2012, CURR MOL MED, V12, P883, DOI 10.2174/156652412801318764; Blumental-Perry A., 2012, ENDO RETICU STRESS C, V1, P1; Budnik A, 2009, FEBS LETT, V583, P3796, DOI 10.1016/j.febslet.2009.10.038; Cantin Andre M, 2010, Proc Am Thorac Soc, V7, P368, DOI 10.1513/pats.201001-014AW; Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645; Dombroski BA, 2010, AM J HUM GENET, V86, P719, DOI 10.1016/j.ajhg.2010.03.017; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Geraghty P, 2011, INT J CHRONIC OBSTR, V6, P309, DOI 10.2147/COPD.S19599; Haspel JA, 2011, AM J RESP CRIT CARE, V184, P1237, DOI 10.1164/rccm.201106-0966CI; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Hengstermann A, 2008, FREE RADICAL BIO MED, V44, P1097, DOI 10.1016/j.freeradbiomed.2007.12.009; Henson Peter M, 2006, Proc Am Thorac Soc, V3, P713, DOI 10.1513/pats.200605-104SF; Hetz C, 2011, CURR OPIN CELL BIOL, V23, P123, DOI 10.1016/j.ceb.2011.01.004; Jacob C, 2012, CHEM RES TOXICOL, V25, P588, DOI 10.1021/tx200342b; Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC; Kelsen SG, 2012, PULM PHARMACOL THER, V25, P447, DOI 10.1016/j.pupt.2012.07.005; Kim KM, 2012, INT J CANCER, V131, pE362, DOI 10.1002/ijc.26463; Korfei M, 2008, AM J RESP CRIT CARE, V178, P838, DOI 10.1164/rccm.200802-313OC; Lawless MW, 2012, CYTOKINE, V59, P195, DOI 10.1016/j.cyto.2012.04.003; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Mao CH, 2006, J BIOL CHEM, V281, P8877, DOI 10.1074/jbc.M505784200; Marcinak Stefan J, 2010, Proc Am Thorac Soc, V7, P356, DOI 10.1513/pats.201001-015AW; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Min T, 2011, J MOL MED, V89, P577, DOI 10.1007/s00109-011-0732-8; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mortaz E, 2011, BBA-MOL BASIS DIS, V1812, P1104, DOI 10.1016/j.bbadis.2011.06.002; Nawa D, 2007, GLYCOBIOLOGY, V17, P913, DOI 10.1093/glycob/cwm067; Oda K, 1996, BIOCHEM J, V316, P623, DOI 10.1042/bj3160623; Ribeiro CMP, 2012, CURR MOL MED, V12, P872; Roth DM, 2011, CURR OPIN CELL BIOL, V23, P126, DOI 10.1016/j.ceb.2010.11.001; Ryter Stefan W, 2010, Proc Am Thorac Soc, V7, P40, DOI 10.1513/pats.200909-100JS; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; Shapiro SD, 2005, AM J RESP CELL MOL, V32, P367, DOI 10.1165/rcmb.F296; Stephens DJ, 2000, J CELL SCI, V113, P2177; Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; Townsend DM, 2009, CANCER RES, V69, P7626, DOI 10.1158/0008-5472.CAN-09-0493; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vidal RL, 2012, HUM MOL GENET, V21, P2245, DOI 10.1093/hmg/dds040; Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046144; Wang Y, 2000, J BIOL CHEM, V275, P27013; Weston RT, 2010, ADV EXP MED BIOL, V687, P65; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wilhelm JE, 2005, DEV CELL, V9, P675, DOI 10.1016/j.devcel.2005.09.015; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373	63	57	58	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					965	977		10.1096/fj.12-216234	http://dx.doi.org/10.1096/fj.12-216234			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23169770				2022-12-28	WOS:000315585200012
J	Pusic, K; Aguilar, Z; McLoughlin, J; Kobuch, S; Xu, H; Tsang, M; Wang, A; Hui, G				Pusic, Kae; Aguilar, Zoraida; McLoughlin, Jaclyn; Kobuch, Sophie; Xu, Hong; Tsang, Mazie; Wang, Andrew; Hui, George			Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine	FASEB JOURNAL			English	Article						adjuvant; particle-mediated immunizations; inhibitory antibodies	MEROZOITE SURFACE PROTEIN-1; VIRUS-LIKE PARTICLES; C-TERMINAL FRAGMENT; PLASMODIUM-FALCIPARUM; DENDRITIC CELLS; AOTUS MONKEYS; INHIBITORY ANTIBODIES; ADJUVANT FORMULATIONS; EFFICACY; IMMUNOGENICITY	This study explored the novel use of iron oxide (IO) nanoparticles (<20 nm) as a vaccine delivery platform without additional adjuvants. A recombinant malaria vaccine antigen, the merozoite surface protein 1 (rMSP1), was conjugated to IO nanoparticles (rMSP1-IO). Immunizations in outbred mice with rMSP1-IO achieved 100% responsiveness with antibody titers comparable to those obtained with rMSP1 formulated with a clinically acceptable adjuvant, Montanide ISA51 (2.7 x 10(-3) vs. 1.6 x 10(-3); respectively). Only rMSP1-1O could induce significant levels (80%) of parasite inhibitory antibodies. The rMSP1-IO was highly stable at 4 C and was amenable to lyophilization, maintaining its antigenicity, immunogenicity, and ability to induce inhibitory antibodies. Further testing in nonhuman primates, Aotus monkeys, also elicited 100% immune responsiveness and high levels of parasite inhibitory antibodies (55-100% inhibition). No apparent local or systemic toxicity was associated with IO immunizations. Murine macrophages and dendritic cells efficiently (>90%) internalized IO nanoparticles, but only the latter were significantly activated, with elevated expression/secretion of CD86, cytokines (IL-6, TNF-alpha, IL1-b, IFN-gamma, and IL-12), and chemokines (CXCL1, CXCL2, CCL2, CCL3, CCL4, and CXCL10). Thus, the IO nanoparticles is a novel, safe, and effective vaccine platform, with built-in adjuvancy, that is highly stable and field deployable for cost-effective vaccine delivery.-Pusic, K., Aguilar, Z., McLoughlin, J., Kobuch, S., Xu, H., Tsang, M., Wang, A., Hui, G. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J. 27, 1153-1166 (2013). www.fasebj.org	[Pusic, Kae; McLoughlin, Jaclyn; Kobuch, Sophie; Hui, George] Univ Hawaii, Dept Trop Med, Honolulu, HI 96813 USA; [Tsang, Mazie] Univ Hawaii, Sch Med, Honolulu, HI 96813 USA; [Aguilar, Zoraida; Xu, Hong; Wang, Andrew] Ocean NanoTech LLC, Springdale, AR USA	University of Hawaii System; University of Hawaii System	Pusic, K (corresponding author), Univ Hawaii, Sch Med, Dept Trop Med, 651 Ilalo St,BSB320, Honolulu, HI 96813 USA.	kae@hawaii.edu			U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [A1076955]; NIH/National Institutes of General Medical Sciences [P20GM103516]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK078386]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R25DK078386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103516] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases; NIH/National Institutes of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank S. Chang, W. Gosnell, K. Kramer, and S. Case for their help with the Aotus monkey immunizations. The authors also thank Dr. Lozanoff and Dr. Somponpun for their help with the toxicity studies. The authors additionally thank D. Clements of Hawaii Biotech Inc. (Aiea, HI, USA) for providing the MSP1 recombinant protein; and D. Clements and A. Stridiron for their technical support. This work was supported by a grant from the U.S. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (A1076955) and NIH/National Institutes of General Medical Sciences (P20GM103516). K. P. was supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases (DK078386).	Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; Anzai Yoshimi, 2004, Top Magn Reson Imaging, V15, P103, DOI 10.1097/01.rmr.0000130602.65243.87; Barton GM, 2009, NAT REV IMMUNOL, V9, P535, DOI 10.1038/nri2587; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; Chang SP, 1996, INFECT IMMUN, V64, P253, DOI 10.1128/IAI.64.1.253-261.1996; CHANG SP, 1992, J IMMUNOL, V149, P548; CHANG SP, 1989, P NATL ACAD SCI USA, V86, P6343, DOI 10.1073/pnas.86.16.6343; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Figuerola A, 2010, PHARMACOL RES, V62, P126, DOI 10.1016/j.phrs.2009.12.012; Fischer NO, 2010, BIOCONJUGATE CHEM, V21, P1018, DOI 10.1021/bc100083d; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; Hirosue S, 2010, VACCINE, V28, P7897, DOI 10.1016/j.vaccine.2010.09.077; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; Hui G, 2008, CLIN VACCINE IMMUNOL, V15, P1145, DOI 10.1128/CVI.00058-08; Hui G, 2007, VACCINE, V25, P8549, DOI 10.1016/j.vaccine.2007.10.010; Hui G, 2007, VACCINE, V25, P948, DOI 10.1016/j.vaccine.2006.08.041; HUI GSN, 1992, EXP PARASITOL, V75, P155, DOI 10.1016/0014-4894(92)90131-S; HUI GSN, 1994, J IMMUNOL, V153, P2544; HUI GSN, 1991, J IMMUNOL, V147, P3935; HUI GSN, 1994, J IMMUNOL, V153, P1195; HUI GSN, 1994, AM J TROP MED HYG, V50, P41, DOI 10.4269/ajtmh.1994.50.41; HUI GSN, 1987, EXP PARASITOL, V64, P519, DOI 10.1016/0014-4894(87)90068-3; Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; John CC, 2004, J IMMUNOL, V173, P666, DOI 10.4049/jimmunol.173.1.666; Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957; Kirkpatrick RB, 1999, GENE EXPRESSION SYSTEMS, P289, DOI 10.1016/B978-012253840-7/50012-2; Kumar S, 2000, INFECT IMMUN, V68, P2215, DOI 10.1128/IAI.68.4.2215-2223.2000; Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leung WH, 2004, BBA-GEN SUBJECTS, V1675, P62, DOI 10.1016/j.bbagen.2004.08.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Masotti A, 2009, MINI-REV MED CHEM, V9, P463, DOI 10.2174/138955709787847976; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Pang ALY, 2002, INFECT IMMUN, V70, P2772, DOI 10.1128/IAI.70.6.2772-2779.2002; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Perraut R, 2005, J INFECT DIS, V191, P264, DOI 10.1086/426398; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pusic K, 2011, VACCINE, V29, P8898, DOI 10.1016/j.vaccine.2011.09.070; Pusic KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024782; Rudra JS, 2012, BIOMATERIALS, V33, P6476, DOI 10.1016/j.biomaterials.2012.05.041; Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140; Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05; Skene CD, 2006, METHODS, V40, P53, DOI 10.1016/j.ymeth.2006.05.019; Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001; Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Szymczak WA, 2010, INFECT IMMUN, V78, P2125, DOI 10.1128/IAI.00065-10; Ueno Y, 2005, J CONTROL RELEASE, V103, P93, DOI 10.1016/j.jconrel.2004.11.015; van der Lubben IM, 2001, ADV DRUG DELIVER REV, V52, P139, DOI 10.1016/S0169-409X(01)00197-1; Xu H., 2009, BIOMEDICAL ENG INFOR, DOI [10.1109/BMEI.2009.5305551, DOI 10.1109/BMEI.2009.5305551]; Xu HY, 2009, ECS TRANSACTIONS, V25, P69, DOI 10.1149/1.3236409; Xu HYY, 2010, ECS TRANSACTIONS, V25, P1, DOI 10.1149/1.3327196; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	67	50	52	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1153	1166		10.1096/fj.12-218362	http://dx.doi.org/10.1096/fj.12-218362			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195035	Green Published			2022-12-28	WOS:000315585200028
J	Cox, LM; Cho, I; Young, SA; Anderson, WHK; Waters, BJ; Hung, SC; Gao, Z; Mahana, D; Bihan, M; Alekseyenko, AV; Methe, BA; Blaser, MJ				Cox, Laura M.; Cho, Ilseung; Young, Scott A.; Anderson, W. H. Kerr; Waters, Bartholomew J.; Hung, Shao-Ching; Gao, Zhan; Mahana, Douglas; Bihan, Monika; Alekseyenko, Alexander V.; Methe, Barbara A.; Blaser, Martin J.			The nonfermentable dietary fiber hydroxypropyl methylcellulose modulates intestinal microbiota	FASEB JOURNAL			English	Article						prebiotics; microbial ecology; obesity; cholesterol; liver adiposity	CHAIN FATTY-ACIDS; GUT MICROBIOTA; WEIGHT-LOSS; DISTAL GUT; OBESITY; VISCOSITY; HYDROXYPROPYLMETHYLCELLULOSE; FERMENTATION; OLIGOSACCHARIDES; CHOLESTEROL	Diet influences host metabolism and intestinal microbiota; however, detailed understanding of this tripartite interaction is limited. To determine whether the nonfermentable fiber hydroxypropyl methylcellulose (HPMC) could alter the intestinal microbiota and whether such changes correlated with metabolic improvements, C57B/L6 mice were normalized to a high-fat diet (HFD), then either maintained on HFD (control), or switched to HFD supplemented with 10% HPMC, or a low-fat diet (LFD). Compared to control treatment, both LFD and HPMC reduced weight gain (11.8 and 5.7 g, respectively), plasma cholesterol (23.1 and 19.6%), and liver triglycerides (73.1 and 44.6%), and, as revealed by 454-pyrosequencing of the microbial 16S rRNA gene, decreased microbial alpha-diversity and differentially altered intestinal microbiota. Both LFD and HPMC increased intestinal Erysipelotrichaceae (7.3- and 12.4-fold) and decreased Lachnospiraceae (2.0- and 2.7-fold), while only HPMC increased Peptostreptococcaceae (3.4-fold) and decreased Ruminococcaceae (2.7-fold). Specific microorganisms were directly linked with weight change and metabolic parameters in HPMC and HFD mice, but not in LFD mice, indicating that the intestinal microbiota may play differing roles during the two dietary modulations. This work indicates that HPMC is a potential prebiotic fiber that influences intestinal microbiota and improves host metabolism.-Cox, L. M., Cho, I., Young, S. A., Kerr Anderson, W. H., Waters, B. J., Hung, S.-C., Gao, Z., Mahana, D., Bihan, M., Alekseyenko, A. V., Methe, B. A., Blaser, M. J. The nonfermentable dietary fiber hydroxypropyl methylcellulose modulates intestinal microbiota. FASEB J. 27, 692-702 (2013). www.fasebj.org	[Cox, Laura M.; Cho, Ilseung; Gao, Zhan; Mahana, Douglas; Blaser, Martin J.] NYU, Langone Med Ctr, Dept Med, New York, NY 10016 USA; [Cox, Laura M.; Cho, Ilseung; Gao, Zhan; Blaser, Martin J.] NYU, Langone Med Ctr, Dept Microbiol, New York, NY 10016 USA; [Alekseyenko, Alexander V.] NYU, Langone Med Ctr, Ctr Hlth Informat & Bioinformat, New York, NY 10016 USA; [Cho, Ilseung; Blaser, Martin J.] Vet Affairs Med Ctr, New York Harbor Dept, New York, NY USA; [Young, Scott A.; Anderson, W. H. Kerr; Waters, Bartholomew J.; Hung, Shao-Ching] Dow Chem Co USA, Midland, MI 48674 USA; [Bihan, Monika; Methe, Barbara A.] J Craig Venter Inst, Rockville, MD USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Dow Chemical Company; J. Craig Venter Institute	Blaser, MJ (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave,OBV A606, New York, NY 10016 USA.	martin.blaser@nyumc.org	Bihan, Monika/C-7469-2014; Blaser, Martin/ABF-6878-2021; Cox, Laura/ABG-5883-2020	Cox, Laura/0000-0002-9564-9894; Alekseyenko, Alexander/0000-0002-5748-2085; Cho, Ilseung/0000-0002-7308-8707	U.S. National Institutes of Health [1UL1RR029893, R01DK098989]; Dow Chemical Company; Diane Belfer Program for Human Microbial Ecology; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090989] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dow Chemical Company; Diane Belfer Program for Human Microbial Ecology; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the U.S. National Institutes of Health (1UL1RR029893 and R01DK098989), the Dow Chemical Company, and the Diane Belfer Program for Human Microbial Ecology. The authors declare no conflicts of interest.	Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Ban SJ, 2012, INT J MOL SCI, V13, P3738, DOI 10.3390/ijms13033738; BeMiller J.N., 1996, FOOD CHEM, V3rd ed.; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRAUN WH, 1974, FOOD COSMET TOXICOL, V12, P373, DOI 10.1016/0015-6264(74)90010-8; Burdock GA, 2007, FOOD CHEM TOXICOL, V45, P2341, DOI 10.1016/j.fct.2007.07.011; Cai X, 2009, BIORESOURCE TECHNOL, V100, P4164, DOI 10.1016/j.biortech.2009.04.005; Cani PD, 2009, CURR PHARM DESIGN, V15, P1546, DOI 10.2174/138161209788168164; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carr TP, 1996, J NUTR, V126, P1463, DOI 10.1093/jn/126.5.1463; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Clark J.D., 1996, GUIDE CARE USE LAB A; COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812, DOI 10.1099/00207713-44-4-812; Cook SI, 1998, ALIMENT PHARM THER, V12, P499, DOI 10.1046/j.1365-2036.1998.00337.x; Delzenne NM, 2011, NAT REV ENDOCRINOL, V7, P639, DOI 10.1038/nrendo.2011.126; Faith JJ, 2011, SCIENCE, V333, P101, DOI 10.1126/science.1206025; Ferguson MJ, 2000, J SCI FOOD AGR, V80, P166, DOI [10.1002/(SICI)1097-0010(20000101)80:1<166::AID-JSFA512>3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000101)80:1&lt;166::AID-JSFA512&gt;3.0.CO;2-K]; Fisher R.A., 1924, METRON, V3, P329; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flier JS, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000483; GALLAHER DD, 1993, J NUTR, V123, P244; Gao Z, 2010, J CLIN MICROBIOL, V48, P3575, DOI 10.1128/JCM.00597-10; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gortmaker SL, 2011, LANCET, V378, P838, DOI 10.1016/S0140-6736(11)60815-5; GORZINSKI SJ, 1986, DRUG CHEM TOXICOL, V9, P83, DOI 10.3109/01480548608998268; Guo XL, 2008, ANAEROBE, V14, P224, DOI 10.1016/j.anaerobe.2008.04.001; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Hong YJ, 2007, J AGR FOOD CHEM, V55, P9750, DOI 10.1021/jf071798+; Hooda S, 2012, J NUTR, V142, P1259, DOI 10.3945/jn.112.158766; Huang XF, 2011, MOL NUTR FOOD RES, V55, P1118, DOI 10.1002/mnfr.201100095; Hung SC, 2011, J DIABETES, V3, P158, DOI 10.1111/j.1753-0407.2011.00118.x; Hung SC, 2009, J DIABETES, V1, P194, DOI 10.1111/j.1753-0407.2009.00034.x; Islam A, 2012, OBESITY, V20, P349, DOI 10.1038/oby.2011.341; Kim SH, 2006, MOL BIOL EVOL, V23, P1068, DOI 10.1093/molbev/msj115; Kootte RS, 2012, DIABETES OBES METAB, V14, P112, DOI 10.1111/j.1463-1326.2011.01483.x; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Louis P, 2004, J BACTERIOL, V186, P2099, DOI 10.1128/JB.186.7.2099-2106.2004; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Lozupone CA, 2008, FEMS MICROBIOL REV, V32, P557, DOI 10.1111/j.1574-6976.2008.00111.x; Ludwig W, 2009, BERGEYS MANUAL SYSTE, V3, P1, DOI DOI 10.1007/978-0-387-68489-5_; Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe; Machle W, 1944, J BIOL CHEM, V153, P551; Maki KC, 2008, J NUTR, V138, P292, DOI 10.1093/jn/138.2.292; Maki KC, 2007, DIABETES CARE, V30, P1039, DOI 10.2337/dc06-2344; Maki KC, 2009, DIABETES TECHNOL THE, V11, P119, DOI 10.1089/dia.2008.0036; Martinez I, 2009, APPL ENVIRON MICROB, V75, P4175, DOI 10.1128/AEM.00380-09; MAYER J, 1955, ANN NY ACAD SCI, V63, P15, DOI 10.1111/j.1749-6632.1955.tb36543.x; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Neyrinck AM, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2011.24; Neyrinck AM, 2012, J NUTR BIOCHEM, V23, P51, DOI 10.1016/j.jnutbio.2010.10.008; Neyrinck AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020944; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Pataky Z, 2010, EXP CLIN ENDOCR DIAB, V118, P427, DOI 10.1055/s-0029-1233448; Prokhorov A. V., 2002, ENCY MATH; Psaltopoulou Theodora, 2010, Rev Diabet Stud, V7, P26, DOI 10.1900/RDS.2010.7.26; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; R Core Team, 2020, R LANG ENV STAT COMP; Ramirez-Farias C, 2009, BRIT J NUTR, V101, P541, DOI 10.1017/S0007114508019880; Ravussin Y, 2012, OBESITY, V20, P738, DOI 10.1038/oby.2011.111; Reppas C, 2009, EUR J CLIN NUTR, V63, P71, DOI 10.1038/sj.ejcn.1602903; Santos E., 1986, J AM COLL TOXICOL, V5, P1; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SAVAGE DC, 1986, ANNU REV NUTR, V6, P155, DOI 10.1146/annurev.nu.06.070186.001103; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Slavin JL, 2005, NUTRITION, V21, P411, DOI 10.1016/j.nut.2004.08.018; Sonnenburg JL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001626; Stecher B, 2011, CURR OPIN MICROBIOL, V14, P82, DOI 10.1016/j.mib.2010.10.003; TOPPING DL, 1988, BRIT J NUTR, V59, P21, DOI 10.1079/BJN19880006; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Turnbaugh PJ, 2009, J PHYSIOL-LONDON, V587, P4153, DOI 10.1113/jphysiol.2009.174136; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; Weickert MO, 2011, AM J CLIN NUTR, V94, P459, DOI 10.3945/ajcn.110.004374; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; WYATT GM, 1988, BRIT J NUTR, V60, P197, DOI 10.1079/BJN19880091; Yokoyama WH, 2002, J AGR FOOD CHEM, V50, P7726, DOI 10.1021/jf020653u	82	59	62	2	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					692	702		10.1096/fj.12-219477	http://dx.doi.org/10.1096/fj.12-219477			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23154883	Green Published			2022-12-28	WOS:000314358000028
J	Arroyo, DS; Soria, JA; Gaviglio, EA; Garcia-Keller, C; Cancela, LM; Rodriguez-Galan, MC; Wang, JM; Iribarren, P				Arroyo, Daniela S.; Soria, Javier A.; Gaviglio, Emilia A.; Garcia-Keller, Constanza; Cancela, Liliana M.; Rodriguez-Galan, Maria C.; Wang, Ji Ming; Iribarren, Pablo			Toll-like receptor 2 ligands promote microglial cell death by inducing autophagy	FASEB JOURNAL			English	Article						inflammation; peptidoglycan; CNS	ADAPTIVE IMMUNE-RESPONSES; POPULATION-CONTROL; DENDRITIC CELLS; ACTIVATION; APOPTOSIS; TLR2; BETA; INTERLEUKIN-4; PEPTIDOGLYCAN; NECROPTOSIS	Microglial cells are phagocytes in the central nervous system (CNS) and become activated in pathological conditions, resulting in microgliosis, manifested by increased cell numbers and inflammation in the affected regions. Thus, controlling microgliosis is important to prevent pathological damage to the brain. Here, we evaluated the contribution of Toll-like receptor 2 (TLR2) to microglial survival. We observed that activation of microglial cells with peptidoglycan (PGN) from Staphylococcus aureus and other TLR2 ligands results in cell activation followed by the induction of autophagy and autophagy-dependent cell death. In C57BL/6J mice, intracerebral injection of PGN increased the autophagy of microglial cells and reduced the microglial/macrophage cell number in brain parenchyma. Our results demonstrate a novel role of TLRs in the regulation of microglial cell activation and survival, which are important for the control of microgliosis and associated inflammatory responses in the CNS.-Arroyo, D. S., Soria, J. A., Gaviglio, E. A., Garcia-Keller, C., Cancela, L. M., Rodriguez-Galan, M. C., Wang, J. M., Iribarren, P. Toll-like receptor 2 ligands promote microglial cell death by inducing autophagy. FASEB J. 27, 299-312 (2013). www.fasebj.org	[Arroyo, Daniela S.; Soria, Javier A.; Gaviglio, Emilia A.; Rodriguez-Galan, Maria C.; Iribarren, Pablo] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CIBICI,CONICET, RA-5000 Cordoba, Argentina; [Garcia-Keller, Constanza; Cancela, Liliana M.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farmacol, IFEC,CONICET, RA-5000 Cordoba, Argentina; [Wang, Ji Ming] NCI, Mol Immunoregulat Lab, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA	National University of Cordoba; National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Iribarren, P (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CIBICI,CONICET, Ciudad Univ,X5000HUA, RA-5000 Cordoba, Argentina.	piribarr@fcq.unc.edu.ar			Fogarty International Center, U.S. National Institutes of Health (HIH) [1R01TW007621]; Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina; Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba (SECyT-UNC), Argentina; FOGARTY INTERNATIONAL CENTER [R01TW007621] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010015, ZIABC010725] Funding Source: NIH RePORTER	Fogarty International Center, U.S. National Institutes of Health (HIH); Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba (SECyT-UNC), Argentina; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank biochemist Paula Icely for technical support and secretarial assistance. This work was supported by the Fogarty International Center, U.S. National Institutes of Health (HIH; grant 1R01TW007621); Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina; and Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba (SECyT-UNC), Argentina. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Fogarty International Center, NIH. The authors declare no conflicts of interest.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arroyo DS, 2011, INT IMMUNOPHARMACOL, V11, P1415, DOI 10.1016/j.intimp.2011.05.006; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Burscha W, 2008, TOXICOLOGY, V254, P147, DOI 10.1016/j.tox.2008.07.048; Chen KQ, 2006, J BIOL CHEM, V281, P3651, DOI 10.1074/jbc.M508125200; Choi DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005482; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Franklin K.B.J., 2008, MOUSE BRAIN STEREOTA; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Iribarren P, 2002, ARCH IMMUNOL THER EX, V50, P187; Iribarren Pablo, 2002, BMC Immunol, V3, P6, DOI 10.1186/1471-2172-3-6; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; Jung DY, 2005, J IMMUNOL, V174, P6467, DOI 10.4049/jimmunol.174.10.6467; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaneko YS, 2009, BRAIN RES, V1279, P9, DOI 10.1016/j.brainres.2009.05.008; Kielian T, 2005, GLIA, V49, P567, DOI 10.1002/glia.20144; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Lu BF, 2007, AUTOPHAGY, V3, P158, DOI 10.4161/auto.3637; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mayo L, 2007, CELL DEATH DIFFER, V14, P183, DOI 10.1038/sj.cdd.4401989; Mayo L, 2008, J IMMUNOL, V181, P92, DOI 10.4049/jimmunol.181.1.92; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Munafo DB, 2001, J CELL SCI, V114, P3619; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Rabinovich GA, 1999, EUR J IMMUNOL, V29, P563, DOI 10.1002/(SICI)1521-4141(199902)29:02<563::AID-IMMU563>3.0.CO;2-A; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Soria JA, 2011, NEUROBIOL DIS, V43, P616, DOI 10.1016/j.nbd.2011.05.010; Stenzel W, 2008, AM J PATHOL, V172, P132, DOI 10.2353/ajpath.2008.070567; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Suk K, 2001, BRAIN RES, V900, P342, DOI 10.1016/S0006-8993(01)02326-5; Vidlak D, 2011, BRAIN BEHAV IMMUN, V25, P905, DOI 10.1016/j.bbi.2010.09.016; Wirenfeldt M, 2005, J NEUROSCI RES, V82, P507, DOI 10.1002/jnr.20659; Wirenfeldt M, 2007, AM J PATHOL, V171, P617, DOI 10.2353/ajpath.2007.061044; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	55	39	42	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					299	312		10.1096/fj.12-214312	http://dx.doi.org/10.1096/fj.12-214312			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23073832	Green Published			2022-12-28	WOS:000313103200028
J	Taub, DD; Hesdorffer, CS; Ferrucci, L; Madara, K; Schwartz, JB; Goetzl, EJ				Taub, Dennis D.; Hesdorffer, Charles S.; Ferrucci, Luigi; Madara, Karen; Schwartz, Janice B.; Goetzl, Edward J.			Distinct energy requirements for human memory CD4 T-cell homeostatic functions	FASEB JOURNAL			English	Article						adherence; chemotaxis; apoptosis; glycolysis; fatty acid oxidation; immunosenescence	ACTIVATED PROTEIN-KINASE; LIPID-METABOLISM; GLUCOSE-UPTAKE; EXPRESSION; GENERATION; EFFECTOR; FATE	Differentiation and activation of CD4 memory T cells (T-mem cells) require energy from different sources, but little is known about energy sources for maintenance and surveillance activities of unactivated T-mem cells. Mitochondrial fatty acid oxidation (FAO) in human unactivated CD4 T-mem cells was significantly enhanced by inhibition of glycolysis, with respective means of 1.7- and 4.5-fold for subjects <45 yr and >65 yr, and by stimulation of AMP-activated protein kinase, with respective means of 1.3- and 5.2-fold. However, CCL19 and sphingosine 1-phosphate (S1P), which control homeostatic lymphoid trafficking of unactivated T-mem cells, altered FAO and glycolysis only minimally or not at all. Inhibition of CD4 T-mem-cell basal FAO, but not basal glycolysis, significantly suppressed CCL19- and S1P-mediated adherence to collagen by >50 and 20%, respectively, and chemotaxis by >20 and 50%. Apoptosis of unactivated T-mem cells induced by IL-2 deprivation or CCL19 was increased significantly by >150 and 70%, respectively, with inhibition of FAO and by >110 and 30% with inhibition of glycolysis. Anti-TCR antibody activation of T-mem cells increased their chemotaxis to CCL5, which was dependent predominantly on glycolysis rather than FAO. The sources supplying energy for diverse functions of unactivated T-mem cells differ from that required for function after immune activation.-Taub, D. D., Hesdorffer, C. S., Ferrucci, L., Madara, K., Schwartz, J. B., Goetzl, E. J. Distinct energy requirements for human memory CD4 T-cell homeostatic functions. FASEB J. 27, 342-349 (2013). www.fasebj.org	[Schwartz, Janice B.; Goetzl, Edward J.] Jewish Home San Francisco, Geriatr Res Labs, San Francisco, CA 94112 USA; [Taub, Dennis D.; Hesdorffer, Charles S.; Ferrucci, Luigi; Madara, Karen; Goetzl, Edward J.] NIA, NIH, Baltimore, MD 21224 USA; [Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Jewish Home San Francisco, UCSF Geriatr Res Labs, 302 Silver Ave, San Francisco, CA 94112 USA.	edward.goetzl@ucsf.edu	Schwartz, Janice/K-6354-2019		endowment funds of the Jewish Home of San Francisco; U.S. National Institute on Aging; NATIONAL INSTITUTE ON AGING [ZIAAG000104] Funding Source: NIH RePORTER	endowment funds of the Jewish Home of San Francisco; U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by endowment funds of the Jewish Home of San Francisco and the intramural research program of the U.S. National Institute on Aging. The authors are grateful to Judith H. Goetzl for preparation of the figures and table. The authors declare no conflicts of interest.	Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670; Chan O, 2012, J BIOL CHEM, V287, P29406, DOI 10.1074/jbc.M112.348946; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; DeBerardinis RJ, 2006, J BIOL CHEM, V281, P37372, DOI 10.1074/jbc.M608372200; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Finkel T, 2012, J BIOL CHEM, V287, P4434, DOI 10.1074/jbc.R111.271999; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; FRANCUS T, 1991, CELL IMMUNOL, V134, P520, DOI 10.1016/0008-8749(91)90323-4; Gerriets VA, 2012, TRENDS IMMUNOL, V33, P168, DOI 10.1016/j.it.2012.01.010; Goetzl EJ, 2010, FASEB J, V24, P3580, DOI 10.1096/fj.10-160911; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476; MacIver NJ, 2008, J LEUKOCYTE BIOL, V84, P949, DOI 10.1189/jlb.0108024; MacIver NJ, 2011, J IMMUNOL, V187, P4187, DOI 10.4049/jimmunol.1100367; MacLeod MKL, 2010, IMMUNOLOGY, V130, P10, DOI 10.1111/j.1365-2567.2010.03260.x; McKinstry KK, 2012, J CLIN INVEST, V122, P2847, DOI 10.1172/JCI63689; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Watt MJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE1315, DOI 10.1152/ajpendo.00561.2011; Younes SA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001171	26	9	9	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					342	349		10.1096/fj.12-217620	http://dx.doi.org/10.1096/fj.12-217620			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22972918	Green Published			2022-12-28	WOS:000313103200032
J	Wang, JF; Zurawski, TH; Meng, JH; Lawrence, GW; Aoki, KR; Wheeler, L; Dolly, JO				Wang, Jiafu; Zurawski, Tomas H.; Meng, Jianghui; Lawrence, Gary W.; Aoki, K. Roger; Wheeler, Larry; Dolly, J. Oliver			Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis	FASEB JOURNAL			English	Article						neuromuscular junction; neurotransmission; retrograde axonal transport; SNAREs; spinal cord	CENTRAL-NERVOUS-SYSTEM; BLOCK NEUROTRANSMITTER RELEASE; RETROGRADE AXONAL-TRANSPORT; CLOSTRIDIAL NEUROTOXINS; HIPPOCAMPAL-NEURONS; C-FRAGMENT; SEROTYPE-F; TOXIN-A; PROTEIN; BINDING	Botulinum neurotoxin (BoNT) A or E and tetanus toxin (TeTx) bind to motor-nerve endings and undergo distinct trafficking; their light-chain (LC) proteases cleave soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) peripherally or centrally and cause flaccid or spastic paralysis, respectively. To seek protein domains responsible for local blockade of transmitter release (BoNTs) rather than retroaxonal transport to spinal neurons (TeTx), their acceptor-binding moieties (H-C)-or in one case, heavy chain (HC)-were exchanged by gene recombination. Each chimera, expressed and purified from Escherichia coli, entered rat cerebellar neurons to cleave their substrates, blocked in vitro nerve-induced muscle contractions, and produced only flaccid paralysis in mice. Thus, the local cytosolic delivery of BoNT/A or BoNT/E proteases and the contrasting retrograde transport of TeTx are not specified solely by their HC or HC; BoNT/A LC translocated locally irrespective of being targeted by either of the latter TeTx domains. In contrast, BoNT/E protease fused to a TeTx enzymatically inactive mutant (TeTIM) caused spastic paralysis and cleaved SNAP-25 in spinal cord but not the injected muscle. Apparently, TeTIM precludes cytosolic release of BoNT/E protease at motor nerve endings. It is deduced that the LCs of the toxins, acting in conjunction with HC domains, dictate their local or distant destinations.-Wang, J., Zurawski, T. H., Meng, J., Lawrence, G. W., Aoki, K. R., Wheeler, L., Dolly, J. O. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J. 26, 5035-5048 (2012). www.fasebj.org	[Wang, Jiafu; Zurawski, Tomas H.; Meng, Jianghui; Lawrence, Gary W.; Dolly, J. Oliver] Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland; [Aoki, K. Roger; Wheeler, Larry] Allergan Pharmaceut Inc, Irvine, CA 92715 USA	Dublin City University; AbbVie; Allergan	Dolly, JO (corresponding author), Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland.	oliver.dolly@dcu.ie	Dolly, Oliver/G-1532-2012; Wang, Jiafu/AAX-9388-2020; Meng, Jianghui/H-4302-2014; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Wang, Jiafu/0000-0002-3654-4400; Dolly, Oliver/0000-0002-0861-5320; Meng, Jianghui/0000-0002-3107-4200	Science Foundation Ireland; Neuroscience section of the Programme for Research in Third Level Institutions (PRTLI); European Regional Development Fund (ERDF), European Union Structural Funds Programme	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Neuroscience section of the Programme for Research in Third Level Institutions (PRTLI); European Regional Development Fund (ERDF), European Union Structural Funds Programme	The authors thank Liam Ryan and Catherine Hagedorn for assistance with purifying the recombinant proteins and testing their activities in vivo. This work was supported by a PI award from Science Foundation Ireland, and the Neuroscience section of the Programme for Research in Third Level Institutions (PRTLI) Cycle 4. The PRTLI is cofunded through the European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme 2007-2013.	Antonucci F, 2008, J NEUROSCI, V28, P3689, DOI 10.1523/JNEUROSCI.0375-08.2008; Aoki KR, 2001, TOXICON, V39, P1815, DOI 10.1016/S0041-0101(01)00101-5; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; Blum FC, 2012, INFECT IMMUN, V80, P1662, DOI 10.1128/IAI.00057-12; Bohnert S, 2005, J BIOL CHEM, V280, P42336, DOI 10.1074/jbc.M506750200; Brunger AT, 2009, TOXICON, V54, P550, DOI 10.1016/j.toxicon.2008.12.027; Chaddock JA, 2002, PROTEIN EXPRES PURIF, V25, P219, DOI 10.1016/S1046-5928(02)00002-5; Chen C, 2009, J BIOL CHEM, V284, P26569, DOI 10.1074/jbc.M109.027391; Coen L, 1997, P NATL ACAD SCI USA, V94, P9400, DOI 10.1073/pnas.94.17.9400; Deinhardt K, 2006, NEURON, V52, P293, DOI 10.1016/j.neuron.2006.08.018; DEPAIVA A, 1993, J BIOL CHEM, V268, P20838; Dolly J. O., 1990, NEUROMUSCULAR TRANSM, P107; Dolly JO, 2009, CURR OPIN PHARMACOL, V9, P326, DOI 10.1016/j.coph.2009.03.004; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; Dong M, 2007, J CELL BIOL, V179, P1511, DOI 10.1083/jcb.200707184; Dong M, 2008, MOL BIOL CELL, V19, P5226, DOI 10.1091/mbc.E08-07-0765; FERNANDEZSALAS E, 2005, 5 INT C BAS THER ASP; Figueiredo DM, 1997, EXP NEUROL, V145, P546, DOI 10.1006/exnr.1997.6490; FISHMAN PS, 1990, J NEUROL SCI, V98, P311, DOI 10.1016/0022-510X(90)90272-O; Fishman PS, 1999, NAT TOXINS, V7, P151, DOI 10.1002/(SICI)1522-7189(199907/08)7:4<151::AID-NT51>3.3.CO;2-B; Foran PG, 2003, J BIOL CHEM, V278, P1363, DOI 10.1074/jbc.M209821200; FRANCIS JW, 1995, J BIOL CHEM, V270, P15434, DOI 10.1074/jbc.270.25.15434; Fu ZJ, 2009, BIOCHEMISTRY-US, V48, P5631, DOI 10.1021/bi9002138; Geny B, 2006, BIOL CELL, V98, P633, DOI 10.1042/BC20060038; HABERMANN E, 1980, N-S ARCH PHARMACOL, V311, P33, DOI 10.1007/BF00500299; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Kumaran D, 2009, J MOL BIOL, V386, P233, DOI 10.1016/j.jmb.2008.12.027; Lalli G, 2003, TRENDS MICROBIOL, V11, P431, DOI 10.1016/S0966-842X(03)00210-5; Li Y, 2001, J BIOL CHEM, V276, P31394, DOI 10.1074/jbc.M103517200; Mahrhold S, 2006, FEBS LETT, V580, P2011, DOI 10.1016/j.febslet.2006.02.074; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MATSUDA M, 1982, BIOCHEM BIOPH RES CO, V104, P799, DOI 10.1016/0006-291X(82)90708-2; Matteoli M, 1996, P NATL ACAD SCI USA, V93, P13310, DOI 10.1073/pnas.93.23.13310; MELLANBY J, 1968, J GEN MICROBIOL, V54, P161, DOI 10.1099/00221287-54-2-161; Montal M, 2010, ANNU REV BIOCHEM, V79, P591, DOI 10.1146/annurev.biochem.051908.125345; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Montecucco C, 2004, TRENDS MICROBIOL, V12, P442, DOI 10.1016/j.tim.2004.08.002; Morgan J. C., 2002, SCI THERAPEUTIC ASPE, P151; PARTON RG, 1987, J NEUROCHEM, V49, P1057; Peng LS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002008; PRICE DL, 1975, SCIENCE, V188, P945, DOI 10.1126/science.49080; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHWAB ME, 1979, J CELL BIOL, V82, P798, DOI 10.1083/jcb.82.3.798; SIMPSON LL, 1984, BRAIN RES, V305, P177, DOI 10.1016/0006-8993(84)91136-3; SIMPSON LL, 1985, J PHARMACOL EXP THER, V234, P100; SIMPSON LL, 1994, J PHARMACOL EXP THER, V269, P256; Sun SH, 2011, CELL HOST MICROBE, V10, P237, DOI 10.1016/j.chom.2011.06.012; Toivonen JM, 2010, TOXINS, V2, P2622, DOI 10.3390/toxins2112622; Verderio C, 1999, J NEUROCHEM, V73, P372, DOI 10.1046/j.1471-4159.1999.0730372.x; Verderio C, 2007, TRAFFIC, V8, P142, DOI 10.1111/j.1600-0854.2006.00520.x; Wang JF, 2008, J BIOL CHEM, V283, P16993, DOI 10.1074/jbc.M710442200; Wang JF, 2012, BIOCHEM J, V444, P59, DOI 10.1042/BJ20120100; Wang JF, 2011, J BIOL CHEM, V286, P6375, DOI 10.1074/jbc.M110.181784; Ward AB, 2007, CLINICAL USES OF BOTULINUM TOXINS, P1, DOI 10.1017/CBO9780511544842; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7; WILLIAMSON LC, 1994, J NEUROCHEM, V63, P2342; Yeh FL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001207	58	27	30	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5035	5048		10.1096/fj.12-210112	http://dx.doi.org/10.1096/fj.12-210112			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22942075				2022-12-28	WOS:000311838300025
J	Losfeld, ME; Soncin, F; Ng, BG; Singec, I; Freeze, HH				Losfeld, Marie-Estelle; Soncin, Francesca; Ng, Bobby G.; Singec, Ilyas; Freeze, Hudson H.			A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy	FASEB JOURNAL			English	Article						congenital disorders of glycosylation; stem cells; genetic disease	PLURIPOTENT STEM-CELLS; CONGENITAL DISORDERS; LINKED GLYCOSYLATION; SERUM TRANSFERRIN; GFP	N-glycosylation mediates many biological functions. Genetic defects in the N-glycosylation pathway cause > 35 inherited human disorders called congenital disorders of glycosylation (CDGs). As a result, some N-glycosylation sites are unoccupied. Serum transferrin is a diagnostic marker for these patients, but there are no corresponding cellular markers to assess glycosylation competence. Therefore, we engineered a green fluorescent protein (GFP) construct to measure N-glycosylation site occupancy. We designed an endoplasmic reticulum-retained GFP biomarker whose fluorescence is lost when it is N-glycosylated due to steric hindrance by the glycan. This marker is a highly sensitive indicator of N-glycosylation site occupancy. In CDG cells carrying the GFP construct, a 25% decrease of glycosylation efficiency induces a 5-fold increase in fluorescence, while cDNA complementation of the genetic defect results in a 5-fold decrease in fluorescence. This engineered GFP detects impaired N-glycosylation in multiple cell lines, including CHO cells, HeLa cells, normal and patient fibroblasts, induced pluripotent stem cells (iPSCs), and human embryonic stem cells (hESCs). This marker is a highly sensitive tool to study N-glycosylation site occupancy. It can be used to screen for compounds that reverse poor N-glycosylation site occupancy.-Losfeld, M.-E., Soncin, F., Ng, B. G., Singec, I., Freeze, H. H. A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy. FASEB J. 26, 4210-4217 (2012). www.fasebj.org	[Losfeld, Marie-Estelle; Soncin, Francesca; Ng, Bobby G.; Freeze, Hudson H.] Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA 92037 USA; [Singec, Ilyas] Sanford Burnham Med Res Inst, Neurosci Aging & Stem Cell Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Freeze, HH (corresponding author), Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@sanfordburnham.org	Soncin, Francesca/AAB-6143-2021	SINGEC, ILYAS/0000-0003-3941-1838; Freeze, Hudson/0000-0001-6316-0501	U.S. National Institutes of Health grant [R01DK 55615]; The Rocket Fund; Mason's Hope; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055615] Funding Source: NIH RePORTER	U.S. National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Rocket Fund; Mason's Hope; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grant R01DK 55615, The Rocket Fund, and Mason's Hope. The authors greatly appreciate the help of Dr. J. R. Bishop for bioinformatics approach. The authors thank Brandon Nelson, Shira Geller, and the Sanford-Burnham Medical Research Institute (SBMRI) Stem Cell Core Facility for technical and material support on the hESC/iPSC work. The authors thank Dr. Anne Bang of the Conrad Prebys Center for Chemical Genomics/ Screening Center (SBMRI) for guidance on the iPSC work. The authors thank Drs. Geetha Srikrishna and Ping He for providing constructive comments on the manuscript.	CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Contessa JN, 2010, CLIN CANCER RES, V16, P3205, DOI 10.1158/1078-0432.CCR-09-3331; Eklund EA, 2005, GLYCOBIOLOGY, V15, P1084, DOI 10.1093/glycob/cwj006; Eklund Erik A, 2006, NeuroRx, V3, P254; Freeze HH, 2007, CURR MOL MED, V7, P389, DOI 10.2174/156652407780831548; Goh YY, 2002, PROTEIN ENG, V15, P493, DOI 10.1093/protein/15.6.493; Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577; Haeuptle MA, 2009, HUM MUTAT, V30, P1628, DOI 10.1002/humu.21126; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hendriksz CJ, 2001, ARCH DIS CHILD, V85, P339, DOI 10.1136/adc.85.4.339; Jaeken J, 2010, ANN NY ACAD SCI, V1214, P190, DOI 10.1111/j.1749-6632.2010.05840.x; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Marklova E, 2007, CLIN CHIM ACTA, V385, P6, DOI 10.1016/j.cca.2007.07.002; Nishikawa A, 2001, BIOCHEM J, V355, P245, DOI 10.1042/0264-6021:3550245; Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231; Peanne R, 2011, GLYCOBIOLOGY, V21, P864, DOI 10.1093/glycob/cwq176; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Rashid ST, 2010, J CLIN INVEST, V120, P3127, DOI 10.1172/JCI43122; Richmond TA, 2000, BIOCHEM BIOPH RES CO, V268, P462, DOI 10.1006/bbrc.1999.1244; Sharma V, 2011, J BIOL CHEM, V286, P39431, DOI 10.1074/jbc.M111.285502; STIBLER H, 1990, ARCH DIS CHILD, V65, P107, DOI 10.1136/adc.65.1.107; Sun LW, 2005, AM J MED GENET A, V137A, P22, DOI 10.1002/ajmg.a.30831; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; WADA Y, 1992, BIOCHEM BIOPH RES CO, V189, P832, DOI 10.1016/0006-291X(92)92278-6; Wolff M, 2008, COMB CHEM HIGH T SCR, V11, P602, DOI 10.2174/138620708785739880; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zimmer M, 2002, CHEM REV, V102, P759, DOI 10.1021/cr010142r	28	22	24	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4210	4217		10.1096/fj.12-211656	http://dx.doi.org/10.1096/fj.12-211656			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22691915	Green Published			2022-12-28	WOS:000309704000026
J	Schuler, B; Vogel, J; Grenacher, B; Jacobs, RA; Arras, M; Gassmann, M				Schuler, Beat; Vogel, Johannes; Grenacher, Beat; Jacobs, Robert A.; Arras, Margarete; Gassmann, Max			Acute and chronic elevation of erythropoietin in the brain improves exercise performance in mice without inducing erythropoiesis	FASEB JOURNAL			English	Article						Epo; cerebral; doping; neurotrophic effect; motivation	MAXIMAL OXYGEN-UPTAKE; OVEREXPRESSING ERYTHROPOIETIN; EXCESSIVE ERYTHROCYTOSIS; HIPPOCAMPAL RESPONSE; HYPOXIC VENTILATION; MEMORY RETRIEVAL; GENE-EXPRESSION; TRANSGENIC MICE; NERVOUS-SYSTEM; MOUSE	Application of recombinant human erythropoietin (rhEpo) improves exercise capacity by stimulating red blood cell production that, in turn, enhances oxygen delivery and utilization. Apart from this, when applied at high doses, rhEpo crosses the blood-brain barrier, triggering protective neuronal effects. Here we show a fundamental new role by which the presence of Epo in the brain augments exercise performance without altering red blood cell production. Two different animal models, the transgenic mouse line Tg21, which constitutively overexpresses human Epo exclusively in the brain without affecting erythropoiesis, and wild-type mice treated with a single high dose of rhEpo, demonstrate an unexpected improvement in maximal exercise performance independent of changes in total hemoglobin mass, as well as in whole blood volume and cardiovascular parameters. This novel finding builds a more complete understanding regarding the central effects of endogenously produced and exogenously applied Epo on exercise performance.-Schuler, B., Vogel, J., Grenacher, B., Jacobs, R. A., Arras, M., Gassmann, M. Acute and chronic elevation of erythropoietin in the brain improves exercise performance in mice without inducing erythropoiesis. FASEB J. 26, 3884-3890 (2012). www.fasebj.org	[Gassmann, Max] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, DVM, CH-8057 Zurich, Switzerland; [Schuler, Beat; Vogel, Johannes; Grenacher, Beat; Jacobs, Robert A.; Gassmann, Max] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Arras, Margarete] Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; [Arras, Margarete] Univ Zurich Hosp, Div Surg Res, CH-8091 Zurich, Switzerland; [Gassmann, Max] Univ Peruana Cayetano Heredia, Lima, Peru	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University of Zurich; University Zurich Hospital; Universidad Peruana Cayetano Heredia	Gassmann, M (corresponding author), Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, DVM, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	maxg@access.uzh.ch	Jacobs, Robert A/G-8439-2015	Jacobs, Robert A/0000-0003-0180-8266; Gassmann, Max/0000-0003-2750-8878; Vogel, Johannes/0000-0003-4181-4521; Arras, Margarete/0000-0003-3864-9879	Nachwuchsforderungskredit (University of Zurich); Zurich Center for Integrative Human Physiology (ZIHP); Swiss National Science Foundation; Roche Foundation for Anemic Research (RoFAR)	Nachwuchsforderungskredit (University of Zurich); Zurich Center for Integrative Human Physiology (ZIHP); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Roche Foundation for Anemic Research (RoFAR)	The authors thank Mar a Alvarez Sanchez, Cornelia Albrecht, and Mirzet Delic, as well as Prof. Kurt Burki and Prof. Carsten Lundby, for technical assistance and discussion, respectively. This work was supported by the Nachwuchsforderungskredit (University of Zurich), the Zurich Center for Integrative Human Physiology (ZIHP), including the help of the Zurich Integrative Rodent Physiology (ZIRP) facility, the Swiss National Science Foundation, and the Roche Foundation for Anemic Research (RoFAR).	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Astorino TA, 2005, BRIT J SPORT MED, V39, P655, DOI 10.1136/bjsm.2004.016550; Bassett DR, 1997, MED SCI SPORT EXER, V29, P591, DOI 10.1097/00005768-199705000-00002; BERGLUND B, 1991, J INTERN MED, V229, P125, DOI 10.1111/j.1365-2796.1991.tb00319.x; BLOMSTRAND E, 1989, ACTA PHYSIOL SCAND, V136, P473, DOI 10.1111/j.1748-1716.1989.tb08689.x; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Crisafulli A, 2007, PHYSIOL MEAS, V28, P1201, DOI 10.1088/0967-3334/28/10/006; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Duncan GE, 1997, MED SCI SPORT EXER, V29, P273, DOI 10.1097/00005768-199702000-00017; Ehrenreich H, 2004, METAB BRAIN DIS, V19, P195, DOI 10.1023/B:MEBR.0000043969.96895.3c; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; El-Kordi A, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-37; Fleg JL, 2000, CIRCULATION, V102, P1591, DOI 10.1161/01.CIR.102.13.1591; FOLINSBEE LJ, 1983, MED SCI SPORT EXER, V15, P503; Frietsch T, 2007, J CEREBR BLOOD F MET, V27, P469, DOI 10.1038/sj.jcbfm.9600360; Fueger PT, 2005, J PHYSIOL-LONDON, V566, P533, DOI 10.1113/jphysiol.2005.085043; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Glaus TM, 2004, COMP BIOCHEM PHYS A, V138, P355, DOI 10.1016/j.cbpb.2004.05.008; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hale T, 2008, J SPORT SCI, V26, P365, DOI 10.1080/02640410701701016; Heinicke K, 2006, AM J PHYSIOL-REG I, V291, pR947, DOI 10.1152/ajpregu.00152.2006; Jelkmann W, 2007, METHOD ENZYMOL, V435, P179, DOI 10.1016/S0076-6879(07)35010-6; KANSTRUP IL, 1984, MED SCI SPORT EXER, V16, P256; Kayser B, 2003, EUR J APPL PHYSIOL, V90, P411, DOI 10.1007/s00421-003-0902-7; Leite LHR, 2010, MED SCI SPORT EXER, V42, P1469, DOI 10.1249/MSS.0b013e3181d03d36; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Meeusen R, 2007, APPL PHYSIOL NUTR ME, V32, P857, DOI 10.1139/H07-080; Miskowiak K, 2008, NEUROPSYCHOPHARMACOL, V33, P611, DOI 10.1038/sj.npp.1301439; Miskowiak K, 2007, PSYCHOPHARMACOLOGY, V195, P451, DOI 10.1007/s00213-007-0907-8; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Ninot G, 2006, J SPORT SCI, V24, P383, DOI 10.1080/02640410500131340; Nybo L, 2004, PROG NEUROBIOL, V72, P223, DOI 10.1016/j.pneurobio.2004.03.005; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Rasmussen P, 2010, J APPL PHYSIOL, V109, P476, DOI 10.1152/japplphysiol.00234.2010; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Schuler B, 2010, P NATL ACAD SCI USA, V107, P419, DOI 10.1073/pnas.0912924107; Schuler B, 2009, BMC VET RES, V5, DOI 10.1186/1746-6148-5-28; Siren AL, 2009, NEUROTHERAPEUTICS, V6, P108, DOI 10.1016/j.nurt.2008.10.041; Soliz J, 2005, J PHYSIOL-LONDON, V568, P559, DOI 10.1113/jphysiol.2005.093328; Soliz J, 2009, AM J PHYSIOL-REG I, V296, pR1837, DOI 10.1152/ajpregu.90967.2008; Taylor JL, 2000, J APPL PHYSIOL, V89, P305, DOI 10.1152/jappl.2000.89.1.305; Teng RF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1526; Vogel J, 2003, BLOOD, V102, P2278, DOI 10.1182/blood-2003-01-0283; Vogel J, 2011, J PHYSIOL-LONDON, V589, P1259, DOI 10.1113/jphysiol.2010.196147; Wenger RH, 2011, COMPR PHYSIOL, V1, P1759, DOI 10.1002/cphy.c100075; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011; Wustenberg T, 2011, MOL PSYCHIATR, V16, P26, DOI 10.1038/mp.2010.51	49	24	25	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3884	3890		10.1096/fj.11-191197	http://dx.doi.org/10.1096/fj.11-191197			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22683849	Green Accepted			2022-12-28	WOS:000308391600028
J	Vianello, S; Yu, H; Voisin, V; Haddad, H; He, X; Foutz, AS; Sebrie, C; Gillet, B; Roulot, M; Fougerousse, F; Perronnet, C; Vaillend, C; Matecki, S; Escolar, D; Bossi, L; Israel, M; de la Porte, S				Vianello, Sara; Yu, Hua; Voisin, Vincent; Haddad, Hafedh; He, Xun; Foutz, Arthur S.; Sebrie, Catherine; Gillet, Brigitte; Roulot, Morgane; Fougerousse, Francoise; Perronnet, Caroline; Vaillend, Cyrille; Matecki, Stefan; Escolar, Diana; Bossi, Laura; Israel, Maurice; de la Porte, Sabine			Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						DMD; mdx; pharmacology; treatment; NO; histone deacetylase	DEFICIENT SKELETAL-MUSCLE; GLOBIN GENE-EXPRESSION; NITRIC-OXIDE; MDX MICE; BETA-HEMOGLOBINOPATHIES; SATELLITE CELLS; UTROPHIN TRANSGENE; REGENERATION; DYSTROPHINOPATHIES; LOCALIZATION	As a strategy to treat Duchenne muscular dystrophy, we used arginine butyrate, which combines two pharmacological activities: nitric oxide pathway activation, and histone deacetylase inhibition. Continuous intraperitoneal administration to dystrophin-deficient mdx mice resulted in a near 2-fold increase in utrophin (protein homologous to dystrophin) in skeletal muscle, heart, and brain, accompanied by an improvement of the dystrophic phenotype in both adult and newborn mice (45 and 70% decrease in creatine kinase level, respectively; 14% increase in tidal volume, 30% decrease in necrotic area in limb and 23% increase in isometric force). Intermittent administration, as performed in clinical trials, was then used to reduce the frequency of injections and to improve safety. This also enhanced utrophin level around 2-fold (EC50 = 284 mg/ml) and alleviated the dystrophic phenotype (inverted grid and grip test performance near to wild-type values, creatine kinase level decreased by 50%). Skin biopsies were used to monitor treatment efficacy, instead of invasive muscle biopsies, and this could be done a few days after the start of treatment. A 2-fold increase in utrophin expression was also shown in cultured human myotubes. In vivo and in vitro experiments demonstrated that the drug combination acts synergistically. Together, these data constitute a proof of principle of the beneficial effects of arginine butyrate on muscular dystrophy.-Vianello, S., Yu, H., Voisin, V., Haddad, H., He, X., Foutz, A. S., Sebrie, C., Gillet, B., Roulot, M., Fougerousse, F., Perronnet, C., Vaillend, C., Matecki, S., Escolar, D., Bossi, L., Israel, M., de la Porte, S. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.	[Vianello, Sara; Yu, Hua; Voisin, Vincent; Haddad, Hafedh; He, Xun; Roulot, Morgane; Israel, Maurice; de la Porte, Sabine] Inst Neurobiol Alfred Fessard, FRC2118, CNRS, UPR Neurobiol & Dev 3294, Gif Sur Yvette, France; [Foutz, Arthur S.] Inst Neurobiol Alfred Fessard, FRC2118, CNRS, UPR Neurobiol Genet & Integrat 2216, Gif Sur Yvette, France; [Sebrie, Catherine; Gillet, Brigitte] Inst Chim Subst Nat Resonance Magnet Nucl RMN Bio, CNRS, Gif Sur Yvette, France; [Fougerousse, Francoise] Genethon, Evry, France; [Perronnet, Caroline; Vaillend, Cyrille] Univ Paris 11, Ctr Neurosci Paris Sud, Orsay, France; [Perronnet, Caroline; Vaillend, Cyrille] CNRS, UMR 8195, F-91405 Orsay, France; [Matecki, Stefan] Univ Montpellier, INSERM, ERI, Ctr Hosp Univ CHU A Villeneuve, F-34059 Montpellier, France; [Escolar, Diana] Johns Hopkins Sch Med, Baltimore, MD USA; [Bossi, Laura] BioParc, Domain Therapeut, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite Jean Monnet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Johns Hopkins University; Johns Hopkins Medicine	de la Porte, S (corresponding author), CNRS, Inst Neurobiol Alfred Fessard Neurobiol & Dev, UPR 3294, Ave Terrasse,Bat 32-33, F-91198 Gif Sur Yvette, France.	sabine.delaporte@inaf.cnrs-gif.fr	de la PORTE, Sabine/AAE-4208-2022; Vaillend, Cyrille/K-4626-2012; de la Porte, Sabine/N-5275-2018	de la PORTE, Sabine/0000-0002-7725-8646; Vaillend, Cyrille/0000-0002-8783-8185; 	European Community [QLRI-CT-2002-02769]; Association Francaise contre les Myopathies [2004.001/10689, 2007.1563/12507, 2008.0797/13466]; Muscular Dystrophy Association [MDA3561, MDA4078]	European Community(European Commission); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Muscular Dystrophy Association(Muscular Dystrophy Association)	The authors thank Francesca Consolaro for technical assistance for the experiments on the chromatin acetylation state. The authors thank the French Banque de Tissus pour la Recherche (BTR; Institut de Myologie) for providing surgical residues of human paravertebral striated muscles. BTR is a partner of the EuroBioBank network funded by the European Community under the Fifth Framework Program (QLRI-CT-2002-02769). The authors thank M. Bonora (Paris) for help with the respiration protocols and the Imagif qPCR platform. This work was supported by the Association Francaise contre les Myopathies (2004.001/10689, 2007.1563/12507, 2008.0797/13466); and the Muscular Dystrophy Association (MDA3561, MDA4078). The authors declare no conflicts of interest.	Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Anderson JE, 2003, NEUROMUSCULAR DISORD, V13, P388, DOI 10.1016/S0960-8966(03)00029-4; Anderson JL, 2002, BRAIN, V125, P4, DOI 10.1093/brain/awf012; Archer JD, 2006, FASEB J, V20, P738, DOI 10.1096/fj.05-4821fje; Baby SM, 2010, BRAIN PATHOL, V20, P323, DOI 10.1111/j.1750-3639.2009.00275.x; Barton ER, 2005, MUSCLE NERVE, V32, P751, DOI 10.1002/mus.20425; Benabdellah F, 2009, NEUROBIOL DIS, V36, P252, DOI 10.1016/j.nbd.2009.07.013; Bia BL, 1999, J MOL CELL CARDIOL, V31, P1857, DOI 10.1006/jmcc.1999.1018; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Chaubourt E, 1999, NEUROBIOL DIS, V6, P499, DOI 10.1006/nbdi.1999.0256; Chaubourt E, 2002, J PHYSIOLOGY-PARIS, V96, P43, DOI 10.1016/S0928-4257(01)00079-1; Chazalette D, 2005, FEBS LETT, V579, P1079, DOI 10.1016/j.febslet.2004.12.081; Colussi C, 2009, FASEB J, V23, P2131, DOI 10.1096/fj.08-115618; EDOM F, 1994, DEV BIOL, V164, P219, DOI 10.1006/dbio.1994.1193; Fairclough RJ, 2011, EXP PHYSIOL, V96, P1101, DOI 10.1113/expphysiol.2010.053025; Faller D V, 1995, Curr Opin Hematol, V2, P109; Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446; Fisher R, 2001, NEUROMUSCULAR DISORD, V11, P713, DOI 10.1016/S0960-8966(01)00220-6; Guerron AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011220; Guilhermet R. G., 1996, Productions Animales (Paris), V9, P265; Gurpur PB, 2009, AM J PATHOL, V174, P999, DOI 10.2353/ajpath.2009.080537; Hnia K, 2008, AM J PATHOL, V172, P1509, DOI 10.2353/ajpath.2008.071009; Hoey A. J., 2006, P AUSTR PHYSL SOC, V37, P57; Ishikawa K, 1997, JPN HEART J, V38, P163; Jeng MR, 2002, AM J HEMATOL, V69, P103, DOI 10.1002/ajh.10047; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; Marbini A, 1996, J NEUROL SCI, V143, P156, DOI 10.1016/S0022-510X(96)00210-9; Marques MJ, 2005, NEUROSCI LETT, V382, P342, DOI 10.1016/j.neulet.2005.03.023; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Nico B, 2004, NEUROSCIENCE, V125, P921, DOI 10.1016/j.neuroscience.2004.02.008; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1993, EXPERIENTIA, V49, P133, DOI 10.1007/BF01989417; PERRINE SP, 1994, AM J PEDIAT HEMATOL, V16, P67; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Perrine SP, 2008, PEDIATR ANN, V37, P339, DOI 10.3928/00904481-20080501-10; Perronnet C, 2012, HUM MOL GENET, V21, P2263, DOI 10.1093/hmg/dds047; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Salimena M, 2004, HISTOCHEM CELL BIOL, V122, P435, DOI 10.1007/s00418-004-0707-8; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Segalat L, 2005, EXP CELL RES, V302, P170, DOI 10.1016/j.yexcr.2004.09.007; SHER GD, 1995, NEW ENGL J MED, V332, P1606, DOI 10.1056/NEJM199506153322404; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tanveer N, 2009, CLIN NEUROL NEUROSUR, V111, P496, DOI 10.1016/j.clineuro.2009.01.011; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Voisin V, 2004, INT REV CYTOL, V240, P1, DOI 10.1016/S0074-7696(04)40001-1; Voisin V, 2005, NEUROBIOL DIS, V20, P123, DOI 10.1016/j.nbd.2005.02.010	51	19	19	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2256	2269		10.1096/fj.12-215723	http://dx.doi.org/10.1096/fj.12-215723			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430975	Green Submitted, Bronze			2022-12-28	WOS:000319667600016
J	Hu, LYR; Kontrogianni-Konstantopoulos, A				Hu, Li-Yen R.; Kontrogianni-Konstantopoulos, Aikaterini			The kinase domains of obscurin interact with intercellular adhesion proteins	FASEB JOURNAL			English	Article						myosin light chain; N-cadherin; sodium-potassium ATPase	UNC-89 OBSCURIN; GENE; ISOFORM; FAMILY; MLCK; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION; INVOLVEMENT; EXPRESSION	Obscurins comprise a family of giant (similar to 870- to 600-kDa) and small (similar to 250- to 55-kDa) proteins that play important roles in myofibrillogenesis, cytoskeletal organization, and cell adhesion and are implicated in hypertrophic cardiomyopathy and tumorigenesis. Giant obscurins are composed of tandem structural and signaling motifs, including 2 serine/threonine kinase domains, SK1 and SK2, present at the COOH terminus of giant obscurin-B. Using biochemical and cellular approaches, we show for the first time that both SK1 and SK2 possess enzymatic activities and undergo autophosphorylation. SK2 can phosphorylate the cytoplasmic domain of N-cadherin, a major component of adherens junctions, and SK1 can interact with the extracellular domain of the beta(1)-subunit of the Na+/K+-ATPase, which also resides in adherens junctions. Immunostaining of nonpermeabilized myofibers and cardiocytes revealed that some obscurin kinase isoforms localize extracellularly. Quantification of the exofacial expression of obscurin kinase proteins indicated that they occupy similar to 16 and similar to 5% of the sarcolemmal surface in myofibers and cardiocytes, respectively. Treatment of heart lysates with peptide-N-glycosidase F revealed that while giant obscurin-B localizes intracellularly, possessing dual kinase activity, a small obscurin kinase isoform that contains SK1 localizes extracellularly, where it undergoes N-glycosylation. Collectively, our studies demonstrate that the obscurin kinase domains are enzymatically active and may be involved in the regulation of cell adhesion.	[Hu, Li-Yen R.; Kontrogianni-Konstantopoulos, Aikaterini] Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.	akons001@umaryland.edu			U.S. National Institutes of Health [5T32GM08181-23, 2T32AR7592-16]; American Heart Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. J. W. Lederer, B. Prosser, and M. Bamgboye (University of Maryland) for providing the primary cultures of adult mouse cardiocytes. This work was supported by U.S. National Institutes of Health training grants 5T32GM08181-23 and 2T32AR7592-16 (L.-Y.R.H.) and the American Heart Association (A.K.K.).	Ackermann MA, 2009, MOL BIOL CELL, V20, P2963, DOI 10.1091/mbc.E08-12-1251; Borisov AB, 2003, BIOCHEM BIOPH RES CO, V310, P910, DOI 10.1016/j.bbrc.2003.09.035; Borisov AB, 2008, J CELL BIOCHEM, V103, P1621, DOI 10.1002/jcb.21551; Bowman AL, 2007, FEBS LETT, V581, P1549, DOI 10.1016/j.febslet.2007.03.011; Carlsson L, 2008, HISTOCHEM CELL BIOL, V130, P91, DOI 10.1007/s00418-008-0413-z; Ding PG, 2010, J BIOL CHEM, V285, P40819, DOI 10.1074/jbc.M110.160499; Fukuzawa A, 2005, J MUSCLE RES CELL M, V26, P427, DOI 10.1007/s10974-005-9025-6; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hsieh CM, 2000, J BIOL CHEM, V275, P36966, DOI 10.1074/jbc.M006028200; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Kamm KE, 2011, J BIOL CHEM, V286, P9941, DOI 10.1074/jbc.R110.198697; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kontrogianni-Konstantopoulos A, 2006, FASEB J, V20, P2102, DOI 10.1096/fj.06-5761com; Kontrogianni-Konstantopoulos A, 2009, PHYSIOL REV, V89, P1217, DOI 10.1152/physrev.00017.2009; Lange S, 2009, J CELL SCI, V122, P2640, DOI 10.1242/jcs.046193; Liu XL, 2009, CIRCULATION, V119, P261, DOI 10.1161/CIRCULATIONAHA.108.799536; McDonough AA, 1996, AM J PHYSIOL-CELL PH, V270, pC1221, DOI 10.1152/ajpcell.1996.270.4.C1221; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Perry NA, 2012, FASEB J, V26, P2764, DOI 10.1096/fj.12-205419; Prosser BL, 2011, SCIENCE, V333, P1440, DOI 10.1126/science.1202768; Qadota H, 2008, MOL BIOL CELL, V19, P2424, DOI 10.1091/mbc.E08-01-0053; Qadota H, 2007, MOL BIOL CELL, V18, P4317, DOI 10.1091/mbc.E07-03-0278; Qi JF, 2006, MOL BIOL CELL, V17, P1261, DOI 10.1091/mbc.E05-10-0927; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Small TM, 2004, J MOL BIOL, V342, P91, DOI 10.1016/j.jmb.2004.07.006; Spooner PM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040182; Sutter SB, 2004, DEV GENES EVOL, V214, P352, DOI 10.1007/s00427-004-0413-5; Tokhtaeva E, 2012, J CELL SCI, V125, P1605, DOI 10.1242/jcs.100149; Vagin O, 2012, AM J PHYSIOL-CELL PH, V302, pC1271, DOI 10.1152/ajpcell.00456.2011; Weinert S, 2006, J CELL BIOL, V173, P559, DOI 10.1083/jcb.200601014; Xiong G, 2009, J MOL BIOL, V386, P976, DOI 10.1016/j.jmb.2009.01.016	32	30	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2001	2012		10.1096/fj.12-221317	http://dx.doi.org/10.1096/fj.12-221317			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23392350	Green Published			2022-12-28	WOS:000318226100020
J	Sakai, N; Chun, J; Duffield, JS; Wada, T; Luster, AD; Tager, AM				Sakai, Norihiko; Chun, Jerold; Duffield, Jeremy S.; Wada, Takashi; Luster, Andrew D.; Tager, Andrew M.			LPA(1)-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation	FASEB JOURNAL			English	Article						lysophosphatidic acid; Rho GTPases; myocardin-related transcription factor-A; myocardin-related transcription factor-B; serum response factor	TISSUE GROWTH-FACTOR; ENCAPSULATING PERITONEAL SCLEROSIS; TGF-BETA ACTIVATION; PULMONARY-FIBROSIS; MESOTHELIAL CELLS; DIALYSIS PATIENTS; GENE-EXPRESSION; ACTIN DYNAMICS; LUNG FIBROSIS; C-FOS	There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA(1), in fibrotic diseases, but the mechanisms by which LPA-LPA(1) signaling promotes pathological fibrosis remain to be fully elucidated. Using a mouse peritoneal fibrosis model, we demonstrate central roles for LPA and LPA(1) in fibroblast proliferation. Genetic deletion or pharmacological antagonism of LPA(1) protected mice from peritoneal fibrosis, blunting the increases in peritoneal collagen by 65.4 and 52.9%, respectively, compared to control animals and demonstrated that peritoneal fibroblast proliferation was highly LPA(1) dependent. Activation of LPA1 on mesothelial cells induced these cells to express connective tissue growth factor (CTGF), driving fibroblast proliferation in a paracrine fashion. Activation of mesothelial cell LPA(1) induced CTGF expression by inducing cytoskeleton reorganization in these cells, causing nuclear translocation of myocardin-related transcription factor (MRTF)-A and MRTF-B. Pharmacological inhibition of MRTF-induced transcription also diminished CTGF expression and fibrosis in the peritoneal fibrosis model, mitigating the increase in peritoneal collagen content by 57.9% compared to controls. LPA(1)-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA(1)-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 27, 1830-1846 (2013). www.fasebj.org	[Sakai, Norihiko; Luster, Andrew D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA; [Sakai, Norihiko; Luster, Andrew D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA; [Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA USA; [Chun, Jerold] Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, La Jolla, CA 92037 USA; [Duffield, Jeremy S.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA; [Duffield, Jeremy S.] Univ Washington, Ctr Lung Biol, Seattle, WA 98195 USA; [Duffield, Jeremy S.] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA; [Wada, Takashi] Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Div Nephrol,Dept Lab Med, Kanazawa, Ishikawa, Japan	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Scripps Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kanazawa University	Tager, AM (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St,Rm 8301, Charlestown, MA 02129 USA.	amtager@partners.org	Chun, Jerold/Y-4670-2019; Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	U.S. National Institutes of Health (NIH) [R01-HL095732, R01-HL108975]; Scleroderma Research Foundation; Pulmonary Fibrosis Foundation; Coalition for Pulmonary Fibrosis; Nirenberg Center for Advanced Lung Disease; Japan Society for the Promotion of Science (JSPS) Excellent Young Researcher Overseas Visit Program; NIH [R01-MH051699, R01-DA019674]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108975, R01HL095732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093493, P30DK043351, R01DK084077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019674] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scleroderma Research Foundation; Pulmonary Fibrosis Foundation; Coalition for Pulmonary Fibrosis; Nirenberg Center for Advanced Lung Disease; Japan Society for the Promotion of Science (JSPS) Excellent Young Researcher Overseas Visit Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors gratefully acknowledge support from U.S. National Institutes of Health (NIH) grants R01-HL095732 and R01-HL108975, and Scleroderma Research Foundation, Pulmonary Fibrosis Foundation, Coalition for Pulmonary Fibrosis, and Nirenberg Center for Advanced Lung Disease grants to A.M.T, the Japan Society for the Promotion of Science (JSPS) Excellent Young Researcher Overseas Visit Program to N.S., and NIH grants R01-MH051699 and R01-DA019674 to J.C. The authors also thank B. A. Fontaine for his expert assistance, and Amira Pharmaceuticals (San Diego, CA, USA) for the kind gift of AM095. The authors declare no conflicts of interest.	Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Bansal Saurabh, 2010, Adv Perit Dial, V26, P75; Cabello-Verrugio C, 2011, CELL SIGNAL, V23, P449, DOI 10.1016/j.cellsig.2010.10.019; Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Contos J.J., 2000, MOL PHARM, V58, P13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Deng XL, 2008, MOL BIOL CELL, V19, P2520, DOI 10.1091/mbc.E07-07-0720; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Gan L, 2011, BIOCHEM BIOPH RES CO, V409, P7, DOI 10.1016/j.bbrc.2011.04.084; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 2005, FASEB J, V19, P729, DOI 10.1096/fj.04-3217com; Heusinger-Ribeiro J, 2001, J AM SOC NEPHROL, V12, P1853, DOI 10.1681/ASN.V1291853; Higuchi C, 2006, THER APHER DIAL, V10, P372, DOI 10.1111/j.1744-9987.2006.00391.x; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; HJELLE JT, 1989, PERITON DIALYSIS INT, V9, P341; Hoyles RK, 2011, AM J RESP CRIT CARE, V183, P249, DOI 10.1164/rccm.201002-0279OC; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Kawaguchi Y, 2000, PERITON DIALYSIS INT, V20, pS43; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; Leask A, 2009, J CELL COMMUN SIGNAL, V3, P89, DOI 10.1007/s12079-009-0037-7; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; Liu SX, 2011, ARTHRITIS RHEUM-US, V63, P239, DOI 10.1002/art.30074; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mizutani M, 2010, AM J PHYSIOL-RENAL, V298, pF721, DOI 10.1152/ajprenal.00368.2009; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Muehlich S, 2007, AM J PHYSIOL-CELL PH, V292, pC1732, DOI 10.1152/ajpcell.00552.2006; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Rigby RJ, 1998, NEPHROL DIAL TRANSPL, V13, P154, DOI 10.1093/ndt/13.1.154; Sawada T, 2002, PHARMACOL RES, V46, P505, DOI 10.1016/S1043661802002281; Scotton CJ, 2007, CHEST, V132, P1311, DOI 10.1378/chest.06-2568; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200; Small EM, 2010, CIRC RES, V107, P294, DOI 10.1161/CIRCRESAHA.110.223172; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Swaney JS, 2011, J PHARMACOL EXP THER, V336, P693, DOI 10.1124/jpet.110.175901; Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Tatter AL, 2011, J IMMUNOL, V187, P6094, DOI 10.4049/jimmunol.1003507; van der Wal JBC, 2007, COLORECTAL DIS, V9, P9, DOI 10.1111/j.1463-1318.2007.01345.x; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Watanabe N, 2007, LIFE SCI, V81, P1009, DOI 10.1016/j.lfs.2007.08.013; Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160; Yoshio Y, 2004, KIDNEY INT, V66, P1677, DOI 10.1111/j.1523-1755.2004.00935.x; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yung S, 2006, PERITON DIALYSIS INT, V26, P162	53	108	110	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1830	1846		10.1096/fj.12-219378	http://dx.doi.org/10.1096/fj.12-219378			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23322166	Green Published			2022-12-28	WOS:000318226100004
J	Jones, DR; Foulger, R; Keune, WJ; Bultsma, Y; Divecha, N				Jones, David R.; Foulger, Rebecca; Keune, Willem-Jan; Bultsma, Yvette; Divecha, Nullin			PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation	FASEB JOURNAL			English	Article						phosphoinositide; phosphatidylinositol-5-phosphate kinase; lipid kinase	PHOSPHATIDYLINOSITOL 5-PHOSPHATE; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; MAMMALIAN-CELLS; LIPID KINASE; IN-VIVO; PIKFYVE; INSULIN; IDENTIFICATION	Oxidative stress initiates signaling pathways, which protect from stress-induced cellular damage, initiate apoptosis, or drive cells into senescence or into tumorigenesis. Oxidative stress regulates the activity of the cell survival factor PKB, through the regulation of PtdIns(3,4,5)P-3 synthesis. Whether oxidative stress regulates other phosphoinositides to control PKB activation is not clear. Here we show that PtdIns5P is a redox-regulated second messenger. In response to hydrogen peroxide (H2O2), we measured an increase in PtdIns5P in cells derived from human osteosarcoma, U2OS (5-fold); breast tumors, MDA-MB-468 (2-fold); and fibrosarcoma, HT1080 (3-fold); and in p53-null murine embryonic fibroblasts (8-fold). In U2OS cells, the increase in H2O2-dependent PtdIns5P did not require mTOR, PDK1, PKB, ERK, and p38 signaling or PIKfyve, a lipid kinase that increases PtdIns5P in response to osmotic and oncogenic signaling. A reduction in H2O2-induced PtdIns5P levels by the overexpression of PIP4K revealed its role in PKB activation. Suppression of H2O2-induced PtdIns5P generation reduced PKB activation and, surprisingly, reduced cell sensitivity to growth inhibition by H2O2. These data suggest that inhibition of PIP4K signaling might be useful as a novel strategy to increase the susceptibility of tumor cells to therapeutics that function through increased oxidative stress.-Jones, D. R., Foulger, R., Keune, W.-J., Bultsma, Y., Divecha, N. PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation. FASEB J. 27, 1644-1656 (2013). www.fasebj.org	[Jones, David R.; Foulger, Rebecca; Keune, Willem-Jan; Bultsma, Yvette; Divecha, Nullin] Univ Manchester, Paterson Inst Canc Res, Canc Res UK Inositide Lab, Manchester M20 4BX, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Divecha, N (corresponding author), Univ Manchester, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	ndivecha@picr.man.ac.uk		Keune, Willem-Jan/0000-0001-6607-5898; divecha, nullin/0000-0001-9695-6039	Cancer Research UK	Cancer Research UK(Cancer Research UK)	The authors acknowledge Cancer Research UK for funding. The authors thank members of the Inositide Laboratory for technical support and suggestions.	Bultsma Y, 2010, BIOCHEM J, V430, P223, DOI 10.1042/BJ20100341; Carricaburu V, 2003, P NATL ACAD SCI USA, V100, P9867, DOI 10.1073/pnas.1734038100; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Coronas S, 2008, BIOCHEM BIOPH RES CO, V372, P351, DOI 10.1016/j.bbrc.2008.05.062; Ding Y, 2012, PLANT J, V70, P866, DOI 10.1111/j.1365-313X.2012.04936.x; Falasca M, 2012, BIOCHEM J, V443, P587, DOI 10.1042/BJ20120008; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Grainger DL, 2011, PFLUG ARCH EUR J PHY, V462, P723, DOI 10.1007/s00424-011-1008-4; Guittard G, 2009, J IMMUNOL, V182, P3974, DOI 10.4049/jimmunol.0804172; Halstead JR, 2006, CURR BIOL, V16, P1850, DOI 10.1016/j.cub.2006.07.066; Ikonomov OC, 2011, J BIOL CHEM, V286, P13404, DOI 10.1074/jbc.M111.222364; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jefferies HBJ, 2008, EMBO REP, V9, P164, DOI 10.1038/sj.embor.7401155; Jones DR, 2006, MOL CELL, V23, P685, DOI 10.1016/j.molcel.2006.07.014; Jones David R., 2009, V462, P75, DOI 10.1007/978-1-60327-115-8_5; Jones DR, 2004, CURR OPIN GENET DEV, V14, P196, DOI 10.1016/j.gde.2004.02.003; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Ndamukong I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013396; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Paulsen CE, 2010, ACS CHEM BIOL, V5, P47, DOI 10.1021/cb900258z; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ramel D, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001619; Roberts HF, 2005, FEBS LETT, V579, P2868, DOI 10.1016/j.febslet.2005.04.027; Sarkes D, 2010, BIOCHEM J, V428, P375, DOI 10.1042/BJ20100129; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2004, ENDOCRINOLOGY, V145, P4853, DOI 10.1210/en.2004-0489; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Shimizu T, 2010, GERIATR GERONTOL INT, V10, pS70, DOI 10.1111/j.1447-0594.2010.00604.x; Shisheva A, 2008, CELL BIOL INT, V32, P591, DOI 10.1016/j.cellbi.2008.01.006; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tronchere H, 2004, J BIOL CHEM, V279, P7304, DOI 10.1074/jbc.M311071200; Ungewickell A, 2005, P NATL ACAD SCI USA, V102, P18854, DOI 10.1073/pnas.0509740102; Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035; Wilcox A, 2008, FEBS LETT, V582, P1391, DOI 10.1016/j.febslet.2008.03.022; Zolov SN, 2012, P NATL ACAD SCI USA, V109, P17472, DOI 10.1073/pnas.1203106109	40	34	35	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1644	1656		10.1096/fj.12-218842	http://dx.doi.org/10.1096/fj.12-218842			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23241309				2022-12-28	WOS:000316940800034
J	Jiang, XY; Bar, HY; Yan, J; Jones, S; Brannon, PM; West, AA; Perry, CA; Ganti, A; Pressman, E; Devapatla, S; Vermeylen, F; Wells, MT; Caudill, MA				Jiang, Xinyin; Bar, Haim Y.; Yan, Jian; Jones, Sara; Brannon, Patsy M.; West, Allyson A.; Perry, Cydne A.; Ganti, Anita; Pressman, Eva; Devapatla, Srisatish; Vermeylen, Francoise; Wells, Martin T.; Caudill, Marie A.			A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1)	FASEB JOURNAL			English	Article						genomics; preeclampsia; angiogenesis; vascular function	ANGIOGENIC FACTORS; GENE-EXPRESSION; DIETARY CHOLINE; RECEPTOR; DNA; PREECLAMPSIA; HYPERTENSION; METABOLISM; ORIGINS; ALTERS	This study investigated the influence of maternal choline intake on the human placental transcriptome, with a special interest in its role in modulating placental vascular function. Healthy pregnant women (n = 26, wk 26-29 gestation) were randomized to 480 mg choline/d, an intake level approximating the adequate intake of 450 mg/d, or 930 mg/d for 12 wk. Maternal blood and placental samples were retrieved at delivery. Whole genome expression microarrays were used to identify placental genes and biological processes impacted by maternal choline intake. Maternal choline intake influenced a wide array of genes (n = 166) and biological processes (n = 197), including those related to vascular function. Of special interest was the 30% down-regulation (P = 0.05) of the antiangiogenic factor and preeclampsia risk marker fms-like tyrosine kinase-1 (sFLT1) in the placenta tissues obtained from the 930 vs. 480 mg/d choline intake group. Similar decreases (P = 0.04) were detected in maternal blood sFLT1 protein concentrations. The down-regulation of sFLT1 by choline treatment was confirmed in a human trophoblast cell culture model and may be related to enhanced acetylcholine signaling. These findings indicate that supplementing the maternal diet with extra choline may improve placental angiogenesis and mitigate some of the pathological antecedents of pre-eclampsia.-Jiang, X., Bar, H. Y., Yan, J., Jones, S., Brannon, P. M., West, A. A., Perry, C. A., Ganti, A., Pressman, E., Devapatla, S., Vermeylen, F., Wells, M. T., and Caudill, M. A. A higher maternal choline intake among third-trimester pregnant women lowers placental and circulating concentrations of the antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). FASEB J. 27, 1245-1253 (2013). www.fasebj.org	[Jiang, Xinyin; Yan, Jian; Jones, Sara; Brannon, Patsy M.; West, Allyson A.; Perry, Cydne A.; Ganti, Anita; Caudill, Marie A.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; [Bar, Haim Y.; Vermeylen, Francoise] Cornell Univ, Cornell Univ Stat Consulting Unit, Ithaca, NY 14853 USA; [Wells, Martin T.] Cornell Univ, Dept Stat Sci, Ithaca, NY 14853 USA; [Pressman, Eva] Univ Rochester, Med Ctr, Dept Obstet & Gynecol, Rochester, NY 14642 USA; [Devapatla, Srisatish] Cayuga Med Ctr, Dept Pediat, Ithaca, NY USA	Cornell University; Cornell University; Cornell University; University of Rochester	Caudill, MA (corresponding author), Cornell Univ, Div Nutr Sci & Genom, 228 Savage Hall, Ithaca, NY 14853 USA.	mac379@cornell.edu	Jiang, Xinyin/I-5096-2014; Pressman, Eva K/AAG-5564-2020	Jiang, Xinyin/0000-0001-6090-371X; Pressman, Eva K/0000-0002-2556-9290	Egg Checkoff, through the Egg Nutrition Center; Beef Checkoff, through the National Cattlemen's Beef Association; Nebraska Beef Council; U. S. Department of Agriculture Cooperative State Research, Education, and Extension Service (CSREES) [00444528]; Affinito-Stewart Grants Program, through the President's Council of Cornell Women	Egg Checkoff, through the Egg Nutrition Center; Beef Checkoff, through the National Cattlemen's Beef Association; Nebraska Beef Council; U. S. Department of Agriculture Cooperative State Research, Education, and Extension Service (CSREES)(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); Affinito-Stewart Grants Program, through the President's Council of Cornell Women	This work was funded by the Egg Checkoff, through the Egg Nutrition Center; the Beef Checkoff, through the National Cattlemen's Beef Association and the Nebraska Beef Council; the U. S. Department of Agriculture Cooperative State Research, Education, and Extension Service (CSREES), Special Research grant 00444528; and the Affinito-Stewart Grants Program, through the President's Council of Cornell Women. The funding sources had no role in the study design, interpretation of the data, and/or publication of the results.	Bar H, 2010, LEMMA LAPLACE APPROX; Bar H, 2010, STAT SCI, V25, P388, DOI 10.1214/10-STS339; Blusztajn Jan Krzysztof, 2012, Central Nervous System Agents in Medicinal Chemistry, V12, P82; Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108; Burton GJ, 2009, REPRODUCTION, V138, P895, DOI 10.1530/REP-09-0092; Caudill MA, 2010, J AM DIET ASSOC, V110, P1198, DOI 10.1016/j.jada.2010.05.009; Chew TW, 2011, J NUTR, V141, P1475, DOI 10.3945/jn.111.138859; da Costa KA, 2006, AM J CLIN NUTR, V84, P88, DOI 10.1093/ajcn/84.1.88; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Hartmer R, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng047; Hopfer U, 2009, DIABETES, V58, P1672, DOI 10.2337/db08-0183; Huppertz B, 2008, HYPERTENSION, V51, P970, DOI 10.1161/HYPERTENSIONAHA.107.107607; Huppertz B, 2011, PREGNANCY HYPERTENS, V1, P79, DOI 10.1016/j.preghy.2010.10.003; Jankowski M, 2000, P NATL ACAD SCI USA, V97, P6207, DOI 10.1073/pnas.110137497; Jiang XY, 2012, FASEB J, V26, P3563, DOI 10.1096/fj.12-207894; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kim JY, 2009, EPIGENETICS-US, V4, P313, DOI 10.4161/epi.4.5.9160; Kovacheva VP, 2009, FASEB J, V23, P1054, DOI 10.1096/fj.08-122168; Lam C, 2005, HYPERTENSION, V46, P1077, DOI 10.1161/01.HYP.0000187899.34379.b0; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Meck WH, 2008, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.007.2007; Mehedint MG, 2010, P NATL ACAD SCI USA, V107, P12834, DOI 10.1073/pnas.0914328107; Mehta AK, 2010, IMMUNOBIOLOGY, V215, P527, DOI 10.1016/j.imbio.2009.09.004; Murphy SR, 2010, HYPERTENSION, V55, P394, DOI 10.1161/HYPERTENSIONAHA.109.141473; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Reddy A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004453; Sastry BVR, 1997, BIOCHEM PHARMACOL, V53, P1577, DOI 10.1016/S0006-2952(97)00017-8; Shen CJ, 2011, EXP CELL RES, V317, P1860, DOI 10.1016/j.yexcr.2011.05.006; Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490; Tsatsaris V, 2003, J CLIN ENDOCR METAB, V88, P5555, DOI 10.1210/jc.2003-030528; Wang A, 2009, PHYSIOLOGY, V24, P147, DOI 10.1152/physiol.00043.2008; Wolf M, 2005, AM J OBSTET GYNECOL, V193, P16, DOI 10.1016/j.ajog.2005.03.016; Yan J, 2012, AM J CLIN NUTR, V95, P1060, DOI 10.3945/ajcn.111.022772; Zeeberg BR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-168; Zeisel SH, 2006, J PEDIATR-US, V149, pS131, DOI 10.1016/j.jpeds.2006.06.065; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	39	63	65	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1245	1253		10.1096/fj.12-221648	http://dx.doi.org/10.1096/fj.12-221648			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195033				2022-12-28	WOS:000315585200036
J	Canton, I; Massignani, M; Patikarnmonthon, N; Chierico, L; Robertson, J; Renshaw, SA; Warren, NJ; Madsen, JP; Armes, SP; Lewis, AL; Battaglia, G				Canton, Irene; Massignani, Marzia; Patikarnmonthon, Nisa; Chierico, Luca; Robertson, James; Renshaw, Stephen A.; Warren, Nicholas J.; Madsen, Jeppe P.; Armes, Steven P.; Lewis, Andrew L.; Battaglia, Giuseppe			Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells	FASEB JOURNAL			English	Article						immunotargeting; protein; antibody; nanovector	NF-KAPPA-B; IN-VITRO; GENE DELIVERY; DNA; LOCALIZATION; COMPLEXES; SELECTION; CYTOKINE; THERAPY; MODEL	There is an emerging need both in pharmacology and within the biomedical industry to develop new tools to target intracellular mechanisms. The efficient delivery of functionally active proteins within cells is potentially a powerful research strategy, especially through the use of antibodies. In this work, we report on a nanovector for the efficient encapsulation and delivery of antibodies into live cells with no significant loss of cell viability or any deleterious effect on cell metabolic activity. This delivery system is based on poly[2-(methacryloyloxy) ethyl phosphorylcholine]-block-[2-(diisopropylamino) ethyl methacrylate] (PMPC-PDPA), a pH-sensitive diblock copolymer that self-assembles to form nanometer-sized vesicles, also known as polymersomes, at physiological pH. Polymersomes can successfully deliver relatively high antibody payloads within different types of live cells. We demonstrate that these antibodies can target their respective epitope showing immunolabeling of gamma-tubulin, actin, Golgi protein, and the transcription factor NF-kappa B in live cells. Finally, we demonstrate that intracellular delivery of antibodies can control specific subcellular events, as well as modulate cell activity and proinflammatory processes.-Canton, I., Massignani, M., Patikarnmonthon, N., Chierico, L., Robertson, J., Renshaw, S. A., Warren, N. J., Madsen, J. P., Armes, S P., Lewis, A. L., Battaglia, G. Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells. FASEB J. 27, 98-108 (2013). www.fasebj.org	[Canton, Irene; Massignani, Marzia; Patikarnmonthon, Nisa; Chierico, Luca; Robertson, James; Renshaw, Stephen A.; Madsen, Jeppe P.; Battaglia, Giuseppe] Univ Sheffield, Krebs Inst, Sheffield S10 2TN, S Yorkshire, England; [Canton, Irene; Patikarnmonthon, Nisa; Chierico, Luca; Robertson, James; Madsen, Jeppe P.; Battaglia, Giuseppe] Univ Sheffield, Ctr Membrane Interact & Dynam, Sheffield S10 2TN, S Yorkshire, England; [Canton, Irene; Massignani, Marzia; Patikarnmonthon, Nisa; Chierico, Luca; Robertson, James; Warren, Nicholas J.; Madsen, Jeppe P.; Battaglia, Giuseppe] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England; [Robertson, James; Renshaw, Stephen A.] Univ Sheffield, MRC, Ctr Dev & Biomed Genet, Sheffield S10 2TN, S Yorkshire, England; [Renshaw, Stephen A.] Univ Sheffield, Dept Infect & Immun, Sheffield S10 2TN, S Yorkshire, England; [Warren, Nicholas J.; Madsen, Jeppe P.; Armes, Steven P.] Univ Sheffield, Dept Chem, Sheffield S10 2TN, S Yorkshire, England; [Lewis, Andrew L.] Biocompatibles UK Ltd, Farnham, Surrey, England	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Biocompatibles International PLC	Battaglia, G (corresponding author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	g.battaglia@sheffield.ac.uk	Patikarnmonthon, Nisa/AAF-3078-2020; Madsen, Jeppe/A-3184-2015; Battaglia, Giuseppe/I-2142-2013; Renshaw, Steve/E-6192-2010; Warren, Nicholas J/I-1588-2013; Warren, Nicholas/AAE-9388-2021	Patikarnmonthon, Nisa/0000-0001-5787-0785; Madsen, Jeppe/0000-0001-7625-9498; Battaglia, Giuseppe/0000-0003-3349-6770; Renshaw, Steve/0000-0003-1790-1641; Warren, Nicholas J/0000-0002-8298-1417; Warren, Nicholas/0000-0002-8298-1417; Canton, Irene/0000-0003-2768-4425; Lewis, Andrew/0000-0001-5779-5631; Armes, Steven/0000-0002-8289-6351; Robertson, James/0000-0002-9961-0073	MRC [G0701932] Funding Source: UKRI; Medical Research Council [G0701932] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreakos E, 2003, ARTHRITIS RHEUM, V48, P1901, DOI 10.1002/art.11044; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baron S, 2000, J IMMUNOL METHODS, V242, P115, DOI 10.1016/S0022-1759(00)00242-8; BATRA RK, 1994, GENE THER, V1, P255; Battaglia G, 2005, J AM CHEM SOC, V127, P8757, DOI 10.1021/ja050742y; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Biswas A, 2011, ACS NANO, V5, P1385, DOI 10.1021/nn1031005; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Du JZ, 2005, J AM CHEM SOC, V127, P17982, DOI 10.1021/ja056514l; Ferguson LR, 2007, MUTAT RES-FUND MOL M, V623, P14, DOI 10.1016/j.mrfmmm.2007.03.014; Giacomelli C, 2006, BIOMACROMOLECULES, V7, P817, DOI 10.1021/bm0508921; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hinata K, 2003, ONCOGENE, V22, P1955, DOI 10.1038/sj.onc.1206198; Hoog G, 2011, FASEB J, V25, P3815, DOI 10.1096/fj.11-187484; Horejsi B, 2012, J CELL PHYSIOL, V227, P367, DOI 10.1002/jcp.22772; Kondo Y, 2008, J IMMUNOL METHODS, V332, P10, DOI 10.1016/j.jim.2007.12.008; Kuriyama R, 2009, J CELL SCI, V122, P2014, DOI 10.1242/jcs.036715; Lesca C, 2005, ONCOGENE, V24, P5165, DOI 10.1038/sj.onc.1208723; Li GH, 2009, INT J PHARMACEUT, V368, P109, DOI 10.1016/j.ijpharm.2008.10.008; Li HH, 2007, MUTAT RES-FUND MOL M, V623, P98, DOI 10.1016/j.mrfmmm.2007.03.013; Lomas H, 2008, FARADAY DISCUSS, V139, P143, DOI 10.1039/b717431d; Lomas H, 2007, ADV MATER, V19, P4238, DOI 10.1002/adma.200700941; LoPresti C, 2011, ACS NANO, V5, P1775, DOI 10.1021/nn102455z; LoPresti C, 2009, J MATER CHEM, V19, P3576, DOI 10.1039/b818869f; Massignani M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010459; Massignani M, 2009, SMALL, V5, P2424, DOI 10.1002/smll.200900578; Murdoch C, 2010, NANOMEDICINE-UK, V5, P1025, DOI 10.2217/NNM.10.97; Nelson AL, 2009, NAT BIOTECHNOL, V27, P331, DOI 10.1038/nbt0409-331; Perfetto B, 2003, RES MICROBIOL, V154, P337, DOI 10.1016/S0923-2508(03)00084-6; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Rahmanzadeh R, 2010, CANCER RES, V70, P9234, DOI 10.1158/0008-5472.CAN-10-1190; Raynaud-Messina B, 2007, CURR OPIN CELL BIOL, V19, P24, DOI 10.1016/j.ceb.2006.12.008; Raz-Prag D, 2010, P NATL ACAD SCI USA, V107, P12710, DOI 10.1073/pnas.0913472107; Robinson KL, 2002, J MATER CHEM, V12, P890, DOI 10.1039/b200348c; Sidhu SS, 2006, NAT CHEM BIOL, V2, P682, DOI 10.1038/nchembio843; Visintin M, 2008, J BIOTECHNOL, V135, P1, DOI 10.1016/j.jbiotec.2008.02.012; Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]; Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195	41	59	62	0	120	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					98	108		10.1096/fj.12-212183	http://dx.doi.org/10.1096/fj.12-212183			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23033321				2022-12-28	WOS:000313103200011
J	Li, ST; Sun, BD; Nilsson, MI; Bird, A; Tarnopolsky, MA; Thurberg, BL; Bali, D; Koeberl, DD				Li, Songtao; Sun, Baodong; Nilsson, Mats I.; Bird, Andrew; Tarnopolsky, Mark A.; Thurberg, Beth L.; Bali, Deeksha; Koeberl, Dwight D.			Adjunctive beta 2-agonists reverse neuromuscular involvement in murine Pompe disease	FASEB JOURNAL			English	Article						mannose-6-phosphate receptor; gene therapy; adeno-associated virus; acid alpha-glucosidase; acid maltase; glycogen storage disease type II	ACID-ALPHA-GLUCOSIDASE; ENZYME REPLACEMENT THERAPY; BETA-ADRENOCEPTOR AGONISTS; BECKER MUSCULAR-DYSTROPHY; GLYCOGEN-STORAGE; SKELETAL-MUSCLE; MOUSE MODEL; IMMUNE-RESPONSE; PILOT TRIAL; IN-VITRO	Pompe disease has resisted enzyme replacement therapy with acid alpha-glucosidase (GAA), which has been attributed to inefficient cation-independent mannose-6-phosphate receptor (CI-MPR) mediated uptake. We evaluated beta 2-agonist drugs, which increased CI-MPR expression in GAA knockout (KO) mice. Clenbuterol along with a low-dose adeno-associated virus vector increased Rotarod latency by 75% at 4 wk, in comparison with vector alone (P < 2 x 10(-5)). Glycogen content was lower in skeletal muscles, including soleus (P < 0.01), extensor digitorum longus (EDL; P < 0.001), and tibialis anterior (P < 0.05) following combination therapy, in comparison with vector alone. Glycogen remained elevated in the muscles following clenbuterol alone, indicating an adjunctive effect with gene therapy. Elderly GAA-KO mice treated with combination therapy demonstrated 2-fold increased wire-hang latency, in comparison with vector or clenbuterol alone (P < 0.001). The glycogen content of skeletal muscle decreased following combination therapy in elderly mice (P < 0.05). Finally, CI-MPR-KO/GAA-KO mice did not respond to combination therapy, indicating that clenbuterol's effect depended on CI-MPR expression. In summary, adjunctive beta 2-agonist treatment increased CI-MPR expression and enhanced efficacy from gene therapy in Pompe disease, which has implications for other lysosomal storage disorders that involve primarily the brain.-Li, S., Sun, B., Nilsson, M. I., Bird, A., Tarnopolsky, M. A., Thurberg, B. L., Bali, D., Koeberl, D. D. Adjunctive beta 2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J. 27, 34-44 (2013). www.fasebj.org	[Li, Songtao; Sun, Baodong; Bird, Andrew; Bali, Deeksha; Koeberl, Dwight D.] Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA; [Nilsson, Mats I.; Tarnopolsky, Mark A.] McMaster Univ, Med Ctr, Dept Pediat, Hamilton, ON, Canada; [Nilsson, Mats I.; Tarnopolsky, Mark A.] McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Thurberg, Beth L.] Genzyme Corp, Dept Pathol, Framingham, MA 01701 USA	Duke University; McMaster University; McMaster University; Sanofi-Aventis; Genzyme Corporation	Koeberl, DD (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Box 103856, Durham, NC 27710 USA.	koebe001@mc.duke.edu	Nilsson, Mats/AAG-2068-2021	Nilsson, Mats/0000-0001-5656-5578	U.S. National Insitutes of Health (NIH) from the National Heart, Lung, and Blood Institute [R01 HL081122]; Genzyme Corp.; Muscular Dystrophy Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081122] Funding Source: NIH RePORTER	U.S. National Insitutes of Health (NIH) from the National Heart, Lung, and Blood Institute; Genzyme Corp.(Sanofi-AventisGenzyme Corporation); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Insitutes of Health (NIH) grant R01 HL081122 from the National Heart, Lung, and Blood Institute. Partial research grant support for this work from Genzyme Corp. to Y. T. C., D. B., and A. M. W. under a sponsored research agreement is highly appreciated. B. S. was supported by a development grant from the Muscular Dystrophy Association. Ms. Jian Dai provided outstanding technical support for Western blot analysis. Dr. Sarah Young assisted with statistical analyses. GAA-KO mice were provided courtesy of Dr. Nina Raben (NIH, Bethesda, MD, USA). Muscle-specific CI-MPR-KO mice were provided courtesy of Dr. Randy Jirtle (Duke University, Durham, NC, USA). rhGAA was provided under agreement with Genzyme Corp. The AAV8 packaging plasmid was provided courtesy of Dr. James M. Wilson (University of Pennsylvania, Philadelphia, PA, USA). Conflicts of interest: D. B. and D. D. K. have received research/grant support from Genzyme Corp. in the past. B. T. is an employee of Genzyme Corp.	Amalfitano A, 1999, P NATL ACAD SCI USA, V96, P8861, DOI 10.1073/pnas.96.16.8861; Angelini EPC, 2004, BASIC APPL MYOL, V14, P71; Awede BL, 2002, AM J PHYSIOL-ENDOC M, V282, pE31, DOI 10.1152/ajpendo.2002.282.1.E31; Cardone Monica, 2008, Pathogenetics, V1, P6, DOI 10.1186/1755-8417-1-6; Cresawn KO, 2005, HUM GENE THER, V16, P68, DOI 10.1089/hum.2005.16.68; Desnick RJ, 2004, J INHERIT METAB DIS, V27, P385, DOI 10.1023/B:BOLI.0000031101.12838.c6; Fowler EG, 2004, NEUROLOGY, V62, P1006, DOI 10.1212/01.WNL.0000118530.71646.0F; Franco LM, 2005, MOL THER, V12, P876, DOI 10.1016/j.ymthe.2005.04.024; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Grubb JH, 2010, REJUV RES, V13, P229, DOI 10.1089/rej.2009.0920; Hoshino D, 2012, AM J PHYSIOL-REG I, V302, pR373, DOI 10.1152/ajpregu.00183.2011; Iizuka Hiroyuki, 1998, Journal of Smooth Muscle Research, V34, P139; Jones HN, 2010, DYSPHAGIA, V25, P277, DOI 10.1007/s00455-009-9252-x; Kamalakkannan G, 2008, J HEART LUNG TRANSPL, V27, P457, DOI 10.1016/j.healun.2008.01.013; Kishnani PS, 2007, NEUROLOGY, V68, P99, DOI 10.1212/01.wnl.0000251268.41188.04; Kissel JT, 2001, NEUROLOGY, V57, P1434, DOI 10.1212/WNL.57.8.1434; Kobayashi H, 2010, MOL GENET METAB, V100, P14, DOI 10.1016/j.ymgme.2010.01.015; Koeberl DD, 2008, MOL THER, V16, P665, DOI 10.1038/mt.2008.15; Koeberl DD, 2012, MOL GENET METAB, V105, P221, DOI 10.1016/j.ymgme.2011.11.005; Koeberl DD, 2011, MOL GENET METAB, V103, P107, DOI 10.1016/j.ymgme.2011.02.006; Lynch GS, 2008, PHYSIOL REV, V88, P729, DOI 10.1152/physrev.00028.2007; MACLENNAN PA, 1989, BIOCHEM J, V264, P573, DOI 10.1042/bj2640573; Mah CS, 2010, MOL THER, V18, P502, DOI 10.1038/mt.2009.305; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Matsumoto T, 2006, ARCH ORAL BIOL, V51, P603, DOI 10.1016/j.archoralbio.2006.01.003; Matthes F, 2011, J BIOL CHEM, V286, P17487, DOI 10.1074/jbc.M110.189381; McVie-Wylie AJ, 2008, MOL GENET METAB, V94, P448, DOI 10.1016/j.ymgme.2008.04.009; Miura S, 2007, ENDOCRINOLOGY, V148, P3441, DOI 10.1210/en.2006-1646; Mounier R, 2007, PFLUG ARCH EUR J PHY, V453, P497, DOI 10.1007/s00424-006-0122-1; NIALS AT, 1993, BRIT J PHARMACOL, V110, P1112, DOI 10.1111/j.1476-5381.1993.tb13929.x; Nicolino M, 2009, GENET MED, V11, P210, DOI 10.1097/GIM.0b013e31819d0996; Raben N, 2005, MOL THER, V11, P48, DOI 10.1016/j.ymthe.2004.09.017; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Ryall JG, 2008, PHARMACOL THERAPEUT, V120, P219, DOI 10.1016/j.pharmthera.2008.06.003; Sandri M, 2008, PHYSIOLOGY, V23, P160, DOI 10.1152/physiol.00041.2007; Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718; Skura CL, 2008, NEUROLOGY, V70, P137, DOI 10.1212/01.WNL.0000287070.00149.a9; Soraru G, 2006, AMYOTROPH LATERAL SC, V7, P246, DOI 10.1080/14660820600600558; Strothotte S, 2010, J NEUROL, V257, P91, DOI 10.1007/s00415-009-5275-3; Sun B., 2010, J GENE MED, V25, P277; Sun B, 2007, AM J HUM GENET, V81, P1042, DOI 10.1086/522236; Sun BD, 2010, MOL THER, V18, P353, DOI 10.1038/mt.2009.195; Sun BD, 2009, J GENE MED, V11, P913, DOI 10.1002/jgm.1372; Sun BD, 2005, MOL THER, V11, P57, DOI 10.1016/j.ymthe.2004.10.004; Taksir TV, 2007, J HISTOCHEM CYTOCHEM, V55, P991, DOI 10.1369/jhc.7A7239.2007; Torneke K, 1998, J VET PHARMACOL THER, V21, P388, DOI 10.1046/j.1365-2885.1998.00156.x; Uc EY, 2002, MOVEMENT DISORD, V17, P54, DOI 10.1002/mds.10002.abs; Vandenberghe LH, 2006, NAT MED, V12, P967, DOI 10.1038/nm1445; Wang LL, 2007, HUM GENE THER, V18, P185, DOI 10.1089/hum.2007.001; Wraith JE, 2008, EUR J PEDIATR, V167, P267, DOI 10.1007/s00431-007-0635-4; Wylie AA, 2003, AM J PATHOL, V162, P321, DOI 10.1016/S0002-9440(10)63823-0; Xu F, 2005, J GENE MED, V7, P171, DOI 10.1002/jgm.660; Yanovitch TL, 2010, J PEDIAT OPHTH STRAB, V47, P34, DOI 10.3928/01913913-20100106-08; Zhu Y, 2005, NEUROMUSCULAR DISORD, V15, P712; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37; ZIMMER A, 1976, ARZNEIMITTEL-FORSCH, V26, P1446	56	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					34	44		10.1096/fj.12-207472	http://dx.doi.org/10.1096/fj.12-207472			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22993195	Green Published, Green Submitted			2022-12-28	WOS:000313103200005
J	Motiani, RK; Zhang, XX; Harmon, KE; Keller, RS; Matrougui, K; Bennett, JA; Trebak, M				Motiani, Rajender K.; Zhang, Xuexin; Harmon, Kelly E.; Keller, Rebecca S.; Matrougui, Khalid; Bennett, James A.; Trebak, Mohamed			Orai3 is an estrogen receptor alpha-regulated Ca2+ channel that promotes tumorigenesis	FASEB JOURNAL			English	Article						CRAC; SOCE; Orai1; breast cancer; Ca2+ signaling	CAPACITATIVE CALCIUM-ENTRY; BREAST-CANCER; MICE LACKING; I-CRAC; CELL; ACTIVATION; BORATE; STIM1; DEFICIENCY; APOPTOSIS	Store-operated Ca2+ entry (SOCE) encoded by Orai1 proteins is a ubiquitous Ca2+-selective conductance involved in cellular proliferation and migration. We recently described up-regulation of Orai3 channels that selectively mediate SOCE in estrogen receptor alpha-expressing (ER alpha(+)) breast cancer cells. However, the connection between ER alpha(+) and Orai3 and the role of Orai3 in tumorigenesis remain unknown. Here, we show that ER alpha knockdown decreases Orai3 mRNA (by similar to 63%) and protein (by similar to 44%) with no effect on Orai1. ER alpha knockdown decreases Orai3-mediated SOCE (by similar to 43%) and the corresponding Ca2+ release-activated Ca2+ (CRAC) current (by similar to 42%) in ER alpha(+) MCF7 cells. The abrogation of SOCE in MCF7 cells on ER alpha knockdown can be rescued by ectopic expression of Orai3. ER alpha activation increased Orai3 expression and SOCE in MCF7 cells. Epidermal growth factor (EGF) and thrombin stimulate Ca2+ influx into MCF7 cells through Orai3. Orai3 knockdown inhibited SOCE-dependent phosphorylation of extracellular signal-regulated kinase (ERK1/2; by similar to 44%) and focal adhesion kinase (FAK; by similar to 46%) as well as transcriptional activity of nuclear factor for activated T cells (NFAT; by similar to 49%). Significantly, Orai3 knockdown selectively decreased anchorage-independent growth (by similar to 58%) and Matrigel invasion (by similar to 44%) of ER alpha(+) MCF7 cells with no effect on ER alpha(-) MDA-MB231 cells. Moreover, Orai3 knockdown inhibited ER alpha(+) cell tumorigenesis in immunodeficient mice (similar to 66% reduction in tumor volume). These data establish Orai3 as an ER alpha-regulated channel and a potential selective therapeutic target for ER alpha(+) breast cancers.-Motiani, R. K., Zhang, X., Harmon, K. E., Keller, R. S., Matrougui, K., Bennett, J. A., Trebak, M. Orai3 is an estrogen receptor alpha-regulated Ca2+ channel that promotes tumorigenesis. FASEB J. 27, 63-75 (2013). www.fasebj.org	[Motiani, Rajender K.; Zhang, Xuexin; Harmon, Kelly E.; Keller, Rebecca S.; Trebak, Mohamed] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; [Bennett, James A.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; [Matrougui, Khalid] Tulane Univ, Dept Physiol, Hypertens & Renal Ctr Excellence, New Orleans, LA 70118 USA	Albany Medical College; Albany Medical College; Tulane University	Trebak, M (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, Mail Code 8,47 New Scotland Ave, Albany, NY 12208 USA.	trebakm@mail.amc.edu	Trebak, Mohamed/E-7405-2014; Zhang, Xuexin/I-7600-2013; 张学新, XUEXIN ZHANG/AAD-7645-2019	张学新, XUEXIN ZHANG/0000-0001-8276-3885	U.S. National Institutes of Health (NIH) [HL-097111]; NIH [HL-095566]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097111, R01HL095566] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Research in the authors' laboratory is supported by grant HL-097111 from the U.S. National Institutes of Health (NIH) to M. T., and in part by NIH grant HL-095566 to K.M.	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Bai ZL, 2009, ARCH PHARM, V342, P133, DOI 10.1002/ardp.200800174; Bisaillon JM, 2010, AM J PHYSIOL-CELL PH, V298, pC993, DOI 10.1152/ajpcell.00325.2009; DeHaven WI, 2008, J BIOL CHEM, V283, P19265, DOI 10.1074/jbc.M801535200; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Faouzi M, 2011, J CELL PHYSIOL, V226, P542, DOI 10.1002/jcp.22363; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Flourakis M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.52; Green D, 2010, CELL CYCLE, V9, P656, DOI 10.4161/cc.9.4.10729; Gwack Y, 2008, MOL CELL BIOL, V28, P5209, DOI 10.1128/MCB.00360-08; Gwack Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007; Herynk Matthew H., 2009, P1, DOI 10.1007/978-0-387-09463-2_1; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luqmani YA, 2009, INT J ONCOL, V34, P231, DOI 10.3892/ijo_00000145; McCarl CA, 2009, J ALLERGY CLIN IMMUN, V124, P1311, DOI 10.1016/j.jaci.2009.10.007; McNally B. A., 2012, J PHYSL, V590, P4171; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Motiani RK, 2010, J BIOL CHEM, V285, P19173, DOI 10.1074/jbc.M110.102582; Peinelt C, 2008, J PHYSIOL-LONDON, V586, P3061, DOI 10.1113/jphysiol.2008.151365; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Potier M, 2008, PFLUG ARCH EUR J PHY, V457, P405, DOI 10.1007/s00424-008-0533-2; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Putney JW, 2009, IMMUNOL REV, V231, P10, DOI 10.1111/j.1600-065X.2009.00810.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Santen R, 2009, ANN NY ACAD SCI, V1155, P132, DOI 10.1111/j.1749-6632.2008.03685.x; Schindl R, 2009, CELL CALCIUM, V46, P227, DOI 10.1016/j.ceca.2009.08.003; Schindl R, 2008, J BIOL CHEM, V283, P20261, DOI 10.1074/jbc.M803101200; Shuttleworth TJ, 2012, J PHYSIOL-LONDON, V590, P241, DOI 10.1113/jphysiol.2011.220574; Shuttleworth TJ, 2009, CELL CALCIUM, V45, P602, DOI 10.1016/j.ceca.2009.02.001; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2011, J PHYSIOL-LONDON, V589, P5337, DOI 10.1113/jphysiol.2011.220517; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Yamashita M, 2011, J BIOL CHEM, V286, P9429, DOI 10.1074/jbc.M110.189035; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zhang SYL, 2008, J BIOL CHEM, V283, P17662, DOI 10.1074/jbc.M801536200; Zhang W, 2011, CIRC RES, V109, P534, DOI 10.1161/CIRCRESAHA.111.246777	45	130	133	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					63	75		10.1096/fj.12-213801	http://dx.doi.org/10.1096/fj.12-213801			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22993197	Green Published			2022-12-28	WOS:000313103200008
J	Ong, KT; Mashek, MT; Bu, SY; Mashek, DG				Ong, Kuok Teong; Mashek, Mara T.; Bu, So Young; Mashek, Douglas G.			Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation	FASEB JOURNAL			English	Article						insulin sensitivity; steatosis; fatty acid and glucose metabolism	ADIPOSE TRIGLYCERIDE LIPASE; INSULIN-RESISTANCE; FATTY LIVER; PPAR-ALPHA; TRIACYLGLYCEROL LIPASE; DIABETES-MELLITUS; TRANSGENIC MICE; STEATOSIS; GLUCOKINASE; SENSITIVITY	Adipose triglyceride lipase (ATGL) is the predominant triacylglycerol (TAG) hydrolase in mammals; however, the tissue-specific effects of ATGL outside of adipose tissue have not been well characterized. Hence, we tested the contribution of hepatic ATGL on mediating glucose tolerance and insulin action. Glucose or insulin tolerance tests and insulin signaling were performed in C57BL/6 mice administered control (nongene specific shRNA) or Atgl shRNA adenoviruses. Glucose and lipid metabolism assays were conducted in primary hepatocytes isolated from mice transduced with control or Atgl shRNA adenoviruses. Knocking down hepatic ATGL completely abrogated the increase in serum insulin following either 1 or 12 wk of feeding a high-fat (HF) diet despite higher hepatic TAG content. Glucose tolerance tests demonstrated that ATGL knockdown normalized glucose tolerance in HF-diet-fed mice. The observed improvements in glucose tolerance were present despite unaltered hepatic insulin signaling and increased liver TAG. Mice with suppressed hepatic ATGL had reduced hepatic glucose production in vivo, and hepatocytes isolated from Atgl shRNA-treated mice displayed a 26% decrease in glucose production and a 38% increase in glucose oxidation compared to control cells. Taken together, these data suggest that hepatic ATGL knockdown enhances glucose tolerance by increasing hepatic glucose utilization and uncouples impairments in insulin action from hepatic TAG accumulation.-Ong, K. T., Mashek, M. T., Bu, SY., Mashek, D. G. Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation. FASEB J. 27, 313-321 (2013). www.fasebj.org	[Ong, Kuok Teong; Mashek, Mara T.; Bu, So Young; Mashek, Douglas G.] Univ Minnesota, Dept Food Sci & Nutr, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Mashek, DG (corresponding author), Univ Minnesota, Dept Food Sci & Nutr, 1334 Eckles Ave, St Paul, MN 55108 USA.	dmashek@umn.edu	Mashek, Douglas/ABD-6844-2021; Ong, Kuok Teong/H-8274-2015	Ong, Kuok Teong/0000-0001-8605-375X; Mashek, Douglas/0000-0001-7033-3386	U.S. National Institutes of Health (NIH) [DK090364]; Minnesota Obesity Center [NIH DK050456]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090364, P30DK050456] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Minnesota Obesity Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Katie Ress and Ellen Fischer for their excellent technical support. This work was supported by a grant from the U.S. National Institutes of Health (NIH; DK090364) to D.G.M and the Minnesota Obesity Center (NIH DK050456). K.T.O researched and analyzed the data, and wrote and edited the manuscript. S.Y.B assisted in performing the research. M.T.M assisted in performing the research and editing the manuscript. D.G. M contributed to all aspect of this work and is the guarantor of this article. The authors declare no conflicts of interest.	Ahren B, 1998, EUR J ENDOCRINOL, V139, P461, DOI 10.1530/eje.0.1390461; Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; Brown JM, 2010, J LIPID RES, V51, P3306, DOI 10.1194/jlr.M010256; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Choi CS, 2007, J BIOL CHEM, V282, P22678, DOI 10.1074/jbc.M704213200; Conti R, 2011, DIABETES, V60, P644, DOI 10.2337/db10-0346; Erion DM, 2010, NAT MED, V16, P400, DOI 10.1038/nm0410-400; Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280; Fabbrini E, 2009, P NATL ACAD SCI USA, V106, P15430, DOI 10.1073/pnas.0904944106; Fan YB, 2011, J BIOL CHEM, V286, P40584, DOI 10.1074/jbc.M111.232918; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; FOLCH J, 1957, J BIOL CHEM, V226, P497; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; He L, 2009, CELL, V137, P635, DOI 10.1016/j.cell.2009.03.016; Hubinger A, 1997, HORM METAB RES, V29, P436, DOI 10.1055/s-2007-979072; Hue L, 2009, AM J PHYSIOL-ENDOC M, V297, pE578, DOI 10.1152/ajpendo.00093.2009; Im SS, 2011, J BIOL CHEM, V286, P1157, DOI 10.1074/jbc.M110.157875; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kantartzis K, 2009, CLIN SCI, V116, P531, DOI 10.1042/CS20080306; Kienesberger PC, 2009, J BIOL CHEM, V284, P30218, DOI 10.1074/jbc.M109.047787; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lee JM, 2010, J BIOL CHEM, V285, P32182, DOI 10.1074/jbc.M110.134890; LOPASCHUK GD, 1989, MOL CELL BIOCHEM, V88, P175; MARTIN C, 1991, METABOLISM, V40, P420, DOI 10.1016/0026-0495(91)90154-O; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Minehira K, 2008, J LIPID RES, V49, P2038, DOI 10.1194/jlr.M800248-JLR200; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; Miyoshi H, 2007, J BIOL CHEM, V282, P996, DOI 10.1074/jbc.M605770200; Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Ong KT, 2011, HEPATOLOGY, V53, P116, DOI 10.1002/hep.24006; RANDLE PJ, 1963, LANCET, V1, P785; RATHEISER K, 1991, METABOLISM, V40, P1185, DOI 10.1016/0026-0495(91)90214-H; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Stefan N, 2008, ARCH INTERN MED, V168, P1609, DOI 10.1001/archinte.168.15.1609; Turpin SM, 2011, DIABETOLOGIA, V54, P146, DOI 10.1007/s00125-010-1895-5; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Winzell MS, 2011, EUR J PHARMACOL, V663, P80, DOI 10.1016/j.ejphar.2011.05.009; Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338; Zhang CB, 2012, P NATL ACAD SCI USA, V109, P1667, DOI 10.1073/pnas.1110730109; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	43	39	40	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					313	321		10.1096/fj.12-213454	http://dx.doi.org/10.1096/fj.12-213454			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22993196	Green Published			2022-12-28	WOS:000313103200029
J	Otten, JJT; de Jager, SCA; Kavelaars, A; Seijkens, T; Bot, I; Wijnands, E; Beckers, L; Westra, MM; Bot, M; Busch, M; Bermudez, B; van Berkel, TJC; Heijnen, CJ; Biessen, EAL				Otten, Jeroen J. T.; de Jager, Saskia C. A.; Kavelaars, Annemieke; Seijkens, Tom; Bot, Ilze; Wijnands, Erwin; Beckers, Linda; Westra, Marijke M.; Bot, Martine; Busch, Matthias; Bermudez, Beatriz; van Berkel, Theo J. C.; Heijnen, Cobi J.; Biessen, Erik A. L.			Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice	FASEB JOURNAL			English	Article						mouse model of atherosclerosis; chemotaxis; leukocytes	ACCELERATED ATHEROSCLEROSIS; CHEMOKINE RECEPTORS; INDUCED APOPTOSIS; BONE-MARROW; GRK2; CELLS; CCR5; EXPRESSION; GENE; PHOSPHORYLATION	Leukocyte chemotaxis is deemed instrumental in initiation and progression of atherosclerosis. It is mediated by G-protein-coupled receptors (e. g., CCR2 and CCR5), the activity of which is controlled by G-protein-coupled receptor kinases (GRKs). In this study, we analyzed the effect of hematopoietic deficiency of a potent regulator kinase of chemotaxis (GRK2) on atherogenesis. LDL receptor-deficient (LDLr-/-) mice with heterozygous hematopoietic GRK2 deficiency, generated by bone marrow transplantation (n = 15), displayed a dramatic attenuation of plaque development, with 79% reduction in necrotic core and increased macrophage content. Circulating monocytes decreased and granulocytes increased in GRK2(+/-) chimeras, which could be attributed to diminished granulocyte colony-forming units in bone marrow. Collectively, these data pointed to myeloid cells as major mediators of the impaired atherogenic response in GRK2(+/-) chimeras. LDLr-/- mice with macrophage/granulocyte-specific GRK2 deficiency (LysM-Cre GRK2(flox/flox); n = 8) failed to mimic the aforementioned phenotype, acquitting these cells as major responsible subsets for GRK2 deficiency-associated atheroprotection. To conclude, even partial hematopoietic GRK2 deficiency prevents atherosclerotic lesion progression beyond the fatty streak stage, identifying hematopoietic GRK2 as a potential target for intervention in atherosclerosis.-Otten, J. J. T., de Jager, S. C. A., Kavelaars, A., Seijkens, T., Bot, I., Wijnands, E., Beckers, L., Westra, M. M., Bot, M., Busch, M., Bermudez, B., van Berkel, T. J. C., Heijnen, C. J., Biessen, E. A. L. Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice. FASEB J. 27, 265-276 (2013). www.fasebj.org	[Otten, Jeroen J. T.; Seijkens, Tom; Wijnands, Erwin; Beckers, Linda; Busch, Matthias; Bermudez, Beatriz; Biessen, Erik A. L.] Maastricht Univ, Med Ctr, Expt Vasc Pathol Grp, Dept Pathol,Cardiovasc Res Inst Maastricht, NL-6229 HX Maastricht, Netherlands; [de Jager, Saskia C. A.; Bot, Ilze; Westra, Marijke M.; Bot, Martine; van Berkel, Theo J. C.; Biessen, Erik A. L.] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Leiden, Netherlands; [Kavelaars, Annemieke; Heijnen, Cobi J.] Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Utrecht, Netherlands; [Kavelaars, Annemieke] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA; [Bermudez, Beatriz] CSIC, Inst Grasa & Derivados, Lab Cellular & Mol Nutr, E-41012 Seville, Spain	Maastricht University; Leiden University; Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; University of Texas System; UTMD Anderson Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG)	Biessen, EAL (corresponding author), Maastricht Univ, Med Ctr, Expt Vasc Pathol Grp, Dept Pathol,Cardiovasc Res Inst Maastricht, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands.	erik.biessen@mumc.nl	Busch, Matthias/ABF-4740-2021; Van Berkel, Theo/ABD-7677-2021	de Jager, Saskia/0000-0002-5233-0066; Biessen, Erik/0000-0002-6454-8548; Bot, Ilze/0000-0002-1242-1959; Seijkens, Tom/0000-0001-6370-1267; Busch, Matthias/0000-0001-7324-2471	Netherlands Heart Foundation [2003T201]; U.S. National Institutes of Health [R01-NS003939, NS074999]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073939, R01NS074999] Funding Source: NIH RePORTER	Netherlands Heart Foundation(Netherlands Heart Foundation); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. M. Gijbels for her help in plaque morphology scoring. E. B. is the recipient of an Established Investigator Fellowship (grant 2003T201) of The Netherlands Heart Foundation. This work was supported in part by the U.S. National Institutes of Health (grants R01-NS003939 and NS074999 to A.K.).	Ait-Oufella H, 2007, CIRCULATION, V115, P2168, DOI 10.1161/CIRCULATIONAHA.106.662080; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arai S, 2005, CELL METAB, V1, P201, DOI 10.1016/j.cmet.2005.02.002; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bot I, 2007, CIRCULATION, V115, P2516, DOI 10.1161/CIRCULATIONAHA.106.660472; Braunersreuther V, 2007, ARTERIOSCL THROM VAS, V27, P373, DOI 10.1161/01.ATV.0000253886.44609.ae; Burke-Gaffney A, 2002, VASC PHARMACOL, V38, P283, DOI 10.1016/S1537-1891(02)00253-7; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen XQ, 2010, J BIOL CHEM, V285, P12823, DOI 10.1074/jbc.M109.094243; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DERIJKE YB, 1994, BIOCHEM J, V304, P69, DOI 10.1042/bj3040069; Dinudom A, 2004, P NATL ACAD SCI USA, V101, P11886, DOI 10.1073/pnas.0402178101; Eijkelkamp N, 2010, J NEUROSCI, V30, P2138, DOI 10.1523/JNEUROSCI.5752-09.2010; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; Geng YH, 2002, ARTERIOSCL THROM VAS, V22, P1370, DOI 10.1161/01.ATV.0000031341.84618.A4; Goren I, 2009, AM J PATHOL, V175, P132, DOI 10.2353/ajpath.2009.081002; Hall SE, 2009, MOL PHARMACOL, V75, P1325, DOI 10.1124/mol.108.053470; Han S, 2006, CELL METAB, V3, P257, DOI 10.1016/j.cmet.2006.02.008; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Herijgers N, 1997, ARTERIOSCL THROM VAS, V17, P1995, DOI 10.1161/01.ATV.17.10.1995; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Jimenez-Sainz MC, 2006, MOL BIOL CELL, V17, P25, DOI 10.1091/mbc.e05-05-0399; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Kavelaars A, 2011, BRAIN BEHAV IMMUN, V25, P1055, DOI 10.1016/j.bbi.2011.03.019; LEVINE JD, 1988, P NATL ACAD SCI USA, V85, P4553, DOI 10.1073/pnas.85.12.4553; Liehn Elisa A., 2006, Archives of Physiology and Biochemistry, V112, P229, DOI 10.1080/13813450601093583; Liu J, 2005, ARTERIOSCL THROM VAS, V25, P174, DOI 10.1161/01.ATV.0000148548.47755.22; Liu SL, 2005, NAT MED, V11, P952, DOI 10.1038/nm1289; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13, DOI 10.1002/jlb.59.1.13; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matkovich SJ, 2006, CIRC RES, V99, P996, DOI 10.1161/01.RES.0000247932.71270.2c; Moser B, 2004, ANN RHEUM DIS, V63, P84, DOI 10.1136/ard.2004.028316; MULLER S, 1995, BIOCHEM SOC T, V23, P141; Nijboer CH, 2010, BRAIN BEHAV IMMUN, V24, P420, DOI 10.1016/j.bbi.2009.11.009; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Parvataneni S, 2011, INT J CLIN EXP MED, V4, P320; Patial S, 2011, J CELL PHYSIOL, V226, P627, DOI 10.1002/jcp.22384; Penela P, 2008, EMBO J, V27, P1206, DOI 10.1038/emboj.2008.55; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Raake PW, 2008, CIRC RES, V103, P413, DOI 10.1161/CIRCRESAHA.107.168336; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Vroon A, 2005, J IMMUNOL, V174, P4400, DOI 10.4049/jimmunol.174.7.4400; Vroon A, 2004, J LEUKOCYTE BIOL, V75, P901, DOI 10.1189/jlb.0403136; Weber C, 2005, CIRC RES, V96, P612, DOI 10.1161/01.RES.0000160077.17427.57; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Weiss ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001; Willemen HLDM, 2010, PAIN, V150, P550, DOI 10.1016/j.pain.2010.06.015; Wu JH, 2012, ARTERIOSCL THROM VAS, V32, P308, DOI 10.1161/ATVBAHA.111.239608	61	15	16	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2013	27	1					265	276		10.1096/fj.12-205351	http://dx.doi.org/10.1096/fj.12-205351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047899	Green Published			2022-12-28	WOS:000313103200025
J	Borensztein, M; Viengchareun, S; Montarras, D; Journot, L; Binart, N; Lombes, M; Dandolo, L				Borensztein, Maud; Viengchareun, Say; Montarras, Didier; Journot, Laurent; Binart, Nadine; Lombes, Marc; Dandolo, Luisa			Double Myod and Igf2 inactivation promotes brown adipose tissue development by increasing Prdm16 expression	FASEB JOURNAL			English	Article						adipogenesis; transcription factors; UCP1; differentiation	TRANSCRIPTIONAL CONTROL; PPAR-GAMMA; DISTINCT; MICE; MYF-5; FAT; ADIPOCYTES; DEFICIENCY; ACTIVATION; OBESITY	Brown fat or brown adipose tissue ( BAT), found in newborn mammals as small depots localized in the interscapular region, plays a prominent role in regulating thermogenesis perinatally. The physiological importance of functional BAT has been recently reasserted in human adults. Because myoblasts and adipoblasts emerge from a common mesodermal precursor, we investigated developmental determination and the reciprocal relationship between muscle and adipocyte commitment. Here we show that a mutant mouse defective for both Igf2 and Myod genes exhibits massive BAT hypertrophy compared with wildtype and single-mutant newborns. The increased adipocyte proliferation in BAT of double-mutant newborns was associated with overexpression of the brown fat-specific marker Ucp1. More strikingly, expression of the master key gene Prdm16 involved in the switch between myogenic and brown adipogenic lineages was drastically enhanced. We further demonstrate that concomitant Myod and Igf2 inactivation accelerates differentiation of a brown preadipocyte cell line and induces lipid accumulation and increased Ucp1 and Prdm16 expression. This in vitro approach brings additional support for the implication of both Myod and Igf2 in BAT development. These results provide the first in vivo evidence that a myogenic regulator together with a growth factor act simultaneously but through independent pathways to repress Prdm16, which opens potential therapeutic perspectives for human metabolic disorders.-Borensztein, M., Viengchareun, S., Montarras, D., Journot, L., Binart, N., Lombes, M., Dandolo, L. Double Myod and Igf2 inactivation promotes brown adipose tissue development by increasing Prdm16 expression. FASEB J. 26, 4584-4591 (2012). www.fasebj.org	[Borensztein, Maud; Dandolo, Luisa] Univ Paris 05, CNRS, Inst Cochin, INSERM,Dept Genet & Dev,U567,UMR 8104, F-75014 Paris, France; [Viengchareun, Say; Binart, Nadine; Lombes, Marc] Univ Paris Sud, Fac Med Paris Sud, INSERM, U693,UMR S693, F-94275 Le Kremlin Bicetre, France; [Montarras, Didier] Inst Pasteur, CNRS 2578, Dept Dev Biol, Mol Genet Dev Unit,URA, Paris, France; [Journot, Laurent] Univ Montpellier 2, CNRS, INSERM, Inst Genom Fonct,U661,UMR 5203, Montpellier, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Dandolo, L (corresponding author), Univ Paris 05, CNRS, Inst Cochin, INSERM,Dept Genet & Dev,U567,UMR 8104, 24 Rue Fbg St Jacques, F-75014 Paris, France.	luisa.dandolo@inserm.fr	Journot, Laurent/T-9652-2018; Viengchareun, Say/M-6612-2017; Lombes, Marc/L-5933-2018; Borensztein, Maud/AAR-9303-2021; Viengchareun, Say/GOV-6812-2022; Binart, Nadine/F-2949-2013	Journot, Laurent/0000-0003-3499-8887; Lombes, Marc/0000-0003-3189-023X; Borensztein, Maud/0000-0002-4378-5018; Binart, Nadine/0000-0002-5606-3866; viengchareun, say/0000-0003-4280-3250	Association Francaise contre les Myopathies; ANR Epinet Project; Ministere de la Recherche et de l'Enseignement Superieur; Fondation de la Recherche Medicale	Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); ANR Epinet Project(French National Research Agency (ANR)); Ministere de la Recherche et de l'Enseignement Superieur; Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale)	The authors are grateful to Elizabeth J. Robertson (University of Oxford, Oxford, UK) and Argiris Efstratiadis (Columbia University, New York, NY, USA) for the Igf2<SUP>-/-</SUP> mice and to Michael A. Rudnicki (Ottawa Health Research Institute, Ottawa, ON, Canada) for the Myod<SUP>-/-</SUP> mice. The authors are grateful to Margaret Buckingham for critical reading of the article. This work was supported by funding from the Association Francaise contre les Myopathies and the ANR Epinet Project to L. D. and by fellowships from the Ministere de la Recherche et de l'Enseignement Superieur and the Fondation de la Recherche Medicale to M. B.	Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cypess AM, 2011, ENDOCRINOLOGY, V152, P3680, DOI 10.1210/en.2011-1229; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Fruhbeck G, 2009, TRENDS CELL BIOL, V19, P141, DOI 10.1016/j.tcb.2009.01.007; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Gupta RK, 2010, NATURE, V464, P619, DOI 10.1038/nature08816; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Kablar B, 1998, BIOCHEM CELL BIOL, V76, P1079, DOI 10.1139/bcb-76-6-1079; Kablar B, 1997, DEVELOPMENT, V124, P4729; Kajimura S, 2010, CELL METAB, V11, P257, DOI 10.1016/j.cmet.2010.03.005; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Petrovic N, 2010, J BIOL CHEM, V285, P7153, DOI 10.1074/jbc.M109.053942; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Viengchareun S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001535; Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621; Whittle AJ, 2011, TRENDS MOL MED, V17, P405, DOI 10.1016/j.molmed.2011.04.001; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	28	22	22	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4584	4591		10.1096/fj.12-208496	http://dx.doi.org/10.1096/fj.12-208496			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859371	Green Submitted			2022-12-28	WOS:000310574200020
J	Peng, H; Hamanaka, RB; Katsnelson, J; Hao, LL; Yang, WD; Chandel, NS; Lavker, RM				Peng, Han; Hamanaka, Robert B.; Katsnelson, Julia; Hao, Liang-Liang; Yang, Wending; Chandel, Navdeep S.; Lavker, Robert M.			MicroRNA-31 targets FIH-1 to positively regulate corneal epithelial glycogen metabolism	FASEB JOURNAL			English	Article						Akt signaling; energy metabolism; keratinocytes	HYPOXIA-INDUCIBLE FACTOR; OXYGEN-SENSING PATHWAY; ANKYRIN REPEAT DOMAIN; PROLYL HYDROXYLATION; ASPARAGINYL HYDROXYLATION; TRANSCRIPTIONAL ACTIVITY; HIF; EXPRESSION; PROTEIN; CELLS	Corneal epithelium relies on abundant glycogen stores as its primary energy source. MicroRNA-31 (miR-31), a corneal epithelial-preferred miRNA, negatively regulates factor inhibiting hypoxia-inducible factor-1 (FIH-1). Since HIF-1 alpha is involved in anaerobic energy production, we investigated the role that miR-31 and FIH-1 play in regulating corneal epithelial glycogen. We used antagomirs (antago) to reduce the level of miR-31 in primary human corneal epithelial keratinocytes (HCEKs), and a miR-31-resistant FIH-1 to increase FIH-1 levels. Antago-31 raised FIH-1 levels and significantly reduced glycogen stores in HCEKs compared to irrelevant-antago treatment. Similarly, HCEKs retrovirally transduced with a miR-31-resistant FIH-1 had markedly reduced glycogen levels compared with empty vector controls. In addition, we observed no change in a HIF-1 alpha reporter or known genes downstream of HIF-1 alpha indicating that the action of FIH-1 and miR-31 on glycogen is HIF-1 alpha-independent. An enzyme-dead FIH-1 mutation failed to restore glycogen stores, indicating that FIH-1 negatively regulates glycogen in a hydroxylase-independent manner. FIH-1 overexpression in HCEKs decreased AKT signaling, activated GSK-3 beta, and inactivated glycogen synthase. Treatment of FIH-1-transduced HCEKs with either a myristolated Akt or a GSK-3 beta inhibitor restored glycogen stores, confirming the direct involvement of Akt/GSK-3 beta signaling. Silencing FIH-1 in HCEKs reversed the observed changes in Akt-signaling. Glycogen regulation in a HIF-1 alpha-independent manner is a novel function for FIH-1 and provides new insight into how the corneal epithelium regulates its energy requirements.-Peng, H., Hamanaka, R. B., Katsnelson, J., Hao, L., Yang, W., Chandel, N. S., Lavker, R. M. MicroRNA-31 targets FIH-1 to positively regulate corneal epithelial glycogen metabolism. FASEB J. 26, 3140-3147 (2012). www.fasebj.org	[Peng, Han; Hao, Liang-Liang; Yang, Wending; Lavker, Robert M.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Hamanaka, Robert B.; Chandel, Navdeep S.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Katsnelson, Julia] Rush Univ, Sch Med, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Rush University	Lavker, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, 303 E Chicago Ave,Ward 9-124, Chicago, IL 60611 USA.	r-lavker@northwestern.edu	Peng, Han/I-1922-2012	Hao, Liang/0000-0003-2071-7044; Peng, Han/0000-0002-1105-8254	National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR057216]; U.S. National Institutes of Health grants [EY06769, EY017536, EY019463, 1F32HL099007, 5P30AR057216]; NATIONAL EYE INSTITUTE [R01EY019463, R21EY017536, R01EY006769, F32EY006769] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL099007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); U.S. National Institutes of Health grants; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Nihal Kaplan for critical reading of the manuscript and helpful discussions. The Northwestern University Skin Disease Research Center Pathology Core assisted in morphological analyses, and the DNA/RNA Delivery Core assisted with retroviral and lentiviral constructs with support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant AR057216. This research is supported by U.S. National Institutes of Health grants EY06769, EY017536, and EY019463 (R.M.L.), 1F32HL099007 (R.B.H.), and 5P30AR057216 (N.S.C.).	Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartrons R, 2007, J BIOENERG BIOMEMBR, V39, P223, DOI 10.1007/S10863-007-9080-3; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buchanan J, 2005, ENDOCRINOLOGY, V146, P5341, DOI 10.1210/en.2005-0938; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Coleman ML, 2007, J BIOL CHEM, V282, P24027, DOI 10.1074/jbc.M704102200; Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaji Y, 2005, BRIT J OPHTHALMOL, V89, P254, DOI 10.1136/bjo.2004.055541; Kimura K, 2010, EXP EYE RES, V90, P337, DOI 10.1016/j.exer.2009.11.012; KINOSHITA S, 1982, INVEST OPHTH VIS SCI, V23, P73; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Piatigorsky J, 2008, SEMIN CELL DEV BIOL, V19, P69, DOI 10.1016/j.semcdb.2007.10.010; Rayasam GV, 2009, BRIT J PHARMACOL, V156, P885, DOI 10.1111/j.1476-5381.2008.00085.x; REBUFFESCRIVE M, 1993, METABOLISM, V42, P1405, DOI 10.1016/0026-0495(93)90190-Y; Ryan D, 2006, MOL VIS, V12, P1175; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sridharan V, 2007, AM J PHYSIOL-CELL PH, V292, pC719, DOI 10.1152/ajpcell.00100.2006; Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; THOFT RA, 1977, INVEST OPHTH VIS SCI, V16, P14; THOFT RA, 1975, AM J OPHTHALMOL, V80, P139, DOI 10.1016/0002-9394(75)90884-3; Wei ZG, 1996, INVEST OPHTH VIS SCI, V37, P523; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Xu KP, 2009, DIABETES, V58, P1077, DOI 10.2337/db08-0997; Xu KP, 2011, INVEST OPHTH VIS SCI, V52, P3301, DOI 10.1167/iovs.10-5670; Yamamoto Nobutaka, 2006, Eye Contact Lens, V32, P114, DOI 10.1097/01.icl.0000177384.27778.4c; Yu J, 2010, FASEB J, V24, P3950, DOI 10.1096/fj.10-157404; Yu J, 2008, P NATL ACAD SCI USA, V105, P19300, DOI 10.1073/pnas.0803992105; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001; Zhou MY, 2006, J BIOL CHEM, V281, P19600, DOI 10.1074/jbc.M600777200	43	44	47	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3140	3147		10.1096/fj.11-198515	http://dx.doi.org/10.1096/fj.11-198515			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22532441	Green Published			2022-12-28	WOS:000307162800006
J	Purtell, K; Paroder-Belenitsky, M; Reyna-Neyra, A; Nicola, JP; Koba, W; Fine, E; Carrasco, N; Abbott, GW				Purtell, Kerry; Paroder-Belenitsky, Monika; Reyna-Neyra, Andrea; Nicola, Juan P.; Koba, Wade; Fine, Eugene; Carrasco, Nancy; Abbott, Geoffrey W.			The KCNQ1-KCNE2 K+ channel is required for adequate thyroid I- uptake	FASEB JOURNAL			English	Article						hypothyroidism; Kv7.1; MiRP1; positron emission tomography; sodium/iodide symporter	POTASSIUM CHANNELS; SYMPORTER NIS; ACID; KCNQ1; CLONING	The KCNQ1 alpha subunit and the KCNE2 beta subunit form a potassium channel in thyroid epithelial cells. Genetic disruption of KCNQ1-KCNE2 causes hypothyroidism in mice, resulting in cardiac hypertrophy, dwarfism, alopecia, and prenatal mortality. Here, we investigated the mechanistic requirement for KCNQ1-KCNE2 in thyroid hormone biosynthesis, utilizing whole-animal dynamic positron emission tomography. The KCNQ1-specific antagonist (-)-[3R,4S]-chromanol 293B (C293B) significantly impaired thyroid cell I- uptake, which is mediated by the Na+/I- symporter (NIS), in vivo (dSUV/dt: vehicle, 0.028 +/- 0.004 min(-1); 10 mg/kg C293B, 0.009 +/- 0.006 min(-1)) and in vitro (EC50: 99 +/- 10 mu M C293B). Na+-dependent nicotinate uptake by SMCT, however, was unaffected. Kcne2 deletion did not alter the balance of free vs. thyroglobulin-bound I- in the thyroid (distinguished using ClO4-, a competitive inhibitor of NIS), indicating that KCNQ1-KCNE2 is not required for Duox/TPO-mediated I- organification. However, Kcne2 deletion doubled the rate of free I- efflux from the thyroid following ClO4- injection, a NIS-independent process. Thus, KCNQ1-KCNE2 is necessary for adequate thyroid cell I- uptake, the most likely explanation being that it is prerequisite for adequate NIS activity.-Purtell, K., Paroder-Belenitsky, M., Reyna-Neyra, A., Nicola, J. P., Koba, W., Fine, E., Carrasco, N., Abbott, G. W. The KCNQ1-KCNE2 K+ channel is required for adequate thyroid I- uptake. FASEB J. 26, 3252-3259 (2012). www.fasebj.org	[Purtell, Kerry; Abbott, Geoffrey W.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA; [Paroder-Belenitsky, Monika; Reyna-Neyra, Andrea; Carrasco, Nancy] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Koba, Wade; Fine, Eugene] Albert Einstein Coll Med, M Donald Blaufox MicroPET Lab Mol Imaging, Dept Radiol, Bronx, NY 10467 USA; [Carrasco, Nancy] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; [Nicola, Juan P.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06519 USA	Cornell University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University	Abbott, GW (corresponding author), Univ Calif Irvine, Sch Med, Dept Pharmacol, Zot Code 4625, Irvine, CA 92697 USA.	abbottg@uci.edu	Reyna-Neyra, Andrea/F-5621-2013; Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162; Abbott, Geoffrey/0000-0003-4552-496X	U.S. National Institutes of Health grants [HL079275, DK41544, T32GM073546, 5T32GM002788]; American Heart Association grant [0855756D]; Irma T. Hirschl Career Scientist Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM073546, T32GM007288] Funding Source: NIH RePORTER	U.S. National Institutes of Health grants; American Heart Association grant(American Heart Association); Irma T. Hirschl Career Scientist Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants HL079275 (G.W.A.), DK41544 (N.C.), T32GM073546 (K.P.), and 5T32GM002788 (M.P.B.); American Heart Association grant 0855756D (G.W.A.); and an Irma T. Hirschl Career Scientist Award (G.W.A.).	Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Beaulieu S, 2003, J NUCL MED, V44, P1044; Dadachova E, 2004, SEMIN NUCL MED, V34, P23, DOI 10.1053/j.semnuclmed.2003.09.004; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Dohan O, 2007, P NATL ACAD SCI USA, V104, P20250, DOI 10.1073/pnas.0707207104; ENGLER H, 1982, ENDOCRINOLOGY, V110, P190, DOI 10.1210/endo-110-1-190; Frohlich H, 2011, PFLUG ARCH EUR J PHY, V461, P45, DOI 10.1007/s00424-010-0890-5; Geibel JP, 2005, WORLD J GASTROENTERO, V11, P5259, DOI 10.3748/wjg.v11.i34.5259; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; KISSANE JM, 1958, J BIOL CHEM, V233, P184; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; McDonald DO, 2009, J MOL MED, V87, P971, DOI 10.1007/s00109-009-0511-y; Paroder-Belenitsky M, 2011, P NATL ACAD SCI USA, V108, P17933, DOI 10.1073/pnas.1108278108; Ris-Stalpers C, 2006, ANTIOXID REDOX SIGN, V8, P1563, DOI 10.1089/ars.2006.8.1563; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Roepke TK, 2011, FASEB J, V25, P4264, DOI 10.1096/fj.11-187609; Roepke TK, 2009, NAT MED, V15, P1186, DOI 10.1038/nm.2029; TAKEUCHI K, 1970, J CLIN ENDOCR METAB, V31, P144, DOI 10.1210/jcem-31-2-144; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17	21	40	41	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3252	3259		10.1096/fj.12-206110	http://dx.doi.org/10.1096/fj.12-206110			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22549510	Green Published, Green Submitted			2022-12-28	WOS:000307162800016
J	Zadjali, F; Santana-Farre, R; Vesterlund, M; Carow, B; Mirecki-Garrido, M; Hernandez-Hernandez, I; Flodstrom-Tullberg, M; Parini, P; Rottenberg, M; Norstedt, G; Fernandez-Perez, L; Flores-Morales, A				Zadjali, Fahad; Santana-Farre, Ruyman; Vesterlund, Mattias; Carow, Berit; Mirecki-Garrido, Mercedes; Hernandez-Hernandez, Irene; Flodstrom-Tullberg, Malin; Parini, Paolo; Rottenberg, Martin; Norstedt, Gunnar; Fernandez-Perez, Leandro; Flores-Morales, Amilcar			SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice	FASEB JOURNAL			English	Article						growth hormone; inflammation; suppressor of cytokine signaling	LACKING SUPPRESSOR; LIVER; DEFICIENCY; OBESITY; STEATOHEPATITIS; HYPERLIPIDEMIA; EXPRESSION; PROTEINS	Hepatic steatosis is a prominent feature in patients with growth hormone (GH) deficiency. The ubiquitin ligase SOCS2 attenuates hepatic GH signaling by inhibiting the Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5b (STAT5b) axis. Here, we investigated the role of SOCS2 in the development of diet-induced hepatic steatosis and insulin resistance. SOCS2-knockout (SOCS2(-/-)) mice and wild-type littermates were fed for 4 mo with control or high-fat diet, followed by assessment of insulin sensitivity, hepatic lipid content, and expression of inflammatory cytokines. SOCS2(-/-) mice exhibited increased hepatic TG secretion by 77.6% (P<0.001) as compared with wild-type control mice and were protected from high-fat-diet (HFD)-induced hepatic steatosis, showing 49.3% (P<0.01) reduction in liver TG levels compared to HFD-fed wild-type littermates. In contrast, we found that HFD-triggered attenuation of systemic insulin sensitivity was more marked in SOCS2(-/-) mice. Livers from the HFD-fed SOCS2(-/-) mice showed increased NF-kappa B activity as well as elevated expression of genes for the inflammatory cytokines IFN-gamma and IL-6. An inhibitory role of SOCS2 on Toll-like receptor 4 signaling was demonstrated in macrophages obtained from the SOCS2(-/-) and wild-type mice. This study identified SOCS2 as an important regulator of hepatic homeostasis under conditions of high-fat dietary stress.-Zadjali, F., Santana-Farre, R., Vesterlund, M., Carow, B., Mirecki-Garrido, M., Hernandez-Hernandez, I., Flodstrom-Tullberg, M., Parini, P., Rottenberg, M., Norstedt, G., Fernandez-Perez, L., Flores-Morales, A. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice. FASEB J. 26, 3282-3291 (2012). www.fasebj.org	[Zadjali, Fahad; Vesterlund, Mattias; Flores-Morales, Amilcar] Univ Copenhagen, Novo Nordisk Fdn Ctr Prot Res, Fac Hlth Sci, DK-2200 Copenhagen, Denmark; [Flodstrom-Tullberg, Malin] Karolinska Inst, Dept Med, Stockholm, Sweden; [Zadjali, Fahad; Vesterlund, Mattias; Norstedt, Gunnar] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Parini, Paolo] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Carow, Berit; Rottenberg, Martin] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Zadjali, Fahad] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Biochem, Al Khoud, Oman; [Santana-Farre, Ruyman; Mirecki-Garrido, Mercedes; Fernandez-Perez, Leandro] Univ Las Palmas Gran Canaria, Canary Inst Canc Res ICIC, Fac Hlth Sci, Dept Clin Sci, Las Palmas Gran Canaria, Spain; [Hernandez-Hernandez, Irene] Univ Las Palmas Gran Canaria, Immune Signaling Lab, Dept Biochem & Mol Biol, Las Palmas Gran Canaria, Spain; [Hernandez-Hernandez, Irene] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid, Spain	University of Copenhagen; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sultan Qaboos University; Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Flores-Morales, A (corresponding author), Univ Copenhagen, Novo Nordisk Fdn Ctr Prot Res, Fac Hlth Sci, Blegdamsvej 3B,Bldg 6-1, DK-2200 Copenhagen, Denmark.	amilcar.flores@cpr.ku.dk	Mirecki-Garrido, Mercedes/H-6075-2015; Carow, Berit/AAE-3970-2020; Hernández, Irene/N-7551-2016; Vesterlund, Mattias/AAX-8014-2021; Fernandez-Perez, Leandro/H-1493-2015; ZADJALI, FAHAD/B-5091-2019	Mirecki-Garrido, Mercedes/0000-0003-0488-6307; Hernández, Irene/0000-0001-7174-7599; Fernandez-Perez, Leandro/0000-0001-7802-465X; ZADJALI, FAHAD/0000-0001-5891-4700; Rottenberg, Martin/0000-0003-0514-7434; Flodstrom Tullberg, Malin/0000-0003-2685-2052; Carow, Berit/0000-0002-8760-6253; Norstedt, Gunnar/0000-0002-7759-3241; Vesterlund, Mattias/0000-0001-9471-6592	Novo Nordisk Foundation; The Swedish Research Council [2009-3738]; Danish Research Council; Spanish Ministry of Science and Innovation; European Regional Development Fund-European Social Fund [SAF2006-07824, SAF2009-13296]; Sultan Qaboos University; Karolinska Institutet; University of Las Palmas de Gran Canaria	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); The Swedish Research Council(Swedish Research Council); Danish Research Council(Det Frie Forskningsrad (DFF)); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Regional Development Fund-European Social Fund; Sultan Qaboos University; Karolinska Institutet(Karolinska Institutet); University of Las Palmas de Gran Canaria	The SOCS2<SUP>-/-</SUP> mice were provided by Dr. D. Hilton (Walter and Eliza Hall Institute, Melbourne, VIC, Australia). The authors are indebted to Carlos Mateos-Diaz, M. Mercedes Diaz, and Michael Huhn for their technical assistance. This work was supported by grants from the Novo Nordisk Foundation, The Swedish Research Council (no. 2009-3738), and the Danish Research Council to A.F.-M. and in part by grants to L.F.-P. from the Spanish Ministry of Science and Innovation with funding from the European Regional Development Fund-European Social Fund (SAF2006-07824; SAF2009-13296). F.Z., M.V., and M.M.-G. were supported by fellowships from Sultan Qaboos University, Karolinska Institutet, and the University of Las Palmas de Gran Canaria, respectively.	Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Elam MB, 2009, OBESITY, V17, P1563, DOI 10.1038/oby.2009.49; Emanuelli B, 2008, BIOCHEM BIOPH RES CO, V377, P447, DOI 10.1016/j.bbrc.2008.09.158; Fan Y, 2009, J BIOL CHEM, V284, P19937, DOI 10.1074/jbc.M109.014308; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Goodpaster BH, 2000, METABOLISM, V49, P467, DOI 10.1016/S0026-0495(00)80010-4; Greenhalgh CJ, 2005, J CLIN INVEST, V115, P397, DOI 10.1172/JCI200522710; Harris J, 2006, MOL ENDOCRINOL, V20, P1177, DOI 10.1210/me.2005-0473; Hu J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007178; Knosp CA, 2011, J EXP MED, V208, P1523, DOI 10.1084/jem.20101167; Kodama Y, 2009, GASTROENTEROLOGY, V137, P1467, DOI 10.1053/j.gastro.2009.06.045; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Li XH, 1996, J LIPID RES, V37, P210; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Martinez-Clemente M, 2010, HEPATOLOGY, V51, P817, DOI 10.1002/hep.23463; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Parini P, 2006, EUR J CLIN INVEST, V36, P98, DOI 10.1111/j.1365-2362.2006.01597.x; Rico-Bautista E, 2005, MOL ENDOCRINOL, V19, P781, DOI 10.1210/me.2004-0040; Rico-Bautista E, 2006, CYTOKINE GROWTH F R, V17, P431, DOI 10.1016/j.cytogfr.2006.09.008; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saberi M, 2009, CELL METAB, V10, P419, DOI 10.1016/j.cmet.2009.09.006; Sachithanandan N, 2010, HEPATOLOGY, V52, P1632, DOI 10.1002/hep.23861; Schattenberg JM, 2006, HEPATOLOGY, V43, P163, DOI 10.1002/hep.20999; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Sos BC, 2011, J CLIN INVEST, V121, P1412, DOI 10.1172/JCI42894; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Takahashi Y, 2007, GASTROENTEROLOGY, V132, P938, DOI 10.1053/j.gastro.2006.12.024; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Vesterlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025358; Wormald S, 2006, J BIOL CHEM, V281, P11135, DOI 10.1074/jbc.M509595200; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zhang DY, 2010, CELL METAB, V11, P402, DOI 10.1016/j.cmet.2010.03.012	34	52	53	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3282	3291		10.1096/fj.12-205583	http://dx.doi.org/10.1096/fj.12-205583			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22562833				2022-12-28	WOS:000307162800019
J	Lafargue, M; Xu, LJ; Carles, M; Serve, E; Anjum, N; Iles, KE; Xiong, XX; Giffard, R; Pittet, JF				Lafargue, Mathieu; Xu, Lijun; Carles, Michel; Serve, Emilie; Anjum, Naseem; Iles, Karen E.; Xiong, Xiaoxing; Giffard, Rona; Pittet, Jean-Francois			Stroke-induced activation of the alpha 7 nicotinic receptor increases Pseudomonas aeruginosa lung injury	FASEB JOURNAL			English	Article						vagus nerve; pneumonia	FOCAL CEREBRAL-ISCHEMIA; ACETYLCHOLINE-RECEPTORS; MEDICAL COMPLICATIONS; GENDER-DIFFERENCES; FLUID BALANCE; BRAIN-INJURY; MICE; PNEUMONIA; INFECTION; MELANOCORTINS	Infectious complications, predominantly pneumonia, are the most common cause of death in the postacute phase of stroke, although the mechanisms underlying the corresponding immunosuppression are not fully understood. We tested the hypothesis that activation of the alpha 7 nicotinic acetylcholine receptor (alpha 7nAChR) pathway is important in the stroke-induced increase in lung injury caused by Pseudomonas aeruginosa pneumonia in mice. Prior stroke increased lung vascular permeability caused by P. aeruginosa pneumonia and was associated with decreased lung neutrophil recruitment and bacterial clearance in mice. Pharmacologic inhibition (methyllycaconitine IC50: 0.2-0.6 nM) or genetic deletion of the alpha 7nAChR significantly (P<0.05) attenuates the effect of prior stroke on lung injury and mortality caused by P. aeruginosa pneumonia in mice. Finally, pretreatment with PNU-282987, a pharmacologic activator of the alpha 7nAChR (EC50: 0.2 mu M), significantly (P<0.05) increased lung injury caused by P. aeruginosa pneumonia, significantly (P<0.05) decreased the release of KC, a major neutrophil chemokine, and significantly (P<0.05) decreased intracellular bacterial killing by a mouse alveolar macrophage cell line and primary mouse neutrophils. In summary, the alpha 7 nicotinic cholinergic pathway plays an important role in mediating the systemic immunosuppression observed after stroke and directly contributes to more severe lung damage induced by P. aeruginosa.-Lafargue, M., Xu, L., Carles, M., Serve, E., Anjum, N., Iles, K. E., Xiong, X., Giffard, R., Pittet, J.-F. Stroke-induced activation of the alpha 7 nicotinic receptor increases Pseudomonas aeruginosa lung injury. FASEB J. 26, 2919-2929 (2012). www.fasebj.org	[Serve, Emilie; Anjum, Naseem; Iles, Karen E.; Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35249 USA; [Lafargue, Mathieu] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; [Xu, Lijun; Xiong, Xiaoxing; Giffard, Rona] Stanford Univ, Sch Med, Dept Anesthesia, Palo Alto, CA 94304 USA; [Carles, Michel] Univ Nice Sophia Antipolis, Dept Anesthesia, Nice, France	University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; Stanford University; UDICE-French Research Universities; Universite Cote d'Azur	Pittet, JF (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 619 S 19th St,JT926, Birmingham, AL 35249 USA.	pittetj@uab.edu	Carles, Michel/CAH-0065-2022	Giffard, Rona/0000-0003-2173-4436; CARLES, MICHEL/0000-0001-5485-1511; Xiong, Xiaoxing/0000-0001-6983-8547	U.S. National Institutes of Health [RO1 GM-62188, RO1 GM-49831]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049831, R01GM062188] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in part, by the U.S. National Institutes of Health, grants RO1 GM-62188 (J.F.P.) and RO1 GM-49831 (R.G.).	BERTRAND N, 1993, J CEREBR BLOOD F MET, V13, P789, DOI 10.1038/jcbfm.1993.100; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Brea D, 2009, CEREBROVASC DIS, V27, P48, DOI 10.1159/000200441; Carles M, 2010, ANESTHESIOLOGY, V113, P1134, DOI 10.1097/ALN.0b013e3181f4171b; Chamorro A, 2006, J NEUROL NEUROSUR PS, V77, P1279, DOI 10.1136/jnnp.2006.100800; Chamorro A, 2005, STROKE, V36, P1495, DOI 10.1161/01.STR.0000170644.15504.49; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Cheyuo C, 2011, SHOCK, V35, P258, DOI 10.1097/SHK.0b013e3181f48a37; CZLONKOWSKA A, 1979, J NEUROL SCI, V43, P455, DOI 10.1016/0022-510X(79)90024-8; dos Santos CC, 2011, AM J RESP CRIT CARE, V183, P471, DOI 10.1164/rccm.201002-0314OC; Fukuda M, 2009, INTERNAL MED, V48, P967, DOI 10.2169/internalmedicine.48.1757; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Giebelen IAJ, 2009, EUR RESPIR J, V33, P375, DOI 10.1183/09031936.00103408; Giebelen IAJ, 2007, SHOCK, V28, P700, DOI 10.1097/shk.0b013e318054dd89; Giebelen IAJ, 2008, J INFECT DIS, V198, P750, DOI 10.1086/590432; Giuliani D, 2007, EUR J PHARMACOL, V570, P57, DOI 10.1016/j.ejphar.2007.05.025; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; HENON H, 1995, STROKE, V26, P392, DOI 10.1161/01.STR.26.3.392; Hilker R, 2003, STROKE, V34, P975, DOI 10.1161/01.STR.0000063373.70993.CD; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; Kim JS, 2010, J CLIN NEUROL, V6, P183, DOI 10.3988/jcn.2010.6.4.183; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Matsunaga K, 2001, J IMMUNOL, V167, P6518, DOI 10.4049/jimmunol.167.11.6518; McAuley Danny F, 2005, Treat Respir Med, V4, P297, DOI 10.2165/00151829-200504050-00001; Minnerup J, 2010, J NEUROL NEUROSUR PS, V81, P198, DOI 10.1136/jnnp.2009.182394; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Ottani A, 2009, J CEREBR BLOOD F MET, V29, P512, DOI 10.1038/jcbfm.2008.140; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Prass K, 2006, STROKE, V37, P2607, DOI 10.1161/01.STR.0000240409.68739.2b; Robriquet L, 2011, EXP LUNG RES, V37, P453, DOI 10.3109/01902148.2011.593092; Rosas-Ballina M, 2009, NEURON, V64, P28, DOI 10.1016/j.neuron.2009.09.039; Rothwell PM, 2011, LANCET, V377, P1681, DOI 10.1016/S0140-6736(11)60516-3; Roux J, 2010, J BIOL CHEM, V285, P4278, DOI 10.1074/jbc.M109.036731; Schulte-Herbruggen O, 2006, NEUROIMMUNOMODULAT, V13, P13, DOI 10.1159/000092109; Su X, 2006, AM J PHYSIOL-LUNG C, V290, pL769, DOI 10.1152/ajplung.00334.2005; Su X, 2007, AM J RESP CELL MOL, V37, P186, DOI 10.1165/rcmb.2006-0240OC; Su X, 2010, J IMMUNOL, V184, P401, DOI 10.4049/jimmunol.0901808; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tadie JM, 2012, AM J PHYSIOL-CELL PH, V302, pC249, DOI 10.1152/ajpcell.00302.2011; Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Yamaguchi H, 2003, INFECT IMMUN, V71, P3645, DOI 10.1128/IAI.71.6.3645-3647.2003; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	43	36	37	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2012	26	7					2919	2929		10.1096/fj.11-197384	http://dx.doi.org/10.1096/fj.11-197384			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490926	Green Published			2022-12-28	WOS:000305912500020
J	Kimura, Y; Mikami, Y; Osumi, K; Tsugane, M; Oka, J; Kimura, H				Kimura, Yuka; Mikami, Yoshinori; Osumi, Kimiko; Tsugane, Mamiko; Oka, Jun-ichiro; Kimura, Hideo			Polysulfides are possible H2S-derived signaling molecules in rat brain	FASEB JOURNAL			English	Article						persulfide; hydrogen sulfide; Ca2+ influx; TRP channels	CYSTATHIONINE BETA-SYNTHASE; HYDROGEN-SULFIDE; TRPA1; H2S; PRESERVATION; PROTECTS; CHANNEL	Accumulating evidence shows that hydrogen sulfide (H2S) has a variety of physiological functions. H2S is produced from cysteine by 3 sulfurtransferases. H2S, in turn, generates polysulfides, the functions of which are not well understood. H2S induces Ca2+ influx in astrocytes, a type of glia. However, the receptor that mediates the response has not been identified. Here, we have shown that polysulfides induce Ca2+ influx by activating transient receptor potential (TRP) A1 channels in rat astrocytes (EC50 91 nM, Hill coefficient value 1.77 +/- 0.26) and that the maximum response was induced at 0.5 mu M, which is 1/320 of the concentration of H2S required to achieve a response of similar magnitude (160 mu M, EC50 116 mu M). TRPA1-selective agonists, allyl isothiocyanate and cinnamaldehyde, induced Ca2+ influx, and responses to polysulfides were suppressed by TRPA1-selective inhibitors, HC-030031 and AP-18, as well as by siRNAs selective to TRPA1. The present study suggests that polysulfides are possible H2S-derived signaling molecules that stimulate TRP channels in the brain.-Kimura, Y., Mikami, Y., Osumi, K., Tsugane, M., Oka, J., Kimura, H. Polysulfides are possible H2S-derived signaling molecules in rat brain.	[Kimura, Yuka; Mikami, Yoshinori; Osumi, Kimiko; Tsugane, Mamiko; Kimura, Hideo] Natl Inst Neurosci, Dept Mol Pharmacol, Tokyo, Japan; [Oka, Jun-ichiro] Tokyo Univ Sci, Fac Pharmaceut Sci, Chiba, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo University of Science	Kimura, H (corresponding author), NCNP, Natl Inst Neurosci, Dept Mol Pharmacol, Kodaira, Tokyo 1878502, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Mikami, Yoshinori/W-3056-2019; Kimura, Hideo/J-6811-2016; Mikami, Yoshinori/G-6174-2011	Kimura, Hideo/0000-0002-6069-0475; Mikami, Yoshinori/0000-0002-4335-4170; Mikami, Yoshinori/0000-0002-4335-4170	Japan National Institute of Neuroscience; KAKENHI [23790316, 22590258];  [23659089]; Grants-in-Aid for Scientific Research [23790316] Funding Source: KAKEN	Japan National Institute of Neuroscience; KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a grant from the Japan National Institute of Neuroscience, a Grant-in-Aid for Scientific Research (KAKENHI) for Challenging Exploratory Research (23659089) to H. K., a KAKENHI for Young Scientists (B) (23790316) to Y.M., and a KAKENHI (C) (22590258) to Y.K.	Abe K, 1996, J NEUROSCI, V16, P1066; Benavides GA, 2007, P NATL ACAD SCI USA, V104, P17977, DOI 10.1073/pnas.0705710104; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Furne J, 2008, AM J PHYSIOL-REG I, V295, pR1479, DOI 10.1152/ajpregu.90566.2008; GIGGENBACH W, 1972, INORG CHEM, V11, P1201, DOI 10.1021/ic50112a009; Gun J, 2004, MICROCHIM ACTA, V146, P229, DOI 10.1007/s00604-004-0179-5; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI [10.1089/ars.2008.2132, 10.1089/ARS.2008.2132]; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Kleinjan WE, 2005, IND ENG CHEM RES, V44, P309, DOI 10.1021/ie049579q; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Munchberg U, 2007, ORG BIOMOL CHEM, V5, P1505, DOI 10.1039/b703832a; Nagai Y, 2006, J PHARMACOL SCI, V100, p200P; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Nagy P, 2010, CHEM RES TOXICOL, V23, P1541, DOI 10.1021/tx100266a; Nielsen RW, 2011, ANTIOXID REDOX SIGN, V15, P67, DOI 10.1089/ars.2010.3677; Ogawa H, 2012, NEUROSCIENCE, V218, P335, DOI 10.1016/j.neuroscience.2012.05.044; Oosumi K., 2010, B JPN SOC NEUROCHEM, V49, P517; Papapetropoulos A, 2009, P NATL ACAD SCI USA, V106, P21972, DOI 10.1073/pnas.0908047106; Petrus M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-40; Predmore BL, 2012, AM J PHYSIOL-HEART C, V302, pH2410, DOI 10.1152/ajpheart.00044.2012; Searcy DG, 1998, J EXP ZOOL, V282, P310, DOI 10.1002/(SICI)1097-010X(19981015)282:3<310::AID-JEZ4>3.0.CO;2-P; Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021; Shibuya N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2371; Shibuya N, 2009, ANTIOXID REDOX SIGN, V11, P703, DOI [10.1089/ars.2008.2253, 10.1089/ARS.2008.2253]; Shigetomi E, 2012, NAT NEUROSCI, V15, P70, DOI 10.1038/nn.3000; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Streng T, 2008, EUR UROL, V53, P391, DOI 10.1016/j.eururo.2007.10.024; Toohey JI, 2011, ANAL BIOCHEM, V413, P1, DOI 10.1016/j.ab.2011.01.044; Tsugane M, 2007, ANTIOXID REDOX SIGN, V9, P257, DOI 10.1089/ars.2007.9.257; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; Wintner EA, 2010, BRIT J PHARMACOL, V160, P941, DOI 10.1111/j.1476-5381.2010.00704.x; Xiang Y, 2010, NATURE, V468, P921, DOI 10.1038/nature09576; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	38	253	264	0	82	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2451	2457		10.1096/fj.12-226415	http://dx.doi.org/10.1096/fj.12-226415			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23413359				2022-12-28	WOS:000319667600032
J	Both, L; van Dolleweerd, C; Wright, E; Banyard, AC; Bulmer-Thomas, B; Selden, D; Altmann, F; Fooks, AR; Ma, JKC				Both, Leonard; van Dolleweerd, Craig; Wright, Edward; Banyard, Ashley C.; Bulmer-Thomas, Bianca; Selden, David; Altmann, Friedrich; Fooks, Anthony R.; Ma, Julian K. -C.			Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans	FASEB JOURNAL			English	Article						plant biotechnology; molecular pharming; PEP; tobacco	VIRUS-NEUTRALIZING EPITOPE; POSTEXPOSURE PROPHYLAXIS; GLYCOSYLATION; LYSSAVIRUSES; PATHOGENICITY; GLYCOPROTEIN; COCKTAIL; IDENTIFICATION; IMMUNOTHERAPY; COMBINATION	Rabies kills many people throughout the developing world every year. The murine monoclonal antibody (mAb) 62-71-3 was recently identified for its potential application in rabies postexposure prophylaxis (PEP). The purpose here was to establish a plant-based production system for a chimeric mouse-human version of mAb 62-71-3, to characterize the recombinant antibody and investigate at a molecular level its interaction with rabies virus glycoprotein. Chimeric 62-71-3 was successfully expressed in Nicotiana benthamiana. Glycosylation was analyzed by mass spectroscopy; functionality was confirmed by antigen ELISA, as well as rabies and pseudotype virus neutralization. Epitope characterization was performed using pseudotype virus expressing mutagenized rabies glycoproteins. Purified mAb demonstrated potent viral neutralization at 500 IU/mg. A critical role for antigenic site I of the glycoprotein, as well as for two specific amino acid residues (K226 and G229) within site I, was identified with regard to mAb 62-71-3 neutralization. Pseudotype viruses expressing glycoprotein from lyssaviruses known not to be neutralized by this antibody were the controls. The results provide the molecular rationale for developing 62-71-3 mAb for rabies PEP; they also establish the basis for developing an inexpensive plant-based antibody product to benefit low-income families in developing countries.	[Both, Leonard; van Dolleweerd, Craig; Ma, Julian K. -C.] Univ London, Div Clin Sci, Hotung Mol Immunol Unit, London SW17 0RE, England; [Both, Leonard; Wright, Edward; Banyard, Ashley C.; Selden, David; Fooks, Anthony R.] Dept Virol, Wildlife Zoonoses & Vector Borne Dis Res Grp, Anim Hlth & Vet Labs Agcy, Weybridge, Surrey, England; [Wright, Edward] Univ Westminster, Sch Life Sci, London W1R 8AL, England; [Wright, Edward; Bulmer-Thomas, Bianca] UCL, Wohl Vir Ctr, Div Infect & Immun, London, England; [Altmann, Friedrich] Univ Nat Resources & Life Sci, Dept Chem, Vienna, Austria	University of London; Veterinary Laboratories Agency; University of Westminster; University of London; University College London; University of Natural Resources & Life Sciences, Vienna	Ma, JKC (corresponding author), Univ London, Div Clin Sci, Hotung Mol Immunol Unit, London SW17 0RE, England.	jma@sgul.ac.uk	Banyard, Ashley/C-7998-2011; Fooks, Anthony R/F-5418-2010	Banyard, Ashley/0000-0002-1286-9825; van Dolleweerd, Craig/0000-0002-1380-6930; Wright, Edward/0000-0001-7041-5138; Ma, Julian/0000-0003-0767-0042; Altmann, Friedrich/0000-0002-0112-7877	EU; Dr. Hadwen Trust for Humane Research; Hotung Foundation; St. George's, University of London (London, UK); AHVLA; COST projects [FAO94]	EU(European Commission); Dr. Hadwen Trust for Humane Research; Hotung Foundation; St. George's, University of London (London, UK); AHVLA; COST projects	The authors thank Marie Paule Kieny (World Health Organization, Geneva, Switzerland) and Charles E. Rupprecht (U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA) for providing the 62-71-3 variable domain sequences and Polymun Scientific Immunbiologische Forschung (Klosterneuberg, Austria) for providing the 4E10 constant domain sequences. The authors also thank Thomas Muller [Friedrich Loeffler Institut(FLI), Wusterhausen, Germany] for the E559 hybridoma, Robin Weiss (University College London, London, UK) for help with the PNA, and Derek Healy [Animal Health and Veterinary Laboratories Agency (AHVLA), Weybridge, UK] for help with the FAVN. The authors are grateful to the EU-funded Pharma-Planta, Future-Pharma, and COST (FAO94) projects and the Dr. Hadwen Trust for Humane Research, as well as the Hotung Foundation. This work was supported by St. George's, University of London (London, UK), and AHVLA.	Arai YT, 2003, EMERG INFECT DIS, V9, P333, DOI 10.3201/eid0903.020252; Badrane H, 2001, J VIROL, V75, P3268, DOI 10.1128/JVI.75.7.3268-3276.2001; Bakker ABH, 2008, VACCINE, V26, P5922, DOI 10.1016/j.vaccine.2008.08.050; Bakker ABH, 2005, J VIROL, V79, P9062, DOI 10.1128/JVI.79.14.9062-9068.2005; Bardor M, 2003, GLYCOBIOLOGY, V13, P427, DOI 10.1093/glycob/cwg024; BENMANSOUR A, 1991, J VIROL, V65, P4198, DOI 10.1128/JVI.65.8.4198-4203.1991; Both L, 2012, LANCET INFECT DIS, V12, P397, DOI 10.1016/S1473-3099(11)70340-1; Botvinkin AD, 2003, EMERG INFECT DIS, V9, P1623, DOI 10.3201/eid0912.030374; Champion JM, 2000, J IMMUNOL METHODS, V235, P81, DOI 10.1016/S0022-1759(99)00223-9; CONSTANTINE DG, 1967, RABIES TRANSMISSION; DIETZSCHOLD B, 1990, J VIROL, V64, P3804, DOI 10.1128/JVI.64.8.3804-3809.1990; DIETZSCHOLD B, 1983, P NATL ACAD SCI-BIOL, V80, P70, DOI 10.1073/pnas.80.1.70; DIETZSCHOLD B, 1982, J VIROL, V44, P595, DOI 10.1128/JVI.44.2.595-602.1982; Dodet B, 2009, VACCINE, V27, P5027, DOI [10.1016/j.vaccine.2009.06.030, 10.1016/j.vaccine.2009.02.012]; FISHBEIN DB, 1993, NEW ENGL J MED, V329, P1632, DOI 10.1056/NEJM199311253292208; Fooks A R, 2005, Euro Surveill, V10, P1; Gomord V, 2010, PLANT BIOTECHNOL J, V8, P564, DOI 10.1111/j.1467-7652.2009.00497.x; Goudsmit J, 2006, J INFECT DIS, V193, P796, DOI 10.1086/500470; Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339; Hanlon CA, 2005, VIRUS RES, V111, P44, DOI 10.1016/j.virusres.2005.03.009; Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Horton DL, 2010, J VIROL, V84, P11841, DOI 10.1128/JVI.01153-10; Hultberg A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017665; Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360; Ko K, 2005, VIRUS RES, V111, P93, DOI 10.1016/j.virusres.2005.03.016; Ko KS, 2003, P NATL ACAD SCI USA, V100, P8013, DOI 10.1073/pnas.0832472100; Kuzmin IV, 2003, VIRUS RES, V97, P65, DOI 10.1016/S0168-1702(03)00217-X; Lafay F, 1996, J GEN VIROL, V77, P339, DOI 10.1099/0022-1317-77-2-339; LAFON M, 1983, J GEN VIROL, V64, P843, DOI 10.1099/0022-1317-64-4-843; Luo TR, 1997, VIRUS RES, V51, P35, DOI 10.1016/S0168-1702(97)00080-4; Ma JKC, 2005, VACCINE, V23, P1814, DOI 10.1016/j.vaccine.2004.11.011; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; Mallewa M, 2007, EMERG INFECT DIS, V13, P136, DOI 10.3201/eid1301.060810; Manning Susan E., 2008, Morbidity and Mortality Weekly Report, V57, P1; Mansfield KL, 2004, J GEN VIROL, V85, P3279, DOI 10.1099/vir.0.80362-0; Marissen WE, 2005, J VIROL, V79, P4672, DOI 10.1128/JVI.79.8.4672-4678.2005; McCormick AA, 2008, P NATL ACAD SCI USA, V105, P10131, DOI 10.1073/pnas.0803636105; Muller T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000542; Muhamuda K, 2007, HUM VACCINES, V3, P192, DOI 10.4161/hv.3.5.4386; PREHAUD C, 1988, J VIROL, V62, P1; Prosniak M, 2003, J INFECT DIS, V188, P53, DOI 10.1086/375247; Rupprecht CE, 2004, NEW ENGL J MED, V351, P2626, DOI 10.1056/NEJMcp042140; Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6; Rupprecht CE, 2009, VACCINE, V27, P7141, DOI 10.1016/j.vaccine.2009.09.029; Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x; SATPATHY DM, 2005, J INDIAN MED ASSOC, V103, P241; SEIF I, 1985, J VIROL, V53, P926, DOI 10.1128/JVI.53.3.926-934.1985; Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P77, DOI 10.1086/649873; Sloan SE, 2007, VACCINE, V25, P2800, DOI 10.1016/j.vaccine.2006.12.031; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; Sudarshan M K, 2006, J Commun Dis, V38, P32; Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653; Tekoah Y, 2004, ARCH BIOCHEM BIOPHYS, V426, P266, DOI 10.1016/j.abb.2004.02.034; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; Warrell M, 2010, INT J ANTIMICROB AG, V36, pS47, DOI 10.1016/j.ijantimicag.2010.06.021; Warrell MJ, 2003, VACCINE, V21, P706, DOI 10.1016/S0264-410X(02)00585-6; Wertheim HFL, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000044; WHO, 2002, WHO CONS RAB MON ANT; Winkler W G, 1968, Wildl Dis, V4, P37; World Health Organization, 2012, RAB FACT SHEET 99; Wright E, 2008, J GEN VIROL, V89, P2204, DOI 10.1099/vir.0.2008/000349-0; Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361, DOI 10.1038/4344	63	32	35	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					2055	2065		10.1096/fj.12-219964	http://dx.doi.org/10.1096/fj.12-219964			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23371065	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000318226100025
J	Goncharova, EA				Goncharova, Elena A.			mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects	FASEB JOURNAL			English	Review						pulmonary hypertension; mTORC1; mTORC2; rapamycin	PULMONARY ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE-CELLS; MAMMALIAN TARGET; GROWTH-FACTOR; IN-VITRO; ENHANCED EXPRESSION; ENDOTHELIAL-CELLS; CANCER-CELLS; HYPOXIA; RAPAMYCIN	Mammalian target of rapamycin (mTOR) is a major regulator of cellular metabolism, proliferation, and survival that is implicated in various proliferative and metabolic diseases, including obesity, type 2 diabetes, hamartoma syndromes, and cancer. Emerging evidence suggests a potential critical role of mTOR signaling in pulmonary vascular remodeling. Remodeling of small pulmonary arteries due to increased proliferation, resistance to apoptosis, and altered metabolism of cells forming the pulmonary vascular wall is a key currently irreversible pathological feature of pulmonary hypertension, a progressive pulmonary vascular disorder with high morbidity and mortality. In addition to rare familial and idiopathic forms, pulmonary hypertension is also a life-threatening complication of several lung diseases associated with hypoxia. This review aims to summarize our current knowledge and recent advances in understanding the role of the mTOR pathway in pulmonary vascular remodeling, with a specific focus on the hypoxia component, a confirmed shared trigger of pulmonary hypertension in lung diseases. We also discuss the emerging role of mTOR as a promising therapeutic target and mTOR inhibitors as potential pharmacological approaches to treat pulmonary vascular remodeling in pulmonary hypertension.-Goncharova, E. A. mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J. 27, 1796-1807 (2013). www.fasebj.org	[Goncharova, Elena A.] Univ Penn, Perelman Sch Med, Penn Cardiovasc Inst, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Goncharova, EA (corresponding author), Univ Penn, Perelman Sch Med, Translat Res Labs, Rm 1214,125 South 31st St, Philadelphia, PA 19104 USA.	goncharo@mail.med.upenn.edu			U.S. National Institutes of Health [1R01HL113178]; American Lung Association [RG196551]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113178] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The author thanks Dmitry Goncharov (University of Pennsylvania) for helpful discussion and preparation of figures and Mary McNichol (University of Pennsylvania) for critical reading of the manuscript. This work is supported by U.S. National Institutes of Health grant 1R01HL113178 and American Lung Association grant RG196551 to E.A.G.	Agard C, 2009, BRIT J PHARMACOL, V158, P1285, DOI 10.1111/j.1476-5381.2009.00445.x; Ambalavanan N, 1999, BIOL NEONATE, V76, P311, DOI 10.1159/000014173; Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Archer SL, 2010, CIRCULATION, V121, P2045, DOI 10.1161/CIRCULATIONAHA.108.847707; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barbera JA, 2003, EUR RESPIR J, V21, P892, DOI 10.1183/09031936.03.00115402; Barilli A, 2008, CARDIOVASC RES, V78, P563, DOI 10.1093/cvr/cvn024; Behr J, 2008, EUR RESPIR J, V31, P1357, DOI 10.1183/09031936.00171307; Benisty JI, 2004, CHEST, V126, P1255, DOI 10.1378/chest.126.4.1255; Broughton BRS, 2010, AM J PHYSIOL-LUNG C, V298, pL232, DOI 10.1152/ajplung.00276.2009; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Cottin V, 2012, EUR RESPIR J, V40, P630, DOI 10.1183/09031936.00093111; Deng H, 2010, AM J PHYSIOL-LUNG C, V298, pL793, DOI 10.1152/ajplung.00108.2009; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2006, CIRCULATION, V113, P1857, DOI 10.1161/CIRCULATIONAHA.105.591321; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fagan KA, 2004, AM J PHYSIOL-LUNG C, V287, pL656, DOI 10.1152/ajplung.00090.2003; Fijalkowska I, 2010, AM J PATHOL, V176, P1130, DOI 10.2353/ajpath.2010.090832; Geiger R, 2000, J PATHOL, V191, P202; Gerasimovskaya EV, 2005, J APPL PHYSIOL, V98, P722, DOI 10.1152/japplphysiol.00715.2004; Ghofrani HA, 2006, CARDIOVASC RES, V72, P30, DOI 10.1016/j.cardiores.2006.07.025; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Gulati N, 2009, INT J ONCOL, V35, P731, DOI 10.3892/ijo_00000386; Hands SL, 2009, AGING-US, V1, P586, DOI 10.18632/aging.100070; Hassoun PM, 2009, J AM COLL CARDIOL, V54, pS10, DOI 10.1016/j.jacc.2009.04.006; Hida Q, 2002, RESPIROLOGY, V7, P3, DOI 10.1046/j.1440-1843.2002.00366.x; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Hyvelin JM, 2005, CIRC RES, V97, P185, DOI 10.1161/01.RES.0000174287.17953.83; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Izikki M, 2009, J CLIN INVEST, V119, P512, DOI 10.1172/JCI35070; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Kaizuka T, 2010, J BIOL CHEM, V285, P20109, DOI 10.1074/jbc.M110.121699; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; Krymskaya VP, 2011, FASEB J, V25, P1922, DOI 10.1096/fj.10-175018; Krymskaya VP, 2009, CELL CYCLE, V8, P403, DOI 10.4161/cc.8.3.7555; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacMillan D, 2009, BRIT J PHARMACOL, V158, P1112, DOI 10.1111/j.1476-5381.2009.00369.x; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; McMurtry MS, 2007, AM J PHYSIOL-LUNG C, V293, pL933, DOI 10.1152/ajplung.00310.2006; Merklinger SL, 2005, CIRCULATION, V112, P423, DOI 10.1161/CIRCULATIONAHA.105.540542; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Morrell NW, 2009, J AM COLL CARDIOL, V54, pS20, DOI 10.1016/j.jacc.2009.04.018; Ogawa A, 2009, AM J PHYSIOL-LUNG C, V297, pL666, DOI 10.1152/ajplung.90548.2008; Paddenberg R, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-15; Patel AS, 2013, AM J RESP CELL MOL, V48, P1, DOI 10.1165/rcmb.2012-0282TR; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Rabinovitch M, 2001, CLIN CHEST MED, V22, P433, DOI 10.1016/S0272-5231(05)70282-3; Reddy MK, 2008, CIRC-CARDIOVASC INTE, V1, P209, DOI 10.1161/CIRCINTERVENTIONS.108.830018; Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakao S, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-95; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Stenmark Kurt R, 2012, Pulm Circ, V2, P3, DOI 10.4103/2045-8932.94817; Sutendra G, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001327; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; Tuder RM, 2007, CLIN CHEST MED, V28, P23, DOI 10.1016/j.ccm.2006.11.010; Tuder RM, 2012, AM J RESP CRIT CARE, V185, P260, DOI 10.1164/rccm.201108-1536PP; Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002; Wilkins MR, 2012, EUR RESPIR REV, V21, P19, DOI 10.1183/09059180.00008411; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xu WL, 2007, P NATL ACAD SCI USA, V104, P1342, DOI 10.1073/pnas.0605080104; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Zhang S, 2003, AM J PHYSIOL-LUNG C, V285, pL740, DOI 10.1152/ajplung.00284.2002; Zhou WL, 2007, AM J PHYSIOL-LUNG C, V292, pL1459, DOI 10.1152/ajplung.00143.2006	100	52	57	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1796	1807		10.1096/fj.12-222224	http://dx.doi.org/10.1096/fj.12-222224			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23355268	Green Published			2022-12-28	WOS:000318226100001
J	Corbin, KD; Abdelmalek, MF; Spencer, MD; da Costa, KA; Galanko, JA; Sha, W; Suzuki, A; Guy, CD; Cardona, DM; Torquati, A; Diehl, AM; Zeisel, SH				Corbin, Karen D.; Abdelmalek, Manal F.; Spencer, Melanie D.; da Costa, Kerry-Ann; Galanko, Joseph A.; Sha, Wei; Suzuki, Ayako; Guy, Cynthia D.; Cardona, Diana M.; Torquati, Alfonso; Diehl, Anna Mae; Zeisel, Steven H.			Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis	FASEB JOURNAL			English	Article						single nucleotide polymorphisms; nutrition; nonalcoholic fatty liver disease; metabolic syndrome; obesity	FATTY LIVER-DISEASE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; INSULIN-RESISTANCE; RISK-FACTORS; POLYMORPHISMS; VARIANTS; NUTRIENT; SUSCEPTIBILITY; REQUIREMENT; PROTEIN	Choline metabolism is important for very low-density lipoprotein secretion, making this nutritional pathway an important contributor to hepatic lipid balance. The purpose of this study was to assess whether the cumulative effects of multiple single nucleotide polymorphisms (SNPs) across genes of choline/1-carbon metabolism and functionally related pathways increase susceptibility to developing hepatic steatosis. In biopsy-characterized cases of nonalcoholic fatty liver disease and controls, we assessed 260 SNPs across 21 genes in choline/1-carbon metabolism. When SNPs were examined individually, using logistic regression, we only identified a single SNP (PNPLA3 rs738409) that was significantly associated with severity of hepatic steatosis after adjusting for confounders and multiple comparisons (P=0.02). However, when groupings of SNPs in similar metabolic pathways were defined using unsupervised hierarchical clustering, we identified groups of subjects with shared SNP signatures that were significantly correlated with steatosis burden (P=0.0002). The lowest and highest steatosis clusters could also be differentiated by ethnicity. However, unique SNP patterns defined steatosis burden irrespective of ethnicity. Our results suggest that analysis of SNP patterns in genes of choline/1-carbon metabolism may be useful for prediction of severity of steatosis in specific subsets of people, and the metabolic inefficiencies caused by these SNPs should be examined further.-Corbin, K. D., Abdelmalek, M. F., Spencer, M. D., da Costa, K.-A., Galanko, J. A., Sha, W., Suzuki, A., Guy, C. D., Cardona, D. M., Torquati, A., Diehl, A. M., Zeisel, S. H. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J. 27, 1674-1689 (2013). www.fasebj.org	[Corbin, Karen D.; Spencer, Melanie D.; Zeisel, Steven H.] Univ N Carolina, Inst Nutr Res, Kannapolis, NC 28081 USA; [Corbin, Karen D.; da Costa, Kerry-Ann; Zeisel, Steven H.] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; [Spencer, Melanie D.; Galanko, Joseph A.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA; [Abdelmalek, Manal F.; Suzuki, Ayako; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA; [Guy, Cynthia D.; Cardona, Diana M.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Torquati, Alfonso] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Sha, Wei] Univ North Carolina Charlotte, Bioinformat Serv Div, Kannapolis, NC USA	University of North Carolina; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University; University of North Carolina; University of North Carolina Charlotte	Zeisel, SH (corresponding author), Univ N Carolina, Inst Nutr Res, 500 Laureate Way,Rm 2218, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Abdelmalek, Manal F/AAW-2203-2020	Corbin, Karen/0000-0003-2065-0003; Suzuki, Ayako/0000-0003-1824-1067; Abdelmalek, Manal/0000-0002-5001-8618; Cardona, Diana/0000-0002-6877-2280; Spencer, Melanie/0000-0003-0640-1123	U.S. National Institutes of Health (NIH) [R01DK055865, P30DK056350]; NIH [R01DK055865, P30DK056350, DK034987]; NIH/National Institute of Diabetes and Digestive and Kidney Diseases K23 Career Development award [K23-DK062116]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK062116, R01DK055865, P30DK034987, P30DK056350, T32DK007737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Diabetes and Digestive and Kidney Diseases K23 Career Development award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank their colleagues in Duke Division of Gastroenterology, Duke Bariatric Surgery Program, and Center of Human Genetics for assistance with patient recruitment, acquisition, and/or accessing Duke University Health Systems NAFLD Biorepository samples. The authors also thank the NAFLD Clinical Research study coordinators and support staff, clinical personnel, research and data management personnel, and the patients and their families, without whom, this study would not have been possible. The authors thank Yi-Ping Pan for assistance with review, interpretation, and extraction of all clinical data for the cohort of patients utilized in this analysis. The authors also thank her for obtaining consent and enrolling patients into the Duke Clinical Database and Biorepository, and for performing data entry and data management. This research was supported by grants from the U.S. National Institutes of Health (NIH; R01DK055865 and P30DK056350 to S.Z.). K. C. was supported by a Diversity Post-doctoral Supplement to grant R01DK055865 from the NIH. J.G was supported by grants from the NIH (DK034987 and P30DK056350). M. A. was supported by a NIH/National Institute of Diabetes and Digestive and Kidney Diseases K23 Career Development award (K23-DK062116).	Abu Dayyeh BK, 2011, GASTROENTEROLOGY, V141, P141, DOI 10.1053/j.gastro.2011.03.045; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Buchman AL, 2001, JPEN-PARENTER ENTER, V25, P260, DOI 10.1177/0148607101025005260; Chalasani N, 2010, GASTROENTEROLOGY, V139, P1567, DOI 10.1053/j.gastro.2010.07.057; Chen R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013574; Corbin KD, 2012, CURR OPIN GASTROEN, V28, P159, DOI 10.1097/MOG.0b013e32834e7b4b; da Costa KA, 2006, FASEB J, V20, P1336, DOI 10.1096/fj.06-5734com; da Costa KA, 2011, AM J CLIN NUTR, V93, P968, DOI 10.3945/ajcn.110.011064; Davit-Spraul A, 2010, SEMIN LIVER DIS, V30, P134, DOI 10.1055/s-0030-1253223; Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69; Field LA, 2012, CANCER-AM CANCER SOC, V118, P1334, DOI 10.1002/cncr.26405; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Gao XY, 2008, GENET EPIDEMIOL, V32, P361, DOI 10.1002/gepi.20310; Guerrerio AL, 2012, AM J CLIN NUTR, V95, P892, DOI 10.3945/ajcn.111.020156; Hochrath K, 2012, FASEB J, V26, P5081, DOI 10.1096/fj.12-209379; Hooper AJ, 2011, J LIPID RES, V52, P593, DOI 10.1194/jlr.R008896; Huang YC, 2011, J BIOL CHEM, V286, P37085, DOI 10.1074/jbc.M111.290114; Hung J, 2008, J AM COLL NUTR, V27, P253, DOI 10.1080/07315724.2008.10719697; Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200; Jurinke Christian, 2002, Methods Mol Biol, V187, P179; Kathiresan S, 2008, NEW ENGL J MED, V358, P1240, DOI 10.1056/NEJMoa0706728; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimm SYS, 2002, AM J CLIN NUTR, V75, P714, DOI 10.1093/ajcn/75.4.714; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kohlmeier M, 2005, P NATL ACAD SCI USA, V102, P16025, DOI 10.1073/pnas.0504285102; Kozlitina J, 2011, HEPATOLOGY, V53, P467, DOI 10.1002/hep.24072; Kumar J, 2009, CIRC-CARDIOVASC GENE, V2, P599, DOI 10.1161/CIRCGENETICS.108.841411; Kumari M, 2012, CELL METAB, V15, P691, DOI 10.1016/j.cmet.2012.04.008; Lambrinoudaki I, 2008, EUR J ENDOCRINOL, V159, P233, DOI 10.1530/EJE-07-0848; Lee HY, 2011, HEPATOLOGY, V54, P1650, DOI 10.1002/hep.24571; Lehner B, 2011, TRENDS GENET, V27, P323, DOI 10.1016/j.tig.2011.05.007; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; Michel V, 2009, FASEB J, V23, P2749, DOI 10.1096/fj.08-121491; Miller M, 2007, ARCH MED RES, V38, P444, DOI 10.1016/j.arcmed.2006.10.013; Musso G, 2008, HEPATOLOGY, V47, P1167, DOI 10.1002/hep.22142; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Ong Janus P, 2007, Clin Liver Dis, V11, P1, DOI 10.1016/j.cld.2007.02.009; Peter A, 2012, INT J OBESITY, V36, P774, DOI 10.1038/ijo.2011.154; Petersen KF, 2010, NEW ENGL J MED, V362, P1082, DOI 10.1056/NEJMoa0907295; Pickett-Blakely OE, 2012, OBES SURG, V22, P838, DOI 10.1007/s11695-012-0629-9; Rey JW, 2010, WORLD J GASTROENTERO, V16, P5830, DOI 10.3748/wjg.v16.i46.5830; Rizki G, 2006, J LIPID RES, V47, P2280, DOI 10.1194/jlr.M600198-JLR200; Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257; Schaeffer L, 2006, HUM MOL GENET, V15, P1745, DOI 10.1093/hmg/ddl117; Siddique A, 2011, CLIN LIVER DIS, V15, P281, DOI 10.1016/j.cld.2011.03.007; Song JN, 2005, FASEB J, V19, P1266, DOI 10.1096/fj.04-3580com; Sookoian S, 2008, CYTOKINE, V44, P201, DOI 10.1016/j.cyto.2008.08.001; Speliotes EK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001324; Truong H, 2009, AM J CLIN NUTR, V89, P920, DOI 10.3945/ajcn.2008.27107; Valenti L, 2011, J HEPATOL, V55, P1409, DOI 10.1016/j.jhep.2011.03.035; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Warensjo E, 2007, OBESITY, V15, P1732, DOI 10.1038/oby.2007.206; Yki-Jarvinen H, 2010, CURR OPIN CLIN NUTR, V13, P709, DOI 10.1097/MCO.0b013e32833f4b34; Zeisel SH, 2009, NUTR REV, V67, P615, DOI 10.1111/j.1753-4887.2009.00246.x	56	29	31	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1674	1689		10.1096/fj.12-219097	http://dx.doi.org/10.1096/fj.12-219097			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23292069	Green Published, Green Submitted			2022-12-28	WOS:000316940800037
J	Katter, K; Geurts, AM; Hoffmann, O; Mates, L; Landa, V; Hiripi, L; Moreno, C; Lazar, J; Bashir, S; Zidek, V; Popova, E; Jerchow, B; Becker, K; Devaraj, A; Walter, I; Grzybowksi, M; Corbett, M; Rangel, A; Hodges, MR; Bader, M; Ivics, Z; Jacob, HJ; Pravenec, M; Bosze, Z; Rulicke, T; Izsvak, Z				Katter, Katharina; Geurts, Aron M.; Hoffmann, Orsolya; Mates, Lajos; Landa, Vladimir; Hiripi, Laszlo; Moreno, Carol; Lazar, Jozef; Bashir, Sanum; Zidek, Vaclav; Popova, Elena; Jerchow, Boris; Becker, Katja; Devaraj, Anantharam; Walter, Ingrid; Grzybowksi, Michael; Corbett, Molly; Rangel Filho, Artur; Hodges, Matthew R.; Bader, Michael; Ivics, Zoltan; Jacob, Howard J.; Pravenec, Michal; Bosze, Zsuzsanna; Ruelicke, Thomas; Izsvak, Zsuzsanna			Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits	FASEB JOURNAL			English	Article						SB100X; Sleeping Beauty; mosaicism; piggy-Pac; silencing	SLEEPING-BEAUTY TRANSPOSON; HUMAN-CELLS; PRONUCLEAR MICROINJECTION; LENTIVIRAL VECTORS; BAC TRANSGENESIS; STEM-CELLS; MICE; DNA; MOUSE; INTEGRATION	Germline transgenesis is an important procedure for functional investigation of biological pathways, as well as for animal biotechnology. We have established a simple, nonviral protocol in three important biomedical model organisms frequently used in physiological studies. The protocol is based on the hyperactive Sleeping Beauty transposon system, SB100X, which reproducibly promoted generation of transgenic founders at frequencies of 50-64, 14-72, and 15% in mice, rats, and rabbits, respectively. The SB100X-mediated transgene integrations are less prone to genetic mosaicism and gene silencing as compared to either the classical pronuclear injection or to lentivirus-mediated transgenesis. The method was successfully applied to a variety of transgenes and animal models, and can be used to generate founders with single-copy integrations. The transposon vector also allows the generation of transgenic lines with tissue-specific expression patterns specified by promoter elements of choice, exemplified by a rat reporter strain useful for tracking serotonergic neurons. As a proof of principle, we rescued an inborn genetic defect in the fawn-hooded hypertensive rat by SB100X transgenesis. A side-by-side comparison of the SB100X- and piggyBac-based protocols revealed that the two systems are complementary, offering new opportunities in genome manipulation.-Katter, K., Geurts, A. M., Hoffmann, O., Mates, L., Landa, V., Hiripi, L., Moreno, C., Lazar, J., Bashir, S., Zidek, V., Popova, E., Jerchow, B., Becker, K., Devaraj, A., Walter, I., Grzybowksi, M., Corbett, M., Rangel Filho, A., Hodges, M. R., Bader, M., Ivics, Z., Jacob, H. J., Pravenec, M., Bosze, Z., Rulicke, T., Izsvak, Z. Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB J. 27, 930-941 (2013). www.fasebj.org	[Katter, Katharina; Ruelicke, Thomas] Univ Vet Med Vienna, Inst Lab Anim Sci, Vienna, Austria; [Walter, Ingrid] Univ Vet Med Vienna, Inst Anat Histol & Embryol, Vienna, Austria; [Geurts, Aron M.; Mates, Lajos; Moreno, Carol; Grzybowksi, Michael; Corbett, Molly; Hodges, Matthew R.; Jacob, Howard J.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Geurts, Aron M.; Grzybowksi, Michael; Corbett, Molly] Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; [Geurts, Aron M.; Moreno, Carol; Lazar, Jozef; Jacob, Howard J.] Med Coll Wisconsin, Human Mol Genet Ctr, Milwaukee, WI 53226 USA; [Hodges, Matthew R.] Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI 53226 USA; [Hoffmann, Orsolya; Bosze, Zsuzsanna] Agr Biotechnol Ctr, Inst Anim Biotechnol, H-2101 Godollo, Hungary; [Mates, Lajos] Hungarian Acad Sci, Biol Res Ctr, H-6726 Szeged, Hungary; [Landa, Vladimir; Hiripi, Laszlo; Zidek, Vaclav; Pravenec, Michal] Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic; [Bashir, Sanum; Popova, Elena; Jerchow, Boris; Becker, Katja; Devaraj, Anantharam; Bader, Michael; Ivics, Zoltan; Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany; [Rangel Filho, Artur] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA	University of Veterinary Medicine Vienna; University of Veterinary Medicine Vienna; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Paul Ehrlich Institute; University of Miami	Izsvak, Z (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	mates@brc.hu; zizsvak@mdc-berlin.de	Hodges, Matthew R/N-8567-2013; Zidek, Vaclav/C-6685-2012; Pravenec, Michal/B-1666-2012; Hiripi, Laszlo/AAL-8243-2021; Bosze, Zsuzsanna/N-9689-2019; Hodges, Matthew/GZB-0433-2022; Bader, Michael/K-2124-2013; Landa, Vladimir/B-8908-2012	Pravenec, Michal/0000-0001-9197-5871; Hiripi, Laszlo/0000-0002-1023-0112; Popova, Elena/0000-0002-3043-9650; Jerchow, Boris-Alexander/0000-0002-7031-8730; Mates, Lajos/0000-0002-0058-470X; Bader, Michael/0000-0003-4780-4164; Izsvak, Zsuzsanna/0000-0002-2053-2384; Devaraj, Anantharam/0000-0002-8685-6728	U.S. National Institutes of Health, National Heart, Lung and Blood Institute [P30HL101353, R01HL069321, P301/10/0290]; Grant Agency of the Czech Republic [LH12061, LL1204]; Ministry of Education, Youth, and Sports of the Czech Republic [OM-00118/2008, DFG IZ52/1-2, HEALTH-F4-2010-241504]; Austrian Genome Research Programme, GEN-AU II and III; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P30HL101353, R00HL097033, R01HL069321] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008396] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Ministry of Education, Youth, and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Austrian Genome Research Programme, GEN-AU II and III; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Drs. Mingyu Liang, Allen Cowley, Jr., Duann Pu, Elias Lianos, and Richard Roman for allowing us to share our experiences with their transgenic rat projects. Many thanks also to Tien Yin Yau, Lill Andersen and Dieter Fink for technical assistance and fruitful discussions. This work was supported by the U.S. National Institutes of Health, National Heart, Lung and Blood Institute, grants P30HL101353 (A.G.), R01HL069321 (H.J.), and P301/10/0290 (M.P); the Grant Agency of the Czech Republic, grants LH12061 (V.L.) and LL1204 (within the ERC CZ program; M.P.); the Ministry of Education, Youth, and Sports of the Czech Republic, grants OM-00118/2008 (Z.B.), DFG IZ52/1-2 (Z.Iz.), and HEALTH-F4-2010-241504 (Z.Iz., H.J., M.P., and M.B.); and the Austrian Genome Research Programme, GEN-AU II and III (Austromouse; T. R.). Author contributions: L.M., A.G., Z.Iz., Z.B., M.P., M.B., and T.R designed research, K.K., T.R., I.W., L.M., V.L., L.H., C.M., J.L., I.H., S.B., V.Z., L.P., K.B., A.D., M.H., E.P., M.G., M.C., and A. R.F. performed research; B.J., Z.Iz., M.P., M.B., H.J., Z.B., and T.R. analyzed data; Z.Iz., A.G., Z.Iv., L. M., T.R., and Z.B. wrote the paper.	Ammar I, 2012, NUCLEIC ACIDS RES, V40, P6693, DOI 10.1093/nar/gks317; BESENFELDER U, 1993, J REPROD FERTIL, V99, P53, DOI 10.1530/jrf.0.0990053; Bodrogi L, 2006, TRANSGENIC RES, V15, P627, DOI 10.1007/s11248-006-9015-5; Bosze Z, 2006, WORLD RABBIT SCI, V14, P1; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Cadinanos J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm446; Carlson DF, 2011, TRANSGENIC RES, V20, P29, DOI 10.1007/s11248-010-9386-5; Charreau B, 1996, TRANSGENIC RES, V5, P223, DOI 10.1007/BF01972876; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Datta YH, 2003, THROMB HAEMOSTASIS, V89, P1031; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; Ellis J, 2005, CURR GENE THER, V5, P367, DOI 10.2174/1566523054546233; Filipiak WE, 2006, TRANSGENIC RES, V15, P673, DOI 10.1007/s11248-006-9002-x; Galvan DL, 2009, J IMMUNOTHER, V32, P837, DOI 10.1097/CJI.0b013e3181b2914c; Garrels W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023573; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6; Geurts AM, 2010, METHODS MOL BIOL, V597, P211, DOI 10.1007/978-1-60327-389-3_15; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Grabundzija I, 2010, MOL THER, V18, P1200, DOI 10.1038/mt.2010.47; Hirabayashi M, 2001, EXP ANIM TOKYO, V50, P125, DOI 10.1538/expanim.50.125; Hiripi L, 2003, DNA CELL BIOL, V22, P41, DOI 10.1089/104454903321112488; Hiripi L, 2010, TRANSGENIC RES, V19, P799, DOI 10.1007/s11248-009-9356-y; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Ivics Z, 2011, METHODS, V53, P356, DOI 10.1016/j.ymeth.2010.12.014; Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027; Izsvak Z, 2010, NAT METHODS, V7, P443, DOI [10.1038/NMETH.1461, 10.1038/nmeth.1461]; Kolacsek O, 2011, MOBILE DNA-UK, V2, DOI 10.1186/1759-8753-2-5; Li MA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr764; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Marks MS, 2006, J CELL BIOL, V175, P199, DOI 10.1083/jcb.200608058; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; Moldt B, 2007, HUM GENE THER, V18, P1193, DOI 10.1089/hum.2007.099; Ninkovic I, 2008, J THROMB HAEMOST, V6, P2143, DOI 10.1111/j.1538-7836.2008.03178.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Park F, 2007, PHYSIOL GENOMICS, V31, P159, DOI 10.1152/physiolgenomics.00069.2007; Rostovskaya M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks643; Rulicke T, 2000, EXP PHYSIOL, V85, P589, DOI 10.1017/S0958067000020923; Rulicke T, 2004, METH MOL B, V254, P165; Sauvain MO, 2008, J VIROL, V82, P7111, DOI 10.1128/JVI.00623-08; Scott MM, 2005, J NEUROSCI, V25, P2628, DOI 10.1523/JNEUROSCI.4979-04.2005; Sultana F, 2009, J AM ASSOC LAB ANIM, V48, P52; Sumiyama K, 2010, GENOMICS, V95, P306, DOI 10.1016/j.ygeno.2010.02.006; Suster ML, 2011, NAT PROTOC, V6, P1998, DOI 10.1038/nprot.2011.416; Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9; Walisko O, 2008, MOL THER, V16, P359, DOI 10.1038/sj.mt.6300366; Wall R J, 2001, Cloning Stem Cells, V3, P209, DOI 10.1089/15362300152725936; WHITELAW CBA, 1993, TRANSGENIC RES, V2, P29, DOI 10.1007/BF01977678; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Witschi, 1956, DEV VERTEBRATES; Yant SR, 2002, NAT BIOTECHNOL, V20, P999, DOI 10.1038/nbt738; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568	56	65	69	1	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					930	941		10.1096/fj.12-205526	http://dx.doi.org/10.1096/fj.12-205526			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23195032	Green Published			2022-12-28	WOS:000315585200009
J	Latham, SL; Chaponnier, C; Dugina, V; Couraud, PO; Grau, GER; Combes, V				Latham, Sharissa L.; Chaponnier, Christine; Dugina, Vera; Couraud, Pierre-Olivier; Grau, Georges E. R.; Combes, Valery			Cooperation between beta- and gamma-cytoplasmic actins in the mechanical regulation of endothelial microparticle formation	FASEB JOURNAL			English	Article						cytoskeleton; vesiculation; neuroinflammation	PLASMA-MEMBRANE; CALPAIN ACTIVATION; BINDING PROTEIN; BLEB FORMATION; CELLS; VESICULATION; CYTOSKELETON; EXPOSURE; PHOSPHORYLATION; INHIBITION	Elevated endothelial microparticle (MP) levels are observed in numerous diseases, increasingly supporting roles as effectors and valuable markers of vascular dysfunction. While a contractile role for the actin cytoskeleton has been implicated in vesiculation, i.e., MP production, the precise interactions and mechanisms of its constituents, beta- and gamma-cytoplasmic actins, is unknown. Human cerebral microvascular endothelial cells were stimulated with known agonists, and vesiculation development was monitored by scanning electron microscopy (SEM) and flow cytometry. These data in combination provide new insight into the kinetics, patterns of vesiculating cell recruitment, and degrees of response specific to stimuli. Reorganization of beta- and gamma-actins, F-actin, vinculin, and talin accompanied significant MP release. beta-Actin redistribution into basal stress fibers following stimulation was associated with increased apically situated actin-rich particulate structures, which in turn directly correlated with electronlucent membrane protrusions observed by SEM. Y-27632 Rho-kinase inhibition abolished basal beta-actin fiber formation, minimizing apically associated actin-rich structures, significantly reducing membrane protrusions and MP release to near basal levels. Cytoskeletal protein expression and distribution varied between MPs and mother cells, as determined by Western blot. These data strongly suggest that beta-actin plays an active facilitative role in agonist-induced protuberance formation, through mechanical interactions with newly described actin-rich structures.-Latham, S. L., Chaponnier, C., Dugina, V., Couraud, P.-O., Grau, G. E. R., Combes, V. Cooperation between beta- and gamma-cytoplasmic actins in the mechanical regulation of endothelial microparticle formation. FASEB J. 27, 672-683 (2013). www.fasebj.org	[Latham, Sharissa L.; Grau, Georges E. R.; Combes, Valery] Univ Sydney, Sydney Med Sch, Vasc Immunol Unit, Camperdown, NSW 2050, Australia; [Chaponnier, Christine; Dugina, Vera] Univ Geneva, Dept Pathol & Immunol, Fac Med, CMU, Geneva, Switzerland; [Couraud, Pierre-Olivier] Inst Cochin Genet Mol, INSERM, U1016, F-75014 Paris, France; [Couraud, Pierre-Olivier] CNRS, UMR 8104, Paris, France; [Couraud, Pierre-Olivier] Univ Paris 05, Paris, France	University of Sydney; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Latham, SL (corresponding author), Univ Sydney, Dept Pathol, Vasc Immunol Unit, 92-94 Parramatta Rd, Camperdown, NSW 2050, Australia.	sharissa.latham@sydney.edu.au; valery.combes@sydney.edu.au	Dugina, Vera B/C-9904-2012; Latham, Sharissa/B-2353-2016; Grau, Georges/AGR-7139-2022	Latham, Sharissa/0000-0003-1128-5315; Grau, Georges/0000-0002-0442-0462; Dugina, Vera/0000-0002-7618-5959; Combes, Valery/0000-0003-2178-3596	Australia National Health Medical Research Council [571014]; University of Sydney [2009-02563, 2009-02600]; Swiss National Science Foundation (SNSF) [310030_125320]; Al Kerr Bequest; Sydney Medical School; Vascular Immunology Unit	Australia National Health Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney); Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Al Kerr Bequest; Sydney Medical School; Vascular Immunology Unit	This work was supported by Australia National Health Medical Research Council grant 571014, University of Sydney Bridging Support grants 2009-02563 and 2009-02600, and Swiss National Science Foundation (SNSF) grant 310030_125320 (C. C.). The support of the Al Kerr Bequest, Sydney Medical School, is also gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors acknowledge and thank David Puglisi, V. A. Wheway, and the Vascular Immunology Unit for their invaluable assistance, advice, and support throughout the entirety of this project; Dr. Louise Cole and the Bosch Advanced Microscopy facility, University of Sydney; and the staff in the Australian Microscopy and Microanalysis Research Facility (AMMRF) at the Australian Centre for Microscopy and Microanalysis, University of Sydney.	Amabile N, 2005, J AM SOC NEPHROL, V16, P3381, DOI 10.1681/ASN.2005050535; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; Bernimoulin M, 2009, J THROMB HAEMOST, V7, P1019, DOI 10.1111/j.1538-7836.2009.03434.x; Cerri C, 2006, J IMMUNOL, V177, P1975, DOI 10.4049/jimmunol.177.3.1975; Chaponnier C, 2004, J PATHOL, V204, P386, DOI 10.1002/path.1635; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Coltel N, 2006, MICROBES INFECT, V8, P2305, DOI 10.1016/j.micinf.2006.04.006; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Combes V, 2004, JAMA-J AM MED ASSOC, V291, P2542, DOI 10.1001/jama.291.21.2542-b; Combes V, 2010, PROG NEUROBIOL, V91, P140, DOI 10.1016/j.pneurobio.2010.01.007; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; Dugina V, 2009, J CELL SCI, V122, P2980, DOI 10.1242/jcs.041970; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; FOX JEB, 1991, J BIOL CHEM, V266, P13289; Fu YY, 2010, THROMB HAEMOSTASIS, V104, P1235, DOI 10.1160/TH10-02-0102; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; Itakura Y, 2003, J TRAUMA, V55, P1125, DOI 10.1097/01.TA.0000096663.21402.5C; Jimenez JJ, 2003, THROMB RES, V109, P175, DOI 10.1016/S0049-3848(03)00064-1; Laster SM, 1996, MICROSC RES TECHNIQ, V34, P272, DOI 10.1002/(SICI)1097-0029(19960615)34:3<272::AID-JEMT10>3.0.CO;2-J; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Leroyer AS, 2008, J INTERN MED, V263, P528, DOI 10.1111/j.1365-2796.2008.01957.x; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Mfonkeu JBP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013415; Minagar A, 2001, NEUROLOGY, V56, P1319, DOI 10.1212/WNL.56.10.1319; Miyoshi H, 1996, GASTROENTEROLOGY, V110, P1897, DOI 10.1053/gast.1996.v110.pm8964416; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; PATEL KD, 1992, J BIOL CHEM, V267, P15168; Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	38	36	38	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					672	683		10.1096/fj.12-216531	http://dx.doi.org/10.1096/fj.12-216531			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23159932				2022-12-28	WOS:000314358000026
J	Cattaruzza, M; Nogoy, N; Wojtowicz, A; Hecker, M				Cattaruzza, Marco; Nogoy, Nicole; Wojtowicz, Agnieszka; Hecker, Markus			Zinc finger motif-1 antagonizes PDGF-BB-induced growth and dedifferentiation of vascular smooth muscle cells	FASEB JOURNAL			English	Article						proliferation; cellular phenotype control; early growth response-1; Egr-1	RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR RECEPTOR; PROLIFERATION; ACTIVATION; EWS; METASTASIS; HTAF(II)68; PROTEIN-1	Zinc finger motif-1 (ZFM1) represses proinflammatory gene expression in vascular smooth muscle cells (SMCs) at a global level and thus may also be involved in the attenuation of growth factor-induced phenotype changes in these cells. Using human primary cultured thymus vein SMCs, we have investigated the molecular mechanism by which a potent SMC mitogen, platelet-derived growth factor-BB (PDGF-BB), causes a rapid decrease in ZFM1 expression in a concentration-dependent manner and consequences thereof. Reporter gene analyses and chromatin immunoprecipitation showed that PDGF-BB-induced ZFM1 repression occurs at the level of transcription through replacement of the activating transcription factor Sp1 by Egr-1. The subsequent drop in ZFM1 abundance disinhibits SMC proliferation, migration, and synthetic gene expression in a concerted manner. Stabilizing ZFM1 levels in a PDGF-BB-independent way with a GFP-ZFM1 expression construct or by using Egr-1-specific decoy oligonucleotides abrogates all PDGF-BB effects. Conversely, siRNA-mediated knockdown of ZFM1 alone not only increases the sensitivity of SMCs for PDGF-BB, but even mimics PDGF-BB-induced proliferation and gene expression. Our findings suggest that ZFM1 is an important factor for the stabilization of a contractile SMC phenotype under basal or mildly activating conditions and that, as a prerequisite for efficient action, PDGF-BB must repress ZFM1 expression to alter the SMC phenotype.-Cattaruzza, M., Nogoy, N., Wojtowicz, A., Hecker, M. Zinc finger motif-1 antagonizes PDGF-BB-induced growth and dedifferentiation of vascular smooth muscle cells. FASEB J. 26, 4864-4875 (2012). www.fasebj.org	[Cattaruzza, Marco; Nogoy, Nicole; Wojtowicz, Agnieszka; Hecker, Markus] Heidelberg Univ, Div Cardiovasc Physiol, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Cattaruzza, M (corresponding author), Heidelberg Univ, Div Cardiovasc Physiol, Inst Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	cattaruzza@physiologie.uni-heidelberg.de		Nogoy, Nicole/0000-0002-5192-9835	Deutsche Forschungsgemeinschaft [GRK 335]; European Commission (Marie Curie ITN SmArt)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Commission (Marie Curie ITN SmArt)	The authors thank Renate Cattaruzza for expert technical assistance. This project was supported by the Deutsche Forschungsgemeinschaft (GRK 335), the European Commission (Marie Curie ITN SmArt), and intramural funding. M.C. planned and performed experiments and wrote the manuscript, N.N. planned and performed experiments, A. W. performed luciferin reporter gene assays, and M. H. planned experiments and participated in the writing of the manuscript. The authors declare no conflicts of interest.	Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Cattaruzza M, 2000, FASEB J, V14, P991, DOI 10.1096/fasebj.14.7.991; Cattaruzza M, 2002, J BIOL CHEM, V277, P6582, DOI 10.1074/jbc.M108283200; Chang HJ, 2006, INT J ONCOL, V28, P135; Chen CN, 2006, P NATL ACAD SCI USA, V103, P2665, DOI 10.1073/pnas.0510973103; Christopher P., 2001, ARTERIOSCLER THROMB, V31, P1495; Grazul-Bilska AT, 2003, DRUG TODAY, V39, P787, DOI 10.1358/dot.2003.39.10.799472; Guth S, 2000, J BIOL CHEM, V275, P38059, DOI 10.1074/jbc.M001483200; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Kamimura M, 2004, HYPERTENSION, V44, P944, DOI 10.1161/01.HYP.0000146908.75091.99; Kaplan-Albuquerque N, 2005, CIRC RES, V97, P427, DOI 10.1161/01.RES.0000179776.40216.a9; Kitadai Y, 2006, AM J PATHOL, V169, P2054, DOI 10.2353/ajpath.2006.060653; Kono SA, 2012, CURR CANCER DRUG TAR, V12, P107; Long XC, 2008, ARTERIOSCL THROM VAS, V28, P1505, DOI 10.1161/ATVBAHA.108.166066; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; MARMUR JD, 1992, CIRCULATION, V86, P53; Marumo T, 1997, CIRCULATION, V96, P2361; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Shitashige M, 2007, CANCER SCI, V98, P1862, DOI 10.1111/j.1349-7006.2007.00629.x; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Wojtowicz A, 2010, CIRC RES, V107, P898, DOI 10.1161/CIRCRESAHA.110.227850; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Zhang D, 1998, J BIOL CHEM, V273, P6868, DOI 10.1074/jbc.273.12.6868; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086	35	6	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4864	4875		10.1096/fj.12-210302	http://dx.doi.org/10.1096/fj.12-210302			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22906951				2022-12-28	WOS:000311838300010
J	Dong, MQ; Xu, XQ; Ball, AM; Makhoul, JA; Lam, PCH; Pinon, DI; Orry, A; Sexton, PM; Abagyan, R; Miller, LJ				Dong, Maoqing; Xu, Xiequn; Ball, Alicja M.; Makhoul, Joshua A.; Lam, Polo C. -H.; Pinon, Delia I.; Orry, Andrew; Sexton, Patrick M.; Abagyan, Ruben; Miller, Laurence J.			Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping	FASEB JOURNAL			English	Article						class B GPCRs; molecular modeling; ligand binding	PHOTOAFFINITY CROSS-LINKING; PROTEIN-COUPLED-RECEPTOR; 2ND TRANSMEMBRANE HELIX; PEPTIDE RECEPTOR; ANTAGONIST PEPTIDES; MUTATIONAL ANALYSIS; AGONIST BINDING; MOLECULAR-BASIS; LIGAND-BINDING; BASIC RESIDUES	While it is evident that the carboxylterminal region of natural peptide ligands bind to the amino-terminal domain of class B GPCRs, how their biologically critical amino-terminal regions dock to the receptor is unclear. We utilize cysteine trapping to systematically explore spatial approximations among residues in the first five positions of secretin and in every position within the receptor extracellular loops (ECLs). Only Cys(2) and Cys(5) secretin analogues exhibited full activity and retained moderate binding affinity (IC50: 92+/-4 and 83+/-1 nM, respectively). When these peptides probed 61 human secretin receptor cysteine-replacement mutants, a broad network of receptor residues could form disulfide bonds consistent with a dynamic ligand-receptor interface. Two distinct patterns of disulfide bond formation were observed: Cys2 predominantly labeled residues in the amino terminus of ECL2 and ECL3 (relative labeling intensity: Ser(340), 94+/-7%; Pro(341), 84+/-9%; Phe(258), 73+/-5%; Trp(274) 62+/-8%), and Cys(5) labeled those in the carboxyl terminus of ECL2 and ECL3 (Gln(348), 100%; Ile(347), 73+/-12%; Glu(342), 59+/-10%; Phe(351), 58+/-11%). These constraints were utilized in molecular modeling, providing improved understanding of the structure of the transmembrane bundle and interconnecting loops, the orientation between receptor domains, and the molecular basis of ligand docking. Key spatial approximations between peptide and receptor predicted by this model (H-1-W-274, D-3-N-268, G(4)-F-258) were supported by mutagenesis and residue-residue complementation studies.-Dong, M., Xu, X., Ball, A. M., Makhoul, J. A., Lam, P. C.-H., Pinon, D. I., Orry, A., Sexton, P. M., Abagyan, R., Miller, L. J. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J. 26, 5092-5105 (2012). www.fasebj.org	[Dong, Maoqing; Xu, Xiequn; Ball, Alicja M.; Makhoul, Joshua A.; Pinon, Delia I.; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; [Lam, Polo C. -H.; Orry, Andrew; Abagyan, Ruben] Molsoft LLC, La Jolla, CA USA; [Sexton, Patrick M.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia; [Sexton, Patrick M.] Monash Univ, Dept Pharmacol, Parkville, Vic, Australia; [Abagyan, Ruben] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	Mayo Clinic; Mayo Clinic Phoenix; Monash University; Monash University; University of California System; University of California San Diego	Miller, LJ (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu	Xu, Xiequn/AAS-9773-2021; Sexton, Patrick M/B-1319-2008	Xu, Xiequn/0000-0003-0347-5258; Sexton, Patrick M/0000-0001-8902-2473	U.S. National Institutes of Health [DK46577]; National Health and Medical Research Council of Australia (NHMRC) [519461]; Peking Union Medical College Hospital (Beijing, China); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Peking Union Medical College Hospital (Beijing, China); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the U.S. National Institutes of Health (DK46577), and the National Health and Medical Research Council of Australia (NHMRC), program grant 519461. P.M.S. is a Principal Research Fellow of the NHMRC. X.X. was partially supported by Peking Union Medical College Hospital (Beijing, China). The authors thank Ms. Mary Lou Augustine for her excellent technical assistance, Dr. Ross Potter for his expert assistance in flow cytometry and analysis, and Dr. Kaleeckal G. Harikumar for his assistance and advice.	ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Avlani VA, 2007, J BIOL CHEM, V282, P25677, DOI 10.1074/jbc.M702311200; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Buck E, 2005, P NATL ACAD SCI USA, V102, P2719, DOI 10.1073/pnas.0500016102; Buck E, 2005, J BIOL CHEM, V280, P4009, DOI 10.1074/jbc.C400500200; Ceraudo E, 2012, FASEB J, V26, P2060, DOI 10.1096/fj.11-196444; Chen QA, 2010, J BIOL CHEM, V285, P24508, DOI 10.1074/jbc.M110.135749; Di Paolo E, 1999, RECEPTOR CHANNEL, V6, P309; Di Paolo E, 1998, FEBS LETT, V424, P207, DOI 10.1016/S0014-5793(98)00175-6; Dong MQ, 2008, MOL PHARMACOL, V74, P413, DOI 10.1124/mol.108.047209; Dong M, 2011, J BIOL CHEM, V286, P23888, DOI 10.1074/jbc.M111.245969; Dong MQ, 2011, BIOCHEMISTRY-US, V50, P2983, DOI 10.1021/bi200133u; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Gao F, 2009, MOL PHARMACOL, V76, P264, DOI 10.1124/mol.109.055756; Garcia GL, 2012, AM J PHYSIOL-CELL PH, V302, pC1202, DOI 10.1152/ajpcell.00273.2011; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GARDNER JD, 1977, GASTROENTEROLOGY, V73, P52; Gensure RC, 2001, J BIOL CHEM, V276, P42692, DOI 10.1074/jbc.M106215200; Hagemann IS, 2008, J BIOL CHEM, V283, P7763, DOI 10.1074/jbc.M709467200; Harikumar KG, 2007, J BIOL CHEM, V282, P32834, DOI 10.1074/jbc.M704563200; Harikumar KG, 2007, J BIOL CHEM, V282, P30363, DOI 10.1074/jbc.M702325200; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JIANG SP, 1995, BIOCHEM BIOPH RES CO, V207, P883, DOI 10.1006/bbrc.1995.1268; Kraetke O, 2005, BIOCHEMISTRY-US, V44, P15569, DOI 10.1021/bi0507027; Kruse AC, 2012, NATURE, V482, P552, DOI 10.1038/nature10867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; Monaghan P, 2008, BIOCHEMISTRY-US, V47, P5889, DOI 10.1021/bi800122f; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Neumann JM, 2008, TRENDS BIOCHEM SCI, V33, P314, DOI 10.1016/j.tibs.2008.05.001; Parthier C, 2007, P NATL ACAD SCI USA, V104, P13942, DOI 10.1073/pnas.0706404104; Parthier C, 2009, TRENDS BIOCHEM SCI, V34, P303, DOI 10.1016/j.tibs.2009.02.004; Pellequer JL, 2006, PROTEINS, V65, P192, DOI 10.1002/prot.21059; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Runge S, 2003, J BIOL CHEM, V278, P28005, DOI 10.1074/jbc.M301085200; Shoichet BK, 2012, TRENDS PHARMACOL SCI, V33, P268, DOI 10.1016/j.tips.2012.03.007; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Vertongen P, 2001, BRIT J PHARMACOL, V133, P1249, DOI 10.1038/sj.bjp.0704195; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396	41	29	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5092	5105		10.1096/fj.12-212399	http://dx.doi.org/10.1096/fj.12-212399			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964305	Green Published			2022-12-28	WOS:000311838300030
J	Finn, RM; Ellard, K; Eirin-Lopez, JM; Ausio, J				Finn, Ron M.; Ellard, Katherine; Eirin-Lopez, Jose M.; Ausio, Juan			Vertebrate nucleoplasmin and NASP: egg histone storage proteins with multiple chaperone activities	FASEB JOURNAL			English	Review						chromatin; phosphorylation; embryogenesis; nuclear autoantigenic sperm protein; cancer	AUTOANTIGENIC SPERM PROTEIN; MOUSE SPERMATOGENIC CELLS; NUCLEOSOME CORE PARTICLE; XENOPUS-LAEVIS OOCYTES; EMBRYONIC STEM-CELLS; LONG-TERM EVOLUTION; CRYSTAL-STRUCTURE; BINDING PROTEIN; NUCLEOPHOSMIN/NUCLEOPLASMIN FAMILY; ANGSTROM RESOLUTION	Recent reviews have focused on the structure and function of histone chaperones involved in different aspects of somatic cell chromatin metabolism. One of the most dramatic chromatin remodeling processes takes place immediately after fertilization and is mediated by egg histone storage chaperones. These include members of the nucleoplasmin (NPM2/NPM3), which are preferentially associated with histones H2A-H2B in the egg and the nuclear autoantigenic sperm protein (NASP) families. Interestingly, in addition to binding and providing storage to H3/H4 in the egg and in somatic cells, NASP has been shown to be a unique genuine chaperone for histone H1. This review revolves around the structural and functional roles of these two families of chaperones whose activity is modulated by their own post-translational modifications (PTMs), particularly phosphorylation. Beyond their important role in the remodeling of paternal chromatin in the early stages of embryogenesis, NPM and NASP members can interact with a plethora of proteins in addition to histones in somatic cells and play a critical role in processes of functional cell alteration, such as in cancer. Despite their common presence in the egg, these two histone chaperones appear to be evolutionarily unrelated. In contrast to members of the NPM family, which share a common monophyletic evolutionary origin, the different types of NASP appear to have evolved recurrently within different taxa.-Finn, R. M., Ellard, K., Eirin-Lopez, J. M., Ausio, J. Vertebrate nucleoplasmin and NASP: egg histone storage proteins with multiple chaperone activities. FASEB J. 26, 4788-4804 (2012). www.fasebj.org	[Finn, Ron M.; Ellard, Katherine; Ausio, Juan] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; [Eirin-Lopez, Jose M.] Univ A Coruna, Dept Biol Celular & Mol, Chromatin Struct & Evolut CHROMEVOL Grp, La Coruna, Spain	University of Victoria; Universidade da Coruna	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Petch Bldg 258A, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca	Eirin-Lopez, Jose Maria/A-5618-2008	Eirin-Lopez, Jose Maria/0000-0002-8041-9770	Natural Science and Engineering Research Council of Canada [NSERC-46399-12]; Spanish Ministry of Economy and Competitivity [CGL2011-24812]; Xunta de Galicia [10-PXIB-103-077-PR]; NSERC-PGS-D Fellowship	Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Spanish Ministry of Economy and Competitivity(Spanish Government); Xunta de Galicia(Xunta de GaliciaEuropean Commission); NSERC-PGS-D Fellowship(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work has been supported, in part, by a grant from the Natural Science and Engineering Research Council of Canada (NSERC-46399-12) to J.A. and by grants from the Spanish Ministry of Economy and Competitivity (CGL2011-24812 & Ramon y Cajal Subprogramme) and Xunta de Galicia (10-PXIB-103-077-PR) to J.M.E.-L. R. F. is a recipient of an NSERC-PGS-D Fellowship.	Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; Alekseev OM, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-50; Alekseev OM, 2009, BIOL REPROD, V81, P739, DOI 10.1095/biolreprod.109.076497; Alekseev OM, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-45; Alekseev OM, 2005, J BIOL CHEM, V280, P2904, DOI 10.1074/jbc.M410397200; Alekseev OM, 2005, PROTEINS, V61, P1, DOI 10.1002/prot.20600; Alekseev OM, 2003, J BIOL CHEM, V278, P8846, DOI 10.1074/jbc.M210352200; Ali-Fehmi R, 2010, CANCER BIOMARK, V6, P33, DOI 10.3233/CBM-2009-0117; [Anonymous], 2011, BIOL REPROD, V85, P70, DOI 10.1095/biolreprod.110.089342; Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; Banuelos S, 2007, J BIOL CHEM, V282, P21213, DOI 10.1074/jbc.M702842200; Barthelery M, 2009, PROTEOM CLIN APPL, V3, P505, DOI 10.1002/prca.200800109; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; Batova IN, 2000, CLIN EXP IMMUNOL, V121, P201, DOI 10.1046/j.1365-2249.2000.01303.x; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Braun RE, 2001, NAT GENET, V28, P10, DOI 10.1038/88194; Burns KH, 2003, SCIENCE, V300, P633, DOI 10.1126/science.1081813; Campos EI, 2010, NAT STRUCT MOL BIOL, V17, P1343, DOI 10.1038/nsmb.1911; Campos EI, 2010, GENE DEV, V24, P1334, DOI 10.1101/gad.1946810; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cook AJL, 2011, MOL CELL, V44, P918, DOI 10.1016/j.molcel.2011.11.021; Das C., 2011, BIOCHIM BIOPHYS ACTA, V1819, P332; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Del Rosario BC, 2008, MOL CELL BIOL, V28, P2113, DOI 10.1128/MCB.02136-07; Delorenzi M, 2002, BIOINFORMATICS, V18, P617, DOI 10.1093/bioinformatics/18.4.617; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Dunleavy EM, 2007, MOL CELL, V28, P1029, DOI 10.1016/j.molcel.2007.10.010; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; Eirin-Lopez JM, 2006, GENETICS, V173, P1835, DOI 10.1534/genetics.106.058990; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Finn RM, 2008, BIOPHYS J, V95, P1314, DOI 10.1529/biophysj.108.130021; Formosa T, 2011, BIOCHIM BIOPHYS ACTA, V1819, P247; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Frehlick LJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-99; Gaucher J, 2010, FEBS J, V277, P599, DOI 10.1111/j.1742-4658.2009.07504.x; Ge ZQ, 2011, J BIOL CHEM, V286, P16790, DOI 10.1074/jbc.M110.216846; Gillies EA, 2009, J FLUID MECH, V625, P445, DOI 10.1017/S0022112008005685; Gonzalez-Romero R, 2010, MOL BIOL EVOL, V27, P1802, DOI 10.1093/molbev/msq058; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Gunjan A, 2003, CELL, V115, P537, DOI 10.1016/S0092-8674(03)00896-1; Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008; Hamiche A., 2011, BIOCHIM BIOPHYS ACTA, V1819, P230; Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772; Huang N, 2005, J BIOL CHEM, V280, P5496, DOI 10.1074/jbc.M407856200; Huttlin EL, 2010, CELL, V143, P1174, DOI 10.1016/j.cell.2010.12.001; Inoue A, 2010, FASEB J, V24, P485, DOI 10.1096/fj.09-143370; Jeong EG, 2007, APMIS, V115, P341, DOI 10.1111/j.1600-0463.2007.apm_592.x; Jin JJ, 2005, TRENDS BIOCHEM SCI, V30, P680, DOI 10.1016/j.tibs.2005.10.003; Keck K. M., 2011, BIOCHIM BIOPHYS ACTA, V1819, P277; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1985, COLD SPRING HARB SYM, V50, P657, DOI 10.1101/SQB.1985.050.01.080; LASKEY RA, 1977, COLD SPRING HARB SYM, V42, P171, DOI 10.1101/SQB.1978.042.01.019; Lee HH, 2007, PROTEINS, V69, P672, DOI 10.1002/prot.21504; LEE YH, 1993, ANAT REC, V236, P442, DOI 10.1002/ar.1092360304; Libuda DE, 2010, GENETICS, V184, P985, DOI 10.1534/genetics.109.113662; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma WB, 2012, J BIOL CHEM, V287, P10189, DOI 10.1074/jbc.M111.303636; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McLay DW, 2003, REPRODUCTION, V125, P625, DOI 10.1530/rep.0.1250625; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Miller D, 2010, REPRODUCTION, V139, P287, DOI 10.1530/REP-09-0281; Morange M, 2005, J BIOSCIENCES, V30, P461, DOI 10.1007/BF02703718; Morillo-Huesca M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000964; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nozawa Y, 1996, J PATHOL, V178, P48; Ogushi S, 2008, SCIENCE, V319, P613, DOI 10.1126/science.1151276; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Okuwaki M, 2012, NUCLEIC ACIDS RES, V40, P4861, DOI 10.1093/nar/gks162; OLINS AL, 1974, SCIENCE, V183, P330, DOI 10.1126/science.183.4122.330; ORAND MG, 1992, DEV BIOL, V154, P37, DOI 10.1016/0012-1606(92)90045-I; Osakabe A, 2010, J BIOL CHEM, V285, P11913, DOI 10.1074/jbc.M109.083238; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Platonova O, 2011, BIOCHEMISTRY-US, V50, P8078, DOI 10.1021/bi2006652; Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; Prado F, 2005, MOL CELL BIOL, V25, P1526, DOI 10.1128/MCB.25.4.1526-1536.2005; Prieto C, 2002, BIOCHEMISTRY-US, V41, P7802, DOI 10.1021/bi020120e; Ramos I, 2010, J BIOL CHEM, V285, P33771, DOI 10.1074/jbc.M110.150664; Rau R, 2009, HEMATOL ONCOL, V27, P171, DOI 10.1002/hon.904; RICE P, 1995, BIOCHEMISTRY-US, V34, P7563, DOI 10.1021/bi00023a001; Richardson RI, 2006, GENE, V371, P52, DOI 10.1016/j.gene.2005.11.005; Richardson RT, 2006, J BIOL CHEM, V281, P21526, DOI 10.1074/jbc.M603816200; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; Richardson RT, 2001, GENE, V274, P67, DOI 10.1016/S0378-1119(01)00605-9; Richter S, 2008, NUCLEIC ACIDS RES, V36, pW276, DOI 10.1093/nar/gkn181; Rousseaux S., 2010, EPIGENETICS HUMAN RE; Shackleford G M, 2001, BMC Genomics, V2, P8, DOI 10.1186/1471-2164-2-8; Singh RK, 2010, CELL CYCLE, V9, P4236, DOI 10.4161/cc.9.20.13636; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Szebeni A, 1999, PROTEIN SCI, V8, P905; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takemura M., 1999, BIOCHEMISTRY-US, V125, P904; Talbert PB, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-7; Taneva SG, 2009, J MOL BIOL, V393, P448, DOI 10.1016/j.jmb.2009.08.005; Taneva SG, 2008, BIOCHEMISTRY-US, V47, P13897, DOI 10.1021/bi800975r; Thierry-Mieg D., 2006, GENOME BIOL S1, V7, pS121; VANCUROVA I, 1995, J CELL SCI, V108, P779; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wang HY, 2008, NUCLEIC ACIDS RES, V36, P5763, DOI 10.1093/nar/gkn574; Wang HY, 2012, NUCLEIC ACIDS RES, V40, P660, DOI 10.1093/nar/gkr781; WELCH JE, 1990, BIOL REPROD, V43, P559, DOI 10.1095/biolreprod43.4.559; Winkler DD, 2011, J BIOL CHEM, V286, P18369, DOI 10.1074/jbc.R110.180778; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; Xin H, 2009, MOL CELL, V35, P365, DOI 10.1016/j.molcel.2009.06.024; Yocum AK, 2008, MOL CELL PROTEOMICS, V7, P750, DOI 10.1074/mcp.M700399-MCP200; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	125	30	32	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4788	4804		10.1096/fj.12-216663	http://dx.doi.org/10.1096/fj.12-216663			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22968912				2022-12-28	WOS:000311838300003
J	Seritrakul, P; Samarut, E; Lama, TTS; Gibert, Y; Laudet, V; Jackman, WR				Seritrakul, Pawat; Samarut, Eric; Lama, Tenzing T. S.; Gibert, Yann; Laudet, Vincent; Jackman, William R.			Retinoic acid expands the evolutionarily reduced dentition of zebrafish	FASEB JOURNAL			English	Article						teeth; neural crest cells; retinaldehyde dehydrogenase	MEDAKA ORYZIAS-LATIPES; CRANIAL NEURAL CREST; HOX GENES; TOOTH DEVELOPMENT; EMBRYONIC-DEVELOPMENT; PHARYNGEAL DENTITION; DOLLOS LAW; DLX GENES; IN-VIVO; EXPRESSION	Zebrafish lost anterior teeth during evolution but retain a posterior pharyngeal dentition that requires retinoic acid (RA) cell-cell signaling for its development. The purposes of this study were to test the sufficiency of RA to induce tooth development and to assess its role in evolution. We found that exposure of embryos to exogenous RA induces a dramatic anterior expansion of the number of pharyngeal teeth that later form and shifts anteriorly the expression patterns of genes normally expressed in the posterior tooth-forming region, such as pitx2 and dlx2b. After RA exposure, we also observed a correlation between cartilage malformations and ectopic tooth induction, as well as abnormal cranial neural crest marker gene expression. Additionally, we observed that the RA-induced zebrafish anterior teeth resemble in pattern and number the dentition of fish species that retain anterior pharyngeal teeth such as medaka but that medaka do not express the aldh1a2 RA-synthesizing enzyme in tooth-forming regions. We conclude that RA is sufficient to induce anterior ectopic tooth development in zebrafish where teeth were lost in evolution, potentially by altering neural crest cell development, and that changes in the location of RA synthesis correlate with evolutionary changes in vertebrate dentitions.-Seritrakul, P., Samarut, E., Lama, T. T. S., Gibert, Y., Laudet, V., Jackman, W. R. Retinoic acid expands the evolutionarily reduced dentition of zebrafish. FASEB J. 26, 5014-5024 (2012). www.fasebj.org	[Seritrakul, Pawat; Lama, Tenzing T. S.; Jackman, William R.] Bowdoin Coll, Dept Biol, Brunswick, ME 04011 USA; [Samarut, Eric; Laudet, Vincent] Univ Lyon 1, Ctr Natl Rech Sci, Ecole Normale Super Lyon, Inst Natl Rech Agron,Inst Genom Fonct Lyon,Mol Zo, F-69365 Lyon, France; [Gibert, Yann] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia	Bowdoin College; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Deakin University	Jackman, WR (corresponding author), Bowdoin Coll, Dept Biol, 6500 Coll Stn, Brunswick, ME 04011 USA.	wjackman@bowdoin.edu		SAMARUT, ERIC/0000-0001-7818-2009; Seritrakul, Pawat/0000-0002-8320-6789	U.S. National Institutes of Health [5P20-RR-016463-12, 8P20-GM-103423-12]; Agence Nationale de la Recherche [ANR-09-BLAN-0127-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103423] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agence Nationale de la Recherche(French National Research Agency (ANR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are very grateful to Kristin Artinger (University of Colorado, Aurora, CO, USA) for sharing ideas, pre-publication data, and reagents; Vicki Prince (University of Chicago, Chicago, IL, USA) and Paul Henion (Ohio State University, Columbus, OH, USA) for reagents; and Mike Palopoli, Andrea Jowdry, and David Rivers for helpful suggestions. This work was supported by U.S. National Institutes of Health grants 5P20-RR-016463-12 and 8P20-GM-103423-12 (to W.R.J.) and Agence Nationale de la Recherche grant ANR-09-BLAN-0127-01 (to V.L.).	AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Alexandre D, 1996, DEVELOPMENT, V122, P735; Allan D, 2001, DEV BIOL, V240, P46, DOI 10.1006/dbio.2001.0455; Baker CVH, 1997, MECH DEVELOP, V69, P13, DOI 10.1016/S0925-4773(97)00129-9; Begemann G, 2001, DEVELOPMENT, V128, P3081; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Birkholz DA, 2009, DEV DYNAM, V238, P2575, DOI 10.1002/dvdy.22090; Bohnsack BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022991; Britz R, 2009, P ROY SOC B-BIOL SCI, V276, P2179, DOI 10.1098/rspb.2009.0141; Chai Y, 2000, DEVELOPMENT, V127, P1671; Chiang EFL, 2001, DEV BIOL, V231, P149, DOI 10.1006/dbio.2000.0129; Crump JG, 2004, DEVELOPMENT, V131, P5703, DOI 10.1242/dev.01444; DEBEER GR, 1947, PROC R SOC SER B-BIO, V134, P377; Debiais-Thibaud M, 2007, J EXP ZOOL PART B, V308B, P693, DOI 10.1002/jez.b.21183; Dollo L., 1893, B SOC BELG GEOL, V7, P164; Dorsky RI, 1999, MECH DEVELOP, V86, P147, DOI 10.1016/S0925-4773(99)00101-X; Ellies DL, 1997, MECH DEVELOP, V61, P23, DOI 10.1016/S0925-4773(96)00616-8; Feng L, 2010, DEV BIOL, V338, P1, DOI 10.1016/j.ydbio.2009.10.029; Galis F, 2010, EVOLUTION, V64, P2466, DOI 10.1111/j.1558-5646.2010.01041.x; Gibert Y, 2010, FASEB J, V24, P3298, DOI 10.1096/fj.09-147488; Goldberg EE, 2008, EVOLUTION, V62, P2727, DOI 10.1111/j.1558-5646.2008.00505.x; Gordon CT, 2010, EVOL DEV, V12, P459, DOI 10.1111/j.1525-142X.2010.00432.x; GOSLINE WA, 1973, COPEIA, P761; Grande L, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011114; Hernandez-Lagunas L, 2005, DEV BIOL, V278, P347, DOI 10.1016/j.ydbio.2004.11.014; Houle M, 2003, DEVELOPMENT, V130, P6555, DOI 10.1242/dev.00889; Hunter MP, 2002, DEV BIOL, V247, P367, DOI 10.1006/dbio.2002.0701; Huysseune A, 1998, ANAT EMBRYOL, V198, P289, DOI 10.1007/s004290050185; Ignatius MS, 2008, DEV BIOL, V313, P568, DOI 10.1016/j.ydbio.2007.10.045; Iwamatsu T, 2004, MECH DEVELOP, V121, P605, DOI 10.1016/j.mod.2004.03.012; Jackman WR, 2006, P NATL ACAD SCI USA, V103, P19390, DOI 10.1073/pnas.0609575103; Jackman WR, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-119; Jackman WR, 2004, DEV BIOL, V274, P139, DOI 10.1016/j.ydbio.2004.07.003; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klein OD, 2008, DEVELOPMENT, V135, P377, DOI 10.1242/dev.015081; KRONMILLER JE, 1995, ARCH ORAL BIOL, V40, P589, DOI 10.1016/0003-9969(95)00014-G; Kumar S, 2010, DEV BIOL, V340, P67, DOI 10.1016/j.ydbio.2010.01.027; LANDE R, 1978, EVOLUTION, V32, P73, DOI 10.1111/j.1558-5646.1978.tb01099.x; Laue K, 2008, DEVELOPMENT, V135, P3775, DOI 10.1242/dev.021238; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lister JA, 1999, DEVELOPMENT, V126, P3757; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Luo RS, 2001, DEV DYNAM, V220, P169, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1097>3.0.CO;2-1; Mallo M, 2010, DEV BIOL, V344, P7, DOI 10.1016/j.ydbio.2010.04.024; Manzanares M, 2000, NATURE, V408, P854, DOI 10.1038/35048570; MARK M, 1995, INT J DEV BIOL, V39, P111; MARSHALL CR, 1994, P NATL ACAD SCI USA, V91, P12283, DOI 10.1073/pnas.91.25.12283; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; McDonald J., 2009, HDB BIOL STAT, P70; McGraw HF, 2011, DEVELOPMENT, V138, P3921, DOI 10.1242/dev.062554; Mercader N, 2006, DEVELOPMENT, V133, P2805, DOI 10.1242/dev.02455; Minoux M, 2010, DEVELOPMENT, V137, P2605, DOI 10.1242/dev.040048; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Nelson JS, 2006, FISHES WORLD, DOI DOI 10.1002/9781119174844; Nichols J. T., 1930, COPEIA, V1930, P148; Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Patterson C., 1993, P621; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Portz DE, 2004, ENVIRON BIOL FISH, V71, P233, DOI 10.1007/s10641-004-0300-y; Prince VE, 1998, DEVELOPMENT, V125, P407; Schilling TF, 1996, DEVELOPMENT, V123, P329; Sibbing F., 1991, CYPRINID FISHES SYST, P377; Sperber SM, 2008, DEV BIOL, V314, P59, DOI 10.1016/j.ydbio.2007.11.005; Stock DW, 2007, J EXP ZOOL PART B, V308B, P523, DOI 10.1002/jez.b.21187; Stock DW, 2001, PHILOS T R SOC B, V356, P1633, DOI 10.1098/rstb.2001.0917; Talbot JC, 2010, DEVELOPMENT, V137, P2506, DOI 10.1242/dev.049700; Trinh LA, 2007, BIOTECHNIQUES, V42, P756, DOI 10.2144/000112476; Van der Heyden C, 2000, DEV DYNAM, V219, P486; Venugopalan SR, 2011, J BIOL CHEM, V286, P21372, DOI 10.1074/jbc.M111.252031; Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558; White RJ, 2007, PLOS BIOL, V5, P2522, DOI 10.1371/journal.pbio.0050304; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Yamaguchi M, 1998, P NATL ACAD SCI USA, V95, P7491, DOI 10.1073/pnas.95.13.7491	75	18	19	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5014	5024		10.1096/fj.12-209304	http://dx.doi.org/10.1096/fj.12-209304			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22942074	Green Published			2022-12-28	WOS:000311838300023
J	Hulleman, JD; Balch, WE; Kelly, JW				Hulleman, John D.; Balch, William E.; Kelly, Jeffery W.			Translational attenuation differentially alters the fate of disease-associated fibulin proteins	FASEB JOURNAL			English	Article						eIF2 alpha; age-related macular degeneration; cutis laxa; malattia leventinese; proteostasis	ELASTIC FIBER HOMEOSTASIS; FACTOR 2-ALPHA KINASE; ENDOPLASMIC-RETICULUM; MACULAR DEGENERATION; ABERRANT ACCUMULATION; MALATTIA LEVENTINESE; VISUAL IMPAIRMENT; GENE-EXPRESSION; STRESS; MUTATION	Mutations in fibulin proteins that cause cellular secretion deficiencies are linked to a variety of diseases, ranging from retinopathies to cutis laxa (CL). One secretion-deficient fibulin mutant, R345W fibulin-3, causes the macular dystrophy malattia leventinese by increased endoplasmic reticulum retention and/or extracellular misfolding. Herein, we report that small-molecule activation of the PERK arm of the unfolded protein response partially rescues R345W secretion deficiencies through translational attenuation mediated by eIF2 alpha phosphorylation. Enhanced mutant fibulin-3 secretion can also be achieved by activation of a PERK-independent eIF2 alpha kinase through arsenite treatment and is independent of activating transcription factor 4 signaling and protein translation. However, this translational attenuation strategy was unsuccessful for enhancing the secretion deficiencies of fibulin-5 mutants associated with age-related macular degeneration or CL. While lowered growth temperature enhanced the secretion of mutants associated with CL (C217R and S227P), these effects were not mediated through translational attenuation. In stark contrast to the situation with fibulin-3, protein translation was required for efficient wild-type and mutant fibulin-5 secretion. These data suggest that alteration of specific cellular signaling pathways and proteostasis network components can differentially influence fibulin fate, a hypothesis that could be exploited as a therapy for fibulin-related diseases.-Hulleman, J. D., Balch, W. E., Kelly, J. W. Translational attenuation differentially alters the fate of disease-associated fibulin proteins. FASEB J. 26, 4548-4560 (2012). www.fasebj.org	[Hulleman, John D.; Kelly, Jeffery W.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Hulleman, John D.; Balch, William E.; Kelly, Jeffery W.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Hulleman, John D.; Kelly, Jeffery W.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Balch, William E.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Hulleman, JD (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hulleman@scripps.edu; jkelly@scripps.edu	Hulleman, John D./AAV-8242-2020	Hulleman, John/0000-0001-8149-656X	Lita Annenberg Hazen Foundation; Skaggs Institute for Chemical Biology; Scripps Translational Science Institute [UL1 RR025774]; U.S. National Institutes of Health [AG018917]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018917] Funding Source: NIH RePORTER	Lita Annenberg Hazen Foundation; Skaggs Institute for Chemical Biology; Scripps Translational Science Institute; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank R. Luke Wiseman for his insightful review of the manuscript. This work was supported by the Lita Annenberg Hazen Foundation, the Skaggs Institute for Chemical Biology, grant UL1 RR025774 from the Scripps Translational Science Institute (J. W. K.), and grant AG018917 from the U.S. National Institutes of Health (J. W. K.).	Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Attebo K, 1996, OPHTHALMOLOGY, V103, P357; Badr CE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000571; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Claus S, 2008, J INVEST DERMATOL, V128, P1442, DOI 10.1038/sj.jid.5701211; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Drewes PG, 2007, AM J PATHOL, V170, P578, DOI 10.2353/ajpath.2007.060662; Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; Greene B, 1999, J BIOL CHEM, V274, P16141, DOI 10.1074/jbc.274.23.16141; Gupta R, 2010, FEBS LETT, V584, P3620, DOI 10.1016/j.febslet.2010.07.036; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hu QR, 2006, HUM MOL GENET, V15, P3379, DOI 10.1093/hmg/ddl414; Hulleman JD, 2011, MOL BIOL CELL, V22, P4765, DOI 10.1091/mbc.E11-08-0695; Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620; Jones RPO, 2009, J BIOL CHEM, V284, P25938, DOI 10.1074/jbc.M109.011627; Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x; Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653; Kojima C, 2009, JNCI-J NATL CANCER I, V101, P1670, DOI 10.1093/jnci/djp414; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Maguire CA, 2009, ANAL CHEM, V81, P7102, DOI 10.1021/ac901234r; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; McLaughlin PJ, 2007, HUM MOL GENET, V16, P3059, DOI 10.1093/hmg/ddm264; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Qin XJ, 2008, CHEM RES TOXICOL, V21, P1806, DOI 10.1021/tx8001548; Rahn DD, 2009, AM J PATHOL, V174, P206, DOI 10.2353/ajpath.2009.080212; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070; Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200; Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039; Siller E, 2010, J MOL BIOL, V396, P1310, DOI 10.1016/j.jmb.2009.12.042; Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; Sullivan KM, 2007, LAB INVEST, V87, P818, DOI 10.1038/labinvest.3700594; TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Weigell-Weber M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1184, DOI 10.1001/archopht.121.8.1184; Welsh JP, 2009, BIOCHEM BIOPH RES CO, V389, P563, DOI 10.1016/j.bbrc.2009.09.006; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018	59	19	20	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4548	4560		10.1096/fj.11-202861	http://dx.doi.org/10.1096/fj.11-202861			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872678	Green Published			2022-12-28	WOS:000310574200017
J	Coster, M; Wittkopf, D; Kreuchwig, A; Kleinau, G; Thor, D; Krause, G; Schoneberg, T				Coester, Maxi; Wittkopf, Doreen; Kreuchwig, Annika; Kleinau, Gunnar; Thor, Doreen; Krause, Gerd; Schoeneberg, Torsten			Using ortholog sequence data to predict the functional relevance of mutations in G-protein-coupled receptors	FASEB JOURNAL			English	Article						structure-function relationship; evolution; mutagenesis; nucleotide receptor	NEPHROGENIC DIABETES-INSIPIDUS; V2 VASOPRESSIN RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTORS; SACCHAROMYCES-CEREVISIAE; RANDOM MUTAGENESIS; GPCR STRUCTURE; AMINO-ACIDS; IDENTIFICATION; EXPRESSION; YEAST	Evaluating the functional relevance of naturally occurring gene variants usually requires experimental testing or is even impossible because of the lack of appropriate functional assays. Here we have analyzed whether comparative sequence data from orthologs are suitable to predict the functional relevance of mutations in a model protein, a G-protein-coupled receptor for ADP (P2Y(12)). The functional effect of every possible substitution at each amino acid position within a portion of P2Y(12) (1254 mutants) was individually determined. Sequence analysis of >70 P2Y12 vertebrate orthologs revealed that this amino acid variability ensuring proper receptor function in vivo highly correlates (>90%) with the in vitro experimental data. Therefore, ortholog sequence data are helpful to predict the functional relevance of individual positions and mutations for P2Y(12). It is likely that similar conclusions may be extended for other GPCRs and conserved proteins as well.-Coster, M., Wittkopf, D., Kreuchwig, A., Kleinau, G., Thor, D., Krause, G., Schoneberg, T. Using ortholog sequence data to predict the functional relevance of mutations in G-protein-coupled receptors. FASEB J. 26, 3273-3281 (2012). www.fasebj.org	[Coester, Maxi; Wittkopf, Doreen; Thor, Doreen; Schoeneberg, Torsten] Univ Leipzig, Fac Med, Inst Biochem, D-04103 Leipzig, Germany; [Kreuchwig, Annika; Krause, Gerd] Leibniz Inst Mol Pharmacol, Berlin, Germany; [Kleinau, Gunnar] Charite, Inst Expt Pediat Endocrinol, D-13353 Berlin, Germany	Leipzig University; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schoneberg, T (corresponding author), Univ Leipzig, Fac Med, Inst Biochem, Johannisallee 30, D-04103 Leipzig, Germany.	torsten.schoeneberg@medizin.uni-leipzig.de	Kleinau, Gunnar/GPX-6330-2022; Thor, Doreen/P-6778-2019	Thor, Doreen/0000-0002-9522-5098	Deutsche Forschungsgemeinschaft [FOR 748, Scho 624/7-1]; Medical Faculty, University of Leipzig	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Medical Faculty, University of Leipzig	The authors are very grateful to Elizabeth Dong for proofreading and many helpful suggestions and Kay-Uwe Simon for technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (FOR 748, Scho 624/7-1) and by a student fellowship of the Medical Faculty, University of Leipzig, to D.W. The authors declare no conflicts of interest.	Armistead J, 2009, AM J HUM GENET, V84, P728, DOI 10.1016/j.ajhg.2009.04.017; Bass RT, 1996, MOL PHARMACOL, V50, P709; Boselt I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005573; Caronia LM, 2011, NEW ENGL J MED, V364, P215, DOI 10.1056/NEJMoa0911064; Deflorian F, 2011, J COMPUT AID MOL DES, V25, P329, DOI 10.1007/s10822-011-9423-3; Enard W, 2009, CELL, V137, P961, DOI 10.1016/j.cell.2009.03.041; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Feldman BJ, 2005, NEW ENGL J MED, V352, P1884, DOI 10.1056/NEJMoa042743; Haussler D, 2009, J HERED, V100, P659, DOI 10.1093/jhered/esp086; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hoffmann K, 2008, BIOCHEM PHARMACOL, V76, P1201, DOI 10.1016/j.bcp.2008.08.029; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hullme EC, 2007, BIOCHEM SOC T, V35, P742, DOI 10.1042/BST0350742; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Kleinau G, 2008, FASEB J, V22, P2798, DOI 10.1096/fj.07-104711; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; Kleinau G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009745; Kleinau G, 2009, ENDOCR REV, V30, P133, DOI 10.1210/er.2008-0044; Lalueza-Fox C, 2007, SCIENCE, V318, P1453, DOI 10.1126/science.1147417; Li B, 2005, J BIOL CHEM, V280, P5664, DOI 10.1074/jbc.M411623200; Li B, 2007, NAT METHODS, V4, P169, DOI 10.1038/nmeth990; Liebscher I, 2011, J BIOL CHEM, V286, P2101, DOI 10.1074/jbc.M110.196659; Liu HB, 2011, BIOPHYS CHEM, V155, P74, DOI 10.1016/j.bpc.2011.03.001; Mao YY, 2010, EUR J PHARMACOL, V644, P10, DOI 10.1016/j.ejphar.2010.06.023; Marks DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028766; Michino M, 2009, NAT REV DRUG DISCOV, V8, P455, DOI 10.1038/nrd2877; Minic J, 2005, FEBS J, V272, P524, DOI 10.1111/j.1742-4658.2004.04494.x; Niebauer Ronald T, 2005, Purinergic Signal, V1, P241, DOI 10.1007/s11302-005-6310-1; Nishihara E, 2012, J ENDOCRINOL INVEST, V35, P49, DOI 10.3275/7738; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pausch MH, 2004, BIOCHEM BIOPH RES CO, V324, P171, DOI 10.1016/j.bbrc.2004.09.034; Pausch MH, 1997, TRENDS BIOTECHNOL, V15, P487, DOI 10.1016/S0167-7799(97)01119-0; Peeters MC, 2011, FASEB J, V25, P632, DOI 10.1096/fj.10-164319; Qin Y, 2011, PIGM CELL MELANOMA R, V24, P207, DOI 10.1111/j.1755-148X.2010.00781.x; Remijn JA, 2007, CLIN CHEM LAB MED, V45, P187, DOI 10.1515/CCLM.2007.036; Ritscher L, 2012, BIOCHEM J, V443, P841, DOI 10.1042/BJ20112090; Rompler H, 2006, SCIENCE, V313, P62, DOI 10.1126/science.1128994; Sadeghi H, 1997, MOL ENDOCRINOL, V11, P1806, DOI 10.1210/me.11.12.1806; Sakami S, 2011, J BIOL CHEM, V286, P10551, DOI 10.1074/jbc.M110.209759; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schoneberg T, 2007, PURINERG SIGNAL, V3, P255, DOI 10.1007/s11302-007-9064-0; Schoneberg T, 1998, HUM MUTAT, V12, P196, DOI 10.1002/(SICI)1098-1004(1998)12:3<196::AID-HUMU7>3.0.CO;2-F; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Singh NA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000649; Staubert C, 2007, ENDOCRINOLOGY, V148, P4642, DOI 10.1210/en.2007-0138; Stewart GD, 2010, ACS CHEM BIOL, V5, P365, DOI 10.1021/cb900276p; Strotmann R, 2011, MOL CELL ENDOCRINOL, V331, P170, DOI 10.1016/j.mce.2010.07.012; Thor D, 2008, BIOCHEM J, V412, P103, DOI [10.1042/BJ20071366, 10.1042/bj20071366]; Vassart G, 2011, NAT REV ENDOCRINOL, V7, P362, DOI 10.1038/nrendo.2011.20; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Zaki M, 2006, NEPHROL DIAL TRANSPL, V21, P1082, DOI 10.1093/ndt/gfk024	54	20	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3273	3281		10.1096/fj.12-203737	http://dx.doi.org/10.1096/fj.12-203737			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22611087				2022-12-28	WOS:000307162800018
J	Eneling, K; Brion, L; Pinto, V; Pinho, MJ; Sznajder, JI; Mochizuki, N; Emoto, K; Soares-da-Silva, P; Bertorello, AM				Eneling, Kristina; Brion, Laura; Pinto, Vanda; Pinho, Maria J.; Sznajder, Jacob I.; Mochizuki, Naoki; Emoto, Kazuo; Soares-da-Silva, Patricio; Bertorello, Alejandro M.			Salt-inducible kinase 1 regulates E-cadherin expression and intercellular junction stability	FASEB JOURNAL			English	Article						epithelial polarity; sodium transport; vectorial transport; transepithelial resistance; metastatic transformation; liver kinase B1	EPITHELIAL-CELL PHENOTYPE; SODIUM-TRANSPORT; PROTEIN-KINASES; P120 CATENIN; TUMOR-CELLS; LKB1; MOUSE; CANCER; FAMILY; SNAIL	The protein kinase liver kinase B1 (LKB1) regulates cell polarity and intercellular junction stability. Also, LKB1 controls the activity of salt-inducible kinase 1 (SIK1). The role and relevance of SIK1 and its downstream effectors in linking the LKB1 signals within these processes are partially understood. We hypothesize that SIK1 may link LKB1 signals to the maintenance of epithelial junction stability by regulating E-cadherin expression. Results from our studies using a mouse lung alveolar epithelial (MLE-12) cell line or human renal proximal tubule (HK2) cell line transiently or stably lacking the expression of SIK1 (using SIK1 siRNAs or shRNAs), or with its expression abrogated (sik1(+/+) vs. sik1(-/-) mice), indicate that suppression of SIK1 (similar to 40%) increases the expression of the transcriptional re-pressors Snail2 (similar to 12-fold), Zeb1 (similar to 100%), Zeb2 (similar to 50%), and TWIST (similar to 20-fold) by activating cAMP-response element binding protein. The lack of SIK1 and activation of transcriptional repressors decreases the availability of E-cadherin (mRNA and protein expression by similar to 100 and 80%, respectively) and the stability of intercellular junctions in epithelia (decreases in transepithelial resistance). Furthermore, LKB1-mediated increases in E-cadherin expression are impaired in cells where SIK1 has been disabled. We conclude that SIK1 is a key regulator of E-cadherin expression, and thereby contributes to the stability of intercellular junctions.-Eneling, K., Brion, L., Pinto, V., Pinho, M. J., Sznajder, J. I., Mochizuki, N., Emoto, K., Soares-da-Silva, P., Bertorello, A. M. Salt-inducible kinase 1 regulates E-cadherin expression and intercellular junction stability. FASEB J. 26, 3230-3239 (2012). www.fasebj.org	[Eneling, Kristina; Brion, Laura; Bertorello, Alejandro M.] Karolinska Inst, Karolinska Univ Hosp Solna, Atherosclerosis Res Unit, Membrane Signaling Networks,Dept Med,Ctr Mol Med, S-17176 Stockholm, Sweden; [Pinto, Vanda; Pinho, Maria J.; Soares-da-Silva, Patricio] Fac Med, Dept Pharmacol & Therapeut, Oporto, Portugal; [Sznajder, Jacob I.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Mochizuki, Naoki] Natl Cerebral & Cardiovasc Ctr, Dept Cell Biol, Osaka, Japan; [Emoto, Kazuo] Osaka Biosci Inst, Osaka, Japan	Karolinska Institutet; Karolinska University Hospital; Universidade do Porto; Northwestern University; National Cerebral & Cardiovascular Center - Japan	Bertorello, AM (corresponding author), Karolinska Inst, Karolinska Univ Hosp Solna, Atherosclerosis Res Unit, Membrane Signaling Networks,Dept Med,Ctr Mol Med, CMM L5 01, S-17176 Stockholm, Sweden.	alejandro.bertorello@ki.se	Soares-da-Silva, Patricio/A-6704-2015; Pinto, Vanda/H-9446-2013; EMOTO, KAZUO/G-4992-2014	Soares-da-Silva, Patricio/0000-0002-2446-5078; Pinho, Maria Joao/0000-0001-8173-0379; Pinto, Vanda/0000-0001-9979-1663	Swedish Research Council [10860]; Swedish Heart and Lung Foundation; AFA Insurance Sweden; U.S. National Heart, Lung, and Blood Institute grant [HL-48129]; Fundacao para a Ciencia e a Tecnologia grant [PIC/IC/83204/2007]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048129, R37HL048129] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); AFA Insurance Sweden; U.S. National Heart, Lung, and Blood Institute grant; Fundacao para a Ciencia e a Tecnologia grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Hiroshi Takemori (National Institute of Biomedical Innovation, Osaka, Japan), Giuseppe Bianchi (San Raffaele Hospital, Milan, Italy), and Amparo Cano (Universidad Autonoma de Madrid, Madrid, Spain) for providing reagents. The study was supported by grants from the Swedish Research Council (10860), the Swedish Heart and Lung Foundation, AFA Insurance Sweden, U.S. National Heart, Lung, and Blood Institute grant HL-48129, and Fundacao para a Ciencia e a Tecnologia grant PIC/IC/83204/2007.	Amin N, 2009, P NATL ACAD SCI USA, V106, P8941, DOI 10.1073/pnas.0812469106; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cheng HL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000369; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ferrandi M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001815; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Gomes P, 2006, AM J PHYSIOL-REG I, V290, pR1142, DOI 10.1152/ajpregu.00102.2005; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Larre I, 2010, P NATL ACAD SCI USA, V107, P11387, DOI 10.1073/pnas.1000500107; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; Pearson HB, 2008, CANCER RES, V68, P2223, DOI 10.1158/0008-5472.CAN-07-5169; Pedrosa R, 2008, HYPERTENSION, V51, P1332, DOI 10.1161/HYPERTENSIONAHA.107.102434; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pinto V, 2008, MOL CELL BIOCHEM, V310, P191, DOI 10.1007/s11010-007-9680-6; QUIGLEY JP, 1969, BIOCHIM BIOPHYS ACTA, V173, P456, DOI 10.1016/0005-2736(69)90010-8; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Romito A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009029; Roy BC, 2010, LUNG CANCER, V70, P136, DOI 10.1016/j.lungcan.2010.02.004; RUIZ JC, 1994, MECH DEVELOP, V48, P153, DOI 10.1016/0925-4773(94)90056-6; Sjostrom M, 2007, P NATL ACAD SCI USA, V104, P16922, DOI 10.1073/pnas.0706838104; Stenstrom K, 2009, J HYPERTENS, V27, P2452, DOI 10.1097/HJH.0b013e328330cf15; Takemori H, 2007, FEBS J, V274, P3202, DOI 10.1111/j.1742-4658.2007.05889.x; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; Zhang L, 2011, J BIOL CHEM, V286, P16879, DOI 10.1074/jbc.M110.186932	39	22	24	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3230	3239		10.1096/fj.12-205609	http://dx.doi.org/10.1096/fj.12-205609			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22522110	Green Published			2022-12-28	WOS:000307162800014
J	Mietus-Snyder, ML; Shigenaga, MK; Suh, JH; Shenvi, SV; Lal, A; McHugh, T; Olson, D; Lilienstein, J; Krauss, RM; Gildengoren, G; McCann, JC; Ames, BN				Mietus-Snyder, Michele L.; Shigenaga, Mark K.; Suh, Jung H.; Shenvi, Swapna V.; Lal, Ashutosh; McHugh, Tara; Olson, Don; Lilienstein, Joshua; Krauss, Ronald M.; Gildengoren, Ginny; McCann, Joyce C.; Ames, Bruce N.			A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial	FASEB JOURNAL			English	Article						antioxidant status; cardiovascular disease risk; dyslipidemia; lipid particles; obesity	CARDIOVASCULAR RISK-FACTORS; POLYUNSATURATED FATTY-ACIDS; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIALS; METABOLIC SYNDROME; LIPOPROTEIN CHOLESTEROL; INSULIN-RESISTANCE; FOLIC-ACID; OXIDATIVE STRESS; GLYCEMIC INDEX	Dietary intake modulates disease risk, but little is known how components within food mixtures affect pathophysiology. A low-calorie, high-fiber, fruit-based nutrient-dense bar of defined composition (e. g., vitamins and minerals, fruit polyphenolics, beta-glucan, docosahexaenoic acid) appropriate for deconstruction and mechanistic studies is described and evaluated in a pilot trial. The bar was developed in collaboration with the U. S. Department of Agriculture. Changes in cardiovascular disease and diabetes risk biomarkers were measured after 2 wk twice-daily consumption of the bar, and compared against baseline controls in 25 healthy adults. Plasma HDL-cholesterol (HDL-c) increased 6.2% (P = 0.001), due primarily to a 28% increase in large HDL (HDL-L; P<0.0001). Total plasma homocysteine (Hcy) decreased 19% (P = 0.017), and glutathione (GSH) increased 20% (P = 0.011). The changes in HDL and Hcy are in the direction associated with decreased risk of cardiovascular disease and cognitive decline; increased GSH reflects improved antioxidant defense. Changes in biomarkers linked to insulin resistance and inflammation were not observed. A defined food-based supplement can, within 2 wk, positively impact metabolic biomarkers linked to disease risk. These results lay the groundwork for mechanistic/deconstruction experiments to identify critical bar components and putative synergistic combinations responsible for observed effects.-Mietus-Snyder, M. L., Shigenaga, M. K., Suh, J. H., Shenvi, S. V., Lal, A., McHugh, T., Olson, D., Lilienstein, J., Krauss, R. M., Gildengoren, G., McCann, J. C., Ames, B. N. A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homo-cysteine, and raises glutathione in a 2-wk trial. FASEB J. 26, 3515-3527 (2012). www.fasebj.org	[Mietus-Snyder, Michele L.; Shigenaga, Mark K.; Suh, Jung H.; Shenvi, Swapna V.; Lal, Ashutosh; Krauss, Ronald M.; Gildengoren, Ginny; McCann, Joyce C.; Ames, Bruce N.] Childrens Hosp Oakland Res Inst, Nutr & Metab Ctr, Oakland, CA 94609 USA; [McHugh, Tara; Olson, Don] ARS, Proc Foods Res Unit, USDA, Western Reg Res Ctr, Albany, CA USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; United States Department of Agriculture (USDA)	Shigenaga, MK (corresponding author), Childrens Hosp Oakland Res Inst, Nutr & Metab Ctr, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	mshigenaga@chori.org; bames@chori.org		Lilienstein, Joshua/0000-0003-3189-9170; Mietus-Snyder, Michele/0000-0003-2791-9896	U.S. National Institutes of Health [UL1RR024131]; Bruce and Giovanna Ames Foundation; Department of Atherosclerosis Research at Children's Hospital Oakland Research Institute; S. D. Bechtel, Jr. Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bruce and Giovanna Ames Foundation; Department of Atherosclerosis Research at Children's Hospital Oakland Research Institute; S. D. Bechtel, Jr. Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Many thanks to Alicia Zhou, Casey Geaney, Katie Woojinski, and Devan Block for technical assistance, the extraordinary staff at the Pediatric Clinical Research Center (PCRC) at Children's Hospital Oakland, especially Annie Higa and Vivian Ng. M. K. S. thanks Wally Yokoyama for helpful discussions on soluble fibers. The authors also thank Pharmachem Laboratories (Kearny, NJ, USA) for donating a nutrient blend for the study and Teresa Klask for invaluable administrative assistance. This publication was made possible by U.S. National Institutes of Health Clinical and Translational Science Award grant UL1RR024131. Additional support was from the Bruce and Giovanna Ames Foundation (J.C.M., M. M. S., M. K. S., J.H.S., S. V. S., A. L.), the Department of Atherosclerosis Research at Children's Hospital Oakland Research Institute (R. M. K.), and the S. D. Bechtel, Jr. Foundation (J.H.S.).	Aasheim ET, 2008, AM J CLIN NUTR, V87, P362, DOI 10.1093/ajcn/87.2.362; Adamsson V, 2011, J INTERN MED, V269, P150, DOI 10.1111/j.1365-2796.2010.02290.x; Adeva MM, 2012, AMINO ACIDS, V43, P171, DOI 10.1007/s00726-011-1088-7; Agodi A, 2011, EUR J CLIN NUTR, V65, P1302, DOI 10.1038/ejcn.2011.125; Al-Mohaissen MA, 2010, MINI-REV MED CHEM, V10, P204, DOI 10.2174/138955710791185046; Alley DE, 2006, BRAIN BEHAV IMMUN, V20, P498, DOI 10.1016/j.bbi.2005.10.003; Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103; Ames BN, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/725071; [Anonymous], 2008, AM J BIOCH BIOTECHNO; Ashfaq S, 2006, J AM COLL CARDIOL, V47, P1005, DOI 10.1016/j.jacc.2005.09.063; Asztalos BF, 2004, ARTERIOSCL THROM VAS, V24, P2181, DOI 10.1161/01.ATV.0000146325.93749.a8; Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005; Azadbakht L, 2005, DIABETES CARE, V28, P2823, DOI 10.2337/diacare.28.12.2823; Balk EM, 2006, ATHEROSCLEROSIS, V189, P19, DOI 10.1016/j.atherosclerosis.2006.02.012; Basu A, 2010, J NUTR, V140, P1582, DOI 10.3945/jn.110.124701; Basu TK, 1997, J NUTR, V127, P117, DOI 10.1093/jn/127.1.117; Beck EJ, 2009, MOL NUTR FOOD RES, V53, P1343, DOI 10.1002/mnfr.200800343; Bernstein AM, 2012, J NUTR, V142, P99, DOI 10.3945/jn.111.148973; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Blasbalg TL, 2011, AM J CLIN NUTR, V93, P950, DOI 10.3945/ajcn.110.006643; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Botella-Carretero JI, 2007, CLIN NUTR, V26, P573, DOI 10.1016/j.clnu.2007.05.009; Bremer AA, 2012, PEDIATRICS, V129, P557, DOI 10.1542/peds.2011-2912; Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572; Bueno MB, 2008, NUTRITION, V24, P1110, DOI 10.1016/j.nut.2008.05.020; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Carr DF, 2009, PHARMACOGENOMICS J, V9, P291, DOI 10.1038/tpj.2009.29; Casagrande SS, 2007, AM J PREV MED, V32, P257, DOI 10.1016/j.amepre.2006.12.002; Caulfield MP, 2008, CLIN CHEM, V54, P1307, DOI 10.1373/clinchem.2007.100586; Chan AC, 1999, P SOC EXP BIOL MED, V222, P274, DOI 10.1046/j.1525-1373.1999.d01-144.x; Chapman MJ, 2010, PHARMACOL THERAPEUT, V126, P314, DOI 10.1016/j.pharmthera.2010.01.008; Clarke R, 2011, J INHERIT METAB DIS, V34, P83, DOI 10.1007/s10545-010-9235-y; Cooney MT, 2009, ATHEROSCLEROSIS, V206, P611, DOI 10.1016/j.atherosclerosis.2009.02.041; Crider KS, 2011, AM J CLIN NUTR, V93, P1365, DOI 10.3945/ajcn.110.004671; Culberson A., 2009, INT ARCH MED, V2, P3; Darmon N, 2008, AM J CLIN NUTR, V87, P1107, DOI 10.1093/ajcn/87.5.1107; de Jager CA, 2012, INT J GERIATR PSYCH, V27, P592, DOI 10.1002/gps.2758; Deminice R, 2011, J NUTR, V141, P1799, DOI 10.3945/jn.111.144857; Dierkes Jutta, 2005, Semin Vasc Med, V5, P124; Durstine J L, 1994, Exerc Sport Sci Rev, V22, P477; Elias MF, 2005, AM J EPIDEMIOL, V162, P644, DOI 10.1093/aje/kwi259; Erlund I, 2008, AM J CLIN NUTR, V87, P323, DOI 10.1093/ajcn/87.2.323; Ervin R Bethene, 2009, Natl Health Stat Report, P1; Esmaillzadeh A, 2007, J NUTR, V137, P992, DOI 10.1093/jn/137.4.992; Esmaillzadeh A, 2007, AM J CLIN NUTR, V85, P910, DOI 10.1093/ajcn/85.3.910; EVANS MA, 1992, J AM DIET ASSOC, V92, P1239, DOI 10.1037/10111-000; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Foster-Schubert KE, 2008, J CLIN ENDOCR METAB, V93, P1971, DOI 10.1210/jc.2007-2289; Frassetto LA, 2009, EUR J CLIN NUTR, V63, P947, DOI 10.1038/ejcn.2009.4; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5; Garcia-Sanchez C, 2011, CLIN CHIM ACTA, V412, P292, DOI 10.1016/j.cca.2010.10.021; Gardner CD, 2010, AM J CLIN NUTR, V92, P304, DOI 10.3945/ajcn.2010.29468; Geppert J, 2006, BRIT J NUTR, V95, P779, DOI 10.1079/BJN20051720; Gordon SM, 2011, TRENDS ENDOCRIN MET, V22, P9, DOI 10.1016/j.tem.2010.10.001; Grey Vijaylaxmi, 2003, J Cyst Fibros, V2, P195, DOI 10.1016/S1569-1993(03)00097-3; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Grion CMC, 2010, EUR J CLIN INVEST, V40, P330, DOI 10.1111/j.1365-2362.2010.02269.x; Gutschi LM, 2006, ANN PHARMACOTHER, V40, P1672, DOI 10.1345/aph.1H020; Haan MN, 2007, AM J CLIN NUTR, V85, P511, DOI 10.1093/ajcn/85.2.511; Hartweg J, 2007, DIABETOLOGIA, V50, P1593, DOI 10.1007/s00125-007-0695-z; Hossain MA, 2008, J CARDIOVASC PHARM, V51, P258, DOI 10.1097/FJC.0b013e3181624b22; Houston MC, 2009, PROG CARDIOVASC DIS, V52, P61, DOI 10.1016/j.pcad.2009.02.002; Howarth NC, 2001, NUTR REV, V59, P129, DOI 10.1111/j.1753-4887.2001.tb07001.x; Hu JJ, 1996, CANCER EPIDEM BIOMAR, V5, P263; Innis SM, 2007, AM J CLIN NUTR, V85, P702, DOI 10.1093/ajcn/85.3.702; Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B; Jafri H, 2010, J AM COLL CARDIOL, V55, P2846, DOI 10.1016/j.jacc.2009.12.069; Jia L, 2010, AM J CLIN NUTR, V92, P218, DOI 10.3945/ajcn.2009.28202; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; Jonsson T, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-35; Jun M, 2010, LANCET, V375, P1875, DOI 10.1016/S0140-6736(10)60656-3; Kabir M, 2007, AM J CLIN NUTR, V86, P1670; Kalaria RN, 2010, NUTR REV, V68, pS74, DOI 10.1111/j.1753-4887.2010.00352.x; Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689; Kimmons Joel E, 2006, MedGenMed, V8, P59; Krauss RM, 2004, DIABETES CARE, V27, P1496, DOI 10.2337/diacare.27.6.1496; Krebs-Smith SM, 2010, J NUTR, V140, P1832, DOI 10.3945/jn.110.124826; Krebs-Smith SM, 2010, AM J PREV MED, V38, P472, DOI 10.1016/j.amepre.2010.01.016; Kritchevsky D, 2003, J NUTR, V133, p3827S, DOI 10.1093/jn/133.11.3827S; Kruit JK, 2006, WORLD J GASTROENTERO, V12, P6429, DOI 10.3748/wjg.v12.i40.6429; Laitinen DL, 2010, CURR MED RES OPIN, V26, P933, DOI 10.1185/03007991003656968; Lee IT, 2008, DIABETIC MED, V25, P1473, DOI 10.1111/j.1464-5491.2008.02588.x; Lenton KJ, 2003, AM J CLIN NUTR, V77, P189, DOI 10.1093/ajcn/77.1.189; Li Y, 2010, INT J OBESITY, V34, P1070, DOI 10.1038/ijo.2010.14; Liese AD, 2005, DIABETES CARE, V28, P2832, DOI 10.2337/diacare.28.12.2832; Liu HL, 2004, ANN NY ACAD SCI, V1019, P346, DOI 10.1196/annals.1297.059; Livingstone C, 2007, BRIT J DIABETES VASC, V7, P258, DOI [10.1177/14746514070070060201, DOI 10.1177/14746514070070060201]; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Ludwig DS, 2007, NEW ENGL J MED, V357, P2325, DOI 10.1056/NEJMp0706538; Luhovyy BL, 2007, J AM COLL NUTR, V26, p704S, DOI 10.1080/07315724.2007.10719651; Manco M, 2010, ENDOCR REV, V31, P817, DOI 10.1210/er.2009-0030; Mangravite LM, 2011, J NUTR, V141, P2180, DOI 10.3945/jn.111.139477; Mannery YO, 2010, J PHARMACOL EXP THER, V333, P939, DOI 10.1124/jpet.110.166421; Martins D, 2008, J NATL MED ASSOC, V100, P565, DOI 10.1016/S0027-9684(15)31304-3; Mayer O, 2003, EUR J CLIN PHARMACOL, V59, P367, DOI 10.1007/s00228-003-0616-0; McCann JC, 2011, FASEB J, V25, P1793, DOI 10.1096/fj.11-180885; McCann JC, 2009, AM J CLIN NUTR, V90, P889, DOI 10.3945/ajcn.2009.27930; McGrowder D, 2011, CHOLESTEROL, DOI 10.1155/2011/496925; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Mellor DD, 2010, DIABETIC MED, V27, P1318, DOI 10.1111/j.1464-5491.2010.03108.x; Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094; Meyers CD, 2004, CURR OPIN CARDIOL, V19, P366, DOI 10.1097/01.hco.0000126582.27767.87; Morcos NC, 1999, MED SCI RES, V27, P121; Morris CR, 2008, BLOOD, V111, P402, DOI 10.1182/blood-2007-04-081703; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Mursu J, 2004, FREE RADICAL BIO MED, V37, P1351, DOI 10.1016/j.freeradbiomed.2004.06.002; Na HK, 2008, FOOD CHEM TOXICOL, V46, P1271, DOI 10.1016/j.fct.2007.10.006; Nadtochiy SM, 2011, NUTRITION, V27, P733, DOI 10.1016/j.nut.2010.12.006; Namekata K, 2004, J BIOL CHEM, V279, P52961, DOI 10.1074/jbc.M406820200; Natarajan P, 2010, J AM COLL CARDIOL, V55, P1283, DOI 10.1016/j.jacc.2010.01.008; National Institutes of Health, 2011, NIH PUBL; Neuman RB, 2007, CLIN CHEM, V53, P1652, DOI 10.1373/clinchem.2006.083923; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Nichols GA, 2011, AM J CARDIOL, V108, P1124, DOI 10.1016/j.amjcard.2011.05.047; Nordmann AJ, 2011, AM J MED, V124, P841, DOI 10.1016/j.amjmed.2011.04.024; Olson ML, 2012, J CLIN ENDOCR METAB, V97, P279, DOI 10.1210/jc.2011-1507; Olthof MR, 2005, PLOS MED, V2, P446, DOI 10.1371/journal.pmed.0020135; Oulhaj A, 2010, INT J GERIATR PSYCH, V25, P82, DOI 10.1002/gps.2303; Ozata M, 2002, CLIN BIOCHEM, V35, P627, DOI 10.1016/S0009-9120(02)00363-6; Pachikian BD, 2010, J NUTR, V140, P509, DOI 10.3945/jn.109.117374; Parra D, 2008, APPETITE, V51, P676, DOI 10.1016/j.appet.2008.06.003; Perez-Lopez FR, 2009, MATURITAS, V64, P67, DOI 10.1016/j.maturitas.2009.07.013; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Pfeiffer CM, 2008, CLIN CHEM, V54, P801, DOI 10.1373/clinchem.2007.100214; Popkin BM, 2007, SCI AM, V297, P88, DOI 10.1038/scientificamerican0907-88; Procaccini C, 2011, EXPERT REV CLIN IMMU, V7, P287, DOI [10.1586/ECI.11.18, 10.1586/eci.11.18]; Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P1491, DOI 10.1001/archneurol.2010.297; Reyna-Villasmil Nadia, 2007, Am J Ther, V14, P203, DOI 10.1097/01.pap.0000249917.96509.e7; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Rodriguez P, 1996, GUT, V39, P416, DOI 10.1136/gut.39.3.416; Rodriguez-Rodriguez E, 2009, PUBLIC HEALTH NUTR, V12, P44, DOI 10.1017/S1368980008001912; Rosenson RS, 2011, CLIN CHEM, V57, P392, DOI 10.1373/clinchem.2010.155333; Ruel G, 2006, BRIT J NUTR, V96, P357, DOI 10.1079/BJN20061814; Sacks FM, 2002, AM J MED, V113, P13, DOI 10.1016/S0002-9343(01)00987-1; Salek RM, 2007, PHYSIOL GENOMICS, V29, P99, DOI 10.1152/physiolgenomics.00194.2006; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Selhub J, 2008, FOOD NUTR BULL, V29, pS116, DOI 10.1177/15648265080292S116; Selhub J, 2007, P NATL ACAD SCI USA, V104, P19995, DOI 10.1073/pnas.0709487104; Simopoulos AP, 2011, MOL NEUROBIOL, V44, P203, DOI 10.1007/s12035-010-8162-0; Siri-Tarino PW, 2011, CURR ATHEROSCLER REP, V13, P453, DOI 10.1007/s11883-011-0207-y; Skovby F, 2010, MOL GENET METAB, V99, P1, DOI 10.1016/j.ymgme.2009.09.009; Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244; Smulders YM, 2011, J INHERIT METAB DIS, V34, P93, DOI 10.1007/s10545-010-9151-1; Sola R, 2011, ATHEROSCLEROSIS, V218, P174, DOI 10.1016/j.atherosclerosis.2011.04.026; Sonestedt E, 2012, BRIT J NUTR, V107, P1062, DOI 10.1017/S0007114511003783; SPAETH G, 1990, SURGERY, V108, P240; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suh JH, 2009, J CHROMATOGR B, V877, P3418, DOI 10.1016/j.jchromb.2009.06.041; Suliman ME, 1999, J AM SOC NEPHROL, V10, P1287; Tang WHW, 2009, J AM COLL CARDIOL, V53, P2061, DOI 10.1016/j.jacc.2009.02.036; Tian L, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-118; Tokede OA, 2011, EUR J CLIN NUTR, V65, P879, DOI 10.1038/ejcn.2011.64; Tu Min-Chien, 2010, Acta Neurol Taiwan, V19, P168; U.S. Department of Agriculture; Agricultural Research Service, 2011, USDA NAT NUTR DAT ST; US Department of Agriculture, 2007, USDA DAT FLAV CONT S; Van Dam F, 2009, ARCH GERONTOL GERIAT, V48, P425, DOI 10.1016/j.archger.2008.03.009; van der Ven AJAM, 1998, EUR J CLIN INVEST, V28, P187, DOI 10.1046/j.1365-2362.1998.00267.x; Veeranna V, 2011, J AM COLL CARDIOL, V58, P1025, DOI 10.1016/j.jacc.2011.05.028; Vitaglione P, 2009, APPETITE, V53, P338, DOI 10.1016/j.appet.2009.07.013; Vrolix R, 2010, AM J CLIN NUTR, V92, P366, DOI 10.3945/ajcn.2009.28339; Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X; Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007; Watanabe H, 2006, ARTERIOSCL THROM VAS, V26, P897, DOI 10.1161/01.ATV.0000209577.04246.c0; Weisel Tamara, 2006, Biotechnology Journal, V1, P388, DOI 10.1002/biot.200600004; Wierzbicki AS, 2009, CURR OPIN CARDIOL, V24, P372, DOI 10.1097/HCO.0b013e32832c0b3d; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Wyld B, 2010, PUBLIC HEALTH NUTR, V13, P2105, DOI 10.1017/S136898001000073X; Zhang ZY, 2010, LIPIDS, V45, P765, DOI 10.1007/s11745-010-3463-7; Zhong W, 2010, AM J PHYSIOL-GASTR L, V298, pG625, DOI 10.1152/ajpgi.00350.2009	175	18	18	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3515	3527		10.1096/fj.11-201558	http://dx.doi.org/10.1096/fj.11-201558			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22549511	Green Published			2022-12-28	WOS:000307162800038
J	Overgaard, M; Rasmussen, P; Bohm, AM; Seifert, T; Brassard, P; Zaar, M; Homann, P; Evans, KA; Nielsen, HB; Secher, NH				Overgaard, Morten; Rasmussen, Peter; Bohm, Aske M.; Seifert, Thomas; Brassard, Patrice; Zaar, Morten; Homann, Pernille; Evans, Kevin A.; Nielsen, Henning B.; Secher, Niels H.			Hypoxia and exercise provoke both lactate release and lactate oxidation by the human brain	FASEB JOURNAL			English	Article						cerebral blood flow; cerebral metabolism; tracers	TO-PYRUVATE RATIO; BLOOD-FLOW; CEREBRAL OXYGENATION; ENERGY-SOURCE; METABOLISM; ARTERIAL; GLUCOSE; MUSCLE; CONSUMPTION; ACTIVATION	Lactate is shuttled between organs, as demonstrated in the Cori cycle. Although the brain releases lactate at rest, during physical exercise there is a cerebral uptake of lactate. Here, we evaluated the cerebral lactate uptake and release in hypoxia, during exercise and when the two interventions were combined. We measured cerebral lactate turnover via a tracer dilution method ([1-C-13]lactate), using arterial to right internal jugular venous differences in 9 healthy individuals (5 males and 4 females), at rest and during 30 min of submaximal exercise in normoxia and hypoxia (FiO2 10%, arterial oxygen saturation 72 +/- 10%, mean +/- SD). Whole-body lactate turnover increased 3.5-fold and 9-fold at two workloads in normoxia and 18-fold during exercise in hypoxia. Although middle cerebral artery mean flow velocity increased during exercise in hypoxia, calculated cerebral mitochondrial oxygen tension decreased by 13 mmHg (P<0.001). At the same time, cerebral lactate release increased from 0.15 +/- 0.1 to 0.8 +/- 0.6 mmol min(-1) (P<0.05), corresponding to similar to 10% of cerebral energy consumption. Concurrently, cerebral lactate uptake was 1.0 +/- 0.9 mmol min(-1) (P<0.05), of which 57 +/- 9% was oxidized, demonstrating that lactate oxidation may account for up to similar to 33% of the energy substrate used by the brain. These results support the existence of a cell-cell lactate shuttle that may involve neurons and astrocytes.-Overgaard, M., Rasmussen, P., Bohm, A. M., Seifert, T., Brassard, P., Zaar, M., Homann, P., Evans, K. A., Nielsen, H. B., Secher, N. H. Hypoxia and exercise provoke both lactate release and lactate oxidation by the human brain. FASEB J. 26, 3012-3020 (2012). www.fasebj.org	[Overgaard, Morten; Rasmussen, Peter; Bohm, Aske M.; Seifert, Thomas; Brassard, Patrice; Zaar, Morten; Homann, Pernille; Nielsen, Henning B.; Secher, Niels H.] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, Dept Anesthesia, DK-2100 Copenhagen, Denmark; [Evans, Kevin A.] Univ Glamorgan, Neurovasc Res Lab, Pontypridd CF37 1DL, M Glam, Wales	Rigshospitalet; University of Copenhagen; University of South Wales	Rasmussen, P (corresponding author), Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, Dept Anesthesia, AN2041,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	peter@prec.dk	Brassard, Patrice/H-6115-2019; Ernst-Rasmussen, Peter Bonde/B-8203-2013	Ernst-Rasmussen, Peter Bonde/0000-0003-1761-4562	Anti-Doping Denmark; Lundbeck Foundation; Fonds de la Recherche en Sante du Quebec	Anti-Doping Denmark; Lundbeck Foundation(Lundbeckfonden); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	The skilled assistance by Gorm J. Ravn-Jonsen and Gerrit van Hall is acknowledged. The authors were funded through grants from Anti-Doping Denmark (P. R.), the Lundbeck Foundation (P. R. and N.H.S.), and Fonds de la Recherche en Sante du Quebec (P.B.).	Borg G, 1975, PHYS WORK EFFORT, P39; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; BRADAC GB, 1976, NEURORADIOLOGY, V10, P257, DOI 10.1007/BF00327574; Brooks GA, 1999, ADV EXP MED BIOL, V474, P185; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Chatham JC, 2001, AM J PHYSIOL-ENDOC M, V281, pE794, DOI 10.1152/ajpendo.2001.281.4.E794; Dalsgaard MK, 2007, J NEUROSCI RES, V85, P3334, DOI 10.1002/jnr.21274; Dalsgaard MK, 2004, J PHYSIOL-LONDON, V554, P571, DOI 10.1113/jphysiol.2003.055053; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P1895, DOI 10.1038/jcbfm.2010.151; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; Gjedde A, 2005, J CEREBR BLOOD F MET, V25, P1183, DOI 10.1038/sj.jcbfm.9600113; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413, DOI 10.1152/jappl.1996.81.1.413; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825, DOI 10.1152/jappl.1992.73.5.1825; KETY SS, 1957, FED PROC, V16, P666; Maddock RJ, 2011, NEUROIMAGE, V57, P1324, DOI 10.1016/j.neuroimage.2011.05.048; MADSEN PL, 1993, J CEREBR BLOOD F MET, V13, P646, DOI 10.1038/jcbfm.1993.83; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Matsui T, 2012, J PHYSIOL-LONDON, V590, P607, DOI 10.1113/jphysiol.2011.217919; Matsui T, 2011, J PHYSIOL-LONDON, V589, P3383, DOI [10.1113/jphysiol.2010.203570, 10.1113/jphysiol.2011.203570]; Mintun MA, 2004, P NATL ACAD SCI USA, V101, P659, DOI 10.1073/pnas.0307457100; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Rasmussen P, 2011, ACTA PHYSIOL, V201, P475, DOI 10.1111/j.1748-1716.2010.02223.x; Rasmussen P, 2010, J PHYSIOL-LONDON, V588, P1985, DOI 10.1113/jphysiol.2009.186767; Rasmussen P, 2007, J CEREBR BLOOD F MET, V27, P1082, DOI 10.1038/sj.jcbfm.9600416; Rasmussen P, 2006, J APPL PHYSIOL, V101, P1406, DOI 10.1152/japplphysiol.00423.2006; Rasmussen P, 2011, FASEB J, V25, P2865, DOI 10.1096/fj.11-183822; Rasmussen P, 2010, J CEREBR BLOOD F MET, V30, P1240, DOI 10.1038/jcbfm.2010.25; Rasmussen P, 2009, J APPL PHYSIOL, V107, P1799, DOI 10.1152/japplphysiol.00468.2009; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; Rosiers CD, 2011, CARDIOVASC RES, V90, P210, DOI 10.1093/cvr/cvr055; Rowell LB, 1986, HUMAN CIRCULATION RE, P363; Seifert T, 2009, AM J PHYSIOL-REG I, V297, pR867, DOI 10.1152/ajpregu.00277.2009; Seifert T, 2009, ACTA PHYSIOL, V196, P295, DOI 10.1111/j.1748-1716.2008.01946.x; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; STANLEY WC, 1985, AM J PHYSIOL, V249, pE595, DOI 10.1152/ajpendo.1985.249.6.E595; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; van Hall G, 2010, ACTA PHYSIOL, V199, P499, DOI 10.1111/j.1748-1716.2010.02122.x; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Wyss MT, 2011, J NEUROSCI, V31, P7477, DOI 10.1523/JNEUROSCI.0415-11.2011	43	55	56	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					3012	3020		10.1096/fj.11-191999	http://dx.doi.org/10.1096/fj.11-191999			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22441982				2022-12-28	WOS:000305912500028
J	Cagliero, J; Forget, A; Daldello, E; Silber, J; Zider, A				Cagliero, Julie; Forget, Antoine; Daldello, Enrico; Silber, Joel; Zider, Alain			The Hippo kinase promotes Scalloped cytoplasmic localization independently of Warts in a CRM1/Exportin1-dependent manner in Drosophila	FASEB JOURNAL			English	Article						transcription factor; subcellular localization; tissue growth	CELL-CYCLE EXIT; TUMOR-SUPPRESSOR; WING FORMATION; YORKIE PHOSPHORYLATION; CONTACT INHIBITION; TEAD/TEF FAMILY; GENE-EXPRESSION; SIZE-CONTROL; PROLIFERATION; PATHWAY	Scalloped (SD) is a transcription factor characterized by a TEA/ATTS DNA binding domain. To activate transcription, SD must interact with its coactivators, including Yorkie (YKI) or Vestigial (VG). YKI is the downstream effector of the Hippo signaling pathway that plays a key role in the control of tissue growth. The core components of this pathway are two kinases, Hippo (HPO) and Warts (WTS), which negatively regulate the activity of the SD/YKI complex, retaining YKI in the cytoplasm. We previously showed that HPO kinase can also reduce SD/VG transcriptional activity in Drosophila S2 cells. We further investigated the relationship between the SD/VG complex and the Hippo pathway. We show here that HPO overexpression suppresses overgrowth induced by SD/VG in vivo during Drosophila development. Using S2 cells, we show that HPO promotes the translocation of SD to the cytoplasm in a CRM1-dependent manner, thereby inhibiting the induction of SD/VG target genes. Using RNAi-mediated depletion of yki and a mutant SD protein unable to interact with YKI, we demonstrate that HPO regulates SD localization independently of YKI. This function requires HPO kinase activity, yet surprisingly, not its downstream effector kinase WTS. Taken together, these observations reveal a new and unexpected role of HPO kinase in the regulation of a transcription factor independently of YKI.-Cagliero, J., Forget, A., Daldello, E., Silber, J., Zider, A. The Hippo kinase promotes Scalloped cytoplasmic localization independently of Warts in a CRM1/Exportin1-dependent manner in Drosophila. FASEB J. 27, 1330-1341 (2013). www.fasebj.org	[Cagliero, Julie; Forget, Antoine; Daldello, Enrico; Silber, Joel; Zider, Alain] Univ Paris Diderot, Mol Oncol Team, CNRS, IJM,UMR 7592, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Zider, A (corresponding author), CNRS, Mol Oncol Team, IJM, UMR 7592, F-75205 Paris 13, France.	zider.alain@ijm.univ-paris-diderot.fr	Daldello, enrico/AAJ-1607-2021; Forget, Antoine/AAA-4967-2020	Daldello, enrico/0000-0002-0456-8950; 	Ministere de l'Enseignement Superieur et de la Recherche; Association pour la Recherche sur le Cancer [5119]	Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	The authors acknowledge B. Legois for her excellent technical assistance and D. Pan (Johns Hopkins University School of Medicine, Baltimore, MD, USA), Nicolas Tapon (Cancer Research UK, London, UK), Kenneth D. Irvine (Rutgers University, Piscataway, NJ, USA), and Jin Jiang (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing Drosophila strains, antibodies, and plasmids. The authors also thank the Developmental Studies Hybridoma Bank (DSHB) for providing monoclonal antibodies, developed under the control of the U. S. National Institute of Child Health and Human Development and maintained by The University of Iowa (Iowa City, IA, USA). The authors also thank the Imaging facility at the Jacques Monod Institute (Paris, France) for their precious help in confocal microscopy. J.C. is the recipient of a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche. This work was supported by the Association pour la Recherche sur le Cancer, grant 5119. The manuscript was revised by Anglo-Scribe (Nimes, France) for English language editing.	Badouel C, 2009, CURR OPIN CELL BIOL, V21, P837, DOI 10.1016/j.ceb.2009.09.010; Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Baena-Lopez LA, 2006, P NATL ACAD SCI USA, V103, P13734, DOI 10.1073/pnas.0606092103; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; Chen HH, 2004, GENESIS, V39, P273, DOI 10.1002/gene.20055; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Delanoue R, 2004, CELL DEATH DIFFER, V11, P110, DOI 10.1038/sj.cdd.4401321; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Emoto K, 2006, NATURE, V443, P210, DOI 10.1038/nature05090; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; Halder G, 2001, DEVELOPMENT, V128, P3295; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Karim FD, 1998, DEVELOPMENT, V125, P1; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Liu XF, 2000, DEV BIOL, V228, P287, DOI 10.1006/dbio.2000.9939; Maeda T, 2002, J BIOL CHEM, V9, P9; Magico A. C., PLOS ONE, V6; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Nardozzi JD, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-32; Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Oh H, 2009, DEV BIOL, V335, P188, DOI 10.1016/j.ydbio.2009.08.026; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Paumard-Rigal S, 1998, DEV GENES EVOL, V208, P440, DOI 10.1007/s004270050201; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Simmonds AJ, 1998, GENE DEV, V12, P3815, DOI 10.1101/gad.12.24.3815; Sorokin AV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1439, DOI 10.1134/S0006297907130032; Srivastava A, 2002, GENESIS, V33, P40, DOI 10.1002/gene.10086; Staley BK, 2012, DEV DYNAM, V241, P3, DOI 10.1002/dvdy.22723; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tian W, 2010, P NATL ACAD SCI USA, V107, P7293, DOI 10.1073/pnas.1000293107; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Varelas X, 2012, TRENDS CELL BIOL, V22, P88, DOI 10.1016/j.tcb.2011.10.002; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; XU TA, 1995, DEVELOPMENT, V121, P1053; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B., GENES DEV, V24, P862; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	52	4	4	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1330	1341		10.1096/fj.12-216424	http://dx.doi.org/10.1096/fj.12-216424			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271049				2022-12-28	WOS:000316940800006
J	Mitschke, MM; Hoffmann, LS; Gnad, T; Scholz, D; Kruithoff, K; Mayer, P; Haas, B; Sassmann, A; Pfeifer, A; Kilic, A				Mitschke, Michaela M.; Hoffmann, Linda S.; Gnad, Thorsten; Scholz, Daniela; Kruithoff, Katja; Mayer, Peter; Haas, Bodo; Sassmann, Antonia; Pfeifer, Alexander; Kilic, Ana			Increased cGMP promotes healthy expansion and browning of white adipose tissue	FASEB JOURNAL			English	Article						beige adipocytes; adipokines; obesity	DEPENDENT PROTEIN-KINASE; MITOCHONDRIAL BIOGENESIS; INSULIN-RESISTANCE; FAT-CELL; IN-VITRO; ADIPOCYTES; ACTIVATION; INFLAMMATION; ADIPONECTIN; EXPRESSION	With more than half a billion individuals affected worldwide, obesity has reached pandemic proportions. Development of "brown-like" or "brite" adipocytes within white adipose tissue (WAT) has potential antiobesity and insulin-sensitizing effects. We investigated the role of cyclic GMP (cGMP) signaling, focusing on cGMP-dependent protein kinase I (PKGI) in WAT. PKGI is expressed in murine WAT, primary adipocytes, and 3T3-L1. Treatment of adipocytes with cGMP resulted in increased adipogenesis, with a 54% increase in expression of peroxisome proliferator-activated receptor-gamma. Lentiviral overexpression of PKGI further increased adipogenesis, whereas loss of PKGI significantly reduced adipogenic differentiation. In addition to adipogenic effects, PKGI had an antihypertrophic and anti-inflammatory effect via RhoA phosphorylation and reduction of proinflammatory adipokine expression. Moreover, PKGI induced a 4.3-fold increase in abundance of UCP-1 and the development of a brown-like thermogenic program in primary adipocytes. Notably, treatment of C57BL/6 mice with phosphodiesterase inhibitor sildenafil (12 mg/kg/d) for 7 d caused 4.6-fold increase in uncoupling protein-1 expression and promoted establishment of a brown fat cell-like phenotype ("browning") of WAT in vivo. Taken together, PKGI is a key regulator of cell size, adipokine secretion and browning of white fat depots and thus could be a valuable target in developing novel treatments for obesity.-Mitschke, M. M., Hoffmann, L. S., Gnad, T., Scholz, D., Kruithoff, K., Mayer, P., Haas, B., Sassmann, A., Alexander Pfeifer, A., Kilic, A. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 27, 1621-1630 (2013). www.fasebj.org	[Mitschke, Michaela M.; Hoffmann, Linda S.; Gnad, Thorsten; Scholz, Daniela; Kruithoff, Katja; Haas, Bodo; Pfeifer, Alexander; Kilic, Ana] Univ Bonn, Inst Pharmacol & Toxicol, D-53105 Bonn, Germany; [Pfeifer, Alexander] Univ Bonn, Pharma Ctr, D-53105 Bonn, Germany; [Mayer, Peter; Haas, Bodo] Fed Inst Drugs & Med Devices, Bonn, Germany; [Sassmann, Antonia] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany	University of Bonn; University of Bonn; Max Planck Society	Pfeifer, A (corresponding author), Univ Bonn, Inst Pharmacol & Toxicol, Biomed Ctr, Sigmund Freud Str 25, D-53105 Bonn, Germany.	alexander.pfeifer@uni-bonn.de	Mayer, Peter/HHS-1373-2022	Haas, Bodo/0000-0002-1213-3527	Deutsche Forschungsgemeinschaft (DFG); Forschungskommission der Medizinischen Fakultat der Universitat Bonn (BONFOR)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Forschungskommission der Medizinischen Fakultat der Universitat Bonn (BONFOR)	This work was supported by the Deutsche Forschungsgemeinschaft (DFG). The authors are grateful to Prof. Stefan Offermanns (Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany) for the Adipoq creER(T)<SUP>2</SUP> mice. A. K. and L. S. H. are supported by the Forschungskommission der Medizinischen Fakultat der Universitat Bonn (BONFOR). The authors declare no conflicts of interest.	Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Ayala JE, 2007, DIABETES, V56, P1025, DOI 10.2337/db06-0883; Barbatelli G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1244, DOI 10.1152/ajpendo.00600.2009; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Chen BY, 2011, J ENDOCRINOL INVEST, V34, P742, DOI 10.3275/7727; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; Francis S. H., 2011, PHARMACOL REV, V62, P525; Francis SH, 2011, HANDB EXP PHARMACOL, V204, P47, DOI [10.1007/978-3-642-17969-3_2, 10.1007/978-3-642-13443-2_4]; Frontini A, 2010, CELL METAB, V11, P253, DOI 10.1016/j.cmet.2010.03.004; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Haas B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000511; Hara Y, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001227; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Hofmann Franz, 2009, V191, P137, DOI 10.1007/978-3-540-68964-5_8; Ishii-Yonemoto T, 2010, AM J PHYSIOL-ENDOC M, V298, pE930, DOI 10.1152/ajpendo.00320.2009; Jennissen K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002867; Kajimura S, 2009, NATURE, V460, P1154, DOI 10.1038/nature08262; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Karastergiou K, 2010, MOL CELL ENDOCRINOL, V318, P69, DOI 10.1016/j.mce.2009.11.011; Katafuchi T, 2010, PEPTIDES, V31, P1906, DOI 10.1016/j.peptides.2010.06.025; Kiskinis E, 2007, EMBO J, V26, P4831, DOI 10.1038/sj.emboj.7601908; Koh EH, 2010, AM J PHYSIOL-ENDOC M, V298, pE846, DOI 10.1152/ajpendo.00008.2010; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Lee YH, 2012, CELL METAB, V15, P480, DOI 10.1016/j.cmet.2012.03.009; Leiss V, 2011, DIABETES, V60, P148, DOI 10.2337/db10-0595; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Lutz SZ, 2011, DIABETES, V60, P1566, DOI 10.2337/db10-0760; Miyashita K, 2009, DIABETES, V58, P2880, DOI 10.2337/db09-0393; Nedergaard J, 2010, CELL METAB, V11, P268, DOI 10.1016/j.cmet.2010.03.007; Nikolic D. M., 2010, OBESITY SILVER SPRIN, V19, P784; Nishikimi T, 2009, REGUL PEPTIDES, V153, P56, DOI 10.1016/j.regpep.2008.10.010; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Noguchi M, 2007, J BIOL CHEM, V282, P29574, DOI 10.1074/jbc.M705972200; Nozaki M, 2007, BIOCHEM BIOPH RES CO, V364, P33, DOI 10.1016/j.bbrc.2007.09.084; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Petrovic N, 2010, J BIOL CHEM, V285, P7153, DOI 10.1074/jbc.M109.053942; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Sassmann A, 2010, GENESIS, V48, P618, DOI 10.1002/dvg.20665; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schlossmann Jens, 2009, V191, P163, DOI 10.1007/978-3-540-68964-5_9; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Shen WL, 2011, BRIT J PHARMACOL, V162, P1213, DOI 10.1111/j.1476-5381.2010.01134.x; Shore A, 2010, DIABETOLOGIA, V53, P1164, DOI 10.1007/s00125-010-1701-4; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tateya S, 2011, DIABETES, V60, P2792, DOI 10.2337/db11-0255; Valtcheva N, 2009, J BIOL CHEM, V284, P556, DOI 10.1074/jbc.M806161200; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Zhang XD, 2010, BIOCHEM BIOPH RES CO, V396, P1054, DOI 10.1016/j.bbrc.2010.05.064	56	100	103	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1621	1630		10.1096/fj.12-221580	http://dx.doi.org/10.1096/fj.12-221580			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303211				2022-12-28	WOS:000316940800032
J	Wettstein, G; Bellaye, PS; Kolb, M; Hammann, A; Crestani, B; Soler, P; Marchal-Somme, J; Hazoume, A; Gauldie, J; Gunther, A; Micheau, O; Gleave, M; Camus, P; Garrido, C; Bonniaud, P				Wettstein, Guillaume; Bellaye, Pierre-Simon; Kolb, Martin; Hammann, Arlette; Crestani, Bruno; Soler, Paul; Marchal-Somme, Joelle; Hazoume, Adonis; Gauldie, Jack; Gunther, Andreas; Micheau, Olivier; Gleave, Martin; Camus, Philippe; Garrido, Carmen; Bonniaud, Philippe			Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation	FASEB JOURNAL			English	Article						epithelial-to-mesenchymal transition; mesothelial; pleura; transforming growth factor	HEAT-SHOCK-PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; IDIOPATHIC PULMONARY-FIBROSIS; ACTIN DYNAMICS; CELL-DEATH; BINDING; KINASE; STRESS; PHOSPHORYLATION	Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by myofibroblast proliferation. Transition of epithelial/mesothelial cells into myofibroblasts [epithelial-to-mesenchymal transition (EMT)] occurs under the influence of transforming growth factor (TGF)-beta 1, with Snail being a major transcription factor. We study here the role of the heat-shock protein HSP27 in fibrogenesis and EMT. In vitro, we have up-and down-modulated HSP27 expression in mesothelial and epithelial cell lines and studied the expression of different EMT markers induced by TGF-beta 1. In vivo, we inhibited HSP27 with the antisense oligonucleotide OGX-427 (in phase II clinical trials as anticancer agent) in our rat subpleural/pulmonary fibrosis models. We demonstrate that HSP27 is strongly expressed during the fibrotic process in patients with IPF and in different in vivo models. We showed that HSP27 binds to and stabilizes Snail and consequently induces EMT. Conversely, HSP27 knockdown leads to Snail proteasomal degradation, thus inhibiting TGF-beta 1-induced EMT. Inhibition of HSP27 with OGX-427 efficiently blocks EMT and fibrosis development. Controls in vivo were an empty adenovirus that did not induce fibrosis and a control antisense oligonucleotide. The present work opens the possibility of a new therapeutic use for HSP27 inhibitors against IPF, for which there is no conclusively effective treatment.-Wettstein, G., Bellaye, P.-S., Kolb, M., Hammann, A., Crestani, B., Soler, P., Marchal-Somme, J., Hazoume, A., Gauldie, J., Gunther, A., Micheau, O., Gleave, M., Camus, P., Garrido, C., Bonniaud, P. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB J. 27, 1549-1560 (2013). www.fasebj.org	[Wettstein, Guillaume; Bellaye, Pierre-Simon; Hammann, Arlette; Hazoume, Adonis; Micheau, Olivier; Camus, Philippe; Garrido, Carmen; Bonniaud, Philippe] INSERM, U866, Dijon, France; [Wettstein, Guillaume; Bellaye, Pierre-Simon; Hammann, Arlette; Hazoume, Adonis; Micheau, Olivier; Camus, Philippe; Garrido, Carmen; Bonniaud, Philippe] Univ Burgundy, Fac Med & Pharm, Dijon, France; [Kolb, Martin; Gauldie, Jack] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON, Canada; [Kolb, Martin; Gauldie, Jack] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Crestani, Bruno; Soler, Paul; Marchal-Somme, Joelle] INSERM, U700, Paris, France; [Crestani, Bruno; Soler, Paul; Marchal-Somme, Joelle] Univ Paris Diderot, Paris, France; [Crestani, Bruno; Soler, Paul; Marchal-Somme, Joelle] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Serv Pneumol A, Fac Med Bichat, F-75877 Paris, France; [Gunther, Andreas] Univ Giessen, Lung Ctr, D-35390 Giessen, Germany; [Gleave, Martin] Univ British Columbia, Dept Urol, Vancouver, BC V5Z 1M9, Canada; [Camus, Philippe; Bonniaud, Philippe] Ctr Hosp Univ, Serv Pneumol, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; McMaster University; McMaster University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Justus Liebig University Giessen; University of British Columbia; CHU Dijon Bourgogne	Bonniaud, P (corresponding author), CHU Bocage, 14 Rue Gaffarel, F-21079 Dijon, France.	philippe.bonniaud@chu-dijon.fr	Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; micheau, olivier/C-3574-2011	Garrido, carmen/0000-0003-1368-1493; micheau, olivier/0000-0001-8499-7984; Gleave, Martin/0000-0003-4235-0167; Bellaye, Pierre-Simon/0000-0002-8498-5163	European Community [HEALTH-F2-2007-202224 eurIPFnet]; Agence Nationale de la Recherche Blanc [11-BSV-011-01 meso-IPF]; La Ligue Regionale Grand Est Contre le Cancer; EU [HEALTH-F2-2007-202224 eurIPFnet]; La Recherche en Sante Respiratoire et la Societe de Pneumologie de Langue Francaise	European Community(European Commission); Agence Nationale de la Recherche Blanc(French National Research Agency (ANR)); La Ligue Regionale Grand Est Contre le Cancer; EU(European Commission); La Recherche en Sante Respiratoire et la Societe de Pneumologie de Langue Francaise	The research leading to these results has received funding from the European Community 7th Framework Programme (FP7/2007-2013) under grant agreement HEALTH-F2-2007-202224 eurIPFnet, Agence Nationale de la Recherche Blanc 11-BSV-011-01 meso-IPF and La Ligue Regionale Grand Est Contre le Cancer. G. W. is supported by the EU 7th Framework Programme (2007-2013 agreement HEALTH-F2-2007-202224 eurIPFnet.) and La Recherche en Sante Respiratoire et la Societe de Pneumologie de Langue Francaise. C. G. team has the label from La Ligue National Contre le Cancer.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; Andrieu C, 2010, ONCOGENE, V29, P1883, DOI 10.1038/onc.2009.479; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bonniaud P, 2005, AM J RESP CRIT CARE, V171, P889, DOI 10.1164/rccm.200405-612OC; Boutet A, 2006, EMBO J, V25, P5603, DOI 10.1038/sj.emboj.7601421; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Chapman HA, 2011, ANNU REV PHYSIOL, V73, P413, DOI 10.1146/annurev-physiol-012110-142225; Chilosi M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-95; de Thonel A, 2010, BLOOD, V116, P85, DOI 10.1182/blood-2009-09-241778; Decologne N, 2010, EUR RESPIR J, V35, P176, DOI 10.1183/09031936.00181808; Decologne N, 2007, J IMMUNOL, V179, P6043, DOI 10.4049/jimmunol.179.9.6043; Garrido C, 2003, CELL DEATH DIFFER, V10, P619, DOI 10.1038/sj.cdd.4401229; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Hadaschik BA, 2008, BJU INT, V102, P610, DOI 10.1111/j.1464-410X.2008.07669.x; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Jayachandran A, 2009, THORAX, V64, P1053, DOI 10.1136/thx.2009.121798; Kamada M, 2007, MOL CANCER THER, V6, P299, DOI 10.1158/1535-7163.MCT-06-0417; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; Korfei M, 2011, J PROTEOME RES, V10, P2185, DOI 10.1021/pr1009355; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Landry J, 1999, BIOCHEM SOC SYMP, P79; Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152; Matsui Y, 2009, MOL CANCER THER, V8, P2402, DOI 10.1158/1535-7163.MCT-09-0148; Mubarak KK, 2012, EUR RESPIR J, V39, P133, DOI 10.1183/09031936.00141010; Nasreen N, 2009, AM J PHYSIOL-LUNG C, V297, pL115, DOI 10.1152/ajplung.90587.2008; Parcellier A, 2005, ANTIOXID REDOX SIGN, V7, P404, DOI 10.1089/ars.2005.7.404; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Simioni MB, 2009, ONCOGENE, V28, P3332, DOI 10.1038/onc.2009.188; Vancheri C, 2010, EUR RESPIR J, V35, P496, DOI 10.1183/09031936.00077309; Vargha R, 2008, NEPHROL DIAL TRANSPL, V23, P3494, DOI 10.1093/ndt/gfn353; Vidyasagar A, 2008, AM J PHYSIOL-RENAL, V295, pF707, DOI 10.1152/ajprenal.90240.2008; Wei L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3042; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	50	77	83	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1549	1560		10.1096/fj.12-220053	http://dx.doi.org/10.1096/fj.12-220053			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23288928				2022-12-28	WOS:000316940800026
J	Lim, TC; Rokkappanavar, S; Toh, WS; Wang, LS; Kurisawa, M; Spector, M				Lim, Teck Chuan; Rokkappanavar, Swetha; Toh, Wei Seong; Wang, Li-Shan; Kurisawa, Motoichi; Spector, Myron			Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1 alpha release and compatible structural support	FASEB JOURNAL			English	Article						tissue engineering; cavitary brain lesion; injectable biomaterials; nanoparticles; matrix metalloproteinases	GROWTH-FACTOR; STEM-CELLS; NEUROBLAST MIGRATION; FACTOR-I; NEUROGENESIS; REGENERATION; NEURONS; STROKE; BRAIN; RAT	Without chemotactic cues and structural support, cavitary brain lesions typically fail to recruit endogenous neural progenitor cells (NPCs). Toward resolving this, we engineered multifunctional biomaterials comprising injectable gelatin-hydroxyphenylpropionic acid (Gtn-HPA) hydrogels and dextran sulfate/chitosan polyelectrolyte complex nanoparticles (PCNs) that delivered stromal cell-derived factor-1 alpha (SDF-1 alpha). Over 7 d of interface with in vitro tissue simulant containing adult rat hippocampal NPCs (aNPCs) and their neuronal progeny, Gtn-HPA/SDF-1 alpha-PCN hydrogels promoted chemotactic recruitment to enhance infiltration of aNPCs by 3- to 45-fold relative to hydrogels that lacked SDF-1 alpha or vehicles to sustain SDF-1 alpha release. When cross-linked with 0.85-0.95mM H2O2, Gtn-HPA/SDF-1 alpha-PCN hydrogels provided optimally permissive structural support for migration of aNPCs. Specific matrix metalloproteinase (MMP) inhibitors revealed that 42, 30, and 55% of cell migration into Gtn-HPA/SDF-1 alpha-PCN hydrogels involved MMP-2, 3, and 9, respectively, demonstrating the hydrogels to be compatible toward homing endogenous NPCs, given their expression of similar MMPs. Interestingly, PCNs utilized FGF-2 found in situ to induce chemokinesis, potentiate SDF-1 alpha chemotactic recruitment, and increase proliferation of recruited cells, which collectively orchestrated a higher number of migrated aNPCs. Overall, Gtn-HPA/SDF-1 alpha-PCN hydrogels prove to be promising biomaterials for injection into cavitary brain lesions to recruit endogenous NPCs and enhance neural tissue repair/regeneration.-Lim, T. C., Rokkappanavar, S., Toh, W. S., Wang, L.-S., Kurisawa, M., Spector, M. Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1 alpha release and compatible structural support. FASEB J. 27, 1023-1033 (2013). www.fasebj.org	[Lim, Teck Chuan; Spector, Myron] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lim, Teck Chuan; Rokkappanavar, Swetha; Toh, Wei Seong; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA; [Rokkappanavar, Swetha; Toh, Wei Seong; Spector, Myron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA; [Wang, Li-Shan; Kurisawa, Motoichi] Inst Bioengn & Nanotechnol, Singapore, Singapore	Harvard University; Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Institute of Bioengineering & Nanotechnology (IBN)	Spector, M (corresponding author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151 Res,150 S Huntington Ave, Boston, MA 02130 USA.	mspector@rics.bwh.harvard.edu	KURISAWA, MOTOICHI/C-1325-2014; Wang, Li Shan/F-9460-2013; Toh, Wei Seong/K-7720-2013	KURISAWA, MOTOICHI/0000-0003-2413-6933; Toh, Wei Seong/0000-0001-9147-6423; Spector, Myron/0000-0003-3328-4858; Lim, Teck Chuan/0000-0002-4062-6046	U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore	U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore	The authors thank Marsha Doudna Guy for technical assistance and Chyan Ying Ke for critical reading of the manuscript. This work was supported by the Rehabilitation Research and Development Service of the U.S. Department of Veterans Affairs and Agency for Science, Technology and Research, Singapore ( to T.C.L., W.S.T., L.W., and M.K.).	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Bible E, 2009, BIOMATERIALS, V30, P2985, DOI 10.1016/j.biomaterials.2009.02.012; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Guerra-Crespo M, 2009, NEUROSCIENCE, V160, P470, DOI 10.1016/j.neuroscience.2009.02.029; Haider HK, 2008, J MOL CELL CARDIOL, V45, P554, DOI 10.1016/j.yjmcc.2008.05.004; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Khorana AA, 2003, ARTERIOSCL THROM VAS, V23, P2110, DOI 10.1161/01.ATV.0000090671.56682.D7; Lauten EH, 2010, BIOMACROMOLECULES, V11, P1863, DOI 10.1021/bm100384z; Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140-6736(10)60668-X; Lim TC, 2012, BIOMATERIALS, V33, P3446, DOI 10.1016/j.biomaterials.2012.01.037; Maeda N, 2011, NEUROCHEM RES, V36, P1228, DOI 10.1007/s11064-010-0324-y; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; Shah RN, 2010, P NATL ACAD SCI USA, V107, P3293, DOI 10.1073/pnas.0906501107; Speliotes EK, 1996, MOL BRAIN RES, V39, P31, DOI 10.1016/0169-328X(95)00351-R; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Wang LS, 2010, BIOMATERIALS, V31, P8608, DOI 10.1016/j.biomaterials.2010.07.075; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yu T, 2010, J NEUROSCI RES, V88, P2775, DOI 10.1002/jnr.22454; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040; Zhang RL, 2009, J CEREBR BLOOD F MET, V29, P1240, DOI 10.1038/jcbfm.2009.55; Zhang RL, 2011, J CEREBR BLOOD F MET, V31, P614, DOI 10.1038/jcbfm.2010.134	33	47	48	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1023	1033		10.1096/fj.12-221515	http://dx.doi.org/10.1096/fj.12-221515			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193174				2022-12-28	WOS:000315585200017
J	Martin, D; Charpilienne, A; Parent, A; Boussac, A; D'Autreaux, B; Poupon, J; Poncet, D				Martin, Davy; Charpilienne, Annie; Parent, Auberie; Boussac, Alain; D'Autreaux, Benoit; Poupon, Joel; Poncet, Didier			The rotavirus nonstructural protein NSP5 coordinates a [2Fe-2S] iron-sulfur cluster that modulates interaction to RNA	FASEB JOURNAL			English	Article						metalloprotein; CXXC motif	VIROPLASM-LIKE STRUCTURES; DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; MICROSCALE THERMOPHORESIS; PHOSPHOPROTEIN NSP5; VIRUS-REPLICATION; HUMAN FERREDOXIN; MESSENGER-RNA; IN-VITRO	During rotavirus infection, replication and packaging of the viral genome occur in viral factories, termed viroplasms. The viral nonstructural protein NSP5 is a major building block of viroplasms; it recruits the viral polymerase VP1, the core protein VP2, and the ATPase NSP2 inside the viroplasm to form the viral replication complex. Here we report that NSP5 is a unique viral metalloprotein that coordinates a [2Fe-2S] iron-sulfur cluster as demonstrated by the metal and labile sulfide contents, UV-visible light absorption, and electron paramagnetic resonance. Point mutations in NSP5 allowed us to identify C171 and C174, arranged in a CX2C motif, as essential residues for cluster coordination. When coexpressed with NSP2, an NSP5 mutant devoid of the iron-sulfur cluster still forms viroplasm-like structures. The cluster is therefore neither involved in the interaction with NSP2 nor in the formation of viroplasm-like structures and thus presumably in viroplasm formation. Finally, we show using microscale thermophoresis that the iron-sulfur cluster modulates the affinity of NSP5 for single-stranded RNA. Because the cluster is near the binding sites of both the polymerase VP1 and the ATPase NSP2, we anticipate that this cluster is crucial for NSP5 functions, in either packaging or replication of the viral genome.-Martin, D., Charpilienne, A., Parent, A., Boussac, A., D'Autreaux, B., Poupon, J., Poncet, D. The rotavirus nonstructural protein NSP5 coordinates a [2Fe-2S] iron-sulfur cluster that modulates interaction to RNA. FASEB J. 27, 1074-1083 (2013). www.fasebj.org	[Martin, Davy; Charpilienne, Annie; Poncet, Didier] CNRS, USC, UPR 3296, INRA,Ctr Rech Gif,Virol Mol & Struct, Av Terrasse, F-91198 Gif Sur Yvette, France; [Parent, Auberie; D'Autreaux, Benoit] CNRS, Ctr Rech Gif, UPR 2301, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France; [Boussac, Alain] Commissariat Energie Atom & Energies Alternat CEA, Inst Biol & Technol Saclay IBiTec S, Serv Bioenerget Biol Struct & Mecanismes SB2SM, UMR 8221,CNRS, Gif Sur Yvette, France; [Poupon, Joel] Hop Lariboisiere, AP HP, Lab Toxicol Biol, F-75475 Paris, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Martin, D (corresponding author), CNRS, USC, UPR 3296, INRA,Ctr Rech Gif,Virol Mol & Struct, Av Terrasse, F-91198 Gif Sur Yvette, France.	davy.martin@vms.cnrs-gif.fr	Poncet, Didier/AAV-6583-2021; D'Autreaux, Benoit/M-8520-2018	Poncet, Didier/0000-0001-7689-0175; D'Autreaux, Benoit/0000-0002-1276-3019; Martin, Davy/0000-0003-2421-716X	Conseil General de l'Essonne	Conseil General de l'Essonne	The authors thank Dr. S. Duhr (NanoTemper Technologies, Munich, Germany) for his expert support with microscale thermophoresis. The authors are grateful to Drs. H. Rezaei, L. Oliveira, Y. Gaudin, and A. Pastore for helpful discussions. This work has benefited from the facilities and expertise of IMAGIF (Centre de Recherche de Gif), which is supported by the Conseil General de l'Essonne.	Afrikanova I, 1998, J GEN VIROL, V79, P2679, DOI 10.1099/0022-1317-79-11-2679; Arnoldi F, 2007, J VIROL, V81, P2128, DOI 10.1128/JVI.01494-06; Baaske P, 2010, ANGEW CHEM INT EDIT, V49, P2238, DOI 10.1002/anie.200903998; Bar-Magen T, 2007, VIROLOGY, V369, P389, DOI 10.1016/j.virol.2007.07.029; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Berois M, 2003, J VIROL, V77, P1757, DOI 10.1128/JVI.77.3.1757-1763.2003; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Campagna M, 2005, J GEN VIROL, V86, P1481, DOI 10.1099/vir.0.80598-0; Chnaiderman J, 2002, ARCH VIROL, V147, P1899, DOI 10.1007/s00705-002-0856-9; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930; Duhr S, 2006, P NATL ACAD SCI USA, V103, P19678, DOI 10.1073/pnas.0603873103; Eichwald C, 2004, P NATL ACAD SCI USA, V101, P16304, DOI 10.1073/pnas.0406691101; Eichwald C, 2002, J VIROL, V76, P3461, DOI 10.1128/JVI.76.7.3461-3470.2002; Fabbretti E, 1999, J GEN VIROL, V80, P333, DOI 10.1099/0022-1317-80-2-333; GONZALEZ SA, 1991, VIROLOGY, V182, P8, DOI 10.1016/0042-6822(91)90642-O; Guigliarelli B, 1999, ADV INORG CHEM, V47, P421, DOI 10.1016/S0898-8838(08)60084-7; Hirata A, 2009, CURR OPIN STRUC BIOL, V19, P724, DOI 10.1016/j.sbi.2009.10.006; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; Iwasaki T, 2009, J AM CHEM SOC, V131, P13659, DOI 10.1021/ja903228w; Jerabek-Willemsen M, 2011, ASSAY DRUG DEV TECHN, V9, P342, DOI 10.1089/adt.2011.0380; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KATTOURA MD, 1994, VIROLOGY, V202, P803, DOI 10.1006/viro.1994.1402; Klinge S, 2007, NAT STRUCT MOL BIOL, V14, P875, DOI 10.1038/nsmb1288; Lopez T, 2005, J GEN VIROL, V86, P1609, DOI 10.1099/vir.0.80827-0; Martin D, 2011, J MOL BIOL, V413, P209, DOI 10.1016/j.jmb.2011.08.008; Martin D, 2010, J VIROL, V84, P2522, DOI 10.1128/JVI.01883-09; McDonald SM, 2011, J VIROL, V85, P3095, DOI 10.1128/JVI.02360-10; Netz DJA, 2012, NAT CHEM BIOL, V8, P125, DOI 10.1038/nchembio.721; Parashar UD, 2006, EMERG INFECT DIS, V12, P304; Picciocchi A, 2007, BIOCHEMISTRY-US, V46, P15018, DOI 10.1021/bi7013272; Poncet D, 1997, J VIROL, V71, P34, DOI 10.1128/JVI.71.1.34-41.1997; POTSCH S, 1995, FEBS LETT, V374, P95, DOI 10.1016/0014-5793(95)01082-P; Sen A, 2006, J VIROL, V80, P1807, DOI 10.1128/JVI.80.4.1807-1816.2006; Sen A, 2007, J VIROL, V81, P11758, DOI 10.1128/JVI.01124-07; Silvestri LS, 2004, J VIROL, V78, P7763, DOI 10.1128/JVI.78.14.7763-7774.2004; Taraporewala ZF, 2001, J VIROL, V75, P4519, DOI 10.1128/JVI.75.10.4519-4527.2001; Torres-Vega MA, 2000, J GEN VIROL, V81, P821, DOI 10.1099/0022-1317-81-3-821; Trask SD, 2012, NAT REV MICROBIOL, V10, P165, DOI 10.1038/nrmicro2673; Vende P, 2002, J VIROL, V76, P5291, DOI 10.1128/JVI.76.10.5291-5299.2002; WELCH SKW, 1989, J VIROL, V63, P3974, DOI 10.1128/JVI.63.9.3974-3982.1989; White MF, 2012, CURR OPIN STRUC BIOL, V22, P94, DOI 10.1016/j.sbi.2011.11.004; Wu YL, 2012, NUCLEIC ACIDS RES, V40, P4247, DOI 10.1093/nar/gks039; Xia B, 1996, BIOCHEMISTRY-US, V35, P9488, DOI 10.1021/bi960467f; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770; Zillner K, 2012, METHODS MOL BIOL, V815, P241, DOI 10.1007/978-1-61779-424-7_18	47	15	19	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1074	1083		10.1096/fj.12-217182	http://dx.doi.org/10.1096/fj.12-217182			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23193175				2022-12-28	WOS:000315585200021
J	Qureshi, BM; Hofmann, NE; Arroyo-Olarte, RD; Nickl, B; Hoehne, W; Jungblut, PR; Lucius, R; Scheerer, P; Gupta, N				Qureshi, Bilal M.; Hofmann, Natalie E.; Arroyo-Olarte, Ruben D.; Nickl, Bernadette; Hoehne, Wolfgang; Jungblut, Peter R.; Lucius, Richard; Scheerer, Patrick; Gupta, Nishith			Dynein light chain 8a of Toxoplasma gondii, a unique conoid-localized beta-strand-swapped homodimer, is required for an efficient parasite growth	FASEB JOURNAL			English	Article						Plasmodium falciparum; Eimeria tenella; crystal structure; apical complex; conoid	SELECTABLE MARKER; APICOMPLEXAN; MODEL; LC8; CRYSTALLOGRAPHY; EXPRESSION; SYSTEM; GENE	Dynein light chain 8 (DLC8) is a ubiquitous eukaryotic protein regulating diverse cellular functions. We show that the obligate intracellular parasite Toxoplasma gondii harbors 4 DLC8 proteins (TgDLC8a-d), of which only TgDLC8a clusters in the mainstream LC8 class. TgDLC8b-d proteins form a divergent and alveolate-specific clade. TgDLC8b-d proteins are largely cytosolic, whereas TgDLC8a resides in the conoid at the apical end of T. gondii. The apical location of TgDLC8a is also not shared by its nearly identical Eimeria (EtDLC8a), Plasmodium (PfDLC8), or human (HsDLC8) orthologs. Notwithstanding an exclusive conoid targeting, TgDLC8a exhibits a classical LC8 structure. It forms a homodimer by swapping of the beta(2) strands that interact with the antiparallel beta(1)' strands of the opposing monomers. The TgDLC8a dimer contains two identical binding grooves and appears to be adapted for multitarget recognition. By contrast, the previously reported PfDLC8 homodimer is shaped by binding of the beta(0) strand with the parallel beta(2)' strand and lacks such a distinct binding interface. Our comparisons suggest an unexpected structural and functional divergence of the two otherwise conserved proteins from apicomplexan parasites. Finally, we demonstrate that a phosphomimetic S88E mutation renders the TgDLC8a-S88E mutant monomeric and cytosolic in T. gondii, and its overexpression inhibits the parasite growth in human fibroblasts.-Qureshi, B. M., Hofmann, N. E., Arroyo-Olarte, R. D., Nickl, B., Hoehne, W., Jungblut, P. R., Lucius, R., Scheerer, P., Gupta, N. Dynein light chain 8a of Toxoplasma gondii, a unique conoid-localized beta-strand-swapped homodimer, is required for an efficient parasite growth. FASEB J. 27, 1034-1047 (2013). www.fasebj.org	[Qureshi, Bilal M.; Hofmann, Natalie E.; Arroyo-Olarte, Ruben D.; Nickl, Bernadette; Lucius, Richard; Gupta, Nishith] Humboldt Univ, Dept Mol Parasitol, D-10115 Berlin, Germany; [Qureshi, Bilal M.; Hoehne, Wolfgang; Scheerer, Patrick] Charite, Inst Biochem, D-10098 Berlin, Germany; [Qureshi, Bilal M.; Scheerer, Patrick] Charite, Inst Med Phys & Biophys CC2, D-10098 Berlin, Germany; [Jungblut, Peter R.] Max Planck Inst Infect Biol, Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society	Gupta, N (corresponding author), Humboldt Univ, Dept Mol Parasitol, Philippstr 13,House 14, D-10115 Berlin, Germany.	patrick.scheerer@charite.de; gupta.nishith@staff.hu-berlin.de	Arroyo-Olarte, Ruben D/AAW-3127-2021; Arroyo-Olarte, Ruben D/AAH-8939-2020	Arroyo-Olarte, Ruben D/0000-0002-8096-2423; Qureshi, Bilal Muhammad/0000-0002-0153-7729; Gupta, Nishith/0000-0003-1452-5126; Nickl, Bernadette/0000-0002-1998-8157; Scheerer, Patrick/0000-0001-5028-2075	German Research Foundation (DFG) [SFB618, GRK1121]	German Research Foundation (DFG)(German Research Foundation (DFG))	The authors are grateful to Uwe Muller and to the scientific staff of BESSY-MX at beam lines BL14.1 and BL14.2 (Helmholtz Zentrum fur Materialien und Energie, Berlin) for collection of the X-ray diffraction data sets. The authors thank Christa Scholz, Helga Wessner, and Norbert Krauss (Charite-Universitatsmedizin, Berlin) for help with purification, crystallization, and data analyses and Grit Meusel (Humboldt University, Berlin) for transgenic parasite and biochemical work. The authors thank Katja Faelber and Oliver Daumke (Max Delbruck Center of Molecular Medicine, Berlin) for size-exclusion and static light-scattering assays. This work was supported by grants SFB618 (N.G., R.L.) and GRK1121 (N.G.) from the German Research Foundation (DFG). U.S. National Center for Biotechnology Information (NCBI) database accession numbers of the protein and nucleotide sequences derived from the work are as follows: TgDLC8a, ABL74449; TgDLC8b, ADY76967; TgDLC8c, JF815093; TgDLC8d, JF815094; EtDLC8a, JX306039. The atomic coordinates and structure factors for the TgDLC8a crystal structure have been deposited in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Database (accession code 3RJS).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbar E, 2008, BIOCHEMISTRY-US, V47, P503, DOI 10.1021/bi701995m; Benison G, 2007, J MOL BIOL, V371, P457, DOI 10.1016/j.jmb.2007.05.046; Benison G, 2008, J MOL BIOL, V384, P954, DOI 10.1016/j.jmb.2008.09.083; Blume M, 2009, P NATL ACAD SCI USA, V106, P12998, DOI 10.1073/pnas.0903831106; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Gupta N, 2005, J BIOL CHEM, V280, P16345, DOI 10.1074/jbc.M501523200; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hu K, 2006, PLOS PATHOG, V2, P121, DOI 10.1371/journal.ppat.0020013; Huynh MH, 2009, EUKARYOT CELL, V8, P530, DOI 10.1128/EC.00358-08; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Janouskovec J, 2010, P NATL ACAD SCI USA, V107, P10949, DOI 10.1073/pnas.1003335107; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Makokha M, 2004, PROTEIN SCI, V13, P727, DOI 10.1110/ps.03462204; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Song CY, 2008, J BIOL CHEM, V283, P4004, DOI 10.1074/jbc.M704512200; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; Vedadi M, 2007, MOL BIOCHEM PARASIT, V151, P100, DOI 10.1016/j.molbiopara.2006.10.011; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang WN, 2003, J BIOL CHEM, V278, P41491, DOI 10.1074/jbc.M307118200; Wickstead B, 2007, TRAFFIC, V8, P1708, DOI 10.1111/j.1600-0854.2007.00646.x; Wilkes DE, 2007, CELL MOTIL CYTOSKEL, V64, P82, DOI 10.1002/cm.20165	37	12	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1034	1047		10.1096/fj.11-180992	http://dx.doi.org/10.1096/fj.11-180992			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23233536				2022-12-28	WOS:000315585200018
J	Quinzii, CM; Garone, C; Emmanuele, V; Tadesse, S; Krishna, S; Dorado, B; Hirano, M				Quinzii, Catarina M.; Garone, Caterina; Emmanuele, Valentina; Tadesse, Saba; Krishna, Sindu; Dorado, Beatriz; Hirano, Michio			Tissue-specific oxidative stress and loss of mitochondria in CoQ-deficient Pdss2 mutant mice	FASEB JOURNAL			English	Article						ubiquinone; polyprenyl-diphosphate synthase; ATP; ROS	CULTURED SKIN FIBROBLASTS; REACTIVE OXYGEN; COENZYME-Q; KIDNEY-DISEASE; NEPHROPATHY; UBIQUINONE; MUTATIONS; DEPLETION; CORRELATE; DEFECTS	Primary human CoQ(10) deficiencies are clinically heterogeneous diseases caused by mutations in PDSS2 and other genes required for CoQ(10) biosynthesis. Our in vitro studies of PDSS2 mutant fibroblasts, with <20% CoQ(10) of control cells, revealed reduced activity of CoQ(10)-dependent complex II+III and ATP synthesis, without amplification of reactive oxygen species (ROS), markers of oxidative damage, or antioxidant defenses. In contrast, COQ2 and ADCK3 mutant fibroblasts, with 30-50% CoQ(10) of controls, showed milder bioenergetic defects but significantly increased ROS and oxidation of lipids and proteins. We hypothesized that absence of oxidative stress markers and cell death in PDSS2 mutant fibroblasts were due to the extreme severity of CoQ(10) deficiency. Here, we have investigated in vivo effects of Pdss2 deficiency in affected and unaffected organs of CBA/Pdss2(kd/kd) mice at presymptomatic, phenotypic-onset, and end-stages of the disease. Although Pdss2 mutant mice manifest widespread CoQ(9) deficiency and mitochondrial respiratory chain abnormalities, only affected organs show increased ROS production, oxidative stress, mitochondrial DNA depletion, and reduced citrate synthase activity, an index of mitochondrial mass. Our data indicate that kidney-specific loss of mitochondria triggered by oxidative stress may be the cause of renal failure in Pdss2(kd/kd) mice.-Quinzii, C. M., Garone, C., Emmanuele, V., Tadesse, S., Krishna, S., Dorado, B., Hirano, M. Tissue-specific oxidative stress and loss of mitochondria in CoQ-deficient Pdss2 mutant mice. FASEB J. 27, 612-621 (2013). www.fasebj.org	[Quinzii, Catarina M.; Garone, Caterina; Emmanuele, Valentina; Tadesse, Saba; Krishna, Sindu; Dorado, Beatriz; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Garone, Caterina] Univ Bologna & Turin, Human Genet Joint PhD Program, Turin, Italy; [Emmanuele, Valentina] Univ Genoa, Ist Ricovero & Cura Carattere Sci, G Gaslini Inst, Pediat Clin, Genoa, Italy	Columbia University; University of Bologna; University of Genoa; IRCCS Istituto Giannina Gaslini	Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-432, New York, NY 10032 USA.	mh29@columbia.edu	Garone, Caterina/AAB-8659-2019	Garone, Caterina/0000-0003-4928-1037; Dorado, Beatriz/0000-0002-1958-4558	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1R01HD057543, K23HD065871]; U.S. National Institutes of Health [R01HD056103, 1RC1NS070232]; Muscular Dystrophy Association; Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD065871, R01HD057543, R01HD056103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [RC1NS070232] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors appreciate the kind gift of CBA-Pdss2<SUP>kd</SUP>/J from Dr. David Gasser (University of Pennsylvania, Philadelphia, PA, USA) and helpful advice from Drs. Vernice Jackson-Lewis, Vivette D. D'Agati, and Luis Lopez Garcia. The project described was supported by grants 1R01HD057543 (M. H.) and K23HD065871 (C. M. Q.) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). M. H. is supported by U.S. National Institutes of Health grants R01HD056103 and 1RC1NS070232, by a Muscular Dystrophy Association grant, and by the Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF).	DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833; Dorado B, 2011, HUM MOL GENET, V20, P155, DOI 10.1093/hmg/ddq453; Emmanuele V, 2012, ARCH NEUROL-CHICAGO, V69, P978, DOI 10.1001/archneurol.2012.206; Falk MJ, 2011, EMBO MOL MED, V3, P410, DOI 10.1002/emmm.201100149; Geromel V, 2001, FREE RADICAL RES, V35, P11, DOI 10.1080/10715760100300551; Geromel V, 2002, FREE RADICAL RES, V36, P375, DOI 10.1080/10715760290021216; Hallman TM, 2006, J AUTOIMMUN, V26, P1, DOI 10.1016/j.jaut.2005.10.006; Heeringa SF, 2011, J CLIN INVEST, V121, P2013, DOI 10.1172/JCI45693; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Liu YH, 2009, KIDNEY INT, V76, P1125, DOI 10.1038/ki.2009.352; Lopez LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011897; Lopez LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023; Lopez-Martin JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058; LYON MF, 1971, J MED GENET, V8, P41, DOI 10.1136/jmg.8.1.41; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; Peng M, 2004, KIDNEY INT, V66, P20, DOI 10.1111/j.1523-1755.2004.00702.x; Peng M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000061; Quinzii CM, 2008, FASEB J, V22, P1874, DOI 10.1096/fj.07-100149; Quinzii CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030606; Quinzii CM, 2010, FASEB J, V24, P3733, DOI 10.1096/fj.09-152728; Rodriguez-Hernandez A, 2009, AUTOPHAGY, V5, P19, DOI 10.4161/auto.5.1.7174; Saiki R, 2008, AM J PHYSIOL-RENAL, V295, pF1535, DOI 10.1152/ajprenal.90445.2008; Sohal RS, 2007, MITOCHONDRION, V7, pS103, DOI 10.1016/j.mito.2007.03.006; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Tanji K, 2008, METHODS, V46, P274, DOI 10.1016/j.ymeth.2008.09.027; Tran UC, 2007, MITOCHONDRION, V7, pS62, DOI 10.1016/j.mito.2007.03.007; Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Ziegler CGK, 2012, MITOCHONDRION, V12, P248, DOI 10.1016/j.mito.2011.09.011	33	46	46	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					612	621		10.1096/fj.12-209361	http://dx.doi.org/10.1096/fj.12-209361			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150520	Green Published			2022-12-28	WOS:000314358000020
J	Sarkis, J; Vie, V; Winder, SJ; Renault, A; Le Rumeur, E; Hubert, JF				Sarkis, Joe; Vie, Veronique; Winder, Steve J.; Renault, Anne; Le Rumeur, Elisabeth; Hubert, Jean-Francois			Resisting sarcolemmal rupture: dystrophin repeats increase membrane-actin stiffness	FASEB JOURNAL			English	Article						actin-binding domain; rheology; spectrin-like repeats; lipid-protein interactions	CYTOPLASMIC GAMMA-ACTIN; ROD DOMAIN; LIPID MONOLAYERS; BINDING DOMAIN; SHEAR RHEOLOGY; UTROPHIN; STABILITY; MUSCLE; MODEL; FILAMENTS	Dystrophin is an essential part of a membrane protein complex that provides flexible support to muscle fiber membranes. Loss of dystrophin function leads to membrane fragility and muscle-wasting disease. Given the importance of cytoskeletal interactions in strengthening the sarcolemma, we have focused on actin-binding domain 2 of human dystrophin, constituted by repeats 11 to 15 of the central domain (DYS R11-15). We previously showed that DYS R11-15 also interacts with membrane lipids. We investigated the shear elastic constant (mu) and the surface viscosity (eta(s)) of Langmuir phospholipid monolayers mimicking the inner leaflet of the sarcolemma in the presence of DYS R11-15 and actin. The initial interaction of 100 nM DYS R11-15 with the monolayers slightly modifies their rheological properties. Injection of 0.125 mu M filamentous actin leads to a strong increase of mu and eta(s), from 0 to 5.5 mN/m and 2.4 x 10(-4) N . s/m, respectively. These effects are specific to DYS R11-15, require filamentous actin, and depend on phospholipid nature and lateral surface pressure. These findings suggest that the central domain of dystrophin contributes significantly to the stiffness and the stability of the sarcolemma through its simultaneous interactions with the cytoskeleton and lipid membrane. This mechanical link is likely to be a major contributing factor to the shock absorber function of dystrophin and muscle sarcolemmal integrity on mechanical stress.-Sarkis, J., Vie, V., Winder, S. J., Renault, A., Le Rumeur, E., Hubert, J.-F. Resisting sarcolemmal rupture: dystrophin repeats increase membrane-actin stiffness. FASEB J. 27, 359-367 (2013). www.fasebj.org	[Sarkis, Joe; Vie, Veronique; Renault, Anne; Le Rumeur, Elisabeth; Hubert, Jean-Francois] Univ Europeenne Bretagne, Rennes, France; [Sarkis, Joe; Le Rumeur, Elisabeth; Hubert, Jean-Francois] Fac Med, CNRS, UMR, Inst Genet Dev Rennes, F-35043 Rennes, France; [Sarkis, Joe; Vie, Veronique; Renault, Anne; Le Rumeur, Elisabeth; Hubert, Jean-Francois] Univ Rennes 1, Rennes, France; [Sarkis, Joe; Vie, Veronique; Renault, Anne] Inst Phys Rennes, CNRS, UMR, Rennes, France; [Winder, Steve J.] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	Universite de Bretagne Occidentale; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); University of Sheffield	Hubert, JF (corresponding author), Fac Med, CNRS, UMR 6290, Equipe Struct & Interact Mol, CS 34317,2 Av Pr Leon Bernard, F-35043 Rennes, France.	jfhubert@univ-rennes1.fr		Sarkis, Joe/0000-0002-9342-7198	Association Francaise contre les Myopathies; GIS-BRESMAT-Conseil Regional de Bretagne; French Minister of Research	Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); GIS-BRESMAT-Conseil Regional de Bretagne(Region Bretagne); French Minister of Research	The authors thank Dr. Isabelle Cantat for help with the theoretical data treatment and for critically reading the manuscript. This work was supported by the Association Francaise contre les Myopathies and by GIS-BRESMAT-Conseil Regional de Bretagne. J.S. was the recipient of a doctoral fellowship from the French Minister of Research. The authors thank Christophe Tascon, Angelique Cheron, Adam Smith, Ellen Allwood, Gilles Paboeuf, and Estelle Robert for technical assistance; Aurelie Nicolas for the Becker Muscular Dystrophy database; the Centre de Biochimie des Proteines (UMR-CNRS 6290; Rennes, France); and the Centre de Microscopie Electronique (Biosit, University of Rennes 1, Rennes, France).	Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Deme B, 2000, EUR PHYS J E, V2, P125, DOI 10.1007/s101890050046; DeWolf C, 1997, BIOPHYS J, V72, P2599, DOI 10.1016/S0006-3495(97)78903-3; Espinosa G, 2011, P NATL ACAD SCI USA, V108, P6008, DOI 10.1073/pnas.1018572108; FIEHN W, 1971, J BIOL CHEM, V246, P5617; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Han R, 2009, P NATL ACAD SCI USA, V106, P12573, DOI 10.1073/pnas.0906545106; Hanft LM, 2006, P NATL ACAD SCI USA, V103, P5385, DOI 10.1073/pnas.0600980103; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Helfer E, 2000, PHYS REV LETT, V85, P457, DOI 10.1103/PhysRevLett.85.457; Henderson DM, 2012, J MOL BIOL, V416, P414, DOI 10.1016/j.jmb.2011.12.040; Henderson DM, 2011, HUM MOL GENET, V20, P2955, DOI 10.1093/hmg/ddr199; Isanta S, 2011, SOFT MATTER, V7, P3100, DOI 10.1039/c0sm00880j; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Lai Y, 2009, J CLIN INVEST, V119, P624, DOI 10.1172/JCI36612; Le Floch-Fouere C, 2010, FOOD HYDROCOLLOID, V24, P275, DOI 10.1016/j.foodhyd.2009.10.006; Le Rumeur E, 2003, J BIOL CHEM, V278, P5993, DOI 10.1074/jbc.M207321200; Le Rumeur E, 2010, BBA-PROTEINS PROTEOM, V1804, P1713, DOI 10.1016/j.bbapap.2010.05.001; Legardinier S, 2008, BBA-PROTEINS PROTEOM, V1784, P672, DOI 10.1016/j.bbapap.2007.12.014; Legardinier S, 2009, J MOL BIOL, V389, P546, DOI 10.1016/j.jmb.2009.04.025; Legrand B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023819; Limozin L, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178101; Limozin L, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.168103; Liu MJ, 2005, MOL THER, V11, P245, DOI 10.1016/j.ymthe.2004.09.013; Lodish H, 2000, MOL CELL BIOL; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Marsh D, 2006, BIOPHYS J, V91, P227, DOI 10.1529/biophysj.105.079004; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Norwood FLM, 2000, STRUCTURE, V8, P481, DOI 10.1016/S0969-2126(00)00132-5; Pontani LL, 2009, BIOPHYS J, V96, P192, DOI 10.1016/j.bpj.2008.09.029; Renault A, 1999, BIOPHYS J, V76, P1580, DOI 10.1016/S0006-3495(99)77317-0; Roberts SA, 2005, INT J PHARM, V300, P48, DOI 10.1016/j.ijpharm.2005.05.003; Rybakova IN, 2006, J BIOL CHEM, V281, P9996, DOI 10.1074/jbc.M513121200; Rybakova IN, 2005, J BIOL CHEM, V280, P23018, DOI 10.1074/jbc.M502530200; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Sarkis J, 2011, J BIOL CHEM, V286, P30481, DOI 10.1074/jbc.M111.243881; Sengupta K, 2006, LANGMUIR, V22, P5776, DOI 10.1021/la053310+; Sonnemann KJ, 2006, DEV CELL, V11, P387, DOI 10.1016/j.devcel.2006.07.001; Venien-Bryan C, 1998, BIOPHYS J, V74, P2649, DOI 10.1016/S0006-3495(98)77970-6; Vie V, 2010, BBA-BIOMEMBRANES, V1798, P1503, DOI 10.1016/j.bbamem.2010.04.005; WEGNER A, 1982, J MOL BIOL, V161, P607, DOI 10.1016/0022-2836(82)90411-9; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S	44	13	13	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					359	367		10.1096/fj.12-208967	http://dx.doi.org/10.1096/fj.12-208967			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23033320				2022-12-28	WOS:000313103200034
J	de Magalhaes, JP				de Magalhaes, Joao Pedro			Programmatic features of aging originating in development: aging mechanisms beyond molecular damage?	FASEB JOURNAL			English	Article						epigenetics; functional genomics	TO-HEAD DEBATE; LIFE-SPAN; MESSENGER-RNA; GENES; MICRORNA; AGE; REPRODUCTION; LONGEVITY; EXTENSION; BIOLOGY	The idea that aging follows a predetermined sequence of events, a program, has been discredited by most contemporary authors. Instead, aging is largely thought to occur due to the accumulation of various forms of molecular damage. Recent work employing functional genomics now suggests that, indeed, certain facets of mammalian aging may follow predetermined patterns encoded in the genome as part of developmental processes. It appears that genetic programs coordinating some aspects of growth and development persist into adulthood and may become detrimental. This link between development and aging may occur due to regulated processes, including through the action of microRNAs and epigenetic mechanisms. Taken together with other results, in particular from worms, these findings provide evidence that some aging changes are not primarily a result of a build-up of stochastic damage but are rather a product of regulated processes. These processes are interpreted as forms of antagonistic pleiotropy, the product of a "shortsighted watchmaker," and thus do not assume aging evolved for a purpose. Overall, it appears that the genome does, indeed, contain specific instructions that drive aging in animals, a radical shift in our perception of the aging process.-de Magalhaes, J. P. Programmatic features of aging originating in development: aging mechanisms beyond molecular damage? FASEB J. 26, 4821-4826 (2012). www.fasebj.org	Univ Liverpool, Inst Integrat Biol, Integrat Genom Ageing Grp, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	de Magalhaes, JP (corresponding author), Univ Liverpool, Inst Integrat Biol, Integrat Genom Ageing Grp, Biosci Bldg,Rm 245,Crown St, Liverpool L69 7ZB, Merseyside, England.	jp@senescence.info	de Magalhaes, Joao Pedro/B-4741-2010	de Magalhaes, Joao Pedro/0000-0002-6363-2465	UK Biotechnology and Biological Sciences Resource Council; Wellcome Trust; Ellison Medical Foundation; Marie Curie International Reintegration grant within EC-FP7	UK Biotechnology and Biological Sciences Resource Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Ellison Medical Foundation(Lawrence Ellison Foundation); Marie Curie International Reintegration grant within EC-FP7	The author thanks Pete Estep and George Martin for comments on previous drafts. The author is also grateful for support from the UK Biotechnology and Biological Sciences Resource Council, the Wellcome Trust, the Ellison Medical Foundation, and a Marie Curie International Reintegration grant within EC-FP7 for supporting the work in his laboratory.	Austad SN, 2004, AGING CELL, V3, P249, DOI 10.1111/j.1474-9728.2004.00112.x; Austad SN, 2009, J GERONTOL A-BIOL, V64, P199, DOI 10.1093/gerona/gln060; Ayyadevara S, 2008, AGING CELL, V7, P13, DOI 10.1111/j.1474-9726.2007.00348.x; Biddle FG, 1997, GENOME, V40, P229, DOI 10.1139/g97-032; Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288; Boehm M, 2005, SCIENCE, V310, P1954, DOI 10.1126/science.1115596; Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x; Bredesen DE, 2004, AGING CELL, V3, P255, DOI 10.1111/j.1474-9728.2004.00121.x; Budovskaya YV, 2008, CELL, V134, P291, DOI 10.1016/j.cell.2008.05.044; Comfort A, 1964, AGEING BIOL SENESCEN; Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056; de Magalhaes JP, 2007, J GERONTOL A-BIOL, V62, P149; de Magalhaes JP, 2010, AGEING RES REV, V9, P315, DOI 10.1016/j.arr.2009.10.006; de Magalhaes JP, 2009, BIOINFORMATICS, V25, P875, DOI 10.1093/bioinformatics/btp073; de Magalhaes JP, 2005, MECH AGEING DEV, V126, P1026, DOI 10.1016/j.mad.2005.04.004; de Magalhaes JP, 2005, PHYSIOLOGY, V20, P252, DOI 10.1152/physiol.00010.2005; de Magalhaes JP, 2004, FEBS LETT, V571, P243, DOI 10.1016/j.febslet.2004.07.006; de Magalhaes JP, 2003, BIOGERONTOLOGY, V4, P119, DOI 10.1023/A:1023356005749; FINCH CE, 1976, Q REV BIOL, V51, P49, DOI 10.1086/409053; Finch CE, 1990, LONGEVITY SENESCENCE; Freitas AA, 2011, MUTAT RES-REV MUTAT, V728, P12, DOI 10.1016/j.mrrev.2011.05.001; Gombar S, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-353; Hayflick L., 1994, WHY WE AGE; Hayflick L, 2007, PLOS GENET, V3, P2351, DOI 10.1371/journal.pgen.0030220; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; HIGUCHI K, 1992, J LIPID RES, V33, P1753; Holliday R, 2006, ANN NY ACAD SCI, V1067, P1, DOI 10.1196/annals.1354.002; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Kirkwood TBL, 2008, J INTERN MED, V263, P117, DOI 10.1111/j.1365-2796.2007.01901.x; Kirkwood TBL, 2011, CURR BIOL, V21, pR701, DOI 10.1016/j.cub.2011.07.020; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; Koch CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016679; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Lui JC, 2010, MECH AGEING DEV, V131, P641, DOI 10.1016/j.mad.2010.08.010; Lui JC, 2010, FASEB J, V24, P3083, DOI 10.1096/fj.09-152835; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; McCay C M, 1933, Science, V77, P410, DOI 10.1126/science.77.2000.410; Miller RA, 1999, J GERONTOL A-BIOL, V54, pB297, DOI 10.1093/gerona/54.7.B297; MILLER SE, 1990, SCIENCE, V248, P356, DOI 10.1126/science.248.4953.356; Nicholas A, 2010, MECH AGEING DEV, V131, P445, DOI 10.1016/j.mad.2010.06.001; Partridge L, 2010, PHILOS T R SOC B, V365, P147, DOI 10.1098/rstb.2009.0222; Raff M, 2006, BIOCHEM SOC T, V34, P663, DOI 10.1042/BST0340663; Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109; Rattan SIS, 2006, FREE RADICAL RES, V40, P1230, DOI 10.1080/10715760600911303; Ricklefs RE, 2010, P NATL ACAD SCI USA, V107, P10314, DOI 10.1073/pnas.1005862107; Rollo CD, 2002, EVOL DEV, V4, P55, DOI 10.1046/j.1525-142x.2002.01053.x; Somel M, 2010, GENOME RES, V20, P1207, DOI 10.1101/gr.106849.110; Takasugi M, 2011, MECH AGEING DEV, V132, P65, DOI 10.1016/j.mad.2010.12.003; Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216; Walker RF, 2011, REJUV RES, V14, P429, DOI 10.1089/rej.2011.1162; Walker RF, 2009, MECH AGEING DEV, V130, P350, DOI 10.1016/j.mad.2009.02.003; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Yuan R, 2012, P NATL ACAD SCI USA, V109, P8224, DOI 10.1073/pnas.1121113109	53	62	64	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4821	4826		10.1096/fj.12-210872	http://dx.doi.org/10.1096/fj.12-210872			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964300	hybrid, Green Published			2022-12-28	WOS:000311838300005
J	Faresse, N; Vitagliano, JJ; Staub, O				Faresse, Nourdine; Vitagliano, Jean-Jacques; Staub, Olivier			Differential ubiquitylation of the mineralocorticoid receptor is regulated by phosphorylation	FASEB JOURNAL			English	Article						aldosterone; ubiquitin; post-translational modifications; turnover	GLUCOCORTICOID-RECEPTOR; ALDOSTERONE; EXPRESSION; ACTIVATION; CELLS; DEGRADATION; TRANSPORT; ELEMENT	Aldosterone stimulation of the mineralocorticoid receptor (MR) is involved in numerous physiological responses, including Na+ homeostasis, blood pressure control, and heart failure. Aldosterone binding to MR promotes different post-translational modifications that regulate MR nuclear translocation, gene expression, and finally receptor degradation. Here, we show that aldosterone stimulates rapid phosphorylation of MR via ERK1/2 in a dose-dependent manner (from 0.1 to 10 nM) in renal epithelial cells. This phosphorylation induces an increase of MR apparent molecular weight, with a maximal upward shift of 30 kDa. Strikingly, these modifications are critical for the regulation of the MR ubiquitylation state. Indeed, we find that MR is monoubiquitylated in its basal state, and this status is sustained by the tumor suppressor gene 101 (Tsg101). Phosphorylation leads to disruption of MR/Tsg101 association and monoubiquitin removal. These events prompt polyubiquitin-dependent destabilization of MR and degradation. Preventing MR phosphorylation by ERK1/2 inhibition or mutation of target serines affects the sequential mechanisms of MR ubiquitylation and inhibits the aldosterone-mediated degradation. Our data provide a novel model of negative feedback of aldosterone signaling, involving sequential phosphorylation, monoubiquitin removal and subsequent polyubiquitylation/degradation of MR.-Faresse, N., Vitagliano, J.-J., Staub, O. Differential ubiquitylation of the mineralocorticoid receptor is regulated by phosphorylation. FASEB J. 26, 4373-4382 (2012). www.fasebj.org	[Faresse, Nourdine; Vitagliano, Jean-Jacques; Staub, Olivier] Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Staub, O (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	olivier.staub@unil.ch			Leducq Foundation (Transatlantic Network on Hypertension); Swiss National Science Foundation [31003A_125422/1]; Swiss National Centre of Competence in Research Kidney.ch; European Molecular Biology Organization long-term fellowship	Leducq Foundation (Transatlantic Network on Hypertension)(Leducq Foundation); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Centre of Competence in Research Kidney.ch; European Molecular Biology Organization long-term fellowship(European Molecular Biology Organization (EMBO))	The authors thank Dr. N. Farman for providing the experiment on MR phosphorylation in rCCD cells. The authors also thank Dr. N. Farman, Dr. D. Diviani, and Dr. P. Shaw for critically reading the manuscript and for stimulating discussions. The authors also thank I. Perez Lopez for the cardiomyocyte preparation. This work was supported by the Leducq Foundation (Transatlantic Network on Hypertension), Swiss National Science Foundation (31003A_125422/1), the Swiss National Centre of Competence in Research Kidney.ch, and a European Molecular Biology Organization long-term fellowship to N.F.	ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Faresse N, 2010, AM J PHYSIOL-RENAL, V299, pF1462, DOI 10.1152/ajprenal.00285.2010; Flores SY, 2005, J AM SOC NEPHROL, V16, P2279, DOI 10.1681/ASN.2004100828; Gaeggeler HP, 2005, J AM SOC NEPHROL, V16, P878, DOI 10.1681/ASN.2004121110; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; Gros R, 2011, HYPERTENSION, V57, P442, DOI 10.1161/HYPERTENSIONAHA.110.161653; Grossmann C, 2005, MOL ENDOCRINOL, V19, P1697, DOI 10.1210/me.2004-0469; Grossmann C, 2008, STEROIDS, V73, P973, DOI 10.1016/j.steroids.2007.12.008; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Ismaili N, 2005, J BIOL CHEM, V280, P11120, DOI 10.1074/jbc.M500059200; Kapiloff MS, 1999, J CELL SCI, V112, P2725; Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002; Kodadek T, 2010, J BIOL CHEM, V285, P2221, DOI 10.1074/jbc.R109.077883; Krug AW, 2003, J BIOL CHEM, V278, P43060, DOI 10.1074/jbc.M308134200; Krug AW, 2002, J BIOL CHEM, V277, P45892, DOI 10.1074/jbc.M208851200; La Rosa P, 2011, CELL SIGNAL, V23, P1128, DOI 10.1016/j.cellsig.2011.02.006; La Rosa P, 2011, IUBMB LIFE, V63, P49, DOI 10.1002/iub.414; Le Moellic C, 2004, J AM SOC NEPHROL, V15, P1145; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; Pearce D, 2003, VITAM HORM, V66, P29, DOI 10.1016/S0083-6729(03)01002-1; Pfau A, 2007, MOL CELL ENDOCRINOL, V264, P35, DOI 10.1016/j.mce.2006.10.002; Rogerson FM, 2003, MOL CELL ENDOCRINOL, V200, P45, DOI 10.1016/S0303-7207(02)00413-6; Rogerson FM, 1999, J BIOL CHEM, V274, P36305, DOI 10.1074/jbc.274.51.36305; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Verrey F., 2008, KIDNEY PHYSL PATHOPH, P889, DOI DOI 10.1016/B978-012088488-9.50035-8; Viengchareun Say, 2007, Nucl Recept Signal, V5, pe012, DOI 10.1621/nrs.05012; Ward RD, 2009, BIOFACTORS, V35, P528, DOI 10.1002/biof.66; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101; Yang J, 2012, MOL CELL ENDOCRINOL, V350, P196, DOI 10.1016/j.mce.2011.07.001; Yokota K, 2004, ENDOCR RES, V30, P611, DOI 10.1081/ERC-200043783	36	35	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4373	4382		10.1096/fj.12-209924	http://dx.doi.org/10.1096/fj.12-209924			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22798426				2022-12-28	WOS:000309704000041
J	Carlson, AL; Florek, CA; Kim, JJ; Neubauer, T; Moore, JC; Cohen, RI; Kohn, J; Grumet, M; Moghe, PV				Carlson, Aaron L.; Florek, Charles A.; Kim, Joseph J.; Neubauer, Thomas; Moore, Jennifer C.; Cohen, Rick I.; Kohn, Joachim; Grumet, Martin; Moghe, Prabhas V.			Microfibrous substrate geometry as a critical trigger for organization, self-renewal, and differentiation of human embryonic stem cells within synthetic 3-dimensional microenvironments	FASEB JOURNAL			English	Article						fibrous scaffolds; poly-D-lysine; tissue engineering	DIRECTED DIFFERENTIATION; MATRIX; CULTURE; SURFACES; TYROSINE; LINES; POLYCARBONATES; DERIVATION; SCAFFOLDS; POLYMERS	Substrates used to culture human embryonic stem cells (hESCs) are typically 2-dimensional (2-D) in nature, with limited ability to recapitulate in vivo-like 3-dimensional (3-D) microenvironments. We examined critical determinants of hESC self-renewal in poly-D-lysine-pretreated synthetic polymer-based substrates with variable microgeometries, including planar 2-D films, macroporous 3-D sponges, and microfibrous 3-D fiber mats. Completely synthetic 2-D substrates and 3-D macroporous scaffolds failed to retain hESCs or support self-renewal or differentiation. However, synthetic microfibrous geometries made from electrospun polymer fibers were found to promote cell adhesion, viability, proliferation, self-renewal, and directed differentiation of hESCs in the absence of any exogenous matrix proteins. Mechanistic studies of hESC adhesion within microfibrous scaffolds indicated that enhanced cell confinement in such geometries increased cell-cell contacts and altered colony organization. Moreover, the microfibrous scaffolds also induced hESCs to deposit and organize extracellular matrix proteins like laminin such that the distribution of laminin was more closely associated with the cells than the Matrigel treatment, where the laminin remained associated with the coated fibers. The production of and binding to laminin was critical for formation of viable hESC colonies on synthetic fibrous scaffolds. Thus, synthetic substrates with specific 3-D microgeometries can support hESC colony formation, self-renewal, and directed differentiation to multiple lineages while obviating the stringent needs for complex, exogenous matrices. Similar scaffolds could serve as tools for developmental biology studies in 3-D and for stem cell differentiation in situ and transplantation using defined humanized conditions.-Carlson, A. L., Florek, C. A., Kim, J. J., Neubauer, T., Moore, J. C., Cohen, R. I., Kohn, J., Grumet, M., Moghe, P. V. Microfibrous substrate geometry as a critical trigger for organization, self-renewal, and differentiation of human embryonic stem cells within synthetic 3-dimensional microenvironments. FASEB J. 26, 3240-3251 (2012). www.fasebj.org	[Carlson, Aaron L.; Florek, Charles A.; Kim, Joseph J.; Neubauer, Thomas; Moghe, Prabhas V.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Florek, Charles A.; Kohn, Joachim] Rutgers State Univ, New Jersey Ctr Biomat, Piscataway, NJ 08854 USA; [Moore, Jennifer C.; Cohen, Rick I.; Grumet, Martin] Rutgers State Univ, Rutgers Univ Stem Cell Res Ctr, Piscataway, NJ 08854 USA; [Moore, Jennifer C.; Cohen, Rick I.; Grumet, Martin] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Moore, Jennifer C.; Cohen, Rick I.; Grumet, Martin] Rutgers State Univ, Keck Ctr Collaborat Neurosci, Piscataway, NJ 08854 USA; [Kohn, Joachim] Rutgers State Univ, Dept Chem & Chem Engn, Piscataway, NJ 08854 USA; [Moghe, Prabhas V.] Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Moghe, PV (corresponding author), Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.	moghe@rci.rutgers.edu	grumet, martin/ABC-6462-2020		New Jersey Commission on Science and Technology Stem Cell Core grant; U.S. National Institutes of Health grant [EB000146]; New Jersey Commission on Spinal Cord Research exploratory grant [10-3090-SCR-E-0]; National Science Foundation Integrative Graduate Education and Research Traineeship grant [0801620]	New Jersey Commission on Science and Technology Stem Cell Core grant; U.S. National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission on Spinal Cord Research exploratory grant; National Science Foundation Integrative Graduate Education and Research Traineeship grant	The authors gratefully acknowledge support from the New Jersey Commission on Science and Technology Stem Cell Core grant (principal investigators P.V.M. and M.G.), U.S. National Institutes of Health grant EB000146 (RESBIO: Integrated Resource for Polymeric Materials; principal investigators P.V.M. and J.K.), New Jersey Commission on Spinal Cord Research exploratory grant 10-3090-SCR-E-0 (principal investigator P.V.M.), and National Science Foundation Integrative Graduate Education and Research Traineeship grant 0801620 (Stem Cell Science and Engineering; principal investigator P.V.M.).	Bahney CS, 2011, FASEB J, V25, P1486, DOI 10.1096/fj.10-165514; Bajpai R, 2008, MOL REPROD DEV, V75, P818, DOI 10.1002/mrd.20809; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Bongso A, 2008, J CELL BIOCHEM, V105, P1352, DOI 10.1002/jcb.21957; Bourke SL, 2003, ADV DRUG DELIVER REV, V55, P447, DOI 10.1016/S0169-409X(03)00038-3; Braam SR, 2008, STEM CELLS, V26, P2257, DOI 10.1634/stemcells.2008-0291; Brafman DA, 2010, BIOMATERIALS, V31, P9135, DOI 10.1016/j.biomaterials.2010.08.007; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Cao HQ, 2009, ADV DRUG DELIVER REV, V61, P1055, DOI 10.1016/j.addr.2009.07.009; Carlberg B, 2009, BIOMED MATER, V4, DOI 10.1088/1748-6041/4/4/045004; Chen YF, 2012, HEPATOLOGY, V55, P1193, DOI 10.1002/hep.24790; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dawson E, 2008, ADV DRUG DELIVER REV, V60, P215, DOI 10.1016/j.addr.2007.08.037; Doyle AD, 2009, J CELL BIOL, V184, P481, DOI 10.1083/jcb.200810041; ERTEL SI, 1994, J BIOMED MATER RES, V28, P919, DOI 10.1002/jbm.820280811; Ferreira LS, 2007, BIOMATERIALS, V28, P2706, DOI 10.1016/j.biomaterials.2007.01.021; Gao SY, 2010, J BIOMED MATER RES A, V92A, P683, DOI 10.1002/jbm.a.32401; Gauthaman K, 2009, J CELL MOL MED, V13, P3475, DOI 10.1111/j.1582-4934.2009.00699.x; Gerecht S, 2007, P NATL ACAD SCI USA, V104, P11298, DOI 10.1073/pnas.0703723104; Hu BY, 2010, METHODS MOL BIOL, V636, P123, DOI 10.1007/978-1-60761-691-7_8; Huang HR, 2006, BIOCHEM BIOPH RES CO, V351, P321, DOI 10.1016/j.bbrc.2006.09.171; Lee J, 2008, TISSUE ENG PART B-RE, V14, P61, DOI 10.1089/teb.2007.0150; Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100; Li ZS, 2010, BIOMATERIALS, V31, P404, DOI 10.1016/j.biomaterials.2009.09.070; Lim SH, 2010, BIOMATERIALS, V31, P9031, DOI 10.1016/j.biomaterials.2010.08.021; Lim SH, 2009, ADV DRUG DELIVER REV, V61, P1084, DOI 10.1016/j.addr.2009.07.011; Liu E, 2007, J BIOMED MATER RES B, V82B, P284, DOI 10.1002/jbm.b.30732; Liu H, 2006, BIOMATERIALS, V27, P5978, DOI 10.1016/j.biomaterials.2006.05.053; Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177; Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902; Mahairaki V, 2011, TISSUE ENG PT A, V17, P855, DOI 10.1089/ten.TEA.2010.0377; McDevitt TC, 2008, CURR OPIN BIOTECH, V19, P527, DOI 10.1016/j.copbio.2008.08.005; Meechaisue C, 2006, J BIOMAT SCI-POLYM E, V17, P1039, DOI 10.1163/156856206778365988; Melkoumian Z, 2010, NAT BIOTECHNOL, V28, P606, DOI 10.1038/nbt.1629; Meng Y, 2010, FASEB J, V24, P1056, DOI 10.1096/fj.08-126821; Miyazaki T, 2008, BIOCHEM BIOPH RES CO, V375, P27, DOI 10.1016/j.bbrc.2008.07.111; Nat R, 2007, GLIA, V55, P385, DOI 10.1002/glia.20463; Ouyang A, 2007, STEM CELLS, V25, P447, DOI 10.1634/stemcells.2006-0322; Ranucci CS, 2000, BIOMATERIALS, V21, P783, DOI 10.1016/S0142-9612(99)00238-0; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Sands RW, 2007, CURR OPIN BIOTECH, V18, P448, DOI 10.1016/j.copbio.2007.10.004; Shahbazi E, 2011, TISSUE ENG PT A, V17, P3021, DOI [10.1089/ten.tea.2011.0121, 10.1089/ten.TEA.2011.0121]; Smith LA, 2010, BIOMATERIALS, V31, P5526, DOI 10.1016/j.biomaterials.2010.03.065; Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587; Tai BCU, 2010, BIOMATERIALS, V31, P5927, DOI 10.1016/j.biomaterials.2010.04.003; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107; Villa-Diaz LG, 2010, NAT BIOTECHNOL, V28, P581, DOI 10.1038/nbt.1631; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Yang F, 2010, BIOMACROMOLECULES, V11, P1909, DOI 10.1021/bm100357t; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103	52	43	43	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3240	3251		10.1096/fj.11-192732	http://dx.doi.org/10.1096/fj.11-192732			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22542683	Green Published			2022-12-28	WOS:000307162800015
J	Hsu, YY; Shi, GY; Kuo, CH; Liu, SL; Wu, CM; Ma, CY; Lin, FY; Yang, HY; Wu, HL				Hsu, Yun-Yan; Shi, Guey-Yueh; Kuo, Cheng-Hsiang; Liu, Shu-Lin; Wu, Ching-Ming; Ma, Chih-Yuan; Lin, Feng-Yi; Yang, Hsi-Yuan; Wu, Hua-Lin			Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration	FASEB JOURNAL			English	Article						cell-cell adhesion; keratinocyte; wound healing; neoepidermis	ACTIN-BASED CYTOSKELETONS; EPIDERMAL-GROWTH-FACTOR; LYMPH-NODE METASTASIS; ADHERENS JUNCTIONS; BINDING-SITE; ERM PROTEINS; CYTOPLASMIC DOMAIN; EXPRESSION; CD44; PHOSPHORYLATION	Adhesive interactions between cells are needed to maintain tissue architecture during development, tissue renewal and wound healing. Thrombomodulin (TM) is an integral membrane protein that participates in cell-cell adhesion through its extracellular lectin-like domain. However, the molecular basis of TM-mediated cell-cell adhesion is poorly understood. Here, we demonstrate that TM is linked to the actin cytoskeleton via ezrin. In vitro binding assays showed that the TM cytoplasmic domain bound directly to the N-terminal domain of ezrin. Mutational analysis of the TM cytoplasmic domain identified (RKK524)-R-522 as important ezrin-binding residues. In epidermal epithelial A431 cells, TM colocalized with ezrin and actin filaments at cell-cell contacts. Knockdown of endogenous TM expression by RNA interference induced morphological changes and accelerated cell migration in A431 cells. Moreover, epidermal growth factor, upstream of ezrin activation, stimulated the interaction between ezrin and TM. In skin wound healing of mice, TM and ezrin were highly expressed in neoepidermis, implying that both proteins are key molecules in reepithelialization that requires collective cell migration of epithelial cells. Finally, exogenous expression of TM in TM-deficient melanoma A2058 cells promoted collective cell migration. In summary, TM, which associates with ezrin and actin filaments, maintains epithelial morphology and promotes collective cell migration.-Hsu, Y.-Y., Shi, G.-Y., Kuo, C.-H., Liu, S.-L., Wu, C.-M., Ma, C.-Y., Lin, F.-Y., Yang, H.-Y., Wu, H.-L. Thrombo-modulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration. FASEB J. 26, 3440-3452 (2012). www.fasebj.org	[Shi, Guey-Yueh; Liu, Shu-Lin; Lin, Feng-Yi; Wu, Hua-Lin] Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med, Tainan 701, Taiwan; [Hsu, Yun-Yan; Kuo, Cheng-Hsiang; Ma, Chih-Yuan] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; [Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Cardiovasc Res Ctr, Coll Med, Tainan 701, Taiwan; [Shi, Guey-Yueh; Wu, Hua-Lin] Natl Cheng Kung Univ, Ctr Biosci & Biotechnol, Coll Med, Tainan 701, Taiwan; [Wu, Ching-Ming] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Coll Med, Tainan 701, Taiwan; [Yang, Hsi-Yuan] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 10764, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Taiwan University	Shi, GY (corresponding author), Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.	gyshi@mail.ncku.edu.tw; halnwu@mail.ncku.edu.tw	Kuo, Cheng-Hsiang/GRJ-7463-2022	Kuo, Cheng-Hsiang/0000-0002-4885-9020	National Science Council, Executive Yuan (Taipei, Taiwan) [NSC 99-2320-B-006-008-MY3, NSC 99-2628-B-006-003-MY3, NSC 100-2325-B-006-003-MY3]; National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan	National Science Council, Executive Yuan (Taipei, Taiwan)(Ministry of Science and Technology, Taiwan); National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan	This work was supported by the National Science Council, Executive Yuan (Taipei, Taiwan; grants NSC 99-2320-B-006-008-MY3, NSC 99-2628-B-006-003-MY3, and NSC 100-2325-B-006-003-MY3), and by a National Cheng Kung University Aim for the Top University Plan grant from the Ministry of Education, Taiwan.	AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Federici C, 2009, INT J CANCER, V124, P2804, DOI 10.1002/ijc.24255; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Giepmans BNG, 2009, BBA-BIOMEMBRANES, V1788, P820, DOI 10.1016/j.bbamem.2008.07.015; Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200; Ilina O, 2009, J CELL SCI, V122, P3203, DOI 10.1242/jcs.036525; Kao YC, 2010, MOL CELL BIOL, V30, P4767, DOI 10.1128/MCB.01021-09; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lien WH, 2006, CURR OPIN CELL BIOL, V18, P499, DOI 10.1016/j.ceb.2006.07.001; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Ogawa H, 2000, CANCER LETT, V149, P95, DOI 10.1016/S0304-3835(99)00348-1; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Peterson JJ, 1999, AM J PATHOL, V155, P1569, DOI 10.1016/S0002-9440(10)65473-9; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shaw TJ, 2009, J CELL SCI, V122, P3209, DOI 10.1242/jcs.031187; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; SUEHIRO T, 1995, HEPATOLOGY, V21, P1285, DOI 10.1002/hep.1840210511; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Tanaka Y, 2003, MOL BIOL CELL, V14, P1597, DOI 10.1091/mbc.E02-10-0632; TEZUKA Y, 1995, CANCER RES, V55, P4196; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	41	37	38	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3440	3452		10.1096/fj.12-204917	http://dx.doi.org/10.1096/fj.12-204917			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593542	Green Submitted			2022-12-28	WOS:000307162800031
J	Ming-Lum, A; Shojania, S; So, E; McCarrell, E; Shaw, E; Vu, D; Wang, I; McIntosh, LP; Mui, ALF				Ming-Lum, Andrew; Shojania, Shaheen; So, Eva; McCarrell, Erin; Shaw, Eileen; Vu, David; Wang, Ida; McIntosh, Lawrence P.; Mui, Alice L-F			A pleckstrin homology-related domain in SHIP1 mediates membrane localization during Fc gamma receptor-induced phagocytosis	FASEB JOURNAL			English	Article						phosphoinositide-3 ' kinase; macrophage; lipid-binding domain	INOSITOL 5'-PHOSPHATASE SHIP; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SH2 DOMAIN; IN-VIVO; NMR-SPECTROSCOPY; LARGER PROTEINS; DEFICIENT MICE; C-TERMINUS; CELLS	SH2 domain-containing inositol-5'-phosphatase-1 (SHIP1) inhibits inflammation by hydrolyzing phosphoinositide-3'-kinase generated membrane phosphatidylinositol-3,4,5-trisphosphate (PIP3). Bioinformatic analysis of SHIP1 from multiple species revealed a pleckstrin homololgy-related (PH-R) domain, which we hypothesize mediates SHIP1's association with the membrane, a requirement for its biological function. Recombinant murine SHIP1 PH-R domain was subjected to biophysical and biochemical analysis. Residues K370 and K397 were found to be important for PH-R domain association with membrane PIP3. Wildtype PH-R domain bound PIP3 with 1.9 +/- 0.2 nM affinity, while the affinity of a K370A/K397A substituted mutant was too low to measure. Wild-type ( but not the K370A/K397A substituted) full-length SHIP1 protein, reconstitutes normal inhibition of Fc gamma receptor-mediated phagocytosis when introduced into SHIP1(-/-) murine macrophages, reducing the number of phagocytic events by 2-fold as compared to SHIP1(-/-) cells. In fact, the PH-R-mediated membrane interaction appears to be a major mechanism by which SHIP1 is recruited to the membrane, since the K370A/K397A substitution reduced the recruitment of both full-length SHIP1 and the PH-R domain by >= 2-fold. We have previously shown that SHIP1 enzyme activity can be targeted for therapeutic purposes. The current studies suggest that molecules targeting the PH-R domain can also modulate SHIP1 function.-Ming-Lum, A., Shojania, S., So, E., McCarrell, E., Shaw, E., Vu, D., Wang, I., McIntosh, L. P., Mui, A. L. F. A pleckstrin homology-related domain in SHIP1 mediates membrane localization during Fc gamma receptor-induced phagocytosis. FASEB J. 26, 3163-3177 (2012). www.fasebj.org	[Ming-Lum, Andrew; So, Eva; McCarrell, Erin; Shaw, Eileen; Vu, David; Wang, Ida; Mui, Alice L-F] Univ British Columbia, Dept Surg, Vancouver, BC V6T 1W5, Canada; [Shojania, Shaheen; McIntosh, Lawrence P.; Mui, Alice L-F] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; [McIntosh, Lawrence P.] Univ British Columbia, Dept Chem, Vancouver, BC, Canada; [Ming-Lum, Andrew; So, Eva; McCarrell, Erin; Shaw, Eileen; Vu, David; Wang, Ida; Mui, Alice L-F] Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Mui, ALF (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	alice.mui@ubc.ca			Canadian Institutes for Health Research (CIHR) [MOP-84539]; Canadian Cancer Society Research Institute [017308]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	The authors gratefully acknowledge Dr. Gerald Krystal (University of British Columbia) for the SHIP1-deficient cells and his critical reading of the manuscript; Tina Chang (University of British Columbia) for performing experiments; and Raymond J. Andersen and Christopher J. Ong (University of British Columbia) for the reagents and their critical reading of the manuscript. Funding sources include the Canadian Institutes for Health Research (CIHR; MOP-84539 to A.L.F.M.) and the Canadian Cancer Society Research Institute (017308 to L.P.M). A.M.L. held CIHR doctoral research, Michael Smith Foundation for Health Research (MSFHR), and CIHR Transplantation Training Program graduate scholarships. S.S. held a CIHR Transplantation Training Program postdoctoral fellowship. D.V. held a CIHR Translational Research in Infectious Diseases scholarship. Instrument support for the biophysical studies was provided by the CIHR, the Canadian Foundation for Innovation, the British Columbia Knowledge Development Fund, the University of British Columbia Blusson Fund, and the MSFHR. Author contributions: A.M.L, S.S., L.P.M., and A.L.F.M. designed and performed research, analyzed data, and wrote the paper; E. So, E.M., E. Shaw, D.V., and I.W. performed experiments. Conflict of interest declaration: A.L.M., Raymond J. Andersen, Christopher J. Ong, and Gerald Krystal are scientific founders of Aquinox Pharmaceuticals. They do not receive compensation from the company, nor are they involved in day-to-day operations.	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Ai J, 2006, BLOOD, V107, P813, DOI 10.1182/blood-2005-05-1841; Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BLASI E, 1989, CANCER BIOCHEM BIOPH, V10, P303; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brooks R, 2010, J IMMUNOL, V184, P3582, DOI 10.4049/jimmunol.0902844; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; Damen JE, 2001, BLOOD, V97, P1343, DOI 10.1182/blood.V97.5.1343; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dewitt S, 2006, J CELL SCI, V119, P443, DOI 10.1242/jcs.02756; Dormann D, 2004, J CELL SCI, V117, P6497, DOI 10.1242/jcs.01579; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Edlich C, 2005, STRUCTURE, V13, P277, DOI 10.1016/j.str.2004.11.012; Ganesan LP, 2003, J BIOL CHEM, V278, P35710, DOI 10.1074/jbc.M305078200; Godard T., 2008, SPARKY 3 115; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Harris SJ, 2011, J IMMUNOL, V186, P4936, DOI 10.4049/jimmunol.1002350; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Huang ZY, 2003, J LEUKOCYTE BIOL, V73, P823, DOI 10.1189/jlb.0902454; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Jaumouille V., CURR OPIN CELL BIOL, V23, P22; Kamen LA, 2007, MOL BIOL CELL, V18, P2463, DOI 10.1091/mbc.e07-01-0061; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KEIGHTLEY DD, 1980, J STEROID BIOCHEM, V13, P1317, DOI 10.1016/0022-4731(80)90092-8; Kennah M, 2009, EXP HEMATOL, V37, P1274, DOI 10.1016/j.exphem.2009.08.001; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Kerr WG, 2011, GUT, V60, P177, DOI 10.1136/gut.2009.202283; KIENER PA, 1993, J BIOL CHEM, V268, P24442; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lehmann AK, 2000, J IMMUNOL METHODS, V243, P229, DOI 10.1016/S0022-1759(00)00237-4; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Lemmon MA, 2007, BIOCHEM SOC SYMP, V74, P81, DOI 10.1042/BSS2007c08; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MacDonald SM, 2002, MOL IMMUNOL, V38, P1323, DOI 10.1016/S0161-5890(02)00082-2; March ME, 2002, SEMIN IMMUNOL, V14, P37, DOI 10.1006/smim.2001.0340; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Marsh JA, 2006, PROTEIN SCI, V15, P2795, DOI 10.1110/ps.062465306; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; McLarren KW, 2011, AM J PATHOL, V179, P180, DOI 10.1016/j.ajpath.2011.03.018; Mehta P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021175; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Ong CJ, 2007, BLOOD, V110, P1942, DOI 10.1182/blood-2007-03-079699; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Shojania S, 2006, J BIOL CHEM, V281, P8347, DOI 10.1074/jbc.M510748200; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Swanson JA, 2004, J LEUKOCYTE BIOL, V76, P1093, DOI 10.1189/jlb.0804439; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wada T, 1999, ENDOCRINOLOGY, V140, P4585, DOI 10.1210/en.140.10.4585; Wientjes FB, 2003, CURR OPIN HEMATOL, V10, P2, DOI 10.1097/00062752-200301000-00002; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; Yogo K, 2006, ENDOCRINOLOGY, V147, P3307, DOI 10.1210/en.2005-1309; Zhang H., 2005, THRIFTY WEB SERVER V; Zhang Y., P NATL ACAD SCI US, V107, P19332	65	20	21	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3163	3177		10.1096/fj.11-201475	http://dx.doi.org/10.1096/fj.11-201475			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22651931				2022-12-28	WOS:000307162800008
J	Skaper, SD; Giusti, P; Facci, L				Skaper, Stephen D.; Giusti, Pietro; Facci, Laura			Microglia and mast cells: two tracks on the road to neuroinflammation	FASEB JOURNAL			English	Review						macrophages; innate immunity; inflammation; neurodegeneration; pain; neuroimmune interactions; endocannabinoids	CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; TOLL-LIKE RECEPTORS; FATTY-ACID AMIDE; NF-KAPPA-B; NEUROPATHIC PAIN; SPINAL-CORD	One of the more important recent advances in neuroscience research is the understanding that there is extensive communication between the immune system and the central nervous system (CNS). Proinflammatory cytokines play a key role in this communication. The emerging realization is that glia and microglia, in particular, (which are the brain's resident macrophages), constitute an important source of inflammatory mediators and may have fundamental roles in CNS disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Microglia respond also to proinflammatory signals released from other non-neuronal cells, principally those of immune origin. Mast cells are of particular relevance in this context. These immunity-related cells, while resident in the CNS, are capable of migrating across the blood-spinal cord and blood-brain barriers in situations where the barrier is compromised as a result of CNS pathology. Emerging evidence suggests the possibility of mast cell-glia communications and opens exciting new perspectives for designing therapies to target neuroinflammation by differentially modulating the activation of non-neuronal cells normally controlling neuronal sensitization, both peripherally and centrally. This review aims to provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of microglia, neuroimmune interactions involving mast cells, in particular, and the possibility that mast cell-microglia crosstalk may contribute to the exacerbation of acute symptoms of chronic neurodegenerative disease and accelerate disease progression, as well as promote pain transmission pathways. We conclude by considering the therapeutic potential of treating systemic inflammation or blockade of signaling pathways from the periphery to the brain in such settings.-Skaper, S. D., Giusti, P., Facci, L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 26, 3103-3117 (2012). www.fasebj.org	[Skaper, Stephen D.; Giusti, Pietro; Facci, Laura] Univ Padua, Dipartimento Sci Farmaco, I-35131 Padua, Italy	University of Padua	Skaper, SD (corresponding author), Univ Padua, Dipartimento Sci Farmaco, Largo E Meneghetti 2, I-35131 Padua, Italy.	stephen.skaper@unipd.it		GIUSTi, Pietro/0000-0001-9352-4046	Fondazione Cassa di Risparmio di Padova e Rovigo (CARIPARO), Progetto Dottorati di Ricerca	Fondazione Cassa di Risparmio di Padova e Rovigo (CARIPARO), Progetto Dottorati di Ricerca	The authors thank Stefano Lovison for excellent graphic design assistance. L.F. was supported by Fondazione Cassa di Risparmio di Padova e Rovigo (CARIPARO), Progetto Dottorati di Ricerca, Anno 2009.	Adams RA, 2007, CURR MED CHEM, V14, P2925, DOI 10.2174/092986707782360015; Alvarez JI, 2011, BBA-MOL BASIS DIS, V1812, P252, DOI 10.1016/j.bbadis.2010.06.017; Appel S H, 2011, Acta Myol, V30, P4; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Avigen Inc, 2006, AV333 CHRON NEUR PAI; Ballini E, 2011, BRIT J PHARMACOL, V163, P1315, DOI 10.1111/j.1476-5381.2011.01322.x; Barcia C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.17; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Bennett JL, 2009, J IMMUNOL, V182, P5507, DOI 10.4049/jimmunol.0801485; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bhangoo SK, 2007, BRAIN BEHAV IMMUN, V21, P581, DOI 10.1016/j.bbi.2006.12.003; Biber K, 2011, EMBO J, V30, P1864, DOI 10.1038/emboj.2011.89; Biran V, 2008, BRAIN PATHOL, V18, P1, DOI 10.1111/j.1750-3639.2007.00092.x; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Bulanova E, 2010, PURINERG SIGNAL, V6, P3, DOI 10.1007/s11302-009-9173-z; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Cerrato S, 2010, VET IMMUNOL IMMUNOP, V133, P9, DOI 10.1016/j.vetimm.2009.06.011; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Chew LJ, 2006, MENT RETARD DEV D R, V12, P105, DOI 10.1002/mrdd.20102; Chico LK, 2009, NAT REV DRUG DISCOV, V8, P892, DOI 10.1038/nrd2999; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cocchiara R, 1997, NEUROREPORT, V8, P2961, DOI 10.1097/00001756-199709080-00031; Cole SW, 2010, P NATL ACAD SCI USA, V107, P5681, DOI 10.1073/pnas.0911515107; Costa B, 2002, BRIT J PHARMACOL, V137, P413, DOI 10.1038/sj.bjp.0704900; Costa B, 2008, PAIN, V139, P541, DOI 10.1016/j.pain.2008.06.003; Crown ED, 2008, EXP NEUROL, V213, P257, DOI 10.1016/j.expneurol.2008.05.025; D'Agostino G, 2009, EUR J PHARMACOL, V613, P54, DOI 10.1016/j.ejphar.2009.04.022; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; De Filippis D, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-3; del Zoppo GJ, 2009, NEUROSCIENCE, V158, P972, DOI 10.1016/j.neuroscience.2008.08.028; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Done JD, 2012, J UROLOGY, V187, P1473, DOI 10.1016/j.juro.2011.11.116; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Engler H, 2011, BRAIN BEHAV IMMUN, V25, P1384, DOI 10.1016/j.bbi.2011.04.005; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Fellner L, 2011, ACTA NEUROPATHOL, V121, P675, DOI 10.1007/s00401-011-0833-z; Feuser K, 2012, CYTOKINE, V58, P178, DOI 10.1016/j.cyto.2012.01.001; Fiala M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-76; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Folgueras AR, 2009, P NATL ACAD SCI USA, V106, P16451, DOI 10.1073/pnas.0908507106; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Franklin A, 2003, J NEUROSCI, V23, P7767; Gaestel M, 2012, METHODS MOL BIOL, V795, P35, DOI 10.1007/978-1-61779-337-0_2; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Gasque P, 1997, AM J PATHOL, V150, P31; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gellera C, 2008, NEUROGENETICS, V9, P33, DOI 10.1007/s10048-007-0111-3; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Gosselin RD, 2010, NEUROSCIENTIST, V16, P519, DOI 10.1177/1073858409360822; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Graves MC, 2004, AMYOTROPH LATERAL SC, V5, P213, DOI 10.1080/14660820410020286; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Griffin RS, 2007, J NEUROSCI, V27, P8699, DOI 10.1523/JNEUROSCI.2018-07.2007; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Hamanaka Junya, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P107; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hayashi R, 2011, J PHARM SCI, V106, P559, DOI DOI 10.1254/JPHS.FP0072181; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Henkel JS, 2009, NEUROLOGY, V72, P1614, DOI 10.1212/WNL.0b013e3181a41228; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hinwood M, 2012, CEREB CORTEX, V22, P1442, DOI 10.1093/cercor/bhr229; HOSLI L, 1984, NEUROSCI LETT, V48, P287, DOI 10.1016/0304-3940(84)90052-1; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Inoue K, 2012, EXP NEUROL, V234, P293, DOI 10.1016/j.expneurol.2011.09.016; Itoh K, 2011, NEUROSCIENCE, V192, P721, DOI 10.1016/j.neuroscience.2011.06.083; Jankowski M. P., 2010, TRANSLATIONAL PAIN R; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Jin YX, 2007, DEV NEUROSCI-BASEL, V29, P373, DOI 10.1159/000105478; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; JOHNSON D, 1991, J NEUROPATH EXP NEUR, V50, P227, DOI 10.1097/00005072-199105000-00005; JOHNSON D, 1992, NEUROCHEM RES, V17, P939, DOI 10.1007/BF00993271; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khalil MH, 2003, J NEUROBIOL, V56, P113, DOI 10.1002/neu.10220; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; Kim DY, 2010, J IMMUNOL, V185, P273, DOI 10.4049/jimmunol.1000991; Kim D, 2007, J BIOL CHEM, V282, P14975, DOI 10.1074/jbc.M607277200; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Knerlich-Lukoschus F, 2011, J NEUROSURG-SPINE, V14, P583, DOI 10.3171/2010.12.SPINE10480; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Koda H, 2002, J NEUROPHYSIOL, V87, P2043, DOI 10.1152/jn.00593.2001; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kopsky DJ, 2012, ACUPUNCT MED, V30, P53, DOI 10.1136/acupmed-2011-010119; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kulka M, 2009, J LEUKOCYTE BIOL, V86, P1217, DOI 10.1189/jlb.0908517; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; LAMBRACHTHALL M, 1990, DEV BRAIN RES, V56, P151, DOI 10.1016/0165-3806(90)90077-C; Lazarini F, 2012, J NEUROSCI, V32, P3652, DOI 10.1523/JNEUROSCI.6394-11.2012; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Lee MK, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-57; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Levy D, 2012, BRAIN BEHAV IMMUN, V26, P311, DOI 10.1016/j.bbi.2011.09.016; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; Liu SR, 2012, J IMMUNOL, V188, P1098, DOI 10.4049/jimmunol.1101121; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; Lu DY, 2009, EUR J PHARMACOL, V613, P146, DOI 10.1016/j.ejphar.2009.03.001; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Martin-Moreno AM, 2011, MOL PHARMACOL, V79, P964, DOI 10.1124/mol.111.071290; Mattila OS, 2011, STROKE, V42, P3600, DOI 10.1161/STROKEAHA.111.632224; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; McNamee EN, 2010, NEUROPHARMACOLOGY, V59, P37, DOI 10.1016/j.neuropharm.2010.03.014; Medic N, 2008, J NEUROIMMUNOL, V200, P27, DOI 10.1016/j.jneuroim.2008.05.019; Medic N, 2010, J NEUROIMMUNOL, V218, P57, DOI 10.1016/j.jneuroim.2009.10.011; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Michaloudi H, 2003, DEV BRAIN RES, V140, P269, DOI 10.1016/S0165-3806(02)00613-2; Mika J, 2008, PHARMACOL REP, V60, P297; MILLIGAN ED, 2003, SEM PAIN MED, V1, P171, DOI DOI 10.1016/S1537-5897(03)00044-2); Mitterauer BJ, 2011, CNS NEUROSCI THER, V17, P333, DOI 10.1111/j.1755-5949.2009.00113.x; Moreno B, 2011, ANN NEUROL, V70, P932, DOI 10.1002/ana.22550; Muccioli GG, 2008, NEUROPHARMACOLOGY, V54, P16, DOI 10.1016/j.neuropharm.2007.05.015; Najjar S, 2011, NEUROLOGIST, V17, P249, DOI 10.1097/NRL.0b013e31822aad04; Nakagawa T, 2010, J PHARMACOL SCI, V114, P347, DOI 10.1254/jphs.10R04CP; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; Nicotra L, 2012, EXP NEUROL, V234, P316, DOI 10.1016/j.expneurol.2011.09.038; Niederhoffer N, 2009, INT J IMMUNOPATH PH, V22, P473, DOI 10.1177/039463200902200224; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x; Obata K, 2008, J NEUROCHEM, V105, P2249, DOI 10.1111/j.1471-4159.2008.05353.x; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Oliveira SM, 2011, EUR J PHARMACOL, V672, P88, DOI 10.1016/j.ejphar.2011.10.001; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pietrzak A, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/427473; Piette F, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt75; Polajeva J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025222; Prat Annik, 2011, J Aging Res, V2011, P251517, DOI 10.4061/2011/251517; Raghavendra V., 2003, ADV MOL CEL, V31, P951, DOI 10.1016/S1569-2558(03)31042-2; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Ribes S, 2010, NEUROSCI LETT, V482, P17, DOI 10.1016/j.neulet.2010.06.078; Rivat C, 2010, PAIN, V150, P358, DOI 10.1016/j.pain.2010.05.031; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; Sailasuta N, 2011, NEUROPSYCH DIS TREAT, V7, P495, DOI 10.2147/NDT.S23721; Sand E, 2009, NEUROPHARMACOLOGY, V56, P522, DOI 10.1016/j.neuropharm.2008.10.007; Sayed BA, 2011, J IMMUNOL, V186, P3294, DOI 10.4049/jimmunol.1003574; Schabitz WR, 2002, STROKE, V33, P2112, DOI 10.1161/01.STR.0000023491.63693.18; Schafer T, 2010, ALLERGY, V65, P1242, DOI 10.1111/j.1398-9995.2010.02350.x; Schafer D. P., 2011, Society for Neuroscience Abstract Viewer and Itinerary Planner, V41; Schymick JC, 2007, HUM MOL GENET, V16, pR233, DOI 10.1093/hmg/ddm215; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; SEELDRAYERS PA, 1992, J NEUROIMMUNOL, V36, P239, DOI 10.1016/0165-5728(92)90056-Q; Shi XQ, 2011, GLIA, V59, P231, DOI 10.1002/glia.21093; Silver R, 1996, TRENDS NEUROSCI, V19, P25, DOI 10.1016/0166-2236(96)81863-7; Silverman AJ, 2000, J NEUROSCI, V20, P401, DOI 10.1523/JNEUROSCI.20-01-00401.2000; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Skaper Stephen D, 2009, Cardiovasc Psychiatry Neurol, V2009, P545263, DOI 10.1155/2009/545263; Skaper SD, 2011, CNS NEUROL DISORD-DR, V10, P44; Skuljec J, 2011, CELL IMMUNOL, V270, P164, DOI 10.1016/j.cellimm.2011.05.001; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; Soruri A, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-29; Stadelmann C, 2002, BRAIN, V125, P75, DOI 10.1093/brain/awf015; Strbian D, 2007, CIRCULATION, V116, P411, DOI 10.1161/CIRCULATIONAHA.106.655423; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Subramanian V, 2008, HUM MOL GENET, V17, P130, DOI 10.1093/hmg/ddm290; Suk Kyoungho, 2012, Inflammopharmacology, V20, P151, DOI 10.1007/s10787-011-0108-2; Suzuki A, 2004, BIOL PHARM BULL, V27, P1891, DOI 10.1248/bpb.27.1891; Takata K, 2007, FEBS LETT, V581, P475, DOI 10.1016/j.febslet.2007.01.009; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37; THEOHARIDES TC, 1991, INT J IMMUNOPATH PH, V4, P137; THEOHARIDES TC, 1990, LIFE SCI, V46, P607, DOI 10.1016/0024-3205(90)90129-F; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Truini A, 2011, CNS NEUROL DISORD-DR, V10, P916, DOI 10.2174/187152711799219307; Tsuda M, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-28; Tynan RJ, 2010, BRAIN BEHAV IMMUN, V24, P1058, DOI 10.1016/j.bbi.2010.02.001; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Vichaya EG, 2011, J NEUROIMMUNOL, V239, P44, DOI 10.1016/j.jneuroim.2011.08.006; Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang XB, 2008, BIOCHEM BIOPH RES CO, V371, P283, DOI 10.1016/j.bbrc.2008.04.055; Wang YT, 2012, CURR DRUG TARGETS, V13, P166, DOI 10.2174/138945012799201603; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1; Watkins LR, 2001, PAIN, V93, P201, DOI 10.1016/S0304-3959(01)00359-1; Weller K, 2006, FASEB J, V20, P2366, DOI 10.1096/fj.06-5837fje; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Wood JD, 2011, CURR PHARM DESIGN, V17, P1573; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xanthos DN, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-42; Younan GJ, 2011, PLAST RECONSTR SURG, V128, p649E, DOI 10.1097/PRS.0b013e318230c55d; Yuan HB, 2010, J NEUROSCI RES, V88, P1348, DOI 10.1002/jnr.22304; Zhang HQ, 2011, NEUROTHERAPEUTICS, V8, P206, DOI 10.1007/s13311-011-0038-0; Zhang HY, 2010, CELL PHYSIOL BIOCHEM, V26, P327, DOI 10.1159/000320556; Zhang HY, 2010, CYTOKINE, V50, P138, DOI 10.1016/j.cyto.2010.02.006; Zhang XC, 2008, CEPHALALGIA, V28, P276, DOI 10.1111/j.1468-2982.2007.01523.x; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636; Zhuo M, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-31; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24; Zuo YX, 2003, PAIN, V105, P467, DOI 10.1016/S0304-3959(03)00261-6	241	176	182	1	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3103	3117		10.1096/fj.11-197194	http://dx.doi.org/10.1096/fj.11-197194			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22516295				2022-12-28	WOS:000307162800003
J	Zhao, KQ; Cowan, AT; Lee, RJ; Goldstein, N; Droguett, K; Chen, B; Zheng, CQ; Villalon, M; Palmer, JN; Kreindler, JL; Cohen, NA				Zhao, Ke-Qing; Cowan, Andrew T.; Lee, Robert J.; Goldstein, Natalia; Droguett, Karla; Chen, Bei; Zheng, Chunquan; Villalon, Manuel; Palmer, James N.; Kreindler, James L.; Cohen, Noam A.			Molecular modulation of airway epithelial ciliary response to sneezing	FASEB JOURNAL			English	Article						chronic rhinosinusitis; mucociliary clearance; ATP; calcium	BEAT FREQUENCY; EXTRACELLULAR ATP; INTRACELLULAR CALCIUM; PROTEIN-KINASE; CA2+ RELEASE; STIMULATION; TRANSPORT; CELLS; MECHANOSENSITIVITY; PHOSPHORYLATION	Our purpose was to evaluate the effect of the mechanical force of a sneeze on sinonasal cilia function and determine the molecular mechanism responsible for eliciting the ciliary response to a sneeze. A novel model was developed to deliver a stimulation simulating a sneeze (55 mmHg for 50 ms) at 26 degrees C to the apical surface of mouse and human nasal epithelial cells. Ciliary beating was visualized, and changes in ciliary beat frequency (CBF) were determined. To interrogate the molecular cascades driving sneeze-induced changes of CBF, pharmacologic manipulation of intra- and extracellular calcium, purinergic, PKA, and nitric oxide (NO) signaling were performed. CBF rapidly increases by >= 150% in response to a sneeze, which is dependent on the release of adenosine triphosphate (ATP), calcium influx, and PKA activation. Furthermore, apical release of ATP is independent of calcium influx, but calcium influx and subsequent increase in CBF are dependent on the ATP release. Lastly, we observed a blunted ciliary response in surgical specimens derived from patients with chronic rhinosinusitis compared to control patients. Apical ATP release with subsequent calcium mobilization and PKA activation are involved in sinonasal ciliary response to sneezing, which is blunted in patients with upper-airway disease.-Zhao, K.-Q., Cowan, A. T., Lee, R. J., Goldstein, N., Droguett, K., Chen, B., Zheng, C., Villalon, M., Palmer, J. N., Kreindler, J. L., Cohen, N. A. Molecular modulation of airway epithelial ciliary response to sneezing. FASEB J. 26, 3178-3187 (2012). www.fasebj.org	[Zhao, Ke-Qing; Lee, Robert J.; Goldstein, Natalia; Chen, Bei; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Zhao, Ke-Qing; Zheng, Chunquan] Fudan Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Shanghai Med, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China; [Cowan, Andrew T.] Temple Univ, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA; [Droguett, Karla; Villalon, Manuel] Pontificia Univ Catolica Chile, Dept Physiol, Santiago, Chile; [Goldstein, Natalia] Pontificia Univ Catolica Chile, Dept Med Sci, Santiago, Chile; [Kreindler, James L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Kreindler, James L.] Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA; [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA	University of Pennsylvania; Fudan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Cohen, NA (corresponding author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.	cohenn@uphs.upenn.edu	Lee, Robert J./L-4397-2017	Lee, Robert J./0000-0001-5826-6686; Cohen, Noam/0000-0002-9462-3932	Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator Award (CIA) grant [082478]; Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) grant [1080679]; Proyecto Anillo ACT-79; Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant [24090041]	Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator Award (CIA) grant; Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) grant(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Proyecto Anillo ACT-79(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT PIA/ANILLOS); Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT))	Financial support for these experiments was provided by Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator Award (CIA) grant 082478 to N.A.C., Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) grant 1080679 to M.V., Proyecto Anillo ACT-79 to K.D., and Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant 24090041 to M.V.	Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112531; Bonfils P, 2005, ANN OTO RHINOL LARYN, V114, P74, DOI 10.1177/000348940511400114; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Braiman A, 1998, AM J PHYSIOL-CELL PH, V275, pC790, DOI 10.1152/ajpcell.1998.275.3.C790; Braverman I, 1998, J OTOLARYNGOL, V27, P145; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Chen B, 2007, AM J RHINOL, V21, P346, DOI 10.2500/ajr.2007.21.3029; Chen B, 2006, AM J RHINOL, V20, P325, DOI 10.2500/ajr.2006.20.2870; Cherry Donald K, 2002, Adv Data, P1; Cohen NA, 2006, ANN OTO RHINOL LARYN, V115, P20; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Gwaltney JM, 2000, CLIN INFECT DIS, V30, P387, DOI 10.1086/313661; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; Hochstrasser M, 1996, J EUKARYOT MICROBIOL, V43, P356, DOI 10.1111/j.1550-7408.1996.tb04000.x; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Kultgen PL, 2002, MOL BIOL CELL, V13, P4156, DOI 10.1091/mbc.E02-07-0391; Lansley AB, 1999, BIOPHYS J, V77, P629, DOI 10.1016/S0006-3495(99)76919-5; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Lin L, 2010, HISTOCHEM CELL BIOL, V134, P93, DOI 10.1007/s00418-010-0717-7; Ly Nghi, 2002, Adv Data, P1; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; Ma WY, 2002, J GEN PHYSIOL, V120, P875, DOI 10.1085/jgp.20028695; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Mwimbi XKMS, 2003, CELL SIGNAL, V15, P395, DOI 10.1016/S0898-6568(02)00143-2; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Ramsingh R, 2011, AM J PHYSIOL-LUNG C, V300, pL587, DOI 10.1152/ajplung.00345.2010; SADE J, 1970, AM REV RESPIR DIS, V102, P48; SALATHE M, 1993, J CELL SCI, V106, P1211; Salathe M, 1999, J PHYSIOL-LONDON, V520, P851, DOI 10.1111/j.1469-7793.1999.00851.x; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SANDERSON MJ, 1986, P NATL ACAD SCI USA, V83, P7302, DOI 10.1073/pnas.83.19.7302; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Shaari J, 2006, AM J RHINOL, V20, P150, DOI 10.1177/194589240602000205; Sisson JH, 2003, J MICROSC-OXFORD, V211, P103, DOI 10.1046/j.1365-2818.2003.01209.x; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726; Speert D. P., 2006, NOVART FDN SYMP, V279, P51; Speert D. P., 2006, NOVART FDN SYMP, V279, P216; Speert David P, 2006, Novartis Found Symp, V279, P42; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; VILLALON M, 1989, BIOPHYS J, V56, P1255, DOI 10.1016/S0006-3495(89)82772-9; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; WEISS T, 1992, J MEMBRANE BIOL, V127, P185; Winters SL, 2007, AM J PHYSIOL-LUNG C, V292, pL614, DOI 10.1152/ajplung.00288.2005; WONG LB, 1992, AM J RESP CELL MOL, V7, P447, DOI 10.1165/ajrcmb/7.4.447; Wyatt TA, 2001, AM J PHYSIOL-LUNG C, V281, pL575, DOI 10.1152/ajplung.2001.281.3.L575; Yang B, 1997, ANN OTO RHINOL LARYN, V106, P230, DOI 10.1177/000348949710600309; Zhang L, 2003, J PHYSIOL-LONDON, V551, P765, DOI 10.1113/jphysiol.2003.041707; Zhang L, 2003, J PHYSIOL-LONDON, V546, P733, DOI 10.1113/jphysiol.2002.028704; Zhang L, 2008, ORL-J OTO-RHIN-LARYN, V70, P91, DOI 10.1159/000114531; Zhou HB, 2009, INHAL TOXICOL, V21, P875, DOI 10.1080/08958370802555898; Zsembery A, 2003, J BIOL CHEM, V278, P13398, DOI 10.1074/jbc.M212277200	58	33	33	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3178	3187		10.1096/fj.11-202184	http://dx.doi.org/10.1096/fj.11-202184			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22516297				2022-12-28	WOS:000307162800009
J	Jia, Y; Suzuki, N; Yamamoto, M; Gassmann, M; Noguchi, CT				Jia, Yi; Suzuki, Norio; Yamamoto, Masayuki; Gassmann, Max; Noguchi, Constance Tom			Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage	FASEB JOURNAL			English	Article						PI3K/Akt; myoblast; wound healing; transgenic mice	MICE OVEREXPRESSING ERYTHROPOIETIN; STEM-CELLS; EXCESSIVE ERYTHROCYTOSIS; RECEPTOR; ACTIVATION; ANGIOGENESIS; EXPRESSION; GATA-1; DIFFERENTIATION; PROLIFERATION	Erythropoietin acts by binding to its cell surface receptor on erythroid progenitor cells to stimulate erythrocyte production. Erythropoietin receptor expression in nonhematopoietic tissue, including skeletal muscle progenitor cells, raises the possibility of a role for erythropoietin beyond erythropoiesis. Mice with erythropoietin receptor restricted to hematopoietic tissue were used to assess contributions of endogenous erythropoietin to promote skeletal myoblast proliferation and survival and wound healing in a mouse model of cardiotoxin induced muscle injury. Compared with wild-type controls, these mice had fewer skeletal muscle Pax-7(+) satellite cells and myoblasts that do not proliferate in culture, were more susceptible to skeletal muscle injury and reduced maximum load tolerated by isolated muscle. In contrast, mice with chronic elevated circulating erythropoietin had more Pax-7(+) satellite cells and myoblasts with increased proliferation and survival in culture, decreased muscle injury, and accelerated recovery of maximum load tolerated by isolated muscle. Skeletal muscle myoblasts also produced endogenous erythropoietin that increased at low O-2. Erythropoietin promoted proliferation, survival, and wound recovery in myoblasts via the phosphoinositide 3-kinase/AKT pathway. Therefore, endogenous and exogenous erythropoietin contribute to increasing satellite cell number following muscle injury, improve myoblast proliferation and survival, and promote repair and regeneration in this mouse induced muscle injury model independent of its effect on erythrocyte production.-Jia, Y., Suzuki, N., Yamamoto, M., Gassmann, M., Noguchi, C. T. Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage. FASEB J. 26, 2847-2858 (2012). www.fasebj.org	[Jia, Yi; Noguchi, Constance Tom] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; [Suzuki, Norio; Yamamoto, Masayuki] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Gassmann, Max] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland; [Gassmann, Max] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Gassmann, Max] UPCH, Lima, Peru	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tohoku University; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Universidad Peruana Cayetano Heredia	Noguchi, CT (corresponding author), NIDDK, Mol Med Branch, NIH, Bldg 10,Rm 9N319,10 Ctr Dr,MSC 1822, Bethesda, MD 20892 USA.	connien@mail.nih.gov	Yamamoto, Masayuki/A-4873-2010; Suzuki, Norio/F-3456-2010; Suzuki, Norio/AAZ-9458-2021	Yamamoto, Masayuki/0000-0002-9073-9436; Suzuki, Norio/0000-0001-6100-3350; Gassmann, Max/0000-0003-2750-8878	National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025103] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Li Wang, Heather Rogers, Susan E. Ivie, and Xiaobing Yu for their contributions in studies on transcription regulation and position-holding time. Funding is provided by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. Author contributions: Y.J. performed conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; N.S. provided study material and data analysis and interpretation; M.Y. provided study material and data analysis and interpretation; M. G. provided study material and data analysis and interpretation; and C.T.N. provided conception and design, financial support, data analysis and interpretation, manuscript writing, and final approval of manuscript.	Abedi M, 2007, BRIT J HAEMATOL, V138, P792, DOI 10.1111/j.1365-2141.2007.06720.x; Ameln H, 2005, FASEB J, V19, P1009, DOI 10.1096/fj.04-2304fje; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Cosgrove BD, 2009, DIFFERENTIATION, V78, P185, DOI 10.1016/j.diff.2009.08.004; Deng HB, 2011, INT J BIOCHEM CELL B, V43, P409, DOI 10.1016/j.biocel.2010.11.011; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Fu P, 2007, BIOCHEM BIOPH RES CO, V354, P372, DOI 10.1016/j.bbrc.2007.01.044; Fukada S, 2008, EXP CELL RES, V314, P193, DOI 10.1016/j.yexcr.2007.09.020; Gassmann M, 2008, BIOL REPROD, V78, P1049, DOI 10.1095/biolreprod.107.065532; Hagstrom L, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/137817; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; Heinicke K, 2006, AM J PHYSIOL-REG I, V291, pR947, DOI 10.1152/ajpregu.00152.2006; Jia Y, 2009, FASEB J, V23, P3089, DOI 10.1096/fj.09-130237; Katz O, 2010, J ENDOCRINOL, V205, P87, DOI 10.1677/JOE-09-0425; Kawamura I, 2010, AM J PHYSIOL-HEART C, V299, pH372, DOI 10.1152/ajpheart.00035.2010; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Lundby C, 2008, J APPL PHYSIOL, V104, P1154, DOI 10.1152/japplphysiol.01211.2007; Mao WK, 2008, J MOL CELL CARDIOL, V45, P250, DOI 10.1016/j.yjmcc.2008.05.010; Nakano M, 2007, CIRC RES, V100, P662, DOI 10.1161/01.RES.0000260179.43672.fe; Nouette-Gaulain K, 2009, ANESTHESIOLOGY, V110, P648, DOI 10.1097/ALN.0b013e3181974f7a; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Pelletier S, 2006, MOL CELL BIOL, V26, P8527, DOI 10.1128/MCB.01035-06; Quaschning T, 2002, FASEB J, V16, P259, DOI 10.1096/fj.02-0296fje; Ren HX, 2010, P NATL ACAD SCI USA, V107, P5857, DOI 10.1073/pnas.0909570107; Rotter R, 2008, J ORTHOP RES, V26, P1618, DOI 10.1002/jor.20692; Rundqvist H, 2009, EUR J ENDOCRINOL, V161, P427, DOI 10.1530/EJE-09-0342; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Schuler B, 2010, P NATL ACAD SCI USA, V107, P419, DOI 10.1073/pnas.0912924107; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tedesco FS, 2010, J CLIN INVEST, V120, P11, DOI 10.1172/JCI40373; Teng RF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1526; Teng RF, 2011, BASIC RES CARDIOL, V106, P343, DOI 10.1007/s00395-011-0158-z; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Um M, 2007, CELL SIGNAL, V19, P634, DOI 10.1016/j.cellsig.2006.08.014; Wang KP, 2008, J BIOL CHEM, V283, P34029, DOI 10.1074/jbc.M803012200; Westenbrink BD, 2008, CARDIOVASC DRUG THER, V22, P265, DOI 10.1007/s10557-008-6094-y; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yu XB, 2002, DEVELOPMENT, V129, P505; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	44	36	36	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2847	2858		10.1096/fj.11-196618	http://dx.doi.org/10.1096/fj.11-196618			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22490927	Green Published			2022-12-28	WOS:000305912500013
J	Vidal, R; Sammeta, N; Garringer, HJ; Sambamurti, K; Miravalle, L; Lamb, BT; Ghetti, B				Vidal, Ruben; Sammeta, Neeraja; Garringer, Holly J.; Sambamurti, Kumar; Miravalle, Leticia; Lamb, Bruce T.; Ghetti, Bernardino			The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice	FASEB JOURNAL			English	Article						presenilin; A beta PP processing; animal model	ALZHEIMERS-DISEASE; A-BETA; MUTANT FORM; APP MUTATIONS; ANIMAL-MODELS; MOUSE MODEL; IN-VIVO; SECRETASE; EXPRESSION; GENE	Genetically engineered mice have been generated to model cerebral beta-amyloidosis, one of the hallmarks of Alzheimer disease (AD) pathology, based on the overexpression of a mutated cDNA of the amyloid-beta precursor protein (A beta PP) or by knock-in of the murine A beta PP gene alone or with presenilin 1 mutations. Here we describe the generation and initial characterization of a new mouse line based on the presence of 2 copies of the human genomic region encoding the wild-type A beta PP and the L166P presenilin 1 mutation. At similar to 6 mo of age, double-mutant mice develop amyloid pathology, with signs of neuritic dystrophy, intracellular A beta accumulation, and glial inflammation, an increase in A beta PP C-terminal fragments, and an 8 times increase in A beta 42 levels with a 40% decrease in A beta 40 levels, leading to a significant increase (14 times) of A beta 42/A beta 40 ratios, with minimal effects on presenilin or the Notch1 pathway in the brain. We conclude that in mice, neither mutations in A beta PP nor overexpression of an A beta PP isoform are a prerequisite for A beta pathology. This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant A beta PP isoform using exogenous promoters.-Vidal, R., Sammeta, N., Garringer, H. J., Sambamurti, K., Miravalle, L., Lamb B. T., Ghetti, B. The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. FASEB J. 26, 2899-2910 (2012). www.fasebj.org	[Vidal, Ruben; Sammeta, Neeraja; Garringer, Holly J.; Miravalle, Leticia; Ghetti, Bernardino] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Vidal, Ruben; Sammeta, Neeraja; Garringer, Holly J.; Miravalle, Leticia; Ghetti, Bernardino] Indiana Univ, Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN 46202 USA; [Sambamurti, Kumar] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Lamb, Bruce T.] Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina; Cleveland Clinic Foundation	Vidal, R (corresponding author), Indiana Univ, Sch Med, Dept Pathol & Lab Med, 635 Barnhill Dr,MSB A136, Indianapolis, IN 46202 USA.	rvidal@iupui.edu	Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214	U.S. National Institute on Neurological Disorders and Stroke [NS050227, NS14426]; U.S. National Institute on Aging [AG037338, AG10133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050227, R01NS014426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG010133, R21AG037338] Funding Source: NIH RePORTER	U.S. National Institute on Neurological Disorders and Stroke; U.S. National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Debra Lucas and Rose Richardson for technical assistance and Dr. Jose Bonnin for helpful comments. The authors acknowledge the help of the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core (Charlottesville, VA, USA) for the determination of FSH and LH levels in serum. This study was supported by U.S. National Institute on Neurological Disorders and Stroke grants NS050227 (R. V.) and NS14426 (B. G.) and U.S. National Institute on Aging grants AG037338 (R. V.) and AG10133 (B. G.). Author contributions: R. V. and B. G. conceived and designed the experiments; R. V., N.S., L. M., and H.J.G. performed the experiments; R. V., N.S., H.J.G., K. S., B. T. L., and B. G. analyzed the data; R. V. and B. G. wrote the paper.	Ashe KH, 2010, NEURON, V66, P631, DOI 10.1016/j.neuron.2010.04.031; Barbeito AG, 2009, J NEUROCHEM, V109, P1067, DOI 10.1111/j.1471-4159.2009.06028.x; Bentahir M, 2006, J NEUROCHEM, V96, P732, DOI 10.1111/j.1471-4159.2005.03578.x; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Cole SL, 2008, J BIOL CHEM, V283, P29621, DOI 10.1074/jbc.R800015200; Crews L, 2010, BRAIN STRUCT FUNCT, V214, P111, DOI 10.1007/s00429-009-0232-6; De Jonghe C, 2001, HUM MOL GENET, V10, P1665, DOI 10.1093/hmg/10.16.1665; Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Gotz J, 2008, NAT REV NEUROSCI, V9, P532, DOI 10.1038/nrn2420; Guo QX, 2012, CELL RES, V22, P78, DOI 10.1038/cr.2011.116; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; Holtzman DM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002369; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kokjohn TA, 2009, ALZHEIMERS DEMENT, V5, P340, DOI 10.1016/j.jalz.2009.03.002; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; Menendez-Gonzalez M, 2005, NEURODEGENER DIS, V2, P277, DOI 10.1159/000092315; Miravalle L, 2005, BIOCHEMISTRY-US, V44, P10810, DOI 10.1021/bi0508237; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murrell J, 2000, J NEUROPATH EXP NEUR, V59, P466; Parent A. T., 2010, INT J ALZHEIMERS DIS, V2010, pii; Pimplikar SW, 2009, INT J BIOCHEM CELL B, V41, P1261, DOI 10.1016/j.biocel.2008.12.015; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Saito T, 2011, NAT NEUROSCI, V14, P1023, DOI 10.1038/nn.2858; Sambamurti K, 2011, J NEUROCHEM, V117, P359, DOI 10.1111/j.1471-4159.2011.07213.x; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Trombly DJ, 2009, ENDOCRINOLOGY, V150, P1014, DOI 10.1210/en.2008-0213; Vidal R, 2008, J NEUROSCI, V28, P60, DOI 10.1523/JNEUROSCI.3962-07.2008; Vidal R, 2009, BRAIN PATHOL, V19, P58, DOI 10.1111/j.1750-3639.2008.00164.x; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3	39	11	11	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2899	2910		10.1096/fj.12-205542	http://dx.doi.org/10.1096/fj.12-205542			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459153	Green Published			2022-12-28	WOS:000305912500018
J	Bertacchini, J; Beretti, F; Cenni, V; Guida, M; Gibellini, F; Mediani, L; Marin, O; Maraldi, NM; de Pol, A; Lattanzi, G; Cocco, L; Marmiroli, S				Bertacchini, Jessika; Beretti, Francesca; Cenni, Vittoria; Guida, Marianna; Gibellini, Federica; Mediani, Laura; Marin, Oriano; Maraldi, Nadir M.; de Pol, Anto; Lattanzi, Giovanna; Cocco, Lucio; Marmiroli, Sandra			The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression	FASEB JOURNAL			English	Article						14.3.3; lamina phosphorylation; nuclear signaling; nucleus; cell cycle	LAMIN-A; NUCLEAR-ENVELOPE; PHOSPHORYLATION; AKT; ACTIVATION; LOCALIZATION; SUBSTRATE; APOPTOSIS; AUTOPHAGY; EXTENDS	The serine/threonine kinase Akt/PKB is a major signaling hub integrating metabolic, survival, growth, and cell cycle regulatory signals. The definition of the phospho-motif cipher driving phosphorylation by Akt led to the identification of hundreds of putative substrates, and it is therefore pivotal to identify those whose phosphorylation by Akt is of consequence to biological processes. The Lmna gene products lamin A/C and the lamin A precursor prelamin A are type V intermediate filament proteins forming a filamentous meshwork, the lamina, underneath the inner nuclear membrane, for nuclear envelope structures organization and interphase chromatin anchoring. In our previous work, we reported that A-type lamins are phosphorylated by Akt at S301 and S404 in physiological conditions and are therefore bona fide substrates of Akt. We report here that Akt phosphorylation at S404 targets the precursor prelamin A for degradation. We further demonstrate that Akt also regulates Lmna transcription. Our study unveils a previously unknown function of Akt in the control of prelamin A stability and expression. Moreover, given the large number of diseases related to prelamin A, our findings represent a further important step bridging basic A-type lamin physiology to therapeutic approaches for lamin A-linked disorders.	[Bertacchini, Jessika; Beretti, Francesca; Guida, Marianna; Gibellini, Federica; Mediani, Laura; de Pol, Anto; Marmiroli, Sandra] Univ Modena & Reggio Emilia, Cellular Signaling Lab, Dept Surg Med Dent & Morphol, I-41124 Modena, Italy; [Bertacchini, Jessika; Guida, Marianna; Maraldi, Nadir M.; Cocco, Lucio] Univ Bologna, Dept Biomed Sci, Cellular Signaling Lab, Bologna, Italy; [Cenni, Vittoria; Maraldi, Nadir M.; Lattanzi, Giovanna; Marmiroli, Sandra] Natl Res Council Italy CNR, Inst Mol Genet, IOR, Bologna, Italy; [Marin, Oriano] Univ Padua, Dept Biomed Sci, Padua, Italy	Universita di Modena e Reggio Emilia; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Padua	Marmiroli, S (corresponding author), Univ Modena & Reggio Emilia, Cellular Signaling Lab, Dept Surg Med Dent & Morphol, Via Pozzo 71, I-41124 Modena, Italy.	sandra.marmiroli@unimore.it	BERTACCHINI, JESSIKA/F-4382-2017; Lattanzi, Giovanna/AAY-3186-2020; LATTANZI, GIOVANNA/P-8214-2015; Cenni, Vittoria/C-7361-2019; Cocco, Lucio/AAI-2206-2020; Marmiroli, Sandra/J-5242-2016	BERTACCHINI, JESSIKA/0000-0001-9218-9215; Lattanzi, Giovanna/0000-0002-7103-8722; LATTANZI, GIOVANNA/0000-0002-7103-8722; Cenni, Vittoria/0000-0001-8062-1840; Cocco, Lucio/0000-0002-9206-8277; Marmiroli, Sandra/0000-0001-5545-9319; DE POL, Anto/0000-0003-4279-5422; Mediani, Laura/0000-0002-5870-1155	Fondazione Angela Serra for Cancer Research (Modena, Italy); Italian Ministero dell'Istruzione; dell'Universita e della Ricerca (MIUR)-Programma di Ricerca di Rilevante Interesse Nazionale (PRIN); MIUR-Fondo per gli Investimenti della Ricerca di Base; MIUR-FIRB; Fondazione Carisbo, and Associazione Italiana Progeria Sammy Basso (AIProSaB) Italy	Fondazione Angela Serra for Cancer Research (Modena, Italy); Italian Ministero dell'Istruzione(Ministry of Education, Universities and Research (MIUR)); dell'Universita e della Ricerca (MIUR)-Programma di Ricerca di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR)); MIUR-Fondo per gli Investimenti della Ricerca di Base; MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Fondazione Carisbo, and Associazione Italiana Progeria Sammy Basso (AIProSaB) Italy	The authors are grateful to Maria Ruzzene for helpful discussion, to Loren Fong (University of California, Los Angeles, CA, USA) for antibodies against prelamin A, and to Giacomo Spinsanti for skillful technical assistance with realtime PCR. S.M. and J.B. acknowledge the "International Short Term Mobility Program" from Italian Consiglio Nazionale delle Ricerche (CNR) and Fondazione CaRiMo, respectively. M.G. was supported in part by Fondazione Angela Serra for Cancer Research (Modena, Italy). This work was supported by grants from Italian Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)-Programma di Ricerca di Rilevante Interesse Nazionale (PRIN), MIUR-Fondo per gli Investimenti della Ricerca di Base (FIRB; Human Proteome Net), MIUR-FIRB (Accordi di Programma 2010), Fondazione Carisbo, and Associazione Italiana Progeria Sammy Basso (AIProSaB) Italy.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Butin-Israeli V, 2012, TRENDS GENET, V28, P464, DOI 10.1016/j.tig.2012.06.001; Cao K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002346; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Cenni V, 2011, EUR J HISTOCHEM, V55, P200, DOI 10.4081/ejh.2011.e36; Cenni V, 2008, J PROTEOME RES, V7, P4727, DOI 10.1021/pr800262g; Cenni V, 2011, MOL BIOL CELL, V22, P2946, DOI 10.1091/mbc.E10-11-0928; Christofk HR, 2011, J PROTEOME RES, V10, P4158, DOI 10.1021/pr200578n; Coffinier C, 2010, J BIOL CHEM, V285, P20818, DOI 10.1074/jbc.M110.128835; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; Davies BSJ, 2011, NUCLEUS-PHILA, V2, P4, DOI [10.4161/nucl.2.1.13723, 10.1093/hmg/ddq158]; Davies BSJ, 2009, ANNU REV GENOM HUM G, V10, P153, DOI 10.1146/annurev-genom-082908-150150; Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Graziotto JJ, 2012, AUTOPHAGY, V8, P147, DOI 10.4161/auto.8.1.18331; Jung HJ, 2012, P NATL ACAD SCI USA, V109, pE423, DOI 10.1073/pnas.1111780109; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maraldi NM, 2011, J CELL BIOCHEM, V112, P979, DOI 10.1002/jcb.22992; Maraldi T, 2009, MOL HUM REPROD, V15, P499, DOI 10.1093/molehr/gap048; Maraldi T, 2011, INT J ONCOL, V38, P427, DOI 10.3892/ijo.2010.850; Margalit A, 2007, TRENDS CELL BIOL, V17, P202, DOI 10.1016/j.tcb.2007.02.004; Marmiroli S, 2009, J CELL PHYSIOL, V220, P553, DOI 10.1002/jcp.21807; Mattioli E, 2011, CELL DEATH DIFFER, V18, P1305, DOI 10.1038/cdd.2010.183; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Mirandola P, 2006, INT J ONCOL, V28, P127; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Muchir A, 2010, DEV CELL, V19, P355, DOI 10.1016/j.devcel.2010.08.019; Muralikrishna B, 2001, EUR J BIOCHEM, V268, P3736, DOI 10.1046/j.1432-1327.2001.02281.x; Naetar N, 2008, NAT CELL BIOL, V10, P1341, DOI 10.1038/ncb1793; Okumura K, 2004, BIOCHEM BIOPH RES CO, V320, P487, DOI 10.1016/j.bbrc.2004.05.191; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Prokocimer M, 2009, J CELL MOL MED, V13, P1059, DOI [10.1111/j.1582-4934.2009.00676.x, 10.1111/j.1582-4934.2008.00676.x]; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Stewart CL, 2007, SCIENCE, V318, P1408, DOI 10.1126/science.1142034; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; Worman HJ, 2012, J PATHOL, V226, P316, DOI 10.1002/path.2999	53	58	61	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2145	2155		10.1096/fj.12-218214	http://dx.doi.org/10.1096/fj.12-218214			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430973				2022-12-28	WOS:000319667600006
J	Besaratinia, A; Tommasi, S				Besaratinia, Ahmad; Tommasi, Stella			Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions	FASEB JOURNAL			English	Review						4-aminobiphenyl; 4-ABP; carcinogenesis; DNA adducts; mutation; tumorigenesis	CARCINOGEN 4-AMINOBIPHENYL; DNA-ADDUCTS; METABOLIC-ACTIVATION; MUTATIONAL SPECTRUM; URINARY-BLADDER; LUNG-CANCER; GENE; METHYLATION; RISK; SELECTION	Bladder cancer is a significant public health problem, worldwide. In the United States, bladder cancer is the fourth most common cancer in men, and its recurrence rate is the highest among all malignancies. Tobacco smoking is the leading risk factor for bladder cancer. The risk of bladder cancer is directly related to the intensity and duration of smoking, while quitting smoking reduces this risk. The increased risk of smokers for developing bladder cancer is attributable to their exposure to aromatic amines, which constitute a family of known bladder carcinogens present in tobacco smoke. The underlying mechanism of action of aromatic amines in the genesis of bladder cancer is not, however, fully delineated. Research has identified a genotoxic mode of action, specifically DNA adduction and mutagenicity, for aromatic amines, which may account for their carcinogenicity. The present review summarizes our current knowledge on the DNA adduction and mutagenicity of aromatic amines in relation to smoking-associated bladder cancer. For illustrative purposes, representative results from published research on aromatic amine-induced DNA adduction and mutagenesis are discussed. The direction of future research on the underlying mechanisms of tobacco smoke-associated bladder carcinogenesis is also outlined. Understanding the molecular mechanisms of bladder carcinogenesis is essential for improving future strategies for prevention, early detection, treatment, and prognosis of this malignancy.	[Besaratinia, Ahmad; Tommasi, Stella] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA	University of Southern California	Besaratinia, A (corresponding author), Univ So Calif, Dept Prevent Med, Keck Sch Med, M-C 9603, Los Angeles, CA 90089 USA.	besarati@usc.edu		Tommasi, Stella/0000-0001-6897-4985; Besaratinia, Ahmad/0000-0001-7231-228X	American Cancer Society [RSG-11-083-01-CNE]; University of California Tobacco-Related Disease Research Program [18KT-0040, 20XT-0116]	American Cancer Society(American Cancer Society); University of California Tobacco-Related Disease Research Program(University of California System)	This work was supported by grants from the American Cancer Society (RSG-11-083-01-CNE) and the University of California Tobacco-Related Disease Research Program (18KT-0040 and 20XT-0116) to A.B.	ALATRASH J, 1995, CHEM RES TOXICOL, V8, P747, DOI 10.1021/tx00047a015; American Cancer Society, 2012, CANC FACTS FIG 2012; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; BARTSCH H, 1993, EUR J CANCER, V29A, P1199, DOI 10.1016/S0959-8049(05)80315-6; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; BELAND FA, 1990, CHEM CARCINOGENESIS, V1, P297; Besaratinia A, 2002, CANCER RES, V62, P4331; Besaratinia A, 2008, LANCET ONCOL, V9, P657, DOI 10.1016/S1470-2045(08)70172-4; Besaratinia A, 2008, FASEB J, V22, P2379, DOI 10.1096/fj.07-105437; Besaratinia A, 2006, CARCINOGENESIS, V27, P1526, DOI 10.1093/carcin/bgi311; Besaratinia A, 2005, CARCINOGENIC EFFECTS OF POLYCYCLIC AROMATIC HYDROCARBONS, P171; Besaratinia Ahmad, 2012, Methods Mol Biol, V920, P189, DOI 10.1007/978-1-61779-998-3_14; Besaratinia A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks610; Besaratinia A, 2009, METHODS, V48, P35, DOI 10.1016/j.ymeth.2009.02.008; Biesecker LG, 2010, NAT GENET, V42, P13, DOI 10.1038/ng0110-13; Boffetta P, 2008, SCAND J UROL NEPHROL, V42, P45, DOI 10.1080/03008880802283664; BROYDE S, 1985, CARCINOGENESIS, V6, P719, DOI 10.1093/carcin/6.5.719; Chen H H, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.77.pl1; Chen T, 2005, INT J CANCER, V117, P182, DOI 10.1002/ijc.21173; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; CHOU HC, 1995, CARCINOGENESIS, V16, P413, DOI 10.1093/carcin/16.2.413; CLAVEL J, 1989, INT J CANCER, V44, P605, DOI 10.1002/ijc.2910440408; Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8; Curigliano G, 1996, CARCINOGENESIS, V17, P911, DOI 10.1093/carcin/17.5.911; DAVANZO B, 1990, EUR J CANCER, V26, P714, DOI 10.1016/0277-5379(90)90124-C; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; Dudziec E, 2011, EPIGENOMICS-UK, V3, P35, DOI 10.2217/EPI.10.71; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Faraglia B, 2003, CARCINOGENESIS, V24, P719, DOI 10.1093/carcin/bgg013; Feng ZH, 2002, J NATL CANCER I, V94, P1527; FREDERICKSON SM, 1992, CARCINOGENESIS, V13, P955, DOI 10.1093/carcin/13.6.955; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hecht SS, 2008, CHEM RES TOXICOL, V21, P160, DOI 10.1021/tx7002068; Hsu TM, 1997, CANCER EPIDEM BIOMAR, V6, P193; Hussain SP, 1998, CANCER RES, V58, P4023; *INT AG RES CANC, 1974, SOM AR AM HYDR REL S, P97; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; KADLUBAR FF, 1988, MICROSOMES DRUG OXID, P370; KADLUBAR FF, 1982, ENV MUTAGENS CARCINO, P385; Kim SI, 2012, FASEB J, V26, P1845, DOI 10.1096/fj.11-199984; Komura J, 1998, NUCLEIC ACIDS RES, V26, P1807, DOI 10.1093/nar/26.7.1807; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Lambert LB, 2005, MUTAT RES-REV MUTAT, V590, P1, DOI 10.1016/j.mrrev.2005.04.002; Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; Manjanatha MG, 1996, J TOXICOL ENV HEALTH, V47, P195, DOI 10.1080/009841096161898; McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008; MCMAHON RE, 1980, XENOBIOTICA, V10, P469, DOI 10.3109/00498258009033782; MELCHIOR WB, 1994, CARCINOGENESIS, V15, P889, DOI 10.1093/carcin/15.5.889; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Netto GJ, 2012, NAT REV UROL, V9, P41, DOI 10.1038/nrurol.2011.193; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Nia AB, 2000, MUTAT RES-GEN TOX EN, V468, P125, DOI 10.1016/S1383-5718(00)00049-8; Olivier Magali, 2004, IARC Sci Publ, P247; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; ORZECHOWSKI A, 1994, CARCINOGENESIS, V15, P1549, DOI 10.1093/carcin/15.8.1549; PARKES HG, 1984, CHEM CARCINOGENS, P277; PATRIANAKOS C, 1979, J ANAL CHEM+, P150; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Poirier MC, 2004, NAT REV CANCER, V4, P630, DOI 10.1038/nrc1410; POUPKO JM, 1979, TOXICOL APPL PHARM, V50, P479, DOI 10.1016/0041-008X(79)90401-0; Ru YB, 2011, CURR OPIN UROL, V21, P420, DOI 10.1097/MOU.0b013e32834956d6; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; SCHIEFERSTEIN GJ, 1985, EUR J CANCER CLIN ON, V21, P865, DOI 10.1016/0277-5379(85)90227-5; SCHIEFERSTEIN GJ, 1983, CARCINOGENESIS 4 AMI; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P2198, DOI 10.1021/bi00356a052; Smith C. J., 2001, Food and Chemical Toxicology, V39, P183, DOI 10.1016/S0278-6915(00)00164-2; Smith CJ, 1997, FOOD CHEM TOXICOL, V35, P1107, DOI 10.1016/S0278-6915(97)00063-X; Smith CJ, 2003, FOOD CHEM TOXICOL, V41, P807, DOI 10.1016/S0278-6915(03)00021-8; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; STEINECK G, 1990, AM J IND MED, V17, P371, DOI 10.1002/ajim.4700170310; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; SWAMINATHAN S, 1992, CANCER RES, V52, P3286; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; U.S. Department of Health and Human Services, 2004, HLTH CONS SMOK REP S; Verghis SBM, 1997, CARCINOGENESIS, V18, P2403, DOI 10.1093/carcin/18.12.2403; VINEIS P, 1988, CANCER RES, V48, P3849; Vineis P, 1997, CANCER CAUSE CONTROL, V8, P346, DOI 10.1023/A:1018453104303; Volanis D, 2011, J BUON, V16, P589; World Health Organization, 2008, WHO REP GLOB TOB EP; Yoon JI, 2012, CANCER PREV RES, V5, P299, DOI 10.1158/1940-6207.CAPR-11-0309; Zayas-Rivera B, 2001, BIOMARKERS, V6, P262, DOI 10.1080/13547500010017367; ZIEGLER DM, 1988, P NATL ACAD SCI USA, V85, P2514, DOI 10.1073/pnas.85.8.2514	93	37	37	1	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2090	2100		10.1096/fj.12-227074	http://dx.doi.org/10.1096/fj.12-227074			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23449930	Green Submitted			2022-12-28	WOS:000319667600001
J	Kats, A; Bage, T; Georgsson, P; Jonsson, J; Quezada, HC; Gustafsson, A; Jansson, L; Lindberg, C; Nasstrom, K; Yucel-Lindberg, T				Kats, Anna; Bage, Tove; Georgsson, Pierre; Jonsson, Jorgen; Quezada, Hernan Concha; Gustafsson, Anders; Jansson, Leif; Lindberg, Claes; Nasstrom, Karin; Yucel-Lindberg, Tulay			Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E-2 synthesis in vitro and ameliorates experimental periodontitis in vivo	FASEB JOURNAL			English	Article						cyclooxygenase-2; gingival fibroblasts; interleukin-1 beta; PGE(2); mPGES-1 inhibitor; anti-inflammatory	COLLAGEN-INDUCED ARTHRITIS; GINGIVAL CREVICULAR FLUID; ALVEOLAR BONE LOSS; RHEUMATOID-ARTHRITIS; IDENTIFICATION; EXPRESSION; CYCLOOXYGENASE-2; DISEASE; CELECOXIB; MPGES-1	The potent inflammatory mediator prostaglandin E-2 (PGE(2)) is implicated in the pathogenesis of several chronic inflammatory conditions, including periodontitis. The inducible enzyme microsomal prostaglandin E synthase-1 (mPGES-1), catalyzing the terminal step of PGE(2) biosynthesis, is an attractive target for selective PGE(2) inhibition. To identify mPGES-1 inhibitors, we investigated the effect of aminothiazoles on inflammation-induced PGE(2) synthesis in vitro, using human gingival fibroblasts stimulated with the cytokine IL-1 beta and a cell-free mPGES-1 activity assay, as well as on inflammation-induced bone resorption in vivo, using ligature-induced experimental periodontitis in SpragueDawley rats. Aminothiazoles 4-([4-(2-naphthyl)-1,3-thiazol-2-yl]amino)phenol (TH-848) and 4-(3-fluoro-4-methoxyphenyl)-N-(4-phenoxyphenyl)-1,3-thiazol-2-amine (TH-644) reduced IL-1 beta-induced PGE(2) production in fibroblasts (IC50 1.1 and 1.5 mu M, respectively) as well as recombinant mPGES-1 activity, without affecting activity or expression of the upstream enzyme cyclooxygenase-2. In ligature-induced experimental periodontitis, alveolar bone loss, assessed by X-ray imaging, was reduced by 46% by local treatment with TH-848, compared to vehicle, without any systemic effects on PGE(2), 6-keto PGF(1 alpha), LTB4 or cytokine levels. In summary, these results demonstrate that the aminothiazoles represent novel mPGES-1 inhibitors for inhibition of PGE(2) production and reduction of bone resorption in experimental periodontitis, and may be used as potential anti-inflammatory drugs for treatment of chronic inflammatory diseases, including periodontitis.-Kats, A., Bage, T., Georgsson, P., Jonsson, J., Quezada, H. C., Gustafsson, A., Jansson, L., Lindberg, C., Nasstrom, K., Yucel-Lindberg, T. Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E-2 synthesis in vitro and ameliorates experimental periodontitis in vivo.	[Kats, Anna; Bage, Tove; Georgsson, Pierre; Jonsson, Jorgen; Gustafsson, Anders; Yucel-Lindberg, Tulay] Karolinska Inst, Div Periodontol, Dept Dent Med, S-14104 Huddinge, Sweden; [Kats, Anna; Bage, Tove; Georgsson, Pierre; Yucel-Lindberg, Tulay] Karolinska Inst, Div Pediat Dent, S-14104 Huddinge, Sweden; [Nasstrom, Karin] Karolinska Inst, Ctr Infect Med, S-14104 Huddinge, Sweden; [Quezada, Hernan Concha] Karolinska Inst, Div Image & Funct Odontol & Oral Pathol, S-14104 Huddinge, Sweden; [Jansson, Leif] Stockholm Cty Council, Dept Periodontol Skanstull, Stockholm, Sweden; [Lindberg, Claes] MedicinTeknik AB, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm County Council	Yucel-Lindberg, T (corresponding author), Karolinska Inst, Div Periodontol, Dept Dent Med, Box 4064, S-14104 Huddinge, Sweden.	tulay.lindberg@ki.se		Yucel-Lindberg, Tulay/0000-0003-0129-8809	Swedish Patent Revenue Fund; Swedish Research Council [73XD-15005]; Swedish Dental Society; Karolinska Institutet	Swedish Patent Revenue Fund; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Dental Society; Karolinska Institutet(Karolinska Institutet)	This work was supported by grants from the Swedish Patent Revenue Fund (T.Y.-L.); the Swedish Research Council, project number 73XD-15005 (T.Y.-L.); the Swedish Dental Society (A.K.); and Karolinska Institutet (A.K., T.Y.-L.). The authors thank Ms. Ann-Britt Lundberg and Professor Dowen Birkhed (Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden) for disc diffusion tests; Ms. Haleh Davanian and Ms. Kaja Eriksson (Department of Dental Medicine, Karolinska Institutet) for assistance with laboratory work; and Dr. Rachael Sugars (Department of Dental Medicine, Karolinska Institutet) for editing the English language.	Akaogi Jun, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P383; Anderson GD, 2009, INFLAMM RES, V58, P109, DOI 10.1007/s00011-009-8149-3; Armitage GC, 2004, PERIODONTOL 2000, V34, P9, DOI 10.1046/j.0906-6713.2002.003421.x; Bage T, 2007, BBA-MOL CELL RES, V1773, P1589, DOI 10.1016/j.bbamcr.2007.07.008; Bage T, 2011, AM J PATHOL, V178, P1676, DOI 10.1016/j.ajpath.2010.12.048; Bage T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-241; Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003; Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004; Blinkhorn A, 2009, BRIT DENT J, V207, P117, DOI 10.1038/sj.bdj.2009.669; Bruno A, 2010, BIOCHEM PHARMACOL, V79, P974, DOI 10.1016/j.bcp.2009.11.011; Cannon CP, 2012, SCIENCE, V336, P1386, DOI 10.1126/science.1224398; Capone ML, 2007, PROSTAG OTH LIPID M, V82, P85, DOI 10.1016/j.prostaglandins.2006.05.019; Cavanaugh PF, 1998, J PERIODONTAL RES, V33, P75; Chang HH, 2012, INVEST NEW DRUG, V30, P1865, DOI 10.1007/s10637-011-9748-8; Chang HH, 2011, FUTURE MED CHEM, V3, P1909, DOI [10.4155/FMC.11.136, 10.4155/fmc.11.136]; Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110; Cheng WC, 2010, J PERIODONTAL RES, V45, P788, DOI 10.1111/j.1600-0765.2010.01301.x; Cho YS, 2010, PHARMACOLOGY, V86, P65, DOI 10.1159/000315488; Di Paola R, 2006, J DENT RES, V85, P156, DOI 10.1177/154405910608500208; El-Rayes BF, 2004, MOL CANCER THER, V3, P1421; Friesen RW, 2008, J MED CHEM, V51, P4059, DOI 10.1021/jm800197b; Giroux A, 2009, BIOORG MED CHEM LETT, V19, P5837, DOI 10.1016/j.bmcl.2009.08.085; Gudis K, 2005, LAB INVEST, V85, P225, DOI 10.1038/labinvest.3700200; Guimaraes MR, 2011, J PERIODONTAL RES, V46, P269, DOI 10.1111/j.1600-0765.2010.01342.x; Guimaraes MR, 2012, INNATE IMMUN-LONDON, V18, P155, DOI 10.1177/1753425910392935; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jegerschold C, 2008, P NATL ACAD SCI USA, V105, P11110, DOI 10.1073/pnas.0802894105; Kinney JS, 2007, ANN NY ACAD SCI, V1098, P230, DOI 10.1196/annals.1384.028; Koeberle A, 2009, CURR MED CHEM, V16, P4274, DOI 10.2174/092986709789578178; Koeberle A, 2008, J PHARMACOL EXP THER, V326, P975, DOI 10.1124/jpet.108.139444; Koeberle A, 2009, MOL CANCER THER, V8, P2348, DOI 10.1158/1535-7163.MCT-09-0290; Luan Q, 2008, J DENT RES, V87, P148, DOI 10.1177/154405910808700208; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Mbalaviele G, 2010, BIOCHEM PHARMACOL, V79, P1445, DOI 10.1016/j.bcp.2010.01.003; Moldovan CM, 2011, EUR J MED CHEM, V46, P526, DOI 10.1016/j.ejmech.2010.11.032; Moon Y, 2005, J PHARMACOL EXP THER, V315, P788, DOI 10.1124/jpet.105.084434; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Mustafa M, 2005, J CLIN PERIODONTOL, V32, P6, DOI 10.1111/j.1600-051X.2004.00622.x; Ng SC, 2010, CURR OPIN GASTROEN, V26, P611, DOI 10.1097/MOG.0b013e32833e91eb; NISHIKAKU F, 1993, IMMUNOPHARMACOLOGY, V25, P65, DOI 10.1016/0162-3109(93)90031-K; NISHIKAKU F, 1994, INT J IMMUNOPHARMACO, V16, P91, DOI 10.1016/0192-0561(94)90064-7; OFFENBACHER S, 1993, J PERIODONTOL, V64, P432, DOI 10.1902/jop.1993.64.5s.432; Ohno H, 2008, EUR J IMMUNOL, V38, P283, DOI 10.1002/eji.200737199; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; Pawelzik SC, 2010, J BIOL CHEM, V285, P29254, DOI 10.1074/jbc.M110.114454; Pouliot M, 2000, BIOCHEMISTRY-US, V39, P4761, DOI 10.1021/bi992551b; Preshaw PM, 2002, J CLIN PERIODONTOL, V29, P15, DOI 10.1034/j.1600-051x.2002.290103.x; Ricart M, 2010, AQUAT TOXICOL, V100, P346, DOI 10.1016/j.aquatox.2010.08.010; Rosenstock M, 1999, BBA-MOL CELL BIOL L, V1440, P127, DOI 10.1016/S1388-1981(99)00105-5; Saleh S, 2011, LETT APPL MICROBIOL, V52, P87, DOI 10.1111/j.1472-765X.2010.02976.x; Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878; Sanghi Sandhya, 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P85; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tonetti MS, 2011, J CLIN PERIODONTOL, V38, P114, DOI 10.1111/j.1600-051X.2010.01675.x; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Tseng CH, 2012, MOL DIVERS, V16, P215, DOI 10.1007/s11030-011-9347-9; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wang M, 2008, J INTERN MED, V263, P500, DOI 10.1111/j.1365-2796.2008.01938.x; Westman M, 2004, ARTHRITIS RHEUM-US, V50, P1774, DOI 10.1002/art.20286; Yen CA, 2008, J PERIODONTOL, V79, P104, DOI [10.1902/jop.2008.070271, 10.1902/jop.2008.070271 ]; Yucel-Lindberg T, 2004, INFLAMMATION, V28, P89, DOI 10.1023/B:IFLA.0000033024.13748.c1; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	67	23	24	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2328	2341		10.1096/fj.12-214445	http://dx.doi.org/10.1096/fj.12-214445			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23447581	hybrid, Green Published			2022-12-28	WOS:000319667600022
J	Monteserin-Garcia, J; Al-Massadi, O; Seoane, LM; Alvarez, CV; Shan, B; Stalla, J; Paez-Pereda, M; Casanueva, FF; Stalla, GK; Theodoropoulou, M				Monteserin-Garcia, Jose; Al-Massadi, Omar; Seoane, Luisa M.; Alvarez, Clara V.; Shan, Bing; Stalla, Johanna; Paez-Pereda, Marcelo; Casanueva, Felipe F.; Stalla, Guenter K.; Theodoropoulou, Marily			Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis	FASEB JOURNAL			English	Article						resveratrol; GSK3 beta; phosphatase; acetylation	GLYCOGEN-SYNTHASE KINASE-3-BETA; LIFE-SPAN EXTENSION; FACTOR-I AXIS; CALORIE RESTRICTION; GENE-EXPRESSION; PROTEIN PHOSPHATASE-1; LIPID-METABOLISM; CELL-GROWTH; CYCLIC-AMP; RESVERATROL	Growth hormone (GH) is a major anabolic hormone and the primary regulator of organism growth. Its transcription is triggered by GH-releasing hormone (GHRH) through the transcription factor cAMP response element-binding protein (CREB) and by caloric intake. In contrast, the deacetylase Sirt1 is activated by caloric restriction. Therefore, the present study investigates how Sirt1 affects CREB function and GH synthesis. Sirt1 pharmacological activation with resveratrol (IC50 =87 mu M) suppressed GHRH-induced GH secretion from rat anterior pituitary cells in vivo and in vitro, while vehicle controls showed no effect. Resveratrol's effects were abolished after knocking down Sirt1 with RNA interference, but not in control scrambled siRNA-transfected rat somatotrophs, confirming the Sirt1 specificity. Sirt1 activation and overexpression suppressed forskolin-induced CREB-Ser(133) phosphorylation, but no effect was seen with vehicle and empty plasmid controls. The deacetylase-dead mutant Sirt1 retained CREB-Ser133 phosphorylation by keeping protein phosphatase protein phosphatase 1 activity low. Sirt1 activation suppressed glycogen synthase kinase 3 beta acetylation, and a mutation on the GSK3 beta-Lys(205) residue mimicking a hypoacetylated form revealed increased activity. In summary, this is a novel mechanism through which Sirt1 intercepts the cAMP pathway by suppressing CREB transcriptional activation, resulting in decreased GH synthesis.-Monteserin-Garcia, J., Al-Massadi, O., Seoane, L. M., Alvarez, C. V., Shan, B., Stalla, J., Paez-Pereda, M., Casanueva, F. F., Stalla, G. K., Theodoropoulou, M. Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis. FASEB J. 27, 1561-1571 (2013). www.fasebj.org	[Monteserin-Garcia, Jose; Shan, Bing; Stalla, Johanna; Paez-Pereda, Marcelo; Stalla, Guenter K.; Theodoropoulou, Marily] Max Planck Inst Psychiat, Dept Endocrinol, D-80804 Munich, Germany; [Al-Massadi, Omar; Seoane, Luisa M.] Univ Hosp Complex Santiago de Compostela, Serv Galego Saude SERGAS, Endocrine Physiopathol Grp, Santiago De Compostela, Spain; [Al-Massadi, Omar; Seoane, Luisa M.; Casanueva, Felipe F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; [Alvarez, Clara V.] Univ Santiago de Compostela, Sch Med, Ctr Invest Med, Santiago De Compostela, Spain; [Alvarez, Clara V.] Univ Santiago de Compostela, Sch Med, Dept Physiol, Inst Invest Sanitarias CIMUS IDIS, Santiago De Compostela, Spain	Max Planck Society; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela	Theodoropoulou, M (corresponding author), Max Planck Inst Psychiat, Dept Endocrinol, Kraepelinstr 10, D-80804 Munich, Germany.	marily@mpipsykl.mpg.de	Alvarez, Clara V/AAN-4173-2020; Monteserin-Garcia, Jose Luis/AAC-7052-2020; Theodoropoulou, Marily/S-9546-2017; Al-Massadi, Omar/C-1526-2017; Álvarez, Carmen/B-2582-2015; seoane, luisa M/E-6570-2013	Monteserin-Garcia, Jose Luis/0000-0002-4508-6771; Theodoropoulou, Marily/0000-0002-7378-4374; Al-Massadi, Omar/0000-0003-0645-6159; Álvarez, Carmen/0000-0003-1874-1045; Shan, Bing/0000-0003-4178-3526; Paez-Pereda, Marcelo/0000-0001-6029-0706; Alvarez, Clara V/0000-0003-1500-4058	Pfizer Young Investigator research fellowship	Pfizer Young Investigator research fellowship	The authors are grateful to A. Gutierrez-Hartman (University of Colorado Health Sciences Center, Denver, CO, USA) for the pA3GHluc reporter plasmid and M. Bidlingmaier (Ludwig-Maximilians University, Munich, Germany) for the mouse monoclonal GH antibody. The study was supported in part by a Pfizer Young Investigator research fellowship to M. T. The funding source had no role in the conceptualization, interpretation, and writing of this study. The authors declare no conflicts of interest.	Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Akieda-Asai S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011755; Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-40; ARZT E, 1993, ENDOCRINOLOGY, V132, P459, DOI 10.1210/en.132.1.459; Bakhtiarova A, 2006, BIOCHEM BIOPH RES CO, V351, P481, DOI 10.1016/j.bbrc.2006.10.057; Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Bonkowski MS, 2006, P NATL ACAD SCI USA, V103, P7901, DOI 10.1073/pnas.0600161103; Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; Dekkers OM, 2008, J CLIN ENDOCR METAB, V93, P61, DOI 10.1210/jc.2007-1191; DIEGUEZ C, 1995, TRENDS ENDOCRIN MET, V6, P55, DOI 10.1016/1043-2760(94)00206-J; Dunn SE, 1997, CANCER RES, V57, P4667; Ezzat S, 2005, MOL ENDOCRINOL, V19, P1004, DOI 10.1210/me.2004-0432; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Frojdo S, 2007, BIOCHEM J, V406, P511, DOI 10.1042/BJ20070236; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Guevara-Aguirre J., 2011, SCI TRANSL MED, V3, pra13; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Holzenberger M, 2004, EUR J ENDOCRINOL, V151, pS23, DOI 10.1530/eje.0.151S023; Imai S, 2010, TRENDS PHARMACOL SCI, V31, P212, DOI 10.1016/j.tips.2010.02.003; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jin JL, 2009, MOL CELL BIOL, V29, P3867, DOI 10.1128/MCB.00456-09; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Li MG, 2007, BIOCHEMISTRY-US, V46, P2380, DOI 10.1021/bi602369m; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; Melmed S, 2009, J CLIN INVEST, V119, P3189, DOI 10.1172/JCI39375; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Moller N, 2009, ENDOCR REV, V30, P152, DOI 10.1210/er.2008-0027; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104; OSTER MH, 1995, J CLIN INVEST, V95, P2258, DOI 10.1172/JCI117916; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Qiang L, 2011, CELL METAB, V14, P758, DOI 10.1016/j.cmet.2011.10.007; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schenk S, 2011, J CLIN INVEST, V121, P4281, DOI 10.1172/JCI58554; Seoane LM, 2004, EUR J ENDOCRINOL, V150, P731, DOI 10.1530/eje.0.1500731; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; Shimokawa I, 2003, FASEB J, V17, P1108, DOI 10.1096/fj.02-0819fje; STALLA GK, 1989, ENDOCRINOLOGY, V125, P699, DOI 10.1210/endo-125-2-699; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; Theodoropoulou M, 2004, ENDOCR-RELAT CANCER, V11, P333, DOI 10.1677/erc.0.0110333; Theodoropoulou M, 2006, CANCER RES, V66, P1576, DOI 10.1158/0008-5472.CAN-05-1189; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Yu JJ, 2010, PHARMACOL RES, V62, P35, DOI 10.1016/j.phrs.2009.12.006; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019	71	53	55	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1561	1571		10.1096/fj.12-220129	http://dx.doi.org/10.1096/fj.12-220129			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23292070	Bronze			2022-12-28	WOS:000316940800027
J	Zhu, GY; Ye, RS; Jung, DY; Barron, E; Friedline, RH; Benoit, VM; Hinton, DR; Kim, JK; Lee, AS				Zhu, Genyuan; Ye, Risheng; Jung, Dae Young; Barron, Ernesto; Friedline, Randall H.; Benoit, Vivian M.; Hinton, David R.; Kim, Jason K.; Lee, Amy S.			GRP78 plays an essential role in adipogenesis and postnatal growth in mice	FASEB JOURNAL			English	Article						conditional-knockout mouse model; aP2-Cre-recombinase; adipokine secretion	UNFOLDED PROTEIN RESPONSE; EMBRYONIC-DEVELOPMENT; REGULATOR GRP78/BIP; INSULIN-RESISTANCE; ADIPOSE-TISSUE; ER; STRESS; EXPRESSION; PATHWAY; MOUSE	To investigate the role of GRP78 in adipogenesis and metabolic homeostasis, we knocked down GRP78 in mouse embryonic fibroblasts and 3T3-L1 preadipocytes induced to undergo differentiation into adipocytes. We also created an adipose Grp78-knockout mouse utilizing the aP2 (fatty acid binding protein 4) promoter-driven Cre-recombinase. Adipogenesis was monitored by molecular markers and histology. Tissues were analyzed by micro-CT and electron microscopy. Glucose homeostasis and cytokine analysis were performed. Our results indicate that GRP78 is essential for adipocyte differentiation in vitro. aP2-cremediated GRP78 deletion leads to lipoatrophy with similar to 90% reduction in gonadal and subcutaneous white adipose tissue and brown adipose tissue, severe growth retardation, and bone defects. Despite severe abnormality in adipose mass and function, adipose Grp78-knockout mice showed normal plasma triglyceride levels, and plasma glucose and insulin levels were reduced by 40-60% compared to wild-type mice, suggesting enhanced insulin sensitivity. The endoplasmic reticulum is grossly expanded in the residual mutant white adipose tissue. Thus, these studies establish that GRP78 is required for adipocyte differentiation, glucose homeostasis, and balanced secretion of adipokines. Unexpectedly, the phenotypes and metabolic parameters of the mutant mice, which showed early postnatal mortality, are uniquely distinct from previously characterized lipodystrophic mouse models.-Zhu, G., Ye, R., Jung, D. Y., Barron, E., Friedline, R. H., Benoit, V. M., Hinton, D. R., Kim, J. K., Lee, A. S. GRP78 plays an essential role in adipogenesis and postnatal growth in mice. FASEB J. 27, 955-964 (2013). www.fasebj.org	[Zhu, Genyuan; Lee, Amy S.] Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Barron, Ernesto; Hinton, David R.] Univ So Calif, Dept Pathol, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; [Ye, Risheng] Univ Texas SW Med Ctr Dallas, Touchstone Diabet Ctr, Dept Internal Med, Dallas, TX 75390 USA; [Jung, Dae Young; Friedline, Randall H.; Benoit, Vivian M.; Kim, Jason K.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Kim, Jason K.] Univ Massachusetts, Sch Med, Dept Med, Div Endocrinol, Worcester, MA USA	University of Southern California; University of Southern California; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lee, AS (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, 1441 Eastlake Ave,Rm 5308, Los Angeles, CA 90089 USA.	amylee@ccnt.usc.edu	Zhu, Genyuan/R-8142-2016	Kim, Jason/0000-0002-7185-042X; Lee, Amy/0000-0002-0378-5443	U.S. National Institutes of Health (NIH) [R01 DK 079999, R01 DK 080756]; NIH from the National Cancer Institute [P30 CA014089]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079999, U24DK093000, R01DK080756] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. My Chouinard (University of Massachusetts Medical School, Worcester, MA, USA) and Drs. Mike Gray, Yvonne Lin, and Parkash Gill [Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA] for the gifts of cell lines and reagents. The authors thank Ms. Archana Tank (USC Comprehensive Cancer Center Small Animal Imaging Core and Translational Pathology Core) and Dr. Dongyun Yang (USC Biostatistics Core) for assistance. The authors also thank the USC Comprehensive Cancer Center Cell and Tissue Imaging Core for assistance in electron microscopy. This work is supported in part by U.S. National Institutes of Health (NIH) grants R01 DK 079999 to A.S.L and R01 DK 080756 to J.K.K. The USC cores described were supported by NIH grant P30 CA014089 from the National Cancer Institute.	Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991; Bastie CC, 2007, CELL METAB, V5, P371, DOI 10.1016/j.cmet.2007.04.005; Burkart A, 2011, J BIOL CHEM, V286, P4081, DOI 10.1074/jbc.M110.134106; Federovitch CM, 2005, CURR OPIN CELL BIOL, V17, P409, DOI 10.1016/j.ceb.2005.06.010; Flint OP, 2009, TOXICOL PATHOL, V37, P65, DOI 10.1177/0192623308327119; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gregor MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Lowe CE, 2012, INT J OBESITY, V36, P1248, DOI 10.1038/ijo.2011.233; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Luu YK, 2009, MED ENG PHYS, V31, P34, DOI 10.1016/j.medengphy.2008.03.006; Mao JQ, 2009, P NATL ACAD SCI USA, V106, P17576, DOI 10.1073/pnas.0909055106; Martens K, 2010, FEBS LETT, V584, P1054, DOI 10.1016/j.febslet.2010.01.061; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006868; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sha HB, 2009, CELL METAB, V9, P556, DOI 10.1016/j.cmet.2009.04.009; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Urs S, 2006, TRANSGENIC RES, V15, P647, DOI 10.1007/s11248-006-9000-z; Ushioda R, 2008, SCIENCE, V321, P569, DOI 10.1126/science.1159293; Verdelis K, 2011, BONE, V49, P580, DOI 10.1016/j.bone.2011.05.013; Wang M, 2010, CELL DEATH DIFFER, V17, P488, DOI 10.1038/cdd.2009.144; Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]; Wang ZV, 2010, ENDOCRINOLOGY, V151, P2933, DOI 10.1210/en.2010-0136; Ye RS, 2010, AM J PATHOL, V177, P2827, DOI 10.2353/ajpath.2010.100368; Ye RS, 2010, DIABETES, V59, P6, DOI 10.2337/db09-0755	34	34	34	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					955	964		10.1096/fj.12-213330	http://dx.doi.org/10.1096/fj.12-213330			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23180827	Green Published			2022-12-28	WOS:000315585200011
J	Otazo, MRD; Lorenzo, J; Tort, O; Aviles, FX; Bautista, JM				de la Vega Otazo, Monica Rodriguez; Lorenzo, Julia; Tort, Olivia; Aviles, Francesc X.; Bautista, Jose M.			Functional segregation and emerging role of cilia-related cytosolic carboxypeptidases (CCPs)	FASEB JOURNAL			English	Article						basal bodies; microtubules; tubulin modifications; polyglutamylation; detyrosination	PURKINJE-CELL DEGENERATION; TUBULIN POLYGLUTAMYLASE; EVOLUTION; ORIGIN; PROTEINS; MOUSE; DEGLUTAMYLASE; CILIOGENESIS; MECHANISMS; TRANSPORT	Recent experimental data indicating axonal regeneration, axogenesis, dendritogenesis, and ciliary axoneme assembly and wellness have linked the role of cytosolic metallocarboxypeptidase 1 (CCP1/AGTPBP1/Nna1) to the microtubule network. In addition, 5 of the 6 mammalian ccp genes have been shown to participate in post-translational modifications of tubulin, which occur in the microtubules of neurons, mitotic spindles, cilia, and basal bodies. Here, we compile evidence for the idea that the occurrence of CCPs strongly correlates with the presence of cilia, suggesting that CCP functions might be primarily related to cilia and basal bodies (CBBs). In agreement with this hypothesis, CCPs were localized in centrioles, basal bodies, and mitotic spindles in HeLa cells by confocal microscopy. By reconstructing the evolutionary history of CCPs, we show their presence in the last eukaryotic common ancestor and relate each group of CCP orthologs to specific roles in CBBs. The clues presented in this study suggest that during the evolution of eukaryotes, mechanisms mediated by CCPs through tubulin post-translational modifications controlling assembly, trafficking, and signaling in the microtubules, were transferred from cilia to cell and axon microtubules.-Rodriguez de la Vega Otazo, M., Lorenzo, J., Tort, O., Aviles, F. X., Bautista, J. M. Functional segregation and emerging role of cilia-related cytosolic carboxypeptidases (CCPs). FASEB J. 27, 424-431 (2013). www.fasebj.org	[de la Vega Otazo, Monica Rodriguez; Lorenzo, Julia; Tort, Olivia; Aviles, Francesc X.] Univ Autonoma Barcelona, Inst Biotechnol & Biomed, Barcelona, Spain; [de la Vega Otazo, Monica Rodriguez; Lorenzo, Julia; Tort, Olivia; Aviles, Francesc X.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain; [Bautista, Jose M.] Univ Complutense Madrid, Dept Biochem & Mol Biol 4, Fac Vet, E-28040 Madrid, Spain; [Bautista, Jose M.] Univ Complutense Madrid, Inst Invest Hosp Octubre 12, E-28040 Madrid, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Complutense University of Madrid; Complutense University of Madrid; Hospital Universitario 12 de Octubre	Bautista, JM (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol 4, Ciudad Univ, E-28040 Madrid, Spain.	francescxavier.aviles@uab.es; jmbau@vet.ucm.es	Lorenzo, Julia/E-9015-2011; Avilés, Francesc Xavier/A-2664-2015; Rodriguez de la Vega Otazo, Monica Margarita/H-7008-2015; Aviles, Francesc Xavier/F-3482-2019; Bautista, José M./B-7899-2013; Tort, Olivia/P-1828-2015	Lorenzo, Julia/0000-0001-5659-6008; Avilés, Francesc Xavier/0000-0002-1399-6789; Rodriguez de la Vega Otazo, Monica Margarita/0000-0002-1061-3471; Aviles, Francesc Xavier/0000-0002-1399-6789; Bautista, José M./0000-0001-8926-881X; Tort, Olivia/0000-0002-1841-125X	Spanish Ministry of Science and Innovation [BIO2010-22321, BIO2010-17039]; Network of Excellence of the Generalitat de Catalunya (Xarxa de Referencia en Biotecnologia; Spain); Iberoamerican Ciencia y Tecnologia Para el Desarrollo (CYTED) network [210RT0398]; Consolidated Research Teams of the Universidad Complutense de Madrid (Comunidad de Madrid, Spain) [920267]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Network of Excellence of the Generalitat de Catalunya (Xarxa de Referencia en Biotecnologia; Spain)(Generalitat de Catalunya); Iberoamerican Ciencia y Tecnologia Para el Desarrollo (CYTED) network; Consolidated Research Teams of the Universidad Complutense de Madrid (Comunidad de Madrid, Spain)	The authors thank Dr. Luis Serrano (Centre de Regulacio Genomica, Barcelona, Spain), Jesus Avila (Centro de Biologia Molecular-Consejo Superior de Investigaciones Cientificas, Madrid, Spain), and Oscar Yanes (Universitat Rovira i Virgili, Tarragona, Spain) for discussions and reading of the manuscript; M. Roldan and N. Barba for technical assistance with confocal microscopy imaging and analyses; and F. Cortes for technical support in cell culturing. This work was funded by grants from the Spanish Ministry of Science and Innovation (BIO2010-22321 and BIO2010-17039), by the Network of Excellence of the Generalitat de Catalunya (Xarxa de Referencia en Biotecnologia; Spain), by the Iberoamerican Ciencia y Tecnologia Para el Desarrollo (CYTED) network (210RT0398), and by the Program of Consolidated Research Teams of the Universidad Complutense de Madrid (J.M.B., Research Team 920267; Comunidad de Madrid, Spain).	Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; BARRA HS, 1988, MOL NEUROBIOL, V2, P133, DOI 10.1007/BF02935343; Berezniuk I, 2012, J BIOL CHEM, V287, P6503, DOI 10.1074/jbc.M111.309138; Berger L, 2005, DIS AQUAT ORGAN, V68, P51, DOI 10.3354/dao068051; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Bornens M, 2007, ADV EXP MED BIOL, V607, P119; Carvalho-Santos Z, 2010, J CELL SCI, V123, P1414, DOI 10.1242/jcs.064931; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; Tommaso P, 2011, NUCLEIC ACIDS RES, V39, pW13, DOI 10.1093/nar/gkr245; Dolan MF, 2002, ANAT REC, V268, P290, DOI 10.1002/ar.10161; DOPAZO J, 1994, J MOL EVOL, V38, P300, DOI 10.1007/BF00176092; Escalier D, 2006, HUM REPROD UPDATE, V12, P449, DOI 10.1093/humupd/dml013; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Follit JA, 2006, MOL BIOL CELL, V17, P3781, DOI 10.1091/mbc.E06-02-0133; Fritz-Laylin LK, 2010, EUKARYOT CELL, V9, P860, DOI 10.1128/EC.00381-09; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/0968-0004(96)20013-1; Gupta RS, 2005, MICROBIAL PHYLOGENY, P160; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; Hodges ME, 2010, J CELL SCI, V123, P1407, DOI 10.1242/jcs.064873; Ishikawa H, 2011, NAT REV MOL CELL BIO, V12, P222, DOI 10.1038/nrm3085; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kimura Y, 2010, J BIOL CHEM, V285, P22934, DOI 10.1074/jbc.C110.128280; Lalle M, 2011, J BIOL CHEM, V286, P4471, DOI 10.1074/jbc.M110.181511; Le Bot N, 1998, J CELL BIOL, V143, P1559, DOI 10.1083/jcb.143.6.1559; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; O'Hagan R, 2011, CURR BIOL, V21, P1685, DOI 10.1016/j.cub.2011.08.049; Otero A, 2012, FASEB J, V26, P3754, DOI 10.1096/fj.12-209601; PICKETTHEAPS JD, 1978, CELL, V14, P455, DOI 10.1016/0092-8674(78)90232-5; Regnard C, 1999, J CELL SCI, V112, P4281; Rogowski K, 2010, CELL, V143, P564, DOI 10.1016/j.cell.2010.10.014; Rogowski K, 2009, CELL, V137, P1076, DOI 10.1016/j.cell.2009.05.020; RZHETSKY A, 1992, J MOL EVOL, V35, P367, DOI 10.1007/BF00161174; Sahab ZJ, 2011, CANCER RES, V71, P1219, DOI 10.1158/0008-5472.CAN-10-2294; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Suryavanshi S, 2010, CURR BIOL, V20, P435, DOI 10.1016/j.cub.2009.12.062; TACHI S, 1974, BIOL REPROD, V10, P391, DOI 10.1095/biolreprod10.4.391; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Valero J, 2006, MOL CELL NEUROSCI, V33, P283, DOI 10.1016/j.mcn.2006.08.002; van Dijk J, 2007, MOL CELL, V26, P437, DOI 10.1016/j.molcel.2007.04.012; Wloga D, 2010, J CELL SCI, V123, P3447, DOI 10.1242/jcs.063727; Woodland HR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003778; Wu HY, 2012, FASEB J, V26, P4468, DOI 10.1096/fj.12-205047; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	50	21	24	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					424	431		10.1096/fj.12-209080	http://dx.doi.org/10.1096/fj.12-209080			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085998				2022-12-28	WOS:000314358000003
J	Norring, SA; Ednie, AR; Schwetz, TA; Du, DP; Yang, H; Bennett, ES				Norring, Sarah A.; Ednie, Andrew R.; Schwetz, Tara A.; Du, Dongping; Yang, Hui; Bennett, Eric S.			Channel sialic acids limit hERG channel activity during the ventricular action potential	FASEB JOURNAL			English	Article						cardiac; voltage-gated potassium channel; arrhythmias; N-glycosylation; ion channel; sialylation	I-KR CHANNELS; CONGENITAL DISORDERS; POTASSIUM CHANNEL; N-GLYCOSYLATION; CELLULAR MECHANISMS; CARDIAC-ARRHYTHMIA; K+ CHANNELS; QT SYNDROME; CARDIOMYOPATHY; INACTIVATION	Activity of human ether-a-go-go-related gene (hERG) 1 voltage-gated K+ channels is responsible for portions of phase 2 and phase 3 repolarization of the human ventricular action potential. Here, we questioned whether and how physiologically and pathophysiologically relevant changes in surface N-glycosylation modified hERG channel function. Voltage-dependent hERG channel gating and activity were evaluated as expressed in a set of Chinese hamster ovary (CHO) cell lines under conditions of full glycosylation, no sialylation, no complex N-glycans, and following enzymatic deglycosylation of surface N-glycans. For each condition of reduced glycosylation, hERG channel steady-state activation and inactivation relationships were shifted linearly by significant depolarizing similar to 9 and similar to 18 mV, respectively. The hERG window current increased significantly by 50-150%, and the peak shifted by a depolarizing similar to 10 mV. There was no significant change in maximum hERG current density. Deglycosylated channels were significantly more active (20-80%) than glycosylated controls during phases 2 and 3 of action potential clamp protocols. Simulations of hERG current and ventricular action potentials corroborated experimental data and predicted reduced sialylation leads to a 50-70-ms decrease in action potential duration. The data describe a novel mechanism by which hERG channel gating is modulated through physiologically and pathophysiologically relevant changes in N-glycosylation; reduced channel sialylation increases hERG channel activity during the action potential, thereby increasing the rate of action potential repolarization.-Norring, S. A., Ednie, A. R., Schwetz, T. A., Du, D., Yang, H., Bennett, E. S. Channel sialic acids limit hERG channel activity during the ventricular action potential. FASEB J. 27, 622-631 (2013). www.fasebj.org	[Norring, Sarah A.; Ednie, Andrew R.; Schwetz, Tara A.; Bennett, Eric S.] Univ S Florida, Morsani Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL USA; [Bennett, Eric S.] Univ S Florida, Morsani Coll Med, Program Neurosci, Tampa, FL USA; [Bennett, Eric S.] Univ S Florida, Morsani Coll Med, Program Cardiovasc Sci, Tampa, FL USA; [Du, Dongping; Yang, Hui] Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Bennett, ES (corresponding author), MDC 8,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	esbennet@health.usf.edu		Yang, Hui/0000-0001-5997-6823	American Heart Association; James and Esther King Florida Biomedical Research Program; U.S. National Science Foundation; Division Of Integrative Organismal Systems [1146882] Funding Source: National Science Foundation	American Heart Association(American Heart Association); James and Esther King Florida Biomedical Research Program; U.S. National Science Foundation(National Science Foundation (NSF)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	The authors thank Dr. Gail Robertson (University of Wisconsin, Madison, WI., USA) for generously supplying the hERG1A cDNA. This work was supported by an American Heart Association predoctoral fellowship (S.A.N.), bridge and challenge grants from the James and Esther King Florida Biomedical Research Program (E. S. B.), and a grant from the U.S. National Science Foundation (E. S. B., H.Y.). The authors declare no conflicts of interest.	Al-Owain M, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-7; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Bennett ES, 2002, J PHYSIOL-LONDON, V538, P675, DOI 10.1113/jphysiol.2001.013285; Bertaso F, 2002, BASIC RES CARDIOL, V97, P424, DOI 10.1007/s00395-002-0377-4; Cordeiro JM, 2005, CARDIOVASC RES, V67, P498, DOI 10.1016/j.cardiores.2005.02.018; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Drici MD, 2000, THERAPIE, V55, P185; Du DP, 2011, IEEE ENG MED BIO, P104, DOI 10.1109/IEMBS.2011.6089907; Ednie AR, 2012, COMPR PHYSIOL, V2, P1269, DOI 10.1002/cphy.c110044; Footitt EJ, 2009, J INHERIT METAB DIS, V32, pS313, DOI 10.1007/s10545-009-1262-1; Freeze HH, 2006, NAT REV GENET, V7, P537, DOI 10.1038/nrg1894; Gehrmann J, 2003, CARDIOL YOUNG, V13, P345, DOI 10.1017/S1047951103000702; Gintant G, 2011, PHARMACOL THERAPEUT, V129, P109, DOI 10.1016/j.pharmthera.2010.08.008; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Hayashi K, 2011, J MOL CELL CARDIOL, V50, P50, DOI 10.1016/j.yjmcc.2010.10.007; Hong K, 2005, J CARDIOVASC ELECTR, V16, P394, DOI 10.1046/j.1540-8167.2005.40621.x; Jaeken J, 2004, CURR OPIN PEDIATR, V16, P434, DOI 10.1097/01.mop.0000133636.56790.4a; Jaeken J, 2004, J Inherit Metab Dis, V27, P423, DOI 10.1023/B:BOLI.0000031221.44647.9e; Jaeken J, 2003, J INHERIT METAB DIS, V26, P99, DOI 10.1023/A:1024431131208; Jo SH, 2009, PHARMACOL RES, V60, P429, DOI 10.1016/j.phrs.2009.05.008; Johnson D, 2004, J BIOL CHEM, V279, P44303, DOI 10.1074/jbc.M408900200; Johnson D, 2008, PFLUG ARCH EUR J PHY, V456, P393, DOI 10.1007/s00424-007-0378-0; Johnson D, 2006, J BIOL CHEM, V281, P25875, DOI 10.1074/jbc.M605060200; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kranz C, 2007, AM J MED GENET A, V143A, P1371, DOI 10.1002/ajmg.a.31791; Krasemann T, 2010, CLIN RES CARDIOL, V99, P309, DOI 10.1007/s00392-010-0120-3; Leroy JG, 2006, PEDIATR RES, V60, P643, DOI 10.1203/01.pdr.0000246802.57692.ea; Liengme BV., 2002, GUIDE MICROSOFT EXCE; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; Montpetit ML, 2009, P NATL ACAD SCI USA, V106, P16517, DOI 10.1073/pnas.0905414106; Nakajima T, 2007, J BIOL CHEM, V282, P5506, DOI 10.1074/jbc.M605976200; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Pond AL, 2001, TRENDS CARDIOVAS MED, V11, P286, DOI 10.1016/S1050-1738(01)00127-X; Priest BT, 2008, CHANNELS, V2, P87, DOI 10.4161/chan.2.2.6004; Roden DM, 1999, CARDIOVASC RES, V44, P242, DOI 10.1016/S0008-6363(99)00224-2; Sanguinetti MC, 2006, NATURE, V440, P463, DOI 10.1038/nature04710; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Schwetz TA, 2011, J BIOL CHEM, V286, P4123, DOI 10.1074/jbc.M110.171322; Schwetz TA, 2010, BBA-BIOMEMBRANES, V1798, P367, DOI 10.1016/j.bbamem.2009.11.018; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Stocker PJ, 2006, J GEN PHYSIOL, V127, P253, DOI 10.1085/jgp.200509423; Taubel J, 2010, BRIT J CLIN PHARMACO, V69, P391, DOI 10.1111/j.1365-2125.2009.03595.x; ten Tusscher KHWJ, 2006, AM J PHYSIOL-HEART C, V291, pH1088, DOI 10.1152/ajpheart.00109.2006; ten Tusscher KHWJ, 2004, AM J PHYSIOL-HEART C, V286, pH1573, DOI 10.1152/ajpheart.00794.2003; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Ufret-Vincenty CA, 2001, J BIOL CHEM, V276, P28197, DOI 10.1074/jbc.M102548200; Ufret-Vincenty CA, 2001, AM J PHYSIOL-CELL PH, V281, pC464, DOI 10.1152/ajpcell.2001.281.2.C464; Vargas Hugo M., 2008, Journal of Pharmacological and Toxicological Methods, V58, P72, DOI 10.1016/j.vascn.2008.04.001; Wang HZ, 1999, AM J PHYSIOL-HEART C, V277, pH1081, DOI 10.1152/ajpheart.1999.277.3.H1081; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Watanabe I., 2003, J PHYSL, V550, P51; Watanabe I, 2007, BRAIN RES, V1144, P1, DOI 10.1016/j.brainres.2007.01.092; Witchel HJ, 2011, CARDIOVASC THER, V29, P251, DOI 10.1111/j.1755-5922.2010.00154.x; Zhu I, 2009, BRAIN RES, V1251, P16, DOI 10.1016/j.brainres.2008.11.033	60	14	14	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					622	631		10.1096/fj.12-214387	http://dx.doi.org/10.1096/fj.12-214387			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23139156				2022-12-28	WOS:000314358000021
J	Perinpanayagam, MA; Beauchamp, E; Martin, DDO; Sim, JYW; Yap, MC; Berthiaume, LG				Perinpanayagam, Maneka A.; Beauchamp, Erwan; Martin, Dale D. O.; Sim, Jacky Y. W.; Yap, Megan C.; Berthiaume, Luc G.			Regulation of co- and post-translational myristoylation of proteins during apoptosis: interplay of N-myristoyltransferases and caspases	FASEB JOURNAL			English	Article						NMT; programmed cell death; cancer	FATTY-ACYLATION; RAPID DETECTION; CLEAVAGE; ASSAY; PALMITOYLATION; TRANSFERASE; KINASES; ENZYME	Myristoylation occurs cotranslationally on nascent proteins and post-translationally during apoptosis after caspase cleavages expose cryptic myristoylation sites. We demonstrate a drastic change in the myristoylated protein proteome in apoptotic cells, likely as more substrates are revealed by caspases. We show for the first time that both N-myristoyltransferases (NMTs) 1 and 2 are cleaved during apoptosis and that the caspase-3- or -8-mediated cleavage of NMT1 at Asp-72 precedes the cleavage of NMT2 by caspase-3 mainly at Asp-25. The cleavage of NMTs did not significantly affect their activity in apoptotic cells until the 8 h time point. However, the cleavage of the predominantly membrane bound NMT1 (64%) removed a polybasic domain stretch and led to a cytosolic relocalization (>55%), whereas predominantly cytosolic NMT2 (62%) relocalized to membranes when cleaved (>80%) after the removal of a negatively charged domain. The interplay between caspases and NMTs during apoptosis is of particular interest since caspases may not only control the rates of substrate production but also their myristoylation rate by regulating the location and perhaps the specificity of NMTs. Since apoptosis is often suppressed in cancer, the reduced caspase activity seen in cancer cells might also explain the higher NMT levels observed in many cancers.-Perinpanayagam, M. A., Beauchamp, E., Martin, D. D. O., Sim, J. Y. W., Yap, M. C., Berthiaume, L. G. Regulation of co- and post-translational myristoylation of proteins during apoptosis: interplay of N-myristoyltransferases and caspases. FASEB J. 27, 811-821 (2013). www.fasebj.org	[Perinpanayagam, Maneka A.; Beauchamp, Erwan; Martin, Dale D. O.; Sim, Jacky Y. W.; Yap, Megan C.; Berthiaume, Luc G.] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Sch Mol & Syst Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Berthiaume, LG (corresponding author), Univ Alberta, Fac Med & Dent, Dept Cell Biol, Sch Mol & Syst Biol, 5-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	luc.berthiaume@ualberta.ca	martel, celine/O-6651-2016; Martin, Dale/L-6351-2015	martel, celine/0000-0002-1800-4558; Berthiaume, Luc/0000-0003-0926-059X	Canadian Institute of Health Research (CIHR) [MOP 81248]; Alberta Cancer Research Institute (ACRI) [24425]; University of Alberta-Faculty of Medicine and Dentistry; CIHR; Alberta Heritage Foundation for Medical Research	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Research Institute (ACRI); University of Alberta-Faculty of Medicine and Dentistry(University of Alberta); CIHR(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric)	This work was initiated by Canadian Institute of Health Research (CIHR) grant MOP 81248 and continued with Alberta Cancer Research Institute (ACRI) grant 24425 (to L. G. B). M. A. P. held an ACRI graduate studentship and a University of Alberta-Faculty of Medicine and Dentistry 75th Anniversary Award. D.D.O.M. held a Canada Graduate Scholarships Doctoral Award from CIHR and a Medical Research Studentship Incentive Award from the Alberta Heritage Foundation for Medical Research. The authors thank Alexandra Janowicz and Ryan J. Heit for technical assistance.	Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Charron G, 2009, J AM CHEM SOC, V131, P4967, DOI 10.1021/ja810122f; Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038; Ducker CE, 2005, MOL CANCER RES, V3, P463, DOI 10.1158/1541-7786.MCR-05-0037; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; Hang HC, 2007, J AM CHEM SOC, V129, P2744, DOI 10.1021/ja0685001; Hang HC, 2011, CHEM REV, V111, P6341, DOI 10.1021/cr2001977; Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z; Heal WP, 2008, CHEM COMMUN, P480, DOI 10.1039/b716115h; Jakobi R, 2004, DRUG RESIST UPDATE, V7, P11, DOI 10.1016/j.drup.2004.01.001; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; Kumar Sujeet, 2011, Cancers (Basel), V3, P1372, DOI 10.3390/cancers3011372; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Mahrus S, 2008, CELL, V134, P866, DOI 10.1016/j.cell.2008.08.012; Martin BR, 2009, NAT METHODS, V6, P135, DOI [10.1038/NMETH.1293, 10.1038/nmeth.1293]; Martin DDO, 2008, FASEB J, V22, P797, DOI 10.1096/fj.07-9198com; Martin DDO, 2012, FASEB J, V26, P13, DOI 10.1096/fj.11-182360; Martin DDO, 2011, BIOCHIMIE, V93, P18, DOI 10.1016/j.biochi.2010.10.018; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Patwardhan P, 2010, MOL CELL BIOL, V30, P4094, DOI 10.1128/MCB.00246-10; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Raju RVS, 1999, METH MOL B, V116, P193; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; Sakurai N, 2006, J BIOL CHEM, V281, P14288, DOI 10.1074/jbc.M510338200; Selvakumar P, 2006, FEBS LETT, V580, P2021, DOI 10.1016/j.febslet.2006.02.076; Selvakumar P, 2007, PROG LIPID RES, V46, P1, DOI 10.1016/j.plipres.2006.05.002; Shawgo ME, 2009, J BIOL CHEM, V284, P33447, DOI 10.1074/jbc.M109.032359; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; Takamune N, 2010, BIOL PHARM BULL, V33, P2018, DOI 10.1248/bpb.33.2018; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Vilas GL, 2006, P NATL ACAD SCI USA, V103, P6542, DOI 10.1073/pnas.0600824103; Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105; Yap MC, 2010, J LIPID RES, V51, P1566, DOI 10.1194/jlr.D002790; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhao Y, 2000, MOL BIOL CELL, V11, P721, DOI 10.1091/mbc.11.2.721	43	25	26	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					811	821		10.1096/fj.12-214924	http://dx.doi.org/10.1096/fj.12-214924			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23150525				2022-12-28	WOS:000314358000039
J	Pan, H; Myerson, JW; Hu, LZ; Marsh, JN; Hou, K; Scott, MJ; Allen, JS; Hu, G; San Roman, S; Lanza, GM; Schreiber, RD; Schlesinger, PH; Wickline, SA				Pan, Hua; Myerson, Jacob W.; Hu, Lingzhi; Marsh, Jon N.; Hou, Kirk; Scott, Michael J.; Allen, John S.; Hu, Grace; San Roman, Susana; Lanza, Gregory M.; Schreiber, Robert D.; Schlesinger, Paul H.; Wickline, Samuel A.			Programmable nanoparticle functionalization for in vivo targeting	FASEB JOURNAL			English	Article						postformulation; molecular targeting; inflammation; atherosclerosis; cancer	CELL-ADHESION MOLECULE-1; LIPID-PROTEIN INTERACTIONS; E-SELECTIN; VCAM-1 EXPRESSION; APOLIPOPROTEIN-E; MOUSE MODELS; KAPPA-B; MELITTIN; ICAM-1; BINDING	The emerging demand for programmable functionalization of existing base nanocarriers necessitates development of an efficient approach for cargo loading that avoids nanoparticle redesign for each individual application. Herein, we demonstrate in vivo a postformulation strategy for lipidic nanocarrier functionalization with the use of a linker peptide, which rapidly and stably integrates cargos into lipidic membranes of nanocarriers after simple mixing through a self-assembling process. We exemplified this strategy by generating a VCAM-1-targeted perfluorocarbon nanoparticle for in vivo targeting in atherosclerosis (ApoE-deficient) and breast cancer (STAT-1-deficient) models. In the atherosclerotic model, a 4.1-fold augmentation in binding to affected aortas was observed for targeted vs. nontargeted nanoparticles (P < 0.0298). Likewise, in the breast cancer model, a 4.9-fold increase in the nanoparticle signal from tumor vasculature was observed for targeted vs. nontargeted nanoparticles (P < 0.0216). In each case, the nanoparticle was registered with fluorine (F-19) magnetic resonance spectroscopy of the nanoparticle perfluorocarbon core, yielding a quantitative estimate of the number of tissue-bound nanoparticles. Because other common nanocarriers with lipid coatings (e. g., liposomes, micelles, etc.) can employ this strategy, this peptide linker postformulation approach is applicable to more than half of the available nanosystems currently in clinical trials or clinical uses.-Pan, H., Myerson, J. W., Hu, L., Marsh, J. N., Hou K., Scott, M. J., Allen, J. S., Hu, G., San Roman, S., Lanza, G. M., Schreiber, R. D., Schlesinger, P. H., Wickline, S. A. Programmable nanoparticle functionalization for in vivo targeting. FASEB J. 27, 255-264 (2013). www.fasebj.org	[Pan, Hua; Wickline, Samuel A.] Washington Univ, Sch Med, C TRAIN, Dept Med, St Louis, MO 63108 USA; [Myerson, Jacob W.; Lanza, Gregory M.; Wickline, Samuel A.] Washington Univ, Dept Biomed Engn, St Louis, MO 63108 USA; [Hu, Lingzhi; Schlesinger, Paul H.; Wickline, Samuel A.] Washington Univ, Dept Phys, St Louis, MO 63108 USA; [Hou, Kirk; Wickline, Samuel A.] Washington Univ, Div Biol & Biomed Sci, St Louis, MO 63108 USA; [Schreiber, Robert D.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Pan, H (corresponding author), Washington Univ, Sch Med, C TRAIN, Dept Med, 4320 Forest Pk Ave,Ste 101,Campus Box 8215, St Louis, MO 63108 USA.	hpan@dom.wustl.edu; wicklines@aol.com	Schreiber, Robert/Q-7550-2019; Scott, Michael/AAY-3110-2021; Pan, Hua/C-7662-2011	Schreiber, Robert/0000-0003-1590-2341	U.S. National Institutes of Health [HL-073646, CA-119342]; NATIONAL CANCER INSTITUTE [R01CA043059, U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056223] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Ralph Fuhrhop for PFC nanoparticle formulation, and Suqin Yao for the statistical analysis. This work was supported by U.S. National Institutes of Health grants (HL-073646 and CA-119342) to S.A.W.	Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Boroujerdi M., 2001, PHARMACOKINETICS PRI; Burtea C, 2012, ARTERIOSCL THROM VAS, V32, pE36, DOI 10.1161/ATVBAHA.112.245415; Cavalieri F, 2010, CURR TOP MED CHEM, V10, P1198, DOI 10.2174/156802610791384180; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Chen JJ, 2010, WIRES NANOMED NANOBI, V2, P431, DOI 10.1002/wnan.87; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; Defense Advanced Projects Research Agency, 2012, DARPABAA1234 CONTR M; Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013; Fazio S, 2001, FRONT BIOSCI-LANDMRK, V6, pD515, DOI 10.2741/Fazio; FEHLNER PF, 1991, J IMMUNOL, V146, P799; Galkina E, 2007, ARTERIOSCL THROM VAS, V27, P2292, DOI 10.1161/ATVBAHA.107.149179; Gavina M, 2006, BLOOD, V108, P2857, DOI 10.1182/blood-2006-04-018564; Hughes M, 2011, J ACOUST SOC AM, V129, P3756, DOI 10.1121/1.3578459; Hughes MS, 2006, IEEE T ULTRASON FERR, V53, P1609, DOI 10.1109/TUFFC.2006.1678189; JARISCH R, 1979, CLIN ALLERGY, V9, P535, DOI 10.1111/j.1365-2222.1979.tb02518.x; Jawien J, 2004, J PHYSIOL PHARMACOL, V55, P503; Kaneda MM, 2009, ANN BIOMED ENG, V37, P1922, DOI 10.1007/s10439-009-9643-z; Kelly KA, 2005, CIRC RES, V96, P327, DOI 10.1161/01.RES.0000155722.17881.dd; KING TP, 1994, J IMMUNOL, V153, P1124; KING TP, 1984, J IMMUNOL, V133, P2668; Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h; Klover PJ, 2010, NEOPLASIA, V12, P899, DOI 10.1593/neo.10716; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mall S, 1998, FARADAY DISCUSS, V111, P127; Markowska A, 2008, POL J PATHOL, V59, P49; Marsh JN, 2007, ULTRASOUND MED BIOL, V33, P950, DOI 10.1016/j.ultrasmedbio.2006.12.007; Masotti A, 2010, RECENT PAT NANOTECH, V4, P53, DOI 10.2174/187221010790712093; Matheny HE, 2000, J IMMUNOL, V164, P6550, DOI 10.4049/jimmunol.164.12.6550; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moon DO, 2008, TOXICON, V51, P112, DOI 10.1016/j.toxicon.2007.08.015; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Moreira JN, 2002, PHARMACEUT RES, V19, P265, DOI 10.1023/A:1014434732752; Nahrendorf M, 2009, JACC-CARDIOVASC IMAG, V2, P1213, DOI 10.1016/j.jcmg.2009.04.016; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; O'Hanlon DM, 2002, EUR J CANCER, V38, P2252, DOI 10.1016/S0959-8049(02)00218-6; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Pan H, 2012, METHOD ENZYMOL, V508, P17, DOI 10.1016/B978-0-12-391860-4.00002-1; Pan H, 2011, BIOMATERIALS, V32, P231, DOI 10.1016/j.biomaterials.2010.08.080; Pan H, 2010, FASEB J, V24, P2928, DOI 10.1096/fj.09-153130; Perrier T, 2010, CHEM-EUR J, V16, P11516, DOI 10.1002/chem.201000808; Perrier T, 2010, INT J PHARMACEUT, V396, P204, DOI 10.1016/j.ijpharm.2010.06.019; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Powl AM, 2003, BIOCHEMISTRY-US, V42, P14306, DOI 10.1021/bi034995k; Preiss DJ, 2007, INT J CLIN PRACT, V61, P697, DOI 10.1111/j.1742-1241.2007.01330.x; Raven JF, 2011, CELL CYCLE, V10, P794, DOI 10.4161/cc.10.5.14956; Regidor PA, 1998, EUR J GYNAECOL ONCOL, V19, P377; Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r; Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842; Son DJ, 2006, J PHARMACOL EXP THER, V317, P627, DOI 10.1124/jpet.105.095901; Van Dijk KW, 2000, INT J TISSUE REACT, V22, P49; von Maltzahn G, 2008, BIOCONJUGATE CHEM, V19, P1570, DOI 10.1021/bc800077y; Wang C, 2009, J BIOL CHEM, V284, P3804, DOI 10.1074/jbc.M807191200; Waters EA, 2008, MAGN RESON MED, V60, P1232, DOI 10.1002/mrm.21794; WEISSMANN G, 1969, BIOCHEM PHARMACOL, V18, P1771, DOI 10.1016/0006-2952(69)90167-1; Zibara K, 2000, ARTERIOSCL THROM VAS, V20, P2288, DOI 10.1161/01.ATV.20.10.2288	59	49	49	1	60	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					255	264		10.1096/fj.12-218081	http://dx.doi.org/10.1096/fj.12-218081			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047896	Green Published			2022-12-28	WOS:000313103200024
J	Yang, J; McNeish, B; Butterfield, C; Moses, MA				Yang, Jiang; McNeish, Brendan; Butterfield, Catherine; Moses, Marsha A.			Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer	FASEB JOURNAL			English	Article						vascular endothelial growth factor; hypoxia-inducible factor 1 alpha; extracellular signal-regulated kinase	GELATINASE-ASSOCIATED LIPOCALIN; TUMOR ANGIOGENESIS; GENE; NGAL; RAS; EXPRESSION; INHIBITOR; INVASION; COMPLEX; KINASE	Lipocalin 2 (Lcn2), a member of the lipocalin family, is up-regulated in a variety of epithelial cancers. We have previously reported that Lcn2 induces the epithelial to mesenchymal transition in breast cancer through the estrogen receptor alpha/Slug axis and that it is a potential noninvasive biomarker of this disease. Here, we report the novel finding that Lcn2 regulates breast cancer angiogenesis. Vascular endothelial growth factor (VEGF), a key angiogenic activator, was significantly increased with Lcn2 expression in MCF-7 human breast cancer cells as well as in an angiogenic line derived from MDA-MB-436 cells. Treatment with a VEGF-neutralizing antibody demonstrates that VEGF is essential for the angiogenic activity of Lcn2. We further demonstrate that Lcn2-induced VEGF is mediated through hypoxia-inducible factor 1 alpha (HIF-1 alpha) and that Lcn2 regulates HIF-1 alpha through extracellular signal-regulated kinase (Erk). The regulation of HIF-1 alpha and VEGF by Lcn2 was also demonstrated in the aggressive MDA-MB-231 cell line. Using the mouse corneal pocket assay, we found that Lcn2 significantly enhanced the angiogenesis induced by VEGF. Taken together, these results are the first to demonstrate that Lcn2 promotes angiogenesis in vitro and in vivo and suggest a novel mechanism through which Lcn2 may promote tumor progression.-Yang, J., McNeish, B., Butterfield, C., Moses, M. A. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 27, 45-50 (2013). www.fasebj.org	[Yang, Jiang; McNeish, Brendan; Butterfield, Catherine; Moses, Marsha A.] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; [Yang, Jiang; McNeish, Brendan; Butterfield, Catherine; Moses, Marsha A.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Yang, Jiang; Moses, Marsha A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Moses, MA (corresponding author), Childrens Hosp, Vasc Biol Program, 300 Longwood Ave,Karp 12-129, Boston, MA 02115 USA.	marsha.moses@childrens.harvard.edu		McNeish, Brendan/0000-0002-8285-168X	U.S. National Institutes of Health [R01 CA118764, P01 CA045548]; JoAnn Webb Fund for Angiogenesis Research; S. Elizabeth O'Brien Trust; Advanced Medical Foundation; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P01CA045548, R01CA118764] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JoAnn Webb Fund for Angiogenesis Research; S. Elizabeth O'Brien Trust; Advanced Medical Foundation; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Dipak Panigrahy for his guidance and help with the in vivo studies. The authors gratefully acknowledge the following financial support: U.S. National Institutes of Health grants R01 CA118764 and P01 CA045548, the JoAnn Webb Fund for Angiogenesis Research, the S. Elizabeth O'Brien Trust, the Advanced Medical Foundation, and the Breast Cancer Research Foundation.	Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Ebrahem Q, 2010, AM J PATHOL, V176, P496, DOI 10.2353/ajpath.2010.080642; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gruvberger S, 2001, CANCER RES, V61, P5979; Harper J, 2006, EXP SUPPL, V96, P223; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hu LM, 2009, LAB INVEST, V89, P531, DOI 10.1038/labinvest.2009.17; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Klausen P, 2005, EUR J HAEMATOL, V75, P332, DOI 10.1111/j.1600-0609.2005.00511.x; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Moniaux N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; Tong ZM, 2005, BIOCHEM J, V391, P441, DOI 10.1042/BJ20051020; Venkatesha S, 2006, MOL CANCER RES, V4, P821, DOI 10.1158/1541-7786.MCR-06-0110; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106	29	78	80	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					45	50		10.1096/fj.12-211730	http://dx.doi.org/10.1096/fj.12-211730			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	22982376	Green Published			2022-12-28	WOS:000313103200006
J	Azuma, M; Koyama, D; Kikuchi, J; Yoshizawa, H; Thasinas, D; Shiizaki, K; Kuro-o, M; Furukawa, Y; Kusano, E				Azuma, Masahiro; Koyama, Daisuke; Kikuchi, Jiro; Yoshizawa, Hiromichi; Thasinas, Dissayabutra; Shiizaki, Kazuhiro; Kuro-o, Makoto; Furukawa, Yusuke; Kusano, Eiji			Promoter methylation confers kidney-specific expression of the Klotho gene	FASEB JOURNAL			English	Article						CpG island; VISTA analysis; aging; kl/ kl mouse	DNA DEMETHYLATION; FUNCTIONAL VARIANT; ANTIAGING GENE; TET PROTEINS; CPG-ISLANDS; 5-METHYLCYTOSINE; IDENTIFICATION; PLURIPOTENT; SUPPRESSION; ASSOCIATION	The aging suppressor geneKlotho is predominantly expressed in the kidney irrespective of species. Because Klotho protein is an essential component of an endocrine axis that regulates renal phosphate handling, the kidney-specific expression is biologically relevant; however, little is known about its underlying mechanisms. Here we provide in vitro and in vivo evidence indicating that promoter methylation restricts the expression of the Klotho gene in the kidney. Based on evolutionary conservation and histone methylation patterns, the region up to - 1200 bp was defined as a major promoter element of the human Klotho gene. This region displayed promoter activity equally in Klotho-expressing and -nonexpressing cells in transient reporter assays, but the activity was reduced to similar to 20% when the constructs were integrated into the chromatin in the latter. Both endogenous and transfected Klotho promoters were 30-40% methylated in Klotho-nonexpressing cells, but unmethylated in Klotho-expressing renal tubular cells. DNA demethylating agents increased Klotho expression 1.5- to 3.0-fold in nonexpressing cells and restored the activity of silenced reporter constructs. Finally, we demonstrated that a severe hypomorphic allele of Klotho had aberrant CpG methylation in kl/kl mice. These findings might be useful in therapeutic intervention for accelerated aging and several complications caused by Klotho downregulation.- Azuma, M., Koyama, D., Kikuchi, J., Yoshizawa, H., Thasinas, D., Shiizaki, K., Kuro-o, M., Furukawa, Y., Kusano, E. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J. 26, 4264-4274 (2012). www.fasebj.org	[Azuma, Masahiro; Koyama, Daisuke; Kikuchi, Jiro; Furukawa, Yusuke] Jichi Med Univ, Div Stem Cell Regulat, Ctr Mol Med, Shimotsuke, Tochigi 3290498, Japan; [Azuma, Masahiro; Yoshizawa, Hiromichi; Thasinas, Dissayabutra; Shiizaki, Kazuhiro; Kusano, Eiji] Jichi Med Univ, Dept Internal Med, Div Nephrol, Shimotsuke, Tochigi 3290498, Japan; [Shiizaki, Kazuhiro; Kuro-o, Makoto] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	Jichi Medical University; Jichi Medical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Furukawa, Y (corresponding author), Jichi Med Univ, Div Stem Cell Regulat, Ctr Mol Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Ministry of Education, Culture, Sports, Science and Technology of Japan; U.S. National Institutes of Health [R01-DK091392 to M.K]; JKA Foundation from Keirin Race;  [C22591047 to Y.F]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK091392] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JKA Foundation from Keirin Race; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by a grant-in-aid for scientific research (C22591047 to Y.F.) and the Support Program for Strategic Research Foundation at Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a grant from the U.S. National Institutes of Health (R01-DK091392 to M.K.). This publication was subsidized by the JKA Foundation through its promotion funds from Keirin Race. The authors declare no conflicts of interest.	Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30; Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110; Duce JA, 2008, GLIA, V56, P106, DOI 10.1002/glia.20593; Friedman DJ, 2009, J BONE MINER RES, V24, P1847, DOI [10.1359/JBMR.090516, 10.1359/jbmr.090516]; Furukawa Y, 2005, MOL CANCER RES, V3, P325, DOI 10.1158/1541-7786.MCR-04-0105; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Globisch D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015367; Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Hu MC, 2011, J AM SOC NEPHROL, V22, P124, DOI 10.1681/ASN.2009121311; Hu MC, 2010, FASEB J, V24, P3438, DOI 10.1096/fj.10-154765; Hu MC, 2010, KIDNEY INT, V78, P1240, DOI 10.1038/ki.2010.328; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; John GB, 2011, AM J KIDNEY DIS, V58, P127, DOI 10.1053/j.ajkd.2010.12.027; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; King GD, 2012, AGE, V34, P1405, DOI 10.1007/s11357-011-9315-4; King GD, 2012, BIOCHEM J, V441, P453, DOI 10.1042/BJ20101909; Kobayashi T, 2009, KIDNEY INT, V75, P1173, DOI 10.1038/ki.2009.44; Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226; Kuro-O M, 2011, KIDNEY INT, V79, pS20, DOI 10.1038/ki.2011.26; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Kusano E, 2011, CLIN EXP NEPHROL, V15, P627, DOI 10.1007/s10157-011-0461-x; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Moreno JA, 2011, J AM SOC NEPHROL, V22, P1315, DOI 10.1681/ASN.2010101073; Nakamura T, 2007, NAT CELL BIOL, V9, P64, DOI 10.1038/ncb1519; Narumiya H, 2004, CARDIOVASC RES, V64, P331, DOI 10.1016/j.cardiores.2004.07.011; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Shih PH, 2007, BIOGERONTOLOGY, V8, P71, DOI 10.1007/s10522-006-9033-y; Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066; Sugiura H, 2010, NEPHROL DIAL TRANSPL, V25, P60, DOI 10.1093/ndt/gfp451; Sun CY, 2012, KIDNEY INT, V81, P640, DOI 10.1038/ki.2011.445; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Wada T, 2012, EMBO REP, V13, P142, DOI 10.1038/embor.2011.247; Wada T, 2009, J BIOL CHEM, V284, P30673, DOI 10.1074/jbc.M109.042242; Wang LJ, 2011, AM J CANCER RES, V1, P111; Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yoon HE, 2011, NEPHROL DIAL TRANSPL, V26, P800, DOI 10.1093/ndt/gfq537; Zhang H, 2008, KIDNEY INT, V74, P732, DOI 10.1038/ki.2008.244	60	63	68	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4264	4274		10.1096/fj.12-211631	http://dx.doi.org/10.1096/fj.12-211631			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22782974	Green Published			2022-12-28	WOS:000309704000031
J	Morag, N; Klement, E; Saroya, Y; Lensky, I; Gottlieb, Y				Morag, Neta; Klement, Eyal; Saroya, Yonatan; Lensky, Itamar; Gottlieb, Yuval			Prevalence of the symbiont Cardinium in Culicoides (Diptera: Ceratopogonidae) vector species is associated with land surface temperature	FASEB JOURNAL			English	Article						biting midges; insect symbiosis; satellite imagery data	CYTOPLASMIC INCOMPATIBILITY; BACTERIAL SYMBIONT; BEMISIA-TABACI; NATURAL-POPULATIONS; PEA APHID; WOLBACHIA; ENDOSYMBIONTS; BLUETONGUE; DIVERSITY; INFECTION	Prevalence of infection by bacterial symbionts may reflect their interactions with the host and has been shown to be correlated with environmental factors. Yet, it is still unclear whether infection by symbionts is determined by environmental factors affecting the early or imago stage of the host. Here, we identified and localized the symbiont Candidatus Cardinium hertigii (Bacteroidetes) in sympatric Culicoides biting midge species, examined its abundance, and studied its association with environmental factors. The prevalence of adult infection differed, with 50.7% from C. imicola, 31.4% from C. oxystoma, and 0% from C. schultzei gp., although phylogenetic analyses showed that Cardinium in these species is almost identical. In addition, prevalence of infection differed between climate regions, with lowest prevalence in the arid region and highest prevalence in the Mediterranean region. Multivariate linear regression analysis of Cardinium prevalence together with climatic and satellite imagery data-derived environmental variables revealed that infection prevalence is significantly associated with land surface temperature and explained up to 89.7% of infection prevalence variability. These findings suggest that the observed variation of Cardinium infection of the imago stage of Culicoides may be influenced by environmental conditions during the latter's early developmental stages.-Morag, N., Klement, E., Saroya, Y., Lensky, I., Gottlieb, Y. Prevalence of the symbiont Cardinium in Culicoides (Diptera: Ceratopogonidae) vector species is associated with land surface temperature. FASEB J. 26, 4025-4034 (2012). www.fasebj.org	[Morag, Neta; Klement, Eyal; Saroya, Yonatan; Gottlieb, Yuval] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Koret Sch Vet Med, IL-76100 Rehovot, Israel; [Lensky, Itamar] Bar Ilan Univ, Dept Geog & Environm, Ramat Gan, Israel	Hebrew University of Jerusalem; Bar Ilan University	Gottlieb, Y (corresponding author), Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Koret Sch Vet Med, POB 12, IL-76100 Rehovot, Israel.	yuvalgd@yahoo.com	Gottlieb, Yuval/H-6461-2013; Klement, Eyal/H-8388-2019; Lensky, Itamar/B-5285-2014	Klement, Eyal/0000-0002-2384-2345; Lensky, Itamar/0000-0001-7594-5277	U.S.-Israel Binational Agricultural Research and Development (BARD) [IS-4185-09, IS-4380-11C]; Robert H. Smith scholarship for outstanding Ph.D. students	U.S.-Israel Binational Agricultural Research and Development (BARD)(US-Israel Binational Science Foundation); Robert H. Smith scholarship for outstanding Ph.D. students	The authors thank Prof. Yehuda Braverman profusely for help with Culicoides working methods. The authors thank Karin Aharonson-Raz for her assistance with Culicoides trapping, and Yifat Guthmann and Navot Morag for assistance with the map construction. This research was supported by U.S.-Israel Binational Agricultural Research and Development (BARD) research grants IS-4185-09 and IS-4380-11C to Y.G. and by The Robert H. Smith scholarship for outstanding Ph.D. students to N.M. DNA sequences used were from GenBank (accession nos. JN166961-JN166964).	Baumann P, 2005, ANNU REV MICROBIOL, V59, P155, DOI 10.1146/annurev.micro.59.030804.121041; Bensadia F, 2006, J INSECT PHYSIOL, V52, P146, DOI 10.1016/j.jinsphys.2005.09.011; BIRLEY M H, 1987, Israel Journal of Entomology, V21, P39; Boorman J., 2006, GUIDE BRIT CULICOIDE; Boyd D. S., 1998, REMOTE SENSING REV, V16, P293, DOI DOI 10.1080/02757259809532357; BRAVERMAN Y, 1974, MOSQ NEWS, V34, P303; Braverman Y, 1996, J AM MOSQUITO CONTR, V12, P437; BRAVERMAN Y, 1985, P191; Breeuwer H, 2012, FRONT MICROBIOL SER, P207; Brownlie JC, 2009, TRENDS MICROBIOL, V17, P348, DOI 10.1016/j.tim.2009.05.005; Burke G, 2010, ISME J, V4, P242, DOI 10.1038/ismej.2009.114; Cetre-Sossah C, 2004, VET RES, V35, P325, DOI 10.1051/vetres:2004015; Chiel E, 2007, B ENTOMOL RES, V97, P407, DOI 10.1017/S0007485307005159; Dallas JF, 2003, MED VET ENTOMOL, V17, P379, DOI 10.1111/j.1365-2915.2003.00454.x; Duron O, 2008, MOL ECOL, V17, P1427, DOI 10.1111/j.1365-294X.2008.03689.x; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Frohlich DR, 1999, MOL ECOL, V8, P1683, DOI 10.1046/j.1365-294x.1999.00754.x; Goldreich Y., 2012, CLIMATE ISRAEL OBSER; Gotoh T, 2007, HEREDITY, V98, P13, DOI 10.1038/sj.hdy.6800881; Gottlieb Y, 2008, FASEB J, V22, P2591, DOI 10.1096/fj.07-101162; Gottlieb Y, 2010, J VIROL, V84, P9310, DOI 10.1128/JVI.00423-10; Guay JF, 2009, J INSECT PHYSIOL, V55, P919, DOI 10.1016/j.jinsphys.2009.06.006; Gueguen G, 2010, MOL ECOL, V19, P4365, DOI 10.1111/j.1365-294X.2010.04775.x; Haine ER, 2008, P ROY SOC B-BIOL SCI, V275, P353, DOI 10.1098/rspb.2007.1211; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Himler AG, 2011, SCIENCE, V332, P254, DOI 10.1126/science.1199410; Hunter MS, 2003, P ROY SOC B-BIOL SCI, V270, P2185, DOI 10.1098/rspb.2003.2475; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kedmi M, 2010, J DAIRY SCI, V93, P2486, DOI 10.3168/jds.2009-2850; Kurtti TJ, 1996, J INVERTEBR PATHOL, V67, P318, DOI 10.1006/jipa.1996.0050; Liu Y, 2006, J APPL ENTOMOL, V130, P523, DOI 10.1111/j.1439-0418.2006.01112.x; Mellor PS, 2000, ANNU REV ENTOMOL, V45, P307, DOI 10.1146/annurev.ento.45.1.307; MELLOR PS, 1984, J HYG-CAMBRIDGE, V93, P621, DOI 10.1017/S0022172400065190; Montllor CB, 2002, ECOL ENTOMOL, V27, P189, DOI 10.1046/j.1365-2311.2002.00393.x; Morag N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033610; Mullen G.R., 2009, MED ENTOMOL, P163; Mullens BA, 1999, J INVERTEBR PATHOL, V73, P231, DOI 10.1006/jipa.1998.4838; Muyzer G, 1998, MOL MICROBIAL ECOLOG; Nakamura Y, 2009, APPL ENVIRON MICROB, V75, P6757, DOI 10.1128/AEM.01583-09; Neelakanta G, 2010, J CLIN INVEST, V120, P3179, DOI 10.1172/JCI42868; Oliver KM, 2009, SCIENCE, V325, P992, DOI 10.1126/science.1174463; Simon JC, 2003, P ROY SOC B-BIOL SCI, V270, P1703, DOI 10.1098/rspb.2003.2430; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Suzuki M, 1999, INT J SYST BACTERIOL, V49, P1551, DOI 10.1099/00207713-49-4-1551; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tatem Andrew J, 2004, Int J Appl Earth Obs Geoinf, V6, P33, DOI 10.1016/j.jag.2004.07.001; Toju H, 2011, MOL ECOL, V20, P853, DOI 10.1111/j.1365-294X.2010.04980.x; Tsuchida T, 2002, MOL ECOL, V11, P2123, DOI 10.1046/j.1365-294X.2002.01606.x; Van Opijnen T, 1999, EXP APPL ACAROL, V23, P871, DOI 10.1023/A:1006363604916; Velthuis AGJ, 2010, PREV VET MED, V93, P294, DOI 10.1016/j.prevetmed.2009.11.007; Walker T, 2011, NATURE, V476, P450, DOI 10.1038/nature10355; Weeks AR, 2001, SCIENCE, V292, P2479, DOI 10.1126/science.1060411; Weeks AR, 2003, P ROY SOC B-BIOL SCI, V270, P1857, DOI 10.1098/rspb.2003.2425; Weeks AR, 2004, P ROY SOC B-BIOL SCI, V271, pS193, DOI 10.1098/rsbl.2003.0137; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Werren John H, 2008, Nat Rev Microbiol, V6, P741, DOI 10.1038/nrmicro1969; White JA, 2011, HEREDITY, V106, P585, DOI 10.1038/hdy.2010.89; Zchori-Fein E, 2004, MOL ECOL, V13, P2009, DOI 10.1111/j.1365-294X.2004.02203.x; Zchori-Fein E, 2001, P NATL ACAD SCI USA, V98, P12555, DOI 10.1073/pnas.221467498; Zindel R, 2011, J APPL ECOL, V48, P864, DOI 10.1111/j.1365-2664.2011.01984.x	60	37	39	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4025	4034		10.1096/fj.12-210419	http://dx.doi.org/10.1096/fj.12-210419			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22700874				2022-12-28	WOS:000309704000010
J	van de Wetering, K; Sapthu, S				van de Wetering, Koen; Sapthu, Sunny			ABCG2 functions as a general phytoestrogen sulfate transporter in vivo	FASEB JOURNAL			English	Article						metabolomics; BCRP; phase II metabolism; vesicular transport	GLUCURONIDE; METABOLISM; GENISTEIN; ACETAMINOPHEN; DISPOSITION; INFERTILITY; EXPRESSION; EXCRETION; BCRP	ABCG2 is an ATP-dependent efflux transporter that limits the systemic exposure of its substrates. The preferred substrates of ABCG2 in vivo are largely unknown. We aimed to identify the compounds transported by ABCG2 under physiological conditions. In vitro, ABCG2 transports several sulfate conjugates at high rates. We therefore used targeted metabolomics, specifically detecting compounds conjugated to sulfate, to search in plasma, urine, and bile samples of wild-type and Abcg2(-/-) mice for differentially present compounds, which are likely to represent in vivo ABCG2 substrates. Levels of many sulfate conjugates were up to 15-fold higher in plasma and urine of Abcg2(-/-) than of wild-type mice, with the opposite effect seen in bile. These differentially present compounds were identified as the sulfate conjugates of phytoestrogens, compounds with weak pro- or antiestrogenic properties. We confirmed that these sulfate conjugates were ABCG2 substrates using transportomics, a method that uses vesicular transport assays to screen for substrates of ABC transporters in body fluids. In conclusion, our results show that ABCG2 limits the systemic exposure to many different phytoestrogens, a class of compounds to which mammals are exposed on a daily basis via food of plant origin, by directing their sulfate conjugates for excretion via the feces.-Van de Wetering, K., Sapthu, S. ABCG2 functions as a general phytoestrogen sulfate transporter in vivo. FASEB J. 26, 4014-4024 (2012). www.fasebj.org	[van de Wetering, Koen; Sapthu, Sunny] Netherlands Canc Inst, Div Mol Oncol, Amsterdam, Netherlands	Netherlands Cancer Institute	van de Wetering, K (corresponding author), Div Mol Oncol H5, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	k.vd.wetering@nki.nl			ZonMw (TOP grant) [40-00812-98-07-028]	ZonMw (TOP grant)	The authors thank their colleagues Alfred Schinkel, Robert Jansen, Serge Zander, and Piet Borst for fruitful discussions and critical reading of the manuscript. The experimental work in the authors' laboratory is supported by ZonMw (TOP grant 40-00812-98-07-028, to K.V.D.W.). The authors declare no conflicts of interest.	Adachi Y, 2005, MOL PHARMACOL, V67, P923, DOI 10.1124/mol.104.007393; ADAMS NR, 1990, AUST VET J, V67, P197, DOI 10.1111/j.1751-0813.1990.tb07758.x; Alvarez AI, 2011, DRUG METAB DISPOS, V39, P2008, DOI 10.1124/dmd.111.040881; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Breedveld P, 2007, MOL PHARMACOL, V71, P240, DOI 10.1124/mol.106.028167; D'Alessandro TL, 2005, METHOD ENZYMOL, V400, P316, DOI 10.1016/S0076-6879(05)00019-4; de Loor H, 2005, CLIN CHEM, V51, P1535, DOI 10.1373/clinchem.2005.050781; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; Eeckhaut E, 2008, J AGR FOOD CHEM, V56, P4806, DOI 10.1021/jf800101s; Enokizono J, 2007, DRUG METAB DISPOS, V35, P922, DOI 10.1124/dmd.106.011239; Jansen GHE, 2005, ARCH BIOCHEM BIOPHYS, V435, P74, DOI 10.1016/j.abb.2004.12.015; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Krumpochova P, 2012, FASEB J, V26, P738, DOI 10.1096/fj.11-195743; Lafaye A, 2004, J MASS SPECTROM, V39, P655, DOI 10.1002/jms.635; Lee JK, 2009, DRUG METAB DISPOS, V37, P1916, DOI 10.1124/dmd.109.026815; Lewis RW, 2003, TOXICOL SCI, V71, P74, DOI 10.1093/toxsci/71.1.74; Pal A, 2007, J PHARMACOL EXP THER, V321, P1085, DOI 10.1124/jpet.106.119289; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Roth M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/j.1476-5381.2011.01724.x; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225, DOI 10.1016/0016-5085(87)91006-7; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; van de Wetering K, 2007, MOL PHARMACOL, V72, P387, DOI 10.1124/mol.107.035592; Van De Wetering K, 2009, GASTROENTEROLOGY, V137, P1725, DOI 10.1053/j.gastro.2009.06.052; van de Wetering K, 2009, MOL PHARMACOL, V75, P876, DOI 10.1124/mol.108.052019; Vlaming MLH, 2009, ADV DRUG DELIVER REV, V61, P14, DOI 10.1016/j.addr.2008.08.007; WHITTEN PL, 1993, BIOL REPROD, V49, P1117, DOI 10.1095/biolreprod49.5.1117; Zamek-Gliszczynski MJ, 2006, MOL PHARMACOL, V70, P2127, DOI 10.1124/mol.106.026955; Zhu W, 2010, AAPS J, V12, P525, DOI 10.1208/s12248-010-9209-x	30	26	26	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4014	4024		10.1096/fj.12-210039	http://dx.doi.org/10.1096/fj.12-210039			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22707564				2022-12-28	WOS:000309704000009
J	Kurihara, T; Jones, CN; Yu, YM; Fischman, AJ; Watada, S; Tompkins, RG; Fagan, SP; Irimia, D				Kurihara, Tomohiro; Jones, Caroline N.; Yu, Yong-Ming; Fischman, Alan J.; Watada, Susumu; Tompkins, Ronald G.; Fagan, Shawn P.; Irimia, Daniel			Resolvin D2 restores neutrophil directionality and improves survival after burns	FASEB JOURNAL			English	Article						chemotaxis; microfluidics; inflammation; innate immunity; lipid mediators	THERMAL-INJURY; D1; SEPSIS; INFECTION; MEDIATORS; TRAUMA; INFLAMMATION; MICE; RESOLUTION; MORTALITY	Following severe burns and trauma injuries, the changes of neutrophil migratory phenotype are a double-edged sword. Activated neutrophils migrate into injured tissues and help contain microbial infections, but they can also enter normal tissues and damage vital organs. Depleting the neutrophils from circulation protects vital organs against neutrophil-induced damage but leaves the body exposed to infectious complications. Here we show that restoring normal neutrophil migratory phenotype in rats with burn injuries correlates with improved survival in a classical double-injury model of sequential burn and septic insults. We uncovered that the directionality of neutrophils from burned rats can be restored both in vitro by 1 nM resolvin D2 (RvD2) and in vivo by RvD2 for 7 d, 25 ng/kg body mass (8-10 ng/rat). Restoring neutrophil directionality dramatically increases survival after a second septic insult at d 9 postburn. Survival of RvD2-treated animals increases from 0 to 100% after lipopolysaccharide injection and is extended by 1 wk after cecal ligation. Survival does not significantly increase when the restoration of neutrophil directionality is incomplete, following shorter regimens of RvD2. We conclude that restoring neutrophil directionality using RvD2 could have prophylactic value and delay lethal complications after burn injuries.-Kurihara T., Jones, C. N., Yu, Y.-M., Fischman, A. J., Watada, S., Tompkins, R. G., Fagan, S. P., Irimia, D. Resolvin D2 restores neutrophil directionality and improves survival after burns.	[Kurihara, Tomohiro; Jones, Caroline N.; Yu, Yong-Ming; Fischman, Alan J.; Watada, Susumu; Tompkins, Ronald G.; Fagan, Shawn P.; Irimia, Daniel] Shriners Hosp Children, Boston, MA USA; [Kurihara, Tomohiro; Jones, Caroline N.; Yu, Yong-Ming; Watada, Susumu; Tompkins, Ronald G.; Fagan, Shawn P.; Irimia, Daniel] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Jones, Caroline N.; Irimia, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, BioMEMS Resource Ctr, Boston, MA USA; [Fischman, Alan J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Nucl Med, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Irimia, D (corresponding author), MGH CNY, 114 16th St,1404, Boston, MA 02129 USA.	dirimia@hms.harvard.edu	Irimia, Daniel/A-4095-2008; Irimia, Daniel/S-5404-2019	Irimia, Daniel/0000-0001-7347-2082; Irimia, Daniel/0000-0001-7347-2082	Shriners Burns Hospital; U.S. National Institutes of Health [GM-092804, GM-007035, DE-019938]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007035, R01GM092804] Funding Source: NIH RePORTER	Shriners Burns Hospital; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by funds from Shriners Burns Hospital and U.S. National Institutes of Health grants GM-092804, GM-007035, and DE-019938.	Ambravaneswaran V, 2010, INTEGR BIOL-UK, V2, P639, DOI 10.1039/c0ib00011f; BABCOCK GF, 1990, CLIN IMMUNOL IMMUNOP, V54, P117, DOI 10.1016/0090-1229(90)90011-E; Bento AF, 2011, J IMMUNOL, V187, P1957, DOI 10.4049/jimmunol.1101305; Bohr S, 2013, WOUND REPAIR REGEN, V21, P35, DOI 10.1111/j.1524-475X.2012.00853.x; Branski LK, 2009, SURG INFECT, V10, P389, DOI 10.1089/sur.2009.024; Butler KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011921; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Carter EA, 1996, J TRAUMA, V40, P930, DOI 10.1097/00005373-199606000-00011; Centers for Disease Control and Prevention, 2012, WEB BAS INJ STAT QUE; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Chipp E, 2010, ANN PLAS SURG, V65, P228, DOI 10.1097/SAP.0b013e3181c9c35c; Claria J, 2012, J IMMUNOL, V189, P2597, DOI 10.4049/jimmunol.1201272; Fazal N, 2000, CRIT CARE MED, V28, P1550, DOI 10.1097/00003246-200005000-00048; Greenhalgh DG, 2007, J BURN CARE RES, V28, P776, DOI 10.1097/BCR.0b013e3181599bc9; Hu ZH, 2004, AM J PHYSIOL-CELL PH, V286, pC170, DOI 10.1152/ajpcell.00187.2003; Huber-Lang MS, 2001, FASEB J, V15, P568; Irimia D, 2010, ANNU REV BIOMED ENG, V12, P259, DOI 10.1146/annurev-bioeng-070909-105241; Jones CN, 2012, P NATL ACAD SCI USA, V109, P20560, DOI 10.1073/pnas.1210269109; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; Kotz KT, 2010, NAT MED, V16, P1042, DOI 10.1038/nm.2205; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liu T, 2006, MOL CELL PROTEOMICS, V5, P1899, DOI 10.1074/mcp.M600068-MCP200; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mann EA, 2012, SHOCK, V37, P4, DOI 10.1097/SHK.0b013e318237d6bf; Noel G, 2011, SHOCK, V36, P149, DOI 10.1097/SHK.0b013e3182205cbc; Norling LV, 2012, ARTERIOSCL THROM VAS, V32, P1970, DOI 10.1161/ATVBAHA.112.249508; Park CK, 2011, J NEUROSCI, V31, P18433, DOI 10.1523/JNEUROSCI.4192-11.2011; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sheridan R. L., 1997, Journal of Burn Care and Rehabilitation, V18, P455; SOLOMKIN JS, 1990, J TRAUMA, V30, pS80; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; TCHERVENKOV JI, 1988, ARCH SURG-CHICAGO, V123, P1477; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Williams FN, 2009, CRIT CARE, V13, DOI 10.1186/cc8170; Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Zhang MJ, 2012, ANNU REV NUTR, V32, P203, DOI 10.1146/annurev-nutr-071811-150726	44	62	69	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2270	2281		10.1096/fj.12-219519	http://dx.doi.org/10.1096/fj.12-219519			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430978	Green Published			2022-12-28	WOS:000319667600017
J	Okamoto, R; Li, YX; Noma, K; Hiroi, Y; Liu, PY; Taniguchi, M; Ito, M; Liao, JK				Okamoto, Ryuji; Li, Yuxin; Noma, Kensuke; Hiroi, Yukio; Liu, Ping-Yen; Taniguchi, Masaya; Ito, Masaaki; Liao, James K.			FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2	FASEB JOURNAL			English	Article						Rho kinase; angiotensin; four-and-a-half LIM-only protein; serum response factor; extracellular regulated signaling kinase	SERUM RESPONSE FACTOR; LONG-TERM INHIBITION; RHO-FAMILY GTPASES; ACTIN CYTOSKELETON; MYOCARDIAL-INFARCTION; PROTEIN FHL2; IN-VIVO; KINASE; MUSCLE; CELLS	The Rho-associated coiled-coil containing kinases, ROCK1 and ROCK2, are important regulators of cell shape, migration, and proliferation through effects on the actin cytoskeleton. However, it is not known whether ROCK2 plays an important role in the development of cardiac hypertrophy. To determine whether the loss of ROCK2 could prevent cardiac hypertrophy, cardiomyocyte-specific ROCK2-null (c-ROCK2(-/-)) were generated using conditional ROCK2(flox/flox) mice and alpha-myosin heavy-chain promoter-driven Cre recombinase transgenic mice. Cardiac hypertrophy was induced by Ang II infusion (400 ng/kg/min, 28 d) or transverse aortic constriction (TAC). Under basal conditions, hemodynamic parameters, cardiac anatomy, and function of c-ROCK2(-/-) mice were comparable to wild-type (WT) mice. However, following Ang II infusion or TAC, c-ROCK2(-/-) mice exhibited a substantially smaller increase in heart-to-body weight ratio, left ventricular mass, myocyte cross-sectional area, hypertrophy-related fetal gene expression, intraventricular fibrosis, cardiac apoptosis, and oxidative stress compared to control mice. Deletion of ROCK2 in cardiomyocytes leads to increased expression of four-and-a-half LIM-only protein-2 (FHL2) and FHL2-mediated inhibition of serum response factor (SRF) and extracellular signal-regulated mitogen-activated protein kinase (ERK). Knockdown of FHL2 expression in ROCK2-deficient cardiomyocytes or placing ROCK2-haploinsufficient (ROCK2(+/-)) mice on FHL2(+/-)-haploinsufficient background restored the hypertrophic response to Ang II. These results indicate that cardiomyocyte ROCK2 is essential for the development of cardiac hypertrophy and that up-regulation of FHL2 may contribute to the antihypertrophic phenotype that is observed in cardiac-specific ROCK2-deficient mice.-Okamoto, R., Li, Y., Noma, K., Hiroi, Y., Liu, P.-Y., Taniguchi, M., Ito, M., Liao, J. K. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J. 27, 1439-1449 (2013). www.fasebj.org	[Okamoto, Ryuji; Li, Yuxin; Noma, Kensuke; Hiroi, Yukio; Liu, Ping-Yen; Liao, James K.] Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA 02115 USA; [Okamoto, Ryuji; Li, Yuxin; Noma, Kensuke; Hiroi, Yukio; Liu, Ping-Yen; Liao, James K.] Harvard Univ, Sch Med, Boston, MA USA; [Okamoto, Ryuji; Taniguchi, Masaya; Ito, Masaaki] Mie Univ, Sch Med, Dept Cardiol & Nephrol, Tsu, Mie, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Mie University	Liao, JK (corresponding author), Brigham & Womens Hosp, 65 Landsdowne St,PRB 275, Cambridge, MA 02139 USA.	jliao@rics.bwh.harvard.edu	Li, yuxin/GSD-1668-2022; li, Yu/HCI-9086-2022; li, yu/HGL-9518-2022; Li, yu/HHZ-5236-2022		U.S. National Institutes of Health [HL-052233, HL-080187, DK-086005, NS-070001]; Mie University School of Medicine; Mie Medical Association and Scientific Research from the Ministry of Education, Science, Technology, Sports and Culture, Japan; Uehara Memorial Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080187, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070001] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mie University School of Medicine; Mie Medical Association and Scientific Research from the Ministry of Education, Science, Technology, Sports and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Uehara Memorial Foundation(Uehara Memorial Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Ju Chen (University of California, San Diego, CA, USA) for providing us with FHL2 KO mice. In addition, we are grateful for the following reagents: C2C12 cells (Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, TX, USA); Sf9 cells (Karin M. Hoffmeister, Brigham and Women's Hospital, Boston, MA, USA); baculovirus containing CA-ROCK2 and plasmids of ROCK2, CAROCK2, and DN-ROCK2 (Kozo Kaibuchi, Nagoya University, Nagoya, Japan); ROCK1 cDNA (Shuh Narumiya, Kyoto University, Kyoto, Japan), and adenovirus containing CA-ROCK (Zhihong Yang, University of Fribourg, Fribourg, Switzerland). This work was supported by grants from the U.S. National Institutes of Health (HL-052233, HL-080187, DK-086005, NS-070001), Mie University School of Medicine, Mie Medical Association and Scientific Research from the Ministry of Education, Science, Technology, Sports and Culture, Japan. R.O. was supported by a research fellowship from the Uehara Memorial Foundation.	Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chrissobolis S, 2006, STROKE, V37, P2174, DOI 10.1161/01.STR.0000231647.41578.df; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Fielitz J, 2007, P NATL ACAD SCI USA, V104, P4377, DOI 10.1073/pnas.0611726104; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; Hattori T, 2004, CIRCULATION, V109, P2234, DOI 10.1161/01.CIR.0000127939.16111.58; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kong YF, 2001, CIRCULATION, V103, P2731; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; Noma K, 2006, AM J PHYSIOL-CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005; Noma K, 2008, J CLIN INVEST, V118, P1632, DOI 10.1172/JCI29226; Parlakian A, 2005, CIRCULATION, V112, P2930, DOI 10.1161/CIRCULATIONAHA.105.533778; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Powell SR, 2006, AM J PHYSIOL-HEART C, V291, pH1, DOI 10.1152/ajpheart.00062.2006; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Rikitake Y, 2005, STROKE, V36, P2251, DOI 10.1161/01.STR.0000181077.84981.11; Rikitake Y, 2005, CIRCULATION, V111, P3261, DOI 10.1161/CIRCULATIONAHA.105.534024; Satoh M, 2006, P NATL ACAD SCI USA, V103, P7432, DOI 10.1073/pnas.0510444103; Shi JJ, 2008, J MOL CELL CARDIOL, V44, P551, DOI 10.1016/j.yjmcc.2007.11.018; Shimokawa H, 2005, ARTERIOSCL THROM VAS, V25, P1767, DOI 10.1161/01.ATV.0000176193.83629.c8; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Thumkeo D, 2005, GENES CELLS, V10, P825, DOI 10.1111/j.1365-2443.2005.00882.x; Wang YX, 2005, EUR J PHARMACOL, V512, P215, DOI 10.1016/j.ejphar.2005.02.024; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhang YM, 2006, FASEB J, V20, P916, DOI 10.1096/fj.05-5129com	44	66	69	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1439	1449		10.1096/fj.12-217018	http://dx.doi.org/10.1096/fj.12-217018			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23271052	Green Published			2022-12-28	WOS:000316940800016
J	Wuttke, A; Idevall-Hagren, O; Tengholm, A				Wuttke, Anne; Idevall-Hagren, Olof; Tengholm, Anders			P2Y(1) receptor-dependent diacylglycerol signaling microdomains in beta cells promote insulin secretion	FASEB JOURNAL			English	Article						ATP; pancreatic islets; protein kinase C; oscillations; pulsatile insulin release	PROTEIN-KINASE-C; PANCREATIC-ISLETS; PHOSPHOLIPASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; ADENINE-NUCLEOTIDES; GLUCOSE; RELEASE; ACTIVATION; EXOCYTOSIS; CA2+	Diacylglycerol (DAG) controls numerous cell functions by regulating the localization of C1-domain-containing proteins, including protein kinase C (PKC), but little is known about the spatiotemporal dynamics of the lipid. Here, we explored plasma membrane DAG dynamics in pancreatic beta cells and determined whether DAG signaling is involved in secretagogue-induced pulsatile release of insulin. Single MIN6 cells, primary mouse beta cells, and human beta cells within intact islets were transfected with translocation biosensors for DAG, PKC activity, or insulin secretion and imaged with total internal reflection fluorescence microscopy. Muscarinic receptor stimulation triggered stable, homogenous DAG elevations, whereas glucose induced short-lived (7.1 +/- 0.4 s) but high-amplitude elevations (up to 109 +/- 10% fluorescence increase) in spatially confined membrane regions. The spiking was mimicked by membrane depolarization and suppressed after inhibition of exocytosis or of purinergic P2Y(1), but not P2X receptors, reflecting involvement of autocrine purinoceptor activation after exocytotic release of ATP. Each DAG spike caused local PKC activation with resulting dissociation of its substrate protein MARCKS from the plasma membrane. Inhibition of spiking reduced glucose-induced pulsatile insulin secretion. Thus, stimulus-specific DAG signaling patterns appear in the plasma membrane, including distinct microdomains, which have implications for the kinetic control of exocytosis and other membrane-associated processes.-Wuttke, A., Idevall-Hagren, O., Tengholm, A. P2Y(1) receptor-dependent diacylglycerol signaling microdomains in beta cells promote insulin secretion. FASEB J. 27, 1610-1620 (2013). www.fasebj.org	[Wuttke, Anne; Idevall-Hagren, Olof; Tengholm, Anders] Uppsala Univ, Biomed Ctr, Dept Med Cell Biol, SE-75123 Uppsala, Sweden	Uppsala University	Tengholm, A (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Cell Biol, Box 571, SE-75123 Uppsala, Sweden.	anders.tengholm@mcb.uu.se		Idevall Hagren, Olof/0000-0002-0241-6304	Swedish Research Council; EFSD/MSD; Novo Nordisk Foundation; Swedish Diabetes Foundation; Family Ernfors Foundation; Swedish national strategic research initiative Exodiab (Excellence of Diabetes Research in Sweden); Juvenile Diabetes Research Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); EFSD/MSD; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Swedish Diabetes Foundation; Family Ernfors Foundation; Swedish national strategic research initiative Exodiab (Excellence of Diabetes Research in Sweden); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation)	The authors thank Dr. Tobias Meyer (Stanford University, Palo Alto, CA, USA) and Dr. Naoaki Saito (Kobe University, Hyogo, Japan) for generously providing expression plasmids; H. Dansk, H. Emanuelsson, and I. Morsare for technical assistance; and Drs. S. Barg, E. Gylfe, and B. Hellman for helpful discussions. This study was supported by grants from the Swedish Research Council, EFSD/MSD, the Novo Nordisk Foundation, the Swedish Diabetes Foundation, and the Family Ernfors Foundation. Human pancreatic islets were obtained from the Nordic network for clinical islet transplantation, supported by the Swedish national strategic research initiative Exodiab (Excellence of Diabetes Research in Sweden) and the Juvenile Diabetes Research Foundation. A. W. and A. T. designed the study, analyzed data, and wrote the article; A. W. acquired the DAG data; O.I-H. acquired the PIP<INF>3</INF> data.	ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERTRAND G, 1989, BRIT J PHARMACOL, V98, P998, DOI 10.1111/j.1476-5381.1989.tb14631.x; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; Biden TJ, 2008, BIOCHEM SOC T, V36, P916, DOI 10.1042/BST0360916; Carrasco S, 2007, TRENDS BIOCHEM SCI, V32, P27, DOI 10.1016/j.tibs.2006.11.004; CHAPAL J, 1981, EUR J PHARMACOL, V74, P127, DOI 10.1016/0014-2999(81)90522-7; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Dyachok O, 2004, J BIOL CHEM, V279, P45455, DOI 10.1074/jbc.M407673200; Dyachok O, 2008, CELL METAB, V8, P26, DOI 10.1016/j.cmet.2008.06.003; Ferdaoussi M, 2012, DIABETOLOGIA, V55, P2682, DOI 10.1007/s00125-012-2650-x; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Goto M, 2004, TRANSPLANTATION, V78, P1367, DOI 10.1097/01.TP.0000140882.53773.DC; Grapengiesser E, 2004, BIOCHEM PHARMACOL, V68, P667, DOI 10.1016/j.bcp.2004.04.018; Hashimoto N, 2005, J CLIN INVEST, V115, P138, DOI 10.1172/JCI200522232; Hellman B, 2004, AM J PHYSIOL-ENDOC M, V286, pE759, DOI 10.1152/ajpendo.00452.2003; Henquin JC, 2009, DIABETOLOGIA, V52, P739, DOI 10.1007/s00125-009-1314-y; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Idevall-Hagren O, 2006, J BIOL CHEM, V281, P39121; Jacques-Silva MC, 2010, P NATL ACAD SCI USA, V107, P6465, DOI 10.1073/pnas.0908935107; Kang LJ, 2006, CELL METAB, V3, P463, DOI 10.1016/j.cmet.2006.04.012; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kittel A, 2002, J HISTOCHEM CYTOCHEM, V50, P549, DOI 10.1177/002215540205000412; Kong KC, 2010, P NATL ACAD SCI USA, V107, P21181, DOI 10.1073/pnas.1011651107; LEITNER JW, 1975, ENDOCRINOLOGY, V96, P662; Leon Catherine, 2005, Purinergic Signal, V1, P145, DOI 10.1007/s11302-005-6209-x; MacDonald PE, 2006, CELL METAB, V4, P283, DOI 10.1016/j.cmet.2006.08.011; Mendez CF, 2003, J BIOL CHEM, V278, P44753, DOI 10.1074/jbc.M308664200; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Nesher R, 2002, DIABETES, V51, pS68, DOI 10.2337/diabetes.51.2007.S68; Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Obermuller S, 2005, J CELL SCI, V118, P4271, DOI 10.1242/jcs.02549; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PETIT P, 1989, BRIT J PHARMACOL, V98, P875, DOI 10.1111/j.1476-5381.1989.tb14616.x; Petit P, 2009, EUR J PHARM SCI, V37, P67, DOI 10.1016/j.ejps.2009.01.007; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Poulsen CR, 1999, DIABETES, V48, P2171, DOI 10.2337/diabetes.48.11.2171; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; Rodriguez-Diaz R, 2011, NAT MED, V17, P888, DOI 10.1038/nm.2371; Salehi A, 2005, DIABETES, V54, P2126, DOI 10.2337/diabetes.54.7.2126; Sato M, 2006, NAT METHODS, V3, P797, DOI 10.1038/nmeth930; Schmitz-Peiffer C, 2007, CELL METAB, V6, P320, DOI 10.1016/j.cmet.2007.08.012; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Suzuki Y, 2006, J BIOL CHEM, V281, P28499, DOI 10.1074/jbc.M604291200; Tengholm A, 2009, MOL CELL ENDOCRINOL, V297, P58, DOI 10.1016/j.mce.2008.07.009; Thore S, 2005, J CELL SCI, V118, P4463, DOI 10.1242/jcs.02577; Thore S, 2004, J BIOL CHEM, V279, P19396, DOI 10.1074/jbc.C400088200; Toker A, 2005, EMBO REP, V6, P310, DOI 10.1038/sj.embor.7400378; Uchida T, 2007, J BIOL CHEM, V282, P2707, DOI 10.1074/jbc.M610482200; Verspohl EJ, 2002, CAN J PHYSIOL PHARM, V80, P562, DOI 10.1139/Y02-079; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409; Zhang H, 2004, J PHYSIOL-LONDON, V561, P133, DOI 10.1113/jphysiol.2004.071241	63	37	37	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1610	1620		10.1096/fj.12-221499	http://dx.doi.org/10.1096/fj.12-221499			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23299857				2022-12-28	WOS:000316940800031
J	Clocchiatti, A; Di Giorgio, E; Ingrao, S; Meyer-Almes, FJ; Tripodo, C; Brancolini, C				Clocchiatti, Andrea; Di Giorgio, Eros; Ingrao, Sabrina; Meyer-Almes, Franz-Josef; Tripodo, Claudio; Brancolini, Claudio			Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors	FASEB JOURNAL			English	Article						KLF2; proliferation; Nur77; apoptosis; GSEA	HISTONE DEACETYLASE; GENE-EXPRESSION; CELL-GROWTH; MICROARRAY ANALYSIS; CANCER PATIENTS; GENOMIC GRADE; DIFFERENTIATION; INHIBITORS; APOPTOSIS; MEF2	MEF2s transcription factors and class IIa HDACs compose a fundamental axis for several differentiation pathways. Functional relationships between this axis and cancer are largely unexplored. We have found that class IIa HDACs are heterogeneously expressed and display redundant activities in breast cancer cells. Applying gene set enrichment analysis to compare the expression profile of a list of putative MEF2 target genes, we have discovered a correlation between the down-regulation of the MEF2 signature and the aggressiveness of ER+ breast tumors. Kaplan-Meier analysis in ER+ breast tumors evidenced an association between increased class IIa HDACs expression and reduced survival. The important role of the MEF2-HDAC axis in ER+ breast cancer was confirmed in cultured cells. MCF7 ER+ cells were susceptible to silencing of class IIa HDACs in terms of both MEF2-dependent transcription and apoptosis. Conversely, in ER- MDA-MB-231 cells, the repressive influence of class IIa HDACs was dispensable. Similarly, a class IIa HDAC-specific inhibitor preferentially promoted the up-regulation of several MEF2 target genes and apoptosis in ER+ cell lines. The prosurvival function of class IIa HDACs could be explained by the repression of NR4A1/Nur77, a proapoptotic MEF2 target. In summary, our studies underscore a contribution of class IIa HDACs to aggressiveness of ER+ tumors.-Clocchiatti, A., Di Giorgio, E., Ingrao, S., Meyer-Almes, F.-J., Tripodo, C., Brancolini, C. Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors. FASEB J. 27, 942-954 (2013). www.fasebj.org	[Clocchiatti, Andrea; Di Giorgio, Eros; Brancolini, Claudio] Univ Udine, Dipartimento Sci Med & Biol, I-33100 Udine, Italy; [Clocchiatti, Andrea; Di Giorgio, Eros; Brancolini, Claudio] Univ Udine, Micrograv Aging Training & Immobil MATI Ctr Excel, I-33100 Udine, Italy; [Ingrao, Sabrina; Tripodo, Claudio] Univ Palermo, Sch Med, Dept Human Pathol, Tumor Immunol Sect, Palermo, Italy; [Meyer-Almes, Franz-Josef] Univ Appl Sci, Dept Chem Engn & Biotechnol, Darmstadt, Germany	University of Udine; University of Udine; University of Palermo; Hochschule Darmstadt	Brancolini, C (corresponding author), Univ Udine, Dipartimento Sci Med & Biol, Ple Kolbe 4, I-33100 Udine, Italy.	claudio.brancolini@uniud.it	Tripodo, Claudio/AAB-6004-2022; Clocchiatti, Andrea/AAA-1992-2021; Meyer-Almes, Franz-Josef/D-9219-2017; Di Giorgio, Eros/AAF-4468-2020; Tripodo, Claudio/O-4536-2016	Tripodo, Claudio/0000-0002-0821-6231; Meyer-Almes, Franz-Josef/0000-0002-1001-3249; Tripodo, Claudio/0000-0002-0821-6231; Di Giorgio, Eros/0000-0003-0202-2222; BRANCOLINI, Claudio/0000-0002-6597-5373	Associazione Italiana Ricerca sul Cancro (AIRC) [IG-10437]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG-10437). The authors thank Ivana Manini (Universita di Udine), for help in the use of the cytofluorimeter, and Xiao-kun Zhang (Burnham Institute, San Diego, CA, USA), for providing Nur77 plasmid. A.C. received a Gemma del Corn fellowship from AIRC.	Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10-07-0616; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chinnaiyan P, 2006, INT J CANCER, V118, P1041, DOI 10.1002/ijc.21465; Clocchiatti A, 2011, J CELL MOL MED, V15, P1833, DOI 10.1111/j.1582-4934.2011.01321.x; Cohen TJ, 2009, FASEB J, V23, P99, DOI 10.1096/fj.08-115931; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Haus P, 2011, J BIOMOL SCREEN, V16, P1206, DOI 10.1177/1087057111424605; Henderson CJ, 2005, CELL DEATH DIFFER, V12, P1240, DOI 10.1038/sj.cdd.4401729; Huang YH, 2002, CANCER RES, V62, P2913; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kumar A, 2009, FASEB J, V23, P4344, DOI 10.1096/fj.09-138743; Liedtke C, 2009, J CLIN ONCOL, V27, P3185, DOI 10.1200/JCO.2008.18.5934; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Mihaylova MM, 2011, CELL, V145, P607, DOI 10.1016/j.cell.2011.03.043; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pfister TD, 2009, MOL CANCER THER, V8, P1878, DOI 10.1158/1535-7163.MCT-09-0016; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Zhang CY, 2011, MOL CANCER THER, V10, P1137, DOI 10.1158/1535-7163.MCT-10-1028	41	29	29	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					942	954		10.1096/fj.12-209346	http://dx.doi.org/10.1096/fj.12-209346			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23159930	Green Submitted			2022-12-28	WOS:000315585200010
J	Furuya, H; Wada, M; Shimizu, Y; Yamada, PM; Hannun, YA; Obeid, LM; Kawamori, T				Furuya, Hideki; Wada, Masayuki; Shimizu, Yoshiko; Yamada, Paulette M.; Hannun, Yusuf A.; Obeid, Lina M.; Kawamori, Toshihiko			Effect of sphingosine kinase 1 inhibition on blood pressure	FASEB JOURNAL			English	Article						sphingolipids; cardiovascular functions; chemoprevention; prostacyclin; COX-2; mPGES-1	PROSTAGLANDIN-E SYNTHASE-1; SIGNAL-REGULATED KINASE; II-INDUCED HYPERTENSION; CYCLOOXYGENASE-2 INHIBITOR; OXIDATIVE STRESS; E-2 PROTECTS; 1-PHOSPHATE; DELETION; RECEPTORS; CELECOXIB	Accumulating evidence suggests that sphingosine kinase 1 (SphK1) plays a key role in carcinogenesis by regulating cyclooxygenase-2 (COX-2) expression. Recent clinical studies have revealed that COX-2 inhibitors cause adverse cardiovascular side effects, likely due to inhibition of prostacyclin (PGI(2)). In this work, we investigated the roles of SphK1 inhibition on blood pressure (BP). The results show that lack of SphK1 expression did not exacerbate angiotensin II (Ang II)-induced acute hypertension, whereas celecoxib, a COX-2 inhibitor, augmented and sustained higher BP in mice. Interestingly, SphK1-knockout mice inhibited prostaglandin E-2 (PGE(2)) but not PGI(2) production in response to Ang II, whereas celecoxib blocked both PGE(2) and PGI(2) production. Mechanistically, SphK1 down-regulation by siRNA in human umbilical vein endothelial cells decreased cytokine-induced PGE(2) production primarily through inhibition of microsomal PGE synthase-1 (mPGES-1), not COX-2. SphK1 downregulation also decreased MKK6 expression, which phosphorylates and activates P38 MAPK, which, in turn, regulates early growth response-1 (Egr-1), a transcription factor of mPGES-1. Together, these data indicate that SphK1 regulates PGE(2) production by mPGES-1 expression via the p38 MAPK pathway, independent of COX-2 signaling, in endothelial cells, suggesting that SphK1 inhibition may be a promising strategy for cancer chemoprevention with lack of the adverse cardiovascular side effects associated with coxibs.-Furuya, H., Wada, M., Shimizu, Y., Yamada, P. M., Hannun, Y. A., Obeid, L. M., Kawamori, T. Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J. 27, 656-664 (2013). www.fasebj.org	[Furuya, Hideki; Shimizu, Yoshiko; Yamada, Paulette M.; Kawamori, Toshihiko] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA; [Furuya, Hideki; Wada, Masayuki; Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Shimizu, Yoshiko; Kawamori, Toshihiko] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA; [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Cancer Research Center of Hawaii; University of Hawaii System; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of Hawaii System; University of Hawaii Manoa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kawamori, T (corresponding author), Univ Hawaii, Ctr Canc, 651 Ilalo St,BSB 222H, Honolulu, HI 96813 USA.	kawamori@cc.hawaii.edu	Furuya, Hideki/AAH-5719-2021	Furuya, Hideki/0000-0002-9536-8662; obeid, lina/0000-0002-0734-0847	U.S. National Institutes of Health (NIH) [R01CA124687, P20RR17677, P01CA97132]; Hollings Cancer Center, MUSC; NIH Extramural Research Facilities Program of the National Center for Research Resources [C06RR015455]; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA124687] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677, C06RR015455] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hollings Cancer Center, MUSC; NIH Extramural Research Facilities Program of the National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors thank the Lipidomics Core Facility and Animal Carcinogenesis Core, Hollings Cancer Center, Medical University of South Carolina (MUSC), and Animal Carcinogenesis Shared Resource, University of Hawaii Cancer Center. This work was supported by U.S. National Institutes of Health (NIH) grants (R01CA124687 and P20RR17677 to T. K., P01CA97132 to T. K., Y.A.H., and L.M.O.) and a seed grant to T. K. from the Hollings Cancer Center, MUSC. This work was conducted in a facility constructed with support from the NIH Extramural Research Facilities Program of the National Center for Research Resources (C06RR015455).	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Cipollone F, 2008, PHARMACOL THERAPEUT, V118, P161, DOI 10.1016/j.pharmthera.2008.01.002; DIZ DI, 1983, J CLIN INVEST, V72, P466, DOI 10.1172/JCI110994; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Facemire CS, 2010, HYPERTENSION, V55, P531, DOI 10.1161/HYPERTENSIONAHA.109.145631; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Francois H, 2007, J AM SOC NEPHROL, V18, P1466, DOI 10.1681/ASN.2006040343; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Hemmings DG, 2006, N-S ARCH PHARMACOL, V373, P18, DOI 10.1007/s00210-006-0046-5; JACKSON EK, 1993, HYPERTENSION, V22, P688, DOI 10.1161/01.HYP.22.5.688; Jia ZJ, 2008, HYPERTENSION, V52, P952, DOI 10.1161/HYPERTENSIONAHA.108.111229; Jia ZJ, 2006, CIRC RES, V99, P1243, DOI 10.1161/01.RES.0000251306.40546.08; Jia ZJ, 2010, AM J PHYSIOL-RENAL, V299, pF155, DOI 10.1152/ajprenal.90702.2008; Jia ZJ, 2010, HYPERTENSION, V55, P539, DOI 10.1161/HYPERTENSIONAHA.109.144840; Kaneshiro T, 2009, PROSTAG OTH LIPID M, V90, P31, DOI 10.1016/j.prostaglandins.2009.07.003; Kawamori T, 2003, CARCINOGENESIS, V24, P985, DOI 10.1093/carcin/bgg033; Kawamori T, 1998, CANCER RES, V58, P409; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Levkau B, 2008, CIRC RES, V103, P231, DOI 10.1161/CIRCRESAHA.108.181610; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; MURATA S, 1995, STROKE, V26, P650, DOI 10.1161/01.STR.26.4.650; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Qi ZH, 2002, J CLIN INVEST, V110, P61, DOI 10.1172/JCI200214752; Qi ZH, 2006, HYPERTENSION, V48, P323, DOI 10.1161/01.HYP.0000231934.67549.b7; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Shirai K, 2011, CANCER PREV RES, V4, P454, DOI 10.1158/1940-6207.CAPR-10-0299; Shoji Y, 2004, GUT, V53, P1151, DOI 10.1136/gut.2003.028787; Siragy HM, 1999, J CLIN INVEST, V104, P181, DOI 10.1172/JCI6063; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886; Vascular Research Division Department of Pathology Brigham and Women's Hospital, 2004, IS MOUS LUNG END CEL; Wang M, 2008, CIRCULATION, V117, P1302, DOI 10.1161/CIRCULATIONAHA.107.731398; Wang M, 2006, P NATL ACAD SCI USA, V103, P14507, DOI 10.1073/pnas.0606586103; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484	52	15	15	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					656	664		10.1096/fj.12-219014	http://dx.doi.org/10.1096/fj.12-219014			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23109673	Green Published			2022-12-28	WOS:000314358000024
J	Pekcec, A; Yigitkanli, K; Jung, JE; Pallast, S; Xing, CH; Antipenko, A; Minchenko, M; Nikolov, DB; Holman, TR; Lo, EH; van Leyen, K				Pekcec, Anton; Yigitkanli, Kazim; Jung, Joo Eun; Pallast, Stefanie; Xing, Changhong; Antipenko, Alexander; Minchenko, Maria; Nikolov, Dimitar B.; Holman, Theodore R.; Lo, Eng H.; van Leyen, Klaus			Following experimental stroke, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling	FASEB JOURNAL			English	Article						eicosanoid; 12-HPETE; cortex; axon growth; second messenger	UP-REGULATION; ARACHIDONIC-ACID; INFARCT SIZE; CELL-DEATH; ANGIOGENESIS; MECHANISMS; EXPRESSION; RECEPTOR; KINASE; NEUROPILIN	Recovery from stroke is limited, in part, by an inhibitory environment in the postischemic brain, but factors preventing successful remodeling are not well known. Using cultured cortical neurons from mice, brain endothelial cells, and a mouse model of ischemic stroke, we show that signaling from the axon guidance molecule Sema3A via eicosanoid second messengers can contribute to this inhibitory environment. Either 90 nM recombinant Sema3A, or the 12/15-lipoxygenase (12/15-LOX) metabolites 12-HETE and 12-HPETE at 300 nM, block axon extension in neurons compared to solvent controls, and decrease tube formation in endothelial cells. The Sema3A effect is reversed by inhibiting 12/15-LOX, and neurons derived from 12/15-LOX-knockout mice are insensitive to Sema3A. Following middle cerebral artery occlusion to induce stroke in mice, immunohistochemistry shows both Sema3A and 12/15-LOX are increased in the cortex up to 2 wk. To determine whether a Sema3A-dependent damage pathway is activated following ischemia, we injected recombinant Sema3A into the striatum. Sema3A alone did not cause injury in normal brains. But when injected into postischemic brains, Sema3A increased cortical damage by 79%, and again, this effect was reversed by 12/15-LOX inhibition. Our findings suggest that blocking the semaphorin pathway should be investigated as a therapeutic strategy to improve stroke recovery.-Pekcec, A., Yigitkanli, K., Jung, J. E., Pallast, S., Xing, C., Antipenko, A., Minchenko, M., Nikolov, D. B., Holman, T. R., Lo, E. H., van Leyen, K. Following experimental stroke, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling. FASEB J. 27, 437-445 (2013). www.fasebj.org	[Pekcec, Anton; Yigitkanli, Kazim; Jung, Joo Eun; Pallast, Stefanie; Xing, Changhong; Lo, Eng H.; van Leyen, Klaus] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Charlestown, MA USA; [Antipenko, Alexander; Minchenko, Maria; Nikolov, Dimitar B.] Sloan Kettering Inst, Dept Biol Struct, New York, NY USA; [Holman, Theodore R.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	Harvard University; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; University of California System; University of California Santa Cruz	van Leyen, K (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, 149 13th St,R 2401, Charlestown, MA 02129 USA.	klaus_vanleyen@hms.harvard.edu	yigitkanli, kazım/AAK-6184-2021; van Leyen, Klaus/C-9126-2013	van Leyen, Klaus/0000-0003-1032-3754	U.S. National Institutes of Health [NS049430, NS069939, NS048372, GM056062]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056062, R01GM056062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS069939, R01NS049430, R01NS048372] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Emiri Mandeville for help with the injection experiments. This work was supported by U.S. National Institutes of Health grants NS049430 and NS069939 to K. V. L., NS048372 to D.B.N., and GM056062 to T.R.H.	Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Clarkson AN, 2009, BIOCHEM SOC T, V37, P1412, DOI 10.1042/BST0371412; Dawson TM, 2006, NAT MED, V12, P993, DOI 10.1038/nm0906-993; Foerch C, 2008, STROKE, V39, P3397, DOI 10.1161/STROKEAHA.108.517482; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Grundy RI, 2002, BRAIN RES, V926, P142, DOI 10.1016/S0006-8993(01)03325-X; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Hoang S, 2009, J CEREBR BLOOD F MET, V29, P385, DOI 10.1038/jcbfm.2008.128; Hou ST, 2008, BIOCHEM BIOPH RES CO, V367, P109, DOI 10.1016/j.bbrc.2007.12.103; Hung RJ, 2010, NATURE, V463, P823, DOI 10.1038/nature08724; Jiang SX, 2010, J BIOL CHEM, V285, P9908, DOI 10.1074/jbc.M109.080689; Jin G, 2008, STROKE, V39, P2538, DOI 10.1161/STROKEAHA.108.514927; Jin Z, 1997, J NEUROSCI, V17, P6256; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Kunz A, 2008, J NEUROSCI, V28, P1649, DOI 10.1523/JNEUROSCI.5205-07.2008; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Lo EH, 2009, STROKE, V40, pS2, DOI 10.1161/STROKEAHA.108.534404; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Mikule K, 2003, J BIOL CHEM, V278, P21168, DOI 10.1074/jbc.M211828200; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Montolio M, 2009, CHEM BIOL, V16, P691, DOI 10.1016/j.chembiol.2009.05.006; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Nie DT, 2006, J BIOL CHEM, V281, P18601, DOI 10.1074/jbc.M601887200; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Nishiyama M, 1998, EUR J PHARMACOL, V341, P57, DOI 10.1016/S0014-2999(97)01353-8; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; Pallast S, 2010, J CEREBR BLOOD F MET, V30, P1157, DOI 10.1038/jcbfm.2009.281; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; Sanfor SD, 2012, J NEUROCHEM, V120, P974, DOI 10.1111/j.1471-4159.2012.07651.x; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Simao F, 2012, J CEREBR BLOOD F MET, V32, P884, DOI 10.1038/jcbfm.2012.2; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; van Leyen K, 2008, J NEUROSCI RES, V86, P904, DOI 10.1002/jnr.21543; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5; Wang XY, 2004, STROKE, V35, P2726, DOI 10.1161/01.STR.0000143219.16695.af; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Williams G, 2005, J NEUROCHEM, V92, P1180, DOI 10.1111/j.1471-4159.2004.02950.x; Willmot M, 2005, NITRIC OXIDE-BIOL CH, V12, P141, DOI 10.1016/j.niox.2005.01.003; Willmot M, 2005, FREE RADICAL BIO MED, V39, P412, DOI 10.1016/j.freeradbiomed.2005.03.028; Xing CH, 2009, J NEUROSCI RES, V87, P2571, DOI 10.1002/jnr.22076; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yigitkanli K, 2013, ANN NEUROL, V73, P129, DOI 10.1002/ana.23734; Zafirou MP, 2007, PROSTAG LEUKOTR ESS, V77, P209, DOI 10.1016/j.plefa.2007.08.007; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008; Zlokovic BV, 2010, NAT MED, V16, P1370, DOI 10.1038/nm1210-1370	66	31	34	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					437	445		10.1096/fj.12-206896	http://dx.doi.org/10.1096/fj.12-206896			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23070608	Green Published			2022-12-28	WOS:000314358000005
J	Karunasekara, Y; Rebbeck, RT; Weaver, LM; Board, PG; Dulhunty, AF; Casarotto, MG				Karunasekara, Yamuna; Rebbeck, Robyn T.; Weaver, Llara M.; Board, Philip G.; Dulhunty, Angela F.; Casarotto, Marco G.			An alpha-helical C-terminal tail segment of the skeletal L-type Ca2+ channel beta(1a) subunit activates ryanodine receptor type 1 via a hydrophobic surface	FASEB JOURNAL			English	Article						excitation-contraction coupling; protein-protein interaction	BETA-1A SUBUNIT; EXCITATION; MUSCLE; SPECTROSCOPY; INVOLVEMENT	Excitation-contraction (EC) coupling in skeletal muscle depends on protein interactions between the transverse tubule dihydropyridine receptor (DHPR) voltage sensor and intracellular ryanodine receptor (RyR1) calcium release channel. We present novel data showing that the C-terminal 35 residues of the beta(1a) subunit adopt a nascent alpha-helix in which 3 hydrophobic residues align to form a hydrophobic surface that binds to RyR1 isolated from rabbit skeletal muscle. Mutation of the hydrophobic residues (L496, L500, W503) in peptide beta(1a)V490-M524, corresponding to the C-terminal 35 residues of beta(1a), reduced peptide binding to RyR1 to 15.2 +/- 7.1% and prevented the 2.9 +/- 0.2-fold activation of RyR1 by 10 nM wild-type peptide. An upstream hydrophobic heptad repeat implicated in beta(1a) binding to RyR1 does not contribute to RyR1 activation. Wild-type beta(1a)A474-A508 peptide (10 nM), containing heptad repeat and hydrophobic surface residues, increased RyR1 activity by 2.3 +/- 0.2- and 2.2 +/- 0.3-fold after mutation of the heptad repeat residues. We conclude that specific hydrophobic surface residues in the 35 residue beta(1a) C-terminus bind to RyR1 and increase channel activity in lipid bilayers and thus may support skeletal EC coupling.-Karunasekara, Y., Rebbeck, R. T., Weaver, L. M., Board, P. G., Dulhunty, A. F., Casarotto, M. G. An alpha-helical C-terminal tail segment of the skeletal L-type Ca2+ channel beta(1a) subunit activates ryanodine receptor type 1 via a hydrophobic surface. FASEB J. 26, 5049-5059 (2012). www.fasebj.org	[Karunasekara, Yamuna; Rebbeck, Robyn T.; Weaver, Llara M.; Board, Philip G.; Dulhunty, Angela F.; Casarotto, Marco G.] Australian Natl Univ, John Curtin Sch Med Res, Dept Translat Biosci, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Casarotto, MG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Dept Translat Biosci, POB 334, Canberra, ACT 2601, Australia.	marco.casarotto@anu.edu.au	Dulhunty, Angela/AAO-5421-2020	Dulhunty, Angela/0000-0001-9493-4944; Casarotto, Marco/0000-0002-0571-7671				Bannister RA, 2007, J MUSCLE RES CELL M, V28, P275, DOI 10.1007/s10974-007-9118-5; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beam KG, 2010, J GEN PHYSIOL, V136, P7, DOI 10.1085/jgp.201010461; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; Cheng WJ, 2005, P NATL ACAD SCI USA, V102, P19225, DOI 10.1073/pnas.0504334102; Dayal A, 2010, CELL CALCIUM, V47, P500, DOI 10.1016/j.ceca.2010.04.003; Goddard T. D., THESIS U CALIFORNIA; Karunasekara Y, 2009, EUR BIOPHYS J BIOPHY, V39, P75, DOI 10.1007/s00249-009-0467-4; Kimura T, 2005, HUM MOL GENET, V14, P2189, DOI 10.1093/hmg/ddi223; Kourie JI, 1996, AM J PHYSIOL-CELL PH, V270, pC1675, DOI 10.1152/ajpcell.1996.270.6.C1675; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rebbeck RT, 2011, BIOPHYS J, V100, P922, DOI 10.1016/j.bpj.2011.01.022; Schredelseker J, 2009, J BIOL CHEM, V284, P1242, DOI 10.1074/jbc.M807767200; Sheridan DC, 2004, BIOPHYS J, V87, P929, DOI 10.1529/biophysj.104.043810; Wei L, 2009, INT J BIOCHEM CELL B, V41, P2214, DOI 10.1016/j.biocel.2009.04.017; Wurthrich K., 1986, NMR PROTEINS NUCL AC	18	16	16	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2012	26	12					5049	5059		10.1096/fj.12-211334	http://dx.doi.org/10.1096/fj.12-211334			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22962299				2022-12-28	WOS:000311838300026
J	Alessandri, C; Barbati, C; Vacirca, D; Piscopo, P; Confaloni, A; Sanchez, M; Maselli, A; Colasanti, T; Conti, F; Truglia, S; Perl, A; Valesini, G; Malorni, W; Ortona, E; Pierdominici, M				Alessandri, Cristiano; Barbati, Cristiana; Vacirca, Davide; Piscopo, Paola; Confaloni, Annamaria; Sanchez, Massimo; Maselli, Angela; Colasanti, Tania; Conti, Fabrizio; Truglia, Simona; Perl, Andras; Valesini, Guido; Malorni, Walter; Ortona, Elena; Pierdominici, Marina			T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy	FASEB JOURNAL			English	Article						autoimmunity; cell fate; autoantibodies	GENOME-WIDE ASSOCIATION; CELL-ACTIVATION; APOPTOSIS; DEATH; AUTOIMMUNITY; DIFFERENTIATION; ABNORMALITIES; PATHOGENESIS; INHIBITION; IMMUNITY	Autophagy, the cytoprotection mechanism that takes place under metabolic impairment, has been implicated in the pathogenesis of autoimmunity. Here, we investigated the spontaneous and induced autophagic behavior of T lymphocytes from patients with systemic lupus erythematosus (SLE) compared with that of T lymphocytes from healthy donors by measuring the autophagy marker microtubule-associated protein 1 light chain 3 (LC3)-II. No significant differences in spontaneous autophagy were found between T lymphocytes from patients with SLE and from healthy donors, apart from CD4(+) naive T cells from patients with SLE in which constitutively higher levels of autophagy (P<0.001) were detected. At variance, whereas treatment of T lymphocytes from healthy donors with serum IgG from patients with SLE resulted in a 2-fold increase in LC3-II levels (P<0.001), T lymphocytes from SLE patients were resistant to autophagic induction and also displayed an up-regulation of genes negatively regulating autophagy, e.g., alpha-synuclein. These findings could open new perspectives in the search for pathogenetic determinants of SLE progression and in the development of therapeutic strategies aimed to recover T-cell compartment homeostasis by restoring autophagic susceptibility.-Alessandri, C., Barbati, C., Vacirca, D., Piscopo, P., Confaloni, A., Sanchez, M., Maselli, A., Colasanti, T., Conti, F., Truglia, S., Perl, A., Valesini, G., Malorni, W., Ortona, E., Pierdominici, M. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J. 26, 4722-4732 (2012). www.fasebj.org	[Malorni, Walter] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy; [Alessandri, Cristiano; Conti, Fabrizio; Truglia, Simona; Valesini, Guido] Sapienza Univ, Lupus Clin, Dipartimento Med Interna & Specialita Med, Rome, Italy; [Barbati, Cristiana; Vacirca, Davide; Piscopo, Paola; Confaloni, Annamaria; Sanchez, Massimo; Maselli, Angela; Colasanti, Tania; Ortona, Elena; Pierdominici, Marina] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Barbati, Cristiana; Colasanti, Tania; Malorni, Walter] San Raffaele Inst Sulmona, Laquila, Italy; [Perl, Andras] SUNY Syracuse, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA; [Malorni, Walter] Ctr Integrated Metabol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome; Istituto Superiore di Sanita (ISS); State University of New York (SUNY) System	Malorni, W (corresponding author), Ist Super Sanita, Dept Therapeut Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Malorni, Walter/G-5874-2016; Sanchez, Massimo/AAD-1746-2021; COLASANTI, Tania/AFI-8434-2022; Piscopo, Paola/J-6504-2016; COLASANTI, Tania/AAF-4074-2022; Pierdominici, Marina/J-6436-2016; ortona, elena/J-6395-2016	Sanchez, Massimo/0000-0003-3696-7582; COLASANTI, Tania/0000-0002-4413-1817; Piscopo, Paola/0000-0002-0693-4969; COLASANTI, Tania/0000-0002-4413-1817; Confaloni, Annamaria/0000-0002-5390-8536; Pierdominici, Marina/0000-0002-6372-3754; , simona/0000-0001-9515-2135; malorni, walter/0000-0002-1223-7000; ortona, elena/0000-0001-9845-8105; Perl, Andras/0000-0002-5017-1348; Alessandri, Cristiano/0000-0003-4149-5321	Ministero della Salute; Associazione Italiana Ricerca Cancro (AIRC) [MCO-9998]; Programma di Ricerca di Rilevante Interesse Nazionale (PRIN); U.S. National Institutes of Health [AI048079, AI072648]; Alliance for Lupus Research; Central New York Community Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048079, R01AI048079] Funding Source: NIH RePORTER	Ministero della Salute(Ministry of Health, Italy); Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Programma di Ricerca di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Lupus Research; Central New York Community Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by grants from the Ministero della Salute (W.M. and E.O.), Associazione Italiana Ricerca Cancro (AIRC) MCO-9998 (W. M.), Programma di Ricerca di Rilevante Interesse Nazionale (PRIN) 2007 (G. V.), the U.S. National Institutes of Health (AI048079 and AI072648), the Alliance for Lupus Research, and the Central New York Community Foundation.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007; Ciuffreda L, 2010, CURR CANCER DRUG TAR, V10, P484, DOI 10.2174/156800910791517172; Crispin JC, 2010, TRENDS MOL MED, V16, P47, DOI 10.1016/j.molmed.2009.12.005; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; EMLEN W, 1994, J IMMUNOL, V152, P3685; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Fernandez D, 2006, ARTHRITIS RHEUM-US, V54, P2983, DOI 10.1002/art.22085; Fernandez D, 2010, DISCOV MED, V9, P173; Fritsch RD, 2006, ARTHRITIS RHEUM, V54, P2184, DOI 10.1002/art.21943; Gaipl US, 2007, J AUTOIMMUN, V28, P114, DOI 10.1016/j.jaut.2007.02.005; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Gerland LM, 2004, EXP GERONTOL, V39, P789, DOI 10.1016/j.exger.2004.01.013; Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932; Gros F, 2012, AUTOPHAGY, V8, P1113, DOI 10.4161/auto.20275; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Harr MW, 2010, AUTOPHAGY, V6, P912, DOI 10.4161/auto.6.7.13290; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Ikeda T, 2010, J IMMUNOL, V185, P5259, DOI 10.4049/jimmunol.0902797; Juang YT, 2005, J CLIN INVEST, V115, P996, DOI 10.1172/JCI22854; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kohler S, 2009, BLOOD, V113, P769, DOI 10.1182/blood-2008-02-139154; Kovacs B, 1996, CLIN IMMUNOL IMMUNOP, V81, P293, DOI 10.1006/clin.1996.0192; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lee BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023939; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li CY, 2006, J IMMUNOL, V177, P5163, DOI 10.4049/jimmunol.177.8.5163; Liao JJ, 2009, FASEB J, V23, P1786, DOI 10.1096/fj.08-124891; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lleo A, 2007, J AUTOIMMUN, V29, P61, DOI 10.1016/j.jaut.2007.06.003; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; MINOTA S, 1987, J IMMUNOL, V138, P1750; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mosca M, 2006, CLIN EXP RHEUMATOL, V24, pS100; Moulton VR, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3251; Perl A, 2010, AUTOIMMUNITY, V43, P32, DOI 10.3109/08916930903374774; Pierdominici M, 2012, FASEB J, V26, P1400, DOI 10.1096/fj.11-194175; Powell JD, 2010, IMMUNITY, V33, P301, DOI 10.1016/j.immuni.2010.09.002; Pua HH, 2007, AUTOPHAGY, V3, P266, DOI 10.4161/auto.3908; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Pua HH, 2009, CURR TOP MICROBIOL, V335, P85, DOI 10.1007/978-3-642-00302-8_4; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Spronk PE, 1996, CLIN EXP IMMUNOL, V104, P446, DOI 10.1046/j.1365-2249.1996.44754.x; Tamai K, 2007, BIOCHEM BIOPH RES CO, V360, P721, DOI 10.1016/j.bbrc.2007.06.105; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Towns R, 2005, AUTOPHAGY, V1, P163, DOI 10.4161/auto.1.3.2068; Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Walsh CM, 2010, IMMUNOL REV, V236, P95, DOI 10.1111/j.1600-065X.2010.00919.x; WEISSMANN G, 1964, LANCET, V2, P1373; Winslow AR, 2010, J CELL BIOL, V190, P1023, DOI 10.1083/jcb.201003122; Zhou XJ, 2011, ANN RHEUM DIS, V70, P1330, DOI 10.1136/ard.2010.140111	60	107	117	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4722	4732		10.1096/fj.12-206060	http://dx.doi.org/10.1096/fj.12-206060			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835828	Green Published			2022-12-28	WOS:000310574200032
J	Czyzyk, TA; Romero-Pico, A; Pintar, J; McKinzie, JH; Tschop, MH; Statnick, MA; Nogueiras, R				Czyzyk, Traci A.; Romero-Pico, Amparo; Pintar, John; McKinzie, Jaime H.; Tschoep, Matthias H.; Statnick, Michael A.; Nogueiras, Ruben			Mice lacking delta-opioid receptors resist the development of diet-induced obesity	FASEB JOURNAL			English	Article						body weight; fat mass; energy expenditure; brown adipose tissue	DEFICIENT MICE; BETA-FUNALTREXAMINE; INSULIN-SECRETION; MET-ENKEPHALIN; ZUCKER RATS; FOOD-INTAKE; PEPTIDES; THERMOGENESIS; MECHANISMS; LY255582	Pharmacological manipulation of opioid receptors alters feeding behavior. However, the individual contributions of each opioid receptor subtype on energy balance remain largely unknown. Herein, we investigated whether genetic disruption of the delta-opioid receptor (DOR) also controls energy homeostasis. Mice lacking DOR and wild-type mice were fed with standard diet and high-energy diet (HED). Mice were analyzed in vivo with the indirect calorimetry system, and tissues were analyzed by real-time PCR and Western blot analysis. DOR-knockout (KO) mice gained less weight (P < 0.01) and had lower fat mass (P < 0.01) when compared to WT mice fed an HED. Although DOR-KO mice were hyperphagic, they showed higher energy expenditure (P < 0.05), which was the result of an increased activation of the thermogenic program in brown adipose tissue. The increased nonshivering thermogenesis involved the stimulation of uncoupling protein 1 (UCP1; P < 0.01), peroxisome proliferator-activated receptor gamma coactivator (PGC1 alpha; P < 0.05), and fibroblast growth factor 21 (FGF21; P < 0.01). DOR deficiency also led to an attenuation of triglyceride content in the liver (P < 0.05) in response to an HED. These findings reveal a novel role of DOR in the control of thermogenic markers and energy expenditure, and they provide a potential new therapeutic approach for the treatment of obesity.-Czyzyk, T. A., Romero-Pico, A., Pintar, J., McKinzie, J. H., Tschp, M. H., Statnick, M. A., Nogueiras, R. Mice lacking delta-opioid receptors resist the development of diet-induced obesity. FASEB J. 26, 3483-3492 (2012). www.fasebj.org	[Romero-Pico, Amparo; Nogueiras, Ruben] Univ Santiago de Compostela, Dept Physiol, Sch Med,Inst Invest Sanitaria, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Santiago De Compostela 15782, A Coruna, Spain; [Czyzyk, Traci A.; McKinzie, Jaime H.; Statnick, Michael A.] Lilly Res Labs, Obes Res, Indianapolis, IN USA; [Pintar, John] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Tschoep, Matthias H.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA	CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Universidade de Santiago de Compostela; Eli Lilly; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; University of Cincinnati	Nogueiras, R (corresponding author), Univ Santiago de Compostela, Dept Physiol, Sch Med,Inst Invest Sanitaria, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, S Francisco S-N, Santiago De Compostela 15782, A Coruna, Spain.	statnick_michael_a@lilly.com; ruben.nogueiras@usc.es	Nogueiras, Ruben/AAS-9427-2021; Tschoep, Matthias H/I-5443-2014	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X; Romero-Pico, Amparo/0000-0001-5104-6998; Czyzyk, Traci/0000-0002-3888-8338	Ministerio de Educacion y Ciencia [RYC-2008-02219, SAF2009-07049]; Xunta de Galicia [2010/14]; European Union [Health-F2-2008-223713]; Reprobesity; FP7 [245009]; NeuroFAST; ERC-2011-StG-OBESITY53-281408; U.S. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [NIDDK59630, NIDDK69987, NIDDK56863]	Ministerio de Educacion y Ciencia(Spanish Government); Xunta de Galicia(Xunta de GaliciaEuropean Commission); European Union(European Commission); Reprobesity; FP7; NeuroFAST; ERC-2011-StG-OBESITY53-281408; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work has been supported by grants from Ministerio de Educacion y Ciencia (R.N.: RYC-2008-02219 and SAF2009-07049), Xunta de Galicia (R.N.: 2010/14), and the European Union (R.N.: Health-F2-2008-223713, Reprobesity; FP7/2007-2013 under grant agreement no. 245009, NeuroFAST; and ERC-2011-StG-OBESITY53-281408). Centro de Investigacion Biomedica en Red de Fisiopatolog a de la Obesidad y Nutricion is an initiative of Instituto de Salud Carlos III. Research at the University of Cincinnati was funded by the U.S. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants NIDDK59630, NIDDK69987, and NIDDK56863 (M.H.T.). Author contributions: T.A.C., conception and design of data and drafting the article; A.R., analysis and interpretation of data; J.P., analysis and interpretation of data; J.H.M., analysis and interpretation of data; M.H.T. and M.A.S., critical revision for important intellectual content; R.N., conception and design of data, drafting the article or critical revision for important intellectual content. During the course of these studies, T.A.C., J.H.M, and M.A.S. were employees of Lilly Research Laboratories, Eli Lilly and Company. Sponsorship was indirect through personnel and generation of some of the data. No direct funds were granted.	AHREN B, 1989, INT J PANCREATOL, V5, P165; BAILEY CJ, 1987, DIABETOLOGIA, V30, P33, DOI 10.1007/BF01788904; Bodnar RJ, 2009, PEPTIDES, V30, P2432, DOI 10.1016/j.peptides.2009.09.027; Brugman S, 2002, ENDOCRINOLOGY, V143, P4265, DOI 10.1210/en.2002-220230; Cole JL, 1997, PEPTIDES, V18, P1201, DOI 10.1016/S0196-9781(97)00074-0; Coppola A, 2007, CELL METAB, V5, P21, DOI 10.1016/j.cmet.2006.12.002; Czyzyk T. A., FASEB J, V24, P1151; Evans AAL, 2001, METABOLISM, V50, P1402, DOI 10.1053/meta.2001.28158; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; Gaveriaux-Ruff C., PAIN, V152, P1238; GIUGLIANO D, 1987, METABOLISM, V36, P286, DOI 10.1016/0026-0495(87)90190-9; GOSNELL BA, 1986, LIFE SCI, V38, P1081, DOI 10.1016/0024-3205(86)90243-2; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Herz A, 1998, CAN J PHYSIOL PHARM, V76, P252, DOI 10.1139/cjpp-76-3-252; HIMMSHAGEN J, 1984, NEW ENGL J MED, V311, P1549, DOI 10.1056/NEJM198412133112407; HOLTZMAN SG, 1979, LIFE SCI, V24, P219, DOI 10.1016/0024-3205(79)90222-4; Hondares E., CELL METAB, V11, P206; JORDAN D, 1986, NEUROSCI LETT, V67, P289, DOI 10.1016/0304-3940(86)90324-1; KOTZ CM, 1993, BRAIN RES, V631, P325, DOI 10.1016/0006-8993(93)91552-4; Le Merrer J, 2011, BIOL PSYCHIAT, V69, P700, DOI 10.1016/j.biopsych.2010.10.021; Lee S. J., EMBO REP, V11, P226; LEVINE AS, 1991, BRAIN RES, V562, P281, DOI 10.1016/0006-8993(91)90632-6; Levine AS, 1997, ANNU REV NUTR, V17, P597, DOI 10.1146/annurev.nutr.17.1.597; Lopez M., NAT MED, V16, P1001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MARTIN WR, 1983, PHARMACOL REV, V35, P283; Minkler PE, 2006, ANAL BIOCHEM, V352, P24, DOI 10.1016/j.ab.2006.02.015; MITSUMA T, 1983, LIFE SCI, V32, P241, DOI 10.1016/0024-3205(83)90036-X; NEGRI M, 1992, METABOLISM, V41, P460, DOI 10.1016/0026-0495(92)90200-T; Nogueiras R, 2009, J NEUROSCI, V29, P5916, DOI 10.1523/JNEUROSCI.5977-08.2009; Ong K. T., HEPATOLOGY, V53, P116; Papaleo F, 2007, EUR J NEUROSCI, V25, P3398, DOI 10.1111/j.1460-9568.2007.05595.x; REID LD, 1985, AM J CLIN NUTR, V42, P1099, DOI 10.1093/ajcn/42.5.1099; Rodd D W, 1994, Obes Res, V2, P246; Sahr AE, 2008, AM J PHYSIOL-REG I, V295, pR463, DOI 10.1152/ajpregu.00390.2007; SHAW WN, 1993, PHARMACOL BIOCHEM BE, V46, P653, DOI 10.1016/0091-3057(93)90557-A; SHAW WN, 1991, INT J OBESITY, V15, P387; Silva JE, 2006, PHYSIOL REV, V86, P435, DOI 10.1152/physrev.00009.2005; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Statnick MA, 2003, AM J PHYSIOL-REG I, V284, pR1399, DOI 10.1152/ajpregu.00632.2002; Sweet DC, 2004, PEPTIDES, V25, P307, DOI 10.1016/j.peptides.2003.12.014; Tabarin A, 2005, DIABETES, V54, P3510, DOI 10.2337/diabetes.54.12.3510; Velasquez D. A., DIABETES, V60, P1177; Vuong C., ENDOCR REV, V31, P98; Welch CC, 1996, BRAIN RES, V721, P126, DOI 10.1016/0006-8993(96)00151-5; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Zechner R, 2009, J LIPID RES, V50, P3, DOI 10.1194/jlr.R800031-JLR200; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zuberi AR, 2008, EUR J PHARMACOL, V585, P14, DOI 10.1016/j.ejphar.2008.01.047	49	52	52	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3483	3492		10.1096/fj.12-208041	http://dx.doi.org/10.1096/fj.12-208041			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593549	Green Published			2022-12-28	WOS:000307162800035
J	Van, DN; Roberts, CF; Marion, JD; Lepine, S; Harikumar, KB; Schreiter, J; Dumur, CI; Fang, XJ; Spiegel, S; Bell, JK				Van, Danielle N.; Roberts, Charlotte F.; Marion, James D.; Lepine, Sandrine; Harikumar, Kuzhuvelil B.; Schreiter, Jessica; Dumur, Catherine I.; Fang, Xianjun; Spiegel, Sarah; Bell, Jessica K.			Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics	FASEB JOURNAL			English	Article						pattern recognition receptors; targeted therapy; biomarker; type I interferon; caspase	DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; RIG-I; TARGETED ACTIVATION; EXPRESSION; GENE; HELICASE; INDUCTION; CARCINOMA	Ovarian cancer is the most lethal gynecological cancer. Here we show that innate immune agonist, dsRNA, directly induces ovarian cancer cell death and identify biomarkers associated with responsiveness to this targeted treatment. Nuclear staining and MTT assays following dsRNA stimulation revealed two subpopulations, sensitive (OVCAR-3, CAOV-3; patient samples malignant 1 and 2) and resistant (DOV-13, SKOV-3). Microarray analysis identified 75 genes with differential expression that further delineated these two subpopulations. qPCR and immunoblot analyses showed increased dsRNA receptor expression after stimulation as compared to resistant and immortalized ovarian surface epithelial cells (e.g., 70-fold with malignant 2, 43-fold with OVCAR-3). Using agonists, antagonists, and shRNA-mediated knockdown of dsRNA receptors, we show that TLR3, RIG-I, and mda5 coordinated a caspase 8/9- and interferon-dependent cell death. In resistant cells, dsRNA receptor overexpression restored dsRNA sensitivity. When dsRNA was combined with carboplatin or paclitaxel, cell viability significantly decreased over individual treatments (1.5- to 7.5-fold). Isobologram analyses showed synergism in dsRNA combinations (CI=0.4-0.82) vs. an additive effect in carboplatin/paclitaxel treatment (CI=1.5-2). Our data identify a predictive marker, dsRNA receptor expression, to target dsRNA responsive populations and show that, in dsRNA-sensitive cells, dsRNA induces apoptosis and enhances the potency of cytotoxic chemotherapeutics.-Van, D. N., Roberts, C. F., Marion, J. D., Lepine, S., Harikumar, K. B., Schreiter, J., Dumur, C. I., Fang, X., Spiegel, S., Bell, J. K. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J. 26, 3188-3198 (2012). www.fasebj.org	[Van, Danielle N.; Roberts, Charlotte F.; Marion, James D.; Lepine, Sandrine; Harikumar, Kuzhuvelil B.; Fang, Xianjun; Spiegel, Sarah; Bell, Jessica K.] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA USA; [Dumur, Catherine I.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA; [Schreiter, Jessica] Centocor Res & Dev Inc, Discovery Res, Radnor, PA USA	Virginia Commonwealth University; Virginia Commonwealth University; Johnson & Johnson; Johnson & Johnson USA	Bell, JK (corresponding author), Sanger 2-040D,1101 E Marshall St, Richmond, VA 23298 USA.	jbell6@vcu.edu	Dumur, Catherine/AAH-9489-2020; Harikumar, Kuzhuvelil/AAC-2407-2020; Bell, Jessica/I-3893-2013	Harikumar, Kuzhuvelil/0000-0002-1763-4179; Bell, Jessica/0000-0003-1455-3274	U.S. National Institutes of Health (NIH) grants [CA144083, CA102196, CA61774, GM043880, CA12282801]; V Scholar award (Jimmy V Foundation); NIH-National Institute of Neuological Disease and Stroke Center core grant [5P30NS047463-02]; NIH-National Cancer Institute Cancer Center [P30 CA016059]; NATIONAL CANCER INSTITUTE [F31CA144083, R01CA102196, P30CA016059, R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047463] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Scholar award (Jimmy V Foundation); NIH-National Institute of Neuological Disease and Stroke Center core grant; NIH-National Cancer Institute Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Drs. Charles Chalfant, Paul Fisher, Andrew Larner [Virginia Commonwealth University (VCU), Richmond, VA, USA] and the Canadian Ovarian Cancer Research Culture Bank for generously sharing reagents. The authors also thank Drs. Paul Dent and Tomasz Kordula for helpful discussions during the development of these experiments. This work was funded by U.S. National Institutes of Health (NIH) grants CA144083 (D.N.V.), CA102196 (X.F.), CA61774 (S.S.), GM043880 (S.S.), and CA12282801 (J.K.B) and by a V Scholar award (Jimmy V Foundation; J.K.B). Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility with funding from NIH-National Institute of Neuological Disease and Stroke Center core grant 5P30NS047463-02. VCU Massey Cancer Center Tissue and Data Acquisition and Analysis Core services were supported with funding from NIH-National Cancer Institute Cancer Center support grant P30 CA016059.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Besch R, 2009, J CLIN INVEST, V119, P2399, DOI 10.1172/JCI37155; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Dumur CI, 2008, DIAGN MOL PATHOL, V17, P200, DOI 10.1097/PDM.0b013e318169bfaf; Dumur CI, 2004, CLIN CHEM, V50, P1994, DOI 10.1373/clinchem.2004.033225; Friboulet L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-327; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Howlader N, 2011, SEER CANC STAT REV 1; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jeung HC, 2008, ANN ONCOL, V19, P520, DOI 10.1093/annonc/mdm536; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kubler K, 2011, EUR J IMMUNOL, V41, P3028, DOI 10.1002/eji.201141555; Kubler K, 2010, CANCER RES, V70, P5293, DOI 10.1158/0008-5472.CAN-10-0825; LACOUR J, 1980, LANCET, V2, P161; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Nomi N, 2010, ONCOL REP, V24, P225, DOI 10.3892/or_00000850; Paone A, 2008, CARCINOGENESIS, V29, P1334, DOI 10.1093/carcin/bgn149; Peng S, 2009, CANCER SCI, V100, P529, DOI 10.1111/j.1349-7006.2008.01062.x; Perrot I, 2010, J IMMUNOL, V185, P2080, DOI 10.4049/jimmunol.1000532; Pignata S, 2011, CANCER LETT, V303, P73, DOI 10.1016/j.canlet.2011.01.026; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Salaun B, 2011, CANCER RES, V71, P1607, DOI 10.1158/0008-5472.CAN-10-3490; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Teoh D, 2011, GYNECOL ONCOL, V121, P187, DOI 10.1016/j.ygyno.2010.11.017; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yu M, 2011, CYTOKINE GROWTH F R, V22, P63, DOI 10.1016/j.cytogfr.2011.02.001; Zhang L, 2002, J MOL BIOL, V317, P225, DOI 10.1006/jmbi.2001.5350	39	26	27	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3188	3198		10.1096/fj.11-202333	http://dx.doi.org/10.1096/fj.11-202333			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22532440	Green Published			2022-12-28	WOS:000307162800010
J	Choi, KE; Hall, CL; Sun, JM; Wei, L; Mohamad, O; Dix, TA; Yu, SP				Choi, Ko-Eun; Hall, Casey L.; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Dix, Thomas A.; Yu, Shan P.			A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice	FASEB JOURNAL			English	Article						neurotensin analog; brain protection; autophagy; sensorimotor function	MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; NEUROTENSIN ANALOG; BODY-TEMPERATURE; ARTERY INFARCTION; BRAIN TEMPERATURE; HYPOXIC-ISCHEMIA; EMERGING ROLE; ACUTE-PHASE	Compelling evidence from preclinical and clinical studies has shown that mild to moderate hypothermia is neuroprotective against ischemic stroke. Clinical applications of hypothermia therapy, however, have been hindered by current methods of physical cooling, which is generally inefficient and impractical in clinical situations. In this report, we demonstrate the potential of pharmacologically induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal ischemic model of adult mice. ABS-201 (1.5-2.5 mg/kg, i.p.) reduces body and brain temperature by 2-5 degrees C in 15-30 min in a dose-dependent manner without causing shivering or altering physiological parameters. Infarct volumes at 24 h after stroke are reduced by similar to 30-40% when PIH therapy is initiated either immediately after stroke induction or after 30-60 min delay. ABS-201 treatment increases bcl-2 expression, decreases caspase-3 activation, and TUNEL-positive cells in the peri-infarct region, and suppresses autophagic cell death compared to stroke controls. The PIH therapy using ABS-201 improves recovery of sensorimotor function as tested 21 d after stroke. These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising candidates for treatment of ischemic stroke and possibly for other ischemic or traumatic injuries. Choi, K.-E., Hall, C. L., Sun, J.-M., Wei, L., Mohamad, O., Dix, T. A., Yu, S. P. A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J. 26, 2799-2810 (2012). www.fasebj.org	[Choi, Ko-Eun; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Yu, Shan P.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Hall, Casey L.; Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.; Yu, Shan P.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut, Charleston, SC USA	Emory University; Emory University; Medical University of South Carolina	Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Cir,Woodruff Mem Res Bldg,Ste 620, Atlanta, GA 30322 USA.	spyu@emory.edu			U.S. National Institutes of Health (NIH) [NS057255, NS058710, NS062097, R41NS073378, GM079044, MH65099]; Yerkes National Primate Center/NIH [P51]; NIH from National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM079044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R44MH065099, R41MH065099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057255, R01NS058710, R01NS062097, R41NS073378] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yerkes National Primate Center/NIH; NIH from National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health (NIH) grants NS057255, NS058710, NS062097, R41NS073378 (S.P.Y., L. W.), GM079044 (S.P.Y., T. A. D.), and MH65099 (T. A. D.) and by a Yerkes National Primate Center/NIH P51 pilot grant. This work was also supported by NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	BABCOCK AM, 1993, BRAIN RES BULL, V32, P373, DOI 10.1016/0361-9230(93)90202-M; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Dawaliby R, 2010, MOL BIOL CELL, V21, P4173, DOI 10.1091/mbc.E09-09-0782; Den Hertog H. M., 2009, COCHRANE DB SYST REV, V21; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Froehler MT, 2010, EXPERT REV CARDIOVAS, V8, P593, DOI [10.1586/erc.09.129, 10.1586/ERC.09.129]; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hammer MD, 2003, NEUROLOGIST, V9, P280, DOI 10.1097/01.nrl.0000094628.29312.2b; Hughes FM, 2010, J MED CHEM, V53, P4623, DOI 10.1021/jm100092s; Humeau A, 2007, MED BIOL ENG COMPUT, V45, P421, DOI 10.1007/s11517-007-0170-5; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Katz LM, 2001, ACAD EMERG MED, V8, P1115, DOI 10.1111/j.1553-2712.2001.tb01126.x; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lampe JW, 2011, ANNU REV MED, V62, P79, DOI 10.1146/annurev-med-052009-150512; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martinet W, 2006, AUTOPHAGY, V2, P55, DOI 10.4161/auto.2217; Miyazawa T, 2003, NEUROL RES, V25, P457, DOI 10.1179/016164103101201850; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650; Smith KE, 2011, BEHAV BRAIN RES, V224, P344, DOI 10.1016/j.bbr.2011.06.014; Sun J., 2011, SOC NEUR ANN M SESS; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427; Torok E, 2009, NEUROSURGERY, V65, P352, DOI 10.1227/01.NEU.0000345632.09882.FF; Torup L, 2003, NEUROSCI LETT, V351, P173, DOI 10.1016/j.neulet.2003.08.008; Tyler-McMahon BM, 2000, EUR J PHARMACOL, V390, P107, DOI 10.1016/S0014-2999(99)00877-8; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Yanagawa Y, 2002, RESUSCITATION, V53, P93, DOI 10.1016/S0300-9572(01)00499-3; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	69	65	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2799	2810		10.1096/fj.11-201822	http://dx.doi.org/10.1096/fj.11-201822			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459147	Green Published			2022-12-28	WOS:000305912500009
J	Lu, BX; Palacino, J				Lu, Boxun; Palacino, James			A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration	FASEB JOURNAL			English	Article						aggregation; high-throughput imaging	INACTIVATION; INHIBITION; LETHALITY	Most neurodegenerative diseases are linked to aberrant accumulation of aggregation-prone proteins. Among them, Huntington's disease (HD) is caused by an expanded polyglutamine repeat stretch in the N terminus of the mutant huntingtin protein (mHTT), which gets cleaved and aggregates in the brain. Recently established human induced pluripotent stem cell-derived HD neurons exhibit some disease-relevant phenotypes and provide tools for HD research. However, they have limitations such as genetic heterogeneity and an absence of mHTT aggregates and lack a robust neurodegeneration phenotype. In addition, the relationship between the phenotype and mHTT levels has not been elucidated. Herein, we present a human embryonic stem cell (hESC)-derived HD neuronal model expressing HT-Texon1 fragments, which addresses the deficiencies enumerated above. The wild-type and HD lines are derived from an isogenic background and exhibit insoluble mHTT aggregates and neurodegeneration. We also demonstrate a quantitative relationship between neurodegeneration and soluble monomeric (but not oligomeric or aggregated) mHTT levels. Reduction of similar to 10% of mHTT is sufficient to prevent toxicity, whereas similar to 90% reduction of wild-type HTT is safe and well-tolerated in these cells. A known HD toxicity modifier (Rhes) showed expected rescue of neurodegeneration. Therefore, the hESC-derived neuronal models complement existing induced pluripotent stem cell-derived neuronal models and provide valuable tools for HD research.-Lu, B., Palacino, J. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 27, 1820-1829 (2013). www.fasebj.org	[Lu, Boxun] Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China; [Lu, Boxun; Palacino, James] Novartis Inst BioMed Res Inc, Dev & Mol Pathways, Cambridge, MA USA	Fudan University; Novartis	Palacino, J (corresponding author), Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA.	luboxun@fudan.edu.cn; james.palacino@novartis.com			Novartis Institutes for Biomedical Research	Novartis Institutes for Biomedical Research	The authors thank Dr. Andreas Weiss for providing technical help on TR-FRET assays, Drs. Gul Erdemli and Chiawei Lin for providing assistance with electrophysiology recordings, Drs. Marian Difiglia and Sarah Luchansky for critical readings of earlier versions of the manuscript, and Dr. Arnaud Lacoste, Frada Berenshteyn, Philip Manos, and Christopher Littlefield for work on human stem cell culture and neuron differentiation, including some of the quality control experiments. The study was funded by Novartis Institutes for Biomedical Research. The authors declare no conflicts of interest.	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Baldo B, 2012, CHEM BIOL, V19, P264, DOI 10.1016/j.chembiol.2011.12.020; Boudreau RL, 2009, MOL THER, V17, P1053, DOI 10.1038/mt.2009.17; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Grondin R, 2012, BRAIN, V135, P1197, DOI 10.1093/brain/awr333; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HD iPSC Consortium, 2012, CELL STEM CELL, V11, P264, DOI 10.1016/j.stem.2012.04.027; KIDD M, 1985, LANCET, V1, P278; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ratovitski T, 2007, CELL CYCLE, V6, P2970, DOI 10.4161/cc.6.23.4992; Rodriguez-Lebron E, 2005, MOL THER, V12, P618, DOI 10.1016/j.ymthe.2005.05.006; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Subramaniam S, 2009, SCIENCE, V324, P1327, DOI 10.1126/science.1172871; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Thon JN, 2012, BLOOD, V120, P1975, DOI 10.1182/blood-2012-04-420968; Weiss A, 2009, ANAL BIOCHEM, V395, P8, DOI 10.1016/j.ab.2009.08.001; Weiss A, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-11; Yu DB, 2012, CELL, V150, P895, DOI 10.1016/j.cell.2012.08.002; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	23	60	65	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1820	1829		10.1096/fj.12-219220	http://dx.doi.org/10.1096/fj.12-219220			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23325320				2022-12-28	WOS:000318226100003
J	Ishii, T; Asai, T; Oyama, D; Agato, Y; Yasuda, N; Fukuta, T; Shimizu, K; Minamino, T; Oku, N				Ishii, Takayuki; Asai, Tomohiro; Oyama, Dai; Agato, Yurika; Yasuda, Nodoka; Fukuta, Tatsuya; Shimizu, Kosuke; Minamino, Tetsuo; Oku, Naoto			Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506	FASEB JOURNAL			English	Article						neuroprotectant; tacrolimus; apoptosis; inflammation; motor function	TACROLIMUS FK506; BRAIN-DAMAGE; PHOSPHORYLATION; ACCUMULATION; CALCINEURIN; APOPTOSIS; PROTECTS; SYSTEM; AGENT; MICE	FK506 (Tacrolimus) has the potential to decrease cerebral ischemia-reperfusion injury. However, the clinical trial of FK506 as a neuroprotectant failed due to adverse side effects. This present study aimed to conduct the selective delivery of FK506 to damaged regions, while at the same time reducing the dosage of FK506, by using a liposomal drug delivery system. First, the cytoprotective effect of polyethylene glycol-modified liposomes encapsulating FK506 (FK506-liposomes) on neuron-like pheochromocytoma PC12 cells was examined. FK506-liposomes protected these cells from H2O2-induced toxicity in a dose-dependent manner. Next, we investigated the usefulness of FK506-liposomes in transient middle cerebral artery occlusion (t-MCAO) rats. FK506-liposomes accumulated in the brain parenchyma by passing through the disrupted blood-brain barrier at an early stage after reperfusion had been initiated. Histological analysis showed that FK506-liposomes strongly suppressed neutrophil invasion and apoptotic cell death, events that lead to a poor stroke outcome. Corresponding to these results, a single injection of FK506-liposomes at a low dosage significantly reduced cerebral cell death and ameliorated motor function deficits in t-MCAO rats. These results suggest that liposomalization of FK506 could reduce the administration dose by enhancing the therapeutic efficacy; hence, FK506-liposomes should be a promising neuroprotectant after cerebral stroke.-Ishii, T., Asai, T., Oyama, D., Agato, Y., Yasuda, N., Fukuta, T., Shimizu, K., Minamino, T., Oku, N. Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J. 27, 1362-1370 (2013). www.fasebj.org	[Ishii, Takayuki; Asai, Tomohiro; Oyama, Dai; Agato, Yurika; Yasuda, Nodoka; Fukuta, Tatsuya; Shimizu, Kosuke; Oku, Naoto] Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Shizuoka 4228526, Japan; [Minamino, Tetsuo] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan	University of Shizuoka; Osaka University	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp		Fukuta, Tatsuya/0000-0001-8878-8602; Shimizu, Kosuke/0000-0003-3789-2447	Japan Society for the Promotion of Science; Grants-in-Aid for Scientific Research [24790047] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Astellas Pharmaceutical Co., Ltd. (Tokyo, Japan) for the gift of the FK506. This research was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science.	Asai T, 2011, BIOCONJUGATE CHEM, V22, P429, DOI 10.1021/bc1004697; Chuang YC, 2011, NEUROUROL URODYNAM, V30, P421, DOI 10.1002/nau.20981; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Duzgunes N, 1999, ADV DRUG DELIVER REV, V40, P3, DOI 10.1016/S0169-409X(99)00037-X; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Furuichi Y, 2003, J CEREBR BLOOD F MET, V23, P1183, DOI 10.1097/01.WCB.0000088761.02615.EB; Ginsberg MD, 2009, STROKE, V40, pS111, DOI 10.1161/STROKEAHA.108.528877; Hashiguchi A, 2003, NEUROSCIENCE, V121, P379, DOI 10.1016/S0306-4522(03)00490-1; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Ishii T, 2012, J CONTROL RELEASE, V160, P81, DOI 10.1016/j.jconrel.2012.02.004; Ishii T, 2010, BRAIN RES, V1321, P164, DOI 10.1016/j.brainres.2010.01.039; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Li JY, 2006, NEUROSCIENCE, V142, P789, DOI 10.1016/j.neuroscience.2006.06.064; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Micheli Maria-Rita, 2012, Recent Pat CNS Drug Discov, V7, P71; Moffatt SD, 1999, TRANSPLANTATION, V67, P1205, DOI 10.1097/00007890-199905150-00001; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Noto T, 2007, BIOL PHARM BULL, V30, P313, DOI 10.1248/bpb.30.313; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Sahota P, 2011, NEUROTHERAPEUTICS, V8, P434, DOI 10.1007/s13311-011-0040-6; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shichinohe H, 2004, BRAIN RES, V1001, P51, DOI 10.1016/j.brainres.2003.11.054; SHIRAGA T, 1994, BIOCHEM PHARMACOL, V47, P727, DOI 10.1016/0006-2952(94)90136-8; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Tan ML, 2010, PEPTIDES, V31, P184, DOI 10.1016/j.peptides.2009.10.002; Torres E, 2011, J CONTROL RELEASE, V154, P196, DOI 10.1016/j.jconrel.2011.05.017; Toung TJ, 1999, STROKE, V30, P1279, DOI 10.1161/01.STR.30.6.1279; Tuma RF, 2012, CURR PHARM BIOTECHNO, V13, P46; VertutDoi A, 1996, BBA-BIOMEMBRANES, V1278, P19, DOI 10.1016/0005-2736(95)00185-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wong CHY, 2008, CURR MED CHEM, V15, P1; Yura H, 1999, J CONTROL RELEASE, V57, P87, DOI 10.1016/S0168-3659(98)00150-3; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06	34	54	59	2	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1362	1370		10.1096/fj.12-221325	http://dx.doi.org/10.1096/fj.12-221325			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23241312				2022-12-28	WOS:000316940800009
J	Gugusheff, JR; Ong, ZY; Muhlhausler, BS				Gugusheff, Jessica R.; Ong, Zhi Yi; Muhlhausler, Beverly S.			A maternal "junk-food" diet reduces sensitivity to the opioid antagonist naloxone in offspring postweaning	FASEB JOURNAL			English	Article						fetal programming; high-fat diet; reward	HIGH-FAT DIET; VENTRAL TEGMENTAL AREA; LOW-BIRTH-WEIGHT; NUTRIENT SELECTION; NUCLEUS-ACCUMBENS; GENE-EXPRESSION; CAFETERIA DIET; PROTEIN-DIET; BREAST-MILK; RAT-BRAIN	Perinatal exposure to a maternal "junk-food" diet has been demonstrated to increase the preference for palatable diets in adult offspring. We aimed to determine whether this increased preference could be attributed to changes in mu-opioid receptor expression within the mesolimbic reward pathway. We report here that mRNA expression of the mu-opioid receptor in the ventral tegmental area (VTA) at weaning was 1.4-fold (males) and 1.9-fold (females) lower in offspring of junk-food (JF)-fed rat dams than in offspring of dams fed a standard rodent diet (control) (P<0.05). Administration of the opioid antagonist naloxone to offspring given a palatable diet postweaning significantly reduced fat intake in control offspring (males: 7.7 +/- 0.7 vs. 5.4 +/- 0.6 g/kg/d; females: 6.9 +/- 0.3 vs. 3.9 +/- 0.5g/kg/d; P<0.05), but not in male JF offspring (8.6 +/- 0.6 vs. 7.1 +/- 0.5g/kg/d) and was less effective at reducing fat intake in JF females (42.2 +/- 6.0 vs. 23.1 +/- 4.1% reduction, P<0.05). Similar findings were observed for total energy intake. Naloxone treatment did not affect intake of standard rodent feed in control or JF offspring. These findings suggest that exposure to a maternal junk-food diet results in early desensitization of the opioid system which may explain the increased preference for junk food in these offspring.-Gugusheff, J. R., Ong, Z. Y., Muhlhausler, B. S. A maternal " junk-food" diet reduces sensitivity to the opioid antagonist naloxone in offspring postweaning. FASEB J. 27, 1275-1284 (2013). www.fasebj.org	[Gugusheff, Jessica R.; Ong, Zhi Yi; Muhlhausler, Beverly S.] Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia; [Ong, Zhi Yi; Muhlhausler, Beverly S.] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia	University of Adelaide; University of South Australia	Muhlhausler, BS (corresponding author), Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia.	beverly.muhlhausler@adelaide.edu.au	Ong, Zhi Yi/AFP-0699-2022	Gugusheff, Jessica/0000-0003-2327-8403; Ong, Zhi Yi/0000-0002-8300-6955; Muhlhausler, Beverly/0000-0002-9021-6790	National Health and Medical Research Council of Australia; Australian Postgraduate Award; University of South Australia; Healthy Development Adelaide	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); University of South Australia; Healthy Development Adelaide	B. M. is supported by a Career Development Award from the National Health and Medical Research Council of Australia. J.G. is supported by an Australian Postgraduate Award. Z.O. is supported by a President's Scholarship from the University of South Australia. Both Z.O. and J.G. are the recipients of top-up scholarships from Healthy Development Adelaide. The authors acknowledge the expert assistance of Pamela Sim with animal protocols. The authors also thank John Carragher for editorial assistance.	Acosta-Martinez M, 2002, NEUROENDOCRINOLOGY, V76, P235, DOI 10.1159/000065953; BAKSHI VP, 1993, J PHARMACOL EXP THER, V265, P1253; BARDO MT, 1983, NEUROPHARMACOLOGY, V22, P453, DOI 10.1016/0028-3908(83)90163-6; BARDO MT, 1981, DEV BRAIN RES, V1, P487, DOI 10.1016/0165-3806(81)90003-1; Bayol SA, 2008, J PHYSIOL-LONDON, V586, P3219, DOI 10.1113/jphysiol.2008.153817; Bayol SA, 2007, BRIT J NUTR, V98, P843, DOI 10.1017/S0007114507812037; Bellinger L, 2004, BRIT J NUTR, V92, P513, DOI 10.1079/BJN20041224; Bergevin A, 2002, NEUROPHARMACOLOGY, V42, P1065, DOI 10.1016/S0028-3908(02)00061-8; BERKOWITZ BA, 1975, J PHARMACOL EXP THER, V195, P499; BRANDS B, 1979, LIFE SCI, V24, P1773, DOI 10.1016/0024-3205(79)90066-3; Chandorkar GA, 1999, ADV DRUG DELIVER REV, V38, P59, DOI 10.1016/S0169-409X(99)00006-X; CHILDERS SR, 1979, EUR J PHARMACOL, V55, P11, DOI 10.1016/0014-2999(79)90142-0; Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66; COOPER SJ, 1980, PSYCHOPHARMACOLOGY, V71, P1, DOI 10.1007/BF00433244; GIRAUDO SQ, 1993, PHARMACOL BIOCHEM BE, V46, P917, DOI 10.1016/0091-3057(93)90222-F; Glass MJ, 1996, AM J PHYSIOL-REG I, V271, pR217, DOI 10.1152/ajpregu.1996.271.1.R217; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Kelley AE, 2003, EUR J NEUROSCI, V18, P2592, DOI 10.1046/j.1460-9568.2003.02991.x; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; KLITENICK MA, 1992, J NEUROSCI, V12, P2623; Le Saux M, 2005, PSYCHONEUROENDOCRINO, V30, P251, DOI 10.1016/j.psyneuen.2004.08.002; Lindemalm S, 2009, J HUM LACT, V25, P199, DOI 10.1177/0890334408328295; MARKSKAUFMAN R, 1985, PSYCHOPHARMACOLOGY, V85, P414, DOI 10.1007/BF00429656; MARKSKAUFMAN R, 1981, PSYCHOPHARMACOLOGY, V74, P321, DOI 10.1007/BF00432739; Naef L, 2011, NEUROSCIENCE, V176, P225, DOI 10.1016/j.neuroscience.2010.12.037; Naef L, 2008, PSYCHOPHARMACOLOGY, V197, P83, DOI 10.1007/s00213-007-1008-4; Ong ZY, 2011, FASEB J, V25, P2167, DOI 10.1096/fj.10-178392; REPKE JT, 1991, AM J CLIN NUTR, V54, pS237, DOI 10.1093/ajcn/54.1.237S; ROBIEUX I, 1990, J TOXICOL-CLIN TOXIC, V28, P365, DOI 10.3109/15563659008994437; Roca P, 1999, PFLUG ARCH EUR J PHY, V438, P628, DOI 10.1007/s004240051086; SAKAGUCHI T, 1988, J CLIN INVEST, V82, P282, DOI 10.1172/JCI113584; Sampey BP, 2011, OBESITY, V19, P1109, DOI 10.1038/oby.2011.18; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Takaya J, 2006, MAGNESIUM RES, V19, P63; Teegarden SL, 2009, NEUROSCIENCE, V162, P924, DOI 10.1016/j.neuroscience.2009.05.029; Van Ree JM, 2000, EUR J PHARMACOL, V405, P89, DOI 10.1016/S0014-2999(00)00544-6; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313; Zhang M, 1998, J PHARMACOL EXP THER, V285, P908; Zhu YX, 1998, J NEUROSCI, V18, P2538	40	23	23	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2013	27	3					1275	1284		10.1096/fj.12-217653	http://dx.doi.org/10.1096/fj.12-217653			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23233534	Green Submitted			2022-12-28	WOS:000315585200039
J	Sundaresan, S; Shahid, R; Riehl, TE; Chandra, R; Nassir, F; Stenson, WF; Liddle, RA; Abumrad, NA				Sundaresan, Sinju; Shahid, Rafiq; Riehl, Terrence E.; Chandra, Rashmi; Nassir, Fatiha; Stenson, William F.; Liddle, Rodger A.; Abumrad, Nada A.			CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin	FASEB JOURNAL			English	Article						CCK; cAMP; calcium	PROTEIN-COUPLED RECEPTORS; IMMUNOFLUORESCENT LOCALIZATION; GASTROINTESTINAL-TRACT; CHOLESTEROL UPTAKE; DIETARY LIPIDS; CD36; ACTIVATION; INTESTINE; APPETITE; FOOD	Genetic variants in the fatty acid (FA) translocase FAT/CD36 associate with abnormal postprandial lipids and influence risk for the metabolic syndrome. CD36 is abundant on apical enterocyte membranes in the proximal small intestine, where it facilitates FA uptake and FA-initiated signaling. We explored whether CD36 signaling influences FA-mediated secretion of cholecystokinin (CCK) and secretin, peptides released by enteroendocrine cells (EECs) in the duodenum/jejunum, which regulate events important for fat digestion and homeostasis. CD36 was immunodetected on apical membranes of secretin- and CCK-positive EECs and colocalized with cytosolic granules. Intragastric lipid administration to CD36(-/-) mice released less secretin (-60%) and CCK (-50%) compared with wild-type mice. Likewise, diminished secretin and CCK responses to FA were observed with CD36(-/-) intestinal segments in vitro, arguing against influence of alterations in fat absorption. Signaling mechanisms underlying peptide release were examined in STC-1 cells stably expressing human CD36 or a signaling-impaired mutant (CD36K/A). FA stimulation of cells expressing CD36 (vs. vector or CD36K/A) released more secretin (3.5- to 4-fold) and CCK (2- to 3-fold), generated more cAMP (2- to 2.5-fold), and enhanced protein kinase A activation. Protein kinase A inhibition (H-89) blunted secretin (80%) but not CCK release, which was reduced (50%) by blocking of calmodulin kinase II (KN-62). Coculture of STC-1 cells with Caco- 2 cells stably expressing CD36 did not alter secretin or CCK release, consistent with a minimal effect of adjacent enterocytes. In summary, CD36 is a major mediator of FA-induced release of CCK and secretin. These peptides contribute to the role of CD36 in fat absorption and to its pleiotropic metabolic effects.-Sundaresan, S., Shahid, R., Riehl, T. E., Chandra, R., Nassir, F., Stenson, W. F., Liddle, R. A., Abumrad, N. A. CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin. FASEB J. 27, 1191-1202 (2013). www.fasebj.org	[Sundaresan, Sinju; Nassir, Fatiha; Abumrad, Nada A.] Washington Univ, Sch Med, Dept Med, Ctr Human Nutr, St Louis, MO 63110 USA; [Riehl, Terrence E.; Stenson, William F.] Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA; [Shahid, Rafiq; Chandra, Rashmi; Liddle, Rodger A.] Duke Univ, Dept Med, Div Gastroenterol, Durham, NC 27706 USA	Washington University (WUSTL); Washington University (WUSTL); Duke University	Abumrad, NA (corresponding author), Ctr Human Nutr, Dept Med, 660 S Euclid Ave,Campus Box 8031, St Louis, MO 63110 USA.	nabumrad@dom.wustl.edu		Nassir, Fatiha/0000-0002-3653-3621	U. S. National Institutes of Health [DK033301, DK60022, DK33165, DK55753, DK091946]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301, R37DK033165, R01DK098796, R01DK055753, R01DK060022, R01DK091946, R01DK033165, P30DK056341] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge valuable assistance by Terri Pietka (Adipocyte Biology and Molecular Nutrition Core, Nutrition and Obesity Research Center, Washington University School of Medicine; P30-DK056341) and are grateful to Dr. Ondrej Kuda for help with the calcium flux studies and to Dr. Doug Hanahan for the permission to obtain STC-1 cells from American Type Culture Collection (Manassas, VA, USA). This work was supported by funding from U. S. National Institutes of Health grants DK033301, DK60022 (to N. A. A.), DK33165, DK55753 (to W. F. S.), and DK091946 (to R. A. L.). R. S., T. E. R., R. C., and F. N. assisted in data acquisition and reviewed the manuscript; W. F. S. and R. A. L. critically reviewed the manuscript; S. S. obtained and analyzed data; and S. S. and N. A. A. were involved in development of the study concept and design, data analysis and interpretation, and manuscript preparation.	Abumrad NA, 2012, PHYSIOL REV, V92, P1061, DOI 10.1152/physrev.00019.2011; Beglinger C, 2004, PHYSIOL BEHAV, V83, P617, DOI 10.1016/j.physbeh.2004.07.031; Berna MJ, 2007, CURR TOP MED CHEM, V7, P1211; BUCHAN AMJ, 1978, GUT, V19, P403, DOI 10.1136/gut.19.5.403; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chandra R, 2010, CELL TISSUE RES, V341, P289, DOI 10.1007/s00441-010-0997-1; Chang CH, 1998, AM J PHYSIOL-GASTR L, V275, pG192, DOI 10.1152/ajpgi.1998.275.2.G192; Cheng CYY, 2011, NEUROPSYCHOPHARMACOL, V36, P459, DOI 10.1038/npp.2010.178; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Chey WY, 2003, J GASTROENTEROL, V38, P1025, DOI 10.1007/s00535-003-1235-3; Dockray GJ, 2012, CURR OPIN ENDOCRINOL, V19, P8, DOI 10.1097/MED.0b013e32834eb77d; Drover VA, 2005, J CLIN INVEST, V115, P1290, DOI 10.1172/JCI200521514; Edfalk S, 2008, DIABETES, V57, P2280, DOI 10.2337/db08-0307; El-Yassimi A, 2008, J BIOL CHEM, V283, P12949, DOI 10.1074/jbc.M707478200; Habib AM, 2012, ENDOCRINOLOGY, V153, P3054, DOI 10.1210/en.2011-2170; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hsieh J, 2009, GASTROENTEROLOGY, V137, P997, DOI 10.1053/j.gastro.2009.05.051; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Khan NA, 2009, BBA-MOL CELL BIOL L, V1791, P149, DOI 10.1016/j.bbalip.2009.01.001; Kuda O, 2011, J BIOL CHEM, V286, P17785, DOI 10.1074/jbc.M111.232975; Lam IPY, 2008, INT REV CYTOL, V265, P159, DOI 10.1016/S0074-7696(07)65004-9; Lam IPY, 2006, ANN NY ACAD SCI, V1070, P371, DOI 10.1196/annals.1317.047; Laugerette F, 2005, J CLIN INVEST, V115, P3177, DOI 10.1172/JCI25299; Levy E, 2000, MICROSC RES TECHNIQ, V49, P374, DOI 10.1002/(SICI)1097-0029(20000515)49:4<374::AID-JEMT6>3.0.CO;2-W; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; Liddle RA, 2000, J GASTROENTEROL, V35, P181, DOI 10.1007/s005350050328; Liou AP, 2011, GASTROENTEROLOGY, V140, P903, DOI 10.1053/j.gastro.2010.10.012; Lipsky RH, 1997, RECEPT SIGNAL TRANS, V7, P1; Little TJ, 2011, PHYSIOL BEHAV, V104, P613, DOI 10.1016/j.physbeh.2011.04.038; Lobo MVT, 2001, J HISTOCHEM CYTOCHEM, V49, P1253, DOI 10.1177/002215540104901007; Love-Gregory L, 2011, HUM MOL GENET, V20, P193, DOI 10.1093/hmg/ddq449; Masuda D, 2009, J LIPID RES, V50, P999, DOI 10.1194/jlr.P700032-JLR200; Mathias A, 2010, J BIOL CHEM, V285, P33906, DOI 10.1074/jbc.M110.135111; Nassir F, 2007, J BIOL CHEM, V282, P19493, DOI 10.1074/jbc.M703330200; Nauli AM, 2006, GASTROENTEROLOGY, V131, P1197, DOI 10.1053/j.gastro.2006.08.012; Oh DY, 2011, CURR OPIN CLIN NUTR, V14, P322, DOI 10.1097/MCO.0b013e3283479230; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Parker HE, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239940900132X; Pepino MY, 2012, J LIPID RES, V53, P561, DOI 10.1194/jlr.M021873; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; POLAK JM, 1971, GUT, V12, P605, DOI 10.1136/gut.12.8.605; POLAK JM, 1971, SCAND J GASTROENTERO, V6, P739, DOI 10.3109/00365527109179946; PortelaGomes GM, 1997, J HISTOCHEM CYTOCHEM, V45, P815, DOI 10.1177/002215549704500606; PRPIC V, 1994, BIOCHEM BIOPH RES CO, V201, P1483, DOI 10.1006/bbrc.1994.1871; Rehfeld JF, 1998, CLIN CHEM, V44, P991; RINDI G, 1990, AM J PATHOL, V136, P1349; Sclafani A, 2012, AM J PHYSIOL-REG I, V302, pR1119, DOI 10.1152/ajpregu.00038.2012; Scott L, 1996, AM J PHYSIOL-GASTR L, V270, pG291, DOI 10.1152/ajpgi.1996.270.2.G291; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Sidhu S. S., 2000, J PHYSL 1, V528, P165; Silverstein RL, 2009, CLIN LIPIDOL, V4, P767, DOI 10.2217/CLP.09.57; Smith J, 2008, WESTERN HUM REV, V62, P36; Suzuki S, 2010, NEUROGASTROENT MOTIL, V22, P585, DOI 10.1111/j.1365-2982.2009.01444.x; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P523, DOI 10.1007/s00210-007-0200-8; Tashiro M, 2004, AM J PHYSIOL-GASTR L, V286, pG784, DOI 10.1152/ajpgi.00446.2003; Thi TTT, 2011, J BIOL CHEM, V286, P25201, DOI 10.1074/jbc.M111.233551; VARNDELL IM, 1985, HISTOCHEM J, V17, P981, DOI 10.1007/BF01417947; Vinolo MAR, 2012, CURR OPIN CLIN NUTR, V15, P112, DOI 10.1097/MCO.0b013e32834f4598	60	69	70	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1191	1202		10.1096/fj.12-217703	http://dx.doi.org/10.1096/fj.12-217703			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23233532	Green Published			2022-12-28	WOS:000315585200031
J	Kosicka, A; Cunliffe, AD; Mackenzie, R; Zariwala, MG; Perretti, M; Flower, RJ; Renshaw, D				Kosicka, Anna; Cunliffe, Adam D.; Mackenzie, Richard; Zariwala, M. Gulrez; Perretti, Mauro; Flower, Roderick J.; Renshaw, Derek			Attenuation of plasma annexin A1 in human obesity	FASEB JOURNAL			English	Article						anti-inflammatory; adipocytes; adipocytokines; SGBS cells; inflammation	AIR-DISPLACEMENT PLETHYSMOGRAPHY; BODY-MASS INDEX; NF-KAPPA-B; ADIPOSE-TISSUE; DIABETES-MELLITUS; ANTHROPOMETRIC INDEXES; WAIST CIRCUMFERENCE; INSULIN SENSITIVITY; SUBCUTANEOUS FAT; INFLAMMATION	Obesity-related metabolic disorders are characterized by mild chronic inflammation, leukocyte infiltration, and tissue fibrosis as a result of adipocytokine production from the expanding white adipose tissue. Annexin A1 (AnxA1) is an endogenous glucocorticoid regulated protein, which modulates systemic anti-inflammatory processes and, therefore, may be altered with increasing adiposity in humans. Paradoxically, we found that plasma AnxA1 concentrations inversely correlated with BMI, total percentage body fat, and waist-to-hip ratio in human subjects. Plasma AnxA1 was also inversely correlated with plasma concentrations of the acute-phase protein, C-reactive protein (CRP), and the adipocytokine leptin, suggesting that as systemic inflammation increases, anti-inflammatory AnxA1 is reduced. In addition, AnxA1 gene expression and protein were significantly up-regulated during adipogenesis in a human adipocyte cell line compared to vehicle alone, demonstrating for the first time that AnxA1 is expressed and excreted from human adipocytes. These data demonstrate a failure in the endogenous anti-inflammatory system to respond to increasing systemic inflammation resulting from expanding adipose tissue, a condition strongly linked to the development of type 2 diabetes and cardiovascular disease. These data raise the possibility that a reduction in plasma AnxA1 may contribute to the chronic inflammatory phenotype observed in human obesity.-Kosicka, A., Cunliffe, A. D., Mackenzie, R., Gulrez Zariwala, M., Perretti, M., Flower, R. J., Renshaw, D. Attenuation of plasma annexin A1 in human obesity. FASEB J. 27, 368-378 (2013). www.fasebj.org	[Kosicka, Anna; Mackenzie, Richard; Zariwala, M. Gulrez; Renshaw, Derek] Univ Westminster, Sch Life Sci, Dept Human & Hlth Sci, London W1W 6UW, England; [Cunliffe, Adam D.] London S Bank Univ, Dept Appl Sci, London, England; [Perretti, Mauro; Flower, Roderick J.] Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Ctr Biochem Pharmacol, London, England	Roehampton University; University of Westminster; London South Bank University; University of London; Queen Mary University London	Renshaw, D (corresponding author), Univ Westminster, Sch Life Sci, Dept Human & Hlth Sci, 115 New Cavendish St, London W1W 6UW, England.	renshad@wmin.ac.uk		Zariwala, Mohammed Gulrez/0000-0001-9944-8451; Renshaw, Derek/0000-0002-2759-0229	Human and Health Sciences Department, School of Life Sciences, University of Westminster (London, UK); Society for Endocrinology	Human and Health Sciences Department, School of Life Sciences, University of Westminster (London, UK); Society for Endocrinology	A.K. was supported by a 2-yr scholarship from the Human and Health Sciences Department, School of Life Sciences, University of Westminster (London, UK). D.R. was supported by an Early Career grant from the Society for Endocrinology. The authors thank Dr. Niloufar Moradi-Bidhendi for proofreading the manuscript.	Ahmed M, 2010, OBESITY, V18, P27, DOI 10.1038/oby.2009.208; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Babbin BA, 2008, J IMMUNOL, V181, P5035, DOI 10.4049/jimmunol.181.7.5035; Babbin BA, 2006, J BIOL CHEM, V281, P19588, DOI 10.1074/jbc.M513025200; Barac A, 2012, J CLIN HYPERTENS, V14, P13, DOI 10.1111/j.1751-7176.2011.00560.x; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Bensalem N, 2005, MOL CELL PROTEOMICS, V4, P1591, DOI 10.1074/mcp.M500019-MCP200; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Black PH, 2006, MED HYPOTHESES, V67, P879, DOI 10.1016/j.mehy.2006.04.008; Borai A, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-158; Carroll JF, 2008, OBESITY, V16, P600, DOI 10.1038/oby.2007.92; Cheuk BLY, 2011, EUR J VASC ENDOVASC, V41, P364, DOI 10.1016/j.ejvs.2010.11.021; D'Acquisto F, 2008, BRIT J PHARMACOL, V155, P152, DOI 10.1038/bjp.2008.252; D'Acquisto F, 2008, RHEUMATOLOGY, V47, P636, DOI 10.1093/rheumatology/ken062; Dalli J, 2012, FASEB J, V26, P387, DOI 10.1096/fj.11-182089; Dalli J, 2010, AM J PATHOL, V177, P176, DOI 10.2353/ajpath.2010.091149; DAVIDSON J, 1991, BRIT J PHARMACOL, V102, P7, DOI 10.1111/j.1476-5381.1991.tb12122.x; DeLoach Stephanie, 2011, Ther Adv Cardiovasc Dis, V5, P149, DOI 10.1177/1753944711408757; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; Do MS, 2006, YONSEI MED J, V47, P729, DOI 10.3349/ymj.2006.47.5.729; Doyle SL, 2012, P NUTR SOC, V71, P181, DOI 10.1017/S002966511100320X; Fields DA, 2002, AM J CLIN NUTR, V75, P453, DOI 10.1093/ajcn/75.3.453; Fischer-Posovszky P, 2008, OBESITY FACTS, V1, P184, DOI 10.1159/000145784; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694; GARN SM, 1986, AM J CLIN NUTR, V44, P996, DOI 10.1093/ajcn/44.6.996; Geiger K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026465; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Guven SF, 2012, SLEEP BREATH, V16, P217, DOI 10.1007/s11325-011-0492-2; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Hockley T., 2007, EUROPEAN CHOLESTEROL; HORTOBAGYI T, 1994, EUR J CLIN NUTR, V48, P369; Hyatt TC, 2009, OBESITY, V17, P276, DOI 10.1038/oby.2008.549; Indulekha K, 2011, CLIN BIOCHEM, V44, P281, DOI 10.1016/j.clinbiochem.2010.12.015; Kim SY, 2011, EPIDEMIOL HEALTH, V33, DOI 10.4178/epih/e2011007; Ko GTC, 1999, INT J OBESITY, V23, P1136, DOI 10.1038/sj.ijo.0801043; Kuo SM, 2011, INT J OBESITY, V35, P1487, DOI 10.1038/ijo.2011.20; Lam JCM, 2012, RESPIROLOGY, V17, P223, DOI 10.1111/j.1440-1843.2011.02081.x; Lau DCW, 2007, CAN MED ASSOC J, V176, P1103, DOI 10.1503/cmaj.070306; Lear SA, 2007, OBESITY, V15, P2817, DOI 10.1038/oby.2007.334; Lee SW, 2011, YONSEI MED J, V52, P939, DOI 10.3349/ymj.2011.52.6.939; Life Measurement Inc., 2005, CUST TRAIN BOD COMP; Lockner DW, 2000, ANN NY ACAD SCI, V904, P72; LOHMAN TG, 1997, HLTH FITNESS J, V1, P30; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; McArthur S, 2010, J IMMUNOL, V185, P6317, DOI 10.4049/jimmunol.1001095; McCrory MA, 1998, J APPL PHYSIOL, V84, P1475, DOI 10.1152/jappl.1998.84.4.1475; Mulla A, 2005, J CLIN ENDOCR METAB, V90, P557, DOI 10.1210/jc.2004-1230; National Institute for Health and Clinical Excellence, 2011, HYPERT CLIN MAN PRI; National Institutes of Health, 2000, PRACT GUID ID EV TRE; Nevill AM, 2006, AM J PHYS ANTHROPOL, V129, P151, DOI 10.1002/ajpa.20262; Nishimura Satoshi, 2009, Discov Med, V8, P55; Organization WH, 1998, WELLB MEAS PRIM HLTH; Otani H, 2011, ANTIOXID REDOX SIGN, V15, P1911, DOI 10.1089/ars.2010.3739; Parkin D. M., 2011, BR J CANC S2, V105, pS34; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; Permana PA, 2006, BIOCHEM BIOPH RES CO, V341, P507, DOI 10.1016/j.bbrc.2006.01.012; Perretti M, 2003, NEWS PHYSIOL SCI, V18, P60, DOI 10.1152/nips.01424.2002; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 2009, BRIT J PHARMACOL, V158, P936, DOI 10.1111/j.1476-5381.2009.00483.x; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Pupjalis D, 2011, EMBO MOL MED, V3, P102, DOI 10.1002/emmm.201000113; Raynal P., 1993, BIOCH J 3, V292, P759; Renshaw D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012771; Rhodes D, 2011, INFLAMM RES, V60, P261; Rosales JL, 1997, J IMMUNOL, V159, P6195; Rosenow A, 2010, J PROTEOME RES, V9, P5389, DOI 10.1021/pr100621g; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shafer KJ, 2008, NUTRITION, V24, P148, DOI 10.1016/j.nut.2007.10.015; Solito E, 2003, FASEB J, V17, P1544, DOI 10.1096/fj.02-0941fje; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Sudlow AW, 1996, BRIT J PHARMACOL, V117, P1449, DOI 10.1111/j.1476-5381.1996.tb15305.x; Tirosh A, 2005, NEW ENGL J MED, V353, P1454, DOI 10.1056/NEJMoa050080; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Trayhurn P, 2005, ACTA PHYSIOL SCAND, V184, P285, DOI 10.1111/j.1365-201X.2005.01468.x; Tsuriya D, 2011, INTERNAL MED, V50, P2767, DOI 10.2169/internalmedicine.50.5908; Uwaifo GI, 2002, J CLIN ENDOCR METAB, V87, P2899, DOI 10.1210/jc.87.6.2899; Vazzana N, 2011, CURR MED CHEM, V18, P5267, DOI 10.2174/092986711798184299; WABITSCH M, 1995, J CLIN ENDOCR METAB, V80, P3469, DOI 10.1210/jc.80.12.3469; Wagner DR, 2000, MED SCI SPORT EXER, V32, P1339, DOI 10.1097/00005768-200007000-00023; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; Wang ZM, 2011, J ETHNOPHARMACOL, V137, P774, DOI 10.1016/j.jep.2011.06.037; Warne JP, 2006, AM J PHYSIOL-ENDOC M, V291, pE1264, DOI 10.1152/ajpendo.00655.2005; Wauters M, 2000, METABOLISM, V49, P724, DOI 10.1053/meta.2000.6255; Wilson JP, 2012, AM J CLIN NUTR, V95, P25, DOI 10.3945/ajcn.111.019273; Wood IS, 2009, P NUTR SOC, V68, P370, DOI 10.1017/S0029665109990206; Wood IS, 2009, BIOCHEM BIOPH RES CO, V384, P105, DOI 10.1016/j.bbrc.2009.04.081; Yazid S, 2009, BIOCHEM PHARMACOL, V77, P1814, DOI 10.1016/j.bcp.2009.03.010; Ye J, 2009, INT J OBESITY, V33, P54, DOI 10.1038/ijo.2008.229; Ye JP, 2011, CURR DIABETES REP, V11, P203, DOI 10.1007/s11892-011-0183-1; Yudkin JS, 2007, HORM METAB RES, V39, P707, DOI 10.1055/s-2007-985898; Yudkin JS, 2003, INT J OBESITY, V27, pS25, DOI 10.1038/sj.ijo.0802496; Zalesin KC, 2011, MED CLIN N AM, V95, P919, DOI 10.1016/j.mcna.2011.06.005; Zhang ZQ, 2010, CANCER RES, V70, P2379, DOI 10.1158/0008-5472.CAN-09-4204; Zhao YM, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-14	101	36	36	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					368	378		10.1096/fj.12-213728	http://dx.doi.org/10.1096/fj.12-213728			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038751				2022-12-28	WOS:000313103200035
J	Murray, J; Auwerx, J; Huss, JM				Murray, Jennifer; Auwerx, Johan; Huss, Janice M.			Impaired myogenesis in estrogen-related receptor gamma (ERR gamma)-deficient skeletal myocytes due to oxidative stress	FASEB JOURNAL			English	Article						orphan nuclear receptors; differentiation; metabolism; reactive oxygen species	NF-KAPPA-B; FORKHEAD TRANSCRIPTION FACTOR; NECROSIS-FACTOR-ALPHA; MUSCLE ATROPHY; ERR-ALPHA; MYOBLAST DIFFERENTIATION; GENE-EXPRESSION; MITOCHONDRIAL BIOGENESIS; PROTEIN-KINASE; CELL-SURVIVAL	Specialized contractile function and increased mitochondrial number and oxidative capacity are hallmark features of myocyte differentiation. The estrogen-related receptors (ERRs) can regulate mitochondrial biogenesis or mitochondrial enzyme expression in skeletal muscle, suggesting that ERRs may have a role in promoting myogenesis. Therefore, we characterized myogenic programs in primary myocytes isolated from wild-type (M-ERR gamma WT) and muscle-specific ERR gamma(-/-) (M-ERR gamma(-/-)) mice. Myotube maturation and number were decreased throughout differentiation in M-ERR gamma(-/-) primary myocytes, resulting in myotubes with reduced mitochondrial content and sarcomere assembly. Compared with M-ERR gamma WT myocytes at the same differentiation stage, the glucose oxidation rate was reduced by 30% in M-ERR gamma(-/-) myotubes, while medium-chain fatty acid oxidation was increased by 34% in M-ERR gamma(-/-) myoblasts and 36% in M-ERR gamma(-/-) myotubes. Concomitant with increased reliance on mitochondrial beta-oxidation, H2O2 production was significantly increased by 40% in M-ERR gamma(-/-) myoblasts and 70% in M-ERR gamma(-/-) myotubes compared to M-ERR gamma WT myocytes. ROS activation of FoxO and NF-kappa B and their downstream targets, atrogin-1 and MuRF1, was observed in M-ERR gamma(-/-) myocytes. The antioxidant N-acetyl cysteine rescued myotube formation and atrophy gene induction in M-ERR gamma(-/-) myocytes. These results suggest that loss of ERR gamma causes metabolic defects and oxidative stress that impair myotube formation through activation of skeletal muscle atrophy pathways.-Murray, J., Auwerx, J., Huss, J. M. Impaired myogenesis in estrogen-related receptor gamma (ERR gamma)-deficient skeletal myocytes due to oxidative stress. FASEB J. 27, 135-150 (2013). www.fasebj.org	[Huss, Janice M.] City Hope Natl Med Ctr, Dept Diabet & Metab Dis Res, Leslie & Susan Gonda Goldschmied Diabet & Genet R, Div Cellular & Mol Diabet Res,Beckman Res Inst, Duarte, CA 91010 USA; [Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, Lausanne, Switzerland	City of Hope; Beckman Research Institute of City of Hope; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Huss, JM (corresponding author), City Hope Natl Med Ctr, Dept Diabet & Metab Dis Res, Leslie & Susan Gonda Goldschmied Diabet & Genet R, Div Cellular & Mol Diabet Res,Beckman Res Inst, Rm 2132,1500 E Duarte Rd, Duarte, CA 91010 USA.	jhuss@coh.org	Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01DK074700]; Beckman Research Institute (City of Hope); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074700] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Beckman Research Institute (City of Hope); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Marisa McDonald for technical assistance. The authors acknowledge assistance from the Light Microscopy and Digital Imaging Core and the Animal Resources Center (Department of Comparative Medicine, City of Hope). This work is supported by U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases funding (R01DK074700; to J. M. H.) and the Beckman Research Institute (City of Hope). The authors declare no conflicts of interest.	Alaynick WA, 2007, CELL METAB, V6, P13, DOI 10.1016/j.cmet.2007.06.007; Ardite E, 2004, AM J PATHOL, V165, P719, DOI 10.1016/S0002-9440(10)63335-4; Bakkar N, 2010, PHYSIOL REV, V90, P495, DOI 10.1152/physrev.00040.2009; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Biswas M, 2010, TOXICOL APPL PHARM, V244, P16, DOI 10.1016/j.taap.2009.07.034; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Campbell KJ, 2004, BIOCHEM SOC T, V32, P1087, DOI 10.1042/BST0321087; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Caron AZ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-185; Chung SS, 2009, MOL CELL BIOL, V29, P20, DOI 10.1128/MCB.00544-08; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Cuschieri J, 2005, CRIT CARE MED, V33, pS417, DOI 10.1097/01.CCM.0000191714.39495.A6; DENYER GS, 1991, PFLUG ARCH EUR J PHY, V419, P115, DOI 10.1007/BF00372995; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; Hansen JM, 2007, CELL BIOL INT, V31, P546, DOI 10.1016/j.cellbi.2006.11.027; Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jackson MJ, 2011, ANTIOXID REDOX SIGN, V15, P2477, DOI 10.1089/ars.2011.3976; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Langen RCJ, 2002, AM J PHYSIOL-CELL PH, V283, pC714, DOI 10.1152/ajpcell.00418.2001; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee S, 2011, CELL RES, V21, P817, DOI 10.1038/cr.2011.55; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Malinska D, 2012, MITOCHONDRION, V12, P144, DOI 10.1016/j.mito.2011.06.015; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; Murray J, 2011, AM J PHYSIOL-CELL PH, V301, pC630, DOI 10.1152/ajpcell.00033.2011; Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Olmos Y, 2009, J BIOL CHEM, V284, P14476, DOI 10.1074/jbc.M807397200; Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad; Rangwala SM, 2010, J BIOL CHEM, V285, P22619, DOI 10.1074/jbc.M110.125401; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Senf SM, 2010, AM J PHYSIOL-CELL PH, V298, pC38, DOI 10.1152/ajpcell.00315.2009; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Toyoda T, 2004, AM J PHYSIOL-ENDOC M, V287, pE166, DOI 10.1152/ajpendo.00487.2003; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	62	31	31	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2013	27	1					135	150		10.1096/fj.12-212290	http://dx.doi.org/10.1096/fj.12-212290			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23038752	Green Published			2022-12-28	WOS:000313103200014
J	Watanabe, K; Ishima, Y; Akaike, T; Sawa, T; Kuroda, T; Ogawa, W; Watanabe, H; Suenaga, A; Kai, T; Otagiri, M; Maruyama, T				Watanabe, Kaori; Ishima, Yu; Akaike, Takaaki; Sawa, Tomohiro; Kuroda, Teruo; Ogawa, Wakano; Watanabe, Hiroshi; Suenaga, Ayaka; Kai, Toshiya; Otagiri, Masaki; Maruyama, Toru			S-nitrosated alpha-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis	FASEB JOURNAL			English	Article						nitric oxide; acute-phase protein; post-translational modification	NITRIC-OXIDE; ALPHA(1)-ACID GLYCOPROTEIN; ANTIBACTERIAL; NITROSYLATION; EXPRESSION; IDENTIFICATION; CHROMATOGRAPHY; CELLS	Treating infections with exogenous NO, which shows broad-spectrum antimicrobial activity, appears to be effective. Similar to NO biosynthesis, biosynthesis of alpha-1-acid glycoprotein variant A (AGPa), with a reduced cysteine (Cys149), increases markedly during inflammation and infection. We hypothesized that AGPa is an S-nitrosation target in acute-phase proteins. This study aimed to determine whether S-nitrosated AGPa (SNO-AGPa) may be the first compound of this novel antibacterial class against multidrug-resistant bacteria. AGPa was incubated with RAW264.7 cells activated by lipopolysaccharide and interferon-gamma. The antimicrobial effects of SNO-AGPa were determined by measuring the turbidity of the bacterial suspensions in vitro and survival in a murine sepsis model in vivo, respectively. Results indicated that endogenous NO generated by activated RAW264.7 cells caused S-nitrosation of AGPa at Cys149. SNO-AGPa strongly inhibited growth of gram-positive, gram-negative, and multidrug-resistant bacteria and was an extremely potent bacteriostatic compound (IC50: 10(-9) to 10(-6) M). The antibacterial mechanism of SNO-AGPa involves S-transnitrosation from SNO-AGPa to bacterial cells. Treatment with SNO-AGPa, but not with AGPa, markedly reduced bacterial counts in blood and liver in a mouse sepsis model. The sialyl residues of AGPa seem to suppress the antibacterial activity, since SNO-asialo AGPa was more potent than SNO-AGPa.-Watanabe, K., Ishima, Y., Akaike, T., Sawa, T., Kuroda, T., Ogawa, W., Watanabe, H., Suenaga, A., Kai, T., Otagiri, M., Maruyama, T. S-nitrosated alpha-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis. FASEB J. 27, 391-398 (2013). www.fasebj.org	[Watanabe, Kaori; Ishima, Yu; Watanabe, Hiroshi; Suenaga, Ayaka; Kai, Toshiya; Otagiri, Masaki; Maruyama, Toru] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Kumamoto 8620973, Japan; [Akaike, Takaaki; Sawa, Tomohiro] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Microbiol, Kumamoto 8620973, Japan; [Ishima, Yu; Watanabe, Hiroshi; Maruyama, Toru] Kumamoto Univ, Sch Pharm, Ctr Clin Pharmaceut Sci, Kumamoto 8620973, Japan; [Sawa, Tomohiro] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan; [Kuroda, Teruo; Ogawa, Wakano] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Microbiol, Okayama 7008530, Japan; [Kai, Toshiya] Tohoku Nipro Pharmaceut Corp, Fukushima, Japan; [Otagiri, Masaki] Sojo Univ, Fac Pharmaceut Sci, Kumamoto, Japan; [Otagiri, Masaki] Sojo Univ, Drug Delivery Syst DDS Res Inst, Kumamoto, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Japan Science & Technology Agency (JST); Okayama University; Sojo University; Sojo University	Maruyama, T (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	tomaru@gpo.kumamoto-u.ac.jp	Ogawa, Wakano/AAI-2887-2020; OGAWA, Wakano/B-1997-2011; KURODA, Teruo/B-2028-2011		Japan Society for the Promotion of Science (JSPS) [KAKENHI 18390051, 22790162]; Uehara Memorial Fund; Kumayaku Alumni Research Fund; Grants-in-Aid for Scientific Research [23651239, 24659076] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uehara Memorial Fund; Kumayaku Alumni Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Ms. Judith B. Gandy for editing the manuscript. Thanks are also due to members of the Gene Technology Center in Kumamoto University for their important contributions to the experiments. The authors also thank the members of the Chemo-Sero-Therapeutic Research Institute (Kumamoto, Japan) for donation of lyophilized AGP. This research was supported in part by grants-in-aid for scientific research from the Japan Society for the Promotion of Science (JSPS; KAKENHI 18390051 and 22790162). This work was also supported in part by grants from the Uehara Memorial Fund and the Kumayaku Alumni Research Fund.	Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Cordero EM, 2008, TUBERCULOSIS, V88, P203, DOI 10.1016/j.tube.2007.10.004; Cross AS, 2003, J BIOL CHEM, V278, P4112, DOI 10.1074/jbc.M207591200; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Ewing JF, 1997, J PHARMACOL EXP THER, V283, P947; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Foley E, 2003, GENE DEV, V17, P115, DOI 10.1101/gad.1018503; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Greco TM, 2006, P NATL ACAD SCI USA, V103, P7420, DOI 10.1073/pnas.0600729103; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; HERVE F, 1992, J CHROMATOGR-BIOMED, V577, P43, DOI 10.1016/0378-4347(92)80597-J; Hochepied T, 2000, J BIOL CHEM, V275, P14903, DOI 10.1074/jbc.275.20.14903; Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e; INCZE K, 1974, APPL MICROBIOL, V27, P202, DOI 10.1128/AEM.27.1.202-205.1974; Ishima Y, 2007, J PHARMACOL EXP THER, V320, P969, DOI 10.1124/jpet.106.114959; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; LAMBRE CR, 1988, CLIN EXP IMMUNOL, V73, P230; Levy S.B, 2002, ANTIBIOTIC PARADOX, V2nd; Matsumoto K, 2010, DRUG METAB PHARMACOK, V25, P101, DOI 10.2133/dmpk.25.101; Miyamoto Y, 2000, BBA-PROTEIN STRUCT M, V1477, P90, DOI 10.1016/S0167-4838(99)00264-2; Miyamoto Y, 2000, BIOCHEM BIOPH RES CO, V267, P918, DOI 10.1006/bbrc.1999.2046; Mnaimneh S, 1997, J IMMUNOL, V158, P308; Muchitsch EM, 1998, FUNDAM CLIN PHARM, V12, P173, DOI 10.1111/j.1472-8206.1998.tb00938.x; Nan XL, 2007, J LEUKOCYTE BIOL, V81, P284, DOI 10.1189/jlb.1105692; Nishi K, 2011, J BIOL CHEM, V286, P14427, DOI 10.1074/jbc.M110.208926; Nishi K, 2010, DRUG METAB PHARMACOK, V25, P200, DOI 10.2133/dmpk.25.200; Piagnerelli M, 2003, CRIT CARE MED, V31, P2156, DOI 10.1097/01.CCM.0000079608.00875.14; PRIMOZIC S, 1985, J PHARM SCI, V74, P473, DOI 10.1002/jps.2600740421; Sakarya S, 2010, J APPL MICROBIOL, V108, P1313, DOI 10.1111/j.1365-2672.2009.04525.x; Miranda MS, 2006, INT J EXP PATHOL, V87, P485, DOI 10.1111/j.1365-2613.2006.00504.x; WARREN L, 1959, J BIOL CHEM, V234, P1971; WHO, 2008, PHARMAFORUM 0121; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	37	10	10	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					391	398		10.1096/fj.12-217794	http://dx.doi.org/10.1096/fj.12-217794			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047897				2022-12-28	WOS:000313103200037
J	Mo, M; Erdelyi, I; Szigeti-Buck, K; Benbow, JH; Ehrlich, BE				Mo, Michelle; Erdelyi, Ildiko; Szigeti-Buck, Klara; Benbow, Jennifer H.; Ehrlich, Barbara E.			Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment	FASEB JOURNAL			English	Article						neuronal calcium sensor-1; inositol; 1,4,5 trisphosphate receptor; intracellular calcium signaling; ibudilast	NEURONAL CALCIUM SENSOR-1; ORAL GLUTAMINE; RAT MODELS; CANCER; RECEPTOR; TAXOL; THERAPY; GLUTATHIONE; HOMEOSTASIS; INHIBITION	Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect that occurs in many patients undergoing chemotherapy. It is often irreversible and frequently leads to early termination of treatment. In this study, we have identified two compounds, lithium and ibudilast, that when administered as a single prophylactic injection prior to paclitaxel treatment, prevent the development of CIPN in mice at the sensory-motor and cellular level. The prevention of neuropathy was not observed in paclitaxel-treated mice that were only prophylactically treated with a vehicle injection. The coadministration of lithium with paclitaxel also allows for administration of higher doses of paclitaxel (survival increases by 60%), protects against paclitaxel-induced cardiac abnormalities, and, notably, does not interfere with the antitumor effects of paclitaxel. Moreover, we have determined a mechanism by which CIPN develops and have discovered that lithium and ibudilast inhibit development of peripheral neuropathy by disrupting the interaction between paclitaxel, neuronal calcium sensor 1 (NCS-1), and the inositol 1,4,5-trisphosphate receptor (InsP3R) to prevent treatment-induced decreases in intracellular calcium signaling. This study shows that lithium and ibudilast are candidate therapeutics for the prevention of paclitaxel-induced neuropathy and could enable patients to tolerate more aggressive treatment regimens.-Mo, M., Erdelyi, I., Szigeti-Buck, K., Benbow, J. H., Ehrlich, B. E. Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J. 26, 4696-4709 (2012). www.fasebj.org	[Mo, Michelle; Benbow, Jennifer H.; Ehrlich, Barbara E.] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; [Erdelyi, Ildiko] Yale Univ, Dept Comparat Med, New Haven, CT 06520 USA; [Szigeti-Buck, Klara] Yale Univ, Dept Obstet & Gynecol, New Haven, CT 06520 USA; [Benbow, Jennifer H.; Ehrlich, Barbara E.] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	U.S. Department of Defense [W81XWH-10-1-0033]; U.S. National Institutes of Health [DK 57751, DK61747]; National Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057751, R01DK061747] Funding Source: NIH RePORTER	U.S. Department of Defense(United States Department of Defense); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by grants from the U.S. Department of Defense (W81XWH-10-1-0033) and the U.S. National Institutes of Health (DK 57751 and DK61747) and a National Science Foundation predoctoral fellowship. The authors are grateful for the insightful conversations regarding this study with Ivana Kuo, Colleen Feriod, Brenda DeGray, and Ed Kaftan. The authors thank Gordon Terwilliger and Caroline Zeiss for their help and expertise in histological processing and analysis; Nikki Mikkush and Kerry Russell for their assistance and knowledge in performing and analyzing echocardiograms; and Jiang Zaoli and Tommy Cheng for their expertise and assistance in creating a xenograft mouse model.	Agam G, 2009, BIOCHEM SOC T, V37, P1121, DOI 10.1042/BST0371121; Amara S, 2008, ANN PHARMACOTHER, V42, P1481, DOI 10.1345/aph.1L179; Baird RD, 2010, NAT REV CLIN ONCOL, V7, P575, DOI 10.1038/nrclinonc.2010.120; Benbow JH, 2011, J BIOL CHEM, V286, P34575, DOI 10.1074/jbc.M111.265751; Boehmerle W, 2007, P NATL ACAD SCI USA, V104, P11103, DOI 10.1073/pnas.0701546104; Boehmerle W, 2006, P NATL ACAD SCI USA, V103, P18356, DOI 10.1073/pnas.0607240103; Chang A. Y., 1995, SEMIN ONCOL, V22, P70; CHANG AY, 1995, SEMIN ONCOL, V22, P66; COLOMBO N, 1995, INT J GYNECOL CANCER, V5, P81, DOI 10.1046/j.1525-1438.1995.05020081.x; Costa R, 2011, BRIT J PHARMACOL, V164, P681, DOI 10.1111/j.1476-5381.2011.01408.x; Fernyhough P, 2010, CELL CALCIUM, V47, P130, DOI 10.1016/j.ceca.2009.11.008; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Grothey A, 2011, J CLIN ONCOL, V29, P421, DOI 10.1200/JCO.2010.31.5911; Hama AT, 2012, J NEUROTRAUM, V29, P600, DOI 10.1089/neu.2011.1863; Johenning FW, 2002, J NEUROSCI, V22, P5344; Johenning FW, 2004, BIOCHEM J, V382, P687, DOI 10.1042/BJ20040418; Ledeboer A, 2006, NEURON GLIA BIOL, V2, P279, DOI 10.1017/S1740925X0700035X; LEE M, 1980, AM J HOSP PHARM, V37, P1066, DOI 10.1093/ajhp/37.8.1066; Lema MJ, 2010, ONCOLOGIST, V15, P3, DOI 10.1634/theoncologist.2009-S505; Lersch Christian, 2002, Clin Colorectal Cancer, V2, P54, DOI 10.3816/CCC.2002.n.011; LYMAN GH, 1981, AM J MED, V70, P1222, DOI 10.1016/0002-9343(81)90831-7; LYMAN GH, 1980, NEW ENGL J MED, V302, P257, DOI 10.1056/NEJM198001313020503; Makoukji J, 2012, P NATL ACAD SCI USA, V109, P3973, DOI 10.1073/pnas.1121367109; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; O'Brien WT, 2009, BIOCHEM SOC T, V37, P1133, DOI 10.1042/BST0371133; Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Pourmohammadi N, 2012, BASIC CLIN PHARMACOL, V110, P231, DOI 10.1111/j.1742-7843.2011.00795.x; Rahn EJ, 2008, J PHARMACOL EXP THER, V327, P584, DOI 10.1124/jpet.108.141994; Rousset M, 2003, J BIOL CHEM, V278, P7019, DOI 10.1074/jbc.M209537200; Rowinsky E K, 1993, J Natl Cancer Inst Monogr, P107; Saha L, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/143579; Sarosy GA, 2010, CANCER-AM CANCER SOC, V116, P1476, DOI 10.1002/cncr.24861; Schlecker C, 2006, J CLIN INVEST, V116, P1668, DOI 10.1172/JCI22466; Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x; SHARMA A, 1994, PHARMACEUT RES, V11, P889, DOI 10.1023/A:1018994111594; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Siau C, 2006, ANESTH ANALG, V102, P1485, DOI 10.1213/01.ane.0000204318.35194.ed; Smyth JF, 1997, ANN ONCOL, V8, P569, DOI 10.1023/A:1008211226339; STEINHERZ LJ, 1995, MED PEDIATR ONCOL, V24, P352, DOI 10.1002/mpo.2950240604; Wada A, 2009, FRONT BIOSCI-LANDMRK, V14, P1558, DOI 10.2741/3324; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Wang MS, 2004, BRAIN, V127, P671, DOI 10.1093/brain/awh078; Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Weiss JL, 2010, CELL MOL NEUROBIOL, V30, P1283, DOI 10.1007/s10571-010-9588-7; Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x; WOOD AJ, 1986, NEUROPHARMACOLOGY, V25, P1285, DOI 10.1016/0028-3908(86)90149-8; Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050; Zhang K, 2010, J MOL CELL CARDIOL, V49, P829, DOI 10.1016/j.yjmcc.2010.08.018	50	52	54	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4696	4709		10.1096/fj.12-214643	http://dx.doi.org/10.1096/fj.12-214643			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22889832	Green Published			2022-12-28	WOS:000310574200030
J	Shen, CJ; Jia, YH; Tian, RR; Ding, M; Zhang, CY; Wang, JH				Shen, Chan-Juan; Jia, Yan-Hui; Tian, Ren-Rong; Ding, Ming; Zhang, Chiyu; Wang, Jian-Hua			Translation of Pur-alpha is targeted by cellular miRNAs to modulate the differentiation-dependent susceptibility of monocytes to HIV-1 infection	FASEB JOURNAL			English	Article						host factor; microRNA	VIRUS TYPE-1 REPLICATION; BLOOD MONOCYTES; LATENT HIV-1; PROTEIN; RESTRICTION; TAT; SAMHD1; CELLS; ASSOCIATION; MACROPHAGES	The postentry restriction of HIV-1 replication in monocytes can be relieved when they differentiate to dendritic cells (DCs) or macrophages. Multiple mechanisms have been proposed to interpret the differentiation-dependent susceptibility of monocytes to HIV-1 infection, and the absence of host-cell-encoded essential factors for HIV-1 completing the life cycle may provide an explanation. We have analyzed the gene expression profile in monocytes by mRNA microarray and compared it with that of differentiated DCs. We demonstrated that purine-rich element binding protein alpha (Pur-alpha), a host-cell-encoded ubiquitous, sequence-specific DNA-and RNA-binding protein, showed inadequate expression in monocytes, and the translation of Pur-alpha mRNA was repressed by cell-expressed microRNA (miRNA). These Pur-alpha-targeted miRNAs modulated the differentiation-dependent susceptibility of monocytes/DCs to HIV-1 infection, because rescue of Pur-alpha expression by transfection of miRNA inhibitors relieved the restriction of HIV-1 infection in monocytes, and ectopic input of miRNA mimics significantly reduced HIV-1 infection of monocyte-derived DCs (MDDCs). Collectively, our data emphasized that inadequate host factors contribute to HIV-1 restriction in monocytes, and cellular miRNAs modulate differentiation-dependent susceptibility of host cells to HIV-1 infection. Elaboration of HIV-1 restriction in host cells facilitates our understanding of viral pathogenesis and the search for a new antiviral strategy.-Shen, C.-J., Jia, Y.-H., Tian, R.-R., Ding, M., Zhang, C., Wang, J.-H. Translation of Pur-alpha is targeted by cellular miRNAs to modulate the differentiation-dependent susceptibility of monocytes to HIV-1 infection. FASEB J. 26, 4755-4764 (2012). www.fasebj.org	[Shen, Chan-Juan; Jia, Yan-Hui; Tian, Ren-Rong; Zhang, Chiyu; Wang, Jian-Hua] Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China; [Jia, Yan-Hui; Zhang, Chiyu] Jiangsu Univ, Inst Life Sci, Zhenjiang, Peoples R China; [Ding, Ming] Zhejiang Sci & Technol Univ, Lab Prote & Mol Enzymol, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); Jiangsu University; Zhejiang Sci-Tech University	Wang, JH (corresponding author), Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol, Shanghai Inst Biol Sci, Hefei Rd 411, Shanghai 200025, Peoples R China.	jh_wang@sibs.ac.cn	DING, MING/E-6964-2015	DING, MING/0000-0002-9135-9275	100 Talent Program of the CAS [KSCX2-KW-BR-1]; National Basic Research Program of China (973 Program) [2012CB519004]; Knowledge Innovation Program of the CAS [KSCX2-YW-R210, KSCX2-EW-Q-2]; Natural Science Foundation of Shanghai [10ZR1435200]; Natural Science Foundation of China [81171567, 31100631]; 49th National Science Foundation for Postdoctoral Scientists of China [20110490076]; Sanofi-Aventis-SIBS Scholarship Program	100 Talent Program of the CAS; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Knowledge Innovation Program of the CAS(Knowledge Innovation Program of the Chinese Academy of Sciences); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 49th National Science Foundation for Postdoctoral Scientists of China; Sanofi-Aventis-SIBS Scholarship Program	The authors thank Dr. Li Wu (The Ohio State University, Columbus, OH, USA), Dr. Vineet Kewal Ramani (National Cancer Institute, U. S. National Institutes of Health, Bethesda, MD, USA), and Dr. Ke Lan, Dr. Xian-Zhi Lin, Dr. De-Guang Liang, and Dr. Paul Zhou (Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China) for the gifts of plasmids or cell lines. This work was supported by grants to J. H. W from the 100 Talent Program of the CAS (KSCX2-KW-BR-1), the National Basic Research Program of China (973 Program; 2012CB519004), the Knowledge Innovation Program of the CAS (KSCX2-YW-R210, KSCX2-EW-Q-2), the Natural Science Foundation of Shanghai (10ZR1435200), the Natural Science Foundation of China (81171567), and the Shanghai Rising-Star Program (A type; 11QA1407700). The work was also sponsored by grants to C. J. S. from the Natural Science Foundation of China (31100631) and the 49th National Science Foundation for Postdoctoral Scientists of China (20110490076). J. H. W. gratefully acknowledges the support of the Sanofi-Aventis-SIBS Scholarship Program.	Arfi V, 2008, J VIROL, V82, P6557, DOI 10.1128/JVI.02321-07; Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31; Berger A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002425; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51; Collini P, 2010, CURR MOL MED, V10, P727, DOI 10.2174/156652410793384141; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; Daniel DC, 2001, J GEN VIROL, V82, P1543, DOI 10.1099/0022-1317-82-7-1543; Dong CS, 2009, J VIROL, V83, P3518, DOI 10.1128/JVI.02665-08; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Goff SP, 2008, CELL, V135, P417, DOI 10.1016/j.cell.2008.10.007; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639; Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719; Kedzierska K, 2002, CURR MED CHEM, V9, P1893, DOI 10.2174/0929867023368935; Kok KH, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-78; Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114; Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32; Leavy O, 2011, NAT REV IMMUNOL, V11, DOI 10.1038/nri3018; Lin XZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016224; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; MIKOVITS JA, 1992, J CLIN INVEST, V90, P1486, DOI 10.1172/JCI116016; Naghavi MH, 2007, CURR OPIN IMMUNOL, V19, P402, DOI 10.1016/j.coi.2007.07.003; Neil S, 2001, J VIROL, V75, P5448, DOI 10.1128/JVI.75.12.5448-5456.2001; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Sonza S, 2001, AIDS, V15, P17, DOI 10.1097/00002030-200101050-00005; St Gelais C, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-55; Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263; Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004; VALENTIN A, 1991, J ACQ IMMUN DEF SYND, V4, P751; Van den Bergh R, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-53; Wang JH, 2007, J VIROL, V81, P8933, DOI 10.1128/JVI.00878-07; Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000; Wortman MJ, 2000, J CELL BIOCHEM, V77, P65, DOI 10.1002/(SICI)1097-4644(20000401)77:1<65::AID-JCB7>3.0.CO;2-U; Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004; Zhu T, 2002, J ANTIMICROB CHEMOTH, V50, P309, DOI 10.1093/jac/dkf143; Zhu TF, 2000, J LEUKOCYTE BIOL, V68, P338; Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002	43	45	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4755	4764		10.1096/fj.12-209023	http://dx.doi.org/10.1096/fj.12-209023			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835829				2022-12-28	WOS:000310574200035
J	Borgeson, E; McGillicuddy, FC; Harford, KA; Corrigan, N; Higgins, DF; Maderna, P; Roche, HM; Godson, C				Boergeson, Emma; McGillicuddy, Fiona C.; Harford, Karen A.; Corrigan, Niamh; Higgins, Debra F.; Maderna, Paola; Roche, Helen M.; Godson, Catherine			Lipoxin A(4) attenuates adipose inflammation	FASEB JOURNAL			English	Article						resolution; proresolving eicosanoids; obesity; insulin resistance	NECROSIS-FACTOR-ALPHA; MACROPHAGE ACCUMULATION; APOPTOTIC NEUTROPHILS; INSULIN SENSITIVITY; TISSUE MACROPHAGES; LINOLEIC-ACID; CUTTING EDGE; BONE-MARROW; RESOLVIN D1; IN-VITRO	Aging and adiposity are associated with chronic low-grade inflammation, which underlies the development of obesity-associated complications, including type 2 diabetes mellitus (T2DM). The mechanisms underlying adipose inflammation may include macrophage infiltration and activation, which, in turn, affect insulin sensitivity of adipocytes. There is a growing appreciation that specific lipid mediators (including lipoxins, resolvins, and protectins) can promote the resolution of inflammation. Here, we investigated the effect of lipoxin A(4) (LXA(4)), the predominant endogenously generated lipoxin, on adipose tissue inflammation. Using adipose tissue explants from perigonadal depots of aging female C57BL/6J mice (Animalia, Chordata, Mus musculus) as a model of age-associated adipose inflammation, we report that LXA(4) (1 nM) attenuates adipose inflammation, decreasing IL-6 and increasing IL-10 expression (P<0.05). The altered cytokine milieu correlated with increased GLUT-4 and IRS-1 expression, suggesting improved insulin sensitivity. Further investigations revealed the ability of LXA(4) to rescue macrophage-induced desensitization to insulin-stimulated signaling and glucose uptake in cultured adipocytes, using vehicle-stimulated cells as controls. This was associated with preservation of Akt activation and reduced secretion of proinflammatory cytokines, including TNF-alpha. We therefore propose that LXA(4) may represent a potentially useful and novel therapeutic strategy to subvert adipose inflammation and insulin resistance, key components of T2DM.-Borgeson, E., McGillicuddy, F. C., Harford, K. A., Corrigan, N., Higgins, D. F., Maderna, P., Roche, H. M., Godson C. Lipoxin A(4) attenuates adipose inflammation. FASEB J. 26, 4287-4294 (2012). www.fasebj.org	[Boergeson, Emma; Corrigan, Niamh; Higgins, Debra F.; Maderna, Paola; Godson, Catherine] Univ Coll Dublin, Diabet Res Ctr, Conway Inst, Sch Med & Med Sci, Dublin 2, Ireland; [McGillicuddy, Fiona C.; Harford, Karen A.; Roche, Helen M.] Univ Coll Dublin, Nutrigen Res Grp, Conway Inst, Dublin 2, Ireland; [McGillicuddy, Fiona C.; Harford, Karen A.; Roche, Helen M.] Univ Coll Dublin, Sch Publ Hlth, Dublin 2, Ireland	University College Dublin; University College Dublin; University College Dublin	Godson, C (corresponding author), Univ Coll Dublin, Diabet Res Ctr, Conway Inst, Sch Med & Med Sci, Dublin 2, Ireland.	catherine.godson@ucd.ie	Borgeson, Emma/O-3128-2017; Roche, Helen M/AAF-4164-2019	Borgeson, Emma/0000-0002-2290-9472; Roche, Helen M/0000-0002-0628-3318; McGillicuddy, Fiona/0000-0003-3623-3503; Godson, Catherine/0000-0003-0655-1041	Science Foundation Ireland [06/IN.1/B114, 06/IN.1/B105]; Health Research Board; Government of Ireland Programme for Research in Third Level Institutions; Irish Research Council for Science, Engineering, and Technology Embark postgraduate research scholarship	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Government of Ireland Programme for Research in Third Level Institutions; Irish Research Council for Science, Engineering, and Technology Embark postgraduate research scholarship(Irish Research Council for Science, Engineering and Technology)	The authors acknowledge valuable advice from Prof. Mauro Perretti (William Harvey Research Institute, Queen Mary University, London, UK). The authors also acknowledge technical help of the University College Dublin (UCD) Conway Institute Transcriptomics Core facility and staff at the UCD Biomedical animal facility, as well as Dr. Deirdre Keane and Dr. Claire Kennedy. E.B. is a recipient of an Irish Research Council for Science, Engineering, and Technology Embark postgraduate research scholarship. Work in the C.G. laboratory is supported by Science Foundation Ireland (06/IN.1/B114), the Health Research Board, and the Government of Ireland Programme for Research in Third Level Institutions. The H.M.R. laboratory is supported by Science Foundation Ireland (06/IN.1/B105).	Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Borgeson E, 2011, FASEB J, V25, P2967, DOI 10.1096/fj.11-185017; Borgeson E, 2010, THESCIENTIFICWORLDJO, V10, P1370, DOI 10.1100/tsw.2010.120; Borgeson E, 2011, INFECT IMMUN, V79, P1489, DOI 10.1128/IAI.00777-10; Brancaleone V, 2011, J IMMUNOL, V186, P4905, DOI 10.4049/jimmunol.1003145; Cevenini E, 2010, CURR PHARM DESIGN, V16, P609, DOI 10.2174/138161210790883840; Chen AR, 2005, OBES RES, V13, P1311, DOI 10.1038/oby.2005.159; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cusi K, 2010, CURR DIABETES REP, V10, P306, DOI 10.1007/s11892-010-0122-6; de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057; Decker Y, 2009, AM J PHYSIOL-CELL PH, V296, pC1420, DOI 10.1152/ajpcell.00380.2008; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Dragunow M, 2007, J BIOMOL SCREEN, V12, P999, DOI 10.1177/1087057107306502; Gangemi S, 2005, EXP GERONTOL, V40, P612, DOI 10.1016/j.exger.2005.04.004; GAO JL, 1993, J BIOL CHEM, V268, P25395; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Goh J, 2001, J IMMUNOL, V167, P2772, DOI 10.4049/jimmunol.167.5.2772; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Gonzalez-Periz A, 2010, THESCIENTIFICWORLDJO, V10, P832, DOI 10.1100/tsw.2010.77; Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Halade GV, 2011, J NUTR BIOCHEM, V22, P459, DOI 10.1016/j.jnutbio.2010.03.015; Harford KA, 2011, P NUTR SOC, V70, P408, DOI 10.1017/S0029665111000565; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Huggins A, 2009, FASEB J, V23, P985, DOI 10.1096/fj.08-119040; Inouye KE, 2007, DIABETES, V56, P2242, DOI 10.2337/db07-0425; Kure I, 2010, J PHARMACOL EXP THER, V332, P541, DOI 10.1124/jpet.109.159046; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Liu LF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-212; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2007, AM J PHYSIOL-ENDOC M, V292, pE166, DOI 10.1152/ajpendo.00284.2006; Lumeng CN, 2011, J IMMUNOL, V187, P6208, DOI 10.4049/jimmunol.1102188; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mathew AV, 2011, CURR DIABETES REV, V7, P41, DOI 10.2174/157339911794273928; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Moloney F, 2007, DIABETES, V56, P574, DOI 10.2337/db06-0384; Nascimento-Silva V, 2007, THROMB HAEMOSTASIS, V97, P88, DOI 10.1160/TH06-06-0315; Nishiumi S, 2007, BIOSCI BIOTECH BIOCH, V71, P2343, DOI 10.1271/bbb.70342; Oliver E, 2012, J NUTR BIOCHEM, V23, P1192, DOI 10.1016/j.jnutbio.2011.06.014; Oliver E, 2010, P NUTR SOC, V69, P232, DOI 10.1017/S0029665110000042; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Pouliot M, 1999, J PERIODONTAL RES, V34, P370, DOI 10.1111/j.1600-0765.1999.tb02268.x; Rachdaoui N, 2003, AM J PHYSIOL-ENDOC M, V285, pE545, DOI 10.1152/ajpendo.00160.2003; Rajakariarl R, 2008, BLOOD, V111, P4184, DOI 10.1182/blood-2007-08-108936; Reville K, 2006, J IMMUNOL, V176, P1878, DOI 10.4049/jimmunol.176.3.1878; Romano M, 2007, THESCIENTIFICWORLDJO, V7, P1393, DOI 10.1100/tsw.2007.186; Romano M, 2010, THESCIENTIFICWORLDJO, V10, P1048, DOI 10.1100/tsw.2010.113; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; Spencer M, 2010, AM J PHYSIOL-ENDOC M, V299, pE1016, DOI 10.1152/ajpendo.00329.2010; Stables MJ, 2011, PROG LIPID RES, V50, P35, DOI 10.1016/j.plipres.2010.07.005; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Wu J, 2011, BIOCHEM BIOPH RES CO, V408, P382, DOI 10.1016/j.bbrc.2011.04.013; Wu SH, 2006, AM J RESP CELL MOL, V34, P65, DOI 10.1165/rcmb.2005-0184OC; Wu SH, 2005, KIDNEY INT, V68, P35, DOI 10.1111/j.1523-1755.2005.00379.x	67	78	85	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					4287	4294		10.1096/fj.12-208249	http://dx.doi.org/10.1096/fj.12-208249			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22700871	Bronze			2022-12-28	WOS:000309704000033
J	Ishihara, K; Miyazaki, A; Nabe, T; Fushimi, H; Iriyama, N; Kanai, S; Sato, T; Uozumi, N; Shimizu, T; Akiba, S				Ishihara, Keiichi; Miyazaki, Akira; Nabe, Takeshi; Fushimi, Hideaki; Iriyama, Nao; Kanai, Shiho; Sato, Takashi; Uozumi, Naonori; Shimizu, Takao; Akiba, Satoshi			Group IVA phospholipase A(2) participates in the progression of hepatic fibrosis	FASEB JOURNAL			English	Article						proteomics; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; inflammation; mouse model	MONOCYTE CHEMOATTRACTANT PROTEIN-1; FATTY LIVER-DISEASE; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; ACTIVATED STELLATE CELLS; KILLER T-CELLS; NONALCOHOLIC STEATOHEPATITIS; PROSTAGLANDIN E-2; NUTRITIONAL MODEL; ANIMAL-MODELS; UP-REGULATION	Group IVA phospholipase A(2) (IVA-PLA(2)) is an enzyme that intiates the arachidonic acid pathway and plays an important role in inflammation. We demonstrate that IVA-PLA(2) deficiency suppresses lipid deposition in the liver, which was induced by administration of a high-fat and -cholesterol diet (HFCD) for 16 wk in mice. Herein, we performed 2-dimensional gel-based comparative proteomics to further define the suppressive effect of IVA-PLA(2) deficiency on fatty liver formation. In comparisons among 4 groups, wild-type (WT)/normal diet (ND), IVA-PLA(2)-deficient knockout (KO)/ND, WT/HFCD, and KO/HFCD, 4 proteins, 3 of which are associated with hepatic fibrosis, were identified as molecules, of which altered expression by HFCD was suppressed in KO mice compared to WT mice. Therefore, we assessed the effect of IVA-PLA(2) deficiency on hepatic fibrosis induced by HFCD or carbon tetrachloride (CCl4) in mouse models. Biochemical and histological analyses revealed that IVA-PLA(2) deficiency markedly reduced overall collagen accumulation in the liver of HFCD- and CCl4-derived mouse models. We found that IVA-PLA2 deficiency prevented activation of hepatic stellate cells and infiltration of F4/80-positive macrophages without affecting other immunocytes such as CD8(+) lymphocytes and natural killer cells. In summary, IVA-PLA(2) deficiency attenuates not only lipid deposition in the liver but also hepatic fibrosis formation.-Ishihara, K., Miyazaki, A., Nabe, T., Fushimi, H., Iriyama, N., Kanai, S., Sato, T., Uozumi, N., Shimizu, T., Akiba, S. Group IVA phospholipase A(2) participates in the progression of hepatic fibrosis. FASEB J. 26, 4111-4121 (2012). www.fasebj.org	[Akiba, Satoshi] Kyoto Pharmaceut Univ, Dept Pathol Biochem, Yamashina Ku, Kyoto 6078414, Japan; [Uozumi, Naonori; Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Nabe, Takeshi] Kyoto Pharmaceut Univ, Dept Pharmacol, Kyoto 6078414, Japan	Kyoto Pharmaceutical University; University of Tokyo; Kyoto Pharmaceutical University	Akiba, S (corresponding author), Kyoto Pharmaceut Univ, Dept Pathol Biochem, Yamashina Ku, Misasagi Nakauchi Cho 5, Kyoto 6078414, Japan.	akiba@mb.kyoto-phu.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019; Ishihara, Keiichi/M-5743-2019; Shimizu, Takao/AAV-7052-2021	Nabe, Takeshi/0000-0002-5225-8375	Ministry of Education, Science, Culture and Sports of Japan (MEXT) Program for the Strategic Research Foundation at Private Universities [20590072, 22790091]; Takeda Science Foundation; Grants-in-Aid for Scientific Research [23590093] Funding Source: KAKEN	Ministry of Education, Science, Culture and Sports of Japan (MEXT) Program for the Strategic Research Foundation at Private Universities; Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Drs. Y. Kiso and Y. Sohma (Kyoto Pharmaceutical University) for the technical assistance in MALDI-TOF MS analysis. This study was supported in part by a grant-in-aid for scientific research (C; project 20590072; to S.A.) and a grant-in-aid for young scientists (B; project 22790091; to K. I.) from the Ministry of Education, Science, Culture and Sports of Japan (MEXT) Program for the Strategic Research Foundation at Private Universities, and by the Takeda Science Foundation (to K. I.).	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Blom KG, 2009, CLIN EXP IMMUNOL, V155, P320, DOI 10.1111/j.1365-2249.2008.03815.x; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5; Day CP, 2002, BEST PRACT RES CL GA, V16, P663, DOI 10.1053/bega.2002.0333; den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Efsen E, 2001, HEPATOLOGY, V33, P713, DOI 10.1053/jhep.2001.22761; Enomoto N, 2000, AM J PHYSIOL-GASTR L, V279, pG100, DOI 10.1152/ajpgi.2000.279.1.G100; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Guido M, 1997, HEPATOLOGY, V26, P310, DOI 10.1002/hep.510260209; Horrillo R, 2007, J PHARMACOL EXP THER, V323, P778, DOI 10.1124/jpet.107.128264; Huang L, 2004, ARTERIOSCL THROM VAS, V24, P1783, DOI 10.1161/01.ATV.0000140063.06341.09; Hui AY, 2004, J HEPATOL, V41, P251, DOI 10.1016/j.jhep.2004.04.033; Ii H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008089; Ishihara K, 2005, MOL CELL BIOCHEM, V276, P21, DOI 10.1007/s11010-005-2465-x; JAMALL IS, 1981, ANAL BIOCHEM, V112, P70, DOI 10.1016/0003-2697(81)90261-X; Kassel KM, 2010, LAB INVEST, V90, P1794, DOI 10.1038/labinvest.2010.143; Kirsch R, 2003, J GASTROEN HEPATOL, V18, P1272, DOI 10.1046/j.1440-1746.2003.03198.x; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Lieber CS, 2004, AM J CLIN NUTR, V79, P502; Marchesini G, 2008, J CLIN ENDOCR METAB, V93, pS74, DOI 10.1210/jc.2008-1399; Marra F, 1999, HEPATOLOGY, V29, P140, DOI 10.1002/hep.510290107; Mazid MA, 2006, FEBS LETT, V580, P6885, DOI 10.1016/j.febslet.2006.11.049; Melhem A, 2006, J HEPATOL, V45, P60, DOI 10.1016/j.jhep.2005.12.025; Muhanna N, 2008, HEPATOLOGY, V48, P963, DOI 10.1002/hep.22413; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; Panini SR, 2001, J LIPID RES, V42, P1678; Park O, 2009, HEPATOLOGY, V49, P1683, DOI 10.1002/hep.22813; Perez S, 2006, BBA-MOL CELL BIOL L, V1761, P160, DOI 10.1016/j.bbalip.2006.02.003; Planaguma A, 2005, FASEB J, V19, P1120, DOI 10.1096/fj.04-2753fje; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Rinella ME, 2004, J HEPATOL, V40, P47, DOI 10.1016/j.jhep.2003.09.020; Safadi R, 2004, GASTROENTEROLOGY, V127, P870, DOI 10.1053/j.gastro.2004.04.062; Sahai A, 2004, AM J PHYSIOL-GASTR L, V287, pG264, DOI 10.1152/ajpgi.00002.2004; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Seki E, 2009, HEPATOLOGY, V50, P185, DOI 10.1002/hep.22952; Stowell R.E., 1951, CANCER RES, V2, P345; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8	44	30	30	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					4111	4121		10.1096/fj.12-205625	http://dx.doi.org/10.1096/fj.12-205625			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22750514				2022-12-28	WOS:000309704000018
J	Laubenthal, J; Zlobinskaya, O; Poterlowicz, K; Baumgartner, A; Gdula, MR; Fthenou, E; Keramarou, M; Hepworth, SJ; Kleinjans, JCS; van Schooten, FJ; Brunborg, G; Godschalk, RW; Schmid, TE; Anderson, D				Laubenthal, Julian; Zlobinskaya, Olga; Poterlowicz, Krzysztof; Baumgartner, Adolf; Gdula, Michal R.; Fthenou, Eleni; Keramarou, Maria; Hepworth, Sarah J.; Kleinjans, Jos C. S.; van Schooten, Frederik-Jan; Brunborg, Gunnar; Godschalk, Roger W.; Schmid, Thomas E.; Anderson, Diana			Cigarette smoke-induced transgenerational alterations in genome stability in cord blood of human F1 offspring	FASEB JOURNAL			English	Article						toxicants; DNA damage; male germline; transmission; germ cell mutagen	TOBACCO-SMOKE; DNA-DAMAGE; CRITICAL WINDOWS; GENE-EXPRESSION; EXPOSURE; PREGNANCY; MOTHERS; LINE; SUSCEPTIBILITY; RNA	The relevance of preconceptional and prenatal toxicant exposures for genomic stability in offspring is difficult to analyze in human populations, because gestational exposures usually cannot be separated from preconceptional exposures. To analyze the roles of exposures during gestation and conception on genomic stability in the offspring, stability was assessed via the Comet assay and highly sensitive, semiautomated confocal laser scans of gamma H2AX foci in cord, maternal, and paternal blood as well as spermatozoa from 39 families in Crete, Greece, and the United Kingdom. With use of multivariate linear regression analysis with backward selection, preconceptional paternal smoking (% tail DNA: P>0.032; gamma H2AX foci: P>0.018) and gestational maternal (% tail DNA: P>0.033) smoking were found to statistically significantly predict DNA damage in the cord blood of F1 offspring. Maternal passive smoke exposure was not identified as a predictor of DNA damage in cord blood, indicating that the effect of paternal smoking may be transmitted via the spermatozoal genome. Taken together, these studies reveal a role for cigarette smoke in the induction of DNA alterations in human F1 offspring via exposures of the fetus in utero or the paternal germline. Moreover, the identification of transgenerational DNA alterations in the unexposed F1 offspring of smoking-exposed fathers supports the claim that cigarette smoke is a human germ cell mutagen.-Laubenthal, J., Zlobinskaya, O., Poterlowicz, K., Baumgartner, A., Gdula, M. R., Fthenou, E., Keramarou, M., Hepworth, S. J., Kleinjans, J. C. S., van Schooten, F.-J., Brunborg, G., Godschalk, R. W., Schmid, T. E., Anderson, D. Cigarette smoke-induced transgenerational alterations in genome stability in cord blood of human F1 offspring. FASEB J. 26, 3946-3956 (2012). www.fasebj.org	[Laubenthal, Julian; Baumgartner, Adolf; Anderson, Diana] Univ Bradford, Sch Life Sci, Div Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; [Poterlowicz, Krzysztof] Univ Bradford, Sch Life Sci, Ctr Skin Sci, Bradford BD7 1DP, W Yorkshire, England; [Zlobinskaya, Olga; Schmid, Thomas E.] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Therapy, D-8000 Munich, Germany; [Baumgartner, Adolf] Univ Leipzig, Cardiac Ctr, Dept Paediat Cardiol, Leipzig, Germany; [Gdula, Michal R.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; [Fthenou, Eleni; Keramarou, Maria] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece; [Hepworth, Sarah J.] Univ Leeds, Div Epidemiol, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England; [van Schooten, Frederik-Jan; Godschalk, Roger W.] Univ Maastricht, Dept Toxicol, Maastricht, Netherlands; [Kleinjans, Jos C. S.] Univ Maastricht, Dept Toxicogen, Maastricht, Netherlands; [Brunborg, Gunnar] Norwegian Inst Publ Hlth, Div Environm Med, Dept Chem Toxicol, Oslo, Norway	University of Bradford; University of Bradford; Technical University of Munich; Leipzig University; Boston University; University of Crete; University of Leeds; Maastricht University; Maastricht University; Norwegian Institute of Public Health (NIPH)	Anderson, D (corresponding author), Univ Bradford, Sch Life Sci, Div Biomed Sci, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.	d.anderson1@bradford.ac.uk	Laubenthal, Julian/GPK-1372-2022; Anderson, Diana/J-6472-2015; Poterlowicz, Krzysztof/AAS-2395-2020; Gdula, Michal/AAX-2755-2020; Kleinjans, Jos C.S./E-7241-2015	Anderson, Diana/0000-0001-9673-0398; Poterlowicz, Krzysztof/0000-0001-6173-5674; Gdula, Michal/0000-0002-8667-7359; Schmid, Thomas/0000-0002-8894-8087; Laubenthal, Julian/0000-0001-9214-5538; Fleming, Sarah/0000-0002-7655-4806; Fthenou, Eleni/0000-0002-1178-6841	European Union Integrated Project NewGeneris, 6th Framework Programme, Priority 5: Food Quality and Safety [FOOD-CT-2005-016320]	European Union Integrated Project NewGeneris, 6th Framework Programme, Priority 5: Food Quality and Safety	The authors thank M. Kogevinas (Centre for Research in Environmental Epidemiology, Barcelona, Spain) for enabling samples to be provided from the NewGeneris subcohort in Crete, Greece; Leda Chatzi for her considerable contribution to the cotinine data (University of Crete, Heraklion, Greece); G. Chalkiadaki and T. Roumeliwtaki (University of Crete) as well as M. Kurzawa-Zegota and E. Cemeli (Food Standards Agency, London, UK) for support with sample collection and preparation; V. A. Botchkarev (University of Boston, Boston, MA, USA) for support with LSCM; Constantine Vardavas (Harvard University, Boston, MA, USA) for discussion on cotinine analysis; and M. Kogevinas and I. F. Merlo (Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-IST-National Cancer Research Institute, Genoa, Italy) for critical review of the article. This work was financed by the European Union Integrated Project NewGeneris, 6th Framework Programme, Priority 5: Food Quality and Safety, contract FOOD-CT-2005-016320 (http://www.newgeneris.org).	Aitken RJ, 2004, NATURE, V432, P48, DOI 10.1038/432048a; Amer Soc Reproductive Med, 2008, FERTIL STERIL, V90, pS254, DOI 10.1016/j.fertnstert.2008.08.035; Anderson Diana, 2005, Toxicol Appl Pharmacol, V207, P506, DOI 10.1016/j.taap.2005.01.022; Anderson LM, 2000, ENVIRON HEALTH PERSP, V108, P573, DOI 10.2307/3454549; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Barber RC, 2006, ONCOGENE, V25, P7336, DOI 10.1038/sj.onc.1209723; Bennett LM, 2010, MUTAT RES-GEN TOX EN, V696, P81, DOI 10.1016/j.mrgentox.2009.12.015; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Brevik A., 2012, INT J CELL BIOL, V2012, P407; Brevik A, 2011, REPROD TOXICOL, V32, P463, DOI 10.1016/j.reprotox.2011.09.005; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chandler VL, 2004, NAT REV GENET, V5, P532, DOI 10.1038/nrg1378; Chatzi L, 2009, AM J EPIDEMIOL, V170, P829, DOI 10.1093/aje/kwp211; de la Chica RA, 2005, JAMA-J AM MED ASSOC, V293, P1212, DOI 10.1001/jama.293.10.1212; DeMarini DM, 2012, ENVIRON MOL MUTAGEN, V53, P166, DOI 10.1002/em.21685; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DeMarini DM, 2005, JAMA-J AM MED ASSOC, V293, P1264, DOI 10.1001/jama.293.10.1264; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2003, ONCOGENE, V22, P7087, DOI 10.1038/sj.onc.1206993; Glen CD, 2008, CANCER RES, V68, P3630, DOI 10.1158/0008-5472.CAN-08-0484; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Hammadeh ME, 2010, HUM REPROD, V25, P2708, DOI 10.1093/humrep/deq226; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hecht SS, 1999, CANCER RES, V59, P590; Hecht SS, 2006, CANCER EPIDEM BIOMAR, V15, P988, DOI 10.1158/1055-9965.EPI-05-0596; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Keohavong P, 2005, MUTAT RES-FUND MOL M, V572, P156, DOI 10.1016/j.mrfmmm.2005.01.014; Leonardi-Bee J, 2011, PEDIATRICS, V127, P734, DOI 10.1542/peds.2010-3041; Linschooten JO, 2011, REPROD TOXICOL, V32, P106, DOI 10.1016/j.reprotox.2011.05.004; Linschooten JO, 2009, MUTAT RES-FUND MOL M, V667, P70, DOI 10.1016/j.mrfmmm.2008.12.014; Marchetti F, 2011, P NATL ACAD SCI USA, V108, P12811, DOI 10.1073/pnas.1106896108; Merlo DF, 2009, CANCER EPIDEM BIOMAR, V18, P5, DOI 10.1158/1055-9965.EPI-08-0876; Ng HK, 2010, PLACENTA, V31, P259, DOI 10.1016/j.placenta.2010.01.009; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Olsen AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011349; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P1133, DOI 10.1289/ehp.6833; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Scares SR, 2008, CURR OPIN OBSTET GYN, V20, P281, DOI 10.1097/GCO.0b013e3282fc9c1e; Schmid TE, 2010, INT J RADIAT BIOL, V86, P682, DOI 10.3109/09553001003734543; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Shutin D, 2010, COMPUT METH PROG BIO, V97, P114, DOI 10.1016/j.cmpb.2009.05.009; Singer TM, 2010, ENVIRON MOL MUTAGEN, V51, P919, DOI 10.1002/em.20613; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sipinen V, 2010, MUTAGENESIS, V25, P417, DOI 10.1093/mutage/geq024; Vande Loock K, 2011, ENVIRON HEALTH PERSP, V119, P1460, DOI 10.1289/ehp.1003246; Vardavas CI, 2013, TOB CONTROL, V22, P194, DOI 10.1136/tobaccocontrol-2011-050144; Venners SA, 2004, AM J EPIDEMIOL, V159, P993, DOI 10.1093/aje/kwh128; Verhofstad N, 2011, TOXICOL SCI, V119, P218, DOI 10.1093/toxsci/kfq325; Verhofstad N, 2010, ENVIRON MOL MUTAGEN, V51, P123, DOI 10.1002/em.20516; Waters DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1906, DOI 10.1158/1055-9965.EPI-07-0034; Wild CP, 2003, CANCER EPIDEM BIOMAR, V12, P1389; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th; Wyatt NP, 2007, MUTAGENESIS, V22, P123, DOI 10.1093/mutage/gel062; Yauk C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/pnas.0705896105; Yauk CL, 2007, CANCER RES, V67, P5103, DOI 10.1158/0008-5472.CAN-07-0279; Youngson NA, 2008, ANNU REV GENOM HUM G, V9, P233, DOI 10.1146/annurev.genom.9.081307.164445; Zenzes MT, 1999, MOL HUM REPROD, V5, P125, DOI 10.1093/molehr/5.2.125; Zlobinskaya O, 2012, RADIAT ENVIRON BIOPH, V51, P23, DOI 10.1007/s00411-011-0398-1	59	54	55	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					3946	3956		10.1096/fj.11-201194	http://dx.doi.org/10.1096/fj.11-201194			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22730438				2022-12-28	WOS:000309704000003
J	Holt, LJ; Turner, N; Mokbel, N; Trefely, S; Kanzleiter, T; Kaplan, W; Ormandy, CJ; Daly, RJ; Cooney, GJ				Holt, Lowenna J.; Turner, Nigel; Mokbel, Nancy; Trefely, Sophie; Kanzleiter, Timo; Kaplan, Warren; Ormandy, Christopher J.; Daly, Roger J.; Cooney, Gregory J.			Grb10 regulates the development of fiber number in skeletal muscle	FASEB JOURNAL			English	Article						metabolism; signal transduction; growth factors; proliferation; aging	GROWTH-FACTOR-I; INSULIN-RECEPTOR; TRANSGENIC MICE; SH2 DOMAIN; MOUSE; EXPRESSION; GENE; HYPERTROPHY; DYSFUNCTION; DISRUPTION	Grb10 is an intracellular adaptor protein that acts as a negative regulator of insulin and insulin-like growth factor 1 (IGF1) receptors. Since global deletion of Grb10 in mice causes hypermuscularity, we have characterized the skeletal muscle physiology underlying this phenotype. Compared to wild-type (WT) controls, adult mice deficient in Grb10 have elevated body mass and muscle mass throughout adulthood, up to 12 mo of age. The muscle enlargement is not due to increased myofiber size, but rather an increase in myofiber number (142% of WT, P<0.01). There is no change in myofiber type proportions between WT and Grb 10-deficient muscles, nor are the metabolic properties of the muscles altered on Grb10 deletion. Notably, the weight and cross-sectional area of hindlimbs from neonatal mice are increased in Grb10-deficient animals (198 and 137% of WT, respectively, both P<0.001). Functional gene signatures for myogenic signaling and proliferation are up-regulated in Grb10-deficient neonatal muscle. Our findings indicate that Grb10 plays a previously unrecognized role in regulating the development of fiber number during murine embryonic growth. In addition, Grb10-ablated muscle from adult mice shows coordinate gene changes that oppose those of muscle wasting pathologies, highlighting Grb10 as a potential therapeutic target for these conditions.-Holt, L. J., Turner, N., Mokbel, N., Trefely, S., Kanzleiter, T., Kaplan, W., Ormandy, C. J., Daly, R. J., Cooney, G. J. Grb10 regulates the development of fiber number in skeletal muscle. FASEB J. 26, 3658-3669 (2012). www.fasebj.org	[Holt, Lowenna J.; Turner, Nigel; Mokbel, Nancy; Trefely, Sophie; Kanzleiter, Timo; Cooney, Gregory J.] Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW 2010, Australia; [Kaplan, Warren] Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Sydney, NSW 2010, Australia; [Ormandy, Christopher J.; Daly, Roger J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Turner, Nigel; Ormandy, Christopher J.; Daly, Roger J.; Cooney, Gregory J.] Univ New S Wales, St Vincents Hosp Clin Sch, Sydney, NSW, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; Garvan Institute of Medical Research; University of New South Wales Sydney	Holt, LJ (corresponding author), Garvan Inst Med Res, Diabet & Obes Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	l.holt@garvan.org.au	Trefely, Sophie/AAL-9434-2020; Turner, Nigel/H-7176-2013; Ormandy, Chris/G-4165-2014	Turner, Nigel/0000-0002-0119-9328; Daly, Roger/0000-0002-5739-8027; Trefely, Sophie/0000-0003-3816-6869; Ormandy, Christopher/0000-0002-2504-7919; Holt, Lowenna/0000-0002-4703-9696	U.S. National Institute for Child Health and Human Development; National Health and Medical Research Council (NHMRC) of Australia [481335]	U.S. National Institute for Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The authors are grateful to William E. Hughes, Katarina Mele, and James G. Burchfield at the Garvan Institute of Medical Research for helpful discussions regarding the analysis of myofiber morphometry, and Alice Boulghourjian for assistance with H&E stains for histology. The monoclonal antibodies to MyHC-2A (SC-71) and MyHC-2B (BF-F3), developed by S. Schiaffino, were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the U.S. National Institute for Child Health and Human Development and maintained by The University of Iowa, Department of Biology (Iowa City, IA, USA). The authors thank Kim Moran-Jones and Tristan J. Iseli at the Garvan Institute for critical reading of the manuscript. The authors also thank the Biological Testing Facility at the Garvan Institute for assistance with animal care. This work was supported by funding from the National Health and Medical Research Council (NHMRC) of Australia (481335). N.T. is supported by a career development award, and C.J.O., G. J. C., and R. J. D. are supported by research fellowships, from the NHMRC of Australia. The authors declare no conflicts of interest.	Amthor H, 2007, P NATL ACAD SCI USA, V104, P1835, DOI 10.1073/pnas.0604893104; Callahan Leigh Ann, 2009, Crit Care Med, V37, pS354, DOI 10.1097/CCM.0b013e3181b6e439; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Depetris RS, 2005, MOL CELL, V20, P325, DOI 10.1016/j.molcel.2005.09.001; Dougnac A, 2001, REV MED CHILE, V129, P347; Elashry MI, 2009, REJUV RES, V12, P269, DOI 10.1089/rej.2009.0870; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Evans W, 1997, J NUTR, V127, pS998; Gnocchi VF, 2008, BIOCHEM SOC T, V36, P1344, DOI 10.1042/BST0361344; GOLLNICK PD, 1972, J APPL PHYSIOL, V33, P312, DOI 10.1152/jappl.1972.33.3.312; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Holt LJ, 2005, BIOCHEM J, V388, P393, DOI 10.1042/BJ20050216; Holt LJ, 2009, MOL ENDOCRINOL, V23, P1406, DOI 10.1210/me.2008-0386; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; Janssen I, 2000, J APPL PHYSIOL, V89, P81; Kusminski CM, 2009, APOPTOSIS, V14, P1484, DOI 10.1007/s10495-009-0352-8; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lindstedt SL, 2001, J EXP BIOL, V204, P3195; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Liu Qi, 2009, Yichuan, V31, P732, DOI 10.3724/SP.J.1005.2009.00732; Liu X, 2003, DOMEST ANIM ENDOCRIN, V25, P215, DOI 10.1016/S0739-7240(03)00061-4; MacArthur DG, 2008, HUM MOL GENET, V17, P1076, DOI 10.1093/hmg/ddm380; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONTELL M, 1984, AM J ANAT, V171, P149, DOI 10.1002/aja.1001710203; Ruegg MA, 2011, ANNU REV PHARMACOL, V51, P373, DOI 10.1146/annurev-pharmtox-010510-100537; Schiaffino S, 2010, ACTA PHYSIOL, V199, P451, DOI 10.1111/j.1748-1716.2010.02130.x; Shaw CS, 2010, ANNU REV NUTR, V30, P13, DOI 10.1146/annurev.nutr.012809.104817; Smith FM, 2007, MOL CELL BIOL, V27, P5871, DOI 10.1128/MCB.02087-06; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Velleman SG, 2007, POULTRY SCI, V86, P1050, DOI 10.1093/ps/86.5.1050; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang L, 2007, MOL CELL BIOL, V27, P6497, DOI 10.1128/MCB.00679-07; Wells GD, 2008, CAN J NEUROL SCI, V35, P31, DOI 10.1017/S0317167100007538	46	27	27	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3658	3669		10.1096/fj.11-199349	http://dx.doi.org/10.1096/fj.11-199349			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22623587				2022-12-28	WOS:000308391600008
J	Roy, S; Short, MK; Stanley, ER; Jubinsky, PT				Roy, Soumit; Short, Mary K.; Stanley, E. Richard; Jubinsky, Paul T.			Essential role of Drosophila black-pearl is mediated by its effects on mitochondrial respiration	FASEB JOURNAL			English	Article						reactive oxygen species; electron transport chain; melanotic inclusions; Magmas; Pam 16	PROTEIN IMPORT MOTOR; CELL-CYCLE PROGRESSION; PRESEQUENCE TRANSLOCASE; INNER MEMBRANE; OXIDATIVE STRESS; HOST-DEFENSE; MAGMAS; MELANOGASTER; AUTOPHAGY; GENE	Black-pearl (Blp) is a highly conserved, essential inner-mitochondrial membrane protein. The yeast Blp homologue, Magmas/Pam16, is required for mitochondrial protein transport, growth, and survival. Our purpose was to determine the role of Drosophila Blp in mitochondrial function, cell survival, and proliferation. To this end, we performed mitotic recombination in Drosophila melanogaster, RNAi-mediated knockdown, MitoTracker staining, measurement of reactive oxygen species (ROS), flow cytometry, electron transport chain complex assays, and hemocyte isolation from Drosophila larvae. Proliferation-defective, Blp-deficient Drosophila Schneider cells exhibited mitochondrial membrane depolarization, a 60% decrease in ATP levels, increased amounts of ROS (3.5-fold), cell cycle arrest, and activation of autophagy that were associated with a selective 65% reduction of cytochrome c oxidase activity. N-acetyl cysteine (NAC) rescued Blp-RNAi-treated cells from cell cycle arrest, indicating that increased production of ROS is the primary cause of the proliferation and survival defects in Blp-depleted cells. blp hypomorph larvae had a 35% decreased number of plasmatocytes with a 45% reduced active mitochondrial staining and their viability was increased 2-fold by administration of NAC, which blocked melanotic lesions. Loss of Blp decreases cytochrome c oxidase activity and uncouples oxidative phosphorylation, causing ROS production, which selectively affects mitochondria-rich plasmatocyte survival and function, leading to melanotic lesions in Blp-deficient flies.-Roy, S., Short, M. K., Stanley, E. R., Jubinsky, P. T. Essential role of Drosophila black-pearl is mediated by its effects on mitochondrial respiration. FASEB J. 26, 3822-3833 (2012). www.fasebj.org	[Roy, Soumit; Short, Mary K.; Stanley, E. Richard; Jubinsky, Paul T.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; [Jubinsky, Paul T.] Yale Univ, Sch Med, Sect Pediat Hematol Oncol, New Haven, CT USA	Yeshiva University; Albert Einstein College of Medicine; Yale University	Stanley, ER (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.	richard.stanley@einstein.yu.edu	Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	U.S. National Institutes of Health [CA26504]; Albert Einstein College of Medicine Cancer Center [5P30-CA13330]; James B. Ax Family Foundation; SAS Foundation for Cancer Research; Magmas Research Fund; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA026504, R37CA026504] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Albert Einstein College of Medicine Cancer Center; James B. Ax Family Foundation; SAS Foundation for Cancer Research; Magmas Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Nicholas Baker (Albert Einstein College of Medicine) for reagents and advice with the mosaic analysis and hemocyte isolation, Dr. Erich Buchner (Biozentrum der Universitat Wurzburg, Am Hubland, Wurzburg, Germany) for the Drosophila blp lines, the Einstein Analytical Imaging and Flow Cytometry Core Facilities, and Donna Alex, Pete Walker, and Mary and Robert Cancilla for their support. This work was supported by U.S. National Institutes of Health grant CA26504 (E. R. S.), the Albert Einstein College of Medicine Cancer Center grant 5P30-CA13330, the James B. Ax Family Foundation, The SAS Foundation for Cancer Research, and the Magmas Research Fund (P.T.J.).	Becker S, 2001, GENE, V262, P15, DOI 10.1016/S0378-1119(00)00548-5; Bjorklund M, 2006, NATURE, V439, P1009, DOI 10.1038/nature04469; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; D'Silva P, 2004, NAT STRUCT MOL BIOL, V11, P1084, DOI 10.1038/nsmb846; D'Silva PR, 2008, MOL BIOL CELL, V19, P424, DOI 10.1091/mbc.E07-08-0748; D'Silva PR, 2005, P NATL ACAD SCI USA, V102, P12419, DOI 10.1073/pnas.0505969102; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Jubinsky PT, 2011, BIOORG MED CHEM LETT, V21, P3479, DOI 10.1016/j.bmcl.2011.03.050; Jubinsky PT, 2005, J MOL HISTOL, V36, P69, DOI 10.1007/s10735-004-3840-8; Jubinsky PT, 2001, EXP HEMATOL, V29, P1392, DOI 10.1016/S0301-472X(01)00749-4; Ladha JS, 2005, CELL DEATH DIFFER, V12, P1417, DOI 10.1038/sj.cdd.4401668; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; Liang HL, 2010, FREE RADICAL BIO MED, V49, P1550, DOI 10.1016/j.freeradbiomed.2010.08.018; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Meister M, 2004, CURR OPIN IMMUNOL, V16, P10, DOI 10.1016/j.coi.2003.11.002; Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Pais JE, 2011, MOL BIOL CELL, V22, P4740, DOI 10.1091/mbc.E11-08-0715; Perrimon N, 1996, GENETICS, V144, P1681; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Schwarze SR, 1998, FREE RADICAL BIO MED, V25, P740, DOI 10.1016/S0891-5849(98)00153-1; Sinha D, 2010, HUM MOL GENET, V19, P1248, DOI 10.1093/hmg/ddq002; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Sriram V, 2003, J CELL BIOL, V161, P593, DOI 10.1083/jcb.200210166; Tagliati F, 2010, ENDOCRINOLOGY, V151, P4635, DOI 10.1210/en.2010-0441; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020; van der Laan M, 2010, BBA-MOL CELL RES, V1803, P732, DOI 10.1016/j.bbamcr.2010.01.013; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wang YC, 2011, J BIOL CHEM, V286, P21742, DOI 10.1074/jbc.M110.160697; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; WATSON KL, 1991, DEV GENET, V12, P173, DOI 10.1002/dvg.1020120302; Wiedemann N, 2007, J CELL BIOL, V179, P1115, DOI 10.1083/jcb.200709087; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; XU T, 1993, DEVELOPMENT, V117, P1223; Yu WF, 2008, J LEUKOCYTE BIOL, V84, P852, DOI 10.1189/jlb.0308171	50	10	10	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2012	26	9					3822	3833		10.1096/fj.11-193540	http://dx.doi.org/10.1096/fj.11-193540			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22700875	Green Published			2022-12-28	WOS:000308391600022
J	Boutin, A; Allen, MD; Neumann, S; Gershengorn, MC				Boutin, Alisa; Allen, Michael D.; Neumann, Susanne; Gershengorn, Marvin C.			Persistent signaling by thyrotropin-releasing hormone receptors correlates with G-protein and receptor levels	FASEB JOURNAL			English	Article						TRH receptor; inositolmonophosphate	COUPLED RECEPTORS; TRH RECEPTOR; FLUORESCENT PROTEIN; INVERSE AGONISTS; ACTIVATION; SUBTYPES; CELLS; INTERNALIZATION; CONFORMATIONS; EXPRESSION	G-protein-coupled receptors with dissociable agonists for thyrotropin, parathyroid hormone, and sphingosine-1-phosphate were found to signal persistently hours after agonist withdrawal. Here we show that mouse thyrotropin-releasing hormone (TRH) receptors, subtypes 2 and 1(TRH-R2 and TRH-R1), can signal persistently in HEK-EM293 cells under appropriate conditions, but TRH-R2 exhibits higher persistent signaling activity. Both receptors couple primarily to G alpha(q/11). To gain insight into the mechanism of persistent signaling, we compared proximal steps of inositolmonophosphate (IP1) signaling by TRH-Rs. Persistent signaling was not caused by slower dissociation of TRH from TRH-R2 (t(1/2) = 77 +/- 8.1 min) compared with TRH-R1 (t(1/2) = 82 +/- 12 min) and was independent of internalization, as inhibition of internalization did not affect persistent signaling (115% of control), but required continuously activated receptors, as an inverse agonist decreased persistent signaling by 60%. G alpha(q/11) knockdown decreased persistent signaling by TRH-R2 by 82%, and overexpression of G alpha(q/11) induced persistent signaling in cells expressing TRH-R1. Lastly, persistent signaling was induced in cells expressing high levels of TRH-R1. We suggest that persistent signaling by TRHRs is exhibited when sufficient levels of agonist/receptor/G-protein complexes are established and maintained and that TRH-R2 forms and maintains these complexes more efficiently than TRH-R1.-Boutin, A., Allen, M. D., Neumann, S., Gershengorn, M. C. Persistent signaling by thyrotropin-releasing hormone receptors correlates with G-protein and receptor levels. FASEB J. 26, 3473-3482 (2012). www.fasebj.org	[Boutin, Alisa; Allen, Michael D.; Neumann, Susanne; Gershengorn, Marvin C.] NIDDK, LERB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), NIDDK, LERB, NIH, 50 South Dr, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boutin A, 2011, MOL PHARMACOL, V80, P240, DOI 10.1124/mol.111.072157; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; Calebiro D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000172; Carter PH, 2001, ENDOCRINOLOGY, V142, P1534, DOI 10.1210/en.142.4.1534; Engel S, 2008, J AM CHEM SOC, V130, P5115, DOI 10.1021/ja077620l; Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545; Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206; GERSHENGORN MC, 1994, J BIOL CHEM, V269, P6779; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; Gloriam DE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-338; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jones BW, 2008, MOL PHARMACOL, V74, P195, DOI 10.1124/mol.108.045948; Kleinau G, 2010, FASEB J, V24, P2347, DOI 10.1096/fj.09-149146; Lu XP, 2003, ENDOCRINOLOGY, V144, P1842, DOI 10.1210/en.2002-221074; Mekuchi M, 2011, GEN COMP ENDOCR, V170, P374, DOI 10.1016/j.ygcen.2010.10.013; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; Neumann S, 2010, METHOD ENZYMOL, V485, P147, DOI [10.1016/S0076-6879(10)85009-8, 10.1016/B978-0-12-381296-4.00009-9]; Robbins AK, 1998, BIOTECHNIQUES, V25, P240, DOI 10.2144/98252st04; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sun Y, 2003, J MOL ENDOCRINOL, V30, P87, DOI 10.1677/jme.0.0300087; Sun YH, 2002, ENDOCRINOLOGY, V143, P2886, DOI 10.1210/en.143.8.2886; Tao YX, 2008, PHARMACOL THERAPEUT, V120, P129, DOI 10.1016/j.pharmthera.2008.07.005; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; Waters D, 2006, FASEB J, V20, pA1058; Werthmann RC, 2012, FASEB J, V26, P2043, DOI 10.1096/fj.11-195248; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004	34	8	8	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3473	3482		10.1096/fj.12-207860	http://dx.doi.org/10.1096/fj.12-207860			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593547	Green Published			2022-12-28	WOS:000307162800034
J	Kapusta, DR; Pascale, CL; Wainford, RD				Kapusta, Daniel R.; Pascale, Crissey L.; Wainford, Richard D.			Brain heterotrimeric G alpha i(2)-subunit protein-gated pathways mediate central sympathoinhibition to maintain fluid and electrolyte homeostasis during stress	FASEB JOURNAL			English	Article						renal sympathetic nerve activity; RSNA; natriuresis; sodium homeostasis; blood pressure regulation; G-protein-coupled receptors	SYMPATHETIC-NERVOUS-SYSTEM; PARAVENTRICULAR NUCLEUS; PRESSURE REGULATION; PLASMA SODIUM; RENAL NERVES; SALT; VOLUME; HYPERTENSION; KIDNEYS; BODY	Fluid and electrolyte homeostasis is integral to blood pressure regulation. However, the central molecular mechanisms regulating the neural control of sodium excretion remain unclear. We have demonstrated that brain G alpha i(2)-subunit protein pathways mediate the natriuretic response to alpha(2)-adrenoreceptor activation in vivo. Consequently, we examined the role of brain G alpha i(2) proteins in the neural mechanisms facilitating fluid and electrolyte homeostasis in response to acute [i.v. volume expansion (VE)] or chronic stressful stimuli (dietary sodium restriction vs. supplementation) in conscious Sprague-Dawley rats. Selective oligodeoxy-nucleotide (ODN)-mediated down-regulation of brain G alpha i(2) proteins, but not a scrambled ODN, abolished the renal sympathoinhibitory response and attenuated the natriuresis to VE. In scrambled ODN-treated rats, chronic changes in dietary sodium intake evoked an endogenous, hypothalamic paraventricular nucleus (PVN)-specific, decrease (sodium deficiency) or increase (sodium excess) in PVN G alpha i(2) proteins; plasma norepinephrine levels were inversely related to dietary sodium content. Finally, in rats treated with an ODN to prevent high salt-induced up-regulation of brain G alpha i(2) proteins, animals exhibited sodium retention, global sympathoexcitation, and elevated blood pressure. Collectively, these data demonstrate that PVN G alpha i(2) protein pathways play an endogenous role in maintaining fluid and electrolyte balance by controlling the influence the sympathetic nervous system has on the renal handling of sodium.-Kapusta, D. R., Pascale, C. L., Wainford, R. D. Brain heterotrimeric G alpha i(2)-subunit protein-gated pathways mediate central sympathoinhibition to maintain fluid and electrolyte homeostasis during stress. FASEB J. 26, 2776-2787 (2012). www.fasebj.org	[Kapusta, Daniel R.; Pascale, Crissey L.; Wainford, Richard D.] Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA USA; [Kapusta, Daniel R.; Pascale, Crissey L.; Wainford, Richard D.] Louisiana State Univ, Hlth Sci Ctr, Cardiovasc Ctr Excellence, New Orleans, LA USA; [Kapusta, Daniel R.] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, New Orleans, LA USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wainford, RD (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Whitaker Cardiovasc Inst, 72 E Concord St, Boston, MA 02118 USA.	rwainf@bu.edu	Wainford, Richard/ABC-1735-2020	Wainford, Richard/0000-0003-2830-5618	American Heart Association (AHA) [0855293E, 2250585]; U.S. National Institutes of Health (NIH) National Center for Research Resources (NCRR) [P20RR018766]; NIH [R01HL107330]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107330] Funding Source: NIH RePORTER	American Heart Association (AHA)(American Heart Association); U.S. National Institutes of Health (NIH) National Center for Research Resources (NCRR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by American Heart Association (AHA) Beginning-Grant-in-Aid 0855293E (R. D. W.), AHA Grant-in-Aid 2250585 (D. R. K.), U.S. National Institutes of Health (NIH) National Center for Research Resources (NCRR) grant P20RR018766 (R. D. W. and D. R. K.), and NIH grant R01HL107330 (R.D.W.).	Akine A, 2003, AUTON NEUROSCI-BASIC, V108, P17, DOI 10.1016/j.autneu.2003.08.009; Bayorh MA, 1998, PHYSIOL BEHAV, V65, P563, DOI 10.1016/S0031-9384(98)00194-2; Brooks VL, 2005, CLIN EXP PHARMACOL P, V32, P426, DOI 10.1111/j.1440-1681.2005.04206.x; Coote JH, 1995, BIOL SIGNAL, V4, P142; de Wardener HE, 2004, KIDNEY INT, V66, P2454, DOI 10.1111/j.1523-1755.2004.66018.x; DiBona GF, 2005, AM J PHYSIOL-REG I, V289, pR633, DOI 10.1152/ajpregu.00258.2005; DiBona GF, 2004, HYPERTENSION, V43, P147, DOI 10.1161/01.HYP.0000113047.47711.fa; Frithiof R, 2009, AM J PHYSIOL-REG I, V297, pR185, DOI 10.1152/ajpregu.00058.2008; Gottlieb HB, 2005, AM J PHYSIOL-REG I, V289, pR1289, DOI 10.1152/ajpregu.00302.2005; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; GUYTON AC, 1992, HYPERTENSION, V19, pI2, DOI 10.1161/01.HYP.19.1_Suppl.I2; HASELTON JR, 1994, J AUTONOM NERV SYST, V50, P1, DOI 10.1016/0165-1838(94)90117-1; He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2; KAPUSTA DR, 1995, J PHARMACOL EXP THER, V273, P199; Kompanowska-Jezierska E, 2008, AM J PHYSIOL-REG I, V294, pR1130, DOI 10.1152/ajpregu.00908.2007; Lastra G, 2010, NAT REV CARDIOL, V7, P577, DOI 10.1038/nrcardio.2010.123; Leenen FHH, 2002, CURR HYPERTENS REP, V4, P129, DOI 10.1007/s11906-002-0037-y; Lohmeier TE, 1999, HYPERTENSION, V33, P487, DOI 10.1161/01.HYP.33.1.487; May CN, 2010, EXP PHYSIOL, V95, P34, DOI 10.1113/expphysiol.2008.046342; Nasman J, 2001, BIOCHEM PHARMACOL, V62, P913, DOI 10.1016/S0006-2952(01)00730-4; Odagaki Y, 2001, NEUROSCI LETT, V297, P137, DOI 10.1016/S0304-3940(00)01692-X; PATEL KP, 1991, J AUTONOM NERV SYST, V36, P47, DOI 10.1016/0165-1838(91)90129-Q; Rodriguez-Iturbe B, 2007, NEPHROL DIAL TRANSPL, V22, P992, DOI 10.1093/ndt/gfl757; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; Sly DJ, 2001, AM J PHYSIOL-REG I, V281, pR1637, DOI 10.1152/ajpregu.2001.281.5.R1637; Toney GM, 2003, ACTA PHYSIOL SCAND, V177, P43, DOI 10.1046/j.1365-201X.2003.01046.x; Wainford RD, 2012, BRIT J PHARMACOL, V166, P210, DOI 10.1111/j.1476-5381.2011.01662.x; Wainford RD, 2010, ENDOCRINOLOGY, V151, P5403, DOI 10.1210/en.2010-0345; Wainford RD, 2009, AM J PHYSIOL-REG I, V296, pR280, DOI 10.1152/ajpregu.00096.2008; WEISS ML, 1990, BRAIN RES BULL, V24, P231, DOI 10.1016/0361-9230(90)90210-Q	31	21	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2776	2787		10.1096/fj.11-196550	http://dx.doi.org/10.1096/fj.11-196550			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459149	Green Published			2022-12-28	WOS:000305912500007
J	Perry, NA; Shriver, M; Mameza, MG; Grabias, B; Balzer, E; Kontrogianni-Konstantopoulos, A				Perry, Nicole A.; Shriver, Marey; Mameza, Marie G.; Grabias, Bryan; Balzer, Eric; Kontrogianni-Konstantopoulos, Aikaterini			Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance	FASEB JOURNAL			English	Article						OBSCN gene; TP53 gene; MCF10; MCF7; MDA-MB-231	EXCHANGE FACTOR DOMAIN; M-BAND; CANCER; GENE; EXPRESSION; LOCALIZATION; ISOFORM; MUSCLE; TITIN; ORGANIZATION	Obscurins (similar to 70-870 kDa), encoded by the single OBSCN gene, are cytoskeletal proteins originally identified in striated muscles with structural and regulatory roles. Recently, analysis of 13,023 genes in breast and colorectal cancers identified OBSCN as one of the most frequently mutated genes, implicating it in cancer formation. Herein we studied the expression profile of obscurins in breast, colon, and skin cancer cell lines and their involvement in cell survival. Immunoblot analysis demonstrated significant reduction of obscurins in cancer cells, resulting from decreased mRNA levels and/or the presence of mutant transcripts. In normal epithelium, obscurins localize in cytoplasmic puncta, the cell membrane, and the nucleus. Accordingly, subcellular fractionation demonstrated the presence of 2 novel nuclear isoforms of similar to 110 and similar to 120 kDa. Nontumorigenic MCF10A breast epithelial cells stably transduced with shRNAs targeting giant obscurins exhibited increased viability (similar to 30%) and reduced apoptosis (similar to 20%) following exposure to the DNA-damaging agent etoposide. Quantitative RTPCR further indicated that the antiapoptotic genes BAG4 and HAX1 were up-regulated (1.5- and 1.4-fold, respectively), whereas initiator caspase-9 and death caspase-3 transcripts were down-regulated (0.8- and 0.6-fold, respectively). Our findings are the first to pinpoint critical roles for obscurins in cancer development by contributing to the regulation of cell survival.-Perry, N. A., Shriver, M., Mameza, M. G., Grabias, B., Balzer, E., Kontrogianni-Konstantopoulos, A. Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance. FASEB J. 26, 2764-2775 (2012). www.fasebj.org	[Kontrogianni-Konstantopoulos, Aikaterini] Univ Maryland, Sch Med, BRF, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Grabias, Bryan; Balzer, Eric] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland, Sch Med, BRF, Dept Biochem & Mol Biol, 108 N Greene St,215A, Baltimore, MD 21201 USA.	akons001@umaryland.edu		Lieberman, Nicole/0000-0001-9334-8150; Shriver, Marey/0000-0002-1644-6408	Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for Nanobiotechnology [U54CA143868]; NATIONAL CANCER INSTITUTE [U54CA143868] Funding Source: NIH RePORTER	Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for Nanobiotechnology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Konstantinos Konstantopoulos (Department of Chemical and Biomolecular Engineering, Johns Hopkins University) and Drs. Michele I. Vitolo and Stuart S. Martin (Department of Physiology, University of Maryland) for helpful discussions and detailed protocols, Drs. Gautam Adhikary and Richard L. Eckert (Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine) for providing primary cultures of keratinocytes, and Ms. Li-Yen Hu for contributing to the analysis of the mutation data. Flow cytometry analyses were performed at the Greenebaum Cancer Center Shared Flow Cytometry Facility (University of Maryland). This work was supported by a pilot grant from the Johns Hopkins Physical Sciences-Oncology Center, the Johns Hopkins Institute for Nanobiotechnology (U54CA143868), to A.K.-K.	Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; Ackermann MA, 2009, MOL BIOL CELL, V20, P2963, DOI 10.1091/mbc.E08-12-1251; Arimura T, 2007, BIOCHEM BIOPH RES CO, V362, P281, DOI 10.1016/j.bbrc.2007.07.183; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Borisov A, 2003, CIRCULATION, V108, P243; Borisov AB, 2004, J HISTOCHEM CYTOCHEM, V52, P1117, DOI 10.1369/jhc.3A6183.2004; Borisov AB, 2008, J CELL BIOCHEM, V103, P1621, DOI 10.1002/jcb.21551; Bowman AL, 2008, MOL BIOL CELL, V19, P3782, DOI 10.1091/mbc.E08-03-0237; Bowman AL, 2007, FEBS LETT, V581, P1549, DOI 10.1016/j.febslet.2007.03.011; Coisy-Quivy M, 2009, J CELL SCI, V122, P947, DOI 10.1242/jcs.040121; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Fadeel B, 2009, BBA-GEN SUBJECTS, V1790, P1139, DOI 10.1016/j.bbagen.2009.06.004; FAN SJ, 1994, CANCER RES, V54, P5824; Ford-Speelman DL, 2009, MOL BIOL CELL, V20, P3905, DOI 10.1091/mbc.E08-10-1029; Fukuzawa A, 2008, J CELL SCI, V121, P1841, DOI 10.1242/jcs.028019; Fukuzawa A, 2005, J MUSCLE RES CELL M, V26, P427, DOI 10.1007/s10974-005-9025-6; Futreal PA, 2001, NATURE, V409, P850, DOI 10.1038/35057046; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Healy ZR, 2005, P NATL ACAD SCI USA, V102, P14010, DOI 10.1073/pnas.0506620102; Hu L.-Y. R., 2010, MOL BIOL CELL S, V21; Kontrogianni-Konstantopoulos A, 2004, AM J PHYSIOL-CELL PH, V287, pC209, DOI 10.1152/ajpcell.00497.2003; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kontrogianni-Konstantopoulos A, 2005, J MUSCLE RES CELL M, V26, P419, DOI 10.1007/s10974-005-9024-7; Kontrogianni-Konstantopoulos A, 2006, FASEB J, V20, P2102, DOI 10.1096/fj.06-5761com; Kontrogianni-Konstantopoulos A, 2009, PHYSIOL REV, V89, P1217, DOI 10.1152/physrev.00017.2009; Lange S, 2009, J CELL SCI, V122, P2640, DOI 10.1242/jcs.046193; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Ozawa F., 2000, BIOCHEM BIOPH RES CO, V271; Price ND, 2007, P NATL ACAD SCI USA, V104, P3414, DOI 10.1073/pnas.0611373104; Qadota H, 2008, MOL BIOL CELL, V19, P2424, DOI 10.1091/mbc.E08-01-0053; Raeker MO, 2006, DEV DYNAM, V235, P2018, DOI 10.1002/dvdy.20812; Raeker MO, 2010, DEV BIOL, V337, P432, DOI 10.1016/j.ydbio.2009.11.018; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sherry ST, 1999, GENOME RES, V9, P677; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Trebinska A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-76; VINEY JL, 1995, CANCER METAST REV, V14, P77, DOI 10.1007/BF00665792; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yap SV, 2011, J CELL PHYSIOL, V226, P2752, DOI 10.1002/jcp.22638; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Zhu F, 2010, CELL DEATH DIFFER, V17, P1325, DOI 10.1038/cdd.2010.13	54	25	27	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2764	2775		10.1096/fj.12-205419	http://dx.doi.org/10.1096/fj.12-205419			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22441987	Green Published			2022-12-28	WOS:000305912500006
J	Voigt, T; Sebald, HJ; Schoenauer, R; Levano, S; Girard, T; Hoppeler, HH; Babiychuk, EB; Draeger, A				Voigt, Tilman; Sebald, Hans-Joerg; Schoenauer, Roman; Levano, Soledad; Girard, Thierry; Hoppeler, Hans H.; Babiychuk, Eduard B.; Draeger, Annette			Annexin A1 is a biomarker of T-tubular repair in skeletal muscle of nonmyopathic patients undergoing statin therapy	FASEB JOURNAL			English	Article						plasma membrane repair; Ca2+-dependent translocation; dysferlin	MEMBRANE REPAIR; MUSCULAR-DYSTROPHY; TRANSVERSE TUBULES; DYSFERLIN; SYSTEM; DIFFERENTIATION; VACUOLATION; MECHANISMS; CAVEOLIN-3; EXPRESSION	Skeletal muscle complaints are a common consequence of cholesterol-lowering therapy. Transverse tubular (T-tubular) vacuolations occur in patients having statin-associated myopathy and, to a lesser extent, in statin-treated patients without myopathy. We have investigated quantitative changes in T-tubular morphology and looked for early indicators of T-tubular membrane repair in skeletal muscle biopsy samples from patients receiving cholesterol-lowering therapy who do not have myopathic side effects. Gene expression and protein levels of incipient membrane repair proteins were monitored in patients who tolerated statin treatment without myopathy and in statinnaive subjects. In addition, morphometry of the T-tubular system was performed. Only the gene expression for annexin A1 was up-regulated, whereas the expression of other repair genes remained unchanged. However, annexin A1 and dysferlin protein levels were significantly increased. In statin-treated patients, the volume fraction of the T-tubular system was significantly increased, but the volume fraction of the sarcoplasmic reticulum remained unchanged. A complex surface structure in combination with high mechanical loads makes skeletal muscle plasma membranes susceptible to injury. Ca2+-dependent membrane repair proteins such as dysferlin and annexin A1 are deployed at T-tubular sites. The up-regulation of annexin A1 gene expression and protein points to this protein as a biomarker for T-tubular repair.	[Voigt, Tilman; Schoenauer, Roman; Hoppeler, Hans H.; Babiychuk, Eduard B.; Draeger, Annette] Univ Bern, Inst Anat, CH-3012 Bern, Switzerland; [Sebald, Hans-Joerg] Univ Bern, Dept Orthoped Surg, Inselspital, CH-3012 Bern, Switzerland; [Levano, Soledad; Girard, Thierry] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Levano, Soledad; Girard, Thierry] Univ Basel Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland	University of Bern; University of Bern; University of Basel; University of Basel	Draeger, A (corresponding author), Univ Bern, Inst Anat, Baltzerstr 2, CH-3012 Bern, Switzerland.	draeger@ana.unibe.ch	Babiychuk, Eduard/AAV-7223-2021	Babiychuk, Eduard/0000-0003-1786-0085; Levano, Soledad/0000-0002-0963-7951	Swiss National Science Foundation [320030_ 128064/1, 3100A0-121980/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The authors acknowledge the excellent technical assistance of Andrea Hostettler and Catherine Allemann. The study was supported by grants from the Swiss National Science Foundation (320030_ 128064/1 to A.D. and 3100A0-121980/1 to E.B.). T.V., R.S., S.L., and T.G. performed experiments; H.-J.S. provided medical expertise and the biopsy samples; A.D., E.B., and H.H.H. designed the study; and A.D. wrote the manuscript. The authors declare no conflicts of interest.	Abd TT, 2011, EXPERT OPIN DRUG SAF, V10, P373, DOI 10.1517/14740338.2011.540568; Al-Qusairi L, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-26; Arcuri C, 2002, NEUROSCIENCE, V109, P371, DOI 10.1016/S0306-4522(01)00330-X; Babiychuk EB, 2011, CELL DEATH DIFFER, V18, P80, DOI 10.1038/cdd.2010.81; Babiychuk EB, 2009, CELL DEATH DIFFER, V16, P1126, DOI 10.1038/cdd.2009.30; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barrientos G, 2002, J MEMBRANE BIOL, V188, P163, DOI 10.1007/s00232-001-0179-x; Bizzarro V, 2012, J CELL PHYSIOL, V227, P3007, DOI 10.1002/jcp.24032; Bouter A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1270; Cai CX, 2009, J BIOL CHEM, V284, P15894, DOI 10.1074/jbc.M109.009589; Cai CX, 2009, NAT CELL BIOL, V11, P56, DOI 10.1038/ncb1812; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Draeger A, 2003, DEV BIOL, V262, P324, DOI 10.1016/S0012-1606(03)00398-1; Draeger A, 2006, J PATHOL, V210, P94, DOI 10.1002/path.2018; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Draeger A, 2010, AM J PATHOL, V177, P291, DOI 10.2353/ajpath.2010.091140; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Egan A, 2011, NEW ENGL J MED, V365, P285, DOI 10.1056/NEJMp1106689; EISENBERG BR, 1974, J CELL BIOL, V60, P732, DOI 10.1083/jcb.60.3.732; Engel A.G., 2004, MYOLOGY; Evesson FJ, 2010, J BIOL CHEM, V285, P28529, DOI 10.1074/jbc.M110.111120; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; FRANZINIARMSTRONG C, 1991, DEV BIOL, V146, P353, DOI 10.1016/0012-1606(91)90237-W; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Han R, 2007, CURR OPIN CELL BIOL, V19, P409, DOI 10.1016/j.ceb.2007.07.001; Han R, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-35; Han RZ, 2011, SKELET MUSCLE, V1, DOI [10.1186/2044-5040-1-10, 10.1186/2044-5040-1-35]; HOPPELER H, 1986, INT J SPORTS MED, V7, P187, DOI 10.1055/s-2008-1025758; Klinge L, 2010, MUSCLE NERVE, V41, P166, DOI 10.1002/mus.21166; KROLENKO SA, 1995, J MUSCLE RES CELL M, V16, P401, DOI 10.1007/BF00114505; Krolenko SA, 2002, CELL BIOL INT, V26, P893, DOI 10.1006/cbir.2002.0945; Lannergren J, 2002, CELL BIOL INT, V26, P911, DOI 10.1006/cbir.2002.0941; Launikonis BS, 2004, J GEN PHYSIOL, V123, P231, DOI 10.1085/jgp.200308946; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Lo HP, 2008, NEUROMUSCULAR DISORD, V18, P34, DOI 10.1016/j.nmd.2007.08.009; Marg A, 2010, BIOCHEM BIOPH RES CO, V401, P143, DOI 10.1016/j.bbrc.2010.09.030; McNeil AK, 2006, J BIOL CHEM, V281, P35202, DOI 10.1074/jbc.M606406200; Meador BM, 2010, MUSCLE NERVE, V42, P469, DOI 10.1002/mus.21817; Mohaupt MG, 2009, CAN MED ASSOC J, V181, pE11, DOI 10.1503/cmaj.081785; Moyer MW, 2010, NAT MED, V16, P150, DOI 10.1038/nm0210-150; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PEDERSEN TR, 1994, LANCET, V344, P1383; Potez S, 2011, J BIOL CHEM, V286, P17982, DOI 10.1074/jbc.M110.187625; Roostalu U, 2012, DEV CELL, V22, P515, DOI 10.1016/j.devcel.2011.12.008; Schache AG, 2010, GAIT POSTURE, V32, P136, DOI 10.1016/j.gaitpost.2010.03.006; Selbert S, 1996, EXP CELL RES, V222, P199, DOI 10.1006/excr.1996.0025; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Voigt T, 2001, J NEUROCYTOL, V30, P159, DOI 10.1023/A:1011943324781; Waddell LB, 2011, J NEUROPATH EXP NEUR, V70, P302, DOI 10.1097/NEN.0b013e31821350b0; Wallace GQ, 2009, ANNU REV PHYSIOL, V71, P37, DOI 10.1146/annurev.physiol.010908.163216; Wang PC, 2007, AM J RESP CELL MOL, V37, P467, DOI 10.1165/rcmb.2006-0447OC; WEIBEL ER, 1979, B EUR PHYSIOPATH RES, V15, P999	56	17	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2156	2164		10.1096/fj.12-219345	http://dx.doi.org/10.1096/fj.12-219345			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23413360				2022-12-28	WOS:000319667600007
J	Yang, SZ; Cui, HC; Xie, N; Icyuz, M; Banerjee, S; Antony, VB; Abraham, E; Thannickal, VJ; Liu, G				Yang, Shanzhong; Cui, Huachun; Xie, Na; Icyuz, Mert; Banerjee, Sami; Antony, Veena B.; Abraham, Edward; Thannickal, Victor J.; Liu, Gang			miR-145 regulates myofibroblast differentiation and lung fibrosis	FASEB JOURNAL			English	Article						smooth muscle actin alpha; KLF4; contraction	GROWTH-FACTOR-BETA; EPIGENETIC REGULATION; PULMONARY-FIBROSIS; MICRORNAS; FIBROBLASTS; ACTIVATION; PRINCIPLES; TGF-BETA-1; MIR-29; TARGET	The expression of smooth muscle actin-alpha (SMA-alpha) by fibroblasts defines phenotypic transition to myofibroblasts and is a primary contributor to contractile force generation by these differentiated cells. Although the regulation of SMA-alpha expression has been the focus of many studies, there is presently only limited information concerning miRNA regulation of lung myofibroblast differentiation and the involvement of these miRNAs in pulmonary fibrosis. To determine the role of miR-145 in regulating lung myofibroblast differentiation and pulmonary fibrosis. Wild-type and miR-145(-/-) mice were studied. Lung fibrosis models and cell culture systems were employed. miR-145 mimics or inhibitors were transfected into pulmonary fibroblasts. Fibrogenic and contractile activities of lung fibroblasts were determined. We found that miR-145 expression is upregulated in TGF-beta 1-reated lung fibroblasts. miR-145 expression is also increased in the lungs of patients with idiopathic pulmonary fibrosis as compared to in normal human lungs. Overexpression of miR-145 in lung fibroblasts increased SMA-alpha expression, enhanced contractility, and promoted formation of focal and fibrillar adhesions. In contrast, miR-145 deficiency diminished TGF-beta 1 induced SMA-alpha expression. miR-145 did not affect the activity of TGF-beta 1, but promoted the activation of latent TGF-beta 1. miR-145 targets KLF4, a known negative regulator of SMA-alpha expression. Finally, we found that miR-145(-/-) mice are protected from bleomycin-induced pulmonary fibrosis. miR-145 plays an important role in the differentiation of lung myofibroblasts. miR-145 deficiency is protective against bleomycin-induced lung fibrosis, suggesting that miR-145 may be a potential target in the development of novel therapies to treat pathological fibrotic disorders.-Yang, S., Cui, H., Xie, N., Icyuz, M., Banerjee, S., Antony, V. B., Abraham, E., Thannickal, V. J., Liu, G. miR-145 regulates myofibroblast differentiation and lung fibrosis.	[Yang, Shanzhong; Cui, Huachun; Xie, Na; Icyuz, Mert; Banerjee, Sami; Antony, Veena B.; Thannickal, Victor J.; Liu, Gang] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Abraham, Edward] Wake Forest Sch Med, Winston Salem, NC USA	University of Alabama System; University of Alabama Birmingham; Wake Forest University	Liu, G (corresponding author), Univ Alabama Birmingham, Dept Med, 901 19th St So,BMR 2 233, Birmingham, AL 35294 USA.	gliu@uab.edu	Icyuz, Mert/J-6598-2013	Icyuz, Mert/0000-0003-1681-0115; Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	U.S. National Institutes of Health (NIH) [HL105473, HL097218, HL076206, HL067967, HL10781]; American Heart Association [10SDG4210009]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076206, R01HL105473, R01HL067967, R21HL097218] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health (NIH) grants HL105473 (to G. L.), HL097218 (to G. L.), HL076206 (to G. L.), HL067967 (to V.J.T.), and HL10781 (to V.J.T.) and by American Heart Association award 10SDG4210009 (to G. L.). Author contributions: conception and design, V.J.T. and G.L.; execution and interpretation, S.Y., N.X., H.C., S.B., E.A., V.J.T., and G.L.; drafting the manuscript, S.Y., N.X., H.C., M.I., V.B.A., E.A., V.J.T, and G.L.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Caruso P, 2012, CIRC RES, V111, P290, DOI 10.1161/CIRCRESAHA.112.267591; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC; Cutroneo KR, 2007, J CELL PHYSIOL, V211, P585, DOI 10.1002/jcp.20972; Davis-Dusenbery BN, 2011, J BIOL CHEM, V286, P28097, DOI 10.1074/jbc.M111.236950; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Hardie WD, 2009, AM J PATHOL, V175, P3, DOI 10.2353/ajpath.2009.081170; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hinz Boris, 2012, Proc Am Thorac Soc, V9, P137, DOI 10.1513/pats.201202-017AW; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Hu B, 2007, AM J RESP CELL MOL, V36, P78, DOI 10.1165/rcmb.2006-0043OC; Hu B, 2010, AM J PATHOL, V177, P21, DOI 10.2353/ajpath.2010.090999; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Latronico MVG, 2009, NAT REV CARDIOL, V6, P418, DOI 10.1038/nrcardio.2009.56; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P476; Liao XD, 2010, J MOL CELL CARDIOL, V49, P334, DOI 10.1016/j.yjmcc.2010.04.008; Liu G, 2008, FASEB J, V22, P2285, DOI 10.1096/fj.07-101816; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu Y, 2005, J BIOL CHEM, V280, P9719, DOI 10.1074/jbc.M412862200; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; Mishra PK, 2009, J CELL MOL MED, V13, P778, DOI 10.1111/j.1582-4934.2009.00744.x; Pandey AK, 2009, CELL PHYSIOL BIOCHEM, V23, P221, DOI 10.1159/000218169; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Pottier N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006718; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sanders YY, 2011, AM J RESP CELL MOL, V45, P16, DOI 10.1165/rcmb.2010-0154OC; Thum T, 2008, CARDIOVASC RES, V79, P562, DOI 10.1093/cvr/cvn137; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Xiao J, 2012, MOL THER, V20, P1251, DOI 10.1038/mt.2012.36; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yang SZ, 2012, AM J PATHOL, V180, P484, DOI 10.1016/j.ajpath.2011.10.005; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zhou Y, 2004, AM J PATHOL, V165, P659, DOI 10.1016/S0002-9440(10)63330-5	44	114	121	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2382	2391		10.1096/fj.12-219493	http://dx.doi.org/10.1096/fj.12-219493			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23457217	Green Published			2022-12-28	WOS:000319667600026
J	Anderson, OS; Peterson, KE; Sanchez, BN; Zhang, ZZ; Mancuso, P; Dolinoy, DC				Anderson, Olivia S.; Peterson, Karen E.; Sanchez, Brisa N.; Zhang, Zhenzhen; Mancuso, Peter; Dolinoy, Dana C.			Perinatal bisphenol A exposure promotes hyperactivity, lean body composition, and hormonal responses across the murine life course	FASEB JOURNAL			English	Article						developmental origins of health and disease; energy expenditure; glucose; insulin; metabolic homeostasis	ENDOCRINE-DISRUPTING CHEMICALS; OXYGEN-CONSUMPTION; METABOLIC SYNDROME; RECEPTOR; URINARY; BRAIN; RATS; MICE; BEHAVIOR; ASSOCIATION	The development of adult-onset diseases is influenced by perinatal exposure to altered environmental conditions. One such exposure, bisphenol A (BPA), has been associated with obesity and diabetes, and consequently labeled an obesogen. Using an isogenic murine model, we examined the effects of perinatal exposure through maternal diet to 50 ng (n=20), 50 mu g (n=21), or 50 mg (n=18) BPA/kg diet, as well as controls (n=20) on offspring energy expenditure, spontaneous activity, and body composition at 3, 6, and 9 mo of age, and hormone levels at 9 and 10 mo of age. Overall, exposed females and males exhibited increased energy expenditure (P<0.001 and 0.001, respectively) throughout the life course. In females, horizontal and vertical activity increased (P=0.07 and 0.06, respectively) throughout the life course. Generally, body composition measures were not different throughout the life course in exposed females or males (all P>0.44), although body fat and weight decreased in exposed females at particular ages (all P<0.08). Milligram-exposed females had improved glucose, insulin, adiponectin, and leptin profiles (all P<0.10). Thus, life-course analysis illustrates that BPA is associated with hyperactive and lean phenotypes. Variability across studies may be attributable to differential exposure duration and timing, dietary fat and phytoestrogen content, or lack of sophisticated phenotyping across the life course.-Anderson, O.S., Peterson, K. E., Sanchez, B.N., Zhang, Z., Mancuso, P., Dolinoy, D. C. Perinatal bisphenol A exposure promotes hyperactivity, lean body composition, and hormonal responses across the murine life course. FASEB J. 27, 1784-1792 (2013). www.fasebj.org	[Anderson, Olivia S.; Peterson, Karen E.; Mancuso, Peter; Dolinoy, Dana C.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Peterson, Karen E.] Univ Michigan, Ctr Human Growth & Dev, Ann Arbor, MI 48109 USA; [Sanchez, Brisa N.; Zhang, Zhenzhen] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dolinoy, DC (corresponding author), Univ Michigan, 1415 Washington Hts, Ann Arbor, MI 48109 USA.	ddolinoy@umich.edu	Mancuso, Peter/AGZ-3550-2022	Mancuso, Peter/0000-0002-2559-7320	MNORC [P30 DK089503]; U.S. National Institutes of Health [R01 ES017524]; University of Michigan National Institute of Environmental Health Sciences (NIEHS) Center of Excellence grant [P30 ES017885]; University of Michigan NIEHS/Environmental Protection Agency Children's Environmental Health Formative Center grant [P20 ES018171/RD83480001]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK097153, P30DK089503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES017885, R01ES017524, P20ES018171] Funding Source: NIH RePORTER	MNORC; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan National Institute of Environmental Health Sciences (NIEHS) Center of Excellence grant; University of Michigan NIEHS/Environmental Protection Agency Children's Environmental Health Formative Center grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Charles Burant, Nathan Qi, Malcolm Low, Katie Gee, and Melanie Schmidt [University of Michigan Nutrition and Obesity Research Center (MNORC) Animal Phenotyping Core] and Edmund O'Brien (Department of Environmental Health Sciences, University of Michigan) for their technical and intellectual assistance with this project. This work was supported by a pilot grant from the MNORC (P30 DK089503), as well as U.S. National Institutes of Health grant R01 ES017524, University of Michigan National Institute of Environmental Health Sciences (NIEHS) Center of Excellence grant P30 ES017885, and University of Michigan NIEHS/Environmental Protection Agency Children's Environmental Health Formative Center grant P20 ES018171/RD83480001. The authors declare no conflicts of interest.	Ahima RS, 2006, OBESITY, V14, p9S, DOI 10.1038/oby.2006.276; Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Batista TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033814; Becker JB, 2005, ENDOCRINOLOGY, V146, P1650, DOI 10.1210/en.2004-1142; Ben-Jonathan N, 2009, MOL CELL ENDOCRINOL, V304, P49, DOI 10.1016/j.mce.2009.02.022; Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335; Braun JM, 2009, ENVIRON HEALTH PERSP, V117, P1945, DOI 10.1289/ehp.0900979; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Decherf S, 2011, J TOXICOL ENV HEAL B, V14, P423, DOI 10.1080/10937404.2011.578561; Ferguson SA, 2011, TOXICOL SCI, V124, P149, DOI 10.1093/toxsci/kfr201; Goodell S, 1998, MECH AGEING DEV, V101, P245, DOI 10.1016/S0047-6374(97)00182-6; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Heindel JJ, 2009, MOL CELL ENDOCRINOL, V304, P90, DOI 10.1016/j.mce.2009.02.025; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Institute for Laboratory Animal Resources, 1966, GUIDE CARE USE LAB A; Ishido M, 2005, REGUL PEPTIDES, V126, P145, DOI 10.1016/j.regpep.2004.08.035; Jasarevic E, 2011, P NATL ACAD SCI USA, V108, P11715, DOI 10.1073/pnas.1107958108; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones BA, 2012, HORM BEHAV, V61, P605, DOI 10.1016/j.yhbeh.2012.02.011; Kruger T, 2008, TOXICOLOGY, V246, P112, DOI 10.1016/j.tox.2007.12.028; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kundakovic M, 2011, BRAIN BEHAV IMMUN, V25, P1084, DOI 10.1016/j.bbi.2011.02.005; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Masuo Y, 2011, J TOXICOL ENV HEAL B, V14, P346, DOI 10.1080/10937404.2011.578557; Matsuda S, 2010, CHEMOSPHERE, V78, P894, DOI 10.1016/j.chemosphere.2009.11.010; McKenzie DJ, 2007, PHILOS T R SOC B, V362, P2043, DOI 10.1098/rstb.2007.2100; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209; Newbold RR, 2010, HORM-INT J ENDOCRINO, V9, P206, DOI 10.14310/horm.2002.1271; Osman AF, 2000, J AM COLL CARDIOL, V36, P2126, DOI 10.1016/S0735-1097(00)00985-2; Patisaul HB, 2008, BRAIN RES REV, V57, P352, DOI 10.1016/j.brainresrev.2007.06.008; Rubin BS, 2009, MOL CELL ENDOCRINOL, V304, P55, DOI 10.1016/j.mce.2009.02.023; Ryan KK, 2010, ENDOCRINOLOGY, V151, P2603, DOI 10.1210/en.2009-1218; Saal FSV, 2012, MOL CELL ENDOCRINOL, V354, P74, DOI 10.1016/j.mce.2012.01.001; Saili KS, 2012, TOXICOLOGY, V291, P83, DOI 10.1016/j.tox.2011.11.001; Sieli PT, 2011, ENVIRON HEALTH PERSP, V119, P1260, DOI 10.1289/ehp.1003385; Somm E, 2009, ENVIRON HEALTH PERSP, V117, P1549, DOI 10.1289/ehp.11342; Stern JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048790; Sui YP, 2012, ENVIRON HEALTH PERSP, V120, P399, DOI 10.1289/ehp.1104426; Takahashi O, 2003, FOOD CHEM TOXICOL, V41, P1035, DOI 10.1016/S0278-6915(03)00031-0; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Viberg H, 2011, TOXICOLOGY, V290, P187, DOI 10.1016/j.tox.2011.09.006; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wei J, 2011, ENDOCRINOLOGY, V152, P3049, DOI 10.1210/en.2011-0045; Wolstenholme JT, 2011, HORM BEHAV, V59, P296, DOI 10.1016/j.yhbeh.2010.10.001; Zhang ZF, 2011, ENVIRON SCI TECHNOL, V45, P7044, DOI 10.1021/es200976k; Zhou R, 2011, NEUROPHARMACOLOGY, V60, P789, DOI 10.1016/j.neuropharm.2011.01.031	54	78	79	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1784	1792		10.1096/fj.12-223545	http://dx.doi.org/10.1096/fj.12-223545			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23345456	Green Submitted, Green Published			2022-12-28	WOS:000316940800046
J	Debbabi, M; Kroviarski, Y; Bournier, O; Gougerot-Pocidalo, MA; El-Benna, J; Dang, PMC				Debbabi, Maya; Kroviarski, Yolande; Bournier, Odile; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel; Dang, Pham My-Chan			NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1 assembly and activation	FASEB JOURNAL			English	Article						reactive oxygen species; NOX1; p22(PHOX); NOXA1; inflammation	PROTEIN-KINASE-C; RESPIRATORY BURST OXIDASE; COLON EPITHELIAL-CELLS; GASTROINTESTINAL-TRACT; NEUTROPHIL ACTIVATION; SUPEROXIDE-PRODUCTION; P47(PHOX); P67(PHOX); P22(PHOX); BINDING	Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phosphorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.-Debbabi, M., Kroviarski, Y., Bournier, O., Gougerot-Pocidalo, M.-A., El-Benna, J., Dang, P. M.-C. NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1 assembly and activation. FASEB J. 27, 1733-1748 (2013). www.fasebj.org	[Debbabi, Maya; Kroviarski, Yolande; Bournier, Odile; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel; Dang, Pham My-Chan] INSERM, Ctr Rech Biomed Bichat Beaujon CRB3, U773, F-75018 Paris, France; [Debbabi, Maya; Kroviarski, Yolande; Bournier, Odile; Gougerot-Pocidalo, Marie-Anne; El-Benna, Jamel; Dang, Pham My-Chan] Univ Paris 07, UMR 773, Paris, France; [Debbabi, Maya] Univ Paris 11, Orsay, France; [Kroviarski, Yolande; Bournier, Odile; Gougerot-Pocidalo, Marie-Anne] Ctr Hosp Univ Xavier Bichat, AP HP, CIB Phenogen, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Dang, PMC (corresponding author), INSERM, Fac Med Xavier Bichat, U773, 16 Rue Henri Huchard, F-75018 Paris, France.	my-chan.dang@inserm.fr			Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; French Research Ministry	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); French Research Ministry(Ministry of Research, France)	The authors thank Dr. Samira Benadda (Institut Claude Bernard-IFR2 Site Bichat, Paris, France) for confocal microscopy analysis and Dr. Francoise Braut for measurement of ROS by DCF-mediated fluorescence. This work was supported by Institut National de la Sante et de la Recherche Medicale and Centre National de la Recherche Scientifique. M. D. is the recipient of fellowships from the French Research Ministry.	Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Cheng GJ, 2005, GENE, V356, P118, DOI 10.1016/j.gene.2005.03.008; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Dutta S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010478; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kroviarski Y, 2010, FASEB J, V24, P2077, DOI 10.1096/fj.09-147629; Kuwano Y, 2008, FREE RADICAL BIO MED, V45, P1642, DOI 10.1016/j.freeradbiomed.2008.08.033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lewis EM, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.030643; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Quinn MT, 2006, CLIN SCI, V111, P1, DOI 10.1042/cs20060059; Raad H, 2009, FASEB J, V23, P1011, DOI 10.1096/fj.08-114553; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Rokutan K, 2008, SEMIN IMMUNOPATHOL, V30, P315, DOI 10.1007/s00281-008-0124-5; Rokutan K, 2006, ANTIOXID REDOX SIGN, V8, P1573, DOI 10.1089/ars.2006.8.1573; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Yamamoto A, 2007, BIOCHEM BIOPH RES CO, V352, P560, DOI 10.1016/j.bbrc.2006.11.060	31	32	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1733	1748		10.1096/fj.12-216432	http://dx.doi.org/10.1096/fj.12-216432			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23322165				2022-12-28	WOS:000316940800042
J	Zindel, R; Ofek, M; Minz, D; Palevsky, E; Zchori-Fein, E; Aebi, A				Zindel, Renate; Ofek, Maya; Minz, Dror; Palevsky, Eric; Zchori-Fein, Einat; Aebi, Alexandre			The role of the bacterial community in the nutritional ecology of the bulb mite Rhizoglyphus robini (Acari: Astigmata: Acaridae)	FASEB JOURNAL			English	Article						symbiont; chitin digestion; DGGE; 16S rRNA pyrosequencing	CLAPAREDE ACARI; GUT BACTERIA; DIVERSITY; CHITINASE; INSECTS; PLANTS; RHIZOSPHERE; MANAGEMENT; SYMBIONTS; LYSOZYME	The biology of many arthropods can only be understood when their associated microbiome is considered. The nutritional requirements of the bulb mite Rhizoglyphus robini Claparede (Acari: Astigmata: Acaridae) in the laboratory have been shown to be very easily satisfied, and in the field the mites prefer fungus-infected over uninfected plants. To test whether symbiotic bacteria facilitate the survival of R. robini on a temporarily nutritionally unbalanced diet, we investigated the composition of its microbiome. Using 454 pyrosequencing of 16S rRNA gene fragments, 3 genera were found to dominate the bacterial community: Myroides (41.4%), Serratia (11.4%), and Alcaligenes (4.5%); the latter 2 are known to include chitinase-producing species. Laboratory experiments demonstrated that mite fecundity is significantly higher (2 times) on fungus than on controls (sterilized potato dextrose agar and filter paper). Also, when mite homogenate was applied to a chitin layer, the halo produced through degradation was clearly visible, while the saline control did not produce a halo. We thus concluded that R. robini utilizes fungal chitin, at least to a certain extent, as a food source with the help of its associated bacteria. This information supports the general concept of multigenome organisms and the involvement of bacteria in the mite's nutritional ecology.-Zindel, R., Ofek, M., Minz, D., Palevsky, E., Zchori-Fein, E., Aebi, A. The role of the bacterial community in the nutritional ecology of the bulb mite Rhizoglyphus robini (Acari: Astigmata: Acaridae). FASEB J. 27, 1488-1497 (2013). www.fasebj.org	[Zindel, Renate; Aebi, Alexandre] Agroscope Reckenholz Tanikon, Res Stn ART, CH-8046 Zurich, Switzerland; [Ofek, Maya; Minz, Dror] Agr Res Org, Inst Soil Water & Environm Sci, IL-50250 Bet Dagan, Israel; [Palevsky, Eric; Zchori-Fein, Einat] Agr Res Org, Newe Yaar Res Ctr, Dept Entomol, Ramat Yishay, Israel	Swiss Federal Research Station Agroscope; Swiss Federal Research Station for Agroecology & Agriculture; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Zindel, R (corresponding author), Agroscope Reckenholz Tanikon, Res Stn ART, Reckenholzstr 191, CH-8046 Zurich, Switzerland.	zirena@bluewin.ch		Palevsky, Eric/0000-0002-4958-8920; Minz, Dror/0000-0001-6746-9151	European Cooperation in Science and Technology-Secretariat for Education and Research (COST-SER) [C08AE0109]; COST Action [FA0701]	European Cooperation in Science and Technology-Secretariat for Education and Research (COST-SER); COST Action(European Cooperation in Science and Technology (COST))	This article was supported by European Cooperation in Science and Technology-Secretariat for Education and Research (COST-SER) project C08AE0109 to A. A., part of COST Action FA0701. The authors thank Shira Gal and Netta Moses-Daube for help and support in the laboratory in Israel, and Steven Bacon, Mario Waldburger, Irene Banziger, and Franco Widmer in the laboratory in Switzerland. The authors also thank Max Kolton and Pilar Junier for their assistance and advice on experiments involving chitin and two anonymous reviewers for comments and suggestions to improve the manuscript.	Andreotti R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-6; Annamalai N, 2011, ANN MICROBIOL, V61, P801, DOI 10.1007/s13213-011-0198-5; Arakane Y, 2010, CELL MOL LIFE SCI, V67, P201, DOI 10.1007/s00018-009-0161-9; BANDI C, 1994, P ROY SOC B-BIOL SCI, V257, P43, DOI 10.1098/rspb.1994.0092; Berg G, 2005, FEMS MICROBIOL ECOL, V51, P215, DOI 10.1016/j.femsec.2004.08.006; Bextine B, 2004, CURR MICROBIOL, V48, P327, DOI 10.1007/s00284-003-4178-2; BOWMAN CE, 1982, COMP BIOCHEM PHYS B, V72, P551, DOI 10.1016/0305-0491(82)90505-3; BRURBERG MB, 2001, RRD MICROBIOL 1, V5, P187; CHAO A, 1984, SCAND J STAT, V11, P265; CHILDS M, 1981, COMP BIOCHEM PHYS B, V70, P615, DOI 10.1016/0305-0491(81)90305-9; CHRISTIAS C, 1975, APPL MICROBIOL, V29, P250, DOI 10.1111/1741-5705.00031; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; Dharne MS, 2008, BRAZ J MICROBIOL, V39, P397, DOI 10.1590/S1517-838220080002000035; Diaz A, 2000, EXP APPL ACAROL, V24, P85, DOI 10.1023/A:1006304300657; Dillon RJ, 2004, ANNU REV ENTOMOL, V49, P71, DOI 10.1146/annurev.ento.49.061802.123416; Dowd SE, 2008, BMC MICROBIOL, V8, DOI [10.1186/1471-2180-8-125, 10.1186/1471-2180-8-43]; Erban T, 2008, EXP APPL ACAROL, V44, P199, DOI 10.1007/s10493-008-9138-x; Faramarzi M. A., 2009, Biotechnology, V8, P93; Feldhaar H, 2009, INT J MED MICROBIOL, V299, P1, DOI 10.1016/j.ijmm.2008.05.010; Frohlich DR, 1999, MOL ECOL, V8, P1683, DOI 10.1046/j.1365-294x.1999.00754.x; GERSON U, 1991, EXP APPL ACAROL, V12, P103, DOI 10.1007/BF01204403; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Gottlieb Y, 2006, APPL ENVIRON MICROB, V72, P3646, DOI 10.1128/AEM.72.5.3646-3652.2006; Grunwald S, 2010, SYST APPL MICROBIOL, V33, P25, DOI 10.1016/j.syapm.2009.10.002; Gunduz EA, 2009, P ROY SOC B-BIOL SCI, V276, P987, DOI 10.1098/rspb.2008.1476; Hanuny T., 2008, Bulletin OILB/SROP, V32, P71; Harichova J, 2006, BIOLOGIA, V61, P663, DOI 10.2478/s11756-006-0138-1; Hariprasad P, 2011, CROP PROT, V30, P1606, DOI 10.1016/j.cropro.2011.02.032; Hudson HJ, 1986, FUNGAL BIOL; Jaffe K, 2001, CAN J ZOOL, V79, P1120, DOI 10.1139/cjz-79-6-1120; Jin FL, 2011, INT J MOL SCI, V12, P3055, DOI 10.3390/ijms12053055; Jones RT, 2010, ISME J, V4, P223, DOI 10.1038/ismej.2009.111; Kleespies RG, 2008, BIOCONTROL SCI TECHN, V18, P439, DOI 10.1080/09583150802011618; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; MANSON D C M, 1972, Acarologia (Paris), V13, P621; McBride MJ, 2009, APPL ENVIRON MICROB, V75, P6864, DOI 10.1128/AEM.01495-09; McBride MJ, 2004, J BACTERIOL, V186, P2295, DOI 10.1128/JB.186.8.2295-2302.2004; McCall C, 2001, VET IMMUNOL IMMUNOP, V78, P231, DOI 10.1016/S0165-2427(00)00258-0; MONREAL J, 1969, CAN J MICROBIOL, V15, P689, DOI 10.1139/m69-122; Mrazek J, 2008, FOLIA MICROBIOL, V53, P229, DOI 10.1007/s12223-008-0032-z; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; O'Neil SE, 2006, CLIN EXP ALLERGY, V36, P831, DOI 10.1111/j.1365-2222.2006.02497.x; OKABE K, 1990, APPL ENTOMOL ZOOL, V25, P397, DOI 10.1303/aez.25.397; OKABE K, 1991, APPL ENTOMOL ZOOL, V26, P129, DOI 10.1303/aez.26.129; Okabe K, 2001, EXP APPL ACAROL, V25, P493, DOI 10.1023/A:1011843407167; Oliver KM, 2006, P ROY SOC B-BIOL SCI, V273, P1273, DOI 10.1098/rspb.2005.3436; ORDENTLICH A, 1988, PHYTOPATHOLOGY, V78, P84; Reichenbach H, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 6, THIRD EDITION, P939, DOI 10.1007/0-387-30746-x_37; Sabree ZL, 2009, P NATL ACAD SCI USA, V106, P19521, DOI 10.1073/pnas.0907504106; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Seo WT, 2010, J KOREAN SOC APPL BI, V53, P493, DOI 10.3839/jksabc.2010.075; SIEPEL H, 1993, SOIL BIOL BIOCHEM, V25, P1491, DOI 10.1016/0038-0717(93)90004-U; Smrz J, 2010, SYMBIOSIS, V52, P33, DOI 10.1007/s13199-010-0099-6; Snyder AK, 2010, P ROY SOC B-BIOL SCI, V277, P2389, DOI 10.1098/rspb.2010.0364; Someya N, 2011, MICROBES ENVIRON, V26, P7, DOI 10.1264/jsme2.ME10149; Soukalova H, 2008, INTEGRATIVE ACAROLOG, P374; Spiteller D, 2000, BIOL CHEM, V381, P755, DOI 10.1515/BC.2000.096; Srivastava Shilpi, 2011, Toxicol Int, V18, P111, DOI 10.4103/0971-6580.84262; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Teixeira LCRS, 2010, ISME J, V4, P989, DOI 10.1038/ismej.2010.35; Tripathi AK, 2002, RES MICROBIOL, V153, P579, DOI 10.1016/S0923-2508(02)01371-2; Vaidya R, 2003, BIOTECHNOL LETT, V25, P715, DOI 10.1023/A:1023406630791; Wang H, 2011, J APPL MICROBIOL, V110, P1390, DOI 10.1111/j.1365-2672.2011.05001.x; Wong CNA, 2011, ENVIRON MICROBIOL, V13, P1889, DOI 10.1111/j.1462-2920.2011.02511.x; Wooddy Mark W., 1993, International Journal of Acarology, V19, P345; Zaspel JM, 2008, ANN ENTOMOL SOC AM, V101, P1050, DOI 10.1603/0013-8746-101.6.1050; Zilber-Rosenberg I, 2008, FEMS MICROBIOL REV, V32, P723, DOI 10.1111/j.1574-6976.2008.00123.x; Zindel R, 2011, J APPL ECOL, V48, P864, DOI 10.1111/j.1365-2664.2011.01984.x	68	26	28	0	52	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1488	1497		10.1096/fj.12-216242	http://dx.doi.org/10.1096/fj.12-216242			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23307835	Green Submitted			2022-12-28	WOS:000316940800021
J	Ho, L; Ferruzzi, MG; Janle, EM; Wang, J; Gong, B; Chen, TY; Lobo, J; Cooper, B; Wu, QL; Talcott, ST; Percival, SS; Simon, JE; Pasinetti, GM				Ho, Lap; Ferruzzi, Mario G.; Janle, Elsa M.; Wang, Jun; Gong, Bing; Chen, Tzu-Ying; Lobo, Jessica; Cooper, Bruce; Wu, Qing Li; Talcott, Stephen T.; Percival, Susan S.; Simon, James E.; Pasinetti, Giulio Maria			Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease	FASEB JOURNAL			English	Article						polyphenol bioavailability; cognitive deterioration; neuroplasticity	LONG-TERM POTENTIATION; RED WINE; MOUSE MODEL; VARIETAL DIFFERENCES; SYNAPTIC PLASTICITY; TRANSGENIC MICE; VITIS-VINIFERA; POLYPHENOLS; QUERCETIN; GRAPES	Epidemiological and preclinical studies indicate that polyphenol intake from moderate consumption of red wines may lower the relative risk for developing Alzheimer's disease (AD) dementia. There is limited information regarding the specific biological activities and cellular and molecular mechanisms by which wine polyphenolic components might modulate AD. We assessed accumulations of polyphenols in the rat brain following oral dosage with a Cabernet Sauvignon red wine and tested brain-targeted polyphenols for potential beneficial AD disease-modifying activities. We identified accumulations of select polyphenolic metabolites in the brain. We demonstrated that, in comparison to vehicle-control treatment, one of the brain-targeted polyphenol metabolites, quercetin-3-O-glucuronide, significantly reduced the generation of beta-amyloid (A beta\) peptides by primary neuron cultures generated from the Tg2576 AD mouse model. Another brain-targeted metabolite, malvidin-3-O-glucoside, had no detectable effect on A beta generation. Moreover, in an in vitro analysis using the photo-induced cross-linking of unmodified proteins (PICUP) technique, we found that quercetin-3-O-glucuronide is also capable of interfering with the initial protein-protein interaction of A beta(1-40) and A beta(1-42) that is necessary for the formation of neurotoxic oligomeric A beta species. Lastly, we found that quercetin-3-O-glucuronide treatment, compared to vehicle-control treatment, significantly improved AD-type deficits in hippocampal formation basal synaptic transmission and long-term potentiation, possibly through mechanisms involving the activation of the c-Jun N-terminal kinases and the mitogen-activated protein kinase signaling pathways. Brain-targeted quercetin-3-O-glucuronide may simultaneously modulate multiple independent AD disease-modifying mechanisms and, as such, may contribute to the benefits of dietary supplementation with red wines as an effective intervention for AD.-Ho, L., Ferruzzi, M. G., Janle, E. M., Wang, J., Gong, B., Chen, T.-Y., Lobo, J., Cooper, B., Wu, Q. L., Talcott, S. T., Percival, S. S., Simon, J. E., Pasinetti, G. M. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. FASEB J. 27, 769-781 (2013). www.fasebj.org	[Ho, Lap; Wang, Jun; Gong, Bing; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA; [Ferruzzi, Mario G.; Lobo, Jessica] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA; [Ferruzzi, Mario G.; Janle, Elsa M.; Chen, Tzu-Ying] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA; [Cooper, Bruce] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA; [Wu, Qing Li; Simon, James E.] Rutgers State Univ, Dept Plant Biol & Plant Pathol, New Brunswick, NJ 08903 USA; [Talcott, Stephen T.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA; [Percival, Susan S.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL USA	Icahn School of Medicine at Mount Sinai; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick; Texas A&M University System; Texas A&M University College Station; State University System of Florida; University of Florida	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Rm 20-02, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Ferruzzi, Mario/0000-0003-1384-2672; Pasinetti, Giulio/0000-0002-1524-5196	U.S. National Institutes of Health [National Center for Complementary and Alternative Medicine (NCCAM)] [PO1 AT004511]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT004511] Funding Source: NIH RePORTER	U.S. National Institutes of Health [National Center for Complementary and Alternative Medicine (NCCAM)]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	These studies were supported by the U.S. National Institutes of Health [grant PO1 AT004511; National Center for Complementary and Alternative Medicine (NCCAM) Project 1 to L. H. and Project 3 to G. M. P.]. The authors thank Dr. Kenjiro Ono (Kanazawa University Graduate School of Medical Science, Takara-Machi, Kanazawa, Japan), for valuable assistance and support with the PICUP analysis.	Alberini CM, 2005, TRENDS NEUROSCI, V28, P51, DOI 10.1016/j.tins.2004.11.001; Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001; Andres-Lacueva C, 2005, NUTR NEUROSCI, V8, P111, DOI 10.1080/10284150500078117; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Bastianetto S, 2011, CURR ALZHEIMER RES, V8, P445, DOI 10.2174/156720511796391854; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Bito H, 2003, CELL CALCIUM, V34, P425, DOI 10.1016/S0143-4160(03)00140-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Borbalan AMA, 2003, J CHROMATOGR A, V1012, P31, DOI 10.1016/S0021-9673(03)01187-7; Brouillard R, 1997, BIOFACTORS, V6, P403, DOI 10.1002/biof.5520060406; Cantos E, 2002, J AGR FOOD CHEM, V50, P5691, DOI 10.1021/jf0204102; Craggs L, 2011, NEUROREPORT, V22, P1, DOI 10.1097/WNR.0b013e328342741c; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Darvesh AS, 2010, EXPERT REV NEUROTHER, V10, P729, DOI [10.1586/ern.10.42, 10.1586/ERN.10.42]; Day AJ, 2003, BIOCHEM PHARMACOL, V65, P1199, DOI 10.1016/S0006-2952(03)00039-X; de Boer VCJ, 2005, J NUTR, V135, P1718, DOI 10.1093/jn/135.7.1718; Dorozynski A, 1997, BRIT MED J, V314, P997; Esteban MA, 2001, J SCI FOOD AGR, V81, P409, DOI 10.1002/1097-0010(200103)81:4&lt;409::AID-JSFA830&gt;3.0.CO;2-H; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; Germain S, 2009, J ALZHEIMERS DIS, V17, P105, DOI 10.3233/JAD-2009-1016; German JB, 2000, ANNU REV NUTR, V20, P561, DOI 10.1146/annurev.nutr.20.1.561; Ginjom IR, 2010, J AGR FOOD CHEM, V58, P10133, DOI 10.1021/jf100822n; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; Gonzalez Elizabeth W, 2011, Issues Ment Health Nurs, V32, P528, DOI 10.3109/01612840.2011.573123; Guedj F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004606; Han X., 2007, INT J MOL SCI, V8, P47; Ho L, 2009, J ALZHEIMERS DIS, V16, P59, DOI 10.3233/JAD-2009-0916; Ho L, 2010, EXPERT REV PROTEOMIC, V7, P579, DOI 10.1586/EPR.10.69; Hou Y, 2010, NEUROPHARMACOLOGY, V58, P911, DOI 10.1016/j.neuropharm.2009.11.002; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu P, 2008, N-S ARCH PHARMACOL, V378, P43, DOI 10.1007/s00210-008-0301-z; Joseph J, 2009, J NEUROSCI, V29, P12795, DOI 10.1523/JNEUROSCI.3520-09.2009; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Larrieu S, 2004, J Nutr Health Aging, V8, P150; Lee JE, 2009, ANAL CHIM ACTA, V648, P71, DOI 10.1016/j.aca.2009.06.039; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Luchsinger JA, 2004, J AM GERIATR SOC, V52, P540, DOI 10.1111/j.1532-5415.2004.52159.x; Magrone T, 2011, CURR TOP MED CHEM, V11, P1780, DOI 10.2174/156802611796235116; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Mandel Silvia A, 2012, Front Biosci (Schol Ed), V4, P581; Masa A, 2007, J CHROMATOGR A, V1164, P291, DOI 10.1016/j.chroma.2007.06.058; Mausbach B. T., 2012, AM J GERIAT PSYCHIAT, DOI [10.1097/JGP.0b013e31824472d5, DOI 10.1097/JGP.0B013E31824472D5]; Meiers S, 2001, J AGR FOOD CHEM, V49, P958, DOI 10.1021/jf0009100; Mohamed S, 2010, AM J GERIAT PSYCHIAT, V18, P917, DOI 10.1097/JGP.0b013e3181d5745d; Moon JH, 2001, FREE RADICAL BIO MED, V30, P1274, DOI 10.1016/S0891-5849(01)00522-6; Ohta K, 2011, BIOCHEM BIOPH RES CO, V416, P362, DOI 10.1016/j.bbrc.2011.11.042; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Orts MLD, 2005, J INT SCI VIGNE VIN, V39, P47; Percival SS, 2000, J NUTR, V130, P1091, DOI 10.1093/jn/130.5.1091; Perez-Magarino S, 2004, J AGR FOOD CHEM, V52, P1181, DOI 10.1021/jf035099i; Porat Y, 2006, CHEM BIOL DRUG DES, V67, P27, DOI 10.1111/j.1747-0285.2005.00318.x; Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044; Radovanovic BC, 2010, J SCI FOOD AGR, V90, P2455, DOI 10.1002/jsfa.4106; Ramesh BN, 2010, J ALZHEIMERS DIS, V19, P1123, DOI 10.3233/JAD-2010-1312; Rangel-Ordonez L, 2010, PLANTA MED, V76, P1683, DOI 10.1055/s-0030-1249962; Rivera F, 2004, NEUROTOX RES, V6, P543, DOI 10.1007/BF03033450; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Shih PH, 2011, J AGR FOOD CHEM, V59, P1683, DOI 10.1021/jf103822h; Shimmyo Y, 2008, BBA-GEN SUBJECTS, V1780, P819, DOI 10.1016/j.bbagen.2008.01.017; Singh M, 2008, J AGR FOOD CHEM, V56, P4855, DOI 10.1021/jf0735073; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; Talcott ST, 2002, J AGR FOOD CHEM, V50, P3186, DOI 10.1021/jf011500u; Tchantchou F, 2009, J ALZHEIMERS DIS, V18, P787, DOI 10.3233/JAD-2009-1189; Thies W, 2011, ALZHEIMERS DEMENT, V7, P175, DOI [10.1016/j.jalz.2011.02.004, 10.1016/j.jalz.2011.02.002]; Thimothe J, 2007, J AGR FOOD CHEM, V55, P10200, DOI 10.1021/jf0722405; Truelsen T, 2002, NEUROLOGY, V59, P1313, DOI 10.1212/01.WNL.0000031421.50369.E7; Urquiaga I, 2000, BIOL RES, V33, P55, DOI 10.4067/s0716-97602000000200004; Vafeiadou K., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P211, DOI 10.2174/187153007781662521; Vafeiadou K, 2008, ARCH BIOCHEM BIOPHYS, V478, P195, DOI 10.1016/j.abb.2008.07.014; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com; Wang J, 2012, J NEUROSCI, V32, P5144, DOI 10.1523/JNEUROSCI.6437-11.2012; Wang J, 2010, J ALZHEIMERS DIS, V22, P653, DOI 10.3233/JAD-2010-101074; Xu Y, 2007, EUR J NEUROSCI, V26, P2931, DOI 10.1111/j.1460-9568.2007.05905.x; Xu YP, 2011, J AGR FOOD CHEM, V59, P10586, DOI 10.1021/jf202438d; Yao Y, 2010, PHYTOTHER RES, V24, P136, DOI 10.1002/ptr.2902; Yokotsuka K, 1999, AM J ENOL VITICULT, V50, P1; Zenebe W, 2002, Bratisl Lek Listy, V103, P159; ZOECKLEIN BW, 1990, PRODUCTION WINE ANAL	80	141	147	2	84	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					769	781		10.1096/fj.12-212118	http://dx.doi.org/10.1096/fj.12-212118			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23097297	Green Published			2022-12-28	WOS:000314358000035
J	Maatta, JA; Buki, KG; Gu, GL; Alanne, MH; Vaaraniemi, J; Liljenback, H; Poutanen, M; Harkonen, P; Vaananen, K				Maatta, Jorma A.; Buki, Kalman G.; Gu, Guoliang; Alanne, Maria H.; Vaaraniemi, Jukka; Liljenback, Heidi; Poutanen, Matti; Harkonen, Pirkko; Vaananen, Kalervo			Inactivation of estrogen receptor alpha in bone-forming cells induces bone loss in female mice	FASEB JOURNAL			English	Article						osteoblast; osteoporosis	GENE-EXPRESSION; TRABECULAR BONE; CORTICAL BONE; SEX STEROIDS; FAS LIGAND; IN-VITRO; DIFFERENTIATION; SPECIFICITY; OSTEOBLASTS; KNOCKOUT	The role of the estrogen receptor alpha (ER alpha) in bone-forming cells is incompletely understood at present. To examine the in vivo effects of ER alpha in these cells, we generated a mouse strain in which the ER alpha gene is inactivated in osteoblasts via osteocalcin promoter-regulated cyclic recombinase (Cre) activity (ER alpha(Delta OB/Delta OB)). This enabled micro-computed tomography- and histomorphometry-based analysis of ER alpha-mediated effects in bone-forming cells in mice, in which the systemic ER alpha-mediated effects are intact. In female ER alpha(Delta OB/Delta OB) mice, trabecular and cortical bone volumes were significantly reduced (31.5 and 11.4%, respectively) at 3.5 mo of age compared with control ER alpha(fl/fl) animals, and their response to ovariectomy was small compared with that of controls. In contrast with females, no differences could be detected in the bone phenotype of young males, whereas in 6-mo-old ER alpha(Delta OB/Delta OB) males, trabecular bone volume (Tb.BV) was decreased (27.5%). The ER alpha inactivation-related effects were compared with those of controls having a similar genetic background. Parental osteocalcin-Cre mice did not show Cre-related changes. Our results suggest that in female mice, Tb.BV and cortical bone volume are critically dependent on the ER alpha regulation of osteoblasts, whereas in male mice, osteoblastic ER alpha is not required for the regulation of bone formation during rapid skeletal growth, but it is involved in the maintenance of Tb.BV.-Maatta, J. A., Buki, K. G., Gu, G., Alanne, M. H., Vaaraniemi, J., Liljenback, H., Poutanen, M., Harkonen, P., Vaananen, K. Inactivation of estrogen receptor alpha in bone-forming cells induces bone loss in female mice. FASEB J. 27, 478-488 (2013). www.fasebj.org	[Maatta, Jorma A.; Buki, Kalman G.; Gu, Guoliang; Alanne, Maria H.; Vaaraniemi, Jukka; Harkonen, Pirkko; Vaananen, Kalervo] Univ Turku, Dept Cell Biol & Anat, FI-20520 Turku, Finland; [Maatta, Jorma A.; Liljenback, Heidi; Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, FI-20520 Turku, Finland; [Liljenback, Heidi; Poutanen, Matti] Univ Turku, Dept Physiol, FI-20520 Turku, Finland	University of Turku; University of Turku; University of Turku	Maatta, JA (corresponding author), Univ Turku, Dept Cell Biol & Anat, Inst Biomed, FI-20520 Turku, Finland.	jmaatta@utu.fi	Alanne, Maria/F-2500-2013; Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734; Liljenback, Heidi/0000-0001-9372-1584; Maatta, Jorma/0000-0001-8752-6862; Alanne, Maria/0000-0003-0405-7496	Finnish Funding Agency for Technology and Innovation; Academy of Finland; Sigrid Juselius Foundation	Finnish Funding Agency for Technology and Innovation(Finnish Funding Agency for Technology & Innovation (TEKES)); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation)	The authors thank Tommi Kauko for statistical analysis, Dr. Kaisa Ivaska for fruitful discussions, and Anu Salminen, Liudmila Shumskaya, Natalia Habilainen-Kirillov, Soili Jussila, and Jani Seppanen for their excellent technical help. The ER alpha<SUP>L2/L2</SUP> mice were a generous gift from Prof. Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Sante et de la Recherche Medicale/Universite Louis Pasteur, College de France, Illkirch, France), and the osteocalcin-Cre mice were provided by Prof. Thomas Clemens (Johns Hopkins University School of Medicine, Baltimore, MD, USA). This work was supported by grants from the Finnish Funding Agency for Technology and Innovation, the Academy of Finland, and the Sigrid Juselius Foundation. The authors declare no conflicts of interests.	Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200; Alatalo SL, 2000, CLIN CHEM, V46, P1751; Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017; Borjesson AE, 2010, J BONE MINER RES, V25, P2414, DOI 10.1002/jbmr.156; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Callewaert F, 2010, J BONE MINER RES, V25, P617, DOI 10.1359/jbmr.090828; Callewaert F, 2009, FASEB J, V23, P232, DOI 10.1096/fj.08-113456; Dupont S, 2000, DEVELOPMENT, V127, P4277; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; Falahati-Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Frank GR, 2003, MED PEDIATR ONCOL, V41, P217, DOI 10.1002/mpo.10340; Frenkel B, 1997, ENDOCRINOLOGY, V138, P2109, DOI 10.1210/en.138.5.2109; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367; Jessop HL, 2004, J BONE MINER RES, V19, P938, DOI 10.1359/jbmr.2004.19.6.938; Kallio A, 2008, MOL CELL ENDOCRINOL, V289, P38, DOI 10.1016/j.mce.2008.03.005; Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984; Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a; LIAN JB, 1993, J CELL BIOCHEM, V52, P206, DOI 10.1002/jcb.240520212; Lindberg MK, 2001, J ENDOCRINOL, V171, P425, DOI 10.1677/joe.0.1710425; Lindberg MK, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740167; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Martin-Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009-0354; Modder UI, 2012, J CELL BIOCHEM, V113, P2248, DOI 10.1002/jcb.24095; Moverare S, 2003, P NATL ACAD SCI USA, V100, P13573, DOI 10.1073/pnas.2233084100; Mueller MB, 2008, ARTHRITIS RHEUM-US, V58, P1377, DOI 10.1002/art.23370; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117; Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509; Parikka V, 2005, EUR J ENDOCRINOL, V152, P301, DOI 10.1530/eje.1.01832; Peng ZQ, 2004, J BONE MINER RES, V19, P1320, DOI 10.1359/JBMR.040510; Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756-3282(97)00276-7; Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P155, DOI 10.1007/s00223-007-9101-6; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097; Syed FA, 2011, BONE, V49, P208, DOI 10.1016/j.bone.2011.03.771; Vanderschueren D, 1997, ENDOCRINOLOGY, V138, P2301, DOI 10.1210/en.138.6.2301; Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103; Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474; Visigalli D, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-147; Windahl SH, 2007, ENDOCRINOLOGY, V148, P5688, DOI 10.1210/en.2007-0508; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200	47	50	55	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					478	488		10.1096/fj.12-213587	http://dx.doi.org/10.1096/fj.12-213587			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23073829				2022-12-28	WOS:000314358000008
J	Snead, AN; Insel, PA				Snead, Aaron N.; Insel, Paul A.			Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts	FASEB JOURNAL			English	Article						G-protein-coupled receptors; 7-transmembrane receptors; cardiac fibrosis; thrombin; myofibroblasts	SIGNALING PATHWAYS; LIVER FIBROSIS; ANGIOTENSIN; MYOFIBROBLAST; CONTRIBUTES; RESPONSES; COLLAGEN; TARGETS; EPAC; CAMP	G-protein-coupled receptors (GPCRs) have many roles in cell regulation and are commonly used as drug targets, but the repertoire of GPCRs expressed by individual cell types has not been defined. Here we use an unbiased approach, GPCR RT-PCR array, to define the expression of nonchemosensory GPCRs by cardiac fibroblasts (CFs) isolated from Rattus norvegicus. CFs were selected because of their importance for cardiac structure and function and their contribution to cardiac fibrosis, which occurs with advanced age, after acute injury (e. g., myocardial infarction), and in disease states (e. g., diabetes mellitus, hypertension). We discovered that adult rat CFs express 190 GPCRs and that activation of protease-activated receptor 1 (PAR1), the most highly expressed receptor, raises the expression of profibrotic markers in rat CFs, resulting in a 60% increase in collagen synthesis and conversion to a profibrogenic myofibroblast phenotype. We use siRNA knockdown of PAR1 (90% decrease in mRNA) to show that the profibrotic effects of thrombin are PAR1-dependent. These findings, which define the expression of GPCRs in CFs, provide a proof of principle of an approach to discover previously unappreciated, functionally relevant GPCRs and reveal a potential role for thrombin and PAR1 in wound repair and pathophysiology of the adult heart.-Snead, A. N., Insel, P. A. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J. 26, 4540-4547 (2012). www.fasebj.org	[Snead, Aaron N.; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,MC 0636, La Jolla, CA 92093 USA.	pinsel@ucsd.edu			U.S. National Institutes of Health [2P01-HL-066941, 5T32-HL-007444, GM-68524]; University of California at San Diego Cancer Center [P30-CA-23100]; Ellison Medical Foundation; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007444, P01HL066941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM068524] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California at San Diego Cancer Center; Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health grants 2P01-HL-066941, 5T32-HL-007444, and GM-68524; University of California at San Diego Cancer Center specialized support grant P30-CA-23100; and the Ellison Medical Foundation.	Baker JE, 2009, INT J RADIAT BIOL, V85, P1089, DOI 10.3109/09553000903264473; Braun OO, 2010, J MOL CELL CARDIOL, V49, P362, DOI 10.1016/j.yjmcc.2010.05.001; Cevikbas F, 2011, EXP DERMATOL, V20, P69, DOI 10.1111/j.1600-0625.2010.01184.x; Chambers RC, 2008, BRIT J PHARMACOL, V153, pS367, DOI 10.1038/sj.bjp.0707603; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dobaczewski M, 2011, J MOL CELL CARDIOL, V51, P600, DOI 10.1016/j.yjmcc.2010.10.033; Einstein R, 2008, P NATL ACAD SCI USA, V105, P5230, DOI 10.1073/pnas.0801319105; Fiorucci S, 2004, HEPATOLOGY, V39, P365, DOI 10.1002/hep.20054; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Ghosh AK, 2012, J CELL PHYSIOL, V227, P493, DOI 10.1002/jcp.22783; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hansen A, 2007, NAT METHODS, V4, P35, DOI 10.1038/NMETH977; Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536; Insel PA, 2012, BRIT J PHARMACOL, V166, P447, DOI 10.1111/j.1476-5381.2012.01847.x; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kishi K, 1999, BRIT J PLAST SURG, V52, P579, DOI 10.1054/bjps.1999.3163; Laeremans H, 2010, CARDIOVASC RES, V87, P514, DOI 10.1093/cvr/cvq067; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Leger AJ, 2006, CIRCULATION, V114, P1070, DOI 10.1161/CIRCULATIONAHA.105.574830; Lu D, 2012, FASEB J, V26, P2580, DOI 10.1096/fj.12-204677; Moore-Morris T, 2009, MOL PHARMACOL, V75, P1108, DOI 10.1124/mol.108.054155; Obreztchikova M, 2006, J BIOL CHEM, V281, P20197, DOI 10.1074/jbc.M601859200; Oro C, 2007, PHARMACOL THERAPEUT, V113, P210, DOI 10.1016/j.pharmthera.2006.10.001; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Ozgen N, 2008, J BIOL CHEM, V283, P17009, DOI 10.1074/jbc.M709851200; Pawlinski R, 2007, CIRCULATION, V116, P2298, DOI 10.1161/CIRCULATIONAHA.107.692764; Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040; Ruster C, 2011, J AM SOC NEPHROL, V22, P1189, DOI 10.1681/ASN.2010040384; Russo A, 2009, MOL INTERV, V9, P87, DOI 10.1124/mi.9.2.8; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; Steinberg SF, 2005, MOL PHARMACOL, V67, P2, DOI 10.1124/mol.104.003103; Strande JL, 2007, BASIC RES CARDIOL, V102, P350, DOI 10.1007/s00395-007-0653-4; Sullivan BP, 2010, AM J PATHOL, V177, P2837, DOI 10.2353/ajpath.2010.100425; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vignon-Zellweger N, 2012, LIFE SCI, V91, P490, DOI 10.1016/j.lfs.2012.03.026; Yokoyama U, 2006, AM J PHYSIOL-HEART C, V290, pH1660, DOI 10.1152/ajpheart.00100.2004; Yokoyama U, 2008, P NATL ACAD SCI USA, V105, P6386, DOI 10.1073/pnas.0801490105; Zhang GQ, 2007, J AM SOC NEPHROL, V18, P846, DOI 10.1681/ASN.2006080886	41	52	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4540	4547		10.1096/fj.12-213496	http://dx.doi.org/10.1096/fj.12-213496			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22859370	Green Published			2022-12-28	WOS:000310574200016
J	Akchiche, N; Bossenmeyer-Pourie, C; Kerek, R; Martin, N; Pourie, G; Koziel, V; Helle, D; Alberto, JM; Ortiou, S; Camadro, JM; Leger, T; Gueant, JL; Daval, JL				Akchiche, Nassila; Bossenmeyer-Pourie, Carine; Kerek, Racha; Martin, Nicolas; Pourie, Gregory; Koziel, Violette; Helle, Deborah; Alberto, Jean-Marc; Ortiou, Sandrine; Camadro, Jean-Michel; Leger, Thibaut; Gueant, Jean-Louis; Daval, Jean-Luc			Homocysteinylation of neuronal proteins contributes to folate deficiency-associated alterations of differentiation, vesicular transport, and plasticity in hippocampal neuronal cells	FASEB JOURNAL			English	Article						homocysteine; apoptosis; histone deacetylases; motor proteins; aggregation	NEURAL-TUBE DEFECTS; FOLIC-ACID SUPPLEMENTATION; B-VITAMIN DEFICIENCY; METHYLENETETRAHYDROFOLATE REDUCTASE; COGNITIVE IMPAIRMENT; IN-VITRO; ALZHEIMERS-DISEASE; RANDOMIZED-TRIALS; METABOLISM; HYPERHOMOCYSTEINEMIA	Despite the key role in neuronal development of a deficit in the methyl donor folate, little is known on the underlying mechanisms. We therefore studied the consequences of folate deficiency on proliferation, differentiation, and plasticity of the rat H19-7 hippocampal cell line. Folate deficit reduced proliferation (17%) and sensitized cells to differentiation-associated apoptosis (+16%). Decreased production (-58%) of S-adenosylmethionine (the universal substrate for transmethylation reactions) and increased expression of histone deacetylases (HDAC4,6,7) would lead to epigenomic changes that may impair the differentiation process. Cell polarity, vesicular transport, and synaptic plasticity were dramatically affected, with poor neurite outgrowth (-57%). Cell treatment by an HDAC inhibitor (SAHA) led to a noticeable improvement of cell polarity and morphology, with longer processes. Increased homocysteine levels (+55%) consecutive to folate shortage produced homocysteinylation, evidenced by coimmunoprecipitations and mass spectrometry, and aggregation of motor proteins dynein and kinesin, along with functional alterations, as reflected by reduced interactions with partner proteins. Prominent homocysteinylation of key neuronal proteins and subsequent aggregation certainly constitute major adverse effects of folate deficiency, affecting normal development with possible long-lasting consequences.-Akchiche, N., Bossenmeyer-Pourie, C., Kerek, R., Martin, N., Pourie, G., Koziel, V., Helle, D., Alberto, J.-M., Ortiou, S., Camadro, J.-M., Leger, T., Gueant, J.-L., Daval, J.-L. Homocysteinylation of neuronal proteins contributes to folate deficiency-associated alterations of differentiation, vesicular transport, and plasticity in hippocampal neuronal cells. FASEB J. 26, 3980-3992 (2012). www.fasebj.org	[Daval, Jean-Luc] Inserm U954, Fac Med, F-54500 Vandoeuvre Les Nancy, France; [Akchiche, Nassila; Bossenmeyer-Pourie, Carine; Kerek, Racha; Martin, Nicolas; Pourie, Gregory; Koziel, Violette; Helle, Deborah; Alberto, Jean-Marc; Ortiou, Sandrine; Gueant, Jean-Louis; Daval, Jean-Luc] Univ Lorraine, Fac Med, Vandoeuvre Les Nancy, France; [Gueant, Jean-Louis] Inst Res Mental Retardat & Brain Aging, Oasi Maria SS, IRCCS, Troina, Italy; [Camadro, Jean-Michel; Leger, Thibaut] Univ Paris Diderot, CNRS, Inst Jacques Monod, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Universite de Lorraine; IRCCS Oasi Maria SS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Daval, JL (corresponding author), Inserm U954, Fac Med, 9 Ave Foret Haye, F-54500 Vandoeuvre Les Nancy, France.	jean-luc.daval@inserm.fr	Bossenmeyer-Pourié, Carine/F-7695-2019; Daval, Jean-Luc/G-6502-2014; Léger, Thibaut/GPP-5828-2022	Bossenmeyer-Pourié, Carine/0000-0003-3831-4809; Kerek, Racha/0000-0003-0159-5993; Leger, Thibaut/0000-0002-6304-3433; Camadro, Jean-Michel/0000-0002-8549-2707	French National Agency for Research [Agence Nationale de la Recherche (ANR) Nutrivigene]; Institut National de la Sante et de la Recherche Medicale; Region Lorraine	French National Agency for Research [Agence Nationale de la Recherche (ANR) Nutrivigene](French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Region Lorraine(Region Grand-Est)	The study was supported by a grant from the French National Agency for Research [Agence Nationale de la Recherche (ANR) Nutrivigene]. N.A. is indebted to the Institut National de la Sante et de la Recherche Medicale and the Region Lorraine for financial support.	Akchiche N, 2010, HIPPOCAMPUS, V20, P949, DOI 10.1002/hipo.20690; Amouzou EK, 2004, AM J CLIN NUTR, V79, P619; Andrabi S, 2007, P NATL ACAD SCI USA, V104, P19011, DOI 10.1073/pnas.0706696104; Balk EM, 2007, ARCH INTERN MED, V167, P21, DOI 10.1001/archinte.167.1.21; Battaglia-Hsu SF, 2009, P NATL ACAD SCI USA, V106, P21930, DOI 10.1073/pnas.0811794106; Bjorklund NK, 2006, INT J DEV BIOL, V50, P135, DOI 10.1387/ijdb.052102nb; Blaise S, 2005, PEDIATR RES, V57, P777, DOI 10.1203/01.PDR.0000161406.19231.98; Blaise SA, 2007, AM J PATHOL, V170, P667, DOI 10.2353/ajpath.2007.060339; Bourne JN, 2008, ANNU REV NEUROSCI, V31, P47, DOI 10.1146/annurev.neuro.31.060407.125646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chery C, 2002, CLIN CHEM LAB MED, V40, P1105, DOI 10.1515/CCLM.2002.193; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Coppede F, 2010, CURR GENOMICS, V11, P246, DOI 10.2174/138920210791233090; Daval JL, 2009, P NATL ACAD SCI USA, V106, pE1, DOI 10.1073/pnas.0809217106; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; Ellinson M, 2004, J HUM NUTR DIET, V17, P371, DOI 10.1111/j.1365-277X.2004.00532.x; Eves EM, 1996, J NEUROCHEM, V67, P1908; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Farias GG, 2009, J BIOL CHEM, V284, P15857, DOI 10.1074/jbc.M808986200; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hirabayashi Y, 2010, NAT REV NEUROSCI, V11, P377, DOI 10.1038/nrn2810; Howell JM, 2006, PROTEOMICS, V6, P2050, DOI 10.1002/pmic.200500517; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Hubmacher D, 2010, J BIOL CHEM, V285, P1188, DOI 10.1074/jbc.M109.021246; Jakubowski H, 2008, FASEB J, V22, P4071, DOI 10.1096/fj.08-112086; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; Kruman II, 2005, NEUROREPORT, V16, P1055, DOI 10.1097/00001756-200507130-00005; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Mattson MP, 1999, J NEUROSCI RES, V57, P577, DOI 10.1002/(SICI)1097-4547(19990901)57:5<577::AID-JNR1>3.0.CO;2-H; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; McMillen IC, 2008, BASIC CLIN PHARMACOL, V102, P82, DOI 10.1111/j.1742-7843.2007.00188.x; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Obeid R, 2007, CLIN CHEM LAB MED, V45, P1590, DOI 10.1515/CCLM.2007.356; Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088; Oliver M H, 2007, Soc Reprod Fertil Suppl, V64, P397; Paoli P, 2010, J MOL BIOL, V400, P889, DOI 10.1016/j.jmb.2010.05.039; Perna AF, 2006, KIDNEY INT, V69, P869, DOI 10.1038/sj.ki.5000070; Petralia RS, 2005, MOL CELL NEUROSCI, V29, P436, DOI 10.1016/j.mcn.2005.03.013; Pitkin RM, 2007, AM J CLIN NUTR, V85, p285S, DOI 10.1093/ajcn/85.1.285S; Ren D, 2009, ANAL BIOCHEM, V392, P12, DOI 10.1016/j.ab.2009.05.018; Schlager MA, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-25; Serra E, 2008, NAT CLIN PRACT NEURO, V4, P594, DOI 10.1038/ncpneuro0936; Sibrian-Vazquez M, 2010, P NATL ACAD SCI USA, V107, P551, DOI 10.1073/pnas.0909737107; Stroylova YY, 2011, BBA-PROTEINS PROTEOM, V1814, P1234, DOI 10.1016/j.bbapap.2011.05.017; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Troen AM, 2008, P NATL ACAD SCI USA, V105, P12474, DOI 10.1073/pnas.0805350105; van der Put NMJ, 2001, EXP BIOL MED, V226, P243, DOI 10.1177/153537020122600402; Wald DS, 2010, AM J MED, V123, P522, DOI 10.1016/j.amjmed.2010.01.017; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yu IT, 2009, NEUROPHARMACOLOGY, V56, P473, DOI 10.1016/j.neuropharm.2008.09.019; Zhang XM, 2008, J NUTR SCI VITAMINOL, V54, P353, DOI 10.3177/jnsv.54.353	56	55	55	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2012	26	10					3980	3992		10.1096/fj.12-205757	http://dx.doi.org/10.1096/fj.12-205757			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22713523				2022-12-28	WOS:000309704000006
J	Krishnamurthy, N; Hu, YD; Siedlak, S; Doughman, YQ; Watanabe, M; Montano, MM				Krishnamurthy, Nirmala; Hu, Yanduan; Siedlak, Sandra; Doughman, Yong Qiu; Watanabe, Michiko; Montano, Monica M.			Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis	FASEB JOURNAL			English	Article						aromatase; hyperplasia; oxidative DNA damage	ESTROGEN-RECEPTOR-BETA; BREAST-CANCER CELLS; SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; TRANSGENIC MICE; ER-BETA; AROMATASE CYTOCHROME-P450; DNA-DAMAGE; HYPERPLASIA; APOPTOSIS	We have previously shown that estrogen receptor beta (ER beta)-mediated up-regulation of quinone reductase (QR) is involved in the protection against estrogen-induced mammary tumorigenesis. Our present study provides evidence that the ER beta agonist, 2,3-bis-(4-hydroxy-phenyl)-propionitrile (DPN), and the selective estrogen receptor modulator tamoxifen (Tam), inhibit estrogen-induced DNA damage and mammary tumorigenesis in the aromatase transgenic (Arom) mouse model. We also show that either DPN or Tam treatment increases QR levels and results in a decrease in ductal hyperplasia, proliferation, oxidative DNA damage (ODD), and an increase in apoptosis. To corroborate the role of QR, we provide additional evidence in triple transgenic MMTV/QR/Arom mice, wherein the QR expression is induced in the mammary glands via doxycycline, causing a decrease in ductal hyperplasia and ODD. Overall, we provide evidence that up-regulation of QR through induction by Tam or DPN can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a novel mechanism of prevention against breast cancer. Thus, our data have important clinical implications in the management of breast cancer; our findings bring forth potentially new therapeutic strategies involving ER beta agonists. Krishnamurthy, N., Hu, Y., Siedlak, S., Doughman, Y. Q., Watanabe, M., Montano, M. M. Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis. FASEB J. 26, 3993-4002 (2012). www.fasebj.org	[Montano, Monica M.] Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; [Doughman, Yong Qiu; Watanabe, Michiko] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Siedlak, Sandra] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu			U.S. Department of Defense Breast Cancer Postdoctoral award [BC087610]; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	U.S. Department of Defense Breast Cancer Postdoctoral award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a U.S. Department of Defense Breast Cancer Postdoctoral award (BC087610) to N.K. The authors thank Dr. Rajeswar Tekmal (University of Texas Health Science Center, San Antonio, TX, USA) for providing the transgenic Arom mice.	Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Cushman M, 2003, BRIT J HAEMATOL, V120, P109, DOI 10.1046/j.1365-2141.2003.03976.x; Cuzick J, 2007, JNCI-J NATL CANCER I, V99, P272, DOI 10.1093/jnci/djk049; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157; Iskander K, 2005, CHEM-BIOL INTERACT, V153, P147, DOI 10.1016/j.cbi.2005.03.019; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Kirma N, 2001, CANCER RES, V61, P1910; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lu B, 2000, J MOL ENDOCRINOL, V25, P229, DOI 10.1677/jme.0.0250229; Mandava U, 2001, J STEROID BIOCHEM, V79, P27, DOI 10.1016/S0960-0760(01)00133-9; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Miller WR, 1997, J STEROID BIOCHEM, V61, P193; Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nair HB, 2011, STEROIDS, V76, P792, DOI 10.1016/j.steroids.2011.02.038; O'Regan RM, 1998, JNCI-J NATL CANCER I, V90, P1552, DOI 10.1093/jnci/90.20.1552; Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3; Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016; Schafer JM, 2000, CLIN CANCER RES, V6, P4373; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sollner S, 2009, FEMS YEAST RES, V9, P885, DOI 10.1111/j.1567-1364.2009.00546.x; Sripathy SP, 2008, ONCOGENE, V27, P6376, DOI 10.1038/onc.2008.235; Tekmal RR, 2005, J STEROID BIOCHEM, V95, P9, DOI 10.1016/j.jsbmb.2005.04.007; Tekmal RR, 1996, CANCER RES, V56, P3180; Tekmal RR, 1999, ENDOCR-RELAT CANCER, V6, P307, DOI 10.1677/erc.0.0060307; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Walf AA, 2008, BEHAV NEUROSCI, V122, P974, DOI 10.1037/a0012749; Weiser MJ, 2009, ENDOCRINOLOGY, V150, P1817, DOI 10.1210/en.2008-1355; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	48	2	2	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2012	26	10					3993	4002		10.1096/fj.12-208330	http://dx.doi.org/10.1096/fj.12-208330			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	018YM	22700872	Green Published			2022-12-28	WOS:000309704000007
J	Mohammad, I; Arora, PD; Naghibzadeh, Y; Wang, YQ; Li, J; Mascarenhas, W; Janmey, PA; Dawson, JF; McCulloch, CA				Mohammad, Ibrahim; Arora, Pamma D.; Naghibzadeh, Yeganeh; Wang, Yongqiang; Li, Jeff; Mascarenhas, Wendall; Janmey, Paul A.; Dawson, John F.; McCulloch, Christopher A.			Flightless I is a focal adhesion-associated actin-capping protein that regulates cell migration	FASEB JOURNAL			English	Article						connective tissue; actin-binding proteins; wound healing; collagen; integrins; vinculin	LEUCINE-RICH REPEAT; COLLAGEN PHAGOCYTOSIS; INTERFERENCE-REFLECTION; BINDING PROTEIN; GELSOLIN-LIKE; FIBROBLASTS; FILAMIN; ACTIVATION; INTEGRINS; TALIN	The role of adhesion-associated actin-binding proteins in cell migration is not well defined. In mouse fibroblasts we screened for focal adhesion-associated proteins that were isolated with collagen-coated beads and detected by tandem mass spectrometry. We identified flightless I (FliI) as an actin-binding protein in focal adhesion fractions, which was verified by immuno-blotting. By confocal microscopy most FliI was distributed throughout the cytosol and in focal adhesions. By sedimentation assays and in vitro binding assays, we found that FliI associates with actin filaments and actin monomers. Assays using purified proteins showed that FliI inhibits actin polymerization and caps but does not sever actin filaments. Cells with FliI knockdown or cells overexpressing FliI migrated more or less rapidly, respectively, than wild-type controls. Compared with controls, cells with FliI knockdown were less adherent than wild-type cells, exhibited reduced numbers of focal adhesions containing activated beta 1 integrins and vinculin, and exhibited increased incorporation of actin monomers into nascent filaments at focal adhesions. These data indicate that FliI regulates cell migration through its localization to focal adhesions and its ability to cap actin filaments, which collectively affect focal adhesion maturation.-Mohammad, I., Arora, P. D., Naghibzadeh, Y., Wang, Y., Li, J., Mascarenhas, W., Janmey, P. A., Dawson, J. F., McCulloch, C. A. Flightless I is a focal adhesion-associated actin-capping protein that regulates cell migration. FASEB J. 26, 3260-3272 (2012). www.fasebj.org	[Mohammad, Ibrahim; Arora, Pamma D.; Naghibzadeh, Yeganeh; Wang, Yongqiang; Li, Jeff; Mascarenhas, Wendall; McCulloch, Christopher A.] Univ Toronto, Matrix Dynam Grp, Toronto, ON M5S 3E2, Canada; [Janmey, Paul A.] Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; [Dawson, John F.] Univ Guelph, Guelph, ON N1G 2W1, Canada	University of Toronto; University of Pennsylvania; Pennsylvania Medicine; University of Guelph	McCulloch, CA (corresponding author), Univ Toronto, Matrix Dynam Grp, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca	Dawson, John/HDM-6702-2022		Canadian Institutes of Health Research operating grant [MOP-36322]; Ontario Heart and Stroke Foundation grant [T-6022]; Canada Research Chair	Canadian Institutes of Health Research operating grant(Canadian Institutes of Health Research (CIHR)); Ontario Heart and Stroke Foundation grant; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by Canadian Institutes of Health Research operating grant MOP-36322 and Ontario Heart and Stroke Foundation grant T-6022 to C.A.M., who is also supported by a Canada Research Chair (tier 1). Mouse FliI cDNA was provided by Dr. J. Yuan (Department of Cell Biology, Harvard Medical School, Boston, MA, USA).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Abreu MTH, 2008, AM J PHYSIOL-CELL PH, V294, pC931, DOI 10.1152/ajpcell.00359.2007; Adams DH, 2008, INT J BIOCHEM CELL B, V40, P1555, DOI 10.1016/j.biocel.2007.11.024; Alberts B., 2008, MOL BIOL CEL, V5th ed.; ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Arora PD, 2008, MOL BIOL CELL, V19, P5032, DOI 10.1091/mbc.E08-04-0430; Arora PD, 2004, MOL BIOL CELL, V15, P588, DOI 10.1091/mbc.E03-07-0468; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; AXELROD D, 1976, P NATL ACAD SCI USA, V73, P4594, DOI 10.1073/pnas.73.12.4594; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; Chong SAC, 2007, J BIOL CHEM, V282, P8510, DOI 10.1074/jbc.M609859200; Cowin AJ, 2007, J PATHOL, V211, P572, DOI 10.1002/path.2143; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Darzynkiewicz Zbigniew, 2004, Curr Protoc Immunol, VChapter 5, DOI 10.1002/0471142735.im0507s60; Davy DA, 2001, J CELL SCI, V114, P549; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Dzamba B. J., 2001, CELL ADHESION INTEGR; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Glogauer M, 1997, J CELL SCI, V110, P11; Goshima M, 1999, BIOCHEM BIOPH RES CO, V257, P111, DOI 10.1006/bbrc.1999.0420; HEATH JP, 1978, J CELL SCI, V29, P197; Higashi T, 2010, J BIOL CHEM, V285, P16231, DOI 10.1074/jbc.M109.079236; IZZARD CS, 1976, J CELL SCI, V21, P129; JACOBSON K, 1984, P NATL ACAD SCI-BIOL, V81, P6747, DOI 10.1073/pnas.81.21.6747; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Kim H, 2008, EXP CELL RES, V314, P834, DOI 10.1016/j.yexcr.2007.11.022; Kim H, 2010, EXP CELL RES, V316, P1829, DOI 10.1016/j.yexcr.2010.02.007; Kim H, 2010, AM J PHYSIOL-CELL PH, V298, pC221, DOI 10.1152/ajpcell.00323.2009; Kligys K, 2009, J INVEST DERMATOL, V129, P1856, DOI 10.1038/jid.2009.171; Kopecki Z, 2011, J INVEST DERMATOL, V131, P1450, DOI 10.1038/jid.2011.69; Kopecki Z, 2009, J INVEST DERMATOL, V129, P2031, DOI 10.1038/jid.2008.461; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Li JY, 2008, J CELL BIOL, V181, P321, DOI 10.1083/jcb.200711082; Liu YT, 1998, J BIOL CHEM, V273, P7920, DOI 10.1074/jbc.273.14.7920; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Morrison SS, 2007, ANAL BIOCHEM, V364, P159, DOI 10.1016/j.ab.2007.02.027; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pedersen SF, 1999, EXP CELL RES, V252, P63, DOI 10.1006/excr.1999.4615; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Porter KE, 2009, PHARMACOL THERAPEUT, V123, P255, DOI 10.1016/j.pharmthera.2009.05.002; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Vicente-Manzanares M, 2009, J CELL SCI, V122, P199, DOI 10.1242/jcs.018564; Wang Q, 2009, J BIOL CHEM, V284, P20763, DOI 10.1074/jbc.M808828200; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; Yuen A, 2010, MATRIX BIOL, V29, P537, DOI 10.1016/j.matbio.2010.04.004; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765; Ziegler WH, 2008, BIOCHEM SOC T, V36, P235, DOI 10.1042/BST0360235	61	23	24	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3260	3272		10.1096/fj.11-202051	http://dx.doi.org/10.1096/fj.11-202051			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22581781				2022-12-28	WOS:000307162800017
J	Twohig, JP; Marsden, M; Cuff, SM; Ferdinand, JR; Gallimore, AM; Perks, WV; Al-Shamkhani, A; Humphreys, IR; Wang, ECY				Twohig, Jason P.; Marsden, Morgan; Cuff, Simone M.; Ferdinand, John R.; Gallimore, Awen M.; Perks, William V.; Al-Shamkhani, Aymen; Humphreys, Ian R.; Wang, Eddie C. Y.			The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4(+) and CD8(+) T-cell immunity	FASEB JOURNAL			English	Article						murine cytomegalovirus; vaccinia virus	MURINE CYTOMEGALOVIRUS-INFECTION; DOMAIN-CONTAINING RECEPTOR; TUMOR-NECROSIS-FACTOR; TNF-LIKE LIGAND; ALLERGIC LUNG INFLAMMATION; LATENT INFECTION; TL1A; DR3; RESPONSES; VIRUS	Death receptor 3 (DR3, TNFRSF25), the closest family relative to tumor necrosis factor receptor 1, promotes CD4(+) T-cell-driven inflammatory disease. We investigated the in vivo role of DR3 and its ligand TL1A in viral infection, by challenging DR3-deficient (DR3(KO)) mice and their DR3(WT) littermates with the beta-herpesvirus murine cytomegalovirus or the poxvirus vaccinia virus. The phenotype and function of splenic T-cells were analyzed using flow cytometry and molecular biological techniques. We report surface expression of DR3 by naive CD8(+) T cells, with TCR activation increasing its levels 4-fold and altering the ratio of DR3 splice variants. T-cell responses were reduced up to 90% in DR3(KO) mice during acute infection. Adoptive transfer experiments indicated this was dependent on T-cell-restricted expression of DR3. DR3-dependent CD8(+) T-cell expansion was NK and CD4 independent and due to proliferation, not decreased cell death. Notably, impaired immunity in DR3(KO) hosts on a C57BL/6 background was associated with 4- to 7-fold increases in viral loads during the acute phase of infection, and in mice with suboptimal NK responses was essential for survival (37.5%). This is the first description of DR3 regulating virus-specific T-cell function in vivo and uncovers a critical role for DR3 in mediating antiviral immunity.-Twohig, J. P., Marsden, M., Cuff, S. M., Ferdinand, J. R., Gallimore, A. M., Perks, W. V., AlShamkhani, A., Humphreys, I. R., Wang, E. C. Y. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4(+) and CD8(+) T-cell immunity. FASEB J. 26, 3575-3586 (2012). www.fasebj.org	[Wang, Eddie C. Y.] Cardiff Univ, Dept Med Microbiol & Infect Dis, Inst Infect & Immun, Sch Med, Cardiff CF14 4XN, S Glam, Wales; [Ferdinand, John R.; Al-Shamkhani, Aymen] Univ Southampton, Sch Med, Southampton, Hants, England	Cardiff University; University of Southampton	Wang, ECY (corresponding author), Cardiff Univ, Dept Med Microbiol & Infect Dis, Inst Infect & Immun, Sch Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	wangec@cf.ac.uk	Humphreys, Ian/E-6683-2010	Wang, Eddie/0000-0002-2243-4964; Gallimore, Awen/0000-0001-6675-7004; Al-Shamkhani, Aymen/0000-0003-0727-4189; Humphreys, Ian/0000-0002-9512-5337; Ferdinand, John Robert/0000-0003-0936-0128	British Medical Research Council (MRC); Wellcome Trust; MRC [G0901119]; Wellcome Trust Career Development Fellowship; Biotechnology and Biological Sciences Research Council; Cancer Research UK [13211] Funding Source: researchfish; Medical Research Council [G0901119] Funding Source: researchfish	British Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Career Development Fellowship(Wellcome Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank the Central Biotechnology Service (School of Medicine, Cardiff University) for supply and access to flow cytometers. This work was supported by grant funding from the British Medical Research Council (MRC) and the Wellcome Trust. J.P.T. is funded by MRC grant G0901119 awarded to E.C.Y.W. and I. R. H. I. R. H. holds a Wellcome Trust Career Development Fellowship. S. M. C. is funded by a Biotechnology and Biological Sciences Research Council project grant.	Al-Lamki RS, 2008, J AM SOC NEPHROL, V19, P953, DOI 10.1681/ASN.2007060706; Al-Lamki RS, 2012, AM J PATHOL, V180, P1454, DOI 10.1016/j.ajpath.2012.01.003; Arens R, 2011, J IMMUNOL, V186, P3874, DOI 10.4049/jimmunol.1003231; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bamias G, 2003, J IMMUNOL, V171, P4868, DOI 10.4049/jimmunol.171.9.4868; Bamias G, 2006, P NATL ACAD SCI USA, V103, P8441, DOI 10.1073/pnas.0510903103; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOOTH TWM, 1993, ARCH VIROL, V132, P209, DOI 10.1007/BF01309855; Buchan SL, 2012, EUR J IMMUNOL, V42, P580, DOI 10.1002/eji.201041950; Bull MJ, 2008, J EXP MED, V205, P2457, DOI 10.1084/jem.20072378; Calder CJ, 2012, OCUL IMMUNOL INFLAMM, V20, P212, DOI 10.3109/09273948.2012.658135; Cavanaugh VJ, 2003, J VIROL, V77, P1703, DOI 10.1128/JVI.77.3.1703-1717.2003; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Corbett AJ, 2011, J IMMUNOL, V186, P1713, DOI 10.4049/jimmunol.1003308; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Fang L, 2008, J EXP MED, V205, P1037, DOI 10.1084/jem.20072528; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Holtappels R, 2008, J VIROL, V82, P5781, DOI 10.1128/JVI.00155-08; Humphreys IR, 2007, J IMMUNOL, V179, P2195, DOI 10.4049/jimmunol.179.4.2195; Humphreys IR, 2010, EUR J IMMUNOL, V40, P2762, DOI 10.1002/eji.200940256; Jones GW, 2011, FASEB J, V25, P409, DOI 10.1096/fj.10-166843; Kamada N, 2010, INFLAMM BOWEL DIS, V16, P568, DOI 10.1002/ibd.21124; Kang YJ, 2005, CYTOKINE, V29, P229, DOI 10.1016/j.cyto.2004.12.001; Kim S, 2005, J IMMUNOL METHODS, V298, P1, DOI 10.1016/j.jim.2004.12.019; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lathbury LJ, 1996, J GEN VIROL, V77, P2605, DOI 10.1099/0022-1317-77-10-2605; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McLaren JE, 2010, J IMMUNOL, V184, P5827, DOI 10.4049/jimmunol.0903782; Meylan F, 2011, MUCOSAL IMMUNOL, V4, P172, DOI 10.1038/mi.2010.67; Meylan F, 2008, IMMUNITY, V29, P79, DOI 10.1016/j.immuni.2008.04.021; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Moss P, 2004, HUM IMMUNOL, V65, P456, DOI 10.1016/j.humimm.2004.02.014; Muck C, 2010, J GERONTOL A-BIOL, V65, P1165, DOI 10.1093/gerona/glq129; Munks MW, 2006, J IMMUNOL, V177, P450, DOI 10.4049/jimmunol.177.1.450; Papadakis KA, 2005, J IMMUNOL, V174, P4985, DOI 10.4049/jimmunol.174.8.4985; Pappu BP, 2008, J EXP MED, V205, P1049, DOI 10.1084/jem.20071364; Pfeffer K, 2003, CYTOKINE GROWTH F R, V14, P185, DOI 10.1016/S1359-6101(03)00022-4; Pobezinskaya YL, 2011, J IMMUNOL, V186, P5212, DOI 10.4049/jimmunol.1002374; Polic B, 1998, J EXP MED, V188, P1047, DOI 10.1084/jem.188.6.1047; Prehn JL, 2007, J IMMUNOL, V178, P4033, DOI 10.4049/jimmunol.178.7.4033; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; REDDEHASE MJ, 1984, J IMMUNOL, V132, P482; Reddehase MJ, 2002, J CLIN VIROL, V25, pS23; REDDEHASE MJ, 1984, EUR J IMMUNOL, V14, P56, DOI 10.1002/eji.1830140111; Richards H, 2008, J IMMUNOL, V180, P198, DOI 10.4049/jimmunol.180.1.198; Salek-Ardakani S, 2008, J IMMUNOL, V181, P7969, DOI 10.4049/jimmunol.181.11.7969; Schreiber TH, 2010, J CLIN INVEST, V120, P3629, DOI 10.1172/JCI42933; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Simon CO, 2006, J VIROL, V80, P10436, DOI 10.1128/JVI.01248-06; Slebioda TJ, 2011, EUR J IMMUNOL, V41, P2606, DOI 10.1002/eji.201141477; Smith LM, 2008, J VIROL, V82, P6689, DOI 10.1128/JVI.00160-08; Snyder CM, 2009, J IMMUNOL, V183, P3932, DOI 10.4049/jimmunol.0900227; Su WB, 2006, EXP CELL RES, V312, P266, DOI 10.1016/j.yexcr.2005.10.015; Takedatsu H, 2008, GASTROENTEROLOGY, V135, P552, DOI 10.1053/j.gastro.2008.04.037; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Taraban VY, 2011, MUCOSAL IMMUNOL, V4, P186, DOI 10.1038/mi.2010.70; Taraban VY, 2011, J CLIN INVEST, V121, P463, DOI 10.1172/JCI45832; Twohig JP, 2010, J NEUROSCI, V30, P3782, DOI 10.1523/JNEUROSCI.1928-09.2010; Walton SM, 2008, J IMMUNOL, V181, P1128, DOI 10.4049/jimmunol.181.2.1128; Walton SM, 2011, EUR J IMMUNOL, V41, P2248, DOI 10.1002/eji.201141575; Wang ECY, 2001, MOL CELL BIOL, V21, P3451, DOI 10.1128/MCB.21.10.3451-3461.2001; Wang ECY, 2001, IMMUNOGENETICS, V53, P59, DOI 10.1007/s002510000290; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Zhao Y, 2012, IMMUNOL LETT, V141, P220, DOI 10.1016/j.imlet.2011.10.008	68	39	46	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2012	26	8					3575	3586		10.1096/fj.11-200618	http://dx.doi.org/10.1096/fj.11-200618			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22593543	Green Accepted, hybrid			2022-12-28	WOS:000307162800043
J	Thomas, CE; Gaffney-Stomberg, E; Sun, BH; O'Brien, KO; Kerstetter, JE; Insogna, KL				Thomas, Carrie E.; Gaffney-Stomberg, Erin; Sun, Ben-Hua; O'Brien, Kimberly O.; Kerstetter, Jane E.; Insogna, Karl L.			Increasing dietary protein acutely augments intestinal iron transporter expression and significantly increases iron absorption in rats	FASEB JOURNAL			English	Article						DMT1; microarray; Dcytb; IRE	NONHEME IRON; HEPCIDIN; FOOD; DEFICIENCY; NRAMP2; MICE	Iron (Fe) deficiency is endemic worldwide. Little data are available regarding acute effects of dietary protein on intestinal Fe absorption. The current study evaluated the short-term effects of increasing dietary protein on Fe absorption and expression of genes involved in Fe homeostasis. Sprague Dawley rats (24, female) were randomly assigned to custom-formulated isocaloric diets containing 40, 20 (control), or 5% protein (as percentage of total kilocalories) for 7 d. Whole-body Fe balance studies demonstrated that Fe retention was greater in the 40% group than in the 5% group (30.8 vs. 7.3%; P<0.01). In a separate study utilizing stable iron isotopes, the 40% group absorbed 30% of ingested Fe, while the 20% group absorbed 18% (P=0.005). Whole-genome profiling revealed that increasing dietary protein from 5 to 40% increased duodenal transcript expression of divalent metal transporter 1 (DMT1) 3.2-fold, duodenal cytochrome b (Dcytb) 1.8-fold, and transferrin receptor (TfR) 1.8-fold. Consistent with these findings, DMT1 transcript expression was 4-fold higher in RNA prepared from duodenal mucosa in the 40% group compared to the 20% group (P<0.001). These data suggest that increasing dietary protein increases intestinal Fe absorption in part by up-regulating DMT1, Dcytb, and TfR.-Thomas, C. E., Gaffney-Stomberg, E., Sun, B.-H., O'Brien, K. O., Kerstetter, J. E., Insogna, K. L. Increasing dietary protein acutely augments intestinal iron transporter expression and significantly increases iron absorption in rats.	[Thomas, Carrie E.] Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA; [Kerstetter, Jane E.] Univ Connecticut, Dept Allied Hlth Sci, Storrs, CT 06269 USA; [Gaffney-Stomberg, Erin] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA; [Sun, Ben-Hua; Insogna, Karl L.] Yale Univ, Dept Internal Med Endocrinol, New Haven, CT USA; [O'Brien, Kimberly O.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of Connecticut; University of Connecticut; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yale University; Cornell University	Thomas, CE (corresponding author), Univ Connecticut, Dept Allied Hlth Sci, 358 Mansfield Rd,Unit 1101, Storrs, CT 06269 USA.	carrie.cucchi@yale.edu	Gaffney-Stomberg, Erin/Y-1016-2018; Gaffney-Stomberg, Erin/AAT-8826-2020	Gaffney-Stomberg, Erin/0000-0002-0241-2282; Gaffney-Stomberg, Erin/0000-0002-0241-2282; Insogna, Karl/0000-0001-6973-5679	Yale Bone Center; University of Connecticut	Yale Bone Center; University of Connecticut	C.T., E.G.-S., K.O., J.K., and K.I., designed the research; C.T. and E.G.-S. conducted the research; E.G.-S. conducted the microarray screen; C.T., E.G.-S., and K.I. analyzed the data; C.T. and K.I. wrote the paper; and J.K. and K.I. had responsibility for the final content. All authors read and approved the final manuscript. The authors thank Gang-Qing Yao for assistance with the isoform-specific qPCR analysis, Tera Kent for assistance with the mass spectrometry analyses, and Heidi Vogeli and Stacey Brown for technical assistance with the oral gavage studies. This project was funded by the Yale Bone Center and by a Hatch grant from the University of Connecticut. The authors report no conflicts of interest.	Aisen P, 2004, INT J BIOCHEM CELL B, V36, P2137, DOI 10.1016/j.biocel.2004.02.007; Ammann P, 2000, J BONE MINER RES, V15, P683, DOI 10.1359/jbmr.2000.15.4.683; Argyri K, 2007, J AGR FOOD CHEM, V55, P10221, DOI 10.1021/jf0727387; Argyri K, 2009, J AGR FOOD CHEM, V57, P1538, DOI 10.1021/jf802877n; BALLOT D, 1987, BRIT J NUTR, V57, P331, DOI 10.1079/BJN19870041; BJORNRASMUSSEN E, 1974, NUTR METAB, V16, P94; Bouhallab S, 2002, J AGR FOOD CHEM, V50, P7127, DOI 10.1021/jf025554v; Chaud MV, 2002, J AGR FOOD CHEM, V50, P871, DOI 10.1021/jf0111312; COOK JD, 1976, AM J CLIN NUTR, V29, P859, DOI 10.1093/ajcn/29.8.859; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gaffney-Stomberg E., ENDOCRINOLOGY, V151, P1071; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HURRELL RF, 1989, AM J CLIN NUTR, V49, P546, DOI 10.1093/ajcn/49.3.546; KAPSOKEFALOU M, 1991, J FOOD SCI, V56, P352, DOI 10.1111/j.1365-2621.1991.tb05278.x; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P571, DOI 10.1007/s00424-003-1141-9; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; National Research Council, 1995, NUTR REQ LAB AN; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Peres JM, 1999, J NUTR BIOCHEM, V10, P215, DOI 10.1016/S0955-2863(98)00101-6; Probst RJ, 2006, J AM ASSOC LAB ANIM, V45, P49; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Young MF, 2009, AM J CLIN NUTR, V89, P533, DOI 10.3945/ajcn.2008.26589	27	8	8	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2013	27	6					2476	2483		10.1096/fj.12-221945	http://dx.doi.org/10.1096/fj.12-221945			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23447582				2022-12-28	WOS:000319667600035
J	Delhanty, PJD; Huisman, M; Baldeon-Rojas, LY; van den Berge, I; Grefhorst, A; Abribat, T; Leenen, PJM; Themmen, APN; van der Lely, AJ				Delhanty, Patric J. D.; Huisman, Martin; Baldeon-Rojas, Lucy Y.; van den Berge, Iris; Grefhorst, Aldo; Abribat, Thierry; Leenen, Pieter J. M.; Themmen, Axel P. N.; van der Lely, Aart-Jan			Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis	FASEB JOURNAL			English	Article						obesity; insulin resistance; inflammation	BROWN ADIPOSE-TISSUE; MESSENGER-RNA EXPRESSION; UNACYLATED GHRELIN; GROWTH-HORMONE; INSULIN SENSITIVITY; INDUCED OBESITY; FOOD-INTAKE; T-CELLS; MICE; THERMOGENESIS	There is clinical evidence that des-acyl ghrelin (DAG) favorably modulates glucose and lipid metabolism, although its mode of action is unknown. A murine model of prediabetes was used to assess possible mechanisms of action for DAG and a newly developed bioactive analog, AZP531. C57BL/6J mice were infused with saline, DAG, or AZP531 continuously for 4 wk, and fed either normal diet (ND) or normal diet for 2 wk followed by a high-fat diet (HFD) for 2 wk. Compared with mice in the ND group, HFD increased body and fat mass, caused glucose intolerance and insulin resistance, had proinflammatory effects in white adipose tissue, and caused lipid accumulation in brown adipose tissue. DAG and AZP531 treatment prevented HFD-induced proinflammatory effects, stimulated expression of mitochondrial function markers in brown adipose tissue, and prevented development of a prediabetic metabolic state. AZP531 also prevented a HFD-induced increase in acyl ghrelin levels. Our data indicate DAG analogs as potential treatment for the prevention of metabolic syndrome.-Delhanty, P. J. D., Huisman, M., Baldeon-Rojas, L.Y., van den Berge, I., Grefhorst, A., Abribat, T., Leenen, P. J. M., Themmen, A. P. N., van der Lely, A.-J. Des-acyl ghrelin analogs prevent high-fat diet-induced dysregulation of glucose homeostasis. FASEB J. 27, 1690-1700 (2013). www.fasebj.org	[Delhanty, Patric J. D.; Huisman, Martin; van den Berge, Iris; Grefhorst, Aldo; Themmen, Axel P. N.; van der Lely, Aart-Jan] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; [Baldeon-Rojas, Lucy Y.; Leenen, Pieter J. M.] Erasmus MC, Dept Immunol, NL-3000 CA Rotterdam, Netherlands; [Abribat, Thierry] Alize Pharma, Ecully, France	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Delhanty, PJD (corresponding author), Erasmus MC, Dept Internal Med, Rm Ee532,POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.delhanty@erasmusmc.nl	Leenen, Pieter JM/I-5839-2013; Baldeon, Lucy/AAE-6323-2022	Leenen, Pieter JM/0000-0001-9860-2920; Baldeon, Lucy/0000-0002-0447-0136				Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; Anderson EK, 2010, CURR OPIN LIPIDOL, V21, P172, DOI 10.1097/MOL.0b013e3283393867; Asakawa A, 2005, GUT, V54, P18, DOI 10.1136/gut.2004.038737; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Barazzoni R, 2007, J CLIN ENDOCR METAB, V92, P3935, DOI 10.1210/jc.2006-2527; Barnett BP, 2010, SCIENCE, V330, P1689, DOI 10.1126/science.1196154; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Benso A, 2012, EUR J ENDOCRINOL, V166, P911, DOI 10.1530/EJE-11-0982; Bluher S, 2005, BEST PRACT RES CL EN, V19, P577, DOI 10.1016/j.beem.2005.07.011; Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003-031964; Buysschaert M, 2011, MED CLIN N AM, V95, P289, DOI 10.1016/j.mcna.2010.11.002; Cederberg H, 2012, CLIN ENDOCRINOL, V76, P39, DOI 10.1111/j.1365-2265.2011.04135.x; Colagiuri S, 2011, MED CLIN N AM, V95, P299, DOI 10.1016/j.mcna.2010.11.003; Delhanty PJD, 2011, PEPTIDES, V32, P2309, DOI 10.1016/j.peptides.2011.03.001; Delhanty PJD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011749; Dixit VD, 2005, EXP GERONTOL, V40, P900, DOI 10.1016/j.exger.2005.09.003; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Fujisaka S, 2009, DIABETES, V58, P2574, DOI 10.2337/db08-1475; Garcia B, 2002, AM J PHYSIOL-CELL PH, V282, pC105, DOI 10.1152/ajpcell.01396.2000; Gauna C, 2004, J CLIN ENDOCR METAB, V89, P5035, DOI 10.1210/jc.2004-0363; Granata R, 2012, J MED CHEM, V55, P2585, DOI 10.1021/jm201223m; Guo S, 2009, MOL CELL BIOL, V29, P5070, DOI 10.1128/MCB.00138-09; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Hamdy O, 2006, CURR DIABETES REV, V2, P367, DOI 10.2174/1573399810602040367; Hattori N, 2001, J CLIN ENDOCR METAB, V86, P4284, DOI 10.1210/jc.86.9.4284; Hayashi T, 2008, DIABETES, V57, P1269, DOI 10.2337/db07-1378; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Julien M, 2012, EUR J PHARM SCI, V47, P625, DOI 10.1016/j.ejps.2012.07.014; Kellokoski E, 2009, PEPTIDES, V30, P2292, DOI 10.1016/j.peptides.2009.09.008; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Leonie E, 2012, ENDOCRINOLOGY, V153, P2861, DOI 10.1210/en.2011-1754; Lidell ME, 2010, NAT REV ENDOCRINOL, V6, P319, DOI 10.1038/nrendo.2010.64; Loomans CJM, 2009, MOL MED, V15, P152, DOI 10.2119/molmed.2009.00032; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2007, AM J PHYSIOL-ENDOC M, V292, pE166, DOI 10.1152/ajpendo.00284.2006; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Mack CM, 2006, INT J OBESITY, V30, P1332, DOI 10.1038/sj.ijo.0803284; Mano-Otagiri A, 2010, REGUL PEPTIDES, V160, P81, DOI 10.1016/j.regpep.2009.11.010; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Perreault M, 2004, INT J OBESITY, V28, P879, DOI 10.1038/sj.ijo.0802640; Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106; Ravussin E, 2011, ANNU REV NUTR, V31, P33, DOI 10.1146/annurev-nutr-072610-145209; Sears DD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007250; Souza-Moreira L, 2011, NEUROENDOCRINOLOGY, V94, P89, DOI 10.1159/000328636; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Sutherland LN, 2008, AM J PHYSIOL-ENDOC M, V295, pE1076, DOI 10.1152/ajpendo.90408.2008; Szayna M, 2000, ENDOCRINOLOGY, V141, P1936, DOI 10.1210/en.141.6.1936; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tsubone T, 2005, REGUL PEPTIDES, V130, P97, DOI 10.1016/j.regpep.2005.04.004; van der Lely AJ, 2007, MOL CELL ENDOCRINOL, V274, P30, DOI 10.1016/j.mce.2006.05.010; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wadden D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045748; Whittle AJ, 2012, CELL, V149, P871, DOI 10.1016/j.cell.2012.02.066; Wu QW, 2006, DIABETES, V55, P3229, DOI 10.2337/db06-0749; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; Yi CX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032100; Zhang WZ, 2008, ENDOCRINOLOGY, V149, P4710, DOI 10.1210/en.2008-0263; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107	62	58	59	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2013	27	4					1690	1700		10.1096/fj.12-221143	http://dx.doi.org/10.1096/fj.12-221143			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23299855				2022-12-28	WOS:000316940800038
J	Cimino, D; De Pitta, C; Orso, F; Zampini, M; Casara, S; Penna, E; Quaglino, E; Forni, M; Damasco, C; Pinatel, E; Ponzone, R; Romualdi, C; Brisken, C; De Bortoli, M; Biglia, N; Provero, P; Lanfranchi, G; Taverna, D				Cimino, Daniela; De Pitta, Cristiano; Orso, Francesca; Zampini, Matteo; Casara, Silvia; Penna, Elisa; Quaglino, Elena; Forni, Marco; Damasco, Christian; Pinatel, Eva; Ponzone, Riccardo; Romualdi, Chiara; Brisken, Cathrin; De Bortoli, Michele; Biglia, Nicoletta; Provero, Paolo; Lanfranchi, Gerolamo; Taverna, Daniela			miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1	FASEB JOURNAL			English	Article						microRNA profiling; malignancy; mammary tumor; integrin signaling; prognosis	PHOSPHATIDYLINOSITOL 3-KINASE; PROGNOSTIC VALUE; EXPRESSION; METASTASIS; PROSTATE; INTEGRIN; GROWTH; PLOTS	Breast cancer is often fatal during its metastatic dissemination. To unravel the role of microRNAs (miRs) during malignancy, we analyzed miR expression in 77 primary breast carcinomas and identified 16 relapse-associated miRs that correlate with survival and/or distinguish tumor subtypes in different data-sets. Among them, miR-148b, down-regulated in aggressive breast tumors, was found to be a major coordinator of malignancy. In fact, it is able to oppose various steps of tumor progression when overexpressed in cell lines by influencing invasion, survival to anoikis, extravasation, lung metastasis formation, and chemotherapy response. miR-148b controls malignancy by coordinating a novel pathway involving over 130 genes and, in particular, it directly targets players of the integrin signaling, such as ITGA5, ROCK1, PIK3CA/p110 alpha, and NRAS, as well as CSF1, a growth factor for stroma cells. Our findings reveal the importance of the identified 16 miRs for disease outcome predictions and suggest a critical role for miR-148b in the control of breast cancer progression.-Cimino, D., De Pitta, C., Orso, F., Zampini, M., Casara, C., Penna, E., Quaglino, E., Forni, M., Damasco, C., Pinatel, E., Ponzone, R., Romualdi, C., Brisken, C., De Bortoli, M., Biglia, N., Provero, P., Lanfranchi, G., Taverna, D. miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 27, 1223-1235 (2013). www.fasebj.org	[Cimino, Daniela; Orso, Francesca; Penna, Elisa; Quaglino, Elena; Forni, Marco; Damasco, Christian; Pinatel, Eva; Provero, Paolo; Taverna, Daniela] Univ Turin, MBC, I-10126 Turin, Italy; [Cimino, Daniela; Orso, Francesca; Penna, Elisa; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Dept Oncol Sci, I-10126 Turin, Italy; [Cimino, Daniela; Orso, Francesca; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Ctr Mol Syst Biol, I-10126 Turin, Italy; [Quaglino, Elena] Univ Turin, Dept Clin & Biol Sci, I-10126 Turin, Italy; [Damasco, Christian; Pinatel, Eva; Provero, Paolo] Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; [Biglia, Nicoletta] Univ Turin, Dept Gynecol & Obstet, I-10126 Turin, Italy; [De Pitta, Cristiano; Zampini, Matteo; Casara, Silvia; Romualdi, Chiara; Lanfranchi, Gerolamo] Univ Padua, Dept Biol, Padua, Italy; [De Pitta, Cristiano; Zampini, Matteo; Casara, Silvia; Romualdi, Chiara; Lanfranchi, Gerolamo] Univ Padua, Ctr Biotechnol, CRIBI, Padua, Italy; [Ponzone, Riccardo] Inst Canc Res & Treatment IRCC, Candiolo, Italy; [Brisken, Cathrin] Ecole Polytech Fed Lausanne, ISREC, Natl Ctr Competence Res NCCR Mol Oncol, Sch Life Sci, CH-1015 Lausanne, Switzerland	University of Turin; University of Turin; University of Turin; University of Turin; University of Turin; University of Turin; University of Padua; University of Padua; IRCCS Fondazione del Piemonte per l'Oncologia; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Taverna, D (corresponding author), Univ Turin, MBC, Via Nizza 52, I-10126 Turin, Italy.	daniela.taverna@unito.it	taverna, daniela/J-8358-2016; Romualdi, Chiara/K-1132-2016; De Pitta, Cristiano/AAY-7302-2020; Biglia, Nicoletta/F-8801-2013; Orso, Francesca/B-1985-2014; Provero, Paolo/AAC-1930-2019; Zampini, Matteo/L-9027-2018; Ponzone, Riccardo/AAI-4612-2020; Pinatel, Eva Maria/AAC-1365-2019	taverna, daniela/0000-0002-6365-527X; Romualdi, Chiara/0000-0003-4792-9047; De Pitta, Cristiano/0000-0001-8013-8162; Biglia, Nicoletta/0000-0003-1009-5309; Zampini, Matteo/0000-0002-9952-1142; Pinatel, Eva Maria/0000-0002-2544-4594; De Bortoli, Michele/0000-0002-6666-9052; Orso, Francesca/0000-0003-4706-6464; Quaglino, Elena/0000-0002-8151-9124; Ponzone, Riccardo/0000-0002-8822-2454; Brisken, Cathrin/0000-0002-6857-3230	University of Torino; Compagnia-San-Paolo [2008.1054]; Programma di Ricerca di Rilevante Interesse Nazionale; Associazione Italiana Ricerca Cancro (AIRC) [2008-IG6014, 2009-IG-9408, 2010-IG-10104]; Fondo per gli Investimenti della Ricerca di Base (FIRB-giovani) [RBFR08F2FS-002]	University of Torino; Compagnia-San-Paolo(Compagnia di San Paolo); Programma di Ricerca di Rilevante Interesse Nazionale; Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondo per gli Investimenti della Ricerca di Base (FIRB-giovani)	This work was supported by grants from the University of Torino (Local Research Funding, 2007 and 2008; D. T.), Compagnia-San-Paolo (2008.1054; D. T.), Programma di Ricerca di Rilevante Interesse Nazionale (PRIN; 2008; D. T. and PRIN 2009; M. D. B.), Associazione Italiana Ricerca Cancro (AIRC; 2008-IG6014, G. L.; 2009-IG-9408, P. P.; 2010-IG-10104; D. T.), and Fondo per gli Investimenti della Ricerca di Base (FIRB-giovani2008, RBFR08F2FS-002; F. O.). F. O. and D. C. were fellows of the Regione Piemonte. The authors thank P. P. Pandolfi for helpful discussions; V. Poli and E. Hirsch for critical reading of the manuscript; J. Massague (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) and L. Primo and P. Circosta (University of Torino, Turin, Italy) for providing cell lines; A. R. Elia for the FACS analysis; A. Mana for performing some experiments; L. Fuso, G. M. Milano, F. Maggiorotto, and C. Robba for the patient datasets; and A. F. Horwitz (University of Illinois, Urbana-Champaign, IL, USA, via Addgene, Cambridge, MA, USA) for the 15238 plasmid. The authors declare no conflicts of interest.	Abraham D., INT J CANC, V126, P1339; Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Colozza Mariantonietta, 2005, Clin Breast Cancer, V6, P61, DOI 10.3816/CBC.2005.n.010; Damasco C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014737; Desgrosellier JS, NAT REV CANC, V10, P9; Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; Gill R, 1982, Experientia Suppl, V41, P187; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Le X. F., CANC MICROENVIRON, V3, P137; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808; Liu S., J MAMMARY GLAND BIOL, V17, P15; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Liu Y, 2008, TRANSFUSION, V48, P2279, DOI 10.1111/j.1537-2995.2008.01925.x; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mierke CT, 2011, J CELL SCI, V124, P369, DOI 10.1242/jcs.071985; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Nam JM, 2009, INT J RADIAT BIOL, V85, P923, DOI 10.3109/09553000903232876; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; Penna E, 2011, EMBO J, V30, P1990, DOI 10.1038/emboj.2011.102; Renner O, 2008, CANCER RES, V68, P9643, DOI 10.1158/0008-5472.CAN-08-1539; Risso D, 2009, BIOINFORMATICS, V25, P2685, DOI 10.1093/bioinformatics/btp443; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Shi JJ, 2007, ARCH IMMUNOL THER EX, V55, P61, DOI 10.1007/s00005-007-0009-7; Shi M., CANC METASTASIS REV, V29, P785; Simpson JF, 2000, J CLIN ONCOL, V18, P2059, DOI 10.1200/JCO.2000.18.10.2059; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; TARONE G, 1993, DEVELOPMENT, V117, P1369; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Taverna D, 2001, CANCER RES, V61, P5255; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Valastyan S., CANC RES, V70, P5147; Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709; Wang XC, 2008, MOL BIOTECHNOL, V38, P57, DOI 10.1007/s12033-007-0073-6; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Zheng B., CLIN CANC RES, V17, P7574; ZWEIG MH, 1993, CLIN CHEM, V39, P561	50	115	118	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1223	1235		10.1096/fj.12-214692	http://dx.doi.org/10.1096/fj.12-214692			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23233531	Green Submitted			2022-12-28	WOS:000315585200034
J	Jansen, M; Wang, W; Greco, D; Bellenchi, GC; di Porzio, U; Brown, AJ; Ikonen, E				Jansen, Maurice; Wang, Wei; Greco, Dario; Bellenchi, Gian Carlo; di Porzio, Umberto; Brown, Andrew J.; Ikonen, Elina			What dictates the accumulation of desmosterol in the developing brain?	FASEB JOURNAL			English	Article						progesterone; 3 beta-hydroxysterol 24-reductase; liver X receptor; cholesterol precursor; central nervous system	CHOLESTEROL-SYNTHESIS; ALZHEIMERS-DISEASE; RAT-BRAIN; STEROL BIOSYNTHESIS; REDUCTASE-ACTIVITY; NERVOUS-SYSTEM; LIPID RAFTS; METABOLISM; LIVER; PROGESTERONE	The brain is the most cholesterol-enriched tissue in the body. During brain development, desmosterol, an immediate precursor of cholesterol, transiently accumulates up to 30% of total brain sterols. This massive desmosterol deposition appears to be present in all mammalian species reported so far, including humans, but how it is achieved is not well understood. Here, we propose that desmosterol accumulation in the developing brain may be primarily caused by post-transcriptional repression of 3 beta-hydroxysterol 24-reductase (DHCR24) by progesterone. Furthermore, distinct properties of desmosterol may serve to increase the membrane active pool of sterols in the brain: desmosterol cannot be hydroxylated to generate 24S-hydroxycholesterol, a brain derived secretory sterol, desmosterol has a reduced propensity to be esterified as compared to cholesterol, and desmosterol may activate LXR to stimulate astrocyte sterol secretion. This regulated accumulation of desmosterol by progesterone-induced suppression of DHCR24 may facilitate the rapid enrichment and distribution of membrane sterols in the developing brain.-Jansen, M., Wang, W., Greco, D., Bellenchi, G. C., di Porzio, U., Brown, A. J., and Ikonen, E. What dictates the accumulation of desmosterol in the developing brain? FASEB J. 27, 865- 870 ( 2013). www.fasebj.org	[Jansen, Maurice; Wang, Wei; Ikonen, Elina] Univ Helsinki, Inst Biomed, Helsinki, Finland; [Greco, Dario] Univ Helsinki, Res Unit Mol Med, Helsinki, Finland; [Jansen, Maurice; Wang, Wei; Ikonen, Elina] Minerva Fdn, Helsinki, Finland; [Greco, Dario] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Bellenchi, Gian Carlo; di Porzio, Umberto] Inst Genet & Biophys, Naples, Italy; [Brown, Andrew J.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia	University of Helsinki; University of Helsinki; Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of New South Wales Sydney	Ikonen, E (corresponding author), Haartmaninkatu 8, Helsinki 00290, Finland.	elina.ikonen@helsinki.fi	Greco, Dario/T-7113-2019	Greco, Dario/0000-0001-9195-9003; Ikonen, Elina/0000-0001-8382-1135; di Porzio, Umberto/0000-0002-2139-8754; BELLENCHI, GIANCARLO/0000-0002-9302-0021	Academy of Finland [131489]; EU FP7 LipidomicNet [202272]; National Health and Medical Research Council [1008081]; National Heart Foundation of Australia [G11S 5757]; Fondo per gli Investimenti i Ricerca di Base [FIRB-RBIN062YH4]; Medical Research Italy [MERIT-RBNE08LN4P]; Progetti di Ricerca di Interesse Nazionale [PRIN-2009TBCZJB_003]	Academy of Finland(Academy of Finland); EU FP7 LipidomicNet; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia(National Heart Foundation of Australia); Fondo per gli Investimenti i Ricerca di Base; Medical Research Italy; Progetti di Ricerca di Interesse Nazionale(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	The authors thank Eser J. Zerenturk for performing the experiments in DHCR24-overexpressing cells, Valerio Piscopo for the RT-PCR experiments, and Pipsa Kaipainen for technical assistance. This work was financially supported by the Academy of Finland (grant 131489 to E.I.), EU FP7 LipidomicNet (grant 202272 to E.I.), the National Health and Medical Research Council (grant 1008081 to A.J.B.), the National Heart Foundation of Australia (G11S 5757 to A.J.B.), Fondo per gli Investimenti i Ricerca di Base (FIRB-RBIN062YH4 to U.D.P.), Medical Research Italy (MERIT-RBNE08LN4P to U.D.P.), and Progetti di Ricerca di Interesse Nazionale (PRIN-2009TBCZJB_003 to U.D.P.).	ARTHUR JR, 1976, BIOCHEM J, V158, P47, DOI 10.1042/bj1580047; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogan RL, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.096347; CONNOR WE, 1969, J LIPID RES, V10, P388; DENNICK RG, 1973, J NEUROCHEM, V20, P1293, DOI 10.1111/j.1471-4159.1973.tb00102.x; Fan X, 2008, P NATL ACAD SCI USA, V105, P13445, DOI 10.1073/pnas.0806974105; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; FUMAGALLI R, 1963, LIFE SCI, P291; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gill S, 2011, CELL METAB, V13, P260, DOI 10.1016/j.cmet.2011.01.015; Greeve I, 2000, J NEUROSCI, V20, P7345; Heverin M, 2007, ARTERIOSCL THROM VAS, V27, P2191, DOI 10.1161/ATVBAHA.107.149823; HINSE CH, 1971, J NEUROCHEM, V18, P1989, DOI 10.1111/j.1471-4159.1971.tb09604.x; Ibanez C, 2003, ENDOCRINOLOGY, V144, P2902, DOI 10.1210/en.2002-0073; Iivonen S, 2002, NEUROSCIENCE, V113, P301, DOI 10.1016/S0306-4522(02)00180-X; Jansen M, 2008, J BIOL CHEM, V283, P14610, DOI 10.1074/jbc.M710355200; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; KRITCHEVSKY D, 1962, BIOCHEM BIOPH RES CO, V7, P128, DOI 10.1016/0006-291X(62)90160-2; Lindenthal B, 2001, FASEB J, V15, P775, DOI 10.1096/fj.00-0214com; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Megha M, 2006, J BIOL CHEM, V281, P21903, DOI 10.1074/jbc.M600395200; Mutka AL, 2004, J BIOL CHEM, V279, P48654, DOI 10.1074/jbc.M405345200; Nieweg K, 2009, J NEUROCHEM, V109, P125, DOI 10.1111/j.1471-4159.2009.05917.x; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; PANINI SR, 1987, J BIOL CHEM, V262, P14435; Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002; Quan G, 2003, DEV BRAIN RES, V146, P87, DOI 10.1016/j.devbrainres.2003.09.015; Ruan BF, 1996, P NATL ACAD SCI USA, V93, P11603, DOI 10.1073/pnas.93.21.11603; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Sharpe LJ, 2012, J ALZHEIMERS DIS, V30, P35, DOI 10.3233/JAD-2012-111955; Spann NJ, 2012, CELL, V151, P138, DOI 10.1016/j.cell.2012.06.054; TAVANI DM, 1982, J LIPID RES, V23, P774; Vainio S, 2006, J BIOL CHEM, V281, P348, DOI 10.1074/jbc.M509530200; Volpicelli F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030661; Wang N, 2008, FASEB J, V22, P1073, DOI 10.1096/fj.07-9944com; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Yang CD, 2006, J BIOL CHEM, V281, P27816, DOI 10.1074/jbc.M603781200; Zerenturk E. J., 2011, BIOCHIM BIOPHYS ACTA, V1821, P1269	43	27	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					865	870		10.1096/fj.12-211235	http://dx.doi.org/10.1096/fj.12-211235			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23230282	Green Submitted			2022-12-28	WOS:000315585200003
J	Schreurs, MPH; Hubel, CA; Bernstein, IM; Jeyabalan, A; Cipolla, MJ				Schreurs, Malou P. H.; Hubel, Carl A.; Bernstein, Ira M.; Jeyabalan, Arun; Cipolla, Marilyn J.			Increased oxidized low-density lipoprotein causes blood-brain barrier disruption in early-onset preeclampsia through LOX-1	FASEB JOURNAL			English	Article						pregnancy; peroxynitrite; vascular permeability; neurological complications	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE; ECLAMPSIA; PLASMA; WOMEN; PEROXYNITRITE; CELLS; ATHEROSCLEROSIS; DYSFUNCTION; PREGNANCY	Early-onset preeclampsia (EPE) is a severe form of preeclampsia that involves life-threatening neurological complications. However, the underlying mechanism by which EPE affects the maternal brain is not known. We hypothesized that plasma from women with EPE increases blood-brain barrier (BBB) permeability vs. plasma from women with late-onset preeclampsia (LPE) or normal pregnancy (NP) and investigated its underlying mechanism by perfusing cerebral veins from nonpregnant rats (n=6-7/group) with human plasma from women with EPE, LPE, or NP and measuring permeability. We show that plasma from women with EPE significantly increased BBB permeability vs. plasma from women with LPE or NP (P<0.001). BBB disruption in response to EPE plasma was due to a 260% increase of circulating oxidized LDL (oxLDL) binding to its receptor, LOX-1, and subsequent generation of peroxynitrite (P<0.001). A rat model with pathologically high lipid levels in pregnancy showed symptoms of preeclampsia, including elevated blood pressure, growth-restricted fetuses, and LOX-1-dependent BBB disruption, similar to EPE (P<0.05). Thus, we have identified LOX-1 activation by oxLDL and subsequent peroxynitrite generation as a novel mechanism by which disruption of the BBB occurs in EPE. As increased BBB permeability is a primary means by which seizure and other neurological symptoms ensue, our findings highlight oxLDL, LOX-1, and peroxynitrite as important therapeutic targets in EPE.-Schreurs, M. P. H., Hubel, C. A., Bernstein, I. M., Jeyabalan, A., and Cipolla, M. J. Increased oxidized low-density lipoprotein causes blood-brain barrier disruption in early-onset preeclampsia through LOX-1. FASEB J. 27, 1254-1263 (2013). www.fasebj.org	[Schreurs, Malou P. H.; Cipolla, Marilyn J.] Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; [Bernstein, Ira M.; Cipolla, Marilyn J.] Univ Vermont, Coll Med, Dept Obstet Gynecol & Reprod Sci, Burlington, VT 05405 USA; [Cipolla, Marilyn J.] Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA; [Hubel, Carl A.; Jeyabalan, Arun] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Hubel, Carl A.; Jeyabalan, Arun] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA	University of Vermont; University of Vermont; University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Cipolla, MJ (corresponding author), Univ Vermont, Dept Neurol, 149 Beaumont Ave,HSRF 416, Burlington, VT 05405 USA.	marilyn.cipolla@uvm.edu			U. S. National Institute of Neurological Disorders and Stroke [RO1-NS045940]; Neural Environment Cluster supplement [RO1-NS045940-06S1]; American Recovery and Reinvestment Act supplement [RO1-NS045940-05S1]; U. S. National Heart, Lung, and Blood Institute [PO1HL095488, HL-071944]; Totman Medical Research Trust; University of Pittsburgh; PPG [P01HD30367]; Magee-Womens Hospital CRC [MO1-RR000056/1 UL1RR024153-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD030367] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153, M01RR000056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071944, P01HL095488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045940] Funding Source: NIH RePORTER	U. S. National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Neural Environment Cluster supplement; American Recovery and Reinvestment Act supplement; U. S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Totman Medical Research Trust; University of Pittsburgh(University of Pittsburgh); PPG; Magee-Womens Hospital CRC; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Karen Oppenheimer (Obstetrics/Gynecology Molecular Core Facility, University of Vermont) for performing the RT-PCR and Dr. Siu-Lung Chan (Department of Neurology, University of Vermont) for supervising the ELISA. Also, the authors gratefully acknowledge the support of U. S. National Institute of Neurological Disorders and Stroke grant RO1-NS045940, Neural Environment Cluster supplement RO1-NS045940-06S1, and American Recovery and Reinvestment Act supplement RO1-NS045940-05S1. The authors also gratefully acknowledge the support of U. S. National Heart, Lung, and Blood Institute grants PO1HL095488 and HL-071944 and the Totman Medical Research Trust. Lastly, the authors acknowledge the support of the Program Project Grant (PPG) core of the University of Pittsburgh, including PPG grant P01HD30367, and Magee-Womens Hospital CRC grant MO1-RR000056/1 UL1RR024153-01.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Amburgey OA, 2010, HYPERTENSION, V56, P1003, DOI 10.1161/HYPERTENSIONAHA.110.158931; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Belo B, 2005, ATHEROSCLEROSIS, V183, P185, DOI 10.1016/j.athersclerosis.2005.06.028; BRANCH DW, 1994, LANCET, V343, P645, DOI 10.1016/S0140-6736(94)92639-5; Buhimschi IA, 1998, HUM REPROD UPDATE, V4, P25, DOI 10.1093/humupd/4.1.25; Chen MJ, 2002, PHARMACOL THERAPEUT, V95, P89, DOI 10.1016/S0163-7258(02)00236-X; Chen XP, 2007, VASC PHARMACOL, V47, P1, DOI 10.1016/j.vph.2007.01.004; Cipolla MJ, 2007, HYPERTENSION, V50, P14, DOI 10.1161/HYPERTENSIONAHA.106.079442; Cominacini L, 2001, J BIOL CHEM, V276, P13750, DOI 10.1074/jbc.M010612200; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Duley L, 2009, SEMIN PERINATOL, V33, P130, DOI 10.1053/j.semperi.2009.02.010; Engelter ST, 2000, NEURORADIOLOGY, V42, P818, DOI 10.1007/s002340000439; Enquobahrie DA, 2004, AM J HYPERTENS, V17, P574, DOI 10.1016/j.amjhyper.2004.03.666; Foyouzi N, 2006, INT J GYNECOL OBSTET, V92, P32, DOI 10.1016/j.ijgo.2005.09.004; Friedman A, 2009, EPILEPSY RES, V85, P142, DOI 10.1016/j.eplepsyres.2009.03.005; Heeba G, 2007, J CARDIOVASC PHARM, V50, P391, DOI 10.1097/FJC.0b013e31811f3fd0; Hubel CA, 1998, METABOLISM, V47, P1281, DOI 10.1016/S0026-0495(98)90337-7; Kim YJ, 2007, EUR J OBSTET GYN R B, V133, P47, DOI 10.1016/j.ejogrb.2006.07.046; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Lee H, 2005, PLACENTA, V26, P226, DOI 10.1016/j.placenta.2004.05.012; Lin YL, 2010, J NUTR, V140, P2187, DOI 10.3945/jn.110.123505; Loureiro R, 2003, AM J OBSTET GYNECOL, V189, P1350, DOI 10.1067/S0002-9378(03)00651-3; Marchi N, 2010, BRAIN RES, V1353, P176, DOI 10.1016/j.brainres.2010.06.051; MAYHAN WG, 1995, BRAIN RES, V686, P99, DOI 10.1016/0006-8993(95)00460-8; Miller AA, 2009, AM J PHYSIOL-HEART C, V296, pH220, DOI 10.1152/ajpheart.00987.2008; Mitra S, 2011, CARDIOVASC DRUG THER, V25, P419, DOI 10.1007/s10557-011-6341-5; Morton JS, 2012, HYPERTENSION, V59, P1014, DOI 10.1161/HYPERTENSIONAHA.112.191825; Nakano A, 2010, J HYPERTENS, V28, P1273, DOI 10.1097/HJH.0b013e32833835d4; Neal CR, 2004, CLIN SCI, V107, P399, DOI 10.1042/CS20040018; Ogge G, 2011, J PERINAT MED, V39, P641, DOI [10.1515/JPM.2011.098, 10.1515/jpm.2011.098]; Ogura S, 2009, CIRC J, V73, P1993, DOI 10.1253/circj.CJ-09-0587; Okanloma KA, 2000, INT J GYNECOL OBSTET, V71, P223, DOI 10.1016/S0020-7292(00)00295-2; Palomares SM, 2012, J CEREBR BLOOD F MET, V32, P1035, DOI 10.1038/jcbfm.2012.14; Pecks U, 2012, HYPERTENS PREGNANCY, V31, P156, DOI 10.3109/10641955.2010.544805; Qiu C, 2006, PHYSIOL RES, V55, P491, DOI 10.33549/physiolres.930813; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Reyes LM, 2012, GROWTH FACTORS, V30, P158, DOI 10.3109/08977194.2012.674035; Roberts TJM, 2009, AM J PHYSIOL-HEART C, V297, pH1347, DOI 10.1152/ajpheart.00630.2009; Roggensack AM, 1999, HYPERTENSION, V33, P83, DOI 10.1161/01.HYP.33.1.83; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sanchez SE, 2005, GYNECOL ENDOCRINOL, V21, P193, DOI 10.1080/09513590500154019; Sankaralingam S, 2009, HYPERTENSION, V53, P270, DOI 10.1161/HYPERTENSIONAHA.108.122630; Schreurs MPH, 2013, REPROD SCI, V20, P391, DOI 10.1177/1933719112459228; Schreurs MPH, 2012, FASEB J, V26, P355, DOI 10.1096/fj.11-191916; Staff AC, 2010, HYPERTENSION, V56, P1026, DOI 10.1161/HYPERTENSIONAHA.110.157743; Uzun H, 2005, GYNECOL OBSTET INVES, V60, P195, DOI 10.1159/000087205; von Dadelszen P, 2003, HYPERTENS PREGNANCY, V22, P143, DOI 10.1081/PRG-120021060; Wikstrom AK, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.06.024; Xie Z, 2002, J NEUROSCI, V22, P3484; Zeeman GG, 2009, SEMIN PERINATOL, V33, P166, DOI 10.1053/j.semperi.2009.02.003	51	45	47	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1254	1263		10.1096/fj.12-222216	http://dx.doi.org/10.1096/fj.12-222216			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23230281	Green Published			2022-12-28	WOS:000315585200037
J	Rodriguez, S; Huynh-Do, U				Rodriguez, Stephane; Huynh-Do, Uyen			Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor	FASEB JOURNAL			English	Article						PTEN protein phosphatase; PTEN dephosphorylation; c-Cbl; NHERF1	TUMOR-SUPPRESSOR GENE; CELL-MIGRATION; TYROSINE KINASE; UP-REGULATION; C-CBL; EXPRESSION; PTEN; PROTEIN; PHOSPHORYLATION; ACTIVATION	Deregulation of receptor tyrosine kinases (RTKs) is linked to a broad range of cancers, stressing the necessity of studying their regulatory pathways. We and others demonstrated previously that c-Cbl is necessary for the lysosomal degradation of erythropoietin-producing hepatocellular B1 (EphB1) carcinoma and epidermal growth factor receptor (EGFR) RTKs. Moreover, the tumor suppressor phosphatase and tensin homolog (PTEN) was shown to modulate c-Cbl-dependent EGFR degradation. We therefore investigated the involvement of PTEN in EphB1 signaling and degradation. We used PTEN mutants, PTEN, and NHERF1 small interfering RNA in CHO-EphB1 and SW480 cells endogenously expressing EphB1 to delineate EphB1-PTEN interactions. PTEN was constitutively associated with c-Cbl, protecting it from degradation. EphB1 stimulation triggered similar to 50% serine-threonine PTEN dephosphorylation and PTEN-Cbl complex disruption, a process requiring PTEN protein phosphatase activity. Both proteins independently translocated to EphB1, with PTEN in association with the scaffold protein NHERF1. Biologically, PTEN lipid phosphatase activity impairs EphB1-dependent cell adhesion and chemotaxis. This study demonstrates for the first time in mammalian cells that the Eph receptor and PTEN associate and influence their signaling. Moreover, it contributes to the emerging concept that PTEN regulates expression of RTKs through modulation of their degradation. Finally, it reveals a new role for PTEN protein phosphatase activity involved in this process.-Rodriguez, S., Huynh-Do, U. Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor. FASEB J. 27, 632-644 (2013). www.fasebj.org	[Huynh-Do, Uyen] Univ Bern, Sch Med, Div Nephrol & Hypertens, Inselspital, CH-3010 Bern, Switzerland; [Huynh-Do, Uyen] Univ Bern, Sch Med, Dept Clin Res, Inselspital, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Huynh-Do, U (corresponding author), Univ Bern, Sch Med, Div Nephrol & Hypertens, Inselspital, KiKli G4 E212, CH-3010 Bern, Switzerland.	uyen.huynh-do@insel.ch			Swiss National Science Foundation [3100A0-1183691]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The authors thank Dr. D. Stroka (Clinic of Visceral Surgery and Medicine, University of Bern, Bern, Switzerland) and Professors B. M. Frey and F. J. Frey (Division of Nephrology and Hypertension, Inselspital, University of Bern) for continuous support and fruitful discussion and are very grateful to Dr. Kenneth Yamada (U. S. National Institutes of Health, National Institute of Dental Research, Bethesda, MD, USA) and Dr. Nick R. Leslie (College of Life Sciences, University of Dundee, Dundee, UK), who provided PTEN mutants. This work was supported by grant 3100A0-1183691 from the Swiss National Science Foundation to U. H. The authors declare no conflicts of interest.	Abounader R, 2004, ONCOGENE, V23, P9173, DOI 10.1038/sj.onc.1208146; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Berardi AC, 2008, ANTICANCER RES, V28, P763; Bourgin C, 2007, J CELL BIOL, V178, P1295, DOI 10.1083/jcb.200610139; Brisbin S, 2009, DEV CELL, V17, P459, DOI 10.1016/j.devcel.2009.08.009; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chi JH, 2008, J NEUROSURG, V108, P299, DOI 10.3171/JNS/2008/108/2/0299; Claperon A, 2012, ONCOGENE, V31, P1376, DOI 10.1038/onc.2011.334; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Dou H, 2012, NAT STRUCT MOL BIOL, V19, P184, DOI 10.1038/nsmb.2231; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Fasen K, 2008, TRAFFIC, V9, P251, DOI 10.1111/j.1600-0854.2007.00679.x; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hu YL, 2007, ARCH BIOCHEM BIOPHYS, V467, P1, DOI 10.1016/j.abb.2007.07.027; Huang XD, 2008, J CELL BIOL, V183, P711, DOI 10.1083/jcb.200801192; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Onnockx S, 2008, J CELL PHYSIOL, V214, P260, DOI 10.1002/jcp.21193; Panner A, 2009, CANCER RES, V69, P7911, DOI 10.1158/0008-5472.CAN-09-1287; Rabinovsky R, 2009, MOL CELL BIOL, V29, P5377, DOI 10.1128/MCB.01649-08; Sheng Z, 2008, PATHOBIOLOGY, V75, P274, DOI 10.1159/000151707; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stephen LJ, 2007, DEV BIOL, V302, P66, DOI 10.1016/j.ydbio.2006.08.058; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Uyen HD, 2002, J CELL SCI, V115, P3073; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vihanto MM, 2006, J CELL SCI, V119, P2299, DOI 10.1242/jcs.02946; Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Vivanco I, 2010, P NATL ACAD SCI USA, V107, P6459, DOI 10.1073/pnas.0911188107; Wang JD, 2007, ONCOLOGY-BASEL, V73, P238, DOI 10.1159/000127421; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Yang NY, 2011, CELL SIGNAL, V23, P201, DOI 10.1016/j.cellsig.2010.09.004	50	5	5	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					632	644		10.1096/fj.12-215582	http://dx.doi.org/10.1096/fj.12-215582			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23118026				2022-12-28	WOS:000314358000022
J	Belogurov, AA; Stepanov, AV; Smirnov, IV; Melamed, D; Bacon, A; Mamedov, AE; Boitsov, VM; Sashchenko, LP; Ponomarenko, NA; Sharanova, SN; Boyko, AN; Dubina, MV; Friboulet, A; Genkin, DD; Gabibov, AG				Belogurov, Alexey A., Jr.; Stepanov, Alexey V.; Smirnov, Ivan V.; Melamed, Dobroslav; Bacon, Andrew; Mamedov, Azad E.; Boitsov, Vitali M.; Sashchenko, Lidia P.; Ponomarenko, Natalia A.; Sharanova, Svetlana N.; Boyko, Alexey N.; Dubina, Michael V.; Friboulet, Alain; Genkin, Dmitry D.; Gabibov, Alexander G.			Liposome-encapsulated peptides protect against experimental allergic encephalitis	FASEB JOURNAL			English	Article						multiple sclerosis; myelin basic protein; small unilamellar vesicles; brain-derived neurotrophic factor; remyelination	MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; T-CELLS; SUPPRESSION; ANTIGEN; AUTOANTIBODIES; IMMUNOTHERAPY; DEGRADATION; SPECIFICITY	Multiple sclerosis (MS) is a severe inflammatory and neurodegenerative disease with an autoimmune background. Despite the variety of therapeutics available against MS, the development of novel approaches to its treatment is of high importance in modern pharmaceutics. In this study, experimental autoimmune encephalomyelitis (EAE) in Dark Agouti rats has been treated with immunodominant peptides of the myelin basic protein (MBP) encapsulated in mannosylated small unilamellar vesicles. The results show that liposome-encapsulated MBP46-62 is the most effective in reducing maximal disease score during the first attack, while MBP124-139 and MBP147-170 can completely prevent the development of the exacerbation stage. Both mannosylation of liposomes and encapsulation of peptides are critical for the therapeutic effect, since neither naked peptides nor nonmannosylated liposomes, loaded or empty, have proved effective. The liposome-mediated synergistic effect of the mixture of 3 MBP peptides significantly suppresses the progression of protracted EAE, with the median cumulative disease score being reduced from 22 to 14 points, compared to the placebo group; prevents the production of circulating autoantibodies; down-regulates the synthesis of Th1 cytokines; and induces the production of brain-derived neurotrophic factor in the central nervous system. Thus, the proposed formulation ameliorates EAE, providing for a less severe first attack and rapid recovery from exacerbation, and offers a promising therapeutic modality in MS treatment.-Belogurov, A. A., Jr., Stepanov, A. V., Smirnov, I. V., Melamed, D., Bacon, A., Mamedov, A. E., Boitsov, V. M., Sashchenko, L. P., Ponomarenko, N. A., Sharanova, S. N., Boyko, A. N., Dubina, M. V., Friboulet, A., Genkin, D. D., Gabibov, A. G. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 27, 222-231 (2013). www.fasebj.org	[Belogurov, Alexey A., Jr.; Stepanov, Alexey V.; Smirnov, Ivan V.; Mamedov, Azad E.; Ponomarenko, Natalia A.; Gabibov, Alexander G.] RAS, MM Shemyakin & YA Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; [Belogurov, Alexey A., Jr.; Sashchenko, Lidia P.; Gabibov, Alexander G.] RAS, Inst Gene Biol, Moscow 117997, Russia; [Smirnov, Ivan V.; Gabibov, Alexander G.] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia; [Melamed, Dobroslav] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; [Bacon, Andrew; Genkin, Dmitry D.] Xenet Biosci, London, England; [Boitsov, Vitali M.; Dubina, Michael V.] St Petersburg Acad Univ, RAS, Nanotechnol Res & Educ Ctr, St Petersburg, Russia; [Sharanova, Svetlana N.; Boyko, Alexey N.] NI Pirogov Natl Res Med Univ, City Hosp 11, Dept Neurol & Neurosurg, Moscow Multiple Sclerosis Ctr, Moscow, Russia; [Friboulet, Alain] Univ Technol Compiegne, CNRS, UMR 6022, Compiegne, France	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; St Petersburg Academic University; Pirogov Russian National Research Medical University; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS)	Gabibov, AG (corresponding author), RAS, MM Shemyakin & YA Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia.	gabibov@mx.ibch.ru	Smirnov, Ivan V/B-2491-2014; Belogurov, Alexey/L-5859-2017; Stepanov, Alexey/AAN-8721-2020; Dubina, Michael/E-1888-2014; Smirnov, Ivan/N-5635-2017; Boitsov, Vitali/E-1863-2014; Mamedov, Azad E/O-6863-2017; Boyko, Alexey N/Z-2106-2018	Smirnov, Ivan V/0000-0002-0384-6568; Belogurov, Alexey/0000-0002-2033-9621; Stepanov, Alexey/0000-0003-1616-4408; Dubina, Michael/0000-0002-6606-3309; Smirnov, Ivan/0000-0002-0384-6568; Boitsov, Vitali/0000-0002-4857-2046; Boyko, Alexei/0000-0003-3306-9541; Bacon, Andrew/0000-0002-9099-9158; Ponomarenko, Natalia/0000-0003-3129-3515; Mamedov, Azad/0000-0001-9343-4550	Ministry of Industry and Trade of the Russian Federation [11411.0810200. 13. B20, 3.1]; Russian Foundation for Basic Research [10-04-00673-a]; Presidium of the Russian Academy of Sciences [2046.2012.4, 24];  [CRP/RUS09-01]	Ministry of Industry and Trade of the Russian Federation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Presidium of the Russian Academy of Sciences(Russian Academy of Sciences); 	This work was performed within the framework of innovative projects launched by the Ministry of Industry and Trade of the Russian Federation (state contract 11411.0810200. 13. B20, code Copolymer 3.1) and supported by the Skolkovo program, Russian Foundation for Basic Research (project 10-04-00673-a); CRP/RUS09-01, The Role of B Cell Response in Multiple Sclerosis; Scientific Schools 2046.2012.4, Chemical Basis of Biocatalysis, Federal Special Purpose; and programs Detection of Viral Antigens as Possible Triggers of Autoimmune Neurodegeneration and Nanotechnologies and Nanomaterials (no. 24) of the Presidium of the Russian Academy of Sciences.	Aharoni R, 2003, P NATL ACAD SCI USA, V100, P14157, DOI 10.1073/pnas.2336171100; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Avnir Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025721; AVRILIONIS K, 1991, J NEUROIMMUNOL, V35, P201, DOI 10.1016/0165-5728(91)90174-6; Belogurov AA, 2009, AUTOIMMUNITY, V42, P362, DOI 10.1080/08916930902832090; Belogurov AA, 2008, J IMMUNOL, V180, P1258, DOI 10.4049/jimmunol.180.2.1258; Belogurov A, 2009, BIOESSAYS, V31, P1161, DOI 10.1002/bies.200900020; Bielekova B, 2004, J IMMUNOL, V172, P3893, DOI 10.4049/jimmunol.172.6.3893; Cavaletti G, 2009, MOL PHARMACEUT, V6, P1363, DOI 10.1021/mp8001478; Croxford JL, 1998, J IMMUNOL, V160, P5181; Durova OM, 2009, MOL IMMUNOL, V47, P87, DOI 10.1016/j.molimm.2008.12.020; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; Espuelas S, 2003, BIOORG MED CHEM LETT, V13, P2557, DOI 10.1016/S0960-894X(03)00472-4; Gabibov AG, 2011, FASEB J, V25, P4211, DOI 10.1096/fj.11-190769; Garren H., 2009, RESULTS PROBLEMS CEL, P259; Garren H, 2008, ANN NEUROL, V63, P611, DOI 10.1002/ana.21370; Hikada Masaki, 2010, Nat Immunol, V11, P1065, DOI 10.1038/ni1210-1065; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Katsara M, 2008, J NEUROIMMUNOL, V200, P77, DOI 10.1016/j.jneuroim.2008.06.013; Katsara M, 2009, J MED CHEM, V52, P214, DOI 10.1021/jm801250v; Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Luca ME, 2005, J NEUROIMMUNOL, V160, P178, DOI 10.1016/j.jneuroim.2004.11.014; Miyakoshi A, 2003, J IMMUNOL, V170, P6371, DOI 10.4049/jimmunol.170.12.6371; Oliver AR, 2003, J IMMUNOL, V171, P462, DOI 10.4049/jimmunol.171.1.462; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schweingruber N, 2011, J IMMUNOL, V187, P4310, DOI 10.4049/jimmunol.1101604; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; StLouis J, 1997, J NEUROIMMUNOL, V73, P90, DOI 10.1016/S0165-5728(96)00174-9; van Bergen J, 1999, IMMUNOL REV, V172, P87; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003	32	37	40	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					222	231		10.1096/fj.12-213975	http://dx.doi.org/10.1096/fj.12-213975			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047895	Green Published			2022-12-28	WOS:000313103200021
J	Pitt, J; Thorner, M; Brautigan, D; Larner, J; Klein, WL				Pitt, Jason; Thorner, Michael; Brautigan, David; Larner, Joseph; Klein, William L.			Protection against the synaptic targeting and toxicity of Alzheimer's-associated A beta oligomers by insulin mimetic chiro-inositols	FASEB JOURNAL			English	Article						therapeutics; cell culture; neurodegeneration; dementia	CENTRAL-NERVOUS-SYSTEM; RECEPTOR-DEPENDENT MECHANISM; GROWTH-FACTOR EXPRESSION; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; DIABETES-MELLITUS; MEDIATED ENDOCYTOSIS; CARDIOVASCULAR RISK; SOLUBLE OLIGOMERS; GLYCOGEN-SYNTHASE	Alzheimer's disease (AD) is a progressive dementia that correlates highly with synapse loss. This loss appears due to the synaptic accumulation of toxic A beta oligomers (ADDLs), which damages synapse structure and function. Although it has been reported that oligomer binding and toxicity can be prevented by stimulation of neuronal insulin signaling with PPAR gamma agonists, these agonists have problematic side effects. We therefore investigated the therapeutic potential of chiro-inositols, insulin-sensitizing compounds safe for human consumption. Chiro-inositols have been studied extensively for treatment of diseases associated with peripheral insulin resistance, but their insulin mimetic function in memory-relevant central nervous system (CNS) cells is unknown. Here we demonstrate that mature cultures of hippocampal neurons respond to D-chiro-inositol (DCI), pinitol (3-O-methyl DCI), and the inositol glycan INS-2 (pinitol beta-1-4 galactosamine) with increased phosphorylation in key upstream components in the insulin-signaling pathway (insulin receptor, insulin receptor substrate-1, and Akt). Consistent with insulin stimulation, DCI treatment promotes rapid withdrawal of dendritic insulin receptors. With respect to neuroprotection, DCI greatly enhances the ability of insulin to prevent ADDL-induced synapse damage (EC50 of 90 nM). The mechanism comprises inhibition of oligomer binding at synapses and requires insulin/IGF signaling. DCI showed no effects on A beta oligomerization. We propose that inositol glycans and DCI, a compound already established as safe for human consumption, have potential as AD therapeutics by protecting CNS synapses against A beta oligomers through their insulin mimetic activity.-Pitt, J., Thorner, M., Brautigan, D., Larner, J., Klein, W. L. Protection against the synaptic targeting and toxicity of Alzheimer's-associated A beta oligomers by insulin mimetic chiro-inositols. FASEB J. 27, 199-207 (2013). www.fasebj.org	[Pitt, Jason; Klein, William L.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA; [Thorner, Michael] Univ Virginia, Dept Med, Charlottesville, VA USA; [Brautigan, David] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Larner, Joseph] Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; [Brautigan, David] Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Larner, Joseph] Allomed Pharmaceut, Charlottesville, VA USA	Northwestern University; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Pitt, J (corresponding author), Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA.	wklein@northwestern.edu		Pitt, Jason/0000-0002-1876-4565	U.S. National Institutes of Health [AG020418, AG022547, AG029460, 1F31AG039216-01A1]; NATIONAL INSTITUTE ON AGING [R01AG022547, R01AG029460, T32AG020418, F31AG039216] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S. National Institutes of Health grants AG020418, AG022547, AG029460, and 1F31AG039216-01A1 (National Institute of Neurological Disorders and Stroke). Author contributions: J. P. designed and performed research, analyzed data, and wrote the manuscript; M. T. collaborated in providing ideas and edited the manuscript; D. B. collaborated in providing ideas and edited the manuscript; J. L. initiated work with W. K., provided ideas, and edited the manuscript; W. K. initiated work with J. L., provided ideas, and wrote the manuscript.	Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Baillargeon JP, 2006, DIABETES CARE, V29, P300, DOI 10.2337/diacare.29.02.06.dc05-1070; Bitel CL, 2012, J ALZHEIMERS DIS, V32, P291, DOI 10.3233/JAD-2012-120571; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Brautigan DL, 2005, BIOCHEMISTRY-US, V44, P11067, DOI 10.1021/bi0508845; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chakraborty A, 2010, CELL, V143, P897, DOI 10.1016/j.cell.2010.11.032; Coady MJ, 2002, J BIOL CHEM, V277, P35219, DOI 10.1074/jbc.M204321200; Copps KD, 2010, CELL METAB, V11, P84, DOI 10.1016/j.cmet.2009.11.003; Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; De Felice F. G., 2012, SOC NEUR NAN NEW ORL; De Felice FG, 2008, NEUROBIOL AGING, V29, P1334, DOI 10.1016/j.neurobiolaging.2007.02.029; De Felice FG, 2007, J BIOL CHEM, V282, P11590, DOI 10.1074/jbc.M607483200; De Felice FG, 2009, P NATL ACAD SCI USA, V106, P1971, DOI 10.1073/pnas.0809158106; de la Monte Suzanne M, 2008, J Diabetes Sci Technol, V2, P1101; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; Farias VX, 2011, DIABETES OBES METAB, V13, P243, DOI 10.1111/j.1463-1326.2010.01344.x; Fenili D, 2007, J MOL MED, V85, P603, DOI 10.1007/s00109-007-0156-7; Fenili D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024032; Fernandes MLDA, 2001, ENDOCRINE, V16, P227; Fonteles MC, 2000, HORM METAB RES, V32, P129, DOI 10.1055/s-2007-978606; Geldmacher DS, 2010, CLEV CLIN J MED, V77, P689, DOI 10.3949/ccjm.77gr.2010; Gual P, 2003, DIABETOLOGIA, V46, P1532, DOI 10.1007/s00125-003-1223-4; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hawkes CA, 2010, EUR J NEUROSCI, V31, P203, DOI 10.1111/j.1460-9568.2009.07052.x; Isoda F, 2003, BRAIN RES, V993, P172, DOI 10.1016/j.brainres.2003.09.008; Jolivalt CG, 2010, EXP NEUROL, V223, P422, DOI 10.1016/j.expneurol.2009.11.005; Kaech S, 2006, NAT PROTOC, V1, P2406, DOI 10.1038/nprot.2006.356; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kim JI, 2005, EUR J CLIN NUTR, V59, P456, DOI 10.1038/sj.ejcn.1602081; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; Krafft GA, 2010, NEUROPHARMACOLOGY, V59, P230, DOI 10.1016/j.neuropharm.2010.07.012; Kunjara S, 2000, MOL GENET METAB, V69, P144, DOI 10.1006/mgme.2000.2964; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larner J, 2003, J MED CHEM, V46, P3283, DOI 10.1021/jm030071j; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; Larner J, 2010, MOL MED, V16, P543, DOI 10.2119/molmed.2010.00107; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Marks DR, 2009, J NEUROSCI, V29, P6734, DOI 10.1523/JNEUROSCI.1350-09.2009; Matsumura S, 2011, J BIOL CHEM, V286, P11555, DOI 10.1074/jbc.M110.181313; Moloney AM, 2010, NEUROBIOL AGING, V31, P224, DOI 10.1016/j.neurobiolaging.2008.04.002; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nascimento NRF, 2006, P NATL ACAD SCI USA, V103, P218, DOI 10.1073/pnas.0509779103; Nestler JE, 1999, NEW ENGL J MED, V340, P1314, DOI 10.1056/NEJM199904293401703; Nunes-Tavares N, 2012, J BIOL CHEM, V287, P19377, DOI 10.1074/jbc.M111.321448; ORTMEYER HK, 1993, ENDOCRINOLOGY, V132, P646, DOI 10.1210/en.132.2.646; ORTMEYER HK, 1995, J NUTR BIOCHEM, V6, P499, DOI 10.1016/0955-2863(95)00080-J; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Pasinetti GM, 2008, J NEUROCHEM, V106, P1503, DOI 10.1111/j.1471-4159.2008.05454.x; Pitt J, 2009, TOXICOL APPL PHARM, V240, P189, DOI 10.1016/j.taap.2009.07.018; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Renner M, 2010, NEURON, V66, P739, DOI 10.1016/j.neuron.2010.04.029; Rivera EJ, 2005, J ALZHEIMERS DIS, V8, P247; Schnabel J, 2011, NATURE, V475, pS12, DOI 10.1038/475S12a; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Stull AJ, 2008, METABOLISM, V57, P1545, DOI 10.1016/j.metabol.2008.06.009; Takeda S, 2010, P NATL ACAD SCI USA, V107, P7036, DOI 10.1073/pnas.1000645107; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; van der Heide LP, 2006, PROG NEUROBIOL, V79, P205, DOI 10.1016/j.pneurobio.2006.06.003; van der Heide LP, 2005, J NEUROCHEM, V94, P1158, DOI 10.1111/j.1471-4159.2005.03269.x; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; Wilcox KC, 2011, CELL MOL NEUROBIOL, V31, P939, DOI 10.1007/s10571-011-9691-4; Yoshizaki T, 2004, J BIOL CHEM, V279, P22715, DOI 10.1074/jbc.M313745200; Zhao WQ, 2008, FASEB J, V22, P246, DOI 10.1096/fj.06-7703com; Zhao WQ, 2010, J BIOL CHEM, V285, P7619, DOI 10.1074/jbc.M109.057182; Zhao WQ, 2009, J BIOL CHEM, V284, P18742, DOI 10.1074/jbc.M109.011015	82	39	42	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					199	207		10.1096/fj.12-211896	http://dx.doi.org/10.1096/fj.12-211896			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23073831	Green Published			2022-12-28	WOS:000313103200019
J	Tarry-Adkins, JL; Martin-Gronert, MS; Fernandez-Twinn, DS; Hargreaves, I; Alfaradhi, MZ; Land, JM; Aiken, CE; Ozanne, SE				Tarry-Adkins, Jane L.; Martin-Gronert, Malgorzata S.; Fernandez-Twinn, Denise S.; Hargreaves, Iain; Alfaradhi, Maria Z.; Land, John M.; Aiken, Catherine E.; Ozanne, Susan E.			Poor maternal nutrition followed by accelerated postnatal growth leads to alterations in DNA damage and repair, oxidative and nitrosative stress, and oxidative defense capacity in rat heart	FASEB JOURNAL			English	Article						developmental programming; aging; cardiovascular disease	MANGANESE-SUPEROXIDE-DISMUTASE; CATCH-UP GROWTH; NOX2 EXPRESSION; FETAL; PEROXYNITRITE; PROTEIN; CARDIOMYOCYTES; INACTIVATION; TELOMERES; DISEASE	Low birth weight and accelerated postnatal growth lead to increased risk of cardiovascular disease. We reported previously that rats exposed to a low-protein diet in utero and postnatal catch-up growth (recuperated) develop metabolic dysfunction and have reduced life span. Here we explored the hypothesis that cardiac oxidative and nitrosative stress leading to DNA damage and accelerated cellular aging could contribute to these phenotypes. Recuperated animals had a low birth weight (P<0.001) but caught up in weight to controls during lactation. At weaning, recuperated cardiac tissue had increased (P<0.05) protein nitrotyrosination and DNA single-stranded breaks. This condition was preceded by increased expression of DNA damage repair molecules 8-oxoguanine-DNA-glycosylase-1, nei-endonuclease-VIII-like, X-ray-repair-complementing-defective-repair-1, and Nthl endonuclease III-like-1 on d 3. These differences were maintained on d 22 and became more pronounced in the case of 8-oxoguanine-DNA-glycosylase-1 and nei-endonuclease-VIII-like. This was accompanied by increases in xanthine oxidase (P<0.001) and NADPH oxidase (P<0.05), major sources of reactive oxygen species (ROS). The detrimental effects of increased ROS in recuperated offspring may be exaggerated at 22 d by reductions (P<0.001) in the antioxidant enzymes peroxiredoxin-3 and CuZn-superoxide-dismutase. We conclude that poor fetal nutrition followed by accelerated postnatal growth results in increased cardiac nitrosative and oxidative-stress and DNA damage, which could contribute to age-associated disease risk.-Tarry-Adkins, J. L., Martin-Gronert, M. S., Fernandez-Twinn, D. S., Hargreaves, I., Alfaradhi, M. Z., Land, J. M., Aiken, C. E., Ozanne, S. E. Poor maternal nutrition followed by accelerated postnatal growth leads to alterations in DNA damage and repair, oxidative and nitrosative stress and oxidative defense capacity in rat heart. FASEB J. 27, 379-390 (2013). www.fasebj.org	[Tarry-Adkins, Jane L.] Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Cambridge CB2 OQQ, England; [Hargreaves, Iain; Land, John M.] UCL, Natl Hosp, Neurometabol Unit, London, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Level 4,Box 289,Hills Rd, Cambridge CB2 OQQ, England.	janeadkins@googlemail.com	Fernandez-Twinn, Denise/B-3881-2011; Hargreaves, Iain/AAJ-6757-2020	Fernandez-Twinn, Denise/0000-0003-2610-277X; Tarry-Adkins, Jane/0000-0001-9569-6132; Ozanne, Susan/0000-0001-8753-5144	UK Department of Health's National Institute for Health Research Biomedical Research Centres; British Heart Foundation; Biotechnology and Biological Sciences Research Council [BB/F015364/1] Funding Source: researchfish; British Heart Foundation [PG/09/037/27387, FS/09/029/27902] Funding Source: researchfish; Medical Research Council [G0600717, MC_UU_12012/4, G0600717B] Funding Source: researchfish; BBSRC [BB/F015364/1] Funding Source: UKRI; MRC [MC_UU_12012/4, G0600717, MC_PC_12012] Funding Source: UKRI	UK Department of Health's National Institute for Health Research Biomedical Research Centres(National Institute for Health Research (NIHR)); British Heart Foundation(British Heart Foundation); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank A. Wayman and D. Hawkes for their technical expertise. Part of this work was undertaken at University College London Hospital, University College London, which received a proportion of funding from the UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. This work was supported by The British Heart Foundation. S.E.O. is a British Heart Foundation Senior Fellow and a member of the UK Medical Research Council Centre for Obesity and Related Metabolic Diseases.	Ago T, 2010, AGING-US, V2, P1012, DOI 10.18632/aging.100261; Alvarez B, 2004, FREE RADICAL BIO MED, V37, P813, DOI 10.1016/j.freeradbiomed.2004.06.006; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Cas AD, 2013, NUTR METAB CARDIOVAS, V23, P272, DOI 10.1016/j.numecd.2011.04.005; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; Csiszar Anna, 2005, Current Vascular Pharmacology, V3, P285, DOI 10.2174/1570161054368616; Eriksson J, 2000, HYPERTENSION, V36, P790, DOI 10.1161/01.HYP.36.5.790; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Godfrey KM, 2011, SEMIN REPROD MED, V29, P257, DOI 10.1055/s-0031-1275518; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Haussmann MF, 2003, P ROY SOC B-BIOL SCI, V270, P1387, DOI 10.1098/rspb.2003.2385; Hazra TK, 2007, DNA REPAIR, V6, P470, DOI 10.1016/j.dnarep.2006.10.011; Heistad DD, 2006, ARTERIOSCL THROM VAS, V26, P689, DOI 10.1161/01.ATV.0000203525.62147.28; Horton JK, 2008, CELL RES, V18, P48, DOI 10.1038/cr.2008.7; Jemielity S, 2007, AGING CELL, V6, P225, DOI 10.1111/j.1474-9726.2007.00279.x; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Kawanishi S, 2004, ANN NY ACAD SCI, V1019, P278, DOI 10.1196/annals.1297.047; Kim YM, 2005, CIRC RES, V97, P629, DOI 10.1161/01.RES.0000183735.09871.61; KING TE, 1967, METHOD ENZYMOL, V10, P446; Krijnen PAJ, 2003, J CLIN PATHOL, V56, P194, DOI 10.1136/jcp.56.3.194; Kuroda J, 2010, P NATL ACAD SCI USA, V107, P15565, DOI 10.1073/pnas.1002178107; Leeson CPM, 2001, CIRCULATION, V103, P1264; Lehrer-Graiwer JE, 2000, NEUROSCI LETT, V288, P107, DOI 10.1016/S0304-3940(00)01205-2; Li LQ, 2007, BIOCHEM BIOPH RES CO, V355, P715, DOI 10.1016/j.bbrc.2007.02.022; Li LQ, 2009, J BIOCHEM, V145, P425, DOI 10.1093/jb/mvp011; Lim KJ, 2006, PEDIATR RES, V60, P83, DOI 10.1203/01.pdr.0000220361.08181.c3; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Meischl C, 2006, APOPTOSIS, V11, P913, DOI 10.1007/s10495-006-6304-7; Minamino T, 2008, FRONT BIOSCI-LANDMRK, V13, P2971, DOI 10.2741/2902; Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Ragan CI, 1988, MITOCHONDRIA PRACTIC, P79; Richter T, 2007, EXP GERONTOL, V42, P1039, DOI 10.1016/j.exger.2007.08.005; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Sasaki T, 2010, GERIATR GERONTOL INT, V10, pS10, DOI 10.1111/j.1447-0594.2010.00601.x; Sen S, 2010, DIABETES, V59, P3058, DOI 10.2337/db10-0301; Shelley P, 2007, MECH AGEING DEV, V128, P681, DOI 10.1016/j.mad.2007.10.002; Shepherd JA, 1969, METHOD ENZYMOL, V13, P11; Sindhu RK, 2005, LIFE SCI, V76, P945, DOI 10.1016/j.lfs.2004.10.014; Singhal A, 2004, CIRCULATION, V109, P1108, DOI 10.1161/01.CIR.0000118500.23649.DF; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; Skilton MR, 2006, CLIN SCI, V111, P281, DOI 10.1042/CS20060036; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Son E, 2005, BIOCHEM PHARMACOL, V70, P590, DOI 10.1016/j.bcp.2005.05.027; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tarry-Adkins JL, 2006, AM J PHYSIOL-RENAL, V290, pF509, DOI 10.1152/ajprenal.00215.2005; Thakor AS, 2010, J PHYSIOL-LONDON, V588, P4235, DOI 10.1113/jphysiol.2010.196402; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Wang MY, 2010, J MOL CELL CARDIOL, V48, P765, DOI 10.1016/j.yjmcc.2010.01.006; Wharton DC., 1967, METHOD ENZYMOL, P245; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085	56	65	67	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					379	390		10.1096/fj.12-218685	http://dx.doi.org/10.1096/fj.12-218685			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23024373				2022-12-28	WOS:000313103200036
J	Chan, ME; Adler, BJ; Green, DE; Rubin, CT				Chan, M. Ete; Adler, Benjamin J.; Green, Danielle E.; Rubin, Clinton T.			Bone structure and B-cell populations, crippled by obesity, are partially rescued by brief daily exposure to low-magnitude mechanical signals	FASEB JOURNAL			English	Article						adiposity; diabetes	RESISTANT ACID-PHOSPHATASE; HIGH-FREQUENCY; POSTMENOPAUSAL WOMEN; VISCERAL ADIPOSITY; RISK-FACTORS; DIET; FAT; MASS; OSTEOCLASTOGENESIS; EXERCISE	Deterioration of the immune and skeletal systems, each of which parallel obesity, reflects a fragile interrelationship between adiposity and osteo-immunology. Using a murine model of diet-induced obesity, this study investigated the ability of mechanical signals to protect the skeletal-immune systems at the tissue, cellular, and molecular level. A long-term (7 mo) high-fat diet increased total adiposity (+62%), accelerated age-related loss of trabecular bone (-61%), and markedly reduced B-cell number in the marrow (-52%) and blood (-36%) compared to mice fed a regular diet. In the final 4 mo of the protocol, the application of low-magnitude mechanical signals (0.2 g at 90 Hz, 15 min/d, 5 d/wk) restored both bone structure and B cells to those levels measured in control mice fed a regular diet. These phenotypic outcomes were achieved, in part, by reductions in osteoclastic activity and a biasing of hematopoietic stem cell differentiation toward the lymphoid B-cell lineage and away from a myeloid fate. These results emphasize that obesity undermines both the skeletal and immune systems, yet brief exposure to mechanical signals, perhaps as a surrogate to the salutary influence of exercise, diminishes the consequences of diabetes and obesity, restoring bone structure and normalizing B-cell populations by biasing of the fate of stem cells through mechanosensitive pathways.-Chan, M. E., Adler, B. J., Green, D. E., Rubin, C. T. Bone structure and B-cell populations, crippled by obesity, are partially rescued by brief daily exposure to low-magnitude mechanical signals. FASEB J. 26, 4855-4863 (2012). www.fasebj.org	[Chan, M. Ete; Adler, Benjamin J.; Green, Danielle E.; Rubin, Clinton T.] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rubin, CT (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.	clinton.rubin@sunysb.edu			U.S. National Institutes of Health through National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR043498]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043498] Funding Source: NIH RePORTER	U.S. National Institutes of Health through National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the U.S. National Institutes of Health through National Institute of Arthritis and Musculoskeletal and Skin Diseases grant AR043498. The authors are grateful for the help from Gunes Uzer, Ada Tsoi, Mario Botros, Elizabeth Fievisohn, Michelle Cheung, Kim Kawatra, and Engin Ozcivici for their technical assistance related to this project. Conflict of interest: C. T. R. is a founder of Marodyne Medical, Inc. (Lakeland, FL, USA) and has a U. S. Patent and Trademark Office application under review for the ability of mechanical signals to control metabolic disorders. The other authors declare no conflicts of interest.	Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; Barbeau P, 2007, OBESITY, V15, P2077, DOI 10.1038/oby.2007.247; Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.3.CO;2-4; Cao JJ, 2010, ANN NY ACAD SCI, V1192, P292, DOI 10.1111/j.1749-6632.2009.05252.x; Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017; Compston JE, 2011, AM J MED, V124, P1043, DOI 10.1016/j.amjmed.2011.06.013; CREVEL RWR, 1992, BRIT J NUTR, V67, P17, DOI 10.1079/BJN19920005; DILSEN G, 1989, Clinical Rheumatology, V8, P70, DOI 10.1007/BF02207238; DODDS RA, 1995, J BONE MINER RES, V10, P1666; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Ferguson V L, 1999, Biomed Sci Instrum, V35, P85; Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756-3282(03)00199-6; Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355; Gutin B, 2008, OBESITY, V16, P2193, DOI 10.1038/oby.2008.348; Haffner SM, 2007, AM J MED, V120, P10, DOI 10.1016/j.amjmed.2007.06.006; Haffner SM, 2007, AM J MED, V120, P16; Halade GV, 2011, EXP GERONTOL, V46, P43, DOI 10.1016/j.exger.2010.09.014; Halade GV, 2010, J NUTR BIOCHEM, V21, P1162, DOI 10.1016/j.jnutbio.2009.10.002; Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044; Hollberg K, 2002, EXP CELL RES, V279, P227, DOI 10.1006/excr.2002.5612; Horowitz MC, 2004, J IMMUNOL, V173, P6583, DOI 10.4049/jimmunol.173.11.6583; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Judex S, 2010, J MUSCULOSKEL NEURON, V10, P3; Judex S, 2010, METHODS, V50, P14, DOI 10.1016/j.ymeth.2009.05.017; Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014; Kahn SE, 2006, DIABETES, V55, P2357, DOI 10.2337/db06-0116; Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031; LINDUNGER A, 1990, BONE MINER, V10, P109, DOI 10.1016/0169-6009(90)90086-U; Lublinsky S, 2007, CALCIFIED TISSUE INT, V81, P285, DOI 10.1007/s00223-007-9063-8; Lublinsky S, 2009, J DIGIT IMAGING, V22, P222, DOI 10.1007/s10278-008-9152-x; Luu YK, 2010, INT J OBESITY, V34, P401, DOI 10.1038/ijo.2009.240; Luu YK, 2009, MED ENG PHYS, V31, P34, DOI 10.1016/j.medengphy.2008.03.006; Luu YK, 2009, J BONE MINER RES, V24, P50, DOI [10.1359/jbmr.080817, 10.1359/JBMR.080817]; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Rourke RW, 2005, OBES SURG, V15, P1463, DOI 10.1381/096089205774859308; Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001; Ozcivici E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011178; Pan X, 1995, Zhonghua Nei Ke Za Zhi, V34, P108; Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023; Premaor MO, 2011, J CLIN ENDOCR METAB, V96, P2414, DOI 10.1210/jc.2011-0076; Reilly JJ, 2011, INT J OBESITY, V35, P891, DOI 10.1038/ijo.2010.222; Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104; Russell M, 2010, J CLIN ENDOCR METAB, V95, P1247, DOI 10.1210/jc.2009-1475; Sato-Mito N, 2009, J NUTR HEALTH AGING, V13, P602, DOI 10.1007/s12603-009-0170-2; Sen B, 2011, STEM CELLS, V29, P1829, DOI 10.1002/stem.732; Slatkovska L., 2011, ANN INTERN MED, V155, pW205; Slatkovska L, 2011, ANN INTERN MED, V155, P668, DOI 10.7326/0003-4819-155-10-201111150-00005; Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047; Taguchi R, 2001, ATHEROSCLEROSIS, V157, P203, DOI 10.1016/S0021-9150(00)00709-7; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Thivel D, 2011, PHYSIOL BEHAV, V102, P132, DOI 10.1016/j.physbeh.2010.10.011; Tolomio S, 2010, J WOMEN AGING, V22, P241, DOI 10.1080/08952841.2010.518866; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672; Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015; Weksberg DC, 2008, BLOOD, V111, P2444, DOI 10.1182/blood-2007-09-115006; Zhou QD, 2011, P NATL ACAD SCI USA, V108, P2867, DOI 10.1073/pnas.1019270108	59	46	49	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4855	4863		10.1096/fj.12-209841	http://dx.doi.org/10.1096/fj.12-209841			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22898923	Green Published			2022-12-28	WOS:000311838300009
J	Robson, A; Harris, LK; Innes, BA; Lash, GE; Aljunaidy, MM; Aplin, JD; Baker, PN; Robson, SC; Bulmer, JN				Robson, Andrew; Harris, Lynda K.; Innes, Barbara A.; Lash, Gendie E.; Aljunaidy, Mais M.; Aplin, John D.; Baker, Philip N.; Robson, Stephen C.; Bulmer, Judith N.			Uterine natural killer cells initiate spiral artery remodeling in human pregnancy	FASEB JOURNAL			English	Article						angiogenic growth factors; proteases; vascular smooth muscle cells	GROWTH-FACTOR; TROPHOBLAST INVASION; EXTRAVILLOUS TROPHOBLAST; GRANULATED LYMPHOCYTES; CARDIOVASCULAR-DISEASE; MATERNAL ARTERIES; SMOOTH-MUSCLE; IN-VITRO; EXPRESSION; FACTS	Uterine spiral artery remodeling is required for successful human pregnancy; impaired remodeling is associated with pregnancy complications, including late miscarriage, preeclampsia, and fetal growth restriction. The molecular triggers of remodeling are not known, but it is now clear that there are "trophoblast-independent" and "trophoblast-dependent" stages. Uterine natural killer (uNK) cells are abundant in decidualized endometrium in early pregnancy; they surround spiral arteries and secrete a range of angiogenic growth factors. We hypothesized that uNK cells mediate the initial stages of spiral artery remodeling. uNK cells and extravillous trophoblast (EVT) cells were isolated from early pregnancy decidua and placenta. Chorionic plate arteries from full-term placentas and spiral arteries from nonpregnant myometrium were cultured with angiogenic growth factors or conditioned medium (CM) from uNK cells or EVT or uNK cell/EVT cocultures. In both vessel models, uNK cell CM induced disruption of vascular smooth muscle cells (VSMCs) and breakdown of extracellular matrix components. Angiopoietin (Ang)-1, Ang-2, interferon-gamma, and VEGF-C also disrupted VSMC integrity with an Ang-2 inhibitor abrogating the effect of uNK cell CM. These results provide compelling evidence that uNK cells contribute to the early stages of spiral artery remodeling; failure of this process could contribute to pregnancy pathology.-Robson, A., Harris, L. K., Innes, B. A., Lash, G. E., Aljunaidy, M. M., Aplin, J. D., Baker, P. N., Robson, S. C., Bulmer, J. N. Uterine natural killer cells initiate spiral artery remodeling in human pregnancy. FASEB J. 26, 4876-4885 (2012). www.fasebj.org	[Robson, Andrew; Innes, Barbara A.; Lash, Gendie E.; Robson, Stephen C.; Bulmer, Judith N.] Newcastle Univ, Inst Cellular Med, Reprod & Vasc Biol Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Harris, Lynda K.; Aljunaidy, Mais M.; Aplin, John D.; Baker, Philip N.] Univ Manchester, Maternal & Fetal Hlth Res Ctr, Manchester, Lancs, England; [Baker, Philip N.] Univ Alberta, Dept Obstet & Gynecol, Edmonton, AB, Canada	Newcastle University - UK; University of Manchester; University of Alberta	Bulmer, JN (corresponding author), Newcastle Univ, Inst Cellular Med, Reprod & Vasc Biol Grp, 3rd Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	judith.bulmer@ncl.ac.uk	Harris, Lynda K/I-2628-2019; Lash, Gendie/AAI-4116-2021; Aplin, John/AET-4363-2022	Harris, Lynda K/0000-0001-7709-5202; Aplin, John/0000-0001-8777-9261; Baker, Philip/0000-0002-4592-6427; Lash, Gendie/0000-0002-3606-1361	UK Biotechnology and Biological Sciences Research Council [BB/E016790/1]; BBSRC [BB/E016790/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E016790/1] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Amgen (Thousand Oaks, CA, USA) for the peptibody AMG 386 neutralizing antibody and the research midwives team at the Royal Victoria Infirmary for help in obtaining consent and collecting samples. The authors also thank all the women who donated tissues to be used for these studies. This work was supported by a grant from the UK Biotechnology and Biological Sciences Research Council (BB/E016790/1). Author contributions: A. R. performed experiments and wrote the manuscript; L. K. H. performed experiments and wrote the manuscript; B. A. I. performed experiments; G. E. L. designed the study and wrote the manuscript; M. M. A. performed experiments; J.D.A. designed the study and wrote the manuscript; P.N.B. designed the study; S. C. R. designed the study and collected samples; J.N.B. designed the study and wrote the manuscript.	Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; Ball E, 2006, J PATHOL, V208, P535, DOI 10.1002/path.1927; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; Cartwright JE, 1999, BRIT J PHARMACOL, V128, P181, DOI 10.1038/sj.bjp.0702757; Cartwright JE, 2002, PLACENTA, V23, P232, DOI 10.1053/plac.2001.0760; Choy MY, 1998, HUM REPROD, V13, P2941, DOI 10.1093/humrep/13.10.2941; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; Crocker IP, 2005, J PATHOL, V206, P476, DOI 10.1002/path.1801; Distler JHW, 2003, Q J NUCL MED, V47, P149; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gastrich MD, 2010, J MATERN-FETAL NEO M, V23, P751, DOI 10.3109/14767058.2010.481316; Geelhoed JJM, 2010, EUR J EPIDEMIOL, V25, P677, DOI 10.1007/s10654-010-9510-0; Guimond MJ, 1998, J EXP MED, V187, P217, DOI 10.1084/jem.187.2.217; Harris LK, 2010, AM J PATHOL, V177, P2103, DOI 10.2353/ajpath.2010.100182; Kam EPY, 1999, HUM REPROD, V14, P2131, DOI 10.1093/humrep/14.8.2131; Lash GE, 2010, PLACENTA, V31, pS87, DOI 10.1016/j.placenta.2009.12.022; Lash GE, 2010, PLACENTA, V31, P545, DOI 10.1016/j.placenta.2010.02.020; Lash GE, 2011, HUM REPROD, V26, P2289, DOI 10.1093/humrep/der198; Lash GE, 2006, J LEUKOCYTE BIOL, V80, P572, DOI 10.1189/jlb.0406250; Leonard S, 2006, PLACENTA, V27, pS40, DOI 10.1016/j.placenta.2005.11.007; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Lyall F, 2002, PLACENTA, V23, P555, DOI 10.1053/plac.2002.0850; Naruse K, 2009, HUM REPROD, V24, P553, DOI 10.1093/humrep/den408; Nuyt AM, 2009, CURR OPIN NEPHROL HY, V18, P144, DOI 10.1097/MNH.0b013e328326092c; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; Smith SD, 2009, AM J PATHOL, V174, P1959, DOI 10.2353/ajpath.2009.080995; Staun-Ram Elsebeth, 2004, Reprod Biol Endocrinol, V2, P59, DOI 10.1186/1477-7827-2-59; Sweeney M, 2006, PLACENTA, V27, P635, DOI 10.1016/j.placenta.2005.05.010; van der Heijden OWH, 2005, BIOL REPROD, V73, P1289, DOI 10.1095/biolreprod.105.044438; van Weel V, 2007, ARTERIOSCL THROM VAS, V27, P2310, DOI 10.1161/ATVBAHA.107.151407; Vassiliadou N, 1998, IMMUNOLOGY, V94, P368, DOI 10.1046/j.1365-2567.1998.00497.x; Whitman SC, 2004, ARTERIOSCL THROM VAS, V24, P1049, DOI 10.1161/01.ATV.0000124923.95545.2c	33	206	222	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4876	4885		10.1096/fj.12-210310	http://dx.doi.org/10.1096/fj.12-210310			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22919072	Green Submitted			2022-12-28	WOS:000311838300011
J	Bolton, JL; Smith, SH; Huff, NC; Gilmour, MI; Foster, WM; Auten, RL; Bilbo, SD				Bolton, Jessica L.; Smith, Susan H.; Huff, Nicole C.; Gilmour, M. Ian; Foster, W. Michael; Auten, Richard L.; Bilbo, Staci D.			Prenatal air pollution exposure induces neuroinflammation and predisposes offspring to weight gain in adulthood in a sex-specific manner	FASEB JOURNAL			English	Article						high-fat diet; cytokines; microglia; prenatal programming; diesel exhaust	DIET-INDUCED OBESITY; INSULIN-RESISTANCE; SOCIOECONOMIC-STATUS; FETAL-GROWTH; FAT; INFLAMMATION; BRAIN; MICROGLIA; ANXIETY; RISK	Emerging evidence suggests environmental chemical exposures during critical windows of development may contribute to the escalating prevalence of obesity. We tested the hypothesis that prenatal air pollution exposure would predispose the offspring to weight gain in adulthood. Pregnant mice were exposed to filtered air (FA) or diesel exhaust (DE) on embryonic days (E) 9-17. Prenatal DE induced a significant fetal brain cytokine response at E18 (46-390% over FA). As adults, offspring were fed either a low-fat diet (LFD) or high-fat diet (HFD) for 6 wk. Adult DE male offspring weighed 12% more and were 35% less active than FA male offspring at baseline, whereas there were no differences in females. Following HFD, DE males gained weight at the same rate as FA males, whereas DE females gained 340% more weight than FA females. DE-HFD males had 450% higher endpoint insulin levels than FA-HFD males, and all males on HFD showed decreased activity and increased anxiety, whereas females showed no differences. Finally, both DE males and females fed HFD showed increased microglial activation (30-66%) within several brain regions. Thus, prenatal air pollution exposure can "program" offspring for increased susceptibility to diet-induced weight gain and neuroinflammation in adulthood in a sex-specific manner.-Bolton, J. L., Smith, S. H., Huff, N. C., Gilmour, M. I., Foster, W. M., Auten, R. L., Bilbo, S. D. Prenatal air pollution exposure induces neuroinflammation and predisposes offspring to weight gain in adulthood in a sex-specific manner. FASEB J. 26, 4743-4754 (2012). www.fasebj.org	[Bolton, Jessica L.; Smith, Susan H.; Huff, Nicole C.; Bilbo, Staci D.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA; [Gilmour, M. Ian] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Foster, W. Michael] Duke Univ, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Durham, NC 27710 USA; [Auten, Richard L.] Duke Univ, Med Ctr, Dept Pediat, Div Neonatal Med, Durham, NC 27710 USA	Duke University; United States Environmental Protection Agency; Duke University; Duke University	Bolton, JL (corresponding author), Duke Univ, Dept Psychol & Neurosci, 210 Res Dr,Box 91050,3019 GSRB II, Durham, NC 27708 USA.	jessica.bolton@duke.edu	Bolton, Jessica L/AAE-8243-2020; Bilbo, Staci D/L-5076-2016	Bolton, Jessica L/0000-0002-8872-4999; Bilbo, Staci D/0000-0001-6736-7841; Bilbo, Staci/0000-0001-7395-5033	U.S. Environmental Protection Agency Children's Environmental Health Center [RD 83329301]; Duke Institute for Brain Sciences	U.S. Environmental Protection Agency Children's Environmental Health Center(United States Environmental Protection Agency); Duke Institute for Brain Sciences	The authors thank Charly King and Todd Krantz for assistance in conducting the inhalation exposures and monitoring, and Nicholas Mason and Erin Potts Kant for assistance with the multiplex protein assay. The authors also thank Rishi Mistry, Paige Sholar, Anthony Franco, Farah Dadabhoy, Divya Natesan, Isabella Dreyfuss, and Tania Hassanzadeh for technical assistance with diet monitoring procedures and brain Iba-1 quantification. This paper has been reviewed by the U.S. Environmental Protection Agency and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the Agency, nor does the mention of trade names or commercial products constitute endorsement or recommendations for use. J.L.B. is supported by a National Science Foundation graduate research fellowship. This work was supported by U.S. Environmental Protection Agency Children's Environmental Health Center award RD 83329301 and a Research Incubator award from the Duke Institute for Brain Sciences.	Alonso-Magdalena P, 2010, ENVIRON HEALTH PERSP, V118, P1243, DOI 10.1289/ehp.1001993; Auten RL, 2012, AM J RESP CELL MOL, V46, P454, DOI 10.1165/rcmb.2011-0256OC; Auten RL, 2009, AM J RESP CRIT CARE, V180, P1218, DOI 10.1164/rccm.200901-0116OC; Bilbo SD, 2007, BRAIN BEHAV IMMUN, V21, P332, DOI 10.1016/j.bbi.2006.10.005; Bilbo SD, 2012, J NEUROIMMUNE PHARM, V7, P24, DOI 10.1007/s11481-011-9299-y; Bilbo SD, 2010, FASEB J, V24, P2104, DOI 10.1096/fj.09-144014; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009; Calderon-Garciduenas L, 2008, BRAIN COGNITION, V68, P117, DOI 10.1016/j.bandc.2008.04.008; Deverman BE, 2009, NEURON, V64, P61, DOI 10.1016/j.neuron.2009.09.002; Dubowsky SD, 2006, ENVIRON HEALTH PERSP, V114, P992, DOI 10.1289/ehp.8469; Evans GW, 2002, ANNU REV PUBL HEALTH, V23, P303, DOI 10.1146/annurev.publhealth.23.112001.112349; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Garcia-Patterson A, 2011, DIABETIC MED, V28, P436, DOI 10.1111/j.1464-5491.2011.03227.x; Godfrey K M, 2001, Public Health Nutr, V4, P611; GOLD RM, 1970, J COMP PHYSIOL PSYCH, V71, P347, DOI 10.1037/h0029119; Grun F, 2009, MOL ENDOCRINOL, V23, P1127, DOI 10.1210/me.2008-0485; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; Hancox RJ, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-23; Heindel JJ, 2009, MOL CELL ENDOCRINOL, V304, P90, DOI 10.1016/j.mce.2009.02.025; Hofer TPJ, 2004, J LEUKOCYTE BIOL, V75, P856, DOI 10.1189/jlb.0803387; Hurvitz PM, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-46; Hwang LL, 2010, OBESITY, V18, P463, DOI 10.1038/oby.2009.273; Inoue K, 2006, ARCH TOXICOL, V80, P275, DOI 10.1007/s00204-005-0040-6; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; Keith SW, 2006, INT J OBESITY, V30, P1585, DOI 10.1038/sj.ijo.0803326; Kennedy A, 2009, J NUTR, V139, P1, DOI 10.3945/jn.108.098269; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; Lawlor DA, 2006, INT J EPIDEMIOL, V35, P3, DOI 10.1093/ije/dyi309; Levesque S, 2011, ENVIRON HEALTH PERSP, V119, P1149, DOI 10.1289/ehp.1002986; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Ornoy A, 2011, REPROD TOXICOL, V32, P205, DOI 10.1016/j.reprotox.2011.05.002; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; Pereira G, 2011, AUST NZ J PUBL HEAL, V35, P451, DOI 10.1111/j.1753-6405.2011.00760.x; Perera FP, 2009, PEDIATRICS, V124, pE195, DOI 10.1542/peds.2008-3506; Pryor LE, 2011, ARCH PEDIAT ADOL MED, V165, P906, DOI 10.1001/archpediatrics.2011.153; Rundle A, 2012, AM J EPIDEMIOL, V175, P1163, DOI 10.1093/aje/kwr455; Saberi M, 2009, CELL METAB, V10, P419, DOI 10.1016/j.cmet.2009.09.006; Schwarz JM, 2012, J NEUROCHEM, V120, P948, DOI 10.1111/j.1471-4159.2011.07630.x; Sharkhuu T, 2010, TOXICOL LETT, V196, P12, DOI 10.1016/j.toxlet.2010.03.017; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001; Sun QH, 2009, CIRCULATION, V119, P538, DOI 10.1161/CIRCULATIONAHA.108.799015; Tamashiro KLK, 2009, DIABETES, V58, P1116, DOI 10.2337/db08-1129; Tang XD, 2005, PHYSIOL BEHAV, V84, P105, DOI 10.1016/j.physbeh.2004.10.017; Tannenbaum BM, 1997, AM J PHYSIOL-ENDOC M, V273, pE1168, DOI 10.1152/ajpendo.1997.273.6.E1168; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; van den Hooven EH, 2012, ENVIRON HEALTH PERSP, V120, P150, DOI 10.1289/ehp.1003316; Vatten LJ, 2004, EARLY HUM DEV, V76, P47, DOI 10.1016/j.earlhumdev.2003.10.006; Wakselman S, 2008, J NEUROSCI, V28, P8138, DOI 10.1523/JNEUROSCI.1006-08.2008; Wohlfahrt-Veje C, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-79; Xu XH, 2010, ARTERIOSCL THROM VAS, V30, P2518, DOI 10.1161/ATVBAHA.110.215350	54	155	156	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4743	4754		10.1096/fj.12-210989	http://dx.doi.org/10.1096/fj.12-210989			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22815382				2022-12-28	WOS:000310574200034
J	de Sio, FRS; Barde, I; Offner, S; Kapopoulou, A; Corsinotti, A; Bojkowska, K; Genolet, R; Thomas, JH; Luescher, IF; Pinschewer, D; Harris, N; Trono, D				de Sio, Francesca R. Santoni; Barde, Isabelle; Offner, Sandra; Kapopoulou, Adamandia; Corsinotti, Andrea; Bojkowska, Karolina; Genolet, Raphael; Thomas, James H.; Luescher, Immanuel F.; Pinschewer, Daniel; Harris, Nicola; Trono, Didier			KAP1 regulates gene networks controlling T-cell development and responsiveness	FASEB JOURNAL			English	Article						epigenetics; adaptive immune cells; Kruppelassociated box zinc finger proteins; KRAB-ZFP; KRAB-ZFPassociated protein 1; KAP1	FINGER GENES; CHROMATIN; EXPRESSION; PROTEINS; DIFFERENTIATION; COREPRESSOR; CONTRIBUTES; REPRESSION; THYMOCYTES; PROMOTERS	Chromatin remodeling at specific genomic loci controls lymphoid differentiation. Here, we investigated the role played in this process by Kruppel-associated box (KRAB)-associated protein 1 (KAP1), the universal cofactor of KRAB-zinc finger proteins (ZFPs), a tetrapod-restricted family of transcriptional repressors. T-cell-specific Kap1-deleted mice displayed a significant expansion of immature thymocytes, imbalances in CD4(+)/CD8(+) cell ratios, and altered responses to TCR and TGF(+) stimulation when compared to littermate KAP1 control mice. Transcriptome and chromatin studies revealed that KAP1 binds T-cell-specific cis-acting regulatory elements marked by the H3K9me3 repressive mark and enriched in Ikaros/NuRD complexes. Also, KAP1 directly controls the expression of several genes involved in TCR and cytokine signaling. Among these, regulation of FoxO1 seems to play a major role in this system. Likely responsible for tethering KAP1 to at least part of its genomic targets, a small number of KRAB-ZFPs are selectively expressed in T-lymphoid cells. These results reveal the so far unsuspected yet important role of KAP1-mediated epigenetic regulation in T-lymphocyte differentiation and activation.-Santoni de Sio, F. R., Barde, I., Offner, S., Kapopoulou, A., Corsinotti, A., Bojkowska, K., Genolet, R., Thomas, J. H., Luescher, I. F., Pinschewer, D., Harris, N., Trono, D. KAP1 regulates gene networks controlling T-cell development and responsiveness. FASEB J. 26, 4561-4575 (2012). www.fasebj.org	[de Sio, Francesca R. Santoni; Barde, Isabelle; Offner, Sandra; Kapopoulou, Adamandia; Corsinotti, Andrea; Bojkowska, Karolina; Harris, Nicola; Trono, Didier] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland; [de Sio, Francesca R. Santoni; Barde, Isabelle; Offner, Sandra; Kapopoulou, Adamandia; Corsinotti, Andrea; Bojkowska, Karolina; Harris, Nicola; Trono, Didier] Ecole Polytech Fed Lausanne, Frontiers Genet Program, CH-1015 Lausanne, Switzerland; [Harris, Nicola] Ecole Polytech Fed Lausanne, Swiss Vaccine Res Inst, CH-1015 Lausanne, Switzerland; [Kapopoulou, Adamandia] SIB, Lausanne, Switzerland; [Genolet, Raphael; Luescher, Immanuel F.] Ludwig Inst Canc Res, Lausanne, Switzerland; [Thomas, James H.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Pinschewer, Daniel] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Washington; University of Washington Seattle; University of Geneva	Trono, D (corresponding author), EPFL SV DO, Stn 19, CH-1015 Lausanne, Switzerland.	didier.trono@epfl.ch	de Sio, Francesca Santoni/AAF-3432-2020; harris, nicola/E-5342-2019	harris, nicola/0000-0003-2922-0210; Santoni de Sio, Francesca Romana/0000-0002-6522-0499; Bojkowska, Karolina/0000-0002-7961-8676; Pinschewer, Daniel/0000-0002-1594-3189	Swiss National Science Foundation; European Research Council	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council(European Research Council (ERC)European Commission)	The authors thank Andrea Annoni for great help with Treg experiments; Fabio Aloisio for histological analyses; Sonia Verp for technical help; Ute Koch, Frederic Radtke, Anna Groner, Helen Rowe, and Corinne Schar for fruitful discussion; Giovanna Ambrosini, Jacques Rougemont, Patrick Descombes, and the Genomics Platform of the Frontiers in Genetics program for help in high-throughput analyses; Jessica Dessimoz and the EPFL Histology Core Facility; and Miguel Garcia and the EPFL Flow Cytometry Core Facility. Part of the computation was performed on the Swiss Institute of Bioinformatics Vital-IT facility (http://www.vital-it.ch). This work was supported by grants from the Swiss National Science Foundation and the European Research Council to D. T. Author contributions: F. R. S. D. S designed and performed experiments, analyzed data, and wrote the paper; A. C., I. B., K. B., N.H., D. P., and I. L. helped in designing experiments and provided reagents; I. B., S. O., A. A., and R. G. performed experiments; J. H. T. and A. K. analyzed data; D. T. designed experiments, analyzed data, and wrote the paper. The authors declare no conflicts of interest.	Blahnik KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017121; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cammas F, 2000, DEVELOPMENT, V127, P2955; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Carpenter AC, 2010, NAT IMMUNOL, V11, P666, DOI 10.1038/ni.1887; Chikuma S, 2012, NAT IMMUNOL, V13, P596, DOI 10.1038/ni.2293; Cuddapah S, 2010, CURR OPIN IMMUNOL, V22, P341, DOI 10.1016/j.coi.2010.02.007; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; de Sio FRS, 2012, BLOOD, V119, P4675, DOI 10.1182/blood-2011-12-401117; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fayard E, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3135re5; Flatz L, 2010, NAT MED, V16, P339, DOI 10.1038/nm.2104; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Genolet R, 2012, EMBO J, V31, P1666, DOI 10.1038/emboj.2012.48; Gubelmann C, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar040; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Kerdiles YM, 2009, NAT IMMUNOL, V10, P176, DOI 10.1038/ni.1689; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kioussis D, 2002, NAT REV IMMUNOL, V2, P909, DOI 10.1038/nri952; Kioussis D, 2007, SCIENCE, V317, P620, DOI 10.1126/science.1143777; Koch F, 2011, NAT STRUCT MOL BIOL, V18, P956, DOI 10.1038/nsmb.2085; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Ma J, 2012, J IMMUNOL, V188, P5337, DOI 10.4049/jimmunol.1102979; Malkov Vladislav A, 2009, BMC Res Notes, V2, P80, DOI 10.1186/1756-0500-2-80; Marsland BJ, 2005, P NATL ACAD SCI USA, V102, P14374, DOI 10.1073/pnas.0506250102; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meylan S, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-378; Misslitz A, 2004, J EXP MED, V200, P481, DOI 10.1084/jem.20040383; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Morrow Michael, 2011, PDA J Pharm Sci Technol, V65, P692, DOI 10.5731/pdajpst.2011.00841; Nowick K, 2010, MOL BIOL EVOL, V27, P2606, DOI 10.1093/molbev/msq157; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; Ouyang WM, 2011, TRENDS IMMUNOL, V32, P26, DOI 10.1016/j.it.2010.10.005; Ouyang WM, 2009, IMMUNITY, V30, P358, DOI 10.1016/j.immuni.2009.02.003; Park JH, 2010, NAT IMMUNOL, V11, P257, DOI 10.1038/ni.1840; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shannon M, 2003, GENOME RES, V13, P1097, DOI 10.1101/gr.963903; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Thomas JH, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-51; van Steensel B, 2011, EMBO J, V30, P1885, DOI 10.1038/emboj.2011.135; Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Zhang JW, 2012, NAT IMMUNOL, V13, P86, DOI 10.1038/ni.2150; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	55	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4561	4575		10.1096/fj.12-206177	http://dx.doi.org/10.1096/fj.12-206177			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22872677	Green Accepted, Bronze			2022-12-28	WOS:000310574200018
J	Mutt, SJ; Karhu, T; Lehtonen, S; Lehenkari, P; Carlberg, C; Saarnio, J; Sebert, S; Hypponen, E; Jarvelin, MR; Herzig, KH				Mutt, Shivaprakash J.; Karhu, Toni; Lehtonen, Siri; Lehenkari, Petri; Carlberg, Carsten; Saarnio, Juha; Sebert, Sylvain; Hyppoenen, Elina; Jarvelin, Marjo-Ritta; Herzig, Karl-Heinz			Inhibition of cytokine secretion from adipocytes by 1,25-dihydroxyvitamin D-3 via the NF-kappa B pathway	FASEB JOURNAL			English	Article						obesity; vitamin D; interleukin 6; chronic inflammation	VITAMIN-D SUPPLEMENTATION; NECROSIS-FACTOR-ALPHA; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; D DEFICIENCY; STEM-CELLS; RISK; INTERLEUKIN-6; 1-ALPHA,25(OH)(2)D-3; RECRUITMENT; EXPRESSION	Adipose tissue inflammation is an important pathological process in obese people, associated with diabetes and cardiovascular disease. We hypothesized that 1,25-dihydroxyvitamin D-3 [1,25(OH)2D(3)] inhibits cytokine secretion from adipocytes via direct inhibition of transcription factor nuclear factor-kappa B (NF-kappa B). We utilized two different human models. Bone marrow-derived human mesenchymal stromal cells (hMSCs) differentiated into adipocytes, and adipocytes isolated from biopsies stimulated with lipopolysaccharide (LPS) were treated with or without 1,25(OH) 2D(3). Expression and secretion of interleukin-6 (IL-6) were measured by quantitative RT-PCR analysis and ELISA. Assessment of NF-kappa B nuclear translocation, DNA binding activity was performed by immunofluorescence (IF) and electrophoretic mobility assay (EMSA). Inhibitor kappa B (I kappa B) and its phosphorylation were detected by Western blot (WB) analysis. Simultaneous 1,25(OH) 2D(3) cotreatment significantly re-duced LPS-stimulated (10 ng/ml) IL-6 secretion dose dependently by 15% at 10(-10) M and 26% at 10(-7) M (P<0.05) in hMSCs, while preincubation with 1,25(OH) 2D(3) (10(-7) M) for 24 h reduced IL-6 secretion by 24 and 35% (P<0.001) and mRNA levels by 34 and 30% (P<0.05) in hMSCs and isolated adipocytes, respectively. 1,25(OH) 2D(3) suppressed LPS-stimulated I kappa B phosphorylation-mediated NF-kappa B translocation into the nucleus were evident from WB, IF, and EMSA. 1,25(OH) 2D(3) inhibits LPS-stimulated IL-6 secretion in two human adipocyte models via interference with NF-kappa B signaling.-Mutt, S.J., Karhu, T., Lehtonen, S., Lehenkari, P., Carlberg, C., Saarnio, J., Sebert, S., Hypponen, E., Jorvelin, M.-R., Herzig, K.-H. Inhibition of cytokine secretion from adipocytes by 1,25-dihydroxyvitamin D-3 via the NF-kappa B pathway. FASEB J. 26, 4400-4407 (2012). www.fasebj.org	[Mutt, Shivaprakash J.; Karhu, Toni; Lehtonen, Siri; Lehenkari, Petri; Herzig, Karl-Heinz] Univ Oulu, Dept Physiol, Inst Biomed, FIN-90014 Oulu, Finland; [Mutt, Shivaprakash J.; Karhu, Toni; Jarvelin, Marjo-Ritta; Herzig, Karl-Heinz] Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; [Lehtonen, Siri; Lehenkari, Petri] Univ Oulu, Dept Anat, FIN-90014 Oulu, Finland; [Lehtonen, Siri; Lehenkari, Petri; Saarnio, Juha] Univ Oulu, Oulu Univ Hosp, Dept Surg, FIN-90014 Oulu, Finland; [Jarvelin, Marjo-Ritta] Univ Oulu, Inst Hlth Sci, FIN-90014 Oulu, Finland; [Lehtonen, Siri; Lehenkari, Petri] Clin Res Ctr, Oulu, Finland; [Carlberg, Carsten] Univ Eastern Finland, Inst Biomed, Sch Med, Kuopio, Finland; [Sebert, Sylvain; Jarvelin, Marjo-Ritta] Natl Inst Hlth & Welf, Dept Life Course & Serv, Oulu, Finland; [Sebert, Sylvain; Jarvelin, Marjo-Ritta] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England; [Sebert, Sylvain; Jarvelin, Marjo-Ritta] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Med Res Council Hlth Protect Agcy Ctr, London, England; [Hyppoenen, Elina] UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England; [Herzig, Karl-Heinz] Kuopio Univ Hosp, Dept Psychiat, SF-70210 Kuopio, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Eastern Finland; Finland National Institute for Health & Welfare; Imperial College London; Imperial College London; University of London; University College London; Kuopio University Hospital; University of Eastern Finland	Herzig, KH (corresponding author), Univ Oulu, Dept Physiol, Inst Biomed, POB 5000, FIN-90014 Oulu, Finland.	karl-heinz.herzig@oulu.fi	Lehenkari, Petri/O-3009-2016; Hypponen, Elina/B-2596-2014; Carlberg, Carsten/C-9075-2011; Mutt, Shivaprakash Jagalur/AAC-9768-2019	Lehenkari, Petri/0000-0002-0055-5183; Hypponen, Elina/0000-0003-3670-9399; Carlberg, Carsten/0000-0003-2633-0684; Mutt, Shivaprakash Jagalur/0000-0001-8285-551X; Sebert, Sylvain/0000-0001-6681-6983; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Lehtonen, Siri/0000-0002-5578-8232	Academy of Finland [104781, 120315, 129269, 1114194]; Academy of Finland [Responding to Public Health Challenges Research Programme (SALVE)]; University Hospital Oulu; Biocenter of Oulu; University of Oulu, Finland [75617]; Medical Research Council, UK (PrevMetSyn/SALVE); Medical Research Council [G0801056B] Funding Source: researchfish; National Institute for Health Research [PHCS/C4/4/016] Funding Source: researchfish	Academy of Finland(Academy of Finland); Academy of Finland [Responding to Public Health Challenges Research Programme (SALVE)]; University Hospital Oulu; Biocenter of Oulu; University of Oulu, Finland; Medical Research Council, UK (PrevMetSyn/SALVE)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by the grants from the Academy of Finland [project grants 104781, 120315, 129269, 1114194, and Responding to Public Health Challenges Research Programme (SALVE)], University Hospital Oulu, Biocenter of Oulu, University of Oulu, Finland (75617), and the Medical Research Council, UK (PrevMetSyn/SALVE). The authors declare no conflicts of interest.	Adorini L, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P631; Andersen R, 2005, EUR J CLIN NUTR, V59, P533, DOI 10.1038/sj.ejcn.1602108; Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Baroni E, 2007, J LEUKOCYTE BIOL, V81, P250, DOI 10.1189/jlb.0506322; Calvo MS, 2003, NUTR REV, V61, P107, DOI 10.1301/nr.2003.marr.107-113; Canning MO, 2001, EUR J ENDOCRINOL, V145, P351, DOI 10.1530/eje.0.1450351; Carlberg C, 2010, CHROMOSOMA, V119, P479, DOI 10.1007/s00412-010-0283-8; Carlin Arthur M, 2006, Surg Obes Relat Dis, V2, P98, DOI 10.1016/j.soard.2005.12.001; Cohen-Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254; Cohen-Lahav M., 2007, J STEROID BIOCHEM, V103, P558; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; Fain JN, 1998, METABOLISM, V47, P1455, DOI 10.1016/S0026-0495(98)90069-5; Giarratana N, 2004, J IMMUNOL, V173, P2280, DOI 10.4049/jimmunol.173.4.2280; Giovannucci E, 2009, ANN EPIDEMIOL, V19, P84, DOI 10.1016/j.annepidem.2007.12.002; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Gustafson B, 2007, ARTERIOSCL THROM VAS, V27, P2276, DOI 10.1161/ATVBAHA.107.147835; Hoareau L, 2006, CYTOKINE, V34, P291, DOI 10.1016/j.cyto.2006.06.005; Hoch M, 2008, CYTOKINE, V41, P29, DOI 10.1016/j.cyto.2007.10.008; HOLICK MF, 1989, LANCET, V2, P1104; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Huotari A, 2008, INT J CIRCUMPOL HEAL, V67, P164, DOI 10.3402/ijch.v67i2-3.18258; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Janderova L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11; Jenab Mazda, 2010, BMJ, V340, pb5500, DOI 10.1136/bmj.b5500; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jorde R, 2000, AM J CLIN NUTR, V71, P1530; Joyner JM, 2000, J ENDOCRINOL, V166, P145, DOI 10.1677/joe.0.1660145; Kodiha M., 2009, NAT NETW PROTOC, DOI [10.1038/nprot.2009.16, DOI 10.1038/NPROT.2009.16]; Konradsen S, 2008, EUR J NUTR, V47, P87, DOI 10.1007/s00394-008-0700-4; Lamberg-Allardt CJE, 2001, J BONE MINER RES, V16, P2066, DOI 10.1359/jbmr.2001.16.11.2066; Leskela HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lorente-Cebrian S, 2012, EUR J NUTR, V51, P335, DOI 10.1007/s00394-011-0218-z; Matilainen JM, 2010, BBA-MOL CELL RES, V1803, P1276, DOI 10.1016/j.bbamcr.2010.07.009; MAXWELL JD, 1994, P NUTR SOC, V53, P533, DOI 10.1079/PNS19940063; Perakyla M, 2005, MOL ENDOCRINOL, V19, P2060, DOI 10.1210/me.2004-0417; Peterson CA, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-10; Rapuri PB, 2002, J CLIN ENDOCR METAB, V87, P2024, DOI 10.1210/jc.87.5.2024; Riis JL, 2004, ARCH DERMATOL RES, V296, P195, DOI 10.1007/s00403-004-0509-9; Ross AC, 2011, DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN D, P35; Samuelson G, 2000, EUR J CLIN NUTR, V54, pS21, DOI 10.1038/sj.ejcn.1600980; Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005; Suzuki Y, 2009, J STEROID BIOCHEM, V113, P134, DOI 10.1016/j.jsbmb.2008.12.004; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Vieth R, 2007, AM J CLIN NUTR, V85, P649, DOI 10.1093/ajcn/85.3.649; Vlasova M, 2010, ACTA PHYSIOL, V200, P107, DOI 10.1111/j.1748-1716.2010.02171.x; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127; Wu SP, 2010, INT J BIOCHEM CELL B, V42, P329, DOI 10.1016/j.biocel.2009.11.012; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Zipitis CS, 2008, ARCH DIS CHILD, V93, P512, DOI 10.1136/adc.2007.128579	54	68	71	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4400	4407		10.1096/fj.12-210880	http://dx.doi.org/10.1096/fj.12-210880			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22798425				2022-12-28	WOS:000310574200004
J	Cronier, S; Carimalo, J; Schaeffer, B; Jaumain, E; Beringue, V; Miquel, MC; Laude, H; Peyrin, JM				Cronier, Sabrina; Carimalo, Julie; Schaeffer, Brigitte; Jaumain, Emilie; Beringue, Vincent; Miquel, Marie-Christine; Laude, Hubert; Peyrin, Jean-Michel			Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death	FASEB JOURNAL			English	Article						neurodegeneration; primary culture; astrocyte; scrapie	PRP KNOCKOUT MICE; IN-VIVO; SCRAPIE; INFECTION; NEURODEGENERATION; OLIGOMERS; TOXICITY; DISEASE; MECHANISMS; ASTROCYTES	Prions cause fatal neurodegenerative conditions and result from the conversion of host-encoded cellular prion protein (PrPC) into abnormally folded scrapie PrP (PrPSc). Prions can propagate both in neurons and astrocytes, yet neurotoxicity mechanisms remain unclear. Recently, PrPC was proposed to mediate neurotoxic signaling of beta-sheet-rich PrP and non-PrP conformers independently of conversion. To investigate the role of astrocytes and neuronal PrPC in prion-induced neurodegeneration, we set up neuron and astrocyte primary cocultures derived from PrP transgenic mice. In this system, prion-infected astrocytes delivered ovine PrPSc to neurons lacking PrPC (prion-resistant), or expressing a PrPC convertible (sheep) or not (mouse, human). We show that interaction between neuronal PrPC and exogenous PrPSc was not sufficient to induce neuronal death but that efficient PrPC conversion was required for prion-associated neurotoxicity. Prion-infected astrocytes markedly accelerated neurodegeneration in homologous cocultures compared to infected single neuronal cultures, despite no detectable neurotoxin release. Finally, PrPSc accumulation in neurons led to neuritic damages and cell death, both potentiated by glutamate and reactive oxygen species. Thus, conversion of neuronal PrPC rather than PrPC-mediated neurotoxic signaling appears as the main culprit in prion-induced neurodegeneration. We suggest that active prion replication in neurons sensitizes them to environmental stress regulated by neighboring cells, including astrocytes.-Cronier, S., Carimalo, J., Schaeffer, B., Jaumain, E., Beringue, V., Miquel, M.-C., Laude, H., Peyrin, J.-M. Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death. FASEB J. 26, 3854-3861 (2012). www.fasebj.org	[Cronier, Sabrina; Jaumain, Emilie; Beringue, Vincent; Laude, Hubert; Peyrin, Jean-Michel] INRA, Virol & Immunol Mol UR892, F-78352 Jouy En Josas, France; [Schaeffer, Brigitte] INRA, Math & Informat Appl UR0341, F-78352 Jouy En Josas, France; [Carimalo, Julie; Miquel, Marie-Christine; Peyrin, Jean-Michel] Univ Paris 06, CNRS, UMR 7102, Paris, France; [Carimalo, Julie] Univ Gottingen, Natl Reference Ctr Transmissible Spongiform Encep, Dept Neurol, Gottingen, Germany	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Gottingen	Cronier, S (corresponding author), INRA, Virol & Immunol Mol UR892, F-78352 Jouy En Josas, France.	sabrina.cronier@jouy.inra.fr; jean-michel.peyrin@snv.jussieu.fr		Miquel, Marie-Christine/0000-0002-9332-2572; Peyrin, Jean-Michel/0000-0002-0108-1266; Peyrin, Jean-Michel/0000-0002-8705-8672	French government (GIS-Infections a Prion); European Union [Neurodegeneration-QLG3CT2001]; French Ministry of Research and Education (MRE); MRE; French Foundation France Alzheimer	French government (GIS-Infections a Prion); European Union(European Commission); French Ministry of Research and Education (MRE); MRE; French Foundation France Alzheimer	This project was supported by grants from the French government (GIS-Infections a Prion) and from the European Union (Neurodegeneration-QLG3CT2001). S. C. was a recipient of a French Ministry of Research and Education (MRE) fellowship. J.C. was funded by an MRE fellowship and the French Foundation France Alzheimer. The authors thank S. Hawke (Imperial College, London, UK; now at University of Sydney, Sydney, NSW, Australia) and G. S. Jackson (Medical Research Council Prion Unit, London, UK) for kindly providing the antibodies ICSM18 and ICSM35, and ICSM33, respectively; J. Grassi and S. Simon (Commissariat a l'energie Atomique et aux energies Alternatives, Saclay, France) for Sha31 antibody; C. Weissmann (Scripps Research Institute, Jupiter, FL, USA) for authorizing the inclusion of tga20 and PrP<SUP>0/0</SUP> mice in this study. The authors thank T. Szeto for careful reading of the manuscript and R. Young for preparation of the figures.	Balducci C, 2010, P NATL ACAD SCI USA, V107, P2295, DOI 10.1073/pnas.0911829107; Beringue V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001419; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 2002, J NEUROCHEM, V82, P209, DOI 10.1046/j.1471-4159.2002.01004.x; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Calella AM, 2010, EMBO MOL MED, V2, P306, DOI 10.1002/emmm.201000082; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Cronier S, 2004, P NATL ACAD SCI USA, V101, P12271, DOI 10.1073/pnas.0402725101; Cronier S, 2007, J VIROL, V81, P13794, DOI 10.1128/JVI.01502-07; Custer SK, 2006, NAT NEUROSCI, V9, P1302, DOI 10.1038/nn1750; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gavin R, 2005, FEBS LETT, V579, P4099, DOI 10.1016/j.febslet.2005.06.037; Goold R, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1282; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Haidet-Phillips AM, 2011, NAT BIOTECHNOL, V29, P824, DOI 10.1038/nbt.1957; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Jeffrey M, 2004, ANN NEUROL, V55, P781, DOI 10.1002/ana.20093; Jin M, 2011, P NATL ACAD SCI USA, V108, P5819, DOI 10.1073/pnas.1017033108; Klohn PC, 2012, SCIENCE, V335, P52, DOI 10.1126/science.1215579; Kristiansen M, 2007, MOL CELL, V26, P175, DOI 10.1016/j.molcel.2007.04.001; Kunz B, 1999, FEBS LETT, V458, P65, DOI 10.1016/S0014-5793(99)01123-0; Langevin C, 2011, NEUROBIOL DIS, V41, P219, DOI 10.1016/j.nbd.2010.09.010; Laude H, 2002, CR BIOL, V325, P49, DOI 10.1016/S1631-0691(02)01393-8; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Lefebvre-Roque M, 2007, PRION, V1, P198, DOI 10.4161/pri.1.3.4870; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Nygaard HB, 2009, ARCH NEUROL-CHICAGO, V66, P1325, DOI 10.1001/archneurol.2009.223; Paquet S, 2007, J GEN VIROL, V88, P706, DOI 10.1099/vir.0.82336-0; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Resenberger UK, 2011, EMBO J, V30, P2057, DOI 10.1038/emboj.2011.86; Sakudo A, 2009, CURR MED CHEM, V16, P380, DOI 10.2174/092986709787002673; Sandberg MK, 2011, NATURE, V470, P540, DOI 10.1038/nature09768; Schengrund CL, 2010, BRAIN RES BULL, V82, P7, DOI 10.1016/j.brainresbull.2010.02.013; Schneider B, 2011, FRONT BIOSCI-LANDMRK, V16, P169, DOI 10.2741/3682; Silveira JR, 2004, CURR TOP MICROBIOL, V284, P1; Simoneau S, 2007, PLOS PATHOG, V3, P1175, DOI 10.1371/journal.ppat.0030125; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Westergard L, 2007, BBA-MOL BASIS DIS, V1772, P629, DOI 10.1016/j.bbadis.2007.02.011	48	19	19	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3854	3861		10.1096/fj.11-201772	http://dx.doi.org/10.1096/fj.11-201772			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22661006				2022-12-28	WOS:000308391600025
J	Diaz-Guerra, E; Lillo, MA; Santamaria, S; Garcia-Sanz, JA				Diaz-Guerra, Eva; Lillo, M. Angeles; Santamaria, Silvia; Garcia-Sanz, Jose A.			Intrinsic cues and hormones control mouse mammary epithelial tree size	FASEB JOURNAL			English	Article						stem cell expansion; stem cells; puberty; estrogens	ESTROGEN-RECEPTOR-ALPHA; STEM-CELLS; ORGAN SIZE; GLAND; BREAST; MICE; PROLIFERATION; AMPHIREGULIN; INACTIVATION; EXPRESSION	Organ size control is a long-standing question in biology. In mammals, using conditional cell ablation, two mutually exclusive mechanisms involving either intrinsic or extrinsic programs have been described to control organ size. The mammary gland is an ideal model for such studies, since it undergoes size and morphological changes during puberty and pregnancy. The role of stem cells in controlling mammary epithelial tree size is unclear, although mammary stem cells are able to reconstitute a functional organ on transplantation. Here, we show that mammary gland cellularity was strictly dependent on mammary stem cell number, even following a 20-fold expansion of the mammary stem cell pool at puberty and transient 3-fold expansions with each pregnancy. In addition, the expansion of the mammary stem cell pool was hormone dependent, as demonstrated by female bilateral ovariectomies during puberty and transplants of male-derived cells into female recipients. In these transplants, apart from a mammary stem cell expansion, we also observed the donor cells reconstituting functional mammary glands, developing alveolar structures, and secreting milk after the recipient's parturition. Taken together, these data suggest that in the mammary gland, there is a third organ size control mechanism, combining intrinsic cues throughout the organism's lifetime, with extrinsic hormone signals at particular developmental windows (puberty, pregnancy), where an expansion of the mammary stem cell pool occurs. This mechanism might have strong implications for the understanding of mammary tumorigenesis, since the expansion of the mammary stem cell pool precedes the generation of breast tumors.-Diaz-Guerra, E., Lillo, M. A., Santamaria, S., Garcia-Sanz, J. A. Intrinsic cues and hormones control mouse mammary epithelial tree size. FASEB J. 26, 3844-3853 (2012). www.fasebj.org	[Diaz-Guerra, Eva; Lillo, M. Angeles; Santamaria, Silvia; Garcia-Sanz, Jose A.] Spanish Natl Res Council CIB CSIC, Dept Cellular & Mol Med, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Garcia-Sanz, JA (corresponding author), CIB CSIC, Ramiro Maeztu 9, E-28040 Madrid, Spain.	jasanz@cib.csic.es	Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019; Diaz Guerra, Eva/F-8048-2016	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; Diaz Guerra, Eva/0000-0003-4866-5880	Spanish Ministry of Science and Technology [SAF2009-07974]; ISCIII [RD06/0010/1010]; Spanish National Research Council (CSIC) [PIE200420E240, PIE200420E586]	Spanish Ministry of Science and Technology(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); ISCIII(Instituto de Salud Carlos III); Spanish National Research Council (CSIC)	The authors thank E. W. Mullner, Z. Garcia, G. Elvira, P. Perez-Arnaiz, and M. L. Martinez for critically reading the manuscript; A. Silva for helpful comments, critical discussions, and continuous support; C. Brisken and R. Clarke for instruction on purifying and growing mammospheres; M. I. Gallego [Instituto de Salud Carlos III (ISCIII), Madrid, Spain] for helpful comments and sharing reagents; P. Lastres for FACS analyses; and R. Vernal for statistical analyses. The authors are grateful to the personnel at the Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientificas (CIB-CSIC) animal facility for animal care and the CNB-CSIC histology service for sample processing. G. Gimenez (CIB-CSIC, Madrid) kindly provided the bFGF and J. Biber (University of Zurich, Zurich, Switzerland) the NaPi 11b antisera. The work in the authors' laboratory was supported by grants from the Spanish Ministry of Science and Technology, contract SAF2009-07974; ISCIII, contract number RD06/0010/1010; and the Spanish National Research Council (CSIC), contract number PIE200420E240 and PIE200420E586. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Bonnefoix T, 1996, J IMMUNOL METHODS, V194, P113, DOI 10.1016/0022-1759(96)00077-4; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2007, STEM CELL REV, V3, P147, DOI 10.1007/s12015-007-0019-1; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke RB, 1997, CANCER RES, V57, P4987; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DEOME KB, 1959, CANCER RES, V19, P515; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Horner MJ, 2009, SEER CANC STAT REV 1; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kanhai RCJ, 2000, AM J SURG PATHOL, V24, P74, DOI 10.1097/00000478-200001000-00009; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Martins RAP, 2008, GENE DEV, V22, P179, DOI 10.1101/gad.1608008; Molyneux G, 2007, CELL MOL LIFE SCI, V64, P3248, DOI 10.1007/s00018-007-7391-5; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Stanger BZ, 2008, DIABETES OBES METAB, V10, P16, DOI 10.1111/j.1463-1326.2008.00938.x; Stanger BZ, 2007, NATURE, V445, P886, DOI 10.1038/nature05537; STEVENSON RD, 1995, P ROY SOC B-BIOL SCI, V259, P105, DOI 10.1098/rspb.1995.0016; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	32	7	7	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3844	3853		10.1096/fj.11-200782	http://dx.doi.org/10.1096/fj.11-200782			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22683848	Green Submitted			2022-12-28	WOS:000308391600024
J	Pashover-Schallinger, E; Aswad, M; Schif-Zuck, S; Shapiro, H; Singer, P; Ariel, A				Pashover-Schallinger, Ester; Aswad, Miran; Schif-Zuck, Sagie; Shapiro, Haim; Singer, Pierre; Ariel, Amiram			The atypical chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the resolution of inflammation	FASEB JOURNAL			English	Article						chemokine receptors; apoptotic cell clearance; acute immune responses; leukocytes	APOPTOTIC CELLS; ALTERNATIVE ACTIVATION; NEUTROPHILS; PHAGOCYTOSIS; ENGULFMENT; EXPRESSION; CLEARANCE; SIGNALS; IL-10; BETA	The resolution of acute inflammation is hallmarked by the apoptotic death of inflammatory polymorphonuclear (PMN) cells, followed by their clearance by macrophages. In turn, resolution-phase macrophages exert reduced proinflammatory cytokine production, termed immune silencing. In this study, we found that the atypical chemokine receptor D6 plays an important and chemokine scavenging-independent role in promoting macrophage-mediated resolution. D6(-/-) mice displayed increased numbers of macrophages (2.2-fold increase), but not neutrophils, in their peritonea during the resolution of murine zymosan A-initiated peritonitis, in comparison to D6(+/+) animals. Moreover, D6-deficient macrophages engulfed higher numbers of apoptotic PMN cells in vivo (1.6-fold increase), and secreted higher amounts of TNF-alpha, CCL3, and CCL5 ex vivo than their wild-type (WT) counterparts. In addition, D6 was found to be expressed on apoptotic neutrophils from healthy humans and rodents. Moreover, the immune silencing of LPS-stimulated macrophages following their incubation with senescent PMN cells ex vivo (in terms of TNF-alpha, IL-1 beta, and CCL5 secretion) was diminished (50-65% decrease) when D6(-/-) PMN cells were applied. Accordingly, the adhesive responses induced by macrophage interactions with senescent PMN cells were reduced with D6-deficient PMN cells. Thus, our results indicate a novel mode of action for D6 during the resolution of inflammation that is instrumental to the shaping of resolving macrophage phenotypes and the completion of resolution.-Pashover-Schallinger, E., Aswad, M., Schif-Zuck, S., Shapiro, H., Singer, P., Ariel, A. The atypical chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the resolution of inflammation. FASEB J. 26, 3891-3900 (2012). www.fasebj.org	[Pashover-Schallinger, Ester; Aswad, Miran; Schif-Zuck, Sagie; Ariel, Amiram] Univ Haifa, Fac Nat Sci, Dept Biol, IL-31905 Haifa, Israel; [Shapiro, Haim; Singer, Pierre] Rabin Med Ctr, Inst Nutr Res, Petah Tiqwa, Israel	University of Haifa; Rabin Medical Center	Ariel, A (corresponding author), Univ Haifa, Fac Nat Sci, Dept Biol, IL-31905 Haifa, Israel.	amiram@research.haifa.ac.il	Shapiro, Haim/E-1854-2018	Shapiro, Haim/0000-0001-9374-4049; Schif-Zuck, Sagie/0000-0001-5415-9488	Israel Science Foundation [534/09]; Nutricia Research Foundation; Marc Rich Foundation; Teva Pharmaceuticals Ltd. (Natania, Israel)	Israel Science Foundation(Israel Science Foundation); Nutricia Research Foundation(Danone Nutricia); Marc Rich Foundation; Teva Pharmaceuticals Ltd. (Natania, Israel)(Teva Pharmaceutical Industries)	The authors thank Profs. Alberto Mantovani and Massimo Locati (Instituto Clinico Humanitas, Milan, Italy) for providing the D6<SUP>-/-</SUP> mice and for their helpful advice and Simaan Assi for technical assistance with animal procedures. This work was supported by grants from the Israel Science Foundation (grant 534/09), the Nutricia Research Foundation, and the Marc Rich Foundation (to A. A.). A. A. is a recipient of the young scientist award from Teva Pharmaceuticals Ltd. (Natania, Israel). The authors declare no conflicts of interest.	Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529; Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398; Ariel A, 2006, NAT IMMUNOL, V7, P1209, DOI 10.1038/ni1392; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; Bonecchi R, 2008, BLOOD, V112, P493, DOI 10.1182/blood-2007-08-108316; Bordon Y, 2009, J IMMUNOL, V182, P5032, DOI 10.4049/jimmunol.0802802; Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968; Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; de la Torre YM, 2007, P NATL ACAD SCI USA, V104, P2319, DOI 10.1073/pnas.0607514104; de la Torre YM, 2005, EUR J IMMUNOL, V35, P1342, DOI 10.1002/eji.200526114; Di Liberto D, 2008, J EXP MED, V205, P2075, DOI 10.1084/jem.20070608; Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Golpon HA, 2004, FASEB J, V18, P1716, DOI 10.1096/fj.04-1853fje; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hart D, 2008, J IMMUNOL, V181, P8053, DOI 10.4049/jimmunol.181.11.8053; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Jamieson T, 2005, NAT IMMUNOL, V6, P403, DOI 10.1038/ni1182; Kim SJ, 2004, IMMUNITY, V21, P643, DOI 10.1016/j.immuni.2004.09.009; KOWOLENKO M, 1990, J IMMUNOL METHODS, V127, P71, DOI 10.1016/0022-1759(90)90342-S; Lee KM, 2011, BLOOD, V118, P6220, DOI 10.1182/blood-2011-03-344044; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liu LP, 2006, J IMMUNOL, V177, P17, DOI 10.4049/jimmunol.177.1.17; Majno G., 2004, CELLS TISSUES DIS PR; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; McKimmie CS, 2008, J IMMUNOL, V181, P8170, DOI 10.4049/jimmunol.181.11.8170-a; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Nibbs RJB, 2009, METHOD ENZYMOL, V460, P245, DOI 10.1016/S0076-6879(09)05212-4; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; ROSSI AG, 1998, LUNG BIOL HEALTH DIS, V112, P9; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Vetrano S, 2010, GUT, V59, P197, DOI 10.1136/gut.2009.183772; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weigert A, 2009, BIOL CHEM, V390, P379, DOI 10.1515/BC.2009.048; Whitehead GS, 2007, AM J RESP CRIT CARE, V175, P243, DOI 10.1164/rccm.200606-839OC	45	29	30	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3891	3900		10.1096/fj.11-194894	http://dx.doi.org/10.1096/fj.11-194894			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22651933				2022-12-28	WOS:000308391600029
J	Harmancey, R; Lam, TN; Lubrano, GM; Guthrie, PH; Vela, D; Taegtmeyer, H				Harmancey, Romain; Lam, Truong N.; Lubrano, Genna M.; Guthrie, Patrick H.; Vela, Deborah; Taegtmeyer, Heinrich			Insulin resistance improves metabolic and contractile efficiency in stressed rat heart	FASEB JOURNAL			English	Article						high-sucrose diet; metabolism; hyperglycemia; glucotoxicity	UNCOUPLING PROTEIN-3; SKELETAL-MUSCLE; FAILURE; GLUCOSE; HYPERGLYCEMIA; EXPRESSION	Insulin resistance is a prominent feature in heart failure, while hyperglycemia impairs cardiac contraction. We propose that decreased insulin-mediated glucose uptake by the heart preserves cardiac function in response to metabolic and hemodynamic stress. To test this hypothesis, we fed rats a high-sucrose diet (HSD). Energy substrate metabolism and cardiac work were determined ex vivo in a sequential protocol simulating metabolic and hemodynamic stress. Compared to chow-fed, control rats, HSD impaired myocardial insulin responsiveness and induced profound metabolic changes in the heart, characterized by reduced rates of glucose uptake (7.91 +/- 0.30 vs. 10.73 +/- 0.67 mu mol/min/g dry weight; P<0.001) but increased rates of glucose oxidation (2.38 +/- 0.17 vs. 1.50 +/- 0.15 mu mol/min/g dry weight; P<0.001) and oleate oxidation (2.29 +/- 0.11 vs. 1.96 +/- 0.12 mu mol/min/g dry weight; P<0.05). Tight coupling of glucose uptake and oxidation and improved cardiac efficiency were associated with a reduction in glucose 6-phosphate and oleoyl-CoA levels, as well as a reduction in the content of uncoupling protein 3. Our results suggest that insulin resistance lessens fuel toxicity in the stressed heart. This calls for a new exploration of the mechanisms regulating substrate uptake and oxidation in the insulin-resistant heart.-Harmancey, R., Lam, T. N., Lubrano, G. M., Guthrie, P. H., Vela, D., Taegtmeyer, H. Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J. 26, 3118-3126 (2012). www.fasebj.org	[Harmancey, Romain; Lam, Truong N.; Lubrano, Genna M.; Guthrie, Patrick H.; Vela, Deborah; Taegtmeyer, Heinrich] Univ Texas Med Sch Houston, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Taegtmeyer, H (corresponding author), Univ Texas Med Sch Houston, Div Cardiol, Dept Internal Med, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.	heinrich.taegtmeyer@uth.tmc.edu		Lam, Truong/0000-0001-8634-8398	U.S. National Heart, Lung, and Blood Institute; American Heart Association; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483] Funding Source: NIH RePORTER	U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank the Mouse Metabolism Core (Baylor College of Medicine, Houston, TX, USA) for the plasma analyses and Roxy Tate for editorial assistance. Figure 6 was produced using Servier Medical Art (http://www.servier.com/servier-medical-art). This work was supported by grants from the U.S. National Heart, Lung, and Blood Institute and the American Heart Association.	Azzu V, 2010, BBA-BIOENERGETICS, V1797, P785, DOI 10.1016/j.bbabio.2010.02.035; Chess DJ, 2008, CARDIOVASC RES, V79, P269, DOI 10.1093/cvr/cvn074; Christopher BA, 2010, AM J PHYSIOL-HEART C, V299, pH1917, DOI 10.1152/ajpheart.00687.2010; Clark RJ, 2003, J BIOL CHEM, V278, P44230, DOI 10.1074/jbc.M303810200; GARVEY WT, 1993, AM J PHYSIOL, V264, pH837, DOI 10.1152/ajpheart.1993.264.3.H837; Goodwin GW, 1998, AM J PHYSIOL-HEART C, V274, pH1239, DOI 10.1152/ajpheart.1998.274.4.H1239; Harmancey R, 2010, J LIPID RES, V51, P1380, DOI 10.1194/jlr.M001230; Ingelsson E, 2005, JAMA-J AM MED ASSOC, V294, P334, DOI 10.1001/jama.294.3.334; Jimenez M, 2002, EUR J BIOCHEM, V269, P2878, DOI 10.1046/j.1432-1033.2002.02953.x; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KATZ J, 1967, BIOCHEMISTRY-US, V6, P1, DOI 10.1021/bi00853a001; Kontani Y, 2002, J BIOCHEM, V132, P309, DOI 10.1093/oxfordjournals.jbchem.a003225; Lang G., 1981, METHOD ENZYMAT AN, P1238; Luiken JJFP, 2002, DIABETES, V51, P3113, DOI 10.2337/diabetes.51.10.3113; Mellor KM, 2010, CAN J PHYSIOL PHARM, V88, P525, DOI [10.1139/Y10-005, 10.1139/y10-005]; Pagliassotti MJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE170, DOI 10.1152/ajpendo.2002.282.1.E170; PAGLIASSOTTI MJ, 1994, AM J PHYSIOL, V266, pR1637, DOI 10.1152/ajpregu.1994.266.5.R1637; RANDLE PJ, 1963, LANCET, V1, P785; Rodriguez-Sureda V, 2005, ANAL BIOCHEM, V343, P277, DOI 10.1016/j.ab.2005.05.009; Rossetti L, 2004, DIABETES MELLITUS FU, P939; Rubin J, 2012, J AM COLL CARDIOL, V59, P484, DOI 10.1016/j.jacc.2011.10.875; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; STARNES JW, 1985, AM J PHYSIOL, V249, pH799, DOI 10.1152/ajpheart.1985.249.4.H799; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; Tang WH, 2010, AM J PHYSIOL-CELL PH, V299, pC643, DOI 10.1152/ajpcell.00137.2010	25	33	34	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3118	3126		10.1096/fj.12-208991	http://dx.doi.org/10.1096/fj.12-208991			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22611083	Green Published			2022-12-28	WOS:000307162800004
J	Jin, L; Sturgis, EM; Cao, XL; Song, XC; Salahuddin, T; Wei, QY; Li, GJ				Jin, Lei; Sturgis, Erich M.; Cao, Xiaolin; Song, Xicheng; Salahuddin, Taufiq; Wei, Qingyi; Li, Guojun			Interleukin-10 promoter variants predict HPV-positive tumors and survival of squamous cell carcinoma of the oropharynx	FASEB JOURNAL			English	Article						IL-10 variants; HPV; oropharyngeal cancer; smoking; biomarkers; survival	HUMAN-PAPILLOMAVIRUS; IL-10 POLYMORPHISMS; CYTOKINE SYNTHESIS; TONSILLAR CANCER; GENE PROMOTER; NECK-CANCER; RISK-FACTOR; HEAD; ASSOCIATION; INFECTION	Interleukin-10 (IL-10) plays an important role in a host's defense against human papillomavirus (HPV) infection. IL-10 promoter variants may affect its expression level or functional efficiency and, subsequently, susceptibility to and survival of HPV16-associated squamous cell carcinoma of oropharynx (SCCOP). We determined tumor HPV16 DNA and genotyped three IL-10 promoter polymorphisms in 309 incident patients with SCCOP. Compared with the patients with corresponding common homozygous genotypes, patients carrying variant genotypes of IL-10 rs1800871 and rs1800872 were similar to 2.5 times more likely to have HPV16(+) tumors among patients with SCCOP. Among HPV16(+) patients with SCCOP only, compared to those with the corresponding variant genotypes, the patients with IL-10 rs1800871 and rs1800872 CC genotypes had significantly better survival and similar to 70-80% reduced risk of death/recurrence after multivariable adjustment. Additionally, functional relevance of these variants was characterized to explore the genotype-phenotype correlation. Our findings indicate that IL-10 genetic variants may be associated with tumor HPV16(+) SCCOP and predict survival of HPV16(+) patients with SCCOP. Larger studies are needed to validate our findings.	[Jin, Lei; Sturgis, Erich M.; Cao, Xiaolin; Song, Xicheng; Salahuddin, Taufiq; Li, Guojun] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Wei, Qingyi; Li, Guojun] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; [Jin, Lei; Sturgis, Erich M.] Southern Med Univ, Sch Med, Jinling Hosp, Dept Stomatol, Nanjing, Jiangsu, Peoples R China; [Song, Xicheng] Qingdao Univ, Yuhuangding Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Yantai, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Southern Medical University - China; Qingdao University	Li, GJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 1445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gli@mdanderson.org			U.S. National Institute of Environmental Health Sciences [R01 ES-11740]; U.S. National Institutes of Health [CA 135679, CA133099]; NATIONAL CANCER INSTITUTE [R03CA135679, K07CA133099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011740] Funding Source: NIH RePORTER	U.S. National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors gratefully thank Ms. Dawn Chalaire for article editing, and Dr. Chong Zhao and Ms. Yingdong Li for laboratory support. This study was supported by U.S. National Institute of Environmental Health Sciences grant R01 ES-11740 (to Q. W.) and U.S. National Institutes of Health grants CA 135679 and CA133099 (to G. L.) The authors declare no conflicts of interest.	Bolpetti A, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-27; Dahlstrom KR, 2003, CLIN CANCER RES, V9, P2620; Farzaneh F, 2006, BJOG-INT J OBSTET GY, V113, P961, DOI 10.1111/j.1471-0528.2006.00956.x; Fortis C, 1996, CANCER LETT, V104, P1, DOI 10.1016/0304-3835(96)04213-9; Gerger A, 2010, BREAST CANCER RES TR, V119, P701, DOI 10.1007/s10549-009-0417-y; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Guan XX, 2010, CLIN CANCER RES, V16, P1416, DOI 10.1158/1078-0432.CCR-09-2877; Hammarstedt L, 2006, INT J CANCER, V119, P2620, DOI 10.1002/ijc.22177; Huang SY, 1999, J INTERF CYTOK RES, V19, P697, DOI 10.1089/107999099313532; Ivansson EL, 2007, INT J CANCER, V121, P2451, DOI 10.1002/ijc.22989; Jeong SW, 2010, J KOREAN MED SCI, V25, P1024, DOI 10.3346/jkms.2010.25.7.1024; Ji XM, 2009, CANCER-AM CANCER SOC, V115, P1660, DOI 10.1002/cncr.24184; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; Lech-Maranda E, 2004, BLOOD, V103, P3529, DOI 10.1182/blood-2003-06-1850; MALEFYT RD, 1991, J EXP MED, V174, P1209; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Mellin H, 2000, INT J CANCER, V89, P300, DOI 10.1002/1097-0215(20000520)89:3<300::AID-IJC14>3.0.CO;2-G; Michaud DS, 2006, CANCER RES, V66, P4525, DOI 10.1158/0008-5472.CAN-05-3987; Miller CS, 2001, ORAL SURG ORAL MED O, V91, P622, DOI 10.1067/moe.2001.115392; Miller DL, 2012, BIOCHEM J, V443, P339, DOI 10.1042/BJ20112017; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Park JS, 2001, INT J CANCER, V91, P822, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0; Ritchie JM, 2003, INT J CANCER, V104, P336, DOI 10.1002/ijc.10960; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Seifart C, 2005, DIS MARKERS, V21, P157, DOI 10.1155/2005/707131; Shrestha S, 2007, CANCER EPIDEM BIOMAR, V16, P1626, DOI 10.1158/1055-9965.EPI-06-0881; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sturgis EM, 2002, CURR OPIN ONCOL, V14, P310, DOI 10.1097/00001622-200205000-00010; Sturgis EM, 2007, CANCER-AM CANCER SOC, V110, P1429, DOI 10.1002/cncr.22963; TAN JQ, 1993, J IMMUNOL, V151, P4545; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; VELDE AAT, 1992, J IMMUNOL, V149, P4048; Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014; Vuoristo MS, 2007, CANCER GENET CYTOGEN, V176, P54, DOI 10.1016/j.cancergencyto.2007.03.002; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; Yao JG, 2008, CLIN CHIM ACTA, V388, P84, DOI 10.1016/j.cca.2007.10.012; Zoodsma M, 2005, INT J GYNECOL CANCER, V15, P282, DOI 10.1111/j.1525-1438.2005.00433.x	37	12	13	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2013	27	6					2496	2503		10.1096/fj.12-226803	http://dx.doi.org/10.1096/fj.12-226803			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	154II	23430974	Green Published			2022-12-28	WOS:000319667600037
J	Rubin, CT; Seeherman, H; Qin, YX; Gross, TS				Rubin, Clinton T.; Seeherman, Howard; Qin, Yi-Xian; Gross, Ted S.			The mechanical consequences of load bearing in the equine third metacarpal across speed and gait: the nonuniform distributions of normal strain, shear strain, and strain energy density	FASEB JOURNAL			English	Article						stress history; locomotion; skeleton; cannon bone; bone remodeling; bone adaptation; vertebrate morphology	BONE-MINERAL LOSS; LONG BONES; LOCOMOTION; STRESS; ADAPTATION; RACEHORSES; SIMILARITY; FORELIMB; STIMULUS; TISSUE	Distributions of normal strain, shear strain, and strain energy density (SED) were determined across the midshaft of the third metacarpal (MCIII, or cannon bone) of 3 adult thoroughbred horses as a function of speed and gait. A complete characterization of the mechanical demands of the bone made through the stride and from mild through the extremes of locomotion was possible by using three 3-element rosette strain gauges bonded at the diaphyseal midshaft of the MCIII and evaluating the strain output with beam theory and finite element analysis. Mean +/- SD values of normal strain, shear strain, and SED increased with speed and peaked during a canter (-3560 +/- 380 microstrain, 1760 +/- 470 microstrain, and 119 +/- 23 kPa, respectively). While the location of these peaks was similar across animals and gaits, the resulting strain distributions across the cortex were consistently nonuniform, establishing between a 73-fold (slow trot) to a 330-fold (canter) disparity between the sites of maximum and minimum SED for each gait cycle. Using strain power density as an estimate of strain history across the bone revealed a 154-fold disparity between peak and minimum at the walk but fell to similar to 32-fold at the canter. The nonuniform, minimally varying, strain environment suggests either that bone homeostasis is mediated by magnitude-independent mechanical signals or that the duration of stimuli necessary to establish and maintain tissue integrity is relatively brief, and thus the vast majority of strain information is disregarded.	[Rubin, Clinton T.; Qin, Yi-Xian] SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, Stony Brook, NY 11794 USA; [Seeherman, Howard] Pfizer Res, Tissue Repair Grp, Cambridge, MA USA; [Gross, Ted S.] Univ Washington, Orthopaed Sci Labs, Dept Orthoped & Sports Med, Seattle, WA 98195 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pfizer; University of Washington; University of Washington Seattle	Rubin, CT (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Musculoskeletal Res Lab, Stony Brook, NY 11794 USA.	clinton.rubin@stonybrook.edu			U.S. National Institutes of Health [AR-49438, EB914351]; U.S. Army; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061821, R01AR052379] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Army(United States Department of DefenseUnited States Army); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was kindly supported by U.S. National Institutes of Health grants AR-49438 and EB914351 and by the U.S. Army. The authors are grateful to the veterinary staff at Tufts University in general and to Linda Kinney in particular, as well as to Ken McLeod for his tremendous help with data collection. This work was performed at the Equine Sports Medicine Center at the Cummings School of Veterinary Medicine (Tufts University, North Grafton, MA, USA). The authors declare no conflicts of interest.	Adams DJ, 1997, J BIOMECH, V30, P671, DOI 10.1016/S0021-9290(97)00004-3; BEAUPRE GS, 1990, J ORTHOPAED RES, V8, P662, DOI 10.1002/jor.1100080507; BIEWENER AA, 1986, CALCIFIED TISSUE INT, V39, P390, DOI 10.1007/BF02555177; BIEWENER AA, 1983, J BIOMECH, V16, P565, DOI 10.1016/0021-9290(83)90107-0; BIEWENER AA, 1990, SCIENCE, V250, P1097, DOI 10.1126/science.2251499; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756-3282(96)00028-2; COWIN SC, 1987, J BIOMECH, V20, P1111, DOI 10.1016/0021-9290(87)90028-5; CURREY JD, 1979, J BIOMECH, V12, P313, DOI 10.1016/0021-9290(79)90073-3; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; FROST HM, 1990, ANAT REC, V226, P403, DOI 10.1002/ar.1092260402; FROST HM, 1992, BONE MINER, V19, P257, DOI 10.1016/0169-6009(92)90875-E; Frost HM, 1986, INTERMEDIARY ORG SKE; Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982; GROSS TS, 1992, J BIOMECH, V25, P1081, DOI 10.1016/0021-9290(92)90044-2; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307; LANYON LE, 1970, ACTA ORTHOP SCAND, V41, P238, DOI 10.3109/17453677008991511; LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021-9290(87)90026-1; LEBLANC AD, 1990, J BONE MINER RES, V5, P843; Moreno CA, 2008, J EXP BIOL, V211, P1148, DOI 10.1242/jeb.012419; NUNAMAKER DM, 1990, J ORTHOPAED RES, V8, P604, DOI 10.1002/jor.1100080417; NUNAMAKER DM, 1991, AM J VET RES, V52, P97; OCONNOR JA, 1982, J BIOMECH, V15, P767, DOI 10.1016/0021-9290(82)90092-6; Qin YX, 1996, J ORTHOPAED RES, V14, P862, DOI 10.1002/jor.1100140604; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; RUBIN CT, 1984, J THEOR BIOL, V107, P321, DOI 10.1016/S0022-5193(84)80031-4; RYBICKI EF, 1977, J BIOMECH, V10, P701, DOI 10.1016/0021-9290(77)90085-9; Skedros JG, 1996, ANAT RECORD, V246, P47; Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076; van der Meulen MCH, 2002, J BIOMECH, V35, P401, DOI 10.1016/S0021-9290(01)00184-1; Weinbaum S, 2001, BIORHEOLOGY, V38, P119; Wolff J, 1892, GESETZ TRANSFORMATIO	36	20	20	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2013	27	5					1887	1894		10.1096/fj.12-216804	http://dx.doi.org/10.1096/fj.12-216804			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23355269	Green Published			2022-12-28	WOS:000318226100009
J	Yu, WQ; Sun, XF; Robson, SC; Hill, WG				Yu, Weiqun; Sun, Xiaofeng; Robson, Simon C.; Hill, Warren G.			Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y(6) activation of the phospholipase C/inositol trisphosphate pathway	FASEB JOURNAL			English	Article						detrusor; uridine nucleotides; urinary tract; micturition; myography	PURINERGIC RECEPTOR EXPRESSION; AGE-RELATED-CHANGES; URINARY-BLADDER; UROTHELIAL CELLS; HUMAN DETRUSOR; ATP RELEASE; PURINOCEPTOR EXPRESSION; QUANTITATIVE-ANALYSIS; P2X(3) RECEPTOR; RELAXATION	Bladder dysfunction characterized by abnormal bladder smooth muscle (BSM) contractions is pivotal to the disease process in overactive bladder, urge incontinence, and spinal cord injury. Purinergic signaling comprises one key pathway in modulating BSM contractility, but molecular mechanisms remain unclear. Here we demonstrate, using myography, that activation of P2Y(6) by either UDP or a specific agonist (MRS 2693) induced a sustained increase in BSM tone (up to 2 mN) in a concentration-dependent manner. Notably, activation of P2Y(6) enhanced ATP-mediated BSM contractile force by up to 45%, indicating synergistic interactions between P2X and P2Y signaling. P2Y(6)-activated responses were abolished by phospholipase C (PLC) and inositol trisphosphate (IP3) receptor antagonists U73122 and xestospongin C, demonstrating involvement of the PLC/ IP3 signal pathway. Mice null for Entpd1, an ectonucleotidase on BSM, demonstrated increased force generation on P2Y(6) activation (150%). Thus, in vivo perturbations to purinergic signaling resulted in altered P2Y(6) activity and bladder contractility. We conclude that UDP, acting on P2Y(6), regulates BSM tone and in doing so selectively maximizes P2X(1)-mediated contraction forces. This novel neurotransmitter pathway may play an important role in urinary voiding disorders characterized by abnormal bladder motility.	[Yu, Weiqun; Hill, Warren G.] Beth Israel Deaconess Med Ctr, Lab Voiding Dysfunct, Boston, MA 02215 USA; [Yu, Weiqun] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA; [Sun, Xiaofeng; Robson, Simon C.] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; [Hill, Warren G.] Beth Israel Deaconess Med Ctr, Div Matrix Biol, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hill, WG (corresponding author), Beth Israel Deaconess Med Ctr, RN349,330 Brookline Ave, Boston, MA 02215 USA.	whill@bidmc.harvard.edu	Hill, Warren/AAM-1917-2020; Robson, Simon C./AAA-8537-2021	Hill, Warren/0000-0002-2772-7264; 	U.S. National Institute of Diabetes and Digestive and Kidney Diseases [DK083299]; U.S. National Heart, Lung, and Blood Institute [P01-HL076540, R01-HL094400]; NATIONAL CANCER INSTITUTE [R21CA164970] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076540, R01HL094400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI074490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083299] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Bernard Robaye (Universite Libre de Bruxelles, Brussels, Belgium) for providing bladders from P2Y<INF>6</INF>-knockout mice. The project described was supported by the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (grant DK083299 to W.G.H.) and the U.S. National Heart, Lung, and Blood Institute (grants P01-HL076540 and R01-HL094400 to S.C.R.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. National Institutes of Health.	Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Bar I, 2008, MOL PHARMACOL, V74, P777, DOI 10.1124/mol.108.046904; Bayliss M, 1999, J UROLOGY, V162, P1833, DOI 10.1016/S0022-5347(05)68247-X; Berridge MJ, 2008, J PHYSIOL-LONDON, V586, P5047, DOI 10.1113/jphysiol.2008.160440; Birder LA, 2004, AM J PHYSIOL-RENAL, V287, pF1084, DOI 10.1152/ajprenal.00118.2004; Birder LA, 2003, AM J PHYSIOL-RENAL, V285, pF423, DOI 10.1152/ajprenal.00056.2003; BOLAND B, 1993, BRIT J PHARMACOL, V108, P749, DOI 10.1111/j.1476-5381.1993.tb12872.x; BOLEGO C, 1995, BRIT J PHARMACOL, V114, P1557, DOI 10.1111/j.1476-5381.1995.tb14939.x; Brady CM, 2004, EUR UROL, V46, P247, DOI 10.1016/j.eururo.2003.12.017; BURNSTOCK G, 1972, BRIT J PHARMACOL, V46, P234, DOI 10.1111/j.1476-5381.1972.tb06868.x; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Burnstock G, 2011, BJU INT, V107, P192, DOI 10.1111/j.1464-410X.2010.09926.x; Calvert RC, 2001, J UROLOGY, V166, P1530, DOI 10.1016/S0022-5347(05)65825-9; Chua WCN, 2007, EXP GERONTOL, V42, P686, DOI 10.1016/j.exger.2007.02.003; de Groat WC, 2010, NEUROUROL URODYNAM, V29, P63, DOI 10.1002/nau.20761; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FINKBEINER AE, 1980, UROLOGY, V16, P650, DOI 10.1016/0090-4295(80)90582-8; Ford Anthony P D W, 2011, Handb Exp Pharmacol, P485, DOI 10.1007/978-3-642-16499-6_22; Frazier EP, 2008, N-S ARCH PHARMACOL, V377, P449, DOI 10.1007/s00210-007-0208-0; Fry CH, 2012, AM J PHYSIOL-RENAL, V302, pF1447, DOI 10.1152/ajprenal.00436.2011; Heppner TJ, 2009, J PHYSIOL-LONDON, V587, P5275, DOI 10.1113/jphysiol.2009.178806; Jacobson KA, 2009, PURINERG SIGNAL, V5, P75, DOI 10.1007/s11302-008-9106-2; Kageyama A, 2008, NEUROSCI LETT, V436, P81, DOI 10.1016/j.neulet.2008.02.065; Kim JC, 2008, BJU INT, V101, P371, DOI 10.1111/j.1464-410X.2007.07251.x; King BF, 2004, BRIT J PHARMACOL, V142, P519, DOI 10.1038/sj.bjp.0705790; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kumar V, 2010, EUR UROL, V57, P1087, DOI 10.1016/j.eururo.2009.11.042; Moore KH, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0002.2001; Nishida M, 2008, EMBO J, V27, P3104, DOI 10.1038/emboj.2008.237; O'Reilly BA, 2001, BJU INT, V87, P617, DOI 10.1046/j.1464-410x.2001.02179.x; O'Reilly BA, 2001, J UROLOGY, V165, P1730, DOI 10.1016/S0022-5347(05)66403-8; Pinna C, 2006, LIFE SCI, V79, P1301, DOI 10.1016/j.lfs.2006.03.035; Ray FR, 2003, CELL TISSUE RES, V314, P351, DOI 10.1007/s00441-003-0788-z; Rayment SJ, 2007, BRIT J PHARMACOL, V150, P604, DOI 10.1038/sj.bjp.0707120; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; SIBLEY GNA, 1984, J PHYSIOL-LONDON, V354, P431, DOI 10.1113/jphysiol.1984.sp015386; SJOGREN C, 1982, J UROLOGY, V128, P1368, DOI 10.1016/S0022-5347(17)53509-0; Smith CP, 2008, NEUROCHEM INT, V52, P1068, DOI 10.1016/j.neuint.2007.11.006; Smith CP, 2005, NEUROCHEM INT, V47, P291, DOI 10.1016/j.neuint.2005.04.021; Sugaya K, 2009, BIOMED RES-TOKYO, V30, P287, DOI 10.2220/biomedres.30.287; Sun Y, 2006, AM J PHYSIOL-CELL PH, V290, pC27, DOI 10.1152/ajpcell.00552.2004; Sun Y, 2004, J UROLOGY, V171, P448, DOI 10.1097/01.ju.0000099660.46774.3c; Sun Y, 2002, BJU INT, V90, P381, DOI 10.1046/j.1464-410X.2002.02912.x; Sun Y, 2010, CURR BLADDER DYSFUNC, V5, P219, DOI 10.1007/s11884-010-0063-6; Tempest HV, 2004, BJU INT, V93, P1344, DOI 10.1111/j.1464-410X.2004.04858.x; Tong YC, 1997, NEUROSCI LETT, V225, P181, DOI 10.1016/S0304-3940(97)00212-7; Vial C, 2000, BRIT J PHARMACOL, V131, P1489, DOI 10.1038/sj.bjp.0703720; Yoshida M, 2004, UROLOGY, V63, P17, DOI 10.1016/j.urology.2003.11.003; Yoshida M, 2001, EXP GERONTOL, V36, P99, DOI 10.1016/S0531-5565(00)00175-3; Yu WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018704	50	25	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2013	27	5					1895	1903		10.1096/fj.12-219006	http://dx.doi.org/10.1096/fj.12-219006			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134PU	23362118	Green Published			2022-12-28	WOS:000318226100010
J	Gu, BJ; Baird, PN; Vessey, KA; Skarratt, KK; Fletcher, EL; Fuller, SJ; Richardson, AJ; Guymer, RH; Wiley, JS				Gu, Ben J.; Baird, Paul N.; Vessey, Kirstan A.; Skarratt, Kristen K.; Fletcher, Erica L.; Fuller, Stephen J.; Richardson, Andrea J.; Guymer, Robyn H.; Wiley, James S.			A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration	FASEB JOURNAL			English	Article						drusen; microglia; scavenger receptor	RETINAL-PIGMENT EPITHELIUM; EXTRACELLULAR ATP; APOPTOTIC CELLS; P2X(7) RECEPTOR; SCAVENGER RECEPTOR; BRUCHS MEMBRANE; P2X7 RECEPTOR; POLYMORPHISM; MICROGLIA; BRAIN	Age-related macular degeneration (AMD) is a leading cause of blindness in Western countries and is diagnosed by the clinical appearance of yellow subretinal deposits called drusen. Genetic changes in immune components are clearly implicated in the pathology of this disease. We have previously shown that the purinergic receptor P2X7 can act as a scavenger receptor, mediating phagocytosis of apoptotic cells and insoluble debris. We performed a genetic association study of functional polymorphisms in the P2RX7 and P2RX4 genes in a cohort of 744 patients with AMD and 557 age-matched Caucasian control subjects. The P2X4 Tyr315Cys variant was 2-fold more frequent in patients with AMD compared to control subjects, with the minor allele predicting susceptibility to disease. Pairwise linkage disequilibrium was observed between Tyr315Cys in the P2RX4 gene and Gly150Arg in the P2RX7 gene, and these two minor alleles formed a rare haplotype that was overrepresented in patients with AMD (n=17) compared with control subjects (n=3) (odds ratio 4.05, P=0.026). Expression of P2X7 (wild type or variant 150Arg) in HEK293 cells conferred robust phagocytosis toward latex beads, whereas coexpression of the P2X7 150Arg with P2X4 315Cys variants almost completely inhibited phagocytic capacity. Fresh human monocytes harboring this heterozygous 150Arg-315Cys haplotype showed 40% reduction in bead phagocytosis. In the primate eye, immunohistochemistry indicated that P2X7 and P2X4 receptors were coexpressed on microglia and macrophages, but neither receptor was seen on retinal pigment epithelial cells. These results demonstrate that a haplotype including two rare variants in P2RX7 and P2RX4 confers a functional interaction between these two variant receptors that impairs the normal scavenger function of macrophages and microglia. Failure of this P2X7-mediated phagocytic pathway may impair removal of subretinal deposits and predispose individuals toward AMD.-Gu, B. J., Baird, P. N., Vessey, K. A., Skarratt, K. K., Fletcher, E. L., Fuller, S. J., Richardson, A. J., Guymer, R. H., Wiley, J. S. A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age related macular degeneration. FASEB J. 27, 1479-1487 (2013). www.fasebj.org	[Gu, Ben J.; Wiley, James S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia; [Vessey, Kirstan A.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia; [Baird, Paul N.; Richardson, Andrea J.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia; [Skarratt, Kristen K.; Fuller, Stephen J.; Wiley, James S.] Univ Sydney, Nepean Hosp, Nepean Clin Sch, Penrith, NSW, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne; Nepean Hospital; University of Sydney	Wiley, JS (corresponding author), Univ Melbourne, Florey Neurosci Inst, Parkville, Vic 3010, Australia.	james.wiley@florey.edu.au	Fletcher, Erica/E-6364-2012; Skarratt, Kristy/AAN-1479-2020; Fuller, Stephen/W-6646-2019	Fletcher, Erica/0000-0001-9412-9523; Fuller, Stephen/0000-0003-4637-7391; Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502; Gu, Ben/0000-0001-5500-4453; Skarratt, Kristy/0000-0003-4971-2773; Vessey, Kirstan/0000-0003-1031-1964; Wiley, James/0000-0001-9421-4154	Australian National Health and Medical Research Council (NHMRC) [1048082, 633275, 566814, 529905, 1028444]; Centre for Clinical Research Excellence [529923]; American Health Assistance Foundation; Macular Degeneration Research grant; Australian Research Council [FT120100581]; Centre for Eye Research Australia	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Centre for Clinical Research Excellence; American Health Assistance Foundation; Macular Degeneration Research grant; Australian Research Council(Australian Research Council); Centre for Eye Research Australia	This study was supported by Australian National Health and Medical Research Council (NHMRC) project grants 1048082, 633275, and 566814; Centre for Clinical Research Excellence grant 529923 (Translational Clinical Research in Major Eye Diseases); an American Health Assistance Foundation, Macular Degeneration Research grant to E. L. F.; Australian Research Council Future Fellowship FT120100581 to B.J.G.; NHMRC Practitioner Fellowship 529905 to R. H. G.; and NHMRC Senior Research Fellowship 1028444 to P.N.B. Centre for Eye Research Australia receives operational infrastructure support from the Victorian government.	Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003; Antonio LS, 2011, BRIT J PHARMACOL, V163, P1069, DOI 10.1111/j.1476-5381.2011.01303.x; Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285; Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x; Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861; Fletcher EL, 2010, OPTOMETRY VISION SCI, V87, P269, DOI 10.1097/OPX.0b013e3181c9132b; Gerszten RE, 2012, NEW ENGL J MED, V366, P1734, DOI 10.1056/NEJMcibr1200164; Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178; Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744; Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3; Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714; Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537; Karala AR, 2010, J MOL BIOL, V396, P883, DOI 10.1016/j.jmb.2009.12.014; Kawate T, 2009, NATURE, V460, P592, DOI 10.1038/nature08198; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Okumura M, 2011, FEBS J, V278, P1137, DOI 10.1111/j.1742-4658.2011.08039.x; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964; Qureshi OS, 2007, J CELL SCI, V120, P3838, DOI 10.1242/jcs.010348; Richardson AJ, 2006, J LAB CLIN MED, V147, P290, DOI 10.1016/j.lab.2006.01.005; Stokes L, 2011, HYPERTENSION, V58, P1086, DOI 10.1161/HYPERTENSIONAHA.111.176180; Stokes L, 2010, FASEB J, V24, P2916, DOI 10.1096/fj.09-150862; Stokes L, 2009, EUR J IMMUNOL, V39, P986, DOI 10.1002/eji.200838818; Sugiyama T, 2010, INVEST OPHTH VIS SCI, V51, P3236, DOI 10.1167/iovs.09-4192; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016; Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x; Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5; Wixey JA, 2009, J NEUROIMMUNOL, V212, P35, DOI 10.1016/j.jneuroim.2009.04.016; Young MT, 2010, TRENDS BIOCHEM SCI, V35, P83, DOI 10.1016/j.tibs.2009.09.006; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	45	50	52	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2013	27	4					1479	1487		10.1096/fj.12-215368	http://dx.doi.org/10.1096/fj.12-215368			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	117GF	23303206				2022-12-28	WOS:000316940800020
J	Aagaard, K; Petrosino, J; Keitel, W; Watson, M; Katancik, J; Garcia, N; Patel, S; Cutting, M; Madden, T; Hamilton, H; Harris, E; Gevers, D; Simone, G; McInnes, P; Versalovic, J				Aagaard, Kjersti; Petrosino, Joseph; Keitel, Wendy; Watson, Mark; Katancik, James; Garcia, Nathalia; Patel, Shital; Cutting, Mary; Madden, Tessa; Hamilton, Holli; Harris, Emily; Gevers, Dirk; Simone, Gina; McInnes, Pamela; Versalovic, James			The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters	FASEB JOURNAL			English	Article						metagenomics; HMP clinical data; clinical metadata; clinical research studies; metagenomic medicine	CORE GUT MICROBIOME; INTESTINAL MICROBIOTA; HUMAN SKIN; BODY HABITATS; DIVERSITY; COMMUNITIES; EVOLUTION; DELIVERY; HEALTH; FLORA	The Human Microbiome Project used rigorous good clinical practice standards to complete comprehensive body site sampling in healthy 18- to 40-yr-old adults, creating an unparalleled reference set of microbiome specimens. To ensure that specimens represented minimally perturbed microbiomes, we first screened potential participants using exclusion criteria based on health history, including the presence of systemic diseases (e.g., hypertension, cancer, or immunodeficiency or autoimmune disorders), use of potential immunomodulators, and recent use of antibiotics or probiotics. Subsequent physical examinations excluded individuals based on body mass index (BMI), cutaneous lesions, and oral health. We screened 554 individuals to enroll 300 (149 men and 151 women, mean age 26 yr, mean BMI 24 kg/m(2), 20.0% racial minority, and 10.7% Hispanic). We obtained specimens from the oral cavity, nares, skin, gastrointestinal tract, and vagina (15 specimens from men and 18 from women). The study evaluated longitudinal changes in an individual's microbiome by sampling 279 participants twice (mean 212 d after the first sampling; range 30-359 d) and 100 individuals 3 times (mean 72 d after the second sampling; range 30-224 d). This sampling strategy yielded 11,174 primary specimens, from which 12,479 DNA samples were submitted to 4 centers for metagenomic sequencing. Our clinical design and well-defined reference cohort has laid a foundation for microbiome research.-Aagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., Patel, S., Cutting, M., Madden, T., Hamilton, H., Harris, E., Gevers, D., Simone, G., McInnes, P., Versalovic, J. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J. 27, 1012-1022 (2013). www.fasebj.org	[Aagaard, Kjersti; Petrosino, Joseph; Keitel, Wendy; Patel, Shital; Versalovic, James] Baylor Coll Med, Houston, TX 77030 USA; [Watson, Mark; Madden, Tessa] Washington Univ, St Louis, MO USA; [Katancik, James] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Garcia, Nathalia] St Louis Univ, St Louis, MO 63103 USA; [Cutting, Mary; Hamilton, Holli; Harris, Emily; McInnes, Pamela] NIH, Bethesda, MD 20892 USA; [Gevers, Dirk] MIT, Broad Inst, Cambridge, MA 02139 USA; [Simone, Gina] EMMES Corp, Rockville, MD USA; [Versalovic, James] Texas Childrens Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Washington University (WUSTL); University of Texas System; University of Texas Health Science Center Houston; Saint Louis University; National Institutes of Health (NIH) - USA; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Emmes Corporation; Baylor College of Medicine	Aagaard, K (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.	aagaardt@bcm.edu	Gevers, Dirk/C-1451-2009; Petrosino, Joseph F./AAF-1621-2019	Madden, Tessa/0000-0001-9455-1943; Garcia, M. Nathalia/0000-0003-3685-027X	U.S. National Instiutes of Health (NIH); National Human Genome Research Institute at NIH [U54HG004973, U54HG004968]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD070979] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004973, U54HG004968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	U.S. National Instiutes of Health (NIH); National Human Genome Research Institute at NIH; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank the staff directly involved in clinical evaluation of subjects, human body sampling, and specimen processing. At Baylor College of Medicine (BCM), the staff included Chanei Henry, Michelle Rubio-Gonzales, Janet Wells, V. A. Mancha, Joanna Allaire, Kavitha Parthasarathy, Jayne McWherter, Antone Opekun, Coni Cheesman, Shannon Hawkins, Matthew Ross, Tulin Ayvaz, Bonnie Youmans, and Yue Shang. At Washington University in St. Louis (WUSTL), the staff included Sally Anderson, Shea Roesel, Linda Ventimiglia, Debra Kemp, Teresa Arb, Arlyn Pittler, Cindy Neske, Laura Granderson, Beth Reagan, Amy Brink, Nicole Gaudin, Emily Rozycki, and Amanda Alyatim. At St Louis University, the staff included Mary Signorino and Diane Collier. The authors are grateful to Dr. Sarah Highlander (BCM) for assisting with protocol development for DNA isolation and sample processing, and to Dr. Curtis Huttenhower (Harvard School of Public Health) for generating essential data used in Fig. 2. The authors gratefully acknowledge the support of the Human Microbiome Project funded through the U.S. National Instiutes of Health (NIH) Director's Common Fund (as part of NIH RoadMap 1.5). The genome centers participating in this study were funded by direct support from the National Human Genome Research Institute at NIH (U54HG004973, BCM; and U54HG004968, WUSTL).	Aagaard K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036466; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bollinger RR, 2007, J THEOR BIOL, V249, P826, DOI 10.1016/j.jtbi.2007.08.032; Brown CJ, 2007, J MED MICROBIOL, V56, P271, DOI 10.1099/jmm.0.46607-0; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Favier CF, 2002, APPL ENVIRON MICROB, V68, P219, DOI 10.1128/AEM.68.1.219-226.2002; Forney LJ, 2006, J INFECT DIS, V194, P1468, DOI 10.1086/508497; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jorup-Ronstrom C, 2012, SCAND J GASTROENTERO, V47, P548, DOI 10.3109/00365521.2012.672587; Kim TK, 2009, J CLIN MICROBIOL, V47, P1181, DOI 10.1128/JCM.00854-08; Kurokawa K, 2007, DNA RES, V14, P169, DOI 10.1093/dnares/dsm018; Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Liu YH, 2010, BRIEF FUNCT GENOMICS, V9, P355, DOI 10.1093/bfgp/elq011; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Morowitz MJ, 2011, P NATL ACAD SCI USA, V108, P1128, DOI 10.1073/pnas.1010992108; Mulye TP, 2009, J ADOLESCENT HEALTH, V45, P8, DOI 10.1016/j.jadohealth.2009.03.013; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Pamer EG, 2007, NAT IMMUNOL, V8, P1173, DOI 10.1038/ni1526; Paulino LC, 2006, J CLIN MICROBIOL, V44, P2933, DOI 10.1128/JCM.00785-06; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Petrosino JF, 2009, CLIN CHEM, V55, P856, DOI 10.1373/clinchem.2008.107565; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Reinhardt C, 2009, J PEDIATR GASTR NUTR, V48, P249, DOI 10.1097/MPG.0b013e318183187c; Schloss PD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027310; Tap J, 2009, ENVIRON MICROBIOL, V11, P2574, DOI 10.1111/j.1462-2920.2009.01982.x; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Turnbaugh PJ, 2009, J PHYSIOL-LONDON, V587, P4153, DOI 10.1113/jphysiol.2009.174136; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Ward DV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039315; Zhao LP, 2010, J BIOTECHNOL, V149, P183, DOI 10.1016/j.jbiotec.2010.02.008; Zhou Xiaoping, 2007, U S Forest Service Pacific Northwest Research Station General Technical Report PNW-GTR, P1; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854	44	214	228	1	178	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					1012	1022		10.1096/fj.12-220806	http://dx.doi.org/10.1096/fj.12-220806			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	23165986	Green Published			2022-12-28	WOS:000315585200016
J	Portal-Celhay, C; Nehrke, K; Blaser, MJ				Portal-Celhay, Cynthia; Nehrke, Keith; Blaser, Martin J.			Effect of Caenorhabditis elegans age and genotype on horizontal gene transfer in intestinal bacteria	FASEB JOURNAL			English	Article						conjugation; mating; in vivo	INFECTIOUS DRUG-RESISTANCE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; CONJUGAL TRANSFER; LACTOBACILLUS-PLANTARUM; ENTEROCOCCUS-FAECALIS; HELICOBACTER-PYLORI; RHYTHMIC BEHAVIOR; PLASMID; EVOLUTION	Horizontal gene transfer (HGT) between bacteria occurs in the intestinal tract of their animal hosts and facilitates both virulence and antibiotic resistance. A model in which both the pathogen and the host are genetically tractable facilitates developing insight into mechanistic processes enabling or restricting the transfer of antibiotic resistance genes. Here we develop an in vivo experimental system to study HGT in bacteria using Caenorhabditis elegans as a model host. Using a thermosensitive conjugative system, we provide evidence that conjugation between two Escherichia coli strains can take place in the intestinal lumen of N2 wild-type worms at a rate of 10(-3) and 10(-2) per donor. We also show that C. elegans age and genotype are important determinants of the frequency of conjugation. Whereas similar to 1 transconjugant for every 100 donor cells could be recovered from the intestine of N2 C. elegans, for the age-1 and tol-1 mutants, the detected rate of transconjugation (10(-3) and 10(-4) per donor cell, respectively) was significantly lower. This work demonstrates that increased recombination among lumenal microbial populations is a phenotype associated with host aging, and the model provides a framework to study the dynamics of bacterial horizontal gene transfer within the intestinal environment.-Portal-Celhay, C., Nehrke, K., Blaser, M. J. Effect of Caenorhabditis elegans age and genotype on horizontal gene transfer in intestinal bacteria. FASEB J. 27, 760-768 (2013). www.fasebj.org	[Portal-Celhay, Cynthia; Blaser, Martin J.] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA; [Portal-Celhay, Cynthia; Blaser, Martin J.] NYU, Dept Microbiol, Langone Med Ctr, New York, NY 10016 USA; [Nehrke, Keith] Univ Rochester, Sch Med & Dent, Rochester, NY USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; University of Rochester	Blaser, MJ (corresponding author), 550 1st Ave,OBV A606, New York, NY 10016 USA.	martin.blaser@nyumc.org		Nehrke, Keith/0000-0001-9697-726X	U.S. National Institutes of Health (NIH) [RO1 GM63270]; National Science Foundation [IOS0919848]; Michael Saperstein Medical Scholars Program; Ellison Medical Foundation; Diane Belfer Program for Human Microbial Ecology; NIH Office of Research Infrastructure Programs [P40 OD010440]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Michael Saperstein Medical Scholars Program; Ellison Medical Foundation(Lawrence Ellison Foundation); Diane Belfer Program for Human Microbial Ecology; NIH Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by U.S. National Institutes of Health (NIH) grant RO1 GM63270 and National Science Foundation grant IOS0919848 (K.N.), the Michael Saperstein Medical Scholars Program, the Ellison Medical Foundation, and the Diane Belfer Program for Human Microbial Ecology. C. elegans strains were provided by the Caenorhabditis Genetic Center (University of Minnesota, Minneapolis, MN, USA), which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440).	Aballay A, 2000, CURR BIOL, V10, P1539, DOI 10.1016/S0960-9822(00)00830-7; Alegado RA, 2008, CELL MICROBIOL, V10, P1259, DOI 10.1111/j.1462-5822.2008.01124.x; Allman E, 2009, AM J PHYSIOL-CELL PH, V297, pC1071, DOI 10.1152/ajpcell.00284.2009; Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; Arber W, 2009, J BIOTECHNOL, V144, P242, DOI 10.1016/j.jbiotec.2009.05.010; Atherton JC, 2009, J CLIN INVEST, V119, P2475, DOI 10.1172/JCI38605; AVERY L, 1993, GENETICS, V133, P897; Barkay T, 2010, ENVIRON MICROBIOL, V12, P2904, DOI 10.1111/j.1462-2920.2010.02260.x; Blaser MJ, 1997, J PHYSIOL PHARMACOL, V48, P307; Boto L, 2010, P ROY SOC B-BIOL SCI, V277, P819, DOI 10.1098/rspb.2009.1679; Bourgeois-Nicolaos N, 2006, FEMS MICROBIOL LETT, V254, P27, DOI 10.1111/j.1574-6968.2005.00004.x; Dahl KH, 2007, J ANTIMICROB CHEMOTH, V59, P478, DOI 10.1093/jac/dkl530; de Boer P, 2002, MOL MICROBIOL, V44, P351, DOI 10.1046/j.1365-2958.2002.02930.x; Feld L, 2008, J ANTIMICROB CHEMOTH, V61, P845, DOI 10.1093/jac/dkn033; FISHER KW, 1957, J GEN MICROBIOL, V16, P136, DOI 10.1099/00221287-16-1-136; FRETER R, 1983, INFECT IMMUN, V39, P676, DOI 10.1128/IAI.39.2.676-685.1983; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Jacobsen L, 2007, FEMS MICROBIOL ECOL, V59, P158, DOI 10.1111/j.1574-6941.2006.00212.x; JAROLMEN H, 1969, J BACTERIOL, V99, P487, DOI 10.1128/JB.99.2.487-490.1969; Kassen R, 2004, ANNU REV MICROBIOL, V58, P207, DOI 10.1146/annurev.micro.58.030603.123654; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; Lampkowska J, 2008, INT J FOOD MICROBIOL, V127, P172, DOI 10.1016/j.ijfoodmicro.2008.06.017; Lawley TD, 2002, J BACTERIOL, V184, P2173, DOI 10.1128/JB.184.8.2173-2180.2002; Lester CH, 2004, FEMS MICROBIOL LETT, V235, P385, DOI 10.1016/j.femsle.2004.04.050; Levin BR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000601; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Licht TR, 1999, MICROBIOL-SGM, V145, P2615, DOI 10.1099/00221287-145-9-2615; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; Marteau P, 1993, World Rev Nutr Diet, V74, P1; Nagachinta S, 2008, APPL ENVIRON MICROB, V74, P5063, DOI 10.1128/AEM.00517-08; Nehrke K, 2003, J BIOL CHEM, V278, P44657, DOI 10.1074/jbc.M307351200; Pacheco ABF, 1997, J CLIN MICROBIOL, V35, P1521, DOI 10.1128/JCM.35.6.1521-1525.1997; Pang T, 1998, TRENDS MICROBIOL, V6, P131, DOI 10.1016/S0966-842X(98)01236-0; Pfeiffer J, 2008, CURR BIOL, V18, P297, DOI 10.1016/j.cub.2008.01.054; Portal-Celhay C, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-49; Portal-Celhay C, 2012, INFECT IMMUN, V80, P1288, DOI 10.1128/IAI.05522-11; Power EGM, 1996, J HOSP INFECT, V34, P247, DOI 10.1016/S0195-6701(96)90106-1; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Rae R, 2012, INT J PARASITOL, V42, P747, DOI 10.1016/j.ijpara.2012.05.005; Riddle DL, 1997, C ELEGANS; Roeder T, 2010, DEV COMP IMMUNOL, V34, P203, DOI 10.1016/j.dci.2009.09.010; Rooker MM, 1999, PLASMID, V41, P226, DOI 10.1006/plas.1999.1396; Salyers AA, 2004, TRENDS MICROBIOL, V12, P412, DOI 10.1016/j.tim.2004.07.004; Schjorring S, 2008, J ANTIMICROB CHEMOTH, V62, P1086, DOI 10.1093/jac/dkn323; Sherburne C, 1997, J BACTERIOL, V179, P952, DOI 10.1128/jb.179.3.952-955.1997; Shoemaker NB, 2001, APPL ENVIRON MICROB, V67, P561, DOI 10.1128/AEM.67.2.561-568.2001; Singh V, 2006, P NATL ACAD SCI USA, V103, P13092, DOI 10.1073/pnas.0604050103; SINGLETON P, 1983, APPL ENVIRON MICROB, V46, P291, DOI 10.1128/AEM.46.1.291-292.1983; SINGLETON P, 1981, APPL ENVIRON MICROB, V42, P789, DOI 10.1128/AEM.42.5.789-791.1981; Stiernagle Theresa, 2006, WormBook, P1; Sundin GW, 1996, MOL ECOL, V5, P133, DOI 10.1111/j.1365-294X.1996.tb00299.x; Taylor D. E., 1989, HDB EXPT PHARM, V91; TAYLOR DE, 1980, J GEN MICROBIOL, V116, P475; Tenor JL, 2008, EMBO REP, V9, P103, DOI 10.1038/sj.embor.7401104; Thomas CM, 2005, NAT REV MICROBIOL, V3, P711, DOI 10.1038/nrmicro1234; Vedantam G, 2003, CURR OPIN MICROBIOL, V6, P457, DOI 10.1016/j.mib.2003.09.006; WALTON JR, 1966, LANCET, V2, P1300; WALTON JR, 1967, NATURE, V215, P179, DOI 10.1038/215179a0; Witte W, 2000, INT J ANTIMICROB AG, V14, P321, DOI 10.1016/S0924-8579(00)00144-8; Zaneveld J, 2008, CURR OPIN CHEM BIOL, V12, P109, DOI 10.1016/j.cbpa.2008.01.015	62	8	10	3	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					760	768		10.1096/fj.12-218420	http://dx.doi.org/10.1096/fj.12-218420			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	23085995	Green Published			2022-12-28	WOS:000314358000034
J	Frisan, T; Coppotelli, G; Dryselius, R; Masucci, MG				Frisan, Teresa; Coppotelli, Giuseppe; Dryselius, Rikard; Masucci, Maria G.			Ubiquitin C-terminal hydrolase-L1 interacts with adhesion complexes and promotes cell migration, survival, and anchorage independent growth	FASEB JOURNAL			English	Article						adherens junction; anoikis; DUB; UCH-L1	GENE-PRODUCT 9.5; PROTEIN; UCH-L1; L1; PGP9.5; DEGRADATION; EXPRESSION; DYNAMICS; CLEAVAGE; INVASION	Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is a deubiquitinating enzyme of unknown function that is highly expressed in neurons and overexpressed in several human cancers. UCH-L1 has been implicated in the regulation of phenotypic properties associated with malignant cell growth but the underlying mechanisms have not been elucidated. By comparing cells expressing catalytically active or inactive versions of UCH-L1, we found that the active enzyme enhances cell adhesion, spreading, and migration; inhibits anoikis; and promotes anchorage independent growth. UCH-L1 accumulates at the motile edge of the cell membrane during the initial phases of adhesion, colocalizes with focal adhesion kinase (FAK), p120-catenin, and vinculin, and enhances the formation of focal adhesions, which correlates with enhanced FAK activation. The involvement of UCH-L1 in the regulation of focal adhesions and adherens junctions is supported by coimmunoprecipitation with key components of these complexes, including FAK, paxillin, p120-catenin, beta-catenin, and vinculin. UCH-L1 stabilizes focal adhesion signaling in the absence of adhesion, as assessed by reduced caspase-dependent cleavage of FAK following cell detachment and sustained activity of the AKT signaling pathway. These findings offer new insights on the molecular interactions through which the deubiquitinating enzyme regulates the survival, proliferation, and metastatic potential of malignant cells.-Frisan, T., Coppotelli, G., Dryselius, R., Masucci, M. G. Ubiquitin C-terminal hydrolase-L1 interacts with adhesion complexes and promotes cell migration, survival, and anchorage independent growth. FASEB J. 26, 5060-5070 (2012). www.fasebj.org	[Frisan, Teresa; Coppotelli, Giuseppe; Dryselius, Rikard; Masucci, Maria G.] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Frisan, T (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.	teresa.frisan@ki.se; maria.masucci@ki.se	Frisan, Teresa/H-8444-2019; Masucci, Maria/AAC-6666-2019	Frisan, Teresa/0000-0002-1209-0942; Masucci, Maria/0000-0002-5541-2809	Swedish Research Council; Swedish Cancer Society; Karolinska Institute; European Community [LSHC-CT-2005-018704]; AkeWiberg Foundation; Magnus Bergvall Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute(Karolinska Institutet); European Community(European Commission); AkeWiberg Foundation; Magnus Bergvall Foundation	This work was supported by grants awarded by the Swedish Research Council, the Swedish Cancer Society, and the Karolinska Institute to M. G. M. and T. F.; the European Community Integrated Project on Infection and Cancer (INCA), Project LSHC-CT-2005-018704 to M. G. M.; and the AkeWiberg and Magnus Bergvall Foundations to T.F. T.F. is a fellow of the Swedish Cancer Society.	Aumuller G, 1999, PROSTATE, V38, P261; Basseres E, 2010, CELL MICROBIOL, V12, P1622, DOI 10.1111/j.1462-5822.2010.01495.x; Bheda A, 2010, CELL CYCLE, V9, P980, DOI 10.4161/cc.9.5.10934; Bheda A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006764; Block MR, 2008, EUR J CELL BIOL, V87, P491, DOI 10.1016/j.ejcb.2008.02.012; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Buus R, 2009, CURR BIOL, V19, P1463, DOI 10.1016/j.cub.2009.07.040; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; D'Andrea V, 1997, G Chir, V18, P521; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; Didier C, 2003, MOL CELL BIOL, V23, P5331, DOI 10.1128/MCB.23.15.5331-5345.2003; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; Franke TF, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe29; Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927; Huang C, 2010, CELL ADHES MIGR, V4, P10, DOI 10.4161/cam.4.1.9834; Hussain S, 2010, LEUKEMIA, V24, P1641, DOI 10.1038/leu.2010.138; Jang MJ, 2011, CANCER LETT, V302, P128, DOI 10.1016/j.canlet.2011.01.006; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim HJ, 2009, ONCOGENE, V28, P117, DOI 10.1038/onc.2008.364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Liu ZH, 2009, P NATL ACAD SCI USA, V106, P4635, DOI 10.1073/pnas.0806474106; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Naze P, 2002, NEUROSCI LETT, V328, P1, DOI 10.1016/S0304-3940(02)00231-8; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Peng XA, 2011, INT REV CEL MOL BIO, V287, P191, DOI 10.1016/B978-0-12-386043-9.00005-0; Rolen U, 2009, J CELL MOL MED, V13, P1666, DOI 10.1111/j.1582-4934.2008.00501.x; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Sasaki H, 2001, JPN J CLIN ONCOL, V31, P532, DOI 10.1093/jjco/hye113; SCHUMACHER U, 1994, DNA CELL BIOL, V13, P839, DOI 10.1089/dna.1994.13.839; Sekine Y, 2007, J IMMUNOL, V179, P2397, DOI 10.4049/jimmunol.179.4.2397; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Tezel E, 2000, CLIN CANCER RES, V6, P4764; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; Vasudevan KM, 2011, CURR TOP MICROBIOL, V347, P105, DOI 10.1007/82_2010_66; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Yanagisawa TY, 1998, TOHOKU J EXP MED, V184, P229; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765	45	20	23	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5060	5070		10.1096/fj.12-211946	http://dx.doi.org/10.1096/fj.12-211946			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22932395				2022-12-28	WOS:000311838300027
J	Peigneur, S; Beress, L; Moller, C; Mari, F; Forssmann, WG; Tytgat, J				Peigneur, Steve; Beress, Laszlo; Moeller, Carolina; Mari, Frank; Forssmann, Wolf-Georg; Tytgat, Jan			A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins	FASEB JOURNAL			English	Article						voltage-gated sodium channel; voltage-gated potassium channel; ion channel inhibitor; ion channel modulator	NEURONAL SODIUM-CHANNELS; ANTHOPLEURA-ELEGANTISSIMA; HUWENTOXIN-IV; INFLAMMATORY PAIN; VOLTAGE-SENSOR; PEPTIDE TOXINS; ION CHANNELS; K+ CHANNEL; NA+; VENOM	APETx3, a novel peptide isolated from the sea anemone Anthopleura elegantissima, is a naturally occurring mutant from APETx1, only differing by a Thr to Pro substitution at position 3. APETx1 is believed to be a selective modulator of human ether-a-go-go related gene (hERG) potassium channels with a K-d of 34 nM. In this study, APETx1, 2, and 3 have been subjected to an electrophysiological screening on a wide range of 24 ion channels expressed in Xenopus laevis oocytes: 10 cloned voltage-gated sodium channels (Na-V 1.2-Na(V)1.8, the insect channels DmNa(V)1, BgNa(V)1-1a, and the arachnid channel VdNa(V)1) and 14 cloned voltage-gated potassium channels (K(V)1.1-K(V)1.6, K(V)2.1, K(V)3.1, K(V)4.2, K(V)4.3, K(V)7.2, K(V)7.4, hERG, and the insect channel Shaker IR). Surprisingly, the Thr3Pro substitution results in a complete abolishment of APETx3 modulation on hERG channels and provides this toxin the ability to become a potent (EC50 276 nM) modulator of voltage-gated sodium channels (Na(V)s) because it slows down the inactivation of mammalian and insect Na-V channels. Our study also shows that the homologous toxins APETx1 and APETx2 display promiscuous properties since they are also capable of recognizing Na-V channels with IC50 values of 31 nM and 114 nM, respectively, causing an inhibition of the sodium conductance without affecting the inactivation. Our results provide new insights in key residues that allow these sea anemone toxins to recognize distinct ion channels with similar potency but with different modulatory effects. Furthermore, we describe for the first time the target promiscuity of a family of sea anemone toxins thus far believed to be highly selective.-Peigneur, S., Beress, L., Moller, C., Mari, F., Forssmann, W.-G., Tytgat, J. A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins. FASEB J. 26, 5141-5151 (2012). www.fasebj.org	[Peigneur, Steve; Tytgat, Jan] Katholieke Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; [Beress, Laszlo; Forssmann, Wolf-Georg] Hannover Med Sch, Dept Immunol & Rheumatol, Hannover, Germany; [Beress, Laszlo; Forssmann, Wolf-Georg] Pharis Biotec GmbH, Hannover, Germany; [Moeller, Carolina; Mari, Frank] Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	KU Leuven; Hannover Medical School; State University System of Florida; Florida Atlantic University	Tytgat, J (corresponding author), Katholieke Univ Leuven, Toxicol Lab, Campus Gasthuisberg O&N2,Herestr 49,POB 922, B-3000 Louvain, Belgium.	jan.tytgat@pharm.kuleuven.be		Tytgat, Jan/0000-0003-1778-6022; Peigneur, Steve/0000-0003-0504-5702	Fonds Wetenschappelijk Onderzoek Vlaanderen [G.0433.12]; Inter-University Attraction Poles (IUAP) Program (Belgian State, Belgian Science Policy) [7/19]; Katholieke Universiteit Leuven [OT/12/081]	Fonds Wetenschappelijk Onderzoek Vlaanderen(FWO); Inter-University Attraction Poles (IUAP) Program (Belgian State, Belgian Science Policy); Katholieke Universiteit Leuven(KU Leuven)	The authors thank John N. Wood (University College London, London, UK) for sharing rNa<INF>V</INF>1.8; A. L. Goldin (University of California, Irvine, CA, USA) for sharing rNa<INF>V</INF>1.2, rNa<INF>V</INF>1.3, and mNa<INF>V</INF>1.6; G. Mandel (State University of New York, Stony Brook, NY, USA) for sharing rNa<INF>V</INF>1.4; R. G. Kallen (Roche Institute of Molecular Biology, Nutley, NJ, USA) for sharing hNa<INF>V</INF>1.5; S. H. Heinemann (Friedrich-Schiller-Universitat Jena, Jena, Germany) for sharing the rat beta 1 subunit; S. C. Cannon (University of Texas Southwestern Medical Center, Dallas, TX, USA) for sharing the h beta 1 subunit; M. Keating (University of Utah, Salt Lake City, UT, USA) for sharing hERG; and Martin S. Williamson (Rothhamsted Research, Harpenden, UK) for providing the Para and tipE clone. The Na<INF>V</INF>1.7 clone was kindly provided by Roche (Basel, Switzerland). The authors are grateful to K. Dong (Michigan State University, East Lansing, MI, USA) for sharing BgNa<INF>V</INF>1.1 and VdNa<INF>V</INF>1. The authors thank Dr. Piet Herdewyn and Dr. Eveline Lescrinier for help with experiments. The authors are grateful to Dr. Bert Billen for constructive discussions. The authors thank Sarah Debaveye for her work in molecular biology. The authors thank Dr. Sylvie Diochot (Universite de Nice-Sophia-Antipolis, Valbonne, France) for sharing APETx1. This work was supported by the following grants: G.0433.12 (Fonds Wetenschappelijk Onderzoek Vlaanderen), Inter-University Attraction Poles (IUAP) Program 7/19 (Belgian State, Belgian Science Policy), and OT/12/081 (Katholieke Universiteit Leuven).	Rodriguez AA, 2012, PEPTIDES, V34, P26, DOI 10.1016/j.peptides.2011.10.011; Andreev YA, 2008, J BIOL CHEM, V283, P23914, DOI 10.1074/jbc.M800776200; Billen B, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00133; Blanchard MG, 2011, BRIT J PHARMACOL, V165, P2167; Bosmans F, 2007, TOXICON, V49, P550, DOI 10.1016/j.toxicon.2006.11.029; Bruhn T, 2001, TOXICON, V39, P693, DOI 10.1016/S0041-0101(00)00199-9; Campos FV, 2008, J GEN PHYSIOL, V132, P251, DOI 10.1085/jgp.200809995; Castaneda O, 2009, TOXICON, V54, P1119, DOI 10.1016/j.toxicon.2009.02.032; Catterall WA, 2007, TOXICON, V49, P124, DOI 10.1016/j.toxicon.2006.09.022; Chagot B, 2005, PROTEINS, V59, P380, DOI 10.1002/prot.20425; Deval E, 2008, EMBO J, V27, P3047, DOI 10.1038/emboj.2008.213; Diochot S, 1998, J BIOL CHEM, V273, P6744, DOI 10.1074/jbc.273.12.6744; Diochot S, 2004, EMBO J, V23, P1516, DOI 10.1038/sj.emboj.7600177; Diochot S, 2003, MOL PHARMACOL, V64, P59, DOI 10.1124/mol.64.1.59; Diochot S., 2009, V46, P99, DOI 10.1007/978-3-540-87895-7_4; Ekberg J, 2006, INT J BIOCHEM CELL B, V38, P2005, DOI 10.1016/j.biocel.2006.06.008; Fozzard HA, 2010, MAR DRUGS, V8, P219, DOI 10.3390/md8020219; French RJ, 2010, MAR DRUGS, V8, P2153, DOI 10.3390/md8072153; Honma T, 2006, MAR BIOTECHNOL, V8, P1, DOI 10.1007/s10126-005-5093-2; Jarvis MF, 2007, P NATL ACAD SCI USA, V104, P8520, DOI 10.1073/pnas.0611364104; Karczewski J, 2010, BRIT J PHARMACOL, V161, P950, DOI 10.1111/j.1476-5381.2010.00918.x; Kozlov S, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-88; LIANG SP, 1993, TOXICON, V31, P969, DOI 10.1016/0041-0101(93)90256-I; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu M, 2011, PAIN MED, V12, pS93, DOI 10.1111/j.1526-4637.2011.01158.x; Liu P, 2012, J NEUROPHYSIOL, V107, P3155, DOI 10.1152/jn.00785.2011; Oliveira JS, 2006, BBA-PROTEINS PROTEOM, V1764, P1592, DOI 10.1016/j.bbapap.2006.08.010; Peigneur S., 2012, INSECTICIDES ADV INT; Peigneur S, 2011, BIOCHEM PHARMACOL, V82, P81, DOI 10.1016/j.bcp.2011.03.023; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Prikhod'ko EA, 1999, J VIROL, V73, P6691; Redaelli E, 2010, J BIOL CHEM, V285, P4130, DOI 10.1074/jbc.M109.054718; Salceda E, 2006, BRAIN RES, V1110, P136, DOI 10.1016/j.brainres.2006.06.113; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Stevens M, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00071; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Van Der Haegen A, 2011, FEBS J, V278, P3408, DOI 10.1111/j.1742-4658.2011.08264.x; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Wang MC, 2012, PEPTIDES, V34, P19, DOI 10.1016/j.peptides.2011.10.029; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Xiao YC, 2008, J BIOL CHEM, V283, P27300, DOI 10.1074/jbc.M708447200; Xiao YC, 2011, J BIOL CHEM, V286, P27301, DOI 10.1074/jbc.M111.246876; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zhang M, 2007, MOL PHARMACOL, V72, P259, DOI 10.1124/mol.107.035840	46	61	65	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5141	5151		10.1096/fj.12-218479	http://dx.doi.org/10.1096/fj.12-218479			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22972919				2022-12-28	WOS:000311838300034
J	Suter, MA; Chen, AS; Burdine, MS; Choudhury, M; Harris, RA; Lane, RH; Friedman, JE; Grove, KL; Tackett, AJ; Aagaard, KM				Suter, Melissa A.; Chen, Aishe; Burdine, Marie S.; Choudhury, Mahua; Harris, R. Alan; Lane, Robert H.; Friedman, Jacob E.; Grove, Kevin L.; Tackett, Alan J.; Aagaard, Kjersti M.			A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates	FASEB JOURNAL			English	Article						epigenetics; developmental origins of adult disease; NAFLD; histone modification; sirtuins	MAMMALIAN SIRTUIN-1; GENE-EXPRESSION; CELL-SURVIVAL; DBC1; P53; METABOLISM; ACTIVATION; REGULATOR; LIVER; MODEL	In nonhuman primates, we previously demonstrated that a maternal high-fat diet (MHFD) induces fetal nonalcoholic fatty liver disease (NAFLD) and alters the fetal metabolome. These changes are accompanied by altered acetylation of histone H3 (H3K14ac). However, the mechanism behind this alteration in acetylation remains unknown. As SIRT1 is both a lysine deacetylase and a crucial sensor of cellular metabolism, we hypothesized that SIRT1 may be involved in fetal epigenomic alterations. Here we show that in utero exposure to a MHFD, but not maternal obesity per se, increases fetal H3K14ac with concomitant decreased SIRT1 expression and diminished in vitro protein and histone deacetylase activity. MHFD increased H3K14ac and DBC1-SIRT1 complex formation in fetal livers, both of which were abrogated with diet reversal despite persistent maternal obesity. Moreover, MHFD was associated with altered expression of known downstream effectors deregulated in NAFLD and modulated by SIRT1 (e.g., PPARA, PPARG, SREBF1, CYP7A1, FASN, and SCD). Finally, ex vivo purified SIRT1 retains deacetylase activity on an H3K14ac peptide substrate with preferential activity toward acetylated histone H3; mutagenesis of the catalytic domain of SIRT1 (H363Y) abrogates H3K14ac deacetylation. Our data implicate SIRT1 as a likely molecular mediator of the fetal epigenome and metabolome under MHFD conditions.-Suter, M. A., Chen, A., Burdine, M. S., Choudhury, M., Harris, R. A., Lane, R. H., Friedman, J. E., Grove, K. L., Tackett, A. J., Aagaard, K. M. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB J. 26, 5106-5114 (2012). www.fasebj.org	[Suter, Melissa A.; Chen, Aishe; Harris, R. Alan; Aagaard, Kjersti M.] Baylor Coll Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; [Harris, R. Alan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Burdine, Marie S.; Tackett, Alan J.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Choudhury, Mahua; Friedman, Jacob E.] Univ Colorado, Sch Med, Dept Pediat Biochem & Mol Genet, Aurora, CO USA; [Lane, Robert H.] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT USA; [Grove, Kevin L.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA	Baylor College of Medicine; Baylor College of Medicine; University of Arkansas System; University of Arkansas Medical Sciences; University of Colorado System; University of Colorado Anschutz Medical Campus; Utah System of Higher Education; University of Utah; Oregon Health & Science University; Oregon National Primate Research Center	Aagaard, KM (corresponding author), Baylor Coll Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, 1 Baylor Plaza,Jones 314, Houston, TX 77030 USA.	aagaardt@bcm.tmc.edu	Burdine, Marie Schluterman/GLU-1812-2022; Harris, R. Alan/AAI-2784-2020	Burdine, Marie Schluterman/0000-0002-3940-5748; Harris, R. Alan/0000-0002-7333-4752	U.S. National Institutes of Health (NIH) [DP2120OD001500-01]; U.S. National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases [R01DK080558-01]; NIH [DK79194, R000163, R01DA025755, 5R01DK078590, R24DK090964, K12 GM084897]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079194, R01DK080558, R24DK090964, R01DK078590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM084897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA025755] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD001500] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors acknowledge the helpful comments of members of the laboratories of K. M. A. and Shannon Hawkins at Baylor College of Medicine, Diana Takahashi for coordination of sample acquisition, and Dr. Tony Kouzarides (University of Cambridge, Cambridge, UK) for the SIRT1 plasmid. This work was supported by the U.S. National Institutes of Health (NIH) Director New Innovator Award (DP2120OD001500-01; to K. M. A.); U.S. National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK080558-01 (to R. H. L and K. M. A.); NIH grants DK79194 (to K. L. G.), R000163 (to K. L. G.), R01DA025755 (to A. J. T.), 5R01DK078590 (to J. E. F.), and R24DK090964 (to K. L. G. and J. E. F.); and NIH Reasearch Education and Career Horizon Institutional Research and Academic Career Development Award grant K12 GM084897 (to M. A. S.). In addition, the authors acknowledge the University of Arkansas for Medical Sciences Proteomics Facility for mass spectrometric support. The authors report no conflicts of interest.	Aagaard-Tillery KM, 2008, J MOL ENDOCRINOL, V41, P91, DOI 10.1677/JME-08-0025; Ajmo JM, 2008, AM J PHYSIOL-GASTR L, V295, pG833, DOI 10.1152/ajpgi.90358.2008; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Belden WJ, 2008, CELL, V134, P212, DOI 10.1016/j.cell.2008.07.010; Blair LP, 2009, BIOCHEMISTRY-US, V48, P2321, DOI 10.1021/bi801919s; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Chanda D, 2010, NUCLEIC ACIDS RES, V38, P4607, DOI 10.1093/nar/gkq227; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cox J, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.06.041; Dilworth DJ, 2005, J CELL BIOL, V171, P955, DOI 10.1083/jcb.200509061; Dominy JE, 2010, BBA-PROTEINS PROTEOM, V1804, P1676, DOI 10.1016/j.bbapap.2009.11.023; Draper S, 2010, BRAIN RES, V1350, P139, DOI 10.1016/j.brainres.2010.03.082; Escande C, 2010, J CLIN INVEST, V120, P545, DOI 10.1172/JCI39319; Frias AE, 2011, ENDOCRINOLOGY, V152, P2456, DOI 10.1210/en.2010-1332; Gradolatto A, 2009, MOL CELL BIOL, V29, P4604, DOI 10.1128/MCB.00160-09; Grant WF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017261; Grayson BE, 2010, ENDOCRINOLOGY, V151, P1622, DOI 10.1210/en.2009-1019; Green MF, 2013, J GERONTOL A-BIOL, V68, P105, DOI 10.1093/gerona/gls132; Hirschey MD, 2011, MOL CELL, V44, P177, DOI 10.1016/j.molcel.2011.07.019; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; INOUE A, 1969, BIOCHEM BIOPH RES CO, V36, P146, DOI 10.1016/0006-291X(69)90661-5; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Nin V, 2012, J BIOL CHEM, V287, P23489, DOI 10.1074/jbc.M112.365874; Palou M., 2012, BR J NUTR; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Ponugoti B, 2010, J BIOL CHEM, V285, P33959, DOI 10.1074/jbc.M110.122978; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schug TT, 2011, ANN MED, V43, P198, DOI 10.3109/07853890.2010.547211; Schwer B, 2008, CELL METAB, V7, P104, DOI 10.1016/j.cmet.2007.11.006; Sugden MC, 2010, J ENDOCRINOL, V204, P93, DOI 10.1677/JOE-09-0359; Sullivan EL, 2011, NEUROENDOCRINOLOGY, V93, P1, DOI 10.1159/000322038; Sullivan EL, 2010, J NEUROSCI, V30, P3826, DOI 10.1523/JNEUROSCI.5560-09.2010; Suter M., 2012, MOL ENDOCRI IN PRESS; Suter M, 2011, FASEB J, V25, P714, DOI 10.1096/fj.10-172080; Tackett AJ, 2005, J CELL BIOL, V169, P35, DOI 10.1083/jcb.200502104; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yao YL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/146493; You M, 2008, AM J PHYSIOL-GASTR L, V294, pG892, DOI 10.1152/ajpgi.00575.2007; You M, 2008, J NUTR, V138, P497, DOI 10.1093/jn/138.3.497; Zhang T, 2010, BBA-PROTEINS PROTEOM, V1804, P1666, DOI 10.1016/j.bbapap.2009.10.022; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	53	118	120	4	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					5106	5114		10.1096/fj.12-212878	http://dx.doi.org/10.1096/fj.12-212878			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22982377	Green Published			2022-12-28	WOS:000311838300031
J	Wu, HY; Wang, TY; Li, LY; Correia, K; Morgan, JI				Wu, Hui-Yuan; Wang, Taiyu; Li, Leyi; Correia, Kristen; Morgan, James I.			A structural and functional analysis of Nna1 in Purkinje cell degeneration (pcd) mice	FASEB JOURNAL			English	Article						CCP; enzyme kinetics; neurodegeneration; transgenic rescue; deglutamylation	CARBOXYPEPTIDASE-A; ALPHA-TUBULIN; BETA-TUBULIN; HUMAN ASPARTOACYLASE; SUBSTRATE-BINDING; GLUTAMIC-ACID; MUTANT MOUSE; BRAIN; SITE; METALLOCARBOXYPEPTIDASES	The axotomy-inducible enzyme Nna1 defines a subfamily of M14 metallocarboxypeptidases, and its mutation underlies the Purkinje cell degeneration (pcd) mouse. However, the relationship among its catalytic activity, substrate specificities, and the critical processes of neurodegeneration/axon regeneration is incompletely understood. Here we used a transgenic rescue strategy targeting expression of modified forms of Nna1 to Purkinje cells in pcd mice to determine structure-activity relationships for neuronal survival and in parallel characterized the enzymatic properties of purified recombinant Nna1. The Nna1 subfamily uniquely shares conserved substrate-determining residues with aspartoacylase that, when mutated, cause Canavan disease. Homologous mutations (D1007E and R1078E) inactivate Nna1 in vivo, as does mutation of its catalytic glutamate (E1094A), which implies that metabolism of acidic substrates is essential for neuronal survival. Consistent with reports that Nna1 is a tubulin glutamylase, recombinant Nna1-but not the catalytic mutants-removes glutamate from tubulin. Recombinant Nna1 metabolizes synthetic substrates with 2 or more C-terminal glutamate (but not aspartate) residues (V-max for 3 glutamates is similar to 7-fold higher than 2 glutamates although K-M is similar). Catalysis is not ATP/GTP dependent, and mutating the ATP/GTP binding site of Nna1 has no effect in vivo. Nna1 is a monomeric enzyme essential for neuronal survival through hydrolysis of polyglutamate-containing substrates.Wu, H.-Y., Wang, T., Li, L., Correia, K., Morgan, J. I. A structural and functional analysis of Nna1 in Purkinje cell degeneration (pcd) mice. FASEB J. 26, 4468-4480 (2012). www.fasebj.org	[Wu, Hui-Yuan; Wang, Taiyu; Li, Leyi; Correia, Kristen; Morgan, James I.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Morgan, JI (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 262 Danny Thomas Pl,Rm D2025,MS 323, Memphis, TN 38105 USA.	jim.morgan@stjude.org	Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018; Wu, Huiyuan/C-1575-2013	Morgan, James/0000-0002-8920-1065; 	U.S. National Cancer Institute [CA 21765]; U.S. National Institutes of Health [NS051537]; American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051537] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Drs. Jaeki Min and Fangyi Zhu (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital) and Drs. Parmil Bansal, Roberto Pattarini, and Hong Guo (Department of Developmental Neurobiology, St. Jude Children's Research Hospital) for assistance with chemical synthesis, mass spectrometry, and FPLC analysis, as well as the Hartwell Center for Bioinformatics and Biotechnology and Protein Production Facility (St. Jude Children's Research Hospital) for molecular biology and proteomics support. This work was supported in part by U.S. National Cancer Institute cancer center support grant CA 21765, U.S. National Institutes of Health grant NS051537 to J.I.M., and American Lebanese Syrian Associated Charities (ALSAC). The authors declare no conflicts of interest.	ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; Arolas JL, 2007, CURR PHARM DESIGN, V13, P349, DOI 10.2174/138161207780162980; Berezniuk I, 2010, AUTOPHAGY, V6, P558, DOI 10.4161/auto.6.4.11813; Berezniuk I, 2010, FASEB J, V24, P1813, DOI 10.1096/fj.09-147942; Bitto E, 2007, P NATL ACAD SCI USA, V104, P456, DOI 10.1073/pnas.0607817104; BLANKS JC, 1992, EXP EYE RES, V54, P637, DOI 10.1016/0014-4835(92)90019-O; Chakrabarti L, 2008, VISION RES, V48, P1999, DOI 10.1016/j.visres.2008.05.026; Chakrabarti L, 2010, NEURON, V66, P835, DOI 10.1016/j.neuron.2010.05.024; Chakrabarti L, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-24; Cho JH, 2001, BIOCHEMISTRY-US, V40, P10197, DOI 10.1021/bi010807j; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; CHRISTIANSON DW, 1986, J AM CHEM SOC, V108, P545, DOI 10.1021/ja00263a052; COOMBS TL, 1962, BIOCHEMISTRY-US, V1, P899, DOI 10.1021/bi00911a024; Cullen DA, 2004, NEUROSCI LETT, V357, P175, DOI 10.1016/j.neulet.2003.12.055; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; EATON DL, 1991, J BIOL CHEM, V266, P21833; EDDE B, 1992, BIOCHEMISTRY-US, V31, P403, DOI 10.1021/bi00117a014; Edge M, 1998, PROTEIN ENG, V11, P1229, DOI 10.1093/protein/11.12.1229; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Gagnon C, 1996, J CELL SCI, V109, P1545; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GREER CA, 1982, BRAIN RES, V235, P156, DOI 10.1016/0006-8993(82)90206-2; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HIROSE J, 1987, BIOCHEMISTRY-US, V26, P6561, DOI 10.1021/bi00394a041; Ikegami K, 2007, P NATL ACAD SCI USA, V104, P3213, DOI 10.1073/pnas.0611547104; Janke C, 2008, EMBO REP, V9, P636, DOI 10.1038/embor.2008.114; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; KAUL R, 1993, NAT GENET, V5, P118, DOI 10.1038/ng1093-118; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kimura Y, 2010, J BIOL CHEM, V285, P22934, DOI 10.1074/jbc.C110.128280; Le Coq J, 2006, BIOCHEMISTRY-US, V45, P5878, DOI 10.1021/bi052608w; LIPSCOMB WN, 1980, P NATL ACAD SCI-BIOL, V77, P3875, DOI 10.1073/pnas.77.7.3875; Lyons PJ, 2011, J BIOL CHEM, V286, P39023, DOI 10.1074/jbc.M111.265819; Makarova KS, 1999, J MOL BIOL, V292, P11, DOI 10.1006/jmbi.1999.3059; MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234; Mathews C. K., 2000, BIOCHEMISTRY-US, P375; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; OGORMAN S, 1985, J COMP NEUROL, V234, P277, DOI 10.1002/cne.902340302; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rogowski K, 2010, CELL, V143, P564, DOI 10.1016/j.cell.2010.10.014; Rong YQ, 2004, MOL BRAIN RES, V132, P128, DOI 10.1016/j.molbrainres.2004.10.015; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; Skidgel RA, 2007, INT IMMUNOPHARMACOL, V7, P1888, DOI 10.1016/j.intimp.2007.07.014; SMITH EL, 1949, P NATL ACAD SCI USA, V35, P80, DOI 10.1073/pnas.35.2.80; VALLEE BL, 1955, J BIOL CHEM, V217, P253; Van Dijk J, 2008, J BIOL CHEM, V283, P3915, DOI 10.1074/jbc.M705813200; Vendrell J., 2004, HDB METALLOPROTEINS, P167; Wang TY, 2007, BRAIN RES, V1140, P26, DOI 10.1016/j.brainres.2006.07.065; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; Wei P, 2011, MOL CELL BIOL, V31, P2838, DOI 10.1128/MCB.05208-11; Wei SW, 2002, J BIOL CHEM, V277, P14954, DOI 10.1074/jbc.M112254200; ZHANG FM, 1991, J BIOL CHEM, V266, P24606	60	19	20	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2012	26	11					4468	4480		10.1096/fj.12-205047	http://dx.doi.org/10.1096/fj.12-205047			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	030MG	22835831	Green Published			2022-12-28	WOS:000310574200010
J	Tabone-Eglinger, S; Wehrle-Haller, M; Aebischer, N; Jacquier, MC; Wehrle-Haller, B				Tabone-Eglinger, Severine; Wehrle-Haller, Monique; Aebischer, Nicole; Jacquier, Marie-Claude; Wehrle-Haller, Bernhard			Membrane-bound Kit ligand regulates melanocyte adhesion and survival, providing physical interaction with an intraepithelial niche	FASEB JOURNAL			English	Article						c-kit; stem cells; motility; spreading; integrin; epidermis	RECEPTOR TYROSINE KINASE; C-KIT; STEEL FACTOR; DOMINANT ROLE; IN-VIVO; CELLS; MIGRATION; ROLES; PROLIFERATION; EXPRESSION	Morphogenesis, as illustrated by melanocyte migration and homing to the skin, requires cadherin adhesion, integrin-dependent migration and Kit-ligand growth factor signaling. However, it is not known how Kit ligand regulates integrin or cadherin-dependent intraepidermal melanocyte behavior. To answer this question, we developed specific 2-dimensional (2D) and 3D culture systems analyzing how soluble or immobilized Kit-ligand-regulated melanocyte migration on vitronectin and laminin, or within a monolayer of kidney epithelial cells. In a 2D system, soluble Kit ligand stimulated integrin-dependent melanoblast migration and chemotaxis and accelerated integrin turnover. In contrast, immobilized, but not soluble, Kit ligand, enhanced integrin-dependent melanocyte spreading on suboptimal laminin concentrations. In 3D, membrane-bound Kit ligand induced intraepithelial melanocyte proliferation, survival, and tight adhesion to epithelial cells, while cleavable Kit ligand was less effective. In contrast, melanocyte motility was independent of membrane-bound Kit ligand, but increased in the presence of the cleavable Kit-ligand isoform. Trans-membrane-dimerization or basolateral-targeting mutants of Kit ligand altered intraepithelial melanocyte localization, survival, and adhesion to epithelial cells. These data and the identification of c-kit/Kit-ligand clusters at cell contacts suggest that membrane-bound Kit ligand captures cell surface-expressed c-kit, providing mechanical anchoring and survival signaling within intraepithelial niches, and thereby defining a new mechanism for melanocyte homeostasis and requirement for environmental niches.-Tabone-Eglinger, S., Wehrle-Haller, M., Aebischer, N., Jacquier, M.-C., Wehrle-Haller, B. Membrane-bound Kit ligand regulates melanocyte adhesion and survival, providing physical interaction with an intraepithelial niche. FASEB J. 26, 3738-3753 (2012). www.fasebj.org	[Tabone-Eglinger, Severine; Wehrle-Haller, Monique; Aebischer, Nicole; Jacquier, Marie-Claude; Wehrle-Haller, Bernhard] Univ Geneva, Dept Cell Physiol & Metab, Ctr Med Univ, CH-1211 Geneva 4, Switzerland	University of Geneva	Wehrle-Haller, B (corresponding author), Univ Geneva, Dept Cell Physiol & Metab, Ctr Med Univ, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	bernhard.wehrle-haller@unige.ch		TABONE-eglinger, Severine/0000-0003-4247-1321	Nevus Outreach; Swiss National Science foundation [1003A-130742]; Connective Tissue Cancers Network (CONTICANET; University of Lyon, Lyon, France); Dr. Henri Dubois-Ferriere Dinu Lipatti foundation (Geneva, Switzerland)	Nevus Outreach; Swiss National Science foundation(Swiss National Science Foundation (SNSF)European Commission); Connective Tissue Cancers Network (CONTICANET; University of Lyon, Lyon, France); Dr. Henri Dubois-Ferriere Dinu Lipatti foundation (Geneva, Switzerland)	The authors thank Jozsef Kiss for critical reading of the manuscript and Jean-Yves Blay for discussion. This work was supported by research grants from Nevus Outreach and the Swiss National Science foundation (31003A-130742) to B. W. H. S. T. E. was supported by the Connective Tissue Cancers Network (CONTICANET; University of Lyon, Lyon, France) and the Dr. Henri Dubois-Ferriere Dinu Lipatti foundation (Geneva, Switzerland). The authors declare no conflicts of interest.	ADACHI S, 1992, BLOOD, V79, P650; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; Deshpande S, 2010, DEV BIOL, V337, P199, DOI 10.1016/j.ydbio.2009.10.022; Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783; Engler AJ, 2009, SCIENCE, V324, P208, DOI 10.1126/science.1170107; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; Gu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025984; Gu Y, 2009, DEVELOPMENT, V136, P1295, DOI 10.1242/dev.030619; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Hirobe T, 2005, PIGM CELL RES, V18, P2, DOI 10.1111/j.1600-0749.2004.00198.x; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Inomata K, 2009, CELL, V137, P1088, DOI 10.1016/j.cell.2009.03.037; Jordan SA, 2000, DEV BIOL, V225, P424, DOI 10.1006/dbio.2000.9856; Kimura Y, 2004, P NATL ACAD SCI USA, V101, P6015, DOI 10.1073/pnas.0305363101; KINASHI T, 1994, BLOOD, V83, P1033; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; KOVACH NL, 1995, BLOOD, V85, P159, DOI 10.1182/blood.V85.1.159.bloodjournal851159; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Li A, 2011, DEV CELL, V21, P722, DOI 10.1016/j.devcel.2011.07.008; Luo R, 2003, DEVELOPMENT, V130, P321, DOI 10.1242/dev.00213; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; MAEDA H, 1992, DEVELOPMENT, V116, P369; Martino M. M., 2011, SCI TRANSL MED, V3, P100; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Mierke CT, 2000, J EXP MED, V192, P801, DOI 10.1084/jem.192.6.801; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; Nishikawa-Torikai S, 2011, J INVEST DERMATOL, V131, P2358, DOI 10.1038/jid.2011.195; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Paulhe F, 2004, J BIOL CHEM, V279, P55545, DOI 10.1074/jbc.M407813200; Paulhe F, 2009, FASEB J, V23, P3037, DOI 10.1096/fj.09-129577; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Salaita K, 2010, SCIENCE, V327, P1380, DOI 10.1126/science.1181729; Saldana-Caboverde A, 2010, PIGM CELL MELANOMA R, V23, P160, DOI 10.1111/j.1755-148X.2010.00678.x; Santiago-Walker A, 2009, SKIN PHARMACOL PHYS, V22, P114, DOI 10.1159/000178870; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; Waskow C, 2002, IMMUNITY, V17, P277, DOI 10.1016/S1074-7613(02)00386-2; Waskow C, 2007, BLOOD, V109, P5363, DOI 10.1182/blood-2006-08-039131; Waskow C, 2009, NAT METHODS, V6, P267, DOI [10.1038/nmeth.1309, 10.1038/NMETH.1309]; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Wehrle-Haller B, 2003, PIGM CELL RES, V16, P287, DOI 10.1034/j.1600-0749.2003.00055.x; Wehrle-Haller B, 2001, DEV BIOL, V232, P471, DOI 10.1006/dbio.2001.0167; Wehrle-Haller B, 2001, J BIOL CHEM, V276, P12667, DOI 10.1074/jbc.M008357200; Wehrle-Haller Bernhard, 2007, Methods Mol Biol, V370, P173; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zicha D, 1997, Methods Mol Biol, V75, P449	68	14	17	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2012	26	9					3738	3753		10.1096/fj.12-206045	http://dx.doi.org/10.1096/fj.12-206045			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	000MY	22637532				2022-12-28	WOS:000308391600015
J	Norder, M; Gutierrez, MG; Zicari, S; Cervi, E; Caruso, A; Guzman, CA				Noerder, Miriam; Gutierrez, Maximiliano G.; Zicari, Sonia; Cervi, Edoardo; Caruso, Arnaldo; Guzman, Carlos A.			Lymph node-derived lymphatic endothelial cells express functional costimulatory molecules and impair dendritic cell-induced allogenic T-cell proliferation	FASEB JOURNAL			English	Article						antigen presentation; indoleamine 2,3-dioxygenase; immune modulation	HUMAN PERIPHERAL-BLOOD; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN CATABOLISM; INTERFERON-GAMMA; INDUCIBLE PROTEIN-10; ANTIGEN; ACTIVATION; MECHANISM; LIGAND; TOLERANCE	Lymphatic endothelial cells (LECs) interact with different immune cells, including T cells within lymph nodes (LNs). However, direct interactions of LECs with immune cells have yet to be investigated. In vitro studies were performed to characterize primary cultures of human LECs derived from LNs in their capacity of interacting with T cells. The results show that LECs express HLA molecules and functional costimulatory molecules needed for T-cell activation. A direct binding of LECs and T cells was detected in cell cultures connected with a clustering of costimulatory molecules on the contact phase. LECs were also able to take up and process antigens. However, major histocompatibility complex class II+ LECs fail to induce allogeneic T-cell proliferation. Interestingly, supernatants of IFN-gamma activated LECs impair proliferation of T cells cocultured with allogeneic dendritic cells, suggesting an inhibitory role of LECs. Indoleamine 2,3 dioxygenase was identified as one inhibitory molecule, which may be responsible for the impaired CD4(+) T-cell proliferation. Our observations suggest a regulatory function for activated LECs on CD4(+) T cells, which may play a role in vivo in the maintenance of the critical balance between tolerance and recall responses.-Norder, M., Gutierrez, M. G., Zicari, S., Cervi, E., Caruso, A., Guzman, C. A. Lymph node-derived lymphatic endothelial cells express functional costimulatory molecules and impair dendritic cell-induced allogenic T-cell proliferation. FASEB J. 26, 2835-2846 (2012). www.fasebj.org	[Noerder, Miriam; Gutierrez, Maximiliano G.; Guzman, Carlos A.] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, Braunschweig, Germany; [Gutierrez, Maximiliano G.] Helmholtz Ctr Infect Res, Res Grp Phagosome Biol, Braunschweig, Germany; [Zicari, Sonia; Caruso, Arnaldo] Univ Brescia, Microbiol Sect, Dept Expt & Appl Med, Brescia, Italy; [Cervi, Edoardo] Univ Brescia, Vasc Surg Sect, Dept Med & Surg Sci, Brescia, Italy	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; University of Brescia; University of Brescia	Guzman, CA (corresponding author), Inhoffenstr 7, D-38124 Braunschweig, Germany.	carlos.guzman@helmholtz-hzi.de	Caruso, Arnaldo/H-7818-2014; ZICARI, SONIA/AAB-8731-2019	Gutierrez, Maximiliano/0000-0003-3199-0337; Zicari, Sonia/0000-0003-1240-8057; CARUSO, Arnaldo/0000-0001-5178-566X; Cervi, Edoardo/0000-0002-3127-2864	Initiative and Networking funds of the Helmholtz Association	Initiative and Networking funds of the Helmholtz Association	M.G.G. is supported by a Helmholtz Young Investigator grant (Initiative and Networking funds of the Helmholtz Association).	Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; BAUMHUETER S, 1994, BLOOD, V84, P2554; Beutelspacher SC, 2006, AM J TRANSPLANT, V6, P1320, DOI 10.1111/j.1600-6143.2006.01324.x; CARLIN JM, 1989, J LEUKOCYTE BIOL, V45, P29, DOI 10.1002/jlb.45.1.29; Choi J, 2004, ANNU REV IMMUNOL, V22, P683, DOI 10.1146/annurev.immunol.22.012703.104639; CIVIN CI, 1984, J IMMUNOL, V133, P157; Cohen JN, 2010, J EXP MED, V207, P681, DOI 10.1084/jem.20092465; Cunningham AC, 1997, IMMUNOLOGY, V91, P458, DOI 10.1046/j.1365-2567.1997.d01-2249.x; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; Fiedler U, 2006, AM J PATHOL, V168, P1045, DOI 10.2353/ajpath.2006.050554; Fontenot AP, 2003, J CLIN INVEST, V112, P776, DOI 10.1172/JCI200318317; Garrafa E, 2011, IMMUNOL CELL BIOL, V89, P475, DOI 10.1038/icb.2010.111; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hamann D, 1996, BLOOD, V88, P3513, DOI 10.1182/blood.V88.9.3513.bloodjournal8893513; Hanaoka R, 2003, ARTHRITIS RES THER, V5, pR74, DOI 10.1186/ar616; Hansen AB, 2001, APMIS, V109, P849, DOI 10.1034/j.1600-0463.2001.091207.x; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; Hayashi T, 2001, INFECT IMMUN, V69, P6156, DOI 10.1128/IAI.69.10.6156-6164.2001; HUGHES CCW, 1990, J EXP MED, V171, P1453, DOI 10.1084/jem.171.5.1453; Kawai T, 1999, J IMMUNOL, V163, P3269; Kotani A, 2002, IMMUNOL LETT, V84, P1, DOI 10.1016/S0165-2478(02)00082-2; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; McDouall RM, 1996, IMMUNOLOGY, V89, P220, DOI 10.1046/j.1365-2567.1996.d01-736.x; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mestas J, 2001, J IMMUNOL, V167, P4378, DOI 10.4049/jimmunol.167.8.4378; Murphy K, 2008, JANEWAYS IMMUNOBIOLO; Neville Lewis F., 1997, Cytokine and Growth Factor Reviews, V8, P207, DOI 10.1016/S1359-6101(97)00015-4; Opitz B, 2007, THROMB HAEMOSTASIS, V98, P319, DOI 10.1160/TH06-12-0694; Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x; Pegu A, 2008, J IMMUNOL, V180, P3399, DOI 10.4049/jimmunol.180.5.3399; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Podgrabinska S, 2009, J IMMUNOL, V183, P1767, DOI 10.4049/jimmunol.0802167; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Saada JI, 2006, J IMMUNOL, V177, P5968, DOI 10.4049/jimmunol.177.9.5968; SAVAGE COS, 1991, CELL IMMUNOL, V137, P150, DOI 10.1016/0008-8749(91)90065-J; SAVAGE COS, 1993, TRANSPLANTATION, V56, P128, DOI 10.1097/00007890-199307000-00024; SEINO K, 1995, INT IMMUNOL, V7, P1331, DOI 10.1093/intimm/7.8.1331; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Swartz MA, 2008, SEMIN IMMUNOL, V20, P147, DOI 10.1016/j.smim.2007.11.007; Tan PH, 2004, ATHEROSCLEROSIS, V173, P171, DOI 10.1016/j.atherosclerosis.2003.12.011; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walker JD, 2009, J IMMUNOL, V182, P1548, DOI 10.4049/jimmunol.182.3.1548; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	55	48	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2835	2846		10.1096/fj.12-205278	http://dx.doi.org/10.1096/fj.12-205278			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459150	Bronze			2022-12-28	WOS:000305912500012
J	Melas, PA; Rogdaki, M; Osby, U; Schalling, M; Lavebratt, C; Ekstrom, TJ				Melas, Philippe A.; Rogdaki, Maria; Osby, Urban; Schalling, Martin; Lavebratt, Catharina; Ekstrom, Tomas J.			Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset	FASEB JOURNAL			English	Article						COMT; haloperidol; SERT	LUMINOMETRIC METHYLATION; BIPOLAR DISORDER; MESSENGER-RNA; COMT PROMOTER; HYPOMETHYLATION; EXPRESSION; PSYCHOSIS; DIAGNOSIS; GENETICS; ASSAY	Even though schizophrenia has a strong hereditary component, departures from simple genetic transmission are prominent. DNA methylation has emerged as an epigenetic explanatory candidate of schizophrenia's nonmendelian characteristics. To investigate this assumption, we examined genome-wide (global) and gene-specific DNA methylation levels, which are associated with genomic stability and gene expression activity, respectively. Analyses were conducted using DNA from leukocytes of patients with schizophrenia and controls. Global methylation results revealed a highly significant hypomethylation in patients with schizophrenia (P<2.0 x 10(-6)) and linear regression among patients generated a model in which antipsychotic treatment and disease onset explained 11% of the global methylation variance (adjusted R-2=0.11, ANOVA P<0.001). Specifically, haloperidol was associated with higher ("control-like") methylation (P=0.001), and early onset (a putative marker of schizophrenia severity) was associated with lower methylation (P=0.002). With regard to the gene-specific methylation analyses, and in accordance with the dopamine hypothesis of psychosis, we found that the analyzed region of S-COMT was hypermethylated in patients with schizophrenia (P=0.004). In summary, these data support the notion of a dysregulated epigenome in schizophrenia, which, at least globally, is more pronounced in early-onset patients and can be partly rescued by antipsychotic medication. In addition, blood DNA-methylation signatures show promise of serving as a schizophrenia biomarker in the future.-Melas, P. A., Rogdaki, M., sby, U., Schalling, M., Lavebratt, C., Ekstrom, T. J. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 26, 2712-2718 (2012). www.fasebj.org	[Lavebratt, Catharina] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Dept Mol Med & Surg,Neurogenet Unit, S-17176 Stockholm, Sweden; [Ekstrom, Tomas J.] Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, S-17176 Stockholm, Sweden; [Osby, Urban] Tiohundra AB, Dept Psychiat, Norrtalje, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Lavebratt, C (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Dept Mol Med & Surg,Neurogenet Unit, L8 00, S-17176 Stockholm, Sweden.	catharina.lavebratt@ki.se	Schalling, Martin/F-1518-2015; Ekström, Tomas/B-7764-2013	Schalling, Martin/0000-0001-5011-2922; , Maria/0000-0003-2685-1789; Lavebratt, Catharina/0000-0003-4987-2718; Melas, Philippe/0000-0002-7889-9250	Swedish Cancer Society; Karolinska Institute; Bodossaki Foundation; Swedish Research Council; ALF from Stockholm County Council [20060100, 20080022]; Department of Drug Management and Informatics, Stockholm County Council; Soderstrom-Konigska Hospital; Bristol-Myers Squibb; Janssen-Cilag	Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute(Karolinska Institutet); Bodossaki Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); ALF from Stockholm County Council; Department of Drug Management and Informatics, Stockholm County Council(Stockholm County Council); Soderstrom-Konigska Hospital; Bristol-Myers Squibb(Bristol-Myers Squibb); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	This work was supported by funds from the Swedish Cancer Society, the Karolinska Institute Faculty Funds (KID), the Bodossaki Foundation, and Swedish Research Council grants. The Swedish Study of Metabolic Risks in Psychosis (SSMP) was supported by ALF Grants 20060100 and 20080022 from Stockholm County Council and Karolinska Institutet, and by grants from the Department of Drug Management and Informatics, Stockholm County Council, and from Soderstrom-Konigska Hospital. None of the funding sources were involved in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the paper for publication. The authors also thank Dr. Nimrod Kiss and Dr. Mohsen Karimi Arzenani for experimental support and expertise, and Carina Schmidt for work with the patient sample. U.O. has received honoraria as a speaker or advisor or for attending congresses from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Eli Lilly, and Pfizer, and grant support from Bristol-Myers Squibb and Janssen-Cilag. The other authors declare no conflicts of interest.	Abdolmaleky HM, 2006, HUM MOL GENET, V15, P3132, DOI 10.1093/hmg/ddl253; American Academy of Child and Adolescent Psychiatry, 2001, J AM ACAD CHILD ADOL, V40, p4S; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Ban TA, 2004, PROG NEURO-PSYCHOPH, V28, P753, DOI 10.1016/j.pnpbp.2004.05.021; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Craddock N, 2005, J MED GENET, V42, P193, DOI 10.1136/jmg.2005.030718; Dempster EL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-10; Dempster EL, 2011, HUM MOL GENET, V20, P4786, DOI 10.1093/hmg/ddr416; Dong E, 2008, P NATL ACAD SCI USA, V105, P13614, DOI 10.1073/pnas.0805493105; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; Frazier JA, 2007, J AM ACAD CHILD PSY, V46, P979, DOI 10.1097/chi.0b013e31807083fd; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Karimi M, 2011, METHODS MOL BIOL, V791, P135, DOI 10.1007/978-1-61779-316-5_11; Kyriakopoulos M, 2007, INT REV PSYCHIATR, V19, P315, DOI 10.1080/09540260701486258; Lappalainen T, 2009, ANN HUM GENET, V73, P61, DOI 10.1111/j.1469-1809.2008.00487.x; Melas PA, 2011, INT J NEUROPSYCHOPH, P1, DOI DOI 10.1017/S1461145711000940; Mill J, 2008, AM J HUM GENET, V82, P696, DOI 10.1016/j.ajhg.2008.01.008; Murphy BC, 2005, AM J MED GENET B, V133B, P37, DOI 10.1002/ajmg.b.30134; Nohesara S, 2011, J PSYCHIATR RES, V45, P1432, DOI 10.1016/j.jpsychires.2011.06.013; Petronis A, 2004, BIOL PSYCHIAT, V55, P965, DOI 10.1016/j.biopsych.2004.02.005; Petronis A, 2003, SCHIZOPHRENIA BULL, V29, P169, DOI 10.1093/oxfordjournals.schbul.a006988; Philibert R, 2007, AM J MED GENET B, V144B, P101, DOI 10.1002/ajmg.b.30414; Pidsley R, 2011, BIOL PSYCHIAT, V69, P146, DOI 10.1016/j.biopsych.2010.03.029; Shimabukuro M, 2007, J PSYCHIATR RES, V41, P1042, DOI 10.1016/j.jpsychires.2006.08.006; Shin JK, 2011, CURR MED CHEM, V18, P1380; SNYDER SH, 1976, AM J PSYCHIAT, V133, P197; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132	31	145	150	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2012	26	6					2712	2718		10.1096/fj.11-202069	http://dx.doi.org/10.1096/fj.11-202069			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	955KI	22426120				2022-12-28	WOS:000305017200046
